FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Wilhelm, B
   Waddell, L
   Greig, J
   Young, I
AF Wilhelm, Barbara
   Waddell, Lisa
   Greig, Judy
   Young, Ian
TI Systematic review and meta-analysis of the seroprevalence of hepatitis E
   virus in the general population across non-endemic countries
SO PLOS ONE
LA English
DT Review
ID ALANINE AMINOTRANSFERASE LEVEL; LINKED-IMMUNOSORBENT-ASSAY; JAPANESE
   BLOOD-DONORS; ANTI-HEV; HIGH PREVALENCE; UNITED-STATES; NATIONWIDE
   SURVEY; E ANTIBODIES; IGM ANTIBODIES; RISK-FACTORS
AB Background
   Hepatitis E virus (HEV) has commonly been associated with large waterborne outbreaks of human jaundice in endemic areas but it has been increasingly recognised as a cause of sporadic human cases of jaundice in non-endemic areas, in individuals with no history of travel. Zoonotic exposure is widely hypothesized to be an important potential transmission route in these sporadic human cases. Serosurveys conducted to determine the frequency of HEV human exposure report wide ranges in prevalence across studies and locations. Our study objective was to compute meta-analysis summary estimates of human seroprevalence of HEV IgG within countries considered HEV non-endemic, where possible, and to determine whether this varied significantly across these countries, as well as investigating the role of potential HEV seroprevalence predictors such as population age structure.
   Materials and methods
   A broad literature search was conducted in six electronic databases. Citations were appraised, and relevant data extracted using forms designed and pre-tested a priori. Meta-analysis and meta-regression were conducted in R, with HEV IgG seroprevalence in blood donors or the general population being the outcome of interest, and country, assay, population age and sex structure, and chronological time investigated as predictors of the outcome.
   Results
   From 4163 unique citations initially captured, data were extracted from 135 studies investigating HEV serology in blood donors or the general population, of 31 countries among those categorised as 'very high human development' by the United Nations. Country of sampling and assay employed were consistently significant predictors of HEV IgG seroprevalence with chronological time being a non-significant predictor in the dataset of captured studies.
   Conclusions
   While country of sampling and assay employed were significant predictors of HEV seroprevalence, comparison of HEV seroprevalence across non-endemic countries is hampered by the lack of a gold standard assay and uncertainty regarding residual bias across studies, as well as regional differences within some countries.
C1 [Wilhelm, Barbara] Big Sky Hlth Analyt, Vermilion, AB, Canada.
   [Waddell, Lisa; Greig, Judy] Publ Hlth Agcy Canada, Natl Microbiol Lab Guelph, Guelph, ON, Canada.
   [Young, Ian] Ryerson Univ, Sch Occupat & Publ Hlth, Toronto, ON, Canada.
RP Wilhelm, B (reprint author), Big Sky Hlth Analyt, Vermilion, AB, Canada.
EM barbwilhelm16@gmail.com
CR Abdelaal M, 1998, IRISH J MED SCI, V167, P94, DOI 10.1007/BF02937946
   Abravanel F, 2013, MED MALADIES INFECT, V43, P263, DOI 10.1016/j.medmal.2013.03.005
   Adlhoch C, 2016, J CLIN VIROL, V82, P9, DOI 10.1016/j.jcv.2016.06.010
   Ahn JM, 2005, J CLIN MICROBIOL, V43, P3042, DOI 10.1128/JCM.43.7.3042-3048.2005
   Andenaes S, 2000, AVIAT SPACE ENVIR MD, V71, P1178
   ARIF M, 1994, ANN TROP MED PARASIT, V88, P163, DOI 10.1080/00034983.1994.11812854
   Atiq M, 2009, EMERG INFECT DIS, V15, P479, DOI 10.3201/eid1503.080740
   Ayoola EA, 2002, J MED VIROL, V66, P329, DOI 10.1002/jmv.2149
   BALAYAN MS, 1990, J MED VIROL, V32, P58, DOI 10.1002/jmv.1890320110
   Barendregt JJ, 2013, J EPIDEMIOL COMMUN H, V67, P974, DOI 10.1136/jech-2013-203104
   Baylis SA, 2010, VOX SANG, V98, P479, DOI 10.1111/j.1423-0410.2009.01258.x
   Beale MA, 2011, VOX SANG, V100, P340, DOI 10.1111/j.1423-0410.2010.01412.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bendall R, 2010, J MED VIROL, V82, P799, DOI 10.1002/jmv.21656
   Borenstein M, 2009, INTRO METAANALYSIS, P289, DOI [10.1002/jmv.21056, DOI 10.1002/JMV.21056]
   Boutrouille A, 2007, J CLIN MICROBIOL, V45, P2009, DOI 10.1128/JCM.00235-07
   Bouwknegt M, 2008, EPIDEMIOL INFECT, V136, P567, DOI 10.1017/S0950268807008941
   Bukowska A, 2016, VOX SANG, V111, P200
   BUTI M, 1995, J VIROL METHODS, V55, P49, DOI 10.1016/0166-0934(95)00044-U
   Buti M, 2006, CLIN VACCINE IMMUNOL, V13, P1328, DOI 10.1128/CVI.00255-06
   Capai L, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10060285
   Carpentier A, 2012, J CLIN MICROBIOL, V50, P2888, DOI 10.1128/JCM.00989-12
   Caruso C, 2017, TRANSBOUND EMERG DIS, V64, P1443, DOI 10.1111/tbed.12533
   Caspari G, 2000, VOX SANG, V78, P198
   Chaussade H, 2013, J CLIN VIROL, V58, P504, DOI 10.1016/j.jcv.2013.08.030
   Choi IS, 2003, J CLIN MICROBIOL, V41, P3602, DOI 10.1128/JCM.41.8.3602-3608.2003
   Christensen PB, 2008, CLIN INFECT DIS, V47, P1026, DOI 10.1086/591970
   Cleland A, 2013, VOX SANG, V105, P283, DOI 10.1111/vox.12056
   COURSAGET P, 1994, RES VIROLOGY, V145, P51, DOI 10.1016/S0923-2516(07)80007-0
   Dalekos GN, 1998, TRANSFUSION, V38, P589, DOI 10.1046/j.1537-2995.1998.38698326339.x
   Dalton H, 2010, GUT, V59, pA43, DOI [10.1136/gut.2010.223362.105, DOI 10.1136/GUT.2010.223362.105]
   Dalton HR, 2008, EUR J CLIN MICROBIOL, V27, P579, DOI 10.1007/s10096-008-0480-z
   Dalton HR, 2007, J GASTROEN HEPATOL, V22, P1236, DOI 10.1111/j.1440-1746.2007.04894.x
   Dalton HR, 2016, TRANSFUS APHER SCI, V55, P271, DOI 10.1016/j.transci.2016.10.016
   Dalton HR, 2011, EUR J GASTROEN HEPAT, V23, P1200, DOI 10.1097/MEG.0b013e32834ca4da
   DAWSON GJ, 1992, J VIROL METHODS, V38, P175, DOI 10.1016/0166-0934(92)90180-L
   de Vries A, 2015, R DUMMIES
   Debes JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160082
   Ding X, 2003, HEPATOL RES, V27, P169, DOI 10.1016/S1386-6346(03)00233-X
   Ditah I, 2014, HEPATOLOGY, V60, P815, DOI 10.1002/hep.27219
   Dohoo I, 2009, VET EPIDEMIOLOGIC RE
   Dong C, 2011, J CLIN MICROBIOL, V49, P4164, DOI 10.1128/JCM.05481-11
   Dremsek P, 2012, MED MICROBIOL IMMUN, V201, P189, DOI 10.1007/s00430-011-0221-2
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elsheikh A. A., 2012, The Journal of American Science, V8, P674
   Engle RE, 2002, J CLIN MICROBIOL, V40, P4576, DOI 10.1128/JCM.40.12.4576-4580.2002
   European Centre for Disease Prevention and Control, 2017, HEP E EU EAA 2005 20
   Faber MS, 2012, EMERG INFECT DIS, V18, P1654, DOI 10.3201/eid1810.111756
   Fearon MA, 2017, TRANSFUSION, V57, P1420, DOI 10.1111/trf.14089
   Fischer C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119576
   Fogeda M, 2012, J MED VIROL, V84, P71, DOI 10.1002/jmv.22270
   FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756
   Fukae J, 2016, NEUROL SCI, V37, P1849, DOI 10.1007/s10072-016-2644-4
   Fukuda S, 2007, ARCH VIROL, V152, P1623, DOI 10.1007/s00705-007-0996-z
   Fukuda S, 2004, J MED VIROL, V73, P554, DOI 10.1002/jmv.20125
   Gallian P, 2014, EMERG INFECT DIS, V20, P1914, DOI 10.3201/eid2011.140516
   Gessoni G, 1996, J VIRAL HEPATITIS, V3, P197, DOI 10.1111/j.1365-2893.1996.tb00095.x
   Gotanda Y, 2007, J MED VIROL, V79, P734, DOI 10.1002/jmv.20834
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011
   Herremans M, 2007, CLIN VACCINE IMMUNOL, V14, P562, DOI 10.1128/CVI.00231-06
   Herremans M, 2007, J VIRAL HEPATITIS, V14, P140, DOI 10.1111/j.1365-2893.2006.00786.x
   Hickey C, 2016, Ir Med J, V109, P451
   Higgins J, 2011, COCHRANE COLLAB, V5, P1, DOI DOI 10.1002/9780470712184
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hogema BM, 2014, TRANSFUSION, V54, P3092, DOI 10.1111/trf.12733
   Holm DK, 2015, TRANSFUSION, V55, P1662, DOI 10.1111/trf.13028
   Hornik K, 2018, R FAQ
   Ijaz S, 2009, J CLIN VIROL, V44, P272, DOI 10.1016/j.jcv.2009.01.005
   Ioannidis JPA, 2007, CAN MED ASSOC J, V176, P1091, DOI 10.1503/cmaj.060410
   Izopet J, 2015, J CLIN VIROL, V70, P39, DOI 10.1016/j.jcv.2015.06.103
   Johargy AK, 2013, J PAK MED ASSOC, V63, P185
   Juhl D, 2014, TRANSFUSION, V54, P49, DOI 10.1111/trf.12121
   Karetnyi YV, 1999, J CLIN VIROL, V14, P51, DOI 10.1016/S1386-6532(99)00037-2
   Karetnyi YV, 1996, CLIN DIAGN VIROL, V6, P73, DOI 10.1016/0928-0197(96)00204-8
   Khudyakov Y, 2011, VIRUS RES, V161, P84, DOI 10.1016/j.virusres.2011.06.006
   Krumbholz A, 2014, MED MICROBIOL IMMUN, V203, P273, DOI 10.1007/s00430-014-0336-3
   Krumbholz A, 2012, MED MICROBIOL IMMUN, V201, P239, DOI 10.1007/s00430-011-0210-5
   Kuniholm MH, 2009, J INFECT DIS, V200, P48, DOI 10.1086/599319
   Lagler H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087669
   Lange H, 2017, EPIDEMIOL INFECT, V145, P181, DOI 10.1017/S0950268816002144
   LAVANCHY D, 1994, LANCET, V344, P747, DOI 10.1016/S0140-6736(94)92235-7
   Li TC, 2000, J MED VIROL, V62, P327, DOI 10.1002/1096-9071(200011)62:3<327::AID-JMV4>3.0.CO;2-1
   LOK ASF, 1992, LANCET, V340, P1205, DOI 10.1016/0140-6736(92)92901-Q
   Love A, 2018, SCAND J GASTROENTERO, V53, P293, DOI 10.1080/00365521.2017.1420218
   Lucarelli C, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.30.30299
   Mansuy JM, 2015, EUROSURVEILLANCE, V20, P27, DOI 10.2807/1560-7917.ES2015.20.19.21127
   Mansuy JM, 2008, J MED VIROL, V80, P289, DOI 10.1002/jmv.21056
   Mansuy JM, 2016, HEPATOLOGY, V63, P1145, DOI 10.1002/hep.28436
   Mansuy JM, 2011, EMERG INFECT DIS, V17, P2309, DOI 10.3201/eid1712.110371
   Masia G, 2009, J Prev Med Hyg, V50, P227
   Mast EE, 1997, J INFECT DIS, V176, P34, DOI 10.1086/514037
   Mateos ML, 1999, VOX SANG, V76, P78
   Mauceri C, 2018, J INFECT PUBLIC HEAL, V11, P1, DOI 10.1016/j.jiph.2017.08.004
   MEDRANO FJ, 1995, LANCET, V345, P127
   Meng XJ, 2002, J CLIN MICROBIOL, V40, P117, DOI 10.1128/JCM.40.1.117-122.2002
   Meng XJ, 2003, CURR TOP MICROBIOL, V278, P185
   Mesquita JR, 2014, J MED VIROL, V86, P954, DOI 10.1002/jmv.23927
   Miletic Lovric M, 2016, VOX SANG, V111, P199
   Mitsui T, 2005, J MED VIROL, V76, P526, DOI 10.1002/jmv.20393
   MOAVEN L, 1995, J MED VIROL, V45, P326, DOI 10.1002/jmv.1890450316
   MOHER D, 2009, PLOS MED, V6
   Mor O, 2015, EMERG INFECT DIS, V21, P692, DOI 10.3201/eid2104.140245
   Munn Z, 2015, INT J EVID-BASED HEA, V13, P147, DOI 10.1097/XEB.0000000000000054
   Munne MS, 2014, ANN HEPATOL, V13, P496, DOI 10.1016/S1665-2681(19)31248-7
   Nasrallah G, 2016, VOX SANG, V111, P9
   Nemecek V, 2015, J CLIN VIROL, V70, pS116, DOI 10.1016/j.jcv.2015.07.270
   Niederhauser C, 2016, VOX SANG, V111, P175
   Norder H, 2016, J CLIN MICROBIOL, V54, P549, DOI 10.1128/JCM.02343-15
   O'Riordan J, 2016, TRANSFUSION, V56, P2868, DOI 10.1111/trf.13757
   Obriadina A, 2002, J Gastroenterol Hepatol, V17 Suppl 3, pS360, DOI 10.1046/j.1440-1746.17.s3.28.x
   Olsen BR, 2006, SCAND J INFECT DIS, V38, P55, DOI 10.1080/00365540500321470
   Ooi WW, 1999, AM J TROP MED HYG, V61, P822, DOI 10.4269/ajtmh.1999.61.822
   Park HK, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-142
   PAUL DA, 1994, J INFECT DIS, V169, P801, DOI 10.1093/infdis/169.4.801
   Pavia M, 1998, INFECTION, V26, P36, DOI 10.1007/BF02768749
   Pereira SS, 2016, J HEPATOL, V64, pS206, DOI 10.1016/S0168-8278(16)01724-4
   Pischke S, 2014, TRANSPL INFECT DIS, V16, P333, DOI 10.1111/tid.12183
   Pischke S, 2011, Z GASTROENTEROL, V49, P1255, DOI 10.1055/s-0031-1273394
   Pischke S, 2010, J HEPATOL, V52, pS135, DOI 10.1016/S0168-8278(10)60324-8
   Pischke S, 2016, CLIN INFECT DIS, V63, P569, DOI 10.1093/cid/ciw309
   Pittaras T, 2014, VOX SANG, V106, P387, DOI 10.1111/vox.12122
   Psichogiou M, 1996, SCAND J INFECT DIS, V28, P443, DOI 10.3109/00365549609037936
   Purcell RH, 2000, LANCET, V355, P578, DOI 10.1016/S0140-6736(05)73231-1
   PURDY MA, 2010, PLOS ONE, V5
   Puttini Camilla, 2015, Infez Med, V23, P253
   Rapicetta M, 2013, INFECTION, V41, P69, DOI 10.1007/s15010-012-0385-8
   Reinheimer C, 2012, MED MICROBIOL IMMUN, V201, P171, DOI 10.1007/s00430-011-0218-x
   Rey, 1997, J Travel Med, V4, P100, DOI 10.1111/j.1708-8305.1997.tb00788.x
   Ricco G, 2016, DIGEST LIVER DIS, V48, P536, DOI 10.1016/j.dld.2016.01.007
   Riveiro-Barciela M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103028
   Sadik S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2007-z
   Sakata H, 2008, TRANSFUSION, V48, P2568, DOI 10.1111/j.1537-2995.2008.01910.x
   Sargento C, 2016, VOX SANG, V111, P198
   Sargento C, 2014, VOX SANG, V107, P165
   Sauleda S, 2015, TRANSFUSION, V55, P972, DOI 10.1111/trf.12929
   Schnegg A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062980
   Schwarzer G, 2018, PACKAGE META
   Schwarzer G., 2007, R NEWS, V7, P40, DOI DOI 10.3389/FPSYG.2014.01521
   Scotto G, 2014, EPIDEMIOL INFECT, V142, P287, DOI 10.1017/S0950268813001167
   Shaz BH, 2011, J NATL MED ASSOC, V103, P351, DOI 10.1016/S0027-9684(15)30316-3
   Shrestha AC, 2014, EMERG INFECT DIS, V20, P1940, DOI 10.3201/eid2011.140412
   Slot E, 2013, EUROSURVEILLANCE, V18, P23, DOI 10.2807/1560-7917.ES2013.18.31.20550
   Strakova P, 2014, EPIDEMIOL MIKROBI IM, V63, P92
   Stramer SL, 2016, TRANSFUSION, V56, P481, DOI 10.1111/trf.13355
   Sulkowska E, 2016, VOX SANG S1, V111, P198
   Sylvan SPE, 1998, J MED VIROL, V54, P38, DOI 10.1002/(SICI)1096-9071(199801)54:1<38::AID-JMV6>3.0.CO;2-Q
   Takahashi M, 2005, J CLIN MICROBIOL, V43, P49, DOI 10.1128/JCM.43.1.49-56.2005
   Takahashi M, 2010, J MED VIROL, V82, P271, DOI 10.1002/jmv.21678
   Takeda H, 2010, VOX SANG, V99, P307, DOI 10.1111/j.1423-0410.2010.01362.x
   Tei S, 2004, J MED VIROL, V74, P67, DOI 10.1002/jmv.20147
   Teixeira J, 2017, MED MICROBIOL IMMUN, V206, P77, DOI 10.1007/s00430-016-0484-8
   Teshale EH, 2015, J INFECT DIS, V211, P366, DOI 10.1093/infdis/jiu466
   Toft N, 2005, PREV VET MED, V68, P19, DOI 10.1016/j.prevetmed.2005.01.006
   Toyoda K, 2008, J GASTROEN HEPATOL, V23, P1885, DOI 10.1111/j.1440-1746.2008.05568.x
   United Nations Development Programme, 2016, HUM DEV REP 2016 HUM
   Unzueta A, 2016, ANN HEPATOL, V15, P33, DOI 10.5604/16652681.1184202
   van den Berg B, 2014, NEUROLOGY, V82, P491, DOI 10.1212/WNL.0000000000000111
   Verhoef L, 2012, EPIDEMIOL INFECT, V140, P1838, DOI 10.1017/S0950268811002913
   Victor D, 2018, NY TIMES
   Viechtbauer W, 2005, J EDUC BEHAV STAT, V30, P261, DOI 10.3102/10769986030003261
   Viechtbauer W, 2011, METHODS DATA
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1
   Vilibic-Cavlek T, 2016, ZOONOSES PUBLIC HLTH, V63, P494, DOI 10.1111/zph.12254
   Vollmer T, 2012, J CLIN MICROBIOL, V50, P2708, DOI 10.1128/JCM.01119-12
   Wenzel JJ, 2014, HEPATOLOGY, V60, P1180, DOI 10.1002/hep.27244
   Wenzel JJ, 2013, J INFECT DIS, V207, P497, DOI 10.1093/infdis/jis688
   Wong KH, 2004, J MED VIROL, V72, P538, DOI 10.1002/jmv.2003
   Xu CY, 2013, TRANSFUSION, V53, P2505, DOI 10.1111/trf.12326
   Yoo D, 2001, CLIN DIAGN LAB IMMUN, V8, P1213, DOI 10.1128/CDLI.8.6.1213-1219.2001
   Yoon Y, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-517
   Yugo DM, 2013, INT J ENV RES PUB HE, V10, P4507, DOI 10.3390/ijerph10104507
   Zaaijer HL, 2015, HEPATOLOGY, V62, P654, DOI 10.1002/hep.27611
   ZAAIJER HL, 1995, J MED VIROL, V46, P244, DOI 10.1002/jmv.1890460313
   ZAAIJER HL, 1992, LANCET, V340, P681, DOI 10.1016/0140-6736(92)92224-4
   ZANETTI AR, 1994, J MED VIROL, V42, P318, DOI 10.1002/jmv.1890420321
   Zervou EZ, 2015, VOX SANG, V109, P242
   2016, VOX SANG, V110, P93
NR 178
TC 0
Z9 0
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 7
PY 2019
VL 14
IS 6
AR e0216826
DI 10.1371/journal.pone.0216826
PG 27
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IC0OB
UT WOS:000470658500006
PM 31173594
OA DOAJ Gold
DA 2019-07-16
ER

PT J
AU Tharabenjasin, P
   Pabalan, N
   Jarjanazi, H
AF Tharabenjasin, Phuntila
   Pabalan, Noel
   Jarjanazi, Hamdi
TI Association of the ACTN3 R577X (rs1815739) polymorphism with elite power
   sports: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID ALPHA-ACTININ-3 DEFICIENCY; MUSCLE POWER; POLYGENIC PROFILE; ATHLETE
   STATUS; GENOTYPE; PERFORMANCE; GENE; PHENOTYPES; ACE; STRENGTH
AB Objective
   The special status accorded to elite athletes stems from their uncommon genetic potential to excel in world-class power sports (PS). Genetic polymorphisms have been reported to influence elite PS status. Reports of associations between the alpha-actinin-3 gene (ACTN3) R577X polymorphism and PS have been inconsistent. In light of new published studies, we perform a meta-analysis to further explore the roles of this polymorphism in PS performance among elite athletes.
   Methods
   Multi-database literature search yielded 44 studies from 38 articles. Pooled odds ratios (ORs) and 95% confidence intervals (Cis) were used in estimating associations (significance threshold was set at P-a <= 0.05) using the allele-genotype model (R and X alleles, RX genotype). Outlier analysis was used to examine its impact on association and heterogeneity outcomes. Subgroup analysis was race (Western and Asian) and gender (male/female)-based. Interaction tests were applied to differential outcomes between the subgroups, P-values of which were Bonferroni corrected (P-interaction (BC)). Tests for sensitivity and publication bias were performed.
   Results
   Significant overall R allele effects (OR 1.21, 95% CI 1.07-1.37, P-a = 0.002) were confirmed in the Western subgroup (OR 1.11, 95% CI 1.01-1.22, P-a = 0.02) and with outlier treatment (ORs 1.12-1.20, 95% CIs 1.02-1.30, P-a < 10(-5)-0.01). This treatment resulted in acquired significance of the RX effect in Asian athletes (OR 1.91, 95% CI 1.25-2.92, P-a = 0.003). Gender analysis dichotomized the RX genotype and R allele effects as significantly higher in male (OR 1.14, 95% CI 1.02-1.28, P-a = 0.02) and female (OR 1.58, 95% CI 1.21-2.06, P-a = 0.0009) athletes, respectively, when compared with controls. Significant R female association was improved with a test of interaction (P-interaction (BC) = 0.03). The overall, Asian and female outcomes were robust. The R allele results were more robust than the RX genotype outcomes. No evidence of publication bias was found.
   Conclusions
   In this meta-analysis, we present clear associations between the R allele/RX genotype in the ACTN3 polymorphism and elite power athlete status. Significant effects of the R allele (overall analysis, Western and female subgroups) and RX genotype (Asians and males) were for the most part, results of outlier treatment. Interaction analysis improved the female outcome. These robust findings were free of publication bias.
C1 [Tharabenjasin, Phuntila; Pabalan, Noel] Thammasat Univ, Chulabhorn Int Coll Med, Pathum Thani, Thailand.
   [Jarjanazi, Hamdi] Ontario Minist Environm Conservat & Pk, Environm Monitoring & Reporting Branch, Toronto, ON, Canada.
RP Pabalan, N (reprint author), Thammasat Univ, Chulabhorn Int Coll Med, Pathum Thani, Thailand.
EM noelpabalan@mail.com
CR Abramson JH, 2004, EPIDEMIOL PERSPECT I, V1, P6, DOI DOI 10.1186/1742-5573-1-6
   Ahmetov II, 2015, ADV CLIN CHEM, V70, P247, DOI 10.1016/bs.acc.2015.03.003
   Ahmetov II, 2011, EXP PHYSIOL, V96, P1302, DOI 10.1113/expphysiol.2011.060293
   Alfred T, 2011, HUM MUTAT, V32, P1008, DOI 10.1002/humu.21526
   Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berman Y, 2010, PHYSIOLOGY, V25, P250, DOI 10.1152/physiol.00008.2010
   Berthold MR, 2010, TEXTS COMPUT SCI, P1, DOI 10.1007/978-1-84882-260-3_1
   Bouchard C, 2015, BRIT J SPORT MED, V49, P1492, DOI 10.1136/bjsports-2015-095294
   Broos S, 2015, EUR J APPL PHYSIOL, V115, P1637, DOI 10.1007/s00421-015-3144-6
   Celikkaya H, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00023
   Chan S, 2008, AM J PHYSIOL-CELL PH, V295, pC897, DOI 10.1152/ajpcell.00179.2008
   Clark MF, 2006, INTENS CARE MED, V32, P1706, DOI 10.1007/s00134-006-0327-y
   Delmonico MJ, 2007, J GERONTOL A-BIOL, V62, P206, DOI 10.1093/gerona/62.2.206
   Delmonico MJ, 2008, J GERONTOL A-BIOL, V63, P1227, DOI 10.1093/gerona/63.11.1227
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Druzhevskaya AM, 2008, EUR J APPL PHYSIOL, V103, P631, DOI 10.1007/s00421-008-0763-1
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Egorova ES, 2014, J SPORT SCI, V32, P1286, DOI 10.1080/02640414.2014.898853
   Eynon N, 2009, INT J SPORTS MED, V30, P695, DOI 10.1055/s-0029-1220731
   Eynon N, 2014, J SCI MED SPORT, V17, P102, DOI 10.1016/j.jsams.2013.02.005
   Eynon N, 2013, SPORTS MED, V43, P803, DOI 10.1007/s40279-013-0059-4
   Eynon N, 2013, J SCI MED SPORT, V16, P135, DOI 10.1016/j.jsams.2012.05.004
   Eynon N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043132
   Eynon N, 2011, J PHYSIOL-LONDON, V589, P3063, DOI 10.1113/jphysiol.2011.207035
   Eynon N, 2010, METABOLISM, V59, P861, DOI 10.1016/j.metabol.2009.10.003
   Fuku N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166605
   GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807
   Garatachea N, 2014, INT J SPORT PHYSIOL, V9, P226, DOI [10.1123/ijspp.2012-0331, 10.1123/IJSPP.2012-0331]
   Garatachea N, 2013, AGE, V35, P207, DOI 10.1007/s11357-011-9327-0
   Garatachea N, 2012, EUR J APPL PHYSIOL, V112, P2409, DOI 10.1007/s00421-011-2217-4
   Garton FC, 2018, AM J HUM GENET, V102, P845, DOI 10.1016/j.ajhg.2018.03.009
   Gineviciene V, 2016, BIOL SPORT, V33, P199, DOI 10.5604/20831862.1201051
   Gineviciene V, 2011, MED LITH, V47, P284
   Grenda A, 2014, J HUM KINET, V42, P127, DOI 10.2478/hukin-2014-0067
   Hanson ED, 2010, INT J SPORTS MED, V31, P834, DOI 10.1055/s-0030-1263116
   He HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083103
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Ioannidis JPA, 2007, CAN MED ASSOC J, V176, P1091, DOI 10.1503/cmaj.060410
   Jacques M, 2019, NUTR ENHANCED SPORTS
   Juffer P, 2009, INT J SPORTS MED, V30, P387, DOI 10.1055/s-0028-1105931
   Kikuchi Naoki, 2015, J Exerc Nutrition Biochem, V19, P157, DOI 10.5717/jenb.2015.15093001
   Kikuchi N, 2013, INT J SPORT PHYSIOL, V8, P57, DOI 10.1123/ijspp.8.1.57
   Kothari ST, 2011, INT J HUM GENET, V11, P149
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lee FXZ, 2016, BBA-MOL CELL RES, V1863, P686, DOI 10.1016/j.bbamcr.2016.01.013
   LILLIEFORS HW, 1967, J AM STAT ASSOC, V62, P399, DOI 10.2307/2283970
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Lorenz DS, 2013, SPORTS HEALTH, V5, P542, DOI 10.1177/1941738113479763
   MacArthur D, 2005, HUM GENET, V116, P331, DOI 10.1007/s00439-005-1261-8
   MacArthur DG, 2007, NAT GENET, V39, P1261, DOI 10.1038/ng2122
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Massidda Myosotis, 2015, Sports Med Open, V1, P6
   McCauley T, 2009, EXP PHYSIOL, V94, P81, DOI 10.1113/expphysiol.2008.043075
   Mikami E, 2014, INT J SPORTS MED, V35, P172, DOI 10.1055/s-0033-1347171
   Moran CN, 2007, EUR J HUM GENET, V15, P88, DOI 10.1038/sj.ejhg.5201724
   Nikolakopoulou A, 2014, EVID-BASED MENT HEAL, V17, P53, DOI 10.1136/eb-2014-101795
   Norman B, 2009, J APPL PHYSIOL, V106, P959, DOI 10.1152/japplphysiol.91435.2008
   North K, 2008, TWIN RES HUM GENET, V11, P384, DOI 10.1375/twin.11.4.384
   North KN, 1999, NAT GENET, V21, P353, DOI 10.1038/7675
   Papadimitriou ID, 2008, INT J SPORTS MED, V29, P352, DOI 10.1055/s-2007-965339
   Peplonska B, 2017, SCAND J MED SCI SPOR, V27, P788, DOI 10.1111/sms.12687
   Pereira A, 2013, AGE, V35, P1949, DOI 10.1007/s11357-012-9461-3
   Pickering C, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00015
   Pickering C, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01080
   Pitsiladis Y, 2013, BRIT J SPORT MED, V47, P550, DOI 10.1136/bjsports-2013-092400
   Roth S M, 2000, J Nutr Health Aging, V4, P143
   Roth SM, 2012, MED SCI SPORT EXER, V44, P809, DOI 10.1249/MSS.0b013e31824f28b6
   Ruiz JR, 2013, SCAND J MED SCI SPOR, V23, pe162, DOI 10.1111/sms.12045
   Ruiz JR, 2011, SCAND J MED SCI SPOR, V21, pE34, DOI 10.1111/j.1600-0838.2010.01134.x
   Ruiz JR, 2010, J APPL PHYSIOL, V108, P561, DOI 10.1152/japplphysiol.01242.2009
   Santiago C, 2008, BRIT J SPORT MED, V42, DOI 10.1136/bjsm.2007.039172
   Santiago C, 2010, SCAND J MED SCI SPOR, V20, P771, DOI 10.1111/j.1600-0838.2009.01017.x
   Santiago C, 2010, SCAND J MED SCI SPOR, V20, pE188, DOI 10.1111/j.1600-0838.2009.00943.x
   SEDGWICK P, 2015, BMJ-BRIT MED J, V350, DOI DOI 10.1136/BMJ.H1435
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Vincent B, 2007, PHYSIOL GENOMICS, V32, P58, DOI 10.1152/physiolgenomics.00173.2007
   Walsh S, 2008, J APPL PHYSIOL, V105, P1486, DOI 10.1152/japplphysiol.90856.2008
   Wang G, 2014, GENETICS
   Wang G, 2016, MED SPORT SCI, V61, P55, DOI 10.1159/000445241
   Wang G, 2013, MED SCI SPORT EXER, V45, P892, DOI 10.1249/MSS.0b013e31827c501f
   Weyerstrass J, 2018, J SCI MED SPORT, V21, P213, DOI 10.1016/j.jsams.2017.06.012
   Yang N, 2003, AM J HUM GENET, V73, P627, DOI 10.1086/377590
   Yang RY, 2017, J STRENGTH COND RES, V31, P1107, DOI 10.1519/JSC.0000000000001558
NR 85
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 30
PY 2019
VL 14
IS 5
AR e0217390
DI 10.1371/journal.pone.0217390
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IA2XG
UT WOS:000469425500017
PM 31145768
OA DOAJ Gold
DA 2019-07-16
ER

PT J
AU da Costa, VG
   Saivish, MV
   Rodrigues, RL
   Silva, RFD
   Moreli, ML
   Kruger, RH
AF da Costa, Vivaldo Gomes
   Saivish, Marielena Vogel
   Rodrigues, Roger Luiz
   de Lima Silva, Rebeca Francielle
   Moreli, Marcos Lazaro
   Kruger, Ricardo Henrique
TI Molecular and serological surveys of canine distemper virus: A
   meta-analysis of cross-sectional studies
SO PLOS ONE
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; RT-PCR; DOMESTIC DOGS;
   GENETIC-CHARACTERIZATION; HEMAGGLUTININ GENE; VIRAL PATHOGENS; WILD
   CARNIVORES; STRAY DOGS; PARVOVIRUS; EPIDEMIOLOGY
AB Background
   Canine morbillivirus (canine distemper virus, CDV) persists as a serious threat to the health of domestic dogs and wildlife. Although studies have been conducted on the frequency and risk factors associated with CDV infection, there are no comprehensive data on the current epidemiological magnitude in the domestic dog population at regional and national levels. Therefore, we conducted a cross-sectional study and included our results in a meta-analysis to summarize and combine available data on the frequency and potential risk factors associated with CDV infection.
   Methods
   For the cross-sectional study, biological samples from dogs suspected to have canine distemper (CD) were collected and screened for viral RNA. Briefly, the PRISMA protocol was used for the meta-analysis, and data analyses were performed using STATA IC 13.1 software.
   Results CDV RNA was detected in 34% (48/141) of dogs suspected to have CD. Following our meta-analysis, 53 studies were selected for a total of 11,527 dogs. Overall, the pooled frequency of CDV positivity based on molecular and serological results were 33% (95% CI: 23-43) and 46% (95% CI: 36-57), respectively. The pooled subgroup analyses of clinical signs, types of biological samples, diagnostic methods and dog lifestyle had a wide range of CDV positivity (range 8-75%). Free-ranging dogs (OR: 1.44, 95% CI: 1.05-1.97), dogs > 24 months old (OR: 1.83, 95% CI: 1.1-3) and unvaccinated dogs (OR: 2.92, 95% CI: 1.266.77) were found to be positively associated with CDV infection. In contrast, dogs < 12 months old (OR: 0.36, 95% CI: 0.20-0.64) and dogs with a complete anti-CDV vaccination (OR: 0.18, 95% CI: 0.05-0.59) had a negative association.
   Conclusion
   Considering the high frequency of CDV positivity associated with almost all the variables analyzed in dogs, it is necessary to immediately and continuously plan mitigation strategies to reduce the CDV prevalence, especially in determined endemic localities.
C1 [da Costa, Vivaldo Gomes; Kruger, Ricardo Henrique] Univ Brasilia, Dept Cell Biol, Enzymol Lab, Brasilia, DF, Brazil.
   [da Costa, Vivaldo Gomes; Saivish, Marielena Vogel; Rodrigues, Roger Luiz; de Lima Silva, Rebeca Francielle; Moreli, Marcos Lazaro] Univ Fed Goias, Inst Hlth Sci, Virol Lab, Jatai, Go, Brazil.
RP da Costa, VG (reprint author), Univ Brasilia, Dept Cell Biol, Enzymol Lab, Brasilia, DF, Brazil.; da Costa, VG; Moreli, ML (reprint author), Univ Fed Goias, Inst Hlth Sci, Virol Lab, Jatai, Go, Brazil.
EM vivbiom@gmail.com; marcos_moreli@ufg.br
OI Silva, Rebeca Francielle de Lima/0000-0003-4637-211X; Rodrigues, Roger
   Luiz/0000-0001-8042-4636; Moreli, Marcos/0000-0002-9599-361X
FU Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); FAPDF;
   CAPES
FX This work was carried out as part of the doctoral thesis of VGC
   (Programa de Posgraduacao em Biotecnologia e Biodiversidade, UnB). VGC
   was supported by scholarships from Fundacao de Apoio a Pesquisa do
   Distrito Federal (FAPDF) and Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior-Brasil (CAPES). In addition, funding for this study
   was financed in part by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), FAPDF and CAPES. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Acosta-Jamett G, 2015, VET MICROBIOL, V178, P260, DOI 10.1016/j.vetmic.2015.05.012
   Acosta-Jamett G, 2011, VET MICROBIOL, V152, P247, DOI 10.1016/j.vetmic.2011.05.008
   Albrechtova K, 2011, VET PARASITOL, V182, P230, DOI 10.1016/j.vetpar.2011.05.042
   Alcalde R., 2013, Brazilian Journal of Veterinary Research and Animal Science, V50, P74
   Alves CDBT, 2018, BRAZ J MICROBIOL, V49, P790, DOI 10.1016/j.bjm.2018.02.006
   Amude AM, 2007, RES VET SCI, V82, P416, DOI 10.1016/j.rvsc.2006.08.008
   An DJ, 2008, J VIROL METHODS, V147, P244, DOI 10.1016/j.jviromet.2007.09.006
   Anis E, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1027-2
   APPEL M, 1973, AM J VET RES, V34, P1459
   APPEL MJG, 1995, VET MICROBIOL, V44, P187, DOI 10.1016/0378-1135(95)00011-X
   Ashmi JM, 2017, INDIAN J ANIM SCI, V87, P1062
   Athanasiou LV, 2018, VIRAL IMMUNOL, V31, P272, DOI 10.1089/vim.2017.0101
   Avizeh R, 2007, Pak J Biol Sci, V10, P3970
   Barendregt JJ, 2013, J EPIDEMIOL COMMUN H, V67, P974, DOI 10.1136/jech-2013-203104
   Barret T., 2010, DESK ENCY ANIMAL BAC, P221
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beineke A, 2009, VET IMMUNOL IMMUNOP, V127, P1, DOI 10.1016/j.vetimm.2008.09.023
   Beineke A, 2015, ONE HEALTH, V1, P49, DOI 10.1016/j.onehlt.2015.09.002
   Belsare AV, 2014, TRANSBOUND EMERG DIS, V61, P78, DOI 10.1111/tbed.12265
   Budaszewski RD, 2014, VIRUS RES, V180, P76, DOI 10.1016/j.virusres.2013.12.024
   Calderon MG, 2007, VET MICROBIOL, V125, P341, DOI 10.1016/j.vetmic.2007.05.020
   Carvalho OV, 2012, ADV VIROL, DOI 10.1155/2012/163860
   Castanheira P, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-91
   Chen M, 2018, POL J VET SCI, V21, P623, DOI 10.24425/124301
   Cho HS, 2005, J VET MED B, V52, P410, DOI 10.1111/j.1439-0450.2005.00886.x
   Custilho JG, 2007, ARQ BRAS MED VET ZOO, V59, P654, DOI 10.1590/S0102-09352007000300016
   Gizzi ABD, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-23
   da Silva VCL, 2018, PERNAMBUCO, V12, P1, DOI [10.26605/medvet-v12n1-2136, DOI 10.26605/MEDVET-V12N1-2136]
   Nava AFD, 2008, ECOHEALTH, V5, P513, DOI 10.1007/s10393-008-0207-8
   Curi NHD, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0646-3
   Curi NHD, 2010, BIODIVERS CONSERV, V19, P3513, DOI 10.1007/s10531-010-9911-0
   Decaro N, 2016, VET MICROBIOL, V192, P21, DOI 10.1016/j.vetmic.2016.06.009
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DEZENGRINI R, 2007, RURAL, V37, P183, DOI DOI 10.1590/S0103-84782007000100029
   Di Francesco CE, 2012, J VET DIAGN INVEST, V24, P107, DOI 10.1177/1040638711425700
   Diaz NM, 2016, PREV VET MED, V123, P128, DOI 10.1016/j.prevetmed.2015.11.016
   Dong XY, 2015, IRAN J VET RES, V16, P172
   Dowgier G, 2017, VET MICROBIOL, V204, P54, DOI 10.1016/j.vetmic.2017.04.007
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elia G, 2006, J VIROL METHODS, V136, P171, DOI 10.1016/j.jviromet.2006.05.004
   Elia G, 2015, J VIROL METHODS, V213, P127, DOI 10.1016/j.jviromet.2014.12.004
   Fischer CDB, 2016, INFECT GENET EVOL, V41, P135, DOI 10.1016/j.meegid.2016.03.029
   FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756
   Frisk AL, 1999, J CLIN MICROBIOL, V37, P3634
   Fung HL, 2014, ACTA TROP, V135, P67, DOI 10.1016/j.actatropica.2014.03.010
   Furtado MM, 2013, J WILDLIFE DIS, V49, P510, DOI 10.7589/2012-02-056
   Garde Elena, 2013, Animals (Basel), V3, P843, DOI 10.3390/ani3030843
   Gebara CMS, 2004, ARQ BRAS MED VET ZOO, V56, P480, DOI 10.1590/S0102-09352004000400009
   Gencay A, 2004, REV MED VET-TOULOUSE, V155, P432
   Gowtage-Sequeira S, 2009, J WILDLIFE DIS, V45, P1008, DOI 10.7589/0090-3558-45.4.1008
   Greene C. E., 1984, Clinical microbiology and infectious diseases of the dog and cat, P386
   Griot Christian, 2003, Animal Health Research Reviews, V4, P1, DOI 10.1079/AHRR20047
   Hass R, 2008, ARQ BRAS MED VET ZOO, V60, P270, DOI 10.1590/S0102-09352008000100039
   Haydon DT, 2006, NATURE, V443, P692, DOI 10.1038/nature05177
   Headley S. A., 2000, Brazilian Journal of Veterinary Research and Animal Science, V37, P136
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jin YP, 2017, ONCOTARGET, V8, P113910, DOI 10.18632/oncotarget.23042
   Jozwik A, 2002, J VET MED B, V49, P413, DOI 10.1046/j.1439-0450.2002.00549.x
   Kapil S, 2011, VET CLIN N AM-SMALL, V41, P1069, DOI 10.1016/j.cvsm.2011.08.005
   Ki O, 2017, SAUDI MED J, V2, P121
   Kim D, 2006, J VET MED SCI, V68, P877, DOI 10.1292/jvms.68.877
   Kim HH, 2018, J VET MED SCI, V80, P1424, DOI 10.1292/jvms.18-0012
   Kim Y H, 2001, J Vet Sci, V2, P59
   Latha D., 2007, Indian Journal of Biotechnology, V6, P35
   Lavan R, 2015, J SMALL ANIM PRACT, V56, P572, DOI 10.1111/jsap.12389
   Levy JK, 2008, J VET INTERN MED, V22, P60, DOI 10.1111/j.1939-1676.2007.0034.x
   Li CQ, 2018, J VET MED SCI, V80, P1029, DOI 10.1292/jvms.17-0559
   Licitra BN, 2014, VIRUSES-BASEL, V6, P3363, DOI 10.3390/v6083363
   Lucio EC, 2014, SEMIN-CIENC AGRAR, V35, P1323, DOI 10.5433/1679-0359.2014v35n3p1323
   Luo HQ, 2017, INDIAN J ANIM RES, V51, P159, DOI 10.18805/ijar.9553
   Martinez-Gutierrez M, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0702-z
   McRee A, 2014, J S AFR VET ASSOC, V85, DOI 10.4102/jsava.v85i1.1110
   Millan J, 2013, EMERG INFECT DIS, V19, P680, DOI 10.3201/eid1904.121143
   Mira F, 2018, VET ITAL, V54, P225, DOI 10.12834/VetIt.1455.7862.2
   Miranda C, 2016, J GEN VIROL, V97, P2043, DOI 10.1099/jgv.0.000540
   Moher D, 2015, SYST REV, V4, DOI 10.1186/2046-4053-4-1
   Muller A, 2011, J WILDLIFE DIS, V47, P725, DOI 10.7589/0090-3558-47.3.725
   Negrao FJ, 2007, ARQ BRAS MED VET ZOO, V59, P253, DOI 10.1590/S0102-09352007000100042
   Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39
   Posuwan N, 2010, ASIAN BIOMED, V4, P563, DOI 10.2478/abm-2010-0071
   Pratelli A, 2011, VET J, V187, P290, DOI 10.1016/j.tvjl.2010.02.007
   Romanutti C, 2016, J VIROL METHODS, V228, P79, DOI 10.1016/j.jviromet.2015.11.011
   Saito TB, 2006, RES VET SCI, V80, P116, DOI 10.1016/j.rvsc.2005.03.002
   Sepulveda MA, 2014, ECOHEALTH, V11, P409, DOI 10.1007/s10393-014-0917-z
   Shin YJ, 2004, AUST VET J, V82, P83, DOI 10.1111/j.1751-0813.2004.tb14651.x
   Vandenbroucke JP, 2007, PLOS MED, V4, P1628, DOI 10.1371/journal.pmed.0040297
   Viana M, 2015, P NATL ACAD SCI USA, V112, P1464, DOI 10.1073/pnas.1411623112
   von Messling V, 2003, J VIROL, V77, P12579, DOI 10.1128/JVI.77.23.12579-12591.2003
   von Ruden EL, 2012, NEUROPATH APPL NEURO, V38, P426, DOI 10.1111/j.1365-2990.2011.01218.x
   Waner T, 2003, VET REC, V152, P588, DOI 10.1136/vr.152.19.588
   Wang J, 2018, ARCH VIROL, V163, P3345, DOI 10.1007/s00705-018-3982-8
   Woodroffe R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030099
   Zaccaria G, 2016, VIROLOGY, V490, P69, DOI 10.1016/j.virol.2016.01.007
NR 93
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2019
VL 14
IS 5
AR e0217594
DI 10.1371/journal.pone.0217594
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IA1LO
UT WOS:000469323000065
PM 31141576
OA DOAJ Gold
DA 2019-07-16
ER

PT J
AU del-Pino-Casado, R
   Cardosa, MR
   Lopez-Martinez, C
   Orgeta, V
AF del-Pino-Casado, Rafael
   Rodriguez Cardosa, Marta
   Lopez-Martinez, Catalina
   Orgeta, Vasiliki
TI The association between subjective caregiver burden and depressive
   symptoms in carers of older relatives: A systematic review and
   meta-analysis
SO PLOS ONE
LA English
DT Review
ID QUALITY-OF-LIFE; INFORMAL CAREGIVERS; DEMENTIA CAREGIVERS; FAMILY
   CAREGIVERS; ALZHEIMER-DISEASE; SELF-EFFICACY; PSYCHOLOGICAL SYMPTOMS;
   PERCEIVED BURDEN; MENTAL-HEALTH; ANXIETY
AB Background
   Family carers are an important source of care for older people. Although several studies have reported that subjective caregiver burden is related to depressive symptoms there are no systematic reviews quantifying this association.
   Objective
   To establish the extent to which subjective caregiver burden is associated with depressive symptoms and whether this association would vary by study or care characteristics.
   Methods
   We searched major databases such as PubMed, CINAHL, PsycINFO, Scopus and ISI Proceedings up to March 2018, and conducted a meta-analysis of included studies. Summary estimates of the association were obtained using a random-effects model to improve generalisation of findings.
   Results
   After screening of 4,688 articles, 55 studies were included providing a total of 56 independent comparisons with a total of 9,847 carers from data across 20 countries. There was a large, positive association between subjective caregiver burden and depressive symptoms ((r) over bar = 0.514; 95% CI = 0.486, 0.541), with very low heterogeneity amongst individual studies (I-2 = 8.6%). Sensitivity analyses showed no differences between cross-sectional or repeated measures ((r) over bar = 0.521; 95% CI = 0.491, 0.550; 51 samples) and longitudinal studies ((r) over bar = 0.454; 95% CI = 0.398, 0.508; 6 samples). We found a higher effect size for those caring for people living with dementia compared to those caring for frail older people, and stroke survivors. Carer sex, age and kinship did not change the estimate of the effect.
   Conclusions
   Subjective caregiver burden is a significant risk factor for depressive symptoms in carers of older people and may precipitate clinical depression. Those caring for people with dementia experience greater burden. There is a need for longitudinal evaluations examining the effects of potential mediators of the association of subjective burden and depressive symptoms. Future interventions should test whether minimizing subjective burden may modify the risk of developing depression in carers of older relatives.
C1 [del-Pino-Casado, Rafael; Rodriguez Cardosa, Marta; Lopez-Martinez, Catalina] Univ Jaen, Sch Hlth Sci, Dept Nursing, Jaen, Spain.
   [Orgeta, Vasiliki] UCL, Fac Brain Sci, Div Psychiat, London, England.
RP del-Pino-Casado, R (reprint author), Univ Jaen, Sch Hlth Sci, Dept Nursing, Jaen, Spain.
EM rdelpino@ujaen.es
RI del-Pino-Casado, Rafael/L-3733-2018
OI del-Pino-Casado, Rafael/0000-0003-2263-2415
CR Adams K. B., 2008, DEMENTIA-LONDON, V7, P301, DOI DOI 10.1177/1471301208093286
   Alspaugh MEL, 1999, PSYCHOL AGING, V14, P34, DOI 10.1037/0882-7974.14.1.34
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Aneshensel CS, 1995, PROFILES CAREGIVING
   Ar Y, 2017, THESIS
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Bachner YG, 2016, J AM PSYCHIAT NURSES, V22, P27, DOI 10.1177/1078390316629959
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bianchi M, 2016, REV LAT-AM ENFERM, V24, DOI 10.1590/1518-8345.1379.2835
   Bin Sallim A, 2015, J AM MED DIR ASSOC, V16, P1034, DOI 10.1016/j.jamda.2015.09.007
   Borenstein M., 2009, INTRO METAANALYSIS, P45, DOI [DOI 10.1002/9780470743386.CH7, 10.1002/9780470743386.ch7]
   Boyle M. H., 1998, EVID BASED MENT HLTH, V1, P37, DOI DOI 10.1136/EBMH.1.2.37
   Brandao D, 2017, SCAND J CARING SCI, V31, P984, DOI 10.1111/scs.12423
   Byun E, 2013, THESIS
   Carter JH, 2008, MOVEMENT DISORD, V23, P1211, DOI 10.1002/mds.21686
   Cheng ST, 2013, AM J GERIAT PSYCHIAT, V21, P1029, DOI 10.1016/j.jagp.2013.01.041
   Chow EOW, 2012, AGING MENT HEALTH, V16, P1016, DOI 10.1080/13607863.2012.692769
   Clark MC, 2013, BIOL RES NURS, V15, P112, DOI 10.1177/1099800411414872
   Clyburn LD, 2000, J GERONTOL B-PSYCHOL, V55, pS2
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Cooper C, 2008, INT PSYCHOGERIATR, V20, P494, DOI 10.1017/S104161020700645X
   Cooper H, 2009, HDB RES SYNTHESIS ME
   Corazza Danilla I, 2014, Rev Esp Geriatr Gerontol, V49, P173, DOI 10.1016/j.regg.2014.03.007
   D'Aoust RF, 2015, INT J OLDER PEOPLE N, V10, P14, DOI 10.1111/opn.12043
   del-Pino-Casado R, 2019, J AFFECT DISORDERS, V242, P14, DOI 10.1016/j.jad.2018.08.002
   del-Pino-Casado R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189874
   del-Pino-Casado R, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0667-1
   Del-Pino-Casado R, 2015, RES NURS HEALTH, V38, P384, DOI 10.1002/nur.21671
   del-Pino-Casado R, 2011, J ADV NURS, V67, P2311, DOI 10.1111/j.1365-2648.2011.05725.x
   Diehl-Schmid J, 2013, J GERIATR PSYCH NEUR, V26, P221, DOI 10.1177/0891988713498467
   Domingues NS, 2018, AM J ALZHEIMERS DIS, V33, P401, DOI 10.1177/1533317518788151
   dos Santos GD, 2017, PSYCHOGERIATRICS, V17, P317, DOI 10.1111/psyg.12241
   DRINKA TJK, 1987, J AM GERIATR SOC, V35, P522, DOI 10.1111/j.1532-5415.1987.tb01398.x
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Edelstein OE, 2018, AGING MENT HEALTH, V22, P639, DOI 10.1080/13607863.2017.1289363
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feast A, 2016, INT PSYCHOGERIATR, V28, P1761, DOI 10.1017/S1041610216000922
   Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3
   Gallagher D, 2011, AGING MENT HEALTH, V15, P663, DOI 10.1080/13607863.2011.562179
   Geng HM, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011863
   GOLDBERG D, 1988, BRIT MED J, V297, P897, DOI 10.1136/bmj.297.6653.897
   Gonzalez-Abraldes I, 2013, ARCH GERONTOL GERIAT, V56, P91, DOI 10.1016/j.archger.2012.07.011
   Graf R, 2017, TOP STROKE REHABIL, V24, P488, DOI 10.1080/10749357.2017.1338371
   Grano C, 2017, INT PSYCHOGERIATR, V29, P1095, DOI 10.1017/S1041610217000059
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011
   Hedges LV, 2001, PSYCHOL METHODS, V6, P203, DOI 10.1037/1082-989X.6.3.203
   Heo GJ, 2013, J APPL GERONTOL, V32, P582, DOI 10.1177/0733464811433484
   Higgins Julian, 2002, J Health Serv Res Policy, V7, P51, DOI 10.1258/1355819021927674
   Hirschman KB, 2004, J AM GERIATR SOC, V52, P1724, DOI 10.1111/j.1532-5415.2004.52468.x
   Jaracz K, 2012, NEUROL NEUROCHIR POL, V46, P224, DOI 10.5114/ninp.2012.29130
   Jones SBW, 2015, J PSYCHOSOC ONCOL, V33, P178, DOI 10.1080/07347332.2014.1002657
   Karabekiroglu A, 2018, SINGAP MED J, V59, P572, DOI 10.11622/smedj.2018066
   Khalaila R, 2011, AGING MENT HEALTH, V15, P679, DOI 10.1080/13607863.2011.569479
   Kim SK, 2017, INT PSYCHOGERIATR, V29, P227, DOI 10.1017/S1041610216001770
   Kowalska J, 2017, AM J ALZHEIMERS DIS, V32, P509, DOI 10.1177/1533317517734350
   Kruithof WJ, 2016, PATIENT EDUC COUNS, V99, P1632, DOI 10.1016/j.pec.2016.04.007
   Lacey Rebecca E, 2019, Psychol Med, V49, P1652, DOI 10.1017/S0033291718002222
   Lai DWL, 2009, SOC WORK HEALTH CARE, V48, P432, DOI 10.1080/00981380802591759
   LAWTON MP, 1991, J GERONTOL, V46, pP181, DOI 10.1093/geronj/46.4.P181
   Lazarus RS, 1984, STRESS APPRAISAL COP
   Li CY, 2013, AGING MENT HEALTH, V17, P924, DOI 10.1080/13607863.2013.814098
   Liu HY, 2017, J ADV NURS, V73, P2962, DOI 10.1111/jan.13379
   Liu J, 2012, ARCH GERONTOL GERIAT, V55, P560, DOI 10.1016/j.archger.2012.05.014
   Loh AZ, 2017, J AM MED DIR ASSOC, V18, P111, DOI 10.1016/j.jamda.2016.08.014
   Lopez-Martinez C, 2019, GAC SANIT, V33, P185, DOI 10.1016/j.gaceta.2017.09.005
   Luther K, 2014, THESIS
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Mausbach BT, 2012, AGING MENT HEALTH, V16, P27, DOI 10.1080/13607863.2011.615738
   McCullagh E, 2005, STROKE, V36, P2181, DOI 10.1161/01.STR.0000181755.23914.53
   Meader N, 2014, SYST REV, V3, DOI 10.1186/2046-4053-3-82
   Medrano Martin, 2014, Dement. neuropsychol., V8, P384, DOI 10.1590/S1980-57642014DN84000013
   Mohamed S, 2010, AM J GERIAT PSYCHIAT, V18, P917, DOI 10.1097/JGP.0b013e3181d5745d
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Morlett Paredes A, 2014, THESIS
   OECD, 2017, HLTH GLANC 2017 OECD
   Ornstein K, 2012, INT PSYCHOGERIATR, V24, P1536, DOI 10.1017/S1041610212000737
   Parker LD, 2007, THESIS
   Pinquart M, 2003, J GERONTOL B-PSYCHOL, V58, pP112, DOI 10.1093/geronb/58.2.P112
   Powers SM, 2014, THESIS
   Raveis VH, 1998, CANCER, V83, P1652, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1652::AID-CNCR22>3.3.CO;2-H
   Robinson Shurgot GS, 2005, J MENTAL HLTH AGING, V3, P37
   Roche L, 2015, J GERIATR PSYCH NEUR, V28, P218, DOI 10.1177/0891988715588830
   Roe B, 2007, REVIEWING RESEARCH EVIDENCE FOR NURSING PRACTICE: SYSTEMATIC REVIEWS, P9, DOI 10.1002/9780470692127.ch2
   Romero-Moreno R, 2011, AGING MENT HEALTH, V15, P221, DOI 10.1080/13607863.2010.505231
   Rothman KJ, 2008, MODERN EPIDEMIOLOGY
   Schoenmakers B, 2010, MATURITAS, V66, P191, DOI 10.1016/j.maturitas.2010.02.009
   Sherwood PR, 2005, J AGING HEALTH, V17, P125, DOI 10.1177/0898264304274179
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sutter M, 2016, J TRANSCULT NURS, V27, P376, DOI 10.1177/1043659615573081
   van der Lee J, 2014, AGEING RES REV, V15, P76, DOI 10.1016/j.arr.2014.03.003
   Viswanathan M, 2013, ASSESSING RISK BIAS
   VITALIANO PP, 1991, PSYCHOL AGING, V6, P392, DOI 10.1037/0882-7974.6.3.392
   Vogeli C, 2007, J GEN INTERN MED, V22, P391, DOI 10.1007/s11606-007-0322-1
   Wang W., 2017, J TEXTURE STUD, V10, P1111
   Watson B, 2018, GERONTOLOGIST
   Williams Francesca, 2018, Aging Ment Health, P1, DOI 10.1080/13607863.2018.1515886
   Yates ME, 1999, J GERONTOL B-PSYCHOL, V54, pP12, DOI 10.1093/geronb/54B.1.P12
   ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649
   Zhu W, 2018, J STROKE CEREBROVASC, V27, P3636, DOI 10.1016/j.jstrokecerebrovasdis.2018.08.037
NR 99
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2019
VL 14
IS 5
AR e0217648
DI 10.1371/journal.pone.0217648
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IA1LO
UT WOS:000469323000073
PM 31141556
OA DOAJ Gold
DA 2019-07-16
ER

PT J
AU van Aert, RCM
   Wicherts, JM
   van Assen, MALM
AF van Aert, Robbie C. M.
   Wicherts, Jelte M.
   van Assen, Marcel A. L. M.
TI Publication bias examined in meta-analyses from psychology and medicine:
   A meta-meta-analysis
SO PLOS ONE
LA English
DT Article
ID BETWEEN-STUDY HETEROGENEITY; ESTIMATING EFFECT SIZE;
   PREDICTIVE-DISTRIBUTIONS; CONDUCTING METAANALYSES; STATISTICAL TESTS;
   JUDGMENT CALLS; FUNNEL-PLOT; FILL METHOD; PREVALENCE; SCIENCE
AB Publication bias is a substantial problem for the credibility of research in general and of meta-analyses in particular, as it yields overestimated effects and may suggest the existence of non-existing effects. Although there is consensus that publication bias exists, how strongly it affects different scientific literatures is currently less well-known. We examined evidence of publication bias in a large-scale data set of primary studies that were included in 83 meta-analyses published in Psychological Bulletin (representing meta-analyses from psychology) and 499 systematic reviews from the Cochrane Database of Systematic Reviews (CDSR; representing meta-analyses from medicine). Publication bias was assessed on all homogeneous subsets (3.8% of all subsets of meta-analyses published in Psychological Bulletin) of primary studies included in meta-analyses, because publication bias methods do not have good statistical properties if the true effect size is heterogeneous. Publication bias tests did not reveal evidence for bias in the homogeneous subsets. Overestimation was minimal but statistically significant, providing evidence of publication bias that appeared to be similar in both fields. However, a Monte-Carlo simulation study revealed that the creation of homogeneous subsets resulted in challenging conditions for publication bias methods since the number of effect sizes in a subset was rather small (median number of effect sizes equaled 6). Our findings are in line with, in its most extreme case, publication bias ranging from no bias until only 5% statistically nonsignificant effect sizes being published. These and other findings, in combination with the small percentages of statistically significant primary effect sizes (28.9% and 18.9% for subsets published in Psychological Bulletin and CDSR), led to the conclusion that evidence for publication bias in the studied homogeneous subsets is weak, but suggestive of mild publication bias in both psychology and medicine.
C1 [van Aert, Robbie C. M.; Wicherts, Jelte M.; van Assen, Marcel A. L. M.] Tilburg Univ, Dept Methodol & Stat, Tilburg, Netherlands.
   [van Assen, Marcel A. L. M.] Univ Utrecht, Dept Sociol, Utrecht, Netherlands.
RP van Aert, RCM (reprint author), Tilburg Univ, Dept Methodol & Stat, Tilburg, Netherlands.
EM R.C.M.vanAert@tilburguniversity.edu
RI Wicherts, Jelte/A-2664-2008
OI Wicherts, Jelte/0000-0003-2415-2933
FU Netherlands Organization for Scientific Research (NWO) [406-13-050];
   Berkeley Initiative for Transparency in the Social Sciences; Laura and
   John Arnold Foundation; European Research Council [726361]
FX RvA received Grant number: 406-13-050 from The Netherlands Organization
   for Scientific Research (NWO), URL funder website: www.nwo.nl. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. RvA also received
   funding from Berkeley Initiative for Transparency in the Social Sciences
   and the Laura and John Arnold Foundation, URL funder website:
   www.bitss.org. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript. JW
   received Grant number: 726361 (IMPROVE) from The European Research
   Council, URL funder website: www.erc.europa.eu. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aarts AA, 2015, SCIENCE, V349, DOI 10.1126/science.aac4716
   Aguinis H, 2011, J MANAGE, V37, P5, DOI 10.1177/0149206310377113
   Alinaghi N, 2018, RES SYNTH METHODS, V9, P285, DOI 10.1002/jrsm.1298
   Anderson SF, 2017, PSYCHOL SCI, V28, P1547, DOI 10.1177/0956797617723724
   Augusteijn HEM, PSYCHOL METHODS
   Auspurg K, 2014, KOLNER Z SOZIOL SOZ, V66, P549, DOI 10.1007/s11577-014-0284-3
   Aytug ZG, 2012, ORGAN RES METHODS, V15, P103, DOI 10.1177/1094428111403495
   Bakker M, 2012, PERSPECT PSYCHOL SCI, V7, P543, DOI 10.1177/1745691612459060
   Banks GC, 2012, EDUC EVAL POLICY AN, V34, P259, DOI 10.3102/0162373712446144
   Banks GC, 2012, INT J SELECT ASSESS, V20, P182, DOI 10.1111/j.1468-2389.2012.00591.x
   Becker BJ, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P111
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Borenstein M., 2009, HDB RES SYNTHESIS ME, P221
   Borenstein M., 2009, INTRO METAANALYSIS
   Bouter Lex M, 2016, Res Integr Peer Rev, V1, P17, DOI 10.1186/s41073-016-0024-5
   Brodeur A, 2016, AM ECON J-APPL ECON, V8, P1, DOI 10.1257/app.20150044
   Carter E, 2018, CORRECTING BIAS PSYC
   Citkowicz M, 2017, PSYCHOL METHODS, V22, P28, DOI 10.1037/met0000119
   Coburn KM, 2015, PSYCHOL METHODS, V20, P310, DOI 10.1037/met0000046
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   COHEN J, 1990, AM PSYCHOL, V45, P1304, DOI 10.1037/0003-066X.45.12.1304
   Cohen J, 1988, STAT POWER ANAL BEHA
   Cooper H, 1997, PSYCHOL METHODS, V2, P447
   Copas J, 1999, J R STAT SOC A STAT, V162, P95, DOI 10.1111/1467-985X.00123
   COURSOL A, 1986, PROF PSYCHOL-RES PR, V17, P136, DOI 10.1037/0735-7028.17.2.136
   Dear KB, 1992, STAT SCI, V7, P237, DOI DOI 10.1214/SS/1177011363
   DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3
   Dickersin K, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P11
   Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Else-Quest NM, 2006, PSYCHOL BULL, V132, P33, DOI 10.1037/0033-2909.132.1.33
   Fanelli D, 2017, P NATL ACAD SCI USA, V114, P3714, DOI 10.1073/pnas.1618569114
   Fanelli D, 2013, P NATL ACAD SCI USA, V110, P15031, DOI 10.1073/pnas.1302997110
   Fanelli D, 2012, SCIENTOMETRICS, V90, P891, DOI 10.1007/s11192-011-0494-7
   Fanelli D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010068
   Ferguson CJ, 2012, PSYCHOL METHODS, V17, P120, DOI 10.1037/a0024445
   Field AP, 2010, BRIT J MATH STAT PSY, V63, P665, DOI 10.1348/000711010X502733
   Fleiss J. L, 2009, HDB RES SYNTHESIS ME, P237
   Francis G, 2013, J MATH PSYCHOL, V57, P153, DOI 10.1016/j.jmp.2013.02.003
   Franco A, 2016, SOC PSYCHOL PERS SCI, V7, P8, DOI 10.1177/1948550615598377
   Franco A, 2014, SCIENCE, V345, P1502, DOI 10.1126/science.1255484
   Glass G.V., 1976, EDUC RES, V5, P3, DOI [DOI 10.3102/0013189X005010003, 10.3102/0013189X005010003, 10.3102/0013189x005010003]
   Guan M, 2016, PSYCHON B REV, V23, P74, DOI 10.3758/s13423-015-0868-6
   Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D
   Hartgerink CHJ, 2017, PEERJ, V5, DOI 10.7717/peerj.3068
   Hartgerink CHJ, 2016, PEERJ, V4, DOI 10.7717/peerj.1935
   Head ML, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002106
   Hedges L. V., 1984, J EDUC STATIST, V9, P61, DOI DOI 10.3102/10769986009001061
   Hedges LV, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P145
   HEDGES LV, 1992, STAT SCI, V7, P246, DOI DOI 10.1214/SS/1177011364
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2008, INT J EPIDEMIOL, V37, P1158, DOI 10.1093/ije/dyn204
   Hopewell S, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P49, DOI 10.1002/0470870168.ch4
   Ioannidis JPA, 2008, EPIDEMIOLOGY, V19, P640, DOI 10.1097/EDE.0b013e31818131e7
   Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80
   Ioannidis JPA, 2007, CLIN TRIALS, V4, P245, DOI 10.1177/1740774507079441
   Ioannidis JPA, 2007, CAN MED ASSOC J, V176, P1091, DOI 10.1503/cmaj.060410
   Ioannidis JPA, 2006, J CLIN EPIDEMIOL, V59, P1023, DOI 10.1016/j.jclinepi.2006.02.013
   Iyengar S., 1988, STAT SCI, V3, P133, DOI [10.1214/ss/1177013019, DOI 10.1214/SS/1177013019]
   Iyengar Shanto, 1988, STAT SCI, V3, P109, DOI DOI 10.1214/SS/1177013012
   Jackson D, 2006, STAT MED, V25, P2911, DOI 10.1002/sim.2293
   Jackson D, 2012, STAT MED, V31, P3805, DOI 10.1002/sim.5453
   Jager LR, 2014, BIOSTATISTICS, V15, P1, DOI 10.1093/biostatistics/kxt007
   Jones CW, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6104
   Jurgens G, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004022.pub2CD004022, DOI 10.1002/14651858.CD004022.PUB2CD004022]
   Kepes S, 2012, ORGAN RES METHODS, V15, P624, DOI 10.1177/1094428112452760
   Kirkham JJ, 2010, BMJ-BRIT MED J, V340, pc365, DOI DOI 10.1136/BMJ.C365
   Klein R. A., 2018, ADV METHODS PRACT PS, V1, P443, DOI [10.1177/2515245918810225, DOI 10.1177/2515245918810225]
   Koenker R, 2005, QUANTILE REGRESSION
   Krawczyk M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127872
   LANE DM, 1978, BRIT J MATH STAT PSY, V31, P107, DOI 10.1111/j.2044-8317.1978.tb00578.x
   Langan D, 2017, RES SYNTH METHODS, V8, P181, DOI 10.1002/jrsm.1198
   Light RJ, 1984, SUMMING SCI REV RES
   LOEVINGER J, 1948, PSYCHOL BULL, V45, P507, DOI 10.1037/h0055827
   Macaskill P, 2001, STAT MED, V20, P641, DOI 10.1002/sim.698
   McShane BB, 2016, PERSPECT PSYCHOL SCI, V11, P730, DOI 10.1177/1745691616662243
   Moreno SG, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-2
   Nuijten MB, 2015, REV GEN PSYCHOL, V19, P172, DOI 10.1037/gpr0000034
   Olsson-Collentine A, 2019, LTD EVIDENCE W UNPUB
   PAULE RC, 1982, J RES NAT BUR STAND, V87, P377, DOI 10.6028/jres.087.022
   Peters JL, 2007, STAT MED, V26, P4544, DOI 10.1002/sim.2889
   R Core Team, 2018, R LANG ENV STAT COMP
   Raudenbush SW, 2009, HDB RES SYNTHESIS ME, V2, P295
   Reed WR, 2015, ECONOMICS-KIEL, V9, DOI 10.5018/economics-ejournal.ja.2015-30
   Rhodes KM, 2015, J CLIN EPIDEMIOL, V68, P52, DOI 10.1016/j.jclinepi.2014.08.012
   ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638
   Rothstein HR, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P1
   Rothstein HR, 2012, PSYCHOL METHODS, V17, P129, DOI 10.1037/a0027128
   Rucker G, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-79
   Simonsohn U, 2014, PERSPECT PSYCHOL SCI, V9, P666, DOI 10.1177/1745691614553988
   Song F, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14080
   Springate DA, 2014, COCHRANE SCRAPER TOO
   Stanley TD, 2017, SOC PSYCHOL PERS SCI, V8, P581, DOI 10.1177/1948550617693062
   Stanley TD, 2017, STAT MED, V36, P1580, DOI 10.1002/sim.7228
   Stanley TD, 2014, RES SYNTH METHODS, V5, P60, DOI 10.1002/jrsm.1095
   Stanley TD, 2010, AM STAT, V64, P70, DOI 10.1198/tast.2009.08205
   STERLING TD, 1995, AM STAT, V49, P108, DOI 10.2307/2684823
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002
   Sutton AJ, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P175
   Terrin N, 2005, J CLIN EPIDEMIOL, V58, P894, DOI 10.1016/j.jclinepi.2005.01.006
   Terrin N, 2003, STAT MED, V22, P2113, DOI 10.1002/sim.1461
   Turner RM, 2015, STAT MED, V34, P984, DOI 10.1002/sim.6381
   van Aert RCM, 2018, PUNIFORM METAANALYSI
   van Aert RCM, CORRECTING PUB UNPUB
   van Aert RCM, 2018, BEHAV RES METHODS, V50, P1515, DOI 10.3758/s13428-017-0967-6
   van Aert RCM, 2016, PERSPECT PSYCHOL SCI, V11, P713, DOI 10.1177/1745691616650874
   van Assen MALM, 2015, PSYCHOL METHODS, V20, P293, DOI 10.1037/met0000025
   Veroniki AA, 2016, RES SYNTH METHODS, V7, P55, DOI 10.1002/jrsm.1164
   Vevea JL, 2005, PSYCHOL METHODS, V10, P428, DOI 10.1037/1082-989X.10.4.428
   VEVEA JL, 1995, PSYCHOMETRIKA, V60, P419, DOI 10.1007/BF02294384
   Viechtbauer W, 2007, BRIT J MATH STAT PSY, V60, P29, DOI 10.1348/000711005X64042
   Viechtbauer W, 2007, J EDUC BEHAV STAT, V32, P39, DOI 10.3102/1076998606298034
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1
   von Hippel PT, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0024-z
NR 117
TC 1
Z9 1
U1 5
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 12
PY 2019
VL 14
IS 4
AR e0215052
DI 10.1371/journal.pone.0215052
PG 32
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HT1UC
UT WOS:000464349000032
PM 30978228
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, J
   Chen, YL
   Xu, WH
   Lu, NF
   Cao, J
   Yu, SY
AF Wang, Jing
   Chen, Yalei
   Xu, Weihao
   Lu, Nianfang
   Cao, Jian
   Yu, Shengyuan
TI Effects of intensive blood pressure lowering on mortality and
   cardiovascular and renal outcomes in type 2 diabetic patients: A
   meta-analysis
SO PLOS ONE
LA English
DT Article
ID ISOLATED SYSTOLIC HYPERTENSION; MICROVASCULAR COMPLICATIONS; RISK;
   GUIDELINES; STROKE; TRIAL; PREVALENCE; PREVENTION; MANAGEMENT; VALSARTAN
AB Background
   Previous studies have demonstrated that intensive blood pressure (BP) lowering treatment reduces the risk of all-cause mortality and provides greater vascular protection for patients with hypertension. Whether intensive BP lowering treatment is associated with such benefits in patients with type 2 diabetes mellitus remain unknown. We aimed to clarify these benefits by method of meta-analysis.
   Methods
   The PubMed, EMBASE, Science Citation Index and Cochrane Library databases were searched to identify randomized controlled trials (RCT) that fulfilled study inclusion criteria. Two investigators independently extracted and summarized the relevant data of the included trials. Random-effects model was applied to calculate the estimates of all effect measures.
   Results
   We included 16 RCTs and our meta-analysis showed that intensive BP lowering treatment vs less intensive BP lowering treatment resulted in significant reductions in the all-cause mortality risk [relative risk (RR), 0.82; 95% CI, 0.70-0.96], major CV events (RR, 0.82; 95% CI, 0.73-0.92, MI (RR, 0.86; 95% CI, 0.77-0.96), stroke (RR, 0.72; 95% CI, 0.60-0.88, CV death (RR, 0.73; 95% CI, 0.58-0.92) and albuminuria progression (RR, 0.91 95% CI, 0.84-0.98). However, intensive BP lowering treatment had no clear effect on non-CV death (RR, 0.97; 95% CI, 0.79-1.20), heart failure (HF) (RR, 0.88; 95% CI, 0.71-1.08) or end-stage kidney disease (ESKD) (RR, 1.00; 95% CI, 0.75-1.33). Subgroup analysis showed that the reduction in all cause-mortality was consistent across most patient groups, and intensive BP lowering treatment had a clear benefit even in patients with systolic blood pressure lower than 140 mm Hg. However, the benefit differed in patients with different CV risk (>= 10%: RR, 0.77, 95% CI, 0.64-0.91; < 10%: RR, 1.04, 95% CI, 0.84-1.29; P-hetero = 0.028).
   Conclusions
   Our data indicate that intensive BP lowering treatment provides greater benefits than less intensive treatment among patients with type 2 diabetes mellitus. Further studies are required to more clearly evaluate the benefits and harms of BP targets below those currently recommended with intensive BP lowering treatment.
C1 [Wang, Jing; Yu, Shengyuan] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Neurol, Beijing, Peoples R China.
   [Wang, Jing; Yu, Shengyuan] Nankai Univ, Sch Med, Tianjin, Peoples R China.
   [Chen, Yalei; Lu, Nianfang] Beijing Elect Power Hosp, Dept Crit Care Med, Beijing, Peoples R China.
   [Xu, Weihao; Cao, Jian] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 2, Geriatr Cardiol Dept, Beijing, Peoples R China.
   [Xu, Weihao; Cao, Jian] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China.
RP Yu, SY (reprint author), Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Neurol, Beijing, Peoples R China.; Yu, SY (reprint author), Nankai Univ, Sch Med, Tianjin, Peoples R China.; Cao, J (reprint author), Chinese Peoples Liberat Army Gen Hosp, Med Ctr 2, Geriatr Cardiol Dept, Beijing, Peoples R China.; Cao, J (reprint author), Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China.
EM caojian301@hotmail.com; 1124187485@qq.com
FU Special Project of Healthcare Scientific Research of Military [16BJZ15]
FX This work was supported by Special Project of Healthcare Scientific
   Research of Military, author: CJ, Grant number: 16BJZ15. The funder had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR AMERY A, 1985, LANCET, V1, P1349
   Assmann G, 2002, CIRCULATION, V105, P310, DOI 10.1161/hc0302.102575
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benavente OR, 2013, LANCET, V382, P507, DOI 10.1016/S0140-6736(13)60852-1
   Berthet K, 2004, BLOOD PRESSURE, V13, P7, DOI 10.1080/08037050410029605
   Brunstrom M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i717
   Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886
   Cushman WC, 2010, NEW ENGL J MED, V362, P1575, DOI 10.1056/NEJMoa1001286
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Emdin CA, 2015, JAMA-J AM MED ASSOC, V313, P603, DOI 10.1001/jama.2014.18574
   Estacio RO, 2006, AM J HYPERTENS, V19, P1241, DOI 10.1016/j.amjhyper.2006.05.011
   Estacio RO, 2000, DIABETES CARE, V23, pB54
   Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   James PA, 2014, JAMA-J AM MED ASSOC, V311, P1809, DOI 10.1001/jama.2013.284427
   Jatos Study Grp, 2008, HYPERTENS RES, V31, P2115, DOI 10.1291/hypres.31.2115
   Malhotra R, 2017, JAMA INTERN MED, V177, P1498, DOI 10.1001/jamainternmed.2017.4377
   Mancia G, 2007, J HYPERTENS, V25, P1751, DOI 10.1097/HJH.0b013e3282f0580f
   Mancia G, 2013, EUR HEART J, V34, P2159, DOI [10.1093/eurheartj/eht151, 10.1097/01.hjh.0000431740.32696.cc]
   Moher D, 2015, SYST REV, V4, DOI 10.1186/2046-4053-4-1
   Nerenberg KA, 2018, CAN J CARDIOL, V34, P506, DOI 10.1016/j.cjca.2018.02.022
   Ogihara T, 2010, HYPERTENSION, V56, P196, DOI 10.1161/HYPERTENSIONAHA.109.146035
   Patel A, 2007, LANCET, V370, P829, DOI 10.1016/S0140-6736(07)61303-8
   Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI [10.1093/eurheartj/ehw106, 10.1016/j.rec.2016.09.009]
   Reboldi G, 2011, J HYPERTENS, V29, P1253, DOI 10.1097/HJH.0b013e3283469976
   Schrier RW, 2002, KIDNEY INT, V61, P1086, DOI 10.1046/j.1523-1755.2002.00213.x
   STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Thomopoulos C, 2017, J HYPERTENS, V35, P922, DOI 10.1097/HJH.0000000000001276
   Thomopoulos C, 2014, J HYPERTENS, V32, P2305, DOI 10.1097/HJH.0000000000000380
   Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902
   Wang JG, 2000, ARCH INTERN MED, V160, P211, DOI 10.1001/archinte.160.2.211
   Whelton PK, 2018, J AM COLL CARDIOL, V71, pE127, DOI 10.1016/j.jacc.2017.11.006
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Woodward M, 2003, DIABETES CARE, V26, P360
   Wright JT, 2015, NEW ENGL J MED, V373, P2103, DOI 10.1056/NEJMoa1511939
   Wright RA, 1997, JAMA-J AM MED ASSOC, V277, P157
   Xie XF, 2016, LANCET, V387, P435, DOI 10.1016/S0140-6736(15)00805-3
   Xu Y, 2013, JAMA-J AM MED ASSOC, V310, P948, DOI 10.1001/jama.2013.168118
NR 40
TC 0
Z9 0
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 12
PY 2019
VL 14
IS 4
AR e0215362
DI 10.1371/journal.pone.0215362
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HT1UC
UT WOS:000464349000056
PM 30978254
OA DOAJ Gold
DA 2019-07-16
ER

PT J
AU Sabarimurugan, S
   Kumarasamy, C
   Baxi, S
   Devi, A
   Jayaraj, R
AF Sabarimurugan, Shanthi
   Kumarasamy, Chellan
   Baxi, Siddhartha
   Devi, Arikketh
   Jayaraj, Rama
TI Systematic review and meta-analysis of prognostic microRNA biomarkers
   for survival outcome in nasopharyngeal carcinoma
SO PLOS ONE
LA English
DT Review
ID DIAGNOSTIC-TEST ACCURACY; THERAPEUTIC TARGETS; POOR-PROGNOSIS;
   UP-REGULATION; CANCER; PROLIFERATION; METASTASIS; BIOGENESIS;
   EXPRESSION; INVASION
AB Background
   Nasopharyngeal cancer (NPC), despite being one of the most malignant head and neck carcinomas (HNC), lacks comprehensive prognostic biomarkers that predict patient survival. Therefore, this systematic review and meta-analysis is aimed to evaluate the potential prognostic value of miRNAs as prognostic biomarkers in NPC.
   Methods
   PRISMA guidelines were used to conduct this systematic review and meta-analysis study. Permutations of multiple " search key-words" were used for the search strategy, which was limited to articles published between January 2012 and March 2018. The retrieved articles were meticulously searched with multi-level screening by two reviewers and confirmed by other reviewers. Meta-analysis was performed using Hazard Ratios (HR) and associated 95% Confidence Interval (CI) of survival obtained from previously published studies. Publication bias was assessed by Egger's bias indicator test and funnel plot symmetry.
   Results
   A total of 5069 patients across 21 studies were considered eligible for inclusion in the systematic review, with 65 miRNAs being evaluated in the subsequent meta-analysis. Most articles included in this study originated from China and one study from North Africa. The forest plot was generated using cumulated survival data, resulting in a pooled HR value of 1.196 (95% CI: 0.893-1.601) indicating that the upregulated miRNAs increased the likelihood of death of NPC patients by 19%.
   Conclusion
   To our knowledge, this is the first meta-analysis that examines the prognostic effectiveness of miRNAs as biomarkers in NPC patients. We noted that the combined effect estimate of HR across multiple studies indicated that increased miRNA expression in NPC potentially leads to poor overall survival. However, further large-scale prospective studies on the clinical significance of the miRNAs, with sizable cohorts are necessary in order to obtain conclusive results.
C1 [Sabarimurugan, Shanthi] VIT, Sch Biosci & Technol, Vellore, Tamil Nadu, India.
   [Kumarasamy, Chellan] Univ Adelaide, North Terrace Campus, Adelaide, SA, Australia.
   [Baxi, Siddhartha] Genesis Cancer Care Ctr, Bunbury, WA, Australia.
   [Devi, Arikketh] SRM Inst Sci & Technol, Dept Genet Engn, Kattangulathur, Tamil Nadu, India.
   [Jayaraj, Rama] Charles Darwin Univ, Coll Hlth & Human Sci, Clin Sci, Ellengowan Dr, Casuarina, NT, Australia.
RP Jayaraj, R (reprint author), Charles Darwin Univ, Coll Hlth & Human Sci, Clin Sci, Ellengowan Dr, Casuarina, NT, Australia.
EM Rama.Jayaraj@cdu.edu.au
RI ; Jayaraj, Rama/A-6526-2012
OI Sabarimurugan, Shanthi/0000-0003-2247-3426; ARIKKETH,
   DEVI/0000-0002-8542-3760; Jayaraj, Rama/0000-0002-2179-0510
CR Allaya N, 2015, TUMOR BIOL, V36, P3807, DOI 10.1007/s13277-014-3022-6
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bruce JP, 2015, J CLIN ONCOL, V33, P3346, DOI 10.1200/JCO.2015.60.7846
   Bruce JP, 2014, CHIN J CANCER, V33, P539, DOI 10.5732/cjc.014.10175
   Cao Su-Mei, 2011, Chin J Cancer, V30, P114
   Chang ET, 2006, CANCER EPIDEM BIOMAR, V15, P1765, DOI 10.1158/1055-9965.EPI-06-0353
   Chen C, 2016, CANCER MED-US, V5, P3489, DOI 10.1002/cam4.863
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farias TP, 2003, ARCH OTOLARYNGOL, V129, P794, DOI 10.1001/archotol.129.7.794
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   He ML, 2012, BBA-REV CANCER, V1825, P1, DOI 10.1016/j.bbcan.2011.09.001
   He Y, 2017, INT J CLIN EXP PATHO, V10, P7362
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Huang T, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0465-1
   Jamali Z, 2015, ORAL ONCOL, V51, P321, DOI 10.1016/j.oraloncology.2015.01.008
   Jayaraj R, 2018, CANCER MANAG RES, V10, P4669, DOI 10.2147/CMAR.S183181
   Jayaraj R, 2018, CANCER MANAG RES, V10, P3501, DOI 10.2147/CMAR.S177875
   Kim KW, 2015, KOREAN J RADIOL, V16, P1175, DOI 10.3348/kjr.2015.16.6.1175
   Kim YH, 2017, ONCOTARGET, V8, P8726, DOI 10.18632/oncotarget.14429
   Kumarasamy C, 2018, SYST REV, V7, DOI 10.1186/s13643-018-0812-8
   Lages E, 2012, FRONT BIOSCI-LANDMRK, V17, P2508, DOI 10.2741/4068
   Lee KTW, 2016, CRIT REV ONCOL HEMAT, V103, P1, DOI 10.1016/j.critrevonc.2016.04.006
   Liang SQ, 2016, DIS MARKERS, DOI 10.1155/2016/7648215
   Liu N, 2014, INT J CANCER, V134, P1359, DOI 10.1002/ijc.28468
   Liu N, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-123
   Liu N, 2013, CANCER LETT, V329, P181, DOI 10.1016/j.canlet.2012.10.032
   Liu N, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70102-X
   Long MJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016582
   Luan JW, 2016, ONCOTARGET, V7, P10513, DOI 10.18632/oncotarget.7013
   Lubov J, 2017, ONCOTARGET, V8, P55511, DOI 10.18632/oncotarget.19224
   Luo ZH, 2013, CARCINOGENESIS, V34, P415, DOI 10.1093/carcin/bgs329
   Ma L, 2014, FEBS LETT, V588, P1562, DOI 10.1016/j.febslet.2014.02.039
   Mahdavifar Neda, 2016, Osong Public Health Res Perspect, V7, P360, DOI 10.1016/j.phrp.2016.11.002
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Poddar A, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020014
   ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638
   Sabarimurugan S, 2018, MOL DIAGN THER, V22, P653, DOI 10.1007/s40291-018-0357-5
   Spence T, 2016, CHIN CLIN ONCOL, V5, DOI 10.21037/cco.2016.03.09
   Tan GJ, 2015, TUMOR BIOL, V36, P69, DOI 10.1007/s13277-014-2847-3
   Wang HY, 2014, CLIN CHEM, V60, P773, DOI 10.1373/clinchem.2013.214213
   Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6
   Xie SH, 2013, EUR J CANCER, V49, P150, DOI 10.1016/j.ejca.2012.07.004
   Xu XL, 2014, ANN THORAC SURG, V97, P1037, DOI 10.1016/j.athoracsur.2013.10.042
   Yu MC, 2002, SEMIN CANCER BIOL, V12, P421, DOI 10.1016/S1044-579X(02)00085-8
   Yu QS, 2015, INT J CLIN EXP MED, V8, P13296
   YU X, 2013, CELL DEATH DIS, V4
   Zeng X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046367
   Zhang AQ, 2017, ONCOTARGETS THER, V10, P4935, DOI 10.2147/OTT.S144223
   Zhang HX, 2016, ONCOTARGETS THER, V9, P3579, DOI 10.2147/OTT.S105470
   Zhao C, 2017, ONCOTARGET, V8, P91603, DOI 10.18632/oncotarget.21342
   Zhao MY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11309
   ZHEN Y, 2013, CELL DEATH DIS, V4
   Zheng J, 2013, CANCER RES, V73, P5151, DOI 10.1158/0008-5472.CAN-13-0395
NR 55
TC 1
Z9 1
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 8
PY 2019
VL 14
IS 2
AR e0209760
DI 10.1371/journal.pone.0209760
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HK7PK
UT WOS:000458181200011
PM 30735523
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Razi, B
   Reykandeh, SE
   Alizadeh, S
   Amirzargar, A
   Saghazadeh, A
   Rezaei, N
AF Razi, Bahman
   Reykandeh, Samira Esmaeili
   Alizadeh, Shahab
   Amirzargar, AliAkbar
   Saghazadeh, Amene
   Rezaei, Nima
TI TIM family gene polymorphism and susceptibility to rheumatoid arthritis:
   Systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID T-CELL IMMUNOGLOBULIN; MUCIN DOMAIN; ASSOCIATION; RISK; LOCUS;
   PHOSPHATIDYLSERINE; PROMOTER; IMMUNITY; ASTHMA; REGION
AB Background
   TIM-family proteins are expressed on different immune cells such as dendritic cells, macrophages, type 1 and 2 T helper (Th) cells. Therefore, they have the ability to contribute to the various intracellular signals and immune responses, importantly the regulation of Th1 and Th17 cell differentiation, which plays a remarked role in fight against inflammatory and autoimmune diseases. Association of TIM family gene polymorphisms with rheumatoid arthritis (RA) has been frequently investigated. The findings however are not entirely consistent. Therefore, we carried out the present meta-analysis to examine the association between RA and the following TIM family gene polymorphisms: rs41297579, rs1036199, rs10515746, and rs7700944.
   Methods
   A systematic search of Scopus, PubMed, and Web of Science databases was conducted through December 2018. Combined odds ratios (OR) with their corresponding 95% confidence intervals (CI) were calculated under different possible genetic models.
   Results
   A total of eight case-control studies were included in the present meta-analysis. The results demonstrated significant association of RA with TIM-3 rs1036199 polymorphism under dominant (OR, 1.93, 95% CI, 1.43-2.61) and allelic models (OR, 1.74, 95% CI, 1.31-2.30). None of the other examined polymorphisms indicated significant association with RA.
   Conclusions
   The present meta- analysis revealed that the TIM- 3 rs1036199 polymorphism might confer susceptibility to RA. Further studies are required to reassert our findings.
C1 [Razi, Bahman] Tehran Univ Med Sci, Sch Allied Med Sci, Dept Hematol & Blood Banking, Tehran, Iran.
   [Reykandeh, Samira Esmaeili; Amirzargar, AliAkbar] Tehran Univ Med Sci, Mol Immunol Res Ctr, Tehran, Iran.
   [Alizadeh, Shahab] Tehran Univ Med Sci, Sch Nutr Sci & Dietet, Dept Cellular & Mol Nutr, Tehran, Iran.
   [Amirzargar, AliAkbar; Rezaei, Nima] Tehran Univ Med Sci, Sch Med, Dept Immunol, Tehran, Iran.
   [Saghazadeh, Amene; Rezaei, Nima] Univ Tehran Med Sci, Childrens Med Ctr, Res Ctr Immunodeficiencies, Tehran, Iran.
   [Saghazadeh, Amene] USERN, SRMEG, Tehran, Iran.
   [Rezaei, Nima] USERN, NIIMA, Tehran, Iran.
RP Rezaei, N (reprint author), Tehran Univ Med Sci, Sch Med, Dept Immunol, Tehran, Iran.; Rezaei, N (reprint author), Univ Tehran Med Sci, Childrens Med Ctr, Res Ctr Immunodeficiencies, Tehran, Iran.; Rezaei, N (reprint author), USERN, NIIMA, Tehran, Iran.
EM rezaei_nima@tums.ac.ir
RI Rezaei, Nima/B-4245-2008
OI Rezaei, Nima/0000-0002-3836-1827
CR AMOS RS, 1977, BRIT MED J, V1, P195, DOI 10.1136/bmj.1.6055.195
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chae SC, 2005, IMMUNOGENETICS, V56, P696, DOI 10.1007/s00251-004-0743-5
   Chae SC, 2004, HUM IMMUNOL, V65, P1427, DOI 10.1016/j.humimm.2004.07.002
   Chae SC, 2004, IMMUNOL LETT, V95, P91, DOI 10.1016/j.imlet.2004.06.008
   Chae SC, 2003, HUM IMMUNOL, V64, P1177, DOI 10.1016/j.humimm.2003.09.011
   Cross M, 2014, ANN RHEUMATIC DIS
   de Rooy DPC, 2014, ANN RHEUM DIS, V73, P1163, DOI 10.1136/annrheumdis-2013-203375
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Freeman GJ, 2010, IMMUNOL REV, V235, P172, DOI 10.1111/j.0105-2896.2010.00903.x
   Gao PS, 2005, J ALLERGY CLIN IMMUN, V115, P982, DOI 10.1016/j.jaci.2005.01.035
   Gibofsky Allan, 2012, Am J Manag Care, V18, pS295
   Graves PE, 2005, J ALLERGY CLIN IMMUN, V116, P650, DOI 10.1016/j.jaci.2005.05.004
   Hofstra CL, 1998, J IMMUNOL, V161, P5054
   Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193
   Kobayashi N, 2007, IMMUNITY, V27, P927, DOI 10.1016/j.immuni.2007.11.011
   Kuchroo VK, 2003, NAT REV IMMUNOL, V3, P454, DOI 10.1038/nri1111
   LAWRENCE JS, 1958, ANN RHEUM DIS, V17, P160, DOI 10.1136/ard.17.2.160
   Li G, 2017, RHEUMATOL INT, P1
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   MacGregor AJ, 2000, ARTHRITIS RHEUM, V43, P30, DOI 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B
   Mazrouei F, 2016, INT J IMMUNOGENET, V43, P131, DOI 10.1111/iji.12264
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Mosaad YM, 2015, INT J IMMUNOGENET, V42, P254, DOI 10.1111/iji.12201
   Mou Z, 2010, J INVEST ALLERG CLIN, V20, P3
   Neidhart M, 2014, NAT REV RHEUMATOL, V10, P199, DOI 10.1038/nrrheum.2014.21
   NICHOLSON LB, 1995, IMMUNITY, V3, P397, DOI 10.1016/1074-7613(95)90169-8
   Okada Y, 2012, NAT GENET, V44, P511, DOI 10.1038/ng.2231
   Orozco G, 2014, ARTHRITIS RHEUMATOL, V66, P24, DOI 10.1002/art.38196
   Page NS, 2006, INT ARCH ALLERGY IMM, V141, P331, DOI 10.1159/000095459
   Rennert PD, 2011, IMMUNOL LETT, V141, P28, DOI 10.1016/j.imlet.2011.08.003
   Song YW, 2011, HUM IMMUNOL, V72, P652, DOI 10.1016/j.humimm.2011.04.007
   Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Symmons D, 2002, RHEUMATOLOGY, V41, P793, DOI 10.1093/rheumatology/41.7.793
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thatayatikom A, 2003, PEDIATRICS S2, V112, P470
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Xie XC, 2017, LUNG, V195, P353, DOI 10.1007/s00408-017-0006-5
   Xu J, 2012, INT J IMMUNOGENET, V39, P409, DOI 10.1111/j.1744-313X.2012.01103.x
   Xu J, 2011, INT J IMMUNOGENET, V38, P513, DOI 10.1111/j.1744-313X.2011.01046.x
   Xu JR, 2012, GENET MOL RES, V11, P61, DOI 10.4238/2012.January.9.7
   Yaghoobi E, 2016, IRAN J PUBLIC HEALTH, V45, P644
   You CG, 2007, CLIN CHEM LAB MED, V45, P968, DOI 10.1515/CCLM.2007.156
   Zakeri Z, 2013, REV BRAS REUMATOL, V53, P341, DOI 10.1590/S0482-50042013000400005
NR 48
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 7
PY 2019
VL 14
IS 2
AR e0211146
DI 10.1371/journal.pone.0211146
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HK5RX
UT WOS:000458026000015
PM 30730912
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Guo, BP
   Tan, XH
   Ke, Q
   Cen, H
AF Guo, Baoping
   Tan, Xiaohong
   Ke, Qing
   Cen, Hong
TI Prognostic value of baseline metabolic tumor volume and total lesion
   glycolysis in patients with lymphoma: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID B-CELL LYMPHOMA; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY;
   PROGRESSION-FREE SURVIVAL; F-18-FDG PET/CT; RESPONSE ASSESSMENT;
   HODGKIN-LYMPHOMA; FDG-PET/CT; FOLLICULAR LYMPHOMA; INTERIM; PREDICTOR
AB Whether baseline metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) measured by FDG-PET/CT affected prognosis of patients with lymphoma was controversial. We searched PubMed, EMBASE and Cochrane to identify studies assessing the effect of baseline TMTV and TLG on the survival of lymphoma patients. Pooled hazard ratios (HR) for overall survival (OS) and progression-free survival (PFS) were calculated, along with 95% confidence intervals (CI). Twenty-seven eligible studies including 2,729 patients were analysed. Patients with high baseline TMTV showed a worse prognosis with an HR of 3.05 (95% CI 2.55-3.64, p<0.00001) for PFS and an HR of 3.07 (95% CI 2.47-3.82, p<0.00001) for OS. Patients with high baseline TLG also showed a worse prognosis with an HR of 3.44 (95% CI 2.37-5.01, p<0.00001) for PFS and an HR of 3.08 (95% CI 1.84-5.16, p<0.00001) for OS. A high baseline TMTV was significantly associated with worse survival in DLBCL patients treated with R-CHOP (OS, pooled HR = 3.52; PFS, pooled HR = 2.93). A high baseline TLG was significantly associated with worse survival in DLBCL patients treated with R-CHOP (OS, pooled HR = 3.06; PFS, pooled HR = 2.93). The negative effect of high baseline TMTV on PFS was demonstrated in HL (pooled HR = 3.89). A high baseline TMTV was significantly associated with worse survival in ENKL patients (OS, pooled HR = 2.24; PFS, pooled HR = 3.25). A high baseline TLG was significantly associated with worse survival in ENKL patients (OS, pooled HR = 2.58; PFS, pooled HR = 2.99). High baseline TMTV or TLG predict significantly worse PFS and OS in patients with lymphoma. Future studies are warranted to explore whether TMTV or TLG could be integrated into various prognostic models for clinical decision making.
C1 [Cen, Hong] Guangxi Med Univ, Dept Chemotherapy, Guangxi Canc Hosp, Nanning, Guangxi, Peoples R China.
   Guangxi Med Univ, Affiliated Canc Hosp, Nanning, Guangxi, Peoples R China.
RP Cen, H (reprint author), Guangxi Med Univ, Dept Chemotherapy, Guangxi Canc Hosp, Nanning, Guangxi, Peoples R China.
EM cenhong01@163.com
CR Adams HJA, 2015, BRIT J HAEMATOL, V170, P356, DOI 10.1111/bjh.13441
   Adams HJA, 2015, BRIT J HAEMATOL, V170, P185, DOI 10.1111/bjh.13420
   Adams HJA, 2015, EUR J HAEMATOL, V94, P532, DOI 10.1111/ejh.12467
   Barrington SF, 2014, J CLIN ONCOL, V32, P3048, DOI 10.1200/JCO.2013.53.5229
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713
   Chang CC, 2017, ONCOTARGET, V8, P99587, DOI 10.18632/oncotarget.20447
   Chang Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep41057
   Cheson BD, MANAGEMENT OF HEMATO, P65, DOI [10.1182/blood-2007-06-095331, DOI 10.1182/BLOOD-2007-06-095331]
   Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800
   Cottereau AS, 2016, ANN ONCOL, V27, P719, DOI 10.1093/annonc/mdw011
   Cottereau AS, 2018, BLOOD, V131, P1456, DOI 10.1182/blood-2017-07-795476
   Delfau-Larue MH, 2018, BLOOD ADV, V2, P807, DOI 10.1182/bloodadvances.2017015164
   Ding C Y, 2018, Zhonghua Zhong Liu Za Zhi, V40, P528, DOI 10.3760/cma.j.issn.0253-3766.2018.07.009
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Galaly TC, 2015, AM J HEMATOL, V90, P975, DOI 10.1002/ajh.24128
   Esfahani SA, 2013, AM J NUCL MED MOLEC, V3, P272
   Gallamini A, 2004, BLOOD, V103, P2474, DOI 10.1182/blood-2003-09-3080
   Gallicchio R, 2014, EUR J HAEMATOL, V92, P382, DOI 10.1111/ejh.12268
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Hoster E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331
   Ilyas H, 2018, EUR J NUCL MED MOL I, V45, P1142, DOI 10.1007/s00259-018-3953-z
   Kanoun S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140830
   Kesavan M, 2017, DIAGNOSTICS, V7, DOI 10.3390/diagnostics7020026
   Kim CY, 2013, EUR J NUCL MED MOL I, V40, P1321, DOI 10.1007/s00259-013-2443-6
   Kim J, 2014, NUCL MED MOLEC IMAG, V48, P187, DOI 10.1007/s13139-014-0280-6
   Kim TM, 2013, CANCER-AM CANCER SOC, V119, P1195, DOI 10.1002/cncr.27855
   Kostakoglu L, 2018, SEMIN NUCL MED, V48, P50, DOI 10.1053/j.semnuclmed.2017.09.005
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Linet MS, 2016, INT J CANCER, V138, P1862, DOI 10.1002/ijc.29924
   Manohar K, 2012, NUCL MED COMMUN, V33, P974, DOI 10.1097/MNM.0b013e32835673ec
   Meignan M, 2016, J CLIN ONCOL, V34, P3618, DOI 10.1200/JCO.2016.66.9440
   Meignan M, 2014, EUR J NUCL MED MOL I, V41, P1113, DOI 10.1007/s00259-014-2705-y
   Mikhaeel NG, 2016, EUR J NUCL MED MOL I, V43, P1209, DOI 10.1007/s00259-016-3315-7
   Moccia AA, 2012, J CLIN ONCOL, V30, P3383, DOI 10.1200/JCO.2011.41.0910
   Oh MY, 2013, INT J HEMATOL, V97, P397, DOI 10.1007/s12185-013-1282-3
   Pak K, 2018, AM J OTOLARYNG, V39, P1, DOI 10.1016/j.amjoto.2017.10.009
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Sasanelli M, 2014, EUR J NUCL MED MOL I, V41, P2017, DOI 10.1007/s00259-014-2822-7
   Schoder H, 2016, J CLIN ONCOL, V34, P3591, DOI 10.1200/JCO.2016.69.3747
   Schoder H, 2016, J NUCL MED, V57, P728, DOI 10.2967/jnumed.115.166769
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Solal-Celigny P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434
   Song MK, 2017, ONCOTARGET, V8, P79337, DOI 10.18632/oncotarget.18107
   Song MK, 2016, LEUKEMIA RES, V42, P1, DOI 10.1016/j.leukres.2016.01.010
   Song MK, 2013, CANCER SCI, V104, P1656, DOI 10.1111/cas.12282
   Song MK, 2012, ANN HEMATOL, V91, P697, DOI 10.1007/s00277-011-1357-2
   Soret M, 2007, J NUCL MED, V48, P932, DOI 10.2967/jnumed.106.035774
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Swerdlow SC, 2017, WHO CLASSIFICATION T
   Toledano MN, 2018, EUR J NUCL MED MOL I, V45, P680, DOI 10.1007/s00259-017-3907-x
   Unal I, 2017, COMPUT MATH METHOD M, DOI 10.1155/2017/3762651
   Vaidya R, 2014, ANN ONCOL, V25, P2124, DOI 10.1093/annonc/mdu109
   Yu YT, 2018, COMPUT MED IMAG GRAP, V70, P1, DOI 10.1016/j.compmedimag.2018.09.001
   Zhou MG, 2016, ONCOTARGET, V7, P83544, DOI 10.18632/oncotarget.13180
NR 55
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 9
PY 2019
VL 14
IS 1
AR e0210224
DI 10.1371/journal.pone.0210224
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HG9VK
UT WOS:000455359400078
PM 30625203
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Boneya, DJ
   Ahmed, AA
   Yalew, AW
AF Boneya, Dube Jara
   Ahmed, Ahmed Ali
   Yalew, Alemayehu Worku
TI The effect of gender on food insecurity among HIV-infected people
   receiving anti-retroviral therapy: A systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID HIV/AIDS; INDIVIDUALS; ADHERENCE; SUPPRESSION; HOMELESS
AB Background
   HIV-infected adults receiving anti-retroviral therapy have a high prevalence of food insecurity in both high- and low-income settings., Women bear an inequitable burden of food insecurity due to lack of control over resources and over household food allocation decision making. The few studies conducted on the association between food insecurity and gender among HIV-infected adults have inconclusive findings. Therefore, the objective of this systematic review and meta-analysis was to estimate the pooled effect of gender on food insecurity among HIV-infected adults receiving antiretroviral therapy.
   Method
   We conducted an electronic, web-based search using PubMed, CINAHL, PopLine, MedNar, Embase, Cochrane library, the JBI Library, the Web of Science and Google Scholar. We included studies which reported the association between food insecurity and gender among HIV-infected adults receiving antiretroviral therapy whose age was greater than 18 years. The analysis was conducted using STATA 14 software. A random effects model was used to estimate the pooled effect a 95% confidence interval(CI). Forest plots were used to visualize the presence of heterogeneity. Funnel plots and Egger's and Begg's tests were used to check for publication bias.
   Results
   A total of 776 studies were identified of which seventeen studies were included in the meta analysis, with a total of 5827 HIV infected adults receiving antiretroviral therapy. We found that the gender of HIV-infected adults receiving anti-retroviral therapy had statistically significant effects on food insecurity. The pooled odds of developing food insecurity among female HIV infected adults receiving anti-retroviral therapy was 53% higher than male HIV infected adults (OR: 1.53, 95% CI: 1.29, 1.83). Our analysis indicate the findings of studies conducted in the high-income countries showed weakest associations between gender and food insecurity than those conducted in low- and middle-income countries.
   Conclusion
   Our systematic review and meta-analysis showed statistically significant effect of gender on food insecurity among HIV-infected adults receiving anti-retroviral therapy in which odds of food insecurity was higher among female HIV-infected adults compared to male HIV-infected adults. These findings suggest that the need to include within food and nutrition interventions for HIV-infected adults receiving antiretroviral treatment, culture- and context-specific gender-based policies to address the sex/gender related vulnerability to food insecurity.
C1 [Boneya, Dube Jara] Debre Markos Univ, Dept Publ Hlth, Coll Hlth Sci, Debre Markos, Ethiopia.
   [Boneya, Dube Jara; Ahmed, Ahmed Ali; Yalew, Alemayehu Worku] Addis Ababa Univ, Sch Publ Hlth, Dept Prevent Med, Coll Hlth Sci, Addis Ababa, Ethiopia.
RP Boneya, DJ (reprint author), Debre Markos Univ, Dept Publ Hlth, Coll Hlth Sci, Debre Markos, Ethiopia.; Boneya, DJ (reprint author), Addis Ababa Univ, Sch Publ Hlth, Dept Prevent Med, Coll Hlth Sci, Addis Ababa, Ethiopia.
EM jaradube@gmail.com
OI Jara, Dube/0000-0002-7095-9941
CR Aibibula W, 2017, AIDS BEHAV, V21, P754, DOI 10.1007/s10461-016-1605-5
   Anema A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157630
   Anema A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061277
   Anema Aranka, 2009, Curr HIV/AIDS Rep, V6, P224
   Asnakew M., 2015, OPEN ACCESS LIB J FO, V02, P1
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benzekri NA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141819
   Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12
   Chop E, 2017, HEALTH CARE WOMEN IN, V38, P927, DOI 10.1080/07399332.2017.1337774
   Coates J, 2007, HOUSEHOLD FOOD INSEC, P34
   Medeiros ARC, 2017, CIENC SAUDE COLETIVA, V22, P3353, DOI 10.1590/1413-812320172210.02462017
   Dasgupta Pallabi, 2016, J Prev Med Public Health, V49, P240, DOI 10.3961/jpmph.16.023
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Frankenberger T., 2007, FOOD ASSISTANCE PROG
   Frega R, 2010, FOOD NUTR BULL, V31, pS292, DOI 10.1177/15648265100314S402
   Gedle D., 2015, J NUTR FOOD SCI, V5, P2
   Gillespie S., 2005, HIV AIDS FOOD NUTR S, V7
   Heylen E, 2015, AIDS BEHAV, V19, P1548, DOI 10.1007/s10461-014-0966-x
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hong SY, 2014, JAIDS-J ACQ IMM DEF, V67, pE115, DOI 10.1097/QAI.0000000000000308
   Idrisov B, 2017, AIDS BEHAV, V21, P3486, DOI 10.1007/s10461-017-1885-4
   Institute JB, 2006, MET STAT ASS REV INS
   Joint United Nations Programme on HIV and AIDS (UNAIDS), 2017, UNAIDS DAT 2017
   Kalichman SC, 2014, J COMMUN HEALTH, V39, P1133, DOI 10.1007/s10900-014-9868-0
   Kalichman SC, 2014, J BEHAV MED, V37, P1009, DOI 10.1007/s10865-013-9536-3
   McMahon JH, 2011, JAIDS-J ACQ IMM DEF, V58, P60, DOI 10.1097/QAI.0b013e318227f8dd
   Mensa ZNBaM, 2017, GEN MED, V5, P3
   Moher D, 2009, PHYS THER, V89, P873
   Normen L, 2005, J NUTR, V135, P820
   Salvador Castell G, 2015, NUTR HOSP, V31
   Tiyou A, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-51
   Tsai AC, 2012, SOC SCI MED, V74, P2012, DOI 10.1016/j.socscimed.2012.02.033
   Weiser SD, 2015, FOOD INSECURITY HLTH
   Weiser SD, 2007, PLOS MED, V4, P1589, DOI 10.1371/journal.pmed.0040260
   Weiser SD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010340
   Weiser SD, 2009, AIDS BEHAV, V13, P841, DOI 10.1007/s10461-009-9597-z
   Weiser SD, 2009, J GEN INTERN MED, V24, P14, DOI 10.1007/s11606-008-0824-5
NR 37
TC 0
Z9 0
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 7
PY 2019
VL 14
IS 1
AR e0209903
DI 10.1371/journal.pone.0209903
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HG5UW
UT WOS:000455045900032
PM 30615692
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, TT
   Chen, ZH
   Dang, J
   Li, G
AF Liu, Tingting
   Chen, Zihao
   Dang, Jun
   Li, Guang
TI The role of surgery in stage I to III small cell lung cancer: A
   systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID PROPHYLACTIC CRANIAL IRRADIATION; NONSURGICAL MANAGEMENT; THORACIC
   RADIOTHERAPY; SURGICAL RESECTION; SURVIVAL OUTCOMES; EPIDEMIOLOGY;
   SURVEILLANCE; CHEMOTHERAPY; CARCINOMA; EFFICACY
AB Background
   The role of surgery in treating small cell lung cancer (SCLC) remains controversial. This meta-analysis aims to determine whether surgical-based treatment improves survival in comparison to radiotherapy, chemotherapy, and chemoradiotherapy for stage I to III SCLC.
   Methods
   PubMed, PubMed Central, EMBASE, Web of Science, and Cochrane Library were searched for relevant articles. The main outcome were overall survival (OS), reported as hazard ratios (HRs), and 95% confidence intervals (CIs).
   Results
   Two randomized control trials (RCTs) and 13 retrospective studies that included a total of 41,483 patients were eligible. Surgical resection significantly improved OS when compared to non-surgical treatment in retrospective studies (HR = 0.56, 95% CI: 0.49-0.64, P < 0.001), but not in the 2 "older" RCTs (HR = 0.77, 95% CI: 0.32-1.84, P = 0.55). In the subgroup analysis for retrospective studies, surgical resection was associated with superior OS in stage I (HR = 0.56, 95% CI: 0.49-0.64, P < 0.001), stage II (HR = 0.75, 95% CI: 0.570.99, P = 0.04), and stage III diseases (HR = 0.70, 95% CI: 0.56-0.88, P = 0.002). Sublobar resection resulted in worse OS than a lobectomy (HR = 0.64, 95% CI: 0.56-0.74, P < 0.001) for patients undergoing surgical resection.
   Conclusions
   Surgery-based multi-modality treatment appears to be associated with a favorable survival advantage in stage I and selected stage II to III SCLC. Lobectomy is likely to provide superior OS when compared to sublobar resection. Further prospective RCTs are needed to confirm these findings.
C1 [Liu, Tingting; Chen, Zihao; Dang, Jun; Li, Guang] China Med Univ, Hosp 1, Dept Radiat Oncol, Shenyang, Liaoning, Peoples R China.
RP Dang, J (reprint author), China Med Univ, Hosp 1, Dept Radiat Oncol, Shenyang, Liaoning, Peoples R China.
EM dangjunsy@163.com
OI Dang, Jun/0000-0002-1408-4749
CR Ahmed Z, 2017, CLIN LUNG CANCER, V18, pE315, DOI 10.1016/j.cllc.2017.03.003
   Auperin A, 1999, NEW ENGL J MED, V341, P476, DOI 10.1056/NEJM199908123410703
   Badzio A, 2004, EUR J CARDIO-THORAC, V26, P183, DOI 10.1016/j.ejcts.2004.04.012
   Barnes H, 2017, COCHRANE DB SYST REV, V4
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Che KY, 2018, J CANCER, V9, P1421, DOI 10.7150/jca.23583
   Combs SE, 2015, J THORAC ONCOL, V10, P316, DOI 10.1097/JTO.0000000000000402
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FOX W, 1973, LANCET, V2, P63
   Gaspar LE, 2012, CLIN LUNG CANCER, V13, P115, DOI 10.1016/j.cllc.2011.05.008
   Goldberg SB, 2013, SURG ONCOL CLIN N AM, V22, P329, DOI 10.1016/j.soc.2012.12.002
   Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859
   HARA N, 1991, J SURG ONCOL, V47, P53, DOI 10.1002/jso.2930470112
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hou SZ, 2017, CANCER BIOMARK, V19, P249, DOI 10.3233/CBM-160332
   ICHINOSE Y, 1992, ANN THORAC SURG, V53, P95, DOI 10.1016/0003-4975(92)90765-V
   LAD T, 1994, CHEST, V106, pS320, DOI 10.1378/chest.106.6.320S
   Liao M, 1995, Zhonghua Zhong Liu Za Zhi, V17, P384
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302
   Schreiber D, 2010, CANCER-AM CANCER SOC, V116, P1350, DOI 10.1002/cncr.24853
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Takenaka T, 2015, LUNG CANCER, V88, P52, DOI 10.1016/j.lungcan.2015.01.010
   Thomson D, 2011, LUNG CANCER, V73, P121, DOI 10.1016/j.lungcan.2011.03.013
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Turrisi Andrew T 3rd, 2003, Curr Treat Options Oncol, V4, P61, DOI 10.1007/s11864-003-0032-9
   Turrisi AT, 1999, NEW ENGL J MED, V340, P265, DOI 10.1056/NEJM199901283400403
   van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7
   Wakeam E, 2017, LUNG CANCER, V109, P78, DOI 10.1016/j.lungcan.2017.04.021
   Yin KP, 2018, J CANCER, V9, P3500, DOI 10.7150/jca.26157
   Yu JB, 2010, J THORAC ONCOL, V5, P215, DOI 10.1097/JTO.0b013e3181cd3208
   Zhang J, 2014, THORAC CANCER, V5, P405, DOI 10.1111/1759-7714.12109
   Zhu H, 2013, EUR J CANCER CARE, V22, P789, DOI 10.1111/ecc.12082
NR 34
TC 0
Z9 0
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2018
VL 13
IS 12
AR e0210001
DI 10.1371/journal.pone.0210001
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HG0IO
UT WOS:000454627200122
PM 30596754
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Farooqi, MAM
   Malhotra, N
   Mukherjee, SD
   Sanger, S
   Dhesy-Thind, SK
   Ellis, P
   Leong, DP
AF Farooqi, Mohammed A. M.
   Malhotra, Nikita
   Mukherjee, Som D.
   Sanger, Stephanie
   Dhesy-Thind, Sukhbinder K.
   Ellis, Peter
   Leong, Darryl P.
TI Statin therapy in the treatment of active cancer: A systematic review
   and meta-analysis of randomized controlled trials
SO PLOS ONE
LA English
DT Review
ID PREVIOUSLY TREATED PATIENTS; PHASE-II; PLUS SIMVASTATIN; DOUBLE-BLIND;
   PRAVASTATIN; BIAS; CHEMOTHERAPY; MULTICENTER; INHIBITION; CARCINOMA
AB Background
   Preclinical evidence suggests statins may have anti-tumor properties. Large observational studies are also consistent with improved survival and cancer-specific outcomes among cancer patients on statins. We sought to evaluate the randomized controlled trials of statins in addition to usual anti-cancer therapy.
   Methods
   A systematic search of MEDLINE, Embase, CINAHL, Cochrane Library, Web of Science, Papers First and Clinicaltrials. gov was performed from inception through to July 4, 2017 to identify randomized clinical trials that investigated statin therapy in cancer patients. Our primary outcome was overall survival and our secondary outcome was progression-free survival. We calculated summary hazard ratio's (HR) and 95% confidence intervals (CI) based on random-effects models using aggregate data. PROSPERO (CRD42017065503).
   Results
   Ten studies with 1,881 individuals were included with 1,572 deaths and a median follow-up of 23 months. All trials included patients with advanced (stage 3 or higher) disease. There was minimal between-study statistical heterogeneity (I-2 = 1.8%, for OS; I-2 = 0%, for PFS). The pooled HR for overall survival in patients randomized to statins plus standard anti-cancer therapy versus standard therapy alone was 0.94 (95% CI, 0.85 to 1.04). In the 9 studies that reported progression-free survival (1,798 participants), the pooled HR for statin plus standard therapy versus standard therapy alone was 0.97 (95% CI, 0.87 to 1.07).
   Conclusions In patients with advanced cancer and a prognosis < 2 years, the addition of statins to standard anti-cancer therapy does not appear to improve overall survival or progression-free survival. Future research should assess if cancer patients with better prognosis benefit from longer-term statin therapy.
C1 [Farooqi, Mohammed A. M.; Malhotra, Nikita; Leong, Darryl P.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Farooqi, Mohammed A. M.; Leong, Darryl P.] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.
   [Farooqi, Mohammed A. M.; Leong, Darryl P.] McMaster Univ, Hamilton Hlth Sci, Hamilton, ON, Canada.
   [Mukherjee, Som D.; Dhesy-Thind, Sukhbinder K.; Ellis, Peter] McMaster Univ, Div Med Oncol, Dept Oncol, Hamilton, ON, Canada.
   [Sanger, Stephanie] McMaster Univ, Hlth Sci Lib, Hamilton, ON, Canada.
RP Leong, DP (reprint author), McMaster Univ, Dept Med, Hamilton, ON, Canada.; Leong, DP (reprint author), McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.; Leong, DP (reprint author), McMaster Univ, Hamilton Hlth Sci, Hamilton, ON, Canada.
EM darryl.leong@phri.ca
OI Leong, Darryl/0000-0002-1968-169X; Farooqi, Mohammed/0000-0001-5282-4034
FU Hamilton Health Sciences Strategic Research Initiative; Heart and Stroke
   Foundation of Canada; Canadian Institutes of Health Research
FX Dr. Darryl Leong is supported by the Hamilton Health Sciences Strategic
   Research Initiative, the Heart and Stroke Foundation of Canada, and the
   Canadian Institutes of Health Research.
CR Altwairgi AK, 2015, ONCOL REP, V33, P1019, DOI 10.3892/or.2015.3741
   Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chan KKW, 2003, CLIN CANCER RES, V9, P10
   Clutterbuck RD, 1998, BRIT J HAEMATOL, V102, P522, DOI 10.1046/j.1365-2141.1998.00783.x
   Collins R, 2016, LANCET, V388, P2532, DOI 10.1016/S0140-6736(16)31357-5
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Hamamsy M, 2016, ONCOL RES, V24, P521, DOI 10.3727/096504016X14719078133528
   Gbelcova H, 2008, INT J CANCER, V122, P1214, DOI 10.1002/ijc.23242
   Georgescu EF, 2011, HEPATOL INT, V5, P423
   Gizzo S, 2015, CURR DRUG TARGETS, V16, P1142, DOI 10.2174/1389450116666150330113239
   Han JY, 2011, CLIN CANCER RES, V17, P1553, DOI 10.1158/1078-0432.CCR-10-2525
   Higgins JPT, 2011, BMJ, V343
   Hindler K, 2006, ONCOLOGIST, V11, P306, DOI 10.1634/theoncologist.11-3-306
   Hong JY, 2014, CANCER CHEMOTH PHARM, V73, P125, DOI 10.1007/s00280-013-2328-1
   Hus M, 2011, ANN HEMATOL, V90, P1161, DOI 10.1007/s00277-011-1276-2
   Inano H, 1997, CARCINOGENESIS, V18, P1723, DOI 10.1093/carcin/18.9.1723
   Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462
   Kawata S, 2001, BRIT J CANCER, V84, P886, DOI 10.1054/bjoc.2001.1716
   Khanzada UK, 2006, ONCOGENE, V25, P877, DOI 10.1038/sj.onc.1209117
   Kim ST, 2014, EUR J CANCER, V50, P2822, DOI 10.1016/j.ejca.2014.08.005
   Konings IRHM, 2010, EUR J CANCER, V46, P3200, DOI 10.1016/j.ejca.2010.07.036
   Lee Y, 2017, CANCER RES TREAT, V49, P1001, DOI 10.4143/crt.2016.546
   Lim SH, 2015, BRIT J CANCER, V113, P1421, DOI 10.1038/bjc.2015.371
   Lyman Gary H, 2005, BMC Med Res Methodol, V5, P14, DOI 10.1186/1471-2288-5-14
   Mei ZB, 2017, INT J CANCER, V140, P1068, DOI 10.1002/ijc.30526
   Mullen PJ, 2016, NAT REV CANCER, V16, P718, DOI 10.1038/nrc.2016.76
   Narisawa T, 1996, TOHOKU J EXP MED, V180, P131, DOI 10.1620/tjem.180.131
   Nielsen SF, 2012, NEW ENGL J MED, V367, P1792, DOI 10.1056/NEJMoa1201735
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Samura B, 2016, Georgian Med News, P56
   Seckl MJ, 2017, J CLIN ONCOL, V35, P1506, DOI 10.1200/JCO.2016.69.7391
   Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324
   Thompson PD, 2016, J AM COLL CARDIOL, V67, P2395, DOI 10.1016/j.jacc.2016.02.071
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393
   Wong WWL, 2001, CLIN CANCER RES, V7, P2067
   Yusuf S, 2016, NEW ENGL J MED, V374, P2021, DOI 10.1056/NEJMoa1600176
NR 40
TC 0
Z9 0
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2018
VL 13
IS 12
AR e0209486
DI 10.1371/journal.pone.0209486
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HF0HP
UT WOS:000453841700081
PM 30571754
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xiao, DQ
   Zhu, TT
   Qui, Y
   Gou, XY
   Huang, Q
   Li, XH
   Mu, DZ
AF Xiao, Dongqiong
   Zhu, Tingting
   Qui, Yi
   Gou, Xiaoyun
   Huang, Qun
   Li, Xihong
   Mu, Dezhi
TI Maternal chorioamnionitis and neurodevelopmental outcomes in preterm and
   very preterm neonates: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID BIRTH-WEIGHT INFANTS; WHITE-MATTER INJURY; CEREBRAL-PALSY; RISK-FACTOR;
   AGE; OLIGODENDROCYTE; INFECTIONS; PREGNANCY; IMPAIRMENT; GROWTH
AB Context
   No consensus exists regarding the association between maternal chorioamnionitis and neurodevelopmental outcomes in preterm and very preterm neonates.
   Objectives
   To investigate whether maternal chorioamnionitis affects neurodevelopmental outcomes and to identify the factors that may explain these effects.
   Data sources
   We used Ovid Medline, EMBASE and Web of Science to conduct a meta-analysis of studies published in English before August 25, 2017, with titles or abstracts that discussed an association between maternal chorioamnionitis and mental/motor development.
   Study selection
   Among the 603 initially identified studies, we selected those that addressed an association between maternal chorioamnionitis and mental/motor development according to our preselected inclusion criteria as follows: (1) the study compared infants with and without exposure to maternal chorioamnionitis and (2) the neurodevelopmental outcome was followed up using the Bayley Scales of Infant Development 2 nd edition.
   Data synthesis
   Our meta-analysis included 10 studies. According to a random effect model, infants with maternal chorioamnionitis exposure had poorer mental development (d = -2.25 [95% CI, -4.33, -0.17], p<0.05) than infants without maternal chorioamnionitis, and infants with maternal clinical chorioamnionitis exposure had poorer motor development (d = -2.37 [95% CI, -4.62 to -0.12], p<0.05) than infants without maternal clinical chorioamnionitis exposure. Factors in the meta-analysis that showed differences between the two patient groups included an MDI assessment blinded to medical history, MDI assessment at the correct age, and time of the MDI assessment.
   Conclusion
   This study suggests that maternal chorioamnionitis may affect mental development in preterm and very preterm neonates, and that maternal clinical chorioamnionitis may affect motor development in offspring. Further studies are required to confirm these results and to detect the influence of variables across studies.
C1 [Xiao, Dongqiong; Zhu, Tingting; Qui, Yi; Gou, Xiaoyun; Huang, Qun; Li, Xihong; Mu, Dezhi] Sichuan Univ, West China Univ Hosp 2, Dept Pediat, Chengdu, Sichuan, Peoples R China.
   [Xiao, Dongqiong; Zhu, Tingting; Qui, Yi; Gou, Xiaoyun; Huang, Qun; Li, Xihong; Mu, Dezhi] Sichuan Univ, Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Sichuan, Peoples R China.
RP Qui, Y; Mu, DZ (reprint author), Sichuan Univ, West China Univ Hosp 2, Dept Pediat, Chengdu, Sichuan, Peoples R China.; Qui, Y; Mu, DZ (reprint author), Sichuan Univ, Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Sichuan, Peoples R China.
EM Quyi712002@163.com; mudz@scu.edu.cn
FU National Science Foundation of China [81330016, 81630038, 81771634];
   Major State Basic Research Development Program [2017YFA0104200]; Science
   and Technology Bureau of Sichuan Province [2016TD0002]
FX This work was supported by the National Science Foundation of China (No.
   81330016, 81630038, 81771634), the Major State Basic Research
   Development Program (2017YFA0104200), grants from the Science and
   Technology Bureau of Sichuan Province (2016TD0002).; This work was
   supported by the National Science Foundation of China (No. 81330016,
   81630038, 81771634), the Major State Basic Research Development Program
   (2017YFA0104200), grants from the Science and Technology Bureau of
   Sichuan Province (2016TD0002).
CR Ambalavanan N, 2000, J Perinatol, V20, P496, DOI 10.1038/sj.jp.7200419
   Back SA, 2014, CLIN PERINATOL, V41, P1, DOI 10.1016/j.clp.2013.11.001
   Basilious A, 2015, DEV MED CHILD NEUROL, V57, P420, DOI 10.1111/dmcn.12599
   Bear JJ, 2016, PEDIATR NEUROL, V57, P74, DOI 10.1016/j.pediatrneurol.2015.12.018
   Been JV, 2013, J PEDIATR-US, V162, P236, DOI 10.1016/j.jpeds.2012.07.012
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berger A, 2009, J PERINAT MED, V37, P72, DOI 10.1515/JPM.2009.016
   Connolly Barbara H, 2006, Pediatr Phys Ther, V18, P190, DOI 10.1097/01.pep.0000226746.57895.57
   Cordeiro CN, 2015, OBSTET GYNECOL SURV, V70, P644, DOI 10.1097/OGX.0000000000000236
   Dammann O, 2003, DEV MED CHILD NEUROL, V45, P148, DOI 10.1017/S001216220300029X
   Dexter SC, 2000, OBSTET GYNECOL, V96, P172, DOI 10.1016/S0029-7844(00)00886-3
   Domingues HS, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00071
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Forthun I, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0874
   Freilich RW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079416
   Galloway DA, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00059
   Gou XY, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020735
   Gussenhoven R, 2017, DEV NEUROSCI-BASEL, V39, P472, DOI 10.1159/000479021
   Haar EV, 2016, OBSTET GYNECOL, V127, P437, DOI 10.1097/AOG.0000000000001295
   HARDT NS, 1985, OBSTET GYNECOL, V65, P5
   Hartling L, 2012, ARCH DIS CHILD-FETAL, V97, pF8, DOI 10.1136/adc.2010.210187
   Hartzel J, 2001, STAT MODEL, V1, P81, DOI 10.1177/1471082X0100100201
   Hendson L, 2011, J PEDIATR-US, V158, P397, DOI 10.1016/j.jpeds.2010.09.010
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang Huei-Lin, 2000, Kaohsiung Journal of Medical Sciences, V16, P197
   Janik MDC, 2013, J PEDIATR-US, V163, P1307, DOI 10.1016/j.jpeds.2013.06.062
   Kamyar M, 2016, BJOG-INT J OBSTET GY, V123, P1161, DOI 10.1111/1471-0528.13460
   Kaukola T, 2006, PEDIATR RES, V59, P478, DOI 10.1203/01.pdr.0000182596.66175.ee
   Kronenberg ME, 2006, DEV MED CHILD NEUROL, V48, P200, DOI 10.1017/S0012162206000430
   Kuypers E, 2012, EARLY HUM DEV, V88, P931, DOI 10.1016/j.earlhumdev.2012.09.011
   Mir IN, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.09.072
   MORALES WJ, 1987, OBSTET GYNECOL, V70, P183
   Mu Shu-Chi, 2007, Acta Paediatrica Taiwanica, V48, P207
   NELLIS L, 1994, J SCHOOL PSYCHOL, V32, P201, DOI 10.1016/0022-4405(94)90011-6
   Pan C, 2014, J CHILD NEUROL, V29, pNP196, DOI 10.1177/0883073813510971
   Pappas A, 2014, JAMA PEDIATR, V168, P137, DOI 10.1001/jamapediatrics.2013.4248
   Perlman JM, 1998, EARLY HUM DEV, V53, P99, DOI 10.1016/S0378-3782(98)00037-1
   Persson M, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001648
   Polam S, 2005, ARCH PEDIAT ADOL MED, V159, P1032, DOI 10.1001/archpedi.159.11.1032
   Redline RW, 1998, ARCH PATHOL LAB MED, V122, P1091
   Rovira N, 2011, EARLY HUM DEV, V87, P253, DOI 10.1016/j.earlhumdev.2011.01.024
   Schlapbach LJ, 2010, ACTA PAEDIATR, V99, P1504, DOI 10.1111/j.1651-2227.2010.01861.x
   Shatrov JG, 2010, OBSTET GYNECOL, V116, P387, DOI 10.1097/AOG.0b013e3181e90046
   Sommerfelt K, 1998, EUR J PEDIATR, V157, P53, DOI 10.1007/s004310050766
   van Tilborg E, 2016, PROG NEUROBIOL, V136, P28, DOI 10.1016/j.pneurobio.2015.11.002
   van Vliet EOG, 2013, JAMA PEDIATR, V167, P662, DOI 10.1001/jamapediatrics.2013.1199
   Versland LB, 2006, ACTA PAEDIATR, V95, P231, DOI 10.1080/08035250500352151
   Villamor E, 2017, JAMA-J AM MED ASSOC, V317, P925, DOI 10.1001/jama.2017.0945
   WANG Y, 2016, SCI REP UK, V6
   Watterberg KL, 2007, PEDIATRICS, V120, P40, DOI 10.1542/peds.2006-3158
   Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417
   Xiao DQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205733
   Zhu TT, 2015, SCI REP-UK, V5, DOI 10.1038/srep18386
NR 53
TC 0
Z9 0
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 11
PY 2018
VL 13
IS 12
AR e0208302
DI 10.1371/journal.pone.0208302
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HD8CS
UT WOS:000452782500016
PM 30533009
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Behrens, G
   Niedermaier, T
   Berneburg, M
   Schmid, D
   Leitzmann, MF
AF Behrens, Gundula
   Niedermaier, Tobias
   Berneburg, Mark
   Schmid, Daniela
   Leitzmann, Michael F.
TI Physical activity, cardiorespiratory fitness and risk of cutaneous
   malignant melanoma: Systematic review and meta- analysis
SO PLOS ONE
LA English
DT Review
ID MELANOCYTIC NEVI; CANCER INCIDENCE; TELOMERE LENGTH; NATIONAL-HEALTH;
   SEDENTARY TIME; BREAST-CANCER; METAANALYSIS; POPULATION; EXERCISE;
   COHORT
AB Background
   Numerous epidemiologic studies have examined the relation of physical activity or cardiorespiratory fitness to risk of cutaneous melanoma but the available evidence has not yet been quantified in a systematic review and meta-analysis.
   Methods
   Following the preferred reporting items for systematic reviews and meta-analyses (PRISMA), we identified 3 cohort studies (N = 12,605 cases) and 5 case-control studies (N = 1,295 cases) of physical activity and melanoma incidence, and one cohort study (N = 49 cases) of cardiorespiratory fitness and melanoma risk.
   Results
   Cohort studies revealed a statistically significant positive association between high versus low physical activity and melanoma risk (RR = 1.27, 95% CI = 1.16-1.40). In contrast, casecontrol studies yielded a statistically non-significant inverse risk estimate for physical activity and melanoma (RR = 0.85, 95% CI = 0.63-1.14; P-difference = 0.02). The only available cohort study of cardiorespiratory fitness and melanoma risk reported a positive but statistically not significant association between the two (RR = 2.19, 95% CI = 0.99-4.96). Potential confounding by ultraviolet (UV) radiation-related risk factors was a major concern in cohort but not case-control studies.
   Conclusions
   It appears plausible that the positive relation of physical activity and cardiorespiratory fitness to melanoma observed in cohort studies is due to residual confounding by UV radiationrelated risk factors.
C1 [Behrens, Gundula; Niedermaier, Tobias; Schmid, Daniela; Leitzmann, Michael F.] Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany.
   [Berneburg, Mark] Univ Hosp Regensburg, Dept Dermatol, Regensburg, Germany.
RP Behrens, G (reprint author), Univ Regensburg, Dept Epidemiol & Prevent Med, Regensburg, Germany.
EM Gundula.Behrens@klinik.uni-regensburg.de
OI Behrens, Gundula/0000-0002-9355-6491
CR Baade P, 2012, INT J CANCER, V130, P170, DOI 10.1002/ijc.25996
   Bassett DR, 2008, J PHYS ACT HEALTH, V5, P795, DOI 10.1123/jpah.5.6.795
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERWICK M, 1995, AM J EPIDEMIOL, V141, P1033, DOI 10.1093/oxfordjournals.aje.a117367
   BROWNSON RC, 1991, AM J PUBLIC HEALTH, V81, P639, DOI 10.2105/AJPH.81.5.639
   Caini S, 2009, EUR J CANCER, V45, P3054, DOI 10.1016/j.ejca.2009.05.009
   Cash SW, 2014, J PHYS ACT HEALTH, V11, P770, DOI 10.1123/jpah.2012-0278
   Chilton W, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122573
   Dai H, 2017, DIABETIC MED, V34, P925, DOI 10.1111/dme.13297
   de Sousa CV, 2017, SPORTS MED, V47, P277, DOI 10.1007/s40279-016-0566-1
   Dennis LK, 2008, ANN EPIDEMIOL, V18, P614, DOI 10.1016/j.annepidem.2008.04.006
   Dinh HC, 2017, CALCIFIED TISSUE INT, V100, P193, DOI 10.1007/s00223-016-0212-9
   DOSEMECI M, 1993, CANCER CAUSE CONTROL, V4, P313, DOI 10.1007/BF00051333
   Edwards MK, 2017, J CLIN LIPIDOL, V11, P119, DOI 10.1016/j.jacl.2016.10.014
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Erdmann F, 2013, INT J CANCER, V132, P385, DOI 10.1002/ijc.27616
   Fedewa MV, 2017, BRIT J SPORT MED, V51, P670, DOI 10.1136/bjsports-2016-095999
   Fountzilas G, 2008, ANN ONCOL, V19, P853, DOI [10.1093/annonc/mdm539, 10.1093/annonc/mdm464]
   Franks PW, 2004, DIABETES CARE, V27, P1187, DOI 10.2337/diacare.27.5.1187
   Gandini S, 2005, EUR J CANCER, V41, P28, DOI 10.1016/j.ejca.2004.10.015
   Geller AC, 2013, J CLIN ONCOL, V31, P4172, DOI 10.1200/JCO.2012.47.3728
   Halliday GA, 2005, MUTAT RES-FUND MOL M, V571, P107, DOI 10.1016/j.mrfmmm.2004.09.013
   Han JL, 2006, INT J EPIDEMIOL, V35, P1514, DOI 10.1093/ije/dyl197
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holman DM, 2014, PREV MED, V63, P6, DOI 10.1016/j.ypmed.2014.02.018
   Jardine A, 2012, HEALTH PROMOT J AUST, V23, P52
   Kaskel P, 2001, BRIT J DERMATOL, V145, P602, DOI 10.1046/j.1365-2133.2001.04432.x
   Kennedy C, 2003, J INVEST DERMATOL, V120, P1087, DOI 10.1046/j.1523-1747.2003.12246.x
   Kojo K, 2006, ENVIRON RES, V101, P123, DOI 10.1016/j.envres.2005.09.007
   Kubica AW, 2012, MAYO CLIN PROC, V87, P991, DOI 10.1016/j.mayocp.2012.04.018
   Kyrgidis Athanassios, 2010, J Carcinog, V9, P3, DOI 10.4103/1477-3163.62141
   Lai JKC, 2013, J BONE MINER RES, V28, P2222, DOI 10.1002/jbmr.1963
   Lavie CJ, 2011, J CARDIOPULM REHABIL, V31, P137, DOI 10.1097/HCR.0b013e3182122827
   Lazovich D, 2011, CANCER EPIDEM BIOMAR, V20, P2583, DOI 10.1158/1055-9965.EPI-11-0705
   Lee TK, 2009, MELANOMA RES, V19, P260, DOI 10.1097/CMR.0b013e32832e0bae
   Loprinzi PD, 2015, AM J EPIDEMIOL, V182, P198, DOI 10.1093/aje/kwv056
   Malagoli C, 2008, TUMORI, V94, P669
   Mangino M, 2015, J MED GENET, V52, P157, DOI 10.1136/jmedgenet-2014-102681
   Martin-Gorgojo A, 2017, ONCOTARGET, V8, P98876, DOI 10.18632/oncotarget.22016
   May AM, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-148
   Mehanna E, 2016, CURR ATHEROSCLER REP, V18, DOI 10.1007/s11883-016-0580-7
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Monninkhof EM, 2007, EPIDEMIOLOGY, V18, P137, DOI 10.1097/01.ede.0000251167.75581.98
   Moore SC, 2016, JAMA INTERN MED, V176, P816, DOI 10.1001/jamainternmed.2016.1548
   Mundstock E, 2015, AGEING RES REV, V22, P72, DOI 10.1016/j.arr.2015.02.004
   Nikolaou V, 2014, BRIT J DERMATOL, V170, P11, DOI [10.1111/bjd.12492, 10.1111/bjd.12712]
   Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P
   Olsen CM, 2010, CANCER PREV RES, V3, P233, DOI 10.1158/1940-6207.CAPR-09-0108
   Olsen CM, 2010, CANCER EPIDEM BIOMAR, V19, P65, DOI 10.1158/1055-9965.EPI-09-0928
   PAFFENBARGER RS, 1987, AM J CLIN NUTR, V45, P312, DOI 10.1093/ajcn/45.1.312
   Parent ME, 2011, CANCER EPIDEMIOL, V35, P151, DOI 10.1016/j.canep.2010.09.004
   Parr CL, 2009, AM J EPIDEMIOL, V169, P257, DOI 10.1093/aje/kwn363
   Pukkala E, 2000, INT J SPORTS MED, V21, P216, DOI 10.1055/s-2000-8878
   Pustisek N, 2010, COLLEGIUM ANTROPOL, V34, P233
   R Core Team, 2016, A LANGUAGE AND ENVIR
   Ragnarsson-Olding BK, 2011, ACTA ONCOL, V50, P323, DOI 10.3109/0284186X.2010.535846
   Ramos JS, 2015, SPORTS MED, V45, P679, DOI 10.1007/s40279-015-0321-z
   Rawson RV, 2017, LAB INVEST, V97, P130, DOI 10.1038/labinvest.2016.143
   Ribero S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116863
   Robsahm TE, 2017, CANCER MED-US, V6, P865, DOI 10.1002/cam4.1043
   Savage SA, 2008, BMC GENET, V9, DOI 10.1186/1471-2156-9-31
   Schaefer L, 2014, J PEDIATR-US, V165, P516, DOI 10.1016/j.jpeds.2014.05.029
   Scragg R, 2008, AM J EPIDEMIOL, V168, P577, DOI 10.1093/aje/kwn163
   Sergentanis TN, 2013, EUR J CANCER, V49, P642, DOI 10.1016/j.ejca.2012.08.028
   Shors AR, 2001, CANCER CAUSE CONTROL, V12, P599, DOI 10.1023/A:1011211615524
   Sormunen J, 2014, J SCI MED SPORT, V17, P479, DOI 10.1016/j.jsams.2013.10.239
   Sport New Zealand, 2015, SPORT ACT RECR LIV N
   Svobodova A, 2010, INT J RADIAT BIOL, V86, P999, DOI 10.3109/09553002.2010.501842
   Tjonneland A, 2007, SCAND J PUBLIC HEALT, V35, P432, DOI 10.1080/14034940601047986
   van der Leest RJT, 2015, EUR J CANCER, V51, P2833, DOI 10.1016/j.ejca.2015.09.008
   Van Loon AJM, 2003, ANN EPIDEMIOL, V13, P105, DOI 10.1016/S1047-2797(02)00257-0
   Veierod MB, 1997, INT J CANCER, V71, P600, DOI 10.1002/(SICI)1097-0215(19970516)71:4<600::AID-IJC15>3.3.CO;2-C
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1
   Vissers D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056415
   WEINSTOCK MA, 1991, AM J EPIDEMIOL, V133, P240, DOI 10.1093/oxfordjournals.aje.a115868
   Whiteman DC, 2003, J NATL CANCER I, V95, P806, DOI 10.1093/jnci/95.11.806
   Wientzek A, 2014, INT J SPORT NUTR EXE, V24, P215, DOI 10.1123/ijsnem.2013-0048
NR 77
TC 0
Z9 0
U1 2
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 31
PY 2018
VL 13
IS 10
AR e0206087
DI 10.1371/journal.pone.0206087
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GY7VH
UT WOS:000448823700088
PM 30379884
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xiao, DQ
   Qu, Y
   Huang, L
   Wang, Y
   Li, XH
   Mu, DZ
AF Xiao, Dongqiong
   Qu, Yi
   Huang, Lan
   Wang, Yan
   Li, Xihong
   Mu, Dezhi
TI Association between maternal overweight or obesity and cerebral palsy in
   children: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID BODY-MASS INDEX; RISK-FACTORS; PREPREGNANCY OBESITY; PREGNANCY;
   CHORIOAMNIONITIS; DISORDERS; BRAIN
AB Context
   There is no consensus regarding the association between maternal obesity or overweight and cerebral palsy (CP) in children.
   Objectives
   To investigate whether maternal obesity or overweight is associated with CP and identify the factors that explain the differences in the study results.
   Data sources
   We conducted a meta-analysis of studies published in English with titles or abstracts that discussed the relationships between maternal obesity or overweight and CP before August 23, 2017, using Ovid Medline, EMBASE and Web of Science.
   Study selection
   Of 2699 initially identified studies, 8 studies that addressed the association between maternal obesity and CP met our final inclusion criteria.
   Data extraction
   Information from the individual studies was abstracted using standardized forms by 2 independent observers who were blinded to the authors' names and journal titles.
   Data synthesis
   According to a random effects model, maternal overweight was significantly associated with CP in offspring [RR = 1.29 (95% CI, 1.04-1.60), heterogeneity (I-2 = 45.5%, P = 0.103)]; maternal obesity was significantly associated with CP in offspring [RR = 1.45 (95% CI, 1.25-1.69), heterogeneity (I-2 = 24.1%, P = 0.253)]; and maternal obesity III was significantly associated with CP in offspring [RR = 2.25 (95% CI, 1.82-2.79), heterogeneity (I-2 = 0%, P = 0.589)]. However, maternal underweight was not significantly associated with CP in offspring [RR = 1.11 95% CI, 0.88-1.38), low heterogeneity (I-2 = 0%, P = 0.435)]. Factors that explained the differences in the meta-analysis results included study design, study location, and whether individual studies adjusted for potential confounders.
   Conclusion
   This study suggests that maternal obesity and overweight increase the risk of CP in offspring. Further studies are required to confirm these results and determine the influence of variables across studies.
C1 [Xiao, Dongqiong; Qu, Yi; Huang, Lan; Wang, Yan; Li, Xihong; Mu, Dezhi] Sichuan Univ, Dept Pediat, West China Univ Hosp 2, Chengdu, Sichuan, Peoples R China.
   [Xiao, Dongqiong; Qu, Yi; Huang, Lan; Wang, Yan; Li, Xihong; Mu, Dezhi] Sichuan Univ, Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Sichuan, Peoples R China.
RP Qu, Y; Mu, DZ (reprint author), Sichuan Univ, Dept Pediat, West China Univ Hosp 2, Chengdu, Sichuan, Peoples R China.; Qu, Y; Mu, DZ (reprint author), Sichuan Univ, Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Sichuan, Peoples R China.
EM quyi712002@163.com; mudz@scu.edu.cn
FU National Science Foundation of China [81330016, 81630038, 81771634];
   Major State Basic Research Development Program [2017YFA0104200]; Science
   and Technology Bureau of Sichuan Province [2016TD0002]
FX This work was supported by the National Science Foundation of China (No.
   81330016, 81630038, 81771634), the Major State Basic Research
   Development Program (2017YFA0104200), and grants from the Science and
   Technology Bureau of Sichuan Province (2016TD0002) to DM. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.; This work was supported by
   the National Science Foundation of China (No. 81330016, 81630038, and
   81771634), the Major State Basic Research Development Program
   (2017YFA0104200), and grants from the Science and Technology Bureau of
   Sichuan Province (2016TD0002). The search strategy was evaluated by a
   trained librarian from Sichuan University, and we would like to thank
   American Journal Experts (www.aje.com) for English language editing.
CR Adane AA, 2016, INT J OBESITY, V40, P1608, DOI 10.1038/ijo.2016.140
   Ahlin K, 2013, BJOG-INT J OBSTET GY, V120, P724, DOI 10.1111/1471-0528.12164
   Altmae S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169223
   Baxter B., 2017, PREDOMINANTLY PART P, DOI [10.1186/s12865-016-0184-6, DOI 10.1186/S12865-016-0184-6]
   Bear JJ, 2016, PEDIATR NEUROL, V57, P74, DOI 10.1016/j.pediatrneurol.2015.12.018
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   CATALANO PM, 2017, BMJ-BRIT MED J, V356, DOI DOI 10.1136/BMJ.J1
   Daraki V, 2017, EUR CHILD ADOLES PSY, V26, P703, DOI 10.1007/s00787-016-0934-2
   Di Cesare M, 2016, LANCET, V387, P1377, DOI 10.1016/S0140-6736(16)30054-X
   Duquenne M, 2016, ENDOCRINOLOGY, V157, P2201, DOI 10.1210/en.2016-1262
   Eastwood KA, 2017, J PERINAT MED, V45, P1061, DOI 10.1515/jpm-2016-0048
   Edlow AG, 2017, PRENATAL DIAG, V37, P95, DOI 10.1002/pd.4932
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elshenawy S, 2016, MOL CELL ENDOCRINOL, V435, P2, DOI 10.1016/j.mce.2016.07.002
   Forthun I, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0874
   Godfrey KM, 2017, LANCET DIABETES ENDO, V5, P53, DOI 10.1016/S2213-8587(16)30107-3
   Hartzel J, 2001, STAT MODEL, V1, P81, DOI 10.1177/1471082X0100100201
   Hasegawa J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148122
   Hatanaka Y, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00035
   Hernandez-Trejo M, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-016-0184-6
   Herzog M, 2015, EUR J OBSTET GYN R B, V187, P57, DOI 10.1016/j.ejogrb.2015.02.008
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hinkle SN, 2013, INT J OBESITY, V37, P1344, DOI 10.1038/ijo.2013.128
   Howell KR, 2017, REPRODUCTION, V153, pR97, DOI 10.1530/REP-16-0495
   Janik MDC, 2013, J PEDIATR-US, V163, P1307, DOI 10.1016/j.jpeds.2013.06.062
   Kanadys WM, 2012, GINEKOL POL, V83, P270
   Love ER, 2012, EUR J OBSTET GYN R B, V165, P219, DOI 10.1016/j.ejogrb.2012.08.015
   Mann JR, 2013, DEV MED CHILD NEUROL, V55, P58, DOI 10.1111/j.1469-8749.2012.04409.x
   McPherson JA, 2017, AM J PERINAT, V34, P563, DOI 10.1055/s-0036-1594015
   Mina TH, 2017, PSYCHOL MED, V47, P353, DOI 10.1017/S0033291716002452
   Mukerji A, 2015, PEDIATRICS, V136, P1132, DOI 10.1542/peds.2015-0944
   Niculescu MD, 2009, INT J DEV NEUROSCI, V27, P627, DOI 10.1016/j.ijdevneu.2009.08.005
   Nielsen LF, 2008, BJOG-INT J OBSTET GY, V115, P1518, DOI 10.1111/j.1471-0528.2008.01896.x
   Odding E, 2006, DISABIL REHABIL, V28, P183, DOI 10.1080/09638280500158422
   Pan C, 2014, J CHILD NEUROL, V29, pNP196, DOI 10.1177/0883073813510971
   Parnell AS, 2017, MATERN CHILD HLTH J, V21, P1105, DOI 10.1007/s10995-016-2209-4
   Persson M, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001648
   Prince CS, 2017, PLACENTA, V49, P55, DOI 10.1016/j.placenta.2016.11.010
   Stothard KJ, 2009, JAMA-J AM MED ASSOC, V301, P636, DOI 10.1001/jama.2009.113
   Teo JD, 2017, BRAIN BEHAV IMMUN, V63, P186, DOI 10.1016/j.bbi.2016.10.010
   Tozuka Y, 2009, FASEB J, V23, P1920, DOI 10.1096/fj.08-124784
   Villamor E, 2017, JAMA-J AM MED ASSOC, V317, P925, DOI 10.1001/jama.2017.0945
   Walstab J, 2002, AUST NZ J OBSTET GYN, V42, P138, DOI 10.1111/j.0004-8666.2002.00138.x
   Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep34248
   Willi C, 2007, JAMA-J AM MED ASSOC, V298, P2654, DOI 10.1001/jama.298.22.2654
   Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417
   Ylijoki M, 2016, NEONATOLOGY, V110, P286, DOI 10.1159/000446236
   Zhu TT, 2015, SCI REP-UK, V5, DOI 10.1038/srep18386
NR 48
TC 2
Z9 2
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2018
VL 13
IS 10
AR e0205733
DI 10.1371/journal.pone.0205733
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GX0VS
UT WOS:000447430800038
PM 30325944
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Isaacs, AM
   Riva-Cambrin, J
   Yavin, D
   Hockley, A
   Pringsheim, TM
   Jette, N
   Lethebe, BC
   Lowerison, M
   Dronyk, J
   Hamilton, MG
AF Isaacs, Albert M.
   Riva-Cambrin, Jay
   Yavin, Daniel
   Hockley, Aaron
   Pringsheim, Tamara M.
   Jette, Nathalie
   Lethebe, Brendan Cord
   Lowerison, Mark
   Dronyk, Jarred
   Hamilton, Mark G.
TI Age-specific global epidemiology of hydrocephalus: Systematic review,
   metanalysis and global birth surveillance
SO PLOS ONE
LA English
DT Review
ID NORMAL-PRESSURE HYDROCEPHALUS; NEURAL-TUBE DEFECTS; SHUNT-DEPENDENT
   HYDROCEPHALUS; CONGENITAL HYDROCEPHALUS; INFANTILE HYDROCEPHALUS;
   FOLIC-ACID; PRENATAL-DIAGNOSIS; NATIONAL REGISTRY; NATURAL-HISTORY;
   CHILDREN BORN
AB Background
   Hydrocephalus is a debilitating disorder, affecting all age groups. Evaluation of its global epidemiology is required for healthcare planning and resource allocation.
   Objectives
   To define age-specific global prevalence and incidence of hydrocephalus.
   Methods
   Population-based studies reporting prevalence of hydrocephalus were identified (MEDLINE, EMBASE, Cochrane, and Google Scholar (1985-2017)). Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Two authors reviewed abstracts, full text articles and abstracted data. Metanalysis and meta-regressions were used to assess associations between key variables. Heterogeneity and publication bias were assessed. Main outcome of interest was hydrocephalus prevalence among pediatric (<= 18 years), adults (19-64 years), and elderly (>= 65) patients. Annual hydrocephalus incidence stratified by country income level and folate fortification requirements were obtained (2003-2014) from the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR).
   Results
   Of 2,460 abstracts, 52 met review eligibility criteria (aggregate population 171,558,651). Mean hydrocephalus prevalence was 85/100,000 [95% CI 62, 116]. The prevalence was 88/100,000 [95% CI 72, 107] in pediatrics; 11/100,000 [95% CI 5, 25] in adults; and 175/100,000 [95% CI 67, 458] in the elderly. The ICBDSR-based incidence of hydrocephalus diagnosed at birth remained stable over 11 years: 81/100,000 [95% CI 69, 96]. A significantly lower incidence was identified in high-income countries.
   Conclusion
   This systematic review established age-specific global hydrocephalus prevalence. While high-income countries had a lower hydrocephalus incidence according to the ICBDSR registry, folate fortification status was not associated with incidence. Our findings may inform future healthcare resource allocation and study.
C1 [Isaacs, Albert M.; Riva-Cambrin, Jay; Yavin, Daniel; Hockley, Aaron; Dronyk, Jarred; Hamilton, Mark G.] Univ Calgary, Dept Clin Neurosci, Div Neurosurg, Calgary, AB, Canada.
   [Isaacs, Albert M.] Washington Univ, Sch Med, Dept Neurosci, St Louis, MO USA.
   [Riva-Cambrin, Jay] Univ Calgary, Alberta Childrens Hosp, Dept Neurosurg, Calgary, AB, Canada.
   [Hockley, Aaron] NYU, Dept Orthoped Surg, New York, NY USA.
   [Pringsheim, Tamara M.; Jette, Nathalie] Univ Calgary, Dept Clin Neurosci, Div Neurol, Calgary, AB, Canada.
   [Pringsheim, Tamara M.] Univ Calgary, Alberta Childrens Hosp, Dept Neurol, Calgary, AB, Canada.
   [Jette, Nathalie] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
   [Lethebe, Brendan Cord; Lowerison, Mark] Univ Calgary, Clin Res Unit, Calgary, AB, Canada.
RP Hamilton, MG (reprint author), Univ Calgary, Dept Clin Neurosci, Div Neurosurg, Calgary, AB, Canada.
EM mghamilton.hydro@gmail.com
RI Pringsheim, Tamara/L-5955-2019
OI Hockley, Aaron/0000-0002-9348-503X
FU Public Health Agency of Canada
FX This study has been sponsored by the Public Health Agency of Canada.
   Funding was received by Drs. Mark Hamilton, Tamara Pringsheim and
   Nathalie Jette. However, the funder had no role in study design, data
   collection, data analysis, data interpretation, writing of the report,
   or decision to submit the findings for publication.
CR Abdullah J, 2001, PEDIATR NEUROSURG, V34, P13, DOI 10.1159/000055987
   Ahrens K, 2011, EPIDEMIOLOGY, V22, P731, DOI 10.1097/EDE.0b013e3182227887
   Al Salloum AA, 2011, J CHILD NEUROL, V26, P21, DOI 10.1177/0883073810371510
   Al-Jama F, 2001, J Obstet Gynaecol, V21, P595
   Baer RJ, 2014, AM J OBSTET GYNECOL, V211, DOI 10.1016/j.ajog.2014.06.025
   Balogun OO, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004073.pub4
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bekelis K, 2014, J NEUROINTERV SURG, V6, P342, DOI 10.1136/neurintsurg-2013-010815
   Bodilsen J, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-321
   Botto LD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069077
   Boyle M. H., 1998, EVID BASED MENT HLTH, V1, P37, DOI DOI 10.1136/EBMH.1.2.37
   Brean A, 2009, ACTA NEUROL SCAND, V120, P314, DOI 10.1111/j.1600-0404.2009.01250.x
   Cavalcanti Denise P., 2003, J. Pediatr. (Rio J.), V79, P135, DOI 10.1590/S0021-75572003000200008
   Chang CJ, 2004, BRAIN DEV-JPN, V26, P168, DOI 10.1016/S0387-7604(03)00122-0
   Cherian AG, 2016, J TROP PEDIATRICS, V62, P361, DOI 10.1093/tropej/fmw019
   Ciurea AV, 2004, PEDIATRIC HYDROCEPHALUS, P201
   CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602
   Dai L, 2011, WORLD J PEDIATR, V7, P302, DOI 10.1007/s12519-011-0326-0
   de Oliveira JG, 2007, NEUROSURGERY, V61, P924, DOI 10.1227/01.NEU.0000280090.83866.26
   De-Regil LM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007950.pub3
   Del Bigio MR, 1998, CAN J NEUROL SCI, V25, P123
   Delshad S, 2009, TROP DOCT, V39, P156, DOI 10.1258/td.2008.070434
   Dewan MC, 2019, J NEUROSURG, V130, P1065, DOI 10.3171/2017.10.JNS17439
   Edwards RJ, 2004, BRAIN PATHOL, V14, P325
   Egbe A, 2015, PEDIATR NEONATOL, V56, P25, DOI 10.1016/j.pedneo.2014.03.010
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Gaidi MA, 2015, J NEUROSURG-PEDIATR, V15, P4, DOI 10.3171/2014.8.PEDS14146
   ELAWAD ME, 1992, ANN TROP PAEDIATR, V12, P335
   Espay AJ, 2017, ANN NEUROL, V82, P503, DOI 10.1002/ana.25046
   Fan LC, 2013, BIRTH DEFECTS RES A, V97, P750, DOI 10.1002/bdra.23148
   Fernell E, 1998, ACTA PAEDIATR, V87, P392
   Fleetwood IG, 2005, CAN J NEUROL SCI, V32, P57, DOI 10.1017/S0317167100016887
   Garne E, 2010, EUR J PAEDIATR NEURO, V14, P150, DOI 10.1016/j.ejpn.2009.03.005
   Glinianaia SV, 1999, EUR J PEDIATR SURG, V9, P46
   Gonzalez-Andrade F, 2010, APPL CLIN GENET, V3, P29
   GRAFFRADFORD NR, 1989, NEUROLOGY, V39, P1596, DOI 10.1212/WNL.39.12.1596
   Groisman B, 2013, ARCH ARGENT PEDIATR, V111, P484, DOI [10.5546/aap.2013.484, 10.1590/S0325-00752013000600006]
   Group TWB, COUNTR EC 2017
   Guardiola A, 2009, ARQ NEURO-PSIQUIAT, V67, P807, DOI 10.1590/S0004-282X2009000500005
   Haider BA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004905.pub5
   Hamilton MG, 2009, SEMIN PEDIATR NEUROL, V16, P34, DOI 10.1016/j.spen.2009.02.001
   Hannon T, 2012, OBSTET GYNECOL, V120, P1345, DOI [10.1097/AOG.0b013e3182732b53, http://10.1097/AOG.0b013e3182732b53]
   Harmat G, 2001, Eur J Ultrasound, V12, P209, DOI 10.1016/S0929-8266(00)00120-8
   Hiraoka K, 2008, NEUROL MED-CHIR, V48, P197, DOI 10.2176/nmc.48.197
   Hoh BL, 2011, WORLD NEUROSURG, V76, P548, DOI 10.1016/j.wneu.2011.05.054
   Inamasu J, 2003, CLIN NEUROL NEUROSUR, V106, P9, DOI 10.1016/S0303-8467(03)00060-X
   Initiative FF, COUNTR PROF 2017
   Isaacs A, 2016, GLOBAL PREVALENCE IN
   Isaacs AM, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.6.FOCUS16193
   Iseki C, 2014, J NEUROL SCI, V339, P108, DOI 10.1016/j.jns.2014.01.033
   Iseki C, 2009, J NEUROL SCI, V277, P54, DOI 10.1016/j.jns.2008.10.004
   Jaraj D, 2017, ALZHEIMERS DEMENT, V13, P850, DOI 10.1016/j.jalz.2017.01.013
   Jaraj D, 2014, NEUROLOGY, V82, P1449, DOI 10.1212/WNL.0000000000000342
   Jeng S, 2011, PEDIATR NEUROL, V45, P67, DOI 10.1016/j.pediatrneurol.2011.03.009
   Jit M, 2010, J INFECTION, V61, P114, DOI 10.1016/j.jinf.2010.04.008
   Kahle KT, 2016, LANCET, V387, P788, DOI 10.1016/S0140-6736(15)60694-8
   Kasanmoentalib ES, 2010, NEUROLOGY, V75, P918, DOI 10.1212/WNL.0b013e3181f11e10
   Klassen BT, 2011, NEUROLOGY, V77, P118, DOI 10.1212/WNL.0b013e318224af8d
   Kulkarni AV, 2013, J NEUROSURG-PEDIATR, V12, P235, DOI 10.3171/2013.6.PEDS12535
   Kumar R, 2008, ACTA NEUROPSYCHIATR, V20, P87, DOI 10.1111/j.1601-5215.2008.00273.x
   Kuriyama N, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.635
   Loney PL, 1999, PHYS THER, V79, P384
   Mahmoud Mustafa Z, 2014, Glob J Health Sci, V6, P1, DOI 10.5539/gjhs.v6n5p1
   Martin-Laez R, 2016, WORLD NEUROSURG, V87, P298, DOI 10.1016/j.wneu.2015.10.069
   Martin-Laez R, 2015, WORLD NEUROSURG, V84, P2002, DOI 10.1016/j.wneu.2015.07.005
   McAllister JP, 2015, J NEUROSURG, V123, P1427, DOI 10.3171/2014.12.JNS132352
   Miyakoshi A, 2013, ACTA NEUROCHIR, V155, P1271, DOI 10.1007/s00701-013-1742-9
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Moussa HN, 2016, FUTUR SCI OA, V2, DOI 10.4155/fsoa-2015-0015
   Movafagh A, 2008, PAK J MED SCI, V24, P80
   Msamati B C, 2000, Cent Afr J Med, V46, P292
   Munch TN, 2012, BRAIN, V135, P2409, DOI 10.1093/brain/aws158
   Murshid WR, 2000, PEDIATR NEUROSURG, V32, P119, DOI 10.1159/000028915
   Nakling J, 2005, ACTA OBSTET GYN SCAN, V84, P1042, DOI 10.1111/j.0001-6349.2005.00785.x
   NOGUEIRA GJ, 1992, CHILD NERV SYST, V8, P40, DOI 10.1007/BF00316561
   Ogunyemi D, 2000, J Matern Fetal Med, V9, P219
   Persson EK, 2005, ACTA PAEDIATR, V94, P726, DOI 10.1080/08035250510027336
   Persson EK, 2007, CHILD NERV SYST, V23, P1111, DOI 10.1007/s00381-007-0324-7
   R Core Team, 2013, R LANG ENV STAT COMP
   Rajab A, 1998, J TROP PEDIATRICS, V44, P300, DOI 10.1093/tropej/44.5.300
   Raut T, 2013, J INFECTION, V66, P330, DOI 10.1016/j.jinf.2012.12.009
   Rekate HL, 2009, SEMIN PEDIATR NEUROL, V16, P9, DOI 10.1016/j.spen.2009.01.002
   Research ICfBDSa, ANN REP 2017
   Rintoul NE, 2002, PEDIATRICS, V109, P409, DOI 10.1542/peds.109.3.409
   Saper CB, 2017, ANN NEUROL, V82, P514, DOI 10.1002/ana.25053
   Schneider C, 2015, J NEUROSURG-PEDIATR, V15, P236, DOI 10.3171/2014.9.PEDS14280
   Sethna F, 2011, OBSTET GYNECOL, V117, P867, DOI 10.1097/AOG.0b013e3182117471
   Shawky RM, 2011, EGYPTIAN J MED HUM G, V12, P69, DOI [DOI 10.1016/J.EJMHG.2011.02.016, 10.1016/j.ejmhg.2011.02.016]
   Simon TD, 2008, J NEUROS-PEDIATR, V1, P131, DOI 10.3171/PED/2008/1/2/131
   Smith ER, 2004, J NEUROSURG, V100, P90, DOI 10.3171/ped.2004.100.2.0090
   Sun G, 2011, WORLD J PEDIATR, V7, P331, DOI 10.1007/s12519-011-0328-y
   Synnes AR, 2004, AM J PERINAT, V21, P199, DOI 10.1055/s-2004-828604
   Tanaka N, 2009, NEUROEPIDEMIOLOGY, V32, P171, DOI 10.1159/000186501
   Tang YW, 2006, MATERN CHILD HLTH J, V10, P75, DOI 10.1007/s10995-005-0031-5
   Tisell M, 2005, ACTA NEUROL SCAND, V112, P72, DOI 10.1111/j.1600-0404-2005-00451.x
   Toriello HV, 2011, GENET MED, V13, P593, DOI 10.1097/GIM.0b013e31821d4188
   Tso MK, 2016, WORLD NEUROSURG, V86, P226, DOI 10.1016/j.wneu.2015.09.056
   Tulipan N, 2003, PEDIATR NEUROSURG, V38, P27, DOI 10.1159/000067560
   Vinchon M, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-18
   Viswanathan M, 2017, US PREVENTIVE SERVIC
   Viswanathan M, 2017, JAMA-J AM MED ASSOC, V317, P190, DOI 10.1001/jama.2016.19193
   WALD N, 1991, LANCET, V338, P131
   Wald NJ, 2001, LANCET, V358, P2069, DOI 10.1016/S0140-6736(01)07104-5
   Waller DK, 2000, FETAL DIAGN THER, V15, P348, DOI 10.1159/000021035
   Wang SS, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-59
   Warf BC, 2011, J NEUROSURG-PEDIATR, V8, P502, DOI 10.3171/2011.8.PEDS11221
   Warf BC, 2010, WORLD NEUROSURG, V73, P296, DOI 10.1016/j.wneu.2010.02.009
   Wilson CD, 2017, J NEUROSURG, V126, P586, DOI 10.3171/2015.11.JNS152094
   Wilson RK, 2007, J NEUROL NEUROSUR PS, V78, P508, DOI 10.1136/jnnp.2006.108761
   Wolf HT, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.03.029
   Xie DH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147280
   Zhang XG, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-125
NR 112
TC 2
Z9 2
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 1
PY 2018
VL 13
IS 10
AR e0204926
DI 10.1371/journal.pone.0204926
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GV5EV
UT WOS:000446124700051
PM 30273390
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Pietschnig, J
   Gittler, G
   Stieger, S
   Forster, M
   Gadek, N
   Gartus, A
   Kocsis-Bogar, K
   Kubicek, B
   Luftenegger, M
   Olsen, J
   Prem, R
   Ruiz, N
   Serfas, BG
   Voracek, M
AF Pietschnig, Jakob
   Gittler, Georg
   Stieger, Stefan
   Forster, Michael
   Gadek, Natalia
   Gartus, Andreas
   Kocsis-Bogar, Krisztina
   Kubicek, Bettina
   Lueftenegger, Marko
   Olsen, Jerome
   Prem, Roman
   Ruiz, Nina
   Serfas, Benjamin G.
   Voracek, Martin
TI Indirect (implicit) and direct (explicit) self-esteem measures are
   virtually unrelated: A meta-analysis of the initial preference task
SO PLOS ONE
LA English
DT Article
ID NAME-LETTER PREFERENCES; CONDUCTING METAANALYSES;
   INDIVIDUAL-DIFFERENCES; PUBLICATION BIAS; VALIDITY
AB Background
   The initial preference task (IPT) is an implicit measure that has featured prominently in the literature and enjoys high popularity because it offers to provide an unobtrusive and objective assessment of self-esteem that is easy to administer. However, its use for self-esteem assessment may be limited because of weak associations with direct personality measures. Moreover, moderator effects of sample- and study-related variables need investigation to determine the value of IPT-based assessments of self-esteem.
   Methods
   Conventional and grey-literature database searches, as well as screening of reference lists of obtained articles, yielded a total of 105 independent healthy adult samples (N = 17,777) originating from 60 studies. Summary effect estimates and subgroup analyses for potential effect moderators (e.g., administration order, algorithm, rating type) were calculated by means of meta-analytic random- %and mixed-effects models. Moreover, we accounted for potential influences of publication year, publication status (published vs. not), and participant sex in a weighted stepwise hierarchical multiple meta-regression. We tested for dissemination bias through six methods.
   Results
   There was no noteworthy correlation between IPT-based implicit and explicit self-esteem (r=.102), indicating conceptual independence of these two constructs. Effects were stronger when the B-algorithm was used for calculation of IPT-scores and the IPT was administered only once, whilst all other moderators did not show significant influences. Regression analyses revealed a somewhat stronger (albeit non-significant) effect for men. Moreover, there was no evidence for dissemination bias or a decline effect, although effects from published studies were numerically somewhat stronger than unpublished effects.
   Discussion
   We show that there is no noteworthy association between IPT-based implicit and explicit self-esteem, which is broadly consistent with dual-process models of implicit and explicit evaluations on the one hand, but also casts doubt on the suitability of the IPT for the assessment of implicit self-esteem on the other hand.
C1 [Pietschnig, Jakob; Gittler, Georg; Gadek, Natalia; Kocsis-Bogar, Krisztina; Ruiz, Nina] Univ Vienna, Fac Psychol, Dept Appl Psychol Hlth Dev Enhancement & Interven, Vienna, Austria.
   [Stieger, Stefan] Univ Konstanz, Dept Psychol, Constance, Germany.
   [Stieger, Stefan] Karl Landsteiner Univ Hlth Sci, Dept Psychol, Krems, Austria.
   [Forster, Michael; Gartus, Andreas; Voracek, Martin] Univ Vienna, Fac Psychol, Dept Basic Psychol Res & Res Methods, Vienna, Austria.
   [Kubicek, Bettina; Lueftenegger, Marko; Olsen, Jerome; Prem, Roman; Serfas, Benjamin G.] Univ Vienna, Fac Psychol, Dept Appl Psychol Work Educ & Econ, Vienna, Austria.
RP Pietschnig, J (reprint author), Univ Vienna, Fac Psychol, Dept Appl Psychol Hlth Dev Enhancement & Interven, Vienna, Austria.
EM jakob.pietschnig@univie.ac.at
RI Forster, Michael/G-1420-2012; Stieger, Stefan/Q-5329-2019; Lueftenegger,
   Marko/K-8661-2013; Stieger, Stefan/G-2572-2012; Serfas, Benjamin
   G/E-3070-2014; Voracek, Martin/S-5865-2016; Prem, Roman/G-1979-2011
OI Forster, Michael/0000-0003-4634-4434; Stieger,
   Stefan/0000-0002-7784-6624; Lueftenegger, Marko/0000-0001-8112-976X;
   Stieger, Stefan/0000-0002-7784-6624; Serfas, Benjamin
   G/0000-0003-4358-6139; Voracek, Martin/0000-0001-6109-6155; Prem,
   Roman/0000-0001-6147-2069; Kocsis-Bogar, Krisztina/0000-0003-4188-5047
FU University of Vienna
FX Open access funding was provided by University of Vienna.; We thank
   Petra Gradinger, Barbara Hartl, Matea Paskvan, Bernhard Piskernik, Lukas
   Teufl, and Takuya Yanagida for their assistance in coding. Open access
   funding was provided by University of Vienna.
CR Albers L, 2009, SELF IDENTITY, V8, P63, DOI 10.1080/15298860802091062
   [Anonymous], 2016, THESIS
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Borenstein M., 2009, INTRO METAANALYSIS
   Bosson JK, 2000, J PERS SOC PSYCHOL, V79, P631, DOI 10.1037//0022-3514.79.4.631
   Cattell R. B., 1967, OBJECTIVE PERSONALIT
   Chaiken S, 1999, DUAL PROCESS MODELS
   Cohen J, 1988, STAT POWER ANAL BEHA
   Dijksterhuis A, 2004, J PERS SOC PSYCHOL, V86, P345, DOI 10.1037/0022-3514.86.2.345
   Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529
   Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081
   Fazio R. H., 2009, ATTITUDES INSIGHTS N, P229
   Gawronski B, 2007, PERSPECT PSYCHOL SCI, V2, P181, DOI 10.1111/j.1745-6916.2007.00036.x
   Gawronski B, 2006, PSYCHOL BULL, V132, P692, DOI 10.1037/0033-2909.132.5.692
   Gebauer JE, 2008, J EXP SOC PSYCHOL, V44, P1346, DOI 10.1016/j.jesp.2008.03.016
   Greenwald AG, 1998, J PERS SOC PSYCHOL, V74, P1464, DOI 10.1037/0022-3514.74.6.1464
   Gregg AP, 2010, SELF IDENTITY, V9, P142, DOI 10.1080/15298860902815451
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hoorens V, 2015, PSYCHOL ASSESSMENT, V27, P905, DOI 10.1037/pas0000092
   Hoorens V, 2014, EUR REV SOC PSYCHOL, V25, P228, DOI 10.1080/10463283.2014.980085
   Ioannidis JPA, 2007, CLIN TRIALS, V4, P245, DOI 10.1177/1740774507079441
   Ioannidis JPA, 2014, TRENDS COGN SCI, V18, P235, DOI 10.1016/j.tics.2014.02.010
   Kitayama S, 1997, PERS SOC PSYCHOL B, V23, P736, DOI 10.1177/0146167297237006
   Krause S, 2011, EUR J PERSONALITY, V25, P239, DOI 10.1002/per.792
   Krizan Z, 2008, PERS INDIV DIFFER, V44, P521, DOI 10.1016/j.paid.2007.09.017
   Krizan Z, 2008, J RES PERS, V42, P1635, DOI 10.1016/j.jrp.2008.07.002
   Lebel EP, 2009, EUR J PERSONALITY, V23, P85, DOI 10.1002/per.705
   Meehl PE, 1990, WHY SUMMARIES RES PS
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   NUTTIN JM, 1987, EUR J SOC PSYCHOL, V17, P381, DOI 10.1002/ejsp.2420170402
   Nuttin Jr M.J., 1985, EUROPEAN J SOCIAL PS, V64, P723
   Perinelli E, 2018, J PERS SOC PSYCHOL, V114, P959, DOI 10.1037/pspp0000125
   Pietschnig J, 2017, 14 ARBEITSTAGUNG FAC
   Pietschnig J, 2017, 17 ANN M ISIR MONTR
   R Core Team, 2015, R LANG ENV STAT COMP
   Ranganath KA, 2008, J EXP SOC PSYCHOL, V44, P386, DOI 10.1016/j.jesp.2006.12.008
   Rudman LA, 2007, J PERS SOC PSYCHOL, V93, P798, DOI 10.1037/0022-3514.93.5.798
   Rudolph A, 2008, EUR J PSYCHOL ASSESS, V24, P273, DOI 10.1027/1015-5759.24.4.273
   Sakellaropoulo M, 2007, J EXP SOC PSYCHOL, V43, P995, DOI 10.1016/j.jesp.2006.10.009
   Schooler J, 2011, NATURE, V470, P437, DOI 10.1038/470437a
   Simonsohn U, 2014, PERSPECT PSYCHOL SCI, V9, P666, DOI 10.1177/1745691614553988
   Simonsohn U, 2014, J EXP PSYCHOL GEN, V143, P534, DOI 10.1037/a0033242
   Spalding LR, 1999, PSYCHOL SCI, V10, P535, DOI 10.1111/1467-9280.00202
   Sterne JAC, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P99
   Stieger S, 2017, BEHAV GENET, V47, P175, DOI 10.1007/s10519-016-9829-8
   Stieger S, 2013, SELF IDENTITY, V12, P201, DOI 10.1080/15298868.2012.655897
   Stieger S, 2012, EUR J PERSONALITY, V26, P63, DOI 10.1002/per.823
   Stieger S, 2012, PERS INDIV DIFFER, V52, P51, DOI 10.1016/j.paid.2011.08.028
   Stieger S, 2010, CYBERPSYCH BEH SOC N, V13, P681, DOI 10.1089/cyber.2009.0426
   Strack F, 2004, PERS SOC PSYCHOL REV, V8, P220, DOI 10.1207/s15327957pspr0803_1
   van Aert RCM, 2016, PERSPECT PSYCHOL SCI, V11, P713, DOI 10.1177/1745691616650874
   van Assen MALM, 2015, PSYCHOL METHODS, V20, P293, DOI 10.1037/met0000025
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1
   Wegener I, 2015, COMPR PSYCHIAT, V58, P57, DOI 10.1016/j.comppsych.2014.12.001
NR 54
TC 0
Z9 0
U1 3
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 6
PY 2018
VL 13
IS 9
AR e0202873
DI 10.1371/journal.pone.0202873
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GT1KN
UT WOS:000444228700013
PM 30188907
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ashworth, AJ
   Toler, HD
   Allen, FL
   Auge, RM
AF Ashworth, Amanda J.
   Toler, Heather D.
   Allen, Fred L.
   Auge, Robert M.
TI Global meta-analysis reveals agro-grassland productivity varies based on
   species diversity over time
SO PLOS ONE
LA English
DT Article
ID NITROGEN USE EFFICIENCY; FILE-DRAWER PROBLEM; DINITROGEN FIXATION;
   ELEVATED CO2; BIODIVERSITY; PLANTS; YIELD; SWITCHGRASS; CROPS
AB Ecological research suggests increased diversity may improve ecosystem services, as well as yield stability; however, such theories are sometimes disproven by agronomic research, particularly at higher diversity levels. We conducted a meta-analysis on 2,753 studies in 48 articles published over the last 53 years to test: if biological N-2 fixation (BNF) supplies adequate nitrogen (N) for plant growth relative to synthetic fertilizers; how crop physiological traits affect legume-grass symbiosis; and, how cultural practices affect BNF over a range of soils and climates overtime (in polycultures versus sole grasslands). Globally, net primary productivity (NPP; total aboveground production response of grass and legume in higher-diversity treatments) increased 44% via legume associations relative to sole grass controls (including both with and without N fertilizer). Several moderating variables affected NPP including: (i) plant photosynthetic pathway (mixtures of C-3 grasses resulted in a 57% increase in NPP, whereas mixtures of C-4 grasses resulted in a 31% increase; similarly cool-season legumes increased NPP 52% compared to a 27% increase for warm-season legumes relative to grasslands without diversity); (ii) legume life cycle [NPP response for perennial legume mixtures was 50% greater than sole grass controls, followed by a 28% increase for biennial, and a 0% increase for annual legumes)]; and, (iii) species richness (one leguminous species in a grassland agroecosystem resulted in 52% increase in NPP, whereas >2 legumes resulted in only 6% increases). Temporal and spatial effect sizes also influenced facilitation, considering facilitation was greatest (114% change) in Mediterranean climates followed by oceanic (84%), and tropical savanna (65%) environments; conversely, semiarid and subarctic systems had lowest Rhizobium-induced changes (5 and 0% change, respectively). Facilitation of grass production by legumes was also affected by soil texture. For example, a 122% NPP increase was observed in silt clay soils compared to 14% for silt loam soils. Niche complementarity effects were greatest prior to 1971 (61% change), compared to recent studies (2011-2016; -7% change), likely owing to reduced global sulfur deposition and increased ambient temperatures overtime. These historical trends suggest potential for legume intercrops to displace inorganic-N fertilizer and sustainably intensify global NPP. Results herein provide a framework for ecologists and agronomists to improve crop diversification systems, refine research goals, and heighten BNF capacities in agro-grasslands.
C1 [Ashworth, Amanda J.] ARS, USDA, Poultry Prod & Prod Safety Res Unit, Fayetteville, AR 72701 USA.
   [Toler, Heather D.; Allen, Fred L.; Auge, Robert M.] Univ Tennessee, Dept Plant Sci, Knoxville, TN USA.
RP Ashworth, AJ (reprint author), ARS, USDA, Poultry Prod & Prod Safety Res Unit, Fayetteville, AR 72701 USA.
EM Amanda.Ashworth@ARS.USDA.GOV
OI Ashworth, Amanda/0000-0002-3218-8939
FU University of Tennessee, Plant Sciences Department; United States
   Department of Agriculture
FX Salaries for authors were provided by the University of Tennessee, Plant
   Sciences Department (Allen, Toler, and Auge) and the United States
   Department of Agriculture (Ashworth). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adams DC, 1997, ECOLOGY, V78, P1277, DOI 10.1890/0012-9658(1997)078[1277:RTFMAO]2.0.CO;2
   ALBRECHT SL, 1984, FIELD CROP RES, V8, P61, DOI 10.1016/0378-4290(84)90052-2
   Ashworth AJ, 2015, J SOIL WATER CONSERV, V70, P374, DOI 10.2489/jswc.70.6.374
   Ashworth AJ, 2015, J CLEAN PROD, V87, P227, DOI 10.1016/j.jclepro.2014.10.002
   Auge R. M., 2016, FRONT PLANT SCI, V7, P1
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BOHLOOL BB, 1992, PLANT SOIL, V141, P1, DOI 10.1007/BF00011307
   Borenstein M., 2009, INTRO METAANALYSIS
   Bristow SM, 2013, BRIT J NUTR, V110, P1384, DOI 10.1017/S0007114513001050
   BROCKWELL J, 1995, PLANT SOIL, V174, P143, DOI 10.1007/BF00032245
   BROWN RH, 1978, CROP SCI, V18, P93, DOI 10.2135/cropsci1978.0011183X001800010025x
   Cardinale BJ, 2006, NATURE, V443, P989, DOI 10.1038/nature05202
   Census of Agriculture, 2012, CENS AGR, V1
   Cooper Harris, 2016, RES SYNTHESIS METAAN
   Cumming G., 2012, UNDERSTANDING NEW ST
   Dalla Lana F, 2015, PHYTOPATHOLOGY, V105, P307, DOI 10.1094/PHYTO-06-14-0157-R
   Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529
   Erisman JW, 2007, ENVIRON POLLUT, V150, P140, DOI 10.1016/j.envpol.2007.06.033
   Ferraretto LF, 2015, J DAIRY SCI, V98, P2662, DOI 10.3168/jds.2014-9045
   Frankow-Lindberg BE, 2009, ANN BOT-LONDON, V103, P913, DOI 10.1093/aob/mcp008
   Fustec J, 2010, AGRON SUSTAIN DEV, V30, P57, DOI 10.1051/agro/2009003
   Graham PH, 2005, PRINCIPLES APPL SOIL, P405
   Hector A, 1999, SCIENCE, V286, P1123, DOI 10.1126/science.286.5442.1123
   Hector A, 2002, ECOL LETT, V5, P502, DOI 10.1046/j.1461-0248.2002.00337.x
   HEICHEL GH, 1991, CROP SCI, V31, P202, DOI 10.2135/cropsci1991.0011183X003100010045x
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hirel B, 2007, J EXP BOT, V58, P2369, DOI 10.1093/jxb/erm097
   Houlton BZ, 2008, NATURE, V454, P327, DOI 10.1038/nature07028
   Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180
   Jorgensen FV, 1997, ANN BOT-LONDON, V80, P641, DOI 10.1006/anbo.1997.0501
   Karl T.R., 2009, GLOBAL CLIMATE CHANG
   Koricheva J., 2013, HDB METAANALYSIS ECO
   Koricheva J, 2014, J ECOL, V102, P828, DOI 10.1111/1365-2745.12224
   Laurent A, 2015, RENEW SUST ENERG REV, V46, P41, DOI 10.1016/j.rser.2015.02.023
   Liu YY, 2011, AGRON SUSTAIN DEV, V31, P155, DOI 10.1051/agro/2010008
   Loreau M, 2001, NATURE, V412, P72, DOI 10.1038/35083573
   Mayerhofer MS, 2013, MYCORRHIZA, V23, P119, DOI 10.1007/s00572-012-0456-9
   McGrath JM, 2013, PLANT CELL ENVIRON, V36, P697, DOI 10.1111/pce.12007
   Mengersen K., 2013, HDB METAANALYSIS ECO, P255
   NCSS Statistical Software, 2015, NCSS 10 US GUID
   Nyfeler D, 2009, J APPL ECOL, V46, P683, DOI 10.1111/j.1365-2664.2009.01653.x
   Pelzer E, 2014, AGRON J, V106, P1775, DOI 10.2134/agronj13.0590
   Philibert A, 2012, AGR ECOSYST ENVIRON, V148, P72, DOI 10.1016/j.agee.2011.12.003
   Picasso VD, 2008, CROP SCI, V48, P331, DOI 10.2135/cropsci2007.04.0225
   Pimentel D, 2008, HUM ECOL, V36, P459, DOI 10.1007/s10745-008-9184-3
   REGANOLD JP, 1990, SCI AM, V262, P112, DOI 10.1038/scientificamerican0690-112
   Rogatgi A., 2011, WEBPLOTDIGITIZER
   Rosenberg MS, 2005, EVOLUTION, V59, P464, DOI 10.1554/04-602
   Rosenberg MS, 2000, METAWIN STAT SOFTWAR, P128
   ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638
   Rothstein HR, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P1
   SAGE RF, 1987, PLANT PHYSIOL, V84, P959, DOI 10.1104/pp.84.3.959
   Scherer Heinrich W., 2008, P43, DOI 10.1007/978-3-540-76326-0_3
   Suter M, 2015, GLOBAL CHANGE BIOL, V21, P2424, DOI 10.1111/gcb.12880
   Sutton AJ, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P175
   Tilman D, 2002, BIODIVERSITY AND ECOSYSTEM FUNCTIONING: SYNTHESIS AND PERSPECTIVES, P21
   Tilman D, 1996, NATURE, V379, P718, DOI 10.1038/379718a0
   Tremblay N, 2012, AGRON J, V104, P1658, DOI 10.2134/agronj2012.0184
   U.S. Environmental Protection Agency, 2017, CLEAN AIR ACT OV PRO
   Vellend M, 2013, P NATL ACAD SCI USA, V110, P19456, DOI 10.1073/pnas.1312779110
   Wang JY, 2015, CLIMATIC CHANGE, V130, P529, DOI 10.1007/s10584-015-1374-6
   Warwick K, 2016, J SOIL WATER CONSERV, V71, P21, DOI 10.2489/jswc.71.1.21
NR 62
TC 2
Z9 2
U1 10
U2 29
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 10
PY 2018
VL 13
IS 7
AR e0200274
DI 10.1371/journal.pone.0200274
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GM5IS
UT WOS:000438170300036
PM 29990337
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, WY
   Luo, XJ
   Liu, ZY
   Chen, YQ
   Li, ZH
AF Li, Wenyi
   Luo, Xujun
   Liu, Zhongyue
   Chen, Yanqiao
   Li, Zhihong
TI Prognostic value of C-reactive protein levels in patients with bone
   neoplasms: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID SYSTEMIC INFLAMMATORY RESPONSE; TO-LYMPHOCYTE RATIO; POOR SURVIVAL;
   NEUTROPHIL; INDICATOR; PLATELET
AB Objective
   The aim of this study was to conduct a meta-analysis of retrospective studies that investigated the association of preoperative C-reactive protein (CRP) levels with the overall survival (OS) of patients with bone neoplasms.
   Methods
   A detailed literature search was performed in the Cochrane Library, Web of Science, Embase and PubMed databases up to August 28, 2017, for related research publications written in English. We extracted the data from these studies and combined the hazard ratios (HR) and 95% confidence intervals (CIs) to assess the correlation between CRP levels and OS in patients with bone neoplasms.
   Results
   Five studies with a total of 816 participants from several countries were enrolled in this current meta-analysis. In a pooled analysis of all the publications, increased serum CRP levels had an adverse prognostic effect on the overall survival of patients with bone neoplasms. However, the combined data showed no significant relationship between the level of CRP and OS in Asian patients (HR = 1.73; 95% CI: 0.86-3.49; P = 0.125). Similar trends were observed in patients with bone neoplasms when stratified by ethnicity, histology, metastasis and study sample size.
   Conclusions
   The results of this meta-analysis suggest that increased CRP expression indicates a poorer prognosis in patients with bone neoplasms. More prospective studies are needed to confirm the prognostic significance of CRP levels in patients with bone neoplasms.
C1 [Li, Wenyi; Luo, Xujun; Liu, Zhongyue; Li, Zhihong] Cent S Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Hunan, Peoples R China.
   [Chen, Yanqiao] Cent S Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha, Hunan, Peoples R China.
RP Li, ZH (reprint author), Cent S Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Hunan, Peoples R China.
EM lizhihong@csu.edu.cn
FU National Natural Science Foundation of China [81372180]
FX This study was funded by the National Natural Science Foundation of
   China grant no. 81372180 to Z. Li. The funder had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.; This study was funded by the National
   Natural Science Foundation of China (No.81372180).
CR Aggerholm-Pedersen N, 2016, TRANSL ONCOL, V9, P322, DOI 10.1016/j.tranon.2016.05.006
   Alifano M, 2011, J THORAC CARDIOV SUR, V142, P1161, DOI 10.1016/j.jtcvs.2011.07.021
   Allin KH, 2011, CRIT REV CL LAB SCI, V48, P155, DOI 10.3109/10408363.2011.599831
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   CASTELL JV, 1990, HEPATOLOGY, V12, P1179, DOI 10.1002/hep.1840120517
   Eggers H, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0705-6
   Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611
   Evola FR, 2017, FRONT PHARMACOL, P8
   Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3
   Funovics PT, 2011, INT ORTHOP, V35, P1529, DOI 10.1007/s00264-011-1208-8
   Gagnon B, 2010, BRIT J CANCER, V102, P1113, DOI 10.1038/sj.bjc.6605603
   Gakis G, 2011, BJU INT, V108, P1800, DOI 10.1111/j.1464-410X.2011.10234.x
   Gockel I, 2006, WORLD J GASTROENTERO, V12, P3746, DOI 10.3748/wjg.v12.i23.3746
   Hashimoto K, 2005, CANCER-AM CANCER SOC, V103, P1856, DOI 10.1002/cncr.20976
   Hefler LA, 2008, CLIN CANCER RES, V14, P710, DOI 10.1158/1078-0432.CCR-07-1044
   Heikkila K, 2007, J EPIDEMIOL COMMUN H, V61, P824, DOI 10.1136/jech.2006.051292
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Howlader N., 2017, SEER CANC STAT REV
   Johnson T, 2011, CRP BASED CLASSIFICA, pe667
   Kinoshita A, 2012, MED ONCOL, V29, P2800, DOI 10.1007/s12032-012-0220-1
   Kos M, 2016, WIEN KLIN WOCHENSCHR, V128, P635, DOI 10.1007/s00508-015-0724-8
   Lamb GWA, 2006, BRIT J CANCER, V94, P781, DOI 10.1038/sj.bjc.6603034
   Lan HD, 2017, ONCOTARGET, V8, P35301, DOI 10.18632/oncotarget.13312
   Li XC, 2015, TUMOR BIOL, V36, P5663, DOI 10.1007/s13277-015-3240-6
   Li YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064158
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Liu BJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep39862
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Marnell L, 2005, CLIN IMMUNOL, V117, P104, DOI 10.1016/j.clim.2005.08.04
   Morris-Stiff G, 2008, EJSO-EUR J SURG ONC, V34, P727, DOI 10.1016/j.ejso.2008.01.016
   Muir KW, 1999, STROKE, V30, P981, DOI 10.1161/01.STR.30.5.981
   Nakamura T, 2013, BONE JOINT J, V95B, P411, DOI 10.1302/0301-620X.95B3.30344
   Nozoe T, 2001, AM J SURG, V182, P197, DOI 10.1016/S0002-9610(01)00684-5
   O'Rourke K, 2001, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USING S-PLUS, P397
   Oh BS, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-78
   Prins RC, 2012, UROL ONCOL-SEMIN ORI, P22, DOI [10.18632/oncotarget.12601, DOI 10.18632/ONCOTARGET.12601]
   Proctor MJ, 2011, EUR J CANCER, V47, P2633, DOI 10.1016/j.ejca.2011.03.028
   Qian BZ, 2017, SEMIN CANCER BIOL, V47, P170, DOI 10.1016/j.semcancer.2017.08.006
   Ridker PM, 1998, CIRCULATION, V97, P2007, DOI 10.1161/01.CIR.97.20.2007
   Rost NS, 2001, STROKE, V32, P2575, DOI 10.1161/hs1101.098151
   Roxburgh CSD, 2010, FUTURE ONCOL, V6, P149, DOI 10.2217/FON.09.136
   Sanchez-Salcedo P, 2016, LUNG CANCER, V97, P28, DOI 10.1016/j.lungcan.2016.04.010
   Shao N, 2015, TUMOR BIOL, V36, P8465, DOI 10.1007/s13277-015-3611-z
   Su KJ, 2016, INT J CLIN EXP MED, V9, P16353
   Szkandera J, 2014, BRIT J CANCER, V110, P183, DOI 10.1038/bjc.2013.701
   Thomsen M, 2016, ONCOTARGET, V7, P75013, DOI 10.18632/oncotarget.12601
   TILLETT WILLIAM S., 1930, JOUR EXP MED, V52, P561, DOI 10.1084/jem.52.4.561
   Tomita M, 2012, ANTICANCER RES, V32, P3535
   Wang X, 2016, ONCOTARGETS THER, V9, P5761, DOI 10.2147/OTT.S106296
   Yi JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094632
   Zhou F, 2017, ONCOTARGET, V8, P100384, DOI 10.18632/oncotarget.22233
NR 51
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 18
PY 2018
VL 13
IS 4
AR e0195769
DI 10.1371/journal.pone.0195769
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GD1VU
UT WOS:000430290200056
PM 29668751
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Micha, R
   Karageorgou, D
   Bakogianni, I
   Trichia, E
   Whitsel, LP
   Story, M
   Penalvo, JL
   Mozaffarian, D
AF Micha, Renata
   Karageorgou, Dimitra
   Bakogianni, Ioanna
   Trichia, Eirini
   Whitsel, Laurie P.
   Story, Mary
   Penalvo, Jose L.
   Mozaffarian, Dariush
TI Effectiveness of school food environment policies on children's dietary
   behaviors: A systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIAL; SUGAR-SWEETENED BEVERAGES; OBESITY
   PREVENTION; VEGETABLE CONSUMPTION; PHYSICAL-ACTIVITY; COMPETITIVE FOOD;
   NUTRIENT CONTENT; FRESH FRUIT; CHILDHOOD OBESITY; LUNCH PROGRAM
AB Background
   School food environment policies may be a critical tool to promote healthy diets in children, yet their effectiveness remains unclear.
   Objective
   To systematically review and quantify the impact of school food environment policies on dietary habits, adiposity, and metabolic risk in children.
   Methods
   We systematically searched online databases for randomized or quasi-experimental interventions assessing effects of school food environment policies on children's dietary habits, adiposity, or metabolic risk factors. Data were extracted independently and in duplicate, and pooled using inverse-variance random-effects meta-analysis. Habitual (within+outside school) dietary intakes were the primary outcome. Heterogeneity was explored using meta-regression and subgroup analysis. Funnel plots, Begg's and Egger's test evaluated potential publication bias.
   Results
   From 6,636 abstracts, 91 interventions (55 in US/Canada, 36 in Europe/New Zealand) were included, on direct provision of healthful foods/beverages (N = 39 studies), competitive food/beverage standards (N = 29), and school meal standards (N = 39) (some interventions assessed multiple policies). Direct provision policies, which largely targeted fruits and vegetables, increased consumption of fruits by 0.27 servings/d (n = 15 estimates (95% CI: 0.17, 0.36)) and combined fruits and vegetables by 0.28 servings/d (n = 16 (0.17, 0.40)); with a slight impact on vegetables (n = 11; 0.04 (0.01, 0.08)), and no effects on total calories (n = 6; -56 kcal/d (-174, 62)). In interventions targeting water, habitual intake was unchanged (n = 3; 0.33 glasses/d (-0.27, 0.93)). Competitive food/beverage standards reduced sugarsweetened beverage intake by 0.18 servings/d (n = 3 (-0.31, -0.05)); and unhealthy snacks by 0.17 servings/d (n = 2 (-0.22, -0.13)), without effects on total calories (n = 5; -79 kcal/d (-179, 21)). School meal standards (mainly lunch) increased fruit intake (n = 2; 0.76 servings/d (0.37, 1.16)) and reduced total fat (-1.49% energy; n = 6 (-2.42, -0.57)), saturated fat (n = 4; -0.93% energy (-1.15, -0.70)) and sodium (n = 4; -170 mg/d (-242, -98)); but not total calories (n = 8; -38 kcal/d (-137, 62)). In 17 studies evaluating adiposity, significant decreases were generally not identified; few studies assessed metabolic factors (blood lipids/glucose/pressure), with mixed findings. Significant sources of heterogeneity or publication bias were not identified.
   Conclusions
   Specific school food environment policies can improve targeted dietary behaviors; effects on adiposity and metabolic risk require further investigation. These findings inform ongoing policy discussions and debates on best practices to improve childhood dietary habits and health.
C1 [Micha, Renata; Penalvo, Jose L.; Mozaffarian, Dariush] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
   [Karageorgou, Dimitra; Bakogianni, Ioanna; Trichia, Eirini] Agr Univ Athens, Dept Food Sci & Human Nutr, Athens, Greece.
   [Whitsel, Laurie P.] Amer Heart Assoc, Policy Res, Dallas, TX USA.
   [Story, Mary] Duke Univ, Global Hlth Inst, Durham, NC USA.
   [Story, Mary] Duke Univ, Community & Family Med, Durham, NC USA.
RP Micha, R (reprint author), Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
EM renata.micha@tufts.edu
FU NHLBI NIH HHS [R01 HL115189]; NIH HHS [R01 HL115189, R01 HL130735]
CR Amin SA, 2015, PUBLIC HEALTH REP, V130, P453, DOI 10.1177/003335491513000508
   Anderson AS, 2005, PUBLIC HEALTH NUTR, V8, P650, DOI 10.1079/PHN2004721
   Anderson LM, 2013, J SCH NURS, V29, P52, DOI 10.1177/1059840512453602
   [Anonymous], 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19430
   Ashfield-Watt PA, 2009, PILOT STUDY EFFECT P
   Ask AS, 2010, PUBLIC HEALTH NUTR, V13, P238, DOI 10.1017/S1368980009990772
   Bae Sang Geun, 2012, J Prev Med Public Health, V45, P47, DOI 10.3961/jpmph.2012.45.1.47
   Baranowski T, 2010, NEW ENGL J MED, V363, P443, DOI 10.1056/NEJMoa1001933
   Bartholomew JB, 2006, J AM DIET ASSOC, V106, P248, DOI 10.1016/j.jada.2005.10.030
   Bartlett S, 2013, EVALUATION FRESH FRU
   Bauhoff S, 2013, EC HUMAN BIOL
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bere E, 2005, PREV MED, V41, P463, DOI 10.1016/j.ypmed.2004.11.024
   Bere E, 2006, FREE SCH FRUIT SUSTA, P268
   Bere E, 2007, INT J BEHAV NUTR PHY, V4, DOI 10.1186/1479-5868-4-5
   Bere E, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0301-6
   Bere E, 2010, BRIT J NUTR, V104, P589, DOI 10.1017/S0007114510000814
   Bergman EA, 2014, J CHILD NUTR MANAG, V38
   Birch LL, 1998, P NUTR SOC, V57, P617, DOI 10.1079/PNS19980090
   Blum JEW, 2008, J NUTR EDUC BEHAV, V40, P341, DOI 10.1016/j.jneb.2007.12.004
   Bogart LM, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2493
   Bonsergent E, 2013, AM J PREV MED, V44, P30, DOI 10.1016/j.amepre.2012.09.055
   Burgess-Champoux TL, 2008, PUBLIC HEALTH NUTR, V11, P849, DOI 10.1017/S1368980007001346
   Chriqui JF, 2014, JAMA PEDIATR, V168, P279, DOI 10.1001/jamapediatrics.2013.4457
   Cohen JFW, 2014, AM J PREV MED, V46, P388, DOI 10.1016/j.amepre.2013.11.013
   Cohen JFW, 2014, J ACAD NUTR DIET, V114, P48, DOI 10.1016/j.jand.2013.08.014
   Cohen JFW, 2012, J ACAD NUTR DIET, V112, P927, DOI 10.1016/j.jand.2012.01.015
   Coleman KJ, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-80
   Coyle KK, 2009, PUBLIC HEALTH REP, V124, P660, DOI 10.1177/003335490912400508
   Cradock AL, 2011, PREV CHRONIC DIS, V8
   Craigie AM, 2011, MATURITAS, V70, P266, DOI 10.1016/j.maturitas.2011.08.005
   Cullen KW, 2015, J ACAD NUTR DIET, V115, P743, DOI 10.1016/j.jand.2014.10.021
   Cullen KW, 2008, AM J PUBLIC HEALTH, V98, P111, DOI 10.2105/AJPH.2007.111765
   Cummings PL, 2014, PREV MED, V67, pS21, DOI 10.1016/j.ypmed.2014.03.004
   Davis EM, 2009, J AM DIET ASSOC, V109, P1227, DOI 10.1016/j.jada.2009.04.017
   de Sa J, 2008, EUR J PUBLIC HEALTH, V18, P558, DOI 10.1093/eurpub/ckn061
   Delgado-Noguera M, 2011, PREV MED, V53, P3, DOI 10.1016/j.ypmed.2011.04.016
   Driessen CE, 2014, OBES REV, V15, P968, DOI 10.1111/obr.12224
   Dwyer J, 1996, IMPACT MODIFYING S S, V20, P21
   Dwyer JT, 1996, PREV MED, V25, P413, DOI 10.1006/pmed.1996.0073
   Eagle TF, 2013, AM J MED, V126, P903, DOI 10.1016/j.amjmed.2013.04.019
   Elbel B, 2015, AM J PUBLIC HEALTH, V105, P365, DOI 10.2105/AJPH.2014.302221
   Eriksen K, 2003, PUBLIC HEALTH NUTR, V6, P57, DOI 10.1079/PHN2002356
   Evans CEL, 2012, AM J CLIN NUTR, V96, P889, DOI 10.3945/ajcn.111.030270
   Fiske A, 2004, J AM DIET ASSOC, V104, P90, DOI 10.1016/j.jada.2003.10.011
   Fogarty AW, 2007, INT J EPIDEMIOL, V36, P1080, DOI 10.1093/ije/dym133
   Folta SC, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-157
   Foster GD, 2008, PEDIATRICS, V121, pE794, DOI 10.1542/peds.2007-1365
   French SA, 2004, AM J PUBLIC HEALTH, V94, P1507, DOI 10.2105/AJPH.94.9.1507
   Fu R, 2008, METHODS GUIDE EFFECT
   Fung C, 2013, PREVENTIVE MED
   Ganann Rebecca, 2014, BMC Res Notes, V7, P422, DOI 10.1186/1756-0500-7-422
   Haroun D, 2011, PUBLIC HEALTH NUTR, V14, P209, DOI 10.1017/S1368980010002132
   He MZ, 2009, PUBLIC HEALTH NUTR, V12, P2199, DOI 10.1017/S1368980009005801
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hollar Danielle, 2010, J Health Care Poor Underserved, V21, P93, DOI 10.1353/hpu.0.0304
   Hoppu U, 2010, PUBLIC HEALTH NUTR, V13, P973, DOI 10.1017/S1368980010001163
   Howerton MW, 2007, J NUTR EDUC BEHAV, V39, P186, DOI 10.1016/j.jneb.2007.01.010
   Huehnergarth NF, 2016, FORBES
   Jensen C. D., 2012, ICAN: Infant, Child & Adolescent Nutrition, V4, P276, DOI 10.1177/1941406412458314
   Johnson DB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2015.3918
   Katz DL, 2008, INT J OBESITY, V32, P1780, DOI 10.1038/ijo.2008.158
   Kaufman F., 2011, Childhood Obesity, V7, P291
   Khambalia AZ, 2012, OBES REV, V13, P214, DOI 10.1111/j.1467-789X.2011.00947.x
   Kim K, 2012, NUTR RES PRACT, V6, P138, DOI 10.4162/nrp.2012.6.2.138
   Kocken PL, 2015, PUBLIC HEALTH NUTR, V18, P1545, DOI 10.1017/S1368980014002985
   Kocken PL, 2012, J SCHOOL HEALTH, V82, P115, DOI 10.1111/j.1746-1561.2011.00674.x
   Levy DT, 2011, ADV NUTR, V2, p182S, DOI 10.3945/an.111.000356
   Loughridge JL, 2005, J HUM NUTR DIET, V18, P281, DOI 10.1111/j.1365-277X.2005.00622.x
   Luepker RV, 1996, JAMA-J AM MED ASSOC, V275, P768, DOI 10.1001/jama.275.10.768
   Lytle LA, 2004, HEALTH EDUC BEHAV, V31, P270, DOI 10.1177/1090198103260635
   Marcus C, 2009, INT J OBESITY, V33, P408, DOI 10.1038/ijo.2009.38
   Mikkila V, 2005, BRIT J NUTR, V93, P923, DOI 10.1079/BJN20051418
   Mobley CC, 2012, J SCHOOL HEALTH, V82, P82, DOI 10.1111/j.1746-1561.2011.00670.x
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moore L, 2008, J EPIDEMIOL COMMUN H, V62, P926, DOI 10.1136/jech.2007.070953
   Mozaffarian D, 2016, CIRCULATION, V133, P187, DOI 10.1161/CIRCULATIONAHA.115.018585
   Mozaffarian D, 2012, CIRCULATION, V126, P1514, DOI 10.1161/CIR.0b013e318260a20b
   Muckelbauer R, 2009, PEDIATRICS, V123, pE661, DOI 10.1542/peds.2008-2186
   Mullally ML, 2010, CAN J PUBLIC HEALTH, V101, P40
   Murphy S, 2011, PUBLIC HEALTH NUTR, V14, P219, DOI 10.1017/S1368980010001886
   Nelson M, 2011, NUTR BULL, V36, P381, DOI 10.1111/j.1467-3010.2011.01914.x
   Nixon CA, 2012, OBES REV, V13, P106, DOI 10.1111/j.1467-789X.2011.00962.x
   Olsho LEW, 2015, J ACAD NUTR DIET, V115, P1283, DOI 10.1016/j.jand.2014.12.026
   Osganian SK, 2003, HEALTH EDUC BEHAV, V30, P418, DOI 10.1177/109098103253509
   Palakshappa D, 2016, PREV MED, V90, P107, DOI 10.1016/j.ypmed.2016.06.039
   Perry CL, 2004, HEALTH EDUC BEHAV, V31, P65, DOI 10.1177/1090198103255530
   Rahmani K, 2011, J RES MED SCI, V16, P469
   Ransley JK, 2007, J EPIDEMIOL COMMUN H, V61, P699, DOI 10.1136/jech.2006.052696
   Reinaerts E, 2008, HEALTH EDUC RES, V23, P987, DOI 10.1093/her/cyn027
   Sanchez-Vaznaugh EV, 2015, JAMA PEDIATR, V169, DOI 10.1001/jamapediatrics.2015.0781
   Sanchez-Vaznaugh EV, 2010, HEALTH AFFAIR, V29, P436, DOI 10.1377/hlthaff.2009.0745
   Schwartz AE, 2016, JAMA PEDIATR, V170, P220, DOI 10.1001/jamapediatrics.2015.3778
   Schwartz MB, 2015, CHILD OBES, V11, P242, DOI 10.1089/chi.2015.0019
   Schwartz MB, 2009, HEALTH EDUC BEHAV, V36, P999, DOI 10.1177/1090198108329998
   Simmonds M, 2016, OBES REV, V17, P95, DOI 10.1111/obr.12334
   SIMONSMORTON BG, 1991, AM J PUBLIC HEALTH, V81, P986, DOI 10.2105/AJPH.81.8.986
   Slusser WM, 2007, PUBLIC HEALTH NUTR, V10, P1490, DOI 10.1017/S1368980007000444
   SNYDER MP, 1992, J AM DIET ASSOC, V92, P1087
   Sobol-Goldberg S, 2013, OBESITY, V21, P2422, DOI 10.1002/oby.20515
   Spence S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112648
   Spence S, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/s12966-014-0128-6
   Spence S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078298
   Story M, 2003, PREV MED, V37, pS35, DOI 10.1016/j.ypmed.2003.08.009
   Summerbell CD, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001871.pub2
   Taber DR, 2012, PEDIATRICS, V130, P437, DOI 10.1542/peds.2011-3353
   Taber DR, 2012, ARCH PEDIAT ADOL MED, V166, P452, DOI 10.1001/archpediatrics.2011.1839
   Tak NI, 2009, PUBLIC HEALTH NUTR, V12, P1213, DOI 10.1017/S1368980008003777
   te Velde SJ, 2008, BRIT J NUTR, V99, P893, DOI 10.1017/S000711450782513X
   U. S. Department of Agriculture Food and Nutrition Service, FRESH FRUIT VEG PROG
   U. S. Department of Agriculture Food and Nutrition Service, NUTR STAND SCH MEALS
   U. S. Department of Agriculture Food and Nutrition Service, SCH MEALS HLTH HUNG
   U. S. Department of Agriculture Food and Nutrition Service, HLTH SCH DAY TOOLS S
   Van Cauwenberghe E, 2010, BRIT J NUTR, V103, P781, DOI 10.1017/S0007114509993370
   van de Gaar VMV, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/s12966-014-0098-8
   Vargas-Garcia EJ, 2017, OBES REV, V18, P1350, DOI 10.1111/obr.12580
   Visscher TLS, 2010, OBESITY FACTS, V3, P109, DOI 10.1159/000300848
   Wang Y, 2013, CHILDHOOD OBESITY PR
   Welker E, 2016, CURR OBES REP, V5, P145, DOI 10.1007/s13679-016-0204-0
   WHITAKER RC, 1993, PEDIATRICS, V91, P1107
   Williams CL, 2002, J AM COLL NUTR, V21, P62, DOI 10.1080/07315724.2002.10719195
   Williamson DA, 2007, OBESITY, V15, P906, DOI 10.1038/oby.2007.597
   Williamson DA, 2012, OBESITY, V20, P1653, DOI 10.1038/oby.2012.60
   Woodward-Lopez G, 2010, AM J PUBLIC HEALTH, V100, P2137, DOI 10.2105/AJPH.2010.193490
   Wordell D, 2012, J ACAD NUTR DIET, V112, P137, DOI 10.1016/j.jada.2011.09.008
NR 125
TC 12
Z9 12
U1 11
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 29
PY 2018
VL 13
IS 3
AR e0194555
DI 10.1371/journal.pone.0194555
PG 27
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GA8ZI
UT WOS:000428630000029
PM 29596440
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, F
   Jin, T
   Liu, L
   Xiang, ZZ
   Yan, RN
   Yang, H
AF Liu, Fang
   Jin, Tao
   Liu, Lei
   Xiang, Zhongzheng
   Yan, Ruonan
   Yang, Hui
TI The role of concurrent chemotherapy for stage II nasopharyngeal
   carcinoma in the intensity-modulated radiotherapy era: A systematic
   review and meta-analysis
SO PLOS ONE
LA English
DT Article
ID CONVENTIONAL 2-DIMENSIONAL RADIOTHERAPY; RADIATION-THERAPY;
   CLINICAL-OUTCOMES; CHEMORADIOTHERAPY; SURVIVAL; TRIAL; BIAS
AB Objectives
   To compare clinical outcomes of concurrent chemoradiotherapy (CCRT) with those of radiotherapy alone for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy (IMRT) era.
   Materials and methods
   We comprehensively searched PubMed, Embase, and the Cochrane Library to identify eligible studies. Overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional recurrence-free survival (LRRFS) with hazard ratios (HRs), and toxicities with odd ratios (ORs) were analyzed.
   Results
   A total of seven studies met the criteria, with 1302 patients who were treated with IMRT alone or IMRT plus concurrent chemotherapy. No significant survival benefit was shown by CCRT regardless of OS (HR = 1.17, 95% CI 0.73-1.89, P = 0.508), PFS (HR = 0.76, 95% CI 0.38-1.50, P = 0.430), DMFS (HR = 0.89, 95% CI 0.33-2.41, P = 0.816), or LRRFS (HR = 1.03, 95% CI 0.95-1.12, P = 0.498). Additionally, CCRT notably increased the risk of acute grade 3-4 leukopenia (OR = 4.432, 95% CI 2.195-8.952, P < 0.001), compared to IMRT alone.
   Conclusion
   Adding concurrent chemotherapy to IMRT led to no survival benefit and increased acute toxicity reactions for stage II nasopharyngeal carcinoma.
C1 [Liu, Fang; Liu, Lei; Xiang, Zhongzheng; Yan, Ruonan] Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol,State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China.
   [Jin, Tao] Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Sichuan, Peoples R China.
   [Yang, Hui] Sichuan Univ, West China Hosp, Dept Otolaryngol Head & Neck Surg, Chengdu, Sichuan, Peoples R China.
RP Liu, L (reprint author), Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol,State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China.; Yang, H (reprint author), Sichuan Univ, West China Hosp, Dept Otolaryngol Head & Neck Surg, Chengdu, Sichuan, Peoples R China.
EM liuleihx@gmail.com; yangfree1966@163.com
FU Major programs of Sichuan Science and Technology Department [2017SZ0015]
FX This work was sponsored by the Major programs of Sichuan Science and
   Technology Department (No. 2017SZ0015). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [Anonymous], BMJ, V339, pb2700
   [Anonymous], 2009, EPIDEMIOLOGY BIOSTAT, V6, pe1
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cao Su-Mei, 2011, Chin J Cancer, V30, P114
   Chan ATC, 2012, ANN ONCOL, V23, P83, DOI 10.1093/annonc/mds266
   Chang ET, 2006, CANCER EPIDEM BIOMAR, V15, P1765, DOI 10.1158/1055-9965.EPI-06-0353
   Chen KH, 2016, ONCOTARGET, V7, P69041, DOI 10.18632/oncotarget.11978
   Chen QY, 2011, JNCI-J NATL CANCER I, V103, P1761, DOI 10.1093/jnci/djr432
   Cheng SH, 2000, J CLIN ONCOL, V18, P2040, DOI 10.1200/JCO.2000.18.10.2040
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fang FM, 2008, INT J RADIAT ONCOL, V72, P356, DOI 10.1016/j.ijrobp.2007.12.054
   Guo QJ, 2016, JPN J CLIN ONCOL, V46, P241, DOI 10.1093/jjco/hyv192
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins Julian PT, 2008, COCHRANE HDB SYSTEMA, P102
   Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024
   Lee N, 2009, J CLIN ONCOL, V27, P3684, DOI 10.1200/JCO.2008.19.9109
   Luo SQ, 2014, HEAD NECK-J SCI SPEC, V36, P841, DOI 10.1002/hed.23386
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Ng AWY, 2015, INT J RADIAT ONCOL, V93, pE306, DOI 10.1016/j.ijrobp.2015.07.1329
   Ng WT, 2011, INT J RADIAT ONCOL, V79, P420, DOI 10.1016/j.ijrobp.2009.11.024
   Peng G, 2012, RADIOTHER ONCOL, V104, P286, DOI 10.1016/j.radonc.2012.08.013
   Phillips B, 2009, LEVELS EVIDENCE
   Su SF, 2012, INT J RADIAT ONCOL, V82, P327, DOI 10.1016/j.ijrobp.2010.09.011
   Su Z, 2016, TUMOR BIOL, V37, P4429, DOI 10.1007/s13277-015-4266-5
   Tham IWK, 2010, AM J CLIN ONCOL-CANC, V33, P294, DOI 10.1097/COC.0b013e3181d2edab
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Wells GA, 2014, APPL ENG AGRIC, V18, P727
   Xiao WW, 2009, INT J RADIAT ONCOL, V74, P1070, DOI 10.1016/j.ijrobp.2008.09.008
   Xu C, 2017, J CANCER, V8, P287, DOI 10.7150/jca.17317
   Xu T, 2015, MEDICINE, V94, pE293
   Xu TT, 2011, ORAL ONCOL, V47, P408, DOI 10.1016/j.oraloncology.2011.03.008
   Yi J, 2015, INT J RADIAT ONCOL, V93, pS128, DOI 10.1016/j.ijrobp.2015.07.305
   Zhang AM, 2012, RADIOTHER ONCOL, V104, P279, DOI 10.1016/j.radonc.2012.08.022
   Zhang LN, 2015, ONCOTARGET, V6, P44019, DOI 10.18632/oncotarget.5806
NR 35
TC 3
Z9 4
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 22
PY 2018
VL 13
IS 3
AR e0194733
DI 10.1371/journal.pone.0194733
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GA1RF
UT WOS:000428093900098
PM 29566078
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Han, XF
   Zhang, XX
   Liu, KM
   Tan, H
   Zhang, Q
AF Han, Xiao-fang
   Zhang, Xin-xiu
   Liu, Ke-mei
   Tan, Hua
   Zhang, Qiu
TI Contrast-induced nephropathy in patients with diabetes mellitus between
   iso- and low-smolar contrast media: A meta-analysis of full-text
   prospective, randomized controlled trials
SO PLOS ONE
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; PERCUTANEOUS CORONARY INTERVENTION; RENALLY
   IMPAIRED PATIENTS; LOW-OSMOLAR; INDUCED NEPHROTOXICITY; IODIXANOL;
   ANGIOGRAPHY; FAILURE; INSUFFICIENCY; PREVENTION
AB Purpose
   This study was conducted to compare iso-osmolar contrast medium, iodixanol, with low-osmolar contrast media (LOCM) for assessing contrast-induced nephropathy (CIN) incidence, exclusively in the diabetic population.
   Method
   A systematic search was conducted for full-text, prospective, randomized controlled trials (RCTs). The primary outcome was incidence of CIN. Medline, Cochrane Central Register of Controlled Trials, and other sources were searched until May 31, 2017.
   Results
   Twelve RCTs finally met the search criteria. Iodixanol did not significantly reduce the risk of CIN (risk ratio [RR]: 0.72, 95% confidence interval (CI): [0.49, 1.04], p = 0.08). However, there was significantly reduced risk of CIN when iodixanol was compared to a LOCM agent iohexol (RR: 0.32, 95% CI [0.12, 0.89]). There were no differences between iodixanol and the other non-iohexol LOCM (RR: 0.92, 95% CI [0.68, 1.25]).
   Conclusion
   In diabetic populations, iodixanol is not associated with a significant reduction of CIN risk. Iodixanol is associated with a reduced risk of CIN compared with iohexol, whereas no significant difference between iodixanol and other LOCM could be found.
C1 [Han, Xiao-fang; Zhang, Qiu] Anhui Med Univ, Affiliated Hosp 1, Dept Endocrinol, Hefei, Anhui, Peoples R China.
   [Han, Xiao-fang; Zhang, Xin-xiu; Liu, Ke-mei] Second Peoples Hosp Hefei, Dept Endocrinol, Hefei, Anhui, Peoples R China.
   [Tan, Hua] Wake Forest Sch Med, Dept Radiol, Ctr Bioinformat & Syst Biol, Winston Salem, NC USA.
RP Zhang, Q (reprint author), Anhui Med Univ, Affiliated Hosp 1, Dept Endocrinol, Hefei, Anhui, Peoples R China.
EM qiuzhang_ah@sina.com
FU Anhui Provincial Natural Science Foundation [1608085MH208]
FX This work was supported by Anhui Provincial Natural Science Foundation,
   1608085MH208.
CR Aspelin P, 2003, NEW ENGL J MED, V348, P491, DOI 10.1056/NEJMoa021833
   Bachorzewska-Gajewska H, 2006, NEPHROLOGY, V11, P549, DOI 10.1111/j.1440-1797.2006.00709.x
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bartholomew BA, 2004, AM J CARDIOL, V93, P1515, DOI 10.1016/j.amjcard.2004.03.008
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benko A, 2007, CAN ASSOC RADIOL J, V58, P79
   Brown JR, 2008, AM HEART J, V155, P260, DOI 10.1016/j.ahj.2007.10.007
   Chen YD, 2012, EUROINTERVENTION, V8, P830, DOI 10.4244/EIJV8I7A126
   Chuang FR, 2009, RENAL FAILURE, V31, P181, DOI 10.1080/08860220802669636
   Dangas G, 2005, AM J CARDIOL, V95, P13, DOI 10.1016/j.amjcard.2004.08.056
   Feldkamp T, 2006, CLIN NEPHROL, V66, P322
   From AM, 2010, CIRC-CARDIOVASC INTE, V3, P351, DOI 10.1161/CIRCINTERVENTIONS.109.917070
   Gupta R, 2005, CATHETER CARDIO INTE, V64, P442, DOI 10.1002/ccd.20316
   Hardiek KJ, 2008, J DIABETES COMPLICAT, V22, P171, DOI 10.1016/j.jdiacomp.2006.11.002
   Heinrich MC, 2009, RADIOLOGY, V250, P68, DOI 10.1148/radiol.2501080833
   Hernandez F, 2009, REV ESP CARDIOL, V62, P1373, DOI 10.1016/S0300-8932(09)73122-7
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA, Vxxi
   Jo SH, 2006, J AM COLL CARDIOL, V48, P924, DOI 10.1016/j.jacc.2006.06.047
   Kuhn MJ, 2008, AM J ROENTGENOL, V191, P151, DOI 10.2214/AJR.07.3370
   Laskey W, 2009, AM HEART J, V158, P822, DOI 10.1016/j.ahj.2009.08.016
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Liss P, 2006, KIDNEY INT, V70, P1811, DOI 10.1038/sj.ki.5001887
   McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2
   McCullough PA, 2006, J AM COLL CARDIOL, V48, P692, DOI 10.1016/j.jacc.2006.02.073
   Mehran R, 2004, J AM COLL CARDIOL, V44, P1393, DOI 10.1016/j.jacc.2004.06.068
   Middleton RJ, 2006, NEPHROL DIAL TRANSPL, V21, P88, DOI 10.1093/ndt/gfi163
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Morcos SK, 1999, EUR RADIOL, V9, P1602, DOI 10.1007/s003300050894
   Nash K, 2002, AM J KIDNEY DIS, V39, P930, DOI 10.1053/ajkd.2002.32766
   New JP, 2007, DIABETIC MED, V24, P364, DOI 10.1111/j.1464-5491.2007.02075.x
   Reed M, 2009, JACC-CARDIOVASC INTE, V2, P645, DOI 10.1016/j.jcin.2009.05.002
   Rihal CS, 2002, CIRCULATION, V105, P2259, DOI 10.1161/01.CIR.0000016043.87291.33
   Rudnick MR, 2008, AM HEART J, V156, P776, DOI 10.1016/j.ahj.2008.05.023
   Shin DH, 2011, AM J CARDIOL, V108, P189, DOI 10.1016/j.amjcard.2011.03.019
   Solomon RJ, 2007, CIRCULATION, V115, P3189, DOI 10.1161/CIRCULATIONAHA.106.671644
   Stacul F, 2011, EUR RADIOL, V21, P2527, DOI 10.1007/s00330-011-2225-0
   Tan H, 2016, ONCOTARGET, V7, P73130, DOI 10.18632/oncotarget.12233
NR 37
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 20
PY 2018
VL 13
IS 3
AR e0194330
DI 10.1371/journal.pone.0194330
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FZ9AH
UT WOS:000427901500025
PM 29558481
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, ZS
   Wang, T
   Wu, Z
   Zhang, KY
   Li, W
   Yang, JB
   Chen, CX
   Chen, L
   Xing, JC
AF Liu, Zhengsheng
   Wang, Tao
   Wu, Zhun
   Zhang, Kaiyan
   Li, Wei
   Yang, Jianbin
   Chen, Chenxi
   Chen, Lei
   Xing, Jinchun
TI Association between TERT rs2853669 polymorphism and cancer risk: A
   meta-analysis of 9,157 cases and 11,073 controls
SO PLOS ONE
LA English
DT Article
ID TELOMERASE-REVERSE-TRANSCRIPTASE; SINGLE NUCLEOTIDE POLYMORPHISM;
   PROMOTER MUTATIONS; HTERT GENE; BREAST-CANCER; LUNG-CANCER;
   SUSCEPTIBILITY; LENGTH; REACTIVATION; MAINTENANCE
AB Background
   It has been reported that the functional telomerase reverse transcriptase (TERT) rs2853669 polymorphism might contribute to different types of human cancer. However, the association of this mutation with cancer remains controversial. Here, we conducted a meta-analysis to characterize this relationship.
   Materials and methods/Main results
   A systematic search of studies on the association of TERT rs2853669 polymorphism with all types of cancer was conducted in PubMed, Embase and Cochrane Library. The summary odds ratios (ORs) and corresponding 95% confidence intervals (95% Cls) were used to pool the effect size in a fixed-effects model or a random-effects model where appropriate. A total of 13 articles and 15 case-control studies, including 9,157 cases and 11,073 controls, were included in this meta-analysis. Overall, the pooled results indicated that the rs2853669 polymorphism was significantly associated with increased cancer risk in a homozygote comparison model (CT vs. TT: OR = 1.085, 95% Cl: 1.015-1.159, P = 0.016). In the stratified analyses, a significant increased cancer risk was observed in Asian, but not Caucasian patients. A subgroup analysis by cancer type also revealed a significant increase in the risk of lung cancer, but not breast cancer.
   Conclusions
   The results of this meta-analysis suggest that the TERT rs2853669 polymorphism is associated with a significantly increased risk of cancer, particularly lung cancer, in Asian populations.
C1 [Liu, Zhengsheng; Wang, Tao; Wu, Zhun; Zhang, Kaiyan; Li, Wei; Yang, Jianbin; Chen, Chenxi; Xing, Jinchun] Xiamen Univ, Affiliated Hosp 1, Dept Urol, Xiamen, Fujian, Peoples R China.
   [Liu, Zhengsheng; Yang, Jianbin; Chen, Chenxi] Fujian Med Univ, Clin Med Coll 1, Fuzhou, Fujian, Peoples R China.
   [Chen, Lei] Zhuxi People Hosp, Shiyan, Hubei, Peoples R China.
RP Xing, JC (reprint author), Xiamen Univ, Affiliated Hosp 1, Dept Urol, Xiamen, Fujian, Peoples R China.
EM xmcua2007@sina.com
FU Fujian Provincial Department of Science and Technology [2016D009]; Key
   Laboratory of Xiamen Urological Center
FX This work was supported by Fujian Provincial Department of Science and
   Technology (Grant No. 2016D009) and the Key Laboratory of Xiamen
   Urological Center. The funder had no role instudy design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akincilar SC, 2016, CELL MOL LIFE SCI, V73, P1659, DOI 10.1007/s00018-016-2146-9
   Bayram S, 2016, GENE, V585, P84, DOI 10.1016/j.gene.2016.03.030
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bianchi A, 2008, MOL CELL, V31, P153, DOI 10.1016/j.molcel.2008.06.013
   Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656
   Borah S, 2015, SCIENCE, V347, P1006, DOI 10.1126/science.1260200
   COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x
   Cukusic A, 2008, CYTOGENET GENOME RES, V122, P263, DOI 10.1159/000167812
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Giardini MA, 2014, PROG MOL BIOL TRANSL, V125, P1, DOI 10.1016/B978-0-12-397898-1.00001-3
   Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275
   Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085
   Hosen I, 2015, INT J CANCER, V136, P2448, DOI 10.1002/ijc.29279
   Hsu CP, 2006, EUR J CANCER, V42, P1466, DOI 10.1016/j.ejca.2006.02.014
   Jannuzzi AT, 2015, GENET TEST MOL BIOMA, V19, P692, DOI 10.1089/gtmb.2015.0150
   Kachuri L, 2016, CANC EPIDEMIOLOGY BI
   Karami S, 2016, INT J CANCER, V139, P2655, DOI 10.1002/ijc.30288
   Ko E, 2016, ONCOTARGET, V7, P684, DOI 10.18632/oncotarget.6331
   Kumar M, 2016, GENES-BASEL, V7, DOI 10.3390/genes7080043
   Li ZY, 2016, J CANCER RES THER, V12, P1040, DOI 10.4103/0973-1482.164701
   Liu ZS, 2011, CANCER EPIDEM BIOMAR, V20, P2642, DOI 10.1158/1055-9965.EPI-11-0890
   Mirabello L, 2010, HUM MUTAT, V31, P1050, DOI 10.1002/humu.21314
   Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299
   Mosrati MA, 2015, ONCOTARGET, V6, P25109, DOI 10.18632/oncotarget.4668
   Mosrati MA, 2015, ONCOTARGET, V6, P16663, DOI 10.18632/oncotarget.4389
   Nencha U, 2016, J NEURO-ONCOL, V126, P441, DOI 10.1007/s11060-015-1999-3
   Opresko P.L., 2016, AGEING RES REV
   Oztas E, 2016, GENET TEST MOL BIOMA, V20, P459, DOI 10.1089/gtmb.2015.0339
   Park CK, 2014, ONCOTARGET, V5, P3399, DOI 10.18632/oncotarget.1975
   Petersen GM, 2015, NAT GENET, V11
   Savage SA, 2007, BRIT J CANCER, V97, P832, DOI 10.1038/sj.bjc.6603934
   Shadrina AS, 2015, TUMOR BIOL, V36, P841, DOI 10.1007/s13277-014-2688-0
   Shen J, 2010, CANCER EPIDEM BIOMAR, V19, P219, DOI 10.1158/1055-9965.EPI-09-0771
   Varadi V, 2009, CANCER GENET CYTOGEN, V190, P71, DOI 10.1016/j.cancergencyto.2008.12.006
   Vinagre J, 2014, VIRCHOWS ARCH, V465, P119, DOI 10.1007/s00428-014-1608-4
   Wu DP, 2015, MOL MED REP, V12, P489, DOI 10.3892/mmr.2015.3410
   Xing YL, 2016, J CLIN LAB ANAL, V30, P1071, DOI 10.1002/jcla.21982
   Yamaguchi H, 2005, NEW ENGL J MED, V352, P1413, DOI 10.1056/NEJMoa042980
   Yoo SS, 2015, J KOREAN MED SCI, V30, P1423, DOI 10.3346/jkms.2015.30.10.1423
   Zhong R, 2013, MOL CARCINOGEN, V52, P118, DOI 10.1002/mc.22043
NR 40
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 13
PY 2018
VL 13
IS 3
AR e0191560
DI 10.1371/journal.pone.0191560
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FZ0JA
UT WOS:000427253500001
PM 29534075
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Meng, FJ
   Pan, XP
   Tong, WZ
AF Meng, Fanjie
   Pan, Xiangpo
   Tong, Wenzhen
TI Rifampicin versus streptomycin for brucellosis treatment in humans: A
   meta-analysis of randomized controlled trials
SO PLOS ONE
LA English
DT Article
ID DOXYCYCLINE PLUS STREPTOMYCIN; ANTIMICROBIAL REGIMENS; THERAPY
AB Brucellosis is a zoonotic disease with a high morbidity in developing countries, but there the optimal treatment is not yet determined. Therefore, the development of a simple and effective treatment is important. The aim of this study was to summarize the available evidences and compare rifampicin with streptomycin in human brucellosis with doxycycline as background regimen. We systematically searched PubMed, EmBase, and the Cochrane Library from their inception up through December 2016. We included studies with a randomized controlled design that evaluated the effect of streptomycin compared with rifampicin in human brucellosis patients who received doxycycline therapy as background regimen. The overall failure and relapse were summarized using random-effects model. Our meta-analysis included 1,383 patients with brucellosis from 14 trials. We found that patients who received rifampicin therapy had a higher risk of overall failure (RR: 2.36; 95% CI: 1.72-3.23; P<0.001) and relapse (RR: 2.74; 95% CI: 1.80-4.19; P<0.001) compared with streptomycin. Results of the sensitivity analysis were consistent with the overall analysis. Subgroup analysis indicated that mean age of the patients and percentage of male participants might influence the treatment effects. Furthermore, no publication bias was detected. The findings of this study indicated that rifampicin therapy significantly increased the risk of overall failure and relapse compared with streptomycin. Hence, it can be recommended to patients with human brucellosis receiving streptomycin therapy.
C1 [Meng, Fanjie; Tong, Wenzhen] Yidu Cent Hosp Weifang, Clin Lab, Qingzhou, Shandong, Peoples R China.
   [Pan, Xiangpo] Weifang Peoples Hosp, Weifang, Shandong, Peoples R China.
RP Meng, FJ (reprint author), Yidu Cent Hosp Weifang, Clin Lab, Qingzhou, Shandong, Peoples R China.
EM mengfj45@163.com
CR ACOCELLA G, 1989, J ANTIMICROB CHEMOTH, V23, P433, DOI 10.1093/jac/23.3.433
   Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   ARIZA J, 1992, ANN INTERN MED, V117, P25, DOI 10.7326/0003-4819-117-1-25
   ARIZA J, 1985, ANTIMICROB AGENTS CH, V28, P548, DOI 10.1128/AAC.28.4.548
   ARNOW PM, 1984, JAMA-J AM MED ASSOC, V251, P505, DOI 10.1001/jama.251.4.505
   Bayindir Y, 2003, J CHEMOTHERAPY, V15, P466, DOI 10.1179/joc.2003.15.5.466
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   CASTILLO JDC, 1989, CHEMOTHERAPY, V35, P146
   Centers for Disease C Prevention, 1994, MMWR-MORBID MORTAL W, V43, P113
   COLMENERO JD, 1994, ANTIMICROB AGENTS CH, V38, P2798, DOI 10.1128/AAC.38.12.2798
   Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DP MS, 1988, ESTUDIO PROSPECTIVE
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   EJ Y, 1995, BRUCELLA SPECIES PRI, P2053
   Ersoy Y, 2005, TROP DOCT, V35, P210, DOI 10.1258/004947505774938765
   del Pozo JSG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032090
   Geyik MF, 2002, SWISS MED WKLY, V132, P98
   Hashemi SH, 2012, INT J INFECT DIS, V16, pE247, DOI 10.1016/j.ijid.2011.12.003
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   J H, 2008, COCHRANE HDB SYSTEMA
   Kosmidis J, 1982, CHEMOTHERAPIA S4, V1, P107
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   MONTEJO JM, 1993, CLIN INFECT DIS, V16, P671, DOI 10.1093/clind/16.5.671
   Organization FaAO-WH, 1986, WHO TECHNICAL REPORT, P56
   Rodriguez Zapata M, 1987, Chemioterapia, V6, P360
   Saltoglu N, 2002, SAUDI MED J, V23, P921
   Skalsky K, 2008, BMJ-BRIT MED J, V336, P701, DOI 10.1136/bmj.39497.500903.25
   SOLERA J, 1991, MED CLIN-BARCELONA, V96, P649
   SOLERA J, 1995, ANTIMICROB AGENTS CH, V39, P2061, DOI 10.1128/AAC.39.9.2061
   Tobias A., 1999, STATA TECHNICAL B, V8
   YOUNG EJ, 1995, CLIN INFECT DIS, V21, P283, DOI 10.1093/clinids/21.2.283
   YOUNG EJ, 1975, ARCH INTERN MED, V135, P240, DOI 10.1001/archinte.135.2.240
   Yousefi-Nooraie Reza, 2012, Cochrane Database Syst Rev, V10, pCD007179, DOI 10.1002/14651858.CD007179.pub2
NR 35
TC 0
Z9 0
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2018
VL 13
IS 2
AR e0191993
DI 10.1371/journal.pone.0191993
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FW8CI
UT WOS:000425554200012
PM 29462155
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Cui, F
   Sun, LQ
   Xiong, JM
   Li, JY
   Zhao, YG
   Huang, XS
AF Cui, Fang
   Sun, Liuqing
   Xiong, Jianmei
   Li, Jianyong
   Zhao, Yangang
   Huang, Xusheng
TI Therapeutic effects of percutaneous endoscopic gastrostomy on survival
   in patients with amyotrophic lateral sclerosis: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID ENTERAL NUTRITION; TUBE PLACEMENT; ALS; COMPLICATIONS; MANAGEMENT; ONSET
AB Percutaneous endoscopic gastrostomy (PEG) is a method widely used for patients with amyotrophic lateral sclerosis (ALS); nevertheless, its effect on survival remains unclear. The purpose of this meta-analysis study was to determine the effects of PEG on survival in ALS patients. Relevant studies were retrieved from PubMed, EmBase, and the Cochrane Library databases, from inception to June 2017. Studies comparing PEG with other procedures in ALS patients were included. Odds ratios (ORs) in a random-effects model were used to assess the survival at different follow-up periods. Briefly, ten studies involving a total of 996 ALS patients were included. Summary ORs indicated that PEG administration was not associated with 30-day (OR = 1.59; 95% CI 0.93-2.71; P = 0.092), 10-month (OR = 1.25; 95% CI 0.72-2.17; P = 0.436), and 30-month (OR = 1.28; 95% CI 0.77-2.11; P = 0.338) survival rates, while they showed a beneficial effect in 20-month survival rate (OR = 1.97; 95% CI 1.21-3.21; P = 0.007). The survival rate was significantly prominent in reports published before 2005, and in studies with a retrospective design, sample size < 100, mean age <60.0 years, and percentage male >= 50.0%. To sum up, these findings suggested that ALS patients administered with PEG had an increased 20-month survival rates, while there was no significant effect in 30-day, 10-month, and 30-month survival rates.
C1 [Cui, Fang; Sun, Liuqing; Xiong, Jianmei; Li, Jianyong; Zhao, Yangang] Chinese Peoples Liberat Army Gen Hosp, Dept Neurol, Hainan Branch, Sanya, Hainan, Peoples R China.
   [Huang, Xusheng] Chinese Peoples Liberat Army Gen Hosp, Dept Neurol, Beijing, Peoples R China.
RP Huang, XS (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Neurol, Beijing, Peoples R China.
EM lewish301@sina.com
FU National Natural Science Foundation of China [81601096]; Key Research &
   Developement Plan of Hainan Province [ZDYF2016120]
FX This study was supported by the National Natural Science Foundation of
   China (Grant number 81601096) (http://www.nsfc.gov.cn/); Key Research &
   Developement Plan of Hainan Province (Grant number ZDYF2016120)
   (http://dost.hainan.gov.cn/).
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Allen JA, 2013, AMYOTROPH LAT SCL FR, V14, P308, DOI 10.3109/21678421.2012.751613
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blondet A, 2010, J VASC INTERV RADIOL, V21, P527, DOI 10.1016/j.jvir.2009.11.022
   Bouteloup C, 2009, J NEUROL, V256, P1236, DOI 10.1007/s00415-009-5100-z
   Bradley WG, 2001, NEUROLOGY, V57, P500, DOI 10.1212/WNL.57.3.500
   Chio A, 2004, J NEUROL NEUROSUR PS, V75, P645, DOI 10.1136/jnnp.2003.020347
   CHRISTENSEN PB, 1990, NEUROLOGY, V40, P600, DOI 10.1212/WNL.40.4.600
   Deeks JJ, 2008, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Desport JC, 1999, NEUROLOGY, V53, P1059, DOI 10.1212/WNL.53.5.1059
   Desport JC, 2005, AMYOTROPH LATERAL SC, V6, P88, DOI 10.1080/14660820410021258
   Desport JC, 2005, NEURODEGENER DIS, V2, P202, DOI 10.1159/000089626
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Genton L, 2011, CLIN NUTR, V30, P553, DOI 10.1016/j.clnu.2011.06.004
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   LEE JRJ, 1995, J NEUROL SCI, V132, P207, DOI 10.1016/0022-510X(95)00154-T
   LOPES J, 1982, AM J CLIN NUTR, V36, P602
   MATHUSVLIEGEN LMH, 1994, GASTROINTEST ENDOSC, V40, P463, DOI 10.1016/S0016-5107(94)70211-X
   MAZZINI L, 1995, J NEUROL, V242, P695, DOI 10.1007/BF00866922
   McDermott CJ, 2008, BMJ-BRIT MED J, V336, P658, DOI 10.1136/bmj.39493.511759.BE
   McDermott CJ, 2015, LANCET NEUROL, V14, P702, DOI 10.1016/S1474-4422(15)00104-0
   Mitchell SL, 2000, J GERONTOL A-BIOL, V55, pM735, DOI 10.1093/gerona/55.12.M735
   Mitsumoto H, 2003, AMYOTROPH LATERAL SC, V4, P177, DOI 10.1080/14660820310011728
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   NORRIS F, 1993, J NEUROL SCI, V118, P48, DOI 10.1016/0022-510X(93)90245-T
   Preux PM, 1996, NEUROEPIDEMIOLOGY, V15, P153, DOI 10.1159/000109902
   Rigaud D, 1997, AM J CLIN NUTR, V65, P1845
   RUSSELL TR, 1984, AM J SURG, V148, P132, DOI 10.1016/0002-9610(84)90300-3
   Shaw AS, 2006, AMYOTROPH LATERAL SC, V7, P16, DOI 10.1080/14660820510012013
   Spataro R, 2011, J NEUROL SCI, V304, P44, DOI 10.1016/j.jns.2011.02.016
   Thornton FJ, 2002, RADIOLOGY, V224, P713, DOI 10.1148/radiol.2243010909
   Tobias A, 1999, STATA TECH B, V8, P15
   Traynor BJ, 2000, ARCH NEUROL-CHICAGO, V57, P1171, DOI 10.1001/archneur.57.8.1171
   Vaisman N, 2009, J NEUROL SCI, V279, P26, DOI 10.1016/j.jns.2008.12.027
   Wells GA, 2000, NEWCASTLE OTTAWA SCA
NR 37
TC 3
Z9 3
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 6
PY 2018
VL 13
IS 2
AR e0192243
DI 10.1371/journal.pone.0192243
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FV1EC
UT WOS:000424302800052
PM 29408898
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, ZY
   Shan, F
   Wang, YK
   Zhang, Y
   Zhang, LH
   Li, SX
   Jia, YN
   Xue, K
   Miao, RL
   Li, ZM
   Ji, JF
AF Li, Ziyu
   Shan, Fei
   Wang, Yinkui
   Zhang, Yan
   Zhang, Lianhai
   Li, Shuangxi
   Jia, Yongning
   Xue, Kan
   Miao, Rulin
   Li, Zhemin
   Ji, Jiafu
TI Correlation of pathological complete response with survival after
   neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer
   treated with radical surgery: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID PERIOPERATIVE CHEMOTHERAPY; ESOPHAGOGASTRIC ADENOCARCINOMA; PHASE-II;
   PREOPERATIVE CHEMOTHERAPY; RECURRENCE; THERAPY; TUMOR; TRIAL; RESECTION;
   PATTERNS
AB Background
   Neoadjuvant chemotherapy before radical gastrectomy is preferred for locally advanced gastric cancer. To avoid the problematic use of pTNM for patients after neoadjuvant chemotherapy, the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) gastric cancer TNM staging system (8th edition) added ypTNM for the first time. But patients achieving pathological complete response were not covered by the new ypTNM staging system. To investigate whether pathological complete response is associated with better outcome in gastric cancer, as was reported in rectal, breast and bladder cancer.
   Methods
   We systematically searched the databases of PubMed, EMBASE, Web of Science and Cochrane Collaboration's Central register of controlled trials from January 1988 to April 2015 for publications which reported outcomes of patients with and without pathological complete response (pCR) (pT0N0M0) to investigate whether pCR after neoadjuvant chemotherapy in gastric or gastroesophageal junction (GEJ) treated with radical surgery is associated with better survival. The primary outcome was overall survival (OS). The secondary outcome was disease-free survival (DFS). Both were measured with a relative risk (RR). A meta-analysis was performed using the fixed effects model. Forest plots and the Q test was used to evaluate overall heterogeneity for OS and DFS.
   Results
   A total of seven trials, 1143 patients were included and analyzed after neoadjuvant chemotherapy and radical surgery with no other preoperative treatment. The average rate of pCR was 6.74% (range: 3%-15%). The RR of patients who achieved pCR in the primary tumor and lymph nodes is 0.5 (95% confidence interval [CI], 0.25-0.98; p = 0.04), 0.34 (95% CI, 0.21-0.55; p<0.0001) and 0.44 (95% CI, 0.30-0.63; p<0.0001) for one-year-OS, three-year-OS and five-year-OS, respectively. The summary RR for three-year-DFS was 0.43 (95% CI, 0.25-0.72; p = 0.002).
   Conclusion
   Patients with resectable gastric or GEJ cancer who achieved pCR after neoadjuvant chemotherapy can gain a better outcome than patients without pCR.
C1 [Li, Ziyu; Shan, Fei; Wang, Yinkui; Zhang, Yan; Zhang, Lianhai; Li, Shuangxi; Jia, Yongning; Xue, Kan; Miao, Rulin; Li, Zhemin; Ji, Jiafu] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Surg, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China.
RP Ji, JF (reprint author), Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Surg, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China.
EM jijiafu@hsc.pku.edu.cn
RI Shan, Fei/P-9216-2018
OI Shan, Fei/0000-0002-4792-3385; Wang, Yinkui/0000-0002-5607-5138; Miao,
   Rulin/0000-0002-7196-1234
FU Beijing Municipal Science and Technology Commission [Z151100004015070,
   D141100000414004]; Beijing Science and Technology Commission
FX This study was supported by Beijing Municipal Science and Technology
   Commission, Z151100004015070, to ZYL, http://www.bjkw.gov.cn/; and
   Beijing Municipal Science and Technology Commission, D141100000414004,
   to JFJ, http://www.bjkw.gov.cn/. The funders played a role in paying for
   the expense of data collection, analysis and article publication.; This
   work was supported by Beijing Science and Technology Commission. We
   thank the key laboratory of gastrointestinal department of Peking
   University Cancer Hospital & Institute for assistance with the
   literature search and project management.
CR [Anonymous], PATH COMPL RESP NEOA
   [Anonymous], 2015, NCCN GUID VERS 1 201
   Becker K, 2011, ANN SURG, V253, P934, DOI 10.1097/SLA.0b013e318216f449
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brenner B, 2006, ANN ONCOL, V17, P1404, DOI 10.1093/annonc/mdl133
   Cho H, 2015, ANN SURG ONCOL, V22, P787, DOI 10.1245/s10434-014-4084-9
   Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8
   Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fields RC, 2011, BRIT J CANCER, V104, P1840, DOI 10.1038/bjc.2011.175
   Fu T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1341-7
   GUNDERSON LL, 1974, CANCER-AM CANCER SOC, V34, P1278, DOI 10.1002/1097-0142(197410)34:4<1278::AID-CNCR2820340440>3.0.CO;2-F
   Heger U, 2014, ANN SURG ONCOL, V21, P1739, DOI 10.1245/s10434-013-3462-z
   Houssami N, 2012, EUR J CANCER, V48, P3342, DOI 10.1016/j.ejca.2012.05.023
   Koh YW, 2013, AM J SURG PATHOL, V37, P1022, DOI 10.1097/PAS.0b013e31828778fd
   LEICHMAN L, 1992, J CLIN ONCOL, V10, P1933, DOI 10.1200/JCO.1992.10.12.1933
   Lorenzen S, 2013, ANN ONCOL, V24, P2068, DOI 10.1093/annonc/mdt141
   Lorenzen S, 2012, ANN SURG ONCOL, V19, P2119, DOI 10.1245/s10434-012-2254-1
   Lowy AM, 1999, ANN SURG, V229, P303, DOI 10.1097/00000658-199903000-00001
   Maas M, 2010, LANCET ONCOL, V11, P835, DOI 10.1016/S1470-2045(10)70172-8
   Mansour JC, 2007, ANN SURG ONCOL, V14, P3412, DOI 10.1245/s10434-007-9574-6
   Nakagawa M, 2014, EJSO-EUR J SURG ONC, V40, P1376, DOI 10.1016/j.ejso.2014.04.015
   Ott K, 2013, LANGENBECK ARCH SURG, V398, P239, DOI 10.1007/s00423-012-1039-0
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Peixoto RD, 2014, CURR ONCOL, V21, P77, DOI 10.3747/co.21.1788
   Persiani R, 2005, J SURG ONCOL, V89, P227, DOI 10.1002/jso.20207
   Petrelli F, 2014, EUR UROL, V65, P350, DOI 10.1016/j.eururo.2013.06.049
   Schulz C, 2015, INT J CANCER, V137, P678, DOI 10.1002/ijc.29403
   Spolverato G, 2014, J AM COLL SURGEONS, V219, P664, DOI 10.1016/j.jamcollsurg.2014.03.062
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   von Minckwitz G, 2011, BREAST CANCER RES TR, V125, P145, DOI 10.1007/s10549-010-1228-x
   Wang LB, 2012, J SURG ONCOL, V105, P293, DOI 10.1002/jso.22085
   Williamson PR, 2002, STAT MED, V21, P3337, DOI 10.1002/sim.1303
   Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597
   Yoshikawa T, 2014, ANN SURG ONCOL, V21, P213, DOI 10.1245/s10434-013-3055-x
NR 36
TC 3
Z9 4
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 25
PY 2018
VL 13
IS 1
AR e0189294
DI 10.1371/journal.pone.0189294
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FT8QE
UT WOS:000423416600004
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Roh, HF
   Nam, SH
   Kim, JM
AF Roh, Hyunsuk Frank
   Nam, Seung Hyuk
   Kim, Jung Mogg
TI Robot-assisted laparoscopic surgery versus conventional laparoscopic
   surgery in randomized controlled trials: A systematic review and
   meta-analysis
SO PLOS ONE
LA English
DT Review
ID GASTROESOPHAGEAL-REFLUX DISEASE; PELVIC ORGAN PROLAPSE; SHORT-TERM
   OUTCOMES; RADICAL PROSTATECTOMY; NISSEN FUNDOPLICATION; CLINICAL-TRIAL;
   RECTAL-CANCER; GASTRIC-CANCER; HYSTERECTOMY; SACROCOLPOPEXY
AB Importance
   This review provides a comprehensive comparison of treatment outcomes between robot-assisted laparoscopic surgery (RLS) and conventional laparoscopic surgery (CLS) based on randomly-controlled trials (RCTs).
   Objectives
   We employed RCTs to provide a systematic review that will enable the relevant community to weigh the effectiveness and efficacy of surgical robotics in controversial fields on surgical procedures both overall and on each individual surgical procedure.
   Evidence review
   A search was conducted for RCTs in PubMed, EMBASE, and Cochrane databases from 1981 to 2016. Among a total of 1,517 articles, 27 clinical reports with a mean sample size of 65 patients per report (32.7 patients who underwent RLS and 32.5 who underwent CLS), met the inclusion criteria.
   Findings
   CLS shows significant advantages in total operative time, net operative time, total complication rate, and operative cost (p < 0.05 in all cases), whereas the estimated blood loss was less in RLS (p < 0.05). As subgroup analyses, conversion rate on colectomy and length of hospital stay on hysterectomy statistically favors RLS (p < 0.05).
   Conclusions
   Despite higher operative cost, RLS does not result in statistically better treatment outcomes, with the exception of lower estimated blood loss. Operative time and total complication rate are significantly more favorable with CLS.
C1 [Roh, Hyunsuk Frank] Hanyang Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.
   [Roh, Hyunsuk Frank; Kim, Jung Mogg] Grad Sch Biomed Sci & Engn, Seoul, South Korea.
   [Nam, Seung Hyuk] Hanyang Univ, Guri Hosp, Dept Thorac & Cardiovasc Surg, Guri, Gyunggi, South Korea.
   [Roh, Hyunsuk Frank; Kim, Jung Mogg] Hanyang Univ, Coll Med, Dept Microbiol & Biomed Sci, Seoul, South Korea.
RP Kim, JM (reprint author), Grad Sch Biomed Sci & Engn, Seoul, South Korea.; Kim, JM (reprint author), Hanyang Univ, Coll Med, Dept Microbiol & Biomed Sci, Seoul, South Korea.
EM jungmogg@hanyang.ac.kr
RI ; Dangal, Ganesh/O-1989-2017
OI Roh, Hyunsuk/0000-0002-8527-6553; Dangal, Ganesh/0000-0002-5834-5525
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education, Science and Technology (MEST),
   Republic of Korea [NRF-2015R1D1A1A01058565]
FX We state that the funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
   Please note that this research was supported by the Basic Science
   Research Program through the National Research Foundation of Korea (NRF)
   funded by the Ministry of Education, Science and Technology (MEST)
   (NRF-2015R1D1A1A01058565), Republic of Korea. The role of the National
   Research Foundation (http://www.nrf.re.kr/eng/main) is to promote an
   independent research to benefit basic science research. In this regard,
   we state that any individual, other than the three authors, and the
   funder had no role in study design, data collection, and analysis,
   decision to publish, or preparation of the manuscript.
CR Aiono S, 2002, SURG ENDOSC, V16, P1267, DOI 10.1007/s00464-001-9174-7
   Albright BB, 2016, J MINIM INVAS GYN, V23, P18, DOI 10.1016/j.jmig.2015.08.003
   Allan C, 2016, UROL INT, V96, P373, DOI 10.1159/000435861
   Martinez-Maestre MA, 2014, SURG INNOV, V21, P250, DOI 10.1177/1553350613492023
   Anger JT, 2014, OBSTET GYNECOL, V123, P5, DOI 10.1097/AOG.0000000000000006
   Ansari MT, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000151
   Asimakopoulos AD, 2011, J SEXUAL MED
   Asimakopoulos AD, 2011, J SEX MED, V8, P1503, DOI 10.1111/j.1743-6109.2011.02215.x
   Baik SH, 2008, SURG ENDOSC, V22, P1601, DOI 10.1007/s00464-008-9752-z
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhattu AS, 2015, J ENDOUROL, V29, P1334, DOI 10.1089/end.2015.0213
   Braga LHP, 2009, EUR UROL, V56, P848, DOI 10.1016/j.eururo.2009.03.063
   Brandao LF, 2014, EUR UROL, V65, P1154, DOI 10.1016/j.eururo.2013.09.021
   Broholm M, 2016, SURG LAPARO ENDO PER, V26, P117, DOI 10.1097/SLE.0000000000000248
   Cadiere GB, 2001, SURG ENDOSC, V15, P918, DOI 10.1007/s004640000217
   Callewaert G, 2016, GYNECOL SURG, V13, P115, DOI 10.1007/s10397-016-0930-z
   Cao C, 2012, ANN CARDIOTHORAC SUR, V1, P3, DOI 10.3978/j.issn.2225-319X.2012.04.03
   Chuan L, 2014, MINIM INVASIV THER, V3, P1
   Cundy TP, 2014, J PEDIATR SURG, V49, P646, DOI 10.1016/j.jpedsurg.2013.12.014
   Draaisma WA, 2006, BRIT J SURG, V93, P1351, DOI 10.1002/bjs.5535
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El Nakadi I, 2006, WORLD J SURG, V30, P1050, DOI 10.1007/s00268-005-7950-6
   Finkelstein Julia, 2010, Rev Urol, V12, P35
   Furukawa TA, 2006, J CLIN EPIDEMIOL, V59, P7, DOI 10.1016/j.jclinepi.2005.06.006
   Huang X, 2017, SURG ENDOSC, V31, P1045, DOI 10.1007/s00464-016-5125-1
   Rodriguez RMJ, 2011, CIR ESPAN, V89, P432, DOI 10.1016/j.ciresp.2011.01.017
   Khan MS, 2016, EUR UROL, V69, P613, DOI 10.1016/j.eururo.2015.07.038
   Kudsi OY, 2016, SURG ENDOSC
   Lee SH, 2015, ANN SURG TREAT RES, V89, P190, DOI 10.4174/astr.2015.89.4.190
   Liao GX, 2013, ASIAN PAC J CANCER P, V14, P4871, DOI 10.7314/APJCP.2013.14.8.4871
   Liao GX, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-122
   Lim S, 2016, ANN SURG TREAT RES, V90, P328, DOI 10.4174/astr.2016.90.6.328
   Lin S, 2011, WORLD J GASTROENTERO, V17, P5214, DOI 10.3748/wjg.v17.i47.5214
   Liu HQ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011422
   Lonnerfors C, 2015, J MINIM INVAS GYN, V22, P78, DOI 10.1016/j.jmig.2014.07.010
   Maenpaa MM, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.06.005
   Makela-Kaikkonen J, 2016, COLORECTAL DIS, V18, P1010, DOI 10.1111/codi.13309
   Markar SR, 2010, INT J MED ROBOT COMP, V6, P125, DOI 10.1002/rcs.309
   Moran PS, 2013, INT J UROL, V20, P312, DOI 10.1111/iju.12070
   Morino M, 2006, BRIT J SURG, V93, P553, DOI 10.1002/bjs.5325
   Morino M, 2004, SURG ENDOSC, V18, P1742, DOI 10.1007/s00464-004-9046-z
   Muller-Stich BP, 2007, SURG ENDOSC, V21, P1800, DOI 10.1007/s00464-007-9268-y
   Nio D, 2004, SURG ENDOSC, V18, P379, DOI 10.1007/s00464-003-9133-6
   O'Neill M, 2013, ARCH GYNECOL OBSTET, V287, P907, DOI 10.1007/s00404-012-2681-z
   Paraiso MFR, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.02.008
   Paraiso MFR, 2011, OBSTET GYNECOL, V118, P1005, DOI 10.1097/AOG.0b013e318231537c
   Park JS, 2012, BRIT J SURG, V99, P1219, DOI 10.1002/bjs.8841
   Patriti A, 2009, JSLS-J SOC LAPAROEND, V13, P176
   Pietrabissa A, 2016, SURG ENDOSC, V30, P3089, DOI 10.1007/s00464-015-4601-3
   Porpiglia F, 2013, EUR UROL, V63, P606, DOI 10.1016/j.eururo.2012.07.007
   Ran L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108361
   Roh HF, 2017, EUR J CARDIO-THORAC, V52, P673, DOI 10.1093/ejcts/ezx209
   Sanchez Barry R, 2005, Surg Obes Relat Dis, V1, P549, DOI 10.1016/j.soard.2005.08.008
   Salinas CS, 2013, ADV UROL, DOI 10.1155/2013/105651
   Sarlos D, 2012, OBSTET GYNECOL, V120, P604, DOI 10.1097/AOG.0b013e318265b61a
   Serati M, 2014, EUR UROL, V66, P303, DOI 10.1016/j.eururo.2014.02.053
   Tekkis PP, 2005, ANN SURG, V242, P83, DOI 10.1097/01.sla.0000167857.14690.68
   Wang ZH, 2012, ANZ J SURG, V82, P112, DOI 10.1111/j.1445-2197.2011.05964.x
   Xiong BH, 2012, SURG ONCOL, V21, P274, DOI 10.1016/j.suronc.2012.05.004
NR 59
TC 11
Z9 11
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 23
PY 2018
VL 13
IS 1
AR e0191628
DI 10.1371/journal.pone.0191628
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FT4YS
UT WOS:000423161800043
PM 29360840
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Marot, A
   Dubois, M
   Trepo, E
   Moreno, C
   Deltenre, P
AF Marot, Astrid
   Dubois, Margaux
   Trepo, Eric
   Moreno, Christophe
   Deltenre, Pierre
TI Liver transplantation for alcoholic hepatitis: A systematic review with
   meta-analysis
SO PLOS ONE
LA English
DT Review
ID DISEASE; CIRRHOSIS; ABSTINENCE; TRIALS; BANK
AB Background
   The rate of alcohol relapse among patients who underwent liver transplantation for alcoholic hepatitis (AH) is not precisely known.
   Aim
   Synthesize the available evidence on liver transplantation for AH to assess alcohol relapse and 6-month survival.
   Methods
   Meta-analysis of trials evaluating liver transplantation for AH, either clinically severe or diagnosed on the explant. Results Eleven studies were included. The pooled estimate rate for alcohol relapse was 0.22 (95% CI = 0.12 +/- 0.36) in overall analysis with high heterogeneity between studies (I-2 = 76%), 0.20 (95% CI = 0.07 +/- 0.43) in the subgroup analysis including patients with clinically severe AH (I-2 = 84%), 0.14 (95% CI = 0.08 +/- 0.23) among patients with clinically severe AH in sensitivity analysis excluding the discrepant studies that did not use stringent selection criteria for liver transplantation (I-2 = 0%), and 0.15 (95% CI = 0.07 +/- 0.27) for recurrent harmful alcohol consumption among patients with clinically severe AH (I-2 = 3%). The risk of alcohol relapse was not different between AH transplanted patients and patients with alcoholic cirrhosis who underwent elective liver transplantation in sensitivity analysis excluding the discrepant studies (OR = 1.68, 95% CI = 0.79 +/- 3.58, p = 0.2, I-2 = 16%). The pooled estimate rate for 6-month survival was 0.85 (95% CI = 0.77 +/- 0.91, I-2 = 49%), and 0.80 among patients transplanted for clinically severe AH (95% CI = 0.69 +/- 0.88, I-2 = 30%). AH transplanted patients had similar 6-month survival to patients with alcoholic cirrhosis who underwent elective liver transplantation (OR = 2.00, 95% CI = 0.95 +/- 4.23, p = 0.07, I-2 = 0%).
   Conclusion
   Using stringent selection criteria, 14% of patients with clinically severe AH have alcohol relapse after liver transplantation. The percentage of alcohol relapse of AH transplanted patients is similar than that of patients who underwent elective liver transplantation.
C1 [Marot, Astrid; Dubois, Margaux; Deltenre, Pierre] Univ Lausanne, CHU Vaudois, Div Gastroenterol & Hepatol, Lausanne, Switzerland.
   [Trepo, Eric; Moreno, Christophe; Deltenre, Pierre] Univ Libre Bruxelles, CUB Hop Erasme, Dept Gastroenterol Hepatopancreatol & Digest Onco, Brussels, Belgium.
   [Trepo, Eric; Moreno, Christophe] Univ Libre Bruxelles, Lab Expt Gastroenterol, Brussels, Belgium.
RP Deltenre, P (reprint author), Univ Lausanne, CHU Vaudois, Div Gastroenterol & Hepatol, Lausanne, Switzerland.; Deltenre, P (reprint author), Univ Libre Bruxelles, CUB Hop Erasme, Dept Gastroenterol Hepatopancreatol & Digest Onco, Brussels, Belgium.
EM pierre.deltenre01@gmail.com
OI Deltenre, Pierre/0000-0002-4253-6028
CR Artru F, 2017, LIVER INT, V37, P337, DOI 10.1111/liv.13248
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Deeks J.J., 2005, SYSTEMATIC REV HLTH, P285
   Deltenre P, 2015, EUR J GASTROEN HEPAT, V27, pE1, DOI 10.1097/MEG.0000000000000403
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DiMartini A, 2006, LIVER TRANSPLANT, V12, P813, DOI 10.1002/lt.20688
   Donckier V, 2014, J HEPATOL, V60, P866, DOI 10.1016/j.jhep.2013.11.015
   Foster PF, 1997, HEPATOLOGY, V25, P1469, DOI 10.1002/hep.510250627
   Hanouneh IA, 2014, HEPATOLOGY, V60, p258A
   Hasanin M, 2015, LIVER TRANSPLANT, V21, P1449, DOI 10.1002/lt.24208
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Im GY, 2016, AM J TRANSPLANT, V16, P841, DOI 10.1111/ajt.13586
   Im GY, 2016, HEPATOLOGY, V64, p687A
   Immordino G, 2009, TRANSPL P, V41, P1253, DOI 10.1016/j.transproceed.2009.03.092
   Lee BP, 2017, ANN SURG, V265, P20, DOI 10.1097/SLA.0000000000001831
   Louvet A, 2007, HEPATOLOGY, V45, P1348, DOI 10.1002/hep.21607
   Margulis AV, 2014, CLIN EPIDEMIOL, V6, P359, DOI 10.2147/CLEP.S66677
   Marot A, 2015, ALIMENT PHARM THER, V42, P1250, DOI 10.1111/apt.13424
   Marot A, 2017, LIVER INT, V37, P707, DOI 10.1111/liv.13318
   Mathurin P, 2011, NEW ENGL J MED, V365, P1790, DOI 10.1056/NEJMoa1105703
   Pageaux GP, 2003, J HEPATOL, V38, P629, DOI 10.1016/S0168-8278(03)00088-6
   Shakil A O, 1997, Liver Transpl Surg, V3, P240, DOI 10.1053/jlts.1997.v3.ajlts0030240
   Siddachari RC, 2014, LIVER TRANSPLANT, V20, pS328
   Singal AK, 2012, HEPATOLOGY, V55, P1398, DOI 10.1002/hep.25544
   Stroh G, 2015, AM J TRANSPLANT, V15, P1598, DOI 10.1111/ajt.13176
   Tome S, 2002, J HEPATOL, V36, P793, DOI 10.1016/S0168-8278(02)00047-8
   VANTHIEL DH, 1995, ALCOHOL CLIN EXP RES, V19, P1151
   Wells JT, 2007, LIVER TRANSPLANT, V13, P1728, DOI 10.1002/lt.21298
NR 28
TC 17
Z9 17
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 11
PY 2018
VL 13
IS 1
AR e0190823
DI 10.1371/journal.pone.0190823
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FS7BJ
UT WOS:000419952400061
PM 29324766
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Guo, HW
   Yuan, TZ
   Chen, JX
   Zheng, Y
AF Guo, Hui-Wen
   Yuan, Tang-Zhan
   Chen, Jia-Xi
   Zheng, Yang
TI Prognostic value of pretreatment albumin/globulin ratio in digestive
   system cancers: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID TO-GLOBULIN RATIO; PREOPERATIVE ALBUMIN; COLORECTAL-CANCER; PUBLICATION
   BIAS; CELL CARCINOMA; SERUM GLOBULIN; SURVIVAL; INFLAMMATION; MORTALITY;
   RESECTION
AB The albumin/globulin ratio (AGR) has been widely reported to be a potential predictor of prognosis in digestive system cancers (DSCs), but convincing conclusions have not been made. Therefore, herein, we performed a meta-analysis of relevant studies regarding this topic to evaluate the prognostic value of AGR in patients with DSCs. Three databases, including PubMed, EMBase, and Web of science, were searched comprehensively for eligible studies through September 8, 2017. The outcomes of interest included overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS). In our meta-analysis, pooled analysis of 13 studies with 9269 patients showed that a low AGR was significantly correlated with poor OS (HR = 1.94; 95% CI: 1.57 +/- 2.38; P < 0.001). Five studies with 6538 participants involved DFS, and our pooled analysis of these studies also demonstrated that there was a significant association of a low AGR with worse DFS (HR = 1.49; 95% CI: 1.10 to 2.00; P < 0.001). In addition, only 2 studies referred to CSS, and we also detected a significant relationship between a low AGR and worse CSS from the results of our meta-analysis. In summary, a low pretreatment AGR was related to unfavorable survival in human digestive system cancers. A low pretreatment AGR may be a useful predictive prognostic biomarker in human digestive system cancers.
C1 [Guo, Hui-Wen; Yuan, Tang-Zhan; Chen, Jia-Xi; Zheng, Yang] Nan Chang Univ, Affiliated Hosp 4, Dept Gen Surg, Nanchang, Jiangxi, Peoples R China.
RP Zheng, Y (reprint author), Nan Chang Univ, Affiliated Hosp 4, Dept Gen Surg, Nanchang, Jiangxi, Peoples R China.
EM dryangz@126.com
OI Zheng, Yang/0000-0002-5304-1928
CR Azab B, VALUE PRETREATMENT A
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boonpipattanapong T, 2006, J CLIN GASTROENTEROL, V40, P592, DOI 10.1097/00004836-200608000-00006
   Chen J, 2016, TUMOR BIOL, V37, P3905, DOI 10.1007/s13277-015-3778-3
   Chen Z, 2017, ONCOTARGET, V8, P48291, DOI 10.18632/oncotarget.15162
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611
   Fujii T, 2012, NUTR CANCER, V64, P1169, DOI 10.1080/01635581.2012.718034
   Fujikawa H, PROGNOSTIC IMPACT PR, P1791
   Heys SD, 1998, J ROY COLL SURG EDIN, V43, P163
   Isik A, 2014, MINERVA CHIR, V69, P147
   Li Q, HIGH PREOPERATIVE SE, P2156
   Li QG, 2015, AM J CANCER RES, V5, P2856
   Li XH, 2017, J CANCER, V8, P1833, DOI 10.7150/jca.19062
   Li Y, NOMOGRAMS PREDICTING, P1097
   Li YQ, 2016, INT J CANCER, V139, P220, DOI 10.1002/ijc.30071
   Lin Q, 2017, CURR RES TRANSL MED, V65, P83, DOI 10.1016/j.retram.2017.06.002
   Liu JJ, 2017, ONCOTARGETS THER, V10, P2155, DOI 10.2147/OTT.S99282
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mao MJ, CLIN SIGNIFICANCE PR, P2314
   Oki S, 2017, AM J SURG
   Shibutani M, PRETREATMENT ALBUMIN, P1471
   Siddiqui A, 2007, AM J SURG, V194, P362, DOI 10.1016/j.amjsurg.2007.02.007
   Siegel RL, 2015, CANC STAT, P1542
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Toiyama Y, 2017, AM J SURG, V213, P120, DOI 10.1016/j.amjsurg.2016.05.012
   Wu J, POOR PROGNOSIS HEXOK, P1949
   Xu J, 2017, J GASTROEN HEPATOL, V32, P1394, DOI 10.1111/jgh.13676
   Zhang F, 2016, ONCOTARGET, V7, P30550, DOI 10.18632/oncotarget.8868
   Zhang JH, 2016, J BUON, V21, P925
NR 31
TC 2
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 4
PY 2018
VL 13
IS 1
AR e0189839
DI 10.1371/journal.pone.0189839
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FR7HZ
UT WOS:000419239900008
PM 29300750
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU del-Pino-Casado, R
   Frias-Osuna, A
   Palomino-Moral, PA
   Ruzafa-Martinez, M
   Ramos-Morcillo, AJ
AF del-Pino-Casado, Rafael
   Frias-Osuna, Antonio
   Palomino-Moral, Pedro A.
   Ruzafa-Martinez, Maria
   Ramos-Morcillo, Antonio J.
TI Social support and subjective burden in caregivers of adults and older
   adults: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; FAMILY CAREGIVERS; INFORMAL
   CAREGIVERS; PUBLICATION BIAS; ALZHEIMERS-DISEASE; PERCEIVED BURDEN;
   MENTAL-HEALTH; NURSING-HOME; DEMENTIA
AB Background & para;& para;Despite the generally accepted belief that social support improves caregiver adjustment in general and subjective burden in particular, the literature shows mixed findings, and a recent review concluded that the predictive strength of caregiver social support in determining caregiver burden is less evident, due to the conceptual diversity of this determinant.& para;& para;Objective & para;& para;The purpose of this review is to analyse the relationship of perceived and received social support with subjective burden among informal caregivers of an adult or older adult.& para;& para;Methods & para;& para;A systematic search was carried out up to September 2017 in the following databases: MEDLINE (PubMed), CINAHL, EMBASE, PsycINFO), Scopus and ISI Proceedings, and a meta-analysis was performed with the results of the selected and included studies.& para;& para;Results & para;& para;Fifty-six studies were included in the meta-analysis, which provided 46 independent comparisons for perceived support and 16 for received support. Most of these studies were cross-sectional. There was a moderate, negative association of perceived social support on subjective burden (r =-0.36; CI 95%=-0.40,-0.32) and a very small, negative association of received support on subjective burden (r =-0.05; CI 95%=-0.095,-0.001). & para;& para;Conclusions & para;& para;1) perceived and received support are not redundant constructs, 2) the relationships between social support and subjective burden depend on whether the social support is measured as perceived or received, 3) the relationship of perceived social support with subjective burden has a bigger effect size than that of received social support, the relation between received support and subjective burden being clinically irrelevant, 4) perceived social support may be a good predictor of subjective burden.& para;& para;Implications of key findings & para;& para;Our findings broadly support interventions promoting social support in caregivers to prevent or alleviate subjective burden, and specifically, to intervene on the promotion of perceived social support more than on the promotion of received social support when preventing or alleviating burden.& para;& para;Implications of key findings & para;& para;Our findings broadly support interventions promoting social support in caregivers to prevent or alleviate subjective burden, and specifically, to intervene on the promotion of perceived social support more than on the promotion of received social support when preventing or alleviating burden.
C1 [del-Pino-Casado, Rafael; Frias-Osuna, Antonio; Palomino-Moral, Pedro A.] Univ Jaen, Fac Hlth Sci, Dept Nursing, Jaen, Spain.
   [Ruzafa-Martinez, Maria; Ramos-Morcillo, Antonio J.] Univ Murcia, Fac Nursing, Dept Nursing, Murcia, Spain.
RP del-Pino-Casado, R (reprint author), Univ Jaen, Fac Hlth Sci, Dept Nursing, Jaen, Spain.
EM rdelpino@ujaen.es
RI Ramos-Morcillo, Antonio Jesus/J-2195-2016; del-Pino-Casado,
   Rafael/L-3733-2018
OI Ramos-Morcillo, Antonio Jesus/0000-0002-3490-3326; Ruzafa-Martinez,
   Maria/0000-0001-6570-738X; del-Pino-Casado, Rafael/0000-0003-2263-2415
CR Adriaansen JJE, 2011, PATIENT EDUC COUNS, V85, pE48, DOI 10.1016/j.pec.2010.12.011
   Alvarez-Ude F, 2004, J NEPHROL, V17, P841
   Aneshensel CS, 1995, PROFILES CAREGIVING
   Annisa F, 2015, THAI PHARM HLTH SCI, V10, P87
   Artaso B., 2003, Revista Espanola de Geriatria y Gerontologia, V38, P212
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Bainbridge D, 2009, AGING MENT HEALTH, V13, P537, DOI 10.1080/13607860802607322
   Barrera Jr M., 1983, CONNECTIONS, V3, P8
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blake H, 2000, CLIN REHABIL, V14, P307, DOI 10.1191/026921500667530134
   Boyle M. H., 1998, EVID BASED MENT HLTH, V1, P37, DOI DOI 10.1136/EBMH.1.2.37
   Burton Allison M, 2008, Palliat Support Care, V6, P149, DOI 10.1017/S1478951508000230
   Carretero S, 2009, ARCH GERONTOL GERIAT, V49, P74, DOI 10.1016/j.archger.2008.05.004
   Cassidy T, 2013, PSYCHOL HEALTH, V28, P250, DOI 10.1080/08870446.2012.717623
   Chang BL, 2001, WOMEN HEALTH, V33, P39, DOI 10.1300/J013v33n01_04
   Cheng ST, 2013, GERONTOLOGIST, V53, P998, DOI 10.1093/geront/gns195
   Chiou CJ, 2009, ARCH GERONTOL GERIAT, V48, P419, DOI 10.1016/j.archger.2008.04.001
   CLAIR JM, 1995, SOCIOL PERSPECT, V38, P195, DOI 10.2307/1389290
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310
   Cohen S, 2004, AM PSYCHOL, V59, P676, DOI 10.1037/0003-066X.59.8.676
   Cooper C, 2007, INT PSYCHOGERIATR, V19, P175, DOI 10.1017/S1041610206004297
   Cooper H, 2009, HDB RES SYNTHESIS ME
   Cotelo Natalia Verez, 2015, Pharm Pract (Granada), V13, P521
   Dam AEH, 2016, MATURITAS, V85, P117, DOI 10.1016/j.maturitas.2015.12.008
   Davis LC, 2009, J HEAD TRAUMA REHAB, V24, P145, DOI 10.1097/HTR.0b013e3181a0b291
   del-Pino-Casado R, 2014, J NURS SCHOLARSHIP, V46, P176, DOI 10.1111/jnu.12070
   del-Pino-Casado R, 2011, J ADV NURS, V67, P2311, DOI 10.1111/j.1365-2648.2011.05725.x
   Dorfman LT, 1996, FAM RELAT, V45, P46, DOI 10.2307/584769
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Edwards Nancy E, 2002, J Neurosci Nurs, V34, P184
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elvish R, 2013, PSYCHOL INTERVENTION
   FOLKMAN S, 1994, J CONSULT CLIN PSYCH, V62, P746, DOI 10.1037/0022-006X.62.4.746
   Gallart A, 2013, J ADV NURS, V69, P642, DOI 10.1111/j.1365-2648.2012.06049.x
   Gold DP, 1995, INT J AGING HUM DEV, V41, P183, DOI 10.2190/RGYJ-5KA2-7THX-7BQ5
   Goldsworthy B, 2008, J GERONTOL B-PSYCHOL, V63, pP372, DOI 10.1093/geronb/63.6.P372
   Goris S, 2016, HOLIST NURS PRACT, V30, P227, DOI 10.1097/HNP.0000000000000153
   Gottlieb BH, 2010, J PSYCHOSOM RES, V69, P511, DOI 10.1016/j.jpsychores.2009.10.001
   Greenberger H, 2003, J ADV NURS, V41, P332, DOI 10.1046/j.1365-2648.2003.02531.x
   Greene MC, 2013, AIDS BEHAV, V17, P1775, DOI 10.1007/s10461-012-0396-6
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011
   Hanks RA, 2007, NEUROREHABILITATION, V22, P43
   Higgins Julian, 2002, J Health Serv Res Policy, V7, P51, DOI 10.1258/1355819021927674
   Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316
   Kahriman Fatma, 2015, Asian Pac J Cancer Prev, V16, P3313
   Kaur N, 2014, DELHI PSYCHIAT J, V17, P337
   Kim H, 2012, J ADV NURS, V68, P846, DOI 10.1111/j.1365-2648.2011.05787.x
   Kruithof WJ, 2016, PATIENT EDUC COUNS, V99, P1632, DOI 10.1016/j.pec.2016.04.007
   Lazarus RS, 1984, STRESS APPRAISAL COP
   LECHNER VM, 1993, SOC WORK, V38, P461
   Leibach G, 2013, EXAMINING RELATIONS
   Liu Y, 2012, NURS RES, V61, P39, DOI 10.1097/NNR.0b013e31823bc451
   Lopez S. R., 2005, ENFERMERIA COMUNITAR, V1, P12
   Losada A, 2010, AGING MENT HEALTH, V14, P193, DOI 10.1080/13607860903167838
   Losada A, 2010, ARCH GERONTOL GERIAT, V50, P347, DOI 10.1016/j.archger.2009.06.001
   Lubben J, 2006, GERONTOLOGIST, V46, P503, DOI 10.1093/geront/46.4.503
   Majerovitz SD, 2007, AGING MENT HEALTH, V11, P323, DOI 10.1080/13607860600963380
   Manso Martínez Mª Esperanza, 2013, Clínica y Salud, V24, P37, DOI 10.5093/cl2013a5
   Marwit SJ, 2002, GERONTOLOGIST, V42, P751, DOI 10.1093/geront/42.6.751
   Meader N, 2014, SYST REV, V3, DOI 10.1186/2046-4053-3-82
   Meiland FJM, 2001, SCAND J PUBLIC HEALT, V29, P113, DOI 10.1177/14034948010290020801
   Melrose KL, 2015, PERS INDIV DIFFER, V77, P97, DOI 10.1016/j.paid.2014.12.047
   Moller-Leimkuhler AM, 2012, EUR ARCH PSY CLIN N, V262, P157, DOI 10.1007/s00406-011-0215-5
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Molina J. M., 2005, PSICOLOGIA SALUD, V15, P33
   Moral Serrano M S, 2003, Aten Primaria, V32, P77, DOI 10.1157/13049173
   Bermejo LM, 2015, REV ROL ENFERM, V38, P852
   Pinquart M, 2003, J GERONTOL B-PSYCHOL, V58, pP112, DOI 10.1093/geronb/58.2.P112
   Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250
   Prati G, 2010, J COMMUNITY PSYCHOL, V38, P403, DOI 10.1002/jcop.20371
   REIS MF, 1994, INT J AGING HUM DEV, V39, P257, DOI 10.2190/6LYN-YFWQ-P87D-MKWX
   Riemsma RP, 1999, PSYCHOL HEALTH, V14, P773, DOI 10.1080/08870449908407347
   Robinson K M, 1990, Sch Inq Nurs Pract, V4, P189
   Rodakowski J, 2012, ARCH PHYS MED REHAB, V93, P2229, DOI 10.1016/j.apmr.2012.07.004
   Roe B, 2007, REVIEWING RESEARCH EVIDENCE FOR NURSING PRACTICE: SYSTEMATIC REVIEWS, P9, DOI 10.1002/9780470692127.ch2
   Rothman KJ, 2008, MODERN EPIDEMIOLOGY
   Ryan KA, 2012, DEMENT GERIATR COGN, V34, P206, DOI 10.1159/000339955
   SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127
   Schoenmakers B, 2010, MATURITAS, V66, P191, DOI 10.1016/j.maturitas.2010.02.009
   Shieh SC, 2012, J NURS SCHOLARSHIP, V44, P223, DOI 10.1111/j.1547-5069.2012.01453.x
   Smerglia VL, 2007, AGING MENT HEALTH, V11, P205, DOI 10.1080/13607860600844515
   Son Gwi-Ryung, 2003, J Gerontol Nurs, V29, P19
   SPAID WM, 1994, J GERONTOL SOC WORK, V21, P197
   Stevens LF, 2013, AM J PHYS MED REHABI
   STOMMEL M, 1990, J AGING HEALTH, V2, P81, DOI DOI 10.1177/089826439000200106
   Tang Y, 2006, OBLIGATION FILIAL PI
   Teixeira RJ, 2013, PSYCHO-ONCOLOGY, V22, P1587, DOI 10.1002/pon.3173
   THOMPSON EH, 1993, J GERONTOL, V48, pS245, DOI 10.1093/geronj/48.5.S245
   Uchino BN, 2012, SOC SCI MED, V74, P949, DOI 10.1016/j.socscimed.2011.11.023
   van der Lee J, 2014, AGEING RES REV, V15, P76, DOI 10.1016/j.arr.2014.03.003
   Verbakel E, 2016, CAREGIVING OLDER ADU
   Viswanathan M, 2013, ASSESSING RISK BIAS
   Vrabec N J, 1997, Image J Nurs Sch, V29, P383, DOI 10.1111/j.1547-5069.1997.tb01062.x
   Wang Hsiu-Hung, 2003, Kaohsiung Journal of Medical Sciences, V19, P345
   Wang Li-Chieh, 2011, Hu Li Za Zhi, V58, P54
   Wittenberg-Lyles E, 2014, HEALTH COMMUN, V29, P901, DOI 10.1080/10410236.2013.815111
   Yuksel MM, 2013, WELL BEING SIBLINGS
   Yurtsever S., 2013, J NURSING ED PRACTIC, V3, P1, DOI DOI 10.5430/JNEP.V3N9P1
   ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649
   Zegwaard MI, 2011, J CLIN NURS, V20, P2233, DOI 10.1111/j.1365-2702.2010.03524.x
NR 101
TC 1
Z9 1
U1 2
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 2
PY 2018
VL 13
IS 1
AR e0189874
DI 10.1371/journal.pone.0189874
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FR5JA
UT WOS:000419101600038
PM 29293522
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, YZ
   Niu, TH
AF Yang, Yunzhong
   Niu, Tianhua
TI A meta-analysis of associations of &ITLEPR&IT Q223R and K109R
   polymorphisms with Type 2 diabetes risk
SO PLOS ONE
LA English
DT Article
ID LEPTIN RECEPTOR GENE; INSULIN-RESISTANCE; HUMAN PHYSIOLOGY; CANDIDATE
   GENE; MELLITUS; OBESITY; LEPR; IDENTIFICATION; EXPRESSION; MUTATIONS
AB Background & para;& para;Leptin receptor (LEPR) plays a pivotal role in the control of body weight, energy metabolism, and insulin sensitivity. Various genetic association studies were performed to evaluate associations of LEPR genetic variants with type 2 diabetes (T2D) susceptibility.& para;& para;Methods & para;& para;A comprehensive search was conducted to identify all eligible case-control studies for examining the associations of LEPR single nucleotide polymorphisms (SNPs) Q223R (rs1137101) and K109R (rs1137100) with T2D risk. Odds ratios (OR) and corresponding 95% confidence intervals (CIs) were used to measure the magnitudes of association.& para;& para;Results & para;& para;For Q223R, 13 studies (11 articles) consisting of a total of 4030 cases and 2844 controls, and for K109R 7 studies (7 articles) consisting of 3319 cases and 2465 controls were avail-able. Under an allele model, Q223R was not significantly associated with T2D risk (OR = 1.09, 95% CI: 0.80-1.48, P-value = 0.5989), which was consistent with results obtained under four genotypic models (ranges: ORs 1.08-1.20, 95% CIs: 0.58-2.02 to 0.64-2.26; P-values, 0.3650-0.8177, which all exceeded multiplicity-adjusted alpha = 0.05/5 = 0.01). In addition, no significant association was found between K109R and T2D risk based on either an allele model (OR = 0.93, 95% CI: 0.85-1.03, P-value = 0.1868) or four genotypic models (ranges: ORs 0.81-0.99, 95% CIs: 0.67-0.86 to 0.97-1.26, P-values, 0.0207-0.8804 which all exceeded multiplicity-adjusted alpha of 0.01). The magnitudes of association for these two SNPs were not dramatically changed in subgroup analyses by ethnicity or sensitivity analyses. Funnel plot inspections as well as Begg and Mazumdar adjusted rank correlation test and Egger linear regression test did not reveal significant publication biases in main and subgroup analyses. Bioinformatics analysis predicted that both missense SNPs were functionally neutral and benig.& para;& para;Conclusions & para;& para;The present meta-analysis did not detect significant genetic associations between LEPR Q223R and K109R polymorphisms and T2D risk.
C1 [Yang, Yunzhong] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Global Biostat & Data Sci, New Orleans, LA USA.
   [Niu, Tianhua] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA.
RP Niu, TH (reprint author), Tulane Univ, Sch Med, Dept Biochem & Mol Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA.
EM tniu@tulane.edu
FU Center for Bioinformatics and Genomics, Department of Global
   Biostatistics and Data Science, Tulane University
FX T.N. is supported by a start-up fund of the Center for Bioinformatics
   and Genomics, Department of Global Biostatistics and Data Science,
   Tulane University. There was no additional external funding received for
   this study.
CR Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76
   Ahima RS, 2004, PHYSIOL BEHAV, V81, P223, DOI 10.1016/j.physbeh.2004.02.014
   An BQ, 2016, HEPAT MON, V16, DOI 10.5812/hepatmon.35055
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bender N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026157
   Brunham LR, 2005, PLOS GENET, V1, P739, DOI 10.1371/journal.pgen.0010083
   Calabrese R, 2009, HUM MUTAT, V30, P1237, DOI 10.1002/humu.21047
   Choi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046688
   Chung WK, 1996, GENOME RES, V6, P431, DOI 10.1101/gr.6.5.431
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Considine Robert V, 2005, Semin Vasc Med, V5, P15, DOI 10.1055/s-2005-871738
   Cottrell Elizabeth C, 2012, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-642-24716-3_1
   Cruz M, 2010, DIABETES-METAB RES, V26, P261, DOI 10.1002/dmrr.1082
   De Luis DA, 2009, MINERVA MED, V100, P229
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313
   Etemad A, 2013, INT J MOL SCI, V14, P19230, DOI 10.3390/ijms140919230
   Fan SH, 2014, J PHYSIOL ANTHROPOL, V33, DOI 10.1186/1880-6805-33-15
   Fletcher Barbara, 2002, J Cardiovasc Nurs, V16, P17
   Fruhbeck G, 2006, BIOCHEM J, V393, P7, DOI 10.1042/BJ20051578
   Furusawa T, 2010, HUM GENET, V127, P287, DOI 10.1007/s00439-009-0768-9
   Gan RT, 2012, MOL BIOL REP, V39, P4759, DOI 10.1007/s11033-011-1268-2
   Han HR, 2008, CLIN GENET, V74, P105, DOI 10.1111/j.1399-0004.2008.01033.x
   Hansel NN, 2009, EUR RESPIR J, V34, P103, DOI 10.1183/09031936.00120408
   Hegyi K, 2004, CELL BIOL INT, V28, P159, DOI 10.1016/j.cellbi.2003.12.003
   HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915
   Heo M, 2002, INT J OBESITY, V26, P640, DOI [10.1038/sj.ijo.0801990, 10.1038/sj/ijo/0801990]
   Hepp D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121812
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Himms-Hagen J, 1999, CRIT REV CL LAB SCI, V36, P575, DOI 10.1080/10408369991239259
   Hu FB, 2011, DIABETES CARE, V34, P1249, DOI 10.2337/dc11-0442
   Hu ZJ, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-1
   Jiang B, 2014, MOL BIOL REP, V41, P925, DOI 10.1007/s11033-013-2937-0
   Liao WL, 2012, INT J OBESITY, V36, P790, DOI 10.1038/ijo.2011.174
   Liu Y, 2015, DIABETES RES CLIN PR, V109, pE21, DOI 10.1016/j.diabres.2015.05.042
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mantzoros CS, 2011, AM J PHYSIOL-ENDOC M, V301, pE567, DOI 10.1152/ajpendo.00315.2011
   Mantzoros CS, 1998, CLIN ENDOCRINOL, V49, P551, DOI 10.1046/j.1365-2265.1998.00571.x
   Marti A, 2009, NUTR NEUROSCI, V12, P183, DOI 10.1179/147683009X423355
   Mohammadzadeh G, 2013, ARCH IRAN MED, V16, P636, DOI 0131611/AIM.005
   Morton GJ, 2005, CELL METAB, V2, P411, DOI 10.1016/j.cmet.2005.10.009
   Murugesan Devi, 2010, Indian J Hum Genet, V16, P72, DOI 10.4103/0971-6866.69350
   Niu TH, 2004, GENET EPIDEMIOL, V27, P334, DOI 10.1002/gepi.20024
   Niu TH, 2002, AM J HUM GENET, V70, P157, DOI 10.1086/338446
   Niu Tianhua, 2005, Int J Bioinform Res Appl, V1, P18, DOI 10.1504/IJBRA.2005.006900
   Niu TH, 2016, J BONE MINER RES, V31, P358, DOI 10.1002/jbmr.2687
   Paracchini V, 2005, AM J EPIDEMIOL, V162, P101, DOI 10.1093/aje/kwi174
   Parillo M, 2004, BRIT J NUTR, V92, P7, DOI 10.1079/BJN20041117
   Park KS, 2006, J HUM GENET, V51, P85, DOI 10.1007/s10038-005-0327-8
   Park S, 2014, SCI REP-UK, V4, DOI 10.1038/srep03623
   Qi DF, 2015, INT J CLIN EXP MED, V8, P20701
   Qu YC, 2007, OBES RES CLIN PRACT, V1, P261, DOI 10.1016/j.orcp.2007.10.002
   Reva B, 2011, NUCLEIC ACIDS RES, V39, pE118, DOI 10.1093/nar/gkr407
   Roszkowska-Gancarz M, 2014, ENDOKRYNOL POL, V65, P11, DOI 10.5603/EP.2014.0002
   Saukko M, 2010, METAB SYNDR RELAT D, V8, P425, DOI 10.1089/met.2010.0004
   Sober S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006034
   Song JW, 2017, BMC MED GENET, V18, DOI 10.1186/s12881-017-0422-7
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Su S, 2016, DIABETES RES CLIN PR, V121, P49, DOI 10.1016/j.diabres.2016.08.008
   Sun Hong, 2011, Progress in Modern Biomedicine, V11, P4852
   Suzuki K, 2012, EXP DIABETES RES, DOI 10.1155/2012/824305
   Takahashi-Yasuno A, 2004, METABOLISM, V53, P650, DOI 10.1016/j.metabol.2003.12.012
   Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5
   Thibault V, 2016, DIABETOL METAB SYNDR, V8, DOI 10.1186/s13098-016-0186-9
   Thomas PD, 2004, P NATL ACAD SCI USA, V101, P15398, DOI 10.1073/pnas.0404380101
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Thompson DB, 1997, HUM MOL GENET, V6, P675, DOI 10.1093/hmg/6.5.675
   Wang B, 2014, EUR J ENDOCRINOL, V171, pR173, DOI 10.1530/EJE-14-0365
   Wang Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088118
   Wang XY, 2016, J DIABETES, V8, P24, DOI 10.1111/1753-0407.12323
   Wilding John P. H., 2001, Current Opinion in Pharmacology, V1, P656, DOI 10.1016/S1471-4892(01)00111-4
   Winick JD, 1996, GENOMICS, V36, P221, DOI 10.1006/geno.1996.0455
   Wong KH, 2015, SCI REP-UK, V5, DOI 10.1038/srep16672
   Wu YL, 2014, INT J MED SCI, V11, P1185, DOI 10.7150/ijms.10001
   Yadav VK, 2011, J EXP MED, V208, P41, DOI 10.1084/jem.20101940
   Yang MM, 2016, J DIABETES RES, DOI 10.1155/2016/5412084
   Yiannakouris N, 2001, J CLIN ENDOCR METAB, V86, P4434, DOI 10.1210/jc.86.9.4434
   Yin QX, 2014, INT J NANOMED, V9, P17, DOI 10.2147/IJN.S52005
   Yue P, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-166
   Zhang Heping, 2007, Cancer Genomics & Proteomics, V4, P27
   Zhang YangDan, 2011, Journal of Third Military Medical University, V33, P1932
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
   [赵林双 ZHAO Linshuang], 2008, [中国糖尿病杂志, Chinese Journal of Diabetes], V16, P159
   Zhao LS, 2008, MIL MED J S CHINA, V22, P25
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 87
TC 5
Z9 6
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 2
PY 2018
VL 13
IS 1
AR e0189366
DI 10.1371/journal.pone.0189366
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FR5JA
UT WOS:000419101600015
PM 29293570
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, DY
   Dai, YK
   Zhang, YZ
   Huang, MX
   Li, RL
   Ou-Yang, J
   Chen, WJ
   Hu, L
AF Li, Dan-yan
   Dai, Yun-kai
   Zhang, Yun-zhan
   Huang, Meng-xin
   Li, Ru-liu
   Ou-yang, Jia
   Chen, Wei-jing
   Hu, Ling
TI Systematic review and meta-analysis of traditional Chinese medicine in
   the treatment of constipation-predominant irritable bowel syndrome
SO PLOS ONE
LA English
DT Review
ID FUNCTIONAL GASTROINTESTINAL DISORDERS; PERMEABILITY; DIAGNOSIS
AB Aim
   This meta-analysis analyzed the efficacy and safety of traditional Chinese medicine (TCM) for the treatment of irritable bowel syndrome with constipation (IBS-C).
   Methods
   We searched seven electronic databases for randomized controlled trials investigating the efficacy of TCM in the treatment of IBS-C. The search period was from inception to June 1, 2017. Eligible RCTs compared TCM with cisapride and mosapride. Article quality was evaluated with the Cochrane Risk Bias Tool in the Cochrane Handbook by two independent reviewers. Begg's test was performed to evaluate publication bias. Review Manager 5.3 and Stata 12.0 were used for analyses.
   Results
   Eleven eligible studies comprising a total of 906 participants were identified. In the primary outcome, TCM showed significant improvement in overall clinical efficacy compared with cisapride and mosapride (odds ratio [OR] = 4.00; 95% confidence interval [CI]: 2.74,5.84; P < 0.00001). In terms of secondary outcomes, TCM significantly alleviated abdominal pain (OR = 5.69; 95% CI: 2.35, 13.78; P = 0.0001), defecation frequency (OR = 4.38; 95% CI: 1.93, 9.93. P = 0.0004), and stool form (OR = 4.96; 95% CI: 2.11, 11.65; P = 0.0002) in the treatment group as compared to the control group. A lower recurrence rate was associated with TCM as compared to cisapride and mosapride (OR = 0.15; 95% CI: 0.08, 0.27; P < 0.00001). No adverse effects were observed during TCM treatment.
   Conclusions TCM showed greater improvement in terms of clinical efficacy in the treatment of IBS-C than cisapride and mosapride, although it was not possible to draw a definitive conclusion due to the small sample size, high risk, and low quality of the studies. Large multi-center and long-term high-quality randomized control trials are needed.
C1 [Li, Dan-yan; Dai, Yun-kai; Zhang, Yun-zhan; Huang, Meng-xin; Li, Ru-liu; Chen, Wei-jing; Hu, Ling] Guangzhou Univ Chinese Med, Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China.
   [Ou-yang, Jia] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Jiangsu, Peoples R China.
RP Hu, L (reprint author), Guangzhou Univ Chinese Med, Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China.
EM drhuling@163.com
FU National Natural Science Foundation of China [81373563, 81774238];
   Innovation team to foster scientific research projects of Guangzhou
   University of Chinese Medicine, Guangzhou University of Chinese Medicine
   [7, 2016KYTD07]; Construction of high-level university of Guangzhou
   University of Chinese Medicine, Guangzhou University of Chinese Medicine
   [64]
FX This research was supported by National Natural Science Foundation of
   China, No.81373563; Innovation team to foster scientific research
   projects of Guangzhou University of Chinese Medicine, Guangzhou
   University of Chinese Medicine (2016) No.7, No.2016KYTD07; Construction
   of high-level university of Guangzhou University of Chinese Medicine,
   Guangzhou University of Chinese Medicine (2016) No.64; National Natural
   Science Foundation of China, No.81774238. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Barbara G, 2012, J CLIN GASTROENTEROL, V46, pS52, DOI 10.1097/MCG.0b013e318264e918
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brandt LJ, 2009, AM J GASTROENTEROL, V104, pS1, DOI 10.1038/ajg.2008.122
   Cai W., 2005, SHANGHAI ZHONG YI YA, V39, P14
   Camilleri M, 2012, AM J PHYSIOL-GASTR L, V303, pG775, DOI 10.1152/ajpgi.00155.2012
   Chang JY, 2010, TRENDS PHARMACOL SCI, V31, P326, DOI 10.1016/j.tips.2010.04.008
   Chen JF, 2013, MATH PROBL ENG, V2013, P11
   Chen XG, 2005, SHANDONG ZHONG YI ZA, V24, P526
   Chinese Society of Digestive Diseases and Chinese Association of Chinese Medicine, 2010, CHINA J TRAD CHIN ME, V25, P1062
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Drossman DA, 1999, GUT, V45, P1
   Drossman DA, 2006, GASTROENTEROLOGY, V130, P1377, DOI 10.1053/j.gastro.2006.03.008
   Enck P, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.14
   Everhart JE, 2009, GASTROENTEROLOGY, V136, P376, DOI 10.1053/j.gastro.2008.12.015
   Fan L, 2009, CHINA PHARMACIST, V9, P1360
   Fu F., 2015, CLIN STUDY MAREN PIL
   Grundmann O, 2010, J GASTROEN HEPATOL, V25, P691, DOI 10.1111/j.1440-1746.2009.06120.x
   Gwee KA, 2010, J GASTROEN HEPATOL, V25, P1189, DOI 10.1111/j.1440-1746.2010.06353.x
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hussain Z, 2006, ALIMENT PHARM THER, V23, P465, DOI 10.1111/j.1365-2036.2006.02776.x
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jiang XY, 2013, CLIN STUDY MECH KUAN
   Krogius-Kurikka L, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-95
   Leung WK, 2006, AM J GASTROENTEROL, V101, P1574, DOI 10.1111/j.1572-0241.2006.00576.x
   Li HY, 2011, ZHEJIANG J TRADITION, V46, P788
   Li Q, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/232147
   Liao J, 2011, J SICHUAN TRADITIONA, V29, P59
   Lin ZY, 2014, MODERN J INTEGRATED, V23, P343
   Liu JP, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004116.pub2
   Longstreth GF, 2006, GASTROENTEROLOGY, V130, P1480, DOI 10.1053/j.gastro.2005.11.061
   Lovell RM, 2012, CLIN GASTROENTEROL H, V10, P712, DOI 10.1016/j.cgh.2012.02.029
   National TCM Authority, 1994, TRAFF SAF FACTS 1994, P11
   Pan G, 2000, Zhonghua Liu Xing Bing Xue Za Zhi, V21, P26
   Qian CJ, 2011, CLIN STUDY SUPPLEMEN
   Qiu B., 2013, EXPT STUDY MA ZHI JI
   Schmulson MJ, 2017, J NEUROGASTROENTEROL, V23, P151, DOI 10.5056/jnm16214
   Shi J, 2008, WORLD J GASTROENTERO, V14, P454, DOI 10.3748/wjg.14.454
   Stanghellini V, 2002, AM J GASTROENTEROL, V97, P2738
   Sung JJY, 2004, ALIMENT PHARM THER, V20, P1205, DOI 10.1111/j.1365-2036.2004.02242.x
   Tillisch K, 2011, GASTROENTEROLOGY, V140, P407, DOI 10.1053/j.gastro.2010.12.014
   Tillisch K, 2011, GASTROENTEROLOGY, V140, P91, DOI 10.1053/j.gastro.2010.07.053
   Wang CL, 2008, JIANGXI J TRADITIONA, V39, P21
   Wang FD, 2015, CLIN STUDY SAN ZANG
   Wu JH, 2006, GUANGMING J CHINESE, V21, P34
   Xiao Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122397
   Xiong Li-shou, 2004, Zhonghua Yi Xue Za Zhi, V84, P278
   Xu YY, 2014, LISHIZHEN MED MATERI, P2192
   Yang SW, 2016, ZHEJIANG J TRADITION
   Yuan R, 2000, PHARMACOL THERAPEUT, V86, P191, DOI 10.1016/S0163-7258(00)00039-5
   Yue C, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002126
   Zhang XP, 2014, CHINA J CHINESE MED, V29, P1667
   Zhang ZY, 2016, CHINA PRACTICAL MED, V11, P37
   Zheng XY, 2002, CHINESE HERBAL MED N, P124
NR 53
TC 2
Z9 2
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 18
PY 2017
VL 12
IS 12
AR e0189491
DI 10.1371/journal.pone.0189491
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FQ5HM
UT WOS:000418389500033
PM 29253850
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, SM
   Liu, Y
   Zheng, GY
AF Wang, Shiming
   Liu, Yue
   Zheng, Guangying
TI Hypothyroidism as a risk factor for open angle glaucoma: A systematic
   review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID POPULATION; ASSOCIATION; PREVALENCE; BIAS; DISEASE; EYE
AB Purpose
   The relationship between hypothyroidism and primary open angle glaucoma (POAG) has attracted intense interest recently, but the reported results have been controversial. This meta-analysis was carried out to determine the association between hypothyroidism and POAG.
   Methods
   The literature was identified from three databases (Web of Science, Embase, and PubMed). The meta-analyses were performed using random-effects models, with results reported as adjusted odds ratios (ORs) with 95% confidence intervals (CI 95%).
   Results
   A total of 11 studies meeting the inclusion criteria were included in the final meta-analysis. The pooled OR based on 11 risk estimates showed a statistically significant increased risk of POAG prevalence among individuals with hypothyroidism (OR = 1.64, 95% CI = 1.27-2.13). Substantial heterogeneity among these studies was detected (P < 0.001; I-2 = 83.2%). Sub-group analysis revealed that the cohort studies and case-control studies showed a significant association between hypothyroidism and POAG, which was not observed in cross-sectional studies. There was no significant publication bias in this study.
   Conclusions
   The findings of this meta-analysis indicate that individuals with hypothyroidism have an increased risk of developing POAG.
C1 [Wang, Shiming; Liu, Yue; Zheng, Guangying] Zhengzhou Univ, Dept Ophthalmol, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
   [Wang, Shiming] Chongqing Aier Eye Hosp, Aier Eye Hosp Grp, Chongqing, Peoples R China.
RP Zheng, GY (reprint author), Zhengzhou Univ, Dept Ophthalmol, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
EM zzzgy01@126.com
OI wang, Shiming/0000-0003-1296-7887
FU Science Research Foundation of Aier Eye Hospital Group [AF1602D1,
   AM142D17, AF1602D2]
FX This study was funded by Science Research Foundation of Aier Eye
   Hospital Group (Grant No. AF1602D1, AM142D17, AF1602D2). The funder had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR [Anonymous], 1920, EINIGES AUGENDRUCK G
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Carenini BB, 1997, ACTA OPHTHALMOL SCAN, V75, P47
   Chung SD, 2014, EYE, V28, P225, DOI 10.1038/eye.2013.235
   Chung SD, 2014, AM J RHINOL ALLERGY, V28, pE148, DOI 10.2500/ajra.2014.28.4060
   Dedecjus M, 2011, THYROID, V21, P533, DOI 10.1089/thy.2010.0183
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Gillow JT, 1997, EYE, V11, P113, DOI 10.1038/eye.1997.22
   Girkin CA, 2004, OPHTHALMOLOGY, V111, P1649, DOI 10.1016/j.ophtha.2004.05.026
   Helfand M., 2004, SCREENING THYROID DI
   Hewitt AW, 2010, ACTA OPHTHALMOL, V88, P70, DOI 10.1111/j.1755-3768.2009.01786.x
   Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489
   Kakigi C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133688
   Karadimas P, 2001, AM J OPHTHALMOL, V131, P126, DOI 10.1016/S0002-9394(00)00724-8
   Kim M, 2012, JPN J OPHTHALMOL, V56, P324, DOI 10.1007/s10384-012-0153-4
   Lee AJ, 2004, EYE, V18, P600, DOI 10.1038/sj.eye.6700731
   Lin CC, 2013, OPHTHALMOLOGY, V120, P1559, DOI 10.1016/j.ophtha.2013.01.006
   Lin HC, 2010, OPHTHALMOLOGY, V117, P2088, DOI 10.1016/j.ophtha.2010.03.003
   Lin HC, 2010, OPHTHALMOLOGY, V117, P1960, DOI 10.1016/j.ophtha.2010.02.005
   Motsko SP, 2008, OPHTHALMOLOGY, V115, P1581, DOI 10.1016/j.ophtha.2008.01.016
   Munoz-Negrete FJ, 2000, OPHTHALMOLOGICA, V214, P347, DOI 10.1159/000027518
   Pan CW, 2017, AM J OPHTHALMOL
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Sanderson S, 2007, INT J EPIDEMIOL, V36, P666, DOI 10.1093/ije/dym018
   Shim SH, 2015, AM J OPHTHALMOL, V160, P1191, DOI 10.1016/j.ajo.2015.09.006
   SMITH KD, 1993, OPHTHALMOLOGY, V100, P1580
   SMITH KD, 1992, CAN J OPHTHALMOL, V27, P341
   STEIN R, 1982, METAB PEDIATR SYST O, V6, P169
   Sun J, 2012, EYE, V26, P283, DOI 10.1038/eye.2011.243
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   Wise LA, 2011, ANN EPIDEMIOL, V21, P430, DOI 10.1016/j.annepidem.2011.03.006
   Zhou MW, 2015, INVEST OPHTH VIS SCI, V56, P2279, DOI 10.1167/iovs.14-16279
   Zhou MW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102972
NR 34
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 25
PY 2017
VL 12
IS 10
AR e0186634
DI 10.1371/journal.pone.0186634
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FK7DC
UT WOS:000413663600020
PM 29069095
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU She, YY
   Nong, XL
   Zhang, M
   Wang, ML
AF She, Yangyang
   Nong, Xiaolin
   Zhang, Min
   Wang, Menglin
TI Epstein-Barr virus infection and oral squamous cell carcinoma risk: A
   meta-analysis
SO PLOS ONE
LA English
DT Article
ID PREVALENCE; CANCER; MUCOSA; DNA; EBV; ASSOCIATION; DYSPLASIA; LANGUAGE;
   DISEASES; ALCOHOL
AB Background
   The evidence for association between Epstein-Barr virus (EBV) infection and risk of oral squamous cell carcinoma (OSCC) is inconsistent in the literature. Therefore, this meta-analysis was conducted to clarify this association.
   Methods
   A literature search was conducted in electronic databases for English-and Chinese-language publications until March 31, 2017 to include eligible case-control studies. The pooled odds ratio (OR) and 95% confidence interval (95% CI) were estimated to determine the association between EBV infection and OSCC risk using a fixed- or random-effects model based on heterogeneity. Publication bias was assessed using funnel plot analysis.
   Results
   A total of 13 case-control studies with 686 OSCC patients and 433 controls were included based on predetermined inclusion and exclusion criteria. The pooled OR with 95% CI between EBV infection and OSCC risk was 5.03 (1.80 - 14.01) with significant heterogeneity observed (I-2 = 87%). The subgroup analysis indicates that the year of publication, study location, economic level, sample size, tissue type, detection method and marker, control type, and language might explain potential sources of heterogeneity. Publication bias was not observed, and sensitivity analysis showed stable results.
   Conclusions
   The results of the current meta-analysis suggest that EBV infection is statistically associated with increased risk of OSCC. However, additional high-quality studies with larger sample sizes are needed to further confirm the relationship between EBV and OSCC.
C1 [She, Yangyang; Nong, Xiaolin] Guangxi Med Univ, Coll & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Nanning, Guangxi, Peoples R China.
   [Zhang, Min] Peking Univ, Dept Prosthodont, Coll & Hosp Stomatol, Beijing, Peoples R China.
   [Wang, Menglin] Guangxi Med Univ, Affiliated Hosp 1, Dept Otorhinolaryngol & Head & Neck Surg, Nanning, Peoples R China.
RP Nong, XL (reprint author), Guangxi Med Univ, Coll & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Nanning, Guangxi, Peoples R China.
EM xnong@gxmu.edu.cn
FU National Natural Science Foundation of China [81360404]; Guangxi Natural
   Science Foundation [0832013]; Innovation Project of Guangxi Graduate
   Education [201010598RY10]
FX This study was funded by National Natural Science Foundation of China
   (81360404, http://www.nsfc.gov.cn/); Guangxi Natural Science Foundation
   (0832013, http://gxnsf.gxsti.net/stms/ login.isp); Innovation Project of
   Guangxi Graduate Education (201010598RY10), funding receiver XLN. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adeyemi BF, 2011, J NATL MED ASSOC, V103, P498, DOI 10.1016/S0027-9684(15)30364-3
   ADLERSTORTHZ K, 1992, J ORAL PATHOL MED, V21, P164, DOI 10.1111/j.1600-0714.1992.tb00095.x
   Bagan JV, 2008, MED ORAL PATOL ORAL, V13, pE110
   Bagos PG, 2009, J CLIN EPIDEMIOL, V62, P1037, DOI 10.1016/j.jclinepi.2008.12.008
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen WL, 1998, J ORAL MAXILLOFAC SU, V8, P23
   Cruz I, 1997, ORAL ONCOL, V33, P182, DOI 10.1016/S0964-1955(96)00054-1
   D'Costa J, 1998, J ORAL PATHOL MED, V27, P78
   DEACON EM, 1991, J PATHOL, V163, P351, DOI 10.1002/path.1711630413
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ding XQ, 1997, ACAD J SUM S, V18, P140
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feller L L J, 2012, J CANC THERAPY, V3, P263, DOI DOI 10.4236/JCT.2012.34037
   Goldstein BY, 2010, EUR J CANCER PREV, V19, P431, DOI 10.1097/CEJ.0b013e32833d936d
   Grywalska E, 2015, SEMIN ONCOL, V42, P291, DOI 10.1053/j.seminoncol.2014.12.030
   Gupta Kanupriya, 2013, Patholog Res Int, V2013, P642496, DOI 10.1155/2013/642496
   Hermann R M, 2004, Cancer Radiother, V8, P262, DOI 10.1016/j.canrad.2004.06.003
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   HORIUCHI K, 1995, ORAL SURG ORAL MED O, V79, P57, DOI 10.1016/S1079-2104(05)80075-7
   Javier RT, 2008, CANCER RES, V68, P7693, DOI 10.1158/0008-5472.CAN-08-3301
   Jiang HB, 2015, SCI REP-UK, V5, DOI 10.1038/srep14543
   Jiang R, 2012, ORAL ONCOL, V48, P836, DOI 10.1016/j.oraloncology.2012.03.017
   Kis A, 2009, EUR J ORAL SCI, V117, P536, DOI 10.1111/j.1600-0722.2009.00660.x
   Liyanage SS, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003604
   Marur S, 2008, MAYO CLIN PROC, V83, P489, DOI 10.4065/83.4.489
   Mesri EA, 2014, CELL HOST MICROBE, V15, P266, DOI 10.1016/j.chom.2014.02.011
   Morrison A, 2012, INT J TECHNOL ASSESS, V28, P138, DOI 10.1017/S0266462312000086
   Nguyen SP, 2009, CLIN GASTROENTEROL H, V7, P676, DOI 10.1016/j.cgh.2009.01.008
   Pham B, 2005, J CLIN EPIDEMIOL, V58, P769, DOI 10.1016/j.jclinepi.2004.08.021
   Prabhu SR, 2016, J CAN DENT ASSOC, V82
   Reichart PA, 2008, J ORAL PATHOL MED, V37, P511, DOI 10.1111/j.1600-0714.2008.00669.x
   Sand LP, 2002, ORAL SURG ORAL MED O, V93, P586, DOI 10.1067/moe.2002.124462
   Saravani S, 2014, INT J PREVENTIVE MED, V5
   Shamaa AA, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-45
   Shi X, 2017, ONCOTARGET, V8, P28526, DOI 10.18632/oncotarget.16095
   Shimakage M, 2002, HUM PATHOL, V33, P608, DOI 10.1053/hupa.2002.129786
   Shimakage M, 2010, EXP THER MED, V1, P285, DOI 10.3892/etm_00000044
   Sinevici N, 2016, ORAL ONCOL, V61, P12, DOI 10.1016/j.oraloncology.2016.07.013
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Suresh Kp, 2012, J Hum Reprod Sci, V5, P7, DOI 10.4103/0974-1208.97779
   Thompson MP, 2004, CLIN CANCER RES, V10, P803, DOI 10.1158/1078-0432.CCR-0670-3
   Van Rensburg E. J., 1995, In Vivo (Attiki), V9, P199
   VanHeerden WFP, 1995, ANTICANCER RES, V15, P2335
   Verma M., 2015, MULTIPLE INFECT CANC, P133
   Wells GA, NEWCASTLE OTTAWA SCA
   Zhong LP, 2015, ONCOTARGET, V6, P18707, DOI 10.18632/oncotarget.4531
NR 48
TC 7
Z9 7
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2017
VL 12
IS 10
AR e0186860
DI 10.1371/journal.pone.0186860
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FK5VD
UT WOS:000413568900051
PM 29065191
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Galvao, EL
   Rabello, A
   Cota, GF
AF Galvao, Endi Lanza
   Rabello, Ana
   Cota, Glaucia Fernandes
TI Efficacy of azole therapy for tegumentary leishmaniasis: A systematic
   review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID WORLD CUTANEOUS LEISHMANIASIS; CONTROLLED CLINICAL-TRIAL; DOUBLE-BLIND;
   ITRACONAZOLE; KETOCONAZOLE; FLUCONAZOLE; BRAZILIENSIS; EXPERIENCE;
   FAILURE; PHARMACOKINETICS
AB Background
   Several controlled and uncontrolled studies addressing azole antifungal drugs for cutaneous and mucosal leishmaniasis have been published with inconclusive results. We conducted a systematic literature review of studies evaluating the efficacy and toxicity associated with azole therapy for tegumentary leishmaniasis.
   Methodology
   PRISMA guidelines for systematic reviews and the Cochrane manual were followed, and the review methodology was registered (PROSPERO; CRD42016048668). Sources included the EMBASE, Web of Science, MEDLINE, LILACS, and IBECS databases along with a manual search of references from evaluated studies. Additional resources such as Google Scholar and clinicaltrials. gov were also searched. We included all studies reporting cure rate after cutaneous or mucosal leishmaniasis treatment with systemic azole drugs, regardless of their design. R software was used to estimate global rates of success and adverse events with each drug. The main outcome of interest was clinical cure, defined as complete re-epithelialization of all lesions.
   Results
   A total of 37 studies involving 1259 patients that reported outcomes after fluconazole (9), ketoconazole (14) and itraconazole (15) treatments were included. Only 14 (38%) were randomized controlled trials (RCT). The pooled azole final efficacy rate was 64% (CI95%: 57-70%) for all studies and 60% (CI95%: 50-70%) (p = 0.41) if only RCTs studies were considered. Twenty-four studies were conducted in the Old World and 13 studies in the Americas. The final efficacy rate according to New and Old World were 62% (CI95%: 43-77%) and 66% (CI95%: 58-73%), respectively. The final efficacy rate of azoles according to species were 89% (CI95%: 50-98%) for L. mexicana; 88% for L. infantum (CI95%: 27-99%); 80% for L. donovani; 53% (CI95%: 29-76%) for L. major; 49% for L. braziliensis (CI95%: 21-78%); and 15% (CI95%: 1-84%) for L. tropica. The cure rates were similar among the fluconazole, ketoconazole and itraconazole group arms (p = 0.89), specifically 61% (CI95%: 48-72%), 64% (CI95%: 44-80%) 65% (CI95%: 56-72%), respectively. Adverse events during fluconazole, itraconazole and ketoconazole therapy were reported in 7% (CI95%: 3-14%), 12% (CI95% 8-19%) and 13% (CI95%: 6-29%) of treated patients, respectively, without difference among them (p = 0.35). This systematic review included studies with small samples and both non-comparative and non-randomized studies and the main limitation was the low quality of the available studies.
   Conclusions
   Available evidence suggests that fluconazole, ketoconazole and itraconazole have similar and modest efficacy rates for tegumentary leishmaniasis treatment. There is insufficient evidence to support the exclusive use of azole therapy as a single agent for leishmaniasis treatment.
C1 [Galvao, Endi Lanza; Rabello, Ana; Cota, Glaucia Fernandes] Fiocruz MS, Rachou Fundacao Oswaldo Cruz, Pesquisa Clin & Polit Publ Doencas Infectoparasit, Belo Horizonte, MG, Brazil.
RP Galvao, EL (reprint author), Fiocruz MS, Rachou Fundacao Oswaldo Cruz, Pesquisa Clin & Polit Publ Doencas Infectoparasit, Belo Horizonte, MG, Brazil.
EM endi.lanza@cpqrr.fiocruz.br
FU CNPq (National Counsel of Technological and Scientific Development)
   [311641/2009-1]; FAPEMIG (Foundation for Research Support of the State
   of Minas Gerais)
FX AR is currently receiving a grant [311641/2009-1] from CNPq (National
   Counsel of Technological and Scientific Development). ELG is a Ph.D.
   student and is receiving a scholarship from FAPEMIG (Foundation for
   Research Support of the State of Minas Gerais). The authors received no
   specific funding for this work.
CR Al-Mutairi N, 2009, INT J DERMATOL, V48, P862, DOI 10.1111/j.1365-4632.2008.04010.x
   ALFOUZAN AS, 1991, INT J DERMATOL, V30, P519, DOI 10.1111/j.1365-4362.1991.tb04878.x
   Alrajhi AA, 2002, NEW ENGL J MED, V346, P891, DOI 10.1056/NEJMoa011882
   ALSALEH QA, 1995, INT J DERMATOL, V34, P495, DOI 10.1111/j.1365-4362.1995.tb00622.x
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Amato  V S, 2000, Int J Infect Dis, V4, P153, DOI 10.1016/S1201-9712(00)90077-8
   Amato VS, 2009, J EUR ACAD DERMATOL, V23, P1026, DOI 10.1111/j.1468-3083.2009.03238.x
   Baron S, 2004, CLIN EXP DERMATOL, V29, P546, DOI 10.1111/j.1365-2230.2004.01561.x
   BEACH DH, 1988, MOL BIOCHEM PARASIT, V31, P149, DOI 10.1016/0166-6851(88)90166-1
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cabrejos Pita Jose Gabriel, 2002, Rev Med Hered, V13, P144
   Calvopina M, 2004, INT J DERMATOL, V43, P659, DOI 10.1111/j.1365-4632.2004.02183.x
   Chahed MK, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005090
   Consigli J, 2006, INT J DERMATOL, V45, P46, DOI 10.1111/j.1365-4632.2004.02429.x
   Cota GF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149697
   Croft SL, 2002, CURR PHARM DESIGN, V8, P319, DOI 10.2174/1381612023396258
   DEDET JP, 1986, T ROY SOC TROP MED H, V80, P176, DOI 10.1016/0035-9203(86)90239-7
   DOGRA J, 1994, INT J ANTIMICROB AG, V4, P309, DOI 10.1016/0924-8579(94)90031-0
   Dogra J, 1996, INT J PARASITOL, V26, P1413, DOI 10.1016/S0020-7519(96)00128-2
   DOGRA J, 1990, INT J DERMATOL, V29, P661, DOI 10.1111/j.1365-4362.1990.tb02593.x
   Emad M, 2011, J AM ACAD DERMATOL, V64, P606, DOI 10.1016/j.jaad.2010.04.014
   Gonzalez U, 2009, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004834.PUB2
   Gonzalez U, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005067.pub3
   Gurel MS, 2005, INT J DERMATOL, V44, P933, DOI 10.1111/j.1365-4632.2004.02225.x
   HEYKANTS J, 1989, MYCOSES, V32, P67, DOI 10.1111/j.1439-0507.1989.tb02296.x
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   JOLLIFFE DS, 1986, CLIN EXP DERMATOL, V11, P62, DOI 10.1111/j.1365-2230.1986.tb00425.x
   Kassi M, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000259
   Khan W, 2014, IRAN J PARASITOL, V9, P365
   Khatami A, 2007, J AM ACAD DERMATOL, V57, P335, DOI 10.1016/j.jaad.2007.01.016
   LAROSA E, 1986, EUR J OBSTET GYN R B, V23, P85, DOI 10.1016/0028-2243(86)90109-7
   Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Momeni AZ, 1996, ARCH DERMATOL, V132, P784, DOI 10.1001/archderm.132.7.784
   Morizot G, 2007, AM J TROP MED HYG, V76, P48
   Mosimann V, 2013, INFECTION, V41, P1177, DOI 10.1007/s15010-013-0500-5
   Nassiri-Kashani M, 2005, J EUR ACAD DERMATOL, V19, P80, DOI 10.1111/j.1468-3083.2004.01133.x
   NAVIN TR, 1992, J INFECT DIS, V165, P528, DOI 10.1093/infdis/165.3.528
   Netto E M, 1989, Rev Soc Bras Med Trop, V22, P105
   NORTON SA, 1992, ARCH DERMATOL, V128, P83, DOI 10.1001/archderm.128.1.83
   Oliveira LF, 2011, ACTA TROP, V118, P87, DOI 10.1016/j.actatropica.2011.02.007
   Olliaro P, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002130
   Ozgoztasi O, 1997, INT J DERMATOL, V36, P61, DOI 10.1046/j.1365-4362.1997.00022.x
   Prates FVD, 2017, CLIN INFECT DIS, V64, P67, DOI 10.1093/cid/ciw662
   Rafaa M, 2007, ANN DERMATOL VENER, V134, P682, DOI 10.1016/S0151-9638(07)91833-5
   Restrepo M, 1987, ACTA MED COLOMB, V12, P294
   Reveiz L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061843
   SAENZ RE, 1990, AM J MED, V89, P147, DOI 10.1016/0002-9343(90)90292-L
   Saleem K, 2007, JCPSP-J COLL PHYSICI, V17, P713, DOI 12.2007/JCPSP.713716
   Salmanpour R, J DERMATOLOG TREAT, V12, P159
   Santos I, 1995, AN BRAS DERMATOL, V70
   Santos MF, 1988, AN BRAS DERMATOL, V63
   Scorza J. V., 1988, Boletin de la Direccion de Malariologia y Saneamiento Ambiental, V28, P32
   Shokri A, 2017, ACTA TROP, V167, P73, DOI 10.1016/j.actatropica.2016.12.027
   Siddiqui MA, 1998, J DERMATOL TREAT, V9, P235, DOI 10.3109/09546639809160701
   Silva CGL, 2012, THESIS
   Singh KK, 1993, INDIAN J DERMATOL VE, V59, P120
   SINGH S, 1995, INT J DERMATOL, V34, P120, DOI 10.1111/j.1365-4362.1995.tb03595.x
   Sousa AQ, 2011, CLIN INFECT DIS, V53, P693, DOI 10.1093/cid/cir496
   Tuon FF, 2008, INT J DERMATOL, V47, P109, DOI 10.1111/j.1365-4632.2008.03417.x
   VANDENENDEN E, 1994, INT J DERMATOL, V33, P285
   Viriyavejakul Parnpen, 1997, Southeast Asian Journal of Tropical Medicine and Public Health, V28, P558
   Vita GF, 2016, REV INST MED TROP SP, V58, DOI [10.1590/S1678-9946201658071, 10.1590/s1678-9946201658071]
   WEINRAUCH L, 1983, ARCH DERMATOL RES, V275, P353, DOI 10.1007/BF00417211
   Wells G, 2011, NEWCASTLE OTTAWA SCA
   WHO, 2010, WHO TECHN REP SER
   Willard RJ, 2005, J AM ACAD DERMATOL, V52, P977, DOI 10.1016/j.jaad.2005.01.109
   ZAHAF A, 1987, MED MALADIES INFECT, V17, P420, DOI 10.1016/S0399-077X(87)80054-9
   Zeegelaar JE, 2005, CLIN EXP DERMATOL, V30, P1, DOI 10.1111/j.1365-2230.2004.01677.x
NR 69
TC 6
Z9 6
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2017
VL 12
IS 10
AR e0186117
DI 10.1371/journal.pone.0186117
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FJ3AF
UT WOS:000412601800039
PM 29016694
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Qiao, WQ
   Jia, ZQ
   Liu, HY
   Liu, QP
   Zhang, T
   Quo, WY
   Li, P
   Deng, M
   Li, SQ
AF Qiao, Weiqiang
   Jia, Zhiqiang
   Liu, Heyang
   Liu, Qipeng
   Zhang, Ting
   Quo, Wanying
   Li, Peng
   Deng, Miao
   Li, Sanqiang
TI Prognostic and clinicopathological value of Twist expression in breast
   cancer: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID TRANSCRIPTION FACTOR TWIST; GENE-EXPRESSION; CARCINOMA; METASTASIS;
   SNAIL; RESISTANCE; PATHWAYS; SURVIVAL; INVASION; CADHERIN
AB Background
   Despite initial indications that the transcription factor Twist could be used as a breast cancer prognostic marker, there still exists some controversy about its reliability. Thus, the aim of the present study was to assess the relationship between Twist expression and prognosis in breast carcinoma.
   Materials and methods
   We identified eligible studies that reported an association between Twist expression and breast cancer prognosis by searching the literature in PubMed, Embase, the Cochrane Library, and Web of Science databases, through June 5, 2017. Studies investigating Twist protein or mRNA expression as well as reporting survival data in breast cancer were included. The pooled hazard ratio (HR) and odds radio (OR) with a 95% confidence interval (95% CI) were used to estimate associations.
   Results
   A total of 2,671 patients from seven included studies were assessed, and the data indicated that increased Twist expression significantly correlated with poor overall survival (OS) (HR, 1.15; 95% CI, 1.00-1.33; P = 0.04) in breast cancer. In addition, we also observed a significant correlation of elevated Twist expression with larger tumor size (OR, 1.92; 95% CI, 1.31-2.81; P = 0.0009), lymph node involvement (OR, 3.81; 95% CI, 1.16-12.54; P = 0.03), higher nuclear grade (OR, 1.45; 95% CI, 1.06-2.00; P = 0.02), and positive human epidermal growth factor receptor 2 (HER2) status (OR, 1.49; 95% CI, 1.06-2.09; P = 0.02). However, no correlation between Twist expression and disease-free survival (DFS), age, estrogen receptor (ER) status, and progesterone receptor (PR) status was observed.
   Conclusions
   Our results demonstrate that Twist over-expression is a statistically significant indicator of OS in breast cancer. In addition, our meta-analysis shows that increased Twist expression is significantly associated with larger tumor size, lymph node involvement, higher nuclear grade, and positive HER2 status.
C1 [Qiao, Weiqiang; Liu, Qipeng; Zhang, Ting; Quo, Wanying; Li, Peng; Deng, Miao] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Breast Surg, Luoyang, Peoples R China.
   [Qiao, Weiqiang; Liu, Heyang; Liu, Qipeng; Zhang, Ting; Quo, Wanying; Li, Peng; Deng, Miao] Henan Univ Sci & Technol, Coll Clin Med, Luoyang, Peoples R China.
   [Jia, Zhiqiang] Henan Univ Sci & Technol, Affiliated Hosp 2, Dept Spinal Surg, Luoyang, Peoples R China.
   [Liu, Heyang] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Oncol, Luoyang, Peoples R China.
   [Li, Sanqiang] Henan Univ Sci & Technol, Med Coll, Mol Med Key Lab Liver Injury & Repair, Luoyang, Peoples R China.
RP Deng, M (reprint author), Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Breast Surg, Luoyang, Peoples R China.; Deng, M (reprint author), Henan Univ Sci & Technol, Coll Clin Med, Luoyang, Peoples R China.; Li, SQ (reprint author), Henan Univ Sci & Technol, Med Coll, Mol Med Key Lab Liver Injury & Repair, Luoyang, Peoples R China.
EM dengmiao1973@163.com; sanqiangli2001@163.com
OI Deng, Miao/0000-0001-7146-0619; Qiao, Weiqiang/0000-0003-4178-4617
FU Program for Science &Technology Innovation teams in Universities of
   Henan Province [181RTSTHN026]; innovation team of Henan University of
   Science and Technology [2015XTD003]; Henan province's Key Project of
   tackle key problems of science and technology [172102310693]
FX This work was supported by the Program for Science &Technology
   Innovation teams in Universities of Henan Province (#181RTSTHN026), the
   innovation team of Henan University of Science and Technology
   (#2015XTD003) and Henan province's Key Project of tackle key problems of
   science and technology (#172102310693). The funders had no role in the
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alexander NR, 2006, CANCER RES, V66, P3365, DOI 10.1158/0008-5472.CAN-05-3401
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cakouros D, 2012, MOL CELL BIOL, V32, P1433, DOI 10.1128/MCB.06315-11
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   DerSimonian R, 2015, CONTEMP CLIN TRIALS, V45, P139, DOI 10.1016/j.cct.2015.09.002
   Ehinger A, 2017, ACTA ONCOL, V56, P68, DOI 10.1080/0284186X.2016.1237778
   Entz-Werle N, 2005, INT J CANCER, V117, P349, DOI 10.1002/ijc.21068
   Ezhkova E, 2011, GENE DEV, V25, P485, DOI 10.1101/gad.2019811
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Grzegrzolka J, 2015, ANTICANCER RES, V35, P3961
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731
   Hung JJ, 2009, THORAX, V64, P1082, DOI 10.1136/thx.2009.115691
   Inoue K, 2007, ONCOGENE, V26, P4329, DOI 10.1038/sj.onc.1210226
   Kwilas AR, 2015, ONCOTARGET, V6, P28194, DOI 10.18632/oncotarget.4442
   Kwok WK, 2007, CARCINOGENESIS, V28, P2467, DOI 10.1093/carcin/bgm185
   Lee TK, 2006, CLIN CANCER RES, V12, P5369, DOI 10.1158/1078-0432.CCR-05-2722
   Lim JCT, 2015, BREAST CANCER RES TR, V150, P19, DOI 10.1007/s10549-015-3296-4
   Luo GQ, 2008, WORLD J GASTROENTERO, V14, P2487, DOI 10.3748/wjg.14.2487
   Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207
   Markiewicz A, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-226
   Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010
   Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299
   Montserrat N, 2011, HUM PATHOL, V42, P103, DOI 10.1016/j.humpath.2010.05.019
   Ono M, 2017, CLIN BREAST CANCER, V17, P41, DOI 10.1016/j.clbc.2016.06.012
   PARK S, 2017, MEDICINE, V96
   Puisieux A, 2006, BRIT J CANCER, V94, P13, DOI 10.1038/sj.bjc.6602876
   Ranganathan S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141370
   Riaz M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3317
   Selmi A, 2015, CANCER LETT, V357, P412, DOI 10.1016/j.canlet.2014.11.056
   Shamanin VA, 2004, MOL CELL BIOL, V24, P2144, DOI 10.1128/MCB.24.5.2144-2152.2004
   Shiota M, 2011, BJU INT, V108, pE142, DOI 10.1111/j.1464-410X.2010.09810.x
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Soini Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-73
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033
   van Doorn R, 2004, CANCER RES, V64, P5578, DOI 10.1158/0008-5472.CAN-04-1253
   Vasconcelos I, 2016, BREAST, V29, P181, DOI 10.1016/j.breast.2016.07.016
   Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483
   Vesuna F, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3033-3
   Wang XH, 2004, ONCOGENE, V23, P474, DOI 10.1038/sj.onc.1207128
   Wushou A, 2014, INT J MOL SCI, V15, P21621, DOI 10.3390/ijms151221621
   Xu Y, 2017, ONCOGENE, V36, P1157, DOI 10.1038/onc.2016.286
   Xu Y, 2014, INT J BIOL SCI, V10, P396, DOI 10.7150/ijbs.8193
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Zhang P, 2014, EUR J CLIN INVEST, V44, P1072, DOI 10.1111/eci.12343
   Zhang YQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135851
   Zhao M, 2013, EXP THER MED, V6, P97, DOI 10.3892/etm.2013.1099
NR 49
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2017
VL 12
IS 10
AR e0186191
DI 10.1371/journal.pone.0186191
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FJ3AF
UT WOS:000412601800045
PM 29016671
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zheng, X
   Zhan, Z
   Naren, D
   Li, J
   Yan, TY
   Gong, YP
AF Zheng, Xue
   Zhan, Zhi
   Naren, Duolan
   Li, Jing
   Yan, Tianyou
   Gong, Yuping
TI Prognostic value of SRSF2 mutations in patients with de novo
   myelodysplastic syndromes: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID SCORING SYSTEM; SPLICEOSOME; MACHINERY; STABILITY; PATHWAY; IMPACT;
   U2AF1
AB Background
   The recent application of gene-sequencing technology has identified many new somatic mutations in patients with myelodysplastic syndromes (MDS). Among them, serine and arginine rich splicing factor 2 (SRSF2) mutations belonging to the RNA splicing pathway were of interest. Many studies have already reported the potential prognostic value of SRSF2 mutations in MDS patients, with controversial results. Therefore, a meta-analysis was performed to investigate their prognostic impact on MDS.
   Methods
   Databases, including PubMed, Embase and the Cochrane Library, were searched for relevant studies published up to 14 October 2016. Overall survival (OS) was selected as the primary endpoint, and acute myeloid leukemia (AML) transformation was the secondary endpoint. We extracted the corresponding hazard ratios (HRs) and their 95% confidence intervals (Cis) for OS and AML transformation from multivariate Cox proportional hazards models. The combined HRs with their 95% Cls were calculated using fixed or random effect models.
   Results
   A total of 10 cohort studies, covering 1864 patients with de novo MDS and 294 patients with SRSF2 mutations, were included in the final meta-analysis. Our results indicated that SRSF2 mutations had an adverse prognostic impact on OS (p<0.0001) and AML transformation (p = 0.0005) in the total population. Among the MDS patients with low or intermediate-1 risk defined according to the International Prognostic Scoring System (IPSS), SRSF2 mutations predicted a shorter OS (p = 0.009) and were more likely to transform to AML (p = 0.007).
   Conclusions
   This meta-analysis indicates an independent, adverse prognostic impact of SRSF2 mutations on OS and AML transformation in patients with de novo MDS. This also applies to the subgroup of low- or intermediate-1-IPSS risk MDS. The identification of mutations in SRSF2 can improve current risk stratification and help make treatment decisions.
C1 [Zheng, Xue; Naren, Duolan; Yan, Tianyou; Gong, Yuping] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Sichuan, Peoples R China.
   [Zhan, Zhi] Fu Dan Univ, Zhong Shan Hosp, Dept Cardiol, Shanghai, Peoples R China.
   [Li, Jing] Sichuan Univ, West China Hosp, Dept Evidence Based Med & Clin Epidemiol, Chengdu, Sichuan, Peoples R China.
RP Gong, YP (reprint author), Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Sichuan, Peoples R China.
EM gongyuping2010@aliyun.com
FU Foundation of the Science & Technology Department of Sichuan Province
   [2015SZ0234-5]; Foundation of Administration of traditional Chinese
   medicine of Sichuan Province [2014A038]; Foundation of Science and
   Technology Bureau of Chengdu [2016-HM0100001-SF]
FX The work was supported by the Foundation of the Science & Technology
   Department of Sichuan Province (No. 2015SZ0234-5), Foundation of
   Administration of traditional Chinese medicine of Sichuan Province (No.
   2014A038) and the Foundation of Science and Technology Bureau of Chengdu
   (No. 2016-HM0100001-SF), http://www.scst.gov.cn/. YPG received these
   funding. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ades L, 2014, LANCET, V383, P2239, DOI 10.1016/S0140-6736(13)61901-7
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bejar R, 2012, J CLIN ONCOL, V30, P3376, DOI 10.1200/JCO.2011.40.7379
   Boultwood Jacqueline, 2014, Advances in Biological Regulation, V54, P153, DOI 10.1016/j.jbior.2013.09.005
   Cui YJ, 2015, EXP HEMATOL ONCOL, V4, DOI 10.1186/s40164-015-0009-y
   Damm F, 2012, BLOOD, V119, P3211, DOI 10.1182/blood-2011-12-400994
   Dehm SM, 2013, CLIN CANCER RES, V19, P6064, DOI 10.1158/1078-0432.CCR-13-2461
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ganguly BB, 2016, MUTAT RES-REV MUTAT, V769, P47, DOI 10.1016/j.mrrev.2016.04.009
   Greenberg P, 1997, BLOOD, V89, P2079
   Greenberg PL, 2012, BLOOD, V120, P2454, DOI 10.1182/blood-2012-03-420489
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hoskins AA, 2012, TRENDS BIOCHEM SCI, V37, P179, DOI 10.1016/j.tibs.2012.02.009
   Itzykson R, 2013, J CLIN ONCOL, V31, P2428, DOI 10.1200/JCO.2012.47.3314
   Kang MG, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1493-5
   Karimi M, 2015, HAEMATOLOGICA, V100, pE223, DOI 10.3324/haematol.2014.118034
   Kim E, 2015, CANCER CELL, V27, P617, DOI 10.1016/j.ccell.2015.04.006
   Kim M, 2015, BONE MARROW TRANSPL, V50, P1132, DOI 10.1038/bmt.2015.110
   Lin J, 2014, PLOS ONE
   Maciejewski JP, 2012, BRIT J HAEMATOL, V158, P165, DOI 10.1111/j.1365-2141.2012.09158.x
   Mian SA, 2013, HAEMATOLOGICA, V98, P1058, DOI 10.3324/haematol.2012.075325
   Papaemmanuil E, 2013, BLOOD, V122, P3616, DOI 10.1182/blood-2013-08-518886
   Thol F, 2012, BLOOD, V119, P3578, DOI 10.1182/blood-2011-12-399337
   Walter MJ, 2013, LEUKEMIA, V27, P1275, DOI 10.1038/leu.2013.58
   Wells GA, NEWCASTLE OTTAWA SCA
   Wu LY, 2016, TUMOR BIOL, V37, P4633, DOI 10.1007/s13277-015-4305-2
   Wu SJ, 2012, BLOOD, V120, P3106, DOI 10.1182/blood-2012-02-412296
   Xiao R, 2007, MOL CELL BIOL, V27, P5393, DOI 10.1128/MCB.00288-07
   Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496
NR 29
TC 4
Z9 4
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 27
PY 2017
VL 12
IS 9
AR e0185053
DI 10.1371/journal.pone.0185053
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FI4WR
UT WOS:000411980300030
PM 28953917
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, F
   Xu, XX
   Yang, JJ
   Min, LF
   Liang, SD
   Chen, Y
AF Wang, Fang
   Xu, Xingxiang
   Yang, Junjun
   Min, Lingfeng
   Liang, Sudong
   Chen, Yong
TI Height and lung cancer risk: A meta-analysis of observational studies
SO PLOS ONE
LA English
DT Article
ID BODY-MASS INDEX; DIFFERENT ANATOMIC SITES; ADULT HEIGHT; NORWEGIAN
   WOMEN; LEG LENGTH; FOLLOW-UP; COHORT; MORTALITY; MEN; DISEASE
AB Background
   The association between height and lung cancer risk has been investigated by epidemiological studies but the results are inconsistent. This meta- analysis was to evaluate whether the height is associated with lung cancer.
   Methods
   We identified relevant articles by searching the MEDLINE and EMBASE databases, and reviewed the reference lists of selected papers. A random effect model was used to calculate summary odds ratios (OR) and relative risk (RR) with 95% confidence intervals (95% CI). Publication bias was estimated using Egger's regression asymmetry test.
   Results
   We included a total 16 studies (15 prospective studies and one case-control study) on adult height and lung cancer risk in the meta-analysis. Overall, per 10-cm height increases were associated with increased risk of lung cancer (RR 1.06; 95% CI 1.03-1.09, I-2 = 43.6%).
   Conclusions
   In this meta-analysis, high adult height is related to increased lung cancer risk. Well-designed, large prospective studies are required to obtain a better indication of the relationship.
C1 [Wang, Fang; Xu, Xingxiang; Yang, Junjun; Min, Lingfeng] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Clin Med Sch, Dept Respirat, Yangzhou, Jiangsu, Peoples R China.
   [Liang, Sudong] Taizhou Peoples Hosp Jiangsu Prov, Dept Urol, Taizhou, Jiangsu, Peoples R China.
   [Chen, Yong] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Dept Med Oncol, Clin Med Sch, Yangzhou, Jiangsu, Peoples R China.
RP Xu, XX (reprint author), Yangzhou Univ, Northern Jiangsu Peoples Hosp, Clin Med Sch, Dept Respirat, Yangzhou, Jiangsu, Peoples R China.
EM xuxx63@sina.com
CR ALBANES D, 1988, CANCER RES, V48, P1658
   Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410
   Aune D, 2012, CANCER CAUSE CONTROL, V23, P1213, DOI 10.1007/s10552-012-9983-0
   Batty GD, 2010, ANN ONCOL, V21, P646, DOI 10.1093/annonc/mdp363
   Batty GD, 2009, ECON HUM BIOL, V7, P137, DOI 10.1016/j.ehb.2009.06.004
   Batty GD, 2006, ANN ONCOL, V17, P157, DOI 10.1093/annonc/mdj018
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bjorge T, 2007, INT J CANCER, V120, P378, DOI 10.1002/ijc.22260
   COOK NR, 1994, AM J EPIDEMIOL, V139, P1066, DOI 10.1093/oxfordjournals.aje.a116950
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DRINKARD CR, 1995, AM J EPIDEMIOL, V142, P600, DOI 10.1093/oxfordjournals.aje.a117681
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Engeland A, 2003, JNCI-J NATL CANCER I, V95, P1244, DOI 10.1093/jnci/djg010
   Engeland A, 2005, CANCER CAUSE CONTROL, V16, P987, DOI 10.1007/s10552-005-3638-3
   Engeland A, 2007, AM J EPIDEMIOL, V165, P44, DOI 10.1093/aje/kwj353
   Green J, 2011, LANCET ONCOL, V12, P785, DOI 10.1016/S1470-2045(11)70154-1
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Gunnell D, 2001, EPIDEMIOL REV, V23, P313, DOI 10.1093/oxfordjournals.epirev.a000809
   Gunnell D, 2003, NUTR CANCER, V47, P34, DOI 10.1207/s15327914nc4701_4
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Hebert PR, 1997, CANCER CAUSE CONTROL, V8, P591, DOI 10.1023/A:1018442329319
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jousilahti P, 2000, AM J EPIDEMIOL, V151, P1112
   Kabat GC, 2014, CANCER CAUSE CONTROL, V25, P1697, DOI 10.1007/s10552-014-0476-1
   Kabat GC, 2013, CANCER EPIDEM BIOMAR, V22, P1353, DOI 10.1158/1055-9965.EPI-13-0305
   Kabat GC, 2013, INT J CANCER, V132, P1125, DOI 10.1002/ijc.27704
   Key TJ, 2010, LANCET ONCOL, V11, P530, DOI 10.1016/S1470-2045(10)70095-4
   Khankari NK, 2016, ASS ADULT HEIGHT RIS, V13
   LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5
   Lerro CC, 2010, BRIT J CANCER, V103, P1467, DOI 10.1038/sj.bjc.6605934
   Liang SD, 2015, J CANCER RES CLIN, V141, P1799, DOI 10.1007/s00432-014-1870-5
   Lynch J, 2005, ANNU REV PUBL HEALTH, V26, P1, DOI 10.1146/annurev.publhealth.26.021304.144505
   Mao Y, 2003, AM J EPIDEMIOL, V158, P564, DOI 10.1093/aje/kwg186
   Mao YS, 2016, SURG ONCOL CLIN N AM, V25, P439, DOI 10.1016/j.soc.2016.02.001
   MARMOT MG, 1984, LANCET, V1, P1003
   Minami Y, 2008, JPN J CLIN ONCOL, V38, P205, DOI 10.1093/jjco/hym170
   Olsen CM, 2008, INT J CANCER, V122, P1100, DOI 10.1002/ijc.23214
   PECK AMN, 1989, J EPIDEMIOL COMMUN H, V43, P380, DOI 10.1136/jech.43.4.380
   Perola M, 2007, PLOS GENET, V3, P1019, DOI 10.1371/journal.pgen.0030097
   Rinaldi S, 2010, INT J CANCER, V126, P1702, DOI 10.1002/ijc.24927
   Silventoinen K, 2003, J BIOSOC SCI, V35, P263, DOI 10.1017/S0021932003000087
   Smith GD, 2000, J EPIDEMIOL COMMUN H, V54, P97, DOI 10.1136/jech.54.2.97
   Sung J, 2009, AM J EPIDEMIOL, V170, P53, DOI 10.1093/aje/kwp088
   Tang R-Q, 2012, TUMOR, V32, P27
   THUNE I, 1993, INT J CANCER, V55, P555, DOI 10.1002/ijc.2910550406
   Tripaldi R, 2013, BBA-REV CANCER, V1836, P27, DOI 10.1016/j.bbcan.2013.02.002
   Walter RB, 2013, JNCI-J NATL CANCER I, V105, P860, DOI 10.1093/jnci/djt102
   Welch V, 2000, NEWCASTLE SCALE ASSE
   Wormser D, 2012, INT J EPIDEMIOL, V41, P1419, DOI 10.1093/ije/dys086
   Zuccolo L, 2008, CANCER EPIDEM BIOMAR, V17, P2325, DOI 10.1158/1055-9965.EPI-08-0342
NR 52
TC 2
Z9 2
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 26
PY 2017
VL 12
IS 9
AR e0185316
DI 10.1371/journal.pone.0185316
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FI1DL
UT WOS:000411671000036
PM 28949980
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Huang, JC
   Zhang, L
   Kang, BY
   Zhu, TT
   Li, YF
   Zhao, FY
   Qu, Y
   Mu, DZ
AF Huang, Jichong
   Zhang, Li
   Kang, Bingyao
   Zhu, Tingting
   Li, Yafei
   Zhao, Fengyan
   Qu, Yi
   Mu, Dezhi
TI Association between perinatal hypoxic-ischemia and periventricular
   leukomalacia in preterm infants: A systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID OBSTETRIC RISK-FACTORS; RENIN-ANGIOTENSIN SYSTEM; PATENT
   DUCTUS-ARTERIOSUS; BIRTH-WEIGHT INFANTS; WHITE-MATTER INJURY;
   CEREBRAL-PALSY; METABOLIC-ACIDOSIS; PREMATURE RUPTURE; GESTATIONAL-AGE;
   DAMAGE
AB Background
   Although investigators have implicated hypoxic-ischemia (HI) as a potential cause of periventricular leukomalacia (PVL), the role of clinical risk factors or markers for HI in the development of PVL remains controversial. The aim of this study was to identify perinatal HI-related factors associated with PVL.
   Method
   The PubMed, EMBASE, and Cochrane Library databases were searched. The last search was performed on January 2017. Summary effect estimates (pooled odds ratios [ORs]) were calculated for each risk factor using fixed or random effects models with tests for heterogeneity and publication bias.
   Results
   Fifteen studies with a total of 12,851 participants were included in this meta-analysis, and 14 potential risk factors were analyzed. The pooled results showed that mothers with oligohydramnios (OR, 1.55; 95% confidence interval [CI], 1.05 to 2.30), preterm infants with acidemia (OR, 1.87; 95% CI, 1.18 to 2.97), 1-minute Apgar score <7 (OR 2.69; 95% CI, 1.13 to 6.41), 5-minute Apgar score <7 (OR, 1.89; 95% CI, 1.39 to 2.56), apnea (OR, 1.76; 95% CI, 1.07 to 2.90), respiratory distress syndrome (OR, 1.46; 95% CI, 1.04 to 2.03), and seizures (OR, 4.60; 95% CI, 2.84 to 7.46) were associated with increased risk of PVL.
   Conclusion
   This study identified perinatal HI-related risk factors for the development of PVL in preterm infants. Future large-scale prospective clinical studies are required to validate and extend these findings.
C1 [Huang, Jichong; Zhang, Li; Kang, Bingyao; Zhu, Tingting; Li, Yafei; Zhao, Fengyan; Qu, Yi; Mu, Dezhi] Sichuan Univ, West China Univ Hosp 2, Dept Pediat, Chengdu, Sichuan, Peoples R China.
   [Huang, Jichong; Zhang, Li; Kang, Bingyao; Zhu, Tingting; Li, Yafei; Zhao, Fengyan; Qu, Yi; Mu, Dezhi] Sichuan Univ, Minist Educ, Key Lab Obstet & Gynecol & Pediat Dis & Birth De, Chengdu, Sichuan, Peoples R China.
RP Mu, DZ (reprint author), Sichuan Univ, West China Univ Hosp 2, Dept Pediat, Chengdu, Sichuan, Peoples R China.; Mu, DZ (reprint author), Sichuan Univ, Minist Educ, Key Lab Obstet & Gynecol & Pediat Dis & Birth De, Chengdu, Sichuan, Peoples R China.
EM mudz@scu.edu.cn
FU National Science Foundation of China [81330016, 81630038]; Major State
   Basic Research Development Program [2013CB967404, 2012BAI04604]; Science
   and Technology Bureau of Sichuan province [2014SZ0149, 2016TD0002];
   Ministry of Health of China [1311200003303]
FX This work was supported by the National Science Foundation of China (no.
   81330016, 81630038), the Major State Basic Research Development Program
   (2013CB967404, 2012BAI04604), the Grants from Science and Technology
   Bureau of Sichuan province (2014SZ0149, 2016TD0002), and the Grant of
   clinical discipline program (neonatology) from the Ministry of Health of
   China (1311200003303).; This work was supported by the National Science
   Foundation of China (No.81330016, 81630038), the Major State Basic
   Research Development Program (2013CB967404, 2012BAI04B04), the Grants
   from Science and Technology Bureau of Sichuan province (2014SZ0149,
   2016TD0002), and the Grant of clinical discipline program (Neonatology)
   from the Ministry of Health of China (1311200003303).
CR Adams-Chapman I, 2013, J PEDIATR-US, V163, P961, DOI 10.1016/j.jpeds.2013.04.034
   Al Tawil KI, 2012, PEDIATR NEUROL, V46, P149, DOI 10.1016/j.pediatrneurol.2011.12.008
   Ancel PY, 2005, AM J OBSTET GYNECOL, V193, P178, DOI 10.1016/j.jajog.2004.11.057
   Bauer M, 2009, EARLY HUM DEV, V85, P163, DOI 10.1016/j.earlhumdev.2008.07.007
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Carlo WA, 2012, J PEDIATR-US, V160, P781, DOI 10.1016/j.jpeds.2011.10.007
   Cooper AC, 1999, PLACENTA, V20, P467, DOI 10.1053/plac.1999.0404
   Cota GF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002195
   Dammann O, 1997, PEDIATR RES, V42, P1, DOI 10.1203/00006450-199707000-00001
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ekin A, 2015, J MATERN-FETAL NEO M, V28, P1918, DOI 10.3109/14767058.2014.972927
   Folkerth RD, 2006, PEDIATR DEVEL PATHOL, V9, P3, DOI 10.2350/06-01-0024.1
   GOLDABER KG, 1991, OBSTET GYNECOL, V78, P1103
   Graham EM, 2004, AM J OBSTET GYNECOL, V191, P1305, DOI 10.1016/j.ajog.2004.06.058
   Hatzidaki E, 2009, ACTA OBSTET GYN SCAN, V88, P110, DOI 10.1080/00016340802503039
   Iliodromiti S, 2014, LANCET, V384, P1749, DOI 10.1016/S0140-6736(14)61135-1
   Ito M, 2002, J CLIN ENDOCR METAB, V87, P1871, DOI 10.1210/jc.87.4.1871
   Kakita H, 2009, BRAIN DEV-JPN, V31, P641, DOI 10.1016/j.braindev.2008.10.008
   Kubota H, 2001, ACTA PAEDIATR, V90, P302, DOI 10.1080/080352501300067659
   Lemmers PMA, 2008, PEDIATRICS, V121, P142, DOI 10.1542/peds.2007-0925
   Leuthner SR, 2004, PEDIATR CLIN N AM, V51, P737, DOI 10.1016/j.pcl.2004.01.016
   LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z
   Locatelli A, 2005, AM J OBSTET GYNECOL, V193, P947, DOI 10.1016/j.ajog.2005.06.039
   Low JA, 1997, AM J OBSTET GYNECOL, V177, P1391, DOI 10.1016/S0002-9378(97)70080-2
   Mukhopadhyay K, 2013, INDIAN PEDIATR, V50, P1119, DOI 10.1007/s13312-013-0305-8
   Murata Y, 2005, BRAIN DEV-JPN, V27, P17, DOI 10.1016/j.braindev.2004.02.011
   Nemerofsky SL, 2008, AM J PERINAT, V25, P661, DOI 10.1055/s-0028-1090594
   Oda N, 2008, FETAL DIAGN THER, V24, P345, DOI 10.1159/000161573
   Osmond E, 2014, ACTA PAEDIATR, V103, P820, DOI 10.1111/apa.12583
   Perlman JM, 1996, PEDIATRICS, V97, P822
   Pladys P, 2001, ACTA PAEDIATR, V90, P309, DOI 10.1080/080352501300067677
   Resch B, 2012, EARLY HUM DEV, V88, P27, DOI 10.1016/j.earlhumdev.2011.06.011
   Resch B, 2000, EUR J PEDIATR, V159, P663, DOI 10.1007/PL00008403
   Robertson HT, 2009, J APPL PHYSIOL, V106, P1034, DOI 10.1152/japplphysiol.00015.2009
   Shatrov JG, 2010, OBSTET GYNECOL, V116, P387, DOI 10.1097/AOG.0b013e3181e90046
   Silva AM, 2006, OBSTET GYNECOL, V107, P550, DOI 10.1097/01.AOG.0000195066.43243.56
   Spinillo A, 1998, BRIT J OBSTET GYNAEC, V105, P865, DOI 10.1111/j.1471-0528.1998.tb10231.x
   Takkouche B, 1999, AM J EPIDEMIOL, V150, P206
   Tsimis ME, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.09.108
   Vincer MJ, 2006, PEDIATRICS, V118, pE1621, DOI 10.1542/peds.2006-1522
   Volpe JJ, 2001, PEDIATR RES, V50, P553, DOI 10.1203/00006450-200111000-00003
   VOLPE JJ, 2001, NEUROLOGY NEWBORN
   Wells GA, 2015, NEWCASTLE OTTAWA SCO
   Wharton KN, 2004, EARLY HUM DEV, V77, P77, DOI 10.1016/j.earlhumdev.2004.02.001
   Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417
   Zupan V, 1996, DEV MED CHILD NEUROL, V38, P1061
NR 46
TC 4
Z9 6
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 20
PY 2017
VL 12
IS 9
AR e0184993
DI 10.1371/journal.pone.0184993
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FH6UK
UT WOS:000411314700053
PM 28931047
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Blanco-Guillot, F
   Delgado-Sanchez, G
   Mongua-Rodriguez, N
   Cruz-Hervert, P
   Ferreyra-Reyes, L
   Ferreira-Guerrero, E
   Yanes-Lane, M
   Montero-Campos, R
   Bobadilla-del-Valle, M
   Torres-Gonzalez, P
   Ponce-de-Leon, A
   Sifuentes-Osornio, J
   Garcia-Garcia, L
AF Blanco-Guillot, Francles
   Delgado-Sanchez, Guadalupe
   Mongua-Rodriguez, Norma
   Cruz-Hervert, Pablo
   Ferreyra-Reyes, Leticia
   Ferreira-Guerrero, Elizabeth
   Yanes-Lane, Mercedes
   Montero-Campos, Rogelio
   Bobadilla-del-Valle, Miriam
   Torres-Gonzalez, Pedro
   Ponce-de-Leon, Alfredo
   Sifuentes-Osornio, Jose
   Garcia-Garcia, Lourdes
TI Molecular clustering of patients with diabetes and pulmonary
   tuberculosis: A systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; RISK-FACTORS; 1ST INSIGHT;
   TRANSMISSION PATTERNS; HIGH PREVALENCE; EPIDEMIOLOGY; HIV; DIVERSITY;
   MELLITUS
AB Introduction
   Many studies have explored the relationship between diabetes mellitus (DM) and tuberculosis (TB) demonstrating increased risk of TB among patients with DM and poor prognosis of patients suffering from the association of DM/TB. Owing to a paucity of studies addressing this question, it remains unclear whether patients with DM and TB are more likely than TB patients without DM to be grouped into molecular clusters defined according to the genotype of the infecting Mycobacterium tuberculosis bacillus. That is, whether there is convincing molecular epidemiological evidence for TB transmission among DM patients. Objective: We performed a systematic review and meta-analysis to quantitatively evaluate the propensity for patients with DM and pulmonary TB (PTB) to cluster according to the genotype of the infecting M. tuberculosis bacillus.
   Materials and methods
   We conducted a systematic search in MEDLINE and LILACS from 1990 to June, 2016 with the following combinations of key words "tuberculosis AND transmission" OR "tuberculosis diabetes mellitus" OR "Mycobacterium tuberculosis molecular epidemiology" OR "RFLPIS6110" OR "Spoligotyping" OR "MIRU-VNTR". Studies were included if they met the following criteria: (i) studies based on populations from defined geographical areas; (ii) use of genotyping by IS6110-restriction fragment length polymorphism (RFLP) analysis and spoligotyping or mycobacterial interspersed repetitive unit-variable number of tandem repeats (MIRU-VNTR) or other amplification methods to identify molecular clustering; (iii) genotyping and analysis of 50 or more cases of PTB; (iv) study duration of 11 months or more; (v) identification of quantitative risk factors for molecular clustering including DM; (vi) > 60% coverage of the study population; and (vii) patients with PTB confirmed bacteriologically. The exclusion criteria were: (i) Extrapulmonary TB; (ii) TB caused by nontuberculous mycobacteria; (iii) patients with PTB and HIV; (iv) pediatric PTB patients; (v) TB in closed environments (e.g. prisons, elderly homes, etc.); (vi) diabetes insipidus and (vii) outbreak reports. Hartung-Knapp-Sidik-Jonkman method was used to estimate the odds ratio (OR) of the association between DM with molecular clustering of cases with TB. In order to evaluate the degree of heterogeneity a statistical Q test was done. The publication bias was examined with Begg and Egger tests. Review Manager 5.3.5 CMA v. 3 and Biostat and Software package R were used.
   Results
   Selection criteria were met by six articles which included 4076 patients with PTB of which 13% had DM. Twenty seven percent of the cases were clustered. The majority of cases (48%) were reported in a study in China with 31% clustering. The highest incidence of TB occurred in two studies from China. The global OR for molecular clustering was 0.84 (IC 95% 0.40-1.72). The heterogeneity between studies was moderate (I-2 = 55%, p = 0.05), although there was no publication bias (Beggs test p = 0.353 and Eggers p = 0.429).
   Conclusion
   There were very few studies meeting our selection criteria. The wide confidence interval indicates that there is not enough evidence to draw conclusions about the association. Clustering of patients with DM in TB transmission chains should be investigated in areas where both diseases are prevalent and focus on specific contexts.
C1 [Blanco-Guillot, Francles] Inst Nacl Salud Publ, Ctr Invest Enfermedad Infecciosas, Doctorado Ciencias Enfermedades Infecciosas, Cuernavaca, Morelos, Mexico.
   [Delgado-Sanchez, Guadalupe; Mongua-Rodriguez, Norma; Cruz-Hervert, Pablo; Ferreyra-Reyes, Leticia; Ferreira-Guerrero, Elizabeth; Yanes-Lane, Mercedes; Montero-Campos, Rogelio; Garcia-Garcia, Lourdes] Inst Nacl Salud Publ, Ctr Invest Enfermedad Infecciosas, Cuernavaca, Morelos, Mexico.
   [Mongua-Rodriguez, Norma] Univ Nacl Autonoma Mexico, Fac Med, Maestria Ciencias Med Enfasis Epidemiol, Distrito Federal, Mexico.
   [Yanes-Lane, Mercedes] Univ Autonoma San Luis Potosi, Fac Med, San Luis Potosi, San Luis Potosi, Mexico.
   [Bobadilla-del-Valle, Miriam; Torres-Gonzalez, Pedro; Ponce-de-Leon, Alfredo] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Lab Microbiol, Mexico City, DF, Mexico.
   [Sifuentes-Osornio, Jose] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Direcc Med, Mexico City, DF, Mexico.
RP Garcia-Garcia, L (reprint author), Inst Nacl Salud Publ, Ctr Invest Enfermedad Infecciosas, Cuernavaca, Morelos, Mexico.
EM garcigarml@gmail.com
RI Garcia-Garcia, Lourdes/I-2724-2019
OI Ponce-de-Leon, Alfredo/0000-0003-2640-2916; BOBADILLA-DEL VALLE,
   MIRIAM/0000-0003-1184-827X
FU Consejo Nacional de Ciencia y Tecnologia [360456, PDC-PN-2015-01-1557,
   PDCPN2014-01-247582, S0008- FONSEC SSA/IMSS/ISSSTE -2015-1 261599]
FX FBG received a doctoral scholarship from the Consejo Nacional de Ciencia
   y Tecnologia, http://www.conacyt.gob.mx (360456). The study was
   partially funded by the Consejo Nacional de Ciencia y Tecnologia,
   http://www.conacyt.gob.mx (PDC-PN-2015-01-1557 (to Dr. EFG),
   PDCPN2014-01-247582 (to Dr. LGG) and S0008- FONSEC SSA/IMSS/ISSSTE
   -2015-1 261599 to Dr. GDS). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Al-Attiyah RJ, 2009, CLIN EXP IMMUNOL, V158, P64, DOI 10.1111/j.1365-2249.2009.04000.x
   Alavi SM, 2014, JUNDISHAPUR J MICROB, V7
   Alisjahbana B, 2007, CLIN INFECT DIS, V45, P428, DOI 10.1086/519841
   Baker MA, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-81
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bock NN, 2007, J INFECT DIS, V196, pS108, DOI 10.1086/518661
   Borgdorff MW, 2013, CLIN MICROBIOL INFEC, V19, P889, DOI 10.1111/1469-0691.12253
   Borgdorff MW, 2001, AM J EPIDEMIOL, V154, P934, DOI 10.1093/aje/154.10.934
   Borrell S, 2010, CLIN MICROBIOL INFEC, V16, P568, DOI 10.1111/j.1469-0691.2009.02886.x
   Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23
   Chang JT, 2011, J FORMOS MED ASSOC, V110, P372, DOI 10.1016/S0929-6646(11)60055-7
   Chen KS, 2016, INT J TUBERC LUNG D, V20, P57, DOI 10.5588/ijtld.15.0215
   Chiang CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121698
   Coker R, 2006, BRIT MED J, V332, P85, DOI 10.1136/bmj.38684.687940.80
   Davey J, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-160
   Dawson P, 2016, AM J PUBLIC HEALTH, V106, P563, DOI 10.2105/AJPH.2015.302910
   de Beer JL, 2013, J CLIN MICROBIOL, V51, P1193, DOI 10.1128/JCM.03061-12
   Dekhil N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153983
   Demay C, 2012, INFECT GENET EVOL, V12, P755, DOI 10.1016/j.meegid.2012.02.004
   Devi KR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145860
   Diab HM, 2016, TUBERCULOSIS, V96, P13, DOI 10.1016/j.tube.2015.11.002
   Dobler CC, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000666
   Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533
   Jimenez-Corona ME, 2013, THORAX, V68, P214, DOI 10.1136/thoraxjnl-2012-201756
   Fok A, 2008, INT J TUBERC LUNG D, V12, P480
   Garcia-Garcia MD, 2000, INT J TUBERC LUNG D, V4, P12
   Geng E, 2002, NEW ENGL J MED, V346, P1453, DOI 10.1056/NEJMoa012972
   Gomez DI, 2013, TUBERCULOSIS, V93, P192, DOI 10.1016/j.tube.2012.10.003
   Diaz AG, 2015, TROP MED INT HEALTH, V20, P1534, DOI 10.1111/tmi.12569
   Gonzalez Y, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-19
   Gurjav U, 2016, INFECT GENET EVOL, V40, P346, DOI 10.1016/j.meegid.2015.07.014
   Harries AD, 2011, INT J TUBERC LUNG D, V15, P1436, DOI 10.5588/ijtld.11.0503
   Harris TG, 2013, AM J INFECT CONTROL, V41, P155, DOI 10.1016/j.ajic.2012.02.015
   Heldal E, 2003, EUR RESPIR J, V22, P637, DOI 10.1183/09031936.03.00019103
   Hernandez-Garduno E, 2002, CAN MED ASSOC J, V167, P349
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hong MS, 2017, EUROPEAN J CLIN MICR
   Houben RMGJ, 2011, INT J TUBERC LUNG D, V15, P24
   Hoza AS, 2016, TUBERCULOSIS, V98, P116, DOI 10.1016/j.tube.2016.02.002
   Hu Y, 2016, TUBERCULOSIS, V97, P18, DOI 10.1016/j.tube.2015.11.007
   Huang CC, 2014, CLIN INFECT DIS, V58, P765, DOI 10.1093/cid/cit948
   Inigo J, 2007, J CLIN MICROBIOL, V45, P63, DOI 10.1128/JCM.01644-06
   IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25
   Jagielski T, 2015, EUR J CLIN MICROBIOL, V34, P41, DOI 10.1007/s10096-014-2202-z
   Jagielski T, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/645802
   Jeon CY, 2008, PLOS MED, V5, P1091, DOI 10.1371/journal.pmed.0050152
   Kanamori H, 2016, INT J TUBERC LUNG D, V20, P505, DOI 10.5588/ijtld.15.0607
   Kik SV, 2008, AM J RESP CRIT CARE, V178, P96, DOI 10.1164/rccm.200708-1256OC
   Kozinska M, 2016, POL ARCH MED WEWN, V126, P32
   Kumar NP, 2013, J INFECT DIS, V208, P739, DOI 10.1093/infdis/jit241
   Leung CC, 2008, AM J EPIDEMIOL, V167, P1486, DOI 10.1093/aje/kwn075
   Li YA, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1441-2
   Lieberman TD, 2016, NAT MED, V22, P1470, DOI 10.1038/nm.4205
   Lonnroth K, 2014, LANCET DIABETES ENDO, V2, P730, DOI 10.1016/S2213-8587(14)70109-3
   Martinez N, 2014, EUR J IMMUNOL, V44, P617, DOI 10.1002/eji.201344301
   Mathema B, 2006, CLIN MICROBIOL REV, V19, P658, DOI 10.1128/CMR.00061-05
   Middelkoop K, 2015, J INFECT DIS, V211, P53, DOI 10.1093/infdis/jiu403
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Morcillo N., 2007, Rev. argent. microbiol., V39, P145
   Murase Y, 2010, EMERG INFECT DIS, V16, P948, DOI 10.3201/eid1606.091844
   Nava-Aguilera E, 2009, INT J TUBERC LUNG D, V13, P17
   Nogueira CL, 2016, TUBERCULOSIS, V97, P57, DOI 10.1016/j.tube.2015.12.005
   Oni T, 2013, LANCET RESP MED, V1, P356, DOI 10.1016/S2213-2600(13)70116-4
   Outhred AC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150550
   Penuelas-Urquides K, 2014, MEM I OSWALDO CRUZ, V109, P814, DOI 10.1590/0074-0276130550
   Perez A, 2006, AM J TROP MED HYG, V74, P604, DOI 10.4269/ajtmh.2006.74.604
   Perez-Lago L, 2016, J CLIN MICROBIOL, V54, P779, DOI 10.1128/JCM.02851-15
   Pigott T. D., 2012, ADV METAANALYSIS
   Ponce-De-Leon A, 2004, DIABETES CARE, V27, P1584, DOI 10.2337/diacare.27.7.1584
   Reis-Santos B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062604
   Restrepo BI, 2008, CLIN INFECT DIS, V47, P634, DOI 10.1086/590565
   Restrepo BI, 2014, DIABETES RES CLIN PR, V106, P191, DOI 10.1016/j.diabres.2014.06.011
   Restrepo BI, 2013, TUBERCULOSIS, V93, pS10, DOI 10.1016/S1472-9792(13)70004-0
   Restrepo BI, 2011, B WORLD HEALTH ORGAN, V89, P352, DOI 10.2471/BLT.10.085738
   Ruslami R, 2010, TROP MED INT HEALTH, V15, P1289, DOI 10.1111/j.1365-3156.2010.02625.x
   Shabbeer A, 2012, INFECT GENET EVOL, V12, P767, DOI 10.1016/j.meegid.2011.08.019
   Shariff NM, 2015, INT J MYCOBACT, V4, P323, DOI 10.1016/j.ijmyco.2015.09.003
   Singla R, 2006, INT J TUBERC LUNG D, V10, P74
   Small Peter M., 1994, P569
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402
   Stavrum R, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-309
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Surikova OV, 2005, EUR J EPIDEMIOL, V20, P963, DOI 10.1007/s10654-005-3636-5
   Suwanpimolkul G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114442
   Talarico S, 2011, TUBERCULOSIS, V91, P244, DOI 10.1016/j.tube.2011.01.007
   Tian PW, 2014, EUR REV MED PHARMACO, V18, P1482
   Tsukaguchi Katsuhiko, 2002, Kekkaku, V77, P409
   Valentine JC, 2010, J EDUC BEHAV STAT, V35, P215, DOI 10.3102/1076998609346961
   Vallerskog T, 2010, J IMMUNOL, V184, P6275, DOI 10.4049/jimmunol.1000304
   van Soolingen D, 1999, J INFECT DIS, V180, P726, DOI 10.1086/314930
   Varma-Basil M, 2011, MEM I OSWALDO CRUZ, V106, P524, DOI 10.1590/S0074-02762011000500002
   Vynnycky E, 2001, EPIDEMIOL INFECT, V126, P43
   Wang C.-H., 1999, Tubercle and Lung Disease, V79, P235, DOI 10.1054/tuld.1998.0167
   Wang QM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100949
   Yang CG, 2015, CLIN INFECT DIS, V61, P219, DOI 10.1093/cid/civ255
   Yates TA, 2016, LANCET INFECT DIS, V16, P227, DOI 10.1016/S1473-3099(15)00499-5
   Yuen CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153728
   Zetola NM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010046
NR 98
TC 2
Z9 2
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 13
PY 2017
VL 12
IS 9
AR e0184675
DI 10.1371/journal.pone.0184675
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FG8GZ
UT WOS:000410669200052
PM 28902922
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Jin, J
   Hu, KJ
   Zhou, YZ
   Li, WM
AF Jin, Jing
   Hu, Kejia
   Zhou, Yongzhao
   Li, Weimin
TI Clinical utility of the modified Glasgow prognostic score in lung
   cancer: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID NEUTROPHIL-TO-LYMPHOCYTE; C-REACTIVE PROTEIN; SYSTEMIC INFLAMMATORY
   RESPONSE; PRETREATMENT NEUTROPHIL; SURVIVAL; RATIO; PLATELET;
   ASSOCIATION; STATISTICS; PREDICTS
AB Objective
   To perform a meta-analysis of prospective and retrospective studies exploring the association of the modified Glasgow prognostic score (mGPS) with overall survival (OS) in patients with lung cancer.
   Methods
   Relevant studies were identified by searching the Cochrane Library, Web of Science, Embase and PubMed until April 16, 2017. We combined hazard ratios (HRs) and 95% confidence intervals (CIs) to assess the correlation between mGPS and OS in patients with lung cancer.
   Results
   Eleven studies involving 5817 participants from several countries were included in the meta-analysis. In a pooled analysis of all studies, elevated mGPS predicted poorer OS (HR = 1.77; 95% CI: 1.35-2.31; P<0.05). Subgroup analyses stratified by mGPS showed that mGPS of 1 or 2 and mGPS >= 1 were predictive of poorer OS and that the HR for mGPS of 2 (HR = 5.82; 95% CI: 1.85-18.22; P = 0.003) was significantly greater than that for mGPS of 1 (HR = 1.74; 95% CI: 1.24-2.45; P = 0.001) and mGPS >= 1 (HR = 1.42; 95% CI: 1.14-1.76; P = 0.002). Among patients undergoing surgery, elevated mGPS had a non-significant correlation with reduced OS (HR = 2.48; 95% CI: 0.90-6.85; P = 0.079), whereas the correlation was significant for patients receiving chemotherapy or other palliative treatment (HR = 1.74; 95% CI: 1.31-2.30; P<0.05).
   Conclusions
   Our findings indicate that mGPS may have prognostic value in lung cancer, as we detected a significant association between elevated mGPS and poorer OS. The association between mGPS and poorer OS was non-significant among patients undergoing surgery, which may be attributable to lower tumor load. However, further studies are warranted to draw firm conclusions.
C1 [Jin, Jing; Zhou, Yongzhao; Li, Weimin] Sichuan Univ, West China Hosp, Dept Pulm & Crit Care, Chengdu, Sichuan, Peoples R China.
   [Hu, Kejia] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Sichuan, Peoples R China.
RP Li, WM (reprint author), Sichuan Univ, West China Hosp, Dept Pulm & Crit Care, Chengdu, Sichuan, Peoples R China.
EM weimi003@yahoo.com
FU Technology Support Program of Science and Technology Department of
   Sichuan Province [2014SZ023]
FX This work was supported by grants from Technology Support Program of
   Science and Technology Department of Sichuan Province (2014SZ023) and
   the funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; This work was
   supported by grants from the Technology Support Program of Science and
   the Technology Department of Sichuan Province (2014SZ023).
CR Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873
   Alifano M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106914
   Alifano M, 2011, J THORAC CARDIOV SUR, V142, P1161, DOI 10.1016/j.jtcvs.2011.07.021
   Bambury RM, 2013, J NEURO-ONCOL, V114, P149, DOI 10.1007/s11060-013-1164-9
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen H, 2016, PANMINERVA MED
   Eggers H, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0705-6
   Fan H, 2016, J CANCER RES CLIN, V142, P1285, DOI 10.1007/s00432-015-2113-0
   Grose D, 2014, LUNG CANC INT, V2014
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hooper CE, 2015, BRIT J CANCER, V112, P1175, DOI 10.1038/bjc.2015.62
   Kinoshita A, 2012, MED ONCOL, V29, P2800, DOI 10.1007/s12032-012-0220-1
   Kishi T, 2015, INT J RADIAT ONCOL, V92, P619, DOI 10.1016/j.ijrobp.2015.02.018
   Kos M, 2016, WIEN KLIN WOCHENSCHR, V128, P635, DOI 10.1007/s00508-015-0724-8
   Lan H, 2016, ONCOTARGET
   Leung EYL, 2012, J THORAC ONCOL, V7, P655, DOI 10.1097/JTO.0b013e318244ffe1
   Liu ZQ, 2014, ASIAN J ANDROL, V16, P467, DOI 10.4103/1008-682X.123686
   McMillan DC, 2013, CANCER TREAT REV, V39, P534, DOI 10.1016/j.ctrv.2012.08.003
   Meek CL, 2010, CLIN NUTR, V29, P206, DOI 10.1016/j.clnu.2009.08.013
   Morris-Stiff G, 2008, EJSO-EUR J SURG ONC, V34, P727, DOI 10.1016/j.ejso.2008.01.016
   Nikolic I, 2016, CROAT MED J, V57, P287, DOI 10.3325/cmj.2016.57.287
   O'Rourke K, 2001, META ANAL CLIN TRIAL, P397
   Oh BS, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-78
   Osugi J, 2016, J CANCER RES THER, V12, P945, DOI 10.4103/0973-1482.176168
   Pinato DJ, 2014, BRIT J CANCER, V110, P1930, DOI 10.1038/bjc.2014.145
   Proctor MJ, 2011, EUR J CANCER, V47, P2633, DOI 10.1016/j.ejca.2011.03.028
   Rinehart J, 2013, CANCER CHEMOTH PHARM, V71, P1375, DOI 10.1007/s00280-013-2111-3
   Roxburgh CSD, 2010, FUTURE ONCOL, V6, P149, DOI 10.2217/FON.09.136
   Sanchez-Salcedo P, 2016, LUNG CANCER, V97, P28, DOI 10.1016/j.lungcan.2016.04.010
   Shao N, 2015, TUMOR BIOL, V36, P8465, DOI 10.1007/s13277-015-3611-z
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
   Simmons CP, 2015, LUNG CANCER, V88, P304, DOI 10.1016/j.lungcan.2015.03.020
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Tomita M, 2012, ANTICANCER RES, V32, P3535
   Wang X, 2016, ONCOTARGETS THER, V9, P5761, DOI 10.2147/OTT.S106296
   Woo HD, 2015, CANCER CAUSE CONTROL, V26, P1661, DOI 10.1007/s10552-015-0663-8
   Wu YX, 2016, INT IMMUNOPHARMACOL, V36, P94, DOI 10.1016/j.intimp.2016.04.006
   Zhang XW, 2015, INT J CLIN EXP MED, V8, P15222
   ZHAO XW, 2017, SCI REP-UK, V7, DOI DOI 10.1038/S41598-017-
   Zhou T, 2015, TUMOR BIOL, V36, P337, DOI 10.1007/s13277-014-2623-4
   Zhu LZ, 2016, ONCOTARGETS THER, V9, P4879, DOI 10.2147/OTT.S107279
NR 42
TC 4
Z9 5
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 8
PY 2017
VL 12
IS 9
AR e0184412
DI 10.1371/journal.pone.0184412
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FG2YO
UT WOS:000410001100111
PM 28886134
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Lavia, C
   Dallorto, L
   Maule, M
   Ceccarelli, M
   Fea, AM
AF Lavia, Carlo
   Dallorto, Laura
   Maule, Milena
   Ceccarelli, Manuela
   Fea, Antonio Maria
TI Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A
   systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID TRABECULAR MICROBYPASS STENTS; EXCIMER-LASER TRABECULOTOMY; MICRO-BYPASS
   STENT; AB-INTERNO; INTRAOCULAR-PRESSURE; CATARACT-SURGERY; MEDICATION
   ADHERENCE; PHACOEMULSIFICATION; IMPLANTATION; OUTCOMES
AB Background
   MIGS have been developed as a surgical alternative for glaucomatous patients.
   Purpose
   To analyze the change in intraocular pressure (IOP) and glaucoma medications using different MIGS devices (Trabectome, iStent, Excimer Laser Trabeculotomy (ELT), iStent Supra, CyPass, XEN, Hydrus, Fugo Blade, Ab interno canaloplasty, Goniscopy-assisted transluminal trabeculotomy) as a solo procedure or in association with phacoemulsification.
   Methods
   Randomized control trials (RCT) and non-RCT (non randomized comparative studies, NRS, and before-after studies) were included. Studies with at least one year of follow-up in patients affected by primary open angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma were considered. Risk of Bias assessment was performed using the Cochrane Risk of Bias and the ROBINS-I tools. The main outcome was the effect of MIGS devices compared to medical therapy, cataract surgery, other glaucoma surgeries and other MIGS on both IOP and use of glaucoma medications 12 months after surgery. Outcomes measures were the mean difference in the change of IOP and glaucoma medication compared to baseline at one and two years and all ocular adverse events. The current meta-analysis is registered on PROSPERO (reference n degrees CRD42016037280).
   Results
   Over a total of 3,069 studies, nine RCT and 21 case series with a total of 2.928 eyes were included. Main concerns about risk of bias in RCTs were lack of blinding, allocation concealment and attrition bias while in non-RCTs they were represented by patients' selection, masking of participants and co-intervention management. Limited evidence was found based on both RCTs and non RCTs that compared MIGS surgery with medical therapy or other MIGS. In before-after series, MIGS surgery seemed effective in lowering both IOP and glaucoma drug use. MIGS showed a good safety profile: IOP spikes were the most frequent complications and no cases of infection or BCVA loss due to glaucoma were reported.
   Conclusions
   Although MIGS seem efficient in the reduction of the IOP and glaucoma medication and show good safety profile, this evidence is mainly derived from non-comparative studies and further, good quality RCTs are warranted.
C1 [Lavia, Carlo; Dallorto, Laura; Fea, Antonio Maria] Univ Turin, Dept Surg Sci, Eye Clin, Turin, Italy.
   [Maule, Milena] Univ Turin, Dept Med Sci, Turin, Italy.
   [Maule, Milena] AOU Citta Salute & Sci Torino, CPO Piemonte, Turin, Italy.
   [Ceccarelli, Manuela] AOU Citta Salute & Sci Torino, CPO Piemonte, SCDU Epidemiol Tumori, Turin, Italy.
RP Fea, AM (reprint author), Univ Turin, Dept Surg Sci, Eye Clin, Turin, Italy.
EM antoniomfea@gmail.com
RI Maule, Milena/K-3858-2018
OI Maule, Milena/0000-0003-2142-1288
CR Ahmed IIK, 2014, J CATARACT REFR SURG, V40, P1295, DOI 10.1016/j.jcrs.2014.07.004
   Alba AC, 2016, J CLIN EPIDEMIOL, V70, P129, DOI 10.1016/j.jclinepi.2015.09.005
   Arriola-Villalobos P, 2016, J OPHTHALMOL, DOI 10.1155/2016/1056573
   Arriola-Villalobos P, 2013, BRIT J OPHTHALMOL, V97, P1250, DOI 10.1136/bjophthalmol-2012-302394
   Arriola-Villalobos P, 2012, BRIT J OPHTHALMOL, V96, P645, DOI 10.1136/bjophthalmol-2011-300218
   Babighian S, 2010, EYE, V24, P632, DOI 10.1038/eye.2009.172
   Babighian S, 2006, OPHTHALMOLOGICA, V220, P285, DOI 10.1159/000094616
   Baudouin C, 2010, PROG RETIN EYE RES, V29, P312, DOI 10.1016/j.preteyeres.2010.03.001
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belovay GW, 2012, J CATARACT REFR SURG, V38, P1911, DOI 10.1016/j.jcrs.2012.07.017
   Brandao LM, 2013, J OPHTHALMOL, DOI 10.1155/2013/705915
   Caprioli J, 2015, OPHTHALMOLOGY, V122, P1795, DOI 10.1016/j.ophtha.2015.02.029
   Craven ER, 2012, J CATARACT REFR SURG, V38, P1339, DOI 10.1016/j.jcrs.2012.03.025
   Donnenfeld ED, 2015, CLIN OPHTHALMOL, V9, P2057, DOI 10.2147/OPTH.S91732
   Dreer LE, 2012, J GLAUCOMA, V21, P234, DOI 10.1097/IJG.0b013e31821dac86
   European Glaucoma Society, 2014, TERM GUID GLAUC
   Fea AM, 2008, TECH OPHTHALMOL, V6, P45
   Fea AM, 2015, J OPHTHALMOL, V2015, DOI DOI 10.1155/2015/795357
   Fea AM, 2017, CLIN EXP OPHTHALMOL, V45, P120, DOI 10.1111/ceo.12805
   Fea AM, 2014, CLIN OPHTHALMOL, V8, P875, DOI 10.2147/OPTH.S59932
   Fernandez-Barrientos Y, 2010, INVEST OPHTH VIS SCI, V51, P3327, DOI 10.1167/iovs.09-3972
   Fogagnolo P, 2012, OPHTHALMOLOGICA, V228, P154, DOI 10.1159/000337838
   Francis BA, 2011, OPHTHALMOLOGY, V118, P1466, DOI 10.1016/j.ophtha.2011.03.028
   Friedrich JO, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-32
   Gandolfi SA, 2016, J OPHTHALMOL, DOI 10.1155/2016/3410469
   Garciia-Feijoo J, 2015, AM J OPHTHALMOL, V159, P1075, DOI 10.1016/j.ajo.2015.02.018
   Gedde SJ, 2012, AM J OPHTHALMOL, V153, P789, DOI 10.1016/j.ajo.2011.10.026
   Gedde SJ, 2012, CURR OPIN OPHTHALMOL, V23, P118, DOI 10.1097/ICU.0b013e32834ff2d1
   Gonnermann J, 2017, GRAEF ARCH CLIN EXP, V255, P359, DOI 10.1007/s00417-016-3514-8
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Higgins JPT, 2008, STAT MED, V27, P6072, DOI 10.1002/sim.3427
   Katz LJ, 2015, CLIN OPHTHALMOL, V9, P2313, DOI 10.2147/OPTH.S96695
   Khan M, 2015, J CATARACT REFR SURG, V41, P1716, DOI 10.1016/j.jcrs.2014.12.061
   Klamann MKJ, 2013, GRAEF ARCH CLIN EXP, V251, P2195, DOI 10.1007/s00417-013-2408-2
   Kurji K, 2017, CAN J OPHTHALMOL, V52, P99, DOI 10.1016/j.jcjo.2016.06.018
   Lindstrom R, 2016, ADV THER, V33, P2082, DOI 10.1007/s12325-016-0420-8
   Manasses DT, 2016, OPHTHALMOL THER, V5, P135, DOI 10.1007/s40123-016-0054-6
   Melancia D, 2015, OPHTHALMIC RES, V53, P141, DOI 10.1159/000377635
   Newman-Casey PA, 2015, OPHTHALMOLOGY, V122, P1308, DOI 10.1016/j.ophtha.2015.03.026
   Pahlitzsch M, 2015, KLIN MONATSBL AUGENH, V232, P1198, DOI 10.1055/s-0041-105941
   Pahlitzsch M, 2017, CAN J OPHTHALMOL, V52, P92, DOI 10.1016/j.jcjo.2016.07.011
   Parrish RK, 2003, AM J OPHTHALMOL, V135, P688, DOI 10.1016/S0002-9394(03)00098-9
   Perez-Torregrosa V T, 2016, Arch Soc Esp Oftalmol, V91, P415, DOI 10.1016/j.oftal.2016.02.006
   Pfeiffer N, 2015, OPHTHALMOLOGY, V122, P1283, DOI 10.1016/j.ophtha.2015.03.031
   Poley BJ, 2009, J CATARACT REFR SURG, V35, P1946, DOI 10.1016/j.jcrs.2009.05.061
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Richter GM, 2016, CLIN OPHTHALMOL, V10, P189, DOI 10.2147/OPTH.S80490
   Saheb H, 2012, CURR OPIN OPHTHALMOL, V23, P96, DOI 10.1097/ICU.0b013e32834ff1e7
   Samuelson TW, 2011, OPHTHALMOLOGY, V118, P459, DOI 10.1016/j.ophtha.2010.07.007
   Schuman JS, 2000, CLIN THER, V22, P167, DOI 10.1016/S0149-2918(00)88478-7
   Schwartz GR, 2008, SURV OPHTHALMOL, V53, pS57, DOI 10.1016/j.survophthal.2008.08.002
   Shrivastava A, 2010, CURR OPIN OPHTHALMOL, V21, P118, DOI 10.1097/ICU.0b013e3283360ac3
   Spiegel D, 2009, EUR J OPHTHALMOL, V19, P393
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Ting JLM, 2012, J CATARACT REFR SURG, V38, P315, DOI 10.1016/j.jcrs.2011.08.043
   Toteberg-Harms M, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-24
   Vold S, 2016, OPHTHALMOLOGY, V123, P2103, DOI 10.1016/j.ophtha.2016.06.032
   Vold SD, 2016, OPHTHALMOL THER, V5, P161, DOI 10.1007/s40123-016-0065-3
   Voskanyan L, 2014, ADV THER, V31, P189, DOI 10.1007/s12325-014-0095-y
NR 59
TC 23
Z9 24
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 29
PY 2017
VL 12
IS 8
AR e0183142
DI 10.1371/journal.pone.0183142
PG 33
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FE9SU
UT WOS:000408544200010
PM 28850575
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Seta, T
   Takahashi, Y
   Noguchi, Y
   Shikata, S
   Sakai, T
   Sakai, K
   Yamashita, Y
   Nakayama, T
AF Seta, Takeshi
   Takahashi, Yoshimitsu
   Noguchi, Yoshinori
   Shikata, Satoru
   Sakai, Tatsuya
   Sakai, Kyoko
   Yamashita, Yukitaka
   Nakayama, Takeo
TI Effectiveness of Helicobacter pylori eradication in the prevention of
   primary gastric cancer in healthy asymptomatic people: A systematic
   review and meta-analysis comparing risk ratio with risk difference
SO PLOS ONE
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIAL; FOLLOW-UP; CLINICAL-TRIALS; CONSENSUS
   REPORT; INFECTION; CHEMOPREVENTION; GUIDELINES; MANAGEMENT; REDUCTION;
   STATEMENT
AB Background
   Helicobacter pylori infection is strongly associated with gastric cancer occurrence. However, it is unclear whether eradication therapy reduces the risk of gastric cancer occurrence. We evaluated whether H. pylori eradication reduces the risk of primary gastric cancer by using both risk ratio (RR) and risk difference (RD).
   Methods
   Searches of PubMed, EMBASE, Google scholar, the Cochrane Library, and the Japan Medical Abstracts Society as well as those registered in databases of the Cochrane Central Register of Controlled Trials, metaRegister of Controlled Trials, ClinicalTrials. gov, controlledtrials. com, UMIN-CTR, JMACCT-CTR, and JAPIC-CTI between January 1965 and March 2017, supplemented with manual screening. Randomized controlled trials (RCTs) in which eradication therapy were implemented for the interventional group but not for the control group, and assessed the subsequent occurrence of primary gastric cancer as the main outcome. Two authors independently reviewed articles and extracted data. Integrated results for all data were presented as RR and RD.
   Results
   Seven studies met inclusion criteria. The reductions in risk of primary gastric cancer occurrence in terms of overall RR and RD were 0.67 (95% CI: 0.48 to 0.95) and -0.00 ([ 95% CI: -0.01 to 0.00]; number needed to treat: 125.5 [ 95% CI: 70.0 to 800.9]), respectively.
   Conclusions
   The effectiveness of H. pylori eradication therapy in suppressing the occurrence of primary gastric cancer was significant and comparable to that of previous studies in terms of the estimated RR. However, the estimated RD was slight and not statistically significant.
C1 [Seta, Takeshi; Yamashita, Yukitaka] Japanese Red Cross Wakayama Med Ctr, Dept Gastroenterol & Hepatol, Wakayama, Japan.
   [Seta, Takeshi; Takahashi, Yoshimitsu; Nakayama, Takeo] Kyoto Univ, Dept Hlth Informat, Sch Publ Hlth, Kyoto, Japan.
   [Noguchi, Yoshinori] Japanese Red Cross Nagoya Daini Hosp, Div Gen Internal Med, Nagoya, Aichi, Japan.
   [Shikata, Satoru] Mie Prefectural Ichishi Hosp, Dept Family Med, Tsu, Mie, Japan.
   [Sakai, Tatsuya] Kyoto Katsura Hosp, Dept Internal Med, Kyoto, Japan.
   [Sakai, Kyoko] Suita Saiseikai Hosp, Dept Lab Med, Suita, Osaka, Japan.
RP Nakayama, T (reprint author), Kyoto Univ, Dept Hlth Informat, Sch Publ Hlth, Kyoto, Japan.
EM t-nakayama@umin.ac.jp
FU Japan Primary Care Association
FX This study was supported by a grant-in-aid from the Japan Primary Care
   Association in 2015.
CR [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P177
   Asaka M, 2010, HELICOBACTER, V15, P486, DOI 10.1111/j.1523-5378.2010.00799.x
   Asaka Masahiro, 2009, Nihon Rinsho, V67, P2227
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Citrome L, 2010, ACTA PSYCHIAT SCAND, V121, P94, DOI [10.1111/j.1600-0447.2009.01449.x, 10.1111/j.1600-0447.2009.1449.x]
   Correa P, 2000, JNCI-J NATL CANCER I, V92, P1881, DOI 10.1093/jnci/92.23.1881
   CORREA P, 1992, CANCER RES, V52, P6735
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001
   Dwan K, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001666
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elting LS, 1999, BRIT MED J, V318, P1527, DOI 10.1136/bmj.318.7197.1527
   Fagerlin A, 2011, COMMUNICATING RISKS, P57
   Fock KM, 2009, J GASTROEN HEPATOL, V24, P1587, DOI 10.1111/j.1440-1746.2009.05982.x
   FORD AC, 2014, BMJ-BRIT MED J, V348, DOI DOI 10.1136/BMJ.G3174
   Ford AC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005583.pub2
   Ford AC, 2009, ANN INTERN MED, V151, P513, DOI 10.7326/0003-4819-151-7-200910060-00014
   Fuccio L, 2009, ANN INTERN MED, V151, P121, DOI 10.7326/0003-4819-151-2-200907210-00009
   Fukase K, 2008, LANCET, V372, P392, DOI 10.1016/S0140-6736(08)61159-9
   Gigerenzer G, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4830
   GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P407, DOI 10.1016/j.jclinepi.2010.07.017
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hu FL, 2008, J DIGEST DIS, V9, P178, DOI 10.1111/j.1751-2980.2008.00342.x
   ICHINOSE M, 2001, CANC SCREENING COMMO, P87
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kim Nayoung, 2009, Korean J Gastroenterol, V54, P269
   Lane PW, 2013, STAT METHODS MED RES, V22, P117, DOI 10.1177/0962280211432218
   Lee YC, 2016, GASTROENTEROLOGY, V150, P1113, DOI 10.1053/j.gastro.2016.01.028
   Leung WK, 2004, GUT, V53, P1244, DOI 10.1136/gut.2003.034629
   Light RJ, 1984, SUMMING SCI REV RES
   Ma JL, 2012, J NATL CANCER I, V104, P488, DOI 10.1093/jnci/djs003
   Malfertheiner P, 2007, GUT, V56, P772, DOI 10.1136/gut.2006.101634
   Mera R, 2005, GUT, V54, P1536, DOI 10.1136/gut.2005.072009
   Miehlke S, 2001, WORLD J GASTROENTERO, V7, P243
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Nakayama T, 1998, LANCET, V351, P1179, DOI 10.1016/S0140-6736(05)79123-6
   Nakayama T, 2000, EPIDEMIOLOGY, V11, P366, DOI 10.1097/00001648-200005000-00032
   NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916
   Nuovo J, 2002, JAMA-J AM MED ASSOC, V287, P2813, DOI 10.1001/jama.287.21.2813
   Porta M, 2014, DICT EPIDEMIOLOGY
   Raghav KPS, 2015, J CLIN ONCOL, V33, P3583, DOI 10.1200/JCO.2015.62.4148
   RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351
   Saito D, 2005, GASTROENTEROLOGY, V128, pA4
   Schechtman E, 2002, VALUE HEALTH, V5, P431
   Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232
   SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001
   StataCorp, 2015, STAT STAT SOFTW REL
   Take S, 2005, AM J GASTROENTEROL, V100, P1037, DOI 10.1111/j.1572-0241.2005.41384.x
   Take S, 2007, J GASTROENTEROL, V42, P21, DOI 10.1007/s00535-006-1924-9
   Tan VPY, 2013, GASTROENTEROL CLIN N, V42, P299, DOI 10.1016/j.gtc.2013.02.001
   van den Bogert CA, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007827
   Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187
   Wong BCY, 2012, GUT, V61, P812, DOI 10.1136/gutjnl-2011-300154
   You WC, 2006, J NATL CANCER I, V98, P974, DOI 10.1093/jnci/djj264
   Young T, 2011, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14651858.MR000027.PUB2/FULL
   Zhou LY, 2008, GASTROENTEROLOGY, V134, pA233
   Zhou LY, 2014, CHINESE MED J-PEKING, V127, P1454, DOI 10.3760/cma.j.issn.0366-6999.20132494
NR 58
TC 5
Z9 6
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 17
PY 2017
VL 12
IS 8
AR e0183321
DI 10.1371/journal.pone.0183321
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FD9QG
UT WOS:000407856600104
PM 28817628
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhuang, RY
   Li, S
   Li, Q
   Guo, X
   Shen, F
   Sun, H
   Liu, TS
AF Zhuang, Rongyuan
   Li, Song
   Li, Qian
   Guo, Xi
   Shen, Feng
   Sun, Hong
   Liu, Tianshu
TI The prognostic value of KRAS mutation by cell-free DNA in cancer
   patients: A systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID METASTATIC COLORECTAL-CANCER; CIRCULATING TUMOR DNA; ADVANCED
   PANCREATIC-CANCER; K-RAS MUTATIONS; LUNG-CANCER; PLASMA DNA;
   HEALTHY-INDIVIDUALS; CLINICAL UTILITY; LIQUID BIOPSIES; SERUM
AB KRAS mutation has been found in various types of cancer. However, the prognostic value of KRAS mutation in cell-free DNA (cfDNA) in cancer patients was conflicting. In the present study, a meta-analysis was conducted to clarify its prognostic significance. Literature searches of Cochrane Library, EMBASE, PubMed and Web of Science were performed to identify studies related to KRAS mutation detected by cfDNA and survival in cancer patients. Two evaluators reviewed and extracted the information independently. Review Manager 5.3 software was used to perform the statistical analysis. Thirty studies were included in the present meta-analysis. Our analysis showed that KRAS mutation in cfDNA was associated with a poorer survival in cancer patients for overall survival (OS, HR 2.02, 95% CI 1.63-2.51, P<0.01) and progression-free survival (PFS, HR 1.64, 95% CI 1.27-2.13, P<0.01). In subgroup analyses, KRAS mutation in pancreatic cancer, colorectal cancer, non-small cell lung cancer and ovarian epithelial cancer had HRs of 2.81 (95% CI 1.83-4.30, P<0.01), 1.67 (95% CI 1.25-2.42, P<0.01), 1.64 (95% CI 1.13-2.39, P = 0.01) and 2.17 (95% 1.12-4.21, p = 0.02) for OS, respectively. In addition, the ethnicity didn't influence the prognostic value of KRAS mutation in cfDNA in cancer patients (p = 0.39). Prognostic value of KRAS mutation was slightly higher in plasma than in serum (HR 2.13 vs 1.65), but no difference was observed (p = 0.37). Briefly, KRAS mutation in cfDNA was a survival prognostic biomarker in cancer patients. Its prognostic value was different in various types of cancer.
C1 [Zhuang, Rongyuan; Li, Qian; Guo, Xi; Shen, Feng; Liu, Tianshu] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China.
   [Li, Song] Anhui Univ Sci & Technol, Huainan City Dongfang Tumor Hosp, Affiliated Tumor Hosp, Dept Surg, Huainan, Anhui, Peoples R China.
   [Sun, Hong] Fudan Univ, Sch Pharm, Dept Clin Pharm, Shanghai, Peoples R China.
RP Liu, TS (reprint author), Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China.
EM liutianshu1969@126.com
FU Doctoral Fund of Ministry of Education of China [20130071110069]
FX The project was supported by Doctoral Fund of Ministry of Education of
   China (20130071110069).; The project was supported by Doctoral Fund of
   Ministry of Education of China (20130071110069).
CR Ai B, 2016, ONCOTARGET, V7, P44583, DOI 10.18632/oncotarget.10069
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benson AB, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Brembeck FH, 2003, CANCER RES, V63, P2005
   Camps C, 2005, LUNG CANCER, V50, P339, DOI 10.1016/j.lungcan.2005.06.007
   Camps C, 2011, LUNG CANCER, V72, P365, DOI 10.1016/j.lungcan.2010.09.005
   Castells A, 1999, J CLIN ONCOL, V17, P578, DOI 10.1200/JCO.1999.17.2.578
   Chen H, 2010, EJSO-EUR J SURG ONC, V36, P657, DOI 10.1016/j.ejso.2010.05.014
   Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227
   Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011
   Dobrzycka B, 2011, ANN ONCOL, V22, P1133, DOI 10.1093/annonc/mdq584
   Earl J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1779-7
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El Messaoudi S, 2016, CLIN CANCER RES, V22, P3067, DOI 10.1158/1078-0432.CCR-15-0297
   Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0021
   Gautschi O, 2007, CANCER LETT, V254, P265, DOI 10.1016/j.canlet.2007.03.008
   Hadano N, 2016, BRIT J CANCER, V115, P59, DOI 10.1038/bjc.2016.175
   Han JY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2678-2
   Hara M, 2017, SURG TODAY, V47, P483, DOI 10.1007/s00595-016-1404-7
   Hofman P, 2016, VIRCHOWS ARCH, V469, P601, DOI 10.1007/s00428-016-2004-z
   Janowski E, 2017, ONCOL REP, V37, P57, DOI 10.3892/or.2016.5284
   Kim ST, 2015, CANCER RES TREAT, V47, P796, DOI 10.4143/crt.2014.106
   Kimura T, 2004, ANN NY ACAD SCI, V1022, P55, DOI 10.1196/annals.1318.010
   Kingham TP, 2017, ONCOTARGET, V8, P18821, DOI 10.18632/oncotarget.13816
   Kinugasa H, 2015, CANCER-AM CANCER SOC, V121, P2271, DOI 10.1002/cncr.29364
   Van Laethem JL, 2017, TARGET ONCOL, V12, P97, DOI 10.1007/s11523-016-0469-y
   Li T, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0777-1
   Lin SH, 2015, 16 WORLD C LUNG CANC, pS287
   Nygaard AD, 2013, ONCOL REP, V31, P312
   Nygaard AD, 2014, ONCOL REP, V31, P969, DOI 10.3892/or.2013.2906
   Oxnard GR, 2014, CLIN CANCER RES, V20, P1698, DOI 10.1158/1078-0432.CCR-13-2482
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Pereira E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145754
   Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612
   Qian JY, 2005, CANCER RES, V65, P5045, DOI 10.1158/0008-5472.CAN-04-3208
   Ramirez JL, 2003, CANCER LETT, V193, P207, DOI 10.1016/S0304-3835(02)00740-1
   Riediger AL, 2016, SCI REP-UK, V6, DOI 10.1038/srep33505
   Semrad T, 2015, INT J CLIN ONCOL, V20, P518, DOI 10.1007/s10147-014-0730-2
   Singh N, 2015, CANCER INVEST, V33, P78, DOI 10.3109/07357907.2014.1001894
   Spindler KG, 2013, BRIT J CANCER, V109, P3067, DOI 10.1038/bjc.2013.633
   Spindler KLG, 2015, EUR J CANCER, V51, P2678, DOI 10.1016/j.ejca.2015.06.118
   Spindler KLG, 2014, INT J CANCER, V135, P2984, DOI 10.1002/ijc.28946
   Spindler KLG, 2012, CLIN CANCER RES, V18, P1177, DOI 10.1158/1078-0432.CCR-11-0564
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tabernero J, 2015, LANCET ONCOL, V16, P937, DOI 10.1016/S1470-2045(15)00138-2
   Takai E, 2015, SCI REP-UK, V5, DOI 10.1038/srep18425
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Tjensvoll K, 2016, MOL ONCOL, V10, P635, DOI 10.1016/j.molonc.2015.11.012
   Wang J. Q., 2015, SCI WORLD J, V2015, P1, DOI DOI 10.1371/J0URNAL.P0NE.0124261
   Wang SH, 2010, CLIN CANCER RES, V16, P1324, DOI 10.1158/1078-0432.CCR-09-2672
   Xu JM, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0104-7
   Yamada T, 1998, CLIN CANCER RES, V4, P1527
   Yang SJ, 2017, CANCER BIOL THER, V18, P158, DOI 10.1080/15384047.2017.1281499
   Zeitouni D, 2016, CANCERS, V8, pE45
   Zhou BY, 2016, SEMIN CELL DEV BIOL, V58, P60, DOI 10.1016/j.semcdb.2016.07.012
NR 55
TC 8
Z9 9
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 10
PY 2017
VL 12
IS 8
AR e0182562
DI 10.1371/journal.pone.0182562
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FD2WT
UT WOS:000407396200060
PM 28796802
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Salvi, V
   Grua, I
   Cerveri, G
   Mencacci, C
   Barone-Adesi, F
AF Salvi, Virginio
   Grua, Ilaria
   Cerveri, Giancarlo
   Mencacci, Claudio
   Barone-Adesi, Francesco
TI The risk of new-onset diabetes in antidepressant users - A systematic
   review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID ELEVATED DEPRESSIVE SYMPTOMS; LONG-TERM USE; METABOLIC SYNDROME;
   MEDICATION USE; INSULIN SENSITIVITY; BIPOLAR DISORDER; WEIGHT-GAIN;
   MELLITUS; TYPE-2; PREVALENCE
AB Background
   Antidepressant Drugs (ADs) are among the most commonly prescribed medications in developed countries. The available epidemiological evidence suggests an association between AD use and higher risk of developing type 2 diabetes mellitus. However, some methodological issues make the interpretation of these results difficult. Moreover, very recent studies provided conflicting results. Given the high prevalence of both diabetes and AD use in many countries, clarifying whether this association is causal is of extreme relevance for the public health. The aim of the present study is to provide an up-to-date evaluation of the evidence in support of a causal role of ADs in inducing diabetes.
   Methods and findings
   A systematic literature search was conducted to identify relevant studies in MEDLINE (PubMed), PsycINFO, and International Pharmaceutical Abstracts (IPA) through 31st December 2016. Only studies assessing the incidence of new -onset diabetes in subjects treated with ADs were included. Results were pooled using a random -effects meta -analysis. Moreover, we extensively reviewed the role of the different sources of bias that have been proposed to explain the association between AD and diabetes. Twenty studies met the inclusion criteria. In the meta -analysis, the association between AD use and diabetes was still evident after the inclusion of the recent negative studies [pooled relative risk = 1.27, 95% confidence interval (CI), 1.19-1.35; p<0.001]. None of the biases proposed by previous authors seemed able to fully explain the observed association.
   Conclusions
   This updated meta -analysis confirms the association between AD use and incident diabetes. It still remains a matter of debate whether single ADs exert a different effect on the risk of diabetes. Given the possible heterogeneity, we suggest that a classification of ADs according to their pharmacological profiles could be useful in better elucidating the nature of this association.
C1 [Salvi, Virginio; Cerveri, Giancarlo; Mencacci, Claudio] ASST Fatebenefratelli Sacco, Dept Neurosci, Milan, Italy.
   [Grua, Ilaria; Barone-Adesi, Francesco] Univ Piemonte Orientale, Dept Pharmaceut Sci, Novara, Italy.
RP Salvi, V (reprint author), ASST Fatebenefratelli Sacco, Dept Neurosci, Milan, Italy.
EM virginiosalvi@gmail.com
OI SALVI, Virginio/0000-0003-3374-018X
FU University of Eastern Piedmont
FX The study was partially supported by the University of Eastern Piedmont.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. There was no
   additional external funding received for this study.
CR Andersohn F, 2009, AM J PSYCHIAT, V166, P591, DOI 10.1176/appi.ajp.2008.08071065
   Atlantis E, 2010, INT J GERIATR PSYCH, V25, P688, DOI 10.1002/gps.2409
   Barone-Adesi F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142565
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhattacharjee S, 2013, DIABETES-METAB RES, V29, P273, DOI 10.1002/dmrr.2393
   Bhattacharya R, 2014, DIABETES RES CLIN PR, V105, P251, DOI 10.1016/j.diabres.2014.04.016
   Campayo A, 2010, AM J PSYCHIAT, V167, P580, DOI 10.1176/appi.ajp.2009.09010038
   Centorrino F, 2012, HUM PSYCHOPHARM CLIN, V27, P521, DOI 10.1002/hup.2257
   Chang KJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000919
   Conradi HJ, 2011, PSYCHOL MED, V41, P1165, DOI 10.1017/S0033291710001911
   Consonni D, 2014, BRIT J CANCER, V111, P1674, DOI 10.1038/bjc.2013.823
   Da Silva MA, 2015, INT J EPIDEMIOL, V44, P1927, DOI 10.1093/ije/dyv153
   Derijks HJ, 2008, EUR J CLIN PHARMACOL, V64, P531, DOI 10.1007/s00228-007-0441-y
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Deuschle M, 2013, CURR OPIN PSYCHIATR, V26, P60, DOI 10.1097/YCO.0b013e32835a4206
   Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fava M, 2006, J CLIN PSYCHIAT, V67, P1754, DOI 10.4088/JCP.v67n1113
   Frisard C, 2015, BMC ENDOCR DISORD, V15, DOI 10.1186/s12902-015-0049-7
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jerrell JM, 2010, CNS NEUROSCI THER, V16, P83, DOI 10.1111/j.1755-5949.2009.00106.x
   Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766
   Khoza S, 2012, EUR J CLIN PHARMACOL, V68, P1295, DOI 10.1007/s00228-011-1168-3
   Kisely S, 2009, CAN J PSYCHIAT, V54, P269, DOI 10.1177/070674370905400408
   Kivimaki M, 2015, INT J EPIDEMIOL, V44, P1940, DOI 10.1093/ije/dyv186
   Kivimaki M, 2011, BIOL PSYCHIAT, V70, P978, DOI 10.1016/j.biopsych.2011.07.008
   Kivimaki M, 2010, DIABETES CARE, V33, P2611, DOI 10.2337/dc10.1187
   Knol MJ, 2007, INT CLIN PSYCHOPHARM, V22, P382, DOI 10.1097/YIC.0b013e3282202c0e
   Knol MJ, 2006, DIABETOLOGIA, V49, P837, DOI 10.1007/s00125-006-0159-x
   Ma YS, 2011, DIABETES CARE, V34, P2390, DOI 10.2337/dc11-1223
   Mezuk B, 2008, DIABETES CARE, V31, P2383, DOI 10.2337/dc08-0985
   Mojtabai R, 2014, J CLIN PSYCHIAT, V75, P169, DOI 10.4088/JCP.13m08443
   Noordam R, 2016, J CLIN PSYCHIAT, V77, pE1124, DOI 10.4088/JCP.15m10048
   Okamura F, 2000, METABOLISM, V49, P1255, DOI 10.1053/meta.2000.9515
   Pan A, 2012, DIABETOLOGIA, V55, P63, DOI 10.1007/s00125-011-2268-4
   Perez-Pinar M, 2016, EUR PSYCHIAT, V35, P8, DOI 10.1016/j.eurpsy.2016.02.004
   Qiao YC, 2016, J DIABETES RES, DOI 10.1155/2016/3694957
   Raeder MB, 2006, J CLIN PSYCHIAT, V67, P1974, DOI 10.4088/JCP.v67n1219
   Rotella F, 2013, J CLIN PSYCHIAT, V74, P32, DOI 10.4088/JCP.12r07922
   Rubin RR, 2010, DIABETES CARE, V33, P2549, DOI 10.2337/dc10.1033
   Salvi V, 2016, EUR NEUROPSYCHOPHARM, V26, P1673, DOI 10.1016/j.euroneuro.2016.08.012
   Salvi V, 2016, PSYCHOPHARMACOLOGY, V233, P49, DOI 10.1007/s00213-015-4085-9
   Salvi V, 2012, J AFFECT DISORDERS, V136, P599, DOI 10.1016/j.jad.2011.10.025
   Serretti A, 2010, J CLIN PSYCHIAT, V71, P1259, DOI 10.4088/JCP.09r05346blu
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   Stubbs B, 2015, ACTA PSYCHIAT SCAND, V132, P144, DOI 10.1111/acps.12439
   Vancampfort D, 2013, AM J PSYCHIAT, V170, P265, DOI 10.1176/appi.ajp.2012.12050620
   Vimalananda VG, 2014, DIABETES CARE, V37, P2211, DOI 10.2337/dc13-2642
   Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4
   Weber-Hamann B, 2006, J CLIN PSYCHIAT, V67, P1856, DOI 10.4088/JCP.v67n1204
   Wells G, 2011, NEWCASTLE OTTAWA SCA
   Weston-Green K, 2013, CNS DRUGS, V27, P1069, DOI 10.1007/s40263-013-0115-5
   Wilkins Tricia Lee, 2011, Int Clin Psychopharmacol, V26, P159, DOI 10.1097/YIC.0b013e328342ce31
   Wu CS, 2014, J CLIN PSYCHIAT, V75, P31, DOI 10.4088/JCP.13m08421
   Yoon JM, 2013, KOREAN J FAM MED, V34, P228, DOI 10.4082/kjfm.2013.34.4.228
NR 55
TC 11
Z9 11
U1 2
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 31
PY 2017
VL 12
IS 7
AR e0182088
DI 10.1371/journal.pone.0182088
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FC3TH
UT WOS:000406761600051
PM 28759599
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, Y
   Yang, JJ
   Zhu, SH
   Xu, B
   Wang, L
AF Li, Yang
   Yang, Jing-Jing
   Zhu, Su-Hui
   Xu, Biao
   Wang, Lian
TI Long-term efficacy and safety of carotid artery stenting versus
   endarterectomy: A meta-analysis of randomized controlled trials
SO PLOS ONE
LA English
DT Article
ID FOLLOW-UP; STENOSIS; ANGIOPLASTY; OUTCOMES; SOCIETY; STROKE; RISK
AB Background
   Many recent trials have investigated the long-term efficacy and safety of endarterectomy versus stenting in treating patients with carotid artery stenosis. We aimed to determine the long-term comparative efficacy and safety of both procedures by pooling this evidence in a meta-analysis.
   Methods
   We searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials for studies published until May 6, 2016. Randomized controlled trials, which reported outcomes of interest with a median follow-up of at least 4-year, were included.
   Results
   Eight trials involving 7005 patients and 41824 patient-years of follow-up were included. In terms of the periprocedural outcomes, stenting was associated with a lower risk of myocardial infarction (OR: 0.51; 95% CI: 0.33 to 0.80; P = 0.003) but a higher risk of death or stroke (the composite endpoint, OR: 1.76; 95% CI: 1.38 to 2.25; P < 0.0001), a result that was primarily driven by minor stroke (OR: 2.19; 95% CI: 1.59 to 3.01; P < 0.0001), less so by periprocedural death (OR: 1.68; 95% CI: 0.82 to 3.44; P = 0.16) and major stroke (OR: 1.41; 95% CI: 0.95 to 2.09; P = 0.09). In terms of the long-term outcomes, stenting was associated with a higher risk of stroke (OR 1.45; 95% CI: 1.22 to 1.73; P < 0.0001) and the composite outcome of death or stroke (OR 1.25; 95% CI: 1.05 to 1.48; P = 0.01). No difference was found in long-term all-cause mortality between stenting and endarterectomy (OR: 1.09; 95% CI: 0.95 to 1.26; P = 0.21) and restenosis (OR: 1.48 (95% CI: 0.93 to 2.35; P = 0.10). No evidence of significant heterogeneity was found in any of the analyses.
   Conclusions
   Carotid endarterectomy was found to be superior to stenting for short- and long-term outcomes, although endarterectomy was associated with a higher risk of periprocedural myocardial infarction. Carotid endarterectomy should be offered as the first choice for carotid stenosis at present, however, more evidence is needed because rapid progress in concurrent devices and medical treatments is being made.
C1 [Li, Yang; Zhu, Su-Hui; Xu, Biao; Wang, Lian] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Cardiol, Nanjing, Jiangsu, Peoples R China.
   [Yang, Jing-Jing] Nanjing Univ Chinese Med, Clin Coll Tradit Chinese & Western Med, Dept Tradit Chinese Med, Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China.
RP Xu, B; Wang, L (reprint author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Cardiol, Nanjing, Jiangsu, Peoples R China.
EM xubiao@medmail.com.cn; wanglian@medmail.com.cn
CR Abbott AL, 2015, STROKE, V46, P3288, DOI 10.1161/STROKEAHA.115.003390
   Albucher JF, 2004, CEREBROVASC DIS, V18, P62, DOI 10.1159/000078751
   Arquizan C, 2011, STROKE, V42, P1015, DOI 10.1161/STROKEAHA.110.589309
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bonati LH, 2015, LANCET, V385, P529, DOI 10.1016/S0140-6736(14)61184-3
   Bonati LH, 2009, LANCET NEUROL, V8, P908, DOI 10.1016/S1474-4422(09)70227-3
   Boulanger M, 2015, STROKE, V46, P2843, DOI 10.1161/STROKEAHA.115.010052
   Brooks WH, 2004, NEUROSURGERY, V54, P318, DOI 10.1227/01.NEU.0000103447.30087.D3
   Brooks WH, 2001, J AM COLL CARDIOL, V38, P1589, DOI 10.1016/S0735-1097(01)01595-9
   Brooks WH, 2014, JACC-CARDIOVASC INTE, V7, P163, DOI 10.1016/j.jcin.2013.09.010
   Brott TG, 2016, NEW ENGL J MED, V374, P1021, DOI 10.1056/NEJMoa1505215
   Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   Choi JC, 2015, STROKE, V46, P120, DOI 10.1161/STROKEAHA.114.006209
   Coward LJ, 2005, STROKE, V36, P905, DOI 10.1161/01.STR.0000158921.51037.64
   Cronenwett JL, 2012, J VASC SURG, V55, P1529, DOI 10.1016/j.jvs.2012.03.016
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dumont TM, 2012, J NEUROSURG, V116, P1251, DOI 10.3171/2012.3.JNS111320
   Eckstein HH, 2008, LANCET NEUROL, V7, P893, DOI 10.1016/S1474-4422(08)70196-0
   Ederle J, 2010, LANCET, V375, P985, DOI 10.1016/S0140-6736(10)60239-5
   Ederle J, 2009, LANCET NEUROL, V8, P898, DOI 10.1016/S1474-4422(09)70228-5
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Grant EG, 2003, RADIOLOGY, V229, P340, DOI 10.1148/radiol.2292030516
   Halliday A, 2010, LANCET, V376, P1074, DOI 10.1016/S0140-6736(10)61197-X
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   HOFFMANN CTA, 2008, CAROTID ARTERY STENT, DOI DOI 10.1227/01.NEU.0000103447.30087.D3
   Howard G, 2016, LANCET, V387, P1305, DOI 10.1016/S0140-6736(15)01309-4
   Lal BK, 2012, LANCET NEUROL, V11, P755, DOI 10.1016/S1474-4422(12)70159-X
   Luebke T, 2016, J CARDIOVASC SURG, V57, P519
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mas JL, 2008, LANCET NEUROL, V7, P885, DOI 10.1016/S1474-4422(08)70195-9
   Mas JL, 2014, STROKE, V45, P2750, DOI 10.1161/STROKEAHA.114.005671
   Meier P, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c467
   Moore WS, 2016, ANGIOLOGY, V67, P408, DOI 10.1177/0003319715611281
   Mozaffarian D, 2016, CIRCULATION, V133, P447, DOI 10.1161/CIR.0000000000000366
   Rosenfield K, 2016, NEW ENGL J MED, V374, P1011, DOI [10.1056/NEJMoa1515706, 10.1016/j.jvs.2016.06.057]
   Rudarakanchana N, 2009, EUR J VASC ENDOVASC, V38, P239, DOI 10.1016/j.ejvs.2009.05.010
   Steinbauer MGM, 2008, J VASC SURG, V48, P93, DOI 10.1016/j.jvs.2008.02.049
   Vincent S, 2015, CIRC-CARDIOVASC QUAL, V8, pS99, DOI 10.1161/CIRCOUTCOMES.115.001933
   Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127
   Zhang L, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001060
   2001, LANCET, V357, P1729, DOI DOI 10.1016/S1474-4422(08)70195-9
NR 43
TC 15
Z9 16
U1 2
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 14
PY 2017
VL 12
IS 7
AR e0180804
DI 10.1371/journal.pone.0180804
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FA7TM
UT WOS:000405649800022
PM 28708869
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Nilsson, T
   Wahlstrom, J
   Burstrom, L
AF Nilsson, Tohr
   Wahlstrom, Jens
   Burstrom, Lage
TI Hand-arm vibration and the risk of vascular and neurological diseases -
   A systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID INDUCED WHITE FINGER; THERMAL PERCEPTION THRESHOLDS; DOSE-RESPONSE
   RELATION; CARPAL-TUNNEL-SYNDROME; TRANSMITTED VIBRATION;
   RAYNAUDS-PHENOMENON; FORESTRY WORKERS; COLD RESPONSE; EXPOSURE;
   PREVALENCE
AB Background
   Increased occurrence of Raynaud's phenomenon, neurosensory injury and carpal tunnel syndrome has been reported for more than 100 years in association with work with vibrating machines. The current risk prediction modelling (ISO-5349) for "Raynaud's phenomenon" is based on a few studies published 70 to 40 years ago. There are no corresponding risk prediction models for neurosensory injury or carpal tunnel syndrome, nor any systematic reviews comprising a statistical synthesis (meta-analysis) of the evidence.
   Objectives
   Our aim was to provide a systematic review of the literature on the association between Raynaud's phenomenon, neurosensory injuries and carpal tunnel syndrome and hand-arm vibration (HAV) exposure. Moreover the aim was to estimate the magnitude of such an association using meta-analysis.
   Methods
   This systematic review covers the scientific literature up to January 2016. The databases used for the literature search were PubMed and Science Direct. We found a total of 4,335 abstracts, which were read and whose validity was assessed according to pre-established criteria. 294 articles were examined in their entirety to determine whether each article met the inclusion criteria. The possible risk of bias was assessed for each article. 52 articles finally met the pre-established criteria for inclusion in the systematic review.
   Results
   The results show that workers who are exposed to HAV have an increased risk of vascular and neurological diseases compared to non-vibration exposed groups. The crude estimate of the risk increase is approximately 4-5 fold. The estimated effect size (odds ratio) is 6.9 for the studies of Raynaud's phenomenon when including only the studies judged to have a low risk of bias. The corresponding risk of neurosensory injury is 7.4 and the equivalent of carpal tunnel syndrome is 2.9.
   Conclusion
   At equal exposures, neurosensory injury occurs with a 3-time factor shorter latency than Raynaud's phenomenon. Which is why preventive measures should address this vibration health hazard with greater attention.
C1 [Nilsson, Tohr; Wahlstrom, Jens; Burstrom, Lage] Umea Univ, Dept Publ Hlth & Clin Med, Occupat & Environm Med, Umea, Sweden.
RP Nilsson, T (reprint author), Umea Univ, Dept Publ Hlth & Clin Med, Occupat & Environm Med, Umea, Sweden.
EM Tohr.Nilsson@envmed.umu.se
OI Nilsson, Tohr/0000-0003-2789-6321
FU Swedish AFA Insurance [090326]
FX The financial support of the Swedish AFA Insurance is gratefully
   acknowledged (Dnr: part of project 090326
   https://www.afaforsakring.se/forskning/projektkatalog/Projekt/3889/ and
   supplied through Occupational and Environmental medicine,
   https://gupea.ub.gu.se/handle/2077/42452. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aiba Y, 2012, J OCCUP HEALTH, V54, P96, DOI 10.1539/joh.11-0058-OA
   Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   [Anonymous], 2001, 53491 ISO
   Anttonen H, 1994, Arctic Med Res, V53 Suppl 3, P19
   Barregard L, 2003, OCCUP ENVIRON MED, V60, P287, DOI 10.1136/oem.60.4.287
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Borenstein M., 2009, INTRO METAANALYSIS
   BOVENZI M, 1980, INT ARCH OCC ENV HEA, V46, P251, DOI 10.1007/BF00380015
   Bovenzi M, 1998, INT ARCH OCC ENV HEA, V71, P493, DOI 10.1007/s004200050311
   Bovenzi M, 2000, INT ARCH OCC ENV HEA, V73, P519, DOI 10.1007/s004200000177
   Bovenzi M, 2005, INT ARCH OCC ENV HEA, V78, P303, DOI 10.1007/s00420-004-0574-6
   BOVENZI M, 1985, BRIT J IND MED, V42, P253
   BOVENZI M, 1995, OCCUP ENVIRON MED, V52, P722, DOI 10.1136/oem.52.11.722
   BOVENZI M, 1994, OCCUP ENVIRON MED, V51, P603, DOI 10.1136/oem.51.9.603
   Bovenzi M, 2010, OCCUP ENVIRON MED, V67, P38, DOI 10.1136/oem.2009.046128
   BOVENZI M, 1988, INT ARCH OCC ENV HEA, V61, P25, DOI 10.1007/BF00381604
   Bovenzi M, 1998, SCAND J WORK ENV HEA, V24, P138, DOI 10.5271/sjweh.291
   Bovenzi M, 2008, INT ARCH OCC ENV HEA, V81, P613, DOI 10.1007/s00420-007-0255-3
   Bovenzi M, 2008, INT ARCH OCC ENV HEA, V81, P401, DOI 10.1007/s00420-007-0225-9
   Bovenzi M, 2011, SCAND J WORK ENV HEA, V37, P244, DOI 10.5271/sjweh.3129
   Bovenzi M, 2011, INT ARCH OCC ENV HEA, V84, P325, DOI 10.1007/s00420-010-0549-8
   Bovenzi M, 2010, INT ARCH OCC ENV HEA, V83, P259, DOI 10.1007/s00420-009-0461-2
   BRAMMER AJ, 1986, SCAND J WORK ENV HEA, V12, P284, DOI 10.5271/sjweh.2139
   BRAMMER AJ, 1987, SCAND J WORK ENV HEA, V13, P279, DOI 10.5271/sjweh.2050
   Brubaker R, 1985, J LOW FREQ NOISE VIB, V4, P66
   BRUBAKER RL, 1987, SCAND J WORK ENV HEA, V13, P305, DOI 10.5271/sjweh.2035
   BURDORF A, 1991, ANN OCCUP HYG, V35, P287, DOI 10.1093/annhyg/35.3.287
   Burstrom L, 2010, SCAND J WORK ENV HEA, V36, P509, DOI 10.5271/sjweh.3072
   Carmeli Y, 1999, ARCH INTERN MED, V159, P2461, DOI 10.1001/archinte.159.20.2461
   CHATTERJEE DS, 1978, BRIT J IND MED, V35, P208
   Cherniack M, 2004, AM J IND MED, V45, P500, DOI 10.1002/ajim.20019
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Edlund M, 2013, SCAND J WORK ENV HLT
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Futatsuka M, 2005, J OCCUP HEALTH, V47, P165, DOI 10.1539/joh.47.165
   FUTATSUKA M, 1985, J OCCUP ENVIRON MED, V27, P257
   GEMNE G, 1987, SCAND J WORK ENV HEA, V13, P275, DOI 10.5271/sjweh.2038
   Gerhardsson L, 2005, APPL ERGON, V36, P55, DOI 10.1016/j.apergo.2004.09.001
   Hagberg Mats, 2008, J Occup Med Toxicol, V3, P13, DOI 10.1186/1745-6673-3-13
   Hamilton A., 1918, US BUREAU LABOUR STA, P53
   Hamilton A., 1943, EXPLORING DANGEROUS
   Harazin B, 1996, Cent Eur J Public Health, V4, P130
   Hewitt S, 2015, CRITICAL REV EVIDENC
   HO ST, 1986, INT ARCH OCC ENV HEA, V58, P259, DOI 10.1007/BF00377883
   Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80
   Jang JY, 2002, AIHAJ, V63, P305, DOI 10.1080/15428110208984718
   KOSKIMIES K, 1992, INT ARCH OCC ENV HEA, V64, P251, DOI 10.1007/BF00378282
   Lawson IJ, 2010, HUNTER'S DISEASES OF OCCUPATIONS, 10TH EDITION, P489
   LETZ R, 1992, BRIT J IND MED, V49, P53
   Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006
   Loriga G., 1911, BOLL INSPETT LAVORO, V2, P35
   Lundstrom R, 1999, AM J IND MED, V35, P456, DOI 10.1002/(SICI)1097-0274(199905)35:5<456::AID-AJIM2>3.0.CO;2-#
   Malchaire J, 2001, ANN OCCUP HYG, V45, P479, DOI 10.1016/S0003-4878(00)00084-3
   Matsumoto T, 1995, Cent Eur J Public Health, V3 Suppl, P93
   MIRBOD SM, 1994, INT ARCH OCC ENV HEA, V66, P13
   MIRBOD SM, 1992, INT ARCH OCC ENV HEA, V64, P93, DOI 10.1007/BF00381475
   Mirbod SM, 1999, IND HEALTH, V37, P415, DOI 10.2486/indhealth.37.415
   MUSSON Y, 1989, ANN OCCUP HYG, V33, P85, DOI 10.1093/annhyg/33.1.85
   Nilsson T, 2008, INT ARCH OCC ENV HEA, V81, P519, DOI 10.1007/s00420-007-0258-0
   NILSSON T, 1994, SCAND J WORK ENV HEA, V20, P189, DOI 10.5271/sjweh.1409
   Nilsson T, 2002, INT ARCH OCC ENV HEA, V75, P55
   Nilsson T, 2001, OCCUP ENVIRON MED, V58, P472, DOI 10.1136/oem.58.7.472
   NILSSON T, 1989, INT ARCH OCC ENV HEA, V61, P473, DOI 10.1007/BF00386482
   Palmer K, 1998, OCCUP ENVIRON MED, V55, P716, DOI 10.1136/oem.55.10.716
   Palmer KT, 2011, BEST PRACT RES CL RH, V25, P15, DOI 10.1016/j.berh.2011.01.014
   Pelmear PL, 1998, HAND ARM VIBRATION, P1
   Petitti DB, 2001, STAT MED, V20, P3625, DOI 10.1002/sim.1091
   Sanden H, 2010, J OCCUP MED TOXICOL, V5, DOI 10.1186/1745-6673-5-21
   Seyring M, 1931, B HYGIENE, V6
   Su AT, 2013, OCCUP ENVIRON MED, V70, P498, DOI 10.1136/oemed-2012-101321
   Tominaga Y, 1994, Nagoya J Med Sci, V57 Suppl, P235
   van Rijn RM, 2009, SCAND J WORK ENV HEA, V35, P19, DOI 10.5271/sjweh.1306
   Virokannas H, 1995, Cent Eur J Public Health, V3 Suppl, P109
   WALKER DD, 1985, BRIT J IND MED, V42, P672
   Yamada S, 1995, Nagoya J Med Sci, V58, P1
NR 75
TC 8
Z9 8
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 13
PY 2017
VL 12
IS 7
AR e0180795
DI 10.1371/journal.pone.0180795
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FA7TL
UT WOS:000405649700050
PM 28704466
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Onyedum, CC
   Alobu, I
   Ukwaja, KN
AF Onyedum, Cajetan C.
   Alobu, Isaac
   Ukwaja, Kingsley Nnanna
TI Prevalence of drug-resistant tuberculosis in Nigeria: A systematic
   review and metaanalysis
SO PLOS ONE
LA English
DT Review
ID SUB-SAHARAN AFRICA; MYCOBACTERIUM-TUBERCULOSIS; MULTIDRUG-RESISTANCE;
   RISK-FACTORS; RIFAMPICIN
AB Background
   Drug-resistant tuberculosis TB) undermines control efforts and its burden is poorly understood in resource-limited settings. We performed a systematic review and meta-analysis to provide an up-to-date summary of the extent of drug-resistant TB in Nigeria.
   Methods
   We searched PubMed, Scopus, Embase, HINARI, AJOL, the Cochrane library, Web of Science, and Google Scholar for reports published before January 31 2017, that included any resistance, mono-resistance or multidrug resistance to anti-TB drugs in Nigeria. Summary estimates were calculated using random effects models.
   Results
   We identified 34 anti-TB drug resistance surveys with 8002 adult TB patients consisting of 2982 new and 5020 previously-treated cases. The prevalence rate of any drug resistance among new TB cases was 32.0% 95% CI 24.0 -40.0%; 734/ 2892) and among previouslytreated cases, the rate was 53.0% 95% CI 35.0 -71.0%; 1467/ 5020). Furthermore, multidrug resistance among new and previously-treated cases was 6.0% 95% CI 4.0 -8.0%; 161/ 2502) and 32.0% 95% CI 20.0 -44.0; 357/ 949), respectively. There was significant heterogeneity between the studies p< 0.001, I 2 tests). The prevalence of drug-resistant TB varied according to methods of drug susceptibility testing and geographic region of Nigeria.
   Conclusion
   The burden of drug-resistant TB in Nigeria is high. We recommend that a national anti-TB drug resistance survey be carried out, and strategies for case detection and programmatic management of drug-resistant TB in Nigeria need to be strengthened.
C1 [Onyedum, Cajetan C.] Univ Nigeria, Dept Med, Coll Med, Enugu Campus, Enugu, Nigeria.
   [Alobu, Isaac] Minist Hlth, Natl TB & Leprosy Control Programme, Abakaliki, Ebonyi State, Nigeria.
   [Ukwaja, Kingsley Nnanna] Fed Teaching Hosp, Dept Internal Med, Abakaliki, Ebonyi State, Nigeria.
RP Ukwaja, KN (reprint author), Fed Teaching Hosp, Dept Internal Med, Abakaliki, Ebonyi State, Nigeria.
EM ukwajakingsley@yahoo.co.uk
RI Ukwaja, Kingsley N./A-7794-2013
OI Ukwaja, Kingsley N./0000-0002-1974-8735
CR Adamu A. U., 2015, The Journal of American Science, V11, P293
   Aghaji MN, 2010, NIGER J CLIN PRACT, V13, P58
   Aliyu Gambo, 2013, Tuberc Res Treat, V2013, P650561, DOI 10.1155/2013/650561
   Alobu I, 2014, ASIAN PAC J TROP MED, V7, P977, DOI 10.1016/S1995-7645(14)60172-3
   Ani AE, 2009, T ROY SOC TROP MED H, V103, P67, DOI 10.1016/j.trstmh.2008.08.004
   Antunes ML, 2000, INT J TUBERC LUNG D, V4, P223
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bello LA, 2014, INT J RES MED SCI, V2, P1134
   Berhan A, 2013, ETHIOP J HEALTH SCI, V23, P271, DOI 10.4314/ejhs.v23i3.10
   Blondal K, 2007, BULL WORLD HEALTH OR, V85
   Daniel O, 2011, AFR J RESPIR MED, V6, P18
   Daniel O, 2011, ASIAN PAC J TROP MED, V4, P148, DOI 10.1016/S1995-7645(11)60057-6
   Deutschendorf C, 2012, BRAZ J INFECT DIS, V16, P142, DOI 10.1590/S1413-86702012000200006
   Dosumu EA, 2008, AFR J RESP MED, V4, P22
   Duan QH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148041
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egbe K, 2016, SCI J PUBLIC HLTH, V4, P214
   Eltayeb O, J PULMON RESP MED S, VS6
   FAWCETT IW, 1976, TUBERCLE, V57, P71, DOI 10.1016/0041-3879(76)90020-9
   Federal Ministry of Health, 2015, NATIONAL TUBERCULOSI
   Gehre F, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0704-5
   Halilu TB, 2013, J PHARM COSMET SCI V, V1, P45
   Hamza TH, 2008, J CLIN EPIDEMIOL, V61, P41, DOI 10.1016/j.jclinepi.2007.03.016
   IDIGBE EO, 1992, J TROP MED HYG, V95, P186
   Ifebunandu NA, 2012, TROP DOCT, V42, P74, DOI 10.1258/td.2011.110421
   Jindani A, 2004, LANCET, V364, P1244, DOI 10.1016/S0140-6736(04)17141-9
   Kehinde A O, 2013, Niger J Physiol Sci, V28, P187
   Kehinde AO, 2007, J NATL MED ASSOC, V99, P1185
   Kehinde AO, 2012, J MED MICROB DIAGN S, VS3
   Kolo I, 1991, THESIS
   Lawson L, 2011, TROP MED INT HEALTH, V16, P974, DOI 10.1111/j.1365-3156.2011.02792.x
   Lawson L, 2010, ANN AFR MED, V9, P184, DOI 10.4103/1596-3519.68355
   Lukoye D, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1614-8
   Mawak JD, 2006, NIG J EXP APPL BIOL, V7, P128
   Mustapha G, 2015, SAARC J TUBERC LUNG, VXII, P1
   Nasiri MJ, 2014, AM J INFECT CONTROL, V42, P1212, DOI 10.1016/j.ajic.2014.07.017
   Nwachukwu NO, 2016, J INFEC DIS TREAT, V2, P1
   Nwofor AC, 2015, CURR HIV RES, V13, P308, DOI 10.2174/1570162X13666150407143147
   Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39
   Okodua M, 2012, INT J BASIC APPL INN, V1, P48
   Oluwaseun E., 2013, AM J RES COMMUN, V1, P224
   Otu A, 2013, NIGERIA PULM MED, V2013
   Pokam BT, 2013, INT J MYCOBACT, V2, P89, DOI 10.1016/j.ijmyco.2013.03.002
   Rasaki SO, 2014, J INFECT DIS THER, V2, P3
   Rikoto JA, 2015, THESIS
   Sanders M, 2006, INT J TUBERC LUNG D, V10, P178
   Sogaolu OM, 2012, AM J RESP CRIT CARE, V185, pA3257
   Suchindran S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005561
   The Joanna Briggs Institute, 2014, JOANNA BRIGGS INSTIT
   Ukaegbu CO, 2016, BR J PHARM RES, V9, P1
   Ukoli CO, 2012, JOS J MED, V6, P26
   Umubyeyi AN, 2007, INT J TUBERC LUNG D, V11, P860
   Uzoewulu NG, 2014, J MED MICROB DIAGN, V3, P2, DOI DOI 10.4172/2161-0703.1000141
   van der Werf MJ, 2012, EUR RESPIR J, V39, P1511, DOI 10.1183/09031936.00125711
   Weldegebreal S, 2017, INT J TUBERC LUNG D, V21, P18, DOI 10.5588/ijtld.16.0286
   World Health Organization, 2016, GLOBAL TUBERCULOSIS
   World Health Organization, 2015, GUIDELINES FOR SURVE
   Zhao P, 2012, J INT MED RES, V40, P436, DOI 10.1177/147323001204000205
NR 58
TC 5
Z9 5
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 13
PY 2017
VL 12
IS 7
AR 0180996
DI 10.1371/journal.pone.0180996
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FA7TL
UT WOS:000405649700071
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Catala-Lopez, F
   Hutton, B
   Nunez-Beltran, A
   Page, MJ
   Ridao, M
   St-Gerons, DM
   Catala, MA
   Tabares-Seisdedos, R
   Moher, D
AF Catala-Lopez, Ferran
   Hutton, Brian
   Nunez-Beltran, Amparo
   Page, Matthew J.
   Ridao, Manuel
   Macias St-Gerons, Diego
   Catala, Miguel A.
   Tabares-Seisdedos, Rafael
   Moher, David
TI The pharmacological and non-pharmacological treatment of attention
   deficit hyperactivity disorder in children and adolescents: A systematic
   review with network meta-analyses of randomised trials
SO PLOS ONE
LA English
DT Review
ID CHILDHOOD PSYCHIATRIC-DISORDER; DEFICIT/HYPERACTIVITY DISORDER; COMPLEX
   INTERVENTIONS; CONSORT STATEMENT; CLINICAL-TRIALS; ADHD;
   METHYLPHENIDATE; CARE; BIAS; INCONSISTENCY
AB Background Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed psychiatric disorders in childhood. A wide variety of treatments have been used for the management of ADHD. We aimed to compare the efficacy and safety of pharmacological, psychological and complementary and alternative medicine interventions for the treatment of ADHD in children and adolescents.
   Methods and findings We performed a systematic review with network meta-analyses. Randomised controlled trials (>= 3 weeks follow-up) were identified from published and unpublished sources through searches in PubMed and the Cochrane Library (up to April 7, 2016). Interventions of interest were pharmacological (stimulants, non-stimulants, antidepressants, antipsychotics, and other unlicensed drugs), psychological (behavioural, cognitive training and neurofeedback) and complementary and alternative medicine (dietary therapy, fatty acids, amino acids, minerals, herbal therapy, homeopathy, and physical activity). The primary outcomes were efficacy (treatment response) and acceptability (all-cause discontinuation). Secondary outcomes included discontinuation due to adverse events (tolerability), as well as serious adverse events and specific adverse events. Random-effects Bayesian network meta-analyses were conducted to obtain estimates as odds ratios (ORs) with 95% credibility intervals. We analysed interventions by class and individually. 190 randomised trials (52 different interventions grouped in 32 therapeutic classes) that enrolled 26114 participants with ADHD were included in complex networks. At the class level, behavioural therapy (alone or in combination with stimulants), stimulants, and non-stimulant seemed significantly more efficacious than placebo. Behavioural therapy in combination with stimulants seemed superior to stimulants or non-stimulants. Stimulants seemed superior to behavioural therapy, cognitive training and non-stimulants. Behavioural therapy, stimulants and their combination showed the best profile of acceptability. Stimulants and non-stimulants seemed well tolerated. Among medications, methylphenidate, amphetamine, atomoxetine, guanfacine and clonidine seemed significantly more efficacious than placebo. Methylphenidate and amphetamine seemed more efficacious than atomoxetine and guanfacine. Methylphenidate and clonidine seemed better accepted than placebo and atomoxetine. Most of the efficacious pharmacological treatments were associated with harms (anorexia, weight loss and insomnia), but an increased risk of serious adverse events was not observed. There is lack of evidence for cognitive training, neurofeedback, antidepressants, antipsychotics, dietary therapy, fatty acids, and other complementary and alternative medicine. Overall findings were limited by the clinical and methodological heterogeneity, small sample sizes of trials, short-term follow-up, and the absence of high-quality evidence; consequently, results should be interpreted with caution.
   Conclusions Clinical differences may exist between the pharmacological and non-pharmacological treatment used for the management of ADHD. Uncertainties about therapies and the balance between benefits, costs and potential harms should be considered before starting treatment. There is an urgent need for high-quality randomised trials of the multiple treatments for ADHD in children and adolescents. PROSPERO, number CRD42014015008.
C1 [Catala-Lopez, Ferran; Hutton, Brian; Moher, David] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
   [Catala-Lopez, Ferran; Ridao, Manuel] Fdn Inst Invest Serv Salud, Valencia, Spain.
   [Catala-Lopez, Ferran; Tabares-Seisdedos, Rafael] Univ Valencia, INCLIVA Hlth Res Inst, Dept Med, Valencia, Spain.
   [Catala-Lopez, Ferran; Tabares-Seisdedos, Rafael] CIBERSAM, Valencia, Spain.
   [Hutton, Brian; Moher, David] Univ Ottawa, Fac Med, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada.
   [Nunez-Beltran, Amparo] Reg Hlth Council, CAID Norte, Madrid, Spain.
   [Page, Matthew J.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.
   [Page, Matthew J.] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.
   [Ridao, Manuel] IACS, REDISSEC, Zaragoza, Spain.
   [Macias St-Gerons, Diego] AEMPS, Spanish Med & Healthcare Prod Agcy, Div Pharmacoepidemiol & Pharmacovigilance, Madrid, Spain.
   [Catala, Miguel A.] Univ Valencia, Fac Med, Valencia, Spain.
   [Nunez-Beltran, Amparo] Dionisia Plaza Rehabil Ctr, Madrid, Spain.
RP Catala-Lopez, F (reprint author), Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.; Catala-Lopez, F (reprint author), Fdn Inst Invest Serv Salud, Valencia, Spain.; Catala-Lopez, F (reprint author), Univ Valencia, INCLIVA Hlth Res Inst, Dept Med, Valencia, Spain.; Catala-Lopez, F (reprint author), CIBERSAM, Valencia, Spain.
EM ferran_catala@hotmail.com
RI Catala-Lopez, Ferran/N-6018-2018; Tabares-Seisdedos, Rafael/H-6432-2013;
   Moher, David/I-3408-2019
OI Catala-Lopez, Ferran/0000-0002-3833-9312; Moher,
   David/0000-0003-2434-4206; Hutton, Brian/0000-0001-5662-8647; Page,
   Matthew/0000-0002-4242-7526; Macias Saint-Gerons,
   Diego/0000-0002-2572-2160
CR Abikoff H, 2004, J AM ACAD CHILD PSY, V43, P802, DOI 10.1097/01.chi.0000128791.10014.ac
   Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080
   [Anonymous], 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19450
   [Anonymous], 2011, GUID REC ADHD CHILDR
   [Anonymous], 2014, LANCET, V384, P104, DOI DOI 10.1016/S0140-6736(14)61146-6
   Attention Deficit Hyperactivity Disorder, 2009, NICE GUID DIAGN MAN
   Austin PC, 2004, STAT MED, V23, P1159, DOI 10.1002/sim.1687
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bero LA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000075
   Bonini S, 2014, NEW ENGL J MED, V371, P2452, DOI 10.1056/NEJMp1409464
   Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008
   Bowers S, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6082
   Boyle MH, 1999, CAN J PSYCHIAT, V44, P991, DOI 10.1177/070674379904401005
   Caldwell DM, 2016, EVID-BASED MENT HEAL, V19, P16, DOI 10.1136/eb-2015-102275
   Carlson Gabrielle A, 2007, Child Adolesc Psychiatry Ment Health, V1, P10, DOI 10.1186/1753-2000-1-10
   Catala-Lopez F, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001971
   Catala-Lopez F, 2015, SYST REV, V4, DOI 10.1186/s13643-015-0005-7
   Catala-Lopez F, 2014, RHEUMATOL INT, V34, P1489, DOI 10.1007/s00296-014-2994-2
   Catala-Lopez F, 2014, REV ESP CARDIOL, V67, P597, DOI 10.1016/j.rec.2013.11.016
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Chan E, 2016, JAMA-J AM MED ASSOC, V315, P1997, DOI 10.1001/jama.2016.5453
   Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5
   Clyburne-Sherin AVP, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0954-0
   Coates J, 2015, J ATTEN DISORD, V19, P831, DOI 10.1177/1087054714535952
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Connor DF, 2000, CLIN PEDIATR, V39, P15, DOI 10.1177/000992280003900102
   Cooper WO, 2011, NEW ENGL J MED, V365, P1896, DOI 10.1056/NEJMoa1110212
   Dalsgaard S, 2015, LANCET, V385, P2190, DOI 10.1016/S0140-6736(14)61684-6
   Del Re AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063509
   Dias S, 2013, MED DECIS MAKING, V33, P618, DOI 10.1177/0272989X13485157
   Dias S, 2013, MED DECIS MAKING, V33, P607, DOI 10.1177/0272989X12458724
   Dopfner M, 2004, EUR CHILD ADOLES PSY, V13, P117, DOI 10.1007/s00787-004-1011-9
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Epstein JN, 2014, PEDIATRICS, V134, P1136, DOI 10.1542/peds.2014-1500
   Feldman HM, 2014, NEW ENGL J MED, V370, P838, DOI 10.1056/NEJMcp1307215
   Gelman A, 1992, STAT SCI, V7, P457, DOI DOI 10.1214/SS/1177011136
   Gotzsche PC., 2014, COCHRANE LIB
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hodgson K, 2014, J ATTEN DISORD, V18, P275, DOI 10.1177/1087054712444732
   Hutton B, 2015, SYST REV, V4, DOI 10.1186/s13643-015-0099-y
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Hutton B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092508
   Hutton B, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-44
   Ioannidis JPA, 2014, LANCET, V383, P166, DOI 10.1016/S0140-6736(13)62227-8
   Ioannidis JPA, 2009, CAN MED ASSOC J, V181, P488, DOI 10.1503/cmaj.081086
   Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009
   Jakobsen JC, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-016-1173-2
   Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073
   Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31460-X
   Keen D, 2011, BMJ CLIN EVID, V2011, P312
   King S, 2006, HEALTH TECHNOL ASSES, V10, P1
   Kollins SH, 2011, PEDIATRICS, V127, pE1406, DOI 10.1542/peds.2010-1260
   Kurlan R, 2002, NEUROLOGY, V58, P527
   Linden S, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3199
   Lundh A, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000033.pub3
   Mayo-Wilson E, 2014, LANCET PSYCHIAT, V1, P368, DOI 10.1016/S2215-0366(14)70329-3
   Melendez-Torres GJ, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0040-z
   Mills EJ, 2012, JAMA-J AM MED ASSOC, V308, P1246, DOI 10.1001/2012.jama.11228
   Mills Edward J, 2011, Clin Epidemiol, V3, P193, DOI 10.2147/CLEP.S16526
   National Institute for Health and Care Excellence, 2008, ATT DEF HYP DIS DIAG
   Palumbo DR, 2008, J AM ACAD CHILD PSY, V47, P180, DOI 10.1097/chi.0b013e31815d9af7
   Patel V, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001448
   Pelsser LM, 2011, LANCET, V377, P494, DOI 10.1016/S0140-6736(10)62227-1
   Petticrew M, 2013, J CLIN EPIDEMIOL, V66, P1209, DOI 10.1016/j.jclinepi.2013.06.004
   Phillips CB, 2006, PLOS MED, V3, P433, DOI 10.1371/journal.pmed.0030182
   Pliszka S, 2007, J AM ACAD CHILD PSY, V46, P894, DOI 10.1097/chi.0b013e318054e724
   Polanczyk GV, 2015, J CHILD PSYCHOL PSYC, V56, P345, DOI 10.1111/jcpp.12381
   Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630
   Punja S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009996.pub2
   Renoux C, 2016, BRIT J CLIN PHARMACO, V82, P858, DOI 10.1111/bcp.13000
   Rochwerg B, 2014, ANN INTERN MED, V161, P347, DOI 10.7326/M14-0178
   Sampson M, 2008, J CLIN EPIDEMIOL, V61, P755, DOI 10.1016/j.jclinepi.2007.10.003
   Schulz KF, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000251
   Scottish Intercollegiate Guidelines Network, 2009, MANAGEMENT OF ATTENT
   Seixas M, 2012, J PSYCHOPHARMACOL, V26, P753, DOI 10.1177/0269881111412095
   Shin JY, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2550
   Snell T, 2013, J CHILD PSYCHOL PSYC, V54, P977, DOI 10.1111/jcpp.12055
   So CYC, 2008, BEHAV RES THER, V46, P983, DOI 10.1016/j.brat.2008.06.007
   Sonuga-Barke EJS, 2013, AM J PSYCHIAT, V170, P275, DOI 10.1176/appi.ajp.2012.12070991
   Steele M, 2006, CLIN THER, V28, P1892, DOI 10.1016/j.clinthera.2006.11.006
   Sterne JAC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000076
   Storebo OJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009885.pub2
   Storebo OJ, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5203
   Stuhec M, 2015, J AFFECT DISORDERS, V178, P149, DOI 10.1016/j.jad.2015.03.006
   Swanson JM, 2001, J AM ACAD CHILD PSY, V40, P168, DOI 10.1097/00004583-200102000-00011
   Thapar A, 2016, LANCET, V387, P1240, DOI 10.1016/S0140-6736(15)00238-X
   Thomas R, 2015, PEDIATRICS, V135, pE994, DOI 10.1542/peds.2014-3482
   Thomas R, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6172
   US Food and Drug Administration, 2004, FDA LAUNCH MULT STRA
   US Food and Drugs Administration, 2007, MOD MARK PROV SER SK
   van der Oord S, 2007, EUR CHILD ADOLES PSY, V16, P48, DOI 10.1007/s00787-006-0574-z
   Verkuijl N, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2168
   Visser SN, 2016, MMWR-MORBID MORTAL W, V65, P443, DOI 10.15585/mmwr.mm6517e1
   Visser SN, 2014, J AM ACAD CHILD PSY, V53, P34, DOI 10.1016/j.jaac.2013.09.001
   Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6
   Welton NJ, 2009, AM J EPIDEMIOL, V169, P1158, DOI 10.1093/aje/kwp014
   Wilens TE, 2012, J AM ACAD CHILD PSY, V51, P74, DOI 10.1016/j.jaac.2011.10.012
   Wolraich M, 2011, PEDIATRICS, V128, P1007, DOI 10.1542/peds.2011-2654
   Wykes T, 2015, LANCET PSYCHIAT, V2, P1036, DOI 10.1016/S2215-0366(15)00332-6
NR 101
TC 32
Z9 35
U1 6
U2 50
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 12
PY 2017
VL 12
IS 7
AR e0180355
DI 10.1371/journal.pone.0180355
PG 31
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FA7TK
UT WOS:000405649600029
PM 28700715
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Huang, XYN
   Ribeiro, JD
   Musacchio, KM
   Franklin, JC
AF Huang, Xieyining
   Ribeiro, Jessica D.
   Musacchio, Katherine M.
   Franklin, Joseph C.
TI Demographics as predictors of suicidal thoughts and behaviors: A
   meta-analysis
SO PLOS ONE
LA English
DT Article
ID CROSS-SECTIONAL SURVEY; PUBLICATION BIAS; FOLLOW-UP; RISK-FACTORS;
   EFFECT SIZE; PREVALENCE; MORTALITY; IDEATION; PERSONALITY; PSYCHACHE
AB Background
   Certain demographic factors have long been cited to confer risk or protection for suicidal thoughts and behaviors. However, many studies have found weak or non-significant effects. Determining the effect strength and clinical utility of demographics as predictors is crucial for suicide risk assessment and theory development. As such, we conducted a meta-analysis to determine the effect strength and clinical utility of demographics as predictors.
   Methods
   We searched PsycInfo, PubMed, and GoogleScholar for studies published before January 1st, 2015. Inclusion criteria required that studies use at least one demographic factor to longitudinally predict suicide ideation, attempt, or death. The initial search yielded 2,541 studies, 159 of which were eligible. A total of 752 unique statistical tests were included in analysis.
   Results
   Suicide death was the most commonly studied outcome, followed by attempt and ideation. The average follow-up length was 9.4 years. The overall effects of demographic factors studied in the field as risk factors were significant but weak, and that of demographic factors studied as protective factors were non-significant. Adjusting for publication bias further reduced effect estimates. No specific demographic factors appeared to be strong predictors. The effects were consistent across multiple moderators.
   Conclusions
   At least within the narrow methodological constraints of the existing literature, demographic factors were statistically significant risk factors, but not protective factors. Even as risk factors, demographics offer very little improvement in predictive accuracy. Future studies that go beyond the limitations of the existing literature are needed to further understand the effects of demographics.
C1 [Huang, Xieyining; Ribeiro, Jessica D.; Musacchio, Katherine M.; Franklin, Joseph C.] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA.
   [Ribeiro, Jessica D.] Mil Suicide Res Consortium, Tallahassee, FL USA.
RP Huang, XYN (reprint author), Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA.
EM huang@psy.fsu.edu
FU Military Suicide Research Consortium (MSRC); Office of the Assistant
   Secretary of Defense for Health Affairs [W81XWH-10-2-0181]; National
   Institute of Mental Health (NIH) [T32MH18921]
FX This work was supported in part by funding from the Military Suicide
   Research Consortium (MSRC; msrc.fsu.edu), an effort supported by the
   Office of the Assistant Secretary of Defense for Health Affairs (Award
   No. W81XWH-10-2-0181). This work was also supported in part through a
   training grant (T32MH18921) from the National Institute of Mental Health
   (NIH; nih.gov). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
   Opinions, interpretations, conclusions, and recommendations are those of
   the authors and are not necessarily endorsed by the funding agencies.
CR Angst J, 1998, J AFFECT DISORDERS, V51, P55, DOI 10.1016/S0165-0327(98)00156-6
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blosnich JR, 2013, AM J PUBLIC HEALTH, V103, pE27, DOI 10.2105/AJPH.2013.301507
   Borenstein M., 2009, INTRO METAANALYSIS
   Centers for Disease Control and Prevention, 2016, SUICIDE RISK AND PRO
   Cha CB, ACCOUNTING DIVERSITY
   Chan LF, 2014, PSYCHIAT RES, V220, P867, DOI 10.1016/j.psychres.2014.08.055
   Chen HN, 2010, COMMUN STAT-SIMUL C, V39, P860, DOI 10.1080/03610911003650383
   Chen YY, 2012, EPIDEMIOL REV, V34, P129, DOI 10.1093/epirev/mxr025
   Corcoran P, 2010, SOC PSYCH PSYCH EPID, V45, P795, DOI 10.1007/s00127-009-0120-7
   CULLBERG J, 1988, ACTA PSYCHIAT SCAND, V77, P598, DOI 10.1111/j.1600-0447.1988.tb05173.x
   Dekovic M, 1999, J YOUTH ADOLESCENCE, V28, P667, DOI 10.1023/A:1021635516758
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eynan R, 2002, SUICIDE LIFE-THREAT, V32, P418, DOI 10.1521/suli.32.4.418.22341
   HOYER G, 1993, ARCH GEN PSYCHIAT, V50, P134
   Joiner T. E, 2005, WHY PEOPLE DIE SUICI
   Kaplan KJ, 2012, SUICIDE LIFE-THREAT, V42, P614, DOI 10.1111/j.1943-278X.2012.00116.x
   Kessler RC, 2005, TRENDS SUICIDE IDEAT, V293, P1990
   Kposowa AJ, 2001, PSYCHOL MED, V31, P127, DOI 10.1017/S0033291799002925
   Kraemer HC, 1997, ARCH GEN PSYCHIAT, V54, P337
   Lindeman S, 1996, BRIT J PSYCHIAT, V168, P274, DOI 10.1192/bjp.168.3.274
   Loas G, 2009, PSYCHOPATHOLOGY, V42, P185, DOI 10.1159/000209331
   Lukaschek K, 2014, BRIT J PSYCHIAT, V205, P398, DOI 10.1192/bjp.bp.113.139352
   LUTHAR SS, 1993, J CHILD PSYCHOL PSYC, V34, P441, DOI 10.1111/j.1469-7610.1993.tb01030.x
   Nock MK, 2008, EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002
   Nock MK, 2008, BRIT J PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113
   Nock MK, 2010, ANNU REV CLIN PSYCHO, V6, P339, DOI 10.1146/annurev.clinpsy.121208.131258
   O'Connor RC, 2013, J CONSULT CLIN PSYCH, V81, P1137, DOI 10.1037/a0033751
   Okamura T, 2014, SOC PSYCH PSYCH EPID, V49, P573, DOI 10.1007/s00127-013-0791-y
   Orwin RG, 1983, J ED STAT, V8, P157, DOI DOI 10.2307/1164923
   Panczak R, 2013, SUICIDE LIFE-THREAT, V43, P213, DOI 10.1111/sltb.12009
   Platt B, 2010, OCCUP MED-OXFORD, V60, P436, DOI 10.1093/occmed/kqq044
   Qin P, 2003, ARCH GEN PSYCHIAT, V60, P797, DOI 10.1001/archpsyc.60.8.797
   Qin P, 2003, AM J PSYCHIAT, V160, P765, DOI 10.1176/appi.ajp.160.4.765
   Rahman A, 2003, ACTA PSYCHIAT SCAND, V108, P392, DOI 10.1034/j.1600-0447.2003.00220.x
   Rahman S, 2014, PLOS ONE, V9
   Ramberg IL, 2000, PSYCHOL MED, V30, P1189, DOI 10.1017/S003329179900238X
   Rasic DT, 2009, J AFFECT DISORDERS, V114, P32, DOI 10.1016/j.jad.2008.08.007
   Ribeiro JD, 2016, PSYCHOL MED, V46, P2009, DOI 10.1017/S0033291716000611
   ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638
   Russell ST, 2001, AM J PUBLIC HEALTH, V91, P1276, DOI 10.2105/AJPH.91.8.1276
   Sauvola A, 2001, EUR J PUBLIC HEALTH, V11, P284, DOI 10.1093/eurpub/11.3.284
   Schernhammer ES, 2004, AM J PSYCHIAT, V161, P2295, DOI 10.1176/appi.ajp.161.12.2295
   Schooler J, 2011, NATURE, V470, P437, DOI 10.1038/470437a
   Shneidman ES, 1998, SUICIDE LIFE-THREAT, V28, P245
   SHNEIDMAN ES, 1993, J NERV MENT DIS, V181, P145, DOI 10.1097/00005053-199303000-00001
   Shneidman ES, 1999, PERTURBATION LETHALI
   Simonsohn U, 2014, PERSPECT PSYCHOL SCI, V9, P666, DOI 10.1177/1745691614553988
   Simonsohn U, 2014, J EXP PSYCHOL GEN, V143, P534, DOI 10.1037/a0033242
   Soloff PH, 2012, AM J PSYCHIAT, V169, P484, DOI 10.1176/appi.ajp.2011.11091378
   STACK S, 1990, SOCIOL QUART, V31, P359, DOI 10.1111/j.1533-8525.1990.tb00333.x
   TROVATO F, 1987, J MARRIAGE FAM, V49, P193, DOI 10.2307/352683
   Tyssen R, 2001, PHYSIOL REV, V11, P10
   Van Orden KA, 2010, PSYCHOL REV, V117, P575, DOI 10.1037/a0018697
   Vevea JL, 2005, PSYCHOL METHODS, V10, P428, DOI 10.1037/1082-989X.10.4.428
   VEVEA JL, 1995, PSYCHOMETRIKA, V60, P419, DOI 10.1007/BF02294384
   Votta E, 2004, J ADOLESCENT HEALTH, V34, P237, DOI 10.1016/j.jadohealth.2003.06.002
   Wells K, 2009, RES SOCIAL WORK PRAC, V19, P52, DOI 10.1177/1049731508317278
   World Health Organisation, 2016, SUICIDE
   Wyder M, 2009, J AFFECT DISORDERS, V116, P208, DOI 10.1016/j.jad.2008.11.007
NR 61
TC 6
Z9 6
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 10
PY 2017
VL 12
IS 7
AR e0180793
DI 10.1371/journal.pone.0180793
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FA6HV
UT WOS:000405544800077
PM 28700728
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Deng, JL
   Wang, LZ
   Zhang, YF
   Chang, XY
   Ma, XJ
AF Deng, Jiali
   Wang, Lizhong
   Zhang, Yinfa
   Chang, Xiangyang
   Ma, Xingjie
TI Insertion of an intrathecal catheter in parturients reduces the risk of
   post-dural puncture headache: A retrospective study and meta-analysis
SO PLOS ONE
LA English
DT Article
ID ACCIDENTAL DURAL PUNCTURE; OBSTETRIC PATIENTS; EPIDURAL ANALGESIA;
   MANAGEMENT; LABOR; COMPLICATIONS; EXPERIENCE; BIAS
AB This study aimed to determine whether insertion of an intrathecal catheter following accidental dural puncture (ADP) in obstetric patients can reduce the incidence of post-dural puncture headache (PDPH) and the requirement of a therapeutic epidural blood patch (TEBP). This was also compared with relocating the epidural catheter at a different vertebral interspace. A retrospective study was performed, as well as a meta-analysis of the literature to further validate our findings. We reviewed the records of 86 obstetric patients who suffered from ADP during epidural anesthesia or combined spinal-epidural anesthesia from October 2015 to November 2016 at our institution. Although, there was no significant decrease in the incidence of PDPH (P = 0.08), the requirement for a TEBP (P = 0.025) was significantly reduced in the intrathecal catheter group compared with the relocated group. In the metaanalysis, 13 eligible studies including 1044 obstetric patients were finally identified. To estimate the pooled risk ratios (RRs), fixed or random effect models were used depending on the heterogeneity. We initially found that an intrathecal catheter significantly reduced the incidence of PDPH (pooled RR = 0.823; 95% CI = 0.700-0.967; P = 0.018) and the requirement of a TEBP (pooled RR = 0.616; 95% CI = 0.443-0.855; P = 0.004). Our study shows that insertion of an intrathecal catheter following ADP might be an effective and dependable method for reducing the risk of a PDPH and requirement for a TEBP in obstetric patients.
C1 [Deng, Jiali; Wang, Lizhong; Zhang, Yinfa; Chang, Xiangyang] Jiaxing Univ, Sch Med, Jiaxing Matern & Child Hlth Hosp, Dept Anesthesia, Jiaxing, Zhejiang, Peoples R China.
   [Ma, Xingjie] Jiaxing Univ, Sch Med, Hosp Jiaxing 1, Dept Cardiothorac Surg, Jiaxing, Zhejiang, Peoples R China.
RP Ma, XJ (reprint author), Jiaxing Univ, Sch Med, Hosp Jiaxing 1, Dept Cardiothorac Surg, Jiaxing, Zhejiang, Peoples R China.
EM dr_maixngjie@163.com
FU Jiaxing Science and Technology Bureau in Zhengjiang Province, China
   [2013AY21050-2]
FX This study was supported by the grant from Jiaxing Science and
   Technology Bureau in Zhengjiang Province, China (no. 2013AY21050-2). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Antunes MV, 2016, ACTA MEDICA PORT, V29, P268, DOI 10.20344/amp.6815
   Apfel CC, 2010, BRIT J ANAESTH, V105, P255, DOI 10.1093/bja/aeq191
   Ayad S, 2003, REGION ANESTH PAIN M, V28, P512, DOI 10.1016/S1098-7339(03)00393-6
   Baraz R, 2005, ANAESTHESIA, V60, P673, DOI 10.1111/j.1365-2044.2005.04222.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bolden N, 2016, REGION ANESTH PAIN M, V41, P169, DOI 10.1097/AAP.0000000000000339
   COHEN S, 1994, ACTA ANAESTH SCAND, V38, P716, DOI 10.1111/j.1399-6576.1994.tb03983.x
   de Velde MV, 2008, INT J OBSTET ANESTH, V17, P329, DOI 10.1016/j.ijoa.2007.04.009
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Heesen M, 2013, INT J OBSTET ANESTH, V22, P26, DOI 10.1016/j.ijoa.2012.10.004
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jagannathan DK, 2016, INT J OBSTET ANESTH, V25, P23, DOI 10.1016/j.ijoa.2015.09.002
   Kaddoum R, 2014, J ANESTH, V28, P628, DOI 10.1007/s00540-013-1761-y
   NORRIS MC, 1990, REGION ANESTH, V15, P285
   Paech M, 2001, INT J OBSTET ANESTH, V10, P162, DOI 10.1054/ijoa.2000.0825
   Russell IF, 2012, INT J OBSTET ANESTH, V21, P7, DOI 10.1016/j.ijoa.2011.10.005
   Rutter SV, 2001, INT J OBSTET ANESTH, V10, P177, DOI 10.1054/ijoa.2001.0854
   Tien M, 2016, CURR MED RES OPIN, V32, P841, DOI 10.1185/03007995.2016.1146665
   Verstraete S, 2014, ACTA ANAESTH SCAND, V58, P1233, DOI 10.1111/aas.12394
NR 20
TC 2
Z9 2
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 5
PY 2017
VL 12
IS 7
AR e0180504
DI 10.1371/journal.pone.0180504
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FA2LF
UT WOS:000405272200068
PM 28678882
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Luo, CQ
   Chen, XY
   Jin, HC
   Yao, K
AF Luo, Chenqi
   Chen, Xinyi
   Jin, Hongchuan
   Yao, Ke
TI The association between gout and cataract risk: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID SOCIOECONOMIC-FACTORS; ALLOPURINOL THERAPY; EXPOSURE
AB Purpose
   To evaluate the relationship between gout and age-related cataracts (ARCs).
   Methods
   A comprehensive literature search of the PubMed and Web of Science databases was conducted to identify papers on the association between gout and cataract risk that had been published between February 1991 and January 2017. Pooled relative risks (RRs) or odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were calculated. The random-effects model was used instead of the fixed-effects model when heterogeneity was identified, as indicated by a Cochran's Q statistic P-value <0.10 or I2 index score >50%.
   Results
   A total of 3 cross-sectional studies and 3 case-control studies were included in the meta-analysis. Gout was significantly associated with increased odds of ARCs (OR 1.53, 95% CI 1.27-1.84). In the subgroup analysis, gout exhibited positive associations with the odds of posterior subcapsular cataracts (PSCs, OR 1.69, 95% CI: 1.06-2.70) and cortical cataracts (CCs, OR 1.39, 95% CI: 1.06-1.81). However, no association was identified between gout and the odds of nuclear cataracts.
   Conclusions
   The current literature suggested that gout may be associated with increased odds of ARCs, especially PSCs and CCs. Further efforts should be made to confirm these findings and clarify the effect of gout and gout medications on the development of cataracts.
C1 [Luo, Chenqi; Chen, Xinyi; Yao, Ke] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou, Zhejiang, Peoples R China.
   [Jin, Hongchuan] Zhejiang Univ, Sir Runrun Shaw Hosp, Dept Med Oncol, Key Lab Biotherapy Zhejiang,Med Sch, Hangzhou, Zhejiang, Peoples R China.
RP Yao, K (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou, Zhejiang, Peoples R China.; Jin, HC (reprint author), Zhejiang Univ, Sir Runrun Shaw Hosp, Dept Med Oncol, Key Lab Biotherapy Zhejiang,Med Sch, Hangzhou, Zhejiang, Peoples R China.
EM jinhc@zju.edu.cn; xlren@zju.edu.cn
FU Zhejiang Key Laboratory Fund of China [2011E10006]; National Natural
   Science Foundation of China [81570822]
FX This work was supported by Zhejiang Key Laboratory Fund of China (Grant
   No. 2011E10006) and the National Natural Science Foundation of China
   (Grant No. 81570822).
CR Asbell PA, 2005, LANCET, V365, P599
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Dalbeth N, 2016, LANCET, V388, P2039, DOI 10.1016/S0140-6736(16)00346-9
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FRAUNFELDER FT, 1982, AM J OPHTHALMOL, V94, P137, DOI 10.1016/0002-9394(82)90067-8
   Garbe E, 1998, ARCH OPHTHALMOL-CHIC, V116, P1652, DOI 10.1001/archopht.116.12.1652
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   LERMAN S, 1984, AM J OPHTHALMOL, V97, P205, DOI 10.1016/S0002-9394(14)76091-X
   LERMAN S, 1982, AM J OPHTHALMOL, V94, P141, DOI 10.1016/0002-9394(82)90068-X
   Leske MC, 1998, AM J EPIDEMIOL, V147, P36
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   LIU C S C, 1988, Eye (London), V2, P600
   McCarty CA, 2000, INVEST OPHTH VIS SCI, V41, P3720
   McCarty CA, 1999, AM J OPHTHALMOL, V128, P446, DOI 10.1016/S0002-9394(99)00218-4
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Mukesh BN, 2006, ARCH OPHTHALMOL-CHIC, V124, P79, DOI 10.1001/archopht.124.1.79
   Pascolini D, 2010, BR J OPHTHALMOL, V96, P614, DOI DOI 10.1136/BJ0PHTHALM0L-2011-300539
   Pogue J, 1998, LANCET, V351, P47, DOI 10.1016/S0140-6736(97)08461-4
   Robman L, 2005, EYE, V19, P1074, DOI 10.1038/sj.eye.6701964
   Tarwadi KV, 2011, NUTRITION, V27, P40, DOI 10.1016/j.nut.2009.11.015
   TSUKIDATE K, 1993, AM J PATHOL, V143, P918
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Wu RY, 2010, ARCH OPHTHALMOL-CHIC, V128, P1029, DOI 10.1001/archophthalmol.2010.147
   Zubenko GS, 2007, J GERONTOL A-BIOL, V62, P500, DOI 10.1093/gerona/62.5.500
NR 27
TC 1
Z9 1
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 29
PY 2017
VL 12
IS 6
AR e0180188
DI 10.1371/journal.pone.0180188
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EZ3JX
UT WOS:000404608300122
PM 28662131
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, HY
   Han, Y
   Chen, XS
   Bai, L
   Guo, SP
   Li, L
   Wu, P
   Yin, YP
AF Liu, Hong-ye
   Han, Yan
   Chen, Xiang-sheng
   Bai, Li
   Guo, Shu-ping
   Li, Li
   Wu, Peng
   Yin, Yue-ping
TI Comparison of efficacy of treatments for early syphilis: A systematic
   review and network meta-analysis of randomized controlled trials and
   observational studies
SO PLOS ONE
LA English
DT Review
AB Background
   Parenteral penicillin is the first-line regimen for treating syphilis, but unsuitable for some patients due to penicillin allergy and lacking health resources. Unfortunately, the efficacy of penicillin alternatives remains poorly understood. This study aimed to assess the efficacy of ceftriaxone and doxycycline/tetracycline in treating early syphilis relative to that of penicillin, and thereby to determine which antibiotic is a better replacement for penicillin.
   Method
   By searching literature from PubMed, Cochrane Central Register of Controlled Trials, Embase, the Web of Science, and ClinicalTrials. gov and systematically screening relevant studies, eligible randomized controlled trials (RCTs) and observational studies on treatments with penicillin, doxycycline/tetracycline, and ceftriaxone for early syphilis were identified and combined in this systematic review. Estimated risk ratios (RRs) and 95% confidence intervals (CIs) were utilized to compare their serological response and treatment failure rates. At 12-month follow up, serological response rates were compared by a direct meta-analysis and network meta-analysis (NMA), while treatment failure rates were compared with a direct meta-analysis.
   Result
   Three RCTs and seven cohort studies were included in this research. The results of NMA demonstrated that no significant differences existed in serological response rate at 12month follow-up between any two of the three treatments (doxycycline/tetracycline vs. penicillin RR = 1.01, 95% CI 0.89-1.14; ceftriaxone vs. penicillin RR = 1.00, 95% CI 0.89-1.13; ceftriaxone vs. doxycycline/tetracycline RR = 0.99, 95% CI 0.96-1.03), which was consistent with the outcomes of the direct meta-analysis. In addition, the direct meta-analysis indicated that, at 12-month follow-up, penicillin and ceftriaxone treatment groups had similar treatment failure rates (RR = 0.92, 95% CI 0.12-6.93), while treatment failure rate was significantly lower among penicillin recipients than among doxycycline/tetracycline recipients (RR = 0.58, 95% CI 0.38-0.89).
   Conclusion
   Ceftriaxone is as effective as penicillin in treating early syphilis with regard to serological response and treatment failure rate. Compared with doxycycline/tetracycline, ceftriaxone appears to be a better choice as the substitution of penicillin.
C1 [Liu, Hong-ye; Han, Yan; Chen, Xiang-sheng; Yin, Yue-ping] Chinese Acad Med Sci, Peking Union Med Coll, Inst Dermatol,Chinese CDC, Reference STD Lab,Natl Ctr STD Control,Jiangsu Ke, Nanjing, Jiangsu, Peoples R China.
   [Liu, Hong-ye; Bai, Li; Guo, Shu-ping; Li, Li] Shanxi Med Univ, Affiliated Hosp 1, Dept Dermatol & Venereol, Taiyuan, Peoples R China.
   [Wu, Peng] Shanxi Med Univ, Sch Publ Hlth, Hlth Stat Teaching & Res Sect, Taiyuan, Peoples R China.
RP Yin, YP (reprint author), Chinese Acad Med Sci, Peking Union Med Coll, Inst Dermatol,Chinese CDC, Reference STD Lab,Natl Ctr STD Control,Jiangsu Ke, Nanjing, Jiangsu, Peoples R China.
EM yinyp@ncstdlc.org
FU Scientific and technological innovation projects of medicine and health
   of Chinese Academy of Medical Sciences [2016-I2M-3-021]
FX This work was supported by Scientific and technological innovation
   projects of medicine and health of Chinese Academy of Medical Sciences
   (2016-I2M-3-021). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ARCILLA JD, 1974, CURR THER RES CLIN E, V16, P1126
   Bai ZG, 2012, COCHRANE DB SYST REV, V6, pD7270
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen XS, 2013, CLIN MICROBIOL INFEC, V19, P975, DOI 10.1111/1469-0691.12098
   Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5
   Clement ME, 2014, JAMA-J AM MED ASSOC, V312, P1905, DOI 10.1001/jama.2014.13259
   Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767
   Eaton Molly, 2009, Curr Infect Dis Rep, V11, P157, DOI 10.1007/s11908-009-0023-5
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ghanem KG, 2006, CLIN INFECT DIS, V42, pE45, DOI 10.1086/500406
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hook EW, 2010, J INFECT DIS, V201, P1729, DOI 10.1086/652239
   Hook ER, 2004, NEW ENGL J MED, V2, P122
   Hutton B, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5798
   Janier M, 2014, J EUR ACAD DERMATOL, V28, P1581, DOI 10.1111/jdv.12734
   Karp G, 2009, EUR J INTERN MED, V20, P9, DOI 10.1016/j.ejim.2008.04.002
   Kingston M, 2016, INT J STD AIDS, V27, P421, DOI 10.1177/0956462415624059
   Li J, 2014, J INFECT DEV COUNTR, V8, P228, DOI [10.3855/jidc.3013, 10.3855/jidc.3103]
   Liang Z, 2016, INT J ANTIMICROB AG, V47, P6, DOI 10.1016/j.ijantimicag.2015.10.020
   Lukehart SA, 2004, NEW ENGL J MED, V351, P154, DOI 10.1056/NEJMoa040216
   Merins V, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-015-0175-8
   MOORTHY TT, 1987, SEX TRANSM DIS, V14, P116, DOI 10.1097/00007435-198704000-00013
   Potthoff A, 2009, HIV MED, V10, P21
   Psomas KC, 2012, MED MALADIES INFECT, V42, P15, DOI 10.1016/j.medmal.2011.10.003
   Riedner G, 2005, NEW ENGL J MED, V353, P1236, DOI 10.1056/NEJMoa044284
   Robertson C, 2013, BJU INT, V112, P798, DOI 10.1111/bju.12247
   SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471
   SCOFER H, 1989, CHEMOTHERAPY, V35, P140, DOI 10.1159/000238661
   Spornraft-Ragaller P, 2011, EUR J MED RES, V16, P47, DOI 10.1186/2047-783X-16-2-47
   Stamm LV, 2010, ANTIMICROB AGENTS CH, V54, P583, DOI 10.1128/AAC.01095-09
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stegeman BH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5298
   Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187
   Tsai JC, 2014, PLOS ONE, P10
   Verde PE, 2015, RES SYNTH METHODS, V6, P45, DOI 10.1002/jrsm.1122
   Whitehead A., 2002, METAANALYSIS CONTROL
   Wong T, 2008, AM J MED, V121, P903, DOI 10.1016/j.amjmed.2008.04.042
   Workowski KA, 2015, MMWR RECOMM REP, V64, P1
   Yates AB, 2008, AM J MED, V121, P572, DOI 10.1016/j.amjmed.2007.12.005
   Zetola NM, 2007, MAYO CLIN PROC, V82, P1091, DOI 10.4065/82.9.1091
NR 42
TC 4
Z9 4
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 28
PY 2017
VL 12
IS 6
AR e0180001
DI 10.1371/journal.pone.0180001
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EZ3JT
UT WOS:000404607900050
PM 28658325
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ye, YC
   Yang, M
   Zhang, SY
   Zeng, Y
AF Ye, Yicong
   Yang, Ming
   Zhang, Shuyang
   Zeng, Yong
TI Percutaneous coronary intervention in left main coronary artery disease
   with or without intravascular ultrasound: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID ELUTING STENT IMPLANTATION; 5-YEAR OUTCOMES; BYPASS-SURGERY; IMPACT;
   GUIDANCE; LESIONS
AB This meta-analysis compared IVUS-guided with angiography-guided PCI to determine the effect of IVUS on the mortality in patients with LM CAD. Current guidelines recommend intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI)) in patients with left main coronary artery disease (LM CAD; Class IIa, level of evidence B). A systematic search of the MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases was conducted to identify randomized or non-randomized studies comparing IVUS-guided PCI with angiography-guided PCI in LM CAD. Ten studies (9 non-randomized and 1 randomized) with 6,480 patients were included. The primary outcome was mortality including all-cause death and cardiac death. Compared with angiography-guide PCI, IVUS-guided PCI was associated with significantly lower risks of all-cause death (risk ratio [RR] 0.60, 95% confidence interval [CI] 0.47-0.75, p<0.001), cardiac death (RR 0.47, 95% CI 0.33-0.66, p<0.001), target lesion revascularization (RR 0.43, 95% CI 0.25-0.73, p = 0.002), and in-stent thrombosis (RR 0.28, 95% CI 0.12-0.67, p = 0.004). Subgroup analyses indicated the beneficial effect of IVUS-guide PCI was consistent across different types of studies (unadjusted non-randomized studies, propensity score-matched non-randomized studies, or randomized trial), study populations (Asian versus non-Asian), and lengths of follow-up (<3 years versus >= 3 years). IVUS-guided PCI in LM CAD significantly reduced the risks of all-cause death by similar to 40% compared with conventional angiography-guided PCI.
C1 [Zhang, Shuyang; Zeng, Yong] Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Cardiol, Beijing, Peoples R China.
   Chinese Acad Med Sci, Beijing, Peoples R China.
RP Zhang, SY; Zeng, Y (reprint author), Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Cardiol, Beijing, Peoples R China.
EM pumchzhangsy@163.com; pumchzy@163.com
OI Zhang, Shuyang/0000-0002-1532-0029
FU CAMS Major Collaborative Innovation Project [2016-I2M-1-011]
FX This work was supported by CAMS Major Collaborative Innovation Project
   (No. 2016-I2M-1-011). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.; This work was supported by CAMS Major Collaborative
   Innovation Project (No. 2016-I2M-1-011).
CR Agostoni P, 2005, AM J CARDIOL, V95, P644, DOI 10.1016/j.amjcard.2004.10.042
   Ahn JM, 2015, J AM COLL CARDIOL, V65, P2198, DOI 10.1016/j.jacc.2015.03.033
   Andell P, 2017, CIRC-CARDIOVASC INTE, V10, DOI 10.1161/CIRCINTERVENTIONS.116.004813
   Bavishi C, 2017, AM HEART J, V185, P26, DOI [10.10164/j.ahj.2016.10.008, 10.1016/j.ahj.2016.10.008]
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Capodanno D, 2011, J AM COLL CARDIOL, V58, P1426, DOI 10.1016/j.jacc.2011.07.005
   Chen SL, 2013, CATHETER CARDIO INTE, V81, P456, DOI 10.1002/ccd.24601
   Hernandez JM, 2014, JACC-CARDIOVASC INTE, V7, P244, DOI 10.1016/j.jcin.2013.09.014
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DETRE KM, 1975, CIRCULATION, V52, P979, DOI 10.1161/01.CIR.52.6.979
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FISHER LD, 1982, CATHETER CARDIO DIAG, V8, P565, DOI 10.1002/ccd.1810080605
   Furuichi S, 2007, CATHETER CARDIO INTE, V70, P856, DOI 10.1002/ccd.21219
   Gao XF, 2014, PATIENT PREFER ADHER, V8, P1299, DOI 10.2147/PPA.S65768
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jama A, 2011, J AM COLL CARDIOL, V58, pB167
   Kang SJ, 2014, CATHETER CARDIO INTE, V83, P545, DOI 10.1002/ccd.25057
   Kang SJ, 2011, CIRC-CARDIOVASC INTE, V4, P562, DOI 10.1161/CIRCINTERVENTIONS.111.964643
   Kim BK, 2015, CIRC-CARDIOVASC INTE, V8, DOI 10.1161/CIRCINTERVENTIONS.115.002592
   Kinoshita N, 2010, AM J CARDIOL, V105, p59B
   Kolh P, 2014, EUR J CARDIO-THORAC, V46, P517, DOI [10.1093/eurheartj/ehu278, 10.1093/ejcts/ezu366]
   Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006
   Morice MC, 2014, CIRCULATION, V129, P2388, DOI 10.1161/CIRCULATIONAHA.113.006689
   Narbute I, 2012, EURO INTERVENTION J, V8, pN101
   Nerlekar N, 2016, EUROINTERVENTION J E, Patent No. 27840327
   Oviedo C, 2010, CIRC-CARDIOVASC INTE, V3, P105, DOI 10.1161/CIRCINTERVENTIONS.109.906016
   Park SH, 2012, AM J CARDIOL, V109, p123S, DOI 10.1016/j.amjcard.2012.01.433
   Park Seung-Jung, 2015, EuroIntervention, V11 Suppl V, pV120, DOI 10.4244/EIJV11SVA27
   Park SJ, 2009, CIRC-CARDIOVASC INTE, V2, P167, DOI 10.1161/CIRCINTERVENTIONS.108.799494
   Park SJ, 2001, J AM COLL CARDIOL, V38, P1054, DOI 10.1016/S0735-1097(01)01491-7
   Park Y, 2011, INT J CARDIOL, V148, P174, DOI 10.1016/j.ijcard.2009.10.052
   Roh Jae-Hyung, 2015, EuroIntervention, V11 Suppl V, pV125, DOI 10.4244/EIJV11SVA28
   Shah BR, 2005, J CLIN EPIDEMIOL, V58, P550, DOI 10.1016/j.jclinepi.2004.10.016
   Shin DH, 2016, JACC-CARDIOVASC INTE, V9, P2232, DOI [10.1016/j.jcin.2016.07.021, 10.1016/j.jcin.2016.07.02]
   Stone GW, 2016, NEW ENGL J MED, V375, P2223, DOI 10.1056/NEJMoa1610227
   Tan Q, 2015, SAUDI MED J, V36, P549, DOI 10.15537/smj.2015.5.11251
   Tang YD, 2016, J AM COLL CARDIOL, V68, pB224, DOI 10.1016/j.jacc.2016.09.693
   Trac MH, 2016, CAN MED ASSOC J, V188, pE120, DOI 10.1503/cmaj.150901
   Valentine JC, 2013, RES SYNTH METHODS, V4, P26, DOI 10.1002/jrsm.1064
   ZIR LM, 1976, CIRCULATION, V53, P627, DOI 10.1161/01.CIR.53.4.627
NR 41
TC 14
Z9 16
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 22
PY 2017
VL 12
IS 6
AR e0179756
DI 10.1371/journal.pone.0179756
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EY6ZV
UT WOS:000404135800060
PM 28640875
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Song, W
   Tian, C
   Wang, K
   Zhang, RJ
   Zou, SB
AF Song, Wei
   Tian, Chuan
   Wang, Kai
   Zhang, Run-jin
   Zou, Shu-bing
TI Preoperative platelet lymphocyte ratio as independent predictors of
   prognosis in pancreatic cancer: A systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID NEUTROPHIL-LYMPHOCYTE; DUCTAL ADENOCARCINOMA; SURVIVAL; INFILTRATION;
   STATISTICS; LEVEL; CELLS
AB Background
   Recently, the preoperative platelet to lymphocyte ratio (PLR) has been found reported to predict oncologic outcomes in multiple malignancies. However, its prognostic value in patients with pancreatic cancer (PC) remains controversial. The aim of this study was to assess the prognostic value of preoperative PLR in PC.
   Methods
   MEDLINE, EMBASE, and Cochrane databases were searched to identify studies evaluating the prognostic significance of preoperative PLR in PC. Pooled hazard ratios (HRs) for overall survival (OS) were calculated using fixed-effects/random-effects models.
   Results
   A total of eight studies comprising 1,904 patients with PC were included in the meta-analysis. The pooled analysis demonstrated that elevated PLR had an association with decreased OS (HR: 1.22, 95% CI: 1.04-1.43, p = 0.02). Subgroup analysis showed that a high PLR significantly predicted poor OS in Asian studies (HR: 1.25, 95% CI: 1.03-1.52, p = 0.02), patients with metastatic disease (HR: 1.34, 95% CI: 1.01-1.77, p = 0.04) and patients with PLR > 150 (HR: 1.73, 95% CI: 1.21-2.49, p = 0.003).
   Conclusions
   The preoperative PLR may be a significant independent prognostic factor in patients with PC.
C1 [Song, Wei; Wang, Kai; Zhang, Run-jin; Zou, Shu-bing] Nanchang Univ, Affiliated Hosp 2, Dept Hepatobiliary Surg, Nanchang, Jiangxi, Peoples R China.
   [Tian, Chuan] Guizhou Prov Peoples Hosp, Dept Nucl Med, Guiyang, Peoples R China.
RP Zou, SB (reprint author), Nanchang Univ, Affiliated Hosp 2, Dept Hepatobiliary Surg, Nanchang, Jiangxi, Peoples R China.
EM tofsw@sina.com
CR Asari S, 2016, SURG TODAY, V46, P583, DOI 10.1007/s00595-015-1206-3
   Banks RE, 1998, BRIT J CANCER, V77, P956, DOI 10.1038/bjc.1998.158
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brimnes MK, 2010, SCAND J IMMUNOL, V72, P540, DOI 10.1111/j.1365-3083.2010.02463.x
   Ceze N, 2011, CANCER CHEMOTH PHARM, V68, P1305, DOI 10.1007/s00280-011-1610-3
   Dogan M, 2015, EUR J CANCER, V51, pS429, DOI 10.1016/S0959-8049(16)31208-4
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Facciorusso A, 2016, WORLD J GASTROENTERO, V22, P4211, DOI 10.3748/wjg.v22.i16.4211
   Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Hoffmann TK, 2002, CLIN CANCER RES, V8, P2553
   Kitayama J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-64
   Kou T, 2016, INT J CLIN ONCOL, V21, P118, DOI 10.1007/s10147-015-0864-x
   Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Man YG, 2013, J CANCER, V4, P84, DOI 10.7150/jca.5482
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Martin HL, 2014, INTERN MED J
   Nakamura K, 2016, ONCOL LETT, V11, P3975, DOI 10.3892/ol.2016.4513
   Obata J, 2016, BJU INT, V118, P598, DOI 10.1111/bju.13414
   Palumbo JS, 2010, THROMB RES, V125, pS39, DOI 10.1016/S0049-3848(10)70011-6
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Sarkut P, 2016, HPB, V18, pe426
   Shirai Y, 2015, SURGERY, V158, P360, DOI 10.1016/j.surg.2015.03.043
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Vayrynen JP, 2013, BRIT J CANCER, V109, P1839, DOI 10.1038/bjc.2013.508
   WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646
   Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224
NR 30
TC 13
Z9 13
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 2
PY 2017
VL 12
IS 6
AR e0178762
DI 10.1371/journal.pone.0178762
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EW6MJ
UT WOS:000402624300111
PM 28575033
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, YY
   Zhao, Y
   Wu, JP
AF Li, Yuanyuan
   Zhao, Ying
   Wu, Jianping
TI Serum HBV surface antigen positivity is associated with low prevalence
   of metabolic syndrome: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID HEPATITIS-B-VIRUS; NONALCOHOLIC FATTY LIVER; INSULIN-RESISTANCE;
   DIABETES-MELLITUS; INCREASED RISK; INFECTION; DISEASE; POPULATION;
   STEATOSIS; CARRIERS
AB Background and aim
   As there is conflicting evidence for the relationship between hepatitis B virus surface antigen (HBsAg) positivity and the prevalence of metabolic syndrome (MetS), we performed a metaanalysis to investigate whether HBsAg positivity affects the incidence of MetS.
   Methods
   Observational studies on the relationship between HBsAg positivity and MetS were obtained from PubMed, Web of Science, and the Cochrane Library in April 2016. The pooled odds ratios (ORs) of MetS and its components (central obesity, increased fasting glucose, increased blood pressure, dyslipidemia) for subjects with or without HBsAg positivity were synthesized. The standardized mean difference of MetS components between HBsAg-positive participants and healthy controls was calculated. Heterogeneity was explored with subgroup analysis and sensitivity analysis. Publication bias was detected using Egger's test and Begg's test.
   Results
   Thirty studies were eligible for meta-analysis. The MetS OR for HBsAg-positive participants was significantly decreased compared with the controls [OR = 0.80, 95% confidence interval (CI), 0.70-0.90]. The negative effect of HBsAg positivity on elevated triglycerides (OR = 0.62, 95% CI, 0.59-0.64) was strong, while that for increased fasting blood glucose was weak (OR = 0.94, 95% CI, 0.90-0.98). The pooled ORs of central obesity (OR = 0.97, 95% CI, 0.91-1.04), reduced high-density lipoprotein cholesterol (OR = 0.98, 95% CI, 0.83-1.14), and elevated blood pressure (OR = 1.00, 95% CI, 0.80-1.25) for HBsAg-positive participants were all not significantly different compared with the controls. No publication bias was detected.
   Conclusions
   Serum HBsAg positivity is inversely associated with the prevalence of MetS. Among the five components of MetS, elevated triglycerides had the strongest inverse relationship with HBsAg positivity.
C1 [Li, Yuanyuan; Zhao, Ying; Wu, Jianping] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Lab Med, Hangzhou, Zhejiang, Peoples R China.
RP Wu, JP (reprint author), Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Lab Med, Hangzhou, Zhejiang, Peoples R China.
EM jpwuzyyy@126.com
FU Medical Science and Technology Project of Zhejiang Province [2016KYB107]
FX Support was provided by the Medical Science and Technology Project of
   Zhejiang Province (2016KYB107); [http://kj.zjwst.gov.cn/]. The funders
   played roles in decision to publish and preparation of the manuscript.
CR Ahmadieh H, 2014, DIABETES RES CLIN PR, V104, P53, DOI 10.1016/j.diabres.2014.01.003
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen JY, 2010, J GASTROEN HEPATOL, V25, P1763, DOI 10.1111/j.1440-1746.2010.06300.x
   Cheng Y., 2013, PLOS ONE, V8
   Chiang CH, 2014, WORLD J GASTROENTERO, V20, P7213, DOI 10.3748/wjg.v20.i23.7213
   Chiang CH, 2013, OBESITY, V21, P291, DOI 10.1002/oby.20000
   Choi JS, 2015, J EPIDEMIOL, V25, P74, DOI 10.2188/jea.JE20140053
   Chu CM, 2007, INT J OBESITY, V31, P871, DOI 10.1038/sj.ijo.0803479
   Chung TH, 2014, KOREAN J FAM MED, V35, P81, DOI 10.4082/kjfm.2014.35.2.81
   Dai Fu-hong, 2012, Zhonghua Gan Zang Bing Za Zhi, V20, P517, DOI 10.3760/cma.j.issn.1007-3418.2012.07.008
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Eckel RH, 2010, LANCET, V375, P181, DOI 10.1016/S0140-6736(09)61794-3
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fan JY, 2015, CANCER NURS, V38, P169, DOI 10.1097/NCC.0000000000000153
   Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6
   Ha M, 2015, OBES RES CLIN PRACT
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Holstein A, 2002, J GASTROEN HEPATOL, V17, P677, DOI 10.1046/j.1440-1746.2002.02755.x
   Hsieh PS, 2011, WORLD J GASTROENTERO, V17, P5240, DOI 10.3748/wjg.v17.i48.5240
   Hsu CS, 2012, J VIRAL HEPATITIS, V19, pE48, DOI 10.1111/j.1365-2893.2011.01535.x
   Hsu CS, 2015, HEPATOL INT, V9, P231, DOI 10.1007/s12072-015-9616-2
   Huang CY, 2016, OBESITY, V24, P483, DOI 10.1002/oby.21333
   Huang ZS, 2010, J GASTROEN HEPATOL, V25, P1420, DOI 10.1111/j.1440-1746.2010.06268.x
   Ishizaka N, 2008, HEPATOL RES, V38, P775, DOI 10.1111/j.1872-034X.2008.00334.x
   Jan CF, 2006, INT J OBESITY, V30, P794, DOI 10.1038/sj.ijo.0803204
   Jarcuska P, 2014, EUR J INTERN MED, V25, P286, DOI 10.1016/j.ejim.2014.01.006
   Jinjuvadia R, 2014, AM J MED SCI, V347, P23, DOI 10.1097/MAJ.0b013e31828b25a5
   Karsen H, 2012, AFR HEALTH SCI, V12, P114, DOI 10.4314/ahs.v12i2.6
   Katoonizadeh A, 2016, J MED VIROL, V88, P1230, DOI 10.1002/jmv.24466
   Kim KH, 2007, GASTROENTEROLOGY, V132, P1955, DOI 10.1053/j.gastro.2007.03.039
   Lee JG, 2012, WORLD J GASTROENTERO, V18, P6120, DOI 10.3748/wjg.v18.i42.6120
   Li WC, 2013, LIVER INT, V33, P1194, DOI 10.1111/liv.12224
   Lin YC, 2007, WORLD J GASTROENTERO, V13, P1805, DOI 10.3748/wjg.v13.i12.1805
   Liu PT, 2013, METABOLISM, V62, P220, DOI 10.1016/j.metabol.2012.07.022
   Locarnini S, 2015, J HEPATOL, V62, pS76, DOI 10.1016/j.jhep.2015.01.018
   Luo BY, 2007, CLIN CHIM ACTA, V380, P238, DOI 10.1016/j.cca.2007.01.012
   Machado MV, 2011, J GASTROEN HEPATOL, V26, P1361, DOI 10.1111/j.1440-1746.2011.06801.x
   Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161
   McManus DD, 2012, OBESITY, V20, P1882, DOI 10.1038/oby.2011.32
   Moritani M, 2005, J GASTROENTEROL, V40, P1049, DOI 10.1007/s00535-005-1655-3
   Park B, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000091
   Patton HM, 2010, AM J GASTROENTEROL, V105, P2093, DOI 10.1038/ajg.2010.152
   Qiao LP, 2008, DIABETES, V57, P1824, DOI 10.2337/db07-0435
   Sheikh MY, 2008, HEPATOLOGY, V47, P2127, DOI 10.1002/hep.22269
   Shlomai A, 2008, MED HYPOTHESES, V71, P53, DOI 10.1016/j.mehy.2007.08.032
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Su TC, 2004, J FORMOS MED ASSOC, V103, P286
   Targher G, 2007, J HEPATOL, V46, P1126, DOI 10.1016/j.jhep.2007.01.021
   Wang CC, 2008, J GASTROEN HEPATOL, V23, P779, DOI 10.1111/j.1440-1746.2007.05216.x
   Wang CC, 2015, J GASTROEN HEPATOL, V30, P14, DOI 10.1111/jgh.12700
   Wells GA, NEWCASTLE OTTAWA SCA
   Wong VWS, 2012, J HEPATOL, V56, P533, DOI 10.1016/j.jhep.2011.09.013
   Wong VWS, 2010, AM J GASTROENTEROL, V105, P132, DOI 10.1038/ajg.2009.560
   Yang KC, 2007, ATHEROSCLEROSIS, V195, P392, DOI 10.1016/j.atherosclerosis.2006.10.018
   Yang KC, 2016, SCI REP-UK, V6, DOI 10.1038/srep27034
NR 58
TC 4
Z9 4
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 15
PY 2017
VL 12
IS 5
AR e0177713
DI 10.1371/journal.pone.0177713
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EV0YN
UT WOS:000401473500035
PM 28505202
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, D
   Li, QP
   Gong, YH
   Yuan, Y
AF Wang, Dan
   Li, Qiuping
   Gong, Yuehua
   Yuan, Yuan
TI The association between vacA or cagA status and eradication outcome of
   Helicobacter pylori infection: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID NONULCER DYSPEPSIA; VIRULENCE FACTORS; PEPTIC-ULCER; TREATMENT FAILURE;
   CONTROLLED-TRIAL; GASTRIC-CANCER; TRIPLE THERAPY; RESISTANCE; STRAINS;
   EFFICACY
AB Background
   H. pylori virulence factors, especially vacA and cagA are important in gastroduodenal disease pathogenesis and affect cure rates. This meta-analysis aimed to clarify the association between vacA or cagA status and eradication outcome of H. pylori infection.
   Methods
   A literature search was performed using electronic databases to identify studies. Twenty-six prospective studies were determined eligible. Meta-analytical techniques were conducted to calculate eradication rates and pooled relative ratios (RR).
   Results
   The eradication rate was greater approximately 10% in vacA s1 compared with vacA s2 infected patients, and the pooled RR was 1.164 (95% CI: 1.040-1.303, P = 0.008). A significant association existed between vacA s1 and higher eradication rates in Europe (RR: 1.203, 95% CI: 1.003-1.442, P = 0.046) and Asia (RR: 1.187, 95% CI: 1.028-1.371, P = 0.020), in triple therapy patients (RR: 1.175, 95% CI: 1.012-1.365, P = 0.035). Eradication rates were similar for vacA m1 and m2 genotypes (RR: 0.981, 95% CI: 0.891-1.080, P = 0.690), whereas they were higher by approximately 8% in cagA-positive compared with cagA-negative infected patients, with a pooled RR of 1.094 (95% CI: 1.025-1.168, P = 0.007). A significant association existed between cagA-positive and increased eradication rates in Europe (RR: 1.138, 95% CI: 1.000-1.295, P = 0.049) and Asia (RR: 1.118, 95% CI: 1.051-1.190, P<0.001), in using PCR (RR: 1.232, 95% CI: 1.142-1.329, P<0.001) and protein chips (RR: 1.200, 95% CI: 1.060-1.359, P = 0.004), in triple therapy patients (RR: 1.090, 95% CI: 1.006-1.181, P = 0.034).
   Conclusions
   Evidence indicates that infection with vacA s1, cagA-positive strains, but not vacA s2, cagA-negative, is more conducive to H. pylori eradication.
C1 [Gong, Yuehua; Yuan, Yuan] China Med Univ, Tumor Etiol & Screening Dept, Canc Inst, Affiliated Hosp 1, Shenyang, Peoples R China.
   China Med Univ, Affiliated Hosp 1, Gen Surg, Shenyang, Peoples R China.
   China Med Univ, Key Lab Canc Etiol & Prevent, Liaoning Prov Educ Dept, Shenyang, Peoples R China.
RP Gong, YH; Yuan, Y (reprint author), China Med Univ, Tumor Etiol & Screening Dept, Canc Inst, Affiliated Hosp 1, Shenyang, Peoples R China.
EM yhgong@cmu.edu.cn; yuanyuan@cmu.edu.cn
CR Baryshnikova NV, 2012, HELICOBACTER, V17, P105
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boyanova L, 2016, MICROB DRUG RESIST, V22, P227, DOI 10.1089/mdr.2015.0199
   Broutet N, 2001, J CLIN MICROBIOL, V39, P1319, DOI 10.1128/JCM.39.4.1319-1322.2001
   Cen C, 2009, GUANG XI MED J, V01
   Chaudhuri S, 2003, J GASTROEN HEPATOL, V18, P190, DOI 10.1046/j.1440-1746.2003.02944.x
   Cui MH, 2013, CHINESE GEN PRACTICE, V08
   De Francesco V, 2004, ALIMENT PHARM THER, V19, P407, DOI 10.1046/j.1365-2036.2004.01818.x
   De Francesco V, 2002, AM J GASTROENTEROL, V97, P2686, DOI 10.1016/S0002-9270(02)04420-9
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Greenberg PD, 1999, ARCH INTERN MED, V159, P2283, DOI 10.1001/archinte.159.19.2283
   Hajimahmoodi M, 2011, NAT PROD RES, V25, P1059, DOI 10.1080/14786419.2010.501763
   He CY, 2014, MUTAT RES-REV MUTAT, V759, P14, DOI 10.1016/j.mrrev.2013.09.002
   [何兴祥 He Xingxiang], 2002, [中国抗生素杂志, Chinese Journal of Antibiotics], V27, P427
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Huang YN, 2012, CLIN OBSERVATION ECA
   Kim IJ, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00037
   Lerro P, 2000, ACTA PAEDIAT, V89
   Liu JW, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-555
   Lopez-Brea M, 1999, FEMS IMMUNOL MED MIC, V24, P183, DOI 10.1016/S0928-8244(99)00024-3
   Magalhaes A F Novaes de, 2005, Gastroenterol Hepatol, V28, P441
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mao HV, 2000, ALIMENT PHARM THERAP, V14, P97
   Niu SL, 2014, CHINESE J PRACTICAL, V02
   Queiroz DMM, 2002, J CLIN GASTROENTEROL, V35, P315, DOI 10.1097/01.MCG.0000028650.86049.F1
   Rudi J, 2002, DIGESTION, V65, P11, DOI 10.1159/000051925
   Russo F, 2003, ALIMENT PHARM THER, V17, P421, DOI 10.1046/j.0269-2813.2003.01443.x
   Saruc M, 2001, REV BRASILEIRA PESQU, V34, P1435
   Scholte GHA, 2002, AM J GASTROENTEROL, V97, P1687, DOI 10.1111/j.1572-0241.2002.05775.x
   Shiota S, 2012, J CLIN GASTROENTEROL, V46, P297, DOI 10.1097/MCG.0b013e318243201c
   Spiller RC, 1999, EUR J GASTROEN HEPAT, V11, pS25
   Spiller RC, 1999, EUR J GASTROEN HEPAT, V11, pS43
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sugimoto M, 2009, EUR J CLIN MICROBIOL, V28, P1227, DOI 10.1007/s10096-009-0772-y
   Suzuki T, 2006, ALIMENT PHARM THER, V24, P273, DOI 10.1111/j.1365-2036.2006.02994.x
   Take S, 2015, J GASTROENTEROL, V50, P638, DOI 10.1007/s00535-014-1004-5
   Treiber G, 2002, ARCH INTERN MED, V162, P153, DOI 10.1001/archinte.162.2.153
   Uotani T, 2015, EXPERT OPIN THER TAR, V19, P1637, DOI 10.1517/14728222.2015.1073261
   van Doorn LJ, 2000, GUT, V46, P321, DOI 10.1136/gut.46.3.321
   van Doorn LJ, 1998, GASTROENTEROLOGY, V115, P58, DOI 10.1016/S0016-5085(98)70365-8
   van Doorn LJ, 2001, ANTIMICROB AGENTS CH, V45, P1500, DOI 10.1128/AAC.45.5.1500-1504.2001
   vanderHulst RWM, 1997, GASTROENTEROLOGY, V113, P25, DOI 10.1016/S0016-5085(97)70076-3
   Wu J, 2012, CLIN FOCUS, V19
   Xia HHX, 2003, ALIMENT PHARM THER, V17, P935, DOI 10.1046/j.0269-2813.2003.01525.x
   You WC, 2006, J NATL CANCER I, V98, P974, DOI 10.1093/jnci/djj264
   Zhao JJ, 2007, J GASTROEN HEPATOL, V22, P2251, DOI 10.1111/j.1440-1746.2007.04836.x
NR 47
TC 2
Z9 2
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 11
PY 2017
VL 12
IS 5
AR e0177455
DI 10.1371/journal.pone.0177455
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EU8UP
UT WOS:000401314300114
PM 28493953
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Jing, XR
   Lin, JR
   Wang, HW
   Tian, LY
   Tian, RH
   Zhang, YY
   Chen, X
   Zhang, JY
AF Jing, Xuran
   Lin, Jieru
   Wang, Hongwei
   Tian, Liyuan
   Tian, Runhua
   Zhang, Yunyuan
   Chen, Xian
   Zhang, Jinyu
TI Prognostic value of lncRNA SOX2OT for Chinese cancer patients: A
   meta-analysis
SO PLOS ONE
LA English
DT Article
ID LONG NONCODING RNA; GASTRIC-CANCER; HETEROGENEITY; INVOLVEMENT;
   PROGRESSION; STATISTICS; EXPRESSION; CARCINOMA
AB SOX2OT has been demonstrated to be aberrantly expressed in several types of cancer and maybe serve as a prognostic marker for cancer patients. However, most individual studies have been limited by small sample sizes and controversial results. Therefore, the present meta-analysis was conducted to analyze available data to reveal the potential clinical application of SOX2OT on cancer prognosis, tumor progression, distance metastasis and lymph node metastasis. Up to February 20, 2017, literature collections were conducted by comprehensive searching electronic databases, including Cochrane Library, PubMed, Embase, BioMed Central, Springer, ScienceDirect, ISI Web of Knowledge, together with three Chinese databases: China National Knowledge Internet (CNKI), Weipu and Wanfang. The hazard ratios (HR) with 95% confidence interval (95% CI) were calculated to assess the strength of the association. Five studies with a total of 481 cancer patients were included in the present meta-analysis. The results indicated that elevated SOX2OT significantly predicted unfavorable overall survival (OS) (HR = 2.44, 95% CI: 1.75-3.39, P<0.0001) and tumor progression (III/IV vs. I/II: HR 1.62, 95% CI: 1.30-2.02, P<0.0001), but failed to predict distant metastasis (HR: 3.30, 95% CI: 0.74-14.61, P = 0.12) and lymph node metastasis (HR: 1.29, 95% CI: 0.87-1.91, P = 0.21). The results revealed that SOX2OT expression level was an independent prognostic biomarker for OS and tumor progression in Chinese cancer patients.
C1 [Jing, Xuran; Tian, Liyuan] Qingdao Univ, Med Coll, Qingdao, Shandong, Peoples R China.
   [Lin, Jieru] Guizhou Prov Peoples Hosp, Dept Resp & Crit Care Med, Guiyang, Guizhou, Peoples R China.
   [Wang, Hongwei; Tian, Runhua; Zhang, Yunyuan; Chen, Xian] Qingdao Univ, Affiliated Hosp, Dept Clin Lab, Qingdao, Shandong, Peoples R China.
   [Tian, Runhua; Zhang, Jinyu] Qingdao Univ, Coll Med, Dept Biochem & Mol Biol, Qingdao, Shandong, Peoples R China.
RP Chen, X (reprint author), Qingdao Univ, Affiliated Hosp, Dept Clin Lab, Qingdao, Shandong, Peoples R China.; Zhang, JY (reprint author), Qingdao Univ, Coll Med, Dept Biochem & Mol Biol, Qingdao, Shandong, Peoples R China.
EM cxkakicoco2014@163.com; zhangjinyu6768@163.com
OI chen, xian/0000-0002-5141-7979
FU National Natural Science Foundation of China [81601821, 81501872]; China
   Postdoctoral Science Foundation [2016M590621, 2016M592144];
   Distinguished Middle-Aged and Young Scientist Encourage and Reward
   Foundation of Shandong Province [BS2014YY034]; Postdoctoral innovation
   project of Shandong Province [201603069]
FX This study is fully supported by the National Natural Science Foundation
   of China (No. 81601821 and No. 81501872), China Postdoctoral Science
   Foundation (No. 2016M590621 and No. 2016M592144), Distinguished
   Middle-Aged and Young Scientist Encourage and Reward Foundation of
   Shandong Province (No. BS2014YY034), Postdoctoral innovation project of
   Shandong Province (No. 201603069).
CR Askarian-Amiri ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102140
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bowden J, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-41
   Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Fantes J, 2003, NAT GENET, V33, P461, DOI 10.1038/ng1120
   Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hou ZB, 2014, INT J BIOCHEM CELL B, V53, P380, DOI 10.1016/j.biocel.2014.06.004
   Iranpour M, 2016, TUMOR BIOL, V37, P2933, DOI 10.1007/s13277-015-4135-2
   Johnsson P, 2014, BBA-GEN SUBJECTS, V1840, P1063, DOI 10.1016/j.bbagen.2013.10.035
   Maruyama R, 2012, BMB REP, V45, P604, DOI 10.5483/BMBRep.2012.45.11.227
   Moran VA, 2012, NUCLEIC ACIDS RES, V40, P6391, DOI 10.1093/nar/gks296
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Shahryari A, 2014, STEM CELLS, V32, P126, DOI 10.1002/stem.1542
   Shi XM, 2015, INT J CLIN EXP PATHO, V8, P4008
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638
   Tian D, 2010, CELL, V143, P390, DOI 10.1016/j.cell.2010.09.049
   Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483
   Wu YS, 2014, TUMOR BIOL, V35, P9531, DOI 10.1007/s13277-014-2523-7
   Zhang H, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-37
   Zhang YY, 2016, AM J TRANSL RES, V8, P5035
   Zhang YY, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018-015-0328-z
   Zou JH, 2016, EUR REV MED PHARMACO, V20, P4482
NR 26
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 10
PY 2017
VL 12
IS 5
AR e0176889
DI 10.1371/journal.pone.0176889
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EU8UN
UT WOS:000401314100034
PM 28489861
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ma, JJ
   Wu, DD
   Hu, X
   Li, J
   Cao, MW
   Dong, WG
AF Ma, Jingjing
   Wu, Dandan
   Hu, Xue
   Li, Jiao
   Cao, Mingwei
   Dong, Weiguo
TI Associations between cytokine gene polymorphisms and susceptibility to
   Helicobacter pylori infection and Helicobacter pylori related gastric
   cancer, peptic ulcer disease: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID INCREASED RISK; DUODENAL-ULCER; INTERLEUKIN-1 POLYMORPHISMS; CHINESE
   POPULATION; INDIAN POPULATION; TNF-ALPHA; IL-8; SEROPOSITIVITY;
   GENOTYPES; CHILDREN
AB Objectives
   The aim of this study is to clarify the associations between IL-1B31C/T, IL-1B-511C/T, IL-8-251T/A gene polymorphisms and the risk of Helicobacter pylori (H. pylori) infection together with H. pylori-related gastric cancer (GC), peptic ulcer disease (PUD).
   Methods
   All eligible literature published up to July 2016 were identified by searching Pubmed, Embase, Web of Science and CNKI. Pooled odds ratio (OR) and 95% confidence interval (95% CI) were calculated using a fixed or random effects model.
   Results
   29 case-control studies were eligible, and each of them may focus on more than one gene polymorphism. Ultimately, there were 21 studies (3159 cases and 2816 controls) for IL-1B-31C/T, 16 studies (2486 cases and 1989 controls) for IL-1B-511C/T polymorphisms, 9 studies (1963 cases and 1205 controls) for IL-8-251T/A polymorphisms. Overall, an increased risk of H. pylori infection was found for IL-1B-31C/T polymorphisms in total population [OR = 1.134, 95% CI = 1.008- 1.275 for recessive model; OR = 1.145, 95% CI = 1.007-1.301 for TT vs CC model]. While, for IL-1B-511C/T and IL8-251T/A polymorphisms, no evidence indicated that they were associated with the risk of H. pylori infection in all genetic models. Furthermore, we found an increased risk of H. pylori-related GC with IL-1B-511C/T polymorphisms [OR = 1.784, 95% CI = 1.289-2.469 for recessive model; OR = 1.772, 95% CI = 1.210-2.594 for TT vs CC model] and IL8-251A/T polymorphisms [OR = 1.810, 95% CI = 1.229-2.667 for recessive model; OR = 1.717, 95% CI = 1.143-2.580 for TT vs AA model], an increased risk of H. pylori-related PUD with IL8-251T/A polymorphisms [OR = 1.364, 95% CI = 1.010-1.843 for recessive model; OR = 1.427, 95% CI = 1.039-1.959 for AA vs TT model].
   Conclusions
   IL-1B-31C/T gene polymorphisms might increase H. pylori infection risk. IL-1B-511-C/T and IL-8-251T/A gene polymorphisms might act as a risk factor to H. pylori-related diseases including GC or PUD
C1 [Ma, Jingjing; Wu, Dandan; Hu, Xue; Li, Jiao; Cao, Mingwei; Dong, Weiguo] Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan, Hubei Province, Peoples R China.
RP Dong, WG (reprint author), Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan, Hubei Province, Peoples R China.
EM dwg@whu.edu.cn
FU Natural Science Fundation from Hubei province [81372551]
FX We received Natural Science Fundation from Hubei province for this work.
   The grant number is 81372551.
CR Abdiev S, 2010, NAGOYA J MED SCI, V72, P167
   Atherton JC, 1998, BRIT MED BULL, V54, P105
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Neto AC, 2014, J VENOM ANIM TOXINS, V20, DOI 10.1186/1678-9199-20-17
   Chakravorty M, 2006, HUM MUTAT, V27, P411, DOI 10.1002/humu.20299
   Chakravorty M, 2008, J GENET, V87, P299, DOI 10.1007/s12041-008-0048-9
   Chang YW, 2005, INT J CANCER, V114, P465, DOI 10.1002/ijc.20724
   Vinagre Ruth Maria Dias Ferreira, 2011, Arq. Gastroenterol., V48, P46, DOI 10.1590/S0004-28032011000100010
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4
   El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081
   Farshad S, 2010, IRAN J IMMUNOL, V7, P96, DOI IJIv7i2A5
   Furuta T, 2001, CLIN PHARMACOL THER, V69, P158, DOI 10.1067/mcp.2001.113959
   Go MF, 1997, GASTROENTEROLOGY, V113, pS15, DOI 10.1016/S0016-5085(97)80005-4
   Hamajima N, 2001, JPN J CANCER RES, V92, P383, DOI 10.1111/j.1349-7006.2001.tb01106.x
   Hamajima Nobuyuki, 2002, Asian Pac J Cancer Prev, V3, P23
   Hamis IB, 2015, J MICROBIOL IMMUNOL
   He BS, 2011, DIGEST DIS SCI, V56, P2017, DOI 10.1007/s10620-010-1557-y
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hofner P, 2007, HELICOBACTER, V12, P124, DOI 10.1111/j.1523-5378.2007.00481.x
   Hu S, 2005, WORLD J GASTROENTERO, V11, P6549, DOI 10.3748/wjg.v11.i41.6549
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Jayaraman P, 2013, J IMMUNOL, V190, P4196, DOI 10.4049/jimmunol.1202688
   Jiang S, 2007, J HUBEI COLL TCM, P31
   Kang JM, 2009, J CLIN GASTROENTEROL, V43, P420, DOI 10.1097/MCG.0b013e318178d1d3
   Kang Won Kyung, 2004, Korean J Gastroenterol, V44, P25
   Katsuda N, 2003, JPN J CLIN ONCOL, V33, P192, DOI 10.1093/jjco/hyg034
   Kimang'a AN, 2012, ETHIOP J HEALTH SCI, V22, P163
   KUIPERS EJ, 1995, LANCET, V345, P1525, DOI 10.1016/S0140-6736(95)91084-0
   Kulmambetova GN, 2014, ASIAN PAC J CANCER P, V15, P7763, DOI 10.7314/APJCP.2014.15.18.7763
   Kumar S, 2015, META GENE, V6, P9, DOI 10.1016/j.mgene.2015.07.008
   Kumar S, 2009, BIOCHEM BIOPH RES CO, V387, P456, DOI 10.1016/j.bbrc.2009.07.033
   Li C, 2007, J GASTROEN HEPATOL, V22, P234, DOI 10.1111/j.1440-1746.2006.04379.x
   Li J, 2011, HELICOBACTER, V16, P246, DOI 10.1111/j.1523-5378.2011.00837.x
   Li Q, 2010, INFLUENCE IL 1B IL 1
   Liu YE, 2012, POL J MICROBIOL, V61, P147
   Miftahussurur M, 2015, EXPERT REV GASTROENT, V9, P1535, DOI 10.1586/17474124.2015.1095089
   Mitchell HM, 1999, CURR TOP MICROBIOL, V241, P11
   Ohyauchi M, 2005, GUT, V54, P330, DOI 10.1136/gut.2003.033050
   Park MJ, 2015, MOL BIOL REP, V42, P119, DOI 10.1007/s11033-014-3748-7
   Qadri Q, 2014, IMMUNOL INVEST, V43, P324, DOI 10.3109/08820139.2013.854378
   Queiroz DMM, 2009, MICROBES INFECT, V11, P980, DOI 10.1016/j.micinf.2009.07.008
   Risch HA, 2014, CANCER EPIDEM BIOMAR, V23, P172, DOI 10.1158/1055-9965.EPI-13-0447
   Saijo Y, 2007, WORLD J GASTROENTERO, V13, P4445
   Shin A, 2011, J GASTRIC CANCER, V11, P135, DOI 10.5230/jgc.2011.11.3.135
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
   Sonnenberg A, 2013, AM J GASTROENTEROL, V108, P208, DOI 10.1038/ajg.2012.407
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sugimoto M, 2007, J GASTROEN HEPATOL, V22, P51, DOI 10.1111/j.1440-1746.2006.04442.x
   Sugimoto M, 2009, J GASTROEN HEPATOL, V24, P1725, DOI 10.1111/j.1440-1746.2009.06047.x
   Taguchi A, 2005, CANCER EPIDEM BIOMAR, V14, P2487, DOI 10.1158/1055-9965.EPI-05-0326
   Arango MT, 2010, BIOMEDICA, V30, P199, DOI 10.7705/biomedica.v30i2.183
   Tseng FC, 2006, HELICOBACTER, V11, P425, DOI 10.1111/j.1523-5378.2006.00433.x
   Uno M, 2002, INT J MOL MED, V10, P321
   Venerito M, 2013, HELICOBACTER, V18, P39, DOI 10.1111/hel.12078
   Waghray M, 2010, GASTROENTEROLOGY, V138, P562, DOI 10.1053/j.gastro.2009.10.043
   Wang JQ, 2015, MICROB PATHOGENESIS, V82, P15, DOI 10.1016/j.micpath.2015.03.011
   Wang MC, 1999, J GASTROENTEROL, V34, P10
   Yakar T, 2015, TURK J GASTROENTEROL, V26, P304, DOI 10.5152/tjg.2015.0161
   Yang J, 2004, CANCER LETT, V215, P191, DOI 10.1016/j.canlet.2004.07.012
   Ying HY, 2016, J CELL MOL MED, V20, P526, DOI 10.1111/jcmm.12737
   Zeng ZR, 2003, GUT, V52, P1684, DOI 10.1136/gut.52.12.1684
   Zhao Y, 2013, WORLD J GASTROENTERO, V19, P8758, DOI 10.3748/wjg.v19.i46.8758
NR 64
TC 5
Z9 7
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 28
PY 2017
VL 12
IS 4
AR e0176463
DI 10.1371/journal.pone.0176463
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ET6EO
UT WOS:000400383900026
PM 28453551
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhao, TC
   Li, CF
   Wu, YH
   Li, BJ
   Zhang, B
AF Zhao, Tiancheng
   Li, Changfeng
   Wu, Yanhua
   Li, Bingjin
   Zhang, Bin
TI Prognostic value of PD-L1 expression in tumor infiltrating immune cells
   in cancers: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID DEATH-LIGAND 1; T-CELLS; MICROENVIRONMENT; SURVIVAL; LYMPHOCYTES;
   BLOCKADE; ANTIBODIES; MPDL3280A; B7-H1
AB Programmed death-ligand 1 (PD-L1) is a promising target of cancer immune therapy. It not only expressed in tumor cells (TCs) but also up regulated in tumor infiltrating immune cells (TIICs). Although the previous meta-analysis have shown that PD-L1 expression in TCs was a valuable biomarker in predicting cancer prognosis, but few researches systematic evaluated the association between its expression in TIICs and survival of cancer patients. Thus, we performed this meta-analysis to evaluate the prognostic value of PD-L1 expression in TIICs in different types of cancers. Our results are valuable supplements when using PD-L1 expression to predict the survival of cancer patients and to select the beneficial patients from PD-L1 target therapy. PubMed, Embase, Web of Science and the Cochrane Central Search Library were used to perform our systematic literature search. Overall survival (OS) at 5th years and hazard ratios (HRs) were calculated using random effects models. Eighteen studies involving 3674 patients were included. The median positive rate of PD-L1 staining in TIICs was 36.37%. PD-L1 positive expression in TIICs related to a lower risk of death (HR = 0.784, 95% CI: 0.616-0.997, P = 0.047). Subgroup analyses found that PD-L1 positive expression in TIICs indicated a better prognosis especially in breast cancer patients (HR = 0.359, P = 0.041). When using whole tissue section slides, or using 'any expression in TIICs' as a cutoff value to assessing the results of IHC staining, PD-L1 expression in TIICs had a good prognostic value in cancer prognosis (HR = 0.587, P = 0.001 and HR = 0.549, P = 0.002). Our findings suggested that PD-L1 expression in TIICs was related to a better survival of cancer. The comprehensive evaluation of tumor cells and tumor infiltrating immune cells are required when evaluating the effect of PD-L1 expression on prognosis of cancer in future research.
C1 [Zhao, Tiancheng; Li, Changfeng; Zhang, Bin] Jilin Univ, China Japan Union Hosp, Dept Endoscopy Ctr, Changchun, Jilin, Peoples R China.
   [Wu, Yanhua] Jilin Univ, Hosp 1, Div Clin Res, Changchun, Jilin, Peoples R China.
   [Li, Bingjin] Jilin Univ, Hosp 2, Jilin Prov Key Lab Mol & Chem Genet, Changchun, Jilin, Peoples R China.
RP Zhang, B (reprint author), Jilin Univ, China Japan Union Hosp, Dept Endoscopy Ctr, Changchun, Jilin, Peoples R China.; Li, BJ (reprint author), Jilin Univ, Hosp 2, Jilin Prov Key Lab Mol & Chem Genet, Changchun, Jilin, Peoples R China.
EM libingjin@jlu.edu.cn; zhangbin_bio@163.com
FU Finance Department of Jilin Province [sczsy201606]
FX This work was supported by the Finance Department of Jilin Province
   (No.sczsy201606) [http://czt.jl.gov.cn/jlcz/16/tindex.shtml].
CR Aguiar PN, 2016, IMMUNOTHERAPY-UK, V8, P479, DOI 10.2217/imt-2015-0002
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bellmunt J, 2015, ANN ONCOL, V26, P812, DOI 10.1093/annonc/mdv009
   Boger C, 2016, ONCOTARGET, V7, P24269, DOI 10.18632/oncotarget.8169
   Boussiotis VA, 2016, NEW ENGL J MED, V375, P1767, DOI 10.1056/NEJMra1514296
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Choueiri TK, 2014, ANN ONCOL, V25, P2178, DOI 10.1093/annonc/mdu445
   Costa R, 2016, ONCOTARGET
   Darb-Esfahani S, 2016, ONCOTARGET, V7, P1486, DOI 10.18632/oncotarget.6429
   Du ZM, 2015, ONCOTARGET, V6, P4704, DOI 10.18632/oncotarget.3082
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gandini S, 2016, CRIT REV ONCOL HEMAT, V100, P88, DOI 10.1016/j.critrevonc.2016.02.001
   Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5
   Hatogai K, 2016, ONCOTARGET, V7, P47252, DOI 10.18632/oncotarget.10055
   Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hou JY, 2014, EXP MOL PATHOL, V96, P284, DOI 10.1016/j.yexmp.2014.03.005
   Hwang WT, 2012, GYNECOL ONCOL, V124, P192, DOI 10.1016/j.ygyno.2011.09.039
   Jo JC, 2017, ANN HEMATOL, V96, P25, DOI 10.1007/s00277-016-2818-4
   Kawazoe A, 2016, GASTRIC CANC
   Kim HR, 2016, SCI REP-UK, V6, DOI 10.1038/srep36956
   Kiyasu J, 2015, BLOOD, V126, P2193, DOI 10.1182/blood-2015-02-629600
   Koirala P, 2016, SCI REP-UK, V6, DOI 10.1038/srep30093
   Li XX, 2016, AM J CLIN PATHOL, V146, P496, DOI [10.1093/AJCP/AQW134, 10.1093/ajcp/aqw134]
   Li X, 2016, TARGET ONCOL, V11, P753, DOI 10.1007/s11523-016-0451-8
   Lin SJ, 2015, GUT, V64, P1721, DOI 10.1136/gutjnl-2014-308252
   Liu Y, 2016, INT J NANOMED, V11, P3891, DOI 10.2147/IJN.S108128
   Luo DD, 2017, ADV SCI, V4, DOI 10.1002/advs.201600106
   Paiva B, 2015, LEUKEMIA, V29, P2110, DOI 10.1038/leu.2015.79
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Paulsen E-E, 2016, CLIN LUNG CANC
   Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904
   Saito R, 2016, MODERN PATHOLOGY
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sun WY, 2016, J TRANSLATIONAL MED, V14
   Sznol M, 2013, CLIN CANCER RES, V19, P1021, DOI 10.1158/1078-0432.CCR-12-2063
   Teng FF, 2015, CANCER LETT, V365, P23, DOI 10.1016/j.canlet.2015.05.012
   Thompson ED, 2017, GUT, V66, P794, DOI 10.1136/gutjnl-2015-310839
   Tie Y, 2017, INT J CANCER, V140, P948, DOI 10.1002/ijc.30501
   Wang LS, 2016, MOL DIAGN THER, V20, P175, DOI 10.1007/s40291-016-0188-1
   Wu P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131403
   Yang CY, 2016, EUR J CANCER, V57, P91, DOI 10.1016/j.ejca.2015.12.033
   Zeng DQ, 2016, ONCOTARGET, V7, P13765, DOI 10.18632/oncotarget.7282
   Zhang TF, 2016, ONCOTARGET, V7, P73068, DOI 10.18632/oncotarget.12230
   Zou MX, 2016, AM J TRANSL RES, V8, P3274
NR 45
TC 19
Z9 20
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 28
PY 2017
VL 12
IS 4
AR e0176822
DI 10.1371/journal.pone.0176822
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ET6EO
UT WOS:000400383900059
PM 28453554
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Micha, R
   Shulkin, ML
   Penalvo, JL
   Khatibzadeh, S
   Singh, GM
   Rao, M
   Fahimi, S
   Powles, J
   Mozaffarian, D
AF Micha, Renata
   Shulkin, Masha L.
   Penalvo, Jose L.
   Khatibzadeh, Shahab
   Singh, Gitanjali M.
   Rao, Mayuree
   Fahimi, Saman
   Powles, John
   Mozaffarian, Dariush
TI Etiologic effects and optimal intakes of foods and nutrients for risk of
   cardiovascular diseases and diabetes: Systematic reviews and
   meta-analyses from the Nutrition and Chronic Diseases Expert Group
   (NutriCoDE)
SO PLOS ONE
LA English
DT Review
ID CORONARY-HEART-DISEASE; SUGAR-SWEETENED BEVERAGES; DIETARY FIBER INTAKE;
   TRANS-FATTY-ACIDS; BLOOD-PRESSURE; MEDITERRANEAN DIET; WHOLE-GRAIN;
   INCREASED CONSUMPTION; CARBOHYDRATE INTAKE; FISH CONSUMPTION
AB Background Dietary habits are major contributors to coronary heart disease, stroke, and diabetes. However, comprehensive evaluation of etiologic effects of dietary factors on cardiometabolic outcomes, their quantitative effects, and corresponding optimal intakes are not well established.
   Objective To systematically review the evidence for effects of dietary factors on cardiometabolic diseases, including comprehensively assess evidence for causality; estimate magnitudes of etiologic effects; evaluate heterogeneity and potential for bias in these etiologic effects; and determine optimal population intake levels.
   Methods We utilized Bradford-Hill criteria to assess probable or convincing evidence for causal effects of multiple diet-cardiometabolic disease relationships. Etiologic effects were quantified from published or de novo meta-analyses of prospective studies or randomized clinical trials, incorporating standardized units, dose-response estimates, and heterogeneity by age and other characteristics. Potential for bias was assessed in validity analyses. Optimal intakes were determined by levels associated with lowest disease risk.
   Results We identified 10 foods and 7 nutrients with evidence for causal cardiometabolic effects, including protective effects of fruits, vegetables, beans/legumes, nuts/seeds, whole grains, fish, yogurt, fiber, seafood omega-3s, polyunsaturated fats, and potassium; and harms of unprocessed red meats, processed meats, sugar-sweetened beverages, glycemic load, trans-fats, and sodium. Proportional etiologic effects declined with age, but did not generally vary by sex. Established optimal population intakes were generally consistent with observed national intakes and major dietary guidelines. In validity analyses, the identified effects of individual dietary components were similar to quantified effects of dietary patterns on cardiovascular risk factors and hard endpoints.
   Conclusions These novel findings provide a comprehensive summary of causal evidence, quantitative etiologic effects, heterogeneity, and optimal intakes of major dietary factors for cardiometabolic diseases, informing disease impact estimation and policy planning and priorities.
C1 [Micha, Renata; Shulkin, Masha L.; Penalvo, Jose L.; Singh, Gitanjali M.; Mozaffarian, Dariush] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
   [Shulkin, Masha L.] Univ Michigan, Sch Med, Ann Arbor, MI USA.
   [Khatibzadeh, Shahab] Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA USA.
   [Rao, Mayuree] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Fahimi, Saman] Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, Iran.
   [Powles, John] Cambridge Inst Publ Hlth, Cambridge, England.
RP Mozaffarian, D (reprint author), Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
EM dariush.mozaffarian@tufts.edu
OI Penalvo, Jose L/0000-0003-0096-6238
FU NHLBI, NIH [R01 HL115189, R01 HL130735]; Bill & Melinda Gates Foundation
FX Funded by NHLBI, NIH (R01 HL115189, PI Mozaffarian; R01 HL130735, PI
   Micha); Bill & Melinda Gates Foundation (PI Mozaffarian). The sponsors
   had no role in study design, data collection, data analysis, data
   interpretation, or writing of the report. RM and DM had full access to
   all data in the study and had final responsibility for the decision to
   submit for publication.
CR Aburto NJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1326
   Afshin A, 2015, CURR CARDIOL REP, V17, DOI 10.1007/s11886-015-0658-9
   Afshin A, 2014, AM J CLIN NUTR, V100, P278, DOI 10.3945/ajcn.113.076901
   [Anonymous], 1988, BMJ, V297, P319
   Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601
   Appel LJ, 2005, JAMA-J AM MED ASSOC, V294, P2455, DOI 10.1001/jama.294.19.2455
   Aune D, 2013, EUR J EPIDEMIOL, V28, P845, DOI 10.1007/s10654-013-9852-5
   Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhupathiraju SN, 2014, AM J CLIN NUTR, V100, P218, DOI 10.3945/ajcn.113.079533
   Cai XL, 2015, ASIA-PAC J PUBLIC HE, V27, P486, DOI 10.1177/1010539514566742
   Capewell S, 2011, LANCET, V378, P752, DOI 10.1016/S0140-6736(10)62302-1
   Chen M, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0215-1
   D'Elia L, 2011, J AM COLL CARDIOL, V57, P1210, DOI 10.1016/j.jacc.2010.09.070
   Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X
   Danaei G, 2011, LANCET, V377, P568, DOI 10.1016/S0140-6736(10)62036-3
   Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619
   Ellander A, 2015, EUR J LIPID SCI TECH, V117, P1370, DOI 10.1002/ejlt.201400513
   Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303
   Ezzati M, 2004, COMP QUANTIFICATION, V1
   Ezzati M, 2004, COMP QUANTIFICATION, V2
   FAO, 2010, FATS FATTV AC HUM NU, V91
   Fardet A, 2014, NUTR REV, V72, P741, DOI 10.1111/nure.12153
   Farvid MS, 2014, CIRCULATION, V130, P1568, DOI 10.1161/CIRCULATIONAHA.114.010236
   Farzadfar F, 2011, LANCET, V377, P578, DOI 10.1016/S0140-6736(10)62038-7
   Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5
   Forouzanfar MH, 2015, LANCET, V386, P2287, DOI 10.1016/S0140-6736(15)00128-2
   Fung TT, 2009, CIRCULATION, V119, P1093, DOI 10.1161/CIRCULATIONAHA.108.816736
   Fung TT, 2001, ARCH INTERN MED, V161, P1857, DOI 10.1001/archinte.161.15.1857
   Gan Y, 2015, INT J CARDIOL, V183, P129, DOI 10.1016/j.ijcard.2015.01.077
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   He FJ, 2007, J HUM HYPERTENS, V21, P717, DOI 10.1038/sj.jhh.1002212
   He K, 2004, STROKE, V35, P1538, DOI 10.1161/01.STR.0000130856.31468.47
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   HILL AB, 1965, P ROY SOC MED, V58, P295
   Hu FB, 2000, AM J CLIN NUTR, V72, P912
   Imamura F, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3576
   Johnsen SP, 2003, AM J CLIN NUTR, V78, P57
   Joshipura KJ, 1999, JAMA-J AM MED ASSOC, V282, P1233, DOI 10.1001/jama.282.13.1233
   Khatibzadeh S, 2016, B WORLD HEALTH ORGAN, V94, P931, DOI 10.2471/BLT.15.156323
   Larsson SC, 2009, EUR J CLIN NUTR, V63, P1016, DOI 10.1038/ejcn.2009.16
   Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423
   Lawes CMM, 2003, J HYPERTENS, V21, P707, DOI 10.1097/01.hjh.0000052492.18130.07
   Lewington S, 2002, LANCET, V360, P1903
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
   Lloyd-Jones DM, 2010, CIRCULATION, V121, P586, DOI 10.1161/CIRCULATIONAHA.109.192703
   Martinez-Gonzalez MA, 2011, PUBLIC HEALTH NUTR, V14, P2309, DOI 10.1017/S1368980011002564
   Mellen PB, 2008, NUTR METAB CARDIOVAS, V18, P283, DOI 10.1016/j.numecd.2006.12.008
   Mente A, 2009, ARCH INTERN MED, V169, P659, DOI 10.1001/archinternmed.2009.38
   Micha R, 2012, EUR J CLIN NUTR, V66, P119, DOI 10.1038/ejcn.2011.147
   Micha R, 2017, JAMA-J AM MED ASSOC, V317, P912, DOI 10.1001/jama.2017.0947
   Micha R, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008705
   Micha R, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2272
   Micha R, 2010, CIRCULATION, V121, P2271, DOI 10.1161/CIRCULATIONAHA.109.924977
   Michas G, 2014, ATHEROSCLEROSIS, V234, P320, DOI 10.1016/j.atherosclerosis.2014.03.013
   Mirrahimi A, 2014, CURR ATHEROSCLER REP, V16, DOI 10.1007/s11883-013-0381-1
   Mizrahi A, 2009, BRIT J NUTR, V102, P1075, DOI 10.1017/S0007114509359097
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Mozaffarian D, 2006, NEW ENGL J MED, V354, P1601, DOI 10.1056/NEJMra054035
   MOZAFFARIAN D, 2013, GLOB PUBLIC HEALTH, V8, P673, DOI DOI 10.1056/
   Mozaffarian D, 2006, JAMA-J AM MED ASSOC, V296, P1885, DOI 10.1001/jama.296.15.1885
   Mozaffarian D, 2016, CIRCULATION, V133, P187, DOI 10.1161/CIRCULATIONAHA.115.018585
   Mozaffarian D, 2014, NEW ENGL J MED, V371, P624, DOI 10.1056/NEJMoa1304127
   Mozaffarian D, 2012, CIRCULATION, V126, P1514, DOI 10.1161/CIR.0b013e318260a20b
   Mozaffarian D, 2011, NEW ENGL J MED, V364, P2392, DOI 10.1056/NEJMoa1014296
   Mozaffarian D, 2010, JAMA-J AM MED ASSOC, V304, P681, DOI 10.1001/jama.2010.1116
   Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805
   Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
   Nagura J, 2009, BRIT J NUTR, V102, P285, DOI 10.1017/S0007114508143586
   National Institute for Health and Clinical Excellence, 2010, PREV CARD DIS POP LE, V25
   Nishida C, 2009, EUR J CLIN NUTR, V63, pS1, DOI 10.1038/ejcn.2009.13
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Oude Griep LM, 2011, EUR J CLIN NUTR, V65, P791, DOI 10.1038/ejcn.2011.36
   Pan A, 2011, AM J CLIN NUTR, V94, P1088, DOI 10.3945/ajcn.111.018978
   Poggio R, 2015, PUBLIC HEALTH NUTR, V18, P695, DOI 10.1017/S1368980014000949
   Powles J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003733
   Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7
   Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101
   Sauvaget C, 2003, STROKE, V34, P2355, DOI 10.1161/01.STR.0000089293.29739.97
   Scientific Advisory Committee on Nutrition, 2003, SALT HLTH
   Singh GM, 2015, CIRCULATION, V132, P639, DOI 10.1161/CIRCULATIONAHA.114.010636
   Singh GM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124845
   Singh GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065174
   Steffen LM, 2003, AM J CLIN NUTR, V78, P383
   Threapleton DE, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6879
   Threapleton DE, 2013, STROKE, V44, P1360, DOI 10.1161/STROKEAHA.111.000151
   Trichopoulou A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2337
   U. S. Department of Agriculture U. S. Department of Health and Human Services, 2015, 2015 2020 DIET GUID
   UN General Assembly, 2011, UN NAT HIGH LEV HIGH
   Wang Q, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002891
   Whelton PK, 2012, CIRCULATION, V126, P2880, DOI 10.1161/CIR.0b013e318279acbf
   World Cancer Research Fund/ American Institute for Cancer Research, CONT UPD PROJ
   World Cancer Research Fund/American Institute forCancer Research, 2007, FOOD NUTR PHYS ACT P
   World Health Organization, 2012, WHO GUID POT INT AD
   World Health Organization, 2012, WHO GUID SOD INT AD
   World Health Organization [WHO], 2002, WORLD HLTH REP 2002
   Xi B, 2015, BRIT J NUTR, V113, P709, DOI 10.1017/S0007114514004383
   Yao BD, 2014, EUR J EPIDEMIOL, V29, P79, DOI 10.1007/s10654-013-9876-x
   Zatonski W, 2008, EUR J EPIDEMIOL, V23, P3, DOI 10.1007/s10654-007-9195-1
   Zheng JS, 2012, PUBLIC HEALTH NUTR, V15, P725, DOI 10.1017/S1368980011002254
NR 100
TC 37
Z9 39
U1 1
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 27
PY 2017
VL 12
IS 4
AR e0175149
DI 10.1371/journal.pone.0175149
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ET6EL
UT WOS:000400383600008
PM 28448503
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Poorolajal, J
   Zeraati, F
   Soltanian, AR
   Sheikh, V
   Hooshmand, E
   Maleki, A
AF Poorolajal, Jalal
   Zeraati, Fatemeh
   Soltanian, Ali Reza
   Sheikh, Vida
   Hooshmand, Elham
   Maleki, Akram
TI Oral potassium supplementation for management of essential hypertension:
   A meta-analysis of randomized controlled trials
SO PLOS ONE
LA English
DT Article
ID PLACEBO-CONTROLLED TRIAL; BLOOD-PRESSURE; SYSTEMATIC REVIEWS; DIETARY
   POTASSIUM; DOUBLE-BLIND; SODIUM; MAGNESIUM; REDUCTION; BIAS; KCL
AB Importance
   Increased dietary potassium intake is thought to be associated with low blood pressure (BP). Whether potassium supplementation may be used as an antihypertensive agent is a question that should be answered.
   Objective
   To assess the effect of oral potassium supplementation on blood pressure in patients with primary hypertension.
   Search methods
   We searched Medline, Web of Science, Scopus, Cochrane Central Register of Controlled Trials until October 2016. We also screened reference lists of articles and previous reviews. We applied no language restrictions.
   Selection criteria
   We included randomized placebo-controlled clinical trials addressing the effect of potassium supplementation on primary hypertension for a minimum of 4 weeks.
   Data collection and analysis
   We extracted data on systolic and diastolic BP (SBP and DBP) at the final follow-up. We explored the heterogeneity across studies using Cochran's test and I-2 statistic and assessed the probability of publication bias using Begg's and Egger's tests. We reported the mean difference (MD) of SBP and DBP in a random-effects model.
   Results
   We found a total of 9059 articles and included 23 trials with 1213 participants. Compared to placebo, potassium supplementation resulted in modest but significant reductions in both SBP (MD -4.25 mmHg; 95% CI: -5.96 to -2.53; I-2 = 41%) and DBP (MD -2.53 mmHg; 95% CI: -4.05 to -1.02; I-2 = 65%). According to the change-score analysis, based on 8 out of 23 trials, compared to baseline, the mean changes in SBP (MD -8.89 mmHg; 95% CI: -13.67 to -4.11) and DBP (MD -6.42 mmHg; 95% CI: -10.99 to -1.84) was significantly higher in the intervention group than the control group.
   Conclusions
   Our findings indicated that potassium supplementation is a safe medication with no important adverse effects that has a modest but significant impact BP and may be recommended as an adjuvant antihypertensive agent for patients with essential hypertension.
C1 [Poorolajal, Jalal; Maleki, Akram] Hamadan Univ Med Sci, Dept Epidemiol, Sch Publ Hlth, Hamadan, Iran.
   [Poorolajal, Jalal] Hamadan Univ Med Sci, Res Ctr Hlth Sci, Hamadan, Iran.
   [Poorolajal, Jalal; Soltanian, Ali Reza] Hamadan Univ Med Sci, Noncommunicable Dis Res Ctr, Hamadan, Iran.
   [Zeraati, Fatemeh] Hamadan Univ Med Sci, Med Plants & Nat Prod Res Ctr, Hamadan, Iran.
   [Soltanian, Ali Reza] Hamadan Univ Med Sci, Dept Biostat, Sch Publ Hlth, Hamadan, Iran.
   [Sheikh, Vida] Hamadan Univ Med Sci, Sch Med, Dept Internal Med, Hamadan, Iran.
   [Hooshmand, Elham] Neyshabur Univ Med Sci, Dept Publ Hlth, Neyshabur, Iran.
RP Maleki, A (reprint author), Hamadan Univ Med Sci, Dept Epidemiol, Sch Publ Hlth, Hamadan, Iran.
EM arak.maleki@gmail.com
RI hooshmand, elham/F-6030-2018; Soltanian, Ali Reza/L-2231-2017;
   Poorolajal, Jalal/D-3506-2013
OI hooshmand, elham/0000-0003-1801-493X; Soltanian, Ali
   Reza/0000-0002-7483-3502; Zeraati, fatemeh/0000-0002-1678-954X
FU Hamadan University of Medical Sciences
FX The Vice-Chancellor for Research and Technology, the Hamadan University
   of Medical Sciences.; This was part of the MSc thesis in Epidemiology.
   We would like to appreciate the Vice-Chancellor for Research and
   Technology of the Hamadan University of Medical Sciences for supporting
   this work.
CR Aburto NJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1378
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Binia A, 2015, J HYPERTENS, V33, P1509, DOI 10.1097/HJH.0000000000000611
   Buemi M, 2002, MED RES REV, V22, P419, DOI 10.1002/med.10013
   Burgess E, 1999, CAN MED ASSOC J, V160, pS35
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dickinson HO, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004641.pub2
   Dietary Guidelines Advisory Committee, 2005, REP DIET GUID ADV CO
   Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3
   FORRESTER TE, 1988, W INDIAN MED J, V37, P92
   FOTHERBY MD, 1992, J HYPERTENS, V10, P1403, DOI 10.1097/00004872-199211000-00013
   Franzoni F, 2005, BIOMED PHARMACOTHER, V59, P25, DOI 10.1016/j.biopha.2004.11.002
   Gijsbers L, 2015, J HUM HYPERTENS, V29, P592, DOI 10.1038/jhh.2015.3
   GRIMM RH, 1988, J HYPERTENS, V6, pS591, DOI 10.1097/00004872-198812040-00185
   GROBBEE DE, 1987, J HYPERTENS, V5, P115, DOI 10.1097/00004872-198702000-00016
   He FJ, 2010, HYPERTENSION, V55, P681, DOI 10.1161/HYPERTENSIONAHA.109.147488
   HESELTINE D, 1990, AGE AGEING, V19, P409, DOI 10.1093/ageing/19.6.409
   Higgins JP, COCHRANE HDB SYSTEMA
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   KAPLAN NM, 1985, NEW ENGL J MED, V312, P746, DOI 10.1056/NEJM198503213121203
   Kawano Y, 1998, AM J HYPERTENS, V11, P1141, DOI 10.1016/S0895-7061(98)00037-5
   KHAW KT, 1988, CIRCULATION, V77, P53, DOI 10.1161/01.CIR.77.1.53
   LAWTON WJ, 1990, CIRCULATION, V81, P173, DOI 10.1161/01.CIR.81.1.173
   MACGREGOR GA, 1982, LANCET, V2, P567
   MACGREGOR GA, 1984, J CARDIOVASC PHARM, V6, pS244, DOI 10.1097/00005344-198400061-00038
   Maleki Akram, 2016, Clin Hypertens, V22, P18, DOI 10.1186/s40885-016-0054-9
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   OBEL AO, 1989, J CARDIOVASC PHARM, V14, P294, DOI 10.1097/00005344-198908000-00016
   PATKI PS, 1990, BRIT MED J, V301, P521, DOI 10.1136/bmj.301.6751.521
   Patsopoulos NA, 2008, INT J EPIDEMIOL, V37, P1148, DOI 10.1093/ije/dyn065
   Rahimi ARO, 2007, PAK J MED SCI, V23, P589
   RICHARDS AM, 1984, LANCET, V1, P757, DOI 10.1016/S0140-6736(84)91276-5
   Sawka MN, 2000, AM J CLIN NUTR, V72, p564S, DOI 10.1093/ajcn/72.2.564S
   SIANI A, 1991, ANN INTERN MED, V115, P753, DOI 10.7326/0003-4819-115-10-753
   SIANI A, 1987, BMJ-BRIT MED J, V294, P1453, DOI 10.1136/bmj.294.6585.1453
   SMITH SJ, 1985, BMJ-BRIT MED J, V290, P110, DOI 10.1136/bmj.290.6462.110
   SVETKEY LP, 1987, HYPERTENSION, V9, P444, DOI 10.1161/01.HYP.9.5.444
   VALDES G, 1991, J HUM HYPERTENS, V5, P91
   Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0
   Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624
   World Health Organization, 2014, GUID POT INT AD CHIL
   Wu GR, 2006, CLIN EXP HYPERTENS, V28, P489, DOI 10.1080/10641960600798705
   Young DB, 2001, ROLE POTASSIUM PREVE
NR 46
TC 4
Z9 4
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 18
PY 2017
VL 12
IS 4
AR e0174967
DI 10.1371/journal.pone.0174967
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ES9KH
UT WOS:000399875200006
PM 28419159
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, P
   Tong, ZD
   Li, KF
   Tang, A
   Dai, YX
   Yan, JB
AF Li, Peng
   Tong, Zhen-Dong
   Li, Ke-Feng
   Tang, An
   Dai, Ya-Xin
   Yan, Jian-Bo
TI Seroprevalence of severe fever with thrombocytopenia syndrome virus in
   China: A systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID SHANDONG PROVINCE; RISK-FACTORS; EPIDEMIOLOGIC FEATURES; SYNDROME
   BUNYAVIRUS; TICK-BORNE; SFTS VIRUS; INFECTION; ANTIBODIES; TRANSMISSION;
   ANIMALS
AB Objective
   Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by a novel bunyavirus-SFTSV. The seroprevalence of anti-SFTSV antibodies including immunoglobulin G (IgG) and immunoglobulin M (IgM), specific to SFTSV in the general population has been investigated in various epidemiological studies with inconsistent results. Here, we clarify this discrepancy and reach a more comprehensive result by mean of a meta-analysis.
   Methods
   All relevant articles were searched in the electronic databases (PubMed, Web of science, Embase, Chinese National Knowledge Infrastructure database, Chinese Wanfang database) up to November 2016. The pooled seroprevalence and 95% confidence intervals (95% CIs) were calculated by random-or fixed-model on the basis of heterogeneity.
   Results
   In total, 21 studies containing 23,848 blood samples from 7 provinces were included in this meta-analysis. The minimum and maximum reported seroprevalences of SFTSV among humans in China were 0.23% and 9.17%, respectively. The overall pooled seroprevalence of SFTSV antibodies was 4.3% (95% CI: 3.2%-5.5%). The pooled prevalence was 5.9% (95% CI: 4.7%-7.0%) in Zhejiang province, 4.9% (95% CI: 4.1-5.8%) in Anhui province, 3.9% (95% CI: 1.3%-6.4%) in Shandong province, and 0.7% (95% CI: 0.2%-1.1%) in Jiangsu province. Stratified by occupation, the pooled prevalence of farmer was 6.1% (95% CI: 3.4%-8.9%) and others (mainly are students) was 3.3% (95% CI: 2.4%-4.2%). Additionally, seroprevalence of SFTSV in people who lived in the same village with the patient were higher than that of people who lived in a different village. Seropositive rates in sampling years after 2012 were higher than that before 2012. The prevalence of SFTSV did not differ by age or gender. Sensitive analysis by omitting one study at a time indicated the results of the pooled seroprevalence were robust.
   Conclusions
   Seroprevalence of SFTSV among healthy population in central and eastern China is high. Surveillance efforts on mild or asymptomatic infections among endemic persons are needed.
C1 [Li, Peng; Tong, Zhen-Dong; Li, Ke-Feng; Tang, An; Dai, Ya-Xin; Yan, Jian-Bo] Zhoushan Municipal Ctr Dis Control & Prevent, Zhoushan, Zhejiang, Peoples R China.
   [Li, Peng; Tong, Zhen-Dong; Li, Ke-Feng; Tang, An; Dai, Ya-Xin; Yan, Jian-Bo] Zhoushan Municipal Ctr Dis Control & Prevent, Zhejiang Prov Key Lab Hlth Risk Factors Seafood, Zhoushan, Zhejiang, Peoples R China.
RP Tong, ZD; Yan, JB (reprint author), Zhoushan Municipal Ctr Dis Control & Prevent, Zhoushan, Zhejiang, Peoples R China.; Tong, ZD; Yan, JB (reprint author), Zhoushan Municipal Ctr Dis Control & Prevent, Zhejiang Prov Key Lab Hlth Risk Factors Seafood, Zhoushan, Zhejiang, Peoples R China.
EM zscdc@hotmail.com; yanjianbo02@163.com
OI Li, Peng/0000-0002-2533-1864
FU science and technology program of Zhoushan City [2014C31075]; medical
   and health projects of Zhoushan City [2016A12]
FX This work was supported by the science and technology program of
   Zhoushan City (2014C31075) and the medical and health projects of
   Zhoushan City (2016A12). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cui F, 2013, AM J TROP MED HYG, V88, P510, DOI 10.4269/ajtmh.11-0760
   Diang SJ, 2014, JPN J INFECT DIS, V67, P1, DOI 10.7883/yoken.67.1
   Ding F, 2013, CLIN INFECT DIS, V56, P1682, DOI 10.1093/cid/cit100
   Gai ZT, 2012, CLIN INFECT DIS, V54, P249, DOI 10.1093/cid/cir776
   Hu CY, 2015, AM J TROP MED HYG, V92, P479, DOI 10.4269/ajtmh.14-0447
   Huang X, 2016, JPN J INFECT DIS
   Jiang XL, 2015, CLIN MICROBIOL INFEC, V21, P274, DOI 10.1016/j.cmi.2014.10.006
   Jiao YJ, 2012, J CLIN MICROBIOL, V50, P372, DOI 10.1128/JCM.01319-11
   Khan SU, 2015, J INFECT DIS, V212, P562, DOI 10.1093/infdis/jiv109
   Li DX, 2015, CLIN MICROBIOL INFEC, V21, P614, DOI 10.1016/j.cmi.2015.03.001
   Li YC, 2014, BIOTECHNOL LETT, V36, P2011, DOI 10.1007/s10529-014-1581-7
   Li ZF, 2014, J CLIN VIROL, V60, P185, DOI 10.1016/j.jcv.2014.03.020
   Liang S, 2011, AM J TROP MED HYG, V90, P256, DOI DOI 10.4269/AJTMH.13-0423
   Liu JW, 2014, EMERG INFECT DIS, V20, P2126, DOI 10.3201/eid2012.141013
   Liu K, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002820
   Liu Q, 2014, LANCET INFECT DIS, V14, P763, DOI 10.1016/S1473-3099(14)70718-2
   Liu Y, 2012, VECTOR-BORNE ZOONOT, V12, P156, DOI 10.1089/vbz.2011.0758
   Luo LM, 2015, EMERG INFECT DIS, V21, P1770, DOI 10.3201/eid2110.150126
   Luo LM, 2016, INVESTIGATION OF RES
   Lyu Y, 2016, INFECT DIS-NOR, V48, P544, DOI 10.3109/23744235.2016.1165351
   Meng K, 2015, PARASITOL RES, V114, P4703, DOI 10.1007/s00436-015-4718-2
   Niu GY, 2016, EPIDEMIOLOGICAL INVE
   Nyakarahuka L, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2045-6
   Rostom A, CELIAC DIS
   Sun JM, 2015, EPIDEMIOL INFECT, V143, P851, DOI 10.1017/S0950268814001319
   Sun JM, 2014, INT J INFECT DIS, V25, P180, DOI 10.1016/j.ijid.2014.02.022
   Takahashi T, 2014, J INFECT DIS, V209, P816, DOI 10.1093/infdis/jit603
   Tan WenWen, 2015, China Tropical Medicine, V15, P359
   Wang D, 2016, EXP APPL ACAROL, V68, P213, DOI 10.1007/s10493-015-9992-2
   Wang Jingli, 2016, J CHINESE AGR MECH, V37, P37, DOI DOI 10.3760/CMA.J.ISSN.0254-6450.2016.02.029
   Wang L, 2013, MODERN PREVENTIVE ME, V40, P3471
   Wang SW, 2015, AM J TROP MED HYG, V92, P684, DOI 10.4269/ajtmh.14-0008
   Wei J, 2015, INT J INFECT DIS, V35, P37, DOI 10.1016/j.ijid.2015.02.014
   Xing XS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002533
   Xu PengPeng, 2015, Modern Preventive Medicine, V42, P1948
   Yang BY, 2015, PEDIATR INFECT DIS J, V34, P1399, DOI 10.1097/INF.0000000000000900
   Yu XJ, 2011, NEW ENGL J MED, V364, P1523, DOI 10.1056/NEJMoa1010095
   Zhan J.B., 2013, CHIN J HLTH LAB TECH, V4, P992
   Zhang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111127
   Zhang L, 2014, EMERG INFECT DIS, V20, P1355, DOI 10.3201/eid2008.131796
   Zhang WenShuai, 2011, Disease Surveillance, V26, P676
   Zhao L, 2012, EMERG INFECT DIS, V18, P963, DOI 10.3201/eid1806.111345
   Zhou ShuQin, 2015, Modern Preventive Medicine, V42, P476
NR 45
TC 8
Z9 8
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 11
PY 2017
VL 12
IS 4
AR e0175592
DI 10.1371/journal.pone.0175592
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ET0JS
UT WOS:000399949000052
PM 28399161
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, YY
   Gu, FF
   Liang, JY
   Dai, XM
   Wan, C
   Hong, XH
   Zhang, K
   Liu, L
AF Liu, Yangyang
   Gu, Feifei
   Liang, Jinyan
   Dai, Xiaomeng
   Wan, Chao
   Hong, Xiaohua
   Zhang, Kai
   Liu, Li
TI The efficacy and toxicity profile of metronomic chemotherapy for
   metastatic breast cancer: A meta-analysis
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ANGIOGENIC MARKERS; ANTITUMOR-ACTIVITY;
   PERIPHERAL-BLOOD; ORAL VINORELBINE; CYCLOPHOSPHAMIDE; CAPECITABINE;
   THERAPY; BEVACIZUMAB; METHOTREXATE
AB Purpose
   The current meta-analysis aimed to summarize the available evidence for the efficacy and serious adverse events (AEs) associated with use of metronomic chemotherapy (MCT) in patients with metastatic breast cancer (MBC).
   Method
   Electronic databases (PubMed, EMBASE database, Web of Knowledge, and the Cochrane database) were systematically searched for articles related to the use of MCT in MBC patients. Eligible studies included clinical trials of MBC patients treated with MCT that presented sufficient data related to tumor response, progression-free survival (PFS), overall survival (OS), and grade 3/4 AEs. A meta-analysis was performed using a random effects model.
   Results
   This meta-analysis consists of 22 clinical trials with 1360 patients. The pooled objective response rate and clinical benefit rate of MCT were 34.1% (95% CI 27.4-41.5) and 55.6% (95% CI 49.2-61.9), respectively. The overall 6-month PFS, 12-month OS, and 24-month OS rates were 56.8% (95% CI 48.3-64.9), 70.3% (95% CI 62.6-76.9), and 40.0% (95% CI 30.6-50.2), respectively. The pooled incidence of grade 3/4 AEs was 29.5% (95% CI 21.1- 39.5). There was no statistically significant difference observed in any endpoint between subgroups defined by concomitant anti-cancer therapies or chemotherapy regimens. After excluding one controversial study, we observed a trend showing lower toxicity rates with the use of MCT alone compared to use of MCT with other anti-cancer therapies (P = 0.070).
   Conclusions
   Metronomic chemotherapy may be effective for use in patients with metastatic breast cancer. MCT used alone is possibly equally effective and less toxic than combination therapies. Well-designed RCTs are needed to obtain more evidence.
C1 [Liu, Yangyang; Gu, Feifei; Liang, Jinyan; Dai, Xiaomeng; Wan, Chao; Hong, Xiaohua; Zhang, Kai; Liu, Li] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China.
RP Liu, L (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China.
EM liulist2013@163.com
FU National Natural Science Foundation of China [81372260]
FX This study was funded by National Natural Science Foundation of China
   (grant number 81372260).
CR Addeo R, 2010, CLIN BREAST CANCER, V10, P301, DOI 10.3816/CBC.2010.n.039
   Perroud HA, 2016, CANCER CHEMOTH PHARM, V77, P365, DOI 10.1007/s00280-015-2947-9
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bouche G, 2014, ECANCERMEDICALSCIENC, V8, DOI 10.3332/ecancer.2014.463
   Bramante S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1078057
   Brems-Eskildsen AS, 2016, EUR J CANCER, V57, pS110
   Cazzaniga ME, 2016, BREAST CANCER RES TR, V160, P501, DOI 10.1007/s10549-016-4009-3
   Colleoni M, 2006, ANN ONCOL, V17, P232, DOI 10.1093/annonc/mdj066
   Colleoni M, 2002, ANN ONCOL, V13, P73, DOI 10.1093/annonc/mdf013
   De Iuliis F, 2015, TUMORI, V101, P30, DOI 10.5301/tj.5000207
   Dellapasqua S, 2008, J CLIN ONCOL, V26, P4899, DOI 10.1200/JCO.2008.17.4789
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Arab LRE, 2012, J EGYPT NATL CANCER, V24, P15, DOI 10.1016/j.jnci.2011.12.002
   Fedele P, 2012, EUR J CANCER, V48, P24, DOI 10.1016/j.ejca.2011.06.040
   Garcia-Saenz JA, 2008, J CHEMOTHERAPY, V20, P632, DOI 10.1179/joc.2008.20.5.632
   Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8
   Green MC, 2005, J CLIN ONCOL, V23, P5983, DOI 10.1200/JCO.2005.06.232
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Kader YA, 2013, BREAST CANCER-TARGET, V5, P37, DOI 10.2147/BCTT.S44728
   Kareva I, 2015, CANCER LETT, V358, P100, DOI 10.1016/j.canlet.2014.12.039
   Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369
   Kerbel RS, 2002, ANN ONCOL, V13, P12, DOI 10.1093/annonc/mdf093
   Korantzis I, 2012, ANTICANCER RES, V32, P4569
   Licchetta A, 2010, J CHEMOTHERAPY, V22, P201, DOI 10.1179/joc.2010.22.3.201
   Lien K, 2013, EUR J CANCER, V49, P3387, DOI 10.1016/j.ejca.2013.06.038
   Mancuso P, 2006, BLOOD, V108, P452, DOI 10.1182/blood-2005-11-4570
   Martin M, 2015, ONCOLOGIST, V20, P111, DOI 10.1634/theoncologist.2014-0379
   Montagna E, 2014, CANCER TREAT REV, V40, P942, DOI 10.1016/j.ctrv.2014.06.002
   Montagna E, 2012, CLIN BREAST CANCER, V12, P207, DOI 10.1016/j.clbc.2012.03.008
   Munzone E, 2015, NAT REV CLIN ONCOL, V12, P631, DOI 10.1038/nrclinonc.2015.131
   Nishijima TF, 2016, BREAST CANCER RES TR, V156, P227, DOI 10.1007/s10549-016-3756-5
   Otsuka H, 2015, BREAST CANCER-TOKYO, V22, P335, DOI 10.1007/s12282-013-0483-1
   Pectasides D, 2012, ONCOL REP, V27, P216, DOI 10.3892/or.2011.1504
   Perez EA, 2009, BREAST CANCER RES TR, V114, P195, DOI 10.1007/s10549-008-0005-6
   Perroud HA, 2013, INDIAN J CANCER, V50, P115, DOI 10.4103/0019-509X.117031
   Pritchard KI, 2008, CANCER, V112, P718, DOI 10.1002/cncr.23189
   Rochlitz C, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2823-y
   Salem Dina A, 2008, J Egypt Natl Canc Inst, V20, P134
   Saloustros E, 2011, J BUON, V16, P215
   Sandri MT, 2007, CANCER, V110, P509, DOI 10.1002/cncr.22825
   Schwartzberg LS, 2014, CLIN BREAST CANCER, V14, P13, DOI 10.1016/j.clbc.2013.09.003
   Soriano JL, 2011, INT J BREAST CANCER, DOI 10.4061/2011/710292
   Stockler MR, 2011, J CLIN ONCOL, V29, P4498, DOI 10.1200/JCO.2010.33.9101
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Torrisi R, 2011, BREAST CANCER RES TR, V126, P431, DOI 10.1007/s10549-010-1340-y
   Vives M, 2013, INT J CANCER, V133, P2464, DOI 10.1002/ijc.28259
   Wang X, 2016, CLIN TRANSL ONCOL, V18, P82, DOI 10.1007/s12094-015-1339-2
   Wang ZH, 2012, CANCER CHEMOTH PHARM, V69, P515, DOI 10.1007/s00280-011-1728-3
   Wong NS, 2010, J CLIN ONCOL, V28, P723, DOI 10.1200/JCO.2009.24.0143
   Yoshimoto M, 2012, CANCER CHEMOTH PHARM, V70, P331, DOI 10.1007/s00280-012-1826-x
   Zafer M, 2016, FERTIL STERIL, V105, P645, DOI 10.1016/j.fertnstert.2015.11.028
NR 52
TC 6
Z9 6
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 15
PY 2017
VL 12
IS 3
AR e0173693
DI 10.1371/journal.pone.0173693
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN9HQ
UT WOS:000396311700053
PM 28296916
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Afshin, A
   Penalvo, JL
   Del Gobbo, L
   Silva, J
   Michaelson, M
   O'Flaherty, M
   Capewell, S
   Spiegelman, D
   Danaei, G
   Mozaffarian, D
AF Afshin, Ashkan
   Penalvo, Jose L.
   Del Gobbo, Liana
   Silva, Jose
   Michaelson, Melody
   O'Flaherty, Martin
   Capewell, Simon
   Spiegelman, Donna
   Danaei, Goodarz
   Mozaffarian, Dariush
TI The prospective impact of food pricing on improving dietary consumption:
   A systematic review and meta-analysis
SO PLOS ONE
LA English
DT Article
ID NUTRITION EDUCATION; PREVENT OBESITY; PUBLIC-HEALTH; PURCHASES; PRICES;
   FRUIT; INTERVENTION; INCOME; TAXES; DISCOUNTS
AB Background
   While food pricing is a promising strategy to improve diet, the prospective impact of food pricing on diet has not been systematically quantified.
   Objective
   To quantify the prospective effect of changes in food prices on dietary consumption.
   Design
   We systematically searched online databases for interventional or prospective observational studies of price change and diet; we also searched for studies evaluating adiposity as a secondary outcome. Studies were excluded if price data were collected before 1990. Data were extracted independently and in duplicate. Findings were pooled using DerSimonianLaird's random effects model. Pre-specified sources of heterogeneity were analyzed using meta-regression; and potential for publication bias, by funnel plots, Begg's and Egger's tests.
   Results
   From 3,163 identified abstracts, 23 interventional studies and 7 prospective cohorts with 37 intervention arms met inclusion criteria. In pooled analyses, a 10% decrease in price (i.e., subsidy) increased consumption of healthful foods by 12% (95% CI = 10-15%; N = 22 studies/intervention arms) whereas a 10% increase price (i.e. tax) decreased consumption of unhealthful foods by 6% (95% CI = 4-8%; N = 15). By food group, subsidies increased intake of fruits and vegetables by 14% (95% CI = 11-17%; N = 9); and other healthful foods, by 16% (95% CI = 10-23%; N = 10); without significant effects on more healthful beverages (-3%; 95% CI = -16-11%; N = 3). Each 10% price increase reduced sugar-sweetened beverage intake by 7% (95% CI = 3-10%; N = 5); fast foods, by 3% (95% CI = 1-5%; N = 3); and other unhealthful foods, by 9% (95% CI = 6-12%; N = 3). Changes in price of fruits and vegetables reduced body mass index (-0.04 kg/m(2) per 10% price decrease, 95% CI = -0.08-0 kg/m(2); N = 4); price changes for sugar-sweetened beverages or fast foods did not significantly alter body mass index, based on 4 studies. Meta-regression identified direction of price change (tax vs. subsidy), number of intervention components, intervention duration, and study quality score as significant sources of heterogeneity (P-heterogeneity<0.05 each). Evidence for publication bias was not observed.
   Conclusions
   These prospective results, largely from interventional studies, support efficacy of subsidies to increase consumption of healthful foods; and taxation to reduce intake of unhealthful beverages and foods. Use of subsidies and combined multicomponent interventions appear most effective.
C1 [Afshin, Ashkan] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.
   [Afshin, Ashkan; Penalvo, Jose L.; Del Gobbo, Liana; Mozaffarian, Dariush] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
   [Del Gobbo, Liana] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
   [Silva, Jose] Boston Med Ctr, Dept Cardiol, Boston, MA USA.
   [Michaelson, Melody] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [O'Flaherty, Martin; Capewell, Simon] Univ Liverpool, Dept Publ Hlth & Policy, Liverpool, Merseyside, England.
   [Spiegelman, Donna] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Spiegelman, Donna; Danaei, Goodarz] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Spiegelman, Donna; Danaei, Goodarz] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA.
   [Spiegelman, Donna] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA.
RP Afshin, A (reprint author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.; Afshin, A (reprint author), Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
EM aafshin@uw.edu
OI Penalvo, Jose L/0000-0003-0096-6238
FU National Heart, Lung, and Blood Institute [T32 HL098048]; National
   Heart, Lung, and Blood Institute and a Research Award from The New York
   Academy of Sciences' Sacker Institute for Nutrition Science [R01
   HL115189]; Bunge Fellowship in Global Nutrition; McKinsey Health Systems
   Institute; Foodminds; Nutrition Impact; Amarin; Omthera; Winston and
   Strawn LLP; GlaxoSmithKline; Sigma Tau; Pronova; Gates Foundation;
   Sackler Institute of Nutrition; National Institutes of Health
FX AA was supported by T32 HL098048 from the National Heart, Lung, and
   Blood Institute. DM was supported by R01 HL115189 from the National
   Heart, Lung, and Blood Institute and a Research Award from The New York
   Academy of Sciences' Sacker Institute for Nutrition Science. JP was
   partly supported by a Bunge Fellowship in Global Nutrition. DM reports
   ad hoc travel reimbursement or honoraria from Bunge, Pollock Institute,
   Quaker Oats, and Life Sciences Research Organization; ad hoc consulting
   fees from McKinsey Health Systems Institute, Foodminds, Nutrition
   Impact, Amarin, Omthera, and Winston and Strawn LLP; membership,
   Unilever North America Scientific Advisory Board; royalties from
   UpToDate; and research grants from GlaxoSmithKline, Sigma Tau, Pronova,
   the Gates Foundation, the Sackler Institute of Nutrition, and the
   National Institutes of Health. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Afshin A, 2014, HDB GLOBAL HLTH POLI
   Afshin A, 2015, CURR CARDIOL REP, V17, DOI 10.1007/s11886-015-0658-9
   An RP, 2013, PUBLIC HEALTH NUTR, V16, P1215, DOI 10.1017/S1368980012004715
   An RP, 2013, AM J HEALTH BEHAV, V37, P56, DOI 10.5993/AJHB.37.1.6
   Anderson JV, 2001, J AM DIET ASSOC, V101, P195, DOI 10.1016/S0002-8223(01)00052-9
   Andreyeva T, 2010, AM J PUBLIC HEALTH, V100, P216, DOI 10.2105/AJPH.2008.151415
   Anliker J, 1992, EVALUATION CONNECTIC
   [Anonymous], 2011, POLITICAL DECLARATIO
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bihan H, 2012, EUR J CLIN NUTR, V66, P369, DOI 10.1038/ejcn.2011.173
   Blakely T, 2011, J EPIDEMIOL COMMUN H, V65, P902, DOI 10.1136/jech.2010.118588
   Block JP, 2010, AM J PUBLIC HEALTH, V100, P1427, DOI 10.2105/AJPH.2009.175687
   Briss PA, 2000, AM J PREV MED, V18, P35, DOI 10.1016/S0749-3797(99)00119-1
   Brown DM, 2009, J AM DIET ASSOC, V109, P2036, DOI 10.1016/j.jada.2009.09.008
   Duffey KJ, 2010, ARCH INTERN MED, V170, P420, DOI 10.1001/archinternmed.2009.545
   Elbel B, 2013, AM J PREV MED, V45, P49, DOI 10.1016/j.amepre.2013.02.023
   Epstein LH, 2012, AM J CLIN NUTR, V95, P789, DOI 10.3945/ajcn.111.024380
   Escobar MAC, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1072
   Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303
   Fletcher JM, 2010, CONTEMP ECON POLICY, V28, P23, DOI 10.1111/j.1465-7287.2009.00182.x
   French SA, 1997, J AM DIET ASSOC, V97, P1008, DOI 10.1016/S0002-8223(97)00242-3
   French SA, 1997, AM J PUBLIC HEALTH, V87, P849, DOI 10.2105/AJPH.87.5.849
   French SA, 2001, AM J PUBLIC HEALTH, V91, P112
   French SA, 2010, PREV MED, V50, P180, DOI 10.1016/j.ypmed.2010.01.002
   Gordon-Larsen P, 2011, HEALTH PLACE, V17, P1235, DOI 10.1016/j.healthplace.2011.07.011
   Green R, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3703
   Herman DR, 2008, AM J PUBLIC HEALTH, V98, P98, DOI 10.2105/AJPH.2005.079418
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Horgen KB, 2002, HEALTH PSYCHOL, V21, P505, DOI 10.1037/0278-6133.21.5.505
   JEFFERY RW, 1994, PREV MED, V23, P788, DOI 10.1006/pmed.1994.1135
   Jue JJS, 2012, PREV MED, V55, P629, DOI 10.1016/j.ypmed.2012.10.009
   Khan T, 2012, J OBES, DOI 10.1155/2012/857697
   Kocken PL, 2012, J SCHOOL HEALTH, V82, P115, DOI 10.1111/j.1746-1561.2011.00674.x
   Kottke TE, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.120214
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
   Lowe MR, 2010, EAT BEHAV, V11, P144, DOI 10.1016/j.eatbeh.2010.01.002
   Maniadakis N, 2013, CLINICOECONOMIC OUTC, V5, P519, DOI 10.2147/CEOR.S49659
   Meyer KA, 2014, JAMA INTERN MED, V174, P434, DOI 10.1001/jamainternmed.2013.13922
   Michels KB, 2008, J AM COLL NUTR, V27, P6, DOI 10.1080/07315724.2008.10719669
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Mozaffarian D, 2014, JAMA-J AM MED ASSOC, V312, P889, DOI 10.1001/jama.2014.8232
   Mozaffarian D, 2012, CIRCULATION, V126, P1514, DOI 10.1161/CIR.0b013e318260a20b
   Mozaffarian D, 2011, CIRCULATION, V123, P2870, DOI 10.1161/CIRCULATIONAHA.110.968735
   Mozaffarian D, 2011, NEW ENGL J MED, V364, P2392, DOI 10.1056/NEJMoa1014296
   Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805
   Paine-Andrews A, 1996, Health Mark Q, V14, P85
   Powell L, 2011, AM J AGR EC, V93
   Powell LM, 2013, OBES REV, V14, P110, DOI 10.1111/obr.12002
   Powell LM, 2009, ECON HUM BIOL, V7, P64, DOI 10.1016/j.ehb.2009.01.004
   Snyder LB, 2004, J HEALTH COMMUN, V9, P71, DOI 10.1080/10810730490271548
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Thow AM, 2014, NUTR REV
   Waterlander WE, 2013, AM J CLIN NUTR, V97, P886, DOI 10.3945/ajcn.112.041632
   Wendt M, 2011, EFFECT FOOD BEVERAGE
   World Health Organization, 2013, GLOB ACT PLAN PREV C
   World Health Organization, 2003, DIET NUTR PREV CHRON, V916, pi
   World Health Organization, 2004, GLOB STRAT DIET PHYS
NR 57
TC 38
Z9 38
U1 1
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 1
PY 2017
VL 12
IS 3
AR e0172277
DI 10.1371/journal.pone.0172277
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN4NF
UT WOS:000395983500034
PM 28249003
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Cai, FC
   Xiao, XY
   Niu, X
   Zhong, Y
AF Cai, Fucheng
   Xiao, Xiyue
   Niu, Xun
   Zhong, Yi
TI Association between promoter methylation of DAPK lgene and HNSCC: A
   meta-analysis
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; PROTEIN-KINASE; NECK-CANCER; HYPERMETHYLATION;
   TUMOR; GENES; HEAD; APOPTOSIS; METASTASIS; TISSUES
AB Background
   The death-associated protein kinase (DAPK) is a tumor suppressor gene, which is a mediator of cell death of INF-gamma-induced apoptosis. Aberrant methylation of DAPK promoter has been reported in patients with head and neck squamous cell carcinoma (HNSCC). However, the results of these studies are inconsistent. Hence, the present study aimed to evaluate the association between the promoter methylation of DAPK gene and HNSCC.
   Methods
   Relevant studies were systematically searched in PubMed, Web of Science, Ovid, and Embase. The association between DAPK promoter methylation and HNSCC was assessed by odds ratio (ORs) and 95% confidence intervals (CI). To evaluate the potential sources of heterogeneity, we conducted the meta-regression analysis and subgroup analysis.
   Results
   Eighteen studies were finally included in the meta-analysis. The frequency of DAPK promoter methylation in patients with HNSCC was 4.09-fold higher than the non-cancerous controls (OR = 3.96, 95% CI = 2.26-6.95). A significant association between DAPK promoter methylation and HNSCC was found among the Asian region and the Non-Asia region (Asian region, OR = 4.43, 95% CI = 2.29-8.58; Non-Asia region, OR = 3.39, 95% CI = 1.18-9.78). In the control source, the significant association between DAPK promoter methylation and HNSCC was seen among the autologous group and the heterogeneous group (autologous group, OR = 2.71, 95% CI = 1.49-4.93; heterogeneous group, OR = 9.50, 95% CI = 2.98 - 30.27). DAPK promoter methylation was significantly correlated with alcohol status (OR = 1.85, 95% CI = 1.07-3.21).
   Conclusion
   The results of this meta-analysis suggested that aberrant methylation of DAPK promoter was associated with HNSCC.
C1 [Cai, Fucheng] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China.
   [Xiao, Xiyue] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Obstet & Gynecol, Wuhan, Peoples R China.
   [Niu, Xun; Zhong, Yi] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Otorhinolaryngol, Wuhan, Peoples R China.
RP Zhong, Y (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Otorhinolaryngol, Wuhan, Peoples R China.
EM zyzy0411@163.com
FU National Nature Science Foundation of China [81200745, 81501297]
FX This work was supported by the National Nature Science Foundation of
   China (No. 81200745 and No. 81501297). The funder had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Arantes LMRB, 2015, EUR J CANCER, V51, P632, DOI 10.1016/j.ejca.2015.01.060
   Bai J, 2016, ONCOTARGET
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Choudhury JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129808
   Christoph F, 2006, BRIT J CANCER, V95, P1701, DOI 10.1038/sj.bjc.6603482
   Cohen O, 1999, J CELL BIOL, V146, P141
   De Schutter H, 2009, ONCOL REP, V21, P507, DOI 10.3892/or_00000251
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459
   Guerrero-Preston R, 2014, EPIGENETICS-US, V9, P1031, DOI 10.4161/epi.29025
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Inbal B, 1997, NATURE, V390, P180
   Kong WJ, 2005, LARYNGOSCOPE, V115, P1395, DOI 10.1097/01.MLG.0000166708.23673.3A
   Kulkarni V, 2004, ORAL ONCOL, V40, P145, DOI 10.1016/S1368-8375(03)00143-X
   Laytragoon-Lewin N, 2010, ANTICANCER RES, V30, P4643
   Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
   Li CY, 2013, ONCOL LETT, V6, P280, DOI 10.3892/ol.2013.1353
   Liberati A, PRISMA STATEMENT REP
   Liu Y, 2012, MED ONCOL, V29, P729, DOI 10.1007/s12032-011-9953-5
   Misawa K, 2016, ONCOTARGET
   Misawa Y, 2014, CANCER-AM CANCER SOC, V120, P205, DOI 10.1002/cncr.28411
   Niklinska W, 2009, FOLIA HISTOCHEM CYTO, V47, P275, DOI 10.2478/v10042-009-0091-2
   Ogi K, 2002, CLIN CANCER RES, V8, P3164
   Paluszczak J, 2011, ORAL ONCOL, V47, P104, DOI 10.1016/j.oraloncology.2010.11.006
   Pierini S, 2014, HEAD NECK-J SCI SPEC, V36, P1103, DOI 10.1002/hed.23413
   Rettori MM, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-316
   Righini CA, 2007, CLIN CANCER RES, V13, P1179, DOI 10.1158/1078-0432.CCR-06-2027
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Steinmann K, 2009, ONCOL REP, V22, P1519, DOI 10.3892/or_00000596
   Su PF, 2010, ORAL ONCOL, V46, P734, DOI 10.1016/j.oraloncology.2010.07.002
   Supic G, 2009, ORAL ONCOL, V45, P1051, DOI 10.1016/j.oraloncology.2009.07.007
   Velentza AV, 2001, J BIOL CHEM, V276, P38956, DOI 10.1074/jbc.M104273200
   Wang WM, 2016, ONCOL REP, V35, P139, DOI 10.3892/or.2015.4347
   Wong YK, 2011, J DENT SCI, V6, P158, DOI 10.1016/j.jds.2011.05.006
NR 35
TC 3
Z9 3
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 1
PY 2017
VL 12
IS 3
AR e0173194
DI 10.1371/journal.pone.0173194
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN4NF
UT WOS:000395983500081
PM 28249042
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, JN
   Zhang, DD
   Huang, RZ
   Li, XS
   Huang, WX
AF Wang, Junna
   Zhang, Dandan
   Huang, Rongzhong
   Li, Xingsheng
   Huang, Wenxiang
TI Gamma-glutamyltransferase and risk of cardiovascular mortality: A
   dose-response meta-analysis of prospective cohort studies
SO PLOS ONE
LA English
DT Article
ID CORONARY-HEART-DISEASE; ALCOHOL-CONSUMPTION; OXIDATIVE STRESS;
   REGRESSION-MODELS; PUBLICATION BIAS; BLOOD-PRESSURE; FLOW RESERVE;
   TRANSPEPTIDASE; POPULATION; WOMEN
AB Background
   Serum gamma-glutamyltransferase (GGT) elevation likely contributes to cardiovascular (CV) mortality, however it has remained unknown whether a dose-response relationship exists between serum GGT and CV mortality.
   Methods
   We searched the PubMed, EMBASE, and Cochrane library databases for prospective cohort studies published up to October 2, 2016. Summary hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs) were calculated using a fixed effects model.
   Findings
   Nine prospective studies, including 527,589 participants and more than 7,011 cases, were included in this meta-analysis. For the moderate, high, and highest levels of GGT, the pooled HRs of CV mortality were 1.11 (95% CI = 1.04-1.19), 1.29 (95% CI = 1.21-1.38) and 1.59 (95% CI = 1.47-1.72), respectively (all p < 0.05 as compared to the lowest levels of GGT). Additionally, the HR per incremental increase of GGT by 10 U/L was 1.10 (95% CI = 1.08-1.11). Evidence of a positive relationship with nonlinear trend for GGT elevation with CV mortality in females was found (P = 0.04 for nonlinearity). However, a linear model was better fit to illustrate the GGT-CV mortality among males (P = 0.304 for nonlinearity).
   Conclusions
   These findings indicate that serum GGT activity within the reference interval is positively associated with increased risk of CV mortality in a dose-response manner.
C1 [Wang, Junna; Huang, Wenxiang] Chongqing Med Univ, Dept Infect Dis, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Zhang, Dandan; Li, Xingsheng] Chongqing Med Univ, Dept Gerontol, Affiliated Hosp 2, Chongqing, Peoples R China.
   [Huang, Rongzhong] Chongqing Med Univ, Dept Rehabil Med, Affiliated Hosp 2, Chongqing, Peoples R China.
RP Huang, WX (reprint author), Chongqing Med Univ, Dept Infect Dis, Affiliated Hosp 1, Chongqing, Peoples R China.; Li, XS (reprint author), Chongqing Med Univ, Dept Gerontol, Affiliated Hosp 2, Chongqing, Peoples R China.
EM lxs2858@163.com; hwx8623@163.com
FU Chongqing Science Foundation, China [KJ130332]; young elite talents
   project in the second Affiliated Hospital of Chongqing Medical
   University [2014]; Health Bureau, Chongqing, China [20102153]
FX This project was supported by the Chongqing Science Foundation, China
   (No: KJ130332), The young elite talents project (No: 2014) in the second
   Affiliated Hospital of Chongqing Medical University and the research
   projects of Health Bureau, Chongqing, China (No:20102153). The funders
   play a role in decision to publish, or preparation of the manuscript.
CR Ali SS, 2016, NUTR METAB, V13, DOI 10.1186/s12986-016-0097-7
   Angeli V, 2009, ARCH BIOCHEM BIOPHYS, V481, P191, DOI 10.1016/j.abb.2008.10.027
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belcastro E, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0687-6
   Bradley RD, 2014, ATHEROSCLEROSIS, V233, P387, DOI 10.1016/j.atherosclerosis.2014.01.010
   Breitling LP, 2011, J HEPATOL, V55, P594, DOI 10.1016/j.jhep.2010.12.029
   Bulusu S, 2016, ANN CLIN BIOCHEM, V53, P312, DOI 10.1177/0004563215597010
   Chen JT, 2016, AGING CLIN EXP RES, V28, P619, DOI 10.1007/s40520-015-0460-y
   Ciftci O, 2013, CORONARY ARTERY DIS, V24, P201, DOI 10.1097/MCA.0b013e32835e5c86
   Daeppen JB, 1998, ALCOHOL CLIN EXP RES, V22, P941, DOI 10.1097/00000374-199806000-00027
   Danielsson J, 2013, INT J MOL SCI, V14, P11929, DOI 10.3390/ijms140611929
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ding M, 2014, CIRCULATION, V129, P643, DOI 10.1161/CIRCULATIONAHA.113.005925
   Du GL, 2013, PREV MED, V57, P31, DOI 10.1016/j.ypmed.2013.03.011
   Dugani S, 2016, CURR CARDIOL REP, V18, DOI 10.1007/s11886-015-0679-4
   DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Emdin M, 2005, CIRCULATION, V112, P2078, DOI 10.1161/CIRCULATIONAHA.105.571919
   Emdin M, 2002, STROKE, V33, P1163, DOI 10.1161/01.STR.0000012344.35312.13
   Erdogan D, 2005, BLOOD PRESSURE, V14, P345, DOI 10.1080/08037050500356550
   Ezzati M, 2015, NAT REV CARDIOL, V12, P508, DOI 10.1038/nrcardio.2015.82
   Fraser A, 2007, ARTERIOSCL THROM VAS, V27, P2729, DOI 10.1161/ATVBAHA.107.152298
   Galderisi M, 2002, AM J CARDIOL, V90, P860, DOI 10.1016/S0002-9149(02)02708-X
   GJERDE H, 1987, BRIT J ADDICT, V82, P1027
   Haring R, 2009, HEPATOLOGY, V50, P1403, DOI 10.1002/hep.23135
   HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hozawa A, 2007, ATHEROSCLEROSIS, V194, P498, DOI 10.1016/j.atherosclerosis.2006.08.058
   Kengne AP, 2012, J HEPATOL, V57, P1083, DOI 10.1016/j.jhep.2012.06.034
   Kim DJ, 2005, DIABETIC MED, V22, P1134, DOI 10.1111/j.1464-5491.2005.01581.x
   KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005
   Klatsky AL, 2015, J INTERN MED, V278, P238, DOI 10.1111/joim.12390
   Koehler EM, 2014, LIVER INT, V34, P296, DOI 10.1111/liv.12311
   Kontis V, 2014, LANCET, V384, P427, DOI 10.1016/S0140-6736(14)60616-4
   Kunutsor SK, 2015, J HYPERTENS, V33, P2373, DOI 10.1097/HJH.0000000000000763
   Kunutsor SK, 2014, ANN EPIDEMIOL, V24, P809, DOI 10.1016/j.annepidem.2014.09.001
   Lee DS, 2007, ARTERIOSCL THROM VAS, V27, P127, DOI 10.1161/01.ATV.0000251993.20372.40
   Lee DH, 2008, ARTERIOSCL THROM VAS, V28, pE26, DOI 10.1161/ATVBAHA.107.159376
   Lee DH, 2006, EUR HEART J, V27, P2170, DOI 10.1093/eurheartj/ehl086
   Lee DH, 2009, EUR J CARDIOV PREV R, V16, P16, DOI 10.1097/HJR.0b013e32830aba5c
   Li YY, 2016, J ATHEROSCLER THROMB, V23, P792, DOI 10.5551/jat.32698
   Long Y, 2014, FREE RADICAL RES, V48, P716, DOI 10.3109/10715762.2014.902055
   Loomba R, 2013, J CLIN EXP HEPATOL, V3, P4, DOI 10.1016/j.jceh.2012.10.004
   MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9
   Mahady S. E., 2016, J CLIN GASTROENTEROL
   Meisinger C, 2006, ATHEROSCLEROSIS, V189, P297, DOI 10.1016/j.atherosclerosis.2006.01.010
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   NILSSEN O, 1994, AM J EPIDEMIOL, V139, P787, DOI 10.1093/oxfordjournals.aje.a117075
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Paolicchi A, 2004, CIRCULATION, V109, P1440, DOI 10.1161/01.CIR.0000120558.41356.E6
   Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010
   Petitti D. B., 1999, METAANALYSIS DECISIO
   ROLLASON JG, 1972, CLIN CHIM ACTA, V39, P75, DOI 10.1016/0009-8981(72)90301-4
   Rong Y, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e8539
   Ruhl CE, 2009, GASTROENTEROLOGY, V136, P477, DOI 10.1053/j.gastro.2008.10.052
   RUMBERGER JA, 1995, CIRCULATION, V92, P2157, DOI 10.1161/01.CIR.92.8.2157
   Ruttmann E, 2005, CIRCULATION, V112, P2130, DOI 10.1161/CIRCULATIONAHA.105.552547
   Saijo Y, 2008, NUTR METAB CARDIOVAS, V18, P211, DOI 10.1016/j.numecd.2006.10.002
   Silva ERDE, 2000, CIRCULATION, V102, P2347, DOI 10.1161/01.CIR.102.19.2347
   Sinn DH, 2016, GASTROENTEROLOGY, V150
   Sung KC, 2015, CLIN CHEM, V61, P1173, DOI 10.1373/clinchem.2015.240424
   Turgut O, 2011, J ATHEROSCLER THROMB, V18, P177, DOI 10.5551/jat.6189
   Ucar H, 2015, SCAND J CLIN LAB INV, V75, P7, DOI 10.3109/00365513.2014.954141
   van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040
   VANBARNEVELD T, 1989, EUR J CLIN NUTR, V43, P809
   Wallin A, 2011, BRIT J CANCER, V104, P1196, DOI 10.1038/bjc.2011.49
   Wannamethee SG, 2008, ATHEROSCLEROSIS, V201, P168, DOI 10.1016/j.atherosclerosis.2008.01.019
   Wells GA, 2000, NEWCASTLE OTTAWA SCA
   Whitfield JB, 2001, CRIT REV CL LAB SCI, V38, P263, DOI 10.1080/20014091084227
   Wickham S, 2011, ANAL BIOCHEM, V414, P208, DOI 10.1016/j.ab.2011.03.026
NR 70
TC 6
Z9 6
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 23
PY 2017
VL 12
IS 2
AR e0172631
DI 10.1371/journal.pone.0172631
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EL5SX
UT WOS:000394682400063
PM 28231268
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Qiao, WQ
   Pan, LL
   Kou, CG
   Li, K
   Yang, M
AF Qiao, Weiqiang
   Pan, Linlin
   Kou, Changgui
   Li, Ke
   Yang, Ming
TI Prognostic and clinicopathological value of poly (adenosine
   diphosphate-ribose) polymerase expression in breast cancer: A
   meta-analysis
SO PLOS ONE
LA English
DT Article
ID PATHOLOGICAL COMPLETE RESPONSE; NEOADJUVANT CHEMOTHERAPY; THERAPY;
   PARP1; GEMCITABINE; CARBOPLATIN; INHIBITORS; INIPARIB
AB Background
   Previous studies have shown that the poly (adenosine diphosphate-ribose) polymerase (PARP) level is a promising indicator of breast cancer. However, its prognostic value remains controversial. The present meta-analysis evaluated the prognostic value of PARP expression in breast cancer.
   Materials and methods
   Eligible studies were retrieved from the PubMed, Web of Science, Embase, and Cochrane Library databases through July 20, 2016. Studies investigating PARP expression as well as reporting survival data in breast cancer were included. Two independent reviewers carried out all literature searches. The pooled relative risk (RR) and hazard ratio (HR) with 95% confidence interval (95% CI) were applied to assess the association between PARP expression and the clinicopathological features and survival outcome in breast cancer.
   Results
   A total of 3506 patients from eight eligible studies were included. We found that higher PARP expression indicated a worse clinical outcome in early stage breast cancer, with a HR of 3.08 (95% CI, 1.14-8.29, P = 0.03) for disease-free survival and a HR of 1.82 (95% CI, 1.20-2.76; P = 0.005) for overall survival. Moreover, increased PARP expression was significantly associated with higher nuclear grade (RR, 1.51; 95% CI, 1.12-2.04; P = 0.008) in breast cancer. A similar correlation was detected in triple-negative breast cancer (TNBC; RR, 1.81; 95% CI, 1.04-3.17; P = 0.04).
   Conclusions
   Our findings indicated that elevated PARP expression correlated with worse prognosis in early stage breast cancer. Furthermore, high PARP expression was associated with higher nuclear grade and TNBC.
C1 [Qiao, Weiqiang; Pan, Linlin; Yang, Ming] Jilin Univ, Hosp 1, Dept Breast Surg, Changchun, Peoples R China.
   [Kou, Changgui] Jilin Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Changchun, Peoples R China.
   [Li, Ke] Jilin Univ, Hosp 1, Dept Emergency, Changchun, Peoples R China.
RP Yang, M (reprint author), Jilin Univ, Hosp 1, Dept Breast Surg, Changchun, Peoples R China.
EM yangming196701@163.com
OI Pan, Linlin/0000-0002-5909-0309; Qiao, Weiqiang/0000-0003-4178-4617
FU Science and Technology Development Project of Jilin Province
   [20150312033ZG]
FX This work was supported by the Science and Technology Development
   Project of Jilin Province: NO. 20150312033ZG (http://www.jlkjxm.com/).
   The funders had no role in the study design, data collection and
   analysis, decision to publish,or preparation of the manuscript.
CR Aiad HA, 2015, APPL IMMUNOHISTO M M, V23, P571, DOI 10.1097/PAI.0000000000000124
   Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085
   Bao ZQ, 2016, ONCOTARGET, V7, P7629, DOI 10.18632/oncotarget.5367
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berruti A, 2014, J CLIN ONCOL, V32, P3883, DOI 10.1200/JCO.2014.55.2836
   Broglio KR, 2016, JAMA ONCOL, V2, P751, DOI 10.1001/jamaoncol.2015.6113
   Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8
   Comen EA, 2010, CANCER J, V16, P48, DOI 10.1097/PPO.0b013e3181cf01eb
   Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8
   DerSimonian R, 2015, CONTEMP CLIN TRIALS, V45, P139, DOI 10.1016/j.cct.2015.09.002
   Donizy P, 2014, ONCOL REP, V31, P1777, DOI 10.3892/or.2014.3024
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Gilabert M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104302
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Goncalves A, 2011, BREAST CANCER RES TR, V127, P273, DOI 10.1007/s10549-010-1199-y
   Gralow JR, 2008, J CLIN ONCOL, V26, P814, DOI 10.1200/JCO.2007.15.3510
   Green AR, 2015, BREAST CANCER RES TR, V149, P353, DOI 10.1007/s10549-014-3230-1
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Kong XN, 2011, EUR J CANCER, V47, P2084, DOI 10.1016/j.ejca.2011.06.014
   Lee YCG, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005269
   Legrand AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055883
   Mazzotta A, 2016, TUMOR BIOL, V37, P6143, DOI 10.1007/s13277-015-4465-0
   Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010
   O'Shaughnessy J, 2014, J CLIN ONCOL, V32, P3840, DOI 10.1200/JCO.2014.55.2984
   O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418
   Rojo F, 2012, ANN ONCOL, V23, P1156, DOI 10.1093/annonc/mdr361
   Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Telli ML, 2015, J CLIN ONCOL, V33, P1895, DOI 10.1200/JCO.2014.57.0085
   Tian MY, 2015, ONCOL LETT, V9, P2825, DOI 10.3892/ol.2015.3072
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Torre LA, 2012, CA-CANCER J CLIN, V2015, P87, DOI DOI 10.3322/CAAC.21262
   von Minckwitz G, 2011, J CLIN ONCOL, V29, P2150, DOI 10.1200/JCO.2010.31.9079
   Zhai LL, 2015, PATHOL RES PRACT, V211, P130, DOI 10.1016/j.prp.2014.11.004
NR 34
TC 0
Z9 0
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 17
PY 2017
VL 12
IS 2
AR e0172413
DI 10.1371/journal.pone.0172413
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EL2BI
UT WOS:000394424700045
PM 28212434
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Shao, CH
   Dai, WZ
   Li, HL
   Tang, WR
   Jia, ST
   Wu, XM
   Luo, Y
AF Shao, Chihao
   Dai, Wenzhu
   Li, Haili
   Tang, Wenru
   Jia, Shuting
   Wu, Xiaoming
   Luo, Ying
TI The relationship between RASSF1A gene promoter methylation and the
   susceptibility and prognosis of melanoma: A meta-analysis and
   bioinformatics
SO PLOS ONE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENES; EPIGENETIC INACTIVATION; CUTANEOUS MELANOMA;
   MALIGNANT-MELANOMA; CPG ISLAND; CANCER; LUNG; ASSOCIATION; KINASE;
   BREAST
AB Background
   The function of the tumor suppressor gene RASSF1A in cancer cells has been detailed in many studies. However, due to the methylation of its promoter, the expression of RASSF1A is missing in most cancers. In the literature, we found that the conclusion regarding the relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma was not unified. This study adopts the use of a meta-analysis and bioinformatics to explore the relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma.
   Methods
   Data on melanoma susceptibility were downloaded from the PubMed, Cochrane Library, Web of Science and Google Scholar databases, which were analyzed via a meta-analysis. The effect sizes were estimated by measuring an odds ratio (OR) with a 95% confidence interval (CI). We also used a chi-squared-based Q test to examine the between-study heterogeneity, and used funnel plots to evaluate publication bias. The data on melanoma prognosis, which were analyzed by bioinformatics methods, were downloaded from The Cancer Genome Atlas (TCGA) project. The effect sizes were estimated by measuring the hazard ratios (HRs) with a 95% confidence interval (CI).
   Results
   Our meta-analysis included 10 articles. We found that RASSF1A gene promoter methylation was closely related to melanoma susceptibility (OR = 12.67, 95% CI: 6.16 similar to 26.05, z = 6.90, P<0.0001 according to a fixed effects model and OR = 9.25, 95% CI: 4.37 similar to 19.54, z = 5.82, P<0.0001 according to a random effects model). The results of the meta-analysis did not reveal any heterogeneity (tau(2) = 0.00; H =1 [1; 1.55]; I-2 = 0% [0%; 58.6%], P = 0.5158) or publication bias (t = 0.87, P = 0.4073 by Egger's test; Z = 0.45, P = 0.6547 by Begg's test); therefore, we believe that the results of our meta-analysis were more reliable. To explore the relationship between RASSF1A gene methylation, the prognosis of melanoma and the clinical features of this cancer type, we used the melanoma DNA methylation data and clinical data from TCGA project. We found that RASSF1A gene promoter methylation and melanoma prognosis did not demonstrate any relationship (HR was 0.94 (95% CI = [0.69; 1.27], P = 0.694) with disease-free survival and 0.74 (95% CI = [0.53; 1.05], P = 0.106) for overall survival), and no significant difference was observed between RASSF1A gene promoter methylation and the clinical-pathological features of melanoma.
   Conclusions
   In conclusion, the meta-analysis of the data in these articles provides strong evidence that the methylation status of the RASSF1A gene promoter was strongly related to melanoma susceptibility. Our bioinformatics analysis revealed no significant difference between RASSF1A gene promoter methylation and the prognosis and clinical-pathological features of melanoma.
C1 [Shao, Chihao; Dai, Wenzhu; Li, Haili; Tang, Wenru; Jia, Shuting; Wu, Xiaoming; Luo, Ying] Kunming Univ Sci & Technol, Lab Mol Genet Aging & Tumor, Fac Med, Kunming, Yunnan, Peoples R China.
RP Wu, XM; Luo, Y (reprint author), Kunming Univ Sci & Technol, Lab Mol Genet Aging & Tumor, Fac Med, Kunming, Yunnan, Peoples R China.
EM xiao_tracy@163.com; luoyingabc@yahoo.com
FU area of national natural science fund project China [81460224];
   scientific research fund project of Yunnan province education department
   [KKJA201560039]
FX This work was financially supported by the area of national natural
   science fund project China (No. 81460224) and the scientific research
   fund project of Yunnan province education department (KKJA201560039).
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   [Anonymous], 2014, WORLD CANC REPORT 20
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Calipel A, 2011, MOL CANCER RES, V9, P1187, DOI 10.1158/1541-7786.MCR-10-0437
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chow C, 2012, ONCOGENE, V31, P1975, DOI 10.1038/onc.2011.372
   Dammann R, 2000, NAT GENET, V25, P315
   Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ OPEN
   Furuta J, 2004, CANCER SCI, V95, P962, DOI 10.1111/j.1349-7006.2004.tb03184.x
   Ge YZ, 2014, TUMOR BIOL, V35, P3881, DOI 10.1007/s13277-013-1515-3
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505
   Jiang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036780
   Koyanagi K, 2006, CANCER RES, V66, P6111, DOI 10.1158/0008-5472.CAN-05-4198
   Li YS, 2014, MOL BIOL REP, V41, P3925, DOI 10.1007/s11033-014-3260-0
   Liu SH, 2008, PIGM CELL MELANOMA R, V21, P545, DOI 10.1111/j.1755-148X.2008.00484.x
   Liu WJ, 2013, ASIAN PAC J CANCER P, V14, P3719, DOI 10.7314/APJCP.2013.14.6.3719
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marini A, 2006, J INVEST DERMATOL, V126, P422, DOI 10.1038/sj.jid.5700073
   Mori T, 2005, J CLIN ONCOL, V23, P9351, DOI 10.1200/JCO.2005.02.9876
   Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097
   Reifenberger J, 2004, INT J CANCER, V109, P377, DOI 10.1002/ijc.11722
   Romano D, 2010, CANCER RES, V70, P1195, DOI 10.1158/0008-5472.CAN-09-3147
   Rong R, 2007, ONCOGENE, V26, P7700, DOI 10.1038/sj.onc.1210575
   Shi H., 2013, J APPL MATH, V2013, P1, DOI DOI 10.1371/J0URNAL.P0NE.0076787
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Spugnardi M, 2003, CANCER RES, V63, P1639
   Tanemura A, 2009, CLIN CANCER RES, V15, P1801, DOI 10.1158/1078-0432.CCR-08-1361
   Vichalkovski A, 2008, CURR BIOL, V18, P1889, DOI 10.1016/j.cub.2008.10.060
   Wang HX, 2014, ADV MECH ENG, DOI 10.1155/2014/971756
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
NR 36
TC 4
Z9 5
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 16
PY 2017
VL 12
IS 2
AR e0171676
DI 10.1371/journal.pone.0171676
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EL2BG
UT WOS:000394424500045
PM 28207831
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, QS
   Wang, Y
   Ma, T
   Lv, Y
   Wu, RQ
AF Li, Qingshan
   Wang, Yue
   Ma, Tao
   Lv, Yi
   Wu, Rongqian
TI Clinical outcomes of patients with and without diabetes mellitus after
   hepatectomy: A systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID LONG-TERM PROGNOSIS; HEPATOCELLULAR-CARCINOMA; PERIOPERATIVE MORTALITY;
   RISK-FACTOR; RESECTION; IMPACT; BIAS; RECURRENCE; THERAPY; WORSENS
AB Background
   Clinical data regarding the influence of diabetes mellitus (DM) on the outcomes of patients undergoing hepatectomy are conflicting. To determine the impact of DM on the clinical outcomes of patients undergoing hepatectomy, we systematically reviewed published studies and carried out a meta-analysis.
   Methods
   A systematic literature search of Pubmed, Sciencedirect, Web of Science, and Chinese Biomedical Database was conducted from their inception through February 2, 2016. The combined relative risk (RR) or hazard ratio (HR) with 95% confidence intervals (95% CI) was calculated.
   Results
   A total of 16 observational studies with 15710 subjects were eligible for meta-analysis. The pooled results showed that DM significantly increased the risk of overall postoperative complications (RR 1.34; 95% CI 1.19-1.51; P<0.001), DM-associated complications (RR 1.8; 95% CI 1.29-2.53; P<0.001), liver failure (RR 2.21; 95% CI 1.3-3.76; P = 0.028) and postoperative infections (RR 1.59; 95% CI 1.01-2.5; P = 0.045). In addition, DM was also found to be significantly associated with unfavorable overall survival and disease free survival after liver resection. The pooled HR was 1.63 (95% CI 1.33-1.99; P<0.001) for overall survival and 1.55 (95% CI 1.07-2.25; P = 0.019) for disease free survival.
   Conclusion
   DM is associated with poor outcomes in patients undergoing hepatectomy. DM should be taken into account cautiously in the management of patients undergoing hepatectomy. Further prospective studies are warranted to explore effective interventions to improve the poor outcomes of diabetic patients undergoing hepatectomy.
C1 [Li, Qingshan; Wang, Yue; Ma, Tao; Lv, Yi; Wu, Rongqian] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1,Shaanxi Ctr Regenerat Med & Sur, Dept Hepatobiliary Surg,Inst Adv Surg Technol & E, Xian, Shaanxi Provinc, Peoples R China.
RP Lv, Y; Wu, RQ (reprint author), Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1,Shaanxi Ctr Regenerat Med & Sur, Dept Hepatobiliary Surg,Inst Adv Surg Technol & E, Xian, Shaanxi Provinc, Peoples R China.
EM Luyi169@126.com; rwu001@mail.xjtu.edu.cn
RI Wu, Rongqian/I-3614-2012
OI Wu, Rongqian/0000-0003-0993-4531
CR Amptoulach S, 2015, J SURG RES, V199, P378, DOI 10.1016/j.jss.2015.05.059
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bucerius J, 2005, Z KARDIOL, V94, P575, DOI 10.1007/s00392-005-0273-7
   Donadon V, 2010, LIVER INT, V30, P750, DOI 10.1111/j.1478-3231.2010.02223.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Facciorusso A, 2013, CURR DIABETES REV, V9, P382, DOI 10.2174/15733998113099990068
   Guckelberger O, 2006, EXP CLIN ENDOCR DIAB, V114, P257, DOI 10.1055/s-2006-924234
   Huo TI, 2004, AM J GASTROENTEROL, V99, P1479, DOI 10.1111/j.1572-0241.2004.30024.x
   Huo TI, 2003, AM J GASTROENTEROL, V98, P2293, DOI 10.1016/S0002-9270(03)00694-4
   Ikeda Y, 1998, HEPATOLOGY, V27, P1567, DOI 10.1002/hep.510270615
   Kawamura Y, 2008, J GASTROEN HEPATOL, V23, P1739, DOI 10.1111/j.1440-1746.2008.05436.x
   Komura T, 2007, AM J GASTROENTEROL, V102, P1939, DOI 10.1111/j.1572-0241.2007.01354.x
   Kuroda S, 2011, WORLD J SURG, V35, P834, DOI 10.1007/s00268-010-0929-y
   Lai SW, 2012, AM J GASTROENTEROL, V107, P46, DOI 10.1038/ajg.2011.384
   Little SA, 2002, J GASTROINTEST SURG, V6, P88, DOI 10.1016/S1091-255X(01)00019-1
   Mik Michal, 2016, Pol Przegl Chir, V88, P26, DOI 10.1515/pjs-2016-0023
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Neal CP, 2012, J GASTROINTEST SURG, V16, P2064, DOI 10.1007/s11605-012-2008-1
   Newhook TE, 2016, AM J SURG, V211, P102, DOI 10.1016/j.amjsurg.2015.06.010
   Ou DP, 2007, ZHONG HUA GAN DAN WA, V13, P317
   Pang PYK, 2016, ANN ACAD MED SINGAP, V45, P83
   Poon RTP, 2002, AM J GASTROENTEROL, V97, P1480, DOI 10.1016/S0002-9270(02)04148-5
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Song FJ, 1998, BRIT MED J, V316, P471
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Ting CT, 2012, TOHOKU J EXP MED, V227, P73, DOI 10.1620/tjem.227.73
   Tsai MS, 2014, ANN SURG ONCOL, V21, P3810, DOI 10.1245/s10434-014-3777-4
   WANG Y, 2014, INT J DISTRIB SENS N, V2014, P9, DOI DOI 10.1371/J0URNAL.P0NE.0110024
   Wang YG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095485
   Wells GA, 2012, NEWCASTLE OTTAWA SCA
   Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029
   YANAGA K, 1993, ARCH SURG-CHICAGO, V128, P445
   Yeh CC, 2013, DIABETES CARE, V36, P3216, DOI 10.2337/dc13-0770
NR 34
TC 3
Z9 4
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 9
PY 2017
VL 12
IS 2
AR e0171129
DI 10.1371/journal.pone.0171129
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EK9GJ
UT WOS:000394231800037
PM 28182632
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, LF
   Lin, J
   Jin, ZC
   Cai, XB
   Gao, WY
AF Wu, Lingfeng
   Lin, Jun
   Jin, Zhicheng
   Cai, Xiaobin
   Gao, Weiyang
TI Comparison of clinical and radiological outcomes between opening-wedge
   and closing-wedge high tibial osteotomy: A comprehensive meta-analysis
SO PLOS ONE
LA English
DT Article
ID CLOSED-WEDGE; PATELLAR HEIGHT; KNEE; OSTEOARTHRITIS; ALIGNMENT; SLOPE;
   RADIOSTEREOMETRY; HEMICALLOTASIS; LENGTH; TRIAL
AB High tibial osteotomy (HTO) has been widely used for clinical treatment of osteoarthritis of the medial compartment of the knee, and both opening-wedge and closing-wedge HTO are the most commonly used methods. However, it remains unclear which technique has better clinical and radiological outcomes in practice. To systematically evaluate this issue, we conducted a comprehensive meta-analysis by pooling all available data for the opening-wedge HTO and closing-wedge HTO techniques from the electronic databases including PubMed, Embase, Wed of Science and Cochrane Library. A total of 22 studies encompassing 2582 cases were finally enrolled in the meta-analysis. There was no significant difference regarding surgery time, duration of hospitalization, knee pain VAS, Lysholm score and HSS knee score (clinical outcomes) between the opening-wedge and closing-wedge HTO groups (P > 0.05). However, the opening-wedge HTO group showed wider range of motion than the closing-wedge HTO group (P = 0.003). Moreover, as for Hip-Knee-Ankle angle and mean angle of correction, no significant difference was observed between the opening-wedge and closing-wedge HTO groups (P > 0.05), while the opening-wedge HTO group showed greater posterior tibial slope angle (P < 0.001) and lesser patellar height than the closing-wedge HTO group (P < 0.001). On light of the above analysis, we believe that individualized surgical approach should be introduced based on the clinical characteristics of each patient.
C1 [Wu, Lingfeng; Cai, Xiaobin] Wenzhou Med Univ, Affiliated Hosp 5, Dept Orthoped, Lishui, Peoples R China.
   [Wu, Lingfeng; Cai, Xiaobin] Wenzhou Med Univ, Cent Hosp Lishui City, Lishui, Peoples R China.
   [Lin, Jun] Qingyuan Country Peoples Hosp, Dept Orthoped, Lishui, Peoples R China.
   [Jin, Zhicheng] Wenzhou Med Univ, Clin Med Coll 2, Dept Surg, Wenzhou, Peoples R China.
   [Gao, Weiyang] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, Wenzhou, Peoples R China.
   [Gao, Weiyang] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
RP Gao, WY (reprint author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, Wenzhou, Peoples R China.; Gao, WY (reprint author), Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
EM wmu_gwy@163.com
FU Science and Technology Bureau of Lishui [2014JYZB24]
FX This study was supported by the Science and Technology Bureau of Lishui
   (No. 2014JYZB24). The funder has no role in study design, data
   collection, manuscript preparation and submission.
CR Agneskirchner JD, 2007, ARTHROSCOPY, V23, P852, DOI 10.1016/j.arthro.2007.05.018
   Amzallag J, 2013, KNEE SURG SPORT TR A, V21, P255, DOI 10.1007/s00167-012-2304-z
   Asada S, 2012, KNEE SURG SPORT TR A, V20, P571, DOI 10.1007/s00167-011-1610-1
   Bae DK, 2013, KNEE SURG SPORT TR A, V21, P120, DOI 10.1007/s00167-012-1898-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brouwer RW, 2006, J BONE JOINT SURG BR, V88B, P1454, DOI 10.1302/0301-620X.88B11.17743
   Brouwer RW, 2005, J BONE JOINT SURG BR, V87B, P1227, DOI 10.1302/0301-620X.87B9.15972
   Brouwer RW, 2014, COCHRANE DB SYST REV, V12
   Clark HD, 1999, CONTROL CLIN TRIALS, V20, P448, DOI 10.1016/S0197-2456(99)00026-4
   Deie M, 2014, KNEE, V21, P1046, DOI 10.1016/j.knee.2014.04.007
   Ducat A, 2012, ORTHOP TRAUMATOL-SUR, V98, P68, DOI 10.1016/j.otsr.2011.08.013
   Duivenvoorden T, 2014, J BONE JOINT SURG AM, V96A, P1425, DOI 10.2106/JBJS.M.00786
   Duivenvoorden T., 2015, KNEE SURG SPORTS TRA
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Azab H, 2008, J BONE JOINT SURG BR, V90B, P1193, DOI 10.1302/0301-620X.90B9.20688
   El-Azab H, 2010, AM J SPORT MED, V38, P323, DOI 10.1177/0363546509348050
   Esenkaya I, 2012, STRATEG TRAUMA LIMB, V7, P13, DOI 10.1007/s11751-012-0131-x
   Fibel KH, 2015, WORLD J CLIN CASES, V3, P89, DOI 10.12998/wjcc.v3.i2.89
   Gaasbeek RDA, 2010, INT ORTHOP, V34, P201, DOI 10.1007/s00264-009-0861-7
   Giffin JR, 2004, AM J SPORT MED, V32, P376, DOI 10.1177/0363546503258880
   Hankemeier S, 2010, KNEE SURG SPORT TR A, V18, P1328, DOI 10.1007/s00167-009-1020-9
   Hoell S, 2005, ARCH ORTHOP TRAUM SU, V125, P638, DOI 10.1007/s00402-005-0004-6
   Lee Dong Chul, 2012, Knee Surg Relat Res, V24, P61, DOI 10.5792/ksrr.2012.24.2.61
   Luites JWH, 2009, J BONE JOINT SURG BR, V91B, P1459, DOI 10.1302/0301-620X.91B11.22614
   Magnussen RA, 2011, AM J SPORT MED, V39, P1900, DOI 10.1177/0363546511410025
   Magyar G, 1999, ACTA ORTHOP SCAND, V70, P473, DOI 10.3109/17453679909000983
   Magyar G, 1999, J BONE JOINT SURG BR, V81B, P444, DOI 10.1302/0301-620X.81B3.8925
   Nakamura E, 2001, J BONE JOINT SURG BR, V83B, P1111, DOI 10.1302/0301-620X.83B8.11993
   Nerhus TK, 2015, KNEE SURG SPORTS TRA
   Portner O, 2014, CLIN ORTHOP RELAT R, V472, P3432, DOI 10.1007/s11999-014-3821-5
   Schaefer TK, 2008, J INT MED RES, V36, P1085, DOI 10.1177/147323000803600528
   Song EK, 2010, J BONE JOINT SURG BR, V92B, P1245, DOI 10.1302/0301-620X.92B9.23660
   Song IH, 2012, ARTHROSCOPY, V28, P1087, DOI 10.1016/j.arthro.2012.02.002
   Tabrizi A, 2013, MALAYS ORTHOP J, V7, P7, DOI 10.5704/MOJ.1303.009
   Takeuchi R, 2009, ARTHROSCOPY, V25, P46, DOI 10.1016/j.arthro.2008.08.015
   van den Bekerom Michel P J, 2008, J Knee Surg, V21, P68
   van Egmond N, 2016, KNEE SURG SPORT TR A, V24, P34, DOI 10.1007/s00167-014-3303-z
   van Raaij TM, 2008, ACTA ORTHOP, V79, P508, DOI 10.1080/17453670710015508
NR 38
TC 8
Z9 9
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 9
PY 2017
VL 12
IS 2
AR e0171700
DI 10.1371/journal.pone.0171700
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EK9GJ
UT WOS:000394231800093
PM 28182736
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhai, JY
   Bo, YC
   Lu, Y
   Liu, CL
   Zhang, LS
AF Zhai, Junya
   Bo, Yacong
   Lu, Yan
   Liu, Chunli
   Zhang, Lishi
TI Effects of Coenzyme Q10 on Markers of Inflammation: A Systematic Review
   and MetaAnalysis
SO PLOS ONE
LA English
DT Review
ID C-REACTIVE PROTEIN; RANDOMIZED CLINICAL-TRIAL; CORONARY-ARTERY-DISEASE;
   FATTY LIVER-DISEASE; METABOLIC SYNDROME; DOUBLE-BLIND; SUPPLEMENTATION;
   Q(10); PLACEBO; EXPRESSION
AB Background/Objective
   Chronic inflammation contributes to the onset and development of metabolic diseases. Clinical evidence has suggested that coenzyme Q10 (CoQ10) has some effects on inflammatory markers. However, these results are equivocal. The aim of this systematic review was to assess the effects of CoQ10 on serum levels of inflammatory markers in people with metabolic diseases.
   Methods
   Electronic databases were searched up to February 2016 for randomized controlled trials (RCTs). The outcome parameters were related to inflammatory factors, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and C reactive protein (CRP). RevMan software was used for meta-analysis. Meta-regression analysis, Egger line regression test and Begg rank correlation test were performed by STATA software.
   Results
   Nine trials involving 428 subjects were included in this meta-analysis. The results showed that compared with control group, CoQ10 supplementation has significantly improved the serum level of CoQ10 by 1.17 mu g/ml [ MD = 1.17, 95% CI (0.47 to 1.87) mu g/ml, I-2 = 94%]. Meanwhile, it has significantly decreased TNF-a by 0.45 pg/ml [ MD = -0.45, 95% CI (-0.67 to -0.24) pg/ml, I-2 = 0%]. No significant difference was observed between CoQ10 and placebo with regard to CRP [ MD = -0.21, 95% CI (-0.60 to 0.17) mg/L, I-2 = 21%] and IL-6 [ MD = -0.89, 95% CI (-1.95 to 0.16) pg/ml, I-2 = 84%].
   Conclusions
   CoQ10 supplementation may partly improve the process of inflammatory state. The effects of CoQ10 on inflammation should be further investigated by conducting larger sample size and well-defined trials of long enough duration.
C1 [Zhai, Junya; Zhang, Lishi] Sichuan Univ, Dept Nutr Food Safety & Toxicol, West China Sch Publ Hlth, Chengdu, Peoples R China.
   [Bo, Yacong] Zhengzhou Univ, Coll Publ Hlth, Dept Nutr & Food Hyg, Zhengzhou, Henan, Peoples R China.
   [Lu, Yan] Shanghai Jiao Tong Univ, Sch Med, Dept Surg, Shanghai Peoples Hosp North 9, Shanghai, Peoples R China.
   [Liu, Chunli] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
RP Zhang, LS (reprint author), Sichuan Univ, Dept Nutr Food Safety & Toxicol, West China Sch Publ Hlth, Chengdu, Peoples R China.
EM lishizhang_56@163.com
CR Basaranoglu M, 2014, TURK J GASTROENTEROL, V25, P127, DOI 10.5152/tjg.2014.7675
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Crane FL, 2001, J AM COLL NUTR, V20, P591, DOI 10.1080/07315724.2001.10719063
   Dai YL, 2011, ATHEROSCLEROSIS, V216, P395, DOI 10.1016/j.atherosclerosis.2011.02.013
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Engeli S, 2003, DIABETES, V52, P942, DOI 10.2337/diabetes.52.4.942
   Esser N, 2015, EXPERT OPIN INV DRUG, V24, P283, DOI 10.1517/13543784.2015.974804
   Farsi F, 2016, J AM COLL NUTR, V35, P346, DOI 10.1080/07315724.2015.1021057
   Fischer A, 2016, BIOFACTORS, V42, P268, DOI 10.1002/biof.1269
   Groneberg DA, 2005, INT J BIOCHEM CELL B, V37, P1208, DOI 10.1016/j.biocel.2004.11.017
   Guarner V, 2015, INTERD T GERONT GERI, V40, P99, DOI 10.1159/000364934
   Higgins JP, 2001, COCHRANE HDB SYSTEMA
   Kawano Jordan, 2009, J Cardiometab Syndr, V4, P44, DOI 10.1111/j.1559-4572.2008.00030.x
   Kunitomo M, 2008, J PHARMACOL SCI, V107, P128, DOI 10.1254/jphs.FP0072365
   Lee BJ, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-142
   Lee BJ, 2012, NUTRITION, V28, P767, DOI 10.1016/j.nut.2011.11.008
   Lee YJ, 2011, J MED FOOD, V14, P386, DOI 10.1089/jmf.2010.1202
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mohseni M, 2015, INT J PREVENTIVE MED, V6, DOI 10.4103/2008-7802.162461
   Mori TA, 2009, J HYPERTENS, V27, P1863, DOI 10.1097/HJH.0b013e32832e1bd9
   Nesami NB, 2015, INT J VITAM NUTR RES, V85, P156, DOI 10.1024/0300-9831/a000234
   Niklowitz P, 2016, J CLIN BIOCHEM NUTR, V58, P240, DOI 10.3164/jcbn.15-73
   Olivieri F, 2013, FREE RADICAL BIO MED, V63, P410, DOI 10.1016/j.freeradbiomed.2013.05.033
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Pittas AG, 2004, J CLIN ENDOCR METAB, V89, P447, DOI 10.1210/jc.2003-031005
   Pradhan A, 2007, NUTR REV, V65, pS152, DOI 10.1301/nr.2007.dec.S152-S156
   Raygan F, 2015, EUR J NUTR, V55, P1
   Sanoobar M, 2015, NUTR NEUROSCI, V18, P169, DOI 10.1179/1476830513Y.0000000106
   Schmelzer C, 2008, BIOFACTORS, V32, P179, DOI 10.1002/biof.5520320121
   Schmelzer C, 2007, BIOFACTORS, V31, P211, DOI 10.1002/biof.5520310308
   Sohet FM, 2009, BIOCHEM PHARMACOL, V78, P1391, DOI 10.1016/j.bcp.2009.07.008
   Zhou Y, 2011, J ECON GEOGR, V10, P1
NR 33
TC 2
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 26
PY 2017
VL 12
IS 1
AR e170172
DI 10.1371/journal.pone.0170172
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN7IT
UT WOS:000396176100127
PM 28125601
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wei, YC
   George, NI
   Chang, CW
   Hicks, KA
AF Wei, Yu-Chung
   George, Nysia I.
   Chang, Ching-Wei
   Hicks, Karen A.
TI Assessing Sex Differences in the Risk of Cardiovascular Disease and
   Mortality per Increment in Systolic Blood Pressure: A Systematic Review
   and Meta-Analysis of Follow-Up Studies in the United States
SO PLOS ONE
LA English
DT Review
ID CORONARY-HEART-DISEASE; ALL-CAUSE MORTALITY; ACUTE
   MYOCARDIAL-INFARCTION; PULSE PRESSURE; MIDDLE-AGE; MEN; WOMEN; HEALTH;
   HYPERTENSION; BLACK
AB In the United States (US), cardiovascular (CV) disease accounts for nearly 20% of national health care expenses. Since costs are expected to increase with the aging population, informative research is necessary to address the growing burden of CV disease and sex-related differences in diagnosis, treatment, and outcomes. Hypertension is a major risk factor for CV disease and mortality. To evaluate whether there are sex-related differences in the effect of systolic blood pressure (SBP) on the risk of CV disease and mortality, we performed a systematic review and meta-analysis. We conducted a comprehensive search using PubMed and Google Scholar to identify US-based studies published prior to 31 December, 2015. We identified eight publications for CV disease risk, which provided 9 female and 8 male effect size (ES) observations. We also identified twelve publications for CV mortality, which provided 10 female and 18 male ES estimates. Our meta-analysis estimated that the pooled ES for increased risk of CV disease per 10 mmHg increment in SBP was 25% for women (95% Confidence Interval (CI): 1.18, 1.32) and 15% for men (95% CI: 1.11, 1.19). The pooled increase in CV mortality per 10 mm Hg SBP increment was similar for both women and men (Women: 1.16; 95% CI: 1.10, 1.23; Men: 1.17; 95% CI: 1.12, 1.22). After adjusting for age and baseline SBP, the results demonstrated that the risk of CV disease per 10 mm Hg SBP increment for women was 1.1-fold higher than men (P<0.01; 95% CI: 1.04, 1.17). Heterogeneity was moderate but significant. There was no significant sex difference in CV mortality.
C1 [Wei, Yu-Chung; George, Nysia I.; Chang, Ching-Wei] US FDA, Div Bioinformat & Biostat, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
   [Wei, Yu-Chung] Feng Chia Univ, Dept Stat, Taichung, Taiwan.
   [Chang, Ching-Wei] Genentech Inc, San Francisco, CA 94080 USA.
   [Hicks, Karen A.] US FDA, Off Drug Evaluat 1, Div Cardiovasc & Renal Prod, Ctr Drug Evaluat & Res, Silver Spring, MD USA.
RP George, NI; Chang, CW (reprint author), US FDA, Div Bioinformat & Biostat, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.; Chang, CW (reprint author), Genentech Inc, San Francisco, CA 94080 USA.
EM wei0917@gmail.com; nysia.george@fda.hhs.gov
FU FDA Office of Women's Health [E0754201]; ORISE Research Participation
   Program at the National Center for Toxicological Research, U.S. Food and
   Drug Administration
FX This work was supported by the FDA Office of Women's Health (Project ID:
   E0754201). This project was supported in part by an appointment to the
   ORISE Research Participation Program at the National Center for
   Toxicological Research, U.S. Food and Drug Administration, administered
   by the Oak Ridge Institute for Science and Education through an
   interagency agreement between the U.S. Department of Energy and
   FDA/Center. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144
   Ambrosius WT, 2014, CLIN TRIALS, DOI 10.1177-1740774514537404
   Anand IS, 2008, CIRC-HEART FAIL, V1, P34, DOI 10.1161/CIRCHEARTFAILURE.107.736975
   ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475
   BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Black HR, 1999, HYPERTENSION, V34, P386, DOI 10.1161/01.HYP.34.3.386
   Boggia J, 2011, HYPERTENSION, V57, P397, DOI 10.1161/HYPERTENSIONAHA.110.156828
   Bowman TS, 2006, AM J HYPERTENS, V19, P47, DOI 10.1016/j.amjhyper.2005.06.024
   BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Crimmins EM, 2010, EUROPEAN J PUBLIC HL
   Daviglus ML, 2004, JAMA-J AM MED ASSOC, V292, P1588, DOI 10.1001/jama.292.13.1588
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ford ES, 2011, CIRCULATION, V123, P1737, DOI 10.1161/CIRCULATIONAHA.110.005645
   Glynn RJ, 2002, HYPERTENSION, V39, P105, DOI 10.1161/hy1201.097199
   Gray L, 2011, J AM COLL CARDIOL, V58, P2396, DOI 10.1016/j.jacc.2011.07.045
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hochman JS, 1999, NEW ENGL J MED, V341, P226, DOI 10.1056/NEJM199907223410402
   Hsia J, 2007, CIRCULATION, V115, P855, DOI 10.1161/CIRCULATIONAHA.106.656850
   Kannel WB, 2000, AM J CARDIOL, V85, P251, DOI 10.1016/S0002-9149(99)00635-9
   KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201
   Klag M J, 1993, Ann Epidemiol, V3, P442
   Kochanek K. D., 2014, NCHS DATA BRIEF, V178, P1
   Lewington S, 2002, LANCET, V360, P1903
   Malacrida R, 1998, NEW ENGL J MED, V338, P8, DOI 10.1056/NEJM199801013380102
   Marino M, 2014, AM J PREV MED, V47, P131, DOI 10.1016/j.amepre.2014.03.006
   Marmot M, 2007, FOOD NUTR PHYS ACT P
   Marrugat J, 1998, JAMA-J AM MED ASSOC, V280, P1405, DOI 10.1001/jama.280.16.1405
   Miura K, 2001, HYPERTENSION, V38, P232, DOI 10.1161/01.HYP.38.2.232
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336
   Mosca L, 2011, CIRCULATION, V124, P2145, DOI 10.1161/CIRCULATIONAHA.110.968792
   Mozaffarian D., 2015, CIRCULATION
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152
   Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805
   Nair GV, 2005, CHEST, V127, P1498, DOI 10.1378/chest.127.5.1498
   Paynter NP, 2012, ANN EPIDEMIOL, V22, P191, DOI 10.1016/j.annepidem.2011.12.001
   Peters SAE, 2013, STROKE, V44, P2394, DOI 10.1161/STROKEAHA.113.001624
   Prevention CfDCa, HEART DIS STROK PREV
   Psaty BM, 1999, ARCH INTERN MED, V159, P1339, DOI 10.1001/archinte.159.12.1339
   RAGLAND DR, 1988, AM J EPIDEMIOL, V127, P462, DOI 10.1093/oxfordjournals.aje.a114823
   Roerecke M, 2014, OPEN HEART, V1, DOI 10.1136/openhrt-2014-000135
   Roush GC, 2015, J HYPERTENS, V33, P212, DOI 10.1097/HJH.0000000000000435
   SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136
   SEEMAN T, 1993, AM J EPIDEMIOL, V138, P1037, DOI 10.1093/oxfordjournals.aje.a116822
   Sesso HD, 2000, HYPERTENSION, V36, P801, DOI 10.1161/01.HYP.36.5.801
   Specogna AV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096743
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4
   TYROLER HA, 1984, AM HEART J, V108, P738, DOI 10.1016/0002-8703(84)90667-7
   Vaccarino V, 1999, NEW ENGL J MED, V341, P217, DOI 10.1056/NEJM199907223410401
   VACCARO O, 1992, DIABETES CARE, V15, P1328, DOI 10.2337/diacare.15.10.1328
   Vasan RS, 2001, NEW ENGL J MED, V345, P1291, DOI 10.1056/NEJMoa003417
   Wells GA, 2000, NEWCASTLE OTTAWA SCA
   Woodfield SL, 1997, J AM COLL CARDIOL, V29, P35, DOI 10.1016/S0735-1097(96)00449-4
   Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9
   Zhao LL, 2014, J CLIN HYPERTENS, V16, P678, DOI 10.1111/jch.12375
NR 61
TC 13
Z9 13
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 25
PY 2017
VL 12
IS 1
AR e0170218
DI 10.1371/journal.pone.0170218
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN7FK
UT WOS:000396167300052
PM 28122035
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ding, XF
   Li, LF
   Zhou, XL
   Guo, LN
   Dou, MM
   Chi, YY
   Wu, SX
   Zhang, YN
   Shan, ZZ
   Zhang, YJ
   Wang, F
   Fan, QX
   Zhao, J
   Sun, TW
AF Ding, Xian-Fei
   Li, Li-Feng
   Zhou, Xue-Liang
   Guo, Li-Na
   Dou, Meng-Meng
   Chi, Yan-Yan
   Wu, Shao-Xuan
   Zhang, Ya-Na
   Shan, Zheng-Zheng
   Zhang, Yi-Jie
   Wang, Feng
   Fan, Qing-Xia
   Zhao, Jie
   Sun, Tong-Wen
TI P-mTOR Expression and Implication in Breast Carcinoma: A Systematic
   Review and MetaAnalysis
SO PLOS ONE
LA English
DT Article
ID PHOSPHORYLATED MAMMALIAN TARGET; AKT EXPRESSION; CANCER; RAPAMYCIN;
   PATHWAY; DOWNSTREAM; PROGNOSIS; NODE; ADENOCARCINOMA; TRASTUZUMAB
AB Objective
   Phosphorylated mammalian target of rapamycin (p-mTOR) is a promising prognostic marker in many types of cancer. However, its survival benefit in patients with breast carcinoma remains unknown. The aim of the present study was to assess the relationship between p-mTOR expression and prognosis in breast carcinoma based on a systematic review and meta-analysis.
   Materials and Methods
   Electronic databases (including Pubmed, Embase, ISI web of science, and Cochrane Library) were searched up to November 24, 2015. The outcome measures were hazard ratios (HRs) with 95% confidence interval (CI) for the association between the prognosis of breast carcinoma patients and p-mTOR expression. Primary end points were disease-free survival (DFS), overall survival (OS), and recurrence-free survival (RFS). Statistical analysis was performed with STATA 12.0.
   Results
   Nine cohort studies including 3051 patients met full eligibility criteria. The pooled HRs (95% CI) for OS, DFS, and RFS were 0.84 (0.27-2.63), 0.71 (0.40-1.23), and 0.48 (0.20-1.18), respectively.
   Conclusions
   Our findings suggested that p-mTOR overexpression was not significantly related to prognosis in breast carcinoma regarding OS and disease recurrence. Prospective studies are warranted to examine the association between p-mTOR expression and survival outcomes in breast carcinoma.
C1 [Ding, Xian-Fei; Sun, Tong-Wen] Zhengzhou Univ, Affiliated Hosp 1, Dept Gen ICU, Zhengzhou, Henan, Peoples R China.
   [Ding, Xian-Fei; Li, Li-Feng; Zhou, Xue-Liang; Chi, Yan-Yan; Wu, Shao-Xuan; Zhang, Ya-Na; Shan, Zheng-Zheng; Wang, Feng; Fan, Qing-Xia] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Henan, Peoples R China.
   [Li, Li-Feng; Zhao, Jie] Zhengzhou Univ, Affiliated Hosp 1, Dept Pharm, Zhengzhou, Henan, Peoples R China.
   [Guo, Li-Na] Zhengzhou Univ, Affiliated Hosp 1, Dept Gerontol, Zhengzhou, Henan, Peoples R China.
   [Dou, Meng-Meng] Zhengzhou Univ, Affiliated Hosp 1, Dept Integrated Med, Zhengzhou, Henan, Peoples R China.
   [Zhang, Yi-Jie] Zhengzhou Univ, Affiliated Hosp 1, Dept MRI, Zhengzhou, Henan, Peoples R China.
RP Sun, TW (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Gen ICU, Zhengzhou, Henan, Peoples R China.
EM suntongwen@163.com
FU National Natural Science Foundation of China [81370364, 71673254];
   Science and Technology Innovation Team in Universities of Henan province
   [16IRTSTHN021]
FX This study was supported by grants from the National Natural Science
   Foundation of China (nos. 81370364, 71673254), Science and Technology
   Innovation Team in Universities of Henan province (no. 16IRTSTHN021).
   The funders had no role in the study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR An J, 2010, J BREAST CANCER, V13, P337, DOI 10.4048/jbc.2010.13.4.337
   Anagnostou VK, 2009, CLIN CANCER RES, V15, P4157, DOI 10.1158/1078-0432.CCR-09-0099
   Andre F, 2014, LANCET ONCOL, V15, P580, DOI 10.1016/S1470-2045(14)70138-X
   Annovazzi L, 2009, ANTICANCER RES, V29, P3087
   Asnaghi L, 2004, PHARMACOL RES, V50, P545, DOI 10.1016/j.phrs.2004.03.007
   Bakarakos P, 2010, HISTOPATHOLOGY, V56, P876, DOI 10.1111/j.1365-2559.2010.03570.x
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Beca F, 2014, J CLIN PATHOL, V67, P961, DOI 10.1136/jclinpath-2014-202320
   Beelen K, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3598
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bose S, 2006, MODERN PATHOL, V19, P238, DOI 10.1038/modpathol.3800525
   Cai Wenke, 2014, Zhonghua Zhong Liu Za Zhi, V36, P120
   Chen X, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0167-2
   CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0
   Cota GF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002195
   Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202
   Dobashi Y, 2011, INT J CLIN EXP PATHO, V4, P476
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Heinonen H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-348
   Holz MK, 2012, CELL CYCLE, V11, P3159, DOI 10.4161/cc.21194
   Ito Yoshinori, 2015, Gan To Kagaku Ryoho, V42, P67
   Janssen EAM, 2007, CELL ONCOL, V29, P25
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kenerson HL, 2002, CANCER RES, V62, P5645
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lauring J, 2013, J NATL COMPR CANC NE, V11, P670, DOI 10.6004/jnccn.2013.0086
   Lazaridis G, 2014, STRAHLENTHER ONKOL, V190, P636, DOI 10.1007/s00066-014-0620-6
   Leal P, 2013, ARCH PATHOL LAB MED, V137, P552, DOI 10.5858/arpa.2012-0032-OA
   Ma BL, 2015, MOL MED REP, V12, P5246, DOI 10.3892/mmr.2015.4037
   Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888
   Paplomata E, 2014, THER ADV MED ONCOL, V6, P154, DOI 10.1177/1758834014530023
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Rolfo C, 2014, CANCER TREAT REV, V40, P990, DOI 10.1016/j.ctrv.2014.05.009
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Ueng SH, 2012, INT J CLIN EXP PATHO, V5, P806
   Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Yu GZ, 2009, CLIN CANCER RES, V15, P1821, DOI 10.1158/1078-0432.CCR-08-2138
   Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112
NR 43
TC 1
Z9 1
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 23
PY 2017
VL 12
IS 1
AR e170302
DI 10.1371/journal.pone.0170302
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN6QR
UT WOS:000396129000036
PM 28114374
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, FJ
   Sun, YT
   Xu, TH
   Sun, L
   Liu, LL
   Sun, W
   Feng, X
   Ma, JF
   Wang, LN
   Yao, L
AF Liu, Fangjie
   Sun, Yiting
   Xu, Tianhua
   Sun, Li
   Liu, Linlin
   Sun, Wei
   Feng, Xin
   Ma, Jianfei
   Wang, Lining
   Yao, Li
TI Effect of Nocturnal Hemodialysis versus Conventional Hemodialysis on
   End-Stage Renal Disease: A Meta-Analysis and Systematic Review
SO PLOS ONE
LA English
DT Review
ID LEFT-VENTRICULAR MASS; RANDOMIZED-CONTROLLED-TRIAL; QUALITY-OF-LIFE;
   FREQUENT HEMODIALYSIS; HOME HEMODIALYSIS; PUBLICATION BIAS; DIALYSIS
   PATIENTS; RISK-FACTORS; TRANSPLANTATION; SURVIVAL
AB Objectives
   The purpose of this study is to assess the efficacy and safety of nocturnal hemodialysis on end-stage renal disease (ESRD) patients.
   Methods
   We searched Medline, EmBase, and the Cochrance Central Register of Controlled Trials for studies up to January 2016. Analysis was done to compare variant outcomes of different hemodialysis schedules, including mortality, cardiovascular-associated variables, uremia-associated variables, quality of life (QOL), side-effects, and drug usage.
   Results
   We collected and analyzed the results of 28 studies involving 22,508 patients in our meta-analysis. The mortality results in this meta-analysis indicated that the nocturnal hemodialysis (NHD) group was not significantly different from conventional hemodialysis (CHD) group (Mortality: OR: 0.75; 95% confidence intervals (CIs): 0.52 to 1.10; p = 0.145), but the CHD group had significantly fewer number of hospitalizations than the NHD group (OR: 1.54; 95% CI: 1.32 to 1.79; p<0.001). NHD was superior to CHD for cardiovascular-associated (left ventricular hypertrophy [LVH]: SMD: -0.39; 95% CI: -0.68 to -0.10; p = 0.009, left ventricular hypertrophy index [LVHI]: SMD: -0.64; 95% CI: -0.83 to -0.46; p<0.001) and uremia-associated intervention results (Serum albumin: SMD: 0.89; 95% CI: 0.41 to 1.36; p<0.001). For the assessment of quality of life, NHD treatment significantly improved the patients' QOL only for SF36-Physical Components Summary (SMD: 0.43; 95% CI: 0.26 to 0.60; p<0.001). NHD intervention was relatively better than CHD for anti-hypertensive drug usage (SMD: -0.48; 95% CI: -0.91 to -0.05; p = 0.005), and there was no difference between groups in our side-effects assessment.
   Conclusion
   NHD and CHD performed similarly in terms of ESRD patients' mortality and side-effects. NHD was superior to CHD for cardiovascular-associated and uremia-associated results, QOL, and drug usage; for number of hospitalizations, CHD was relatively better than NHD.
C1 [Liu, Fangjie; Xu, Tianhua; Sun, Li; Liu, Linlin; Ma, Jianfei; Wang, Lining; Yao, Li] China Med Univ, Dept Nephrol, Hosp 1, Shenyang, Liaoning, Peoples R China.
   [Sun, Yiting] China Med Univ, Dept Clin Med, Shenyang, Liaoning, Peoples R China.
   [Sun, Wei] China Med Univ, Dept Gen Surg, Shengjing Hosp, Shenyang, Liaoning, Peoples R China.
   [Feng, Xin] Liaoning Elect Power Ctr Hosp, Blood Purificat Ctr, Shenyang, Liaoning, Peoples R China.
RP Yao, L (reprint author), China Med Univ, Dept Nephrol, Hosp 1, Shenyang, Liaoning, Peoples R China.
EM liyao_cmu@163.com
FU scientific research project for the Universities of Educational
   Commission of Liaoning Province of China [L2011134]; Key Social
   Development Program of Science and Technology Commission of Liaoning
   Province of China [2013225303, 201404046]; Key Social Development
   Program of Science and Technology Commission of Shenyang of China
   [F16-206-9-04]
FX This work was supported by a grant from the scientific research project
   for the Universities of Educational Commission of Liaoning Province of
   China (Grant No. L2011134), the Key Social Development Program of
   Science and Technology Commission of Liaoning Province of China (Grant
   No. 2013225303), the Key Social Development Program of Science and
   Technology Commission of Shenyang of China (Grant No. F16-206-9-04), the
   Key Social Development Program of Science and Technology Commission of
   Liaoning Province of China (Grant No. 201404046). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Alkhouli M, 2015, NEFROLOGIA, V35, P234, DOI 10.1016/j.nefro.2015.03.001
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chan CT, 2013, CLIN J AM SOC NEPHRO, V8, P2106, DOI 10.2215/CJN.03280313
   Chan CT, 2012, CIRC-CARDIOVASC IMAG, V5, P251, DOI 10.1161/CIRCIMAGING.111.969923
   Chan CT, 2002, KIDNEY INT, V61, P2235, DOI 10.1046/j.1523-1755.2002.00362.x
   Culleton BF, 2007, JAMA-J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291
   Demirci C, 2013, AM J NEPHROL, V37, P559, DOI 10.1159/000351182
   Demirci MS, 2012, ATHEROSCLEROSIS, V220, P477, DOI 10.1016/j.atherosclerosis.2011.11.015
   do Sameiro-Faria M, 2014, BIOMED RES INT, DOI 10.1155/2014/175286
   Friedman AN, 2002, J AM SOC NEPHROL, V13, P265
   HARNETT JD, 1994, J AM SOC NEPHROL, V4, P1486
   Heidenheim AP, 2003, AM J KIDNEY DIS, V42, pS36, DOI 10.1016/S0272-6386(03)00536-5
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Jin HM, 2013, NEPHRON CLIN PRACT, V123, P220, DOI 10.1159/000354709
   Jin XC, 2012, THER APHER DIAL, V16, P334, DOI 10.1111/j.1744-9987.2012.01070.x
   Jin XC, 2011, HEMODIAL INT, V15, P200, DOI 10.1111/j.1542-4758.2011.00537.x
   Johansen KL, 2009, KIDNEY INT, V76, P984, DOI 10.1038/ki.2009.291
   Karkar A, 2015, SAUDI J KIDNEY DIS T, V26, P1095, DOI 10.4103/1319-2442.168556
   Kotanko P, 2015, HEMODIAL INT, V19, P386, DOI 10.1111/hdi.12255
   Kramann R, 2012, NEPHROL DIAL TRANSPL, V27, P4298, DOI 10.1093/ndt/gfs400
   Lacson E, 2012, J AM SOC NEPHROL, V23, P687, DOI 10.1681/ASN.2011070674
   Lacson E, 2010, CLIN J AM SOC NEPHRO, V5, P220, DOI 10.2215/CJN.06070809
   Lewicki MC, 2015, SEMIN DIALYSIS, V28, P147, DOI 10.1111/sdi.12322
   Lindsay RM, 2004, SEMIN DIALYSIS, V17, P85, DOI 10.1111/j.0894-0959.2004.17202.x
   Longenecker JC, 2002, J AM SOC NEPHROL, V13, P1918, DOI 10.1097/01.ASN.0000019641.41496.IE
   Manns BJ, 2009, KIDNEY INT, V75, P542, DOI 10.1038/ki.2008.639
   Moher David, 2009, Open Med, V3, pe123
   Moradi H, 2013, AM J NEPHROL, V38, P136, DOI 10.1159/000351758
   Nesrallah G, 2003, AM J KIDNEY DIS, V42, pS13, DOI 10.1016/S0272-6386(03)00532-8
   Niakas D, 2009, HEALTH POLICY, V89, P329, DOI 10.1016/j.healthpol.2008.07.005
   O'Lone E, 2016, AM J KIDNEY DIS
   Ok E, 2011, NEPHROL DIAL TRANSPL, V26, P1287, DOI 10.1093/ndt/gfq724
   Overgaard CB, 2011, CAN J CARDIOL, V27, pS114, DOI 10.1016/j.cjca.2011.07.102
   Overgaard CB, 2013, CIRCULATION, V128
   Papageorgiou SN, 2015, J EVID-BASED DENT PR, V15, P8, DOI 10.1016/j.jebdp.2014.09.001
   Peters JL, 2007, STAT MED, V26, P4544, DOI 10.1002/sim.2889
   Pierratos Andreas, 2004, Hemodial Int, V8, P45, DOI 10.1111/j.1492-7535.2004.00074.x
   Powell JR, 2009, CLIN J AM SOC NEPHRO, V4, P1097, DOI 10.2215/CJN.06651208
   Rocco MV, 2011, KIDNEY INT, V80, P1080, DOI 10.1038/ki.2011.213
   Rocco MV, 2011, AM J KIDNEY DIS, V57, P90, DOI 10.1053/j.ajkd.2010.08.024
   Salari A, 2012, TRANSPL P, V44, P3007, DOI 10.1016/j.transproceed.2012.03.060
   Sawant A, 2014, PHYSIOTHER CAN, V66, P44, DOI 10.3138/ptc.2012-59
   Schwartz DI, 2005, CLIN NEPHROL, V63, P202
   Shantha GPS, 2015, PEERJ, V3, DOI 10.7717/peerj.835
   Silva LSV, 2012, SAUDI J KIDNEY DIS T, V23, P262
   Stenvinkel P, 2006, NEPHROLOGY, V11, P36, DOI 10.1111/j.1440-1797.2006.00541.x
   Susantitaphong P, 2012, AM J KIDNEY DIS, V59, P689, DOI 10.1053/j.ajkd.2011.12.020
   Thumfart J, 2014, DTSCH ARZTEBL INT, V111, P237, DOI 10.3238/arztebl.2014.0237
   Van Eps CL, 2010, HEMODIAL INT, V14, P451, DOI 10.1111/j.1542-4758.2010.00463.x
   Wald R, 2016, CAN J CARDIOL, V32, P369, DOI 10.1016/j.cjca.2015.07.004
   Walsh M, 2010, HEMODIAL INT, V14, P174, DOI 10.1111/j.1542-4758.2009.00418.x
NR 52
TC 9
Z9 9
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 20
PY 2017
VL 12
IS 1
AR e0169203
DI 10.1371/journal.pone.0169203
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EI3QC
UT WOS:000392405300021
PM 28107451
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yin, SC
   Huang, JY
   Li, Z
   Zhang, JY
   Luo, JZ
   Lu, CY
   Xu, H
   Xu, HM
AF Yin, Songcheng
   Huang, Jinyu
   Li, Zhan
   Zhang, Junyan
   Luo, Jiazi
   Lu, Chunyang
   Xu, Hao
   Xu, Huimian
TI The Prognostic and Clinicopathological Significance of Tumor-Associated
   Macrophages in Patients with Gastric Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID INFILTRATING MACROPHAGES; FAVORABLE PROGNOSIS; CARCINOMA-CELLS;
   SURVIVAL; ANGIOGENESIS; POLARIZATION; PROGRESSION; STATISTICS;
   DIVERSITY; DENSITY
AB Objective
   Comprehensive studies have investigated the prognostic and clinicopathological value of tumor-associated macrophages (TAMs) in gastric cancer patients, yet results remain controversial. Therefore, we performed a meta-analysis to clarify this issue.
   Methods
   PubMed, Embase, and the Cochrane Library databases were searched to identify eligible studies. We extracted hazard ratios (HRs) and odds ratios (ORs) with their corresponding 95% confidence intervals (95% Cls) to estimate the effect sizes. In addition, subgroup analysis and sensitivity analysis were also conducted.
   Results
   A total of 19 studies involving 2242 patients were included. High generalised TAMs density was significantly associated with poor overall survival (OS) (HR 1.49, 95% CI 1.15-1.95). Subgroup analysis revealed that CD68(+) TAMs had no significant effect on OS (HR 1.38, 95% CI 1.00-1.91). High M1 TAMs density was correlated with better OS (HR 0.45, 95% CI 0.32-0.65). By contrast, high density of M2 TAMs was correlated with a poor prognosis for OS (HR 1.48, 95% CI 1.25-1.75). Furthermore, high M2 TAMs density was correlated with larger tumor size, diffuse Lauren type, poor histologic differentiation, deeper tumor invasion, lymph node metastasis, and advanced TNM stage.
   Conclusions
   Overall, this meta-analysis reveal that although CD68+ TAMs infiltration has the neutral prognostic effects on OS, the M1/M2 polarization of TAMs are predicative factor of prognosis in gastric cancer patients.
C1 [Yin, Songcheng; Huang, Jinyu; Zhang, Junyan; Luo, Jiazi; Lu, Chunyang; Xu, Hao; Xu, Huimian] China Med Univ, Hosp 1, Dept Surg Oncol, Shenyang, Liaoning, Peoples R China.
   [Li, Zhan] China Med Univ, Hosp 1, Dept Breast Surg, Shenyang, Liaoning, Peoples R China.
RP Xu, HM (reprint author), China Med Univ, Hosp 1, Dept Surg Oncol, Shenyang, Liaoning, Peoples R China.
EM xuhuimian@126.com
FU National Natural Science Foundation of China [81372550]; Key Laboratory
   Programme of Liaoning Province [LZ2015080]
FX This work was supported by National Natural Science Foundation of China
   (No. 81372550); and Key Laboratory Programme of Liaoning Province
   (LZ2015080). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027
   Biswas SK, 2013, SEMIN IMMUNOPATHOL, V35, P585, DOI 10.1007/s00281-013-0367-7
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Ding HX, 2016, BIOMED PHARMACOTHER, V77, P142, DOI 10.1016/j.biopha.2015.12.004
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Haas M, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-65
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Ichimura T, 2016, HUM PATHOL, V56, P74, DOI 10.1016/j.humpath.2016.06.002
   Ishigami S, 2003, ANTICANCER RES, V23, P4079
   Kawahara A, 2010, ONCOL REP, V24, P405, DOI 10.3892/or_00000873
   Kim KJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144192
   Komohara Y, 2016, ADV DRUG DELIVER REV, V99, P180, DOI 10.1016/j.addr.2015.11.009
   Komohara Y, 2014, CANCER SCI, V105, P1, DOI 10.1111/cas.12314
   Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159
   Li YW, 2009, J CANCER RES CLIN, V135, P439, DOI 10.1007/s00432-008-0469-0
   Lin CN, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1114-3
   Liu JY, 2016, MINERVA MED, V107, P314
   Liu XY, 2013, BIOCHEM BIOPH RES CO, V439, P378, DOI 10.1016/j.bbrc.2013.08.073
   Mahmoud SMA, 2012, J CLIN PATHOL, V65, P159, DOI 10.1136/jclinpath-2011-200355
   Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295
   Mantovani A, 2013, ARTERIOSCL THROM VAS, V33, P1478, DOI 10.1161/ATVBAHA.113.300168
   Mei JD, 2016, ONCOTARGET, V7, P34217, DOI 10.18632/oncotarget.9079
   Merelli B, 2014, CRIT REV ONCOL HEMAT, V89, P140, DOI 10.1016/j.critrevonc.2013.08.002
   Nonomura N, 2011, BJU INT, V107, P1918, DOI 10.1111/j.1464-410X.2010.09804.x
   Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010
   Ohno S, 2005, ANTICANCER RES, V25, P463
   Ohno S, 2003, ANTICANCER RES, V23, P5015
   Osinsky S, 2011, CLIN TRANSL ONCOL, V13, P133, DOI 10.1007/s12094-011-0630-0
   Pantano F, 2013, J CELL MOL MED, V17, P1415, DOI 10.1111/jcmm.12109
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Park JY, 2016, CLIN RES HEPATOL GAS, V40, P357, DOI 10.1016/j.clinre.2015.09.005
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Peng CW, 2012, BIOMATERIALS, V33, P5742, DOI 10.1016/j.biomaterials.2012.04.034
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Rahbari NN, 2012, J CLIN ONCOL, V30, P60, DOI 10.1200/JCO.2011.36.9504
   Rahbari NN, 2010, GASTROENTEROLOGY, V138, P1714, DOI 10.1053/j.gastro.2010.01.008
   Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015
   Sawada T, 2015, GASTRIC CANCER, V18, P119, DOI 10.1007/s10120-014-0338-2
   Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Tjiu JW, 2009, J INVEST DERMATOL, V129, P1016, DOI 10.1038/jid.2008.310
   Wang B, 2011, ANN SURG ONCOL, V18, P2585, DOI 10.1245/s10434-011-1609-3
   Wu MH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134122
   Yamaguchi T, 2016, GASTRIC CANCER, V19, P1052, DOI 10.1007/s10120-015-0579-8
   Yan Y, 2016, ONCOTARGETS THER, V9, DOI 10.2147/OTT.S103112
   Zhang BC, 2011, MED ONCOL, V28, P1447, DOI 10.1007/s12032-010-9638-5
   Zhang BC, 2012, CLINICS, V67, P901, DOI 10.6061/clinics/2012(08)08
   Zhang H, 2015, GASTRIC CANCER, V18, P740, DOI 10.1007/s10120-014-0422-7
   Zhang J, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002636
   Zhang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031230
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 55
TC 10
Z9 11
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 12
PY 2017
VL 12
IS 1
AR e0170042
DI 10.1371/journal.pone.0170042
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EH7JQ
UT WOS:000391949500121
PM 28081243
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, GH
   Tzekov, R
   Li, WS
   Jiang, FZ
   Mao, SH
   Tong, YH
AF Chen, Guohai
   Tzekov, Radouil
   Li, Wensheng
   Jiang, Fangzheng
   Mao, Sihong
   Tong, Yuhua
TI Subfoveal Choroidal Thickness in Central Serous Chorioretinopathy: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; FLUENCE PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; EYES; ABNORMALITIES; PATHOPHYSIOLOGY; RESOLUTION; UPDATE;
   ADULTS; BIAS
AB Purpose
   To evaluate the relationship between subfoveal choroidal thickness (SFCT) and eyes with central serous chorioretinopathy (CSC) versus fellow or control eyes.
   Methods
   We performed a meta-analysis using databases including PubMed, Embase and ISI Web of Science to find relevant studies. Weighted mean difference (WMD) was calculated for the SFCT in CSC eyes, the unaffected fellow eyes and normal controls.
   Results
   Twelve studies were selected for this meta-analysis, including 1108 eyes (397 CSC eyes, 228 unaffected fellow eyes and 483 eyes of normal controls). The meta-analysis clearly demonstrated that the subfoveal choiroid of eyes with a clinical presentation of CSC was thickened compared to unaffected fellow eyes (WMD = 52.81, 95% confidence interval (CI), 39.13-66.49, P<0.00001) and was thickened compared to control eyes (WMD = 145.03, 95% CI, 121.33-168.73, P<0.00001). The mean SFCT measurement of the unaffected fellow eyes showed also significantly increased choroidal thickness compared to that of normal control eyes (WMD = 77.20, 95% CI, 44.98-109.42, P<0.00001). Similar results were obtained in a sub-analysis based on the same instrument.
   Conclusion
   It is demonstrated that SFCT is significantly increased in eyes with clinical manifestation of CSC, and in the clinically non-manifested fellow eyes. These results support the hypothesis that CSC is a bilateral disorder with an initial unilateral clinical presentation.
C1 [Chen, Guohai; Jiang, Fangzheng; Mao, Sihong; Tong, Yuhua] Quzhou Peoples Hosp, Dept Ophthalmol, Quzhou, Zhejiang, Peoples R China.
   [Tzekov, Radouil] Univ S Florida, Dept Ophthalmol, Tampa, FL USA.
   [Tzekov, Radouil] Roskamp Inst, Sarasota, FL USA.
   [Li, Wensheng] Xiamen Univ, Xiamen Eye Ctr, Xiamen 361005, Fujian, Peoples R China.
RP Li, WS (reprint author), Xiamen Univ, Xiamen Eye Ctr, Xiamen 361005, Fujian, Peoples R China.
EM drlws@qq.com
FU National Natural Science Foundation of China [81570875]; Health Systems
   Young Personnel Training Projects Foundation in Fujian Province of China
   [2013-ZQN-JC-37]; Science and Technology Program Foundation of Xiamen
   City in China [3502720144044]
FX The study design, data collection and analysis, decision to publish, and
   preparation of the manuscript were supported by grants from the National
   Natural Science Foundation of China (No. 81570875 to WL
   [http://www.nsfc.gov.cn]); the Health Systems Young Personnel Training
   Projects Foundation in Fujian Province of China (No. 2013-ZQN-JC-37 to
   WL [http://www.fjhfpc.gov.cn]) and Science and Technology Program
   Foundation of Xiamen City in China (No. 3502720144044 to WL
   [http://www.xminfo.net.cn]).
CR Baran NV, 2005, CLIN EXP OPHTHALMOL, V33, P369, DOI 10.1111/j.1442-9071.2005.01027.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   CASTROCORREIA J, 1992, DOC OPHTHALMOL, V81, P379
   Chappelow AV, 2000, ARCH OPHTHALMOL-CHIC, V118, P1211
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Desai UR, 2003, J NATL MED ASSOC, V95, P553
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fujimoto H, 2008, OPHTHALMOLOGY, V115, P1494, DOI 10.1016/j.ophtha.2008.01.021
   Gass J. D., 1967, AM J OPHTHALMOL S, V63, P1
   Gemenetzi M, 2010, EYE, V24, P1743, DOI 10.1038/eye.2010.130
   Goktas A, 2014, EYE, V28, P1431, DOI 10.1038/eye.2014.219
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Kang HM, 2015, OPHTHALMOLOGY, V122, P2363, DOI 10.1016/j.ophtha.2015.05.015
   Kang NH, 2013, EYE, V27, P387, DOI 10.1038/eye.2012.273
   Karapetyan A, 2016, RETINA-J RET VIT DIS, V36, P82, DOI 10.1097/IAE.0000000000000654
   Kim JH, 2013, EYE, V27, P809, DOI 10.1038/eye.2013.78
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Kuroda S, 2013, RETINA-J RET VIT DIS, V33, P302, DOI 10.1097/IAE.0b013e318263d11f
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Liegl R, 2014, OPHTHALMOLOGICA, V232, P65, DOI 10.1159/000360014
   Liew G, 2013, CLIN EXP OPHTHALMOL, V41, P201, DOI 10.1111/j.1442-9071.2012.02848.x
   Manabe S, 2015, AM J OPHTHALMOL, V159, P644, DOI 10.1016/j.ajo.2015.01.006
   Marmor MF, 1999, ARCH OPHTHALMOL-CHIC, V117, P184
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Maul EA, 2011, OPHTHALMOLOGY, V118, P1571, DOI 10.1016/j.ophtha.2011.01.016
   NEGI A, 1984, ARCH OPHTHALMOL-CHIC, V102, P445
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Oh JH, 2014, INVEST OPHTH VIS SCI, V55, P1502, DOI 10.1167/iovs.13-13183
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   PRUNTE C, 1995, INT OPHTHALMOL, V19, P77, DOI 10.1007/BF00133176
   Sizmaz S, 2013, BRIT J OPHTHALMOL, V97, P601, DOI 10.1136/bjophthalmol-2012-302393
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Yang LH, 2013, ACTA OPHTHALMOL, V91, pE358, DOI 10.1111/aos.12059
   Yannuzzi L A, 1986, Trans Am Ophthalmol Soc, V84, P799
   Yun C, 2015, RETINA-J RET VIT DIS, V35, P1860, DOI 10.1097/IAE.0000000000000539
NR 44
TC 5
Z9 5
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 11
PY 2017
VL 12
IS 1
AR e0169152
DI 10.1371/journal.pone.0169152
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EH6BJ
UT WOS:000391857100025
PM 28076442
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, K
   Ren, Y
   He, JJ
AF Wang, Ke
   Ren, Yu
   He, Jianjun
TI Cavity Shaving plus Lumpectomy versus Lumpectomy Alone for Patients with
   Breast Cancer Undergoing Breast-Conserving Surgery: A Systematic Review
   and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID TUMOR BED POSITIVITY; RE-EXCISION RATES; 20-YEAR FOLLOW-UP; CARCINOMA
   IN-SITU; MARGIN STATUS; LOCAL RECURRENCE; SHAVED MARGINS; NEOADJUVANT
   CHEMOTHERAPY; CONSERVATION SURGERY; COMPUTED-TOMOGRAPHY
AB The margin status is a well-established prognostic predictor for patients undergoing breast conserving surgery (BCS). Recent data suggested that cavity shaving in addition to lumpectomy might be a promising approach for improving the clinical outcomes. We aimed to compare the efficacy and safety between cavity shaving plus lumpectomy and lumpectomy alone with a systematic review and meta-analysis. We searched the PubMed, Embase, and Cochrane CENTRAL databases for studies comparing cavity shaving with lumpectomy before June 10, 2016. Both comparative studies and self-control studies were included. A random-effects model was used to estimate the odds ratios (ORs) for positive margin rate, reoperation rate, recurrence rate, and weighted mean difference (WMD) for excised tissue volume. Twenty-six studies were included in the meta-analysis. The cavity shaving group had a significantly lower positive margin rate than the BCS-alone group (16.4% vs. 31.9%; OR = 0.41, 95% CI 0.32-0.53, P < 0.05). Cavity shaving was associated with a significantly decreased rate of reoperation (OR = 0.42, 95% CI 0.30-0.59, P < 0.05). The overall locoregional rate was low for cavity shaving and BCS-alone (3% vs. 4%). Cavity shaving had no significant effect on the risk of locoregional recurrence (OR = 0.86, 95% CI 0.32-2.35; P = 0.78). The excised tissue volume did not differ substantially between cavity shaving and BCS alone (WMD =-23.88, 95% CI-55.20 to 7.44, P = 0.14). For patients undergoing BCS, additional cavity shaving was an effective method to decrease the positive margin rate and avoid reoperation. The addition of cavity shaving did not appear to have excessive excised tissue volume compared with partial mastectomy alone.
C1 [Wang, Ke; Ren, Yu; He, Jianjun] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Breast Surg, Xian, Shaanxi Provinc, Peoples R China.
RP He, JJ (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Breast Surg, Xian, Shaanxi Provinc, Peoples R China.
EM hejianjun811@sina.com
CR Akashi-Tanaka S, 2004, ANN SURG, V239, P238, DOI 10.1097/01.sla.0000109157.15687.d9
   Barthelmes L, 2003, EUR J SURG ONCOL, V29, P644, DOI 10.1016/S0748-7983(03)00122-7
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Besana-Ciani Isabella, 2008, Int Semin Surg Oncol, V5, P13, DOI 10.1186/1477-7800-5-13
   Bolger JC, 2015, BREAST CANCER-TOKYO, V22, P262, DOI 10.1007/s12282-013-0473-3
   Camp ER, 2005, J AM COLL SURGEONS, V201, P855, DOI 10.1016/j.jamcollsurg.2005.06.274
   Cao DF, 2005, AM J SURG PATHOL, V29, P1625, DOI 10.1097/01.pas.0000180448.08203.70
   Chagpar AB, 2015, NEW ENGL J MED, V373, P503, DOI 10.1056/NEJMoa1504473
   Chen K, 2011, AM SURGEON, V77, P1700
   Cody HS, 2015, NEW ENGL J MED, V373, P568, DOI 10.1056/NEJMe1507190
   Coopey SB, 2011, ANN SURG ONCOL, V18, P3036, DOI 10.1245/s10434-011-1909-7
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feron JG, 2011, BREAST, V20, P358, DOI 10.1016/j.breast.2011.01.014
   Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152
   Gibson GR, 2001, ANN SURG ONCOL, V8, P693, DOI 10.1245/aso.2001.8.9.693
   Guidi AJ, 1997, CANCER, V79, P1568, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1568::AID-CNCR19>3.3.CO;2-7
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012
   Hequet D, 2013, EJSO-EUR J SURG ONC, V39, P899, DOI 10.1016/j.ejso.2013.05.012
   Hequet D, 2011, ANN SURG ONCOL, V18, P114, DOI 10.1245/s10434-010-1211-0
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huston TL, 2006, AM J SURG, V192, P509, DOI 10.1016/j.amjsurg.2006.06.021
   Iaccarino G, 2007, J EXP CLIN CANC RES, V26, P543
   Jacobson AF, 2008, AM J SURG, V196, P556, DOI 10.1016/j.amjsurg.2008.06.007
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Janes SEJ, 2006, BREAST, V15, P326, DOI 10.1016/j.breast.2005.10.006
   Jones V, 2016, ANN SURG ONCOL, V23, P456, DOI 10.1245/s10434-015-4789-4
   Keskek M, 2004, EJSO-EUR J SURG ONC, V30, P1058, DOI 10.1016/j.ejso.2004.07.019
   Kobbermann A, 2011, ANN SURG ONCOL, V18, P1349, DOI 10.1245/s10434-010-1420-6
   Lovrics PJ, 2009, AM J SURG, V197, P740, DOI 10.1016/j.amjsurg.2008.03.007
   MACMILLAN RD, 1994, BRIT J SURG, V81, P56, DOI 10.1002/bjs.1800810119
   MacMillan RD, 1997, BRIT J SURG, V84, P1559, DOI 10.1111/j.1365-2168.1997.02850.x
   Marudanayagam R, 2008, BREAST J, V14, P570, DOI 10.1111/j.1524-4741.2008.00649.x
   McCahill LE, 2012, JAMA-J AM MED ASSOC, V307, P467, DOI 10.1001/jama.2012.43
   McCahill LE, 2011, AM J SURG, V201, P374, DOI 10.1016/j.amjsurg.2010.09.024
   Merrill AL, 2016, ANN SURG ONCOL, V23, P3453, DOI 10.1245/s10434-016-5251-y
   Merrill AL, 2016, ANN SURG ONCOL, V23, P729, DOI 10.1245/s10434-015-4916-2
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Mook J, 2012, ANN SURG ONCOL, V19, P886, DOI 10.1245/s10434-011-1982-y
   Moran MS, 2014, J CLIN ONCOL, V32, P1507, DOI 10.1200/JCO.2013.53.3935
   Pata G, 2016, ANN SURG ONCOL, V23, P2802, DOI 10.1245/s10434-016-5210-7
   Povoski SP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-254
   Rizzo M, 2010, ANN SURG ONCOL, V17, P228, DOI 10.1245/s10434-009-0643-x
   Rubio IT, 2016, EJSO-EUR J SURG ONC, V42, P631, DOI 10.1016/j.ejso.2016.01.019
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Silverstein MJ, 1999, NEW ENGL J MED, V340, P1455, DOI 10.1056/NEJM199905133401902
   Singletary SE, 2002, AM J SURG, V184, P383, DOI 10.1016/S0002-9610(02)01012-7
   Tang R, 2013, BREAST J, V19, P485, DOI 10.1111/tbj.12146
   Tengher-Barna I, 2009, MODERN PATHOL, V22, P299, DOI 10.1038/modpathol.2008.186
   Umpleby HC, 1998, ANN R COLL SURG ENGL, V70, P246
   Unzeitig A, 2012, INT J SURG ONCOL, DOI 10.1155/2012/725121
   Veronesi U, 2002, NEW ENGL J MED, V347, P1227, DOI 10.1056/NEJMoa020989
   Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135
   Wanis ML, 2013, AM SURGEON, V79, P1119
   Wells GA, NEWCASTLE OTTAWA SCA
   Wolf JH, 2011, INT J SURG ONCOL, DOI 10.1155/2011/785803
   Yang H, 2012, J SURG RES, V178, P751, DOI 10.1016/j.jss.2012.05.030
   Zavagno G, 2010, EJSO-EUR J SURG ONC, V36, P632, DOI 10.1016/j.ejso.2010.05.018
   Zysk AM, 2015, ANN SURG ONCOL, V22, P3356, DOI 10.1245/s10434-015-4665-2
NR 58
TC 5
Z9 5
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 3
PY 2017
VL 12
IS 1
AR e0168705
DI 10.1371/journal.pone.0168705
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EH2QJ
UT WOS:000391612300046
PM 28046058
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Shen, ZR
   Zhu, YN
   Song, XH
   Yan, J
   Yao, K
AF Shen, Zeren
   Zhu, Yanan
   Song, Xiaohui
   Yan, Jie
   Yao, Ke
TI Dry Eye after Small Incision Lenticule Extraction (SMILE) versus
   Femtosecond Laser-Assisted in Situ Keratomileusis (FS-LASIK) for Myopia:
   A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID INDUCED NEUROTROPHIC EPITHELIOPATHY; CORNEAL SENSITIVITY; REFRACTIVE
   SURGERY; OCULAR SURFACE; OUTCOMES; PATHOPHYSIOLOGY; SENSATION
AB Purpose
   To compare dry eye after small incision lenticule extraction (SMILE) and femtosecond laser-assisted LASIK (FS-LASIK) for correcting myopia.
   Methods
   CENTRAL, Embase and PubMed were searched in November 2016. All randomized controlled trials (RCTs) and prospective cohorts that compared dry eye after SMILE with FS-LASIK were selected.
   Results
   Five cohorts and one RCT were identified for comparing dry eye after SMILE (291 eyes) and FS-LASIK (277 eyes). The pooled results revealed that the SMILE and FS-LASIK groups did not differ significantly in terms of Schirmer's I test (SIT) and tear film osmolarity (TFO) at any postoperative visits. By contrast, tear break up time (TBUT; p = 0.04 for one month, p < 0.001 for three months, and p = 0.02 for six months) and ocular surface disease index (OSDI; p < 0.001 for one month and three months, and p = 0.006 for six months) were significantly worse in the FS-LASIK group than in the SMILE group at follow-up. At six months postoperatively, TBUT and TFO values in both the SMILE and FS-LASIK groups and OSDI scores in the SMILE group returned to preoperative levels, but SIT values in both groups (p = 0.02 for the SMILE group and p < 0.001 for the FS-LASIK group) and OSDI in the FS-LASIK group (p < 0.001) were still statistically impaired.
   Conclusion
   Dry eye after both SMILE and FS-LASIK usually occurs transiently. SMILE does not show obvious superiority over FS-LASIK by exhibiting similar and acceptable objective parameters, and SMILE may have milder subjective symptoms.
C1 [Shen, Zeren; Zhu, Yanan; Song, Xiaohui; Yan, Jie; Yao, Ke] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou, Zhejiang, Peoples R China.
RP Yao, K (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou, Zhejiang, Peoples R China.
EM xlren@zju.edu.cn
FU National Natural Science Foundation [81570822]; Zhejiang Key Laboratory
   Fund of China [2011E10006]; Zhejiang Province Key Research and
   Development Program [2015C03042]; Zhejiang Provincial Natural Science
   Foundation of China [LQ15H120002]; National Natural Science Foundation
   of China [81500704]
FX This work was supported by Program of National Natural Science
   Foundation (No. 81570822), Zhejiang Key Laboratory Fund of China (No.
   2011E10006) and Zhejiang Province Key Research and Development Program
   (2015C03042). KY is the recipient. This work was also supported by
   Zhejiang Provincial Natural Science Foundation of China (LQ15H120002)
   and Program of National Natural Science Foundation of China (No.
   81500704). YZ is the recipient. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Albietz JM, 2004, J CATARACT REFR SURG, V30, P675, DOI 10.1016/j.jcrs.2003.07.003
   Ambrosio R, 2008, J REFRACT SURG, V24, P396, DOI 10.3928/1081597X-20080401-14
   Battat L, 2001, OPHTHALMOLOGY, V108, P1230, DOI 10.1016/S0161-6420(01)00623-6
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Binder PS, 2004, J CATARACT REFR SURG, V30, P26, DOI 10.1016/S0886-3350(03)00578-9
   Demirok A, 2013, OPTOMETRY VISION SCI, V90, P1040, DOI 10.1097/OPX.0b013e31829d9926
   Denoyer A, 2015, OPHTHALMOLOGY, V122, P669, DOI 10.1016/j.ophtha.2014.10.004
   Friedlaender Mitchell H., 2006, International Ophthalmology Clinics, V46, P145, DOI 10.1097/00004397-200604630-00013
   Ganesh S, 2014, J REFRACT SURG, V30, P590, DOI 10.3928/1081597X-20140814-02
   He M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0129-5
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kezirian GM, 2004, J CATARACT REFR SURG, V30, P804, DOI 10.1016/j.jcrs.2003.10.026
   Kobashi H, 2016, CORNEA, P1
   Kumano Y, 2003, J CATARACT REFR SURG, V29, P757, DOI 10.1016/S0886-3350(02)01840-0
   Levinson BA, 2008, J CATARACT REFR SURG, V34, P32, DOI 10.1016/j.1crs.2007.08.028
   Li MY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077797
   Nassaralla BA, 2003, OPHTHALMOLOGY, V110, P497, DOI 10.1016/S0161-6420(02)01897-3
   Savini G, 2004, J REFRACT SURG, V20, P803
   Shen ZR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158176
   Stern ME, 2004, EXP EYE RES, V78, P409, DOI 10.1016/j.exer.2003.09.003
   Sugar Alan, 2002, Curr Opin Ophthalmol, V13, P246, DOI 10.1097/00055735-200208000-00011
   Toda I, 2001, AM J OPHTHALMOL, V132, P1, DOI 10.1016/S0002-9394(01)00959-X
   Wang BJ, 2015, J OPHTHALMOL, DOI 10.1155/2015/132417
   Wells GA, NEWCASTLE OTTAWA SCA
   Wen D, 2015, CLIN EXPT OPHTHALMOL, V43, P523
   Wilson SE, 2001, AM J OPHTHALMOL, V132, P405, DOI 10.1016/S0002-9394(01)00995-3
   Xia L, 2016, CURR EYE RES, V1, P1
   Xu YS, 2014, J REFRACT SURG, V30, P186, DOI 10.3928/1081597X-20140219-02
   Zhang YJ, 2016, J REFRACT SURG, V32, P256, DOI 10.3928/1081597X-20151111-06
NR 30
TC 7
Z9 7
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 16
PY 2016
VL 11
IS 12
AR e0168081
DI 10.1371/journal.pone.0168081
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EI8LN
UT WOS:000392758000026
PM 27992482
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Kim, JS
   Kwon, SH
AF Kim, Jong Seung
   Kwon, Sam Hyun
TI Mupirocin in the Treatment of Staphylococcal Infections in Chronic
   Rhinosinusitis: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID BACTERIAL BIOFILMS; CONFIDENCE-INTERVALS; PUBLICATION BIAS; SINUS
   SURGERY; AUREUS; SUPERANTIGENS; IRRIGATION; EFFICACY; AGENTS; SALINE
AB Background
   Saline irrigation of the nasal cavity is a classic and effective treatment for acute or chronic rhinosinusitis. Topical antibiotics such as mupirocin have been widely used for recalcitrant chronic rhinosinusitis. Therefore, the purpose of this study was to evaluate the effect of saline irrigation using mupirocin.
   Methods
   A systematic literature review and meta-analysis of mupirocin saline irrigation were performed using EMBASE, MEDLINE, and Cochrane library through December 2015. Data were analyzed with R 3.2.2 software. A random effects model was used because of the diversity of included studies. Sensitivity analysis of particular tested groups and single proportion tests were also performed. The main outcome measure was residual staphylococcal infection, as confirmed by culture or PCR.
   Results
   Two RCTs, two prospective studies and two retrospective studies were included. A random effects model meta-analysis of the pooled data identified a relative risk of residual infection of 0.13 (95% CI: 0.06-0.26, p<0.05) with low heterogeneity (I-2 = 0%). The proportion of residual staphylococcal infections after 1 month was 0.08 (95% Cl: 0.04-0.16). However, this proportion increased to 0.53 at 6 months (95% Cl: 0.27-0.78).
   Conclusions
   The short-term use of mupirocin has a strongly reductive effect on staphylococcal infection in chronic rhinosinusitis. Although there is currently a lack of clear evidence, future studies with well-designed inclusion criteria and randomized controlled trials are needed to examine mupirocin's long-term effect on chronic rhinosinusitis.
C1 [Kim, Jong Seung; Kwon, Sam Hyun] Chonbuk Natl Univ, Coll Med, Dept Otolaryngol Head & Neck Surg, Jeonju, South Korea.
   [Kim, Jong Seung; Kwon, Sam Hyun] Chonbuk Natl Univ, Res Inst Clin Med, Biomed Res Inst, Chonbuk Natl Univ Hosp, Jeonju, South Korea.
RP Kwon, SH (reprint author), Chonbuk Natl Univ, Coll Med, Dept Otolaryngol Head & Neck Surg, Jeonju, South Korea.; Kwon, SH (reprint author), Chonbuk Natl Univ, Res Inst Clin Med, Biomed Res Inst, Chonbuk Natl Univ Hosp, Jeonju, South Korea.
EM shkwon@jbnu.ac.kr
OI Kim, Jong Seung/0000-0002-1384-6799
FU Biomedical Research Institute at Chonbuk National University Hospital
FX This paper was supported by a fund of the Biomedical Research Institute
   at Chonbuk National University Hospital.
CR Agresti A, 2005, STAT MED, V24, P729, DOI 10.1002/sim.1781
   Al-Mutairi D, 2011, CURR OPIN ALLERGY CL, V11, P18, DOI 10.1097/ACI.0b013e3283423376
   Bachert C, 2008, CURR OPIN ALLERGY CL, V8, P34, DOI 10.1097/ACI.0b013e3282f4178f
   Barham HP, 2015, BRAZ J OTORHINOLAR, V81, P457, DOI 10.1016/j.bjorl.2015.07.002
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Borenstein M, 2009, INTRO METAANALYSIS, P84
   Brown Christopher L, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P9, DOI 10.1097/00020840-200402000-00004
   Brown CL, 2004, LARYNGOSCOPE, V114, P2021, DOI 10.1097/01.mlg.0000147939.90249.47
   Conley DB, 2006, AM J RHINOL, V20, P451, DOI 10.2500/ajr.2006.20.2880
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DOEBBELING BN, 1994, ARCH INTERN MED, V154, P1505, DOI 10.1001/archinte.154.13.1505
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Edmundson SP, 2011, EUR J CLIN MICROBIOL, V30, P1063, DOI 10.1007/s10096-011-1192-3
   Ezzat WF, 2015, EUR ARCH OTO-RHINO-L, V272, P2355, DOI 10.1007/s00405-014-3301-2
   Grossman EM, 2012, J DRUGS DERMATOL, V11, P1490
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jervis-Bardy J, 2012, LARYNGOSCOPE, V122, P2148, DOI 10.1002/lary.23486
   Jervis-Bardy J, 2012, INT FORUM ALLERGY RH, V2, P111, DOI 10.1002/alr.20106
   Khalil Yaser, 2011, Ear Nose Throat J, V90, pE1
   Knapp G, 2003, STAT MED, V22, P2693, DOI 10.1002/sim.1482
   Lanza DC, 1997, OTOLARYNG HEAD NECK, V117, pS1, DOI 10.1016/S0194-5998(97)70001-9
   Liberati A, 2009, ANN INTERN MED, V151, pW65, DOI 10.7326/0003-4819-151-4-200908180-00136
   Matthijs S, 2014, RES MICROBIOL, V165, P695, DOI 10.1016/j.resmic.2014.09.009
   McConeghy KW, 2009, PHARMACOTHERAPY, V29, P263, DOI 10.1592/phco.29.3.263
   Moore EJ, 2001, AM J RHINOL, V15, P355, DOI 10.1177/194589240101500601
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Nikfar R, 2015, IRAN J MICROBIOL, V7, P67
   Ou J, 2016, INT FORUM ALLERGY RH, V6, P792, DOI 10.1002/alr.21758
   Park SH, 2015, ANN DERMATOL, V27, P551, DOI 10.5021/ad.2015.27.5.551
   Psaltis AJ, 2008, AM J RHINOL, V22, P1, DOI 10.2500/ajr.2008.22.3119
   Rezai MS, 2016, CASP J INTERN MED, V7, P114
   Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549
   Rohrer JW, 2012, AM J RHINOL ALLERGY, V26, P197, DOI 10.2500/ajra.2012.26.3761
   Rotenberg BW, 2011, LARYNGOSCOPE, V121, P2702, DOI 10.1002/lary.22396
   Seiberling KA, 2013, INT FORUM ALLERGY RH, V3, P94, DOI 10.1002/alr.21076
   Solares CA, 2006, AM J OTOLARYNG, V27, P161, DOI 10.1016/j.amjoto.2005.09.006
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   SUTHERLAND R, 1985, ANTIMICROB AGENTS CH, V27, P495, DOI 10.1128/AAC.27.4.495
   Sutton AJ, 2000, BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574
   Uren B, 2008, LARYNGOSCOPE, V118, P1677, DOI 10.1097/MLG.0b013e31817aec47
   Xie S, 2015, CANCER MED-US, V4, P1639, DOI 10.1002/cam4.504
   Zabner J, 2000, P NATL ACAD SCI USA, V97, P11614, DOI 10.1073/pnas.97.21.11614
   Zhang N, 2005, RHINOLOGY, V43, P162
NR 43
TC 4
Z9 4
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 1
PY 2016
VL 11
IS 12
AR e0167369
DI 10.1371/journal.pone.0167369
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE3JC
UT WOS:000389482700132
PM 27907108
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chan, H
   Tang, YL
   Lv, XH
   Zhang, GF
   Wang, M
   Yang, HP
   Li, Q
AF Chan, Han
   Tang, Yan-Ling
   Lv, Xiao-Hang
   Zhang, Gao-Fu
   Wang, Mo
   Yang, Hai-Ping
   Li, Qiu
TI Risk Factors Associated with Renal Involvement in Childhood
   Henoch-Schonlein Purpura: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CHILDREN; NEPHRITIS; CLASSIFICATION; CRITERIA; TURKEY; BIAS
AB Background and objective
   Henoch-Schonlein purpura (HSP) is an important cause of chronic kidney disease in children. This meta-analysis identified risk factors associated with renal involvement in childhood HSP.
   Methods
   PubMed, Embase, and Web of Science were searched. The quality of all eligible studies was assessed using the Newcastle-Ottawa scale criteria. An analysis of possible risk factors was conducted to report the odds ratio (OR) and weighted mean difference (WMD).
   Results
   Thirteen studies (2398 children) revealed 20 possible and 13 significant risk factors associated with renal involvement in HSP, with the following meta-analysis estimates of OR and WMD, with 95% confidence intervals: older age (0.90, 0.61-1.19); age > 10 y (3.13, 1.39-7.07); male gender (1.36, 1.07-1.74); abdominal pain (1.94,1.24-3.04); gastrointestinal bleeding (1.86, 1.30-2.65); severe bowel angina (3.38, 1.17-9.80); persistent purpura (4.02, 1.22-13.25); relapse (4.70, 2.42-9.14); WBC > 15 x 10(9)/L (2.42, 1.39-4.22); platelets > 500 x 10(9)/L (2.98, 1.22-7.25); elevated antistreptolysin O (ASO) (2.17, 1.29-3.64); and decreased complement component 3 (C3) (3.13, 1.62-6.05). Factors not significantly associated with renal involvement were: blood pressure; orchitis; elevated C-reactive protein; elevated erythrocyte sedimentation rate (ESR); and elevated serum IgA/IgE or IgG. Arthritis/arthralgia may be a risk factor according to the criteria of the American College of Rheumatology (1.41, 1.01-1.96).
   Conclusion
   The following are associated with renal involvement in pediatric HSP: male gender; > 10 y old; severe gastrointestinal symptoms (abdominal pain, gastrointestinal bleeding, and severe bowel angina); arthritis/arthralgia; persistent purpura or relapse; WBC > 15 x 10(9)/L; platelets > 500 x 10(9)/L; elevated ASO; and low C3. Relevant clinical interventions for these risk factors may exert positive effects on the prevention of kidney disease during the early stages of HSP. However, the results should be interpreted cautiously due to the limitations of the studies.
C1 [Chan, Han; Tang, Yan-Ling; Lv, Xiao-Hang; Zhang, Gao-Fu; Wang, Mo; Yang, Hai-Ping; Li, Qiu] Chongqing Med Univ, Dept Nephrol, Key Lab, Minist Educ,Childrens Hosp, Chongqing, Peoples R China.
RP Yang, HP; Li, Q (reprint author), Chongqing Med Univ, Dept Nephrol, Key Lab, Minist Educ,Childrens Hosp, Chongqing, Peoples R China.
EM oyhp0708@163.com; liqiu809@126.com
FU National Natural Science Foundation of China [81270802, 81470946,
   81200520]
FX This work was supported by the National Natural Science Foundation of
   China (Grant numbers 81270802, 81470946, 81200520),
   https//isisn.nsfc.gov.cn/egrantindex/funcindex/prjsearch-list.
CR Ai Sheyyab M, 1996, J TROP PEDIATRICS, V42, P200
   Alfredo CS, 2007, J PEDIAT, V83, P177, DOI [10.1590/S0021-75572007000200013, 10.2223/JPED.1595]
   ALLEN DM, 1960, AMA J DIS CHILD, V99, P833, DOI 10.1001/archpedi.1960.02070030835021
   Anil M, 2009, TURKISH J PEDIATR, V51, P429
   Audemard Verger A, AUTOIMMUN REV, V14, P579, DOI [10.1016/j.autrev.2015.02.003, DOI 10.1016/J.AUTREV.2015.02.003]
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Butani L, 2007, CLIN PEDIATR, V46, P505, DOI 10.1177/0009922806298896
   Cakir M, 2006, ANN TROP PAEDIATR, V26, P59, DOI 10.1179/146532806X90628
   Calvino MC, 2001, MEDICINE, V80, P279, DOI 10.1097/00005792-200109000-00001
   Chan SM, 2001, CHINESE J PRACTICAL, V4, P193, DOI [10.1007/s00296-004-0452-2, DOI 10.1007/S00296-004-0452-2]
   Chartapisak W, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005128.pub2
   Davin JC, 2001, EUR J PEDIATR, V160, P689, DOI 10.1007/s004310100841
   Davin JC, 2014, NAT REV NEPHROL, V10, P563, DOI 10.1038/nrneph.2014.126
   Davin JC, 2011, CLIN J AM SOC NEPHRO, V6, P679, DOI 10.2215/CJN.06710810
   de Almeida JLJ, 2007, J PEDIAT-BRAZIL, V83, P259, DOI [10.1590/S0021-75572007000400012, 10.2223/JPED.1638]
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elmahdi A., 2014, J CLIN LAB ANAL, P1
   FARINE M, 1986, CLIN PEDIATR, V25, P257, DOI 10.1177/000992288602500505
   FARLEY TA, 1989, AM J DIS CHILD, V143, P798, DOI 10.1001/archpedi.1989.02150190048019
   Fretzayas A, 2008, JCR-J CLIN RHEUMATOL, V14, P324, DOI 10.1097/RHU.0b013e31817a240a
   Gardner-Medwin JMM, 2002, LANCET, V360, P1197, DOI 10.1016/S0140-6736(02)11279-7
   Ghrahani R, 2014, ASIA PAC ALLERGY, V4, P42, DOI 10.5415/apallergy.2014.4.1.42
   Gonzalez Gay MA, 2004, CLIN EXP RHEUMATOL, V22, P781
   Hahn D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005128.pub3
   [何艳燕 He Yanyan], 2002, [中华儿科杂志, Chinese Journal of Pediatrics], V40, P99
   Jauhola O, 2010, ARCH DIS CHILD, V95, P877, DOI 10.1136/adc.2009.182394
   Jiang JH, 2008, SKIN VENEREAL DIS, V30, P3
   Kawasaki K, 2003, J CLIN NEPHROLOGY, V60, P153
   Limpongsanurak W, 2011, MED ASS THAILAND, V94, P204
   Mao S, 2016, INT J CLIN EXP MED, V9, P3607
   Mao YY, 2014, J INT MED RES, V42, P1043, DOI 10.1177/0300060514530879
   MILLS JA, 1990, ARTHRITIS RHEUM, V33, P1114
   Nickavar A, 2012, IRAN J KIDNEY DIS, V6, P437
   Nishiyama R, 2008, DIGESTION, V77, P236, DOI 10.1159/000150697
   Oki E, 2008, RHEUMATOL INT, V28, P1181, DOI 10.1007/s00296-008-0610-z
   Ozen S, 2006, ANN RHEUM DIS, V65, P936, DOI 10.1136/ard.2005.046300
   Ozen S., 2002, CLIN RHEUMATOL, V16, P411
   Porrua C Garcia, 2002, SEMIN ARTHRITIS RHEU, V32, P149, DOI [10.1053/sarh.2002.33980, DOI 10.1053/SARH.2002.33980]
   Rigante D, 2005, RHEUMATOL INT, V25, P45, DOI 10.1007/s00296-004-0452-2
   Ronkainen J, 2002, LANCET, V360, P666, DOI 10.1016/S0140-6736(02)09835-5
   Sanders JT, 2008, CURR OPIN PEDIATR, V20, P163, DOI 10.1097/MOP.0b013e3282f4308b
   Sano H, 2002, EUR J PEDIATR, V161, P196, DOI 10.1007/s00431-002-0922-z
   Shin JI, 2006, SCAND J RHEUMATOL, V35, P56, DOI 10.1080/03009740510026841
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   StataCorp, 2011, STAT STAT SOFTW REL
   STEWART M, 1988, EUR J PEDIATR, V147, P113, DOI 10.1007/BF00442205
   Trapani S, 2005, SEMIN ARTHRITIS RHEU, V35, P143, DOI 10.1016/j.semarthrit.2005.08.007
   Vandenbroucke JP, 2007, PLOS MED, V4, P1628, DOI 10.1371/journal.pmed.0040297
   Wakaki H, 2011, PEDIATR NEPHROL, V26, P921, DOI 10.1007/s00467-011-1827-8
   Wang XH, 2016, PEDIATR RHEUMATOL, V14, DOI 10.1186/s12969-016-0080-x
   Zhao Y- R, 2015, J EUROPEAN J PEDIAT, P1
   [朱建建 Zhu Jianjian], 2014, [临床皮肤科杂志, Journal of Clinical Dermatology], V43, P336
NR 52
TC 11
Z9 12
U1 2
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 30
PY 2016
VL 11
IS 11
AR e0167346
DI 10.1371/journal.pone.0167346
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE3FV
UT WOS:000389474100076
PM 27902749
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, SG
   Xin, XY
   Hua, T
   Shi, R
   Chi, SQ
   Jin, ZS
   Wang, HB
AF Liu, Shuangge
   Xin, Xiaoyan
   Hua, Teng
   Shi, Rui
   Chi, Shuqi
   Jin, Zhishan
   Wang, Hongbo
TI Efficacy of Anti-VEGF/VEGFR Agents on Animal Models of Endometriosis: A
   Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID GROWTH-FACTOR; PUBLICATION BIAS; MOUSE MODEL; RAT MODEL; THERAPY;
   ANGIOGENESIS; INHIBITION; SORAFENIB; VEGF; SUNITINIB
AB Background/Objective
   Vascular endothelial growth factor (VEGF) is the most important promotor of angiogenesis. Some studies indicate that anti-angiogenic agents that interfere with VEGF and its receptor (VEGFR), i.e., anti-VEGF/VEGFR agents, may be applied to treat endometriosis. This meta-analysis investigated the efficacy of anti-VEGF/VEGFR agents in animal models of endometriosis.
   Methods
   A systematic literature search was performed for animal studies published in English or Chinese from January 1995 to June 2016, which evaluated the effect of anti-VEGF/VEGFR agents on endometriosis. The databases were: PubMed, Web of Science, BIOSIS, Embase, and CNKI. The quality of included studies was assessed using the SYRCLE tool. The random-effect models were used to combine the results of selected studies. Heterogeneity was assessed using H-2 statistic and I-2 statistic. Subgroup analyses were performed to determine the source of heterogeneity in endometriosis scores and follicle numbers.
   Results
   We identified 13 studies that used anti-VEGF/VEGFR agents in various animal models. The meta-analysis showed that anti-VEGF/VEGFR agents were associated with smaller size (standardized mean difference (SMD) -0.96, 95% CI - 1.31 to -0.62; P < 0.0001) and weight (SMD-1.70, 95% CI -2.75 to -0.65; P = 0.002) of endometriosis lesions, relative to the untreated controls, as well as a lower incidence rate of endometriosis (risk ratio 0.26, 95% CI 0.07 to 0.93; P = 0.038) and endometriosis score (SMD -1.17, 95% CI -1.65 to -0.69; P < 0.0001); the number of follicles were similar (SMD -0.78, 95% CI -1.65 to 0.09; P = 0.08).
   Conclusions
   Anti-VEGF/VEGFR agents appeared to inhibit the growth of endometriosis, with no effect on ovarian function. Anti-angiogenic therapy may be a novel strategy in treating endometriosis.
C1 [Liu, Shuangge; Xin, Xiaoyan; Hua, Teng; Shi, Rui; Chi, Shuqi; Jin, Zhishan; Wang, Hongbo] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Obstet & Gynecol, Wuhan, Peoples R China.
RP Wang, HB (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Obstet & Gynecol, Wuhan, Peoples R China.
EM whbdoc@163.com
CR Abbas MA, 2013, EUR J PHARM SCI, V49, P732, DOI 10.1016/j.ejps.2013.05.021
   Becker CM, 2006, FERTIL STERIL, V85, P71, DOI 10.1016/j.fertnstert.2005.07.1290
   Becker CM, 2005, FERTIL STERIL, V84, P1144, DOI 10.1016/j.fertnstert.2005.04.040
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brockwell SE, 2001, STAT MED, V20, P825, DOI 10.1002/sim.650
   Delgado-Rosas F, 2011, REPRODUCTION, V142, P745, DOI 10.1530/REP-11-0223
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ricci AG, 2011, REPROD SCI, V18, P614, DOI 10.1177/1933719110395406
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   Groothuis P. G., 2005, Angiogenesis, V8, P147, DOI 10.1007/s10456-005-9005-x
   Guo SW, 2009, HUM REPROD UPDATE, V15, P441, DOI 10.1093/humupd/dmp007
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hong SD, 2015, J CANCER RES CLIN, V141, P909, DOI 10.1007/s00432-014-1862-5
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
   Hull ML, 2003, J CLIN ENDOCR METAB, V88, P2889, DOI 10.1210/jc.2002-021912
   [蒋红清 JIANG Hongqing], 2007, [中国实用妇科与产科杂志, Chineses Journal of Practical Gynecology and Obstetrics], V23, P361
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kontopantelis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069930
   Krajewska J, 2015, EXPERT OPIN PHARMACO, V16, P573, DOI 10.1517/14656566.2015.1005601
   Laschke MW, 2012, HUM REPROD UPDATE, V18, P682, DOI 10.1093/humupd/dms026
   Laschke MW, 2006, HUM REPROD, V21, P262, DOI 10.1093/humrep/dei308
   Leconte M, 2015, REPROD SCI, V22, P1171, DOI 10.1177/1933719115592708
   Light RJ, 1984, SUMMING SCI REV RES
   Liu F, 2015, INT J CLIN EXP PATHO, V8, P1165
   Meuleman C, 2009, FERTIL STERIL, V92, P68, DOI 10.1016/j.fertnstert.2008.04.056
   Mittlbock M, 2006, STAT MED, V25, P4321, DOI 10.1002/sim.2692
   Moraloglu O, 2011, FERTIL STERIL, V95, P2638, DOI 10.1016/j.fertnstert.2011.02.005
   Nap AW, 2004, J CLIN ENDOCR METAB, V89, P1089, DOI 10.1210/jc.2003-031406
   Novella-Maestre E, 2012, FERTIL STERIL, V98, P1209, DOI 10.1016/j.fertnstert.2012.07.1103
   Novella-Maestre E, 2009, HUM REPROD, V24, P1025, DOI 10.1093/humrep/den499
   Ozer H, 2013, REPROD SCI, V20, P26, DOI 10.1177/1933719112452941
   Pala HG, 2015, J OBSTET GYNAECOL, V35, P183, DOI 10.3109/01443615.2014.941345
   Park A, 2004, FERTIL STERIL, V82, pS71, DOI 10.1016/j.fertnstert.2004.07.181
   Sevket O, 2013, REPROD SCI, V20, P1224, DOI 10.1177/1933719113483012
   Simoens S, 2012, HUM REPROD, V27, P1292, DOI 10.1093/humrep/des073
   Song WW, 2014, INT J CLIN EXP PATHO, V7, P7752
   Soysal D, 2014, BALK J MED GENET, V17, P73, DOI 10.2478/bjmg-2014-0077
   Yildiz C, 2015, REPROD SCI, V22, P1445, DOI 10.1177/1933719115584448
   Zhang TT, 2012, J INT MED RES, V40, P1840, DOI 10.1177/030006051204000522
NR 41
TC 4
Z9 6
U1 0
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 17
PY 2016
VL 11
IS 11
AR e0166658
DI 10.1371/journal.pone.0166658
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EC2AC
UT WOS:000387910200042
PM 27855197
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, ZQ
   Luo, GY
   Tang, HF
   Cheng, CC
   Wang, P
AF Zhang, Zhiqiao
   Luo, Guanying
   Tang, Hongfeng
   Cheng, Canchang
   Wang, Peng
TI Prognostic Significance of High VEGF-C Expression for Patients with
   Breast Cancer: An Update Meta Analysis
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-C; IMMUNOHISTOCHEMICAL EXPRESSION; CLINICAL-SIGNIFICANCE;
   METAANALYSIS; METASTASIS; CARCINOMA; LYMPHANGIOGENESIS; OVEREXPRESSION;
   ASSOCIATION; BIAS
AB Background
   The prognostic significance of vascular endothelial growth factor C (VEGF-C) expression in breast cancer (BC) patients remains controversial. Therefore, this meta-analysis was performed to determine the prognostic significance of VEGF-C expression in BC patients.
   Materials and Methods
   Several electronic databases were searched from January 1991 to August 2016. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the prognostic significance of VEGF-C expression for disease free survival (DFS) and overall survival (OS).
   Results
   The present meta analysis totally included 21 eligible studies and 2828 patients with BC. The combined HRs were 1.87(95% CI 1.25-2.79, P = 0.001) for DFS and 1.96(95% CI 1.15-3.31, P = 0.001) for OS. The pooled HRs of non-Asian subgroup were 2.04(95% CI 1.36-3.05, P = 0.001) for DFS and 2.61(95% CI 1.51-4.52, P = 0.001) for OS, which were significantly higher than that of Asian subgroup. The funnel plot for publication bias was symmetrical. The further Egger's test and Begg's test did not detect significant publication bias (all P>0.05).
   Conclusions
   The present meta analysis strongly supported the prognostic role of VEGF-C expression for DFS and OS in BC patients, especially for patients in non-Asian countries. Furthermore, stratification by VEGF-C expression may help to optimize the treatments and the integrated managements for BC patients.
C1 [Zhang, Zhiqiao; Wang, Peng] First Peoples Hosp Shunde, Dept Infect Dis, Shunde, Guangdong, Peoples R China.
   [Luo, Guanying; Cheng, Canchang] First Peoples Hosp Shunde, Dept Internal Med, Chencun Affiliated Hosp, Shunde, Guangdong, Peoples R China.
   [Tang, Hongfeng] First Peoples Hosp Shunde, Dept Sci & Educ, Shunde, Guangdong, Peoples R China.
RP Wang, P (reprint author), First Peoples Hosp Shunde, Dept Infect Dis, Shunde, Guangdong, Peoples R China.
EM sdgrxjbk@163.com
OI zhang, zhiqiao/0000-0003-4631-8818
FU Guangdong Provincial Health Department [A2013695, A2016450]; Finance
   Department of Guangdong Province [RMB 15000]
FX This study was funded in part by Guangdong Provincial Health Department.
   The Grant Numbers were No: A2013695 (Grant Recipient: Peng Wang) and No:
   A2016450 (Grant Recipient: Zhiqiao Zhang). The total funding account was
   RMB 15000. The funding was given by Finance Department of Guangdong
   Province. The received authors of the funding was Peng Wang (No:
   A2013695) and Zhiqiao Zhang (A2016450). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bando H, 2006, ONCOL REP, V15, P653
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Callagy GM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-153
   [曹友德 Cao Youde], 2003, [实用肿瘤杂志, Journal of Practical oncology], V18, P206
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gao S, 2014, TUMOR BIOL, V35, P1523, DOI 10.1007/s13277-013-1211-3
   Gisterek I, 2010, PATHOL ONCOL RES, V16, P337, DOI 10.1007/s12253-009-9211-8
   Gu Y, 2008, CLIN EXP METASTAS, V25, P717
   Hayes DF, 2005, BREAST, V14, P493, DOI 10.1016/j.breast.2005.08.023
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jiang H, 2014, CLIN CHIM ACTA, V427, P94, DOI 10.1016/j.cca.2013.10.002
   Kinoshita J, 2001, BREAST CANCER RES TR, V66, P159, DOI 10.1023/A:1010692132669
   [李鹏 LI Peng], 2009, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V36, P207
   Liang B, 2014, IRAN J PUBLIC HEALTH, V43, P128
   Lin Y, 2015, INT J CLIN EXP PATHO, V8, P8028
   Linardou H, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3354
   Liu XL, 2013, ACAD J SEC MIL MED U, V10, P1078
   Mohammed RAA, 2007, BRIT J CANCER, V96, P1092, DOI 10.1038/sj.bjc.6603678
   Mylona E, 2007, EJSO-EUR J SURG ONC, V33, P294, DOI 10.1016/j.ejso.2006.10.015
   Nakamura Y, 2006, CLIN CANCER RES, V12, P1201, DOI 10.1158/1078-0432.CCR-05-1269
   Nakamura Y, 2003, MODERN PATHOL, V16, P309, DOI 10.1097/01.MP.0000062858.98295.9F
   Ni XJ, 2013, J BIOMED RES, V27, P478, DOI 10.7555/JBR.27.20130021
   Ran Sophia, 2010, Pathophysiology, V17, P229, DOI 10.1016/j.pathophys.2009.11.003
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tezuka K, 2008, ONCOL REP, V20, P25
   Tsutsui S, 2010, ONCOL REP, V23, P621, DOI 10.3892/or_00000677
   Wang F, 2016, BREAST, V28, P45, DOI 10.1016/j.breast.2016.04.016
   Wang J, 2012, MOL BIOL REP, V39, P11153, DOI 10.1007/s11033-012-2024-y
   Watanabe O, 2005, J EXP CLIN CANC RES, V24, P75
   Yang WT, 2002, CANCER, V94, P2855, DOI 10.1002/cncr.10553
   Zhang Gui-hong, 2006, Zhonghua Bing Li Xue Za Zhi, V35, P473
   Zhang XH, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-4
   Zhao YC, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-165
   Zhou L, 2004, CARCINOGENESIS TERAT, V17, P291
   Zong SQ, 2016, CLIN CHIM ACTA, V458, P106, DOI 10.1016/j.cca.2016.04.037
NR 37
TC 5
Z9 5
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 3
PY 2016
VL 11
IS 11
AR e0165725
DI 10.1371/journal.pone.0165725
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EA8SX
UT WOS:000386910000053
PM 27812168
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ye, R
   Shen, T
   Jiang, Y
   Xu, LJ
   Si, XL
   Zhang, BR
AF Ye, Rong
   Shen, Ting
   Jiang, Yasi
   Xu, Lingjia
   Si, Xiaoli
   Zhang, Baorong
TI The Relationship between Parkinson Disease and Brain Tumor: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID DIAGNOSTIC-CRITERIA; CANCER COMORBIDITY; MALIGNANT-MELANOMA; INVERSE;
   HEMIPARKINSONISM; ASSOCIATION; MENINGIOMA; DISORDERS; SYNUCLEIN; PEOPLE
AB Objective
   Epidemiological studies have investigated the association between Parkinson disease (PD) occurrence and the risk of brain tumors, while the results remain controversial. We performed a meta-analysis to clarify the exact relationship between PD and brain tumors.
   Methods
   A systematic literature search was conducted using PubMed, Embase, ScienceDirect and CBM (China Biology Medicine Disc) before February 2016. Eligible studies were those that reported risk estimates of brain tumors among patients with PD or vice versa. A random-effects model was used to calculate the pooled odds ratio (OR) of the outcomes. Subgroup analyses and sensitivity analysis were conducted to explore the potential sources of heterogeneity.
   Results
   In total, eight studies involving 329,276 participants met our inclusion criteria. The pooled OR was 1.51 (95% CI 1.21-1.89), indicating that PD carried a higher risk of brain tumor. Analyses by temporal relationship found that the occurrence of brain tumor was significantly higher after the diagnosis of PD (OR 1.55, 95% CI 1.18-2.05), but not statistically significant before PD diagnosis (OR 1.21, 95% CI 0.93-1.58). Subgroup analysis showed that gender differences, ethnicity differences and the characteristic of the tumor (benign or malignant) did not make much change in the association between brain tumor and PD.
   Conclusions
   Our meta-analysis collecting epidemiological studies suggested a positive association of PD with brain tumors, while the influence of anti-parkinson drugs and ascertainment bias could not be excluded. Further studies with larger sample size and more strict inclusion criteria should be conducted in the future.
C1 [Ye, Rong; Shen, Ting; Jiang, Yasi; Xu, Lingjia; Si, Xiaoli; Zhang, Baorong] Zhejiang Univ, Sch Med, Dept Neurol, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China.
RP Zhang, BR (reprint author), Zhejiang Univ, Sch Med, Dept Neurol, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China.
EM brzhang@zju.edu.cn
CR Bajaj A, 2010, CANCER CAUSE CONTROL, V21, P697, DOI 10.1007/s10552-009-9497-6
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benincasa D, 2008, ACTA NEUROL BELG, V108, P29
   Bostantjopoulou S, 2007, PARKINSONISM RELAT D, V13, P372, DOI 10.1016/j.parkreldis.2006.07.017
   Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9
   Catala-Lopez F, 2014, PSYCHOTHER PSYCHOSOM, V83, P89, DOI 10.1159/000356498
   Checler F, 2014, NEURODEGENER DIS, V13, P118, DOI 10.1159/000354075
   D'Amelio M, 2009, ANN NY ACAD SCI, V1155, P324, DOI 10.1111/j.1749-6632.2008.03681.x
   Devine MJ, 2011, NAT REV CANCER, V11, P812, DOI 10.1038/nrc3150
   Dickson DW, 2009, LANCET NEUROL, V8, P1150, DOI 10.1016/S1474-4422(09)70238-8
   Driver JA, 2007, CANCER EPIDEM BIOMAR, V16, P1260, DOI 10.1158/1055-9965.EPI-07-0038
   Driver JA, 2014, BIOGERONTOLOGY, V15, P547, DOI 10.1007/s10522-014-9523-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feng DD, 2015, TRANSL NEURODEGENER, V4, DOI 10.1186/s40035-015-0043-z
   Fois AF, 2010, J NEUROL NEUROSUR PS, V81, P215, DOI 10.1136/jnnp.2009.175463
   Kalia LV, 2016, NAT REV NEUROL, V12, P65, DOI 10.1038/nrneurol.2015.249
   Kalia LV, 2015, LANCET, V386, P896, DOI 10.1016/S0140-6736(14)61393-3
   Kawashima M, 2000, ACTA NEUROPATHOL, V99, P154, DOI 10.1007/PL00007419
   Lin PY, 2015, JAMA ONCOL, V1, P633, DOI 10.1001/jamaoncol.2015.1752
   Lipski J, 2011, PROG NEUROBIOL, V94, P389, DOI 10.1016/j.pneurobio.2011.06.005
   Marrie RA, 2015, MULT SCLER J, V21, P294, DOI 10.1177/1352458514564489
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Olsen JH, 2006, EPIDEMIOLOGY, V17, P582, DOI 10.1097/01.ede.0000229445.90471.5e
   Ong ELH, 2014, EUR J CANCER, V50, P2456, DOI 10.1016/j.ejca.2014.06.018
   Postuma RB, 2015, MOVEMENT DISORD, V30, P1591, DOI 10.1002/mds.26424
   Rugbjerg K, 2012, INT J CANCER, V131, P1904, DOI 10.1002/ijc.27443
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tabares-Seisdedos R, 2013, NAT REV NEUROSCI, V14, P293, DOI 10.1038/nrn3464
   Tang CF, 2016, ACTA NEUROL SCAND, V134, P148, DOI 10.1111/ane.12524
   Tansey MG, 2010, NEUROBIOL DIS, V37, P510, DOI 10.1016/j.nbd.2009.11.004
   Tolosa E, 2015, BRAIN, V138, P2120, DOI 10.1093/brain/awv164
   Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491
   Wirdefeldt K, 2014, AM J EPIDEMIOL, V179, P85, DOI 10.1093/aje/kwt232
NR 33
TC 6
Z9 6
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 20
PY 2016
VL 11
IS 10
AR e0164388
DI 10.1371/journal.pone.0164388
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DZ9NZ
UT WOS:000386204500029
PM 27764145
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Cai, FC
   Xiao, XY
   Niu, X
   Shi, H
   Zhong, Y
AF Cai, Fucheng
   Xiao, Xiyue
   Niu, Xun
   Shi, Hao
   Zhong, Yi
TI Aberrant Methylation of MGMT Promoter in HNSCC: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE;
   TUMOR-ASSOCIATED GENES; NECK-CANCER PATIENTS; HUMAN-PAPILLOMAVIRUS;
   LARYNGEAL-CANCER; PROGNOSTIC VALUE; HEAD; HYPERMETHYLATION; P16
AB Background
   O6-methylguanine-DNA methyl-transferase (MGMT) gene, a DNA repair gene, plays a critical role in the repair of alkylated DNA adducts that form following exposure to genotoxic agents. MGMT is generally expressed in various tumors, and its function is frequently lost because of hypermethylation in the promoter. The promoter methylation of MGMT has been extensively investigated in head and neck squamous cell carcinoma (HNSCC). However, the association between the promoter methylation of MGMT and HNSCC risk remains inconclusive and inconsistent. Therefore, we performed a meta-analysis to better clarify the association between the promoter methylation of MGMT and HNSCC risk.
   Methods
   A systematical search was conducted in PubMed, Web of Science, EMBASE, and Ovid for studies on the association between MGMT promoter methylation and HNSCC. Odds ratio (ORs) and 95% confidence intervals (CI) were calculated to estimate association between MGMT promoter methylation and risk of HNSCC. The meta-regression and subgroup analysis were undertaken to explore the potential sources of heterogeneity.
   Results
   Twenty studies with 1,030 cases and 775 controls were finally included in this study. The frequency of MGMT promoter methylation was 46.70% in HNSCC group and 23.23% in the control group. The frequency of MGMT promoter methylation in HNSCC group was significantly higher than the control group (OR = 2.83, 95% CI = 2.25-3.56).
   Conclusion
   This meta-analysis indicates that aberrant methylation of MGMT promoter was significantly associated with the risk of HNSCC, and it may be a potential molecular marker for monitoring the disease and may provide new insights to the treatment of HNSCC.
C1 [Cai, Fucheng] Huazhong Univ Sci & Technol, Union Hosp, Dept Pediat, Tongji Med Coll, Wuhan, Peoples R China.
   [Xiao, Xiyue] Huazhong Univ Sci & Technol, Union Hosp, Dept Obstet & Gynecol, Tongji Med Coll, Wuhan, Peoples R China.
   [Niu, Xun; Zhong, Yi] Huazhong Univ Sci & Technol, Union Hosp, Dept Otorhinolaryngol, Tongji Med Coll, Wuhan, Peoples R China.
   [Shi, Hao] Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Epidemiol & Biostat, Tongji Med Coll, Wuhan, Peoples R China.
   [Shi, Hao] Huazhong Univ Sci & Technol, Sch Publ Hlth, Minist Educ, Key Lab Environm & Hlth,Tongji Med Coll, Wuhan, Peoples R China.
RP Zhong, Y (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Dept Otorhinolaryngol, Tongji Med Coll, Wuhan, Peoples R China.
EM zyzy0411@163.com
FU National Nature Science Foundation of China [81200745, 81501297]
FX This work was supported by the National Nature Science Foundation of
   China (No. 81200745 and No. 81501297). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhatia V, 2014, PROMOTER REGION HYPE, V2014, DOI [10.1155/2014/248419, DOI 10.1155/2014/248419]
   BURGER PC, 1987, CANCER, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO;2-X
   Celebi OO, 2013, VIRCHOWS ARCH, V463, P318
   Celebi OO, 2016, PATHOL RES PRACT, V212, P456, DOI 10.1016/j.prp.2016.02.022
   De Schutter H, 2009, ONCOL REP, V21, P507, DOI 10.3892/or_00000251
   Demokan S, 2011, CLIN EPIGENETICS, V2, P123, DOI 10.1007/s13148-011-0045-3
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709
   Hashibe M, 2009, CANCER EPIDEM BIOMAR, V18, P541, DOI 10.1158/1055-9965.EPI-08-0347
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hu ZY, 2015, TUMOR BIOL, V36, P1487, DOI 10.1007/s13277-014-2632-3
   Jeelani S, 2014, J CLIN DIAGN RES, V8, pZE9, DOI 10.7860/JCDR/2014/9245.4584
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kato K, 2006, J CANCER RES CLIN, V132, P735, DOI 10.1007/s00432-006-0122-8
   Kordi-Tamandani DM, 2010, ARCH ORAL BIOL, V55, P809, DOI 10.1016/j.archoralbio.2010.06.017
   Koutsimpelas D, 2012, ONCOL REP, V27, P1135, DOI 10.3892/or.2012.1624
   Krakowczyk L, 2008, MED SCI MONITOR, V14, pBR219
   Kulkarni V, 2004, ORAL ONCOL, V40, P145, DOI 10.1016/S1368-8375(03)00143-X
   Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
   Martone T, 2007, CLIN CANCER RES, V13, P5089, DOI 10.1158/1078-0432.CCR-07-0119
   Maruya SI, 2004, CLIN CANCER RES, V10, P3825, DOI 10.1158/1078-0432.CCR-03-0370
   Misawa K, 2016, ONCOTARGET, V7, P26087, DOI 10.18632/oncotarget.8317
   Paluszczak J, 2011, ORAL ONCOL, V47, P104, DOI 10.1016/j.oraloncology.2010.11.006
   Park TJ, 2001, CANCER, V92, P2760, DOI 10.1002/1097-0142(20011201)92:11<2760::AID-CNCR10123>3.0.CO;2-8
   PEGG AE, 1990, CANCER RES, V50, P6119
   Rettori MM, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-316
   Righini CA, 2007, CLIN CANCER RES, V13, P1179, DOI 10.1158/1078-0432.CCR-06-2027
   Rosas SLB, 2001, CANCER RES, V61, P939
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Scully C, 2000, ORAL ONCOL, V36, P256, DOI 10.1016/S1368-8375(00)00007-5
   Shi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122302
   Soejima H, 2005, BIOCHEM CELL BIOL, V83, P429, DOI 10.1139/O05-140
   Steinmann K, 2009, ONCOL REP, V22, P1519, DOI 10.3892/or_00000596
   Su PF, 2010, ORAL ONCOL, V46, P734, DOI 10.1016/j.oraloncology.2010.07.002
   Tao T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058858
   Viswanathan M, 2003, INT J CANCER, V105, P41, DOI 10.1002/ijc.11028
   Weiss D, 2011, MOL CARCINOGEN, V50, P680, DOI 10.1002/mc.20798
   Wong YK, 2011, J DENT SCI, V6, P158, DOI 10.1016/j.jds.2011.05.006
   Worsham MJ, 2014, CANCER LETT, V342, P178, DOI 10.1016/j.canlet.2012.02.018
   Wu PF, 2010, LUNG CANCER, V68, P484, DOI 10.1016/j.lungcan.2009.08.010
   Yang J, 2015, ONCOL LETT, V9, P35, DOI 10.3892/ol.2014.2662
   Yates DR, 2006, ONCOGENE, V25, P1984, DOI 10.1038/sj.onc.1209209
   Zuo CL, 2004, CANCER EPIDEM BIOMAR, V13, P967
NR 45
TC 2
Z9 2
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 22
PY 2016
VL 11
IS 9
AR e0163534
DI 10.1371/journal.pone.0163534
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW8GO
UT WOS:000383893200141
PM 27657735
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Gu, XB
   Gao, XS
   Qin, SB
   Li, XY
   Qi, X
   Ma, MW
   Yu, H
   Sun, SQ
   Zhou, D
   Wang, W
   Xiong, W
AF Gu, Xiaobin
   Gao, Xian-Shu
   Qin, Shangbin
   Li, Xiaoying
   Qi, Xin
   Ma, Mingwei
   Yu, Hao
   Sun, Shaoqian
   Zhou, Dong
   Wang, Wen
   Xiong, Wei
TI Elevated Platelet to Lymphocyte Ratio Is Associated with Poor Survival
   Outcomes in Patients with Colorectal Cancer
SO PLOS ONE
LA English
DT Article
ID PROGNOSTIC VALUE; PREOPERATIVE PLATELET; SOLID TUMORS; COLON-CANCER;
   INFLAMMATION; RECURRENCE; PREDICTOR; COUNT; METAANALYSIS; INHIBITION
AB Platelet to lymphocyte ratio (PLR) is a parameter reflecting inflammatory responses in patients with cancer. Several studies have investigated the prognostic value of PLR in patients with colorectal cancer (CRC); however, the results are controversial. Thus, we carried out a meta-analysis to evaluate the association between PLR and CRC prognostication. Relevant articles were retrieved through PubMed, Embase, and Web of Science, and pooled hazard ratio (HR) and 95% confidence interval (CI) were computed by using STATA V.12.0. Both the random-effects model and fixed-effects model were utilized. A total of 13 studies (14 cohorts) with 8,601 patients were included in the meta-analysis. Pooled HRs and 95% CIs demonstrated that increased PLR predicted poor overall survival (OS) (HR = 1.81, 95% CI: 1.42-2.31, p< 0.001; I-2 = 65%, Ph = 0.002), disease-free survival (DFS) (HR = 1.84, 95% CI: 1.22-2.76, p = 0.003; I-2 = 78.3%, Ph < 0.001) and recurrence-free survival (RFS) (HR = 1.84, 95% CI: 1.41-2.41, p< 0.001; I 2 = 0, Ph = 0.686), although this was not the case for cancer-specific survival (CSS) (HR = 1.75, 95% CI: 0.59-5.17, p = 0.309; I-2 = 66.2%, Ph = 0.085) or time to recurrence (TTR) (HR = 1.21 95% CI: 0.62-2.36, p = 0.573; I-2 = 58.4%, Ph = 0.121). Subgroup analysis showed that PLR enhanced the prognostic value for OS in Caucasian patients, in small sample studies and for metastatic disease; however, this was not the case with rectal cancer. Furthermore, elevated PLR predicted reduced DFS in Caucasians and not in Asians. In conclusion, our meta-analysis showed that high PLR was a significant biomarker for poor OS, DFS, and RFS in patients with CRC; however, it had no association with CSS or TTR.
C1 [Gu, Xiaobin; Gao, Xian-Shu; Qin, Shangbin; Li, Xiaoying; Qi, Xin; Ma, Mingwei; Yu, Hao; Sun, Shaoqian; Zhou, Dong; Wang, Wen] Peking Univ, First Hosp, Dept Radiat Oncol, Beijing, Peoples R China.
   [Xiong, Wei] Tangshan Peoples Hosp, Tangshan, Hebei, Peoples R China.
RP Gao, XS (reprint author), Peking Univ, First Hosp, Dept Radiat Oncol, Beijing, Peoples R China.
EM doctorgaoxs@126.com
FU Clinical Features Research of Capital [Z141107002514160]
FX This work was supported by a grant from the Clinical Features Research
   of Capital (No. Z141107002514160); This work was supported by a grant
   from the Clinical Features Research of Capital (No. Z141107002514160).
   We thank Editage (www.editage.com) for their English language editing
   service.
CR Azab B, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0432-4
   Baranyai Z, 2014, THROMB HAEMOSTASIS, V111, P483, DOI 10.1160/TH13-08-0632
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Carruthers R, 2012, COLORECTAL DIS, V14, pE701, DOI 10.1111/j.1463-1318.2012.03147.x
   Cetin EHO, 2016, ANGIOLOGY, V67, P336, DOI 10.1177/0003319715591751
   Choi WJ, 2015, ANN SURG ONCOL, V22, pS603, DOI 10.1245/s10434-015-4571-7
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Frattini M, 2004, CLIN CANCER RES, V10, P4015, DOI 10.1158/1078-0432.CCR-04-0031
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Gunaldi M, 2015, INT J CLIN EXP MED, V8, P5937
   Gunduz S, 2015, ASIA-PAC J CLIN ONCO, V11, P288, DOI 10.1111/ajco.12358
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huh JW, 2012, ARCH SURG-CHICAGO, V147, P366, DOI 10.1001/archsurg.2012.35
   Kim HE, 1997, INT J RADIAT ONCOL, V39, P731, DOI 10.1016/S0360-3016(97)00358-1
   Kinoshita A, 2012, BRIT J CANCER, V107, P988, DOI 10.1038/bjc.2012.354
   Klampfer L, 2011, CURR CANCER DRUG TAR, V11, P451, DOI 10.2174/156800911795538066
   Ko HM, 2006, FEBS LETT, V580, P3006, DOI 10.1016/j.febslet.2006.04.042
   Kraus S, 2009, CURR OPIN PHARMACOL, V9, P405, DOI 10.1016/j.coph.2009.06.006
   Labelle M, 2014, P NATL ACAD SCI USA, V111, pE3053, DOI 10.1073/pnas.1411082111
   Lei HT, 2011, MOL CELL BIOL, V31, P1788, DOI 10.1128/MCB.01321-10
   Li YQ, 2016, INT J CANCER, V139, P220, DOI 10.1002/ijc.30071
   Li ZM, 2016, COLORECTAL DIS, V18, P255, DOI 10.1111/codi.13123
   Lin MS, 2012, HEPATO-GASTROENTEROL, V59, P1687, DOI 10.5754/hge12277
   Liu WY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002596
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   McArdle CS, 2002, BRIT J CANCER, V86, P331, DOI 10.1038/sj/bjc/6600120
   Miyazaki T, 2015, EUR J CARDIO-THORAC, V47, pE140, DOI 10.1093/ejcts/ezu514
   Monreal M, 1998, THROMB HAEMOSTASIS, V79, P916
   Mori K, 2015, DIGEST DIS SCI, V60, P2477, DOI 10.1007/s10620-015-3648-2
   Neofytou K, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0239-6
   Nishijima TF, 2015, CANCER TREAT REV, V41, P971, DOI 10.1016/j.ctrv.2015.10.003
   Ozawa T, 2015, INT J COLORECTAL DIS, V30, P1165, DOI 10.1007/s00384-015-2276-9
   Qiang GL, 2016, ONCOTARGETS THER, V9, P869, DOI 10.2147/OTT.S96804
   Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246
   Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Sierko E, 2004, SEMIN THROMB HEMOST, V30, P95
   Sierko E, 2007, SEMIN THROMB HEMOST, V33, P712, DOI 10.1055/s-2007-991540
   Son HJ, 2013, ANN SURG ONCOL, V20, P2908, DOI 10.1245/s10434-013-2968-8
   Suzuki K, 2004, PANCREAS, V29, P132, DOI 10.1097/00006676-200408000-00008
   Szkandera J, 2014, AM J SURG, V208, P210, DOI 10.1016/j.amjsurg.2013.10.030
   Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124
   Templeton AJ, 2014, CANCER EPIDEM BIOMAR, V23, P1204, DOI 10.1158/1055-9965.EPI-14-0146
   Toiyama Y, 2015, INT SURG, V100, P199, DOI 10.9738/INTSURG-D-13-00178.1
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X
   Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098
   Ying HQ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0305-0
   Zhou X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101119
   Zou ZY, 2016, ONCOL LETT, V11, P2241, DOI 10.3892/ol.2016.4216
NR 54
TC 14
Z9 15
U1 2
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 22
PY 2016
VL 11
IS 9
AR e0163523
DI 10.1371/journal.pone.0163523
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW8GO
UT WOS:000383893200138
PM 27658306
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xiao, XY
   Cai, FC
   Niu, X
   Shi, H
   Zhong, Y
AF Xiao, Xiyue
   Cai, Fucheng
   Niu, Xun
   Shi, Hao
   Zhong, Yi
TI Association between P16(INK4a) Promoter Methylation and Ovarian Cancer:
   A Meta-Analysis of 12 Published Studies
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION; GRAPHICAL TEST; P16 GENE; HYPERMETHYLATION; EXPRESSION;
   CARCINOMA; BIAS; POPULATION; MUTATIONS; PROFILE
AB Background
   Ovarian cancer is the primary cause of death in women diagnosed with gynecological malignancies worldwide. Absence of early symptoms prevents prompt diagnosis or successful therapeutic intervention. P16(INK4a) is a well-known tumor suppressor gene (TSG). Aberrant methylation of TSG promoter is an important epigenetic silencing mechanism leading to ovarian cancer progression. Studies have reported differences in methylation frequencies of the p16(INK4a) promoter between ovarian cancer and the corresponding control group. However, the association between p16(INK4a) promoter methylation and ovarian cancer remains unclear and controversial. Therefore, a meta-analysis was conducted to clarify the relationship between p16(INK4a) promoter methylation and ovarian cancer.
   Methods
   PubMed, Web of Science, EMBASE and CNKI were searched to identify eligible studies for the evaluation of the association between p16(INK4a) promoter methylation and ovarian cancer. Odds ratio (ORs) and 95% confidence intervals (95% CI) were calculated to determine the strength of association between p16(INK4a) promoter methylation and ovarian cancer.
   Results
   A total of 612 ovarian cancer patients and 289 controls from 12 eligible studies were included in the meta-analysis. Overall, a significant association was observed between p16(INK4a) methylation status and ovarian cancer risk using a fixed-effects model (OR = 2.02, 95% CI = 1.39-2.94).
   Conclusion
   The results of our meta-analysis show that aberrant methylation of p16(INK4a) promoter was significantly associated with ovarian cancer. It may represent a promising molecular marker to monitor the disease and provides new insights into the treatment of human ovarian cancer.
C1 [Xiao, Xiyue] Huazhong Univ Sci & Technol, Union Hosp, Dept Obstet & Gynecol, Tongji Med Coll, Wuhan, Peoples R China.
   [Cai, Fucheng] Huazhong Univ Sci & Technol, Union Hosp, Dept Pediat, Tongji Med Coll, Wuhan, Peoples R China.
   [Niu, Xun; Zhong, Yi] Huazhong Univ Sci & Technol, Union Hosp, Dept Otorhinolaryngol, Tongji Med Coll, Wuhan, Peoples R China.
   [Shi, Hao] Huazhong Univ Sci & Technol, Dept Epidemiol & Biostat, Wuhan, Peoples R China.
   [Shi, Hao] Huazhong Univ Sci & Technol, Minist Educ, Key Lab Environm & Hlth, Sch Publ Hlth,Tongji Med Coll, Wuhan, Peoples R China.
RP Zhong, Y (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Dept Otorhinolaryngol, Tongji Med Coll, Wuhan, Peoples R China.
EM zyzy0411@163.com
FU National Nature Science Foundation of China [81200745, 81501297]
FX This work was supported by the National Nature Science Foundation of
   China (No.81200745 and No.81501297). The sponsors had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Askari M, 2013, MOL BIOL REP, V40, P4921, DOI 10.1007/s11033-013-2592-5
   Bammidi LS, 2012, INT J GYNECOL CANCER, V22, P553, DOI 10.1097/IGC.0b013e31823fa90c
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belinsky SA, 2005, CLIN CANCER RES, V11, P6505, DOI 10.1158/1078-0432.CCR-05-0625
   Bhagat R, 2014, TUMOR BIOL, V35, P9069, DOI 10.1007/s13277-014-2136-1
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dong R, 2012, J INT MED RES, V40, P681, DOI 10.1177/147323001204000231
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fraser HB, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-2-r8
   Ghazizadeh M, 2005, RESPIRATION, V72, P68, DOI 10.1159/000083403
   Hennessy BT, 2009, LANCET, V374, P1371, DOI 10.1016/S0140-6736(09)61338-6
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hsu LS, 2006, ONCOL REP, V15, P507
   Hu ZY, 2015, TUMOR BIOL, V36, P1487, DOI 10.1007/s13277-014-2632-3
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kim BN, 2005, INT J ONCOL, V26, P1217
   Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6
   Li Min, 2006, Zhonghua Fu Chan Ke Za Zhi, V41, P408
   Liu ZS, 2005, CLIN CANCER RES, V11, P4968, DOI 10.1158/1078-0432.CCR-04-2293
   Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455
   Mino A, 2006, ONCOL REP, V15, P615
   de Assis LVM, 2014, BBA-REV CANCER, V1845, P232, DOI 10.1016/j.bbcan.2014.01.008
   Niederacher D, 1999, BRIT J CANCER, V80, P1920, DOI 10.1038/sj.bjc.6690621
   NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0
   OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045
   Shen WJ, 2007, CHIN J CANC PREV TRE, V15, P530
   Shi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122302
   Shih YC, 1997, INT J CANCER, V70, P508, DOI 10.1002/(SICI)1097-0215(19970304)70:5<508::AID-IJC3>3.3.CO;2-6
   Stuck AE, 1998, BRIT MED J, V316, P469, DOI 10.1136/bmj.316.7129.469
   Tam KF, 2007, J CANCER RES CLIN, V133, P331, DOI 10.1007/s00432-006-0178-5
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang Q, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0231-1
   Wei SH, 2006, CLIN CANCER RES, V12, P2788, DOI 10.1158/1078-0432.CCR-05-1551
   Wei W, 1999, CURRENT ADV OBSTET G, V8, P109
   Wong YF, 1999, CANCER LETT, V136, P231, DOI 10.1016/S0304-3835(98)00327-9
   Xu B, 2003, MEDJQILU, V18, P227
NR 37
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 20
PY 2016
VL 11
IS 9
AR e0163257
DI 10.1371/journal.pone.0163257
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW8GE
UT WOS:000383892100071
PM 27648827
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Tang, SF
   Wei, LL
   Sun, YF
   Zhou, F
   Zhu, SB
   Yang, RQ
   Huang, YY
   Zhang, HY
   Xu, H
   Yang, JQ
AF Tang, Shifu
   Wei, Lili
   Sun, Yifan
   Zhou, Fang
   Zhu, Shengbo
   Yang, Renqi
   Huang, Yiyong
   Zhang, Hongyu
   Xu, Hong
   Yang, Jianqing
TI CA153 in Breast Secretions as a Potential Molecular Marker for
   Diagnosing Breast Cancer: A Meta Analysis
SO PLOS ONE
LA English
DT Article
ID NIPPLE DISCHARGE; SCREENING MAMMOGRAPHY; CARCINOEMBRYONIC ANTIGEN; RISK;
   MANAGEMENT; PATTERNS; CURVE; FLUID; CEA
AB Purpose
   Many studies have reported that carbohydrate antigen 153 (CA153) in breast secretions (BS) can discriminate breast cancer (BC) patients from healthy individuals, indicating CA153 in BS as a potential index for BC. This meta-analysis aimed to evaluate the actual diagnostic value of CA153 in BS.
   Methods
   Related papers were obtained from Pubmed, Embase, Scopus, Ovid, Sciverse, the Cochrane library, Chinese Biomedical literature Database (CBM), Technology of Chongqing (VIP), Wan Fang Data, and Chinese National Knowledge Infrastructure (CNKI). Pooled sensitivity, specificity, and diagnostic odds ratio (DOR) of CA153 in BS for BC diagnosis were analyzed with the random effect model. SROC and the area under the curve (AUC) were applied to assess overall diagnostic efficiency.
   Results
   This meta-analysis included five studies with a total of 329 BC patients and 381 healthy subjects. For CA153 in BS, the summary sensitivity, specificity, and DOR to diagnose BC were 0.63 (95% confidence interval (CI): 0.57 similar to 0.68), 0.82 (95% CI: 0.78 similar to 0.86), and 9.18 (95% CI: 4.22 similar to 19.95), respectively. Furthermore, the AUC of BS CA153 in the diagnosis of BC was 0.8614.
   Conclusions
   CA153 in BS is a valuable molecular marker in diagnosing BC and should be applied in standard clinical practices of BC screening upon confirmation of our findings in a larger prospective study.
C1 [Tang, Shifu; Sun, Yifan; Zhu, Shengbo; Yang, Renqi; Huang, Yiyong; Zhang, Hongyu] Guangxi Univ Chinese Med, Affiliated Hosp 3, Dept Lab Med, Guangxi, Peoples R China.
   [Wei, Lili; Xu, Hong] Guangxi Univ Chinese Med, Affiliated Hosp 3, Dept Internal Med, Guangxi, Peoples R China.
   [Zhou, Fang] Guangxi Med Univ, Affiliated Hosp 4, Dept Rheumatol, Guangxi, Peoples R China.
   [Yang, Jianqing] Guangxi Univ Chinese Med, Affiliated Hosp 4, Dept Gen Surg, Guangxi, Peoples R China.
RP Yang, JQ (reprint author), Guangxi Univ Chinese Med, Affiliated Hosp 4, Dept Gen Surg, Guangxi, Peoples R China.
EM 524908210@qq.com; yangjianqing2004@163.com
CR Ali RM, 2015, RADIOGRAPHY, V21, P298, DOI 10.1016/j.radi.2015.07.008
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brooks, 2009, METHOD MOL BIOL, V472, P307, DOI [10.1007/978-1-60327-492-0_13, DOI 10.1007/978-1-60327-492-0_13]
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chen WY, 2011, JAMA-J AM MED ASSOC, V306, P1884, DOI 10.1001/jama.2011.1590
   Dinkel HP, 2000, BRIT J RADIOL, V73, P706, DOI 10.1259/bjr.73.871.11089460
   Fan L, 2014, LANCET ONCOL, V15, pE279, DOI 10.1016/S1470-2045(13)70567-9
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gewefel H, 2014, CLIN BREAST CANCER, V14, P390, DOI 10.1016/j.clbc.2014.06.002
   GION M, 1991, BRIT J CANCER, V63, P809, DOI 10.1038/bjc.1991.179
   Howe LR, 2013, CLIN CANCER RES, V19, P6074, DOI 10.1158/1078-0432.CCR-12-2603
   Ichihara S, 2011, VIRCHOWS ARCH, V458, P547, DOI 10.1007/s00428-011-1065-2
   Jardines L, 1996, AM SURGEON, V62, P119
   Jones CM, 2005, ANN THORAC SURG, V79, P16, DOI 10.1016/j.athoracsur.2004.09.040
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kolb TM, 2002, RADIOLOGY, V225, P165, DOI 10.1148/radiol.2251011667
   Kurebayashi, 2004, GAN TO KAGAKU RYOHO, V31, P1021
   Loberg M, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0525-z
   Macacu A, 2015, BREAST CANCER RES TR, V154, P213, DOI 10.1007/s10549-015-3628-4
   Mannello Ferdinando, 2008, Expert Opin Med Diagn, V2, P1221, DOI 10.1517/17530059.2.11.1221
   Mantas D, 2016, ATHEROSCLEROSIS, V248, P1, DOI 10.1016/j.atherosclerosis.2016.02.019
   Morrow M, 2011, LANCET, V378, P1804, DOI 10.1016/S0140-6736(11)61350-0
   Pinto MM, 1996, ACTA CYTOL, V40, P437
   Sauter ER, 1999, BRIT J CANCER, V81, P1222, DOI 10.1038/sj.bjc.6690832
   Schennink A, 2015, REPROD TOXICOL, V54, P93, DOI 10.1016/j.reprotox.2014.10.020
   Shield KD, 2016, ALCOHOL CLIN EXP RES, V40, P1166, DOI 10.1111/acer.13071
   Siu AL, 2009, ANN INTERN MED, V151, P716, DOI [10.7326/0003-4819-151-10-200911170-00008, DOI 10.7326/0003-4819-151-10-200911170-00008]
   Tang S, 2016, BREAST CANC
   Vargas Hernan I, 2002, Curr Treat Options Oncol, V3, P157, DOI 10.1007/s11864-002-0061-9
   Walter SD, 2002, STAT MED, V21, P1237, DOI 10.1002/sim.1099
   Wang GP, 2014, INT J MOL SCI, V15, P9546, DOI 10.3390/ijms15069546
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Wong AW, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-75
   Yip CH, 2011, BREAST, V20, pS12, DOI 10.1016/j.breast.2011.02.015
   Zamora Javier, 2006, BMC Med Res Methodol, V6, P31, DOI 10.1186/1471-2288-6-31
   Zhao S, 2015, INT J CLIN EXP MED, V8, P20837
   Zhao S, 2015, CHINESE J PHYSIOL, V58, P385, DOI 10.4077/CJP.2015.BAD336
   [庄志刚 Zhuang Zhigang], 2005, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V32, P690
NR 38
TC 4
Z9 6
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 16
PY 2016
VL 11
IS 9
AR e0163030
DI 10.1371/journal.pone.0163030
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW5YN
UT WOS:000383723700027
PM 27636552
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Mihara, T
   Ishii, T
   Ka, K
   Goto, T
AF Mihara, Takahiro
   Ishii, Tomoko
   Ka, Koui
   Goto, Takahisa
TI Effects of Steroids on Quality of Recovery and Adverse Events after
   General Anesthesia: Meta-Analysis and Trial Sequential Analysis of
   Randomized Clinical Trials
SO PLOS ONE
LA English
DT Article
ID PREOPERATIVE DEXAMETHASONE; POSTOPERATIVE QUALITY; DOUBLE-BLIND; NAUSEA;
   PAIN; DISCREPANCIES; VALIDITY; OUTCOMES; SURGERY
AB Background
   Quality of recovery (QoR) after surgery is a relevant outcome. The early postoperative quality of recovery of a patient can be determined using the QoR-40 questionnaire. The aim of this meta-analysis and Trial Sequential Analysis was to determine if perioperative administration of glucocorticosteroids improved patients' quality of recovery after general anesthesia and if adverse events occurred.
   Methods
   We searched six databases, including trial registration sites. Randomized clinical trials reporting the efficacy of glucocorticosteroids on quality of recovery evaluated using the QoR-40 after general anesthesia were eligible. The QoR-40 data were combined as the mean difference with confidence intervals using a random-effects model. The I-2 statistic was used to assess heterogeneity. The quality of the trials was evaluated using the Cochrane methodology. Moreover, Trial Sequential Analysis was carried out to prevent the inflation of type 1 errors caused by multiple testing and sparse data. We also assessed adverse events.
   Results
   Three randomized clinical trials (totaling 301 patients) were analyzed. The results from one published and four unpublished randomized clinical trialswere unavailable. Dexamethasone was investigated in all three trials, and the results suggested that it significantly improved QoR-40 at postoperative day one scores compared with placebo (mean difference [95% confidence interval]: 14.2 points [10.4 to 18.1]; P < 0.001; I-2 = 0%). We could not conduct sensitivity analysis because of the absence of trials with low risk of bias. The Trial Sequential Analysis-adjusted confidence interval was -1.6 to 30.0, indicating that further trials are required. The reporting of adverse events was insufficient.
   Conclusions
   These findings indicate that perioperative dexamethasone administrationmay improve short-term(i.e., one day) quality of recovery after general anesthesia and surgery. We need more randomized clinical trials with low risk of bias assessing the effects of glucocorticosteroids on quality of life, other outcomes, and adverse events. Updated systematic reviews should then be conducted.
C1 [Mihara, Takahiro; Ishii, Tomoko; Ka, Koui] Kanagawa Childrens Med Ctr, Dept Anesthesiol, Minami Ku, Mutsukawa 2-138-4, Yokohama, Kanagawa, Japan.
   [Mihara, Takahiro; Ka, Koui; Goto, Takahisa] Yokohama City Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa, Japan.
RP Mihara, T (reprint author), Kanagawa Childrens Med Ctr, Dept Anesthesiol, Minami Ku, Mutsukawa 2-138-4, Yokohama, Kanagawa, Japan.; Mihara, T (reprint author), Yokohama City Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa, Japan.
EM miharaxxxtotoro@yahoo.co.jp
CR Aasboe V, 1998, ANESTH ANALG, V87, P319, DOI 10.1097/00000539-199808000-00015
   Afshari A, 2015, EUR J ANAESTH, V32, P85, DOI 10.1097/EJA.0000000000000186
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bisgaard T, 2003, ANN SURG, V238, P651, DOI 10.1097/01.sla.0000094390.82352.cb
   Brok J, 2009, INT J EPIDEMIOL, V38, P287, DOI 10.1093/ije/dyn188
   Brok J, 2008, J CLIN EPIDEMIOL, V61, P763, DOI 10.1016/j.jclinepi.2007.10.007
   Chen CC, 2012, WORLD J SURG, V36, P61, DOI 10.1007/s00268-011-1343-9
   De Oliveira GS, 2011, BRIT J ANAESTH, V107, P362, DOI 10.1093/bja/aer156
   De Oliveira GS, 2013, ANESTH ANALG, V116, P58, DOI 10.1213/ANE.0b013e31826f0a0a
   De Oliveira GS, 2011, ANESTHESIOLOGY, V115, P575, DOI 10.1097/ALN.0b013e31822a24c2
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Fukami Y, 2009, J HEPATO-BILIARY-PAN, V16, P367, DOI 10.1007/s00534-009-0079-5
   Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002
   Garattini S, 2016, EUR J INTERN MED, V32, P13, DOI 10.1016/j.ejim.2016.03.020
   Gornall BF, 2013, BRIT J ANAESTH, V111, P161, DOI 10.1093/bja/aet014
   Herrera FJ, 2007, ANESTH ANALG, V105, P63, DOI 10.1213/01.ane.0000265534.73169.95
   Higgins JP, COCHRANE HDB SYSTEMA
   Holte K, 2002, J AM COLL SURGEONS, V195, P694, DOI 10.1016/S1072-7515(02)01491-6
   Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13
   Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010
   Kluivers KB, 2008, SURGERY, V143, P206, DOI 10.1016/j.surg.2007.08.017
   LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Mihara T, 2015, EUR J ANAESTH, V32, P862, DOI 10.1097/EJA.0000000000000323
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Murphy GS, 2011, J CARDIOTHOR VASC AN, V25, P950, DOI 10.1053/j.jvca.2011.03.002
   Murphy GS, 2011, ANESTHESIOLOGY, V114, P882, DOI 10.1097/ALN.0b013e3181ec642e
   Myles PS, 2000, BRIT J ANAESTH, V84, P11
   Pauls RN, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.05.061
   Romundstad L, 2006, ANESTH ANALG, V102, P418, DOI 10.1213/01.ane.0000194358.46119.e1
   Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55
   Savovic J, 2012, ANN INTERN MED, V157, P429, DOI 10.7326/0003-4819-157-6-201209180-00537
   Thorlund K, 2011, USER MANUAL FOR TRIA
   Thorlund K, 2009, INT J EPIDEMIOL, V38, P276, DOI 10.1093/ije/dyn179
   Turner RM, 2015, STAT MED, V34, P984, DOI 10.1002/sim.6381
   VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0
   Waldron NH, 2013, BRIT J ANAESTH, V110, P191, DOI 10.1093/bja/aes431
   Wetterslev J, 2008, J CLIN EPIDEMIOL, V61, P64, DOI 10.1016/j.jclinepi.2007.03.013
   Wood L, 2008, BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD
NR 40
TC 4
Z9 4
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 15
PY 2016
VL 11
IS 9
AR e0162961
DI 10.1371/journal.pone.0162961
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW5SJ
UT WOS:000383706900101
PM 27631490
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Pacella, E
   Mipatrini, D
   Pacella, F
   Amorelli, G
   Bottone, A
   Smaldone, G
   Turchetti, P
   La Torre, G
AF Pacella, Elena
   Mipatrini, Daniele
   Pacella, Fernanda
   Amorelli, Giulia
   Bottone, Andrea
   Smaldone, Gianpaolo
   Turchetti, Paolo
   La Torre, Giuseppe
TI Suspensory Materials for Surgery of Blepharoptosis: A Systematic Review
   of Observational Studies
SO PLOS ONE
LA English
DT Review
ID AUTOGENOUS FASCIA-LATA; SILICONE FRONTALIS SUSPENSION; DIFFERENT
   SURGICAL DESIGNS; RANDOMIZED CLINICAL-TRIAL; SEVERE CONGENITAL PTOSIS;
   MESH BROW SUSPENSION; UPPER EYELID PTOSIS; MERSILENE MESH; LEVATOR
   FUNCTION; SUTURE MATERIAL
AB Background
   Frontalis suspension surgery is considered the procedure of choice in cases of blepharoptosis. Among all the materials used in this type of surgery, ophthalmic and plastic surgeons prefer to use autologous Fascia Lata. However, during years, other autogenous and exogenous materials have been introduced.
   Objectives
   The aim of this study was therefore that of systematically reviewing the functional results and the rate of complications of different synthetic materials, as compared to autogenous Fascia Lata. The primary objective was to determine the rates of Successful Surgeries (SSs) of these materials. The secondary objective was to assess the onset of complications. The following materials were investigated: Fascia Lata, Mersilene, polytetrafluoroethylene (PTFE) and Silicon.
   Data Source and Methods
   Following the Prisma procedure, on January 30th, 2016 we used the following electronic databases to select the studies: MEDLINE and Scopus.
   Results
   The search strategy retrieved 48 publications that met the eligibility criteria of the systematic review. All studies were non-comparative. PTFE (n = 5) showed the best rate of SSs among the materials compared (statistically significant). Surgeries performed with autogenous Fascia Lata (n = 19) had a 87% rate of success those performed with Mersilene (n = 12) had 92% and those performed with Silicon (n = 17) 88%. PTFE had the best outcome, with 99% success rate. As for complications, surgeries performed with PTFE had a higher rate of suture infections (1.9%) as compared to Fascia Lata, but lower incidence for all other complications.
   Conclusions
   Although most studies were good quality cohort studies, the overall quality of this evidence should be regarded as low due to their non-comparative design. Our data suggest that PTFE seems to be the most valid alternative material for frontalis suspension surgery, with low recurrence rates and good cosmetic and functional results.
C1 [Pacella, Elena; Pacella, Fernanda; Amorelli, Giulia; Bottone, Andrea; Smaldone, Gianpaolo] Sapienza Univ Rome, Fac Med & Dent, Dept Sense Organs, Rome, Italy.
   [Mipatrini, Daniele; La Torre, Giuseppe] Sapienza Univ Rome, Fac Pharm & Med, Dept Publ Hlth & Infect Dis, Rome, Italy.
   [Turchetti, Paolo] Natl Inst Hlth Migrat & Poverty INMP NIHMP, Rome, Italy.
RP Pacella, F (reprint author), Sapienza Univ Rome, Fac Med & Dent, Dept Sense Organs, Rome, Italy.
EM fernanda.pacella@gmail.com
OI La Torre, Giuseppe/0000-0002-1233-2040
CR Abou-Setta AM, 2011, NEWCASTLE OTTAWA SCA
   Ali Zulfiquar, 2011, J Ayub Med Coll Abbottabad, V23, P30
   Allen RC, 2012, BRIT J OPHTHALMOL, V96, P841, DOI 10.1136/bjophthalmol-2011-300667
   Arajy ZY, 2012, J CRANIO MAXILL SURG, V40, P129, DOI 10.1016/j.jcms.2011.03.002
   Bagheri A, 2007, OPHTHAL PLAST RECONS, V23, P217, DOI 10.1097/IOP.0b013e3180557479
   Bansal RK, 2015, J PEDIAT OPHTH STRAB, V52, P93, DOI 10.3928/01913913-20150313-11
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Ben Simon GJ, 2005, AM J OPHTHALMOL, V140, P877, DOI 10.1016/j.ajo.2005.05.031
   Bernardini Francesco P, 2002, Orbit, V21, P195, DOI 10.1076/orbi.21.3.195.7171
   Bernardini FP, 2013, CURR OPIN OPHTHALMOL, V24, P484, DOI 10.1097/ICU.0b013e328363861a
   Bilgin Lale Kozer, 2010, Plast Surg Int, V2010, P609462, DOI 10.1155/2010/609462
   Buttanri IB, 2013, OPHTHAL PLAST RECONS, V29, P98, DOI 10.1097/IOP.0b013e31827a0068
   Can I, 1996, Eur J Ophthalmol, V6, P150
   Carter SR, 1996, OPHTHALMOLOGY, V103, P623, DOI 10.1016/S0161-6420(96)30643-X
   Cates CA, 2008, ORBIT, V27, P83, DOI 10.1080/01676830701376072
   Chong KKL, 2010, EYE, V24, P44, DOI 10.1038/eye.2009.48
   CRAWFORD J S, 1956, Trans Am Acad Ophthalmol Otolaryngol, V60, P672
   Davies BW, 2013, OPHTHAL PLAST RECONS, V29, pE111, DOI 10.1097/IOP.0b013e318281eb1f
   Deenstra W, 1996, ANN PLAS SURG, V36, P348, DOI 10.1097/00000637-199604000-00004
   DeMartelaere SL, 2007, OPHTHAL PLAST RECONS, V23, P279, DOI 10.1097/IOP.0b013e31806b16a9
   DOWNES RN, 1989, BRIT J OPHTHALMOL, V73, P498, DOI 10.1136/bjo.73.7.498
   DOWNES RN, 1990, EYE, V4, P456, DOI 10.1038/eye.1990.58
   El-Toukhy E, 2001, EYE, V15, P178, DOI 10.1038/eye.2001.56
   Evereklioglu C, 2012, BRIT J OPHTHALMOL, V96, P570, DOI 10.1136/bjophthalmol-2011-300400
   Finsterer J, 2003, AESTHET PLAST SURG, V27, P193, DOI 10.1007/s00266-003-0127-5
   Fogagnolo P, 2008, EUR J OPHTHALMOL, V18, P723
   Friedhofer H, 2012, PLAST RECONSTR SURG, V129, p453E, DOI 10.1097/PRS.0b013e3182402deb
   Gabrieli CB, 1996, OPHTHALMIC SURG LAS, V27, P924
   Hafez A, 2008, MIDDLE EAST AFR J OP, V15, P117, DOI 10.4103/0974-9233.51986
   Hayashi K, 2013, AM J OPHTHALMOL, V155, P654, DOI 10.1016/j.ajo.2012.10.022
   HINTSCHICH CR, 1995, BRIT J OPHTHALMOL, V79, P358, DOI 10.1136/bjo.79.4.358
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   KEMP EG, 1986, T OPHTHAL SOC UK, V105, P84
   Kemp EG, 2001, OPHTHALMIC PLAST REC, V17, P419, DOI 10.1097/00002341-200111000-00006
   Khwarg SI, 1999, OPHTHALMOLOGY, V106, P1191, DOI 10.1016/S0161-6420(99)90258-0
   Kim CY, 2015, BRIT J OPHTHALMOL, V99, P346, DOI 10.1136/bjophthalmol-2014-305101
   Lam DSC, 1997, EYE, V11, P806, DOI 10.1038/eye.1997.210
   Lamont M, 2010, ORBIT, V29, P102, DOI 10.3109/01676830903452957
   Lee MJ, 2009, OPHTHALMOLOGY, V116, P123, DOI 10.1016/j.ophtha.2008.08.049
   Leibovitch I, 2003, AM J OPHTHALMOL, V136, P866, DOI 10.1016/S0002-9394(03)00466-5
   Lelli GJ, 2009, OPHTHAL PLAST RECONS, V25, P361, DOI 10.1097/IOP.0b013e3181b3b183
   LEONE CR, 1981, OPHTHALMIC SURG LAS, V12, P881
   Mehta P, 2004, BRIT J OPHTHALMOL, V88, P361, DOI 10.1136/bjo.2002.009951
   Morris CL, 2008, J PEDIAT OPHTH STRAB, V45, P280, DOI 10.3928/01913913-20080901-11
   Mutlu FM, 1999, OPHTHALMIC SURG LAS, V30, P47
   Nakauchi K, 2013, CLIN OPHTHALMOL, V7, P131, DOI 10.2147/OPTH.S39057
   Naugle TC, 1997, OPHTHALMOLOGY, V104, P1480, DOI 10.1016/S0161-6420(97)30107-9
   Nucci P, 2015, SEMIN OPHTHALMOL, V21, P1
   OLDER JJ, 1984, OPHTHALMIC SURG LAS, V15, P379
   Payr E, 1909, DTSCH MED WOCHENSCHR, V35
   Philandrianos C, 2010, J PLAST RECONSTR AES, V63, P782, DOI 10.1016/j.bjps.2009.01.083
   Razavi ME, 2014, ORBIT, V33, P91, DOI 10.3109/01676830.2013.841714
   Rizvi SAR, 2014, OPHTHAL PLAST RECONS, V30, P11, DOI 10.1097/IOP.0b013e3182a74f44
   Rong G, 2013, SCI WORLD J, DOI 10.1155/2013/589215
   Salour H, 2008, EUR J OPHTHALMOL, V18, P853
   Sharma TK, 2003, EYE, V17, P759, DOI 10.1038/sj.eye.6700498
   Shimizu Y, 2015, J PLAST RECONSTR AES, V68, P49, DOI 10.1016/j.bjps.2014.08.068
   Sokol JA, 2011, OPHTHAL PLAST RECONS, V27, P211, DOI 10.1097/IOP.0b013e3181ef72cd
   STEINKOGLER FJ, 1993, PLAST RECONSTR SURG, V92, P1057, DOI 10.1097/00006534-199311000-00009
   Suh Ji Young, 2013, Korean J Ophthalmol, V27, P311, DOI 10.3341/kjo.2013.27.5.311
   TILLETT CW, 1966, AM J OPHTHALMOL, V62, P521, DOI 10.1016/0002-9394(66)91334-1
   van Sorge AJ, 2012, ACTA OPHTHALMOL, V90, P188, DOI 10.1111/j.1755-3768.2010.01876.x
   WAGNER RS, 1984, OPHTHALMOLOGY, V91, P245
   Wasserman BN, 2001, ARCH OPHTHALMOL-CHIC, V119, P687, DOI 10.1001/archopht.119.5.687
   Wei YH, 2009, J FORMOS MED ASSOC, V108, P943, DOI 10.1016/S0929-6646(10)60007-1
   Wheatcroft SM, 1997, BRIT J OPHTHALMOL, V81, P581, DOI 10.1136/bjo.81.7.581
   Woo KI, 2014, AM J OPHTHALMOL, V157, P1221, DOI 10.1016/j.ajo.2014.02.041
   Wright WW., 1922, ARCH OPHTHALMOL-CHIC, V51, P99
   Yoon JS, 2009, OPHTHALMOLOGY, V116, P1405, DOI 10.1016/j.ophtha.2009.01.040
NR 69
TC 4
Z9 4
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 15
PY 2016
VL 11
IS 9
AR e0160827
DI 10.1371/journal.pone.0160827
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW5SJ
UT WOS:000383706900013
PM 27631781
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ayubi, E
   Doosti-Irani, A
   Moghaddam, AS
   Sani, M
   Nazarzadeh, M
   Mostafavi, E
AF Ayubi, Erfan
   Doosti-Irani, Amin
   Moghaddam, Ali Sanjari
   Sani, Mohadeseh
   Nazarzadeh, Milad
   Mostafavi, Ehsan
TI The Clinical Usefulness of Tuberculin Skin Test versus Interferon-Gamma
   Release Assays for Diagnosis of Latent Tuberculosis in HIV Patients: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID QUANTIFERON-TB GOLD; IMMUNODEFICIENCY-VIRUS-INFECTION; IN-TUBE;
   LOW-PREVALENCE; RISK-FACTORS; INDIVIDUALS; KAPPA; AGREEMENT; BIAS;
   ASSOCIATION
AB Background
   Accurate diagnosis of latent tuberculosis infection (LTBI) is becoming increasingly concerning due to the increasing the HIV epidemic, which have increased the risk for reactivation to active tuberculosis (TB) infection. LTBI is diagnosed by tuberculin skin test (TST) and inter-feron- gamma release assays (IGRAs).
   Objectives
   The aim of the present study was to conduct a meta-analysis of published papers on the agreement (kappa) between TST and QuantiFERON-TB Gold In-Tube (QFT-GIT) tests for diagnosis of LTBI in HIV patient.
   Methods
   Electronic databases including PubMed/ Medline, Elsevier/ Scopus and Embase/ Ovidwere reviewed up Jan. 2016. We performed a random effect model meta-analysis for estimation of pooled Kappa between the two methods of diagnosis. Meta regression was used for assessing potential heterogeneity and Egger's test was used for assessing small study effect and publication bias.
   Results
   The initial search strategy produced 6744 records. Of them, 23 cross-sectional studies met the inclusion criteria and 20 studies entered in meta-analysis. The pooled kappa was andprevalence-adjusted and bias-adjusted kappa (PABAK) were 0.37 (95% CI: 0.28, 0.46) and 0.59 (0.49, 0.69). The discordance of TST-/QFT-GIT+ was more than TST+/QFT-GIT-. Kappa estimate between two tests was linearly associated with age and prevalence index and inversely associated with bias index.
   Conclusion
   Fair agreement between TST and QFT-GIT makes it difficult to know whether TST is as useful as the QFT-GIT in HIV-infected patients. The higher discordance of TST-/QFT-GIT+ in compared to TST+/QFT-GIT-can induce the higher sensitivity of QFT-GIT for diagnosis LTBI in HIV patients. Disagreement between two tests can be influenced by error in measurements and prevalence of HIV.
C1 [Ayubi, Erfan] Shahid Beheshti Univ Med Sci, Sch Publ Hlth, Dept Epidemiol, Tehran, Iran.
   [Ayubi, Erfan; Doosti-Irani, Amin; Mostafavi, Ehsan] Pasteur Inst Iran, Dept Epidemiol, Tehran, Iran.
   [Ayubi, Erfan; Doosti-Irani, Amin] Univ Tehran Med Sci, Sch Publ Hlth, Dept Epidemiol, Tehran, Iran.
   [Moghaddam, Ali Sanjari] Shahid Beheshti Univ Med Sci, Sch Med, Tehran, Iran.
   [Sani, Mohadeseh] Zabol Univ Med Sci, Sch Med, Zabol, Iran.
   [Nazarzadeh, Milad] Sabzevar Univ Med Sci, Iranian Res Ctr Hlth Aging, Collaborat Ctr Metaanal Res ccMETA, Sabzevar, Iran.
   [Mostafavi, Ehsan] Res Ctr Emerging & Reemerging Infect Dis Akanlu, Hamadan, Iran.
RP Mostafavi, E (reprint author), Pasteur Inst Iran, Dept Epidemiol, Tehran, Iran.; Mostafavi, E (reprint author), Res Ctr Emerging & Reemerging Infect Dis Akanlu, Hamadan, Iran.
EM mmostafavi@pasteur.ac.ir
RI Mostfavi, Ehsan/A-7627-2011; Doosti-Irani, Amin/Q-1260-2016; Nazarzadeh,
   Milad/J-8970-2014
OI Mostfavi, Ehsan/0000-0002-1997-517X; Doosti-Irani,
   Amin/0000-0003-0623-7503; Nazarzadeh, Milad/0000-0002-0576-8874
CR Aichelburg MC, 2014, INT J TUBERC LUNG D, V18, P709, DOI 10.5588/ijtld.13.0813
   Balcells ME, 2008, INT J INFECT DIS, V12, P645, DOI 10.1016/j.ijid.2008.03.005
   Banerjee M, 1997, RES NURS HEALTH, V20, P465, DOI 10.1002/(SICI)1098-240X(199710)20:5<465::AID-NUR10>3.0.CO;2-8
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blackman NJM, 2000, STAT MED, V19, P723, DOI 10.1002/(SICI)1097-0258(20000315)19:5<723::AID-SIM379>3.0.CO;2-A
   BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V
   Cattamanchi A, 1999, J ACQ IMMUN DEF SYND, V56, P230
   Cheallaigh CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053330
   Chkhartishvili N, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-513
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Converse PJ, 1997, J INFECT DIS, V176, P144, DOI 10.1086/514016
   Davarpanah MA, 2009, IRAN RED CRESCENT ME, V11, P71
   Diel R, 2011, EUR RESPIR J, V37, P88, DOI 10.1183/09031936.00115110
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192
   Fleiss JL, 2013, STAT METHODS RATES P
   Garcia-Elorriaga G, 2013, ASIAN PAC J TROP MED, V6, P135, DOI 10.1016/S1995-7645(13)60009-7
   Gray J, 2012, CLIN INFECT DIS, V54, pE20, DOI 10.1093/cid/cir792
   Hoehler FK, 2000, J CLIN EPIDEMIOL, V53, P499, DOI 10.1016/S0895-4356(99)00174-2
   Jones S, 2007, INT J TUBERC LUNG D, V11, P1190
   Kabeer BSA, 2011, DIAGN MICR INFEC DIS, V71, P236, DOI 10.1016/j.diagmicrobio.2011.07.012
   Kimura M, 1999, J INFECT DIS, V179, P1297, DOI 10.1086/314707
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lee YM, 2013, INFECTION, V41, P1089, DOI 10.1007/s15010-013-0478-z
   Luetkemeyer AF, 2007, AM J RESP CRIT CARE, V175, P737, DOI 10.1164/rccm.200608-1088OC
   Mandalakas AM, 2008, INT J TUBERC LUNG D, V12, P417
   Menzies D, 2007, ANN INTERN MED, V146, P340, DOI 10.7326/0003-4819-146-5-200703060-00006
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Oni T, 2012, CLIN VACCINE IMMUNOL, V19, P1243, DOI 10.1128/CVI.00166-12
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X
   Pullar ND, 2014, INT J TUBERC LUNG D, V18, P180, DOI 10.5588/ijtld.13.0276
   Ramos JM, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-169
   Rangaka MX, 2007, AM J RESP CRIT CARE, V175, P514, DOI 10.1164/rccm.200610-1439OC
   Richeldi L, 2009, CHEST, V136, P198, DOI 10.1378/chest.08-2575
   Santin M, 2011, DIAGN MICR INFEC DIS, V69, P59, DOI 10.1016/j.diagmicrobio.2010.09.005
   Sauzullo I, 2010, INT J TUBERC LUNG D, V14, P834
   Seshadri C, 2008, East Afr Med J, V85, P442
   Sim J, 2005, PHYS THER, V85, P257
   Stephan C, 2008, AIDS, V22, P2471, DOI 10.1097/QAD.0b013e3283188415
   Talati NJ, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-264
   Talati NJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-15
   Taylor Zachary, 2005, Morbidity and Mortality Weekly Report, V54, P1
   von Elm E, 2007, BMJ-BRIT MED J, V335, P806
   Weinfurter P, 2011, INT J TUBERC LUNG D, V15, P1056, DOI 10.5588/ijtld.10.0650
   WHO, 2012, GLOB TUB CONTR WHO R
   World Health Organization, 2014, GLOB TUB CONTR WHO R
   World Health Organization (WHO), TUB COUNTR PROF
NR 47
TC 7
Z9 7
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 13
PY 2016
VL 11
IS 9
AR e0161983
DI 10.1371/journal.pone.0161983
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW5JR
UT WOS:000383681000011
PM 27622293
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Deng, K
   Zhu, CJ
   Ma, XL
   Jia, HY
   Wei, ZG
   Xiao, Y
   Xu, J
AF Deng, Ke
   Zhu, Chenjing
   Ma, Xuelei
   Jia, Hongyuan
   Wei, Zhigong
   Xiao, Yue
   Xu, Jing
TI Rapid Discrimination of Malignant Breast Lesions from Normal Tissues
   Utilizing Raman Spectroscopy System: A Systematic Review and
   Meta-Analysis of In Vitro Studies
SO PLOS ONE
LA English
DT Review
ID CONSERVING SURGERY; DIAGNOSTIC-TEST; CANCER; MASTECTOMY; MARGINS
AB Purpose
   The aim of this study is to evaluate the diagnostic accuracy of Raman spectroscopy system in the detection of malignant breast lesions through a systemic review and meta-analysis of published studies.
   Methods
   We conducted a comprehensive literature search of PubMed and Embase from 2000 to June 2015. Published studies that evaluated the diagnostic performance of Raman spectroscopy in distinguishing malignant breast lesions from benign lesions and normal tissues were included in our study. The pooled sensitivity, specificity, diagnostic odds ratio, and the area under the curve of summary receiver-operating characteristic curves was derived. A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies guidelines was used to assess the quality of included studies.
   Results
   The initial search produced a total of 157 articles after removing duplicates. Nine studies (8 in vitro and 1 in vivo) were eligible in this meta-analysis. We analyzed the eight in vitro studies with 1756 lesions, the pooled sensitivity and specificity of Raman spectroscopy system for the diagnosis of malignant breast lesions were 0.92 (95% CI 0.86-0.96) and 0.97 (97% CI 0.93-0.98), respectively. Diagnostic odds ratio was 266.70 (95% CI 89.38-795.79), and the area under the curve of summary receiver-operating characteristic curves was 0.98 (95% CI 0.97-0.99). Significant heterogeneity was found between studies. There was no evidence of considerable publication bias.
   Conclusions
   Raman spectroscopy system is an optical diagnostic technology with great value for detecting malignant breast lesions. At the same time, it has advantages of being non-invasive, real-time, and easy to use. Thus it deserves to be further explored for intra-operatory breast tumor margin detection.
C1 [Deng, Ke; Zhu, Chenjing; Ma, Xuelei; Jia, Hongyuan; Wei, Zhigong; Xiao, Yue] Sichuan Univ, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China.
   [Deng, Ke; Zhu, Chenjing; Ma, Xuelei; Jia, Hongyuan; Wei, Zhigong; Xiao, Yue] Sichuan Univ, Ctr Canc, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Xu, Jing] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China.
RP Ma, XL (reprint author), Sichuan Univ, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China.; Ma, XL (reprint author), Sichuan Univ, Ctr Canc, West China Hosp, Chengdu, Sichuan, Peoples R China.
EM drmaxuelei@gmail.com
CR Barman I, 2013, CANCER RES, V73, P3206, DOI 10.1158/0008-5472.CAN-12-2313
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Dinnes J, 2005, HEALTH TECHNOL ASSES, V9, P1, DOI 10.3310/hta9120
   Haka AS, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3247154
   Haka AS, 2006, CANCER RES, V66, P3317, DOI 10.1158/0008-5472.CAn-05-2815
   Haka AS, 2005, P NATL ACAD SCI USA, V102, P12371, DOI 10.1073/pnas.0501390102
   Hargreaves AC, 2014, J SURG ONCOL, V110, P21, DOI 10.1002/jso.23645
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hu CX, 2013, MED PHYS, V40, DOI 10.1118/1.4804054
   Huser T, 2015, ADV DRUG DELIVER REV, V89, P57, DOI 10.1016/j.addr.2015.06.011
   Jatoi I, 2005, AM J CLIN ONCOL-CANC, V28, P289, DOI 10.1097/01.coc.0000156922.58631.d7
   Keller MD, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3600708
   Kong K, 2015, ADV DRUG DELIVER REV, V89, P121, DOI 10.1016/j.addr.2015.03.009
   Kong K, 2014, PHYS MED BIOL, V59, P6141, DOI 10.1088/0031-9155/59/20/6141
   Krishna CM, 2008, EXPERT REV MOL DIAGN, V8, P149, DOI 10.1586/14737159.8.2.149
   Lovrics PJ, 2009, AM J SURG, V197, P740, DOI 10.1016/j.amjsurg.2008.03.007
   Mahadevan-Jansen A, 1996, J Biomed Opt, V1, P31, DOI 10.1117/12.227815
   Majumder SK, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2975962
   McGuire KP, 2009, ANN SURG ONCOL, V16, P2682, DOI 10.1245/s10434-009-0635-x
   Moran MS, 2014, ANN SURG ONCOL, V21, P704, DOI 10.1245/s10434-014-3481-4
   MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203
   Ouyang H, 2015, J CANCER RES CLIN, V141, P1835, DOI 10.1007/s00432-015-1971-9
   Reble C, 2011, BIOMED OPT EXPRESS, V2, P520, DOI 10.1364/BOE.2.000520
   Shim MG, 1996, PHOTOCHEM PHOTOBIOL, V63, P662, DOI 10.1111/j.1751-1097.1996.tb05671.x
   Stewart LA, 2015, JAMA-J AM MED ASSOC, V313, P1657, DOI 10.1001/jama.2015.3656
   Surmacki J, 2015, ANALYST, V140, P2121, DOI 10.1039/c4an01876a
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Zamora Javier, 2006, BMC Med Res Methodol, V6, P31, DOI 10.1186/1471-2288-6-31
   Zhang Y, 2010, CURR PHARM BIOTECHNO, V11, P654, DOI 10.2174/138920110792246483
NR 30
TC 3
Z9 3
U1 2
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 26
PY 2016
VL 11
IS 7
AR e0159860
DI 10.1371/journal.pone.0159860
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT5IH
UT WOS:000381515600057
PM 27459193
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Lin, JL
   Peng, Y
   Xu, P
   Zhang, T
   Bai, C
   Lin, DX
   Ou, QT
   Yao, ZJ
AF Lin, Jialing
   Peng, Yang
   Xu, Ping
   Zhang, Ting
   Bai, Chan
   Lin, Dongxin
   Ou, Qianting
   Yao, Zhenjiang
TI Methicillin-Resistant Staphylococcus aureus Nasal Colonization in
   Chinese Children: A Prevalence Meta-Analysis and Review of Influencing
   Factors
SO PLOS ONE
LA English
DT Article
ID RISK-FACTORS; STREPTOCOCCUS-PNEUMONIAE; CLINICAL-FEATURES;
   ATOPIC-DERMATITIS; CARE-CENTERS; CARRIAGE; EPIDEMIOLOGY; INFECTION;
   OUTBREAK; TAIWAN
AB Objective
   To determine the pooled prevalence and review the influencing factors of methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in Chinese children.
   Methods
   Articles published between January 2005 and October 2015 that studied prevalence or influencing factors of MRSA nasal colonization in Chinese children were retrieved from Chinese Biomedical Literature database (CBM), China National Knowledge Infrastructure (CNKI) database, Chinese VIP database, Chinese Wanfang database, Medline database and Ovid database. Prevalence and influencing factors were analyzed by STATA 13.1.
   Results
   Thirteen articles were included. The overall prevalence of MRSA nasal colonization was 4.4% (95% confidence interval [CI]: 0.027-0.062). With an MRSA prevalence of 3.9% (95% CI: 0.018-0.061) in healthy children and 5.8% (95% CI: 0.025-0.092) in children with underlying medical conditions. Children recruited in the hospitals presented MRSA prevalence of 6.4% (95% CI: 0.037-0.091), which was higher than those recruited in the communities [2.7% (95% CI: 0.012-0.043)]. A number of influencing factors for MRSA nasal colonization were noted in three eligible studies: gender (male vs female; OR: 0.67; 95% CI: 0.55-0.82), younger age (OR: 2.98; 95% CI: 1.31-6.96 and OR: 1.56; 95% CI: 1.21-2.00), attending day care centers (OR: 2.97; 95% CI: 1.28-6.76), having infectious diseases (OR: 2.31; 95% CI: 1.10-4.52), using antibiotics (OR: 2.77; 95% CI: 1.45-5.05), residing in northern Taiwan (OR: 1.41; 95% CI: 1.15-1.71), passive smoking (OR: 1.30; 95% CI: 1.02-1.63), and pneumococcal vaccination (OR: 1.22; 95% CI: 1.01-1.48).
   Conclusions
   Children could act as reservoirs of MRSA transmissions. Hospitals remained the most frequent microorganism-circulated settings. More MRSA infection control strategies are required to prevent the dissemination among children.
C1 [Lin, Jialing; Xu, Ping; Zhang, Ting; Bai, Chan; Lin, Dongxin; Ou, Qianting; Yao, Zhenjiang] Guangdong Pharmaceut Univ, Dept Epidemiol & Hlth Stat, Guangzhou, Guangdong, Peoples R China.
   [Peng, Yang] Univ Queensland, Ctr Chron Dis, Brisbane, Qld, Australia.
RP Yao, ZJ (reprint author), Guangdong Pharmaceut Univ, Dept Epidemiol & Hlth Stat, Guangzhou, Guangdong, Peoples R China.
EM zhjyao2001@yahoo.com
RI Peng, Yang/J-8980-2016; Yao, Zhenjiang/N-7450-2016
OI Peng, Yang/0000-0002-9119-5506; Yao, Zhenjiang/0000-0002-2156-7896;
   Zhang, Ting/0000-0002-2274-6677; Lin, Jialing/0000-0002-0643-9191
FU Guangdong Science and Technology Planning Project [2014A020213013]
FX The work was supported by the Guangdong Science and Technology Planning
   Project (No. 2014A020213013), http://pro.gdstc.gov.cn/egrantweb/. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aguilar-Company Juan, 2016, Med Clin (Barc), V146, pe1, DOI 10.1016/j.medcli.2015.05.011
   Albrich WC, 2004, EMERG INFECT DIS, V10, P514, DOI 10.3201/eid1003.030252
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bitterman Y, 2010, EUR J CLIN MICROBIOL, V29, P391, DOI 10.1007/s10096-009-0869-3
   Boyle M. H., 1998, EVID BASED MENT HLTH, V1, P37, DOI DOI 10.1136/EBMH.1.2.37
   Casey JA, 2013, EPIDEMIOL INFECT, V141, P1166, DOI 10.1017/S0950268812001872
   Chambers HF, 2009, NAT REV MICROBIOL, V7, P629, DOI 10.1038/nrmicro2200
   Chen CJ, 2011, J CLIN MICROBIOL, V49, P131, DOI 10.1128/JCM.01774-10
   Chen CC, 2013, AM J INFECT CONTROL, V41, P1100, DOI 10.1016/j.ajic.2013.01.035
   Chen J, 2014, INT J INFECT DIS, V26, P17, DOI 10.1016/j.ijid.2014.02.025
   Chen Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096255
   Costelloe C, 2012, INT J ANTIMICROB AG, V39, P135, DOI 10.1016/j.ijantimicag.2011.09.022
   de Kraker MEA, 2013, CLIN MICROBIOL INFEC, V19, P860, DOI 10.1111/1469-0691.12028
   DeLeo FR, 2010, LANCET, V375, P1557, DOI 10.1016/S0140-6736(09)61999-1
   Deng Jian-jun, 2012, Sichuan Da Xue Xue Bao Yi Xue Ban, V43, P391
   [邓建军 Deng Jianjun], 2012, [临床儿科杂志, Journal of Chinical Pediatrics], V30, P507
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   ERIKSEN K R, 1961, Ugeskr Laeger, V123, P384
   Esposito S, 2015, J MED MICROBIOL, V64, P427, DOI 10.1099/jmm.0.000029
   Fan Juan, 2011, Zhongguo Dang Dai Er Ke Za Zhi, V13, P16
   Fortuin-de Smidt MC, 2015, INT J INFECT DIS, V30, P41, DOI 10.1016/j.ijid.2014.10.011
   Gesualdo F, 2013, PEDIATR INFECT DIS J, V32, P479, DOI 10.1097/INF.0b013e3182864e4c
   Gu FF, 2016, AM J INFECT IN PRESS
   [郭宏湘 Guo Hongxiang], 2013, [中华实用儿科临床杂志, Chinese Journal of Applied Clinical Pediatrics], V28, P752
   Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hisata K, 2005, J CLIN MICROBIOL, V43, P3364, DOI 10.1128/JCM.43.7.3364-3372.2005
   Ho PL, 2012, J INFECTION, V64, P500, DOI 10.1016/j.jinf.2012.02.018
   Hon KLE, 2005, ANN ACAD MED SINGAP, V34, P602
   Huang YC, 2005, PEDIATR INFECT DIS J, V24, P276, DOI 10.1097/01.inf.0000154333.46032.0f
   Huang YC, 2007, J CLIN MICROBIOL, V45, P3992, DOI 10.1128/JCM.01202-07
   Jinjian F, 2015, MATERN CHILD HLTH CA, V30, P227
   Jones TF, 2002, EMERG INFECT DIS, V8, P82, DOI 10.3201/eid0801.010174
   Kock R, 2010, EUROSURVEILLANCE, V15, P12
   Lamaro-Cardoso J, 2009, J CLIN MICROBIOL, V47, P3991, DOI 10.1128/JCM.01322-09
   LAYTON MC, 1995, INFECT CONT HOSP EP, V16, P12
   Lu PL, 2005, J CLIN MICROBIOL, V43, P132, DOI 10.1128/JCM.43.1.132-139.2005
   Madani TA, 2001, INFECT CONT HOSP EP, V22, P211, DOI 10.1086/501891
   Maguire GP, 1998, J HOSP INFECT, V38, P273, DOI 10.1016/S0195-6701(98)90076-7
   Malhotra-Kumar S, 2007, LANCET, V369, P482, DOI 10.1016/S0140-6736(07)60235-9
   Naimi TS, 2001, CLIN INFECT DIS, V33, P990, DOI 10.1086/322693
   Rings T, 1998, NEW ZEAL MED J, V111, P151
   Salmenlinna S, 2002, EMERG INFECT DIS, V8, P602, DOI 10.3201/eid0806.010313
   Shahin R, 1999, ARCH PEDIAT ADOL MED, V153, P864, DOI 10.1001/archpedi.153.8.864
   Stacey AR, 1998, BRIT J SPORT MED, V32, P153, DOI 10.1136/bjsm.32.2.153
   Tan Shan, 2015, Zhongguo Dang Dai Er Ke Za Zhi, V17, P299
   Tang CS, 2011, PEDIATR INT, V53, P363, DOI 10.1111/j.1442-200X.2010.03227.x
   van Sorge NM, 2013, J BIOL CHEM, V288, P6417, DOI 10.1074/jbc.M112.448738
   Wang JT, 2009, J CLIN MICROBIOL, V47, P2957, DOI 10.1128/JCM.00853-09
   Yang N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125922
   Ye XH, 2015, AM J INFECT CONTROL, V43, P676, DOI 10.1016/j.ajic.2015.03.026
   Yuanquan L., 2013, CHIN J CLIN PATHO, V5, P187
   [周淑群 Zhou Shuqun], 2012, [中华医院感染学杂志, Chinese Journal of Nosocomiology], V22, P598
   2004, AM J INFECT CONTROL, V32, P470, DOI DOI 10.1016/J.AJIC.2004.10.001
NR 55
TC 3
Z9 3
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 21
PY 2016
VL 11
IS 7
AR e0159728
DI 10.1371/journal.pone.0159728
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DS5CG
UT WOS:000380797500128
PM 27442424
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Poorolajal, J
   Darvishi, N
AF Poorolajal, Jalal
   Darvishi, Nahid
TI Smoking and Suicide: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID NATIONALLY REPRESENTATIVE SAMPLE; HIGH-SCHOOL-STUDENTS;
   CIGARETTE-SMOKING; RISK-FACTORS; COMPLETED SUICIDE; FOLLOW-UP;
   PROTECTIVE FACTORS; UNITED-STATES; SUBSTANCE USE; IDEATION
AB Background
   Many studies have reported a positive association between smoking and suicide, but the results are inconsistent. This meta-analysis was carried out to estimate the association between smoking and suicidal ideation, suicide plan, suicide attempt, and suicide death.
   Methods
   Major electronic databases including PubMed, Web of Science, Scopus, and ScienceDirect were searched until May 2015. The reference lists of included studies were screened too. Epidemiological studies addressing the association between smoking and suicidal behaviors were enrolled. The heterogeneity across studies was explored by Q-test and I-2 statistic. The possibility of publication bias was assessed using Begg's and Egger's tests and Trim & Fill analysis. The results were reported based on risk ratio (RR) and odds ratio (OR) with 95% confidence intervals (CI) using a random-effects model.
   Results
   We identified a total of 8062 references and included 63 studies with 8,063,634 participants. Compared to nonsmokers, the current smokers were at higher risk of suicidal ideation (OR = 2.05; 95% CI: 1.53, 2.58; 8 studies; I-2 = 80.8%; P<0.001), suicide plan (OR = 2.36; 95% CI: 1.69, 3.02; 6 studies; I-2 = 85.2%; P<0.001), suicide attempt (OR = 2.84; 95% CI: 1.49, 4.19; 5 studies; I-2 = 89.6%; (P<0.001), and suicide death (RR = 1.83; 95% CI: 1.64, 2.02; 14 studies; I-2 = 49.7%; P = 0.018).
   Conclusions
   There is sufficient evidence that smoking is associated with an increased risk of suicidal behaviors. Therefore, smoking is a contributing factor for suicide. Although this association does not imply causation, however, smoking prevention and cessation should be the target of suicide prevention programs.
C1 [Poorolajal, Jalal] Hamadan Univ Med Sci, Sch Publ Hlth, Modeling Noncommunicable Dis Res Ctr, Hamadan, Iran.
   [Poorolajal, Jalal] Hamadan Univ Med Sci, Sch Publ Hlth, Dept Epidemiol, Hamadan, Iran.
   [Darvishi, Nahid] Hamadan Univ Med Sci, Psychol Counseling Ctr, Hamadan, Iran.
RP Darvishi, N (reprint author), Hamadan Univ Med Sci, Psychol Counseling Ctr, Hamadan, Iran.
EM nahiddarvishi2008@yahoo.com
RI Poorolajal, Jalal/D-3506-2013
FU Hamadan University of Medical Sciences
FX The authors would like to thank the Vice-chancellor of Research and
   Technology, Hamadan University of Medical Sciences, for financial
   support of this study. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.; We would like to thank the Vice-chancellor of Research and
   Technology, Hamadan University of Medical Sciences, for financial
   support of this study.
CR Afifi TO, 2007, CAN J PSYCHIAT, V52, P666, DOI 10.1177/070674370705201007
   Almeida OP, 2012, BRIT J PSYCHIAT, V201, P466, DOI 10.1192/bjp.bp.112.110130
   Amiri B, 2012, J RES HEALTH SCI, V12, P88
   Angst J, 1998, J AFFECT DISORDERS, V51, P55, DOI 10.1016/S0165-0327(98)00156-6
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BENWELL MEM, 1990, PSYCHOPHARMACOLOGY, V102, P68, DOI 10.1007/BF02245746
   Beratis S, 1997, COMPR PSYCHIAT, V38, P74, DOI 10.1016/S0010-440X(97)90084-5
   Berlin I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122607
   Boden JM, 2008, PSYCHOL MED, V38, P433, DOI 10.1017/S0033291707001547
   Bohnert KM, 2014, ADDICTION, V109, P155, DOI 10.1111/add.12381
   Bolton JM, 2010, AM J PUBLIC HEALTH, V100, P2473, DOI 10.2105/AJPH.2010.192252
   Botega NJ, 2010, GEN HOSP PSYCHIAT, V32, P396, DOI 10.1016/j.genhosppsych.2010.02.004
   Bronisch T, 2008, J AFFECT DISORDERS, V108, P135, DOI 10.1016/j.jad.2007.10.010
   Castro-Diaz Sergio, 2013, Rev Colomb Psiquiatr, V43 Suppl 1, P27, DOI 10.1016/j.rcp.2013.11.003
   Centers for Disease Control and Prevention, 2013, UND SUIC FACT SHEET
   Centers for Disease Control and Prevention, 2014, DEF SELF DIR VIOL
   Clarke DE, 2010, SUICIDE LIFE-THREAT, V40, P307, DOI 10.1521/suli.2010.40.4.307
   Darvishi N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126870
   Silva RLD, 2014, SCI WORLD J, DOI 10.1155/2014/357052
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dervic K, 2007, WIEN KLIN WOCHENSCHR, V119, P174, DOI 10.1007/s00508-006-0753-4
   Deveci A, 2005, TURK PSIKIYATR DERG, V16, P170
   Donald M, 2006, AUST NZ J PSYCHIAT, V40, P87, DOI 10.1080/j.1440-1614.2006.01747.x
   Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529
   Eaton DK, 2011, ARCH SUICIDE RES, V15, P113, DOI 10.1080/13811118.2011.565268
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Epstein JA, 2009, SUICIDE LIFE-THREAT, V39, P241, DOI 10.1521/suli.2009.39.3.241
   Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3
   GARRISON CZ, 1993, AM J PUBLIC HEALTH, V83, P179, DOI 10.2105/AJPH.83.2.179
   Goodwin RD, 2013, J AFFECT DISORDERS, V145, P111, DOI 10.1016/j.jad.2012.05.003
   Hallfors DD, 2004, AM J PREV MED, V27, P224, DOI 10.1016/j.amepre.2004.06.001
   Han MA, 2009, PREV MED, V49, P248, DOI 10.1016/j.ypmed.2009.06.014
   Hawton K, 2012, LANCET, V379, P2373, DOI 10.1016/S0140-6736(12)60322-5
   Hawton K, 2009, LANCET, V373, P1372, DOI 10.1016/S0140-6736(09)60372-X
   HEMENWAY D, 1993, AM J PUBLIC HEALTH, V83, P249, DOI 10.2105/AJPH.83.2.249
   Hemmingsson T, 2003, INT J EPIDEMIOL, V32, P1000, DOI 10.1093/ije/dyg203
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hintikka J, 2009, SOC PSYCH PSYCH EPID, V44, P29, DOI 10.1007/s00127-008-0401-6
   Hockenberry JM, 2010, NICOTINE TOB RES, V12, P235, DOI 10.1093/ntr/ntp199
   Husky MM, 2013, J AFFECT DISORDERS, V151, P1059, DOI 10.1016/j.jad.2013.08.035
   Iwasaki M, 2005, ANN EPIDEMIOL, V15, P286, DOI 10.1016/j.annepidem.2004.08.011
   Jee SH, 2011, EUR HEART J, V32, P2773, DOI 10.1093/eurheartj/ehr229
   Jokinen J, 2007, PSYCHIAT RES, V150, P297, DOI 10.1016/j.psychres.2006.12.001
   Juan W, 2010, J AFFECT DISORDERS, V126, P180, DOI 10.1016/j.jad.2010.02.121
   Kessler RC, 2009, MOL PSYCHIATR, V14, P1132, DOI 10.1038/mp.2008.78
   Kessler RC, 2007, J NERV MENT DIS, V195, P369, DOI 10.1097/NMD.0b013e3180303eb8
   Kim CM, 2007, TISSUE ENG REGEN MED, V4, P60
   Kokkevi A, 2012, EUR CHILD ADOLES PSY, V21, P443, DOI 10.1007/s00787-012-0276-7
   Kumar MB, 2012, INT J CIRCUMPOL HEAL, V71, DOI 10.3402/ijch.v71i0.18829
   Lee SJ, 2014, ASIAN PAC J CANCER P, V15, P2945, DOI 10.7314/APJCP.2014.15.7.2945
   Legleye S, 2010, J AFFECT DISORDERS, V123, P108, DOI 10.1016/j.jad.2009.10.016
   Leistikow B N, 2000, Inj Prev, V6, P277, DOI 10.1136/ip.6.4.277
   Li DJ, 2012, J PSYCHIATR RES, V46, P1257, DOI 10.1016/j.jpsychires.2012.03.013
   Lucas M, 2013, J AFFECT DISORDERS, V151, P1053, DOI 10.1016/j.jad.2013.08.033
   Malone KM, 2003, AM J PSYCHIAT, V160, P773, DOI 10.1176/appi.ajp.160.4.773
   Mann JJ, 2006, INT J NEUROPSYCHOPH, V9, P465, DOI 10.1017/S1461145705005687
   McGee R, 2005, AM J PSYCHIAT, V162, P619, DOI 10.1176/appi.ajp.162.3.619
   Miller M, 2000, AM J PUBLIC HEALTH, V90, P768, DOI 10.2105/AJPH.90.5.768
   Miller M, 2011, DRUG ALCOHOL DEPEN, V113, P110, DOI 10.1016/j.drugalcdep.2010.07.016
   Miller M, 2000, AM J EPIDEMIOL, V151, P1060
   Miller M, 2012, ANNU REV PUBL HEALTH, V33, P393, DOI 10.1146/annurev-publhealth-031811-124636
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   PAFFENBARGER RS, 1994, ACTA PSYCHIAT SCAND, V89, P16, DOI 10.1111/j.1600-0447.1994.tb05796.x
   Park E, 2008, J KOREAN ACAD NURS, V38, P465, DOI 10.4040/jkan.2008.38.3.465
   Park HS, 2006, J SCHOOL HEALTH, V76, P181, DOI 10.1111/j.1746-1561.2006.00092.x
   Patsopoulos NA, 2008, INT J EPIDEMIOL, V37, P1148, DOI 10.1093/ije/dyn065
   Perez-Amezcua B, 2010, SALUD PUBLICA MEXICO, V52, P324
   Pfaff JJ, 2005, BRIT J GEN PRACT, V55, P269
   Poorolajal J, 2016, J PUBLIC HL IN PRESS
   Poorolajal J, 2015, ARCH IRAN MED, V18, P39, DOI 0151801/AIM.0010
   Poorolajal Jalal, 2012, Epidemiol Health, V34, pe2012005, DOI 10.4178/epih/e2012005
   Riala K, 2009, ANN EPIDEMIOL, V19, P329, DOI 10.1016/j.annepidem.2008.12.004
   Rudatsikira E., 2007, J PSYCHOL AFR, V17, P93
   Rudatsikira E, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-67
   Sankaranarayanan A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138147
   Schneider B, 2005, EUR PSYCHIAT, V20, P129, DOI 10.1016/j.eurpsy.2004.04.016
   SMITH GD, 1992, LANCET, V340, P709
   Sonderman JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114852
   Tanskanen A, 2000, ACTA PSYCHIAT SCAND, V101, P243, DOI 10.1034/j.1600-0447.2000.101003243.x
   Tomori M, 2001, EUR CHILD ADOLES PSY, V10, P143, DOI 10.1007/s007870170038
   Ursoniu S, 2009, WIEN KLIN WOCHENSCHR, V121, P564, DOI 10.1007/s00508-009-1218-3
   Varnik P, 2012, INT J ENV RES PUB HE, V9, P760, DOI 10.3390/ijerph9030760
   Valdivia M, 2015, REV MED CHILE, V143, P320, DOI 10.4067/S0034-98872015000300006
   Wells GA, 2009, NEWCASTLE OTTAWA SCA
   Wilson ML, 2012, INT J ENV RES PUB HE, V9, P4122, DOI 10.3390/ijerph9114122
   Wong SS, 2013, SOC PSYCH PSYCH EPID, V48, P1611, DOI 10.1007/s00127-013-0721-z
   Woods ER, 1997, PEDIATRICS, V99, P791, DOI 10.1542/peds.99.6.791
   World Health Organization, 1998, GUID CONTR MON TOB E
   World Health Organization, 2014, PREV SUIC GLOB IMP
   Wu P, 2004, SUICIDE LIFE-THREAT, V34, P408, DOI 10.1521/suli.34.4.408.53733
   Yi S, 2011, J KOREAN ACAD NURS, V41, P652, DOI 10.4040/jkan.2011.41.5.652
   Zhang J, 2005, ANN EPIDEMIOL, V15, P167, DOI 10.1016/j.annepidem.2004.07.095
NR 92
TC 23
Z9 23
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 8
PY 2016
VL 11
IS 7
AR e0156348
DI 10.1371/journal.pone.0156348
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DR6IK
UT WOS:000380005400004
PM 27391330
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Shen, ZR
   Shi, KD
   Yu, YH
   Yu, XN
   Lin, YC
   Yao, K
AF Shen, Zeren
   Shi, Keda
   Yu, Yinhui
   Yu, Xiaoning
   Lin, Yuchen
   Yao, Ke
TI Small Incision Lenticule Extraction (SMILE) versus Femtosecond
   Laser-Assisted In Situ Keratomileusis (FS-LASIK) for Myopia: A
   Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID REFRACTIVE SURGERY; CLINICAL-OUTCOMES; ASTIGMATISM; ABERRATIONS;
   PLATFORMS; EFFICACY; SAFETY; BIAS
AB Purpose
   The goal of this study was to compare small incision lenticule extraction (SMILE) with femtosecond laser-assisted in situ keratomileusis (FS-LASIK) for treating myopia.
   Methods
   The CENTRAL, EMBASE, PubMed databases and a Chinese database (SinoMed) were searched in May of 2016. Twelve studies with 1,076 eyes, which included three randomized controlled trials (RCTs) and nine cohorts, met our inclusion criteria. The overall quality of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group framework. Data were extracted and analysed at three to six months postoperatively. Primary outcome measures included a loss of one or more lines of best spectacle corrected visual acuity (BSCVA), uncorrected visual acuity (UCVA) of 20/20 or better, mean logMAR UCVA, postoperative mean spherical equivalent (SE) and postoperative refraction within +/- 1.0 D of the target refraction. Secondary outcome measures included ocular surface disease index (OSDI), tear breakup time (TBUT) and Schirmer's 1 test (S1T) as dry eye parameters, along with corneal sensitivity.
   Results
   The overall quality of evidence was considered to be low to very low. Pooled results revealed no significant differences between the two groups with regard to a loss of one or more lines in the BSCVA (OR 1.71; 95% CI: 0.81, 3.63; P = 0.16), UCVA of 20/20 or better (OR 0.71; 95% CI: 0.44, 1.15; P = 0.16), logMAR UCVA (MD 0.00; 95% CI: -0.03, 0.04; P = 0.87), postoperative refractive SE (MD -0.00; 95% CI: -0.05, 0.05; P = 0.97) or postoperative refraction within +/- 1.0 D of the target refraction (OR 0.78; 95% CI: 0.22, 2.77; P = 0.70) within six months postoperatively. The pooled analysis also indicated that the FS-LASIK group suffered more severely from dry eye symptoms (OSDI; MD -6.68; 95% CI: -11.76, -2.00; P = 0.006) and lower corneal sensitivity (MD 12.40; 95% CI: 10.23, 14.56; P < 0.00001) at six months postoperatively.
   Conclusions
   In conclusion, both FS-LASIK and SMILE are safe, effective and predictable surgical options for treating myopia. However, dry eye symptoms and loss of corneal sensitivity may occur less frequently after SMILE than after FS-LASIK.
C1 [Shen, Zeren; Yu, Yinhui; Yu, Xiaoning; Lin, Yuchen; Yao, Ke] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou 310003, Zhejiang, Peoples R China.
   [Shi, Keda] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Gastroenterol, Hangzhou 310003, Zhejiang, Peoples R China.
RP Yao, K (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou 310003, Zhejiang, Peoples R China.
EM xlren@zju.edu.cn
FU Zhejiang Key Laboratory Fund of China [2011E10006]; Project of National
   Clinical Key Discipline of Chinese Ministry of Health
FX This work was supported by Zhejiang Key Laboratory Fund of China
   (2011E10006) and Project of National Clinical Key Discipline of Chinese
   Ministry of Health. KY is the recipient. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ang M, 2013, J CATARACT REFR SURG, V39, P1647, DOI 10.1016/j.jcrs.2013.04.044
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blanton CL, 2015, US OPHTHALMIC REV, V8, P23
   Bohac M, 2014, GRAEF ARCH CLIN EXP, V252, P1679, DOI 10.1007/s00417-014-2776-2
   Chan TCY, 2016, BRIT J OPHTHALMOL, V100, P553, DOI 10.1136/bjophthalmol-2015-307238
   Chen SH, 2012, J REFRACT SURG, V28, P15, DOI 10.3928/1081597X-20111228-02
   Denoyer A, 2015, OPHTHALMOLOGY, V122, P669, DOI 10.1016/j.ophtha.2014.10.004
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ganesh S, 2014, J REFRACT SURG, V30, P590, DOI 10.3928/1081597X-20140814-02
   Gimeno FL, 2011, J CATARACT REFR SURG, V37, P538, DOI 10.1016/j.jcrs.2010.10.039
   Gyldenkerne A, 2015, J REFRACT SURG, V31, P223, DOI 10.3928/1081597X-20150303-01
   Hall RC, 2014, J CATARACT REFR SURG, V40, P423, DOI 10.1016/j.jcrs.2013.08.056
   He M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0129-5
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hu Y-K, 2013, INT EYE SCI, V13, P2074
   Lee JK, 2015, CURR OPIN OPHTHALMOL, V26, P260, DOI 10.1097/ICU.0000000000000158
   Li MY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077797
   Li WJ, 2014, INT EYE SCI, V14, P1971
   Liang JW, 2014, EJSO-EUR J SURG ONC, V40, P1614, DOI 10.1016/j.ejso.2014.04.009
   Lin FY, 2014, J REFRACT SURG, V30, P248, DOI 10.3928/1081597X-20140320-03
   Liu ML, 2016, CORNEA, V35, P210, DOI 10.1097/ICO.0000000000000707
   Moher D, 2009, PLOS MED
   Petznick A, 2013, CLIN OPHTHALMOL, V7, P591, DOI 10.2147/OPTH.S42266
   Rosman M, 2013, J CATARACT REFR SURG, V39, P1066, DOI 10.1016/j.jcrs.2013.02.038
   Sandoval HP, 2005, J CATARACT REFR SURG, V31, P221, DOI 10.1016/j.jcrs.2004.08.047
   Sefat SM, 2015, CURR EYE RES, V8, P1
   Sekundo W, 2011, BRIT J OPHTHALMOL, V95, P335, DOI 10.1136/bjo.2009.174284
   Shah R, 2011, J CATARACT REFR SURG, V37, P127, DOI 10.1016/j.jcrs.2010.07.033
   Shen Y, 2014, J REFRACT SURG, V30, P310, DOI 10.3928/1081597X-20140422-01
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sugar Alan, 2002, Curr Opin Ophthalmol, V13, P246, DOI 10.1097/00055735-200208000-00011
   Vestergaard AH, 2014, J CATARACT REFR SURG, V40, P403, DOI 10.1016/j.jcrs.2013.07.053
   Wells GA, 2014, NEWCASTLE OTTAWA SCA
   Wilson SE, 2001, AM J OPHTHALMOL, V132, P405, DOI 10.1016/S0002-9394(01)00995-3
   Xia L, 2016, CURR EYE RES, V1, P1
   Yao PJ, 2013, J REFRACT SURG, V29, P669, DOI 10.3928/1081597X-20130806-01
   Yu CQ, 2014, J CATARACT REFR SURG, V40, P412, DOI 10.1016/j.jcrs.2013.08.050
   Zhang JM, 2016, CORNEA, V35, P523, DOI 10.1097/ICO.0000000000000782
   Zhang YJ, 2016, J REFRACT SURG, V32, P256, DOI 10.3928/1081597X-20151111-06
   Zhao LQ, 2010, OPHTHALMOLOGY, V117, P1912, DOI 10.1016/j.ophtha.2010.02.004
NR 42
TC 24
Z9 24
U1 1
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 1
PY 2016
VL 11
IS 7
AR e0158176
DI 10.1371/journal.pone.0158176
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DQ0TX
UT WOS:000378914900019
PM 27367803
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, Z
   Qu, ZG
   Fu, CF
   Xu, F
   Chen, Y
   Wang, ZY
   Liu, Y
AF Wang, Zheng
   Qu, Zhigang
   Fu, Changfeng
   Xu, Feng
   Chen, Yong
   Wang, Zhenyu
   Liu, Yi
TI Interleukin 1 Polymorphisms Contribute to Intervertebral Disc
   Degeneration Risk: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID LOW-BACK-PAIN; GENE POLYMORPHISM; ANNULUS FIBROSUS; IL-1-BETA;
   ASSOCIATION; HERNIATION; BIOLOGY; PROTEIN; MATRIX; BIAS
AB Objective
   We performed a meta-analysis to assess association between interleukin 1 (IL-1) polymorphisms and the risk of Intervertebral Disc Degeneration (IDD).
   Background
   A series of studies have investigated the association between common single nucleotide polymorphisms in IL-1 and IDD risk; however, the overall results are inconclusive.
   Methods
   Two independent investigators conducted a systematic search for relevant available studies. Allele frequencies were extracted from each study. The association between the IL-1 alpha (+889C/T) or IL-1 beta (+3954C/T) polymorphism and IDD risk was measured by odds ratios (OR) with 95% confidence intervals (95% CI).
   Results
   Five and six studies, respectively, were ultimately included in the meta-analysis for the IL-1 alpha (+889C/T) and IL-1 beta (+3954C/T) polymorphism. The combined results showed that the IL-1 alpha (+889C/T) polymorphism was significantly associated with increased susceptibility to IDD, particularly in Caucasians (TT versus CC: OR = 2.95, 95% CI: 1.45, 6.04; P-heterogeneity = 0.82; TT versus CC/CT: OR = 2.29, 95% CI: 1.18, 4.47; P-heterogeneity = 0.20). In contrast, the IL-1 beta (+3954C/T) polymorphism showed a trend towards increased risk in Caucasians but no association in Asians.
   Conclusion
   This meta-analysis suggested that the IL-1 alpha (+889C/T) polymorphism is significantly associated with risk of IDD, especially in Caucasian populations.
C1 [Wang, Zheng; Qu, Zhigang; Fu, Changfeng; Xu, Feng; Wang, Zhenyu; Liu, Yi] Jilin Univ, Hosp 1, Dept Spinal Surg, 71 Xinmin Ave, Changchun 130021, Jilin Province, Peoples R China.
   [Chen, Yong] Jilin Univ, Hosp 1, Dept Neurosurg, 71 Xinmin Ave, Changchun 130021, Jilin Province, Peoples R China.
RP Wang, ZY; Liu, Y (reprint author), Jilin Univ, Hosp 1, Dept Spinal Surg, 71 Xinmin Ave, Changchun 130021, Jilin Province, Peoples R China.
EM wangzheng13@mails.jlu.edu.cn; Liuyi89757@gmail.com
CR Adams MA, 2006, SPINE, V31, P2151, DOI 10.1097/01.brs.0000231761.73859.2c
   Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berger P, 2002, CYTOKINE, V17, P171, DOI 10.1006/cyto.2001.0974
   BUCKWALTER JA, 1995, SPINE, V20, P1307, DOI 10.1097/00007632-199506000-00022
   Serrano SC, 2014, INT J GENOMICS, DOI 10.1155/2014/302568
   Chen ZX, 2015, SCI REP-UK, V5, DOI 10.1038/srep16983
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Dominici R, 2002, IMMUNOGENETICS, V54, P82, DOI 10.1007/s00251-002-0445-9
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Freemont AJ, 2009, RHEUMATOLOGY, V48, P5, DOI 10.1093/rheumatology/ken396
   Gao LB, 2011, BREAST CANCER RES TR, V125, P827, DOI 10.1007/s10549-010-0995-8
   Herkowitz HN, 2004, LUMBAR SPINE
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hulkkonen J, 2000, EUR CYTOKINE NETW, V11, P251
   Hwang PY, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026360
   Kalb S, 2012, WORLD NEUROSURG, V77, P491, DOI 10.1016/j.wneu.2011.07.014
   Kang JD, 1997, SPINE, V22, P1065, DOI 10.1097/00007632-199705150-00003
   Karppinen J, 2008, SPINE, V33, P1236, DOI 10.1097/BRS.0b013e318170fd0e
   Karppinen J, 2009, EUR SPINE J, V18, P1963, DOI 10.1007/s00586-009-1139-x
   Kim NK, 2011, ACTA NEUROCHIR, V153, P129, DOI 10.1007/s00701-010-0831-2
   Le Maitre CL, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2275
   Maeda S, 2000, SPINE, V25, P166, DOI 10.1097/00007632-200001150-00005
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Molinos M, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2014.1191
   Mu JH, 2013, J NEUROSURG-SPINE, V19, P243, DOI 10.3171/2013.4.SPINE12782
   Aparicio JP, 2011, EUR SPINE J, V20, P383, DOI 10.1007/s00586-011-1915-2
   POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x
   Rannou F, 2004, AM J PATHOL, V164, P915, DOI 10.1016/S0002-9440(10)63179-3
   Roughley PJ, 2004, SPINE, V29, P2691, DOI 10.1097/01.brs.0000146101.53784.b1
   Schistad EI, 2014, CLIN J PAIN, V30, P869, DOI 10.1097/AJP.0000000000000048
   Solovieva S, 2004, EPIDEMIOLOGY, V15, P626, DOI 10.1097/01.ede.0000135179.04563.35
   Solovieva S, 2004, PAIN, V109, P8, DOI 10.1016/j.pain.2003.10.020
   Solovieva S, 2006, EUR SPINE J, V15, P613, DOI 10.1007/s00586-005-0988-1
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   van den Berg WB, 1999, BEST PRACT RES CL RH, V13, P577, DOI 10.1053/berh.1999.0047
   Wang S, 2014, CELL PROLIFERAT, V47, P381, DOI 10.1111/cpr.12121
   Yang W, 2015, CLIN CHIM ACTA, V450, P262, DOI 10.1016/j.cca.2015.08.029
   Ye Wei, 2007, Yichuan, V29, P923, DOI 10.1360/yc-007-0923
NR 41
TC 12
Z9 13
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 2
PY 2016
VL 11
IS 6
AR e0156412
DI 10.1371/journal.pone.0156412
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DN6XB
UT WOS:000377218700027
PM 27253397
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhao, SJ
   Zhong, ZS
   Qi, GX
   Shi, LY
   Chen, L
   Tian, W
AF Zhao, Shi-jie
   Zhong, Zhao-shuang
   Qi, Guo-xian
   Shi, Li-ye
   Chen, Ling
   Tian, Wen
TI Effect of Pioglitazone in Preventing In-Stent Restenosis after
   Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID IMPAIRED GLUCOSE-TOLERANCE; DRUG-ELUTING STENTS; NEOINTIMAL TISSUE
   PROLIFERATION; ACUTE MYOCARDIAL-INFARCTION; LOW-DOSE PIOGLITAZONE;
   BARE-METAL STENT; CLINICAL-OUTCOMES; INTRAVASCULAR ULTRASOUND;
   CARDIOVASCULAR EVENTS; SYSTEMATIC REVIEWS
AB Background
   The benefits of pioglitazone in patients with type 2 diabetes mellitus (T2DM) after percutaneous coronary intervention (PCI) is unclear.
   Objectives
   To evaluate the effect of pioglitazone on prevention of in-stent restenosis (ISR) in patients with T2DM after PCI.
   Methods
   All full-text published relevant studies compared the effect of pioglitazone with control group (placebo or no pioglitazone treatment) on ISR in patients with T2DM after PCI were identified by searching the databases including PubMed, EMBASE, Cochrane Library and ISI Web of Science through October 2015. The endpoints were defined as the rate of ISR, late lumen loss, in-stent neointimal volume, target lesion revascularization (TLR) and major adverse cardiac events (MACE).
   Results
   Six studies (5 RCTs and 1 retrospective study), comprising 503 patients, were included into this meta-analysis. In the pioglitazone group, as compared with the control group, the risk ratio for ISR was 0.48 (I-2 = 14.5%, P = 0.322; 95% CI 0.35 to 0.68, P<0.001), the risk ratio for TLR was 0.58 (I-2 = 6.0%, P = 0.363; 95% CI 0.38 to 0.87, P = 0.009). The result showed there was no association between the use of pioglitazone and the events of MACE (I-2 = 36.7%, P = 0.209; RR 0.56, 95% CI 0.30 to 1.05, P = 0.071). For the considerable heterogeneity, further analysis was not suitable for the endpoints of late lumen loss (I-2 = 81.9%, P<0.001) and neointimal volume (I-2 = 75.9%, P = 0.016).
   Conclusions
   The treatment of pioglitazone was associated with a reduction in ISR and TLR in T2DM patients suffering from PCI, except the incidence of MACE.
C1 [Zhao, Shi-jie; Qi, Guo-xian; Shi, Li-ye; Chen, Ling; Tian, Wen] China Med Univ, Affiliated Hosp 1, Dept Geriatr Cardiol, Shenyang, Peoples R China.
   [Zhong, Zhao-shuang] Shenyang Med Coll, Cent Hosp, Dept Resp, Shenyang, Peoples R China.
RP Tian, W (reprint author), China Med Univ, Affiliated Hosp 1, Dept Geriatr Cardiol, Shenyang, Peoples R China.
EM dr_wentian@163.com
CR Abizaid A, 1998, J AM COLL CARDIOL, V32, P584, DOI 10.1016/S0735-1097(98)00286-1
   Ahn CM, 2011, J AM COLL CARDIOL, V57, pE1914, DOI 10.1016/S0735-1097(11)61914-1
   Barlaka E, 2015, CARDIOVASC THER
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cheang WS, 2013, CIRC J, V77, P2664, DOI 10.1253/circj.CJ-13-0647
   Delhaye C, 2010, AM J CARDIOL, V105, P826, DOI 10.1016/j.amjcard.2009.10.064
   Erdmann E, 2016, DIABETES OBES METAB, V18, P266, DOI 10.1111/dom.12608
   Gilbert RE, 2013, CIRC J, V77, P849, DOI 10.1253/circj.CJ-13-0236
   Goldberg RB, 2005, DIABETES CARE, V28, P1547, DOI 10.2337/diacare.28.7.1547
   Guerra E, 2014, EXPERT OPIN PHARMACO, V15, P2155, DOI 10.1517/14656566.2014.948844
   Henney JE, 2000, JAMA-J AM MED ASSOC, V283, P2228, DOI 10.1001/jama.283.17.2228-b
   Higgins J, 2010, COCHRANE HDB SYSTEMA
   Hong SJ, 2006, HEART, V92, P1119, DOI 10.1136/hrt.2005.075960
   Hong SJ, 2015, CIRC J, V79, P880, DOI 10.1253/circj.CJ-14-0964
   Hong SJ, 2010, CATHETER CARDIO INTE, V76, P924, DOI 10.1002/ccd.22369
   Joner M, 2007, ARTERIOSCL THROM VAS, V27, P182, DOI 10.1161/01.ATV.0000251021.28725.e8
   Kasai T, 2008, ATHEROSCLEROSIS, V197, P612, DOI 10.1016/j.atherosclerosis.2007.08.030
   Kitoga M, 2008, DIABETES METAB, V34, P62, DOI 10.1016/j.diabet.2007.09.002
   Kornowski R, 1998, J AM COLL CARDIOL, V31, P224, DOI 10.1016/S0735-1097(97)00450-6
   Lee HW, 2013, YONSEI MED J, V54, P1313, DOI 10.3349/ymj.2013.54.6.1313
   Lincoff AM, 2007, JAMA-J AM MED ASSOC, V298, P1180, DOI 10.1001/jama.298.10.1180
   Mizoguchi M, 2011, JACC-CARDIOVASC IMAG, V4, P1110, DOI 10.1016/j.jcmg.2011.08.007
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Moussa I, 2004, CIRCULATION, V109, P2273, DOI 10.1161/01.CIR.0000129767.45513.71
   Nishio K, 2006, DIABETES CARE, V29, P101, DOI 10.2337/diacare.29.1.101
   Nissen SE, 2008, JAMA-J AM MED ASSOC, V299, P1561, DOI 10.1001/jama.299.13.1561
   Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761
   Nitta Y, 2013, JACC-CARDIOVASC IMAG, V6, P1172, DOI 10.1016/j.jcmg.2013.09.004
   Okura H, 2013, CURR VASC PHARMACOL, V11, P399
   Oremus M, 2001, DEMENT GERIATR COGN, V12, P232, DOI 10.1159/000051263
   Ozawa T, 2009, J CARDIOL, V53, P402, DOI 10.1016/j.jjcc.2009.01.011
   Patel D, 2011, JACC-CARDIOVASC INTE, V4, P353, DOI 10.1016/j.jcin.2010.10.016
   Roiron C, 2006, HEART, V92, P641, DOI 10.1136/hrt.2005.061622
   Saremi A, 2013, ARTERIOSCL THROM VAS, V33, P393, DOI 10.1161/ATVBAHA.112.300346
   Satoh N, 2003, DIABETES CARE, V26, P2493, DOI 10.2337/diacare.26.9.2493
   Silva JA, 1999, AM HEART J, V138, P446, DOI 10.1016/S0002-8703(99)70146-8
   Takagi T, 2003, AM HEART J, V146, DOI 10.1016/S0002-8703(03)00146-7
   Takagi T, 2002, J DIABETES COMPLICAT, V16, P50, DOI 10.1016/S1056-8727(01)00190-8
   Takagi Tsutomu, 2005, J Cardiol, V45, P139
   Takagi T, 2009, JACC-CARDIOVASC INTE, V2, P524, DOI 10.1016/j.jcin.2009.04.007
   Woods TC, 2004, ANNU REV MED, V55, P169, DOI 10.1146/annurev.med.55.091902.105243
   Yang TH, 2005, AM J CARDIOL, V96, P1389, DOI 10.1016/j.amjcard.2005.07.043
   Yeh HT, 2012, CLIN THER, V34, P885, DOI 10.1016/j.clinthera.2012.02.024
   Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001
   Yokoyama J, 2007, HEART VESSELS, V22, P146, DOI 10.1007/s00380-006-0951-z
NR 45
TC 4
Z9 4
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 10
PY 2016
VL 11
IS 5
AR e0155273
DI 10.1371/journal.pone.0155273
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DM8BN
UT WOS:000376585700017
PM 27163676
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Sun, MY
   Zhang, L
   Shi, SL
   Lin, JN
AF Sun, Man-Yi
   Zhang, Li
   Shi, Song-Li
   Lin, Jing-Na
TI Associations between Methylenetetrahydrofolate Reductase (MTHFR)
   Polymorphisms and Non-Alcoholic Fatty Liver Disease (NAFLD) Risk: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID COMMON MUTATION; HOMOCYSTEINE LEVELS; C677T POLYMORPHISM; GENE
   POLYMORPHISMS; DNA METHYLATION; PATHOGENESIS; DIAGNOSIS;
   STEATOHEPATITIS; SUSCEPTIBILITY; HETEROGENEITY
AB Background
   C677T and A1298C are the most common allelic variants of Methylenetetrahydrofolate Reductase (MTHFR) gene. The association between MTHFR polymorphisms and the occurrence of non-alcoholic fatty liver disease (NAFLD) remains controversial. This study was thus performed to examine whether MTHFR mutations are associated with the susceptibility to NAFLD.
   Methods
   A first meta-analysis on the association between the MTHFR polymorphisms and NAFLD risks was carried out via Review Manager 5.0 and Stata/SE 12.0 software. The on-line databases, such as PubMed, EMBASE, CENTRAL, WOS, Scopus and EBSCOhost (updated to April 1st, 2016), were searched for eligible case-control studies. The odd radio (OR), 95% confidence interval (CI) and P value were calculated through Mantel-Haenszel statistics under random-or fixed-effect model.
   Results
   Eight articles (785 cases and 1188 controls) contributed data to the current meta-analysis. For C677T, increased NAFLD risks were observed in case group under homozygote model (T/T vs C/C, OR = 1.49, 95% CI = 1.03 similar to 2.15, P = 0.04) and recessive model (T/T vs C/C+C/T, OR = 1.42, 95% CI = 1.07 similar to 1.88, P = 0.02), but not the other genetics models, compared with control group. For A1298C, significantly increased NAFLD risks were detected in allele model (C vs A, OR = 1.53, 95% CI = 1.13 similar to 2.07, P = 0.006), homozygote model (C/C vs A/A, OR = 2.81, 95% CI = 1.63 similar to 4.85, P = 0.0002), dominant model (A/C+ C/C vs A/A, OR = 1.60, 95% CI = 1.06 similar to 2.41, P = 0.03) and recessive model (C/C vs A/A+ A/C, OR = 2.08, 95% CI = 1.45 similar to 3.00, P< 0.0001), but not heterozygote model.
   Conclusion
   T/T genotype of MTHFR C677T polymorphism and C/C genotype of MTHFR A1298C are more likely to be associated with the susceptibility to NAFLD.
C1 [Sun, Man-Yi] Tianjin Union Med Ctr, Dept Gastroenterol, Tianjin, Peoples R China.
   [Sun, Man-Yi; Zhang, Li; Shi, Song-Li; Lin, Jing-Na] Tianjin Peoples Hosp, Tianjin, Peoples R China.
   [Zhang, Li; Shi, Song-Li] Tianjin Union Med Ctr, Dept Pathol, Tianjin, Peoples R China.
   [Lin, Jing-Na] Tianjin Union Med Ctr, Dept Endocrinol, Tianjin, Peoples R China.
RP Lin, JN (reprint author), Tianjin Peoples Hosp, Tianjin, Peoples R China.; Lin, JN (reprint author), Tianjin Union Med Ctr, Dept Endocrinol, Tianjin, Peoples R China.
EM jingna_lin_tianjin@163.com
CR Angulo P, 2007, ALIMENT PHARM THERAP, V25, P883, DOI 10.1111/j.1365-2036.2007.03246.x
   Armstrong MJ, 2014, HEPATOLOGY, V59, P1174, DOI 10.1002/hep.26717
   Basaranoglu M, 2014, TURK J GASTROENTEROL, V25, P127, DOI 10.5152/tjg.2014.7675
   Basaranoglu M, 2010, WORLD J GASTROENTERO, V16, P2223, DOI 10.3748/wjg.v16.i18.2223
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cardona H, 2008, NUTR HOSP, V23, P277
   Catalano D, 2014, EUR REV MED PHARMACO, V18, P151
   Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762
   Chen H, 2014, CHINESE J GEN PRACTI, V12
   Clark JM, 2006, J CLIN GASTROENTEROL, V40, pS5
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Dowman JK, 2010, QJM-INT J MED, V103, P71, DOI 10.1093/qjmed/hcp158
   Duthie SJ, 2002, J NUTR, V132, p2444S, DOI 10.1093/jn/132.8.2444S
   Brochado MJF, 2013, ANN NUTR METAB, V63, P193, DOI 10.1159/000353139
   Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   Goyette P, 1998, MAMM GENOME, V9, P652, DOI 10.1007/s003359900838
   GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195
   Guenther BD, 1999, NAT STRUCT BIOL, V6, P359, DOI 10.1038/7594
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hu L, 2009, CHINESE J GEN PRATIT, V08, P385
   Kasapoglu B, 2015, CLIN MED, V15, P248, DOI 10.7861/clinmedicine.15-3-248
   Liang TJ, 2014, TUMOR BIOL, V35, P339, DOI 10.1007/s13277-013-1046-y
   Liew SC, 2015, EUR J MED GENET, V58, P1, DOI 10.1016/j.ejmg.2014.10.004
   Lim JW, 2014, WORLD J GASTROENTERO, V20, P8325, DOI 10.3748/wjg.v20.i26.8325
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Loomba R, 2013, NAT REV GASTRO HEPAT, V10, P686, DOI 10.1038/nrgastro.2013.171
   Macaluso FS, 2015, WORLD J GASTROENTERO, V21, P11088, DOI 10.3748/wjg.v21.i39.11088
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moll S, 2015, CIRCULATION, V132, pe6, DOI 10.1161/CIRCULATIONAHA.114.013311
   Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193
   Orlovskiy V, 2015, Georgian Med News, P38
   Pereira AC, 2004, CLIN CHIM ACTA, V340, P99, DOI 10.1016/j.cccn.2003.09.016
   Petta S, 2009, DIGEST LIVER DIS, V41, P615, DOI 10.1016/j.dld.2009.01.004
   Qi YH, 2014, CLIN RES HEPATOL GAS, V38, P172, DOI 10.1016/j.clinre.2013.10.002
   Qin XH, 2017, INT J CANCER, V141, P837, DOI 10.1002/ijc.30094
   de Carvalho SCR, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-37
   Rozen R, 1997, THROMB HAEMOSTASIS, V78, P523
   Sameer AS, 2011, GENET MOL RES, V10, P1200, DOI 10.4238/vol10-2gmr1067
   Santilli F, 2016, VASC PHARMACOL, V78, P1, DOI 10.1016/j.vph.2015.06.009
   Sazci A, 2008, CELL BIOCHEM FUNCT, V26, P291, DOI 10.1002/cbf.1424
   Schreuder TCMA, 2008, WORLD J GASTROENTERO, V14, P2474, DOI 10.3748/wjg.14.2474
   Serin E, 2007, DIGEST DIS SCI, V52, P1183, DOI 10.1007/s10620-006-9565-7
   Speliotes EK, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001324
   Sun HL, 2014, TUMOR BIOL, V35, P189, DOI 10.1007/s13277-013-1023-5
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Than NN, 2015, ATHEROSCLEROSIS, V239, P192, DOI 10.1016/j.atherosclerosis.2015.01.001
   Trovato Francesca M, 2015, World J Nephrol, V4, P127, DOI 10.5527/wjn.v4.i1.127
   Ueland PM, 2001, TRENDS PHARMACOL SCI, V22, P195, DOI 10.1016/S0165-6147(00)01675-8
   van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825
   Wang Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151140
   Xia LZ, 2014, WORLD J GASTROENTERO, V20, P11429, DOI 10.3748/wjg.v20.i32.11429
   Yan LF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041689
   Yang L, 2012, TUMOR BIOL, V33, P1445, DOI 10.1007/s13277-012-0395-2
   Zhou TB, 2015, RENAL FAILURE, V37, P1247, DOI 10.3109/0886022X.2015.1064743
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 57
TC 7
Z9 7
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 29
PY 2016
VL 11
IS 4
AR e0154337
DI 10.1371/journal.pone.0154337
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DK8XM
UT WOS:000375212600028
PM 27128842
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Huang, JC
   Zhu, TT
   Qu, Y
   Mu, DZ
AF Huang, Jichong
   Zhu, Tingting
   Qu, Yi
   Mu, Dezhi
TI Prenatal, Perinatal and Neonatal Risk Factors for Intellectual
   Disability: A Systemic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID MENTAL-RETARDATION; PREGNANCY; CHILDREN; SMOKING; OUTCOMES; PRETERM;
   FETAL; BORN; BIAS; AGE
AB Background
   The etiology of non-genetic intellectual disability (ID) is not fully known, and we aimed to identify the prenatal, perinatal and neonatal risk factors for ID.
   Method
   PubMed and Embase databases were searched for studies that examined the association between pre-, peri-and neonatal factors and ID risk (keywords "intellectual disability" or "mental retardation" or "ID" or "MR" in combination with "prenatal" or "pregnancy" or "obstetric" or "perinatal" or "neonatal". The last search was updated on September 15, 2015. Summary effect estimates (pooled odds ratios) were calculated for each risk factor using random effects models, with tests for heterogeneity and publication bias.
   Results
   Seventeen studies with 55,344 patients and 5,723,749 control individuals were eligible for inclusion in our analysis, and 16 potential risk factors were analyzed. Ten prenatal factors (advanced maternal age, maternal black race, low maternal education, third or more parity, maternal alcohol use, maternal tobacco use, maternal diabetes, maternal hypertension, maternal epilepsy and maternal asthma), one perinatal factor (preterm birth) and two neonatal factors (male sex and low birth weight) were significantly associated with increased risk of ID.
   Conclusion
   This systemic review and meta-analysis provides a comprehensive evidence-based assessment of the risk factors for ID. Future studies are encouraged to focus on perinatal and neonatal risk factors and the combined effects of multiple factors.
C1 [Huang, Jichong; Zhu, Tingting; Qu, Yi; Mu, Dezhi] Sichuan Univ, West China Univ Hosp 2, Dept Pediat, Chengdu 610041, Peoples R China.
   [Huang, Jichong; Zhu, Tingting; Qu, Yi; Mu, Dezhi] Sichuan Univ, Minist Educ, Key Lab Obstetr & Gynecol & Pediat Dis & Birth De, Chengdu 610041, Peoples R China.
   [Mu, Dezhi] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.
RP Mu, DZ (reprint author), Sichuan Univ, West China Univ Hosp 2, Dept Pediat, Chengdu 610041, Peoples R China.; Mu, DZ (reprint author), Sichuan Univ, Minist Educ, Key Lab Obstetr & Gynecol & Pediat Dis & Birth De, Chengdu 610041, Peoples R China.; Mu, DZ (reprint author), Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.
EM mudz@scu.edu.cn
FU National Science Foundation of China [81330016, 81300524, 81172174,
   81270724, 81200462]; State Commission of Science Technology of China
   [2013CB967404, 2012BAI04B04]; Ministry of Education of China [IRT0935,
   313037]; Science and Technology Bureau of Sichuan province [2014SZ0149,
   2016TD0002]; Ministry of Health of China [1311200003303]
FX This work was supported by the National Science Foundation of China (No.
   81330016, 81300524, 81172174, 81270724 and 81200462), grants from the
   State Commission of Science Technology of China (2013CB967404,
   2012BAI04B04), grants from the Ministry of Education of China (IRT0935,
   313037), grants from the Science and Technology Bureau of Sichuan
   province (2014SZ0149, 2016TD0002), and a grant of clinical discipline
   program (neonatology) from the Ministry of Health of China
   (1311200003303).
CR ADAMS MM, 1993, OBSTET GYNECOL, V82, P955
   American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   Anderson JE, 2006, MATERN CHILD HLTH J, V10, pS101, DOI 10.1007/s10995-006-0093-z
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhutta AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/jama.288.6.728
   Bilder DA, 2013, AJIDD-AM J INTELLECT, V118, P156, DOI 10.1352/1944-7558-118.2.156
   Boyle CA, 1995, ANN EPIDEMIOL, P347
   Croen LA, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e86
   Curry CJ, 1997, AM J MED GENET, V72, P468, DOI 10.1002/(SICI)1096-8628(19971112)72:4<468::AID-AJMG18>3.0.CO;2-P
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DREWS CD, 1995, AM J PUBLIC HEALTH, V85, P329, DOI 10.2105/AJPH.85.3.329
   Drews CD, 1996, PEDIATRICS, V97, P547
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ekblad M, 2015, ACTA PAEDIATR, V104, P12, DOI 10.1111/apa.12791
   Elyasi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133918
   Griffith MI, 2011, HYPERTENS PREGNANCY, V30, P108, DOI 10.3109/10641955.2010.507837
   Hagberg H, 2012, ANN NEUROL, V71, P444, DOI 10.1002/ana.22620
   Kaufman L, 2010, J NEURODEV DISORD, V2, P182, DOI 10.1007/s11689-010-9055-2
   Kerr-Wilson CO, 2012, J PUBLIC HEALTH-UK, V34, P209, DOI 10.1093/pubmed/fdr024
   Khoshdel A, 2006, INT J CLIN PRACT, V60, P1287, DOI 10.1111/j.1742-1241.2006.01078.x
   Langridge AT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050963
   Leonard H, 2006, ANN EPIDEMIOL, V16, P448, DOI 10.1016/j.annepidem.2005.05.002
   Lyall K, 2011, J AUTISM DEV DISORD, V41, P618, DOI 10.1007/s10803-010-1079-7
   Mann JR, 2013, BJOG-INT J OBSTET GY, V120, P309, DOI 10.1111/1471-0528.12052
   Mann JR, 2013, MATERN CHILD HLTH J, V17, P928, DOI 10.1007/s10995-012-1072-1
   Mann JR, 2009, ANN EPIDEMIOL, V19, P891, DOI 10.1016/j.annepidem.2009.08.004
   Maulik PK, 2011, RES DEV DISABIL, V32, P419, DOI 10.1016/j.ridd.2010.12.018
   McDermott S, 1993, Paediatr Perinat Epidemiol, V7, P195, DOI 10.1111/j.1365-3016.1993.tb00393.x
   McDermott S, 2007, HDB INTELLECTUAL DEV, P3
   O'Leary C, 2013, DEV MED CHILD NEUROL, V55, P271, DOI 10.1111/dmcn.12029
   Onicescu G, 2014, ENVIRON SCI POLLUT R, V21, P10775, DOI 10.1007/s11356-014-3072-8
   Rauch A, 2006, AM J MED GENET A, V140A, P2063, DOI 10.1002/ajmg.a.31416
   Rindfuss RR, 1996, DEMOGRAPHY, V33, P277, DOI 10.2307/2061761
   Robinson M, 2009, J PEDIATR-US, V154, P218, DOI 10.1016/j.jpeds.2008.07.061
   ROELEVELD N, 1992, PREV MED, V21, P110, DOI 10.1016/0091-7435(92)90010-F
   Takkouche B, 1999, AM J EPIDEMIOL, V150, P206
   Wells BS GA, 2015, NEWCASTLE OTTAWA SCO
   Williams LO, 1999, AM J EPIDEMIOL, V149, P814
   YEARGINALLSOPP M, 1995, AM J PUBLIC HEALTH, V85, P324, DOI 10.2105/AJPH.85.3.324
NR 39
TC 16
Z9 16
U1 1
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 25
PY 2016
VL 11
IS 4
AR e0153655
DI 10.1371/journal.pone.0153655
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DK5OX
UT WOS:000374970600019
PM 27110944
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Su, B
   Liu, TS
   Fan, HJ
   Chen, F
   Ding, H
   Wu, ZW
   Wang, HW
   Hou, SK
AF Su, Bin
   Liu, Tiansheng
   Fan, Haojun
   Chen, Feng
   Ding, Hui
   Wu, Zhouwei
   Wang, Hongwu
   Hou, Shike
TI Inflammatory Markers and the Risk of Chronic Obstructive Pulmonary
   Disease: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID C-REACTIVE PROTEIN; SMOKING-CESSATION INTERVENTIONS; INDUCED SPUTUM;
   COPD; OUTCOMES
AB Systemic inflammatory factors are inconsistently associated with the pathogenesis of chronic obstructive pulmonary disease (COPD). We conducted a systematic review and meta-analysis to summarize the evidence supporting the association between systemic inflammation and the risk of COPD. Pertinent studies were retrieved from PubMed, EmBase, and the Cochrane Library until April 2015. A random-effects model was used to process the data, and the analysis was further stratified by factors affecting these associations. Sensitivity analyses for publication bias were performed. We included 24 observational studies reporting data on 10,677 COPD patients and 28,660 controls. Overall, we noted that COPD was associated with elevated serum CRP (SMD: 1.21; 95% CI: 0.92-1.50; P < 0.001), leukocytes (SMD: 1.07; 95%: 0.25-1.88; P = 0.010), IL-6 (SMD: 0.90; 95% CI: 0.48-1.31; P < 0.001), IL-8 (SMD: 2.34; 95% CI: 0.69-4.00; P = 0.006), and fibrinogen levels (SMD: 0.87; 95% CI: 0.44-1.31; P < 0.001) when compared with control. However, COPD was not significantly associated with TNF-alpha levels when compared with control (SMD: 0.60; 95% CI: -0.46 to 1.67; P = 0.266). Our findings suggested that COPD was associated with elevated serum CRP, leukocytes, IL-6, IL-8, and fibrinogen, without any significant relationship with TNF-alpha.
C1 [Su, Bin] Chinese Peoples Armed Police Forces, Logist Univ, Affiliated Hosp, Med Simulat Teaching Base, Tianjin, Peoples R China.
   [Liu, Tiansheng] Chinese Peoples Armed Police Forces, Logist Univ, Affiliated Hosp, Dept Orthoped, Tianjin, Peoples R China.
   [Fan, Haojun; Chen, Feng; Ding, Hui; Wu, Zhouwei; Hou, Shike] Chinese Peoples Armed Police Forces, Logist Univ, Affiliated Hosp, Tianjin, Peoples R China.
   [Su, Bin; Wang, Hongwu] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China.
RP Su, B (reprint author), Chinese Peoples Armed Police Forces, Logist Univ, Affiliated Hosp, Med Simulat Teaching Base, Tianjin, Peoples R China.; Su, B (reprint author), Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China.
EM subin150@sina.com
FU Tianjin Municipal Natural Science Foundation [15JCYBJC28500]; key
   cultivated academic construction project of state administrative bureau
   for prophylactic medicine of traditional Chinese medicine [2012]
FX This work was supported by Tianjin Municipal Natural Science Foundation
   (15JCYBJC28500). This work was also supported by key cultivated academic
   construction project of state administrative bureau for prophylactic
   medicine of traditional Chinese medicine (NO. 2012). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aaron SD, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-41
   Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Agusti AGN, 2003, EUR RESPIR J, V21, P347, DOI 10.1183/09031936.03.00405703
   Agusti A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037483
   Agusti Alvar G N, 2005, Proc Am Thorac Soc, V2, P367, DOI 10.1513/pats.200504-026SR
   Barbaro MPF, 2007, INT J IMMUNOPATH PH, V20, P753, DOI 10.1177/039463200702000411
   Barreiro E, 2008, THORAX, V63, P100, DOI 10.1136/thx.2007.078030
   Bartlett YK, 2014, BRIT J HEALTH PSYCH, V19, P181, DOI 10.1111/bjhp.12071
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bircan A, 2008, MED PRIN PRACT, V17, P202, DOI 10.1159/000117793
   Bucchioni E, 2003, RESP MED, V97, P1299, DOI 10.1016/j.rmed.2003.07.008
   Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fattouh M, 2014, EGYPT J CHEST DIS TU, V63, P799, DOI 10.1016/j.ejcdt.2014.06.011
   Feng EZ, 2013, EXP THER MED, V6, P747, DOI 10.3892/etm.2013.1192
   Forey BA, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-36
   Gan WQ, 2004, THORAX, V59, P574, DOI 10.1136/thx.2003.019588
   Garcia-Rio F, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-63
   Hacker S, 2009, CLIN LAB, V55, P31
   Harting JR, 2012, J TOXICOL ENV HEAL A, V75, P1456, DOI 10.1080/15287394.2012.722186
   He ZH, 2010, RESPIROLOGY, V15, P478, DOI 10.1111/j.1440-1843.2010.01709.x
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jefferson T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000975.pub2
   Karadag F, 2008, EUR J INTERN MED, V19, P104, DOI 10.1016/j.ejim.2007.04.026
   Kersul AL, 2011, ARCH BRONCONEUMOL, V47, P176, DOI 10.1016/j.arbres.2010.12.003
   Liu XJ, 2009, NUTRITION, V25, P373, DOI 10.1016/j.nut.2008.09.008
   Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4
   Mannino DM, 2003, AM J MED, V114, P758, DOI 10.1016/S0002-9343(03)00185-2
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Petersen AMW, 2008, SCAND J MED SCI SPOR, V18, P557, DOI 10.1111/j.1600-0838.2007.00727.x
   Pinto-Plata VM, 2006, THORAX, V61, P23, DOI 10.1136/thx.2005.042200
   Strassmann R, 2009, EUR RESPIR J, V34, P634, DOI 10.1183/09031936.00167708
   Tobias A, 1999, STATA TECH B, V8, P15
   Undas A, 2009, THROMB HAEMOSTASIS, V102, P1176, DOI 10.1160/TH09-02-0118
   Valvi D, 2012, INT J CHRONIC OBSTR, V7, P173, DOI 10.2147/COPD.S29892
   van den Borst B, 2011, AM J CLIN NUTR, V94, P1504, DOI 10.3945/ajcn.111.023911
   Van Helvoort HAC, 2006, MED SCI SPORT EXER, V38, P1543, DOI 10.1249/01.mss.0000228331.13123.53
   Vernooy JH, 2002, AM J RESP CRIT CARE, V166, P1218, DOI 10.1064/rccm.2202023
   Wang XR, 2014, INT J CHRONIC OBSTR, V9, P543, DOI 10.2147/COPD.S62700
   Wells GA, 2000, NEWCASTLE OTTAWA SCA
   Yasuda N, 1998, RESP MED, V92, P993, DOI 10.1016/S0954-6111(98)90343-2
NR 42
TC 22
Z9 23
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 22
PY 2016
VL 11
IS 4
AR e0150586
DI 10.1371/journal.pone.0150586
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DJ9WX
UT WOS:000374565100002
PM 27104349
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, XM
   Fu, JJ
   Li, QX
   Zeng, DY
AF Wang, Xingmin
   Fu, Jinjian
   Li, Qianxi
   Zeng, Dingyuan
TI Geographical and Ethnic Distributions of the MTHFR C677T, A1298C and
   MTRR A66G Gene Polymorphisms in Chinese Populations: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID METHYLENETETRAHYDROFOLATE REDUCTASE MTHFR; METHIONINE SYNTHASE; HIGH
   PREVALENCE; FOLATE STATUS; HOMOCYSTEINE; ASSOCIATION; MUTATION; WOMEN;
   HYPERHOMOCYSTEINEMIA; ADULTS
AB Background
   The geographical and ethnic distributions of the polymorphic methylenetetrahydrofolate reductase (MTHFR) mutations (C677T and A1298C) and methionine synthase reductase (MTRR) mutation (A66G) remain heterogeneous in China. The goal of this study was to estimate the pooled frequencies of the alleles and associated genotypes of these gene polymorphisms among healthy populations in Mainland China.
   Objective and Methods
   We systematically reviewed published epidemiological studies on the distributions of 3 genetic variants in Chinese healthy populations living in Mainland China through a meta-analysis. The relevant electronic databases were searched. All of the raw data of the eligible citations were extracted. The frequency estimates were stratified by geography, ethnicity and sex.
   Results
   Sixty-six studies were identified with a total of 92277 study participants. The meta-analysis revealed that the frequencies of the MTHFR C677T, A1298C, and MTRR A66G gene polymorphisms varied significantly between different ethnic groups and along geographical gradients. The frequencies of the 677T allele and 677TT genotype increased along the southern-central-northern direction across Mainland China (all P values <= 0.001). The frequencies of the 1298C, 1298CC, 66G and 66GG genotypes decreased along the southcentral- north direction across the country (all P values <= 0.001).
   Conclusions
   Our meta-analysis strongly indicates significant geographical and ethnic variations in the frequencies of the C677T, A1298C, and A66G gene polymorphisms in the folate metabolism pathway among Chinese populations.
C1 [Wang, Xingmin; Fu, Jinjian; Li, Qianxi; Zeng, Dingyuan] Liuzhou Municipal Matern & Child Healthcare Hosp, Dept Gynecol, Liuzhou, Guangxi, Peoples R China.
RP Zeng, DY (reprint author), Liuzhou Municipal Matern & Child Healthcare Hosp, Dept Gynecol, Liuzhou, Guangxi, Peoples R China.
EM zdylzsfy@126.com
FU Guangxi Medical and Health Self-funding Project [Z2014373]
FX This manuscript was funded by Guangxi Medical and Health Self-funding
   Project (No Z2014373). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amouzou EK, 2004, AM J CLIN NUTR, V79, P619
   Angeline T, 2004, EXP MOL PATHOL, V77, P85, DOI 10.1016/j.yexmp.2004.04.006
   Barbosa PR, 2008, CLIN CHIM ACTA, V388, P139, DOI 10.1016/j.cca.2007.10.023
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brustolin S, 2010, BRAZ J MED BIOL RES, V43, P1, DOI 10.1590/S0100-879X2009007500021
   Cai BX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089609
   Callejon G, 2007, HUM REPROD, V22, P3249, DOI 10.1093/humrep/dem337
   Chen F, 2009, ZHENG ZHOU DA XUEXUE, V44, P317
   Chen PL, 2015, GENET MOL RES, V14, P19191, DOI 10.4238/2015.December.29.29
   Chen SQ, 2002, ZHONGGUO YOU SHENG Y, V10, P22
   Chen XL, 2014, CHINESE J WOMEN CHIL, V5, P17
   Chen YX, 2010, ZHONGGUO GONG GONG W, V26, P958
   Chen YX, 2013, SHAN XI YI KE DA XUE, V44, P130
   Cheng HB, 2012, CHANG ZHI YI XUE YUA, V26, P401
   Cong YY, 2012, XIAN DAI FU CHAN KEJ, V21, P779
   Cui Huiling, 2015, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V40, P710, DOI 10.11817/j.issn.1672-7347.2015.07.002
   Dai XJ, 2008, NING XIA YI XUE YUAN, V30, P152
   Du LL, 2013, ZHONGGUO DONG MAI ZH, V24, P325
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferretti A, 2013, MED HYPOTHESES, V81, P524, DOI 10.1016/j.mehy.2013.06.025
   Gao LJ, 2013, ZHONG SHAN DA XUEXUE, V34, P140
   Gao X, 2014, ZHONGGUO YOU SHENG Y, V22, P35
   Gaughan DJ, 2001, ATHEROSCLEROSIS, V157, P451, DOI 10.1016/S0021-9150(00)00739-5
   GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195
   Gueant-Rodriguez RM, 2006, AM J CLIN NUTR, V83, P701
   Guo H, 2013, JIAN YAN YI XUE YU L, V10, P1655
   Hao L, 2003, J NUTR, V133, P3630
   Hao YY, 2014, ZHONGGUO FU YOU BAO, V29, P3495
   He XM, 2010, ZHONGGUOJI HUA SHENG, V1, P13
   He YX, 2012, SHI YONG JIAN YAN YI, V4, P6
   Higgins J. P., 2002, STAT MED, V21
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hogeveen M, 2012, AM J CLIN NUTR, V95, P130, DOI 10.3945/ajcn.111.016212
   Hu XW, 2015, ZHONGGUO FU YOU BAO, V25, P4336
   Huang GuiXiang, 2013, China Tropical Medicine, V13, P1446
   Huang QH, 2015, CHIN J FAM PLANN, V23, P15
   Jia XP, 2015, J WANNAN MED COLL, V34, P317
   Jiang HO, 2010, ZHONGGUO YOU SHENG Y, V18, P18
   Jiang W, 2014, GUANG XI YI XUE, V36, P1517
   Jiao FY, 2014, MOLDIAGNTHER, V6, P105
   Lange LA, 2010, HUM MOL GENET, V19, P2050, DOI 10.1093/hmg/ddq062
   Lao HH, 2011, ZHONGGUOJI HUA SHENG, V19, P655
   Li AF, 2007, ZHONGGUO YOU SHENG Y, V15, P19
   Li JH, 2014, BASIC CLIN MED, V11, P1564
   [李欣欣 Li Xinxin], 2015, [基础医学与临床, Basic & Clinical Medicine], V35, P1228
   Liang JN, 2002, GUANGZHOU YI XUE YUA, V30, P38
   Liu XL, 2014, J NINGXIA MED U, V36, P1216
   Lu GR, 2014, HENAN MED RES, V23, P7
   Luo SQ, 2015, ZHONGGUO YOU SHENG Y, V23, P20
   Luo XL, 2014, J PUB HLTH PREV MED, V25, P29
   Ma LM, 2015, PRACTPREV MED, V22, P289
   Mao RF, 2008, CELL BIOCHEM FUNCT, V26, P352, DOI 10.1002/cbf.1450
   Mao WC, 2015, CHIN J FAMPLANN, V23, P310
   Markan S, 2007, MOL CELL BIOCHEM, V302, P125, DOI 10.1007/s11010-007-9434-5
   Marti-Carvajal AJ, 2013, COCHRANE DB SYST REV, V31
   Ott J., 1988, UTILITY PROGRAMS ANA
   Ouyang QQ, 2014, ZHONGGUO YOU SHENG Y, V22, P6
   Pei Li-jun, 2000, HEREDITAS BEIJING, V22, P369
   Rady PL, 2002, AM J MED GENET, V107, P162, DOI 10.1002/ajmg.10122
   Rai Vandana, 2013, Indian J Hum Genet, V19, P183, DOI 10.4103/0971-6866.116123
   Rai Vandana, 2012, Indian J Med Sci, V66, P136, DOI 10.4103/0019-5359.114200
   Reyes-Engel A, 2002, MOL HUM REPROD, V8, P952, DOI 10.1093/molehr/8.10.952
   Sabbagh AS, 2008, GENET TEST, V12, P75, DOI 10.1089/gte.2007.0064
   Saraswathy KN, 2012, MOL BIOL REP, V39, P5025, DOI 10.1007/s11033-011-1299-8
   Shan KR, 2009, ZHONGGUO YOU SHENG Y, V17, P16
   Shen LP, 2005, ZHONGGUO LIN CHUANG, V9, P8
   Sun WP, 2003, DI SI JUN YI DA XUEX, V24, P634
   Szvetko AL, 2007, J NEUROL SCI, V252, P49, DOI 10.1016/j.jns.2006.10.006
   Tang HY, 2014, CHINA MED HERALD, V11, P8
   Tian Y, 2014, XIN YI XUE, V45, P253
   van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825
   Wang FeiXia, 2014, Journal of Modern Laboratory Medicine, V29, P35
   Wang Li-na, 2012, Zhonghua Pifuke Zazhi, V45, P178, DOI 10.3760/cma.j.issn.0412-4030.2012.03.010
   Wang SY, 2015, TIANJIN MED J, V42, P1205
   Wang WP, 2013, ZHONGGUO FU YOU BAO, V28, P140
   Wilcken B, 2003, J MED GENET, V40, P619, DOI 10.1136/jmg.40.8.619
   Wu HZ, 2011, BAOTOU YI XUE YUAN X, V27, P4
   Wu WQ, 2015, JIANGSU MED J, V41, P71
   Xiang CG, 2015, SHAN DONG YI YAO, V55, P22
   Xiao Y, 2005, ZHONGGUO YOU SHENG Y, V13, P14
   Xiao Yan, 2005, Zhonghua Yixue Yichuanxue Zazhi, V22, P219
   [肖雁 Xiao Yan], 2005, [人类学学报, Acta Anthropologica Sinica], V24, P315
   Xing JF, 2014, J MED FORUM, V35, P10
   Xiu X, 2013, SHAN DONG YI YAO, V53, P31
   Xue Y, 2000, Anthropol Anz, V58, P253
   Yakub M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033222
   Yamada K, 2006, P NATL ACAD SCI USA, V103, P9476, DOI 10.1073/pnas.0603694103
   Yan Q, 2014, J SHANDONG U HLTH SC, V52, P79
   Yan ZM, 2013, HAI NAN YI XUE YUAN, V19, P18
   Yang BH, 2001, WAN NAN YI XUE YUAN, V20, P308
   Yang BY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057917
   Yang Y, 2012, NAN JING YI KE DA XU, V32, P1250
   Yu JM, 2000, HUM HERED, V50, P268, DOI 10.1159/000022929
   Yu YH, 2015, CHIN J FAMPLANN, V23, P591
   Zhang CS, 2005, QI LU YI XUEZAZHI, V30, P310
   Zhang L, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-123
   Zhang QF, 2010, ZHONGGUO RE DAI YI X, V10, P1346
   Zhang T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059570
   [张婷 Zhang Ting], 2013, [重庆医学, Chongqing Medicine], V42, P3413
   Zhang Y, 2012, ZHONGGUOXUN ZHENG YI, V12, P631
   Zhang Yan-li, 2012, Zhonghua Yixue Yichuanxue Zazhi, V29, P705, DOI 10.3760/cma.j.issn.1003-9406.2012.06.018
   Zhu HP, 2000, ZHONGGUO YOU SHENG Y, V11, P51
NR 102
TC 13
Z9 17
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 18
PY 2016
VL 11
IS 4
AR e0152414
DI 10.1371/journal.pone.0152414
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DJ9IK
UT WOS:000374527000006
PM 27089387
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Rai, H
   Sinha, N
   Kumar, S
   Sharma, AK
   Agrawal, S
AF Rai, Himanshu
   Sinha, Nakul
   Kumar, Sudeep
   Sharma, Ajay Kumar
   Agrawal, Suraksha
TI Interleukin-1 Gene Cluster Polymorphisms and Their Association with
   Coronary Artery Disease: Separate Evidences from the Largest
   Case-Control Study amongst North Indians and an Updated Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID RECEPTOR ANTAGONIST GENE; MYOCARDIAL-INFARCTION; ISCHEMIC-STROKE; RISK;
   CELLS; IL-1; ATHEROSCLEROSIS; INVOLVEMENT; MECHANISMS; INHIBITOR
AB Several researchers have reported significant association of numerous single nucleotide polymorphisms (SNPs) residing in the interleukin-1 (IL-1) gene cluster with coronary artery disease (CAD). However, their association status amongst North Indian ancestry (NIA) have never been systematically assessed. Despite a published meta-analysis on this subject, their association status worldwide as well as amongst different major ancestral subgroups still remains unclear. We therefore decided to prospectively test the association of 11 IL-1 gene cluster SNPs with CAD, vide a case-control study amongst a cohort of NIA and attempted to validate our results with the help of an updated meta-analysis of all relevant published association studies. Included studies were segregated into ancestral subgroups and association statuses for each subgroup were determined. A total of 323 cases and 400 healthy, age and sex matched controls belonging to NIA were prospectively enrolled and subsequently genotyped for 11 selected IL-1 gene cluster SNPs. Although results for none of the evaluated IL-1 gene cluster SNPs reached the adjusted level of significance (p<0.0045), clear trends of association were seen for IL1B -511 C>T and IL1RN 86bp VNTR in several of the constructed genetic models (p range = 0.01-0.044 and 0.005-0.034 respectively). The presence of >1, 'T' (minor) allele of IL1B -511 C>T in a genotype seemed to provide protection against CAD (OR = 0.62, p = 0.044), while the presence of >1, 'C' (major) allele seemed to increase the risk of CAD (OR = 1.36, p = 0.041). The minor allele (allele 2) of IL1RN 86bp VNTR and its homozygous genotype (2/2 genotype) also seemed to carry an increased risk for CAD (OR = 1.62, p = 0.005 and OR = 2.25, p = 0.031 respectively). On the other hand, several haplotype combinations constructed out of IL1B and IL1RN gene variants clearly showed statistically significant associations with CAD (p<0.0045). Our meta-analysis was conducted for 8 previously assessed IL-1 SNPs. We included 53 different studies which involved a total sample of 26,210 (13,982 cases and 12,228 controls). Our pooled results concurred with the findings of our case-control study and was not able to deduce any statistically significant associations for any of the 8 studied SNPs (p>0.05). Subgroup analysis, however, yielded interesting results, where significant differences in association statuses were seen for IL1A +4845 G>T, IL1B -511 C>T, IL1RN 86bp VNTR and IL1RN +8006 T>C for select ancestral subgroups. The hints of associations deduced for subjects belonging to NIA in our case-control study for both IL1B -511 C>T and IL1RN 86bp VNTR were duly validated vide significant p values seen for NIA in all three genetic models (OR range = 0.62-0.76, p range = 0.01-0.04 and OR range = 1.51-2.25, p range = 0.004-0.04 respectively). On the other hand, Mixed Ancestry (MA) subgroup carrying IL1B -511 C>T, IL1RN 86bp VNTR or IL1RN +8006 T>C polymorphisms seemed to enjoy significant protection against CAD. A few other ancestral subgroups also demonstrated significant associations for a few of the studied SNPs vide one of the three genetic models. Clinical interpretation of derived results is however recommended.
C1 [Rai, Himanshu; Sinha, Nakul; Kumar, Sudeep] Sanjay Gandhi Post Grad Inst Med Sci, Dept Cardiol, Lucknow, Uttar Pradesh, India.
   [Sharma, Ajay Kumar] Univ Lucknow, Dept Zool, Lucknow 226007, Uttar Pradesh, India.
   [Agrawal, Suraksha] Sanjay Gandhi Post Grad Inst Med Sci, Dept Med Genet, Lucknow, Uttar Pradesh, India.
   [Sinha, Nakul] Sahara India Med Inst, Dept Cardiol, Lucknow, Uttar Pradesh, India.
RP Rai, H (reprint author), Sanjay Gandhi Post Grad Inst Med Sci, Dept Cardiol, Lucknow, Uttar Pradesh, India.; Agrawal, S (reprint author), Sanjay Gandhi Post Grad Inst Med Sci, Dept Med Genet, Lucknow, Uttar Pradesh, India.
EM himanshurai1981@gmail.com; sur_ksha_agrawal@yahoo.co.in
RI Rai, Himanshu/N-7726-2016
OI Rai, Himanshu/0000-0003-3917-1934
CR Arman A, 2008, ARQ BRAS CARDIOL, V91, P268
   Banerjee I, 2009, J THROMB THROMBOLYS, V27, P88, DOI 10.1007/s11239-007-0184-8
   Bashour Lina, 2013, ISRN Dent, V2013, P195678, DOI 10.1155/2013/195678
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553
   Cantagrel A, 1999, ARTHRITIS RHEUM, V42, P1093, DOI 10.1002/1529-0131(199906)42:6<1093::AID-ANR5>3.0.CO;2-P
   Coker A, 2011, INT J IMMUNOGENET, V38, P201, DOI 10.1111/j.1744-313X.2010.00988.x
   COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487
   Deloukas P, 2013, NAT GENET, V45, P25, DOI 10.1038/ng.2480
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13
   Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Francis SE, 1999, CIRCULATION, V99, P861, DOI 10.1161/01.CIR.99.7.861
   Geismar K, 2008, J PERIODONTOL, V79, P2322, DOI [10.1902/jop.2008.070454, 10.1902/jop.2008.070454 ]
   Gong MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121147
   Goracy J, 2011, ARCH MED RES, V42, P426, DOI 10.1016/j.arcmed.2011.08.002
   GRAMSE M, 1986, BIOCHEM BIOPH RES CO, V139, P720, DOI 10.1016/S0006-291X(86)80050-X
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Iacoviello L, 2005, ARTERIOSCL THROM VAS, V25, P222, DOI 10.1161/01.ATV.0000150039.60906.02
   Iacoviello L, 2000, CIRCULATION, V101, pE193
   Kariz S, 2007, COLLEGIUM ANTROPOL, V31, P503
   Latkovskis G, 2004, EUR J IMMUNOGENET, V31, P207, DOI 10.1111/j.1365-2370.2004.00476.x
   LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346
   Licastro F, 2004, MECH AGEING DEV, V125, P575, DOI 10.1016/j.mad.2004.06.008
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Fragoso JM, 2010, IMMUNOL LETT, V133, P106, DOI 10.1016/j.imlet.2010.08.003
   Momiyama Y, 2001, J AM COLL CARDIOL, V38, P712, DOI 10.1016/S0735-1097(01)01438-3
   Napoleone E, 1997, BLOOD, V89, P541
   Offner FA, 1996, AM J PATHOL, V148, P1679
   Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530
   Panic N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083138
   Ray KK, 2002, CLIN SCI, V103, P303, DOI 10.1042/cs1030303
   Rios DLS, 2010, CYTOKINE, V50, P292, DOI 10.1016/j.cyto.2010.02.012
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Rywik TM, 2011, KARDIOL POL, V69, P881
   Santtila S, 1998, SCAND J IMMUNOL, V47, P195
   SCHWAGER I, 1994, BLOOD, V83, P152
   Sinha Nakul, 2012, Indian Heart J, V64, P229, DOI 10.1016/S0019-4832(12)60078-9
   Soylu O, 2008, EUR CYTOKINE NETW, V19, P42, DOI 10.1684/ecn.2008.0119
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stein JM, 2009, J PERIODONTOL, V80, P1095, DOI 10.1902/jop.2009.080639
   STEINKASSERER A, 1992, GENOMICS, V13, P654, DOI 10.1016/0888-7543(92)90137-H
   Timms AE, 2004, AM J HUM GENET, V75, P587, DOI 10.1086/424695
   van Minkelen R, 2009, ATHEROSCLEROSIS, V203, P201, DOI 10.1016/j.atherosclerosis.2008.06.029
   Vohnout B, 2003, HAEMATOLOGICA, V88, P54
   Volzke H, 2004, CLIN SCI, V106, P35
   Zee RYL, 2008, ATHEROSCLEROSIS, V201, P124, DOI 10.1016/j.atherosclerosis.2008.01.004
   Zee RYL, 2001, THROMB HAEMOSTASIS, V86, P1141
   Zhou L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045641
NR 51
TC 5
Z9 6
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 14
PY 2016
VL 11
IS 4
AR e0153480
DI 10.1371/journal.pone.0153480
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DJ3UH
UT WOS:000374131700062
PM 27078871
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yin, XH
   Wang, YD
   Luo, H
   Zhao, K
   Huang, GL
   Luo, SY
   Peng, JX
   Song, JK
AF Yin, Xin-Hai
   Wang, Ya-Dong
   Luo, Hong
   Zhao, Ke
   Huang, Guang-Lei
   Luo, Si-Yang
   Peng, Ju-Xiang
   Song, Ju-Kun
TI Association between Tooth Loss and Gastric Cancer: A Meta-Analysis of
   Observational Studies
SO PLOS ONE
LA English
DT Article
ID MALE HEALTH-PROFESSIONALS; SQUAMOUS-CELL CARCINOMA; HELICOBACTER-PYLORI
   INFECTION; PERIODONTAL-DISEASE; ORAL HYGIENE; GLYCEMIC INDEX; INCREASED
   RISK; UNITED-STATES; LIFE-STYLE; INSULIN
AB Observational studies showed that tooth loss is associated with gastric cancer, but the findings are inconsistent. In this study, a meta-analysis was conducted to evaluate the relationship between tooth loss and gastric cancer. Relevant studies were screened in PubMed and Embase databases, and nine observational studies were considered eligible for the analysis. The combined relative risks for the highest versus the lowest categories of tooth loss were 1.86 (95% CI: 1.08-3.21) and 1.31 (95% CI: 1.12-1.53) in case control and cohort studies, respectively. However, unstable results were observed in the stratified and sensitivity analysis. The current evidence, based solely on four case-control studies and five cohort studies, suggested that tooth loss is a potential marker of gastric cancer. However, we can not concluded at this time that tooth loss may be a risk factor for gastric cancer due to significant heterogeneity among studies and mixed results between case-control studies and cohort studies. Additional large-scale and high-quality prospective studies are required to evaluate the association between tooth loss and risk of gastric cancer.
C1 [Yin, Xin-Hai; Wang, Ya-Dong; Luo, Hong; Zhao, Ke; Huang, Guang-Lei; Luo, Si-Yang; Song, Ju-Kun] Gui Zhou Prov Peoples Hosp, Dept Oral & Maxillary Surg, Guiyang, Peoples R China.
   [Peng, Ju-Xiang] Stomatol Hosp Gui Yang, Dept Orthodont, Guiyang, Peoples R China.
RP Song, JK (reprint author), Gui Zhou Prov Peoples Hosp, Dept Oral & Maxillary Surg, Guiyang, Peoples R China.; Peng, JX (reprint author), Stomatol Hosp Gui Yang, Dept Orthodont, Guiyang, Peoples R China.
EM 599280715@qq.com; songjukun@163.com
CR Abnet CC, 2005, SCAND J GASTROENTERO, V40, P681, DOI 10.1080/00365520510015430
   Abnet CC, 2005, INT J EPIDEMIOL, V34, P467, DOI 10.1093/ije/dyh375
   Abnet CC, 2001, CANCER CAUSE CONTROL, V12, P847, DOI 10.1023/A:1012290009545
   Abnet CC, 2008, CANCER EPIDEM BIOMAR, V17, P3062, DOI 10.1158/1055-9965.EPI-08-0558
   Ahn J, 2012, CARCINOGENESIS, V33, P1055, DOI 10.1093/carcin/bgs112
   Begenik H, 2015, ARCH MED SCI, V11, P346, DOI 10.5114/aoms.2015.50967
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Biddinger SB, 2005, AM J CLIN NUTR, V82, P277
   Boylan MR, 2014, CLIN TRANSL GASTROEN, V5, DOI 10.1038/ctg.2013.14
   Brand-Miller JC, 2004, AM J CLIN NUTR, V80, P243
   CHAUNCEY HH, 1989, CARIES RES, V23, P200, DOI 10.1159/000261178
   DEMIRER T, 1990, CANCER, V65, P2344, DOI 10.1002/1097-0142(19900515)65:10<2344::AID-CNCR2820651030>3.0.CO;2-H
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dye BA, 2002, AM J PUBLIC HEALTH, V92, P1809, DOI 10.2105/AJPH.92.11.1809
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Hartling L, 2013, J CLIN EPIDEMIOL, V66, P982, DOI 10.1016/j.jclinepi.2013.03.003
   Hidaka A, 2015, INT J CANCER, V136, P1402, DOI 10.1002/ijc.29098
   Hiraki A, 2008, CANCER EPIDEM BIOMAR, V17, P1222, DOI 10.1158/1055-9965.EPI-07-2761
   Hujoel PP, 2003, ANN EPIDEMIOL, V13, P312, DOI 10.1016/S1047-2797(02)00425-8
   Kaaks R, 2001, P NUTR SOC, V60, P91, DOI 10.1079/PNS200070
   Kamangar F, 2011, ARCH IRAN MED, V14, P192, DOI 011143/AIM.0010
   MAKINEN KK, 1988, PROG FOOD NUTR SCI, V12, P73
   Meyer MS, 2008, CANCER CAUSE CONTROL, V19, P895, DOI 10.1007/s10552-008-9163-4
   Michaud DS, 2008, LANCET ONCOL, V9, P550, DOI 10.1016/S1470-2045(08)70106-2
   Michaud DS, 2007, J NATL CANCER I, V99, P171, DOI 10.1093/inci/djk021
   Moye ZD, 2014, J ORAL MICROBIOL, V6, DOI 10.3402/jom.v6.24878
   Nasrollahzadeh D, 2012, BRIT J CANCER, V107, P888, DOI 10.1038/bjc.2012.332
   Rocco A, 2007, WORLD J GASTROENTERO, V13, P2901, DOI 10.3748/wjg.v13.i21.2901
   Rosenquist K, 2005, ACTA OTO-LARYNGOL, V125, P1327, DOI 10.1080/00016480510012273
   Salazar CR, 2012, CARCINOGENESIS, V33, P399, DOI 10.1093/carcin/bgr284
   Sanders TAB, 2016, P NUTR SOC, V75, P147, DOI 10.1017/S0029665115004188
   Saunders Ralph H Jr, 2005, Dent Clin North Am, V49, P293
   Seymour RA, 2010, DENT UPDATE, V37, P82
   Seymour Robin A, 2010, Dent Update, V37, P279
   Shakeri R, 2013, CANCER PREV RES, V6, P477, DOI 10.1158/1940-6207.CAPR-12-0491
   Shamami MS, 2011, IRAN J CANCER PREV, V4, P189
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
   Tseng CH, 2014, WORLD J GASTROENTERO, V20, P1701, DOI 10.3748/wjg.v20.i7.1701
   Watabe K, 1998, ONCOL REP, V5, P1191
NR 39
TC 10
Z9 10
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 2
PY 2016
VL 11
IS 3
AR e0149653
DI 10.1371/journal.pone.0149653
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DG0AN
UT WOS:000371724200044
PM 26934048
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, ZL
   Yu, CP
   Velet, L
   Li, YH
   Jiang, LJ
   Zhou, FJ
AF Zhang, Zhiling
   Yu, Chunping
   Velet, Liliya
   Li, Yonghong
   Jiang, Lijuan
   Zhou, Fangjian
TI The Difference in Prognosis between Renal Sinus Fat and Perinephric Fat
   Invasion for pT3a Renal Cell Carcinoma: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID INVOLVEMENT; SURVIVAL; BIAS
AB Background
   In the current Tumour-Node-Metastasis (TNM) classification system for renal cell carcinoma (RCC), both renal sinus fat invasion (SFI) and perinephric fat invasion (PFI) are defined as T3a, suggesting that the prognosis should be similar for the two pathologic findings. Several studies, however, have reported a worse prognosis for SFI in patients with a T3a tumor. In order to compare the prognosis of these two pathologic findings (SFI versus. PFI) in a more comprehensive way, this meta-analysis was performed.
   Methods
   To identify relevant studies, Medline, Embase, Cochrane Library, and Scopus database were searched from the inception until October 2014. A meta-analysis was performed using Review Manager 5.2 and STATA 11. Pooled Odds ratio (OR) and/or hazard ratio (HR) with 95% confidence interval (CI) were calculated to examine the risk or hazard association.
   Results
   A total of 6 studies including 1031 patients qualified for analysis. T3a RCC patients with SFI were significantly associated with poor cancer specific survival(CSS) (HR: 1.47, 95% CI: 1.19-1.83; P<0.001) compared to those with PFI. In T3aNx/N0M0 subgroup, SFI patients also showed a worse prognosis than those with PFI (CSS, HR: 1.94, 95% CI: 1.21-3.12; P = 0.006). T3a RCC patients with SFI had higher Furhman grade, greater possibility of lymph node metastasis, sarcomatoid differentiation and tumour necrosis. Main limitation is the relatively small number of included studies.
   Conclusion
   The present meta-analysis suggested that SFI is associated with worse CSS in patients with pT3a RCC. However, due to the small number of included studies, future studies with a large sample size are required to further verify our findings.
C1 [Zhang, Zhiling; Yu, Chunping; Li, Yonghong; Jiang, Lijuan; Zhou, Fangjian] Sun Yat Sen Univ, Ctr Canc, Dept Urol, Guangzhou 510275, Guangdong, Peoples R China.
   [Zhang, Zhiling; Yu, Chunping; Li, Yonghong; Jiang, Lijuan; Zhou, Fangjian] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.
   [Zhang, Zhiling; Yu, Chunping; Li, Yonghong; Jiang, Lijuan; Zhou, Fangjian] Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China.
   [Zhang, Zhiling] Guangdong Acad Med Sci, Guangdong Gen Hosp, Dept Nephrol, Guangzhou, Guangdong, Peoples R China.
   [Velet, Liliya] Northeast Ohio Med Univ, Rootstown, OH USA.
RP Zhou, FJ (reprint author), Sun Yat Sen Univ, Ctr Canc, Dept Urol, Guangzhou 510275, Guangdong, Peoples R China.; Zhou, FJ (reprint author), State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.; Zhou, FJ (reprint author), Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China.
EM zhoufj@sysucc.org.cn
FU Natural Science Foundation of China [81272810, 81402114, 81300597];
   Natural Science Foundation of Guangdong Province, China
   [S2013040015908]; China Scholarship Council
FX This study was supported by grants from the Natural Science Foundation
   of China (Nos. 81272810, 81402114 and 81300597), the Natural Science
   Foundation of Guangdong Province, China (No. S2013040015908), and China
   Scholarship Council.
CR Bedke J, 2009, BJU INT, V103, P1349, DOI 10.1111/j.1464-410X.2008.08236.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bertini R, 2009, J UROLOGY, V181, P2027, DOI 10.1016/j.juro.2009.01.048
   Bonsib SM, 2005, J UROLOGY, V174, P1199, DOI 10.1097/01.ju.0000173631.01329.1f
   Bonsib SM, 2000, AM J SURG PATHOL, V24, P451, DOI 10.1097/00000478-200003000-00015
   Portela SC, 2011, ROM J MORPHOL EMBRYO, V52, P569
   Delahunt B, 2014, UROLOGY, V83, P969, DOI 10.1016/j.urology.2014.02.004
   Edge S BD, 2010, AJCC CANC STAGING MA
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ficarra V, 2007, EUR UROL, V51, P722, DOI 10.1016/j.eururo.2006.07.010
   Greene FL PD, 2002, AJCC CANC STAGING MA
   Han KR, 2003, J UROLOGY, V169, P899, DOI 10.1097/01.ju.0000051480.62175.35
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Margulis V, 2007, J UROLOGY, V178, P1878, DOI 10.1016/j.juro.2007.07.011
   Poon SA, 2009, BJU INT, V103, P1622, DOI 10.1111/j.1464-410X.2008.08239.x
   Thompson RH, 2005, J UROLOGY, V173, P918, DOI 10.1097/01.ju.0000153419.98715.24
   Thompson RH, 2007, AM J SURG PATHOL, V31, P1089
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Van Poppel H, 2011, EUR UROL, V59, P543, DOI 10.1016/j.eururo.2010.12.013
   Wells G., 2003, NEWCASTLE OTTAWA SCA
NR 20
TC 8
Z9 8
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 18
PY 2016
VL 11
IS 2
AR e0149420
DI 10.1371/journal.pone.0149420
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF3CO
UT WOS:000371221500044
PM 26891054
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Hua, YF
   Wang, GQ
   Jiang, W
   Huang, J
   Chen, GC
   Lu, CD
AF Hua, Yong-Fei
   Wang, Gao-Qing
   Jiang, Wei
   Huang, Jing
   Chen, Guo-Chong
   Lu, Cai-De
TI Vitamin C Intake and Pancreatic Cancer Risk: A Meta-Analysis of
   Published Case-Control and Cohort Studies
SO PLOS ONE
LA English
DT Article
ID NUTRITIONAL FACTORS; LIFE-STYLE; PHYSICIANS HEALTH; TREND ESTIMATION;
   DIETARY FACTORS; NUTRIENT INTAKE; MICRONUTRIENTS; CARCINOGENESIS;
   ANTIOXIDANTS; MEN
AB Background
   Observational studies inconsistently reported the relationship between vitamin C intake and risk of pancreatic cancer. We conducted a meta-analysis of published case-control and cohort studies to quantify the association.
   Methods
   Potentially eligible studies were found on PubMed and EMBASE databases through May 31, 2015. A random-effects model was assigned to compute summary point estimates with corresponding 95% confidence intervals (CIs). Subgroup and meta-regression analyses were also performed to explore sources of heterogeneity.
   Results
   Our final analyses included 20 observational studies comprising nearly 5 thousand cases of pancreatic cancer. When comparing the highest with the lowest categories of vitamin C intake, the summary odds ratio/relative risk for case-control studies (14 studies), cohort studies (6 studies) and all studies combined was 0.58 (95% CI: 0.52-0.66), 0.93 (95% CI: 0.78-1.11) and 0.66 (95% CI: 0.58-0.75), respectively. The difference in the findings between case-control and cohort studies was statistically significant (P < .001). Possible publication bias was shown in the meta-analysis of case-control studies.
   Conclusion
   There is insufficient evidence to conclude any relationship between vitamin C intake and risk of pancreatic cancer. The strong inverse association observed in case-control studies may be affected by biases (eg, recall and selection biases) that particularly affect case-control studies and/or potential publication bias. Future prospective studies of vitamin C intake and pancreatic cancer are needed.
C1 [Hua, Yong-Fei; Wang, Gao-Qing; Jiang, Wei; Huang, Jing; Lu, Cai-De] Ningbo Med Treatment Ctr Lihuili Hosp, Dept Hepatobiliary & Pancreat Surg, Ningbo 315000, Zhejiang, Peoples R China.
   [Chen, Guo-Chong] Soochow Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Suzhou 215123, Peoples R China.
RP Lu, CD (reprint author), Ningbo Med Treatment Ctr Lihuili Hosp, Dept Hepatobiliary & Pancreat Surg, Ningbo 315000, Zhejiang, Peoples R China.
EM lucaide@nbu.edu.cn
RI Chen, Guo-Chong/K-4046-2017
CR Anderson LN, 2009, CANCER CAUSE CONTROL, V20, P825, DOI 10.1007/s10552-009-9303-5
   BAGHURST PA, 1991, AM J EPIDEMIOL, V134, P167, DOI 10.1093/oxfordjournals.aje.a116069
   Banim PJR, 2013, GUT, V62, P1489, DOI 10.1136/gutjnl-2011-301908
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bjelakovic G, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007176
   Bravi F, 2011, ANN ONCOL, V22, P202, DOI 10.1093/annonc/mdq302
   Cappellani A, 2012, EUR REV MED PHARMACO, V16, P192
   DEMESQUITA HBB, 1991, INT J CANCER, V48, P540, DOI 10.1002/ijc.2910480411
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FALK RT, 1988, AM J EPIDEMIOL, V128, P324, DOI 10.1093/oxfordjournals.aje.a114972
   Fan H, 2015, SCI REP-UK, V5, DOI 10.1038/srep13973
   Garcea G, 2005, PANCREATOLOGY, V5, P514, DOI 10.1159/000087493
   Gaziano JM, 2009, JAMA-J AM MED ASSOC, V301, P52, DOI 10.1001/jama.2008.862
   GHADIRIAN P, 1991, INT J CANCER, V47, P1, DOI 10.1002/ijc.2910470102
   Gong ZH, 2010, INT J CANCER, V127, P1893, DOI 10.1002/ijc.25208
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Han XS, 2013, CANCER-AM CANCER SOC, V119, P1314, DOI 10.1002/cncr.27936
   Heinen MM, 2012, INT J CANCER, V130, P147, DOI 10.1002/ijc.25989
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   HOWE GR, 1990, INT J CANCER, V45, P604, DOI 10.1002/ijc.2910450405
   HOWE GR, 1992, INT J CANCER, V51, P365, DOI 10.1002/ijc.2910510306
   Inoue-Choi M, 2011, CANCER EPIDEM BIOMAR, V20, P711, DOI 10.1158/1055-9965.EPI-11-0026
   Jansen Rick J, 2013, J Gastrointest Cancer, V44, P152, DOI 10.1007/s12029-012-9441-y
   Jeurnink SM, 2015, INT J CANCER, V136, pE665, DOI 10.1002/ijc.29175
   JI BT, 1995, CANCER EPIDEM BIOMAR, V4, P885
   KALAPOTHAKI V, 1993, CANCER CAUSE CONTROL, V4, P383, DOI 10.1007/BF00051342
   Leung PS, 2009, ANTIOXID REDOX SIGN, V11, P135, DOI 10.1089/ars.2008.2109
   Lin YS, 2005, J GASTROENTEROL, V40, P297, DOI 10.1007/s00535-004-1537-0
   Lowenfels AB, 2006, BEST PRACT RES CL GA, V20, P197, DOI 10.1016/j.bpg.2005.10.001
   McCullough ML, 2004, ONCOGENE, V23, P6349, DOI 10.1038/sj.onc.1207716
   Michl P, 2013, GUT, V62, P317, DOI 10.1136/gutjnl-2012-303588
   OLSEN GW, 1991, CANCER CAUSE CONTROL, V2, P291, DOI 10.1007/BF00051668
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   SHIBATA A, 1994, INT J CANCER, V58, P46, DOI 10.1002/ijc.2910580109
   Silverman DT, 1998, JNCI-J NATL CANCER I, V90, P1710, DOI 10.1093/jnci/90.22.1710
   Stolzenberg-Solomon RZ, 2002, AM J EPIDEMIOL, V155, P783, DOI 10.1093/aje/155.9.783
   Wang L, 2014, AM J CLIN NUTR, V100, P915, DOI 10.3945/ajcn.114.085480
   World Cancer Research Fund, 2012, CONT UPD PROJ SUMM F
   Woutersen RA, 1999, FOOD CHEM TOXICOL, V37, P981, DOI 10.1016/S0278-6915(99)00093-9
   Wu QJ, 2015, EUR J CANC PREV
   ZATONSKI W, 1991, INT J CANCER, V48, P390, DOI 10.1002/ijc.2910480314
NR 42
TC 6
Z9 6
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 9
PY 2016
VL 11
IS 2
AR e0148816
DI 10.1371/journal.pone.0148816
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DD6MN
UT WOS:000370038400091
PM 26859881
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, JB
   Shen, B
   Shi, MX
   Cai, J
AF Liu, Jibin
   Shen, Biao
   Shi, Minxin
   Cai, Jing
TI Higher Caffeinated Coffee Intake Is Associated with Reduced Malignant
   Melanoma Risk: A Meta-Analysis Study
SO PLOS ONE
LA English
DT Article
ID DOSE-RESPONSE METAANALYSIS; BASAL-CELL CARCINOMA; SKIN CARCINOGENESIS;
   PROSPECTIVE COHORT; NORWEGIAN MEN; DNA-DAMAGE; SKH-1 MICE; CONSUMPTION;
   CANCER; INHIBITION
AB Background
   Several epidemiological studies have determined the associations between coffee intake level and skin cancer risk; however, the results were not yet conclusive. Herein, we conducted a systematic review and meta-analysis of the cohort and case-control studies for the association between coffee intake level and malignant melanoma (MM) risk.
   Methods
   Studies were identified through searching the PubMed and MEDLINE databases (to November, 2015). Study-specific risk estimates were pooled under the random-effects model.
   Results
   Two case-control studies (846 MM patients and 843 controls) and five cohort studies (including 844,246 participants and 5,737 MM cases) were identified. For caffeinated coffee, the pooled relative risk (RR) of MM was 0.81 [95% confidential interval (95% CI) = 0.68-0.97; P-value for Q-test = 0.003; I-2 = 63.5%] for those with highest versus lowest quantity of intake. In the dose-response analysis, the RR of MM was 0.955 (95% CI = 0.912-0.999) for per 1 cup/day increment of caffeinated coffee consumption and linearity dose-response association was found (P-value for nonlinearity = 0.326). Strikingly, no significant association was found between the decaffeinated coffee intake level and MM risk (pooled RR = 0.92, 95% CI = 0.81-1.05; P-value for Q-test = 0.967; I-2 = 0%; highest versus lowest quantity of intake).
   Conclusions
   This meta-analysis suggested that caffeinated coffee might have chemo-preventive effects against MM but not decaffeinated coffee. However, larger prospective studies and the intervention studies are warranted to confirm these findings.
C1 [Liu, Jibin; Shen, Biao; Shi, Minxin; Cai, Jing] Nantong Tumor Hosp, Tong Yang Rd 30, Nantong Pingchao Town 226361, Jiangsu, Peoples R China.
RP Cai, J (reprint author), Nantong Tumor Hosp, Tong Yang Rd 30, Nantong Pingchao Town 226361, Jiangsu, Peoples R China.
EM caijingnantong@sina.com
FU China Post-doctoral Science Foundation [2013M541563]
FX This work was supported by the China Post-doctoral Science Foundation
   (NO: 2013M541563) and the peak of six personnel Foundation in Jiangsu
   Province. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Bakos L, 2013, AN BRAS DERMATOL, V88, P226, DOI 10.1590/S0365-05962013000200007
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BOWDEN GT, 1980, CHEM-BIOL INTERACT, V33, P101, DOI 10.1016/0009-2797(80)90047-2
   Conney AH, 2007, TOXICOL APPL PHARM, V224, P209, DOI 10.1016/j.taap.2006.11.001
   Conney AH, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00144
   Crippa A, 2014, AM J EPIDEMIOL, V180, P763, DOI 10.1093/aje/kwu194
   de Waure C, 2015, PUBLIC HEALTH, V129, P1099, DOI 10.1016/j.puhe.2015.06.015
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferrucci LM, 2014, EUR J CANCER PREV, V23, P296, DOI 10.1097/CEJ.0000000000000037
   Fortes C, 2013, CANCER CAUSE CONTROL, V24, P1779, DOI 10.1007/s10552-013-0255-4
   Gude RP, 2001, J EXP CLIN CANC RES, V20, P287
   Higuchi K, 2000, CANCER LETT, V152, P157, DOI 10.1016/S0304-3835(99)00449-8
   Jiang AJ, 2015, BRIT J DERMATOL, V172, P885, DOI 10.1111/bjd.13500
   Jiang XB, 2014, EUR J NUTR, V53, P25, DOI 10.1007/s00394-013-0603-x
   Kang NJ, 2009, CARCINOGENESIS, V30, P321, DOI 10.1093/carcin/bgn282
   Lang R, 2008, J AGR FOOD CHEM, V56, P11114, DOI 10.1021/jf802838s
   Larsson SC, 2014, STROKE, V45, P309, DOI 10.1161/STROKEAHA.113.003131
   Lee Kyu Hwan, 2012, [Jornal of the Microelectronics and Packaging Society, 마이크로전자 및 패키징학회지], V19, P1, DOI 10.6117/kmeps.2012.19.3.001
   Lee KJ, 2007, TOXICOL LETT, V173, P80, DOI 10.1016/j.toxlet.2007.06.008
   Lee WJ, 2006, CARCINOGENESIS, V27, P269, DOI 10.1093/carcin/bgi206
   Lentini A, 1998, MELANOMA RES, V8, P131, DOI 10.1097/00008390-199804000-00005
   Liu H, 2015, NUTR CANCER, V67, P392, DOI 10.1080/01635581.2015.1004727
   Loftfield E, 2015, J NATL CANC I, V107
   Lu YP, 2008, CANCER RES, V68, P2523, DOI 10.1158/0008-5472.CAN-07-5955
   Lu YP, 2011, CANCER PREV RES, V4, P1118, DOI 10.1158/1940-6207.CAPR-11-0116
   Lu YP, 2000, CANCER RES, V60, P4785
   Naldi L, 2004, EUR J CANCER PREV, V13, P503, DOI 10.1097/00008469-200412000-00007
   Nilsson LM, 2010, CANCER CAUSE CONTROL, V21, P1533, DOI 10.1007/s10552-010-9582-x
   Orsini N B R, 2006, STATA J, P40
   Ravi D, 2008, MOL CELL BIOCHEM, V308, P193, DOI 10.1007/s11010-007-9628-x
   Sarkaria JN, 1999, CANCER RES, V59, P4375
   Shen ZY, 2015, CLIN RES HEPATOL GAS, V39, P245, DOI 10.1016/j.clinre.2014.09.005
   Song FJ, 2012, CANCER RES, V72, P3282, DOI 10.1158/0008-5472.CAN-11-3511
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   STENSVOLD I, 1994, CANCER CAUSE CONTROL, V5, P401, DOI 10.1007/BF01694753
   Thompson BC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117491
   Thompson BC, 2014, EXP DERMATOL, V23, P509, DOI 10.1111/exd.12430
   Veierod MB, 1997, INT J CANCER, V71, P600, DOI 10.1002/(SICI)1097-0215(19970516)71:4<600::AID-IJC15>3.3.CO;2-C
   Wei WC, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-94
   Wu HT, 2015, EUR J CANCER PREV, V24, P347, DOI 10.1097/CEJ.0000000000000093
   Wu SW, 2015, EPIDEMIOLOGY, V26, P898, DOI 10.1097/EDE.0000000000000360
   Wu WX, 2015, SCI REP-UK, V5, DOI 10.1038/srep09051
   Xie Y, 2015, EUR J CLIN NUTR
   Yang G, 2014, CANCER PREV RES, V7, P1056, DOI 10.1158/1940-6207.CAPR-14-0141
   Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140
   Zajdela F, 1978, Natl Cancer Inst Monogr, P133
   Zhou Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep13410
NR 48
TC 20
Z9 20
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 27
PY 2016
VL 11
IS 1
AR e0147056
DI 10.1371/journal.pone.0147056
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DC9GD
UT WOS:000369528200023
PM 26816289
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Cui, H
   Gong, TT
   Liu, CX
   Wu, QJ
AF Cui, Hong
   Gong, Ting-Ting
   Liu, Cai-Xia
   Wu, Qi-Jun
TI Associations between Passive Maternal Smoking during Pregnancy and
   Preterm Birth: Evidence from a Meta-Analysis of Observational Studies
SO PLOS ONE
LA English
DT Article
ID ENVIRONMENTAL TOBACCO-SMOKE; ENDOMETRIAL CANCER-RISK; DOSE-RESPONSE
   METAANALYSIS; SECONDHAND SMOKE; SERUM COTININE; EXPOSURE; OUTCOMES;
   WEIGHT; WOMEN; SUSCEPTIBILITY
AB Previous studies investigating the relationship between passive maternal smoking and preterm birth reveal inconsistent results. We conducted the current meta-analysis of observational studies to evaluate the relationship between passive maternal smoking and preterm birth. We identified relevant studies by searching PubMed, EMBASE, and ISI Web of Science databases. We used random-effects models to estimate summary odds ratios (SORs) and 95% confidence intervals (CIs) for aforementioned association. For the analysis, we included 24 studies that involved a total of 5607 women who experienced preterm birth. Overall, the SORs of preterm birth for women who were ever exposed to passive smoking versus women who had never been exposed to passive smoking at any place and at home were 1.20 (95% CI = 1.07-1.34, I-2 = 36.1%) and 1.16 (95% CI = 1.04-1.30, I-2 = 4.4%), respectively. When we conducted a stratified analysis according to study design, the risk estimate was slightly weaker in cohort studies (SOR = 1.10, 95% CI = 1.00-1.21, n = 16) than in cross-sectional studies (SOR = 1.47, 95% CI = 1.23-1.74, n = 5). Additionally, the associations between passive maternal smoking and preterm birth were statistically significant for studies conducted in Asia (SOR = 1.26, 95% CI = 1.05-1.52), for studies including more than 100 cases of preterm birth (SOR = 1.22, 95% CI = 1.05-1.41), and for studies adjusted for maternal age (SOR = 1.27,95% CI = 1.09-1.47), socioeconomic status and/or education (SOR = 1.28, 95% CI = 1.10-1.49), body mass index (SOR = 1.33, 95% CI = 1.04-1.71), and parity (SOR = 1.27, 95% CI = 1.13-1.43). Our findings demonstrate that passive maternal smoking is associated with an increased risk of preterm birth. Future prospective cohort studies are warranted to provide more detailed results stratified by passive maternal smoking during different trimesters of pregnancy and by different types and causes of preterm birth.
C1 [Cui, Hong; Gong, Ting-Ting; Liu, Cai-Xia] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang 110001, Peoples R China.
   [Wu, Qi-Jun] China Med Univ, Shengjing Hosp, Dept Clin Epidemiol, Shenyang 110001, Peoples R China.
RP Wu, QJ (reprint author), China Med Univ, Shengjing Hosp, Dept Clin Epidemiol, Shenyang 110001, Peoples R China.
EM wuqj@sj-hospital.org
CR AHLBORG G, 1991, AM J EPIDEMIOL, V133, P338, DOI 10.1093/oxfordjournals.aje.a115886
   Ahluwalia IB, 1997, AM J EPIDEMIOL, V146, P42
   Andriani H, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0414-y
   [Anonymous], TECHN ASS PROGR
   Ashford KB, 2010, JOGNN-J OBST GYN NEO, V39, P525, DOI 10.1111/j.1552-6909.2010.01169.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4
   Centers for Disease C Prevention National Center for Chronic Disease P Health P Office on S Health, 2010, CTR DIS C PREV PUBL
   DeLorenze GN, 2002, ENVIRON RES, V90, P21, DOI 10.1006/enrs.2001.4380
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   EKWO EE, 1993, INT J EPIDEMIOL, V22, P495, DOI 10.1093/ije/22.3.495
   Eliopoulos C, 1996, CLIN INVEST MED, V19, P231
   ESKENAZI B, 1995, AM J PUBLIC HEALTH, V85, P395, DOI 10.2105/AJPH.85.3.395
   Fantuzzi G, 2007, PAEDIATR PERINAT EP, V21, P194, DOI 10.1111/j.1365-3016.2007.00815.x
   Goel P, 2004, J Postgrad Med, V50, P12
   Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4
   Gong TT, 2015, SCI REP-UK, V5, DOI 10.1038/srep14051
   Gong TT, 2015, INT J CANCER, V137, P1967, DOI 10.1002/ijc.29561
   Greenland S, 2001, Biostatistics, V2, P463, DOI 10.1093/biostatistics/2.4.463
   GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248
   Greenland S, 2008, MODERN EPIDEMIOLOGY, V3, P652
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Hanke W, 1999, HUM EXP TOXICOL, V18, P265, DOI 10.1191/096032799678840020
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P557, DOI 10.2307/3455027
   Jauniaux E, 2007, EARLY HUM DEV, V83, P699, DOI 10.1016/j.earlhumdev.2007.07.016
   Kaufmann R. B., 2010, Morbidity and Mortality Weekly Report, V59, P1141
   Khader YS, 2011, MATERN CHILD HLTH J, V15, P453, DOI 10.1007/s10995-010-0599-2
   Kim YJ, 2005, GYNECOL OBSTET INVES, V60, P206, DOI 10.1159/000087207
   LAZZARONI F, 1990, INT J EPIDEMIOL, V19, P960, DOI 10.1093/ije/19.4.960
   Leonardi-Bee J, 2008, ARCH DIS CHILD-FETAL, V93, pF351, DOI 10.1136/adc.2007.133553
   Leonardi-Bee J, 2011, PEDIATRICS, V127, P734, DOI 10.1542/peds.2010-3041
   Luan NN, 2013, AM J CLIN NUTR, V98, P1020, DOI 10.3945/ajcn.113.062794
   Luo YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049155
   March of Dimes, 2012, BORN TOO SOON GLOB A
   MARTIN TR, 1986, AM J EPIDEMIOL, V124, P633, DOI 10.1093/oxfordjournals.aje.a114436
   MATHAI M, 1992, BRIT J OBSTET GYNAEC, V99, P342, DOI 10.1111/j.1471-0528.1992.tb13736.x
   Meeker JD, 2013, CURR WOMENS HEALTH R, V9, P41, DOI 10.2174/1573404811309010003
   Miyake Y, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-157
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Office on S Health, 2010, OFF S HLTH PUBL REP
   Perera FP, 2004, ENVIRON HEALTH PERSP, V112, P1133, DOI 10.1289/ehp.6833
   Pichini S, 2000, ENVIRON HEALTH PERSP, V108, P1079, DOI 10.1289/ehp.001081079
   Pickett KE, 2005, PAEDIATR PERINAT EP, V19, P368, DOI 10.1111/j.1365-3016.2005.00660.x
   Qiu J, 2014, AM J EPIDEMIOL, V180, P94, DOI 10.1093/aje/kwu092
   Sadler L, 1999, AM J EPIDEMIOL, V150, P695
   Salmasi G, 2010, ACTA OBSTET GYN SCAN, V89, P423, DOI 10.3109/00016340903505748
   Tuormaa Tuula E., 1995, Nutrition and Health (Bicester), V10, P105
   Wang CH, 2015, SCI REP-UK, V5, DOI 10.1038/srep10834
   Ward C, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-81
   Windham GC, 2000, EPIDEMIOLOGY, V11, P427, DOI 10.1097/00001648-200007000-00011
   Wu FY, 2007, SCI TOTAL ENVIRON, V386, P124, DOI 10.1016/j.scitotenv.2007.06.003
   Wu QJ, 2013, ANN ONCOL, V24, P1079, DOI 10.1093/annonc/mds601
   Wu QJ, 2015, ONCOTARGET, V6, P42988, DOI 10.18632/oncotarget.5557
   Wu QJ, 2015, ONCOTARGET, V6, P36081, DOI 10.18632/oncotarget.5555
   Wu QJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep14243
   Wu T, 2007, AM J EPIDEMIOL, V166, P313, DOI 10.1093/aje/kwm090
   Zenzes MT, 2000, HUM REPROD UPDATE, V6, P122, DOI 10.1093/humupd/6.2.122
NR 59
TC 18
Z9 18
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 25
PY 2016
VL 11
IS 1
AR e0147848
DI 10.1371/journal.pone.0147848
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DC9FZ
UT WOS:000369527800228
PM 26808045
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Shentu, XC
   Zhang, X
   Tang, XJ
   Yu, XN
AF Shentu, Xingchao
   Zhang, Xin
   Tang, Xiajing
   Yu, Xiaoning
TI Coaxial Microincision Cataract Surgery versus Standard Coaxial
   Small-Incision Cataract Surgery: A Meta-Analysis of Randomized
   Controlled Trials
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL-CELL LOSS; SURGICALLY INDUCED ASTIGMATISM; CORNEAL WOUND
   ARCHITECTURE; HIGH-ORDER ABERRATIONS; CLEAR CORNEAL;
   INTRAOCULAR-PRESSURE; BIMANUAL MICROINCISION; TORSIONAL HANDPIECE;
   MICRO-INCISION; SHAPE CHANGES
AB Background
   We conducted this meta-analysis to compare the outcomes of coaxial microincision cataract surgery (C-MICS) and standard coaxial small incision cataract surgery (C-SICS).
   Methods
   The outcomes of randomized controlled trials (RCTs) reporting C-MICS and C-SICS were collected from PubMed, Web of Science, and The Cochrane Library in May 2015. The final meta-analysis was conducted on the following intraoperative and postoperative outcomes: ultrasound time (UST), effective phacoemulsification time (EPT), balanced salt solution use (BSS use), cumulative dissipated energy (CDE), mean surgery time, endothelial cell loss percentage (ECL%), best corrected visual acuity (BCVA), increased central corneal thickness (CCT), laser flare photometry values and surgically induced astigmatism (SIA).
   Results
   A total of 15 RCTs, involving 1136 eyes, were included in the final meta-analysis. No significant between-group differences were detected in EPT, BSS use, CDE, BCVA, laser flare photometry values or increased CCT. However, the C-MICS group showed less SIA (at postoperative day 7: p<0.01; at postoperative day 30 or more: p<0.01) and greater ECL% (at postoperative day 60 or more: p<0.01), whereas the C-SICS group required a shorter UST (p<0.01).
   Conclusions
   The present meta-analysis suggested that the C-MICS technique was more advantageous than C-SICS in terms of SIA, but C-MICS required a longer UST and induced a higher ECL %. Further studies should be done to confirm our results.
C1 [Shentu, Xingchao; Zhang, Xin; Tang, Xiajing; Yu, Xiaoning] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou 310003, Zhejiang, Peoples R China.
RP Yu, XN (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou 310003, Zhejiang, Peoples R China.
EM yxnzju@163.com
CR Alio J, 2005, OPHTHALMOLOGY, V112, P1997, DOI 10.1016/j.ophtha.2005.06.024
   Alio JL, 2005, J CATARACT REFR SURG, V31, P1549, DOI 10.1016/j.jcrs.2005.01.030
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berdahl JP, 2007, J CATARACT REFR SURG, V33, P510, DOI 10.1016/j.jcrs.2006.11.012
   Berdahl JP, 2008, J CATARACT REFR SURG, V34, P2091, DOI 10.1016/j.jcrs.2008.08.025
   BOURNE WM, 1994, OPHTHALMOLOGY, V101, P1014
   Brousseaud FX, 2008, IOVS, V1, P379
   Can I, 2010, J CATARACT REFR SURG, V36, P740, DOI 10.1016/j.jcrs.2009.11.013
   Capella M.J., 2010, Arch Soc Esp Oftalmol, V85, P268, DOI 10.1016/j.oftal.2010.09.004
   Cavallini GM, 2007, J CATARACT REFR SURG, V33, P387, DOI 10.1016/j.jcrs.2006.11.016
   Chang SW, 2015, J REFRACT SURG, V31, P82, DOI 10.3928/1081597X-20150122-02
   Chen C, 2015, EUR J OPHTHALMOL, V25, P119, DOI 10.5301/ejo.5000521
   Cheng B, 2011, CORNEA, V30, P634, DOI 10.1097/ICO.0b013e3181f7f149
   Cleary G, 2009, J CATARACT REFR SURG, V35, P265, DOI 10.1016/j.jcrs.2008.10.048
   Crema AS, 2007, J CATARACT REFR SURG, V33, P1014, DOI 10.1016/j.jcrs.2007.02.035
   Crowther M, 2010, BLOOD, V116, P3140, DOI 10.1182/blood-2010-05-280883
   [崔巍 Cui Wei], 2014, [中国实用眼科杂志, Chinese Journal of Practical Ophthalmology], V32, P1424
   Denoyer A, 2013, J CATARACT REFR SURG, V39, P1204, DOI 10.1016/j.jcrs.2013.02.052
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   Dick HB, 1996, J CATARACT REFR SURG, V22, P63
   Dosso AA, 2008, J CATARACT REFR SURG, V34, P284, DOI 10.1016/j.jcrs.2007.09.037
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Hashemi H, 2010, IRAN J OPHTHALMOL, V22, P13
   Hayashi K, 1996, J CATARACT REFR SURG, V22, P1079, DOI 10.1016/S0886-3350(96)80121-0
   HAYASHI K, 1995, OPHTHALMOLOGY, V102, P550, DOI 10.1016/S0161-6420(95)30983-9
   Hayashi K, 2014, JPN J OPHTHALMOL, V58, P402, DOI 10.1007/s10384-014-0331-7
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1313, DOI 10.1016/j.ophtha.2009.11.041
   Hayashi K, 2009, J CATARACT REFR SURG, V35, P233, DOI 10.1016/j.jcrs.2008.10.031
   Heng W, SURG INDUCED ASTIGMA
   Higa A, 2010, AM J OPHTHALMOL, V149, P794, DOI 10.1016/j.ajo.2009.12.029
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jian-Gang Zhu, 2014, INT EYE SCI, V14, P1433
   Jiang YX, 2006, J REFRACT SURG, V22, pS1083
   Jun B, 2010, OPHTHAL SURG LAS IM, V41, P128, DOI 10.3928/15428877-20091230-23
   Kahraman G, 2007, J CATARACT REFR SURG, V33, P618, DOI 10.1016/j.jcrs.2007.01.013
   Kim EC, 2011, J CATARACT REFR SURG, V37, P1799, DOI 10.1016/j.jcrs.2011.04.024
   Kim Yong-Kyu, 2014, Korean J Ophthalmol, V28, P130, DOI 10.3341/kjo.2014.28.2.130
   Klamann MKJ, 2013, EUR J OPHTHALMOL, V23, P202, DOI 10.5301/ejo.5000207
   Kocabora M S, 2010, Bull Soc Belge Ophtalmol, P25
   Kreutzer TC, 2010, J CATARACT REFR SURG, V36, P53, DOI 10.1016/j.jcrs.2009.07.035
   Lee KM, 2009, J CATARACT REFR SURG, V35, P874, DOI 10.1016/j.jcrs.2008.12.031
   Li YJ, 2011, JPN J OPHTHALMOL, V55, P196, DOI 10.1007/s10384-011-0007-5
   Liu YZ, 2007, J CATARACT REFR SURG, V33, P287, DOI 10.1016/j.jcrs.2006.10.044
   Lundberg B, 2005, AM J OPHTHALMOL, V139, P1035, DOI 10.1016/j.ajo.2004.12.080
   Luo LX, 2012, AM J OPHTHALMOL, V153, P831, DOI 10.1016/j.ajo.2011.10.034
   Masket S, 2009, J REFRACT SURG, V25, P21
   Mencucci R, 2006, J CATARACT REFR SURG, V32, P1351, DOI 10.1016/j.jcrs.2006.02.070
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Musanovic Zlatko, 2012, Med Arh, V66, P125
   Orczykowska Maria, 2014, Klin Oczna, V116, P7
   Osher RH, 2007, J CATARACT REFR SURG, V33, P401, DOI 10.1016/j.jcrs.2006.10.058
   Park YG, 2012, OPHTHALMOLOGICA, V227, P55, DOI 10.1159/000329599
   Sik Hwang Ho, 2015, ACTA OPHTHALMOL, DOI [10.1111/aos.12716, DOI 10.1111/A0S.12716]
   Torres RM, 2006, IOVS, V47, P636
   Wang J, 2009, CLIN EXP OPHTHALMOL, V37, P664, DOI 10.1111/j.1442-9071.2009.02117.x
   Weikert MP, 2012, J CATARACT REFR SURG, V38, P1460, DOI 10.1016/j.jcrs.2012.03.036
   Wilczyn ski M, 2004, OKULISTYKA, V3, P38
   Wilczynski Michal, 2011, Klin Oczna, V113, P314
   Wilczynski M, 2009, J CATARACT REFR SURG, V35, P1563, DOI 10.1016/j.jcrs.2009.04.037
   Wylegala Edward, 2009, Klin Oczna, V111, P207
   Yao K, 2006, J REFRACT SURG, V22, pS1079
   Yao Ke, 2011, Zhonghua Yan Ke Za Zhi, V47, P903
   김운형, 2015, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V56, P19
NR 63
TC 6
Z9 7
U1 2
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 8
PY 2016
VL 11
IS 1
AR e0146676
DI 10.1371/journal.pone.0146676
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DA5AX
UT WOS:000367815600076
PM 26745279
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, J
   Dong, M
   Sun, XR
   Li, WW
   Xing, LG
   Yu, JM
AF Liu, Jing
   Dong, Min
   Sun, Xiaorong
   Li, Wenwu
   Xing, Ligang
   Yu, Jinming
TI Prognostic Value of F-18-FDG PET/CT in Surgical Non-Small Cell Lung
   Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; STANDARDIZED UPTAKE VALUE; TOTAL LESION
   GLYCOLYSIS; METABOLIC TUMOR BURDEN; STAGE-I; VOLUMETRIC PARAMETERS; FDG
   PET/CT; F-18-FLUORODEOXYGLUCOSE UPTAKE; DISEASE PROGRESSION; SURVIVAL
AB Background
   The identification of surgical non-small cell lung cancer (NSCLC) patients with poor prognosis is a priority in clinical oncology because of their high 5-year mortality. This meta-analysis explored the prognostic value of maximal standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on disease-free survival (DFS) and overall survival (OS) in surgical NSCLC patients.
   Materials and Methods
   MEDLINE, EMBASE and Cochrane Libraries were systematically searched until August 1, 2015. Prospective or retrospective studies that evaluated the prognostic roles of preoperative 18F-FDG PET/CT with complete DFS and OS data in surgical NSCLC patients were included. The impact of SUVmax, MTV or TLG on survival was measured using hazard ratios (HR). Sub-group analyses were performed based on disease stage, pathological classification, surgery only and cut-off values.
   Results
   Thirty-six studies comprised of 5807 patients were included. The combined HRs for DFS were 2.74 (95% CI 2.33-3.24, unadjusted) and 2.43 (95% CI: 1.76-3.36, adjusted) for SUVmax, 2.27 (95% CI 1.77-2.90, unadjusted) and 2.49 (95% CI 1.23-5.04, adjusted) for MTV, and 2.46 (95% CI 1.91-3.17, unadjusted) and 2.97 (95% CI 1.68-5.28, adjusted) for TLG. The pooled HRs for OS were 2.54 (95% CI 1.86-3.49, unadjusted) and 1.52 (95% CI 1.16-2.00, adjusted) for SUVmax, 2.07 (95% CI 1.16-3.69, unadjusted) and 1.91 (95% CI 1.13-3.22, adjusted) for MTV, and 2.47 (95% CI 1.38-4.43, unadjusted) and 1.94 (95% CI 1.12-3.33, adjusted) for TLG. Begg's test detected publication bias, the trim and fill procedure was performed, and similar HRs were obtained. The prognostic role of SUVmax, MTV and TLG remained similar in the sub-group analyses.
   Conclusions
   High values of SUVmax, MTV and TLG predicted a higher risk of recurrence or death in patients with surgical NSCLC. We suggest the use of FDG PET/CT to select patients who are at high risk of disease recurrence or death and may benefit from aggressive treatments.
C1 [Liu, Jing; Xing, Ligang; Yu, Jinming] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China.
   [Liu, Jing; Xing, Ligang; Yu, Jinming] Shandong Canc Hosp & Inst, Shandong Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China.
   [Dong, Min] Peoples Hosp Pingyi Cty, Dept Oncol, Pingyi, Shandong, Peoples R China.
   [Sun, Xiaorong; Li, Wenwu] Shandong Canc Hosp & Inst, Dept Radiol, Jinan, Shandong, Peoples R China.
RP Xing, LG (reprint author), Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China.
EM xinglg@medmail.com.cn
FU National Health and Family Planning Commission Institutes of the
   People's Republic of China [201402011]; National Natural Science
   Foundation of China [81272502, L1322016]
FX This work was supported in part by the grant from National Health and
   Family Planning Commission Institutes of the People's Republic of China
   (201402011), and the grants from National Natural Science Foundation of
   China (81272502 and L1322016) to LX. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agarwal M, 2010, EUR J NUCL MED MOL I, V37, P691, DOI 10.1007/s00259-009-1291-x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berghmans T, 2008, J THORAC ONCOL, V3, P6, DOI 10.1097/JTO.0b013e31815e6d6b
   Bille A, 2013, CLIN LUNG CANCER, V14, P149, DOI 10.1016/j.cllc.2012.04.007
   Boellaard R, 2004, J NUCL MED, V45, P1519
   Cistaro A, 2013, RADIOL ONCOL, V47, P219, DOI 10.2478/raon-2013-0023
   Cook GJR, 2013, J NUCL MED, V54, P19, DOI 10.2967/jnumed.112.107375
   Davison J, 2013, AM J ROENTGENOL, V200, P635, DOI 10.2214/AJR.12.9138
   Dhital K, 2000, EUR J CARDIO-THORAC, V18, P425, DOI 10.1016/S1010-7940(00)00535-2
   Dinnes J, 2005, HEALTH TECHNOL ASSES, V9, P1, DOI 10.3310/hta9120
   Domachevsky L, 2015, EUR RADIOL, V25, P3361, DOI 10.1007/s00330-015-3754-8
   Dooms C, 2009, J THORAC ONCOL, V4, P822, DOI 10.1097/JTO.0b013e3181a97df7
   Downey RJ, 2007, J THORAC CARDIOV SUR, V133, P1419, DOI 10.1016/j.tcvs.2007.01.041
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a
   Goodgame B, 2008, J THORAC ONCOL, V3, P130, DOI 10.1097/JTO.0b013e318160c122
   Hanin FX, 2008, EUR J CARDIO-THORAC, V33, P819, DOI 10.1016/j.ejcts.2008.02.005
   Higashi K, 2002, J NUCL MED, V43, P39
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hyun SH, 2013, ANN SURG, V257, P364, DOI 10.1097/SLA.0b013e318262a6ec
   Im HJ, 2015, EUR J NUCL MED MOL I, V42, P241, DOI 10.1007/s00259-014-2903-7
   Kang SR, 2014, NUCL MED MOLEC IMAG, V48, P16, DOI 10.1007/s13139-013-0231-7
   Kim DH, 2014, ANN SURG ONCOL, V21, P589, DOI 10.1245/s10434-013-3270-5
   Kim HR, 2009, EUR J CARDIO-THORAC, V35, P712, DOI 10.1016/j.ejcts.2008.12.030
   Kim K, 2012, NUCL MED COMMUN, V33, P613, DOI 10.1097/MNM.0b013e328351d4f5
   Kim YS, 2011, NEOPLASMA, V58, P245, DOI 10.4149/neo_2011_03_245
   Ko KH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000434
   Koo HK, 2011, LUNG CANCER, V73, P222, DOI 10.1016/j.lungcan.2010.11.013
   Lee P, 2007, INT J RADIAT ONCOL, V69, P328, DOI 10.1016/j.ijrobp.2007.04.036
   Lin Y, 2012, ANTICANCER RES, V32, P5087
   Machtay M, 2013, J CLIN ONCOL, V31, P3823, DOI 10.1200/JCO.2012.47.5947
   Melloni G, 2013, EJSO-EUR J SURG ONC, V39, P1254, DOI 10.1016/j.ejso.2013.07.092
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moon SH, 2013, KOREAN J RADIOL, V14, P1, DOI 10.3348/kjr.2013.14.1.1
   Motono N, 2014, ASIAN PAC J CANCER P, V15, P10171, DOI 10.7314/APJCP.2014.15.23.10171
   Na FF, 2014, J THORAC ONCOL, V9, P834, DOI 10.1097/JTO.0000000000000185
   Nair VS, 2009, J THORAC ONCOL, V4, P1473, DOI 10.1097/JTO.0b013e3181bccbc6
   Nair VS, 2010, CHEST, V137, P1150, DOI 10.1378/chest.09-2356
   Naruke T, 2001, ANN THORAC SURG, V71, P1759, DOI 10.1016/S0003-4975(00)02609-6
   Ohtaka K, 2013, ANTICANCER RES, V33, P5193
   Ohtsuka T, 2006, CANCER, V107, P2468, DOI 10.1002/cncr.22268
   Paesmans M, 2010, J THORAC ONCOL, V5, P612, DOI 10.1097/JTO.0b013e3181d0a4f5
   Paidpally Vasavi, 2012, Imaging Med, V4, P633
   Pak K, 2014, J NUCL MED, V55, P884, DOI 10.2967/jnumed.113.133801
   Pan LL, 2009, EUR J GASTROEN HEPAT, V21, P1008, DOI 10.1097/MEG.0b013e328323d6fa
   Park SY, 2015, J NUCL MED, V56, P45, DOI 10.2967/jnumed.114.147561
   Pelosi E, 2011, Q J NUCL MED MOL IM, V55, P72
   Shimizu K, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-343
   Shiono S, 2011, J THORAC ONCOL, V6, P43, DOI 10.1097/JTO.0b013e3181f9abca
   Stahl A, 2004, EUR J NUCL MED MOL I, V31, P1471, DOI 10.1007/s00259-004-1626-6
   Stiles BM, 2013, ANN THORAC SURG, V95, P397, DOI 10.1016/j.athoracsur.2012.07.038
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Tixier F, 2014, J NUCL MED, V55, P1235, DOI 10.2967/jnumed.113.133389
   Tomita M, 2012, ASIA-PAC J CLIN ONCO, V8, P244, DOI 10.1111/j.1743-7563.2012.01549.x
   Tsutani Y, 2011, JPN J CLIN ONCOL, V41, P890, DOI 10.1093/jjco/hyr062
   Um SW, 2009, J THORAC ONCOL, V4, P1331, DOI 10.1097/JTO.0b013e3181b6be3e
   Vaidya M, 2012, RADIOTHER ONCOL, V102, P239, DOI 10.1016/j.radonc.2011.10.014
   van Baardwijk A, 2007, EUR J CANCER, V43, P1392, DOI 10.1016/j.ejca.2007.03.027
   Vesselle H, 2007, CLIN CANCER RES, V13, P3255, DOI 10.1158/1078-0432.CCR-06-1128
   Yoo IR, 2014, BIO-MED MATER ENG, V24, P3091, DOI 10.3233/BME-141131
   Zhang H, 2013, ACAD RADIOL, V20, P32, DOI 10.1016/j.acra.2012.07.002
   Zhang ZJ, 2007, CHINESE MED J-PEKING, V120, P125, DOI 10.1097/00029330-200701020-00010
   Zheng XP, 2014, INT J RADIAT ONCOL, V90, P603, DOI 10.1016/j.ijrobp.2014.05.055
   Zhu AZ, 2011, SEMIN ONCOL, V38, P55, DOI 10.1053/j.seminoncol.2010.11.012
NR 66
TC 45
Z9 48
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 4
PY 2016
VL 11
IS 1
AR e0146195
DI 10.1371/journal.pone.0146195
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DA3FF
UT WOS:000367681500065
PM 26727114
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Rughooputh, MS
   Zeng, R
   Yao, Y
AF Rughooputh, Mahesh Shumsher
   Zeng, Rui
   Yao, Ying
TI Protein Diet Restriction Slows Chronic Kidney Disease Progression in
   Non-Diabetic and in Type 1 Diabetic Patients, but Not in Type 2 Diabetic
   Patients: A Meta-Analysis of Randomized Controlled Trials Using
   Glomerular Filtration Rate as a Surrogate
SO PLOS ONE
LA English
DT Article
ID RENAL-FAILURE; ALBUMINURIA; NEPHROPATHY; MELLITUS
AB Background/Objective
   Studies, including various meta-analyses, on the effect of Protein Diet Restriction on Glomerular Filtration Rate (GFR) in Chronic Kidney Disease (CKD) have reported conflicting results. In this paper, we have provided an update on the evidence available on this topic. We have investigated the reasons why the effect has been inconsistent across studies. We have also compared the effect on GFR in various subgroups including type 1 diabetics, type 2 diabetics and non-diabetics.
   Method
   We searched for Randomized Controlled Trials on this intervention from MEDLINE, EMBASE, and other information sources. The PRISMA guidelines, as well as recommended meta-analysis practices were followed in the selection process, analysis and reporting of our findings. The effect estimate used was the change in mean GFR. Heterogeneity across the considered studies was explored using both subgroup analyses and meta-regression. Quality assessment was done using the Cochrane risk of bias tool and sensitivity analyses.
   Results
   15 randomized controlled trials, including 1965 subjects, were analyzed. The pooled effect size, as assessed using random-effects model, for all the 15 studies was -0.95 ml/min/1.73m(2)/year (95% CI: -1.79, -0.11), with a significant p value of 0.03. The combined effect estimate for the non-diabetic and type 1 diabetic studies was -1.50 ml/min/1.73m(2)/year (95% CI: -2.73, -0.26) with p value of 0.02. The effect estimate for the type 2 diabetic group was -0.17 ml/min/1.73m(2)/year (95% CI: -1.88, 1.55) with p value of 0.85. There was significant heterogeneity across the included studies (I-2 = 74%, p value for Q < 0.0001), explained by major variations in the percentage of type 2 diabetic subjects, the number of subjects and overall compliance level to diet prescribed.
   Conclusion
   Our findings suggest that protein diet restriction slows chronic renal disease progression in non-diabetic and in type 1 diabetic patients, but not in type 2 diabetic patients.
C1 [Rughooputh, Mahesh Shumsher; Zeng, Rui; Yao, Ying] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Nephrol, Wuhan 430074, Peoples R China.
   [Yao, Ying] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Clin Nutr, Wuhan 430074, Peoples R China.
RP Rughooputh, MS (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Nephrol, Wuhan 430074, Peoples R China.
EM mrughooputh@hotmail.com; zengrui@tjh.tjmu.edu.cn; yaoyingkk@126.com
FU National Natural Science Foundation of China [81170686]
FX This study was supported by the National Natural Science Foundation of
   China (81170686).
CR [Anonymous], 2014, EARL ID MAN CHRON KI
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BROUHARD BH, 1990, AM J MED, V89, P427, DOI 10.1016/0002-9343(90)90370-S
   Cianciaruso B, 2009, AM J KIDNEY DIS, V54, P1052, DOI 10.1053/j.ajkd.2009.07.021
   DAMICO G, 1994, NEPHROL DIAL TRANSPL, V9, P1590
   David Jr W, 2013, APPL LOGISTIC REGRES
   Disease Kidney, 2013, KIDNEY INT S, V3, P1, DOI DOI 10.1038/KISUP.2012.76.AVAILABLE
   DULLAART RPF, 1993, DIABETES CARE, V16, P483, DOI 10.2337/diacare.16.2.483
   Dussol B, 2005, J RENAL NUTR, V15, P398, DOI 10.1053/j,jrn.2005.07.003
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140
   Emrich IE, 2015, AM J KIDNEY DIS, V65, P636, DOI 10.1053/j.ajkd.2014.12.006
   FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q
   Fouque D, 2015, NEPHROL DIAL TRANSPL, V30, P6, DOI 10.1093/ndt/gfu340
   Gagnier Joel J., 2010, PRESENTATIO COCHRANE
   Greene T, 2014, AM J KIDNEY DIS, V64, P867, DOI 10.1053/j.ajkd.2014.08.019
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Hansen HP, 2002, KIDNEY INT, V62, P220, DOI 10.1046/j.1523-1755.2002.00421.x
   Higgins JPT, 2011, COCHRANE COLLABORATI
   IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601
   Jesudason DR, 2013, AM J CLIN NUTR, V98, P494, DOI 10.3945/ajcn.113.060889
   John Chambers M, 1983, GRAPHICAL METHODS DA, P194
   Kasiske BL, 1998, AM J KIDNEY DIS, V31, P954, DOI 10.1053/ajkd.1998.v31.pm9631839
   Klahr S, 2003, AM J KIDNEY DIS, V41, pS3, DOI 10.1053/ajkd.2003.50074
   KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301
   Koya D, 2009, DIABETOLOGIA, V52, P2037, DOI 10.1007/s00125-009-1467-8
   Larsen RN, 2011, DIABETOLOGIA, V54, P731, DOI 10.1007/s00125-010-2027-y
   Levey AS, 1999, J AM SOC NEPHROL, V10, P2426
   MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10
   Meloni C, 2004, J RENAL NUTR, V14, P208, DOI 10.1053/j.jm.2004.07.011
   Metafor-project. org, MET PACK MET PACK R
   Mircescu G, 2007, J RENAL NUTR, V17, P179, DOI [10.1053/j.jrn.2006.12.012, 10.1053/jrn.2006.12.012]
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Nezu U, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002934
   Pan Y, 2008, AM J CLIN NUTR, V88, P660
   Pedrini MT, 1996, ANN INTERN MED, V124, P627, DOI 10.7326/0003-4819-124-7-199604010-00002
   Pijls LTJ, 2002, EUR J CLIN NUTR, V56, P1200, DOI 10.1038/sj.ejcn.1601474
   Robertson L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002181.pub2
   ROSMAN JB, 1984, LANCET, V2, P1291
   Schulz KF, 2010, ANN INTERN MED, P152, DOI DOI 10.7326/0003-4819-152-11-201006010-00232.EPUB
   Schwingshackl L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097656
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1
   WILLIAMS PS, 1991, Q J MED, V81, P837
   ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202
NR 44
TC 12
Z9 13
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 28
PY 2015
VL 10
IS 12
AR e0145505
DI 10.1371/journal.pone.0145505
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CZ9XO
UT WOS:000367451400057
PM 26710078
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Dong, J
   Chen, Y
   Tang, YC
   Xu, F
   Yu, CH
   Li, YM
   Pankaj, P
   Dai, N
AF Dong, Jie
   Chen, Yi
   Tang, Yuchen
   Xu, Fei
   Yu, Chaohui
   Li, Youming
   Pankaj, Prasoon
   Dai, Ning
TI Body Mass Index Is Associated with Inflammatory Bowel Disease: A
   Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID COMPREHENSIVE NUTRITIONAL-STATUS; CROHNS-DISEASE; METABOLIC FEATURES;
   ULCERATIVE-COLITIS; ADIPOSE-TISSUE; OBESITY; RISK; POPULATION; CANCER;
   OSTEOPOROSIS
AB Background
   Prior work suggested that patients with inflammatory bowel diseases (IBD) have lower body mass index (BMI) than controls and patients with lower BMI have more serious complications.
   Goal
   The study was aimed to find relationship between BMI in patients with and without IBD, investigate effects of medicine therapy and disease stages on patients' BMI.
   Methods
   Potentially eligible studies were identified through searching PubMed, Cochrane and Embase databases. Outcome measurements of mean BMI and the number of patients from each study were pooled by a random-effect model. Publication bias test, sensitivity analysis and subgroup analysis were conducted.
   Results
   A total of 24 studies containing 1442 patients and 2059 controls were included. Main results were as follows: (1) BMI in Crohn's disease (CD) patients was lower than that in health controls (-1.88, 95% CI -2.77 to -1.00, P<0.001); (2) Medical therapy significantly improved BMI of CD patients (with therapy: -1.58, -3.33 to 0.16; without: -2.09, 95% CI -3.21 to -0.98) while on the contrary not significantly improving BMI of UC patients (with therapy: -0.24, 95% CI -3.68 to 3.20; without: -1.34, 95% CI -2.87 to 0.20, P = 0.57); (3) Both CD and UC patients in active phase showed significantly greater BMI difference compared with controls than those in remission (CD patients: remission: -2.25, 95% CI -3.38 to -1.11; active phase: -4.25, 95% CI -5.58 to -2.92, P = 0.03; UC patients: remission: 0.4, 95% CI -2.05 to 2.84; active phase: -5.38, -6.78 to -3.97, P = 0.001).
   Conclusions
   BMI is lower in CD patients; medical therapy couldn't improve BMI of IBD patients; the state of disease affects BMI of CD patients and UC patients.
C1 [Dong, Jie; Xu, Fei; Dai, Ning] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gastroenterol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Chen, Yi; Yu, Chaohui; Li, Youming] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Gastroenterol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Tang, Yuchen] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Endocrinol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Pankaj, Prasoon] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Hangzhou 310003, Zhejiang, Peoples R China.
RP Dai, N (reprint author), Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gastroenterol, Hangzhou 310003, Zhejiang, Peoples R China.
EM ningdai2008@126.com
OI Ma, Han/0000-0001-9985-3035
CR Ali T, 2009, AM J MED, V122, P599, DOI 10.1016/j.amjmed.2009.01.022
   Anandam A, 2013, SLEEP BREATH, V17, P227, DOI 10.1007/s11325-012-0677-3
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bryant RV, 2013, ALIMENT PHARM THER, V38, P213, DOI 10.1111/apt.12372
   Burnham JM, 2005, AM J CLIN NUTR, V82, P413
   Capristo E, 1998, J INTERN MED, V243, P339
   Capristo E, 1999, ALIMENT PHARM THERAP, V13, P209
   Capristo E, 1998, AM J GASTROENTEROL, V93, P2411, DOI 10.1016/S0002-9270(98)00577-2
   Chan SSM, 2013, AM J GASTROENTEROL, V108, P575, DOI 10.1038/ajg.2012.453
   Chen Y, 2013, CANCER EPIDEM BIOMAR, V22, P1395, DOI 10.1158/1055-9965.EPI-13-0042
   Choi Y, 2013, INT J CANCER, V132, P625, DOI 10.1002/ijc.27639
   Cravo M, 2010, INFLAMM BOWEL DIS, V16, P2117, DOI 10.1002/ibd.21297
   Cuoco L, 2008, INT J CARDIOL, V127, P219, DOI 10.1016/j.ijcard.2007.06.006
   Dai Z, 2007, WORLD J GASTROENTERO, V13, P4199, DOI 10.3748/wjg.v13.i31.4199
   Discacciati A, 2012, ANN ONCOL, V23, P1665, DOI 10.1093/annonc/mdr603
   Filippi J, 2006, INFLAMM BOWEL DIS, V12, P185, DOI 10.1097/01.MIB.0000206541.15963.c3
   Flores A, 2015, DIGEST DIS SCI, V60, P2436, DOI 10.1007/s10620-015-3629-5
   Geerling BJ, 1998, AM J CLIN NUTR, V67, P919
   Geerling BJ, 1999, EUR J CLIN NUTR, V53, P479, DOI 10.1038/sj.ejcn.1600780
   Geerling BJ, 2000, EUR J CLIN NUTR, V54, P514, DOI 10.1038/sj.ejcn.1601049
   Ghoshal Uday C, 2008, Trop Gastroenterol, V29, P95
   Greenfield JR, 2004, CIRCULATION, V109, P3022, DOI 10.1161/01.CIR.0000130640.77501.79
   Gustafson B, 2007, ARTERIOSCL THROM VAS, V27, P2276, DOI 10.1161/ATVBAHA.107.147835
   Harper JW, 2013, INFLAMM BOWEL DIS, V19, P2118, DOI 10.1097/MIB.0b013e31829cf401
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936
   Jahnsen J, 1997, GUT, V40, P313, DOI 10.1136/gut.40.3.313
   James SL, 2015, GUT, V64, P562, DOI 10.1136/gutjnl-2014-307198
   Jeong Seung Uk, 2012, Korean J Gastroenterol, V59, P27
   Jiang LY, 2012, JOINT BONE SPINE, V79, P291, DOI 10.1016/j.jbspin.2011.05.015
   Kanis JA, 2004, BONE, V35, P375, DOI 10.1016/j.bone.2004.03.024
   Kessler H, 2011, WORLD J GASTROENTERO, V17, P1116, DOI 10.3748/wjg.v17.i9.1116
   Lanham-New SA, 2008, P NUTR SOC, V67, P163, DOI 10.1017/S0029665108007003
   Lankarani KB, 2013, WORLD J GASTROENTERO, V19, P8571, DOI 10.3748/wjg.v19.i46.8571
   Long MD, 2011, INFLAMM BOWEL DIS, V17, P2162, DOI 10.1002/ibd.21585
   Mijac DD, 2010, EUR J INTERN MED, V21, P315, DOI 10.1016/j.ejim.2010.04.012
   Mingrone G, 1999, AM J CLIN NUTR, V69, P325
   Mingrone G, 1996, DIGEST DIS SCI, V41, P72, DOI 10.1007/BF02208586
   Mingrone G, 1998, AM J CLIN NUTR, V67, P118
   Mohamed-Hussein AAR, 2007, RESP MED, V101, P977, DOI 10.1016/j.rmed.2006.09.005
   Nic Suibhne T, 2012, J CROHNS COLITIS
   Peng LJ, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003619.pub3
   Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra020831
   Rui R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044522
   Sajjadi M, 2015, DIGEST DIS SCI, V60, P1755, DOI 10.1007/s10620-014-3510-y
   Sakellariou GT, 2006, JOINT BONE SPINE, V73, P725, DOI 10.1016/j.jbspin.2006.01.017
   Schneider SM, 2008, INFLAMM BOWEL DIS, V14, P1562, DOI 10.1002/ibd.20504
   Stabroth-Akil D, 2015, INT J COLORECTAL DIS, V30, P237, DOI 10.1007/s00384-014-2051-3
   Wells GA, 2000, NEWCASTLE OTTAWA SCA
   Wiroth JB, 2005, INFLAMM BOWEL DIS, V11, P296, DOI 10.1097/01.MIB.0000160810.76729.9c
   Ye LN, 2013, SCI WORLD J, DOI 10.1155/2013/296470
   Zoli G, 1996, DIGEST DIS SCI, V41, P1754, DOI 10.1007/BF02088741
NR 52
TC 16
Z9 16
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 14
PY 2015
VL 10
IS 12
AR e0144872
DI 10.1371/journal.pone.0144872
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CY9GR
UT WOS:000366715900128
PM 26658675
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Barone-Adesi, F
   Dent, JE
   Dajnak, D
   Beevers, S
   Anderson, HR
   Kelly, FJ
   Cook, DG
   Whincup, PH
AF Barone-Adesi, Francesco
   Dent, Jennifer E.
   Dajnak, David
   Beevers, Sean
   Anderson, H. Ross
   Kelly, Frank J.
   Cook, Derek G.
   Whincup, Peter H.
TI Long-Term Exposure to Primary Traffic Pollutants and Lung Function in
   Children: Cross-Sectional Study and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID AMBIENT AIR-POLLUTION; RESPIRATORY SYMPTOMS; PULMONARY-FUNCTION;
   SCHOOLCHILDREN; BIAS; ASSOCIATIONS; PUBLICATION; PREVALENCE; DISEASE;
   HEALTH
AB Background
   There is widespread concern about the possible health effects of traffic-related air pollution. Nitrogen dioxide (NO2) is a convenient marker of primary pollution. We investigated the associations between lung function and current residential exposure to a range of air pollutants (particularly NO2, NO, NOx and particulate matter) in London children. Moreover, we placed the results for NO2 in context with a meta-analysis of published estimates of the association.
   Methods and Findings
   Associations between primary traffic pollutants and lung function were investigated in 4884 children aged 9-10 years who participated in the Child Heart and Health Study in England (CHASE). A systematic literature search identified 13 studies eligible for inclusion in a meta-analysis. We combined results from the meta-analysis with the distribution of the values of FEV1 in CHASE to estimate the prevalence of children with abnormal lung function (FEV1<80% of predicted value) expected under different scenarios of NO2 exposure. In CHASE, there were non-significant inverse associations between all pollutants except ozone and both FEV1 and FVC. In the meta-analysis, a 10 mu g/m(3) increase in NO2 was associated with an 8 ml lower FEV1 (95% CI: -14 to -1 ml; p: 0.016). The observed effect was not modified by a reported asthma diagnosis. On the basis of these results, a 10 mu g/m(3) increase in NO2 level would translate into a 7% (95% CI: 4% to 12%) increase of the prevalence of children with abnormal lung function.
   Conclusions
   Exposure to traffic pollution may cause a small overall reduction in lung function and increase the prevalence of children with clinically relevant declines in lung function.
C1 [Barone-Adesi, Francesco; Dent, Jennifer E.; Anderson, H. Ross; Cook, Derek G.; Whincup, Peter H.] Univ London, Populat Hlth Res Inst, MRC PHE Ctr Environm & Hlth, London, England.
   [Dajnak, David; Beevers, Sean; Anderson, H. Ross; Kelly, Frank J.] Kings Coll London, MRC PHE Ctr Environm & Hlth, London WC2R 2LS, England.
RP Barone-Adesi, F (reprint author), Univ London, Populat Hlth Res Inst, MRC PHE Ctr Environm & Hlth, London, England.
EM fbarone@sgul.ac.uk
RI Cook, Derek/C-3271-2008; Kelly, Frank J/C-6125-2009
OI Kelly, Frank J/0000-0003-2558-8392
FU cross-Research Council Environmental Exposure and Health Initiative
   (EEHI) grant [NE/I008039/1]; Natural Environment Research Council
   (NERC); Medical Research Council (MRC); Department of Health (DoH);
   Wellcome Trust [068362/Z/02/Z]; Medical Research Council [MR/L01341X/1];
   Natural Environment Research Council [NE/I008039/1, NE/I007857/1]
FX The TRAFFIC study was supported by a cross-Research Council
   Environmental Exposure and Health Initiative (EEHI) grant (grant
   reference NE/I008039/1) with funds from the Natural Environment Research
   Council (NERC), the Medical Research Council (MRC), and the Department
   of Health (DoH). Data collection in the CHASE Study was supported by
   grant funding from the Wellcome Trust (grant reference 068362/Z/02/Z).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anderson HR, 2013, AIR QUAL ATMOS HLTH, V6, P47, DOI 10.1007/s11869-011-0144-5
   [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI DOI 10.1164/AJRCCM.152.3.7663792
   Beevers SD, 2013, J EXPO SCI ENV EPID, V23, P647, DOI 10.1038/jes.2013.6
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cook DG, 1998, THORAX, V53, P884, DOI 10.1136/thx.53.10.884
   Dales R, 2008, ENVIRON HEALTH PERSP, V116, P1423, DOI 10.1289/ehp.10943
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   European commission, 2014, SCOELSUM53 EUR COMM
   Favarato G, 2014, AIR QUAL ATMOS HLTH, V7, P459, DOI 10.1007/s11869-014-0265-8
   FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x
   Gehring U, 2013, ENVIRON HEALTH PERSP, V121, P1357, DOI 10.1289/ehp.1306770
   Gotschi T, 2008, EPIDEMIOLOGY, V19, P690, DOI 10.1097/EDE.0b013e318181650f
   HEI Panel on the Health Effects of Traffic-Related Air Pollution, 2010, 17 HEI PAN HLTH EFF
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holguin F, 2007, AM J RESP CRIT CARE, V176, P1236, DOI 10.1164/rccm.200611-1616OC
   Kelly FJ, 2011, CLIN EXP ALLERGY, V41, P1059, DOI 10.1111/j.1365-2222.2011.03776.x
   Kunzli N, 2000, EUR RESPIR J, V15, P131
   Lee YL, 2011, INT J HYG ENVIR HEAL, V214, P369, DOI 10.1016/j.ijheh.2011.05.004
   Morales E, 2015, THORAX, V70, P64, DOI 10.1136/thoraxjnl-2014-205413
   Noble M, 2007, ENGLISH INDICES DEPR
   Office for National Statistics, NAT STAT SOC CLASS N
   Oftedal B, 2008, EPIDEMIOLOGY, V19, P129, DOI 10.1097/EDE.0b013e31815c0827
   Peters JM, 1999, AM J RESP CRIT CARE, V159, P768, DOI 10.1164/ajrccm.159.3.9804144
   Pizzi C, 2011, J EPIDEMIOL COMMUN H, V65, P407, DOI 10.1136/jech.2009.107185
   ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32
   Rosenlund M, 2009, THORAX, V64, P573, DOI 10.1136/thx.2007.094953
   Sin DD, 2005, CHEST, V127, P1952, DOI 10.1378/chest.127.6.1952
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   Svendsen ER, 2012, AM J EPIDEMIOL, V176, pS131, DOI 10.1093/aje/kws274
   Thomas C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032619
   U.S. EPA, 2008, EPA600R08071
   Urman R, 2014, THORAX, V69, P540, DOI 10.1136/thoraxjnl-2012-203159
   Whincup PH, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000263
   WHO, 2013, REV EV HLTH ASP AIR
   World Health Organization, 2006, AIR QUAL GUID GLOB U
NR 36
TC 20
Z9 22
U1 1
U2 29
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 30
PY 2015
VL 10
IS 11
AR e0142565
DI 10.1371/journal.pone.0142565
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CX7NW
UT WOS:000365889800014
PM 26619227
OA DOAJ Gold, Green Accepted, Green Published
DA 2019-07-16
ER

PT J
AU Robles, MC
   Campoy, C
   Fernandez, LG
   Lopez-Pedrosa, JM
   Rueda, R
   Martin, MJ
AF Camprubi Robles, Maria
   Campoy, Cristina
   Garcia Fernandez, Llenalia
   Lopez-Pedrosa, Jose M.
   Rueda, Ricardo
   Martin, Maria J.
TI Maternal Diabetes and Cognitive Performance in the Offspring: A
   Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID AGE-CHILDREN BORN; SCHOOL-AGE; SOCIOECONOMIC-STATUS; RECOGNITION MEMORY;
   INFANTS; MELLITUS; MOTHERS; RISK; OBESITY; PREVALENCE
AB Objective
   Diabetes during gestation is one of the most common pregnancy complications associated with adverse health effects for the mother and the child. Maternal diabetes has been proposed to negatively affect the cognitive abilities of the child, but experimental research assessing its impact is conflicting. The main aim of our study was to compare the cognitive function in children of diabetic and healthy pregnant women.
   Methods
   A systematic review and meta-analysis was conducted through a literature search using different electronic databases from the index date to January 31, 2015. We included studies that assessed the cognitive abilities in children (up to 14 years) of diabetic and non-diabetic mothers using standardized and validated neuropsychological tests.
   Results
   Of 7,698 references reviewed, 12 studies involving 6,140 infants met our inclusion criteria and contributed to meta-analysis. A random effect model was used to compute the standardized mean differences and 95% confidence interval (CI) were calculated. Infants (1-2 years) of diabetic mothers had significantly lower scores of mental and psychomotor development compared to control infants. The effect size for mental development was -0.41 (95% CI -0.59, -0.24; p<0.0001) and for psychomotor development was -0.31 (95% CI -0.55, -0.07; p = 0.0125) with non-significant heterogeneity. Diabetes during pregnancy could be associated with decreased intelligence quotient scores in school-age children, although studies showed significant heterogeneity.
   Conclusion
   The association between maternal diabetes and deleterious effects on mental/psychomotor development and overall intellectual function in the offspring must be taken with caution. Results are based on observational cohorts and a direct causal influence of intrauterine hyperglycemia remains uncertain. Therefore, more trials that include larger populations are warranted to elucidate whether gestational diabetes mellitus (GDM) has a negative impact on offspring central nervous system (CNS).
C1 [Camprubi Robles, Maria; Lopez-Pedrosa, Jose M.; Rueda, Ricardo; Martin, Maria J.] Abbott Nutr Res & Dev, Granada, Spain.
   [Campoy, Cristina] Univ Granada, Sch Med, Dept Pediat, Granada, Spain.
   [Garcia Fernandez, Llenalia] SEPLIN Soluciones Estadist SL, Granada, Spain.
RP Martin, MJ (reprint author), Abbott Nutr Res & Dev, Granada, Spain.
EM maria.j.martin@abbott.com
RI Campoy, Cristina/F-4946-2017
OI Campoy, Cristina/0000-0002-9860-6785
CR Albrecht SS, 2010, DIABETES CARE, V33, P768, DOI 10.2337/dc09-1801
   Altman G, 1991, PRACTICAL STAT MED R
   Anderson JL, 2005, EPIDEMIOLOGY, V16, P87, DOI 10.1097/01.ede.0000147122.97061.bb
   [Anonymous], 2008, NICE CLIN GUID 63 DI
   Bayley N., 1969, BAYLEY SCALES INFANT
   Bayley N, 1993, MANUAL BAYLEY SCALES
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Borenstein M, 2009, INTRO METAANALYSIS F
   Bos AF, 2013, DEV MED CHILD NEUROL, V55, P978, DOI 10.1111/dmcn.12234
   Bradley RH, 2002, ANNU REV PSYCHOL, V53, P371, DOI 10.1146/annurev.psych.53.100901.135233
   Chu SY, 2007, DIABETES CARE, V30, P2070, DOI 10.2337/dc06-2559a
   Clausen TD, 2011, DIABETIC MED, V28, P838, DOI 10.1111/j.1464-5491.2011.03300.x
   Clausen TD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067107
   DeBoer T, 2005, DEV MED CHILD NEUROL, V47, P525, DOI 10.1017/S0012162205001039
   deReginer RA, 2000, J PEDIATR-US, V137, P777, DOI 10.1067/mpd.2000.109149
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dionne G, 2008, PEDIATRICS, V122, pE1073, DOI 10.1542/peds.2007-3028
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fraser A, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-014-0489-x
   Fraser A, 2012, EXP DIABETES RES, DOI 10.1155/2012/963735
   Georgieff Michael K, 2006, Minn Med, V89, P44
   Hami J, 2015, WORLD J DIABETES, V6, P412, DOI 10.4239/wjd.v6.i3.412
   Hedges L. V., 1985, STAT METHODS METAANA
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hod M, 1999, J PEDIATR ENDOCR MET, V12, P867
   IDF, 2013, IDF DIABETES ATLAS
   Knorr S, 2015, DIABETES CARE, V38, P1238, DOI 10.2337/dc15-0223
   Krakowiak P, 2012, PEDIATRICS, V129, pE1121, DOI 10.1542/peds.2011-2583
   Lawrence JM, 2008, DIABETES CARE, V31, P899, DOI 10.2337/dc07-2345
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Metzger BE, 2008, NEW ENGL J MED, V358, P1991, DOI 10.1056/NEJMoa0707943
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Nelson CA, 2000, BEHAV NEUROSCI, V114, P950, DOI 10.1037//0735-7044.114.5.950
   Nelson CA, 2003, J PEDIATR-US, V142, P575, DOI 10.1067/mpd.2003.210
   Nomura Y, 2012, ARCH PEDIAT ADOL MED, V166, P337, DOI 10.1001/archpediatrics.2011.784
   Ornoy A, 1998, ARCH DIS CHILD, V79, pF94, DOI 10.1136/fn.79.2.F94
   Ornoy A, 1999, ARCH DIS CHILD, V81, pF10, DOI 10.1136/fn.81.1.F10
   Ornoy A, 2001, J PEDIATR ENDOCR MET, V14, P681
   Perna R, 2015, APPL NEUROPSYCH-CHIL, V4, P217, DOI 10.1080/21622965.2013.874951
   Poolsup N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092485
   RIZZO T, 1991, NEW ENGL J MED, V325, P911, DOI 10.1056/NEJM199109263251303
   SELLS CJ, 1994, J PEDIATR-US, V125, pS9, DOI 10.1016/S0022-3476(94)70170-9
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Thorndike RL, 1986, GUIDE ADM SCORING ST
   Torres-Espinola FJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133010
   Townsend E. L., 2005, COGNITE CREIER COMPO, V9, P363
   Van Lieshout RJ, 2011, OBES REV, V12, pe548, DOI 10.1111/j.1467-789X.2010.00850.x
   Veena SR, 2010, DIABETOLOGIA, V53, P2134, DOI 10.1007/s00125-010-1847-0
   Wechsler D, 1989, MANUAL WECHSLER PRES
   Wechsler D., 1991, MANUAL WECHSLER INTE
   Wells GA, 2000, NEWCASTLE OTTAWA SCA
   Whitehead A., 2002, METAANALYSIS CONTROL
   Xiong X, 2001, INT J GYNECOL OBSTET, V75, P221, DOI 10.1016/S0020-7292(01)00496-9
   Yamashita Y, 1996, ACTA PAEDIATR, V85, P1192
NR 54
TC 26
Z9 26
U1 0
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 13
PY 2015
VL 10
IS 11
AR e0142583
DI 10.1371/journal.pone.0142583
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DA2MI
UT WOS:000367628500035
PM 26566144
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, F
   Wang, XW
   Wu, G
   Chen, L
   Hu, P
   Ren, H
   Hu, HD
AF Liu, Fen
   Wang, Xiwei
   Wu, Gang
   Chen, Ling
   Hu, Peng
   Ren, Hong
   Hu, Huaidong
TI Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GAMMA-GLUTAMYL-TRANSFERASE; LIVER FIBROSIS; HEPATOCELLULAR-CARCINOMA;
   CAFFEINE CONSUMPTION; ALCOHOL-CONSUMPTION; DRINKING; DIETARY;
   REPRODUCIBILITY; MECHANISMS; NAFLD
AB Background and Aim
   Previous studies have demonstrated that coffee consumption may be inversely correlated with hepatic fibrosis and cirrhosis. However, the reported results have been inconsistent. To summarize previous evidences quantitatively, a meta-analysis was performed.
   Methods
   The Medline, Web of Science, and Embase databases (from inception to June 2015) were searched to identify relevant trials that evaluated the effects of coffee consumption on hepatic fibrosis or cirrhosis. Odds ratios (ORs) of advanced hepatic fibrosis or cirrhosis for low or moderate, high, and any coffee consumption versus no consumption were pooled. Two cups per day was used as the cut-off level between low or moderate and high consumption.
   Results
   Sixteen studies were included, involving 3034 coffee consumers and 132076 people who do not consume coffee. The pooled results of the meta-analysis indicated that coffee consumers were less likely to develop cirrhosis compared with those who do not consume coffee, with a summary OR of 0.61 (95% CI: 0.45-0.84). For low or moderate coffee consumption versus no consumption, the pooled OR of hepatic cirrhosis was 0.66 (95% CI: 0.47-0.92). High coffee consumption could also significantly reduce the risk for hepatic cirrhosis when compared with no coffee consumption (OR = 0.53, 95% CI: 0.42-0.68). The effect of coffee consumption on hepatic fibrosis was summarized as well. The pooled OR of advanced hepatic fibrosis for coffee consumption versus no consumption was 0.73 (95% CI: 0.58-0.92). The protective effect of coffee on hepatic fibrosis and cirrhosis was also identified in subgroup meta-analyses of patients with alcoholic liver disease and chronic hepatitis C virus (HCV) infection.
   Conclusion
   Coffee consumption can significantly reduce the risk for hepatic fibrosis and cirrhosis.
C1 [Liu, Fen; Wang, Xiwei; Chen, Ling; Hu, Peng; Ren, Hong; Hu, Huaidong] Chongqing Med Univ, Dept Clin Nutr, Affiliated Hosp 2, Chongqing, Peoples R China.
   [Liu, Fen; Wang, Xiwei; Chen, Ling; Hu, Huaidong] Chongqing Med Univ, Key Lab Mol Biol Infect Dis, Affiliated Hosp 2, Dept Infect Dis,Inst Viral Hepatitis, Chongqing, Peoples R China.
   [Wu, Gang] Luzhou Med Coll, Dept Infect Dis, Affiliated Hosp, Luzhou, Peoples R China.
RP Hu, HD (reprint author), Chongqing Med Univ, Dept Clin Nutr, Affiliated Hosp 2, Chongqing, Peoples R China.
EM huaidong.hu@gmail.com
FU National Natural Science Foundation of China [81171560]; National Key
   Technology Support Program [2012BAI35B03]; "Par-Eu Scholars Program" of
   Chongqing city; National Science and Technology Major Project of China
   [2008ZX10002-006, 2012ZX10002007001, 2011ZX09302005, 2012ZX09303001-001,
   2012ZX10002003]; Key Project of Chongqing Science and Technology
   [cstc2012gg-yyjsB10007]; Chongqing Natural Science Commission Foundation
   [cstc2011jjA10025]; Medical Research Fund by Chongqing Municipal Health
   Bureau [2009-1-71]
FX Funding: Funding was provided by the National Natural Science Foundation
   of China (81171560), National Key Technology Support Program
   (2012BAI35B03), and the "Par-Eu Scholars Program" of Chongqing city.
   This study was also supported by the National Science and Technology
   Major Project of China (2008ZX10002-006, 2012ZX10002007001,
   2011ZX09302005, 2012ZX09303001-001, 2012ZX10002003), the Key Project of
   Chongqing Science and Technology (cstc2012gg-yyjsB10007), the Chongqing
   Natural Science Commission Foundation (cstc2011jjA10025), the Medical
   Research Fund by Chongqing Municipal Health Bureau (2009-1-71), and the
   "Par-Eu Scholars Program" of Chongqing city. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anty R, 2012, J HEPATOL, V57, P1090, DOI 10.1016/j.jhep.2012.07.014
   Bambha K, 2014, LIVER INT, V34, P1250, DOI 10.1111/liv.12379
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bravi F, 2007, HEPATOLOGY, V46, P430, DOI 10.1002/hep.21708
   Bravi F, 2013, CLIN GASTROENTEROL H, V11, P1413, DOI 10.1016/j.cgh.2013.04.039
   CASIGLIA E, 1993, EUR J EPIDEMIOL, V9, P293, DOI 10.1007/BF00146266
   Chu CM, 2006, SEMIN LIVER DIS, V26, P142, DOI 10.1055/s-2006-939752
   Corrao G, 2001, ANN EPIDEMIOL, V11, P458, DOI 10.1016/S1047-2797(01)00223-X
   CORRAO G, 1994, EUR J EPIDEMIOL, V10, P657, DOI 10.1007/BF01719277
   Costentin CE, 2011, J HEPATOL, V54, P1123, DOI 10.1016/j.jhep.2010.08.027
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dranoff JA, 2014, HEPATOLOGY, V60, P464, DOI 10.1002/hep.27032
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Serag H, 2014, GASTROENTEROLOGY, V146, pS129
   Esposito F, 2003, ALIMENT PHARM THERAP, V17, P595, DOI 10.1046/j.0269-2813.2003.01429.x
   Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gast.2004.09.014
   Freedman ND, 2009, HEPATOLOGY, V50, P1360, DOI 10.1002/hep.23162
   FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828
   GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807
   Gallus S, 2002, ANN EPIDEMIOL, V12, P202, DOI 10.1016/S1047-2797(01)00304-0
   HASEGAWA M, 1989, HEPATOLOGY, V10, P973, DOI 10.1002/hep.1840100614
   Hedges LV, 2001, PSYCHOL METHODS, V6, P203, DOI 10.1037/1082-989X.6.3.203
   Heidelbaugh JJ, 2006, AM FAM PHYSICIAN, V74, P756
   Higgins J, 2011, COCHRANE COLLABORATI, V5
   Honjo S, 2001, J CLIN EPIDEMIOL, V54, P823, DOI 10.1016/S0895-4356(01)00344-4
   Hu FB, 1999, AM J CLIN NUTR, V69, P243
   Hui Alex Y., 2003, Expert Reviews in Molecular Medicine, V5, P1, DOI 10.1017/S1462399403005684
   Imbert-Bismut F, 2001, LANCET, V357, P1069, DOI 10.1016/S0140-6736(00)04258-6
   Khalaf N, 2015, CLIN GASTROENTEROL H, V13, P1521, DOI 10.1016/j.cgh.2015.01.030
   Klatsky AL, 2006, ARCH INTERN MED, V166, P1190, DOI 10.1001/archinte.166.11.1190
   KONO S, 1994, AM J EPIDEMIOL, V139, P723, DOI 10.1093/oxfordjournals.aje.a117062
   Larsson SC, 2007, GASTROENTEROLOGY, V132, P1740, DOI 10.1053/j.gastro.2007.03.044
   Larter CZ, 2013, OBESITY, V21, P1189, DOI 10.1002/oby.20123
   Machado SR, 2014, BRAZ J INFECT DIS, V18, P170, DOI 10.1016/j.bjid.2013.09.001
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Modi AA, 2010, HEPATOLOGY, V51, P201, DOI 10.1002/hep.23279
   Moreno MG, 2011, HEPATOL INT, V5, P857, DOI 10.1007/s12072-010-9247-6
   Ong A, 2011, LIVER INT, V31, P1047, DOI 10.1111/j.1478-3231.2011.02555.x
   Ruhl CE, 2005, GASTROENTEROLOGY, V128, P24, DOI 10.1053/j.gastro.2004.09.075
   Shim SG, 2013, J GASTROEN HEPATOL, V28, P1877, DOI 10.1111/jgh.12317
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stroffolini T, 2010, LIVER INT, V30, P867, DOI 10.1111/j.1478-3231.2010.02261.x
   Tanaka K, 1998, INT J EPIDEMIOL, V27, P438, DOI 10.1093/ije/27.3.438
   TOKUNAGA S, 1994, ENVIRON HEALTH PERSP, V102, P5, DOI 10.1289/ehp.94102s85
   Triantos C, 2013, GASTROENTEROLOGY, V144, pS1008
   Vitaglione P, 2010, HEPATOLOGY, V52, P1652, DOI 10.1002/hep.23902
   Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346
   Walton HB, 2013, SCOT MED J, V58, P217, DOI 10.1177/0036933013507869
   Wang XW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100128
   White DL, 2011, DIGEST DIS SCI, V56, P1835, DOI 10.1007/s10620-010-1505-x
NR 50
TC 23
Z9 23
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 10
PY 2015
VL 10
IS 11
AR e0142457
DI 10.1371/journal.pone.0142457
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CV7CT
UT WOS:000364430700110
PM 26556483
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ni, HB
   Liu, HX
   Gao, R
AF Ni, Haibo
   Liu, Huixiang
   Gao, Rong
TI Serum Lipids and Breast Cancer Risk: A Meta-Analysis of Prospective
   Cohort Studies
SO PLOS ONE
LA English
DT Article
ID DENSITY-LIPOPROTEIN CHOLESTEROL; METABOLIC SYNDROME; TREND ESTIMATION;
   BLOOD-LIPIDS; DYSLIPIDEMIA; POPULATION; WEIGHT; LEVEL; WOMEN; SCALE
AB Purpose
   Epidemiologic studies exploring causal associations between serum lipids and breast cancer risk have reported contradictory results. We conducted a meta-analysis of prospective cohort studies to evaluate these associations.
   Methods
   Relevant studies were identified by searching PubMed and EMBASE through April 2015. We included prospective cohort studies that reported relative risk (RR) estimates with 95% confidence intervals (CIs) for the associations of specific lipid components (i.e., total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], and triglycerides [TG]) with breast cancer risk. Either a fixed-or a random-effects model was used to calculate pooled RRs.
   Results
   Fifteen prospective cohort studies involving 1,189,635 participants and 23,369 breast cancer cases were included in the meta-analysis. The pooled RRs of breast cancer for the highest versus lowest categories were 0.96 (95% CI: 0.86-1.07) for TC, 0.92 (95% CI: 0.73-1.16) for HDL-C, 0.90 (95% CI: 0.77-1.06) for LDL-C, and 0.93 (95% CI: 0.86-1.00) for TG. Notably, for HDL-C, a significant reduction of breast cancer risk was observed among postmenopausal women (RR = 0.77, 95% CI: 0.64-0.93) but not among premenopausal women. Similar trends of the associations were observed in the dose-response analysis.
   Conclusions
   Our findings suggest that serum levels of TG but not TC and LDL-C may be inversely associated with breast cancer risk. Serum HDL-C may also protect against breast carcinogenesis among postmenopausal women.
C1 [Ni, Haibo; Liu, Huixiang; Gao, Rong] First Peoples Hosp Zhangjiagang City, Dept Neurosurg, Suzhou, Jiangsu, Peoples R China.
RP Gao, R (reprint author), First Peoples Hosp Zhangjiagang City, Dept Neurosurg, Suzhou, Jiangsu, Peoples R China.
EM tsong@vip.sina.com
CR Abdelsalam KEA, 2012, J RES MED SCI, V17, P562
   Agnoli C, 2010, NUTR METAB CARDIOVAS, V20, P41, DOI 10.1016/j.numecd.2009.02.006
   Araujo F, 2014, EUR J PREV CARDIOL, V21, P1004, DOI 10.1177/2047487313497864
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116
   Bjorge T, 2010, CANCER EPIDEM BIOMAR, V19, P1737, DOI 10.1158/1055-9965.EPI-10-0230
   Borena W, 2011, CANCER CAUSE CONTROL, V22, P291, DOI 10.1007/s10552-010-9697-0
   Bosco JLF, 2012, BREAST CANCER RES TR, V134, P1247, DOI 10.1007/s10549-012-2131-4
   BOYD NF, 1991, FREE RADICAL BIO MED, V10, P185, DOI 10.1016/0891-5849(91)90074-D
   Capasso I, 2010, CANCER BIOL THER, V10, P1240, DOI 10.4161/cbt.10.12.13473
   Danilo C, 2012, CURR OPIN PHARMACOL, V12, P677, DOI 10.1016/j.coph.2012.07.009
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eliassen AH, 2008, ADV EXP MED BIOL, V630, P148
   Eliassen AH, 2005, ARCH INTERN MED, V165, P2264, DOI 10.1001/archinte.165.19.2264
   Esposito K, 2013, MENOPAUSE, V20, P1301, DOI [10.1097/gme.0b013e31828ce95d, 10.1097/GME.0b013e31828ce95d]
   Esteve E, 2005, CLIN NUTR, V24, P16, DOI 10.1016/j.clnu.2004.08.004
   Fagherazzi G, 2010, EUR J CANCER PREV, V19, P120, DOI 10.1097/CEJ.0b013e3283354918
   Furberg AS, 2004, J NATL CANCER I, V96, P1152, DOI 10.1093/jnci/djh216
   GAARD M, 1994, CANCER CAUSE CONTROL, V5, P501, DOI 10.1007/BF01831377
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Ha M, 2009, CANCER CAUSE CONTROL, V20, P1055, DOI 10.1007/s10552-009-9301-7
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   HIATT RA, 1982, J NATL CANCER I, V68, P885
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   His M, 2014, EUR J EPIDEMIOL, V29, P119, DOI 10.1007/s10654-014-9884-5
   Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014
   HOYER AP, 1992, CANCER CAUSE CONTROL, V3, P403, DOI 10.1007/BF00051352
   Inoue M, 2009, EUR J CANCER PREV, V18, P240, DOI 10.1097/CEJ.0b013e3283240460
   Iso H, 2009, INT J CANCER, V125, P2679, DOI 10.1002/ijc.24668
   Kabat GC, 2009, CANCER EPIDEM BIOMAR, V18, P2046, DOI 10.1158/1055-9965.EPI-09-0235
   Kelley GA, 2012, CLIN NUTR, V31, P156, DOI 10.1016/j.clnu.2011.11.011
   Kitahara CM, 2011, J CLIN ONCOL, V29, P1592, DOI 10.1200/JCO.2010.31.5200
   Kucharska-Newton AM, 2008, ANN EPIDEMIOL, V18, P671, DOI 10.1016/j.annepidem.2008.06.006
   Langsenlehner U, 2005, BREAST CANCER RES TR, V90, P113, DOI 10.1007/s10549-004-3607-7
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Mainous AG, 2005, AM J EPIDEMIOL, V161, P1115, DOI 10.1093/aje/kwi131
   Manjer J, 2001, EUR J CANCER PREV, V10, P281, DOI 10.1097/00008469-200106000-00013
   Manjer J, 2001, EUR J CANCER PREV, V10, P33, DOI 10.1097/00008469-200102000-00004
   Melvin JC, 2012, CANCER EPIDEM BIOMAR, V21, P1381, DOI 10.1158/1055-9965.EPI-12-0188
   Moorman PG, 1998, CANCER EPIDEM BIOMAR, V7, P483
   Nelson ER, 2014, TRENDS ENDOCRIN MET, V25, P649, DOI 10.1016/j.tem.2014.10.001
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Osaki Y, 2012, CANCER EPIDEMIOL, V36, P141, DOI 10.1016/j.canep.2011.03.007
   Ray G, 2001, CLIN BIOCHEM, V34, P71, DOI 10.1016/S0009-9120(00)00200-9
   Reeves KW, 2012, CANCER CAUSE CONTROL, V23, P1241, DOI 10.1007/s10552-012-0002-2
   Rossi RE, 2014, ANTICANCER RES, V34, P6861
   Sarrel PM, 1998, SEMIN REPROD ENDOCR, V16, P121, DOI 10.1055/s-2007-1016262
   Schernhammer ES, 2005, CANCER EPIDEM BIOMAR, V14, P699, DOI 10.1158/1055-9965.EPI-04-0561
   Smith DG, 2007, AM J MANAG CARE, V13, pS68
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Strohmaier S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054242
   TORNBERG SA, 1988, ACTA ONCOL, V27, P31
   Tulinius H, 1997, CANCER EPIDEM BIOMAR, V6, P863
   Undela K, 2012, BREAST CANCER RES TR, V135, P261, DOI 10.1007/s10549-012-2154-x
   VATTEN LJ, 1990, CANCER RES, V50, P2341
NR 55
TC 30
Z9 30
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 10
PY 2015
VL 10
IS 11
AR e0142669
DI 10.1371/journal.pone.0142669
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CV7CT
UT WOS:000364430700154
PM 26554382
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, JW
   Huang, Y
   Wang, XL
   Lin, K
   Wu, KS
AF Zhang, Jingwen
   Huang, Yue
   Wang, Xiaoling
   Lin, Kun
   Wu, Kusheng
TI Environmental Polychlorinated Biphenyl Exposure and Breast Cancer Risk:
   A Meta-Analysis of Observational Studies
SO PLOS ONE
LA English
DT Article
ID ADIPOSE-TISSUE CONCENTRATIONS; ORGANOCHLORINE PESTICIDES; SERUM
   ORGANOCHLORINES; AFRICAN-AMERICAN; TEMPORAL TRENDS; LONG-ISLAND;
   POLLUTANTS; PCBS; WOMEN; MILK
AB Background
   Association between polychlorinated biphenyl (PCB) exposure and breast cancer risk has been widely studied, but the results remain controversial. We performed a meta-analysis to evaluate the evidences from observational studies on PCB exposure and breast cancer risk.
   Methods
   Relevant studies with data on internal PCB dose were identified from PubMed, EMBASE, CBM and CNKI databases through November 2014. Multivariable-adjusted odds ratio (OR) with 95% confidence intervals (CIs) were applied to assess the association between PCB exposure and breast cancer risk. Heterogeneity test, sensitivity analysis, subgroup analysis and publication bias test were also performed. To further explore the association between specific groups of PCB congeners and breast cancer, we examined the PCB congeners classified, according to their structural, biological and pharmacokinetics properties, as group I (potentially estrogenic), group II (potentially anti-estrogenic and immunotoxic, dioxin-like), and group III (phenobarbital, CYP1A and CYP2B inducers, biologically persistent).
   Results
   Of 660 studies screened, 25 studies which met criteria were selected, involving a total of 12866 participants (6088 cases and 6778 controls) from eight countries. The results showed that the risk of breast cancer was associated with group II (OR = 1.23, 95% CI: 1.08-1.40) and group III (OR = 1.25, 95% CI: 1.09-1.43) PCBs, but not with group I (OR = 1.10, 95% CI: 0.97-1.24) PCBs or total PCB exposure (OR = 1.09, 95% CI: 0.97-1.22).
   Conclusions
   Our meta-analysis based on the selected studies found group II and group III PCB exposure might contribute to the risk of breast cancer. More studies in developing countries with higher PCB levels are needed, as well as studies to explore the relationships between mixtures of organochlorine compounds and breast cancer risk.
C1 [Zhang, Jingwen; Huang, Yue; Wang, Xiaoling; Lin, Kun; Wu, Kusheng] Shantou Univ, Dept Prevent Med, Coll Med, Shantou, Guangdong, Peoples R China.
RP Wu, KS (reprint author), Shantou Univ, Dept Prevent Med, Coll Med, Shantou, Guangdong, Peoples R China.
EM kswu@stu.edu.cn
RI Wu, Kusheng/O-5141-2019
OI Wu, Kusheng/0000-0001-5163-2524
FU National Natural Science Foundation of China [81470152]
FX Funding: This work was supported by the National Natural Science
   Foundation of China (no.: 81470152). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Annamalai J, 2015, ENVIRON INT, V76, P78, DOI 10.1016/j.envint.2014.12.006
   Aronson KJ, 2000, CANCER EPIDEM BIOMAR, V9, P55
   Aube M, 2011, ENVIRON RES, V111, P337, DOI 10.1016/j.envres.2011.01.010
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bonefeld-Jorgensen EC, 2001, TOXICOLOGY, V158, P141, DOI 10.1016/S0300-483X(00)00368-1
   Bonefeld-Jorgensen Eva C, 2006, Environ Health, V5, P12, DOI 10.1186/1476-069X-5-12
   Bonefeld-Jorgensen EC, 2014, BASIC CLIN PHARMACOL, V115, P118, DOI 10.1111/bcpt.12263
   Bonefeld-Jorgensen EC, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-88
   Brody JG, 2003, ENVIRON HEALTH PERSP, V111, P1007, DOI 10.1289/ehp.6310
   Brody JG, 2007, CANCER-AM CANCER SOC, V109, P2667, DOI 10.1002/cncr.22655
   Brouwer A, 1999, ENVIRON HEALTH PERSP, V107, P639, DOI 10.2307/3434557
   Charlier CJ, 2004, CLIN CHIM ACTA, V347, P177, DOI 10.1016/j.cccn.2004.04.025
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Cohn BA, 2012, BREAST CANCER RES TR, V136, P267, DOI 10.1007/s10549-012-2257-4
   Demers A, 2002, AM J EPIDEMIOL, V155, P629, DOI 10.1093/aje/155.7.629
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dorgan JF, 1999, CANCER CAUSE CONTROL, V10, P1, DOI 10.1023/A:1008824131727
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fang J, 2015, ENVIRON SCI POLLUT R, V22, P8989, DOI 10.1007/s11356-015-4080-z
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   FINKLEA J, 1972, AM J PUBLIC HEALTH N, V62, P645, DOI 10.2105/AJPH.62.5.645
   Fredslund SO, 2012, INT J CIRCUMPOL HEAL, V71, DOI 10.3402/ijch.v71i0.19155
   FURST P, 1994, ENVIRON HEALTH PERSP, V102, P187, DOI 10.1289/ehp.102-1566908
   Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P686
   Gatto NM, 2007, CANCER CAUSE CONTROL, V18, P29, DOI 10.1007/s10552-006-0070-2
   Ghisari M, 2014, ENVIRON HEALTH-GLOB, V13, DOI 10.1186/1476-069X-13-19
   Ghisari M, 2013, INT J CIRCUMPOL HEAL, V72, DOI 10.3402/ijch.v72i0.21113
   Helzlsouer KJ, 1999, CANCER EPIDEM BIOMAR, V8, P525
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hoyer AP, 1998, LANCET, V352, P1816, DOI 10.1016/S0140-6736(98)04504-8
   HSU ST, 1985, ENVIRON HEALTH PERSP, V59, P5, DOI 10.2307/3429867
   Itoh H, 2009, CANCER CAUSE CONTROL, V20, P567, DOI 10.1007/s10552-008-9265-z
   Konishi Y, 2015, ENV SCI POLLUT RES I
   KRIEGER N, 1994, JNCI-J NATL CANCER I, V86, P589, DOI 10.1093/jnci/86.8.589
   Kuratsune M, 1972, Environ Health Perspect, V1, P119, DOI 10.2307/3428163
   Laden F, 2001, INT J CANCER, V91, P568, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1081>3.0.CO;2-W
   Lauby-Secretan B, 2013, LANCET ONCOL, V14, P287, DOI 10.1016/S1470-2045(13)70104-9
   Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40
   Liljegren G, 1998, EUR J CANCER PREV, V7, P135
   Lopez-Carrillo L, 2002, EUR J CANCER PREV, V11, P129, DOI 10.1097/00008469-200204000-00004
   Malisch R, 2014, SCI TOTAL ENVIRON, V491, P2, DOI 10.1016/j.scitotenv.2014.03.022
   MARTUCCI CP, 1993, PHARMACOL THERAPEUT, V57, P237, DOI 10.1016/0163-7258(93)90057-K
   MCKINNEY JD, 1994, ENVIRON HEALTH PERSP, V102, P290, DOI 10.1289/ehp.94102290
   Millikan R, 2000, CANCER EPIDEM BIOMAR, V9, P1233
   Moysich KB, 1998, CANCER EPIDEM BIOMAR, V7, P181
   Muto T, 2002, TOXICOLOGY, V177, P197, DOI 10.1016/S0300-483X(02)00224-X
   NIP Korea DPR, 2008, DEM PEOPL REP KOR NA
   Olsen JH, 1997, APMIS, V105, P141
   Parkin DM, 2001, EUR J CANCER, V37, pS4
   Pavuk M, 2003, J EXPO ANAL ENV EPID, V13, P267, DOI 10.1038/sj.jea.7500277
   Pelekanou V, 2011, INT J DEV BIOL, V55, P869, DOI 10.1387/ijdb.113369vp
   Polder A, 2008, CHEMOSPHERE, V73, P14, DOI 10.1016/j.chemosphere.2008.06.002
   Raaschou-Nielsen O, 2005, CANCER EPIDEM BIOMAR, V14, P67
   Recio-Vega R, 2011, J APPL TOXICOL, V31, P270, DOI 10.1002/jat.1672
   Rogan WJ, 1996, ARCH PEDIAT ADOL MED, V150, P981, DOI 10.1001/archpedi.1996.02170340095018
   Rubin CH, 2006, INT J CIRCUMPOLAR HL, V65
   SAFE SH, 1994, CRIT REV TOXICOL, V24, P87, DOI 10.3109/10408449409049308
   Salehi F, 2008, J TOXICOL ENV HEAL B, V11, P276, DOI 10.1080/10937400701875923
   Shakeel MK, 2010, ASIAN PAC J CANCER P, V11, P173
   SOONTORNCHAT S, 1994, ENVIRON HEALTH PERSP, V102, P568, DOI 10.1289/ehp.94102568
   Stellman SD, 2000, CANCER EPIDEM BIOMAR, V9, P1241
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Ward EM, 2000, CANCER EPIDEM BIOMAR, V9, P1357
   Wells G, 2011, NEWCASTLE OTTAWA SCA
   Wolff MS, 2000, ENVIRON RES, V84, P151, DOI 10.1006/enrs.2000.4075
   Wolff MS, 2000, CANCER EPIDEM BIOMAR, V9, P271
   WOLFF MS, 1995, ENVIRON HEALTH PERSP, V103, P141, DOI 10.2307/3432524
   Wolff MS, 1997, ENVIRON HEALTH PERSP, V105, P13, DOI 10.2307/3433043
   Ye HZ, 2009, CASE CONTROL STUDY R
   Zani C, 2013, J ENVIRON SCI HEAL C, V31, P99, DOI 10.1080/10590501.2013.782174
   Zhang Hong, 2013, Wei Sheng Yan Jiu, V42, P44
   Zheng TZ, 2000, CANCER EPIDEM BIOMAR, V9, P167
NR 73
TC 11
Z9 13
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 10
PY 2015
VL 10
IS 11
AR e0142513
DI 10.1371/journal.pone.0142513
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CV7CT
UT WOS:000364430700120
PM 26555153
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chanson-Rolle, A
   Aubin, F
   Braesco, V
   Hamasaki, T
   Kitakaze, M
AF Chanson-Rolle, Aurelie
   Aubin, Francois
   Braesco, Veronique
   Hamasaki, Toshimitsu
   Kitakaze, Masafumi
TI Influence of the Lactotripeptides Isoleucine-Proline-Proline and
   Valine-Proline-Proline on Systolic Blood Pressure in Japanese Subjects:
   A Systematic Review and Meta-Analysis of Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID CASEIN HYDROLYSATE; SOUR MILK; ANTIHYPERTENSIVE PEPTIDES; INHIBITORS;
   BLIND
AB Background
   The lactotripeptides isoleucine-proline-proline (IPP) and valine-proline-proline (VPP)have been shown to decrease systolic blood pressure (SBP) in several populations, but the size of the effect varies among studies. We performed a meta-analysis including all published studies to evaluate the SBP-lowering effect of IPP/VPP in Japanese subjects more comprehensively.
   Methods and Findings
   Eligible randomized controlled trials were searched for within four bibliographic databases, including two Japanese ones. Eighteen studies (including a total of 1194 subjects) were included in the meta-analysis. A random effect model using the restricted maximum likelihood (REML) estimator was used for the analysis. The analysis showed that consumption of IPP/VPP induced a significant reduction in SBP as compared with placebo in Japanese subjects, with an estimated effect of -5.63 mm Hg (95% CI, -6.87 to -4.39, P<0.0001) and no evidence of publication bias. A significant heterogeneity between series was evident, which could be explained by a significant influence of the baseline blood pressure status of the subjects, the effect of IPP/VPP on SBP being stronger in hypertensive subjects (-8.35 mm Hg, P< 0.0001) than in non-hypertensive subjects (-3.42mm Hg, P<0.0001). Furthermore, the effect of IPP/VPP on SBP remained significant when limiting the analysis to series that tested the usual doses of IPP/VPP consumed daily (below 5 mg/d), with estimated effects of -6.01 mm Hg in the overall population and -3.32 mm Hg in non-hypertensive subjects.
   Conclusions Results from this meta-analysis show that IPP/VPP lactotripeptides can significantly reduce office SBP in Japanese subjects with or without overt hypertension, and for doses that can potentially be consumed as an everyday supplement. This suggests that these peptides could play a role in controlling blood pressure in Japanese subjects. The systematic review protocol was published on the PROSPERO register (CRD42014014322).
C1 [Chanson-Rolle, Aurelie; Braesco, Veronique] VAB Nutr, Clermont Ferrand, France.
   [Aubin, Francois] Venn Life Sci, Paris, France.
   [Hamasaki, Toshimitsu] Natl Cerebral & Cardiovasc Ctr, Dept Adv Med Technol, Osaka, Japan.
   [Kitakaze, Masafumi] Natl Cerebral & Cardiovasc Ctr, Dept Clin Med & Dev, Osaka, Japan.
RP Chanson-Rolle, A (reprint author), VAB Nutr, Clermont Ferrand, France.
EM aurelie.chanson-rolle@vab-nutrition.com
RI Hamasaki, Toshimitsu/N-3851-2015
OI Hamasaki, Toshimitsu/0000-0002-4928-1160
FU Calpis Co., Ltd., Japan; VAB-nutrition; Venn Life Sciences
FX This work was sponsored by Calpis Co., Ltd. (a subsidiary of Asahi Group
   Holdings, Ltd), 1110, 5-chome, Fuchinobe, Chuo-ku, Sagamihara-shi,
   Kanagawa 252-0206, Japan. The funder had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. ACR and VB are employed by VAB-nutrition. FA is employed by
   Venn Life Sciences. VAB-nutrition and Venn Life Sciences provided
   support in the form of salaries for authors ACR, VB and FA, but did not
   have any additional role in the study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. The
   specific roles of these authors are articulated in the 'author
   contributions' section.
CR Aihara K, 2005, J AM COLL NUTR, V24, P257, DOI 10.1080/07315724.2005.10719473
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Cicero AFG, 2011, J HUM HYPERTENS, V25, P425, DOI 10.1038/jhh.2010.85
   Cicero AFG, 2013, AM J HYPERTENS, V26, P442, DOI 10.1093/ajh/hps044
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Fekete AA, 2015, NUTRIENTS, V7, P659, DOI 10.3390/nu7010659
   He FJ, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004937
   Hirata H., 2002, J NEW REM CLIN, V51, P61
   Hirota T, 2011, HEART VESSELS, V26, P549, DOI 10.1007/s00380-010-0096-y
   Ishida Y., 2007, J PHARM THER, V35, P1249
   Ishida Y., 2006, JAPANESE PHARM THERA, V34, P1107
   Ishida Y, 2011, BIOSCI BIOTECH BIOCH, V75, P427, DOI 10.1271/bbb.100560
   Itakura H., 2001, J JPN SOC CLIN NUTR, V23, P26
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jurgens G, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004022.pub2, 10.4330/wjc.v6.i7.531, DOI 10.1002/14651858.CD004022.PUB2]
   Kajimoto O., 2001, Journal of Japanese Society of Nutrition and Food Science, V54, P347
   Kajimoto O., 2001, J NUTR FOOD, V4, P51
   Kajimoto O., 2002, J NUTR FOOD, V5, P55
   Kajimoto O, 2007, J NEW REM CLIN, V56, P129
   Kajimoto O., 2001, J NUTR FOOD, V4, P37
   Lawes CMM, 2003, J HYPERTENS, V21, P707, DOI 10.1097/01.hjh.0000052492.18130.07
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Mancia G, 2013, EUR HEART J, V34, P2159, DOI [10.1093/eurheartj/eht151, 10.1097/01.hjh.0000431740.32696.cc]
   Masuda O, 1996, J NUTR, V126, P3063
   Messerli FH, 2007, LANCET, V370, P591, DOI 10.1016/S0140-6736(07)61299-9
   Mizuno S, 2005, BRIT J NUTR, V94, P84, DOI 10.1079/BJN20051422
   Mizushima S, 2004, AM J HYPERTENS, V17, P701, DOI 10.1016/j.amjhyper.2004.03.674
   Murakami Y, 2008, HYPERTENSION, V51, P1483, DOI 10.1161/HYPERTENSIONAHA.107.102459
   Nakamura K, 2014, WORLD J CARDIOL, V6, P531, DOI 10.4330/wjc.v6.i7.531
   Nakamura T, 2011, ATHEROSCLEROSIS, V219, P298, DOI 10.1016/j.atherosclerosis.2011.06.007
   NAKAMURA Y, 1995, J DAIRY SCI, V78, P1253, DOI 10.3168/jds.S0022-0302(95)76745-5
   NAKAMURA Y, 1995, J DAIRY SCI, V78, P777, DOI 10.3168/jds.S0022-0302(95)76689-9
   Nakamura Y., 2004, J NUTR FOOD, V7, P123
   Pina AS, 2009, J MOL RECOGNIT, V22, P162, DOI 10.1002/jmr.905
   Pripp A. H., 2008, Food & Nutrition Research, V52, P1
   Sano J, 2005, J MED FOOD, V8, P423, DOI 10.1089/jmf.2005.8.423
   Sano J, 2004, J NUTR FOOD, V7, P17
   Sutton AJ, 2000, METHODS METAANALYSIS
   UESHIMA H, 1987, J HUM HYPERTENS, V1, P113
   Usinger L, 2010, CLIN PHYSIOL FUNCT I, V30, P162, DOI 10.1111/j.1475-097X.2009.00921.x
   van der Zander K, 2008, AM J CLIN NUTR, V88, P1697, DOI 10.3945/ajcn.2008.26003
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1
   Xu JY, 2008, NUTRITION, V24, P933, DOI 10.1016/j.nut.2008.04.004
   Yamaguchi N, 2009, EUR J PHARMACOL, V620, P71, DOI 10.1016/j.ejphar.2009.08.005
   Yoshizawa M, 2010, AM J HYPERTENS, V23, P368, DOI 10.1038/ajh.2009.270
NR 46
TC 4
Z9 4
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 4
PY 2015
VL 10
IS 11
AR e0142235
DI 10.1371/journal.pone.0142235
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CV5GZ
UT WOS:000364298400147
PM 26536628
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Mao, BJ
   Li, YF
   Zhang, ZM
   Chen, C
   Chen, YY
   Ding, CC
   Lei, L
   Li, J
   Jiang, M
   Wang, D
   Wang, G
AF Mao, Bijing
   Li, Yafei
   Zhang, Zhimin
   Chen, Chuan
   Chen, Yuanyuan
   Ding, Chenchen
   Lei, Lin
   Li, Jian
   Jiang, Mei
   Wang, Dong
   Wang, Ge
TI One-Carbon Metabolic Factors and Risk of Renal Cell Cancer: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID FOLATE INTAKE; PHYSICAL-ACTIVITY; VEGETABLE INTAKE; POOLED ANALYSIS;
   BREAST-CANCER; COLORECTAL-CANCER; TREND ESTIMATION; PROSTATE-CANCER;
   FRUIT; MICRONUTRIENTS
AB Background
   Nutrients related to one-carbon metabolism were previously shown to be significantly associated with the risk of cancer. The aim of this meta-analysis was to evaluate potential relationships between one-carbon metabolic factors and renal cell cancer (RCC) risk.
   Methods
   PubMed, EMBASE, and Cochrane Library databases were searched through March 2015 for observational studies of quantitative RCC risk estimates in relation to one-carbon metabolic factors. The relative risks (RRs) with 95% confidence intervals (CIs) measured the relationship between one-carbon metabolic factors and RCC risk using a random-effects model.
   Results
   Of the 463 citations and abstracts identified by database search, seven cohorts from five observational studies reported data on 133,995 individuals, and included 2,441 RCC cases. Comparing the highest with the lowest category, the pooled RRs of RCC were 0.72 (95% CI: 0.52-1.00; P = 0.048) for vitamin B-12. In addition, an increase in folic acid supplementation of 100 mu g/day was associated with a 3% lower risk of RCC (RR, 0.97; 95% CI: 0.93-1.00; P = 0.048). Similarly, an increase of 5 nmol/L of vitamin B-2 was associated with a reduced risk of RCC 0.94 (95% CI: 0.89-1.00; P = 0.045). Sensitivity analyses suggested that a higher serum vitamin B-6 might contribute to a reduced risk of RCC (RR, 0.83; 95% CI: 0.77-0.89; P < 0.001).
   Conclusions
   Higher levels of serum vitamin B-2, B-6, B-12, and folic acid supplementation lowered the risk of RCC among the study participants.
C1 [Mao, Bijing; Zhang, Zhimin; Chen, Chuan; Chen, Yuanyuan; Ding, Chenchen; Lei, Lin; Li, Jian; Jiang, Mei; Wang, Dong; Wang, Ge] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Ctr Canc, Chongqing 400042, Peoples R China.
   [Li, Yafei] Third Mil Med Univ, Coll Prevent Med, Dept Epidemiol, Chongqing 400038, Peoples R China.
RP Wang, G (reprint author), Third Mil Med Univ, Daping Hosp, Inst Surg Res, Ctr Canc, Chongqing 400042, Peoples R China.
EM wangge70@hotmail.com
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Aune D, 2011, GASTROENTEROLOGY, V141, P106, DOI 10.1053/j.gastro.2011.04.013
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bellocco R, 2012, ANN ONCOL, V23, P2235, DOI 10.1093/annonc/mds022
   Bertuccio P, 2013, ANN ONCOL, V24, P1450, DOI 10.1093/annonc/mdt108
   Bosetti C, 2007, INT J CANCER, V120, P892, DOI 10.1002/ijc.22374
   Brock KE, 2012, BRIT J NUTR, V108, P1077, DOI 10.1017/S0007114511006489
   Chen P, 2014, BRIT J CANCER, V110, P2327, DOI 10.1038/bjc.2014.155
   Cho E, 2013, CANCER CAUSE CONTROL, V24, P373, DOI 10.1007/s10552-012-0123-7
   Collin SM, 2010, CANCER EPIDEM BIOMAR, V19, P1632, DOI 10.1158/1055-9965.EPI-10-0180
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DeVita V, 2001, CANCER PRINCIPLES PR
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498
   Galeone C, 2015, INT J CANCER, V136, P904, DOI 10.1002/ijc.29044
   Gibson TM, 2010, CANCER CAUSE CONTROL, V21, P1061, DOI 10.1007/s10552-010-9534-5
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   He HD, 2014, INT J FOOD SCI NUTR, V65, P286, DOI 10.3109/09637486.2013.866641
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hu JY, 2015, ASIA PAC J CLIN NUTR, V24, P101, DOI 10.6133/apjcn.2015.24.1.22
   Johansson M, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju327
   Jung S, 2013, JNCI-J NATL CANCER I, V105, P219, DOI 10.1093/jnci/djs635
   Kim YI, 2007, MOL NUTR FOOD RES, V51, P267, DOI 10.1002/mnfr.200600191
   Larsson SC, 2006, GASTROENTEROLOGY, V131, P1271, DOI 10.1053/j.gastro.2006.08.010
   Lee JE, 2006, CANCER EPIDEM BIOMAR, V15, P2445, DOI 10.1158/1055-9965.EPI-06-0553
   Lee JE, 2009, CANCER EPIDEM BIOMAR, V18, P1730, DOI 10.1158/1055-9965.EPI-09-0045
   Lee JE, 2008, J NATL CANCER I, V100, P1695, DOI 10.1093/jnci/djn386
   Mahabir S, 2004, INT J CANCER, V108, P600, DOI 10.1002/ijc.11580
   Meng HZ, 2014, ASIA-PAC J CLIN ONCO, V10, P133, DOI 10.1111/ajco.12067
   Moore SC, 2008, AM J EPIDEMIOL, V168, P149, DOI 10.1093/aje/kwn102
   Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2
   Song DY, 2012, BRIT J CANCER, V106, P1881, DOI 10.1038/bjc.2012.136
   Tavani A, 2007, INT J CANCER, V120, P1977, DOI 10.1002/ijc.22438
   Tobias A., 1999, STATA TECHNICAL B, V8
   van Dijk BAC, 2008, CANCER CAUSE CONTROL, V19, P125, DOI 10.1007/s10552-007-9078-5
   Weikert S, 2006, INT J CANCER, V118, P3133, DOI 10.1002/ijc.21765
   Wells G., 2013, NEWCASTLE OTTAWA SCA
   Wu W, 2013, BRIT J CANCER, V109, P1926, DOI 10.1038/bjc.2013.438
   Zhang YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093465
NR 41
TC 4
Z9 5
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 29
PY 2015
VL 10
IS 10
AR e0141762
DI 10.1371/journal.pone.0141762
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CV0ED
UT WOS:000363920300080
PM 26513161
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Perinetti, G
   Primozic, J
   Franchi, L
   Contardo, L
AF Perinetti, Giuseppe
   Primozic, Jasmina
   Franchi, Lorenzo
   Contardo, Luca
TI Treatment Effects of Removable Functional Appliances in Pre-Pubertal and
   Pubertal Class II Patients: A Systematic Review and Meta-Analysis of
   Controlled Studies
SO PLOS ONE
LA English
DT Article
ID CERVICAL VERTEBRAL MATURATION; TWIN-BLOCK; ORTHODONTIC TREATMENT;
   MANDIBULAR CHANGES; HERBST APPLIANCES; SKELETAL; GROWTH; MALOCCLUSION;
   PUBLICATION; EFFICACY
AB Background
   Treatment effects of removable functional appliances in Class II malocclusion patients according to the pre-pubertal or pubertal growth phase has yet to be clarified.
   Objectives
   To assess and compare skeletal and dentoalveolar effects of removable functional appliances in Class II malocclusion treatment between pre-pubertal and pubertal patients.
   Search methods
   Literature survey using the Medline, SCOPUS, LILACS and SciELO databases, the Cochrane Library from inception to May 31, 2015. A manual search was also performed.
   Selection criteria
   Randomised (RCTs) or controlled clinical trials with a matched untreated control group. No restrictions were set regarding the type of removable appliance whenever used alone.
   Data collection and analysis
   For the meta-analysis, cephalometric parameters on the supplementary mandibular growth were the main outcomes, with other cephalometric parameters considered as secondary outcomes. Risk of bias in individual and across studies were evaluated along with sensitivity analysis for low quality studies. Mean differences and 95% confidence intervals for annualised changes were computed according to a random model. Differences between prepubertal and pubertal patients were assessed by subgroup analyses. GRADE assessment was performed for the main outcomes.
   Results
   Twelve articles (but only 3 RCTs) were included accounting for 8 pre-pubertal and 7 pubertal groups. Overall supplementary total mandibular length and mandibular ramus height were 0.95 mm (0.38, 1.51) and 0.00 mm (-0.52, 0.53) for pre-pubertal patients and 2.91 mm (2.04, 3.79) and 2.18 mm (1.51, 2.86) for pubertal patients, respectively. The subgroup difference was significant for both parameters (p<0.001). No maxillary growth restrain or increase in facial divergence was seen in either subgroup. The GRADE assessment was low for the pre-pubertal patients, and generally moderate for the pubertal patients.
   Conclusions
   Taking into account the limited quality and heterogeneity of the included studies, functional treatment by removable appliances may be effective in treating Class II malocclusion with clinically relevant skeletal effects if performed during the pubertal growth phase.
C1 [Perinetti, Giuseppe; Contardo, Luca] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy.
   [Primozic, Jasmina] Univ Ljubljana, Fac Med, Dept Orthodont & Jaw Orthopaed, Ljubljana, Slovenia.
   [Franchi, Lorenzo] Univ Florence, Dept Orthodont, Sch Dent, Florence, Italy.
   [Franchi, Lorenzo] Univ Michigan, Sch Dent, Dept Orthodont & Pediat Dent, Ann Arbor, MI 48109 USA.
RP Perinetti, G (reprint author), Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy.
EM G.Perinetti@fmc.units.it
RI Franchi, Lorenzo/B-2730-2009
OI FRANCHI, LORENZO/0000-0002-2072-460X; Perinetti,
   Giuseppe/0000-0002-7226-5134
CR Antonarakis GS, 2007, ANGLE ORTHOD, V77, P907, DOI 10.2319/061706-244
   Baccetti T, 2000, AM J ORTHOD DENTOFAC, V118, P159, DOI 10.1067/mod.2000.105571
   Baccetti T, 2005, SEMIN ORTHOD, V11, P119, DOI DOI 10.1053/J.S0D0.2005.04.005
   Baccetti Tiziano, 2010, Prog Orthod, V11, P145, DOI 10.1016/j.pio.2010.09.003
   Baysal A, 2014, EUR J ORTHODONT, V36, P164, DOI 10.1093/ejo/cjt013
   Baysal A, 2013, EUR J ORTHODONT, V35, P71, DOI 10.1093/ejo/cjq187
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Borenstein M., 2009, INTRO METAANALYSIS
   Centre for Reviews Dissemination, 2009, SYST REV CRDS GUID U
   Chen JY, 2002, AM J ORTHOD DENTOFAC, V122, P470, DOI 10.1067/mod.2002.126730
   Cozza P, 2006, AM J ORTHOD DENTOFAC, V129, DOI 10.1016/j.ajodo.2005.11.010
   [崔丽娟 Cui Li-juan], 2010, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V14, P1572
   de Almeida-Pedrin RR, 2007, AM J ORTHOD DENTOFAC, V132, P191, DOI 10.1016/j.ajodo.2005.07.030
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ehsani S, 2014, EUR J ORTHODONT, DOI [10.1093/ejo/cju030, DOI 10.1093/EJ0/CJU030]
   Faltin K, 2003, ANGLE ORTHOD, V73, P221
   FISHMAN LS, 1982, ANGLE ORTHOD, V52, P88
   Flores-Mir C, 2007, AM J ORTHOD DENTOFAC, V131, P707, DOI 10.1016/j.ajodo.2007.02.041
   Franchi L, 2000, AM J ORTHOD DENTOFAC, V118, P335, DOI 10.1067/mod.2000.107009
   Franchi L, 2006, ANGLE ORTHOD, V76, P950, DOI 10.2319/110205-385
   Gupta Shreya, 2015, Dental Press J. Orthod., V20, P68, DOI 10.1590/2176-9451.20.2.068-075.oar
   Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011
   Hagg U, 1982, AM J ORTHOD, V82, P309
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006
   Marsico E, 2011, AM J ORTHOD DENTOFAC, V139, P24, DOI 10.1016/j.ajodo.2010.04.028
   Martina R, 2013, ORTHOD CRANIOFAC RES, V16, P116, DOI 10.1111/ocr.12013
   Masoud M, 2008, AM J ORTHOD DENTOFAC, V134, P209, DOI 10.1016/j.ajodo.2006.09.063
   MCNAMARA JA, 1982, AM J ORTHOD DENTOFAC, V82, P288, DOI 10.1016/0002-9416(82)90463-8
   McNamara JA, 2001, ORTHODONTICS DENTOFA
   O'Brien K, 2003, AM J ORTHOD DENTOFAC, V124, P234, DOI 10.1016/S0889-5406(03)00352-4
   PANCHERZ H, 1984, AM J ORTHOD DENTOFAC, V85, P125, DOI 10.1016/0002-9416(84)90004-6
   Patil AS, 2012, J CELL PHYSIOL, V227, P1796, DOI 10.1002/jcp.22905
   Perillo L, 2013, PROG ORTHOD, V14, DOI 10.1186/2196-1042-14-18
   Perillo L, 2011, EUR J ORTHODONT, V33, P84, DOI 10.1093/ejo/cjq033
   Perinetti G, 2014, ORTHOD CRANIOFAC RES, V17, P270, DOI 10.1111/ocr.12052
   Perinetti G, 2015, ANGLE ORTHOD, V85, P480, DOI 10.2319/102813-790.1
   Perinetti G, 2014, ANGLE ORTHOD, V84, P951, DOI 10.2319/120913-906.1
   Proff P, 2007, ANN ANAT, V189, P269, DOI 10.1016/j.aanat.2006.09.006
   Quintao C, 2006, EUR J ORTHODONT, V28, P35, DOI 10.1093/ejo/cji067
   Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549
   Shrier I, 2007, AM J EPIDEMIOL, V166, P1203, DOI 10.1093/aje/kwm189
   Singh S, 2010, J CLIN PEDIATR DENT, V35, P233, DOI 10.17796/jcpd.35.2.9572h13218806871
   Stahl F, 2008, AM J ORTHOD DENTOFAC, V134, P125, DOI 10.1016/j.ajodo.2006.06.028
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   Thiruvenkatachari B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003452.pub3
   Tulloch JFC, 1997, AM J ORTHOD DENTOFAC, V111, P391, DOI 10.1016/S0889-5406(97)80021-2
NR 52
TC 26
Z9 27
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 28
PY 2015
VL 10
IS 10
AR e0141198
DI 10.1371/journal.pone.0141198
PG 35
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CV0DL
UT WOS:000363918100059
PM 26510187
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xu, C
   Tang, PJ
   Ding, C
   Li, C
   Chen, J
   Xu, ZL
   Mao, Y
   Wu, MY
   Zhao, J
AF Xu, Chun
   Tang, Peijun
   Ding, Cheng
   Li, Chang
   Chen, Jun
   Xu, Zhenlei
   Mao, Yi
   Wu, Meiying
   Zhao, Jun
TI Vitamin D Receptor Gene FOKI Polymorphism Contributes to Increasing the
   Risk of HIV-Negative Tuberculosis: Evidence from a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CHINESE-HAN POPULATION; PULMONARY TUBERCULOSIS; SUSCEPTIBILITY;
   ASSOCIATION; VARIANTS; INFECTION; DISEASE; AFRICA; REGION; INDIA
AB Background
   Vitamin D receptor (VDR) gene FokI polymorphism have been studied in relation to tuberculosis (TB) in many populations and provided inconsistent results. In this study, we carried out a meta-analysis to derive a more reliable assessment on FokI polymorphism and the risk of HIV-negative TB.
   Methods
   The Embase, PubMed, and Cochrane Library databases were used to undertake a comprehensive systematic literature review of all current published VDR gene FOKI association studies aimed at the risk of TB up to June 30, 2015. Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were used to measure the strength of the models.
   Results
   A total of 14 studies (1,668 cases and 1,893 controls) were retrieved in the meta-analysis. The pooled OR was 1.60 (95% = 1.28-1.97, P < 0.001; I-2 = 29.5%, and P = 0.141 for heterogeneity) in the best genetic model (recessive model: ff vs. fF + FF). In the subgroup analysis by ethnicities, a significantly increased risk was found in the Asian group (OR = 1.82, 95% CI = 1.42-2.33, P < 0.001; I-2 = 31.0%, and P = 0.150 for heterogeneity) in the recessive model. Similarly, significant associations were also found in the polymerase chain reaction-restriction fragment length polymorphism group, high-quality studies, and the population based or hospital based groups. Moderate heterogeneity was found in this study.
   Conclusion
   Our results suggested that VDR FokI polymorphism contributes to increasing the risk of TB in HIV-negative individuals, especially in the Asian region. Further studies on this topic in other races are expected to be conducted in future.
C1 [Xu, Chun; Ding, Cheng; Li, Chang; Chen, Jun; Xu, Zhenlei; Mao, Yi; Zhao, Jun] Soochow Univ, Hosp Affiliated 1, Dept Cardiothorac Surg, Suzhou, Jiangsu, Peoples R China.
   [Tang, Peijun; Wu, Meiying] Soochow Univ, Affiliated Infect Hosp, Dept TB, Suzhou, Jiangsu, Peoples R China.
RP Wu, MY (reprint author), Soochow Univ, Affiliated Infect Hosp, Dept TB, Suzhou, Jiangsu, Peoples R China.
EM wu_my@126.com; zhaojia0327@126.com
FU Special Project of Key Clinical Disease Diagnosis and Treatment
   Technology in Suzhou [LCZX201314]; Preventive Medicine Scientific
   Research in Jiangsu Province [Y2013023]
FX This research was supported by Special Project of Key Clinical Disease
   Diagnosis and Treatment Technology in Suzhou (Grant No: LCZX201314) and
   Preventive Medicine Scientific Research in Jiangsu Province (Grant No:
   Y2013023).
CR Alagarasu K, 2009, J CLIN IMMUNOL, V29, P196, DOI 10.1007/s10875-008-9234-z
   Ansari A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004778
   Babb C, 2007, TUBERCULOSIS, V87, P295, DOI 10.1016/j.tube.2007.03.001
   Banoei MM, 2010, INT J INFECT DIS, V14, pE84, DOI 10.1016/j.ijid.2009.05.001
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bornman L, 2004, J INFECT DIS, V190, P1631, DOI 10.1086/424462
   Chen C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083843
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Facchini L, 2015, J CHEMOTHERAPY, V27, P128, DOI 10.1179/1973947815Y.0000000043
   Gao L, 2010, INT J TUBERC LUNG D, V14, P15
   Garcia-Laorden MI, 2006, MOL IMMUNOL, V43, P2143, DOI 10.1016/j.molimm.2006.01.008
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   Liu W, 2004, INT J TUBERC LUNG D, V8, P428
   Lombard Z, 2006, HUM IMMUNOL, V67, P643, DOI 10.1016/j.humimm.2006.04.008
   Manolagas S, 1994, SEMINARS NEPHROLOGY
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Olesen R, 2007, GENES IMMUN, V8, P456, DOI 10.1038/sj.gene.6364410
   Pfeffer PE, 2012, THORAX, V67, P1018, DOI 10.1136/thoraxjnl-2012-202139
   Raghavan S, 2012, TUBERCULOSIS, V92, P18, DOI 10.1016/j.tube.2011.08.004
   Rashedi J, 2014, ADV PHARM BULL, V4, P607, DOI 10.5681/apb.2014.089
   Remus N, 2004, J INFECT DIS, V190, P580, DOI 10.1086/422534
   Roth DE, 2004, J INFECT DIS, V190, P920, DOI 10.1086/423212
   Salimi S, 2015, BIOMED REP, V3, P189, DOI 10.3892/br.2014.402
   Sato S, 2012, RESPIR INVESTIG, V50, P40, DOI 10.1016/j.resinv.2012.05.002
   Selvaraj P, 2008, J CLIN IMMUNOL, V28, P306, DOI 10.1007/s10875-007-9152-5
   Selvaraj P, 2009, J CLIN IMMUNOL, V29, P470, DOI 10.1007/s10875-009-9277-9
   Selvaraj P, 2006, JAIDS-J ACQ IMM DEF, V43, P497, DOI 10.1097/01.qai.0000233312.36226.76
   Sinaga BYM, 2014, ACTA MED INDONES, V46, P275
   Singh A, 2011, INT J TUBERC LUNG D, V15, P1468, DOI 10.5588/ijtld.11.0089
   Soborg C, 2007, MOL IMMUNOL, V44, P2213, DOI 10.1016/j.molimm.2006.11.002
   Sun YP, 2015, GENET MOL RES, V14, P6156, DOI 10.4238/2015.June.9.1
   Swaminathan S, 2000, INT J TUBERC LUNG D, V4, P839
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   WHO, 2014, GLOB TUB REP 2014 WH
   Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6
   Wu F, 2013, BIOMED RES INT, DOI 10.1155/2013/484535
   Ye X, 2013, EURASIP J WIREL COMM, V2013, P1, DOI DOI 10.1186/1687-1499-2013-282
   Zhang HQ, 2010, ARCH MED RES, V41, P46, DOI 10.1016/j.arcmed.2009.12.004
NR 41
TC 5
Z9 5
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 20
PY 2015
VL 10
IS 10
AR e0140634
DI 10.1371/journal.pone.0140634
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CT7XI
UT WOS:000363028100053
PM 26485279
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xie, DX
   Zeng, C
   Wang, YL
   Li, YS
   Wei, J
   Li, H
   Yang, T
   Yang, TB
   Lei, GH
AF Xie, Dong-xing
   Zeng, Chao
   Wang, Yi-lun
   Li, Yu-sheng
   Wei, Jie
   Li, Hui
   Yang, Tuo
   Yang, Tu-bao
   Lei, Guang-hua
TI A Single-Dose Intra-Articular Morphine plus Bupivacaine versus Morphine
   Alone following Knee Arthroscopy: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID LOCAL-ANESTHETICS; PAIN-CONTROL; POSTARTHROSCOPY ANALGESIA;
   ARTICULAR-CARTILAGE; SURGERY; PLACEBO; RELIEF; CHONDROTOXICITY;
   MANAGEMENT; INJECTION
AB Objectives
   The purpose of this study was to compare the efficacy and safety of a single-dose intra-articular morphine plus bupivacaine versus morphine alone in patients undergoing arthroscopic knee surgery.
   Methods
   Randomized controlled trials comparing a combination of morphine and bupivacaine with morphine alone injected intra-articularly in the management of pain after knee arthrocopic surgery were retrieved (up to August 10, 2014) from MEDLINE, the Cochrane Library and Embase databases. The weighted mean difference (WMD), relative risk (RR) and their corresponding 95% confidence intervals (CIs) were calculated using RevMan statistical software.
   Results
   Thirteen randomized controlled trials were included. Statistically significant differences were observed with regard to the VAS values during the immediate period (0-2h) (WMD -1.16; 95% CI -2.01 to -0.31; p = 0.007) and the time to first request for rescue analgesia (WMD = 2.05; 95% CI 0.19 to 3.92; p = 0.03). However, there was no significant difference in the VAS pain score during the early period (2-6h) (WMD -0.36; 95% CI -1.13 to 0.41; p = 0.35), the late period (6-48h) (WMD 0.11; 95% CI -0.40 to 0.63; p = 0.67), and the number of patients requiring supplementary analgesia (RR = 0.78; 95% CI 0.57 to 1.05; p = 0.10). In addition, systematic review showed that intra-articular morphine plus bupivacaine would not increase the incidence of adverse effects compared with morphine alone.
   Conclusion
   The present study suggested that the administration of single-dose intra-articular morphine plus bupivacaine provided better pain relief during the immediate period (0-2h), and lengthened the time interval before the first request for analgesic rescue without increasing the short-term side effects when compared with morphine alone.
C1 [Xie, Dong-xing; Zeng, Chao; Wang, Yi-lun; Li, Yu-sheng; Li, Hui; Yang, Tuo; Lei, Guang-hua] Cent S Univ, Xiangya Hosp, Dept Orthopaed, Changsha, Hunan, Peoples R China.
   [Wei, Jie; Yang, Tu-bao] Cent S Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China.
RP Lei, GH (reprint author), Cent S Univ, Xiangya Hosp, Dept Orthopaed, Changsha, Hunan, Peoples R China.
EM lgh9640@sina.cn
FU National Natural Science Foundation of China [81272034, 81472130]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81272034, 81472130).
CR Aasbo V, 1996, ACTA ANAESTH SCAND, V40, P585, DOI 10.1111/j.1399-6576.1996.tb04492.x
   Alagol A, 2005, KNEE SURG SPORT TR A, V13, P658, DOI 10.1007/s00167-004-0612-7
   ALLEN GC, 1993, ANESTHESIOLOGY, V79, P475, DOI 10.1097/00000542-199309000-00010
   Anz A, 2009, ARTHROSCOPY, V25, P225, DOI 10.1016/j.arthro.2008.12.003
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BJORNSSON A, 1994, REGION ANESTH, V19, P104
   Breu A, 2013, ANESTH ANALG, V117, P514, DOI 10.1213/ANE.0b013e31829481ed
   Calmet J, 2004, KNEE SURG SPORT TR A, V12, P552, DOI 10.1007/s00167-003-0483-3
   Chan S. T., 1995, Singapore Medical Journal, V36, P35
   Chirwa SS, 1998, ARTHROSCOPY, V5, P33
   Chu CR, 2010, J BONE JOINT SURG AM, V92A, P599, DOI 10.2106/JBJS.I.00425
   De Andres J, 1998, EUR J ANAESTH, V15, P10, DOI 10.1097/00003643-199801000-00003
   Denti M, 1997, Knee Surg Sports Traumatol Arthrosc, V5, P206, DOI 10.1007/s001670050051
   Dragoo JL, 2008, AM J SPORT MED, V36, P1484, DOI 10.1177/0363546508318190
   Dragoo JL, 2012, AM J SPORT MED, V40, P794, DOI 10.1177/0363546511434571
   Dragoo JL, 2010, AM J SPORT MED, V38, P1154, DOI 10.1177/0363546509359680
   Drosos Gl, 2000, KNEE, V9, P335
   Eroglu A, 2010, KNEE SURG SPORT TR A, V18, P1487, DOI 10.1007/s00167-010-1061-0
   Foley NC, 2006, PHYS THER, V86, P817
   Goodwin RC, 2005, ARTHROSCOPY, V21, P307, DOI 10.1016/j.arthro.2004.11.015
   HENDERSON RC, 1990, AM J SPORT MED, V18, P614, DOI 10.1177/036354659001800610
   Hosseini H, 2012, KNEE SURG SPORT TR A, V20, P1839, DOI 10.1007/s00167-011-1791-7
   Ickert I, 2015, KNEE SURG SPORT TR A, V23, P2674, DOI 10.1007/s00167-014-2989-2
   JOSHI GP, 1993, ANESTH ANALG, V76, P333
   KAEDING C C, 1990, Arthroscopy, V6, P33, DOI 10.1016/0749-8063(90)90094-T
   Kalso E, 1997, PAIN, V71, P127, DOI 10.1016/S0304-3959(97)03344-7
   Kalso E, 2002, PAIN, V98, P269, DOI 10.1016/S0304-3959(02)00019-2
   Karlsson J, 1995, Knee Surg Sports Traumatol Arthrosc, V3, P55, DOI 10.1007/BF01553527
   KATZ JA, 1988, ANESTH ANALG, V67, P872
   KHOURY GF, 1992, ANESTHESIOLOGY, V77, P263, DOI 10.1097/00000542-199208000-00007
   MCSWINEY MM, 1993, ANAESTH INTENS CARE, V21, P201, DOI 10.1177/0310057X9302100212
   Piper SL, 2011, AM J SPORT MED, V39, P2245, DOI 10.1177/0363546511402780
   Reuben SS, 2000, J BONE JOINT SURG AM, V82A, P1754, DOI 10.2106/00004623-200012000-00010
   Reuben SS, 1998, ANESTH ANALG, V86, P374, DOI 10.1097/00000539-199802000-00029
   Rosseland LA, 2003, ACTA ANAESTH SCAND, V47, P732, DOI 10.1034/j.1399-6576.2003.00155.x
   RUWE PA, 1995, AM J SPORT MED, V23, P59, DOI 10.1177/036354659502300110
   Solheim N, 2006, REGION ANESTH PAIN M, V31, P506, DOI 10.1016/j.rapm.2006.06.206
   STEIN C, 1991, NEW ENGL J MED, V325, P1123, DOI 10.1056/NEJM199110173251602
   STPIERRE DMM, 1995, SPORTS MED, V20, P338, DOI 10.2165/00007256-199520050-00005
   STUBHAUG A, 1995, BAILLIERE CLIN ANAES, V9, P555, DOI 10.1016/S0950-3501(95)80022-0
   Tetzlaff JE, 1999, REGION ANESTH PAIN M, V24, P220, DOI 10.1016/S1098-7339(99)90131-1
   Wang YL, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006815
   Wei J, 2014, KNEE SURG SPORT TR A, V22, P1517, DOI 10.1007/s00167-013-2543-7
   Yang Y., 2015, KNEE SURG SPORTS TRA
   Zeng C, 2013, ARTHROSCOPY, V29, P1450, DOI 10.1016/j.arthro.2013.04.005
NR 45
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2015
VL 10
IS 10
AR e0140512
DI 10.1371/journal.pone.0140512
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CU0DF
UT WOS:000363185500062
PM 26474401
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zeng, YH
   Zhang, YJ
   Ma, JP
   Xu, JG
AF Zeng, Yunhui
   Zhang, Yujie
   Ma, Junpeng
   Xu, Jianguo
TI Progesterone for Acute Traumatic Brain Injury: A Systematic Review of
   Randomized Controlled Trials
SO PLOS ONE
LA English
DT Review
ID CLINICAL-TRIAL; NEUROPROTECTION; BIAS
AB Objective
   To evaluate the efficacy and safety of progesterone administrated in patients with acute traumatic brain injury (TBI).
   Methods
   PubMed/MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials (CENTRAL), Clinicaltrials.gov, ISRCTN registry and WHO International Clinical Trials Registry Platform (ICTRP) were searched for randomized controlled trials (RCTs) comparing progesterone and placebo administrated in acute TBI patients. The primary outcome was mortality and the secondary outcomes were unfavorable outcomes and adverse events. A meta-analysis was conducted to evaluate the efficacy and safety of progesterone administrated in patients with acute TBI.
   Results
   A total of 6 studies met inclusion criteria, involving 2,476 patients. The risk of bias was considered to be low in 4 studies but high in the other 2 studies. The results of meta-analysis indicated progesterone did not reduce the mortality (RR = 0.83, 95% CI = 0.57-1.20) or unfavorable outcomes (RR = 0.89, 95% CI = 0.78-1.02) of acute TBI patients in comparison with placebo. Sensitivity analysis yielded consistent results. Progesterone was basically safe and well tolerated in TBI patients with the exception of increased risk of phlebitis or thrombophlebitis (RR = 3.03, 95% CI = 1.96-4.66).
   Conclusions
   Despite some modest bias, present evidence demonstrated that progesterone was well tolerated but did not reduce the mortality or unfavorable outcomes of adult patients with acute TBI.
C1 [Zeng, Yunhui; Ma, Junpeng; Xu, Jianguo] Sichuan Univ, West China Med Sch, West China Hosp, Dept Neurosurg, Chengdu 610064, Sichuan, Peoples R China.
   [Zhang, Yujie] Sichuan Univ, West China Med Sch, West China Hosp, Integrated Unit 2, Chengdu 610064, Sichuan, Peoples R China.
RP Xu, JG (reprint author), Sichuan Univ, West China Med Sch, West China Hosp, Dept Neurosurg, Chengdu 610064, Sichuan, Peoples R China.
EM jgx_2015@163.com
CR Abokhabar H, 2012, INTENS CARE MED, V38, pS14
   Aminmansour Bahram, 2012, Adv Biomed Res, V1, P58, DOI 10.4103/2277-9175.100176
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023
   Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017
   Centers for Disease Control and Prevention, TRAUMATIC BRAIN INJU
   Chase Alex, 2015, Nat Rev Neurol, V11, P65, DOI 10.1038/nrneurol.2014.258
   Deutsch ER, 2013, BRAIN RES, V1530, P82, DOI 10.1016/j.brainres.2013.07.014
   Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019
   EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183
   Higgins JP, COCHRANE HDB SYSTEMA
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   James ML, 2015, STROKE, V46
   Kim J, 2013, NEUROBIOL DIS, V59, P80, DOI 10.1016/j.nbd.2013.07.011
   Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001
   Ma JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008409.pub3
   Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9
   Peterson TC, 2015, J NEUROTRAUM, V32, P765, DOI 10.1089/neu.2014.3530
   Reddy DS, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00115
   Robertson CL, 2015, PEDIATR CRIT CARE ME, V16, P236, DOI 10.1097/PCC.0000000000000323
   Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22
   Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2
   Samson N, 2013, NEUROSURGERY, V60, P175, DOI 10.1227/01.neu.0000432756.38655.f1
   Schwamm LH, 2014, NEW ENGL J MED, V371, P2522, DOI 10.1056/NEJMe1412951
   Shakeri M, 2013, CLIN NEUROL NEUROSUR, V115, P2019, DOI 10.1016/j.clineuro.2013.06.013
   Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090
   Slomski A, 2015, JAMA-J AM MED ASSOC, V313, P786
   Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549
   Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206
   Tang H, 2014, J NEUROTRAUM, V31, pA76
   Uysal N, 2013, TURK NEUROSURG, V23, P129, DOI 10.5137/1019-5149.JTN.5582-11.1
   VanLandingham JW, 2008, J CEREBR BLOOD F MET, V28, P1786, DOI 10.1038/jcbfm.2008.73
   Vanlandingham JW, 2009, FASEB J, V23
   Wang M, 2015, NEUROSURGERY, V76, pN12, DOI 10.1227/01.neu.0000462693.00394.d5
   Won S, 2013, STROKE, V44
   Wright DW, 2008, BRAIN INJURY, V22, P107, DOI 10.1080/02699050701867399
   Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932
   Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304
   Xiao Guo-min, 2007, Zhonghua Wai Ke Za Zhi, V45, P106
   Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887
   Yan F, 2013, NEUROSCI LETT, V543, P163, DOI 10.1016/j.neulet.2013.03.005
   Yousuf S, 2013, STROKE, V44
NR 44
TC 11
Z9 12
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2015
VL 10
IS 10
AR e0140624
DI 10.1371/journal.pone.0140624
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CU0DF
UT WOS:000363185500074
PM 26473361
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Muller-Stich, BP
   Kenngott, HG
   Gondan, M
   Stock, C
   Linke, GR
   Fritz, F
   Nickel, F
   Diener, MK
   Gutt, CN
   Wente, M
   Buchler, MW
   Fischer, L
AF Mueller-Stich, Beat P.
   Kenngott, Hannes G.
   Gondan, Matthias
   Stock, Christian
   Linke, Georg R.
   Fritz, Franziska
   Nickel, Felix
   Diener, Markus K.
   Gutt, Carsten N.
   Wente, Moritz
   Buechler, Markus W.
   Fischer, Lars
TI Use of Mesh in Laparoscopic Paraesophageal Hernia Repair: A
   Meta-Analysis and Risk-Benefit Analysis
SO PLOS ONE
LA English
DT Article
ID LIFE-THREATENING COMPLICATION; OBJECTIVE FOLLOW-UP; III HIATAL-HERNIA;
   BIOLOGIC PROSTHESIS; CARDIAC-TAMPONADE; RECURRENCE; QUALITY;
   IMPLANTATION; MULTICENTER
AB Introduction
   Mesh augmentation seems to reduce recurrences following laparoscopic paraesophageal hernia repair (LPHR). However, there is an uncertain risk of mesh-associated complications. Risk-benefit analysis might solve the dilemma.
   Materials and Methods A systematic literature search was performed to identify randomized controlled trials (RCTs) and observational clinical studies (OCSs) comparing laparoscopic mesh-augmented hiatoplasty (LMAH) with laparoscopic mesh-free hiatoplasty (LH) with regard to recurrences and complications. Random effects meta-analyses were performed to determine potential benefits of LMAH. All data regarding LMAH were used to estimate risk of mesh-associated complications. Risk-benefit analysis was performed using a Markov Monte Carlo decision-analytic model.
   Results
   Meta-analysis of 3 RCTs and 9 OCSs including 915 patients revealed a significantly lower recurrence rate for LMAH compared to LH (pooled proportions, 12.1% vs. 20.5%; odds ratio (OR), 0.55; 95% confidence interval (CI), 0.34 to 0.89; p = 0.04). Complication rates were comparable in both groups (pooled proportions, 15.3% vs. 14.2%; OR, 1.02; 95% CI, 0.63 to 1.65; p = 0.94). The systematic review of LMAH data yielded a mesh-associated complication rate of 1.9% (41/2121; 95% CI, 1.3% to 2.5%) for those series reporting at least one mesh-associated complication. The Markov Monte Carlo decision-analytic model revealed a procedure-related mortality rate of 1.6% for LMAH and 1.8% for LH.
   Conclusions
   Mesh application should be considered for LPHR because it reduces recurrences at least in the mid-term. Overall procedure-related complications and mortality seem to not be increased despite of potential mesh-associated complications.
C1 [Mueller-Stich, Beat P.; Kenngott, Hannes G.; Linke, Georg R.; Fritz, Franziska; Nickel, Felix; Diener, Markus K.; Wente, Moritz; Buechler, Markus W.; Fischer, Lars] Heidelberg Univ, Dept Gen Visceral & Transplant Surg, D-69120 Heidelberg, Germany.
   [Gondan, Matthias] Univ Copenhagen, Dept Psychol, DK-1315 Copenhagen K, Denmark.
   [Stock, Christian] Heidelberg Univ, Inst Med Biometry & Informat, D-69120 Heidelberg, Germany.
   [Diener, Markus K.] Heidelberg Univ, Study Ctr German Surg Soc, D-69120 Heidelberg, Germany.
   [Gutt, Carsten N.] Klinikum Memmingen, Gen Visceral Thorac & Vasc Surg, D-87700 Memmingen, Germany.
RP Muller-Stich, BP (reprint author), Heidelberg Univ, Dept Gen Visceral & Transplant Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
EM Beat.Mueller@med.uni-heidelberg.de
RI Nickel, Felix/I-3430-2019; Stock, Christian/F-6180-2015
OI Nickel, Felix/0000-0001-6066-8238; Stock, Christian/0000-0002-3493-3234
CR Antoniou SA, 2012, LANGENBECK ARCH SURG, V397, P19, DOI 10.1007/s00423-011-0829-0
   BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bundesamt D-S, 2011, AKTUELLE STERBETAFEL
   CLAVIEN PA, 1992, SURGERY, V111, P518
   Dallemagne B, 2011, ANN SURG, V253, P291, DOI 10.1097/SLA.0b013e3181ff44c0
   Dally E, 2004, AM J SURG, V187, P226, DOI 10.1016/j.amjsurg.2003.11.028
   De Moor V, 2012, SURG LAPARO ENDO PER, V22, pE222, DOI 10.1097/SLE.0b013e318253e440
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Frantzides CT, 2012, SURGERY, V152, P133, DOI 10.1016/j.surg.2011.08.009
   Frantzides CT, 2010, SURG ENDOSC, V24, P1017, DOI 10.1007/s00464-009-0718-6
   Frantzides CT, 2002, ARCH SURG-CHICAGO, V137, P649, DOI 10.1001/archsurg.137.6.649
   FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202
   Furnee E, 2013, SURG ENDOSC, V27, P3998, DOI 10.1007/s00464-013-3036-y
   Halpern EF, 2000, MED DECIS MAKING, V20, P314, DOI 10.1177/0272989X0002000308
   Harrell AG, 2007, SURG ENDOSC, V21, P1170, DOI 10.1007/s00464-006-9147-y
   Hashemi M, 2000, J AM COLL SURGEONS, V190, P553, DOI 10.1016/S1072-7515(00)00260-X
   Haynes RB, 2005, BMJ-BRIT MED J, V330, P1179, DOI 10.1136/bmj.38446.498542.8F
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   KAPLAN RM, 1976, HEALTH SERV RES, V11, P478
   Kemppainen E, 2000, Surg Endosc, V14, P593
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Muller-Stich BP, 2009, AM J SURG, V198, P17, DOI 10.1016/j.amjsurg.2008.07.050
   Muller-Stich BP, 2009, SURG ENDOSC, V23, P1372, DOI 10.1007/s00464-008-0185-5
   Muller-Stich BP, 2006, AM J SURG, V191, P139, DOI 10.1016/j.amjsurg.2005.08.006
   Nason KS, 2008, J GASTROINTEST SURG, V12, P2066, DOI 10.1007/s11605-008-0712-7
   Novitsky YW, 2007, J SURG RES, V140, P6, DOI 10.1016/j.jss.2006.09.015
   Obeid NM, 2013, ANN SURG, V257, P655, DOI 10.1097/SLA.0b013e3182822c8c
   Oelschlager BK, 2006, ANN SURG, V244, P481, DOI 10.1097/01.sla.0000237759.42831.03
   Oelschlager BK, 2011, J AM COLL SURGEONS, V213, P461, DOI 10.1016/j.jamcollsurg.2011.05.017
   Otto J, 2009, BMC SURG, V9, DOI 10.1186/1471-2482-9-5
   Parker M, 2010, SURG ENDOSC, V24, P3095, DOI 10.1007/s00464-010-1095-x
   Puri V, 2004, Hernia, V8, P311, DOI 10.1007/s10029-004-0255-0
   Schwarzer G, 2010, META ANALYSIS WITH R
   Schwarzer G, 2013, METAANALYSIS R R PAC
   Senft J, 2014, J LAPAROENDOSC ADV S, V24, P383, DOI 10.1089/lap.2013.0588
   SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409
   Stadlhuber RJ, 2009, SURG ENDOSC, V23, P1219, DOI 10.1007/s00464-008-0205-5
   Stylopoulos N, 2002, ANN SURG, V236, P492, DOI 10.1097/01.SLA.0000029000.06861.17
   Targarona EM, 2004, ARCH SURG-CHICAGO, V139, P1286, DOI 10.1001/archsurg.139.12.1286
   Watson DI, 2015, ANN SURG, V261, P282, DOI 10.1097/SLA.0000000000000842
   Wykypiel H, 2005, SURG ENDOSC, V19, P1315, DOI 10.1007/s00464-004-2208-1
   Zaninotto G, 2007, WORLD J SURG, V31, P2177, DOI 10.1007/s00268-007-9212-2
NR 44
TC 16
Z9 16
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2015
VL 10
IS 10
AR e0139547
DI 10.1371/journal.pone.0139547
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CU0CX
UT WOS:000363184600012
PM 26469286
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, MH
   Wei, SY
   Hu, JY
   Quan, S
AF Chen, Minghao
   Wei, Shiyou
   Hu, Junyan
   Quan, Song
TI Can Comprehensive Chromosome Screening Technology Improve IVF/ICSI
   Outcomes? A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PREIMPLANTATION GENETIC DIAGNOSIS; IN-VITRO FERTILIZATION; COMPARATIVE
   GENOMIC HYBRIDIZATION; ONGOING PREGNANCY RATES; SINGLE-EMBRYO-TRANSFER;
   BLASTOCYST BIOPSY; MORPHOKINETIC PARAMETERS; CLINICAL-APPLICATION;
   SELECTION CRITERIA; CULTURE-MEDIUM
AB Objective
   To examine whether comprehensive chromosome screening (CCS) for preimplantation genetic screening (PGS) has an effect on improving in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes compared to traditional morphological methods.
   Methods
   A literature search was conducted in PubMed, EMBASE, CNKI and ClinicalTrials.gov up to May 2015. Two reviewers independently evaluated titles and abstracts, extracted data and assessed quality. We included studies that compared the IVF/ICSI outcomes of CCS-based embryo selection with those of the traditional morphological method. Relative risk (RR) values with corresponding 95% confidence intervals (CIs) were calculated in RevMan 5.3, and subgroup analysis and Begg's test were used to assess heterogeneity and potential publication bias, respectively.
   Results
   Four RCTs and seven cohort studies were included. Ameta-analysis of the outcomes showed that compared to morphological criteria, euploid embryos identified by CCS were more likely to be successfully implanted (RCT RR 1.32, 95% CI 1.18-1.47; cohort study RR 1.74, 95% CI 1.35-2.24). CCS-based PGS was also related to an increased clinical pregnancy rate (RCT RR 1.26, 95% CI 0.83-1.93; cohort study RR 1.48, 95% CI 1.20-1.83), an increased ongoing pregnancy rate (RCT RR 1.31, 95% CI 0.64-2.66; cohort study RR 1.61, 95% CI 1.30-2.00), and an increased live birth rate (RCT RR 1.26, 95% CI 1.05-1.50; cohort study RR 1.35, 95% CI 0.85-2.13) as well as a decreased miscarriage rate (RCT RR 0.53, 95% CI 0.24-1.15; cohort study RR 0.31, 95% CI 0.21-0.46) and a decreased multiple pregnancy rate (RCT RR 0.02, 95% CI 0.00-0.26; cohort study RR 0.19, 95% CI 0.07-0.51). The results of the subgroup analysis also showed a significantly increased implantation rate in the CCS group.
   Conclusions
   The effectiveness of CCS-based PGS is comparable to that of traditional morphological methods, with better outcomes for women receiving IVF/ICSI technology. The transfer of both trophectoderm-biopsied and blastomere-biopsied CCS-euploid embryos can improve the implantation rate.
C1 [Chen, Minghao; Quan, Song] Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, Reprod Ctr, Guangzhou, Guangdong, Peoples R China.
   [Wei, Shiyou] Sichuan Univ, Thorac Dept, West China Hosp, Chengdu 610064, Peoples R China.
   [Hu, Junyan] Guangzhou Med Univ, Emergency Dept, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
RP Quan, S (reprint author), Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, Reprod Ctr, Guangzhou, Guangdong, Peoples R China.
EM 821760475@qq.com
CR Adler A, 2014, REPROD BIOMED ONLINE, V28, P485, DOI 10.1016/j.rbmo.2013.11.018
   Alfarawati S, 2011, FERTIL STERIL, V95, P520, DOI 10.1016/j.fertnstert.2010.04.003
   Armstrong S, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011320.pub2
   Baruch S, 2008, GENET MED, V10, P685, DOI [10.1097/GIM.0b013e31818180a1, 10.1097GIM.0b013e31818180a1]
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bettio D, 2008, PLACENTA, V29, pS126, DOI 10.1016/j.placenta.2008.08.015
   Campbell A, 2014, REPROD BIOMED ONLINE, V28, P279, DOI 10.1016/j.rbmo.2013.11.016
   Capalbo A, 2013, HUM REPROD, V28, P509, DOI 10.1093/humrep/des394
   CONAGHAN J, 1993, J ASSIST REPROD GEN, V10, P21, DOI 10.1007/BF01204436
   Dahdouh EM, 2015, REPROD BIOMED ONLINE, V30, P281, DOI 10.1016/j.rbmo.2014.11.015
   Fiorentino F, 2014, HUM REPROD, V29, P2802, DOI 10.1093/humrep/deu277
   Fiorentino F, 2014, FERTIL STERIL, V101, P1375, DOI 10.1016/j.fertnstert.2014.01.051
   Forman EJ, 2012, HUM REPROD, V27, P1217, DOI 10.1093/humrep/des020
   Forman EJ, 2013, FERTIL STERIL, V100, P100, DOI 10.1016/j.fertnstert.2013.02.056
   Fragouli E, 2008, HUM REPROD, V23, P2596, DOI 10.1093/humrep/den287
   Fragouli E, 2011, CYTOGENET GENOME RES, V133, P107, DOI 10.1159/000323801
   Fragouli E, 2010, FERTIL STERIL, V94, P875, DOI 10.1016/j.fertnstert.2009.04.053
   Gianaroli L, 2001, MOL CELL ENDOCRINOL, V183, pS13, DOI 10.1016/S0303-7207(01)00570-6
   Ginsburg ES, 2011, FERTIL STERIL, V96, P865, DOI 10.1016/j.fertnstert.2011.07.1139
   Greco E, 2014, BIOMED RES INT, DOI 10.1155/2014/457913
   Handyside AH, 2013, FERTIL STERIL, V100, P595, DOI 10.1016/j.fertnstert.2013.07.1965
   Handyside AH, 2010, J MED GENET, V47, P651, DOI 10.1136/jmg.2009.069971
   Hardarson T, 2012, HUM REPROD, V27, P89, DOI 10.1093/humrep/der373
   Harper JC, 2012, HUM REPROD UPDATE, V18, P234, DOI 10.1093/humupd/dmr052
   Harper JC, 2010, FERTIL STERIL, V94, P1173, DOI 10.1016/j.fertnstert.2010.04.064
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Johnson DS, 2010, MOL HUM REPROD, V16, P944, DOI 10.1093/molehr/gaq062
   Kahraman S, 2004, REPROD BIOMED ONLINE, V9, P79, DOI 10.1016/S1472-6483(10)62114-1
   Keltz MD, 2013, J ASSIST REPROD GEN, V30, P1333, DOI 10.1007/s10815-013-0070-6
   Kiss A, 2009, REV BRAS GINECOL OBS, V31, P68, DOI 10.1590/S0100-72032009000200004
   Konings P, 2012, NAT PROTOC, V7, P281, DOI 10.1038/nprot.2011.426
   Kotze DJ, 2010, J ASSIST REPROD GEN, V27, P309, DOI 10.1007/s10815-010-9403-x
   Kramer YG, 2014, J ASSIST REPROD GEN, V31, P1231, DOI 10.1007/s10815-014-0285-1
   Lee E, 2015, HUM REPROD, V30, P473, DOI 10.1093/humrep/deu303
   Lukaszuk K, 2015, FERTIL STERIL, V103, P1031, DOI 10.1016/j.fertnstert.2014.12.123
   Mantzouratou A, 2007, HUM REPROD, V22, P1844, DOI 10.1093/humrep/dem102
   Mastenbroek S, 2011, HUM REPROD UPDATE, V17, P454, DOI 10.1093/humupd/dmr003
   Mastenbroek S, 2007, NEW ENGL J MED, V357, P9, DOI 10.1056/NEJMoa067744
   Mir P, 2013, J ASSIST REPROD GEN, V30, P143, DOI 10.1007/s10815-012-9918-4
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Munne S, 2006, REPROD BIOMED ONLINE, V12, P340, DOI 10.1016/S1472-6483(10)61007-3
   Munne S, 2004, PRENATAL DIAG, V24, P638, DOI 10.1002/pd.957
   Nagy ZP, 2008, REPROD BIOMED ONLINE, V17, P502, DOI 10.1016/S1472-6483(10)60236-2
   Nasseri A, 1999, FERTIL STERIL, V71, P715, DOI 10.1016/S0015-0282(98)00525-1
   Ottawa Hospital Research Institute, NEWCASTLE OTTAWA SCA
   Polanski LT, 2014, ULTRASOUND OBST GYN, V44, P394, DOI 10.1002/uog.13428
   Renwick PJ, 2007, PRENATAL DIAG, V27, P206, DOI 10.1002/pd.1638
   Rubio C, 2013, FERTIL STERIL, V99, P1044, DOI 10.1016/j.fertnstert.2013.01.094
   Schoolcraft WB, 2012, FERTIL STERIL, V98, pS1, DOI 10.1016/j.fertnstert.2012.07.002
   Schoolcraft WB, 2013, FERTIL STERIL, V100, P615, DOI 10.1016/j.fertnstert.2013.07.1972
   Schoolcraft WB, 2010, FERTIL STERIL, V94, P1700, DOI 10.1016/j.fertnstert.2009.10.015
   Scott RT, 2014, FERTIL STERIL, V102, P660, DOI 10.1016/j.fertnstert.2014.06.022
   Scott RT, 2013, FERTIL STERIL, V100, P697, DOI 10.1016/j.fertnstert.2013.04.035
   Scott RT, 2013, FERTIL STERIL, V100, P624, DOI 10.1016/j.fertnstert.2013.04.039
   Scriven PN, 2012, HUM REPROD, V27, P951, DOI 10.1093/humrep/des017
   Simpson JL, 2012, BEST PRACT RES CL OB, V26, P805, DOI 10.1016/j.bpobgyn.2012.05.009
   Siristatidis C, 2015, J ASSIST REPROD GEN, V32, P563, DOI 10.1007/s10815-015-0436-z
   Soares SR, 2003, FERTIL STERIL, V80, P656, DOI 10.1016/S0015-0282(03)00787-8
   STEPTOE PC, 1978, LANCET, V2, P366
   Swain JE, 2013, J ASSIST REPROD GEN, V30, P1081, DOI 10.1007/s10815-013-0048-4
   Tan YQ, 2013, HUM REPROD, V28, P2581, DOI 10.1093/humrep/det271
   Treff NR, 2013, J ASSIST REPROD GEN, V30, P787, DOI 10.1007/s10815-013-0008-z
   Treff NR, 2013, FERTIL STERIL, V99, P1377, DOI 10.1016/j.fertnstert.2012.12.018
   Treff NR, 2012, SEMIN REPROD MED, V30, P283, DOI 10.1055/s-0032-1313907
   Treff NR, 2012, FERTIL STERIL, V97, P819, DOI 10.1016/j.fertnstert.2012.01.115
   Treff NR, 2011, MOL HUM REPROD, V17, P335, DOI 10.1093/molehr/gaq103
   Treff NR, 2010, FERTIL STERIL, V94, P2017, DOI 10.1016/j.fertnstert.2010.01.052
   Vergouw CG, 2012, HUM REPROD, V27, P2304, DOI 10.1093/humrep/des175
   Voullaire L, 2002, MOL HUM REPROD, V8, P1035, DOI 10.1093/molehr/8.11.1035
   Wang J, 2014, RERODUCTION CONTRACE, P121
   Wang L, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.116459
   Wells D, 2008, MOL HUM REPROD, V14, P703, DOI 10.1093/molehr/gan062
   Yang ZH, 2012, MOL CYTOGENET, V5, DOI 10.1186/1755-8166-5-24
   Yin XY, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.106211
   Zhang Yin-feng, 2012, Zhonghua Yixue Yichuanxue Zazhi, V29, P431, DOI 10.3760/cma.j.issn.1003-9406.2012.04.011
NR 76
TC 45
Z9 48
U1 1
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2015
VL 10
IS 10
AR e0140779
DI 10.1371/journal.pone.0140779
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CU0CX
UT WOS:000363184600110
PM 26470028
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, T
   Zhong, SM
   Liao, XX
   Chen, J
   He, TT
   Lai, SK
   Jia, YB
AF Liu, Tao
   Zhong, Shuming
   Liao, Xiaoxiao
   Chen, Jian
   He, Tingting
   Lai, Shunkai
   Jia, Yanbin
TI A Meta-Analysis of Oxidative Stress Markers in Depression
SO PLOS ONE
LA English
DT Article
ID SERUM-LIPID CONCENTRATIONS; TERM ANTIDEPRESSANT TREATMENT; TOTAL
   ANTIOXIDANT CAPACITY; MAJOR DEPRESSION; NITRIC-OXIDE; NITROSATIVE
   STRESS; PLASMA-LEVELS; AUTOIMMUNE RESPONSES; CARDIOVASCULAR DISORDER;
   TREATMENT RESISTANCE
AB Object
   Studies have suggested that depression was accompanied by oxidative stress dysregulation, including abnormal total antioxidant capacity (TAC), antioxidants, free radicals, oxidative damage and autoimmune response products. This meta-analysis aims to analyse the clinical data quantitatively by comparing the oxidative stress markers between depressed patients and healthy controls.
   Methods
   A search was conducted to collect the studies that measured the oxidative stress markers in depressed patients. Studies were searched in Embase, Medline, PsychINFO, Science direct, CBMDisc, CNKI and VIP from 1990 to May 2015. Data were subjected to meta-analysis by using a random effects model for examining the effect sizes of the results. Bias assessments, heterogeneity assessments and sensitivity analyses were also conducted.
   Results
   115 articles met the inclusion criteria. Lower TAC was noted in acute episodes (AEs) of depressed patients (p<0.05). Antioxidants, including serum paraoxonase, uric acid, albumin, high-density lipoprotein cholesterol and zinc levels were lower than controls (p<0.05); the serum uric acid, albumin and vitamin C levels were increased after antidepressant therapy (p<0.05). Oxidative damage products, including red blood cell (RBC) malondialdehyde (MDA), serum MDA and 8-F-2-isoprostanes levels were higher than controls (p<0.05). After antidepressant medication, RBC and serum MDA levels were decreased (p<0.05). Moreover, serum peroxide in free radicals levels were higher than controls (p<0.05). There were no differences between the depressed patients and controls for other oxidative stress markers.
   Conclusion
   This meta-analysis supports the facts that the serum TAC, paraoxonase and antioxidant levels are lower, and the serum free radical and oxidative damage product levels are higher than controls in depressed patients. Meanwhile, the antioxidant levels are increased and the oxidative damage product levels are decreased after antidepressant medication. The pathophysiological relationships between oxidative stress and depression, and the potential benefits of antioxidant supplementation deserve further research.
C1 [Liu, Tao; Zhong, Shuming; Jia, Yanbin] Jinan Univ, Affiliated Hosp 1, Dept Psychiat, Guangzhou, Guangdong, Peoples R China.
   [Liu, Tao] Guangzhou Brain Hosp, Guangzhou, Guangdong, Peoples R China.
   [Liao, Xiaoxiao; Lai, Shunkai] Jinan Univ, Sch Clin Med 1, Guangzhou, Guangdong, Peoples R China.
   [Chen, Jian; He, Tingting] Jinan Univ, Sch Management, Guangzhou, Guangdong, Peoples R China.
RP Jia, YB (reprint author), Jinan Univ, Affiliated Hosp 1, Dept Psychiat, Guangzhou, Guangdong, Peoples R China.
EM yanbinjia2006@163.com
FU Planned Science and Technology Project of Guangdong Province, China
   [2014A020212401, 2014B020212022]; Educational Commission of Guangdong
   Province, China [2013KJCX0025]; Humanities and Social Sciences Planning
   Fund [13YJA190008]; Scientific Cultivation and Innovation Fund of Jinan
   University [21615466]
FX This work was supported by grants from the Planned Science and
   Technology Project of Guangdong Province, China (No:2014A020212401,
   2014B020212022), the Educational Commission of Guangdong Province, China
   (No: 2013KJCX0025), the Humanities and Social Sciences Planning Fund
   (No: 13YJA190008) and the Scientific Cultivation and Innovation Fund of
   Jinan University (No:21615466). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aboul-Fotouh S, 2013, PHARMACOL BIOCHEM BE, V104, P105, DOI 10.1016/j.pbb.2012.12.027
   Akpinar A, 2013, PROG NEURO-PSYCHOPH, V46, P120, DOI 10.1016/j.pnpbp.2013.07.003
   Amani R, 2010, BIOL TRACE ELEM RES, V137, P150, DOI 10.1007/s12011-009-8572-x
   Amr M, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-31
   Mico JA, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-26
   Arslan A, 2008, EUR REV MED PHARMACO, V12, P309
   Bal N, 2012, DUNSEN ADAM, V25, P206, DOI 10.5350/DAJPN2012250302
   Barim AO, 2009, CLIN BIOCHEM, V42, P1076, DOI 10.1016/j.clinbiochem.2009.02.020
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berton O, 2006, NAT REV NEUROSCI, V7, P137, DOI 10.1038/nrn1846
   Bilici M, 2001, J AFFECT DISORDERS, V64, P43, DOI 10.1016/S0165-0327(00)00199-3
   Bortolasci CC, 2014, J AFFECT DISORDERS, V159, P23, DOI 10.1016/j.jad.2014.02.018
   Brody S, 2002, BIOL PSYCHIAT, V52, P371, DOI 10.1016/S0006-3223(02)01329-X
   Canan F, 2012, J PSYCHIATR RES, V46, P298, DOI 10.1016/j.jpsychires.2011.11.016
   Canpolat S, 2014, SCI WORLD J, DOI 10.1155/2014/624395
   Chang XR, 2001, CHINESE J BEHAV MED, V10, P589
   Chaudhari K, 2010, INDIAN J CLIN BIOCHE, V25, P77, DOI 10.1007/s12291-010-0016-z
   Che RP, 2014, J PRACTICAL MED TECH, V21, P664
   Chen MF, 2012, CHIN J PREV CHRON DI, V20, P529
   Chen MF, 2010, CHIN J PREV CHRON DI, V18, P302
   Chen Y, SICHUAN MENTAL HLTH, V16, P76
   Chen YK, 2010, J INF PROCESS SYST, V6, P1, DOI 10.3745/JIPS.2010.6.1.001
   Chen ZM, 1995, J XIN XIANG MED COLL, V12, P153
   Chrapko WE, 2004, BIOL PSYCHIAT, V56, P129, DOI 10.1016/j.biopsych.2004.03.003
   Crayton JW, 2007, J TRACE ELEM MED BIO, V21, P17, DOI 10.1016/j.jtemb.2006.10.001
   Cumurcu BE, 2009, PSYCHIAT CLIN NEUROS, V63, P639, DOI 10.1111/j.1440-1819.2009.02004.x
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dimopoulos N, 2008, PSYCHIAT RES, V161, P59, DOI 10.1016/j.psychres.2007.07.019
   Dimopoulos N, 2007, J GERIATR PSYCH NEUR, V20, P138, DOI 10.1177/0891988707301867
   Ebesunun MO, 2012, AFR J PSYCHIATRY, V15, P25, DOI [http://dx.doi.org/10.4314/ajpsy.v15i1.3, 10.4314/ajpsy.v15i1.3]
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fadillioglu E, 2000, ANTIOXIDANTS LIPID P, V10, P194
   Fernandez-Gonzalez MD, 1998, QUIMICA CLIN, V17, P208
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Flatow J, 2013, BIOL PSYCHIAT, V74, P400, DOI 10.1016/j.biopsych.2013.03.018
   Forlenza MJ, 2006, PSYCHOSOM MED, V68, P1, DOI 10.1097/01.psy.0000195780.37277.2a
   Galecki P, 2009, PHARMACOL REP, V61, P436
   Galecki P, 2009, HUM PSYCHOPHARM CLIN, V24, P277, DOI 10.1002/hup.1014
   Gao SF, 2013, CEREB CORTEX, V23, P2956, DOI 10.1093/cercor/bhs285
   Gautam Medhavi, 2012, Indian J Psychiatry, V54, P244, DOI 10.4103/0019-5545.102424
   Ghodake SR, 2012, CURR NEUROBIOL, V3, P107
   Godlewska BR, 2015, PSYCHOPHARMACOLOGY, V232, P501, DOI 10.1007/s00213-014-3687-y
   [郭新胜 GUO Xinsheng], 2006, [检验医学, Laboratory medicine], V21, P143
   Guo XQ, 2011, CHINA HLTH MONTHLY, V1, P136
   He J, 2000, CHINESE J BEHAV MED, V9, P139
   He WL, 2013, WORLD HLTH DIGEST ME, V10, P413
   Herken H, 2007, ARCH MED RES, V38, P247, DOI 10.1016/j.arcmed.2006.10.005
   Hocaoglu C, 2012, METAB BRAIN DIS, V27, P425, DOI 10.1007/s11011-012-9323-9
   Hovatta I, 2010, NEUROSCI RES, V68, P261, DOI 10.1016/j.neures.2010.08.007
   Hu JM, 1996, CHINESE J NERVOUS ME, V22, P86
   Huang Tiao-Lai, 2002, Chang Gung Med J, V25, P509
   Huang TL, 2003, PSYCHIAT RES, V118, P147, DOI 10.1016/S0165-1781(03)00071-4
   Huang XB, 2003, J CLIN PSYCHOL MED S, V13, P94
   Huang ZZ, 1999, CHIN J PSYCHIAT, V32, P191
   Ikenouchi-Sugita A, 2011, HUM PSYCHOPHARM CLIN, V26, P531, DOI 10.1002/hup.1239
   Jiao YM, 2006, SHANGHAI ARCH PSYCHI, V18, P266
   Jorgensen A, 2013, J AFFECT DISORDERS, V149, P355, DOI 10.1016/j.jad.2013.02.011
   Karlovic D, 2004, J KOREAN MED SCI, V19, P431, DOI 10.3346/jkms.2004.19.3.431
   Kerling A, 2015, J AFFECT DISORDERS, V177, P1, DOI 10.1016/j.jad.2015.01.006
   Khalid A, 1998, Indian J Psychiatry, V40, P217
   Khanzode SD, 2003, REDOX REP, V8, P365, DOI 10.1179/135100003225003393
   Kim YK, 2006, PROG NEURO-PSYCHOPH, V30, P1091, DOI 10.1016/j.pnpbp.2006.04.008
   Kotan VO, 2011, PROG NEURO-PSYCHOPH, V35, P1284, DOI 10.1016/j.pnpbp.2011.03.021
   Lapidus KAB, 2014, NEUROSCI LETT, V569, P74, DOI 10.1016/j.neulet.2014.03.056
   Lawlor DA, 2007, J EPIDEMIOL COMMUN H, V61, P85, DOI 10.1136/jech.2006.049247
   Lehto SM, 2008, PROG NEURO-PSYCHOPH, V32, P1557, DOI 10.1016/j.pnpbp.2008.05.021
   Lehto SM, 2010, PSYCHIAT CLIN NEUROS, V64, P279, DOI 10.1111/j.1440-1819.2010.02079.x
   Li CY, 2011, MED J CHINESE PEOPLE, V23, P1355
   Liu KB, 2008, STUDY ASS TRACE ELEM
   Lu J, 2010, MED J CHINESE PEOPLE, V22, P2242
   Lv YC, 2011, J MED FORUM, V32, P7
   Maes M, 1997, PSYCHONEUROENDOCRINO, V22, P65, DOI 10.1016/S0306-4530(96)00040-6
   Maes M, 2013, ACTA PSYCHIAT SCAND, V127, P344, DOI 10.1111/j.1600-0447.2012.01908.x
   Maes M, 1999, PSYCHIAT RES, V85, P275, DOI 10.1016/S0165-1781(99)00014-1
   MAES M, 1994, J AFFECT DISORDERS, V31, P135, DOI 10.1016/0165-0327(94)90117-1
   Maes M, 1999, J AFFECT DISORDERS, V56, P189, DOI 10.1016/S0165-0327(99)00011-7
   Maes M, 1997, BIOL PSYCHIAT, V42, P349, DOI 10.1016/S0006-3223(96)00365-4
   Maes M, 1996, NEUROPSYCHOPHARMACOL, V15, P243, DOI 10.1016/0893-133X(95)00181-C
   Maes M, 1997, EUR ARCH PSY CLIN N, V247, P154, DOI 10.1007/BF03033069
   MAES M, 1991, J AFFECT DISORDERS, V23, P25, DOI 10.1016/0165-0327(91)90032-N
   Maes M, 1997, ACTA PSYCHIAT SCAND, V95, P212, DOI 10.1111/j.1600-0447.1997.tb09622.x
   MAES M, 1995, J AFFECT DISORDERS, V34, P61, DOI 10.1016/0165-0327(94)00106-J
   Maes M, 2008, NEUROENDOCRINOL LETT, V29, P313
   Maes M, 2013, J AFFECT DISORDERS, V149, P23, DOI 10.1016/j.jad.2012.06.039
   Maes M, 2011, J AFFECT DISORDERS, V135, P414, DOI 10.1016/j.jad.2011.08.023
   Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P769, DOI 10.1016/j.pnpbp.2010.06.008
   Maes M, 2010, J AFFECT DISORDERS, V125, P287, DOI 10.1016/j.jad.2009.12.014
   Maes M, 2009, NEUROENDOCRINOL LETT, V30, P462
   Magalhaes PVS, 2012, INT J NEUROPSYCHOPH, V15, P1043, DOI 10.1017/S1461145711001532
   Pinto VLM, 2012, J AFFECT DISORDERS, V140, P187, DOI 10.1016/j.jad.2012.02.008
   MCLOUGHLIN IJ, 1990, ACTA PSYCHIAT SCAND, V82, P451, DOI 10.1111/j.1600-0447.1990.tb03077.x
   Milaneschi Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065406
   Moreno-Fernandez AM, 2012, J PSYCHIATR RES, V46, P341, DOI 10.1016/j.jpsychires.2011.11.002
   Moylan S, 2014, NEUROSCI BIOBEHAV R, V45, P46, DOI 10.1016/j.neubiorev.2014.05.007
   NARANG R L, 1991, Indian Journal of Physiology and Pharmacology, V35, P272
   Ng F, 2008, INT J NEUROPSYCHOPH, V11, P851, DOI 10.1017/S1461145707008401
   Ni SL, 2011, GUIDE CHINA MED, V9, P265
   Nowak G, 2000, HUMAN PSYCHOPHARMACO, V14, P83
   Nunes SOV, 2002, BRAZ J MED BIOL RES, V35, P581, DOI 10.1590/S0100-879X2002000500011
   Olusi SO, 1996, BIOL PSYCHIAT, V40, P1128, DOI 10.1016/S0006-3223(95)00599-4
   do Carmo MBOO, 2015, J PSYCHIATR RES, V61, P19, DOI 10.1016/j.jpsychires.2014.12.009
   Owen AJ, 2005, EUR J CLIN NUTR, V59, P304, DOI 10.1038/sj.ejcn.1602072
   Palta P, 2014, PSYCHOSOM MED, V76, P12, DOI 10.1097/PSY.0000000000000009
   Pomara N, 2012, AM J PSYCHIAT, V169, P523, DOI 10.1176/appi.ajp.2011.11081153
   Pratico D, 2004, CHEM PHYS LIPIDS, V128, P165, DOI 10.1016/j.chemphyslip.2003.09.012
   Prohan M, 2014, REDOX REP, V19, P133, DOI 10.1179/1351000214Y.0000000085
   Qian ZP, 2012, MED LAB SCI CLIN, V23, P64
   Rawdin BJ, 2013, BRAIN BEHAV IMMUN, V31, P143, DOI 10.1016/j.bbi.2012.11.011
   Razavi AE, 2012, J RES MED SCI, V17, P1020
   Russo AJ, 2010, NUTR METAB INSIGHTS, V3, P37, DOI 10.4137/NMI.S5044
   Rybka J, 2013, FREE RADICAL BIO MED, V63, P187, DOI 10.1016/j.freeradbiomed.2013.05.019
   Rytila P, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-69
   Salimi S, 2008, J MED SCI, V8, P587, DOI DOI 10.3923/JMS.2008.587.590
   Salustri C, 2010, J AFFECT DISORDERS, V127, P321, DOI 10.1016/j.jad.2010.05.012
   Sarandol A, 2006, PROG NEURO-PSYCHOPH, V30, P1103, DOI 10.1016/j.pnpbp.2006.04.012
   Sarandol A, 2007, HUM PSYCHOPHARM CLIN, V22, P67, DOI 10.1002/hup.829
   Selek S, 2012, NEUROLOGY PSYCHIAT B, V18, P15
   Selley ML, 2004, J AFFECT DISORDERS, V80, P249, DOI 10.1016/S0165-0327(03)00135-6
   Sevincok L, 2001, CAN J PSYCHIAT, V46, P68, DOI 10.1177/070674370104600110
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Suzuki E, 2001, J AFFECT DISORDERS, V63, P221, DOI 10.1016/S0165-0327(00)00164-6
   Szuster-Ciesielska A, 2008, PROG NEURO-PSYCHOPH, V32, P686, DOI 10.1016/j.pnpbp.2007.11.012
   Talarowska M, 2012, NEUROSCI LETT, V510, P127, DOI 10.1016/j.neulet.2012.01.018
   Tao R, 2014, MED J CHIN PAPF, V24, P363
   Uzbekov MG, 2006, HUM PSYCHOPHARM CLIN, V21, P109, DOI 10.1002/hup.749
   VanHunsel F, 1996, PSYCHIAT RES, V65, P159, DOI 10.1016/S0165-1781(96)03010-7
   Vargas HO, 2014, LIFE SCI, V102, P65, DOI 10.1016/j.lfs.2014.02.033
   Vargas HO, 2013, NEUROSCI LETT, V544, P136, DOI 10.1016/j.neulet.2013.03.059
   Vogelzangs N, 2014, BRAIN BEHAV IMMUN, V41, P109, DOI 10.1016/j.bbi.2014.05.004
   Wang GH, 2003, MED J WUHAN U, V24, P174
   Wang XH, 2014, XINJIANG MED J, V44, P61
   Wen ShengLin, 2013, Chinese Preventive Medicine, V14, P579
   Wen SL, 2012, CLIN BIOCHEM, V45, P49, DOI 10.1016/j.clinbiochem.2011.10.010
   Wiener C, 2014, EUR PSYCHIAT, V29, P58, DOI 10.1016/j.eurpsy.2013.05.006
   Wu FX, 1998, J CLIN PSYCHOL MED S, V8, P341
   Wu GF, 2012, PUBLIC HLTH, V6, P61
   Wu MD, 2004, J SICHUAN CONTINUING, V23, P175
   Xia QC, 2009, J CLIN PSYCHIAT, V19, P241
   Xu MZ, 2000, CHIN J PSYCHIAT, V33, P155
   Xu XW, 2010, MED INNOVATION CHIN, V7, P175
   Yager S, 2010, PSYCHONEUROENDOCRINO, V35, P1356, DOI 10.1016/j.psyneuen.2010.03.010
   [杨坤 Yang Kun], 2005, [中国行为医学科学, Chinese Journal of Behavioral Medical Science], V14, P792
   Yanik M, 2004, ACTA NEUROPSYCHIATR, V16, P200, DOI 10.1111/j.0924-2708.2004.00090.x
   Yapislar H, 2012, INT J PSYCHIAT CLIN, V16, P27, DOI 10.3109/13651501.2011.620127
   Yu HY, 1997, HEBEI MENTAL HLTH, V10, P10
   Yuan YG, 2003, J CLIN PSYCHOL MED S, V13, P67
   YUAN YG, 2006, CHIN GEN PRACT, V9, P106
   [袁勇贵 Yuan Yonggui], 2002, [中国神经精神疾病杂志, Chinese Journal of Nervous and Mental Diseases], V28, P33
   Zhang WJ, 2012, CHIN J LAB DIAGN, V16, P712
   Zhang XH, 1997, J CONVALESCEN REHABI, V12, P157
   Zhang YN, 2007, STUDY BRAIN FUNCTION
NR 151
TC 73
Z9 74
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 7
PY 2015
VL 10
IS 10
AR e0138904
DI 10.1371/journal.pone.0138904
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CT0TS
UT WOS:000362510600039
PM 26445247
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Han, J
   Jiang, Y
   Liu, X
   Meng, QY
   Xi, QL
   Zhuang, QL
   Han, YS
   Gao, Y
   Ding, QR
   Wu, GH
AF Han, Jun
   Jiang, Yi
   Liu, Xiao
   Meng, Qingyang
   Xi, Qiulei
   Zhuang, Qiulin
   Han, Yusong
   Gao, Ying
   Ding, Qiurong
   Wu, Guohao
TI Dietary Fat Intake and Risk of Gastric Cancer: A Meta-Analysis of
   Observational Studies
SO PLOS ONE
LA English
DT Article
ID DOSE-RESPONSE DATA; COLORECTAL-CANCER; NUTRIENT INTAKE; BREAST-CANCER;
   STOMACH-CANCER; HELICOBACTER-PYLORI; NUTRITIONAL FACTORS;
   PANCREATIC-CANCER; TREND ESTIMATION; AARP DIET
AB Background and Objectives
   Consumption of dietary fat has been reported to be associated with gastric cancer risk, but the results of epidemiologic studies remain inconsistent. We conducted a meta-analysis to summarize the evidence regarding the association between dietary fat intake and gastric cancer risk.
   Methods
   A comprehensive search of PubMed and EMBASE was performed to identify observational studies providing quantitative estimates between dietary fat and gastric cancer risk. Random effects model was used to calculate the summary relative risk(SRR) in the highest versus lowest analysis. Categorical dose-response analysis was conducted to quantify the association between dietary fat intake and gastric cancer risk. Heterogeneity among studies was evaluated using I-2 and tau2(between study variance) statistics. Subgroup analysis and publication bias analysis were also performed.
   Results
   Twenty-two articles were included in the meta-analysis. The SRR for gastric cancer was 1.18 for individuals with highest intake versus lowest intake of total fat (95% confidence interval [CI]: 0.999-1.39; n = 28; P< 0.001; tau(2) = 0.12; I-2 = 69.5%, 95% CI: 55%-79%) and 1.08 with a daily increase in total fat intake (20 g/d) (95% CI: 1.02-1.14; n = 6; P = 0.09; tau(2) = 0.002; I-2 = 46.8%, 95% CI: 0%-79%). Positive association between saturated fat intake (SRR = 1.31; 95% CI: 1.09-1.58; n = 18; P<0.001; tau(2) = 0.08; I-2 = 60.6%, 95% CI: 34%-76%), inverse association between polyunsaturated fat intake (SRR = 0.77; 95% CI: 0.65-0.92; n = 16; P = 0.003; tau(2) = 0.06; I-2 = 56.2%, 95% CI: 23%-75%) and vegetable fat intake (SRR = 0.55; 95% CI: 0.41-0.74; n = 4; P = 0.12; tau(2) = 0.04; I-2 = 48.6%, 95% CI: 0%-83%), and no association between monounsaturated fat intake (SRR = 1.00; 95% CI: 0.79-1.25; n = 14; P< 0.001; tau(2) = 0.10; I-2 = 63.0%, 95% CI: 34%-79%) and animal fat intake (SRR = 1.10; 95% CI: 0.90-1.33; n = 6; P = 0.13; tau(2) = 0.02; I-2 = 42.0%, 95% CI: 0%-70%) and gastric cancer risk were observed.
   Conclusions
   Our results suggest that intake of total fat is potentially positively associated with gastric cancer risk, and specific subtypes of fats account for different effects. However, these findings should be confirmed by further well-designed cohort studieswith detailed dietary assessments and strict control of confounders.
C1 [Han, Jun; Jiang, Yi; Meng, Qingyang; Xi, Qiulei; Zhuang, Qiulin; Han, Yusong; Wu, Guohao] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Clin Nutr Ctr Shanghai, Shanghai 200433, Peoples R China.
   [Liu, Xiao] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Dept Nursing, Nanjing, Jiangsu, Peoples R China.
   [Gao, Ying; Ding, Qiurong] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai, Peoples R China.
RP Wu, GH (reprint author), Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Clin Nutr Ctr Shanghai, Shanghai 200433, Peoples R China.
EM profwugh@163.com
FU National Natural Science Foundation of China [81372197]
FX This study was supported by National Natural Science Foundation of China
   (81372197).
CR Akinsete JA, 2012, CARCINOGENESIS, V33, P140, DOI 10.1093/carcin/bgr238
   Arem H, 2013, ANN EPIDEMIOL, V23, P571, DOI 10.1016/j.annepidem.2013.06.006
   Aune D, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6617
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BROWN LM, 1995, J NATL CANCER I, V87, P104
   Buckland G, 2010, AM J CLIN NUTR, V91, P381, DOI 10.3945/ajcn.2009.28209
   BUIATTI E, 1990, INT J CANCER, V45, P896, DOI 10.1002/ijc.2910450520
   BUIATTI E, 1991, INT J CANCER, V48, P369, DOI 10.1002/ijc.2910480310
   BUIATTI E, 1989, INT J CANCER, V44, P611, DOI 10.1002/ijc.2910440409
   Butler LM, 2009, INT J CANCER, V124, P678, DOI 10.1002/ijc.23950
   Chen HL, 2002, NUTR CANCER, V42, P33, DOI 10.1207/S15327914NC421_5
   CORNEE J, 1995, EUR J EPIDEMIOL, V11, P55, DOI 10.1007/BF01719946
   Corsetto PA, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-73
   D'Elia L, 2012, CLIN NUTR, V31, P489, DOI 10.1016/j.clnu.2012.01.003
   Davies HTO, 1998, BRIT MED J, V316, P989, DOI 10.1136/bmj.316.7136.989
   de Martel C, 2013, GASTROENTEROL CLIN N, V42, P219, DOI 10.1016/j.gtc.2013.01.003
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   du Toit-Kohn JL, 2009, J NUTR BIOCHEM, V20, P106, DOI 10.1016/j.jnutbio.2007.12.005
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Escrich E, 2007, MOL NUTR FOOD RES, V51, P1279, DOI 10.1002/mnfr.200700213
   Freedman ND, 2008, CANCER CAUSE CONTROL, V19, P459, DOI 10.1007/s10552-007-9107-4
   Fung TT, 2006, J NUTR, V136, P466
   Gao Y, 2011, CANCER EPIDEMIOL, V35, pE91, DOI 10.1016/j.canep.2011.06.006
   Ge S, 2012, GASTROENT RES PRACT, DOI 10.1155/2012/808120
   GONZALEZ CA, 1991, INT J CANCER, V49, P513, DOI 10.1002/ijc.2910490407
   GONZALEZ CA, 1994, AM J EPIDEMIOL, V139, P466, DOI 10.1093/oxfordjournals.aje.a117029
   Gonzalez CA, 2006, PUBLIC HEALTH NUTR, V9, P124, DOI 10.1079/PHN2005934
   GRAHAM S, 1990, NUTR CANCER, V13, P19, DOI 10.1080/01635589009514042
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Halkjaer J, 2009, EUR J CLIN NUTR, V63, pS16, DOI 10.1038/ejcn.2009.73
   Hanf V, 2005, EUR J OBSTET GYN R B, V123, P139, DOI 10.1016/j.ejogrb.2005.05.011
   HANSSON LE, 1994, INT J CANCER, V57, P638, DOI 10.1002/ijc.2910570505
   Harrison LE, 1997, CANCER-AM CANCER SOC, V80, P1021
   Hashim YZHY, 2005, NUTR REV, V63, P374, DOI 10.1301/nr.2005.nov.374-386
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hu JF, 2015, CANCER CAUSE CONTROL, V26, P839, DOI 10.1007/s10552-015-0557-9
   Jansen RJ, 2014, INT J CANCER, V134, P1935, DOI 10.1002/ijc.28525
   Jedrychowski W, 2001, Int J Occup Med Environ Health, V14, P391
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jeurnink SM, 2012, INT J CANCER, V131, pE963, DOI 10.1002/ijc.27517
   Ji BT, 1998, INT J CANCER, V76, P659, DOI 10.1002/(SICI)1097-0215(19980529)76:5<659::AID-IJC8>3.0.CO;2-P
   Kaaks R, 1998, INT J CANCER, V78, P415, DOI 10.1002/(SICI)1097-0215(19981109)78:4<415::AID-IJC4>3.0.CO;2-X
   KABAT GC, 1993, CANCER CAUSE CONTROL, V4, P123, DOI 10.1007/BF00053153
   Kicinski M, 2011, STAT MED, V22, P725
   Kim HJ, 2005, NUTR CANCER, V52, P138, DOI 10.1207/s15327914nc5202_4
   KITTS DD, 1994, CAN J PHYSIOL PHARM, V72, P423, DOI 10.1139/y94-062
   Kontopantelis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069930
   Kuriki K, 2006, CANCER SCI, V97, P1226, DOI 10.1111/j.1349-7006.2006.00314.x
   Lawrence GD, 2013, ADV NUTR, V4, P294, DOI 10.3945/an.113.003657
   Li PW, 2014, INT J CANCER, V135, P1444, DOI 10.1002/ijc.28777
   Li WQ, 2013, CLIN GASTROENTEROL H, V11, P1130, DOI 10.1016/j.cgh.2013.03.023
   Liu L, 2011, EUR J NUTR, V50, P173, DOI 10.1007/s00394-010-0128-5
   Lopez-Carrillo L, 1999, INT J CANCER, V83, P601, DOI 10.1002/(SICI)1097-0215(19991126)83:5<601::AID-IJC5>3.0.CO;2-6
   Lucenteforte E, 2009, ANN ONCOL, V20, P1434, DOI 10.1093/annonc/mdp009
   MacLean CH, 2006, JAMA-J AM MED ASSOC, V295, P403, DOI 10.1001/jama.295.4.403
   Mayne ST, 2001, CANCER EPIDEM BIOMAR, V10, P1055
   McColl KEL, 2010, GUT, V59, P282, DOI 10.1136/gut.2009.186825
   Munoz N, 2001, INT J CANCER, V93, P417, DOI 10.1002/ijc.1333
   Nouraie M, 2005, CANCER EPIDEM BIOMAR, V14, P2087, DOI 10.1158/1055-9965.EPI-05-0038
   O'Doherty MG, 2012, INT J CANCER, V131, P1376, DOI 10.1002/ijc.27366
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Pakseresht M, 2011, CANCER CAUSE CONTROL, V22, P725, DOI 10.1007/s10552-011-9744-5
   Palli D, 2001, CANCER RES, V61, P5415
   Palli D, 1997, CANCER EPIDEM BIOMAR, V6, P1065
   PALLI D, 1992, BRIT J CANCER, V65, P263, DOI 10.1038/bjc.1992.52
   Palli D, 2001, CANCER CAUSE CONTROL, V12, P163, DOI 10.1023/A:1008970310963
   Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731
   Qiu JL, 2005, WORLD J GASTROENTERO, V11, P4311
   Reedy J, 2008, AM J EPIDEMIOL, V168, P38, DOI 10.1093/aje/kwn097
   RISCH HA, 1985, AM J EPIDEMIOL, V122, P947, DOI 10.1093/oxfordjournals.aje.a114199
   Rolland-Cachera MF, 2000, EUR J CLIN NUTR, V54, pS41, DOI 10.1038/sj.ejcn.1600891
   Satia-Abouta J, 2002, J AM DIET ASSOC, V102, P1105, DOI 10.1016/S0002-8223(02)90247-6
   Shen QW, 2015, EUR J CANCER PREV, V24, P278, DOI 10.1097/CEJ.0000000000000073
   Sheng H, 2014, FRONT BIOSCI-LANDMRK, V19, P854, DOI 10.2741/4252
   Song KS, 2011, PANCREATOLOGY, V11, P574, DOI 10.1159/000334468
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Terry P, 2000, NUTR CANCER, V38, P186, DOI 10.1207/S15327914NC382_7
   Terry P, 2001, CANCER EPIDEM BIOMAR, V10, P913
   Thiebaut ACM, 2007, JNCI-J NATL CANCER I, V99, P451, DOI 10.1093/jnci/djk094
   Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187
   Tran GD, 2005, INT J CANCER, V113, P456, DOI 10.1002/ijc.20616
   Trichopoulou A, 2000, CANCER EPIDEM BIOMAR, V9, P869
   Tsubura A, 2009, HISTOL HISTOPATHOL, V24, P223, DOI 10.14670/HH-24.223
   Turner LB, 2011, AM J HUM BIOL, V23, P601, DOI 10.1002/ajhb.21176
   TUYNS AJ, 1992, INT J CANCER, V51, P1, DOI 10.1002/ijc.2910510102
   Webb PM, 2001, GUT, V49, P347
   Wei ZR, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-25
   Welch AA, 2002, PUBLIC HEALTH NUTR, V5, P1273, DOI 10.1079/PHN2002404
   Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X
   Wu AH, 2007, CANCER CAUSE CONTROL, V18, P713, DOI 10.1007/s10552-007-9014-8
   Yang P, 2009, EUR J CANCER, V45, P2867, DOI 10.1016/j.ejca.2009.04.019
   Zhou YP, 2016, CLIN NUTR, V35, P109, DOI 10.1016/j.clnu.2015.02.003
   Zhu HC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070955
NR 93
TC 12
Z9 13
U1 2
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 24
PY 2015
VL 10
IS 9
AR e0138580
DI 10.1371/journal.pone.0138580
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS1BS
UT WOS:000361798100030
PM 26402223
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ye, H
   Zhao, Q
   Wang, YF
   Wang, DP
   Zheng, ZY
   Schroder, PM
   Lu, Y
   Kong, Y
   Liang, WH
   Shang, YS
   Guo, ZY
   He, XS
AF Ye, Hui
   Zhao, Qiang
   Wang, Yufang
   Wang, Dongping
   Zheng, Zhouying
   Schroder, Paul Michael
   Lu, Yao
   Kong, Yuan
   Liang, Wenhua
   Shang, Yushu
   Guo, Zhiyong
   He, Xiaoshun
TI Outcomes of Technical Variant Liver Transplantation versus Whole Liver
   Transplantation for Pediatric Patients: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID HEPATIC-ARTERY THROMBOSIS; WAITING-LIST MORTALITY; LATE GRAFT LOSS;
   DONOR LIVER; VASCULAR COMPLICATIONS; LIVING-DONOR; FULL-SIZE; SEGMENTAL
   GRAFTS; SINGLE-CENTER; EXPERIENCE
AB Objective
   To overcome the shortage of appropriate-sized whole liver grafts for children, technical variant liver transplantation has been practiced for decades. We perform a meta-analysis to compare the survival rates and incidence of surgical complications between pediatric whole liver transplantation and technical variant liver transplantation.
   Methods
   To identify relevant studies up to January 2014, we searched PubMed/Medline, Embase, and Cochrane library databases. The primary outcomes measured were patient and graft survival rates, and the secondary outcomes were the incidence of surgical complications. The outcomes were pooled using a fixed-effects model or random-effects model.
   Results
   The one-year, three-year, five-year patient survival rates and one-year, three-year graft survival rates were significantly higher in whole liver transplantation than technical variant liver transplantation (OR = 1.62, 1.90, 1.65, 1.78, and 1.62, respectively, p<0.05). There was no significant difference in five-year graft survival rate between the two groups (OR = 1.47, p = 0.10). The incidence of portal vein thrombosis and biliary complications were significantly lower in the whole liver transplantation group (OR = 0.45 and 0.42, both p<0.05). The incidence of hepatic artery thrombosis was comparable between the two groups (OR = 1.21, p = 0.61).
   Conclusions
   Pediatric whole liver transplantation is associated with better outcomes than technical variant liver transplantation. Continuing efforts should be made to minimize surgical complications to improve the outcomes of technical variant liver transplantation.
C1 [Ye, Hui; Zhao, Qiang; Wang, Yufang; Wang, Dongping; Zheng, Zhouying; Lu, Yao; Kong, Yuan; Liang, Wenhua; Shang, Yushu; Guo, Zhiyong; He, Xiaoshun] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou 510080, Guangdong, Peoples R China.
   [Schroder, Paul Michael] Univ Toledo, Coll Med, Toledo, OH 43614 USA.
RP He, XS (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou 510080, Guangdong, Peoples R China.
EM rockyucsf1981@126.com; gdtrc@126.com
FU National High Technology Research and Development Program of China (863
   Program) [2012AA021007, 2012AA021008]; National Natural Science
   Foundation of China [81373156, 81471583]; Special Fund for Science
   Research by Ministry of Health [201302009]; Key Clinical Specialty
   Construction Project of National Health and Family Planning Commission
   of the People's Republic of China; Guangdong Provincial Key Laboratory
   Construction Projection on Organ Donation and Transplant Immunology
   [2013A061401007]; Pearl River Nova Program of Guangzhou; Guangdong
   Provincial Natural Science Funds for Distinguished Young Scholars
FX This study was supported by the National High Technology Research and
   Development Program of China (863 Program) (2012AA021007 &
   2012AA021008), the National Natural Science Foundation of China
   (81373156 and 81471583), the Special Fund for Science Research by
   Ministry of Health (201302009), the Key Clinical Specialty Construction
   Project of National Health and Family Planning Commission of the
   People's Republic of China, the Guangdong Provincial Key Laboratory
   Construction Projection on Organ Donation and Transplant Immunology
   (2013A061401007), Pearl River Nova Program of Guangzhou, and Guangdong
   Provincial Natural Science Funds for Distinguished Young Scholars. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abt PL, 2004, LIVER TRANSPLANT, V10, P1287, DOI 10.1002/lt.20270
   [Anonymous], 1983, HEPATOLOGY S, V4, p107S
   Asensio M, 2001, Cir Pediatr, V14, P116
   Austin MT, 2005, ARCH SURG-CHICAGO, V140, P465, DOI 10.1001/archsurg.140.5.465
   BACKMAN L, 1993, TRANSPLANTATION, V55, P1078
   Baliga P, 2004, LIVER TRANSPLANT, V10, P1364, DOI 10.1002/lt.20252
   Becker NS, 2008, LIVER TRANSPLANT, V14, P1125, DOI 10.1002/lt.21491
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   BISMUTH H, 1984, SURGERY, V95, P367
   Bourdeaux C, 2005, TRANSPLANTATION, V79, P1273, DOI 10.1097/00007890-200505150-00060
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Burgos L, 2008, EUR J PEDIATR SURG, V18, P372, DOI 10.1055/s-2008-1038900
   Busuttil RW, 1999, ANN SURG, V229, P313, DOI 10.1097/00000658-199903000-00003
   Cacciarelli TV, 1997, TRANSPLANTATION, V64, P242, DOI 10.1097/00007890-199707270-00011
   Chardot C, 1999, EUR J PEDIATR SURG, V9, P146, DOI 10.1055/s-2008-1072231
   D'Alessandro AM, 2007, PEDIATR TRANSPLANT, V11, P661, DOI 10.1111/j.1399-3046.2007.00737.x
   de Goyet JD, 2009, CURR OPIN ORGAN TRAN, V14, P507, DOI 10.1097/MOT.0b013e32833067f3
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   EMOND JC, 1989, HEPATOLOGY, V10, P867, DOI 10.1002/hep.1840100520
   EMOND JC, 1993, TRANSPLANTATION, V55, P835, DOI 10.1097/00007890-199304000-00029
   EMOND JC, 1993, SURG GYNECOL OBSTET, V176, P11
   EMOND JC, 1990, ANN SURG, V212, P14, DOI 10.1097/00000658-199007000-00003
   Goss JA, 1997, TRANSPLANTATION, V64, P871, DOI 10.1097/00007890-199709270-00014
   Gridelli B, 2003, TRANSPLANTATION, V75, P1197, DOI 10.1097/01.TP.0000061940.96949.A1
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ko EY, 2003, RADIOLOGY, V229, P806, DOI 10.1148/radiol.2293020700
   LANGNAS AN, 1992, TRANSPLANTATION, V53, P387, DOI 10.1097/00007890-199202010-00023
   Leal N, 2007, Cir Pediatr, V20, P143
   Lucianetti A, 2005, TRANSPLANT P, V37, P1143, DOI 10.1016/j.transproceed.2004.12.307
   Otte JB, 2005, PEDIATR TRANSPLANT, V9, P557, DOI 10.1111/j.1399-3046.2005.00354.x
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   Pareja E, 2010, TRANSPL P, V42, P2970, DOI 10.1016/j.transproceed.2010.07.063
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   Pinelli D, 2005, TRANSPL P, V37, P1146, DOI 10.1016/j.transproceed.2004.12.302
   Rela M, 1998, ANN SURG, V227, P282, DOI 10.1097/00000658-199802000-00019
   Roberts JP, 2004, AM J TRANSPLANT, V4, P373, DOI 10.1111/j.1600-6143.2004.00359.x
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
   RYCKMAN FC, 1991, J PEDIATR SURG, V26, P422, DOI 10.1016/0022-3468(91)90989-7
   Salzedas-Netto AA, 2010, TRANSPL P, V42, P507, DOI 10.1016/j.transproceed.2010.01.040
   SANTAMARIA ML, 1995, TRANSPLANT P, V27, P2292
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   Sieders E, 2002, ANN SURG, V235, P125, DOI 10.1097/00000658-200201000-00016
   Sieders E, 1999, TRANSPLANTATION, V68, P540, DOI 10.1097/00007890-199908270-00017
   Sindhi R, 1999, J PEDIATR SURG, V34, P107, DOI 10.1016/S0022-3468(99)90238-5
   SINGER PA, 1988, CLIN RES, V36, P539
   SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1
   Spada M, 2009, WORLD J GASTROENTERO, V15, P648, DOI 10.3748/wjg.15.648
   Squires RH, 2006, J PEDIATR-US, V148, P652, DOI 10.1016/j.jpeds.2005.12.051
   STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106
   SUWATA J, 1994, TRANSPLANT P, V26, P1780
   Tannuri U, 2005, PEDIATR TRANSPLANT, V9, P293, DOI 10.1111/j.1399-3046.2005.00306.x
   Wallot MA, 2002, LIVER TRANSPLANT, V8, P615, DOI 10.1053/jlts.2002.34149
   WHITINGTON PF, 1994, SEMIN LIVER DIS, V14, P303, DOI 10.1055/s-2007-1007320
   WOZNEY P, 1986, AM J ROENTGENOL, V147, P657, DOI 10.2214/ajr.147.4.657
   Yamauchi Y, 2006, DIGEST SURG, V23, P65, DOI 10.1159/000093496
NR 57
TC 8
Z9 9
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 14
PY 2015
VL 10
IS 9
AR e0138202
DI 10.1371/journal.pone.0138202
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CR8KS
UT WOS:000361601100241
PM 26368552
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zeng, YH
   Zhang, QW
   Zhang, YJ
   Lu, MX
   Liu, Y
   Zheng, TY
   Feng, SJ
   Hao, MQ
   Shi, HS
AF Zeng, Yunhui
   Zhang, Qiongwen
   Zhang, Yujie
   Lu, Minxun
   Liu, Yang
   Zheng, Tianying
   Feng, Shijian
   Hao, Meiqin
   Shi, Huashan
TI MUC1 Predicts Colorectal Cancer Metastasis: A Systematic Review and
   Meta-Analysis of Case Controlled Studies
SO PLOS ONE
LA English
DT Article
ID DEEPEST INVASIVE PORTION; CLINICAL-SIGNIFICANCE; PANCREATIC-CANCER;
   CARCINOEMBRYONIC ANTIGEN; LIVER METASTASIS; BREAST-CANCER; KL-6 MUCIN;
   EXPRESSION; CARCINOMA; ADENOCARCINOMA
AB Objective
   To evaluate the predicting value of MUC1 expression in lymph node and distant metastasis of colorectal cancer (CRC).
   Methods
   Pubmed/MEDLINE and EMBASE were searched to identify eligible studies that evaluated the correlation between MUC1 and CRC. A meta-analysis was conducted to evaluate the impact of MUC1 expression on CRC metastasis.
   Results
   A total of 18 studies (n = 3271) met inclusion criteria and the mean Newcastle-Ottawa Scale (NOS) score was 6.3 with a range from 4 to 8. The pooled OR in the meta-analysis of 15 studies indicated that positive MUC1 expression correlated with more CRC node metastasis (OR = 2.32, 95% CI = 1.63-3.29). The data synthesis of 6 studies suggested that MUC1 expression predicted more possibility of CRC distant metastasis (OR = 2.22, 95% CI = 1.23-4.00). In addition, the combined OR of 7 studies showed that MUC1 expression indicated higher Duke's stage (OR = 3.02, 95% CI = 2.11-4.33). No publication bias was found in the mate-analysis by Begg's test or Egger's test with the exception of the meta-analysis of MUC1 with CRC node metastasis (Begg's test p = 0.729, Egger's test p = 0.000).
   Conclusions
   Despite of some modest bias, the pooled evidence suggested that MUC1 expression was significantly correlated with CRC metastasis.
C1 [Zeng, Yunhui; Zhang, Qiongwen; Lu, Minxun; Liu, Yang; Zheng, Tianying; Feng, Shijian; Hao, Meiqin; Shi, Huashan] Sichuan Univ, West China Med Sch, West China Hosp, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China.
   [Zhang, Qiongwen; Shi, Huashan] Sichuan Univ, West China Med Sch, West China Hosp, Ctr Canc, Chengdu 610064, Sichuan, Peoples R China.
   [Zhang, Qiongwen; Shi, Huashan] Sichuan Univ, West China Med Sch, West China Hosp, Dept Head & Neck Oncol, Chengdu 610064, Sichuan, Peoples R China.
   [Zhang, Yujie] Sichuan Univ, West China Med Sch, West China Hosp, Integrated Unit 2, Chengdu 610064, Sichuan, Peoples R China.
RP Zhang, QW (reprint author), Sichuan Univ, West China Med Sch, West China Hosp, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China.
EM qiongwen2009@163.com; hx_natlife@163.com
CR Ajioka Y, 1996, J CLIN PATHOL, V49, P560, DOI 10.1136/jcp.49.7.560
   Baldus SE, 2004, CLIN CANCER RES, V10, P2790, DOI 10.1158/1078-0432.CCR-03-0163
   Baldus SE, 2002, HISTOPATHOLOGY, V40, P440, DOI 10.1046/j.1365-2559.2002.01389.x
   Beatson RE, 2010, IMMUNOTHERAPY-UK, V2, P305, DOI [10.2217/imt.10.17, 10.2217/IMT.10.17]
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Behrens ME, 2010, ONCOGENE, V29, P5667, DOI 10.1038/onc.2010.327
   Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439
   Bitler BG, 2010, J CELL SCI, V123, P1716, DOI 10.1242/jcs.062661
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Chaika NV, 2012, P NATL ACAD SCI USA, V109, P13787, DOI 10.1073/pnas.1203339109
   Costa NR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026970
   DAVIDSON BR, 1989, GUT, V30, P1260, DOI 10.1136/gut.30.9.1260
   DAVIDSON BR, 1988, INT J CANCER, P56
   Duncan Timothy J, 2007, World J Surg Oncol, V5, P31, DOI 10.1186/1477-7819-5-31
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811
   Guo Q, 2006, WORLD J GASTROENTERO, V12, P54, DOI 10.3748/wjg.v12.i1.54
   Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659
   Hattrup CL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1515
   Hayashi T, 2001, DIGESTION, V63, P87, DOI 10.1159/000051917
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA
   Hiraga Y, 1998, ONCOLOGY-BASEL, V55, P307, DOI 10.1159/000011868
   Huang MY, 2012, DNA CELL BIOL, V31, P43, DOI 10.1089/dna.2011.1264
   HUANG W J, 2002, DECIDUOUS FRUITS, V1, P1
   Jang KT, 2002, J KOREAN MED SCI, V17, P29, DOI 10.3346/jkms.2002.17.1.29
   Kaneko I, 2007, WORLD J GASTROENTERO, V13, P3829
   Karamitopoulou E, 2011, PATHOLOGY, V43, P133, DOI 10.1097/PAT.0b013e3283425b7f
   Kashiwagi H, 2000, INT J ONCOL, V16, P455
   Khalifa A, 2001, CANC MOL BIOL, V8, P1625
   Kimura T, 2000, INT J ONCOL, V16, P55
   Kimura T, 2013, CANCER PREV RES, V6, P18, DOI 10.1158/1940-6207.CAPR-12-0275
   Kitamoto S, 2013, ONCOGENE, V32, P4614, DOI 10.1038/onc.2012.478
   Kovjazin R, 2011, VACCINE, V29, P4676, DOI 10.1016/j.vaccine.2011.04.103
   Kraus D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030716
   Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761
   Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4
   Lugli A, 2007, J CLIN PATHOL, V60, P534, DOI 10.1136/jcp.2006.039552
   Luttges J, 2002, AM J SURG PATHOL, V26, P466, DOI 10.1097/00000478-200204000-00008
   Matsuda K, 2000, JPN J CLIN ONCOL, V30, P89, DOI 10.1093/jjco/hyd023
   McAuley JL, 2007, J CLIN INVEST, V117, P2313, DOI 10.1172/JCI26705
   Mohr AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073306
   Mulder WMC, 1996, CANCER IMMUNOL IMMUN, V42, P351, DOI 10.1007/s002620050293
   NAKAMORI S, 1994, GASTROENTEROLOGY, V106, P353, DOI 10.1016/0016-5085(94)90592-4
   Nakamura H, 1998, J GASTROENTEROL, V33, P354, DOI 10.1007/s005350050096
   Nath S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.16
   Oshima T, 2007, PATHOL INT, V57, P82, DOI 10.1111/j.1440-1827.2006.02061.x
   Patton S, 1995, BBA-REV BIOMEMBRANES, V1241, P407, DOI 10.1016/0304-4157(95)00014-3
   Perez RO, 2008, INT J COLORECTAL DIS, V23, P757, DOI 10.1007/s00384-008-0486-0
   Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200
   Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526
   SAFI F, 1991, CANCER-AM CANCER SOC, V68, P574, DOI 10.1002/1097-0142(19910801)68:3<574::AID-CNCR2820680322>3.0.CO;2-B
   Sahraei M, 2012, ONCOGENE, V31, P4935, DOI 10.1038/onc.2011.651
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Singh PK, 2008, J BIOL CHEM, V283, P26985, DOI 10.1074/jbc.M805036200
   Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647
   Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006
   SPICER AP, 1995, J BIOL CHEM, V270, P30093
   Wells GA, NEWCASTLE OTTAWA SCA
   WHO, 2014, CANCER
   Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200
   Yu Xiu-Wen, 2007, Ai Zheng, V26, P1204
   Zhang W, 2008, ONCOL REP, V20, P1013, DOI 10.3892/or_00000103
   Zhang X. D., 2014, IMAGING, V1, P3
NR 63
TC 11
Z9 11
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 14
PY 2015
VL 10
IS 9
AR e0138049
DI 10.1371/journal.pone.0138049
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CR8KS
UT WOS:000361601100210
PM 26367866
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Lin, SC
   Gan, ZH
   Yao, Y
   Min, DL
AF Lin, Shu Chen
   Gan, Zhi Hua
   Yao, Yang
   Min, Da Liu
TI The Prognostic Value of Forkhead Box P3 Expression in Operable Breast
   Cancer: A Large-Scale Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID REGULATORY T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; FOXP3 EXPRESSION;
   ESTROGEN-RECEPTOR; PUBLICATION BIAS; GASTRIC-CANCER; SURVIVAL;
   PROLIFERATION; ANGIOGENESIS; CHEMOTHERAPY
AB Background
   Recent studies have shown that the forkhead box P3 (FOXP3) protein has a prognostic role in breast cancer. However, these results are controversial. Therefore, the aim of this metaanalysis was to clarify the prognostic role of FOXP3 expression in operable breast cancer cases.
   Methods
   Eligible studies describing the use of FOXP3 as a prognostic factor for operable breast cancer cases were identified. Clinicopathological features, disease-free survival (DFS), and overall survival (OS) data were collected from these studies and were analyzed using Stata software.
   Results
   A total of 16 articles containing data from 13,217 breast cancer patients met the inclusion criteria established for this study. The subsequent meta-analysis that was performed showed that high levels of FOXP3 are not significantly associated with DFS and OS with significant heterogeneity. An additional subgroup analysis demonstrated that intratumoral FOXP3+ regulatory T cells (Tregs) were positively correlated with adverse clinicopathological parameters, yet they did not show an association with DFS or OS. For tumor cells, the pooled results revealed that FOXP3 is significantly associated with DFS (HR: 2.55, 95% CI: 1.23-5.30) but is not associated with clinicopathological parameters or OS. We also observed a significant correlation between FOXP3 expression and survival in the estrogen receptor-positive (ER)+ subgroup (HR: 1.83, 95% CI: 1.36-2.47 for DFS, HR: 1.87, 95% CI 1.28-2.73 for OS), in the Asian region (HR: 1.98, 95% CI: 1.56-2.50 for DFS, HR: 1.93, 95% CI: 1.12-3.35 for OS) and using the median as the FOXP3-positive cut-off value (HR: 1.94, 95% CI: 1.57-2.39 for DFS, HR: 2.06; 95% CI: 1.36-3.11 for OS).
   Conclusion
   This meta-analysis indicates that a prognostic role for FOXP3 expression in operable breast cancer cases depends on the FOXP3-positive region, ER status, geographic region and the FOXP3-positive cut-off value.
C1 [Lin, Shu Chen; Gan, Zhi Hua; Min, Da Liu] Shanghai Jiao Tong Univ, Dept Oncol, Shanghai Peoples Hosp 6, Shanghai 200030, Peoples R China.
   [Yao, Yang] Shanghai Jiao Tong Univ, Dept Oncol, Peoples Hosp 6, Shanghai 200030, Peoples R China.
RP Min, DL (reprint author), Shanghai Jiao Tong Univ, Dept Oncol, Shanghai Peoples Hosp 6, East Campus, Shanghai 200030, Peoples R China.
EM scl543042177@163.com
CR Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191
   Ali HR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3061
   Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chu R, 2015, MOL CELL ENDOCRINOL, V399, P228, DOI 10.1016/j.mce.2014.10.006
   deLeeuw RJ, 2012, CLIN CANCER RES, V18, P3022, DOI 10.1158/1078-0432.CCR-11-3216
   Devaud C, 2014, CANCER IMMUNOL IMMUN, V63, P869, DOI 10.1007/s00262-014-1581-4
   Droeser R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-134
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Earl HM, 2012, BRIT J CANCER, V107, P1257, DOI 10.1038/bjc.2012.370
   Facciabene A, 2012, CANCER RES, V72, P2162, DOI 10.1158/0008-5472.CAN-11-3687
   Gobert M, 2009, CANCER RES, V69, P2000, DOI 10.1158/0008-5472.CAN-08-2360
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189
   Gupta S, 2007, ACTA ONCOL, V46, P792, DOI 10.1080/02841860701233443
   Hao Q, 2014, CELL SIGNAL, V26, P564, DOI 10.1016/j.cellsig.2013.11.030
   Kim MH, 2013, ONCOLOGY-BASEL, V85, P128, DOI 10.1159/000351473
   Kim ST, 2013, AM J CLIN ONCOL-CANC, V36, P224, DOI 10.1097/COC.0b013e3182467d90
   Kim S, 2014, J BREAST CANCER, V17, P8, DOI 10.4048/jbc.2014.17.1.8
   Ladoire S, 2012, ANN ONCOL, V23, P2552, DOI 10.1093/annonc/mds028
   Ladoire S, 2008, CLIN CANCER RES, V14, P2413, DOI 10.1158/1078-0432.CCR-07-4491
   Ladoire S, 2011, CANCER IMMUNOL IMMUN, V60, P909, DOI 10.1007/s00262-011-1046-y
   Liu FF, 2011, BREAST CANCER RES TR, V130, P645, DOI 10.1007/s10549-011-1647-3
   Liu SZ, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0432-8
   Ma GF, 2014, BRIT J CANCER, V110, P1552, DOI 10.1038/bjc.2014.47
   Maeda N, 2014, ANN SURG ONCOL, V21, pS546, DOI 10.1245/s10434-014-3564-2
   Mahmoud SMA, 2011, BREAST CANCER RES TR, V127, P99, DOI 10.1007/s10549-010-0987-8
   Merlo A, 2009, J CLIN ONCOL, V27, P1746, DOI 10.1200/JCO.2008.17.9036
   Nishikawa H, 2014, CURR OPIN IMMUNOL, V27, P1, DOI 10.1016/j.coi.2013.12.005
   Ohara M, 2009, CANCER IMMUNOL IMMUN, V58, P441, DOI 10.1007/s00262-008-0570-x
   Paulsson J, 2014, SEMIN CANCER BIOL, V25, P61, DOI 10.1016/j.semcancer.2014.02.006
   Prieto GA, 2006, IMMUNOLOGY, V118, P58, DOI 10.1111/j.1365-2567.2006.02339.x
   Stockmann C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00069
   Sun SY, 2014, CANCER IMMUNOL IMMUN, V63, P395, DOI 10.1007/s00262-014-1519-x
   Takenaka M, 2013, MOL CLIN ONCOL, V1, P625, DOI 10.3892/mco.2013.107
   Tan B, 2014, ONCOTARGET, V5, P264, DOI 10.18632/oncotarget.1600
   Tanchot C, 2013, CANCER MICROENVIRON, V6, P147, DOI 10.1007/s12307-012-0122-y
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Triulzi T, 2013, J CELL PHYSIOL, V228, P30, DOI 10.1002/jcp.24125
   Weller P, 2014, EUR J CANCER, V50, P1291, DOI 10.1016/j.ejca.2014.02.016
   Wells GA, 2003, 11 INT COCHR C, P26
   West NR, 2013, BRIT J CANCER, V108, P155, DOI 10.1038/bjc.2012.524
   Won KY, 2013, PATHOL RES PRACT, V209, P767, DOI 10.1016/j.prp.2013.08.010
   Yan M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2869
   YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7
NR 45
TC 7
Z9 8
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 25
PY 2015
VL 10
IS 8
AR e0136374
DI 10.1371/journal.pone.0136374
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CP6KK
UT WOS:000359995500070
PM 26305693
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ruan, D
   Yu, XB
   Shrestha, S
   Wang, L
   Chen, G
AF Ruan, Di
   Yu, Xiao-Bo
   Shrestha, Sudeep
   Wang, Lin
   Chen, Gao
TI The Role of Hemosiderin Excision in Seizure Outcome in Cerebral
   Cavernous Malformation Surgery: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID CENTRAL-NERVOUS-SYSTEM; EPILEPTIC SEIZURES; VASCULAR MALFORMATIONS;
   RESECTION; PREDICTORS; ANGIOMAS; HEMANGIOMAS; MANAGEMENT; NEURONS;
   RESPECT
AB Background and Purpose
   Whether the excision of hemosiderin surrounding cerebral cavernous malformations (CCMs) is necessary to achieve a seizure-free result has been the subject of debate. Here, we report a systematic review of related literature up to Jan 1, 2015 including 594 patients to assess the effect of hemosiderin excision on seizure outcome in patients with CCMs by meta-analysis.
   Methods
   Ten studies comparing extended hemosiderin excision with only lesion resection were identified by searching the English-language literature. Meta-analyses, subgroup analyses and sensitivity analysis were conducted to determine the association between hemosiderin excision and seizure outcome after surgery.
   Results
   Seizure outcome was significantly improved in the patients who underwent an extended excision of the surrounding hemosiderin (OR, 0.62; 95% CI: 0.42-0.91; P = 0.01). In subgroup analysis, studies from Asia (OR, 0.42; 95% CI: 0.25-0.71; P = 0.001), male-majority (female ratio < 50%) studies (OR, 0.56; 95% CI: 0.33-0.96; P = 0.04), low occurrence rate of multiple CCMs (OR, 0.37; 95% CI: 0.20-0.71; P = 0.003), cohort studies (OR, 0.44; 95% CI: 0.28-0.68; P = 0.78), longer duration of seizure symptoms (> 1 year) before surgery (OR, 0.43; 95% CI: 0.22-0.84; P = 0.01), lesion diameter > 2 cm (OR, 0.41; 95% CI: 0.19-0.87; P = 0.02) and short-term (< 3 years) follow-up (OR, 0.48; 95% CI: 0.29-0.80; P = 0.005) tended to correlate with a significantly favorable outcome.
   Conclusion
   Patients who underwent extended surrounding hemosiderin excision could exhibit significantly improved seizure outcomes compared to patients without hemosiderin excision. However, further well-designed prospective multiple-center RCT studies are still needed.
C1 [Ruan, Di; Yu, Xiao-Bo; Shrestha, Sudeep; Wang, Lin; Chen, Gao] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310003, Zhejiang, Peoples R China.
RP Chen, G (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310003, Zhejiang, Peoples R China.
EM d.chengao@163.com
CR AWAD IA, 1993, NEUROSURGERY, V33, P179, DOI 10.1227/00006123-199308000-00001
   Baumann CR, 2007, EPILEPSIA, V48, P559, DOI 10.1111/j.1528-1167.2006.00941.x
   Baumann CR, 2006, EPILEPSIA, V47, P563, DOI 10.1111/j.1528-1167.2006.00468.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bertalanffy H, 2002, NEUROSURG REV, V25, P1, DOI 10.1007/s101430100179
   Cappabianca P, 1997, CLIN NEUROL NEUROSUR, V99, P179, DOI 10.1016/S0303-8467(97)00023-1
   Cascino GD, 2008, EPILEPSIA, V49, P79, DOI 10.1111/j.1528-1167.2008.01930.x
   Chang EF, 2009, NEUROSURGERY, V65, P31, DOI 10.1227/01.NEU.0000346648.03272.07
   Cramer JA, 2010, EXPERT REV NEUROTHER, V10, P885, DOI 10.1586/ERN.10.71
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Englot DJ, 2014, NEUROSURG REV, V37, P389, DOI 10.1007/s10143-014-0527-9
   Englot DJ, 2011, J NEUROSURG, V115, P1169, DOI 10.3171/2011.7.JNS11536
   Hammen T, 2007, SEIZURE-EUR J EPILEP, V16, P248, DOI 10.1016/j.seizure.2007.01.001
   Huang C, 2013, PAK J MED SCI, V29, P1116
   Jin YC, 2014, CLIN NEUROL NEUROSUR, V119, P59, DOI 10.1016/j.clineuro.2014.01.013
   Kim W, 2011, J CLIN NEUROSCI, V18, P877, DOI 10.1016/j.jocn.2010.12.008
   Kondziolka Douglas, 1995, Journal of Neurosurgery, V83, P822
   KRAEMER DL, 1994, EPILEPSIA, V35, pS30, DOI 10.1111/j.1528-1157.1994.tb05987.x
   Kwon CS, 2013, CLIN NEUROL NEUROSUR, V115, P2377, DOI 10.1016/j.clineuro.2013.08.024
   Mehdorn HM, 1998, NEUROL MED-CHIR, V38, P245, DOI 10.2176/nmc.38.suppl_245
   Moran NF, 1999, J NEUROL NEUROSUR PS, V66, P561, DOI 10.1136/jnnp.66.5.561
   Noto S, 2005, SURG NEUROL, V64, P495, DOI 10.1016/j.surneu.2005.03.045
   Stavrou I, 2008, NEUROSURGERY, V63, P888, DOI 10.1227/01.NEU.0000327881.72964.6E
   Stefan H, 2004, NERVENARZT, V75, P755, DOI 10.1007/s00115-004-1697-4
   Tymianski M, 1996, NEUROSURGERY, V38, P1176
   Van Gompel JJ, 2010, NEUROSURG FOCUS, V29
   VOLTERRA A, 1994, J NEUROSCI, V14, P2924
   von der Brelie C, 2013, EPILEPSIA, V54, P1699, DOI 10.1111/epi.12327
   vonEssen C, 1996, J NEUROCHEM, V67, P260
   Wang XY, 2013, NEUROL INDIA, V61, P288, DOI 10.4103/0028-3886.115070
   Washington CW, 2010, NEUROSURG FOCUS, V29
   Wells GA, NEWCASTLE OTTAWA SCA
   Wieser HG, 2001, EPILEPSIA, V42, P282, DOI 10.1046/j.1528-1157.2001.4220282.x
   Williamson A, 2003, EPILEPSIA, V44, P1413, DOI 10.1046/j.1528-1157.2003.23603.x
   Yeon JY, 2009, SEIZURE-EUR J EPILEP, V18, P14, DOI 10.1016/j.seizure.2008.05.010
   Zevgaridis D, 1996, ACTA NEUROCHIR, V138, P672, DOI 10.1007/BF01411470
NR 36
TC 12
Z9 14
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 25
PY 2015
VL 10
IS 8
AR e0136619
DI 10.1371/journal.pone.0136619
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CP6KK
UT WOS:000359995500099
PM 26305879
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Bianco, A
   Chiefari, E
   Nobile, CGA
   Foti, D
   Pavia, M
   Brunetti, A
AF Bianco, Aida
   Chiefari, Eusebio
   Nobile, Carmelo G. A.
   Foti, Daniela
   Pavia, Maria
   Brunetti, Antonio
TI The Association between HMGA1 rs146052672 Variant and Type 2 Diabetes: A
   Transethnic Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; INSULIN-RECEPTOR GENE; INCREASED RISK; BETA;
   HETEROGENEITY; PATHOGENESIS; PUBLICATION; SELECTION; PROTEINS; PATHWAY
AB The high-mobility group A1 (HMGA1) gene has been previously identified as a potential novel candidate gene for susceptibility to insulin resistance and type 2 diabetes (T2D) mellitus. For this reason, several studies have been conducted in recent years examining the association of the HMGA1 gene variant rs146052672 (also designated IVS5-13insC) with T2D. Because of non-univocal data and non-overlapping results among laboratories, we conducted the current meta-analysis with the aim to yield a more precise and reliable conclusion for this association. Using predetermined inclusion criteria, MEDLINE, PubMed, Web of Science, Scopus, Google Scholar and Embase were searched for all relevant available literature published until November 2014. Two of the authors independently evaluated the quality of the included studies and extracted the data. Values from the single studies were combined to determine the meta-analysis pooled estimates. Heterogeneity and publication bias were also examined. Among the articles reviewed, five studies (for a total of 13,789 cases and 13,460 controls) met the predetermined criteria for inclusion in this meta-analysis. The combined adjusted odds ratio estimates revealed that the rs146052672 variant genotype had an overall statistically significant effect on increasing the risk of development of T2D. As most of the study subjects were Caucasian, further studies are needed to establish whether the association of this variant with an increased risk of T2D is generalizable to other populations. Also, in the light of this result, it would appear to be highly desirable that further in-depth investigations should be undertaken to elucidate the biological significance of the HMGA1 rs146052672 variant.
C1 [Bianco, Aida; Chiefari, Eusebio; Nobile, Carmelo G. A.; Foti, Daniela; Pavia, Maria; Brunetti, Antonio] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
RP Pavia, M (reprint author), Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
EM pavia@unicz.it; brunetti@unicz.it
RI Foti, Daniela P/K-8038-2016; Bianco, Aida/R-6612-2016; Brunetti,
   Antonio/K-7756-2016; Odeku, Oluwatoyin A./D-3462-2011
OI Odeku, Oluwatoyin A./0000-0002-0732-1304; NOBILE, Carmelo Giuseppe
   Angelo/0000-0002-0762-513X; Foti, Daniela/0000-0002-9536-5736; Brunetti,
   Antonio/0000-0003-1533-8779; Chiefari, Eusebio/0000-0001-5329-3124;
   PAVIA, Maria/0000-0003-3879-1322
CR American Diabetes Association, 2014, DIABETES CARE S1, V37
   Arcidiacono B, 2015, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00237
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brunetti A, 2001, FASEB J, V15, P492, DOI 10.1096/fj.00-0190com
   Brunetti A, 2012, DIABETES, V61, P524
   Brunetti A, 2014, WORLD J DIABETES, V5, P128, DOI 10.4239/wjd.v5.i2.128
   Chen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076653
   Chiefari E, 2013, SCI REP-UK, V3, DOI 10.1038/srep01491
   Chiefari E, 2012, SCI REP-UK, V2, DOI 10.1038/srep00251
   Chiefari E, 2011, JAMA-J AM MED ASSOC, V305, P903, DOI 10.1001/jama.2011.207
   Chiefari E, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1040
   Chiefari E, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-24
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Doria A, 2008, CELL METAB, V8, P186, DOI 10.1016/j.cmet.2008.08.006
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Foti D, 2005, NAT MED, V11, P765, DOI 10.1038/nm1254
   Foti D, 2003, MOL CELL BIOL, V23, P2720, DOI 10.1128/MCB.23.8.2720.2732.2003
   Fradin DD, 2009, BMC PROC SUPPLEMENT, V3
   Froguel Philippe, 2012, Diabetes, V61, pe15, DOI 10.2337/db12-0800
   Gavin JR, 1999, DIABETES CARE, V22, pS5
   Genuth S, 2003, DIABETES CARE, V26, P3160
   HANIS CL, 1991, DIABETES CARE, V14, P618, DOI 10.2337/diacare.14.7.618
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hunter LH, 2014, J DIABETES METAB DIS, V1
   Iiritano S, 2012, MOL ENDOCRINOL, V26, P1578, DOI 10.1210/me.2011-1379
   Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159
   Karnes JH, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-12
   Liu L, 2012, DIABETOLOGIA, V55, P1685, DOI 10.1007/s00125-012-2518-0
   Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marquez M, 2012, DIABETES, V61, P524, DOI 10.2337/db11-0728
   McCarthy MI, 2009, CURR DIABETES REP, V9, P164, DOI 10.1007/s11892-009-0027-4
   Melillo RM, 2001, MOL CELL BIOL, V21, P2485, DOI 10.1128/MCB.21.7.2485-2495.2001
   MIETTINEN OS, 1985, J CHRON DIS, V38, P543, DOI 10.1016/0021-9681(85)90039-6
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Nakaoka H, 2009, J HUM GENET, V54, P615, DOI 10.1038/jhg.2009.95
   NEEL JV, 1962, AM J HUM GENET, V14, P353
   Pullinger CR, 2014, METAB SYNDR RELAT D, V12, P25, DOI 10.1089/met.2013.0086
   Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8
   Rothman KJ, 2008, MODERN EPIDEMIOLOGY
   Schneiderman N, 2014, DIABETES CARE, V37, P2233, DOI 10.2337/dc13-2939
   Semple Robert K., 2009, Journal of Biology (London), V8, P64, DOI [10.1186/jbiol64, 10.1186/jbiol164]
   Smith S, 2013, BMC GENET, V14, DOI 10.1186/1471-2156-14-124
   Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Stumvoll M, 2008, LANCET, V371, P2153, DOI 10.1016/S0140-6736(08)60932-0
   Taylor LE, 2014, VACCINE, V32, P3623, DOI 10.1016/j.vaccine.2014.04.085
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1
   Unger RH, 2008, JAMA-J AM MED ASSOC, V299, P1185, DOI 10.1001/jama.299.10.1185
   WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397
   Wei CD, 2013, INT J MED SCI, V10, P457, DOI 10.7150/ijms.5234
   Wells G., 2013, NEWCASTLE OTTAWA SCA
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Wray NR, 2012, EUR J HUM GENET, V20, P668, DOI 10.1038/ejhg.2011.257
   Wu WX, 2015, SCI REP-UK, V5, DOI 10.1038/srep11350
   Ye XH, 2014, MOL BIOL REP, V41, P373, DOI 10.1007/s11033-013-2871-1
   Zhang XP, 2010, DIABETES CARE, V33, P1665, DOI 10.2337/dc09-1939
   Zheng G, 2005, STAT MED, V24, P869, DOI 10.1002/sim.1976
NR 60
TC 11
Z9 11
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 21
PY 2015
VL 10
IS 8
AR e0136077
DI 10.1371/journal.pone.0136077
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CP5MR
UT WOS:000359926900069
PM 26296198
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, XL
   Zhu, QQ
   Zhu, L
   Jiang, H
   Xie, J
   Huang, W
   Xu, B
AF Zhang, Xinlin
   Zhu, Qingqing
   Zhu, Li
   Jiang, He
   Xie, Jun
   Huang, Wei
   Xu, Biao
TI Spatial/Frontal QRS-T Angle Predicts All-Cause Mortality and Cardiac
   Mortality: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CORONARY-HEART-DISEASE; RISK STRATIFICATION; MYOCARDIAL-INFARCTION;
   ELECTROCARDIOGRAPHIC ABNORMALITIES; CARDIOVASCULAR-DISEASE;
   POSTMENOPAUSAL WOMEN; GENERAL-POPULATION; EJECTION FRACTION; PROGNOSTIC
   VALUE; SUDDEN-DEATH
AB Background
   A number of studies have assessed the predictive effect of QRS-T angles in various populations since the last decade. The objective of this meta-analysis was to evaluate the prognostic value of spatial/frontal QRS-T angle on all-cause death and cardiac death.
   Methods PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were searched from their inception until June 5, 2014. Studies reporting the predictive effect of spatial/frontal QRS-T angle on all-cause/cardiac death in all populations were included. Relative risk (RR) was used as a measure of effect.
   Results
   Twenty-two studies enrolling 164,171 individuals were included. In the combined analysis in all populations, a wide spatial QRS-T angle was associated with an increase in all-cause death (maximum-adjusted RR: 1.40; 95% confidence interval [CI]: 1.32 to 1.48) and cardiac death (maximum-adjusted RR: 1.71; 95% CI: 1.54 to 1.90), a wide frontal QRS-T angle also predicted a higher rate of all-cause death (maximum-adjusted RR: 1.71; 95% CI: 1.54 to 1.90). Largely similar results were found using different methods of categorizing for QRS-T angles, and similar in subgroup populations such as general population, populations with suspected coronary heart disease or heart failure. Other stratified analyses and meta-analyses using unadjusted data also generated consistent findings.
   Conclusions
   Spatial QRS-T angle held promising prognostic value on all-cause death and cardiac death. Frontal QRS-T angle was also a promising predictor of all-cause death. Given the good predictive value of QRS-T angle, a combined stratification strategy in which QRS-T angle is of vital importance might be expected.
C1 [Zhang, Xinlin; Jiang, He; Xie, Jun; Huang, Wei; Xu, Biao] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Cardiol, Nanjing 210008, Jiangsu, Peoples R China.
   [Zhu, Qingqing] Nanjing Univ, Sch Med, Jinling Hosp, Dept Resp Med, Nanjing 210008, Jiangsu, Peoples R China.
   [Zhu, Li] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Radiol, Nanjing 210008, Jiangsu, Peoples R China.
RP Huang, W (reprint author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Cardiol, Nanjing 210008, Jiangsu, Peoples R China.
EM huangweisd@126.com; xubiao@medmail.com.cn
RI xie, jun/C-2193-2017
OI xie, jun/0000-0002-9385-3242
FU National Natural Science Foundation of China [81070195, 81270281,
   81200148]
FX This work was supported by the National Natural Science Foundation of
   China (NO. 81070195, 81270281, and 81200148). The funder had no role in
   the study design, data collection and analysis, writing of the report,
   and decision to submit the article for publication.
CR Aro AL, 2012, EUROPACE, V14, P872, DOI 10.1093/europace/eur393
   Bailey JJ, 2001, J AM COLL CARDIOL, V38, P1902, DOI 10.1016/S0735-1097(01)01667-9
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Borleffs CJW, 2009, CIRC-ARRHYTHMIA ELEC, V2, P548, DOI 10.1161/CIRCEP.109.859108
   Brosnan M, 2015, HEART RHYTHM, V12, P130, DOI 10.1016/j.hrthm.2014.09.060
   Church TR, 2002, J ELECTROCARDIOL, V35, P117, DOI 10.1054/jelc.2002.37168
   de Bie MK, 2013, EUROPACE, V15, P290, DOI 10.1093/europace/eus306
   de Bruyne MC, 1999, EUR HEART J, V20, P278, DOI 10.1053/euhj.1998.1276
   de Torbal A, 2004, CARDIOLOGY, V101, P199, DOI 10.1159/000076697
   DERN PL, 1967, CIRCULATION, V36, P823, DOI 10.1161/01.CIR.36.6.823
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Goldberger JJ, 2014, J AM COLL CARDIOL, V63, P1879, DOI 10.1016/j.jacc.2013.12.021
   Goldberger JJ, 2011, CIRCULATION, V123, P2423, DOI 10.1161/CIRCULATIONAHA.110.959734
   Goldenberg I, 2008, J AM COLL CARDIOL, V51, P288, DOI 10.1016/j.jacc.2007.08.058
   Gotsman I, 2013, AM J CARDIOL, V111, P1452, DOI 10.1016/j.amjcard.2013.01.294
   Halkin A, 2012, J AM COLL CARDIOL, V60, P2271, DOI 10.1016/j.jacc.2012.09.003
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   KANNEL WB, 1987, AM HEART J, V113, P370, DOI 10.1016/0002-8703(87)90280-8
   Kardys I, 2003, EUR HEART J, V24, P1357, DOI 10.1016/S0195-668X(03)00203-3
   Kentta T, 2011, EUROPACE, V13, P701, DOI 10.1093/europace/euq461
   Laukkanen JA, 2014, AM J CARDIOL, V113, P1178, DOI 10.1016/j.amjcard.2013.12.026
   Leslie LK, 2012, CIRCULATION, V125, P2621, DOI 10.1161/CIRCULATIONAHA.111.087940
   Lipton JA, 2010, CORONARY ARTERY DIS, V21, P26, DOI 10.1097/MCA.0b013e328332ee32
   Lown MT, 2012, AM J CARDIOL, V109, P307, DOI 10.1016/j.amjcard.2011.09.014
   Macfarlane PW, 2012, EUROPACE, V14, P773, DOI 10.1093/europace/eus057
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Maron BJ, 2014, J AM COLL CARDIOL, V64, P1479, DOI 10.1016/j.jacc.2014.05.006
   Maron BJ, 1998, CIRCULATION, V97, P2294, DOI 10.1161/01.CIR.97.22.2294
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Pavri BB, 2008, CIRCULATION, V117, P3181, DOI 10.1161/CIRCULATIONAHA.107.733451
   Raposeiras-Roubin S, 2014, AM J CARDIOL, V113, P1312, DOI 10.1016/j.amjcard.2014.01.406
   Rautaharju PM, 2006, AM J CARDIOL, V97, P309, DOI 10.1016/j.amjcard.2005.08.046
   Rautaharju PM, 2006, CIRCULATION, V113, P481, DOI 10.1161/CIRCULATIONAHA.105.537415
   Rautaharju PM, 2006, CIRCULATION, V113, P473, DOI 10.1161/CIRCULATIONAHA.104.496091
   Rubulis A, 2010, J ELECTROCARDIOL, V43, P310, DOI 10.1016/j.jelectrocard.2010.05.004
   Selvaraj S, 2014, J AM SOC ECHOCARDIOG, V27, P74, DOI 10.1016/j.echo.2013.08.023
   Strauss DG, 2013, CIRC-ARRHYTHMIA ELEC, V6, P1156, DOI 10.1161/CIRCEP.113.000411
   Vend N, 2013, HEART RHYTHM, V10, pS110
   Wells GA, NEWCASTLE OTTAWA SCA
   Whang W, 2012, AM J CARDIOL, V109, P981, DOI 10.1016/j.amjcard.2011.11.027
   Yamazaki T, 2005, HEART RHYTHM, V2, P73, DOI 10.1016/j.hrthm.2004.10.040
   Zhang ZM, 2007, AM J CARDIOL, V100, P844, DOI 10.1016/j.amjcard.2007.03.104
NR 43
TC 5
Z9 6
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 18
PY 2015
VL 10
IS 8
AR e0136174
DI 10.1371/journal.pone.0136174
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CP1VY
UT WOS:000359666100107
PM 26284799
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Han, C
   He, X
   Xia, XH
   Li, YZ
   Shi, XG
   Shan, ZY
   Teng, WP
AF Han, Cheng
   He, Xue
   Xia, Xinghai
   Li, Yongze
   Shi, Xiaoguang
   Shan, Zhongyan
   Teng, Weiping
TI Subclinical Hypothyroidism and Type 2 Diabetes: A Systematic Review and
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID INTIMA-MEDIA THICKNESS; THYROID-DISEASE; HEART-DISEASE; DOUBLE-BLIND;
   RISK-FACTOR; ASSOCIATION; DYSFUNCTION; PREVALENCE; NEPHROPATHY;
   GUIDELINES
AB Background
   Abundant evidence suggests an association between subclinical hypothyroidism (SCH) and type 2 diabetes mellitus (T2DM), but small sample sizes and inconclusive data in the literature complicate this assertion.
   Objective
   We measured the prevalence of SCH in T2DM population, and investigated whether T2DM increase the risk of SCH and whether SCH was associated with diabetic complications.
   METHODS
   We conducted a meta-analysis using PubMed, EMBASE, Web of Science, Wan Fang, CNKI and VIP databases for literature search. We obtained studies published between January 1, 1980 to December 1, 2014. The studies were selected to evaluate the prevalence of SCH in T2DM subjects, compare the prevalence of SCH in T2DM subjects with those nondiabetics, and investigate whether diabetic complications were more prevalent in SCH than those who were euthyroid. Fixed and random effects meta-analysis models were used, and the outcome was presented as a pooled prevalence with 95% confidence interval (95% CI) or a summary odds ratio (OR) with 95% CI.
   RESULTS
   Through literature search, 36 articles met the inclusion criteria and these articles contained a total of 61 studies. Funnel plots and Egger's tests showed no publication bias in our studies, except for the pooled prevalence of SCH in T2DM (P = 0.08) and OR for SCH in T2DM (P = 0.04). Trim and fill method was used to correct the results and five potential missing data were replaced respectively. The adjusted pooled prevalence of SCH in T2DM patients was 10.2%, meanwhile, T2DM was associated with a 1.93-fold increase in risk of SCH (95% CI: 1.66, 2.24). Furthermore, SCH might affect the development of diabetic complications with an overall OR of 1.74 (95% CI: 1.34, 2.28) for diabetic nephropathy, 1.42 (95% CI: 1.21, 1.67) for diabetic retinopathy, 1.85 (95% CI: 1.35, 2.54) for peripheral arterial disease, and 1.87 (95% CI: 1.06, 3.28) for diabetic peripheral neuropathy.
   Conclusions
   T2DM patients are more likely to have SCH when compared with healthy population and SCH may be associated with increased diabetic complications. It is necessary to screen thyroid function in patients with T2DM, and appropriate individualized treatments in addition to thyroid function test should be given to T2DM patients with SCH as well.
C1 [Han, Cheng; He, Xue; Xia, Xinghai; Li, Yongze; Shi, Xiaoguang; Shan, Zhongyan; Teng, Weiping] China Med Univ, Affiliated Hosp 1, Liaoning Prov Key Lab Endocrine Dis, Dept Endocrinol & Metab,Inst Endocrinol, Shenyang, Liaoning Provin, Peoples R China.
RP Shi, XG (reprint author), China Med Univ, Affiliated Hosp 1, Liaoning Prov Key Lab Endocrine Dis, Dept Endocrinol & Metab,Inst Endocrinol, Shenyang, Liaoning Provin, Peoples R China.
EM xiaoguangshi_cmu@163.com
OI Xia, Xinghai/0000-0002-4860-4562; Han, Cheng/0000-0001-8553-4420
FU National Natural Science Foundation [81370893]
FX This work was supported by the National Natural Science Foundation
   (81370893) (URL:
   http://npd.nsfc.gov.cn/fundingProjectSearchAction.action). Sponsors had
   no role in study design, data collection and analysis, decision to
   publish, or in manuscript preparation.
CR Al-Hamodi Z, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-99
   Asvold BO, 2011, EUR J ENDOCRINOL, V164, P101, DOI 10.1530/EJE-10-0705
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526
   Cappelli C, 2009, DIABETES CARE, V32, P1589, DOI 10.2337/dc09-0273
   Chen HS, 2007, DIABETIC MED, V24, P1336, DOI 10.1111/j.1464-5491.2007.02270.x
   Chen Y, 2014, MED INFORM, V27, P169
   Deng X, 2011, CHINESE COMMUNITY DO, V13, P124
   Diez JJ, 2012, DIABETIC MED, V29, P1510, DOI 10.1111/j.1464-5491.2012.03687.x
   Diez JJ, 2011, EXP CLIN ENDOCR DIAB, V119, P201, DOI 10.1055/s-0031-1271691
   Distiller LA, 2014, DIABETIC MED, V31, P172, DOI 10.1111/dme.12342
   Duan Q, 2014, ACTA ACAD MED NEIMON, V36, P439
   [付秀立 Fu Xiuli], 2013, [中国全科医学, Chinese General Practice], V16, P2674
   Furukawa S, 2014, ENDOCR J, V61, P1011, DOI 10.1507/endocrj.EJ14-0206
   Garber JR, 2012, THYROID, V22, P1200, DOI 10.1089/thy.2012.0205
   Ghazali S M, 2010, Niger J Physiol Sci, V25, P173
   Gopinath Bamini, 2008, Diabetes Res Clin Pract, V82, pe11, DOI 10.1016/j.diabres.2008.08.017
   Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404
   Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004
   Hellstrom A, 2002, J CLIN ENDOCR METAB, V87, P3413, DOI 10.1210/jc.87.7.3413
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489
   KABADI UM, 1993, ARCH INTERN MED, V153, P957, DOI 10.1001/archinte.153.8.957
   Kadiyala R, 2010, INT J CLIN PRACT, V64, P1130, DOI 10.1111/j.1742-1241.2010.02376.x
   Kim SK, 2009, ENDOCR J, V56, P753, DOI 10.1507/endocrj.K09E-049
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1
   Kotsis V, 2007, J HYPERTENS, V25, P993, DOI 10.1097/HJH.0b013e328082e2ff
   Li JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108315
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Liu C, 2014, J CLIN RES, V31, P323
   [刘红 Liu Hong], 2014, [中国糖尿病杂志, Chinese Journal of Diabetes], V22, P511
   Liu W, 2009, CLIN FOCUS, V24, P2063
   Liu W, 2007, CLIN FOCUS, V22, P1558
   Liu X, 2012, GUIDE CHINA MED, V10, P55
   Lu L, 2014, SHANXI MED J, V43, P2374
   Lv B, 2014, GUIDE CHINA MED, V12, P135
   Meng FG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081294
   Monami M, 2011, DIABETES-METAB RES, V27, P362, DOI 10.1002/dmrr.1184
   Monzani F, 2004, J CLIN ENDOCR METAB, V89, P2099, DOI 10.1210/jc.2003-031669
   Nagasaki T, 2009, EUR J ENDOCRINOL, V160, P409, DOI 10.1530/EJE-08-0742
   Navegantes LCC, 1996, BRAZ J MED BIOL RES, V29, P665
   Ortiga-Carvalho TM, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740121
   Owen PJD, 2006, J CLIN ENDOCR METAB, V91, P2126, DOI 10.1210/jc.2005-2108
   Pearce SHS, 2013, EUR THYROID J, V2, P215, DOI 10.1159/000356507
   PERNEGER TV, 1994, ANN INTERN MED, V121, P912, DOI 10.7326/0003-4819-121-12-199412150-00002
   Razvi S, 2008, J CLIN ENDOCR METAB, V93, P2998, DOI 10.1210/jc.2008-0167
   Razvi S, 2007, J CLIN ENDOCR METAB, V92, P1715, DOI 10.1210/jc.2006-1869
   Reusch CE, 1999, J AM VET MED ASSOC, V215, P1297
   Ripoli A, 2005, J AM COLL CARDIOL, V45, P439, DOI 10.1016/j.jacc.2004.10.044
   Rivolta G, 1999, J ENDOCRINOL INVEST, V22, P693, DOI 10.1007/BF03343631
   SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386
   Sevilla-Romero E, 2002, OPHTHALMIC RES, V34, P181, DOI 10.1159/000063885
   Shao F, 2014, J CLIN RES, V31, P1291
   Shen Y, 2012, WUHAN U J, V33, P415
   Shi Y, 2012, GUIDE CHINA MED, V10, P25
   SHIRABE T, 1975, J NEUROL NEUROSUR PS, V38, P241, DOI 10.1136/jnnp.38.3.241
   Sun L, 2013, ZEEJIANG PRACTICAL M, V17, P342
   Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228
   Tamez-Perez HE, 2012, MED CLIN-BARCELONA, V138, P475, DOI 10.1016/j.medcli.2011.08.009
   Tang J, 2012, CLIN J PREV CONTR CH, V20, P591
   Taylor PN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6681
   TUNBRIDGE WMG, 1981, BRIT MED J, V282, P258, DOI 10.1136/bmj.282.6260.258
   TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x
   Turemen EE, 2011, ENDOCR J, V58, P349
   VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x
   Wang C, 1997, ENDOCRIN METAB CLIN, V26, P189, DOI 10.1016/S0889-8529(05)70240-1
   [王玫 Wang Mei], 2012, [中国现代医学杂志, China Journal of Modern Medicine], V22, P66
   Wang Y, 2012, J MODERN LAB MED, V27, P132
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Xi W, 2014, INNER MONGOLIA MED, P686
   Xu J, 2014, SCI WORLD J, DOI 10.1155/2014/926932
   Xu X, 2013, ACTA U MED ANHUI, V48, P675
   Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292
   Yerdelen D, 2010, J NEUROL SCI, V294, P89, DOI 10.1016/j.jns.2010.03.026
   Zang S, 2011, J MED RES, V40, P114
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
   [张冬梅 Zhang Dongmei], 2014, [中国糖尿病杂志, Chinese Journal of Diabetes], V22, P25
   Zhang H, 2012, SHANDONG MED J, V52, P52
   Zhang JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078151
   Zhang M, 2012, J NANCHANG U MED SCI, V52, P42
   [张妮娅 ZHANG Ni-ya], 2009, [中国实用内科杂志, Chinese Journal of Practical Internal Medicine], V29, P1106
   Zhao F, 2012, CHIN J DIABETES, V11, P417
   Zhao R, 2013, NINGXIA MED J, V35, P810
   Zhao W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109549
   Zhou J, 2013, MED RECAPITULATE, V19, P4383
   Zhu Y, 2014, ZHEJIANG CLIN MED J, V16, P1451
   Zou SR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040718
   洪畋, 2012, [中国老年学杂志, Chinese Journal of Gerontology], V32, P3909
NR 88
TC 37
Z9 38
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 13
PY 2015
VL 10
IS 8
AR e0135233
DI 10.1371/journal.pone.0135233
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO9JX
UT WOS:000359492800043
PM 26270348
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, YL
   Lei, HB
   Zhang, JX
   Wang, J
   Li, K
   Dong, WG
AF Liu, Yulan
   Lei, Hongbo
   Zhang, Jixiang
   Wang, Jun
   Li, Kui
   Dong, Weiguo
TI Associations between the Genetic Polymorphisms of Osteopontin Promoter
   and Susceptibility to Cancer in Chinese Population: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CELL LUNG-CANCER; GASTRIC-CANCER; OPN EXPRESSION; BREAST-CANCER; MARKER;
   METASTASIS; SURVIVAL; DISEASE; COHORT; RISK
AB Background and Aim
   Several studies have been conducted to examine the associations between osteopontin (OPN) promoter gene SPP1 polymorphisms with human cancers in Chinese population, but the results remain inconsistent. The aim of this meta-analysis is to clarify the associations between SPP1 polymorphisms and cancer susceptibility.
   Methods
   All eligible case-control studies published up to March 2015 were identified by searching PubMed, Web of Science, Embase, and Cochrane Library without language restrictions. Pooled odds ratio (OR) and 95% confidence interval (95% CI) were calculated using fixed- or random-effect model.
   Results
   A total of 11 case-control studies were included; of those, there were eleven studies (3130 cases and 3828 controls) for -443T>C polymorphism, ten studies (3019 cases and 3615 controls) for -156G>GG polymorphism, eight studies (2258 cases and 2846 controls) for -66T>G polymorphism. Overall, no evidence indicated that the -443T>C polymorphism was associated with cancer risk (OR = 0.93, 95% CI 0.62-1.38 for dominant model, OR = 1.06, 95% CI 0.73-1.55 for recessive model, OR = 0.88, 95% CI 0.62-1.26 for CT vs TT model, OR = 1.03, 95% CI 0.61-1.73 for CC vs TT model). While, a significantly increase risk was found for -156 G>GG polymorphism (OR = 1.22, 95% CI 1.10-1.35 for dominant model, OR = 1.25, 95% CI 1.10-1.41 for recessive model, OR = 1.18, 95% CI 1.06-1.32 for GGG vs GG model, OR = 1.35, 95% CI 1.09-1.68 for GGGG vs GG model). For -66T>G polymorphism, we found a decrease risk of cancer (OR = 0.84, 95% CI 0.71-0.98 for dominant model), but this result changed (OR = 0.93, 95% CI 0.77-1.12 for dominant model) when we excluded a study.
   Conclusion
   This meta-analysis suggests that in Chinese population the - 156G>GG polymorphism of SPP1 might be a risk factor for human cancers, while - 443T>C mutation is not associated with cancer risk. For - 66T>G polymorphism, it may be a protective factor for human cancers.
C1 [Liu, Yulan; Zhang, Jixiang; Wang, Jun; Li, Kui; Dong, Weiguo] Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan 430072, Peoples R China.
   [Lei, Hongbo] Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan 430072, Peoples R China.
RP Dong, WG (reprint author), Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan 430072, Peoples R China.
EM dwg@whu.edu.cn
CR Alain K, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-444
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chang YS, 2007, LUNG CANCER, V57, P373, DOI 10.1016/j.lungcan.2007.04.005
   Chen JX, 2010, J HUM GENET, V55, P456, DOI 10.1038/jhg.2010.48
   Chen YZ, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-45
   Chiu YW, 2010, ORAL ONCOL, V46, P302, DOI 10.1016/j.oraloncology.2010.01.018
   Chu H, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0018108, DOI 10.1371/J0URNAL.P0NE.0018108]
   Chu ML, 2011, INVEST OPHTH VIS SCI, V52, P7084, DOI 10.1167/iovs.11-7539
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dudemaine PL, 2014, ANIM GENET, V45, P629, DOI 10.1111/age.12176
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fan Y, 2013, DNA CELL BIOL, V32, P594, DOI 10.1089/dna.2013.2090
   Hashiguchi Y, 2006, MED ONCOL, V23, P205, DOI 10.1385/MO:23:2:205
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255
   Hudson TJ, 2013, J INTERN MED, V274, P440, DOI 10.1111/joim.12097
   Irita J, 2011, AM J PHYSIOL-RENAL, V301, pF833, DOI 10.1152/ajprenal.00557.2010
   Kato R, 2009, CIRC J, V73, P152, DOI 10.1253/circj.CJ-08-0687
   Lee TY, 2013, J CLIN GASTROENTEROL, V47, pE55, DOI 10.1097/MCG.0b013e31827b9325
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mirza M, 2008, INT J CANCER, V122, P889, DOI 10.1002/ijc.23204
   Mu GY, 2013, CELL PHYSIOL BIOCHEM, V32, P171, DOI 10.1159/000350133
   Ramchandani D, 2013, ONCOL REP, V30, P1860, DOI 10.3892/or.2013.2632
   Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005
   Schultz J, 2009, MOL CARCINOGEN, V48, P14, DOI 10.1002/mc.20452
   SENGER DR, 1979, CELL, V16, P885, DOI 10.1016/0092-8674(79)90103-X
   Shen ZP, 2014, CELL PHYSIOL BIOCHEM, V34, P1190, DOI 10.1159/000366331
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stepien E, 2011, CLIN BIOCHEM, V44, P826, DOI 10.1016/j.clinbiochem.2011.04.016
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang JD, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0211-5
   Weber GF, 2010, BRIT J CANCER, V103, P861, DOI 10.1038/sj.bjc.6605834
   Weber GF, 2011, ONCOL REP, V25, P433, DOI 10.3892/or.2010.1106
   Wu CY, 2007, GUT, V56, P782, DOI 10.1136/gut.2006.109868
   Xu Q, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0065208, DOI 10.1371/J0URNAL.P0NE.0065208]
   Xu Q, 2011, CANCER BIOMARK, V10, P233, DOI 10.3233/CBM-2012-0251
   Zhang R, 2015, CELL PHYSIOL BIOCHEM, V35, P175, DOI 10.1159/000369685
   Zhao FJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-477
   Zhao XQ, 2014, INT J CLIN EXP PATHO, V7, P6914
NR 40
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 12
PY 2015
VL 10
IS 8
AR e0135318
DI 10.1371/journal.pone.0135318
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO9JT
UT WOS:000359492300095
PM 26267616
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, ML
   Wu, L
   Ming, QS
AF Liu, Mingli
   Wu, Lang
   Ming, Qingsen
TI How Does Physical Activity Intervention Improve Self-Esteem and
   Self-Concept in Children and Adolescents? Evidence from a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID BODY-COMPOSITION; OVERWEIGHT CHILDREN; PUBLIC-HEALTH; DEPRESSION;
   EXERCISE; PROGRAM; ANXIETY; PARTICIPATION; VALIDATION; SYMPTOMS
AB Objective
   To perform a systematic review and meta-analysis for the effects of physical activity intervention on self-esteem and self-concept in children and adolescents, and to identify moderator variables by meta-regression. Design A meta-analysis and meta-regression.
   Method
   Relevant studies were identified through a comprehensive search of electronic databases. Study inclusion criteria were: (1) intervention should be supervised physical activity, (2) reported sufficient data to estimate pooled effect sizes of physical activity intervention on self-esteem or self-concept, (3) participants' ages ranged from 3 to 20 years, and (4) a control or comparison group was included. For each study, study design, intervention design and participant characteristics were extracted. R software (version 3.1.3) and Stata (version 12.0) were used to synthesize effect sizes and perform moderation analyses for determining moderators.
   Results
   Twenty-five randomized controlled trial (RCT) studies and 13 non-randomized controlled trial (non-RCT) studies including a total of 2991 cases were identified. Significant positive effects were found in RCTs for intervention of physical activity alone on general self outcomes (Hedges' g = 0.29, 95% confidence interval [CI]: 0.14 to 0.45; p = 0.001), self-concept (Hedges' g = 0.49, 95% CI: 0.10 to 0.88, p = 0.014) and self-worth (Hedges' g = 0.31, 95% CI: 0.13 to 0.49, p = 0.005). There was no significant effect of intervention of physical activity alone on any outcomes in non-RCTs, as well as in studies with intervention of physical activity combined with other strategies. Meta-regression analysis revealed that higher treatment effects were associated with setting of intervention in RCTs (beta = 0.31, 95% CI: 0.07 to 0.55, p = 0.013).
   Conclusion
   Intervention of physical activity alone is associated with increased self-concept and self-worth in children and adolescents. And there is a stronger association with school-based and gymnasium-based intervention compared with other settings.
C1 [Liu, Mingli; Ming, Qingsen] Cent S Univ, Xiangya Hosp 2, Inst Med Psychol, Changsha 410011, Hunan, Peoples R China.
   [Liu, Mingli] Hunan Univ Sci & Technol, Sch Educ, Xiangtan 411201, Hunan, Peoples R China.
   [Wu, Lang] Mayo Clin, Ctr Clin & Translat Sci, Rochester, MN 55905 USA.
RP Liu, ML (reprint author), Cent S Univ, Xiangya Hosp 2, Inst Med Psychol, Changsha 410011, Hunan, Peoples R China.
EM mlliupsy@163.com
RI Wu, Lang/M-4053-2017
FU Hunan Provincial Education Department [914 \ B41120]
FX This research was supported by Scientific Research Fund of Hunan
   Provincial Education Department (grant number 914 vertical bar B41120)
   (URL: http://gov.hnedu.cn/). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ahn S, 2011, J PEDIATR PSYCHOL, V36, P385, DOI 10.1093/jpepsy/jsq107
   ALPERT B, 1990, HEALTH PSYCHOL, V9, P48, DOI 10.1037/0278-6133.9.1.48
   Annesi JJ, 2006, J PSYCHOSOM RES, V61, P515, DOI 10.1016/j.jpsychores.2006.04.009
   Atlas WHO, 2005, CHILD AD MENT HLTH R
   Babyak M, 2000, PSYCHOSOM MED, V62, P633, DOI 10.1097/00006842-200009000-00006
   Baumeister R. F., 1998, HDB SOCIAL PSYCHOL, P680
   BECKER BJ, 1988, BRIT J MATH STAT PSY, V41, P257, DOI 10.1111/j.2044-8317.1988.tb00901.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belfer ML, 2008, J CHILD PSYCHOL PSYC, V49, P226, DOI 10.1111/j.1469-7610.2007.01855.x
   Borenstein M., 2009, INTRO METAANALYSIS
   Brown HE, 2013, SPORTS MED, V43, P195, DOI 10.1007/s40279-012-0015-8
   Buffart LM, 2014, J SCI MED SPORT, V17, P67, DOI 10.1016/j.jsams.2013.02.015
   Butler R. J., 2005, CHILD ADOLESCENT MEN, V4, P190, DOI DOI 10.1111/J.1475-3588.2005.00368.X
   CAMPBELL JD, 1990, J PERS SOC PSYCHOL, V59, P538, DOI 10.1037/0022-3514.59.3.538
   CROCKER J, 1989, PSYCHOL REV, V96, P608, DOI 10.1037/0033-295X.96.4.608
   Davis CL, 2011, HEALTH PSYCHOL, V30, P91, DOI 10.1037/a0021766
   Dishman R, 1986, MENTAL HLTH, P303
   DISHMAN RK, 1995, QUEST, V47, P362, DOI 10.1080/00336297.1995.10484164
   Dishman RK, 2006, HEALTH PSYCHOL, V25, P396, DOI 10.1037/0278-6133.25.3.396
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ekeland E, 2005, BRIT J SPORT MED, V39, P792, DOI 10.1136/bjsm.2004.017707
   Green JPHaS, 2008, COCHRANE HDB SYSTEMA
   Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D
   Hassmen P, 2000, PREV MED, V30, P17, DOI 10.1006/pmed.1999.0597
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HILYER JC, 1982, J COUNS PSYCHOL, V29, P292, DOI 10.1037/0022-0167.29.3.292
   Hoagwood K, 2003, J SCHOOL PSYCHOL, V41, P3, DOI 10.1016/S0022-4405(02)00141-3
   Holley J, 2011, BRIT J CLIN PSYCHOL, V50, P84, DOI 10.1348/014466510X496220
   Hutzler Y, 1998, PERCEPT MOTOR SKILL, V86, P111, DOI 10.2466/pms.1998.86.1.111
   IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25
   Jelalian E, 2011, CHILD HEALTH CARE, V40, P197, DOI 10.1080/02739615.2011.590391
   Larun L, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004691.pub2
   Lee A, 2009, J CLIN CHILD ADOLESC, V38, P219, DOI 10.1080/15374410802698396
   Lubans DR, 2010, PSYCHOL SPORT EXERC, V11, P497, DOI 10.1016/j.psychsport.2010.06.009
   Marsh HW, 1990, EDUC PSYCHOL REV, V2, P77, DOI 10.1007/BF01322177
   Mazzoni ER, 2009, ADAPT PHYS ACT Q, V26, P259, DOI 10.1123/apaq.26.3.259
   McGee R, 2000, J ADOLESCENCE, V23, P569, DOI 10.1006/jado.2000.0344
   McGee R, 2001, J ABNORM CHILD PSYCH, V29, P281, DOI 10.1023/A:1010353711369
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105
   O'Brien E, 2006, SELF ESTEEM ISSUES A, P306
   Orth U, 2008, J PERS SOC PSYCHOL, V95, P695, DOI 10.1037/0022-3514.95.3.695
   Penedo FJ, 2005, CURR OPIN PSYCHIATR, V18, P189, DOI 10.1097/00001504-200503000-00013
   PERCY LE, 1981, PERCEPT MOTOR SKILL, V52, P42, DOI 10.2466/pms.1981.52.1.42
   Robinson TN, 2010, ARCH PEDIAT ADOL MED, V164, P995, DOI 10.1001/archpediatrics.2010.197
   Rosenberg M, 1985, SELF CONCEPT PSYCHOL, P205
   Schranz N, 2014, BRIT J SPORT MED, V48, P1482, DOI 10.1136/bjsports-2013-092209
   Seabra AC, 2014, SCAND J MED SCI SPOR, V24, P10, DOI 10.1111/sms.12268
   SHAVELSON RJ, 1976, REV EDUC RES, V46, P407, DOI 10.2307/1170010
   Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x
   Staiano AE, 2013, OBESITY, V21, P598, DOI [10.1002/oby.20282, 10.1038/oby.2012.143]
   Trzesniewski KH, 2006, DEV PSYCHOL, V42, P381, DOI 10.1037/0012-1649.42.2.381
   Van Wely L, 2014, CLIN REHABIL, V28, P972, DOI 10.1177/0269215513500971
   Velez A, 2010, J STRENGTH COND RES, V24, P1065, DOI 10.1519/JSC.0b013e3181cc230a
   Weintraub DL, 2008, ARCH PEDIAT ADOL MED, V162, P232, DOI 10.1001/archpediatrics.2007.43
NR 56
TC 53
Z9 53
U1 8
U2 126
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 4
PY 2015
VL 10
IS 8
AR e0134804
DI 10.1371/journal.pone.0134804
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO1VB
UT WOS:000358942700068
PM 26241879
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, SC
   Xia, L
   Zhang, J
   Lu, XH
   Hu, DK
   Zhang, HT
   Li, HJ
AF Liu, Shuang-Chun
   Xia, Lei
   Zhang, Jin
   Lu, Xue-Hong
   Hu, Da-Kang
   Zhang, Hai-Tao
   Li, Hai-Jun
TI Gout and Risk of Myocardial Infarction: A Systematic Review and
   Meta-Analysis of Cohort Studies
SO PLOS ONE
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; US GENERAL-POPULATION; MIDDLE-AGED MEN; SERUM
   URIC-ACID; HEART-DISEASE; CARDIOVASCULAR MORTALITY; GLOMERULAR
   HYPERTENSION; INDEPENDENT IMPACT; ALL-CAUSE; HYPERURICEMIA
AB Introduction
   A high incidence of myocardial infarction among patients with gout has been suggested by several observational studies. We performed a meta-analysis to evaluate the association between gout and the risk of myocardial infarction.
   Materials and Methods
   The PubMed and Embase databases were searched from inception to October 2014 for cohort studies that evaluating the association between gout and the risk of myocardial infarction. Summary estimates were derived using a random-effects model and reported as relative risks (RRs) with 95% confidence intervals (CIs).
   Results
   Five studies involving 8,656,413 participants with a total of 1000 MI events were included. Overall, gout was associated with an increased risk of myocardial infarction (RR 1.45; 95% CI, 1.19-1.75; p<0.001), and the association referred to non-fatal myocardial infarction (RR 1.29; 95% CI, 1.19-1.39; p<0.001) but not fatal myocardial infarction (RR 1.11; 95% CI, 0.96-1.28; p = 0.174). The increased risk was observed in both women (RR 1.62; 95% CI, 1.18-2.21; p = 0.003) and men (RR 1.45; 95% CI, 1.21-1.74; p<0.001). Stratified analysis revealed a gradual increase in myocardial infarction risk with a younger age of gout onset (age 20-44 years old (RR 2.82; 95% CI, 1.38-5.79; p = 0.05); 45-69 years old (RR 1.85; 95% CI, 1.22-2.82; p = 0.04); >= 70 years old (RR 1.52; 95% CI, 1.22-1.88; p<0.001)).
   Conclusion
   This meta-analysis suggests that patients with gout have an increased risk of myocardial infarction.
C1 [Liu, Shuang-Chun; Zhang, Jin; Hu, Da-Kang] Taizhou Municipal Hosp, Dept Clin Lab, Taizhou, Zhejiang, Peoples R China.
   [Xia, Lei] Shanghai Jiao Tong Univ, Dept Urinary Surg, Affiliated Renji Hosp, Sch Med, Shanghai 200030, Peoples R China.
   [Lu, Xue-Hong] Taizhou Municipal Hosp, Dept Pediat, Taizhou, Zhejiang, Peoples R China.
   [Zhang, Hai-Tao] Taizhou Municipal Hosp, Dept Urinary Surg, Taizhou, Zhejiang, Peoples R China.
   [Li, Hai-Jun] Taizhou Municipal Hosp, Dept Neurol, Taizhou, Zhejiang, Peoples R China.
RP Zhang, HT (reprint author), Taizhou Municipal Hosp, Dept Urinary Surg, Taizhou, Zhejiang, Peoples R China.
EM tzzhanghaitao@hotmail.com; lhjyy@126.com
FU Medical Science and Technology Support of Zhejiang Province [2013ZHB015]
FX The present study was supported by Medical Science and Technology
   Support of Zhejiang Province (2013ZHB015). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Annemans L, 2008, ANN RHEUM DIS, V67, P960, DOI 10.1136/ard.2007.076232
   Arromdee E, 2002, J RHEUMATOL, V29, P2403
   Ballocca F, 2014, EUR J PREV CARDIOL
   Bardin T, 2014, ANN RHEUM DIS, V73, P787, DOI 10.1136/annrheumdis-2014-eular.5164
   Becker MA, 2006, RHEUM DIS CLIN N AM, V32, P275, DOI 10.1016/j.rdc.2006.02.005
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brodov Y, 2010, AM J CARDIOL, V106, P1717, DOI 10.1016/j.amjcard.2010.07.046
   Busso N, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2952
   Choi HK, 2007, CIRCULATION, V116, P894, DOI 10.1161/CIRCULATIONAHA.107.703389
   Clarson LE, 2015, EUR J PREV CARDIOL, V22, P335, DOI 10.1177/2047487313514895
   Dalbeth N, 2005, RHEUMATOLOGY, V44, P1090, DOI 10.1093/rheumatology/keh640
   De Vera MA, 2010, ANN RHEUM DIS, V69, P1162, DOI 10.1136/ard.2009.122770
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Edwards N Lawrence, 2008, Cleve Clin J Med, V75 Suppl 5, pS13
   Fang J, 2000, JAMA-J AM MED ASSOC, V283, P2404, DOI 10.1001/jama.283.18.2404
   Feig DI, 2008, NEW ENGL J MED, V359, P1811, DOI 10.1056/NEJMra0800885
   FREEDMAN DS, 1995, AM J EPIDEMIOL, V141, P637, DOI 10.1093/oxfordjournals.aje.a117479
   Gersch C, 2008, NUCLEOS NUCLEOT NUCL, V27, P967, DOI 10.1080/15257770802257952
   Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad
   Gur M, 2013, J CARDIOL, V61, P144, DOI 10.1016/j.jjcc.2012.08.023
   Halligan C, 2005, CURR RHEUMATOL REV, V1, P193, DOI 10.2174/1573397054023128
   Hartling L, 2013, J CLIN EPIDEMIOL, V66, P982, DOI 10.1016/j.jclinepi.2013.03.003
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Johnson RJ, 2003, HYPERTENSION, V41, P1183, DOI 10.1161/01.HYP.0000069700.62727.C5
   Kanellis J, 2003, HYPERTENSION, V41, P1287, DOI 10.1161/01.HYP.0000072820.07472.3B
   Kanellis J, 2005, SEMIN NEPHROL, V25, P39, DOI 10.1016/j.semnephrol.2004.09.007
   Kim SY, 2010, ARTHRIT CARE RES, V62, P170, DOI 10.1002/acr.20065
   Krishnan E, 2008, ARCH INTERN MED, V168, P1104, DOI 10.1001/archinte.168.10.1104
   Krishnan E, 2006, ARTHRITIS RHEUM-US, V54, P2688, DOI 10.1002/art.22014
   Kuo CF, 2013, RHEUMATOLOGY, V52, P111, DOI 10.1093/rheumatology/kes169
   Kuo CF, 2010, RHEUMATOLOGY, V49, P141, DOI 10.1093/rheumatology/kep364
   LEE J, 1995, AM J EPIDEMIOL, V142, P288, DOI 10.1093/oxfordjournals.aje.a117634
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878
   Mazzali M, 2001, HYPERTENSION, V38, P1101, DOI 10.1161/hy1101.092839
   Netea MG, 1997, BLOOD, V89, P577
   Niskanen LK, 2004, ARCH INTERN MED, V164, P1546, DOI 10.1001/archinte.164.14.1546
   PASCUAL E, 1991, ARTHRITIS RHEUM, V34, P141, DOI 10.1002/art.1780340203
   PUIG JG, 1991, ARCH INTERN MED, V151, P726, DOI 10.1001/archinte.151.4.726
   Roddy E, 2007, NAT CLIN PRACT RHEUM, V3, P443, DOI 10.1038/ncprheum0556
   Sanchez-Lozada LG, 2002, AM J PHYSIOL-RENAL, V283, pF1105, DOI 10.1152/ajprenal.00170.2002
   Sanchez-Lozada LG, 2005, KIDNEY INT, V67, P237, DOI 10.1111/j.1523-1755.2005.00074.x
   Seminog OO, 2013, RHEUMATOLOGY, V52, P2251, DOI 10.1093/rheumatology/ket293
   So A, 2010, NAT REV RHEUMATOL, V6, P386, DOI 10.1038/nrrheum.2010.78
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tiong AY, 2005, AM HEART J, V150, P11, DOI 10.1016/j.ahj.2004.12.019
   Verdecchia P, 2000, HYPERTENSION, V36, P1072, DOI 10.1161/01.HYP.36.6.1072
   Weaver Arthur L, 2008, Cleve Clin J Med, V75 Suppl 5, pS9
   Wells G., 2013, NEWCASTLE OTTAWA SCA
   World Health Organization, 10 LEAD CAUS DEATH B
   World Health Organization, 2008, GLOB BURD DIS 2004 U
   Xu Jiaquan, 2010, Natl Vital Stat Rep, V58, P1
   Zhu YY, 2012, AM J MED, V125, P679, DOI 10.1016/j.amjmed.2011.09.033
   Zhu YY, 2011, ARTHRITIS RHEUM-US, V63, P3136, DOI 10.1002/art.30520
NR 54
TC 10
Z9 12
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 31
PY 2015
VL 10
IS 7
AR e0134088
DI 10.1371/journal.pone.0134088
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO0JY
UT WOS:000358838400070
PM 26230580
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Jin, PP
   Sun, LL
   Ding, BJ
   Qin, N
   Zhou, B
   Xia, F
   Li, L
   Liu, LJ
   Liu, XD
   Zhao, G
   Wang, W
   Deng, YC
   Hou, SX
AF Jin, Peng-Peng
   Sun, Li-Li
   Ding, Bo-Jun
   Qin, Na
   Zhou, Bin
   Xia, Feng
   Li, Li
   Liu, Li-Juan
   Liu, Xue-Dong
   Zhao, Gang
   Wang, Wen
   Deng, Yan-Chun
   Hou, Shuang-Xing
TI Human Leukocyte Antigen DQB1 (HLA-DQB1) Polymorphisms and the Risk for
   Guillain-Barre Syndrome: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CAMPYLOBACTER-JEJUNI INFECTION; CLASS-II ALLELES; SYNDROME GBS; HLA-DQ;
   ASSOCIATION; SUSCEPTIBILITY; ANTIBODIES; TRIALS; BIAS
AB Guillain-Barre syndrome (GBS) is an autoimmune disorder of the peripheral nervous system. There is no consensus regarding reported associations between human leukocyte antigen DQB1 (HLA-DQB1) polymorphisms and the risk for developing GBS. Here, we evaluated possible associations between HLA-DQB1 polymorphisms and the risk for GBS using a meta-analysis. We searched PubMed for case-control genetic association studies for HLA-DQB1 polymorphisms (*020x, *030x, *040x, *050x, and *060x) and the risk for GBS. Fixed-effect meta-analytical methods were used for the outcome measure and subgroup analyses. Estimated odds ratios (ORs) and 95% confidence intervals (CIs) were used to investigate the associations between HLA-DQB1 polymorphisms and the risk for GBS. Nine case-control studies involving 780 cases of GBS and 1353 controls were identified in the current study. The meta-analysis demonstrated no significant associations between HLA-DQB1 polymorphisms and the risk for GBS in Asian and Caucasian populations. There were two associations that approached significance: HLA-DQB1*030x in Asian patients (P = 0.07; OR: 0.76, 95% CI: 0.57-1.03) and HLA-DQB1*060x in all patients (P = 0.08; OR: 1.48, 95% CI: 0.96-2.29). Additional studies with larger sample sizes are required to establish a definitive assessment of the contribution of HLA-DQB1 polymorphisms to GBS risk.
C1 [Jin, Peng-Peng] Fudan Univ, Shanghai Pudong Hosp, Ctr Med Res & Innovat, Pudong Med Ctr, Shanghai 201399, Peoples R China.
   [Sun, Li-Li; Ding, Bo-Jun; Qin, Na; Zhou, Bin; Xia, Feng; Li, Li; Liu, Li-Juan; Liu, Xue-Dong; Zhao, Gang; Deng, Yan-Chun] Fourth Mil Med Univ, Xijing Hosp, Dept Neurol, Xian 710032, Peoples R China.
   [Wang, Wen] Fourth Mil Med Univ, Unit Evidence Based Med, KK Leung Brain Res Ctr, Xian 710032, Peoples R China.
   [Hou, Shuang-Xing] Fudan Univ, Shanghai Pudong Hosp, Dept Neurol, Pudong Med Ctr, Shanghai 201399, Peoples R China.
RP Hou, SX (reprint author), Fudan Univ, Shanghai Pudong Hosp, Dept Neurol, Pudong Med Ctr, 2800 Gongwei Rd, Shanghai 201399, Peoples R China.
EM housx120@126.com
FU Natural Science Foundation of China [31070976, 81172291, 81030010];
   Fourth Military Medical University (China); Key Science and Technology
   Program of Shaanxi Province, China [2011 SK11-33]
FX This study was supported by grants from the Natural Science Foundation
   of China (No. 31070976, 81172291, and 81030010), intramural funds of the
   Fourth Military Medical University (China, 2012), and the Key Science
   and Technology Program of Shaanxi Province, China (2011 SK11-33). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andreoni A, 2009, PHOTOCH PHOTOBIO SCI, V8, P1202, DOI 10.1039/b906043j
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   ENDERS U, 1993, ANN NEUROL, V34, P136, DOI 10.1002/ana.410340208
   Fekih-Mrissa N, 2014, CLIN NEUROL NEUROSUR, V121, P19, DOI 10.1016/j.clineuro.2014.03.014
   Geleijns K, 2005, NEUROLOGY, V64, P44, DOI 10.1212/01.WNL.0000148727.02732.01
   Geleijns K, 2006, J IMMUNOL, V177, P4211, DOI 10.4049/jimmunol.177.6.4211
   GORODEZKY C, 1983, J NEUROIMMUNOL, V4, P1, DOI 10.1016/0165-5728(83)90058-9
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HILLERT J, 1991, J NEUROIMMUNOL, V31, P67, DOI 10.1016/0165-5728(91)90088-O
   HO TW, 1995, BRAIN, V118, P597, DOI 10.1093/brain/118.3.597
   Huang W, 1996, J CLIN ENDOCR METAB, V81, P2559, DOI 10.1210/jc.81.7.2559
   Huh K B, 1986, Korean J Intern Med, V1, P243
   Kimoto K, 2006, NEUROLOGY, V67, P1837, DOI 10.1212/01.wnl.0000244468.22377.6b
   Klein J, 2000, NEW ENGL J MED, V343, P782, DOI 10.1056/NEJM200009143431106
   Koga M, 1998, J NEUROIMMUNOL, V88, P62, DOI 10.1016/S0165-5728(98)00072-1
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Li HF, 2000, CHINESE MED J-PEKING, V113, P429
   Luppi P, 2001, J AUTOIMMUN, V16, P3, DOI 10.1006/jaut.2000.0462
   Ma JJ, 1998, NEUROLOGY, V51, P379, DOI 10.1212/WNL.51.2.379
   Magira EE, 2003, J IMMUNOL, V170, P3074, DOI 10.4049/jimmunol.170.6.3074
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   McCombe PA, 2006, J NEUROIMMUNOL, V180, P172, DOI 10.1016/j.jneuroim.2006.07.017
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Nyati KK, 2013, BIOMED RES INT, DOI 10.1155/2013/852195
   Pithadia AB, 2010, PHARMACOL REP, V62, P220, DOI 10.1016/S1734-1140(10)70261-9
   REES JH, 1995, J NEUROIMMUNOL, V62, P53, DOI 10.1016/0165-5728(95)00102-8
   Repiska V, 2010, INT J GYNECOL OBSTET, V110, P152, DOI 10.1016/j.ijgo.2010.03.019
   Schroeder S, 1999, CRIT CARE MED, V27, P1265, DOI 10.1097/00003246-199907000-00006
   Sinha S, 2010, ACTA NEUROL SCAND, V122, P21, DOI 10.1111/j.1600-0404.2009.01229.x
   Wu LY, 2012, J NEUROIMMUNOL, V243, P18, DOI 10.1016/j.jneuroim.2011.12.003
NR 33
TC 12
Z9 12
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 23
PY 2015
VL 10
IS 7
AR e0131374
DI 10.1371/journal.pone.0131374
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN7NJ
UT WOS:000358621000002
PM 26204120
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, JY
   Hu, LR
   Zhang, GH
   Wu, FP
   He, TP
AF Wu, Jiayuan
   Hu, Liren
   Zhang, Gaohua
   Wu, Fenping
   He, Taiping
TI Accuracy of Presepsin in Sepsis Diagnosis: A Systematic Review and
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PREDICTING BACTEREMIA; EMERGENCY-DEPARTMENT; SUBTYPE PRESEPSIN;
   PROGNOSTIC VALUE; SEPTIC SHOCK; LUNG-CANCER; SCD14-ST; PROCALCITONIN;
   BIOMARKERS; MANAGEMENT
AB Objective
   It's difficult to differentiate sepsis from non-sepsis, especially non-infectious SIRS, because no good standard exists for proof of infection. Soluble CD14 subtype (sCD14-ST), recently re-named presepsin, was identified as a new marker for the diagnosis of sepsis in several reports. However, the findings were based on the results of individual clinical trials, rather than a comprehensive and overall estimation. Thus, we conducted this systematic review and meta-analysis to estimate the pooled accuracy of presepsin in patients with sepsis suspect.
   Methods
   A comprehensive electronic search was performed via internet retrieval system up to 15 December 2014. Methodological quality assessment was applied by using the QUADAS2 tool. The diagnostic value of presepsin in sepsis was evaluated by using the pooled estimate of sensitivity, specificity, likelihood ratio, and diagnostic odds ratio, as well as summary receiver operating characteristics curve.
   Results
   Nine studies with 10 trials and 2159 cases were included in the study. Only two trials had low concerns regarding applicability, whereas all trials were deemed to be at high risk of bias. Heterogeneity existed in the non-threshold effect, but not in the threshold effect. The pooled sensitivity of presepsin for sepsis was 0.78 (0.76-0.80), pooled specificity was 0.83 (0.80-0.85), pooled positive likelihood ratio was 4.63 (3.27-6.55), pooled negative likelihood ratio was 0.22 (0.16-0.30), and pooled diagnostic odds ratio was 21.73 (12.81-36.86). The area under curve of summary receiver operating characteristics curve was 0.89 (95% CI: 0.84 to 0.94) and Q* index was 0.82 (95% CI: 0.77 to 0.87).
   Conclusion
   This meta-analysis demonstrates that presepsin had some superiority in the management of patients, and may be a helpful and valuable biomarker in early diagnosis of sepsis. However, presepsin showed a moderate diagnostic accuracy in differentiating sepsis from nonsepsis which prevented it from being recommended as a definitive test for diagnosing sepsis in isolation, but the results should be interpreted cautiously.
C1 [Wu, Jiayuan] Guangdong Med Coll, Affiliated Hosp, Dept Nutr, Zhanjiang, Guangdong, Peoples R China.
   [Hu, Liren; Zhang, Gaohua] Guangdong Med Coll, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Zhanjiang, Guangdong, Peoples R China.
   [Wu, Fenping] Oncol Hosp Chengdu, Peoples Hosp Chengdu 7, Dept Radiotherapy, Chengdu, Sichuan, Peoples R China.
   [He, Taiping] Guangdong Med Coll, Sch Publ Hlth, Zhanjiang, Guangdong, Peoples R China.
RP Wu, JY (reprint author), Guangdong Med Coll, Affiliated Hosp, Dept Nutr, Zhanjiang, Guangdong, Peoples R China.
EM 87537665@qq.com; taipinghe@163.com
OI taiping, He/0000-0001-6213-0837; Jiayuan, Wu/0000-0002-4626-2773
FU Scientific and Technological Innovation Project of Educational
   Commission of Guangdong Province [2013KJCX0092]
FX This study (TH) was funded by the Scientific and Technological
   Innovation Project of Educational Commission of Guangdong Province
   (Grant No. 2013KJCX0092). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ACCP/SCCM Consensus Conference Committee, 1992, CRIT CARE MED, V20, P867
   Balci C, 2003, CRIT CARE, V7, P85, DOI 10.1186/cc1843
   BATES DW, 1990, ANN INTERN MED, V113, P495, DOI 10.7326/0003-4819-113-7-495
   Bates DW, 1997, J INFECT DIS, V176, P1538, DOI 10.1086/514153
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Behnes M, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0507-z
   Cargnin S, 2014, PHARMACOGENOMICS, V15, P963, DOI 10.2217/pgs.14.52
   Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41
   Dombrovskiy VY, 2007, CRIT CARE MED, V35, P1244, DOI 10.1097/01.CCM.0000261890.41311.E9
   Dwamena B., 2007, STAT SOFTWARE COMPON
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Endo S, 2012, J INFECT CHEMOTHER, V18, P891, DOI 10.1007/s10156-012-0435-2
   Gatsonis C, 2006, AM J ROENTGENOL, V187, P271, DOI 10.2214/AJR.06.0226
   Kweon OJ, 2014, J CRIT CARE, V29, P965, DOI 10.1016/j.jcrc.2014.06.014
   Lamy PJ, 2000, LUNG CANCER-J IASLC, V29, P197, DOI 10.1016/S0169-5002(00)00113-6
   Lee SH, 2013, INT J CLIN PRACT, V67, P1350, DOI 10.1111/ijcp.12278
   Levy Mitchell M, 2003, Intensive Care Med, V29, P530
   Lijmer JG, 2002, STAT MED, V21, P1525, DOI 10.1002/sim.1185
   Liu B, 2013, CRIT CARE, V17, DOI 10.1186/cc13070
   Liu T, 2014, INT J LAB MED, V35, P2794
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Mussap M, 2011, J MATERN-FETAL NEO M, V24, P13, DOI 10.3109/14767058.2011.601923
   Nisman B, 2009, ANTICANCER RES, V29, P4827
   Okamura Y, 2011, CLIN CHIM ACTA, V412, P2157, DOI 10.1016/j.cca.2011.07.024
   Palmiere C, 2013, INT J LEGAL MED, V127, P799, DOI 10.1007/s00414-012-0804-5
   Sandquist M, 2014, EXPERT REV CLIN IMMU, V10, P1349, DOI 10.1586/1744666X.2014.949675
   Sargentini V, 2015, CLIN CHEM LAB MED, V53, P567, DOI 10.1515/cclm-2014-0119
   Shirakawa K, 2011, CLIN CHEM LAB MED, V49, P937, DOI 10.1515/CCLM.2011.145
   Shozushima T, 2011, J INFECT CHEMOTHER, V17, P764, DOI 10.1007/s10156-011-0254-x
   [苏明环 Su Minghuan], 2014, [临床检验杂志, Chinese Journal of Clinical Laboratory Science], V32, P106
   Tang BMP, 2007, LANCET INFECT DIS, V7, P210, DOI 10.1016/S1473-3099(07)70052-X
   Ulla M, 2013, CRIT CARE, V17, DOI 10.1186/cc12847
   Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754
   Vodnik T, 2013, CLIN CHEM LAB MED, V51, P2053, DOI 10.1515/cclm-2013-0061
   Wacker C, 2013, LANCET INFECT DIS, V13, P426, DOI 10.1016/S1473-3099(12)70323-7
   Walker SD, 2002, STAT MED, V15, P1237
   Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Yaegashi Yasunori, 2005, Journal of Infection and Chemotherapy, V11, P234, DOI 10.1007/s10156-005-0400-4
   [余建 Yu Jian], 2014, [临床检验杂志, Chinese Journal of Clinical Laboratory Science], V32, P200
   Zamora Javier, 2006, BMC Med Res Methodol, V6, P31, DOI 10.1186/1471-2288-6-31
   Zou Q, 2014, WORLD J EMERG MED, V5, P16, DOI [10.5847/wjem.j.1920-8642.2014.01.002, 10.5847/wjem.j.issn.1920-8642.2014.01.002]
NR 43
TC 44
Z9 49
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 20
PY 2015
VL 10
IS 7
AR e0133057
DI 10.1371/journal.pone.0133057
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN6LN
UT WOS:000358546400050
PM 26192602
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, ZY
   Zhang, SL
   Li, J
   Chen, S
   Li, P
   Sun, F
   Wen, XT
   Zheng, WJ
   Zhang, FC
   Li, YZ
AF Wu, Ziyan
   Zhang, Shulan
   Li, Jing
   Chen, Si
   Li, Ping
   Sun, Fei
   Wen, Xiaoting
   Zheng, Wenjie
   Zhang, Fengchun
   Li, Yongzhe
TI Association between MEFV Mutations M694V and M680I and Behcet's Disease:
   A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID FAMILIAL MEDITERRANEAN FEVER; GENOME-WIDE ASSOCIATION; SAMPLE-SIZE
   CALCULATIONS; GENE-MUTATIONS; SUSCEPTIBILITY LOCI; TURKISH PATIENTS;
   MESSENGER-RNA; PYRIN; IL23R-IL12RB2; PREVALENCE
AB Objective
   Several studies have identified an association between Behcet's disease (BD) and mutations in the Mediterranean fever (MEFV) gene, which was originally linked to the autosomal recessive disease, Familial Mediterranean fever. However, no consensus has been reached. Here, a meta-analysis was conducted on published data to comprehensively evaluate this relationship.
   Methods
   Literature searches were performed in Pubmed, Embase, the Web of Science, and HuGE Navigator databases, in order to identify studies pertaining to the association between MEFV mutations and BD. Two investigators independently extracted and evaluated the data from eligible studies. The association between MEFV mutations (M694V, M680I, and E148Q) and BD was estimated overall by the odds ratio (OR) and 95% confidence intervals (95% CI). Further analysis was conducted with STATA 12.0 software (Stata Corp.; College Station, TX).
   Results
   Eligible studies (n=8) included genotyping data obtained from 2538 BD patients and 2792 healthy controls. Of the three mutations, M694V (pooled OR: 2.60, 95% CI: 2.02-3.34) and M680I (pooled OR: 1.74, 95% CI: 1.23-2.46) were found to be associated with BD in the overall analysis. The third mutation, E148Q, however, was not found to be linked with BD (pooled OR: 1.26, 95% CI: 0.69-2.31). Subgroup analysis furthermore revealed that M694V and M680I were risk loci for BD specifically in Turkish patients.
   Conclusions
   The meta-analysis confirmed that MEFV mutations M694V and M680I were associated with BD. Additional studies from other ethnic populations and functional experiments are necessary to determine the extent to which the MEFV gene underlies the development of BD.
C1 [Li, Yongzhe] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Rheumatol & Clin Immunol, Beijing 100730, Peoples R China.
   Peking Union Med Coll, Minist Educ, Key Lab Rheumatol & Clin Immunol, Beijing 100021, Peoples R China.
RP Li, YZ (reprint author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Rheumatol & Clin Immunol, Beijing 100730, Peoples R China.
EM yongzhelipumch@126.com
FU Research Special Fund for Public Welfare Industry of Health [201202004];
   National Natural Science Foundation of China [81373188, 81172857,
   81302592]; Chinese National High Technology Research and Development
   Program, Ministry of Science and Technology Grant [2011AA02A113];
   National Science Technology Pillar Program in the 12nd Five-year Plan
   [2014BAI07B00]; capital health research and development of special
   grants [2014-1-4011]
FX This work was supported by the Research Special Fund for Public Welfare
   Industry of Health No. 201202004 (to F-C. Z.); the National Natural
   Science Foundation of China Grants No. 81373188, 81172857 (to Y.-Z. L.),
   and 81302592 (to S.-L. Z.); the Chinese National High Technology
   Research and Development Program, Ministry of Science and Technology
   Grant No. 2011AA02A113; the National Science Technology Pillar Program
   in the 12nd Five-year Plan No. 2014BAI07B00; and the capital health
   research and development of special grants No. 2014-1-4011 (to Y.-Z.
   L.).
CR Akkurt ZM, 2015, J CLIN LAB ANAL, V29, P317, DOI 10.1002/jcla.21772
   Aksentijevich I, 1997, CELL, V90, P797
   Akyuz F, 2013, J CLIN GASTROENTEROL, V47, pE23, DOI 10.1097/MCG.0b013e3182597992
   Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933
   Atagunduz P, 2003, CLIN EXP RHEUMATOL, V21, pS35
   Azizlerli G, 2003, INT J DERMATOL, V42, P803, DOI 10.1046/j.1365-4362.2003.01893.x
   Baruch Y, 2011, CLIN EXP RHEUMATOL, V29, pS24
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Ben-Chetrit E, 2002, J RHEUMATOL, V29, P530
   Bernot A, 1997, NAT GENET, V17, P25
   Bilginer Y, 2010, CLIN RHEUMATOL, V29, P209, DOI 10.1007/s10067-009-1279-8
   Centola M, 2000, BLOOD, V95, P3223
   Chae JJ, 2006, P NATL ACAD SCI USA, V103, P9982, DOI 10.1073/pnas.0602081103
   Chae JJ, 2011, IMMUNITY, V34, P755, DOI 10.1016/j.immuni.2011.02.020
   Cosan F, 2010, ARTHRITIS RHEUM-US, V62, P3232, DOI 10.1002/art.27683
   Dupont WD, 1998, CONTROL CLIN TRIALS, V19, P589, DOI 10.1016/S0197-2456(98)00037-3
   DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Esmaeili M, 2011, SCAND J RHEUMATOL, V40, P383, DOI 10.3109/03009742.2011.562532
   Espinosa G, 2005, CLIN EXP RHEUMATOL, V23, pS64
   Gershoni-Baruch R, 2001, EUR J HUM GENET, V9, P634, DOI 10.1038/sj.ejhg.5200672
   Gul A, 2014, CURR OPIN RHEUMATOL, V26, P56, DOI 10.1097/BOR.0000000000000003
   HAMZAOUI K, 1990, J RHEUMATOL, V17, P1428
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hou SP, 2012, ARTHRITIS RHEUM-US, V64, P4104, DOI 10.1002/art.37708
   Imirzalioglu N, 2005, SCAND J RHEUMATOL, V34, P56, DOI 10.1080/03009740510017931
   Jiang ZX, 2010, ANN RHEUM DIS, V69, P1325, DOI 10.1136/ard.2009.119420
   Kirino Y, 2013, P NATL ACAD SCI USA, V110, P8134, DOI 10.1073/pnas.1306352110
   Kirino Y, 2013, NAT GENET, V45, P202, DOI 10.1038/ng.2520
   Konstantopoulos K, 2012, W INDIAN MED J, V61, P28, DOI 10.7727/wimj.2011.041
   Lee YJ, 2013, ANN RHEUM DIS, V72, P1510, DOI 10.1136/annrheumdis-2011-200288
   Livneh A, 1997, ARTHRITIS RHEUM-US, V40, P1879, DOI 10.1002/art.1780401023
   Lo CKL, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-45
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Masters SL, 2009, ANNU REV IMMUNOL, V27, P621, DOI 10.1146/annurev.immunol.25.022106.141627
   Mat MC, 2014, CLIN DERMATOL, V32, P435, DOI 10.1016/j.clindermatol.2013.11.012
   Matsuda M, 2006, INTERNAL MED, V45, P799, DOI 10.2169/internalmedicine.45.1560
   Meguro A, 2010, ANN RHEUM DIS, V69, P747, DOI 10.1136/ard.2009.108571
   Mizuki N, 2010, NAT GENET, V42, P703, DOI 10.1038/ng.624
   Mobini Maryam, 2011, Caspian J Intern Med, V2, P344
   Notarnicola C, 2002, ARTHRITIS RHEUM-US, V46, P2785, DOI 10.1002/art.10575
   Omenetti A, 2014, ANN RHEUM DIS, V73, P462, DOI 10.1136/annrheumdis-2012-202774
   Remmers EF, 2010, NAT GENET, V42, P698, DOI 10.1038/ng.625
   Sakane T, 1999, NEW ENGL J MED, V341, P1284, DOI 10.1056/NEJM199910213411707
   Salanti G, 2005, GENET MED, V7, P13, DOI 10.1097/01.GIM.0000151839.12032.1A
   Schwartz T, 2000, SEMIN ARTHRITIS RHEU, V29, P286, DOI 10.1016/S0049-0172(00)80015-3
   Seshadri S, 2007, J IMMUNOL, V179, P1274, DOI 10.4049/jimmunol.179.2.1274
   Tasliyurt T, 2013, GENE, V530, P100, DOI 10.1016/j.gene.2013.08.026
   Touitou I, 2004, HUM MUTAT, V24, P194, DOI 10.1002/humu.20080
   Touitou I, 2001, EUR J HUM GENET, V9, P473, DOI 10.1038/sj.ejhg.5200658
   Touitou I, 2000, HUM MUTAT, V16, DOI 10.1002/1098-1004(200009)16:3<271::AID-HUMU16>3.0.CO;2-A
   Ustek D, 2007, ARTHRITIS RHEUM, V56, P345, DOI 10.1002/art.22320
   Yazici A, 2012, RHEUMATOL INT, V32, P3025, DOI 10.1007/s00296-011-2011-y
   Yazici H, 2012, CLIN REV ALLERG IMMU, V43, P275, DOI 10.1007/s12016-012-8319-x
   Yu HS, 2014, J MOL MED, V92, P961, DOI 10.1007/s00109-014-1159-9
   Zhou QY, 2014, ANN RHEUM DIS, V73, P170, DOI 10.1136/annrheumdis-2012-201627
NR 56
TC 15
Z9 16
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 15
PY 2015
VL 10
IS 7
AR e0132704
DI 10.1371/journal.pone.0132704
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1RL
UT WOS:000358197600144
PM 26176758
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, YL
   Wang, YT
   Li, JF
   Zhang, YZ
   Yin, HL
   Han, B
AF Wang, Yun-Liang
   Wang, Yu-Tong
   Li, Jin-Feng
   Zhang, Yu-Zheng
   Yin, Hong-Lei
   Han, Bing
TI Body Mass Index and Risk of Parkinson's Disease: A Dose-Response
   Meta-Analysis of Prospective Studies
SO PLOS ONE
LA English
DT Article
ID PROSPECTIVE COHORT; TREND ESTIMATION; FUTURE RISK; OBESITY; ALCOHOL;
   SMOKING; WEIGHT; BIAS
AB Background
   A number of epidemiologic studies examining the relationship between body mass index (BMI) and the future occurrence of Parkinson's disease (PD) reported largely inconsistent findings. We conducted a dose-response meta-analysis of prospective studies to clarify this association.
   Methods
   Eligible prospective studies were identified by a search of PubMed and by checking the references of related publications. The generalized least squares trend estimation was employed to compute study-specific relative risks (RR) and 95% confidence intervals (CI) for an increase in BMI of 5 kg/m(2), and the random-effects model was used to compute summary RR and 95% CI.
   Results
   A total of 10 prospective studies were included in the final analysis. An increase in BMI of 5 kg/m(2) was not associated with PD risk, with a summary RR of 1.00 (95% CI = 0.89-1.12). Results of subgroup analysis found similar results except for a week positive association in studies that adjusted for alcohol consumption (RR = 1.13, 95% CI = 0.99-1.29), and a week inverse association in studies that did not (RR = 0.90, 95% CI = 0.78-1.04). In a separate meta-analysis, no significant association between overweight (25 kg/m(2) <= BMI <= 29.9 kg/m(2)), obesity (BMI >= 30 kg/m(2)) or excess weight (BMI >= 25 kg/m(2)) and PD risk was observed.
   Conclusion
   This meta-analysis does not support the notion that higher BMI materially increases PD risk. However, a week positive BMI-PD association that may be masked by confounders still cannot be excluded, and future prospective studies with a good control for potential confounding factors are needed.
C1 [Wang, Yun-Liang; Li, Jin-Feng; Zhang, Yu-Zheng; Yin, Hong-Lei; Han, Bing] PLA, Cent Hosp 148, Dept Neurol, Zibo 255000, Peoples R China.
   [Wang, Yu-Tong] Henan Univ, Sch Med, Kaifeng 475000, Peoples R China.
RP Wang, YL (reprint author), PLA, Cent Hosp 148, Dept Neurol, Zibo 255000, Peoples R China.
EM wangylneuro@126.com
CR Abbott RD, 2002, NEUROLOGY, V59, P1051, DOI 10.1212/WNL.59.7.1051
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cereda E, 2011, DIABETES CARE, V34, P2614, DOI 10.2337/dc11-1584
   Chen H, 2010, NEUROLOGY, V74, P878, DOI 10.1212/WNL.0b013e3181d55f38
   Chen HL, 2004, AM J EPIDEMIOL, V159, P547, DOI 10.1093/aje/kwh059
   Chen J, 2014, INT J ENDOCRINOL, V2014, DOI DOI 10.1155/2014/203930
   Costa J, 2010, J ALZHEIMERS DIS, V20, pS221, DOI 10.3233/JAD-2010-091525
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Driver JA, 2008, DIABETES CARE, V31, P2003, DOI 10.2337/dc08-0688
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hu G, 2006, NEUROLOGY, V67, P1955, DOI 10.1212/01.wnl.0000247052.18422.e5
   Kyrozis A, 2013, EUR J EPIDEMIOL, V28, P67, DOI 10.1007/s10654-012-9760-0
   Logroscino G, 2007, AM J EPIDEMIOL, V166, P1186, DOI 10.1093/aje/kwm211
   Ma L, 2006, ACTA NEUROL SCAND, V113, P278, DOI 10.1111/j.1600-0404.2005.00571.x
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Palacios N, 2011, MOVEMENT DISORD, V26, P2253, DOI 10.1002/mds.23855
   Pan A, 2013, INT J OBESITY, V37, P1378, DOI 10.1038/ijo.2012.225
   Saaksjarvi K, 2014, EUR J EPIDEMIOL, V29, P285, DOI 10.1007/s10654-014-9887-2
   Thanvi B, 2005, AGE AGEING, V34, P114, DOI 10.1093/ageing/afi025
   van der Marck MA, 2012, PARKINSONISM RELAT D, V18, P263, DOI 10.1016/j.parkreldis.2011.10.016
   Wannamethee SG, 2003, AM J CLIN NUTR, V77, P1312
   Xu Q, 2010, NEUROLOGY, V75, P341, DOI 10.1212/WNL.0b013e3181ea1597
   Yang Y, 2013, INT J CANCER, V132, P1162, DOI 10.1002/ijc.27719
   Zhang DF, 2014, MOVEMENT DISORD, V29, P819, DOI 10.1002/mds.25863
NR 26
TC 10
Z9 11
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 29
PY 2015
VL 10
IS 6
AR e0131778
DI 10.1371/journal.pone.0131778
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1BL
UT WOS:000358150400158
PM 26121579
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yao, X
   Tian, Z
AF Yao, Xu
   Tian, Zhong
TI Saturated, Monounsaturated and Polyunsaturated Fatty Acids Intake and
   Risk of Pancreatic Cancer: Evidence from Observational Studies
SO PLOS ONE
LA English
DT Article
ID NUTRITIONAL FACTORS; DIETARY-FAT; METAANALYSIS; CARCINOGENESIS; COHORT;
   MEAT; SUSCEPTIBILITY; PROTEIN; CANADA; DAIRY
AB Background
   Although the relationship between dietary monounsaturated fatty acids (MUFAs), polyunsaturated fatty acids (PUFAs), and saturated fatty acids (SFAs) intake and pancreatic cancer risk has been reported by several studies, the evidence is controversial. We firstly conducted this comprehensive meta-analysis to summarize the aforementioned evidence from observational studies.
   Methods
   The MEDLINE (PubMed), Embase, and ISI Web of Science databases were used to search for epidemiological studies of dietary SFA, MUFA, and PUFA and pancreatic cancer risk that were published until the end of June 2014. Random-or fixed-effects models were used to estimate the relative risks (RRs) and 95% confidence intervals (CIs). We also carried out subgroup, sensitivity, and publication bias analyses.
   Results
   We identified 13 case-control studies and 7 prospective studies which including 6270 pancreatic cancer cases in the meta-analysis of SFA, MUFA, and PUFA and risk of pancreatic cancer. The summary RR was 1.13 (95% CI = 0.94-1.35, I-2 = 70.7%) for SFA, 1.00 (95% CI = 0.87-1.14, I-2 = 43.4%) for MUFA, and 0.87 (95% CI = 0.75-1.00, I-2 = 55.3%) for PUFA for high versus low intake categories. We found no evidence of publication bias.
   Conclusion
   In summary, findings of this study supports an inverse association between diets high in PUFA and pancreatic cancer risk. Further large prospective studies are warranted to report the results stratified by the subtypes of MUFA and PUFA and adjust for other potential risk factors to eliminate residual confounding.
C1 [Yao, Xu; Tian, Zhong] China Med Univ, Shengjing Hosp, Dept Gen Surg, Shenyang 110001, Peoples R China.
RP Tian, Z (reprint author), China Med Univ, Shengjing Hosp, Dept Gen Surg, Shenyang 110001, Peoples R China.
EM zhongt_sjhospital@126.com
CR APPEL MJ, 1990, CANCER LETT, V55, P239, DOI 10.1016/0304-3835(90)90125-H
   APPEL MJ, 1994, CANCER RES, V54, P2113
   Arem H, 2013, ANN EPIDEMIOL, V23, P571, DOI 10.1016/j.annepidem.2013.06.006
   Aune D, 2012, ANN ONCOL, V23, P2536, DOI 10.1093/annonc/mds076
   Aune D, 2012, ANN ONCOL, V23, P843, DOI 10.1093/annonc/mdr398
   BAGHURST PA, 1991, AM J EPIDEMIOL, V134, P167, DOI 10.1093/oxfordjournals.aje.a116069
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chan JM, 2007, CANCER CAUSE CONTROL, V18, P1153, DOI 10.1007/s10552-007-9054-0
   Chu M, 1997, CARCINOGENESIS, V18, P315, DOI 10.1093/carcin/18.2.315
   CLANDININ MT, 1993, ANN NY ACAD SCI, V683, P151
   DEMESQUITA HBB, 1990, INT J CANCER, V46, P435, DOI 10.1002/ijc.2910460319
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   EVERHART J, 1995, JAMA-J AM MED ASSOC, V273, P1605, DOI 10.1001/jama.273.20.1605
   FALCONER JS, 1994, BRIT J CANCER, V69, P826, DOI 10.1038/bjc.1994.161
   Ferlay J, 2013, GLOBOCAN 2012 V1 0 C
   GHADIRIAN P, 1995, CANCER EPIDEM BIOMAR, V4, P895
   Guan HB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092738
   Guan HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075279
   He K, 2013, AM J EPIDEMIOL, V177, P152, DOI 10.1093/aje/kws232
   Heinen MM, 2009, INT J CANCER, V125, P1118, DOI 10.1002/ijc.24387
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   HOWE GR, 1990, INT J CANCER, V45, P604, DOI 10.1002/ijc.2910450405
   Jansen RJ, 2014, INT J CANCER, V134, P1935, DOI 10.1002/ijc.28525
   Jing W, 2014, MOL CANCER THER, V13, P2127, DOI 10.1158/1535-7163.MCT-14-0175
   KALAPOTHAKI V, 1993, CANCER CAUSE CONTROL, V4, P383, DOI 10.1007/BF00051342
   Karim-Kos HE, 2008, EUR J CANCER, V44, P1345, DOI 10.1016/j.ejca.2007.12.015
   Kipnis V, 2003, AM J EPIDEMIOL, V158, P14, DOI 10.1093/aje/kwg091
   Klein AP, 2012, MOL CARCINOGEN, V51, P14, DOI 10.1002/mc.20855
   Lin YS, 2005, J GASTROENTEROL, V40, P297, DOI 10.1007/s00535-004-1537-0
   Lucenteforte E, 2010, EUR J CANCER, V46, P581, DOI 10.1016/j.ejca.2009.09.024
   Michaud DS, 2003, AM J EPIDEMIOL, V157, P1115, DOI 10.1093/aje/kwg098
   Nkondjock A, 2005, BRIT J CANCER, V92, P971, DOI 10.1038/sj.bjc.6602380
   Nothlings U, 2005, JNCI-J NATL CANCER I, V97, P1458, DOI 10.1093/jnci/dji292
   OLSEN GW, 1991, CANCER CAUSE CONTROL, V2, P291, DOI 10.1007/BF00051668
   ROEBUCK BD, 1987, CANCER RES, V47, P1333
   Shen QW, 2014, EUR J CANC PREV
   Sievenpiper JL, 2002, CAN J DIET PRACT RES, V63, P20, DOI 10.3148/63.1.2002.20
   Stolzenberg-Solomon RZ, 2002, AM J EPIDEMIOL, V155, P783, DOI 10.1093/aje/155.9.783
   Storlien LH, 2000, BRIT J NUTR, V83, pS85
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Thiebaut ACM, 2009, JNCI-J NATL CANCER I, V101, P1001, DOI 10.1093/jnci/djp168
   Wells GA, 2014, NEWCASTLE OTTAWA SCA
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   World Cancer Research Fund/American Institute forCancer Research, 2007, FOOD NUTR PHYS ACT P
   Woutersen RA, 1999, MUTAT RES-GEN TOX EN, V443, P111, DOI 10.1016/S1383-5742(99)00014-9
   Wu L, 2014, CANCER EPIDEM BIOMAR, V23, P1121, DOI 10.1158/1055-9965.EPI-13-0627
   Xu B, 2013, ANN EPIDEMIOL, V23, P215, DOI 10.1016/j.annepidem.2012.12.016
   ZATONSKI W, 1991, INT J CANCER, V48, P390, DOI 10.1002/ijc.2910480314
   Zhang JJ, 2009, NUTR CANCER, V61, P457, DOI 10.1080/01635580902718941
   Zou L, 2014, EUR J CANCER, V50, P193, DOI 10.1016/j.ejca.2013.08.014
NR 51
TC 7
Z9 7
U1 2
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 25
PY 2015
VL 10
IS 6
AR e0130870
DI 10.1371/journal.pone.0130870
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CL4OY
UT WOS:000356933800096
PM 26110621
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chanson-Rolle, A
   Meynier, A
   Aubin, F
   Lappi, J
   Poutanen, K
   Vinoy, S
   Braesco, V
AF Chanson-Rolle, Aurelie
   Meynier, Alexandra
   Aubin, Franois
   Lappi, Jenni
   Poutanen, Kaisa
   Vinoy, Sophie
   Braesco, Veronique
TI Systematic Review and Meta-Analysis of Human Studies to Support a
   Quantitative Recommendation for Whole Grain Intake in Relation to Type 2
   Diabetes
SO PLOS ONE
LA English
DT Review
ID CARDIOVASCULAR-DISEASE; RISK; CONSUMPTION; GLUCOSE; FIBER; ASSOCIATION;
   DEATH
AB Background
   Due to the increasing evidence of their health benefits, whole grains are recommended for consumption worldwide. Such recommendations are, however, rarely quantitative. Our aim was to perform a quantitative evaluation of the relationship between whole grain consumption and the occurrence of type 2 diabetes (T2D) to support a recommendation on the daily consumption of whole grains.
   Methods and Findings
   We conducted a systematic review by searching three bibliographic databases. We included human studies addressing the relationship between whole grain consumption and T2D occurrence, and providing quantitative information on daily intake of whole grains. A dose-response meta-regression analysis between whole grain intake and T2D occurrence was performed, using a hierarchical mixed least square linear regression model. Eight observational studies were included (all but one prospective), with a total of 15,573 cases of T2D among 316,051 participants. Quantitative meta-regression demonstrated a significant linear inverse relationship between whole grain intake and T2D occurrence (P<0.0001), with an overall absolute reduction of 0.3% in the T2D rate for each additional 10 g of whole grain ingredient consumed daily. The association persisted when adjusted on sex, age, country, study design, follow up duration, and mode of report of whole grain intakes (as foods or ingredients).
   Conclusions
   The meta-regression model made it possible to estimate the decrease in T2D risk corresponding to various changes in whole grain intakes, and the results contribute to setting up quantitative recommendations. For instance, consuming three servings of whole grain foods (45 g of whole grain ingredients) daily would induce a 20% relative reduction in the T2D risk as compared to consuming a half serving (7.5 g of whole grain ingredients). These results should be considered for future recommendations, by considering the actual whole grain intake of the concerned populations. The systematic review protocol was published on the PROSPERO register (CRD42013006925).
C1 [Chanson-Rolle, Aurelie; Braesco, Veronique] VAB Nutr, Clermont Ferrand, France.
   [Meynier, Alexandra; Vinoy, Sophie] Mondelez France R&D SAS, Saclay, France.
   [Aubin, Franois] Venn Life Sci SAS, Paris, France.
   [Lappi, Jenni; Poutanen, Kaisa] Univ Eastern Finland, Dept Clin Nutr, Kuopio, Finland.
   [Poutanen, Kaisa] VTT Tech Res Ctr Finland, Espoo, Finland.
RP Meynier, A (reprint author), Mondelez France R&D SAS, Saclay, France.
EM alexandra.meynier@mdlz.com
OI VINOY, Sophie/0000-0002-1038-6985
FU Mondelez France R&D SAS (6 rue Rene Razel - Batiment K SACLAY France)
FX This work was sponsored by Mondelez France R&D SAS (6 rue Rene Razel -
   Batiment K 91400 SACLAY France). The funder provided support in the form
   of salaries for authors [AM, SV], but did not have any additional role
   in the study design, data collection and analysis, decision to publish,
   or preparation of the manuscript. The specific roles of these authors
   are articulated in the 'author contributions' section.
CR AACC International, 2014, AACC MEMBERS AGREE O, V2, P14
   Agostoni C, 2010, EFSA J, V8, DOI 10.2903/j.efsa.2010.1462
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bell BA, 2013, PROC MIXED SAS GLOBA
   Centers for Disease Control and Prevention, 2014, NATIONAL DIABETES FA, V3, P5
   Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X
   de Munter JSL, 2007, PLOS MED, V4, P1385, DOI 10.1371/journal.pmed.0040261
   Esmaillzadeh A, 2005, EUR J CLIN NUTR, V59, P353, DOI 10.1038/sj.ejcn.1602080
   Fardet A, 2010, NUTR RES REV, V23, P65, DOI 10.1017/S0954422410000041
   Ferruzzi MG, 2014, ADV NUTR, V5, P164, DOI 10.3945/an.113.005223
   Grooms KN, 2013, AM J MED, V126, P1059, DOI 10.1016/j.amjmed.2013.07.023
   [IOM The National Academies Press], 2005, DIET REF INT EN CARB, P339
   Jacobs DR, 2007, AM J CLIN NUTR, V85, P1606
   Jacobs DR, 1998, AM J CLIN NUTR, V68, P248
   Koh-Banerjee P, 2004, AM J CLIN NUTR, V80, P1237
   Kyro C, 2012, SCAND J PUBLIC HEALT, V40, P76, DOI 10.1177/1403494811421057
   Lund O, 2006, J THORAC CARDIOV SUR, V132, P20, DOI 10.1016/j.jtcvs.2006.01.043
   Maras JE, 2009, J FOOD COMPOS ANAL, V22, P53, DOI 10.1016/j.jfca.2008.10.005
   Mejborn H, 2013, E ARTIKEL FRA DTU FO, P2
   Mellen PB, 2008, NUTR METAB CARDIOVAS, V18, P283, DOI 10.1016/j.numecd.2006.12.008
   Meyer KA, 2000, AM J CLIN NUTR, V71, P921
   Montonen J, 2003, AM J CLIN NUTR, V77, P622
   Nettleton JA, 2010, DIABETES CARE, V33, P2684, DOI [10.2337/dc10-1150, 10.2337/dc10.1150]
   O'Neil CE, 2010, NUTR RES, V30, P815, DOI 10.1016/j.nutres.2010.10.013
   Parker ED, 2013, ANN EPIDEMIOL, V23, P321, DOI 10.1016/j.annepidem.2013.03.010
   Priebe MG, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006061.pub2
   Slavin J., 2013, Cereal Foods World, V58, P191
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sun Q, 2010, ARCH INTERN MED, V170, P961, DOI 10.1001/archinternmed.2010.109
   Thane CW, 2007, BRIT J NUTR, V97, P987, DOI 10.1017/S0007114507659078
   van der Kamp JW, 2014, FOOD NUTR RES, V58, DOI 10.3402/fnr.v58.22100
   van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040
   Wirstrom T, 2013, AM J CLIN NUTR, V97, P179, DOI 10.3945/ajcn.112.045583
   Yao B, 2014, EUROPEAN JOURNAL OF
   Ye EQ, 2012, J NUTR, V142, P1304, DOI 10.3945/jn.111.155325
NR 35
TC 26
Z9 28
U1 1
U2 40
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 22
PY 2015
VL 10
IS 6
AR UNSP e0131377
DI 10.1371/journal.pone.0131377
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CL3FM
UT WOS:000356835800174
PM 26098118
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Song, YZ
   Han, FJ
   Liu, M
   Xia, CC
   Shi, WY
   Dong, LH
AF Song, Yu-Zhe
   Han, Fu-Jun
   Liu, Min
   Xia, Cheng-Cheng
   Shi, Wei-Yan
   Dong, Li-Hua
TI Association between Single Nucleotide Polymorphisms in XRCC3 and
   Radiation-Induced Adverse Effects on Normal Tissue: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; BREAST-CANCER RISK; DOUBLE-STRAND BREAKS;
   DNA-REPAIR; THR241MET POLYMORPHISM; GENETIC POLYMORPHISMS;
   HEPATOCELLULAR-CARCINOMA; ERECTILE DYSFUNCTION; EPIGENETIC FEATURES;
   PROTEIN-KINASE
AB The X-ray repair cross-complementing group 3 (XRCC3) protein plays an important role in the repair of DNA double-strand breaks. The relationship between XRCC3 polymorphisms and the risk of radiation-induced adverse effects on normal tissue remains inconclusive. Thus, we performed a meta-analysis to elucidate the association between XRCC3 polymorphisms and radiation-induced adverse effects on normal tissue. All eligible studies up to December 2014 were identified through a search of the PubMed, Embase and Web of Science databases. Seventeen studies involving 656 cases and 2193 controls were ultimately included in this meta-analysis. The pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated to evaluate the association between XRCC3 polymorphisms and the risk of radiation-induced normal tissue adverse effects. We found that the XRCC3 p.Thr241Met (rs861539) polymorphism was significantly associated with early adverse effects induced by radiotherapy (OR = 1.99, 95% CI: 1.31-3.01, P = 0.001). A positive association lacking statistical significance with late adverse effects was also identified (OR = 1.28, 95% CI: 0.97-1.68, P = 0.08). In addition, the rs861539 polymorphism was significantly correlated with a higher risk of adverse effects induced by head and neck area irradiation (OR = 2.41, 95% CI: 1.49-3.89, p = 0.0003) and breast irradiation (OR = 1.41, 95% CI: 1.02-1.95, p = 0.04), whereas the correlation was not significant for lung irradiation or pelvic irradiation. Furthermore, XRCC3 rs1799794 polymorphism may have a protective effect against late adverse effects induced by radiotherapy (OR = 0.47, 95% CI: 0.26-0.86, P = 0.01). Well-designed large-scale clinical studies are required to further validate our results.
C1 [Song, Yu-Zhe; Liu, Min; Xia, Cheng-Cheng; Shi, Wei-Yan; Dong, Li-Hua] Jilin Univ, Hosp 1, Dept Radiat Oncol, Changchun 130023, Jilin, Peoples R China.
   [Han, Fu-Jun] Jilin Univ, Hosp 1, Ctr Canc, Changchun 130023, Jilin, Peoples R China.
RP Dong, LH (reprint author), Jilin Univ, Hosp 1, Dept Radiat Oncol, Changchun 130023, Jilin, Peoples R China.
EM songyz37@126.com
CR Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899
   Alsbeih G, 2010, RADIAT RES, V173, P505, DOI 10.1667/RR1769.1
   Alsner J, 2008, SEMIN RADIAT ONCOL, V18, P126, DOI 10.1016/j.semradonc.2007.10.004
   Andreassen CN, 2012, RADIOTHER ONCOL, V105, P337, DOI 10.1016/j.radonc.2012.11.004
   Andreassen CN, 2003, RADIOTHER ONCOL, V69, P127, DOI 10.1016/j.radonc.2003.09.010
   Andreassen CN, 2002, RADIOTHER ONCOL, V64, P131, DOI 10.1016/S0167-8140(02)00154-8
   Andreassen CN, 2005, ACTA ONCOL, V44, P801, DOI 10.1080/02841860500374513
   Araujo FD, 2002, ONCOGENE, V21, P4176, DOI 10.1038/sj.onc.1205539
   Azria D, 2008, CLIN CANCER RES, V14, P6284, DOI 10.1158/1078-0432.CCR-08-0700
   Barnett GC, 2014, RADIOTHER ONCOL, V111, P178, DOI 10.1016/j.radonc.2014.02.012
   Barnett GC, 2012, LANCET ONCOL, V13, P65, DOI 10.1016/S1470-2045(11)70302-3
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bentzen SM, 2003, SEMIN RADIAT ONCOL, V13, P189, DOI 10.1016/S1053-4296(03)00036-5
   Bourguignon MH, 2005, EUR J NUCL MED MOL I, V32, P351, DOI 10.1007/s00259-004-1731-6
   Bourguignon MH, 2005, EUR J NUCL MED MOL I, V32, P229, DOI 10.1007/s00259-004-1730-7
   Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6
   Burri RJ, 2008, RADIAT RES, V170, P49, DOI 10.1667/RR1219.1
   Chang-Claude J, 2009, BRIT J CANCER, V100, P1680, DOI 10.1038/sj.bjc.6605036
   Cheuk IWY, 2014, MOL CLIN ONCOL, V2, P553, DOI 10.3892/mco.2014.276
   De Ruyck K, 2005, INT J RADIAT ONCOL, V62, P1140, DOI 10.1016/j.ijrobp.2004.12.027
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dikomey E, 1998, INT J RADIAT BIOL, V73, P269, DOI 10.1080/095530098142365
   Du L, 2014, TUMOR BIOL, V35, P1371, DOI 10.1007/s13277-013-1187-z
   Duan CY, 2013, TUMOR BIOL, V34, P2827, DOI 10.1007/s13277-013-0841-9
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fachal L, 2014, NAT GENET, V46, P891, DOI 10.1038/ng.3020
   Fachal L, 2012, RADIOTHER ONCOL, V105, P321, DOI 10.1016/j.radonc.2012.09.013
   Fahmideh MA, 2014, NEURO-ONCOLOGY, V16, P807, DOI 10.1093/neuonc/nou003
   Falvo E, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-7
   Falvo E, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-291
   Fang F, 2011, MED ONCOL, V28, P999, DOI 10.1007/s12032-010-9591-3
   Fernet M, 2004, DNA REPAIR, V3, P1237, DOI 10.1016/j.dnarep.2004.03.019
   Ghazali N, 2012, ORAL ONCOL, V48, P1090, DOI 10.1016/j.oraloncology.2012.08.002
   Haber JE, 2000, PARTNERS PATHWAYS, P259
   He XF, 2012, MOL BIOL REP, V39, P5125, DOI 10.1007/s11033-011-1308-y
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Ho AY, 2006, INT J RADIAT ONCOL, V65, P646, DOI 10.1016/j.ijrobp.2006.03.006
   Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687
   Kerns SL, 2013, RADIOTHER ONCOL, V107, P372, DOI 10.1016/j.radonc.2013.05.001
   Kerns SL, 2013, J UROLOGY, V190, P102, DOI 10.1016/j.juro.2013.01.096
   Kerns SL, 2013, INT J RADIAT ONCOL, V85, pE21, DOI 10.1016/j.ijrobp.2012.08.003
   Kerns SL, 2010, INT J RADIAT ONCOL, V78, P1292, DOI 10.1016/j.ijrobp.2010.07.036
   Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384
   LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602
   Liang HJ, 2013, ASIAN PAC J CANCER P, V14, P4243, DOI 10.7314/APJCP.2013.14.7.4243
   Liu L, 2013, MOL BIOL REP, V40, P3943, DOI 10.1007/s11033-012-2471-5
   Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7
   Liu Y, 2015, J CELL PHYSIOL, V230, P1094, DOI 10.1002/jcp.24841
   Ma QT, 2014, TUMOR BIOL, V35, P1473, DOI 10.1007/s13277-013-1203-3
   Mangoni M, 2011, INT J RADIAT ONCOL, V81, P52, DOI 10.1016/j.ijrobp.2010.04.023
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mao CF, 2014, ASIAN PAC J CANCER P, V15, P6613, DOI 10.7314/APJCP.2014.15.16.6613
   Matullo G, 2001, CARCINOGENESIS, V22, P1437, DOI 10.1093/carcin/22.9.1437
   Peng QL, 2014, TUMOR BIOL, V35, P1933, DOI 10.1007/s13277-013-1259-0
   Popanda O, 2006, CANCER EPIDEM BIOMAR, V15, P1048, DOI 10.1158/1055-9965.EPI-06-0046
   Pratesi N, 2011, RADIOTHER ONCOL, V99, P356, DOI 10.1016/j.radonc.2011.05.062
   Qin LY, 2013, ASIAN PAC J CANCER P, V14, P6703, DOI 10.7314/APJCP.2013.14.11.6703
   Qiu MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077005
   Raabe A, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-65
   Rosenstein BS, 2014, INT J RADIAT ONCOL, V89, P709, DOI 10.1016/j.ijrobp.2014.03.009
   ROTH DB, 1985, P NATL ACAD SCI USA, V82, P3355, DOI 10.1073/pnas.82.10.3355
   Rube CE, 2008, INT J RADIAT ONCOL, V72, P1180, DOI 10.1016/j.ijrobp.2008.07.017
   Sakano S, 2010, PHARMACOGENOMICS, V11, P1377, DOI [10.2217/pgs.10.106, 10.2217/PGS.10.106]
   Shen MR, 1998, CANCER RES, V58, P604
   Shen XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069553
   Sterpone S, 2010, J CANCER RES CLIN, V136, P631, DOI 10.1007/s00432-010-0791-1
   Stone HB, 2003, LANCET ONCOL, V4, P529, DOI 10.1016/S1470-2045(03)01191-4
   Tucker SL, 2013, INT J RADIAT ONCOL, V85, P251, DOI 10.1016/j.ijrobp.2012.02.021
   Wang Z, 2014, TUMOR BIOL, V35, P1589, DOI 10.1007/s13277-013-1219-8
   Wang ZZ, 2013, TUMOR BIOL, V34, P1421, DOI 10.1007/s13277-012-0639-1
   Werbrouck J, 2009, INT J RADIAT ONCOL, V73, P1187, DOI 10.1016/j.ijrobp.2008.08.073
   Wu D, 2013, TUMOR BIOL, V34, P3865, DOI 10.1007/s13277-013-0973-y
   Yin M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020055
   Zou Y, 2014, JPN J CLIN ONCOL, V44, P241, DOI 10.1093/jjco/hyt202
NR 76
TC 7
Z9 7
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 19
PY 2015
VL 10
IS 6
AR e0130388
DI 10.1371/journal.pone.0130388
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CL3FE
UT WOS:000356835000111
PM 26091483
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Pletzer, JL
   Nikolova, R
   Kedzior, KK
   Voelpel, SC
AF Pletzer, Jan Luca
   Nikolova, Romina
   Kedzior, Karina Karolina
   Voelpel, Sven Constantin
TI Does Gender Matter? Female Representation on Corporate Boards and Firm
   Financial Performance - A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID ETHNIC DIVERSITY; ROLE AMBIGUITY; ROLE-CONFLICT; WOMEN; IMPACT;
   MANAGEMENT; LEADERSHIP; TEAM; GOVERNANCE; DIRECTORS
AB In recent years, there has been an ongoing, worldwide debate about the representation of females in companies. Our study aimed to meta-analytically investigate the controversial relationship between female representation on corporate boards and firm financial performance. Following a systematic literature search, data from 20 studies on 3097 companies published in peer-reviewed academic journals were included in the meta-analysis. On average, the boards consisted of eight members and female participation was low (mean 14%) in all studies. Half of the 20 studies were based on data from developing countries and 62% from higher income countries. According to the random-effects model, the overall mean weighted correlation between percentage of females on corporate boards and firm performance was small and non-significant (r = .01, 95% confidence interval: - .04, .07). Similar small effect sizes were observed when comparing studies based on developing vs. developed countries and higher vs. lower income countries. The mean board size was not related to the effect sizes in studies. These results indicate that the mere representation of females on corporate boards is not related to firm financial performance if other factors are not considered. We conclude our study with a discussion of its implications and limitations.
C1 [Pletzer, Jan Luca; Voelpel, Sven Constantin] Jacobs Univ Bremen, Focus Area Div, D-28759 Bremen, Germany.
   [Pletzer, Jan Luca] Vrije Univ Amsterdam, Social & Org Psychol, Amsterdam, Netherlands.
   [Nikolova, Romina] Katholieke Univ Leuven, Leuven, Belgium.
   [Nikolova, Romina; Kedzior, Karina Karolina; Voelpel, Sven Constantin] Jacobs Univ Bremen, BIGSSS, D-28759 Bremen, Germany.
   [Kedzior, Karina Karolina] Univ Bremen, Inst Psychol & Transfer, D-28359 Bremen, Germany.
RP Pletzer, JL (reprint author), Jacobs Univ Bremen, Focus Area Div, D-28759 Bremen, Germany.
EM j.pletzer@jacobs-university.de
RI Pletzer, Jan Luca/I-5632-2019; Voelpel, Sven/C-7227-2014
OI Pletzer, Jan Luca/0000-0002-8313-4447; Voelpel, Sven/0000-0002-7808-3227
CR *Abdillahi UA, 2013, INTERNATIONAL JOURNA, V3, P159
   ABRAMS D, 1990, BRIT J SOC PSYCHOL, V29, P87, DOI 10.1111/j.2044-8309.1990.tb00889.x
   Ahern KR, 2012, Q J ECON, V127, P137, DOI 10.1093/qje/qjr049
   Ali M, 2014, J BUS ETHICS, V125, P497, DOI 10.1007/s10551-013-1930-9
   Amason AC, 1996, ACAD MANAGE J, V39, P123, DOI 10.2307/256633
   Bassett-Jones N., 2005, CREATIVITY INNOVATIO, V14, P169, DOI [DOI 10.1111/J.1467-8691.00337.X, 10.1111/j.1467-8691.00337.x]
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bertrand M, 2003, Q J ECON, V118, P1169, DOI 10.1162/003355303322552775
   Bohren O, 2014, J CORP FINANC, V28, P152, DOI 10.1016/j.jcorpfin.2013.12.005
   Borenstein M, 2009, INTRODUCTION TO META
   Brammer S, 2007, CORP GOV, V15, P393, DOI 10.1111/j.1467-8683.2007.00569.x
   Campbell K, 2008, J BUS ETHICS, V83, P435, DOI 10.1007/s10551-007-9630-y
   Carpenter MA, 2001, ACAD MANAGE J, V44, P639, DOI 10.2307/3069408
   Carter DA, 2010, CORP GOV-OXFORD, V18, P396, DOI 10.1111/j.1467-8683.2010.00809.x
   Charness G, 2012, J ECON BEHAV ORGAN, V83, P50, DOI 10.1016/j.jebo.2011.06.007
   Cohen J., 1988, STATISTICAL POWER AN
   Conyon M., 1998, EUROPEAN J FINANCE, V4, P291, DOI [10.1080/135184798337317, DOI 10.1080/135184798337317]
   Croson R, 2009, J ECON LIT, V47, P448, DOI 10.1257/jel.47.2.448
   Dale-Olsen H, 2013, FEM ECON, V19, P110, DOI 10.1080/13545701.2013.830188
   DARMADI S, 2011, CORPORATE OWNERSHIP, V9, P524
   Dechant K., 1997, ACAD MANAGEMENT EXEC, V11, P21, DOI [10.5465/AME.1997.9709231661, DOI 10.5465/AME.1997.9709231661]
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Eagly AH, 2003, PSYCHOL BULL, V129, P569, DOI 10.1037/0033-2909.129.4.569
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farrell KA, 2005, J CORP FINANC, V11, P85, DOI 10.1016/j.jcorpfin.2003.12.001
   Fondas N., 2000, GLOBAL FOCUS, V12, P13
   Galbreath J, 2011, J MANAGE ORGAN, V17, P17
   Garba T, 2014, ASIAN EC FINANCIAL R, V4, P257
   Gardiner M, 1999, J OCCUP ORGAN PSYCH, V72, P301, DOI 10.1348/096317999166699
   Haslam SA, 2010, BRIT J MANAGE, V21, P484, DOI 10.1111/j.1467-8551.2009.00670.x
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   JACKSON SE, 1985, ORGAN BEHAV HUM DEC, V36, P16, DOI 10.1016/0749-5978(85)90020-2
   Jackson SE, 2003, J MANAGE, V29, P801, DOI 10.1016/S0149-2063(03)00080-1
   Jackson SE, 1995, TEAM EFFECTIVENESS D, V204, P261
   Jehn KA, 1999, ADMIN SCI QUART, V44, P741, DOI 10.2307/2667054
   Jianakoplos NA, 1998, ECON INQ, V36, P620, DOI 10.1111/j.1465-7295.1998.tb01740.x
   Joecks J, 2013, J BUS ETHICS, V118, P61, DOI 10.1007/s10551-012-1553-6
   Julizaerma MK, 2012, PROCD SOC BEHV, V65, P1077, DOI 10.1016/j.sbspro.2012.11.374
   KANTER RM, 1977, AM J SOCIOL, V82, P965, DOI 10.1086/226425
   Knight D, 1999, STRATEGIC MANAGE J, V20, P445, DOI 10.1002/(SICI)1097-0266(199905)20:5<445::AID-SMJ27>3.0.CO;2-V
   Kochan T, 2003, HUM RESOURCE MANAGE, V42, P3, DOI 10.1002/hrm.10061
   Koenig AM, 2011, PSYCHOL BULL, V137, P616, DOI 10.1037/a0023557
   *Kyereboah-Coleman A, 2006, J STUDIES EC ECONOME, V30, P19
   Luckerath-Rovers M, 2013, J MANAG GOV, V17, P491, DOI 10.1007/s10997-011-9186-1
   Mahadeo JD, 2012, J BUS ETHICS, V105, P375, DOI 10.1007/s10551-011-0973-z
   Matud MP, 2004, PERS INDIV DIFFER, V37, P1401, DOI 10.1016/j.paid.2004.01.010
   McLeod PL, 1996, SMALL GR RES, V27, P248, DOI 10.1177/1046496496272003
   Miller T, 2009, J MANAGE STUD, V46, P755, DOI 10.1111/j.1467-6486.2009.00839.x
   Milliken FJ, 1996, ACAD MANAGE REV, V21, P402, DOI 10.2307/258667
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Pande R, 2011, WORLD DEVELOPMENT RE
   Pathan S, 2013, J BANK FINANC, V37, P1573, DOI 10.1016/j.jbankfin.2012.12.016
   Post C, 2015, ACAD MANAGE J, V58, P1546, DOI 10.5465/amj.2013.0319
   Richard OC, 2004, ACAD MANAGE J, V47, P255, DOI 10.2307/20159576
   Rodriguez-Dominguez L, 2012, EUR J LAW ECON, V33, P603, DOI 10.1007/s10657-010-9144-4
   Rose C, 2007, CORP GOV-OXFORD, V15, P404, DOI 10.1111/j.1467-8683.2007.00570.x
   ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638
   Sanders WG, 1998, ACAD MANAGE J, V41, P158, DOI 10.2307/257100
   Shafique Y, 2014, EUROPEAN J BUSINESS, V6, P296
   Shukeri S.N., 2012, INT BUSINESS RES, V5, P120, DOI DOI 10.5539/IBR.V5N9P120
   Strom RO, 2014, J BANK FINANC, V42, P60, DOI 10.1016/j.jbankfin.2014.01.014
   Tajfel HE, 1978, DIFFERENTIATION BETW
   Terjesen S, 2008, J BUS ETHICS, V83, P55, DOI 10.1007/s10551-007-9656-1
   Terjesen S, 2009, CORP GOV-OXFORD, V17, P320, DOI 10.1111/j.1467-8683.2009.00742.x
   Tubre TC, 2000, J MANAGE, V26, P155, DOI 10.1177/014920630002600104
   Tuggle CS, 2011, FROM SEATS AT THE TA, P1
   United Nations, 2012, WORLD ECONOMIC SITUA, P131
   van Knippenberg D, 2004, J APPL PSYCHOL, V89, P1008, DOI 10.1037/0021-9010.89.6.1008
   Van Ness RK, 2010, ACAD BUSINESS EC J, V10, P56
   WATSON WE, 1993, ACAD MANAGE J, V36, P590, DOI 10.2307/256593
   Webber SS, 2001, J MANAGE, V27, P141, DOI 10.1016/S0149-2063(00)00093-3
   Wellalage NH, 2013, ASIAN J BUS ETHICS, V2, P113, DOI 10.1007/s13520-012-0020-x
   Westphal JD, 2005, ADMIN SCI QUART, V50, P262, DOI 10.2189/asqu.2005.50.2.262
   Williams KY, 1998, RES ORGAN BEHAV, V20, P77
   Zhou Z, 2012, FRONTIERS OF BUSINES, V6, P261
NR 76
TC 31
Z9 31
U1 3
U2 59
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 18
PY 2015
VL 10
IS 6
AR e0130005
DI 10.1371/journal.pone.0130005
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK9NT
UT WOS:000356567500075
PM 26086454
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, Q
   Ke, JT
   Song, QB
   Hu, WG
   Lu, XZ
   Wang, ZL
   Gong, HY
   Xu, TP
   Chen, XQ
   Xu, B
   Liu, C
   Sun, Y
   Gong, YJ
   Yang, Y
   Zhu, Y
AF Wang, Qi
   Ke, Juntao
   Song, Qibin
   Hu, Weiguo
   Lu, Xuzai
   Wang, Zhenling
   Gong, Hongyun
   Xu, Tangpeng
   Chen, Xueqin
   Xu, Bin
   Liu, Cheng
   Sun, Yun
   Gong, Yajie
   Yang, Yang
   Zhu, Ying
TI The SNP rs931794 in 15q25.1 Is Associated with Lung Cancer Risk: A
   Hospital-Based Case-Control Study and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SUSCEPTIBILITY LOCUS; SEQUENCE VARIANTS; SMOKING; MAPS; BIAS
AB Background
   Lung cancer is one of the most common human malignant diseases and the leading cause of cancer death worldwide. The rs931794, a SNP located in 15q25.1, has been suggested to be associated with lung cancer risk. Nevertheless, several genetic association studies yielded controversial results.
   Methods and Findings
   A hospital-based case-control study involving 611 cases and 1062 controls revealed the variant of rs931794 was related to increased lung cancer risk. Stratified analyses revealed the G allele was significantly associated with lung cancer risk among smokers. Following meta-analysis including 6616 cases and 7697 controls confirmed the relevance of rs931794 variant with increased lung cancer risk once again. Heterogeneity should be taken into account when interpreting the consequences. Stratified analysis found ethnicity, histological type and genotyping method were not the sources of between-study heterogeneity. Further sensitivity analysis revealed that the study "Hsiung et al (2010)" might be the major contributor to heterogeneity. Cumulative meta-analysis showed the trend was increasingly obvious with adding studies, confirming the significant association.
   Conclusions
   Results from our current case-control study and meta-analysis offered insight of association between rs931794 and lung cancer risk, suggesting the variant of rs931794 might be related with increased lung cancer risk.
C1 [Wang, Qi; Song, Qibin; Hu, Weiguo; Gong, Hongyun; Xu, Tangpeng; Xu, Bin] Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan 430072, Peoples R China.
   [Ke, Juntao; Chen, Xueqin; Liu, Cheng; Sun, Yun; Gong, Yajie; Yang, Yang; Zhu, Ying] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430074, Peoples R China.
   [Ke, Juntao; Chen, Xueqin; Liu, Cheng; Sun, Yun; Gong, Yajie; Yang, Yang; Zhu, Ying] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Key Lab Environm & Hlth,Minist Educ, Wuhan 430074, Peoples R China.
   [Lu, Xuzai] Guangdong Maternal & Child Hlth Care Hosp, Guangzhou, Guangdong, Peoples R China.
   [Wang, Zhenling] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hosp Infect Control, Wuhan 430074, Peoples R China.
RP Song, QB (reprint author), Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan 430072, Peoples R China.
EM qibinsong@163.com
FU National Natural Science Foundation of China [81372407]
FX This work was supported by the National Natural Science Foundation of
   China 81372407 to Q. S.;
   http://isisn.nsfc.gov.cn/egrantindex/funcindex/prjsearch-list. The
   funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ashford NA, 2015, SCIENCE, V347, P727, DOI 10.1126/science.aaa6246
   Bailey-Wilson JE, 2004, AM J HUM GENET, V75, P460, DOI 10.1086/423857
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brambilla E, 2001, EUR RESPIR J, V18, P1059, DOI 10.1183/09031936.01.00275301
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gotay C, 2015, SCIENCE, V347, P728, DOI 10.1126/science.aaa6462
   Gu ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037970
   HABER M, 1981, HUM HERED, V31, P161, DOI 10.1159/000153199
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hsiung CA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001051
   Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885
   Improgo MRD, 2010, ONCOGENE, V29, P4874, DOI 10.1038/onc.2010.256
   Ito H, 2012, J THORAC ONCOL, V7, P790, DOI 10.1097/JTO.0b013e3182475028
   Krais AM, 2011, CARCINOGENESIS, V32, P1388, DOI 10.1093/carcin/bgr090
   Li L, 1997, Zhonghua Zhong Liu Za Zhi, V19, P3
   Little J, 2009, PLOS MED, V6, P151, DOI 10.1371/journal.pmed.1000022
   Liu JZ, 2010, NAT GENET, V42, P436, DOI 10.1038/ng.572
   Liu PY, 2008, JNCI-J NATL CANCER I, V100, P1326, DOI 10.1093/jnci/djn268
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Munafo MR, 2012, JNCI-J NATL CANCER I, V104, P740, DOI 10.1093/jnci/djs191
   Ruano-Ravina A, 2003, PUBLIC HEALTH, V117, P149, DOI 10.1016/S0033-3506(02)00023-9
   Schwartz AG, 2009, J THORAC ONCOL, V4, P1195, DOI 10.1097/JTO.0b013e3181b244ef
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Song FJ, 1998, BRIT MED J, V316, P471
   Song MY, 2015, SCIENCE, V347, P728, DOI 10.1126/science.aaa6094
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sterne JA, 2008, ADDRESSING REPORTING, P297
   Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846
   Thorgeirsson TE, 2010, NAT GENET, V42, P448, DOI 10.1038/ng.573
   Timofeeva MN, 2012, HUM MOL GENET, V21, P4980, DOI 10.1093/hmg/dds334
   Tournier JM, 2006, AM J PATHOL, V168, P55, DOI 10.2353/ajpath.2006.050333
   Truong T, 2010, J NATL CANCER I, V102, P959, DOI 10.1093/jnci/djq178
   Wild C, 2015, SCIENCE, V347, P728, DOI 10.1126/science.aaa6799
   Zhu BB, 2015, MOL CARCINOGEN, V54, P761, DOI 10.1002/mc.22140
   Zhu BB, 2014, CLIN GASTROENTEROL H, V12, P1991, DOI 10.1016/j.cgh.2014.03.019
NR 41
TC 1
Z9 1
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 16
PY 2015
VL 10
IS 6
AR e0128201
DI 10.1371/journal.pone.0128201
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK9EB
UT WOS:000356542300009
PM 26079375
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Iozzino, L
   Ferrari, C
   Large, M
   Nielssen, O
   de Girolamo, G
AF Iozzino, Laura
   Ferrari, Clarissa
   Large, Matthew
   Nielssen, Olav
   de Girolamo, Giovanni
TI Prevalence and Risk Factors of Violence by Psychiatric Acute Inpatients:
   A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID SHORT-TERM PREDICTION; THERAPEUTIC ALLIANCE; INTERPERSONAL STYLE;
   PUBLICATION BIAS; SELF-HARM; AGGRESSION; BEHAVIOR; PATIENT; INCIDENTS;
   GENDER
AB Background
   Violence in acute psychiatric wards affects the safety of other patients and the effectiveness of treatment. However, there is a wide variation in reported rates of violence in acute psychiatric wards.
   Objectives
   To use meta-analysis to estimate the pooled rate of violence in published studies, and examine the characteristics of the participants, and aspects of the studies themselves that might explain the variation in the reported rates of violence (moderators).
   Method
   Systematic meta-analysis of studies published between January 1995 and December 2014, which reported rates of violence in acute psychiatric wards of general or psychiatric hospitals in high-income countries. Results Of the 23,972 inpatients described in 35 studies, the pooled proportion of patients who committed at least one act of violence was 17% (95% confidence interval (CI) 14-20%). Studies with higher proportions of male patients, involuntary patients, patients with schizophrenia and patients with alcohol use disorder reported higher rates of inpatient violence.
   Conclusion
   The findings of this study suggest that almost 1 in 5 patients admitted to acute psychiatric units may commit an act of violence. Factors associated with levels of violence in psychiatric units are similar to factors that are associated with violence among individual patients (male gender, diagnosis of schizophrenia, substance use and lifetime history of violence).
C1 [Iozzino, Laura; Ferrari, Clarissa; de Girolamo, Giovanni] IRCCS Ctr San Giovanni Dio Fatebenefratelli, Psychiat Epidemiol & Evaluat Unit, Brescia, Italy.
   [Iozzino, Laura] Univ Verona, Sect Psychiat, Dept Publ Hlth & Community Med, I-37100 Verona, Italy.
   [Large, Matthew] Prince Wales Hosp Sydney, Sydney, NSW, Australia.
   [Nielssen, Olav] St Vincents Hosp, Sydney, NSW 2010, Australia.
   [Large, Matthew; Nielssen, Olav] Univ New S Wales, Sydney, NSW, Australia.
RP de Girolamo, G (reprint author), IRCCS Ctr San Giovanni Dio Fatebenefratelli, Psychiat Epidemiol & Evaluat Unit, Brescia, Italy.
EM gdegirolamo@fatebenefratelli.it
RI de Girolamo, Giovanni/K-3062-2016; IOZZINO, LAURA/I-8467-2018; Ferrari,
   Clarissa/D-6862-2017
OI de Girolamo, Giovanni/0000-0002-1611-8324; IOZZINO,
   LAURA/0000-0002-3633-8316; Ferrari, Clarissa/0000-0002-4101-6872;
   Nielssen, Olav/0000-0001-5172-2781
CR Abderhalden C, 2006, BMC PSYCHIATRY, V25, P6
   Abderhalden C, 2008, BRIT J PSYCHIAT, V193, P44, DOI 10.1192/bjp.bp.107.045534
   Amore M, 2008, PSYCHIAT CLIN NEUROS, V62, P247, DOI 10.1111/j.1440-1819.2008.01790.x
   Ash D, 2003, INT J SOC PSYCHIATR, V49, P112, DOI 10.1177/0020764003049002004
   Audit Commission, 2001, CHANG HER MAN CHANG
   Barlow K, 2000, AUST NZ J PSYCHIAT, V34, P967, DOI 10.1046/j.1440-1614.2000.00802.x
   Beauford JE, 1997, AM J PSYCHIAT, V154, P1272
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Biancosino B, 2009, J NERV MENT DIS, V197, P772, DOI 10.1097/NMD.0b013e3181bb0d6b
   Bjorkdahl A, 2006, ACTA PSYCHIAT SCAND, V113, P224, DOI 10.1111/j.1600-0447.2005.00679.x
   BLOMHOFF S, 1990, HOSP COMMUNITY PSYCH, V41, P771
   Boggild AK, 2004, CAN J PSYCHIAT, V49, P114, DOI 10.1177/070674370404900206
   BOLLEN KA, 1985, SOCIOL METHOD RES, V13, P510, DOI 10.1177/0049124185013004004
   Bowers L, 2003, SOC PSYCH PSYCH EPID, V38, P402, DOI 10.1007/s00127-003-0648-x
   Bowers L., 2005, J MENTAL HLTH, V14, P625, DOI [10.1080/09638230500389105, DOI 10.1080/09638230500389105]
   Bowers Len, 2009, Issues Ment Health Nurs, V30, P260, DOI 10.1080/01612840802710829
   Budd T., 1999, VIOLENCE WORK FINDIN
   CALDWELL MF, 1992, HOSP COMMUNITY PSYCH, V43, P838
   Carr VJ, 2008, AUST NZ J PSYCHIAT, V42, P267, DOI 10.1080/00048670701881520
   Cohen DP, 2008, PSYCHIATR BULL, V32, P455, DOI 10.1192/pb.bp.107.015412
   Cookson A, 2012, INT J MENT HEALTH NU, V21, P20, DOI 10.1111/j.1447-0349.2011.00764.x
   Cooper CL, 2002, WORKPLACE VIOLENCE H
   Cornaggia CM, 2011, PSYCHIAT RES, V189, P10, DOI 10.1016/j.psychres.2010.12.024
   Dack C, 2013, ACTA PSYCHIAT SCAND, V127, P255, DOI 10.1111/acps.12053
   Daffern M, 2006, INT J MENT HEALTH NU, V15, P93, DOI 10.1111/j.1447-0349.2006.00408.x
   Daffern M, 2010, PSYCHIATRY, V73, P365, DOI 10.1521/psyc.2010.73.4.365
   Dumais Alexandre, 2012, Issues Ment Health Nurs, V33, P670
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Duxbury J, 2002, J Psychiatr Ment Health Nurs, V9, P325, DOI 10.1046/j.1365-2850.2002.00497.x
   Eaton S, 2000, MED SCI LAW, V40, P143, DOI 10.1177/002580240004000210
   Ehmann TS, 2001, J NERV MENT DIS, V189, P716, DOI 10.1097/00005053-200110000-00009
   Fajnzylber P, 2002, J LAW ECON, V45, P1, DOI 10.1086/338347
   Fazel S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000120
   Fisher William A, 2003, J Psychiatr Pract, V9, P7, DOI 10.1097/00131746-200301000-00003
   Garcia I, 2005, ACUTE CARE 2004 NATL
   Gilbody SM, 2000, ACTA PSYCHIAT SCAND, V102, P241, DOI 10.1034/j.1600-0447.2000.102004241.x
   Grassi L, 2001, ACTA PSYCHIAT SCAND, V104, P273, DOI 10.1034/j.1600-0447.2001.00292.x
   Hartvig P, 2011, EUR PSYCHIAT, V26, P92, DOI 10.1016/j.eurpsy.2010.01.003
   Hatch-Maillette Mary A, 2007, Violence Vict, V22, P449, DOI 10.1891/088667007781553982
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ketelsen R, 2007, J PSYCHIATR MENT HLT, V14, P92
   Krakowski M, 2004, AM J PSYCHIAT, V161, P459, DOI 10.1176/appi.ajp.161.3.459
   Lam JN, 2000, PSYCHIATR SERV, V51, P1167, DOI 10.1176/appi.ps.51.9.1167
   Large MM, 2008, SOC PSYCH PSYCH EPID, V43, P251, DOI 10.1007/s00127-007-0287-8
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Mauri MC, 2011, PROG NEURO-PSYCHOPH, V35, P1631, DOI 10.1016/j.pnpbp.2011.05.008
   McNiel DE, 2003, J CONSULT CLIN PSYCH, V71, P945, DOI 10.1037/0022-006X.71.5.945
   MCNIEL DE, 1988, AM J PSYCHIAT, V145, P965
   Mellesdal L, 2003, PSYCHOL REP, V92, P1229, DOI 10.2466/pr0.2003.92.3c.1229
   Monahan J., 1983, CRIME JUSTICE ANN RE, V4, P145
   Needham I, 2005, INT J NURS STUD, V42, P649, DOI 10.1016/j.ijnurstu.2004.10.003
   Nielssen O, 2012, PSYCHIAT SERV, V63, P500, DOI 10.1176/appi.ps.201100290
   Nijman H, 2002, ACTA PSYCHIAT SCAND, V105, P390, DOI 10.1034/j.1600-0447.2002.0o426.x
   Nijman HLI, 1997, EUR J PSYCHIAT, V11, P106
   Olofsson B, 2001, J Psychiatr Ment Health Nurs, V8, P357, DOI 10.1046/j.1365-2850.2001.00404.x
   Oulis P, 1996, PSYCHOPATHOLOGY, V29, P174, DOI 10.1159/000284988
   Owen C, 1998, PSYCHIATR SERV, V49, P1452, DOI 10.1176/ps.49.11.1452
   POWELL G, 1994, BRIT J PSYCHIAT, V165, P107, DOI 10.1192/bjp.165.1.107
   R Development Core Team, 2010, R LANG ENV STAT COMP
   Raja M, 1997, SOC PSYCH PSYCH EPID, V32, P428
   Raja M, 2005, CLIN PRACTICE EPIDEM, V29, P1
   Ross J, 2012, J CLIN NURS, V21, P2306, DOI 10.1111/j.1365-2702.2012.04073.x
   Royal College of Nursing, 2005, VIOL SHORT TERM MAN
   Sanderson S, 2007, INT J EPIDEMIOL, V36, P666, DOI 10.1093/ije/dym018
   Saverimuttu A, 2000, Nurs Stand, V14, P33
   Soliman AED, 2001, PSYCHIATR SERV, V52, P75, DOI 10.1176/appi.ps.52.1.75
   Swanson JW, 2006, AM J PSYCHIAT, V163, P1404, DOI 10.1176/appi.ajp.163.8.1404
   Troisi A, 2003, J CLIN PSYCHIAT, V64, P1460, DOI 10.4088/JCP.v64n1210
   Turner RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059202
   Vaaler AE, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-44
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Whittington R, 2006, VIOLENCE MENTAL HLTH
NR 73
TC 66
Z9 68
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 10
PY 2015
VL 10
IS 6
AR e0128536
DI 10.1371/journal.pone.0128536
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK1PO
UT WOS:000355979500086
PM 26061796
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ye, JX
   Jiang, L
   Wu, CL
   Liu, AQ
   Mao, SF
   Ge, LY
AF Ye, Jiaxiang
   Jiang, Li
   Wu, Changliang
   Liu, Aiqun
   Mao, Sufei
   Ge, Lianying
TI Three ADIPOR1 Polymorphisms and Cancer Risk: A Meta-Analysis of
   Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID COLORECTAL-CANCER; BREAST-CANCER; ADIPONECTIN RECEPTORS;
   PROSTATE-CANCER; CELL-PROLIFERATION; PUBLICATION BIAS; GENES; OBESITY;
   EXPRESSION; VARIANTS
AB Background
   Studies have come to conflicting conclusions about whether polymorphisms in the adiponectin receptor 1 gene (ADIPOR1) are associated with cancer risk. To help resolve this question, we meta-analyzed case-control studies in the literature.
   Methods
   PubMed, EMBASE, Cochrane Library, the Chinese Biological Medical Database and the Chinese National Knowledge Infrastructure Database were systematically searched to identify all case-control studies published through February 2015 examining any ADIPOR1 polymorphisms and risk of any type of cancer. Pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated.
   Results
   A total of 13 case-control studies involving 5,750 cases and 6,762 controls were analyzed. Analysis of the entire study population revealed a significant association between rs1342387 (G/A) and overall cancer risk using a homozygousmodel (OR 0.82, 95% CI 0.72 to 0.94), heterozygous model (OR 0.84, 95% CI 0.76 to 0.93), dominant model (OR 0.85, 95% CI 0.75 to 0.97) and allele contrast model (OR 0.88, 95% CI 0.80 to 0.97). However, subgroup analysis showed that this association was significant only for Asians in the case of colorectal cancer. No significant associations were found between rs12733285(C/T) or rs7539542(C/G) and cancer risk, either in analyses of the entire study population or in analyses of subgroups.
   Conclusions
   Our meta-analysis suggests that the ADIPOR1 rs1342387(G/A) polymorphism, but not rs12733285(C/T) or rs7539542(C/G), may be associated with cancer risk, especially risk of colorectal cancer in Asians. Large, well-designed studies are needed to verify our findings.
C1 [Ye, Jiaxiang; Liu, Aiqun; Mao, Sufei; Ge, Lianying] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Med Oncol, Inst Canc, Nanning 530021, Guangxi, Peoples R China.
   [Jiang, Li] Guangxi Med Univ, Grad Sch, Nanning 530021, Guangxi, Peoples R China.
   [Wu, Changliang] Guangxi Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanning 530021, Guangxi, Peoples R China.
RP Wu, CL (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanning 530021, Guangxi, Peoples R China.
EM wuchangliang2013@126.com; gelianying1996@126.com
FU Natural Science Foundation of Guangxi [2012GXNSFDA053021]
FX This study was supported by the Natural Science Foundation of Guangxi
   (No. 2012GXNSFDA053021,
   http://www.gxst.gov.cn/zwgk/kjxmgl/xmxdgg/637057.shtml). The funder had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR An W, 2012, EUR J CANCER PREV, V21, P126, DOI 10.1097/CEJ.0b013e32834c9b55
   Beebe-Dimmer JL, 2010, PROSTATE CANCER P D, V13, P362, DOI 10.1038/pcan.2010.27
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bennett DA, 2004, J CLIN EPIDEMIOL, V57, P349, DOI 10.1016/j.jclinepi.2003.09.015
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Cohen S, 2011, ANAL CELL PATHOL, V34, P1, DOI 10.3233/ACP-2011-0007
   Dalamaga M, 2009, CANCER CAUSE CONTROL, V20, P625, DOI 10.1007/s10552-008-9273-z
   Dhillon PK, 2011, CANCER EPIDEM BIOMAR, V20, P2618, DOI 10.1158/1055-9965.EPI-11-0434
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   He BS, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-94
   Heid IM, 2006, DIABETES, V55, P375, DOI 10.2337/diabetes.55.02.06.db05-0747
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005
   Kaklamani V, 2011, METABOLISM, V60, P1234, DOI 10.1016/j.metabol.2011.01.005
   Kaklamani VG, 2008, JAMA-J AM MED ASSOC, V300, P1523, DOI 10.1001/jama.300.13.1523
   Kaklamani VG, 2008, CANCER RES, V68, P3178, DOI 10.1158/0008-5472.CAN-08-0533
   Kharroubi I, 2003, BIOCHEM BIOPH RES CO, V312, P1118, DOI 10.1016/j.bbrc.2003.11.042
   Kim AY, 2010, MOL ENDOCRINOL, V24, P1441, DOI 10.1210/me.2009-0498
   Korner A, 2007, J CLIN ENDOCR METAB, V92, P1041, DOI 10.1210/jc.2006-1858
   Liu L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027301
   Ogunwobi OO, 2008, MOL CELL ENDOCRINOL, V285, P43, DOI 10.1016/j.mce.2008.01.023
   Ou Y., 2012, THESIS
   Pan ZL, 2005, PLOS MED, V2, P1309, DOI 10.1371/journal.pmed.0020334
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Song MY, 2015, INT J CANCER, V137, P154, DOI 10.1002/ijc.29360
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Teras LR, 2009, CANCER EPIDEM BIOMAR, V18, P2553, DOI 10.1158/1055-9965.EPI-09-0542
   Williams CJ, 2008, ENDOCR-RELAT CANCER, V15, P289, DOI 10.1677/ERC-07-0197
   Wolk A, 2001, CANCER CAUSE CONTROL, V12, P13, DOI 10.1023/A:1008995217664
   Wu MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104630
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Ye JJ, 2014, EUR J CANCER PREV, V23, P158, DOI 10.1097/CEJ.0b013e328364f293
   Yi NJ, 2011, ANN HUM GENET, V75, P90, DOI 10.1111/j.1469-1809.2010.00605.x
   Yu LX, 2014, ASIAN PAC J CANCER P, V15, P7515, DOI 10.7314/APJCP.2014.15.18.7515
   Zhang Ying, 2012, Journal of Jiangsu University - Medicine Edition, V22, P336
NR 35
TC 4
Z9 4
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 5
PY 2015
VL 10
IS 6
AR UNSP e0127253
DI 10.1371/journal.pone.0127253
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ7CR
UT WOS:000355652200018
PM 26047008
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Teng, ZW
   Zhu, Y
   Wu, FH
   Zhu, YH
   Zhang, XG
   Zhang, CL
   Wang, SN
   Zhang, L
AF Teng, Zhaowei
   Zhu, Yun
   Wu, Feihu
   Zhu, Yanhong
   Zhang, Xiguang
   Zhang, Chuanlin
   Wang, Shuangneng
   Zhang, Lei
TI Opioids Contribute to Fracture Risk: A Meta-Analysis of 8 Cohort Studies
SO PLOS ONE
LA English
DT Article
ID CHRONIC PAIN PATIENTS; OLDER-ADULTS; COMPARATIVE SAFETY; NONMALIGNANT
   PAIN; HIP FRACTURE; MEDICATIONS; ANALGESICS; BIAS; EPIDEMIOLOGY;
   ASSOCIATION
AB Objective
   To evaluate the association between chronic opioid use for non-cancer pain and fracture risk by conducting a meta-analysis of cohort studies.
   Methods
   Cohort studies were identified by searching PubMed and EMBASE from their inception to July 2014. A fracture was considered an endpoint. The information was extracted by two authors independently. When the heterogeneity was significant, a random-effects model was used to calculate the overall pooled risk estimates.
   Results
   Eight cohort studies were included in the final meta-analysis. On the basis of the Newcastle-Ottawa Scale (NOS), six studies were considered to be of high quality. The overall combined relative risk for the use of opioids and fractures was 1.88 (95% confidence interval [CI] 1.51-2.34). A subgroup analysis revealed the sources of heterogeneity. The sensitivity analysis indicated stable results, and no publication bias was observed.
   Conclusions
   This meta-analysis of cohort studies demonstrates that opioids significantly increase the risk of fractures.
C1 [Teng, Zhaowei; Zhang, Xiguang; Zhang, Chuanlin; Wang, Shuangneng] Kunming Med Univ, Affiliated Hosp 6, Peoples Hosp Yuxi City, Dept Orthoped Surg, Yuxi, Yunan, Peoples R China.
   [Zhu, Yun] Kunming Med Univ, Affiliated Hosp 6, Peoples Hosp Yuxi City, Dept Nephrol, Yuxi, Yunan, Peoples R China.
   [Wu, Feihu; Zhu, Yanhong] Kunming Med Univ, Affiliated Hosp 6, Peoples Hosp Yuxi City, Dept Anesthesiol, Yuxi, Yunan, Peoples R China.
   [Zhang, Lei] Second Peoples Hosp Yunnan Prov, Trauma Ctr Yunnan Prov, Kunming, Yunan, Peoples R China.
RP Teng, ZW (reprint author), Kunming Med Univ, Affiliated Hosp 6, Peoples Hosp Yuxi City, Dept Orthoped Surg, Yuxi, Yunan, Peoples R China.
EM tengzhaowei2003@163.com; gwkzxg@163.com
CR Ali II, 2004, EPILEPSY BEHAV, V5, P296, DOI 10.1016/j.yebeh.2004.02.005
   Bazelier Marloes T, 2013, Front Endocrinol (Lausanne), V4, P11, DOI 10.3389/fendo.2013.00011
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Carbone LD, 2013, J SPINAL CORD MED, V36, P91, DOI 10.1179/2045772312Y.0000000060
   Card T, 2004, GUT, V53, P251, DOI 10.1136/gut.2003.026799
   Chen L, 2013, J PAIN, V14, P384, DOI 10.1016/j.jpain.2012.12.012
   Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009
   COURSOL A, 1986, PROF PSYCHOL-RES PR, V17, P136, DOI 10.1037/0735-7028.17.2.136
   Daniell HW, 2002, J PAIN, V3, P377, DOI 10.1054/jpai.2002.126790
   Daniell HW, 2004, ARCH INTERN MED, V164, P338, DOI 10.1001/archinte.164.3.338-a
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ensrud KE, 2003, ARCH INTERN MED, V163, P949, DOI 10.1001/archinte.163.8.949
   Eom CS, 2012, J BONE MINER RES, V27, P1186, DOI 10.1002/jbmr.1554
   Eriksen J, 2003, PAIN, V106, P221, DOI 10.1016/S0304-3959(03)00225-2
   Guo ZC, 1998, AM J EPIDEMIOL, V148, P887
   Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Kamal-Bahl Sachin J, 2006, Am J Geriatr Pharmacother, V4, P219, DOI 10.1016/j.amjopharm.2006.09.005
   Kelly JP, 2008, PAIN, V138, P507, DOI 10.1016/j.pain.2008.01.027
   Li L, 2013, AM J EPIDEMIOL, V178, P559, DOI 10.1093/aje/kwt013
   Miller M, 2011, J AM GERIATR SOC, V59, P430, DOI 10.1111/j.1532-5415.2011.03318.x
   Saunders KW, 2010, J GEN INTERN MED, V25, P310, DOI 10.1007/s11606-009-1218-z
   SHORR RI, 1992, J GERONTOL, V47, pM111, DOI 10.1093/geronj/47.4.M111
   Solomon DH, 2010, ARCH INTERN MED, V170, P1979, DOI 10.1001/archinternmed.2010.450
   Solomon DH, 2010, ARCH INTERN MED, V170, P1968, DOI 10.1001/archinternmed.2010.391
   Spector W, 2007, J AM GERIATR SOC, V55, P327, DOI 10.1111/j.1532-5415.2007.01081.x
   Stewart G, 2013, ANAEST INTENS CARE M, V14, P533, DOI 10.1016/j.mpaic.2013.09.002
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Takkouche B, 2007, DRUG SAFETY, V30, P171, DOI 10.2165/00002018-200730020-00006
   Vestergaard P, 2006, J INTERN MED, V260, P76, DOI 10.1111/j.1365-2796.2006.01667.x
   Vestergaard P, 2012, OSTEOPOROSIS INT, V23, P1255, DOI 10.1007/s00198-011-1692-0
   Wells G, 2011, NEWCASTLE OTTAWA SCA, DOI [10.1371/journal.pntd.0002195, DOI 10.1371/JOURNAL.PNTD.0002195]
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Xu T, 2012, BRIT J DERMATOL, V167, P1345, DOI 10.1111/bjd.12002
NR 35
TC 10
Z9 10
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 1
PY 2015
VL 10
IS 6
AR e0128232
DI 10.1371/journal.pone.0128232
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CL0KF
UT WOS:000356630900131
PM 26030421
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zheng, QL
   Wu, HJ
   Cao, J
AF Zheng, Qiaoli
   Wu, Haijian
   Cao, Jiang
TI Circulating Adiponectin and Risk of Endometrial Cancer
SO PLOS ONE
LA English
DT Article
ID INSULIN-RESISTANCE; ADIPOSE-TISSUE; POSTMENOPAUSAL WOMEN; SERUM LEPTIN;
   METAANALYSIS; OBESITY; RECEPTORS; ASSOCIATION; EXPRESSION; SENSITIVITY
AB Background
   Adiponectin is an insulin-sensitizing hormone produced by adipocytes. It has been suggested to be involved in endometrial tumorigenesis. Published data have shown inconsistent results for the association between circulating adiponectin levels and endometrial cancer. In this study, we conducted a meta-analysis to evaluate the predictive value of circulating adiponectin levels on the development of endometrial cancer.
   Methods
   PubMed, Embase, ISI web of knowledge, and Cochrane databases were searched for all eligible studies, and the summary relative risk (SRR) was calculated. Additionally, we performed dose-response analysis with eight eligible studies.
   Results
   A total of 1,955 cases and 3,458 controls from 12 studies were included. The SRR for the 'highest' vs 'lowest' adiponectin levels indicated high adiponectin level reduced the risk of endometrial cancer [SRR = 0.40, 95% confidence interval (CI), 0.33-0.66]. Results from the subgroup analyses were consistent with the overall analysis. The SRR for each 1 mu g/ml increase of adiponectin indicated a 3% reduction in endometrial cancer risk (95% CI: 2%-4%), and a 14% reduction for each increase of 5 mu g/ml (95% CI: 9%-19%). No evidence of publication bias was found.
   Conclusions
   This meta-analysis demonstrates that low level of circulating adiponectin is a risk factor for endometrial cancer.
C1 [Zheng, Qiaoli; Cao, Jiang] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Clin Res Ctr, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zheng, Qiaoli] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Dermatol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wu, Haijian] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310003, Zhejiang, Peoples R China.
RP Cao, J (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Clin Res Ctr, 88 Jiefang Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM caoj@zju.edu.cn
CR Abbasi F, 2004, DIABETES, V53, P585, DOI 10.2337/diabetes.53.3.585
   Ali Aus Tariq, 2013, Ceska Gynekol, V78, P448
   Arikoglu H, 2014, GENE, V534, P10, DOI 10.1016/j.gene.2013.10.039
   Arita Y, 2012, BIOCHEM BIOPH RES CO, V425, P560, DOI 10.1016/j.bbrc.2012.08.024
   Ashizawa N, 2010, GYNECOL ONCOL, V119, P65, DOI 10.1016/j.ygyno.2010.07.007
   Barb D, 2007, AM J CLIN NUTR, V86, p858S, DOI 10.1093/ajcn/86.3.858S
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brakenhielm E, 2004, P NATL ACAD SCI USA, V101, P2476, DOI 10.1073/pnas.0308671100
   Christiansen T, 2010, J CLIN ENDOCR METAB, V95, P911, DOI 10.1210/jc.2008-2505
   Cnop M, 2003, DIABETOLOGIA, V46, P459, DOI 10.1007/s00125-003-1074-z
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Crosbie EJ, 2010, CANCER EPIDEM BIOMAR, V19, P3119, DOI 10.1158/1055-9965.EPI-10-0832
   Cust AE, 2007, J CLIN ENDOCR METAB, V92, P255, DOI 10.1210/jc.2006-1371
   Dal Maso L, 2004, J CLIN ENDOCR METAB, V89, P1160, DOI 10.1210/jc.2003-031716
   Dalamaga M, 2012, ENDOCR REV, V33, P547, DOI 10.1210/er.2011-1015
   Dallal CM, 2013, ENDOCR-RELAT CANCER, V20, P151, DOI 10.1530/ERC-12-0229
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Erdogan S, 2013, ENDOCR-RELAT CANCER, V20, P669, DOI 10.1530/ERC-13-0280
   Friedenreich CM, 2012, ENDOCR-RELAT CANCER, V19, P785, DOI 10.1530/ERC-12-0211
   Furberg AS, 2003, INT J CANCER, V104, P669, DOI 10.1002/ijc.10974
   GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x
   Houde AA, 2014, ADIPOCYTE, V3, P132, DOI 10.4161/adip.28308
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531
   Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005
   Kelesidis I, 2006, BRIT J CANCER, V94, P1221, DOI 10.1038/sj.bjc.6603051
   Kern PA, 2003, DIABETES, V52, P1779, DOI 10.2337/diabetes.52.7.1779
   Lihn AS, 2005, OBES REV, V6, P13, DOI 10.1111/j.1467-789X.2005.00159.x
   Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261
   Luhn P, 2013, CANCER EPIDEM BIOMAR, V22, P1304, DOI 10.1158/1055-9965.EPI-13-0258
   Lukanova A, 2004, INT J CANCER, V108, P262, DOI 10.1002/ijc.11544
   Ma Y, 2013, J GYNECOL ONCOL, V24, P336, DOI 10.3802/jgo.2013.24.4.336
   Macis D, 2014, INT J EPIDEMIOL, V43, P1226, DOI 10.1093/ije/dyu088
   Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724
   Moon HS, 2011, MOL CANCER THER, V10, P2234, DOI 10.1158/1535-7163.MCT-11-0545
   Neumeier M, 2006, J LEUKOCYTE BIOL, V79, P803, DOI 10.1189/jlb.0905521
   Ohbuchi Y, 2013, INT J CLIN ONCOL
   Orsini N, 2012, AM J EPIDEMIOL, V175, P66, DOI 10.1093/aje/kwr265
   Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296
   Ouchi N, 2003, CIRCULATION, V107, P671, DOI 10.1161/01.CIR.0000055188.83694.B3
   Park J, 2011, ENDOCR REV, V32, P550, DOI 10.1210/er.2010-0030
   Petridou E, 2003, J CLIN ENDOCR METAB, V88, P993, DOI 10.1210/jc.2002-021209
   Soliman PT, 2006, CANCER-AM CANCER SOC, V106, P2376, DOI 10.1002/cncr.21866
   Soliman PT, 2011, AM J OBSTET GYNECOL, V204, P167, DOI DOI 10.1016/J.AJ0G.2010.08.045)
   Takemura Y, 2006, ENDOCRINOLOGY, V147, P3203, DOI 10.1210/en.2005-1510
   van Kruijsdijk RCM, 2009, CANCER EPIDEM BIOMAR, V18, P2569, DOI 10.1158/1055-9965.EPI-09-0372
   Wang Y, 2005, J BIOL CHEM, V280, P18341, DOI 10.1074/jbc.M501149200
   Westerink J, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-13
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
   Yokota T, 2000, BLOOD, V96, P1723
NR 52
TC 7
Z9 7
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 1
PY 2015
VL 10
IS 6
AR e0129824
DI 10.1371/journal.pone.0129824
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CL0KF
UT WOS:000356630900233
PM 26030130
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Puetz, TW
   Youngstedt, SD
   Herring, MP
AF Puetz, Timothy W.
   Youngstedt, Shawn D.
   Herring, Matthew P.
TI Effects of Pharmacotherapy on Combat-Related PTSD, Anxiety, and
   Depression: A Systematic Review and Meta-Regression Analysis
SO PLOS ONE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; OF-VETERANS-AFFAIRS; SYMPTOMS;
   METAANALYSIS; EXERCISE; QUALITY; TRIALS; COMORBIDITY; PREVALENCE;
   GUIDELINES
AB The efficacy of pharmacotherapy for PTSD, anxiety, and depression among combat veterans is not well-established.
   Objectives
   To estimate the effect of pharmacotherapy on PTSD, anxiety, and depression among combat veterans; to determine whether the effects varied according to patient and intervention characteristics; and to examine differential effects of pharmacotherapy on outcomes.
   Materials and Methods
   Google Scholar, PILOTS, PsycINFO, PubMed, and Web of Science databases were searched through November 2014. Searches resulted in eighteen double-blind, placebo controlled trials of 773 combat veterans diagnosed with PTSD and included only validated pre- and post-intervention PTSD and anxiety or depression measures. Authors extracted data on effect sizes, moderators, and study quality. Hedges' d effect sizes were computed and random effects models estimated sampling error and population variance. The Johnson-Neyman procedure identified the critical points in significant interactions to define regions of significance.
   Results
   Pharmacotherapy significantly reduced (Delta, 95% CI) PTSD (0.38, 0.23-0.52), anxiety (0.42, 0.30-0.54), and depressive symptoms (0.52, 0.35-0.70). The effects of SSRIs and tricyclic antidepressants on PTSD were greater than other medications independent of treatment duration. The effect of SSRIs and tricyclic antidepressants were greater than other medications up to 5.2 and 13.6 weeks for anxiety and depression, respectively. The magnitude of the effect of pharmacotherapy on concurrently-measured PTSD, anxiety, and depression did not significantly differ.
   Conclusions
   Pharmacotherapy reduced PTSD, anxiety, and depressive symptoms in combat veterans. The effects of SSRIs and tricyclic antidepressants were greater for PTSD and occurred quicker for anxiety and depression than other medications.
C1 [Puetz, Timothy W.] NIH, Ctr Clin, Off Director, Bethesda, MD 20892 USA.
   [Youngstedt, Shawn D.] Arizona State Univ, Coll Nursing & Hlth Innovat, Phoenix, AZ USA.
   [Youngstedt, Shawn D.] Arizona State Univ, Sch Nutr & Hlth Promot, Phoenix, AZ USA.
   [Youngstedt, Shawn D.] Phoenix VA Hlth Care Syst, Phoenix, AZ USA.
   [Herring, Matthew P.] Univ Limerick, Dept Phys Educ & Sport Sci, Limerick, Ireland.
RP Herring, MP (reprint author), Univ Limerick, Dept Phys Educ & Sport Sci, Limerick, Ireland.
EM matthew.herring@ul.ie
RI Herring, Matthew/O-2265-2014
OI Herring, Matthew/0000-0002-6835-5321
FU National Institutes of Health [R01 HL095799]
FX Funding for this work was provided by the National Institutes of Health
   under grant R01 HL095799. The funders had no role in the study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ahearn EP, 2011, INT CLIN PSYCHOPHARM, V26, P193, DOI 10.1097/YIC.0b013e3283473738
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Asnis GM, 2004, DRUGS, V64, P383, DOI 10.2165/00003495-200464040-00004
   Baldwin D, 2001, BMJ-BRIT MED J, V342, pd1199
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berger W, 2009, PROG NEURO-PSYCHOPH, V33, P169, DOI 10.1016/j.pnpbp.2008.12.004
   Betthauser LM, 2012, NEUROPSYCHOL REV, V22, P35, DOI 10.1007/s11065-012-9191-4
   Blanchard EB, 1998, J ANXIETY DISORD, V12, P21, DOI 10.1016/S0887-6185(97)00047-9
   Campbell DG, 2007, J GEN INTERN MED, V22, P711, DOI 10.1007/s11606-006-0101-4
   Celik C, 2011, KLIN PSIKOFARMAKOL B, V21, P179, DOI 10.5455/bcp.20110627111141
   COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452
   Defense Manpower Data Center Department of Defense, 2012, CONT TRACK SYST DEPL
   DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Epidemiology Program Post-Deployment Health Group Office of Public Health Veterans Health Administration Department of Veterans Affairs, 2013, AN VA HLTH CAR UT OP
   Erickson DJ, 2001, J CONSULT CLIN PSYCH, V69, P41, DOI 10.1037//0022-006X.69.1.41
   Gleser LJ, 1994, HDB RES SYNTHESIS, P339
   Hedges L. V., 1985, STAT METHODS METAANA
   Herring MP, 2012, ARCH INTERN MED, V172, P101, DOI 10.1001/archinternmed.2011.696
   Herring MP, 2010, ARCH INTERN MED, V170, P321, DOI 10.1001/archinternmed.2009.530
   Hidalgo RB, 2000, J PSYCHOPHARMACOL, V14, P70, DOI 10.1177/026988110001400110
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   IOM (Institute of Medicine), 2014, TREATM POSTTR STRESS
   Ipser JC, 2012, INT J NEUROPSYCHOPH, V15, P825, DOI 10.1017/S1461145711001209
   Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054
   Krystal JH, 2009, BRAIN RES, V1293, P13, DOI 10.1016/j.brainres.2009.03.044
   Kulka R. A., 1990, TRAUMA VIETNAM WAR G
   Lazar AA, 2011, J EDUC BEHAV STAT, V36, P699, DOI 10.3102/1076998610396889
   Lipsey M., 2001, PRACTICAL METAANALYS
   Mohamed S, 2008, J CLIN PSYCHIAT, V69, P959, DOI 10.4088/JCP.v69n0611
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Monnelly EP, 2003, J CLIN PSYCHOPHARM, V23, P193, DOI 10.1097/00004714-200304000-00012
   O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390
   Preacher KJ, 2006, J EDUC BEHAV STAT, V31, P437, DOI 10.3102/10769986031004437
   Puetz TW, 2013, JAMA INTERN MED, V173, P960, DOI 10.1001/jamainternmed.2013.836
   Puetz TW, 2012, AM J PREV MED, V43, pE1, DOI 10.1016/j.amepre.2012.04.027
   Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597
   Rosenthal R., 1991, METAANALYTIC PROCEDU
   Schnurr PP, 2003, ARCH GEN PSYCHIAT, V60, P481, DOI 10.1001/archpsyc.60.5.481
   Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE
   Steckler T, 2012, NEUROPHARMACOLOGY, V62, P617, DOI 10.1016/j.neuropharm.2011.06.012
   Stein DJ, 2009, CNS SPECTRUMS, V14, P25
   Stein MB, 2002, AM J PSYCHIAT, V159, P1777, DOI 10.1176/appi.ajp.159.10.1777
   Stewart CL, 2009, MIL MED, V174, P460, DOI 10.7205/MILMED-D-04-1507
   United States Census Bureau, 2012, VET STAT 2012 AM COM
NR 45
TC 12
Z9 14
U1 1
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 28
PY 2015
VL 10
IS 5
AR e0126529
DI 10.1371/journal.pone.0126529
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ0SC
UT WOS:000355187300025
PM 26020791
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yin, XH
   Huang, GL
   Lin, DR
   Wan, CC
   Wang, YD
   Song, JK
   Xu, P
AF Yin, Xin-Hai
   Huang, Guang-Lei
   Lin, Du-Ren
   Wan, Cheng-Cheng
   Wang, Ya-Dong
   Song, Ju-Kun
   Xu, Ping
TI Exposure to Fluoride in Drinking Water and Hip Fracture Risk: A
   Meta-Analysis of Observational Studies
SO PLOS ONE
LA English
DT Article
ID BONE-MINERAL DENSITY; OSTEOPOROSIS; COHORT; BIAS
AB Background
   Many observational studies have shown that exposure to fluoride in drinking water is associated with hip fracture risk. However, the findings are varied or even contradictory. In this work, we performed a meta-analysis to assess the relationship between fluoride exposure and hip fracture risk.
   Methods
   PubMed and EMBASE databases were searched to identify relevant observational studies from the time of inception until March 2014 without restrictions. Data from the included studies were extracted and analyzed by two authors. Summary relative risks (RRs) with corresponding 95% confidence intervals (CIs) were pooled using random-or fixed-effects models as appropriate. Sensitivity analyses and meta-regression were conducted to explore possible explanations for heterogeneity. Finally, publication bias was assessed.
   Results
   Fourteen observational studies involving thirteen cohort studies and one case-control study were included in the meta-analysis. Exposure to fluoride in drinking water does not significantly increase the incidence of hip fracture (RRs, 1.05; 95% CIs, 0.96-1.15). Sensitivity analyses based on adjustment for covariates, effect measure, country, sex, sample size, quality of Newcastle-Ottawa Scale scores, and follow-up period validated the strength of the results. Meta-regression showed that country, gender, quality of Newcastle-Ottawa Scale scores, adjustment for covariates and sample size were not sources of heterogeneity. Little evidence of publication bias was observed.
   Conclusion
   The present meta-analysis suggests that chronic fluoride exposure from drinking water does not significantly increase the risk of hip fracture. Given the potential confounding factors and exposure misclassification, further large-scale, high-quality studies are needed to evaluate the association between exposure to fluoride in drinking water and hip fracture risk.
C1 [Yin, Xin-Hai; Huang, Guang-Lei; Lin, Du-Ren; Wan, Cheng-Cheng; Wang, Ya-Dong; Song, Ju-Kun; Xu, Ping] Gui Zhou Prov Peoples Hosp, Dept Oral & Maxillary Surg, Guiyang, Gui Zhou, Peoples R China.
RP Song, JK (reprint author), Gui Zhou Prov Peoples Hosp, Dept Oral & Maxillary Surg, Guiyang, Gui Zhou, Peoples R China.
EM songjukun@163.com
CR ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   CAULEY JA, 1995, J BONE MINER RES, V10, P1076
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   DANIELSON C, 1992, JAMA-J AM MED ASSOC, V268, P746
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   EKSTRAND J, 1978, CLIN PHARMACOL THER, V23, P329
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hillier S, 2000, LANCET, V355, P265, DOI 10.1016/S0140-6736(99)07161-5
   Jacobsen S J, 1992, Ann Epidemiol, V2, P617
   JACOBSEN SJ, 1993, AM J PUBLIC HEALTH, V83, P743, DOI 10.2105/AJPH.83.5.743
   Karagas MR, 1996, ANN EPIDEMIOL, V6, P209, DOI 10.1016/1047-2797(96)00006-3
   Kurttio P, 1999, AM J EPIDEMIOL, V150, P817
   Lehmann R, 1998, BONE, V22, P273, DOI 10.1016/S8756-3282(97)00273-1
   Li YM, 2001, J BONE MINER RES, V16, P932, DOI 10.1359/jbmr.2001.16.5.932
   Nasman P, 2013, J DENT RES, V92, P1029, DOI 10.1177/0022034513506443
   Park Eun Young, 2008, J Prev Med Public Health, V41, P147
   Phipps KR, 2000, BRIT MED J, V321, P860, DOI 10.1136/bmj.321.7265.860
   RAO HV, 1995, REGUL TOXICOL PHARM, V22, P30, DOI 10.1006/rtph.1995.1065
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   Schemitsch E, 2009, J ORTHOP TRAUMA, V23, P385, DOI 10.1097/BOT.0b013e3181acc51f
   Scrivo R, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0445-5
   SIMONEN O, 1985, LANCET, V2, P432
   SOWERS MR, 1991, AM J EPIDEMIOL, V133, P649, DOI 10.1093/oxfordjournals.aje.a115940
   Whitford GM, 1996, MONOGR ORAL SCI, V16, P1
NR 25
TC 3
Z9 3
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 28
PY 2015
VL 10
IS 5
AR e0126488
DI 10.1371/journal.pone.0126488
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ0SC
UT WOS:000355187300023
PM 26020536
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhong, GC
   Wang, Y
   Zhang, Y
   Zhao, Y
AF Zhong, GuoChao
   Wang, Yi
   Zhang, Yong
   Zhao, Yong
TI Association between Benzodiazepine Use and Dementia: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PSYCHOTROPIC-DRUG USE; NESTED CASE-CONTROL; LONG-TERM USE;
   ALZHEIMERS-DISEASE; RISK; PREVALENCE; DISORDERS; SYMPTOMS; HEALTH; BIAS
AB Background
   The association between long-term benzodiazepine use and risk of dementia remains controversial. Therefore, current study aimed to quantify this association, and to explore a potential dose-response pattern.
   Methods
   We searched PubMed, Embase and the Cochrane Library through August 17, 2014. We included nested case-control or prospective cohort studies that provided risk estimates on the association of benzodiazepine use with risk of dementia, and a clear definition of status of benzodiazepine use. Overall effect size was calculated using a random-effects model.
   Findings
   Six studies were eligible for inclusion, involving 11,891 dementia cases and 45,391 participants. Compared with never users, pooled adjusted risk ratios (RRs) for dementia were 1.49 (95% confidence interval (CI) 1.30-1.72) for ever users, 1.55 (95% CI 1.31-1.83) for recent users, and 1.55 (95% CI 1.17-2.03) for past users. The risk of dementia increased by 22% for every additional 20 defined daily dose per year (RR, 1.22, 95% CI 1.18-1.25). When we restricted our meta-analyses to unadjusted RRs, all initial significant associations persisted.
   Conclusions
   Long-term benzodiazepine users have an increased risk of dementia compared with never users. However, findings from our study should be treated with caution due to limited studies and potential reverse causation. Large prospective cohort studies with long follow-up duration are warranted to confirm these findings.
C1 [Zhong, GuoChao; Wang, Yi] Chongqing Med Univ, Student Off 2, Chongqing, Peoples R China.
   [Zhang, Yong; Zhao, Yong] Chongqing Med Univ, Sch Publ Hlth & Management, Chongqing, Peoples R China.
RP Zhong, GC (reprint author), Chongqing Med Univ, Student Off 2, Chongqing, Peoples R China.
EM gczhong1991@163.com; zhaoyong@cqmu.edu.cn
CR Amieva H, 2008, ANN NEUROL, V64, P492, DOI 10.1002/ana.21509
   [Anonymous], 2012, DEM PUBL HLTH PRIOR
   Ashton H, 2005, CURR OPIN PSYCHIATR, V18, P249, DOI 10.1097/01.yco.0000165594.60434.84
   Barbui C, 2013, EPIDEMIOL PSYCH SCI, V22, P307, DOI 10.1017/S2045796013000358
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bennett S, 2014, MATURITAS
   Bocti C, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7986
   Chen PL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049113
   de Gage SB, 2015, EXPERT OPIN DRUG SAF, V14, P733, DOI 10.1517/14740338.2015.1014796
   de Gage SB, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5205
   de Gage SB, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6231
   Dell'osso B, 2013, EUR PSYCHIAT, V28, P7, DOI 10.1016/j.eurpsy.2011.11.003
   Dong JY, 2011, J AM COLL CARDIOL, V58, P1378, DOI 10.1016/j.jacc.2011.06.024
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   European Medicines Agency, 1994, SUMM PROD CHAR BENZ
   Fastbom J, 1998, ALZ DIS ASSOC DIS, V12, P14, DOI 10.1097/00002093-199803000-00002
   Froehlich TE, 2001, J AM GERIATR SOC, V49, P477, DOI 10.1046/j.1532-5415.2001.49096.x
   Gallacher J, 2012, J EPIDEMIOL COMMUN H, V66, P869, DOI 10.1136/jech-2011-200314
   GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
   Griffiths RR, 1997, PSYCHOPHARMACOLOGY, V134, P1, DOI 10.1007/s002130050422
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hsiao F-Y, 2014, J AM MED DIRECTORS A
   Lagnaoui R, 2002, J CLIN EPIDEMIOL, V55, P314, DOI 10.1016/S0895-4356(01)00453-X
   Lesen E, 2011, INT PSYCHOGERIATR, V23, P1270, DOI 10.1017/S1041610211000524
   Linden M, 2004, INT PSYCHOGERIATR, V16, P461, DOI 10.1017/S1041610204000420
   Mamdani M, 2005, AM J GERIAT PSYCHIAT, V13, P892, DOI 10.1176/appi.ajgp.13.10.892
   Mirza SS, 2014, ALZHEIMERS DEMENTIA
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Pariente A, 2008, DRUG AGING, V25, P61, DOI 10.2165/00002512-200825010-00007
   Parikh NM, 2011, INT J GERIATR PSYCH, V26, P749, DOI 10.1002/gps.2604
   Puustinen J, 2007, DRUG AGING, V24, P1045, DOI 10.2165/00002512-200724120-00007
   RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303
   SHORR RI, 1994, DRUG AGING, V4, P9, DOI 10.2165/00002512-199404010-00002
   Smith AD, 2014, J ALZHEIMERS DIS, V38, P699, DOI 10.3233/JAD-132372
   Ster MP, 2011, CROAT MED J, V52, P16, DOI 10.3325/cmj.2011.52.16
   Vinkers CH, 2012, ADV PHARMACOL SCI, DOI 10.1155/2012/416864
   Wells GA, 2000, NEWCASTLE OTTAWA SCA
   *WHO, 2000, WHO COLL CTR DRUG ST
   Wu CS, 2011, AM J GERIAT PSYCHIAT, V19, P151, DOI 10.1097/JGP.0b013e3181e049ca
   Wu CS, 2009, AM J GERIAT PSYCHIAT, V17, P614, DOI 10.1097/JGP.0b013e3181a65210
   Xiang YT, 2008, SLEEP, V31, P1655, DOI 10.1093/sleep/31.12.1655
NR 42
TC 37
Z9 39
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 27
PY 2015
VL 10
IS 5
AR UNSP e0127836
DI 10.1371/journal.pone.0127836
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ0RO
UT WOS:000355185600097
PM 26016483
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Darvishi, N
   Farhadi, M
   Haghtalab, T
   Poorolajal, J
AF Darvishi, Nahid
   Farhadi, Mehran
   Haghtalab, Tahereh
   Poorolajal, Jalal
TI Alcohol-Related Risk of Suicidal Ideation, Suicide Attempt, and
   Completed Suicide: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID MIDDLE-AGED MEN; USE DISORDERS; YOUNG MEN; DRUG-USE; DEPRESSION;
   BEHAVIOR; COHORT; ABUSE; ASSOCIATION; ADOLESCENTS
AB Background
   Several original studies have investigated the effect of alcohol use disorder (AUD) on suicidal thought and behavior, but there are serious discrepancies across the studies. Thus, a systematic assessment of the association between AUD and suicide is required.
   Methods
   We searched PubMed, Web of Science, and Scopus until February 2015. We also searched the Psycinfo web site and journals and contacted authors. We included observational (cohort, case-control, and cross-sectional) studies addressing the association between AUD and suicide. The exposure of interest was AUD. The primary outcomes were suicidal ideation, suicide attempt, and completed suicide. We assessed heterogeneity using Q-test and I2 statistic. We explored publication bias using the Egger's and Begg's tests and funnel plot. We meta-analyzed the data with the random-effects models. For each outcome we calculated the overall odds ratio (OR) or risk ratio (RR) with 95% confidence intervals (CI).
   Results
   We included 31 out of 8548 retrieved studies, with 420,732 participants. There was a significant association between AUD and suicidal ideation (OR=1.86; 95% CI: 1.38, 2.35), suicide attempt (OR=3.13; 95% CI: 2.45, 3.81); and completed suicide (OR=2.59; 95% CI: 1.95, 3.23 and RR=1.74; 95% CI: 1.26, 2.21). There was a significant heterogeneity among the studies, but little concern to the presence of publication bias.
   Conclusions
   There is sufficient evidence that AUD significantly increases the risk of suicidal ideation, suicide attempt, and completed suicide. Therefore, AUD can be considered an important predictor of suicide and a great source of premature death.
C1 [Darvishi, Nahid; Haghtalab, Tahereh] Islamic Azad Univ, Hamadan Branch, Dept Clin Psychol, Hamadan, Iran.
   [Farhadi, Mehran] Bu Ali Sina Univ Hamadan, Fac Econ & Social Sci, Dept Psychol, Hamadan, Iran.
   [Poorolajal, Jalal] Hamadan Univ Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Modeling Noncommunicable Dis Res Ctr, Hamadan, Iran.
RP Poorolajal, J (reprint author), Hamadan Univ Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Modeling Noncommunicable Dis Res Ctr, Hamadan, Iran.
EM poorolajal@umsha.ac.ir
RI Poorolajal, Jalal/D-3506-2013
FU Islamic Azad University, Hamadan Branch
FX The authors would like to thank the Islamic Azad University, Hamadan
   Branch, for financial support of this study. The funder had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agrawal A, 2013, J STUD ALCOHOL DRUGS, V74, P406, DOI 10.15288/jsad.2013.74.406
   Akechi T, 2006, BRIT J PSYCHIAT, V188, P231, DOI 10.1192/bjp.188.3.231
   Amiri B, 2012, J RES HEALTH SCI, V12, P88
   ANDREASSON S, 1991, BRIT J ADDICT, V86, P877
   Aseltine RH, 2009, J AM ACAD CHILD PSY, V48, P262, DOI 10.1097/CHI.0b013e318195bce8
   Bagge CL, 2013, J STUD ALCOHOL DRUGS, V74, P552, DOI 10.15288/jsad.2013.74.552
   BECK AT, 1989, J AFFECT DISORDERS, V17, P203, DOI 10.1016/0165-0327(89)90001-3
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bernal M, 2007, J AFFECT DISORDERS, V101, P27, DOI 10.1016/j.jad.2006.09.018
   Borges G, 2010, CURR OPIN PSYCHIATR, V23, P195, DOI 10.1097/YCO.0b013e3283386322
   Bunevicius R, 2014, SCAND J PRIM HEALTH, V32, P24, DOI 10.3109/02813432.2013.873604
   Centers for Disease Control and Prevention, 2013, UND SUIC FACT SHEET
   Centers for Disease Control and Prevention, 2014, DEF SELF DIR VIOL
   Cheryl J, 2004, ALCOHOL CLIN EXP RES, V28, p18S
   Coelho BM, 2010, REV BRAS PSIQUIATR, V32, P396, DOI 10.1590/S1516-44462010000400013
   Conner KR, 2006, J STUD ALCOHOL, V67, P95, DOI 10.15288/jsa.2006.67.95
   DeLeo D, 2002, WORLD REPORT VIOLENC, P183
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Donald M, 2006, AUST NZ J PSYCHIAT, V40, P87, DOI 10.1080/j.1440-1614.2006.01747.x
   Dunn N, 1999, HOSP MED, V60, P169, DOI 10.12968/hosp.1999.60.3.1060
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   ELIZABETH AS, 2009, J ADOLESCENT HEALTH, V44, P335, DOI DOI 10.1016/J.JADOHEALTH.2008.08.006
   Fazel S, 2005, LANCET, V366, P1301, DOI 10.1016/S0140-6736(05)67325-4
   Fazel S, 2008, J CLIN PSYCHIAT, V69, P1721, DOI 10.4088/JCP.v69n1107
   Flensborg-Madsen T, 2009, PSYCHIAT RES, V167, P123, DOI 10.1016/j.psychres.2008.01.008
   GROSSMAN DC, 1991, AM J PUBLIC HEALTH, V81, P870, DOI 10.2105/AJPH.81.7.870
   Gururaj G, 2004, Inj Control Saf Promot, V11, P183
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA, DOI [10.1097/BRS.0b013e3181b1c99f, DOI 10.1097/BRS.0B013E3181B1C99F]
   Kaslow N, 2000, DEPRESS ANXIETY, V12, P13, DOI 10.1002/1520-6394(2000)12:1<13::AID-DA2>3.0.CO;2-Y
   KETTL P, 1993, AM INDIAN ALASKA NAT, V5, P34
   LESAGE AD, 1994, AM J PSYCHIAT, V151, P1063
   Mean M, 2005, ACTA PAEDIATR, V94, P952, DOI 10.1080/08035250510029505
   Morin J, 2013, AM J GERIAT PSYCHIAT, V21, P196, DOI 10.1016/j.jagp.2012.10.020
   National Institute on Alcohol Abuse and Alcoholism, 2013, NIH PUBLICATION, V13-7999
   National Institutes of Health, 2014, ALC US DIS COMP DSM
   Nilsson SF, 2014, EUR J PUBLIC HEALTH, V24, P50, DOI 10.1093/eurpub/ckt025
   Orui Masatsugu, 2011, Environmental Health and Preventive Medicine, V16, P384, DOI 10.1007/s12199-011-0209-y
   PETRONIS KR, 1990, SOC PSYCH PSYCH EPID, V25, P193
   Pompili M, 2010, INT J ENV RES PUB HE, V7, P1392, DOI 10.3390/ijerph7041392
   Poorolajal J, 2012, EPIDEMIOL HEALTH, V34, DOI 10.4178/epih/e2012005
   Poorolajal J, 2015, ARCH IRAN MED, V18, P39, DOI 0151801/AIM.0010
   Preti A, 2006, MED SCI LAW, V46, P127, DOI 10.1258/rsmmsl.46.2.127
   Pridemore WA, 2013, ADDICTION, V108, P1933, DOI 10.1111/add.12294
   Randall JR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088233
   ROSSOW I, 1995, ADDICTION, V90, P685, DOI 10.1111/j.1360-0443.1995.tb02206.x
   Rossow I, 1999, ADDICTION, V94, P1199, DOI 10.1046/j.1360-0443.1999.948119910.x
   Sher L, 2006, QJM-INT J MED, V99, P57, DOI 10.1093/qjmed/hci146
   Shoval G, 2014, ALCOHOL CLIN EXP RES, V38, P820, DOI 10.1111/acer.12290
   Smith GS, 1999, ANN EMERG MED, V33, P659, DOI 10.1016/S0196-0644(99)70195-2
   Swahn MH, 2014, INT J PUBLIC HEALTH, V57, P95
   Szklo M, 2007, EPIDEMIOLOGY BASICS
   Tidemalm D, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2205
   Wells G, 2011, NEWCASTLE OTTAWA SCA, DOI [10.1371/journal.pntd.0002195, DOI 10.1371/JOURNAL.PNTD.0002195]
   WHO (World Health Organization), 2013, SUIC PREV
   Wilcox HC, 2004, DRUG ALCOHOL DEPEN, V76, pS11, DOI 10.1016/j.drugalcdep.2004.08.003
   Wojnar M, 2008, DRUG ALCOHOL DEPEN, V97, P268, DOI 10.1016/j.drugalcdep.2008.04.006
   World Health Organization, 2013, SUIC PREV SUPRE
   World Health Organization, 2013, 10 FACTS INJ VIOL BE
   World Health Organization, 2013, ALCOHOL
   Zhang YL, 2010, ADDICT BEHAV, V35, P152, DOI 10.1016/j.addbeh.2009.09.020
   Zonda T, 2006, CRISIS, V27, P125, DOI 10.1027/0227-5910.27.3.125
NR 62
TC 77
Z9 77
U1 3
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2015
VL 10
IS 5
AR e0126870
DI 10.1371/journal.pone.0126870
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI7CV
UT WOS:000354921400081
PM 25993344
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, SL
   Huang, LX
   Sun, KY
   Wu, DX
   Li, MR
   Li, MY
   Zhong, BH
   Chen, MH
   Zhang, SH
AF Chen, Shuling
   Huang, Lixia
   Sun, Kaiyu
   Wu, Dexi
   Li, Minrui
   Li, Manying
   Zhong, Bihui
   Chen, Minhu
   Zhang, Shenghong
TI Enhancer of Zeste Homolog 2 as an Independent Prognostic Marker for
   Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; GROUP PROTEIN EZH2; GASTRIC-CANCER;
   BREAST-CANCER; HIGH EXPRESSION; POOR-PROGNOSIS; THERAPEUTIC TARGET;
   TUMOR PROGRESSION; PROSTATE-CANCER; E-CADHERIN
AB Background
   Novel biomarkers are of particular interest for predicting cancer prognosis. This study aimed to explore the associations between enhancer of zeste homolog 2 (EZH2) and patient survival in various cancers.
   Methods
   Relevant literature was retrieved from PubMed and Web of Science databases. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated.
   Results
   Forty-nine studies (8,050 patients) were included. High EZH2 expression was significantly associated with shorter overall (hazard ratio [HR] 1.74, 95% CI: 1.46-2.07), disease-free (HR 1.59, 95% CI: 1.27-1.99), metastasis-free (HR 2.19, 95% CI: 1.38-3.47), progression-free (HR 2.53, 95% CI: 1.52-4.21), cancer-specific (HR 3.13, 95% CI: 1.70-5.74), and disease-specific (HR 2.29, 95% CI: 1.56-3.35) survival, but not recurrence-free survival (HR 1.38, 95% CI: 0.93-2.06). Moreover, EZH2 expression significantly correlated with distant metastasis (OR 3.25, 95% CI: 1.07-9.87) in esophageal carcinoma; differentiation (OR 3.00, 95% CI: 1.37-6.55) in non-small cell lung cancer; TNM stage (OR 3.18, 95% CI: 2.49-4.08) in renal cell carcinoma; and histological grade (OR 4.50, 95% CI: 3.33-6.09), estrogen receptor status (OR 0.15, 95% CI: 0.11-0.20) and progesterone receptor status (OR 0.30, 95% CI: 0.23-0.39) in breast cancer.
   Conclusions
   Our results suggested that EZH2 might be an independent prognostic factor for multiple survival measures in different cancers.
C1 [Chen, Shuling; Li, Minrui; Li, Manying; Zhong, Bihui; Chen, Minhu; Zhang, Shenghong] Sun Yat Sen Univ, Affiliated Hosp 1, Div Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China.
   [Huang, Lixia] Sun Yat Sen Univ, Affiliated Hosp 1, Div Respirat, Guangzhou 510275, Guangdong, Peoples R China.
   [Sun, Kaiyu] Sun Yat Sen Univ, Affiliated Hosp 1, Div Gastrointestinal Surg, Guangzhou 510275, Guangdong, Peoples R China.
   [Wu, Dexi] Sun Yat Sen Univ, Affiliated Hosp 1, Div Cardiol, Guangzhou 510275, Guangdong, Peoples R China.
RP Chen, MH (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Div Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China.
EM chenminhu@vip.163.com; shenghongzhang@163.com
FU Natural Scientific Foundation of Guangdong Province [S2012040007685];
   Doctoral Program Foundation of Institutions of Higher Education of China
   [20120171120090]; National Natural Science Foundation of China
   [81301769]; Outstanding Youth Talent Supporting Grand of the First
   Affiliated Hospital of Sun Yat-sen University
FX This work was supported by the Natural Scientific Foundation of
   Guangdong Province (S2012040007685), Doctoral Program Foundation of
   Institutions of Higher Education of China (20120171120090), National
   Natural Science Foundation of China (81301769) and Outstanding Youth
   Talent Supporting Grand of the First Affiliated Hospital of Sun Yat-sen
   University for SZ. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alford SH, 2012, BREAST CANCER RES TR, V132, P429, DOI 10.1007/s10549-011-1591-2
   Altman DG, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001216
   Athanassiadou AM, 2011, ACTA CYTOL, V55, P180, DOI 10.1159/000320790
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946
   Cao W, 2012, CANCER-AM CANCER SOC, V118, P2858, DOI 10.1002/cncr.26575
   Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551
   Changchien YC, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-216
   Choi JH, 2010, APMIS, V118, P196, DOI 10.1111/j.1600-0463.2009.02579.x
   Chokunonga E, 2013, INT J CANCER, V133, P721, DOI 10.1002/ijc.28063
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Crea F, 2012, ANN ONCOL, V23, P1207, DOI 10.1093/annonc/mdr387
   De Brot M, 2012, PATHOLOGY, V44, P303, DOI 10.1097/PAT.0b013e3283534bcb
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fluge O, 2009, BRIT J CANCER, V101, P1282, DOI 10.1038/sj.bjc.6605333
   Gong Y, 2011, CANCER-AM CANCER SOC, V117, P5476, DOI 10.1002/cncr.26179
   Guo L, 2014, TUMOR BIOL, V35, P6649, DOI 10.1007/s13277-014-1888-y
   Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241
   Ha SY, 2012, PATHOL RES PRACT, V208, P462, DOI 10.1016/j.prp.2012.05.012
   Hayashi A, 2014, VIRCHOWS ARCH, V464, P463, DOI 10.1007/s00428-014-1541-6
   He LR, 2010, INT J CANCER, V127, P138, DOI 10.1002/ijc.25031
   He LJ, 2012, ASIAN PAC J CANCER P, V13, P3173, DOI 10.7314/APJCP.2012.13.7.3173
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huqun, 2012, CANCER-AM CANCER SOC, V118, P1599, DOI 10.1002/cncr.26441
   Hussein YR, 2012, HUM PATHOL, V43, P1638, DOI 10.1016/j.humpath.2011.12.004
   Hwang CF, 2012, INT J RADIAT ONCOL, V82, P597, DOI 10.1016/j.ijrobp.2010.11.062
   Kidani K, 2009, ORAL ONCOL, V45, P39, DOI 10.1016/j.oraloncology.2008.03.016
   Kikuchi J, 2010, CANCER-AM CANCER SOC, V116, P3015, DOI 10.1002/cncr.25128
   Knudsen ES, 2013, CELL CYCLE, V12, P2042, DOI 10.4161/cc.25065
   Laitinen S, 2008, INT J CANCER, V122, P595, DOI 10.1002/ijc.23145
   Lee HW, 2012, PATHOL INT, V62, P735, DOI 10.1111/pin.12001
   Lee H, 2012, HUM PATHOL, V43, P1704, DOI 10.1016/j.humpath.2011.12.019
   Li H, 2010, MOL CANCER RES, V8, P1610, DOI 10.1158/1541-7786.MCR-10-0398
   Li ZW, 2013, ONCOTARGET, V4, P2532, DOI 10.18632/oncotarget.1503
   Liu DC, 2011, PATHOL RES PRACT, V207, P472, DOI 10.1016/j.prp.2011.05.010
   Liu L, 2014, BJU INT IN PRESS
   Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081484
   Liu Xiao-dong, 2011, Nan Fang Yi Ke Da Xue Xue Bao, V31, P1029
   Liu YY, 2014, INT J GYNECOL PATHOL, V33, P218, DOI 10.1097/PGP.0b013e31829c6574
   Marchesi I, 2012, CELL CYCLE, V11, P3828, DOI 10.4161/cc.22025
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   McShane LM, 2005, JNCI-J NATL CANCER I, V97, P1180, DOI 10.1093/jnci/dji237
   Mimori K, 2005, EJSO-EUR J SURG ONC, V31, P376, DOI 10.1016/j.ejso.2004.11.001
   Nakagawa S, 2013, ANN SURG ONCOL, V20, pS667, DOI 10.1245/s10434-013-3135-y
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150
   Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546
   Sakurai T, 2012, BIOCHEM BIOPH RES CO, V422, P607, DOI 10.1016/j.bbrc.2012.05.035
   Steels E, 2001, EUR RESPIR J, V18, P705, DOI 10.1183/09031936.01.00062201
   Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vekony H, 2008, J CLIN PATHOL, V61, P744, DOI 10.1136/jcp.2007.054262
   Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524
   Wang C, 2013, MOL CARCINOGEN, V52, P229, DOI 10.1002/mc.21848
   Wang CG, 2010, WORLD J GASTROENTERO, V16, P2421, DOI 10.3748/wjg.v16.i19.2421
   Wang H, 2012, UROL ONCOL-SEMIN ORI, V30, P428, DOI 10.1016/j.urolonc.2010.09.005
   Wang Haoran, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P99
   Xing XB, 2013, INT J CANCER, V132, P2589, DOI 10.1002/ijc.27947
   Xu B, 2013, ARCH PATHOL LAB MED, V137, P1326, DOI 10.5858/arpa.2012-0525-OA
   Yamada A, 2011, INT J ONCOL, V38, P345, DOI 10.3892/ijo.2010.868
   Yamaga K, 2008, MOL MED REP, V1, P633, DOI 10.3892/mmr_00000004
   Yonemitsu Y, 2009, HUM PATHOL, V40, P1304, DOI 10.1016/j.humpath.2009.01.017
   Zhou J, 2013, GYNECOL ONCOL, V128, P344, DOI 10.1016/j.ygyno.2012.07.128
NR 65
TC 7
Z9 7
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2015
VL 10
IS 5
AR e0125480
DI 10.1371/journal.pone.0125480
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI2AC
UT WOS:000354545600017
PM 25974088
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Shang, WF
   Ning, Y
   Xu, X
   Li, ML
   Guo, SM
   Han, M
   Zeng, R
   Ge, SW
   Xu, G
AF Shang, Weifeng
   Ning, Yong
   Xu, Xiu
   Li, Menglan
   Guo, Shuiming
   Han, Min
   Zeng, Rui
   Ge, Shuwang
   Xu, Gang
TI Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of
   Observational Studies
SO PLOS ONE
LA English
DT Article
ID ANTIBODY-ASSOCIATED VASCULITIS; WEGENERS-GRANULOMATOSIS;
   CLINICAL-TRIALS; FOLLOW-UP; RISK; CYCLOPHOSPHAMIDE; COHORT;
   EPIDEMIOLOGY; POLYANGIITIS; MALIGNANCIES
AB Objective
   The purpose of this paper is to examine cancer incidence in patients with ANCA-associated vasculitis (AASV) derived from population-based cohort studies by means of meta-analysis.
   Methods
   Relevant electronic databases were searched for studies characterizing the associated risk of overall malignancy in patients with AASV. Standardized incidence rates (SIRs) with 95% confidence intervals (CIs) were used to evaluate the strength of association. We tested for publication bias and heterogeneity and stratified for site-specific cancers.
   Results
   Six studies (n = 2,578) were eventually identified, of which six provided the SIR for overall malignancy, five reported the SIR for non-melanoma skin cancer (NMSC), four for leukemia, five for bladder cancer, three for lymphoma, three for liver cancer, four for lung cancer, three for kidney cancer, four for prostate cancer, four for colon cancer and four for breast cancer. Overall, the pooled SIR of cancer in AASV patients was 1.74 (95% CI = 1.37-2.21), with moderate heterogeneity among these studies (I-2 = 65.8%, P = 0.012). In sub-analyses for site-specific cancers, NMSC, leukemia and bladder cancer were more frequently observed in patients with AASV with SIR of 5.18 (95% CI = 3.47-7.73), 4.89 (95% CI = 2.93-8.16) and 3.84 (95% CI = 2.72-5.42) respectively. There was no significant increase in the risk of kidney cancer (SIR = 2.12, 95% CI = 0.66-6.85), prostate cancer (SIR = 1.45, 95% CI = 0.87-2.42), colon cancer (SIR = 1.26, 95% CI = 0.70-2.27), and breast cancer (SIR = 0.95, 95% CI = 0.50-1.79). Among these site-specific cancers, only NMSC showed moderate heterogeneity (I-2 = 55.8%, P = 0.06). No publication bias was found by using the Begg's test and Egger's test.
   Conclusions
   This meta-analysis shows that AASV patients treatment with cyclophosphamide (CYC) are at increased risk of late-occurring malignancies, particularly of the NMSC, leukemia and bladder cancer. However, there is no significant association between AASV and kidney cancer, prostate cancer, colon cancer and breast cancer. These findings emphasize monitoring and preventative management in AASV patients after cessation of CYC therapy is momentous.
C1 [Shang, Weifeng; Ning, Yong; Xu, Xiu; Li, Menglan; Guo, Shuiming; Han, Min; Zeng, Rui; Ge, Shuwang; Xu, Gang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Nephrol, Wuhan, Hunan, Peoples R China.
RP Ge, SW (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Nephrol, Wuhan, Hunan, Peoples R China.
EM geshuwang@tjh.tjmu.edu.cn; xugang@tjh.tjmu.edu.cn
FU National Nature Science Foundation of China (NSFC) [81200531, 81470948,
   81270770]
FX This work was supported by the National Nature Science Foundation of
   China (NSFC) (No. 81200531 for Shuwang Ge; No. 81470948 and 81270770 for
   Gang Xu). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berden A, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e26
   Bosch X, 2007, JAMA-J AM MED ASSOC, V298, P655, DOI 10.1001/jama.298.6.655
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76
   Faurschou M, 2008, J RHEUMATOL, V35, P100
   Flossmann O, 2011, ANN RHEUM DIS, V70, P488, DOI 10.1136/ard.2010.137778
   Fortin Paul R., 1996, Current Opinion in Rheumatology, V8, P30, DOI 10.1097/00002281-199601000-00005
   Heijl C, 2011, ANN RHEUM DIS, V70, P1415, DOI 10.1136/ard.2010.145250
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488
   Holle JU, 2011, ARTHRITIS RHEUM-US, V63, P257, DOI 10.1002/art.27763
   Ioannidis JPA, 2014, ANN ONCOL, V25, P16, DOI 10.1093/annonc/mdt372
   Jennette JC, 2013, ANNU REV PATHOL-MECH, V8, P139, DOI 10.1146/annurev-pathol-011811-132453
   Keogh KA, 2006, AM J RESP CRIT CARE, V173, P180, DOI 10.1164/rccm.200507-1144OC
   Knight A, 2002, INT J CANCER, V100, P82, DOI 10.1002/ijc.10444
   Le Guenno G, 2011, ARTHRITIS RHEUM-US, V63, P1435, DOI 10.1002/art.30296
   Mahr A, 2013, BEST PRACT RES CL RH, V27, P45, DOI 10.1016/j.berh.2012.12.003
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Monach PA, 2010, ARTHRITIS RHEUM-US, V62, P9, DOI 10.1002/art.25061
   Nath R, 2007, ARTHRIT RHEUM-ARTHR, V57, P619, DOI 10.1002/art.22667
   O'Donovan P, 2005, SCIENCE, V309, P1871, DOI 10.1126/science.1114233
   PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9
   Roussou M, 2008, UROLOGY, V71, DOI 10.1016/j.urology.2007.11.046
   Scott DGI, 2013, CLIN EXP NEPHROL, V17, P607, DOI 10.1007/s10157-013-0830-8
   Silva F, 2011, ARTHRITIS RHEUM-US, V63, P2495, DOI 10.1002/art.30394
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   TalarWilliams C, 1996, ANN INTERN MED, V124, P477, DOI 10.7326/0003-4819-124-5-199603010-00003
   Westman KWA, 1998, J AM SOC NEPHROL, V9, P842
   Weyand CM, 2006, ARTHRITIS RHEUM, V54, P685, DOI 10.1002/art.21674
   Zintzaras E, 2005, ARCH INTERN MED, V165, P2337, DOI 10.1001/archinte.165.20.2337
   Zycinska K, 2013, ADV EXP MED BIOL, V788, P349, DOI 10.1007/978-94-007-6627-3_47
NR 34
TC 14
Z9 14
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2015
VL 10
IS 5
AR UNSP e0126016
DI 10.1371/journal.pone.0126016
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI2AC
UT WOS:000354545600037
PM 25973882
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, PP
   Qiu, TM
   Qin, C
AF Li, Pingping
   Qiu, Tangmeng
   Qin, Chao
TI Efficacy of Acupuncture for Bell's Palsy: A Systematic Review and
   Meta-Analysis of Randomized Controlled Trials
SO PLOS ONE
LA English
DT Review
ID HERPES-SIMPLEX-VIRUS; POLYMERASE-CHAIN-REACTION; FACIAL PARALYSIS; BIAS;
   DNA
AB Acupuncture has emerged as an alternative therapy for Bell's palsy in both adults and children. However, the use of acupuncture is controversial. We conducted a systematic review and meta-analysis to assess the efficacy of acupuncture for Bell's palsy. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials, irrespective of any language restrictions. Randomized controlled trials comparing acupuncture with other therapies for Bell's palsy in adults or children were included. Fourteen randomized controlled trials involving 1541 individuals were included in this meta-analysis. Significant association was observed in acupuncture with a higher effective response rate for Bell's palsy (relative risk, 1.14; 95% confidence interval, 1.04-1.25; P = 0.005) but there was a heterogeneity among the studies (I-2 = 87%). An assessment of the included studies revealed a high risk of bias in methodological quality. An evaluation of the incidence of complications was not available, owing to incomplete data. Acupuncture seems to be an effective therapy for Bell's palsy, but there was insufficient evidence to support the efficacy and safety of acupuncture. However, the results should be interpreted cautiously, because of the poor quality and heterogeneity of the included studies.
C1 [Li, Pingping; Qiu, Tangmeng; Qin, Chao] Guangxi Med Univ, Affiliated Hosp 1, Dept Neurol, Nanning, Guangxi, Peoples R China.
RP Qin, C (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Neurol, Nanning, Guangxi, Peoples R China.
EM qc6699@yeah.net
CR ADOUR KK, 1975, JAMA-J AM MED ASSOC, V233, P527, DOI 10.1001/jama.233.6.527
   Ahn CB, 2011, J ACUPUNCT MERIDIAN, V4, P29, DOI 10.1016/S2005-2901(11)60005-8
   [Anonymous], 2007, SICHUAN TRADIT CHIN, P109
   [Anonymous], 2005, CHINESE J REHABILITA, V11, P1037
   [Anonymous], 2004, J CLIN ACUPUNCTURE M, V20, P26
   [Anonymous], 1996, J CLIN ACUPUNCT MOXI, P56
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BURGESS LPA, 1984, LARYNGOSCOPE, V94, P1472
   Chen N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002914.pub5
   Chen XQ, 2009, CONTEMP CLIN TRIALS, V30, P347, DOI 10.1016/j.cct.2009.02.006
   Cumberworth A, 2012, INT J SURG, V10, P310, DOI 10.1016/j.ijsu.2012.04.019
   Dai FY ZY, 2009, ZHEJIANG J TRADIT CH, P444
   Du LZ, 2013, WORLD J ACUPUNCTURE, P42
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fu Xiao-hu, 2007, Zhongguo Zhen Jiu, V27, P494
   Furuta Y, 1997, J MED VIROL, V52, P316, DOI 10.1002/(SICI)1096-9071(199707)52:3<316::AID-JMV13>3.3.CO;2-6
   Gilden DH, 2004, NEW ENGL J MED, V351, P1323, DOI 10.1056/NEJMcp041120
   Grogan PM, 2001, NEUROLOGY, V56, P830, DOI 10.1212/WNL.56.7.830
   Harwood-Nuss A, 2009, HARWOOD NUSS CLIN PR
   HAUSER WA, 1971, MAYO CLIN PROC, V46, P258
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA
   Holland NJ, 2004, BRIT MED J, V329, P553, DOI 10.1136/bmj.329.7465.553
   Jiangping L., 2005, CHINESE CLIN MED RES, V11, P1715
   Kim JI, 2012, CHIN J INTEGR MED, V18, P48, DOI 10.1007/s11655-011-0861-5
   Kwon HJ, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-71
   Li J, 2005, CHINESE CLIN MED RES, P1715
   Li Y, 2004, CHINESE MED J-PEKING, V117, P1502
   Li Y, 2011, ZHONGGUO ZHEN JIU, P289
   Li Y, 2011, WOODHEAD PUBL MATER, P1
   Liang Fanrong, 2006, J Tradit Chin Med, V26, P3
   Liu Li-An, 2012, Zhongguo Zhen Jiu, V32, P587
   Ma Z, 2004, SNANGHAI J ACUPUNCTU, P19
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Morris AM, 2002, NEUROEPIDEMIOLOGY, V21, P255, DOI 10.1159/000065645
   Murakami S, 1996, ANN INTERN MED, V124, P27, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00005
   PEITERSEN E, 1982, AM J OTOL, V4, P107
   Qi Qi-Hua, 2013, Zhongguo Zhen Jiu, V33, P965
   Qu Yong, 2005, Zhongguo Zhen Jiu, V25, P545
   Reheman Ainiwan, 2009, Zhongguo Zhen Jiu, V29, P17
   Schirm J, 1997, APMIS, V105, P815, DOI 10.1111/j.1699-0463.1997.tb05089.x
   Shannon S, 2003, J FAM PRACTICE, V52, P156
   Shao SF WZ, 1999, NEW MED, P16
   Stjernquist-Desatnik A, 2006, ANN OTO RHINOL LARYN, V115, P306, DOI 10.1177/000348940611500410
   Teixeira LJ, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006283.pub3
   Theil D, 2001, BRAIN PATHOL, V11, P408, DOI 10.1111/j.1750-3639.2001.tb00408.x
   Tong FM, 2009, ACUPUNCT MED, V27, P169, DOI 10.1136/aim.2009.000638
   Uchino K, 2013, ANN INTERN MED, V159, DOI 10.7326/0003-4819-159-10-201311190-02008
   Wang HW, 2013, ZHONGGUO ZHEN JIU, P306
   White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485
   Wong XH ZL, 2004, ZHONGHUA LINCHUANG K, V8, P616
   Xia F, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-158
   Xu SB, 2013, CAN MED ASSOC J, V185, P473, DOI 10.1503/cmaj.121108
   Xuan LH WL, 2007, CHIN J TRADIT MED SC, P6
   Yang C, 2006, SCI TECH INFO GANSU, V35, P240
   Yang G, 2001, J ACUPUNCTURE MOXIBU, P28
   Yang SB, 2012, ZHONGGUO ZHEN JIU, P21
   Yang SB, 2013, WORLD J ACUPUNCTURE, P15
   Yaqin Y, 1999, SHANGHAI J ACUPUNCTU, V18, P26
   Zhang CY, 2011, ZHEN CI YAN JIU, P433
   Zhao JP, 2010, J TRADIT CHIN MED, V30, P118, DOI 10.1016/S0254-6272(10)60026-X
   Zhao Y, 2005, CHINESE J CLIN REHAB, P41
   Zhou M, 2009, J ALTERN COMPLEM MED, V15, P759, DOI 10.1089/acm.2008.0179
   Zhu H-Q, 2004, CHINESE J PAIN MED
   Zhu L., 2006, SHANGHAI J ACUPUNCT, V25, P17
   이참결, 2013, [THE ACUPUNCTURE, 대한침구의학회지], V30, P51, DOI 10.13045/acupunct.2013005
NR 66
TC 10
Z9 10
U1 1
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2015
VL 10
IS 5
AR e0121880
DI 10.1371/journal.pone.0121880
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI2AC
UT WOS:000354545600005
PM 25974022
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Sun, J
   Zheng, JY
   Tang, LJ
   Healy, J
   Sinnett, D
   Dai, YE
AF Sun, Jian
   Zheng, Jinyu
   Tang, Linjun
   Healy, Jasmine
   Sinnett, Daniel
   Dai, Yue-e
TI Association between CEBPE Variant and Childhood Acute Leukemia Risk:
   Evidence from a Meta-Analysis of 22 Studies
SO PLOS ONE
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; SUSCEPTIBILITY
   LOCI; PUBLICATION BIAS; CLINICAL-TRIALS; 10Q21.2; ARID5B; 7P12.2;
   POLYMORPHISMS; POPULATION
AB The CCAAT/enhancer binding proteins (CEBPs) have been involved in the etiology of acute leukemia (AL) and investigated in numerous genetic association studies, however, the results were inconclusive. The current meta-analysis was conducted to clarify the effect of CEBPE rs2239633 variant on childhood AL risk. Electronic literature search was performed on August 15, 2014, from databases of Medline, PubMed, Embase, and Web of Science. A total of 22 case-control studies were eligible for the pooled analysis. The results demonstrated that rs2239633 A allele was significantly associated with a decreased risk of childhood AL (A vs G: OR=0.87, 95% CI = 0.80, 0.94, p<0.001), especially in B-cell ALL subgroup (A vs G: OR = 0.79, 95% CI = 0.74, 0.83, p<0.001), but not among T-cell ALL or AML subgroups. In the stratified analysis by ethnicity, the association was observed in Europeans (A vs G: OR = 0.80, 95% CI = 0.76, 0.84, p<0.001) but not in Asian and mixed populations. Moreover, the results of sensitivity and cumulative meta-analysis indicated the robustness of our results. Also, Begg's and Egger's tests did not indicate any evidence of obvious asymmetry. In summary, our study provided evidence that CEBPE rs2239633 variant is associated with decreased risk of childhood B-cell ALL in Europeans.
C1 [Sun, Jian] Huaian Matenal & Child Hlth Hosp, Dept Anesthesiol, Huaian, Jiangsu, Peoples R China.
   [Zheng, Jinyu] Xuzhou Med Coll, Affiliated Huaian Hosp, Dept Neurosurg, Huaian, Peoples R China.
   [Tang, Linjun] Tongling Peoples Hosp, Dept Neurosurg, Tongling, Anhui, Peoples R China.
   [Healy, Jasmine; Sinnett, Daniel] St Justine Univ Hosp, Res Ctr, Montreal, PQ, Canada.
   [Sinnett, Daniel] Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ H3C 3J7, Canada.
   [Dai, Yue-e] Nanjing Med Univ, Nanjing Childrens Hosp, Nanjing, Jiangsu, Peoples R China.
RP Dai, YE (reprint author), Nanjing Med Univ, Nanjing Childrens Hosp, Nanjing, Jiangsu, Peoples R China.
EM yueedai@163.com
RI Sinnett, Daniel/S-4589-2017
OI Sinnett, Daniel/0000-0003-3625-6676
FU Science and Technology Development Foundation of Nanjing Medical
   University [2014NLMU144]
FX The study was supported by Science and Technology Development Foundation
   of Nanjing Medical University (No. 2014NLMU144). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akagi T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015419
   Akasaka T, 2007, BLOOD, V109, P3451, DOI 10.1182/blood-2006-08-041012
   Armstrong SA, 2005, J CLIN ONCOL, V23, P6306, DOI 10.1200/JCO.2005.05.047
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhatia S, 2002, BLOOD, V100, P1957, DOI 10.1182/blood-2002-02-0395
   Copas J, 2000, Biostatistics, V1, P247, DOI 10.1093/biostatistics/1.3.247
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dores GM, 2001, BLOOD, V119, P34
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ellinghaus E, 2012, LEUKEMIA, V26, P902, DOI 10.1038/leu.2011.302
   Emerenciano M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-127
   GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807
   Gibson BES, 2011, BRIT J HAEMATOL, V155, P366, DOI 10.1111/j.1365-2141.2011.08851.x
   Greaves M, 2006, NAT REV CANCER, V6, P193, DOI 10.1038/nrc1816
   He J, 2015, LEUKEMIA LYMPHOMA, V56, P763, DOI 10.3109/10428194.2014.935370
   Healy J, 2010, HAEMATOL-HEMATOL J, V95, P1608, DOI 10.3324/haematol.2010.022459
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hunger SP, 2012, J CLIN ONCOL, V30, P1663, DOI 10.1200/JCO.2011.37.8018
   Inaba H, 2013, LANCET, V381, P1943, DOI 10.1016/S0140-6736(12)62187-4
   Li SH, 2015, LEUKEMIA LYMPHOMA, V56, P978, DOI 10.3109/10428194.2014.939965
   Lim JYS, 2014, CANCER-AM CANCER SOC, V120, P955, DOI 10.1002/cncr.28531
   Lu XC, 2014, AM J EPIDEMIOL, V179, P267, DOI 10.1093/aje/kwt262
   Orsi L, 2012, LEUKEMIA, V26, P2561, DOI 10.1038/leu.2012.148
   Papaemmanuil E, 2009, NAT GENET, V41, P1006, DOI 10.1038/ng.430
   Pastorczak A, 2011, LEUKEMIA RES, V35, P1534, DOI 10.1016/j.leukres.2011.07.034
   Prasad RB, 2010, BLOOD, V115, P1765, DOI 10.1182/blood-2009-09-241513
   PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407
   Qin LY, 2014, TUMOR BIOL, V35, P2521, DOI 10.1007/s13277-013-1333-7
   Ross JA, 2013, PEDIATR BLOOD CANCER, V60, P31, DOI 10.1002/pbc.24131
   Rubnitz JE, 2012, BLOOD, V119, P5980, DOI 10.1182/blood-2012-02-392506
   Rubnitz JE, 2010, LANCET ONCOL, V11, P543, DOI 10.1016/S1470-2045(10)70090-5
   Schmiegelow K, 2008, LEUKEMIA, V22, P2137, DOI 10.1038/leu.2008.212
   Tang QQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078810
   Vijayakrishnan J, 2010, LEUKEMIA LYMPHOMA, V51, P1870, DOI 10.3109/10428194.2010.511356
   Wang C, 2015, ANN HEMATOL, V94, P181, DOI 10.1007/s00277-014-2186-x
   Wang YP, 2013, GENE, V524, P203, DOI 10.1016/j.gene.2013.04.028
   Wiemels J, 2012, CHEM-BIOL INTERACT, V196, P59, DOI 10.1016/j.cbi.2012.01.007
   Xu H, 2013, JNCI-J NATL CANCER I, V105, P733, DOI 10.1093/jnci/djt042
   Zintzaras E, 2008, J CLIN EPIDEMIOL, V61, P634, DOI 10.1016/j.jclinepi.2007.12.011
NR 40
TC 4
Z9 4
U1 2
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 4
PY 2015
VL 10
IS 5
AR UNSP e0125657
DI 10.1371/journal.pone.0125657
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CH3PP
UT WOS:000353943000085
PM 25938438
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, H
   Ge, L
   Sui, QL
   Lin, M
AF Chen, Hong
   Ge, Lin
   Sui, Qiuli
   Lin, Mei
TI Systematic Review and Meta-Analysis of the Relationship between EPHX1
   Polymorphisms and the Risk of Head and Neck Cancer
SO PLOS ONE
LA English
DT Review
ID MICROSOMAL EPOXIDE HYDROLASE; SQUAMOUS-CELL CARCINOMA; GENOTYPES;
   SMOKING; ASSOCIATION; GSTM1; SUSCEPTIBILITY; STATISTICS; EXPRESSION;
   DISEASE
AB Aim
   To evaluate the association between the EPHX1 Tyr113His and His139Arg polymorphisms in the EPHX1 gene and the risk of head and neck cancer.
   Materials and Methods
   Studies on the association of EPHX1 Tyr113His and His139Arg polymorphisms with HNC performed up until June 1st, 2014, were identified using a predefined search strategy. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the strength of these associations.
   Results
   In this meta-analysis, 10 case-control studies, which included 9 studies of Tyr113His (1890 cases and 1894 controls) and 10 studies of His139Arg polymorphisms (1982 cases and 2024 controls), were considered eligible for inclusion. Overall, the pooled results indicated that the EPHX1 Tyr113His polymorphism was significantly associated with increased HNC risk (Tyr/His vs. Tyr/Tyr, OR = 1.26, 95% 1.02-1.57; His/His+ Tyr/His vs. Tyr/Tyr, OR = 1.29, 95% I = 1.03-1.61). However, no significant association was found between the His139Arg polymorphism and HNC risk. In the subgroup analysis, a statistically significant association between the EPHX1 Tyr113His polymorphism and HNC was observed in population-based case-control studies (PCC), which involved less than 500 participants and genotype frequencies in HWE. This association showed minimal heterogeneity after excluding studies that were determined to contribute to heterogeneity. After categorizing the studies by publication time, a sensitivity analysis and cumulative meta-analysis of the two associations were conducted, and the results of the two analyses were consistent.
   Conclusion
   Our meta-analysis suggests that EPHX1 Tyr113His polymorphism may be a risk factor for HNC, while the EPHX1 His139Arg polymorphism has no association with HNC risk.
C1 [Chen, Hong; Sui, Qiuli] Sichuan Univ, State Key Lab Oral Dis, Chengdu 610064, Sichuan, Peoples R China.
   [Ge, Lin] Sichuan Univ, West China Sch Stomatol, Dept Oral Med, Chengdu 610064, Sichuan, Peoples R China.
   [Lin, Mei] Sichuan Univ, West China Sch Stomatol, Dept Oral Med, Chengdu 610064, Sichuan, Peoples R China.
RP Ge, L (reprint author), Sichuan Univ, West China Sch Stomatol, Dept Oral Med, Chengdu 610064, Sichuan, Peoples R China.
EM v1i2c3@163.com; linmei2k@163.com
FU National Natural Science Foundation of China [81102059]
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 81102059).
CR Amador AG, 2002, ORAL SURG ORAL MED O, V93, P440, DOI 10.1067/moe.2002.122586
   Arand M, 2005, METHOD ENZYMOL, V400, P569, DOI 10.1016/S0076-6879(05)00032-7
   Attia J, 2003, J CLIN EPIDEMIOL, V56, P297, DOI 10.1016/S0895-4356(03)00011-8
   Balaji L, 2011, GENET TEST MOL BIOMA, V15, P595, DOI 10.1089/gtmb.2010.0260
   BEETHAM JK, 1995, DNA CELL BIOL, V14, P61, DOI 10.1089/dna.1995.14.61
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benhamou S, 2002, CARCINOGENESIS, V23, P1343, DOI 10.1093/carcin/23.8.1343
   Bhaskar LV, 2012, AM J DRUG ALCOHOL AB
   Boccia S, 2008, J CANCER RES CLIN, V134, P93, DOI 10.1007/s00432-007-0254-5
   Buch C, 2008, HEAD NECK-J SCI SPEC, V30, P1139
   Chen CZ, 2011, J FORMOS MED ASSOC, V110, P685, DOI 10.1016/j.jfma.2011.09.003
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dura P, 2012, ONCOL REP, V27, P1710, DOI 10.3892/or.2012.1734
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fretland AJ, 2000, CHEM-BIOL INTERACT, V129, P41, DOI 10.1016/S0009-2797(00)00197-6
   Geisler SA, 2001, AM J EPIDEMIOL, V154, P95, DOI 10.1093/aje/154.2.95
   Ghattas MH, 2012, ENDOCRINE
   Hassett C, 1997, ARCH BIOCHEM BIOPHYS, V337, P275, DOI 10.1006/abbi.1996.9794
   HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421
   Higgins J, 2001, STAT MED, V21, P1539
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HIYAMA T, 1992, JPN J CANCER RES, V83, P334, DOI 10.1111/j.1349-7006.1992.tb00111.x
   Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232
   JANOT F, 1993, CARCINOGENESIS, V14, P1279, DOI 10.1093/carcin/14.7.1279
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   Jourenkova-Mironova N, 2000, CANCER RES, V60, P534
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Knechtel G, 2010, MOL CARCINOGEN, V49, P805, DOI 10.1002/mc.20655
   Lacko M, 2008, HEAD NECK-J SCI SPEC, V30, P836, DOI 10.1002/hed.20781
   Lacko M, 2013, HEAD NECK-J SCI SPEC, V35, P858, DOI 10.1002/hed.23054
   Liu F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043821
   Liu L, 2011, J CANCER RES CLIN, V137, P1027, DOI 10.1007/s00432-010-0966-9
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marcu LG, 2009, J CANCER RES CLIN, V135, P1303, DOI 10.1007/s00432-009-0648-7
   Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440
   Nisa H, 2012, MOL CARCINOG
   Park JY, 2003, ORAL ONCOL, V39, P483, DOI 10.1016/S1368-8375(03)00008-3
   Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33
   Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803
   To-Figueras J, 2002, CANCER LETT, V187, P95, DOI 10.1016/S0304-3835(02)00406-8
   Varela-Lema L, 2008, J ONCOL, V2008, DOI DOI 10.1155/2008/741310
   Wenghoefer M, 2003, ARCH TOXICOL, V77, P37, DOI 10.1007/s00204-002-0414-y
   Zhang JH, 2003, WORLD J GASTROENTERO, V9, P2654
   Zhao ZQ, 2012, TUMOR BIOL, V33, P523, DOI 10.1007/s13277-011-0287-x
   Zhong JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057064
   Zhong Y, 2011, CHEM RES TOXICOL, V24, P246, DOI 10.1021/tx100345x
NR 47
TC 1
Z9 1
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 29
PY 2015
VL 10
IS 4
AR e0123347
DI 10.1371/journal.pone.0123347
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CH0LO
UT WOS:000353711600041
PM 25923690
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhu, W
   Wu, Y
   Xu, M
   Wang, JY
   Meng, YF
   Gu, Z
   Lu, J
AF Zhu, Wei
   Wu, Yan
   Xu, Ming
   Wang, Jin-Yu
   Meng, Yi-Fang
   Gu, Zheng
   Lu, Jiong
TI Antiphospholipid Antibody and Risk of Retinal Vein Occlusion: A
   Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID HYPERCOAGULABLE STATES; THROMBOPHILIA; HOMOCYSTEINE; THROMBOSIS
AB Background
   Retinal vein occlusion (RVO) is a common retinal vascular disease and it is one of the most frequently reported causes of visual damage and blindness in the elderly. The current study investigated the potential association between antiphospholipid antibodies (APLA) and RVO risk by conducting a meta-analysis of case-control studies.
   Methods
   A systematic literature search of Pubmed and Embase databases was conducted in August 1st, 2014. Odds ratios (ORs) were used to evaluate the associations between APLA and the incidence of RVO. A random-effects model was obtained for the quantitative synthesis.
   Results
   A total of 11 studies were included in this meta-analysis. A meta-analysis of all studies assessing the risk of RVO revealed that APLA was associated with a statistically increased risk of RVO incidence (OR = 5.18, 95% CI = [3.37, 7.95]). The association between anticardiolipin antibodies (ACA) and the risk of RVO was significant (n = 8, OR = 4.59, 95% CI = [ 2.75, 7.66]). However, the association between lupus anticoagulants (LA) and risk of RVO was non-significant (n = 5, OR = 3.90, 95% CI = [0.99, 15.37]). No significant publication bias was found in the 11 selected studies.
   Conclusion
   APLA was significantly associated with the risk of RVO. Advanced analyses showed that ACA rather than LA affected the risk of RVO. Additional well-designed and well-conducted epidemiological studies are required to further our understanding of the relationship between APLA and RVO risk.
C1 [Zhu, Wei; Xu, Ming; Wang, Jin-Yu; Meng, Yi-Fang; Gu, Zheng; Lu, Jiong] Changshu 2 Peoples Hosp, Dept Ophthalmol, Changsha, Hunan, Peoples R China.
   [Wu, Yan] Jiangsu Univ, Peoples Hosp Kunshan 1, Dept Ophthalmol, Suzhou, Peoples R China.
RP Lu, J (reprint author), Changshu 2 Peoples Hosp, Dept Ophthalmol, Changsha, Hunan, Peoples R China.
EM cslujiong@163.com
CR Abayi DAM, 2012, J FR OPHTALMOL, V35, P426, DOI 10.1016/j.jfo.2011.11.008
   Abu El-Asrar AM, 1998, DOC OPHTHALMOL, V95, P133, DOI 10.1023/A:1001795918894
   AbuElAsrar AM, 1997, INT OPHTHALMOL, V20, P197
   Adamczuk YP, 2002, BLOOD COAGUL FIBRIN, V13, P623, DOI 10.1097/00001721-200210000-00007
   Aggarwal Rohina S, 2013, J Hum Reprod Sci, V6, P79, DOI 10.4103/0974-1208.112389
   Ali O, 2011, OPTOMETRY, V82, P428, DOI 10.1016/j.optm.2010.07.032
   Atchaneeyasakul LO, 2005, JPN J OPHTHALMOL, V49, P211, DOI 10.1007/s10384-005-0190-3
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Braithwaite T, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007325.pub3
   Cernak M, 2012, BRATISL MED J, V113, P228, DOI 10.4149/BLL_2012_052
   Cobo-Soriano R, 1999, AM J OPHTHALMOL, V128, P725, DOI 10.1016/S0002-9394(99)00311-6
   de Medeiros DM, 2014, LUPUS
   Dong N, 2013, CURR EYE RES, V38, P1153, DOI 10.3109/02713683.2013.809124
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fiebai B, 2014, NIGER J CLIN PRACT, V17, P462, DOI 10.4103/1119-3077.134040
   GLACETBERNARD A, 1994, ARCH OPHTHALMOL-CHIC, V112, P790, DOI 10.1001/archopht.1994.01090180088041
   Glueck CJ, 2012, CLIN OPHTHALMOL, V6, P1377, DOI 10.2147/OPTH.S34627
   Kamei M, 2014, JAMA OPHTHALMOL, V132, P361, DOI 10.1001/jamaophthalmol.2013.6334
   Kolar P, 2014, J OPHTHALMOL, DOI 10.1155/2014/724780
   Maaroufi R M, 2004, East Mediterr Health J, V10, P627
   Marcucci R, 2001, THROMB HAEMOSTASIS, V86, P772
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Mrad M, 2014, J STROKE CEREBROVASC, V23, P1592, DOI 10.1016/j.jstrokecerebrovasdis.2013.12.048
   Pasoto SG, 2012, CLIN RHEUMATOL, V31, P1331, DOI 10.1007/s10067-012-2019-z
   Plunkett O, 2014, BRIT J OPHTHALMOL, V98, P1141, DOI 10.1136/bjophthalmol-2013-304646
   Risse F, 2014, OPHTHALMOLOGICA, V232, P46, DOI 10.1159/000360013
   Ruffatti A, 2014, THROMB HAEMOST, V112
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Van Cott EM, 2004, BLOOD COAGUL FIBRIN, V15, P393, DOI 10.1097/01.mbc.0000114442.59147.8d
NR 29
TC 2
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 28
PY 2015
VL 10
IS 4
AR UNSP e0122814
DI 10.1371/journal.pone.0122814
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG9SE
UT WOS:000353659400020
PM 25918850
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Corona, G
   Giuliani, C
   Verbalis, JG
   Forti, G
   Maggi, M
   Peri, A
AF Corona, Giovanni
   Giuliani, Corinna
   Verbalis, Joseph G.
   Forti, Gianni
   Maggi, Mario
   Peri, Alessandro
TI Hyponatremia Improvement Is Associated with a Reduced Risk of Mortality:
   Evidence from a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID WORSENING HEART-FAILURE; HOSPITALIZED-PATIENTS; SERUM SODIUM;
   LIVER-TRANSPLANTATION; OUTCOMES; MANAGEMENT; IMPACT; TRIAL;
   OSTEOPOROSIS; TOLVAPTAN
AB Background
   Hyponatremia is the most common electrolyte disorder and it is associated with increased morbidity and mortality. However, there is no clear demonstration that the improvement of serum sodium concentration ([Na+]) counteracts the increased risk of mortality associated with hyponatremia. Thus, we performed a meta-analysis that included the published studies that addressed the effect of hyponatremia improvement on mortality.
   Methods and Findings
   A Medline, Embase and Cochrane search was performed to retrieve all English-language studies of human subjects published up to June 30th 2014, using the following words: "hyponatremia", "hyponatraemia", "mortality", "morbidity" and "sodium". Fifteen studies satisfied inclusion criteria encompassing a total of 13,816 patients. The identification of relevant abstracts, the selection of studies and the subsequent data extraction were performed independently by two of the authors, and conflicts resolved by a third investigator. Across all fifteen studies, any improvement of hyponatremia was associated with a reduced risk of overall mortality (OR=0.57[0.40-0.81]). The association was even stronger when only those studies (n=8) reporting a threshold for serum [Na+] improvement to >130 mmol/L were considered (OR=0.51[0.31-0.86]). The reduced mortality rate persisted at follow-up (OR=0.55[0.36-0.84] at 12 months). Meta-regression analyses showed that the reduced mortality associated with hyponatremia improvement was more evident in older subjects and in those with lower serum [Na+] at enrollment.
   Conclusions
   This meta-analysis documents for the first time that improvement in serum [Na+] in hyponatremic patients is associated with a reduction of overall mortality.
C1 [Corona, Giovanni] Maggiore Bellaria Hosp, Endocrinol Unit, Bologna, Italy.
   [Giuliani, Corinna; Forti, Gianni; Peri, Alessandro] Univ Florence, Endocrine Unit,Careggi Hosp, Ctr Res Transfer & High Educ Chron Inflammatory D, Dept Expt & Clin Biomed Sci Mario Serio, I-50139 Florence, Italy.
   [Verbalis, Joseph G.] Georgetown Univ, Div Endocrinol & Metab, Washington, DC 20007 USA.
   [Maggi, Mario] Univ Florence, Androl Unit,Careggi Hosp, Ctr Res Transfer & High Educ Chron Inflammatory D, Dept Expt & Clin Biomed Sci Mario Serio, I-50139 Florence, Italy.
RP Peri, A (reprint author), Univ Florence, Endocrine Unit,Careggi Hosp, Ctr Res Transfer & High Educ Chron Inflammatory D, Dept Expt & Clin Biomed Sci Mario Serio, I-50139 Florence, Italy.
EM alessandro.peri@unifi.it
FU Otsuka
FX Joseph G. Verbalis has served as a consultant and member of advisory
   boards and Speakers' Bureau for Otsuka and has received research grants
   from Otsuka; Alessandro Peri has served as a consultant and member of
   advisory boards for Otsuka. Giovanni Corona, Corinna Giuliani, Gianni
   Forti and Mario Maggi have nothing to disclose. This does not alter the
   authors' adherence to PLOS ONE policies on sharing data and materials.
CR Ng ACC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061966
   Barsony J, 2012, AGE DORDR, V35, P271
   Barsony J, 2011, J BIOL CHEM, V286, P10864, DOI 10.1074/jbc.M110.155002
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benvenuti S, 2013, NEUROMOL MED, V15, P493, DOI 10.1007/s12017-013-8235-0
   Corona G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080451
   Darmon M, 2014, SHOCK, V41, P394, DOI 10.1097/SHK.0000000000000135
   Doshi SM, 2012, AM J KIDNEY DIS, V59, P222, DOI 10.1053/j.ajkd.2011.08.029
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gheorghiade M, 2007, ARCH INTERN MED, V167, P1998, DOI 10.1001/archinte.167.18.1998
   Gill G, 2006, CLIN ENDOCRINOL, V65, P246, DOI 10.1111/j.1365-2265.2006.02583.x
   Giuliani C, 2013, J ENDOCRINOL INVEST, V36, P693, DOI 10.3275/8925
   Hackworth WA, 2009, LIVER INT, V29, P1071, DOI 10.1111/j.1478-3231.2009.01982.x
   Hansen O, 2010, LUNG CANCER, V68, P111, DOI 10.1016/j.lungcan.2009.05.015
   Hauptman PJ, 2013, J CARD FAIL, V19, P390, DOI 10.1016/j.cardfail.2013.04.001
   Higgins JP, 2008, COCHRANE HDB SYSTEMA
   Hoorn EJ, 2006, NEPHROL DIAL TRANSPL, V21, P70, DOI 10.1093/ndt/gfi082
   Huda MSB, 2006, POSTGRAD MED J, V82, P216, DOI 10.1136/pmj.2005.036947
   Kengne FG, 2008, QJM-INT J MED, V101, P583, DOI 10.1093/qjmed/hcn061
   Kim WR, 2008, NEW ENGL J MED, V359, P1018, DOI 10.1056/NEJMoa0801209
   Kinsella S, 2010, CLIN J AM SOC NEPHRO, V5, P275, DOI 10.2215/CJN.06120809
   Klein L, 2005, CIRCULATION, V111, P2454, DOI 10.1161/01.CIR.0000165065.82609.3D
   Konstam MA, 2007, JAMA-J AM MED ASSOC, V297, P1319, DOI 10.1001/jama.297.12.1319
   Konstam MA, 2011, EUR J HEART FAIL, V13, P242, DOI 10.1093/eurjhf/hfq236
   Lee J, 2013, TOHOKU J EXP MED, V229, P97, DOI 10.1620/tjem.229.97
   Lee SE, 2012, HEART, V98, P1798, DOI 10.1136/heartjnl-2012-302334
   Licata G, 2003, AM HEART J, V145, P459, DOI 10.1067/mhj.2003.166
   Madan VD, 2011, CIRC-HEART FAIL, V4, P637, DOI 10.1161/CIRCHEARTFAILURE.111.961011
   Nzerue CM, 2003, J NATL MED ASSOC, V95, P335
   Peri A, 2010, J ENDOCRINOL INVEST, V33, P671, DOI [10.3275/7290, 10.1007/BF03346668]
   Peri A, 2013, J CLIN ENDOCR METAB, V98, P1321, DOI 10.1210/jc.2012-4082
   Qureshi W, 2013, CLIN RES CARDIOL, V102, P637, DOI 10.1007/s00392-013-0576-z
   Renneboog B, 2006, AM J MED, V119, p71e1, DOI DOI 10.1016/J.AMJMED.2005.09.026
   Rossi Joseph, 2007, Acute Card Care, V9, P82, DOI 10.1080/17482940701210179
   Rusinaru D, 2009, AM J CARDIOL, V103, P405, DOI 10.1016/j.amjcard.2008.09.091
   TERZIAN C, 1994, J GEN INTERN MED, V9, P89, DOI 10.1007/BF02600208
   Upadhyay A, 2006, AM J MED, V119, pS30, DOI 10.1016/j.amjmed.2006.05.005
   Vaishya Richa, 2012, J Indian Med Assoc, V110, P94
   Verbalis JG, 2013, AM J MED, V126, pS5, DOI 10.1016/j.amjmed.2013.07.006
   Verbalis JG, 2010, J BONE MINER RES, V25, P554, DOI 10.1359/jbmr.090827
   Waikar SS, 2009, AM J MED, V122, P857, DOI 10.1016/j.amjmed.2009.01.027
   Wald R, 2010, ARCH INTERN MED, V170, P294, DOI 10.1001/archinternmed.2009.513
   Zilberberg Marya D, 2008, BMC Pulm Med, V8, P16, DOI 10.1186/1471-2466-8-16
NR 43
TC 28
Z9 28
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 23
PY 2015
VL 10
IS 4
AR e0124105
DI 10.1371/journal.pone.0124105
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG5KZ
UT WOS:000353332000058
PM 25905459
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, X
   Yang, Y
   Li, ZL
   Cheng, C
   Yang, T
   Wang, C
   Liu, L
   Liu, SC
AF Yang, Xin
   Yang, Yuan
   Li, Zhilu
   Cheng, Chen
   Yang, Ting
   Wang, Cheng
   Liu, Lin
   Liu, Shengchun
TI Diagnostic Value of Circulating Chromogranin A for Neuroendocrine
   Tumors: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID NEURON-SPECIFIC ENOLASE; MEDULLARY-THYROID CARCINOMA;
   5-HYDROXYINDOLEACETIC ACID; GLYCOPROTEIN HORMONES; CONSENSUS GUIDELINES;
   ENDOCRINE TUMORS; PUBLICATION BIAS; ALPHA-SUBUNIT; PLASMA; MARKER
AB Background
   In previous decades, chromogranin A (CgA) has been demonstrated to be the most promising biomarker for the diagnosis of neuroendocrine tumors (NETs), but its diagnostic value is still controversial. This meta-analysis aimed to estimate the potential diagnostic value of circulating CgA for NETs.
   Methods
   We collected relevant studies from several electronic databases as well as from reference lists. Diagnostic indices of CgA were pooled with random effects models. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and summary receiver operating characteristic (SROC) curves for the diagnosis of NETs were used to estimate the overall diagnostic efficiency.
   Results
   Through a search strategy, 13 studies met the inclusion criteria and were included. These studies contained 1260 patients with NETs and 967 healthy controls in the total sample. As a result, the overall sensitivity, specificity and diagnostic odds ratio (DOR) were 0.73 (95% CI: 0.71 to 0.76), 0.95 (95% CI: 0.93 to 0.96) and 56.29 (95% CI: 25.27 to 125.38), respectively, while the summary positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were 14.56 (95% CI: 6.62 to 32.02) and 0.26 (95% CI: 0.18 to 0.38), respectively. In addition, the area under the curve (AUC) of the circulating CgA in the diagnosis of NETs was 0.8962.
   Conclusions
   These data demonstrate that circulating CgA is an efficient biomarker for the diagnosis of NETs with high sensitivity and specificity, which indicates that it may be helpful for the clinical management of NETs. However, further studies are needed to clarify this issue.
C1 [Yang, Xin; Li, Zhilu; Cheng, Chen; Yang, Ting; Wang, Cheng; Liu, Lin; Liu, Shengchun] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China.
   [Yang, Yuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiovasc Med, Chongqing, Peoples R China.
RP Liu, SC (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China.
EM liushengchun1968@163.com
FU National Natural Science Foundation of China (NSFC) [81272265, 81472658]
FX LS was supported by grants from the National Natural Science Foundation
   of China (NSFC, 81272265 and 81472658, URL: http://www.nsfc.gov.cn/).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ameri P, 2012, NEUROENDOCRINOLOGY, V95, P267, DOI 10.1159/000334612
   Bajetta E, 1999, CANCER, V86, P858, DOI 10.1002/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8
   Baudin E, 1998, BRIT J CANCER, V78, P1102, DOI 10.1038/bjc.1998.635
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belli Susana Haydee, 2009, Acta Gastroenterol Latinoam, V39, P184
   Bernini GP, 2001, BRIT J CANCER, V84, P636, DOI 10.1054/bjoc.2000.1659
   BLIND E, 1992, THYROID, V2, P5, DOI 10.1089/thy.1992.2.5
   Campana D, 2007, J CLIN ONCOL, V25, P1967, DOI 10.1200/JCO.2006.10.1535
   Colombo B, 2002, CANCER RES, V62, P941
   Colombo B, 2002, J BIOL CHEM, V277, P45911, DOI 10.1074/jbc.M202637200
   Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016
   Degg TJ, 2000, ANN CLIN BIOCHEM, V37, P724, DOI 10.1258/0004563001899780
   Donica H, 2010, FOLIA HISTOCHEM CYTO, V48, P603, DOI 10.2478/v10042-010-0088-x
   Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X
   Guignat L, 2001, BRIT J CANCER, V84, P808, DOI 10.1054/bjoc.2000.1677
   Hauser H, 1995, Eur J Surg Oncol, V21, P297, DOI 10.1016/S0748-7983(95)91624-5
   Helle KB, 2007, CELL MOL LIFE SCI, V64, P2863, DOI 10.1007/s00018-007-7254-0
   HSIAO RJ, 1990, J CLIN INVEST, V85, P1555, DOI 10.1172/JCI114604
   Jones CM, 2005, ANN THORAC SURG, V79, P16, DOI 10.1016/j.athoracsur.2004.09.040
   Kaltsas GA, 2004, ENDOCR REV, V25, P458, DOI 10.1210/er.2003-0014
   KEMA IP, 1992, CLIN CHEM, V38, P1730
   Korse CM, 2012, EUR J CANCER, V48, P662, DOI 10.1016/j.ejca.2011.08.012
   Kulke MH, 2012, J NATL COMPR CANC NE, V10, P724, DOI 10.6004/jnccn.2012.0075
   LANGLEY K, 1994, ANN NY ACAD SCI, V733, P1, DOI 10.1111/j.1749-6632.1994.tb17251.x
   Lijmer JG, 2002, STAT MED, V21, P1525, DOI 10.1002/sim.1185
   Lindblom A, 2000, BRIT MED J, V320, P424, DOI 10.1136/bmj.320.7232.424
   Modlin IM, 2005, GASTROENTEROLOGY, V128, P1717, DOI 10.1053/j.gastro.2005.03.038
   Modlin IM, 2008, LANCET ONCOL, V9, P61, DOI 10.1016/S1470-2045(07)70410-2
   Modlin IM, 2006, NEUROENDOCRINOLOGY, V84, P69, DOI 10.1159/000096997
   Modlin IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063364
   Molina R, 2011, TUMOR BIOL, V32, P13, DOI 10.1007/s13277-010-0085-x
   Neary PC, 1997, DIS COLON RECTUM, V40, P349, DOI 10.1007/BF02050428
   Nehar D, 2004, CLIN ENDOCRINOL, V60, P644, DOI 10.1111/j.1365-2265.2004.02030.x
   Nobels FRE, 1997, J CLIN ENDOCR METAB, V82, P2622, DOI 10.1210/jc.82.8.2622
   Nobels FRE, 1998, EUR J CLIN INVEST, V28, P431
   O'Toole D, 2009, NEUROENDOCRINOLOGY, V90, P194, DOI 10.1159/000225948
   OCONNOR DT, 1986, NEW ENGL J MED, V314, P1145, DOI 10.1056/NEJM198605013141803
   OCONNOR DT, 1983, J CLIN ENDOCR METAB, V57, P1084, DOI 10.1210/jcem-57-5-1084
   OCONNOR DT, 1983, REGUL PEPTIDES, V6, P263, DOI 10.1016/0167-0115(83)90145-3
   OCONNOR DT, 1984, NEW ENGL J MED, V311, P764, DOI 10.1056/NEJM198409203111204
   Panzuto F, 2004, J ENDOCRINOL INVEST, V27, P6, DOI 10.1007/BF03350903
   PEARSE AGE, 1968, PROC R SOC SER B-BIO, V170, P71, DOI 10.1098/rspb.1968.0025
   PEARSE AGE, 1976, CLIN ENDOCRINOL, V5, pS229, DOI 10.1111/j.1365-2265.1976.tb03832.x
   Peracchi M, 2003, EUR J ENDOCRINOL, V148, P39, DOI 10.1530/eje.0.1480039
   SOBOL RE, 1986, ANN INTERN MED, V105, P698, DOI 10.7326/0003-4819-105-5-698
   Solcia E., 2000, CLIN ENDOCRINOL, V53, P259, DOI DOI 10.1046/J.1365-2265.2000.01073.X
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   STRIDSBERG M, 1995, J ENDOCRINOL, V144, P49, DOI 10.1677/joe.0.1440049
   TAPIA FJ, 1981, LANCET, V1, P808
   Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405
   Tohmola N, 2014, CLIN CHIM ACTA, V428, P38, DOI 10.1016/j.cca.2013.10.025
   Tomassetti P, 2001, EUR J GASTROEN HEPAT, V13, P55, DOI 10.1097/00042737-200101000-00010
   Vinik AI, 2010, PANCREAS, V39, P713, DOI 10.1097/MPA.0b013e3181ebaffd
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377
   Zamora Javier, 2006, BMC Med Res Methodol, V6, P31, DOI 10.1186/1471-2288-6-31
   Zatelli MC, 2007, ENDOCR-RELAT CANCER, V14, P473, DOI 10.1677/ERC-07-0001
NR 57
TC 20
Z9 20
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 20
PY 2015
VL 10
IS 4
AR e0124884
DI 10.1371/journal.pone.0124884
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG3XA
UT WOS:000353211700126
PM 25894842
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Kim, DH
   Rogers, JR
   Fulchino, LA
   Kim, CA
   Solomon, DH
   Kim, SC
AF Kim, Dae Hyun
   Rogers, James R.
   Fulchino, Lisa A.
   Kim, Caroline A.
   Solomon, Daniel H.
   Kim, Seoyoung C.
TI Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID INTIMA-MEDIA THICKNESS; BONE-MINERAL DENSITY; ATRIAL-FIBRILLATION;
   CLINICAL-TRIALS; SUBCLINICAL ATHEROSCLEROSIS; POSTMENOPAUSAL
   OSTEOPOROSIS; CORONARY ATHEROSCLEROSIS; AORTIC CALCIFICATION; ZOLEDRONIC
   ACID; IN-VITRO
AB Background and Objectives
   Some evidence suggests that bisphosphonates may reduce atherosclerosis, while concerns have been raised about atrial fibrillation. We conducted a meta-analysis to determine the effects of bisphosphonates on total adverse cardiovascular (CV) events, atrial fibrillation, myocardial infarction (MI), stroke, and CV death in adults with or at risk for low bone mass.
   Methods
   A systematic search of MEDLINE and EMBASE through July 2014 identified 58 randomized controlled trials with longer than 6 months in duration that reported CV events. Absolute risks and the Mantel-Haenszel fixed-effects odds ratios (ORs) and 95% confidence intervals (CIs) of total CV events, atrial fibrillation, MI, stroke, and CV death were estimated. Subgroup analyses by follow-up duration, population characteristics, bisphosphonate types, and route were performed.
   Results
   Absolute risks over 25-36 months in bisphosphonate-treated versus control patients were 6.5% versus 6.2% for total CV events; 1.4% versus 1.5% for atrial fibrillation; 1.0% versus 1.2% for MI; 1.6% versus 1.9% for stroke; and 1.5% versus 1.4% for CV death. Bisphosphonate treatment up to 36 months did not have any significant effects on total CV events (14 trials; ORs [95% CI]: 0.98 [0.84-1.14]; I-2 = 0.0%), atrial fibrillation (41 trials; 1.08 [0.92-1.25]; I-2 = 0.0%), MI (10 trials; 0.96 [0.69-1.34]; I-2 = 0.0%), stroke (10 trials; 0.99 [0.82-1.19]; I-2 = 5.8%), and CV death (14 trials; 0.88 [0.72-1.07]; I-2 = 0.0%) with little between-study heterogeneity. The risk of atrial fibrillation appears to be modestly elevated for zoledronic acid (6 trials; 1.24 [0.96-1.61]; I-2 = 0.0%), not for oral bisphosphonates (26 trials; 1.02 [0.83-1.24]; I-2 = 0.0%). The CV effects did not vary by subgroups or study quality.
   Conclusions
   Bisphosphonates do not have beneficial or harmful effects on atherosclerotic CV events, but zoledronic acid may modestly increase the risk of atrial fibrillation. Given the large reduction in fractures with bisphosphonates, changes in osteoporosis treatment decision due to CV risk are not justified.
C1 [Kim, Dae Hyun; Rogers, James R.; Fulchino, Lisa A.; Solomon, Daniel H.; Kim, Seoyoung C.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Boston, MA 02115 USA.
   [Solomon, Daniel H.; Kim, Seoyoung C.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy,Dept Med, Boston, MA USA.
   [Kim, Dae Hyun; Kim, Caroline A.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gerontol,Dept Med, Boston, MA USA.
RP Kim, DH (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Boston, MA 02115 USA.
EM dkim12@partners.org
RI Kim, Seoyoung/L-6561-2019
OI Kim, Seoyoung/0000-0002-2517-3579
FU KL2 Medical Research Investigator Training award from Harvard Catalyst /
   The Harvard Clinical and Translational Science Center (National Center
   for Research Resources, NIH) [1KL2 TR001100-01]; KL2 Medical Research
   Investigator Training award from Harvard Catalyst / The Harvard Clinical
   and Translational Science Center (National Center for Advancing
   Translational Sciences, NIH) [1KL2 TR001100-01]; Alosa Foundation;
   National Heart, Lung, and Blood Institute (NIH) [T32 HL007374-35]; NIH
   [K24-AR055989, P60-AR047782, R01-AR056215, K23 AR059677]; Amgen; Lilly;
   Pfizer; Novartis; Bristol Myers Squibb
FX The authors have read the journal's policy and have the following
   competing interests: * DHK is supported by a KL2 Medical Research
   Investigator Training award from Harvard Catalyst / The Harvard Clinical
   and Translational Science Center (National Center for Research Resources
   and the National Center for Advancing Translational Sciences, NIH Award
   1KL2 TR001100-01). DHK provides paid consultative services on geriatrics
   care to the Alosa Foundation, a nonprofit educational organization with
   no relationship to any drug or device manufacturers. * CAK is supported
   by a T32 Cardiovascular Research Training award from National Heart,
   Lung, and Blood Institute (NIH Award, T32 HL007374-35). * DHS is
   supported by the NIH grants K24-AR055989, P60-AR047782, and
   R01-AR056215. Solomon receives research grants from Amgen, Lilly and
   Pfizer. He serves in unpaid roles on studies sponsored by Pfizer,
   Novartis, Lilly, and Bristol Myers Squibb. He also receives royalties
   from UpToDate.com. * SCK is supported by the NIH grant K23 AR059677. She
   received research support from Pfizer and Lilly". This does not alter
   the authors' adherence to PLOS ONE policies on sharing data and
   materials.
CR Anagnostis P, 2009, OSTEOPOROSIS INT, V20, P197, DOI 10.1007/s00198-008-0648-5
   Barengolts EI, 1998, CALCIFIED TISSUE INT, V62, P209, DOI 10.1007/s002239900419
   Barrett-Connor E, 2012, OSTEOPOROSIS INT, V23, P233, DOI 10.1007/s00198-011-1546-9
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhuriya R, 2010, INT J CARDIOL, V142, P213, DOI 10.1016/j.ijcard.2009.11.041
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Blumenthal RS, 2006, JAMA-J AM MED ASSOC, V295, P1583, DOI 10.1001/jama.0.13.jed60019
   Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528
   BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C
   Celiloglu M, 2009, MENOPAUSE, V16, P689, DOI 10.1097/gme.0b013e318194cafd
   Crouse JR, 2007, JAMA-J AM MED ASSOC, V297, P1344, DOI 10.1001/jama.297.12.1344
   Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132
   D'Ascenzo F, 2013, ATHEROSCLEROSIS, V226, P178, DOI 10.1016/j.atherosclerosis.2012.10.065
   Demer LL, 2003, ARTERIOSCL THROM VAS, V23, P1739, DOI 10.1161/01.ATV.0000093547.63630.0F
   Derry S, 2001, BMC Med Res Methodol, V1, P7, DOI 10.1186/1471-2288-1-7
   Doherty MJ, 1998, J BONE MINER RES, V13, P828, DOI 10.1359/jbmr.1998.13.5.828
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fiore C E, 2009, J Endocrinol Invest, V32, P38
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   HOLLANDER W, 1979, ATHEROSCLEROSIS, V33, P111, DOI 10.1016/0021-9150(79)90202-8
   Howard PA, 2010, AM J CARDIOVASC DRUG, V10, P359, DOI 10.2165/11584720-000000000-00000
   Ikeda K, 2013, EUR J PREV CARDIOL, V20, P1069, DOI 10.1177/2047487312451539
   Jackson B, 2000, ARZNEIMITTEL-FORSCH, V50, pE380
   Jeziorska M, 1998, VIRCHOWS ARCH, V433, P559, DOI 10.1007/s004280050289
   Kado DM, 2000, J BONE MINER RES, V15, P1974, DOI 10.1359/jbmr.2000.15.10.1974
   Kanazawa I, 2010, AM J MED SCI, V339, P519, DOI 10.1097/MAJ.0b013e3181db6dfe
   Kang JH, 2013, OSTEOPOROSIS INT, V24, P271, DOI 10.1007/s00198-012-2213-5
   Kang JH, 2012, OSTEOPOROSIS INT, V23, P2551, DOI 10.1007/s00198-012-1894-0
   Karam R, 2007, NEW ENGL J MED, V357, P712
   Kawahara T, 2013, CIRCULATION, V127, P2327, DOI 10.1161/CIRCULATIONAHA.113.001534
   Kiel DP, 2001, CALCIFIED TISSUE INT, V68, P271, DOI 10.1007/BF02390833
   Kim SY, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2938
   Koshiyama H, 2000, J CLIN ENDOCR METAB, V85, P2793, DOI 10.1210/jc.85.8.2793
   Lewiecki EM, 2010, INT J CLIN PRACT, V64, P821, DOI 10.1111/j.1742-1241.2010.02335.x
   Loke YK, 2009, DRUG SAFETY, V32, P219, DOI 10.2165/00002018-200932030-00004
   Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Mak A, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-113
   McFarlane SI, 2004, ENDOCRINE, V23, P1, DOI 10.1385/ENDO:23:1:01
   Nitta K, 2004, AM J KIDNEY DIS, V44, P680, DOI 10.1053/j.ajkd.2004.06.009
   Pazianas M, 2010, J BONE MINER RES, V25, P2, DOI 10.1359/jbmr.091201
   Santos LL, 2012, CLIN MED INSIGHTS-EN, V5, P47, DOI 10.4137/CMED.S10007
   SCHOR AM, 1990, J CELL SCI, V97, P449
   Shaffer JR, 2007, CALCIFIED TISSUE INT, V81, P430, DOI 10.1007/s00223-007-9079-0
   Sharma A, 2014, AM J CARDIOL, V113, P1815, DOI 10.1016/j.amjcard.2014.03.008
   Sharma A, 2013, CHEST, V144, P1311, DOI 10.1378/chest.13-0675
   Tanko LB, 2005, OSTEOPOROSIS INT, V16, P184, DOI 10.1007/s00198-004-1662-x
   The US Food and Drug Administration, UPD SAF REV FOLL UP
   Toussaint ND, 2010, AM J KIDNEY DIS, V56, P57, DOI 10.1053/j.ajkd.2009.12.039
   van der Klift M, 2002, CALCIFIED TISSUE INT, V70, P443, DOI 10.1007/s00223-001-2076-9
   von der Recke P, 1999, AM J MED, V106, P273, DOI 10.1016/S0002-9343(99)00028-5
   Wolfe F, 2013, J BONE MINER RES, V28, P984, DOI 10.1002/jbmr.1792
   YLITALO R, 1994, J LAB CLIN MED, V123, P769
NR 53
TC 24
Z9 28
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 17
PY 2015
VL 10
IS 4
AR e0122646
DI 10.1371/journal.pone.0122646
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG1EX
UT WOS:000353017000037
PM 25884398
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, N
   Tong, SF
   Xiang, Y
   Wu, L
   Xu, B
   Zhang, Y
   Ma, XY
   Li, YF
   Song, ZY
   Zhong, L
AF Wu, Na
   Tong, Shifei
   Xiang, Ying
   Wu, Long
   Xu, Bin
   Zhang, Yao
   Ma, Xiangyu
   Li, Yafei
   Song, Zhiyuan
   Zhong, Li
TI Association of Hemostatic Markers with Atrial Fibrillation: A
   Meta-Analysis and Meta-Regression
SO PLOS ONE
LA English
DT Article
ID MEAN PLATELET VOLUME; SOLUBLE P-SELECTIN; VON-WILLEBRAND-FACTOR;
   C-REACTIVE PROTEIN; FIBRIN D-DIMER; PROTHROMBOTIC STATE; HYPERCOAGULABLE
   STATE; BETA-THROMBOGLOBULIN; RISK-FACTOR; ENDOTHELIAL DYSFUNCTION
AB Background
   There is growing evidence that indicates the presence of a prothrombotic state in atrial fibrillation (AF). However, the role of hemostatic markers in AF remains inconclusive.
   Methods
   We conducted a meta-analysis of observational studies to evaluate the association between hemostatic markers and AF. A meta-regression was performed to explore potential sources of heterogeneity.
   Results
   A total of 59 studies met our inclusion criteria for the meta-analysis. For platelet activation, increased circulating platelet factor-4, beta-thromboglobulin (BTG) and P-selectin were significantly higher in AF cases compared with controls (standardized mean difference [SMD] [95% confidence interval (CI)]: 1.72[0.96-2.49], 1.61[1.03-2.19] and 0.50[0.23-0.77], respectively). For coagulation activation, increased levels of plasma D-dimer, fibrinogen, thrombin-antithrombin, prothrombin fragment 1+2, and antithrombin-III were significantly associated with AF (SMD[95% CI]: 1.82[1.38-2.26], 0.72[0.55-0.89], 0.42[0.13-0.72], 1.00 [0.00-1.99] and 1.38[0.16-2.60], respectively). For fibrinolytic function, tissue-type plasminogen activator and plasminogen activator inhibitor-1 were significantly increased in AF cases compared with controls (SMD[95% CI]: 0.86[0.04-1.67] and 0.87[0.28-1.47], respectively) but the associations became nonsignificant after performing subgroup analysis by anticoagulants treatment status. For endothelial function, increased von Willebrand factor was significantly associated with AF (SMD, 0.79; 95% CI, 0.60-0.99); however, no association was observed for soluble thrombomodulin (SMD, 0.60; 95% CI, -0.13-1.33).
   Conclusions
   Increased circulating hemostatic factors (PF-4, BTG, P-selectin, D-dimer, fibrinogen, TAT, F1+2, AT-III, and vWf) are significantly associated with AF. Future research is necessary to elucidate the precise mechanism of the prothrombotic state and how hemostatic markers promote thromboembolism in AF.
C1 [Wu, Na; Xiang, Ying; Wu, Long; Xu, Bin; Zhang, Yao; Ma, Xiangyu; Li, Yafei] Third Mil Med Univ, Dept Epidemiol, Coll Prevent Med, Chongqing, Peoples R China.
   [Xiang, Ying; Wu, Long; Xu, Bin; Zhang, Yao; Ma, Xiangyu; Li, Yafei] Third Mil Med Univ, Evidence Based Med & Clin Epidemiol Ctr, Chongqing, Peoples R China.
   [Tong, Shifei; Song, Zhiyuan; Zhong, Li] Third Mil Med Univ, Dept Cardiol, Southwest Hosp, Chongqing, Peoples R China.
RP Song, ZY (reprint author), Third Mil Med Univ, Dept Cardiol, Southwest Hosp, Chongqing, Peoples R China.
EM zysong2010@126.com; zhongli28@hotmail.com
CR Acevedo M, 2012, J THROMB THROMBOLYS, V128, pe113
   Adamsson Eryd S, 2011, EUR J EPIDEMIOL, V26, P449, DOI 10.1007/s10654-011-9565-6
   Akar JG, 2008, J AM COLL CARDIOL, V51, P1790, DOI 10.1016/j.jacc.2007.11.083
   Alberti S, 2009, PLATELETS, V20, P235, DOI 10.1080/09537100902954370
   Alonso A, 2012, INT J CARDIOL, V155, P217, DOI 10.1016/j.ijcard.2010.09.051
   Atalar E, 2003, PLATELETS, V14, P407, DOI 10.1080/09537100310001638814
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blann AD, 2008, INT J CARDIOL, V127, P135, DOI 10.1016/j.ijcard.2007.04.028
   Brotman DJ, 2004, SOUTH MED J, V97, P213, DOI 10.1097/01.SMJ.0000105663.01648.25
   Cecchi E, 2006, AM J CARDIOL, V97, P1745, DOI 10.1016/j.amjcard.2006.01.034
   Choudhury A, 2003, PATHOPHYSIOL HAEMO T, V33, P282, DOI 10.1159/000083815
   Choudhury A, 2008, CHEST, V134, P574, DOI 10.1378/chest.07-2745
   Chung NAY, 2002, STROKE, V33, P2187, DOI 10.1161/01.STR.0000023889.84649.3D
   Colkesen Y, 2008, BLOOD COAGUL FIBRIN, V19, P411, DOI 10.1097/MBC.0b013e3283049697
   Colman R. W., 2006, HEMOSTASIS THROMBOSI
   Conway DSG, 2004, AM J CARDIOL, V93, P1368, DOI 10.1016/j.amjcard.2004.02.032
   Conway DSG, 2004, J AM COLL CARDIOL, V43, P2075, DOI 10.1016/j.jacc.2003.11.062
   Conway DSG, 2003, STROKE, V34, P413, DOI 10.1161/01.STR.0000051728.85133.32
   Das UN, 2005, MED SCI MONITOR, V11, pRA155
   Feng C, 2013, HEART LUNG CIRC, V22, P43, DOI 10.1016/j.hlc.2012.08.052
   Feng DL, 2001, AM J CARDIOL, V87, P168, DOI 10.1016/S0002-9149(00)01310-2
   Fu RB, 2011, EUROPACE, V13, P31, DOI 10.1093/europace/euq346
   Fuster V, 2011, J AM COLL CARDIOL, V57, pE101, DOI 10.1016/j.jacc.2010.09.013
   Gartner W, 2008, CLIN BIOCHEM, V41, P1434, DOI 10.1016/j.clinbiochem.2008.09.096
   Giansante C, 2000, AM HEART J, V140, P423, DOI 10.1067/mhj.2000.108520
   Guo YT, 2012, J AM COLL CARDIOL, V60, P2263, DOI 10.1016/j.jacc.2012.04.063
   GUSTAFSSON C, 1990, STROKE, V21, P47, DOI 10.1161/01.STR.21.1.47
   Ha SI, 2011, PLATELETS, V22, P408, DOI 10.3109/09537104.2011.560306
   Hatzinikolaou-Kotsakou E, 2003, J THROMB THROMBOLYS, V16, P155, DOI 10.1023/B:THRO.0000024053.45693.fc
   Hayashi M, 2011, THROMB RES, V128, pE113, DOI 10.1016/j.thromres.2011.07.013
   Heeringa J, 2006, J THROMB HAEMOST, V4, P1944, DOI 10.1111/j.1538-7836.2006.02115.x
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hou JP, 2010, CLIN BIOCHEM, V43, P1212, DOI 10.1016/j.clinbiochem.2010.07.013
   Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13
   Inoue H, 2004, CHEST, V126, P687, DOI 10.1378/chest.126.3.687
   Kahn SR, 1997, CAN MED ASSOC J, V157, P673
   Kamath S, 2003, HEART, V89, P1093, DOI 10.1136/heart.89.9.1093
   Kamath S, 2002, BLOOD COAGUL FIBRIN, V13, P627, DOI 10.1097/00001721-200210000-00008
   Kamath S, 2002, EUR HEART J, V23, P1788, DOI 10.1053/euhj.2002.3259
   Kamath S, 2002, STROKE, V33, P1237, DOI 10.1161/01.STR.0000013739.82306.7F
   KUMAGAI K, 1990, J AM COLL CARDIOL, V16, P377, DOI 10.1016/0735-1097(90)90589-H
   Li-Saw-Hee FL, 1999, AM J CARDIOL, V83, P1206, DOI 10.1016/S0002-9149(99)00060-0
   Li-Saw-Hee FL, 2001, EUR HEART J, V22, P1741, DOI 10.1053/euhj.2000.2531
   Li-Saw-Hee FL, 2000, J AM COLL CARDIOL, V35, P1926, DOI 10.1016/S0735-1097(00)00627-6
   Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006
   LIP GYH, 1995, LANCET, V346, P1313, DOI 10.1016/S0140-6736(95)92339-X
   LIP GYH, 1995, BRIT HEART J, V73, P527
   Lip GYH, 1996, CIRCULATION, V94, P425, DOI 10.1161/01.CIR.94.3.425
   Lip GYH, 1996, AM HEART J, V131, P724, DOI 10.1016/S0002-8703(96)90278-1
   Little J, 2002, AM J EPIDEMIOL, V156, P300, DOI 10.1093/aje/kwf054
   Liu T, 2007, J AM COLL CARDIOL, V49, P1642, DOI 10.1016/j.jacc.2006.12.042
   Marcus GM, 2008, AM HEART J, V155, P303, DOI 10.1016/j.ahj.2007.09.006
   Marin F, 2003, THROMB RES, V109, P233, DOI 10.1016/S0049-3848(03)00259-7
   Marin F, 2003, STROKE, V34, P1181, DOI 10.1161/01.STR.0000065431.76788.D9
   Marin F, 1999, AM J CARDIOL, V84, P862, DOI 10.1016/S0002-9149(99)00453-1
   Marin V, 2004, HEART, V90, P1162, DOI 10.1136/hrt.2003.024521
   Minamino T, 1997, ARTERIOSCL THROM VAS, V17, P3191, DOI 10.1161/01.ATV.17.11.3191
   Minamino T, 1999, AM J CARDIOL, V83, P194, DOI 10.1016/S0002-9149(98)00823-6
   Mitusch R, 1996, THROMB HAEMOSTASIS, V75, P219
   Mondillo S, 2000, INT J CARDIOL, V75, P227, DOI 10.1016/S0167-5273(00)00336-3
   NAGAO T, 1995, STROKE, V26, P1365, DOI 10.1161/01.STR.26.8.1365
   Roldan V, 2005, AM J CARDIOL, V95, P881, DOI 10.1016/j.amjcard.2004.12.016
   Roldan V, 1998, AM HEART J, V136, P956, DOI 10.1016/S0002-8703(98)70149-8
   Roldan V, 2011, J AM COLL CARDIOL, V57, P2496, DOI 10.1016/j.jacc.2010.12.033
   Schnabel RB, 2010, CIRCULATION, V121, P200, DOI 10.1161/CIRCULATIONAHA.109.882241
   Shiroshita-Takeshita A, 2005, J INTERV CARD ELECTR, V13, P181, DOI 10.1007/s10840-005-2362-y
   Sohara H, 1997, J AM COLL CARDIOL, V29, P106, DOI 10.1016/S0735-1097(96)00427-5
   SOHARA H, 1994, JPN CIRC J, V58, P821, DOI 10.1253/jcj.58.821
   Targonski R, 2008, KARDIOL POL, V66, P729
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Topaloglu S, 2007, ANGIOLOGY, V58, P85, DOI 10.1177/0003319706297917
   Topcuoglu MA, 2000, NEUROL SCI, V21, P235, DOI 10.1007/s100720070082
   Tsai LM, 1998, AM J CARDIOL, V81, P1249, DOI 10.1016/S0002-9149(98)00131-3
   Turgut N, 2006, CLIN APPL THROMB-HEM, V12, P15, DOI 10.1177/107602960601200104
   Turgut O, 2013, PLATELETS, V24, P493, DOI 10.3109/09537104.2012.725876
   Vene N, 2003, THROMB HAEMOSTASIS, V90, P1163, DOI 10.1160/TH03-06-0363
   Wang TD, 2001, J CARDIOVASC ELECTR, V12, P877, DOI 10.1046/j.1540-8167.2001.00877.x
   Watson T, 2009, LANCET, V373, P155, DOI 10.1016/S0140-6736(09)60040-4
   Wells GASB, 2011, THE NEWCASTLE OTTAWA
   Wu N, 2013, INT J CARDIOL, V169, P62, DOI 10.1016/j.ijcard.2013.08.078
   YAMAUCHI K, 1986, JPN HEART J, V27, P481
   Yip HK, 2006, INT HEART J, V47, P371, DOI 10.1536/ihj.47.371
   Zorlu A, 2012, J THROMB THROMBOLYS, V33, P343, DOI 10.1007/s11239-011-0656-8
NR 83
TC 12
Z9 12
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 17
PY 2015
VL 10
IS 4
AR e0124716
DI 10.1371/journal.pone.0124716
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG1EX
UT WOS:000353017000141
PM 25884835
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ye, XH
   Lu, GR
   Huai, JP
   Ding, J
AF Ye, Xiaohua
   Lu, Guangrong
   Huai, Jiaping
   Ding, Jin
TI Impact of Smoking on the Risk of Pancreatitis: A Systematic Review and
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID POPULATION-BASED-COHORT; RETROGRADE CHOLANGIOPANCREATOGRAPHY
   PANCREATITIS; DOSE-RESPONSE DATA; CIGARETTE-SMOKING; ALCOHOLIC
   PANCREATITIS; TOBACCO; CANCER; EPIDEMIOLOGY; PREVALENCE; DISEASE
AB Background and objective
   Cigarette smoking may increase the risk of developing pancreatic cancer, although its impact on pancreatitis has only been discerned in recent years. However, the results of previous studies differ. We performed a meta-analysis to provide a quantitative pooled risk estimate of the association of cigarette smoking with pancreatitis.
   Method
   A literature search of the MEDLINE and Embase databases was conducted, and studies were selected that investigated the association of cigarette smoking with pancreatitis. Summary relative risks (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model.
   Results
   Twenty-two studies were included. The summary RRs (95% CI) associated with ever, current and former smokers for acute and chronic pancreatitis (AP/CP) were as follows: 1.51 (1.10, 2.07)/3.00 (1.46, 6.17), 1.42 (1.08, 1.87)/2.72 (1.74, 4.24), and 1.22 (0.99, 1.52)/1.27 (1.00, 1.62), respectively. Moreover, studies that analyzed both AP and CP were also summarized: 1.73 (1.18, 2.54) for ever smokers, 1.67 (1.03, 2.68) for current smokers and 1.56 (1.16, 2.11) for former smokers, respectively. There was no evidence of publication bias across the studies.
   Conclusion
   The evidence suggests a positive association of cigarette smoking with the development of pancreatitis. It is possible that smoking cessation may be a useful strategy for the management of pancreatitis.
C1 [Ye, Xiaohua; Ding, Jin] Zhejiang Univ, Jinhua Hosp, Jinhua Municipal Cent Hosp, Dept Gastroenterol & Hepatol, Jinhua, Zhejiang, Peoples R China.
   [Lu, Guangrong] Wenzhou Med Univ, Affiliated Hosp 2, Dept Gastroenterol & Hepatol, Wenzhou, Zhejiang, Peoples R China.
   [Huai, Jiaping] Zhejiang Univ, Jinhua Hosp, Jinhua Municipal Cent Hosp, Dept Crit Care Med, Jinhua, Zhejiang, Peoples R China.
RP Lu, GR (reprint author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Gastroenterol & Hepatol, Wenzhou, Zhejiang, Peoples R China.
EM 530392865@qq.com
CR Alexandre M, 2011, PANCREATOLOGY, V11, P469, DOI 10.1159/000332196
   Andriulli A, 2010, PANCREAS, V39, P1205, DOI 10.1097/MPA.0b013e3181df27c0
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERLIN JA, 1993, EPIDEMIOLOGY, V4, P218, DOI 10.1097/00001648-199305000-00005
   Blomgren KB, 2002, EUR J CLIN PHARMACOL, V58, P275, DOI 10.1007/s00228-002-0471-4
   BOURLIERE M, 1991, GUT, V32, P1392, DOI 10.1136/gut.32.11.1392
   Debenedet AT, 2009, CLIN GASTROENTEROL H, V7, P353, DOI 10.1016/j.cgh.2008.11.020
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DiMagno MJ, 2013, PANCREAS, V42, P996, DOI 10.1097/MPA.0b013e31827e95e9
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gonzalez-Perez A, 2010, DIABETES CARE, V33, P2580, DOI [10.2337/dc10-0842, 10.2337/dc10.0842]
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   HABER PS, 1993, PANCREAS, V8, P568, DOI 10.1097/00006676-199309000-00007
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hirota M, 2012, PANCREATOLOGY, V12, P79, DOI 10.1016/j.pan.2012.02.005
   Huai JP, 2014, GEN HOSP PSYCHIAT, V36, P488, DOI 10.1016/j.genhosppsych.2014.05.002
   Iodice S, 2008, LANGENBECK ARCH SURG, V393, P535, DOI 10.1007/s00423-007-0266-2
   Law R, 2010, PANCREATOLOGY, V10, P54, DOI 10.1159/000225927
   LEVY P, 1995, PANCREAS, V10, P231, DOI 10.1097/00006676-199504000-00003
   Li N, 2010, PANCREATOLOGY, V10, P238, DOI 10.1159/000279306
   Lin HH, 2014, PANCREAS, V43, P1117, DOI 10.1097/MPA.0000000000000209
   Lin Y, 2000, PANCREAS, V21, P109, DOI 10.1097/00006676-200008000-00001
   Lindkvist B, 2008, PANCREATOLOGY, V8, P63, DOI 10.1159/000114868
   LOWENFELS AB, 1987, PANCREAS, V2, P694, DOI 10.1097/00006676-198711000-00012
   Lowenfels AB, 2001, JAMA-J AM MED ASSOC, V286, P169, DOI 10.1001/jama.286.2.169
   Malfertheiner P, 2006, AM J GASTROENTEROL, V101, P160, DOI 10.1111/j.1572-0241.2006.00402.x
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
   Morton C, 2004, AM J GASTROENTEROL, V99, P731, DOI 10.1111/j.1572-0241.2004.04143.x
   Rothenbacher D, 2005, SCAND J GASTROENTERO, V40, P697, DOI 10.1080/00365520510023116
   Sadr-Azodi O, 2012, GUT, V61, P262, DOI 10.1136/gutjnl-2011-300566
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Talamini G, 1996, PANCREAS, V12, P131, DOI 10.1097/00006676-199603000-00004
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Tolstrup JS, 2009, ARCH INTERN MED, V169, P603, DOI 10.1001/archinternmed.2008.601
   Wells GA, NEWCASTLE OTTAWA SCA, DOI [10.1371/journal.pntd.0002195, DOI 10.1371/J0URNAL.PNTD.0002195]
   Wittel UA, 2006, AM J GASTROENTEROL, V101, P148, DOI 10.1111/j.1572-0241.2006.00405.x
   Wittel UA, 2006, PANCREAS, V33, P364, DOI 10.1097/01.mpa.0000240601.80570.31
   Yadav D, 2007, PANCREAS, V34, P390, DOI 10.1097/mpa.0b013e318040b332
   Yadav D, 2006, PANCREAS, V33, P323, DOI 10.1097/01.mpa.0000236733.31617.52
   Yadav D, 2013, GASTROENTEROLOGY, V144, P1252, DOI 10.1053/j.gastro.2013.01.068
   Yadav D, 2011, AM J GASTROENTEROL, V106, P2192, DOI 10.1038/ajg.2011.328
   Yadav D, 2009, ARCH INTERN MED, V169, P1035, DOI 10.1001/archinternmed.2009.125
   Yang H, 2014, J DIGEST DIS, V15, P501, DOI 10.1111/1751-2980.12168
   YEN S, 1982, AM J EPIDEMIOL, V116, P407, DOI 10.1093/oxfordjournals.aje.a113425
NR 45
TC 15
Z9 16
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 16
PY 2015
VL 10
IS 4
AR e0124075
DI 10.1371/journal.pone.0124075
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG1ES
UT WOS:000353016500081
PM 25879541
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, Y
   Wang, RX
   Miao, LM
   Zhu, LB
   Jiang, HB
   Yuan, H
AF Zhang, Yu
   Wang, Ruixia
   Miao, Limin
   Zhu, Longbiao
   Jiang, Hongbing
   Yuan, Hua
TI Different Levels in Alcohol and Tobacco Consumption in Head and Neck
   Cancer Patients from 1957 to 2013
SO PLOS ONE
LA English
DT Article
ID UPPER AERODIGESTIVE TRACT; SQUAMOUS-CELL CARCINOMA; ORAL-CAVITY;
   HUMAN-PAPILLOMAVIRUS; PHARYNGEAL CANCER; RISK-FACTORS; SOCIOECONOMIC
   INEQUALITIES; SOUTHERN SWEDEN; SMOKING; DRINKING
AB Objective
   To provide a precise quantification of the association between alcohol and tobacco consumption trends in head and neck cancer patients over the past 45 years.
   Methods
   We combined findings from all studies published until March 2014 and evaluated the association between different levels in alcohol and tobacco consumption and head and neck cancers through a meta-analytic approach.
   Results
   We included 28 studies involving 13830 patients with head and neck cancer. In patients with alcohol consumption, the pooled odds ratio (OR) and 95% confidence interval (CI) were 1.29(1.06-1.57), 2.67(2.05-3.48) and 6.63(5.02-8.74) for light drinkers, moderate drinkers and heavy drinkers, respectively. In patients with tobacco consumption, the pooled OR and 95% CI were 2.33(1.84-2.95), 4.97(3.67-6.71) and 6.77(4.81-9.53) for light smokers, moderate smokers and heavy smokers, respectively.
   Conclusion
   The increased alcohol and tobacco consumption trends increased the risk of head and neck cancer over the past 45 years. Tobacco consumption was found to be a stronger risk factor for head and neck cancer than alcohol consumption. Thus, the control should be considered to limit the intake of alcohol and tobacco.
C1 [Zhang, Yu; Wang, Ruixia; Miao, Limin; Zhu, Longbiao; Jiang, Hongbing; Yuan, Hua] Nanjing Med Univ, Jiangsu Key Lab Oral Dis, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Yu; Jiang, Hongbing; Yuan, Hua] Stomatol Hosp Jiangsu Prov, Dept Oral & Maxillofacial Surg, Nanjing, Jiangsu, Peoples R China.
   [Miao, Limin] Nanjing Med Univ, Ctr Canc, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Clin Epidemiol Sect, Nanjing, Jiangsu, Peoples R China.
RP Yuan, H (reprint author), Nanjing Med Univ, Jiangsu Key Lab Oral Dis, Nanjing, Jiangsu, Peoples R China.
EM rolener@gmail.com
FU National Natural Science Foundation of China [81302361]; Specialized
   Research Fund for the Doctoral Program of Higher Education of China
   [20133234120013]; China Postdoctoral Science Foundation [2013M540457];
   Jiangsu Planned Projects for Postdoctoral Research Funds [1301018A];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD) [2014-37]
FX Funding was provided by National Natural Science Foundation of China
   (81302361), Specialized Research Fund for the Doctoral Program of Higher
   Education of China (20133234120013), China Postdoctoral Science
   Foundation (2013M540457), Jiangsu Planned Projects for Postdoctoral
   Research Funds (1301018A), A Project Funded by the Priority Academic
   Program Development of Jiangsu Higher Education Institutions (PAPD,
   2014-37). The funders had no role in studydesign, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Anantharaman D, 2011, ORAL ONCOL, V47, P725, DOI 10.1016/j.oraloncology.2011.05.004
   Applebaum KM, 2007, JNCI-J NATL CANCER I, V99, P1801, DOI 10.1093/jnci/djm233
   Bagnardi V, 2001, BRIT J CANCER, V85, P1700, DOI 10.1054/bjoc.2001.2140
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BLOT WJ, 1988, CANCER RES, V48, P3282
   Boing AF, 2011, J EPIDEMIOL COMMUN H, V65, P709, DOI 10.1136/jech.2009.097691
   Bouchardy C, 2000, INT J CANCER, V87, P734, DOI 10.1002/1097-0215(20000901)87:5<734::AID-IJC17>3.3.CO;2-5
   Bradshaw PT, 2012, AM J EPIDEMIOL, V175, P1225, DOI 10.1093/aje/kwr468
   Bravi F, 2013, BRIT J CANCER, V109, P2904, DOI 10.1038/bjc.2013.667
   BRUGERE J, 1986, CANCER, V57, P391, DOI 10.1002/1097-0142(19860115)57:2<391::AID-CNCR2820570235>3.0.CO;2-Q
   Castellsague X, 2004, INT J CANCER, V108, P741, DOI 10.1002/ijc.11627
   CHOI SY, 1991, INT J EPIDEMIOL, V20, P878, DOI 10.1093/ije/20.4.878
   Coronado GD, 2011, SALUD PUBLICA MEXICO, V53, P440
   De Stefani E, 2007, CANCER LETT, V246, P282, DOI 10.1016/j.canlet.2006.03.008
   Faggiano F, 1997, IARC Sci Publ, P65
   Fedirko V, 2011, ANN ONCOL, V22, P1958, DOI 10.1093/annonc/mdq653
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   FRANCESCHI S, 1990, CANCER RES, V50, P6502
   Freedman ND, 2008, INT J CANCER, V122, P2330, DOI 10.1002/ijc.23319
   Garrote LF, 2001, BRIT J CANCER, V85, P46, DOI 10.1054/bjoc.2000.1825
   Gillison ML, 2008, JNCI-J NATL CANCER I, V100, P407, DOI 10.1093/jnci/djn025
   GOEDDE HW, 1992, HUM GENET, V88, P344
   GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Hansson BG, 2005, ACTA OTO-LARYNGOL, V125, P1337, DOI 10.1080/00016480510043945
   Harris SL, 2010, HEAD NECK-J SCI SPEC, V32, P499, DOI 10.1002/hed.21220
   Hayes RB, 1999, CANCER CAUSE CONTROL, V10, P27, DOI 10.1023/A:1008876115797
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hobbs CGL, 2006, CLIN OTOLARYNGOL, V31, P259, DOI 10.1111/j.1749-4486.2006.01246.x
   KELLER AZ, 1965, AM J PUBLIC HEALTH N, V55, P1578, DOI 10.2105/AJPH.55.10.1578
   Macfarlane TV, 2010, CANCER CAUSE CONTROL, V21, P2213, DOI 10.1007/s10552-010-9641-3
   MAIER H, 1992, CLIN INVESTIGATOR, V70, P320
   MAIER H, 1994, OTOLARYNG HEAD NECK, V110, P168, DOI 10.1177/019459989411000205
   Matsuo K, 2012, CANCER EPIDEM BIOMAR, V21, P1986, DOI 10.1158/1055-9965.EPI-12-0662
   Menvielle G, 2004, EUR J CANCER PREV, V13, P165, DOI 10.1097/cej.0000130017.93310.76
   Menvielle G, 2007, INT J CANCER, V121, P649, DOI 10.1002/ijc.22721
   MERLETTI F, 1989, CANCER RES, V49, P4919
   Montero PH, 2012, ARCH OTOLARYNGOL, V138, P817, DOI 10.1001/archoto.2012.1792
   OREGGIA F, 1991, CANCER, V67, P180, DOI 10.1002/1097-0142(19910101)67:1<180::AID-CNCR2820670130>3.0.CO;2-R
   Oze I, 2010, CANCER SCI, V101, P1875, DOI 10.1111/j.1349-7006.2010.01599.x
   PAULY JL, 1995, CANCER RES, V55, P253
   Peters ES, 2006, CANCER EPIDEM BIOMAR, V15, P2196, DOI 10.1158/1055-9965.EPI-06-0503
   Radoi L, 2013, EUR J CANCER PREV, V22, P268, DOI 10.1097/CEJ.0b013e3283592cce
   Rethman Michael P, 2012, Tex Dent J, V129, P491
   Rosenquist K, 2005, ACTA OTO-LARYNGOL, V125, P991, DOI 10.1080/00016480510043440
   Schlecht NF, 2001, CANCER CAUSE CONTROL, V12, P579, DOI 10.1023/A:1011226520220
   Schwartz SM, 2001, CANCER EPIDEM BIOMAR, V10, P1137
   Smith EM, 2012, J ONCOL, V2012, DOI DOI 10.1155/2012/571862
   Sobus SL, 2014, CANCER-AM CANCER SOC, V120, P3617, DOI 10.1002/cncr.28904
   Subapriya R, 2007, EUR J CANCER PREV, V16, P251, DOI 10.1097/01.cej.0000228402.53106.9e
   TUYNS AJ, 1988, INT J CANCER, V41, P483, DOI 10.1002/ijc.2910410403
   Vlajinac HD, 2006, CANCER DETECT PREV, V30, P152, DOI 10.1016/j.cdp.2006.02.001
   WYNDER EL, 1957, BRIT MED J, V1, P1137, DOI 10.1136/bmj.1.5028.1137
   WYNDER EL, 1956, CANCER-AM CANCER SOC, V9, P86, DOI 10.1002/1097-0142(195601/02)9:1<86::AID-CNCR2820090108>3.0.CO;2-6
   Yokoyama A, 2001, CARCINOGENESIS, V22, P433, DOI 10.1093/carcin/22.3.433
   Zavras AI, 2001, ORAL ONCOL, V37, P28, DOI 10.1016/S1368-8375(00)00060-9
   ZHENG TZ, 1990, CANCER CAUSE CONTROL, V1, P173, DOI 10.1007/BF00053170
   Znaor A, 2003, INT J CANCER, V105, P681, DOI 10.1002/ijc.11114
NR 58
TC 2
Z9 2
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 13
PY 2015
VL 10
IS 4
AR e0124045
DI 10.1371/journal.pone.0124045
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CF8XK
UT WOS:000352845100234
PM 25875934
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xiao, Y
   Liu, YY
   Huang, SH
   Sun, XM
   Tang, Y
   Cheng, JR
   Wang, T
   Li, F
   Kuang, YX
   Luo, R
   Zhao, XS
AF Xiao, Ya
   Liu, Yanyan
   Huang, Shaohui
   Sun, Xiaomin
   Tang, Yang
   Cheng, Jingru
   Wang, Tian
   Li, Fei
   Kuang, Yuxiang
   Luo, Ren
   Zhao, Xiaoshan
TI The Efficacy of Shugan Jianpi Zhixie Therapy for Diarrhea-Predominant
   Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Double-Blind,
   Placebo-Controlled Trials
SO PLOS ONE
LA English
DT Article
ID CHINESE HERBAL MEDICINE; QUALITY-OF-LIFE; ALTERNATIVE MEDICINE; RESPONSE
   RATE; RISK-FACTORS; COMPLEMENTARY
AB Background
   Shugan Jianpi Zhixie therapy (SJZT) has been widely used to treat diarrhea-predominant irritable bowel syndrome (IBS-D), but the results are still controversial. A meta-analysis of randomized, double-blind, placebo-controlled trials was performed to assess the efficacy and tolerability of SJZT for IBS-D.
   Methods
   The MEDLINE, EMBASE, Cochrane Library, the China National Knowledge Infrastructure database, the Chinese Biomedical Literature database and the Wanfang database were searched up to June 2014 with no language restrictions. Summary estimates, including 95% confidence intervals (CI), were calculated for global symptom improvement, abdominal pain improvement, and Symptom Severity Scale (BSS) score.
   Results
   Seven trials (N=954) were included. The overall risk of bias assessment was low. SJZT showed significant improvement for global symptom compared to placebo (RR 1.61; 95% CI 1.24, 2.10; P = 0.0004; therapeutic gain = 33.0%; number needed to treat (NNT) = 3.0). SJZT was significantly more likely to reduce overall BSS score (SMD-0.67; 95% CI 0.94, -0.40; P < 0.00001) and improve abdominal pain (RR 4.34; 95% CI 2.64, 7.14; P < 0.00001) than placebo. The adverse events of SJZT were no different from those of placebo.
   Conclusions
   This meta-analysis suggests that SJZT is an effective and safe therapy option for patients with IBS-D. However, due to the high clinical heterogeneity and small sample size of the included trials, further standardized preparation, large-scale and rigorously designed trials are needed.
C1 [Xiao, Ya; Tang, Yang; Cheng, Jingru; Wang, Tian; Li, Fei; Luo, Ren] Southern Med Univ, Nanfang Hosp, Dept Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China.
   [Xiao, Ya; Huang, Shaohui; Sun, Xiaomin; Tang, Yang; Cheng, Jingru; Wang, Tian; Li, Fei; Luo, Ren; Zhao, Xiaoshan] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China.
   [Liu, Yanyan] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Rheumat Dis, Guangzhou 510405, Guangdong, Peoples R China.
   [Kuang, Yuxiang] Guangdong Prov Hosp TCM, Digest Dept, Guangzhou 510120, Guangdong, Peoples R China.
RP Zhao, XS (reprint author), Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China.
EM zhaoxs0609@163.com
FU NSFC-Guangdong joint fund [U1132001]; National Science Foundation of
   China [81173146, 81373707, 81403447]; State Administration of
   Traditional Chinese Medicine [JDZX2012013]; Major State Basic Research
   Development Program of China (973 Program) [2013CB531700]; Guangdong
   Provincial Department of Science and Technology and Guangdong Provincial
   Academy of Traditional Chinese Medicine joint fund [2011B032200004,
   2012A032500004]; Guangdong Provincial Department of Science and
   Technology fund [2011B031700018]; China Postdoctoral Science Foundation
   [2014M552187]; Administration of Traditional Chinese Medicine of
   Guangdong Province, China [2012KT1145]
FX This work was supported by the NSFC-Guangdong joint fund (Nos.
   U1132001), the National Science Foundation of China (Nos. 81173146,
   81373707 and 81403447), the State Administration of Traditional Chinese
   Medicine (Nos. JDZX2012013), the Major State Basic Research Development
   Program of China (973 Program Nos. 2013CB531700), the Guangdong
   Provincial Department of Science and Technology and Guangdong Provincial
   Academy of Traditional Chinese Medicine joint fund (Nos. 2011B032200004
   and 2012A032500004), the Guangdong Provincial Department of Science and
   Technology fund (Nos. 2011B031700018), China Postdoctoral Science
   Foundation (Nos. 2014M552187), and Administration of Traditional Chinese
   Medicine of Guangdong Province, China (Nos. 2012KT1145). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alonso-Coello P, 2006, BRIT J SURG, V93, P909, DOI 10.1002/bjs.5378
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bensoussan A, 1998, JAMA-J AM MED ASSOC, V280, P1585, DOI 10.1001/jama.280.18.1585
   Bian ZX, 2006, J ALTERN COMPLEM MED, V12, P401, DOI 10.1089/acm.2006.12.401
   Brandt LJ, 2009, AM J GASTROENTEROL, V104, pS1, DOI 10.1038/ajg.2008.122
   Cai LJ, 2013, CHIN ARCH TRAD CHIN, V5, P1097
   Chang JY, 2010, TRENDS PHARMACOL SCI, V31, P326, DOI 10.1016/j.tips.2010.04.008
   Chen DF, 2010, CHIN J DIG, V30, P327
   Chinese Society of Digestive Diseases and Chinese Association of Chinese Medicine, 2010, CHINA J TRAD CHIN ME, V25, P1062
   Chitkara DK, 2008, AM J GASTROENTEROL, V103, P765, DOI 10.1111/j.1572-0241.2007.01722.x
   Cong J, 2013, WORLD CHIN J DIGEST, V21, P1234
   Dean BB, 2005, AM J MANAG CARE, V11, pS17
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dorn SD, 2007, NEUROGASTROENT MOTIL, V19, P630, DOI 10.1111/j.1365-2982.2007.00937.x
   El-Serag HB, 2002, ALIMENT PHARM THER, V16, P1171, DOI 10.1046/j.1365-2036.2002.01290.x
   Ford AC, 2010, ALIMENT PHARM THER, V32, P144, DOI 10.1111/j.1365-2036.2010.04328.x
   Ford AC, 2009, AM J GASTROENTEROL, V104, P1831, DOI 10.1038/ajg.2009.223
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hussain Z, 2006, ALIMENT PHARM THER, V23, P465, DOI 10.1111/j.1365-2036.2006.02776.x
   Karantanos T, 2010, GUT PATHOG, V2, DOI 10.1186/1757-4749-2-3
   Leung WK, 2006, AM J GASTROENTEROL, V101, P1574, DOI 10.1111/j.1572-0241.2006.00576.x
   Li YM, 2014, CHIN J INTEGR TRAD W, V22, P1
   Li YM, 2010, SHANGHAI J TRAD CHIN, V44, P33
   Lin JZ, 2010, CHINESE J CHEM ENG, V18, P1, DOI 10.1016/S1004-9541(08)60315-8
   Lin M, 2012, SHANGHAI J TCM, V46, P82
   Liu J., 2006, COCHRANE DB SYST REV, V25
   Lovell RM, 2012, CLIN GASTROENTEROL H, V10, P712, DOI 10.1016/j.cgh.2012.02.029
   Pogue JM, 1997, CONTROL CLIN TRIALS, V18, P580, DOI 10.1016/S0197-2456(97)00051-2
   Rapps N, 2008, J PSYCHOSOM RES, V64, P599, DOI 10.1016/j.jpsychores.2008.02.018
   Ringel Y, 2013, AM J PHYSIOL-GASTR L, V305, pG529, DOI 10.1152/ajpgi.00207.2012
   Saito YA, 2002, AM J GASTROENTEROL, V97, P1910
   Sands BE, 2009, DIGEST DIS, V27, P68, DOI 10.1159/000268123
   Shi J, 2008, WORLD J GASTROENTERO, V14, P454, DOI 10.3748/wjg.14.454
   Sung JJY, 2004, ALIMENT PHARM THER, V20, P1205, DOI 10.1111/j.1365-2036.2004.02242.x
   TALLEY NJ, 1995, GASTROENTEROLOGY, V109, P1736, DOI 10.1016/0016-5085(95)90738-6
   Tang XD, 2011, P OFC, P1
   Tornblom H, 2002, GASTROENTEROLOGY, V123, P1972, DOI 10.1053/gast.2002.37059
   Xiao HT, 2015, AM J CHINESE MED, V43, P1, DOI 10.1142/S0192415X15500019
NR 38
TC 8
Z9 9
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 8
PY 2015
VL 10
IS 4
AR e0122397
DI 10.1371/journal.pone.0122397
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CF3WA
UT WOS:000352478400067
PM 25853241
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Shi, H
   Chen, X
   Lu, C
   Gu, CM
   Jiang, HW
   Meng, RW
   Niu, X
   Huang, YX
   Lu, MX
AF Shi, Hao
   Chen, Xiong
   Lu, Cheng
   Gu, Changmei
   Jiang, Hongwei
   Meng, RuiWei
   Niu, Xun
   Huang, Yangxin
   Lu, Meixia
TI Association between P16(INK4a) Promoter Methylation and HNSCC: A
   Meta-Analysis of 21 Published Studies
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; NECK-CANCER PATIENTS;
   HUMAN-PAPILLOMAVIRUS; QUANTITATIVE-EVALUATION; GASTRIC-CANCER; HEAD;
   P16; HYPERMETHYLATION; DNA
AB Background
   The p16(INK4a) is an important tumor suppressor gene (TSG) and aberrant methylation of promoter is known to be a major inactivation mechanism of the tumor suppressor and tumor-related genes. Aberrant TSG methylation was considered an important epigenetic silencing mechanism in the progression of head and neck squamous cell carcinoma (HNSCC). However, some studies have reported differences in the methylation frequencies of P16(INK4a) promoter between cancer and the corresponding control group. Therefore, we conducted a meta-analysis to better identify the association.
   Methods
   PubMed, Ovid, ISI Web of Science, and EMBASE were searched to identify eligible studies to evaluate the association of p16(INK4a) promoter methylation and HNSCC. Odds ratio (ORs) and 95% confidence intervals (95% CI) were calculated to evaluate the strength of association between p16(INK4a) promoter methylation and HNSCC.
   Results
   A total of twenty-one studies with 1155 cases and 1017 controls were included in the meta-analysis. The frequencies of p16(INK4a) promoter methylation in the cancer group were significantly higher than those in the control group (cancer group: median: 46.67%, range = 7.84%-95.12%; control group: median: 18.37%, range = 0-83.33%; respectively). The pooled odds ratio was 3.37 (95% CI = 2.32-4.90) in the cancer group versus the corresponding control group under the random-effects model.
   Conclusion
   This meta-analysis of 21 published studies identified that aberrant methylation of p16(INK4a) promoter was found to be significantly associated with HNSCC.
C1 [Shi, Hao; Gu, Changmei; Jiang, Hongwei; Meng, RuiWei; Lu, Meixia] Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Epidemiol & Biostat, Tongji Med Coll, Wuhan 430074, Hubei, Peoples R China.
   [Shi, Hao; Gu, Changmei; Jiang, Hongwei; Meng, RuiWei; Lu, Meixia] Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, Minist Educ,Key Lab Environm & Hlth, Wuhan 430074, Hubei, Peoples R China.
   [Chen, Xiong; Niu, Xun] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Otolaryngol, Wuhan 430074, Hubei, Peoples R China.
   [Lu, Cheng] Nanchang Univ, Coll Med, Dept Anat, Nanchang, Jiangxi, Peoples R China.
   [Huang, Yangxin] Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Publ Hlth, Tampa, FL USA.
RP Lu, MX (reprint author), Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Epidemiol & Biostat, Tongji Med Coll, Wuhan 430074, Hubei, Peoples R China.
EM mlu@hust.edu.cn
FU National Natural Science Foundation of China [81373092]
FX This work was supported by the National Natural Science Foundation of
   China (81373092).
CR Ai LB, 2003, MODERN PATHOL, V16, P944, DOI 10.1097/01.MP.0000085760.74313.DD
   [Anonymous], 1979, PSYCHOL BULL, P638
   Askari M, 2013, MOL BIOL REP, V40, P4921, DOI 10.1007/s11033-013-2592-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Begum S, 2005, CLIN CANCER RES, V11, P5694, DOI 10.1158/1078-0432.CCR-05-0587
   Belinsky SA, 2005, CLIN CANCER RES, V11, P6505, DOI 10.1158/1078-0432.CCR-05-0625
   Bhatia V, 2014, BIOMED RES INT, DOI 10.1155/2014/248419
   Chen Y, 2013, EUR J HUM GENET, V21, P929, DOI 10.1038/ejhg.2012.281
   Dang J, 2013, J ORAL PATHOL MED, V42, P315, DOI 10.1111/jop.12012
   Demokan S, 2012, HEAD NECK-J SCI SPEC, V34, P1470, DOI 10.1002/hed.21949
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Naggar AK, 1999, HUM PATHOL, V30, P1013, DOI 10.1016/S0046-8177(99)90217-4
   Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011
   Ghosh A, 2009, J PATHOL, V217, P408, DOI 10.1002/path.2464
   Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hsu LS, 2006, ONCOL REP, V15, P507
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kaur J, 2010, INT J CANCER, V127, P2367, DOI 10.1002/ijc.25377
   Kis A, 2014, PATHOL ONCOL RES, V20, P923, DOI 10.1007/s12253-014-9775-9
   Klussmann JP, 2003, AM J PATHOL, V162, P747, DOI 10.1016/S0002-9440(10)63871-0
   Kulkarni V, 2004, ORAL ONCOL, V40, P145, DOI 10.1016/S1368-8375(03)00143-X
   Laytragoon-Lewin N, 2010, ANTICANCER RES, V30, P4643
   Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
   Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197
   Lim AM, 2014, INT J CANCER, V135, P887, DOI 10.1002/ijc.28727
   LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0
   Martone T, 2007, CLIN CANCER RES, V13, P5089, DOI 10.1158/1078-0432.CCR-07-0119
   Maruya SI, 2004, CLIN CANCER RES, V10, P3825, DOI 10.1158/1078-0432.CCR-03-0370
   Mino A, 2006, ONCOL REP, V15, P615
   de Assis LVM, 2014, BBA-REV CANCER, V1845, P232, DOI 10.1016/j.bbcan.2014.01.008
   Nakahara Y, 2001, CANCER LETT, V163, P221, DOI 10.1016/S0304-3835(00)00699-6
   NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0
   O'Regan EM, 2008, HUM PATHOL, V39, P452, DOI 10.1016/j.humpath.2007.08.004
   OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045
   Pande P, 1998, ORAL ONCOL, V34, P396, DOI 10.1016/S1368-8375(98)00024-4
   Piepkorn M, 2000, J AM ACAD DERMATOL, V42, P705, DOI 10.1067/mjd.2000.104687
   Righini CA, 2007, CLIN CANCER RES, V13, P1179, DOI 10.1158/1078-0432.CCR-06-2027
   Rosas SLB, 2001, CANCER RES, V61, P939
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Scully C, 2000, ORAL ONCOL, V36, P256, DOI 10.1016/S1368-8375(00)00007-5
   Shaw RJ, 2006, BRIT J CANCER, V94, P561, DOI 10.1038/sj.bjc.6602972
   Smeets SJ, 2007, INT J CANCER, V121, P2465, DOI 10.1002/ijc.22980
   Song BB, 2013, PAK J MED SCI, V29, P1338
   Steinmann K, 2009, ONCOL REP, V22, P1519, DOI 10.3892/or_00000596
   Su PF, 2010, ORAL ONCOL, V46, P734, DOI 10.1016/j.oraloncology.2010.07.002
   Toyota M, 1999, CANCER RES, V59, P2307
   Weber A, 2003, PATHOL RES PRACT, V199, P391, DOI 10.1078/0344-0338-00435
   Weiss D, 2011, MOL CARCINOGEN, V50, P680, DOI 10.1002/mc.20798
   Wong TS, 2003, EUR J CANCER, V39, P1881, DOI 10.1016/S0959-8049(03)00428-3
   Wong YK, 2011, J DENT SCI, V6, P158, DOI 10.1016/j.jds.2011.05.006
   Wu CL, 1999, GENE CHROMOSOME CANC, V25, P16, DOI 10.1002/(SICI)1098-2264(199905)25:1<16::AID-GCC3>3.3.CO;2-U
   Yates DR, 2006, ONCOGENE, V25, P1984, DOI 10.1038/sj.onc.1209209
NR 54
TC 13
Z9 14
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2015
VL 10
IS 4
AR UNSP e0122302
DI 10.1371/journal.pone.0122302
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CE9BS
UT WOS:000352139000092
PM 25835498
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, N
   He, YL
   Pang, LJ
   Zou, H
   Liu, CX
   Zhao, J
   Hu, JM
   Zhang, WJ
   Qi, Y
   Li, F
AF Wang, Ning
   He, Yong-Lai
   Pang, Li-Juan
   Zou, Hong
   Liu, Chun-Xia
   Zhao, Jin
   Hu, Jian-Ming
   Zhang, Wen-Jie
   Qi, Yan
   Li, Feng
TI Down-Regulated E-Cadherin Expression Is Associated with Poor Five-Year
   Overall Survival in Bone and Soft Tissue Sarcoma: Results of a
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; SYNOVIAL SARCOMA; ADHESION MOLECULES;
   PROGNOSTIC VALUE; EWINGS-SARCOMA; OVARIAN-CANCER; BETA-CATENIN;
   LEIOMYOSARCOMAS; OSTEOSARCOMA; DETERMINANT
AB Purpose
   To conduct a meta-analysis to evaluate the prognostic role of E-cadherin expression in bone and soft tissue sarcomas.
   Methods
   The PubMed, EMBASE, and Web of Science databases were searched using terms related to E-cadherin, sarcoma, and prognosis for all articles published in English before March 2014. Pooled effect was calculated from the available data to evaluate the association between negative E-cadherin expression and 5-year overall survival and tumor clinicopathological features in sarcoma patients. Pooled odds ratios (OR) and risk ratios (RR) with 95% confidence intervals (CI) were calculated using a fixed-effects model.
   Result
   Eight studies met the selection criteria and reported on 812 subjects. A total of 496 subjects showed positive E-cadherin expression (59.9%). Negative E-cadherin expression in bone and soft tissue sarcomas was correlated with lower 5-year overall survival (OR = 3.831; 95% CI: 2.246-6.534), and was associated with higher clinical stage (RR = 1.446; 95% CI: 1.030-2.028) and with male sex (RR = 0.678; 95% CI: 0.493-0.933).
   Conclusion
   In the E-cadherin negative group, 5-year overall survival was significantly worse than in the E-cadherin positive group. However, further studies are required to confirm these results.
C1 [Wang, Ning; Pang, Li-Juan; Zou, Hong; Liu, Chun-Xia; Zhao, Jin; Hu, Jian-Ming; Zhang, Wen-Jie; Qi, Yan; Li, Feng] Shihezi Univ, Sch Med, Dept Pathol, Shihezi, Xinjiang, Peoples R China.
   [Wang, Ning; Pang, Li-Juan; Zou, Hong; Liu, Chun-Xia; Zhao, Jin; Hu, Jian-Ming; Zhang, Wen-Jie; Qi, Yan; Li, Feng] Shihezi Univ, Key Labs Xinjiang Endem & Ethn Dis, Shihezi, Xinjiang, Peoples R China.
   [Wang, Ning; Pang, Li-Juan; Zou, Hong; Liu, Chun-Xia; Zhao, Jin; Hu, Jian-Ming; Zhang, Wen-Jie; Qi, Yan; Li, Feng] Chinese Minist Educ, Shihezi, Xinjiang, Peoples R China.
   [He, Yong-Lai] Shihezi Univ, Sch Med, Affiliated Hosp 1, Dept ICU Intens Care, Shihezi, Xinjiang, Peoples R China.
RP Qi, Y (reprint author), Shihezi Univ, Sch Med, Dept Pathol, Shihezi, Xinjiang, Peoples R China.
EM qiyanyan-2004@126.com; lifeng7855@126.com
FU National Natural Science Foundation of China [81202120]; Outstanding
   Youth Science and Technology Talent Cultivation Plan of Shihezi
   University [2013ZRKXJQ05]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (no. 81202120), and Outstanding Youth Science and
   Technology Talent Cultivation Plan of Shihezi University (2013ZRKXJQ05).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ansenberger K, 2009, GYNECOL ONCOL, V113, P362, DOI 10.1016/j.ygyno.2009.02.011
   Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129
   Chen HP, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-16
   Dian D, 2011, ARCH GYNECOL OBSTET, V284, P437, DOI 10.1007/s00404-010-1657-0
   Gogou P, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-28
   Gogou PN, 2009, CLIN TRANSL ONCOL, V11, P548, DOI 10.1007/s12094-009-0401-3
   He X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070858
   Irwig L, 1998, BRIT MED J, V316, P470
   Izumi T, 2007, AM J SURG PATHOL, V31, P85, DOI 10.1097/01.pas.0000213413.33558.85
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kang H, 2011, ANN SURG ONCOL, V18, P711, DOI 10.1245/s10434-010-1338-z
   Koo JS, 2009, JPN J CLIN ONCOL, V39, P560, DOI 10.1093/jjco/hyp065
   Luo SL, 2014, TUMOR BIOL, V35, P5533, DOI 10.1007/s13277-014-1728-0
   Machado I, 2012, VIRCHOWS ARCH, V461, P333, DOI 10.1007/s00428-012-1288-x
   Peng HL, 2012, ASIAN PAC J CANCER P, V13, P2003, DOI 10.7314/APJCP.2012.13.5.2003
   PRESANT CA, 1986, J CLIN ONCOL, V4, P1658, DOI 10.1200/JCO.1986.4.11.1658
   Qi Y, 2013, INT J CLIN EXP PATHO, V6, P2787
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Saito T, 2000, J PATHOL, V192, P342, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH705>3.0.CO;2-R
   Saito T, 2001, PATHOL INT, V51, P532, DOI 10.1046/j.1440-1827.2001.01232.x
   Saito T, 2001, AM J PATHOL, V159, P2117, DOI 10.1016/S0002-9440(10)63063-5
   Sampson VB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102041
   Sato H, 1999, HUM PATHOL, V30, P1344, DOI 10.1016/S0046-8177(99)90066-7
   Sekar P, 2014, J ONCOL, DOI 10.1155/2014/702527
   Skubitz KM, 2007, MAYO CLIN PROC, V82, P1409, DOI 10.4065/82.11.1409
   Smith MEF, 1998, HISTOPATHOLOGY, V33, P425, DOI 10.1046/j.1365-2559.1998.00544.x
   Taylor BS, 2011, NAT REV CANCER, V11, P541, DOI 10.1038/nrc3087
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tian W, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0401-y
   Wang SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101330
   Wardelmann E, 2010, ANN ONCOL, V21, P265, DOI 10.1093/annonc/mdq381
   Wisanuyotin T, 2013, ASIA-PAC J CLIN ONCO, V9, P80, DOI 10.1111/j.1743-7563.2012.01563.x
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yang JL, 2010, MOL CELL PROTEOMICS, V9, P2405, DOI 10.1074/mcp.M110.000240
   Yin K, 2012, MED ONCOL, V29, P3449, DOI 10.1007/s12032-012-0317-6
   Yoo J, 2002, ARCH PATHOL LAB MED, V126, P33
NR 38
TC 12
Z9 12
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 30
PY 2015
VL 10
IS 3
AR e0121448
DI 10.1371/journal.pone.0121448
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CE9AD
UT WOS:000352134700108
PM 25822802
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Sun, JW
   Zhao, LG
   Yang, Y
   Ma, X
   Wang, YY
   Xiang, YB
AF Sun, Jiang-Wei
   Zhao, Long-Gang
   Yang, Yang
   Ma, Xiao
   Wang, Ying-Ying
   Xiang, Yong-Bing
TI Obesity and Risk of Bladder Cancer: A Dose-Response Meta-Analysis of 15
   Cohort Studies
SO PLOS ONE
LA English
DT Article
ID BODY-MASS INDEX; GROWTH-FACTOR-I; PHYSICAL-ACTIVITY; URINARY-BLADDER;
   PLASMA-LEVELS; SWEDISH MEN; WOMEN; OVERWEIGHT; ASSOCIATIONS; POPULATION
AB Background
   Epidemiological studies have reported inconsistent association between obesity and risk of bladder cancer, and the dose-response relationship between them has not been clearly defined.
   Methods
   We carried out a meta-analysis to summarize available evidence from epidemiological studies on this point. Relevant articles were identified by searching the PubMed and Web of Science databases through September 30, 2014. We pooled the relative risks from individual studies using random-effect model, and the dose-response relationship was estimated by using restricted cubic spline model.
   Results
   Fifteen cohort studies with 38,072 bladder cancer cases among 14,201,500 participants were included. Compared to normal weight, the pooled relative risks and corresponding 95% confidence intervals of bladder cancer were 1.07(1.01-1.14) and 1.10(1.06-1.14) for preobese and obesity, with moderate (I-2 = 37.6%, P = 0.029) and low (I-2 = 15.5%, P = 0.241) heterogeneities between studies, respectively. In a dose-response meta-analysis, body mass index (BMI) was associated with bladder cancer risk in a linear fashion (Pnon-linearity = 0.467) and the risk increased by 4.2% for each 5 kg/m(2) increase. No significant publication bias was found (P = 0.912 for Begg's test, P = 0.712 for Egger's test).
   Conclusions
   Findings from this dose-response meta-analysis suggest obesity is associated with linear-increased risk of bladder cancer.
C1 [Sun, Jiang-Wei; Zhao, Long-Gang; Yang, Yang; Ma, Xiao; Wang, Ying-Ying; Xiang, Yong-Bing] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, State Key Lab Oncogene & Related Genes,Shanghai C, Shanghai, Peoples R China.
   [Sun, Jiang-Wei; Zhao, Long-Gang; Yang, Yang; Ma, Xiao; Wang, Ying-Ying; Xiang, Yong-Bing] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Epidemiol,Shanghai Canc Inst, Shanghai, Peoples R China.
RP Xiang, YB (reprint author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, State Key Lab Oncogene & Related Genes,Shanghai C, Shanghai, Peoples R China.
EM ybxiang@shsci.org
FU Shanghai Health Bureau Key Disciplines and Specialties Foundation
FX This work was supported by the fund of Shanghai Health Bureau Key
   Disciplines and Specialties Foundation. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ALBANES D, 1987, AM J PUBLIC HEALTH, V77, P439, DOI 10.2105/AJPH.77.4.439
   Amadou A, 2013, OBES REV, V14, P665, DOI 10.1111/obr.12028
   Andreotti G, 2010, CANCER CAUSE CONTROL, V21, P1759, DOI 10.1007/s10552-010-9603-9
   Andrews B, 2002, J UROLOGY, V167, P1475, DOI 10.1016/S0022-5347(05)65348-7
   [Anonymous], 2000, OB PREV MAN GLOB EP
   Aune D, 2012, ANN ONCOL, V23, P843, DOI 10.1093/annonc/mdr398
   Bachir BG, 2012, EXPERT REV ANTICANC, V12, P1499, DOI [10.1586/era.12.140, 10.1586/ERA.12.140]
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhaskaran K, 2014, LANCET, V384, P755, DOI 10.1016/S0140-6736(14)60892-8
   Bianchini F, 2002, LANCET ONCOL, V3, P565, DOI 10.1016/S1470-2045(02)00849-5
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Cancer IAfRo, 2013, GLOB 2012 EST CANC I
   Cantwell MM, 2006, INT J CANCER, V119, P2398, DOI 10.1002/ijc.22175
   Crosbie EJ, 2010, CANCER EPIDEM BIOMAR, V19, P3119, DOI 10.1158/1055-9965.EPI-10-0832
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   Desquilbet L, 2010, STAT MED, V29, P1037, DOI 10.1002/sim.3841
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   GORDON T, 1975, AM HEART J, V90, P322, DOI 10.1016/0002-8703(75)90320-8
   Haggstrom C, 2011, INT J CANCER, V128, P1890, DOI 10.1002/ijc.25521
   Harriss DJ, 2009, COLORECTAL DIS, V11, P547, DOI 10.1111/j.1463-1318.2009.01766.x
   Heikkila K, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f165
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hilmy M, 2005, BRIT J CANCER, V92, P625, DOI 10.1038/sj.bjc.6602406
   Holick CN, 2007, INT J CANCER, V120, P140, DOI 10.1002/ijc.22142
   Il'yasova D, 2005, CANCER CAUSE CONTROL, V16, P383, DOI 10.1007/s10552-004-5025-x
   IWAMURA M, 1993, UROL RES, V21, P27, DOI 10.1007/BF00295188
   Jackson D, 2010, STAT MED, V29, P1282, DOI 10.1002/sim.3602
   Jee SH, 2008, INT J CANCER, V123, P1892, DOI 10.1002/ijc.23719
   Koebnick C, 2008, CANCER EPIDEM BIOMAR, V17, P1214, DOI 10.1158/1055-9965.EPI-08-0026
   KUSKOWSKAWOLK A, 1989, INT J OBESITY, V13, P441
   Larsson SC, 2008, EUR J CANCER, V44, P2655, DOI 10.1016/j.ejca.2008.07.012
   Liu Q, 2009, COMPUT STAT DATA AN, V53, P4157, DOI 10.1016/j.csda.2009.05.001
   Nagano J, 2000, INT J CANCER, V86, P132, DOI 10.1002/(SICI)1097-0215(20000401)86:1<132::AID-IJC21>3.0.CO;2-M
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Orsini N, 2012, AM J EPIDEMIOL, V175, P66, DOI 10.1093/aje/kwr265
   Pelucchi C, 2006, NAT CLIN PRACT UROL, V3, P327, DOI 10.1038/ncpuro0510
   Probst-Hensch NM, 2003, CANCER EPIDEM BIOMAR, V12, P739
   Qin Q, 2013, ASIAN PAC J CANCER P, V14, P3117, DOI 10.7314/APJCP.2013.14.5.3117
   Rapp K, 2005, BRIT J CANCER, V93, P1062, DOI 10.1038/sj.bjc.6602819
   Reeves GK, 2007, BRIT MED J, V335, P1134, DOI 10.1136/bmj.39367.495995.AE
   Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009
   Samanic C, 2004, CANCER CAUSE CONTROL, V15, P35, DOI 10.1023/B:CACO.0000016573.79453.ba
   Samanic C, 2006, CANCER CAUSE CONTROL, V17, P901, DOI 10.1007/s10552-006-0023-9
   Smith M, 2008, INT J CANCER, V122, P1604, DOI 10.1002/ijc.23198
   Song X, 2014, EUR J EPIDEMIOL, V29, P477, DOI 10.1007/s10654-014-9934-z
   Tripathi A, 2002, CANCER, V95, P2316, DOI 10.1002/cncr.10975
   Vainio H, 2002, WEIGHT CONTROL PHYS
   Wang FR, 2014, INT J CANCER, V135, P1673, DOI 10.1002/ijc.28813
   Zhang YY, 2014, INT J BIOL MARKER, V29, pE21, DOI 10.5301/jbm.5000047
   Zhao H, 2003, J UROLOGY, V169, P714, DOI 10.1097/01.ju.0000036380.10325.2a
NR 50
TC 36
Z9 37
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 24
PY 2015
VL 10
IS 3
AR e0119313
DI 10.1371/journal.pone.0119313
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CH2XV
UT WOS:000353889600022
PM 25803438
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, Y
   Zhang, F
   Skrip, L
   Lei, H
   Luo, SX
   Lu, K
   Hu, DY
AF Yang, Yuan
   Zhang, Fan
   Skrip, Laura
   Lei, Han
   Luo, Suxin
   Lu, Kai
   Hu, Dayi
TI Lack of an Association between Angiotensin Receptor Blocker Based
   Therapy and Increased Risk of Cancer: Evidence from Large Observational
   Studies
SO PLOS ONE
LA English
DT Article
ID HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CANDESARTAN COMBINATION THERAPY;
   LONG-TERM USE; LUNG-CANCER; CELL-GROWTH; INHIBITION; SYSTEM;
   METAANALYSIS; TRIAL; GEMCITABINE
AB Background A previous meta-analysis of randomized controlled studies that were not designed to investigate cancer as a primary outcome suggested that ARB-based therapy is associated with increased risk of cancer; however, results of recent observational studies considering the association have been contradictory. This study sought to evaluate the association between angiotensin receptor blocker (ARB)-based therapy and risk of cancer by conducting a meta-analysis of observational studies.
   Methods Relevant articles published before February 2014 were identified by searching PubMed and the Cochrane Library. Pooled relative risks (RRs) were determined using a random effects model and were used to assess the strength of association between use of ARB-based therapy and risk of cancer.
   Results Six retrospective cohort studies involving a total of 3,827,109 participants and four case-control studies involving a total of 193,029 cases were included. The present study found that ARB-based therapy was not significantly associated with an increased risk of cancer (RR = 0.87, 95% CI: [0.75, 1.01]). However, an analysis including only cohort studies suggested a significantly decreased risk of cancer among individuals with any history of ARB use as compared to those with no history of ARB use (RR = 0.80, 95% CI: [0.55, 0.95]); no significant association was found between ARB use and risk of cancer when the case-control studies were separately considered (RR = 1.03, 95% CI: [0.93, 1.13]). Subgroup analyses showed that use of ARB-based therapy was associated with decreased risk of lung cancer (RR = 0.81, 95% CI: [0.69, 0.94]); however, no significant associations were found with the other cancer sites investigated. Furthermore, no association was observed upon adjustment by type of ARB drug. No publication bias was detected.
   Conclusion Overall, ARB-based therapy was not associated with increased risk of cancer. However, its use may be related to decreased incidence of lung cancer; this finding should be considered carefully and confirmed with further studies.
C1 [Yang, Yuan; Lei, Han; Luo, Suxin; Lu, Kai; Hu, Dayi] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiovasc Med, Chongqing, Peoples R China.
   [Zhang, Fan] Chongqing Med Univ, Sch Publ Hlth & Hlth Management, Chongqing, Peoples R China.
   [Skrip, Laura] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
RP Hu, DY (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiovasc Med, Chongqing, Peoples R China.
EM ebm_cq@126.com
FU National Key Clinical Specialties Construction Program of China
FX The work was supported by National Key Clinical Specialties Construction
   Program of China.
CR Azoulay L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050893
   Bangalore S, 2011, LANCET ONCOL, V12, P65, DOI 10.1016/S1470-2045(10)70260-6
   BATRA VK, 1994, CANCER LETT, V76, P19, DOI 10.1016/0304-3835(94)90129-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhaskaran K, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2697
   Chang CH, 2011, J CLIN ONCOL, V29, P3001, DOI 10.1200/JCO.2011.35.1908
   Chiang YY, 2014, J CLIN HYPERTENS, V16, P27, DOI 10.1111/jch.12228
   Chin HJ, 2011, J KOREAN MED SCI, V26, P59, DOI 10.3346/jkms.2011.26.1.59
   Deshayes F, 2005, TRENDS ENDOCRIN MET, V16, P293, DOI 10.1016/j.tem.2005.07.009
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fujita M, 2005, CARCINOGENESIS, V26, P271, DOI 10.1093/carcin/bgh324
   Gallagher PE, 2004, CARCINOGENESIS, V25, P2045, DOI 10.1093/carcin/bgh236
   Hallas J, 2012, BRIT J CLIN PHARMACO, V74, P180, DOI 10.1111/j.1365-2125.2012.04170.x
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Huang CC, 2011, AM J CARDIOL, V107, P1028, DOI 10.1016/j.amjcard.2010.11.026
   Kim ST, 2012, ONCOLOGY-BASEL, V83, P354, DOI 10.1159/000337979
   Kinoshita J, 2009, INT J ONCOL, V34, P1573, DOI 10.3892/ijo_00000287
   Koomen ER, 2009, CANCER EPIDEMIOL, V33, P391, DOI 10.1016/j.canep.2009.10.005
   Kosaka T, 2010, PROSTATE, V70, P162, DOI 10.1002/pros.21049
   Makar GA, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt374
   Matsuyama M, 2010, EXP THER MED, V1, P301, DOI 10.3892/etm_00000046
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Nakai Y, 2010, BRIT J CANCER, V103, P1644, DOI 10.1038/sj.bjc.6605955
   Nakai Y, 2013, INVEST NEW DRUG, V31, P1294, DOI 10.1007/s10637-013-9972-5
   Nakai Y, 2012, CANCER SCI, V103, P1489, DOI 10.1111/j.1349-7006.2012.02311.x
   Overton RC, 1998, PSYCHOL METHODS, V3, P354, DOI 10.1037/1082-989X.3.3.354
   Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200
   Pasternak B, 2011, CIRCULATION, V123, P1729, DOI 10.1161/CIRCULATIONAHA.110.007336
   Pickel L, 2010, CANCER BIOL THER, V9, P277, DOI 10.4161/cbt.9.4.10643
   Qian YR, 2013, ONCOL REP, V29, P2408, DOI 10.3892/or.2013.2370
   Rao GA, 2013, J CLIN PHARMACOL, V53, P773, DOI 10.1002/jcph.98
   Rao GA, 2013, J HYPERTENS, V31, P1669, DOI 10.1097/HJH.0b013e3283621ea3
   Sipahi I, 2010, LANCET ONCOL, V11, P627, DOI 10.1016/S1470-2045(10)70106-6
   Sorensen GV, 2013, J CLIN ONCOL, V31, P2265, DOI 10.1200/JCO.2012.43.9190
   Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507
   Sugiura R, 2012, AM J CARDIOL, V109, P576, DOI 10.1016/j.amjcard.2011.09.050
   Teo KK, 2011, J HYPERTENS, V29, P623, DOI 10.1097/HJH.0b013e328344a7de
   Wang KL, 2013, INT J CARDIOL, V167, P2162, DOI 10.1016/j.ijcard.2012.05.096
   WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x
   Wells GA, 2012, NEWCASTLE OTTAWA SCA
   Wilop S, 2009, J CANCER RES CLIN, V135, P1429, DOI 10.1007/s00432-009-0587-3
   Yilmaz MI, 2010, CLIN J AM SOC NEPHRO, V5, P1174, DOI 10.2215/CJN.01110210
   Yoon GJ, 2010, J AM COLL CARDIOL, V56, P1644, DOI 10.1016/j.jacc.2010.07.023
   Yuge K, 2012, ANN SURG ONCOL, V19, P3987, DOI 10.1245/s10434-012-2568-z
   Zhan YM, 2005, J CLIN INVEST, V115, P2508, DOI 10.1172/JCI24403
NR 46
TC 7
Z9 7
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 19
PY 2015
VL 10
IS 3
AR e0119775
DI 10.1371/journal.pone.0119775
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CD9NQ
UT WOS:000351425400105
PM 25790107
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhong, GC
   Wang, Y
   Zhang, Y
   Guo, JJ
   Zhao, Y
AF Zhong, Guochao
   Wang, Yi
   Zhang, Yong
   Guo, Jeff Jianfei
   Zhao, Yong
TI Smoking Is Associated with an Increased Risk of Dementia: A
   Meta-Analysis of Prospective Cohort Studies with Investigation of
   Potential Effect Modifiers
SO PLOS ONE
LA English
DT Article
ID 40-YEAR FOLLOW-UP; ALZHEIMERS-DISEASE; CIGARETTE-SMOKING;
   CARDIOVASCULAR-DISEASE; COGNITIVE IMPAIRMENT; VASCULAR DEMENTIA;
   MENDELIAN RANDOMIZATION; DIAGNOSTIC-CRITERIA; INCIDENT DEMENTIA;
   PHYSICAL-ACTIVITY
AB Background
   Previous studies showed inconsistent results on the association of smoking with all-cause dementia and vascular dementia (VaD), and are limited by inclusion of a small number of studies and unexplained heterogeneity. Our review aimed to assess the risk of all-cause dementia, Alzheimer's disease (AD) and VaD associated with smoking, and to identify potential effect modifiers.
   Methods and Findings
   The PubMed, Embase, Cochrane Library and Psychinfo databases were searched to identify studies that provided risk estimates on smoking and incidence of dementia. A random-effects model was used to yield pooled results. Thirty-seven studies were included. Compared with never smokers, current smokers showed an increased risk of all-cause dementia (risk ratio (RR) 1.30, 95% confidence interval (CI) 1.18-1.45), AD (RR 1.40, 95% CI 1.13-1.73) and VaD (RR 1.38, 95% CI 1.15-1.66). For all-cause dementia, the risk increased by 34% for every 20 cigarettes per day (RR 1.34, 95% CI 1.25-1.43). Former smokers did not show an increased risk of all-cause dementia (RR 1.01, 95% CI 0.96-1.06), AD (RR 1.04, 95% CI 0.96-1.13) and VaD (RR 0.97, 95% CI 0.83-1.13). Subgroup analyses indicated that (1) the significantly increased risk of AD from current smoking was seen only in apolipoprotein E epsilon 4 noncarriers; (2) current smokers aged 65 to 75 years at baseline showed increased risk of all-cause dementia and AD compared to those aged over 75 or under 65 years; and (3) sex, race, study location and diagnostic criteria difference in risk of dementia was not found.
   Conclusions
   Smokers show an increased risk of dementia, and smoking cessation decreases the risk to that of never smokers. The increased risk of AD from smoking is more pronounced in apolipoprotein E epsilon 4 noncarriers. Survival bias and competing risk reduce the risk of dementia from smoking at extreme age.
C1 [Zhong, Guochao; Wang, Yi] Chongqing Med Univ, Coll Clin Med 2, Chongqing, Peoples R China.
   [Zhang, Yong; Zhao, Yong] Chongqing Med Univ, Sch Publ Hlth & Management, Chongqing, Peoples R China.
   [Guo, Jeff Jianfei] Univ Cincinnati, Coll Pharm, Div Pharm Practice & Adm Sci, Cincinnati, OH 45221 USA.
RP Zhao, Y (reprint author), Chongqing Med Univ, Sch Publ Hlth & Management, Chongqing, Peoples R China.
EM yongzhao1970@sina.cn
CR Aggarwal NT, 2006, NEUROEPIDEMIOLOGY, V26, P140, DOI 10.1159/000091654
   Alonso A, 2009, J NEUROL NEUROSUR PS, V80, P1194, DOI 10.1136/jnnp.2009.176818
   Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047
   Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116
   *ASS AP, 1994, DIAGN STAT MAN MENT
   Association AP, 1987, DIAGN STAT MAN MENT
   Batty GD, 2014, J NEGAT RESULTS BIOM, V13, DOI 10.1186/1477-5751-13-8
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beydoun MA, 2008, AM J EPIDEMIOL, V168, P1179, DOI 10.1093/aje/kwn229
   Beydoun MA, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-643
   Bowen ME, 2012, AM J HEALTH PROMOT, V26, P333, DOI 10.4278/ajhp.110311-QUAN-115
   Broe GA, 1998, AUST NZ J PUBL HEAL, V22, P621, DOI 10.1111/j.1467-842X.1998.tb01449.x
   Burke A, 2003, PROG CARDIOVASC DIS, V46, P79, DOI 10.1016/S0033-0620(03)00076-8
   Cataldo JK, 2010, J ALZHEIMERS DIS, V19, P465, DOI 10.3233/JAD-2010-1240
   Chang CCH, 2012, ALZ DIS ASSOC DIS, V26, P300, DOI 10.1097/WAD.0b013e3182420b6e
   Chen RL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024817
   Cherubini A, 2005, NEUROBIOL AGING, V26, P987, DOI 10.1016/j.neurobiolaging.2004.09.002
   Chuang YF, 2010, DEMENT GERIATR COGN, V29, P248, DOI 10.1159/000285166
   Dahl AK, 2008, J AM GERIATR SOC, V56, P2261, DOI 10.1111/j.1532-5415.2008.01958.x
   Didelez V, 2007, STAT METHODS MED RES, V16, P309, DOI 10.1177/0962280206077743
   Doll R, 2000, BRIT MED J, V320, P1097, DOI 10.1136/bmj.320.7242.1097
   Durazzo TC, 2014, ALZHEIMERS DEMENT, V10, pS122, DOI 10.1016/j.jalz.2014.04.009
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Erkinjuntti T, 1997, NEW ENGL J MED, V337, P1667, DOI 10.1056/NEJM199712043372306
   Furberg H, 2010, NAT GENET, V42, P441, DOI 10.1038/ng.571
   Gao S, 1998, ARCH GEN PSYCHIAT, V55, P809, DOI 10.1001/archpsyc.55.9.809
   Gao SJ, 2011, J AM GERIATR SOC, V59, P18, DOI 10.1111/j.1532-5415.2010.03169.x
   GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
   Hassing LB, 2009, INT J OBESITY, V33, P893, DOI 10.1038/ijo.2009.104
   HEBERT LE, 1992, AM J EPIDEMIOL, V135, P347, DOI 10.1093/oxfordjournals.aje.a116296
   Hernan MA, 2008, EPIDEMIOLOGY, V19, P448, DOI [10.1097/EDE.0b013e31816bbe14, 10.1097/EDE.0b013e31816bbc14]
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hirayama T, 1992, TOB CONTROL, V1, P176
   Huriletemuer, 2010, J NEUROL SCI, V288, P167, DOI 10.1016/j.jns.2009.08.058
   Jorm AF, 1998, NEUROLOGY, V51, P728, DOI 10.1212/WNL.51.3.728
   Juan D, 2004, EUR J NEUROL, V11, P277, DOI 10.1046/j.1468-1331.2003.00779.x
   Karantzoulis S, 2011, EXPERT REV NEUROTHER, V11, P1579, DOI [10.1586/ERN.11.155, 10.1586/ern.11.155]
   Katz MJ, 2012, ALZ DIS ASSOC DIS, V26, P335, DOI 10.1097/WAD.0b013e31823dbcfc
   Kaur-Knudsen D, 2012, EUR RESPIR J, V40, P1538, DOI 10.1183/09031936.00176811
   Kimm H, 2011, ARCH GERONTOL GERIAT, V52, pE117, DOI 10.1016/j.archger.2010.09.004
   Kivipelto M, 2008, J CELL MOL MED, V12, P2762, DOI 10.1111/j.1582-4934.2008.00296.x
   Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F
   Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78
   Laurin D, 2004, AM J EPIDEMIOL, V159, P959, DOI 10.1093/aje/kwh124
   Laurin D, 2007, CIRCULATION, V116, P2269, DOI 10.1161/CIRCULATIONAHA.106.686477
   Laurin Danielle, 2003, Journal of Alzheimer's Disease, V5, P315
   Letenneur Luc, 1994, Annals of Epidemiology, V4, P449
   Lin FR, 2011, ARCH NEUROL-CHICAGO, V68, P214, DOI 10.1001/archneurol.2010.362
   Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074
   Ng M, 2014, JAMA-J AM MED ASSOC, V311, P183, DOI 10.1001/jama.2013.284692
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   Merchant C, 1999, NEUROLOGY, V52, P1408, DOI 10.1212/WNL.52.7.1408
   Moffat SD, 2004, NEUROLOGY, V62, P188, DOI 10.1212/WNL.62.2.188
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Newman AB, 2005, J AM GERIATR SOC, V53, P1101, DOI 10.1111/j.1532-5415.2005.53360.x
   Ogunniyi A, 2011, ACTA NEUROL SCAND, V124, P396, DOI 10.1111/j.1600-0404.2011.01491.x
   Organization World Health, 2012, DEM PUBL HLTH PRIOR
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Paciaroni M, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000656
   Peters Ruth, 2008, BMC Geriatr, V8, P36, DOI 10.1186/1471-2318-8-36
   Pohjasvaara T, 1997, STROKE, V28, P785, DOI 10.1161/01.STR.28.4.785
   Power BD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017902
   Reitz C, 2007, NEUROLOGY, V69, P998, DOI 10.1212/01.wnl.0000271395.29695.9a
   Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI 10.1038/nrneurol.2011.2
   ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250
   Ronnemaa E, 2011, DEMENT GERIATR COGN, V31, P460, DOI 10.1159/000330020
   Rosengren A, 2005, ARCH INTERN MED, V165, P321, DOI 10.1001/archinte.165.3.321
   Rusanen M, 2010, DEMENT GERIATR COGN, V30, P277, DOI 10.1159/000320484
   Rusanen M, 2011, ARCH INTERN MED, V171, P333, DOI 10.1001/archinternmed.2010.393
   Scarmeas N, 2009, JAMA-J AM MED ASSOC, V302, P627, DOI 10.1001/jama.2009.1144
   Siristatidis C, 2013, HUM REPROD UPDATE, V19, P105, DOI 10.1093/humupd/dms051
   Taylor AE, 2014, INT J EPIDEMIOL, V43, P1483, DOI 10.1093/ije/dyu151
   Tyas SL, 2003, NEUROBIOL AGING, V24, P589, DOI 10.1016/S0197-4580(02)00156-2
   Tyas SL, 2001, INT J EPIDEMIOL, V30, P590, DOI 10.1093/ije/30.3.590
   Vardarajan BN, 2014, JAMA NEUROL, V71, P315, DOI 10.1001/jamaneurol.2013.5570
   Wang HX, 1999, AM J EPIDEMIOL, V149, P640
   Wells GA, 2000, NEWCASTLE OTTAWA SCA
   Whitmer RA, 2005, BRIT MED J, V330, P1360, DOI 10.1136/bmj.38446.466238.E0
   YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161
   Zhou R, 2011, J ALZHEIMERS DIS, V24, P101, DOI 10.3233/JAD-2010-101467
   Zoccali C, 2006, AM J KIDNEY DIS, V47, P332, DOI 10.1053/j.ajkd.2005.10.027
NR 81
TC 39
Z9 42
U1 1
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 12
PY 2015
VL 10
IS 3
AR e0118333
DI 10.1371/journal.pone.0118333
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CD7ND
UT WOS:000351276300013
PM 25763939
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ge, BH
   Song, YD
   Zhang, Y
   Liu, XW
   Wen, YX
   Guo, XM
AF Ge, Beihai
   Song, Yadong
   Zhang, Yi
   Liu, Xiaowen
   Wen, Yuxiang
   Guo, Xiaomei
TI Glutathione S-Transferase M1 (GSTM1) and T1 (GSTT1) Null Polymorphisms
   and the Risk of Hypertension: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID ISCHEMIC-STROKE RISK; GENE POLYMORPHISMS; CANCER SUSCEPTIBILITY;
   OXIDATIVE STRESS; CLINICAL-TRIALS; ASSOCIATION; DISEASE; POPULATION;
   VARIANTS; GENOTYPE
AB Background
   Some studies have recently focused on the association between glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null polymorphisms and hypertension; however, results have been inconsistent.
   Objective
   In order to drive a more precise estimation, the present systematic review and meta-analysis is performed to investigate the relationship between the GSTM1 and GSTT1 null polymorphisms and hypertension.
   Methods
   Eligible articles were identified by a search of several bibliographic databases for the period up to August 17, 2013. Odds ratios were pooled using either fixed-effects or random-effects models.
   Results
   Regarding the GSTM1 null/present genotype, 14 case-control studies were eligible (2773 hypertension cases and 3189 controls). The meta-analysis revealed that it might present a small increased risk for hypertension, although the effect was not statistically significant (odd ratio (OR) = 1.16, 95% confidence interval (CI): 0.96, 1.40; P = 0.002, I2 = 59.8%). Further subgroup analysis by ethnicity and control source suggested that the association was still not significant. Thirteen case-control studies were eligible for GSTT1 (2497 hypertension cases and 3078 controls). No statistically significant association was observed between the GSTT1 null genotype and hypertension risk (OR = 1.14, 95% CI: 0.85, 1.53; P = 0.000, I2 = 80.3%). Furthermore, stratification by ethnicity and control source indicated no association between the GSTT1 null genotype and hypertension risk. We further confirmed the association by sensitivity analysis. No publication bias was detected.
   Conclusion
   This meta-analysis suggests that the GSTM1 and GSTT1 null polymorphisms are not associated with the risk of hypertension. Future large well-designed epidemiological studies with individual information, lifestyle factors, and environmental factors are warranted to validate the present findings.
C1 [Ge, Beihai; Zhang, Yi; Liu, Xiaowen; Wen, Yuxiang; Guo, Xiaomei] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Cardiol, Tongji Med Coll, Wuhan 430030, Peoples R China.
   [Song, Yadong] Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Nutr & Food Hyg, Tongji Med Coll, Wuhan 430030, Peoples R China.
RP Guo, XM (reprint author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Cardiol, Tongji Med Coll, Wuhan 430030, Peoples R China.
EM xmguo@tjh.tjmu.edu.cn
FU National Nature Science Foundation of China [30971244, 81270353]
FX This work was supported by National Nature Science Foundation of China
   (30971244,81270353) (URL:http://isisn.nsfc.gov.cn/egrantweb/). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aydemir B, 2007, ASIAN J ANDROL, V9, P108, DOI 10.1111/j.1745-7262.2007.00237.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bessa SS, 2009, EUR J INTERN MED, V20, P625, DOI 10.1016/j.ejim.2009.06.003
   Borah PK, 2011, GENET TEST MOL BIOMA, V15, P771, DOI 10.1089/gtmb.2010.0186
   Capoluongo E, 2009, CLIN CHIM ACTA, V399, P92, DOI 10.1016/j.cca.2008.09.017
   Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75
   Cruz-Gonzalez I, 2009, J HUM HYPERTENS, V23, P556, DOI 10.1038/jhh.2009.19
   DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794
   Delles C, 2008, J HYPERTENS, V26, P1343, DOI 10.1097/HJH.0b013e3282fe1d67
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eslami S, 2014, CURR HYPERTENS REP, V16, DOI 10.1007/s11906-014-0432-1
   GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807
   Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1239
   Geisler SA, 2001, AM J EPIDEMIOL, V154, P95, DOI 10.1093/aje/154.2.95
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491
   Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396
   Hengstler JG, 1998, RECENT RES CANCER, V154, P47
   Hussain K, 2012, IRAN RED CRESCENT ME, V14, P479
   Jiang XJ, 2010, CARCINOGENESIS, V31, P1964, DOI 10.1093/carcin/bgq173
   Johnson RJ, 2005, AM J HYPERTENS, V18, P431, DOI 10.1016/j.amjhyper.2004.08.035
   Lawes CMM, 2008, LANCET, V371, P1513, DOI 10.1016/S0140-6736(08)60655-8
   Lee BK, 2012, MOL CELL TOXICOL, V8, P203, DOI 10.1007/s13273-012-0025-5
   Li YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035408
   Liang SQ, 2013, RESPIROLOGY, V18, P774, DOI 10.1111/resp.12097
   Lin PI, 2007, AM J HUM GENET, V80, P531, DOI 10.1086/512133
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marcos M, 2011, ALIMENT PHARM THER, V34, P1159, DOI 10.1111/j.1365-2036.2011.04862.x
   Marinho C, 2007, BIOCHEM BIOPH RES CO, V353, P344, DOI 10.1016/j.bbrc.2006.12.019
   Miranda-Vilela AL, 2010, GENET MOL RES, V9, P2166, DOI 10.4238/vol9-4gmr973
   Moonesinghe R, 2008, P NATL ACAD SCI USA, V105, P617, DOI 10.1073/pnas.0705554105
   Moonesinghe R, 2007, PLOS MED, V4, P218, DOI 10.1371/journal.pmed.0040028
   Norppa H, 2004, TOXICOL LETT, V149, P309, DOI 10.1016/j.toxlet.2003.12.042
   Okcu MF, 2004, CLIN CANCER RES, V10, P2618, DOI 10.1158/1078-0432.CCR-03-0053
   Oniki K, 2008, PHARMACOGENET GENOM, V18, P275, DOI 10.1097/FPC.0b013e3282f56176
   Oparil S, 2003, ANN INTERN MED, V139, P761, DOI 10.7326/0003-4819-139-9-200311040-00011
   Pedro-Botet J, 2000, J HUM HYPERTENS, V14, P343, DOI 10.1038/sj.jhh.1001034
   PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271
   Polimanti R, 2011, MOL CELL BIOCHEM, V357, P227, DOI 10.1007/s11010-011-0893-3
   Rebbeck TR, 1997, CANCER EPIDEM BIOMAR, V6, P733
   Santovito A, 2008, ARCH TOXICOL, V82, P903, DOI 10.1007/s00204-008-0316-8
   Song GG, 2012, MOL BIOL REP, V39, P10739, DOI 10.1007/s11033-012-1965-5
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Tang ST, 2013, GENE, V530, P301, DOI 10.1016/j.gene.2013.08.043
   Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187
   Touyz RM, 2004, HYPERTENSION, V44, P248, DOI 10.1161/01.HYP.0000138070.47616.9d
   Turkanoglu A, 2010, NEUROL SCI, V31, P727, DOI 10.1007/s10072-010-0330-5
   Vaziri ND, 2000, HYPERTENSION, V36, P142, DOI 10.1161/01.HYP.36.1.142
   Wang J, 2010, MUTAGENESIS, V25, P365, DOI 10.1093/mutage/geq014
   Wang R, 2012, NEURAL REGEN RES, V7, P1420, DOI 10.3969/j.issn.1673-5374.2012.18.009
   Xue H, 2012, MOL BIOL REP, V39, P5033, DOI 10.1007/s11033-011-1300-6
   Yang Y, 2004, INT J MOL MED, V14, P855
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 54
TC 3
Z9 4
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 5
PY 2015
VL 10
IS 3
AR e0118897
DI 10.1371/journal.pone.0118897
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC9KG
UT WOS:000350688100057
PM 25742618
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhou, XF
   Zhang, G
   Tian, Y
AF Zhou, Xiaofeng
   Zhang, Guan
   Tian, Ye
TI p53 Status Correlates with the Risk of Recurrence in Non-Muscle Invasive
   Bladder Cancers Treated with Bacillus Calmette-Guerin: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PROGNOSTIC VALUE; ARG72PRO POLYMORPHISM; UROTHELIAL CARCINOMA; PROTEIN
   OVEREXPRESSION; PROLIFERATIVE ACTIVITY; MOLECULAR MARKERS; TUMOR
   RECURRENCE; PRB EXPRESSION; ASSOCIATION; SURVIVAL
AB Objective
   Published studies have yielded inconsistent results on the relationship between p53 status and the prognosis of non-muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG) intravesical therapy. Therefore, we performed a meta-analysis to evaluate the prognostic value of p53 in NMIBC treated with BCG.
   Methods
   We systematically searched for relevant literature in PubMed, EMBASE, CNKI, and Chinese Wanfang databases. Hazard ratios (HRs) with 95% confidence intervals (CIs) were combined as the effect size (ES) across studies for recurrence-free survival (RFS) and progression-free survival (PFS).
   Results
   A total of 11 studies, consisting of 1,049 participants, met the criteria. Overall, there was no clear relationship between p53 status and RFS or PFS for NMIBC patients treated with BCG (HR: 1.40, 95% CI: 0.91-2.16; HR: 1.37, 95% CI: 0.90-2.09, respectively). Obvious heterogeneity was observed across the studies (I-2 = 69.5%, P = 0.001; I-2 = 44.7%, P = 0.081, respectively). In stratified analysis by region, p53 overexpression was a predictor of poor RFS in Asian populations (HR: 1.57, 95% CI: 1.08-2.27). In addition, after excluding the studies that possibly contributed to the heterogeneity by the Galbraith plot, the overall association for RFS became statistically significant (HR: 1.38 95% CI: 1.08-1.77) without evidence of heterogeneity (I-2 = 0.0%, P = 0.499).
   Conclusion
   This meta-analysis suggests that p53 overexpression in NMIBC patients treated with BCG may be associated with RFS, especially in Asian populations. Because of the heterogeneity and other limitations, further studies with rigid criteria and large populations are still warranted to confirm our findings.
C1 [Zhou, Xiaofeng; Tian, Ye] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing 100050, Peoples R China.
   [Zhang, Guan] China Japan Friendship Hosp, Dept Urol, Beijing 100029, Peoples R China.
RP Tian, Y (reprint author), Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Yongan Rd 95, Beijing 100050, Peoples R China.
EM dr_tianye@163.com
FU National Natural Science Foundation of China [81373637]; International
   S&T Cooperation Program of China (ISTCP) [2014DFE30010]
FX This study was supported by grants from the National Natural Science
   Foundation of China (Grant No. 81373637) and International S&T
   Cooperation Program of China (ISTCP) (Grant No. 2014DFE30010). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alkhateeb SS, 2011, UROL ANNALS, V3, P119, DOI 10.4103/0974-7796.84954
   Babjuk M, 2013, EUR UROL, V64, P639, DOI 10.1016/j.eururo.2013.06.003
   Bax L, 2009, AM J EPIDEMIOL, V169, P249, DOI 10.1093/aje/kwn340
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bernardini S, 1999, J UROLOGY, V162, P1496, DOI 10.1016/S0022-5347(05)68347-4
   Burger M, 2013, EUR UROL, V63, P36, DOI 10.1016/j.eururo.2012.08.061
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Cormio L, 2009, ANTICANCER RES, V29, P4201
   da Silva GN, 2011, MOL BIOL REP, V38, P4159, DOI 10.1007/s11033-010-0536-x
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dolicanin Z, 2011, VOJNOSANIT PREGL, V68, P567, DOI 10.2298/VSP1107567D
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Esuvaranathan K, 2007, CANCER-AM CANCER SOC, V109, P1097, DOI 10.1002/cncr.22503
   Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116
   Gontero P, 2000, EUR UROL, V38, P287, DOI 10.1159/000020295
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jiang DK, 2010, UROLOGY, V76, DOI 10.1016/j.urology.2010.04.044
   Jin M, 2013, ANN ONCOL, V24, P807, DOI 10.1093/annonc/mds508
   Lacombe L, 1996, J CLIN ONCOL, V14, P2646, DOI 10.1200/JCO.1996.14.10.2646
   LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406
   Lee E, 1997, Int J Urol, V4, P552, DOI 10.1111/j.1442-2042.1997.tb00307.x
   Li DB, 2010, GENET MOL RES, V9, P1599, DOI 10.4238/vol9-3gmr882
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Liu ZH, 2013, MOL BIOL REP, V40, P2389, DOI 10.1007/s11033-012-2319-z
   Lopez-Beltran A, 2004, EUR UROL, V45, P606, DOI 10.1016/j.eururo.2003.11.011
   Ma YL, 2011, J CLIN ONCOL, V29, P3775, DOI 10.1200/JCO.2011.35.7566
   Malats W, 2005, LANCET ONCOL, V6, P678
   Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059
   Nakopoulou L, 1998, HUM PATHOL, V29, P146, DOI 10.1016/S0046-8177(98)90225-8
   Nepple Kenneth G, 2009, Can Urol Assoc J, V3, pS188
   Oderda M, 2013, UROL INT, V90, P184, DOI 10.1159/000343431
   Oh JJ, 2010, ONCOLOGY-BASEL, V79, P440, DOI 10.1159/000327214
   Park J, 2013, UROL ONCOL-SEMIN ORI, V31, P849, DOI 10.1016/j.urolonc.2011.06.004
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Peyromaure M, 2002, UROLOGY, V59, P409, DOI 10.1016/S0090-4295(01)01551-5
   Ploeg M, 2009, WORLD J UROL, V27, P289, DOI 10.1007/s00345-009-0383-3
   Resnick MJ, 2013, CURR OPIN ONCOL, V25, P281, DOI 10.1097/CCO.0b013e32835eb583
   Saint F, 2004, EUR UROL, V45, P475, DOI 10.1016/j.eururo.2003.11.018
   Sylvester RJ, 2011, EUR UROL, V60, P431, DOI 10.1016/j.eururo.2011.06.001
   van Rhijn BWG, 2012, BJU INT, V110, P1169, DOI 10.1111/j.1464-410X.2012.10996.x
   van Rhijn BWG, 2009, EUR UROL, V56, P430, DOI 10.1016/j.eururo.2009.06.028
   Xu T, 2012, ASIAN PAC J CANCER P, V13, P2349, DOI 10.7314/APJCP.2012.13.5.2349
   Xu X, 2014, EUR J NUTR, V53, P1615, DOI 10.1007/s00394-014-0667-2
   Xylinas E, 2013, BRIT J CANCER, V109, P1460, DOI 10.1038/bjc.2013.372
   Yang ZL, 2013, GENE, V512, P408, DOI 10.1016/j.gene.2012.09.085
NR 47
TC 7
Z9 8
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 5
PY 2015
VL 10
IS 3
AR e0119476
DI 10.1371/journal.pone.0119476
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC9KG
UT WOS:000350688100114
PM 25742650
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, LS
   Zhang, ZH
   Sun, L
   Sun, YH
   Ye, DQ
AF Yang, Lin-Sheng
   Zhang, Zhi-Hua
   Sun, Liang
   Sun, Ye-Huan
   Ye, Dong-Qing
TI Prevalence of Suicide Attempts among College Students in China: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID LIFETIME PREVALENCE; SELF-HARM; IDEATION; PLANS; ADOLESCENTS; BEHAVIOR;
   SYSTEM; RATES
AB Background
   Suicide is the leading cause of death among 15-34 year olds in China, but no national data are available on the suicide and suicide attempts rates of college students, a sub-group of youth with 23 million. Several studies have reported the prevalence of suicide attempts among college students, however, no meta-analysis pooling the prevalence of suicide attempts is found.
   Objective and Methods
   This study aims to estimate the pooled prevalence of suicide attempts among college students in China. The relevant studies up to August 2014 were systematically searched via electronic databases (PubMed-Medline, Embase, Chinese Wanfang database, Chinese National Knowledge Infrastructure and Chinese VIP database). We only selected original articles that either reported the prevalence of suicide attempts or sufficient data for calculating the prevalence.
   Results
   A total of 29 eligible studies, with 88,225 college students, were finally included. The maximum and minimum reported prevalences of suicide attempts among college students in China were 0.4% and 10.5%, respectively. The pooled prevalence of suicide attempts was 2.8% (95% CI: 2.3%-3.3%). Subgroup analyses showed that the pooled estimate of prevalence of life time suicide attempts was 2.7% (95% CI: 2.1%-3.3%), and 12-month suicide attempts was 2.9% (95% CI: 2.0%-3.8%). The prevalence for males was 2.4% (95% CI: 1.8%-3.0%), and for females was 2.7% (95% CI: 1.9%-3.7%). The prevalences among college students in grade 1 through 4 were 2.8% (95% CI: 1.7%-3.8%), 1.8% (95% CI: 1.2%-2.3%), 2.0% (95% CI: 0.8%-3.1%), and 2.9% (95% CI: 0.1%6.7%), respectively. The prevalences among college students from rural and urban areas were 5.1% (95% CI: 2.8%-7.5%) and 3.7% (95% CI: 1.4%-5.9%), respectively.
   Conclusions
   2.8% prevalence of suicide attempts and more than 600,000 suicide attempters among college students indicate that suicide attempt among college students is an important public health problem in China. More attention should be paid to the current situation.
C1 [Yang, Lin-Sheng; Zhang, Zhi-Hua; Sun, Ye-Huan; Ye, Dong-Qing] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hefei, Peoples R China.
   [Sun, Liang] Fuyang Ctr Dis Control & Prevent, Dept Publ Hlth, Fuyang, Peoples R China.
RP Sun, YH (reprint author), Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hefei, Peoples R China.
EM sun611007@163.com; anhuiydq@126.com
FU National Natural Science Foundation of China [81202224]
FX The work was funded by a grant from the National Natural Science
   Foundation of China (grant no. 81202224). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   American College Health Association, 2009, J Am Coll Health, V57, P477, DOI 10.3200/JACH.57.5.477-488
   Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469
   Arria AM, 2009, ARCH SUICIDE RES, V13, P230, DOI 10.1080/13811110903044351
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bertolote JM, 2005, PSYCHOL MED, V35, P1457, DOI 10.1017/S0033291705005404
   Boeninger DK, 2010, SUICIDE LIFE-THREAT, V40, P451, DOI 10.1521/suli.2010.40.5.451
   Cao HY, 2009, CHIN J SCH HLTH, V30, P38
   Chen JL, 2014, INT J DEV NEUROSCI, V35, P35, DOI 10.1016/j.ijdevneu.2014.03.006
   CHEN RR, 2011, FOREIGN MED SCI SECT, V32, P192
   Chen YF, 2008, CHIN J DIS CONTROL P, V12, P450
   Chou CH, 2013, SUICIDE LIFE-THREAT, V43, P185, DOI 10.1111/sltb.12007
   [邓云龙 Deng Yunlong], 2012, [中国临床心理学杂志, Chinese Journal of Clinical Psychology], V20, P332
   Fan YG, 2008, CHIN J SCH HLTH, V29, P328
   Fan Yin-Guang, 2008, Zhonghua Liu Xing Bing Xue Za Zhi, V29, P241
   Feng SS, 2008, CHIN J SCH HLTH, V29, P414
   FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756
   Gao Rong, 2010, Zhonghua Liu Xing Bing Xue Za Zhi, V31, P9
   Gau SSF, 2009, COMPR PSYCHIAT, V50, P276, DOI 10.1016/j.comppsych.2008.08.009
   GUO SF, PSYCHOL PROBLEMS COL
   KUANG L, 2008, CHIN J NERV MENT DIS, V34, P594
   Kuo WH, 2005, AM J PSYCHIAT, V162, P633, DOI 10.1176/appi.ajp.162.3.633
   Law BMF, 2013, J PEDIATR ADOL GYNEC, V26, pS26, DOI 10.1016/j.jpag.2013.03.012
   Lee S, 2007, ACTA PSYCHIAT SCAND, V116, P429, DOI 10.1111/j.1600-0447.2007.01064.x
   LI LH, 2010, J CHIN TRADIT CHIN M, V2, P227
   [刘丹 Liu Dan], 2013, [中华行为医学与脑科学杂志, Chinese Journal of Behavioral Medicine and Brain Science], V22, P856
   Liu Ke-rong, 2009, Nan Fang Yi Ke Da Xue Xue Bao, V29, P1071
   Liu QQ, 2007, CHINA J HLTH PSYCHOL, V15, P57
   MA AH, 2010, CHIN J SCH HLTH, V31, P603
   Ma X, 2009, AUST NZ J PSYCHIAT, V43, P158, DOI 10.1080/00048670802607170
   MILLER JJ, 1978, AM STAT, V32, P138, DOI 10.2307/2682942
   Nath Y, 2012, INT J SOC PSYCHIATR, V58, P393, DOI 10.1177/0020764011401164
   Neeleman J, 2004, J AFFECT DISORDERS, V82, P43, DOI 10.1016/j.jad.2003.09.005
   Nock MK, 2008, EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002
   Nock MK, 2008, BRIT J PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113
   Phillips MR, 2002, LANCET, V359, P835, DOI 10.1016/S0140-6736(02)07954-0
   Rostom A, CELIAC DIS
   Shang YX, 2009, MOD PREV MED, V36, P3092
   SHANG YX, 2008, CHIN J PUBLIC HLTH, V24, P934
   SHI WJ, 2007, CHIN J SCH HLTH, V29, P1083
   Taliaferro LA, 2015, J AM COLL HEALTH, V63, P40, DOI 10.1080/07448481.2014.953166
   Tang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017977
   TAO FB, 1999, CHIN J SCH HLTH, V20, P249
   Toprak S, 2011, PSYCHIAT RES, V187, P140, DOI 10.1016/j.psychres.2010.09.009
   Tresno F, 2012, DEATH STUD, V36, P627, DOI 10.1080/07481187.2011.604464
   Wan Yu-hui, 2012, Zhonghua Liu Xing Bing Xue Za Zhi, V33, P474
   Wang CW, 2014, SOC PSYCH PSYCH EPID, V49, P929, DOI 10.1007/s00127-013-0789-5
   Wang L, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-551
   Wang SY, 2008, LANCET, V372, P1765, DOI 10.1016/S0140-6736(08)61367-7
   Wang Zhizhong, 2013, Shanghai Arch Psychiatry, V25, P287, DOI 10.3969/j.issn.1002-0829.2013.05.004
   XIN X, 2010, ANHUI MED J, V31, P521
   Xu Hui-lan, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P288
   Yang Gonghuan, 2005, Popul Health Metr, V3, P3, DOI 10.1186/1478-7954-3-3
   You ZQ, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004096
   ZEN LN, 2006, CHIN J SCH HLTH, V27, P863
   ZHANG R, 2002, CHIN J DIS CONTROL P, V6, P52
   Zhao Jiubo, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P1111
   Zhao JB, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-668
   ZHU JP, 2006, CHIN J SCH DOCTOR, V20, P228
NR 59
TC 16
Z9 16
U1 0
U2 30
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 9
PY 2015
VL 10
IS 2
AR UNSP e0116303
DI 10.1371/journal.pone.0116303
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA7UO
UT WOS:000349123100007
PM 25664661
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xu, P
   Luo, H
   Huang, GL
   Yin, XH
   Luo, SY
   Song, JK
AF Xu, Ping
   Luo, Hong
   Huang, Guang-Lei
   Yin, Xin-Hai
   Luo, Si-Yang
   Song, Ju-Kun
TI Exposure to Ionizing Radiation during Dental X-Rays Is Not Associated
   with Risk of Developing Meningioma: A Meta-Analysis Based on Seven
   Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID LOS-ANGELES-COUNTY; ATOMIC-BOMB SURVIVORS; INTRACRANIAL MENINGIOMA;
   AMALGAM FILLINGS; TUMORS; BRAIN; EPIDEMIOLOGY; RADIOGRAPHY; GLIOMAS;
   CANCER
AB Background
   Many observational studies have found that exposure to dental X-rays is associated with the risk of development of meningioma. However, these findings are inconsistent. We conducted a meta-analysis to assess the relationship between exposure to dental X-rays and the risk of development of meningioma.
   Methods
   The PubMed and EMBASE databases were searched to identify eligible studies. Summary odds ratio (OR) estimates and 95% confidence intervals (95% CIs) were used to compute the risk of meningioma development according to heterogeneity. Subgroup and sensitivity analyses were performed to further explore the potential heterogeneity. Finally, publication bias was assessed.
   Results
   Seven case-control studies involving 6,174 patients and 19,459 controls were included in the meta-analysis. Neither exposure to dental X-rays nor performance of full-mouth panorex X-rays was associated with an increased risk of development of meningioma (overall: OR, 0.97; 95% CI, 0.70-1.32; dental X-rays: OR, 1.05; 95% CI, 0.89-1.25; panorex X-rays: OR, 1.01; 95% CI, 0.76-1.34). However, exposure to bitewing X-rays was associated with a slightly increased risk of development of meningioma (OR, 1.73; 95% CI, 1.28-2.34). Similar results were obtained in the subgroup and sensitivity analyses. Little evidence of publication bias was observed.
   Conclusion
   Based on the currently limited data, there is no association between exposure to dental X-rays and the risk of development of meningioma. However, these results should be cautiously interpreted because of the heterogeneity among studies. Additional large, high-quality clinical trials are needed to evaluate the association between exposure to dental X-rays and the risk of development of meningioma.
C1 [Xu, Ping; Luo, Hong; Huang, Guang-Lei; Yin, Xin-Hai; Luo, Si-Yang; Song, Ju-Kun] Gui Zhou Prov Peoples Hosp, Guiyang 550002, Peoples R China.
RP Song, JK (reprint author), Gui Zhou Prov Peoples Hosp, Guiyang 550002, Peoples R China.
EM songjukun@163.com
CR Abt E, 2012, EVID BASED DENT, V13, P37, DOI [10.1038/sj.ebd.6400852, DOI 10.1038/SJ.EBD.6400852]
   [Anonymous], 2013, PRESCRIRE INT, V22, P16
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bondy M, 1996, J NEURO-ONCOL, V29, P197, DOI 10.1007/BF00165649
   Calnon WR, 2013, CANCER-AM CANCER SOC, V119, P464, DOI 10.1002/cncr.27812
   Claus EB, 2005, NEUROSURGERY, V57, P1088, DOI 10.1227/01.NEU.0000188281.91351.B9
   Claus EB, 2013, CANCER-AM CANCER SOC, V119, P465, DOI 10.1002/cncr.27708
   Claus EB, 2012, CANCER-AM CANCER SOC, V118, P4530, DOI 10.1002/cncr.26625
   Davis F, 2011, RADIAT RES, V175, P790, DOI 10.1667/RR2186.1
   Dirksen D, 2013, J DENT RES, V92, P397, DOI 10.1177/0022034513484338
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fonzar F, 2012, EUR J ORAL IMPLANTOL, V5, P107
   Hartling L, 2013, J CLIN EPIDEMIOL, V66, P982, DOI 10.1016/j.jclinepi.2013.03.003
   Jorgensen TJ, 2013, CANCER-AM CANCER SOC, V119, P463, DOI 10.1002/cncr.27710
   Lin MC, 2013, ANN ONCOL, V24, P1675, DOI 10.1093/annonc/mdt016
   Longstreth WT, 2004, CANCER-AM CANCER SOC, V100, P1026, DOI 10.1002/cncr.20036
   LONGSTRETH WT, 1993, CANCER, V72, P639, DOI 10.1002/1097-0142(19930801)72:3<639::AID-CNCR2820720304>3.0.CO;2-P
   MAILLIE HD, 1993, ORAL SURG ORAL MED O, V75, P631, DOI 10.1016/0030-4220(93)90239-Z
   McCarthy BJ, 1998, J NEUROSURG, V88, P831, DOI 10.3171/jns.1998.88.5.0831
   NEUBERGER JS, 1991, CANCER DETECT PREV, V15, P31
   Potera C, 2012, AM J NURS, V112, P18, DOI 10.1097/01.NAJ.0000415943.02290.ea
   PRESTON-MARTIN S, 1983, Neuroepidemiology, V2, P164, DOI 10.1159/000110522
   Preston-Martin S, 1985, Natl Cancer Inst Monogr, V69, P175
   PRESTONMARTIN S, 1980, JNCI-J NATL CANCER I, V65, P67
   PRESTONMARTIN S, 1989, CANCER RES, V49, P6137
   PRESTONMARTIN S, 1990, J AM DENT ASSOC, V120, P151, DOI 10.14219/jada.archive.1990.0026
   PRESTONMARTIN S, 1983, J NATL CANCER I, V70, P863
   RICHARDS AG, 1981, J AM DENT ASSOC, V103, P713, DOI 10.14219/jada.archive.1981.0378
   Rodvall Y, 1998, ORAL ONCOL, V34, P265, DOI 10.1016/S1368-8375(98)80006-7
   RYAN P, 1992, ORAL ONCOL, V28B, P91
   Sadamori N, 1996, INT J CANCER, V67, P318, DOI 10.1002/(SICI)1097-0215(19960729)67:3<318::AID-IJC2>3.3.CO;2-N
   Shintani T, 1999, J RADIAT RES, V40, P49, DOI 10.1269/jrr.40.49
   SURAWICZ TS, 1999, NEURO-ONCOLOGY, V1, P14
   Tetradis Sotirios, 2012, J Evid Based Dent Pract, V12, P174, DOI 10.1016/j.jebdp.2012.06.012
   Umansky F, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/5/E7
   White SC, 2013, CANCER-AM CANCER SOC, V119, P464, DOI 10.1002/cncr.27709
NR 36
TC 6
Z9 7
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 6
PY 2015
VL 10
IS 2
AR e0113210
DI 10.1371/journal.pone.0113210
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CB2GK
UT WOS:000349444900003
PM 25658814
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zheng, YT
   Cui, QQ
   Hong, YM
   Yao, WG
AF Zheng, Ya Ting
   Cui, Qi Qi
   Hong, Yi Min
   Yao, Wei Guang
TI A Meta-Analysis of High Dose, Intermittent Vitamin D Supplementation
   among Older Adults
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIALS; PLACEBO-CONTROLLED TRIAL; ORAL
   VITAMIN-D-3; DOUBLE-BLIND; CALCIUM SUPPLEMENTATION; RESIDENTIAL CARE;
   POOLED ANALYSIS; FALLS; PEOPLE; FRACTURES
AB Background
   The effects of intermittent, high dose vitamin D treatment in older adults have not been documented. We conducted a meta-analysis to provide a quantitative assessment of the efficiency of intermittent, high dose vitamin D treatment on falls, fractures, and mortality among older adults.
   Methods
   Electronic databases were searched for randomized controlled trials (RCTs) on high dose, intermittent vitamin D supplementation among older adults. Two researchers independently screened the literature according to specified inclusive and exclusive criteria to extract the data. Meta-analysis was performed by using Review Manager 5.1.0 software.
   Results
   Nine trials were included in this meta-analysis. High dose, intermittent vitamin D therapy did not decrease all-cause mortality among older adults. The risk ratio (95% CI) was 1.04 (0.91-1.17). No benefit was seen in fracture or fall prevention. The risk ratio for hip fractures (95% CI) was 1.17 (0.97-1.41) while for non-vertebral fractures (95% CI) it was 1.06 (0.91-1.22), and the risk ratio for falls (95% CI) was 1.02 (0.96-1.08). Results remained robust after sensitivity analysis.
   Conclusion
   Supplementation of intermittent, high dose vitamin D may not be effective in preventing overall mortality, fractures, or falls among older adults. The route of administration of vitamin D supplements may well change the physiological effects.
C1 [Zheng, Ya Ting; Cui, Qi Qi; Hong, Yi Min; Yao, Wei Guang] Soouthern Med Univ, Coll Humanities & Management, Guangzhou, Guangdong, Peoples R China.
RP Yao, WG (reprint author), Soouthern Med Univ, Coll Humanities & Management, Guangzhou, Guangdong, Peoples R China.
EM yaoweiguang2014@yeah.net
CR Autier P, 2007, ARCH INTERN MED, V167, P1730, DOI 10.1001/archinte.167.16.1730
   Bacon CJ, 2009, OSTEOPOROSIS INT, V20, P1407, DOI 10.1007/s00198-008-0814-9
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bischoff HA, 2003, J BONE MINER RES, V18, P343, DOI 10.1359/jbmr.2003.18.2.343
   Bischoff-Ferrari HA, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3692
   Bischoff-Ferrari HA, 2012, NEW ENGL J MED, V367, P40, DOI 10.1056/NEJMoa1109617
   Bjelakovic G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007470.pub2
   Buell JS, 2008, MOL ASPECTS MED, V29, P415, DOI 10.1016/j.mam.2008.05.001
   Chung Mei, 2009, Evid Rep Technol Assess (Full Rep), P1
   Dhesi JK, 2004, AGE AGEING, V33, P589, DOI 10.1093/ageing/afh209
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Flicker L, 2005, J AM GERIATR SOC, V53, P1881, DOI 10.1111/j.1532-5415.2005.00468.x
   Glendenning P, 2012, J BONE MINER RES, V27, P170, DOI 10.1002/jbmr.524
   Harwood RH, 2004, AGE AGEING, V33, P45, DOI 10.1093/ageing/afh002
   Higgins JP, 2008, COCHRANE HDB SYSTEMA
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hollis BW, 2013, J CLIN ENDOCR METAB, V98, P4619, DOI 10.1210/jc.2013-2653
   Latham NK, 2003, J AM GERIATR SOC, V51, P291, DOI 10.1046/j.1532-5415.2003.51101.x
   Law M, 2006, AGE AGEING, V35, P482, DOI 10.1093/ageing/afj080
   Lyons RA, 2007, OSTEOPOROSIS INT, V18, P811, DOI 10.1007/s00198-006-0309-5
   Murad MH, 2011, J CLIN ENDOCR METAB, V96, P2997, DOI 10.1210/jc.2011-1193
   Pfeifer M, 2009, OSTEOPOROSIS INT, V20, P315, DOI 10.1007/s00198-008-0662-7
   Prince RL, 2008, ARCH INTERN MED, V168, P103, DOI 10.1001/archinternmed.2007.31
   Rejnmark L, 2012, J CLIN ENDOCR METAB, V97, P2670, DOI 10.1210/jc.2011-3328
   Rossini M, 2012, J CLIN ENDOCR METAB, V97, pE622, DOI 10.1210/jc.2011-2448
   Sanders KM, 2013, CALCIFIED TISSUE INT, V92, P191, DOI 10.1007/s00223-012-9679-1
   Sanders KM, 2010, JAMA-J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594
   Smith H, 2007, RHEUMATOLOGY, V46, P1852, DOI 10.1093/rheumatology/kem240
   The DIPART Group, 2010, BMJ-BRIT MED J, V340, pb5463, DOI DOI 10.1136/BMJ.B5463
   Trivedi DP, 2003, BMJ-BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469
   van den Bergh Joop P W, 2011, Curr Osteoporos Rep, V9, P36, DOI 10.1007/s11914-010-0041-0
   Wahl D A, 2012, Arch Osteoporos, V7, P155, DOI 10.1007/s11657-012-0093-0
   Wigg AER, 2006, MED J AUSTRALIA, V185, P195
NR 33
TC 19
Z9 19
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 20
PY 2015
VL 10
IS 1
AR e0115850
DI 10.1371/journal.pone.0115850
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AZ4OZ
UT WOS:000348203500017
PM 25602255
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, GH
   Li, WS
   Tzekov, R
   Jiang, FZ
   Mao, SH
   Tong, YH
AF Chen, Guohai
   Li, Wensheng
   Tzekov, Radouil
   Jiang, Fangzheng
   Mao, Sihong
   Tong, Yuhua
TI Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy
   for Diabetic Macular Edema: A Meta-Analysis of Randomized Controlled
   Trials
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PLUS PROMPT LASER; DEFERRED LASER;
   INTRAVITREAL RANIBIZUMAB; SYSTEMIC SAFETY; TRIAMCINOLONE; RESTORE;
   EFFICACY
AB Objective: To evaluate the relative efficacy of ranibizumab (RBZ) monotherapy or combined with laser (RBZ + Laser) versus laser monotherapy for the treatment of diabetic macular edema (DME).
   Methods: A comprehensive literature search using PUBMED, ClinicalTrials.gov, and the Cochrane Library to identify randomized controlled trials (RCTs) comparing RBZ or RBZ + Laser to laser monotherapy in patients with DME. Efficacy estimates were determined by comparing weighted mean differences (WMD) in the change of best corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline, and the risk ratios (RR) for the proportions of patients with at least 15 letters change from baseline. Safety analysis estimated the RR of cardiac disorders at 6 to 12 months in RBZ therapy vs. laser monotherapy. Statistical analysis was performed using the RevMan 5.1 software.
   Results: Seven RCTs were selected for this meta-analysis, including 1749 patients (394 patients in the RBZ group 642 patients in the RBZ + Laser group and 713 patients in the laser group). RBZ and RBZ + Laser were superior to laser monotherapy in the mean change of BCVA and CMT from baseline (WMD=5.65, 95% confidence interval (CI), 4.44-6.87, P<0.00001; WMD =5.02, 95% CI, 3.83-6.20, P<0.00001, and WMD =-57.91, 95% CI, -77.62 to -38.20, P<0.00001; WMD =-56.63, 95% CI, -104.81 to -8.44, P=0.02, respectively). The pooled RR comparing the proportions of patients with at least 15 letters improvement or deterioration were also in favor of RBZ and RBZ + Laser (RR=2.94, 95% CI, 1.82-4.77, P<0.00001; RR=2.04, 95% CI, 1.50-2.78, P<0.00001, and RR=0.21, 95% CI, 0.06-0.71, P=0.01; RR=0.52, 95% CI, 0.29-0.95, P=0.03, respectively). There were no significant differences between RBZ and RBZ + Laser for any of the parameters. There were no difference in the safety profile between RBZ and laser.
   Conclusion: RBZ and RBZ + Laser had better visual and anatomic outcomes than laser monotherapy in the treatment of DME. RBZ + Laser seemed to be equivalent to RBZ.
C1 [Chen, Guohai; Jiang, Fangzheng; Mao, Sihong; Tong, Yuhua] Quzhou Peoples Hosp, Dept Ophthalmol, Quzhou, Zhejiang, Peoples R China.
   [Li, Wensheng] Xiamen Univ, Xiamen Eye Ctr, Xiamen, Fujian, Peoples R China.
   [Tzekov, Radouil] Roskamp Inst, Sarasota, FL USA.
   [Tzekov, Radouil] Univ S Florida, Dept Ophthalmol, Tampa, FL USA.
RP Li, WS (reprint author), Xiamen Univ, Xiamen Eye Ctr, Xiamen, Fujian, Peoples R China.
EM drlws@vip.tom.com
OI Tzekov, Radouil/0000-0002-3662-9818
CR Abouammoh MA, 2013, CAN J OPHTHALMOL, V48, P317, DOI 10.1016/j.jcjo.2013.03.004
   Ahmadieh H, 2008, GRAEF ARCH CLIN EXP, V246, P483, DOI 10.1007/s00417-007-0688-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Bandello F, 2010, DEV OPHTHALMOL, V47, P73, DOI 10.1159/000320075
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berger A, 2013, CAN J DIABETES, V37, pS48
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Clinicaltrials.gov. Novartis, NOV EFF SAF RAN INTR
   Comyn O, 2014, AM J OPHTHALMOL, V157, P960, DOI 10.1016/j.ajo.2014.02.019
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Do DV, 2013, JAMA OPHTHALMOL, V131, P139, DOI 10.1001/2013.jamaophthalmol.91
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elman MJ, 2012, OPHTHALMOLOGY, V119, P2312, DOI 10.1016/j.ophtha.2012.08.022
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Enders P, 2015, RETINA-J RET VIT DIS, V35, P454, DOI 10.1097/IAE.0000000000000320
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA, P187, DOI DOI 10.1002/9780470712184
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   Lang GE, 2013, OPHTHALMOLOGY, V120, P2004, DOI 10.1016/j.ophtha.2013.02.019
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P1045, DOI 10.1016/j.ophtha.2013.11.041
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Virgili G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub3
   Wang HY, 2012, CURR EYE RES, V37, P661, DOI 10.3109/02713683.2012.675616
   Yanagida Y, 2014, RETINA-J RET VIT DIS, V34, P629, DOI 10.1097/IAE.0000000000000116
   Zechmeister-Koss I, 2012, BRIT J OPHTHALMOL, V96, P167, DOI 10.1136/bjophthalmol-2011-300674
NR 35
TC 10
Z9 12
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 26
PY 2014
VL 9
IS 12
AR e115797
DI 10.1371/journal.pone.0115797
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX9RO
UT WOS:000347239900089
PM 25541937
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, JB
   Long, S
AF Chen, Jiangbo
   Long, Shuo
TI Tea and Coffee Consumption and Risk of Laryngeal Cancer: A Systematic
   Review Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID PROSPECTIVE COHORT; ESOPHAGEAL CANCER; PREVALENCE; ALCOHOL; TRACT
AB Background: Tea and coffee are the most commonly consumed beverages in the worldwide. The relationship between tea and coffee consumption on the risk of laryngeal cancer was still unclear.
   Methods: Relevant studies were identified by searching electronic database (Medline and EMBASE) and reviewing the reference lists of relevant articles until Oct. 2013. Observational studies that reported RRs and 95% CIs for the link of tea and coffee consumption on the risk of laryngeal cancer were eligible. A meta-analysis was obtained to combine study- specific RRs with a random-effects model.
   Results: A total of 2,803 cases and 503,234 controls in 10 independent studies were identified. The overall analysis of all 10 studies, including the case-control and cohort studies, found that tea drinking was not associated with laryngeal carcinoma (RR=1.03; 95% CI: 0.66-1.61). However, coffee consumption was significantly associated with the laryngeal carcinoma (RR=1.47; 95% CI: 1.03-2.11). A dose-response relationship between coffee intake and laryngeal carcinoma was detected; however, no evidence of dose-response link between tea consumption and laryngeal carcinoma risk was detected.
   Conclusions: The results from this meta-analysis of observational studies demonstrate that coffee consumption would increase the laryngeal cancer risk, while tea intake was not associated with risk of laryngeal carcinoma.
C1 [Chen, Jiangbo; Long, Shuo] Cent S Univ, Xiangya Hosp 3, Dept Otolaryngol, Changsha, Hunan, Peoples R China.
RP Long, S (reprint author), Cent S Univ, Xiangya Hosp 3, Dept Otolaryngol, Changsha, Hunan, Peoples R China.
EM longshuo201@163.com
CR Abel EL, 2007, EUR J CANCER PREV, V16, P446, DOI 10.1097/01.cej.0000243850.59362.73
   Babaev VR, 2013, CIRCULATION, V128
   Bandyopadhyay P, 2012, FOOD FUNCT, V3, P592, DOI 10.1039/c2fo00006g
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Braem MGM, 2012, AM J CLIN NUTR, V95, P1172, DOI 10.3945/ajcn.111.026393
   Bray I, 2000, INT J CANCER, V87, P122, DOI 10.1002/1097-0215(20000701)87:1<122::AID-IJC18>3.0.CO;2-W
   Brockmoller J, 2000, PHARMACOLOGY, V61, P212, DOI 10.1159/000028403
   Butt MS, 2011, CRIT REV FOOD SCI, V51, P363, DOI 10.1080/10408390903586412
   Cavin C, 2002, FOOD CHEM TOXICOL, V40, P1155, DOI 10.1016/S0278-6915(02)00029-7
   Chen MH, 2012, AM J IND MED, V55, P669, DOI 10.1002/ajim.22037
   Edefonti V, 2010, CANCER EPIDEM BIOMAR, V19, P18, DOI 10.1158/1055-9965.EPI-09-0900
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Franceschi S, 1999, BRIT J CANCER, V80, P614, DOI 10.1038/sj.bjc.6690400
   Galeone C, 2010, CANCER EPIDEM BIOMAR, V19, P1723, DOI 10.1158/1055-9965.EPI-10-0191
   Garavello W, 2009, ORAL ONCOL, V45, P85, DOI 10.1016/j.oraloncology.2008.02.011
   Geybels MS, 2013, CANC CAUSES CONTROL
   Il'yasova D, 2003, EUR J CANCER PREV, V12, P439, DOI 10.1097/01.cej.0000091884.10855.58
   Islami F, 2009, INT J CANCER, V125, P491, DOI 10.1002/ijc.24445
   Je YJ, 2011, CANCER EPIDEM BIOMAR, V20, P2487, DOI 10.1158/1055-9965.EPI-11-0766
   Kapil Umesh, 2005, Asian Pac J Cancer Prev, V6, P202
   La Vecchia C, 2008, EUR J CANCER PREV, V17, P116, DOI 10.1097/CEJ.0b013e3282b6fd40
   LAVECCHIA C, 1990, CANCER RES, V50, P4497
   LAVECCHIA C, 1992, NUTR CANCER, V17, P27, DOI 10.1080/01635589209514170
   Li XW, 2013, J INFECT DIS, V207, P479, DOI 10.1093/infdis/jis698
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   NOTANI P N, 1987, Nutrition and Cancer, V10, P103
   PINTOS J, 1994, EPIDEMIOLOGY, V5, P583, DOI 10.1097/00001648-199411000-00005
   Poljak M, 2013, VACCINE, V31, pH59, DOI 10.1016/j.vaccine.2013.03.029
   Ren JS, 2010, EUR J CANCER, V46, P1873, DOI 10.1016/j.ejca.2010.03.025
   Sang LX, 2013, NUTR CANCER, V65, P802, DOI 10.1080/01635581.2013.805423
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tang NP, 2010, LUNG CANCER, V67, P17, DOI 10.1016/j.lungcan.2009.03.012
   Turati F, 2011, ANN ONCOL, V22, P536, DOI 10.1093/annonc/mdq603
   Ui A, 2009, CANCER CAUSE CONTROL, V20, P1939, DOI 10.1007/s10552-009-9388-x
   Vassileiou A, 2012, B-ENT, V8, P273
   Villanueva-Reyes A, 2008, P R HEALTH SCI J, V27, P196
   Zvrko E, 2008, ARH HIG RADA TOKSIKO, V59, P11, DOI 10.2478/10004-1254-59-2008-1863
NR 37
TC 7
Z9 7
U1 0
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 12
PY 2014
VL 9
IS 12
AR e112006
DI 10.1371/journal.pone.0112006
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6JI
UT WOS:000346375400003
PM 25502726
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Mao, Y
   Qu, Q
   Zhang, YZ
   Liu, JJ
   Chen, XS
   Shen, KW
AF Mao, Yan
   Qu, Qing
   Zhang, Yuzi
   Liu, Junjun
   Chen, Xiaosong
   Shen, Kunwei
TI The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting
   Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic
   Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID PATHOLOGICAL COMPLETE RESPONSE; SURGICAL ADJUVANT BREAST; REGULATORY
   T-CELLS; PREOPERATIVE CHEMOTHERAPY; ENDOMETRIAL CANCER; SURVIVAL;
   CARCINOMA; PROGNOSIS; THERAPY; TRIAL
AB Background: We carried out a systematic review and meta-analysis to evaluate the predictive roles of tumor infiltrating lymphocytes (TILs) in response to neoadjuvant chemotherapy (NAC) in breast cancer.
   Method: A PubMed and Web of Science literature search was designed. Random or fixed effect models were adopted to estimate the summary odds ratio (OR). Heterogeneity and sensitivity analyses were performed to explore heterogeneity among studies and to assess the effects of study quality. Publication bias was evaluated using a funnel plot, Egger's test and Begg's test. We included studies where the predictive significance of TILs, and/or TILs subset on the pathologic complete response (pCR) were determined in NAC of breast cancer.
   Results: A total of 13 published studies (including 3251 patients) were eligible. In pooled analysis, the detection of higher TILs numbers in pre-treatment biopsy was correlated with better pCR to NAC (OR=3.93, 95% CI, 3.26-4.73). Moreover, TILs predicted higher pCR rates in triple negative (OR=2.49, 95% CI: 1.61-3.83), HER2 positive (OR=5.05, 95% CI: 2.86-8.92) breast cancer, but not in estrogen receptor (ER) positive (OR=6.21, 95% CI: 0.86-45.15) patients. In multivariate analysis, TILs were still an independent marker for high pCR rate (OR=1.41, 95% CI: 1.19-1.66). For TILs subset, higher levels of CD8+ and FOXP3+ T-lymphocytes in pretreatment biopsy respectively predicted better pathological response to NAC (OR=6.44, 95% CI: 2.52-16.46; OR=2.94, 95% CI: 1.05-8.26). Only FOXP3+ lymphocytes in post-NAC breast tissue were a predictive marker for low pCR rate in univariate (OR=0.41, 95% CI: 0.21-0.80) and multivariate (OR=0.36, 95% CI: 0.13-0.95) analysis.
   Conclusion: Higher TILs levels in pre-treatment biopsy indicated higher pCR rates for NAC. TILs subset played different roles in predicting response to NAC.
C1 [Mao, Yan; Zhang, Yuzi; Liu, Junjun; Chen, Xiaosong; Shen, Kunwei] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Comprehens Breast Hlth Ctr, Shanghai 200030, Peoples R China.
   [Qu, Qing] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Oncol, Shanghai 200030, Peoples R China.
RP Shen, KW (reprint author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Comprehens Breast Hlth Ctr, Shanghai 200030, Peoples R China.
EM kunwshenrj@163.com
FU National Natural funding of China [81202087, 81202088, 81172520];
   Shanghai Municipal Science and Technology Commission funding
   [12ZR1446400, 12140901503]; Doctor Innovation funding of Shanghai Jiao
   Tong University School of Medicine [BXJ201213]
FX This study was supported by the National Natural funding of China
   (81202087,81202088, 81172520), Shanghai Municipal Science and Technology
   Commission funding (12ZR1446400, 12140901503); Doctor Innovation funding
   of Shanghai Jiao Tong University School of Medicine (BXJ201213). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andre F, 2013, CLIN CANCER RES, V19, P28, DOI 10.1158/1078-0432.CCR-11-2701
   Aruga T, 2009, ONCOL REP, V22, P273, DOI 10.3892/or_00000434
   Bear HD, 2003, J CLIN ONCOL, V21, P4165, DOI 10.1200/JCO.2003.12.005
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhargava R, 2010, CANCER-AM CANCER SOC, V116, P1431, DOI 10.1002/cncr.24876
   Caras I, 2004, CANCER IMMUNOL IMMUN, V53, P1146, DOI 10.1007/s00262-004-0556-2
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109
   de Jong RA, 2009, GYNECOL ONCOL, V114, P105, DOI 10.1016/j.ygyno.2009.03.022
   Denkert C, 2013, ANN ONCOL, V24, P2786, DOI 10.1093/annonc/mdt350
   Denkert C, 2013, CANC RES S, V73
   Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fasching PA, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-486
   Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483
   Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672
   Fisher CS, 2012, ANN SURG ONCOL, V19, P253, DOI 10.1245/s10434-011-1877-y
   Garcia-Martinez E, 2013, CANC RES S, V73
   Giatromanolaki A, 2008, GYNECOL ONCOL, V110, P216, DOI 10.1016/j.ygyno.2008.04.021
   Hayes DF, 2006, BREAST CANCER RES TR, V100, P237, DOI 10.1007/s10549-006-9253-5
   Hornychova H, 2008, CANCER INVEST, V26, P1024, DOI 10.1080/07357900802098165
   Ino K, 2008, CLIN CANCER RES, V14, P2310, DOI 10.1158/1078-0432.CCR-07-4144
   Ismael G, 2012, LANCET ONCOL, V13, P869, DOI 10.1016/S1470-2045(12)70329-7
   Issa-Nummer Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079775
   Kondratiev S, 2004, CLIN CANCER RES, V10, P4450, DOI 10.1158/1078-0432.CCR-0732-3
   Kong XN, 2011, EUR J CANCER, V47, P2084, DOI 10.1016/j.ejca.2011.06.014
   Ladoire S, 2008, CLIN CANCER RES, V14, P2413, DOI 10.1158/1078-0432.CCR-07-4491
   Lee HJ, 2013, J BREAST CANCER, V16, P32, DOI 10.4048/jbc.2013.16.1.32
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147
   Liu FF, 2012, BREAST CANCER RES TR, V135, P459, DOI 10.1007/s10549-012-2132-3
   Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112
   Loi S, 2013, CANC RES S, V73
   Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902
   Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037
   Mauri D, 2005, JNCI-J NATL CANCER I, V97, P188, DOI 10.1093/jnci/dji021
   McShane LM, 2005, BRIT J CANCER, V93, P387, DOI 10.1038/sj.bjc.6602678
   Mei Z, 2014, BRIT J CANCER, V110, P1595, DOI 10.1038/bjc.2014.46
   Melichar B, 2012, MED ONCOL, V29, P2577, DOI 10.1007/s12032-012-0195-y
   Menard S, 1997, CLIN CANCER RES, V3, P817
   Mohammed ZMA, 2012, BRIT J CANCER, V107, P864, DOI 10.1038/bjc.2012.347
   Montagna E, 2010, BREAST CANCER RES TR, V124, P689, DOI 10.1007/s10549-010-1027-4
   Oda N, 2012, BREAST CANCER RES TR, V136, P107, DOI 10.1007/s10549-012-2245-8
   Ohno S, 2013, BREAST CANCER RES TR, V142, P69, DOI 10.1007/s10549-013-2691-y
   Ono M, 2012, BREAST CANCER RES TR, V132, P793, DOI 10.1007/s10549-011-1554-7
   Seo AN, 2013, BRIT J CANCER, V109, P2705, DOI 10.1038/bjc.2013.634
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Straver ME, 2010, ANN SURG ONCOL, V17, P2411, DOI 10.1245/s10434-010-1008-1
   Tan MC, 2009, AM J SURG, V198, P520, DOI 10.1016/j.amjsurg.2009.06.004
   Tomsova M, 2008, GYNECOL ONCOL, V108, P415, DOI 10.1016/j.ygyno.2007.10.016
   van der Hage JA, 2001, J CLIN ONCOL, V19, P4224, DOI 10.1200/JCO.2001.19.22.4224
   West NR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3072
   Yamagami W, 2011, INT J GYNECOL CANCER, V21, P1628, DOI 10.1097/IGC.0b013e31822c271f
   Yamaguchi R, 2012, HUM PATHOL, V43, P1688, DOI 10.1016/j.humpath.2011.12.013
   Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177
NR 53
TC 73
Z9 75
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 12
PY 2014
VL 9
IS 12
AR e115103
DI 10.1371/journal.pone.0115103
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6JI
UT WOS:000346375400072
PM 25501357
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, JX
   Zhao, YY
   Wu, X
   An, HX
AF Wu, Jing-Xun
   Zhao, Yuan-Yuan
   Wu, Xuan
   An, Han-Xiang
TI Clinicopathological and Prognostic Significance of CD24 Overexpression
   in Patients with Gastric Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID HEAT-STABLE ANTIGEN; P-SELECTIN; SIGNAL-TRANSDUCTION; CELLS; EXPRESSION;
   CARCINOMA; ADENOCARCINOMA; PROGRESSION; METASTASIS; SURVIVAL
AB Objective: The prognostic significance of CD24 expression for survival in patients with gastric cancer remains controversial. We conducted a meta-analysis to investigate the impact of CD24 expression on clinicopathological features and survival outcomes in gastric cancer.
   Methods: A comprehensive literature search of the electronic databases PubMed, Embase, Web of Science and China National Knowledge Infrastructure (CNKI; up to April 8, 2014) was performed for relevant studies using multiple search strategies. Correlations between CD24 expression and clinicopathological features and overall survival (OS) were analyzed.
   Results: A total of 1,041 patients with gastric cancer from 9 studies were included. The pooled odds ratios (ORs) indicated CD24 expression was associated with tumor depth (OR=0.45, 95% confidence interval [CI] 50.32-0.63; P<0.00001), status of lymph nodes (OR=0.40, 95% CI=0.25-0.64; P=0.0001) and tumor node metastasis (TNM) stage (OR=0.56, 95% CI=0.41-0.77; P=0.0003). The pooled hazard ratio (HR) for OS showed overexpression of CD24 reduced OS in gastric cancer (HR=1.99, 95% CI=1.29-3.07, P=0.002). Whereas, combined ORs showed that CD24 expression had no correlation with tumor differentiation or Lauren classifications.
   Conclusion: CD24 overexpression in patients with gastric cancer indicated worse survival outcomes and was associated with common clinicopathological poor prognostic factors.
C1 [Wu, Jing-Xun; An, Han-Xiang] Xiamen Univ, Affiliated Hosp 1, Dept Med Oncol, Xiamen, Fujian, Peoples R China.
   [Zhao, Yuan-Yuan] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.
   [Wu, Xuan] Peking Univ, Shenzhen Hosp, Dept Med Oncol, Shenzhen, Guangdong, Peoples R China.
RP An, HX (reprint author), Xiamen Univ, Affiliated Hosp 1, Dept Med Oncol, Xiamen, Fujian, Peoples R China.
EM anhanxiang@yahoo.com
CR Adachi Y, 2000, CANCER, V89, P1418
   Aigner S, 1998, FASEB J, V12, P1241
   Aigner S, 1997, BLOOD, V89, P3385
   Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bektas S, 2010, PATHOL ONCOL RES, V16, P569, DOI 10.1007/s12253-010-9248-8
   Chen M, 2006, ARCH IMMUNOL THER EX, V54, P75, DOI 10.1007/s00005-006-0010-6
   Chou YY, 2007, ANN SURG ONCOL, V14, P2748, DOI 10.1245/s10434-007-9501-x
   Darwish Nevine S, 2004, Cancer Res Treat, V36, P298, DOI 10.4143/crt.2004.36.5.298
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FISCHER GF, 1990, J IMMUNOL, V144, P638
   Friederichs J, 2000, CANCER RES, V60, P6714
   Hundahl SA, 1997, CANCER, V80, P2333, DOI 10.1002/(SICI)1097-0142(19971215)80:12<2333::AID-CNCR15>3.0.CO;2-V
   Japanese Gastric Cancer Association Registration Committee, 2006, Gastric Cancer, V9, P51
   Jian, 2009, J CHONGQING MED U, V34, P1348
   KADMON G, 1994, BIOCHEM BIOPH RES CO, V198, P1209, DOI 10.1006/bbrc.1994.1171
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Kristiansen G, 2004, J MOL HISTOL, V35, P255
   LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31
   Lee JH, 2009, ONCOL REP, V22, P1149, DOI 10.3892/or_00000548
   Li O, 2004, J EXP MED, V200, P1083, DOI 10.1084/jem.20040779
   Liu XW, 2014, J SURG ONCOL, V109, P859, DOI 10.1002/jso.23599
   Lynch HT, 2005, J SURG ONCOL, V90, P114, DOI 10.1002/jso.20214
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Ming SC, 1998, GASTRIC CANCER, V1, P31
   Nielsen PJ, 1997, BLOOD, V89, P1058
   Niu, 2009, J NONGKEN MED, V31, P129
   PIRRUCCELLO SJ, 1986, J IMMUNOL, V136, P3779
   SAMMAR M, 1994, INT IMMUNOL, V6, P1027, DOI 10.1093/intimm/6.7.1027
   SERLIN O, 1977, CANCER, V40, P1318, DOI 10.1002/1097-0142(197709)40:3<1318::AID-CNCR2820400349>3.0.CO;2-9
   Siewert JR, 1998, ANN SURG, V228, P449, DOI 10.1097/00000658-199810000-00002
   Su MC, 2006, CANCER LETT, V235, P34, DOI 10.1016/j.canlet.2005.03.059
   Suzuki T, 2001, J IMMUNOL, V166, P5567, DOI 10.4049/jimmunol.166.9.5567
   Takahashi M, 2013, HEPATO-GASTROENTEROL, V60, P653, DOI 10.5754/hge12763
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Wells GA, 2011, NEWCATSLE OTTAWA SCA
   [杨世斌 Yang Shibin], 2012, [中国病理生理杂志, Chinese Journal of Pathophysiology], V28, P1224
   姚宏亮, 2008, [中国病理生理杂志, Chinese Journal of Pathophysiology], V24, P1629
NR 39
TC 8
Z9 8
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 12
PY 2014
VL 9
IS 12
AR e114746
DI 10.1371/journal.pone.0114746
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6JI
UT WOS:000346375400048
PM 25503963
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, SN
   Zhang, LL
   Huang, KB
   Lin, ZZ
   Qiao, WG
   Pan, SY
AF Wang, Shengnan
   Zhang, Lili
   Huang, Kaibin
   Lin, Zhenzhou
   Qiao, Weiguang
   Pan, Suyue
TI Predictors of Extubation Failure in Neurocritical Patients Identified by
   a Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SPONTANEOUS BREATHING TRIAL; MECHANICAL VENTILATION; MYASTHENIC CRISIS;
   NEUROSURGICAL PATIENTS; RISK-FACTORS; REINTUBATION; PARAMETERS;
   CRITERIA; SUPPORT; BIAS
AB Background: Prediction of extubation failure, particularly in neurocritical patients, is unique and controversial. We conducted a systematic review and meta-analysis to identify the risk factors for extubation failure in these patients.
   Methods: A literature search of databases (MEDLINE, EMBASE, the Cochrane Library, and Web of Science) was performed up to August of 2013 to identify trials that evaluated extubation failure predictors. Included trials were either prospective or retrospective cohort studies.
   Results: Nine studies involving 928 participants were included. The systematic review and meta-analysis revealed that the following were predictive for extubation failure: pneumonia, atelectasis, mechanical ventilation of >24 h, a low Glasgow Coma Scale score (7-9T) (OR=4.96, 95% CI=1.61-15.26, P=0.005), the inability to follow commands (OR=2.07, 95% C=1.15-3.71, P=0.02), especially the command to close the eyes, thick secretion, and no intact gag reflex. Meanwhile, the following were not predictive for extubation failure: sex, secretion volume, coughing upon suctioning, and the inability to follow one command among showing two fingers, wiggling the toes, or coughing on command. Additionally, some traditional weaning parameters were shown to poorly predict extubation failure in neurocritical patients.
   Conclusions: Besides pneumonia, atelectasis, and the duration of mechanical ventilation, other factors that should be taken into consideration in the prediction of extubation failure when neurocritical patients are weaned from tracheal intubation include neurologic abilities (Glasgow Coma Scale score and following commands), the secretion texture, and the presence of a gag reflex.
C1 [Wang, Shengnan; Zhang, Lili; Huang, Kaibin; Lin, Zhenzhou; Pan, Suyue] Southern Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou 510515, Guangdong, Peoples R China.
   [Zhang, Lili] Second Peoples Hosp Chengdu, Dept Neurol, Chengdu 610017, Peoples R China.
   [Qiao, Weiguang] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China.
RP Pan, SY (reprint author), Southern Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou 510515, Guangdong, Peoples R China.
EM pansuyue82@126.com
FU President Foundation of Nanfang Hospital, Southern Medical University
   [2012C004]
FX The study design was financially supported by President Foundation of
   Nanfang Hospital, Southern Medical University (2012C004). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Anderson CD, 2011, NEUROCRIT CARE, V15, P490, DOI 10.1007/s12028-010-9369-7
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beuret P, 2009, INTENS CARE MED, V35, P1090, DOI 10.1007/s00134-009-1404-9
   BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460
   Castro AAM, 2012, ARCH BRONCONEUMOL, V48, P274, DOI 10.1016/j.arbres.2012.04.010
   Chevron V, 1998, CRIT CARE MED, V26, P1049, DOI 10.1097/00003246-199806000-00026
   Coplin WM, 2000, AM J RESP CRIT CARE, V161, P1530, DOI 10.1164/ajrccm.161.5.9905102
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Epstein SK, 2004, CRIT CARE, V8, P310, DOI 10.1186/cc2927
   Epstein SK, 2001, CHEST, V120, P1061, DOI 10.1378/chest.120.4.1061
   Frutos-Vivar F, 2006, CHEST, V130, P1664, DOI 10.1378/chest.130.6.1664
   Khamiees M, 2001, CHEST, V120, P1262, DOI 10.1378/chest.120.4.1262
   Ko R, 2009, NEUROCRIT CARE, V10, P269, DOI 10.1007/s12028-008-9181-9
   Krishnan JA, 2004, AM J RESP CRIT CARE, V169, P673, DOI 10.1164/rccm.200306-7610C
   Kulkarni AP, 2008, INDIAN J CRIT CARE M, V12, P1, DOI 10.4103/0972-5229.40942
   MacIntyre N R, 2001, Chest, V120, p375S
   Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699
   Namen AM, 2001, AM J RESP CRIT CARE, V163, P658, DOI 10.1164/ajrccm.163.3.2003060
   Navalesi P, 2008, CRIT CARE MED, V36, P2986, DOI 10.1097/CCM.0b013e31818b35f2
   Rabinstein AA, 2005, NEUROCRIT CARE, V3, P213, DOI 10.1385/Neurocrit.Care2005;03:213-215
   Salam A, 2004, INTENS CARE MED, V30, P1334, DOI 10.1007/s00134-004-2231-7
   Seneviratne J, 2008, ARCH NEUROL-CHICAGO, V65, P929, DOI 10.1001/archneur.65.7.929
   Tanios MA, 2006, CRIT CARE MED, V34, P2530, DOI 10.1097/01.CCM.0000236546.98861.25
   Vallverdu I, 1998, AM J RESP CRIT CARE, V158, P1855, DOI 10.1164/ajrccm.158.6.9712135
   Vidotto MC, 2008, NEUROCRIT CARE, V9, P83, DOI 10.1007/s12028-008-9059-x
   Vidotto MC, 2012, RESP CARE, V57, P2059, DOI 10.4187/respcare.01039
   Wells GA, 2012, NEWCASTLE OTTAWA SCA
   Wendell LC, 2011, STROKE RES TREAT, DOI 10.4061/2011/248789
   Wu JY, 2009, NEUROCRIT CARE, V10, P35, DOI 10.1007/s12028-008-9139-y
NR 29
TC 10
Z9 10
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 8
PY 2014
VL 9
IS 12
AR e112198
DI 10.1371/journal.pone.0112198
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX4MX
UT WOS:000346907600007
PM 25486091
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Francis, G
   Tanzman, J
   Matthews, WJ
AF Francis, Gregory
   Tanzman, Jay
   Matthews, William J.
TI Excess Success for Psychology Articles in the Journal Science
SO PLOS ONE
LA English
DT Article
ID PUBLICATION BIAS; DECISION-MAKING; GOOD FIT; CONSEQUENCES; INCENTIVES;
   PREVALENCE; FAILURE; TRUTH; TOO; RED
AB This article describes a systematic analysis of the relationship between empirical data and theoretical conclusions for a set of experimental psychology articles published in the journal Science between 2005-2012. When the success rate of a set of empirical studies is much higher than would be expected relative to the experiments' reported effects and sample sizes, it suggests that null findings have been suppressed, that the experiments or analyses were inappropriate, or that the theory does not properly follow from the data. The analyses herein indicate such excess success for 83% (15 out of 18) of the articles in Science that report four or more studies and contain sufficient information for the analysis. This result suggests a systematic pattern of excess success among psychology articles in the journal Science.
C1 [Francis, Gregory] Purdue Univ, Dept Psychol Sci, W Lafayette, IN 47907 USA.
   [Francis, Gregory] Ecole Polytech Fed Lausanne, Brain Mind Inst, Lausanne, Switzerland.
   [Tanzman, Jay] Tanzman Stat Consulting, Los Angeles, CA USA.
   [Matthews, William J.] Univ Cambridge, Dept Psychol, Cambridge, England.
RP Francis, G (reprint author), Purdue Univ, Dept Psychol Sci, W Lafayette, IN 47907 USA.
EM gfrancis@purdue.edu
RI Francis, Gregory/D-1924-2010
OI Francis, Gregory/0000-0002-8634-794X
CR Ackerman JM, 2010, SCIENCE, V328, P1712, DOI 10.1126/science.1189993
   ANSCOMBE FJ, 1954, BIOMETRICS, V10, P89, DOI 10.2307/3001665
   Bahrami B, 2010, SCIENCE, V329, P1081, DOI 10.1126/science.1185718
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bem DJ, 2011, J PERS SOC PSYCHOL, V100, P407, DOI 10.1037/a0021524
   Bones AK, 2012, PERSPECT PSYCHOL SCI, V7, P307, DOI 10.1177/1745691612441216
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Champely S, 2009, PWR BASIC FUNCTIONS
   Cumming G, 2014, PSYCHOL SCI, V25, P7, DOI 10.1177/0956797613504966
   Dijksterhuis A, 2006, SCIENCE, V311, P1005, DOI 10.1126/science.1121629
   Doyen S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029081
   Fanelli D, 2012, SCIENTOMETRICS, V90, P891, DOI 10.1007/s11192-011-0494-7
   Ferguson CJ, 2012, PERSPECT PSYCHOL SCI, V7, P555, DOI 10.1177/1745691612459059
   Francis G, 2014, GENETICS, V198, P449, DOI 10.1534/genetics.114.163998
   Francis G, 2014, PSYCHON B REV, V21, P1180, DOI 10.3758/s13423-014-0601-x
   Francis G, 2013, J MATH PSYCHOL, V57, P190, DOI 10.1016/j.jmp.2013.06.001
   Francis G, 2013, J MATH PSYCHOL, V57, P153, DOI 10.1016/j.jmp.2013.02.003
   Francis G, 2013, J EXP PSYCHOL GEN, V142, P292, DOI 10.1037/a0027923
   Francis G, 2012, PERSPECT PSYCHOL SCI, V7, P585, DOI 10.1177/1745691612459520
   Francis G, 2012, I-PERCEPTION, V3, P176, DOI 10.1068/i0519ic
   Francis G, 2012, P NATL ACAD SCI USA, V109, pE1587, DOI 10.1073/pnas.1203591109
   Francis G, 2012, PSYCHON B REV, V19, P151, DOI 10.3758/s13423-012-0227-9
   Gervais WM, 2012, SCIENCE, V336, P493, DOI 10.1126/science.1215647
   Halperin E, 2011, SCIENCE, V333, P1767, DOI 10.1126/science.1202925
   Ioannidis JPA, 2007, CLIN TRIALS, V4, P245, DOI 10.1177/1740774507079441
   John LK, 2012, PSYCHOL SCI, V23, P524, DOI 10.1177/0956797611430953
   Johnson CS, 2012, J PERS SOC PSYCHOL, V103, P605, DOI 10.1037/a0030145
   KELLEY K, 2007, J STAT SOFTWARE, V20
   Kerr N L, 1998, Pers Soc Psychol Rev, V2, P196, DOI 10.1207/s15327957pspr0203_4
   Kicinski M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081823
   Kovacs AM, 2010, SCIENCE, V330, P1830, DOI 10.1126/science.1190792
   Kruschke JK, 2010, WIRES COGN SCI, V1, P658, DOI 10.1002/wcs.72
   Levelt Noort Drenth Committees, 2012, FLAW SCI FRAUD RES P
   Masicampo EJ, 2012, Q J EXP PSYCHOL, V65, P2271, DOI 10.1080/17470218.2012.711335
   Matthews WJ, 2011, JUDGM DECIS MAK, V6, P843
   Mehta R, 2009, SCIENCE, V323, P1226, DOI 10.1126/science.1169144
   Morewedge CK, 2010, SCIENCE, V330, P1530, DOI 10.1126/science.1195701
   Morey RD, 2014, PSYCHOL SCI, V25, P1289, DOI 10.1177/0956797614525969
   Myung JI, 2009, PSYCHOL REV, V116, P499, DOI 10.1037/a0016104
   Nosek BA, 2012, PERSPECT PSYCHOL SCI, V7, P615, DOI 10.1177/1745691612459058
   Pashler H, 2012, PERSPECT PSYCHOL SCI, V7, P528, DOI 10.1177/1745691612465253
   Paukner A, 2009, SCIENCE, V325, P880, DOI 10.1126/science.1176269
   Pitt MA, 2002, TRENDS COGN SCI, V6, P421, DOI 10.1016/S1364-6613(02)01964-2
   Ramirez G, 2011, SCIENCE, V331, P211, DOI 10.1126/science.1199427
   Renkewitz F, 2011, JUDGM DECIS MAK, V6, P870
   Roberts S, 2000, PSYCHOL REV, V107, P358, DOI 10.1037//0033-295X.107.2.358
   Schimmack U, 2012, PSYCHOL METHODS, V17, P551, DOI 10.1037/a0029487
   Seeley TD, 2012, SCIENCE, V335, P108, DOI 10.1126/science.1210361
   Shah AK, 2012, SCIENCE, V338, P682, DOI 10.1126/science.1222426
   Shanks DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056515
   Simmons JP, 2011, PSYCHOL SCI, V22, P1359, DOI 10.1177/0956797611417632
   Stapel DA, 2011, SCIENCE, V332, P251, DOI 10.1126/science.1201068
   Strube MJ, 2006, BEHAV RES METHODS, V38, P24, DOI 10.3758/BF03192746
   THOMPSON B, 2002, ED RES, V31, P25, DOI DOI 10.3102/0013189X031003025
   Vohs KD, 2006, SCIENCE, V314, P1154, DOI 10.1126/science.1132491
   Wagenmakers EJ, 2007, PSYCHON B REV, V14, P779, DOI 10.3758/BF03194105
   Wagenmakers EJ, 2012, PERSPECT PSYCHOL SCI, V7, P632, DOI 10.1177/1745691612463078
   Weisbuch M, 2009, SCIENCE, V326, P1711, DOI 10.1126/science.1178358
   Whitson JA, 2008, SCIENCE, V322, P115, DOI 10.1126/science.1159845
   Wood JN, 2007, SCIENCE, V317, P1402, DOI 10.1126/science.1144663
   YONG E, 2012, NATURE, DOI DOI 10.1038/NATURE.2012.11535
   Yong E, 2012, NATURE, V485, P298, DOI 10.1038/485298a
   Zhong CB, 2006, SCIENCE, V313, P1451, DOI 10.1126/science.1130726
NR 63
TC 29
Z9 29
U1 0
U2 31
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 4
PY 2014
VL 9
IS 12
AR e114255
DI 10.1371/journal.pone.0114255
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6MB
UT WOS:000346382500007
PM 25474317
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yu, XN
   Lyu, DN
   Dong, XR
   He, JL
   Yao, K
AF Yu, Xiaoning
   Lyu, Danni
   Dong, Xinran
   He, Jiliang
   Yao, Ke
TI Hypertension and Risk of Cataract: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID AGE-RELATED CATARACT; C-REACTIVE PROTEIN; LONG-TERM INCIDENCE; LENS
   OPACITIES; METABOLIC SYNDROME; CARDIOVASCULAR-DISEASE; SYSTEMIC
   HYPERTENSION; VISUAL IMPAIRMENT; 5-YEAR INCIDENCE; EYE DISEASES
AB Background: Cataract is the major cause of blindness across the world. Many epidemiologic studies indicated that hypertension might play an important role in the development of cataract, while others not. We therefore conducted this meta-analysis to determine the relationship between risk of cataract and hypertension.
   Methods: Retrieved studies on the association of hypertension with cataract risk were collected from PubMed, Web of Science and the Cochrane Library during June 2014 and were included into the final analysis according to the definite inclusion criteria. Odds ratio (OR) or risk ratio (RR) were pooled with 95% confidence interval (CI) to evaluate the relationship between hypertension and cataract risk. Subgroup analyses were carried out on the basis of cataract type, race and whether studies were adjusted for main components of metabolic syndrome (MS).
   Results: The final meta-analysis included 25 studies (9 cohort, 5 case-control and 11 cross-sectional) from 23 articles. The pooled results showed that cataract risk in populations with hypertension significantly increased among cohort studies (RR 1.08; 95% CI: 1.05-1.12) and case-control or cross-sectional studies (OR 1.28; 95% CI: 1.12-1.45). This association was proved to be true among both Mongolians and Caucasians, and the significance was not altered by the adjustment of main components of MS. Subgroup analysis on cataract types indicated that an increased incidence of posterior subcapsular cataract (PSC) resulted among cohort studies (RR 1.22; 95% CI: 1.03-1.46) and cross-sectional/case-control studies (OR 1.23; 95% CI: 1.09-1.39). No association of hypertension with risk of nuclear cataract was found.
   Conclusions: The present meta-analysis suggests that hypertension increases the risk of cataract, especially PSC. Further efforts should be made to explore the potential biological mechanisms.
C1 [Yu, Xiaoning; Lyu, Danni; Dong, Xinran; Yao, Ke] Zhejiang Univ, Sch Med, Ctr Eye, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China.
   [He, Jiliang] Zhejiang Univ, Sch Med, Inst Environm Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [Yao, Ke] Zhejiang Prov Key Lab Ophthalmol, Hangzhou, Zhejiang, Peoples R China.
RP Yao, K (reprint author), Zhejiang Univ, Sch Med, Ctr Eye, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China.
EM xlren@zju.edu.cn
FU Key Program of National Science Foundation of China [81130018]; National
   "Twelfth Five-Year" Plan for Science & Technology Support of China
   [2012BAI08B01]; Project of National Clinical Key Discipline of Chinese
   Ministry of Health
FX The present study was supported by Key Program of National Science
   Foundation of China (No. 81130018), National "Twelfth Five-Year" Plan
   for Science & Technology Support of China (NO. 2012BAI08B01) and Project
   of National Clinical Key Discipline of Chinese Ministry of Health. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Angra SK, 2000, ANN OPHTHALMOL, V32, P101, DOI 10.1007/s12009-000-0025-2
   Bautista LE, 2005, J HUM HYPERTENS, V19, P149, DOI 10.1038/sj.jhh.1001785
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BURGESS CA, 1992, OPTOMETRY VISION SCI, V69, P320, DOI 10.1097/00006324-199204000-00011
   Chen KJ, 2011, J NUTR HEALTH AGING, V15, P304, DOI 10.1007/s12603-010-0282-8
   Cumming RG, 1998, OPHTHALMOLOGY, V105, P1751, DOI 10.1016/S0161-6420(98)99049-2
   Delcourt C, 2003, OPHTHALMOLOGY, V110, P2318, DOI 10.1016/S0161-6420(03)00713-9
   Delcourt C, 2000, AM J EPIDEMIOL, V151, P497
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Galeone C, 2010, ANN EPIDEMIOL, V20, P380, DOI 10.1016/j.annepidem.2010.01.009
   GHAEM MH, 2014, INVEST OPHTH VIS SCI, V5, P641, DOI DOI 10.1167/IOVS.12-10980
   Goldacre MJ, 2012, BRIT J OPHTHALMOL, V96, P872, DOI 10.1136/bjophthalmol-2012-301519
   Goodrich M E, 1999, Ophthalmic Epidemiol, V6, P279, DOI 10.1076/opep.6.4.279.4188
   GREW J, 2011, INVEST OPHTH VIS SCI, V52, P7778, DOI DOI 10.1167/IOVS.10-7113
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HIRVELA H, 1995, OPHTHALMOLOGY, V102, P108
   IRELAND ME, 1991, INVEST OPHTH VIS SCI, V32, P541
   ISAAC NE, 1991, ARCH OPHTHALMOL-CHIC, V109, P256, DOI 10.1001/archopht.1991.01080020102053
   *IT AM CAT STUD GR, 1991, AM J EPIDEMIOL, V133, P541
   Johnson AC, 2013, MAMM GENOME, V24, P95, DOI 10.1007/s00335-013-9447-1
   Kanthan GL, 2009, BRIT J OPHTHALMOL, V93, P1210, DOI 10.1136/bjo.2008.153379
   Klein BEK, 1998, AM J OPHTHALMOL, V126, P782, DOI 10.1016/S0002-9394(98)00280-3
   Klein BEK, 2006, AM J OPHTHALMOL, V141, P116, DOI 10.1016/j.ajo.2005.08.021
   KLEIN BEK, 1995, AM J OPHTHALMOL, V119, P640, DOI 10.1016/S0002-9394(14)70223-5
   Klein BEK, 2001, OPHTHALMOLOGY, V108, P1670, DOI 10.1016/S0161-6420(01)00656-X
   Lee SM, 1997, OPHTHALMIC RES, V29, P83, DOI 10.1159/000268001
   Leske MC, 1998, AM J EPIDEMIOL, V147, P36
   Leske MC, 1999, OPHTHALMOLOGY, V106, P35, DOI 10.1016/S0161-6420(99)90003-9
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   Leske MC, 2002, OPHTHALMOLOGY, V109, P1303, DOI 10.1016/S0161-6420(02)01094-1
   Lindblad BE, 2008, OPHTHALMOLOGY, V115, P1687, DOI 10.1016/j.ophtha.2008.04.004
   Machan CM, 2012, OPTOMETRY VISION SCI, V89, P1165, DOI 10.1097/OPX.0b013e3182644cd1
   Maralani HG, 2013, INVEST OPHTH VIS SCI, V54, P641, DOI 10.1167/iovs.12-10980
   McCarty CA, 2000, INVEST OPHTH VIS SCI, V41, P3720
   McCarty CA, 1999, AM J OPHTHALMOL, V128, P446, DOI 10.1016/S0002-9394(99)00218-4
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Mukesh BN, 2006, ARCH OPHTHALMOL-CHIC, V124, P79, DOI 10.1001/archopht.124.1.79
   NETMET AY, 2010, EYE, V24, P1352
   Nirmalan PK, 2004, BRIT J OPHTHALMOL, V88, P989, DOI 10.1136/bjo.2003.038380
   Ornek K, 2003, EXP EYE RES, V76, P23, DOI 10.1016/S0014-4835(02)00268-3
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Paunksnis A, 2007, EUR J OPHTHALMOL, V17, P605
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richter GM, 2012, OPHTHALMOLOGY, V119, P2040, DOI 10.1016/j.ophtha.2012.05.001
   Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05
   Rim THT, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-4
   Sabanayagam C, 2011, INVEST OPHTH VIS SCI, V52, P2397, DOI 10.1167/iovs.10-6373
   SAGENT CR, 1987, HYPERTENSION, V9, P304
   SARGENT CR, 1996, HYPERTENSION, V28, P440
   Schaumberg DA, 2001, ANN EPIDEMIOL, V11, P104, DOI 10.1016/S1047-2797(00)00178-2
   Schaumberg DA, 1999, ANN EPIDEMIOL, V9, P166, DOI 10.1016/S1047-2797(98)00049-0
   SCREENIVAS V, 1999, J EPIDEMIOL, V9, P327, DOI DOI 10.2188/JEA.9.327
   Shah SP, 2007, OPHTHAL EPIDEMIOL, V14, P381, DOI 10.1080/09286580701375179
   SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712
   Storey P, 2013, INVEST OPHTH VIS SCI, V54, P3010, DOI 10.1167/iovs.12-11412
   Tan JSL, 2008, OPHTHAL EPIDEMIOL, V15, P317, DOI 10.1080/09286580802105806
   Tavani Alessandra, 1995, Annals of Epidemiology, V5, P234, DOI 10.1016/1047-2797(94)00111-6
   Tsai SY, 2003, OPHTHALMOLOGY, V110, P1089, DOI 10.1016/S0161-6420(03)00243-4
   Ughade Suresh N., 1998, Indian Journal of Ophthalmology, V46, P221
   Wang S, 2009, OPHTHALMOLOGY, V116, P2373, DOI 10.1016/j.ophtha.2009.05.041
   Wells G, 2012, THE NEWCASTLE OTTAWA
   Xu L, 2006, OPHTHALMOLOGY, V113, P747, DOI 10.1016/j.ophtha.2006.01.026
   YE JJ, 1992, EXP EYE RES, V55, P797, DOI 10.1016/0014-4835(92)90006-E
   Younan C, 2003, OPHTHALMIC EPIDEMIOL, V10, P227, DOI 10.1076/opep.10.4.227.15905
   Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690
NR 67
TC 26
Z9 27
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 4
PY 2014
VL 9
IS 12
AR e114012
DI 10.1371/journal.pone.0114012
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW6MB
UT WOS:000346382500104
PM 25474403
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Peng, SL
   Zhao, Y
   Xu, F
   Jia, CJ
   Xu, YQ
   Dai, CL
AF Peng, Songlin
   Zhao, Yang
   Xu, Feng
   Jia, Changjun
   Xu, Yongqing
   Dai, Chaoliu
TI An Updated Meta-Analysis of Randomized Controlled Trials Assessing the
   Effect of Sorafenib in Advanced Hepatocellular Carcinoma
SO PLOS ONE
LA English
DT Article
ID PHASE-III TRIAL; CLINICAL-TRIALS; RAF/MEK/ERK PATHWAY; BAY 43-9006;
   EFFICACY; QUALITY; ANGIOGENESIS; EXPERIENCE; INHIBITOR; TARGETS
AB Background: The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains controversial. Therefore, we conducted a meta-analysis to evaluate the efficacy and safety of sorafenib for treating patients with advanced HCC.
   Methods: The PubMed, Embase, and Web of Science databases were searched. Eligible studies were randomized controlled trials (RCTs) that assessed sorafenib therapy in patients with advanced HCC. The outcomes included overall survival (OS), time to progression (TTP), overall response rate (ORR), and toxicities. Hazard ratio (HR) and risk ratio (RR) were used for the meta-analysis and were expressed with 95% confidence intervals (CIs).
   Results: Seven RCTs, with a total of 3807 patients, were included in this metaanalysis. All patients received sorafenib alone, or with other chemotherapeutic regimens. Pooled estimates showed that sorafenib improved the OS (HR=0.74, 95% CI: 0.61, 0.90; P=0.002), or TTP outcomes (HR=0.69, 95% CI: 0.55, 0.86; P=0.001). Subgroup analysis revealed that sorafenib was more effective in the patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1-2 (HR=0.77, 95% CI: 0.60, 1.0; P=0.05), or macroscopic vascular invasion (MVI), and/or extrahepatic spread (EHS) (HR=0.65, 95% CI: 0.46, 0.93; P=0.02), in terms of OS. Patients who received sorafenib did not have a higher ORR (RR=0.85, 95% CI: 0.65, 1.11; P=0.10). In addition, there was a slight increase in toxicity in the sorafenib group.
   Conclusion: Treatment with sorafenib significantly improved OS and TTP in patients with advanced HCC. Additional large-scale, well-designed RCTs are needed to evaluate the efficacy of sorafenib-based therapy in the treatment of advanced HCC.
C1 [Peng, Songlin; Zhao, Yang; Xu, Feng; Jia, Changjun; Xu, Yongqing; Dai, Chaoliu] China Med Univ, Affiliated Shengjing Hosp, Dept Hepatobiliary Surg, Shenyang 110004, Peoples R China.
RP Dai, CL (reprint author), China Med Univ, Affiliated Shengjing Hosp, Dept Hepatobiliary Surg, Shenyang 110004, Peoples R China.
EM daicl@sj-hospital.org
FU Shengyang science and technology project plan [F13-221-924]
FX The study was supported by Shengyang science and technology project plan
   (F13-221-924). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Abdel-Rahman O, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0655-z
   Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441
   Abou-Alfa GK, 2010, JAMA-J AM MED ASSOC, V304, P2154, DOI 10.1001/jama.2010.1672
   Adnane L, 2006, METHOD ENZYMOL, V407, P597, DOI 10.1016/S0076-6879(05)07047-3
   Balsom SM, 2010, ONCOLOGY-BASEL, V78, P210, DOI 10.1159/000313701
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bruix J, 2012, J HEPATOL, V57, P821, DOI 10.1016/j.jhep.2012.06.014
   Brunocilla PR, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0345-2
   Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069
   Cheng AL, 2013, J CLIN ONCOL, V31, P4067, DOI 10.1200/JCO.2012.45.8372
   Cheng AL, 2012, EUR J CANCER, V48, P1452, DOI 10.1016/j.ejca.2011.12.006
   Del Prete S, 2010, CANCER CHEMOTH PHARM, V66, P837, DOI 10.1007/s00280-009-1226-z
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gast.2004.09.014
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Iavarone M, 2011, HEPATOLOGY, V54, P2055, DOI 10.1002/hep.24644
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Johnson PJ, 2013, J CLIN ONCOL, V31, P3517, DOI 10.1200/JCO.2012.48.4410
   Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010
   Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007
   Llovet JM, 1999, HEPATOLOGY, V29, P62, DOI 10.1002/hep.510290145
   Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122
   Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Llovet JM, 2008, J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134
   Manghisi G, 1998, HEPATOLOGY, V28, P751
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Nordenstedt H, 2010, DIGEST LIVER DIS, V42, pS206, DOI 10.1016/S1590-8658(10)60507-5
   Pinter M, 2011, ALIMENT PHARM THER, V34, P949, DOI 10.1111/j.1365-2036.2011.04823.x
   Semela D, 2004, J HEPATOL, V41, P864, DOI 10.1016/j.jhep.2004.09.006
   Song TQ, 2011, EUR J GASTROEN HEPAT, V23, P1233, DOI 10.1097/MEG.0b013e32834bd2d0
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Trojniak MP, 2012, IMMUNOPHARM IMMUNOT, V34, P419, DOI 10.3109/08923973.2011.617373
   Wang Z, 2013, ASIAN PAC J CANCER P, V14, P691, DOI 10.7314/APJCP.2013.14.2.691
   Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Wood LS, 2006, COMMUNITY ONCOL, V3, P558
   Yang YP, 2012, CELL BIOCHEM BIOPHYS, V63, P159, DOI 10.1007/s12013-012-9353-2
   Yau T, 2009, CANCER-AM CANCER SOC, V115, P428, DOI 10.1002/cncr.24029
   Zhang X, 2012, HEPATOB PANCREAT DIS, V11, P458, DOI 10.1016/S1499-3872(12)60209-4
NR 42
TC 15
Z9 15
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2014
VL 9
IS 12
AR e112530
DI 10.1371/journal.pone.0112530
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU8TQ
UT WOS:000345869700018
PM 25460347
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Du, QX
   Sun, YC
   Ding, N
   Lu, LJ
   Chen, Y
AF Du, Qingxia
   Sun, Yongchang
   Ding, Ning
   Lu, Lijin
   Chen, Ying
TI Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients
   with COPD: A Meta-Analysis of Observational Studies
SO PLOS ONE
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; ACUTE MYOCARDIAL-INFARCTION;
   ISCHEMIC-HEART-DISEASE; ELDERLY PATIENTS; CORONARY; THERAPY; ASTHMA;
   EPIDEMIOLOGY; ASSOCIATION; ACTIVATION
AB Background: Cardiovascular disease is a primary cause of death in patients with chronic obstructive pulmonary disease (COPD). Beta-blockers have been proved to reduce morbidity and improve survival in patients with cardiac diseases. But the effects of beta-blockers on outcomes in patients with COPD remain controversial. The objective of this meta-analysis was to assess the effect of beta-blockers on mortality and exacerbation in patients with COPD.
   Methods: An extensive search of the EMBASE, MEDLINE and Cochrane was performed to retrieve the studies of beta-blockers treatment in patients with COPD. The random effects model meta-analysis was used to evaluate effect on overall mortality and exacerbation of COPD.
   Results: Fifteen original observational cohort studies with a follow-up time from 1 to 7.2 years were included. The results revealed that beta-blockers treatment significantly decreased the risk of overall mortality and exacerbation of COPD. The relative risk (RR) for overall mortality was 0.72 (0.63 to 0.83), and for exacerbation of COPD was 0.63 (0.57 to 0.71). In subgroup analysis of COPD patients with coronary heart disease or heart failure, the risk for overall mortality was 0.64 (0.54-0.76) and 0.74 (0.58-0.93), respectively.
   Conclusion: The findings of this meta-analysis confirmed that beta-blocker use in patients with COPD may not only decrease the risk of overall mortality but also reduce the risk of exacerbation of COPD. Beta-blocker prescription for cardiovascular diseases needs to improve in COPD patients.
C1 [Sun, Yongchang] Capital Med Univ, Beijing Tongren Hosp, Dept Resp Med, Beijing 100730, Peoples R China.
   Capital Med Univ, Beijing Tongren Hosp, Dept Emergency, Beijing 100730, Peoples R China.
RP Sun, YC (reprint author), Capital Med Univ, Beijing Tongren Hosp, Dept Resp Med, Beijing 100730, Peoples R China.
EM suny@ccmu.edu.cn
FU National Natural Science Foundation of China [81170039]
FX Funding: This work was supported by the National Natural Science
   Foundation of China (81170039). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Andreas S, 2005, CHEST, V128, P3618, DOI 10.1378/chest.128.5.3618
   Andrikopoulos G, 2012, HELL J CARDIOL, V53, P118
   Angeloni E, 2012, ANN THORACIC SURG
   Asano K, 1997, AVIAT SPACE ENVIR MD, V68, P104
   Au DH, 2004, AM J MED, V117, P925, DOI 10.1016/j.amjmed.2004.07.043
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belli G, 1995, CONT INTERN MED, V7, P51
   Black HR, 1997, ARCH INTERN MED, V157, P2413
   Callaerts-Vegh Z, 2004, P NATL ACAD SCI USA, V101, P4948, DOI 10.1073/pnas.0400452101
   Chapman KR, 2006, EUR RESPIR J, V27, P188, DOI 10.1183/09031936.06.00024505
   Chen J, 2001, J AM COLL CARDIOL, V37, P1950, DOI 10.1016/S0735-1097(01)01225-6
   Craig Timothy, 1996, Comprehensive Therapy, V22, P339
   Dransfield MT, 2008, THORAX, V63, P301, DOI 10.1136/thx.2007.081893
   Egred M, 2005, QJM-INT J MED, V98, P493, DOI 10.1093/qjmed/hci080
   Ekstrom MP, 2013, AM J RESP CRIT CARE, V187, P715, DOI 10.1164/rccm.201208-1565OC
   Etminan M, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-48
   Fleisher LA, 2007, CIRCULATION, V116, pE418, DOI 10.1161/CIRCULATIONAHA.107.185699
   Fleisher LA, 2009, CIRCULATION, V120, pE169, DOI 10.1161/CIRCULATIONAHA.109.192690
   FLETCHER C, 1977, BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645
   Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801
   Hanania NA, 2008, PULM PHARMACOL THER, V21, P134, DOI 10.1016/j.pupt.2007.07.002
   Hawkins NM, 2009, EUR J HEART FAIL, V11, P292, DOI 10.1093/eurjhf/hfp001
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hunt SA, 2009, J AM COLL CARDIOL, V53, pE1, DOI 10.1016/j.jacc.2008.11.013
   Kendall MJ, 1997, AM J CARDIOL, V80, pJ15, DOI 10.1016/S0002-9149(97)00833-3
   KULLER LH, 1989, AM REV RESPIR DIS, V140, pS76, DOI 10.1164/ajrccm/140.3_Pt_2.S76
   Lin R, 2008, PULM PHARMACOL THER, V21, P115, DOI 10.1016/j.pupt.2007.06.003
   Ling Y, 2008, EUR RESPIR J, V31, P905, DOI 10.1183/09031936.00153707
   Mentz RJ, 2013, AM J CARDIOL, V111, P582, DOI 10.1016/j.amjcard.2012.10.041
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Moss AJ, 2007, CIRCULATION, V115, P2481, DOI 10.1161/CIRCULATIONAHA.106.665406
   Nguyen LP, 2008, AM J RESP CELL MOL, V38, P256, DOI 10.1165/rcmb.2007-0279RC
   Olenchock BA, 2009, AM J CARDIOL, V103, P295, DOI 10.1016/j.amjcard.2008.09.081
   OMALLEY K, 1991, AM J MED, V90, pS27, DOI 10.1016/0002-9343(91)90433-X
   Palatini P, 1997, J HUM HYPERTENS, V11, pS19
   Rutten FH, 2010, ARCH INTERN MED, V170, P880, DOI 10.1001/archinternmed.2010.112
   Salpeter S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003566.pub2
   Short PM, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2549
   Sin DD, 2002, AM J MED, V113, P650, DOI 10.1016/S0002-9343(02)01346-3
   Smith SC, 2006, J AM COLL CARDIOL, V47, P2130, DOI 10.1016/j.jacc.2006.04.026
   Staszewsky L, 2007, J CARD FAIL, V13, P797, DOI 10.1016/j.cardfail.2007.07.012
   Stefan MS, 2012, THORAX, V67, P977, DOI 10.1136/thoraxjnl-2012-201945
   Tatters field AE, 1986, J CARDIOVASC PHAR S4, pS35
   TATTERSFIELD A E, 1991, Cardiovascular Drugs and Therapy, V4, P1229, DOI 10.1007/BF00114225
   Tjugen TB, 2010, CURR HYPERTENS REP, V12, P162, DOI 10.1007/s11906-010-0104-8
   van Gestel YRBM, 2008, AM J RESP CRIT CARE, V178, P695, DOI 10.1164/rccm.200803-384OC
NR 46
TC 49
Z9 50
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 26
PY 2014
VL 9
IS 11
AR e113048
DI 10.1371/journal.pone.0113048
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA8CZ
UT WOS:000349145400029
PM 25427000
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhao, ZH
   Liao, GX
   Li, YQ
   Zhou, SL
   Zou, HQ
   Fernando, S
AF Zhao, Zhihong
   Liao, Guixiang
   Li, Yongqiang
   Zhou, Shulu
   Zou, Hequn
   Fernando, Samitha
TI Prognostic Value of Carbonic Anhydrase IX Immunohistochemical Expression
   in Renal Cell Carcinoma: A Meta-Analysis of the Literature
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTORS; GLOBAL EVALUATION
   TRIAL; INDEPENDENT PREDICTOR; INTERLEUKIN-2 THERAPY; TISSUE MICROARRAY;
   GENE-EXPRESSION; POOR-PROGNOSIS; CANCER-THERAPY; KIDNEY CANCER
AB Background: Carbonic anhydrase IX (CAIX) protein has been correlated with progression and survival in patients with renal cell carcinoma (RCC). The prognostic value of CAIX in RCC however, remains inconclusive according to published works. This study aimed to analyze CAIX as a biological marker to predict RCC patient prognosis.
   Methods: A literature search of the PubMed and Web of Knowledge databases was performed to retrieve original studies from their inception to December of 2013. Fifteen studies, collectively including a total of 2611 patients with renal cell carcinoma, were carefully reviewed. Standard meta-analysis methods were applied to evaluate the prognostic impact of CAIX expression on patient prognosis. The hazard ratio (HR) and its 95% confidence interval (CI) were recorded for the relationship between CAIX expression and survival, and the data were analyzed using Review Manager 5.2 software and Stata software 11.0.
   Results: In patients with RCC, low CAIX expression was associated with poor disease-specific survival (HR=1.89, 95% CI: 1.20-2.98, P=0.006), unfavorable progression-free survival (HR=2.62, 95% CI: 1.14-6.05, P=0.02) and worse overall survival (HR=2.03, 95% CI: 1.28-3.21, P=0.002). Furthermore, low CAIX expression was significantly associated with the presence of lymph node metastases (odds ratio (OR) =0.31, 95% CI=0.15-0.62, P=0.0009) and distant metastases (OR=0.66, 95% CI=0.46-0.96, P=0.03) and predicted a higher tumor grade (OR=0.41, 95% CI=0.31-0.54, P<0.00001).
   Conclusions: Low CAIX expression most likely indicates poor prognosis in RCC patients. Moreover, low CAIX expression was significantly associated with unfavorable clinicopathological factors. To strengthen our findings, further well-designed prospective studies should be conducted to investigate the role of CAIX expression in RCC.
C1 [Zhao, Zhihong; Li, Yongqiang; Zhou, Shulu; Zou, Hequn] Southern Med Univ, Affiliated Hosp 3, Inst Urol & Nephrol, Guangzhou, Guangdong, Peoples R China.
   [Liao, Guixiang] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China.
   [Fernando, Samitha] Univ London Imperial Coll Sci Technol & Med, London, England.
RP Zou, HQ (reprint author), Southern Med Univ, Affiliated Hosp 3, Inst Urol & Nephrol, Guangzhou, Guangdong, Peoples R China.
EM hequnzou@hotmail.com
FU Natural Science Foundation of China [81270840]
FX This work was supported by a Natural Science Foundation of China grant
   (81270840) [http://www.nsfc.gov.cn/]. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Atkins M, 2005, CLIN CANCER RES, V11, P3714, DOI 10.1158/1078-0432.CCR-04-2019
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Biswas S, 2012, CARCINOGENESIS, V33, P1717, DOI 10.1093/carcin/bgs222
   Brunelli M, 2008, MODERN PATHOL, V21, P1, DOI 10.1038/modpathol.3800967
   Bui MHT, 2004, J UROLOGY, V171, P2461, DOI 10.1097/01.0000116444.08690.e2
   Bui MHT, 2003, CLIN CANCER RES, V9, P802
   Cho D, 2007, CLIN GENITOURIN CANC, V5, P379, DOI 10.3816/CGC.2007.n.020
   Choschzick M, 2011, VIRCHOWS ARCH, V459, P193, DOI 10.1007/s00428-011-1105-y
   Choueiri TK, 2013, UROL ONCOL-SEMIN ORI, V31, P1788, DOI 10.1016/j.urolonc.2012.07.004
   da Costa WH, 2014, BJU INT, V113, pE157, DOI 10.1111/bju.12426
   Dahinden C, 2010, CLIN CANCER RES, V16, P88, DOI 10.1158/1078-0432.CCR-09-0260
   de la Taille A, 2000, UROLOGY, V56, P393, DOI 10.1016/S0090-4295(00)00647-6
   de Martino M, 2009, J UROLOGY, V182, P728, DOI 10.1016/j.juro.2009.03.077
   Di Napoli A, 2009, CANCER-AM CANCER SOC, V115, P2290, DOI 10.1002/cncr.24233
   Dorai T, 2005, EUR J CANCER, V41, P2935, DOI 10.1016/j.ejca.2005.09.011
   Dornbusch J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076386
   Driessen A, 2006, ANN SURG, V243, P334, DOI 10.1097/01.sla.0000201452.09591.f3
   Dudek AZ, 2010, ANTICANCER RES, V30, P987
   Eckel-Passow JE, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-48
   Edeline J, 2012, HUM PATHOL, V43, P1982, DOI 10.1016/j.humpath.2012.01.023
   Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7
   Garcia-Donas J, 2013, ANN ONCOL, V24, P2409, DOI 10.1093/annonc/mdt219
   Gigante M, 2012, ANTICANCER RES, V32, P5447
   Gilbert SM, 2006, UROLOGY, V67, P942, DOI 10.1016/j.urology.2005.11.034
   Girgis AH, 2012, CANCER RES, V72, P5273, DOI 10.1158/0008-5472.CAN-12-0656
   Gore ME, 2011, BRIT J CANCER, V104, P399, DOI 10.1038/sj.bjc.6606084
   Ilie M, 2013, LUNG CANCER, V82, P16, DOI 10.1016/j.lungcan.2013.07.005
   Jensen HK, 2008, BJU INT, V101, P41, DOI 10.1111/j.1464-410X.2008.07649.x
   Jensen HK, 2009, J CLIN ONCOL, V27, P4709, DOI 10.1200/JCO.2008.18.9498
   Jiang Z, 2006, LANCET ONCOL, V7, P556, DOI 10.1016/S1470-2045(06)70732-X
   Joseph RW, 2014, CANCER-AM CANCER SOC, V120, P1059, DOI 10.1002/cncr.28521
   Kim HL, 2005, J UROLOGY, V173, P1496, DOI 10.1097/01.ju.0000154351.37249.f0
   Kim HL, 2004, CLIN CANCER RES, V10, P5464, DOI 10.1158/1078-0432.CCR-04-0488
   Kim HS, 2010, UROL ONCOL-SEMIN ORI, V28, P157, DOI 10.1016/j.urolonc.2008.08.002
   Klatte T, 2007, CLIN CANCER RES, V13, P7388, DOI 10.1158/1078-0432.CCR-07-0411
   Klatte T, 2009, CLIN CANCER RES, V15, P1162, DOI 10.1158/1078-0432.CCR-08-1229
   Klatte T, 2009, J CLIN ONCOL, V27, P746, DOI 10.1200/JCO.2007.15.8345
   Klatte T, 2009, CANCER EPIDEM BIOMAR, V18, P894, DOI 10.1158/1055-9965.EPI-08-0786
   Koul H, 2011, AM J CANCER RES, V1, P240
   Krieg A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065338
   Kroeger N, 2012, EUR UROL, V61, P888, DOI 10.1016/j.eururo.2012.01.012
   Lam JS, 2005, CANCER-AM CANCER SOC, V103, P2517, DOI 10.1002/cncr.21127
   Leibovich BC, 2007, J CLIN ONCOL, V25, P4757, DOI 10.1200/JCO.2007.12.1087
   Li GR, 2008, J UROLOGY, V180, P510, DOI 10.1016/j.juro.2008.04.024
   Li GR, 2007, CLIN EXP METASTAS, V24, P149, DOI 10.1007/s10585-007-9064-z
   Maroto P., 2014, CLIN CANC RES
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   McCormick RI, 2013, BRIT J CANCER, V108, P1133, DOI 10.1038/bjc.2013.56
   Mocellin S, 2008, INT J CANCER, V123, P2370, DOI 10.1002/ijc.23794
   Lopez CM, 2012, CLIN GENITOURIN CANC, V10, P262, DOI 10.1016/j.clgc.2012.06.005
   Lopez CM, 2012, INVEST NEW DRUG, V30, P2443, DOI 10.1007/s10637-012-9836-4
   Papworth K, 2010, ANTICANCER RES, V30, P2953
   Parker AS, 2009, CANCER-AM CANCER SOC, V115, P2092, DOI 10.1002/cncr.24263
   PASTOREKOVA S, 1992, VIROLOGY, V187, P620, DOI 10.1016/0042-6822(92)90464-Z
   Patard JJ, 2008, INT J CANCER, V123, P395, DOI 10.1002/ijc.23496
   Pena C, 2010, CLIN CANCER RES, V16, P4853, DOI 10.1158/1078-0432.CCR-09-3343
   Phuoc NB, 2008, ONCOL REP, V20, P525, DOI 10.3892/or_00000037
   Potter C, 2004, CELL CYCLE, V3, P164
   Rasmussen S, 2013, IMMUNOPHARM IMMUNOT, V35, P487, DOI 10.3109/08923973.2013.802802
   Sandlund J, 2007, BJU INT, V100, P556, DOI 10.1111/j.1464-410X.2007.07006.x
   Shvarts O, 2005, J UROLOGY, V173, P725, DOI 10.1097/01.ju.0000152354.08057.2a
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Signoretti S, 2008, BJU INT, V101, P31, DOI 10.1111/j.1464-410X.2008.07646.x
   Sim SH, 2012, BRIT J CANCER, V107, P1131, DOI 10.1038/bjc.2012.360
   Soyupak B, 2005, UROL INT, V74, P68, DOI 10.1159/000082713
   Takacova M, 2013, ONCOL LETT, V5, P191, DOI 10.3892/ol.2012.1001
   Thiry A, 2006, TRENDS PHARMACOL SCI, V27, P566, DOI 10.1016/j.tips.2006.09.002
   Tripodi SA, 2004, J ENZYM INHIB MED CH, V19, P287, DOI 10.1080/14756360410001689531
   Xing XB, 2013, INT J CANCER, V132, P2589, DOI 10.1002/ijc.27947
   Xu C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009625
   Yu WJ, 2013, ACTA HISTOCHEM, V115, P452, DOI 10.1016/j.acthis.2012.10.009
   Zerati M, 2013, INT BRAZ J UROL, V39, P484, DOI 10.1590/S1677-5538.IBJU.2013.04.05
   Zhang BY, 2013, BJU INT, V111, P1046, DOI 10.1111/bju.12075
   Zhang YH, 2013, J SURG ONCOL, V108, P414, DOI 10.1002/jso.23402
   Zhou GX, 2010, UROLOGY, V75, P257, DOI 10.1016/j.urology.2009.09.052
NR 75
TC 12
Z9 13
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 26
PY 2014
VL 9
IS 11
AR e114096
DI 10.1371/journal.pone.0114096
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA8CZ
UT WOS:000349145400113
PM 25426861
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Dai, YE
   Tang, LJ
   Healy, J
   Sinnett, D
AF Dai, Yue-e
   Tang, Linjun
   Healy, Jasmine
   Sinnett, Daniel
TI Contribution of Polymorphisms in IKZF1 Gene to Childhood Acute Leukemia:
   A Meta-Analysis of 33 Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; SUSCEPTIBILITY LOCI; ASSOCIATION; ARID5B;
   VARIANTS; RISK; 10Q21.2; 7P12.2; IKAROS; POPULATION
AB Objective: Two common polymorphisms in the IKZF1 gene (rs4132601 and rs11978267 variants) have been reported to be associated with childhood acute leukemia (AL) risk, however the results were inconsistent. Here, we conducted a meta-analysis to generate large-scale evidence on whether IKZF1 variants are risk factors for childhood AL.
   Methods: The PubMed, Embase, EBSCO, and Web of Science were searched up to June 2, 2014 for studies on the association of IKZF1 polymorphisms with childhood AL risk. Data were extracted and the odd ratios (ORs) and95% confidence intervals (95% CIs) were calculated by a fixed-effects orrandom-effects model. Subgroup analysis by ethnicity and leukemia subtype, sensitivity and cumulative meta-analyses were performed. Moreover, publication bias was assessed by Begg's and Egger's tests.
   Results: In total, 33 case control studies were finally included in this meta-analysis. For rs4132601 polymorphism, significantly increased AL risk was observed in all genetic models (the association was still significant when the p value was Bonferroni adjusted to 0.025). In the subgroup analysis by tumor type, statistical association was observed in B-cell precursor ALL (BCP-ALL). Additionally, when stratified by ethnicity, significantly increased AL risk was only observed in European subgroup, but not among African or mixed population subgroups. Finally, similar results were found forrs11978267 polymorphism.
   Conclusion: In summary, this meta-analysis provides evidence that rs4132601 and rs11978267 polymorphisms in the IKZF1 gene mightcontribute to the occurrence of BCP-ALL, especially in European populations. Moreover, further studies with large sample size are required to clarify possibleroles of IKZF1 variants in other ethnic groups (e. g., Asians and Africans).
C1 [Dai, Yue-e] Nanjing Med Univ, Nanjing Childrens Hosp, Nanjing, Jiangsu, Peoples R China.
   [Tang, Linjun] Tongling Peoples Hosp, Dept Neurosurg, Tongling, Anhui, Peoples R China.
   [Healy, Jasmine; Sinnett, Daniel] St Justine Univ Hosp, Res Ctr, Montreal, PQ, Canada.
   [Sinnett, Daniel] Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ H3C 3J7, Canada.
RP Dai, YE (reprint author), Nanjing Med Univ, Nanjing Childrens Hosp, Nanjing, Jiangsu, Peoples R China.
EM yueedai@163.com
RI Sinnett, Daniel/S-4589-2017
OI Sinnett, Daniel/0000-0003-3625-6676
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Eden T, 2010, CANCER TREAT REV, V36, P286, DOI 10.1016/j.ctrv.2010.02.004
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ellinghaus E, 2012, LEUKEMIA, V26, P902, DOI 10.1038/leu.2011.302
   Emerenciano M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-127
   GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3
   Greaves M, 1999, EUR J CANCER, V35, P173, DOI 10.1016/S0959-8049(98)00433-X
   GREAVES MF, 1988, LEUKEMIA, V2, P120
   Harker N, 2002, MOL CELL, V10, P1403, DOI 10.1016/S1097-2765(02)00711-6
   Healy J, 2010, HAEMATOL-HEMATOL J, V95, P1608, DOI 10.3324/haematol.2010.022459
   Huy NT, 2010, CRIT CARE, V14, DOI [10.1186/cc9395, 10.1186/cc9268]
   Jackson D, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-103
   Kersey JH, 1997, BLOOD, V90, P4243
   Lautner-Csorba O, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-42
   Lin CY, 2014, BLOOD CELL MOL DIS, V52, P140, DOI 10.1016/j.bcmd.2013.10.003
   Linabery AM, 2013, LEUKEMIA RES, V37, P936, DOI 10.1016/j.leukres.2013.04.022
   Martinelli G, 2009, J CLIN ONCOL, V27, P5202, DOI 10.1200/JCO.2008.21.6408
   McNeil DE, 2002, MED PEDIATR ONCOL, V39, P554, DOI 10.1002/mpo.10161
   Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866
   Orsi L, 2012, LEUKEMIA, V26, P2561, DOI 10.1038/leu.2012.148
   Papaemmanuil E, 2009, NAT GENET, V41, P1006, DOI 10.1038/ng.430
   Prasad RB, 2010, BLOOD, V115, P1765, DOI 10.1182/blood-2009-09-241513
   Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001
   Pui CH, 2000, CURR OPIN ONCOL, V12, P3, DOI 10.1097/00001622-200001000-00002
   Ross JA, 2013, PEDIATR BLOOD CANCER, V60, P31, DOI 10.1002/pbc.24131
   Rudant J, 2013, LEUKEMIA, V27, P746, DOI 10.1038/leu.2012.244
   Stiller CA, 1996, BRIT MED BULL, V52, P682
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thakkinstian A, 2004, J BONE MINER RES, V19, P419, DOI 10.1359/JBMR.0301265
   Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187
   Trevino LR, 2009, NAT GENET, V41, P1001, DOI 10.1038/ng.432
   Trikalinos TA, 2008, ADV GENET, V60, P311, DOI 10.1016/S0065-2660(07)00413-0
   Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262
   Vijayakrishnan J, 2010, LEUKEMIA LYMPHOMA, V51, P1870, DOI 10.3109/10428194.2010.511356
   Wang YP, 2013, GENE, V524, P203, DOI 10.1016/j.gene.2013.04.028
   Wu JJ, 2012, CLIN CANCER RES, V18, P3972, DOI 10.1158/1078-0432.CCR-11-1531
   Xu H, 2013, JNCI-J NATL CANCER I, V105, P733, DOI 10.1093/jnci/djt042
   Yang YL, 2011, CANCER SCI, V102, P1874, DOI 10.1111/j.1349-7006.2011.02031.x
   Zintzaras E, 2008, J CLIN EPIDEMIOL, V61, P634, DOI 10.1016/j.jclinepi.2007.12.011
NR 40
TC 10
Z9 10
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 25
PY 2014
VL 9
IS 11
AR e113748
DI 10.1371/journal.pone.0113748
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU9GL
UT WOS:000345899700061
PM 25423013
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Rai, H
   Parveen, F
   Sudeep, K
   Kapoor, A
   Sinha, N
AF Rai, Himanshu
   Parveen, Farah
   Kumar, Sudeep
   Kapoor, Aditya
   Sinha, Nakul
TI Association of Endothelial Nitric Oxide Synthase Gene Polymorphisms with
   Coronary Artery Disease: An Updated Meta-Analysis and Systematic Review
SO PLOS ONE
LA English
DT Review
ID ACUTE MYOCARDIAL-INFARCTION; MISSENSE GLU298ASP VARIANT; 27-BP REPEAT
   POLYMORPHISM; TYPE-2 DIABETES-MELLITUS; SOUTH INDIAN POPULATION;
   ISCHEMIC-HEART-DISEASE; ENOS GENE; TURKISH POPULATION; G894T
   POLYMORPHISM; EARLY-ONSET
AB Several association studies of endothelial nitric oxide synthase (NOS3) gene polymorphisms with respect to coronary artery disease (CAD) have been published in the past two decades. However, their association with the disease, especially among different ethnic subgroups, still remains controversial. This prompted us to conduct a systematic review and an updated structured meta-analysis, which is the largest so far (89 articles, 132 separate studies, and a sample size of 69,235), examining association of three polymorphic forms of the NOS3 gene (i.e. Glu298Asp, T786-C and 27bp VNTR b/a) with CAD. In a subgroup analysis, we tested their association separately among published studies originating predominantly from European, Middle Eastern, Asian, Asian-Indian and African ancestries. The pooled analysis confirmed the association of all the three selected SNP with CAD in three different genetic models transcending all ancestries worldwide. The Glu298Asp polymorphism showed strongest association (OR range = 1.28-1.52, and P<0.00001 for all comparisons), followed by T786-C (OR range = 1.34-1.42, and P<0.00001 for all comparisons) and 4b/a, (OR range = 1.19-1.41, and P <= 0.002 for all comparisons) in our pooled analysis. Subgroup analysis revealed that Glu298Asp (OR range = 1.54-1.87, and P<0.004 for all comparisons) and 4b/a (OR range = 1.71-3.02, and P<0.00001 for all comparisons) have highest degree of association amongst the Middle Easterners. On the other hand, T786-C and its minor allele seem to carry a highest risk for CAD among subjects of Asian ancestry (OR range = 1.61-1.90, and P <= 0.01 for all comparisons).
C1 [Rai, Himanshu; Kumar, Sudeep; Kapoor, Aditya] Sanjay Gandhi Post Grad Inst Med Sci, Dept Cardiol, Lucknow, Uttar Pradesh, India.
   [Parveen, Farah] Sanjay Gandhi Post Grad Inst Med Sci, Dept Med Genet, Lucknow, Uttar Pradesh, India.
   [Sinha, Nakul] Sahara India Med Inst, Dept Cardiol, Lucknow, Uttar Pradesh, India.
RP Rai, H (reprint author), Sanjay Gandhi Post Grad Inst Med Sci, Dept Cardiol, Lucknow, Uttar Pradesh, India.
EM himanshurai1981@gmail.com; sudeepkum@yahoo.com
RI Rai, Himanshu/N-7726-2016
OI Rai, Himanshu/0000-0003-3917-1934
CR Abdel-Aziz TA, 2013, MOL BIOL REP, V40, P3065, DOI 10.1007/s11033-012-2380-7
   Afrasyap L, 2004, ACTA BIOCH BIOPH SIN, V36, P661, DOI 10.1093/abbs/36.10.661
   Agema WRP, 2004, CLIN SCI, V107, P255, DOI 10.1042/CS20030360
   Agirbasli D, 2006, CORONARY ARTERY DIS, V17, P413, DOI 10.1097/00019501-200608000-00003
   Agirbasli M, 2011, EUR J CARDIOV PREV R, V18, P803, DOI 10.1177/1741826711398806
   Alkharfy KM, 2010, ARCH MED RES, V41, P134, DOI 10.1016/j.arcmed.2010.02.004
   Alp E, 2009, DNA CELL BIOL, V28, P343, DOI 10.1089/dna.2009.0866
   Alvarez R, 2001, NITRIC OXIDE-BIOL CH, V5, P343, DOI 10.1006/niox.2001.0351
   Andrikopoulos GK, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-43
   Angeline T, 2010, EXP MOL PATHOL, V89, P205, DOI 10.1016/j.yexmp.2010.08.009
   Antoniades C, 2005, J AM COLL CARDIOL, V46, P1101, DOI 10.1016/j.jacc.2005.05.072
   Aras O, 2002, THROMB HAEMOSTASIS, V87, P347
   Bae J, 2010, EXP THER MED, V1, P719, DOI 10.3892/etm_00000111
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berdeli A, 2005, CLIN CHIM ACTA, V351, P87, DOI 10.1016/j.cccn.2004.08.015
   Bhanushali AA, 2010, J COMMUN GENET, V1, P55, DOI 10.1007/s12687-010-0005-1
   Bor-Kucukatay M, 2010, MOL BIOL REP, V37, P171, DOI 10.1007/s11033-009-9572-9
   Cai H, 1999, J MOL MED-JMM, V77, P511, DOI 10.1007/s001099900020
   Cam SF, 2005, THROMB RES, V116, P287, DOI 10.1016/j.thromres.2004.12.002
   Ciftci C, 2008, LIPIDS HEALTH DIS, V7, DOI 10.1186/1476-511X-7-5
   Cine N, 2002, CLIN GENET, V61, P66, DOI 10.1034/j.1399-0004.2002.610113.x
   Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2
   Colombo MG, 2003, CLIN CHEM, V49, P389, DOI 10.1373/49.3.389
   Colombo MG, 2002, HEART, V87, P525, DOI 10.1136/heart.87.6.525
   Dafni C, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-133
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dosenko Victor E, 2006, Exp Clin Cardiol, V11, P11
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ekmekci A, 2013, ACTA CARDIOL, V68, P464, DOI 10.2143/AC.68.5.2994468
   Piccoli JDE, 2012, ARCH MED RES, V43, P205, DOI 10.1016/j.arcmed.2012.03.011
   Fatini C, 2004, AM HEART J, V147, P516, DOI 10.1016/j.ahj.2003.10.032
   Fowkes FGR, 2000, ATHEROSCLEROSIS, V150, P179, DOI 10.1016/S0021-9150(99)00366-4
   Gad MZ, 2012, GENET TEST MOL BIOMA, V16, P695, DOI 10.1089/gtmb.2011.0342
   Gardemann A, 2002, ATHEROSCLEROSIS, V160, P167, DOI 10.1016/S0021-9150(01)00554-8
   Gluba A, 2009, ANGIOLOGY, V60, P588, DOI 10.1177/0003319709335031
   Granath B, 2001, J CARDIOVASC RISK, V8, P235, DOI 10.1097/00043798-200108000-00008
   Gururajan P, 2011, BIOCHEM GENET, V49, P96, DOI 10.1007/s10528-010-9391-7
   Han Y, 2010, PHARMACOLOGY, V85, P211, DOI 10.1159/000275135
   Hibi K, 1998, HYPERTENSION, V32, P521, DOI 10.1161/01.HYP.32.3.521
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hingorani A, 1995, CLIN SCI, V88, p21P
   Hingorani AD, 1999, CIRCULATION, V100, P1515, DOI 10.1161/01.CIR.100.14.1515
   Hooper WC, 1999, CHEST, V116, P880, DOI 10.1378/chest.116.4.880
   Hwang JJ, 2002, CARDIOLOGY, V97, P67, DOI 10.1159/000057674
   Hyndman ME, 2002, HYPERTENSION, V39, P919, DOI 10.1161/01.HYP.0000013703.07316.7F
   Ichihara S, 1998, AM J CARDIOL, V81, P83, DOI 10.1016/S0002-9149(97)10806-2
   Isordia-Salas I, 2010, CLIN CHIM ACTA, V411, P553, DOI 10.1016/j.cca.2010.01.013
   Jaramillo PC, 2008, CLIN CHIM ACTA, V387, P105, DOI 10.1016/j.cca.2007.09.011
   Jaramillo PC, 2006, CLIN CHIM ACTA, V371, P102, DOI 10.1016/j.cca.2006.02.030
   Jaramillo PC, 2010, CLIN CHIM ACTA, V411, P258, DOI 10.1016/j.cca.2009.11.018
   Jeerooburkhan N, 2001, HYPERTENSION, V38, P1054, DOI 10.1161/hy1101.092967
   Jemaa R, 2007, CLIN CHEM LAB MED, V45, P1476, DOI 10.1515/CCLM.2007.312
   Jo I, 2006, CLIN CHIM ACTA, V365, P86, DOI 10.1016/j.cca.2005.07.029
   Kallel A, 2013, CYTOKINE, V64, P646, DOI 10.1016/j.cyto.2013.09.005
   KELM M, 1991, CARDIOVASC RES, V25, P831, DOI 10.1093/cvr/25.10.831
   Kerkeni M, 2006, CLIN CHEM, V52, P53, DOI 10.1373/clinchem.2005.057950
   Kim IJ, 2007, THROMB RES, V119, P579, DOI 10.1016/j.thromres.2006.06.005
   Kincl V, 2009, FOLIA BIOL-PRAGUE, V55, P187
   Kumar ASA, 2013, MOL BIOL REP, V40, P1275, DOI 10.1007/s11033-012-2170-2
   Lee WH, 2001, VASC MED, V6, P103, DOI 10.1177/1358836X0100600206
   Letonja M, 2004, ACTA CARDIOL, V59, P618, DOI 10.2143/AC.59.6.2005244
   Lewis Cathryn M, 2002, Brief Bioinform, V3, P146, DOI 10.1093/bib/3.2.146
   Li JY, 2010, CARDIOLOGY, V116, P271, DOI 10.1159/000316063
   Lin NT, 2008, CHINESE J PHYSIOL, V51, P42
   Liu D, 2013, GENE
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   MARSDEN PA, 1993, J BIOL CHEM, V268, P17478
   Mathew Jomal, 2008, Indian Heart J, V60, P223
   Matyar S, 2005, CLIN CHIM ACTA, V354, P153, DOI 10.1016/j.cccn.2004.11.022
   Meluzin J, 2009, HEART VESSELS, V24, P157, DOI 10.1007/s00380-008-1097-y
   Milutinovic A, 2005, FOLIA BIOL-PRAGUE, V51, P47
   Min BW, 2010, ACTA NEUROL BELG, V110, P255
   Miyamoto Y, 2000, HUM MOL GENET, V9, P2629, DOI 10.1093/hmg/9.18.2629
   Miyamoto Y, 1998, HYPERTENSION, V32, P3, DOI 10.1161/01.HYP.32.1.3
   MONCADA S, 1993, NEW ENGL J MED, V329, P2002
   Motawi T, 2011, ANGIOLOGY, V62, P191, DOI 10.1177/0003319710373094
   Naber CK, 2001, AM J PHYSIOL-HEART C, V281, pH1908
   Nakagami H, 1999, J THROMB THROMBOLYS, V8, P191, DOI 10.1023/A:1008954018658
   Nakayama M, 2000, AM J CARDIOL, V86, P628, DOI 10.1016/S0002-9149(00)01041-9
   Nakayama M, 1999, CIRCULATION, V99, P2864, DOI 10.1161/01.CIR.99.22.2864
   Narne P, 2013, J DIABETES COMPLICAT, V27, P255, DOI 10.1016/j.jdiacomp.2012.10.009
   Nassar BA, 2001, AM HEART J, V142, P586, DOI 10.1067/mhj.2001.118113
   Odawara M, 1998, DIABETOLOGIA, V41, P365, DOI 10.1007/s001250050917
   Panic N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083138
   Park Jeong-Euy, 2000, Korean Journal of Internal Medicine, V15, P65
   Persu A, 2002, HUM MOL GENET, V11, P229, DOI 10.1093/hmg/11.3.229
   Philip I, 1999, CIRCULATION, V99, P3096, DOI 10.1161/01.CIR.99.24.3096
   Poirier O, 1999, EUR J CLIN INVEST, V29, P284
   Pulkkinen A, 2000, J MOL MED-JMM, V78, P372, DOI 10.1007/s001090000124
   Ragia Georgia, 2010, Hum Genomics, V4, P375
   Rahimi Z, 2012, ANGIOLOGY, V63, P131, DOI 10.1177/0003319711409741
   Rai H, 2012, MOL BIOL REP, V39, P5995, DOI 10.1007/s11033-011-1412-z
   Rankinen T, 2000, HYPERTENSION, V36, P885, DOI 10.1161/01.HYP.36.5.885
   Rao S, 2005, ETHNIC DIS, V15, P191
   Rios DLS, 2005, CLIN CHIM ACTA, V362, P138, DOI 10.1016/j.cccn.2005.06.012
   Rios DLS, 2007, ATHEROSCLEROSIS, V193, P135, DOI 10.1016/j.atherosclerosis.2006.05.041
   Rossi GP, 2003, J AM COLL CARDIOL, V41, P930, DOI 10.1016/S0735-1097(02)03012-7
   Saini V, 2012, DIABETES METAB SYND, V6, P106, DOI 10.1016/j.dsx.2012.05.001
   Saini V, 2011, DIS MARKERS, V31, P215, DOI 10.3233/DMA-2011-0819
   Salimi S, 2006, INDIAN J MED RES, V124, P683
   Salimi Saeedeh, 2012, Pathophysiology, V19, P157, DOI 10.1016/j.pathophys.2012.04.003
   Salimi S, 2010, ANN SAUDI MED, V30, P33, DOI 10.4103/0256-4947.59370
   Salom MG, 2005, AM J PHYSIOL-REG I, V289, pR1459, DOI 10.1152/ajpergu.00746.2004
   Sampalo MF, 2007, CLIN CHIM ACTA, V377, P154, DOI 10.1016/j.cca.2006.09.013
   Sandrim VC, 2006, ATHEROSCLEROSIS, V189, P241, DOI 10.1016/j.atherosclerosis.2005.12.011
   Savvidou MD, 2001, HYPERTENSION, V38, P1289, DOI 10.1161/hy1201.097305
   Schmoelzer I, 2003, EUR J CLIN INVEST, V33, P191, DOI 10.1046/j.1365-2362.2003.01108.x
   Shimasaki Y, 1998, J AM COLL CARDIOL, V31, P1506, DOI 10.1016/S0735-1097(98)00167-3
   Sigusch HH, 2000, SCAND J CLIN LAB INV, V60, P229, DOI 10.1080/003655100750044884
   Szperl M, 2008, MED SCI MONITOR, V14, pCR611
   Takagi S, 2001, THROMB HAEMOSTASIS, V86, P1339
   Tamemoto H, 2008, DIABETES RES CLIN PR, V80, P275, DOI 10.1016/j.diabres.2007.12.019
   Tangurek B, 2006, HEART VESSELS, V21, P285, DOI 10.1007/s00380-005-0902-0
   Tesauro M, 2000, P NATL ACAD SCI USA, V97, P2832, DOI 10.1073/pnas.97.6.2832
   Tian GX, 2013, MOL MED REP, V7, P1310, DOI 10.3892/mmr.2013.1301
   Tsukada T, 1998, BIOCHEM BIOPH RES CO, V245, P190, DOI 10.1006/bbrc.1998.8267
   Vasilakou M, 2008, ACTA CARDIOL, V63, P609, DOI 10.2143/AC.63.5.2033229
   Wang CL, 2001, J FORMOS MED ASSOC, V100, P736
   Wang XL, 2000, FEBS LETT, V471, P45, DOI 10.1016/S0014-5793(00)01356-9
   Wang XL, 1996, NAT MED, V2, P41, DOI 10.1038/nm0196-41
   Wang XL, 1997, ARTERIOSCL THROM VAS, V17, P3147, DOI 10.1161/01.ATV.17.11.3147
   Yang YJ, 2014, INT J MOL SCI, V15, P7987, DOI 10.3390/ijms15057987
   Yoon Y, 2000, CLIN CHEM, V46, P1626
   Yoshimura M, 1998, HUM GENET, V103, P65, DOI 10.1007/s004390050785
   Zhang K, 2012, THROMB RES, V130, P192, DOI 10.1016/j.thromres.2012.02.015
   Zigra AM, 2013, DIS MARKERS, V34, P431, DOI 10.3233/DMA-130987
NR 126
TC 21
Z9 21
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 19
PY 2014
VL 9
IS 11
AR e113363
DI 10.1371/journal.pone.0113363
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU3SG
UT WOS:000345533200103
PM 25409023
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, YL
   Luo, XP
   Yang, N
   Feng, RH
   Xian, L
AF Yang, Yanlong
   Luo, Xiuping
   Yang, Nuo
   Feng, Ronghao
   Xian, Lei
TI The Prognostic Value of Excision Repair Cross-Complementation Group 1
   (ERCC1) in Patients with Small Cell Lung Cancer (SCLC) Receiving
   Platinum-Based Chemotherapy: Evidence from Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENE-EXPRESSION; THYMIDYLATE SYNTHASE; COLORECTAL-CANCER; ESOPHAGEAL
   CANCER; PHASE-III; SURVIVAL; STATISTICS; RESISTANCE; MANAGEMENT;
   ETOPOSIDE
AB Recently, the correlation between the efficacy of platinum-based chemotherapy and ERCC1 expression in patients with SCLC has attracted wide-spread attention, and a lot of investigations have been conducted, whereas conflicting results were presented. Therefore, we performed the present meta-analysis of eligible studies to derive a more precise evaluation of the association between ERCC1 expression and the clinical outcome in SCLC patients receiving platinum-based chemotherapy. A literature search for relevant studies was conducted in the electronic databases of PubMed, EMBASE and Web of Science. The inclusive criteria were SCLC patients treated by platinum-based chemotherapy, and evaluated the relationship between ERCC1 expression and the clinical outcomes [including overall response rate (ORR), overall survival (OS) or progression-free survival (PFS)]. Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) was calculated to assess the risk. A total of nine studies including 1129 patients were included in final analysis. Our analysis indicated that positive/high ERCC1 expression was associated with unfavorable OS (HR = 1.18, 95%CI = 1.02-1.37) and PFS (HR = 1.46, 95%CI = 1.14-1.88). Subgroup analysis according to disease stage suggested the significant relationship was found in limited stage (LS-SCLC), but not in extensive stage (ES-SCLC). However, no significant association was found between ERCC1 expression and ORR. Our analysis suggested ERCC1 expression may be a prognostic factor in SCLC patients receiving platinum-based chemotherapy, especially for LS-SCLC.
C1 [Yang, Yanlong; Yang, Nuo; Xian, Lei] Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Nanning, Guangxi Zhuang, Peoples R China.
   [Luo, Xiuping; Feng, Ronghao] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Chemotherapy, Nanning, Guangxi Zhuang, Peoples R China.
RP Xian, L (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Nanning, Guangxi Zhuang, Peoples R China.
EM xianlei59@163.com
RI Mendez, Pedro/J-8955-2016
OI Mendez, Pedro/0000-0001-6713-7907
CR Baba H, 2012, BRIT J CANCER, V107, P1950, DOI 10.1038/bjc.2012.502
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bellmunt J, 2007, ANN ONCOL, V18, P522, DOI 10.1093/annonc/mdl435
   Ceppi P, 2008, J THORAC ONCOL, V3, P583, DOI 10.1097/JTO.0b013e3181734f24
   Cobo M, 2007, J CLIN ONCOL, V25, P2747, DOI 10.1200/JCO.2006.09.7915
   de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Friboulet L, 2013, NEW ENGL J MED, V368, P1101, DOI [10.1056/oa1214271, 10.1056/NEJMoa1214271]
   Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859
   Guldhammer B, 2010, J THORAC ONCOL, V5, P453, DOI 10.1097/JTO.0b013e3181ca063b
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hubner RA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025164
   Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   Joshi MBM, 2005, CLIN CANCER RES, V11, P2215
   Kang CH, 2009, J THORAC ONCOL, V4, P1307, DOI 10.1097/JTO.0b013e3181b9f236
   Karachaliou N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074611
   Kawashima A, 2011, CLIN CANCER RES, V17, P2561, DOI 10.1158/1078-0432.CCR-10-1963
   Kim MK, 2008, EUR J CANCER, V44, P54, DOI 10.1016/j.ejca.2007.09.006
   Kim SH, 2009, AM J CLIN ONCOL-CANC, V32, P38, DOI 10.1097/COC.0b013e31817be58e
   Kim YH, 2009, LUNG CANCER, V65, P105, DOI 10.1016/j.lungcan.2008.10.008
   Knez L, 2011, LUNG CANCER, V72, P271, DOI 10.1016/j.lungcan.2011.02.014
   Kwon HC, 2007, ANN ONCOL, V18, P504, DOI 10.1093/annonc/mdl430
   Lee GW, 2012, J THORAC ONCOL, V7, P528, DOI 10.1097/JTO.0b013e3182417830
   Lee HW, 2008, LUNG CANCER, V59, P95, DOI 10.1016/j.lungcan.2007.07.023
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Murray D, 1996, MUTAT RES-DNA REPAIR, V364, P217, DOI 10.1016/S0921-8777(96)00036-5
   Murray D, 2002, ANTICANCER RES, V22, P21
   Normanno N, 2014, LUNG CANCER, V85, P314, DOI 10.1016/j.lungcan.2014.05.002
   Sandler AB, 2003, SEMIN ONCOL, V30, P9, DOI 10.1053/sonc.2003.50012
   Scheil-Bertram S, 2010, GYNECOL ONCOL, V119, P325, DOI 10.1016/j.ygyno.2010.07.018
   Sereno M, 2012, INT J ONCOL, V40, P2104, DOI 10.3892/ijo.2012.1378
   Shin Hai-Rim, 2004, Cancer Res Treat, V36, P103, DOI 10.4143/crt.2004.36.2.103
   Simon GR, 2005, CHEST, V127, P978, DOI 10.1378/chest.127.3.978
   Smit EF, 2012, ANN ONCOL, V23, P1723, DOI 10.1093/annonc/mdr563
   Sodja E, 2012, EUR J CANCER, V48, P3378, DOI 10.1016/j.ejca.2012.06.011
   Spira A, 2004, NEW ENGL J MED, V350, P379, DOI 10.1056/NEJMra035536
   Thatcher N, 2005, ANN ONCOL, V16, P235, DOI 10.1093/annonc/mdi700
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Wang XY, 2014, CELL BIOCHEM BIOPHYS, V69, P633, DOI 10.1007/s12013-014-9845-3
   Wells G., 2003, NEWCASTLE OTTAWA SCA
   Xia Ying, 2007, Zhongguo Fei Ai Za Zhi, V10, P362, DOI 10.3779/j.issn.1009-3419.2007.05.03
NR 45
TC 5
Z9 5
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 6
PY 2014
VL 9
IS 11
AR e111651
DI 10.1371/journal.pone.0111651
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS6XM
UT WOS:000344402600055
PM 25375151
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Geng, P
   Zhao, XX
   Xiang, LS
   Liao, YM
   Wang, N
   Ou, JJ
   Xie, GF
   Liu, C
   Li, JJ
   Li, HT
   Zeng, R
   Liang, HJ
AF Geng, Peiliang
   Zhao, Xiaoxin
   Xiang, Lisha
   Liao, Yunmei
   Wang, Ning
   Ou, Juanjuan
   Xie, Ganfeng
   Liu, Chen
   Li, Jianjun
   Li, Hongtao
   Zeng, Rui
   Liang, Houjie
TI Distinct Role of CD86 Polymorphisms (rs1129055, rs17281995) in Risk of
   Cancer: Evidence from a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CD86+1057G/A POLYMORPHISM; SUSCEPTIBILITY; MOLECULES
AB Background and Purpose: Previous studies concerning the role of CD86 polymorphisms (rs1129055 and rs17281995) in cancer fail to provide compelling evidence. The aim of this study was to investigate the role of common polymorphisms in the risk of cancer by meta-analysis.
   Methods: By using the search terms Cluster of Differentiation 86/CD86/B7-2/polymorphism/polymorphisms/cancer, we searched PubMed, Embase, CNKI, and Wanfang and identified four studies for rs1129055 (2137 subjects) and rs17281995 (2856 subjects) respectively. Cancer risk was estimated by odds ratio (OR) and 95% confidence interval (95% CI).
   Major Findings: Overall, we observed significant reduced risk of cancer in relation to rs1129055. Compared with the individuals with AA genotype, the individuals with GG genotype appeared to have 62% decreased risk to develop cancer (GG versus AA: OR, 0.62; 95% CI, 0.49-0.79; P-het., 0.996). Similar effects were indicated in the G versus A allele model and the GG versus GA+AA genetic model (OR, 0.83; 95% CI, 0.74-0.93; P-het., 0.987; OR, 0.63; 95% CI, 0.50-0.79; P-het., 0.973). In addition, we found genotypes of rs17281995 had a major effect on overall cancer risk (CC versus GG: OR, 2.38; 95% CI, 1.43-3.95; P-het., 0.433; C versus G: OR, 1.23; 95% CI, 1.06-1.43; P-het., 0.521; CC versus GC+GG: OR, 2.38; 95% CI, 1.45-3.93; P-het., 0.443). The association was also observed in Caucasians and colorectal cancer. No obvious publication bias was detected in this meta-analysis.
   Conclusions: These data reveal that rs1129055 may have protective effects on cancer risk in Asians and that rs17281995 is likely to contribute to risk of cancer, particularly colorectal cancer in Caucasians.
C1 [Liang, Houjie] Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China.
   Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing, Peoples R China.
RP Liang, HJ (reprint author), Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China.
EM lianghoujie@sina.com
FU National Natural Science Foundation of China [81172115]
FX This work was supported in part by grant number 81172115 from the
   National Natural Science Foundation of China (to H.J.L.)
   (www.nsfc.gov.cn). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Azimzadeh Pedram, 2013, Gastroenterol Hepatol Bed Bench, V6, P86
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Corydon TJ, 2007, J MED GENET, V44, P509, DOI 10.1136/jmg.2007.049536
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Landi D, 2008, CARCINOGENESIS, V29, P579, DOI 10.1093/carcin/bgm304
   Landi D, 2011, MUTAT RES-FUND MOL M, V717, P109, DOI 10.1016/j.mrfmmm.2010.10.002
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Liu Y, 2010, HUM IMMUNOL, V71, P1141, DOI 10.1016/j.humimm.2010.08.007
   Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marin LA, 2005, TRANSPL IMMUNOL, V15, P69, DOI 10.1016/j.trim.2005.04.003
   Mokart D, 2011, MINERVA ANESTESIOL, V77, P522
   Palermo MD, 2012, MEM I OSWALDO CRUZ, V107, P167, DOI 10.1590/S0074-02762012000900024
   Pan XM, 2010, DNA CELL BIOL, V29, P381, DOI 10.1089/dna.2009.1003
   Rakoff-Nahoum Seth, 2006, Yale J Biol Med, V79, P123
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225
   Seliger B, 2008, TRENDS MOL MED, V14, P550, DOI 10.1016/j.molmed.2008.09.010
   Slavik JM, 1999, J BIOL CHEM, V274, P3116, DOI 10.1074/jbc.274.5.3116
   Teng Guang-shuai, 2012, Zhonghua Xue Ye Xue Za Zhi, V33, P865
   Wang J, 2012, DNA CELL BIOL, V31, P537, DOI 10.1089/dna.2011.1370
   Wang W, 2011, DNA CELL BIOL, V30, P925, DOI 10.1089/dna.2011.1211
   Xiang HG, 2012, J CANCER RES CLIN, V138, P2061, DOI 10.1007/s00432-012-1289-9
NR 27
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 4
PY 2014
VL 9
IS 11
AR e109131
DI 10.1371/journal.pone.0109131
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS6XG
UT WOS:000344402000007
PM 25369324
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Peng, L
   Zhao, Q
   Ye, XH
   Zhou, Y
   Hu, DN
   Zheng, SS
AF Peng, Ling
   Zhao, Qiong
   Ye, Xianghua
   Zhou, Yun
   Hu, Danna
   Zheng, Shusen
TI Incidence and Risk of Proteinuria with Aflibercept in Cancer Patients: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PHASE-II; VEGF-TRAP; DOUBLE-BLIND; INTRAVENOUS AFLIBERCEPT;
   OVARIAN-CANCER; RECURRENT; PLACEBO; TRIAL; MECHANISMS; DOCETAXEL
AB Background: Aflibercept is a human recombinant fusion protein with antiangiogenic effects that functions as a decoy receptor to bind vascular endothelial growth factor A. Proteinuria is one of its major adverse effects with a substantial variation in the incidence rate, and the overall risk of proteinuria has not been systematically studied. We performed a meta-analysis of published clinical trials to quantify the incidence and relative risk of proteinuria in cancer patients treated with aflibercept.
   Methods: The electronic databases were searched, including PubMed, Embase, Cochrane databases, and ASCO (American Society of Clinical Oncology) abstracts. Eligible studies were phase II and III prospective clinical trials of cancer patients treated with aflibercept with toxicity data on proteinuria. Overall incidence rates, relative risk (RR), and 95% confidence intervals (CI) were calculated using fixed or random effects models depending on the heterogeneity of the included studies.
   Results: A total of 4,596 patients with a variety of solid tumors from 16 prospective clinical trials were included for the meta-analysis. The overall incidences of all-grade and high-grade proteinuria in cancer patients were 33.9% (95% CI: 27.3-42.1%) and 7.9% (95% CI: 6.1-10.2%). The relative risks of proteinuria of aflibercept compared to control were increased for all-grade (RR = 1.41, 95% CI: 1.13-1.77) and high-grade (RR = 6.18, 95% CI: 3.78-10.12) proteinuria. The risk of developing all-grade and high-grade proteinuria with aflibercept was substantially higher than that of bevacizumab (all-grade: RR 1.85, 95% CI: 1.63-2.11; high-grade: RR 2.37, 95% CI: 1.84-3.05).
   Conclusions: Aflibercept is associated with an increased risk of developing proteinuria. Appropriate monitoring and treatment is strongly recommended to prevent potential renal damage. Future studies are still needed to investigate the risk reduction and possible use of aflibercept in cancer patients.
C1 [Peng, Ling; Zhao, Qiong; Hu, Danna] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Thorac Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Ye, Xianghua] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Radiat Dept, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhou, Yun] Zhejiang Food & Drug Adm, Hangzhou, Zhejiang, Peoples R China.
   [Zheng, Shusen] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Hangzhou 310003, Zhejiang, Peoples R China.
RP Zheng, SS (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Hangzhou 310003, Zhejiang, Peoples R China.
EM shusenzhengzy@163.com
FU Natural Science Foundation of Zhejiang Province, China [LQ13H160010];
   Zhejiang Medical Association [2012ZYC-A12]
FX This study was supported by a grant from the Natural Science Foundation
   of Zhejiang Province, China (Grant number: LQ13H160010) and a clinical
   research grant from Zhejiang Medical Association (Grant number:
   2012ZYC-A12). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], 2012, ZALTRAP ZIV AFLIBERC
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Choueiri TK, 2010, J CLIN ONCOL, V28, P2280, DOI 10.1200/JCO.2009.27.2757
   Coleman RL, 2012, GYNECOL ONCOL, V127, P538, DOI 10.1016/j.ygyno.2012.08.020
   Colombo N, 2012, GYNECOL ONCOL, V125, P42, DOI 10.1016/j.ygyno.2011.11.021
   de Groot JF, 2011, J CLIN ONCOL, V29, P2689, DOI 10.1200/JCO.2010.34.1636
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Gotlieb WH, 2012, LANCET ONCOL, V13, P154, DOI 10.1016/S1470-2045(11)70338-2
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Izzedine H, 2010, EUR J CANCER, V46, P439, DOI 10.1016/j.ejca.2009.11.001
   Kanellis John, 2004, Nephron Physiol, V96, pP26, DOI 10.1159/000075577
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Leighl NB, 2010, J THORAC ONCOL, V5, P1054, DOI 10.1097/JTO.0b013e3181e2f7fb
   Mackay HJ, 2012, GYNECOL ONCOL, V125, P136, DOI 10.1016/j.ygyno.2011.11.042
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Ramlau R, 2012, J CLIN ONCOL, V30, P3640, DOI 10.1200/JCO.2012.42.6932
   Rougier P, 2013, EUR J CANCER, V49, P2633, DOI 10.1016/j.ejca.2013.04.002
   Sherman EJ, 2010, J CLIN ONCOL S, V28
   Sideras K, 2012, CLIN BREAST CANCER, V12, P387, DOI 10.1016/j.clbc.2012.09.007
   STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K
   Tang PA, 2012, CLIN CANCER RES, V18, P6023, DOI 10.1158/1078-0432.CCR-11-3252
   Tannock IF, 2013, LANCET ONCOL, V14, P760, DOI 10.1016/S1470-2045(13)70184-0
   Tarhini AA, 2011, CLIN CANCER RES, V17, P6574, DOI 10.1158/1078-0432.CCR-11-1463
   Tesarova P, 2013, FOLIA BIOL-PRAGUE, V59, P15
   Tew WP, 2014, CANCER-AM CANCER SOC, V120, P335, DOI 10.1002/cncr.28406
   Twardowski P, 2010, UROLOGY, V76, P923, DOI 10.1016/j.urology.2010.04.025
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Wu SH, 2010, J AM SOC NEPHROL, V21, P1381, DOI 10.1681/ASN.2010020167
   YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7
   Zhang ZF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090135
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 33
TC 9
Z9 9
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 3
PY 2014
VL 9
IS 11
AR e111839
DI 10.1371/journal.pone.0111839
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU4DB
UT WOS:000345558100128
PM 25365378
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, XB
   Cui, NH
   Yang, J
   Qiu, XP
   Gao, JJ
   Yang, N
   Zheng, F
AF Wang, Xue-bin
   Cui, Ning-hua
   Yang, Jie
   Qiu, Xue-ping
   Gao, Jia-jia
   Yang, Na
   Zheng, Fang
TI Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism Is Not a
   Major Determining Factor in the Development of Sporadic Alzheimer
   Disease: Evidence from an Updated Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENE POLYMORPHISMS; RISK-FACTORS; ACE GENE; DNA POLYMORPHISMS; I/D
   POLYMORPHISM; APOLIPOPROTEIN-E; ASSOCIATION; SUSCEPTIBILITY; GENOTYPE;
   ALLELE
AB Angiotensin-converting enzyme gene (ACE) insertion/deletion (I/D) polymorphism have long been linked to sporadic Alzheimer disease (SAD), but the established data remained controversial. To clarify this inconsistency, a comprehensive meta-analysis was conducted. Through searching of Pubmed, Embase, Alzgene, China National Knowledge Infrastructure (CNKI) and manually searching relevant references, 53 independent studies from 48 articles were included, involving a total of 8153 cases and 14932 controls. The strength of association was assessed by using odds ratios (ORs) with 95% confidence intervals (CIs). Further stratified analyses and heterogeneity analyses were tested, as was publication bias. Overall, significant associations were revealed between I/D polymorphism and SAD risk using allelic comparison (OR = 1.09, 95% CI = 1.01-1.17, p = 0.030), homozygote comparison (OR = 1.17, 95% CI = 1.01-1.34, p = 0.030) and the dominant model (OR = 1.16, 95% CI = 1.04-1.29, p = 0.008), but they were not sufficiently robust to withstand the false-positive report probability (FPRP) analyses. Otherwise, in subgroup analyses restricted to the high quality studies, the large sample size studies and studies with population-based controls, no significant association was observed in any genetic models. In summary, the current meta-analysis suggested that the ACE I/D polymorphism is unlikely to be a major determining factor in the development of SAD.
C1 [Wang, Xue-bin; Yang, Jie; Qiu, Xue-ping; Gao, Jia-jia; Yang, Na; Zheng, Fang] Wuhan Univ, Zhongnan Hosp, Ctr Gene Diag, Wuhan 430072, Hubei, Peoples R China.
   [Cui, Ning-hua] Childrens Hosp Zhengzhou, Dept Clin Lab, Zhengzhou, Henan, Peoples R China.
RP Zheng, F (reprint author), Wuhan Univ, Zhongnan Hosp, Ctr Gene Diag, Wuhan 430072, Hubei, Peoples R China.
EM zhengfang@whu.edu.cn
FU National Basic Research Program of China (973 Program) [2012CB720600]
FX This study was supported by grants from the National Basic Research
   Program of China (973 Program, 2012CB720600). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alvarez R, 1999, J NEUROL NEUROSUR PS, V67, P733, DOI 10.1136/jnnp.67.6.733
   Amouyel P, 2000, ANN NY ACAD SCI, V903, P437, DOI 10.1111/j.1749-6632.2000.tb06395.x
   Arlt S, 2013, CURR ALZHEIMER RES, V10, P72
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Biller H, 2006, EUR RESPIR J, V28, P1085, DOI 10.1183/09031936.00050106
   Buss S, 2002, AM J MED GENET, V114, P440, DOI 10.1002/ajmg.10306
   Camelo D, 2004, J NEUROL SCI, V218, P47, DOI 10.1016/j.jns.2003.10.008
   Carbonell J, 2003, PSYCHIAT GENET, V13, P47, DOI 10.1097/01.ypg.0000054711.85338.5c
   Chalmers KA, 2004, NEUROREPORT, V15, P95, DOI 10.1097/01.wnr.0000096519.69073.ee
   Chapman J, 1998, STROKE, V29, P1401, DOI 10.1161/01.STR.29.7.1401
   Cheng CY, 2002, EUR NEUROL, V47, P26, DOI 10.1159/000047943
   Colton CA, 2006, P NATL ACAD SCI USA, V103, P12867, DOI 10.1073/pnas.0601075103
   Crawford F, 2000, NEUROSCI LETT, V280, P215, DOI 10.1016/S0304-3940(00)00791-6
   Dechartres A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2304
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   Dong LM, 2008, JAMA-J AM MED ASSOC, V299, P2423, DOI 10.1001/jama.299.20.2423
   Drzezga A, 2009, NEUROLOGY, V72, P1487, DOI 10.1212/WNL.0b013e3181a2e8d0
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elkins JS, 2004, NEUROLOGY, V62, P363, DOI 10.1212/01.WNL.0000106823.72493.FF
   Farrer LA, 2000, ARCH NEUROL-CHICAGO, V57, P210, DOI 10.1001/archneur.57.2.210
   Feng YQ, 2004, CHIN J GERIATR HEART, V6, P181
   FOGARTY DG, 1994, LANCET, V343, P851, DOI 10.1016/S0140-6736(94)92050-8
   Han B, 2008, J SHANXI MED U, V39, P692
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hu J, 1999, NEUROSCI LETT, V277, P65, DOI 10.1016/S0304-3940(99)00827-7
   Huy NT, 2010, CRIT CARE, V14, DOI [10.1186/cc9395, 10.1186/cc9268]
   Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749
   Isbir T, 2000, CELL BIOCHEM FUNCT, V18, P141, DOI 10.1002/(SICI)1099-0844(200006)18:2<141::AID-CBF856>3.3.CO;2-#
   Isbir T, 2001, Am J Alzheimers Dis Other Demen, V16, P205, DOI 10.1177/153331750101600407
   Kehoe PG, 2009, TRENDS NEUROSCI, V32, P619, DOI 10.1016/j.tins.2009.07.006
   Kehoe PG, 2003, HUM MOL GENET, V12, P859, DOI 10.1093/hmg/ddg094
   Kehoe PG, 1999, NAT GENET, V21, P71, DOI 10.1038/5009
   Keikhaee MR, 2006, NEUROCHEM RES, V31, P1079, DOI 10.1007/s11064-006-9119-6
   Kolsch H, 2005, NEUROSCI LETT, V377, P37, DOI 10.1016/j.neulet.2004.11.062
   Langan D, 2012, J CLIN EPIDEMIOL, V65, P511, DOI 10.1016/j.jclinepi.2011.10.009
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lehmann DJ, 2005, AM J EPIDEMIOL, V162, P305, DOI 10.1093/aje/kwi202
   Lendon CL, 2002, NEUROSCI LETT, V328, P314, DOI 10.1016/S0304-3940(02)00553-0
   Liu M, 2007, CHINESE J PRACTICAL, V13, P1028
   Lucatelli JF, 2011, NEUROCHEM RES, V36, P1533, DOI 10.1007/s11064-011-0481-7
   Mattila KM, 2000, J MED GENET, V37, P766, DOI 10.1136/jmg.37.10.766
   Meng Y, 2006, AM J HUM GENET, V78, P871, DOI 10.1086/503687
   Miners S, 2009, AM J TRANSL RES, V1, P163
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Monastero R, 2002, NEUROSCI LETT, V335, P147, DOI 10.1016/S0304-3940(02)01182-5
   Mucke L, 2009, NATURE, V461, P895, DOI 10.1038/461895a
   Myllykangas L, 2000, NEUROSCI LETT, V292, P195, DOI 10.1016/S0304-3940(00)01467-1
   Nacmias B, 2007, ARCH GERONTOL GERIAT, V45, P201, DOI 10.1016/j.archger.2006.10.011
   Narain Y, 2000, J MED GENET, V37, P695, DOI 10.1136/jmg.37.9.695
   Ning M, 2010, ALZ DIS ASSOC DIS, V24, P390, DOI 10.1097/WAD.0b013e3181e6a575
   Nirmal S, 2011, INT J NEUROSCI, V121, P557, DOI 10.3109/00207454.2011.591513
   Palumbo B, 1999, NEUROSCI LETT, V267, P97, DOI 10.1016/S0304-3940(99)00329-8
   Panza F, 2003, J NEUROL NEUROSUR PS, V74, P1159, DOI 10.1136/jnnp.74.8.1159
   Paula-Lima AC, 2013, J NEUROCHEM, V126, P191, DOI 10.1111/jnc.12304
   Perry RT, 2001, AM J MED GENET, V105, P332, DOI 10.1002/ajmg.1371
   Richard F, 2001, NEUROLOGY, V56, P1593, DOI 10.1212/WNL.56.11.1593
   Sayed-Tabatabaei FA, 2006, CIRC RES, V98, P1123, DOI 10.1161/01.RES.0000223145.74217.e7
   Scacchi R, 1998, DEMENT GERIATR COGN, V9, P186, DOI 10.1159/000017045
   Schjeide BM, 2009, NEUROGENETICS, V10, P19, DOI 10.1007/s10048-008-0151-3
   Seripa D, 2003, NEUROBIOL AGING, V24, P933, DOI 10.1016/S0197-4580(03)00040-X
   Shcherbatykh T V, 2001, Neurosci Behav Physiol, V31, P179, DOI 10.1023/A:1005264324466
   Shinohara M, 2014, BRAIN, V137, P1533, DOI 10.1093/brain/awu046
   Sleegers K, 2005, NEUROBIOL AGING, V26, P1153, DOI 10.1016/j.neurobiolaging.2004.09.011
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thies W, 2013, ALZHEIMERS DEMENT, V9, P208, DOI 10.1016/j.jalz.2013.02.003
   Thomas DC, 2004, JNCI-J NATL CANCER I, V96, P421, DOI 10.1093/jnci/djh094
   van Esch JHM, 2008, J HYPERTENS, V26, P706, DOI 10.1097/HJH.0b013e3282f465d2
   Vardy ERLC, 2009, J ALZHEIMERS DIS, V16, P609, DOI 10.3233/JAD-2009-1002
   Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075
   Wakutani Y, 2002, ANN NY ACAD SCI, V977, P232, DOI 10.1111/j.1749-6632.2002.tb04820.x
   Wang B, 2010, J HEPATOL, V53, P508, DOI 10.1016/j.jhep.2010.03.026
   Wang BB, 2006, J MOL NEUROSCI, V30, P267, DOI 10.1385/JMN/30:03:267
   Wang HK, 2006, J NEURAL TRANSM, V113, P1499, DOI 10.1007/s00702-005-0424-z
   Wehr H, 2006, DEMENT GERIATR COGN, V22, P1, DOI 10.1159/000092845
   Wu Chuanshen, 2002, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V19, P401
   Wu JJ, 2012, CLIN CANCER RES, V18, P3972, DOI 10.1158/1078-0432.CCR-11-1531
   Wu SJ, 2013, NEUROBIOL AGING, V34, DOI 10.1016/j.neurobiolaging.2013.01.003
   Yang JD, 2000, NEUROSCI LETT, V295, P41, DOI 10.1016/S0304-3940(00)01591-3
   Yang YH, 2008, TOHOKU J EXP MED, V215, P295, DOI 10.1620/tjem.215.295
   Yang YH, 2011, AGE AGEING, V40, P238, DOI 10.1093/ageing/afq179
   [张淑萍 Zhang Shuping], 2014, [中国组织工程研究, Chinese Journal of Tissue Engineering Research], V18, P259
   Zhang JW, 2005, DEMENT GERIATR COGN, V20, P52, DOI 10.1159/000085075
   Zhang ZS, 2012, NEUROSCI LETT, V514, P131, DOI 10.1016/j.neulet.2012.02.074
   Zintzaras E, 2008, J CLIN EPIDEMIOL, V61, P634, DOI 10.1016/j.jclinepi.2007.12.011
   Zuliani G, 2001, ACTA NEUROL SCAND, V103, P304, DOI 10.1034/j.1600-0404.2001.103005304.x
NR 85
TC 34
Z9 34
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 31
PY 2014
VL 9
IS 10
AR e111406
DI 10.1371/journal.pone.0111406
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS0BN
UT WOS:000343943700100
PM 25360660
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yu, D
   Feng, Y
   Yang, L
   Da, M
   Fan, CF
   Wang, S
   Mo, XM
AF Yu, Di
   Feng, Yu
   Yang, Lei
   Da, Min
   Fan, Changfeng
   Wang, Song
   Mo, Xuming
TI Maternal Socioeconomic Status and the Risk of Congenital Heart Defects
   in Offspring: A Meta-Analysis of 33 Studies
SO PLOS ONE
LA English
DT Article
ID ATRIOVENTRICULAR-CANAL DEFECTS; VENTRICULAR SEPTAL-DEFECTS; PARENTAL
   CIGARETTE-SMOKING; BIRTH-DEFECTS; CARDIOVASCULAR-DISEASE; PSYCHOSOCIAL
   FACTORS; DOWN-SYNDROME; HEALTH; MALFORMATIONS; EPIDEMIOLOGY
AB Background: We conducted this meta-analysis to address the open question of a possible association between maternal socioeconomic status and congenital heart defects (CHDs).
   Methods: We searched MEDLINE and EMBASE from their inception to January 1, 2014 for case-control and cohort studies that assessed the association between maternal socioeconomic status and the risk of CHDs. Study-specific relative risk estimates were polled according to random-effect or fixed-effect models.
   Results: From 3343 references, a total of 31 case-control studies and 2 cohort studies were enrolled in this meta-analysis, including more than 50,000 cases. We observed that maternal educational attainment, family income and maternal occupation were negatively associated with an 11% (pooled RR = 1.11, 95% CI: 1.03, 1.21), 5% (pooled RR = 1.05, 95% CI: 1.01, 1.09) and 51% (pooled RR = 1.51, 95% CI: 1.02, 2.24) increased risk of CHDs, respectively. In a subgroup analysis by geographic region, the results were inconsistent for the European region (RR = 1.29, 95% CI: 0.99-1.69) and USA/Canada region (RR = 1.06, 95% CI: 0.97, 1.16) in maternal educational attainment.
   Conclusion: In summary, this meta-analysis suggests that a lower degree of maternal socioeconomic status is modestly associated with an increased risk of CHDs. However, further investigations are needed to confirm the association.
C1 [Yu, Di; Feng, Yu; Yang, Lei; Da, Min; Fan, Changfeng; Wang, Song; Mo, Xuming] Nanjing Med Univ, Nanjing Childrens Hosp, Dept Cardiothorac Surg, Nanjing, Jiangsu, Peoples R China.
RP Mo, XM (reprint author), Nanjing Med Univ, Nanjing Childrens Hosp, Dept Cardiothorac Surg, Nanjing, Jiangsu, Peoples R China.
EM mohsuming15@sina.com
CR ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15
   Agha MM, 2011, BIRTH DEFECTS RES A, V91, P1011, DOI 10.1002/bdra.22857
   Agopian AJ, 2012, PAEDIATR PERINAT EP, V26, P515, DOI 10.1111/ppe.12006
   Alverson CJ, 2011, PEDIATRICS, V127, pE647, DOI 10.1542/peds.2010-1399
   Ariza-Montes A, 2013, INT J ENV RES PUB HE, V10, P3121, DOI 10.3390/ijerph10083121
   Bassili A, 2000, EUR J EPIDEMIOL, V16, P805, DOI 10.1023/A:1007601919164
   Batra M, 2007, ARCH PEDIAT ADOL MED, V161, P89, DOI 10.1001/archpedi.161.1.89
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boneva RS, 2001, CIRCULATION, V103, P2376
   Botto LD, 2000, AM J EPIDEMIOL, V151, P878
   Brent RL, 2004, PEDIATRICS, V113, P957
   Carmichael SL, 2003, PAEDIATR PERINAT EP, V17, P264, DOI 10.1046/j.1365-3016.2003.00498.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fixler DE, 1998, TERATOLOGY, V58, P6, DOI 10.1002/(SICI)1096-9926(199807)58:1<6::AID-TERA4>3.0.CO;2-0
   Gonzalez MA, 1998, INT J EPIDEMIOL, V27, P350, DOI 10.1093/ije/27.3.350
   Grewal J, 2008, BIRTH DEFECTS RES A, V82, P519, DOI 10.1002/bdra.20461
   Hackshaw A, 2011, HUM REPROD UPDATE, V17, P589, DOI 10.1093/humupd/dmr022
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hobbs CA, 2010, OBSTET GYNECOL, V116, P316, DOI 10.1097/AOG.0b013e3181e80979
   Hoffman JIE, 2002, J AM COLL CARDIOL, V39, P1890, DOI 10.1016/S0735-1097(02)01886-7
   Huisman M, 2012, EUR J PUBLIC HEALTH, V22, P238, DOI 10.1093/eurpub/ckr039
   Jenkins KJ, 2007, CIRCULATION, V115, P2995, DOI 10.1161/CIRCULATIONAHA.106.183216
   KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973
   Karatza AA, 2011, INT J CARDIOL, V148, P295, DOI 10.1016/j.ijcard.2009.11.008
   Kavanagh A, 2010, SOC SCI MED, V71, P1150, DOI 10.1016/j.socscimed.2010.05.038
   Kuciene R, 2010, MED LITH, V46, P635, DOI 10.3390/medicina46090090
   Lee LJ, 2013, PEDIATR CARDIOL, V34, P398, DOI 10.1007/s00246-012-0470-x
   Lisowski LA, 2010, HERZ, V35, P19, DOI 10.1007/s00059-010-3244-3
   Liu SW, 2009, J EPIDEMIOL, V19, P122, DOI 10.2188/jea.JE20080039
   Long J, 2010, BIRTH DEFECTS RES A, V88, P971, DOI 10.1002/bdra.20724
   Lupo PJ, 2012, BIRTH DEFECTS RES A, V94, P875, DOI 10.1002/bdra.23071
   Malik S, 2008, PEDIATRICS, V121, pE810, DOI 10.1542/peds.2007-1519
   Manrique-Garcia E, 2011, J EPIDEMIOL COMMUN H, V65, P301, DOI 10.1136/jech.2009.104075
   Mateja WA, 2012, J WOMENS HEALTH, V21, P26, DOI 10.1089/jwh.2010.2582
   Materna-Kiryluk A, 2011, PAEDIATR PERINAT EP, V25, P135, DOI 10.1111/j.1365-3016.2010.01186.x
   McBride KL, 2005, BIRTH DEFECTS RES A, V73, P555, DOI 10.1002/bdra.20169
   Padula AM, 2013, PAEDIATR PERINAT EP, V27, P329, DOI 10.1111/ppe.12055
   Patel SS, 2012, AM J MED GENET A, V158A, P2447, DOI 10.1002/ajmg.a.35555
   PRADAT P, 1993, INT ARCH OCC ENV HEA, V65, P13, DOI 10.1007/BF00586052
   Smedts HPM, 2009, BJOG-INT J OBSTET GY, V116, P416, DOI 10.1111/j.1471-0528.2008.01957.x
   STOLL C, 1989, EUR J EPIDEMIOL, V5, P382, DOI 10.1007/BF00144842
   Strike PC, 2004, PROG CARDIOVASC DIS, V46, P337, DOI 10.1016/S0033-0620(03)00120-8
   Tamayo T, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-525
   TIKKANEN J, 1992, INT ARCH OCC ENV HEA, V64, P59, DOI 10.1007/BF00625952
   Torfs CP, 1999, EPIDEMIOLOGY, V10, P264, DOI 10.1097/00001648-199905000-00013
   Tusting LS, 2013, LANCET, V382, P963, DOI 10.1016/S0140-6736(13)60851-X
   van Beynum IM, 2010, EUR HEART J, V31, P464, DOI 10.1093/eurheartj/ehp479
   van Driel LMJW, 2008, EUR HEART J, V29, P1424, DOI 10.1093/eurheartj/ehn170
   Vereczkey A, 2013, BIRTH DEFECTS RES A, V97, P217, DOI 10.1002/bdra.23124
   Vereczkey A, 2012, J MATERN-FETAL NEO M, V25, P2536, DOI 10.3109/14767058.2012.712568
   Wasserman CR, 1996, TERATOLOGY, V53, P261, DOI 10.1002/(SICI)1096-9926(199604)53:4<261::AID-TERA9>3.3.CO;2-8
   Williams LJ, 2004, BIRTH DEFECTS RES A, V70, P59, DOI 10.1002/bdra.10145
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Yang J, 2008, AM J EPIDEMIOL, V167, P145, DOI 10.1093/aje/kwm283
NR 54
TC 7
Z9 8
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 27
PY 2014
VL 9
IS 10
AR e111056
DI 10.1371/journal.pone.0111056
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AZ1JF
UT WOS:000347994900042
PM 25347676
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Jin, J
   Yu, MX
   Hu, C
   Ye, L
   Xie, LL
   Jin, J
   Chen, FF
   Tong, HY
AF Jin, Jie
   Yu, Mengxia
   Hu, Chao
   Ye, Li
   Xie, Lili
   Jin, Jin
   Chen, Feifei
   Tong, Hongyan
TI Pesticide Exposure as a Risk Factor for Myelodysplastic Syndromes: A
   Meta-Analysis Based on 1,942 Cases and 5,359 Controls
SO PLOS ONE
LA English
DT Article
ID MYELOID LEUKEMIAS; HODGKINS-LYMPHOMA; CANCER; ASSOCIATION; DISEASE;
   UPDATE; AGENTS; BIAS
AB Objective: Pesticide exposure has been linked to increased risk of cancer at several sites, but its association with risk of myelodysplastic syndromes (MDS) is still unclear. A meta-analysis of studies published through April, 2014 was performed to investigate the association of pesticide exposure with the risk of MDS.
   Methods: Studies were identified by searching the Web of Science, Cochrane Library and PubMed databases. Summary odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated using random- or fixed-effect models.
   Results: This meta-analysis included 11 case-control studies, all of which demonstrated a correlation between pesticide exposure and a statistically significant increased risk of MDS (OR = 1.95, 95% CI 1.23-3.09). In subgroup analyses, patients with pesticide exposure had increased risk of developing MDS if they were living in the Europe or Asia and had refractory anemia (RA) or RA with ringed sideroblasts (RARS). Moreover, in the analysis by specific pesticides, increased risk was associated with exposure to insecticides (OR = 1.71, 95% CI 1.22-2.40) but not exposure to herbicides or fungicides.
   Conclusion: This meta-analysis supports the hypothesis that exposure to pesticides increases the risk of developing MDS. Further prospective cohort studies are warranted to verify the association and guide clinical practice in MDS prevention.
C1 [Jin, Jie; Yu, Mengxia; Hu, Chao; Ye, Li; Xie, Lili; Jin, Jin; Chen, Feifei; Tong, Hongyan] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Jin, Jie; Yu, Mengxia; Hu, Chao; Ye, Li; Xie, Lili; Jin, Jin; Chen, Feifei; Tong, Hongyan] Zhejiang Univ, Sch Med, Inst Hematol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Tong, Hongyan] Zhejiang Univ, Sch Med, Myelodysplast Syndromes Diag & Therapy Ctr, Hangzhou 310003, Zhejiang, Peoples R China.
RP Tong, HY (reprint author), Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Hangzhou 310003, Zhejiang, Peoples R China.
EM zjuhongyantong@163.com
FU Key Innovation Team Foundation of Zhejiang Province [2011R50015]; major
   program fund of the Science Technology Department of Zhejiang Province
   [2013c03043-2]; Zhejiang Province Fund for Distinguished Young Scholars
   [LR12H08001]; National Public Health Grand Research Foundation
   [201202017]; National Natural Science Foundation of China [30870914,
   81270582]
FX This study was supported by grants from the Key Innovation Team
   Foundation of Zhejiang Province (2011R50015), major program fund of the
   Science Technology Department of Zhejiang Province (2013c03043-2),
   Zhejiang Province Fund for Distinguished Young Scholars (LR12H08001),
   National Public Health Grand Research Foundation (201202017) and the
   National Natural Science Foundation of China (No. 30870914, No.
   81270582). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Agopian J, 2009, J EXP MED, V206, P1473, DOI 10.1084/jem.20082842
   Alavanja MCR, 2013, CA-CANCER J CLIN, V63, P120, DOI 10.3322/caac.21170
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boros LG, 2001, LEUKEMIA RES, V25, P883, DOI 10.1016/S0145-2126(01)00043-1
   BROWN LM, 1990, CANCER RES, V50, P6585
   Castillo JJ, 2011, J CLIN ONCOL, V29, P3900, DOI 10.1200/JCO.2011.35.4449
   Chiu BCH, 2009, J AGROMEDICINE, V14, P250, DOI 10.1080/10599240902773140
   CICCONE G, 1993, CANCER GENET CYTOGEN, V68, P135, DOI 10.1016/0165-4608(93)90010-J
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   GOLDBERG H, 1990, CANCER RES, V50, P6876
   Hu ZH, 2013, ASIAN PAC J CANCER P, V14, P393, DOI 10.7314/APJCP.2013.14.1.393
   Infante-Rivard C, 2007, J TOXICOL ENV HEAL B, V10, P81, DOI 10.1080/10937400601034589
   Kasner MT, 2009, AM J HEMATOL, V84, P177, DOI 10.1002/ajh.21352
   Kokouva M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-5
   LaFiura KM, 2007, PEDIATR BLOOD CANCER, V49, P624, DOI 10.1002/pbc.21283
   Lv L, 2011, AM J HEMATOL, V86, P163, DOI 10.1002/ajh.21941
   Malek AM, 2012, ENVIRON RES, V117, P112, DOI 10.1016/j.envres.2012.06.007
   MELE A, 1994, AM J EPIDEMIOL, V139, P609, DOI 10.1093/oxfordjournals.aje.a117050
   Merhi M, 2007, CANCER CAUSE CONTROL, V18, P1209, DOI 10.1007/s10552-007-9061-1
   Newman K, 2012, ASIAN PAC J CANCER P, V13, P1081, DOI 10.7314/APJCP.2012.13.4.1081
   Nisse C, 2001, BRIT J HAEMATOL, V112, P927, DOI 10.1046/j.1365-2141.2001.02645.x
   Pekmezovic T, 2006, ANN HEMATOL, V85, P514, DOI 10.1007/s00277-006-0128-y
   Rigolin GM, 1998, BRIT J HAEMATOL, V103, P189, DOI 10.1046/j.1365-2141.1998.00963.x
   SAARNI MI, 1973, AM J MED, V55, P38, DOI 10.1016/0002-9343(73)90148-4
   Schug TT, 2011, J STEROID BIOCHEM, V127, P204, DOI 10.1016/j.jsbmb.2011.08.007
   Smith MT, 2005, TOXICOL APPL PHARM, V206, P237, DOI 10.1016/j.taap.2004.11.026
   Strom SS, 2005, LEUKEMIA, V19, P1912, DOI 10.1038/sj.leu.2403945
   Van Maele-Fabry G, 2007, CANCER CAUSE CONTROL, V18, P457, DOI 10.1007/s10552-007-0122-2
   Warlick ED, 2007, CURR CANCER DRUG TAR, V7, P541, DOI 10.2174/156800907781662284
   Wells GA, 2009, NEWCASTLE OTTAWA SCA
   WEST RR, 1995, LEUKEMIA RES, V19, P127, DOI 10.1016/0145-2126(94)00141-V
   Xu X, 2014, EUR J NUTR
NR 33
TC 4
Z9 6
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 21
PY 2014
VL 9
IS 10
AR e110850
DI 10.1371/journal.pone.0110850
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR7AB
UT WOS:000343731200079
PM 25335083
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liang, WH
   Wu, X
   Hong, SD
   Zhang, YX
   Kang, SY
   Fang, WF
   Qin, T
   Huang, Y
   Zhao, HY
   Zhang, L
AF Liang, Wenhua
   Wu, Xuan
   Hong, Shaodong
   Zhang, Yaxiong
   Kang, Shiyang
   Fang, Wenfeng
   Qin, Tao
   Huang, Yan
   Zhao, Hongyun
   Zhang, Li
TI Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced
   Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled
   Trials and Subgroup Analyses
SO PLOS ONE
LA English
DT Article
ID VANDETANIB PLUS DOCETAXEL; BLIND PHASE-III; 1ST-LINE TREATMENT; PLACEBO;
   CARBOPLATIN; BEVACIZUMAB; PACLITAXEL; SORAFENIB; SUNITINIB; MOTESANIB
AB Background: Multi-targeted antiangiogenic tyrosine kinase inhibitors (MATKIs) have been studied in many randomized controlled trials (RCTs) for treatment of advanced non-small cell lung cancer (NSCLC). We seek to summarize the most up-to-date evidences and perform a timely meta-analysis.
   Methods: Electronic databases were searched for eligible studies. We defined the experimental arm as MATKI-containing group and the control arm as MATKI-free group. The extracted data on objective response rates (ORR), disease control rates (DCR), progression-free survival (PFS) and overall survival (OS) were pooled. Subgroup and sensitivity analyses were conducted.
   Results: Twenty phase II/III RCTs that involved a total of 10834 participants were included. Overall, MATKI-containing group was associated with significant superior ORR (OR 1.29, 95% CI 1.08 to 1.55, P = 0.006) and prolonged PFS (HR 0.83, 0.78 to 0.90, P = 0.005) compared to the MATKI-free group. However, no significant improvements in DCR (OR 1.08, 1.00 to 1.17, P = 0.054) or OS (HR 0.97, 0.93 to 1.01, P = 0.106) were observed. Subgroup analyses showed that the benefits were predominantly presented in pooled results of studies enrolling previously-treated patients, studies not limiting to enroll non-squamous NSCLC, and studies using MATKIs in combination with the control regimens as experimental therapies.
   Conclusions: This up-to-date meta-analysis showed that MATKIs did increase ORR and prolong PFS, with no significant improvement in DCR and OS. The advantages of MATKIs were most prominent in patients who received a MATKI in combination with standard treatments and in patients who had previously experienced chemotherapy. We suggest further discussion as to the inclusion criteria of future studies on MATKIs regarding histology.
C1 [Liang, Wenhua; Wu, Xuan; Hong, Shaodong; Zhang, Yaxiong; Kang, Shiyang; Fang, Wenfeng; Qin, Tao; Huang, Yan; Zhao, Hongyun; Zhang, Li] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China.
RP Zhang, L (reprint author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China.
EM zhangli6@mail.sysu.edu.cn
FU National High Technology Research and Development Program of China
   Molecular classification and individualized diagnosis and treatment of
   lung cancer [2012AA02A502];  [320.6750.1316]
FX This study was funded by the National High Technology Research and
   Development Program of China Molecular classification and individualized
   diagnosis and treatment of lung cancer (grant numbers: 2012AA02A502) and
   the role of monitoring circulating tumor cells and
   drug-resistance-associated molecular in the therapeutic prediction,
   evaluation and mechanism of drug-resistance in EGFR mutant advanced
   NSCLC patients receiving EGFR-TKI (grant numbers: Wu Jieping Funds
   320.6750.1316). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blumenschein GR, 2011, ANN ONCOL, V22, P2057, DOI 10.1093/annonc/mdq731
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Cesca M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00259
   Dearden S, 2013, ANN ONCOL, V24, P2371, DOI 10.1093/annonc/mdt205
   Dy GK, 2013, J THORAC ONCOL, V8, P79, DOI 10.1097/JTO.0b013e318274a85d
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Goss GD, 2010, J CLIN ONCOL, V28, P49, DOI 10.1200/JCO.2009.22.9427
   Hellmann MD, 2013, CANCER CHEMOTH PHARM, V72, P453, DOI 10.1007/s00280-013-2219-5
   Herbst RS, 2010, LANCET ONCOL, V11, P619, DOI 10.1016/S1470-2045(10)70132-7
   Heymach JV, 2007, J CLIN ONCOL, V25, P4270, DOI 10.1200/JCO.2006.10.5122
   Heymach JV, 2008, J CLIN ONCOL, V26, P5407, DOI 10.1200/JCO.2008.17.3138
   Ivy SP, 2009, NAT REV CLIN ONCOL, V6, P569, DOI 10.1038/nrclinonc.2009.130
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022
   Laurie SA, 2012, J CLIN ONCOL, V30
   Lee JS, 2012, J CLIN ONCOL, V30, P1114, DOI 10.1200/JCO.2011.36.1709
   Molina JR, 2011, J CLIN ONCOLOGY, V29
   Natale RB, 2011, J CLIN ONCOL, V29, P1059, DOI 10.1200/JCO.2010.28.5981
   Natale RB, 2009, J CLIN ONCOL, V27, P2523, DOI 10.1200/JCO.2008.18.6015
   National Comprehensive Cancer Network, NCCN CLIN PRACT GUID
   Paz-Ares LG, 2012, J CLIN ONCOL, V30, P3084, DOI 10.1200/JCO.2011.39.7646
   Ramalingam S, 2008, ONCOLOGIST, V13, P5, DOI 10.1634/theoncologist.13-S1-5
   Reck M, 2014, LANCET ONCOL, V15, P143, DOI 10.1016/S1470-2045(13)70586-2
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Scagliotti G, 2010, J CLIN ONCOL, V28, P1835, DOI 10.1200/JCO.2009.26.1321
   Scagliotti GV, 2012, J CLIN ONCOL, V30, P2829, DOI 10.1200/JCO.2011.41.4987
   Scagliotti GV, 2012, J CLIN ONCOL, V30, P2070, DOI 10.1200/JCO.2011.39.2993
   Socinski MA, 2010, J THORAC ONCOL, V5, P354, DOI 10.1097/JTO.0b013e3181c7307e
   Spigel DR, 2011, J CLIN ONCOL, V29, P2582, DOI 10.1200/JCO.2010.30.7678
   Wang Yan, 2011, Zhongguo Fei Ai Za Zhi, V14, P239, DOI 10.3779/j.issn.1009-3419.2011.03.10
   Wozniak A, 2012, CRIT REV ONCOL HEMAT, V82, P200, DOI 10.1016/j.critrevonc.2011.05.003
   Xiao YY, 2013, EUR J CLIN PHARMACOL, V69, P151, DOI 10.1007/s00228-012-1333-3
   Yang CH, 2011, J CLIN ONCOL, V29, P1067
NR 36
TC 13
Z9 13
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2014
VL 9
IS 10
AR e109757
DI 10.1371/journal.pone.0109757
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AQ9XC
UT WOS:000343210800038
PM 25329056
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, W
   Zhang, XL
AF Wang, Wei
   Zhang, Xiulan
TI Systemic Adverse Events after Intravitreal Bevacizumab versus
   Ranibizumab for Age-Related Macular Degeneration: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR INHIBITORS; RANDOMIZED CLINICAL-TRIAL; SAFETY; OUTCOMES;
   PREVALENCE; THERAPIES; INJECTION; MORTALITY; LUCENTIS; EFFICACY
AB Objective: To assess whether the incidence of systemic adverse events differs between those who used bevacizumab and those who used ranibizumab in the treatment of age-related macular degeneration (AMD).
   Methods: A systematic literature search was conducted to identify randomised controlled trials (RCTs) comparing the use of intravitreal bevacizumab with the use of ranibizumab in AMD patients. Results were expressed as risk ratios (RRs) with accompanying 95% confidence intervals (CIs). The data were pooled using the fixed-effect or random-effect model according to the heterogeneity present.
   Results: Four RCTs were included in the final meta-analysis. Overall, the quality of the evidence was high. There were 2,613 treated patients: 1,291 treated with bevacizumab and 1,322 treated with ranibicizumab. No significant differences between bevacizumab use and ranizumab use were found in terms of the incidence of death from all causes, arteriothrombotic events, stroke, nonfatal myocardial infarction, vascular death, venous thrombotic events, and hypertension, with the pooled RRs being 1.11 (0.77, 1.61), 1.03 (0.69,1.55), 0.84 (0.39,1.80), 0.97 (0.48, 1.96), 1.24 (0.63, 2.44), 2.38 (0.94, 6.04), and 1.02 (0.29, 3.62), respectively.
   Conclusions: The meta-analysis shows that both treatments are comparably safe. However, the findings from our study must be confirmed in future research via well-designed cohort or intervention studies because of the limited number of studies.
C1 [Wang, Wei; Zhang, Xiulan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
RP Zhang, XL (reprint author), Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
EM zhangxl2@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81371008]
FX This research was supported by the National Natural Science Foundation
   of China (81371008). No additional external funding was received. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abouammoh MA, 2013, CAN J OPHTHALMOL, V48, P317, DOI 10.1016/j.jcjo.2013.03.004
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Aujla JS, 2012, CLIN EXP OPTOM, V95, P538, DOI 10.1111/j.1444-0938.2012.00735.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Campbell RJ, 2013, CURR OPIN OPHTHALMOL, V24, P197, DOI 10.1097/ICU.0b013e32835f8bbe
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Donahue SP, 2010, AM J OPHTHALMOL, V150, P287, DOI 10.1016/j.ajo.2010.04.006
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   French DD, 2011, RETINA-J RET VIT DIS, V31, P1036, DOI 10.1097/IAE.0b013e31821dc66f
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kodjikian L, 2013, OPHTHALMOLOGY
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Torjesen I, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4678
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 41
TC 10
Z9 10
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2014
VL 9
IS 10
AR e109744
DI 10.1371/journal.pone.0109744
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AQ9XC
UT WOS:000343210800037
PM 25330364
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zou, ZH
   Jiang, YM
   Xiao, MJ
   Zhou, RY
AF Zou, Zhenhong
   Jiang, Yuming
   Xiao, Mingjia
   Zhou, Ruiyao
TI The Impact of Prophylactic Dexamethasone on Nausea and Vomiting after
   Thyroidectomy: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID POSTOPERATIVE NAUSEA; CONTROLLED-TRIAL; SURGERY; PAIN; PREVENTION;
   EFFICACY; RECOMMENDATIONS; STRENGTH; QUALITY
AB Background: We carried out a systematic review and meta-analysis to evaluate the impact of prophylactic dexamethasone on post-operative nausea and vomiting (PONV), post-operative pain, and complications in patients undergoing thyroidectomy.
   Methods: We searched Pubmed, Embase, and Cochrane Library databases for randomized controlled trials (RCTs) that evaluated the prophylactic effect of dexamethasone versus placebo with or without other antiemetics for PONV in patients undergoing thyroidectomy. Meta-analyses were performed using RevMan 5.0 software.
   Results: Thirteen RCTs that considered high quality evidence including 2,180 patients were analyzed. The meta-analysis demonstrated a significant decrease in the incidence of PONV (RR 0.52, 95% CI 0.43 to 0.63, P<0.00001), the need for rescue anti-emetics (RR 0.42, 95% CI 0.30 to 0.57, P<0.00001), post-operative pain scores (WMD -1.17, 95% CI -1.91 to -0.44, P=0.002), and the need for rescue analgesics (RR 0.65, 95% CI 0.50-0.83, P=0.0008) in patients receiving dexamethasone compared to placebo, with or without concomitant antiemetics. Dexamethasone 8-10 mg had a significantly greater effect for reducing the incidence of PONV than dexamethasone 1.25-5 mg. Dexamethasone was as effective as other anti-emetics for reducing PONV (RR 1.25, 95% CI 0.86-1.81, P=0.24). A significantly higher level of blood glucose during the immediate post-operative period in patients receiving dexamethasone compared to controls was the only adverse event.
   Conclusions: Prophylactic dexamethasone 8-10 mg administered intravenously before induction of anesthesia should be recommended as a safe and effective strategy for reducing the incidence of PONV, the need for rescue anti-emetics, postoperative pain, and the need for rescue analgesia in thyroidectomy patients, except those that are pregnant, have diabetes mellitus, hyperglycemia, or contraindications for dexamethasone. More high quality trials are warranted to define the benefits and risks of prophylactic dexamethasone in potential patients with a high risk for PONV.
C1 [Zou, Zhenhong; Jiang, Yuming] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China.
   [Xiao, Mingjia] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Hepatobiliary Surg, Wuxi, Jiangsu, Peoples R China.
   [Zhou, Ruiyao] Wenzhou Med Univ, Affiliated Hosp 3, Dept Gen Surg, Ruian City, Zhejiang, Peoples R China.
RP Zhou, RY (reprint author), Wenzhou Med Univ, Affiliated Hosp 3, Dept Gen Surg, Ruian City, Zhejiang, Peoples R China.
EM doctor_zry@126.com
CR AAPRO MS, 1984, J CLIN ONCOL, V2, P466, DOI 10.1200/JCO.1984.2.5.466
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Barros A, 2013, PHARMACOLOGY, V91, P153, DOI 10.1159/000346612
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bononi M, 2010, HEAD NECK-J SCI SPEC, V32, P1173, DOI 10.1002/hed.21313
   Chen CC, 2012, WORLD J SURG, V36, P61, DOI 10.1007/s00268-011-1343-9
   Doksrod S, 2012, ACTA ANAESTH SCAND, V56, P513, DOI 10.1111/j.1399-6576.2012.02654.x
   Feroci F, 2011, HEAD NECK-J SCI SPEC, V33, P840, DOI 10.1002/hed.21543
   FREDRIKSON M, 1992, BRIT J CANCER, V65, P779, DOI 10.1038/bjc.1992.165
   Fujii Y, 2000, ANAESTH INTENS CARE, V28, P266
   Fujii Y, 2007, OTOLARYNG HEAD NECK, V136, P274, DOI 10.1016/j.otohns.2006.09.013
   Guyatt G, 2006, CHEST, V129, P174, DOI 10.1378/chest.129.1.174
   HARGREAVES KM, 1990, CLIN PHARMACOL THER, V48, P168, DOI 10.1038/clpt.1990.132
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA
   HONG D, 1993, PAIN, V55, P171, DOI 10.1016/0304-3959(93)90146-G
   Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13
   Karanicolas PJ, 2008, ANN SURG, V248, P751, DOI 10.1097/SLA.0b013e3181856024
   Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165/00003495-200059020-00005
   Kranke P, 2011, EUR J ANAESTH, V28, P758, DOI 10.1097/EJA.0b013e32834a4e1e
   Lee Y, 2001, Acta Anaesthesiol Sin, V39, P151
   Lefebvre C, 2011, COCHRANE COLLABORATI
   MATORY YL, 1993, J SURG ONCOL, V53, P17, DOI 10.1002/jso.2930530107
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55
   Schietroma M, 2013, JAMA OTOLARYNGOL, V139, P471, DOI 10.1001/jamaoto.2013.2821
   Schwartz AE, 1998, J CLIN ENDOCR METAB, V83, P1097, DOI 10.1210/jc.83.4.1103
   Song YK, 2013, J ANESTH, V27, P29, DOI 10.1007/s00540-012-1473-8
   Sonner JM, 1997, J CLIN ANESTH, V9, P398, DOI 10.1016/S0952-8180(97)00069-X
   Wang JJ, 2000, ANESTH ANALG, V91, P1404, DOI 10.1097/00000539-200012000-00019
   Wang JJ, 2000, ANESTH ANALG, V91, P136, DOI 10.1097/00000539-200007000-00025
   Wang JJ, 1999, ANESTH ANALG, V89, P200, DOI 10.1097/00000539-199907000-00036
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
   Worni M, 2008, ANN SURG, V248, P1060, DOI 10.1097/SLA.0b013e31818c709a
   Zhou HY, 2012, WORLD J SURG, V36, P1217, DOI 10.1007/s00268-011-1363-5
NR 35
TC 9
Z9 12
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2014
VL 9
IS 10
AR e109582
DI 10.1371/journal.pone.0109582
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AQ9XC
UT WOS:000343210800029
PM 25330115
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhou, YF
   Zhang, SZ
   Li, Z
   Zhu, J
   Bi, YY
   Bai, Y
   Wang, H
AF Zhou, Yanfeng
   Zhang, Shaozun
   Li, Zhen
   Zhu, Jie
   Bi, Yongyi
   Bai, YuE
   Wang, Hong
TI Maternal Benzene Exposure during Pregnancy and Risk of Childhood Acute
   Lymphoblastic Leukemia: A Meta-Analysis of Epidemiologic Studies
SO PLOS ONE
LA English
DT Article
ID PARENTAL OCCUPATIONAL-EXPOSURE; CHILDRENS ONCOLOGY GROUP; NATIONWIDE
   CASE-CONTROL; ALCOHOL-CONSUMPTION; INFANT LEUKEMIA; CIGARETTE-SMOKING;
   UNITED-STATES; CANCER; LYMPHOMA; SOLVENTS
AB Background: The prevalence of childhood leukemia is increasing rapidly all over the world. However, studies on maternal benzene exposure during pregnancy and childhood acute lymphoblastic leukemia (ALL) have not been systematically assessed. Therefore, we performed a meta-analysis to investigate the association between maternal solvent, paint, petroleum exposure, and smoking during pregnancy and risk of childhood ALL.
   Methods: Relevant studies up to September 1st, 2013 were identified by searching the PubMed, EMBASE, Cochrane library and the Web of Science databases. The effects were pooled using either fixed or random effect models based on the heterogeneity of the studies.
   Results: Twenty-eight case-control studies and one cohort study were included for analysis, with a total of 16,695 cases and 1,472,786 controls involved. Pooled odds ratio (OR) with 95% confidence interval (CI) for ALL was 1.25 (1.09, 1.45) for solvent, 1.23 (1.02, 1.47) for paint, 1.42 (1.10, 1.84) for petroleum exposure, and 0.99 (0.93, 1.06) for maternal smoking during pregnancy. No publication bias was found in this meta-analysis and consistent results were observed for subgroup and sensitivity analyses.
   Conclusions: Childhood ALL was associated with maternal solvent, paint, and petroleum exposure during pregnancy. No association was found between ALL and maternal smoking during pregnancy. Avoidance of maternal occupational and environmental benzene exposure during pregnancy could contribute to a decrease in the risk of childhood ALL.
C1 [Zhou, Yanfeng; Zhang, Shaozun; Li, Zhen; Zhu, Jie; Bi, Yongyi; Bai, YuE; Wang, Hong] Wuhan Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan 430072, Peoples R China.
RP Wang, H (reprint author), Wuhan Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan 430072, Peoples R China.
EM whwhgyg@163.com
FU National Natural Science Foundation of China [81102104]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81102104, www.nsfc.gov.cn). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abadi-Korek I, 2006, J OCCUP ENVIRON MED, V48, P165, DOI 10.1097/01.jom.0000183343.81485.7c
   Adam T, 2006, CHEM RES TOXICOL, V19, P511, DOI 10.1021/tx050220w
   Castro-Jimenez MA, 2011, PREV CHRONIC DIS, V8
   Bailey HD, 2011, INT J CANCER, V128, P2405, DOI 10.1002/ijc.25572
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belson M, 2007, ENVIRON HEALTH PERSP, V115, P138, DOI 10.1289/ehp.9023
   Brondum J, 1999, CANCER-AM CANCER SOC, V85, P1380, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1380::AID-CNCR23>3.3.CO;2-F
   Buffler PA, 2005, CANCER INVEST, V23, P60, DOI 10.1081/CNV-200046402
   Chang JS, 2006, AM J EPIDEMIOL, V163, P1091, DOI 10.1093/aje/kwj143
   Chen C, 2011, EUR J NEUROL, V18, P387, DOI 10.1111/j.1468-1331.2010.03187.x
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Eden T, 2010, CANCER TREAT REV, V36, P286, DOI 10.1016/j.ctrv.2010.02.004
   Edraki M., 2011, Eastern Mediterranean Health Journal, V17, P303
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferreira JD, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00151
   Freedman DM, 2001, AM J PUBLIC HEALTH, V91, P564, DOI 10.2105/AJPH.91.4.564
   Glover TW, 1998, RECENT RES CANCER, V154, P185
   GURNEY JG, 1995, CANCER, V75, P2186, DOI 10.1002/1097-0142(19950415)75:8<2186::AID-CNCR2820750825>3.0.CO;2-F
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Howard SC, 2008, CANCER, V112, P461, DOI 10.1002/cncr.23205
   Infante-Rivard C, 2005, ENVIRON HEALTH PERSP, V113, P787, DOI 10.1289/ehp.7707
   INFANTERIVARD C, 1991, J EPIDEMIOL COMMUN H, V45, P11, DOI 10.1136/jech.45.1.11
   KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1
   Klimentopoulou A, 2012, PEDIATR BLOOD CANCER, V58, P344, DOI 10.1002/pbc.23347
   Law GR, 2003, AM J EPIDEMIOL, V158, P328, DOI 10.1093/aje/kwg165
   Lightfoot TJ, 2004, TOXICOL APPL PHARM, V199, P104, DOI 10.1016/j.taap.2003.12.032
   Linabery AM, 2008, CANCER, V112, P416, DOI 10.1002/cncr.23169
   MacArthur AC, 2008, CANCER CAUSE CONTROL, V19, P283, DOI 10.1007/s10552-007-9091-8
   MAGNANI C, 1990, TUMORI, V76, P413
   McKinney PA, 2003, OCCUP ENVIRON MED, V60, P901, DOI 10.1136/oem.60.12.901
   McKinney PA, 2008, RADIAT PROT DOSIM, V132, P232, DOI 10.1093/rpd/ncn265
   McNabola A, 2006, J ENVIRON SCI HEAL A, V41, P799, DOI 10.1080/10934520600614413
   Menegaux F, 2005, CANCER DETECT PREV, V29, P487, DOI 10.1016/j.cdp.2005.06.008
   Menegaux F, 2007, PAEDIATR PERINAT EP, V21, P293, DOI 10.1111/j.1365-3016.2007.00824.x
   Metayer C, 2013, CANCER EPIDEM BIOMAR, V22, P1600, DOI 10.1158/1055-9965.EPI-13-0350
   Miligi L, 2013, OCCUP ENVIRON MED, V70, P648, DOI 10.1136/oemed-2012-100951
   Milne E, 2012, AM J EPIDEMIOL, V175, P43, DOI 10.1093/aje/kwr275
   Mucci LA, 2004, CANCER EPIDEM BIOMAR, V13, P1528
   Okcu MF, 2002, CANCER CAUSE CONTROL, V13, P595, DOI 10.1023/A:1019555912243
   Pang D, 2003, BRIT J CANCER, V88, P373, DOI 10.1038/sj.bjc.6600774
   PARKIN DM, 1988, INT J CANCER, V42, P511, DOI 10.1002/ijc.2910420408
   Petridou E, 1997, BRIT J CANCER, V76, P1241, DOI 10.1038/bjc.1997.541
   Poole C, 2006, INT J EPIDEMIOL, V35, P370, DOI 10.1093/ije/dyi248
   Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001
   Pui CH, 2003, JAMA-J AM MED ASSOC, V290, P2001, DOI 10.1001/jama.290.15.2001
   Pyatt D, 2010, CHEM-BIOL INTERACT, V184, P151, DOI 10.1016/j.cbi.2010.01.002
   Reid A, 2011, CANCER CAUSE CONTROL, V22, P1575, DOI 10.1007/s10552-011-9834-4
   Rudant J, 2008, CANCER CAUSE CONTROL, V19, P1277, DOI 10.1007/s10552-008-9199-5
   Scelo G, 2009, ENVIRON HEALTH PERSP, V117, P133, DOI 10.1289/ehp.11927
   Schuz J, 2000, CANCER EPIDEM BIOMAR, V9, P835
   Shu XO, 1999, CANCER EPIDEM BIOMAR, V8, P783
   Shu XO, 1999, JNCI-J NATL CANCER I, V91, P1765, DOI 10.1093/jnci/91.20.1765
   Shu XO, 1996, JNCI-J NATL CANCER I, V88, P24, DOI 10.1093/jnci/88.1.24
   Slater ME, 2011, PAEDIATR PERINAT EP, V25, P559, DOI 10.1111/j.1365-3016.2011.01229.x
   Slater ME, 2011, CANCER CAUSE CONTROL, V22, P1197, DOI 10.1007/s10552-011-9798-4
   Sorahan T, 1997, BRIT J CANCER, V75, P134, DOI 10.1038/bjc.1997.22
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   STJERNFELDT M, 1992, CANCER DETECT PREV, V16, P129
   SWAEN GMH, 1995, INT ARCH OCC ENV HEA, V67, P85
   Trivers KF, 2006, PAEDIATR PERINAT EP, V20, P110, DOI 10.1111/j.1365-3016.2006.00700.x
   WALLACE L, 1987, ARCH ENVIRON HEALTH, V42, P272, DOI 10.1080/00039896.1987.9935820
   Wallace L, 1996, ENVIRON HEALTH PERSP, V104, P1129, DOI 10.2307/3433152
   WALLACE LA, 1989, ENVIRON HEALTH PERSP, V82, P165, DOI 10.2307/3430770
   Zhu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071153
   Zipf T, 2000, CLIN ONCOLOGY, P2402
NR 65
TC 27
Z9 29
U1 2
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2014
VL 9
IS 10
AR e110466
DI 10.1371/journal.pone.0110466
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX2IH
UT WOS:000346766200120
PM 25333868
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Lou, ZF
   Xing, HB
   Li, D
AF Lou, Zhifeng
   Xing, Haibo
   Li, Da
TI Alcohol Consumption and the Neoplastic Progression in Barrett's
   Esophagus: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID RISK-FACTORS; CANCER-RISK; ADENOCARCINOMA; PATHOGENESIS; METAPLASIA;
   SMOKING; DISEASE
AB Purpose: In the developed countries, the incidence of esophageal adenocarcinoma (EAC) is increasing over recent decades. The purpose of this meta-analysis was to arrive at quantitative conclusions about the contribution of alcohol intakes and the progression of Barrett's esophagus.
   Methods: A comprehensive, systematic bibliographic search of medical literature published up to Oct 2013 was conducted to identify relevant studies. A meta-analysis was conducted for alcohol consumption on the Barrett's esophagus progression.
   Results: A total of 882 cases in 6,867 individuals from 14 observational studies were indemnified in this meta-analysis. The result of this current meta-analysis, including 10 case-control and 4 cohort studies, indicated that alcohol consumption was not associated with the neoplastic progression in Barrett's esophagus (RR, 1.17; 95% CI, 0.93-1.48). When stratified by the study designs, no significant association was detected in either high vs low group or ever vs never group.
   Conclusions: Alcohol drinking is not associated with risk of neoplastic progression in Barrett's esophagus. Further well designed studies are needed in this area.
C1 [Lou, Zhifeng] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Stomatol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Xing, Haibo] Xiasha Hosp, Dept Intens Care Unit, Hangzhou, Zhejiang, Peoples R China.
   [Li, Da] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
RP Li, D (reprint author), Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
EM prlida@163.com
FU Chinese National Natural Science Foundation [81001034]; Zhejiang
   Medicines Health Science and Technology Program [2009B087]; Sir Run Run
   Shaw Hospital Potential Doctor Foundation
FX The authors acknowledge the financial support from Chinese National
   Natural Science Foundation (Project NO. 81001034), Zhejiang Medicines
   Health Science and Technology Program (NO. 2009B087) and Sir Run Run
   Shaw Hospital Potential Doctor Foundation for Da Li. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR ACHKAR JP, 1995, AM J GASTROENTEROL, V90, P39
   Anandasabapathy S, 2007, CANCER-AM CANCER SOC, V109, P668, DOI 10.1002/cncr.22451
   Anderson LA, 2007, WORLD J GASTROENTERO, V13, P1585, DOI 10.3748/wjg.v13.i10.1585
   Bani-Hani KE, 2005, WORLD J GASTROENTERO, V11, P6807, DOI 10.3748/wjg.v11.i43.6807
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bosetti C, 2013, EUR J CANC PREV
   Bresalier R, 2005, SEMIN ONCOL, V32, pS21, DOI 10.1053/j.seminoncol.2005.07.021
   Casson AG, 2005, CARCINOGENESIS, V26, P1536, DOI 10.1093/carcin/bgi115
   Coleman HG, 2012, GASTROENTEROLOGY, V142, P233, DOI 10.1053/j.gastro.2011.10.034
   de Jonge PJF, 2006, AM J GASTROENTEROL, V101, P1421, DOI 10.1111/j.1572-0241.2006.00626.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Francis AM, 2013, ANN SURG, V258, P500, DOI 10.1097/SLA.0b013e3182a196f4
   Gatenby PAC, 2008, DIGEST DIS SCI, V53, P1175, DOI 10.1007/s10620-007-0023-y
   GRAY MR, 1993, GUT, V34, P727, DOI 10.1136/gut.34.6.727
   HANSSON LE, 1993, INT J CANCER, V54, P402, DOI 10.1002/ijc.2910540309
   Hardikar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052192
   Jung KW, 2011, AM J GASTROENTEROL, V106, P1447, DOI 10.1038/ajg.2011.130
   Li WQ, 2013, CLIN GASTROENTEROL H, V11, P1130, DOI 10.1016/j.cgh.2013.03.023
   Lukic M, 2010, COLLEGIUM ANTROPOL, V34, P905
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Olliver JR, 2005, CANCER EPIDEM BIOMAR, V14, P620, DOI 10.1158/1055-9965.EPI-04-0509
   Salehi M, 2013, NUTR REV, V71, P257, DOI 10.1111/nure.12028
   Sikkema M, 2011, AM J GASTROENTEROL, V106, P1231, DOI 10.1038/ajg.2011.153
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
NR 25
TC 5
Z9 6
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2014
VL 9
IS 10
AR e105612
DI 10.1371/journal.pone.0105612
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS0AP
UT WOS:000343941200003
PM 25299129
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Feng, Y
   Di, Y
   Chen, T
   Liu, J
   Tong, X
   Yang, L
   Da, M
   Shen, ST
   Fan, CF
   Wang, S
   Mo, XM
AF Feng, Yu
   Yu, Di
   Chen, Tao
   Liu, Jin
   Tong, Xing
   Yang, Lei
   Da, Min
   Shen, Shutong
   Fan, Changfeng
   Wang, Song
   Mo, Xuming
TI Maternal Parity and the Risk of Congenital Heart Defects in Offspring: A
   Dose-Response Meta-Analysis of Epidemiological Observational Studies
SO PLOS ONE
LA English
DT Article
ID NEURAL-TUBE DEFECTS; FOLIC-ACID; CARDIOVASCULAR DEFECTS; SCIENTIFIC
   STATEMENT; CURRENT KNOWLEDGE; CARDIAC DEFECTS; BIRTH OUTCOMES; DISEASE;
   TEXAS; ASSOCIATION
AB Background: Epidemiological studies have reported conflicting results regarding maternal parity and the risk of congenital heart defects (CHDs). However, a meta-analysis of the association between maternal parity and CHDs in offspring has not been conducted.
   Methods: We searched MEDLINE and EMBASE for articles catalogued between their inception and March 8, 2014; we identified relevant published studies that assessed the association between maternal parity and CHD risk. Two authors independently assessed the eligibility of the retrieved articles and extracted data from them. Study-specific relative risk estimates were pooled by random-effects or fixed-effects models. From the 11272 references, a total of 16 case-control studies and 3 cohort studies were enrolled in this meta-analysis.
   Results: The overall relative risk of CHD in parous versus nulliparous women was 1.01 (95% CI, 0.97-1.06; Q = 32.34; P = 0.006; I-2 = 53.6%). Furthermore, we observed a significant association between the highest versus lowest parity number, with an overall RR = 1.20 (95% CI, 1.10-1.31; (Q = 74.61, P<0.001, I-2 = 82.6%). A dose-response analysis also indicated a positive effect of maternal parity on CHD risk, and the overall increase in relative risk per one live birth was 1.06 (95% CI, 1.02-1.09); Q = 68.09; P<0.001; I-2 = 80.9%). We conducted stratified and meta-regression analyses to identify the origin of the heterogeneity among studies. A Galbraith plot was created to graphically assess the sources of heterogeneity.
   Conclusion: In summary, this meta-analysis provided a robust estimate of the positive association between maternal parity and risk of CHD.
C1 [Feng, Yu; Yu, Di; Yang, Lei; Da, Min; Fan, Changfeng; Wang, Song; Mo, Xuming] Nanjing Med Univ, Affiliated Childrens Hosp, Dept Cardiothorac Surg, Nanjing, Jiangsu, Peoples R China.
   [Chen, Tao; Liu, Jin] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China.
   [Tong, Xing] Nanjing Med Univ, Atherosclerosis Res Ctr, Key Lab Cardiovasc Dis & Mol Intervent, Nanjing, Jiangsu, Peoples R China.
   [Shen, Shutong] Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, Nanjing, Jiangsu, Peoples R China.
RP Mo, XM (reprint author), Nanjing Med Univ, Affiliated Childrens Hosp, Dept Cardiothorac Surg, Nanjing, Jiangsu, Peoples R China.
EM mohsuming15@sina.com
CR ADAMS MM, 1989, J AM COLL CARDIOL, V14, P432, DOI 10.1016/0735-1097(89)90199-X
   Agopian A, 2009, AM J MED GENET A, V149A, P2129, DOI 10.1002/ajmg.a.33000
   Alverson CJ, 2011, PEDIATRICS, V127, pE647, DOI 10.1542/peds.2010-1399
   Baird J T Jr, 1972, Vital Health Stat 11, P1
   Batra M, 2007, ARCH PEDIAT ADOL MED, V161, P89, DOI 10.1001/archpedi.161.1.89
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benjamin BG, 2010, BIRTH DEFECTS RES A, V88, P178, DOI 10.1002/bdra.20642
   BERNSTEIN L, 1986, J NATL CANCER I, V76, P1035
   Bianca S, 2003, DIS ESOPHAGUS, V16, P39, DOI 10.1046/j.1442-2050.2003.00283.x
   Brentlinger PE, 2001, NEW ENGL J MED, V344, P933
   Canfield MA, 2009, PAEDIATR PERINAT EP, V23, P41, DOI 10.1111/j.1365-3016.2008.00975.x
   Carmichael SL, 2007, PAEDIATR PERINAT EP, V21, P210, DOI 10.1111/j.1365-3016.2007.00809.x
   Cedergren MI, 2006, EUR J OBSTET GYN R B, V125, P211, DOI 10.1016/j.ejogrb.2005.07.06
   Cedergren MI, 2002, SCAND J WORK ENV HEA, V28, P12, DOI 10.5271/sjweh.641
   Chubak J, 2004, CANCER EPIDEM BIOMAR, V13, P1296
   Czeizel AE, 2013, NUTRIENTS, V5, P4760, DOI 10.3390/nu5114760
   Duong HT, 2012, BIRTH DEFECTS RES A, V94, P230, DOI 10.1002/bdra.22889
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   GIBSON S, 1952, AMA AM J DIS CHILD, V83, P317, DOI 10.1001/archpedi.1952.02040070063007
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Grisaru-Granovsky S, 2009, CONTRACEPTION, V80, P512, DOI 10.1016/j.contraception.2009.06.006
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Hashmi SS, 2005, AM J MED GENET A, V134A, P368, DOI 10.1002/ajmg.a.30618
   HAY S, 1972, TERATOLOGY, V6, P271, DOI 10.1002/tera.1420060304
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jenkins KJ, 2007, CIRCULATION, V115, P2995, DOI 10.1161/CIRCULATIONAHA.106.183216
   Langlois PH, 2009, BIRTH DEFECTS RES A, V85, P764, DOI 10.1002/bdra.20586
   Liu SL, 2013, CIRCULATION, V128, P583, DOI 10.1161/CIRCULATIONAHA.112.001054
   Long J, 2010, BIRTH DEFECTS RES A, V88, P971, DOI 10.1002/bdra.20724
   Luo YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081369
   Malik S, 2008, PEDIATRICS, V121, pE810, DOI 10.1542/peds.2007-1519
   Orsini N, 2012, AM J EPIDEMIOL, V175, P66, DOI 10.1093/aje/kwr265
   Padula AM, 2013, PAEDIATR PERINAT EP, V27, P329, DOI 10.1111/ppe.12055
   Pierpont ME, 2007, CIRCULATION, V115, P3015, DOI 10.1161/CIRCULATIONAHA.106.183056
   Pradat P, 2003, PEDIATR CARDIOL, V24, P195, DOI 10.1007/s00246-002-9401-6
   Rosenquist TH, 1996, P NATL ACAD SCI USA, V93, P15227, DOI 10.1073/pnas.93.26.15227
   Rovas L, 2006, ULTRASOUND OBST GYN, V28, P761, DOI 10.1002/uog.2857
   Smedts HPM, 2012, NUTR METAB CARDIOVAS, V22, P477, DOI 10.1016/j.numecd.2010.07.016
   STOLL C, 1989, EUR J EPIDEMIOL, V5, P382, DOI 10.1007/BF00144842
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   STUCKEY D, 1956, BRIT HEART J, V18, P519
   Torfs CP, 1999, EPIDEMIOLOGY, V10, P264, DOI 10.1097/00001648-199905000-00013
   van der Bom T, 2011, NAT REV CARDIOL, V8, P50, DOI 10.1038/nrcardio.2010.166
   Vereczkey A, 2013, BIRTH DEFECTS RES A, V97, P217, DOI 10.1002/bdra.23124
   Vereczkey A, 2012, J MATERN-FETAL NEO M, V25, P2536, DOI 10.3109/14767058.2012.712568
   Vieira AR, 2004, J NEUROL SCI, V217, P65, DOI 10.1016/j.jns.2003.08.014
   Wells G., 2013, NEWCASTLE OTTAWA SCA
   Werler MM, 2009, BIRTH DEFECTS RES A, V85, P52, DOI 10.1002/bdra.20524
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Zhu JL, 2013, PEDIATRICS, V131, pE1225, DOI 10.1542/peds.2012-3024
NR 50
TC 5
Z9 5
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2014
VL 9
IS 10
AR e108944
DI 10.1371/journal.pone.0108944
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AT8TE
UT WOS:000345204000028
PM 25295723
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhou, Q
   Wang, CC
   Wang, XF
   Wu, XY
   Zhu, ZG
   Liu, BY
   Su, LP
AF Zhou, Quan
   Wang, Chenchen
   Wang, Xiaofeng
   Wu, Xiongyan
   Zhu, Zhenggang
   Liu, Bingya
   Su, Liping
TI Association between TLR4 (+896A/G and+1196C/T) Polymorphisms and Gastric
   Cancer Risk: An Updated Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID TOLL-LIKE RECEPTORS; HELICOBACTER-PYLORI; GENE POLYMORPHISMS; THR399ILE
   POLYMORPHISMS; SUSCEPTIBILITY; POPULATION; VARIANTS; PATTERNS; LESIONS
AB Background: Toll-like receptor 4 (TLR4) is a receptor of lipopolysaccharide in the signaling transduction of gastric epithelial cell. It plays a pivotal role in activation of innate immunity and pathogen recognition and thus acts as a modulator in the development and progression of gastric cancer. Growing studies explored the association of polymorphisms in TLR4 with susceptibility to gastric cancer, but the results have remained controversial and conflicting. To investigate the effect of two selected TLR4 (+896A/G and +1196C/T) polymorphisms on gastric cancer, we performed a meta-analysis.
   Methods: A comprehensive search was conducted to identify all eligible case-control publications investigating the association between TLR4 polymorphisms and gastric cancer risk. Odds ratios (OR) and corresponding 95% confidence intervals (CI) were used to assess such association.
   Results: Up to March 26 2014, 10 published case-control studies from PubMed and EMBase were available, involving a total of 1888 gastric cancer patients and 3433 control subjects. In the overall meta-analyses, a significantly increased gastric cancer risk was detected in TLR4 +896A/G polymorphism (heterozygous model, AG vs. AA: OR = 1.67, 95% CI, 1.39-2.01; additive model, G vs. A: OR = 1.64, 95% CI, 1.37-1.95) and TLR4 +1196C/T polymorphism (heterozygous model, CT vs. CC: OR = 1.42, 95% CI, 1.11-1.81; additive model, T vs. C: OR = 1.36, 95% CI, 1.08-1.72), similar results were obtained in the subgroup analyses of Caucasian, whereas no associations were detected in any genetic models of non-Caucasian.
   Conclusions: The overall results suggest that TLR4 polymorphisms (+896A/G and +1196C/T) may be associated with a significantly increased gastric cancer risk in Caucasian.
C1 [Zhou, Quan; Wang, Chenchen; Wang, Xiaofeng; Wu, Xiongyan; Zhu, Zhenggang; Liu, Bingya; Su, Liping] Shanghai Jiao Tong Univ, Shanghai Inst Digest Surg, Ruijin Hosp, Dept Surg,Sch Med,Shanghai Key Lab Gastr Neoplasm, Shanghai 200030, Peoples R China.
RP Liu, BY (reprint author), Shanghai Jiao Tong Univ, Shanghai Inst Digest Surg, Ruijin Hosp, Dept Surg,Sch Med,Shanghai Key Lab Gastr Neoplasm, Shanghai 200030, Peoples R China.
EM byliu@sjtu.edu.cn; franesulp@hotmail.com
FU National Natural Science Foundation of China (NSFC) [81272749,
   91229106]; Science and Technology Commission of Shanghai Municipality
   [11jc1407602, 14DZ2272200]; Doctoral Innovation Fund Projects from
   Shanghai Jiao Tong University School of Medicine [BXJ201318]
FX This work was supported by National Natural Science Foundation of China
   (NSFC) - No. 81272749 [LPS] http://www.nsfc.gov.cn/; Science and
   Technology Commission of Shanghai Municipality (No. 11jc1407602). [LPS]
   http://www.stcsm.gov.cn/; National Natural Science Foundation of China
   (NSFC) No. 91229106 [BYL] http://www.nsfc.gov.cn/; Doctoral Innovation
   Fund Projects from Shanghai Jiao Tong University School of Medicine
   (BXJ201318). [QZ] http://yjsy.shsmu.edu.cn/; Science and Technology
   Commission of Shanghai Municipality (No. 14DZ2272200) [ZGZ]
   http://www.stcsm.gov.cn/. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Achyut BR, 2007, HUM IMMUNOL, V68, P901, DOI 10.1016/j.humimm.2007.10.006
   Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228
   Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048
   Armant MA, 2002, GENOME BIOL, V3
   Bagheri N, 2014, CLIN RES HEPATOL GAS, V38, P366, DOI 10.1016/j.clinre.2013.12.004
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4
   Bornschein J, 2011, LANGENBECK ARCH SURG, V396, P729, DOI 10.1007/s00423-011-0810-y
   Chen J, 2013, CANCER BIOTHER RADIO, V28, P674, DOI 10.1089/cbr.2012.1395
   Cole SW, 2009, J CLIN ONCOL, V27, P3418, DOI 10.1200/JCO.2009.21.9782
   Companioni O, 2014, INT J CANCER, V134, P92, DOI 10.1002/ijc.28357
   da Costa BR, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000048
   de Oliveira JG, 2013, DIGEST DIS SCI, V58, P978, DOI 10.1007/s10620-012-2460-5
   de Oliveira JG, 2012, WORLD J GASTROENTERO, V18, P1235, DOI 10.3748/wjg.v18.i11.1235
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Omar EM, 2008, ONCOGENE, V27, P244, DOI 10.1038/sj.onc.1210912
   Fan YF, 2014, HUM IMMUNOL, V75, P176, DOI 10.1016/j.humimm.2013.11.002
   Ferwerda B, 2008, MOL MED, V14, P346, DOI 10.2119/2007-00135.Ferwerda
   Garza-Gonzalez E, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-70
   Hamajima Nobuyuki, 2003, Nagoya J Med Sci, V66, P103
   He CY, 2014, MUTAT RES-REV MUTAT, V759, P14, DOI 10.1016/j.mrrev.2013.09.002
   Hishida A, 2010, WORLD J GASTRO ONCOL, V2, P369, DOI 10.4251/wjgo.v2.i10.369
   Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026
   Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784
   Jing JJ, 2012, GENE, V499, P237, DOI 10.1016/j.gene.2012.03.045
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Kato I, 2007, DIGEST DIS SCI, V52, P254, DOI 10.1007/s10620-006-9303-1
   Kazma R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051680
   Kutikhin AG, 2014, TUMOR BIOL, V35, P4821, DOI 10.1007/s13277-014-1633-6
   Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mockenhaupt FP, 2006, P NATL ACAD SCI USA, V103, P177, DOI 10.1073/pnas.0506803102
   Pharoah PDP, 2004, NAT REV CANCER, V4, P850, DOI 10.1038/nrc1476
   Qadri Q, 2014, IMMUNOL INVEST, V43, P324, DOI 10.3109/08820139.2013.854378
   Rallabhandi P, 2006, J IMMUNOL, V177, P322, DOI 10.4049/jimmunol.177.1.322
   Santini D, 2008, CLIN EXP IMMUNOL, V154, P360, DOI 10.1111/j.1365-2249.2008.03776.x
   Schmausser B, 2004, CLIN EXP IMMUNOL, V136, P521, DOI 10.1111/j.1365-2249.2004.02464.x
   Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186
   Trejo-de la O A, 2008, CLIN IMMUNOL, V129, P333, DOI 10.1016/j.clim.2008.07.009
   Wang F, 2014, CANCER LETT, V345, P196, DOI 10.1016/j.canlet.2013.08.016
   Ward R, 2014, BIOSTATISTICS, V15, P74, DOI 10.1093/biostatistics/kxt028
   WHO: World Health Organization: stomach cancer, 2014, EST INC MORT PREV WO
   Zhang K, 2013, EUR J CANCER, V49, P946, DOI 10.1016/j.ejca.2012.09.022
   Zhu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102443
   Zou TH, 2013, TUMOR BIOL, V34, P2441, DOI 10.1007/s13277-013-0795-y
NR 46
TC 7
Z9 7
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 7
PY 2014
VL 9
IS 10
AR e109605
DI 10.1371/journal.pone.0109605
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AQ4VK
UT WOS:000342798000072
PM 25290654
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, MD
   Zhang, YH
   Zhu, EJ
   Qiao, SB
   Lv, SZ
   Zhao, QM
AF Zhang, Ming-duo
   Zhang, Yu-hui
   Zhu, En-jun
   Qiao, Shi-bin
   Lv, Shu-zheng
   Zhao, Quan-ming
TI Effect of Pioglitazone on In-Stent Restenosis after Coronary
   Drug-Eluting Stent Implantation: A Meta-Analysis of Randomized
   Controlled Trials
SO PLOS ONE
LA English
DT Article
ID MUSCLE-CELL PROLIFERATION; TYPE-2 DIABETES-MELLITUS; ACTIVATED
   RECEPTOR-GAMMA; PPAR-GAMMA; MYOCARDIAL-INFARCTION; CLINICAL-TRIALS;
   DOUBLE-BLIND; PREVENTION; THIAZOLIDINEDIONES; APOPTOSIS
AB Background: In-stent restenosis (ISR) remains a common life-threatening complication and some studies have shown that pioglitazone can reduce the incidence of ISR in patients with drug-eluting stents (DES) implantation. We conducted a meta-analysis to assess the effect of pioglitazone in preventing ISR after DES implantation.
   Methods: Randomized controlled trials (RCTs) investigating the effects of pioglitazone for ISR after DES implantation were identified by systematic searches of multiple online databases and manual searches of related reference lists of identified trials through May 2014. The primary endpoint was the rate of ISR. Secondary endpoints included minimum lumen diameter, percentage stenosis of stented vessels, late loss, in-stent neointimal volume, target vessel revascularization (TVR), target lesion revascularization, myocardial infarction, stent thrombosis and death.
   Results: Five studies, comprising 255 pioglitazone-treated patients and 245 controls, were identified in the current meta-analysis. Pioglitazone did not significantly reduce the rate of ISR (P = 0.20) with low heterogeneity (I-2 = 13.3%, P = 0.32). For the secondary outcomes, pioglitazone did not substantially affect the pooled estimates of these endpoints except late loss (P = 0.01) and TVR (P = 0.04).
   Conclusions: The limited evidence indicates that pioglitazone does not demonstrate markedly beneficial effect in patients subjected to coronary DES implantation. However, the results should be interpreted with care given the small sample size. Further large-scale RCTs are needed.
C1 [Zhang, Ming-duo; Zhang, Yu-hui; Lv, Shu-zheng; Zhao, Quan-ming] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China.
   [Zhang, Ming-duo; Zhang, Yu-hui; Lv, Shu-zheng; Zhao, Quan-ming] Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China.
   [Zhu, En-jun] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiac Surg, Beijing, Peoples R China.
   [Qiao, Shi-bin] Rizhao Peoples Hosp, Dept Cardiol, Rizhao, Shandong, Peoples R China.
RP Lv, SZ (reprint author), Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China.
EM cardio_anzhen@hotmail.com; cardio_zqm@hotmail.com
FU "Twelve Five'' National Key Technology R&D Program of China
   [2011BAI11B05]; Beijing Natural Science Foundation of China [7132078]
FX This study is supported by "Twelve Five'' National Key Technology R&D
   Program of China (Grant No. 2011BAI11B05,
   http://www.most.gov.cn/eng/programmes1/200610/t20061009_36224.htm) and
   Beijing Natural Science Foundation of China (Grant No. 7132078,
   http://www.bjkw.gov.cn/n244495/index.html). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aizawa Y, 2001, CIRCULATION, V104, P455, DOI 10.1161/hc3001.092040
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   D'Ascenzo F, 2013, INT J CARDIOL, V167, P575, DOI 10.1016/j.ijcard.2012.01.080
   Dangas GD, 2010, J AM COLL CARDIOL, V56, P1897, DOI 10.1016/j.jacc.2010.07.028
   Deftereos S, 2013, J AM COLL CARDIOL, V61, P1679, DOI 10.1016/j.jacc.2013.01.055
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dihu JB, 2011, J AM COLL CARDIOL, V57, P2035, DOI 10.1016/j.jacc.2011.01.022
   Douglas JS, 2005, CIRCULATION, V112, P2826, DOI 10.1161/CIRCULATIONAHA.104.530097
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Geng DF, 2009, ATHEROSCLEROSIS, V202, P521, DOI 10.1016/j.atherosclerosis.2008.05.029
   Gensch C, 2007, ATHEROSCLEROSIS, V192, P67, DOI 10.1016/j.atherosclerosis.2006.06.026
   Hausleiter J, 2004, CIRCULATION, V110, P790, DOI 10.1161/01.CIR.0000138935.17503.35
   Henney JE, 2000, JAMA-J AM MED ASSOC, V283, P2228, DOI 10.1001/jama.283.17.2228-b
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hong SJ, 2010, ARTERIOSCL THROM VAS, V30, P2655, DOI 10.1161/ATVBAHA.110.212670
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Joner M, 2007, ARTERIOSCL THROM VAS, V27, P182, DOI 10.1161/01.ATV.0000251021.28725.e8
   Jukema JW, 2012, NAT REV CARDIOL, V9, P53, DOI 10.1038/nrcardio.2011.132
   Kaneda H, 2009, HEART, V95, P1079, DOI 10.1136/hrt.2008.162842
   Kasai T, 2008, ATHEROSCLEROSIS, V197, P612, DOI 10.1016/j.atherosclerosis.2007.08.030
   Katayama T, 2007, AM HEART J, V153, DOI 10.1016/j.ahj.2007.02.022
   Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010
   Kornowski R, 1998, J AM COLL CARDIOL, V31, P224, DOI 10.1016/S0735-1097(97)00450-6
   Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311
   Lee HW, 2013, YONSEI MED J, V54, P1313, DOI 10.3349/ymj.2013.54.6.1313
   Li RJ, 2009, J GUANGDONG MED COLL, V27, P620
   Lim S, 2006, ARTERIOSCL THROM VAS, V26, P808, DOI 10.1161/01.ATV.0000204634.26163.a7
   Lincoff AM, 2007, JAMA-J AM MED ASSOC, V298, P1180, DOI 10.1001/jama.298.10.1180
   Marx N, 2005, CIRCULATION, V112, P2792, DOI 10.1161/CIRCULATIONAHA.105.535484
   Marx SO, 2011, CIRC-CARDIOVASC INTE, V4, P104, DOI 10.1161/CIRCINTERVENTIONS.110.957332
   Mauri L, 2005, CIRCULATION, V111, P321, DOI 10.1161/01.CIR.0000153356.72810.97
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Monraats PS, 2005, CIRCULATION, V112, P2417, DOI 10.1161/CIRCULATIONAHA.105.536268
   Nishio K, 2006, DIABETES CARE, V29, P101, DOI 10.2337/diacare.29.1.101
   Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761
   Pakala R, 2006, J CARDIOVASC PHARM, V48, P299, DOI 10.1097/01.fjc.0000249891.40714.2a
   Palmerini T, 2012, LANCET, V379, P1393, DOI 10.1016/S0140-6736(12)60324-9
   Patel D, 2011, JACC-CARDIOVASC INTE, V4, P353, DOI 10.1016/j.jcin.2010.10.016
   Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012
   Rathore S, 2009, EUROINTERVENTION, V5, P349, DOI 10.4244/V5I3A55
   Riche DM, 2007, DIABETES CARE, V30, P384, DOI 10.2337/dc06-1854
   Roiron C, 2006, HEART, V92, P641, DOI 10.1136/hrt.2005.061622
   Rosmarakis ES, 2007, AM HEART J, V154, P144, DOI 10.1016/j.ahj.2007.04.005
   Takagi T, 2003, AM HEART J, V146, DOI 10.1016/S0002-8703(03)00146-7
   Takagi T, 2009, JACC-CARDIOVASC INTE, V2, P524, DOI 10.1016/j.jcin.2009.04.007
   [魏广和 Wei Guanghe], 2012, [临床心血管病杂志, Journal of Clinical Cardiology], V28, P445
   Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001
   Zhang YJ, 2013, MED PHILOS, V34, P26
NR 49
TC 1
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 3
PY 2014
VL 9
IS 10
AR e109614
DI 10.1371/journal.pone.0109614
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AQ3DZ
UT WOS:000342670800092
PM 25279761
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Rai, V
   Yadav, U
   Kumar, P
   Yadav, SK
   Mishra, OP
AF Rai, Vandana
   Yadav, Upendra
   Kumar, Pradeep
   Yadav, Sushil Kumar
   Mishra, Om Prakesh
TI Maternal Methylenetetrahydrofolate Reductase C677T Polymorphism and Down
   Syndrome Risk: A Meta-Analysis from 34 Studies
SO PLOS ONE
LA English
DT Article
ID FOLATE/METHYL-DEFICIENT RATS; FOLATE-METABOLIZING GENES; HOMOCYSTEINE
   METABOLISM; SYNDROME PREGNANCIES; CHROMOSOME-DAMAGE; VASCULAR-DISEASE;
   COMMON MUTATION; ITALIAN WOMEN; MTHFR C677T; ASSOCIATION
AB Background: Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme of folate metabolic pathway which catalyzes the irreversible conversion of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. 5-methyltetrahydrofolate donates methyl group for the methylation of homocysteine to methionine. Several studies have investigated maternal MTHFR C677T polymorphism as a risk factor for DS, but the results were controversial and inconclusive. To come into a conclusive estimate, authors performed a meta-analysis.
   Aim: A meta-analysis of published case control studies was performed to investigate the association between maternal MTHFR C677T polymorphism and Down syndrome.
   Methods: PubMed, Google Scholar, Elsevier, Springer Link databases were searched to select the eligible case control studies using appropriate keywords. The pooled odds ratio (OR) with 95% confidence interval were calculated for risk assessment.
   Results: Thirty four studies with 3,098 DS case mothers and 4,852 control mothers were included in the present meta-analysis. The pooled OR was estimated under five genetic models and significant association was found between maternal MTHFR 677C>T polymorphism and Down syndrome under four genetic models except recessive model (for T vs. C, OR = 1.26, 95% CI = 1.09-1.46, p = 0.001; for TT vs. CC, OR = 1.49, 95% CI = 1.13-1.97, p = 0.008; for CT vs. CC, OR = 1.29, 95% CI = 1.10-1.51, p = 0.001; for TT+CT vs. CC, OR = 1.35, 95% CI = 1.13-1.60, p = 0.0008; for TT vs. CT+CC, OR = 0.76, 95% CI = 0.60-0.94, p = 0.01).
   Conclusion: The results of the present meta-analysis support that maternal MTHFR C677T polymorphism is a risk factor for DS-affected pregnancy.
C1 [Rai, Vandana; Yadav, Upendra; Kumar, Pradeep; Yadav, Sushil Kumar] VBS Purvanchal Univ, Dept Biotechnol, Human Mol Genet Lab, Jaunpur, India.
   [Mishra, Om Prakesh] Banaras Hindu Univ, Inst Med Sci, Dept Pediat, Varanasi 221005, Uttar Pradesh, India.
RP Rai, V (reprint author), VBS Purvanchal Univ, Dept Biotechnol, Human Mol Genet Lab, Jaunpur, India.
EM raivandana@rediffmail.com
RI Yadav, Upendra/J-7872-2013; Rai, Vandana/H-1463-2017
OI Yadav, Upendra/0000-0003-2469-8071; Kumar, Pradeep/0000-0002-0695-1996;
   Rai, Vandana/0000-0001-8590-9675
CR Acacio GL, 2005, PRENATAL DIAG, V25, P1196, DOI 10.1002/pd.1296
   Bagley PJ, 1998, P NATL ACAD SCI USA, V95, P13217, DOI 10.1073/pnas.95.22.13217
   BALAGHI M, 1993, BIOCHEM BIOPH RES CO, V193, P1184, DOI 10.1006/bbrc.1993.1750
   Bax Leon, 2006, BMC Med Res Methodol, V6, P50, DOI 10.1186/1471-2288-6-50
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benes P, 2001, MOL GENET METAB, V73, P188, DOI 10.1006/mgme.2001.3188
   Biselli JM, 2008, GENET MOL RES, V7, P33, DOI 10.4238/vol7-1gmr388
   Blanton SH, 2011, BIRTH DEFECTS RES A, V91, P50, DOI 10.1002/bdra.20740
   Boduroglu K, 2004, AM J MED GENET A, V127A, P5, DOI 10.1002/ajmg.a.20432
   Botto LD, 2000, AM J EPIDEMIOL, V151, P862
   Bozovic IB, 2011, PEDIATR INT, V53, P546, DOI 10.1111/j.1442-200X.2010.03310.x
   Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520
   Brandalize APC, 2009, AM J MED GENET A, V149A, P2080, DOI 10.1002/ajmg.a.32989
   Chadefaux-Vekemans B, 2002, PEDIATR RES, V51, P766, DOI 10.1023/01.PDR.0000017484.64723.43
   Chen RZ, 1998, NATURE, V395, P89
   Clark MF, 2006, INTENS CARE MED, V32, P1706, DOI 10.1007/s00134-006-0327-y
   Coppede F, 2006, AM J MED GENET A, V140A, P1083, DOI 10.1002/ajmg.a.31217
   Coppede F, 2009, NEUROSCI LETT, V449, P15, DOI 10.1016/j.neulet.2008.10.074
   Coppede F, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-42
   Cyril Cyrus, 2009, Indian J Hum Genet, V15, P60, DOI 10.4103/0971-6866.55217
   da Silva LRJ, 2005, AM J MED GENET A, V135A, P263, DOI 10.1002/ajmg.a.30591
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elsayed GM, 2013, EGYPTIAN J MED HUM G, V15, P39
   Fenech M, 2001, MUTAT RES-FUND MOL M, V475, P57, DOI 10.1016/S0027-5107(01)00079-3
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   Hobbs CA, 2000, AM J HUM GENET, V67, P623, DOI 10.1086/303055
   Hua Y, 2011, INT J NEUROSCI, V121, P462, DOI 10.3109/00207454.2011.578778
   James SJ, 1999, AM J CLIN NUTR, V70, P495
   JAMES SJ, 2002, J NUTR, V132, P2361
   Jonsson EG, 2008, AM J MED GENET B, V147B, P976, DOI 10.1002/ajmg.b.30671
   Kaur Anupam, 2013, Indian J Hum Genet, V19, P412, DOI 10.4103/0971-6866.124368
   Kohli Utkarsh, 2008, Downs Syndr Res Pract, V12, P133, DOI 10.3104/reports.2004
   Kokotas H, 2009, DIS MARKERS, V27, P279, DOI 10.3233/DMA-2009-0673
   Leyton BL, 1995, CELL PROLIFERAT, V28, P481
   Liang X., 2005, CHINA J MODERN MED, V20, P11
   Liao Ya-Ping, 2010, Yichuan, V32, P461, DOI 10.3724/SP.J.1005.2010.00461
   LIBBUS BL, 1990, CANCER GENET CYTOGEN, V46, P231, DOI 10.1016/0165-4608(90)90108-M
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Martinez-Frias ML, 2008, AM J MED GENET A, V146A, P1477, DOI 10.1002/ajmg.a.32308
   Medica I, 2009, CENT EUR J MED, V4, P395, DOI 10.2478/s11536-009-0055-0
   Meguid NA, 2008, DIS MARKERS, V24, P19, DOI 10.1155/2008/214027
   O'Leary VB, 2002, AM J MED GENET, V107, P151, DOI 10.1002/ajmg.10121
   Pandey SK, 2013, INT J PHARM BIO SCI, V4, P249
   Parry EM, 2002, MUTAGENESIS, V17, P509, DOI 10.1093/mutage/17.6.509
   Peerbooms OLJ, 2011, BRAIN BEHAV IMMUN, V25, P1530, DOI 10.1016/j.bbi.2010.12.006
   Pogribna M, 2001, AM J HUM GENET, V69, P88, DOI 10.1086/321262
   Pogribny IP, 2004, MUTAT RES-FUND MOL M, V548, P53, DOI 10.1016/j.mrfmmm.2003.12.014
   POGRIBNY IP, 1995, CANCER RES, V55, P1894
   Pozzi E, 2009, AM J OBSTET GYNECOL, V63, pe1
   Rai AK, 2006, J HUM GENET, V51, P278, DOI 10.1007/s10038-005-0356-3
   Sadiq MF, 2011, GENET TEST MOL BIOMA, V15, P1
   Santos-Reboucas CB, 2008, DIS MARKERS, V25, P149, DOI 10.1155/2008/487023
   Scala I, 2006, GENET MED, V8, P409, DOI 10.1097/01.gim.0000228206.21793.82
   Stuppia L, 2002, EUR J HUM GENET, V10, P388, DOI 10.1038/sj.ejhg.5200819
   Tayeb MT, 2012, EGYPTIAN J MED HUM G, V13, P263
   Titenko-Holland N, 1998, MUTAT RES-GEN TOX EN, V417, P101, DOI 10.1016/S1383-5718(98)00104-1
   vanderPut NMJ, 1997, QJM-MON J ASSOC PHYS, V90, P111, DOI 10.1093/qjmed/90.2.111
   Vranekovic J, 2010, DIS MARKERS, V28, P293, DOI 10.3233/DMA-2010-0704
   Wang SS, 2008, J ZHEJIANG UNIV-SC B, V9, P93, DOI 10.1631/jzus.B0710599
   Wang Wen, 2007, Zhonghua Yixue Yichuanxue Zazhi, V24, P533
   Wu XM, 2013, EUR J OBSTET GYN R B, V167, P154, DOI 10.1016/j.ejogrb.2012.11.022
   Yadav S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057305
   Yadav U, 2015, METAB BRAIN DIS, V30, P7, DOI 10.1007/s11011-014-9575-7
   Yang M, 2013, MUTAGENESIS, V28, P661, DOI 10.1093/mutage/get045
   Zampieri BL, 2012, DIS MARKERS, V32, P73, DOI 10.3233/DMA-2011-0869
   Zhang T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059570
   Zhao MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088242
   Zintzaras E, 2007, J HUM GENET, V52, P943, DOI 10.1007/s10038-007-0202-x
NR 69
TC 21
Z9 22
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 29
PY 2014
VL 9
IS 9
AR e108552
DI 10.1371/journal.pone.0108552
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU6XR
UT WOS:000345745400087
PM 25265565
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhao, JS
   Zhu, SM
   Sun, LB
   Meng, FZ
   Zhao, L
   Zhao, YS
   Tian, H
   Li, P
   Niu, YJ
AF Zhao, Jinsheng
   Zhu, Shimiao
   Sun, Libin
   Meng, Fanzheng
   Zhao, Lin
   Zhao, Yusheng
   Tian, Hao
   Li, Ping
   Niu, Yuanjie
TI Androgen Deprivation Therapy for Prostate Cancer Is Associated with
   Cardiovascular Morbidity and Mortality: A Meta-Analysis of
   Population-Based Observational Studies
SO PLOS ONE
LA English
DT Article
ID CHOLESTEROL-FED RABBITS; CORONARY-HEART-DISEASE; ENDOGENOUS
   TESTOSTERONE; EUROPEAN ORGANIZATION; HORMONE AGONISTS; LOCAL TREATMENT;
   PCBASE SWEDEN; MEN; RISK; TRIAL
AB Background: There is no consensus regarding whether androgen deprivation therapy (ADT) is associated with cardiovascular disease (CVD) and cardiovascular mortality (CVM). The objective of this study was to determine the role of ADT for prostate cancer (PCa) in development of cardiovascular events (CVD and CVM).
   Methods and Findings: We performed a meta-analysis from population-based observational studies comparing ADT vs control aimed at treating PCa in patients with PCa, reporting either CVD or CVM as outcome. Publications were searched using Medline, Embase, Cochrane Library Central Register of observational studies database up to May 31th 2014, and supplementary searches in publications from potentially relevant journals. 6 studies were identified with a total of 129,802 ADT users and 165,605 controls investigating the relationship between ADT and CVD. The incidence of CVD was 10% higher in ADT groups, although no significant association was observed (HR = 1.10, 95% CIs: 1.00-1.21; P = 0.06). For different types of ADT, CVD was related with gonadotropin-releasing hormone (GnRH) (HR = 1.19, 95% CIs: 1.04-1.36; P<0.001) and GnRH plus oral antiandrogen (AA) (HR = 1.46, 95% CIs: 1.03-2.08; P = 0.04), but not with AA alone or orchiectomy. For CVM, 119,625 ADT users and 150,974 controls from 6 eligible studies were included, pooled results suggested that ADT was associated with CVM (HR = 1.17, 95% CIs: 1.04-1.32; P = 0.01). Significantly increased CVM was also detected in GnRH and GnRH plus AA groups. When patients received other treatments (e.g. prostatectomy and radiotherapy) were ruled out of consideration, more increased CVD (HR = 1.19, 95% CIs: 1.08-1.30; P<0.001) and CVM (HR = 1.30, 95% CIs: 1.13-1.50; P<0.001) were found in men treated with ADT monotherapy.
   Conclusions: ADT is associated with both CVD and CVM. Particularly, GnRH alone and GnRH plus AA can significantly increase the incidence of cardiovascular events in patients with PCa.
C1 [Zhao, Jinsheng; Zhu, Shimiao; Sun, Libin; Zhao, Lin; Tian, Hao; Niu, Yuanjie] Tianjin Med Univ, Tianjin, Peoples R China.
   [Zhao, Jinsheng; Meng, Fanzheng] Tianjin Nankai Hosp, Dept Neurol, Tianjin, Peoples R China.
   [Zhao, Jinsheng; Zhu, Shimiao; Sun, Libin; Tian, Hao; Niu, Yuanjie] Tianjin Med Unvers, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin, Peoples R China.
   [Zhao, Yusheng] Tianjin Univ, Teaching Hosp 1, TCM, Tianjin, Peoples R China.
   [Li, Ping] Tianjin Third Cent Hosp, Tianjin, Peoples R China.
RP Niu, YJ (reprint author), Tianjin Med Univ, Tianjin, Peoples R China.
EM yuanjieniu68@hotmail.com
FU National Basic Research Program of China [2012CB518304]; International
   S&T Cooperation Program of China (ISTCP) [S2012GR0142]
FX The work was supported by the National Basic Research Program of China
   (grant no. 2012CB518304) and the International S&T Cooperation Program
   of China (ISTCP) (grant no. S2012GR0142). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alexandersen P, 1999, CIRC RES, V84, P813
   Alibhai SMH, 2009, J CLIN ONCOL, V27, P3452, DOI 10.1200/JCO.2008.20.0923
   [Anonymous], 2014, CLIN INFECT DIS, V58, pi
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blankfield RP, 2012, JAMA-J AM MED ASSOC, V307, P1252, DOI 10.1001/jama.2012.352
   Conteduca V, 2013, CRIT REV ONCOL HEMAT, V86, P42, DOI 10.1016/j.critrevonc.2012.09.008
   Efstathiou JA, 2008, EUR UROL, V54, P816, DOI 10.1016/j.eururo.2008.01.021
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gandaglia G, 2014, BJU INT
   GLUECK CJ, 1993, J LAB CLIN MED, V122, P412
   Handoll HH, 2006, ARCH PHYS MED REHAB, V87, P875, DOI 10.1016/j.apmr.2006.04.006
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang G, 2014, J ONCOL, DOI 10.1155/2014/529468
   Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232
   HUGGINS C, 1967, SCIENCE, V156, P1050, DOI 10.1126/science.156.3778.1050
   Isidori AM, 2005, CLIN ENDOCRINOL, V63, P280, DOI 10.1111/j.1365-2265.2005.02339.x
   Jespersen CG, 2013, EUR UROL
   Keating NL, 2006, J CLIN ONCOL, V24, P4448, DOI 10.1200/JCO.2006.06.2497
   Keating NL, 2012, J NATL CANCER I, V104, P1518, DOI 10.1093/jnci/djs376
   Keating NL, 2010, J NATL CANCER I, V102, P39, DOI 10.1093/jnci/djp404
   Kim J, 2011, INT J RADIAT ONCOL, V80, P742, DOI 10.1016/j.ijrobp.2010.03.018
   Langley RE, 2013, LANCET ONCOL, V14, P306, DOI 10.1016/S1470-2045(13)70025-1
   LARSEN BA, 1993, ATHEROSCLEROSIS, V99, P79, DOI 10.1016/0021-9150(93)90053-W
   Laughlin GA, 2008, J CLIN ENDOCR METAB, V93, P68, DOI 10.1210/jc.2007-1792
   Liu DQ, 2013, WORLD J GASTROENTERO, V19, P4053, DOI 10.3748/wjg.v19.i25.4053
   Martin-Merino E, 2011, DRUG SAFETY, V34, P1061, DOI 10.2165/11594540-000000000-00000
   Merrick GS, 2006, INT J RADIAT ONCOL, V65, P669, DOI 10.1016/j.ijrobp.2006.01.030
   Messing EM, 2006, LANCET ONCOL, V7, P472, DOI 10.1016/S1470-2045(06)70700-8
   Nettleship JE, 2007, CIRCULATION, V116, P2427, DOI 10.1161/CIRCULATIONAHA.107.708768
   Nguyen PL, 2011, JAMA-J AM MED ASSOC, V306, P2359, DOI 10.1001/jama.2011.1745
   Phillips B, 2004, ARCH DIS CHILD, V89, P489, DOI 10.1136/adc.2004.050898
   Punnen S, 2011, J CLIN ONCOL, V29, P3510, DOI 10.1200/JCO.2011.35.1494
   Robinson D, 2012, INT J CANCER, V130, P478, DOI 10.1002/ijc.26022
   Rosmond R, 1996, OBES RES, V4, P245, DOI 10.1002/j.1550-8528.1996.tb00542.x
   Saigal CS, 2007, CANCER-AM CANCER SOC, V110, P1493, DOI 10.1002/cncr.22933
   Saylor PJ, 2010, J NATL COMPR CANC NE, V8, P211, DOI 10.6004/jnccn.2010.0014
   Schroder FH, 2009, EUR UROL, V55, P14, DOI 10.1016/j.eururo.2008.09.008
   Schulz KF, 2006, LANCET HDB ESSENTIAL
   Smith Matthew R, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P247, DOI 10.1097/MED.0b013e32814db88c
   Studer UE, 2006, J CLIN ONCOL, V24, P1868, DOI 10.1200/JCO.2005.04.7423
   Svartberg J, 2004, EUR J ENDOCRINOL, V150, P65, DOI 10.1530/eje.0.1500065
   Traish AM, 2009, J ANDROL, V30, P477, DOI 10.2164/jandrol.108.007245
   Tsai HK, 2007, J NATL CANCER I, V99, P1516, DOI 10.1093/jnci/djm168
   Van Hemelrijck M, 2012, EUR UROL, V61, P690, DOI 10.1016/j.eururo.2011.09.010
   Van Hemelrijck M, 2010, J CLIN ONCOL, V28, P3448, DOI 10.1200/JCO.2010.29.1567
   Wells GA, 2009, NEWCASTLE OTTAWA SCA
   Whitsel EA, 2001, AM J MED, V111, P261, DOI 10.1016/S0002-9343(01)00833-6
   Zhu SM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-332
NR 48
TC 33
Z9 33
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 29
PY 2014
VL 9
IS 9
AR e107516
DI 10.1371/journal.pone.0107516
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU6XR
UT WOS:000345745400025
PM 25264674
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, X
   Rong, SS
   Xu, QH
   Tang, FY
   Liu, Y
   Gu, H
   Tam, POS
   Chen, LJ
   Brelen, ME
   Pang, CP
   Zhao, C
AF Chen, Xue
   Rong, Shi Song
   Xu, Qihua
   Tang, Fang Yao
   Liu, Yuan
   Gu, Hong
   Tam, Pancy O. S.
   Chen, Li Jia
   Brelen, Marten E.
   Pang, Chi Pui
   Zhao, Chen
TI Diabetes Mellitus and Risk of Age-Related Macular Degeneration: A
   Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID BLUE-MOUNTAINS-EYE; GLYCATION END-PRODUCTS; CHOROIDAL
   NEOVASCULARIZATION; CARDIOVASCULAR-DISEASE; MACROMOLECULAR DAMAGE;
   VASCULAR-DISEASE; SEVERITY SCALE; GRADING SYSTEM; STATIN USE;
   MACULOPATHY
AB Age-related macular degeneration (AMD) is a major cause of severe vision loss in elderly people. Diabetes mellitus is a common endocrine disorder with serious consequences, and diabetic retinopathy (DR) is the main ophthalmic complication. DR and AMD are different diseases and we seek to explore the relationship between diabetes and AMD. MEDLINE, EMBASE, and the Cochrane Library were searched for potentially eligible studies. Studies based on longitudinal cohort, cross-sectional, and case-control associations, reporting evaluation data of diabetes as an independent factor for AMD were included. Reports of relative risks (RRs), hazard ratios (HRs), odds ratio (ORs), or evaluation data of diabetes as an independent factor for AMD were included. Review Manager and STATA were used for the meta-analysis. Twenty four articles involving 27 study populations were included for meta-analysis. In 7 cohort studies, diabetes was shown to be a risk factor for AMD (OR, 1.05; 95% CI, 1.00-1.14). Results of 9 cross-sectional studies revealed consistent association of diabetes with AMD (OR, 1.21; 95% CI, 1.00-1.45), especially for late AMD (OR, 1.48; 95% CI, 1.44-1.51). Similar association was also detected for AMD (OR, 1.29; 95% CI, 1.13-1.49) and late AMD (OR, 1.16; 95% CI, 1.11-1.21) in 11 case-control studies. The pooled ORs for risk of neovascular AMD (nAMD) were 1.10 (95% CI, 0.96-1.26), 1.48 (95% CI, 1.44-1.51), and 1.15 (95% CI, 1.11-1.21) from cohort, cross-sectional and case-control studies, respectively. No obvious divergence existed among different ethnic groups. Therefore, we find diabetes a risk factor for AMD, stronger for late AMD than earlier stages. However, most of the included studies only adjusted for age and sex; we thus cannot rule out confounding as a potential explanation for the association. More well-designed prospective cohort studies are still warranted to further examine the association.
C1 [Chen, Xue; Xu, Qihua; Liu, Yuan; Zhao, Chen] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China.
   [Chen, Xue; Xu, Qihua; Liu, Yuan; Zhao, Chen] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.
   [Chen, Xue; Rong, Shi Song; Tang, Fang Yao; Gu, Hong; Tam, Pancy O. S.; Chen, Li Jia; Brelen, Marten E.; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Xu, Qihua] Southeast Univ, Affiliated Jiangyin Hosp, Coll Med, Dept Ophthalmol, Jiangyin, Peoples R China.
   [Gu, Hong] Lihuili Hosp, Ningbo Med Treatment Ctr, Dept Ophthalmol, Ningbo, Peoples R China.
RP Pang, CP (reprint author), Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
EM cppang@cuhk.edu.hk; dr.zhaochen@gmail.com
RI Rong, Shisong Wing/L-9735-2019; liu, yuan/L-9239-2018; Chen, Li
   Jia/I-5078-2014; Brelen, Marten E./D-1133-2016
OI Rong, Shisong Wing/0000-0001-8352-6363; liu, yuan/0000-0003-4887-907X;
   Chen, Li Jia/0000-0003-3500-5840; 
FU National Key Basic Research Program of China [2013CB967500]; National
   Natural Science Foundation of China [81222009, 81170856]; Thousand Youth
   Talents Program of China; Jiangsu Outstanding Young Investigator Program
   [BK2012046]; Jiangsu Province's Key Provincial Talents Program
   [RC201149]; Jiangsu Province's Scientific Research Innovation Program
   for Postgraduates [CXZZ13_0590]; Endowment Fund for the Lim Por-Yen Eye
   Genetics Research Centre; General Research Fund from the Research Grants
   Council of Hong Kong [473410]; Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD)
FX This work was supported by National Key Basic Research Program of China
   (2013CB967500); National Natural Science Foundation of China (No.
   81222009 and 81170856); Thousand Youth Talents Program of China (to
   C.Z.); Jiangsu Outstanding Young Investigator Program (BK2012046);
   Jiangsu Province's Key Provincial Talents Program (RC201149); Jiangsu
   Province's Scientific Research Innovation Program for Postgraduates
   (CXZZ13_0590 to X.C.); an Endowment Fund for the Lim Por-Yen Eye
   Genetics Research Centre; the General Research Fund from the Research
   Grants Council of Hong Kong (No. 473410); and A Project Funded by the
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD). The sponsor or funding organization had no role in
   the design or conduct of this research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cao XR, 2010, DISCRETE EVENT DYN S, V20, P1, DOI 10.1007/s10626-010-0088-1
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619
   Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gemmy Cheung CM, 2013, AM J OPHTHALMOL, V155, pe761
   Gemmy Cheung CM, 2013, AM J OPHTHALMOL, V155, P773
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA
   Ho AC, 2012, OPHTHALMOLOGY, V119, P2179, DOI 10.1016/j.ophtha.2012.07.058
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Karesvuo P, 2013, J PERIODONTOL, V84, P58, DOI 10.1902/jop.2012.110643
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim IK, 2008, MOL VIS, V14, P1487
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2013, AM J OPHTHALMOL
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011
   La Torre G, 2013, EUR J EPIDEMIOL, V28, P445, DOI 10.1007/s10654-013-9798-7
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Mattes D, 2009, MOL VIS, V15, P343
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Monnier VM, 2005, ANN NY ACAD SCI, V1043, P567, DOI 10.1196/annals.1338.065
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Pokharel S, 2009, J NEPAL MED ASSOC, V48, P217
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Rostom A, 2004, EVIDENCE REPORTS TEC
   Sasongko MB, 2012, DIABETES, V61, P1785, DOI 10.2337/db11-1272
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Sogut E, 2013, RETINA
   Sorriento D, 2014, SCIENTIFICWORLDJOURN, V2014
   Soulis T, 1997, DIABETOLOGIA, V40, P619, DOI 10.1007/s001250050725
   Stitt AW, 2010, INVEST OPHTH VIS SCI, V51, P4867, DOI 10.1167/iovs.10-5881
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Turner N, 2014, MOL HUM REPROD
   Vaicaitiene Ramute, 2003, Medicina (Kaunas), V39, P1231
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Xu L, 2009, EYE, V23, P676, DOI 10.1038/sj.eye.6703104
   Yang K, 2012, GRAEF ARCH CLIN EXP, V250, P741, DOI 10.1007/s00417-011-1824-4
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yuan DQ, 2013, OPHTHALMOLOGY, V120, P2051, DOI 10.1016/j.ophtha.2013.03.026
   Zhang Wenbo, 2011, J Cardiovasc Dis Res, V2, P96, DOI 10.4103/0975-3583.83035
NR 84
TC 4
Z9 4
U1 4
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 19
PY 2014
VL 9
IS 9
AR e108196
DI 10.1371/journal.pone.0108196
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AQ0RY
UT WOS:000342491600085
PM 25238063
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, C
   Wang, ZY
   Qin, YY
   Yu, FF
   Zhou, YH
AF Zhang, Chi
   Wang, Zhi-Yong
   Qin, Ying-Yi
   Yu, Fei-Fei
   Zhou, Yu-Hao
TI Association between B Vitamins Supplementation and Risk of
   Cardiovascular Outcomes: A Cumulative Meta-Analysis of Randomized
   Controlled Trials
SO PLOS ONE
LA English
DT Article
ID FOLIC-ACID SUPPLEMENTATION; HOMOCYSTEINE-LOWERING THERAPY;
   CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; STROKE PREVENTION; TOTAL
   MORTALITY; EVENTS; FOLATE; ATHEROSCLEROSIS; HOMOCYST(E)INE
AB Background: Observational studies suggest that B vitamin supplementation reduces cardiovascular risk in adults, but this association remains controversial. This study aimed to summarize the evidence from randomized controlled trials (RCTs) investigating B vitamin supplementation for the primary or secondary prevention of major adverse cardiovascular outcomes and to perform a cumulative meta-analysis to determine the evidence base.
   Methodology and Principal Findings: In April 2013, we searched PubMed, Embase, and the Cochrane Library to identify relevant RCTs. We included RCTs investigating the effect of B vitamin supplementation on cardiovascular outcome. Relative risk (RR) was used to measure the effect using a random-effect model. Statistical heterogeneity scores were assessed using the Q statistic. We included data on 57,952 individuals from 24 RCTs: 12 primary prevention trials and 12 secondary prevention trials. In 23 of these trials, 10,917 major adverse cardiovascular events (MACE) occurred; in 20 trials, 7,203 deaths occurred; in 15 trials, 3,422 cardiac deaths occurred; in 19 trials, 3,623 myocardial infarctions (MI) occurred; and in 18 trials, 2,465 strokes occurred. B vitamin supplementation had little or no effect on the incidence of MACE (RR, 0.98; 95% confidence interval [CI]: 0.93-1.03; P = 0.37), total mortality (RR, 1.01; 95% CI: 0.97-1.05; P = 0.77), cardiac death (RR, 0.96; 95% CI: 0.90-1.02; P = 0.21), MI (RR, 0.99; 95% CI: 0.93-1.06; P = 0.82), or stroke (RR, 0.94; 95% CI: 0.85-1.03; P = 0.18).
   Conclusion/Significance: B vitamin supplementation, when used for primary or secondary prevention, is not associated with a reduction in MACE, total mortality, cardiac death, MI, or stroke.
C1 [Zhang, Chi] Shanghai Seventh Peoples Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Wang, Zhi-Yong] Second Mil Med Univ, Changhai Hosp, Dept Informat, Shanghai, Peoples R China.
   [Qin, Ying-Yi; Yu, Fei-Fei] Second Mil Med Univ, Dept Hlth Stat, Shanghai, Peoples R China.
   [Zhou, Yu-Hao] Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.
RP Zhou, YH (reprint author), Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.
EM zhou_ly@126.com
FU Disciplines Group Construction Project of Pudong Health Bureau of
   Shanghai [PWZxkq2011-01]; Shanghai key speciality of traditional Chinese
   medicine [ZYXK2012010]
FX This study was funded by Disciplines Group Construction Project of
   Pudong Health Bureau of Shanghai (PWZxkq2011-01) and Shanghai key
   speciality of traditional Chinese medicine (ZYXK2012010). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Albert CM, 2008, JAMA-J AM MED ASSOC, V299, P2027, DOI 10.1001/jama.299.17.2027
   Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   Armitage JM, 2010, JAMA-J AM MED ASSOC, V303, P2486, DOI 10.1001/jama.2010.840
   Baker F, 2002, CIRCULATION, V106, P741
   Bazzano LA, 2006, JAMA-J AM MED ASSOC, V296, P2720, DOI 10.1001/jama.296.22.2720
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227
   Bostom AG, 2011, CIRCULATION, V123, P1763, DOI 10.1161/CIRCULATIONAHA.110.000588
   Bots ML, 1999, ARCH INTERN MED, V159, P38, DOI 10.1001/archinte.159.1.38
   Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894
   Chambers JC, 2000, LANCET, V355, P523, DOI 10.1016/S0140-6736(99)93019-2
   Clarke R, 2005, AM J CLIN NUTR, V82, P806
   Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015
   Clarke R, 2010, ARCH INTERN MED, V170, P1622, DOI 10.1001/archinternmed.2010.348
   Cole BF, 2007, JAMA-J AM MED ASSOC, V297, P2351, DOI 10.1001/jama.297.21.2351
   Deeks JJ, 2008, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ebbing M, 2008, JAMA-J AM MED ASSOC, V300, P795, DOI 10.1001/jama.300.7.795
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008
   Evers S, 1997, ARCH NEUROL-CHICAGO, V54, P1276, DOI 10.1001/archneur.1997.00550220074017
   Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204
   Galan P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6273
   Hankey GJ, 2010, LANCET NEUROL, V9, P855, DOI 10.1016/S1474-4422(10)70187-3
   Heinz J, 2010, CIRCULATION, V121, P1432, DOI 10.1161/CIRCULATIONAHA.109.904672
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hodis HN, 2009, STROKE, V40, P730, DOI 10.1161/STROKEAHA.108.526798
   Holmes MV, 2011, LANCET, V378, P584, DOI 10.1016/S0140-6736(11)60872-6
   House AA, 2010, JAMA-J AM MED ASSOC, V303, P1603, DOI 10.1001/jama.2010.490
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jamison RL, 2007, JAMA-J AM MED ASSOC, V298, P1163, DOI 10.1001/jama.298.10.1163
   Jardine MJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3533
   Ji Y, 2013, NEUROLOGY, V81, P1298, DOI 10.1212/WNL.0b013e3182a823cc
   Lange H, 2004, NEW ENGL J MED, V350, P2673, DOI 10.1056/NEJMoa032845
   Lee M, 2010, STROKE, V41, P1205, DOI 10.1161/STROKEAHA.109.573410
   Liem A, 2005, HEART, V91, P1213, DOI 10.1136/hrt.2004.035030
   Liem AH, 2004, INT J CARDIOL, V93, P175, DOI 10.1016/j.ijcard.2003.02.001
   Lonn E, 2006, NEW ENGL J MED, V354, P1567
   Loscalzo J, 2006, NEW ENGL J MED, V354, P1629, DOI 10.1056/NEJMe068060
   Miller ER, 2010, AM J CARDIOL, V106, P517, DOI 10.1016/j.amjcard.2010.03.064
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Pan Y, 2012, BRIT J NUTR, V108, P400, DOI 10.1017/S0007114511007033
   PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8
   Righetti M, 2003, MED SCI MONITOR, V9, pPI19
   Righetti M, 2006, BLOOD PURIFICAT, V24, P379, DOI 10.1159/000093680
   ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825
   Schnyder G, 2002, JAMA-J AM MED ASSOC, V288, P973, DOI 10.1001/jama.288.8.973
   Schwartz SM, 1997, CIRCULATION, V96, P412
   STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877
   Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187
   Tobias A, 1999, STATA TECH B, V8, P15
   Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565
   Verhoef P, 1997, ARTERIOSCL THROM VAS, V17, P989, DOI 10.1161/01.ATV.17.5.989
   Vianna Areuza C A, 2007, Hemodial Int, V11, P210, DOI 10.1111/j.1542-4758.2007.00171.x
   Wang XB, 2007, LANCET, V369, P1876, DOI 10.1016/S0140-6736(07)60854-X
   Wrone EM, 2004, J AM SOC NEPHROL, V15, P420, DOI 10.1097/01.ASN.0000110181.64655.6C
   Zhang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081577
   Zhou YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025142
   Zoungas S, 2006, J AM COLL CARDIOL, V47, P1108, DOI 10.1016/j.jacc.2005.10.064
NR 60
TC 14
Z9 14
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 19
PY 2014
VL 9
IS 9
AR e107060
DI 10.1371/journal.pone.0107060
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AQ0RY
UT WOS:000342491600018
PM 25238614
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, YX
   Sheng, J
   Kang, SY
   Fang, WF
   Yan, Y
   Hu, ZH
   Hong, SD
   Wu, X
   Qin, T
   Liang, WH
   Zhang, L
AF Zhang, Yaxiong
   Sheng, Jin
   Kang, Shiyang
   Fang, Wenfeng
   Yan, Yue
   Hu, Zhihuang
   Hong, Shaodong
   Wu, Xuan
   Qin, Tao
   Liang, Wenhua
   Zhang, Li
TI Patients with Exon 19 Deletion Were Associated with Longer
   Progression-Free Survival Compared to Those with L858R Mutation after
   First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; RANDOMIZED PHASE-3
   TRIAL; OPEN-LABEL; GEFITINIB TREATMENT; JAPANESE PATIENTS;
   GENE-MUTATIONS; II TRIAL; ERLOTINIB; CHEMOTHERAPY
AB Backgrounds: It has been extensively proved that the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is superior to that of cytotoxic chemotherapy in advanced non-small cell lung cancer (NSCLC) patients harboring sensitive EGFR mutations. However, the question of whether the efficacy of EGFR-TKIs differs between exon 19 deletion and exon 21 L858R mutation has not been yet statistically answered.
   Methods: Subgroup data on hazard ratio (HR) for progression-free survival (PFS) of correlative studies were extracted and synthesized based on random-effect model. Comparison of outcomes between specific mutations was estimated through indirect and direct methods, respectively.
   Results: A total of 13 studies of advanced NSCLC patients with either 19 or 21 exon alteration receiving first-line EGFR-TKIs were included. Based on the data from six clinical trials for indirect meta-analysis, the pooled HRTKI/chemotherapy for PFS were 0.28 (95% CI 0.20-0.38, P<0.001) in patients with 19 exon deletion and 0.47 (95% CI 0.35-0.64, P<0.001) in those with exon 21 L858R mutation. Indirect comparison revealed that the patients with exon 19 deletion had longer PFS than those with exon 21 L858R mutation (HR19 exon deletion/exon 21 L858R mutation = 0.59, 95% CI 0.38-0.92; P = 0.019). Additionally, direct meta-analysis showed similar result (HR19 exon deletion/exon 21 L858R mutation = 0.75, 95% CI 0.65 to 0.85; P<0.001) by incorporating another seven studies.
   Conclusions: For advanced NSCLC patients, exon 19 deletion might be associated with longer PFS compared to L858 mutation at exon 21 after first-line EGFR-TKIs.
C1 [Zhang, Yaxiong; Sheng, Jin; Kang, Shiyang; Fang, Wenfeng; Yan, Yue; Hu, Zhihuang; Hong, Shaodong; Wu, Xuan; Qin, Tao; Liang, Wenhua; Zhang, Li] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.
RP Liang, WH (reprint author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.
EM liangwh@sysucc.org.cn; zhangli6@mail.sysu.edu.cn
FU National High Technology Research and Development Program of China
   [2012AA02A502]; Innovative drug R&D center based on real-time
   high-throughput cell-based screening platform and large capacity
   compound library [2013ZX09401003-002]; National Natural Science Funds of
   China [81372502]; Wu Jieping Medical Foundation Project [320.6750.131]
FX This work was supported by the National High Technology Research and
   Development Program of China, Grant No. 2012AA02A502; Innovative drug
   R&D center based on real-time high-throughput cell-based screening
   platform and large capacity compound library, Grant No.
   2013ZX09401003-002; National Natural Science Funds of China, Grant No.
   81372502; Wu Jieping Medical Foundation Project, Grant No. 320.6750.131.
   All the funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Asahina H, 2006, BRIT J CANCER, V95, P998, DOI 10.1038/sj.bjc.6603393
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453
   Cataldo VD, 2011, NEW ENGL J MED, V364, P947, DOI 10.1056/NEJMct0807960
   Chin TM, 2008, CLIN CANCER RES, V14, P6867, DOI 10.1158/1078-0432.CCR-08-0093
   Choi CM, 2014, RADIOLOGY, V270, P574, DOI 10.1148/radiol.13121824
   Chou TY, 2005, CLIN CANCER RES, V11, P3750, DOI 10.1158/1078-0432.CCR-04-1981
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Goto K, 2013, LUNG CANCER, V82, P109, DOI 10.1016/j.lungcan.2013.07.003
   Gridelli C, 2012, J CLIN ONCOL, V30, P3002, DOI 10.1200/JCO.2011.41.2056
   Hata A, 2010, J THORAC ONCOL, V5, P1524, DOI 10.1097/JTO.0b013e3181e8b3c5
   Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714
   Inoue A, 2006, J CLIN ONCOL, V24, P3340, DOI 10.1200/JCO.2005.05.4692
   Jackman DM, 2006, CLIN CANCER RES, V12, P3908, DOI 10.1158/1078-0432.CCR-06-0462
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   Katakami N, 2013, J CLIN ONCOL, V31, P3335, DOI 10.1200/JCO.2012.45.0981
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   Kosaka T, 2009, J THORAC ONCOL, V4, P22, DOI 10.1097/JTO.0b013e3181914111
   Lee CK, 2013, JNCI-J NATL CANCER I, V105, P595, DOI 10.1093/jnci/djt072
   Lee VHF, 2013, J THORAC ONCOL, V8, P1148, DOI 10.1097/JTO.0b013e31829f684a
   Li Jianjie, 2012, Zhongguo Fei Ai Za Zhi, V15, P299, DOI 10.3779/j.issn.1009-3419.2012.05.09
   Lu RL, 2014, PATHOL ONCOL RES, V20, P445, DOI 10.1007/s12253-013-9715-0
   Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
   Mitsudomi T, 2007, CANCER SCI, V98, P1817, DOI 10.1111/j.1349-7006.2007.00607.x
   Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
   Mukohara T, 2005, J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238
   Oxnard GR, 2011, CLIN CANCER RES, V17, P1616, DOI 10.1158/1078-0432.CCR-10-2692
   Paz-Ares L, 2010, J CELL MOL MED, V14, P51, DOI 10.1111/j.1582-4934.2009.00991.x
   Ramalingam S, 2008, ONCOLOGIST, V13, P5, DOI 10.1634/theoncologist.13-S1-5
   Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846
   Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X
   Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494
   Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806
   Wakelee H, 2005, ONCOLOGIST, V10, P1, DOI 10.1634/theoncologist.10-90003-1
   Wu JY, 2008, CLIN CANCER RES, V14, P4877, DOI 10.1158/1078-0432.CCR-07-5123
   Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1
   Yamashita F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071356
   Yang CH, 2008, J CLIN ONCOL, V26, P2745, DOI 10.1200/JCO.2007.15.6695
   Yang Q, 2013, GASTROENT RES PRACT, DOI 10.1155/2013/634929
   Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017
   Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X
NR 42
TC 20
Z9 29
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 15
PY 2014
VL 9
IS 9
AR e107161
DI 10.1371/journal.pone.0107161
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AP0SR
UT WOS:000341774800044
PM 25222496
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, FF
   He, XF
   Shen, HW
   Qin, GJ
AF Wu, Fei-Fei
   He, Xiao-Feng
   Shen, Hu-Wei
   Qin, Gui-Jun
TI Association between the XRCC1 Polymorphisms and Thyroid Cancer Risk: A
   Meta-Analysis from Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID EXCISION-REPAIR GENES; DNA-REPAIR; CARCINOMA RISK; VARIANTS; ARG194TRP;
   ARG280HIS; ARG399GLN; BIAS
AB Background: The previous published data on the association between the X-ray repair cross-conplementation group 1 (XRCC1) polymorphisms and thyroid cancer risk remained controversial. Hence, we performed a meta-analysis on all available studies that provided 1729 cases and 3774 controls (from 11 studies) for XRCC1 Arg399Gln, 1040 cases and 2487 controls for Arg194Trp (from 7 studies), and 1432 cases and 3356 controls for Arg280His (from 8 studies).
   Methodology/Principal Findings: PubMed, CNKI, and EMBASE database were searched to identify relevant studies. Overall, no significant association was found between XRCC1 Arg399Gln (recessive model: OR = 0.95, 95% CI = 0.77-1.15; dominant model: OR = 0.89, 95% CI = 0.75-1.05; homozygote model: OR = 0.92, 95% CI = 0.69-1.23; Heterozygote model: OR = 0.91, 95% CI = 0.80-1.03; additive model: OR = 0.93, 95% CI = 0.81-1.07), Arg194Trp (recessive model: OR = 1.41, 95% CI = 0.62-3.23; dominant model: OR = 1.01, 95% CI = 0.77-1.34; homozygote model: OR = 1.42, 95% CI = 0.55-3.67; Heterozygote model: OR = 1.03, 95% CI = 0.85-1.26; additive model: OR = 1.08, 95% CI = 0.81-1.42), and Arg280His (recessive model: OR = 1.08, 95% CI = 0.56-2.10; dominant model: OR = 1.01, 95% CI = 0.84-1.22; homozygote model: OR = 1.00, 95% CI = 0.51-1.96; Heterozygote model: OR = 1.04, 95% CI = 0.75-1.42; additive model: OR = 1.03, 95% CI = 0.86-1.23) and thyroid cancer risk when all the eligible studies were pooled into the meta-analysis. In the further stratified and sensitivity analyses, significant association was still not found in these three genetic polymorphisms.
   Conclusions/Significance: In summary, this meta-analysis indicates that XRCC1 Arg399Gln, Arg280His, and Arg194Trp are not associated with thyroid cancer.
C1 [Wu, Fei-Fei; Qin, Gui-Jun] Zhengzhou Univ, Affiliated Hosp 1, Dept Endocrinol, Zhengzhou 450052, Peoples R China.
   [He, Xiao-Feng] Changzhi Med Coll, Peace Hosp, Dept Res, Changzhi, Peoples R China.
   [Shen, Hu-Wei] Changzhi Med Coll, Peace Hosp, Dept Endocrinol, Changzhi, Peoples R China.
RP Qin, GJ (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Endocrinol, Zhengzhou 450052, Peoples R China.
EM qinguijun123@163.com
CR Akulevich NM, 2009, ENDOCR-RELAT CANCER, V16, P491, DOI 10.1677/ERC-08-0336
   Bao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064851
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387
   Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)0018-6
   Chiang FY, 2008, CLIN CANCER RES, V14, P5919, DOI 10.1158/1078-0432.CCR-08-0906
   Davey SG, 1997, LANCET, V350, P1182, DOI DOI 10.1016/S0140-6736(05)63833-0
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Du Y, 2013, ASIAN PAC J CANCER P, V14, P5483, DOI 10.7314/APJCP.2013.14.9.5483
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fard-Esfahani Pezhman, 2011, Iranian Biomedical Journal, V15, P73
   Garcia-Quispes WA, 2011, MUTAT RES-FUND MOL M, V709-10, P67, DOI 10.1016/j.mrfmmm.2011.03.003
   Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ho T, 2009, THYROID, V19, P129, DOI 10.1089/thy.2008.0153
   Hu Z, 2013, GENE, V528, P67, DOI 10.1016/j.gene.2013.07.005
   LAMERDIN JE, 1995, GENOMICS, V25, P547, DOI 10.1016/0888-7543(95)80056-R
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Neta G, 2011, CARCINOGENESIS, V32, P1231, DOI 10.1093/carcin/bgr100
   Preston-Martin S, 2003, CANCER CAUSE CONTROL, V14, P787, DOI 10.1023/A:1026312203045
   Qian K, 2012, ASIAN PAC J CANCER P, V13, P6385, DOI 10.7314/APJCP.2012.13.12.6385
   Ryu RA, 2011, J KOREAN MED SCI, V26, P991, DOI 10.3346/jkms.2011.26.8.991
   Santos LS, 2012, ONCOL REP, V28, P1859, DOI 10.3892/or.2012.1975
   Shen MR, 1998, CANCER RES, V58, P604
   Shen NR, 1998, NUCLEIC ACIDS RES, V26, P1032, DOI 10.1093/nar/26.4.1032
   Sigurdson AJ, 2009, RADIAT RES, V171, P77, DOI 10.1667/RR1327.1
   Siraj AK, 2008, J ENDOCRINOL INVEST, V31, P893, DOI 10.1007/BF03346438
   Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232
   Thacker J, 2003, DNA REPAIR, V2, P655, DOI 10.1016/S1568-7864(03)00062-4
   Wang C, 2014, TUMOR BIOL, V35, P4791, DOI 10.1007/s13277-014-1629-2
   Wein RO, 2005, OTOLARYNG CLIN N AM, V38, P161, DOI 10.1016/j.otc.2004.09.003
   Zhu Qian-Xi, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P702
NR 32
TC 7
Z9 7
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 11
PY 2014
VL 9
IS 9
AR e87764
DI 10.1371/journal.pone.0087764
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AP1UA
UT WOS:000341855900001
PM 25211472
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhu, HL
   Bao, JM
   Liu, SG
   Chen, Q
   Shen, H
AF Zhu, Haili
   Bao, Jiming
   Liu, Shuguang
   Chen, Qing
   Shen, Hong
TI Null Genotypes of GSTM1 and GSTT1 and Endometriosis Risk: A
   Meta-Analysis of 25 Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID GLUTATHIONE S-TRANSFERASES; DETOXIFICATION GENE POLYMORPHISMS;
   ADVANCED-STAGE ENDOMETRIOSIS; POLYCHLORINATED-BIPHENYLS; NORTHERN INDIA;
   T1 GENES; ASSOCIATION; WOMEN; SUSCEPTIBILITY; M1
AB Endometriosis is one of the most frequent benign gynecological disorders. Numerous studies have shown an association between GSTM1 and/or GSTT1 polymorphisms and endometriosis susceptibility. However, these associations remain inconclusive. To derive a more precise estimation, we conducted a comprehensive search to identify all existing studies and then performed a meta-analysis. Electronic literature searches of the PubMed, Chinese Biomedical, and China National Knowledge Infrastructure databases were performed up to December 2013. GSTM1-, GSTT1-, and dual-null genotypes were analyzed independently, and pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated by comparing the null genotype with other genotypes using the random-effects or fixed-effects model. Twenty-five and 16 independent studies on GSTM1 and GSTT1 polymorphisms, respectively, and five GSTM1-GSTT1 interaction analyses were identified and included in this meta-analysis. Both GSTM1- and GSTT1-null genotypes increased risk of endometriosis (OR = 1.54, 95% CI: 1.30-1.83, P<0.001; OR = 1.41, 95% CI: 1.10-1.82, P = 0.007; respectively). Moreover, we found a significant positive association between the dual null genotype GSTM1-GSTT1 and endometriosis susceptibility (OR = 1.33, 95% CI: 1.03-1.72, P = 0.027). This meta-analysis provides evidence that null genotypes of GSTM1 and/or GSTT1 contribute to risk of endometriosis. Further investigations are required to confirm these findings.
C1 [Zhu, Haili; Liu, Shuguang; Shen, Hong] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Guangdong, Peoples R China.
   [Zhu, Haili; Liu, Shuguang; Shen, Hong] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Guangdong, Peoples R China.
   [Bao, Jiming] Southern Med Univ, Nanfang Hosp, Dept Urol, Guangzhou, Guangdong, Peoples R China.
   [Chen, Qing] Southern Med Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, Guangzhou, Guangdong, Peoples R China.
RP Shen, H (reprint author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Guangdong, Peoples R China.
EM shenhong2010168@163.com
FU National Natural Science Foundation of China [81271729]
FX This study was supported by a grant from the National Natural Science
   Foundation of China (No. 81271729). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aban M, 2007, J REPROD MED, V52, P715
   An XF, 2009, JILIN MED J, V30, P1614
   Arvanitis DA, 2003, FERTIL STERIL, V79, P702, DOI 10.1016/S0015-0282(02)04817-3
   Babu KA, 2005, PHARMACOGENET GENOM, V15, P167, DOI 10.1097/01213011-200503000-00005
   Baranov V. S., 1999, Genetika, V35, P243
   Baranov VS, 1996, HUM GENET, V97, P516, DOI 10.1007/BF02267078
   Baranova H, 1997, MOL HUM REPROD, V3, P775, DOI 10.1093/molehr/3.9.775
   Baranova H, 1999, MOL HUM REPROD, V5, P636, DOI 10.1093/molehr/5.7.636
   Baxter SW, 2001, CARCINOGENESIS, V22, P63, DOI 10.1093/carcin/22.1.63
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bertram L, 2007, NAT GENET, V39, P17, DOI 10.1038/ng1934
   Bulun SE, 2009, NEW ENGL J MED, V360, P268, DOI 10.1056/NEJMra0804690
   Cao YH, 2009, MATERN CHILD HLTH J, V24, P805
   De Felip E, 2004, TOXICOL LETT, V150, P203, DOI 10.1016/j.toxlet.2004.01.008
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ding Yan, 2004, Zhonghua Fu Chan Ke Za Zhi, V39, P101
   Eaton DL, 1999, TOXICOL SCI, V49, P156, DOI 10.1093/toxsci/49.2.156
   Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61
   Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8
   Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1239
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   Guo SW, 2006, EUR J OBSTET GYN R B, V124, P134, DOI 10.1016/j.ejogrb.2005.10.002
   Guo SW, 2005, MOL HUM REPROD, V11, P729, DOI 10.1093/molehr/gah206
   Hadfield RM, 2001, MOL HUM REPROD, V7, P1073, DOI 10.1093/molehr/7.11.1073
   Huang PC, 2010, HUM REPROD, V25, P986, DOI 10.1093/humrep/deq015
   Hur SE, 2005, MOL HUM REPROD, V11, P15, DOI 10.1093/molehr/gah127
   Ivaschenko T. E., 2003, Genetika, V39, P525
   JOSEPHY PD, 2010, HUM GENOMICS PROTEOM, P876
   Kim SH, 2007, HUM REPROD, V22, P1866, DOI 10.1093/humrep/dem112
   Lin J, 2003, CHINESE MED J-PEKING, V116, P777
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marinho C, 2007, BIOCHEM BIOPH RES CO, V353, P344, DOI 10.1016/j.bbrc.2006.12.019
   Matsuzaka Yasunari, 2012, Environmental Health and Preventive Medicine, V17, P512, DOI 10.1007/s12199-012-0281-y
   MELIS GB, 1994, ANN NY ACAD SCI, V734, P352, DOI 10.1111/j.1749-6632.1994.tb21765.x
   Mittal RD, 2007, J GASTROEN HEPATOL, V22, P920, DOI 10.1111/j.1440-1746.2006.04538.x
   Monizane M, 2004, J SOC GYNECOL INVEST, V11, P118, DOI 10.1016/j.jsgi.2003.07.009
   Pauwels A, 2001, HUM REPROD, V16, P2050, DOI 10.1093/humrep/16.10.2050
   PEARSON WR, 1993, AM J HUM GENET, V53, P220
   PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271
   Peng Dong-xian, 2003, Di Yi Jun Yi Da Xue Xue Bao, V23, P458
   Qiu L, 2008, EUR J CANCER, V44, P2241, DOI 10.1016/j.ejca.2008.06.024
   Roya R, 2009, INDIAN J MED RES, V129, P395
   RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475
   Sobti RC, 2005, CANCER GENET CYTOGEN, V156, P68, DOI 10.1016/j.cancergencyto.2004.04.001
   Srivastava DSL, 2005, BJU INT, V95, P170, DOI 10.1111/j.1464-410X.2005.05271.x
   Stefanson H, 2002, HUM REPROD, V17, P555, DOI 10.1093/humrep/17.3.555
   Steinhoff C, 2000, ARCH TOXICOL, V74, P521, DOI 10.1007/s002040000161
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Tobias A, 1999, STATA TECH B, V8, P15
   Trabert B, 2011, FERTIL STERIL, V96, P1401, DOI 10.1016/j.fertnstert.2011.09.004
   Vichi S, 2012, FERTIL STERIL, V97, P1143, DOI 10.1016/j.fertnstert.2012.02.027
   Wang GY, 2006, BIOCHEM BIOPH RES CO, V341, P310, DOI 10.1016/j.bbrc.2005.12.195
   Webb G, 1996, GENOMICS, V33, P121, DOI 10.1006/geno.1996.0167
   Wells G, 2011, NEWCASTLE OTTAWA SCA
   Wu CH, 2012, AM J REPROD IMMUNOL, V67, P160, DOI 10.1111/j.1600-0897.2011.01077.x
   Yang LP, 2009, MATERN CHILD HLTH J, V24, P2556
   Zhong SL, 2006, CLIN CHIM ACTA, V364, P205, DOI 10.1016/j.cccn.2005.06.021
NR 57
TC 4
Z9 4
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 10
PY 2014
VL 9
IS 9
AR e106761
DI 10.1371/journal.pone.0106761
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AP4EP
UT WOS:000342030300037
PM 25208225
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, Q
   Zhang, X
   Li, WM
   Ji, YQ
   Cao, HZ
   Zheng, PS
AF Chen, Qing
   Zhang, Xin
   Li, Wei-Min
   Ji, Yu-Qiang
   Cao, Hao-Zhe
   Zheng, Pengsheng
TI Prognostic Value of LGR5 in Colorectal Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PROTEIN-COUPLED RECEPTOR; STEM-CELL MARKER; PREOPERATIVE
   CHEMORADIOTHERAPY; RECTAL-CANCER; COLON-CANCER; EXPRESSION;
   OVEREXPRESSION; SURVIVAL; RECURRENCE; STATISTICS
AB Objective: Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) has recently been reported to be a marker of cancer stem cells (CSCs) in colorectal cancer (CRC), and the prognostic value of LGR5 in CRC has been evaluated in several studies. However, the conclusions remain controversial. In this study, we aimed to evaluate the association between the expression of LGR5 and the outcome of CRC patients by performing a meta-analysis.
   Methods: We systematically searched for relevant studies published up to February 2014 using the PubMed, Web of Science, EMBASE and Wangfang databases. Only articles in which LGR5 expression was detected by immunohistochemistry were included. A meta-analysis was performed using STATA 12.0, and pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to estimate the strength of the association between LGR5 expression and the prognosis of CRC patients.
   Results: A total of 7 studies comprising 1833 CRC patients met the inclusion criteria, including 6 studies comprising 1781 patients for overall survival (OS) and 3 studies comprising 528 patients for disease-free survival (DFS). Our results showed that high LGR5 expression was significantly associated with poor prognosis in terms of OS (HR: 1.87, 95% CI: 1.23-2.84; P = 0.003) and DFS (HR: 2.44, 95% CI: 1.49-3.98; P<0.001). Further subgroup analysis revealed that many factors, including the study region, number of patients, follow-up duration and cutoff value, affected the significance of the association between LGR5 expression and a worse prognosis in patients with CRC. In addition, there was no evidence of publication bias, as suggested by Begg's and Egger's tests.
   Conclusions: The present meta-analysis indicated that high LGR5 expression was associated with poor prognosis in patients with CRC and that LGR5 is an efficient prognostic factor in CRC.
C1 [Chen, Qing; Cao, Hao-Zhe; Zheng, Pengsheng] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Reprod Med, Xian, Peoples R China.
   [Zhang, Xin] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 2, Dept Obstet & Gynaecol, Xian, Peoples R China.
   [Li, Wei-Min] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Nutr, Xian, Peoples R China.
   [Ji, Yu-Qiang] First Hosp Xian, Inst Cardiovasc Res, Xian, Peoples R China.
RP Zheng, PS (reprint author), Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Reprod Med, Xian, Peoples R China.
EM zp_sheng@163.com
FU National Natural Science Fund for Distinguished Young Scientists
   [30725043]; National Natural Science Foundation of China [31201118]
FX This work was supported by a grant from the National Natural Science
   Fund for Distinguished Young Scientists (No. 30725043) and a grant from
   the National Natural Science Foundation of China (No. 31201118). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ahlquist DA, 2012, GASTROENTEROLOGY, V142, P248, DOI 10.1053/j.gastro.2011.10.031
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Becker L, 2008, THESCIENTIFICWORLDJO, V8, P1168, DOI 10.1100/tsw.2008.148
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chai Ningli, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P972
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fan XS, 2010, INT J COLORECTAL DIS, V25, P583, DOI 10.1007/s00384-010-0903-z
   Gerger A, 2011, CLIN CANCER RES, V17, P6934, DOI 10.1158/1078-0432.CCR-11-1180
   Haegebarth A, 2009, AM J PATHOL, V174, P715, DOI 10.2353/ajpath.2009.080758
   Handoll HH, 2006, ARCH PHYS MED REHAB, V87, P875, DOI 10.1016/j.apmr.2006.04.006
   He S, 2014, BIOMEDICINE PHARMACO
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hsu HC, 2013, INT J COLORECTAL DIS, V28, P1535, DOI 10.1007/s00384-013-1721-x
   Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   Kleist B, 2012, AM J TRANSL RES, V4, P279
   Kleist B, 2011, INT J CLIN EXP PATHO, V4, P327
   Kobayashi H, 2007, SURGERY, V141, P67, DOI 10.1016/j.surg.2006.07.020
   Liu Z, 2014, NEOPLASMA, V61, P177, DOI 10.4149/neo_2014_016
   McClanahan T, 2006, CANCER BIOL THER, V5, P419, DOI 10.4161/cbt.5.4.2521
   Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Nakata S, 2013, BRAIN PATHOL, V23, P60, DOI 10.1111/j.1750-3639.2012.00618.x
   Peng L, 2010, MODERN DIGESTION INT, V15, P284
   Pitule P, 2013, ANTICANCER RES, V33, P4855
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Saigusa S, 2013, J CANCER RES CLIN, V139, P131, DOI 10.1007/s00432-012-1308-x
   Saigusa S, 2012, INT J ONCOL, V41, P1643, DOI 10.3892/ijo.2012.1598
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Takahashi H, 2011, ANN SURG ONCOL, V18, P1166, DOI 10.1245/s10434-010-1373-9
   Tanese K, 2008, AM J PATHOL, V173, P835, DOI 10.2353/ajpath.2008.071091
   Uchida H, 2010, CANCER SCI, V101, P1731, DOI 10.1111/j.1349-7006.2010.01571.x
   Valladares-Ayerbes M, 2012, INT J MOL SCI, V13, P4367, DOI 10.3390/ijms13044367
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wu XS, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-244
   Yamamoto Y, 2003, HEPATOLOGY, V37, P528, DOI 10.1053/jhep.2003.50029
   Yamanoi K, 2013, PATHOL INT, V63, P13, DOI 10.1111/pin.12013
   Ziskin J. L., 2012, GUT
NR 38
TC 14
Z9 14
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 5
PY 2014
VL 9
IS 9
AR e107013
DI 10.1371/journal.pone.0107013
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AZ1IR
UT WOS:000347993600089
PM 25192390
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Agunos, A
   Waddell, L
   Leger, D
   Taboada, E
AF Agunos, Agnes
   Waddell, Lisa
   Leger, David
   Taboada, Eduardo
TI A Systematic Review Characterizing On-Farm Sources of Campylobacter spp.
   for Broiler Chickens
SO PLOS ONE
LA English
DT Article
ID CHAIN-REACTION DETECTION; RISK-FACTORS; THERMOPHILIC CAMPYLOBACTER;
   JEJUNI STRAINS; MOLECULAR CHARACTERIZATION; VERTICAL TRANSMISSION;
   BIOSECURITY COMPLIANCE; REDUCE CAMPYLOBACTER; PARTIAL DEPOPULATION;
   SALMONELLA-ENTERICA
AB Campylobacter and antimicrobial-resistant Campylobacter are frequently isolated from broiler chickens worldwide. In Canada, campylobacteriosis is the third leading cause of enteric disease and the regional emergence of ciprofloxacin-resistant Campylobacter in broiler chickens has raised a public health concern. This study aimed to identify, critically appraise, and synthesize literature on sources of Campylobacter in broilers at the farm level using systematic review methodology. Literature searches were conducted in January 2012 and included electronic searches in four bibliographic databases. Relevant studies in French or English (n = 95) conducted worldwide in any year and all study designs were included. Risk of Bias and GRADE criteria endorsed by the Cochrane collaboration was used to assess the internal validity of the study and overall confidence in the meta-analysis. The categories for on-farm sources were: broiler breeders/vertical transfer (number of studies = 32), animals (n = 57), humans (n = 26), environment (n = 54), and water (n = 63). Only three studies examined the antimicrobial resistance profiles of Campylobacter from these on-farm sources. Subgroups of data by source and outcome were analyzed using random effect meta-analysis. The highest risk for contaminating a new flock appears to be a contaminated barn environment due to insufficient cleaning and disinfection, insufficient downtime, and the presence of an adjacent broiler flock. Effective biosecurity enhancements from physical barriers to restricting human movement on the farm are recommended for consideration to enhance local on-farm food safety programs. Improved sampling procedures and standardized laboratory testing are needed for comparability across studies. Knowledge gaps that should be addressed include farm-level drug use and antimicrobial resistance information, further evaluation of the potential for vertical transfer, and improved genotyping methods to strengthen our understanding of Campylobacter epidemiology in broilers at the farm-level. This systematic review emphasizes the importance of improved industry-level and on-farm risk management strategies to reduce pre-harvest Campylobacter in broilers.
C1 [Agunos, Agnes; Waddell, Lisa; Leger, David] Publ Hlth Agcy Canada, Lab Foodborne Zoonoses, Guelph, ON, Canada.
   [Waddell, Lisa] Univ Guelph, Dept Populat Med, Guelph, ON N1G 2W1, Canada.
   [Taboada, Eduardo] Publ Hlth Agcy Canada, Lab Foodborne Zoonoses, Lethbridge, AB, Canada.
RP Agunos, A (reprint author), Publ Hlth Agcy Canada, Lab Foodborne Zoonoses, Guelph, ON, Canada.
EM agnes.agunos@phac-aspc.gc.ca
RI Taboada, Eduardo/Y-4854-2018
OI Taboada, Eduardo/0000-0001-8373-3653; waddell, lisa/0000-0003-4887-5124
FU Public Health Agency of Canada
FX This study was funded through the Public Health Agency of Canada
   (http://www.phac-aspc.gc.ca). The funder had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adkin A, 2006, J APPL MICROBIOL, V100, P306, DOI 10.1111/j.1365-2672.2005.02781.x
   Agunos A, 2013, EMERG INFECT DIS, V19, P1121, DOI 10.3201/eid1907.111417
   Ahmed R, 2000, J CLIN MICROBIOL, V38, P2403
   Allen VM, 2008, J FOOD PROTECT, V71, P264, DOI 10.4315/0362-028X-71.2.264
   Allen VM, 2011, BRIT POULTRY SCI, V52, P30, DOI 10.1080/00071668.2010.537306
   [Anonymous], 2014, COCHR HDB SYST REV I
   Arsenault J, 2007, J FOOD PROTECT, V70, P1820, DOI 10.4315/0362-028X-70.8.1820
   Arsenault J, 2007, PREV VET MED, V81, P250, DOI 10.1016/j.prevetmed.2007.04.016
   Arsenault R, 2005, THESIS U GUELPH
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Borck B, 2011, CAMCON DELIVERABLE, P1
   Bouwknegt M, 2004, PREV VET MED, V62, P35, DOI 10.1016/j.prevetmed.2003.09.003
   Bull SA, 2006, APPL ENVIRON MICROB, V72, P645, DOI 10.1128/AEM.72.1.645-652.2006
   Byrd J, 2007, POULTRY SCI, V86, P26, DOI 10.1093/ps/86.1.26
   Callicott KA, 2006, APPL ENVIRON MICROB, V72, P5794, DOI 10.1128/AEM.02991-05
   Canadian Food Inspection Agency, 2009, NAT AV ON FARM BIOS
   Cardinale E, 2004, PREV VET MED, V64, P15, DOI 10.1016/j.prevetmed.2004.03.006
   Carrico JA, 2005, J CLIN MICROBIOL, V43, P5483, DOI 10.1128/JCM.43.11.5483-5490.2005
   Chicken Farmers of Canada, 2013, CHICK DAT BOOKL
   Chicken Farmers of Canada, 2014, CHICK FARM CAN ON FA
   Chuma T, 1997, J VET MED SCI, V59, P1011, DOI 10.1292/jvms.59.1011
   Chuma T, 1997, J VET MED SCI, V59, P85, DOI 10.1292/jvms.59.85
   CHUMA T, 1994, J VET MED SCI, V56, P697, DOI 10.1292/jvms.56.697
   Clark CG, 2012, J CLIN MICROBIOL, V50, P798, DOI 10.1128/JCM.05733-11
   Cokal Y, 2011, AFR J MICROBIOL RES, V5, P389
   Colles FM, 2008, APPL ENVIRON MICROB, V74, P3583, DOI 10.1128/AEM.02491-07
   Collins JD, 2011, EFSA J, V9, DOI [10.2903/j.efsa.2011.2393, 10.2903/j.efsa.2011.2105, 10.2903/j.efsa.2011.2481]
   Cox NA, 2012, J FOOD PROTECT, V75, P1896, DOI 10.4315/0362-028.JFP-11-322
   Cox NA, 2002, AVIAN DIS, V46, P535, DOI 10.1637/0005-2086(2002)046[0535:IOANSO]2.0.CO;2
   Damjanova I, 2011, INT J FOOD MICROBIOL, V150, P95, DOI 10.1016/j.ijfoodmicro.2011.07.011
   Eberle KN, 2012, POULTRY SCI, V91, P255, DOI 10.3382/ps.2011-01414
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ellis-Iversen J, 2012, EPIDEMIOL INFECT, V140, P916, DOI 10.1017/S095026881100118X
   European Food Safety Authority, 2010, EFSA J, V8, DOI 10.2903/j.efsa.2010.1503
   Food and Agriculture Organization/World Health Organization, 2009, MICR RISK ASS SER, V11
   Foreign Affairs and International Trade Canada, 2012, REP MIN FOR AFF RESP
   Ganan M, 2012, J FOOD SCI, V77, pM176, DOI 10.1111/j.1750-3841.2011.02602.x
   Gripp E, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-584
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   Hald B, 2000, AVIAN PATHOL, V29, P123, DOI 10.1080/03079450094153
   Hald B, 2004, EMERG INFECT DIS, V10, P1490, DOI 10.3201/eid1008.040129
   Hald B, 2007, EMERG INFECT DIS, V13, P1951, DOI 10.3201/eid1312.070488
   Hansson I, 2007, J APPL MICROBIOL, V103, P640, DOI 10.1111/j.1365-2672.2007.03291.x
   Hansson I, 2005, J APPL MICROBIOL, V99, P1149, DOI 10.1111/j.1365-2672.2005.02689.x
   Herman L, 2003, EPIDEMIOL INFECT, V131, P1169, DOI 10.1017/S0950268803001183
   Hermans D, 2011, VET MICROBIOL, V152, P219, DOI 10.1016/j.vetmic.2011.03.010
   Hiett KL, 2013, POULTRY SCI, V92, P1134, DOI 10.3382/ps.2012-02812
   Hiett KL, 2007, FOODBORNE PATHOG DIS, V4, P339, DOI 10.1089/fpd.2007.0008
   Hiett KL, 2002, APPL ENVIRON MICROB, V68, P6220, DOI 10.1128/AEM.68.12.6220-6236.2002
   Hiett KL, 2002, AVIAN DIS, V46, P219, DOI 10.1637/0005-2086(2002)046[0219:DPCRDO]2.0.CO;2
   Huneau-Salaun A, 2007, PREV VET MED, V80, P34, DOI 10.1016/j.prevetmed.2007.02.001
   Idris U, 2006, APPL ENVIRON MICROB, V72, P3441, DOI 10.1128/AEM.72.5.3441-3447.2006
   Javed MA, 2012, INFECT IMMUN, V80, P2361, DOI 10.1128/IAI.00151-12
   Johnsen G, 2006, J APPL MICROBIOL, V101, P1130, DOI 10.1111/j.1365-2672.2006.02995.x
   Joldnen CC, 2012, J MICROBIOL METH, V91, P506, DOI 10.1016/j.mimet.2012.09.005
   Katsma WEA, 2007, RISK ANAL, V27, P863, DOI 10.1111/j.1539-6924.2007.00928.x
   KAZWALA RR, 1990, VET REC, V126, P305
   Knudsen KN, 2006, AVIAN DIS, V50, P10, DOI 10.1637/7376-051005R.1
   Kruger NJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088108
   Levesque S, 2008, J CLIN MICROBIOL, V46, P3404, DOI 10.1128/JCM.00042-08
   Levesque S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083731
   Lukinmaa S, 2004, APMIS, V112, P908, DOI 10.1111/j.1600-0463.2004.apm11211-1213.x
   Lyngstad TM, 2008, POULTRY SCI, V87, P1987, DOI 10.3382/ps.2008-00132
   McCarthy ND, 2007, EMERG INFECT DIS, V13, P267, DOI 10.3201/eid1302.060620
   McCrea BA, 2006, J FOOD PROTECT, V69, P2908, DOI 10.4315/0362-028X-69.12.2908
   McDermott PF, 2002, J INFECT DIS, V185, P837, DOI 10.1086/339195
   Messens W, 2009, VET MICROBIOL, V138, P120, DOI 10.1016/j.vetmic.2009.02.012
   Miller WG, 2006, MICROBIOL-SGM, V152, P245, DOI 10.1099/mic.0.28348-0
   Mullner P, 2009, INFECT GENET EVOL, V9, P1311, DOI 10.1016/j.meegid.2009.09.003
   Nesbit EG, 2001, AM J VET RES, V62, P190, DOI 10.2460/ajvr.2001.62.190
   Newell DG, 2011, APPL ENVIRON MICROB, V77, P8605, DOI 10.1128/AEM.01090-10
   O'Mahony E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028490
   Ogden ID, 2007, APPL ENVIRON MICROB, V73, P5125, DOI 10.1128/AEM.00884-07
   Ogden ID, 2009, FOODBORNE PATHOG DIS, V6, P1161, DOI 10.1089/fpd.2009.0327
   Patriarchi A, 2011, FOODBORNE PATHOG DIS, V8, P99, DOI 10.1089/fpd.2010.0637
   Pearson AD, 1996, APPL ENVIRON MICROB, V62, P4614
   PEARSON AD, 1993, APPL ENVIRON MICROB, V59, P987
   Pohjanvirta T, 2013, P 18 WVPA C NANT FRA
   POKAMUNSKI S, 1986, AVIAN PATHOL, V15, P83, DOI 10.1080/03079458608436268
   Pope C, 2007, APPL ENVIRON MICROB, V73, P7959, DOI 10.1128/AEM.01657-07
   Proudfoot F, 1991, RAISING CHICKENS TUR
   Public Health Agency of Canada, 2011, CAN INT PROGR ANT RE
   Public Health Agency of Canada, 2012, C ENTERNET 2011 SHOR
   Racicot M, 2012, PREV VET MED, V103, P208, DOI 10.1016/j.prevetmed.2011.08.004
   Racicot M, 2012, PREV VET MED, V103, P201, DOI 10.1016/j.prevetmed.2011.08.011
   Racicot M, 2011, PREV VET MED, V100, P193, DOI 10.1016/j.prevetmed.2011.04.011
   Rasschaert G, 2007, J FOOD PROTECT, V70, P40, DOI 10.4315/0362-028X-70.1.40
   Refregier-Petton J, 2001, PREV VET MED, V50, P89, DOI 10.1016/S0167-5877(01)00220-3
   Ridley A, 2011, J APPL MICROBIOL, V111, P233, DOI 10.1111/j.1365-2672.2011.05038.x
   Ridley AM, 2011, APPL ENVIRON MICROB, V77, P98, DOI 10.1128/AEM.01388-10
   Ring M, 2005, AVIAN DIS, V49, P390, DOI 10.1637/7319-010305R1.1
   Rivoal K, 2005, APPL ENVIRON MICROB, V71, P6216, DOI 10.1128/AEM.71.10.6216-6227.2005
   Russa AD, 2005, LETT APPL MICROBIOL, V41, P280, DOI 10.1111/j.1472-765X.2005.01751.x
   Sahin O, 2003, J APPL MICROBIOL, V95, P1070, DOI 10.1046/j.1365-2672.2003.02083.x
   Sargeant JM, 2006, PREV VET MED, V75, P141, DOI 10.1016/j.prevetmed.2006.03.002
   Schunemann H, 2011, J EPIDEMIOL COMMUN H, V65, P392, DOI 10.1136/jech.2010.119933
   SHANKER S, 1986, J HYG-CAMBRIDGE, V96, P153, DOI 10.1017/S002217240006592X
   Sheppard SK, 2011, MOL ECOL, V20, P3484, DOI 10.1111/j.1365-294X.2011.05179.x
   Sheppard SK, 2009, CLIN INFECT DIS, V48, P1072, DOI 10.1086/597402
   Shreeve JE, 2002, AVIAN DIS, V46, P378, DOI 10.1637/0005-2086(2002)046[0378:TCOOCI]2.0.CO;2
   Skov MN, 2004, AVIAN DIS, V48, P9, DOI 10.1637/5698
   Slader J, 2002, APPL ENVIRON MICROB, V68, P713, DOI 10.1128/AEM.68.2.713-719.2002
   Snelling WJ, 2005, APPL ENVIRON MICROB, V71, P5560, DOI 10.1128/AEM.71.9.5560-5571.2005
   STEELE TW, 1984, PATHOLOGY, V16, P263, DOI 10.3109/00313028409068535
   Stone D, 2013, BIOMED RES INT, DOI 10.1155/2013/794643
   Taboada EN, 2013, J MICROBIOL METH, V95, P24, DOI 10.1016/j.mimet.2013.07.007
   TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233
   The GRADE Working Group, 2013, GRADE GUID BEST PRAC
   Thomas MK, 2013, FOODBORNE PATHOG DIS, V10, P639, DOI 10.1089/fpd.2012.1389
   Ugarte-Ruiz M, 2013, LETT APPL MICROBIOL, V57, P427, DOI 10.1111/lam.12130
   Ugarte-Ruiz M, 2012, J APPL MICROBIOL, V113, P200, DOI 10.1111/j.1365-2672.2012.05323.x
   United States Environmental Protection Agency, 2012, POULTRY PRODUCTION
   United States Food and Drug Administration, 2013, NARMS RET MEAT ANN R
   Van De Giessen AW, 1998, EPIDEMIOL INFECT, V121, P57, DOI 10.1017/S0950268898008899
   Vandeplas S, 2010, BIOTECHNOL AGRON SOC, V14, P279
   Wales AD, 2010, ZOONOSES PUBLIC HLTH, V57, P299, DOI 10.1111/j.1863-2378.2008.01222.x
   Williams LK, 2012, EPIDEMIOL INFECT, V140, P1227, DOI 10.1017/S0950268811001877
   Wilson DJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000203
   Workman SN, 2008, INT J FOOD MICROBIOL, V121, P106, DOI 10.1016/j.ijfoodmicro.2007.10.014
   Young I, 2014, PREV VET MED, V113, P339, DOI 10.1016/j.prevetmed.2013.11.009
   Young I, 2010, J FOOD PROTECT, V73, P1278, DOI 10.4315/0362-028X-73.7.1278
   Zadoks RN, 2006, VET CLIN N AM-FOOD A, V22, P229, DOI 10.1016/j.cvfa.2005.11.005
   Zimmer M, 2003, AVIAN DIS, V47, P101, DOI 10.1637/0005-2086(2003)047[0101:DOCJSI]2.0.CO;2
   Zweifel C, 2008, INT J FOOD MICROBIOL, V125, P182, DOI 10.1016/j.ijfoodmicro.2008.03.038
NR 125
TC 37
Z9 39
U1 2
U2 49
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 29
PY 2014
VL 9
IS 8
AR e104905
DI 10.1371/journal.pone.0104905
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO2EE
UT WOS:000341127500023
PM 25171228
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Shen, D
   Mao, WD
   Liu, T
   Lin, QF
   Lu, XD
   Wang, Q
   Lin, F
   Ekelund, U
   Wijndaele, K
AF Shen, Dong
   Mao, Weidong
   Liu, Tao
   Lin, Qingfeng
   Lu, Xiangdong
   Wang, Qiong
   Lin, Feng
   Ekelund, Ulf
   Wijndaele, Katrien
TI Sedentary Behavior and Incident Cancer: A Meta-Analysis of Prospective
   Studies
SO PLOS ONE
LA English
DT Article
ID RECREATIONAL PHYSICAL-ACTIVITY; TELEVISION VIEWING TIME; ALL-CAUSE
   MORTALITY; NIH-AARP DIET; CARDIOVASCULAR-DISEASE; ENDOMETRIAL CANCER;
   BREAST-CANCER; SITTING TIME; PROSPECTIVE COHORT; RECTAL-CANCER
AB Background: Sedentary behavior is ubiquitous in modern adults' daily lives and it has been suggested to be associated with incident cancer. However, the results have been inconsistent. In this study, we performed a systematic review and meta-analysis of prospective cohort studies to clarify the association between sedentary behavior and incident cancer.
   Method: PubMed and Embase databases were searched up to March 2014. All prospective cohort studies on the association between sedentary behavior and incident cancer were included. The summary relative risks (RRs) with 95% confidence intervals (CIs) were estimated using random effect model.
   Results: A total of 17 prospective studies from 14 articles, including a total of 857,581 participants and 18,553 cases, were included in the analysis for sedentary behavior and risk of incident cancer. The overall meta-analysis suggested that sedentary behavior increased risk of cancer (RR = 1.20, 95% CI = 1.12-1.28), with no evidence of heterogeneity between studies (I-2 = 7.3%, P = 0.368). Subgroup analyses demonstrated that there were statistical associations between sedentary behavior and some cancer types (endometrial cancer: RR = 1.28, 95% CI = 1.08-1.53; colorectal cancer: RR = 1.30, 95% CI = 1.12-1.49; breast cancer: RR = 1.17, 95% CI = 1.03-1.33; lung cancer: RR = 1.27, 95% CI = 1.06-1.52). However, there was no association of sedentary behavior with ovarian cancer (RR = 1.26, 95% CI = 0.87-1.82), renal cell carcinoma (RR = 1.11, 95% CI = 0.87-1.41) or non-Hodgkin lymphoid neoplasms (RR = 1.09, 95% CI = 0.82-1.43).
   Conclusion: The present meta-analysis suggested that prolonged sedentary behavior was independently associated with an increased risk of incident endometrial, colorectal, breast, and lung cancers, but not with ovarian cancer, renal cell carcinoma or non-Hodgkin lymphoid neoplasms.
C1 [Shen, Dong; Mao, Weidong; Liu, Tao; Lin, Qingfeng; Lu, Xiangdong; Wang, Qiong; Lin, Feng] Southeast Univ, Coll Med, Affiliated Jiangyin Hosp, Dept Oncol, Jiangyin, Peoples R China.
   [Ekelund, Ulf] Norwegian Sch Sport Sci, Dept Sport Med, Oslo, Norway.
   [Ekelund, Ulf; Wijndaele, Katrien] Univ Cambridge, MRC, Epidemiol Unit, Inst Metab Sci, Cambridge, England.
RP Shen, D (reprint author), Southeast Univ, Coll Med, Affiliated Jiangyin Hosp, Dept Oncol, Jiangyin, Peoples R China.
EM dong_shen2000@126.com; weidmao@126.com
FU Medical Research Council [MC_UU_12015/3]; British Heart Foundation
   [FS/12/58/29709]
FX This work is partially funded by the Medical Research Council
   (MC_UU_12015/3) and the British Heart Foundation (FS/12/58/29709). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Avery L, 2012, DIABETES CARE, V35, P2681, DOI 10.2337/dc11-2452
   Barnes J, 2012, APPL PHYSIOL NUTR ME, V37, P540, DOI [10.1139/H2012-024, 10.1139/h2012-024]
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cohen SS, 2013, CANCER PREV RES, V6, P566, DOI 10.1158/1940-6207.CAPR-13-0045
   Cong YJ, 2014, BRIT J CANCER, V110, P817, DOI 10.1038/bjc.2013.709
   Craft LL, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-122
   Edwardson CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034916
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ekelund U, 2012, INT J EPIDEMIOL, V41, P1353, DOI 10.1093/ije/dys128
   Ford ES, 2012, INT J EPIDEMIOL, V41, P1338, DOI 10.1093/ije/dys078
   Friberg E, 2006, CANCER EPIDEM BIOMAR, V15, P2136, DOI 10.1158/1055-9965.EPI-06-0465
   George SM, 2011, ANN EPIDEMIOL, V21, P787, DOI 10.1016/j.annepidem.2011.04.012
   George SM, 2010, AM J PUBLIC HEALTH, V100, P2288, DOI 10.2105/AJPH.2009.180828
   Gierach GL, 2009, INT J CANCER, V124, P2139, DOI 10.1002/ijc.24059
   Grontved A, 2011, JAMA-J AM MED ASSOC, V305, P2448, DOI 10.1001/jama.2011.812
   Hamilton MT, 2008, CURR CARDIOVASC RISK, V2, P292, DOI 10.1007/s12170-008-0054-8
   Healy GN, 2011, EUR HEART J, V32, P590, DOI 10.1093/eurheartj/ehq451
   Howard RA, 2008, CANCER CAUSE CONTROL, V19, P939, DOI 10.1007/s10552-008-9159-0
   Lam TK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070672
   Lollgen H, 2009, INT J SPORTS MED, V30, P213, DOI 10.1055/s-0028-1128150
   Lynch BM, 2010, CANCER EPIDEM BIOMAR, V19, P2691, DOI 10.1158/1055-9965.EPI-10-0815
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Patel AV, 2008, INT J CANCER, V123, P1877, DOI 10.1002/ijc.23716
   Patel AV, 2006, AM J EPIDEMIOL, V163, P709, DOI 10.1093/aje/kwj098
   Pronk A, 2011, BRIT J CANCER, V105, P1443, DOI 10.1038/bjc.2011.370
   Robsahm TE, 2013, EUR J CANC
   Sattelmair J, 2011, CIRCULATION, V124, P789, DOI 10.1161/CIRCULATIONAHA.110.010710
   Simons CCJM, 2013, AM J EPIDEMIOL, V177, P514, DOI 10.1093/aje/kws280
   Teras LR, 2012, INT J CANCER, V131, P1912, DOI 10.1002/ijc.27445
   The Nielsen Company, 3 SCREEN REP
   Ukawa S, 2013, CANCER CAUSE CONTROL, V24, P1547, DOI 10.1007/s10552-013-0231-z
   van Kruijsdijk RCM, 2009, CANCER EPIDEM BIOMAR, V18, P2569, DOI 10.1158/1055-9965.EPI-09-0372
   Wijndaele K, 2011, INT J EPIDEMIOL, V40, P150, DOI 10.1093/ije/dyq105
   Wilmot EG, 2012, DIABETOLOGIA, V55, P2895, DOI 10.1007/s00125-012-2677-z
   Xiao Q, 2013, CANC EPIDEMIOL BIOMA
NR 35
TC 35
Z9 36
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 25
PY 2014
VL 9
IS 8
AR e105709
DI 10.1371/journal.pone.0105709
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AN9TR
UT WOS:000340952200073
PM 25153314
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU He, XF
   Wei, J
   Liu, ZZ
   Xie, JJ
   Wang, W
   Du, YP
   Chen, Y
   Si, HQ
   Liu, Q
   Wu, LX
   Wei, W
AF He, Xiao-Feng
   Wei, Jie
   Liu, Zhi-Zhong
   Xie, Jian-Jun
   Wang, Wei
   Du, Ya-Ping
   Chen, Yu
   Si, Hui-Qiang
   Liu, Qing
   Wu, Li-Xia
   Wei, Wu
TI Association between CYP1A2 and CYP1B1 Polymorphisms and Colorectal
   Cancer Risk: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CARCINOGEN-METABOLIZING ENZYMES; RED MEAT; GENETIC POLYMORPHISMS;
   CYTOCHROME-P450 CYP1B1; CIGARETTE-SMOKING; SUSCEPTIBILITY; CONSUMPTION;
   ACTIVATION; EXPRESSION; NUTRITION
AB Background: The previous published data on the association between CYP1A2*F (rs762551), CYP1B1 Leu432Val (rs1056836), Asn453Ser (rs180040), and Arg48Gly (rs10012) polymorphisms and colorectal cancer risk remained controversial.
   Methodology/Principal Findings: The purpose of this study is to evaluate the role of CYP1A2*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly genotypes in colorectal cancer susceptibility. We performed a meta-analysis on all the eligible studies that provided 5,817 cases and 6,544 controls for CYP1A2*F (from 13 studies), 9219 cases and 10406 controls for CYP1B1 Leu432Val (from 12 studies), 6840 cases and 7761 controls for CYP1B1 Asn453Ser (from 8 studies), and 4302 cases and 4791 controls for CYP1B1Arg48Gly (from 6 studies). Overall, no significant association was found between CYP1A2*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly and colorectal cancer risk when all the eligible studies were pooled into the meta-analysis. And in the subgroup by ethnicity and source of controls, no evidence of significant association was observed in any subgroup analysis.
   Conclusions/Significance: In summary, this meta-analysis indicates that CYP1A2*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms do not support an association with colorectal cancer, and further studies are needed to investigate the association. In addition, our work also points out the importance of new studies for CYP1A2*F polymorphism in Asians, because high heterogeneity was found (dominant model: I-2 = 81.3%; heterozygote model: I-2 = 79.0).
C1 [He, Xiao-Feng; Wu, Li-Xia] Changzhi Med Coll, Peace Hosp, Dept Res, Changzhi, Shanxi Province, Peoples R China.
   [Wei, Jie] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Clin Lab, Guangzhou 510275, Guangdong, Peoples R China.
   [Liu, Zhi-Zhong; Xie, Jian-Jun; Wang, Wei; Du, Ya-Ping; Chen, Yu; Si, Hui-Qiang; Liu, Qing] Second Peoples Hosp Zhuhai, Dept Gastroenterol, Zhuhai, Guangdong, Peoples R China.
   [Wei, Wu] Changzhi Med Coll, Peace Hosp, Dept Hematol, Changzhi, Shanxi Province, Peoples R China.
RP He, XF (reprint author), Changzhi Med Coll, Peace Hosp, Dept Res, Changzhi, Shanxi Province, Peoples R China.
EM 393120823@qq.com
CR Bae SY, 2006, CANCER SCI, V97, P774, DOI 10.1111/j.1349-7006.2006.00241.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bethke L, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-123
   Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977
   Cavalieri EL, 2002, CARCINOGENESIS, V23, P329, DOI 10.1093/carcin/23.2.329
   Chen Kun, 2005, Zhonghua Liu Xing Bing Xue Za Zhi, V26, P659
   Cleary SP, 2010, AM J EPIDEMIOL, V172, P1000, DOI 10.1093/aje/kwq245
   Colbert LH, 2001, CANCER EPIDEM BIOMAR, V10, P265
   COPE GF, 1991, GUT, V32, P70, DOI 10.1136/gut.32.1.70
   Cotterchio M, 2008, CANCER EPIDEM BIOMAR, V17, P3098, DOI 10.1158/1055-9965.EPI-08-0341
   Davey SG, 1997, LANCET, V350, P1182, DOI DOI 10.1016/S0140-6736(05)63833-0
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DEVERDIER MG, 1990, INT J CANCER, V46, P832, DOI 10.1002/ijc.2910460514
   EATON DL, 1995, PHARMACOGENETICS, V5, P259, DOI 10.1097/00008571-199510000-00001
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Hlavata I, 2010, ONCOL REP, V24, P1347, DOI 10.3892/or_0000992
   Huber Ambros, 2005, J Soc Gynecol Investig, V12, pe51, DOI 10.1016/j.jsgi.2005.07.003
   Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159
   Ishibe N, 2002, PHARMACOGENETICS, V12, P145, DOI 10.1097/00008571-200203000-00008
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   Kim JH, 1998, CARCINOGENESIS, V19, P1847, DOI 10.1093/carcin/19.10.1847
   Kiss I, 2007, ANTICANCER RES, V27, P2931
   Klug SJ, 2009, LANCET ONCOL, V10, P772, DOI 10.1016/S1470-2045(09)70187-1
   Kobayashi M, 2009, SCAND J GASTROENTERO, V44, P952, DOI 10.1080/00365520902964721
   Kury S, 2007, CANCER EPIDEM BIOMAR, V16, P1460, DOI 10.1158/1055-9965.EPI-07-0236
   Kushi L, 2002, AM J MED, V113, P63, DOI 10.1016/S0002-9343(01)00994-9
   Landi S, 2005, PHARMACOGENET GENOM, V15, P535, DOI 10.1097/01.fpc.0000165904.48994.3d
   LEVIN B, 1992, CANCER-AM CANCER SOC, V70, P1723, DOI 10.1002/1097-0142(19920915)70:4+<1723::AID-CNCR2820701612>3.0.CO;2-3
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   MCMANUS ME, 1990, CANCER RES, V50, P3367
   Mei Q, 2012, METABOLISM, V61, P1321, DOI 10.1016/j.metabol.2012.02.010
   Murray GI, 1997, CANCER RES, V57, P3026
   Nakajima M, 1999, J BIOCHEM-TOKYO, V125, P803, DOI 10.1093/oxfordjournals.jbchem.a022352
   Nebert DW, 2006, NAT REV CANCER, V6, P947, DOI 10.1038/nrc2015
   Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200
   Nebert DW, 1996, DNA CELL BIOL, V15, P273, DOI 10.1089/dna.1996.15.273
   Norat T, 2005, J NATL CANCER I, V97, P906, DOI 10.1093/jnci/dji164
   Northwood EL, 2010, PHARMACOGENET GENOM, V20, P315, DOI 10.1097/FPC.0b013e3283395c6a
   Potter JD, 1996, CANCER CAUSE CONTROL, V7, P127, DOI 10.1007/BF00115644
   Rudolph A, 2011, ENDOCR-RELAT CANCER, V18, P371, DOI 10.1530/ERC-11-0057
   Sachse C, 2002, CARCINOGENESIS, V23, P1839, DOI 10.1093/carcin/23.11.1839
   Saebo M, 2008, ANTICANCER RES, V28, P2289
   Sainz J, 2011, ENDOCR-RELAT CANCER, V18, P265, DOI 10.1530/ERC-10-0264
   Shimada T, 1996, CANCER RES, V56, P2979
   Stoilov I, 1998, AM J HUM GENET, V62, P573, DOI 10.1086/301764
   Trubicka J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-420
   Tsuchiya Y, 2005, CANCER LETT, V227, P115, DOI 10.1016/j.canlet.2004.10.007
   Wang HS, 2011, CARCINOGENESIS, V32, P203, DOI 10.1093/carcin/bgq237
   Wang J, 2012, INT J CANCER, V130, P1898, DOI 10.1002/ijc.26199
   Williams JA, 2000, CARCINOGENESIS, V21, P1683, DOI 10.1093/carcin/21.9.1683
   Xie Y, 2012, TUMOR BIOL, V33, P809, DOI 10.1007/s13277-011-0298-7
   Yamazaki H, 1998, CHEM RES TOXICOL, V11, P659, DOI 10.1021/tx970217f
   Yoshida K, 2007, ASIAN PAC J CANCER P, V8, P438
   Zhao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071481
NR 54
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 12
PY 2014
VL 9
IS 8
AR e100487
DI 10.1371/journal.pone.0100487
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO3LJ
UT WOS:000341230400002
PM 25115775
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liang, GL
   Wu, J
   Shi, JT
   Liu, J
   He, FY
   Xu, W
AF Liang, Guan-Lu
   Wu, Jing
   Shi, Jun-Ting
   Liu, Jian
   He, Feng-Ying
   Xu, Wen
TI Implantable Collamer Lens Versus Iris-Fixed Phakic Intraocular Lens
   Implantation to Correct Myopia: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID ACADEMY-OF-OPHTHALMOLOGY; IN-SITU KERATOMILEUSIS; PHOTOREFRACTIVE
   KERATECTOMY; REFRACTIVE SURGERY; EXCIMER-LASER; FOLLOW-UP; CONTACT-LENS;
   VISIAN ICL; ARTISAN; ASTIGMATISM
AB This study is a meta-analysis comparing the efficacy, predictability, and safety of correcting myopia via implantation of two types of phakic intraocular lens (PIOLs): the implantable collamer lens (ICL) and iris-fixed PIOL. The Cochrane library, Pubmed, and EMBASE were searched. Study selection, data exclusion, and quality assessment were performed by two independent observers. The pooled relative risk (RR), pooled standardized mean difference (SMD), and their 95% confidence intervals (CIs) were used to compare lenses. Seven studies, involving 511 eyes, were included. The pooled SMD in postoperative uncorrected distance visual acuity (UDVA) comparing ICLs to iris-fixed PIOLs was -0.22 (95% CI, -0.58 to 0.13; P = .22). The pooled RR values of UDVA of 20/20 or better and of 20/40 or better comparing ICLs to iris-fixed PIOLs were 1.15 (95% CI, 0.89 to 1.47; P = .29) and 1.01 (95% CI, 0.95 to 1.08; P = .75), respectively. The pooled RR of loss of best spectacle-corrected visual acuity (BSCVA) and gain in BSCVA comparing ICLs to iris-fixed PIOLs were 1.20 (95% CI, 0.24 to 6.00; P = .82) and 1.14 (95% CI, 0.89 to 1.48; P = .31), respectively. The pooled RR comparing ICLs to iris-fixed PIOLs was 0.78 (95% CI, 0.29 to 2.12; P = .63) for all reported complications and 2.80 (95% CI, 1.04 to 7.52; P = .04) for severe complications. The pooled RR of achieving a result within +/- 0.5 D (diopter) of the intended target comparing ICLs to iris-fixed PIOLs was 1.35 (95% CI, 1.04 to 1.77; P = .03). Overall, there is no significant difference in efficacy between the two types of PIOLs or in safety, except that the ICL is associated with a greater incidence of severe complications, especially anterior subcapsular cataract, primarily in the Version 2 and Version 3 groups. However, ICL has better predictability.
C1 [Liang, Guan-Lu; Wu, Jing; Liu, Jian; He, Feng-Ying; Xu, Wen] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Ctr Eye, Hangzhou 310003, Zhejiang, Peoples R China.
   [Shi, Jun-Ting] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Ophthalmol, Hangzhou 310003, Zhejiang, Peoples R China.
RP Xu, W (reprint author), Zhejiang Univ, Affiliated Hosp 2, Coll Med, Ctr Eye, Hangzhou 310003, Zhejiang, Peoples R China.
EM xuwenhz2002@hotmail.com; xuwenhz2002@hotmail.com
FU Chinese Natural Science Foundation Youth Program [11104246/A040414]; Key
   Lab Fund of Zhejiang Province, China [2011E10006]
FX This study was supported by Chinese Natural Science Foundation Youth
   Program (11104246/A040414) and Key Lab Fund of Zhejiang Province (No.
   2011E10006), China. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alio JL, 2009, BRIT J OPHTHALMOL, V93, P1313, DOI 10.1136/bjo.2007.131748
   Awadein A, 2013, J REFRACT SURG, V29, P445, DOI 10.3928/1081597X-20130617-02
   Barsam A, 2012, DATABASE COCHRANE DA
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benedetti S, 2005, J REFRACT SURG, V21, P116
   Budo C, 2000, J CATARACT REFR SURG, V26, P1163, DOI 10.1016/S0886-3350(00)00545-9
   Chen LJ, 2008, J CATARACT REFR SURG, V34, P1181, DOI 10.1016/j.jcrs.2008.03.029
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Dupps WJ, 2011, J CATARACT REFR SURG, V37, P1, DOI 10.1016/j.jcrs.2010.11.010
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El Danasoury MA, 2002, OPHTHALMOLOGY, V109, P955, DOI 10.1016/S0161-6420(02)00964-8
   Ghoreishi Mohammad, 2011, Oman J Ophthalmol, V4, P116, DOI 10.4103/0974-620X.91266
   Guell JL, 2010, J CATARACT REFR SURG, V36, P1976, DOI 10.1016/j.jcrs.2010.08.014
   Hassaballa MA, 2011, EYE, V25, P1365, DOI 10.1038/eye.2011.187
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang D, 2009, OPHTHALMOLOGY, V116, P2244, DOI 10.1016/j.ophtha.2009.08.018
   Kamiya K, 2009, J REFRACT SURG, V25, P259
   Lackner B, 2004, J CATARACT REFR SURG, V30, P2269, DOI 10.1016/j.jcrs.2004.07.018
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lee SY, 2011, EYE, V25, P1409, DOI 10.1038/eye.2011.176
   Lifshitz Tova, 2004, Int Ophthalmol, V25, P233, DOI 10.1007/s10792-005-5016-2
   Maloney RK, 2002, OPHTHALMOLOGY, V109, P1631, DOI 10.1016/S0161-6420(02)01170-3
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Medical Advisory Secretariat, 2009, Ont Health Technol Assess Ser, V9, P1
   Menezo JL, 2004, J CATARACT REFR SURG, V30, P33, DOI 10.1016/S0886-3350(03)01020-4
   Pesando PM, 1999, J REFRACT SURG, V15, P415
   Rapuano CJ, 1999, OPHTHALMOLOGY, V106, P422
   Reinstein DZ, 2009, J REFRACT SURG, V25, P975, DOI 10.3928/1081597X-20091016-01
   Rosen E, 1998, J CATARACT REFR SURG, V24, P596, DOI 10.1016/S0886-3350(98)80253-8
   Samoocha David, 2010, J Med Internet Res, V12, pe23, DOI 10.2196/jmir.1286
   Sanchez-Galeana CA, 2003, OPHTHALMOLOGY, V110, P781, DOI 10.1016/S0161-6420(02)01973-5
   Sanders DR, 2008, J REFRACT SURG, V24, P566, DOI 10.3928/1081597X-20080601-04
   Sanders DR, 2007, J REFRACT SURG, V23, P537
   Sanders DR, 2004, OPHTHALMOLOGY, V111, P1683, DOI 10.1016/j.ophtha.2004.03.026
   Sanders DR, 2002, J REFRACT SURG, V18, P673
   Sarikkola AU, 2005, J CATARACT REFR SURG, V31, P511, DOI 10.1016/j.jcrs.2004.06.084
   Schallhorn S, 2007, J REFRACT SURG, V23, P853, DOI 10.3928/1081-597X-20071101-01
   Schallhorn SC, 2008, OPHTHALMOLOGY, V115, P1249, DOI 10.1016/j.ophtha.2008.04.010
   SEILER T, 1991, OPHTHALMOLOGY, V98, P1156
   Sharpe D, 1997, CLIN PSYCHOL REV, V17, P881, DOI 10.1016/S0272-7358(97)00056-1
   Smallman DS, 2004, J CATARACT REFR SURG, V30, P905, DOI 10.1016/j.jcrs.2003.09.019
   Sugar A, 2002, OPHTHALMOLOGY, V109, P175, DOI 10.1016/S0161-6420(01)00966-6
   Varley GA, 2004, OPHTHALMOLOGY, V111, P1604, DOI 10.1016/j.ophtha.2004.05.016
   Wachler BSB, 2009, J REFRACT SURG, V25, P765, DOI 10.3928/1081597X-20090813-02
   Waring GO, 2000, J REFRACT SURG, V16, P459
   YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7
   Zhang Zhi-hua, 2011, Zhonghua Yan Ke Za Zhi, V47, P531
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 49
TC 9
Z9 10
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 12
PY 2014
VL 9
IS 8
AR e104649
DI 10.1371/journal.pone.0104649
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO3LJ
UT WOS:000341230400066
PM 25115906
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Lai, H
   Mo, XW
   Yang, Y
   Xiao, J
   He, K
   Chen, JS
   Lin, Y
AF Lai, Hao
   Mo, Xianwei
   Yang, Yang
   Xiao, Jun
   He, Ke
   Chen, Jiansi
   Lin, Yuan
TI Association between Duration of Carbon Dioxide Pneumoperitoneum during
   Laparoscopic Abdominal Surgery and Hepatic Injury: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID LIVER-FUNCTION TESTS; BLOOD-FLOW; GASTRIC-CANCER; LOW-PRESSURE;
   CHOLECYSTECTOMY; ENZYMES; GASTRECTOMY; APPENDECTOMY; INSUFFLATION;
   DYSFUNCTION
AB Background: The aim of this study is to accurately assess whether the duration of intraoperative carbon dioxide pneumoperitoneum (CDP) is associated with the induction of hepatic injury.
   Methods: We conducted a systematic review of PubMed, Embase, and Cochrane Library databases (through February 2014) to identify case-match studies that compared high-pressure CDP with low-pressure CDP or varied the duration of CDP in patients who underwent abdominal surgery. The outcome of interest was postoperative liver function (ALT, AST, TB).
   Results: Eleven comparative studies involving 2,235 participants were included. Overall, levels of ALT, AST, and TB (on postoperative days 1, 3, and 7) were significantly elevated in the study groups. However, the results of the subanalyses of those who underwent laparoscopic colorectal cancer resection (LCR) versus open colorectal cancer resection (OCR) and those who underwent laparoscopic gastric bypass (LGBP) versus open gastric bypass (OGBP) were inconsistent.
   Conclusions: The current evidence suggests that the duration of CDP during laparoscopic abdominal surgery may be associated with hepatic injury. Additional large-scale, randomized, controlled trials are urgently needed to further confirm this.
C1 [Lai, Hao; Mo, Xianwei; Yang, Yang; Xiao, Jun; Chen, Jiansi; Lin, Yuan] Guangxi Med Univ, Affiliated Canc Hosp, Dept Gastrointestinal Surg, Nanning, Guangxi Autonom, Peoples R China.
   [He, Ke] Guangxi Med Univ, Affiliated Canc Hosp, Dept Neck & Head Surg, Nanning, Guangxi Autonom, Peoples R China.
RP Chen, JS (reprint author), Guangxi Med Univ, Affiliated Canc Hosp, Dept Gastrointestinal Surg, Nanning, Guangxi Autonom, Peoples R China.
EM Chenjiansi168@sina.cn; doctoryuanlin@sina.cn
CR Andrei VE, 1998, DIGEST SURG, V15, P256, DOI 10.1159/000018624
   Atila K, 2009, J LAPAROENDOSC ADV S, V19, P39, DOI 10.1089/lap.2008.0085
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bickel A, 2008, J GASTROINTEST SURG, V12, P1418, DOI 10.1007/s11605-008-0557-0
   Bohm B, 1999, VISZERALCHIRURGIE, V34, P20
   Brundell SM, 2002, BRIT J SURG, V89, P617, DOI 10.1046/j.1365-2168.2002.02071.x
   Chen K, 2013, WORLD J GASTROENTERO, V19, P5365, DOI 10.3748/wjg.v19.i32.5365
   CLARKE RSJ, 1976, BRIT J ANAESTH, V48, P119, DOI 10.1093/bja/48.2.119
   Dexter SPL, 1999, SURG ENDOSC, V13, P376, DOI 10.1007/s004649900993
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eryilmaz HB, 2012, SCI WORLD J, DOI 10.1100/2012/172575
   Etoh T, 2007, WORLD J SURG, V31, P1115, DOI 10.1007/s00268-007-0237-3
   Glantzounis GK, 2001, SURG ENDOSC-ULTRAS, V15, P1315, DOI 10.1007/s00464-001-0034-2
   Guven HE, 2007, J GASTROINTEST LIVER, V16, P391
   Gupta R, 2013, J LAPAROENDOSC ADV S, V23, P339, DOI 10.1089/lap.2012.0399
   Gutt CN, 2004, DIGEST SURG, V21, P95, DOI 10.1159/000077038
   HALEVY A, 1994, ANN SURG, V219, P362, DOI 10.1097/00000658-199404000-00006
   Hasukic S, 2005, SURG ENDOSC, V19, P1451, DOI 10.1007/s00464-005-0061-5
   Hasukic SK, 2005, MED PRIN PRACT, V14, P147, DOI 10.1159/000084630
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA
   Jeong GA, 2011, WORLD J GASTROENTERO, V17, P372, DOI 10.3748/wjg.v17.i3.372
   Kinjo Y, 2011, WORLD J SURG, V35, P2730, DOI 10.1007/s00268-011-1301-6
   Li XH, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-129
   Liang YC, 2011, ANZ J SURG, V81, P673, DOI 10.1111/j.1445-2197.2010.05599.x
   Markar SR, 2012, J GASTROINTEST SURG, V16, P1993, DOI 10.1007/s11605-012-1962-y
   Morino M, 1998, SURG ENDOSC-ULTRAS, V12, P968, DOI 10.1007/s004649900758
   Nguyen NT, 2003, AM J SURG, V186, P40, DOI 10.1016/S0002-9610(03)00106-5
   Omari A, 2007, J LAPAROENDOSC ADV S, V17, P419, DOI 10.1089/lap.2006.0160
   Osman Yildirim, 2009, JPMA Journal of the Pakistan Medical Association, V59, P201
   Richter S, 2001, ANESTH ANALG, V93, P872, DOI 10.1097/00000539-200110000-00014
   Saber AA, 2000, AM SURGEON, V66, P699
   Saber AA, 2007, J GASTROINTEST LIVER, V16, P427
   Said-Ahmed HAEF, 2004, ACTA ANAESTHESIOLOGI, V55, P120
   Sakorafas George, 2005, N Z Med J, V118, pU1317
   Sato K, 2000, ANESTH ANALG, V90, P1198, DOI 10.1097/00000539-200005000-00037
   Takagi S, 1998, SURG ENDOSC-ULTRAS, V12, P427, DOI 10.1007/s004649900696
   Tan M, 2003, WORLD J GASTROENTERO, V9, P364, DOI 10.3748/wjg.v9.i2.364
   Tunon MJ, 1999, SURG ENDOSC-ULTRAS, V13, P668, DOI 10.1007/s004649901070
   Yoon HM, 2011, SURG ENDOSC, V25, P1761, DOI 10.1007/s00464-010-1449-4
NR 39
TC 3
Z9 3
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 11
PY 2014
VL 9
IS 8
AR e104067
DI 10.1371/journal.pone.0104067
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO1WB
UT WOS:000341105100027
PM 25110982
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, ZY
   Zhang, YC
   Niu, YL
   Li, K
   Liu, X
   Chen, HJ
   Gao, CF
AF Liu, Zhongyu
   Zhang, Yingchong
   Niu, Yulong
   Li, Ke
   Liu, Xin
   Chen, Huijuan
   Gao, Chunfang
TI A Systematic Review and Meta-Analysis of Diagnostic and Prognostic Serum
   Biomarkers of Colorectal Cancer
SO PLOS ONE
LA English
DT Article
ID CLINICAL-PRACTICE GUIDELINES; TEST ACCURACY EVALUATIONS; MARKERS EGTM
   GUIDELINES; TUMOR-MARKERS; PUBLICATION BIAS; CARCINOEMBRYONIC ANTIGEN;
   GASTROINTESTINAL CANCERS; ADJUVANT CHEMOTHERAPY; EUROPEAN GROUP; TESTS
AB Background: Our systematic review summarizes the evidence concerning the accuracy of serum diagnostic and prognostic tests for colorectal cancer (CRC).
   Methods: The databases MEDLINE and EMBASE were searched iteratively to identify the relevant literature for serum markers of CRC published from 1950 to August 2012. The articles that provided adequate information to meet the requirements of the meta-analysis of diagnostic and prognostic markers were included. A 2-by-2 table of each diagnostic marker and its hazard ratio (HR) and the confidence interval (CI) of each prognostic marker was directly or indirectly extracted from the included papers, and the pooled sensitivity and specificity of the diagnostic marker and the pooled HR and the CI of the prognostic marker were subsequently calculated using the extracted data.
   Results: In total, 104 papers related to the diagnostic markers and 49 papers related to the prognostic serum markers of CRC were collected, and only 19 of 92 diagnostic markers were investigated in more than two studies, whereas 21 out of 44 prognostic markers were included in two or more studies. All of the pooled sensitivities of the diagnostic markers with >=3 repetitions were less than 50%, and the meta-analyses of the prognostic markers with more than 3 studies were performed, VEGF with highest (2.245, CI: 1.347-3.744) and MMP-7 with lowest (1.099, CI: 1.018-1.187)) pooled HRs are presented.
   Conclusions: The quality of studies addressing the diagnostic and prognostic accuracy of the tests was poor, and the results were highly heterogeneous. The poor characteristics indicate that these tests are of little value for clinical practice.
C1 [Liu, Zhongyu; Li, Ke; Liu, Xin; Chen, Huijuan; Gao, Chunfang] Cent Hosp PLA, Anal Colorectal Surg Inst, Luoyang, Henan, Peoples R China.
   [Zhang, Yingchong] Chengdu Municipal Ctr Dis Control & Prevent, Chengdu, Peoples R China.
   [Niu, Yulong] Sichuan Univ, Coll Life Sci, Chengdu 610064, Peoples R China.
RP Liu, ZY (reprint author), Cent Hosp PLA, Anal Colorectal Surg Inst, Luoyang, Henan, Peoples R China.
EM zhongyujohn@gmail.com; gaochunfang2010@163.com
OI Niu, Yulong/0000-0002-1361-6272
FU China Postdoctoral Science Foundation [201150M1569, 2012T50893]; Luoyang
   application technology research and development projects [1401088A-5]
FX Funding for this work was provided by the China Postdoctoral Science
   Foundation (201150M1569 and 2012T50893 to ZL) and Luoyang application
   technology research and development projects (1401088A-5). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Allegra C, 2003, J CLIN ONCOL, V21, P395, DOI 10.1200/JCO.2003.11.073
   ALTMAN DG, 1995, BRIT J CANCER, V72, P511, DOI 10.1038/bjc.1995.364
   Altman DG, 2005, NAT CLIN PRACT ONCOL, V2, P466, DOI 10.1038/ncponc0287
   Altman DG, 1998, BRIT MED J, V317, P468
   Altman DG, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001216
   Bast RC, 1996, J CLIN ONCOL, V14, P2843
   Bast RC, 2001, J CLIN ONCOL, V19, P1865, DOI 10.1200/JCO.2001.19.6.1865
   BATES AS, 1993, J PEDIATR-US, V122, P585, DOI 10.1016/S0022-3476(05)83540-1
   BEGG CB, 1983, BIOMETRICS, V39, P207, DOI 10.2307/2530820
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Behbehani AI, 2000, INT J BIOL MARKER, V15, P51
   Cancer Res UK, 2003, CANC STAT LARGE BOWE, VUK4, P4
   Carpelan-Holmstrom M, 2004, TUMOR BIOL, V25, P228, DOI 10.1159/000081385
   Carpelan-Holmstrom M, 2002, ANTICANCER RES, V22, P2311
   Centre for Reviews and Dissemination University of York, 2001, RES REPORT, V4
   Clarke M, 2008, NEURORADIOLOGY, V50, P653, DOI 10.1007/s00234-008-0411-9
   Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016
   Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15
   Duffy MJ, 2007, EUR J CANCER, V43, P1348, DOI 10.1016/j.ejca.2007.03.021
   Duffy MJ, 1998, ANN CLIN BIOCHEM, V35, P364, DOI 10.1177/000456329803500304
   Duffy MJ, 2001, CLIN CHEM, V47, P624
   Duffy MJ, 2003, EUR J CANCER, V39, P718, DOI 10.1016/S0959-8049(02)00811-0
   Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529
   Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FILELLA X, 1994, TUMOR BIOL, V15, P1, DOI 10.1159/000217867
   Finlay IG, 1994, CURRENT MED, P51
   FLETCHER RH, 1986, ANN INTERN MED, V104, P66, DOI 10.7326/0003-4819-104-1-66
   Glasziou PP, 2002, STAT MED, V21, P1503, DOI 10.1002/sim.1183
   Goldstein MJ, 2005, CANCER INVEST, V23, P338, DOI 10.1081/CNV-200058878
   Graziano F, 2003, ANN ONCOL, V14, P1026, DOI 10.1093/annonc/mdg284
   Grem Jean, 1997, Current Opinion in Oncology, V9, P380, DOI 10.1097/00001622-199709040-00012
   Harbord RM, 2009, METAANALYSIS STATA U, P181
   Hayden JA, 2006, ANN INTERN MED, V144, P427, DOI 10.7326/0003-4819-144-6-200603210-00010
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Keough-Ryan T, 2002, AM J KIDNEY DIS, V39, P1196, DOI 10.1053/ajkd.2002.33391
   Kyzas PA, 2005, JNCI-J NATL CANCER I, V97, P1043, DOI 10.1093/jnci/dji184
   Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061
   Lijmer JG, 2002, STAT MED, V21, P1525, DOI 10.1002/sim.1185
   LINDMARK G, 1995, BRIT J CANCER, V71, P1090, DOI 10.1038/bjc.1995.211
   Ling BS, 2001, J GEN INTERN MED, V16, P822, DOI 10.1046/j.1525-1497.2001.10337.x
   Liu Z, 2013, BRIT J CANCER, V108, P2299, DOI 10.1038/bjc.2013.185
   Locker GY, 2006, J CLIN ONCOL, V24, P5313, DOI 10.1200/JCO.2006.08.2644
   Markers EGoT, 1999, ANTICANCER RES, V19, P2811
   Morikawa T, 2005, GASTROENTEROLOGY, V129, P422, DOI 10.1053/j.gastro.2005.05.056
   Nakayama T, 1997, J SURG ONCOL, V66, P238
   PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Popat S, 2004, J CLIN ONCOL, V22, P529, DOI 10.1200/JCO.2004.05.064
   RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705
   Reiter W, 2000, ANTICANCER RES, V20, P5195
   Reitsma JB, 2005, J CLIN EPIDEMIOL, V58, P982, DOI 10.1016/j.jclinepi.2005.02.022
   REX DK, 1993, AM J GASTROENTEROL, V88, P825
   Rex DK, 2012, AM J GASTROENTEROL, V107, P1315, DOI 10.1038/ajg.2012.161
   Riley R D, 2003, Health Technol Assess, V7, P1
   Rothstein HR, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P1
   Rothstein HR, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P1, DOI 10.1002/0470870168
   Rutter CM, 2001, STAT MED, V20, P2865, DOI 10.1002/sim.942
   Sica GT, 2006, RADIOLOGY, V238, P780, DOI 10.1148/radiol.2383041109
   Simmonds MC, 2005, CLIN TRIALS, V2, P209, DOI 10.1191/1740774505cn087oa
   Smith V, 2007, EUR J OBSTET GYN R B, V133, P134, DOI 10.1016/j.ejogrb.2007.03.005
   Song FJ, 2002, INT J EPIDEMIOL, V31, P88, DOI 10.1093/ije/31.1.88
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Tsuji T, 2003, CLIN CANCER RES, V9, P3700
   van der Bij S, 2011, BRIT J CANCER, V104, P1325, DOI 10.1038/bjc.2011.104
   VATN MH, 1982, CANCER, V49, P819, DOI 10.1002/1097-0142(19820215)49:4<819::AID-CNCR2820490435>3.0.CO;2-D
   Westwood Marie E, 2005, BMC Med Res Methodol, V5, P20, DOI 10.1186/1471-2288-5-20
   Whiting P, 2004, ANN INTERN MED, V140, P189, DOI 10.7326/0003-4819-140-3-200402030-00010
   Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25
   Winawer S J, 1988, Prog Clin Biol Res, V279, P35
   Zamora Javier, 2006, BMC Med Res Methodol, V6, P31, DOI 10.1186/1471-2288-6-31
   Zhou X H, 1998, Stat Methods Med Res, V7, P337, DOI 10.1191/096228098676485370
NR 73
TC 26
Z9 28
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 8
PY 2014
VL 9
IS 8
AR e103910
DI 10.1371/journal.pone.0103910
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR0CG
UT WOS:000343231900030
PM 25105762
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Mavaddat, N
   Parker, RA
   Sanderson, S
   Mant, J
   Kinmonth, AL
AF Mavaddat, Nahal
   Parker, Richard A.
   Sanderson, Simon
   Mant, Jonathan
   Kinmonth, Ann Louise
TI Relationship of Self-Rated Health with Fatal and Non-Fatal Outcomes in
   Cardiovascular Disease: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID BIOMEDICAL RISK-FACTORS; ISCHEMIC-HEART-DISEASE; PERCEIVED HEALTH;
   ALL-CAUSE; MORTALITY; ASSOCIATION; MEN; PREDICTION; MORBIDITY; RATINGS
AB Background: People who rate their health as poor experience higher all-cause mortality. Study of disease-specific association with self-rated health might increase understanding of why this association exists.
   Objectives: To estimate the strength of association between self-rated health and fatal and non-fatal cardiovascular disease.
   Methods: A comprehensive search of PubMed MEDLINE, EMBASE, CINAHL, BIOSIS, PsycINFO, DARE, Cochrane Library, and Web of Science was undertaken during June 2013. Two reviewers independently searched databases and selected studies. Inclusion criteria were prospective cohort studies or cohort analyses of randomised trials with baseline measurement of self-rated health with fatal or non-fatal cardiovascular outcomes. 20 studies were pooled quantitatively in different meta-analyses. Study quality was assessed using Newcastle-Ottawa scales.
   Results: 'Poor' relative to 'excellent' self-rated health (defined by most extreme categories in each study, most often' poor' or 'very poor' and 'excellent' or 'good') was associated over a follow-up of 2.3-23 years with cardiovascular mortality in studies: where varying degrees of adjustments had been made for cardiovascular disease risk (HR 1.79 (95% CI 1.50 to 2.14); 15 studies, I2 = 71.24%), and in studies reporting outcomes in people with pre-existing cardiovascular disease or ischaemic heart disease symptoms (HR 2.42 (95% CI 1.32 to 4.44); 3 studies; I2 = 71.83%). 'Poor' relative to 'excellent' self rated health was also associated with the combined outcome of fatal and non-fatal cardiovascular events (HR 1.90 (95% CI 1.26 to 2.87); 5 studies; I2 = 68.61%), Self-rated health was not significantly associated with non-fatal cardiovascular disease outcomes (HR 1.66 (95% CI 0.96 to 2.87); 5 studies; I2 = 83.60%).
   Conclusions: Poor self rated health is associated with cardiovascular mortality in populations with and without prior cardiovascular disease. Those with current poor self-rated health may warrant additional input from health services to identify and address reasons for their low subjective health.
C1 [Mavaddat, Nahal; Mant, Jonathan] Univ Cambridge, Dept Publ Hlth & Primary Care, Primary Care Unit, Strangeways Lab, Cambridge, England.
   [Parker, Richard A.; Sanderson, Simon; Kinmonth, Ann Louise] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Primary Care Unit, Cambridge, England.
RP Mavaddat, N (reprint author), Univ Cambridge, Dept Publ Hlth & Primary Care, Primary Care Unit, Strangeways Lab, Cambridge, England.
EM nm212@medschl.cam.ac.uk
OI Mant, Jonathan/0000-0002-9531-0268
FU NIHR Walport Clinical Lectureship; National Institute for Health
   Research [632, NF-SI-0508-10072]
FX This report presents independent commissioned research by the National
   Institute for Health Research (NIHR) through the National School for
   Primary Care Research. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. NM was funded through an NIHR Walport Clinical Lectureship.
CR Appels A, 1996, SOC SCI MED, V42, P681, DOI 10.1016/0277-9536(95)00195-6
   Bailis DS, 2003, SOC SCI MED, V56, P203, DOI 10.1016/S0277-9536(02)00020-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benjamins MR, 2004, SOC SCI MED, V59, P1297, DOI 10.1016/j.socscimed.2003.01.001
   Bosworth HB, 1999, MED CARE, V37, P1226, DOI 10.1097/00005650-199912000-00006
   DeSalvo KB, 2006, J GEN INTERN MED, V21, P267, DOI 10.1111/j.1525-1497.2005.0291.x
   Doganay S, 2012, TURK J GERIATR, V15, P396
   Emmelin M, 2003, J HYPERTENS, V21, P887, DOI 10.1097/01.hjh.0000059026.82022.24
   Ernstsen L, 2011, AGE AGEING, V40, P105, DOI 10.1093/ageing/afq141
   Fang Xiang-hua, 2003, Zhonghua Liu Xing Bing Xue Za Zhi, V24, P184
   Fernandez-Ruiz M, 2013, GERONTOLOGY, V59, P368, DOI 10.1159/000348781
   Heidrich J, 2002, ANN EPIDEMIOL, V12, P338, DOI 10.1016/S1047-2797(01)00300-3
   Heistaro S, 2001, J EPIDEMIOL COMMUN H, V55, P227, DOI 10.1136/jech.55.4.227
   Hillen T, 2003, J EPIDEMIOL COMMUN H, V57, P960, DOI 10.1136/jech.57.12.960
   Hirdes JP, 1993, J AGING HEALTH, V5, P101, DOI DOI 10.1177/089826439300500105
   Howell R., 2007, HLTH PSYCHOL REV, V1, P83, DOI [10.1080/17437190701492486, DOI 10.1080/17437190701492486]
   Idler E, 2004, J HEALTH SOC BEHAV, V45, P336, DOI 10.1177/002214650404500307
   Idler EL, 2000, AM J EPIDEMIOL, V152, P874, DOI 10.1093/aje/152.9.874
   Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359
   Jylha M, 2006, J CLIN EPIDEMIOL, V59, P465, DOI 10.1016/j.jclinepi.2005.12.004
   Kamphuis MH, 2009, J AFFECT DISORDERS, V114, P184, DOI 10.1016/j.jad.2008.07.005
   Kaplan G, 2003, SOC SCI MED, V56, P1669, DOI 10.1016/S0277-9536(02)00179-X
   Kaplan GA, 1996, INT J EPIDEMIOL, V25, P259, DOI 10.1093/ije/25.2.259
   Kennedy BS, 2001, AM J EPIDEMIOL, V153, P232, DOI 10.1093/aje/153.3.232
   Kirkwood B. R., 2003, ESSENTIAL MEDIAL STA
   Kuper H, 2006, AM J EPIDEMIOL, V164, P349, DOI 10.1093/aje/kwj212
   LAMB KL, 1990, SOC SCI MED, V31, P963, DOI 10.1016/0277-9536(90)90105-2
   Latham K, 2013, J GERONTOL B-PSYCHOL, V68, P107, DOI 10.1093/geronb/gbs104
   Lyubomirsky S, 2005, PSYCHOL BULL, V131, P803, DOI 10.1037/0033-2909.131.6.803
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   PIJLS LTJ, 1993, AM J EPIDEMIOL, V138, P840, DOI 10.1093/oxfordjournals.aje.a116787
   R Development Core Team, 2012, R LANG ENV STAT COMP
   Rutledge T, 2010, PSYCHOSOM MED, V72, P549, DOI 10.1097/PSY.0b013e3181dc0259
   Sanderson S, 2007, INT J EPIDEMIOL, V36, P666, DOI 10.1093/ije/dym018
   SEGOVIA J, 1989, CAN J PUBLIC HEALTH, V80, P32
   TSUJI I, 1994, J AM GERIATR SOC, V42, P153, DOI 10.1111/j.1532-5415.1994.tb04944.x
   van der Linde RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065290
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1
   von Bothmer MIK, 2003, SCAND J CARING SCI, V17, P347, DOI 10.1046/j.0283-9318.2003.00234.x
   WANNAMETHEE G, 1991, INT J EPIDEMIOL, V20, P239, DOI 10.1093/ije/20.1.239
   Weinehall L, 1998, J INTERN MED, V243, P99
   Wells G., 2007, NEWCASTLE OTTAWA SCA
NR 42
TC 45
Z9 45
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 30
PY 2014
VL 9
IS 7
AR e103509
DI 10.1371/journal.pone.0103509
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM7EZ
UT WOS:000340028800057
PM 25076041
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Oldenburg, CE
   Perez-Brumer, AG
   Reisner, SL
   Mattie, J
   Barnighausen, T
   Mayer, KH
   Mimiaga, MJ
AF Oldenburg, Catherine E.
   Perez-Brumer, Amaya G.
   Reisner, Sari L.
   Mattie, Jason
   Baernighausen, Till
   Mayer, Kenneth H.
   Mimiaga, Matthew J.
TI Global Burden of HIV among Men Who Engage in Transactional Sex: A
   Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID SEXUALLY-TRANSMITTED INFECTIONS; MIDDLE-INCOME COUNTRIES; VIRUS TYPE-2
   INFECTION; RISK-FACTORS; MONEY BOYS; SYPHILIS PREVALENCE; WORKERS;
   BEHAVIOR; CHINA; TRANSGENDERS
AB Background: Men who engage in transactional sex, the exchange of sex for money, goods, or other items of value, are thought to be at increased risk of HIV, but there have been no systematic attempts to characterize HIV burden in this population. We undertook a systematic review and meta-analysis to quantify the burden in this population compared with that of men in the general population to better inform future HIV prevention efforts.
   Methods: We searched seven electronic databases, national surveillance reports, and conference abstracts for studies of men who engage in transactional sex published between 2004-2013. Random effects meta-analysis was used to determine pooled HIV prevalence and prevalence ratios (PR) for the difference in HIV prevalence among men who engage in transactional sex as compared to general population men.
   Findings: Of 66 studies included representing 31,924 men who had engaged in transactional sex in 28 countries, pooled biological assay-confirmed HIV prevalence was 10.5% (95% CI = 9.4 to 11.5%). The highest pooled HIV prevalence was in Sub-Saharan Africa (31.5%, 95% CI = 21.6 to 41.5%), followed by Latin America (19.3%, 95% CI = 15.5 to 23.1%), North America (16.6%, 95% CI = 3.7 to 29.5%), and Europe (12.2%, 95% CI = 6.0 to 17.2%). Men who engaged in transactional sex had an elevated burden of HIV compared to the general male population (PR = 20.7, 95% CI = 16.8 to 25.5).
   Conclusions: The global burden of HIV is disproportionately high among men who engage in transactional sex compared with the general male population. There is an urgent need to include this population in systematic surveillance as well as to scale-up access to quality HIV prevention programs.
C1 [Oldenburg, Catherine E.; Reisner, Sari L.; Mimiaga, Matthew J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Oldenburg, Catherine E.; Reisner, Sari L.; Mattie, Jason; Mayer, Kenneth H.; Mimiaga, Matthew J.] Fenway Community Hlth, Fenway Inst, Boston, MA USA.
   [Perez-Brumer, Amaya G.] Columbia Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY USA.
   [Baernighausen, Till] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
   [Baernighausen, Till] Africa Ctr Hlth & Populat Sci, Mtubatuba, South Africa.
   [Mayer, Kenneth H.] Beth Israel Deaconess, Dept Med, Boston, MA USA.
   [Mimiaga, Matthew J.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Oldenburg, CE (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
EM ceo242@mail.harvard.edu
OI Perez-Brumer, Amaya/0000-0003-2441-4358
FU National Institute of Allergy and Infectious Disease T32 NRSA
   [T32AI007535]; Eunice Kennedy Shriver National Institute of Child Health
   & Human Development T32 NRSA [T32 HD049339]; National Institute On Drug
   Abuse of the National Institutes of Health [R21DA035113, R21DA033720]
FX CEO is supported by a National Institute of Allergy and Infectious
   Disease T32 NRSA grant (T32AI007535; PI: Seage). APB is supported by a
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development T32 NRSA grant (T32 HD049339; PI: Nathanson). MJM, JM and
   KHM were supported in part by the National Institute On Drug Abuse of
   the National Institutes of Health under Award Numbers R21DA035113 and
   R21DA033720 (PI for both awards: Mimiaga). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Altaf A, 2006, BEHAV CHARACTERISTIC
   Altaf A, 2008, EXPLOSIVE EXPANSION, P1
   [Anonymous], 2005, MMWR RECOMM REP, V55, P844
   [Anonymous], 2010, GLOB REP UNAIDS REP
   [Anonymous], 2005, HLTH US 2005 CHARTB, P1
   [Anonymous], 2008, INTEGRATED BIOBEHAVI, P1
   [Anonymous], 2008, HEMSJ FOR KARTL HEMS, P1
   Bacon O, 2006, SEX TRANSM DIS, V33, P228, DOI 10.1097/ol.olq.0000204914.91923.ad
   Ballester R, 2012, AIDS BEHAV, V16, P960, DOI 10.1007/s10461-011-9964-4
   Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339
   Baral S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-482
   Baral S, 2012, LANCET INFECT DIS, V12, P538, DOI 10.1016/S1473-3099(12)70066-X
   Baral S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-766
   Baral S, 2010, AIDS CARE, V22, P112, DOI 10.1080/09540120903012551
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Beaver LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050454
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belza MJ, 2005, SEX TRANSM INFECT, V81, P85, DOI 10.1136/sti.2003.008649
   Beyrer C, 2012, LANCET, V380, P367, DOI 10.1016/S0140-6736(12)60821-6
   Biello KB, 2014, AIDS BEHAV, V18, P1264, DOI 10.1007/s10461-013-0632-8
   Bimbi DS, 2005, J GAY LESBIAN MENT H, V9, P85, DOI 10.1300/J236v09n03_06
   Bokhari A, 2007, INT J STD AIDS, V18, P486, DOI 10.1258/095646207781147201
   Brahmam GNV, 2008, AIDS, V22, pS45, DOI 10.1097/01.aids.0000343763.54831.15
   Bruckova M, 2006, AM J TROP MED HYG, V75, P1017, DOI 10.4269/ajtmh.2006.75.1017
   Burnette ML, 2008, ARCH GEN PSYCHIAT, V65, P337, DOI 10.1001/archpsyc.65.3.337
   Cai WD, 2010, SEX TRANSM INFECT, V86, P15, DOI 10.1136/sti.2009.037440
   Chan PA, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-153
   Chariyalertsak S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024295
   Chemnasiri T, 2010, AIDS EDUC PREV, V22, P100, DOI 10.1521/aeap.2010.22.2.100
   Cheng WB, 2010, ZHONGHUA YU FANG YI
   Clatts MC, 2007, SEX HEALTH, V4, P261, DOI 10.1071/SH07018
   Cohan D, 2006, SEX TRANSM INFECT, V82, P418, DOI 10.1136/sti.2006.020628
   Colby D, 2008, SEX TRANSM INFECT, V84, P439, DOI 10.1136/sti.2008.031294
   Colby D, 2012, INT J INFECT DIS, V16, pE332, DOI 10.1016/j.ijid.2012.05.388
   Colby D, 2010, HIV RISK ACCESS PREV
   Creswell J, 2012, SEX TRANSM INFECT, V88, P633, DOI 10.1136/sextrans-2012-050521
   Cuypers WJ, 2011, SEX TRANSM INFECT, V87, pA127, DOI 10.1136/sextrans-2011-050108.68
   Del Romero Guerrero J, 2011, HIV PREVALENCE MALE
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Farias MSD, 2011, INT J INFECT DIS, V15, pE635, DOI 10.1016/j.ijid.2011.05.007
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fay H, 2011, AIDS BEHAV, V15, P1088, DOI 10.1007/s10461-010-9861-2
   Feng LG, 2009, JAIDS-J ACQ IMM DEF, V52, P79, DOI 10.1097/QAI.0b013e3181a4f53e
   Fujimoto K, 2013, SEX TRANSM DIS, V40, P453, DOI 10.1097/OLQ.0b013e31829186e5
   Gakii G, 2010, AIDS 2010 18 INT AID
   Gayet C, MEN WHO SELL SEX URB
   Guadamuz TE, 2010, AIDS CARE, V22, P597, DOI 10.1080/09540120903280935
   Gupta A, 2006, JAIDS-J ACQ IMM DEF, V43, P483
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Haley N, 2004, SEX TRANSM INFECT, V80, P526, DOI 10.1136/sti.2004.010728
   Harcourt C, 2005, SEX TRANSM INFECT, V81, P201, DOI 10.1136/sti.2004.012468
   Hawkes S, 2009, SEX TRANSM INFECT, V85, P8, DOI 10.1136/sti.2008.033910
   He N, 2007, AIDS, V21, pS73, DOI 10.1097/01.aids.0000304700.85379.f3
   Hernandez AL, 2006, AIDS BEHAV, V10, pS5, DOI 10.1007/s10461-006-9129-z
   Hladik W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038143
   Hoang TV, 2009, RESULTS HIV STI INTE
   Hoang TV, 2006, RESULTS HIV STI INTE
   Integrated Bio-behavioral Survey (IBBS) among MSM Population in Kathmandu Valley, 2005, INT BIOB SURV IBBS M, P1
   Jacobson JO, 2014, AIDS BEHAV, V18, P88, DOI 10.1007/s10461-013-0478-0
   Kladsawad K, 2008, RESULTS 3 ROUND SURV
   Konda KA, 2008, MALE SEX WORKERS MEN
   Kral AH, 2005, J URBAN HEALTH, V82, pI43, DOI 10.1093/jurban/jti023
   Kuyper LM, 2004, SEX TRANSM INFECT, V80, P531, DOI 10.1136/sti.2004.011106
   Lama JR, 2006, J INFECT DIS, V194, P1459, DOI 10.1086/508548
   Leuridan E, 2005, INT J STD AIDS, V16, P744, DOI 10.1258/095646205774763072
   Li A, 2009, AIDS BEHAV, V13, P318, DOI 10.1007/s10461-008-9448-3
   Liu SS, 2012, AIDS BEHAV, V16, P835, DOI 10.1007/s10461-011-9978-y
   Magis C, HIV PREVALENCE FACTO
   McKinnon L, 2013, HIGH HIV PREVALENCE
   Mimiaga MJ, 2013, AIDS CARE, V25, P1109, DOI 10.1080/09540121.2012.749340
   Mimiaga MJ, 2009, J URBAN HEALTH, V86, P54, DOI 10.1007/s11524-008-9316-5
   Montano SM, 2005, P 3 INT C MAT CART C, P1
   Mor Z, 2012, SEX TRANSM INFECT, V88, P574, DOI 10.1136/sextrans-2011-050290
   Muraguri N, 2012, BURDEN HIV SEXUAL BE
   National Institute for Health and Care Excellence, 2011, HYP CLIN MAN PRIM HY, P1
   Ngo TD, 2008, INT J STD AIDS, V19, P694, DOI 10.1258/ijsa.2008.008072
   Nguyen TA, 2008, AIDS BEHAV, V12, P476, DOI 10.1007/s10461-007-9267-y
   Oldenburg CE, 2014, AIDS BEHAV, V18, P217, DOI 10.1007/s10461-013-0567-0
   Opeiario D, 2008, JAIDS-J ACQ IMM DEF, V48, P97, DOI 10.1097/QAI.0b013e31816e3971
   Pisani E, 2004, SEX TRANSM INFECT, V80, P536, DOI 10.1136/sti.2003.007500
   Pitpitan EV, 2014, PREV SCI, V15, P296, DOI 10.1007/s11121-013-0381-y
   Cortez FCP, 2011, ARCH SEX BEHAV, V40, P1223, DOI 10.1007/s10508-011-9776-7
   Prestage G, 2014, AIDS BEHAV, V18, P1293, DOI 10.1007/s10461-014-0755-6
   Reza-Paul S, 2008, HIGH HIV PREVALENCE
   Ruan SM, 2008, AIDS BEHAV, V12, P469, DOI 10.1007/s10461-008-9361-9
   Saleem Naeem Hassan, 2008, Southeast Asian Journal of Tropical Medicine and Public Health, V39, P642
   Schuelter-Trevisol F, 2013, REV SOC BRAS MED TRO, V46, P493, DOI 10.1590/0037-8682-1364-2013
   Segura M, 2007, AIDS RES HUM RETROV, V23, P1322, DOI 10.1089/aid.2007.0063
   Semugoma P, 2012, SAHARA J-J SOC ASP H, V9, P173, DOI 10.1080/17290376.2012.744177
   Sethi G, 2006, SEX TRANSM INFECT, V82, P359, DOI 10.1136/sti.2005.019257
   Shaw SY, 2011, SEX TRANSM INFECT, V87, P73, DOI 10.1136/sti.2009.041335
   Sheridan S, 2009, AIDS, V23, P409, DOI 10.1097/QAD.0b013e32831ef510
   Shinde S, 2009, INDIAN J DERMATOL VE, V75, P41, DOI 10.4103/0378-6323.45219
   Smith Michael D, 2008, Int J Sex Health, V19, P27
   Tao XR, 2010, SE ASIAN J TROP MED, V41, P358
   Timpson SC, 2007, AM J DRUG ALCOHOL AB, V33, P63, DOI 10.1080/00952990601082670
   Toledo CA, 2010, AIDS EDUC PREV, V22, P299, DOI 10.1521/aeap.2010.22.4.299
   Tun W, 2008, SEX TRANSM INFECT, V84, P455, DOI 10.1136/sti.2008.031336
   van der Elst EM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005340
   van Griensven F, 2013, AIDS, V27, P825, DOI 10.1097/QAD.0b013e32835c546e
   Vuylsteke B, 2012, SEX TRANSM INFECT, V88, P288, DOI 10.1136/sextrans-2011-050276
   Wade AS, 2005, AIDS, V19, P2133, DOI 10.1097/01.aids.0000194128.97640.07
   Washington TA, 2010, AM J MENS HEALTH, V4, P104, DOI 10.1177/1557988308330249
   Williams ML, 2006, AIDS EDUC PREV, V18, P204, DOI 10.1521/aeap.2006.18.3.204
   Wong FY, 2008, AIDS CARE, V20, P170, DOI 10.1080/09540120701534707
   Wu ZY, 2013, CLIN INFECT DIS, V57, P298, DOI 10.1093/cid/cit210
   Xiao Y, 2010, JAIDS-J ACQ IMM DEF, V53, pS66, DOI 10.1097/QAI.0b013e3181c7db43
   Yu BN, 2011, EXPLORATORY SURVEY M
   Zhang L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037211
   Zhao J, 2012, SEX TRANSM DIS, V39, P942, DOI 10.1097/OLQ.0b013e31826f356f
NR 110
TC 25
Z9 25
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 28
PY 2014
VL 9
IS 7
AR e103549
DI 10.1371/journal.pone.0103549
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM6RZ
UT WOS:000339993700079
PM 25068720
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Huang, Y
   Huang, JR
   Lan, H
   Zhao, GY
   Huang, CZ
AF Huang, Yi
   Huang, Jianrong
   Lan, Huan
   Zhao, GuanYan
   Huang, ChunZhen
TI A Meta-Analysis of Parental Smoking and the Risk of Childhood Brain
   Tumors
SO PLOS ONE
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; TOBACCO-SPECIFIC CARCINOGEN; MATERNAL SMOKING;
   CIGARETTE-SMOKING; PASSIVE SMOKING; CANCER RISK; PREGNANCY; EXPOSURE;
   CHILDREN; EPIDEMIOLOGY
AB Objective: Previous studies regarding the association between parental smoking and the risk of childhood brain tumors (CBT) have reported inconsistent results. We performed a meta-analysis to summarize evidence on this association and to quantify the potential dose-response relationship.
   Methods: A systematic literature search was conducted in the Medline and Embase databases. The summary relative risks (RRs) with 95% confidence intervals (CIs) were calculated. Dose-response meta-analysis was also performed for studies that reported categorical risk estimates for a series of smoking exposure levels.
   Results: A total of 17 studies fulfilled the inclusion criteria. In the meta-analyses, the summary RRs (95% CIs) of CBT for maternal smoking during pregnancy, paternal smoking during pregnancy, maternal smoking before pregnancy, and paternal smoking before pregnancy were 0.96 (0.86-1.07), 1.09 (0.97-1.22), 0.93 (0.85-1.00), and 1.09 (1.00-1.20), respectively. Dose-response meta-analysis also showed no significant association between parental smoking and the risk of CBT.
   Conclusions: Findings from our meta-analysis indicate that parental smoking may not be associated with a risk of CBT.
C1 [Huang, Yi; Huang, Jianrong; Lan, Huan; Zhao, GuanYan; Huang, ChunZhen] Guangxi Minzu Hosp, Dept Neurosurg, Nanning, Guangxi Provinc, Peoples R China.
RP Huang, Y (reprint author), Guangxi Minzu Hosp, Dept Neurosurg, Nanning, Guangxi Provinc, Peoples R China.
EM yhuang1966@163.com
CR ANDERSON LM, 1989, CANCER RES, V49, P3770
   Antonopoulos CN, 2011, INT J CANCER, V129, P2694, DOI 10.1002/ijc.25929
   Balansky R, 2012, INT J CANCER, V130, P1001, DOI 10.1002/ijc.26103
   Baldwin RT, 2004, TOXICOL APPL PHARM, V199, P118, DOI 10.1016/j.taap.2003.12.029
   Barrington-Trimis JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079110
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brooks DR, 2004, CANCER CAUSE CONTROL, V15, P997, DOI 10.1007/s10552-004-1123-z
   BUNIN GR, 1994, CANCER EPIDEM BIOMAR, V3, P197
   Bunin GR, 2006, AM J EPIDEMIOL, V164, P222, DOI 10.1093/aje/kwj174
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Filippini G, 2002, INT J CANCER, V100, P206, DOI 10.1002/ijc.10465
   Filippini G, 2000, PAEDIATR PERINAT EP, V14, P78
   Flenady V, 2011, LANCET, V377, P1331, DOI 10.1016/S0140-6736(10)62233-7
   Florek E, 2011, J PHYSIOL PHARMACOL, V62, P377
   Florescu A, 2009, THER DRUG MONIT, V31, P14, DOI 10.1097/FTD.0b013e3181957a3b
   Gajjar A, 2013, PEDIATR BLOOD CANCER, V60, P1022, DOI 10.1002/pbc.24427
   Giovino GA, 2012, LANCET, V380, P668, DOI 10.1016/S0140-6736(12)61085-X
   GOLD EB, 1993, AM J EPIDEMIOL, V137, P620, DOI 10.1093/oxfordjournals.aje.a116719
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
   Hargreave M, 2013, FERTIL STERIL, V100, P150, DOI 10.1016/j.fertnstert.2013.03.017
   HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   HOWE GR, 1989, CANCER RES, V49, P4349
   Hu JF, 2000, ACTA ONCOL, V39, P979
   Huncharek M, 2002, J NEURO-ONCOL, V57, P51, DOI 10.1023/A:1015734921470
   Izzotti A, 2003, FASEB J, V17, P1127, DOI 10.1096/fj.02-0967fje
   Ji BT, 1997, J NATL CANCER I, V89, P238, DOI 10.1093/jnci/89.3.238
   JOHN EM, 1991, AM J EPIDEMIOL, V133, P123, DOI 10.1093/oxfordjournals.aje.a115851
   Klimentopoulou A, 2012, PEDIATR BLOOD CANCER, V58, P344, DOI 10.1002/pbc.23347
   Klip H, 2001, HUM REPROD, V16, P2451, DOI 10.1093/humrep/16.11.2451
   KUIJTEN RR, 1990, CANCER RES, V50, P2608
   Kyritsis AP, 2010, NEURO-ONCOLOGY, V12, P104, DOI 10.1093/neuonc/nop011
   Lackmann GM, 1999, J NATL CANCER I, V91, P459, DOI 10.1093/jnci/91.5.459
   Larsson SC, 2010, JAMA-J AM MED ASSOC, V303, P1077, DOI 10.1001/jama.2010.263
   Laubenthal J, 2012, FASEB J, V26, P3946, DOI 10.1096/fj.11-201194
   Linschooten JO, 2013, FASEB J, V27, P2873, DOI 10.1096/fj.13-227694
   Milne E, 2013, INT J CANCER, V133, P253, DOI 10.1002/ijc.28004
   Milunsky A, 2000, PRENATAL DIAG, V20, P307, DOI 10.1002/(SICI)1097-0223(200004)20:4<307::AID-PD797>3.0.CO;2-M
   Mueller S, 2009, NEUROTHERAPEUTICS, V6, P570, DOI 10.1016/j.nurt.2009.04.006
   Murphy SE, 2013, J EXPO SCI ENV EPID, V23, P513, DOI 10.1038/jes.2013.7
   Nielsen SS, 2014, ANN EPIDEMIOL, V24, P236, DOI 10.1016/j.annepidem.2013.12.008
   Oken E, 2008, INT J OBESITY, V32, P201, DOI 10.1038/sj.ijo.0803760
   Orsini N, 2012, AM J EPIDEMIOL, V175, P66, DOI 10.1093/aje/kwr265
   Pang D, 2003, BRIT J CANCER, V88, P373, DOI 10.1038/sj.bjc.6600774
   Plichart M, 2008, EUR J CANCER PREV, V17, P376, DOI 10.1097/CEJ.0b013e3282f75e6f
   Pollack IF, 2011, NAT REV NEUROL, V7, P495, DOI 10.1038/nrneurol.2011.110
   Rice JM, 2004, TOXICOL APPL PHARM, V199, P175, DOI 10.1016/j.taap.2003.12.031
   Schuz J, 2001, MED PEDIATR ONCOL, V36, P274, DOI 10.1002/1096-911X(20010201)36:2<274::AID-MPO1065>3.3.CO;2-4
   Stavrou EP, 2009, CANCER CAUSE CONTROL, V20, P1551, DOI 10.1007/s10552-009-9400-5
   STJERNFELDT M, 1986, LANCET, V2, P687
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   TREDANIEL J, 1994, PAEDIATR PERINAT EP, V8, P233, DOI 10.1111/j.1365-3016.1994.tb00455.x
   Tuomisto J, 2009, EUR J CANCER, V45, P1640, DOI 10.1016/j.ejca.2009.01.017
   Vinchon M, 2011, CHILD NERV SYST, V27, P445, DOI 10.1007/s00381-011-1390-4
   Yang J, 2013, AM J EPIDEMIOL, V178, P1648, DOI 10.1093/aje/kwt182
NR 57
TC 10
Z9 10
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 24
PY 2014
VL 9
IS 7
AR e102910
DI 10.1371/journal.pone.0102910
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO5BG
UT WOS:000341354800042
PM 25058491
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, B
   Tarigan, LH
   Bromet, EJ
   Kim, H
AF Liu, Bian
   Tarigan, Lukman H.
   Bromet, Evelyn J.
   Kim, Hyun
TI World Trade Center Disaster Exposure-Related Probable Posttraumatic
   Stress Disorder among Responders and Civilians: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CENTER TERRORIST ATTACK; LOWER RESPIRATORY SYMPTOMS; OF-THE-LITERATURE;
   CENTER RESCUE; RECOVERY WORKERS; MENTAL-HEALTH; PTSD PREVALENCE; CLEANUP
   WORKERS; RISK-FACTORS; SEPTEMBER 11
AB The World Trade Center (WTC) disaster on September 11, 2001 was an unprecedented traumatic event with long-lasting health consequences among the affected populations in the New York metropolitan area. This meta-analysis aimed to estimate the risk of probable posttraumatic stress disorder (PTSD) associated with specific types of WTC exposures. Meta-analytical findings from 10 studies of 3,271 to 20,294 participants yielded 37 relevant associations. The pooled summary odds ratio (OR) was 2.05 (95% confidence interval (CI): 1.82, 2.32), with substantial heterogeneity linked to exposure classification, cohort type, data source, PTSD assessment instrument/criteria, and lapse time since 9/11. In general, responders (e. g. police, firefighters, rescue/recovery workers and volunteers) had a lower probable PTSD risk (OR = 1.61; 95% CI: 1.39, 1.87) compared to civilians (e. g. residents, office workers, and passersby; OR = 2.71, 95% CI: 2.35, 3.12). The differences in ORs between responders and civilians were larger for physical compared to psychosocial exposure types. We also found that injury, lost someone, and witnessed horror were the three (out of six) most pernicious exposures. These findings suggest that these three exposures should be a particular focus in psychological evaluation and treatment programs in WTC intervention and future emergency preparedness efforts.
C1 [Liu, Bian; Kim, Hyun] Hofstra North Shore LIJ Sch Med, Dept Populat Hlth, Great Neck, NY 11021 USA.
   [Tarigan, Lukman H.] Univ Massachusetts, Dept Work Environm, Lowell, MA USA.
   [Bromet, Evelyn J.] SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA.
RP Liu, B (reprint author), Hofstra North Shore LIJ Sch Med, Dept Populat Hlth, Great Neck, NY 11021 USA.
EM bliu@nshs.edu
FU Centers for Disease Control and Prevention (CDC) [1U01OH010399-01];
   National Institute for Occupational Safety and Health (NIOSH)
FX This research was supported by the grant (1U01OH010399-01) from the
   Centers for Disease Control and Prevention (CDC) and National Institute
   for Occupational Safety and Health (NIOSH). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adams RE, 2006, J NERV MENT DIS, V194, P485, DOI 10.1097/01.nmd.0000228503.95503.e9
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berninger A, 2010, AM J IND MED, V53, P1177, DOI 10.1002/ajim.20894
   Berninger A, 2010, PUBLIC HEALTH REP, V125, P556, DOI 10.1177/003335491012500411
   Bills CB, 2008, MT SINAI J MED, V75, P115, DOI 10.1002/msj.20026
   Bowler RM, 2010, AM J IND MED, V53, P1186, DOI 10.1002/ajim.20876
   Brackbill RM, 2009, JAMA-J AM MED ASSOC, V302, P502, DOI 10.1001/jama.2009.1121
   Chiu S, 2011, ANN CLIN PSYCHIATRY, V23, P95
   Corrigan Malachy, 2009, Am J Public Health, V99 Suppl 3, pS702, DOI 10.2105/AJPH.2008.151605
   Debchoudhury I, 2011, PREV MED, V53, P359, DOI 10.1016/j.ypmed.2011.08.034
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DiGrande L, 2008, J TRAUMA STRESS, V21, P264, DOI 10.1002/jts.20345
   DiGrande L, 2011, AM J EPIDEMIOL, V173, P271, DOI 10.1093/aje/kwq372
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   First MB, 2002, STRUCTURED CLIN INTE
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hoven Christina W, 2003, Curr Psychiatry Rep, V5, P101, DOI 10.1007/s11920-003-0026-0
   KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012
   Kim H, 2012, AM J IND MED, V55, P44, DOI 10.1002/ajim.21025
   Kotov R, 2014, POSTTRAUMAT IN PRESS
   Lin S, 2010, INT J OCCUP ENV HEAL, V16, P44
   Lucchini R G, 2012, G Ital Med Lav Ergon, V34, P529
   Luft BJ, 2012, PSYCHOL MED, V42, P1069, DOI 10.1017/S003329171100256X
   Mitka M, 2008, JAMA-J AM MED ASSOC, V300, P779, DOI 10.1001/jama.300.7.779
   Moline JM, 2008, MT SINAI J MED, V75, P67, DOI 10.1002/msj.20022
   Nair HP, 2012, AM J PUBLIC HEALTH, V102, P1964, DOI 10.2105/AJPH.2012.300690
   Neria Y, 2011, AM PSYCHOL, V66, P429, DOI [10.1037/a0024791, 10.1037/0024791]
   Perlman SE, 2011, LANCET, V378, P925, DOI 10.1016/S0140-6736(11)60967-7
   Perrin MA, 2007, AM J PSYCHIAT, V164, P1385, DOI 10.1176/appi.apj.2007.06101645
   Pietrzak RH, 2012, J PSYCHIATR RES, V46, P835, DOI 10.1016/j.jpsychires.2012.03.011
   Reibman J, 2009, J OCCUP ENVIRON MED, V51, P534, DOI 10.1097/JOM.0b013e3181a0365b
   Solan S, 2013, ENVIRON HEALTH PERSP, V121, P699, DOI 10.1289/ehp.1205894
   Soo J, 2011, DISASTER MED PUBLIC, V5, pS197, DOI 10.1001/dmp.2011.48
   Southwick SM, 1997, AM J PSYCHIAT, V154, P173
   Stellman JM, 2008, ENVIRON HEALTH PERSP, V116, P1248, DOI 10.1289/ehp.11164
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1
   Webber MP, 2011, SLEEP BREATH, V15, P283, DOI 10.1007/s11325-010-0379-7
   Webber MP, 2011, AM J IND MED, V54, P661, DOI 10.1002/ajim.20993
   Wisnivesky JP, 2011, LANCET, V378, P888, DOI 10.1016/S0140-6736(11)61180-X
NR 39
TC 35
Z9 35
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 21
PY 2014
VL 9
IS 7
AR e101491
DI 10.1371/journal.pone.0101491
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM0SW
UT WOS:000339558100010
PM 25047411
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, K
   Lin, XL
   Zhou, Q
   Ma, T
   Han, LY
   Mao, GC
   Chen, J
   Yue, X
   Wang, HQ
   Zhang, L
   Jin, GX
   Jiang, JM
   Zhao, JS
   Zou, BB
AF Liu, Kui
   Lin, Xialu
   Zhou, Qi
   Ma, Ting
   Han, Liyuan
   Mao, Guochuan
   Chen, Jian
   Yue, Xia
   Wang, Huiqin
   Zhang, Lu
   Jin, Guixiu
   Jiang, Jianmin
   Zhao, Jinshun
   Zou, Baobo
TI The Associations between Two Vital GSTs Genetic Polymorphisms and Lung
   Cancer Risk in the Chinese Population: Evidence from 71 Studies
SO PLOS ONE
LA English
DT Article
ID GLUTATHIONE-S-TRANSFERASE; OXIDATIVE DNA-DAMAGE; POOLED-ANALYSIS;
   ADJUVANT IMMUNOTHERAPY; ASIAN POPULATIONS; TOBACCO SMOKING;
   SUSCEPTIBILITY; METAANALYSIS; CYP1A1; CARCINOMA
AB Background: The genetic polymorphisms of glutathione S-transferase (GSTs) have been suspected to be related to the development of lung cancer while the current results are conflicting, especially in the Chinese population.
   Methods: Data on genetic polymorphisms of glutathione S-transferase Mu 1 (GSTM1) from 68 studies, glutathione S-transferase theta 1 (GSTT1) from 17 studies and GSTM1-GSTT1 from 8 studies in the Chinese population were reanalyzed on their association with lung cancer risk. Odds ratios (OR) were pooled using forest plots. 9 subgroups were all or partly performed in the subgroup analyses. The Galbraith plot was used to identify the heterogeneous records. Potential publication biases were detected by Begg's and Egger's tests.
   Results: 71 eligible studies were identified after screening of 1608 articles. The increased association between two vital GSTs genetic polymorphisms and lung cancer risk was detected by random-effects model based on a comparable heterogeneity. Subgroup analysis showed a significant relationship between squamous carcinoma (SC), adenocarcinoma (AC) or small cell lung carcinoma (SCLC) and GSTM1 null genotype, as well as SC or AC and GSTT1 null genotype. Additionally, smokers with GSTM1 null genotype had a higher lung cancer risk than non-smokers. Our cumulative meta-analysis demonstrated a stable and reliable result of the relationship between GSTM1 null genotype and lung cancer risk. After the possible heterogeneous articles were omitted, the adjusted risk of GSTs and lung cancer susceptibility increased (fixed-effects model: ORGSTM1 = 1.23, 95% CI: 1.19 to 1.27, P<0.001; ORGSTT1 = 1.18, 95% CI: 1.10 to 1.26, P<0.001; ORGSTM1-GSTT1 = 1.33, 95% CI: 1.10 to 1.61, P = 0.004).
   Conclusions: An increased risk of lung cancer with GSTM1 and GSTT1 null genotype, especially with dual null genotype, was found in the Chinese population. In addition, special histopathological classification of lung cancers and a wide range of gene-environment and gene-gene interaction analysis should be taken into consideration in future studies.
C1 [Liu, Kui; Lin, Xialu; Zhou, Qi; Ma, Ting; Han, Liyuan; Mao, Guochuan; Yue, Xia; Wang, Huiqin; Jin, Guixiu; Zhao, Jinshun; Zou, Baobo] Ningbo Univ, Sch Med, Dept Preventat Med, Zhejiang Prov Key Lab Pathol & Physiol Technol, Ningbo 315211, Zhejiang, Peoples R China.
   [Liu, Kui; Ma, Ting; Jiang, Jianmin] Zhejiang Prov Ctr Dis Control & Prevent, Dept Sci Res & Informat Management, Hangzhou, Zhejiang, Peoples R China.
   [Mao, Guochuan] Municipal Ctr Dis Prevent & Control Ningbo City, Ningbo, Zhejiang, Peoples R China.
   [Chen, Jian] Anhui Med Univ, Dept Epidemiol & Hlth Stat, Hefei, Anhui, Peoples R China.
   [Zhang, Lu] Anhui Med Univ, Sch Hlth Management, Hefei, Anhui, Peoples R China.
RP Jiang, JM (reprint author), Zhejiang Prov Ctr Dis Control & Prevent, Dept Sci Res & Informat Management, Hangzhou, Zhejiang, Peoples R China.
EM jmjiang@cdc.zj.cn; zhaojinshun@nbu.edu.cn; zoubaobo@nbu.edu.cn
FU National Nature Science Foundation of China [81273111]; Foundations of
   Innovative Research Team of Educational Commission of Zhejiang Province
   [T200907]; Nature Science Foundation of Ningbo city [2012A610185];
   Ningbo Scientific Projects [2012C5019, SZX11073]; Scientific Innovation
   Team Project of Ningbo [2011B82014]; Innovative Research Team of Ningbo
   [2009B21002]; K.C. Wong Magna Fund in Ningbo University
FX This work was supported by the National Nature Science Foundation of
   China (Grant No. 81273111), the Foundations of Innovative Research Team
   of Educational Commission of Zhejiang Province (T200907), the Nature
   Science Foundation of Ningbo city (Grant No. 2012A610185), the Ningbo
   Scientific Projects (2012C5019 and SZX11073), the Scientific Innovation
   Team Project of Ningbo (No. 2011B82014), Innovative Research Team of
   Ningbo (2009B21002), and K.C. Wong Magna Fund in Ningbo University. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ai C, 2011, CONT MED, V17, P50
   *AM CANC SOC, 2012, AM CANC SOC CANC FAC
   [白图雅 BAI Tuya], 2011, [中国公共卫生, China Public Health], V27, P723
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bolt HM, 2006, CURR DRUG METAB, V7, P613, DOI 10.2174/138920006778017786
   [曹燕飞 Cao Yanfei], 2004, [生命科学研究, Life science research], V8, P126
   Carlsten C, 2008, AM J EPIDEMIOL, V167, P759, DOI 10.1093/aje/kwm383
   Chan EC, 2005, CANCER GENET CYTOGEN, V162, P10, DOI 10.1016/j.cancergencyto.2005.03.008
   CHAN Y, 2002, J YUNNAN NORMAL U, V22, P52
   Chan-Yeung M, 2004, LUNG CANCER, V45, P155, DOI 10.1016/j.lungcan.2004.01.016
   Chang FH, 2009, ACAD J XIAN JIAOTONG, V21, P225
   Chang Fuhou, 2006, Zhongguo Fei Ai Za Zhi, V9, P413, DOI 10.3779/j.issn.1009-3419.2006.05.04
   Chen Chun-mei, 2012, Zhonghua Yixue Yichuanxue Zazhi, V29, P23, DOI 10.3760/cma.j.issn.1003-9406.2012.01.007
   Chen H, 2008, SHANDONG MED J, V48, P20
   Chen HC, 2006, DIS MARKERS, V22, P141, DOI 10.1155/2006/436497
   Chen LH, 2003, INT J ADV MANUF TECH, V22, P1, DOI 10.1007/s00170-003-1621-2
   Chen S, 1999, CARCINOGENESIS TERAT, V11, P119
   Chen Senqing, 2001, Mutation Research, V458, P41, DOI 10.1016/S1383-5726(01)00011-5
   [陈思东 Chen Sidong], 2004, [肿瘤, Tumor], V24, P99
   Cheng YW, 2001, ENVIRON MOL MUTAGEN, V37, P304, DOI 10.1002/em.1037
   Cheng YW, 2000, EUR J CANCER, V36, P1381, DOI 10.1016/S0959-8049(00)00131-3
   Chou YC, 2005, J MED SCI, V25, P021
   de Mello RA, 2013, BIOMED CENTRAL LT S2, pP57
   DEJONG JL, 1991, BIOCHEM BIOPH RES CO, V180, P15, DOI 10.1016/S0006-291X(05)81248-3
   Dong CT, 2004, J ENV OCCUP MED, V21, P440
   Du GuoBo, 2011, Chinese Clinical Oncology, V16, P602
   Ebina T, 2008, LUNG CANCER, V60, P246, DOI 10.1016/j.lungcan.2007.09.016
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fan J, 2010, J ONCOLOGY, V16, P922
   Frova C, 2006, BIOMOL ENG, V23, P149, DOI 10.1016/j.bioeng.2006.05.020
   FRYER AA, 1993, BIOCHEM J, V295, P313, DOI 10.1042/bj2950313
   Gackowski D, 2003, CANCER RES, V63, P4899
   Gao JR, 1998, CARCINOGENESIS TERAT, V10, P149
   Gao Y, 1999, MUTAT RES-GEN TOX EN, V444, P441, DOI 10.1016/S1383-5718(99)00092-3
   Ge H, 1996, LUNG CANCER-J IASLC, V15, P355, DOI 10.1016/0169-5002(95)00598-6
   Gu Yan-Fei, 2007, Zhonghua Yi Xue Za Zhi, V87, P3064
   Gu Yanfei, 2004, Zhongguo Fei Ai Za Zhi, V7, P112, DOI 10.3779/j.issn.1009-3419.2004.02.08
   Han RL, 2012, CENTRAL S PHARM, V10, P1
   Hardy GH, 1908, SCIENCE, V28, P49, DOI 10.1126/science.28.706.49
   He DX, 2006, CANC RES PREVENTION, V33, P383
   He DX, 2006, CANC RES PREVENTION, V33, P308
   Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194
   Hedges LV, 1998, PSYCHOL METHODS, V3, P486, DOI 10.1037/1082-989X.3.4.486
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hosgood HD, 2007, MUTAT RES-REV MUTAT, V636, P134, DOI 10.1016/j.mrrev.2007.02.002
   Hu L, 2012, PHARMACOGENET GENOM, V22, P812, DOI 10.1097/FPC.0b013e328358d92b
   Huang X-H, 2004, J PUBLIC HLTH PREV M, V15, P24
   Iwai K, 2012, CANCER IMMUNOL IMMUN, V61, P1781, DOI 10.1007/s00262-012-1226-4
   JARUGA P, 1994, FEBS LETT, V341, P59, DOI 10.1016/0014-5793(94)80240-8
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jin YT, 2011, CANCER EPIDEMIOL, V35, P182, DOI 10.1016/j.canep.2010.06.004
   Jin YT, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-422
   KIMURA H, 1995, LUNG CANCER-J IASLC, V13, P31, DOI 10.1016/0169-5002(95)00478-J
   Klug SJ, 2009, LANCET ONCOL, V10, P772, DOI 10.1016/S1470-2045(09)70187-1
   Lam WK, 2004, INT J TUBERC LUNG D, V8, P1045
   Lan Q, 1999, Wei Sheng Yan Jiu, V28, P9
   Lan Q, 2004, TOXICOLOGY, V198, P301, DOI 10.1016/j.tox.2004.02.006
   Lee KM, 2008, CANCER EPIDEM BIOMAR, V17, P1120, DOI 10.1158/1055-9965.EPI-07-2786
   Lei FM, 2007, MODERN PREVENTIVE ME, V34, P724
   Li C, 2011, CATAL TODAY, V175, P1, DOI 10.1016/j.cattod.2011.08.002
   Li Dairong, 2005, Zhongguo Fei Ai Za Zhi, V8, P14, DOI 10.3779/j.issn.1009-3419.2005.01.03
   Li RM, 2012, CANCER IMMUNOL IMMUN, V61, P2125, DOI 10.1007/s00262-012-1260-2
   Li WY, 2012, LUNG, V190, P91, DOI 10.1007/s00408-011-9338-8
   Li WY, 2003, TUBERCULOSIS THORACI, V4, P280
   Li Y, 2011, J CHINESE PRACTICAL, V25, P140
   [李英 LI Ying], 2006, [郑州大学学报. 医学版, Journal of Zhengzhou University.Medical Sciences], V41, P1061
   [梁戈玉 Liang Geyu], 2004, [遗传, Hereditas(Beijing)], V26, P584
   Liu DZ, 2012, CLIN CHIM ACTA, V414, P188, DOI 10.1016/j.cca.2012.09.016
   [刘京男 Liu Jingnan], 2012, [基础医学与临床, Basic & Clinical Medicine], V32, P1194
   Liu K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057043
   Liu Q, 2008, SHANDONG MED J, V48, P32
   Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/BF00207507
   London SJ, 2000, LANCET, V356, P724, DOI 10.1016/S0140-6736(00)02631-3
   Lu WF, 2002, INT J CANCER, V102, P275, DOI 10.1002/jhc.10712
   [罗晨玲 Luo Chenling], 2004, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V31, P1218
   Luo CL, 2004, CHINESE J CLIN ONCOL, V31, P1224
   Nebert DW, 1996, DNA CELL BIOL, V15, P273, DOI 10.1089/dna.1996.15.273
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Paz-Elizur T, 2003, J NATL CANCER I, V95, P1312, DOI 10.1093/jnci/djg033
   PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271
   Qi XS, 2008, CHIN OCCUP MED, V35, P361
   Qi XS, 2008, CHINA OCCUPATIONAL M, V35, P367
   [钱碧云 Qian BiYun], 2006, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V33, P500
   QIAO G, 2002, ACAD J SUMS, V23, P25
   Qu YH, 1998, ZHONGLIU, V18, P80
   Raimondi S, 2006, AM J EPIDEMIOL, V164, P1027, DOI 10.1093/aje/kwj321
   Ramalingam SS, 2011, CA-CANCER J CLIN, V61, P91, DOI 10.3322/caac.20102
   Sasco AJ, 2004, LUNG CANCER, V45, pS3, DOI 10.1016/j.lungcan.2004.07.000
   Schaid DJ, 1999, AM J EPIDEMIOL, V149, P706
   SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293
   Shi XQ, 2008, LUNG CANCER, V59, P155, DOI 10.1016/j.lungcan.2007.08.004
   [石云 Shi Yun], 2002, [华中科技大学学报. 医学版, Journal of Huazhong University of Science and Technology], V31, P14
   Shukla RK, 2013, ASIAN PAC J CANCER P, V14, P3345, DOI 10.7314/APJCP.2013.14.5.3345
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Smith G, 1995, CANCER SURV, V25, P27
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Sun GF, 1997, CANCER LETT, V113, P169, DOI 10.1016/S0304-3835(97)04612-0
   Sun GF, 1995, CHIN J TUBERC RESP D, V18, P167
   Trikalinos TA, 2006, AM J EPIDEMIOL, V163, P300, DOI 10.1093/aje/kwj046
   Tucker ZCG, 2012, CANCER TREAT REV, V38, P650, DOI 10.1016/j.ctrv.2011.11.008
   Tyczynski JE, 2003, LANCET ONCOL, V4, P45, DOI 10.1016/S1470-2045(03)00960-4
   Udomsinprasert R, 2005, BIOCHEM J, V388, P763, DOI 10.1042/BJ20042015
   Vlastos F, 2013, J CANC THERAPY, V04, P24
   Wang J, 2003, THEOR COMPUT SCI, V296, P1, DOI 10.1016/S0304-3975(02)00427-9
   Wang JW, 2003, CANCER LETT, V201, P185, DOI 10.1016/S0304-3835(03)00480-4
   Wang Na, 2012, Wei Sheng Yan Jiu, V41, P251
   [王启明 WANG Qiming], 2006, [肿瘤防治研究, Cancer Research on Prevention and Treatment], V33, P8
   Wang YD, 2010, CANCER EPIDEMIOL, V34, P593, DOI 10.1016/j.canep.2010.05.008
   Wang Yan-ge, 2007, Journal of Plant Resources and Environment, V16, P1
   Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675
   [夏英 XIA Ying], 2008, [中华放射医学与防护杂志, Chinese Journal of Radiological Medicine and Protection], V28, P327
   Yang XHR, 2004, CANCER LETT, V214, P197, DOI 10.1016/j.canlet.2004.06.040
   Yang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062181
   Yao WA, 2006, STRUCT ENG MECH, V22, P1
   Yao ZG, 2012, CHINESE J MED GUIDE, V14, P185
   Yao ZG, 2012, CHINESE J MED GUIDE, V14, P188
   YE W, 2004, CHIN J PUBLIC HLTH, V20, P1120
   Ye WeiYun, 2005, Acta Nutrimenta Sinica, V27, P17
   Ye Z, 2006, PLOS MED, V3, P524, DOI 10.1371/journal.pmed.0030091
   Yuan Tianzhu, 2005, Zhongguo Fei Ai Za Zhi, V8, P107, DOI 10.3779/j.issn.1009-3419.2005.02.07
   [张吉凯 Zhang Jiakai], 2002, [中国病理生理杂志, Chinese Journal of Pathophysiology], V18, P352
   ZHANG JK, 2002, CHINA PUBLIC HLTH, V18, P273
   Zhang JF, 2011, ACS CATAL, V1, P32, DOI 10.1021/cs100047p
   [章龙珍 Zhang Longzhen], 2002, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V29, P536
   Zhao JS, 2005, INT J ONCOL, V27, P247
   Zheng Dejie, 2010, Zhongguo Fei Ai Za Zhi, V13, P506, DOI 10.3779/j.issn.1009-3419.2010.05.23
   Zhou HF, 2013, MOL BIOL REP, V40, P5713, DOI 10.1007/s11033-013-2674-4
   Zhu Xiao-Xia, 2010, Zhonghua Jie He He Hu Xi Za Zhi, V33, P817
NR 128
TC 9
Z9 10
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 18
PY 2014
VL 9
IS 7
AR e102372
DI 10.1371/journal.pone.0102372
PG 26
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM1OC
UT WOS:000339615200050
PM 25036724
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Tian, Y
   Wang, JR
   Ye, Y
   Sun, LQ
   Fan, YR
   Wang, L
   Li, J
   Wang, ZX
   Wang, KM
AF Tian, Yun
   Wang, Jirong
   Ye, Ying
   Sun, Liqun
   Fan, Yingrui
   Wang, Li
   Li, Juan
   Wang, Zhaoxia
   Wang, Keming
TI Apolipoprotein E Polymorphism and Colorectal Neoplasm: Results from a
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CHOLESTEROL TRANSPORT PROTEIN; TRIGLYCERIDE-RICH PARTICLES;
   AMINO-ACID-SEQUENCE; E GENOTYPE; E PHENOTYPE; METABOLIC GENOTYPES;
   LIPID-METABOLISM; BREAST-CANCER; RECTAL-CANCER; SERUM-LIPIDS
AB To investigate the relationship of Apolipoprotein E (APOE) gene polymorphism to colorectal neoplasia (CRN), we performed a systematic review and meta-analysis. Eligible studies were identified through a systematic literature review from PubMed, EMBASE, and the Science Citation Index up to February 2014. A combined analysis was performed, followed by a subgroup analyses stratified by the study design. We used data collected from 8 prospective studies involving respectively a total of 9243 participants and 4310 CRN cases which including 438 patients with colorectal adenoma (CRA), and 3873 patients with colorectal carcinoma (CRC). The pooled data from this meta-analysis indicated there was no significant association between APOE polymorphism and CRN (epsilon 2: P = 0.51, OR 1.04 95% CI 0.93 to 1.16; epsilon 4: P = 0.72, OR 0.98 95% CI 0.90 to 1.07). Interestingly, subgroup analysis demonstrated there was a significant decreased risk for proximal CRN in patients with APOE epsilon 4 (P = 0.0007, OR 0.52 95% CI 0.35 to 0.76). Data showed no significant association between APOE genotype and overall CRN. However, compared with those carry APOE epsilon 3 alleles, persons with APOE epsilon 4 genotype have significant decreased risk suffering from proximal CRN but not from distal CRN.
C1 [Tian, Yun; Wang, Jirong; Fan, Yingrui; Wang, Li; Li, Juan; Wang, Zhaoxia; Wang, Keming] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 2, Nanjing, Jiangsu, Peoples R China.
   [Ye, Ying] Xuzhou Med Coll, Emergency Ctr, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China.
   [Sun, Liqun] Nanjing Med Univ, Dept Intens Care Unit, Affiliated Hosp 2, Nanjing, Jiangsu, Peoples R China.
RP Wang, KM (reprint author), Nanjing Med Univ, Dept Oncol, Affiliated Hosp 2, Nanjing, Jiangsu, Peoples R China.
EM drkemingwang@sina.cn
FU National Natural Science Foundation of China [81200263, 81302110]
FX Funding provided by the National Natural Science Foundation of China
   (Grant 81200263 and 81302110). The funders had no role in study design,
   decision to publish, or preparation of the manuscript.
CR Anderson WF, 2002, J NATL CANCER I, V94, P1126
   BAYERDORFFER E, 1995, GUT, V36, P268, DOI 10.1136/gut.36.2.268
   BAYERDORFFER E, 1993, GASTROENTEROLOGY, V104, P145, DOI 10.1016/0016-5085(93)90846-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bretsky P, 2003, NEUROLOGY, V60, P1077, DOI 10.1212/01.WNL.0000055875.26908.24
   Butler WJ, 2001, J GASTROEN HEPATOL, V16, P631, DOI 10.1046/j.1440-1746.2001.02501.x
   Cedazo-Minguez A, 2003, J NEUROCHEM, V87, P1152, DOI 10.1046/j.1471-4159.2003.02088.x
   Chang SJ, 2006, BREAST CANCER RES TR, V98, P109, DOI 10.1007/s10549-005-9137-0
   Cohn LD, 2003, PSYCHOL METHODS, V8, P243, DOI 10.1037/1082-989X.8.3.243
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Davidson NO, 1996, GASTROENTEROLOGY, V110, P2006, DOI 10.1053/gast.1996.v110.agast962006
   Davignon J, 1988, Trans Am Clin Climatol Assoc, V99, P100
   DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Ganan A, 2004, HUM BIOL, V76, P253, DOI 10.1353/hub.2004.0031
   Grocott HP, 2001, J THORAC CARDIOV SUR, V122, P622, DOI 10.1067/mtc.2001.115152
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HILL MJ, 1989, BAILLIERE CLIN GASTR, V3, P567, DOI 10.1016/0950-3528(89)90018-3
   Ho YY, 2000, BIOCHEMISTRY-US, V39, P4746, DOI 10.1021/bi992294a
   Jofre-Monseny L, 2007, BRIT J NUTR, V97, P864, DOI 10.1017/S0007114507669219
   Kervinen K, 1996, GASTROENTEROLOGY, V110, P1785, DOI 10.1053/gast.1996.v110.pm8964404
   KESANIEMI YA, 1987, J CLIN INVEST, V80, P578, DOI 10.1172/JCI113107
   Khan TA, 2013, INT J EPIDEMIOL, V42, P475, DOI 10.1093/ije/dyt034
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   MIETTINEN TA, 1991, ANN MED, V23, P181, DOI 10.3109/07853899109148045
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Mrkonjic M, 2009, BRIT J CANCER, V100, P1966, DOI 10.1038/sj.bjc.6605097
   MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944
   Niemi M., 2002, EUR J INTERN MED, V13, P37
   RALL SC, 1982, J BIOL CHEM, V257, P4171
   REDDY BS, 1973, J NATL CANCER I, V50, P1437, DOI 10.1093/jnci/50.6.1437
   Roberts-Thomson IC, 1999, EUR J CANCER PREV, V8, P207, DOI 10.1097/00008469-199906000-00008
   Saadat M, 2012, CANCER RES TREAT, V44, P121, DOI 10.4143/crt.2012.44.2.121
   SANDLER RS, 1993, JNCI-J NATL CANCER I, V85, P884, DOI 10.1093/jnci/85.11.884
   SCHWIEGELSHOHN B, 1995, J BIOL CHEM, V270, P1761, DOI 10.1074/jbc.270.4.1761
   Shin A, 2010, ASIAN PAC J CANCER P, V11, P281
   Shinomiya S, 2001, CANCER LETT, V164, P33, DOI 10.1016/S0304-3835(00)00724-2
   Slattery ML, 2005, CARCINOGENESIS, V26, P1422, DOI 10.1093/carcin/bgi088
   Slattery ML, 2005, NUTR CANCER, V51, P155, DOI 10.1207/s15327914nc5102_5
   Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013
   Souza DRS, 2009, BRAZ J MED BIOL RES, V42, P397, DOI 10.1590/S0100-879X2009000500001
   STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4
   Swertfeger DK, 2001, FRONT BIOSCI, V6, pD526, DOI 10.2741/Swertfeg
   UTERMANN G, 1987, AM HEART J, V113, P433, DOI 10.1016/0002-8703(87)90610-7
   VOGEL T, 1994, J CELL BIOCHEM, V54, P299, DOI 10.1002/jcb.240540306
   Watson MA, 2003, CLIN SCI, V104, P537, DOI 10.1042/CS20020329
   WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077
   Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250
   XHIGNESSE M, 1991, ARTERIOSCLER THROMB, V11, P1100, DOI 10.1161/01.ATV.11.4.1100
   Xue P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045849
   Zhou ZY, 2006, SAUDI MED J, V27, P161
NR 54
TC 2
Z9 2
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 16
PY 2014
VL 9
IS 7
AR e102477
DI 10.1371/journal.pone.0102477
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO4KM
UT WOS:000341306600077
PM 25029444
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, N
   Yang, L
   Ou, W
   Zhang, L
   Zhang, SL
   Wang, SY
AF Li, Ning
   Yang, Lu
   Ou, Wei
   Zhang, Liang
   Zhang, Song-liang
   Wang, Si-yu
TI Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with
   Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small
   Cell Lung Cancer
SO PLOS ONE
LA English
DT Article
ID PHASE-III TRIAL; PROGRESSION-FREE SURVIVAL; OPEN-LABEL;
   RANDOMIZED-TRIAL; SUPPORTIVE CARE; GEFITINIB; DOCETAXEL; ERLOTINIB;
   EFFICACY; MULTICENTER
AB Background: Since efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) versus chemotherapy in the treatment of patients with pretreated advanced non-small cell lung cancer (NSCLC) remain controversial, we performed a meta-analysis to compare them.
   Methods: An internet search of several databases was performed, including PubMed, Embase, and the Cochrane database. Randomized trials that compared an EGFR-TKI with chemotherapy in the second-line setting were included. The outcomes were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and grade 3-4 toxicities. The PFS, OS for the EGFR mutation-positive (EGFR M+) and EGFR mutation-negative (EGFR M-) subgroups were pooled. The pooled hazard ratios (HRs) and odds ratios (ORs) with their corresponding confidence intervals (CIs) were calculated on the STATA software.
   Results: Our meta-analysis combined 3,825 patients from 10 randomized trials. Overall, EGFR-TKIs and second-line chemotherapy have equivalent efficacy in terms of PFS (HR, 1.03; 95% CI, 0.87-1.21; P = 0.73; I-2 = 78.7%, P-heterogeneity<0.001), OS (HR, 1.00; 95% CI, 0.92-1.08; P = 0.90; I-2 = 0.0%, P-heterogeneity = 0.88), and ORR (OR, 1.34; 95% CI, 0.86-2.08; P = 0.20; I-2 = 73.1%, P-heterogeneity<0.001). However, subgroup analysis based on EGFR mutation status showed that second-line chemotherapy significantly improved PFS (HR, 1.35; 95% CI, 1.09-1.66; P = 0.01; I-2 = 55.7%, P-heterogeneity = 0.046) for EGFR M- patients, whereas OS was equal (HR, 0.96; 95% CI, 0.77-1.19; P = 0.69; I-2 = 0.0%, P-heterogeneity = 0.43); EGFR-TKIs significantly improved PFS (HR, 0.28; 95% CI, 0.15-0.53; P<0.001; I-2 = 4.1%, P-heterogeneity = 0.35) for EGFR M+ patients, whereas OS was equal (HR, 0.86; 95% CI, 0.44-1.68; P = 0.65; I-2 = 0.0%, P-heterogeneity = 0.77). Compared with chemotherapy, EGFR-TKIs led to more grade 3-4 rash, but less fatigue/asthenia disorder, leukopenia and thrombocytopenia.
   Conclusions: Our analysis suggests that chemotherapy in the second-line setting can prolong PFS in EGFR M- patients, whereas it has no impact on OS. EGFR-TKIs seem superior over chemotherapy as second-line therapy for EGFR M+ patients. Our findings support obtaining information on EGFR mutational status before initiation of second-line treatment.
C1 [Li, Ning; Ou, Wei; Zhang, Song-liang; Wang, Si-yu] Sun Yat Sen Univ, Dept Thorac Surg, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.
   [Yang, Lu] Sun Yat Sen Univ, Dept Breast Oncol, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.
   [Zhang, Liang] Tianjin First Ctr Hosp, Dept Thorac Surg, Tianjin, Peoples R China.
RP Wang, SY (reprint author), Sun Yat Sen Univ, Dept Thorac Surg, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.
EM wsysums@163.net
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Ciuleanu T, 2012, LANCET ONCOL, V13, P300, DOI 10.1016/S1470-2045(11)70385-0
   Cufer T, 2006, ANTI-CANCER DRUG, V17, P401, DOI 10.1097/01.cad.0000203381.99490.ab
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fossella FV, 2000, J CLIN ONCOL, V18, P2354, DOI 10.1200/JCO.2000.18.12.2354
   Fukuoka M, 2011, J CLIN ONCOL, V29, P2866, DOI 10.1200/JCO.2010.33.4235
   Gao GH, 2013, J CLIN ONCOL S, V31
   Garassino MC, 2012, J CLIN ONCOL S, V30
   Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hotta K, 2013, LUNG CANCER, V79, P20, DOI 10.1016/j.lungcan.2012.10.007
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Karampeazis A, 2013, CANCER-AM CANCER SOC, V119, P2754, DOI 10.1002/cncr.28132
   Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4
   KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011
   Lee CK, 2013, JNCI-J NATL CANCER I, V105, P595, DOI 10.1093/jnci/djt072
   Lee DH, 2010, CLIN CANCER RES, V16, P1307, DOI 10.1158/1078-0432.CCR-09-1903
   Maruyama R, 2008, J CLIN ONCOL, V26, P4244, DOI 10.1200/JCO.2007.15.0185
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
   Mok TSK, 2009, J CLIN ONCOL, V27, P5080, DOI 10.1200/JCO.2008.21.5541
   OKANO Y, 2013, J CLIN ONCOL S, V31
   Paz-Ares L, 2012, LANCET ONCOL, V13, P225, DOI 10.1016/S1470-2045(12)70001-3
   Qi WX, 2012, ASIAN PAC J CANCER P, V13, P5177, DOI 10.7314/APJCP.2012.13.10.5177
   Scagliotti GV, 2002, J CLIN ONCOL, V20, P4285, DOI 10.1200/JCO.2002.02.068
   Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095
   Soria JC, 2010, ANN ONCOL, V21, P2324, DOI 10.1093/annonc/mdq204
   Sun JM, 2012, CANCER-AM CANCER SOC, V118, P6234, DOI 10.1002/cncr.27630
   Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Wang SY, 2013, J CLIN ONCOL S, V31, P2013
   Yang J, 2013, J CLIN ONCOL, V31
NR 34
TC 26
Z9 27
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 16
PY 2014
VL 9
IS 7
AR e102777
DI 10.1371/journal.pone.0102777
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO4KM
UT WOS:000341306600099
PM 25029199
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zuo, PY
   Chen, XL
   Liu, YW
   Xiao, CL
   Liu, CY
AF Zuo, Pei-Yuan
   Chen, Xing-Lin
   Liu, Yu-Wei
   Xiao, Chang-Liang
   Liu, Cheng-Yun
TI Increased Risk of Cerebrovascular Events in Patients with Cancer Treated
   with Bevacizumab: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PHASE-III TRIAL; ARTERIAL THROMBOEMBOLIC EVENTS; DOUBLE-BLIND; PLUS
   BEVACIZUMAB; COLORECTAL-CANCER; PLACEBO; CHEMOTHERAPY; COMBINATION;
   PACLITAXEL; OVARIAN
AB Arterial ischemia and hemorrhage are associated with bevacizumab, an inhibitor of vascular endothelial growth factor that is widely used to treat many types of cancers. As specific types of arterial ischemia and hemorrhage, cerebrovascular events such as central nervous system (CNS) ischemic events and CNS hemorrhage are serious adverse events. However, increased cerebrovascular events have not been uniformly reported by previous studies. New randomized controlled trials (RCTs) have been reported in recent years and we therefore conducted an up-to-date meta-analysis of RCTs to fully characterize the risk of cerebrovascular events with bevacizumab. We searched the databases of PubMed, Web of Science, and the American Society of Clinical Oncology conferences to identify relevant clinical trials up to February 2014. Eligible studies included prospective RCTs that directly compared patients with cancer treated with and without bevacizumab. A total of 12,917 patients from 17 RCTs were included in our analysis. Patients treated with bevacizumab had a significantly increased risk of cerebrovascular events compared with patients treated with control medication, with a relative risk of 3.28 (95% CI, 1.97-5.48). The risks of CNS ischemic events and CNS hemorrhage were increased compared with control, with RRs of 3.22 (95% CI, 1.71-6.07) and 3.09 (95% CI, 1.36-6.99), respectively. Risk varied with the bevacizumab dose, with RRs of 3.97 (95% CI, 2.15-7.36) and 1.96 (95% CI, 0.76-5.06) at 5 and 2.5 mg/kg/week, respectively. Higher risks were observed in patients with metastatic colorectal cancer (RR, 6.42; 95% CI, 1.76-35.57), and no significant risk was observed in other types of tumors. In conclusion, the addition of bevacizumab significantly increased the risk of cerebrovascular events compared with controls, including CNS ischemic events and CNS hemorrhage. The risk may vary with bevacizumab dose and tumor type.
C1 [Zuo, Pei-Yuan; Chen, Xing-Lin; Liu, Yu-Wei; Xiao, Chang-Liang; Liu, Cheng-Yun] Huazhong Univ Sci & Technol, Minist Hlth, Key Lab Geriatr, Dept Geriatr,Union Hosp,Tongji Med Coll, Wuhan 430074, Peoples R China.
RP Liu, CY (reprint author), Huazhong Univ Sci & Technol, Minist Hlth, Key Lab Geriatr, Dept Geriatr,Union Hosp,Tongji Med Coll, Wuhan 430074, Peoples R China.
EM lcyun@medmail.com.cn
FU National Natural Science Foundation of China [81370468]
FX This study is supported by the National Natural Science Foundation of
   China (No81370468). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aghajanian C, 2012, J CLIN ONCOL, V30, P2039, DOI 10.1200/JCO.2012.42.0505
   Allegra CJ, 2009, J CLIN ONCOL, V27, P3385, DOI 10.1200/JCO.2009.21.9220
   Becker J, 2010, CLIN CANCER RES, V16, P1431, DOI 10.1158/1078-0432.CCR-09-1936
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390
   Carden CP, 2008, NEURO-ONCOLOGY, V10, P624, DOI 10.1215/15228517-2008-010
   Chen XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067120
   Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ebbers HC, 2013, DRUG DISCOV TODAY, V18, P872, DOI 10.1016/j.drudis.2013.05.004
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Hapani S, 2010, ONCOLOGY-BASEL, V79, P27, DOI 10.1159/000314980
   Herbst RS, 2011, LANCET, V377, P1846, DOI 10.1016/S0140-6736(11)60545-X
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kelly WK, 2012, J CLIN ONCOL, V30, P1534, DOI 10.1200/JCO.2011.39.4767
   Kim KB, 2012, J CLIN ONCOL, V30, P34, DOI 10.1200/JCO.2011.34.6270
   Kindler HL, 2007, J THORAC ONCOL, V2, pS374, DOI 10.1097/01.JTO.0000283221.63767.ba
   Kindler HL, 2010, J CLIN ONCOL, V28, P3617, DOI 10.1200/JCO.2010.28.1386
   Letarte N, 2013, CANCER CHEMOTH PHARM, V71, P1561, DOI 10.1007/s00280-013-2155-4
   Meade MO, 1997, ANN INTERN MED, V127, P531, DOI 10.7326/0003-4819-127-7-199710010-00005
   Meyerhardt JA, 2012, J CLIN ONCOL, V30, P608, DOI 10.1200/JCO.2011.38.9650
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Narita Y, 2013, JPN J CLIN ONCOL, V43, P587, DOI 10.1093/jjco/hyt051
   Okines AFC, 2013, ANN ONCOL, V24, P702, DOI 10.1093/annonc/mds533
   Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799
   Price TJ, 2012, ANN ONCOL, V23, P1531, DOI 10.1093/annonc/mdr488
   Ranpura V, 2010, AM J HYPERTENS, V23, P460, DOI 10.1038/ajh.2010.25
   Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396
   Rini BI, 2010, J CLIN ONCOL, V28, P2137, DOI 10.1200/JCO.2009.26.5561
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/cjm086
   Schutz FAB, 2011, ANN ONCOL, V22, P1404, DOI 10.1093/annonc/mdq587
   Seet RCS, 2011, NEUROCRIT CARE, V15, P421, DOI 10.1007/s12028-011-9552-5
   Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375
   Zhu XL, 2007, AM J KIDNEY DIS, V49, P186, DOI 10.1053/j.ajkd.2006.11.039
NR 38
TC 25
Z9 25
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 15
PY 2014
VL 9
IS 7
AR e102484
DI 10.1371/journal.pone.0102484
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM6RN
UT WOS:000339992400079
PM 25025282
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Lv, MM
   Zhu, XY
   Zhong, SL
   Chen, WX
   Hu, Q
   Ma, TF
   Zhang, J
   Zhang, XH
   Tang, JH
   Zhao, JH
AF Lv, Mengmeng
   Zhu, Xingya
   Zhong, Shanliang
   Chen, Weixian
   Hu, Qing
   Ma, Tengfei
   Zhang, Jun
   Zhang, Xiaohui
   Tang, Jinhai
   Zhao, Jianhua
TI Radial Scars and Subsequent Breast Cancer Risk: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID COMPLEX SCLEROSING LESION; SCREENING-PROGRAM; DISEASE; WOMEN; CARCINOMA;
   BIOPSIES; HEALTH; BIAS
AB Background: The relationship between radial scars and breast cancer is unclear, as the results of different studies are inconsistent. We aim to solve the controversy and assess the breast cancer risk of radial scars.
   Methods: Case-control or cohort studies about radial scars and breast cancer risk published in PubMed, Web of Science and the Cochrane Library from 2000 to 2013 were searched. Heterogeneity for the eligible data was assessed and a pooled odds ratio (OR) with 95% confidence interval (CI) was calculated.
   Results: Five observational studies involving 2521 cases and 20290 controls were included in our study. From pooled analysis, radial scars were found to have a 1.33 fold increased risk of breast cancer, but which was not significant (P = 0.138). Sample size contributed to heterogeneity. In subgroup analysis, the results pooled from studies with sample size >2000 show that presence of radial scars was associated with 1.6 times breast cancer risk compared to absence of radial scars. Radial scars increased the risk of breast cancer among women with proliferative disease without atypia, but no significant association between radial scars and carcinoma was noted among women with atypical hyperplasia.
   Conclusions: Radial scars tend to be associated with an increased breast cancer risk. Radial scars should be considered among women with proliferative disease without atypia, while atypical hyperplasia is still the primary concern among women with both radial scars and atypical hyperplasia.
C1 [Lv, Mengmeng; Chen, Weixian; Hu, Qing; Zhang, Jun; Tang, Jinhai] Nanjing Med Univ, Canc Inst Jiangsu Prov, Dept Gen Surg, Affiliated Canc Hosp, Nanjing, Jiangsu, Peoples R China.
   [Lv, Mengmeng; Zhu, Xingya] Nanjing Med Univ, Clin Sch 1, Nanjing, Jiangsu, Peoples R China.
   [Zhu, Xingya] Nanjing Med Univ, Gulou Clin Med Coll, Nanjing, Jiangsu, Peoples R China.
   [Zhong, Shanliang; Ma, Tengfei; Zhang, Xiaohui; Zhao, Jianhua] Nanjing Med Univ, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Ctr Clin Lab, Nanjing, Jiangsu, Peoples R China.
RP Tang, JH (reprint author), Nanjing Med Univ, Canc Inst Jiangsu Prov, Dept Gen Surg, Affiliated Canc Hosp, Nanjing, Jiangsu, Peoples R China.
EM jss_zlyy@163.com; jsslcjyzx@126.com
OI Zhong, Shanliang/0000-0001-8200-0511
CR Aroner SA, 2013, BREAST CANCER RES TR, V139, P277, DOI 10.1007/s10549-013-2535-9
   AZAVEDO E, 1992, EUR J RADIOL, V15, P18, DOI 10.1016/0720-048X(92)90196-G
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berg JC, 2008, BREAST CANCER RES TR, V108, P167, DOI 10.1007/s10549-007-9605-9
   Bunting DM, 2011, EJSO-EUR J SURG ONC, V37, P709, DOI 10.1016/j.ejso.2011.04.011
   Cohen MA, 2000, AM J ROENTGENOL, V174, P1075, DOI 10.2214/ajr.174.4.1741075
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DouglasJones AG, 1997, HISTOPATHOLOGY, V30, P214, DOI 10.1046/j.1365-2559.1997.d01-600.x
   DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fasih T, 2005, EJSO-EUR J SURG ONC, V31, P1125, DOI 10.1016/j.ejso.2005.04.004
   FISHER ER, 1979, AM J CLIN PATHOL, V71, P240
   FROUGE C, 1995, RADIOLOGY, V195, P623, DOI 10.1148/radiology.195.3.7753984
   Hartmann LC, 2005, NEW ENGL J MED, V353, P229, DOI 10.1056/NEJMoa044383
   Iqbal M, 2002, HUM PATHOL, V33, P715, DOI 10.1053/hupa.2002.125375
   Jacobs TW, 2002, HUM PATHOL, V33, P29, DOI 10.1053/hupa.2002.30190
   Jacobs TW, 1999, NEW ENGL J MED, V340, P430, DOI 10.1056/NEJM199902113400604
   Kabat GC, 2010, CANCER CAUSE CONTROL, V21, P821, DOI 10.1007/s10552-010-9508-7
   King TA, 2000, AM J SURG, V180, P428, DOI 10.1016/S0002-9610(00)00506-7
   Linell F, 1980, Acta Pathol Microbiol Scand Suppl, P1
   Manfrin E, 2008, BREAST CANCER RES TR, V107, P371, DOI 10.1007/s10549-007-9569-9
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   NIELSEN M, 1985, HISTOPATHOLOGY, V9, P287, DOI 10.1111/j.1365-2559.1985.tb02446.x
   NIELSEN M, 1987, CANCER, V59, P1019, DOI 10.1002/1097-0142(19870301)59:5<1019::AID-CNCR2820590528>3.0.CO;2-N
   Patterson JA, 2004, EJSO, V30, P1065, DOI 10.1016/j.ejso.2004.08.004
   Sanders ME, 2006, CANCER-AM CANCER SOC, V106, P1453, DOI 10.1002/cncr.21730
   Schnitt SJ, 2003, AM J SURG PATHOL, V27, P836, DOI 10.1097/00000478-200306000-00017
   Shaaban AM, 2002, AM J SURG PATHOL, V26, P421, DOI 10.1097/00000478-200204000-00003
   SLOANE JP, 1993, HISTOPATHOLOGY, V23, P225, DOI 10.1111/j.1365-2559.1993.tb01194.x
   WELLINGS SR, 1984, HUM PATHOL, V15, P475, DOI 10.1016/S0046-8177(84)80083-0
   Worsham MJ, 2007, BREAST J, V13, P115, DOI 10.1111/j.1524-4741.2007.00388.x
   Worsham MJ, 2009, BREAST CANCER RES TR, V118, P1, DOI 10.1007/s10549-008-0198-8
NR 32
TC 3
Z9 4
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 14
PY 2014
VL 9
IS 7
AR e102503
DI 10.1371/journal.pone.0102503
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM1PC
UT WOS:000339618600087
PM 25019286
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, B
   Wu, HX
   Liu, XY
   Lin, HW
   Li, J
AF Wu, Bin
   Wu, Haixiang
   Liu, Xiaoyan
   Lin, Houwen
   Li, Jin
TI Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to
   Neovascularisation: A Meta-Analysis of Randomised Controlled Trials
SO PLOS ONE
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; MACULAR DEGENERATION; THERAPY; ANGIOGENESIS;
   CANCER; EVENTS
AB Background: Bevacizumab is believed to be as effective and safe as ranibizumab for ophthalmic diseases; however, its magnitude of effectiveness and safety profile remain controversial. Thus, a meta-analysis and systematic review appears necessary.
   Methods: PubMed and EMBASE were systematically searched with no restrictions. All relevant citations comparing ranibizumab and bevacizumab were considered for inclusion. Pooled effect estimates were obtained using a fixed-and random-effects meta-analysis.
   Results: Nine independent randomised-controlled clinical trials (RCTs) involving 2,289 participants were identified. Compared with bevacizumab, the overall combined weighted mean difference (WMD) of the mean change in visual acuity for ranibizumab was 0.52 letters (95% CI 20.11-1.14). The odds ratios (ORs) of gaining >= 15, gaining 5-14, losing 5-14 and losing <= 15 letters were 1.10 (95% CI 0.90-1.33), 0.93 (95% CI 0.77-1.11), 0.89 (95% CI 0.65-1.22) and 0.95 (95% CI 0.73-1.25), respectively. The risk of serious systemic events increased by 17% (95% CI 6%-27%, p = 0.0042) for bevacizumab treatment in comparison with ranibizumab. No statistically significant differences between the two treatments were found for the nonfatal arterial thrombotic events, ocular serious adverse, death from vascular and all causes events.
   Conclusions: Bevacizumab is not inferior to ranibizumab as a treatment for achieving visual acuity. The use of bevacizumab was associated with an increased risk of developing serious systemic events. Weighing the costs and health outcomes is necessary when selecting between bevacizumab and ranibizumab for ophthalmic diseases. Due to the limitations of the available data, further research is needed.
C1 [Wu, Bin; Liu, Xiaoyan; Lin, Houwen] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Pharm, Shanghai 200030, Peoples R China.
   [Wu, Haixiang] Fudan Univ, Dept Ophthalmol, Shanghai 200433, Peoples R China.
   [Wu, Haixiang] Fudan Univ, Visual Sci Eye & ENT Hosp, Shanghai Med Coll, Shanghai 200433, Peoples R China.
   [Li, Jin] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China.
RP Li, J (reprint author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China.
EM wbwithtg@hotmail.com
FU National Natural Science Foundation of China [71373160]
FX This study was supported by a grant from the National Natural Science
   Foundation of China (NO. 71373160). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Banfi R, 2013, INT J CLIN PHARM-NET, V35, P507, DOI 10.1007/s11096-013-9779-7
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066721
   Cheng JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041325
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho Han Joo, 2012, Korean J Ophthalmol, V26, P157, DOI 10.3341/kjo.2012.26.3.157
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Ford JA, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5182
   Gharbiya M, 2010, AM J OPHTHALMOL, V149, P458, DOI 10.1016/j.ajo.2009.10.010
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hufendiek Katerina, 2012, International Ophthalmology, V32, P259, DOI 10.1007/s10792-012-9562-0
   Iacono P, 2012, RETINA-J RET VIT DIS, V32, P1539, DOI 10.1097/IAE.0b013e31826956b7
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kim Jin-Hyoung, 2013, Korean J Ophthalmol, V27, P235, DOI 10.3341/kjo.2013.27.4.235
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Li J, 2013, INT J OPHTHALMOL-CHI, V6, P169, DOI 10.3980/j.issn.2222-3959.2013.02.12
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCartney M, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6778
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Nepomuceno AB, 2013, AM J OPHTHALMOL, V156, P502, DOI 10.1016/j.ajo.2013.04.026
   Ozturk BT, 2011, J OCUL PHARMACOL TH, V27, P373, DOI 10.1089/jop.2010.0195
   Park SC, 2012, EXPERT OPIN BIOL TH, V12, P1641, DOI 10.1517/14712598.2012.721772
   Parodi MB, 2013, ACTA OPHTHALMOL, V91, P267, DOI 10.1111/j.1755-3768.2011.02265.x
   Presta LG, 1997, CANCER RES, V57, P4593
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/cjm086
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
NR 42
TC 4
Z9 6
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 1
PY 2014
VL 9
IS 7
AR e101253
DI 10.1371/journal.pone.0101253
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM1UX
UT WOS:000339635000078
PM 24983855
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, J
   Guo, XF
   Yu, SJ
   Song, J
   Zhang, JX
   Cao, Z
   Wang, J
   Liu, M
   Dong, WG
AF Wang, Jun
   Guo, Xufeng
   Yu, Shijie
   Song, Jia
   Zhang, Jixiang
   Cao, Zhuo
   Wang, Jing
   Liu, Min
   Dong, Weiguo
TI Association between CD14 Gene Polymorphisms and Cancer Risk: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID HELICOBACTER-PYLORI INFECTION; ACUTE LYMPHOBLASTIC-LEUKEMIA; PROMOTER
   POLYMORPHISMS; FUNCTIONAL-SIGNIFICANCE; DISEASE RISK; CHINESE;
   SUSCEPTIBILITY; TLR4; RECOGNITION; POPULATION
AB Background: Two polymorphisms, -260C/T and -651C/T, in the CD14 gene have been implicated in susceptibility to cancer. However, the results remain inconclusive. This meta-analysis aimed to investigate the association between the two polymorphisms and risk of cancer.
   Methods: All eligible case-control studies published up to March 2014 were identified by searching PubMed, Web of Science, CNKI and Wan Fang database. Pooled odds ratio (OR) with 95% confidence interval (CI) were used to access the strength of this association in fixed- or random-effects model.
   Results: 17 case-control studies from fourteen articles were included. Of those, there were 17 studies (4198 cases and 4194 controls) for -260C/T polymorphism and three studies (832 cases and 1190 controls) for -651C/T polymorphism. Overall, no significant associations between the two polymorphisms of CD14 gene and cancer risk were found. When stratified by ethnicity, cancer type and source of control, similar results were observed among them. In addition, in further subgroups analysis by Helicobacter pylori (H. pylori) infection status and tumor location in gastric cancer subgroup, we found that the CD14 -260C/T polymorphism may increase the risk of gastric cancer in H. pylori-infected individuals.
   Conclusions: This meta-analysis suggests that the CD14 -260C/T polymorphism may increase the risk of gastric cancer in H. pylori-infected individuals. However, large and well-designed studies are warranted to validate our findings.
C1 [Wang, Jun; Guo, Xufeng; Yu, Shijie; Song, Jia; Zhang, Jixiang; Cao, Zhuo; Wang, Jing; Liu, Min; Dong, Weiguo] Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan 430072, Hubei Province, Peoples R China.
RP Dong, WG (reprint author), Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan 430072, Hubei Province, Peoples R China.
EM dwg@whu.edu.cn
CR Andrie E, 2009, EUR J HAEMATOL, V83, P334, DOI 10.1111/j.1600-0609.2009.01288.x
   Areeshi MY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064747
   Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boccia S, 2010, EUR J EPIDEMIOL, V25, P765, DOI 10.1007/s10654-010-9503-z
   Bredberg A, 2011, CANCER-AM CANCER SOC, V117, P440, DOI 10.1002/cncr.25440
   Castano-Rodriguez N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060327
   Chao YC, 2005, WORLD J GASTROENTERO, V11, P6043, DOI 10.3748/wjg.v11.i38.6043
   [陈丽珊 CHEN Lishan], 2006, [中华消化杂志, Chinese Journal of Digestion], V26, P735
   Companioni O, 2014, INT J CANCER, V134, P92, DOI 10.1002/ijc.28357
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876
   Gu W, 2008, CRIT CARE MED, V36, P2274, DOI 10.1097/CCM.0b013e318180b1ed
   Guo QS, 2006, J GASTROEN HEPATOL, V21, P92, DOI 10.1111/j.1440-1746.2005.04156.x
   Hartel C, 2008, HUM IMMUNOL, V69, P338, DOI 10.1016/j.humimm.2008.04.011
   HAO WY, 2010, INFLUENCE CD14260 65
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hold GL, 2009, EUR J CANCER PREV, V18, P117, DOI 10.1097/CEJ.0b013e3283101292
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Karhukorpi J, 2002, CLIN EXP IMMUNOL, V128, P326, DOI 10.1046/j.1365-2249.2002.01837.x
   Landi S, 2006, J NEGAT RESULTS BIOM, V5, DOI 10.1186/1477-5751-5-15
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838
   Liang XH, 2006, PHARMACOGENET GENOM, V16, P229
   Lin BK, 2006, AM J EPIDEMIOL, V164, P1, DOI 10.1093/aje/kwj175
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mason TE, 2010, PROSTATE, V70, P262, DOI 10.1002/pros.21060
   Miedema KGE, 2012, LEUKEMIA, V26, P1203, DOI 10.1038/leu.2011.341
   MIN ZC, 2012, J MOD UROL, V17, P118
   Pharoah PDP, 2004, NAT REV CANCER, V4, P850, DOI 10.1038/nrc1476
   Pu H, 2013, MOL BIOL REP, V40, P4001, DOI 10.1007/s11033-012-2478-y
   PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0
   Tahara T., 2007, Inflammopharmacology, V15, P124, DOI 10.1007/s10787-006-1567-3
   Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0
   Ture-Ozdemir F, 2008, ANTICANCER RES, V28, P3697
   ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253
   Wang ZT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045144
   Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10
   Wu MS, 2006, HEPATO-GASTROENTEROL, V53, P807
   XU Y, 2013, EUR ARCH OTORHINOLAR
   Yu X, 2011, DNA CELL BIOL, V30, P777, DOI 10.1089/dna.2011.1223
   Zeljic K, 2014, ORAL DIS, V20, P416, DOI 10.1111/odi.12144
   Zeng T, 2013, EUR J GASTROEN HEPAT, V25, P1183, DOI 10.1097/MEG.0b013e3283612ff1
   Zhang AQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071237
   Zhang L., 2011, ASS GENE POLYMORPHIS
   Zhao D, 2007, CLIN CANCER RES, V13, P2362, DOI 10.1158/1078-0432.CCR-06-2612
   Zhao LL, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-93
   Zhou W, 2014, ONCOTARGETS THER, V7, P5, DOI 10.2147/OTT.S54547
NR 49
TC 7
Z9 7
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 30
PY 2014
VL 9
IS 6
AR e100122
DI 10.1371/journal.pone.0100122
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK5ZO
UT WOS:000338506400022
PM 24978812
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, YL
   Chen, MW
   Xian, L
AF Yang, Yan-Long
   Chen, Ming-Wu
   Xian, Lei
TI Prognostic and Clinicopathological Significance of Downregulated
   E-Cadherin Expression in Patients with Non-Small Cell Lung Cancer
   (NSCLC): A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; ENDOTHELIAL GROWTH-FACTOR; STAGE-I
   NSCLC; CLINICAL-SIGNIFICANCE; FACTOR RECEPTOR; POOR-PROGNOSIS;
   BETA-CATENIN; ADENOCARCINOMA; CARCINOMA; VIMENTIN
AB Background: Many studies have investigated the prognostic role of E-cadherin in patients with NSCLC; however, the result still remains inconclusive. An up-to data system review and meta-analysis was necessary to give a comprehensive evaluation of prognostic role of E-cadherin in NSCLC.
   Methods: Eligible studies were searched in Pubmed, Embase and Web of Science databases. The inclusion criteria were studies that assessed the relationship between E-cadherin expression detected by immunohistochemistry (IHC) and the prognosis or clinicopathological features in patients with NSCLC. Subgroup analysis according to race, percentage of reduced/negative E-cadherin expression, histological type, and sample size were also conducted. Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were calculated to examine the risk or hazard association.
   Results: A total of 29 studies including 4010 patients were qualified for analysis. The analysis suggested that downregulated E-cadherin expression was significant associated with unfavorable overall survival (OS) and disease-free survival/progression-free survival (DFS/PFS) in patients with NSCLC. Subgroup analysis by race, percentage of reduced/negative E-cadherin expression, sample size also found the significant association in OS. When only the stage I NSCLC were considered, downregulated E-cadherin expression still had an unfavorable impact on OS. Additionally, downregulated E-cadherin expression was significantly associated with differentiation grade, lymphnode metastasis, vascular invasion, and TNM stage.
   Conclusion: Downregulated E-cadherin expression detected by IHC seems to correlate with tumour progression and could serve as an important prognostic factor in patients with NSCLC.
C1 [Yang, Yan-Long; Chen, Ming-Wu; Xian, Lei] Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Nanning, Guangxi Zhuang, Peoples R China.
RP Xian, L (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Nanning, Guangxi Zhuang, Peoples R China.
EM xianlei59@163.com
RI Figueroa, Angelica/K-1266-2014
OI Figueroa, Angelica/0000-0001-5530-5213
FU Guangxi Scientific Research and Technology Development projects
   [10124001A-47]
FX This work was supported by the Guangxi Scientific Research and
   Technology Development projects (grant no. 10124001A-47). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Al-Saad S, 2008, BRIT J CANCER, V99, P1476, DOI 10.1038/sj.bjc.6604713
   Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5
   Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276
   Chansky K, 2009, J THORAC ONCOL, V4, P792, DOI 10.1097/JTO.0b013e3181a7716e
   Cho S, 2008, LUNG, V186, P411, DOI 10.1007/s00408-008-9116-4
   Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872
   Deeb G, 2004, MODERN PATHOL, V17, P430, DOI 10.1038/modpathol.3800041
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feng J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039937
   Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hirata T, 2001, Clin Lung Cancer, V3, P134, DOI 10.3816/CLC.2001.n.024
   Huang C, 2005, BRIT J CANCER, V92, P1231, DOI 10.1038/sj.bjc.6602481
   International Agency for Research on Cancer, 2012, GLOBOCAN 2012 EST CA
   Jin SD, 2012, MED ONCOL, V29, P3157, DOI 10.1007/s12032-012-0229-5
   Kase S, 2000, CLIN CANCER RES, V6, P4789
   Kim H, 2013, KOREAN J PATHOL, V47, P44, DOI 10.4132/KoreanJPathol.2013.47.1.44
   Kimura K, 2000, INT J ONCOL, V16, P1125
   Lee YC, 2000, THORAC CARDIOV SURG, V48, P294, DOI 10.1055/s-2000-7885
   Lim SC, 2000, J KOREAN MED SCI, V15, P501, DOI 10.3346/jkms.2000.15.5.501
   Lin QA, 2010, JPN J CLIN ONCOL, V40, P670, DOI 10.1093/jjco/hyq041
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Morgensztern D, 2010, J THORAC ONCOL, V5, P29, DOI 10.1097/JTO.0b013e3181c5920c
   Ono K, 2010, ANTICANCER RES, V30, P3273
   Pagaki E, 2010, DIAGN CYTOPATHOL, V38, P419, DOI 10.1002/dc.21188
   Paredes J, 2012, BBA-REV CANCER, V1826, P297, DOI 10.1016/j.bbcan.2012.05.002
   Richardson F, 2012, ANTICANCER RES, V32, P537
   Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725
   Shi YL, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-89
   Sterlacci W, 2010, J THORAC ONCOL, V5, P1325, DOI 10.1097/JTO.0b013e3181e77efc
   Tamura M, 2005, J THORAC CARDIOV SUR, V130, P740, DOI 10.1016/j.jtcvs.2004.12.051
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Ucvet A, 2011, ARCH BRONCONEUMOL, V47, P397, DOI 10.1016/j.arbres.2011.04.010
   Vincan E, 2008, CLIN EXP METASTAS, V25, P657, DOI 10.1007/s10585-008-9156-4
   Wells G., 2003, NEWCASTLE OTTAWA SCA
   Wu SW, 2012, ARCH IRAN MED, V15, P707, DOI 0121511/AIM.0012
   Wu Y, 2012, MOL BIOL REP, V39, P9621, DOI 10.1007/s11033-012-1827-1
   Yamashita T, 2010, LUNG CANCER, V70, P320, DOI 10.1016/j.lungcan.2010.02.013
   Ye J, 2012, MOL MED REP, V6, P507, DOI 10.3892/mmr.2012.938
   Yu JH, 2011, VIRCHOWS ARCH, V458, P99, DOI 10.1007/s00428-010-1016-3
   Zhang H, 2013, J CLIN PATHOL, V66, P937, DOI 10.1136/jclinpath-2013-201467
   Zhang X, 2014, CLIN TRANSL ONCOL, V16, P178, DOI 10.1007/s12094-013-1057-6
   Zhao C, 2013, BIOSCI TRENDS, V7, P264, DOI 10.5582/bst.2013.v7.6.264
   Zhao JQ, 2013, ASIAN PAC J CANCER P, V14, P639, DOI 10.7314/APJCP.2013.14.2.639
   Zhu ZH, 2009, J CLIN ONCOL, V27, P1091, DOI 10.1200/JCO.2008.16.6991
NR 48
TC 30
Z9 36
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 30
PY 2014
VL 9
IS 6
AR e99763
DI 10.1371/journal.pone.0099763
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK5ZO
UT WOS:000338506400009
PM 24978478
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, XW
   Liu, F
   Wei, F
   Ren, H
   Hu, HD
AF Wang, Xiwei
   Liu, Fen
   Wei, Fang
   Ren, Hong
   Hu, Huaidong
TI Efficacy and Safety of Pegylated Interferon Plus Ribavirin Therapy for
   Chronic Hepatitis C Genotype 6: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID VIRUS-INFECTION; VIROLOGICAL RESPONSE; COMBINATION THERAPY; HCV
   GENOTYPE-2; EPIDEMIOLOGY; STRATEGIES; MANAGEMENT; INHIBITORS; UPDATE;
   TRIAL
AB Background: Hepatitis C genotype 6 (HCV-6) is prevalent in Southeast Asia. Data on the efficacy of direct-acting antiviral agents in chronic HCV-6 patients is limited and pegylated interferon (Peg-IFN) plus ribavirin (RBV) combination therapy remains standard therapy for those patients.
   Aim: Meta-analysis was performed to assess the efficacy and safety of Peg-IFN plus RBV combination therapy for chronic HCV-6 patients.
   Methods: Relevant studies were found by database search through Medline, Embase, Web of Science and The Cochrane Library. All published clinical trials assessing the efficacy of Peg-IFN plus RBV combination therapy for chronic HCV-6 patients were included. Sustained virological response rate (SVR) was pooled. We performed additional meta-analyses to compare the SVR outcomes of 24 versus 48 weeks of treatment in four head-to-head trials. Another second meta-analysis was also conducted to compare the efficacy of combination Peg-IFN plus RBV therapy in HCV-6 versus HCV-1 patients.
   Results: Thirteen studies met the inclusion criteria. The pooled SVR of all single arms was 75% (95% CI: 0.68-0.81). The SVR of 24 weeks treatment was significantly lower than that at 48 weeks, with a risk difference of 214% (95% CI: 20.25 to 20.02, p = 0.02). However, when restricted to the patients with rapid virological response (RVR), there was no significant effect on SVR between these two treatment groups, with a risk difference of 21% (95% CI: 20.1 to 0.07, p = 0.67). The SVR in HCV-6 patients was significantly higher than that in HCV-1 patients, with a relative risk of 1.35 (95% CI: 1.16-1.57, p < 0.001). Side effects were common, but rarely caused treatment discontinuation.
   Conclusions: The results of this meta-analysis suggest that Peg-IFN plus RBV is effective and safe for HCV-6 patients. Shortening treatment seems to be feasible in HCV-6 patients with RVR when tolerance to treatment is poor. However, this decision should be made cautiously.
C1 [Wang, Xiwei; Liu, Fen; Wei, Fang; Ren, Hong; Hu, Huaidong] Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Inst Viral Hepatitis,Key Lab Mol Biol Infect Dis, Chongqing, Peoples R China.
RP Hu, HD (reprint author), Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Inst Viral Hepatitis,Key Lab Mol Biol Infect Dis, Chongqing, Peoples R China.
EM huaidong.hu@gmail.com
FU Natural Science Foundation of China [81171560, 30930082, 81171561,
   30972584]; National Science and Technology Major Project of China
   [2008ZX10002-006, 2012ZX10002007001, 2011ZX09302005, 2012ZX09303001-001,
   2012ZX10002003]; Key Project of Chongqing Science and Technology
   [cstc2012gg-yyjsB10007]; Chongqing Natural Science Commission Foundation
   [cstc2011jjA10025]; Medical Research Fund by Chongqing Municipal Health
   Bureau [2009-1-71]
FX This research was supported by the Natural Science Foundation of China
   (81171560, 30930082, 81171561, 30972584), the National Science and
   Technology Major Project of China (2008ZX10002-006, 2012ZX10002007001,
   2011ZX09302005, 2012ZX09303001-001, 2012ZX10002003), the Key Project of
   Chongqing Science and Technology (cstc2012gg-yyjsB10007), the Chongqing
   Natural Science Commission Foundation (cstc2011jjA10025), the Medical
   Research Fund by Chongqing Municipal Health Bureau (2009-1-71). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andriulli A, 2008, ALIMENT PHARM THER, V28, P397, DOI 10.1111/j.1365-2036.2008.03763.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bunchorntavakul C, 2013, WORLD J HEPATOL, V5, P496, DOI 10.4254/wjh.v5.i9.496
   Cai QX, 2013, HEPATOLOGY, V58, p1098A
   Cai QX, 2011, HEPATOLOGY, V54, p829A
   Chao DT, 2011, ALIMENT PHARM THER, V34, P286, DOI 10.1111/j.1365-2036.2011.04714.x
   Clark VC, 2013, LIVER INT, V33, P80, DOI 10.1111/liv.12061
   Craxi A, 2011, J HEPATOL, V55, P245, DOI 10.1016/j.jhep.2011.02.023
   DAVIDSON F, 1995, J GEN VIROL, V76, P1197, DOI 10.1099/0022-1317-76-5-1197
   Davies A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055373
   Davis GL, 1997, HEPATOLOGY, V26, pS122, DOI 10.1002/hep.510260721
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Druyts E, 2012, CLIN EXP GASTROENTER, V5, P11, DOI 10.2147/CEG.S28253
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756
   Fung J, 2008, J INFECT DIS, V198, P808, DOI 10.1086/591252
   Gerber L, 2013, LIVER INT, V33, P85, DOI 10.1111/liv.12068
   Ghany MG, 2011, HEPATOLOGY, V54, P1433, DOI 10.1002/hep.24641
   Ghany MG, 2009, HEPATOLOGY, V49, P1335, DOI 10.1002/hep.22759
   Hsu CS, 2013, NEW ENGL J MED, V369, P678, DOI 10.1056/NEJMc1307641
   Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912
   Lam KD, 2010, HEPATOLOGY, V52, P1573, DOI 10.1002/hep.23889
   Lenz O, 2013, J HEPATOL, V58, P445, DOI 10.1016/j.jhep.2012.10.028
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   Mauss S, 2012, Z GASTROENTEROL, V50, P441, DOI 10.1055/s-0031-1282072
   MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884
   Mellor J, 1996, J CLIN MICROBIOL, V34, P417
   Nguyen MH, 2008, AM J GASTROENTEROL, V103, P1131, DOI 10.1111/j.1572-0241.2008.01793.x
   Nguyen Mindie H, 2005, Clin Gastroenterol Hepatol, V3, pS97, DOI 10.1016/S1542-3565(05)00711-1
   Nguyen NH, 2010, J VIRAL HEPATITIS, V17, P691, DOI 10.1111/j.1365-2893.2009.01226.x
   Pham TTT, 2012, J HEPATOL, V56, P1012, DOI 10.1016/j.jhep.2011.12.020
   Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494
   Seto WK, 2013, J VIRAL HEPATITIS, V20, P470, DOI 10.1111/jvh.12047
   Shao X, 2012, J HEPATOL, V56, pS66, DOI 10.1016/S0168-8278(12)60166-4
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Tangkijvanich P, 2012, J VIRAL HEPATITIS, V19, P423, DOI 10.1111/j.1365-2893.2011.01566.x
   Tsang OT, 2008, HEPATOLOGY, V48, p884A
   Tsang OTY, 2010, J GASTROEN HEPATOL, V25, P766, DOI 10.1111/j.1440-1746.2009.06163.x
   Welsch C, 2012, GUT, V61, P36, DOI 10.1136/gutjnl-2012-302144
   Zeuzem S, 2004, J HEPATOL, V40, P993, DOI 10.1016/j.jhep.2004.02.007
   Zeuzem S, 2011, GASTROENTEROLOGY, V141, P2047, DOI 10.1053/j.gastro.2011.08.051
   Zhou YQ, 2011, J VIRAL HEPATITIS, V18, P595, DOI 10.1111/j.1365-2893.2010.01373.x
NR 42
TC 11
Z9 11
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 25
PY 2014
VL 9
IS 6
AR e100128
DI 10.1371/journal.pone.0100128
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK8WO
UT WOS:000338709500028
PM 24963667
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhu, P
   Liu, Y
   Han, L
   Xu, G
   Ran, JM
AF Zhu, Ping
   Liu, Yan
   Han, Lu
   Xu, Gang
   Ran, Jian-min
TI Serum Uric Acid Is Associated with Incident Chronic Kidney Disease in
   Middle-Aged Populations: A Meta-Analysis of 15 Cohort Studies
SO PLOS ONE
LA English
DT Article
ID RENAL-FUNCTION DECLINE; CHINESE POPULATION; RISK-FACTORS; HYPERURICEMIA;
   COMMUNITY; THERAPY; HEALTH; BIAS; CKD; MEN
AB Background: Mounting evidence indicates that elevated serum uric acid may increase the incidence of chronic kidney disease (CKD). Our goal was to systematically evaluate longitudinal cohort studies for the association of serum uric acid levels and incident CKD.
   Methods: We searched electronic databases and the reference lists of relevant articles. The primary outcome was incident CKD, which was defined as an eGFR less than 60 mL/min/1.73 m(2) at the follow-up examination. Study-specific risk estimates were combined using random-effects models. The included studies were stratified into subgroups, and meta-regression analyses were performed.
   Results: Fifteen unique cohorts with a total of 99,205 individuals and 3,492 incident CKD cases were included. The relative risk of CKD was 1.22 (95% CI 1.16-1.28, I-2 = 65.9%) per 1 mg/dL serum uric level increment. This positive association was consistently observed in subgroups stratified according to most of the study-level characteristics. The observed positive association was more pronounced among group with a mean age <60 years (RR 1.26, 95% CI 1.21-1.31), and low-level heterogeneity was observed in the findings for this age group (I-2 = 46.4%, P = 0.022). However, no association was observed among studies with a mean age >= 60 years (RR 1.04, 95% CI 0.96-1.13), and no evidence of heterogeneity was evident among the studies (I-2 = 0%, P = 0.409). This mean age-related difference in the association between serum uric acid levels and CKD was significant (P = 0.004). The sensitivity analysis results were consistent when the analyses were restricted to studies that controlled for proteinuria and metabolic syndrome.
   Conclusions: Our meta-analysis demonstrated a positive association between serum uric acid levels and risk of CKD in middle-aged patients independent of established metabolic risk factors. Future randomized, high-quality clinical trials are warranted to determine whether lowering uric acid levels is beneficial in CKD.
C1 [Zhu, Ping; Xu, Gang; Ran, Jian-min] Jinan Univ, Coll Med, Guangzhou Red Cross Hosp, Dept Endocrinol & Metab, Guangzhou, Guangdong, Peoples R China.
   [Liu, Yan] Jinan Univ, Dept Nephrol, Guangzhou Red Cross Hosp, Coll Med, Guangzhou, Guangdong, Peoples R China.
   [Han, Lu] Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou 510275, Guangdong, Peoples R China.
RP Ran, JM (reprint author), Jinan Univ, Coll Med, Guangzhou Red Cross Hosp, Dept Endocrinol & Metab, Guangzhou, Guangdong, Peoples R China.
EM sumszc@gmail.com
FU National Natural Science Foundation of China [81200613]
FX This study was funded by a grant from the National Natural Science
   Foundation of China (No. 81200613). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bellomo G, 2010, AM J KIDNEY DIS, V56, P264, DOI 10.1053/j.ajkd.2010.01.019
   Ben-Dov IZ, 2011, NEPHROL DIAL TRANSPL, V26, P2558, DOI 10.1093/ndt/gfq740
   Bose B, 2014, NEPHROL DIAL TRANSPL, V29, P406, DOI 10.1093/ndt/gft378
   Chien KL, 2010, AM J MED, V123, P836, DOI 10.1016/j.amjmed.2010.05.010
   Choi HK, 2004, LANCET, V363, P1277, DOI 10.1016/S0140-6736(04)16000-5
   Chonchol M, 2007, AM J KIDNEY DIS, V50, P239, DOI 10.1053/j.ajkd.2007.05.013
   Corry DB, 2008, J HYPERTENS, V26, P269, DOI 10.1097/HJH.0b013e3282f240bf
   Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Domrongkitchaiporn S, 2005, J AM SOC NEPHROL, V16, P791, DOI 10.1681/ASN.2004030208
   Dong JY, 2011, AM J CLIN NUTR, V94, P900, DOI 10.3945/ajcn.111.015578
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feig DI, 2008, NEW ENGL J MED, V359, P1811, DOI 10.1056/NEJMra0800885
   Girillo P, 2006, J AM SOC NEPHROL, V17, pS165, DOI 10.1681/ASN.2006080909
   Hemingway H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000286
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Inker LA, 2014, AM J KIDNEY DIS, V63, P713, DOI 10.1053/j.ajkd.2014.01.416
   Jalal DI, 2013, AM J KIDNEY DIS, V61, P134, DOI 10.1053/j.ajkd.2012.07.021
   Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X
   Johnson RJ, 2013, NEPHROL DIAL TRANSPL, V28, P2221, DOI 10.1093/ndt/gft029
   Kawashima M, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-31
   KDIGO, 2013, KIDNEY INT S, V3, P19, DOI DOI 10.1038/KISUP.2012.64
   Khosla UM, 2005, KIDNEY INT, V67, P1739, DOI 10.1111/j.1523-1755.2005.00273.x
   Kodama S, 2009, DIABETES CARE, V32, P1737, DOI 10.2337/dc09-0288
   Lecoultre V, 2013, DIABETES CARE, V36, pE149, DOI 10.2337/dc13-0866
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Mok Y, 2012, NEPHROL DIAL TRANSPL, V27, P1831, DOI 10.1093/ndt/gfr530
   Obermayr RP, 2008, NEPHROL DIAL TRANSPL, V23, P1265, DOI 10.1093/ndt/gfm790
   Obermayr RP, 2008, J AM SOC NEPHROL, V19, P2407, DOI 10.1681/ASN.2008010080
   Odden MC, 2006, AM J EPIDEMIOL, V164, P1180, DOI 10.1093/aje/kwj333
   Odermatt A, 2011, AM J PHYSIOL-RENAL, V301, pF919, DOI 10.1152/ajprenal.00068.2011
   Ryoo JH, 2013, J KOREAN MED SCI, V28, P855, DOI 10.3346/jkms.2013.28.6.855
   Ryu ES, 2013, AM J PHYSIOL-RENAL, V304, pF471, DOI 10.1152/ajprenal.00560.2012
   Sanchez-Lozada LG, 2005, KIDNEY INT, V67, P237, DOI 10.1111/j.1523-1755.2005.00074.x
   Schlesinger N, 2005, CURR PHARM DESIGN, V11, P4133, DOI 10.2174/138161205774913273
   Sedaghat S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076827
   Selvin E, 2004, ANN INTERN MED, V141, P421, DOI 10.7326/0003-4819-141-6-200409210-00007
   Sonoda H, 2011, AM J NEPHROL, V33, P352, DOI 10.1159/000326848
   Wang F, 2011, NEPHROL DIAL TRANSPL, V26, P2847, DOI 10.1093/ndt/gfq816
   Wang SF, 2011, NEPHROLOGY, V16, P767, DOI 10.1111/j.1440-1797.2011.01513.x
   Weiner DE, 2008, J AM SOC NEPHROL, V19, P1204, DOI 10.1681/ASN.2007101075
   Yamada T, 2011, AM J MED SCI, V342, P461, DOI 10.1097/MAJ.0b013e318218bd89
   Yamagata K, 2007, KIDNEY INT, V71, P159, DOI 10.1038/sj.ki.5002017
   Yen CJ, 2009, J FORMOS MED ASSOC, V108, P921, DOI 10.1016/S0929-6646(10)60004-6
   Zhang LX, 2012, NEPHROL DIAL TRANSPL, V27, P1836, DOI 10.1093/ndt/gfr597
   Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140-6736(12)60033-6
NR 47
TC 33
Z9 36
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 24
PY 2014
VL 9
IS 6
AR e100801
DI 10.1371/journal.pone.0100801
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK7UT
UT WOS:000338633900089
PM 24959886
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU He, M
   Wang, W
   Ragoonundun, D
   Huang, WY
AF He, Miao
   Wang, Wei
   Ragoonundun, Dina
   Huang, Wenyong
TI Meta-Analysis of the Association between Lumican Gene Polymorphisms and
   Susceptibility to High Myopia
SO PLOS ONE
LA English
DT Article
ID FIBROMODULIN; POPULATION; PREVALENCE; CHINESE; SNPS; BIAS
AB Backgrounds: Many studies have evaluated the association between lumican (LUM) gene polymorphisms and high myopia. However, the results remain controversial. This meta-analysis aims to comprehensively evaluate the relationship between two common LUM polymorphisms (rs3759223 and rs3759222) and the risk of high myopia.
   Methods: A comprehensive literature search for studies published up until September of 2013 was performed. Data were extracted independently by two investigators, and the weighted Odds Ratios (ORs) and 95% Confidence Intervals (CIs) for the associations were obtained by using a random-effects model.
   Results: Eight studies (1425cases and 1271 controls) were identified for the analysis of the association between rs3759223 polymorphism and high myopia. The results indicated that rs3759223 polymorphism was associated with high myopia under a recessive model (OR = 1.71, 95% CI 1.04-2.81). Further subgroup analysis indicated that this polymorphism was associated with high myopia among Chinese people in the additive model (OR = 1.17, 95%CI 1.06-1.29) and a recessive model (OR = 1.75, 95%CI 1.00-3.06) with control group coming from hospital based population. Four studies (1024 cases and 1163 controls) were identified for the analysis of the association between rs3759222 polymorphism and high myopia. The results indicated that rs3759222 polymorphism was not associated with high myopia in all genetic models, even the subgroup analysis couldn't provide relative proof to assure the outcome.
   Conclusion: This meta-analysis suggests that LUM polymorphisms are associated with the risk of high myopia. However, well-designed studies with larger sample sizes and more ethnic groups are required to further validate this association.
C1 [He, Miao; Wang, Wei; Ragoonundun, Dina; Huang, Wenyong] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China.
RP Huang, WY (reprint author), Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China.
EM andyhwyz@aliyun.com
FU Scientific and Technology Foundation of Guangdong Province
   [2011B061300049, 2008B030301126]
FX This research was supported by the Scientific and Technology Foundation
   of Guangdong Province (2011B061300049, 2008B030301126). No additional
   external funding was received. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chakravarti S, 2003, INVEST OPHTH VIS SCI, V44, P2422, DOI 10.1167/iovs.02-0783
   Chen YP, 2011, INVEST OPHTH VIS SCI, V52, P4003, DOI 10.1167/iovs.10-7044
   Chen ZTY, 2009, OPHTHALMOLOGY, V116, P1920, DOI 10.1016/j.ophtha.2009.03.023
   Dai LL, 2012, OPHTHALMIC GENET, V33, P171, DOI 10.3109/13816810.2012.675397
   Deng ZJ, 2014, OPHTHALMOLOGICA
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feng YF, 2013, OPTOMETRY VISION SCI, V90, P1321, DOI 10.1097/OPX.0000000000000032
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hornbeak DM, 2009, CURR OPIN OPHTHALMOL, V20, P356, DOI 10.1097/ICU.0b013e32832f8040
   Hrynchak PK, 2013, OPTOM VIS SCI
   Jones D, 2012, EYE CONTACT LENS, V38, P188, DOI 10.1097/ICL.0b013e31824ccbc3
   Kim MH, 2013, INVEST OPHTH VIS SCI, V54, P3644, DOI 10.1167/iovs.12-11254
   Liao X, 2013, INT J OPHTHALMOL-CHI, V6, P696, DOI 10.3980/j.issn.2222-3959.2013.05.28
   Lin HJ, 2010, EYE, V24, P1093, DOI 10.1038/eye.2009.254
   Lin HJ, 2010, INVEST OPHTH VIS SCI, V51, P96, DOI 10.1167/iovs.09-3612
   Majava M, 2007, HUM MUTAT, V28, P336, DOI 10.1002/humu.20444
   Meng WH, 2011, OPHTHALMOLOGICA, V225, P127, DOI 10.1159/000317072
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   Paluru PC, 2004, MOL VIS, V10, P917
   Park SH, 2013, OPHTHALMIC GENET, V34, P43, DOI 10.3109/13816810.2012.736591
   Rahi JS, 2011, OPHTHALMOLOGY, V118, P797, DOI 10.1016/j.ophtha.2010.09.025
   Siegwart JT, 2007, MOL VIS, V13, P1878
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sun J, 2012, INVEST OPHTH VIS SCI, V53, P7504, DOI 10.1167/iovs.11-8343
   Tang WC, 2008, CLIN EXP OPTOM, V91, P4, DOI 10.1111/j.1444-0938.2007.00181.x
   Verhoeven VJM, 2012, HUM GENET, V131, P1467, DOI 10.1007/s00439-012-1176-0
   Wang IJ, 2006, MOL VIS, V12, P852
   Wang PF, 2009, INVEST OPHTH VIS SCI, V50, P1546, DOI 10.1167/iovs.08-2537
   Wells GA, NEWCASTLE OTTAWA SCA
   Wong TY, 2013, AM J OPHTHALMOL
   Yeh LK, 2010, J BIOL CHEM, V285, P28141, DOI 10.1074/jbc.M109.043679
   Yip SP, 2011, INVEST OPHTH VIS SCI, V52, P6396, DOI 10.1167/iovs.11-7639
   Zhang FJ, 2009, J OPHTHALMOL, DOI 10.1155/2009/514306
NR 34
TC 30
Z9 30
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 23
PY 2014
VL 9
IS 6
AR e98748
DI 10.1371/journal.pone.0098748
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AL1WV
UT WOS:000338917900006
PM 24956166
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, LD
   Hu, P
   Chen, X
   Bie, P
AF Zhang, Leida
   Hu, Peng
   Chen, Xi
   Bie, Ping
TI Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for
   Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED-TRIALS; NATIONWIDE SURVEY; CLINICAL-TRIALS; SURVIVAL;
   IMPROVES; ANGIOGENESIS; COMBINATION; JAPANESE; GROWTH; BIAS
AB Background: Sorafenib is used in patients with intermediate or advanced stage hepatocellular carcinoma (HCC) before or after of transarterial chemoembolization (TACE). However, the survival outcomes of TACE combined with sorafenib versus TACE alone remain controversial. Thus, we conducted a meta-analysis to evaluate the efficacy and safety of the combination therapy of TACE plus sorafenib in patients with intermediate or advanced stage of HCC.
   Methods: Pubmed and Embase databases were systematically reviewed for studies published up to November 2013, that compared TACE alone or in combination with sorafenib. Pooled hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated for overall survival (OS), time to progression (TTP), objective response rate (ORR), and progression free survival (PFS) using random-effects or fixed-effects model, depending on the heterogeneity between the included studies.
   Results: Six studies published from 2011 to 2013, with a total of 1254 patients, were included in this meta-analysis. The pooled results showed that TACE combined with sorafenib significantly improved OS (HR = 0.65; 95% CI: 0.47-0.89, P = 0.007), TTP (HR = 0.68; 95% CI: 0.52-0.87, P = 0.003), ORR (HR = 1.06; 95% CI: 1.01-1.12, P = 0.021), but did not affect PFS (HR = 0.84; 95% CI: 0.62-1.14, P = 0.267). The incidence of grade III/IV adverse reaction was higher in the TACE plus sorafenib group than in the TACE group.
   Conclusions: The meta-analysis confirmed that the combination therapy of TACE plus sorafenib in patients with intermediate or advanced stage of HCC, can improve the OS, TTP, and ORR. This combination therapy was also associated with a significantly increased risk of adverse reactions.
C1 [Zhang, Leida; Hu, Peng; Chen, Xi; Bie, Ping] Third Mil Med Univ, Southwest Hosp, Dept Hepatobiliary Surg, Chongqin, Peoples R China.
RP Bie, P (reprint author), Third Mil Med Univ, Southwest Hosp, Dept Hepatobiliary Surg, Chongqin, Peoples R China.
EM pengboyfei@msn.com
OI Lalvani, Ajit/0000-0002-2396-246X
CR Arii S, 2000, HEPATOLOGY, V32, P1224, DOI 10.1053/jhep.2000.20456
   Bai W, 2013, J DIGEST DIS, V14, P181, DOI 10.1111/1751-2980.12038
   Bayer, 2013, PHAS 2 RAND DOUBL BL
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bruix J, 2004, GASTROENTEROLOGY, V127, pS179, DOI 10.1053/j.gastro.23004.09.032
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Cabrera R, 2011, ALIMENT PHARM THER, V34, P205, DOI 10.1111/j.1365-2036.2011.04697.x
   Chang YS, 2007, CANCER CHEMOTH PHARM, V59, P561, DOI 10.1007/s00280-006-0393-4
   Chao Y, 2010, 2010 ASCO GASTR CANC
   Choi GH, 2013, RADIOLOGY, V269, P602, DOI 10.1148/radiol.13130150
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farrell GC, 2010, J GASTROEN HEPATOL, V25, P657, DOI 10.1111/j.1440-1746.2009.06167.x
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ikai I, 2004, CANCER, V101, P796, DOI 10.1002/cncr.20426
   Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007
   Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185
   Lencioni R, 2010, J CLIN ONCOL, V28
   Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mathonnet M, 2006, WORLD J GASTROENTERO, V12, P3782, DOI 10.3748/wjg.v12.i23.3782
   Muhammad A, 2013, WORLD J HEPATOL, V5, P364, DOI 10.4254/wjh.v5.i7.364
   Park J., 2010, P 4 ANN C INT LIV CA, P26
   Qu XD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-263
   Sansonno D, 2012, ONCOLOGIST, V17, P359, DOI 10.1634/theoncologist.2011-0313
   Sergio A, 2008, AM J GASTROENTEROL, V103, P914, DOI 10.1111/j.1572-0241.2007.01712.x
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Wells GA, 2000, 3 S SYST REV BAS, P3
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Yuen MF, 2009, J GASTROEN HEPATOL, V24, P346, DOI 10.1111/j.1440-1746.2009.05784.x
   Zhang T, 2010, ANTI-CANCER DRUG, V21, P326, DOI 10.1097/CAD.0b013e3283350e26
   Zhang X, 2012, HEPATOB PANCREAT DIS, V11, P458, DOI 10.1016/S1499-3872(12)60209-4
NR 34
TC 67
Z9 70
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 19
PY 2014
VL 9
IS 6
AR e100305
DI 10.1371/journal.pone.0100305
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AN6QP
UT WOS:000340721500058
PM 24945380
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Tie, RX
   Zhang, TS
   Fu, HR
   Wang, LM
   Wang, YB
   He, Y
   Wang, BS
   Zhu, N
   Fu, S
   Lai, XY
   Shi, JM
   Huang, H
AF Tie, Ruxiu
   Zhang, Tiansong
   Fu, Huarui
   Wang, Limengmeng
   Wang, Yebo
   He, Ying
   Wang, Binsheng
   Zhu, Ni
   Fu, Shan
   Lai, Xiaoyu
   Shi, Jimin
   Huang, He
TI Association between DNMT3A Mutations and Prognosis of Adults with De
   Novo Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID MICRORNA-EXPRESSION SIGNATURES; ACUTE MYELOGENOUS LEUKEMIA; GROUP-B;
   PUBLICATION BIAS; POOR-PROGNOSIS; CLINICAL-IMPLICATIONS; OLDER PATIENTS;
   FUNNEL PLOTS; GENE; IMPACT
AB Background: DNA methyltransferase 3A (DNMT3A) mutations were considered to be independently associated with unfavorable prognosis in adults with de novo acute myeloid leukemia (AML), however, there are still debates on this topic. Here, we aim to further investigate the association between DNMT3A mutations and prognosis of patients with AML.
   Methods: Eligible studies were identified from several data bases including PubMed, Embase, Web of Science, ClinicalTrials and the Cochrane Library (up to June 2013). The primary endpoint was overall survival (OS), while relapse-free survival (RFS) and event-free survival (EFS) were chosen as secondary endpoints. If possible, we would pool estimate effects (hazard ratio [HR] with 95% confidence interval[CI]) of outcomes in random and fixed effects models respectively.
   Results: That twelve cohort studies with 6377 patients exploring the potential significance of DNMT3A mutations on prognosis were included. Patients with DNMT3A mutations had slightly shorter OS (HR = 1.60; 95% CI, 1.31-1.95; P < 0.001), as compared to wild-type carriers. Among the patients younger than 60 years of age, DNMT3A mutations predicted a worse OS (HR = 1.84; 95% CI, 1.36-2.50; P < 0.001). In addition, mutant DNMT3A predicted inferior OS (HR = 2.30; 95% CI, 1.78-2.97; P = 0.862) in patients with unfavorable genotype abnormalities. Similar results were also found in some other subgroups. However, no significant prognostic value was found on OS (HR = 1.40; 95% CI, 0.98-1.99; P = 0.798) in the favorable genotype subgroup. Similar results were found on RFS and EFS under different conditions.
   Conclusions: DNMT3A mutations have slightly but significantly poor prognostic impact on OS, RFS and EFS of adults with de novo AML in total population and some specific subgroups.
C1 [Tie, Ruxiu; Fu, Huarui; Wang, Limengmeng; Wang, Yebo; He, Ying; Wang, Binsheng; Zhu, Ni; Fu, Shan; Lai, Xiaoyu; Shi, Jimin; Huang, He] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Tiansong] Jingan Dist Cent Hosp, Dept TCM, Shanghai, Peoples R China.
RP Huang, H (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Zhejiang, Peoples R China.
EM hehuang.zju@gmail.com
FU National Natural Science Foundation of China [81170526]; National
   Natural Science Foundation for Distinguished Young Scholars of China
   [81100364]; Zhejiang Province Natural Science Major Foundation
   [Z2100097]; Zhejiang Province Natural Science Foundation [Y2110152];
   Public Welfare Research Subproject from National Ministry of Health
   [201202017]
FX The research article was supported by the National Natural Science
   Foundation of China (No: 81170526), the National Natural Science
   Foundation for Distinguished Young Scholars of China (No: 81100364), the
   Zhejiang Province Natural Science Major Foundation (No: Z2100097), the
   Zhejiang Province Natural Science Foundation (No: Y2110152) and the
   Public Welfare Research Subproject from National Ministry of Health (No:
   201202017). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abdel-Wahab O, 2012, HEMATOLOGY, V17, pS39, DOI 10.1179/102453312X13336169155411
   Becker H, 2010, BLOOD, V116, P255
   Becker H, 2010, J CLIN ONCOL, V28, P596, DOI 10.1200/JCO.2009.25.1496
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772
   Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036
   Deeks J, 2011, COCHRANE HDB SYSTEMA
   Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974
   Gaidzik VI, 2013, BLOOD, V121, P4769, DOI 10.1182/blood-2012-10-461624
   Grimwade D, 1998, BLOOD, V92, P2322
   Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441
   Hou HA, 2012, BLOOD, V119, P559, DOI 10.1182/blood-2011-07-369934
   Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143
   Marcucci G, 2008, J CLIN ONCOL, V26, P5078, DOI 10.1200/JCO.2008.17.5554
   Marcucci G, 2012, J CLIN ONCOL, V30, P742, DOI 10.1200/JCO.2011.39.2092
   Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730
   Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840
   Markova J, 2012, EUR J HAEMATOL, V88, P128, DOI 10.1111/j.1600-0609.2011.01716.x
   Moreno SG, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2981
   Ostronoff F, 2013, LEUKEMIA, V27, P238, DOI 10.1038/leu.2012.168
   Palmer TM, 2008, STATA J, V8, P242, DOI 10.1177/1536867X0800800206
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304
   Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010
   Renneville A, 2012, LEUKEMIA, V26, P1247, DOI 10.1038/leu.2011.382
   Ribeiro AFT, 2012, BLOOD, V119, P5824, DOI 10.1182/blood-2011-07-367961
   Sattar N, 2010, LANCET, V375, P735, DOI 10.1016/S0140-6736(09)61965-6
   Shen Y, 2011, BLOOD, V118, P5593, DOI 10.1182/blood-2011-03-343988
   Shivarov V, 2013, LEUKEMIA RES, V37, P1445, DOI 10.1016/j.leukres.2013.07.032
   Slovak ML, 2000, BLOOD, V96, P4075
   Taskesen E, 2011, BLOOD, V117, P2469, DOI 10.1182/blood-2010-09-307280
   Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326
   Thol F, 2011, J CLIN ONCOL, V29, P2889, DOI 10.1200/JCO.2011.35.4894
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Wells GA, 2012, NEWCASTLE OTTAWA SCA
   Whitman SP, 2010, BLOOD, V116, P3622, DOI 10.1182/blood-2010-05-283648
   Xu Y, 2012, BLOOD, P120
   Yamashita Y, 2010, ONCOGENE, V29, P3723, DOI 10.1038/onc.2010.117
   Yan XJ, 2011, NAT GENET, V43, P309, DOI 10.1038/ng.788
NR 44
TC 24
Z9 24
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 17
PY 2014
VL 9
IS 6
AR e93353
DI 10.1371/journal.pone.0093353
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK5YM
UT WOS:000338503400002
PM 24936645
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Jin, J
   Hu, C
   Yu, MX
   Chen, FF
   Ye, L
   Yin, XF
   Zhuang, ZP
   Tong, HY
AF Jin, Jie
   Hu, Chao
   Yu, Mengxia
   Chen, Feifei
   Ye, Li
   Yin, Xiufeng
   Zhuang, Zhengping
   Tong, Hongyan
TI Prognostic Value of Isocitrate Dehydrogenase Mutations in
   Myelodysplastic Syndromes: A Retrospective Cohort Study and
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; WORLD-HEALTH-ORGANIZATION; SCORING SYSTEM; IDH2
   MUTATIONS; CLASSIFICATION; NEOPLASMS; GENES; TET2; 2-HYDROXYGLUTARATE;
   PATHOGENESIS
AB Background: Recent genomic sequencing efforts have identified a number of recurrent mutations in myelodysplastic syndromes (MDS) that may contribute to disease progression and overall survival, including mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2).
   Methods: Pretreatment bone marrow (BM) samples were acquired from mononuclear cells in 146 adult patients with de novo MDS from January 2006 to June 2013. Polymerase chain reaction (PCR) and direct sequencing were performed on exon 4 of IDH1/2 genes and mutation status was correlated with overall survival (OS) and leukemia-free survival (LFS). We then performed a meta-analysis combining previously published and current studies to explore the effect of IDH mutations on OS and LFS in MDS.
   Results: In our study, somatic mutations of either IDH gene were discovered in 11 MDS patients (7.53%) and were significantly correlated with poorer OS (P = 0.007). IDH mutations were specifically associated with a poorer OS in the intermediate-1 risk group by the International Prognostic Scoring System (IPSS) (P = 0.039). In addition, we discovered decitabine achieved a better therapeutic effect compared to other treatments in IDH mutation-positive patients (P = 0.023). We identified six previous studies of IDH mutations in MDS. A meta-analysis of these studies included 111 MDS patients IDH mutations and 1671 MDS patients with wild-type IDH1/2. The hazard ratios (HRs) of OS and LFS for patients with IDH mutations were 1.62 (95% CI, 1.27-2.09) and 2.21 (95% CI, 1.48-3.30), respectively.
   Conclusion: The results from our study and the meta-analysis provide firm evidence that IDH mutations are significantly associated with poorer clinical outcomes in MDS. Identification of IDH mutations may be pivotal for better risk stratification in MDS patients and improving IPSS score. Additionally, hypomethylating agents may be an effective treatment option for MDS patients with IDH mutations.
C1 [Jin, Jie; Hu, Chao; Yu, Mengxia; Chen, Feifei; Ye, Li; Yin, Xiufeng; Tong, Hongyan] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China.
   [Jin, Jie; Hu, Chao; Yu, Mengxia; Chen, Feifei; Ye, Li; Yin, Xiufeng; Tong, Hongyan] Zhejiang Univ, Sch Med, Inst Hematol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhuang, Zhengping] NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA.
RP Tong, HY (reprint author), Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China.
EM zjuhongyantong@163.com
FU Zhejiang Province Fund for Distinguished Young Scholars [LR12H08001];
   Foundation of Key Innovation Team of Zhejiang Province [2011R50015];
   National Public Health Grand Research Foundation [201202017]; Science
   Technology Department of Zhejiang Province [2013c03043-2]; National
   Natural Science Foundation of China [30870914, 81270582]
FX This study was supported by grants from Zhejiang Province Fund for
   Distinguished Young Scholars (LR12H08001), the Foundation of Key
   Innovation Team of Zhejiang Province (2011R50015), National Public
   Health Grand Research Foundation (201202017), major program of Science
   Technology Department of Zhejiang Province fund (2013c03043-2) and the
   National Natural Science Foundation of China (No. 30870914, No.
   81270582). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abbas S, 2010, BLOOD, V116, P2122, DOI 10.1182/blood-2009-11-250878
   Abdel-Wahab O, 2012, CANCER CELL, V22, P180, DOI 10.1016/j.ccr.2012.06.032
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343
   Bejar R, 2011, J CLIN ONCOL, V29, P504, DOI 10.1200/JCO.2010.31.1175
   Bennett JM, 2000, INT J HEMATOL, V72, P131
   BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
   Caramazza D, 2010, LEUKEMIA, V24, P2120, DOI 10.1038/leu.2010.213
   Chou WC, 2011, LEUKEMIA, V25, P246, DOI 10.1038/leu.2010.267
   Chou WC, 2010, BLOOD, V115, P2749, DOI 10.1182/blood-2009-11-253070
   Chung YR, 2012, INT J HEMATOL, V96, P413, DOI 10.1007/s12185-012-1181-z
   Corey SJ, 2007, NAT REV CANCER, V7, P118, DOI 10.1038/nrc2047
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   DiNardo CD, 2013, BLOOD, V121, P4917, DOI 10.1182/blood-2013-03-493197
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fathi AT, 2012, BLOOD, V120, P4649, DOI 10.1182/blood-2012-06-438267
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Garcia-Manero G, 2008, LEUKEMIA, V22, P538, DOI 10.1038/sj.leu.2405070
   Greenberg P, 1997, BLOOD, V89, P2079
   Greenberg PL, 2012, BLOOD, V120, P2454, DOI 10.1182/blood-2012-03-420489
   Grimes DA, 2002, LANCET, V359, P341, DOI 10.1016/S0140-6736(02)07500-1
   Head DR, 2011, BONE MARROW RES, V2011
   Jin GL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016812
   Kaelin W G Jr, 2011, Cold Spring Harb Symp Quant Biol, V76, P335, DOI 10.1101/sqb.2011.76.010975
   Khan H, 2013, SEMIN HEMATOL, V50, P16, DOI 10.1053/j.seminhematol.2013.01.001
   Kosmider O, 2010, LEUKEMIA, V24, P1094, DOI 10.1038/leu.2010.52
   Krell D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019868
   Lin CC, 2013, AM J HEMATOL
   Lin J, 2012, ANN HEMATOL, V91, P519, DOI 10.1007/s00277-011-1352-7
   Lin TL, 2013, HAEMATOLOGICA
   Malcovati L, 2007, J CLIN ONCOL, V25, P3503, DOI 10.1200/JCO.2006.08.5696
   Muto T, 2013, J EXP MED, V210, P2627, DOI 10.1084/jem.20131144
   Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139
   Pardanani A, 2010, LEUKEMIA, V24, P1146, DOI 10.1038/leu.2010.77
   Patnaik MM, 2012, LEUKEMIA, V26, P101, DOI 10.1038/leu.2011.298
   Reitman ZJ, 2010, J NATL CANCER I, V102, P932, DOI 10.1093/jnci/djq187
   Rocquain J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-401
   Shih AH, 2011, SEMIN ONCOL, V38, P613, DOI 10.1053/j.seminoncol.2011.04.013
   Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Steensma DP, 2006, LEUKEMIA RES, V30, P1227, DOI 10.1016/j.leukres.2005.12.001
   Tefferi A, 2012, LEUKEMIA, V26, P475, DOI 10.1038/leu.2011.253
   Thol F, 2010, HAEMATOL-HEMATOL J, V95, P1668, DOI 10.3324/haematol.2010.025494
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Tong HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067537
   Tong HY, 2012, LEUKEMIA LYMPHOMA, V53, P2412, DOI 10.3109/10428194.2012.696637
   Tothova Z, 2013, CLIN CANCER RES, V19, P1637, DOI 10.1158/1078-0432.CCR-12-1251
   Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199
   Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020
   Yoshida K, 2011, LEUKEMIA, V25, P184, DOI 10.1038/leu.2010.241
   Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944
NR 50
TC 36
Z9 38
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 17
PY 2014
VL 9
IS 6
AR e100206
DI 10.1371/journal.pone.0100206
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK5YM
UT WOS:000338503400092
PM 24936872
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, YF
   Shi, WW
   Gao, HF
   Zhou, L
   Hou, AJ
   Zhou, YH
AF Zhang, Yu-Fei
   Shi, Wei-Wu
   Gao, Hong-Fang
   Zhou, Li
   Hou, An-Ji
   Zhou, Yu-Hao
TI Folate Intake and the Risk of Breast Cancer: A Dose-Response
   Meta-Analysis of Prospective Studies
SO PLOS ONE
LA English
DT Article
ID FOLIC-ACID; POSTMENOPAUSAL WOMEN; TREND ESTIMATION; ALCOHOL;
   VITAMIN-B-12; METHIONINE; CONSUMPTION; PROSTATE; DIET
AB Background: Previous observational studies regarding the existence of an association between folate intake and the risk of breast cancer have been inconsistent. This study aimed to summarize the evidence regarding this relationship using a dose-response meta-analytic approach.
   Methodology and Principal Findings: We performed electronic searches of the PubMed, EmBase, and Cochrane Library databases to identify studies published through June 2013. Only prospective observational studies that reported breast cancer effect estimates with 95% confidence intervals (CIs) for more than 2 folate intake categories were included. We excluded traditional case-control studies because of possible bias from various confounding factors. Overall, we included 14 prospective studies that reported data on 677,858 individuals. Folate intake had little effect on the breast cancer risk (relative risk (RR) for highest versus lowest category = 0.97; 95% CI, 0.90-1.05; P = 0.451). Dose-response meta-analysis also suggested that a 100 mg/day increase in folate intake had no significant effect on the risk of breast cancer (RR = 0.99; 95% CI, 0.98-1.01; P = 0.361). Furthermore, we used restricted cubic splines to evaluate the nonlinear relationship between folate intake and the risk of breast cancer, and discovered a potential J-shaped correlation between folate intake and breast cancer risk (P = 0.007) and revealed that a daily folate intake of 200-320 mg was associated with a lower breast cancer risk; however, the breast cancer risk increased significantly with a daily folate intake >400 mg.
   Conclusion/Significance: Our study revealed that folate intake had little or no effect on the risk of breast cancer; moreover, a dose-response meta-analysis suggested a J-shaped association between folate intake and breast cancer.
C1 [Zhang, Yu-Fei; Gao, Hong-Fang; Zhou, Li; Hou, An-Ji] Shanghai Seventh Peoples Hosp, Dept Oncol, Shanghai, Peoples R China.
   [Shi, Wei-Wu] Taizhou Hosp Zhejiang Prov, Wenzhou Med Coll, Med Res Ctr, Linhai, Zhejiang, Peoples R China.
   [Zhou, Yu-Hao] Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.
RP Zhou, YH (reprint author), Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.
EM zhou_ly@126.com
FU academic pacemaker programming in health systems, Pudong New Area,
   Shanghai [PWRD2012-12]; Fund being innovative of science and technology
   development fund, Pudong New Area, Shanghai [PKJ2012-Y04]; medicant
   project of Shuguang foundation of Chinese medical development office in
   Shanghai [2012JJHM012]
FX This study was funded by the academic pacemaker programming in health
   systems, Pudong New Area, Shanghai (PWRD2012-12), Fund being innovative
   of science and technology development fund, Pudong New Area, Shanghai
   (PKJ2012-Y04) and the medicant project of Shuguang foundation of Chinese
   medical development office in Shanghai (2012JJHM012). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Baglietto L, 2005, BMJ-BRIT MED J, V331, P807, DOI 10.1136/bmj.38551.446470.06
   Bassett JK, 2013, CANCER CAUSE CONTROL, V24, P1555, DOI 10.1007/s10552-013-0232-y
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cho EY, 2003, CANCER EPIDEM BIOMAR, V12, P713
   Choi SW, 2002, J NUTR, V132, p2413S, DOI 10.1093/jn/132.8.2413S
   Collin SM, 2010, CANCER EPIDEM BIOMAR, V19, P1632, DOI 10.1158/1055-9965.EPI-10-0180
   Deeks JJ, 2008, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duffy CM, 2009, BREAST CANCER RES TR, V116, P551, DOI 10.1007/s10549-008-0167-2
   Ebbing M, 2009, JAMA-J AM MED ASSOC, V302, P2119, DOI 10.1001/jama.2009.1622
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ericson U, 2007, AM J CLIN NUTR, V86, P434
   Feigelson HS, 2003, CANCER EPIDEM BIOMAR, V12, P161
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Kennedy DA, 2011, CANCER EPIDEMIOL, V35, P2, DOI 10.1016/j.canep.2010.11.004
   Lajous M, 2006, CANCER CAUSE CONTROL, V17, P1209, DOI 10.1007/s10552-006-0053-3
   Larsson SC, 2007, J NATL CANCER I, V99, P64, DOI 10.1093/jnci/djk006
   Larsson SC, 2006, GASTROENTEROLOGY, V131, P1271, DOI 10.1053/j.gastro.2006.08.010
   Larsson SC, 2008, CANCER EPIDEM BIOMAR, V17, P3444, DOI 10.1158/1055-9965.EPI-08-0692
   Lin J, 2008, AM J CLIN NUTR, V87, P734
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Maruti SS, 2009, AM J CLIN NUTR, V89, P624, DOI 10.3945/ajcn.2008.26568
   Mason J B, 1996, Oncology (Williston Park), V10, P1727
   Mason JB, 2007, CANCER EPIDEM BIOMAR, V16, P1325, DOI 10.1158/1055-9965.EPI-07-0329
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Rohan TE, 2000, J NATL CANCER I, V92, P266, DOI 10.1093/jnci/92.3.266
   Roswall N, 2010, EUR J CANCER PREV, V19, P360, DOI 10.1097/CEJ.0b013e32833ade68
   Sellers TA, 2004, CANCER CAUSE CONTROL, V15, P113, DOI 10.1023/B:CACO.0000019471.97208.c6
   Sellers TA, 2001, EPIDEMIOLOGY, V12, P420, DOI 10.1097/00001648-200107000-00012
   Shrubsole MJ, 2011, AM J EPIDEMIOL, V173, P1171, DOI 10.1093/aje/kwq491
   Stevens VL, 2010, AM J CLIN NUTR, V91, P1708, DOI 10.3945/ajcn.2009.28553
   Stolzenberg-Solomon RZ, 2006, AM J CLIN NUTR, V83, P895
   Tjonneland A, 2006, EUR J CLIN NUTR, V60, P280, DOI 10.1038/sj.ejcn.1602313
   Vollset SE, 2013, LANCET, V381, P1029, DOI 10.1016/S0140-6736(12)62001-7
   Wells GA, 2009, NEWCASTLE OTTAWA SCA
   Zhang SMM, 2008, JAMA-J AM MED ASSOC, V300, P2012, DOI 10.1001/jama.2008.555
   Zhang SM, 1999, JAMA-J AM MED ASSOC, V281, P1632, DOI 10.1001/jama.281.17.1632
NR 40
TC 13
Z9 13
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 16
PY 2014
VL 9
IS 6
AR e100044
DI 10.1371/journal.pone.0100044
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AJ5PV
UT WOS:000337738600086
PM 24932496
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, YF
   Lu, J
   Yu, FF
   Gao, HF
   Zhou, YH
AF Zhang, Yu-Fei
   Lu, Jian
   Yu, Fei-Fei
   Gao, Hong-Fang
   Zhou, Yu-Hao
TI Polyunsaturated Fatty Acid Intake and Risk of Lung Cancer: A
   Meta-Analysis of Prospective Studies
SO PLOS ONE
LA English
DT Article
ID DIETARY-FAT; TREND ESTIMATION; SMOKING; CHOLESTEROL; HABITS; COHORT;
   JAPAN; FOODS
AB Background: Studies have reported inconsistent results for the existence of an association between polyunsaturated fatty acid (PUFA) intake and risk of lung cancer. The purpose of this study is to summarize the evidence regarding this relationship using a dose response meta-analytic approach.
   Methodology and Principal Findings: We searched the PubMed, EmBase, and Cochrane Library electronic databases for related articles published through July 2013. Only prospective studies that reported effect estimates with 95% confidence intervals (CIs) of lung cancer incidence for greater than 2 categories of PUFA intake were included. We did random-effects meta-analyses of study-specific incremental estimates to determine the risk of lung cancer associated with a 5 g per day increase in PUFA intake. Overall, we included 8 prospective cohort studies reporting data on 1,268,442 individuals. High PUFA intake had little or no effect on lung cancer risk (risk ratio [RR], 0.91; 95% CI, 0.78-1.06; P = 0.230). Furthermore, the dose-response meta-analysis also suggested that a 5 g per day increase in PUFA has no significant effect on the risk of lung cancer (RR, 0.98; 95% CI: 0.96-1.01; P = 0.142). Finally, the findings of dose response curve suggested that PUFA intake of up to 15 g/d seemed to increase the risk of lung cancer. Furthermore, PUFA intake greater than 15 g/d was associated with a small beneficial effect and borderline statistical significance. Subgroup analyses for 5 g per day increment in PUFA indicated that the protective effect of PUFA was more evident in women (RR, 0.94; 95% CI, 0.87-1.01; P = 0.095) than in men (RR, 1.00; 95% CI, 0.98-1.02; P = 0.784).
   Conclusion/Significance: Our study indicated that PUFA intake had little or no effect on lung cancer risk. PUFA intake might play an important role in lung cancer prevention in women.
C1 [Zhang, Yu-Fei; Gao, Hong-Fang] Shanghai Seventh Peoples Hosp, Dept Oncol, Shanghai, Peoples R China.
   [Lu, Jian; Yu, Fei-Fei] Second Mil Med Univ, Dept Hlth Stat, Shanghai, Peoples R China.
   [Zhou, Yu-Hao] Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.
RP Zhou, YH (reprint author), Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.
EM zhou_ly@126.com
FU Key disciplines group construction project of Pudong Health Bureau of
   Shanghai [PWZxkq2011-01]; Shanghai key speciality of traditional Chinese
   medicine [ZYXK2012010]; Talents Training Program of Shanghai Seventh
   People's Hospital [XX2012-023]
FX This study was funded by Key disciplines group construction project of
   Pudong Health Bureau of Shanghai (PWZxkq2011-01), Shanghai key
   speciality of traditional Chinese medicine (ZYXK2012010), and Talents
   Training Program of Shanghai Seventh People's Hospital (XX2012-023). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Avula C. P. R., 2000, Recent Research Developments in Lipids, V4, P303
   Bandera EV, 1997, CANCER CAUSE CONTROL, V8, P828, DOI 10.1023/A:1018456127018
   BARONZIO G, 1994, ANTICANCER RES, V14, P1145
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Daniel CR, 2011, CANCER PREV RES, V4, P1903, DOI 10.1158/1940-6207.CAPR-11-0241
   Darby S, 2001, BRIT J CANCER, V84, P728, DOI 10.1054/bjoc.2000.1668
   Deeks JJ, 2008, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DeStefani E, 1997, CANCER CAUSE CONTROL, V8, P913, DOI 10.1023/A:1018424614723
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   GOODMAN MT, 1988, AM J EPIDEMIOL, V128, P1241, DOI 10.1093/oxfordjournals.aje.a115078
   GOODMAN MT, 1992, EPIDEMIOLOGY, V3, P288, DOI 10.1097/00001648-199207000-00004
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   KNEKT P, 1991, NUTR CANCER, V16, P267, DOI 10.1080/01635589109514165
   KOO LC, 1988, NUTR CANCER, V11, P155, DOI 10.1080/01635588809513983
   Laake I, 2013, INT J CANCER, V132, P1389, DOI 10.1002/ijc.27737
   Linseisen J, 2011, CANCER CAUSE CONTROL, V22, P909, DOI 10.1007/s10552-011-9764-1
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Ozasa K, 2001, JPN J CANCER RES, V92, P1259, DOI 10.1111/j.1349-7006.2001.tb02148.x
   PIERCE RJ, 1989, NUTR CANCER, V12, P237, DOI 10.1080/01635588909514023
   PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034
   SANKARANARAYANAN R, 1994, INT J CANCER, V58, P644, DOI 10.1002/ijc.2910580505
   SWANSON CA, 1992, INT J CANCER, V50, P876, DOI 10.1002/ijc.2910500609
   Takezaki T, 2003, NUTR CANCER, V45, P160, DOI 10.1207/S15327914NC4502_04
   Takezaki T, 2011, BRIT J CANCER, V84, P1199
   Troyer D, 1996, NUTR RES, V16, P1959, DOI 10.1016/S0271-5317(96)00219-9
   Veierod MB, 1997, EUR J CANCER PREV, V6, P540, DOI 10.1097/00008469-199712000-00009
   Wakai K, 1999, LUNG CANCER, V25, P147, DOI 10.1016/S0169-5002(99)00051-3
   Wells GA, 2009, NEWCASTLE OTTAWA SCA
   Wingo PA, 2003, CANCER, V97, P3133, DOI 10.1002/cncr.11380
   WYNDER EL, 1987, J NATL CANCER I, V79, P631
NR 36
TC 6
Z9 6
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 12
PY 2014
VL 9
IS 6
AR e99637
DI 10.1371/journal.pone.0099637
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK8TP
UT WOS:000338701300083
PM 24925369
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Sun, LP
   Liu, JW
   Yuan, Q
   Xing, CZ
   Yuan, Y
AF Sun, Liping
   Liu, Jingwei
   Yuan, Quan
   Xing, Chengzhong
   Yuan, Yuan
TI Association between PTEN Gene IVS4 Polymorphism and Risk of Cancer: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GERMLINE MUTATIONS; TUMOR-SUPPRESSOR; PATHWAY
AB Background: Phosphatase and tensin homolog (PTEN) is a well established tumor suppressor gene. Recently, increasing studies investigated the association between PTEN IVS4 polymorphism (rs3830675) and risk of various types of cancer. However, the results from the individual studies were controversial. The aim of this meta-analysis was to elucidate whether PTEN IVS4 polymorphism was associated with cancer risk.
   Methods: Databases including PubMed, Web of knowledge and Chinese National Knowledge Infrastructure (CNKI) were systematically searched to identify potentially eligible literatures. Odds ratios (OR) and their 95% confidence interval (CI) were used to assess the strength of association between PTEN IVS4 polymorphism and cancer risk.
   Results: A total of seven case-control studies were finally included in this meta-analysis. The pooled analysis suggested that individuals with PTEN IVS4 (-/-) genotype were significantly associated with increased risk of cancer (OR = 1.45, 95% CI = 1.19-1.76, P<0.001) and subgroup of digestive tract cancer (OR = 1.67, 95% CI = 1.28-2.18, P<0.001) compared with (+/+) genotype. The allele analysis revealed that (-) allele was significantly associated with increased risk of cancer (OR = 1.30, 95% CI = 1.12-1.50, P = 0.001) and subgroup of digestive tract cancer (OR = 1.42, 95% CI = 1.16-1.74, P = 0.001) compared with (+) allele. No significant association was observed between PTEN IVS4 (+/-) genotype and risk of cancer.
   Conclusion: PTEN IVS4 (-/-) genotype was significantly associated with increased risk of cancer especially for digestive tract cancer compared with (+/+) genotype. The (-) allele of PTEN IVS4 (rs3830675) polymorphism was significantly associated with increased risk of cancer especially for digestive tract cancer compared with (+) allele. The recessive effect model and dominant effect model also demonstrated significant association between PTEN IVS4 (rs3830675) polymorphism and increased cancer risk especially for digestive tract cancer. Further large-scale and well-designed studies regarding different ethnicities are still required to confirm the results of our meta-analysis.
C1 [Xing, Chengzhong] China Med Univ, Affiliated Hosp 1, Tumor Etiol & Screening Dept Canc Inst & Gen Surg, Shenyang, Peoples R China.
   China Med Univ, Liaoning Prov Educ Dept, Key Lab Canc Etiol & Prevent, Shenyang, Peoples R China.
RP Xing, CZ (reprint author), China Med Univ, Affiliated Hosp 1, Tumor Etiol & Screening Dept Canc Inst & Gen Surg, Shenyang, Peoples R China.
EM xcz1966@126.com; yyuan@mail.cmu.edu.cn
FU National Basic Research Program of China (973 Program) [2010CB529304];
   Science and Technology Project of Liaoning province [2011225002,
   2012225016]
FX This study is supported by grants from National Basic Research Program
   of China (973 Program Ref No. 2010CB529304), the grants of the Science
   and Technology Project of Liaoning province (Ref No. 2011225002) and the
   grants of the Science and Technology Project of Liaoning province (Ref
   No. 2012225016). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Canbay E, 2013, GENET TEST MOL BIOMA, V17, P249, DOI 10.1089/gtmb.2012.0306
   Canbay E, 2013, EXPERT OPIN THER TAR, V17, P1, DOI 10.1517/14728222.2013.727398
   Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ge H, 2008, DIS ESOPHAGUS, V21, P409, DOI 10.1111/j.1442-2050.2007.00786.x
   [葛晖 Ge Hui], 2007, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V34, P1261
   George DJ, 2001, CANCER EPIDEM BIOMAR, V10, P411
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333
   Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554
   Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383
   Ortega-Molina A, 2013, TRENDS ENDOCRIN MET, V24, P184, DOI 10.1016/j.tem.2012.11.002
   Pesche S, 1998, ONCOGENE, V16, P2879, DOI 10.1038/sj.onc.1202081
   Rearick D, 2011, NUCLEIC ACIDS RES, V39, P2357, DOI 10.1093/nar/gkq1080
   Risinger JI, 1997, CANCER RES, V57, P4736
   Rose AB, 2008, CURR TOP MICROBIOL, V326, P277
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Wang XJ, 2008, CELL RES, V18, P807, DOI 10.1038/cr.2008.83
   Yang JL, 2010, J CANCER RES CLIN, V136, P1303, DOI 10.1007/s00432-010-0781-3
   Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241
   Ying Shao-Yao, 2009, V487, P387, DOI 10.1007/978-1-60327-547-7_19
   Zaridze DG, 2008, BIOCHEMISTRY-MOSCOW+, V73, P532, DOI 10.1134/S0006297908050064
   Zhao Z H, 2012, CHIN J CANC PREV TRE, V19, P743
NR 29
TC 4
Z9 4
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 5
PY 2014
VL 9
IS 6
AR e98851
DI 10.1371/journal.pone.0098851
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI4NF
UT WOS:000336841400060
PM 24901890
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, SY
   Zheng, G
   Cheng, BR
   Chen, FF
   Wang, ZM
   Chen, YY
   Wang, Y
   Xiong, B
AF Wang, Shuyi
   Zheng, Gang
   Cheng, Boran
   Chen, Fangfang
   Wang, Zhenmeng
   Chen, Yuanyuan
   Wang, You
   Xiong, Bin
TI Circulating Tumor Cells (CTCs) Detected by RT-PCR and Its Prognostic
   Role in Gastric Cancer: A Meta-Analysis of Published Literature
SO PLOS ONE
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; BONE-MARROW MICROMETASTASIS; ANTIGEN
   MESSENGER-RNA; PERIPHERAL-BLOOD; MOLECULAR-DETECTION;
   CLINICAL-SIGNIFICANCE; PROGRESSION; METASTASIS; EXPRESSION; MARKER
AB Objective: The prognostic significance of circulating tumor cells (CTCs) is controversial in gastric cancer (GC). We performed a meta-analysis of available studies to assess its prognostic value detected by RT-PCR for patients diagnosed with GC.
   Methods: EMBase, PubMed, Ovid, Web of Science, Cochrane library and Google Scholar database search was conducted on all studies reporting the outcomes of interest. The studies were set up according to the inclusion/exclusion criteria. Meta-analysis was performed by using a random-effects model; hazard ratio (HR), risk ratio (RR) and their 95% confidence intervals (95% CIs) were set as effect measures. The information about trial design, results from the data was independently extracted. Heterogeneity of the studies was tested for each pooled analysis.
   Results: Nineteen studies published matched the selection criteria and were included in this meta-analysis. CTCs positivity was significantly associated with poor relapse free survival (RFS) (HR 2.42, 95% CI: [1.94-3.02]; P < 0.001) and poor overall survival (OS) (HR 2.42, 95% CI: [1.94-3.02]; P < 0.001). CTCs positivity were also significantly associated with regional lymph nodes (RLNs) metastasis (RR 1.42, 95% CI: [1.20-1.68]; p < 0.0001), depth of infiltration (RR 1.51, 95% CI: [1.27-1.79]; p < 0.0001), vascular invasion (RR = 1.43, 95% CI: [1.18-1.74], p = 0.0002) and TNM stage(I, II versus III) (RR 0.63, 95% CI [0.48-0.84]; p = 0.001).
   Conclusion: Preoperative CTCs positivity indicates poor prognosis in patients with gastric cancer, and associated with poor clinicopathological prognostic factors.
C1 [Wang, Shuyi; Cheng, Boran; Chen, Fangfang; Wang, Zhenmeng; Chen, Yuanyuan; Wang, You; Xiong, Bin] Wuhan Univ, Hubei Key Lab Tumor Biol Behav, Hubei Canc Clin Study Ctr, Dept Oncol,Zhongnan Hosp, Wuhan 430072, Hubei, Peoples R China.
   [Zheng, Gang] 5th Hosp Wuhan, Dept Gen Surg, Wuhan, Hubei, Peoples R China.
RP Xiong, B (reprint author), Wuhan Univ, Hubei Key Lab Tumor Biol Behav, Hubei Canc Clin Study Ctr, Dept Oncol,Zhongnan Hosp, Wuhan 430072, Hubei, Peoples R China.
EM Binxiong1961@gmail.com
FU National High Technology Research and Development Program of China
   [2012AA02A502, 2012AA02A506]
FX The work was supported by National High Technology Research and
   Development Program of China (Grant No. 2012AA02A502, 2012AA02A506). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alix-Panabieres C, 2012, ANNU REV MED, V63, P199, DOI 10.1146/annurev-med-062310-094219
   Arigami T, 2013, ONCOL REP, V30, P2838, DOI 10.3892/or.2013.2775
   Arigami T, 2011, CANCER SCI, V102, P1019, DOI 10.1111/j.1349-7006.2011.01877.x
   Ashworth TR, 1869, AUST MED J, V14
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a
   Bertazza L, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-111
   Bertuccio P, 2009, INT J CANCER, V125, P666, DOI 10.1002/ijc.24290
   Bidard FC, 2010, ANN ONCOL, V21, P729, DOI 10.1093/annonc/mdp391
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Cao WG, 2011, J SURG ONCOL, V103, P110, DOI 10.1002/jso.21777
   Cohen SJ, 2008, J CLIN ONCOL, V26, P3213, DOI 10.1200/JCO.2007.15.8923
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   ENGELL H C, 1955, Acta Chir Scand Suppl, V201, P1
   Ikeguchi M, 2005, SURG TODAY, V35, P436, DOI 10.1007/s00595-004-2978-z
   Illert B, 2005, SCAND J GASTROENTERO, V40, P843, DOI 10.1080/00365520510015557
   Kita Y, 2009, BRIT J CANCER, V100, P153, DOI 10.1038/sj.bjc.6604806
   Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627
   Koga T, 2008, HEPATO-GASTROENTEROL, V55, P1131
   Kosaka Y, 2007, BRIT J CANCER, V96, P1723, DOI 10.1038/sj.bjc.6603785
   Liu MC, 2009, J CLIN ONCOL, V27, P5153, DOI 10.1200/JCO.2008.20.6664
   Majima T, 2000, JPN J CLIN ONCOL, V30, P499, DOI 10.1093/jjco/hyd130
   Miyazono F, 2001, ANN SURG, V233, P189, DOI 10.1097/00000658-200102000-00007
   Nishida S, 2000, ANTICANCER RES, V20, P2155
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Pantel K, 2010, TRENDS MOL MED, V16, P398, DOI 10.1016/j.molmed.2010.07.001
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Pham B, 2005, J CLIN EPIDEMIOL, V58, P769, DOI 10.1016/j.jclinepi.2004.08.021
   Qiu MZ, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-107
   Rahbari NN, 2010, GASTROENTEROLOGY, V138, P1714, DOI 10.1053/j.gastro.2010.01.008
   Seo JH, 2005, AM J CLIN ONCOL-CANC, V28, P24, DOI 10.1097/01.coc.0000139018.47930.a5
   Shaffer DR, 2007, CLIN CANCER RES, V13, P2023, DOI 10.1158/1078-0432.CCR-06-2701
   Shin JH, 2002, ALIMENT PHARM THERAP, V16, P137, DOI 10.1046/j.1365-2036.16.s2.33.x
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Sumikura S, 2003, CANCER LETT, V200, P77, DOI 10.1016/S0304-3835(03)00388-4
   Uen YH, 2006, CLIN CHIM ACTA, V367, P55, DOI 10.1016/j.cca.2005.11.013
   Vincent-Salomon A, 2008, J CLIN PATHOL, V61, P570, DOI 10.1136/jcp.2007.046649
   Wicha MS, 2011, J CLIN ONCOL, V29, P1508, DOI 10.1200/JCO.2010.34.0026
   Wu CH, 2006, DIS MARKERS, V22, P103, DOI 10.1155/2006/281315
   Yang L, 2006, WORLD J GASTROENTERO, V12, P17, DOI 10.3748/wjg.v12.i1.17
   Yie SM, 2008, ANN SURG ONCOL, V15, P3073, DOI 10.1245/s10434-008-0069-x
NR 42
TC 20
Z9 20
U1 0
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 5
PY 2014
VL 9
IS 6
AR e99259
DI 10.1371/journal.pone.0099259
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI4NF
UT WOS:000336841400116
PM 24901848
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, HF
   Wang, F
   Ding, L
   Zhang, ZY
   Sun, DR
   Feng, XM
   An, JL
   Zhu, Y
AF Zhang, Haifei
   Wang, Feng
   Ding, Lin
   Zhang, Zhiyu
   Sun, Deri
   Feng, Xinmin
   An, Jiuli
   Zhu, Yue
TI A Meta Analysis of Lumbar Spinal Fusion Surgery Using Bone Morphogenetic
   Proteins and Autologous Iliac Crest Bone Graft
SO PLOS ONE
LA English
DT Article
ID PROTEIN-2/COMPRESSION RESISTANT MATRIX; INSTRUMENTED POSTEROLATERAL
   FUSIONS; RADIOGRAPHIC OUTCOMES; OSTEOGENIC PROTEIN-1; PUBLICATION BIAS;
   SITE MORBIDITY; RHBMP-2; SAFETY; METAANALYSIS; AUTOGRAFT
AB Background: Bone morphogenetic protein (BMPs) as a substitute for iliac crest bone graft (ICBG) has been increasingly widely used in lumbar fusion. The purpose of this study is to systematically compare the effectiveness and safety of fusion with BMPs for the treatment of lumbar disease.
   Methods: Cochrane review methods were used to analyze all relevant randomized controlled trials (RCTs) published up to nov 2013.
   Results: 19 RCTs (1,852 patients) met the inclusion criteria. BMPs group significantly increased fusion rate (RR: 1.13; 95% CI 1.05-1.23, P = 0.001), while there was no statistical difference in overall success of clinical outcomes (RR: 1.04; 95% CI 0.95-1.13, P = 0.38) and complications (RR: 0.96; 95% CI 0.85-1.09, p = 0.54). A significant reduction of the reoperation rate was found in BMPs group (RR: 0.57; 95% CI 0.42-0.77, p = 0.0002). Significant difference was found in the operating time (MD-0.32; 95% CI-0.55, -0.08; P = 0.009), but no significant difference was found in the blood loss, the hospital stay, patient satisfaction, and work status.
   Conclusion: Compared with ICBG, BMPs in lumbar fusion can increase the fusion rate, while reduce the reoperation rate and operating time. However, it doesn't increase the complication rate, the amount of blood loss and hospital stay. No significant difference was found in the overall success of clinical outcome of the two groups.
C1 [Zhang, Haifei; Wang, Feng; Zhang, Zhiyu; Sun, Deri; Feng, Xinmin; An, Jiuli] China Med Univ, Affiliated Hosp 4, Dept Orthoped, Shenyang, Peoples R China.
   [Ding, Lin] China Med Univ, Ctr Comp, Shenyang, Peoples R China.
   [Zhu, Yue] China Med Univ, Affiliated Hosp 1, Dept Orthoped, Shenyang, Peoples R China.
RP Zhu, Y (reprint author), China Med Univ, Affiliated Hosp 1, Dept Orthoped, Shenyang, Peoples R China.
EM zhuyuedr@163.com
CR Agarwal R, 2009, J NEUROSURG-SPINE, V11, P729, DOI 10.3171/2009.6.SPINE08669
   Ahlmann E, 2002, J BONE JOINT SURG AM, V84A, P716, DOI 10.2106/00004623-200205000-00003
   An H, 2003, SPINE, V28, pS24, DOI 10.1097/00007632-200308011-00005
   Arrington ED, 1996, CLIN ORTHOP RELAT R, P300, DOI 10.1097/00003086-199608000-00037
   Assiri I, 2004, CAN J SURG S, V47, P7
   BANWART JC, 1995, SPINE, V20, P1055, DOI 10.1097/00007632-199505000-00012
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benglis D, 2008, NEUROSURGERY, V62, P423, DOI 10.1227/01.neu.0000326030.24220.d8
   BLUMENTHAL SL, 1993, SPINE, V18, P1186, DOI 10.1097/00007632-199307000-00010
   Boden SD, 2000, SPINE, V25, P376, DOI 10.1097/00007632-200002010-00020
   Boden SD, 2002, SPINE, V27, P2662, DOI 10.1097/00007632-200212010-00005
   Burkus JK, 2005, J BONE JOINT SURG AM, V87A, P1205, DOI 10.2106/JBJS.D.02532
   Burkus JK, 2003, SPINE, V28, P372, DOI 10.1097/00007632-200302150-00012
   Burkus JK, 2002, J SPINAL DISORD TECH, V15, P337, DOI 10.1097/00024720-200210000-00001
   Burkus JK, 2002, SPINE, V27, P2396, DOI 10.1097/01.BRS.0000030193.26290.DD
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843
   Chen ZG, 2012, ARCH ORTHOP TRAUM SU, V132, P1725, DOI 10.1007/s00402-012-1607-3
   Dawson E, 2009, J BONE JOINT SURG AM, V91A, P1604, DOI 10.2106/JBJS.G.01157
   Delawi D, 2010, SPINE, V35, P1185, DOI 10.1097/BRS.0b013e3181d3cf28
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dimar JR, 2006, SPINE, V31, P2534, DOI 10.1097/01.brs.0000240715.78657.81
   Dimar JR, 2009, J BONE JOINT SURG AM, V91A, P1377, DOI 10.2106/JBJS.H.00200
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Donell S, 2011, BONE MORPHOGENETIC P
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3
   Fu RW, 2013, ANN INTERN MED, V158, P890, DOI 10.7326/0003-4819-158-12-201306180-00006
   Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f
   Glassman SD, 2005, SPINE, V30, P1694, DOI 10.1097/01.brs.0000172157.39513.80
   Glassman SD, 2008, SPINE, V33, P2843, DOI 10.1097/BRS.0b013e318190705d
   Haid Regis W Jr, 2004, Spine J, V4, P527, DOI 10.1016/j.spinee.2004.03.025
   HUTCHINSON MR, 1994, SPINE, V19, P62, DOI 10.1097/00007632-199401000-00013
   Johnsson R, 2002, SPINE, V27, P2654, DOI 10.1097/00007632-200212010-00004
   Kanayama M, 2006, SPINE, V31, P1067, DOI 10.1097/01.brs.0000216444.01888.21
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Michielsen J, 2013, J BONE JOINT SURG AM, V95A, P873, DOI 10.2106/JBJS.L.00137
   Mroz TE, 2010, SPINE, V35, pS86, DOI 10.1097/BRS.0b013e3181d81ef2
   Mussano F, 2007, SPINE, V32, P824, DOI 10.1097/01.brs.0000259227.51180.ca
   Papakostidis C, 2008, SPINE, V33, pE680, DOI 10.1097/BRS.0b013e3181844eca
   Poynton AR, 2002, SPINE, V27, pS40, DOI 10.1097/01.BRS.0000020734.34957.6A
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247
   Sen MK, 2007, INJURY, V38, pS75, DOI 10.1016/j.injury.2007.02.012
   Simmonds MC, 2013, ANN INTERN MED, V158, P877, DOI 10.7326/0003-4819-158-12-201306180-00005
   Sutton AJ, 2000, BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Vaccaro AR, 2008, SPINE, V33, P2850, DOI 10.1097/BRS.0b013e31818a314d
   Vaccaro AR, 2005, SPINE, V30, P2709, DOI 10.1097/01.brs.0000190812.08447.ba
   Viera AJ, 2005, FAM MED, V37, P360
   Younger E M, 1989, J Orthop Trauma, V3, P192, DOI 10.1097/00005131-198909000-00002
NR 52
TC 8
Z9 8
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 2
PY 2014
VL 9
IS 6
AR e97049
DI 10.1371/journal.pone.0097049
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI6CB
UT WOS:000336956300011
PM 24886911
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, XL
   Xie, J
   Li, GN
   Chen, QH
   Xu, BA
AF Zhang, Xinlin
   Xie, Jun
   Li, Guannan
   Chen, Qinhua
   Xu, Biao
TI Head-to-Head Comparison of Sirolimus-Eluting Stents versus
   Paclitaxel-Eluting Stents in Patients Undergoing Percutaneous Coronary
   Intervention: A Meta-Analysis of 76 Studies
SO PLOS ONE
LA English
DT Article
ID BARE-METAL STENTS; LONG-TERM OUTCOMES; RANDOMIZED-TRIALS;
   DIABETES-MELLITUS; FOLLOW-UP; EFFICACY
AB Background: The relative short-, long- and overall-term efficacy and safety of sirolimus-eluting stents (SES, Cypher) compared with paclitaxel-eluting stents (PES, Taxus) in large head-to-head comparisons still remain to be defined.
   Methods: We searched Pubmed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) for articles comparing outcomes of interest between SES and PES without language restriction. Short- (<= 1 year), long- (>1 year), and overall-term (the longest follow-up of each study) outcomes were evaluated. The primary endpoint was target lesion revascularization (TLR). Other outcomes of interest were target vessel revascularization (TVR), myocardial infarction, all-cause death, cardiac death, stent thrombosis, major adverse cardiac events (MACEs), restenosis and late lumen loss.
   Results: Seventy-six studies including more than 15000 patients in randomized controlled trials and over 70000 patients in adjusted observational studies were included. At overall-term follow-up, SES significantly reduced TLR (relative risk [RR]: 0.61; 95% confidence interval [CI]: 0.49-0.76), TVR (RR: 0.67; 95% CI: 0.54-0.83), MACE (RR: 0.79; 95% CI: 0.72-0.87), myocardial infarction (RR: 0.85; 95% CI: 0.73-0.99), in-segment restenosis (RR: 0.50; 95% CI: 0.38-0.65), and in-segment late lumen loss (weighted mean difference [WMD]: 20.19; 95% CI: 20.24-20.14) in randomized controlled trials compared with PES. In addition, lower rates of death (RR: 0.91; 95% CI: 0.83-1.00), any stent thrombosis (RR: 0.62; 95% CI: 0.45-0.86), definite stent thrombosis (RR: 0.59; 95% CI: 0.45-0.77) were found in patients receiving SES in adjusted observational studies. Largely similar results were found at short-and long-term follow-up, and in patients with diabetes, acute myocardial infarction or long lesions.
   Conclusions: SES significantly reduced the short-, long-and overall-term risk of TLR/TVR, MACE, and restenosis, and overall-term risk of myocardial infarction in randomized controlled trials, as compared with PES. Lower rates of death and stent thrombosis were also observed in observational studies in SES-treated patients.
C1 [Zhang, Xinlin; Xie, Jun; Li, Guannan; Chen, Qinhua; Xu, Biao] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Cardiol, Nanjing 210008, Jiangsu, Peoples R China.
RP Xu, BA (reprint author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Cardiol, Nanjing 210008, Jiangsu, Peoples R China.
EM xubiao@medmail.com.cn
RI xie, jun/C-2193-2017
OI xie, jun/0000-0002-9385-3242
FU National Natural Science Foundation of China [81070195, 81270281,
   81200148]; Jiangsu Key Laboratory for Molecular Medicine of Nanjing
   University; Funds for Distinguished Young Scientists in Nanjing
FX This work was supported by grants from the National Natural Science
   Foundation of China (research grants 81070195, 81270281 and 81200148),
   Jiangsu Key Laboratory for Molecular Medicine of Nanjing University
   (research grant 2008), and Funds for Distinguished Young Scientists in
   Nanjing (Xie Jun). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bangalore S, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5170
   Bangalore S, 2012, CIRCULATION, V125, P2873, DOI 10.1161/CIRCULATIONAHA.112.097014
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Dahabreh IJ, 2012, EUR HEART J, V33, P1893, DOI 10.1093/eurheartj/ehs114
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dibra A, 2005, NEW ENGL J MED, V353, P663, DOI 10.1056/NEJMoa044372
   Egger M, 2001, SYSTEMATIC REV HLTH, V357
   Elezi S, 1998, J AM COLL CARDIOL, V32, P1866, DOI 10.1016/S0735-1097(98)00467-7
   Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kastrati A, 2005, JAMA-J AM MED ASSOC, V294, P819, DOI 10.1001/jama.294.7.819
   Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7
   Kirtane AJ, 2009, CIRCULATION, V119, P3198, DOI 10.1161/CIRCULATIONAHA.108.826479
   Lupi A, 2011, CIRC J, V75, P280, DOI 10.1253/circj.CJ-10-0186
   Mahmud E, 2008, J AM COLL CARDIOL, V51, P2385, DOI 10.1016/j.jacc.2008.03.028
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071
   Pfisterer M, 2006, J AM COLL CARDIOL, V48, P2584, DOI 10.1016/j.jacc.2006.10.026
   Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643
   Schomig A, 2007, J AM COLL CARDIOL, V50, P1373, DOI 10.1016/j.jacc.2007.06.047
   Stettler C, 2007, LANCET, V370, P937, DOI 10.1016/S0140-6736(07)61444-5
   Wallace EL, 2012, AM J CARDIOL, V109, P932, DOI 10.1016/j.amjcard.2011.11.021
   Wells GA, 2012, NEWCASTLE OTTAWA SCA
NR 26
TC 5
Z9 5
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2014
VL 9
IS 5
AR e97934
DI 10.1371/journal.pone.0097934
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM0UW
UT WOS:000339563400072
PM 24844284
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU He, XF
   Liu, LR
   Wei, W
   Liu, Y
   Su, J
   Wang, SL
   Shen, XL
   Yang, XB
AF He, Xiao-Feng
   Liu, Li-Rong
   Wei, Wu
   Liu, Yi
   Su, Jiao
   Wang, Su-Lan
   Shen, Xu-Liang
   Yang, Xian-Bin
TI Association between the XPG Asp1104His and XPF Arg415Gln Polymorphisms
   and Risk of Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID NUCLEOTIDE EXCISION-REPAIR; XERODERMA-PIGMENTOSUM GENES;
   NON-HODGKIN-LYMPHOMA; DNA-REPAIR; BREAST-CANCER; LUNG-CANCER;
   BLADDER-CANCER; COLORECTAL-CANCER; CUTANEOUS MELANOMA; ENDOMETRIAL
   CANCER
AB Background: The XPG (xeroderma pigmentosum type G) Asp1104His and XPF (xeroderma pigmentosum type F) Arg415Gln polymorphisms had been implicated in cancer susceptibility. The previous published data on the association between XPG Asp1104His and XPF Arg415Gln polymorphisms and cancer risk remained controversial.
   Methodology/Principal Findings: To derive a more precise estimation of the association between the XPG Asp1104His and XPF Arg415Gln polymorphisms and overall cancer risk, we performed a meta-analysis to investigate the association between cancer susceptibility and XPG Asp1104His (32,162 cases and 39,858 controls from 66 studies) and XPF Arg415Gln polymorphisms (17,864 cases and 20,578 controls from 32 studies) in different inheritance models. We used odds ratios with 95% confidence intervals to assess the strength of the association. Overall, significantly elevated cancer risk was found when all studies were pooled into the meta-analysis of XPG Asp1104His (dominant model: OR = 1.05, 95% CI = 1.00-1.10; Asp/His vs. Asp/Asp: OR = 1.06, 95% CI = 1.01-1.11). In the further stratified and sensitivity analyses, significantly decreased lung cancer risk was found for XPF Arg415Gln (dominant model: OR = 0.82, 95% CI = 0.71-0.96; Arg/Gln versus Arg/Arg: OR = 0.83, 95% CI = 0.71-0.97; additive model: OR = 0.83, 95% CI = 0.72-0.95) and significantly increased other cancer risk was found among hospital-based studies for XPG Asp1104His (dominant model: OR = 1.23, 95% CI = 1.02-1.49).
   Conclusions/Significance: In summary, this meta-analysis suggests that XPF Arg415Gln polymorphism may be associated with decreased lung cancer risk and XPG Asp1104His may be a low-penetrant risk factor in some cancers development. And larger scale primary studies are required to further evaluate the interaction of XPG Asp1104His and XPF Arg415Gln polymorphisms and cancer risk in specific populations.
C1 [He, Xiao-Feng; Yang, Xian-Bin] Changzhi Med Coll, Peace Hosp, Dept Res, Changzhi, Peoples R China.
   [Liu, Li-Rong] Guiyang Med Univ, Affiliated Hosp, Dept Clin Biochem, Guiyang, Peoples R China.
   [Wei, Wu; Wang, Su-Lan; Shen, Xu-Liang] Changzhi Med Coll, Peace Hosp, Dept Hematol, Changzhi, Peoples R China.
   [Liu, Yi] Southern Med Univ, Nanfang Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.
   [Su, Jiao] Changzhi Med Coll, Dept Biol Chem, Changzhi, Peoples R China.
RP Wei, W (reprint author), Changzhi Med Coll, Peace Hosp, Dept Hematol, Changzhi, Peoples R China.
EM weiwuhxf@163.com
CR Abbasi R, 2009, INT J CANCER, V125, P1431, DOI 10.1002/ijc.24442
   Agalliu I, 2010, CANCER CAUSE CONTROL, V21, P289, DOI 10.1007/s10552-009-9461-5
   Araujo SJ, 2001, MOL CELL BIOL, V21, P2281, DOI 10.1128/MCB.21.7.2281-2291.2001
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berhane N, 2012, MOL BIOL REP, V39, P2471, DOI 10.1007/s11033-011-0998-5
   Biason P, 2012, PHARMACOGENOMICS J, V12, P476, DOI 10.1038/tpj.2011.33
   Bigler J, 2005, CANCER EPIDEM BIOMAR, V14, P2501, DOI 10.1158/1055-9965.EPI-05-0270
   Blankenburg S, 2005, EUR J HUM GENET, V13, P253, DOI 10.1038/sj.ejhg.5201296
   Canbay E, 2011, CURR MED RES OPIN, V27, P1295, DOI 10.1185/03007995.2011.573544
   Canbay E, 2010, ANTICANCER RES, V30, P1359
   Chang JS, 2008, INT J CANCER, V123, P2095, DOI 10.1002/ijc.23801
   Cheng HB, 2013, ASIAN PAC J CANCER P, V14, P4083, DOI 10.7314/APJCP.2013.14.7.4083
   Cleaver JE, 2000, J DERMATOL SCI, V23, P1, DOI 10.1016/S0923-1811(99)00088-2
   Crew KD, 2007, CANCER EPIDEM BIOMAR, V16, P2033, DOI 10.1158/1055-9965.EPI-07-0096
   Cui Y, 2006, INT J CANCER, V118, P714, DOI 10.1002/ijc.21413
   Davey SG, 1997, LANCET, V350, P1182, DOI DOI 10.1016/S0140-6736(05)63833-0
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Doherty JA, 2011, CANCER EPIDEM BIOMAR, V20, P1873, DOI 10.1158/1055-9965.EPI-11-0119
   Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Zein R, 2009, CANCER, V115, P1651, DOI 10.1002/cncr.24205
   Figl A, 2010, MUTAT RES-GEN TOX EN, V702, P8, DOI 10.1016/j.mrgentox.2010.06.011
   Freidin M. B., 2008, Radiatsionnaya Biologiya Radioekologiya, V48, P439
   Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000
   Garcia-Closas M, 2006, CANCER EPIDEM BIOMAR, V15, P536, DOI 10.1158/1055-9965.EPI-05-0749
   Gil J, 2012, MOL BIOL REP, V39, P527, DOI 10.1007/s11033-011-0767-5
   Gillet LCJ, 2006, CHEM REV, V106, P253, DOI 10.1021/cr040483f
   Goncalves FT, 2011, J DERMATOL SCI, V64, P59, DOI 10.1016/j.jdermsci.2011.06.003
   Han JL, 2009, BREAST CANCER RES TR, V115, P613, DOI 10.1007/s10549-008-0089-z
   He XH, 2008, PATHOBIOLOGY, V75, P356, DOI 10.1159/000164220
   Higgins JP, 2008, COCHRANE HDB SYSTEMA
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hill DA, 2006, BLOOD, V108, P3161, DOI 10.1182/blood-2005-01-026690
   Hooker S, 2008, PROSTATE CANCER P D, V11, P349, DOI 10.1038/sj.pcan.4501027
   Hsu MS, 2010, ANN SURG ONCOL, V17, P760, DOI 10.1245/s10434-009-0802-0
   Huang WY, 2006, CANCER EPIDEM BIOMAR, V15, P306, DOI 10.1158/1055-9965.EPI-05-0751
   Hung RJ, 2008, CANCER EPIDEM BIOMAR, V17, P3081, DOI 10.1158/1055-9965.EPI-08-0411
   Hussain SK, 2009, CANCER EPIDEM BIOMAR, V18, P2304, DOI 10.1158/1055-9965.EPI-09-0233
   Ibarrola-Villava M, 2011, EUR J CANCER, V47, P2618, DOI 10.1016/j.ejca.2011.05.011
   Jeon HS, 2003, CARCINOGENESIS, V24, P1677, DOI 10.1093/carcin/bgg120
   Jorgensen TJ, 2007, BREAST CANCER RES TR, V101, P65, DOI 10.1007/s10549-006-9263-3
   Joshi AD, 2009, CARCINOGENESIS, V30, P472, DOI 10.1093/carcin/bgn260
   Klug SJ, 2009, LANCET ONCOL, V10, P772, DOI 10.1016/S1470-2045(09)70187-1
   Krupa R., 2011, Experimental Oncology, V33, P55
   Kumar R, 2003, INT J CANCER, V103, P671, DOI 10.1002/ijc.10870
   Li CY, 2006, CANCER EPIDEM BIOMAR, V15, P2526, DOI 10.1158/1055-9965.EPI-06-0672
   Li Long-man, 2010, Zhonghua Gan Zang Bing Za Zhi, V18, P271, DOI 10.3760/cma.j.issn.1007-3418.2010.04.009
   Liu D, 2012, MOL CARCINOGEN, V51, pE83, DOI 10.1002/mc.21862
   Liu YH, 2009, CANCER EPIDEM BIOMAR, V18, P204, DOI 10.1158/1055-9965.EPI-08-0632
   Ma HX, 2012, PHARMACOGENET GENOM, V22, P50, DOI 10.1097/FPC.0b013e32834e3cf6
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   McKean-Cowdin R, 2009, CANCER EPIDEM BIOMAR, V18, P1118, DOI 10.1158/1055-9965.EPI-08-1078
   McWilliams RR, 2008, CANCER RES, V68, P4928, DOI 10.1158/0008-5472.CAN-07-5539
   Mechanic LE, 2006, CARCINOGENESIS, V27, P1377, DOI 10.1093/carcin/bgi330
   Millikan RC, 2006, CARCINOGENESIS, V27, P610, DOI 10.1093/carcin/bgi252
   Moreno V, 2006, CLIN CANCER RES, V12, P2101, DOI 10.1158/1078-0432.CCR-05-1363
   Narter KF, 2009, ANTICANCER RES, V29, P1389
   ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0
   Pan J, 2009, CARCINOGENESIS, V30, P785, DOI 10.1093/carcin/bgp058
   Pardini B, 2008, MUTAT RES-FUND MOL M, V638, P146, DOI 10.1016/j.mrfmmm.2007.09.008
   Paszkowska-Szczur K, 2013, INT J CANCER, V133, P1094, DOI 10.1002/ijc.28123
   Povey JE, 2007, CARCINOGENESIS, V28, P1087, DOI 10.1093/carcin/bgl257
   Rajaraman P, 2008, INT J CANCER, V123, P2713, DOI 10.1002/ijc.23779
   Rajaraman P, 2010, NEURO-ONCOLOGY, V12, P37, DOI 10.1093/neuonc/nop012
   Romanowicz-Makowska Hanna, 2007, Pol Merkur Lekarski, V22, P200
   Rouissi K, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-101
   Sakiyama T, 2005, INT J CANCER, V114, P730, DOI 10.1002/ijc.20790
   Santos LS, 2013, ONCOL REP, V30, P2458, DOI 10.3892/or.2013.2702
   Sanyal S, 2004, CARCINOGENESIS, V25, P729, DOI 10.1093/carcin/bgh058
   Shen J, 2006, CANCER EPIDEM BIOMAR, V15, P1614, DOI 10.1158/1055-9965.EPI-06-0218
   Shen M, 2006, HUM GENET, V119, P659, DOI 10.1007/s00439-006-0177-2
   Shen M, 2005, INT J CANCER, V116, P768, DOI 10.1002/ijc.21117
   Shen M, 2007, HAEMATOL-HEMATOL J, V92, P1180, DOI 10.3324/haematol.11324
   Shi TY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038606
   Smith TR, 2008, CARCINOGENESIS, V29, P2132, DOI 10.1093/carcin/bgn193
   Smith TR, 2011, CARCINOGENESIS, V32, P1354, DOI 10.1093/carcin/bgr117
   Smith TR, 2003, CANCER EPIDEM BIOMAR, V12, P1200
   Sugimura T, 2006, J ORAL PATHOL MED, V35, P11, DOI 10.1111/j.1600-0714.2005.00364.x
   Thirumaran RK, 2006, CARCINOGENESIS, V27, P1676, DOI 10.1093/carcin/bgi381
   Visapaa JP, 2004, GUT, V53, P871, DOI 10.1136/gut.2003.018994
   Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030
   Wang LE, 2007, CLIN CANCER RES, V13, P6532, DOI 10.1158/1078-0432.CCR-07-0969
   Wang XF, 2013, GENE, V529, P317, DOI 10.1016/j.gene.2013.07.025
   Weiss JM, 2005, CANCER EPIDEM BIOMAR, V14, P2524, DOI 10.1158/1055-9965.EPI-05-0414
   Weiss JM, 2006, GYNECOL ONCOL, V103, P891, DOI 10.1016/j.ygyno.2006.05.020
   Wen H, 2013, ACTAS UROL ESP, V37, P259, DOI 10.1016/j.acuro.2012.04.007
   Wen H, 2009, INT UROL NEPHROL, V41, P855, DOI 10.1007/s11255-009-9560-y
   Wen Shu-xin, 2006, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V28, P703
   Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154
   Wu XF, 2006, AM J HUM GENET, V78, P464, DOI 10.1086/500848
   Yu HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041853
   Zhu ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036293
   Zienolddiny S, 2006, CARCINOGENESIS, V27, P560, DOI 10.1093/carcin/bgi232
NR 93
TC 4
Z9 4
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 6
PY 2014
VL 9
IS 5
AR e88490
DI 10.1371/journal.pone.0088490
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AJ9KS
UT WOS:000338029800015
PM 24802942
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Kunutsor, SK
   Seddoh, D
AF Kunutsor, Setor K.
   Seddoh, Dorothy
TI Alanine Aminotransferase and Risk of the Metabolic Syndrome: A Linear
   Dose-Response Relationship
SO PLOS ONE
LA English
DT Article
ID GAMMA-GLUTAMYL-TRANSFERASE; FATTY LIVER-DISEASE; GENOME-WIDE
   ASSOCIATION; C-REACTIVE PROTEIN; INSULIN-RESISTANCE; GENETIC
   EPIDEMIOLOGY; TREND ESTIMATION; WOMEN; MEN; METAANALYSIS
AB Background: Elevated baseline circulating alanine aminotransferase (ALT) level has been demonstrated to be associated with an increased risk of the metabolic syndrome (MetS), but the nature of the dose-response relationship is uncertain.
   Methods: We performed a systematic review and meta-analysis of published prospective cohort studies to characterize in detail the nature of the dose-response relationship between baseline ALT level and risk of incident MetS in the general population. Relevant studies were identified in a literature search of MEDLINE, EMBASE, and Web of Science up to December 2013. Prospective studies in which investigators reported relative risks (RRs) of MetS for 3 or more categories of ALT levels were eligible. A potential nonlinear relationship between ALT levels and MetS was examined using restricted cubic splines.
   Results: Of the 489 studies reviewed, relevant data were available on 29,815 non-overlapping participants comprising 2,125 incident MetS events from five prospective cohort studies. There was evidence of a linear association (P for nonlinearity = 0.38) between ALT level and risk of MetS, characterised by a graded increase in MetS risk at ALT levels 640 U/L. The risk of MetS increased by 14% for every 5 U/L increment in circulating ALT level (95% CI: 12-17%). Evidence was lacking of heterogeneity and publication bias among the contributing studies.
   Conclusions: Baseline ALT level is associated with risk of the MetS in a linear dose-response manner. Studies are needed to determine whether the association represents a causal relationship.
C1 [Kunutsor, Setor K.] Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Cambridge, England.
   [Seddoh, Dorothy] Maranatha Univ Coll, Accra, Ghana.
RP Kunutsor, SK (reprint author), Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Cambridge, England.
EM skk31@cantab.net
RI Kunutsor, Setor K/H-9807-2019
OI Kunutsor, Setor K/0000-0002-2625-0273
CR Al-Hamoudi W, 2013, DIGESTIVE DIS SCI
   Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Andre P, 2007, DIABETES CARE, V30, P2355, DOI 10.2337/dc07-0440
   Bathum L, 2001, CLIN CHEM, V47, P81
   Bee Ying Tan Jr, 2008, Malays J Nutr, V14, P65
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chambers JC, 2011, NAT GENET, V43, P1131, DOI 10.1038/ng.970
   Chitturi S, 2002, HEPATOLOGY, V35, P373, DOI 10.1053/jhep.2002.30692
   Clark JM, 2003, JAMA-J AM MED ASSOC, V289, P3000, DOI 10.1001/jama.289.22.3000
   Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI 10.1016/S0002-9270(03)00265-X
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Goessling W, 2008, GASTROENTEROLOGY, V135, P1935, DOI 10.1053/j.gastro.2008.09.018
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Hanley AJG, 2005, DIABETES, V54, P3140, DOI 10.2337/diabetes.54.11.3140
   HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hunt KJ, 2004, CIRCULATION, V110, P1251, DOI 10.1161/01.CIR.0000140762.04598.F9
   Jo SK, 2009, CLIN CHIM ACTA, V403, P234, DOI 10.1016/j.cca.2009.03.035
   Kamatani Y, 2010, NAT GENET, V42, P210, DOI 10.1038/ng.531
   Lee JK, 2010, HEPATOLOGY, V51, P1577, DOI 10.1002/hep.23505
   Lidofsky SD, 2008, CURR DIABETES REP, V8, P25, DOI 10.1007/s11892-008-0006-1
   Liu ZT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080596
   Lorenzo C, 2003, DIABETES CARE, V26, P3153, DOI 10.2337/diacare.26.11.3153
   Marchesini G, 2001, DIABETES, V50, P1844, DOI 10.2337/diabetes.50.8.1844
   McKenzie J, 2006, CLIN ENDOCRINOL, V65, P40, DOI 10.1111/j.1365-2265.2006.02543.x
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Musso G, 2010, HEPATOLOGY, V52, P79, DOI 10.1002/hep.23623
   Nakanishi N, 2004, DIABETES CARE, V27, P1427, DOI 10.2337/diacare.27.6.1427
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Prati D, 2002, ANN INTERN MED, V137, P1, DOI 10.7326/0003-4819-137-1-200207020-00006
   Rahmioglu N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004435
   Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05
   Sattar N, 1998, INT J OBESITY, V22, P432, DOI 10.1038/sj.ijo.0800604
   Sattar N, 2003, CIRCULATION, V108, P414, DOI 10.1161/01.CIR.0000080897.52664.94
   Schindhelm RK, 2007, DIABETIC MED, V24, P430, DOI 10.1111/j.1464-5491.2007.02100.x
   Schindhelm RK, 2006, DIABETES-METAB RES, V22, P437, DOI 10.1002/dmrr.666
   SIEST G, 1975, CLIN CHEM, V21, P1077
   Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070
   Stevens J, 2001, OBES RES, V9, P696, DOI 10.1038/oby.2001.94
   Westerbacka J, 2004, DIABETOLOGIA, V47, P1360, DOI 10.1007/s00125-004-1460-1
   Whitfield JB, 2002, CLIN CHEM, V48, P1426
   Xu Y, 2011, J DIABETES, V3, P38, DOI 10.1111/j.1753-0407.2010.00111.x
   Yadav Dhananjay, 2013, Glob J Health Sci, V5, P142, DOI 10.5539/gjhs.v5n6p142
   Yuan X, 2008, AM J HUM GENET, V83, P520, DOI 10.1016/j.ajhg.2008.09.012
NR 46
TC 19
Z9 21
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 29
PY 2014
VL 9
IS 4
AR e96068
DI 10.1371/journal.pone.0096068
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG6CA
UT WOS:000335504900018
PM 24781277
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Niu, X
   Chen, X
   Xiao, Y
   Dong, JQ
   Zhang, R
   Lu, MX
   Kong, WJ
AF Niu, Xun
   Chen, Xiong
   Xiao, Ying
   Dong, Jiaqi
   Zhang, Rui
   Lu, Meixia
   Kong, Weijia
TI The Differences in Homocysteine Level between Obstructive Sleep Apnea
   Patients and Controls: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PLASMA HOMOCYSTEINE; CARDIOVASCULAR-DISEASE; RISK-FACTOR; SERUM
   HOMOCYSTEINE; OXIDATIVE STRESS; FOLIC-ACID; ASSOCIATION;
   HYPERHOMOCYSTEINEMIA; MANAGEMENT; IMPACT
AB Background: Studies have reported inconsistent findings regarding the relationship between obstructive sleep apnea (OSA) and homocysteine (HCY) level. This study aimed to assess the difference in plasma HCY level between OSA patients and controls by conducting a meta-analysis of published studies.
   Methods: Database of PubMed, SCI, and China National Knowledge Internet (CNKI) were comprehensively searched. Eligible studies regarding plasma HCY level in OSA patients were identified by two independent reviewers. RevMan (version 5.2) and STATA (version 12.0) were employed for data synthesis.
   Results: A total of 10 studies involving 432 subjects were included. Meta-analysis showed that plasma HCY levels in OSA group were 3.11 mu mol/l higher than that in control group (95% confidence interval: 2.08 to 4.15, P<0.01). Subgroup analysis revealed a more significant differences between OSA patients and controls when average body mass index >= 30 (the total weighted mean difference (WMD) was 3.64), average age < 50 (the total WMD was 3.96) and average apnea hypopnea index >= 35 (the total WMD was 4.54).
   Conclusions: In this meta-analysis, plasma HCY levels were found to be higher in OSA patients compared to control subjects.
C1 [Niu, Xun; Chen, Xiong; Xiao, Ying; Dong, Jiaqi; Zhang, Rui; Kong, Weijia] Huazhong Univ Sci & Technol, Dept Otolaryngol, Tongji Med Coll, Union Hosp, Wuhan 430074, Peoples R China.
   [Lu, Meixia] Huazhong Univ Sci & Technol, Dept Epidemiol & Biostat, Wuhan 430074, Hubei, Peoples R China.
   [Lu, Meixia] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ,Key Lab Environm & Hlth, Wuhan 430074, Hubei, Peoples R China.
   [Kong, Weijia] Huazhong Univ Sci & Technol, Tongji Med Coll, Res Inst Otorhinolaryngol, Wuhan 430074, Hubei, Peoples R China.
RP Kong, WJ (reprint author), Huazhong Univ Sci & Technol, Dept Otolaryngol, Tongji Med Coll, Union Hosp, Wuhan 430074, Peoples R China.
EM entwjkong@hust.edu.cn
OI Kong, Wei-Jia/0000-0001-5410-2297
FU Natural Science Foundation of Hubei Province in China [2011CDC072]
FX This study was supported by the Natural Science Foundation of Hubei
   Province in China (number 2011CDC072). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Basoglu OK, 2011, ANN THORAC MED, V6, P120, DOI 10.4103/1817-1737.82440
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049
   Brown DL, 2006, SEMIN NEUROL, V26, P117, DOI 10.1055/s-2006-933315
   Chen MG, 2011, J CLIN NEUROSCI, V18, P1454, DOI 10.1016/j.jocn.2011.01.037
   Cintra F, 2011, CHEST, V139, P246, DOI 10.1378/chest.10-0667
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008
   Ford AH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033345
   Geisel J, 2003, CLIN CHEM LAB MED, V41, P1513, DOI 10.1515/CCLM.2003.232
   Girelli D, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000083
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Kokturk O, 2006, RESP MED, V100, P536, DOI 10.1016/j.rmed.2005.05.025
   Labuz-Roszak Beata, 2004, Pol Merkur Lekarski, V16, P536
   Lavie L, 2001, CHEST, V120, P900, DOI 10.1378/chest.120.3.900
   Macey PM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076631
   Mangoni AA, 2002, AM J MED, V112, P556, DOI 10.1016/S0002-9343(02)01021-5
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Martinez D, 2012, SLEEP BREATH, V16, P695, DOI 10.1007/s11325-011-0559-0
   McNicholas WT, 2007, EUR RESPIR J, V29, P156, DOI 10.1183/09031936.00027406
   Monneret D, 2012, RESP PHYSIOL NEUROBI, V180, P298, DOI 10.1016/j.resp.2011.12.009
   Ozkan Y, 2008, SLEEP BREATH, V12, P149, DOI 10.1007/s11325-007-0148-4
   PEPPARD PE, 2013, AM J EPIDEMIOL
   Petrisor BA, 2006, INJURY, V37, P321, DOI 10.1016/j.injury.2006.02.001
   Ryan CM, 2005, J APPL PHYSIOL, V99, P2440, DOI 10.1152/japplphysiol.00772.2005
   Ryan S, 2007, THORAX, V62, P509, DOI 10.1136/thx.2006.066720
   Sales LV, 2013, CLINICS, V68, P449, DOI 10.6061/clinics/2013(04)03
   Silvestrini M, 2002, STROKE, V33, P1782, DOI 10.1161/01.STR.0000019123.47840.2D
   Stanger O, 2004, Z KARDIOL, V93, P439, DOI 10.1007/s00392-004-0075-3
   Svatikova A, 2004, EUR HEART J, V25, P1325, DOI 10.1016/j.ehj.2004.05.018
   Wang L, 2010, BIOMED ENVIRON SCI, V23, P42, DOI 10.1016/S0895-3988(10)60030-X
   Wang XH, 2008, CONCURRENT ENG-RES A, V16, P253, DOI 10.1177/1063293X08100025
   Wood D, 2001, AM HEART J, V141, pS49, DOI 10.1067/mhj.2001.109951
   Xiao Y, 2011, J HUAZHONG U SCI-MED, V31, P413, DOI 10.1007/s11596-011-0392-5
   Zhou YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025142
NR 38
TC 13
Z9 13
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 25
PY 2014
VL 9
IS 4
AR e95794
DI 10.1371/journal.pone.0095794
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI3CM
UT WOS:000336736600011
PM 24769854
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, MD
   Gu, W
   Qiao, SB
   Zhu, EJ
   Zhao, QM
   Lv, SZ
AF Zhang, Ming-duo
   Gu, Wei
   Qiao, Shi-bin
   Zhu, En-Jun
   Zhao, Quan-ming
   Lv, Shu-zheng
TI Apolipoprotein E Gene Polymorphism and Risk for Coronary Heart Disease
   in the Chinese Population: A Meta-Analysis of 61 Studies Including 6634
   Cases and 6393 Controls
SO PLOS ONE
LA English
DT Article
ID ARTERY-DISEASE; APOE GENOTYPE; ASSOCIATION; PREVALENCE; BIAS
AB Background: Numerous studies have evaluated the association between the apolipoprotein E (apoE) gene polymorphisms in coronary heart disease (CHD). However, the results remain uncertain. We carried out a meta-analysis to derive a more comprehensive estimation of the association in Chinese population.
   Methods: Case-control studies in Chinese and English publications were identified by searching databases of PubMed, EMBASE, Web of Science, CNKI, CBM, Wanfang, VIP and hand searching of relevant journals and the reference lists of retrieved articles. Odds ratio (OR) and 95% confidence interval (CI) were applied to assess the strength of the associations. Subgroup analysis and sensitivity analysis were performed to explore the between-study heterogeneity.
   Results: We finally identified 61 relevant studies which comprised 6634 case-patients and 6393 controls. The pooled OR for epsilon 4 carriers was 96% higher than the epsilon 3/3 genotype for CHD (OR, 1.96; 95% CI, 1.70 to 2.24; P< 0.001). However, there was no evidence of statistically significant association between epsilon 2 carriers and risk of CHD (OR, 1.02; 95% CI, 0.91 to 1.13; P = 0.729). In the subgroup analysis, different endpoints may partially account for the heterogeneity. No publication bias was found.
   Conclusions: Our meta-analysis suggests that the apoE epsilon 4 allele may be a risk factor for CHD in the Chinese population, however, epsilon 2 allele has no significant association.
C1 [Zhang, Ming-duo; Zhao, Quan-ming; Lv, Shu-zheng] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China.
   [Zhang, Ming-duo; Zhu, En-Jun; Zhao, Quan-ming; Lv, Shu-zheng] Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China.
   [Zhu, En-Jun] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiac Surg, Beijing, Peoples R China.
   [Gu, Wei] Anhui Med Univ, Affiliated Hosp 4, Dept Cardiol, Hefei, Anhui, Peoples R China.
RP Zhao, QM (reprint author), Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China.
EM cardio_zqm@hotmail.com; cardio_anzhen@hotmail.com
FU "Twelve Five'' National Key Technology R&D Program of China
   [2011BAI11B05]; Beijing Natural Science Foundation of China [7132078]
FX This study is supported by "Twelve Five'' National Key Technology R&D
   Program of China (Grant No. 2011BAI11B05)(http://www.most.gov.cn/eng/
   programmes1/200610/t20061009_36224.htm) and Beijing Natural Science
   Foundation of China(Grant No. 7132078)
   (http://www.bjkw.gov.cn/n244495/index.html). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anoop S, 2010, INDIAN J MED RES, V132, P363
   Anthopoulos PG, 2010, MOL GENET METAB, V100, P283, DOI 10.1016/j.ymgme.2010.03.008
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bennet AM, 2007, JAMA-J AM MED ASSOC, V298, P1300, DOI 10.1001/jama.298.11.1300
   Brown CM, 2002, FREE RADICAL BIO MED, V32, P1071, DOI 10.1016/S0891-5849(02)00803-1
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Colton CA, 2005, NEUROBIOL AGING, V26, P363, DOI 10.1016/j.neurobiolaging.2004.08.001
   DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1
   Dergunov AD, 2011, BIOMED PHARMACOTHER, V65, P597, DOI 10.1016/j.biopha.2011.04.003
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eichner JE, 2002, AM J EPIDEMIOL, V155, P487, DOI 10.1093/aje/155.6.487
   Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad
   Grammer TB, 2011, ATHEROSCLEROSIS, V215, P487, DOI 10.1016/j.atherosclerosis.2011.01.005
   Greenow K, 2005, J MOL MED, V83, P329, DOI 10.1007/s00109-004-0631-3
   Grimes DA, 2002, LANCET, V359, P248, DOI 10.1016/S0140-6736(02)07451-2
   Gungor Z, 2012, ATHEROSCLEROSIS, V223, P230, DOI 10.1016/j.atherosclerosis.2012.04.021
   HALLMAN DM, 1991, AM J HUM GENET, V49, P338
   Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Khan TA, 2013, INT J EPIDEMIOL, V42, P475, DOI 10.1093/ije/dyt034
   Kullo IJ, 2007, NAT CLIN PRACT CARD, V4, P558, DOI 10.1038/ncpcardio0982
   KUUSI T, 1989, ARTERIOSCLEROSIS, V9, P237, DOI 10.1161/01.ATV.9.2.237
   Little J, 2002, AM J EPIDEMIOL, V156, P300, DOI 10.1093/aje/kwf054
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Mi XJ, 2011, ANN HUM GENET, V75, P255, DOI 10.1111/j.1469-1809.2010.00634.x
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Raber J, 2004, NEUROBIOL AGING, V25, P641, DOI 10.1016/j.neurobiolaging.2003.12.023
   Schunkert H, 2011, NAT GENET, V43, P333, DOI [10.1038/ng.784, 10.1161/CIRCGENETICS.111.960443]
   Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013
   Talmud PJ, 2007, NUTR METAB CARDIOVAS, V17, P148, DOI 10.1016/j.numecd.2006.01.008
   UTERMANN G, 1977, NATURE, V269, P604, DOI 10.1038/269604a0
   WILSON PWF, 1994, JAMA-J AM MED ASSOC, V272, P1666, DOI 10.1001/jama.272.21.1666
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Yamada N, 1995, J Atheroscler Thromb, V2 Suppl 1, pS29
   Yin YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066924
NR 36
TC 23
Z9 23
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 22
PY 2014
VL 9
IS 4
AR e95463
DI 10.1371/journal.pone.0095463
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG2IS
UT WOS:000335240300045
PM 24755673
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, PJ
   Zhang, J
   Sun, GX
   Gao, XY
   Wang, H
   Yan, WJ
   Xu, H
   Zu, MH
   Ma, H
   Wang, W
   Lu, ZJ
AF Zhang, Peijin
   Zhang, Jing
   Sun, Guixiang
   Gao, Xiuyin
   Wang, Hui
   Yan, Wenjun
   Xu, Hao
   Zu, Maoheng
   Ma, He
   Wang, Wei
   Lu, Zhaojun
TI Risk of Budd-Chiari Syndrome Associated with Factor V Leiden and G20210A
   Prothrombin Mutation: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID VENOUS THROMBOEMBOLISM; HEREDITARY THROMBOPHILIA; CHINESE PATIENTS;
   VEIN-THROMBOSIS; GENE MUTATION; PROTEIN-C; PREVALENCE; DEFICIENCIES;
   OBSTRUCTION; SINGLE
AB Background: Various studies have demonstrated that factor V Leiden (FVL) and G20210A prothrombin mutation contribute to the risk of Budd-Chiari syndrome (BCS), while other studies provided conflicting findings. In order to derive more precise estimations of the relationships, a meta-analysis was performed.
   Methods: Eligible articles were identified through search of databases including Pubmed, Chinese Biomedical Database (CBM, Chinese), and Chinese National Knowledge Infrastructure (CNKI, Chinese). Odd ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-or fixed-model.
   Results: Finally, twelve studies were included for FVL and nine studies were included for G20210A prothrombin mutation. With respect to FVL, significantly increased BCS risk was found in the overall population (OR = 6.29, 95% CI = 4.23-9.36). Subgroup analyses suggested that FVL was associated with an increased risk of BCS in the population with high background mutation prevalence (>1% in the normal population). No significant association was found between BCS and G20210A prothrombin mutation (OR = 1.78, 95% CI = 0.77-4.11).
   Conclusion: The presence of FVL should be evaluated in patients with BCS. Conversely, G20210A prothrombin mutation is not significantly associated with risk of BCS. Large-scale well designed studies are necessary to be conducted to further confirm or refute the observed association.
C1 [Zhang, Peijin; Zhang, Jing; Sun, Guixiang; Gao, Xiuyin; Wang, Hui; Yan, Wenjun; Ma, He; Wang, Wei; Lu, Zhaojun] Xuzhou Med Coll, Dept Publ Hlth, Xuzhou, Jiangsu, Peoples R China.
   [Xu, Hao; Zu, Maoheng] Xuzhou Med Coll, Affiliated Hosp, Dept Intervent Radiol, Xuzhou, Jiangsu, Peoples R China.
RP Lu, ZJ (reprint author), Xuzhou Med Coll, Dept Publ Hlth, Xuzhou, Jiangsu, Peoples R China.
EM L23zj@163.com
FU National Natural Science Foundation of China [81172604]
FX This work was supported by the National Natural Science Foundation of
   China (grant number 81172604). The funder had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amarapurkar DN, 2008, WORLD J GASTROENTERO, V14, P278, DOI 10.3748/wjg.14.278
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0
   Bhattacharyya M, 2004, AM J CLIN PATHOL, V121, P844, DOI 10.1309/F2U1XBV4RXYUAYG0
   Bombeli T, 2002, AM J HEMATOL, V70, P126, DOI 10.1002/ajh.10103
   Bucciarelli P, 1998, THROMB HAEMOSTASIS, V79, P445
   Cheng DL, 2013, J GASTROEN HEPATOL, V28, P1061, DOI 10.1111/jgh.12140
   Clark JS, 2013, J APPL GENET
   Colak Y, 2006, EUR J GASTROEN HEPAT, V18, P917, DOI 10.1097/00042737-200608000-00019
   DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004
   Das R, 1998, GUT, V43, P147
   Deltenre P, 2001, GUT, V48, P264, DOI 10.1136/gut.48.2.264
   Dentali F, 2008, THROMB HAEMOSTASIS, V99, P675, DOI 10.1160/TH07-08-0526
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eroglu A, 2013, J THROMB THROMBOLYS, V36, P341, DOI 10.1007/s11239-012-0848-x
   Feng B, 2000, Zhonghua Yi Xue Za Zhi, V80, P354
   Feng B, 2001, ZHONGGUO YI KE DA XU, V30, P53
   Garewal G, 2003, J THROMB HAEMOST, V1, P2253, DOI 10.1046/j.1538-7836.2003.00430.x
   Ghaffar TYA, 2011, TURK J HEMATOL, V28, P299, DOI 10.5152/tjh.2011.84
   Ghosh K, 2001, CLIN APPL THROMB-HEM, V7, P158, DOI 10.1177/107602960100700214
   Gohil R, 2009, THROMB HAEMOSTASIS, V102, P360, DOI 10.1160/TH09-01-0013
   Heller C, 2000, BRIT J HAEMATOL, V111, P534, DOI 10.1046/j.1365-2141.2000.02349.x
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Ho WK, 2006, ARCH INTERN MED, V166, P729, DOI 10.1001/archinte.166.7.729
   Hu YQ, 2003, THROMB HAEMOSTASIS, V89, P446
   Jadaon MM, 2011, MEDITERR J HEMATOL I, V3, DOI 10.4084/MJHID.2011.037
   Janssen HLA, 2000, BLOOD, V96, P2364
   Jun ZJ, 2006, CLIN LAB HAEMATOL, V28, P111, DOI 10.1111/j.1365-2257.2006.00757.x
   Kumar Sirish I, 2005, Indian J Gastroenterol, V24, P211
   Lin Guo-Ling, 2004, Hepatobiliary Pancreat Dis Int, V3, P214
   [林国领 LIN Guoling], 2006, [中华普通外科杂志, Chinese Journal of General Surgery], V21, P275
   Lu YH, 2002, THROMB RES, V106, P7, DOI 10.1016/S0049-3848(02)00064-6
   LUDWIG J, 1990, MAYO CLIN PROC, V65, P51, DOI 10.1016/S0025-6196(12)62109-0
   Madonna P, 2001, GASTROENTEROLOGY, V120, P1059, DOI 10.1053/gast.2001.23083
   Mahmoud AEA, 1997, GUT, V40, P798, DOI 10.1136/gut.40.6.798
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mohanty D, 2001, HEPATOLOGY, V34, P666, DOI 10.1053/jhep.2001.27948
   Murad SD, 2009, ANN INTERN MED, V151, P167, DOI 10.7326/0003-4819-151-3-200908040-00004
   Poort SR, 1996, BLOOD, V88, P3698
   Qi XS, 2013, THROMB HAEMOSTASIS, V109, P878, DOI 10.1160/TH12-10-0784
   Qi XS, 2013, J GASTROEN HEPATOL, V28, P432, DOI 10.1111/jgh.12085
   REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5
   Riva N, 2012, THROMB RES, V130, pS1, DOI 10.1016/j.thromres.2012.08.259
   Rosendaal FR, 1998, THROMB HAEMOSTASIS, V79, P706
   Shetty S, 2011, THROMB RES, V127, P505, DOI 10.1016/j.thromres.2010.09.019
   Shrestha SM, 1996, J GASTROEN HEPATOL, V11, P170, DOI 10.1111/j.1440-1746.1996.tb00056.x
   Simone B, 2013, EUR J EPIDEMIOL, V28, P621, DOI 10.1007/s10654-013-9825-8
   Smalberg JH, 2011, BLOOD, V117, P3968, DOI 10.1182/blood-2010-11-319087
   Valla DC, 2004, J GASTROEN HEPATOL, V19, pS204, DOI DOI 10.1111/J.1440-1746.2004.03642.X
   Valla DC, 2009, J HEPATOL, V50, P195, DOI 10.1016/j.jhep.2008.10.007
   Wang H, 2013, J GASTROENTEROL HEPA
   Wang ZG, 2005, ANZ J SURG, V75, P55, DOI 10.1111/j.1445-2197.2005.03135.x
   Wells G, 2011, NEWCASTLE OTTAWA SCA
   Xu Pei-Qin, 2004, Hepatobiliary Pancreat Dis Int, V3, P391
   Yu CW, 2007, J CLIN SURG, V15, P743
   [郑红 Zheng Hong], 2005, [郑州大学学报. 医学版, Journal of Zhengzhou University.Medical Sciences], V40, P456
   Zhou PL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085135
NR 59
TC 7
Z9 7
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 22
PY 2014
VL 9
IS 4
AR e95719
DI 10.1371/journal.pone.0095719
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG2IS
UT WOS:000335240300080
PM 24755609
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Song, J
   Zhang, JX
   Wang, J
   Guo, XF
   Wang, J
   Liu, Y
   Dong, WG
AF Song, Jia
   Zhang, Jixiang
   Wang, Jun
   Guo, Xufeng
   Wang, Jing
   Liu, Ya
   Dong, Weiguo
TI Meta-Analysis: Narrow Band Imaging for Diagnosis of Gastric Intestinal
   Metaplasia
SO PLOS ONE
LA English
DT Article
ID LIGHT BLUE CREST; MAGNIFYING ENDOSCOPY; INTRAEPITHELIAL NEOPLASIA;
   PUBLICATION BIAS; ROC CURVE; LESIONS; CANCER; ACCURACY; HISTOPATHOLOGY;
   CARCINOGENESIS
AB Background: Distinguishing early gastric cancer is challenging with current imaging techniques. Narrow band imaging (NBI) is effective for characterizing gastric lesions.
   Objectives: The aim of this meta-analysis was to estimate the diagnostic accuracy of NBI in the gastric intestinal metaplasia (GIM).
   Methods: We performed data analysis using Meta-DiSc (version 1.4) and STATA (version 11.0) software. To assess study quality and potential for bias, we used the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool.
   Results: Six studies involving 347 patients were included. On a per-patient basis, the sensitivity of NBI for diagnosis of GIM was 0.65 (95% CI = 0.56-0.74), and the specificity was 0.93 (95% CI = 0.88-0.97). The area under the summary receiver operating characteristic (SROC) curve was 0.8731. However, on a per-lesion basis, the sensitivity and specificity of NBI were 0.69 (95% CI = 0.63-0.74) and 0.91 (95% CI = 0.87-0.94), respectively. The SROC was 0.9009. The pooled sensitivity and specificity of magnification endoscopy (NBI-ME) were 0.76 (95% CI = 0.61-0.87) and 0.89 (95% CI = 0.80-0.94), respectively, on per-patient analysis. On a per-lesion basis, the pooled sensitivity and specificity of NBI-ME were 0.84 (95% CI = 0.76-0.89) and 0.93 (95% CI = 0.89-0.96), respectively. Heterogeneity was observed with an I 2 for diagnostic odds ratio (DOR) of 0.01% and 85.8%, respectively. There was no statistical significance for the evaluation of publication bias.
   Conclusions: Our meta-analysis shows that NBI is a useful tool for differential diagnosis of GIM with relatively low sensitivity and high specificity.
C1 [Song, Jia; Zhang, Jixiang; Wang, Jun; Guo, Xufeng; Wang, Jing; Liu, Ya; Dong, Weiguo] Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan 430072, Hubei Province, Peoples R China.
RP Dong, WG (reprint author), Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan 430072, Hubei Province, Peoples R China.
EM dwg@whu.edu.cn
CR An JK, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-169
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Capelle LG, 2010, DIGEST DIS SCI, V55, P3442, DOI 10.1007/s10620-010-1189-2
   CORREA P, 1988, CANCER RES, V48, P3554
   CORREA P, 1990, CANCER RES, V50, P4731
   CORREA P, 1992, CANCER RES, V52, P6735
   Costamagna G, 2010, EUR REV MED PHARMACO, V14, P272
   Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016
   Edoardo S, 2013, WORLD J GASTROENTERO, V19, P2668
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FILIPE MI, 1994, INT J CANCER, V57, P324, DOI 10.1002/ijc.2910570306
   [高孝忠 GAO Xiao-zhong], 2009, [中华消化杂志, Chinese Journal of Digestion], V29, P289
   Gono K, 2004, J BIOMED OPT, V9, P568, DOI 10.1117/1.1695563
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Hellmich M, 1998, MED DECIS MAKING, V18, P436, DOI 10.1177/0272989X9801800412
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hirata I, 2012, DIGESTION, V85, P74, DOI 10.1159/000334642
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Kanzaki H, 2012, HELICOBACTER, V17, P224, DOI 10.1111/j.1523-5378.2012.00938.x
   Kato M, 2009, GASTROINTEST ENDOSC, V70, P899, DOI 10.1016/j.gie.2009.03.1171
   Kumagai Y, 2002, ENDOSCOPY, V34, P369, DOI 10.1055/s-2002-25285
   Li HY, 2012, GASTROINTEST ENDOSC, V76, P1124, DOI 10.1016/j.gie.2012.08.015
   LITTENBERG B, 1993, MED DECIS MAKING, V13, P313, DOI 10.1177/0272989X9301300408
   Miwa K, 2012, GASTRIC CANCER, V15, P170, DOI 10.1007/s10120-011-0093-6
   MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203
   Nakayoshi T, 2004, ENDOSCOPY, V36, P1080, DOI 10.1055/s-2004-825961
   Omori T, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-17
   Pimentel-Nunes P, 2012, ENDOSCOPY, V44, P236, DOI 10.1055/s-0031-1291537
   Rerknimitr R, 2011, WORLD J GASTROENTERO, V17, P1336, DOI 10.3748/wjg.v17.i10.1336
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Uedo N, 2008, ENDOSCOPY, V40, P881, DOI 10.1055/s-2008-1077598
   Uedo N, 2006, ENDOSCOPY, V38, P819, DOI 10.1055/s-2006-944632
   Wang SF, 2012, WORLD J GASTROENTERO, V18, P4771, DOI 10.3748/wjg.v18.i34.4771
   Wang SF, 2012, CHINESE MED J-PEKING, V125, P728, DOI 10.3760/cma.j.issn.0366-6999.2012.05.002
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Xirouchakis E, 2013, DIGEST DIS SCI, V58, P1084, DOI 10.1007/s10620-012-2431-x
   Zamora Javier, 2006, BMC Med Res Methodol, V6, P31, DOI 10.1186/1471-2288-6-31
NR 37
TC 12
Z9 14
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 17
PY 2014
VL 9
IS 4
AR e94869
DI 10.1371/journal.pone.0094869
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG3IK
UT WOS:000335309100048
PM 24743566
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhou, KG
   Xu, DM
   Cao, Y
   Wang, J
   Yang, YF
   Huang, M
AF Zhou, Kuangguo
   Xu, Danmei
   Cao, Yang
   Wang, Jue
   Yang, Yunfan
   Huang, Mei
TI C-MYC Aberrations as Prognostic Factors in Diffuse Large B-cell
   Lymphoma: A Meta-Analysis of Epidemiological Studies
SO PLOS ONE
LA English
DT Article
ID RITUXIMAB PLUS CYCLOPHOSPHAMIDE; INCREASED COPY NUMBER; POOR-PROGNOSIS;
   EXPRESSION PREDICTS; MESSENGER-RNA; REARRANGEMENTS; BCL2; TRANSLOCATION;
   VINCRISTINE; DOXORUBICIN
AB Objectives: Various studies have investigated the prognostic value of C-MYC aberrations in diffuse large B-cell lymphoma (DLBCL). However, the role of C-MYC as an independent prognostic factor in clinical practice remains controversial. A systematic review and meta-analysis were performed to clarify the clinical significance of C-MYC aberrations in DLBCL patients.
   Methods: The pooled hazard ratios (HRs) for overall survival (OS) and event-free survival (EFS) were calculated as the main effect size estimates. The procedure was conducted according to the Cochrane handbook and PRISMA guidelines, including the use of a heterogeneity test, publication bias assessment, and meta-regression, as well as subgroup analyses.
   Results: Twenty-four eligible studies enrolling 4662 patients were included in this meta-analysis. According to the nature of C-MYC aberrations (gene, protein, and mRNA), studies were divided into several subgroups. For DLBCL patients with C-MYC gene abnormalities, the combined HR was 2.22 (95% confidence interval, 1.89 to 2.61) for OS and 2.29 (95% confidence interval, 1.81 to 2.90) for EFS, compared to patients without C-MYC gene abnormalities. For DLBCL patients with overexpression of C-MYC protein and C-MYC mRNA, pooled HRs for OS were 2.13 and 1.62, respectively. C-MYC aberrations appeared to play an independent role among other well-known prognostic factors in DLBCL. Addition of rituximab could not overcome the inferior prognosis conferred by C-MYC.
   Conclusion: The present systematic review and meta-analysis confirm the prognostic value of C-MYC aberrations. Screening of C-MYC should have definite prognostic meaning for DLBCL stratification, thus guaranteeing a more tailored therapy.
C1 [Zhou, Kuangguo; Xu, Danmei; Cao, Yang; Wang, Jue; Yang, Yunfan; Huang, Mei] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Hematol, Wuhan 430074, Hubei, Peoples R China.
RP Huang, M (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Hematol, Wuhan 430074, Hubei, Peoples R China.
EM huangmei@medmail.com.cn
FU National Natural Science Foundation of China [81270599]
FX This study was sponsored by the Program of the National Natural Science
   Foundation of China (Grant No. 81270599). The funder had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akasaka T, 2000, J CLIN ONCOL, V18, P510, DOI 10.1200/JCO.2000.18.3.510
   Akyurek N, 2012, CANCER-AM CANCER SOC, V118, P4173, DOI 10.1002/cncr.27396
   Aukema SM, 2014, HAEMATOLOGICA, V99, P726, DOI 10.3324/haematol.2013.091827
   Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795
   Cuccuini W, 2012, BLOOD, V119, P4619, DOI 10.1182/blood-2012-01-406033
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342
   Green TM, 2012, AM J SURG PATHOL, V36, P612, DOI 10.1097/PAS.0b013e318244e2ba
   Gupta M, 2012, BLOOD, V120, P4400, DOI 10.1182/blood-2012-05-428466
   Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545
   Horn H, 2013, BLOOD, V121, P2253, DOI 10.1182/blood-2012-06-435842
   Hummel M, 2006, NEW ENGL J MED, V354, P2419, DOI 10.1056/NEJMoa055351
   Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985
   Kawasaki C, 2001, LEUKEMIA LYMPHOMA, V42, P1099, DOI 10.3109/10428190109097730
   Klapper W, 2008, LEUKEMIA, V22, P2226, DOI 10.1038/leu.2008.230
   Kluk MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033813
   Kojima M, 2013, LEUKEMIA LYMPHOMA, V54, P2149, DOI 10.3109/10428194.2013.771398
   Kramer MHH, 1998, BLOOD, V92, P3152
   McClure RE, 2005, AM J SURG PATHOL, V29, P1652, DOI 10.1097/01.pas.0000180442.87022.08
   McShane LM, 2005, J CLIN ONCOL, V23, P9067, DOI 10.1200/JCO.2004.01.0454
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moja L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046175
   Mossafa H, 2006, LEUKEMIA LYMPHOMA, V47, P1885, DOI 10.1080/10428190600687547
   Niitsu N, 2009, CANCER SCI, V100, P233, DOI 10.1111/j.1349-7006.2008.01035.x
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Perry AM, 2014, BR J HAEMATOL
   Perry AM, 2012, CANCER CONTROL, V19, P214, DOI 10.1177/107327481201900306
   Pfreundschuh M, 2012, J CLIN ONCOL, V30, P3433, DOI 10.1200/JCO.2012.44.4729
   Rimsza LM, 2008, BLOOD, V112, P3425, DOI 10.1182/blood-2008-02-137372
   Saez AI, 2003, LAB INVEST, V83, P143, DOI 10.1097/01.LAB.0000057000.41585.FD
   Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095
   Sehn LH, 2012, HEMATOL-AM SOC HEMAT, P402, DOI 10.1182/asheducation-2012.1.402
   SHIPP MA, 1993, NEW ENGL J MED, V329, P987
   Slack GW, 2011, ADV ANAT PATHOL, V18, P219, DOI 10.1097/PAP.0b013e3182169948
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stasik CJ, 2010, HAEMATOL-HEMATOL J, V95, P597, DOI 10.3324/haematol.2009.012864
   Testoni M, 2011, BRIT J HAEMATOL, V155, P274, DOI 10.1111/j.1365-2141.2011.08675.x
   Tzankov A, 2014, MODERN PATHOL, V27, P958, DOI 10.1038/modpathol.2013.214
   Valentino C, 2013, AM J CLIN PATHOL, V139, P242, DOI 10.1309/AJCP2Z0TAGMUYJEB
   Visco C, 2013, HAEMATOLOGICA, V98, P255, DOI 10.3324/haematol.2012.066209
   Yoon SO, 2008, HISTOPATHOLOGY, V53, P205, DOI 10.1111/j.1365-2559.2008.03076.x
   Zhang HW, 2011, HEMATOL ONCOL, V29, P185, DOI 10.1002/hon.991
   Zhang LQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034100
NR 45
TC 38
Z9 46
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 16
PY 2014
VL 9
IS 4
AR e95020
DI 10.1371/journal.pone.0095020
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI4VW
UT WOS:000336863900095
PM 24740248
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Olsen, CM
   Knight, LL
   Green, AC
AF Olsen, Catherine M.
   Knight, Lani L.
   Green, Adele C.
TI Risk of Melanoma in People with HIV/AIDS in the Pre- and Post-HAART
   Eras: A Systematic Review and Meta-Analysis of Cohort Studies
SO PLOS ONE
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY;
   AIDS-DEFINING CANCERS; HIV-INFECTION; UNITED-STATES; TRANSPLANT
   RECIPIENTS; IMMUNOSUPPRESSION; RECOMMENDATIONS; HETEROGENEITY;
   EPIDEMIOLOGY
AB Objective: Following the introduction of highly active antiretroviral therapy (HAART) the risk of AIDS-defining cancers decreased but incidence of many non-AIDS-defining cancers has reportedly increased in those with HIV/AIDS. Whether melanoma risk has also changed in HIV/AIDS patients post-HAART is unknown and therefore we evaluated this in comparison with the risk before HAART.
   Design: Systematic review and meta-analysis.
   Methods: We searched Medline, Embase and ISI science citation index databases to April 2013. All cohort studies of patients diagnosed with HIV/AIDS that permitted quantitative assessment of the association with melanoma were eligible. Detailed quality assessment of eligible studies was conducted, focussing particularly on adjustment for ethnicity, a priori considered essential for an unbiased assessment of melanoma risk. Data were pooled using a random effects model.
   Results: From 288 articles, we identified 21 that met the inclusion criteria, 13 presenting data for the post-HAART era and 8 for the pre-HAART era. Post-HAART the pooled relative risk (pRR) for the association between HIV/AIDS and melanoma was 1.26 (95% CI, 0.97-1.64) and 1.50 (95% CI 1.12-2.01) among studies that accounted for ethnicity, with evidence of significant heterogeneity (P = 0.004, I-2 = 55.5). Pre-HAART pRRs were 1.26 (95% CI 1.11-1.43; P-het = 0.82) and 1.28 (95% CI 1.10-1.49) among studies adjusted for ethnicity.
   Conclusions: People with HIV/AIDS remain at a significantly increased risk of developing melanoma in the post-HAART era. White skinned people with HIV/AIDS should be screened regularly and counselled against excessive sun exposure.
C1 [Olsen, Catherine M.; Knight, Lani L.; Green, Adele C.] QIMR Berghofer Med Res Inst, Dept Populat Hlth, Brisbane, Qld, Australia.
   [Green, Adele C.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Inst Inflammat & Repair, Manchester, Lancs, England.
RP Olsen, CM (reprint author), QIMR Berghofer Med Res Inst, Dept Populat Hlth, Brisbane, Qld, Australia.
EM Catherine.Olsen@qimr.edu.au
RI Olsen, Catherine/C-8785-2009; Green, Adele/P-2736-2014
OI Olsen, Catherine/0000-0003-4483-1888; Green, Adele/0000-0002-2753-4841
CR [Anonymous], 2006, WHO CAS DEF HIV SURV
   Bedimo RJ, 2009, JAIDS-J ACQ IMM DEF, V52, P203, DOI 10.1097/QAI.0b013e3181b033ab
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Calabresi A, 2013, HIV MED
   Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146
   Cebon Jonathan, 2007, Clin Adv Hematol Oncol, V5, P994
   Cooksley CD, 1999, INT J STD AIDS, V10, P795, DOI 10.1258/0956462991913574
   Cress RD, 1997, CANCER CAUSE CONTROL, V8, P246, DOI 10.1023/A:1018432632528
   Dal Maso L, 2009, BRIT J CANCER, V100, P840, DOI 10.1038/sj.bjc.6604923
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dubrow R, 2012, CURR OPIN ONCOL, V24, P506, DOI 10.1097/CCO.0b013e328355e131
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487
   Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Flegg P J, 1990, Int J STD AIDS, V1, P46
   Franceschi S, 2010, BRIT J CANCER, V103, P416, DOI 10.1038/sj.bjc.6605756
   Frisch M, 2001, JAMA-J AM MED ASSOC, V285, P1736, DOI 10.1001/jama.285.13.1736
   Gallagher B, 2001, AM J EPIDEMIOL, V154, P544, DOI 10.1093/aje/154.6.544
   Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2
   Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D
   Herida M, 2003, J CLIN ONCOL, V21, P3447, DOI 10.1200/JCO.2003.01.096
   Hessol NA, 2004, JAIDS-J ACQ IMM DEF, V36, P978, DOI 10.1097/00126334-200408010-00013
   Hessol NA, 2007, AM J EPIDEMIOL, V165, P1143, DOI 10.1093/aje/kwm017
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Houghton AN, 2001, CURR OPIN IMMUNOL, V13, P134, DOI 10.1016/S0952-7915(00)00195-3
   Kalialis LV, 2009, MELANOMA RES, V19, P275, DOI 10.1097/CMR.0b013e32832eabd5
   Le Gal FA, 2001, J INVEST DERMATOL, V117, P1464, DOI 10.1046/j.0022-202x.2001.01605.x
   Long JL, 2008, AIDS, V22, P489, DOI 10.1097/QAD.0b013e3282f47082
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Moore RD, 2011, CLIN INFECT DIS, V52, pS208, DOI 10.1093/cid/ciq044
   Newnham A, 2005, BRIT J CANCER, V92, P194, DOI 10.1038/sj.bjc.6602273
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005
   Powles T, 2009, J CLIN ONCOL, V27, P884, DOI 10.1200/JCO.2008.19.6626
   Seaberg EC, 2010, CANCER-AM CANCER SOC, V116, P5507, DOI 10.1002/cncr.25530
   Serraino D, 2007, EUR J CANCER, V43, P2117, DOI 10.1016/j.ejca.2007.07.015
   Shiels MS, 2009, JAIDS-J ACQ IMM DEF, V52, P611, DOI 10.1097/QAI.0b013e3181b327ca
   Silverberg MJ, 2013, JNCI-J NATL CANCER I, V105, P350, DOI 10.1093/jnci/djs529
   Silverberg MJ, 2011, CANCER EPIDEM BIOMAR, V20, P2551, DOI 10.1158/1055-9965.EPI-11-0777
   Simard EP, 2010, ARCH INTERN MED, V170, P1337, DOI 10.1001/archinternmed.2010.253
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   van Leeuwen MT, 2009, AIDS, V23, P2183, DOI 10.1097/QAD.0b013e328331d384
   Vandenbroucke JP, 2007, ANN INTERN MED, V147, pW163, DOI 10.7326/0003-4819-147-8-200710160-00010-w1
   Vella S, 2012, AIDS, V26, P1231, DOI 10.1097/QAD.0b013e32835521a3
   Vogel M, 2011, EUR J MED RES, V16, P101, DOI 10.1186/2047-783X-16-3-101
   Wong WCW, 2008, EMERG THEMES EPIDEMI, V5, DOI 10.1186/1742-7622-5-23
   Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222
NR 50
TC 20
Z9 21
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 16
PY 2014
VL 9
IS 4
AR e95096
DI 10.1371/journal.pone.0095096
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI4VW
UT WOS:000336863900101
PM 24740329
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xu, J
   Yang, XX
   Wu, YG
   Li, XY
   Bai, B
AF Xu, Jing
   Yang, Xin-xin
   Wu, Yun-gang
   Li, Xiao-yu
   Bai, Bo
TI Meat Consumption and Risk of Oral Cavity and Oropharynx Cancer: A
   Meta-Analysis of Observational Studies
SO PLOS ONE
LA English
DT Article
ID HETEROCYCLIC AMINE CONTENT; N-NITROSO COMPOUNDS; PROCESSED MEAT;
   PHARYNGEAL CANCER; BLADDER-CANCER; ETIOLOGY; FISH; DIET; FOOD;
   EPIDEMIOLOGY
AB Purpose: High meat consumption, especially red and processed meat consumption is associated with an increased risk of several cancers, however, evidence for oral cavity and oropharynx cancer is limited. Thus, we performed this meta-analysis to determine the association between intakes of total meat, processed meat, red meat, and white meat, and the risk of oral cavity and oropharynx cancer.
   Methods: Electronic search of Pubmed, Embase, and Cochrane Library Central database was conducted to select relevant studies. Fixed-effect and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Potential sources of heterogeneity were detected by meta-regression. Subgroup analyses and sensitivity analysis were also performed.
   Results: 12 case-control studies and one cohort study were included in the analyses, including 501,730 subjects and 4,104 oral cavity and oropharynx cancer cases. Pooled results indicated that high consumption of total meat, red meat, and white meat were not significantly associated with increased risk of oral cavity and oropharynx cancer (RR = 1.14, 95% CI[0.78-1.68]; RR = 1.05, 95% CI[0.66, 1.66] and RR = 0.81, 95% CI[0.54, 1.22], respectively), while the high consumption of processed meat was significantly associated with a 91% increased risk of oral cavity and oropharynx cancer (RR = 1.91, 95% CI [1.19-3.06]). Sensitivity analysis indicated that no significant variation in combined RR by excluding any of the study, confirming the stability of present results.
   Conclusions: The present meta-analysis suggested that high consumption of processed meat was significantly associated with an increased risk of oral cavity and oropharynx cancer, while there was no significantly association between total meat, red meat or white meat and the risk of oral cavity and oropharynx cancer. More prospective cohort studies are warranted to confirm these associations.
C1 [Xu, Jing] Jining Med Univ, Affiliated Hosp, Dept Gynecol, Jining, Shandong, Peoples R China.
   [Yang, Xin-xin; Wu, Yun-gang; Li, Xiao-yu] Jining Med Univ, Affiliated Hosp, Dept ENT, Jining, Shandong, Peoples R China.
   [Bai, Bo] Jining Med Univ, Dept Physiol, Jining, Shandong, Peoples R China.
RP Li, XY (reprint author), Jining Med Univ, Affiliated Hosp, Dept ENT, Jining, Shandong, Peoples R China.
EM lixiaoyu1969@126.com
FU Shandong Provincial Natural Science Foundation of China [ZR2010HL045,
   ZR2010HL057]; Jining city science and technology development plan
   program of jining science and technology bureau [2012jnfs02, 2012jnfs11,
   2012jnfs13]; Youth Fund of Jining Medical University [JYQ2011KZ005];
   Project of Shandong Province Higher Educational Science and Technology
   Program [J12LE10]
FX The present work was supported by Shandong Provincial Natural Science
   Foundation of China (No. ZR2010HL045, ZR2010HL057), Jining city science
   and technology development plan program of jining science and technology
   bureau (No. 2012jnfs02; 2012jnfs11; 2012jnfs13), Youth Fund of Jining
   Medical University (No. JYQ2011KZ005), and a Project of Shandong
   Province Higher Educational Science and Technology Program (No.
   J12LE10). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cross AJ, 2004, ENVIRON MOL MUTAGEN, V44, P44, DOI 10.1002/em.20030
   Daniel CR, 2011, CANCER PREV RES, V4, P1903, DOI 10.1158/1940-6207.CAPR-11-0241
   De Stefani E, 2012, BRIT J CANCER, V107, P1584, DOI 10.1038/bjc.2012.433
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Faramawi MF, 2007, CANCER CAUSE CONTROL, V18, P125, DOI 10.1007/s10552-006-0104-9
   Garrote LF, 2001, BRIT J CANCER, V85, P46, DOI 10.1054/bjoc.2000.1825
   Haorah J, 2001, J AGR FOOD CHEM, V49, P6068, DOI 10.1021/jf010602h
   Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang X, 2003, MUTAT RES-FUND MOL M, V533, P153, DOI 10.1016/j.mrfmmm.2003.08.023
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kazerouni N, 2001, FOOD CHEM TOXICOL, V39, P423, DOI 10.1016/S0278-6915(00)00158-7
   Levi F, 2004, ANN ONCOL, V15, P346, DOI 10.1093/annonc/mdh060
   Lissowska J, 2003, EUR J CANCER PREV, V12, P25, DOI 10.1097/01.cej.0000043735.13672.78
   Mehanna H, 2011, CLIN OTOLARYNGOL, V36, P65, DOI 10.1111/j.1749-4486.2010.02231.x
   MIRVISH SS, 1995, CANCER LETT, V93, P17, DOI 10.1016/0304-3835(95)03786-V
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   OHGAKI H, 1984, CARCINOGENESIS, V5, P921, DOI 10.1093/carcin/5.7.921
   Petridou E, 2002, CANCER, V94, P2981, DOI 10.1002/cncr.10560
   Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2
   Puangsombat K, 2011, MEAT SCI, V88, P227, DOI 10.1016/j.meatsci.2010.12.025
   Rajkumar T, 2003, EUR J CANCER PREV, V12, P135, DOI 10.1097/01.cej.0000062796.86004.7c
   Salehi M, 2013, NUTR REV, V71, P257, DOI 10.1111/nure.12028
   Sanchez MJ, 2003, EUR J CANCER PREV, V12, P49, DOI 10.1097/01.cej.0000043739.13672.47
   Sapkota A, 2008, CANCER CAUSE CONTROL, V19, P1161, DOI 10.1007/s10552-008-9183-0
   Sinha R, 1998, FOOD CHEM TOXICOL, V36, P289, DOI 10.1016/S0278-6915(97)00159-2
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Toporcov TN, 2004, ORAL ONCOL, V40, P925, DOI 10.1016/j.oraloncology.2004.04.007
   Uzcudun AE, 2002, J LARYNGOL OTOL, V116, P523, DOI 10.1258/002221502760132395
   Wang CJ, 2012, MED ONCOL, V29, P848, DOI 10.1007/s12032-011-9985-x
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Xu XD, 2013, INT J CANCER, V132, P437, DOI 10.1002/ijc.27625
   Yang WS, 2012, ANN ONCOL, V23, P3163, DOI 10.1093/annonc/mds207
   ZHENG TZ, 1993, ORAL ONCOL, V29B, P45, DOI 10.1016/0964-1955(93)90010-C
   ZHENG W, 1992, CANCER EPIDEM BIOMAR, V1, P441
NR 37
TC 13
Z9 15
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 15
PY 2014
VL 9
IS 4
AR e95048
DI 10.1371/journal.pone.0095048
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI5PW
UT WOS:000336922600136
PM 24736706
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Jiang, PY
   Jiang, ZB
   Shen, KX
   Yue, Y
AF Jiang, Pei-yue
   Jiang, Zhong-bo
   Shen, Ke-xin
   Yue, Ying
TI Fish Intake and Ovarian Cancer Risk: A Meta-Analysis of 15 Case-Control
   and Cohort Studies
SO PLOS ONE
LA English
DT Article
ID N-3 FATTY-ACIDS; NO ASSOCIATION; MEAT INTAKE; CONSUMPTION; EPIDEMIOLOGY;
   DIET
AB Background: Previous epidemiological studies have shown that fish consumption may modify the risk of ovarian cancer. However, these studies yielded controversial results. The present meta-analysis was undertaken to evaluate the relationship between fish intake and ovarian cancer risk.
   Methods: A literature search was carried out using Pubmed, Embase, and Cochrane Library Central database for all relevant studies up to August 2013. We pooled the relative risks (RR) from individual studies using fixed-effect or random-effect model, and carried out heterogeneity and publication bias analyses.
   Results: A total of 15 (ten case-control, and five cohort) studies were included in the present meta-analysis, representing data for 889,033 female subjects and 6,087 ovarian cancer cases. We found that total fish intake was not significantly associated with the risk of ovarian cancer among cohort studies (RR = 1.04 95% CI [0.89, 1.22]) as well as case-control studies (RR = 0.90, 95% CI [0.73,1.12]). There was no evidence of publication bias as suggested by Begg's test (P = 0.55) and Egger's test(P = 0.29).
   Conclusions: The present meta-analysis showed that total fish consumption was not significantly associated with the risk of ovarian cancer. Further analysis on different fish species and food preparation methods should be conducted in future studies.
C1 [Jiang, Pei-yue; Yue, Ying] Jilin Univ, Dept Gynecol Oncol, Hosp 1, Changchun 130023, Peoples R China.
   [Jiang, Zhong-bo] Jilin Univ, Dept Gastroenterol, China Japan Union Hosp, Changchun 130023, Peoples R China.
   [Shen, Ke-xin] Jilin Univ, Dept Colorectal & Anal Surg, China Japan Union Hosp, Changchun 130023, Peoples R China.
RP Yue, Y (reprint author), Jilin Univ, Dept Gynecol Oncol, Hosp 1, Changchun 130023, Peoples R China.
EM dr_yueying@126.com
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1
   Bosetti C, 2001, INT J CANCER, V93, P911, DOI 10.1002/ijc.1422
   Cerchietti LCA, 2007, NUTR CANCER, V59, P14, DOI 10.1080/01635580701365068
   Chapkin RS, 2007, J NUTR, V137, p200S, DOI 10.1093/jn/137.1.200S
   CRAMER DW, 1984, OBSTET GYNECOL, V63, P833
   Daniel CR, 2011, CANCER PREV RES, V4, P1903, DOI 10.1158/1940-6207.CAPR-11-0241
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fernandez E, 1999, AM J CLIN NUTR, V70, P85
   Gilsing AMJ, 2011, AM J CLIN NUTR, V93, P118, DOI 10.3945/ajcn.2010.29888
   Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S
   Hu JF, 2008, NUTR CANCER, V60, P313, DOI 10.1080/01635580701759724
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kiani F, 2006, CANCER CAUSE CONTROL, V17, P137, DOI 10.1007/s10552-005-5383-z
   Kolahdooz F, 2010, AM J CLIN NUTR, V91, P1752, DOI 10.3945/ajcn.2009.28415
   La Vecchia C, 2001, EUR J CANCER PREV, V10, P125, DOI 10.1097/00008469-200104000-00002
   Larsson SC, 2005, CANCER EPIDEM BIOMAR, V14, P1024, DOI 10.1158/1055-9965.EPI-04-0795
   LAVECCHIA C, 1987, J NATL CANCER I, V79, P663
   Lijinsky W, 1999, MUTAT RES-GEN TOX EN, V443, P129, DOI 10.1016/S1383-5742(99)00015-0
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   MORI M, 1988, AM J EPIDEMIOL, V128, P771, DOI 10.1093/oxfordjournals.aje.a115030
   Pan SY, 2004, CANCER EPIDEM BIOMAR, V13, P1521
   Qin B, 2012, J NUTR, V142, P1067, DOI 10.3945/jn.111.156711
   Rohrmann S, 2009, AM J CLIN NUTR, V89, P1418, DOI 10.3945/ajcn.2008.26658
   Salehi M, 2013, NUTR REV, V71, P257, DOI 10.1111/nure.12028
   Schulz M, 2007, CANCER EPIDEM BIOMAR, V16, P852, DOI 10.1158/1055-9965.EPI-07-0054
   Sharma A, 2005, GYNECOL ONCOL, V99, P58, DOI 10.1016/j.ygyno.2005.05.024
   Stoll BA, 2002, BRIT J NUTR, V87, P193, DOI [10.1079/BJNBJN2001512, 10.1079/BJN2002512]
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Szymanski KM, 2010, AM J CLIN NUTR, V92, P1223, DOI 10.3945/ajcn.2010.29530
   Tavani A, 2003, INT J CANCER, V105, P113, DOI 10.1002/ijc.11018
   Wang CJ, 2012, MED ONCOL, V29, P848, DOI 10.1007/s12032-011-9985-x
   Webb PM, 2004, GYNECOL ONCOL, V92, P232, DOI 10.1016/j.ygyno.2003.09.005
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Wu SJ, 2012, AM J MED, V125, P551, DOI 10.1016/j.amjmed.2012.01.022
   Xu XD, 2013, INT J CANCER, V132, P437, DOI 10.1002/ijc.27625
   Yen ML, 2003, GYNECOL ONCOL, V89, P318, DOI 10.1016/S0090-8258(03)00088-X
   Zhang M, 2002, BRIT J CANCER, V86, P712, DOI [10.1038/sj.bjc.6600085, 10.1038/sj/bjc/660085]
NR 41
TC 5
Z9 5
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 14
PY 2014
VL 9
IS 4
AR e94601
DI 10.1371/journal.pone.0094601
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI6GP
UT WOS:000336970400055
PM 24732053
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Coppola, N
   Pisaturo, M
   Sagnelli, C
   Sagnelli, E
   Angelillo, IF
AF Coppola, Nicola
   Pisaturo, Mariantonietta
   Sagnelli, Caterina
   Sagnelli, Evangelista
   Angelillo, Italo F.
TI Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir
   for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
SO PLOS ONE
LA English
DT Article
ID CHRONIC HEPATITIS-C; ACTING ANTIVIRAL AGENTS; VIRUS-INFECTION;
   CLINICAL-TRIALS; CONSENSUS GUIDELINES; PROTEASE INHIBITORS;
   TREATMENT-NAIVE; TRIPLE THERAPY; MANAGEMENT; EFFICACY
AB Background & aim: To compare the efficacy of pegylated-interferon (Peg-IFN) alpha-2a or alpha-2b and ribavirin given as dual therapy versus triple therapy (Peg-IFN and ribavirin plus boceprevir or telaprevir) in patients with HCV-1 chronic hepatitis naive for anti-HCV therapy or relapsers to dual therapy in relation to the presence of constitutional, clinical and virological predictors of treatment response.
   Methods: Included in the meta-analysis were studies meeting these criteria: original data from randomized trials on the efficacy of dual versus triple therapy in therapy-naive patients or relapsers; at least one primary outcome clearly defined: sustained virological response in patients with or without rapid virological response (RVR), with genotype 1a or 1b, low or high HCV load, IL28-B CC or non-CC genotype, mild or severe fibrosis; odds ratio estimates of relative risk (RR) and 95% confidence intervals; English language; and published up to the end of June 2013.
   Results: Seven original studies met the inclusion criteria, allowing a meta-analysis on 3,652 patients. Triple therapy was more effective than dual, regardless of IL-28B genotype, HCV sub-genotype, liver fibrosis, and baseline HCV load. In 1,045 patients who achieved RVR, SVR was more frequently achieved with dual therapy (RR = 1.11; p = 0.002) than triple. The same results were achieved when only the therapy-naive patients were considered.
   Conclusions: Triple therapy provides a significantly higher SVR rate than dual therapy, but dual therapy obtains a significantly higher SVR rate in patients with RVR. The data stress the clinical importance of a 4-week lead-in phase in direct-acting antiviral-based treatment.
C1 [Coppola, Nicola; Pisaturo, Mariantonietta; Sagnelli, Evangelista] Univ Naples 2, Dept Mental Hlth & Publ Med, Infect Dis Sect, Naples, Italy.
   [Sagnelli, Caterina] Univ Naples 2, Dept Clin & Expt Med & Surg F Magrassi & A Lanzar, Naples, Italy.
   [Angelillo, Italo F.] Univ Naples 2, Dept Expt Med, Naples, Italy.
RP Sagnelli, E (reprint author), Univ Naples 2, Dept Mental Hlth & Publ Med, Infect Dis Sect, Naples, Italy.
EM evangelista.sagnelli@unina2.it
RI Sagnelli, caterina/K-9338-2016
OI Sagnelli, caterina/0000-0002-6413-7810; Pisaturo,
   mariantonietta/0000-0001-5870-0956; Angelillo, Italo
   F/0000-0003-1213-6602; Sagnelli, Evangelista/0000-0003-2817-8436;
   Coppola, Nicola/0000-0001-5897-4949
CR Aghemo A, 2013, DIGEST LIVER DIS, V45, P1, DOI 10.1016/j.dld.2012.05.002
   [Anonymous], 2011, J HEPATOL, V55, P245, DOI DOI 10.1016/J.JHEP.2011.02.023]
   Bacon BR, 2011, NEW ENGL J MED, V364, P1207, DOI 10.1056/NEJMoa1009482
   Barritt AS, 2012, GASTROENTEROLOGY, V142, P1314, DOI 10.1053/j.gastro.2012.02.013
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bruno S, 2013, J HEPATOL, V58, P479, DOI 10.1016/j.jhep.2012.11.020
   Butt AA, 2012, CLIN INFECT DIS, V54, P96, DOI 10.1093/cid/cir774
   Chou R, 2013, ANN INTERN MED, V158, P114, DOI 10.7326/0003-4819-158-2-201301150-00576
   Coppola N, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-357
   Cure S, 2012, CURR MED RES OPIN, V28, P1841, DOI 10.1185/03007995.2012.734798
   Dang SS, 2012, HEPATO-GASTROENTEROL, V59, P461, DOI 10.5754/hge11312
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Flamm SL, 2013, CLIN GASTROENTEROL H, V11, P81, DOI 10.1016/j.cgh.2012.10.006
   Gentile I, 2013, CURR MED CHEM   1228, V28
   Gentile I, 2014, EXPERT OPIN INV DRUG, V23, P561, DOI 10.1517/13543784.2014.892581
   Ghany MG, 2011, HEPATOLOGY, V54, P1433, DOI 10.1002/hep.24641
   Hezode C, 2012, LIVER INT, V32, P32, DOI 10.1111/j.1478-3231.2011.02707.x
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Holmes JA, 2012, J VIRAL HEPATITIS, V19, P677, DOI 10.1111/jvh.12003
   Jacobson IM, 2012, J VIRAL HEPATITIS, V19, P1, DOI 10.1111/j.1365-2893.2012.01590.x
   Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kieran J, 2013, CLIN INFECT DIS, V56, P228, DOI 10.1093/cid/cis880
   Kumada H, 2012, J HEPATOL, V56, P78, DOI 10.1016/j.jhep.2011.07.016
   Kwo PY, 2010, LANCET, V376, P705, DOI 10.1016/S0140-6736(10)60934-8
   Lee LY, 2012, INT J CLIN PRACT, V66, P342, DOI 10.1111/j.1742-1241.2012.02895.x
   Leroy V, 2012, LIVER INT, V32, P1477, DOI 10.1111/j.1478-3231.2012.02856.x
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Myers RP, 2012, CAN J GASTROENTEROL, V26, P359, DOI 10.1155/2012/947676
   Pearlman BL, 2012, LANCET INFECT DIS, V12, P717, DOI 10.1016/S1473-3099(12)70060-9
   Pol S, 2013, J HEPATOL, V58, P883, DOI 10.1016/j.jhep.2012.12.023
   Poordad F, 2012, GASTROENTEROLOGY, V143, P608, DOI 10.1053/j.gastro.2012.05.011
   Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494
   Ramachandran P, 2012, ALIMENT PHARM THER, V35, P647, DOI 10.1111/j.1365-2036.2012.04992.x
   Sarrazin C, 2012, J HEPATOL, V56, pS88, DOI 10.1016/S0168-8278(12)60010-5
   Sitole M, 2013, CLIN THER, V35, P190, DOI 10.1016/j.clinthera.2012.12.017
   Thompson AJ, 2012, HEPATOLOGY, V56, P373, DOI 10.1002/hep.25792
   Welsch C, 2012, GUT, V61, P36, DOI 10.1136/gutjnl-2012-302144
   Yee HS, 2012, AM J GASTROENTEROL, V107, P669, DOI 10.1038/ajg.2012.48
   Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086
NR 42
TC 25
Z9 25
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 11
PY 2014
VL 9
IS 4
AR e94542
DI 10.1371/journal.pone.0094542
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI3CI
UT WOS:000336736200092
PM 24728219
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Kelley, JM
   Kraft-Todd, G
   Schapira, L
   Kossowsky, J
   Riess, H
AF Kelley, John M.
   Kraft-Todd, Gordon
   Schapira, Lidia
   Kossowsky, Joe
   Riess, Helen
TI The Influence of the Patient-Clinician Relationship on Healthcare
   Outcomes: A Systematic Review and MetaAnalysis of Randomized Controlled
   Trials
SO PLOS ONE
LA English
DT Review
ID INCREASE PHYSICAL-ACTIVITY; PRACTITIONER AGREEMENT; COMMUNICATION;
   INTERVENTION; BIAS
AB Objective: To determine whether the patient-clinician relationship has a beneficial effect on either objective or validated subjective healthcare outcomes.
   Design: Systematic review and meta-analysis.
   Data Sources: Electronic databases EMBASE and MEDLINE and the reference sections of previous reviews.
   Eligibility Criteria for Selecting Studies: Included studies were randomized controlled trials (RCTs) in adult patients in which the patient-clinician relationship was systematically manipulated and healthcare outcomes were either objective (e.g., blood pressure) or validated subjective measures (e.g., pain scores). Studies were excluded if the encounter was a routine physical, or a mental health or substance abuse visit; if the outcome was an intermediate outcome such as patient satisfaction or adherence to treatment; if the patient-clinician relationship was manipulated solely by intervening with patients; or if the duration of the clinical encounter was unequal across conditions.
   Results: Thirteen RCTs met eligibility criteria. Observed effect sizes for the individual studies ranged from d = 2.23 to.66. Using a random-effects model, the estimate of the overall effect size was small (d =.11), but statistically significant (p =.02).
   Conclusions: This systematic review and meta-analysis of RCTs suggests that the patient-clinician relationship has a small, but statistically significant effect on healthcare outcomes. Given that relatively few RCTs met our eligibility criteria, and that the majority of these trials were not specifically designed to test the effect of the patient-clinician relationship on healthcare outcomes, we conclude with a call for more research on this important topic.
C1 [Kelley, John M.; Kraft-Todd, Gordon; Schapira, Lidia; Riess, Helen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Empathy & Relat Sci Program, Boston, MA 02115 USA.
   [Kossowsky, Joe] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Program Placebo Studies & Therapeut Encounter, Boston, MA USA.
   [Kelley, John M.] Endicott Coll, Dept Psychol, Beverly, MA USA.
   [Schapira, Lidia] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [Kossowsky, Joe] Harvard Univ, Boston Childrens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA.
   [Kossowsky, Joe] Univ Basel, Dept Clin Psychol & Psychotherapy, Basel, Switzerland.
RP Kelley, JM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Empathy & Relat Sci Program, Boston, MA 02115 USA.
EM johnkelley@post.harvard.edu
RI Kraft-Todd, Gordon/O-5520-2016
OI Kraft-Todd, Gordon/0000-0003-1220-9269
FU Arnold P. Gold Foundation [FI-11-004]; Swiss National Science Foundation
   [P2BSP1_148628]
FX This study was made possible with a grant from the Arnold P. Gold
   Foundation (www.humanism-in-medicine.org; grant # FI-11-004). Joe
   Kossowsky's contributions to this study were supported by the Swiss
   National Science Foundation, grant project (P2BSP1_148628). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aiarzaguena JM, 2007, PSYCHOL MED, V37, P283, DOI 10.1017/S0033291706009536
   Astrow AB, 2013, SOCIETY, V50
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bieber C, 2008, J PSYCHOSOM RES, V64, P13, DOI 10.1016/j.jpsychores.2007.05.009
   Bolognesi M, 2006, ANN BEHAV MED, V31, P179, DOI 10.1207/s15324796abm3102_10
   Cals JWL, 2009, BMJ-BRIT MED J, V338, P1112
   Chassany O, 2006, J RHEUMATOL, V33, P1827
   Christian JG, 2008, ARCH INTERN MED, V168, P141, DOI 10.1001/archinternmed.2007.13
   Cleland Jennifer A, 2007, Prim Care Respir J, V16, P311
   COCHRAN WG, 1950, BIOMETRIKA, V37, P256, DOI 10.1093/biomet/37.3-4.256
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Cooper LA, 2001, J GEN INTERNAL MED, V26, P1297
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6
   Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gabbay M, 2003, PSYCHOL MED, V33, P241, DOI 10.1017/S0033291702006992
   Girgis A, 2009, PATIENT EDUC COUNS, V77, P456, DOI 10.1016/j.pec.2009.09.018
   Griffin SJ, 2004, ANN FAM MED, V2, P595, DOI 10.1370/afm.142
   Harrington J, 2004, PATIENT EDUC COUNS, V52, P7, DOI 10.1016/S0738.3991(03)00017-X
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   Higgins JPT, 2008, INT J EPIDEMIOL, V37, P1158, DOI 10.1093/ije/dyn204
   Hojat M, 2011, ACAD MED, V86, P359, DOI 10.1097/ACM.0b013e3182086fe1
   Kessler RC, 2001, ANN INTERN MED, V135, P262, DOI 10.7326/0003-4819-135-4-200108210-00011
   Kinmonth AL, 2008, LANCET, V371, P41, DOI 10.1016/S0140-6736(08)60070-7
   Kleinman A, 2013, NEW ENGL J MED, V368, P1376, DOI 10.1056/NEJMp1300678
   Little P, 2001, BRIT MED J, V323, P908, DOI 10.1136/bmj.323.7318.908
   MUMFORD E, 1982, AM J PUBLIC HEALTH, V72, P141, DOI 10.2105/AJPH.72.2.141
   ONG LML, 1995, SOC SCI MED, V40, P903, DOI 10.1016/0277-9536(94)00155-M
   PROCHASKA JO, 1982, PSYCHOTHER-THEOR RES, V19, P276, DOI 10.1037/h0088437
   PUTNAM SM, 1985, MED CARE, V23, P74, DOI 10.1097/00005650-198501000-00008
   Rosenthal R., 1984, METAANALYTIC PROCEDU
   Rutledge T, 2004, ANN BEHAV MED, V27, P138, DOI 10.1207/s15324796abm2702_9
   Schapira L, 2013, CANCER
   Sequist TD, 2010, ANN INTERN MED, V152, P40, DOI 10.7326/0003-4819-152-1-201001050-00009
   STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127
   Stewart M A, 1979, J R Coll Gen Pract, V29, P77
   STEWART MA, 1995, CAN MED ASSOC J, V152, P1423
   Street RL, 1997, MED DECISION MAKING, V17
   Ward MM, 2003, ARTHRIT RHEUM-ARTHR, V49, P810, DOI 10.1002/art.11467
   White P, 2011, PAIN
   Williams JG, 2001, QUAL HEALTH CARE, V10, P159, DOI 10.1136/qhc.0100159..
NR 43
TC 173
Z9 175
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 9
PY 2014
VL 9
IS 4
AR e94207
DI 10.1371/journal.pone.0094207
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE9PC
UT WOS:000334339000090
PM 24718585
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Tan, L
   Wang, Y
   Zhou, LL
   Shi, Y
   Zhang, F
   Liu, L
   Nie, SF
AF Tan, Li
   Wang, Ying
   Zhou, Lingling
   Shi, Yun
   Zhang, Fan
   Liu, Li
   Nie, Shaofa
TI Parkinson's Disease and Risk of Fracture: A Meta-Analysis of Prospective
   Cohort Studies
SO PLOS ONE
LA English
DT Article
ID BONE-MINERAL DENSITY; HIP FRACTURE; OLDER MEN; OSTEOPOROTIC FRACTURES;
   WOMEN; FALLS; ASSOCIATION; PREDICTION; VALIDITY; PEOPLE
AB Backgrounds/Objective: Parkinson's disease (PD) is the second most common neurodegenerative disease among the elderly population. However, epidemiological evidence on the relationship of PD with risk of fracture has not been systematically assessed. Therefore, we performed this meta-analysis of prospective studies to explore the association between PD and risk of fracture.
   Methods: PubMed, Embase, Web of Science and Cochrane Library up to February 26, 2014 were searched to identify eligible studies. Random-effects model was used to pool the results.
   Results: Six studies that totally involved 69,387 participants were included for analysis. Overall, PD patients had an increased risk of fracture compared with control subjects (pooled hazard ratio = 2.66, 95% confidence interval: 2.10-3.36). No publication bias was observed across studies and the subgroup as well as sensitivity analysis suggested that the general results were robust.
   Conclusion: The present study suggested that PD is associated with an increased risk of fracture. However, given the limited number and moderate quality of included studies, well-designed prospective cohort studies are required to confirm the findings from this meta-analysis.
C1 [Tan, Li; Wang, Ying; Zhou, Lingling; Shi, Yun; Zhang, Fan; Liu, Li; Nie, Shaofa] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430074, Peoples R China.
RP Nie, SF (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430074, Peoples R China.
EM sf_nie@mails.tjmu.edu.cn
CR Ageing WHO Unit LC, 2008, WHO GLOB REP FALLS P
   Allen NE, 2013, PARKINSONS DIS-US, DOI 10.1155/2013/906274
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhattacharya RK, 2012, MOVEMENT DISORD, V27, P1440, DOI 10.1002/mds.25073
   Boonen S, 2008, CURR MED RES OPIN, V24, P1781, DOI 10.1185/03007990802115796
   Chen SD, 2012, TRANSL NEURODEGENER, V1, DOI 10.1186/2047-9158-1-1
   Chen YY, 2012, PARKINSONISM RELAT D, V18, P506, DOI 10.1016/j.parkreldis.2012.01.014
   Chen Z, 2004, MENOPAUSE, V11, P264, DOI 10.1097/01.GME.0000094210.15096.FD
   Cummings SR, 2006, J BONE MINER RES, V21, P1550, DOI 10.1359/JBMR.060708
   de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9
   Dennison EM, 2012, BONE, V50, P1288, DOI 10.1016/j.bone.2012.02.639
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dorsey ER, 2007, NEUROLOGY, V68, P384, DOI 10.1212/01.wnl.0000247740.47667.03
   Edwards MH, 2013, BONE, V52, P541, DOI 10.1016/j.bone.2012.11.006
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fink HA, 2008, OSTEOPOROSIS INT, V19, P1277, DOI 10.1007/s00198-008-0584-4
   Fink HA, 2005, J AM GERIATR SOC, V53, P1559, DOI 10.1111/j.1532-5415.2005.53464.x
   Genever RW, 2005, AGE AGEING, V34, P21, DOI 10.1093/ageing/afh203
   Gottlich M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077336
   Gregson CL, 2013, OSTEOPOROS INT
   GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905
   Hartholt KA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022227
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hiorth YH, 2013, EUR J NEUROL, V20, P160, DOI 10.1111/j.1468-1331.2012.03821.x
   Hundrup YA, 2004, SCAND J PUBLIC HEALT, V32, P136, DOI 10.1080/14034940310017490
   JOHNELL O, 1992, AGE AGEING, V21, P32, DOI 10.1093/ageing/21.1.32
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Melton LJ, 2006, MOVEMENT DISORD, V21, P1361, DOI 10.1002/mds.20946
   Nguyen ND, 2007, J BONE MINER RES, V22, P781, DOI 10.1359/JBMR.070315
   Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003
   Pouwels S, 2013, OSTEOPOROSIS INT, V24, P2283, DOI 10.1007/s00198-013-2300-2
   Rosenthal L, 2010, METHODS MOL BIOL, V594, P427, DOI 10.1007/978-1-60761-411-1_30
   Schneider JL, 2008, OSTEOPOROSIS INT, V19, P1093, DOI 10.1007/s00198-008-0583-5
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Taylor BC, 2004, J AM GERIATR SOC, V52, P1479, DOI 10.1111/j.1532-5415.2004.52410.x
   van den Bos F, 2013, AGE AGEING, V42, P156, DOI 10.1093/ageing/afs161
   Walker RW, 2013, MOVEMENT DISORD, V28, P334, DOI 10.1002/mds.25297
   Wells GA, 2000, NEWCASTLE OTTAWA SCA
   Wood BH, 2002, J NEUROL NEUROSUR PS, V72, P721, DOI 10.1136/jnnp.72.6.721
   Yang J, 2012, BONE, V51, P376, DOI 10.1016/j.bone.2012.05.024
   Zhao Y, 2013, BONE, V52, P498, DOI 10.1016/j.bone.2012.09.013
NR 42
TC 12
Z9 14
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 8
PY 2014
VL 9
IS 4
AR e94379
DI 10.1371/journal.pone.0094379
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE7FA
UT WOS:000334160900124
PM 24714656
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, YF
   Zhou, L
   Zhang, HW
   Hou, AJ
   Gao, HF
   Zhou, YH
AF Zhang, Yu-Fei
   Zhou, Li
   Zhang, Hong-Wei
   Hou, An-Ji
   Gao, Hong-Fang
   Zhou, Yu-Hao
TI Association between Folate Intake and the Risk of Lung Cancer: A
   Dose-Response Meta-Analysis of Prospective Studies
SO PLOS ONE
LA English
DT Article
ID B-VITAMINS; VEGETABLE CONSUMPTION; TREND ESTIMATION; POOLED ANALYSIS;
   DIETARY-INTAKE; POLYMORPHISMS; MULTIVITAMINS; METABOLISM; METHIONINE;
   SMOKERS
AB Background: Studies have reported inconsistent results regarding the existence of an association between folate intake and the risk of lung cancer. The purpose of this study was to summarize the evidence from prospective cohort studies regarding this relationship by using a dose-response meta-analytic approach.
   Methodology and Principal Findings: In September 2013, we performed electronic searches in PubMed, Embase, and the Cochrane Library to identify studies examining the effect of folate intake on the incidence of lung cancer. Only prospective cohort studies that reported the effect estimates about the incidence of lung cancer with 95% confidence intervals (CIs) for more than 2 categories of folate intake were included. Overall, we examined 9 cohort studies reporting the data of 566,921 individuals. High folate intake had little effect on the risk of lung cancer (risk ratio [RR], 0.92; 95% CI, 0.84-1.01; P = 0.076). Dose-response meta-analysis also suggested that a 100 mu g/day increase in folate intake had no significant effect on the risk of lung cancer (RR, 0.99; 95% CI, 0.97-1.01; P = 0.318). Subgroup analysis suggested that the potential protective effect of low folate intake (100-299 mu g/day) was more evident in women than men, while the opposite was true of high folate intake (>400 mu g/day). Finally, subgroup analyses of a 100 mu g/day increment in folate intake indicated that its potential protective effect was more evident in men than in women.
   Conclusion/Significance: Our study revealed that folate intake had little or no effect on the risk of lung cancer. Subgroup analyses indicated that an increased folate intake was associated with a reduced risk of lung cancer in men. Furthermore, low folate intake may be a protective factor for women, and high folate intake for men.
C1 [Zhang, Yu-Fei; Zhou, Li; Zhang, Hong-Wei; Hou, An-Ji; Gao, Hong-Fang] Shanghai Seventh Peoples Hosp, Dept Oncol, Shanghai, Peoples R China.
   [Zhou, Yu-Hao] Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.
RP Zhou, YH (reprint author), Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.
EM zhou_ly@126.com
FU Shanghai Natural Science Foundation [12ZR1422800]; Talents Training
   program of Shanghai Seventh People's Hospital [QMX2014-01]
FX This study was funded by Shanghai Natural Science Foundation (Grant No.
   12ZR1422800) and Talents Training program of Shanghai Seventh People's
   Hospital (Grant No. QMX2014-01). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Bailey LB, 1999, J NUTR, V129, P779
   Bandera EV, 1997, CANCER CAUSE CONTROL, V8, P828, DOI 10.1023/A:1018456127018
   Bassett JK, 2012, EUR J CLIN NUTR, V66, P182, DOI 10.1038/ejcn.2011.157
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cho E, 2006, INT J CANCER, V118, P970, DOI 10.1002/ijc.21441
   Deeks JJ, 2008, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Hartman TJ, 2001, AM J EPIDEMIOL, V153, P688, DOI 10.1093/aje/153.7.688
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hung RJ, 2007, CARCINOGENESIS, V28, P1334, DOI 10.1093/carcin/bgm067
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kabat GC, 2008, BRIT J CANCER, V99, P816, DOI 10.1038/sj.bjc.6604540
   LEMARCHAND L, 1989, JNCI-J NATL CANCER I, V81, P1158, DOI 10.1093/jnci/81.15.1158
   Li RW, 2000, AM J PUBLIC HEALTH, V90, P777, DOI 10.2105/AJPH.90.5.777
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Riboli E, 2003, AM J CLIN NUTR, V78, p559S, DOI 10.1093/ajcn/78.3.559S
   Roswall N, 2010, LUNG CANCER, V67, P275, DOI 10.1016/j.lungcan.2009.11.010
   SELHUB J, 1992, AM J CLIN NUTR, V55, P131
   Shen HB, 2003, CANCER EPIDEM BIOMAR, V12, P980
   Shi QL, 2005, CARCINOGENESIS, V26, P649, DOI 10.1093/carcin/bgh351
   Slatore CG, 2008, AM J RESP CRIT CARE, V177, P524, DOI 10.1164/rccm.200709-1398OC
   Smith-Warner SA, 2003, INT J CANCER, V107, P1001, DOI 10.1002/ijc.11490
   Suzuki T, 2007, CARCINOGENESIS, V28, P1718, DOI 10.1093/carcin/bgm104
   Takata Y, 2013, NUTR CANCER, V65, P51, DOI 10.1080/01635581.2013.741757
   Takata Y, 2012, CANCER CAUSE CONTROL, V23, P1965, DOI 10.1007/s10552-012-0074-z
   Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489
   Voorrips LE, 2000, CANCER EPIDEM BIOMAR, V9, P357
   Wells GA, 2009, NEWCASTLE OTTAWA SCA
   Wingo PA, 2003, CANCER, V97, P3133, DOI 10.1002/cncr.11380
   World Cancer Research Fund/American Institute forCancer Research, 2007, FOOD NUTR PHYS ACT P
   Yuan JM, 2003, CANCER EPIDEM BIOMAR, V12, P890
NR 36
TC 7
Z9 8
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 8
PY 2014
VL 9
IS 4
AR e93465
DI 10.1371/journal.pone.0093465
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE7FA
UT WOS:000334160900027
PM 24713625
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ge, YZ
   Wu, R
   Lu, TZ
   Jia, RP
   Li, MH
   Gao, XF
   Jiang, XM
   Zhu, XB
   Li, LP
   Tan, SJ
   Song, Q
   Li, WC
   Zhu, JG
AF Ge, Yu-Zheng
   Wu, Ran
   Lu, Tian-Ze
   Jia, Rui-Peng
   Li, Ming-Hao
   Gao, Xiao-Fei
   Jiang, Xiao-Min
   Zhu, Xian-Bo
   Li, Liang-Peng
   Tan, Si-Jia
   Song, Qun
   Li, Wen-Cheng
   Zhu, Jia-Geng
TI Combined Effects of TGFB1+869 T/C and+915 G/C Polymorphisms on Acute
   Rejection Risk in Solid Organ Transplant Recipients: A Systematic Review
   and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID CYTOKINE GENE POLYMORPHISMS; GROWTH-FACTOR-BETA; TRANSFORMING
   GROWTH-FACTOR-BETA-1 GENE; GRAFT-REJECTION; MESSENGER-RNA; TGF-BETA;
   ALLOGRAFT-REJECTION; RENAL-TRANSPLANTS; TURKISH PATIENTS; TGF-BETA-1
AB Background: Transforming growth factor-beta 1(TGF-beta 1) is involved in the development of acute rejection (AR) episodes in solid organ transplant recipients; and a number of studies have been conducted to investigate the combined effects of human TGF-beta 1 gene (TGFB1) +869 T/C and +915 G/C polymorphisms on AR risk. However, the results obtained are inconclusive.
   Methods: Eligible studies that investigated the haplotypic association between TGFB1 +869 T/C and +915 G/C polymorphisms and AR risk were comprehensively searched in the PUBMED, EMBASE, China National Knowledge Infrastructure, and Wanfang Database. Statistical analyses were performed by using STATA 12.0 and Review Manager 5.0.
   Results: Fourteen eligible studies with 565 AR cases and 1219 non-AR cases were included. Overall, a significantly decreased risk was detected in patients carried with intermediate producer (IP) haplotypes (T/C G/C, T/T G/C, and C/C G/G) and/or low producer ( LP) haplotypes (C/C G/C, C/C C/C, T/T C/C, and T/C C/C) compared with high producer ( HP) haplotypes (T/T G/G and T/C G/G; IP vs. HP: OR = 0.75, 95% Cl, 0.58-0.96, P (heterogeneity) = 0.238; IP/LP vs. HP: OR = 0.77, 95% Cl, 0.61-0.98, P heterogeneity = 0.144). In addition, subgroup analysis by transplant types demonstrated a similar association in patients receiving heart transplant ( IP vs. HP: OR = 0.32, 95% Cl, 0.14-0.73, P (heterogeneity) = 0.790; IP/LP vs. HP: OR = 0.41, 95% Cl, 0.20-0.85, P (heterogeneity) = 0.320).
   Conclusions: The current meta-analysis and systematic review indicated that recipient TGFB1 HP haplotypes were significantly associated with an increased risk for AR in solid organ transplant recipients, particularly patients receiving cardiac allograft.
C1 [Ge, Yu-Zheng; Wu, Ran; Lu, Tian-Ze; Jia, Rui-Peng; Li, Ming-Hao; Tan, Si-Jia; Song, Qun; Li, Wen-Cheng; Zhu, Jia-Geng] Nanjing Med Univ, Nanjing Hosp 1, Ctr Renal Transplantat, Nanjing, Jiangsu, Peoples R China.
   [Ge, Yu-Zheng; Wu, Ran; Lu, Tian-Ze; Jia, Rui-Peng; Li, Ming-Hao; Tan, Si-Jia; Song, Qun; Li, Wen-Cheng; Zhu, Jia-Geng] Nanjing Med Univ, Nanjing Hosp 1, Dept Urol, Nanjing, Jiangsu, Peoples R China.
   [Gao, Xiao-Fei; Jiang, Xiao-Min] Nanjing Med Univ, Nanjing Hosp 1, Dept Cardiol, Nanjing, Jiangsu, Peoples R China.
   [Zhu, Xian-Bo] Nanjing Med Univ, Nanjing Hosp 1, Dept Gen Surg, Nanjing, Jiangsu, Peoples R China.
   [Li, Liang-Peng] Nanjing Med Univ, Nanjing Hosp 1, Dept Cardiothorac Surg, Nanjing, Jiangsu, Peoples R China.
RP Jia, RP (reprint author), Nanjing Med Univ, Nanjing Hosp 1, Ctr Renal Transplantat, Nanjing, Jiangsu, Peoples R China.
EM ruipeng_jia@yeah.net
FU National Natural Science Foundation of China [81070597, 81370853];
   Science and Education Development Program of the Jiangsu Province Health
   Board [LJ201107]; Six Talent Peaks of the Jiangsu Province Health Bureau
   [2011-WS-093]; Research and Innovation Program for Graduates of Jiangsu
   Province [CXZZ13_0583]
FX This project was supported by grants from the National Natural Science
   Foundation of China (81070597, 81370853), Science and Education
   Development Program of the Jiangsu Province Health Board (LJ201107), Six
   Talent Peaks of the Jiangsu Province Health Bureau (2011-WS-093) and
   Research and Innovation Program for Graduates of Jiangsu Province
   (CXZZ13_0583). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Awad MR, 1998, TRANSPLANTATION, V66, P1014, DOI 10.1097/00007890-199810270-00009
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benza RL, 2009, J HEART LUNG TRANSPL, V28, P1057, DOI 10.1016/j.healun.2009.06.001
   Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807
   Canossi A, 2007, TRANSPL P, V39, P1805, DOI 10.1016/i.transproceed.2007.05.035
   Dai JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028903
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dhaouadi T, 2013, TRANSPL P, V45, P2152, DOI 10.1016/j.transproceed.2012.12.006
   Di Filippo S, 2006, TRANSPLANTATION, V81, P934, DOI 10.1097/01.tp.0000202725.55923.37
   Edgley AJ, 2012, CARDIOVASC THER, V30, pe30, DOI 10.1111/j.1755-5922.2010.00228.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gagliardo R, 2013, INT J IMMUNOPATH PH, V26, P725, DOI 10.1177/039463201302600316
   Ge YZ, 2014, TRANSPL IMMUNOL
   Gomez-Mateo J, 2006, TRANSPL IMMUNOL, V17, P55, DOI 10.1016/j.trim.2006.09.011
   Gourley IS, 2004, HUM IMMUNOL, V65, P248, DOI 10.1016/j.humimm.2004.01.008
   Gu Xin-wei, 2003, Di Yi Jun Yi Da Xue Xue Bao, V23, P1211
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hoffmann S, 2004, KIDNEY INT, V66, P1686, DOI 10.1111/j.1523-1755.2004.00936.x
   Hueso M, 2006, TRANSPLANTATION, V81, P1463, DOI 10.1097/01.tp.0000206102.67063.24
   Hussein YM, 2014, GENE, V536, P393, DOI 10.1016/j.gene.2013.11.042
   Hutchinson IV, 1999, TRANSPLANT P, V31, p9S
   Karasu Z, 2004, TRANSPLANT P, V36, P2791, DOI 10.1016/j.transproceed.2004.10.034
   Kocierz M, 2011, TISSUE ANTIGENS, V77, P283, DOI 10.1111/j.1399-0039.2010.01623.x
   Lacha J, 2005, TRANSPLANT P, V37, P764, DOI 10.1016/j.transproceed.2004.12.224
   Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025
   Lv RX, 2012, TRANSPL IMMUNOL, V26, P11, DOI 10.1016/j.trim.2011.10.003
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Morris-Stiff G, 2005, ANN ROY COLL SURG, V87, P326, DOI 10.1308/003588405X60533
   Opelz G, 2008, TRANSPLANTATION, V85, P661, DOI 10.1097/TP.0b013e3181661695
   Pakosz K, 2012, ANN TRANSPL, V17, P45
   Pelletier R, 2000, TRANSPLANTATION, V70, P674, DOI 10.1097/00007890-200008270-00023
   Perrey C, 1998, TRANSPL IMMUNOL, V6, P193, DOI 10.1016/S0966-3274(98)80045-2
   Pribylova-Hribova P, 2006, KIDNEY INT, V69, P1872, DOI 10.1038/sj.ki.5000328
   Seyhun Y, 2012, TRANSPL P, V44, P1670, DOI 10.1016/j.transproceed.2012.05.046
   Seyhun Y, 2012, TRANSPL P, V44, P1241, DOI 10.1016/j.transproceed.2012.01.125
   Shah R, 2006, HUM GENET, V119, P61, DOI 10.1007/s00439-005-0112-y
   Stehlik J, 2012, J HEART LUNG TRANSPL, V31, P1052, DOI 10.1016/j.healun.2012.08.002
   Suthanthiran M, 2000, P NATL ACAD SCI USA, V97, P3479, DOI 10.1073/pnas.050420897
   Tambur AR, 2001, TRANSPLANTATION, V71, P1475, DOI 10.1097/00007890-200105270-00020
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thurairajah PH, 2013, TRANSPLANTATION, V95, P955, DOI 10.1097/TP.0b013e3182845f6c
   Tian Y, 2001, Zhonghua Yi Xue Za Zhi, V81, P719
   Tian Ye, 2002, Zhonghua Wai Ke Za Zhi, V40, P256
   Yamada Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/jbmr.1998.13.10.1569
NR 46
TC 6
Z9 7
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2014
VL 9
IS 4
AR e93938
DI 10.1371/journal.pone.0093938
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE6MJ
UT WOS:000334107500096
PM 24705444
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, YL
   Luo, XP
   Xian, L
AF Yang, Yan-Long
   Luo, Xiu-Ping
   Xian, Lei
TI The Prognostic Role of the Class III beta-Tubulin in Non-Small Cell Lung
   Cancer (NSCLC) Patients Receiving the Taxane/Vinorebine-Based
   Chemotherapy: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID ADJUVANT CHEMOTHERAPY; CLINICAL-SIGNIFICANCE; RANDOMIZED-TRIAL;
   EXPRESSION; TAXANE; SURVIVAL; ERCC1; RESISTANCE; BENEFIT; STATISTICS
AB Background: A number of studies have examined the relationship between the expression of the class III beta-tubulin (TUBB3) and the treatment responses to the taxane/vinorebine-based chemotherapy in patients with non-small cell lung cancer (NSCLC). However, the results of these studies were inconsistent and inconclusive. Therefore, we conducted an up-to-date meta-analysis to evaluate the prognostic role of TUBB3 in the taxane/vinorebine-based chemotherapy.
   Methods: A literature search for relevant studies was conducted in PubMed, Embase, and CNKI. The inclusion criteria were the taxane/vinorebine-based chemotherapy in patients with NSCLC and the evaluation of the clinical outcomes in relation to the expression of TUBB3. The clinical outcomes analyzed in this study included the overall response rate (ORR), overall survival (OS), and event-free survival (EFS). Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were calculated to assess the risk associated with the TUBB3 expression in the taxane/vinorebine-based chemotherapy.
   Results: A total of 28 studies with 2401 NSCLC patients were qualified for this meta-analysis. We found that the positive or high level of TUBB3 expression was associated with a poorer ORR (OR = 0.24, 95% CI = 0.16-0.36, p<0.001), an unfavorable OS (HR = 1.52, 95% CI = 1.27-1.82, p<0.001), and a worse EFS (HR = 1.47, 95% CI = 1.24-1.74, p<0.001) compared to the negative or low level of TUBB3 expression. The statistically significant associations between TUBB3 and chemotherapy responses were also observed in the stratified subgroup analysis, which included the analysis by ethnic subgroup (Asian and Caucasian), chemotherapy regimen (taxane-based and vinorebine-based), TUBB3 detection method (IHC and PCR), and treatment strategy (surgery plus adjuvant chemotherapy and palliative chemotherapy).
   Conclusions: The expression level of TUBB3 may be a useful biomarker to predict the clinical outcomes of the taxane/vinorebine-based chemotherapy in patients with NSCLC.
C1 [Yang, Yan-Long; Xian, Lei] Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Nanning, Guangxi Zhuang, Peoples R China.
   [Luo, Xiu-Ping] Guangxi Med Univ, Clin Fac, Nanning, Guangxi Zhuang, Peoples R China.
RP Xian, L (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Nanning, Guangxi Zhuang, Peoples R China.
EM xianlei59@163.com
FU Guangxi Scientific Research and Technology Development projects
   [10124001A-592 44]
FX This work was supported by the Guangxi Scientific Research and
   Technology Development projects (grant no. 10124001A-592 44). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Azuma K, 2009, LUNG CANCER, V64, P326, DOI 10.1016/j.lungcan.2008.09.002
   Azuma K, 2009, CANCER CHEMOTH PHARM, V64, P565, DOI 10.1007/s00280-008-0907-3
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Custodio AB, 2009, J THORAC ONCOL, V4, P891, DOI 10.1097/JTO.0b013e3181a4b8fb
   Chiou JF, 2003, LUNG, V181, P267, DOI 10.1007/s00408-003-1029-7
   Christoph DC, 2012, BRIT J CANCER, V107, P823, DOI 10.1038/bjc.2012.324
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061
   Dumontet Charles, 2005, Bull Cancer, V92, pE25
   Dumontet C, 2009, MOL CANCER THER, V8, P17, DOI 10.1158/1535-7163.MCT-08-0986
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Felip E, 2011, VET REC, V169, P1507, DOI 10.1093/annonc/mdr150
   Ferrandina G, 2006, CLIN CANCER RES, V12, P2774, DOI 10.1158/1078-0432.CCR-05-2715
   Galano G, 2011, CURR DRUG SAF, V6, P185, DOI 10.2174/157488611797579302
   Gao LH, 2012, J NANTONG U MED SCI, V32, P188
   [龚健 GONG Jian], 2009, [中国新药杂志, Chinese Journal New Drugs], V18, P815
   Guilbert J J, 2003, Educ Health (Abingdon), V16, P230
   Guo HQ, 2011, ONCOLOGY PROGR, V9, P420
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang CL, 2010, EXP THER MED, V1, P445, DOI 10.3892/etm_00000069
   Ikeda N, 2009, ANN THORAC CARDIOVAS, V15, P144
   Ikeda S, 2009, PATHOL INT, V59, P863, DOI 10.1111/j.1440-1827.2009.02463.x
   *INT AG RES CANC, 2010, GLOBOCAN PROJ
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jiang H, 2013, EXP THER MED, V5, P1506, DOI 10.3892/etm.2013.1007
   Kaira K, 2013, INT J CLIN ONCOL, V18, P371, DOI 10.1007/s10147-012-0386-8
   Kang CH, 2010, LUNG CANCER, V68, P478, DOI 10.1016/j.lungcan.2009.07.004
   Krawczyk P, 2012, CHEMOTHERAPY, V58, P60, DOI 10.1159/000336143
   Liu P, 2013, J CLIN MED PRACTICE, V17, P12
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
   Non-small Cell Lung Cancer Collaborative Group, 2000, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002139
   Okuda K, 2008, LUNG CANCER, V62, P105, DOI 10.1016/j.lungcan.2008.02.021
   OYE RK, 1984, JAMA-J AM MED ASSOC, V252, P2722, DOI 10.1001/jama.252.19.2722
   Pu Xiaolin, 2009, Zhongguo Fei Ai Za Zhi, V12, P49, DOI 10.3779/j.issn.1009-3419.2009.01.008
   Reiman T, 2012, ANN ONCOL, V23, P86, DOI 10.1093/annonc/mdr033
   Rosell R, 2003, ONCOGENE, V22, P3548, DOI 10.1038/sj.onc.1206419
   Seve P, 2005, MOL CANCER THER, V4, P2001, DOI 10.1158/1535-7163.MCT-05-0244
   Seve P, 2005, CLIN CANCER RES, V11, P5481, DOI 10.1158/1078-0432.CCR-05-0285
   Seve P, 2008, LANCET ONCOL, V9, P168, DOI 10.1016/S1470-2045(08)70029-9
   Seve P, 2007, CLIN CANCER RES, V13, P994, DOI 10.1158/1078-0432.CCR-06-1503
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Stewart DJ, 2010, CRIT REV ONCOL HEMAT, V75, P173, DOI 10.1016/j.critrevonc.2009.11.006
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Tommasi S, 2007, INT J CANCER, V120, P2078, DOI 10.1002/ijc.22557
   Urano N, 2006, INT J ONCOL, V28, P375
   Vilmar AC, 2011, CLIN CANCER RES, V17, P5205, DOI 10.1158/1078-0432.CCR-11-0658
   [万一元 WAN Yiyuan], 2011, [中华内科杂志, Chinese Journal of Internal Medicine], V50, P469
   Wells G., 2003, NEWCASTLE OTTAWA SCA
   Xiao YY, 2009, CHIN J LUNG CANC, V12, P14
   Yang JQ, 2009, CHIN CLIN ONCOL, V14, P884
   Yared JA, 2012, DRUG DES DEV THER, V6, P371, DOI 10.2147/DDDT.S28997
   Zhang HL, 2012, LUNG CANCER, V77, P9, DOI 10.1016/j.lungcan.2012.01.005
   Zhang JP, 2012, MED RECAPITULATE, V18, P2637
   Zhang YL, 2013, ONCOL LETT, V6, P220, DOI 10.3892/ol.2013.1323
   Zheng QH, 2012, J CHIN ONCOL, V18, P806
NR 57
TC 23
Z9 25
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2014
VL 9
IS 4
AR e93997
DI 10.1371/journal.pone.0093997
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE6MJ
UT WOS:000334107500107
PM 24705847
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, J
   Uchino, M
   Sastry, SM
   Schaumberg, DA
AF Wu, Juan
   Uchino, Miki
   Sastry, Srinivas M.
   Schaumberg, Debra A.
TI Age-Related Macular Degeneration and the Incidence of Cardiovascular
   Disease: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID MYOCARDIAL-INFARCTION; RISK-FACTORS; APOLIPOPROTEIN-E; EYE DISEASE;
   MACULOPATHY; MORTALITY; GENOTYPES; STROKE; GENE
AB Importance: Research has indicated some shared pathogenic mechanisms between age-related macular degeneration (AMD) and cardiovascular disease (CVD). However, results from prior epidemiologic studies have been inconsistent as to whether AMD is predictive of future CVD risk.
   Objective: To systematically review population-based cohort studies of the association between AMD and risk of total CVD and CVD subtypes, coronary heart disease (CHD) and stroke.
   Data Sources: A systematic search of the PubMed and EMBASE databases and reference lists of key retrieved articles up to December 20, 2012 without language restriction.
   Data Extraction: Two reviewers independently extracted data on baseline AMD status, risk estimates of CVD and methods used to assess AMD and CVD. We pooled relative risks using random or fixed effects models as appropriate.
   Results: Thirteen cohort studies (8 prospective and 5 retrospective studies) with a total of 1,593,390 participants with 155,500 CVD events (92,039 stroke and 62,737 CHD) were included in this meta-analysis. Among all studies, early AMD was associated with a 15% (95% CI, 1.08-1.22) increased risk of total CVD. The relative risk was similar but not significant for late AMD (RR, 1.17; 95% CI, 0.98-1.40). In analyses restricted to the subset of prospective studies, the risk associated with early AMD did not appreciably change; however, there was a marked 66% (95% CI, 1.31-2.10) increased risk of CVD among those with late AMD.
   Conclusion: Whereas the results from all cohort studies suggest that both early and late AMD are predictive of a small increase in risk of future CVD, subgroup analyses limited to prospective studies demonstrate a markedly increased risk of CVD among people with late AMD. Retrospective studies using healthcare databases may have inherent methodological limitations that obscure such association. Additional prospective studies are needed to further elucidate the associations between AMD and specific CVD outcomes.
C1 [Wu, Juan] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Uchino, Miki] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Sastry, Srinivas M.] Suburban Hosp, Bethesda, MD USA.
   [Schaumberg, Debra A.] Harvard Univ, Div Prevent Med, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   [Schaumberg, Debra A.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Ctr Translat Med,John A Moran Eye Ctr, Salt Lake City, UT USA.
   [Schaumberg, Debra A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Schaumberg, Debra A.] Schepens Eye Res Inst, Boston, MA USA.
RP Wu, J (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
EM juan.wu@mail.harvard.edu
FU National Eye Institute [EY021900, EY017362]; Research to Prevent
   Blindness, Inc., New York, NY
FX This work was supported in part by EY021900, and EY017362 from the
   National Eye Institute (Dr. Schaumberg); and by an Unrestricted Grant
   from Research to Prevent Blindness, Inc., New York, NY, to the
   Department of Ophthalmology & Visual Sciences, University of Utah (Dr.
   Schaumberg). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Golan S, 2011, GRAEF ARCH CLIN EXP, V249, P179, DOI 10.1007/s00417-010-1489-4
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitta VP, 2013, JAMA OPHTHALMOL, P1
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sofat R, 2010, ATHEROSCLEROSIS, V213, P184, DOI 10.1016/j.atherosclerosis.2010.07.021
   Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
NR 42
TC 37
Z9 39
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 28
PY 2014
VL 9
IS 3
AR e89600
DI 10.1371/journal.pone.0089600
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE0TC
UT WOS:000333678100002
PM 24681973
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xi, B
   Li, SS
   Liu, ZL
   Tian, H
   Yin, XX
   Huai, PC
   Tang, WH
   Zhou, DH
   Steffen, LM
AF Xi, Bo
   Li, Shuangshuang
   Liu, Zhaolu
   Tian, Huan
   Yin, Xiuxiu
   Huai, Pengcheng
   Tang, Weihong
   Zhou, Donghao
   Steffen, Lyn M.
TI Intake of Fruit Juice and Incidence of Type 2 Diabetes: A Systematic
   Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID SUGAR-SWEETENED BEVERAGES; SOFT DRINK; RISK; CONSUMPTION; MELLITUS;
   VEGETABLES
AB Background: Several prospective studies have been conducted to examine the relationship between fruit juice intake and risk of incident type 2 diabetes, but results have been mixed. In the present study, we aimed to estimate the association between fruit juice intake and risk of type 2 diabetes.
   Methods: PubMed and Embase databases were searched up to December 2013. All prospective cohort studies of fruit juice intake with risk of type 2 diabetes were included. The pooled relative risks (RRs) with 95% confidence intervals (CIs) for highest vs. lowest category of fruit juice intake were estimated using a random-effects model.
   Results: A total of four studies (191,686 participants, including 12,375 with type 2 diabetes) investigated the association between sugar-sweetened fruit juice and risk of incident type 2 diabetes, and four studies (137,663 participants and 4,906 cases) investigated the association between 100% fruit juice and risk of incident type 2 diabetes. A higher intake of sugar-sweetened fruit juice was significantly associated with risk of type 2 diabetes (RR = 1.28, 95%CI = 1.04-1.59, p = 0.02), while intake of 100% fruit juice was not associated with risk of developing type 2 diabetes (RR = 1.03, 95%CI = 0.91-1.18, p = 0.62).
   Conclusions: Our findings support dietary recommendations to limit sugar-sweetened beverages, such as fruit juice with added sugar, to prevent the development of type 2 diabetes.
C1 [Xi, Bo; Li, Shuangshuang; Liu, Zhaolu; Tian, Huan; Yin, Xiuxiu] Shandong Univ, Sch Publ Hlth, Dept Maternal & Child Hlth, Jinan 250100, Peoples R China.
   [Huai, Pengcheng] Shandong Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Jinan 250100, Peoples R China.
   [Tang, Weihong; Steffen, Lyn M.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
   [Zhou, Donghao] Linyi Peoples Hosp, Dept Endocrinol, Linyi, Peoples R China.
RP Zhou, DH (reprint author), Linyi Peoples Hosp, Dept Endocrinol, Linyi, Peoples R China.
EM donghaozhou@163.com; steffen@umn.edu
CR Bazzano LA, 2008, DIABETES CARE, V31, P1311, DOI 10.2337/dc08-0080
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Carter P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4229
   Davis MM, 2007, PEDIATRICS, V120, pS229, DOI 10.1542/peds.2007-2329E
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eshak ES, 2013, CLIN NUTR, V32, P300, DOI 10.1016/j.clnu.2012.08.003
   Fagherazzi G, 2013, AM J CLIN NUTR, V97, P517, DOI 10.3945/ajcn.112.050997
   Hamer M, 2007, J HYPERTENS, V25, P2361, DOI 10.1097/HJH.0b013e3282efc214
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Kaiser KA, 2013, OBES REV, V14, P620, DOI 10.1111/obr.12048
   Kit BK, 2013, AM J CLIN NUTR, V98, P180, DOI 10.3945/ajcn.112.057943
   Livesey G, 2013, AM J CLIN NUTR, V97, P584, DOI 10.3945/ajcn.112.041467
   Malik VS, 2010, DIABETES CARE, V33, P2477, DOI 10.2337/dc10-1079
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Montonen J, 2007, J NUTR, V137, P1447
   Muraki I, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5001
   Mursu J, 2013, AM J CLIN NUTR
   O'Neil CE, 2008, AM J LIFESTYLE MED, V2, P315, DOI 10.1177/1559827608317277
   Odegaard AO, 2010, AM J EPIDEMIOL, V171, P701, DOI 10.1093/aje/kwp452
   Palmer JR, 2008, ARCH INTERN MED, V168, P1487, DOI 10.1001/archinte.168.14.1487
   Paynter NP, 2006, AM J EPIDEMIOL, V164, P1075, DOI 10.1093/aje/kwj323
   Romaguera D, 2013, DIABETOLOGIA, V56, P1520, DOI 10.1007/s00125-013-2899-8
   Schulze MB, 2004, JAMA-J AM MED ASSOC, V292, P927, DOI 10.1001/jama.292.8.927
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Wells GA, NEWCASTLE OTTAWA SCA
   Zenith International, 2008, REP GLOB SOFT DRINKS
NR 26
TC 57
Z9 60
U1 1
U2 40
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 28
PY 2014
VL 9
IS 3
AR e93471
DI 10.1371/journal.pone.0093471
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE0TC
UT WOS:000333678100048
PM 24682091
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, HH
   Wang, HT
   Jin, JJ
   Cui, GB
   Zhou, KC
   Chen, Y
   Chen, GZ
   Dong, YL
   Wang, W
AF Wu, Huang-Hui
   Wang, Hong-Tao
   Jin, Jun-Jie
   Cui, Guang-Bin
   Zhou, Ke-Cheng
   Chen, Yu
   Chen, Guo-Zhong
   Dong, Yu-Lin
   Wang, Wen
TI Does Dexmedetomidine as a Neuraxial Adjuvant Facilitate Better
   Anesthesia and Analgesia? A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIALS; SPINAL DORSAL-HORN; INTRATHECAL
   DEXMEDETOMIDINE; POSTOPERATIVE PAIN; ALPHA-2 AGONISTS; CLINICAL-TRIALS;
   DOSE-RESPONSE; NERVE INJURY; BUPIVACAINE; SURGERY
AB Background: Neuraxial application of dexmedetomidine (DEX) as adjuvant analgesic has been invetigated in some randomized controlled trials (RCTs) but not been approved because of the inconsistency of efficacy and safety in these RCTs. We performed this meta-analysis to access the efficacy and safety of neuraxial DEX as local anaesthetic (LA) adjuvant.
   Methods: We searched PubMed, PsycINFO, Scopus, EMBASE, and CENTRAL databases from inception to June 2013 for RCTs that investigated the analgesia efficacy and safety for neuraxial application DEX as LA adjuvant. Effects were summarized using standardized mean differences (SMDs), weighed mean differences (WMDs) or odds ratio (OR) with suitable effect model. The primary outcomes were postoperative pain intensity and analgesic duration, bradycardia and hypotension.
   Results: Sixteen RCTs involving 1092 participants were included. Neuraxial DEX significantly decreased postoperative pain intensity (SMD, -1.29; 95% confidence interval (CI), -1.70 to -0.89; P < 0.00001), prolonged analgesic duration (WMD, 6.93 hours; 95% CI, 5.23 to 8.62; P < 0.00001) and increased the risk of bradycardia (OR, 2.68; 95% CI, 1.18 to 6.10; P = 0.02). No evidence showed that neuraxial DEX increased the risk of other adverse events, such as hypotension (OR, 1.54; 95% CI, 0.83 to 2.85; P = 0.17). Additionally, neuraxial DEX was associated with beneficial alterations in postoperative sedation scores and number of analgesic requirements, sensory and motor block characteristics, and intro-operative hemodynamics.
   Conclusion: Neuraxial DEX is a favorable LA adjuvant with better and longer analgesia. The greatest concern is bradycardia. Further large sample trials with strict design and focusing on long-term outcomes are needed.
C1 [Wu, Huang-Hui; Chen, Yu; Chen, Guo-Zhong] Fuzhou Gen Hosp Nanjing Mil Reg, Dept Anesthesiol, Fuzhou, Peoples R China.
   [Wu, Huang-Hui; Wang, Hong-Tao; Jin, Jun-Jie; Cui, Guang-Bin; Zhou, Ke-Cheng; Dong, Yu-Lin; Wang, Wen] Fourth Mil Med Univ, Unit Evidence Based Med, Dept Anat Histol & Embryol, Preclin Sch Med, Xian 710032, Peoples R China.
   [Wu, Huang-Hui; Wang, Hong-Tao; Jin, Jun-Jie; Cui, Guang-Bin; Zhou, Ke-Cheng; Dong, Yu-Lin; Wang, Wen] Fourth Mil Med Univ, KK Leung Brain Res Ctr, Preclin Sch Med, Xian 710032, Peoples R China.
   [Wang, Hong-Tao] Fourth Mil Med Univ, Xijing Hosp, Dept Burn & Cutaneous Surg, Xian 710032, Peoples R China.
   [Jin, Jun-Jie] Fuzhou Gen Hosp Nanjing Mil Reg, Dept Neurosurg, Fuzhou, Peoples R China.
   [Cui, Guang-Bin] Fourth Mil Med Univ, Dept Diagnost Radiol, Tangdu Hosp, Xian 710032, Peoples R China.
   [Zhou, Ke-Cheng] China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China.
RP Chen, GZ (reprint author), Fuzhou Gen Hosp Nanjing Mil Reg, Dept Anesthesiol, Fuzhou, Peoples R China.
EM cgzssq2000@sina.com; donganat@fmmu.edu.cn; wangwen@fmmu.edu.cn
FU Fourth Military Medical University;  [NSFC: 31070976];  [81271230]
FX This work is partly supported by the NSFC: 31070976, 81271230 and
   intramural grant of the Fourth Military Medical University. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Abdallah FW, 2013, BRIT J ANAESTH, V110, P915, DOI 10.1093/bja/aet066
   Abdallah FW, 2013, ANESTH ANALG, V117, P271, DOI 10.1213/ANE.0b013e318290c566
   Abdel-Aleem M, 2012, INT J GYNECOL OBSTET, V116, P158, DOI 10.1016/j.ijgo.2011.10.002
   Adams R, 2013, BRIT J ANAESTH, V111, P703, DOI 10.1093/bja/aet194
   Al-Mustafa MM, 2009, SAUDI MED J, V30, P365
   Anand VG, 2011, INDIAN J ANAESTH, V55, P340, DOI 10.4103/0019-5049.84835
   Bagatini Airton, 2002, Rev. Bras. Anestesiol., V52, P606, DOI 10.1590/S0034-70942002000500012
   Becker Daniel E, 2012, Anesth Prog, V59, P90, DOI 10.2344/0003-3006-59.2.90
   Becker DE, 2012, ANESTH PROG, V59, P102
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935
   Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb
   Borenstein M., 2009, INTRO METAANALYSIS
   Chan AKM, 2010, EXPERT OPIN PHARMACO, V11, P2849, DOI 10.1517/14656566.2010.511613
   Degos V, 2013, ANESTHESIOLOGY, V118, P1123, DOI 10.1097/ALN.0b013e318286cf36
   DeKock M, 1997, ANESTHESIOLOGY, V86, P285, DOI 10.1097/00000542-199702000-00003
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eid H, 2011, AIN SHAMS J ANESTHES, V4, P83
   Ekatodramis G., 2001, Current Topics in Medicinal Chemistry, V1, P183
   El-Hennawy AM, 2009, BRIT J ANAESTH, V103, P268, DOI 10.1093/bja/aep159
   Elhakim M, 2010, ACTA ANAESTH SCAND, V54, P703, DOI 10.1111/j.1399-6576.2009.02199.x
   Fairbanks CA, 2009, PHARMACOL THERAPEUT, V123, P224, DOI 10.1016/j.pharmthera.2009.04.001
   Ginosar Y, 2013, BRIT J ANAESTH, V111, P256, DOI 10.1093/bja/aet027
   Gupta R, 2011, INDIAN J ANAESTH, V55, P347, DOI 10.4103/0019-5049.84841
   Gurbet A, 2006, CAN J ANAESTH, V53, P646, DOI 10.1007/BF03021622
   Gurusamy KS, 2009, BRIT J SURG, V96, P342, DOI 10.1002/bjs.6558
   Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   JPT Higgins, 2009, COCHRANE HDB SYSTEMA
   Kairaluoma P, 2013, ACTA ANAESTH SCAND, V57, P118, DOI 10.1111/j.1399-6576.2012.02794.x
   Kanazi GE, 2006, ACTA ANAESTH SCAND, V50, P222, DOI 10.1111/j.1399-6576.2006.00919.x
   Khalili G, 2011, J ANESTH, V25, P892, DOI 10.1007/s00540-011-1227-z
   Kim JE, 2013, BIOL PHARM BULL, V36, P959, DOI 10.1248/bpb.b12-01067
   Kuchalik J, 2013, BRIT J ANAESTH, V111, P793, DOI 10.1093/bja/aet248
   Li SS, 2013, NEUROSCIENCE LETT
   Lilot M, 2013, ANESTH ANALG, V117, P259, DOI 10.1213/ANE.0b013e31828f29f8
   Liu L, 2012, BRAIN RES, V1427, P1, DOI 10.1016/j.brainres.2011.08.019
   Liu YL, 2007, NEUROPHARMACOLOGY, V52, P708, DOI 10.1016/j.neuropharm.2006.09.011
   Mohamed AA, 2012, PAIN PHYSICIAN, V15, P339
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Niu XY, 2013, CNS NEUROSCI THER, V19, P897, DOI 10.1111/cns.12172
   Prochazka J, 2011, PAIN MED, V12, P1309, DOI 10.1111/j.1526-4637.2011.01218.x
   Ramadhyani Usha, 2010, Anesthesiol Clin, V28, P709, DOI 10.1016/j.anclin.2010.08.008
   Saadawy I, 2009, ACTA ANAESTH SCAND, V53, P251, DOI 10.1111/j.1399-6576.2008.01818.x
   Salgado PFS, 2008, REV ASSOC MED BRAS, V54, P110, DOI 10.1590/S0104-42302008000200011
   Schnaider Taylor Brandão, 2005, Rev. Bras. Anestesiol., V55, P525, DOI 10.1590/S0034-70942005000500007
   Selim Mohamed Fouad, 2012, J Prenat Med, V6, P47
   Shukla Deepika, 2011, J Anaesthesiol Clin Pharmacol, V27, P495, DOI 10.4103/0970-9185.86594
   Solanki SL, 2013, ANAESTH INTENS CARE, V41, P51, DOI 10.1177/0310057X1304100110
   Song JW, 2013, BRIT J ANAESTH, V111, P630, DOI 10.1093/bja/aet192
   Tziavrangos E, 2006, CURR OPIN ANESTHESIO, V19, P521, DOI 10.1097/01.aco.0000245278.22658.1e
   Xiang Q, 2013, BRIT J ANAESTH, V110, P420, DOI 10.1093/bja/aes385
NR 52
TC 24
Z9 30
U1 2
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 26
PY 2014
VL 9
IS 3
AR e93114
DI 10.1371/journal.pone.0093114
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE0SR
UT WOS:000333677000115
PM 24671181
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Guan, HB
   Wu, L
   Wu, QJ
   Zhu, JJ
   Gong, TT
AF Guan, Hong-Bo
   Wu, Lang
   Wu, Qi-Jun
   Zhu, Jingjing
   Gong, Tingting
TI Parity and Pancreatic Cancer Risk: A Dose-Response Meta-Analysis of
   Epidemiologic Studies
SO PLOS ONE
LA English
DT Article
ID REPRODUCTIVE FACTORS; ESTROGEN-RECEPTOR; DIABETES-MELLITUS; LUNG-CANCER;
   WEIGHT-GAIN; LIFE-STYLE; WOMEN; COHORT; MORTALITY; CHILDBEARING
AB Background: Previous epidemiologic studies have reported inconsistent results between parity and pancreatic cancer (PC) risk. To our knowledge, a comprehensive and quantitative assessment of this association has not been conducted.
   Methods: Relevant published studies of parity and PC were identified using MEDLINE (PubMed) and Web of Science databases until November 2013. Two authors (H-BG and LW) independently assessed eligibility and extracted data. Eleven prospective and 11 case-control studies reported relative risk (RR) estimates and 95% confidence intervals (CIs) of PC associated with parity. Fixed-and random-effects models were used to estimate the summary RR depending on the heterogeneity of effects.
   Results: The summary RR for PC comparing the highest versus lowest parity was 0.86 (95% CI: 0.73-1.02; Q = 50.49, P<0.001, I-2 = 58.4%). Significant inverse associations were also observed in the studies that adjusted for cigarette smoking (RR = 0.81; 95% CI: 0.68-0.98), Type 2 diabetes mellitus (RR = 0.83; 95% CI: 0.75-0.93), and those that included all confounders or important risk factors (RR = 0.85; 95% CI: 0.76-0.96). Additionally, in the dose-response analysis, the summary RR for per one live birth was 0.97 (95% CI: 0.94-1.01; Q = 62.83, P<0.001, I-2 = 69.8%), which also indicated a borderline statistically significant inverse effect of parity on PC risk. No evidence of publication bias and significant heterogeneity between subgroups were detected by meta-regression analyses.
   Conclusion: In summary, these findings suggest that higher parity is associated with a decreased risk of PC. Future large consortia or pooled studies are warranted to fully adjust for potential confounders to confirm this association.
C1 [Guan, Hong-Bo; Gong, Tingting] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang, Peoples R China.
   [Wu, Lang] Mayo Clin, Ctr Clin & Translat Sci, Rochester, MN USA.
   [Wu, Qi-Jun] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, Dept Epidemiol, Shanghai 200030, Peoples R China.
   [Wu, Qi-Jun] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogene & Related Genes, Shanghai 200030, Peoples R China.
   [Zhu, Jingjing] Univ Minnesota, Dept Educ Psychol, Minneapolis, MN 55455 USA.
RP Guan, HB (reprint author), China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang, Peoples R China.
EM hong_bo_guan@163.com
RI Wu, Lang/M-4053-2017
CR Anderson KE, 2006, CANC EPIDEMIOLOGY PR, P721
   Andren-Sandberg A, 1999, ANN ONCOL, V10, P131, DOI 10.1023/A:1008377928466
   Bagnardi V, 2004, AM J EPIDEMIOL, V159, P1077, DOI 10.1093/aje/kwh142
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BENZ C, 1986, CANCER RES, V46, P2276
   BOURHIS J, 1987, LANCET, V2, P977
   CANTOR KP, 1993, CANCER CAUSE CONTROL, V4, P505, DOI 10.1007/BF00052425
   Chang CC, 2010, PANCREAS, V39, P567, DOI 10.1097/MPA.0b013e3181c7341e
   Dahabreh IJ, 2012, LUNG CANCER, V76, P150, DOI 10.1016/j.lungcan.2011.10.014
   DEMESQUITA HBB, 1992, INT J CANCER, V52, P24, DOI 10.1002/ijc.2910520106
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duell EJ, 2005, AM J EPIDEMIOL, V161, P741, DOI 10.1093/aje/kwi104
   Duell EJ, 2013, INT J CANCER, V132, P2164, DOI 10.1002/ijc.27875
   Duell EJ, 2009, CANCER CAUSE CONTROL, V20, P1757, DOI 10.1007/s10552-009-9408-x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FERNANDEZ E, 1995, INT J CANCER, V62, P11, DOI 10.1002/ijc.2910620104
   GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   GREENWAY B, 1981, BRIT MED J, V283, P751, DOI 10.1136/bmj.283.6294.751
   Guan HB, 2013, CANCER EPIDEM BIOMAR, V22, P2345, DOI 10.1158/1055-9965.EPI-13-0759-T
   HAINES AP, 1982, J CANCER RES CLIN, V103, P93, DOI 10.1007/BF00410309
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Hanley AJG, 2001, INT J CANCER, V94, P140, DOI 10.1002/ijc.1446
   Heuch I, 2008, BRIT J CANCER, V98, P189, DOI 10.1038/sj.bjc.6604095
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holmes MD, 2002, CANCER EPIDEM BIOMAR, V11, P862
   Il'yasova D, 2005, CANCER CAUSE CONTROL, V16, P383, DOI 10.1007/s10552-004-5025-x
   IQBAL MJ, 1983, CLIN SCI, V65, P71, DOI 10.1042/cs0650071
   Jemal A, 2004, CANCER, V101, P3, DOI 10.1002/cncr.20288
   Ji BT, 1996, INT J CANCER, V66, P432
   KALAPOTHAKI V, 1993, CANCER CAUSE CONTROL, V4, P375, DOI 10.1007/BF00051341
   Karlson BM, 1998, INT J CANCER, V77, P224, DOI 10.1002/(SICI)1097-0215(19980717)77:2<224::AID-IJC10>3.0.CO;2-B
   Kreiger N, 2001, ANN EPIDEMIOL, V11, P563, DOI 10.1016/S1047-2797(01)00219-8
   KRITZSILVERSTEIN D, 1989, NEW ENGL J MED, V321, P1214, DOI 10.1056/NEJM198911023211802
   KVALE G, 1994, INT J EPIDEMIOL, V23, P691, DOI 10.1093/ije/23.4.691
   LAVECCHIA C, 1993, INT J CANCER, V53, P215, DOI 10.1002/ijc.2910530207
   Lee E, 2013, AM J EPIDEMIOL, V178, P1403, DOI 10.1093/aje/kwt154
   LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9
   Lin YS, 2006, J GASTROENTEROL, V41, P878, DOI 10.1007/s00535-006-1869-z
   LINDBLAD P, 1995, INT J CANCER, V61, P192, DOI 10.1002/ijc.2910610209
   Lo AC, 2007, PANCREAS, V35, P120, DOI 10.1097/mpa.0b013e318053e7d3
   LONGNECKER DS, 1990, INT J PANCREATOL, V7, P159
   Luan NN, 2013, AM J CLIN NUTR, V98, P1020, DOI 10.3945/ajcn.113.062794
   Lucenteforte E, 2011, PANCREAS, V40, P460, DOI 10.1097/MPA.0b013e31820bf986
   MILLER AB, 1980, J CHRON DIS, V33, P595, DOI 10.1016/0021-9681(80)90002-8
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Nicholson WK, 2006, DIABETES CARE, V29, P2349, DOI 10.2337/dc06-0825
   Prizment AE, 2007, J PANCREAS, V8, P16
   Rosenberg L, 2003, OBES RES, V11, P1526, DOI 10.1038/oby.2003.204
   Royston P, 2000, STAT MED, V19, P1831, DOI 10.1002/1097-0258(20000730)19:14<1831::AID-SIM502>3.0.CO;2-1
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Silvera SAN, 2005, PANCREAS, V30, P369, DOI 10.1097/01.mpa.0000160301.59319.ba
   Singh S, 1997, BRIT J SURG, V84, P1085, DOI 10.1046/j.1365-2168.1997.02724.x
   Skinner HG, 2003, CANCER EPIDEM BIOMAR, V12, P433
   Stevens RJ, 2009, CANCER EPIDEM BIOMAR, V18, P1457, DOI 10.1158/1055-9965.EPI-08-1134
   SUMI C, 1989, CANCER RES, V49, P2332
   SUMI C, 1989, CANCER RES, V49, P6687
   Teras LR, 2005, CANCER CAUSE CONTROL, V16, P1035, DOI 10.1007/s10552-005-0332-4
   Wahi MM, 2009, ANN EPIDEMIOL, V19, P103, DOI 10.1016/j.annepidem.2008.11.003
   Wells GA, NEWCASTLE OTTAWA SCA
   WILLIAMSON DF, 1994, INT J OBESITY, V18, P561
   Wu QJ, 2013, ANN ONCOL, V24, P1918, DOI 10.1093/annonc/mdt119
   Yen SS, 1994, MATERNAL FETAL MED P, P382
   Zhang YQ, 2010, CANCER CAUSE CONTROL, V21, P473, DOI 10.1007/s10552-009-9478-9
NR 64
TC 28
Z9 28
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 21
PY 2014
VL 9
IS 3
AR e92738
DI 10.1371/journal.pone.0092738
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AD6GL
UT WOS:000333355300125
PM 24658609
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, CF
   Liu, SY
   Min, XY
   Ji, YY
   Wang, N
   Liu, D
   Ma, N
   Li, ZF
   Li, K
AF Liu, Cheng-Fei
   Liu, Shu-Yan
   Min, Xiao-Yun
   Ji, Yuan-Yuan
   Wang, Na
   Liu, Dan
   Ma, Ning
   Li, Zong-Fang
   Li, Ke
TI The Prognostic Value of CXCR4 in Ovarian Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CHEMOKINE RECEPTOR CXCR4; EXPRESSION; CXCL12; CARCINOMA; SURVIVAL;
   MARKER; CHEMOTHERAPY; BLOCKADE; CELLS; BIAS
AB Objective: Recent reports have shown that C-X-C chemokine receptor 4 (CXCR4) is expressed in ovarian cancer and plays an important role in metastasis. However, the prognostic value of CXCR4 in ovarian cancer remains controversial and has not been emphasized. The aim of this study is to evaluate the prognostic significance of CXCR4 in ovarian cancer by performing a meta-analysis.
   Methods: We systematically searched for studies evaluating the relationship between CXCR4 expression and the outcome of ovarian cancer patients. Only articles in which CXCR4 expression was detected by immunohistochemical staining were included. Hazard ratios (HRs) and relative risk (RR) with 95% confidence intervals (CIs) were pooled as effect size (ES) across studies for overall survival (OS) and progression-free survival (PFS).
   Results: A total of 729 patients from 7 studies (6 articles) were included in this meta-analysis. Our results showed that high CXCR4 expression was significantly associated with poor prognosis in terms of OS (ES, 2.81; 95% CI, 1.16-6.80; p = 0.022) and PFS (ES, 8.48; 95% CI, 2.13-33.70; p = 0.002) in ovarian cancer patients. The association between high CXCR4 expression and poor ovarian cancer prognosis in OS was also statistically significant in subgroups of Asian and III-IV patients constituting 70%.
   Conclusions: The present meta-analysis indicated that high CXCR4 expression was associated with poor prognosis in ovarian cancer. More studies, especially larger scale and well-matched researches, are warranted to clarify the prognostic effect of CXCR4 on the outcome of ovarian cancer.
C1 [Liu, Cheng-Fei; Liu, Shu-Yan; Min, Xiao-Yun; Ji, Yuan-Yuan; Wang, Na; Liu, Dan; Ma, Ning; Li, Ke] Xi An Jiao Tong Univ, Affiliated Hosp 2, Sch Med, Core Res Lab, Xian 710049, Peoples R China.
   [Liu, Shu-Yan] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Reprod Med, Xian 710049, Peoples R China.
   [Liu, Dan] Fifth Hosp Xian, Inst Rheumatol, Dept Rheumatol & Immunol, Xian 710049, Peoples R China.
   [Li, Zong-Fang] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Gen Surg, Xian 710049, Peoples R China.
RP Li, K (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp 2, Sch Med, Core Res Lab, Xian 710049, Peoples R China.
EM ke.li@mail.xjtu.edu.cn
RI Li, Ke/O-6291-2014
FU Fundamental Research Funds for the Central Universities of China
   [2010jdgz09]; Research Fund for the Doctoral Program of Higher Education
   [SRFDP 20120201110059]
FX This work was supported by the Fundamental Research Funds for the
   Central Universities of China (No. 2010jdgz09), and the specialized
   Research Fund for the Doctoral Program of Higher Education (SRFDP
   20120201110059). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bartolome RA, 2009, AM J PATHOL, V174, P602, DOI 10.2353/ajpath.2009.080636
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chiang YC, 2013, J GYNECOL ONCOL, V24, P342, DOI 10.3802/jgo.2013.24.4.342
   De Falco V, 2007, CANCER RES, V67, P11821, DOI 10.1158/0008-5472.CAN-07-0899
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Hassan S, 2011, INT J CANCER, V129, P225, DOI 10.1002/ijc.25665
   Jiang YP, 2006, GYNECOL ONCOL, V103, P226, DOI 10.1016/j.ygyno.2006.02.036
   Kucia M, 2004, J MOL HISTOL, V35, P233
   Landrum LM, 2013, GYNECOL ONCOL, V130, P12, DOI 10.1016/j.ygyno.2013.04.001
   Li J, 2013, BMB REP IN PRESS
   Mhawech-Fauceglia P, 2012, HISTOPATHOLOGY, V60, P1019, DOI 10.1111/j.1365-2559.2011.04172.x
   Monk BJ, 2014, GYNECOL ONCOL, V132, P176, DOI 10.1016/j.ygyno.2013.10.032
   Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Oda Y, 2007, CANCER SCI, V98, P1020, DOI 10.1111/j.1349-7006.2007.00492.x
   Pils D, 2007, BRIT J CANCER, V96, P485, DOI 10.1038/sj.bjc.6603581
   Popple A, 2012, BRIT J CANCER, V106, P1306, DOI 10.1038/bjc.2012.49
   Salvucci O, 2006, BREAST CANCER RES TR, V97, P275, DOI 10.1007/s10549-005-9121-8
   Sanchez-Martin L, 2011, BLOOD, V117, P88, DOI 10.1182/blood-2009-12-258186
   Scotton CJ, 2002, CANCER RES, V62, P5930
   Sekiya R, 2012, HUM PATHOL, V43, P904, DOI 10.1016/j.humpath.2011.08.002
   Shayegi N, 2014, BRIT J HAEMATOL, V164, P409, DOI 10.1111/bjh.12641
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Skirnisdottir I, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-524
   Spano JP, 2004, ANN ONCOL, V15, P613, DOI 10.1093/annonc/mdh136
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Warner LLM, 2013, INT J GYNECOL CANCER, V23, P1612, DOI 10.1097/01.IGC.0000436089.03581.6b
   Yamada M, 2011, CELL MOL IMMUNOL, V8, P305, DOI 10.1038/cmi.2011.8
   YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7
NR 29
TC 21
Z9 23
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 21
PY 2014
VL 9
IS 3
AR e92629
DI 10.1371/journal.pone.0092629
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AD6GL
UT WOS:000333355300108
PM 24658065
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, ZT
   Ning, HJ
   Que, SP
   Wang, LL
   Qin, X
   Peng, T
AF Liu, Zhengtao
   Ning, Huaijun
   Que, Shuping
   Wang, Linlin
   Qin, Xue
   Peng, Tao
TI Complex Association between Alanine Aminotransferase Activity and
   Mortality in General Population: A Systematic Review and Meta-Analysis
   of Prospective Studies
SO PLOS ONE
LA English
DT Review
ID GAMMA-GLUTAMYL-TRANSFERASE; AGE-RELATED-CHANGES; INDIVIDUAL PATIENT
   DATA; METABOLIC SYNDROME; UNITED-STATES; CARDIOVASCULAR-DISEASE;
   ALL-CAUSE; PREDICT MORTALITY; UPPER LIMITS; LIVER
AB Objective: Controversy exists in using alanine aminotransferase (ALT) activity for predicting long-term survival. Therefore, this research study investigated the association between ALT activity and mortality through a systematic review and meta-analysis of previous prospective studies.
   Methods: Electronic literature databases, including PubMed, Embase, and the Institute for Scientific Information (ISI), were searched for relevant prospective observational studies (published before Dec 30, 2013) on the association between baseline ALT activity and ensuing all-cause/disease-specific mortality. Information on nationality, sample size, participant characteristics, follow-up duration, comparison, outcome assessment, hazard ratios (HRs) and adjusted covariates was extracted. Pooled HRs and corresponding 95% confidence intervals (CIs) were separately calculated for categorical risk estimates (highest vs. lowest ALT categories) and continuous risk estimates (per 5 U/l of ALT increment) in subgroups separated by age (<70/>= 70 years).
   Results: A total of twelve prospective cohort studies, totaling 206,678 participants and 16,249 deaths, were identified and analyzed. In the younger age group, the pooled HR for mortality related to liver-disease was about 1.24 (95% CI: 1.23-1.25) per 5 U/l of ALT increment. The dose-response HRs of all-cause mortality, cardiovascular (CV) disease-related mortality, and cancer-related mortality were 0.91 (0.88-0.94), 0.91 (0.85-0.96), 0.92 (0.86-0.98) respectively per 5 U/l of ALT elevation, with insignificant heterogeneity in the older population. There was an approximate decrease of 4% observed on HRs of all-cause, CV-related, and cancer-related mortality followed with one year's increment through meta-regression (all P < 0.05).
   Conclusions: The ALT-mortality association was inconsistent and seems particularly susceptible to age after synthesizing the previous prospective studies. In terms of the age, ALT activity was more valuable in predicting mortality in the older population; extremely low ALT levels indicated a higher all-cause, CV-related, and cancer-related mortality. ALT activity may therefore be a useful biomarker when predicting the long-term survival of elderly patients.
C1 [Liu, Zhengtao; Peng, Tao] Guangxi Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Nanning, Peoples R China.
   [Liu, Zhengtao] Guangxi Med Univ, Natl Ctr Int Res Biol Targeting Diag & Therapy, Nanning, Peoples R China.
   [Ning, Huaijun; Que, Shuping] Women & Childrens Hosp Guangxi, Dept Pediat, Nanning, Peoples R China.
   [Que, Shuping; Wang, Linlin] Guangxi Med Univ, Affiliated Hosp 1, Dept Pediat, Nanning, Peoples R China.
   [Qin, Xue] Guangxi Med Univ, Affiliated Hosp 1, Clin Lab Ctr, Nanning, Peoples R China.
   [Peng, Tao] Guangxi Med Univ, Guangxi Key Lab Biol Targeting Diag & Therapy Res, Nanning, Peoples R China.
RP Peng, T (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Nanning, Peoples R China.
EM pengtaocn@hotmail.com
FU National Nature Science Foundation of China [NSFC 81072321, 30760243,
   30460143, 30560133]; Program for New Century Excellent Talents in
   University (NCET); Guangxi Nature Sciences Grant [GuiKeGong 1104003A-7];
   Guangxi Health Ministry Medicine Grant (Key-Scientific-Research-Grant)
   [Z201018]; Programs for Changjiang Scholars and Innovative Research Team
   in University [IRT1119]; Innovative Research Team in Guangxi Natural
   Science Foundation [2011GXNSFF018005]
FX This work was supported in part by the National Nature Science
   Foundation of China (NSFC 81072321, 30760243, 30460143 and 30560133),
   2009 Program for New Century Excellent Talents in University (NCET),
   Guangxi Nature Sciences Grant (GuiKeGong 1104003A-7), Guangxi Health
   Ministry Medicine Grant (Key-Scientific-Research-Grant Z201018), grants
   from Programs for Changjiang Scholars and Innovative Research Team in
   University (No. IRT1119) and Innovative Research Team in Guangxi Natural
   Science Foundation (No. 2011GXNSFF018005). No funding body had any
   influence or input into the study design, data collection, analysis,
   data interpretation, or writing of the report.
CR Adams WL, 1990, J AM GERIATRICS SOC
   Al-hamoudi W, 2013, DIGEST DIS SCI, P1
   Arndt V, 1998, INT ARCH OCC ENV HEA, V71, P405, DOI 10.1007/s004200050299
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERLIN JA, 1993, EPIDEMIOLOGY, V4, P218, DOI 10.1097/00001648-199305000-00005
   Chen CH, 2007, J GASTROEN HEPATOL, V22, P1482, DOI 10.1111/j.1440-1746.2003.04615.x
   Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI 10.1016/S0002-9270(03)00265-X
   Custer B, 2004, J CLIN GASTROENTEROL, V38, pS158, DOI 10.1097/00004836-200411003-00008
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dong MH, 2012, CLIN GASTROENTEROL H, V10, P285, DOI 10.1016/j.cgh.2011.10.014
   Dong MH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014254
   Du G, 2013, PREVENTIVE MED
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elinav E, 2005, AM J GASTROENTEROL, V100, P2201, DOI 10.1111/j.1572-0241.2005.41822.x
   Elinav E, 2006, J AM GERIATR SOC, V54, P1719, DOI 10.1111/j.1532-5415.2006.00921.x
   Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP), 2001, JAMA, V285
   Ford I, 2011, INT J EPIDEMIOL, V40, P1530, DOI 10.1093/ije/dyr172
   Fraser A, 2009, DIABETES CARE, V32, P741, DOI 10.2337/dc08-1870
   Giannini EG, 2005, CAN MED ASSOC J, V172, P367, DOI 10.1503/cmaj.1040752
   Goessling W, 2008, GASTROENTEROLOGY, V135, P1935, DOI 10.1053/j.gastro.2008.09.018
   Harris RJ, 2008, STATA J, V8, P3, DOI 10.1177/1536867X0800800102
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hovinen SM, 2010, J AM GERIATR SOC, V58, P1399, DOI 10.1111/j.1532-5415.2010.02901.x
   Hui WS, 2010, EUR J EPIDEMIOL, V25, P375, DOI 10.1007/s10654-010-9459-z
   Ioannou GN, 2006, HEPATOLOGY, V43, P1145, DOI 10.1002/hep.21171
   Kazemi-Shirazi L, 2007, CLIN CHEM, V53, P940, DOI 10.1373/clinchem.2006.081620
   Kim HC, 2004, BMJ-BRIT MED J, V328, P983, DOI 10.1136/bmj.38050.593634.63
   Kim WR, 2008, HEPATOLOGY, V47, P1363, DOI 10.1002/hep.22109
   Koehler EM, 2013, LIVER INT
   Le Couteur DG, 2010, J GERONTOL A-BIOL, V65, P712, DOI 10.1093/gerona/glq082
   Lee BS, 2013, J MED VIROLOGY
   Lee DH, 2009, EUR J CARDIOV PREV R, V16, P16, DOI 10.1097/HJR.0b013e32830aba5c
   Lee JK, 2010, HEPATOLOGY, V51, P1577, DOI 10.1002/hep.23505
   Lee TH, 2008, HEPATOLOGY, V47, P880, DOI 10.1002/hep.22090
   Limdi JK, 2003, POSTGRAD MED J, V79, P307, DOI 10.1136/pmj.79.932.307
   Liu Z, 2012, CLIN BIOCH
   Liu Z, 2013, PLOS ONE, V8
   Marchesini G, 2011, INT J EPIDEMIOL, V40, P1539, DOI 10.1093/ije/dyr187
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Molander RC, 2010, ALCOHOL CLIN EXP RES, V34, P1182, DOI 10.1111/j.1530-0277.2010.01195.x
   Nakamura K, 2006, J EPIDEMIOL, V16, P15, DOI 10.2188/jea.16.15
   Olynyk JK, 2009, AM J GASTROENTEROL, V104, P1715, DOI 10.1038/ajg.2009.229
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Pendino GM, 2005, HEPATOLOGY, V41, P1151, DOI 10.1002/hep.20689
   Polder JJ, 2002, EUR J PUBLIC HEALTH, V12, P57, DOI 10.1093/eurpub/12.1.57
   Prati D, 2002, ANN INTERN MED, V137, P1, DOI 10.7326/0003-4819-137-1-200207020-00006
   Pratt DS, 2000, NEW ENGL J MED, V342, P1266, DOI 10.1056/NEJM200004273421707
   Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221
   Ruhl CE, 2012, HEPATOLOGY, V55, P447, DOI 10.1002/hep.24725
   Ruhl CE, 2009, GASTROENTEROLOGY, V136, P477, DOI 10.1053/j.gastro.2008.10.052
   Ruttmann E, 2005, CIRCULATION, V112, P2130, DOI 10.1161/CIRCULATIONAHA.105.552547
   Schindhelm RK, 2007, ATHEROSCLEROSIS, V191, P391, DOI 10.1016/j.atherosclerosis.2006.04.006
   Schmucker DL, 2005, EXP GERONTOL, V40, P650, DOI 10.1016/j.exger.2005.06.009
   Schooling CM, 2012, ANN EPIDEMIOLOGY
   Sharp S, 2012, STATA TECHNICAL B, V7
   Simmonds MC, 2005, CLIN TRIALS, V2, P209, DOI 10.1191/1740774505cn087oa
   Singh GK, 2012, J URBAN HEALTH, P1
   SLEE VN, 1978, ANN INTERN MED, V88, P424, DOI 10.7326/0003-4819-88-3-424
   Steichen TJ, 1998, STATA TECHNICAL B, V7
   STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K
   STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tolman KG, 2002, AM J CARDIOL, V89, P1374, DOI 10.1016/S0002-9149(02)02355-X
   Turrell G, 2001, INT J EPIDEMIOL, V30, P231, DOI 10.1093/ije/30.2.231
   Vento S, 2008, LANCET, V371, P1822, DOI 10.1016/S0140-6736(08)60778-3
   Wannamethee SG, 2005, DIABETES CARE, V28, P2913, DOI 10.2337/diacare.28.12.2913
   Wells G, 2011, NEWCASTLE OTTAWA SCA
   WOODHOUSE KW, 1988, CLIN PHARMACOKINET, V15, P287, DOI 10.2165/00003088-198815050-00002
   Yang MC, 2002, PHARMACOL TOXICOL, V90, P203, DOI 10.1034/j.1600-0773.2002.900406.x
   Yun JE, 2010, CIRCULATION J OFFICI, V75, P964
   Yun KE, 2009, ATHEROSCLEROSIS, V205, P533, DOI 10.1016/j.atherosclerosis.2008.12.012
NR 73
TC 19
Z9 20
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 14
PY 2014
VL 9
IS 3
AR e91410
DI 10.1371/journal.pone.0091410
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AC9MJ
UT WOS:000332858400061
PM 24633141
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, ZF
   Wang, T
   Liu, LH
   Guo, HQ
AF Zhang, Ze-Feng
   Wang, Tao
   Liu, Li-Hua
   Guo, Hui-Qin
TI Risks of Proteinuria Associated with Vascular Endothelial Growth Factor
   Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Systematic
   Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID RENAL-CELL CARCINOMA; RANDOMIZED PHASE-III; VENOUS THROMBOEMBOLIC
   EVENTS; METASTATIC COLORECTAL-CANCER; ADVANCED PANCREATIC-CANCER;
   SOFT-TISSUE SARCOMA; DOUBLE-BLIND; 2ND-LINE TREATMENT; GASTROINTESTINAL
   PERFORATION; ANGIOGENESIS INHIBITOR
AB Background: Vascular endothelial growth factor tyrosine-kinase inhibitors (VEGFR-TKIs) have emerged as an effective targeted therapy in the treatment of cancer patients, the overall incidence and risk of proteinuria associated these drugs is unclear. We performed a systematic review and meta-analysis of published clinical trials to quantify the incidence and risk of proteinuria associated with VEGFR-TKIs.
   Methodology: Databases from PubMed, Web of Science and abstracts presented at ASCO meeting up to May 31, 2013 were searched to identify relevant studies. Eligible studies included prospective phase II and III trials evaluating VEGFR-TKIs in cancer patients with adequate data on proteinuria. Statistical analyses were conducted to calculate the summary incidence, Odds ratio (OR) and 95% confidence intervals (CIs) by using either random effects or fixed effect models according to the heterogeneity of included studies.
   Principal Findings: A total of 6,882 patients with a variety of solid tumors from 33 clinical trials were included in our analysis. The incidence of all-grade and high-grade (grade 3 or higher) proteinuria was 18.7% (95% CI, 13.3%-25.6%) and 2.4% (95% CI, 1.6%-3.7%), respectively. Patients treated with VEGFR-TKIs had a significantly increased risk of all-grade (OR 2.92, 95%CI: 1.09-7.82, p = 0.033) and high-grade proteinuria (OR 1.97, 95%CI: 1.01-3.84, p = 0.046) when compared to patients treated with control medication. No evidence of publication bias was observed.
   Conclusions: The use of VEGFR-TKIs is associated with a significant increased risk of developing proteinuria. Physicians should be aware of this adverse effect and should monitor cancer patients receiving VEGFR-TKIs.
C1 [Zhang, Ze-Feng; Wang, Tao] Hebei Med Univ, Affiliated Hosp 4, Dept Thorac Surg, Shijiazhuang, Peoples R China.
   [Liu, Li-Hua] Hebei Med Univ, Affiliated Hosp 4, Dept Biol Therapy, Shijiazhuang, Peoples R China.
   [Guo, Hui-Qin] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Pathol, Beijing 100730, Peoples R China.
   [Guo, Hui-Qin] Peking Union Med Coll, Beijing 100021, Peoples R China.
RP Wang, T (reprint author), Hebei Med Univ, Affiliated Hosp 4, Dept Thorac Surg, Shijiazhuang, Peoples R China.
EM wangtao130928@163.com
CR Aghajanian C, 2012, J CLIN ONCOL, V30, P2039, DOI 10.1200/JCO.2012.42.0505
   Batchelor TT, 2010, J CLIN ONCOL, V28, P2817, DOI 10.1200/JCO.2009.26.3988
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bible KC, 2010, LANCET ONCOL, V11, P962, DOI 10.1016/S1470-2045(10)70203-5
   Campbell NP, 2012, LUNG CANCER, V78, P76, DOI 10.1016/j.lungcan.2012.06.011
   Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Choueiri TK, 2010, J CLIN ONCOL, V28, P2280, DOI 10.1200/JCO.2009.27.2757
   Cohen EEW, 2008, J CLIN ONCOL, V26, P4708, DOI 10.1200/JCO.2007.15.9566
   Cortes J, 2012, ANN ONCOL, V23, P1130, DOI 10.1093/annonc/mdr432
   Cunningham D, 2013, BRIT J CANCER, V108, P493, DOI 10.1038/bjc.2012.545
   Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Funakoshi T, 2013, J HUM HYPERTENS, V27, P601, DOI 10.1038/jhh.2013.30
   Gianni L, 2013, J CLIN ONCOL, V31, P1719, DOI 10.1200/JCO.2012.44.7912
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Hainsworth JD, 2013, CLIN GENITOURIN CANC, V11, P270, DOI 10.1016/j.clgc.2013.04.006
   Hapani S, 2009, LANCET ONCOL, V10, P559, DOI 10.1016/S1470-2045(09)70112-3
   Hsu CH, 2010, J HEPATOL, V53, P126, DOI 10.1016/j.jhep.2010.01.035
   Hurwitz HI, 2011, J CLIN ONCOL, V29, P1757, DOI 10.1200/JCO.2010.32.3220
   Ibrahim EM, 2013, INT J CLIN ONCOL, V18, P1060, DOI 10.1007/s10147-012-0497-2
   Infante JR, 2013, CANCER-AM CANCER SOC, V119, P2555, DOI 10.1002/cncr.28112
   Iwamoto FM, 2010, NEURO-ONCOLOGY, V12, P855, DOI [10.1093/neuonc/nop054, 10.1093/neuonc/noq025]
   Je YJ, 2009, LANCET ONCOL, V10, P967, DOI 10.1016/S1470-2045(09)70222-0
   Jonasch E, 2010, CANCER, V116, P57, DOI 10.1002/cncr.24685
   KINCAIDSMITH P, 1991, AM J KIDNEY DIS, V17, P144, DOI 10.1016/S0272-6386(12)81119-X
   Kindler HL, 2012, INVEST NEW DRUG, V30, P382, DOI 10.1007/s10637-010-9526-z
   Kuei A, 2013, J CLIN ONCOL, V31
   Kummar S, 2013, J CLIN ONCOL, V31, P2296, DOI 10.1200/JCO.2012.47.4288
   Launay-Vacher V, 2009, ANTI-CANCER DRUG, V20, P81, DOI 10.1097/CAD.0b013e3283161012
   Lim WT, 2011, CLIN CANCER RES, V17, P5481, DOI 10.1158/1078-0432.CCR-10-3409
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Mayer EL, 2010, ANN ONCOL, V21, P2370, DOI 10.1093/annonc/mdq260
   Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Motzer RJ, 2013, J CLIN ONCOL, V31, P3791, DOI 10.1200/JCO.2012.47.4940
   Motzer RJ, 2013, LANCET ONCOL, V14, P552, DOI 10.1016/S1470-2045(13)70093-7
   Mulders P, 2012, EUR J CANCER, V48, P527, DOI 10.1016/j.ejca.2011.12.022
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   National Kidney Foundation, 2004, AM J KIDNEY DIS S, V43, pS1, DOI DOI 10.1053/J.AJKD.2004.03.003
   NCI Cancer Therapy Evaluation Program, 2006, CTC V 2 0 COMM TERM
   Nosov DA, 2012, J CLIN ONCOL, V30, P1678, DOI 10.1200/JCO.2011.35.3524
   Qi WX, 2013, ANN ONCOL, V24, P2943, DOI 10.1093/annonc/mdt292
   Qi WX, 2014, CRIT REV ONCOL HEMAT, V89, P394, DOI 10.1016/j.critrevonc.2013.10.002
   Qi WX, 2013, BRIT J CLIN PHARMACO, V76, P348, DOI 10.1111/bcp.12149
   Qi WX, 2013, INT J CANCER, V132, P2967, DOI 10.1002/ijc.27979
   Qi WX, 2013, BRIT J CLIN PHARMACO, V75, P919, DOI 10.1111/j.1365-2125.2012.04417.x
   Qi WX, 2013, CANCER CHEMOTH PHARM, V71, P431, DOI 10.1007/s00280-012-2025-5
   Qi WX, 2011, LUNG, V189, P437, DOI 10.1007/s00408-011-9332-1
   Ramalingam SS, 2010, J THORAC ONCOL, V5, P1279, DOI 10.1097/JTO.0b013e3181e2fcb0
   Raymond E, 2011, NEW ENGL J MED, V364, P501, DOI 10.1056/NEJMoa1003825
   Rini B, 2012, CANCER-AM CANCER SOC, V118, P6152, DOI 10.1002/cncr.27632
   Rixe O, 2007, LANCET ONCOL, V8, P975, DOI 10.1016/51470-2045(07)70285-1
   Robinson ES, 2010, CLIN J AM SOC NEPHRO, V5, P477, DOI 10.2215/CJN.08111109
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/cjm086
   Schmoll HJ, 2012, J CLIN ONCOL, V30, P3588, DOI 10.1200/JCO.2012.42.5355
   Schrijvers BF, 2004, KIDNEY INT, V65, P2003, DOI 10.1111/j.1523-1755.2004.00621.x
   Sleijfer S, 2009, J CLIN ONCOL, V27, P3126, DOI 10.1200/JCO.2008.21.3223
   Sonpavde G, 2013, CRIT REV ONCOL HEMAT, V87, P80, DOI 10.1016/j.critrevonc.2012.12.006
   Spano JP, 2008, LANCET, V371, P2101, DOI 10.1016/S0140-6736(08)60661-3
   Sternberg CN, 2013, EUR J CANCER, V49, P1287, DOI 10.1016/j.ejca.2012.12.010
   Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764
   Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761
   Tan EH, 2011, J THORAC ONCOL, V6, P1418, DOI 10.1097/JTO.0b013e318220c93e
   Tannir NM, 2011, EUR J CANCER, V47, P2706, DOI 10.1016/j.ejca.2011.09.002
   Toh HC, 2013, CANCER-AM CANCER SOC, V119, P380, DOI 10.1002/cncr.27758
   Tomita Y, 2011, EUR J CANCER, V47, P2592, DOI 10.1016/j.ejca.2011.07.014
   U.S. Food and Drug Administration. FDA Briefing Document, FDA BRIEF DOC ONC DR
   US Food and Drug Administration, HIGHL PRESCR INF VOT
   van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5
   Vuorela P, 2000, OBSTET GYNECOL, V95, P353, DOI 10.1016/S0029-7844(99)00565-7
   WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101
   Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040
   Wells SA, 2010, J CLIN ONCOL, V28, P767, DOI 10.1200/JCO.2009.23.6604
   Wu SH, 2008, LANCET ONCOL, V9, P117, DOI 10.1016/S1470-2045(08)70003-2
   Wu SH, 2010, J AM SOC NEPHROL, V21, P1381, DOI 10.1681/ASN.2010020167
   YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7
   Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407
   Zhu XL, 2007, AM J KIDNEY DIS, V49, P186, DOI 10.1053/j.ajkd.2006.11.039
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 85
TC 29
Z9 30
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 12
PY 2014
VL 9
IS 3
AR e90135
DI 10.1371/journal.pone.0090135
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AC9HN
UT WOS:000332845300015
PM 24621598
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, Y
   Wang, JW
   Zhong, XJ
   Tian, Z
   Wu, PP
   Zhao, WB
   Jin, CJ
AF Li, Ying
   Wang, JiWen
   Zhong, XiaoJing
   Tian, Zhen
   Wu, Peipei
   Zhao, Wenbo
   Jin, Chenjin
TI Refractive Error and Risk of Early or Late Age-Related Macular
   Degeneration: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID BLUE MOUNTAINS EYE; BEIJING-EYE; 5-YEAR INCIDENCE; GRADING SYSTEM; AXIAL
   LENGTH; MACULOPATHY; PREVALENCE; ASSOCIATIONS; POPULATION; RIGIDITY
AB Objective: To summarize relevant evidence investigating the associations between refractive error and age-related macular degeneration (AMD).
   Design: Systematic review and meta-analysis.
   Methods: We searched Medline, Web of Science, and Cochrane databases as well as the reference lists of retrieved articles to identify studies that met the inclusion criteria. Extracted data were combined using a random-effects meta-analysis. Studies that were pertinent to our topic but did not meet the criteria for quantitative analysis were reported in a systematic review instead.
   Main outcome measures: Pooled odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between refractive error (hyperopia, myopia, per-diopter increase in spherical equivalent [SE] toward hyperopia, per-millimeter increase in axial length [AL]) and AMD (early and late, prevalent and incident).
   Results: Fourteen studies comprising over 5800 patients were eligible. Significant associations were found between hyperopia, myopia, per-diopter increase in SE, per-millimeter increase in AL, and prevalent early AMD. The pooled ORs and 95% CIs were 1.13 (1.06-1.20), 0.75 (0.56-0.94), 1.10 (1.07-1.14), and 0.79 (0.73-0.85), respectively. The per-diopter increase in SE was also significantly associated with early AMD incidence (OR, 1.06; 95% CI, 1.02-1.10). However, no significant association was found between hyperopia or myopia and early AMD incidence. Furthermore, neither prevalent nor incident late AMD was associated with refractive error. Considerable heterogeneity was found among studies investigating the association between myopia and prevalent early AMD (P = 0.001, I-2 = 72.2%). Geographic location might play a role; the heterogeneity became non-significant after stratifying these studies into Asian and non-Asian subgroups.
   Conclusion: Refractive error is associated with early AMD but not with late AMD. More large-scale longitudinal studies are needed to further investigate such associations.
C1 [Li, Ying; Zhong, XiaoJing; Tian, Zhen; Wu, Peipei; Zhao, Wenbo; Jin, Chenjin] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
   [Wang, JiWen] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurosurg, Guangzhou 510275, Guangdong, Peoples R China.
   [Wang, JiWen] Sun Yat Sen Univ, Affiliated Hosp 1, Pituitary Tumor Ctr, Guangzhou 510275, Guangdong, Peoples R China.
RP Jin, CJ (reprint author), Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
EM jinchj@mail.sysu.edu.cn
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Gemmy CC, 2012, AM J OPHTHALMOL
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2231
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Pan CW, 2013, OPHTHALMOLOGY
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Ulvik SO, 2005, ACTA OPHTHALMOL SCAN, V83, P419, DOI 10.1111/J.1600-0420.2005.00520.x
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   WANG Q, 1994, INVEST OPHTH VIS SCI, V35, P4344
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   1992, ARCH OPHTHALMOL, V110, P1701
NR 45
TC 1
Z9 1
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 6
PY 2014
VL 9
IS 3
AR e90897
DI 10.1371/journal.pone.0090897
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AC4ID
UT WOS:000332483600103
PM 24603619
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, F
   Chen, YM
   Feng, XG
   Teng, ZH
   Yuan, Y
   Bin, JP
AF Liu, Feng
   Chen, Yanmei
   Feng, Xuguang
   Teng, Zhonghua
   Yuan, Ye
   Bin, Jianping
TI Effects of Beta-Blockers on Heart Failure with Preserved Ejection
   Fraction: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID VENTRICULAR SYSTOLIC FUNCTION; CLINICAL-TRIALS; MORTALITY; THERAPY;
   SURVIVAL; OUTCOMES; CARVEDILOL; AGE; REHOSPITALIZATION; EPIDEMIOLOGY
AB Background: Effects of beta-blockers on the prognosis of the heart failure patients with preserved ejection fraction (HFpEF) remain controversial. The aim of this meta-analysis was to determine the impact of beta-blockers on mortality and hospitalization in the patients with HFpEF.
   Methods: A search of MEDLINE, EMBASE, and the Cochrane Library databases from 2005 to June 2013 was conducted. Clinical studies reporting outcomes of mortality and/or hospitalization for patients with HFpEF (EF >= 40%), being assigned to beta-blockers treatment and non-beta-blockers control group were included.
   Results: A total of 12 clinical studies (2 randomized controlled trials and 10 observational studies) involving 21,206 HFpEF patients were included for this meta-analysis. The pooled analysis demonstrated that beta-blocker exposure was associated with a 9% reduction in relative risk for all-cause mortality in patients with HFpEF (95% CI: 0.87 - 0.95; P < 0.001). Whereas, the all-cause hospitalization, HF hospitalization and composite outcomes (mortality and hospitalization) were not affected by this treatment (P = 0.26, P = 0.97, and P = 0.88 respectively).
   Conclusions: The beta-blockers treatment for the patients with HFpEF was associated with a lower risk of all-cause mortality, but not with a lower risk of hospitalization. These finding were mainly obtained from observational studies, and further investigations are needed to make an assertion.
C1 [Bin, Jianping] Southern Med Univ, Nanfang Hosp, Dept Cardiol, Guangzhou, Guangdong, Peoples R China.
   Southern Med Univ, Nanfang Hosp, Natl Key Lab Organ Failure Res, Guangzhou, Guangdong, Peoples R China.
RP Bin, JP (reprint author), Southern Med Univ, Nanfang Hosp, Dept Cardiol, Guangzhou, Guangdong, Peoples R China.
EM jianpingbin@126.com
FU National Basic Research Program of China (973 Program) [2013CB733804];
   National Natural Science Foundation of China [81227801, 81271640];
   Natural Science Foundation of Guangdong Province, China [S2011030003134]
FX This work was supported by grants from National Basic Research Program
   of China (973 Program) (No. 2013CB733804), National Natural Science
   Foundation of China (No. 81227801 and No. 81271640), and the Team
   Program of Natural Science Foundation of Guangdong Province, China
   (S2011030003134) to Jianping Bin. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ather S, 2012, J AM COLL CARDIOL, V59, P998, DOI 10.1016/j.jacc.2011.11.040
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Carson P, 1996, J AM COLL CARDIOL, V27, P642, DOI 10.1016/0735-1097(95)00503-X
   Chan JD, 2005, AM HEART J, V150, P464, DOI 10.1016/j.ahj.2004.12.022
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dobre D, 2007, EUR J HEART FAIL, V9, P280, DOI 10.1016/j.ejheart.2006.07.008
   El-Refai M, 2013, J CARD FAIL, V19, P73, DOI 10.1016/j.cardfail.2012.11.011
   Farasat SM, 2010, AM J CARDIOL, V105, P229, DOI 10.1016/j.amjcard.2009.09.008
   Fonarow GC, 2007, J AM COLL CARDIOL, V50, P768, DOI 10.1016/j.jacc.2007.04.064
   Fukuta H, 2005, CIRCULATION, V112, P357, DOI 10.1161/CIRCULATIONAHA.104.519876
   Ghio S, 2006, EUR HEART J, V27, P562, DOI 10.1093/eurheartj/ehi735
   Hernandez AF, 2009, J AM COLL CARDIOL, V53, P184, DOI 10.1016/j.jacc.2008.09.031
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holland DJ, 2011, J AM COLL CARDIOL, V57, P1676, DOI 10.1016/j.jacc.2010.10.057
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Krum H, 2003, JAMA-J AM MED ASSOC, V289, P712, DOI 10.1001/jama.289.6.712
   Lam CSP, 2011, EUR J HEART FAIL, V13, P18, DOI 10.1093/eurjhf/hfq121
   Masoudi FA, 2003, J AM COLL CARDIOL, V41, P217, DOI 10.1016/S0735-1097(02)02696-7
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Nevzorov R, 2012, EUR J INTERN MED, V23, P374, DOI 10.1016/j.ejim.2012.01.011
   Nohria A, 2003, J AM COLL CARDIOL, V41, P1797, DOI 10.1016/S0375-1097(03)00309-7
   Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201
   Pan A, 2011, JAMA-J AM MED ASSOC, V306, P1241, DOI 10.1001/jama.2011.1282
   Paulus WJ, 2010, J AM COLL CARDIOL, V55, P526, DOI 10.1016/j.jacc.2009.06.067
   Shah R, 2008, AM J CARDIOL, V101, P217, DOI 10.1016/j.amjcard.2007.08.050
   Shamagian LG, 2006, J CARD FAIL, V12, P128, DOI 10.1016/j.cardfail.2005.09.001
   Smith GL, 2003, J AM COLL CARDIOL, V41, P1510, DOI 10.1016/S0735-1097(03)00185-2
   Spruance SL, 2004, ANTIMICROB AGENTS CH, V48, P2787, DOI 10.1128/AAC.48.8.2787-2792.2004
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tehrani F, 2009, AM J CARDIOL, V103, P829, DOI 10.1016/j.amjcard.2008.11.047
   van Veldhuisen DJ, 2009, J AM COLL CARDIOL, V53, P2150, DOI 10.1016/j.jacc.2009.02.046
   Willi C, 2007, JAMA-J AM MED ASSOC, V298, P2654, DOI 10.1001/jama.298.22.2654
   Yamamoto K, 2013, EUR J HEART FAIL, V15, P110, DOI 10.1093/eurjhf/hfs141
   Yancy CW, 2013, J AM COLL CARDIOL
   Zhou JM, 2010, EUR J HEART FAIL, V12, P181, DOI 10.1093/eurjhf/hfp193
NR 35
TC 40
Z9 42
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 5
PY 2014
VL 9
IS 3
AR e90555
DI 10.1371/journal.pone.0090555
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AC4GP
UT WOS:000332479400091
PM 24599093
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Gu, WJ
   Wan, YD
   Tie, HT
   Kan, QC
   Sun, TW
AF Gu, Wan-Jie
   Wan, You-Dong
   Tie, Hong-Tao
   Kan, Quan-Cheng
   Sun, Tong-Wen
TI Risk of Acute Lung Injury/Acute Respiratory Distress Syndrome in
   Critically Ill Adult Patients with Pre-Existing Diabetes: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID INTENSIVE INSULIN THERAPY; GLYCATION END-PRODUCTS; NEUTROPHIL MIGRATION;
   PREDICTION SCORE; MORTALITY; OUTCOMES; RECEPTOR; IDENTIFICATION; SEPSIS
AB Background: The impact of pre-existing diabetes on the development of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in critically ill patients remains unclear. We performed a meta-analysis of cohort studies to evaluate the risk of ALI/ARDS in critically ill patients with and without pre-existing diabetes.
   Materials and Methods: We searched PubMed and Embase from the inception to September 2013 for cohort studies assessing the effect of pre-existing diabetes on ALI/ARDS occurrence. Pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using random-or fixed-effect models when appropriate.
   Results: Seven cohort studies with a total of 12,794 participants and 2,937 cases of pre-existing diabetes, and 2,457 cases of ALI/ARDS were included in the meta-analysis. A fixed-effects model meta-analysis showed that pre-existing diabetes was associated with a reduced risk of ALI/ARDS (OR 0.66; 95% CI, 0.55-0.80; p<0.001), with low heterogeneity among the studies (I-2 = 18.9%; p = 0.286). However, the asymmetric funnel plot and Egger's test (p = 0.007) suggested publication bias may exist.
   Conclusions: Our meta-analysis suggests that pre-existing diabetes was associated with a decreased risk of ALI/ARDS in critically ill adult patients. However, the result should be interpreted with caution because of the potential bias and confounding in the included studies.
C1 [Gu, Wan-Jie] Guangxi Med Univ, Affiliated Hosp 1, Dept Anaesthesiol, Nanning, Peoples R China.
   [Gu, Wan-Jie; Wan, You-Dong; Sun, Tong-Wen] Zhengzhou Univ, Affiliated Hosp 1, Dept Integrated Intens Care Unit, Zhengzhou, Peoples R China.
   [Tie, Hong-Tao] Chongqing Med Univ, Affiliated Hosp 1, Coll Clin Med 1, Chongqing, Peoples R China.
   [Kan, Quan-Cheng] Zhengzhou Univ, Affiliated Hosp 1, Dept Pharmaceut, Zhengzhou, Peoples R China.
RP Sun, TW (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Integrated Intens Care Unit, Zhengzhou, Peoples R China.
EM tongwensun1964@sina.com
OI Gu, Wan-Jie/0000-0003-4923-8282
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Calfee CS, 2008, THORAX, V63, P1083, DOI 10.1136/thx.2008.095588
   Cartin-Ceba R, 2012, CRIT CARE RES PRACT, DOI 10.1155/2012/691013
   Cepkova M, 2006, CRIT CARE, V10, DOI 10.1186/cc5037
   Christiansen CF, 2013, EUR J CLIN INVEST, V43, P238, DOI 10.1111/eci.12036
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Filgueiras LR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044987
   Gajic O, 2005, INTENS CARE MED, V31, P922, DOI 10.1007/s00134-005-2625-1
   Gajic O, 2011, AM J RESP CRIT CARE, V183, P462, DOI 10.1164/rccm.201004-0549OC
   Genovese T, 2005, SHOCK, V24, P547, DOI 10.1097/01.shk.0000190825.28783.a4
   Gong MN, 2010, THORAX, V65, P44, DOI 10.1136/thx.2009.117572
   Gong MN, 2005, CRIT CARE MED, V33, P1191, DOI 10.1097/01.CCM.0000165566.82925.14
   Graham BB, 2010, CRIT CARE MED, V38, P16, DOI 10.1097/CCM.0b013e3181b9eaa5
   Hansen TK, 2003, J CLIN ENDOCR METAB, V88, P1082, DOI 10.1210/jc.2002-021478
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Honiden S, 2009, CRIT CARE MED, V37, P2455, DOI 10.1097/CCM.0b013e3181a0fea5
   Iscimen R, 2008, CRIT CARE MED, V36, P1518, DOI 10.1097/CCM.0b013e31816fc2c0
   Janz DR, 2013, SEMIN RESP CRIT CARE, V34, P537, DOI 10.1055/s-0033-1351124
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   Koh GCKW, 2012, CRIT CARE MED, V40, P1835, DOI 10.1097/CCM.0b013e31824e1696
   KOLLEF MH, 1995, NEW ENGL J MED, V332, P27, DOI 10.1056/NEJM199501053320106
   Krein PM, 2003, AM J RESP CRIT CARE, V167, P83, DOI 10.1164/rccm.2201012
   Mangialardi RJ, 2000, CRIT CARE MED, V28, P3137, DOI 10.1097/00003246-200009000-00001
   Mestriner FLAC, 2007, P NATL ACAD SCI USA, V104, P19595, DOI 10.1073/pnas.0709681104
   Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50
   Moss M, 2000, CRIT CARE MED, V28, P2187, DOI 10.1097/00003246-200007000-00001
   Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976
   Schnapp LM, 2006, AM J PATHOL, V169, P86, DOI 10.2353/ajpath.2006.050612
   Siegelaar SE, 2011, CRIT CARE, V15, DOI 10.1186/cc10440
   Spiller F, 2012, DIABETES, V61, P1584, DOI 10.2337/db11-0825
   Stegenga ME, 2010, CRIT CARE MED, V38, P539, DOI 10.1097/CCM.0b013e3181c02726
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Trillo-Alvarez C, 2011, EUR RESPIR J, V37, P604, DOI 10.1183/09031936.00036810
   Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521
   Vincent JL, 2010, CRIT CARE, V14, DOI 10.1186/cc8866
   Wells G., 2013, NEWCASTLE OTTAWA SCA
   Yu S, 2013, CRIT CARE MED, V41, P2720, DOI 10.1097/CCM.0b013e318298a2eb
   Zhang HY, 2008, AM J RESP CRIT CARE, V178, P356, DOI 10.1164/rccm.200707-1069OC
   Zmijewski JW, 2008, AM J RESP CRIT CARE, V178, P168, DOI 10.1164/rccm.200710-1602OC
NR 41
TC 15
Z9 17
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 27
PY 2014
VL 9
IS 2
AR e90426
DI 10.1371/journal.pone.0090426
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AC3BU
UT WOS:000332390800108
PM 24587357
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ye, J
   Lou, LX
   He, JJ
   Xu, YF
AF Ye, Juan
   Lou, Li-Xia
   He, Jin-Jing
   Xu, Yu-Feng
TI Body Mass Index and Risk of Age-Related Cataract: A Meta-Analysis of
   Prospective Cohort Studies
SO PLOS ONE
LA English
DT Article
ID CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; NUCLEAR CATARACT; FAT
   DISTRIBUTION; LENS OPACITIES; POPULATION; OBESITY; ASSOCIATION;
   EXTRACTION; SURGERY
AB Background: Age-related cataract (ARC) is the leading cause of blindness in the world. The relationship between body mass index (BMI) and risk of ARC is controversial across observational studies. We therefore performed this meta-analysis to evaluate the association between BMI and risk of ARC.
   Methods: Eligible studies were identified through an electronic search of PubMed, Embase and the Cochrane Library. We pooled study-specific relative risks (RRs) and 95% confidence intervals (CIs) to determine the risk of ARC associated with BMI categories and per 1 kg/m(2) increase in BMI.
   Results: A total of 17 prospective cohort studies were included in the meta-analysis. The pooled RRs of ARC were 1.08 (95% CI, 1.01-1.16) for overweight and 1.19 (95% CI, 1.10-1.28) for obesity compared with normal weight. These findings were robust when stratified by sex, sample source, outcome types and confounders, while significantly differed by assessment of BMI and ARC, and duration of follow-up. The summary RR suggested that per 1 kg/m(2) increase in BMI was associated with a 2% increased risk of ARC (RR 1.02, 95% CI 1.01-1.03). Pooled estimates of RRs consistently indicated a trend for subjects with a high BMI to develop posterior subcapsular cataracts (RR 1.19, 95% CI 1.06-1.35, for overweight; RR 1.50, 95% CI 1.24-1.81, for obesity; RR 1.04, 95% CI 1.01-1.06, per 1 kg/m(2) increase in BMI) other than nuclear or cortical cataracts.
   Conclusions: The overall findings suggest that elevated BMI may increase the risk of ARC, especially posterior subcapsular cataracts. Further trials are needed to investigate the effect of weight reduction in obese populations on the risk of ARC.
C1 [Ye, Juan; Lou, Li-Xia; He, Jin-Jing; Xu, Yu-Feng] Zhejiang Univ, Dept Ophthalmol, Coll Med, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China.
RP Ye, J (reprint author), Zhejiang Univ, Dept Ophthalmol, Coll Med, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China.
EM yejuan@zju.edu.cn
FU Natural Science Foundation of China [81070756]; National "Twelfth
   Five-Year'' Plan for Science & Technology Support of China
   [2012BAI08B01]; Program for New Century Excellent Talents in University,
   China [NCET-11-0161]; Zhejiang Provincial Program for Cultivation of
   High-Level Innovative Health Talents; Specialized Key Science &
   Technology Foundation of Zhejiang Provincial S T Department
   [2012C13023-2]; Zhejiang Provincial Key Project of Medical and Health
   [2011ZDA014]
FX This study was funded by: 1. Natural Science Foundation of China (No.
   81070756); 2. National "Twelfth Five-Year'' Plan for Science &
   Technology Support of China (No. 2012BAI08B01); 3. Program for New
   Century Excellent Talents in University, China (No. NCET-11-0161); 4.
   Zhejiang Provincial Program for Cultivation of High-Level Innovative
   Health Talents; 5. The Specialized Key Science & Technology Foundation
   of Zhejiang Provincial S & T Department (No. 2012C13023-2); 6. Zhejiang
   Provincial Key Project of Medical and Health (No. 2011ZDA014). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   Appleby PN, 2011, AM J CLIN NUTR, V93, P1128, DOI 10.3945/ajcn.110.004028
   Asbell PA, 2005, LANCET, V365, P599
   Barba C, 2004, LANCET, V363, P157
   Beebe DC, 2010, OPHTHALMIC RES, V44, P155, DOI 10.1159/000316481
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bouloumie A, 1999, FASEB J, V13, P1231
   Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032
   Chodick G, 2008, AM J EPIDEMIOL, V168, P620, DOI 10.1093/aje/kwn171
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Friedemann C, 2012, BMJ-BRIT MED J, V345, P4759
   Glynn RJ, 2009, OPHTHAL EPIDEMIOL, V16, P98, DOI 10.1080/09286580902737532
   Haidar Yarah M, 2011, Clin Colon Rectal Surg, V24, P205, DOI 10.1055/s-0031-1295684
   Hattori A, 2013, OBESITY, V21, P856, DOI 10.1002/oby.20313
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hiller R, 1998, OPHTHALMOLOGY, V105, P1244, DOI 10.1016/S0161-6420(98)97029-4
   Janghorbani M, 2004, OPHTHAL EPIDEMIOL, V11, P347, DOI 10.1080/09286580490888753
   Janghorbani M B, 2000, Ophthalmic Epidemiol, V7, P13
   Kanthan GL, 2010, AM J OPHTHALMOL, V150, P434, DOI 10.1016/j.ajo.2010.04.020
   Karppi J, 2012, BRIT J NUTR, V108, P148, DOI 10.1017/S0007114511005332
   Klein BEK, 2006, AM J OPHTHALMOL, V141, P116, DOI 10.1016/j.ajo.2005.08.021
   Klein BEK, 2003, OPHTHALMIC EPIDEMIOL, V10, P97, DOI 10.1076/opep.10.2.97.13896
   Leske MC, 1999, OPHTHALMOLOGY, V106, P35, DOI 10.1016/S0161-6420(99)90003-9
   Leske MC, 2002, OPHTHALMOLOGY, V109, P1303, DOI 10.1016/S0161-6420(02)01094-1
   Lindblad BE, 2008, OPHTHALMOLOGY, V115, P1687, DOI 10.1016/j.ophtha.2008.04.004
   Mares JA, 2010, ARCH OPHTHALMOL-CHIC, V128, P738, DOI 10.1001/archophthalmol.2010.84
   Muoio DM, 2006, ANNU REV BIOCHEM, V75, P367, DOI 10.1146/annurev.biochem.75.103004.142512
   Nirmalan PK, 2004, BRIT J OPHTHALMOL, V88, P989, DOI 10.1136/bjo.2003.038380
   Ono K, 2010, AM J PUBLIC HEALTH, V100, P1784, DOI 10.2105/AJPH.2009.187930
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pastor-Valero Maria, 2007, BMC Ophthalmol, V7, P18, DOI 10.1186/1471-2415-7-18
   Radzeviciene L, 2013, PUBLIC HEALTH, V127, P241, DOI 10.1016/j.puhe.2012.12.001
   Richter GM, 2012, OPHTHALMOLOGY, V119, P2040, DOI 10.1016/j.ophtha.2012.05.001
   Ritchie SA, 2007, NUTR METAB CARDIOVAS, V17, P319, DOI 10.1016/j.numecd.2006.07.005
   Schaumberg DA, 2000, AM J CLIN NUTR, V72, P1495
   Schaumberg DA, 1999, ANN EPIDEMIOL, V9, P166, DOI 10.1016/S1047-2797(98)00049-0
   Sherwin JC, 2012, OPHTHALMOLOGY, V119, P2141, DOI 10.1016/j.ophtha.2012.04.020
   SPIEGELMAN D, 1992, AM J CLIN NUTR, V55, P1033
   Tan JSL, 2008, OPHTHAL EPIDEMIOL, V15, P317, DOI 10.1080/09286580802105806
   TAUBER WB, 1992, HEALTH PHYS, V63, P13, DOI 10.1097/00004032-199207000-00002
   Weintraub JM, 2002, INT J OBESITY, V26, P1588, DOI [10.1038/sj.ijo.0802158, 10.1038/sj.ijo.802158]
   Wells G., 2013, NEWCASTLE OTTAWA SCA
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P95, DOI 10.1167/iovs.08-1797
   Yamagishi SI, 2003, MICROVASC RES, V65, P186, DOI 10.1016/S0026-2862(03)00005-0
   Yoshida Masao, 2010, Environmental Health and Preventive Medicine, V15, P367, DOI 10.1007/s12199-010-0153-2
   Younan C, 2003, OPHTHALMIC EPIDEMIOL, V10, P227, DOI 10.1076/opep.10.4.227.15905
   Zhang JS, 2011, OPHTHALMOLOGY, V118, P711, DOI 10.1016/j.ophtha.2010.08.021
NR 48
TC 12
Z9 12
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 24
PY 2014
VL 9
IS 2
AR e89923
DI 10.1371/journal.pone.0089923
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AB6EP
UT WOS:000331880700117
PM 24587127
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Deng, J
   You, QH
   Gao, Y
   Yu, Q
   Zhao, P
   Zheng, YL
   Fang, WJ
   Xu, N
   Teng, LS
AF Deng, Jing
   You, Qihan
   Gao, Yang
   Yu, Qing
   Zhao, Peng
   Zheng, Yulong
   Fang, Weijia
   Xu, Nong
   Teng, Lisong
TI Prognostic Value of Perineural Invasion in Gastric Cancer: A Systematic
   Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID EXPRESSION; RECURRENCE; SURVIVAL; ASSOCIATION; RESECTION
AB Background: The prognostic role of perineural invasion in gastric cancer is controversial. Here, we present a systemic review and meta-analysis of the association between perineural invasion and survival in resectable gastric cancer patients.
   Methods: A comprehensive literature search for relevant reports published up to April 2013 was performed using PubMed, Embase, Web of Science and Wanfang Data. Studies that investigated the role of perineural invasion with a sample size greater than 100 were included and analyzed.
   Results: A total of 30,590 gastric cancer patients who had undergone curative gastrectomy from twenty-four studies were included. The median rate of perineural invasion positive was 40.9% (6.8%-75.6%). Fourteen studies investigated overall survival unadjusted for other variables in 23,233 gastric cancer patients. The relative hazard estimates ranged from 0.568-7.901 with a combined random effects estimate of 2.261 (95% CI = 1.841-2.777, P = 0.000). The effect of perineural invasion on overall survival adjusted for other prognostic factors was reported in 17 studies incorporating 8,551 cases. The hazard estimates ranged from 0.420-8.110 with a pooled random effects estimates of 1.484 (95% CI = 1.237-1.781, P = 0.000). There was heterogeneity between the studies (Q = 49.22, I-squared = 67.5%, P = 0.000). Disease-free survival was investigated adjusted in four studies incorporating 9,083 cases and the pooled fixed hazard ratio estimate was 1.371(95% CI = 1.2301.527, P = 0.000).
   Conclusion: Perineural invasion is an independent prognostic factor affecting overall survival and disease-free survival of gastric cancer patients who had undergone the curative resection. This effect is independent of lymph node status, tumor size and the depth of invasion as well as a range of other biological variables on multivariate analysis. Large prospective studies are now needed to establish perineural invasion as an independent prognostic marker for gastric cancer.
C1 [Deng, Jing; Zhao, Peng; Zheng, Yulong; Fang, Weijia; Xu, Nong] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
   [You, Qihan] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Gao, Yang; Yu, Qing] Zhejiang Univ, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [Teng, Lisong] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Surg Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
RP Xu, N (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
EM xunonghz@163.com
FU Medical Science and Technology Program; Health Bureau of Zhejiang
   Province [2013KYB118]; Medicine Research Fund Projects; Administration
   of Traditional Chinese Medicine of Zhejiang Province [2011ZB071,
   2013ZA073]
FX This work was supported by Medical Science and Technology Program
   granted by Health Bureau of Zhejiang Province (No.
   2013KYB118)(URL:http://www.zjwst.gov.cn/) and Medicine Research Fund
   Projects granted by Administration of Traditional Chinese Medicine of
   Zhejiang Province (No.2011ZB071; No.2013ZA073)(URL:
   http://www.zjtcm.gov.cn/public/Default.aspx). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alderson P, 2004, COCHRANE LIB, P102
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bickenbach KA, 2013, ANN SURG ONCOL, V20, P2663, DOI 10.1245/s10434-013-2950-5
   Bilici A, 2010, ANN SURG ONCOL, V17, P2037, DOI 10.1245/s10434-010-1027-y
   Callagy GM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-153
   Chiaravalli AM, 2001, VIRCHOWS ARCH, V439, P158, DOI 10.1007/s004280100441
   Choi MG, 2009, EUR SURG RES, V42, P223, DOI 10.1159/000208521
   Choi MG, 2012, CANCER-AM CANCER SOC, V118, P5227, DOI 10.1002/cncr.27541
   Chou HH, 2013, AM J SURG, V205, P623, DOI 10.1016/j.amjsurg.2012.04.014
   Costa WL, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-169
   Deng J, 2012, ESMO 14 WORLD C GAST
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duraker N, 2003, SURG TODAY, V33, P95, DOI 10.1007/s005950300020
   Fondevila C, 2004, BRIT J CANCER, V90, P206, DOI 10.1038/sj.bjc.6601455
   Handoll HH, 2006, ARCH PHYS MED REHAB, V87, P875, DOI 10.1016/j.apmr.2006.04.006
   Honghu X, 2010, CHIN J GASTROINTEST, P413
   Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80
   Kim DH, 2013, ANN SURG ONCOL, V20, P2317, DOI 10.1245/s10434-012-2700-0
   Kim JW, 2013, CANCER CHEMOTH PHARM, V71, P1435, DOI 10.1007/s00280-013-2141-x
   Kwon KJ, 2013, GASTRIC CANC
   Li P, 2011, CHINESE CLIN ONCOLOG, V16, P97
   Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396
   Luo TH, 2008, J GASTROINTEST SURG, V12, P1263, DOI 10.1007/s11605-008-0529-4
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Ryu WS, 2012, J SURG ONCOL, V106, P456, DOI 10.1002/jso.23097
   Scartozzi M, 2006, BRIT J CANCER, V95, P445, DOI 10.1038/sj.bjc.6603286
   Selcukbiricik F, 2012, ASIAN PAC J CANCER P, V13, P3149, DOI 10.7314/APJCP.2012.13.7.3149
   Setala L, 2001, HISTOPATHOLOGY, V38, P13, DOI 10.1046/j.1365-2559.2001.01038.x
   Setala LP, 1996, BRIT J CANCER, V74, P766, DOI 10.1038/bjc.1996.434
   Smith GD, 1997, LANCET, V350, P1182, DOI 10.1016/S0140-6736(05)63833-0
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   TANAKA A, 1994, CANCER-AM CANCER SOC, V73, P550, DOI 10.1002/1097-0142(19940201)73:3<550::AID-CNCR2820730309>3.0.CO;2-0
   Tural D, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-234
   Ueno H, 2013, AM J SURG PATHOL, V37, P1542, DOI 10.1097/PAS.0b013e318297ef6e
   Wang Chia-Siu, 2002, Chang Gung Med J, V25, P216
   Wen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059154
NR 37
TC 22
Z9 28
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 21
PY 2014
VL 9
IS 2
AR e88907
DI 10.1371/journal.pone.0088907
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AB3VI
UT WOS:000331717900037
PM 24586437
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, JW
   He, CY
   Xu, Q
   Xing, CZ
   Yuan, Y
AF Liu, Jingwei
   He, Caiyun
   Xu, Qian
   Xing, Chengzhong
   Yuan, Yuan
TI NOD2 Polymorphisms Associated with Cancer Risk: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID NON-HODGKIN-LYMPHOMA; INNATE IMMUNITY GENES; EARLY-ONSET BREAST;
   COLORECTAL-CANCER; CROHNS-DISEASE; INFLAMMATORY RESPONSE;
   INTERLYMPH-CONSORTIUM; 3020INSC MUTATION; GASTRIC-CANCER; SUSCEPTIBILITY
AB Background: Emerging evidence indicated that common polymorphisms of NOD2 might impact individual susceptibility to cancer. However, the results from published studies were inconclusive. The aim of this meta-analysis was to elucidate whether NOD2 polymorphisms were associated with cancer risk.
   Methods: A systematically literature search was performed by using electronic databases including PubMed and Web of Science. ORs and their 95% CI were used to assess the strength of association between NOD2 gene polymorphisms and cancer risks.
   Results: Thirty case-control studies were included in this meta-analysis. The pooled analysis indicated that NOD2 rs2066842 C/T polymorphism was not significantly associated with cancer risk; for NOD2 rs2066844 C/T polymorphism, (TT+CT) genotype was associated with increased cancer risk compared with wild-type CC genotype (OR = 1.32, 95% CI = 1.01-1.72, P = 0.041); for NOD2 rs2066845 C/G polymorphism, individuals with (CC+CG) genotype were significantly associated with increased cancer risk compared with GG genotype (OR = 1.32, 95% CI = 1.01-1.72, P = 0.040); for NOD2 rs2066847 (3020insC) polymorphism, carriers of (insC/insC+insC/-) genotype were significantly associated with increased cancer risk compared with -/- carriers (OR = 1.23, 95% CI = 1.10-1.38, P < 0.001). In the subgroup analysis of cancer type, (insC/insC+insC/-) genotype was significantly associated with increased risk of colorectal cancer, gastric cancer and MALT lymphoma, breast cancer, lung cancer, laryngeal cancer but not with urogenital cancer, pancreatic cancer, melanoma or non-Hodgkin lymphoma.
   Conclusion: NOD2 rs2066844 C/T, rs2066845 C/G and rs2066847 (3020insC) polymorphisms might be associated with increased cancer risk. No significant association was observed between NOD2 rs2066842 C/T polymorphism and cancer risk. Further large-scale and well-designed studies are still needed to confirm the results of our meta-analysis.
C1 [Liu, Jingwei; He, Caiyun; Xu, Qian; Xing, Chengzhong; Yuan, Yuan] China Med Univ, Affiliated Hosp 1, Tumor Etiol & Screening Dept, Inst Canc, Shenyang, Peoples R China.
   [Liu, Jingwei; He, Caiyun; Xu, Qian; Xing, Chengzhong; Yuan, Yuan] China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China.
   [Liu, Jingwei; He, Caiyun; Xu, Qian; Xing, Chengzhong; Yuan, Yuan] China Med Univ, Liaoning Prov Educ Dept, Key Lab Canc Etiol & Prevent, Shenyang, Peoples R China.
RP Xing, CZ (reprint author), China Med Univ, Affiliated Hosp 1, Tumor Etiol & Screening Dept, Inst Canc, Shenyang, Peoples R China.
EM xcz1966@126.com; yyuan@mail.cmu.edu.cn
FU National Basic Research Program of China (973 Program) [2010CB529304];
   grants of the Science and Technology Project of Liaoning province
   [2011225002, 2012225016]
FX This study is supported by grants from National Basic Research Program
   of China (973 Program Ref No.2010CB529304), the grants of the Science
   and Technology Project of Liaoning province (Ref No.2011225002) and the
   grants of the Science and Technology Project of Liaoning province (Ref
   No.2012225016). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Alhopuro P, 2004, CANCER RES, V64, P7245, DOI 10.1158/0008-5472.CAN-04-2364
   Angeletti S, 2009, HUM IMMUNOL, V70, P729, DOI 10.1016/j.humimm.2009.04.026
   Ashton KA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-382
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Debniak T, 2005, EUR J CANCER PREV, V14, P143
   Deng WY, 2012, CELL PHYSIOL BIOCHEM, V30, P953, DOI 10.1159/000341472
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ennas MG, 2008, HEMATOL ONCOL, V26, P98, DOI 10.1002/hon.843
   Forrest MS, 2006, BRIT J HAEMATOL, V134, P180, DOI 10.1111/j.1365-2141.2006.06141.x
   Freire P, 2010, INT J COLORECTAL DIS, V25, P1211, DOI 10.1007/s00384-010-1028-0
   Frutuoso MS, 2010, MICROBES INFECT, V12, P819, DOI 10.1016/j.micinf.2010.05.006
   Gazouli M, 2005, WORLD J GASTROENTERO, V11, P681, DOI 10.3748/wjg.v11.i5.681
   Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hnatyszyn A, 2010, EXP MOL PATHOL, V88, P388, DOI 10.1016/j.yexmp.2010.03.003
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Huzarski T, 2005, BREAST CANCER RES TR, V89, P91, DOI 10.1007/s10549-004-1250-y
   Irmejs Arvids, 2006, Hered Cancer Clin Pract, V4, P48, DOI 10.1186/1897-4287-4-1-48
   Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4
   Jaworowska E, 2006, BREAST CANCER RES TR, V97, P215, DOI 10.1007/s10549-005-9116-5
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kersse K, 2011, CYTOKINE GROWTH F R, V22, P257, DOI 10.1016/j.cytogfr.2011.09.003
   Kurzawski G, 2004, CANCER RES, V64, P1604, DOI 10.1158/0008-5472.CAN-03-3791
   Lakatos PL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-54
   Lener MR, 2006, BREAST CANCER RES TR, V95, P141, DOI 10.1007/s10549-005-9057-z
   Lubinski J, 2005, HERED CANCER CLIN PR, V3, P59, DOI 10.1186/1897-4287-3-2-59
   Magnowski P, 2008, GINEKOL POL, V79, P544
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mockelmann N, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-79
   Nej Katarzyna, 2004, Hered Cancer Clin Pract, V2, P149, DOI 10.1186/1897-4287-2-3-149
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   Papaconstantinou L, 2005, INT J CANCER, V114, P433, DOI 10.1002/ijc.20747
   Rigoli L, 2010, ANTICANCER RES, V30, P513
   Roberts RL, 2006, CANCER RES, V66, P2532, DOI 10.1158/0008-5472.CAN-05-4165
   Rosenstiel P, 2006, CELL MICROBIOL, V8, P1188, DOI 10.1111/j.1462-5822.2006.00701.x
   Rothman N, 2006, LANCET ONCOL, V7, P27, DOI 10.1016/S1470-2045(05)70434-4
   Skibola CF, 2010, AM J EPIDEMIOL, V171, P267, DOI 10.1093/aje/kwp383
   Strober W, 2011, MUCOSAL IMMUNOL, V4, P484, DOI 10.1038/mi.2011.29
   Suchy J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-112
   Szeliga J, 2008, MED SCI MONITOR, V14, pCR480
   Thun MJ, 2010, CARCINOGENESIS, V31, P100, DOI 10.1093/carcin/bgp263
   Ture-Ozdemir F, 2008, ANTICANCER RES, V28, P3697
   Tuupanen S, 2007, INT J CANCER, V121, P76, DOI 10.1002/ijc.22651
   Vogel U, 2007, MUTAT RES-FUND MOL M, V624, P88, DOI 10.1016/j.mrfmmm.2007.04.006
   Wex T, 2008, ANTICANCER RES, V28, P757
   Zaridze DG, 2008, BIOCHEMISTRY-MOSCOW+, V73, P532, DOI 10.1134/S0006297908050064
   Zhong Y, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00333
NR 48
TC 22
Z9 22
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2014
VL 9
IS 2
AR e89340
DI 10.1371/journal.pone.0089340
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AB3UC
UT WOS:000331714700106
PM 24586700
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yin, YW
   Sun, QQ
   Wang, PJ
   Qiao, L
   Hu, AM
   Liu, HL
   Wang, Q
   Hou, ZZ
AF Yin, Yan-Wei
   Sun, Qian-Qian
   Wang, Pei-Jian
   Qiao, Li
   Hu, Ai-Min
   Liu, Hong-Li
   Wang, Qi
   Hou, Zhi-Zhen
TI Genetic Polymorphism of Apolipoprotein A5 Gene and Susceptibility to
   Type 2 Diabetes Mellitus: A Meta-Analysis of 15,137 Subjects
SO PLOS ONE
LA English
DT Article
ID APOA5 GENE; CEREBRAL INFARCTION; TRIGLYCERIDE LEVELS; METABOLIC
   SYNDROME; PLASMA-LIPIDS; ASSOCIATION; RISK; CHINESE; POPULATION;
   VARIANTS
AB Background: Several studies have investigated whether the polymorphism in the apolipoprotein A5 (APOA5) is associated with type 2 diabetes mellitus (T2DM) risk. However, those studies have produced inconsistent results. The purpose of this study was to investigate whether the APOA5 -1131T/C polymorphism (rs662799) confers significant susceptibility to T2DM using a meta-analysis.
   Methods: PubMed, Embase, Web of Science, Cochrane database, CBMdisc, CNKI and Google Scholar were searched to get the genetic association studies. All statistical analyses were done with Stata 11.0.
   Results: A total of 19 studies included 4,767 T2DM cases and 10,370 controls (four studies involving 555 T2DM cases and 2958 controls were performed among Europeans and 15 studies involving 4212 T2DM cases and 7412 controls were performed among Asians) were combined showing significant association between the APOA5 -1131T/C polymorphism and T2DM risk (for C allele vs. T allele: OR = 1.28, 95% CI = 1.17-1.40, p, 0.00001; for C/C vs. T/T: OR = 1.57, 95% CI = 1.35-1.83, p, 0.00001; for C/C vs. T/C+ T/T: OR = 1.36, 95% CI = 1.18-1.57, p, 0.0001; for C/C+ T/C vs. T/T: OR = 1.32, 95% CI = 1.16-1.51, p, 0.0001). In the subgroup analysis by ethnicity, significant association was also found among Asians (for C allele vs. T allele: OR = 1.31, 95% CI = 1.22-1.40, p, 0.00001; for C/C vs. T/T: OR = 1.61, 95% CI = 1.38-1.88, p, 0.00001; for C/C vs. T/C+ T/ T: OR = 1.39, 95% CI = 1.20-1.61, p, 0.0001; for C/C+ T/C vs. T/T: OR = 1.42, 95% CI = 1.25-1.62, p, 0.00001). However, no significant association was found between the APOA5 -1131T/C polymorphism and T2DM risk among Europeans.
   Conclusions: The present meta-analysis suggests that the APOA5 -1131T/C polymorphism is associated with an increased T2DM risk in Asian population.
C1 [Yin, Yan-Wei; Hu, Ai-Min; Liu, Hong-Li; Wang, Qi; Hou, Zhi-Zhen] Chinese PLA Air Force Gen Hosp, Dept Emergency, Beijing, Peoples R China.
   [Sun, Qian-Qian] Jinsong Sanat Beijing Air Force, Beijing, Peoples R China.
   [Wang, Pei-Jian] Chengdu Med Coll, Affiliated Hosp 1, Dept Cardiol, Chengdu, Sichuan, Peoples R China.
   [Qiao, Li] Chinese PLA Air Force Gen Hosp, Dept Dermatol, Beijing, Peoples R China.
RP Yin, YW (reprint author), Chinese PLA Air Force Gen Hosp, Dept Emergency, Beijing, Peoples R China.
EM shuaishuaijita@sohu.com
CR Aouizerat BE, 2003, J LIPID RES, V44, P1167, DOI 10.1194/jlr.M200480-JLR200
   Austin MA, 2004, BBA-MOL BASIS DIS, V1688, P1, DOI 10.1016/j.bbadis.2003.10.003
   Baum L, 2007, J DIABETES COMPLICAT, V21, P158, DOI 10.1016/j.jdiacomp.2006.02.003
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406
   Bhaskar S, 2011, GENET TEST MOL BIOMA, V15, P507, DOI 10.1089/gtmb.2010.0207
   Chaaba Raja, 2005, Lipids Health Dis, V4, P1, DOI 10.1186/1476-511X-4-1
   Cheng XQ, 2007, MOL CARDIOLOGY CHINA, V7, P189
   Demirdogen BC, 2012, MOL BIOL REP, V39, P10459, DOI 10.1007/s11033-012-1926-z
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feng CS, 2009, THESIS QINGDAO U, P1
   Freiria Barbosa FA, 2006, J ALZHEIMERS DIS, V10, P365
   Gulliford MC, 2009, AM J EPIDEMIOL, V169, P455, DOI 10.1093/aje/kwn342
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Li HX, 2009, CHINA PRACTICAL MED, V4, P40
   Li Jie, 2007, Zhonghua Yixue Yichuanxue Zazhi, V24, P576
   Li XF, 2002, THEORY APPL TRANSIEN, P1
   Li XF, 2008, J HUAZHONG U SCI-MED, V28, P653, DOI 10.1007/s11596-008-0608-5
   Lin JD, 2010, METABOLISM, V59, P780, DOI 10.1016/j.metabol.2009.09.024
   Liu CF, 2012, GENET TEST MOL BIOMA, V16, P1241, DOI 10.1089/gtmb.2012.0183
   Liu HK, 2005, THESIS SICHUAN U, P1
   Maasz A, 2007, PATHOL ONCOL RES, V13, P243, DOI 10.1007/BF02893505
   Martin S, 2003, BBA-MOL BASIS DIS, V1637, P217, DOI 10.1016/S0925-4439(03)00033-4
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Pennacchio LA, 2002, HUM MOL GENET, V11, P3031, DOI 10.1093/hmg/11.24.3031
   Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852
   Qiao Yan, 2008, Sichuan Da Xue Xue Bao Yi Xue Ban, V39, P965
   Soter MO, 2012, MOL BIOL REP, V39, P7541, DOI 10.1007/s11033-012-1588-x
   Talmud PJ, 2006, DIABETOLOGIA, V49, P2337, DOI 10.1007/s00125-006-0387-0
   Tang LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070301
   van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200
   Wang Wei, 2012, Zhonghua Nei Ke Za Zhi, V51, P516
   Wells G, 2011, NEWCASTLE OTTAWA SCA
   Xiao Hui, 2010, Modern Preventive Medicine, V37, P722
   Xu C, 2013, PLOS ONE, V8
   Yan SK, 2005, CLIN CHEM LAB MED, V43, P607, DOI 10.1515/CCLM.2005.105
   Yao WM, 2013, J HUM HYPERTENS, V27, P265, DOI 10.1038/jhh.2012.23
   Yin YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066924
   Yin YW, 2013, CYTOKINE, V62, P226, DOI 10.1016/j.cyto.2013.02.025
   Zhai Guang-Hua, 2007, Yichuan, V29, P541, DOI 10.1360/yc-007-0541
   Zhang S, 2009, THESIS CHINESE ACAD, P1
   Zhou YL, 2008, J CHINESE PRACTICAL, V22, P815
NR 43
TC 9
Z9 10
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 19
PY 2014
VL 9
IS 2
AR e89167
DI 10.1371/journal.pone.0089167
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AB3TA
UT WOS:000331711900098
PM 24586566
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, X
   Zeng, ZY
   Hou, YX
   Yuan, TX
   Gao, C
   Jia, W
   Yi, XY
   Liu, MR
AF Yang, Xin
   Zeng, Zongyue
   Hou, Yixuan
   Yuan, Taixian
   Gao, Chao
   Jia, Wei
   Yi, Xiaoyan
   Liu, Manran
TI MicroRNA-92a as a Potential Biomarker in Diagnosis of Colorectal Cancer:
   A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID PLASMA MICRORNAS; COLON-CANCER; SERUM; TESTS; BLOOD; RNA; PUBLICATION;
   STATISTICS; EXPRESSION; ACCURACY
AB Introduction: Previous studies demonstrated that MicroRNA-92a (miR-92a) was significantly differential expressed between colorectal cancer (CRC) patients and control cohorts, which provide timely relevant evidence for miR-92a as a novel promising biomarker in the colorectal cancer patients. This meta-analysis aimed to evaluate potential diagnostic value of plasma miR-92a.
   Methods: Relevant literatures were collected in PubMed, Embase, Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI) and Technology of Chongqing (VIP), and Wan Fang Data. Sensitivity, specificity and diagnostic odds ratio (DOR) for miR-92a in the diagnosis of CRC were pooled using random effects models. Summary receiver operating characteristic (SROC) curve analysis and the area under the curve (AUC) were used to estimate the overall test performance.
   Results: This Meta-analysis included six studies with a total of 521 CRC patients and 379 healthy controls. For miR-92a, the pooled sensitivity, specificity and DOR to predict CRC patients were 76% (95% confidence interval [CI]: 72%-79%), 64% (95% confidence interval [CI]: 59%-69%) and 8.05 (95% CI: 3.50-18.56), respectively. In addition, the AUC of miR-92a in diagnosis CRC is 0.7720.
   Conclusions: MicroRNA-92a might be a novel potential biomarker in the diagnosis of colorectal cancer, and more studies are needed to highlight the theoretical strengths.
C1 [Yang, Xin; Zeng, Zongyue; Hou, Yixuan; Yuan, Taixian; Gao, Chao; Jia, Wei; Yi, Xiaoyan; Liu, Manran] Chongqing Med Univ, Chinese Minist Educ, Key Lab Lab Med Diagnost, Chongqing, Peoples R China.
   [Hou, Yixuan] Chongqing Med Univ, Expt Teaching Ctr Basic Med Sci, Chongqing, Peoples R China.
RP Liu, MR (reprint author), Chongqing Med Univ, Chinese Minist Educ, Key Lab Lab Med Diagnost, Chongqing, Peoples R China.
EM martinliu12345@gmail.com
FU National Natural Science Foundation of China [NSFC 81072147, NSFC
   30940096]; Doctoral Fund of Ministry of Education, China
   [20105503110001, 20125503110001]; Scientific Research Foundation for the
   Returned Overseas Chinese Scholars, Ministry of Education, China
   [[2011]508]; Major Program of Chongqing Medical University [XBZD201006];
   Scientific Research Foundation for the Returned Overseas Scholars of
   Chongqing Medical University
FX This work was supported in part by National Natural Science Foundation
   of China (NSFC 81072147, NSFC 30940096); the Doctoral Fund of Ministry
   of Education, China (20105503110001, 20125503110001); the Scientific
   Research Foundation for the Returned Overseas Chinese Scholars, Ministry
   of Education, China ([2011]508); the Major Program of Chongqing Medical
   University XBZD201006; and the Scientific Research Foundation for the
   Returned Overseas Scholars of Chongqing Medical University. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Ahmed FE, 2012, CANCER GENOM PROTEOM, V9, P179
   Barbarotto E, 2008, INT J CANCER, V122, P969, DOI 10.1002/ijc.23343
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Vega AB, 2013, ONCOL REP, V30, P320, DOI 10.3892/or.2013.2475
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282
   Collins JF, 2005, ANN INTERN MED, V142, P81, DOI 10.7326/0003-4819-142-2-200501180-00006
   Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76
   Faltejskova P, 2012, CANCER BIOMARK, V12, P199, DOI 10.3233/CBM-130308
   Gellad ZF, 2010, GASTROENTEROLOGY, V138, P2177, DOI 10.1053/j.gastro.2010.01.056
   Giraldez MD, 2013, CLIN GASTROENTEROL H, V11, P681, DOI 10.1016/j.cgh.2012.12.009
   Giraldez MD, 2011, GASTROENTEROLOGY, V140, pS410
   Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Huang ZH, 2010, INT J CANCER, V127, P118, DOI 10.1002/ijc.25007
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   Jones CM, 2005, ANN THORAC SURG, V79, P16, DOI 10.1016/j.athoracsur.2004.09.040
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lijmer JG, 2002, STAT MED, V21, P1525, DOI 10.1002/sim.1185
   Liu GH, 2013, TUMOR BIOL, V34, P2175, DOI 10.1007/s13277-013-0753-8
   Lo KW, 1999, CLIN CHEM, V45, P1292
   Luo X, 2013, PLOS ONE, V8
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817
   Ng EKO, 2002, CLIN CHEM, V48, P1212
   Nugent M, 2012, J SURG ONCOL, V106, P947, DOI 10.1002/jso.23174
   Silva JM, 2002, GUT, V50, P530, DOI 10.1136/gut.50.4.530
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   Sung JJ, 2009, GASTROENTEROLOGY, V136, pA165
   THOMSON DMP, 1969, P NATL ACAD SCI USA, V64, P161, DOI 10.1073/pnas.64.1.161
   Walsh JME, 2003, JAMA-J AM MED ASSOC, V289, P1288, DOI 10.1001/jama.289.10.1288
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Wittmann J, 2010, BBA-REV CANCER, V1806, P200, DOI 10.1016/j.bbcan.2010.07.002
   Zamora Javier, 2006, BMC Med Res Methodol, V6, P31, DOI 10.1186/1471-2288-6-31
NR 37
TC 29
Z9 31
U1 0
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 14
PY 2014
VL 9
IS 2
AR e88745
DI 10.1371/journal.pone.0088745
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AA7IR
UT WOS:000331271500062
PM 24551148
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liang, B
   Guo, Y
   Li, YH
   Kong, H
AF Liang, Bin
   Guo, Yang
   Li, Yunhui
   Kong, Hong
TI Association between IL-10 Gene Polymorphisms and Susceptibility of
   Tuberculosis: Evidence Based on a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SINGLE NUCLEOTIDE POLYMORPHISMS; PULMONARY TUBERCULOSIS; INTERLEUKIN-10
   POLYMORPHISMS; TNF-ALPHA; CYTOKINES; DISEASE
AB Background: A number of observational studies have been conducted to investigate the association of IL-10 gene polymorphisms with tuberculosis (TB) susceptibility. However, the results of different studies were inconsistent. The aim of this study was to investigate the relationship between IL-10 -1082G/A, -819T/C, and -592A/C polymorphisms and TB risk by meta-analysis.
   Methods: A literature search was conducted among six English databases (PubMed, Embase, Web of Science, Science Direct, SpringerLink and EBSCO) and two Chinese databases (Wanfang and Chinese National Knowledge Infrastructure databases) to identify studies involving association between IL-10 21082G/A, 2819T/C, and 2592A/C polymorphisms and TB susceptibility before May. 2013. Statistical analysis was performed using Revman 5.0 and Stata 12.0.
   Results: A total of 31 studies with 6,559 cases and 7,768 controls were included in this meta-analysis. The results showed that three polymorphisms (-1082G/A, -819T/C, and -592A/C) in the IL-10 gene were not associated with the risk of TB in general population. In the subgroup analysis by ethnicity, IL-10 -1082G/A polymorphism was associated with TB risk in Europeans (AA+ AG vs. GG: OR = 0.57, 95% CI = 0. 0.37-0.89, P = 0.01) and Americans (AA+ AG vs. GG: OR = 0.39, 95% CI = 0.27-0.57, P<0.01), and IL-10 -819T/C (C allele vs. T allele: OR = 0.83, 95% CI = 0.72-0.96, P = 0.01) and -592A/C (CC+AC vs. AA: OR = 0.65, 95% CI = 0.49-0.85, P = 0.002) polymorphisms were significantly associated with TB risk in Asians.
   Conclusion: This meta-analysis provides strong evidence that IL-10-1082G/A polymorphism was associated with TB risk in Europeans and Americans, and IL-10 -819T/C and -592A/C polymorphisms could be risk factors for TB in Asians. Additional well designed large studies were required for the validation of our results.
C1 [Liang, Bin] China Med Univ, High Vocat Technol Coll, Dept Clin Lab, Shenyang, Peoples R China.
   [Guo, Yang] China Med Univ, Dept Breast Surg, Hosp 1, Shenyang, Peoples R China.
   [Li, Yunhui] 202 Hosp, Dept Clin Lab, Shenyang, Peoples R China.
   [Kong, Hong] China Med Univ, Shengjing Hosp, Dept Clin Lab, Shenyang, Peoples R China.
RP Liang, B (reprint author), China Med Univ, High Vocat Technol Coll, Dept Clin Lab, Shenyang, Peoples R China.
EM liangbin_cmu@126.com
FU Liaoning Natural Science Fund, Liaoning Province, China [201102257]
FX This study was supported by Liaoning Natural Science Fund, Liaoning
   Province, China (Topic No: 201102257). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amirzargar AA, 2006, EUR CYTOKINE NETW, V17, P84
   Anand SP, 2007, INDIAN J MED RES, V126, P135
   Ansari A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027848
   Ansari A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004778
   Ates O, 2008, J CLIN IMMUNOL, V28, P232, DOI 10.1007/s10875-007-9155-2
   BARNES PF, 1993, INFECT IMMUN, V61, P3482
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bellamy R., 1998, Tubercle and Lung Disease, V79, P83, DOI 10.1054/tuld.1998.0009
   Ben-Selma W, 2011, MICROBES INFECT, V13, P837, DOI 10.1016/j.micinf.2011.04.009
   Crawley E, 1999, ARTHRITIS RHEUM-US, V42, P1101, DOI 10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y
   Delgado JC, 2002, J INFECT DIS, V186, P1463, DOI 10.1086/344891
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fitness J, 2004, AM J TROP MED HYG, V71, P341, DOI 10.4269/ajtmh.2004.71.341
   Garcia-Elorriaga G, 2013, ASIAN PAC J TROP MED, V6, P505, DOI 10.1016/S1995-7645(13)60086-3
   Henao MI, 2006, TUBERCULOSIS, V86, P11, DOI 10.1016/j.tube.2005.03.001
   Hill AVS, 2001, ANNU REV GENOM HUM G, V2, P373, DOI 10.1146/annurev.genom.2.1.373
   Kleinnijenhuis J, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/405310
   Knight J., 2001, Current Infectious Disease Reports, V3, P427
   Liang L, 2011, FEMS IMMUNOL MED MIC, V62, P84, DOI 10.1111/j.1574-695X.2011.00791.x
   Liu XX, 2009, MODERN PREV MED, V36, P1827
   Lopez-Maderuelo D, 2003, AM J RESP CRIT CARE, V167, P970, DOI 10.1164/rccm.200205-438BC
   [马志明 MA Zhiming], 2007, [广东医学, Guangdong Medical Journal], V28, P1243
   Maurer M, 2000, J NEUROIMMUNOL, V104, P98, DOI 10.1016/S0165-5728(99)00256-8
   Meenagh A, 2002, HUM IMMUNOL, V63, P1055, DOI 10.1016/S0198-8859(02)00440-8
   Meenakshi P, 2013, SCAND J IMMUNOL, V78, P92, DOI 10.1111/sji.12055
   Mhmoud N, 2013, TROP MED INT HEALTH, V18, P1119, DOI 10.1111/tmi.12141
   Moller M, 2010, TUBERCULOSIS, V90, P71, DOI 10.1016/j.tube.2010.02.002
   Mosaad YM, 2010, SCAND J IMMUNOL, V72, P358, DOI 10.1111/j.1365-3083.2010.02426.x
   O'Leary S, 2011, AM J RESP CELL MOL, V45, P172, DOI 10.1165/rcmb.2010-0319OC
   Oh JH, 2007, RESPIROLOGY, V12, P594, DOI 10.1111/j.1440-1843.2007.01108.x
   Oral HB, 2006, CYTOKINE, V35, P143, DOI 10.1016/j.cyto.2006.07.015
   Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312
   Pan F, 2012, MOL BIOL REP, V39, P7143, DOI 10.1007/s11033-012-1546-7
   Scola L, 2003, MECH AGEING DEV, V124, P569, DOI 10.1016/S0047-6374(03)00038-1
   Selvaraj P, 2008, CYTOKINE, V43, P26, DOI 10.1016/j.cyto.2008.04.011
   Shin HD, 2005, EXP MOL MED, V37, P128, DOI 10.1038/emm.2005.17
   Sunder SR, 2012, HUM IMMUNOL, V73, P605, DOI 10.1016/j.humimm.2012.03.012
   Taype CA, 2010, INFECT GENET EVOL, V10, P495, DOI 10.1016/j.meegid.2010.02.011
   Thye T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005420
   Trajkov Dejan, 2009, Indian J Tuberc, V56, P117
   Turner J, 2002, J IMMUNOL, V169, P6343, DOI 10.4049/jimmunol.169.11.6343
   Ulger M, 2013, MIKROBIYOL BUL, V47, P250
   Vannberg FO, 2011, IMMUNOL REV, V240, P105, DOI 10.1111/j.1600-065X.2010.00996.x
   Verbon A, 1999, CLIN EXP IMMUNOL, V115, P110
   Wu F, 2008, J OCCUP HEALTH, V50, P445, DOI 10.1539/joh.L8006
   Yang Hui, 2010, Zhonghua Liu Xing Bing Xue Za Zhi, V31, P155
   Zaduo Meilangqucuo, 2012, MODERN PREVENTIVE ME, V39, P3607
   Zembrzuski VM, 2010, TUBERCULOSIS, V90, P44, DOI 10.1016/j.tube.2009.11.002
   Zhang J, 2011, INT J TUBERC LUNG D, V15, P594, DOI 10.5588/ijtld.09.0703
NR 49
TC 21
Z9 23
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 11
PY 2014
VL 9
IS 2
AR e88448
DI 10.1371/journal.pone.0088448
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AA7DT
UT WOS:000331258100045
PM 24523896
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, Y
   Yu, CH
   Li, YM
AF Chen, Yi
   Yu, Chaohui
   Li, Youming
TI Physical Activity and Risks of Esophageal and Gastric Cancers: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; POPULATION-BASED COHORT; INSULIN SENSITIVITY;
   PUBLICATION BIAS; ADIPOSE-TISSUE; STOMACH-CANCER; LEISURE-TIME;
   BODY-MASS; MEN; EXERCISE
AB Background: The incidence of esophageal and gastric cancer has been increasing rapidly worldwide in recent years, although the reason for this increase is unclear. Here, a statistical synthesis of studies that evaluated the association between physical activity, a well-known protecting factor against death and other chronic diseases, and the risk of esophageal and gastric cancer was performed.
   Methods: Potentially suitable studies were identified using Medline and Embase. The reference lists of all included articles and those of several recent reviews were searched manually. Studies were included if they (1) were published as case-control or cohort studies evaluating the association between physical activity and risk of esophageal or gastric cancer; and (2) reported point estimates (i.e., risk ratios, odds ratios) and measures of variability (i.e., 95% confidence intervals [CIs]) for physical activity and risk of esophageal or gastric cancer.
   Results: Fifteen studies were identified (7 cohorts, 8 case-controls; 984 esophageal and 7,087 gastric cancers). Collectively, they indicated that the risk of gastric cancer was 13% lower among the most physically active people than among the least active people (RR = 0.87, 95% confidence interval [CI] = 0.78 to 0.97) and that of esophageal cancer was 27% lower (RR = 0.73, 95% CI = 0.56 to 0.97).
   Conclusions: Pooled results from observational studies support a protective effect of physical activity against both esophageal and gastric cancer.
C1 [Chen, Yi; Yu, Chaohui; Li, Youming] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Gastroenterol, Hangzhou 310003, Zhejiang, Peoples R China.
RP Li, YM (reprint author), Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Gastroenterol, Hangzhou 310003, Zhejiang, Peoples R China.
EM zlym@zju.edu.cn
OI Ma, Han/0000-0001-9985-3035
FU National Key Basic Research Development Program [2012CB524905]; National
   Science and Technology Support Plan Project [2012BAI06B04]; National
   Natural Science Foundation of China [31070315, 81100278, 81170378];
   Zhejiang Provincial Natural Science Foundation of China [Y2110026];
   Science Foundation of Health Bureau of Zhejiang Province [2012RCA026]
FX This study was supported by National Key Basic Research Development
   Program (No. 2012CB524905), National Science and Technology Support Plan
   Project (No. 2012BAI06B04), National Natural Science Foundation of China
   (Nos. 31070315, 81100278, and 81170378), Zhejiang Provincial Natural
   Science Foundation of China (No. Y2110026), and Science Foundation of
   Health Bureau of Zhejiang Province (No. 2012RCA026). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Accardi R, 2008, WORLD CANC REPORT
   Balbuena L, 2009, FUTURE ONCOL, V5, P1051, DOI 10.2217/FON.09.65
   Batty GD, 2010, ANN EPIDEMIOL, V20, P661, DOI 10.1016/j.annepidem.2010.03.014
   Batty GD, 2001, EUR J EPIDEMIOL, V17, P863, DOI 10.1023/A:1015609909969
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belluco C, 2000, ANN SURG ONCOL, V7, P133, DOI 10.1007/s10434-000-0133-7
   Boccia S, 2005, CANCER LETT, V229, P235, DOI 10.1016/j.canlet.2005.06.035
   Boyle T, 2012, JNCI-J NATL CANCER I, V104, P1548, DOI 10.1093/jnci/djs354
   Bradley RL, 2008, AM J PHYSIOL-ENDOC M, V295, pE586, DOI 10.1152/ajpendo.00309.2007
   Brenner Hermann, 2009, V472, P467, DOI 10.1007/978-1-60327-492-0_23
   BROWNSON RC, 1991, AM J PUBLIC HEALTH, V81, P639, DOI 10.2105/AJPH.81.5.639
   Campbell PT, 2007, EUR J CANCER, V43, P593, DOI 10.1016/j.ejca.2006.11.011
   CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126
   Chen MJ, 2009, WORLD J GASTROENTERO, V15, P5472, DOI 10.3748/wjg.15.5472
   Daly JM, 1996, CANCER, V78, P1820, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO;2-Z
   Jonge PJF, 2007, ALIMENT PHARM THER, V26, P31, DOI 10.1111/j.1365-2036.2007.03344.x
   DOSEMECI M, 1993, CANCER CAUSE CONTROL, V4, P313, DOI 10.1007/BF00051333
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Etemadi A, 2012, ANN ONCOL, V23, P1593, DOI 10.1093/annonc/mdr494
   Hao JJ, 2013, GENE, V513, P196, DOI 10.1016/j.gene.2012.09.091
   Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6
   Inoue M, 2008, AM J EPIDEMIOL, V168, P391, DOI 10.1093/aje/kwn146
   Jessri M, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-137
   John BJ, 2006, ALIMENT PHARM THER, V23, P1511, DOI 10.1111/j.1365-2036.2006.02915.x
   Khushalani NI, 2008, MAYO CLIN PROC, V83, P712
   Kim ES, 2007, OBESITY, V15, P3023, DOI 10.1038/oby.2007.360
   Lagergren J, 1999, ANN INTERN MED, V130, P883, DOI 10.7326/0003-4819-130-11-199906010-00003
   Lam TH, 2004, ANN EPIDEMIOL, V14, P391, DOI 10.1016/j.annepidem.2003.09.005
   Lee CD, 2003, STROKE, V34, P2475, DOI 10.1161/01.STR.0000091843.02517.9D
   Leitzmann MF, 2009, AM J PREV MED, V36, P112, DOI 10.1016/j.amepre.2008.09.033
   Ligibel JA, 2008, J CLIN ONCOL, V26, P907, DOI 10.1200/JCO.2007.12.7357
   Huerta JM, 2010, CANCER CAUSE CONTROL, V21, P657, DOI 10.1007/s10552-009-9493-x
   Parent ME, 2011, CANCER EPIDEMIOL, V35, P151, DOI 10.1016/j.canep.2010.09.004
   Samitz G, 2011, INT J EPIDEMIOL, V40, P1382, DOI 10.1093/ije/dyr112
   SEVERSON RK, 1989, AM J EPIDEMIOL, V130, P522, DOI 10.1093/oxfordjournals.aje.a115366
   Sjodahl K, 2008, CANCER EPIDEM BIOMAR, V17, P135, DOI 10.1158/1055-9965.EPI-07-0704
   Sofi F, 2008, EUR J CARDIOV PREV R, V15, P247, DOI 10.1097/HJR.0b013e3282f232ac
   STUKONIS M, 1969, INT J CANCER, V4, P248, DOI 10.1002/ijc.2910040215
   Sun JY, 2012, ASIAN PAC J CANCER P, V13, P3143, DOI 10.7314/APJCP.2012.13.7.3143
   Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4
   Umar SB, 2008, NAT CLIN PRACT GASTR, V5, P517, DOI 10.1038/ncpgasthep1223
   Vigen C, 2006, INT J CANCER, V118, P1004, DOI 10.1002/ijc.21419
   Wannamethee SG, 2001, BRIT J CANCER, V85, P1311, DOI 10.1054/bjoc.2001.2096
   Wen XY, 2010, ASIAN PAC J CANCER P, V11, P1473
   Wolin KY, 2011, BRIT J CANCER, V104, P882, DOI 10.1038/sj.bjc.6606045
   Wolin KY, 2011, RECENT RESULTS CANC, V186, P73, DOI 10.1007/978-3-642-04231-7_4
   Wu YL, 2013, BREAST CANCER RES TR, V137, P869, DOI 10.1007/s10549-012-2396-7
   Yun YH, 2004, CANCER DETECT PREV, V29, P15, DOI 10.1016/j.cdp.2004.08.006
   Zhang ZF, 1996, CANCER EPIDEM BIOMAR, V5, P761
NR 49
TC 13
Z9 13
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 6
PY 2014
VL 9
IS 2
AR e88082
DI 10.1371/journal.pone.0088082
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AA1BH
UT WOS:000330830700040
PM 24516584
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yi, X
   Jia, W
   Jin, Y
   Zhen, S
AF Yi, Xiao
   Jia, Wei
   Jin, Yin
   Zhen, Shang
TI Statin Use Is Associated with Reduced Risk of Haematological
   Malignancies: Evidence from a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID A REDUCTASE INHIBITORS; LOVASTATIN-INDUCED APOPTOSIS; LOWERING LDL
   CHOLESTEROL; NON-HODGKIN-LYMPHOMA; PRIMARY PREVENTION; MEDICAL
   CONDITIONS; CORONARY EVENTS; FOLLOW-UP; CANCER; CELL
AB Background: Several observational studies have shown that statin use may modify the risk of haematological malignancies. To quantify the association between statin use and risk for haematological malignancies, we performed a detailed meta-analysis of published studies regarding this subject.
   Methods: We conducted a systematic search of multiple databases including PubMed, Embase, and Cochrane Library Central database up to July 2013. Fixed-effect and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Potential sources of heterogeneity were detected by meta-regression. Subgroup analyses and sensitivity analysis were also performed.
   Results: A total of 20 eligible studies (ten case-control studies, four cohort studies, and six RCTs) reporting 1,139,584 subjects and 15,297 haematological malignancies cases were included. Meta-analysis showed that statin use was associated with a statistically significant 19% reduction in haematological malignancies incidence (RR = 0.81, 95% CI [0.70, 0.92]). During subgroup analyses, statin use was associated with a significantly reduced risk of haematological malignancies among observational studies (RR = 0.79, 95% CI [0.67, 0.93]), but not among RCTs (RR = 0.92, 95% CI [0.77, 1.09]).
   Conclusions: Based on this comprehensive meta-analysis, statin use may have chemopreventive effects against haematological malignancies. More studies, especially definitive, randomized chemoprevention trials are needed to confirm this association.
C1 [Yi, Xiao; Jia, Wei; Jin, Yin; Zhen, Shang] Huazhong Univ Sci & Technol, Dept Hematol, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China.
RP Yi, X (reprint author), Huazhong Univ Sci & Technol, Dept Hematol, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China.
EM dr_xiaoyi@126.com
FU Natural Science Foundation of Hubei Province [2012FFB02435]; central
   university special funding [2013QN191]
FX This work was supported by Natural Science Foundation of Hubei Province
   (No. 2012FFB02435) and the central university special funding (No.
   2013QN191). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Bansal D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046691
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blais L, 2000, ARCH INTERN MED, V160, P2363, DOI 10.1001/archinte.160.15.2363
   Bulbulia R, 2011, LANCET, V378, P2013, DOI 10.1016/S0140-6736(11)61125-2
   Chao C, 2011, AIDS, V25, P1771, DOI 10.1097/QAD.0b013e328349c67a
   Coogan PF, 2007, EPIDEMIOLOGY, V18, P213, DOI 10.1097/01.ede.0000254694.03027.a1
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dimitroulakos J, 2002, NEOPLASIA, V4, P337, DOI 10.1038/sj.neo.7900247
   Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fortuny J, 2006, CANCER EPIDEM BIOMAR, V15, P921, DOI 10.1158/1055-9965.EPI-05-0866
   Friedman GD, 2008, PHARMACOEPIDEM DR S, V17, P27, DOI 10.1002/pds.1507
   Friis S, 2005, INT J CANCER, V114, P643, DOI 10.1002/ijc.20758
   Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027
   Griner LN, 2013, BRIT J HAEMATOL, V160, P177, DOI 10.1111/bjh.12103
   Gronich N, 2004, J INVEST MED, V52, P335, DOI 10.1136/jim-52-05-34
   Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Holdaas H, 2003, LANCET, V361, P2024, DOI 10.1016/S0140-6736(03)13638-0
   Iwata H, 2006, CANCER SCI, V97, P133, DOI 10.1111/j.1349-7006.2006.00153.x
   Jacobs EJ, 2011, CANCER RES, V71, P1763, DOI 10.1158/0008-5472.CAN-10-2953
   Kusama T, 2002, GASTROENTEROLOGY, V122, P308, DOI 10.1053/gast.2002.31093
   Kwak B, 2000, NAT MED, V6, P1399
   Landgren O, 2006, CANCER EPIDEM BIOMAR, V15, P2342, DOI 10.1158/1055-9965.EPI-06-0097
   Lutski M, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.120005
   Matar P, 1999, CLIN EXP METASTAS, V17, P19
   Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5
   Mills EJ, 2008, J AM COLL CARDIOL, V52, P1769, DOI 10.1016/j.jacc.2008.08.039
   Nielsen SF, 2012, NEW ENGL J MED, V367, P1792, DOI 10.1056/NEJMoa1201735
   Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C
   Rodriguez-Abreu D, 2007, ANN ONCOL, V18, pI3, DOI 10.1093/annonc/mdl443
   Romano M, 2000, LAB INVEST, V80, P1095, DOI 10.1038/labinvest.3780115
   Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Simes RJ, 2002, LANCET, V359, P1379
   Singh S, 2013, GASTROENTEROLOGY, V144, P323, DOI 10.1053/j.gastro.2012.10.005
   Strandberg TE, 2004, LANCET, V364, P771, DOI 10.1016/S0140-6736(04)16936-5
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Traversa G, 1998, PHARMACOEPIDEM DR S, V7, P113, DOI 10.1002/(SICI)1099-1557(199803/04)7:2<113::AID-PDS329>3.0.CO;2-9
   Vinogradova Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-409
   Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393
   Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058
   Wong WWL, 2002, LEUKEMIA, V16, P508, DOI 10.1038/sj.leu.2402476
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Xia Z, 2001, LEUKEMIA, V15, P1398, DOI 10.1038/sj.leu.2402196
   Zhang YW, 2004, CANCER CAUSE CONTROL, V15, P419, DOI 10.1023/B:CACO.0000027506.55846.5d
NR 46
TC 10
Z9 10
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 31
PY 2014
VL 9
IS 1
AR e87019
DI 10.1371/journal.pone.0087019
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 302RF
UT WOS:000330621900060
PM 24498014
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Luo, JQ
   Wen, JG
   Zhou, HH
   Chen, XP
   Zhang, W
AF Luo, Jian-Quan
   Wen, Jia-Gen
   Zhou, Hong-Hao
   Chen, Xiao-Ping
   Zhang, Wei
TI Endothelial Nitric Oxide Synthase Gene G894T Polymorphism and Myocardial
   Infarction: A Meta-Analysis of 34 Studies Involving 21068 Subjects
SO PLOS ONE
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; MISSENSE GLU298ASP VARIANT; HEART-DISEASE;
   RISK-FACTOR; EXON 7; ASSOCIATION; GENOTYPE; MUTATION; ALLELE; COMMON
AB Background: Researches have revealed that the endothelial nitric oxide synthase (eNOS) gene G894T polymorphism is associated with the risk of Myocardial infarction (MI), but the results remain conflicting.
   Objective and Methods: A meta-analysis was conducted to investigate the association between eNOS G894T polymorphism and MI. Published studies from PubMed, Embase, CNKI and CBM databases were retrieved. The pooled odds ratios (ORs) for the association between eNOS G894T polymorphism and MI and their corresponding 95% confidence intervals (CIs) were estimated using the random-or fixed-effect model.
   Results: A total of 34 studies including 8229 cases and 12839 controls were identified for the meta-analysis. The eNOS G894T polymorphism was significantly associated with MI under a homozygous genetic model (OR = 1.41, 95% CI = 1.08-1.84; P = 0.012), a recessive genetic model (OR = 1.35, 95% CI = 1.06-1.70; P = 0.014), a dominant genetic model (OR = 1.18, 95% CI = 1.04-1.34; P = 0.009). In the subgroup analysis by ethnicity (non-Asian and Asian), no significant association was observed between eNOS G894T polymorphism and MI risk among non-Asians (P > 0.05), but a positive significant association was found among Asians (P < 0.05).
   Conclusions: The eNOS G894T polymorphism is associated with increased MI risk in Asians. The results indicate that ethnicity plays important roles in the association between eNOS G894T polymorphism and MI.
C1 [Luo, Jian-Quan; Wen, Jia-Gen; Zhou, Hong-Hao; Chen, Xiao-Ping; Zhang, Wei] Cent S Univ, Hunan Key Lab Pharmacogenet, Inst Clin Pharmacol, Pharmacogenet Res Inst, Changsha, Hunan, Peoples R China.
RP Chen, XP (reprint author), Cent S Univ, Hunan Key Lab Pharmacogenet, Inst Clin Pharmacol, Pharmacogenet Res Inst, Changsha, Hunan, Peoples R China.
EM chenxp74@hotmail.com; yjsd2003@163.com
FU National Scientific Foundation of China [81273595, 81202594, 81001445];
   "863" Project [2012AA02A518]; Scientific Foundation of Hunan [11K073,
   10JJ4020]
FX The work was supported by the National Scientific Foundation of China
   (No. 81273595, 81202594, 81001445), the "863" Project (No.
   2012AA02A518), the Scientific Foundation of Hunan (No. 11K073,
   10JJ4020). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Agema WRP, 2004, CLIN SCI, V107, P255, DOI 10.1042/CS20030360
   Andrikopoulos GK, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-43
   Angeline T, 2010, EXP MOL PATHOL, V89, P205, DOI 10.1016/j.yexmp.2010.08.009
   Antoniades C, 2005, J AM COLL CARDIOL, V46, P1101, DOI 10.1016/j.jacc.2005.05.072
   Aras O, 2002, THROMB HAEMOSTASIS, V87, P347
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cai H, 1999, J MOL MED-JMM, V77, P511, DOI 10.1007/s001099900020
   Cai H, 1998, DIABETES CARE, V21, P2195, DOI 10.2337/diacare.21.12.2195
   Casas JP, 2004, CIRCULATION, V109, P1359, DOI 10.1161/01.CIR.0000121357.76910.A3
   Chao YX, 2006, ASS ENDOTHELIAL NITR
   Chien YH, 2004, FREE RADICAL BIO MED, V36, P1011, DOI 10.1016/j.freeradbiomed.2004.01.011
   Dafni C, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-133
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Forstermann U, 2006, CIRCULATION, V113, P1708, DOI 10.1161/CIRCULATIONAHA.105.602532
   Franco E, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-27
   Gad MZ, 2012, GENET TEST MOL BIOMA, V16, P695, DOI 10.1089/gtmb.2011.0342
   Gardemann A, 2002, ATHEROSCLEROSIS, V160, P167, DOI 10.1016/S0021-9150(01)00554-8
   Gluba A, 2009, ANGIOLOGY, V60, P588, DOI 10.1177/0003319709335031
   Gong LL, 2012, THROMB RES, V130, pE43, DOI 10.1016/j.thromres.2012.06.015
   Hibi K, 1998, HYPERTENSION, V32, P521, DOI 10.1161/01.HYP.32.3.521
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hingorani AD, 1999, CIRCULATION, V100, P1515, DOI 10.1161/01.CIR.100.14.1515
   Isordia-Salas I, 2010, CLIN CHIM ACTA, V411, P553, DOI 10.1016/j.cca.2010.01.013
   Jo I, 2006, CLIN CHIM ACTA, V365, P86, DOI 10.1016/j.cca.2005.07.029
   Katakami N, 2010, ATHEROSCLEROSIS, V212, P534, DOI 10.1016/j.atherosclerosis.2010.06.010
   Kumar ASA, 2013, MOL BIOL REP, V40, P1275, DOI 10.1007/s11033-012-2170-2
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Narne P, 2013, J DIABETES COMPLICAT, V27, P255, DOI 10.1016/j.jdiacomp.2012.10.009
   Niu WQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024266
   Odeberg J, 2008, BMC CARDIOVASC DISOR, V8, DOI 10.1186/1471-2261-8-36
   Poirier O, 1999, EUR J CLIN INVEST, V29, P284
   [齐霁 Qi Ji], 2003, [中国实用内科杂志, Chinese Journal of Practical Internal Medicine], V23, P470
   Rankinen T, 2000, HYPERTENSION, V36, P885, DOI 10.1161/01.HYP.36.5.885
   Sampalo MF, 2007, CLIN CHIM ACTA, V377, P154, DOI 10.1016/j.cca.2006.09.013
   Schmoelzer I, 2003, EUR J CLIN INVEST, V33, P191, DOI 10.1046/j.1365-2362.2003.01108.x
   Shimasaki Y, 1998, J AM COLL CARDIOL, V31, P1506, DOI 10.1016/S0735-1097(98)00167-3
   Song C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060454
   Song J, 2000, ASS STUD AL REP INS
   Szabo GV, 2009, PATHOL ONCOL RES, V15, P631, DOI 10.1007/s12253-009-9163-z
   Vasilakou M, 2008, ACTA CARDIOL, V63, P609, DOI 10.2143/AC.63.5.2033229
   Veldman BA, 2002, J HYPERTENS, V20, P2023, DOI 10.1097/00004872-200210000-00022
   Verschuren JJW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056262
   Wang CL, 2001, J FORMOS MED ASSOC, V100, P736
   Wei Danhong, 2002, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V19, P471
   Yoshimura M, 1998, HUM GENET, V103, P65, DOI 10.1007/s004390050785
   Yu H, 2006, RELATIONS GENE POLYM
   Zhan Y, 2005, CHINESE J CLIN REHAB, V9, P177
   Zhang K, 2012, THROMB RES, V130, P192, DOI 10.1016/j.thromres.2012.02.015
   Zigra AM, 2013, DIS MARKERS, V34, P431, DOI 10.3233/DMA-130987
NR 51
TC 21
Z9 21
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 30
PY 2014
VL 9
IS 1
AR e87196
DI 10.1371/journal.pone.0087196
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 302PJ
UT WOS:000330617100056
PM 24498040
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xiao, Y
   Yin, J
   Wei, J
   Shang, Z
AF Xiao, Yi
   Yin, Jin
   Wei, Jia
   Shang, Zhen
TI Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the
   Treatment of Cancer: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID STEM-CELL TRANSPLANTATION; PEGYLATED LIPOSOMAL DOXORUBICIN; THALIDOMIDE
   PLUS DEXAMETHASONE; DIAGNOSED MULTIPLE-MYELOMA; RANDOMIZED PHASE-III;
   INDUCTION TREATMENT; DOSE DEXAMETHASONE; CARDIAC-FAILURE; COMBINATION;
   MELPHALAN
AB Background: We conducted a systematic review and meta-analysis to clarify the incidence and risk of cardiotoxicity associated with bortezomib in cancer patients.
   Methods: Databases from PubMed, Web of Science and abstracts presented at ASCO meeting up to July 31, 2013 were searched to identify relevant studies. Eligible studies included prospective phase II and III trials evaluating bortezomib in cancer patients with adequate data on cardiotoxicity. Statistical analyses were conducted to calculate the summary incidence, odds ratio (OR) and 95% confidence intervals (CIs) by using either random effects or fixed effect models according to the heterogeneity of included studies.
   Results: A total of 5718 patients with a variety of malignancies from 25 clinical trials were included in our analysis. The incidence of all-grade and high-grade cardiotoxicity associated with bortezomib was 3.8% (95% CI: 2.6-5.6%) and 2.3% (1.63.5%), with a mortality of 3.0% (1.4-6.5%). Patients treated with bortezomib did not significantly increase the risk of all-grade (OR 1.15, 95% CI: 0.82-1.62, p = 0.41) and high-grade (OR 1.13, 95% CI: 0.58-2.24, p = 0.72) cardiotoxicity compared with patients treated with control medication. Sub-group analysis showed that the incidence of cardiotoxicity varied with tumor types, treatment regimens and phases of trials. No evidence of publication bias was observed.
   Conclusions: The use of bortezomib does not significantly increase the risk of cardiotoxicity compared to control patients. Further studies are recommended to investigate this association and risk differences among different tumor types, treatment regimens and phases of trials.
C1 [Xiao, Yi; Yin, Jin; Wei, Jia; Shang, Zhen] Huazhong Univ Sci & Technol, Dept Hematol, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Hubei, Peoples R China.
RP Xiao, Y (reprint author), Huazhong Univ Sci & Technol, Dept Hematol, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Hubei, Peoples R China.
EM xiaoyi130929@163.com
FU Natural Science Foundation of Hubei Province [2012FFB02435]; central
   university [2013QN191]
FX The study was supported by grants from the Natural Science Foundation of
   Hubei Province (No. 2012FFB02435) and the central university special
   funding (No. 2013QN191). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Albini A, 2010, JNCI-J NATL CANCER I, V102, P14, DOI 10.1093/jnci/djp440
   [Anonymous], 2008, VELCADE LABEL ACCESS
   Baiz D, 2009, BIOCHIMIE, V91, P373, DOI 10.1016/j.biochi.2008.10.015
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belch A, 2007, ANN ONCOL, V18, P116
   Besse B, 2012, LUNG CANCER, V76, P78, DOI 10.1016/j.lungcan.2011.09.006
   Bockorny M, 2012, ACTA HAEMATOL-BASEL, V128, P244, DOI 10.1159/000340050
   Bringhen S, 2010, BLOOD, V116, P4745, DOI 10.1182/blood-2010-07-294983
   Cavo M, 2010, LANCET, V376, P2075, DOI 10.1016/S0140-6736(10)61424-9
   Chanan-Khan Asher, 2004, J Support Oncol, V2, P251
   Charaf E, 2009, CURR CARDIOL REV, V5, P228, DOI 10.2174/157340309788970360
   Chen CI, 2007, J CLIN ONCOL, V25, P1570, DOI 10.1200/JCO.2006.07.8659
   Coiffier B, 2011, LANCET ONCOL, V12, P773, DOI 10.1016/S1470-2045(11)70150-4
   Dispenzieri A, 2010, LEUKEMIA, V24, P1406, DOI 10.1038/leu.2010.129
   Fanucchi MP, 2006, J CLIN ONCOL, V24, P5025, DOI 10.1200/JCO.2006.06.1853
   Fisher RI, 2006, J CLIN ONCOL, V24, P4867, DOI 10.1200/JCO.2006.07.9665
   Galimberti S, 2008, LEUKEMIA RES, V32, P103, DOI 10.1016/j.leukres.2007.05.023
   Garderet L, 2012, J CLIN ONCOL, V30, P2475, DOI 10.1200/JCO.2011.37.4918
   Gupta A, 2012, CARDIOVASC TOXICOL, V12, P184, DOI 10.1007/s12012-011-9146-7
   Hacihanefioglu A, 2008, INT J HEMATOL, V88, P219, DOI 10.1007/s12185-008-0139-7
   Harousseau JL, 2010, J CLIN ONCOL, V28, P4621, DOI 10.1200/JCO.2009.27.9158
   Hjorth M, 2012, EUR J HAEMATOL, V88, P485, DOI 10.1111/j.1600-0609.2012.01775.x
   Houot R, 2012, ANN ONCOL, V23, P1555, DOI 10.1093/annonc/mdr450
   Jakubowiak AJ, 2009, J CLIN ONCOL, V27, P5015, DOI 10.1200/JCO.2008.19.5370
   Jancso G, 2005, J CARDIOVASC PHARM, V46, P295, DOI 10.1097/01.fjc.0000175240.64444.68
   Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056/NEJMoa1002315
   Kropff M, 2007, BRIT J HAEMATOL, V138, P330, DOI 10.1111/j.1365-2141.2007.06656.x
   Lu GR, 2008, CANCER BIOL THER, V7, P603, DOI 10.4161/cbt.7.4.5564
   Mateos MV, 2006, BLOOD, V108, P2165, DOI 10.1182/blood-2006-04-019778
   Mateos MV, 2010, LANCET ONCOL, V11, P934, DOI 10.1016/S1470-2045(10)70187-X
   Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moreau P, 2011, BLOOD, V118, P5752, DOI 10.1182/blood-2011-05-355081
   NCI, 2006, CANC THER EV PROGR C
   Nowis D, 2010, AM J PATHOL, V176, P2658, DOI 10.2353/ajpath.2010.090690
   Orciuolo E, 2007, BRIT J HAEMATOL, V138, P396, DOI 10.1111/j.1365-2141.2007.06659.x
   Palumbo A, 2008, ANN ONCOL, V19, P1160, DOI 10.1093/annonc/mdn018
   Palumbo A, 2010, J CLIN ONCOL, V28, P5101, DOI 10.1200/JCO.2010.29.8216
   Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159
   Parma G, 2012, INT J GYNECOL CANCER, V22, P792, DOI 10.1097/IGC.0b013e318251051a
   Popat R, 2009, BRIT J HAEMATOL, V144, P887, DOI 10.1111/j.1365-2141.2008.07572.x
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Ruan J, 2011, J CLIN ONCOL, V29, P690, DOI 10.1200/JCO.2010.31.1142
   Smith LA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-337
   Sonneveld P, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.10.5460
   Suvannasankha A, 2006, CLIN LYMPHOMA MYELOM, V7, P131, DOI 10.3816/CLM.2006.n.050
   Takamatsu H, 2010, INT J HEMATOL, V91, P903, DOI 10.1007/s12185-010-0586-9
   Versari D, 2006, ARTERIOSCL THROM VAS, V26, P2132, DOI 10.1161/01.ATV.0000232501.08576.73
   Voortman J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-129
   YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 51
TC 42
Z9 44
U1 2
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2014
VL 9
IS 1
AR e87671
DI 10.1371/journal.pone.0087671
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 301ZC
UT WOS:000330570000168
PM 24489948
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, X
   Hu, JW
   Qiu, MT
   Li, M
   Yin, R
   Wang, J
   Xu, L
   Zhang, Q
AF Yang, Xin
   Hu, Jing-Wen
   Qiu, Man-Tang
   Li, Ming
   Yin, Rong
   Wang, Jie
   Xu, Lin
   Zhang, Qin
TI Association of Matrix Metalloproteinase-3-1171(5A > 6A) Polymorphism
   with Cancer Risk: A Meta-Analysis of 41 Studies
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; ORAL SUBMUCOUS FIBROSIS; COLORECTAL-CANCER;
   BREAST-CANCER; PROMOTER REGIONS; METALLOPROTEINASE (MMP)-1; FUNCTIONAL
   POLYMORPHISMS; HEPATOCELLULAR-CARCINOMA; GENE PROMOTER; LUNG-CANCER
AB Background and Objective: Evidence has shown that matrix metalloproteinases-3 (MMP3) is important for cancer progression. Recent studies about the association between the -1171(5A > 6A) polymorphism in MMP3 promoter region and cancer risk have yielded conflicting results.
   Methodology/Principal Findings: We performed a meta-analysis of 41 studies including 11112 cases and 11091 controls to determine whether the -1171(5A > 6A) polymorphism of MMP3 was associated with cancer risk. We assessed the strength of association and performed sub-group analyses by cancer types, ethnicity, smoking status, genotyping method, source of controls and sample size. The pooled results revealed that no significant association of the -1171(5A > 6A) polymorphism with overall cancer risk in any of four models. Further sub-group analysis revealed that individuals with the 6A allele had lower risk of gastrointestinal cancer in two models: heterozygote comparison (6A/5A vs. 5A/5A: OR = 0.74, 95% CI: 0.60-0.91; I-2 = 1.9%), and dominant model (6A/6A+6A/5A vs. 5A/5A: OR = 0.77, 95% CI: 0.64-0.94; I-2 = 29.0%). Additionally, the associations were significant in Asian populations for three models: homozygote comparison (6A/6A vs. 5A/5A, OR = 0.68, 95% CI: 0.52-0.90; I-2 = 26.7%), heterozygote comparison (6A/5A vs. 5A/5A: OR = 0.75, 95% CI: 0.58-0.98; I-2 = 0.0%), and dominant model (6A/6A+6A/5A vs. 5A/5A: OR = 0.69, 95% CI: 0.54-0.88; I-2 = 0.5%). It was noteworthy that we had a contrary finding in non-smokers: the variant 6A/6A homozygote might statistically increase cancer risk compared with 6A/5A+5A/5A genotype (OR = 1.92, 95% CI: 1.25-2.96; I-2 = 72.7%).
   Conclusion: This meta-analysis suggests that the -1171(5A > 6A) polymorphism in MMP3 promoter region is not associated with overall cancer risk, but it may contribute to decreased cancer risk in Asian population when compared with Caucasian population and significantly reduce the risk of gastrointestinal cancer.
C1 [Yang, Xin] Nanjing Med Univ, Clin Coll 1, Nanjing, Jiangsu, Peoples R China.
   [Yang, Xin; Hu, Jing-Wen; Qiu, Man-Tang; Li, Ming; Yin, Rong; Xu, Lin; Zhang, Qin] Nanjing Med Univ, Dept Thorac Surg, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Nanjing, Jiangsu, Peoples R China.
   [Yang, Xin; Hu, Jing-Wen; Qiu, Man-Tang; Li, Ming; Yin, Rong; Wang, Jie; Xu, Lin; Zhang, Qin] Jiangsu Key Lab Mol & Translat Canc Res, Nanjing, Jiangsu, Peoples R China.
   [Wang, Jie] Nanjing Med Univ, Dept Sci Res, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Nanjing, Jiangsu, Peoples R China.
RP Xu, L (reprint author), Nanjing Med Univ, Dept Thorac Surg, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Nanjing, Jiangsu, Peoples R China.
EM xulin83cn@gmail.com; ctzs123@sina.com
RI Qiu, Mantang/L-8937-2019
FU National Natural Science Foundation of China [81201830, 81372321];
   special fund of Jiangsu Key laboratory of Cancer Molecular Biology and
   Translational Medicine [BM2013007]
FX This work was supported by the National Natural Science Foundation of
   China (81201830, 81372321), and the special fund of Jiangsu Key
   laboratory of Cancer Molecular Biology and Translational
   Medicine(BM2013007). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Basset P, 1997, MATRIX BIOL, V15, P535, DOI 10.1016/S0945-053X(97)90028-7
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Biondi ML, 2000, CLIN CHEM, V46, P2023
   BOISSEL JP, 1988, EUR J CLIN PHARMACOL, V34, P535, DOI 10.1007/BF00615213
   BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366
   Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823
   Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260
   Chaudhary AK, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-369
   Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8
   Dey S, 2012, MOL CARCINOGEN, V51, pE42, DOI 10.1002/mc.21837
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elander N, 2006, ANTICANCER RES, V26, P791
   Fakhoury HMA, 2012, GENET TEST MOL BIOMA, V16, P988, DOI 10.1089/gtmb.2012.0042
   Fang SM, 2005, CARCINOGENESIS, V26, P481, DOI 10.1093/carcin/bgh327
   Fathy M, 2013, MOL DIAGN THER
   Ghilardi G, 2002, CLIN CANCER RES, V8, P3820
   Gonzalez-Arriaga P, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-121
   Grudny Jacek, 2013, Pneumonol Alergol Pol, V81, P308
   Han H, 2008, J SHANXI MED, V37, P1088
   Hashimoto T, 2004, CANCER LETT, V211, P19, DOI 10.1016/j.canlet.2004.01.032
   Hinoda Y, 2002, INT J CANCER, V102, P526, DOI 10.1002/ijc.10750
   Hirata H, 2004, CARCINOGENESIS, V25, P2379, DOI 10.1093/carcin/bgh254
   Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6
   Kader AK, 2006, CANCER RES, V66, P11644, DOI 10.1158/0008-5472.CAN-06-1212
   Krippl P, 2004, CLIN CANCER RES, V10, P3518, DOI 10.1158/1078-0432.CCR-04-0010
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lei HX, 2007, BREAST CANCER RES TR, V103, P61, DOI 10.1007/s10549-006-9345-2
   Lei HX, 2002, CLIN CHEM, V48, P798
   Li DH, 2002, CANCER RES, V62, P4566
   Li Y, 2006, GYNECOL ONCOL, V101, P92, DOI 10.1016/j.ygyno.2005.09.058
   Li Yan, 2005, Zhonghua Fu Chan Ke Za Zhi, V40, P472
   Lievre A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-270
   Lu Zhong-Qiang, 2007, Ai Zheng, V26, P463
   Massova I, 1998, FASEB J, V12, P1075
   Moher D, 2011, EPIDEMIOLOGY, V22, P128, DOI 10.1097/EDE.0b013e3181fe7825
   Motovali-Bashi M, 2012, J RES MED SCI, V17, P962
   Nishizawa R, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-187
   Okamoto K, 2005, RES COMMUN MOL PATH, V117, P77
   Okamoto K, 2010, INTERNAL MED, V49, P887, DOI 10.2169/internalmedicine.49.3268
   Pan HF, 2011, LUPUS, V20, P945, DOI 10.1177/0961203311400114
   Peng B, 2010, MUTAGENESIS, V25, P41, DOI 10.1093/mutage/gep041
   Qiu MT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050887
   Smolarz Beata, 2003, Pol J Pathol, V54, P233
   Somerville RPT, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-6-216
   Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347
   Su L, 2006, CARCINOGENESIS, V27, P1024, DOI 10.1093/carcin/bgi283
   Tu HF, 2006, J ORAL PATHOL MED, V35, P99, DOI 10.1111/j.1600-0714.2006.00370.x
   Vairaktaris E, 2009, ORAL ONCOL, V45, P247, DOI 10.1016/j.oraloncology.2008.05.003
   Vairaktaris E, 2007, ANTICANCER RES, V27, P4095
   Van Themsche C, 2004, BIOCHEM BIOPH RES CO, V315, P884, DOI 10.1016/j.bbrc.2004.01.144
   Wang J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050790
   Woo M, 2007, J GASTROEN HEPATOL, V22, P1064, DOI 10.1111/j.1440-1746.2007.04424.x
   Wynder E L, 1992, J Natl Cancer Inst Monogr, P87
   Xu EP, 2006, DIS COLON RECTUM, V49, P1439, DOI 10.1007/s10350-006-0652-9
   Yang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062181
   YE S, 1995, BRIT HEART J, V73, P209
   Yi YC, 2010, CLIN CHEM LAB MED, V48, P337, DOI 10.1515/CCLM.2010.082
   Yin L, 2000, ARCH DERMATOL RES, V292, P188, DOI 10.1007/s004030050476
   Zhai Y, 2007, GUT, V56, P445, DOI 10.1136/gut.2006.112706
   Zhang JH, 2004, CARCINOGENESIS, V25, P2519, DOI 10.1093/carcin/bgh269
   Zhou G, 2007, HUM MUTAT, V28, P1091, DOI 10.1002/humu.20570
   Zinzindohoue F, 2004, ANTICANCER RES, V24, P2021
NR 62
TC 6
Z9 6
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2014
VL 9
IS 1
AR e87562
DI 10.1371/journal.pone.0087562
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 301ZC
UT WOS:000330570000160
PM 24489939
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhu, HL
   Xi, Q
   Liu, LY
   Wang, JN
   Gu, MJ
AF Zhu, Hongling
   Xi, Qian
   Liu, Lianyong
   Wang, Jingnan
   Gu, Mingjun
TI Quantitative Assessment of Common Genetic Variants on FOXE1 and
   Differentiated Thyroid Cancer Risk
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; HUMAN-DISEASE; CLEFT-PALATE; SUSCEPTIBILITY;
   CARCINOMA; LOCI; METAANALYSIS; POLYMORPHISMS; CONFIRMATION; POPULATION
AB Forkhead box E1 encodes the transcription factor FOXE1 (or TTF-2), which together with Homeobox protein NKX2-1, PAX8 and HHEX, are pivotal proteins required for thyroid gland formation, differentiation and function. Recently, genome-wide association studies have identified FOXE1 as a thyroid cancer (TC) susceptibility gene in populations of European descent. After that, a number of studies reported that the rs965513, rs1867277, and rs71369530 polymorphism in FOXE1 has been implicated in TC risk. However, the causal variants remain unknown. To derive a more precise estimation of the relationship, a meta-analysis of 9,828 TC cases and 109,995 controls from 14 case-control studies was performed. Overall, significant results were observed for rs965513 (OR = 1.71, 95% CI: 1.59-1.85, P<10(-5)), rs1867277 (OR = 1.64, 95% CI: 1.51-1.78, P<10(-5)) and rs71369530 (OR = 2.01, 95% CI: 1.66-2.44, P<10(-5)) polymorphism. In the subgroup analysis by ethnicity, we found that rs965513 polymorphism confer high risk for Caucasians with per-allele OR of 1.80 (95% CI: 1.69-1.92, P<10(-5)) compared to East Asians of 1.35 (95% CI: 1.09-1.67, P = 0.006). There was strong evidence of heterogeneity, which largely disappeared after stratification by ethnicity. In the subgroup analysis by sample size, and study design, significantly increased risks were found for the polymorphism. In conclusion, this meta-analysis demonstrated that common variations of FOXE1 are a risk factor associated with increased TC susceptibility.
C1 [Zhu, Hongling; Xi, Qian; Liu, Lianyong; Wang, Jingnan; Gu, Mingjun] Shanghai Pudong New Area Gongli Hosp, Dept Endocrine, Shanghai, Peoples R China.
RP Gu, MJ (reprint author), Shanghai Pudong New Area Gongli Hosp, Dept Endocrine, Shanghai, Peoples R China.
EM mingjun_gu@163.com
FU National Natural Science Foundation of China [81272722]
FX This work was supported by National Natural Science Foundation of China
   (81272722). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Amundadottir LT, 2004, PLOS MED, V1, P229, DOI 10.1371/journal.pmed.0010065
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bullock M, 2012, J CLIN ENDOCR METAB, V97, pE1814, DOI 10.1210/jc.2012-1456
   Carre A, 2007, HUM GENET, V122, P467, DOI 10.1007/s00439-007-0420-5
   Clifton-Bligh RJ, 1998, NAT GENET, V19, P399
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Damiola F, 2014, INT J CANCER, V134, P1659, DOI 10.1002/ijc.28483
   Dathan N, 2002, DEV DYNAM, V224, P450, DOI 10.1002/dvdy.10118
   De Felice M, 1998, NAT GENET, V19, P395
   DeLellis RA, 2004, PATHOLOGY GENETICS T, P320
   Denny JC, 2011, AM J HUM GENET, V89, P529, DOI 10.1016/j.ajhg.2011.09.008
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gudmundsson J, 2012, NAT GENET, V44, P319, DOI 10.1038/ng.1046
   Gudmundsson J, 2009, NAT GENET, V41, P460, DOI 10.1038/ng.339
   Hemminki K, 2006, NAT REV GENET, V7, P958, DOI 10.1038/nrg2009
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hrafnkelsson J, 2001, J MED GENET, V38, P189, DOI 10.1136/jmg.38.3.189
   Jazdzewski K, 2009, P NATL ACAD SCI USA, V106, P1502, DOI 10.1073/pnas.0812591106
   Jones AM, 2012, J MED GENET, V49, P158, DOI 10.1136/jmedgenet-2011-100586
   Kallel R, 2010, CANCER BIOMARK, V8, P43, DOI 10.3233/DMA-2011-0824
   Kohler A, 2013, J CLIN ENDOCR METAB, V98, pE1674, DOI 10.1210/jc.2013-1941
   Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836
   Landa I, 2009, PLOS GENET, V5
   Li DW, 2006, HUM MOL GENET, V15, P1995, DOI 10.1093/hmg/ddl122
   Liyanarachchi S, 2013, THYROID, V23, P1532, DOI 10.1089/thy.2013.0102
   Matsuse M, 2011, J MED GENET, V48, P645, DOI 10.1136/jmedgenet-2011-100063
   McClellan J, 2010, CELL, V141, P210, DOI 10.1016/j.cell.2010.03.032
   Parlato R, 2004, DEV BIOL, V276, P464, DOI 10.1016/j.ydbio.2004.08.048
   Ruiz-Llorente S, 2007, CANCER RES, V67, P9561, DOI 10.1158/0008-5472.CAN-07-1638
   Schneider AB, 2005, NAT CLIN PRACT ENDOC, V1, P82, DOI 10.1038/ncpendmet0022
   Sequeira MJ, THYROID, V11, P995
   Takahashi M, 2010, HUM MOL GENET, V19, P2516, DOI 10.1093/hmg/ddq123
   Tomaz RA, 2012, CLIN ENDOCRINOL, V77, P926, DOI 10.1111/j.1365-2265.2012.04505.x
   Wang YL, 2013, J MED GENET, V50, P689, DOI 10.1136/jmedgenet-2013-101687
   Williams D, 2002, NAT REV CANCER, V2, P543, DOI 10.1038/nrc845
   Wokolorczyk D, 2008, CANCER RES, V68, P9982, DOI 10.1158/0008-5472.CAN-08-1838
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Wu S, 2013, PLOS ONE, V8
   Zhou B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066865
NR 40
TC 19
Z9 19
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2014
VL 9
IS 1
AR e87332
DI 10.1371/journal.pone.0087332
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 301ZC
UT WOS:000330570000133
PM 24489898
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, L
   Wang, XF
   Ma, YS
   Xia, Q
   Zhang, F
   Fu, D
   Wang, YC
AF Zhang, Liang
   Wang, Xiao-Feng
   Ma, Yu-Shui
   Xia, Qing
   Zhang, Feng
   Fu, Da
   Wang, Yi-Chao
TI Quantitative Assessment of the Influence of TP63 Gene Polymorphisms and
   Lung Cancer Risk: Evidence Based on 93,751 Subjects
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCUS; TUMOR-SUPPRESSOR;
   IDENTIFIES 2; METAANALYSIS; SMOKING; P63; ADENOCARCINOMA; POPULATION;
   JAPANESE
AB Background: Several genome-wide association studies on lung cancer (LC) have reported similar findings of a new susceptibility locus, 3q28. After that, a number of studies reported that the rs10937405, and rs4488809 polymorphism in chromosome 3q28 has been implicated in LC risk. However, the studies have yielded contradictory results.
   Methods: PubMed, ISI web of science, EMBASE and the Chinese National Knowledge Infrastructure databases were systematically searched to identify relevant studies. Data were abstracted independently by two reviewers. A meta-analysis was performed to examine the association between rs10937405, rs4488809 polymorphism at 3q28 and susceptibility to LC. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. Heterogeneity and publication bias were also tested.
   Results: A total of 9 studies including 35,961 LC cases and 57,790 controls were involved in this meta-analysis. An overall random-effects per-allele OR of 1.19 (95% CI: 1.14-1.25; P<10(-5)) and 1.19 (95% CI: 1.13-1.25; P<10(-5)) was found for the rs10937405 and rs4488809 polymorphism respectively. Similar results were also observed using dominant or recessive genetic model. After stratified by ethnicity, significant associations were found among East Asians (per-allele OR = 1.22, 95% CI: 1.17-1.27; P<10(-5)); whereas no significant associations were found among Caucasians for rs10937405. In the sub-group analysis by sample size, significantly increased risks were found for these polymorphisms in all genetic models. When analyzed according to histological type, the effects of rs10937405, and rs4488809 at 3q28 on the risk of lung cancer were significant mostly for lung adenocarcinoma.
   Conclusions: Our findings demonstrated that rs10937405-G allele and rs4488809-G allele might be risk-conferring factors for the development of lung cancer, especially for East Asian populations.
C1 [Zhang, Liang; Wang, Xiao-Feng; Xia, Qing; Zhang, Feng; Fu, Da; Wang, Yi-Chao] Fudan Univ, Zhongshan Hosp, Dept Orthopaed, Shanghai 200433, Peoples R China.
   [Ma, Yu-Shui] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Nucl Med, Shanghai 200092, Peoples R China.
   [Fu, Da] Shanghai Jiao Tong Univ, Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai 200030, Peoples R China.
RP Fu, D (reprint author), Fudan Univ, Zhongshan Hosp, Dept Orthopaed, Shanghai 200433, Peoples R China.
EM superdafu@hotmail.com; wang_yichao001@126.com
FU National Natural Science Foundation of China [81201535, 81302065];
   Knowledge Innovation Program of Shanghai Institutes for Biological
   Sciences, Chinese Academy of Sciences [2012KIP203]; Shanghai Natural
   Science Foundation [12ZR1436000]
FX National Natural Science Foundation of China (81201535, 81302065), the
   Knowledge Innovation Program of Shanghai Institutes for Biological
   Sciences, Chinese Academy of Sciences (2012KIP203) and Shanghai Natural
   Science Foundation (12ZR1436000). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Daigo Y, 2008, GEN THORAC CARDIOVAS, V56, P43, DOI 10.1007/s11748-007-0211-x
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Finlan LE, 2007, CELL CYCLE, V6, P1062, DOI 10.4161/cc.6.9.4162
   Flores ER, 2007, CELL CYCLE, V6, P300, DOI 10.4161/cc.6.3.3793
   Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019
   Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   Hosgood HD, 2012, HUM GENET, V131, P1197, DOI 10.1007/s00439-012-1144-8
   Hsiao YH, 2010, INT J BIOL SCI, V6, P428
   Hu QY, 2014, TUMOR BIOL, V35, P1863, DOI 10.1007/s13277-013-1248-3
   Hu ZB, 2011, NAT GENET, V43, P792, DOI 10.1038/ng.875
   Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885
   Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644
   Lan Q, 2012, NAT GENET, V44, P1330, DOI 10.1038/ng.2456
   Li DW, 2006, HUM MOL GENET, V15, P1995, DOI 10.1093/hmg/ddl122
   McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254
   Miki D, 2010, NAT GENET, V42, P893, DOI 10.1038/ng.667
   Munafo MR, 2004, TRENDS GENET, V20, P439, DOI 10.1016/j.tig.2004.06.014
   Osann K E, 1998, Curr Opin Pulm Med, V4, P198, DOI 10.1097/00063198-199807000-00002
   Petitjean A, 2008, CARCINOGENESIS, V29, P273, DOI 10.1093/carcin/bgm258
   Shiraishi K, 2012, NAT GENET, V44, P900, DOI 10.1038/ng.2353
   Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003
   Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846
   Timofeeva MN, 2012, HUM MOL GENET, V21, P4980, DOI 10.1093/hmg/dds334
   Vineis P, 2004, JNCI-J NATL CANCER I, V96, P99, DOI 10.1093/jnci/djh014
   Walser Tonya, 2008, Proc Am Thorac Soc, V5, P811, DOI 10.1513/pats.200809-100TH
   Wang YF, 2011, CANCER EPIDEM BIOMAR, V20, P1453, DOI 10.1158/1055-9965.EPI-11-0042
   Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273
   Wu J, 2010, J CELL BIOCHEM, V109, P702, DOI 10.1002/jcb.22449
   Zhang YJ, 2012, GENE, V497, P93, DOI 10.1016/j.gene.2012.01.053
NR 34
TC 2
Z9 2
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 23
PY 2014
VL 9
IS 1
AR e87004
DI 10.1371/journal.pone.0087004
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 297XI
UT WOS:000330288000183
PM 24466311
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Cai, XL
   Liu, CB
   Mou, SH
AF Cai, Xianli
   Liu, Chibo
   Mou, Sihua
TI Association between Fat Mass- and Obesity-Associated (FTO) Gene
   Polymorphism and Polycystic Ovary Syndrome: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID INSULIN-RESISTANCE; METABOLIC SYNDROME; WOMEN; VARIANTS; WEIGHT; IMPACT;
   INDEX; BIAS; BMI
AB Aims: Many studies have investigated the relationship between FTO gene polymorphism and polycystic ovary syndrome (PCOS) susceptibility but revealed mixed results. In this study, we aimed to perform a meta-analysis to clarify this association.
   Methods: Published literature from PubMed, Embase and CNKI was retrieved. Meta-analysis was performed to calculate pooled odds ratio (OR) with 95% confidence interval (CI) using the random-or fix-effects model.
   Results: A total of 5 studies (4778 cases and 4272 controls) were included in our meta-analysis. The results suggested that FTO rs9939609 polymorphism (or its proxy) was marginally associated with PCOS risk after adjustment for body mass index (BMI) (OR = 1.26; 95% CI: 1.02-1.55). However, the marginal association was not stable after sensitivity analysis. In the subgroup analysis by ethnicity, the association was significant in East Asians (OR = 1.43, 95% CI = 1.30-1.59) but not in Caucasians (OR = 1.04, 95% CI = 0.85-1.29).
   Conclusions: Our present meta-analysis indicated that FTO rs9939609 polymorphism (or its proxy) might not be associated with risk of PCOS in overall population. However, in East Asians, there might be a direct association between FTO variant and PCOS risk, which is independent of BMI (adiposity).
C1 [Cai, Xianli] Taizhou Municipal Hosp, Dept Gynaecol, Taizhou, Peoples R China.
   [Liu, Chibo; Mou, Sihua] Taizhou Municipal Hosp, Dept Clin Lab, Taizhou, Peoples R China.
RP Mou, SH (reprint author), Taizhou Municipal Hosp, Dept Clin Lab, Taizhou, Peoples R China.
EM sihuamou@163.com
CR Asuncion M, 2000, J CLIN ENDOCR METAB, V85, P2434, DOI 10.1210/jc.85.7.2434
   Attaoua R, 2008, BIOCHEM BIOPH RES CO, V373, P230, DOI 10.1016/j.bbrc.2008.06.039
   BALEN AH, 1995, HUM REPROD, V10, P2107, DOI 10.1093/oxfordjournals.humrep.a136243
   Barber TM, 2008, DIABETOLOGIA, V51, P1153, DOI 10.1007/s00125-008-1028-6
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   CLEMENT K, 2007, OBESITY GENOMICS POS, P19
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Diamanti-Kandarakis E, 2006, TRENDS MOL MED, V12, P324, DOI 10.1016/j.molmed.2006.05.006
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ewens KG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016390
   Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634
   Freathy RM, 2008, DIABETES, V57, P1419, DOI 10.2337/db07-1466
   Gambineri A, 2002, INT J OBESITY, V26, P883, DOI [10.1038/sj.ijo/0801994, 10.1038/sj.ijo.0801994]
   Gu JP, 2012, CHINESE J CLIN MED, V19, P213
   Hatziagelaki E, 2012, HORM METAB RES, V44, P810, DOI 10.1055/s-0032-1321817
   Kim JJ, 2012, CLIN ENDOCRINOL, V77, P439, DOI 10.1111/j.1365-2265.2012.04389.x
   Kosova G, 2012, MOL CELL ENDOCRINOL, DOI [10.1016/j.mce.2012.10.00, DOI 10.1016/J.MCE.2012.10.00]
   Kowalska I, 2009, DIABETES METAB, V35, P328, DOI 10.1016/j.diabet.2009.03.004
   Kowalska I, 2012, CLIN ENDOCRINOL, V77, P120, DOI 10.1111/j.1365-2265.2012.04379.x
   Legro RS, 2000, ANN NY ACAD SCI, V900, P193
   Li CY, 2010, DIABETES CARE, V33, P1618, DOI 10.2337/dc09-1788
   Li T, 2013, PLOS ONE, V8
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Rotterdam ESHRE/ ASRM-Sponsored PCOS consensus workshop group, 2004, HUMAN REPROD, V19, P41, DOI [10.1093/humrep/deh098, DOI 10.1093/HUMREP/DEH098]
   Saxena R, 2013, ACTA DIABETOL, V50, P451, DOI 10.1007/s00592-012-0383-4
   Shi YH, 2007, NEUROENDOCRINOL LETT, V28, P807
   Tan S, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-12
   Timpson NJ, 2008, AM J CLIN NUTR, V88, P971
   Wardle J, 2008, J CLIN ENDOCR METAB, V93, P3640, DOI 10.1210/jc.2008-0472
   Wehr E, 2010, METABOLISM, V59, P575, DOI 10.1016/j.metabol.2009.08.023
   Welt CK, 2006, J CLIN ENDOCR METAB, V91, P4361, DOI 10.1210/jc.2006-1191
   Willer CJ, 2009, NAT GENET, V41, P25, DOI 10.1038/ng.287
   Wojciechowski P, 2012, DIABETOLOGIA, V55, P2636, DOI 10.1007/s00125-012-2638-6
   Yan Q, 2009, ENDOCRINE, V36, P377, DOI 10.1007/s12020-009-9257-0
   2004, HUMAN REPROD OXFORD, V81, P19
NR 35
TC 11
Z9 11
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2014
VL 9
IS 1
AR e86972
DI 10.1371/journal.pone.0086972
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 297VL
UT WOS:000330283100238
PM 24466303
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Cao, H
   Hu, XH
   Zhang, Q
   Li, J
   Wang, JP
   Shao, Y
   Liu, B
   Xin, SJ
AF Cao, Hui
   Hu, Xinhua
   Zhang, Qiang
   Li, Jun
   Wang, Junpeng
   Shao, Yang
   Liu, Bing
   Xin, Shijie
TI Homocysteine Level and Risk of Abdominal Aortic Aneurysm: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SMOOTH-MUSCLE-CELLS; PLASMA HOMOCYSTEINE; HEART-DISEASE;
   HYPERHOMOCYSTEINAEMIA; STROKE
AB Objectives: Previous studies have reported inconsistent findings regarding the association between elevated plasma homocysteine (Hcy) levels and abdominal aortic aneurysm (AAA). We investigated this association between Hcy levels in patients with AAA and unaffected controls by conducting a meta-analysis and systematic review.
   Methods: We conducted a systematic literature search (up to August 2013) of the PubMed database and Embase. We selected observational studies that evaluated Hcy levels in subjects with AAA compared to unaffected controls. Criteria for inclusion were the assessment of baseline Hcy and risk of AAA as an outcome. The results were presented as odd ratio (OR) and corresponding 95% confidence intervals (CI) comparing AAA patients to the control subjects.
   Results: 7 studies with 6,445 participants were identified and analyzed. Overall, elevated plasma Hcy was associated with an increased risk of AAA (3.29; 95% CI 1.66-6.51). The pooled adjusted OR from a random effect model of only men participants in the AAA compared with the control group was 2.36 (95% CI 0.63-8.82).
   Conclusion: This meta-analysis and systematic review suggested that Hcy significantly increased the risk of AAA.
C1 [Cao, Hui; Hu, Xinhua; Zhang, Qiang; Li, Jun; Wang, Junpeng; Shao, Yang; Liu, Bing; Xin, Shijie] China Med Univ, Affiliated Hosp 1, Dept Vasc & Thyriod Surg, Shenyang, Peoples R China.
RP Hu, XH (reprint author), China Med Univ, Affiliated Hosp 1, Dept Vasc & Thyriod Surg, Shenyang, Peoples R China.
EM xhhu@mail.cmu.edu.cn
OI Xin, Shijie/0000-0001-6278-8794
FU National Nature Science Foundation of China [81070254, 30872527,
   30672048]
FX This work was supported by National Nature Science Foundation of China
   (81070254, 30872527 and 30672048). URL:
   http://www.nsfc.gov.cn/Portal0/default152.htm. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berti C, 2012, J NUTR METAB, DOI 10.1155/2012/470656
   Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894
   Brunelli T, 2000, J VASC SURG, V32, P531, DOI 10.1067/mva.2000.107563
   Cahill MT, 2003, AM J OPHTHALMOL, V136, P1136, DOI 10.1016/S0002-9394(03)00571-3
   Casas JP, 2005, LANCET, V365, P224, DOI 10.1016/S0140-6736(05)17742-3
   Cosford PA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002945.pub2
   den Heijer M, 2005, EUR J HUM GENET, V13, P753, DOI 10.1038/sj.ejhg.5201389
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feng J, 2009, CARDIOVASC RES, V84, P155, DOI 10.1093/cvr/cvp182
   Forsdahl SH, 2009, CIRCULATION, V119, P2202, DOI 10.1161/CIRCULATIONAHA.108.817619
   Giusti B, 2008, J MED GENET, V45, P721, DOI 10.1136/jmg.2008.057851
   Go AS, 2013, CIRCULATION, V127, P143, DOI 10.1161/CIR.0b013e318282ab8f
   Harrison SC, 2013, EUR HEART J, V34, P3707, DOI 10.1093/eurheartj/ehs354
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Humphrey LL, 2008, MAYO CLIN PROC, V83, P1203, DOI 10.4065/83.11.1203
   Jee SH, 2002, HUM GENET, V111, P128, DOI 10.1007/s00439-002-0757-8
   JourdheuilRahmani D, 1997, CARDIOVASC RES, V34, P597, DOI 10.1016/S0008-6363(97)00048-5
   Ke XD, 2010, MOL CELL BIOCHEM, V335, P203, DOI 10.1007/s11010-009-0270-7
   Krishna SM, 2013, ATHEROSCLEROSIS, V228, P295, DOI 10.1016/j.atherosclerosis.2013.02.019
   Liu ZY, 2012, CIRC RES, V111, P1261, DOI [10.1161/circresaha.112.270520, 10.1161/CIRCRESAHA.112.270520]
   Maegdefessel L, 2013, INT J MOL SCI, V14, P14374, DOI 10.3390/ijms140714374
   Marti-Carvajal AJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006612.pub3
   Moroz P, 2007, ANZ J SURG, V77, P329, DOI 10.1111/j.1445-2197.2007.04052.x
   Peeters AC, 2007, J VASC SURG, V45, P701, DOI 10.1016/j.jvs.2006.12.019
   SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693
   Sofi F, 2005, THROMB HAEMOSTASIS, V94, P1094, DOI 10.1160/TH05-06-0431
   Spark JI, 2003, EUR J VASC ENDOVASC, V26, P558, DOI 10.1016/S1078-5884(03)00381-2
   van Wijngaarden JP, 2013, J NUTR METAB, DOI 10.1155/2013/486186
   Wald DS, 2002, BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202
   Warsi AA, 2004, EUR J VASC ENDOVASC, V27, P75, DOI 10.1016/j.ejvs.2003.09.001
   Wells G., 2013, NEWCASTLE OTTAWA SCA
   Wong YYE, 2013, J VASC SURG, V58, P364, DOI 10.1016/j.jvs.2013.01.046
   Yang J, 2012, BONE, V51, P376, DOI 10.1016/j.bone.2012.05.024
NR 35
TC 15
Z9 16
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 21
PY 2014
VL 9
IS 1
AR e85831
DI 10.1371/journal.pone.0085831
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 297GT
UT WOS:000330244500124
PM 24465733
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, X
   Wang, Z
   Yan, YL
   Li, P
   Yang, Z
   Qin, LY
   Mo, WN
AF Chen, Xu
   Wang, Zhe
   Yan, Yulan
   Li, Ping
   Yang, Zheng
   Qin, Lingyan
   Mo, Wuning
TI XRCC3 C18067T Polymorphism Contributes a Decreased Risk to Both Basal
   Cell Carcinoma and Squamous Cell Carcinoma: Evidence from a
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID REPAIR GENE XRCC3; SINGLE-NUCLEOTIDE POLYMORPHISMS; HOMOLOGOUS
   RECOMBINATION REPAIR; SKIN-CANCER RISK; DNA-REPAIR; T241M POLYMORPHISM;
   CUTANEOUS MELANOMA; GENOTYPING ERRORS; SUSCEPTIBILITY; VARIANT
AB Background: The X-ray repair cross-complementing group 3 (XRCC3) in homologous recombination repair (HRR) pathway plays a very important role in DNA double-strand break repair (DSBR). Variations in the XRCC3 gene might lead to altered protein structure or function which may change DSBR efficiency and result in cancer. The XRCC3 C18067T polymorphism has been reported to be associated with skin cancer susceptibility, yet the results of these previous results have been inconsistent or controversial. To derive a more precise estimation of the association, we conducted a meta-analysis.
   Methods: The quality of the studies was assessed according to a predefined scale. The association between the XRCC3 C18067T polymorphism and skin cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs).
   Results: Overall, no significant association was observed between XRCC3 C18067T polymorphism and skin cancer risk in any genetic model. Stratified analyses according to tumor type, significant association was found in the relationship between XRCC3 C18067T polymorphism and nonmelanoma skin cancer risk (homozygote comparison TT versus CC: OR = 0.74, 95% CI = 0.61-0.90, P = 0.003; recessive model TT versus TC/CC: OR = 0.81, 95% CI = 0.68-0.95, P = 0.01). Furthermore, significant association was also observed in XRCC3 C18067T polymorphism with both basal cell carcinoma risk (homozygote comparison TT versus CC: OR = 0.70, 95% CI = 0.53-0.92, P = 0.011; recessive model TT versus. TC/CC: OR = 0.74, 95% CI = 0.600.92, P = 0.007) and squamous cell carcinoma risk (heterozygote comparison TT versus. CC: OR = 0.81, 95% CI = 0.67-0.99, P = 0.04; dominant model TT/TC versus. CC: OR = 0.81, 95% CI = 0.68-0.98, P = 0.029).
   Conclusion: The present meta-analysis demonstrates that XRCC3 C18067T polymorphism was not associated with risk of cutaneous melanoma but contributed a decreased risk to both basal cell carcinoma and squamous cell carcinoma.
C1 [Chen, Xu; Yan, Yulan; Li, Ping; Yang, Zheng; Qin, Lingyan; Mo, Wuning] Guangxi Med Univ, Affiliated Hosp 1, Dept Clin Lab, Nanning, Guangxi, Peoples R China.
   [Wang, Zhe] Guangxi Med Univ, Affiliated Hosp 1, Div Spine & Osteopathy Surg, Nanning, Guangxi, Peoples R China.
RP Mo, WN (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Clin Lab, Nanning, Guangxi, Peoples R China.
EM mown16300@126.com
RI Wang, Zhe/K-1663-2016
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bertram CG, 2004, J INVEST DERMATOL, V122, P429, DOI 10.1046/j.0022-202X.2003.12541.x
   Brenneman MA, 2000, MUTAT RES-DNA REPAIR, V459, P89, DOI 10.1016/S0921-8777(00)00002-1
   Capell BC, 2009, J INVEST DERMATOL, V129, P2340, DOI 10.1038/jid.2009.103
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duan ZG, 2002, CANCER EPIDEM BIOMAR, V11, P1142
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Festa F, 2005, MUTAT RES-FUND MOL M, V574, P105, DOI 10.1016/j.mrfmmm.2005.01.026
   Figl A, 2010, MUTAT RES-GEN TOX EN, V702, P8, DOI 10.1016/j.mrgentox.2010.06.011
   GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807
   Goncalves FT, 2011, J DERMATOL SCI, V64, P59, DOI 10.1016/j.jdermsci.2011.06.003
   Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513
   Griffin CS, 2002, MUTAT RES-FUND MOL M, V504, P149, DOI 10.1016/S0027-5107(02)00088-X
   Han JL, 2004, CANCER RES, V64, P3009, DOI 10.1158/0008-5472.CAN-04-0246
   Han JL, 2004, CANCER EPIDEM BIOMAR, V13, P330, DOI 10.1158/1055-9965.EPI-03-0332
   Han SZ, 2006, EUR J HUM GENET, V14, P1136, DOI 10.1038/sj.ejhg.5201681
   He XF, 2013, GENE, V523, P10, DOI 10.1016/j.gene.2013.03.071
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hosking L, 2004, EUR J HUM GENET, V12, P395, DOI 10.1038/sj.ejhg.5201164
   Hu YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035220
   Jacobsen NR, 2003, CANCER EPIDEM BIOMAR, V12, P584
   Jiang DK, 2011, J INVEST DERMATOL, V131, P220, DOI 10.1038/jid.2010.270
   Leiter U, 2008, ADV EXP MED BIOL, V624, P89, DOI 10.1007/978-0-387-77574-6_8
   Lin JS, 2011, ANN INTERN MED, V154, P190, DOI 10.7326/0003-4819-154-3-201102010-00009
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Manuguerra M, 2006, AM J EPIDEMIOL, V164, P297, DOI 10.1093/aje/kwj189
   Matullo G, 2006, CARCINOGENESIS, V27, P997, DOI 10.1093/carcin/bgi280
   Mitchell AA, 2003, AM J HUM GENET, V72, P598, DOI 10.1086/368203
   Romanowicz-Makowska H, 2012, J OBSTET GYNAECOL RE, V38, P918, DOI 10.1111/j.1447-0756.2011.01811.x
   Scherer D, 2008, INT J CANCER, V122, P1787, DOI 10.1002/ijc.23257
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Thirumaran RK, 2006, CARCINOGENESIS, V27, P1676, DOI 10.1093/carcin/bgi381
   Thompson JF, 2009, LANCET, V374, P362, DOI 10.1016/S0140-6736(09)61397-0
   Ulrich C, 2008, AM J TRANSPLANT, V8, P2192, DOI 10.1111/j.1600-6143.2008.02386.x
   Wang YG, 2012, ASIAN PAC J CANCER P, V13, P111, DOI 10.7314/APJCP.2012.13.1.111
   Winsey SL, 2000, CANCER RES, V60, P5612
   Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154
   Young C, 2009, OCCUP MED-OXFORD, V59, P82, DOI 10.1093/occmed/kqn170
   Yu Z, 1999, ENVIRON MOL MUTAGEN, V33, P3, DOI 10.1002/(SICI)1098-2280(1999)33:1<3::AID-EM2>3.0.CO;2-L
   Zhang LQ, 2012, MUTAGENESIS, V27, P67, DOI 10.1093/mutage/ger062
NR 42
TC 4
Z9 5
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 15
PY 2014
VL 9
IS 1
AR e84195
DI 10.1371/journal.pone.0084195
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 297DH
UT WOS:000330235100019
PM 24454720
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xu, Y
   Wang, J
   Dong, WG
AF Xu, Yu
   Wang, Jun
   Dong, Weiguo
TI GSTM3 A/B Polymorphism and Risk for Head and Neck Cancer: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GLUTATHIONE-S-TRANSFERASE; SQUAMOUS-CELL CARCINOMA; ORAL-CANCER; GENE
   LOCI; COLORECTAL-CANCER; SUSCEPTIBILITY; GSTT1; GENOTYPES; GSTP1;
   CYTOCHROME-P450
AB Background: Glutathione S-transferase M3 (GSTM3) is an important member of the GSTs that plays a critical role in the development of head and neck cancer (HNC). Several studies have investigated between the GSTM3 A/B polymorphism and risk of HNC, however, the results remain controversial. The aim of this meta-analysis is to evaluate the association between the GSTM3 A/B polymorphism and the risk of HNC.
   Methods: All eligible case-control studies published up to July 2013 were identified by searching PubMed and Web of Science. The HNC risk associated with the GSTM3 A/B polymorphism was estimated for each study by odds ratios (OR) together with its 95% confidence interval (CI), respectively.
   Results: Fourteen studies from ten publications with 2110 patients and 2259 controls were included. Overall, the GSTM3 A/B polymorphism was associated with a decreased risk of HNC using the dominant model, homozygote comparison model and heterozygote comparison model (OR = 0.82, 95% CI: 0.71-0.94; OR = 0.67, 95% CI: 0.49-0.94; and OR = 0.84, 95% CI: 0.73-0.97, respectively); besides, in stratification analyses by ethnicity, similar results were observed in Caucasian populations. Stratification by tumor site indicated that the GSTM3 polymorphism was associated with a decreased risk of laryngeal cancer under recessive model and homozygote comparison (OR = 0.52, 95% CI: 0.30-0.89; and OR = 0.50, 95% CI: 0.29-0.87, respectively); By stratifying source of control, decreased cancer risk was observed in hospital-based population under all genetic models (OR = 0.67, 95% CI: 0.56-0.81 for the dominant model; OR = 0.66, 95% CI: 0.46-0.95 for the recessive model; OR = 0.55, 95% CI: 0.37-0.83 for the homozygote comparison model, and OR = 0.70, 95% CI: 0.58-0.84 for the heterozygote comparison model).
   Conclusions: This meta-analysis suggests that the GSTM3 A/B polymorphism may be an important protective factor for HNC, especially of laryngeal cancer and Caucasian populations.
C1 [Xu, Yu] Wuhan Univ, Renmin Hosp, Dept Otolaryngol, Wuhan 430072, Hubei Province, Peoples R China.
   [Wang, Jun; Dong, Weiguo] Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan 430072, Hubei Province, Peoples R China.
RP Dong, WG (reprint author), Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan 430072, Hubei Province, Peoples R China.
EM dwg@whu.edu.cn
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Buch SC, 2002, CARCINOGENESIS, V23, P803, DOI 10.1093/carcin/23.5.803
   Butkiewicz D, 2000, ENVIRON MOL MUTAGEN, V35, P99, DOI 10.1002/(SICI)1098-2280(2000)35:2<99::AID-EM4>3.3.CO;2-U
   Chatzimichalis M, 2010, J LARYNGOL OTOL, V124, P318, DOI 10.1017/S002221510999154X
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491
   Hirvonen A, 1999, ENVIRON HEALTH PERSP, V107, P37, DOI 10.2307/3434470
   Holley SL, 2006, INT J ONCOL, V28, P231
   Inskip A, 1995, BIOCHEM J, V312, P713, DOI 10.1042/bj3120713
   Jahnke V, 1996, AM J SURG, V172, P671, DOI 10.1016/S0002-9610(96)00298-X
   Jahnke V, 1997, EUR ARCH OTO-RHINO-L, V254, pS147, DOI 10.1007/BF02439747
   Jain M, 2007, CANCER EPIDEM BIOMAR, V16, P178, DOI 10.1158/1055-9965.EPI-06-0542
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jourenkova-Mironova N, 1999, CANCER EPIDEM BIOMAR, V8, P185
   Jourenkova-Mironova N, 1999, INT J CANCER, V81, P44, DOI 10.1002/(SICI)1097-0215(19990331)81:1<44::AID-IJC9>3.0.CO;2-A
   KETTERER B, 1988, MUTAT RES, V202, P343, DOI 10.1016/0027-5107(88)90197-2
   Kim L, 2010, ONCOLOGY-NY, V24, P915
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Loktionov A, 2001, CARCINOGENESIS, V22, P1053, DOI 10.1093/carcin/22.7.1053
   Majumder M, 2005, CANCER EPIDEM BIOMAR, V14, P2106, DOI 10.1158/1055-9965.EPI-05-0108
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marques CFS, 2006, ORAL ONCOL, V42, P632, DOI 10.1016/k.oraloncology.2005.11.003
   Matthias C, 1998, LARYNGO RHINO OTOL, V77, P201, DOI 10.1055/s-2007-996961
   Matthias C, 1998, PHARMACOGENETICS, V8, P91
   Matthias C, 2003, LARYNGO RHINO OTOL, V82, P25, DOI 10.1055/s-2003-36902
   Pandey SN, 2006, BIOMARKERS, V11, P250, DOI 10.1080/13547500600648697
   Park JY, 2000, PHARMACOGENETICS, V10, P123, DOI 10.1097/00008571-200003000-00004
   Rydzanicz M, 2005, CANCER LETT, V224, P263, DOI 10.1016/j.canlet.2005.01.015
   Saarikoski ST, 1998, INT J CANCER, V77, P516, DOI 10.1002/(SICI)1097-0215(19980812)77:4<516::AID-IJC7>3.3.CO;2-B
   Sankaranarayanan R, 1998, ANTICANCER RES, V18, P4779
   Schwartzbaum JA, 2007, CANCER EPIDEM BIOMAR, V16, P559, DOI 10.1158/1055-9965.EPI-06-0918
   Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3
   Sikdar N, 2004, INT J CANCER, V109, P95, DOI 10.1002/ijc.11610
   To-Figueras J, 2002, CANCER LETT, V187, P95, DOI 10.1016/S0304-3835(02)00406-8
   Wu XF, 2004, ONCOGENE, V23, P6500, DOI 10.1038/sj.onc.1207811
   Yengi L, 1996, CANCER RES, V56, P1974
NR 37
TC 5
Z9 5
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 8
PY 2014
VL 9
IS 1
AR e83851
DI 10.1371/journal.pone.0083851
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 291WL
UT WOS:000329862500078
PM 24416175
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, XL
   Cao, CX
   Zhang, Q
   Chen, Y
   Gu, DY
   Shen, YZ
   Gong, YL
   Chen, JF
   Tang, CJ
AF Zhang, Xunlei
   Cao, Chunxiang
   Zhang, Qi
   Chen, Yi
   Gu, Dongying
   Shen, Yunzhu
   Gong, Yongling
   Chen, Jinfei
   Tang, Cuiju
TI Comparison of the Efficacy and Safety of S-1-Based and
   Capecitabine-Based Regimens in Gastrointestinal Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID ADVANCED GASTRIC-CANCER; METASTATIC COLORECTAL-CANCER; ADVANCED
   ESOPHAGOGASTRIC CANCER; S-1 PLUS CISPLATIN; THYMIDINE-PHOSPHORYLASE
   EXPRESSION; PHASE-II TRIAL; 1ST-LINE TREATMENT; SOLID TUMORS;
   DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDYLATE SYNTHASE
AB Purpose: Oral fluoropyrimidine (S-1, capecitabine) has been considered as an important part of various regimens. We aimed to evaluate the efficacy and safety of S-1-based therapy versus capecitabine - based therapy in gastrointestinal cancers.
   Methods: Eligible studies were identified from Pubmed, EMBASE. Additionally, abstracts presented at American Society of Clinical Oncology (ASCO) conferences held between 2000 and 2013 were searched to identify relevant clinical trials. The outcome included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR) and advent events.
   Results: A total of 6 studies (4 RCTs and 2 retrospective analysis studies) containing 790 participants were included in this meta-analysis, including 401 patients in the S-1-based group and 389 patients in the capecitabine-based group. Results of our meta-analysis indicated that S-1-based and capecitabine-based regimens showed very similar efficacy in terms of PFS (HR 0.92, 95% CI 0.78-1.09, P = 0.360), OS (HR 1.01, 95% CI 0.84-1.21, P = 0.949), ORR (HR 1.04, 95% CI 0.87-1.25, P = 0.683) and DCR (HR 1.02, 95% CI 0.94-1.10, P = 0.639). There was also no significant difference in toxicity between regimens other than mild more hand-foot syndrome in capecitabine-based regimens.
   Conclusion: Both the S-1-based and capecitabine-based regimens are equally active and well tolerated, and have the potential of backbone chemotherapy regimen in further studies of gastrointestinal cancers.
C1 [Zhang, Xunlei; Cao, Chunxiang; Zhang, Qi; Gu, Dongying; Shen, Yunzhu; Gong, Yongling; Chen, Jinfei; Tang, Cuiju] Nanjing Med Univ, Nanjing Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
   [Chen, Yi] Southeast Univ, Nanjing Hosp 1, Dept Oncol, Sch Med, Nanjing, Jiangsu, Peoples R China.
RP Tang, CJ (reprint author), Nanjing Med Univ, Nanjing Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
EM tangcuiju@tom.com
FU Project of Plans for the Development of Science and Technology of
   Nanjing, China [201208020]
FX The work was supported by a grant from The Project of Plans for the
   Development of Science and Technology of Nanjing, China; Grant Number:
   201208020; Website: http://www.njh.gov.cn. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ajani JA, 2005, J CLIN ONCOL, V23, P6957, DOI 10.1200/JCO.2005.01.917
   Ajani JA, 2010, J CLIN ONCOL, V28, P1547, DOI 10.1200/JCO.2009.25.4706
   Bang YJ, 2010, LANCET, V376, P687, DOI 10.1016/S0140-6736(10)61121-X
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boku N, 2007, J CLIN ONCOL, V25, DOI DOI 10.1200/JCO.2006.10.0131
   Boku N, 2009, LANCET ONCOL, V10, P1063, DOI 10.1016/S1470-2045(09)70259-1
   Cassidy J, 2004, J CLIN ONCOL, V22, P2084, DOI 10.1200/JCO.2004.11.069
   Cassidy J, 2002, ANN ONCOL, V13, P566, DOI 10.1093/annonc/mdf089
   Chuah B, 2011, CANCER SCI, V102, P478, DOI 10.1111/j.1349-7006.2010.01793.x
   Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149
   Cunningham D, 2010, NEW ENGL J MED, V362, P858, DOI 10.1056/NEJMc0911925
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   Desauw C, 2010, EPIDEMIOLOGY RISK FA, P30
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Hoff PM, 2003, CLIN CANCER RES, V9, P134
   Hong YS, 2012, LANCET ONCOL, V13, P1125, DOI 10.1016/S1470-2045(12)70363-7
   Ichikawa W, 2003, CLIN CANCER RES, V9, P786
   Kang YK, 2009, ANN ONCOL, V20, P666, DOI 10.1093/annonc/mdn717
   Kim GM, 2012, EUR J CANCER, V48, P518, DOI 10.1016/j.ejca.2011.12.017
   Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI [10.1016/S1470-2045(08)70035-4, 10.1016/S1470-204S(08)70035-4]
   Lee JL, 2008, BRIT J CANCER, V99, P584, DOI 10.1038/sj.bjc.6604536
   Maehara Yoshihiko, 2003, Gastric Cancer, V6 Suppl 1, P2, DOI 10.1007/s10120-003-0232-9
   Meropol NJ, 2006, J CLIN ONCOL, V24, P4069, DOI 10.1200/JCO.2005.05.2084
   Napieralski R, 2005, CLIN CANCER RES, V11, P3025, DOI 10.1158/1078-0432.CCR-04-1605
   Ohtsu A, 2011, J CLIN ONCOL, V29, P3968, DOI 10.1200/JCO.2011.36.2236
   Okines AFC, 2009, ANN ONCOL, V20, P1529, DOI 10.1093/annonc/mdp047
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Sakamoto J, 2006, ANTI-CANCER DRUG, V17, P231, DOI 10.1097/00001813-200602000-00016
   Sakata Y, 1998, EUR J CANCER, V34, P1715, DOI 10.1016/S0959-8049(98)00211-1
   Salonga D, 2000, CLIN CANCER RES, V6, P1322
   Schoffski P, 2004, ANTI-CANCER DRUG, V15, P85, DOI 10.1097/01.cad.0000114631.91268.39
   Seol YM, 2009, JPN J CLIN ONCOL, V39, P43, DOI 10.1093/jjco/hyn119
   Shin A, 2011, J GASTRIC CANCER, V11, P135, DOI 10.5230/jgc.2011.11.3.135
   Shitara K, 2013, INT J CLIN ONCOL, V18, P539, DOI 10.1007/s10147-012-0416-6
   Shridhar R, 2011, CANCER-AM CANCER SOC, V117, P3908, DOI 10.1002/cncr.25995
   Sutton AJ, 2000, STAT METHODS MED RES, V9, P421, DOI 10.1191/096228000701555244
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429
   Yamada Y, 2009, J CLIN ONCOL S, V27, p15s
   Zang DY, 2012, J CLIN ONCOL, V2012, P595
   1998, J CLIN ONCOL, V16, P301
NR 41
TC 5
Z9 5
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 2
PY 2014
VL 9
IS 1
AR e84230
DI 10.1371/journal.pone.0084230
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 286ID
UT WOS:000329460100039
PM 24392116
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Pasin, L
   Greco, T
   Feltracco, P
   Vittorio, A
   Neto, CN
   Cabrini, L
   Landoni, G
   Finco, G
   Zangrillo, A
AF Pasin, Laura
   Greco, Teresa
   Feltracco, Paolo
   Vittorio, Annalisa
   Neto, Caetano Nigro
   Cabrini, Luca
   Landoni, Giovanni
   Finco, Gabriele
   Zangrillo, Alberto
TI Dexmedetomidine as a Sedative Agent in Critically Ill Patients: A
   Meta-Analysis of Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID INTENSIVE-CARE; POSTOPERATIVE SEDATION; INFLAMMATORY RESPONSES;
   CARDIAC-SURGERY; PROPOFOL; MIDAZOLAM; INFUSION; DELIRIUM
AB Introduction: The effect of dexmedetomidine on length of intensive care unit (ICU) stay and time to extubation is still unclear.
   Materials and Methods: Pertinent studies were independently searched in BioMedCentral, PubMed, Embase, and the Cochrane Central Register of clinical trials (updated February first 2013). Randomized studies (dexmedetomidine versus any comparator) were included if including patients mechanically ventilated in an intensive care unit (ICU). Co-primary endpoints were the length of ICU stay (days) and time to extubation (hours). Secondary endpoint was mortality rate at the longest follow-up available.
   Results: The 27 included manuscripts (28 trials) randomized 3,648 patients (1,870 to dexmedetomidine and 1,778 to control). Overall analysis showed that the use of dexmedetomidine was associated with a significant reduction in length of ICU stay (weighted mean difference (WMD) = -0.79 [-1.17 to -0.40] days, p for effect <0.001) and of time to extubation (WMD = -2.74 [-3.80 to -1.65] hours, p for effect <0.001). Mortality was not different between dexmedetomidine and controls (risk ratio = 1.00 [0.84 to 1.21], p for effect = 0.9). High heterogeneity between included studies was found.
   Conclusions: This meta-analysis of randomized controlled studies suggests that dexmedetomidine could help to reduce ICU stay and time to extubation, in critically ill patients even if high heterogeneity between studies might confound the interpretation of these results.
C1 [Pasin, Laura; Greco, Teresa; Vittorio, Annalisa; Neto, Caetano Nigro; Cabrini, Luca; Landoni, Giovanni; Zangrillo, Alberto] Ist Sci San Raffaele, Anesthesia & Intens Care Dept, I-20132 Milan, Italy.
   [Feltracco, Paolo] Univ Hosp Padua, Dept Pharmacol & Anesthesiol, Padua, Italy.
   [Landoni, Giovanni] Outcomes Res Consortium, Cleveland, OH USA.
   [Finco, Gabriele] Univ Cagliari, Dept Med Sci M Aresu, Cagliari, Italy.
RP Landoni, G (reprint author), Ist Sci San Raffaele, Anesthesia & Intens Care Dept, I-20132 Milan, Italy.
EM landoni.giovanni@hsr.it
RI Neto, Caetano Nigro/M-4649-2016
OI Neto, Caetano Nigro/0000-0001-8134-3440; LANDONI,
   Giovanni/0000-0002-8594-5980; ZANGRILLO, Alberto/0000-0002-7687-7648
CR Abd Aziz N, 2011, INT J CLIN PHARM-NET, V33, P150, DOI 10.1007/s11096-011-9480-7
   AHO M, 1993, J CLIN ANESTH, V5, P194, DOI 10.1016/0952-8180(93)90014-6
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Biondi-Zoccai G, 2011, HEART LUNG VESSEL, V3, P161
   Chorney SR, 2013, HEART LUNG VESSEL, V5, P17
   Corbett SM, 2005, CRIT CARE MED, V33, P940, DOI 10.1097/01.CCM.0000162565.18193.E5
   Elbaradie Samia, 2004, J Egypt Natl Canc Inst, V16, P153
   Esmaolglu A, 2009, J CRIT CARE, V24, P551, DOI 10.1016/j.jcrc.2009.02.001
   Gertler R, 2001, Proc (Bayl Univ Med Cent), V14, P13
   Guo TZ, 1996, ANESTHESIOLOGY, V84, P873, DOI 10.1097/00000542-199604000-00015
   Herr DL, 2003, J CARDIOTHOR VASC AN, V17, P576, DOI 10.1053/S1053-0770(03)00200-3
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Huupponen E, 2008, ACTA ANAESTH SCAND, V52, P289, DOI 10.1111/j.1399-6576.2007.01537.x
   Iirola T, 2011, CRIT CARE, V15, DOI 10.1186/cc10518
   Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304
   Khalil MA, 2013, SEMIN CARDIOTHORAC V, V17, P66, DOI 10.1177/1089253212463969
   Leino K, 2011, BMC ANESTHESIOL, V11, DOI 10.1186/1471-2253-11-9
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Maldonado JR, 2009, PSYCHOSOMATICS, V50, P206, DOI 10.1176/appi.psy.50.3.206
   Martin Eike, 2003, J Intensive Care Med, V18, P29, DOI 10.1177/0885066602239122
   Memis D, 2007, BRIT J ANAESTH, V98, P550, DOI 10.1093/bja/aem017
   Memis D, 2006, EUR J ANAESTH, V23, P700, DOI 10.1017/S0265021506000512
   Memis D, 2009, J CRIT CARE, V24, P603, DOI 10.1016/j.jcrc.2008.10.005
   Menda F, 2010, ANN CARD ANAESTH, V13, P16, DOI 10.4103/0971-9784.58829
   Morsch RD, 2005, CRITICAL CARE, V9, pP111
   Ozkan N, 2007, GOGUS KALP DAMAR ANE, V13, P161
   Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644
   Paris A, 2005, CURR OPIN ANESTHESIO, V18, P412, DOI 10.1097/01.aco.0000174958.05383.d5
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Reade MC, 2009, CRIT CARE, V13, DOI 10.1186/cc7890
   Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56
   Ruokonen E, 2009, INTENS CARE MED, V35, P282, DOI 10.1007/s00134-008-1296-0
   Sahin N, 2005, EUR J ANAESTH, V22, P40
   Shehabi Y, 2009, ANESTHESIOLOGY, V111, P1075, DOI 10.1097/ALN.0b013e3181b6a783
   TALKE P, 1995, ANESTHESIOLOGY, V82, P620, DOI 10.1097/00000542-199503000-00003
   Tan JA, 2010, INTENS CARE MED, V36, P926, DOI 10.1007/s00134-010-1877-6
   Tasdogan M, 2009, J CLIN ANESTH, V21, P394, DOI 10.1016/j.jclinane.2008.10.010
   Terao Y, 2012, J ANESTH, V26, P179, DOI 10.1007/s00540-011-1300-7
   Triltsch AE, 2002, CRIT CARE MED, V30, P1007, DOI 10.1097/00003246-200205000-00009
   Venn RM, 2001, BRIT J ANAESTH, V87, P684, DOI 10.1093/bja/87.5.684
   Wan Lin-jun, 2011, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V23, P543
   Yao Li, 2010, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V22, P632
   Yazbek-Karam Vanda G., 2006, Middle East Journal of Anesthesiology, V18, P1043
NR 43
TC 29
Z9 31
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2013
VL 8
IS 12
AR e82913
DI 10.1371/journal.pone.0082913
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 284NF
UT WOS:000329325200023
PM 24391726
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, W
   He, M
   Zhou, MW
   Zhang, XL
AF Wang, Wei
   He, Miao
   Zhou, Minwen
   Zhang, Xiulan
TI Fornix-Based versus Limbus-Based Conjunctival Flap in Trabeculectomy: A
   Quantitative Evaluation of the Evidence
SO PLOS ONE
LA English
DT Article
ID INTRAOPERATIVE MITOMYCIN-C; FILTERING SURGERY; COMBINED
   PHACOEMULSIFICATION; CATARACT-SURGERY; FELLOW-EYES; GLAUCOMA;
   METAANALYSIS; PHACOTRABECULECTOMY; COMPLICATIONS; OUTCOMES
AB Objective: To evaluate the efficacy and tolerability of limbus-based (LBCF) compared with fornix-based conjunctival flaps (FBCF) for trabeculectomy in the treatment of patients with uncontrolled glaucoma.
   Methods: A comprehensive literature meta-analysis was performed according to the Cochrane Collaboration methodology to identify controlled clinical trials comparing LBCF with FBCF in trabeculectomy. The efficacy measures were the weighted mean differences (WMDs) for intraocular pressure reduction (IOPR), the reduction in glaucoma medications, and the relative risks (RRs) for success rates. Tolerability estimates were measured by RR for adverse events. The pooled effects were calculated using the random effects model.
   Results: Sixteen controlled clinical trials meeting the predefined criteria were included in the meta-analysis. A total of 1,825 eyes from 1,392 patients with medically uncontrolled glaucoma were included. The WMD of the IOPR from baseline was 1.12 (95% CI: 20.88 to 3.12) when comparing LBCF with FBCF. LBCF was associated with numerically greater but nonsignificant IOP lowering efficacy than FBCF (P = 0.270). LBCF was comparable with FBCF in the reduction of glaucoma medication, with a WMD of 0.15 (20.05 to 0.36) at the follow-up endpoint (P = 0.141). The pooled RR comparing LBCF with FBCF were 1.08 (0.94, 1.23) for the complete success rate and 1.01 (0.92, 1.10) for the qualified success rate. Rates of adverse events did not differ significantly between LBCF and FBCF.
   Conclusions: There is no significant difference in IOP lowering, number of glaucoma medications, or proportion of patients who reached the IOP target between LBCF and FBCF trabeculectomy. Both incision techniques may contribute equally to adverse events.
C1 [Wang, Wei; He, Miao; Zhou, Minwen; Zhang, Xiulan] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China.
RP Zhang, XL (reprint author), Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China.
EM zhangxl2@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81371008]
FX This research was supported by the National Natural Science Foundation
   of China (81371008). No additional external funding was received. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alwitry A, 2005, EYE, V19, P631, DOI 10.1038/sj.eye.6701587
   Auw-Haedrich C, 1998, OPHTHALMIC SURG LAS, V29, P575
   Babushkin AE, 1990, OFTALMOLOGICHESKII Z, P280
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berestka JS, 1997, OPHTHALMOLOGY, V104, P187, DOI 10.1016/S0161-6420(97)30335-2
   BRINCKER P, 1992, ACTA OPHTHALMOL, V70, P641
   Cheng YC, 2012, INT EYE SCI, V12, P2405
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ding Qiong, 2008, Yan Ke Xue Bao, V24, P35
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El Sayyad F, 1999, J GLAUCOMA, V8, P124
   Fukuchi T, 2006, JPN J OPHTHALMOL, V50, P338, DOI 10.1007/s10384-005-0323-8
   Gdih GA, 2011, OPHTHALMOLOGY, V118, P71, DOI 10.1016/j.ophtha.2010.04.008
   GREHN F, 1989, INT OPHTHALMOL, V13, P139, DOI 10.1007/BF02028654
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Khan A. M., 1992, Indian Journal of Ophthalmology, V40, P41
   Kohl Douglas A., 2005, International Ophthalmology Clinics, V45, P107, DOI 10.1097/01.iio.0000176369.93887.65
   Kozobolis VP, 2002, J CATARACT REFR SURG, V28, P1758, DOI 10.1016/S0886-3350(02)01270-1
   Lemon LC, 1998, AM J OPHTHALMOL, V125, P340, DOI 10.1016/S0002-9394(99)80144-5
   Lin YPK, 2007, OPHTHAL SURG LAS IM, V38, P471
   Lin ZJ, 2012, J OCUL PHARMACOL TH, V28, P166, DOI 10.1089/jop.2011.0117
   Mandic Z, 2004, CROAT MED J, V45, P275
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Morita K, 2012, J GLAUCOMA, V21, P383, DOI 10.1097/IJG.0b013e3182120a08
   MURCHISON JF, 1990, AM J OPHTHALMOL, V109, P709, DOI 10.1016/S0002-9394(14)72441-9
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Razeghinejad MR, 2012, SURV OPHTHALMOL, V57, P1, DOI 10.1016/j.survophthal.2011.07.005
   REICHERT R, 1987, OPHTHALMIC SURG LAS, V18, P672
   Shingleton BJ, 1999, OPHTHALMOLOGY, V106, P1152, DOI 10.1016/S0161-6420(99)90252-X
   SHUSTER JN, 1984, ARCH OPHTHALMOL-CHIC, V102, P361, DOI 10.1001/archopht.1984.01040030279018
   Solus JF, 2012, OPHTHALMOLOGY, V119, P703, DOI 10.1016/j.ophtha.2011.09.046
   Song M S, 1996, Korean J Ophthalmol, V10, P97
   STEWART WC, 1994, DOC OPHTHALMOL, V88, P141, DOI 10.1007/BF01204611
   Suhr AW, 2012, J GLAUCOMA, V21, P523, DOI 10.1097/IJG.0b013e318227a565
   Tezel G, 1997, OPHTHALMIC SURG LAS, V28, P551
   TRAVERSO CE, 1987, AM J OPHTHALMOL, V104, P28, DOI 10.1016/0002-9394(87)90289-3
   Wang W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063591
   Wells AP, 2003, OPHTHALMOLOGY, V110, P2192, DOI 10.1016/S0161-6420(03)00800-5
NR 40
TC 6
Z9 6
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 26
PY 2013
VL 8
IS 12
AR e83656
DI 10.1371/journal.pone.0083656
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 281QS
UT WOS:000329116700067
PM 24386246
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhu, LB
   Yuan, H
   Jiang, T
   Wang, RX
   Ma, HX
   Zhang, SY
AF Zhu, Longbiao
   Yuan, Hua
   Jiang, Tao
   Wang, Ruixia
   Ma, Hongxia
   Zhang, Shuangyue
TI Association of TLR2 and TLR4 Polymorphisms with Risk of Cancer: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID TOLL-LIKE RECEPTORS; SINGLE-NUCLEOTIDE POLYMORPHISMS; LYMPHOID-TISSUE
   LYMPHOMA; NORTH INDIAN POPULATION; NON-HODGKIN-LYMPHOMA;
   PROSTATE-CANCER; GENE POLYMORPHISMS; GASTRIC-CANCER;
   HELICOBACTER-PYLORI; CHINESE POPULATION
AB Backgrounds: The activation of Toll-like receptors (TLRs) may be an important event in the immune evasion of tumor cell. Recently, numerous studies have investigated the associations between TLR2 -196 to -174 del and two SNPs of TLR4 (rs4986790 and rs4986791) and the susceptibility to different types of cancer; however, the results remain conflicting. The aim of this study was to assess the association between TLR2 and TLR4 polymorphisms and cancer risk in a meta-analysis with eligible published studies.
   Methodology/Principle Findings: A dataset composed of 14627 cases and 17438 controls from 34 publications were included in a meta-analysis to evaluate the association between overall cancer risk or cancer-specific risk and three SNPs of TLRs (TLR2 -196 to -174 del, TLR4 rs4986790 and rs4986791). The results showed that all of these three polymorphisms were significantly associated with the increased cancer risk (dominant model: OR=1.64, 95% CI: 1.04-2.60 for TLR2 -196 to -174 del; OR=1.19, 95% CI: 1.01-1.41 for TLR4 rs4986790; and OR=1.47, 95% CI: 1.120-1.80 for TLR4 rs4986791; respectively). In stratified analysis, we found the effect of TLR2 -196 to -174 del on cancer risk remained significant in the subgroup of Caucasians and South Asians, but not in East Asians. However, the association between rs4986791 and cancer risk was significant in both South Asians and East Asians, but not in Caucasians. Furthermore, the association between rs4986790 and cancer risk was statistically significant in digestive cancers (dominant model: OR=1.76, 95% CI: 1.13-2.73) and female-specific cancers (dominant model: OR=1.50, 95% Cl: 1.16-1.94). However, no significant association with risk of digestive system cancers was observed for TLR2 -196 to -174 del and TLR4 rs4986791.
   Conclusions/Significance: This meta-analysis presented additional evidence for the association between TLR2 and TLR4 polymorphisms and cancer risk. Further well-designed investigations with large sample sizes are required to confirm this conclusion.
C1 [Zhu, Longbiao; Yuan, Hua; Wang, Ruixia] Nanjing Med Univ, Inst Stomatol, Nanjing, Jiangsu, Peoples R China.
   [Zhu, Longbiao; Yuan, Hua; Ma, Hongxia] Nanjing Med Univ, Clin Epidemiol Sect, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Ctr Canc, Nanjing, Jiangsu, Peoples R China.
   [Jiang, Tao; Ma, Hongxia] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, MOE Key Lab Modern Toxicol, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Shuangyue] Nanjing Med Univ, Huaian Peoples Hosp 1, Cent Lab, Huaian, Peoples R China.
RP Ma, HX (reprint author), Nanjing Med Univ, Clin Epidemiol Sect, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Ctr Canc, Nanjing, Jiangsu, Peoples R China.
EM mahongxia927@gmail.com; zsy2005edu@sina.com
FU National Natural Science Foundation of China [81270044, 81302361];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD); Jiangsu Natural Science Foundation [BK2011764];
   Jiangsu Province Clinical Science and Technology Projects [BL2012008]
FX This work was supported in part by National Natural Science Foundation
   of China (81270044 and 81302361), Priority Academic Program Development
   of Jiangsu Higher Education Institutions (PAPD), Jiangsu Natural Science
   Foundation (BK2011764) and Jiangsu Province Clinical Science and
   Technology Projects (BL2012008). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228
   Agundez JA, 2012, ONCOLOGY-BASEL, V82, P35, DOI 10.1159/000335606
   Ahmed A, 2012, ANN SURG ONCOL
   Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048
   Ashton KA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-382
   Balistreri CR, 2010, CURR PHARM DESIGN, V16, P718, DOI 10.2174/138161210790883877
   Basith S, 2012, ARCH PHARM RES, V35, P1297, DOI 10.1007/s12272-012-0802-7
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Castano-Rodriguez N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060327
   Chen R, 2008, ONCOGENE, V27, P225, DOI 10.1038/sj.onc.1210907
   Chen YC, 2005, CANCER RES, V65, P11771, DOI 10.1158/0008-5472.CAN-05-2078
   Cheng I, 2007, CANCER EPIDEM BIOMAR, V16, P352, DOI 10.1158/1055-9965.EPI-06-0429
   de Oliveira JG, 2012, WORLD J GASTROENTERO, V18, P1235, DOI 10.3748/wjg.v18.i11.1235
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Drexler SK, 2010, INT J BIOCHEM CELL B, V42, P506, DOI 10.1016/j.biocel.2009.10.009
   Etokebe GE, 2009, GENET TEST MOL BIOMA, V13, P729, DOI 10.1089/gtmb.2009.0045
   Ferwerda B, 2008, MOL MED, V14, P346, DOI 10.2119/2007-00135.Ferwerda
   Forrest MS, 2006, BRIT J HAEMATOL, V134, P180, DOI 10.1111/j.1365-2141.2006.06141.x
   Garza-Gonzalez E, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-70
   Gast A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024370
   Harberts E, 2013, J INVEST DERMATOL, V133, P296, DOI 10.1038/jid.2012.288
   He WG, 2007, MOL IMMUNOL, V44, P2850, DOI 10.1016/j.molimm.2007.01.022
   Hellmig S, 2005, LEUKEMIA LYMPHOMA, V46, P869, DOI 10.1080/10428190500086451
   Hishida A, 2010, GASTRIC CANCER, V13, P251, DOI 10.1007/s10120-010-0567-y
   Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026
   Huang B, 2007, CANCER RES, V67, P4346, DOI 10.1158/0008-5472.CAN-06-4067
   Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021
   Jelavic TB, 2006, CLIN GENET, V70, P156, DOI 10.1111/j.1399-0004.2006.00651.x
   Kagan JC, 2008, NAT IMMUNOL, V9, P361, DOI 10.1038/ni1569
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Landi S, 2006, J NEGAT RESULTS BIOM, V5, DOI 10.1186/1477-5751-5-15
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lindstrom S, 2010, CANCER EPIDEM BIOMAR, V19, P873, DOI 10.1158/1055-9965.EPI-09-0618
   Liu L, 2011, CARCINOGENESIS, V32, P336, DOI 10.1093/carcin/bgq264
   Mandal RK, 2012, MOL BIOL REP, V39, P7263, DOI 10.1007/s11033-012-1556-5
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Menendez D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001360
   Miedema KGE, 2012, LEUKEMIA, V26, P1203, DOI 10.1038/leu.2011.341
   Nieters A, 2006, GENES IMMUN, V7, P615, DOI 10.1038/sj.gene.6364337
   Nischalke HD, 2012, INT J CANCER, V130, P1470, DOI 10.1002/ijc.26143
   Pandey S, 2009, GYNECOL ONCOL, V114, P501, DOI 10.1016/j.ygyno.2009.05.032
   Purdue MP, 2009, CARCINOGENESIS, V30, P275, DOI 10.1093/carcin/bgn262
   Rigoli L, 2010, ANTICANCER RES, V30, P513
   Sabroe I, 2005, CLIN INFECT DIS, V41, pS421, DOI 10.1086/431992
   Santini D, 2008, CLIN EXP IMMUNOL, V154, P360, DOI 10.1111/j.1365-2249.2008.03776.x
   Shen YZ, 2013, PATHOL ONCOL RES, V19, P275, DOI 10.1007/s12253-012-9579-8
   Singh V, 2013, ARCH MED RES, V44, P54, DOI 10.1016/j.arcmed.2012.10.008
   Srivastava K, 2010, LIVER INT, V30, P1067, DOI 10.1111/j.1478-3231.2010.02268.x
   Su B, 2003, INFECT IMMUN, V71, P3496, DOI 10.1128/IAI.3496-3502.2003
   Tahara T, 2007, CANCER SCI, V98, P1790, DOI 10.1111/j.1349-7006.2007.00590.x
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   Theodoropoulos GE, 2012, BREAST, V21, P534, DOI 10.1016/j.breast.2012.04.001
   Trejo-de la O A, 2008, CLIN IMMUNOL, V129, P333, DOI 10.1016/j.clim.2008.07.009
   Ture-Ozdemir F, 2008, ANTICANCER RES, V28, P3697
   Wang JH, 2003, J IMMUNOL, V170, P795, DOI 10.4049/jimmunol.170.2.795
   Wang MH, 2009, PROSTATE, V69, P874, DOI 10.1002/pros.20933
   Wang RF, 2008, ONCOGENE, V27, P181, DOI 10.1038/sj.onc.1210906
   Wroblewski LE, 2013, GASTROENTEROL CLIN N, V42, P285, DOI 10.1016/j.gtc.2013.01.006
   Yang ZH, 2012, CANCER SCI, V103, P653, DOI 10.1111/j.1349-7006.2012.02210.x
   Zeng HM, 2011, CANCER EPIDEM BIOMAR, V20, P2594, DOI 10.1158/1055-9965.EPI-11-0702
   Zhang K, 2013, EUR J CANCER, V49, P946, DOI 10.1016/j.ejca.2012.09.022
   Zheng SL, 2004, CANCER RES, V64, P2918, DOI 10.1158/0008-5472.CAN-03-3280
   Zhong R, 2013, CARCINOGENESIS, V34, P936, DOI 10.1093/carcin/bgs395
NR 64
TC 15
Z9 18
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2013
VL 8
IS 12
AR e82858
DI 10.1371/journal.pone.0082858
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276IX
UT WOS:000328745100066
PM 24376595
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Schwingshackl, L
   Dias, S
   Strasser, B
   Hoffmann, G
AF Schwingshackl, Lukas
   Dias, Sofia
   Strasser, Barbara
   Hoffmann, Georg
TI Impact of Different Training Modalities on Anthropometric and Metabolic
   Characteristics in Overweight/Obese Subjects: A Systematic Review and
   Network Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID C-REACTIVE PROTEIN; ALL-CAUSE MORTALITY; RESISTANCE EXERCISE; AEROBIC
   EXERCISE; INSULIN-RESISTANCE; ADIPOSE-TISSUE; RISK-FACTORS;
   CARDIORESPIRATORY FITNESS; CARDIOVASCULAR EVENTS; WAIST CIRCUMFERENCE
AB Background: The aim of this systematic review of randomized controlled trials was to compare the effects of aerobic training (AET), resistance training (RT), and combined aerobic and resistance training (CT) on anthropometric parameters, blood lipids, and cardiorespiratory fitness in overweight and obese subjects.
   Methods: Electronic searches for randomized controlled trials were performed in MEDLINE, EMBASE and the Cochrane Trial Register. Inclusion criteria were: Body Mass Index: >= 25 kg/m 2, 19+ years of age, supervised exercise training, and a minimum intervention period of 8 weeks. Anthropometric outcomes, blood lipids, and cardiorespiratory fitness parameters were included. Pooled effects were calculated by inverse-variance random effect pairwise meta-analyses and Bayesian random effects network meta-analyses.
   Findings: 15 trials enrolling 741 participants were included in the meta-analysis. Compared to RT, AET resulted in a significantly more pronounced reduction of body weight [mean differences (MD): -1.15 kg, p = 0.04], waist circumference [MD: -1.10 cm, p = 0.004], and fat mass [MD: -1.15 kg, p = 0.001] respectively. RT was more effective than AET in improving lean body mass [MD: 1.26 kg, p<0.00001]. When comparing CT with RT, MD in change of body weight [MD: -2.03 kg, p<0.0001], waist circumference [MD: -1.57 cm, p = 0.0002], and fat mass [MD: -1.88 kg, p<0.00001] were all in favor of CT. Results from the network meta-analyses confirmed these findings.
   Conclusion: Evidence from both pairwise and network meta-analyses suggests that CT is the most efficacious means to reduce anthropometric outcomes and should be recommended in the prevention and treatment of overweight, and obesity whenever possible.
C1 [Schwingshackl, Lukas; Hoffmann, Georg] Univ Vienna, Fac Life Sci, Dept Nutr Sci, Vienna, Austria.
   [Dias, Sofia] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.
   [Strasser, Barbara] Univ Hlth Sci Med Informat & Technol, Inst Nutr Sci & Physiol, Hall In Tirol, Austria.
RP Schwingshackl, L (reprint author), Univ Vienna, Fac Life Sci, Dept Nutr Sci, Vienna, Austria.
EM lukas.schwingshackl@univie.ac.at
RI Dias, Sofia/F-1922-2010; Hoffmann, Georg/B-9201-2013
OI Dias, Sofia/0000-0002-2172-0221; 
CR Ahmadizad S, 2007, EUR J ENDOCRINOL, V157, P625, DOI 10.1530/EJE-07-0223
   Ballor DL, 1996, METABOLISM, V45, P179, DOI 10.1016/S0026-0495(96)90050-5
   Banz WJ, 2003, EXP BIOL MED, V228, P434
   Bateman LA, 2011, AM J CARDIOL, V108, P838, DOI 10.1016/j.amjcard.2011.04.037
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395
   Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675
   Davidson LE, 2009, ARCH INTERN MED, V169, P122, DOI 10.1001/archinternmed.2008.558
   de Koning L, 2007, EUR HEART J, V28, P850, DOI 10.1093/eurheartj/ehm026
   Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767
   Dias S., 2011, NICE DSU TECHNICAL S
   Dias S, 2013, MED DECIS MAKING, V33, P607, DOI 10.1177/0272989X12458724
   Donges CE, 2010, MED SCI SPORT EXER, V42, P304, DOI 10.1249/MSS.0b013e3181b117ca
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fisher G, 2011, OBESITY, V19, P1131, DOI 10.1038/oby.2010.310
   Galani C, 2007, INT J PUBLIC HEALTH, V52, P348, DOI 10.1007/s00038-007-7015-8
   Guh DP, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-88
   Haskell WL, 2007, CIRCULATION, V116, P1081, DOI 10.1161/CIRCULATIONAHA.107.185649
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Ismail I, 2012, OBES REV, V13, P68, DOI 10.1111/j.1467-789X.2011.00931.x
   Janssen I, 2002, DIABETES CARE, V25, P431, DOI 10.2337/diacare.25.3.431
   Kelley GA, 2000, HYPERTENSION, V35, P838, DOI 10.1161/01.HYP.35.3.838
   Kelley GA, 2006, METABOLISM, V55, P1500, DOI 10.1016/j.metabol.2006.06.021
   Kelley George A, 2008, Prev Cardiol, V11, P71
   Kodama S, 2007, ARCH INTERN MED, V167, P999, DOI 10.1001/archinte.167.10.999
   Kodama S, 2009, JAMA-J AM MED ASSOC, V301, P2024, DOI 10.1001/jama.2009.681
   Kraemer WJ, 1999, MED SCI SPORT EXER, V31, P1320, DOI 10.1097/00005768-199909000-00014
   Lee DC, 2011, CIRCULATION, V124, P2483, DOI 10.1161/CIRCULATIONAHA.111.038422
   Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Martins RA, 2010, EUR J APPL PHYSIOL, V110, P161, DOI 10.1007/s00421-010-1488-5
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Mourier A, 1997, DIABETES CARE, V20, P385, DOI 10.2337/diacare.20.3.385
   NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909
   Park Sang-Kab, 2003, Journal of Physiological Anthropology and Applied Human Science, V22, P129, DOI 10.2114/jpa.22.129
   Potteiger JA, 2012, EUR J APPL PHYSIOL, V112, P2035, DOI 10.1007/s00421-011-2174-y
   POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9
   PRATLEY R, 1994, J APPL PHYSIOL, V76, P133
   Rice B, 1999, DIABETES CARE, V22, P684, DOI 10.2337/diacare.22.5.684
   ROSS R, 1994, AM J CLIN NUTR, V60, P695
   Sarsan A, 2006, CLIN REHABIL, V20, P773, DOI 10.1177/0269215506070795
   SMUTOK MA, 1993, METABOLISM, V42, P177, DOI 10.1016/0026-0495(93)90032-J
   Stensvold D, 2010, J APPL PHYSIOL, V108, P804, DOI 10.1152/japplphysiol.00996.2009
   Strasser B, 2012, OBES REV, V13, P578, DOI 10.1111/j.1467-789X.2012.00988.x
   Strasser B, 2010, SPORTS MED, V40, P397, DOI 10.2165/11531380-000000000-00000
   Thorogood A, 2011, AM J MED, V124, P747, DOI 10.1016/j.amjmed.2011.02.037
   Wallace MB, 1997, MED SCI SPORT EXER, V29, P1170, DOI 10.1097/00005768-199709000-00008
   Willis LH, 2012, J APPL PHYSIOL, V113, P1831, DOI 10.1152/japplphysiol.01370.2011
   World Health Organization, 2011, OB OV FACT SHEET 311
NR 50
TC 44
Z9 45
U1 1
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 17
PY 2013
VL 8
IS 12
AR e82853
DI 10.1371/journal.pone.0082853
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276GT
UT WOS:000328737700034
PM 24358230
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ma, JX
   Xing, D
   Ma, XL
   Gao, F
   Wei, Q
   Jia, HB
   Feng, R
   Yu, JT
   Wang, J
AF Ma, JianXiong
   Xing, Dan
   Ma, XinLong
   Gao, Feng
   Wei, Qiang
   Jia, HaoBo
   Feng, Rui
   Yu, JingTao
   Wang, Jie
TI Intramedullary Nail versus Dynamic Compression Plate Fixation in
   Treating Humeral Shaft Fractures: Grading the Evidence through a
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PUBLICATION BIAS; QUALITY; RECOMMENDATIONS; OSTEOSYNTHESIS; STRENGTH
AB There is a debate regarding the choice of operative intervention in humeral shaft fractures that require surgical intervention. The choices for operative interventions include intramedullary nailing (IMN) and dynamic compression plate (DCP). This meta-analysis was performed to compare fracture union, functional outcomes, and complication rates in patients treated with IMN or DCP for humeral shaft fractures and to develop GRADE (Grading of Recommendations, Assessment, Development, and Evaluation)-based recommendations for using the procedures to treat humeral shaft fractures. A systematic search of all the studies published through December 2012 was conducted using the Medline, Embase, Sciencedirect, OVID and Cochrane Central databases. The randomized controlled trials (RCTs) and quasi-RCTs that compared IMN with DCP in treating adult patients with humeral shaft fractures and provided data regarding the safety and clinical effects were identified. The demographic characteristics, adverse events and clinical outcomes were manually extracted from all of the selected studies. Ten studies that included a total of 448 patients met the inclusion criteria. The results of a meta-analysis indicated that both IMN and DCP can achieve similar fracture union with a similar incidence of radial nerve injury and infection. IMN was associated with an increased risk of shoulder impingement, more restriction of shoulder movement, an increased risk of intraoperative fracture comminution, a higher incidence of implant failure, and an increased risk of re-operation. The overall GRADE system evidence quality was very low, which reduces our confidence in the recommendations of this system. DCP may be superior to IMN in the treatment of humeral shaft fractures. Because of the low quality evidence currently available, high-quality RCTs are required.
C1 [Ma, JianXiong; Gao, Feng; Wei, Qiang] Tianjin Univ, Coll Precis Instrument & Optoelect Engn, Tianjin 300072, Peoples R China.
   [Ma, JianXiong; Xing, Dan; Ma, XinLong; Jia, HaoBo; Feng, Rui; Yu, JingTao; Wang, Jie] Tianjin Med Univ, Gen Hosp, Dept Orthopaed, Tianjin, Peoples R China.
   [Ma, XinLong] Tianjin Hosp, Dept Orthopaed Inst, Tianjin, Peoples R China.
RP Ma, XL (reprint author), Tianjin Med Univ, Gen Hosp, Dept Orthopaed, Tianjin, Peoples R China.
EM tjmuld@gmail.com; gaofeng@tju.edu.cn
RI wei, qiang/G-6279-2013
OI wei, qiang/0000-0002-4620-5269
FU National Natural Science Foundation of China [81102607]; National
   Natural Science Foundation of Tianjin [043111411, 993607711]; Scientific
   and Technological Project of Tianjin Public Security Bureau
   [2013KYSGAY033]; Key Technologies & Program of Tianjin [11ZCGYSY01800,
   13JCZDJC31800]; Scientific and Technological Project of Tianjin Public
   Health Bureau [11KG 137, 12KG 120]
FX This study was supported by the National Natural Science Foundation of
   China (grant number 81102607), the National Natural Science Foundation
   of Tianjin (043111411, 993607711), the Scientific and Technological
   Project of Tianjin Public Security Bureau (number 2013KYSGAY033), the
   Key Technologies & Program of Tianjin (numbers 11ZCGYSY01800,
   13JCZDJC31800) and the Scientific and Technological Project of Tianjin
   Public Health Bureau (numbers 11KG 137, 12KG 120). The funders had no
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Apivatthakakul T, 2010, INJURY, V41, P169, DOI 10.1016/j.injury.2009.08.002
   Apivatthakakul T, 2009, OPER ORTHOP TRAUMATO, V21, P602, DOI 10.1007/s00064-009-2008-9
   Atkins D, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-38
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benegas Eduardo, 2007, Acta ortop. bras., V15, P87, DOI 10.1590/S1413-78522007000200006
   Bhandari M, 2006, ACTA ORTHOP, V77, P279, DOI 10.1080/17453670610046037
   Bolano L, 1995, OPERATIVE TREATMENT, P33
   Changulani M, 2007, INT ORTHOP, V31, P391, DOI 10.1007/s00264-006-0200-1
   Chapman JR, 2000, J ORTHOP TRAUMA, V14, P162, DOI 10.1097/00005131-200003000-00002
   Cole PA, 2007, HAND CLIN, V23, P437, DOI 10.1016/j.hcl.2007.11.004
   Dimakopoulos P, 2005, ARCH ORTHOP TRAUM SU, V125, P27, DOI 10.1007/s00402-004-0757-3
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FOSTER RJ, 1985, J BONE JOINT SURG AM, V67A, P857, DOI 10.2106/00004623-198567060-00005
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1303, DOI 10.1016/j.jclinepi.2011.04.014
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P407, DOI 10.1016/j.jclinepi.2010.07.017
   Kesemenli Cumhur Cevdet, 2003, Acta Orthop Traumatol Turc, V37, P120
   Kurup H, 2011, COCHRANE DB SYST REV, pD5959
   LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806
   Li Y, 2011, J SHOULDER ELB SURG, V20, P947, DOI 10.1016/j.jse.2010.12.016
   Martinez AA, 2004, ARCH ORTHOP TRAUM SU, V124, P92, DOI 10.1007/s00402-003-0608-7
   McCormack RG, 2000, J BONE JOINT SURG BR, V82B, P336, DOI 10.1302/0301-620X.82B3.9675
   Mulier T, 1997, Acta Orthop Belg, V63, P170
   Ouyang H, 2012, J SHOULDER ELBOW SUR
   Park JY, 2008, J ORTHOP TRAUMA, V22, P419, DOI 10.1097/BOT.0b013e318173f751
   Putti Amit B, 2009, J Orthop Surg (Hong Kong), V17, P139
   Raghavendra S, 2007, Indian J Orthop, V41, P214, DOI 10.4103/0019-5413.33685
   ROBINSON CM, 1992, J BONE JOINT SURG BR, V74, P558
   Rommens PM, 2008, INJURY, V39, P1319, DOI 10.1016/j.injury.2008.01.014
   ROMMENS PM, 1995, J BONE JOINT SURG BR, V77B, P84
   SARMIENTO A, 1977, J BONE JOINT SURG AM, V59, P596, DOI 10.2106/00004623-197759050-00004
   Sarmiento A, 2000, J BONE JOINT SURG AM, V82A, P478, DOI 10.2106/00004623-200004000-00003
   Sarmiento Augusto, 2002, Instr Course Lect, V51, P257
   Shao YC, 2005, J BONE JOINT SURG BR, V87B, P1647, DOI 10.1302/0301-620X.87B12.16132
   Singisetti K, 2010, INT ORTHOP, V34, P571, DOI 10.1007/s00264-009-0813-2
   Tsai CH, 2009, INT ORTHOP, V33, P463, DOI 10.1007/s00264-008-0537-8
NR 40
TC 6
Z9 7
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 16
PY 2013
VL 8
IS 12
AR e82075
DI 10.1371/journal.pone.0082075
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276GD
UT WOS:000328735700032
PM 24358141
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Pan, Y
   Wang, F
   Qiu, Q
   Ding, R
   Zhao, BL
   Zhou, H
AF Pan, Yang
   Wang, Fang
   Qiu, Qin
   Ding, Ren
   Zhao, Baolong
   Zhou, Hua
TI Influence of the Angiotensin Converting Enzyme Insertion or Deletion
   Genetic Variant and Coronary Restenosis Risk: Evidence Based on 11,193
   Subjects
SO PLOS ONE
LA English
DT Article
ID IN-STENT RESTENOSIS; SERIAL INTRAVASCULAR ULTRASOUND; PLACEBO-CONTROLLED
   TRIAL; ARTERY-DISEASE; BALLOON ANGIOPLASTY; MYOCARDIAL-INFARCTION; D
   ALLELE; CARDIOVASCULAR-DISEASE; NEOINTIMA FORMATION; DIABETIC-PATIENTS
AB The insertion/deletion (I/D) polymorphism of the gene encoding angiotensin converting enzyme is a controversial risk factor for restenosis after percutaneous transluminal coronary angioplasties (PTCA) in patients. Genetic association studies can be problematic to reproduce due to insufficient power, phenotypic heterogeneity, population stratification, small effect of the variant and even publication biases. To derive a more precise estimation of the relationship as well as to quantify the between-study heterogeneity and potential bias, a meta-analysis including 11,193 patients from 33 published cohort studies was performed. In a combined analysis, the summary per-allele odds ratio for restenosis was 1.31 (95% CI: 1.08-1.58, P = 0.006), and 1.22 (95% CI: 0.95-1.56, P = 0.12), for PTCA-stent and PTCA-balloon, respectively. In the subgroup analysis by ethnicity, significantly increased restenosis risks after PTCA-stent were found in Asians for the polymorphism; whereas no significant associations were found among Caucasians. As for restenosis risks after PTCA-balloon, no evidence of any gene-disease association was obtained in the stratified analyses according to ethnicity and study size. In conclusion, this meta-analysis demonstrated that the DD homozygous of ACE I/D polymorphism was significantly associated with elevated restenosis susceptibility after PTCA-stent among Asian populations.
C1 [Pan, Yang; Qiu, Qin; Ding, Ren; Zhao, Baolong; Zhou, Hua] Baoshan Hosp Integrated Tradit Chinese & Western, Dept Cardiol, Shanghai, Peoples R China.
   [Wang, Fang] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Cardiol, Shanghai 200030, Peoples R China.
RP Qiu, Q (reprint author), Baoshan Hosp Integrated Tradit Chinese & Western, Dept Cardiol, Shanghai, Peoples R China.
EM qiuqin293@163.com
CR Agema WRP, 2004, EUR HEART J, V25, P1163, DOI 10.1016/j.ehj.2004.05.006
   Agerholm-Larsen B, 2000, ARTERIOSCL THROM VAS, V20, P484, DOI 10.1161/01.ATV.20.2.484
   Amant C, 1997, CIRCULATION, V96, P56
   Andersen HR, 1996, CIRCULATION, V93, P1716
   Arnett DK, 2007, CIRCULATION, V115, P2878, DOI 10.1161/CIRCULATIONAHA.107.183679
   BALCON R, 1992, CIRCULATION, V86, P100
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BEOHAR N, 1995, J INVEST MED, V43, P275
   BONITHONKOPP C, 1994, CIRCULATION, V89, P952, DOI 10.1161/01.CIR.89.3.952
   CASTELLANO M, 1995, CIRCULATION, V91, P2721, DOI 10.1161/01.CIR.91.11.2721
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450
   DANSER AHJ, 1995, CIRCULATION, V92, P1387, DOI 10.1161/01.CIR.92.6.1387
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DESMET W, 1994, CIRCULATION, V89, P385, DOI 10.1161/01.CIR.89.1.385
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FARHY RD, 1993, CIRC RES, V72, P1202, DOI 10.1161/01.RES.72.6.1202
   FAXON DP, 1995, J AM COLL CARDIOL, V25, P362, DOI 10.1016/0735-1097(94)00368-Z
   Ferrari M, 2002, CARDIOLOGY, V97, P29, DOI 10.1159/000047416
   FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802
   [高璀乡 GAO Cuixiang], 2006, [南京医科大学学报. 自然科学版, Acta Universitatis Medicinalis Nanjing], V26, P351
   Gensini F, 1999, Minerva Cardioangiol, V47, P516
   Gomma AH, 2002, EUR HEART J, V23, P1955, DOI 10.1053/euhj.2002.3400
   Guarda E, 1999, REV ESP CARDIOL, V52, P475, DOI 10.1016/S0300-8932(99)74954-7
   Guneri S, 2005, INT HEART J, V46, P889, DOI 10.1536/ihj.46.889
   Guo F, 2005, ZHONGGUO YOU SHENG Y, V13, P18
   Gurlek A, 2000, J CARDIOVASC RISK, V7, P403
   Hamon M, 1998, AM J CARDIOL, V81, P79, DOI 10.1016/S0002-9149(97)00852-7
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hoffmann R, 1996, CIRCULATION, V94, P1247, DOI 10.1161/01.CIR.94.6.1247
   Huang T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069056
   Jorgensen E, 2001, J AM COLL CARDIOL, V38, P1434, DOI 10.1016/S0735-1097(01)01580-7
   KAKUTA T, 1994, CIRCULATION, V89, P2809, DOI 10.1161/01.CIR.89.6.2809
   KAMITANI A, 1995, HYPERTENSION, V25, P950, DOI 10.1161/01.HYP.25.5.950
   Kammerer CM, 2004, HYPERTENSION, V43, P466, DOI 10.1161/01.HYP.0000111830.36999.94
   Kaski JC, 1996, AM J CARDIOL, V77, P875, DOI 10.1016/S0002-9149(97)89187-4
   Koch W, 2000, CIRCULATION, V102, P197, DOI 10.1161/01.CIR.102.2.197
   LAFONT A, 1995, CIRC RES, V76, P996, DOI 10.1161/01.RES.76.6.996
   Langeveld B, 2005, J CARDIOVASC PHARM, V45, P88, DOI 10.1097/00005344-200501000-00015
   Lee MS, 2004, J PATHOL, V203, P861, DOI 10.1002/path.1598
   Lv D, 2012, ZHONGGUO FEN ZI XIN, V12, P76
   Ma J, 1997, CANCER RES, V57, P1098
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mintz GS, 1996, AM J CARDIOL, V78, P18, DOI 10.1016/S0002-9149(96)00493-6
   Mintz GS, 1996, CIRCULATION, V94, P35, DOI 10.1161/01.CIR.94.1.35
   MORISHITA R, 1994, J CLIN INVEST, V94, P978, DOI 10.1172/JCI117464
   NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9
   OHISHI M, 1993, NAT GENET, V5, P324, DOI 10.1038/ng1293-324
   Oike Y, 1995, J CLIN INVEST, V96, P2975, DOI 10.1172/JCI118369
   Okamura A, 1999, ANGIOLOGY, V50, P811, DOI 10.1177/000331979905001005
   Okumura K, 2002, CIRC J, V66, P311, DOI 10.1253/circj.66.311
   Passaro A, 2003, J INTERN MED, V254, P264, DOI 10.1046/j.1365-2796.2003.01184.x
   Peters RJ, 1997, CIRCULATION, V95, P2254, DOI 10.1161/01.CIR.95.9.2254
   POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370
   Prisco D, 2000, INT J CLIN LAB RES, V30, P179, DOI 10.1007/s005990070004
   Qu Xiufen, 2002, Zhonghua Yi Xue Za Zhi, V82, P474
   RAKUGI H, 1994, CIRCULATION, V90, P449, DOI 10.1161/01.CIR.90.1.449
   RAKUGI H, 1994, J CLIN INVEST, V93, P339, DOI 10.1172/JCI116965
   Ribichini F, 2003, AM J CARDIOL, V91, P154, DOI 10.1016/S0002-9149(02)03101-6
   Ribichini F, 1998, CIRCULATION, V97, P147, DOI 10.1161/01.CIR.97.2.147
   RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844
   Roiron C, 2006, HEART, V92, P641, DOI 10.1136/hrt.2005.061622
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Ryu SK, 2002, YONSEI MED J, V43, P461, DOI 10.3349/ymj.2002.43.4.461
   SAMANI NJ, 1995, LANCET, V345, P1013, DOI 10.1016/S0140-6736(95)90756-4
   Sampietro ML, 2011, HUM MOL GENET, V20, P4748, DOI 10.1093/hmg/ddr389
   Serruys PW, 1998, LANCET, V352, P673, DOI 10.1016/S0140-6736(97)11128-X
   SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361
   SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801
   SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201
   Taniguchi I, 2001, JPN CIRC J, V65, P897, DOI 10.1253/jcj.65.897
   Tantai J, 2013, TUMOR BIOL, DOI [10.1007/s13277-013-1094-3, DOI 10.1007/S13277-013-1094-3.PUBMED:23959479]
   Tsukada K, 1997, JPN HEART J, V38, P799
   Ujiie Y, 2006, INT HEART J, V47, P173, DOI 10.1536/ihj.47.173
   VanBelle E, 1997, CIRCULATION, V96, P1454, DOI 10.1161/01.CIR.96.5.1454
   VANBOCKXMEER FM, 1995, CIRCULATION, V92, P2066, DOI 10.1161/01.CIR.92.8.2066
   VIOLARIS AG, 1995, CIRCULATION, V91, P2140, DOI 10.1161/01.CIR.91.8.2140
   Volzke H, 2000, CLIN SCI, V99, P19
   Wang H, 2005, ZHONGGUO LIN CHUANG, V9, P33
   Wang SJ, 2005, ZHONGGUO LIN CHUANG, V12, P386
   WEINTRAUB WS, 1993, J AM COLL CARDIOL, V21, P6, DOI 10.1016/0735-1097(93)90711-9
   Wijpkema JS, 2006, PHARMACOGENET GENOM, V16, P331, DOI 10.1097/01.fpc.0000205001.07054.fa
   Yoshida M, 1999, INT J CARDIOL, V70, P119, DOI 10.1016/S0167-5273(99)00064-9
   Zee RYL, 2001, HYPERTENSION, V37, P851, DOI 10.1161/01.HYP.37.3.851
   Zintzaras E, 2008, J CLIN EPIDEMIOL, V61, P634, DOI 10.1016/j.jclinepi.2007.12.011
NR 85
TC 7
Z9 8
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 13
PY 2013
VL 8
IS 12
AR e83415
DI 10.1371/journal.pone.0083415
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276FP
UT WOS:000328734200086
PM 24349507
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU He, MM
   Wu, WJ
   Wang, F
   Wang, ZQ
   Zhang, DS
   Luo, HY
   Qiu, MZ
   Wang, FH
   Ren, C
   Zeng, ZL
   Xu, RH
AF He, Ming-ming
   Wu, Wen-jing
   Wang, Feng
   Wang, Zhi-qiang
   Zhang, Dong-sheng
   Luo, Hui-yan
   Qiu, Miao-zhen
   Wang, Feng-hua
   Ren, Chao
   Zeng, Zhao-lei
   Xu, Rui-hua
TI S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as
   First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PHASE-II TRIAL; S-1 PLUS CISPLATIN; COMBINATION CHEMOTHERAPY;
   ELDERLY-PATIENTS; ORAL FLUOROPYRIMIDINES; CANCER; OXALIPLATIN; THERAPY;
   EFFICACY; FLUOROURACIL
AB Background: Although both oral fluoropyrimidines were reported effective and safe, doubts exist about whether S-1 or capecitabine is more advantageous in advanced gastric carcinoma (AGC). Herein, we performed a meta-analysis to comprehensively compare the efficacy and safety of S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for AGC.
   Methods: PubMed/Medline, EmBase, Cochrane library, and China National Knowledge Infrastructure databases were searched for articles comparing S-1-based chemotherapy to capecitabine-based chemotherapy for AGC. Primary outcomes were overall response rate (ORR), time to progression (TTP), overall survival (OS), progression-free probability, and survival probability. Secondary outcomes were toxicities. Fixed-effects model were used and all the results were confirmed by random-effects model.
   Results: Five randomized controlled trials and five cohort studies with 821 patients were included. We found equivalent ORR (38.3% vs. 39.1%, odds ratio [OR] 0.92, 95% confidence interval [CI] 0.69-1.24, P = 0.59), TTP (harzad ratio [HR] 0.98, 95% CI 0.82-1.16, P = 0.79), OS (HR 0.99, 95% CI 0.87-1.13, P = 0.91), progression-free probability (3-month OR 1.02, 95% CI 0.62-1.68, P = 0.94; 6-month OR 1.34, 95% CI 0.88-2.04, P = 0.18) and survival probability (0.5-year OR 0.90, 95% CI 0.61-1.31, P = 0.57; 1-year OR 0.97, 95% CI 0.70-1.33, P = 0.84; 2-year OR 1.15, 95% CI 0.61-2.17, P = 0.66). Equivalent grade 3 to 4 hematological and non-hematological toxicities were found except hand-foot syndrome was less prominent in S-1-based chemotherapy (0.3% vs. 5.9%, OR 0.19, 95% CI 0.06-0.56, P = 0.003). There're no significant heterogeneity and publication bias. Cumulative analysis found stable time-dependent trend. Consistent results stratified by study design, age, regimen, cycle, country were observed.
   Conclusion: S-1-based chemotherapy was associated with non-inferior antitumor efficacy and better safety profile, compared with capecitabine-based therapy. We recommended S-1 and capecitabine can be used interchangeably for AGC, at least in Asia.
C1 [Xu, Rui-hua] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China.
   Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.
RP Xu, RH (reprint author), Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China.
EM xurh@sysucc.org.cn
OI Xu, Rui-Hua/0000-0001-9771-8534
FU National High Technology Research and Development Program of China (863
   Program), China [2012AA02A506]; Science and Technology Department of
   Guangdong Province, China [2012B031800088]; Medical Scientific Research
   Foundation of Guangdong Province, China [C2011019]
FX This study was supported by National High Technology Research and
   Development Program of China (863 Program), China (No. 2012AA02A506),
   the Science and Technology Department of Guangdong Province, China (No.
   2012B031800088), and Medical Scientific Research Foundation of Guangdong
   Province, China (No. C2011019). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ajani JA, 2010, J CLIN ONCOL, V28, P1547, DOI 10.1200/JCO.2009.25.4706
   [巴楠 Ba Nan], 2012, [中国全科医学, Chinese General Practice], V15, P672
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bittoni A, 2010, EUR REV MED PHARMACO, V14, P309
   Boku N, 2009, LANCET ONCOL, V10, P1063, DOI 10.1016/S1470-2045(09)70259-1
   Boku N, 2008, INT J CLIN ONCOL, V13, P483, DOI 10.1007/s10147-008-0847-2
   Cascinu S, 2008, LANCET ONCOL, V9, P188, DOI 10.1016/S1470-2045(08)70042-1
   Cassidy J, 2011, ANN ONCOL, V22, P2604, DOI 10.1093/annonc/mdr031
   Cassidy J, 2002, ANN ONCOL, V13, P566, DOI 10.1093/annonc/mdf089
   Cervantes A, 2013, CANCER TREAT REV, V39, P60, DOI 10.1016/j.ctrv.2012.09.007
   Chen XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060320
   Chirila C, 2012, INT J COLORECTAL DIS, V27, P623, DOI 10.1007/s00384-011-1349-7
   Choi KS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050041
   CHUGAI BYL, 2009, J CLIN ONCOL S15, V27, P4535
   Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149
   GAO W, 2012, PRACT GERIATR, V26, P501
   Huang JH, 2011, MED ONCOL, V28, P1004, DOI 10.1007/s12032-010-9594-0
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jeung HC, 2007, ONCOLOGIST, V12, P543, DOI 10.1634/theoncologist.12-5-543
   Jin M, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.4533
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Kim GM, 2012, EUR J CANCER, V48, P518, DOI 10.1016/j.ejca.2011.12.017
   Kim YT, 2011, MAR GEORESOUR GEOTEC, V29, P1, DOI 10.1080/1064119X.2010.514237
   Kobayakawa M, 2011, ONCOTARGETS THER, V4, P193, DOI 10.2147/OTT.S19059
   Koizumi W, 2010, ANN ONCOL, V21, P1001, DOI 10.1093/annonc/mdp464
   Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI [10.1016/S1470-2045(08)70035-4, 10.1016/S1470-204S(08)70035-4]
   Kunisaki C, 2013, ANTICANCER RES, V33, P697
   Kunisaki C, 2011, CANCER CHEMOTH PHARM, V67, P1363, DOI 10.1007/s00280-010-1433-7
   Lee JL, 2008, BRIT J CANCER, V99, P584, DOI 10.1038/sj.bjc.6604536
   Liao MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068453
   Lim DH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-583
   Lordick F, 2011, MEMO-MAG EUR MED ONC, V4, P71, DOI 10.1007/s12254-011-0267-2
   LU HF, 2012, MED HERALD, V9, P61
   Lu M, 2011, CHINESE J CANCER RES, V23, P288, DOI 10.1007/s11670-011-0288-8
   Luo HY, 2011, AM J CLIN ONCOL-CANC, V34, P555, DOI 10.1097/COC.0b013e3181f47ac1
   Mochiki E, 2012, BRIT J CANCER, V107, P31, DOI 10.1038/bjc.2012.222
   Oh SY, 2012, INVEST NEW DRUG, V30, P350, DOI 10.1007/s10637-010-9507-2
   Ohtsu A, 2003, J CLIN ONCOL, V21, P54, DOI 10.1200/JCO.2003.04.130
   Okines AFC, 2009, ANN ONCOL, V20, P1529, DOI 10.1093/annonc/mdp047
   Park YH, 2006, BRIT J CANCER, V94, P959, DOI 10.1038/sj.bjc.6603046
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Pieters A, 2008, ACTA GASTRO-ENT BELG, V71, P361
   Ryu MH, 2009, EXPERT REV ANTICANC, V9, P1745, DOI 10.1586/ERA.09.149
   Sawada N, 2007, ONCOL REP, V18, P775
   Seol YM, 2009, JPN J CLIN ONCOL, V39, P43, DOI 10.1093/jjco/hyn119
   Shitara K, 2013, INT J CLIN ONCOL, V18, P539, DOI 10.1007/s10147-012-0416-6
   Stuck AE, 1998, BRIT MED J, V316, P469, DOI 10.1136/bmj.316.7129.469
   Takashima Atsuo, 2009, Gastrointest Cancer Res, V3, P239
   Takiuchi H, 2005, JPN J CLIN ONCOL, V35, P520, DOI 10.1093/jjco/hyi148
   Thuss-Patience PC, 2011, BRIT J CANCER, V105, P505, DOI 10.1038/bjc.2011.278
   Tsai James Y, 2003, Curr Oncol Rep, V5, P210, DOI 10.1007/s11912-003-0112-9
   Tsuburaya A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-307
   Van Cutsem E, 2008, EUR J CANCER, V44, P182, DOI 10.1016/j.ejca.2007.11.001
   Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429
   Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3
   WELLS GA, 2006, NEWCASTLE OTTAWA SCA
   Wu HL, 2011, ASIAN PAC J CANCER P, V12, P3341
   Wu YT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066252
   Xiang XJ, 2012, CHEMOTHERAPY, V58, P1, DOI 10.1159/000335585
   XIONG HL, 2013, J MOD ONCOL, V21, P581
   Yun J, 2010, EUR J CANCER, V46, P885, DOI 10.1016/j.ejca.2009.12.015
   闫树宁, 2012, [中国老年学杂志, Chinese Journal of Gerontology], V32, P2382
NR 62
TC 8
Z9 8
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 12
PY 2013
VL 8
IS 12
AR UNSP e82798
DI 10.1371/journal.pone.0082798
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276EU
UT WOS:000328731800079
PM 24349363
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU He, M
   Wang, W
   Huang, WY
AF He, Miao
   Wang, Wei
   Huang, Wenyong
TI Efficacy and Tolerability of the Fixed Combinations Latanoprost/Timolol
   versus Dorzolamide/Timolol in Patients with Elevated Intraocular
   Pressure: A Meta-Analysis of Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; VISUAL-FIELD PROGRESSION; NORMAL-TENSION GLAUCOMA;
   OCULAR HYPERTENSION; CLINICAL-TRIALS; TIMOLOL; INTERVENTION;
   MONOTHERAPY; SAFETY; BIAS
AB Objective: To evaluate the efficacy and tolerability of the fixed combination of Latanoprost/Timolol versus Dorzolamide/Timolol in the treatment of patients with elevated intraocular pressure (IOP).
   Methods: A comprehensive literature meta-analysis was performed according to the Cochrane Collaboration methodology to identify randomized clinical trials comparing latanoprost/timolol FC (FCLT) with dorzolamide/timolol (FCDT) in patients with elevated IOP. The efficacy estimates were measured by the weight mean difference (WMD) for the IOP reduction (IOPR) from baseline to end point, including the diurnal mean IOPR, 8 AM IOPR, 12 PM IOPR, and 4 PM IOPR. The tolerability estimates were measured by RR for adverse events. All outcomes were reported with a 95% confidence interval (CI). The data were synthesized by Stata 12.0 SE for Windows.
   Results: Eight studies involving 841 patients (841 eyes) were included in the meta-analysis. With a WMD of IOPR in the diurnal mean of 0.16 mmHg (95% CI, -0.31 to 0.63), the FCLT was as effective as FCDT in lowering IOP in patients with elevated IOP (P = 0.51). The WMDs of IOPR were 0.58 mmHg (95% CI: -0.002 to 1.17) at 8 AM, -0.07 mmHg (95% CI: -0.50 to 0.36) at 12 PM, and 0.41 mmHg (95% CI: -0.18 to 1.00) at 4 PM, and there were no significant difference between FCLT and FCDT. FCLT was associated with a significantly lower incidence of eye pain, bitter taste, and irritation/stinging than FCDT, with pooled RRs of 0.34 (95% CI: 0.14 to 0.82), 0.06 (95% CI: 0.008 to 0.42), and 0.35 (95% CI: 0.14 to 0.85), respectively.
   Conclusion: FCLT was associated with equivalent efficacy in IOP lowering comparing with FCDT. However, FCLT was better tolerated than FCDT.
C1 [He, Miao; Wang, Wei; Huang, Wenyong] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
RP Huang, WY (reprint author), Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
EM andyhwyz@aliyun.com
CR [Anonymous], 2011, COCHRANE HDB SYSTEMA
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beidoe G, 2012, CLIN OPHTHALMOL, V6, P1699, DOI 10.2147/OPTH.S32933
   Calvo P, 2012, INVEST OPHTH VIS SCI, V53, P3875, DOI 10.1167/iovs.11-8817
   Caprioli J, 2008, OPHTHALMOLOGY, V115, P1123, DOI 10.1016/j.ophtha.2007.10.031
   Cheng JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045079
   Cheng JW, 2009, OPHTHALMOLOGY, V116, P1243, DOI 10.1016/j.ophtha.2009.01.036
   Cvenkel B, 2008, CURR EYE RES, V33, P163, DOI 10.1080/02713680701832480
   De Moraes CG, 2012, INVEST OPHTH VIS SCI, V53, P1704, DOI 10.1167/iovs.11-8186
   Deokule S, 2010, J GLAUCOMA, V19, P293, DOI 10.1097/IJG.0b013e3181b6e5b9
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eren MH, 2012, J OCUL PHARMACOL TH, V28, P381, DOI 10.1089/jop.2011.0105
   Ernest PJG, 2012, ACTA OPHTHALMOL, V90, P10, DOI 10.1111/j.1755-3768.2010.01995.x
   Fogagnolo P, 2011, EXPERT OPIN INV DRUG, V20, P947, DOI 10.1517/13543784.2011.579901
   Heijl A, 2013, OPHTHALMOLOGY, V120, P1541, DOI 10.1016/j.ophtha.2013.01.043
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Januleviciene I, 2009, EUR J OPHTHALMOL, V19, P790
   Konstas AGP, 2008, BRIT J OPHTHALMOL, V92, P1498, DOI 10.1136/bjo.2008.145219
   Konstas AGP, 2004, EYE, V18, P1264, DOI 10.1038/sj.eye.6701446
   Lambiase A, 2009, P NATL ACAD SCI USA, V106, P13469, DOI 10.1073/pnas.0906678106
   Lee M, 2012, J GLAUCOMA, V21, P596, DOI 10.1097/IJG.0b013e31824cfbf7
   Li TJ, 2013, OPHTHALMOLOGY, V120, P1113, DOI 10.1016/j.ophtha.2012.11.038
   Martinez A, 2007, INT J CLIN PRACT, V61, P815, DOI 10.1111/j.1742-1241.2006.01126.x
   Miglior S, 2010, EYE, V24, P1234, DOI 10.1038/eye.2009.307
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Orme M, 2010, CURR MED RES OPIN, V26, P511, DOI 10.1185/03007990903498786
   Pajic B, 2010, CURR MED RES OPIN, V26, P2213, DOI 10.1185/03007995.2010.508702
   Quaranta L, 2013, J OCUL PHARMACOL TH, V29, P382, DOI 10.1089/jop.2012.0186
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Rasmussen CA, 2011, DRUG FUTURE, V36, P287, DOI 10.1358/dof.2011.36.4.1587772
   Razeghinejad MR, 2010, EXPERT OPIN PHARMACO, V11, P959, DOI 10.1517/14656561003667540
   Shin DH, 2004, OPHTHALMOLOGY, V111, P276, DOI 10.1016/j.ophtha.2003.05.019
   van der Valk R, 2005, OPHTHALMOLOGY, V112, P1177, DOI 10.1016/j.ophtha.2005.01.042
   van der Valk R, 2009, J CLIN EPIDEMIOL, V62, P1279, DOI 10.1016/j.jclinepi.2008.04.012
   Webers CAB, 2007, OPHTHALMOLOGY, V114, P40, DOI 10.1016/j.ophtha.2006.07.018
   Yuce B, 2012, TURK OFTALMOL DERG, V42, P5, DOI 10.4274/tjo.42.30074
NR 37
TC 0
Z9 0
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 11
PY 2013
VL 8
IS 12
AR e83606
DI 10.1371/journal.pone.0083606
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276EG
UT WOS:000328730300150
PM 24349536
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zheng, YY
   Zhu, JH
   Zhou, MR
   Cui, L
   Yao, WM
   Liu, YY
AF Zheng, Yayuan
   Zhu, Jianhong
   Zhou, Manru
   Cui, Liao
   Yao, Weimin
   Liu, Yuyu
TI Meta-Analysis of Long-Term Vitamin D Supplementation on Overall
   Mortality
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; EARLY
   POSTMENOPAUSAL WOMEN; HIGH-DOSE CHOLECALCIFEROL; NURSING-HOME RESIDENTS;
   CHRONIC KIDNEY-DISEASE; BONE-MINERAL DENSITY; DOUBLE-BLIND;
   ELDERLY-WOMEN; OLDER-PEOPLE
AB Introduction: It has been suggested that vitamin D is effective to prevent mortality. However, there is no consistent conclusion that the effects of vitamin D supplementation on all-cause mortality are associated with duration of treatment. We conducted a meta-analysis regarding this issue in an effort to provide a more robust answer.
   Methods: A comprehensive search in a number of databases, including MEDLINE, Embase and The Cochrane Central Register of Controlled Trials, was conducted for collecting randomized controlled trials (RCTs) on vitamin D supplementation preventing mortality. Two investigators independently screened the literature according to the inclusive and exclusive criteria and the relative data were extracted. Data analysis was performed by using Review Manager 5.0 software.
   Results: Data from forty-two RCT s were included. Vitamin D therapy significantly decreased all-cause mortality with a duration of follow-up longer than 3 years with a RR (95% CI) of 0.94 (0.90-0.98). No benefit was seen in a shorter follow-up periods with a RR (95% CI) of 1.04 (0.97-1.12). Results remain robust after sensitivity analysis. The following subgroups of long-term follow-up had significantly fewer deaths: female only, participants with a mean age younger than 80, daily dose of 800 IU or less, participants with vitamin D insufficiency (baseline 25-hydroxyvitamin D level less than 50 nmol/L) and cholecalciferol therapy. In addition, the combination of vitamin D and calcium significantly reduced mortality and vitamin D alone also had a trend to decrease mortality in a longer time follow up.
   Conclusions: The data suggest that supplementation of vitamin D is effective in preventing overall mortality in a long-term treatment, whereas it is not significantly effective in a treatment duration shorter than 3 years. Future studies are needed to identify the efficacy of vitamin D on specific mortality, such as cancer and cardiovascular disease mortality in a long-term treatment duration.
C1 [Zheng, Yayuan; Zhu, Jianhong; Zhou, Manru; Cui, Liao; Liu, Yuyu] Guangdong Med Coll, Dept Pharmacol, Zhanjiang, Peoples R China.
   [Yao, Weimin] Guangdong Med Coll, Inst Resp Dis, Zhanjiang, Peoples R China.
RP Yao, WM (reprint author), Guangdong Med Coll, Inst Resp Dis, Zhanjiang, Peoples R China.
EM 616286464@qq.com; liuyuyu77@yeah.net
FU National Natural Science Foundation of China [81102450]
FX This study was funded by the grants from National Natural Science
   Foundation of China (81102450). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abbas S, 2009, INT J CANCER, V124, P250, DOI 10.1002/ijc.23904
   Aloia JF, 2005, ARCH INTERN MED, V165, P1618, DOI 10.1001/archinte.165.14.1618
   Alvarez JA, 2012, AM J CLIN NUTR, V96, P672, DOI 10.3945/ajcn.112.040642
   Anderson JL, 2010, AM J CARDIOL, V106, P963, DOI 10.1016/j.amjcard.2010.05.027
   Artaza JN, 2009, CLIN J AM SOC NEPHRO, V4, P1515, DOI 10.2215/CJN.02260409
   Autier P, 2007, ARCH INTERN MED, V167, P1730, DOI 10.1001/archinte.167.16.1730
   Avenell Alison, 2004, Clin Trials, V1, P490, DOI 10.1191/1740774504cn053oa
   Avenell A, 2012, J CLIN ENDOCR METAB, V97, P614, DOI 10.1210/jc.2011-1309
   Baeksgaard L, 1998, OSTEOPOROSIS INT, V8, P255, DOI 10.1007/s001980050062
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bischoff-Ferrari HA, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3692
   Bischoff-Ferrari HA, 2012, NEW ENGL J MED, V367, P40, DOI 10.1056/NEJMoa1109617
   BJELAKOVIC G, 2011, COCHRANE DB SYST REV, V7
   Bjoerkman M, 2008, AGE AGEING, V37, P25, DOI 10.1093/ageing/afm141
   Bolland MJ, 2011, AM J CLIN NUTR, V94, P1144, DOI 10.3945/ajcn.111.015032
   Bolton-Smith C, 2007, J BONE MINER RES, V22, P509, DOI 10.1359/JBMR.070116
   Bouillon R, 2006, J STEROID BIOCHEM, V102, P156, DOI 10.1016/j.jsbmb.2006.09.014
   Brazier M, 2005, CLIN THER, V27, P1885, DOI 10.1016/j.clinthera.2005.12.010
   Broe KE, 2007, J AM GERIATR SOC, V55, P234, DOI 10.1111/j.1532-5415.2007.01048.x
   Burleigh E, 2007, AGE AGEING, V36, P507, DOI 10.1093/ageing/afm087
   Cashman KD, 2012, FOOD NUTR RES, V56, DOI 10.3402/fnr.v56i0.5383
   Chapuy MC, 2002, OSTEOPOROSIS INT, V13, P257, DOI 10.1007/s001980200023
   CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305
   Chel V, 2008, OSTEOPOROSIS INT, V19, P663, DOI 10.1007/s00198-007-0465-2
   Chen PZ, 2010, BREAST CANCER RES TR, V121, P469, DOI 10.1007/s10549-009-0593-9
   Chung Mei, 2009, Evid Rep Technol Assess (Full Rep), P1
   Cooper L, 2003, AM J CLIN NUTR, V77, P1324
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Flicker L, 2005, J AM GERIATR SOC, V53, P1881, DOI 10.1111/j.1532-5415.2005.00468.x
   Gepner AD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036617
   Gilbert R, 2011, CANCER CAUSE CONTROL, V22, P319, DOI 10.1007/s10552-010-9706-3
   Giovannucci E, 2008, ARCH INTERN MED, V168, P1174, DOI 10.1001/archinte.168.11.1174
   Harwood RH, 2004, AGE AGEING, V33, P45, DOI 10.1093/ageing/afh002
   Higgins JP, 2008, COCHRANE HDB SYSTEMA
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Holick MF, 2004, AM J CLIN NUTR, V79, P362
   Hsia J, 2007, CIRCULATION, V115, P846, DOI 10.1161/CIRCULATIONAHA.106.673491
   Kalyani RR, 2010, J AM GERIATR SOC, V58, P1299, DOI 10.1111/j.1532-5415.2010.02949.x
   Kilkkinen A, 2008, CANCER EPIDEM BIOMAR, V17, P3274, DOI 10.1158/1055-9965.EPI-08-0199
   Komulainen M, 1999, J CLIN ENDOCR METAB, V84, P546, DOI 10.1210/jc.84.2.546
   Krieg MA, 1999, OSTEOPOROSIS INT, V9, P483, DOI 10.1007/s001980050265
   Lappe JM, 2007, AM J CLIN NUTR, V85, P1586
   Larsen ER, 2004, J BONE MINER RES, V19, P370, DOI 10.1359/JBMR.0301240
   Latham NK, 2003, J AM GERIATR SOC, V51, P291, DOI 10.1046/j.1532-5415.2003.51101.x
   Lavie CJ, 2011, J AM COLL CARDIOL, V58, P1547, DOI 10.1016/j.jacc.2011.07.008
   Law M, 2006, AGE AGEING, V35, P482, DOI 10.1093/ageing/afj080
   Lee JH, 2008, J AM COLL CARDIOL, V52, P1949, DOI 10.1016/j.jacc.2008.08.050
   Lehouck A, 2012, ANN INTERN MED, V156, P105, DOI 10.7326/0003-4819-156-2-201201170-00004
   Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003
   Lips P, 2010, AM J CLIN NUTR, V91, P985, DOI 10.3945/ajcn.2009.28113
   Lyons RA, 2007, OSTEOPOROSIS INT, V18, P811, DOI 10.1007/s00198-006-0309-5
   Ma YL, 2011, J CLIN ONCOL, V29, P3775, DOI 10.1200/JCO.2011.35.7566
   Margolis KL, 2008, HYPERTENSION, V52, P847, DOI 10.1161/HYPERTENSIONAHA.108.114991
   Mathieu C, 2005, DIABETOLOGIA, V48, P1247, DOI 10.1007/s00125-005-1802-7
   Meier C, 2004, J BONE MINER RES, V19, P1221, DOI 10.1359/JBMR.040511
   Melamed ML, 2008, ARCH INTERN MED, V168, P1629, DOI 10.1001/archinte.168.15.1629
   Meyer HE, 2002, J BONE MINER RES, V17, P709, DOI 10.1359/jbmr.2002.17.4.709
   Michaelsson K, 2010, AM J CLIN NUTR, V92, P841, DOI 10.3945/ajcn.2010.29749
   Mithal A, 2009, OSTEOPOROSIS INT, V20, P1807, DOI 10.1007/s00198-009-0954-6
   OOMS ME, 1995, J CLIN ENDOCR METAB, V80, P1052, DOI 10.1210/jc.80.4.1052
   Porthouse J, 2005, BMJ-BRIT MED J, V330, P1003, DOI 10.1136/bmj.330.7498.1003
   Prince RL, 2008, ARCH INTERN MED, V168, P103, DOI 10.1001/archinternmed.2007.31
   Punthakee Z, 2012, DIABETOLOGIA, V55, P36, DOI 10.1007/s00125-011-2357-4
   Ravani P, 2009, KIDNEY INT, V75, P88, DOI 10.1038/ki.2008.501
   Rejnmark L, 2012, J CLIN ENDOCR METAB, V97, P2670, DOI 10.1210/jc.2011-3328
   Rovner AJ, 2008, PEDIATRICS, V122, P907, DOI 10.1542/peds.2008-1743
   Salovaara K, 2010, J BONE MINER RES, V25, P1487, DOI 10.1002/jbmr.48
   Sanders KM, 2010, JAMA-J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594
   Schleithoff SS, 2006, AM J CLIN NUTR, V83, P754
   Sugden JA, 2008, DIABETIC MED, V25, P320, DOI 10.1111/j.1464-5491.2007.02360.x
   Thacher TD, 2011, MAYO CLIN PROC, V86, P50, DOI 10.4065/mcp.2010.0567
   Touvier M, 2011, CANCER EPIDEM BIOMAR, V20, P1003, DOI 10.1158/1055-9965.EPI-10-1141
   Trivedi DP, 2003, BMJ-BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469
   Uusi-Rasi K, 2013, FOOD NUTR RES, V57, DOI 10.3402/fnr.v57i0.21082
   van den Bergh Joop P W, 2011, Curr Osteoporos Rep, V9, P36, DOI 10.1007/s11914-010-0041-0
   Wahl D A, 2012, Arch Osteoporos, V7, P155, DOI 10.1007/s11657-012-0093-0
   Wang TJ, 2008, CIRCULATION, V117, P503, DOI 10.1161/CIRCULATIONAHA.107.706127
   Wasse H, 2012, AM J CLIN NUTR, V95, P522, DOI 10.3945/ajcn.111.025502
   Wejse C, 2009, AM J RESP CRIT CARE, V179, P843, DOI 10.1164/rccm.200804-567OC
   Witham MD, 2010, CIRC-HEART FAIL, V3, P195, DOI 10.1161/CIRCHEARTFAILURE.109.907899
   Zhu K, 2008, J CLIN ENDOCR METAB, V93, P743, DOI 10.1210/jc.2007-1466
NR 82
TC 44
Z9 49
U1 0
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 3
PY 2013
VL 8
IS 12
AR UNSP e82109
DI 10.1371/journal.pone.0082109
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 265JR
UT WOS:000327947800084
PM 24349197
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Bai, HW
   Qian, YY
   Shi, BY
   Li, G
   Fan, Y
   Wang, Z
   Yuan, M
   Liu, LP
AF Bai, Hong-wei
   Qian, Ye-yong
   Shi, Bing-yi
   Li, Gang
   Fan, Yu
   Wang, Zhen
   Yuan, Ming
   Liu, Lu-peng
TI The Association between Fish Consumption and Risk of Renal Cancer: A
   Meta-Analysis of Observational Studies
SO PLOS ONE
LA English
DT Article
ID N-3 FATTY-ACIDS; CELL CARCINOMA; KIDNEY CANCER; COLORECTAL-CANCER;
   ESOPHAGEAL CANCER; FOOD GROUPS; DIET; MERCURY; POPULATION; MEAT
AB Background: Several case-control studies and cohort studies have investigated the association between fish intake and renal cancer risk, however, they yielded conflicting results. To our knowledge, a comprehensive assessment of the association between fish consumption and risk of renal cancer has not been reported. Hence, we conducted a systematic literature search and meta-analysis to quantify the association between fish consumption and renal cancer.
   Methods: A systematic search was performed using the PubMed, Embase, and Cochrane Library Central database for case-control and cohort studies that assessed fish intake and risk of renal cancer. Two authors independently assessed eligibility and extracted data. Fixed-effect and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Subgroup analyses, sensitivity analysis and cumulative meta-analysis were also performed.
   Results: A total of 12 case-control studies and three cohort studies published between 1990 and 2011 were included in the meta-analysis, involving 9,324 renal cancer cases and 608,753 participants. Meta-analysis showed that fish consumption did not significantly affect the risk of renal cancer (RR=0.99, 95% CI [0.92,1.07]). In our subgroup analyses, the results were not substantially affected by study design, region, gender, and confounder adjustments. Furthermore, sensitivity analysis confirmed the stability of results.
   Conclusions: The present meta-analysis suggested that there was no significant association between fish consumption and risk of renal cancer. More in-depth studies are warranted to report more detailed results, including stratified results by fish type, preparation method, and gender.
C1 [Bai, Hong-wei; Qian, Ye-yong; Shi, Bing-yi; Li, Gang; Fan, Yu; Wang, Zhen; Yuan, Ming; Liu, Lu-peng] 309th Hosp PLA, Inst Organ Transplantat PLA, Dept Urol, Beijing, Peoples R China.
RP Shi, BY (reprint author), 309th Hosp PLA, Inst Organ Transplantat PLA, Dept Urol, Beijing, Peoples R China.
EM shibingyizxl@126.com
CR Aune D, 2011, GASTROENTEROLOGY, V141, P106, DOI 10.1053/j.gastro.2011.04.013
   Barbier O., 2005, NEPHRON PHYSIOL, V99, P105, DOI DOI 10.1159/000083981
   Bates CJ, 2006, BRIT J NUTR, V96, P523, DOI 10.1079/BJN20061847
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boeing H, 1997, Z ERNAHRUNGSWISS, V36, P3, DOI 10.1007/BF01618893
   Bravi F, 2007, INT J CANCER, V120, P681, DOI 10.1002/ijc.22225
   Cerchietti LCA, 2007, NUTR CANCER, V59, P14, DOI 10.1080/01635580701365068
   Chapkin RS, 2007, J NUTR, V137, p200S, DOI 10.1093/jn/137.1.200S
   Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46
   Corrao G, 2007, CURR DRUG SAF, V2, P125, DOI 10.2174/157488607780598296
   Curti BD, 2004, JAMA-J AM MED ASSOC, V292, P97, DOI 10.1001/jama.292.1.97
   Daniel CR, 2011, CANCER PREV RES, V4, P1903, DOI 10.1158/1940-6207.CAPR-11-0241
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dhote R, 2000, BJU INT, V86, P20, DOI 10.1046/j.1464-410x.2000.00708.x
   Dobrowolski Z, 2002, EUR UROL, V42, P475, DOI 10.1016/S0302-2838(02)00400-1
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Faramawi MF, 2007, CANCER CAUSE CONTROL, V18, P125, DOI 10.1007/s10552-006-0104-9
   Fernandez E, 1999, AM J CLIN NUTR, V70, P85
   Ford JH, 2010, AGE, V32, P231, DOI 10.1007/s11357-009-9128-x
   Fujioka T, 2000, WORLD J SURG, V24, P1205, DOI 10.1007/s002680010206
   Grieb SMD, 2009, J AM DIET ASSOC, V109, P656, DOI 10.1016/j.jada.2008.12.020
   Han YJ, 2013, EUR J CLIN NUTR, V67, P147, DOI 10.1038/ejcn.2012.213
   Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hilakivi-Clarke L, 2005, J NUTR, V135, p2946S, DOI 10.1093/jn/135.12.2946S
   Hsu CC, 2007, AM J EPIDEMIOL, V166, P62, DOI 10.1093/aje/kwm043
   Hu JF, 2003, CANCER CAUSE CONTROL, V14, P705, DOI 10.1023/A:1026310323882
   Hu JF, 2008, NUTR CANCER, V60, P313, DOI 10.1080/01635580701759724
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   KREIGER N, 1993, CANCER CAUSE CONTROL, V4, P101, DOI 10.1007/BF00053150
   Li ZY, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-107
   Lindblad P, 1997, CANCER EPIDEM BIOMAR, V6, P215
   Maclure M, 1990, Epidemiology, V1, P430, DOI 10.1097/00001648-199011000-00004
   Mathew A, 2002, EUR J CANCER PREV, V11, P171, DOI 10.1097/00008469-200204000-00010
   MCLAUGHLIN JK, 1992, INT J CANCER, V52, P562, DOI 10.1002/ijc.2910520411
   Mellemgaard A, 1996, EUR J CANCER, V32A, P673, DOI 10.1016/0959-8049(95)00633-8
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Qin B, 2012, J NUTR, V142, P1067, DOI 10.3945/jn.111.156711
   Rashidkhani B, 2005, J NUTR, V135, P1757
   Risher JF, 2002, TOXICOL IND HEALTH, V18, P109, DOI 10.1191/0748233702th138oa
   Salehi M, 2013, NUTR REV, V71, P257, DOI 10.1111/nure.12028
   Stoll BA, 2002, BRIT J NUTR, V87, P193, DOI [10.1079/BJNBJN2001512, 10.1079/BJN2002512]
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Szymanski KM, 2010, AM J CLIN NUTR, V92, P1223, DOI 10.3945/ajcn.2010.29530
   TALAMINI R, 1990, CANCER CAUSE CONTROL, V1, P125, DOI 10.1007/BF00053163
   Wennberg M, 2006, ENVIRON RES, V100, P330, DOI 10.1016/j.envres.2005.08.013
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   Wilson RT, 2009, AM J EPIDEMIOL, V170, P717, DOI 10.1093/aje/kwp178
   Wolk A, 1996, INT J CANCER, V65, P67, DOI 10.1002/(SICI)1097-0215(19960103)65:1<67::AID-IJC12>3.3.CO;2-R
   Wolk A, 2006, JAMA-J AM MED ASSOC, V296, P1371, DOI 10.1001/jama.296.11.1371
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Wu SJ, 2012, AM J MED, V125, P551, DOI 10.1016/j.amjmed.2012.01.022
   Zalups RK, 2000, PHARMACOL REV, V52, P113
   Zhou Y, 2011, GASTROENTEROLOGY, V141, P80, DOI 10.1053/j.gastro.2011.03.057
NR 54
TC 0
Z9 0
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 28
PY 2013
VL 8
IS 11
AR UNSP e81939
DI 10.1371/journal.pone.0081939
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 261IJ
UT WOS:000327657900063
PM 24312383
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, X
   Shan, BE
   Wang, J
   Xing, LP
   Guo, XJ
   Zhang, YH
   Shi, PH
   Wang, ZY
AF Li, Xing
   Shan, Bao-En
   Wang, Juan
   Xing, Lian-Ping
   Guo, Xiao-Jin
   Zhang, Yue-Hua
   Shi, Peng-Hui
   Wang, Zhi-Yu
TI Incidence and Risk of Treatment-Related Mortality with Anti-Epidermal
   Growth Factor Receptor Monoclonal Antibody in Cancer Patients: A
   Meta-Analysis of 21 Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID PHASE-III TRIAL; SQUAMOUS-CELL CARCINOMA; COLORECTAL-CANCER; PLUS
   CETUXIMAB; 1ST-LINE TREATMENT; CHEMOTHERAPY; PANITUMUMAB; OXALIPLATIN;
   FLUOROURACIL; LEUCOVORIN
AB Background: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) cetuximab and panitumumab have emerged as an effective targeted therapy in the treatment of cancer patients, but the overall incidence and risk of fatal adverse events (FAEs) associated with these agents is still unclear.
   Methods: Databases from PubMed, Web of Science and abstracts presented at ASCO meeting up to May 31, 2013 were searched to identify relevant studies. Eligible studies included prospective randomized controlled trials evaluating MoAbs in cancer patients with adequate data on FAEs. Statistical analyses were conducted to calculate the summary incidence, odds ratio and 95% confidence intervals (CIs) by using either random effects or fixed effect models according to the heterogeneity of included studies.
   Results: A total of 14,776 patients with a variety of solid tumors from 21 clinical trials were included in our analysis. The overall incidence of MoAbs associated FAEs was 1.7% (95% CI: 1.1-2.5%), and the incidence of cetuximab-related FAEs was higher than that of panitumumab (2.0% versus 0.9%). Compared with the controls, the use of MoAbs was associated with a significantly increased risk of FAEs, with an OR of 1.37 (95% CI: 1.04-1.81, p=0.024). Subgroup analysis based on EGFR-MoAbs drugs, phase of trials and tumor types demonstrated a tendency to increase the risk of FAEs, but the risk did not increase in breast cancer, esophagus cancer and phase II trials.
   Conclusions: With present evidence, the use of EGFR-MoAbs is associated with an increased risk of FAEs in patients with advanced solid tumors.
C1 [Li, Xing; Wang, Juan; Guo, Xiao-Jin; Zhang, Yue-Hua; Shi, Peng-Hui; Wang, Zhi-Yu] Hebei Med Univ, Hosp 4, Dept Biotherapy, Shijiazhuang, Peoples R China.
   [Shan, Bao-En] Hebei Med Univ, Hosp 4, Ctr Sci Res, Shijiazhuang, Peoples R China.
   [Xing, Lian-Ping] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.
RP Wang, ZY (reprint author), Hebei Med Univ, Hosp 4, Dept Biotherapy, Shijiazhuang, Peoples R China.
EM Wangzhiyu201307@163.com
FU National Natural Science Foundation of China [81202037]
FX The study was supported by grants from the National Natural Science
   Foundation of China (81202037). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alberts SR, 2012, JAMA-J AM MED ASSOC, V307, P1383, DOI 10.1001/jama.2012.385
   Baselga J, 2013, BREAST CANC J CLIN O
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397
   Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422
   Butts CA, 2007, J CLIN ONCOL, V25, P5777, DOI 10.1200/JCO.2007.13.0856
   Cohen MH, 2003, ONCOLOGIST, V8, P303, DOI 10.1634/theoncologist.8-4-303
   Cohen MH, 2005, ONCOLOGIST, V10, P461, DOI 10.1634/theoncologist.10-7-461
   Cohenuram M, 2007, ANTI-CANCER DRUG, V18, P7, DOI 10.1097/CAD.0b013e32800feecb
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Govindan R, 2011, J CLIN ONCOL, V29, P3120, DOI 10.1200/JCO.2010.33.4979
   Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002
   Hecht JR, 2009, J CLIN ONCOL, V27, P672, DOI 10.1200/JCO.2008.19.8135
   ITAKURA Y, 1994, CANCER, V74, P795, DOI 10.1002/1097-0142(19940801)74:3<795::AID-CNCR2820740303>3.0.CO;2-I
   Kari C, 2003, CANCER RES, V63, P1
   Lilenbaum R, 2009, J CLIN ONCOL, V27, P4487, DOI 10.1200/JCO.2009.22.7066
   Lorenzen S, 2009, ANN ONCOL, V20, P1667, DOI 10.1093/annonc/mdp069
   Lynch TJ, 2010, J CLIN ONCOL, V28, P911, DOI 10.1200/JCO.2009.21.9618
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   NCI Cancer Therapy Evaluation Program, CANC THER EV PROGR C
   Oldham RK, 2008, J CLIN ONCOL, V26, P1774, DOI 10.1200/JCO.2007.15.7438
   Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055
   Philip PA, 2010, J CLIN ONCOL, V28, P3605, DOI 10.1200/JCO.2009.25.7550
   Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9
   Qi WX, 2013, RESP MED, V107, P1280, DOI 10.1016/j.rmed.2013.06.005
   Saltz L, 2012, CLIN COLORECTAL CANC, V11, P101, DOI [10.1016/j.clcc.2011.05.006, 10.1016/clcc.2011.05.006]
   Schutz FAB, 2012, J CLIN ONCOL, V30, P871, DOI 10.1200/JCO.2011.37.1195
   Selvaggi G, 2004, ANN ONCOL, V15, P28, DOI 10.1093/annonc/mdh011
   Siena S, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.08.1620
   Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193
   Sok JC, 2006, CLIN CANCER RES, V12, P5064, DOI 10.1158/1078-0432.CCR-06-0913
   Suzuki M, 2005, HUM PATHOL, V36, P1127, DOI 10.1016/j.humpath.2005.08.007
   Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5
   Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656
   Wong SF, 2005, CLIN THER, V27, P684, DOI 10.1016/j.clinthera.2005.06.003
   YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7
   Zhang D, 2013, J CHEMOTHERAPY, V25, P170, DOI 10.1179/1973947813Y.0000000070
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 44
TC 7
Z9 7
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 28
PY 2013
VL 8
IS 11
AR e81897
DI 10.1371/journal.pone.0081897
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 261IJ
UT WOS:000327657900060
PM 24312376
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Kicinski, M
AF Kicinski, Michal
TI Publication Bias in Recent Meta-Analyses
SO PLOS ONE
LA English
DT Article
ID ANTIDEPRESSANT TRIALS; SELECTION MODELS; FILL METHOD; TRIM; PERFORMANCE;
   DATABASE; IMPACT; TESTS; SIZE
AB Introduction: Positive results have a greater chance of being published and outcomes that are statistically significant have a greater chance of being fully reported. One consequence of research underreporting is that it may influence the sample of studies that is available for a meta-analysis. Smaller studies are often characterized by larger effects in published meta-analyses, which can be possibly explained by publication bias. We investigated the association between the statistical significance of the results and the probability of being included in recent meta-analyses.
   Methods: For meta-analyses of clinical trials, we defined the relative risk as the ratio of the probability of including statistically significant results favoring the treatment to the probability of including other results. For meta-analyses of other studies, we defined the relative risk as the ratio of the probability of including biologically plausible statistically significant results to the probability of including other results. We applied a Bayesian selection model for meta-analyses that included at least 30 studies and were published in four major general medical journals (BMJ, JAMA, Lancet, and PLOS Medicine) between 2008 and 2012.
   Results: We identified 49 meta-analyses. The estimate of the relative risk was greater than one in 42 meta-analyses, greater than two in 16 meta-analyses, greater than three in eight meta-analyses, and greater than five in four meta-analyses. In 10 out of 28 meta-analyses of clinical trials, there was strong evidence that statistically significant results favoring the treatment were more likely to be included. In 4 out of 19 meta-analyses of observational studies, there was strong evidence that plausible statistically significant outcomes had a higher probability of being included.
   Conclusions: Publication bias was present in a substantial proportion of large meta-analyses that were recently published in four major medical journals.
C1 Hasselt Univ, Dept Sci, Hasselt, Belgium.
RP Kicinski, M (reprint author), Hasselt Univ, Dept Sci, Hasselt, Belgium.
EM michal.kicinski@uhasselt.be
CR Ahmed I, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d7762
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brien SE, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d636
   CASELLA G, 1992, AM STAT, V46, P167, DOI 10.2307/2685208
   CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405
   Chavers S, 2011, PHARMACOEPIDEM DR S, V20, P1009, DOI 10.1002/pds.2221
   Copas JB, 2001, STAT METHODS MED RES, V10, P251, DOI 10.1191/096228001678227776
   Dear KB, 1992, STAT SCI, V7, P237, DOI DOI 10.1214/SS/1177011363
   Decullier E, 2005, BMJ-BRIT MED J, V331, P19, DOI 10.1136/bmj.38488.385995.8F
   Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016
   DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385
   Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gelman A., 2003, BAYESIAN DATA ANAL
   Gelman A, 2006, BAYESIAN ANAL, V1, P515, DOI 10.1214/06-BA117A
   Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380
   Hedges LV, 1996, J EDUC BEHAV STAT, V21, P299, DOI 10.2307/1165338
   HEDGES LV, 1992, STAT SCI, V7, P246, DOI DOI 10.1214/SS/1177011364
   Hemingway H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000286
   Ioannidis JPA, 2007, CLIN TRIALS, V4, P245, DOI 10.1177/1740774507079441
   Iyengar Shanto, 1988, STAT SCI, V3, P109, DOI DOI 10.1214/SS/1177013012
   Jalota L, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1110
   Jang J, 2009, J STAT COMPUT SIM, V79, P691, DOI 10.1080/00949650801891595
   Kirkham JJ, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c365
   Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010
   Kromrey JD, 2006, EDUC PSYCHOL MEAS, V66, P357, DOI 10.1177/0013164405278585
   KULINSKAYA E, 2008, METAANALYSIS GUIDE C
   Lambert PC, 2005, STAT MED, V24, P2401, DOI 10.1002/sim.2112
   Lau J, 2006, BMJ-BRIT MED J, V333, P597, DOI 10.1136/bmj.333.7568.597
   Lee K, 2008, PLOS MED, V5, P1348, DOI 10.1371/journal.pmed.0050191
   Macaskill P, 2001, STAT MED, V20, P641, DOI 10.1002/sim.698
   Moreno SG, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-2
   Moreno SG, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2981
   Norman RE, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001349
   Nuesch E, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3515
   Peters JL, 2007, STAT MED, V26, P4544, DOI 10.1002/sim.2889
   Peters JL, 2010, J R STAT SOC A STAT, V173, P575, DOI 10.1111/j.1467-985X.2009.00629.x
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Ronksley PE, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d671
   Rucker G, 2008, STAT MED, V27, P746, DOI 10.1002/sim.2971
   Rucker G, 2011, BIOSTATISTICS, V12, P122, DOI 10.1093/biostatistics/kxq046
   Rufibach K, 2011, BIOMETRICAL J, V53, P689, DOI 10.1002/bimj.201000240
   Silliman NP, 1997, J AM STAT ASSOC, V92, P926, DOI 10.2307/2965556
   Song FJ, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-79
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002
   Sutton AJ, 2000, STAT METHODS MED RES, V9, P421, DOI 10.1191/096228000701555244
   Terrin N, 2003, STAT MED, V22, P2113, DOI 10.1002/sim.1461
   Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779
   Zhang ZH, 2013, CRIT CARE, V17, DOI 10.1186/cc11919
NR 52
TC 46
Z9 47
U1 1
U2 33
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 27
PY 2013
VL 8
IS 11
AR UNSP e81823
DI 10.1371/journal.pone.0081823
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 261GG
UT WOS:000327652100101
PM 24363797
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, SY
   Liu, CF
   Min, XY
   Ji, YY
   Wang, N
   Liu, D
   Cai, JY
   Li, K
AF Liu, Shuyan
   Liu, Chengfei
   Min, Xiaoyun
   Ji, Yuanyuan
   Wang, Na
   Liu, Dan
   Cai, Jiangyi
   Li, Ke
TI Prognostic Value of Cancer Stem Cell Marker Aldehyde Dehydrogenase in
   Ovarian Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; INITIATING CELLS; PROSTATE-CANCER; POOR-PROGNOSIS;
   IDENTIFICATION; ALDH1; POPULATION; METASTASIS; EXPRESSION; CARCINOMA
AB Objective: Aldehyde dehydrogenase (ALDH) has recently been reported as a marker of cancer stem-like cells in ovarian cancer. However, the prognostic role of ALDH in ovarian cancer still remains controversial. In this study, we aimed to evaluate the association between the expression of ALDH and the outcome of ovarian cancer patients by performing a meta-analysis.
   Methods: We systematically searched for studies investigating the relationships between ALDH expression and outcome of ovarian cancer patients. Only articles in which ALDH expression was detected by immunohistochemical staining were included. A meta-analysis was performed to generate combined hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS).
   Results: A total of 1,258 patients from 7 studies (6 articles) were included in the analysis. Our results showed that high ALDH expression in patients with ovarian cancer was associated with poor prognosis in terms of Os (HR, 1.25; 95% CI, 1.07-1.47; P = 0.005) and DFS (HR, 1.58; 95% CI, 1.00-2.49; P = 0.052), though the difference for DFS was not statistically significant. In addition, there was no evidence of publication bias as suggested by Begg's and Egger's tests (Begg's test, P = 0.707; Egger's test, P = 0.355).
   Conclusion: The present meta-analysis indicated that elevated ALDH expression was associated with poor prognosis in patients with ovarian cancer.
C1 [Liu, Shuyan; Liu, Chengfei; Min, Xiaoyun; Ji, Yuanyuan; Wang, Na; Liu, Dan; Li, Ke] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 2, Core Res Lab, Xian 710049, Peoples R China.
   [Liu, Shuyan] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Reprod Med, Xian 710049, Peoples R China.
   [Cai, Jiangyi] Aerosp Gen Hosipital, Dept Pathol, Xian, Peoples R China.
RP Li, K (reprint author), Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 2, Core Res Lab, Xian 710049, Peoples R China.
EM ke.li@mail.xjtu.edu.cn
RI Li, Ke/O-6291-2014
FU National Natural Science Foundation of China [81000922]; Fundamental
   Research Funds for the Central Universities [2010jdgz09]
FX This work was supported by grant from the National Natural Science
   Foundation of China (No. 81000922) and the Fundamental Research Funds
   for the Central Universities (No. 2010jdgz09). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Carpentino JE, 2009, CANCER RES, V69, P8208, DOI 10.1158/0008-5472.CAN-09-1132
   Chang B, 2009, MODERN PATHOL, V22, P817, DOI 10.1038/modpathol.2009.35
   Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630
   Chu P, 2009, INT J CANCER, V124, P1312, DOI 10.1002/ijc.24061
   Clay MR, 2010, HEAD NECK-J SCI SPEC, V32, P1195, DOI 10.1002/hed.21315
   Deng S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010277
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808
   Kim MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020636
   Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432
   Kuroda T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065158
   Landen CN, 2010, MOL CANCER THER, V9, P3186, DOI 10.1158/1535-7163.MCT-10-0563
   Liebscher CA, 2013, HUM PATHOL, V44, P1465, DOI 10.1016/j.humpath.2012.12.016
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Luo YC, 2012, STEM CELLS, V30, P2100, DOI 10.1002/stem.1193
   Neumeister V, 2010, AM J PATHOL, V176, P2131, DOI 10.2353/ajpath.2010.090712
   Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009
   Rahadiani N, 2011, CANCER SCI, V102, P903, DOI 10.1111/j.1349-7006.2011.01864.x
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ricci F, 2013, AM J CANCER RES, V3, P221
   Rosen DG, 2009, FRONT BIOSCI-LANDMRK, V14, P2089, DOI 10.2741/3364
   Su Y, 2010, CANCER EPIDEM BIOMAR, V19, P327, DOI 10.1158/1055-9965.EPI-09-0865
   Sullivan JP, 2010, CANCER RES, V70, P9937, DOI 10.1158/0008-5472.CAN-10-0881
   van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806
   Vermeulen L, 2008, CELL DEATH DIFFER, V15, P947, DOI 10.1038/cdd.2008.20
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wang YC, 2012, AM J PATHOL, V180, P1159, DOI 10.1016/j.ajpath.2011.11.015
   Winter WE, 2007, J CLIN ONCOL, V25, P3621, DOI 10.1200/JCO.2006.10.2517
   Zhou L, 2013, HUM PATHOL, V44, P2180, DOI 10.1016/j.humpath.2013.03.021
NR 36
TC 24
Z9 24
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 25
PY 2013
VL 8
IS 11
AR UNSP e81050
DI 10.1371/journal.pone.0081050
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 259RH
UT WOS:000327543500070
PM 24282568
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, C
   Chi, FL
   Xie, TH
   Zhou, YH
AF Zhang, Chi
   Chi, Feng-Ling
   Xie, Tian-Hao
   Zhou, Yu-Hao
TI Effect of B-vitamin Supplementation on Stroke: a Meta-Analysis of
   Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID FOLIC-ACID; PLASMA HOMOCYSTEINE; CARDIOVASCULAR EVENTS; RISK-FACTOR;
   PREVENTION; FOLATE; DISEASE
AB Background: B vitamins have been extensively used to reduce homocysteine levels; however, it remains uncertain whether B vitamins are associated with a reduced risk of stroke. Our aim was to evaluate the effects of B vitamins on stroke.
   Methodology and Principal findings: We systematically searched PubMed, EmBase, and the Cochrane Central Register of Controlled Trials to identify studies for our analysis. Relative risk (RR) was used to measure the effect of B-vitamin supplementation on the risk of stroke. The analysis was further stratified based on factors that could affect the treatment effects. Of the 13,124 identified articles, we included 18 trials reporting data on 57,143 individuals and 2,555 stroke events. B-vitamin supplementation was not associated with a significant reduction in the risk of stroke (RR, 0.91, 95%CI: 0.82-1.01, P = 0.075; RD, -0.003, 95%CI: -0.007-0.001, P = 0.134). Subgroup analyses suggested that B-vitamin supplementation might reduce the risk of stroke if included trials had a man/woman ratio of more than 2 or subjects received dose of folic acid less than 1 mg. Furthermore, in a cumulative meta-analysis for stroke, the originally proposed nonsignificant B-vitamin effect was refuted by the evidence accumulated up to 2006. There is a small effect with borderline statistical significance based on data gathered since 2007.
   Conclusions/Significance: Our study indicates that B-vitamin supplementation is not associated with a lower risk of stroke based on relative and absolute measures of association. Subgroup analyses suggested that B-vitamin supplementation can effectively reduce the risk of stroke if included trials had a man/woman ratio of more than 2 or subjects received dose of folic acid less than 1 mg.
C1 [Zhang, Chi; Chi, Feng-Ling] Shanghai Seventh Peoples Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Xie, Tian-Hao] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Zhou, Yu-Hao] Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.
RP Zhou, YH (reprint author), Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.
EM zhou_ly@126.com
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Al-Delaimy WK, 2004, STROKE, V35, P1259, DOI 10.1161/01.STR.0000127813.12854.9c
   Albert CM, 2008, JAMA-J AM MED ASSOC, V299, P2027, DOI 10.1001/jama.299.17.2027
   Armitage JM, 2010, JAMA-J AM MED ASSOC, V303, P2486, DOI 10.1001/jama.2010.840
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227
   Bostom AG, 2011, CIRCULATION, V123, P1763, DOI 10.1161/CIRCULATIONAHA.110.000588
   BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049
   BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012
   Cole BF, 2007, JAMA-J AM MED ASSOC, V297, P2351, DOI 10.1001/jama.297.21.2351
   Deeks JJ, 2008, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ebbing M, 2008, JAMA-J AM MED ASSOC, V300, P795, DOI 10.1001/jama.300.7.795
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Galan P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6273
   Hankey GJ, 2010, LANCET NEUROL, V9, P855, DOI 10.1016/S1474-4422(10)70187-3
   He K, 2004, STROKE, V35, P169, DOI 10.1161/01.STR.0000106762.55994.86
   Heinz J, 2010, CIRCULATION, V121, P1432, DOI 10.1161/CIRCULATIONAHA.109.904672
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   House AA, 2010, JAMA-J AM MED ASSOC, V303, P1603, DOI 10.1001/jama.2010.490
   Huang T, 2012, CLIN NUTR, V31, P448, DOI 10.1016/j.clnu.2011.01.003
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jamison RL, 2007, JAMA-J AM MED ASSOC, V298, P1163, DOI 10.1001/jama.298.10.1163
   Ji Y, 2013, NEUROLOGY, V81, P1298, DOI 10.1212/WNL.0b013e3182a823cc
   Larsson SC, 2008, AM J EPIDEMIOL, V167, P954, DOI 10.1093/aje/kwm395
   Liem A, 2005, HEART, V91, P1213, DOI 10.1136/hrt.2004.035030
   LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795
   McNulty H, 2008, P NUTR SOC, V67, P232, DOI 10.1017/S0029665108007076
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Righetti M, 2006, BLOOD PURIFICAT, V24, P379, DOI 10.1159/000093680
   Saposnik G, 2009, STROKE, V40, P1365, DOI 10.1161/STROKEAHA.108.529503
   Spence JD, 2011, JAMA-J AM MED ASSOC, V306, P2610, DOI 10.1001/jama.2011.1834
   The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators, 2006, N ENGL J MED, V354
   The Linxian Nutrition Intervention Trial Group, 1996, AM J EPIDEMIOL, V143, P658, DOI [10.1093/oxfordjournals.aje.a008798, DOI 10.1093/0XF0RDJ0URNALS.AJE.A008798.PUBMED:8651227]
   Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187
   Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565
   Vollset SE, 2001, AM J CLIN NUTR, V74, P130
   Wang XB, 2007, LANCET, V369, P1876, DOI 10.1016/S0140-6736(07)60854-X
   Williams GR, 1999, STROKE, V30, P2523, DOI 10.1161/01.STR.30.12.2523
   Wrone EM, 2004, J AM SOC NEPHROL, V15, P420, DOI 10.1097/01.ASN.0000110181.64655.6C
   Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487
   Zoungas S, 2006, J AM COLL CARDIOL, V47, P1108, DOI 10.1016/j.jacc.2005.10.064
NR 42
TC 11
Z9 12
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 25
PY 2013
VL 8
IS 11
AR e81577
DI 10.1371/journal.pone.0081577
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 259RH
UT WOS:000327543500112
PM 24282609
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, HJ
   Liu, H
   Jiang, GF
AF Zhang, Haijun
   Liu, Hang
   Jiang, Gaofeng
TI Genetic Polymorphisms of XRCC1 and Leukemia Risk: A Meta-Analysis of 19
   Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID DNA-REPAIR POLYMORPHISMS; BASE EXCISION-REPAIR; CANCER-RISK; GENOTYPE
   DISTRIBUTION; POLYMERASE BETA; SUSCEPTIBILITY; ASSOCIATION; P14ARF;
   BIAS; XPD
AB Objective: Three common X-ray repair cross-complementing groups 1 (XRCC1) polymorphisms, Arg399Gln, Arg194Trp, and Arg280His, have been reported to be implicated in the development of leukemia. However, previous results from different studies were inconsistent. Consequently, we performed a meta-analysis in order to accurately evaluate the association between XRCC1 Arg399Gln, Arg194Trp, and Arg280His polymorphisms and leukemia risk.
   Methods: Through computerized searching of PubMed, ISI Web of Knowledge, Cochrane, EBSCO, and OpenGrey databases, and manually searching relevant references, a total of 19 studies with 3387 cases and 6168 controls for Arg399Gln (G > A) polymorphism, 12 studies with 2043 cases and 4550 controls for Arg194Trp (C > T), and 6 studies with 1445 cases and 1905 controls for Arg280His (G > A) were collected to perform meta-analysis and stratified analysis to explore the associations between these variants and leukemia susceptibility. Based on three genetic models, the codominant model, dominant model and recessive model, odds ratios (ORs) as well as their 95% confidence intervals (CIs) were used to evaluate the association strength between XRCC1 genotypes and leukemia risk.
   Results: With respect to overall leukemia susceptibility, no association was detected. In stratified analyses by tumor type, Arg399Gln was associated with higher acute lymphoblastic leukemia (ALL) risk (AA vs. GG, OR = 1.50, 95% CI: 1.11-2.02; AA+GA vs. GG, OR = 1.35, 95% CI: 1.02-1.78). Additionally, Arg399Gln, Arg194Trp, and Arg280His may influence the susceptibilities of some leukemia type and race populations.
   Conclusion: This meta-analysis indicates these three polymorphisms of XRCC1 do not associate with overall leukemia risks but could be associated with the risks for some specific subgroups.
C1 [Zhang, Haijun] Cornell Univ, Dept Cell & Dev Biol, Weill Med Coll, New York, NY 10021 USA.
   [Liu, Hang] Columbia Univ, Sch Social Work, New York, NY USA.
   [Jiang, Gaofeng] Wuhan Univ Sci & Technol, Sch Publ Hlth, Coll Med, Wuhan, Hubei, Peoples R China.
RP Zhang, HJ (reprint author), Cornell Univ, Dept Cell & Dev Biol, Weill Med Coll, New York, NY 10021 USA.
EM haz2004@med.cornell.edu; gaofeng.jiang@yahoo.com
FU National Natural Science Foundation of China [81172462]
FX This work was partly supported by the National Natural Science
   Foundation of China (No. 81172462). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. No additional external funding received
   for this study.
CR Abramenko I, 2012, J RADIAT RES, V53, P497, DOI 10.1269/jrr.11093
   Annamaneni S, 2012, HEMATOLOGY
   Armijo-Olivo S, 2012, J EVAL CLIN PRACT, V18, P12, DOI 10.1111/j.1365-2753.2010.01516.x
   Batar B, 2009, LEUKEMIA RES, V33, P759, DOI 10.1016/j.leukres.2008.11.005
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874
   Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387
   Canalle R, 2011, LEUKEMIA LYMPHOMA, V52, P1118, DOI 10.3109/10428194.2011.559672
   Celkan T, 2008, LEUKEMIA LYMPHOMA, V49, P1638, DOI 10.1080/10428190802140063
   Dai LP, 2012, MOL BIOL REP, V39, P9535, DOI 10.1007/s11033-012-1818-2
   Deligezer U, 2007, ANTICANCER RES, V27, P2453
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741
   Duman N, 2012, GENET TEST MOL BIOMA, V16, P287, DOI 10.1089/gtmb.2011.0152
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Din M. S., 2012, Comparative Clinical Pathology, V21, P505
   Ganster C, 2009, GENE CHROMOSOME CANC, V48, P760, DOI 10.1002/gcc.20680
   Ginsberg G, 2011, MUTAT RES-REV MUTAT, V727, P1, DOI 10.1016/j.mrrev.2011.02.001
   Howlader N, 2013, SEER CANC STAT REV 1
   Hu ZB, 2005, CANCER EPIDEM BIOMAR, V14, P1810, DOI 10.1158/1055-9965.EPI-04-0793
   Joseph T, 2005, CANCER LETT, V217, P17, DOI 10.1016/j.canlet.2004.06.055
   Kim HN, 2012, LEUKEMIA LYMPHOMA, V53, P681, DOI 10.3109/10428194.2011.625576
   Li WJ, 2009, CHEMOTHERAPY, V55, P335, DOI 10.1159/000230697
   Matullo G, 2006, CARCINOGENESIS, V27, P997, DOI 10.1093/carcin/bgi280
   Meza-Espinoza J P, 2009, Genet Mol Res, V8, P1451, DOI 10.4238/vol8-4gmr687
   Ozcan A, 2011, AFR J BIOTECHNOL, V10, P8860
   Pakakasama S, 2007, PEDIATR BLOOD CANCER, V48, P16, DOI 10.1002/pbc.20742
   R Development Core Team, 2010, R LANG ENV STAT COMP
   Seedhouse C, 2002, BLOOD, V100, P3761, DOI 10.1182/blood-2002-04-1152
   Shi JY, 2011, INT J CANCER, V128, P233, DOI 10.1002/ijc.25318
   Sorour A, 2013, GENET TEST MOL BIOMA, V17, P195, DOI 10.1089/gtmb.2012.0278
   Stanczyk M, 2011, MOL BIOL REP, V38, P445, DOI 10.1007/s11033-010-0127-x
   Thompson LH, 2000, MUTAT RES-DNA REPAIR, V459, P1, DOI 10.1016/S0921-8777(99)00058-0
   Tumer TB, 2010, LEUKEMIA RES, V34, P1275, DOI 10.1016/j.leukres.2010.02.035
   Wang D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013067
   Zhang HJ, 2010, J CELL BIOCHEM, V109, P693, DOI 10.1002/jcb.22446
   Zhang HJ, 2009, J CELL BIOCHEM, V106, P464, DOI 10.1002/jcb.22033
   Zhang HJ, 2013, TUMOR BIOL, V34, P3003, DOI 10.1007/s13277-013-0865-1
   Zhang HJ, 2011, ANTICANCER RES, V31, P3945
   Zhang HJ, 2011, CANCER RES, V71, P3257, DOI 10.1158/0008-5472.CAN-10-2603
   Zhang H, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00001
NR 42
TC 7
Z9 7
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 25
PY 2013
VL 8
IS 11
AR e80687
DI 10.1371/journal.pone.0080687
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 259RH
UT WOS:000327543500053
PM 24363792
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, YB
   Chen, Q
   Wang, Z
   Zhou, J
AF Chen, Yan-bo
   Chen, Qi
   Wang, Zhong
   Zhou, Juan
TI Insulin Therapy and Risk of Prostate Cancer: a Systematic Review and
   Meta-Analysis of Observational Studies
SO PLOS ONE
LA English
DT Review
ID SMOOTH-MUSCLE-CELLS; PUBLICATION BIAS; ANALOG GLARGINE; CLINICAL-TRIALS;
   RECEPTOR; GLUCOSE; PROLIFERATION; EPIDEMIOLOGY; MALIGNANCIES; PREVALENCE
AB Background: Previous observational studies have shown that insulin therapy may modify the risk of prostate cancer (PCa). However, these studies yielded controversial results. Thus, we performed this meta-analysis to determine whether insulin use was associated with PCa risk in patients with diabetes mellitus (DM).
   Method: A literature search was carried out in PubMed, EMBASE, and Cochrane Library Central database between January 1966 and January 2013. Fixed-effect and random-effect models were used to estimate pooled relative risks (RR) and corresponding 95% confidence intervals (CIs). Subgroup analyses and sensitivity analyses were also performed.
   Result: A total of 11 (10 cohorts, and one case-control) studies published between 2007 and 2013 were included in the meta-analysis, representing data for 205,523 male subjects and 7,053 PCa cases. There were five studies investigating the influence of insulin and other glucose-lowering agents on the risk of PCa, and six studies investigating the influence of glargine and non-glargine insulin. Insulin use was not associated with PCa risk when compared with other glucose-lowering agents (RR=0.89, 95% CI, 0.72-1.09). Use of insulin glargine did not contribute to susceptibility to PCa as compared with use of non-glargine insulin (RR=1.26, 95% CI, 0.86-1.84). Sensitivity analysis confirmed the stability of present results, since no individual study affected the pooled result significantly.
   Conclusions: Our results suggest that, there may be no significant association between insulin use and risk of PCa as compared with other glucose-lowering agents in patients with DM, and there was no substantial evidence for increase risk of PCa among insulin glargine users as compared to non-glargine insulin users. Further studies are warranted to validate these conclusions.
C1 [Chen, Yan-bo; Chen, Qi; Wang, Zhong; Zhou, Juan] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Urol & Androl, Shanghai 200030, Peoples R China.
RP Wang, Z (reprint author), Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Urol & Androl, Shanghai 200030, Peoples R China.
EM wz_wzz@126.com
RI Chen, Yanbo/K-8163-2019
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belfiore A, 2011, ENDOCR-RELAT CANCER, V18, pR125, DOI 10.1530/ERC-11-0074
   Blin P, 2012, DIABETOLOGIA, V55, P644, DOI 10.1007/s00125-011-2429-5
   Carstensen B, 2012, DIABETOLOGIA, V55, P948, DOI 10.1007/s00125-011-2381-4
   CHANG C, 2011, FILM COMMENT, V47, P6, DOI DOI 10.1371/J0URNAL.P0NE.0021368]
   Colhoun HM, 2009, DIABETOLOGIA, V52, P1755, DOI 10.1007/s00125-009-1453-1
   Colmers IN, 2012, DIABETES METAB, V38, P485, DOI 10.1016/j.diabet.2012.08.011
   Cox ME, 2009, PROSTATE, V69, P33, DOI 10.1002/pros.20852
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6
   Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DeWitt DE, 2003, JAMA-J AM MED ASSOC, V289, P2254, DOI 10.1001/jama.289.17.2254
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Eckardt K, 2007, DIABETOLOGIA, V50, P2534, DOI 10.1007/s00125-007-0815-9
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Frasca Francesco, 2008, Archives of Physiology and Biochemistry, V114, P23, DOI [10.1080/13813450801969715, 10.1080/13813450801969715 ]
   Gu YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053411
   Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   Home PD, 2010, DIABETOLOGIA, V53, P1838, DOI 10.1007/s00125-010-1804-y
   Home PD, 2009, LANCET, V373, P2125, DOI 10.1016/S0140-6736(09)60953-3
   Hsieh MC, 2012, EXP DIABETES RES, DOI 10.1155/2012/413782
   Hsing AW, 2006, FRONT BIOSCI-LANDMRK, V11, P1388, DOI 10.2741/1891
   Janghorbani M, 2012, HORM CANCER-US, V3, P137, DOI 10.1007/s12672-012-0112-z
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Koro C, 2007, PHARMACOEPIDEM DR S, V16, P485, DOI 10.1002/pds.1352
   Li QA, 2010, CANCER CAUSE CONTROL, V21, P1025, DOI 10.1007/s10552-010-9530-9
   Ljung R, 2011, ACTA ONCOL, V50, P685, DOI 10.3109/0284186X.2011.558913
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Morden NE, 2011, DIABETES CARE, V34, P1965, DOI 10.2337/dc11-0699
   Ruiter R, 2012, DIABETOLOGIA, V55, P51, DOI 10.1007/s00125-011-2312-4
   Shukla A, 2009, ENDOCR-RELAT CANCER, V16, P429, DOI 10.1677/ERC-08-0240
   Staiger K, 2005, DIABETOLOGIA, V48, P1898, DOI 10.1007/s00125-005-1874-4
   Tseng CH, 2011, ANN MED, V43, P142, DOI 10.3109/07853890.2010.530683
   Tseng CH, 2011, DIABETES CARE, V34, P616, DOI 10.2337/dc10-1640
   Undela K, 2012, BREAST CANCER RES TR, V135, P261, DOI 10.1007/s10549-012-2154-x
   Wada T, 2008, DIABETES RES CLIN PR, V81, P269, DOI 10.1016/j.diabres.2008.05.007
   Weinstein D, 2009, DIABETES-METAB RES, V25, P41, DOI 10.1002/dmrr.912
   Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Wu QJ, 2013, ANN ONCOL, V24, P1079, DOI 10.1093/annonc/mds601
   Xu H, 2013, DIABETES RES CLIN PR
NR 43
TC 9
Z9 10
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 25
PY 2013
VL 8
IS 11
AR e81594
DI 10.1371/journal.pone.0081594
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 259RH
UT WOS:000327543500116
PM 24282613
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, CB
   Mou, SH
   Cai, YQ
AF Liu, Chibo
   Mou, Sihua
   Cai, Yangqun
TI FTO Gene Variant and Risk of Overweight and Obesity among Children and
   Adolescents: a Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID BODY-MASS INDEX; GENOME-WIDE ASSOCIATION; FAT MASS; EARLY-ONSET;
   RS9939609 POLYMORPHISM; CHILDHOOD OBESITY; PHYSICAL-ACTIVITY;
   DIETARY-INTAKE; ADULT OBESITY; ENERGY-INTAKE
AB Objective: The fat mass and obesity associated gene (FTO) polymorphisms have been implicated in the susceptibility of overweight/obesity in children and adolescents. However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the association of FTO gene polymorphisms with overweight/obesity risk among children and adolescents.
   Methods: PubMed and Embase were used to search for eligible published literatures. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-or fixed-effect models.
   Results: A total of 21 articles containing 23 studies (11208cases and 35015controls) were included in our analysis. The results indicated that variant in FTO gene was significantly associated with increased risk of overweight/obesity in children and adolescents (OR=1.35; 95% CI: 1.27-1.44; P<0.001). The overall pooled ORs for risk obesity and overweight were 1.34 (95% CI: 1.21-1.48) and 1.35 (95% CI: 1.25-1.47), respectively. Subgroup analyses also showed similar trends in most subgroups of adjustment for covariates and unadjustment, different ethnicities (Caucasians, Asians, and Amerindians), and each of three investigated polymorphisms (rs9939609, rs1421085, and rs1558902).
   Conclusions: The present meta-analysis suggested a positive association between FTO gene polymorphism and overweight/obesity risk among children and adolescents. Further prospective studies should be recommended to confirm the observed association, and underlying mechanism should be investigated to clarify the association of FTO gene polymorphism with overweight/obesity.
C1 [Liu, Chibo; Mou, Sihua; Cai, Yangqun] Taizhou Municipal Hosp, Dept Clin Lab, Taizhou, Zhejiang, Peoples R China.
RP Liu, CB (reprint author), Taizhou Municipal Hosp, Dept Clin Lab, Taizhou, Zhejiang, Peoples R China.
EM chibo_liu@163.com
CR Albuquerque D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054370
   Almen MS, 2013, INT J OBESITY, V37, P424, DOI 10.1038/ijo.2012.57
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Biondi B, 2010, J CLIN ENDOCR METAB, V95, P3614, DOI 10.1210/jc.2010-1245
   Cauchi S, 2009, J MOL MED, V87, P537, DOI 10.1007/s00109-009-0451-6
   Cecil JE, 2008, NEW ENGL J MED, V359, P2558, DOI 10.1056/NEJMoa0803839
   Church C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000599
   Deckelbaum RJ, 2001, OBES RES, V9, p239S, DOI 10.1038/oby.2001.125
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dina C, 2007, NAT GENET, V39, P724, DOI 10.1038/ng2048
   Dixon JB, 2010, MOL CELL ENDOCRINOL, V316, P104, DOI 10.1016/j.mce.2009.07.008
   Dwivedi OP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047772
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elks CE, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000284
   Fang HY, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-136
   Fischer J, 2009, NATURE, V458, P894, DOI 10.1038/nature07848
   Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634
   Gonzalez JR, 2012, OBESITY, V20, P909, DOI 10.1038/oby.2011.325
   Goran MI, 2001, AM J CLIN NUTR, V73, P158
   Grant SFA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001746
   Hakanen M, 2009, J CLIN ENDOCR METAB, V94, P1281, DOI 10.1210/jc.2008-1199
   Hassanein MT, 2010, HUM MOL GENET, V19, P2907, DOI 10.1093/hmg/ddq178
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hinney A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001361
   Jacobsson JA, 2008, BIOCHEM BIOPH RES CO, V368, P476, DOI 10.1016/j.bbrc.2008.01.087
   Lakshman R, 2012, CIRCULATION, V126, P1770, DOI 10.1161/CIRCULATIONAHA.111.047738
   Lauria F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048876
   Lee HJ, 2010, CLIN CHIM ACTA, V411, P1716, DOI 10.1016/j.cca.2010.07.010
   Liu GF, 2011, EUR J EPIDEMIOL, V26, P463, DOI 10.1007/s10654-011-9583-4
   Luczynski W, 2012, J PHYSIOL PHARMACOL, V63, P241
   Mangge H, 2011, J OBES, DOI 10.1155/2011/186368
   Mantel N, 2004, CHALLENGE EPIDEMIOLO, V1, P533
   Mejia-Benitez A, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-21
   Meyre D, 2009, NAT GENET, V41, P157, DOI 10.1038/ng.301
   Moleres A, 2012, BRIT J NUTR, V107, P533, DOI 10.1017/S0007114511003424
   Muller TD, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-85
   Munafo MR, 2004, TRENDS GENET, V20, P439, DOI 10.1016/j.tig.2004.06.014
   Ntalla I, 2013, ANN HUM GENET, V77, P268, DOI 10.1111/ahg.12012
   Ogden CL, 2012, JAMA-J AM MED ASSOC, V307, P483, DOI 10.1001/jama.2012.40
   Okuda M, 2011, PEDIATR DIABETES, V12, P494, DOI 10.1111/j.1399-5448.2010.00727.x
   Parsons TJ, 1999, INT J OBESITY, V23, pS1
   Peng SH, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-71
   Riffo B, 2012, PEDIATR DIABETES, V13, P392, DOI 10.1111/j.1399-5448.2011.00834.x
   Scherag A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000916
   Scott RA, 2010, EUR J HUM GENET, V18, P1339, DOI 10.1038/ejhg.2010.131
   Tanofsky-Kraff M, 2009, AM J CLIN NUTR, V90, P1483, DOI 10.3945/ajcn.2009.28439
   Timpson NJ, 2008, AM J CLIN NUTR, V88, P971
   Tschritter O, 2007, DIABETOLOGIA, V50, P2602, DOI 10.1007/s00125-007-0839-1
   Wardle J, 2008, J CLIN ENDOCR METAB, V93, P3640, DOI 10.1210/jc.2008-0472
   Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301
   Xi Bo, 2012, PLoS One, V7, pe45731, DOI 10.1371/journal.pone.0045731
   Xi B, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-107
   Zavattari P, 2011, ANN HUM GENET, V75, P648, DOI 10.1111/j.1469-1809.2011.00674.x
   Zhao JH, 2011, J OBES, DOI 10.1155/2011/845148
NR 54
TC 20
Z9 21
U1 1
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 22
PY 2013
VL 8
IS 11
AR e82133
DI 10.1371/journal.pone.0082133
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 259QP
UT WOS:000327541700075
PM 24278475
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, HJ
   Qiao, NA
   Wang, Y
   Jiang, M
   Wang, SK
   Wang, CH
   Hu, LK
AF Wu, Haijian
   Qiao, Naian
   Wang, Yang
   Jiang, Man
   Wang, Shikun
   Wang, Cuihong
   Hu, Likuan
TI Association between the Telomerase Reverse Transcriptase (TERT)
   rs2736098 Polymorphism and Cancer Risk: Evidence from a Case-Control
   Study of Non-Small-Cell Lung Cancer and a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID COMMON GENETIC-VARIANTS; CHINESE POPULATION; SUSCEPTIBILITY LOCUS;
   TERT-CLPTM1L GENES; SEQUENCE VARIANTS; 5P15.33; DISEASE; HTERT;
   EXPRESSION; CONTRIBUTE
AB Background: A common genetic variant, telomerase reverse transcriptase (TERT) rs2736098, was recently reported to be associated with lung cancer risk in Caucasians. In addition, many studies have investigated the role of this polymorphism in the etiology of cancer of various organs. Nevertheless, the results of related case-control studies remain inconsistent. Methods: We hypothesized that the genetic risk variant identified in Caucasians may potentially influence the susceptibility to lung cancer in the Chinese population. To test this hypothesis, a case-control study including 539 non-small-cell lung cancer (NSCLC) cases and 627 cancer-free controls was conducted. Furthermore, to investigate the association between rs2736098 and cancer risk, a meta-analysis based on previously published studies and our case-control study was also performed.
   Results: Multivariate logistic regression demonstrated that individuals carrying the A allele or the AA genotype exhibited a significantly elevated risk of NSCLC compared with those carrying the G allele or GG genotype (A vs. G: OR = 1.21, 95% CI = 1.02-1.43, P = 0.028; AA vs. GG: OR = 1.48, 95% CI = 1.05-2.09, P = 0.025). Additionally, this association was stronger among adenocarcinoma cases (AA vs. GG: OR = 1.67, 95% CI = 1.12-2.50, P = 0.013; A vs. G: OR = 1.28, 95% CI = 1.05-1.57, P = 0.016). In the meta-analysis, a borderline significant association between the rs2736098 polymorphism and overall cancer risk was observed (AA vs. GG: OR = 1.25, 95% CI = 1.07-1.46; AA vs. AG+ GG: OR = 1.22, 95% CI = 1.06-1.41; additive model: OR = 1.10, 95% CI = 1.02-1.18), and further stratifications demonstrated a moderately increased risk for lung and bladder cancer, Asian ethnicity and hospital-based studies.
   Conclusions: Our results suggest that the rs2736098 polymorphism may contribute to the risk of lung cancer, especially adenocarcinoma, in the Chinese population. In addition, the current meta-analysis indicates that this genetic variant is only weakly associated with overall cancer risk. However, the rs2736098 polymorphism may affect individual susceptibility to lung and bladder cancer. Further studies are needed to validate our findings.
C1 [Wu, Haijian; Qiao, Naian; Wang, Yang; Wang, Shikun; Wang, Cuihong; Hu, Likuan] Shandong Univ, Qilu Hosp, Dept Radiat Oncol, Jinan 250100, Shandong, Peoples R China.
   [Jiang, Man] Shandong Univ, Prov Hosp, Dept Gastroenterol, Jinan 250100, Shandong, Peoples R China.
RP Hu, LK (reprint author), Shandong Univ, Qilu Hosp, Dept Radiat Oncol, Jinan 250100, Shandong, Peoples R China.
EM likuan.hu@hotmail.com
CR Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109
   Baird DM, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000147X
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brawley OW, 2011, CA-CANCER J CLIN, V61, P67, DOI 10.3322/caac.20108
   Calado RT, 2009, NEW ENGL J MED, V361, P2353, DOI 10.1056/NEJMra0903373
   Chen HY, 2011, AM J EPIDEMIOL, V173, P915, DOI 10.1093/aje/kwq457
   Choi JE, 2009, CANCER EPIDEM BIOMAR, V18, P2773, DOI 10.1158/1055-9965.EPI-09-0323
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ding Chen-Yue, 2011, Zhonghua Yu Fang Yi Xue Za Zhi, V45, P593
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142
   Gago-Dominguez M, 2011, CARCINOGENESIS, V32, P197, DOI 10.1093/carcin/bgq233
   Gunes C, 2013, CELL, V152, P390, DOI 10.1016/j.cell.2013.01.010
   Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hofer P, 2012, MOL CARCINOGEN, V51, pE176, DOI 10.1002/mc.21911
   Hsiung CA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001051
   Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885
   Jang JS, 2008, CANCER SCI, V99, P1385, DOI 10.1111/j.1349-7006.2008.00831.x
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jin GF, 2009, CARCINOGENESIS, V30, P987, DOI 10.1093/carcin/bgp090
   Kang JU, 2008, CANCER GENET CYTOGEN, V182, P1, DOI 10.1016/j.cancergencyto.2007.12.004
   Lan Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059230
   Landi MT, 2009, AM J HUM GENET, V85, P679, DOI 10.1016/j.ajhg.2009.09.012
   Lantuejoul S, 2004, BRIT J CANCER, V90, P1222, DOI 10.1038/sj.bjc.6601643
   Lantuejoul S, 2007, INT J CANCER, V120, P1835, DOI 10.1002/ijc.22473
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Li C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064988
   Liu ZS, 2010, CARCINOGENESIS, V31, P1977, DOI 10.1093/carcin/bgq179
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Martinez P, 2011, NAT REV CANCER, V11, P161, DOI 10.1038/nrc3025
   McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254
   Mocellin S, 2012, JNCI-J NATL CANCER I, V104, P840, DOI 10.1093/jnci/djs222
   Rafnar T, 2009, NAT GENET, V41, P221, DOI 10.1038/ng.296
   Ramalingam SS, 2011, CA-CANCER J CLIN, V61, P91, DOI 10.3322/caac.20102
   Savage SA, 2007, BRIT J CANCER, V97, P832, DOI 10.1038/sj.bjc.6603934
   Shen M, 2011, LUNG CANCER, V73, P133, DOI 10.1016/j.lungcan.2010.11.009
   Sheng XJ, 2013, CARCINOGENESIS, V34, P228, DOI 10.1093/carcin/bgs325
   Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846
   Wang SM, 2012, MOL CARCINOGEN, V51, pE118, DOI 10.1002/mc.21872
   Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273
   Zhang C, 2013, HEPATOB PANCREAT DIS, V12, P74, DOI 10.1016/S1499-3872(13)60009-0
   Zhao ZH, 2013, EXP LUNG RES, V39, P91, DOI 10.3109/01902148.2012.762436
   Zhu CQ, 2006, BRIT J CANCER, V94, P1452, DOI 10.1038/sj.bjc.6603110
NR 45
TC 21
Z9 22
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 19
PY 2013
VL 8
IS 11
AR e76372
DI 10.1371/journal.pone.0076372
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 256LO
UT WOS:000327311900002
PM 24260099
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Peng, Y
   Ye, XH
   Li, Y
   Bu, T
   Chen, XF
   Bi, JQ
   Zhou, JL
   Yao, ZJ
AF Peng, Yang
   Ye, Xiaohua
   Li, Ying
   Bu, Tao
   Chen, Xiaofeng
   Bi, Jiaqi
   Zhou, Junli
   Yao, Zhenjiang
TI Teicoplanin as an Effective Alternative to Vancomycin for Treatment of
   MRSA Infection in Chinese Population: A Meta-analysis of Randomized
   Controlled Trials
SO PLOS ONE
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; STRAINS
AB Objective: To evaluate whether teicoplanin could be an alternative to vancomycin for treatment of MRSA infection in Chinese population using a meta-analysis in randomized controlled trials.
   Methods: The following databases were searched: Chinese Biomedical Literature database (CBM), Chinese Journal Full-text database (CNKI), Wanfang database, Medline database, Ovid database and Cochrane Library. Articles published from 2002 to 2013 that studied teicoplanin in comparison to vancomycin in the treatment of MRSA infected patients were collected. Overall effects, publishing bias analysis and sensitivity analysis on clinical cure rate, microbiologic eradication rate and adverse events rate were performed by using Review Manager 5.2 and Stata 11.0 softwares.
   Results: Twelve articles met entry criteria. There was no statistically significant difference between the two groups regarding the clinical cure rate (risk ratio [RR], teicoplanin vs vancomycin, 0.94; 95% CI, 0.74 similar to 1.19; P = 0.60), microbiological cure rate (risk ratio [RR], teicoplanin vs vancomycin, 0.99; 95% CI, 0.91 similar to 1.07; P = 0.74) and adverse event rate (risk ratio [RR], teicoplanin vs vancomycin, 0.86; 95% CI, 0.40 similar to 1.84; P = 0.70).
   Conclusions: The meta-analysis results indicate that the two therapies are similar in both efficacy and safety, thus teicoplanin can act as an effective alternative to vancomycin for treating patients infected by MRSA.
C1 [Peng, Yang; Ye, Xiaohua; Li, Ying; Bu, Tao; Chen, Xiaofeng; Bi, Jiaqi; Zhou, Junli; Yao, Zhenjiang] Guangdong Pharmaceut Univ, Dept Epidemiol & Hlth Stat, Guangdong Key Lab Mol Epidemiol, Guangzhou, Guangdong, Peoples R China.
RP Yao, ZJ (reprint author), Guangdong Pharmaceut Univ, Dept Epidemiol & Hlth Stat, Guangdong Key Lab Mol Epidemiol, Guangzhou, Guangdong, Peoples R China.
EM zhjyao2001@yahoo.com
RI Peng, Yang/J-8980-2016; Yao, Zhenjiang/N-7450-2016
OI Peng, Yang/0000-0002-9119-5506; Yao, Zhenjiang/0000-0002-2156-7896
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dong Liang, 2010, Chinese Journal of Nosocomiology, V20, P711
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El Solh N, 2003, J ANTIMICROB CHEMOTH, V52, P691, DOI 10.1093/jac/dkg400
   ERIKSEN K R, 1961, Ugeskr Laeger, V123, P384
   Guo ZY, 2011, CHIN J MOD DRUG APPL, V05, P74
   Hanaki H, 1998, J ANTIMICROB CHEMOTH, V42, P199, DOI 10.1093/jac/42.2.199
   Hidron AI, 2008, INFECT CONT HOSP EP, V29, P996, DOI 10.1086/591861
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hiramatsu K, 2001, Lancet Infect Dis, V1, P147, DOI 10.1016/S1473-3099(01)00091-3
   Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kim MN, 2000, J CLIN MICROBIOL, V38, P3879
   Klein E, 2007, EMERG INFECT DIS, V13, P1840, DOI 10.3201/eid1312.070629
   Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lescure FX, 2006, EUR J CLIN MICROBIOL, V25, P205, DOI 10.1007/s10096-006-0104-4
   Levine DP, 2006, CLIN INFECT DIS, V42, pS5, DOI 10.1086/491709
   Li XiaoBo, 2011, Chinese Journal of Nosocomiology, V21, P3023
   Lodise TP, 2008, ANTIMICROB AGENTS CH, V52, P3315, DOI 10.1128/AAC.00113-08
   Loll PJ, 2000, ANNU REV BIOPH BIOM, V29, P265, DOI 10.1146/annurev.biophys.29.1.265
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marchese A, 2000, J CLIN MICROBIOL, V38, P866
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Soriano A, 2008, CLIN INFECT DIS, V46, P193, DOI 10.1086/524667
   Sun WJ, 2009, ANTIMICROB AGENTS CH, V53, P3642, DOI 10.1128/AAC.00206-09
   Sun XX, 2009, MED J QILU, V24, P533
   Svetitsky S, 2009, ANTIMICROB AGENTS CH, V53, P4069, DOI 10.1128/AAC.00341-09
   Trakulsomboon S, 2001, J CLIN MICROBIOL, V39, P591, DOI 10.1128/JCM.39.2.591-595.2001
   Turnidge JD, 2000, MICROB DRUG RESIST, V6, P223
   Wang F, 2013, PHARM CLIN RES, V21, P81
   Wang H, 2011, CHINESE REMEDIES CLI, V11, P113
   Xie JJ, 2006, PRACTICAL PREVENTIVE, V13, P349
   [张天托 Zhang Tiantuo], 2003, [中国新药杂志, Chinese Journal New Drugs], V12, P1041
   Zhao CJ, 2012, DIAGN MICR INFEC DIS, V73, P174, DOI 10.1016/j.diagmicrobio.2012.03.003
   Zhao N, 2013, GUIDE CHINA MED, V11, P601
   Zhu HL, 2003, CLIN MED J CHINA, V10, P183
   Zhuo C, 2013, INT J ANTIMICROB AGE
   Zu YuNa, 2010, Chinese Journal of Nosocomiology, V20, P552
   赵卫峰, 2003, [江苏医药, Jiangsu medical Journal], V29, P913
NR 41
TC 5
Z9 8
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 18
PY 2013
VL 8
IS 11
AR e79782
DI 10.1371/journal.pone.0079782
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 256KH
UT WOS:000327308500099
PM 24260299
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wersebe, H
   Sijbrandij, M
   Cuijpers, P
AF Wersebe, Hanna
   Sijbrandij, Marit
   Cuijpers, Pim
TI Psychological Group-Treatments of Social Anxiety Disorder: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID BEHAVIORAL GROUP-THERAPY; COGNITIVE THERAPY; PHOBIA; COMORBIDITY;
   PREVALENCE; PHENELZINE; PLACEBO; HELP; BIAS
AB Background: A few meta-analyses have examined psychological treatments for a social anxiety disorder (SAD). This is the first meta-analysis that examines the effects of cognitive behavioural group therapies (CBGT) for SAD compared to control on symptoms of anxiety.
   Method: After a systematic literature search in PubMed, Cochrane, PsychINFO and Embase was conducted; eleven studies were identified that met the inclusion criteria. The studies had to be randomized controlled studies in which individuals with a diagnosed SAD were treated with cognitive-behavioural group therapy (CBGT) and compared with a control group. The overall quality of the studies was moderate.
   Results: The pooled effect size indicated that the difference between intervention and control conditions was 0.53 (96% CI: 0.33-0.73), in favour of the intervention. This corresponds to a NNT 3.24. Heterogeneity was low to moderately high in all analyses. There was some indication of publication bias.
   Conclusions: It was found that psychological group-treatments CBGT are more effective than control conditions in patients with SAD. Since heterogeneity between studies was high, more research comparing group psychotherapies for SAD to control is needed.
C1 [Wersebe, Hanna; Sijbrandij, Marit; Cuijpers, Pim] Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands.
   [Sijbrandij, Marit; Cuijpers, Pim] EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
   [Cuijpers, Pim] Univ Luneburg, Luneburg, Germany.
RP Cuijpers, P (reprint author), Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands.
EM p.cuipers@vu.nl
RI Sijbrandij, Marit/N-6131-2018; Cuijpers, Pim/G-1703-2013
OI Sijbrandij, Marit/0000-0001-5430-9810; Cuijpers, Pim/0000-0001-5497-2743
CR Acarturk C, 2008, SOC PSYCH PSYCH EPID, V43, P273, DOI 10.1007/s00127-008-0309-1
   Acarturk C, 2009, PSYCHOL MED, V39, P241, DOI 10.1017/S0033291708003590
   Andlin-Sobocki P, 2011, EUR NEUROPSYCHOPHARM, V21, P718
   Andrews G, 2011, AUST NZ J PSYCHIAT, V45, P337, DOI 10.3109/00048674.2010.538840
   APA, 1987, DIAGN STAT MAN MENT
   APA, 1994, DIAGN STAT MAN MENT
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bjornsson AS, 2011, DEPRESS ANXIETY, V28, P1034, DOI 10.1002/da.20877
   Blanco C, 2010, ARCH GEN PSYCHIAT, V67, P286, DOI 10.1001/archgenpsychiatry.2010.11
   Brunello N, 2000, J AFFECT DISORDERS, V60, P61, DOI 10.1016/S0165-0327(99)00140-8
   Davidson JRT, 2004, ARCH GEN PSYCHIAT, V61, P1005, DOI 10.1001/archpsyc.61.10.1005
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Fedoroff IC, 2001, J CLIN PSYCHOPHARM, V21, P311, DOI 10.1097/00004714-200106000-00011
   Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3
   FESKE U, 1995, BEHAV THER, V26, P695, DOI 10.1016/S0005-7894(05)80040-1
   Furmark T, 1999, SOC PSYCH PSYCH EPID, V34, P416, DOI 10.1007/s001270050163
   Furmark T, 2002, ACTA PSYCHIAT SCAND, V105, P84, DOI 10.1034/j.1600-0447.2002.1r103.x
   Gould RA, 1997, CLIN PSYCHOL-SCI PR, V4, P291, DOI 10.1111/j.1468-2850.1997.tb00123.x
   Gruber K, 2001, BEHAV THER, V32, P155, DOI 10.1016/S0005-7894(01)80050-2
   Heimberg RG, 1998, ARCH GEN PSYCHIAT, V55, P1133, DOI 10.1001/archpsyc.55.12.1133
   Herbert JD, 2005, BEHAV THER, V36, P125, DOI 10.1016/S0005-7894(05)80061-9
   Higgins JP, 2008, COCHRANE HDB SYSTEMA, P51, DOI DOI 10.1002/9780470712184.CH4
   Hofmann SG, 2004, J CONSULT CLIN PSYCH, V72, P588, DOI 10.1037/0022-0006X.72.4.588
   Hofmann SG, 2006, J ANXIETY DISORD, V20, P961, DOI 10.1016/j.janxdis.2006.03.005
   HOPE DA, 1995, BEHAV RES THER, V33, P637, DOI 10.1016/0005-7967(95)00013-N
   Kasper S, 1998, J AFFECT DISORD S, V50, P3
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617
   Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014
   Magee WJ, 1996, ARCH GEN PSYCHIAT, V53, P159
   Mortberg E, 2007, ACTA PSYCHIAT SCAND, V115, P142, DOI 10.1111/j.1600-0447.2006.00839.x
   Mortberg E, 2006, J ANXIETY DISORD, V20, P646, DOI 10.1016/j.janxdis.2005.07.005
   Piet J, 2010, SCAND J PSYCHOL, V51, P403, DOI 10.1111/j.1467-9450.2009.00801.x
   Pishyar R, 2008, COGNITION EMOTION, V22, P1209, DOI 10.1080/02699930701686008
   Rapee RM, 2007, BRIT J PSYCHIAT, V191, P246, DOI 10.1192/bjp.bp.106.028167
   Rodebaugh TL, 2004, CLIN PSYCHOL REV, V24, P883, DOI 10.1016/j.cpr.2004.07.007
   Schunemann HJ, 2008, COCHRANE HDB SYSTEMA, P359, DOI DOI 10.1002/9780470712184.CH12
   Silverman WK, 1999, J CONSULT CLIN PSYCH, V67, P995, DOI 10.1037/0022-006X.67.6.995
   Stangier U, 2003, BEHAV RES THER, V41, P991, DOI 10.1016/S0005-7967(02)00176-6
   Taylor S, 1996, J BEHAV THER EXP PSY, V27, P1, DOI 10.1016/0005-7916(95)00058-5
   Weiller E., 1996, British Journal of Psychiatry, V168, P169, DOI 10.1192/bjp.168.2.169
   Wong DFK, 2006, HK J PSYCHIAT, V16, P1650
NR 41
TC 15
Z9 15
U1 1
U2 34
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 15
PY 2013
VL 8
IS 11
AR e79034
DI 10.1371/journal.pone.0079034
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 255RX
UT WOS:000327258600016
PM 24260148
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xia, XC
   Yang, BX
   Zhai, XG
   Liu, XY
   Shen, K
   Wu, ZJ
   Cai, J
AF Xia, Xiaochun
   Yang, Baixia
   Zhai, Xiaogang
   Liu, Xiangyang
   Shen, Kang
   Wu, Zhijun
   Cai, Jing
TI Prognostic Role of microRNA-21 in Colorectal Cancer: a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; COLON-CANCER; BREAST-CANCER; MISMATCH-REPAIR;
   SERUM MIR-21; STAGE-II; EXPRESSION; SURVIVAL; METASTASIS; CELLS
AB Background: To date, many studies have shown that microRNAs (miRNA) exhibit altered expression in various cancers and may play an important role as prognostic biomarker of cancers. The present meta-analysis summarizes the recent advances in the use of microRNA-21 (miR-21) in the assessment of colorectal cancer and analyzes the prognostic role of miR-21 for survival outcome.
   Methodology/Principal Findings: The present meta-analysis was performed by searching PubMed through multiple search strategies. Data were extracted from studies comparing overall survival (OS) in patients with colorectal cancer who showed higher expression of miR-21 than similar patients. Pooled hazard ratios (HRs) of miR-21 for survival and 95% confidence intervals (CI) were calculated. Seven studies with a total of 1174 patients were included this meta-analysis. For overall survival (OS), the pooled hazard ratio (HR) of higher miR-21 expression in colorectal cancer was 1.76 (95% CI: 1.34-2.32, P=0.000). After elimination of heterogeneity, the pooled HR was 2.32 (95% CI: 1.82-2.97, P=0.000), which was found to significantly predict poorer survival. The subgroup analysis suggested that elevated miR-21 level and patients' survival correlated with III/IV stage (HR=5.35, 95% CI: 3.73-7.66).
   Conclusions/Significance: The present findings suggest that high expression of miR-21 might predict poor prognosis in patients with colorectal cancer.
C1 [Xia, Xiaochun; Yang, Baixia; Liu, Xiangyang; Wu, Zhijun; Cai, Jing] Nantong Tumor Hosp, Dept Radiat Oncol, Nantong, Jiangsu, Peoples R China.
   [Zhai, Xiaogang] Nantong Tumor Hosp, Dept Nucl Med, Nantong, Jiangsu, Peoples R China.
   [Shen, Kang] Nantong Tumor Hosp, Dept Sci & Educ, Nantong, Jiangsu, Peoples R China.
RP Cai, J (reprint author), Nantong Tumor Hosp, Dept Radiat Oncol, Nantong, Jiangsu, Peoples R China.
EM cj7227@sina.com
FU National Natural Science Foundation of China [81001317]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (No. 81001317). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chan SH, 2008, ANTICANCER RES, V28, P907
   Chen TH, 2013, J NATL CANC I
   Diep CB, 2003, J CLIN ONCOL, V21, P820, DOI 10.1200/JCO.2003.05.190
   Faltejskova P, 2012, INT J COLORECTAL DIS, V27, P1401, DOI 10.1007/s00384-012-1461-3
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   French AJ, 2008, CLIN CANCER RES, V14, P3408, DOI 10.1158/1078-0432.CCR-07-1489
   Fu XN, 2011, EUR J CLIN INVEST, V41, P1245, DOI 10.1111/j.1365-2362.2011.02535.x
   Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08
   Hayes DF, 2001, J MAMMARY GLAND BIOL, V6, P375, DOI 10.1023/A:1014778713034
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hwang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010630
   Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Li XH, 2010, GUT, V59, P579, DOI 10.1136/gut.2008.175497
   Liu GH, 2013, TUMOR BIOL, V34, P2175, DOI 10.1007/s13277-013-0753-8
   Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72
   Ma XL, 2012, ASIAN PAC J CANCER P, V13, P2329, DOI 10.7314/APJCP.2012.13.5.2329
   Mathe EA, 2009, CLIN CANCER RES, V15, P6192, DOI 10.1158/1078-0432.CCR-09-1467
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Nielsen BS, 2011, CLIN EXP METASTAS, V28, P27, DOI 10.1007/s10585-010-9355-7
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Shibuya H, 2010, ONCOLOGY-BASEL, V79, P313, DOI 10.1159/000323283
   Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Toiyama Y, 2013, JNCI-J NATL CANCER I, V105, P849, DOI 10.1093/jnci/djt101
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645
   Wang P, 2009, CANCER RES, V69, P8157, DOI 10.1158/0008-5472.CAN-09-1996
   Williamson PR, 2002, STAT MED, V21, P3337, DOI 10.1002/sim.1303
   Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808
   Yang CH, 2011, J BIOL CHEM, V286, P39172, DOI 10.1074/jbc.M111.285098
   Yang Weining, 2011, Int J Physiol Pathophysiol Pharmacol, V3, P140
   Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200
NR 40
TC 46
Z9 49
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 12
PY 2013
VL 8
IS 11
AR e80426
DI 10.1371/journal.pone.0080426
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 255PK
UT WOS:000327252100158
PM 24265822
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Fu, W
   Ding, LR
   Zhuang, C
   Zhou, YH
AF Fu, Wei
   Ding, Li-Ren
   Zhuang, Cheng
   Zhou, Yu-Hao
TI Effects of Zinc Supplementation on the Incidence of Mortality in
   Preschool Children: A Meta-Analysis of Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID DOUBLE-BLIND; INFANTS; PNEUMONIA; MORBIDITY; DIARRHEA
AB Background: Previous trials have shown that zinc supplementation can decrease the risk of diarrhea, pneumonia, and malaria in children; however, the effects of zinc supplementation on mortality remain unclear. This study aimed at evaluating the benefits and risks of zinc supplementation on both total mortality and cause-specific mortality.
   Methodology and Principal Findings: We searched PubMed, EmBase, and the Cochrane Central Register of Controlled Trials to identify randomized controlled trials in preschool children reporting total mortality or cause-specific mortality. Relative risk (RR) was used as a measure of the effect of zinc supplementation on the risk of mortality using a random effect model. Of the 1,520 identified articles, we included 8 trials reporting data on 87,854 children. Overall, zinc supplementation had no effect on total mortality (RR, 0.76; 95% CI: 0.56-1.04; P = 0.084), diarrhea-related mortality (RR, 0.80; 95% CI: 0.53-1.20; P = 0.276), pneumonia-related mortality (RR, 0.52; 95% CI: 0.11-2.39; P = 0.399), malaria-related mortality (RR, 0.90; 95% CI: 0.77-1.06; P = 0.196), or other causes of mortality (RR, 0.98; 95% CI: 0.67-1.44; P = 0.917). Subgroup analysis indicated that zinc supplementation was associated with a reduction in total mortality risk if the participants were boys, aged greater than 12 months, and the duration of the follow-up period was less than 12 months.
   Conclusions/Significance: Zinc supplementation does not have an effect on total mortality, diarrhea-related mortality, pneumonia-related mortality, malaria-related mortality, or other causes of mortality. Subgroup analysis suggested that zinc supplementation can effectively reduce the risk of total mortality if the participants were boys, aged greater than 12 months, and the duration of the follow-up period was less than 12 months.
C1 [Fu, Wei; Ding, Li-Ren; Zhuang, Cheng] Shanghai Seventh Peoples Hosp, Dept Pediat, Shanghai, Peoples R China.
   [Zhou, Yu-Hao] Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.
RP Zhou, YH (reprint author), Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.
EM zhou_ly@126.com
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bobat R, 2005, LANCET, V366, P1862, DOI 10.1016/S0140-6736(05)67756-2
   Brooks WA, 2004, LANCET, V363, P1683, DOI 10.1016/S0140-6736(04)16252-1
   Brooks WA, 2005, LANCET, V366, P999, DOI 10.1016/S0140-6736(05)67109-7
   Deeks JJ, 2008, COCHRANE COCHRANE HD
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x
   Iqbal A. S. M., 2001, Indian Journal of Pediatrics, V68, P523, DOI 10.1007/BF02723246
   IZiNCG, 2004, FOOD NUTR BULL, V25, pS91
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   KREBS NF, 1986, AM J CLIN NUTR, V43, P288
   Luabeya KKA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000541
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Muller O, 2001, BRIT MED J, V322, P1, DOI [10.1136/bmj.322.7277.1, DOI 10.1136/BMJ.322.7277.1.PUBMED:11141128]
   Osendarp SJM, 2001, LANCET, V357, P1080, DOI 10.1016/S0140-6736(00)04260-4
   Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549
   Sazawal S, 1998, PEDIATRICS, V102, P1, DOI 10.1542/peds.102.1.1
   Sazawal S, 2001, PEDIATRICS, V108, P1280, DOI 10.1542/peds.108.6.1280
   Sazawal S, 2007, LANCET, V369, P927, DOI 10.1016/S0140-6736(07)60452-8
   Shankar AH, 2000, AM J TROP MED HYG, V62, P663, DOI 10.4269/ajtmh.2000.62.663
   The Zinc Investigators' Collaborative Group, 1999, J PEDIAT, V135, P689, DOI DOI 10.1016/S0022-3476(99)70086-7.PUBMED:10586170
   Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187
   Tielsch JM, 2007, LANCET, V370, P1230, DOI 10.1016/S0140-6736(07)61539-6
   Umeta M, 2000, LANCET, V355, P2021, DOI 10.1016/S0140-6736(00)02348-5
   Walker CF, 2004, ANNU REV NUTR, V24, P255, DOI 10.1146/annurev.nutr.23.011702.073054
   Yakoob MY, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S23
NR 29
TC 2
Z9 2
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 11
PY 2013
VL 8
IS 11
AR e79998
DI 10.1371/journal.pone.0079998
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 255EG
UT WOS:000327221600168
PM 24244591
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ye, YC
   Xie, HZ
   Zeng, Y
   Zhao, XL
   Tian, Z
   Zhang, SY
AF Ye, Yicong
   Xie, Hongzhi
   Zeng, Yong
   Zhao, Xiliang
   Tian, Zhuang
   Zhang, Shuyang
TI Efficacy and Safety of Biodegradable Polymer Biolimus-Eluting Stents
   versus Durable Polymer Drug-Eluting Stents: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; BARE-METAL STENTS; CLINICAL-OUTCOMES; NOBORI
   STENT; PACLITAXEL; THROMBOSIS; LEADERS; TRIAL; PHARMACOKINETICS;
   INTERVENTION
AB Backgrounds: Drug-eluting stents (DES) with biodegradable polymers have been developed to address the risk of thrombosis associated with first-generation DES. We aimed to determine the efficacy and safety of biodegradable polymer biolimus-eluting stents (BES) versus durable polymer DES.
   Methods: Systematic database searches of MEDLINE (1950 to June 2013), EMBASE (1966 to June 2013), the Cochrane Central Register of Controlled Trials (Issue 6 of 12, June 2013), and a review of related literature were conducted. All randomized controlled trials comparing biodegradable polymer BES versus durable polymer DES were included.
   Results: Eight randomized controlled trials investigating 11,015 patients undergoing percutaneous coronary interventions were included in the meta-analysis. The risk of major adverse cardiac events did not differ significantly between the patients treated with the biodegradable polymer BES and the durable polymer DES (Relative risk [RR], 0.970; 95% CI, 0.848-1.111; p = 0.662). However, biodegradable polymer BES was associated with reduced risk of very late ST compared with the durable polymer DES, while the risk of early or late ST was similar (RR for early or late ST, 1.167; 95% CI 0.755-1.802; p = 0.487; RR 0.273; 95% CI 0.115-0.652; p = 0.003; p for interaction = 0.003).
   Conclusions: In this meta-analysis of randomized controlled trials, treatments with biodegradable polymer BES did not significantly reduce the risk of major adverse cardiac events, but demonstrated a significantly lower risk of very late ST when compared to durable polymer DES. This conclusion requires confirmation by further studies with long-term follow-up.
C1 [Zhang, Shuyang] Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Cardiol, Beijing 100021, Peoples R China.
   Chinese Acad Med Sci, Beijing 100730, Peoples R China.
RP Zhang, SY (reprint author), Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Cardiol, Beijing 100021, Peoples R China.
EM Zhangebmg@gmail.com
OI Zhang, Shuyang/0000-0002-1532-0029
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Byrne RA, 2009, EUR HEART J, V30, P2441, DOI 10.1093/eurheartj/ehp352
   Chevalier Bernard, 2007, EuroIntervention, V2, P426
   Chevalier B, 2009, CIRC-CARDIOVASC INTE, V2, P188, DOI 10.1161/CIRCINTERVENTIONS.108.823443
   Christiansen EH, 2013, LANCET, V381, P661, DOI 10.1016/S0140-6736(12)61962-X
   Cook S, 2009, CIRCULATION, V120, P391, DOI 10.1161/CIRCULATIONAHA.109.854398
   Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313
   Daemen J, 2007, LANCET, V369, P667, DOI 10.1016/S0140-6736(07)60314-6
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Hagiwara H, 2012, EUROINTERVENTION, V8, P743, DOI 10.4244/EIJV8I6A114
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360
   Jensen LO, 2010, EUROINTERVENTION, V5, P898, DOI 10.4244/
   Joner M, 2006, J AM COLL CARDIOL, V48, P193, DOI 10.1016/j.jacc.2006.03.042
   Kadota K, 2012, CATHETER CARDIO INTE, V80, P789, DOI 10.1002/ccd.23280
   Lefevre T, 2010, EUROINTERVENTION, V6, pJ123, DOI 10.4244/EIJV6SUPJA20
   Li Y, 2011, J MOL MED, V89, P545, DOI 10.1007/s00109-011-0729-3
   Ma XD, 2011, J BIOMED MATER RES A, V96A, P632, DOI 10.1002/jbm.a.33016
   Meredith IT, 2012, J AM COLL CARDIOL, V59, P1362, DOI 10.1016/j.jacc.2011.12.016
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Nakazawa G, 2008, CIRCULATION, V118, P1138, DOI 10.1161/CIRCULATIONAHA.107.762047
   Natsuaki M, 2013, J AM COLL CARDIOL, V62, P181, DOI 10.1016/j.jacc.2013.04.045
   Nishio S, 2012, CIRCULATION, V125, P2343, DOI 10.1161/CIRCULATIONAHA.110.000901
   Ostojic M, 2008, CATHETER CARDIO INTE, V72, P901, DOI 10.1002/ccd.21775
   Ostojic MC, 2011, EUR J CLIN PHARMACOL, V67, P389, DOI 10.1007/s00228-010-0895-1
   Pendyala LK, 2012, JACC-CARDIOVASC INTE, V5, P436, DOI 10.1016/j.jcin.2011.11.013
   Rossi F, 2012, MOL PHARM       0529, V29
   Separham A, 2012, EUROINTERVENTION, V8, pN134
   SERRUYS P, 2012, J AM COLL CARDIOL S, V60, pB13
   Smits PC, 2013, LANCET, V381, P651, DOI 10.1016/S0140-6736(12)61852-2
   Stefanini GG, 2012, EUR HEART J, V33, P1214, DOI 10.1093/eurheartj/ehs086
   Stefanini GG, 2011, LANCET, V378, P1940, DOI 10.1016/S0140-6736(11)61672-3
   Stettler C, 2007, LANCET, V370, P937, DOI 10.1016/S0140-6736(07)61444-5
   Stone GW, 2007, NEW ENGL J MED, V356, P998, DOI 10.1056/NEJMoa067193
   Tamai H, 2000, CIRCULATION, V102, P399
   Windecker S, 2008, LANCET, V372, P1163, DOI 10.1016/S0140-6736(08)61244-1
NR 37
TC 9
Z9 9
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 11
PY 2013
VL 8
IS 11
AR e78667
DI 10.1371/journal.pone.0078667
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 255EG
UT WOS:000327221600044
PM 24244335
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ye, J
   Li, XF
   Wang, YD
   Yuan, Y
AF Ye, Jun
   Li, Xiao-Fen
   Wang, Yong-Dong
   Yuan, Ying
TI Arg72Pro Polymorphism of TP53 Gene and the Risk of Skin Cancer: a
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID P53 CODON-72 POLYMORPHISM; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR
   GENE; CUTANEOUS MELANOMA; SUN EXPOSURE; SUSCEPTIBILITY; PATHOGENESIS;
   INDIVIDUALS; ASSOCIATION; MUTATIONS
AB Background: TP53 gene is one of the most important tumor suppressor genes. We undertook this meta-analysis to explore the association between TP53 Arg72Pro polymorphism and the risk of skin cancer mainly in Caucasians.
   Methods: We searched PubMed for case-control studies published up to March 2013. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association.
   Results: A total of 5276 skin cancer cases and 5315 controls from 20 studies were included. Overall, no significant association between TP53 Arg72Pro polymorphism and skin cancer was observed in all genetic contrast models (Pro/Pro versus Arg/Arg, Pro/Arg versus Arg/Arg, Pro/Pro + Pro/Arg versus Arg/Arg, Pro/Pro versus Arg/Arg + Pro/Arg, Pro allele versus Arg allele). Similar results were obtained in the stratified analysis by ethnicity and histological types of skin cancer, such as melanoma, squamous cell carcinoma and basal cell carcinoma. Power calculations indicated that some studies were underpowered. No publication bias was found by using the funnel plot and Egger's test.
   Conclusions: This meta-analysis indicated that TP53 Arg72Pro polymorphism probably had little association with skin cancer susceptibility mainly in Caucasians. However, larger sample-size studies are required to verify the conclusion as low statistical powers.
C1 [Ye, Jun; Wang, Yong-Dong] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Dermatol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Li, Xiao-Fen; Yuan, Ying] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Yuan, Ying] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Minist Educ,Key Lab Canc Prevent & Intervent, Hangzhou 310003, Zhejiang, Peoples R China.
RP Yuan, Y (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
EM yuanying1999@zju.edu.cn
CR Almquist LM, 2011, CARCINOGENESIS, V32, P327, DOI 10.1093/carcin/bgq256
   BASSETSEGUIN N, 1994, J INVEST DERMATOL, V103, pS102, DOI 10.1111/1523-1747.ep12399372
   Bastiaens MT, 2001, MOL CARCINOGEN, V30, P56, DOI 10.1002/1098-2744(200101)30:1<56::AID-MC1013>3.0.CO;2-2
   Bcnjamin CL, 2008, ADV EXP MED BIOL, V624, P265, DOI 10.1007/978-0-387-77574-6_21
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bendesky A, 2007, MUTAT RES-FUND MOL M, V619, P38, DOI 10.1016/j.mrfmmm.2007.01.001
   Benjamin CL, 2007, TOXICOL APPL PHARM, V224, P241, DOI 10.1016/j.taap.2006.12.006
   Cairey-Remonnay S, 2002, J INVEST DERMATOL, V118, P1026, DOI 10.1046/j.1523-1747.2002.01787.x
   Capasso M, 2010, J HUM GENET, V55, P518, DOI 10.1038/jhg.2010.62
   de Oliveira WRP, 2004, INT J DERMATOL, V43, P489, DOI 10.1111/j.1365-4632.2004.02289.x
   Dokianakis DN, 2000, INT J MOL MED, V5, P405
   Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093
   Dupont WD, 1998, CONTROL CLIN TRIALS, V19, P589, DOI 10.1016/S0197-2456(98)00037-3
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elwood JM, 1996, SEMIN ONCOL, V23, P650
   Godar DE, 2011, SKIN CANC, V2011
   GREENBLATT MS, 1994, CANCER RES, V54, P4855
   Gustafsson AC, 2004, ACTA DERM-VENEREOL, V84, P439, DOI 10.1080/00015550410021673
   Gwosdz C, 2006, INT J CANCER, V118, P577, DOI 10.1002/j.ijc.21366
   Han JL, 2006, MOL CARCINOGEN, V45, P694, DOI 10.1002/mc.20190
   HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079
   Jiang DK, 2011, J INVEST DERMATOL, V131, P220, DOI 10.1038/jid.2010.270
   Leiter U, 2008, ADV EXP MED BIOL, V624, P89, DOI 10.1007/978-0-387-77574-6_8
   Levine Arnold J., 2004, Cell, VS116, pS67, DOI 10.1016/S0092-8674(04)00036-4
   Li CY, 2008, J INVEST DERMATOL, V128, P1585, DOI 10.1038/sj.jid.5701186
   Loeb KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034422
   Marshall SE, 2000, TRANSPLANTATION, V69, P994
   MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961
   McGregor JM, 2002, J INVEST DERMATOL, V119, P84, DOI 10.1046/j.1523-1747.2002.01655.x
   Mueller CSL, 2008, ADV EXP MED BIOL, V624, P215, DOI 10.1007/978-0-387-77574-6_17
   O'Connor DP, 2001, J CLIN PATHOL, V54, P539, DOI 10.1136/jcp.54.7.539
   Oliveria SA, 2006, ARCH DIS CHILD, V91, P131, DOI 10.1136/adc.2005.086918
   Pandith AA, 2012, TUMOR BIOL, V33, P927, DOI 10.1007/s13277-012-0318-2
   Pezeshki A, 2006, PATHOL ONCOL RES, V12, P29, DOI 10.1007/BF02893428
   Queille S, 2007, CARCINOGENESIS, V28, P724, DOI 10.1093/carcin/bgl191
   Rizzato C, 2011, J DERMATOL SCI, V63, P47, DOI 10.1016/j.jdermsci.2011.03.006
   Stefanaki I, 2007, BRIT J DERMATOL, V156, P357, DOI 10.1111/j.1365-2133.2006.07645.x
   Young C, 2009, OCCUP MED-OXFORD, V59, P82, DOI 10.1093/occmed/kqn170
NR 38
TC 7
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 8
PY 2013
VL 8
IS 11
AR e79983
DI 10.1371/journal.pone.0079983
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 255CG
UT WOS:000327216200098
PM 24260330
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Cheng, DY
   Hao, YW
   Zhou, WL
   Ma, YR
AF Cheng, Daye
   Hao, Yiwen
   Zhou, Wenling
   Ma, Yiran
TI Vascular Endothelial Growth Factor+936C/T,-634G/C, 2578C/A, and-1154G/A
   Polymorphisms with Risk of Preeclampsia: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID MATERNAL PLASMA-LEVELS; GENE POLYMORPHISMS; GESTATIONAL HYPERTENSION;
   PLACENTAL GROWTH; NO ASSOCIATION; NITRIC-OXIDE; SERUM LEVELS;
   PREGNANCIES; VEGF; DIMETHYLARGININE
AB Background: Emerging evidence showed that VEGF gene polymorphisms are involved in the regulation of VEGF protein expression, thus increasing an individual's susceptibility to preeclampsia (PE); but individually published results are inconclusive. The aim of this meta-analysis was to investigate the associations between VEGF gene polymorphisms and PE risk.
   Methods: A systematic literature search of MEDLINE, Embase, Web of Science, and CNKI (Chinese National Knowledge Infrastructure) databases was conducted. Statistical analyses were performed using STATA 12.0 software and Review manager 5.1. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations.
   Results: According to the inclusion criteria, 11 case-control studies were finally included in this meta-analysis. A total of 1,069 PE cases and 1,315 controls were included in this study. Our meta-analysis indicated that VEGF +936C/T (T vs. C, OR = 1.52, 95%CI = 1.08-2.12) or -634G/C polymorphism (C vs. G, OR = 1.24, 95%CI = 1.03-1.50) was associated with the risk of PE, whereas there was no association between -2578C/A (A vs. C, OR = 0.98, 95%CI = 0.82-1.16) or -1154G/A (A vs. G, OR = 1.30, 95%CI = 0.94-1.78) polymorphism and PE risk in our study.
   Conclusion: Our meta-analysis suggested that VEGF -2578C/A or -1154G/A polymorphism had no association with PE risk in all examined patients, whereas there was an association between VEGF +936C/T or -634G/C polymorphism and risk of PE.
C1 [Cheng, Daye; Hao, Yiwen; Zhou, Wenling; Ma, Yiran] China Med Univ, Hosp 1, Dept Transfus, Shenyang, Peoples R China.
RP Cheng, DY (reprint author), China Med Univ, Hosp 1, Dept Transfus, Shenyang, Peoples R China.
EM dayecheng_cmu@163.com
FU Liaoning Natural Science Fund, Liaoning Province, China [201102257]
FX This study was supported by Liaoning Natural Science Fund, Liaoning
   Province, China (Topic No: 201102257). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Andraweera PH, 2013, J MATERN-FETAL NEO M, V26, P532, DOI 10.3109/14767058.2012.743520
   Anthony FW, 1997, ANN CLIN BIOCHEM, V34, P276, DOI 10.1177/000456329703400309
   Atis A, 2012, INT J IMMUNOGENET, V39, P241, DOI 10.1111/j.1744-313X.2011.01082.x
   BAKER PN, 1995, OBSTET GYNECOL, V86, P815, DOI 10.1016/0029-7844(95)00259-T
   Banyasz I, 2006, MOL HUM REPROD, V12, P233, DOI 10.1093/molehr/ga1024
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bosio PM, 2001, AM J OBSTET GYNECOL, V184, P146, DOI 10.1067/mob.2001.108342
   Brockelsby J, 1999, LAB INVEST, V79, P1101
   Brownbill P, 2008, PLACENTA, V29, P950, DOI 10.1016/j.placenta.2008.08.020
   Chedraui P, 2013, J MATERN-FETAL NEO M, V26, P226, DOI 10.3109/14767058.2012.733760
   Cunha VMD, 2011, REV BRAS GINECOL OBS, V33, P158, DOI 10.1590/S0100-72032011000700007
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eiland E., 2012, J PREGNANCY, V2012, DOI DOI 10.1155/2012/586578
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Foidart JM, 2009, J REPROD IMMUNOL, V82, P106, DOI 10.1016/j.jri.2009.09.001
   Garza-Veloz I, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-35
   Ghulmiyyah L, 2012, SEMIN PERINATOL, V36, P56, DOI 10.1053/j.semperi.2011.09.011
   Huang Y, 2009, MATERN CHILD HLTH CA, V24, P2712
   Hunter A, 2000, HYPERTENSION, V36, P965, DOI 10.1161/01.HYP.36.6.965
   Jain L, 2009, MOL CANCER THER, V8, P2496, DOI 10.1158/1535-7163.MCT-09-0302
   Kim YJ, 2008, TWIN RES HUM GENET, V11, P77, DOI 10.1375/twin.11.1.77
   Livingston JC, 2000, AM J OBSTET GYNECOL, V183, P1554, DOI 10.1067/mob.2000.108022
   Lyall F, 1997, BRIT J OBSTET GYNAEC, V104, P223, DOI 10.1111/j.1471-0528.1997.tb11050.x
   Madazli R, 2003, ACTA OBSTET GYN SCAN, V82, P797, DOI 10.1034/j.1600-0412.2003.00206.x
   Moodley J, 2004, HYPERTENS PREGNANCY, V23, P247, DOI 10.1081/PRG-200030301
   Ong S, 2000, BEST PRACT RES CL OB, V14, P969, DOI 10.1053/beog.2000.0138
   Papazoglou D, 2004, MOL HUM REPROD, V10, P321, DOI 10.1093/molehr/gah048
   Pasqualetti G, 2007, PHARMACOGENOMICS, V8, P49, DOI 10.2217/14622416.8.1.49
   Renner W, 2000, J VASC RES, V37, P443, DOI 10.1159/000054076
   Reuvekamp A, 1999, BRIT J OBSTET GYNAEC, V106, P1019, DOI 10.1111/j.1471-0528.1999.tb08107.x
   Sandrim VC, 2009, MOL HUM REPROD, V15, P115, DOI 10.1093/molehr/gan076
   Sharkey AM, 1996, EUR J CLIN INVEST, V26, P1182, DOI 10.1046/j.1365-2362.1996.830605.x
   Shim JY, 2007, AM J OBSTET GYNECOL, V197
   Sibai BM, 2003, OBSTET GYNECOL, V102, P181, DOI 10.1016/S0029-7844(03)00475-7
   Stevens A, 2003, CANCER RES, V63, P812
   Yun H, 2011, STUDY ASS VEGF GENE
   2002, INT J GYNAECOL OBSTE, V77, P67
NR 37
TC 17
Z9 17
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 4
PY 2013
VL 8
IS 11
AR e78173
DI 10.1371/journal.pone.0078173
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 245ZC
UT WOS:000326503400036
PM 24223772
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, ZJ
   Cheng, YJ
   Aung, LHH
   Li, BX
AF Wu, Zhenjie
   Cheng, Yunjiu
   Aung, Lynn Htet Htet
   Li, Bixun
TI Association between Adiponectin Concentrations and Cardiovascular
   Disease in Diabetic Patients: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID CORONARY-HEART-DISEASE; EVENTS; EXPRESSION; ADIPOSE; PROTEIN
AB Background: This systematic review and meta-analysis of prospective studies evaluates the association between adiponectin concentrations and risk of cardiovascular disease (CVD) in individuals with diabetes mellitus (DM).
   Methods: PubMed and Embase were searched for prospective studies on the association of adiponectin concentrations and risk of CVD up to June 2013. Random-effect model was selected to pool the relative risk (RR) and 95% CI.
   Results: Five prospective cohort studies and one nested case-control studies met the included criterion. The estimated summary RR and 95% CI of five prospective cohort studies for type 2 diabetes comparing top vs low tertile of adiponectin concentrations was 0.99 (95% CI: 0.67-1.45), with significant heterogeneity between studies (p = 0.037, I-2 = 60.9%). This heterogeneity was explained by one study conducted in Korean.
   Conclusions: This study represents the first meta-analysis between adiponectin levels and CVD in diabetic patients and indicated no association was found. This result should be verified further by large sample size, long duration of follow-up, and well-designed prospective clinical trials.
C1 [Wu, Zhenjie; Li, Bixun] Guangxi Med Univ, Tumor Affiliated Hosp, Dept Gen Internal Med, Nanning, Guangxi, Peoples R China.
   [Cheng, Yunjiu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiol, Guangzhou, Guangdong, Peoples R China.
   [Aung, Lynn Htet Htet] Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiol, Inst Cardiovasc Dis, Nanning, Guangxi, Peoples R China.
RP Li, BX (reprint author), Guangxi Med Univ, Tumor Affiliated Hosp, Dept Gen Internal Med, Nanning, Guangxi, Peoples R China.
EM li4738@126.com
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Costacou T, 2005, DIABETOLOGIA, V48, P41, DOI 10.1007/s00125-004-1597-y
   Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Goldstein BJ, 2009, NAT CLIN PRACT CARD, V6, P27, DOI 10.1038/ncpcardio1398
   Hao G, 2013, ATHEROSCLEROSIS
   Havel PJ, 2004, DIABETES, V53, pS143, DOI 10.2337/diabetes.53.2007.S143
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hung WC, 2010, ENDOCR J, V57, P793, DOI 10.1507/endocrj.K10E-020
   Kang EH, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3218
   Kanhai DA, 2013, OBES REV
   Krzyzanowska K, 2009, TRANSL RES, V153, P199, DOI 10.1016/j.trsl.2009.01.009
   Kumada M, 2004, CIRCULATION, V109, P2046, DOI 10.1161/01.CIR.0000127953.98131.ED
   Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006
   Lihn AS, 2005, OBES REV, V6, P13, DOI 10.1111/j.1467-789X.2005.00159.x
   Lim S, 2008, ATHEROSCLEROSIS, V196, P398, DOI 10.1016/j.atherosclerosis.2006.11.017
   Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587
   Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701
   Sarwar N, 2010, LANCET, V375, P2215, DOI 10.1016/S0140-6736(10)60484-9
   Sattar N, 2006, CIRCULATION, V114, P623, DOI [10.1161/CIRCULATIONAHA.106.618918, 10.1161/CIRCULATIONHA.106.618918]
   Schottker B, 2013, DIABETES CARE
   Schulze MB, 2005, DIABETES, V54, P534, DOI 10.2337/diabetes.54.2.534
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Yang WS, 2001, J CLIN ENDOCR METAB, V86, P3815, DOI 10.1210/jc.86.8.3815
   Zhang BC, 2012, CLIN ENDOCRINOL, V77, P370, DOI 10.1111/j.1365-2265.2011.04260.x
   Zhang H, 2012, AM J MED SCI
NR 26
TC 14
Z9 14
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 4
PY 2013
VL 8
IS 11
AR e78485
DI 10.1371/journal.pone.0078485
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 245ZC
UT WOS:000326503400068
PM 24223814
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Hou, XJ
   Xu, JH
   Wang, J
   Yu, YY
AF Hou, Xin-Jiang
   Xu, Jing-Hang
   Wang, Jun
   Yu, Yan-Yan
TI Can Antidepressants Prevent Pegylated
   Interferon-alpha/Ribavirin-Associated Depression in Patients with
   Chronic Hepatitis C: Meta-Analysis of Randomized, Double-Blind,
   Placebo-Controlled Trials?
SO PLOS ONE
LA English
DT Article
ID ALPHA-INDUCED DEPRESSION; PLUS RIBAVIRIN; PEGINTERFERON ALPHA-2A;
   SUSTAINED RESPONSE; MAJOR DEPRESSION; THERAPY; SYMPTOMS; VIRUS;
   ESCITALOPRAM; CITALOPRAM
AB Background: Antidepressants are effective in treating interferon-alpha/ribavirin (IFN-alpha/RBV)-associated depression during or after treatment of chronic hepatitis C (CHC). Whether antidepressant prophylaxis is necessary in this population remains under debate.
   Methods: Comprehensive searches were performed in Medline, Embase, Cochrane Controlled Trials Register and PubMed. Reference lists were searched manually. The methodology was in accordance with the 2009 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) Statement.
   Results: We identified six randomized, double-blind, placebo-controlled trials involving 522 CHC patients treated with pegylated (PEG)-IFN-alpha plus RBV. The antidepressants used were escitalopram, citalopram, and paroxetine, which are selective serotonin reuptake inhibitors (SSRIs). The rates of depression (17.9% vs. 31.0%, P = 0.0005), and rescue therapy (27.4% vs. 42.7%, P<0.0001) in the SSRI group were significantly lower than those in the placebo group. The rate of sustained virological response (SVR) (56.8% vs. 50.0%, P = 0.60) and drug discontinuation (18.7% vs. 21.1%, P = 0.63) in the SSRI group did not differ significantly to those in the placebo group. In terms of safety, the incidence of muscle and joint pain (40.8% vs. 52.4%, P = 0.03) and respiratory problems (29.3% vs. 40.1%, P = 0.03) were lower, but the incidence of dizziness was significantly higher (22.3% vs. 10.2%, P = 0.001) in the SSRI group.
   Conclusion: Prophylactic SSRI antidepressants can significantly reduce the incidence of PEG-IFN-alpha/RBV-associated depression in patients with CHC, with good safety and tolerability, without reduction of SVR.
C1 [Hou, Xin-Jiang; Xu, Jing-Hang; Wang, Jun; Yu, Yan-Yan] Peking Univ, Hosp 1, Dept Infect Dis, Beijing 100871, Peoples R China.
RP Yu, YY (reprint author), Peking Univ, Hosp 1, Dept Infect Dis, Beijing 100871, Peoples R China.
EM yyy@bjmu.edu.cn
CR Asnis GM, 2006, J CLIN GASTROENTEROL, V40, P322, DOI 10.1097/01.mcg.0000210099.36500.fe
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bernstein D, 2002, HEPATOLOGY, V35, P704, DOI 10.1053/jhep.2002.31311
   Cacoub P, 2002, J HEPATOL, V36, P812, DOI 10.1016/S0168-8278(02)00067-3
   Davis GL, 2003, HEPATOLOGY, V38, P645, DOI 10.1053/jhep.2003.50364
   de Knegt RJ, 2011, ALIMENT PHARM THER, V34, P1306, DOI 10.1111/j.1365-2036.2011.04867.x
   Dieperink E, 2000, AM J PSYCHIAT, V157, P867, DOI 10.1176/appi.ajp.157.6.867
   Diez-Quevedo C, 2011, J CLIN PSYCHIAT, V72, P522, DOI 10.4088/JCP.09m05282blu
   Farah A, 2002, J CLIN PSYCHIAT, V63, P166, DOI 10.4088/JCP.v63n0213c
   Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
   Ghany MG, 2009, HEPATOLOGY, V49, P1335, DOI 10.1002/hep.22759
   Gleason OC, 1999, PSYCHOSOMATICS, V40, P510, DOI 10.1016/S0033-3182(99)71190-4
   Gleason OC, 2004, PSYCHOSOMATICS, V45, P29, DOI 10.1176/appi.psy.45.1.29
   Gleason OC, 2002, J CLIN PSYCHIAT, V63, P194, DOI 10.4088/JCP.v63n0304
   Gleason OC, 2007, DIGEST DIS SCI, V52, P2557, DOI 10.1007/s10620-006-9729-5
   Guadagnino V, 2006, DIGEST LIVER DIS, V38, P119, DOI 10.1016/j.dld.2005.10.008
   Hauser P, 2002, MOL PSYCHIATR, V7, P942, DOI 10.1038/sj.mp.4001119
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kraus MR, 2008, GUT, V57, P531, DOI 10.1136/gut.2007.131607
   Kraus MR, 2005, J VIRAL HEPATITIS, V12, P96, DOI 10.1111/j.1365-2893.2005.00554.x
   Kraus MR, 2002, ALIMENT PHARM THER, V16, P1091, DOI 10.1046/j.1365-2036.2002.01265.x
   Kraus MR, 2001, DIGEST DIS SCI, V46, P2060, DOI 10.1023/A:1011973823032
   Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x
   Maddock C, 2005, MOL PSYCHIATR, V10, P332, DOI 10.1038/sj.mp.4001634
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   McHutchison JG, 2002, GASTROENTEROLOGY, V123, P1061, DOI 10.1053/gast.2002.35950
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Morasco BJ, 2007, J AFFECT DISORDERS, V103, P83, DOI 10.1016/j.jad.2007.01.007
   Morasco BJ, 2010, PSYCHOSOMATICS, V51, P401, DOI 10.1176/appi.psy.51.5.401
   Perz JF, 2006, J HEPATOL, V45, P529, DOI 10.1016/j.jhep.2006.05.013
   Raison CL, 2007, ALIMENT PHARM THER, V25, P1163, DOI 10.1111/j.1365-2036.2007.03316.x
   Raison CL, 2005, BRAIN BEHAV IMMUN, V19, P23, DOI 10.1016/j.bbi.2004.05.001
   Reichenberg A, 2005, AIDS, V19, pS174, DOI 10.1097/01.aids.0000192087.64432.ae
   Schafer A, 2007, INT J METH PSYCH RES, V16, P186, DOI 10.1002/mpr.229
   Schaefer M, 2005, J HEPATOL, V42, P793, DOI 10.1016/j.jhep.2005.01.020
   Schaefer M, 2002, PROG NEURO-PSYCHOPH, V26, P731, DOI 10.1016/S0278-5846(01)00324-4
   Schaefer M, 2012, ANN INTERN MED, V157, P94, DOI 10.7326/0003-4819-157-2-201207170-00006
   Schramm TM, 2000, MED J AUSTRALIA, V173, P359
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Shiffman ML, 2004, GASTROENTEROLOGY, V126, P1015, DOI 10.1053/j.gastro.2004.01.014
   Sockalingam S, 2011, J VIRAL HEPATITIS, V18, P153, DOI 10.1111/j.1365-2893.2010.01393.x
   Trkulja V, 2010, CROAT MED J, V51, P61, DOI 10.3325/cmj.2010.51.61
   Zdilar D, 2000, HEPATOLOGY, V31, P1207, DOI 10.1053/jhep.2000.7880
NR 43
TC 9
Z9 9
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 30
PY 2013
VL 8
IS 10
AR e76799
DI 10.1371/journal.pone.0076799
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 243RL
UT WOS:000326334500010
PM 24204676
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, YD
   Chu, XW
   Meng, XJ
   Zou, F
AF Wang, Yadong
   Chu, Xinwei
   Meng, Xiaojing
   Zou, Fei
TI Association of X-ray Repair Cross Complementing Group 1 Arg399Gln
   Polymorphisms with the Risk of Squamous Cell Carcinoma of the Head and
   Neck: Evidence from an Updated Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID BASE-EXCISION-REPAIR; GENETIC POLYMORPHISMS; XRCC1 POLYMORPHISMS;
   LUNG-CANCER; DNA; SUSCEPTIBILITY; VARIANTS; SMOKING; PATHWAY; XPD
AB Background: Epidemiologic studies have reported the association of X-ray repair cross-complementary group 1 (XRCC1) Arg399Gln polymorphisms with susceptibility to squamous cell carcinoma of the head and neck (HNSCC). However, the results were conflictive rather than conclusive. The purpose of this study was to clarify the association of XRCC1 Arg399Gln variants with HNSCC risk.
   Methods: Systematic searches were performed through the search engines of PubMed, Elsevier, Science Direct, CNKI and Chinese Biomedical Literature Database. Summary odds ratio (OR) with 95% confidence intervals (CI) was computed to estimate the strength association.
   Results: Overall, we did not observe any association of XRCC1 Arg399Gln polymorphisms with HNSCC risk in total population (OR = 0.95, 95% CI: 0.76-1.19 for Gln/Gln vs. Arg/Arg, OR = 1.05, 95% CI: 0.92-1.20 for Arg/Gln vs. Arg/Arg, and OR = 1.03, 95% CI: 0.90-1.18 for Gln/Gln+Arg/Gln vs. Arg/Arg) based on 18 studies including 3917 cases and 4560 controls. In subgroup analyses, we observed an increased risk of XRCC1 399 Arg/Gln genotype for HNSCC in Caucasians (OR = 1.20, 95% CI: 1.00-1.44) and Gln/Gln genotype for larynx squamous cell carcinoma (OR = 1.63, 95% CI: 1.10-2.40). We did not observe any association between XRCC1 Arg399Gln variants and HNSCC risk in additional subgroup analyses.
   Conclusion: The results from this present meta-analysis suggest that XRCC1 Arg399Gln variants may contribute to HNSCC risk among Caucasians and to the risk of larynx squamous cell carcinoma. Further, well-designed studies with larger sample sizes are required to verify our findings.
C1 [Wang, Yadong] Henan Ctr Dis Control & Prevent, Zhengzhou, Peoples R China.
   [Chu, Xinwei] Southern Med Univ, Sch Publ Hlth & Trop Med, Dept Nutr Hlth, Guangzhou, Guangdong, Peoples R China.
   [Wang, Yadong; Meng, Xiaojing; Zou, Fei] Southern Med Univ, Sch Publ Hlth & Trop Med, Dept Occupat Hlth & Occupat Med, Guangzhou, Guangdong, Peoples R China.
RP Zou, F (reprint author), Southern Med Univ, Sch Publ Hlth & Trop Med, Dept Occupat Hlth & Occupat Med, Guangzhou, Guangdong, Peoples R China.
EM zoufei0616@163.com
FU National Basic Research Program of China [2012CB518200]; National Nature
   Science Foundation of China [81272180]
FX This research was supported by National Basic Research Program of China
   (No. 2012CB518200) and National Nature Science Foundation of China (No.
   81272180). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Almeida KH, 2007, DNA REPAIR, V6, P695, DOI 10.1016/j.dnarep.2007.01.009
   Applebaum KM, 2009, INT J CANCER, V124, P2690, DOI 10.1002/ijc.24256
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bogela Aersilan, 2011, Journal of Xinjiang Medical University, V34, P1247
   Csejtei A, 2009, ANTICANCER RES, V29, P4169
   Demokan S, 2005, PATHOL ONCOL RES, V11, P22, DOI 10.1007/BF03032401
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   dos Reis MB, 2013, J ORAL PATHOL MED, V42, P180, DOI 10.1111/j.1600-0714.2012.01192.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Foulkes WD, 1996, BRIT MED J, V313, P716
   Gugatschka M, 2011, EXP MOL PATHOL, V91, P331, DOI 10.1016/j.yexmp.2011.03.004
   Harth V, 2008, J TOXICOL ENV HEAL A, V71, P887, DOI 10.1080/15287390801988160
   Huang GL, 2011, ASIAN PAC J CANCER P, V12, P2329
   Jiang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055597
   Khlifi R, 2012, J GENET, V91, P375, DOI 10.1007/s12041-012-0193-z
   Kietthubthew S, 2006, INT J HYG ENVIR HEAL, V209, P21, DOI 10.1016/j.ijheh.2005.06.002
   Kiyohara C, 2006, LUNG CANCER, V54, P267, DOI 10.1016/j.lungcan.2006.08.009
   Kostrzewska-Poczekaj M, 2013, EUR ARCH OTO-RHINO-L, V270, P271, DOI 10.1007/s00405-012-1993-8
   Kowalski M, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-37
   Krupa R., 2011, Experimental Oncology, V33, P55
   Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x
   Kumar A, 2012, MUTAT RES-FUND MOL M, V729, P24, DOI 10.1016/j.mrfmmm.2011.09.001
   Li CY, 2007, CANCER, V110, P867, DOI 10.1002/cncr.22861
   Li HH, 2009, BREAST, V18, P183, DOI 10.1016/j.breast.2009.03.008
   Liu YF, 2013, STAT INTERFACE, V6, P1
   Long XD, 2004, J GUANGXI MED U, P313
   Majumder M, 2007, INT J CANCER, V120, P2148, DOI 10.1002/ijc.22547
   Olshan AF, 2002, CANCER LETT, V178, P181, DOI 10.1016/S0304-3835(01)00822-9
   Salanti G, 2005, EUR J HUM GENET, V13, P840, DOI 10.1038/sj.ejhg.5201410
   Shen MR, 1998, CANCER RES, V58, P604
   Tae K, 2004, INT J CANCER, V111, P805, DOI 10.1002/ijc.20338
   Thibaudeau E, 2013, INT J OTOLARYNGOL, V2013, DOI DOI 10.1155/2013/43781
   Varzim G, 2003, EUR J CANCER PREV, V12, P495, DOI 10.1097/00008469-200312000-00008
   Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530
   Yang Yuan, 2008, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V25, P211
   Yin JY, 2007, LUNG CANCER, V56, P153, DOI 10.1016/j.lungcan.2006.12.012
   Yu HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041853
   Zhang CY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056294
   Zhang YW, 2006, CANCER EPIDEM BIOMAR, V15, P353, DOI 10.1158/1055-99665.EPI-05-0653
   Zienolddiny S, 2006, CARCINOGENESIS, V27, P560, DOI 10.1093/carcin/bgi232
NR 40
TC 2
Z9 2
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 30
PY 2013
VL 8
IS 10
AR e77898
DI 10.1371/journal.pone.0077898
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 243RL
UT WOS:000326334500073
PM 24205020
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, Y
   He, XF
   Lu, YT
   Long, H
   Song, Y
   Qi, ST
AF Liu Yi
   He Xiao-feng
   Lu Yun-tao
   Long Hao
   Song Ye
   Qi Song-tao
TI Association between the XRCC1 Arg399Gln Polymorphism and Risk of Cancer:
   Evidence from 297 Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID BASE EXCISION-REPAIR; DNA-POLYMERASE BETA; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; GENE POLYMORPHISM; LIGASE III; METAANALYSIS;
   SUSCEPTIBILITY; ARG194TRP
AB Background: The Arg399Gln polymorphism in the X-ray cross-complementing group 1 (XRCC1) had been implicated in cancer susceptibility. The previous published data on the association between XRCC1 Arg399Gln polymorphism and cancer risk remained controversial.
   Methodology/Principal Findings: To derive a more precise estimation of the association between the XRCC1 Arg399Gln polymorphism and overall cancer risk, we performed a meta-analysis of 297 case-control studies, in which a total of 93,941 cases and 121,480 controls were included. Overall, significantly increased cancer risk was observed in any genetic model (dominant model: odds ration [OR] = 1.04, 95% confidence interval [CI] = 1.01-1.07; recessive model: OR = 1.08, 95% CI = 1.03-1.13; additive model: OR = 1.09, 95% CI = 1.04-1.14) when all eligible studies were pooled into the meta-analysis. In further stratified and sensitivity analyses, significantly elevated hepatocellular and breast cancers risk were observed in Asians (dominant model: OR = 1.39, 95% CI = 1.06-1.84) and in Indians (dominant model: OR = 1.64, 95% CI = 1.31-2.04; recessive model: OR = 1.94, 95% CI = 1.09-3.47; additive model: OR = 2.06, 95% CI = 1.50-2.84), respectively.
   Conclusions/Significance: This meta-analysis suggests the participation of XRCC1 Arg399Gln is a genetic susceptibility for hepatocellular cancer in Asians and breast cancer in Indians. Moreover, our work also points out the importance of new studies for Arg399Gln association in some cancer types, such as glioma, gastric cancer, and oral cancer, where at least some of the covariates responsible for heterogeneity could be controlled, to obtain a more conclusive understanding about the function of the XRCC1 Arg399Gln polymorphism in cancer development.
C1 [Liu Yi; Lu Yun-tao; Long Hao; Song Ye; Qi Song-tao] Southern Med Univ, Nanfang Hosp, Neurosurg Dept, Guangzhou, Guangdong, Peoples R China.
   [He Xiao-feng] Peace Hosp, Changzhi Med Coll, Dept Res, Changzhi, Peoples R China.
RP Qi, ST (reprint author), Southern Med Univ, Nanfang Hosp, Neurosurg Dept, Guangzhou, Guangdong, Peoples R China.
EM liuyi86818@126.com
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387
   Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970
   Chen D, 2008, J BIOL CHEM, V283, P15381, DOI 10.1074/jbc.M710296200
   Dai LP, 2012, MOL BIOL REP, V39, P9535, DOI 10.1007/s11033-012-1818-2
   Davey SG, 1997, LANCET, V350, P1182, DOI DOI 10.1016/S0140-6736(05)63833-0
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duan WH, 2012, ASIAN PAC J CANCER P, V13, P3601, DOI 10.7314/APJCP.2012.13.8.3601
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang YS, 2009, MUTAGENESIS, V24, P331, DOI 10.1093/mutage/gep013
   Kiyohara C, 2006, LUNG CANCER, V54, P267, DOI 10.1016/j.lungcan.2006.08.009
   Klug SJ, 2009, LANCET ONCOL, V10, P772, DOI 10.1016/S1470-2045(09)70187-1
   Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x
   Li HH, 2009, BREAST, V18, P183, DOI 10.1016/j.breast.2009.03.008
   Li J, 2013, TUMOR BIOL, V34, P261, DOI 10.1007/s13277-012-0546-5
   Li Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044441
   Liu BM, 2012, GENET MOL RES, V11, P3852, DOI 10.4238/2012.November.12.2
   Liu F, 2011, LIVER INT, V31, P804, DOI 10.1111/j.1478-3231.2011.02508.x
   Liu L, 2013, MOL BIOL REP, V40, P3943, DOI 10.1007/s11033-012-2471-5
   Lu AL, 2001, CELL BIOCHEM BIOPHYS, V35, P141, DOI 10.1385/CBB:35:2:141
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Moore DJ, 2000, P NATL ACAD SCI USA, V97, P13649, DOI 10.1073/pnas.250477597
   Saadat M, 2009, BREAST CANCER RES TR, V115, P137, DOI 10.1007/s10549-008-0051-0
   Shen MR, 1998, CANCER RES, V58, P604
   Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232
   Thacker J, 2003, DNA REPAIR, V2, P655, DOI 10.1016/S1568-7864(03)00062-4
   Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530
   Wang YD, 2009, CANCER LETT, V285, P134, DOI 10.1016/j.canlet.2009.05.005
   Wei B, 2011, PROSTATE CANCER P D, V14, P225, DOI 10.1038/pcan.2011.26
   Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154
   Wu KS, 2011, ASIAN PAC J CANCER P, V12, P2237
   Xie T, 2012, WORLD J GASTROENTERO, V18, P4207, DOI 10.3748/wjg.v18.i31.4207
   Yu Z, 1999, ENVIRON MOL MUTAGEN, V33, P3, DOI 10.1002/(SICI)1098-2280(1999)33:1<3::AID-EM2>3.0.CO;2-L
   Zhang Huina, 2010, Wei Sheng Yan Jiu, V39, P664
NR 35
TC 2
Z9 3
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 29
PY 2013
VL 8
IS 10
AR e78071
DI 10.1371/journal.pone.0078071
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 242VF
UT WOS:000326270700071
PM 24205095
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhao, J
   Zhao, L
AF Zhao, Jun
   Zhao, Long
TI Cruciferous Vegetables Intake Is Associated with Lower Risk of Renal
   Cell Carcinoma: Evidence from a Meta-Analysis of Observational Studies
SO PLOS ONE
LA English
DT Article
ID COLORECTAL-CANCER; PROSTATE-CANCER; FRUIT; CONSUMPTION; CAROTENOIDS;
   INHIBITION; VITAMIN; FIBER; DIET
AB Background: Epidemiologic studies have evaluated the association between cruciferous vegetables(CV) intake and the risk of renal cell carcinoma(RCC); however, the existing results are controversial. The aim of this meta-analysis was to investigate the association between CV intake and RCC risk.
   Methods: A literature search was carried out using PUBMED and EMBASE database between January 1966 and March 2013. Fixed-effect and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Potential sources of heterogeneity were detected by meta-regression. Subgroup analyses, sensitivity analysis and cumulative meta-analysis were also performed.
   Results: A total of 12 studies (six cohorts, six case-control) contributed to the analysis, involving 1,228,518 participants and 5,773 RCC cases. When all studies were pooled, we observed a significantly inverse association between CV intake and RCC risk (RR = 0.81, 95% CI [0.72, 0.91]). This association was also significant when analyses were restricted to six high-quality studies (RR = 0.89, 95% CI [0.82, 0.98]). In subgroup analyses, CV intake was significantly associated with reduced RCC risk among studies conducted in America (RR = 0.77, 95% CI [0.70, 0.86]); however, CV intake had no significant association with RCC risk among studies conducted in Europe (RR = 0.87, 95% CI [0.71, 1.07]). Furthermore, sensitivity analysis confirmed the stability of results.
   Conclusions: The findings of this meta-analysis suggested that high intake of CV was inversely associated with RCC risk among Americans. More studies, especially high quality cohort studies with larger sample size, well controlled confounding factors are warranted to confirm this association.
C1 [Zhao, Jun] Shandong Weifang Peoples Hosp, Dept Nephrol, Weifang, Peoples R China.
   [Zhao, Long] Shandong Univ, Dept Nephrol, Hosp 2, Jinan 250100, Peoples R China.
RP Zhao, J (reprint author), Shandong Weifang Peoples Hosp, Dept Nephrol, Weifang, Peoples R China.
EM junzhao63@126.com
CR Aune D, 2011, GASTROENTEROLOGY, V141, P106, DOI 10.1053/j.gastro.2011.04.013
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bertoia M, 2010, INT J CANCER, V126, P1504, DOI 10.1002/ijc.24829
   Brock KE, 2012, BRIT J NUTR, V108, P1077, DOI 10.1017/S0007114511006489
   Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46
   Conaway CC, 2002, CURR DRUG METAB, V3, P233, DOI 10.2174/1389200023337496
   Daniel CR, 2013, AM J CLIN NUTR, V97, P1036, DOI 10.3945/ajcn.112.045351
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dhote R, 2000, BJU INT, V86, P20, DOI 10.1046/j.1464-410x.2000.00708.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gerhauser C, 2013, CURR OPIN CLIN NUTR
   Hecht SS, 2000, DRUG METAB REV, V32, P395, DOI 10.1081/DMR-100102342
   Hecht SS, 2004, CANCER EPIDEM BIOMAR, V13, P997
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009
   Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hsu CC, 2007, AM J EPIDEMIOL, V166, P62, DOI 10.1093/aje/kwm043
   Hu JF, 2003, CANCER CAUSE CONTROL, V14, P705, DOI 10.1023/A:1026310323882
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kim SH, 2013, CANC PREV RES PHILA
   Kurilich AC, 1999, J AGR FOOD CHEM, V47, P1576, DOI 10.1021/jf9810158
   Lee JE, 2006, CANCER EPIDEM BIOMAR, V15, P2445, DOI 10.1158/1055-9965.EPI-06-0553
   Lee JE, 2009, CANCER EPIDEM BIOMAR, V18, P1730, DOI 10.1158/1055-9965.EPI-09-0045
   Lindblad P, 1997, CANCER EPIDEM BIOMAR, V6, P215
   Liu B, 2013, WORLD J UROL, V31, P127, DOI 10.1007/s00345-012-0850-0
   Liu B, 2012, INT J UROL, V19, P134, DOI 10.1111/j.1442-2042.2011.02906.x
   Maclure M, 1990, Epidemiology, V1, P430, DOI 10.1097/00001648-199011000-00004
   Melchini A, 2013, NUTR CANCER, V65, P132, DOI 10.1080/01635581.2013.741747
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326
   Rashidkhani B, 2005, INT J CANCER, V113, P451, DOI 10.1002/ijc.20577
   Saw CLL, 2011, BIOPHARM DRUG DISPOS, V32, P289, DOI 10.1002/bdd.759
   van Dijk BAC, 2005, INT J CANCER, V117, P648, DOI 10.1002/ijc.21203
   Weikert S, 2006, INT J CANCER, V118, P3133, DOI 10.1002/ijc.21765
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Wu QJ, 2013, ANN ONCOL, V24, P1079, DOI 10.1093/annonc/mds601
   Wu QJ, 2013, ANN ONCOL
   Wu QJ, 2013, CANC SCI
   Yuan JM, 1998, INT J CANCER, V77, P211, DOI 10.1002/(SICI)1097-0215(19980717)77:2<211::AID-IJC7>3.3.CO;2-0
   Zhou Y, 2011, GASTROENTEROLOGY, V141, P80, DOI 10.1053/j.gastro.2011.03.057
NR 41
TC 14
Z9 14
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 28
PY 2013
VL 8
IS 10
AR e75732
DI 10.1371/journal.pone.0075732
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 242KW
UT WOS:000326241200007
PM 24204579
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, JL
   Li, C
   Tao, HT
   Cheng, Y
   Han, L
   Li, XY
   Hu, Y
AF Wang, Jinliang
   Li, Cheng
   Tao, Haitao
   Cheng, Yao
   Han, Lu
   Li, Xiaoyan
   Hu, Yi
TI Statin Use and Risk of Lung Cancer: a Meta-Analysis of Observational
   Studies and Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID COA REDUCTASE INHIBITORS; POPULATION-BASED COHORT; FOLLOW-UP; PRIMARY
   PREVENTION; PANCREATIC-CANCER; POTENT INHIBITION; INDUCED APOPTOSIS;
   TUMOR FORMATION; CELL-GROWTH; IN-VITRO
AB Clinical studies have shown that statin use may alter the risk of lung cancer. However, these studies yielded different results. To quantify the association between statin use and risk of lung cancer, we performed a detailed meta-analysis. A literature search was carried out using MEDLINE, EMBASE and COCHRANE database between January 1966 and November 2012. Before meta-analysis, between-study heterogeneity and publication bias were assessed using adequate statistical tests. Fixed-effect and random-effect models were used to calculate the pooled relative risks (RR) and corresponding 95% confidence intervals (CIs). Subgroup analyses, sensitivity analysis and cumulative meta-analysis were also performed. A total of 20 (five randomized controlled trials, eight cohorts, and seven case-control) studies contributed to the analysis. Pooled results indicated a non-significant decrease of total lung cancer risk among all statin users (RR = 0.89, 95% CI [0.78, 1.02]). Further, long-term statin use did not significantly decrease the risk of total lung cancer (RR = 0.80, 95% CI [0.39, 1.64]). In our subgroup analyses, the results were not substantially affected by study design, participant ethnicity, or confounder adjustment. Furthermore, sensitivity analysis confirmed the stability of results. The findings of this meta-analysis suggested that there was no significant association between statin use and risk of lung cancer. More studies, especially randomized controlled trials and high quality cohort studies are warranted to confirm this association.
C1 [Wang, Jinliang; Li, Cheng; Tao, Haitao; Cheng, Yao; Han, Lu; Li, Xiaoyan; Hu, Yi] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Oncol, Beijing, Peoples R China.
RP Hu, Y (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Gen Oncol, Beijing, Peoples R China.
EM yihubj@163.com
CR Alonso DF, 1998, BREAST CANCER RES TR, V50, P83, DOI 10.1023/A:1006058409974
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blais L, 2000, ARCH INTERN MED, V160, P2363, DOI 10.1001/archinte.160.15.2363
   Chen J, 2012, EUR J PHARMACOL, V682, P161, DOI 10.1016/j.ejphar.2012.02.015
   Chen J, 2012, MOL ONCOL, V6, P62, DOI 10.1016/j.molonc.2011.11.003
   Cheng MH, 2012, LUNG CANCER, V75, P275, DOI 10.1016/j.lungcan.2011.08.014
   Coogan PF, 2007, EPIDEMIOLOGY, V18, P213, DOI 10.1097/01.ede.0000254694.03027.a1
   Cui XB, 2012, CANCER CAUSE CONTROL, V23, P1099, DOI 10.1007/s10552-012-9979-9
   Dimitroulakos J, 2002, NEOPLASIA, V4, P337, DOI 10.1038/sj.neo.7900247
   Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Emberson JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029849
   Farwell WR, 2008, J NATL CANCER I, V100, P134, DOI 10.1093/jnci/djm286
   Ford I, 2007, NEW ENGL J MED, V357, P1477, DOI 10.1056/NEJMoa065994
   Friedman GD, 2008, PHARMACOEPIDEM DR S, V17, P27, DOI 10.1002/pds.1507
   Friis S, 2005, INT J CANCER, V114, P643, DOI 10.1002/ijc.20758
   Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2998
   Ghavami S, 2010, BBA-MOL CELL RES, V1803, P452, DOI 10.1016/j.bbamcr.2009.12.005
   Goldstein MR, 2009, INT J CARDIOL, V135, P128, DOI 10.1016/j.ijcard.2008.01.023
   Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027
   Hamelin BA, 1998, TRENDS PHARMACOL SCI, V19, P26, DOI 10.1016/S0165-6147(97)01147-4
   Hanai J, 2012, J CELL PHYSIOL, V227, P1709, DOI 10.1002/jcp.22895
   Haukka J, 2010, INT J CANCER, V126, P279, DOI 10.1002/ijc.24536
   Hawk MA, 1996, CANCER LETT, V109, P217, DOI 10.1016/S0304-3835(96)04465-5
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hippisley-Cox J, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2197
   Hwang KE, 2011, INVEST NEW DRUG, V29, P945, DOI 10.1007/s10637-010-9450-2
   Jacobs EJ, 2011, CANCER RES, V71, P1763, DOI 10.1158/0008-5472.CAN-10-2953
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kaye JA, 2004, BRIT J CANCER, V90, P635, DOI 10.1038/sj.bjc.6601566
   KEYOMARSI K, 1991, CANCER RES, V51, P3602
   Khanzada UK, 2006, ONCOGENE, V25, P877, DOI 10.1038/sj.onc.1209117
   Khurana V, 2007, CHEST, V131, P1282, DOI 10.1378/chest.06-0931
   Kidera Yasuhiro, 2010, J Exp Clin Cancer Res, V29, P127, DOI 10.1186/1756-9966-29-127
   Kusama T, 2002, GASTROENTEROLOGY, V122, P308, DOI 10.1053/gast.2002.31093
   Lee KJ, 2010, CLIN EXP IMMUNOL, V161, P298, DOI 10.1111/j.1365-2249.2010.04170.x
   Maksimova E, 2008, LUNG, V186, P45, DOI 10.1007/s00408-007-9053-7
   Mausner-Fainberg K, 2008, ATHEROSCLEROSIS, V197, P829, DOI 10.1016/j.atheroscierosis.2007.07.031
   Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5
   Mills EJ, 2008, J AM COLL CARDIOL, V52, P1769, DOI 10.1016/j.jacc.2008.08.039
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55
   Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C
   Park IH, 2011, INVEST NEW DRUG, V29, P883, DOI 10.1007/s10637-010-9439-x
   Park IH, 2010, INVEST NEW DRUG, V28, P791, DOI 10.1007/s10637-009-9319-4
   Pradelli D, 2013, EUR J CANCER PREV, V22, P229, DOI 10.1097/CEJ.0b013e328358761a
   Raemer PC, 2009, EUR J IMMUNOL, V39, P1456, DOI 10.1002/eji.200838863
   Sanli T, 2011, J THORAC ONCOL, V6, P439, DOI 10.1097/JTO.0b013e3182049d8b
   Sato S, 2006, J EPIDEMIOL, V16, P201, DOI 10.2188/jea.16.201
   Serruys PWJC, 2002, JAMA-J AM MED ASSOC, V287, P3215, DOI 10.1001/jama.287.24.3215
   Setoguchi S, 2007, CIRCULATION, V115, P27, DOI 10.1161/CIRCULATIONAHA.106.650176
   Strandberg TE, 2004, LANCET, V364, P771, DOI 10.1016/S0140-6736(04)16936-5
   Undela K, 2012, BREAST CANCER RES TR, V135, P261, DOI 10.1007/s10549-012-2154-x
   Vinogradova Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-409
   Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393
   Wong WWL, 2002, LEUKEMIA, V16, P508, DOI 10.1038/sj.leu.2402476
NR 56
TC 26
Z9 28
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 25
PY 2013
VL 8
IS 10
AR e77950
DI 10.1371/journal.pone.0077950
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 241GW
UT WOS:000326155400064
PM 24205041
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, JM
   Fu, LY
   Shi, JP
   Chen, X
   Li, YZ
   Ma, B
   Zhang, Y
AF Zhang, Jianming
   Fu, Lingyu
   Shi, Jingpu
   Chen, Xin
   Li, Yongze
   Ma, Bing
   Zhang, Yao
TI The Risk of Metabolic Syndrome in Patients with Rheumatoid Arthritis: A
   Meta-Analysis of Observational Studies
SO PLOS ONE
LA English
DT Article
ID ACUTE-PHASE RESPONSE; INSULIN-RESISTANCE; CARDIOVASCULAR RISK; INCREASED
   FREQUENCY; PROVISIONAL REPORT; DISEASE-ACTIVITY; PREVALENCE;
   INFLAMMATION; WOMEN; ATHEROSCLEROSIS
AB Background: Observational studies suggest an association between the incidence of rheumatoid arthritis (RA) and the prevalence of metabolic syndrome (MetS). However, the relationship between RA and MetS is controversial and research in this area is currently lacking.
   Objective: The aim of this study was to assess whether the prevalence of MetS was higher in a group of RA patients compared to subjects without RA.
   Design: A PubMed database search was conducted during April 2013 to identify observational studies of RA and risk of MetS. Reference lists of retrieved articles were also reviewed. Two authors independently extracted information on the study design, the characteristics of the study participants, exposure and outcome assessments, and the method used to control for potential confounding factors. A random-effects model was used for the risk estimates.
   Results: Our meta-analysis of four cross-sectional controlled studies plus eight case-control studies involving a total of 2283 cases and 4403 controls identified a significant association between RA and risk of MetS, with an overall OR of 1.24 (95% CI, 1.03-1.50).
   Conclusion: This meta-analysis provides further evidence supporting patients with RA have a higher prevalence of MetS than subjects without RA. In addition, the geographic region of the population and the criteria used for MetS diagnosis could influence the association. However, these observations would need to be evaluated using prospective, randomized studies.
C1 [Zhang, Jianming; Fu, Lingyu; Shi, Jingpu; Chen, Xin; Ma, Bing; Zhang, Yao] China Med Univ, Dept Clin Epidemiol & Evidence Based Med, Affiliated Hosp 1, Shenyang, Peoples R China.
   [Li, Yongze] China Med Univ, No Hosp, Dept Lab Med, Key Lab AIDS Immunol,Minist Hlth, Shenyang, Liaoning, Peoples R China.
RP Fu, LY (reprint author), China Med Univ, Dept Clin Epidemiol & Evidence Based Med, Affiliated Hosp 1, Shenyang, Peoples R China.
EM fulingyucmu@sina.com
FU National Natural Science Foundation of China [30800944, 30671796]
FX This work was supported by grants from the National Natural Science
   Foundation of China (30800944 and 30671796). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   Altman DG, 2001, BRIT MED J, V323, P224, DOI 10.1136/bmj.323.7306.224
   Baker JF, 2012, AM J MED, V125, DOI 10.1016/j.amjmed.2012.01.025
   Balkau B, 1999, DIABETIC MED, V16, P442
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BOCHAROV AV, 1995, METABOLISM, V44, P730, DOI 10.1016/0026-0495(95)90185-X
   Channual J, 2009, DERMATOL THER, V22, P61, DOI 10.1111/j.1529-8019.2008.01217.x
   Choi HK, 2005, J RHEUMATOL, V32, P2311
   Chung CP, 2008, ATHEROSCLEROSIS, V196, P756, DOI 10.1016/j.atherosclerosis.2007.01.004
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Crowson CS, 2011, J RHEUMATOL, V38, P29, DOI 10.3899/jrheum.100346
   da Cunha VR, 2012, SCAND J RHEUMATOL, V41, P186, DOI 10.3109/03009742.2011.626443
   Dao HH, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3203
   del Rincon I, 2001, ARTHRITIS RHEUM-US, V44, P2737, DOI 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dessein PH, 2007, J RHEUMATOL, V34, P681
   Dessein PH, 2006, J RHEUMATOL, V33, P2425
   Dessein PH, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar428
   Dessein PH, 2002, J RHEUMATOL, V29, P462
   Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferraccioli G, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13211
   Ford ES, 2005, DIABETES CARE, V28, P1769, DOI 10.2337/diacare.28.7.1769
   Gabriel SE, 2001, RHEUM DIS CLIN N AM, V27, P269, DOI 10.1016/S0889-857X(05)70201-5
   Gonzalez-Gay MA, 2010, CLIN EXP RHEUMATOL, V28, P56
   Goshayeshi L, 2012, CLIN RHEUMATOL, V31, P1197, DOI 10.1007/s10067-012-1995-3
   Grundy Scott M, 2004, J Am Coll Cardiol, V44, P720, DOI 10.1016/j.jacc.2004.07.001
   Gualillo O, 2007, TRENDS CARDIOVAS MED, V17, P275, DOI 10.1016/j.tcm.2007.09.005
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Karakoc Mehmet, 2012, J Clin Med Res, V4, P279, DOI 10.4021/jocmr1001w
   Karimi M, 2011, INT J RHEUM DIS, V14, P248, DOI 10.1111/j.1756-185X.2011.01595.x
   Karvounaris SA, 2007, ANN RHEUM DIS, V66, P28, DOI 10.1136/ard.2006.053488
   La Montagna Giovanni, 2007, Diab Vasc Dis Res, V4, P130
   Lee SG, 2013, KOREAN J INTERN MED, V28, P206, DOI 10.3904/kjim.2013.28.2.206
   Maradit-Kremers H, 2005, ARTHRITIS RHEUM-US, V52, P722, DOI 10.1002/art.20878
   Meigs JB, 2004, DIABETES CARE, V27, P2761, DOI 10.2337/diacare.27.11.2761
   Mok CC, 2011, ARTHRIT CARE RES, V63, P195, DOI 10.1002/acr.20363
   Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193
   Ormseth MJ, 2013, ARTHRITIS CARE RES
   Pamuk ON, 2006, J RHEUMATOL, V33, P2447
   Park YB, 2002, AM J MED, V113, P188, DOI 10.1016/S0002-9343(02)01186-5
   Raterman HG, 2010, ANN RHEUM DIS, V69, P39, DOI 10.1136/ard.2008.100776
   Raterman HG, 2009, ARTHRITIS RES THER, V11, pR110, DOI [10.1186/ar2653, DOI 10.1186/AR2653.PUBMED:19607680]
   Reaven G M, 1997, Nutrition, V13, P66
   Reilly MP, 2003, CIRCULATION, V108, P1546, DOI 10.1161/01.CIR.0000088846.10655.E0
   Romeo GR, 2012, ARTERIOSCL THROM VAS, V32, P1771, DOI 10.1161/ATVBAHA.111.241869
   Sahebari M, 2011, THESCIENTIFICWORLDJO, V11, P1195, DOI 10.1100/tsw.2011.111
   Santos MJ, 2010, CARDIOVASCULAR RISK
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   SVENSON KLG, 1987, METABOLISM, V36, P944, DOI 10.1016/0026-0495(87)90129-6
   Terrin N, 2003, STAT MED, V22, P2113, DOI 10.1002/sim.1461
   Toms TE, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2765
   Toms TE, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2578
   Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213
   Wulan SN, 2010, MATURITAS, V65, P315, DOI 10.1016/j.maturitas.2009.12.012
   Zonana-Nacach A, 2008, JCR-J CLIN RHEUMATOL, V14, P74, DOI 10.1097/RHU.0b013e31816b2faa
NR 58
TC 38
Z9 39
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 25
PY 2013
VL 8
IS 10
AR e78151
DI 10.1371/journal.pone.0078151
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 241GW
UT WOS:000326155400073
PM 24205134
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Lai, KR
   Cui, JT
   Ni, S
   Zhang, YD
   He, JL
   Yao, K
AF Lai, Kairan
   Cui, Jiantao
   Ni, Shuang
   Zhang, Yidong
   He, Jiliang
   Yao, Ke
TI The Effects of Postmenopausal Hormone Use on Cataract: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID FEMALE REPRODUCTIVE FACTORS; REPLACEMENT THERAPY; LENS OPACITIES;
   RISK-FACTORS; ESTROGEN-RECEPTOR; EYE DISEASE; AGE; POPULATION; WOMEN;
   PROGRESSION
AB Background: Cataract is the leading cause of blindness worldwide. Many observational studies assessed the relationship between postmenopausal hormone replacement therapy (HRT) and risk of cataract development, but the reported results were controversial. The aim of present meta-analysis was to evaluate the association of postmenopausal hormone replacement therapy with risk of cataract development.
   Methods: The eligible observational studies, including cross-sectional, case-control and cohort studies, were identified by searching PubMed and Embase during March of 2013. Either a fixed-or a random-effects model was used to calculate the pooled odds ratio (OR) with its 95% confidence interval (95% CI). Subgroup analysis on cataract types was performed.
   Results: A total of four cohort and five case-control or cross-sectional studies were finally included into this meta-analysis. Overall, a significant decreased risk of developing any type of cataract was found in ever HRT group as compared with non-HRT group among cohort studies (OR 0.83; 95% CI: 0.71,0.97) and case-control or cross-sectional studies (OR 0.74; 95% CI: 0.59,0.93). Subgroup analysis on cataract types determined that the significantly decreased risk of nuclear cataract in current HRT group (OR 0.72; 95% CI: 0.61,0.85) and also a critically reduced risk of nuclear cataract in ever HRT group (OR 0.80; 95% CI: 0.64,1.01) were found among case-control or cross-sectional studies, as compared with non-HRT group. No association of HRT with risk of cortical and posterior subcapsular cataract was observed.
   Conclusions: The results of present meta-analysis indicate that postmenopausal hormone use may play a protective role in cataract development.
C1 [Lai, Kairan; Cui, Jiantao; Ni, Shuang; Zhang, Yidong; Yao, Ke] Zhejiang Univ, Sch Med, Ctr Eye, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China.
   [He, Jiliang] Zhejiang Univ, Sch Med, Inst Environm Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [Yao, Ke] Zhejiang Prov Key Lab Ophthalmol, Hangzhou, Zhejiang, Peoples R China.
RP Yao, K (reprint author), Zhejiang Univ, Sch Med, Ctr Eye, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China.
EM xlren@zju.edu.cn
FU National Natural Science Foundation of China [81130018, 81371001];
   National "Twelfth Five-Year" Plan for Science & Technology Support of
   China [2012BAI08B01]; Zhejiang Key Innovation Team Project of China
   [2009R50039]; Zhejiang Key Laboratory Fund of China [2011E10006];
   Chinese Ministry of Health
FX The present study was supported by the Key Program of National Natural
   Science Foundation of China (Grant No. 81130018), Program of National
   Natural Science Foundation of China (No. 81371001), National "Twelfth
   Five-Year" Plan for Science & Technology Support of China (No.
   2012BAI08B01), Zhejiang Key Innovation Team Project of China
   (2009R50039), Zhejiang Key Laboratory Fund of China (2011E10006) and
   Project of National Clinical Key Discipline of Chinese Ministry of
   Health. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR ABRAHAM S, 1995, MATURITAS, V21, P91, DOI 10.1016/0378-5122(94)00881-7
   Aina FO, 2006, EYE, V20, P417, DOI 10.1038/sj.eye.6701877
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beral V, 2005, LANCET, V365, P1543
   Bigsby RM, 1999, P NATL ACAD SCI USA, V96, P9328, DOI 10.1073/pnas.96.16.9328
   Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032
   Cumming RG, 1997, AM J EPIDEMIOL, V145, P242
   Davis VL, 2002, P NATL ACAD SCI USA, V99, P9427, DOI 10.1073/pnas.132247999
   Defay R, 2003, ANN EPIDEMIOL, V13, P638, DOI 10.1016/S1047-2797(03)00058-9
   delCastillo JMB, 1997, OPHTHALMOLOGY, V104, P970
   Delcourt C, 2000, AM J EPIDEMIOL, V151, P497
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Durant JS, 2006, EYE, V20, P1254, DOI 10.1038/sj.eye.6702087
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Freeman EE, 2004, EPIDEMIOLOGY, V15, P451, DOI 10.1097/01.ede.0000129517.92192.29
   Freeman EE, 2001, ARCH OPHTHALMOL-CHIC, V119, P1687
   Gray S, 2003, LANCET, V362, P1332, DOI 10.1016/S0140-6736(03)14598-9
   Hales AM, 1997, J EXP MED, V185, P273, DOI 10.1084/jem.185.2.273
   HALES AM, 1994, CURR EYE RES, V13, P885, DOI 10.3109/02713689409015091
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HILLER R, 1986, AM J EPIDEMIOL, V124, P916, DOI 10.1093/oxfordjournals.aje.a114481
   Kanthan GL, 2010, ACTA OPHTHALMOL, V88, P773, DOI 10.1111/j.1755-3768.2009.01565.x
   Klein B E, 1993, Trans Am Ophthalmol Soc, V91, P517
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   KLEIN BEK, 1994, ARCH OPHTHALMOL-CHIC, V112, P85, DOI 10.1001/archopht.1994.01090130095025
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Leske MC, 2000, OPHTHALMOLOGY, V107, P1267, DOI 10.1016/S0161-6420(00)00155-X
   Lindblad BE, 2010, OPHTHALMOLOGY, V117, P424, DOI 10.1016/j.ophtha.2009.07.046
   McCarty CA, 1999, AM J OPHTHALMOL, V128, P446, DOI 10.1016/S0002-9394(99)00218-4
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   MOORADIAN AD, 1993, J STEROID BIOCHEM, V45, P509, DOI 10.1016/0960-0760(93)90166-T
   Nirmalan PK, 2004, INVEST OPHTH VIS SCI, V45, P4273, DOI 10.1167/iovs.04-0285
   Noran NH, 2007, ASIA-PAC J PUBLIC HE, V19, P23, DOI 10.1177/10105395070190020501
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pelit A, 2007, TURK KLIN TIP BILIM, V27, P811
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321
   Uncu G, 2006, GYNECOL ENDOCRINOL, V22, P501, DOI 10.1080/09513590600917919
   Wang XF, 2003, INVEST OPHTH VIS SCI, V44, P2067, DOI 10.1167/iovs.02-0841
   Weintraub JM, 2002, OPHTHALMIC EPIDEMIOL, V9, P179, DOI 10.1076/opep.9.3.179.1513
   Wells GA, 2012, NEWCASTLE OTTAWA SCA
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Worzala K, 2001, ARCH INTERN MED, V161, P1448, DOI 10.1001/archinte.161.11.1448
   Younan C, 2002, AM J EPIDEMIOL, V155, P997, DOI 10.1093/aje/155.11.997
   ZHANG JJ, 1994, J CLIN INVEST, V94, P1690, DOI 10.1172/JCI117514
NR 47
TC 8
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2013
VL 8
IS 10
AR e78647
DI 10.1371/journal.pone.0078647
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 241FR
UT WOS:000326152300076
PM 24205286
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Lu, XZ
   Ke, JT
   Luo, X
   Zhu, YW
   Zou, L
   Li, HJ
   Zhu, BB
   Xiong, ZG
   Chen, W
   Deng, LY
   Lou, J
   Wang, XX
   Zhang, Y
   Wang, ZL
   Miao, XP
   Cheng, LM
AF Lu, Xuzai
   Ke, Juntao
   Luo, Xia
   Zhu, Yaowu
   Zou, Li
   Li, Huijun
   Zhu, Beibei
   Xiong, Zhigang
   Chen, Wei
   Deng, Lingyan
   Lou, Jiao
   Wang, Xianxiu
   Zhang, Yu
   Wang, Zhenling
   Miao, Xiaoping
   Cheng, Liming
TI The SNP rs402710 in 5p15.33 Is Associated with Lung Cancer Risk: A
   Replication Study in Chinese Population and a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCUS; GENETIC-VARIANTS;
   POLYMORPHISMS; BIAS; TERT
AB Background: Lung cancer is the most commonly diagnosed cancer and leading cause of cancer mortality in the world. A single nucleotide polymorphism (SNP), rs402710, located in 5p15.33, was firstly identified to be associated with the lung cancer risk in a genome-wide association study. However, some following replication studies yielded inconsistent results.
   Methodology and Findings: A case-control study of 611 cases and 1062 controls in a Chinese population was conducted, and then a meta-analysis integrating the current and previously published studies with a total 31811 cases and 36333 controls was performed to explore the real effect of rs402710 on lung cancer susceptibility. Significant associations between the SNP rs402710 and lung cancer risk were observed in both case-control study and meta-analysis, with ORs equal to 0.77 (95% CI = 0.63-0.95) and 0.83 (95% CI = 0.81-0.86) in dominant model, respectively. By stratified analysis of our case-control study, the associations were also observed in never smoker group and non-small cell lung cancer(NSCLC) group with ORs equal to 0.71 (95% CI = 0.53-0.95) and 0.69 (95% CI = 0.55-0.87), which was remarkable that larger effect of the minor allele T was seen in the two groups than that in overall lung cancer. Besides, the sensitive and cumulative analysis indicated the robust stability of the current results of meta-analysis.
   Conclusion: The results from our replication study and the meta-analysis provided firm evidence that rs402710 T allele significantly contributed to decreased lung cancer risk, and the case-control study implied that the variant may yield stronger effect on NSCLC and never smokers. However, the mechanism underlying the polymorphism conferring susceptibility to lung cancer is warranted to clarify in the follow-up studies.
C1 [Lu, Xuzai; Ke, Juntao; Zou, Li; Zhu, Beibei; Chen, Wei; Lou, Jiao; Zhang, Yu; Wang, Zhenling; Miao, Xiaoping] Huazhong Univ Sci & Technol, State Key Lab Environm Hlth Incubat, Key Lab Environm & Hlth,Minist Environm Protect, MOE Minist Educ,Key Lab Environm & Hlth Wuhan, Wuhan 430074, Peoples R China.
   [Lu, Xuzai; Ke, Juntao; Zou, Li; Zhu, Beibei; Chen, Wei; Lou, Jiao; Zhang, Yu; Wang, Zhenling; Miao, Xiaoping] Huazhong Univ Sci & Technol, Dept Epidemiol & Biostat, Sch Publ Hlth, Tongji Med Coll, Wuhan 430074, Peoples R China.
   [Luo, Xia; Zhu, Yaowu; Li, Huijun; Xiong, Zhigang; Deng, Lingyan; Wang, Xianxiu; Cheng, Liming] Huazhong Univ Sci & Technol, Dept Lab Med, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China.
   [Lu, Xuzai] Guangdong Maternal & Child Hlth Care Hosp, Guangzhou, Guangdong, Peoples R China.
RP Miao, XP (reprint author), Huazhong Univ Sci & Technol, State Key Lab Environm Hlth Incubat, Key Lab Environm & Hlth,Minist Environm Protect, MOE Minist Educ,Key Lab Environm & Hlth Wuhan, Wuhan 430074, Peoples R China.
EM miaoxp@mail.hust.edu.cn; chengliming@tjh.tjmu.edu.cn
RI miao, xiaoping/C-4336-2011
OI miao, xiaoping/0000-0002-6818-9722
CR Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109
   Bae EY, 2012, RESPIROLOGY, V17, P699, DOI 10.1111/j.1440-1843.2012.02165.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brennan P, 2011, LANCET ONCOL, V12, P399, DOI 10.1016/S1470-2045(10)70126-1
   Broderick P, 2009, CANCER RES, V69, P6633, DOI 10.1158/0008-5472.CAN-09-0680
   Chen XF, 2012, GENET MOL RES, V11, P370, DOI 10.4238/2012.February.16.2
   Chung CC, 2010, CARCINOGENESIS, V31, P111, DOI 10.1093/carcin/bgp273
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Garcia-Barcelo MM, 2010, HUM MOL GENET, V19, P2917, DOI 10.1093/hmg/ddq196
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hsiung CA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001051
   Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885
   Ito H, 2012, J THORAC ONCOL, V7, P790, DOI 10.1097/JTO.0b013e3182475028
   James MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036116
   Jaworowska E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025057
   Jin GF, 2009, CARCINOGENESIS, V30, P987, DOI 10.1093/carcin/bgp090
   Kang JU, 2008, CANCER GENET CYTOGEN, V182, P1, DOI 10.1016/j.cancergencyto.2007.12.004
   Knobloch K, 2011, J CRANIO MAXILL SURG, V39, P91, DOI 10.1016/j.jcms.2010.11.001
   Landi MT, 2009, AM J HUM GENET, V85, P679, DOI 10.1016/j.ajhg.2009.09.012
   Liu L, 2011, CANCER-AM CANCER SOC, V117, P5172, DOI 10.1002/cncr.26154
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254
   Mocellin S, 2012, JNCI-J NATL CANCER I, V104, P840, DOI 10.1093/jnci/djs222
   Mullen B, 2001, PERS SOC PSYCHOL B, V27, P1450, DOI 10.1177/01461672012711006
   Pabalan NA, 2010, ASIAN PAC J CANCER P, V11, P33
   Pande M, 2011, CARCINOGENESIS, V32, P1493, DOI 10.1093/carcin/bgr136
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846
   Truong T, 2010, J NATL CANCER I, V102, P959, DOI 10.1093/jnci/djq178
   Wang L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017608
   Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273
   Wu C, 2012, NAT GENET, V44, P62, DOI 10.1038/ng.1020
   Xun WW, 2011, MUTAGENESIS, V26, P657, DOI 10.1093/mutage/ger030
   Yamamoto K, 2001, BIOCHEM BIOPH RES CO, V280, P1148, DOI 10.1006/bbrc.2001.4250
   Yang P, 2010, CANCER EPIDEM BIOMAR, V19, P240, DOI 10.1158/1055-9965.EPI-09-0710
   Yoon KA, 2010, HUM MOL GENET, V19, P4948, DOI 10.1093/hmg/ddq421
   Young RP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016476
   Zhong H, 2009, GENETIC EPIDEMIOLOGY
   Zienolddiny S, 2009, CARCINOGENESIS, V30, P1368, DOI 10.1093/carcin/bgp131
NR 43
TC 7
Z9 7
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 23
PY 2013
VL 8
IS 10
AR e76252
DI 10.1371/journal.pone.0076252
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 239PE
UT WOS:000326037000010
PM 24194831
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, Y
   Zhang, F
   Skrip, L
   Wang, Y
   Liu, SC
AF Yang, Yuan
   Zhang, Fan
   Skrip, Laura
   Wang, Yang
   Liu, Shengchun
TI Lack of an Association between Passive Smoking and Incidence of Female
   Breast Cancer in Non-Smokers: Evidence from 10 Prospective Cohort
   Studies
SO PLOS ONE
LA English
DT Article
ID N-ACETYLTRANSFERASE 2; CIGARETTE-SMOKING; ACTIVE SMOKING; LUNG-CANCER;
   POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; TOBACCO-SMOKE; RISK;
   METAANALYSIS; EXPOSURE
AB Background: Several case-control studies have suggested that passive smoking may increase the incidence of female breast cancer. However, the results of cohort studies have been inconsistent in establishing an association. The present study evaluated the association between passive smoking and incidence of female breast cancer through a meta-analysis of prospective cohort studies.
   Methods: Relevant articles published before August 2012 were identified by searching the electronic databases PubMed, Embase, and Web of Science. Pooled relative risks (RRs) were determined with either a fixed or random effects model and were used to assess the strength of the association. Sensitivity and subgroup analyses according to ethnicity, menopausal status, and the period and place of exposure to passive smoking were also performed.
   Results: Ten prospective cohort studies involving 782 534 female non-smokers were included in the meta-analysis and 14 831 breast cancer cases were detected. Compared with the women without exposure to passive smoking, the overall combined RR of breast cancer was 1.01 (95% confidence interval: 0.96 to 1.06, P = 0.73) among women with exposure to passive smoking. Similar results were achieved through the subgroup analyses. No evidence of publication bias was observed.
   Conclusion: The results suggest that passive smoking may not be associated with increased incidence of breast cancer. However, the present conclusion should be considered carefully and confirmed with further studies.
C1 [Yang, Yuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiovasc Med, Chongqing, Peoples R China.
   [Zhang, Fan; Wang, Yang] Chongqing Med Univ, Sch Publ Hlth & Hlth Management, Chongqing, Peoples R China.
   [Skrip, Laura] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
   [Liu, Shengchun] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China.
RP Liu, SC (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China.
EM liushengchun1968@126.com
FU National Natural Science Foundation of China [NSFC 81272265]
FX This work was supported by the National Natural Science Foundation of
   China (NSFC 81272265). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Al-Delaimy WK, 2004, CANCER EPIDEM BIOMAR, V13, P398
   BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brennan P, 2007, HUM MOL GENET, V16, P1794, DOI 10.1093/hmg/ddm127
   Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066
   Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243
   Chuang SC, 2011, CANCER CAUSE CONTROL, V22, P487, DOI 10.1007/s10552-010-9723-2
   Conlon MSC, 2010, CANCER EPIDEMIOL, V34, P142, DOI 10.1016/j.canep.2010.02.001
   Cui Y, 2006, BREAST CANCER RES TR, V100, P293, DOI 10.1007/s10549-006-9255-3
   Delfino RJ, 2000, PHARMACOGENETICS, V10, P461, DOI 10.1097/00008571-200007000-00009
   DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134
   Egan KM, 2002, EPIDEMIOLOGY, V13, P138, DOI 10.1097/00001648-200203000-00007
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   ELBAYOUMY K, 1992, CHEM RES TOXICOL, V5, P585, DOI 10.1021/tx00029a001
   GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047
   Gram IT, 2005, CANCER EPIDEM BIOMAR, V14, P61
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Hanaoka T, 2005, INT J CANCER, V114, P317, DOI 10.1002/ijc.20709
   Jee SH, 1999, INT J EPIDEMIOL, V28, P824, DOI 10.1093/ije/28.5.824
   Jemal A, 2008, J NATL CANCER I, V100, P1672, DOI 10.1093/jnci/djn389
   JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602
   Johnson KC, 2008, PREV MED, V46, P492, DOI 10.1016/j.ypmed.2007.11.016
   Johnson KC, 2011, TOB CONTROL, V20, DOI 10.1136/tc.2010.035931
   Kabat GC, 2011, CANCER CAUSE CONTROL, V22, P775, DOI 10.1007/s10552-011-9750-7
   Kabat GC, 2010, AM J EPIDEMIOL, V172, P591, DOI 10.1093/aje/kwq159
   Key TJA, 1996, BRIT J CANCER, V74, P1313, DOI 10.1038/bjc.1996.536
   Kiechl S, 2002, STROKE, V33, P2170, DOI 10.1161/01.STR.0000027209.59821.98
   Lee PN, 2006, INHAL TOXICOL, V18, P1053, DOI 10.1080/08958370600945432
   Lin Y, 2008, J EPIDEMIOL, V18, P77, DOI 10.2188/jea.18.77
   Luo JH, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1016
   MACMAHON B, 1982, NEW ENGL J MED, V307, P1062, DOI 10.1056/NEJM198210213071707
   Millikan RC, 1998, CANCER EPIDEM BIOMAR, V7, P371
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Nishino Y, 2001, CANCER CAUSE CONTROL, V12, P797, DOI 10.1023/A:1012273806199
   Overton RC, 1998, PSYCHOL METHODS, V3, P354, DOI 10.1037/1082-989X.3.3.354
   PETRAKIS NL, 1978, SCIENCE, V199, P303, DOI 10.1126/science.619458
   Pirie K, 2008, INT J EPIDEMIOL, V37, P1069, DOI 10.1093/ije/dyn110
   Pukkala E, 2009, ACTA ONCOL, V48, P646, DOI 10.1080/02841860902913546
   Reynolds P, 2004, J NATL CANCER I, V96, P29, DOI 10.1093/jnci.djh002
   Reynolds P, 2009, CANCER EPIDEM BIOMAR, V18, P3389, DOI 10.1158/1055-9965.EPI-09-0936
   Rushton L, 2010, BRIT J CANCER, V102, P1428, DOI 10.1038/sj.bjc.6605637
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985
   Wartenberg D, 2000, J NATL CANCER I, V92, P1666, DOI 10.1093/jnci/92.20.1666
   Wells GA, 2012, NEWCASTLE OTTAWA SCA
   Xue F, 2011, ARCH INTERN MED, V171, P125, DOI 10.1001/archinternmed.2010.503
   Yang Y, 2012, ASIAN PAC J CANCER P, V13, P3501, DOI 10.7314/APJCP.2012.13.7.3501
   Zhang J, 2010, BREAST CANCER RES TR, V123, P877, DOI 10.1007/s10549-010-0807-1
   Zheng W, 1999, CANCER EPIDEM BIOMAR, V8, P233
NR 49
TC 7
Z9 7
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 18
PY 2013
VL 8
IS 10
AR e77029
DI 10.1371/journal.pone.0077029
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 239MM
UT WOS:000326029300076
PM 24204725
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ye, ZK
   Tang, HL
   Zhai, SD
AF Ye, Zhi-Kang
   Tang, Hui-Lin
   Zhai, Suo-Di
TI Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic
   Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID RESISTANT STAPHYLOCOCCUS-AUREUS; INTENSIVE-CARE-UNIT; SERUM
   CONCENTRATIONS; PEDIATRIC-PATIENTS; COST-EFFECTIVENESS;
   PHARMACOKINETICS; INFECTIONS; EFFICACY; HEMODIALYSIS; BACTEREMIA
AB Background and Objective: The necessity of therapeutic drug monitoring (TDM) for vancomycin is controversial. The objective of the current review was to evaluate the available evidence for the necessity of TDM in patients given vancomycin to treat Gram-positive infections.
   Methods: Medline, Embase, Web of Sciences, the Cochrane Library and two Chinese literature databases (CNKI, CBM) were searched. Randomized controlled studies and observational studies that compared the clinical outcomes of TDM groups vs. non-TDM groups were included. Two reviewers independently extracted the data. The primary outcome was clinical efficacy of therapy. Secondary outcomes included vancomycin associated nephrotoxicity, duration of vancomycin therapy, length of hospital stay, and mortality. Meta-analysis was performed using the Mantel-Haenszel fixed effect method (FEM). Odds ratios (ORs) or weighted mean differences (WMD) with 95% confidence intervals (95%CIs) were calculated for categorical and continuous outcomes, respectively.
   Results: One randomized controlled trial (RCT) and five cohort studies were included in the meta-analysis. Compared with non-TDM groups, TDM groups had significantly higher rates of clinical efficacy (OR = 2.62, 95%CI 1.34-5.11 P = 0.005) and decreased rates of nephrotoxicity (OR = 0.25, 95%CI 0.13-0.48 P<0.0001). Subgroup analyses showed that TDM group had significantly higher rates of clinical efficacy in both cohort studies subgroup (OR = 3.04, 95%CI 1.34-6.90) and in Asian population subgroup (OR = 3.04, 95% CI 1.34-6.90). TDM group had significantly decreased rates of nephrotoxicity in all subgroup. There was no significant difference in duration of vancomycin therapy (WMD = -0.40, 95% CI -2.83-2.02 P = 0.74) or length of stay (WMD = -1.01, 95% CI -7.51-5.49 P = 0.76) between TDM and non-TDM groups. Subgroup analyses showed there were no differences in duration of vancomycin therapy. Only one study reported mortality rates.
   Conclusions: Studies to date show that TDM significantly increases the rate of clinical efficacy and decreases the rate of nephrotoxicity in patients treated with vancomycin.
C1 [Ye, Zhi-Kang; Tang, Hui-Lin; Zhai, Suo-Di] Peking Univ, Hosp 3, Dept Pharm, Beijing 100871, Peoples R China.
   [Ye, Zhi-Kang] Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Beijing 100871, Peoples R China.
RP Zhai, SD (reprint author), Peking Univ, Hosp 3, Dept Pharm, Beijing 100871, Peoples R China.
EM zhaisuodi@163.com
RI Tang, Huilin/M-1668-2017
CR Al-Kofide Hadeel, 2010, J Oncol Pharm Pract, V16, P245, DOI 10.1177/1078155209355847
   Badran EF, 2011, INT J CLIN PHARM TH, V49, P252, DOI 10.5414/CP201456
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   CANTU TG, 1994, CLIN INFECT DIS, V18, P533
   Cataldo MA, 2012, J ANTIMICROB CHEMOTH, V67, P17, DOI 10.1093/jac/dkr442
   Commandeur D, 2011, MED MALADIES INFECT, V41, P410, DOI 10.1016/j.medmal.2011.01.012
   Darko W, 2003, PHARMACOTHERAPY, V23, P643, DOI 10.1592/phco.23.5.643.32199
   De Cock P, 2010, BASIC CLIN PHARM, V107, P250
   deGatta MDF, 1996, CLIN PHARMACOL THER, V60, P332, DOI 10.1016/S0009-9236(96)90060-0
   Dolton M, 2010, BURNS, V36, P469, DOI 10.1016/j.burns.2009.08.010
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eiland LS, 2011, ANN PHARMACOTHER, V45, P582, DOI 10.1345/aph.1P588
   Golestaneh L, 2009, CLIN NEPHROL, V72, P286
   Hidayat LK, 2006, ARCH INTERN MED, V166, P2138, DOI 10.1001/archinte.166.19.2138
   Hochart C, 2011, MED MALADIES INFECT, V41, P652, DOI 10.1016/j.medmal.2011.09.014
   Howden BP, 2004, CLIN INFECT DIS, V38, P521, DOI 10.1086/381202
   Huang YZ, 2011, CHIN J INFEC CHEMOTH, V11, P295
   Iwamoto T, 2003, BIOL PHARM BULL, V26, P876
   Jeffres MN, 2006, CHEST, V130, P947, DOI 10.1378/chest.130.4.947
   Karachalios GN, 1998, EPITHEORESE KLIN FAR, V16, P110
   Khotaei Ghamar Taj, 2010, Acta Med Iran, V48, P91
   LAU A H, 1988, Child Nephrology and Urology, V9, P232
   Levine DP, 2006, CLIN INFECT DIS, V42, pS5, DOI 10.1086/491709
   Li J, 2012, INT J ANTIMICROB AG, V39, P69, DOI 10.1016/j.ijantimicag.2011.08.017
   Lodise TP, 2008, ANTIMICROB AGENTS CH, V52, P3315, DOI 10.1128/AAC.00113-08
   Long C, 2011, EUR J PHARM SCI, V44, P195
   Marengo LL, 2010, BRAZ J INFECT DIS, V14, P203, DOI 10.1590/S1413-86702010000200019
   Mariani-Kurkdjian P, 2008, ARCH PEDIATRIE, V15, P1625, DOI 10.1016/j.arcped.2008.08.016
   Matsumoto K, 2013, J INFECT CHEMOTHER
   Miles MV, 1997, THER DRUG MONIT, V19, P265, DOI 10.1097/00007691-199706000-00004
   MOCHIZUKI T, 2010, JPN J CHEMOTHER, V58, P233
   Moellering RC, 2006, CLIN INFECT DIS, V42, pS3, DOI 10.1086/491708
   MOELLERING RC, 1994, CLIN INFECT DIS, V18, P544, DOI 10.1093/clinids/18.4.544
   O'Connell D, 2005, NEWCASTLE OTTAWA SCA
   Pea F, 2000, J ANTIMICROB CHEMOTH, V45, P329, DOI 10.1093/jac/45.3.329
   Pea F, 2000, CLIN DRUG INVEST, V19, P213, DOI 10.2165/00044011-200019030-00006
   PRYKA RD, 1994, ANN PHARMACOTHER, V28, P1397, DOI 10.1177/106002809402801212
   Reis A G, 1996, J Pediatr (Rio J), V72, P225
   Rybak Michael, 2009, Am J Health Syst Pharm, V66, P82, DOI 10.2146/ajhp080434
   Rybak MJ, 2006, CLIN INFECT DIS, V42, pS35, DOI 10.1086/491712
   Sakoulas G, 2004, J CLIN MICROBIOL, V42, P2398, DOI 10.1128/JCM.42.6.2398-2402.2004
   Sato S, 2007, JPN J CHEMOTHER, V55, P220
   van de Vijsel Lyndsay M, 2010, Can J Hosp Pharm, V63, P196
   Vazquez M, 2008, INT J CLIN PHARM TH, V46, P140
   WELTY TE, 1994, ANN PHARMACOTHER, V28, P1335, DOI 10.1177/106002809402801201
   [张弨 ZHANG Chao], 2009, [中国临床药理学杂志, The Chinese Journal of Clinical Pharmacology], V25, P329
NR 46
TC 45
Z9 53
U1 0
U2 28
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 18
PY 2013
VL 8
IS 10
AR e77169
DI 10.1371/journal.pone.0077169
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 239MM
UT WOS:000326029300086
PM 24204764
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Soeters, HM
   Poole, C
   Patel, MR
   Van Rie, A
AF Soeters, Heidi M.
   Poole, Charles
   Patel, Monita R.
   Van Rie, Annelies
TI The Effect of Tuberculosis Treatment at Combination Antiretroviral
   Therapy Initiation on Subsequent Mortality: A Systematic Review and
   Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID HIV-INFECTED PATIENTS; FOLLOW-UP; TREATMENT OUTCOMES; TREATMENT
   PROGRAMS; RISK-FACTORS; 1ST YEAR; ADULTS; HAART; COINFECTION; PREDICTORS
AB Objective: We aimed to perform a systematic review and meta-analysis examining the impact of TB treatment at the time of combination antiretroviral therapy (cART) initiation on subsequent mortality.
   Methods: We searched PubMed, EMBASE, and selected conference proceedings for studies that report adult mortality on cART, stratified by TB treatment status at cART initiation. Stratified random-effects and meta-regression analyses were used to examine the influence of study and population characteristics.
   Results: 22 eligible cohort studies reported data on 98,350 (range 74-15,225) adults, of whom 14,779 (15%) were receiving TB treatment at cART initiation. Studies of those receiving vs. not receiving TB treatment had an average mortality relative risk of 1.10 (95% confidence interval 0.87-1.40) at 1-3 months (based upon 8 estimates), 1.15 (0.94-1.41) at 6-12 months (11 estimates), and 1.33 (1.02-1.75) at 18-98 months (10 estimates) following cART initiation. However, there was a wide range of estimates and those at later time points were markedly heterogeneous. Meta-regression identified factors associated with elevated average risk estimates: lower median baseline CD4 counts and adjustment for baseline hemoglobin at 1-3 months; longer length of follow-up and women-only studies at 6-12 months; and not adjusting for BMI/weight at 18-98 months.
   Conclusions: Patients receiving TB treatment at cART initiation did not have a statistically significant estimated increase in short-term risk of all-cause mortality as compared to those not receiving TB treatment. TB treatment was significantly associated with increased mortality after about a year of cART, suggesting that patients with concurrent TB treatment at cART initiation may benefit from continued support after TB treatment completion.
C1 [Soeters, Heidi M.; Poole, Charles; Patel, Monita R.; Van Rie, Annelies] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
RP Soeters, HM (reprint author), Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
EM hsoeters@email.unc.edu
RI Soeters, Heidi/H-3271-2019; Van Rie, Annelies/C-2082-2017
OI Soeters, Heidi/0000-0002-9415-9340; Van Rie,
   Annelies/0000-0001-7666-3263
FU National Institutes of Health [2T32AI070114]
FX HMS and MRP were partially supported by National Institutes of Health
   training grant 2T32AI070114. No additional external funding was received
   for this study. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], 2010, GLOB PLAN STOP TB 20
   Bassett IV, 2012, JAIDS-J ACQ IMM DEF, V59, P25, DOI 10.1097/QAI.0b013e31823d3aba
   BASSETT IV, 2010, VIENN AUSTR 18 INT A
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bera E, 2009, SAJOG-S AFR J OBSTET, V15, P26
   Bhowmik A, 2012, ASIAN PAC J TROP MED, V5, P986, DOI 10.1016/S1995-7645(12)60187-4
   Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911
   Borenstein M., 2009, INTRO METAANALYSIS
   Boulle A, 2008, JAMA-J AM MED ASSOC, V300, P530, DOI 10.1001/jama.300.5.530
   Boulle A, 2010, AIDS, V24, P563, DOI 10.1097/QAD.0b013e328333bfb7
   Braitstein P, 2006, LANCET, V367, P817
   Breton G, 2012, INT J TUBERC LUNG D, V16, P1365, DOI 10.5588/ijtld.11.0693
   Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790
   Chu R, 2011, AM J EPIDEMIOL, V173, pS73
   Curran A, 2012, AIDS REV, V14, P231
   Dao CN, 2011, AIDS RES HUM RETROV, V27, P1149, DOI [10.1089/aid.2010.0345, 10.1089/AID.2010.0345]
   Desilva MB, 2009, AIDS CARE, V21, P70, DOI 10.1080/09540120802017636
   Dronda F, 2011, CURR HIV RES, V9, P229, DOI 10.2174/157016211796320324
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Egger M, 2001, SYSTEMATIC REV HLTH
   Greenland S, 2008, MODERN EPIDEMIOLOGY, V3, P652
   Greig J, 2012, JAIDS-J ACQ IMM DEF, V59, pE92, DOI 10.1097/QAI.0b013e31824206c7
   Gupta A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055824
   Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607
   Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x
   Karim SSA, 2011, NEW ENGL J MED, V365, P1492, DOI 10.1056/NEJMoa1014181
   Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848
   Lartey M, 2011, CLIN INFECT DIS, V52, P547, DOI 10.1093/cid/ciq196
   Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd
   Lawn SD, 2006, AIDS, V20, P1605, DOI 10.1097/01.aids.0000238406.93249.cd
   Lawn SD, 2010, AIDS, V24, P1323, DOI 10.1097/QAD.0b013e3283390dd1
   Lawn SD, 2010, CURR OPIN HIV AIDS, V5, P18, DOI 10.1097/COH.0b013e328333850f
   Liechty CA, 2007, TROP MED INT HEALTH, V12, P929, DOI 10.1111/j.1365-3156.2007.01874.x
   LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005
   Makombe SD, 2007, INT J TUBERC LUNG D, V11, P412
   Manosuthi W, 2010, INT J INFECT DIS, V14, pE1013, DOI 10.1016/j.ijid.2010.06.016
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moore DM, 2011, JAIDS-J ACQ IMM DEF, V58, P289, DOI 10.1097/QAI.0b013e3182303716
   Mugusi SF, 2012, ANTIVIR THER, V17, P265, DOI 10.3851/IMP1956
   Murray J, 2007, AIDS, V21, pS97, DOI 10.1097/01.aids.0000299416.61808.24
   Mutevedzi PC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021795
   Nguyen VTT, 2011, ANTIVIR THER, V16, pA51
   Rana FS, 2000, J ACQ IMMUN DEF SYND, V24, P23
   RODGERS A, 1995, THROMB HAEMOSTASIS, V73, P167
   Siika AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053022
   Straetemans M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015241
   Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Volberding PA, 2008, GLOBAL HIV AIDS MED
   Walker AS, 2012, CLIN INFECT DIS, V55, P1707, DOI 10.1093/cid/cis797
   Westreich D, 2012, AIDS, V26, P770, DOI 10.1097/QAD.0b013e328351f6b8
   Westreich D, 2009, AIDS, V23, P707, DOI 10.1097/QAD.0b013e328325d115
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   Wong EB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047542
   World Health Organization, 2010, ANT THER HIV INF AD
   Zachariah R, 2006, AIDS, V20, P2355, DOI 10.1097/QAD.0b013e32801086b0
   Zachariah R, 2009, TROP MED INT HEALTH, V14, P713, DOI 10.1111/j.1365-3156.2009.02291.x
   Zar HJ, 2007, BRIT MED J, V334, P136, DOI 10.1136/bmj.39000.486400.55
NR 59
TC 3
Z9 4
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2013
VL 8
IS 10
AR UNSP e78073
DI 10.1371/journal.pone.0078073
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 237TP
UT WOS:000325894100099
PM 24143260
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, M
   Zhu, XY
   Wang, L
   Lin, Y
AF Wang, Ming
   Zhu, Xiao-Yang
   Wang, Liang
   Lin, Yu
TI The-607C/A Polymorphisms in Interleukin-18 Gene Promoter Contributes to
   Cancer Risk: Evidence from A Meta-Analysis of 22 Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID SERUM INTERLEUKIN-18; IL-18 PROMOTER; CARCINOMA; SUSCEPTIBILITY;
   ASSOCIATION; MARKER; LEVEL
AB Background: Several observational studies have investigated the association between -607 C/A polymorphism of IL-18 gene and cancer risk; however, the results were inconsistent. Therefore, we performed a meta-analysis to derive a more precise estimation of the association to help us better understand the relationship between -607 C/A polymorphism of IL-18 gene promoter and risk of cancer.
   Methods: A literature search was carried out using PubMed, EMBASE, and China National Knowledge Infrastructure (CNKI) database between January 1966 and February 2013. Fixed-effect and random-effect models were used to estimate the pooled odds ratio (OR) and the corresponding 95% confidence intervals (CIs).
   Results: A total of 22 case-control studies including 4100 cancer cases and 4327 controls contributed to the analysis. Significant association between -607C/A polymorphism in IL-18 gene promoter and cancer risk was observed (CA vs CC: OR = 1.221, 95% CI: 1.096, 1.360; P-heterogeneity=0.219; AA/CA vs. CC: OR = 1.203, 95% CI: 1.057, 1.369; P-heterogeneity=0.064). In the subgroup analysis by ethnicity, -607C/A polymorphism significantly increased risk of cancer among Asian population (AA/CA vs. CC: OR = 1.197, 95% CI: 1.023,1.401; P-heterogeneity=0.088); however, no significant association was found in Caucasian or African population. The -607C/A polymorphism was associated with a significantly increased risk of nasopharyngeal carcinoma (CA vs CC: OR = 1.330, 95% CI: 1.029,1.719; P-heterogeneity=0.704; AA/CA vs. CC: OR = 1.323, 95% CI: 1.037,1.687; P-heterogeneity=0.823) and esophageal cancer (AA/CA vs. CC: OR = 1.289, 95% CI: 1.002,1.658; P-heterogeneity=0.700).
   Conclusions: The present meta-analysis suggests that the -607C/A polymorphisms in IL-18 gene promoter is associated with a significantly increased risk of cancer, especially for nasopharyngeal carcinoma and esophageal cancer and in Asian population. More studies with larger sample size, well controlled confounding factors are warranted to validate this association.
C1 [Wang, Ming] Cangzhou Cent Hosp, Dept Radiat Therapy, Cangzhou, Hebei Province, Peoples R China.
   [Zhu, Xiao-Yang] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Radiat Therapy, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wang, Liang] Cangzhou Cent Hosp, Dept Endoscop Profess, Cangzhou, Hebei Province, Peoples R China.
   [Lin, Yu] Inner Mongolia Med Univ, Dept Radiat Therapy, Affiliated Hosp, Hohhot, Neimenggu Provi, Peoples R China.
RP Wang, M (reprint author), Cangzhou Cent Hosp, Dept Radiat Therapy, Cangzhou, Hebei Province, Peoples R China.
EM mwangm@yeah.net
CR Asefi V, 2009, J LARYNGOL OTOL, V123, P444, DOI 10.1017/S0022215108003733
   Babar M, 2012, AM J GASTROENTEROL, V107, P1331, DOI 10.1038/ajg.2012.134
   Baxevanis CN, 2003, J IMMUNOL, V171, P2953, DOI 10.4049/jimmunol.171.6.2953
   Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bushley AW, 2004, GYNECOL ONCOL, V95, P672, DOI 10.1016/j.ygyno.2004.08.024
   Dehaghani AS, 2009, MOL BIOL REP, V36, P2393, DOI 10.1007/s11033-009-9469-7
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dick DM, 2011, ANNU REV CLIN PSYCHO, V7, P383, DOI 10.1146/annurev-clinpsy-032210-104518
   Dinarello CA, 1999, METHODS, V19, P121, DOI 10.1006/meth.1999.0837
   Du B, 2012, MED J W CHINA, V24, P1683
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farhat K, 2008, CYTOKINE, V43, P132, DOI 10.1016/j.cyto.2008.05.004
   Farjadfar A, 2009, ACTA ONCOL, V48, P971, DOI 10.1080/02841860902878145
   Giedraitis V, 2001, J NEUROIMMUNOL, V112, P146, DOI 10.1016/S0165-5728(00)00407-0
   Gunel N, 2002, CANCER-AM CANCER SOC, V95, P663, DOI 10.1002/cncr.10705
   Guo Jun-yu, 2012, Zhonghua Wei Chang Wai Ke Za Zhi, V15, P400
   Haghshenas MR, 2009, J GASTROEN HEPATOL, V24, P1119, DOI 10.1111/j.1440-1746.2009.05791.x
   Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   Jaiswal PK, 2013, GENE, V519, P128, DOI 10.1016/j.gene.2013.01.025
   Kashef MA, 2008, J REPROD MED, V53, P855
   Kawabata T, 2001, CANCER, V92, P2050, DOI 10.1002/1097-0142(20011015)92:8<2050::AID-CNCR1544>3.0.CO;2-5
   Khalili-Azad T, 2009, NEOPLASMA, V56, P22, DOI 10.4149/neo_2009_01_22
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lebel-Binay S, 2000, EUR CYTOKINE NETW, V11, P15
   Liu JM, 2013, GENET MOL RES, V12, P820, DOI 10.4238/2013.March.15.2
   Liu YU, 2007, DNA CELL BIOL, V26, P613, DOI 10.1089/dna.2007.0600
   Nikiteas N, 2007, ANTICANCER RES, V27, P3849
   Nong LG, 2009, DNA CELL BIOL, V28, P507, DOI 10.1089/dna.2009.0912
   Pratesi C, 2006, CANCER IMMUNOL IMMUN, V55, P23, DOI 10.1007/s00262-005-0688-z
   Qi Tao, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P754
   Saenz-Lopez P, 2010, HUM IMMUNOL, V71, P309, DOI 10.1016/j.humimm.2009.11.010
   Sims JE, 2002, CURR OPIN IMMUNOL, V14, P117, DOI 10.1016/S0952-7915(01)00306-5
   Taheri M, 2012, Prague Med Rep, V113, P217
   Thong-Ngam D, 2006, WORLD J GASTROENTERO, V12, P4473, DOI 10.3748/wjg.v12.i28.4473
   Tschoeke SK, 2006, CRIT CARE MED, V34, P1225, DOI 10.1097/01.CCM.0000208356.05575.16
   Tsuboi K, 2004, CANCER LETT, V205, P207, DOI 10.1016/j.canlet.2003.10.010
   Vairaktaris E, 2007, ANTICANCER RES, V27, P4011
   Vidal-Vanaclocha F, 2006, CANCER METAST REV, V25, P417, DOI 10.1007/s10555-006-9013-3
   Wei YS, 2007, ACTA ONCOL, V46, P1090, DOI 10.1080/02841860701373595
   Yang Hong-ling, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P1006
NR 42
TC 7
Z9 7
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2013
VL 8
IS 10
AR e76915
DI 10.1371/journal.pone.0076915
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 236PJ
UT WOS:000325810900104
PM 24130810
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Shi, H
   Li, Y
   Wang, XZ
   Lu, C
   Yang, LL
   Gu, CM
   Xiong, JQ
   Huang, YX
   Wang, SX
   Lu, MX
AF Shi, Hao
   Li, Ya
   Wang, Xiaozhong
   Lu, Cheng
   Yang, Lilan
   Gu, Changmei
   Xiong, Jiaqiang
   Huang, Yangxin
   Wang, Shixuan
   Lu, Meixia
TI Association between RASSF1A Promoter Methylation and Ovarian Cancer: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID FREQUENT EPIGENETIC INACTIVATION; TUMOR-SUPPRESSOR GENES; DNA
   METHYLATION; PUBLICATION BIAS; CHROMOSOME 3P; CPG ISLAND;
   HYPERMETHYLATION; CARCINOMAS; ADENOCARCINOMA; DIAGNOSIS
AB Background: The RAS association domain family protein 1a gene (RASSF1A) is one of the tumor suppressor genes (TSG). Inactivation of RASSF1A is critical to the pathogenesis of cancer. Aberrant TSG methylation was considered an important epigenetic silencing mechanism in the progression of ovarian cancer. A number of studies have discussed association between RASSF1A promoter methylation and ovarian cancer. However, they were mostly based on a small number of samples and showed inconsist results, Therefore, we conducted a meta-analysis to better identify the association.
   Methods: Eligible studies were identified by searching the PubMed, EMBASE, Web of Science, and CNKI databases using a systematic searching strategy. We pooled the odds ratio (ORs) from individual studies using a fixed-effects model. We performed heterogeneity and publication bias analysis simultaneously.
   Results: Thirteen studies, with 763 ovarian cancer patients and 438 controls were included in the meta-analysis. The frequencies of RASSF1A promoter methylation ranged from 30% to 58% (median is 48%) in the cancer group and 0 to 21% (median is 0) in the control group. The frequencies of RASSF1A promoter methylation in the cancer group were significantly higher than those in the control group. The pooled odds ratio was 11.17 (95% CI = 7.51-16.61) in the cancer group versus the corresponding control group under the fixed-effects model.
   Conclusion: The results suggested that RASSF1A promoter methylation had a strong association with ovarian cancer.
C1 [Shi, Hao; Gu, Changmei; Lu, Meixia] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430074, Hubei, Peoples R China.
   [Shi, Hao; Gu, Changmei; Lu, Meixia] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ,Key Lab Environm & Hlth, Wuhan 430074, Hubei, Peoples R China.
   [Li, Ya; Xiong, Jiaqiang; Wang, Shixuan] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, Wuhan 430074, Hubei, Peoples R China.
   [Wang, Xiaozhong] Nanchang Univ, Affiliated Hosp 2, Dept Clin Lab, Nanchang, Jiangxi, Peoples R China.
   [Lu, Cheng] Nanchang Univ, Coll Med, Dept Anat, Nanchang, Jiangxi, Peoples R China.
   [Yang, Lilan] Nanchang Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Nanchang, Jiangxi, Peoples R China.
   [Huang, Yangxin] Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL USA.
RP Lu, MX (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430074, Hubei, Peoples R China.
EM mlu@hust.edu.cn
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Barnholtz-Sloan JS, 2003, AM J OBSTET GYNECOL, V189, P1120, DOI 10.1067/S0002-9378(03)00579-9
   Barton CA, 2008, GYNECOL ONCOL, V109, P129, DOI 10.1016/j.ygyno.2007.12.017
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhagat R, 2012, CELL ONCOL, V35, P473, DOI 10.1007/s13402-012-0106-4
   BonDurant AE, 2011, GYNECOL ONCOL, V123, P581, DOI 10.1016/j.ygyno.2011.08.029
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Byun DS, 2001, CANCER RES, V61, P7034
   Choi YL, 2006, VIRCHOWS ARCH, V448, P331, DOI 10.1007/s00428-005-0091-3
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fraser HB, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-2-r8
   Hall M, 2013, BRIT J CANCER, V108, P250, DOI 10.1038/bjc.2012.541
   He Y, 2011, J BENGBU MED COLL, V36, p[35, 41]
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Ho CM, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-53
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Imura M, 2006, CANCER LETT, V241, P213, DOI 10.1016/j.canlet.2005.10.010
   [蒋文瀚 Jiang Wenhan], 2011, [循证医学, The Journal of Evidence-Based Medicine], V11, P305
   Kuroki T, 2003, CANCER RES, V63, P3724
   Lee JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061658
   Lee MG, 2001, CANCER RES, V61, P6688
   Li QR, 2007, J SHANDONG U MED SCI, P1046
   Ma Lin, 2005, Zhonghua Zhongliu Zazhi, V27, P657
   Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455
   Montavon C, 2012, GYNECOL ONCOL, V124, P582, DOI 10.1016/j.ygyno.2011.11.026
   Ozdemir F, 2012, EXP THER MED, V4, P1092, DOI 10.3892/etm.2012.715
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Pfeifer GP, 2005, BIOCHEMISTRY-MOSCOW+, V70, P576, DOI 10.1007/s10541-005-0151-y
   Rathi A, 2002, CLIN CANCER RES, V8, P3324
   ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638
   Shen WJ, 2008, CHIN J CANC PREV TRE, V15, P530
   Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187
   Wong N, 2002, J HEPATOL, V37, P633, DOI 10.1016/S0168-8278(02)00269-6
   Wu Q, 2007, MOL CANCER, V6, P45
   Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466
   陈冬丽, 2010, [中国癌症杂志, China Oncology], V20, P712
NR 38
TC 3
Z9 4
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2013
VL 8
IS 10
AR e76787
DI 10.1371/journal.pone.0076787
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 233FK
UT WOS:000325552200068
PM 24116157
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Calvert, C
   Ronsmans, C
AF Calvert, Clara
   Ronsmans, Carine
TI HIV and the Risk of Direct Obstetric Complications: A Systematic Review
   and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED DISEASES; ACTIVE
   ANTIRETROVIRAL THERAPY; INFECTED PREGNANT-WOMEN; TO-CHILD TRANSMISSION;
   CESAREAN-SECTION; POSITIVE WOMEN; HIV-1-INFECTED WOMEN; EPIDEMIOLOGIC
   SYNERGY; VAGINAL DELIVERY
AB Background: Women of reproductive age in parts of sub-Saharan Africa are faced both with high levels of HIV and the threat of dying from the direct complications of pregnancy. Clinicians practicing in such settings have reported a high incidence of direct obstetric complications among HIV-infected women, but the evidence supporting this is unclear. The aim of this systematic review is to establish whether HIV-infected women are at increased risk of direct obstetric complications.
   Methods and findings: Studies comparing the frequency of obstetric haemorrhage, hypertensive disorders of pregnancy, dystocia and intrauterine infections in HIV-infected and uninfected women were identified. Summary estimates of the odds ratio (OR) for the association between HIV and each obstetric complication were calculated through meta-analyses. In total, 44 studies were included providing 66 data sets; 17 on haemorrhage, 19 on hypertensive disorders, five on dystocia and 25 on intrauterine infections. Meta-analysis of the OR from studies including vaginal deliveries indicated that HIV-infected women had over three times the risk of a puerperal sepsis compared with HIV-uninfected women [pooled OR: 3.43, 95% confidence interval (CI): 2.00-5.85]; this figure increased to nearly six amongst studies only including women who delivered by caesarean (pooled OR: 5.81, 95% CI: 2.42-13.97). For other obstetric complications the evidence was weak and inconsistent.
   Conclusions: The higher risk of intrauterine infections in HIV-infected pregnant and postpartum women may require targeted strategies involving the prophylactic use of antibiotics during labour. However, as the huge excess of pregnancy-related mortality in HIV-infected women is unlikely to be due to a higher risk of direct obstetric complications, reducing this mortality will require non obstetric interventions involving access to ART in both pregnant and non-pregnant women.
C1 [Calvert, Clara; Ronsmans, Carine] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England.
RP Calvert, C (reprint author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England.
EM clara.calvert@lshtm.ac.uk
FU Economic and Social Research Council; Bill & Melinda Gates Foundation;
   Economic and Social Research Council [1081714]
FX This work was supported by the Economic and Social Research Council and
   through a grant awarded by the Bill & Melinda Gates Foundation to the U.
   S. fund for UNICEF to support the Child Health Epidemiology Reference
   Group. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abdool Karim Q, 2010, LANCET, V375, P1948, DOI 10.1016/S0140-6736(10)60747-7
   Aboud S, 2009, INT J GYNECOL OBSTET, V107, P202, DOI 10.1016/j.ijgo.2009.07.037
   Peret FJA, 2007, REV BRAS GINECOL OBS, V29, P260, DOI 10.1590/S0100-72032007000500007
   Andiman W, 1999, NEW ENGL J MED, V340, P977
   [Anonymous], 2003, J PERINAT ED
   Azria E, 2010, INT J GYNECOL OBSTET, V111, P161, DOI 10.1016/j.ijgo.2010.05.023
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berer M, 1999, SAFE MOTHERHOOD INIT, P198
   Bodkin C, 2006, J CLIN NURS, V15, P735, DOI 10.1111/j.1365-2702.2006.01438.x
   Boer K, 2007, BJOG-INT J OBSTET GY, V114, P148, DOI 10.1111/j.1471-0528.2006.01183.x
   BRADDICK MR, 1990, AIDS, V4, P1001, DOI 10.1097/00002030-199010000-00009
   Calvert C, 2013, AIDS, DOI DOI 10.1097/QAD.1090B1013E32835FD32940
   Cavasin H, 2009, INFECT DIS OBSTET GY, V2009
   Chama CM, 2008, J OBSTET GYNAECOL, V28, P194, DOI 10.1080/01443610801912295
   Chamiso D, 1996, E AFR MED J, V73, P805
   Chanrachakul B, 2001, INT J GYNECOL OBSTET, V72, P229, DOI 10.1016/S0020-7292(00)00364-7
   Chilongozi D, 2008, PEDIATR INFECT DIS J, V27, P808, DOI 10.1097/INF.0b013e31817109a4
   CLOTTEY C, 1993, INFECT DIS CLIN N AM, V7, P753
   Coutsoudis A, LANCET
   de Groot MR, 2003, INT J GYNECOL OBSTET, V81, P9, DOI 10.1016/S0020-7292(02)00399-5
   Figueroa-Damian R, 1999, SALUD PUBLICA MEXICO, V41, P362, DOI 10.1590/S0036-36341999000500003
   FIORE S, 2004, AIDS, V18, P933
   Frank KA, 2004, OBSTET GYNECOL, V104, P238, DOI 10.1097/01.AOG.0000130066.75671.b2
   French R, 1998, BRIT J OBSTET GYNAEC, V105, P827, DOI 10.1111/j.1471-0528.1998.tb10226.x
   Graham W., 2003, WORKSH HIV AIDS AD M
   Grubert TA, 1999, LANCET, V354, P1612, DOI 10.1016/S0140-6736(99)03141-4
   Haeri S, 2009, AM J OBSTET GYNECOL, V201
   Higgens JP, 2011, COCHRANE HDB SYSTEMA
   Higgins JR, 2001, LANCET, V357, P131, DOI 10.1016/S0140-6736(00)03552-2
   Kourtis AP, 2006, AIDS, V20, P1823, DOI 10.1097/01.aids.0000244201.11006.1c
   LEPAGE P, 1991, AIDS, V5, P295, DOI 10.1097/00002030-199103000-00008
   Leroy V, 1998, AIDS, V12, P643, DOI 10.1097/00002030-199806000-00014
   Lindgren S, 1996, SCAND J INFECT DIS, V28, P425, DOI 10.3109/00365549609037933
   Lionel J, 2008, TROP DOCT, V38, P144, DOI 10.1258/td.2007.070081
   Louis J, 2007, OBSTET GYNECOL, V110, P385, DOI 10.1097/01.AOG.0000275263.81272.fc
   Louis Judette, 2006, Infect Dis Obstet Gynecol, V2006, P79512
   Maiques V, 2010, EUR J OBSTET GYN R B, V153, P27, DOI 10.1016/j.ejogrb.2010.07.001
   Maiques-Montesinos V, 1999, ACTA OBSTET GYN SCAN, V78, P789, DOI 10.1034/j.1600-0412.1999.780909.x
   Mattar R, 2004, EUR J OBSTET GYN R B, V117, P240, DOI 10.1016/j.ejogrb.2004.04.014
   McIntyre J, 2003, BRIT MED BULL, V67, P127, DOI 10.1093/bmb/ldg012
   MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P1598
   MMIRO F, 1993, PEDIATR AIDS HIV INF, V4, P67
   Moodliar S, 2007, EUR J OBSTET GYN R B, V131, P138, DOI 10.1016/j.ejogrb.2006.05.004
   National Institute for Clinical Excellence, 2004, CLIN GUID 13 CAES SE
   National Institute for Health and Clinical Excellence, 2011, CAES SECT
   NCCMED, 2012, 5 NCCMED
   Okong P, 2004, INT J STD AIDS, V15, P669, DOI 10.1258/0956462041944394
   Olagbuji BN, 2009, ARCH GYNECOLOGY OBST, V281
   Onah HE, 2007, J OBSTET GYNAECOL, V27, P271, DOI 10.1080/01443610701195108
   Panburana P, 2003, AUST NZ J OBSTET GYN, V43, P160, DOI 10.1046/j.0004-8666.2003.00027.x
   RICH KC, 1995, J INFECT DIS, V172, P1221, DOI 10.1093/infdis/172.5.1221
   Rodriguez EJ, 2001, AM J OBSTET GYNECOL, V184, P1108, DOI 10.1067/mob.2001.115179
   Roman-Poueriet J, 2009, REV PANAM SALUD PUBL, V26, P315, DOI 10.1590/S1020-49892009001000005
   ROSSI G, 1990, AIDS RES HUM RETROV, V6, P261, DOI 10.1089/aid.1990.6.261
   Scaradavou A, 2002, BLOOD REV, V16, P73, DOI 10.1054/bire.2001.0188
   Sebitloane HM, 2008, AM J OBSTET GYNECOL, V198
   SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013
   Singh YA, 2009, JMS J  MED SOC, V23, P116
   SLOAND EM, 1992, EUR J HAEMATOL, V48, P168
   Suy A, 2006, AIDS, V20, P59, DOI 10.1097/01.aids.0000198090.70325.bd
   TEMMERMAN M, 1994, OBSTET GYNECOL, V83, P495, DOI 10.1097/00006250-199404000-00002
   Turan JM, 2008, JOGNN-J OBST GYN NEO, V37, P588, DOI 10.1111/j.1552-6909.2008.00281.x
   UNAIDS, 2011, COUNTD ZER GLOB PLAN
   Urbani G, 2001, INT J GYNECOL OBSTET, V74, P9, DOI 10.1016/S0020-7292(01)00380-0
   van Dillen J, 2010, CURR OPIN INFECT DIS, V23, P249, DOI 10.1097/QCO.0b013e328339257c
   van Eijk AM, 2007, TROP MED INT HEALTH, V12, P342, DOI 10.1111/j.1365-3156.2006.01787.x
   VERKUYL DAA, 1995, LANCET, V346, P293, DOI 10.1016/S0140-6736(95)92171-0
   Wandabwa J, 2008, East Afr Med J, V85, P56
   WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001
   Waweru J., 2009, African Journal of Food, Agriculture, Nutrition and Development, V9, P748
   Wimalasundera RC, 2002, LANCET, V360, P1152, DOI 10.1016/S0140-6736(02)11195-0
   World Health Organization, 2010, ANT THER HIV INF AD
   World Health Organization, 2010, ANT DRUGS TREAT PREG
   Zaba B, LANCET IN PRESS
   Zvandasara P, 2007, Cent Afr J Med, V53, P43
NR 75
TC 34
Z9 35
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 4
PY 2013
VL 8
IS 10
AR e74848
DI 10.1371/journal.pone.0074848
PG 35
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 232JF
UT WOS:000325489100015
PM 24124458
OA DOAJ Gold, Green Accepted, Green Published
DA 2019-07-16
ER

PT J
AU Guan, HB
   Wu, QJ
   Gong, TT
   Lin, B
   Wang, YL
   Liu, CX
AF Guan, Hong-Bo
   Wu, Qi-Jun
   Gong, Ting-Ting
   Lin, Bei
   Wang, Yong-Lai
   Liu, Cai-Xia
TI Parity and Risk of Colorectal Cancer: A Dose-Response Meta-Analysis of
   Prospective Studies
SO PLOS ONE
LA English
DT Article
ID ORAL-CONTRACEPTIVE USE; LARGE-BOWEL-CANCER; REPRODUCTIVE FACTORS;
   COLON-CANCER; MENSTRUAL FACTORS; 1ST BIRTH; WOMEN; HISTORY; AGE; HEALTH
AB Background: Association between parity and colorectal cancer (CRC) risk has been investigated by several epidemiological studies but results are controversial, yet a comprehensive and quantitative assessment of this association has not been reported so far.
   Methods: Relevant published studies of parity and CRC were identified using MEDLINE, EMBASE and Web of Science databases through end of April 2013. Two authors independently assessed eligibility and extracted data. Eleven prospective studies reported relative risk (RR) estimates and 95% confidence intervals (CIs) of CRC risk associated with parity. We pooled the RR from individual studies using fixed-or random-effects models and carried out heterogeneity and publication bias analyses.
   Results: The summary RR for the ever parity vs. nulliparous was 0.95 (95% CI: 0.88-1.02), with no heterogeneity (Q = 9.04, P = 0.443, I-2 = 0.5%). Likewise, no significant association was yielded for the highest vs. lowest parity number (RR = 1.02, 95% CI: 0.89-1.17), with moderate heterogeneity (Q = 17.48, P = 0.094, I-2 = 37.1%). Dose-response analysis still indicated no effect of parity on CRC risk and the summary RR of per one livebirth was 0.99 (95% CI: 0.96-1.02), with moderate of heterogeneity (Q = 16.50, P<0.021, I-2 = 57.6%). Similar results were observed among all the subgroup analyses. No evidence of publication bias and significant heterogeneity between subgroups were detected by meta-regression analyses.
   Conclusion: Results of this dose-response meta-analysis of prospective studies found that there was little evidence of an association between parity and CRC risk.
C1 [Guan, Hong-Bo; Gong, Ting-Ting; Lin, Bei; Wang, Yong-Lai; Liu, Cai-Xia] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang, Peoples R China.
   [Wu, Qi-Jun] Shanghai Jiao Tong Univ, Sch Med, Dept Epidemiol, Shanghai Canc Inst,Renji Hosp, Shanghai 200030, Peoples R China.
   [Wu, Qi-Jun] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogene & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai 200030, Peoples R China.
RP Liu, CX (reprint author), China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang, Peoples R China.
EM caixia_liu_sj@163.com
CR Akhter M, 2008, EUR J CANCER PREV, V17, P515, DOI 10.1097/CEJ.0b013e3282f521f8
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725
   Boyle P, 2008, WORLD CANC REPORT 20
   Broeders MJM, 1996, INT J CANCER, V66, P170, DOI 10.1002/(SICI)1097-0215(19960410)66:2<170::AID-IJC5>3.0.CO;2-#
   Chubak J, 2004, CANCER EPIDEM BIOMAR, V13, P1296
   CHUTE CG, 1991, EPIDEMIOLOGY, V2, P395, DOI 10.1097/00001648-199109000-00019
   Cunningham F KL, 2005, WILLIAMS OBSTET
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Giovannucci E, 2006, CANC EPIDEMIOLOGY PR, P809
   Goldfien A, 1994, BASIC CLIN ENDOCRINO, P419
   Gong TT, 2013, INT J CANCER, V132, P2894, DOI 10.1002/ijc.27952
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   JACOBSEN BK, 1995, J CLIN EPIDEMIOL, V48, P1119, DOI 10.1016/0895-4356(95)00009-S
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kabat GC, 2008, INT J CANCER, V122, P643, DOI 10.1002/ijc.23079
   KRAVDAL O, 1993, INT J CANCER, V53, P56, DOI 10.1002/ijc.2910530112
   KUNE GA, 1989, AM J EPIDEMIOL, V129, P533, DOI 10.1093/oxfordjournals.aje.a115165
   KUNE GA, 1992, EUR J CANCER, V28A, P1484, DOI 10.1016/0959-8049(92)90549-H
   Kuo CH, 2012, CANCER SCI, V103, P1553, DOI 10.1111/j.1349-7006.2012.02336.x
   KVALE G, 1991, INT J CANCER, V47, P390, DOI 10.1002/ijc.2910470314
   Larsson SC, 2005, J NATL CANCER I, V97, P1679, DOI 10.1093/jnci/dji375
   LAVECCHIA C, 1991, CANCER CAUSE CONTROL, V2, P193, DOI 10.1007/BF00056213
   Lin J, 2007, AM J EPIDEMIOL, V165, P794, DOI 10.1093/aje/kwk068
   Lo AC, 2010, DIS COLON RECTUM, V53, P830, DOI 10.1007/DCR.0b013e3181d320b1
   Martinez ME, 1997, CANCER EPIDEM BIOMAR, V6, P1
   MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687
   MCMICHAEL AJ, 1980, J NATL CANCER I, V65, P1201
   Nazeri K, 2006, GYNECOL ENDOCRINOL, V22, P416, DOI 10.1080/09513590600900378
   Newcomb PA, 2008, ADV EXP MED BIOL, V617, P259, DOI 10.1007/978-0-387-69080-3_24
   Orsini N, 2012, AM J EPIDEMIOL, V175, P66, DOI 10.1093/aje/kwr265
   PETERS RK, 1990, BRIT J CANCER, V61, P741, DOI 10.1038/bjc.1990.166
   PLESKO I, 1985, INT J CANCER, V36, P529, DOI 10.1002/ijc.2910360502
   POTTER JD, 1983, J NATL CANCER I, V71, P703
   Sakauchi F, 2007, ASIAN PAC J CANCER P, V8, P129
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tamakoshi K, 2004, CANCER SCI, V95, P602, DOI 10.1111/j.1349-7006.2004.tb02494.x
   Tamakoshi K, 2004, CANCER SCI, V95, P243, DOI 10.1111/j.1349-7006.2004.tb02210.x
   Tran TT, 1996, CANCER EPIDEM BIOMAR, V5, P1013
   Troisi R, 1997, EPIDEMIOLOGY, V8, P75, DOI 10.1097/00001648-199701000-00012
   Tsilidis KK, 2010, BRIT J CANCER, V103, P1755, DOI 10.1038/sj.bjc.6605965
   van Wayenburg CAM, 2000, EPIDEMIOLOGY, V11, P304, DOI 10.1097/00001648-200005000-00013
   Wells G., 2013, NEWCASTLE OTTAWA SCA
   Wernli KJ, 2009, J WOMENS HEALTH, V18, P995, DOI 10.1089/jwh.2008.1068
   WU AH, 1987, BRIT J CANCER, V55, P687, DOI 10.1038/bjc.1987.140
   Wu QJ, 2013, ANN ONCOL, V24, P1079, DOI 10.1093/annonc/mds601
   Zervoudakis A, 2011, J NATL CANCER I, V103, P826, DOI 10.1093/jnci/djr101
NR 50
TC 10
Z9 10
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 30
PY 2013
VL 8
IS 9
AR e75279
DI 10.1371/journal.pone.0075279
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 231NL
UT WOS:000325423500060
PM 24098689
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xiao, MJ
   Wang, YM
   Gao, Y
AF Xiao, Mingjia
   Wang, Yiming
   Gao, Yi
TI Association between Helicobacter pylori Infection and Pancreatic Cancer
   Development: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID VIRULENCE FACTORS; RISK; EPIDEMIOLOGY; SEROPOSITIVITY; PATHOGENESIS;
   ERADICATION; IMMUNOBLOT; ACTIVATION; STOMACH; STRAINS
AB Background: Pancreatic cancer is one of the most troublesome malignancies with dismal prognosis. H. pylori has been recognized as a type I carcinogen. Several studies have evaluated the association between H. pylori infection and pancreatic cancer development, however, the conclusions are inconsistent.
   Methods: Literature search was carried out in PubMed, EMBASE, Cochrane Library and CNKI databases to identify eligible researches. We performed overall meta-analysis of all studies included and subgroup analysis based on regional distribution. Quality of the studies (assessed by Newcastle-Ottawa quality assessment scale for case-control studies) and CagA+ strains of H. pylori were taken into consideration, and we conducted additional analyses including high-quality researches and those concerning CagA+ H. pylori respectively.
   Results: 9 studies involving 3033 subjects (1083 pancreatic cancer cases, 1950 controls) were included. Summary OR and 95% CI of the overall meta-analysis of all included studies were 1.47 and 1.22-1.77, pooled data of the 4 high-quality studies were OR 1.28, 95% CI 1.01-1.63. OR of the 5 studies examined CagA+ strains was 1.42, corresponding 95% CI was 0.79 to 2.57. Summary estimates of subgroup analysis based on regional distribution are as follows, Europe group: OR 1.56, 95% CI 1.15-2.10; East Asia group: OR 2.01, 95% CI 1.33-3.02; North America group: OR 1.17, 95% CI 0.87-1.58. There was not obvious heterogeneity across the 9 studies. No publication bias was detected.
   Conclusion: H. pylori infection is significantly, albeit weakly, associated with pancreatic cancer development. The association is prominent in Europe and East Asia, but not in North America. CagA+ H. pylori strains appear not to be associated with pancreatic cancer. However, more studies, especially prospective studies, are needed to validate our results.
C1 [Xiao, Mingjia] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Hepatobiliary Surg, Wuxi, Jiangsu, Peoples R China.
   [Xiao, Mingjia; Gao, Yi] Southern Med Univ, Zhujiang Hosp, Dept Hepatobiliary Surg 2, Guangzhou, Guangdong, Peoples R China.
   [Wang, Yiming] Southern Med Univ, Zhujiang Hosp, Dept Urol Surg, Guangzhou, Guangdong, Peoples R China.
RP Gao, Y (reprint author), Southern Med Univ, Zhujiang Hosp, Dept Hepatobiliary Surg 2, Guangzhou, Guangdong, Peoples R China.
EM gaoyi6146@163.com
CR [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1
   Aschebrook-Kilfoy B, 2011, AM J EPIDEMIOL, V174, P305, DOI 10.1093/aje/kwr092
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blaser MJ, 2008, GUT, V57, P561, DOI 10.1136/gut.2007.133462
   BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J
   Boncristiano M, 2003, J EXP MED, V198, P1887, DOI 10.1084/jem.20030621
   Brenner H, 2004, AM J EPIDEMIOL, V159, P252, DOI 10.1093/aje/kwh039
   Brown LM, 2000, EPIDEMIOL REV, V22, P283, DOI 10.1093/oxfordjournals.epirev.a018040
   Chey WD, 2001, ARCH INTERN MED, V161, P2129, DOI 10.1001/archinte.161.17.2129
   Chow WH, 1998, CANCER RES, V58, P588
   de Martel C, 2008, CANCER EPIDEM BIOMAR, V17, P1188, DOI 10.1158/1055-9965.EPI-08-0185
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   [窦逾常 DOU Yuchang], 2008, [吉林大学学报. 医学版, Journal of Jilin Univeristy. Medicine edition], V34, P317
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fox JG, 1998, GASTROENTEROLOGY, V114, P755, DOI 10.1016/S0016-5085(98)70589-X
   Gawin Alicja, 2012, Pol Merkur Lekarski, V32, P103
   Goh KL, 2011, HELICOBACTER, V16, P1, DOI 10.1111/j.1523-5378.2011.00874.x
   HANSSON LE, 1993, GASTROENTEROLOGY, V105, P1098, DOI 10.1016/0016-5085(93)90954-B
   Hassan MM, 2007, AM J GASTROENTEROL, V102, P2696, DOI 10.1111/j.1572-0241.2007.01510.x
   Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557
   HOUBEN GMP, 1995, SCAND J GASTROENTERO, V30, P13, DOI 10.3109/00365529509090296
   Huang JQ, 2003, GASTROENTEROLOGY, V125, P1636, DOI 10.1053/S0016-5085(03)01520-8
   Hunt RH, 2011, J GASTROINTEST LIVER, V20, P299, DOI 10.1097/MCG.0b013e31820fb8f6
   Kang R, 2012, AM J CANCER RES, V2, P383
   Kim JM, 2007, INFECT IMMUN, V75, P3373, DOI 10.1128/IAI.01940-06
   Kist M, 1999, FEMS IMMUNOL MED MIC, V24, P239, DOI 10.1111/j.1574-695X.1999.tb01289.x
   KOKKINAKIS DM, 1993, CARCINOGENESIS, V14, P1705, DOI 10.1093/carcin/14.8.1705
   Kosunen TU, 2011, INT J CANCER, V128, P433, DOI 10.1002/ijc.25337
   Kowalski M, 2001, J Physiol Pharmacol, V52, P3
   Ladabaum U, 2002, ALIMENT PHARM THERAP, V16, P1491, DOI 10.1046/j.1365-2036.2002.01306.x
   Larsson SC, 2012, BRIT J CANCER, V106, P603, DOI 10.1038/bjc.2011.585
   Lindkvist B, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-321
   Lowenfels AB, 2002, HEMATOL ONCOL CLIN N, V16, P1, DOI 10.1016/S0889-8588(01)00003-X
   Lu CY, 2005, WORLD J GASTROENTERO, V11, P5672, DOI 10.3748/wjg.v11.i36.5672
   Lu H, 2005, CURR OPIN GASTROEN, V21, P653, DOI 10.1097/01.mog.0000181711.04529.d5
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   MARSHALL BJ, 1984, LANCET, V1, P1311
   Moher D, 2000, ONKOLOGIE, V23, P597, DOI 10.1159/000055014
   Nilsson HO, 2006, WORLD J GASTROENTERO, V12, P3038, DOI 10.3748/wjg.v12.i19.3038
   Noto Jennifer M, 2012, Methods Mol Biol, V921, P7
   Popovic N, 2010, HEPATO-GASTROENTEROL, V57, P167
   Raderer M, 1998, ONCOLOGY-BASEL, V55, P16, DOI 10.1159/000011830
   Raimondi S, 2009, NAT REV GASTRO HEPAT, V6, P699, DOI 10.1038/nrgastro.2009.177
   Risch HA, 2003, JNCI-J NATL CANCER I, V95, P948, DOI 10.1093/jnci/95.13.948
   Risch HA, 2012, MOL CARCINOGEN, V51, P109, DOI 10.1002/mc.20826
   Risch HA, 2010, J NATL CANCER I, V102, P502, DOI 10.1093/jnci/djq007
   Rundle A, 2012, EUR J CLIN INVEST, V42, P1350, DOI 10.1111/j.1365-2362.2012.02727.x
   Shimoyama T, 2010, J GASTROEN HEPATOL, V25, pS86, DOI 10.1111/j.1440-1746.2010.06224.x
   Shiota S, 2013, J DIGEST DIS, V14, P341, DOI 10.1111/1751-2980.12054
   Sorberg M, 1997, SCAND J INFECT DIS, V29, P147, DOI 10.3109/00365549709035875
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stolzenberg-Solomon RZ, 2001, J NATL CANCER I, V93, P937, DOI 10.1093/jnci/93.12.937
   Tonkic A, 2012, HELICOBACTER, V17, P1, DOI 10.1111/j.1523-5378.2012.00975.x
   Trikudanathan G, 2011, J PANCREAS, V12, P26
   Vicari JJ, 1998, GASTROENTEROLOGY, V115, P50, DOI 10.1016/S0016-5085(98)70364-6
   Wu C, 2012, NAT GENET, V44, P62, DOI 10.1038/ng.1020
   Zhang XM, 2011, MOL CARCINOGEN, V50, P876, DOI 10.1002/mc.20784
   Zhou D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027390
   Zhufeng Q, 2012, J GUIYANG MED COLL, V37, P411
NR 59
TC 35
Z9 36
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 26
PY 2013
VL 8
IS 9
AR e75559
DI 10.1371/journal.pone.0075559
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 228VP
UT WOS:000325220000028
PM 24086571
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Hu, Y
   Wang, JL
   Tao, HT
   Wu, BS
   Sun, J
   Cheng, Y
   Dong, WW
   Li, RX
AF Hu, Yi
   Wang, Jingliang
   Tao, Haitao
   Wu, Baishou
   Sun, Jin
   Cheng, Yao
   Dong, Weiwei
   Li, Ruixin
TI Increased Risk of High-Grade Hemorrhage in Cancer Patients Treated with
   Gemcitabine: A Meta-Analysis of 20 Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID CELL LUNG-CANCER; CISPLATIN PLUS GEMCITABINE; PHASE-III TRIAL;
   METASTATIC BREAST-CANCER; UNKNOWN PRIMARY SITE; 1ST-LINE TREATMENT;
   ELDERLY-PATIENTS; PANCREATIC-CANCER; BLADDER-CANCER; VINORELBINE
AB Purpose: Gemcitabine, a third-generation anticancer agent, has been shown to be active in several solid tumors. High-grade hemorrhage (grade >= 3) has been reported with this drug, although the overall risk remains unclear. We conducted a meta-analysis of randomized controlled trials evaluating the incidence and risk of high-grade hemorrhage associated with gemcitabine.
   Methods: Pubmed was searched for articles published from January 1, 1990 to December 31, 2012. Eligible studies included prospective randomized controlled phase II and III trials evaluating gemcitabine-based vs non-gemcitabine-based therapy in patients with solid tumors. Data on high-grade hemorrhage were extracted. Overall incidence rates, relative risk (RR), and 95% confidence intervals (CI) were calculated employing fixed-or random-effects models depending on the heterogeneity of included trials.
   Results: A total of 6433 patients from 20 trials were included. Among patients treated with gemcitabine-based chemotherapy, the overall incidence of high-grade hemorrhage was 1.7% (95% CI: 0.9-3.1%), and the RR of high-grade hemorrhage was 2.727 (95% CI: 1.581-4.702, p<0.001). Exploratory subgroup analysis revealed the highest RR of hemorrhage in non-small-cell lung cancer (NSCLC) patients (RR: 3.234; 95% CI, 1.678-6.233; p<0.001), phase II trials (RR 7.053, 95% CI: 1.591-31.27; p = 0.01), trials reported during 2006-2012 (RR: 3.750; 95% CI: 1.735-8.108, p<0.001) and gemcitabine used as single agent (RR 7.48; 95% CI: 0.78-71.92, p = 0.081).
   Conclusion: Gemcitabine is associated with a significant increase risk of high-grade hemorrhage in patients with solid tumors when compared with non-gemcitabine-based therapy.
C1 [Hu, Yi; Wang, Jingliang; Tao, Haitao; Wu, Baishou; Sun, Jin; Cheng, Yao; Dong, Weiwei; Li, Ruixin] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China.
RP Hu, Y (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China.
EM huyi20130502@163.com
CR Addeo R, 2010, J CLIN ONCOL, V28, P543, DOI 10.1200/JCO.2008.20.8199
   Avvisati G, 2003, CRIT REV ONCOL HEMAT, V48, pS13, DOI 10.1016/j.critrevonc.2003.04.001
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brufsky A, 2011, CLIN BREAST CANCER, V11, P211, DOI 10.1016/j.clbc.2011.03.019
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Cardenal F, 1999, J CLIN ONCOL, V17, P12, DOI 10.1200/JCO.1999.17.1.12
   Carron PL, 2001, INTENS CARE MED, V27, P1554, DOI 10.1007/s001340101037
   CHAIT MM, 1979, AM J GASTROENTEROL, V72, P227
   Comella P, 2004, BRIT J CANCER, V91, P489, DOI 10.1038/sj.bjc.6602011
   Crino L, 1999, J CLIN ONCOL, V17, P3522, DOI 10.1200/JCO.1999.17.11.3522
   Culine S, 2003, J CLIN ONCOL, V21, P3479, DOI 10.1200/JCO.2003.12.104
   De Santis M, 2009, J CLIN ONCOL, V27, P5634, DOI 10.1200/JCO.2008.21.4924
   El-Khoueiry AB, 2012, INVEST NEW DRUG, V30, P1175, DOI 10.1007/s10637-011-9658-9
   Elting LS, 2001, J CLIN ONCOL, V19, P1137, DOI 10.1200/JCO.2001.19.4.1137
   Feher O, 2005, ANN ONCOL, V16, P899, DOI 10.1093/annonc/mdi181
   Frasci G, 2000, ANN ONCOL, V11, P367, DOI 10.1023/A:1008346708604
   Georgoulias V, 2005, J CLIN ONCOL, V23, P2937, DOI 10.1200/JCO.2005.04.016
   Gorter JW, 1999, NEUROLOGY, V53, P1319, DOI 10.1212/WNL.53.6.1319
   Gridelli C, 2011, ANN ONCOL, V22, P1528, DOI 10.1093/annonc/mdq630
   Gridelli C, 2003, J CLIN ONCOL, V21, P3025, DOI 10.1200/JCO.2003.06.099
   Gridelli C, 2007, J CLIN ONCOL, V25, P4663, DOI 10.1200/JCO.2007.12.5708
   Gronberg BH, 2009, J CLIN ONCOL, V27, P3217, DOI 10.1200/JCO.2008.20.9114
   Hainsworth JD, 2010, CANCER J, V16, P70, DOI 10.1097/PPO.0b013e3181c6aa89
   Hang XF, 2011, EUR J CLIN PHARMACOL, V67, P613, DOI 10.1007/s00228-010-0988-x
   Hapani S, 2010, ONCOLOGY-BASEL, V79, P27, DOI 10.1159/000314980
   Je YJ, 2009, LANCET ONCOL, V10, P967, DOI 10.1016/S1470-2045(09)70222-0
   Levine MN, 2001, CHEST, V119, p108S, DOI 10.1378/chest.119.1_suppl.108S
   Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   NCI Cancer Therapy Evaluation Program, 2006, CTC V 2 0 COMM TERM
   Nichols L, 2012, ARCH PATHOL LAB MED, V136, P1552, DOI 10.5858/arpa.2011-0521-OA
   Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267
   Ohe Y, 2007, ANN ONCOL, V18, P317, DOI 10.1093/annonc/mdl377
   Pawarode A, 1998, AM J CLIN ONCOL-CANC, V21, P386, DOI 10.1097/00000421-199808000-00014
   Paz-Ares LG, 2012, J CLIN ONCOL, V30, P3084, DOI 10.1200/JCO.2011.39.7646
   Sandler AB, 2000, J CLIN ONCOL, V18, P122, DOI 10.1200/JCO.2000.18.1.122
   Sculier JP, 2002, ANN ONCOL, V13, P874, DOI 10.1093/annonc/mdf154
   Spigel DR, 2012, J THORAC ONCOL, V7, P196, DOI 10.1097/JTO.0b013e3182307efe
   Thomas P, 2006, LUNG CANCER, V51, P105, DOI 10.1016/j.lungcan.2005.10.004
   Treat JA, 2010, ANN ONCOL, V21, P540, DOI 10.1093/annonc/mdp352
   Ueno H, 2009, BRIT J CANCER, V101, P908, DOI 10.1038/sj.bjc.6605256
   Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721
   von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068
   YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7
   Zielinski C, 2005, J CLIN ONCOL, V23, P1401, DOI 10.1200/JCO.2005.12.106
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 46
TC 1
Z9 1
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 23
PY 2013
VL 8
IS 9
AR e74872
DI 10.1371/journal.pone.0074872
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 246EK
UT WOS:000326520200047
PM 24086388
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Lou, Y
   Peng, WJ
   Cao, DS
   Xie, J
   Li, HH
   Jiang, ZX
AF Lou, Yin
   Peng, Wen-jia
   Cao, Dong-sheng
   Xie, Juan
   Li, Hong-hong
   Jiang, Zheng-xuan
TI DNA Repair Gene XRCC1 Polymorphisms and Head and Neck Cancer Risk: An
   Updated Meta-Analysis Including 16344 Subjects
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; SINGLE-NUCLEOTIDE POLYMORPHISMS; ORAL-CANCER;
   NASOPHARYNGEAL CARCINOMA; LARYNGEAL-CANCER; ASSOCIATION; POPULATION;
   SMOKING; DAMAGE; XPD
AB Background: DNA repair gene X-ray repair cross complementing group 1 (XRCC1) plays an important role in the maintenance of the genomic integrity and protection of cells from DNA damage. Sequence variation in XRCC1 gene may alter head and neck cancer (HNC) susceptibility. However, these results are inconclusive. To derive a more precise estimation of the relationship between XRCC1 polymorphism and HNC risk, we undertook a meta-analysis involving 16,344 subjects.
   Methods: A search of the literature by PubMed, Embase, Web of Science and China National Knowledge Infrastructure was performed to identify studies based on the predetermined inclusion criteria. The odds ratio (OR) with 95% confidence interval (CI) was combined using a random-effects model or a fixed-effects model.
   Results: Twenty-nine studies consisting of 6,719 cases and 9,627 controls were identified and analyzed. Overall, no evidence of significant association was observed between XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln genotypes and the risk of HNC in any genetic models. Subgroup analyses according to ethnicity, tumor site, publication year, genotyping method also detected no significant association in any subgroup, except that oral cancer was associated with Arg194Trp variant in recessive model. Furthermore, no significant effect of these polymorphisms interacted with smoking on HNC risk was detected but Arg194Trp homozygous variant.
   Conclusion: In conclusion, this meta-analysis suggests that the XRCC1 Arg194Trp, Arg280His and Arg399Gln polymorphism may not involve in HNC susceptibility. Further studies about gene-gene and gene-environment interactions in different populations are required.
C1 [Lou, Yin; Cao, Dong-sheng; Xie, Juan; Li, Hong-hong] Anhui Med Univ, Hosp 2, Dept Plast Surg, Hefei, Peoples R China.
   [Peng, Wen-jia] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hefei, Peoples R China.
   [Jiang, Zheng-xuan] Anhui Med Univ, Hosp 2, Dept Ophthalmol, Hefei, Peoples R China.
RP Cao, DS (reprint author), Anhui Med Univ, Hosp 2, Dept Plast Surg, Hefei, Peoples R China.
EM dscao1966@126.com
CR Al-Hadyan KS, 2012, GENET TEST MOL BIOMA, V16, P95, DOI 10.1089/gtmb.2011.0126
   Applebaum KM, 2009, INT J CANCER, V124, P2690, DOI 10.1002/ijc.24256
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cao Y, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-167
   Cho EY, 2003, CANCER EPIDEM BIOMAR, V12, P1100
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Csejtei A, 2009, ANTICANCER RES, V29, P4169
   Demokan S, 2005, PATHOL ONCOL RES, V11, P22, DOI 10.1007/BF03032401
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   dos Reis MB, 2013, J ORAL PATHOL MED, V42, P180, DOI 10.1111/j.1600-0714.2012.01192.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Flores-Obando RE, 2010, BIOMARKERS, V15, P379, DOI 10.3109/13547501003797664
   Gajecka M, 2005, ADV OTO-RHINO-LARYNG, V62, P25
   Gal TJ, 2005, LARYNGOSCOPE, V115, P2221, DOI 10.1097/01.mlg.0000183736.96004.f7
   Geisler SA, 2001, AM J EPIDEMIOL, V154, P95, DOI 10.1093/aje/154.2.95
   Gugatschka M, 2011, EXP MOL PATHOL, V91, P331, DOI 10.1016/j.yexmp.2011.03.004
   Harth V, 2008, J TOXICOL ENV HEAL A, V71, P887, DOI 10.1080/15287390801988160
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   HIYAMA T, 1992, JPN J CANCER RES, V83, P334, DOI 10.1111/j.1349-7006.1992.tb00111.x
   Ho T, 2007, CANCER, V110, P318, DOI 10.1002/cncr.22794
   Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232
   Jelonek K, 2010, J APPL GENET, V51, P343, DOI 10.1007/BF03208865
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Khlifi R, 2012, J GENET, V91, P375, DOI 10.1007/s12041-012-0193-z
   Kietthubthew S, 2006, INT J HYG ENVIR HEAL, V209, P21, DOI 10.1016/j.ijheh.2005.06.002
   Kostrzewska-Poczekaj M, 2013, EUR ARCH OTO-RHINO-L, V270, P271, DOI 10.1007/s00405-012-1993-8
   Kowalski M, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-37
   Kumar A, 2012, TUMOR BIOL, V33, P111, DOI 10.1007/s13277-011-0253-7
   Kumar A, 2012, MUTAT RES-FUND MOL M, V729, P24, DOI 10.1016/j.mrfmmm.2011.09.001
   Laantri N, 2011, MOL CARCINOGEN, V50, P732, DOI 10.1002/mc.20754
   Li CY, 2007, CANCER, V110, P867, DOI 10.1002/cncr.22861
   Mahjabeen I, 2012, PATHOL ONCOL RES, V19, P183
   Majumder M, 2005, CANCER EPIDEM BIOMAR, V14, P2106, DOI 10.1158/1055-9965.EPI-05-0108
   Majumder M, 2007, INT J CANCER, V120, P2148, DOI 10.1002/ijc.22547
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marcu LG, 2009, J CANCER RES CLIN, V135, P1303, DOI 10.1007/s00432-009-0648-7
   Matullo G, 2006, CARCINOGENESIS, V27, P997, DOI 10.1093/carcin/bgi280
   Olshan AF, 2002, CANCER LETT, V178, P181, DOI 10.1016/S0304-3835(01)00822-9
   Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33
   Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803
   Pratesi N, 2011, RADIOTHER ONCOL, V99, P356, DOI 10.1016/j.radonc.2011.05.062
   Ramachandran S, 2006, ORAL ONCOL, V42, P350, DOI 10.1016/j.oraloncology.2005.08.010
   Ruwali M, 2009, ENVIRON MOL MUTAGEN, V50, P473, DOI 10.1002/em.20488
   Rydzanicz M, 2005, CANCER LETT, V224, P263, DOI 10.1016/j.canlet.2005.01.015
   SILVERMAN S, 1990, J AM DENT ASSOC, V120, P495, DOI 10.14219/jada.archive.1990.0082
   Sturgis EM, 1999, CARCINOGENESIS, V20, P2125, DOI 10.1093/carcin/20.11.2125
   Tae K, 2004, INT J CANCER, V111, P805, DOI 10.1002/ijc.20338
   Vaezi A, 2011, PHARMACOGN PERS MED, V4, P47, DOI 10.2147/PGPM.S20317
   Varzim G, 2003, EUR J CANCER PREV, V12, P495, DOI 10.1097/00008469-200312000-00008
   Yang CH, 2012, KAOHSIUNG J MED SCI, V28, P362, DOI 10.1016/j.kjms.2012.02.002
   Yang ZH, 2007, DNA CELL BIOL, V26, P491, DOI 10.1089/dna.2006.0537
   Yen CY, 2008, J ORAL PATHOL MED, V37, P271, DOI 10.1111/j.1600-0714.2007.00608.x
   Yu HP, 2004, CANCER DETECT PREV, V28, P194, DOI 10.1016/j.cdp.2004.01.004
   Yuan H, 2012, EXP THER MED, V3, P719, DOI 10.3892/etm.2012.476
   Zhong Y, 2011, CHEM RES TOXICOL, V24, P246, DOI 10.1021/tx100345x
   Zhou CC, 2009, TOHOKU J EXP MED, V219, P43, DOI 10.1620/tjem.219.43
NR 57
TC 8
Z9 8
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 23
PY 2013
VL 8
IS 9
AR e74059
DI 10.1371/journal.pone.0074059
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 246EK
UT WOS:000326520200019
PM 24086310
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Cho, YA
   Kim, J
   Woo, HD
   Kang, M
AF Cho, Young Ae
   Kim, Jeongseon
   Woo, Hae Dong
   Kang, Moonsu
TI Dietary Cadmium Intake and the Risk of Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID POSTMENOPAUSAL BREAST-CANCER; BODY IRON STORES; PROSTATE-CANCER;
   PROSPECTIVE COHORT; TOENAIL CADMIUM; EXPOSURE; POPULATION; WOMEN;
   HEALTH; ZINC
AB Background: Diet is a major source of cadmium intake among the non-smoking general population. Recent studies have determined that cadmium exposure may produce adverse health effects at lower exposure levels than previously predicted. We conducted a meta-analysis to combine and analyze the results of previous studies that have investigated the association of dietary cadmium intake and cancer risk.
   Methods: We searched PubMed, EMBASE, and MEDLINE database for case-control and cohort studies that assessed the association of dietary cadmium intake and cancer risk. We performed a meta-analysis using eight eligible studies to summarize the data and summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using a random effects model.
   Results: Overall, dietary cadmium intake showed no statistically significant association with cancer risk (RR = 1.10; 95% CI: 0.99-1.22, for highest vs. lowest dietary cadmium group). However, there was strong evidence of heterogeneity, and subgroup analyses were conducted using the study design, geographical location, and cancer type. In subgroup analyses, the positive associations between dietary cadmium intake and cancer risk were observed among studies with Western populations (RR = 1.15; 95% CI: 1.08-1.23) and studies investigating some hormone-related cancers (prostate, breast, and endometrial cancers).
   Conclusion: Our analysis found a positive association between dietary cadmium intake and cancer risk among studies conducted in Western countries, particularly with hormone-related cancers. Additional experimental and epidemiological studies are required to verify our findings.
C1 [Cho, Young Ae; Kim, Jeongseon; Woo, Hae Dong] Natl Canc Ctr, Mol Epidemiol Branch, Goyang, South Korea.
   [Kang, Moonsu] Gangneung Wonju Natl Univ, Dept Informat Stat, Kangnung, South Korea.
RP Kim, J (reprint author), Natl Canc Ctr, Mol Epidemiol Branch, Goyang, South Korea.
EM jskim@ncc.re.kr
FU Korea Food and Drug Administration [10162KFDA994]
FX This research was supported by a grant from Korea Food and Drug
   Administration (10162KFDA994). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adams SV, 2012, CANCER CAUSE CONTROL, V23, P845, DOI 10.1007/s10552-012-9953-6
   Akesson A, 2008, CANCER RES, V68, P6435, DOI 10.1158/0008-5472.CAN-08-0329
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERGLUND M, 1994, ENVIRON HEALTH PERSP, V102, P1058, DOI 10.2307/3431993
   Brama M, 2007, MOL CELL ENDOCRINOL, V264, P102, DOI 10.1016/j.mce.2006.10.013
   Byrne C, 2009, TOXICOL APPL PHARM, V238, P266, DOI 10.1016/j.taap.2009.03.025
   Chen YC, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-429
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gallagher CM, 2010, AGING-US, V2, P804, DOI 10.18632/aging.100226
   GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896
   Godt J, 2006, J OCCUP MED TOXICOL, V1, DOI 10.1186/1745-6673-1-22
   International Agency for Research on Cancer (IARC), 1993, IARC MON EV CARC RIS, P58
   Itoh H, 2013, INT J HYG ENVIR HEAL, DOI [10.1016/j.ijheh.2013.1003.1010, DOI 10.1016/J.IJHEH.2013.1003.1010.PUBMED:23608001]
   Jarup L, 2009, TOXICOL APPL PHARM, V238, P201, DOI 10.1016/j.taap.2009.04.020
   Jin TY, 2002, BIOMETALS, V15, P397, DOI 10.1023/A:1020229923095
   Johnson MD, 2003, NAT MED, V9, P1081, DOI 10.1038/nm902
   Joseph P, 2009, TOXICOL APPL PHARM, V238, P272, DOI 10.1016/j.taap.2009.01.011
   Julin B, 2012, BRIT J CANCER, V107, P895, DOI 10.1038/bjc.2012.311
   Julin B, 2011, BRIT J CANCER, V105, P441, DOI 10.1038/bjc.2011.238
   Julin B, 2012, CANCER RES, V72, P1459, DOI 10.1158/0008-5472.CAN-11-0735
   Julin B, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-105
   Kristal AR, 2005, CANCER EPIDEM BIOMAR, V14, P2826, DOI 10.1158/1055-9965.EPI-editorial
   Martin MB, 2002, ENDOCRINOLOGY, V143, P263, DOI 10.1210/en.143.1.263
   McElroy JA, 2006, JNCI-J NATL CANCER I, V98, P869, DOI 10.1093/jnci/djj233
   Nagata C, 2013, BREAST CANCER RES TR, V138, P235, DOI 10.1007/s10549-013-2414-4
   Nawrot TS, 2010, BIOMETALS, V23, P769, DOI 10.1007/s10534-010-9343-z
   Nimptsch K, 2011, CANCER CAUSE CONTROL, V22, P51, DOI 10.1007/s10552-010-9671-x
   OGUNLEWE JO, 1989, CANCER, V63, P1388, DOI 10.1002/1097-0142(19890401)63:7<1388::AID-CNCR2820630725>3.0.CO;2-M
   Olsson IM, 2002, ENVIRON HEALTH PERSP, V110, P1185, DOI 10.1289/ehp.021101185
   Platz EA, 2002, PROSTATE, V52, P288, DOI 10.1002/pros.10115
   Reeves PG, 2008, SCI TOTAL ENVIRON, V398, P13, DOI 10.1016/j.scitotenv.2008.03.009
   Sawada N, 2012, EPIDEMIOLOGY, V23, P368, DOI 10.1097/EDE.0b013e31824d063c
   Smith-Warner SA, 2001, JAMA-J AM MED ASSOC, V285, P769, DOI 10.1001/jama.285.6.769
   Strumylaite L, 2011, BREAST CANCER RES TR, V125, P511, DOI 10.1007/s10549-010-1007-8
   Vahter M, 2007, ENVIRON RES, V104, P85, DOI 10.1016/j.envres.2006.08.003
   van Wijngaarden E, 2008, PROSTATE, V68, P122, DOI 10.1002/pros.20668
   Vinceti M, 2007, SCI TOTAL ENVIRON, V373, P77, DOI 10.1016/j.scitotenv.2006.11.005
   Watanabe T, 2000, INT ARCH OCC ENV HEA, V73, P26, DOI 10.1007/PL00007934
   WEST DW, 1991, CANCER CAUSE CONTROL, V2, P85, DOI 10.1007/BF00053126
   Zhang ZW, 1997, INT ARCH OCC ENV HEA, V69, P273
NR 41
TC 62
Z9 63
U1 0
U2 28
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 17
PY 2013
VL 8
IS 9
AR e75087
DI 10.1371/journal.pone.0075087
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 219YJ
UT WOS:000324547300070
PM 24069382
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, YC
   Zhao, LY
   Zhu, L
   Li, J
   Chen, AM
AF Li, Yongchuan
   Zhao, Liangyu
   Zhu, Lei
   Li, Jing
   Chen, Aimin
TI Internal Fixation Versus Nonoperative Treatment for Displaced 3-Part or
   4-Part Proximal Humeral Fractures in Elderly Patients: A Meta-Analysis
   of Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID REVERSE SHOULDER PROSTHESIS; UPPER END; EPIDEMIOLOGY; CUFF;
   ARTHROPLASTY; MULTICENTER; ARTHRITIS; RUPTURE; PLATE; BIAS
AB Background: A few studies focused on open reduction and internal fixation (ORIF) or nonoperative treatment of displaced 3-part or 4-part proximal humeral fractures in elderly patients have been published, all of whom had a low number of patients. In this meta-analysis of randomized controlled trials (RCTs), we aimed to assess the effect of ORIF or nonoperative treatment of displaced 3-part or 4-part proximal humeral fractures in elderly patients on the clinical outcomes and re-evaluate of the potential benefits of conservative treatment.
   Methods: We searched PubMed and the Cochrane Central Register of Controlled Trials databases for randomized controlled trials comparing ORIF and nonoperative treatment of displaced 3-part or 4-part proximal humeral fractures in elderly patients. Our outcome measures were the Constant scores. Results: Three randomized controlled trials with a total of 130 patients were identified and analyzed. The overall results based on fixed-effect model did not support the treatment of open reduction and internal fixation to improve the functional outcome when compared with nonoperative treatment for treating elderly patients with displaced 3-part or 4-part proximal humeral fractures (WMD -0.51, 95% CI: -7.25 to 6.22, P = 0.88, I-2 = 0%).
   Conclusions: Although our meta-analysis did not support the treatment of open reduction and internal fixation to improve the functional outcome when compared with nonoperative treatment for treating elderly patients with displaced 3-part or 4-part proximal humeral fractures, this result must be considered in the context of variable patient demographics. Only a limited recommendation can be made based on current data. Considering the limitations of included studies, a large, well designed trial that incorporates the evaluation of clinically relevant outcomes in participants with different underlying risks of shoulder function is required to more adequately assess the role for ORIF or nonoperative treatment.
C1 [Li, Yongchuan; Zhao, Liangyu; Zhu, Lei; Li, Jing; Chen, Aimin] Second Mil Med Univ, Shanghai Changzheng Hosp, Orthopaed Inst PLA, Dept Orthopaed Trauma Surg, Shanghai, Peoples R China.
RP Chen, AM (reprint author), Second Mil Med Univ, Shanghai Changzheng Hosp, Orthopaed Inst PLA, Dept Orthopaed Trauma Surg, Shanghai, Peoples R China.
EM aiminchen@aliyun.com
FU National Natural Science Foundation of China [30973054, 81171161]
FX This work was supported by grants from the National Natural Science
   Foundation of China (30973054, 81171161). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BENGNER U, 1988, CLIN ORTHOP RELAT R, P179
   Boileau P, 2005, J SHOULDER ELB SURG, V14, p147S, DOI 10.1016/j.jse.2004.10.006
   Boileau P, 2006, J SHOULDER ELB SURG, V15, P527, DOI 10.1016/j.jse.2006.01.003
   Court-Brown CM, 2006, INJURY, V37, P691, DOI 10.1016/j.injury.2006.04.130
   Court-Brown CM, 2001, ACTA ORTHOP SCAND, V72, P365, DOI 10.1080/000164701753542023
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fjalestad T, 2012, J ORTHOP TRAUMA, V26, P98, DOI 10.1097/BOT.0b013e31821c2e15
   Frankle M, 2005, J BONE JOINT SURG AM, V87A, P1697, DOI 10.2106/JBJS.D.02813
   Gaebler C, 2003, ACTA ORTHOP SCAND, V74, P580, DOI 10.1080/00016470310017992
   GRAMMONT PM, 1993, ORTHOPEDICS, V16, P65
   Hertel R, 2004, J SHOULDER ELB SURG, V13, P427, DOI 10.1016/j.jse.2004.01.034
   HORAK J, 1975, CLIN ORTHOP RELAT R, P250, DOI 10.1097/00003086-197510000-00032
   Iyengar JJ, 2011, J ORTHOP TRAUMA, V25, P612, DOI 10.1097/BOT.0b013e3182008df8
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kontakis G, 2008, J BONE JOINT SURG BR, V90B, P1407, DOI 10.1302/0301-620X.90B11.21070
   NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1077, DOI 10.2106/00004623-197052060-00001
   NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1090, DOI 10.2106/00004623-197052060-00002
   Olerud P, 2011, J SHOULDER ELB SURG, V20, P747, DOI 10.1016/j.jse.2010.12.018
   Sirveaux F, 2004, J BONE JOINT SURG BR, V86B, P388, DOI 10.1302/0301-620X.86B3.14024
   Sudkamp N, 2009, J BONE JOINT SURG AM, V91A, P1320, DOI 10.2106/JBJS.H.00006
   Thalhammer G, 2009, J TRAUMA, V66, P204, DOI 10.1097/TA.0b013e31815ede7b
   Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0
   Yuksel HY, 2011, J ORTHOP TRAUMA, V25, P588, DOI 10.1097/BOT.0b013e318210ea56
   Zyto K, 1997, J BONE JOINT SURG BR, V79B, P412, DOI 10.1302/0301-620X.79B3.7419
NR 25
TC 5
Z9 6
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 16
PY 2013
VL 8
IS 9
AR e75464
DI 10.1371/journal.pone.0075464
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 219GJ
UT WOS:000324494000164
PM 24066182
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, X
   Qiu, MT
   Hu, JW
   Jiang, F
   Li, M
   Wang, J
   Zhang, Q
   Yin, R
   Xu, L
AF Yang, Xin
   Qiu, Man-Tang
   Hu, Jing-Wen
   Jiang, Feng
   Li, Ming
   Wang, Jie
   Zhang, Qin
   Yin, Rong
   Xu, Lin
TI Association of Interleukin-18 Gene Promoter-607 C > A and-137G > C
   Polymorphisms with Cancer Risk: A Meta-Analysis of 26 Studies
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; NORTH INDIAN POPULATION; IL-18 PROMOTER; SERUM
   INTERLEUKIN-18; A/C POLYMORPHISM; PROSTATE-CANCER; LUNG-CANCER;
   SUSCEPTIBILITY; EXPRESSION; PATHWAY
AB Background: Evidence suggest that IL-18 gene polymorphisms may be risk factors for several cancers. Increasing studies investigating the association between IL-18 gene promoter polymorphisms (-607 C>A and -137G>C) and cancer risk have yielded conflicting results.
   Methodology/Principal Findings: We performed a meta-analysis of 26 studies including 4096 cases and 5222 controls. We assessed the strength of the association of IL-18 gene promoter -607 C>A and -137G>C polymorphisms with cancer risk and performed sub-group analyses by cancer types, ethnicities, source of controls and sample size. The pooled results revealed a significant increased risk of cancer susceptibility for -607 C>A (CA vs. CC: OR = 1.19, 95% CI: 1.04, 1.37, P-heterogeneity = 0.033; CA/AA vs. CC: OR = 1.17, 95% CI: 1.01, 1.34, P-heterogeneity = 0.007), but no significant association for -137 G>C was observed with overall cancer risk. Sub-group analyses revealed that an increased risk of nasopharyngeal carcinoma was both found for -607 C>A (CA/AA vs. CC: OR = 1.32, 95% CI: 1.04, 1.69, P-heterogeneity = 0.823) and -137G>C (GC/CC vs. GG: OR = 1.57, 95% CI: 1.26, 1.96, P-heterogeneity = 0.373). Consistent with the results of the genotyping analyses, the -607A/-137C and -607C/-137C haplotypes were associated with a significantly increased risk of nasopharyngeal carcinoma as compared with the -607C/-137G haplotype (-607A/-137C vs. -607C/-137G: OR = 1.26, 95% CI: 1.13, 1.40; P-heterogeneity = 0.569; -607C/-137C vs. -607C/-137G: OR = 1.14, 95% CI: 1.03, 1.27; P-heterogeneity = 0.775). As for gastrointestinal cancer, we also found that -607 C>A polymorphism was significantly associated with increased cancer risk (CA/AA vs. CC: OR = 1.25, 95% CI: 1.05, 1.50, P-heterogeneity = 0.458). Further sub-group analysis revealed that -137G>C polymorphism contributed to cancer risk in Asians but not in Caucasians (GC/CC vs. GG: OR = 1.31, 95% CI: 1.05, 1.64, P-heterogeneity<0.001).
   Conclusions: The meta-analysis results suggest that IL-18 gene promoter -607 C>A polymorphism is significantly associated with overall cancer risk, especially in nasopharyngeal carcinoma and gastrointestinal cancer; and the -137 G>C polymorphism is associated with increased overall cancer risk in Asian populations and also significantly increases the risk of nasopharyngeal carcinoma.
C1 [Yang, Xin; Hu, Jing-Wen] Nanjing Med Univ, Clin Coll 1, Nanjing, Jiangsu, Peoples R China.
   [Yang, Xin; Qiu, Man-Tang; Hu, Jing-Wen; Jiang, Feng; Li, Ming; Zhang, Qin; Yin, Rong; Xu, Lin] Nanjing Med Univ, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Dept Thorac Surg, Nanjing, Jiangsu, Peoples R China.
   [Qiu, Man-Tang] Nanjing Med Univ, Clin Coll 4, Nanjing, Jiangsu, Peoples R China.
   [Wang, Jie] Nanjing Med Univ, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Dept Sci Res, Nanjing, Jiangsu, Peoples R China.
RP Yin, R (reprint author), Nanjing Med Univ, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Dept Thorac Surg, Nanjing, Jiangsu, Peoples R China.
EM yinhero001@126.com; xulin83cn@gmail.com
RI Qiu, Mantang/L-8937-2019
FU National Natural Science Foundation of China [81201830]; Natural Science
   Foundation of Jiangsu Province, China [BK2010589, BK2011857]
FX This work was supported by the National Natural Science Foundation of
   China (81201830) and Natural Science Foundation of Jiangsu Province
   (BK2010589, BK2011857), China. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Asefi V, 2009, J LARYNGOL OTOL, V123, P444, DOI 10.1017/S0022215108003733
   Babar M, 2012, AM J GASTROENTEROL, V107, P1331, DOI 10.1038/ajg.2012.134
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BOISSEL JP, 1988, EUR J CLIN PHARMACOL, V34, P535, DOI 10.1007/BF00615213
   Bushley AW, 2004, GYNECOL ONCOL, V95, P672, DOI 10.1016/j.ygyno.2004.08.024
   Chang JT, 2000, EUR J IMMUNOL, V30, P1113, DOI 10.1002/(SICI)1521-4141(200004)30:4<1113::AID-IMMU1113>3.0.CO;2-P
   Dehaghani AS, 2009, MOL BIOL REP, V36, P2393, DOI 10.1007/s11033-009-9469-7
   Du B, 2012, MED J W CHINA, V24, P1683
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eissa Soheir A L, 2005, J Egypt Natl Canc Inst, V17, P51
   Farhat K, 2008, CYTOKINE, V43, P132, DOI 10.1016/j.cyto.2008.05.004
   Farjadfar A, 2009, ACTA ONCOL, V48, P971, DOI 10.1080/02841860902878145
   Giedraitis V, 2001, J NEUROIMMUNOL, V112, P146, DOI 10.1016/S0165-5728(00)00407-0
   Gracie JA, 2003, J LEUKOCYTE BIOL, V73, P213, DOI 10.1189/jlb.0602313
   Gunel N, 2002, CANCER-AM CANCER SOC, V95, P663, DOI 10.1002/cncr.10705
   Guo Jun-yu, 2012, Zhonghua Wei Chang Wai Ke Za Zhi, V15, P400
   Haghshenas MR, 2009, J GASTROEN HEPATOL, V24, P1119, DOI 10.1111/j.1440-1746.2009.05791.x
   Han Ming-yong, 2004, J Zhejiang Univ Sci, V5, P472, DOI 10.1631/jzus.2004.0472
   Iwasaki T, 2002, J IMMUNOTHER, V25, pS52, DOI 10.1097/00002371-200203001-00008
   Jaiswal PK, 2013, GENE, V519, P128, DOI 10.1016/j.gene.2013.01.025
   Kashef MA, 2008, J REPROD MED, V53, P855
   Khalili-Azad T, 2009, NEOPLASMA, V56, P22, DOI 10.4149/neo_2009_01_22
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Liu JM, 2013, GENET MOL RES, V12, P820, DOI 10.4238/2013.March.15.2
   Liu YU, 2007, DNA CELL BIOL, V26, P613, DOI 10.1089/dna.2007.0600
   Monroy CM, 2011, MOL CARCINOGEN, V50, P36, DOI 10.1002/mc.20688
   Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423
   Nikiteas N, 2007, ANTICANCER RES, V27, P3849
   Nong LG, 2009, DNA CELL BIOL, V28, P507, DOI 10.1089/dna.2009.0912
   Okano F, 2000, ANTICANCER RES, V20, P3411
   Pan HF, 2011, LUPUS, V20, P945, DOI 10.1177/0961203311400114
   Park CC, 2001, J IMMUNOL, V167, P1644, DOI 10.4049/jimmunol.167.3.1644
   Park S, 2007, CELL MOL IMMUNOL, V4, P329
   Pratesi C, 2006, CANCER IMMUNOL IMMUN, V55, P23, DOI 10.1007/s00262-005-0688-z
   Qi Tao, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P754
   Qiu MT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050887
   Saenz-Lopez P, 2010, HUM IMMUNOL, V71, P309, DOI 10.1016/j.humimm.2009.11.010
   Sobti RC, 2008, ONCOL RES, V17, P159, DOI 10.3727/096504008785114156
   Srivastava S, 2010, CURR MED CHEM, V17, P3353, DOI 10.2174/092986710793176348
   Taheri M, 2012, Prague Med Rep, V113, P217
   Thong-Ngam D, 2006, WORLD J GASTROENTERO, V12, P4473, DOI 10.3748/wjg.v12.i28.4473
   Tschoeke SK, 2006, CRIT CARE MED, V34, P1225, DOI 10.1097/01.CCM.0000208356.05575.16
   Tsuboi K, 2004, CANCER LETT, V205, P207, DOI 10.1016/j.canlet.2003.10.010
   Vairaktaris E, 2007, ANTICANCER RES, V27, P4011
   Wei YS, 2007, ACTA ONCOL, V46, P1090, DOI 10.1080/02841860701373595
   Xia DJ, 2004, CANCER BIOTHER RADIO, V19, P322, DOI 10.1089/1084978041424990
   Yang Hong-ling, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P1006
NR 47
TC 8
Z9 11
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 16
PY 2013
VL 8
IS 9
AR UNSP e73671
DI 10.1371/journal.pone.0073671
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 219GJ
UT WOS:000324494000043
PM 24066061
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, PY
   Gao, ZH
   Jiang, ZH
   Li, XX
   Jiang, BF
   Xie, SY
AF Wang, Ping-Yu
   Gao, Zong-Hua
   Jiang, Zhong-Hua
   Li, Xin-Xin
   Jiang, Bao-Fa
   Xie, Shu-Yang
TI The Associations of Single Nucleotide Polymorphisms in miR-146a,
   miR-196a and miR-499 with Breast Cancer Susceptibility
SO PLOS ONE
LA English
DT Article
ID MICRORNA-RELATED GENES; HEPATOCELLULAR-CARCINOMA; CHINESE POPULATION;
   RISK; METAANALYSIS; VARIANT; EXPRESSION; RS2910164; BIAS; SNP
AB Background: Previous studies have investigated the association between single nucleotide polymorphisms (SNPs) located in microRNAs (miRNAs) and breast cancer susceptibility; however, because of their limited statistical power, many discrepancies are revealed in these studies. The meta-analysis presented here aimed to identify and characterize the roles of miRNA SNPs in breast cancer risk, and evaluate the associations of polymorphisms in miR-146a rs2910164, miR-196a rs11614913 and miR-499 rs3746444 with breast cancer susceptibility, respectively.
   Methodology/Principal Findings: The PubMed and Embases databases were searched updated to 31st December, 2012. The complete data of polymorphisms in miR-146a rs2910164, miR-196a rs11614913 and miR-499 rs3746444 from casecontrol studies for breast cancer were analyzed by odds ratios (ORs) with 95% confidence intervals (CIs) to reveal the associations of SNPs in miRNAs with breast cancer susceptibility. Totally, six studies for rs2910164 in miR-146a, involving 4225 cases and 4469 controls; eight studies for rs11614913 in miR-196a, involving 4110 cases and 5100 controls; and three studies of rs3746444 in miR-499, involving 2588 cases and 3260 controls, were investigated in the meta-analysis. The rs11614913 (TT+CT) genotype of miR-196a2 was revealed to be associated with a decreased breast cancer susceptibility compared with the CC genotypes (OR=0.906, 95% CI: 0.825-0.995, P=0.039); however, no significant associations were observed between rs2910164 in miR-146a (or rs3746444 in miR-499) and breast cancer susceptibility.
   Conclusions: This meta-analysis demonstrates the compelling evidence that the rs11614913 CC genotype in miR-196a2 increases breast cancer risk, which provides useful information for the early diagnosis and prevention of breast cancer.
C1 [Wang, Ping-Yu; Gao, Zong-Hua; Li, Xin-Xin; Xie, Shu-Yang] Binzhou Med Univ, Dept Epidemiol, Yantai, Shandong, Peoples R China.
   [Wang, Ping-Yu; Jiang, Bao-Fa] Shandong Univ, Dept Epidemiol, Sch Publ Hlth, Jinan, Shandong, Peoples R China.
   [Jiang, Zhong-Hua] Yantai Tradit Chinese Med Sci Hosp, Dept Imaging, Yantai, Shandong, Peoples R China.
RP Jiang, BF (reprint author), Shandong Univ, Dept Epidemiol, Sch Publ Hlth, Jinan, Shandong, Peoples R China.
EM bjiang@sdu.edu.cn; shuyangxie@aliyun.com
FU Program for New Century Excellent Talents in University [NCET-10-0919];
   National Natural Science Foundation of China [81141114, 81200601]
FX This study was partly supported by the Program for New Century Excellent
   Talents in University (NCET-10-0919), and National Natural Science
   Foundation of China (No. 81141114, 81200601). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. No additional external funding was
   received for this study.
CR Akkiz H, 2011, GENE, V486, P104, DOI 10.1016/j.gene.2011.07.006
   Alshatwi AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030049
   Bartels CL, 2009, CLIN CHEM, V55, P623, DOI 10.1373/clinchem.2008.112805
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Carthew RW, 2006, CURR OPIN GENET DEV, V16, P203, DOI 10.1016/j.gde.2006.02.012
   Catucci I, 2010, HUM MUTAT, V31, pE1052, DOI 10.1002/humu.21141
   Chen P, 2012, MOL BIOL REP, V39, P10433, DOI 10.1007/s11033-012-1922-3
   Chu H, 2011, PLOS ONE, V6
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Gao LB, 2011, BREAST CANCER RES TR, V125, P571, DOI 10.1007/s10549-010-0993-x
   Greenland S, 2001, Biostatistics, V2, P463, DOI 10.1093/biostatistics/2.4.463
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hoffman AE, 2009, CANCER RES, V69, P5970, DOI 10.1158/0008-5472.CAN-09-0236
   Hu ZB, 2009, HUM MUTAT, V30, P79, DOI 10.1002/humu.20837
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105
   Jazdzewski K, 2009, P NATL ACAD SCI USA, V106, P1502, DOI 10.1073/pnas.0812591106
   Jedlinski DJ, 2011, TWIN RES HUM GENET, V14, P417, DOI 10.1375/twin.14.5.417
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Li XD, 2010, PATHOLOGY, V42, P669, DOI 10.3109/00313025.2010.522175
   Lian H, 2012, PLOS ONE, V7, DOI DOI 10.1371/J0URNAL.P0NE.0031615
   Lin J, 2010, CARCINOGENESIS, V31, P1805, DOI 10.1093/carcin/bgq168
   Linhares JJ, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-119
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Min KT, 2012, MOL CARCINOGEN, V51, pE65, DOI 10.1002/mc.21849
   Pastrello C, 2010, CARCINOGENESIS, V31, P2124, DOI 10.1093/carcin/bgq184
   Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605
   Qiu LX, 2011, CYTOKINE, V56, P589, DOI 10.1016/j.cyto.2011.08.019
   Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392
   Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867
   Garcia AS, 2011, J INVEST ALLERG CLIN, V21, P1
   Shen J, 2008, CARCINOGENESIS, V29, P1963, DOI 10.1093/carcin/bgn172
   Smith RA, 2012, CANCER GENOM PROTEOM, V9, P115
   Vandenbroucke JP, 2009, GAC SANIT, V23, P158, DOI 10.1016/j.gaceta.2008.12.001
   Vinci S, 2011, CLIN CHEM LAB MED, V49, P2073, DOI 10.1515/CCLM.2011.708
   Wang F, 2012, MOL BIOL REP, V39, P269, DOI 10.1007/s11033-011-0735-0
   Wang JB, 2012, MUTAGENESIS, V27, P779, DOI 10.1093/mutage/ges052
   Wang J, 2012, MOL BIOL REP, V39, P4571, DOI 10.1007/s11033-011-1247-7
   Wang PY, 2012, EXP THER MED, V3, P324, DOI 10.3892/etm.2011.399
   Xiang Y, 2012, MOL BIOL REP, V39, P7019, DOI 10.1007/s11033-012-1532-0
   Ye YQ, 2008, CANCER PREV RES, V1, P460, DOI 10.1158/1940-6207.CAPR-08-0135
   Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444
   Zhang LN, 2011, P NATL ACAD SCI USA, V108, P13653, DOI 10.1073/pnas.1103360108
   Zhang M, 2012, EUR J CANCER CARE, V21, P274, DOI 10.1111/j.1365-2354.2011.01308.x
   Zhong SL, 2013, MOL BIOL REP, V40, P3181, DOI 10.1007/s11033-012-2392-3
NR 48
TC 21
Z9 23
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 9
PY 2013
VL 8
IS 9
AR e70656
DI 10.1371/journal.pone.0070656
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 244QV
UT WOS:000326405300002
PM 24039706
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, W
   Li, JL
   He, XF
   Li, AP
   Cai, YL
   Xu, N
   Sun, SM
   Wu, BY
AF Wang, Wei
   Li, Jia-Lin
   He, Xiao-Feng
   Li, An-Ping
   Cai, Yong-Lin
   Xu, Na
   Sun, Shu-Mei
   Wu, Bing-Yi
TI Association between the RAD51 135 G > C Polymorphism and Risk of Cancer:
   A Meta-Analysis of 19,068 Cases and 22,630 Controls
SO PLOS ONE
LA English
DT Article
ID DNA-REPAIR GENES; SINGLE-NUCLEOTIDE POLYMORPHISMS; MODIFIES
   BREAST-CANCER; SQUAMOUS-CELL CARCINOMA; HOMOLOGOUS RECOMBINATION;
   5'-UNTRANSLATED REGION; 135G-GREATER-THAN-C POLYMORPHISM; CANDIDATE
   GENES; NECK-CANCER; BRCA2
AB Background: RAD51 135G>C can modify promoter activity and the penetrance of BRCA1/2 mutations, which plays vital roles in the etiology of various cancer. To date, previous published data on the association between RAD51 135G>C polymorphism and cancer risk remained controversial. Recent meta-analysis only analyzed RAD51 135G>C polymorphism with breast cancer risk, but the results were also inconsistent.
   Methods: A meta-analysis based on 39 case-control studies was performed to investigate the association between cancer susceptibility and RAD51 135G>C. Odds ratios (OR) with 95% confidence intervals (CIs) were used to assess the association in different inheritance models. Heterogeneity among studies was tested and sensitivity analysis was applied.
   Results: Overall, no significant association was found between RAD51 135G>C polymorphism and cancer susceptibility in any genetic model. In further stratified analysis, significantly elevated breast cancer risk was observed in BRCA2 mutation carriers (recessive model: OR = 4.88, 95% CI = 1.10-21.67; additive model: OR = 4.92, 95% CI = 1.11-21.83).
   Conclusions: This meta-analysis suggests that RAD51 variant 135C homozygote is associated with elevated breast cancer risk among BRCA2 mutation carriers. Moreover, our work also points out the importance of new studies for RAD51 135G>C association in acute myeloid leukemia, especially in Caucasians, where at least some of the covariates responsible for heterogeneity could be controlled, to obtain a more conclusive understanding about the function of the RAD51 135G>C polymorphism in cancer development.
C1 [Wang, Wei; Li, An-Ping] Shanxi Zhendong Pharmaceut Co Ltd, Changzhi, Shanxi Province, Peoples R China.
   [Wang, Wei; Wu, Bing-Yi] Southern Med Univ, Res Ctr Clin Med, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China.
   [Li, Jia-Lin] Putuo Dist Cent Hosp, Dept Radiol, Shanghai, Peoples R China.
   [He, Xiao-Feng] Changzhi Med Coll, Informat Sect, Peace Hosp, Changzhi, Shanxi Province, Peoples R China.
   [Cai, Yong-Lin] Wuzhou Red Cross Hosp, Cent Lab, Wuzhou, Guangxi Provinc, Peoples R China.
   [Xu, Na] Southern Med Univ, Dept Hematol, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China.
   [Sun, Shu-Mei] Southern Med Univ, Dept Infect Management, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China.
RP Wu, BY (reprint author), Southern Med Univ, Res Ctr Clin Med, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China.
EM wubingyi66@126.com
FU Multiple Organ Failure Project-Guangdong 211 Project Foundation
FX This research is granted by Multiple Organ Failure Project-Guangdong 211
   Project Foundation. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Andreassen CN, 2002, RADIOTHER ONCOL, V64, P131, DOI 10.1016/S0167-8140(02)00154-8
   Antoniou AC, 2007, AM J HUM GENET, V81, P1186, DOI 10.1086/522611
   Au WW, 2007, INT J HYG ENVIR HEAL, V210, P671, DOI 10.1016/j.ijheh.2006.10.003
   Auranen A, 2005, INT J CANCER, V117, P611, DOI 10.1002/ijc.21047
   Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhatla D, 2008, LEUKEMIA, V22, P265, DOI 10.1038/sj.leu.2405000
   Blasiak J, 2003, ACTA BIOCHIM POL, V50, P249
   BLOT WJ, 1988, CANCER RES, V48, P3282
   Brooks J, 2008, CANCER EPIDEM BIOMAR, V17, P1016, DOI 10.1158/1055-9965.EPI-08-0065
   Chang TW, 2006, BREAST, V15, P754, DOI 10.1016/j.breast.2006.03.008
   Chanock S, 2001, DIS MARKERS, V17, P89, DOI 10.1155/2001/858760
   Cohen SM, 2000, SCAND J UROL NEPHROL, V34, P105, DOI 10.1080/00365590050509869
   Costa S, 2007, BREAST CANCER RES TR, V103, P209, DOI 10.1007/s10549-006-9364-z
   Davey SG, 1997, LANCET, V350, P1182, DOI DOI 10.1016/S0140-6736(05)63833-0
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dhillon VS, 2011, UROL ONCOL-SEMIN ORI, V29, P641, DOI 10.1016/j.urolonc.2009.08.013
   DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192
   Dufloth RM, 2005, GENET MOL RES, V4, P771
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Figueroa JD, 2007, CARCINOGENESIS, V28, P1788, DOI 10.1093/carcin/bgm132
   Gao LB, 2011, BREAST CANCER RES TR, V125, P827, DOI 10.1007/s10549-010-0995-8
   Gil J, 2012, MOL BIOL REP, V39, P527, DOI 10.1007/s11033-011-0767-5
   Hamdy MS, 2011, J INVEST MED, V59, P1124, DOI 10.2310/JIM.0b013e3182281da3
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hu JJ, 2002, TOXICOL APPL PHARM, V185, P64, DOI 10.1006/taap.2002.9518
   Hu Rui, 2008, Sichuan Da Xue Xue Bao Yi Xue Ban, V39, P973
   Hughes DJ, 2008, FAM CANCER, V7, P233, DOI 10.1007/s10689-008-9181-0
   Jakubowska A, 2003, CANCER EPIDEM BIOMAR, V12, P457
   Jakubowska A, 2007, CANCER EPIDEM BIOMAR, V16, P270, DOI 10.1158/1055-9965.EPI-06-0562
   Jakubowska A, 2009, EUR J CANCER, V45, P837, DOI 10.1016/j.ejca.2008.10.021
   Jara L, 2007, CANCER GENET CYTOGEN, V178, P65, DOI 10.1016/j.cancergencyto.2007.05.024
   Jara L, 2010, BREAST CANCER RES TR, V122, P813, DOI 10.1007/s10549-009-0709-2
   Kadouri L, 2004, BRIT J CANCER, V90, P2002, DOI 10.1038/sj.bjc.6601837
   Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798
   Kim PM, 2001, NUCLEIC ACIDS RES, V29, P4352, DOI 10.1093/nar/29.21.4352
   Kotnisa Sarin R, 2005, J BIOSCIENCE, V93, P102
   Krupa R, 2011, MOL BIOL REP, V38, P1163, DOI 10.1007/s11033-010-0214-z
   Krupa R, 2011, MOL BIOL REP, V38, P2849, DOI 10.1007/s11033-010-0430-6
   Krupa R, 2009, EXP MOL PATHOL, V87, P32, DOI 10.1016/j.yexmp.2009.04.005
   Kuschel B, 2002, HUM MOL GENET, V11, P1399, DOI 10.1093/hmg/11.12.1399
   Lee KM, 2005, CLIN CANCER RES, V11, P4620, DOI 10.1158/1078-0432.CCR-04-2534
   Levy-Lahad E, 2001, P NATL ACAD SCI USA, V98, P3232, DOI 10.1073/pnas.051624098
   Liu L, 2011, LEUKEMIA RES, V35, P1020, DOI 10.1016/j.leukres.2011.01.014
   Lo T, 2003, DNA REPAIR, V2, P1015, DOI 10.1016/S1568-7864(03)00097-1
   Lu JC, 2007, CARCINOGENESIS, V28, P988, DOI 10.1093/carcin/bgl225
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mendoza J, 2013, BRIT J CANCER, V109, P68, DOI 10.1038/bjc.2013.303
   Suela SP, 2010, BREAST CANCER RES TR, V119, P87, DOI 10.1007/s10549-009-0316-2
   Pasaje CFA, 2011, J MED VIROL, V83, P1892, DOI 10.1002/jmv.22122
   Persson I, 2000, J STEROID BIOCHEM, V74, P357, DOI 10.1016/S0960-0760(00)00113-8
   Pharoah PDP, 2007, PLOS GENET, V3, P401, DOI 10.1371/journal.pgen.0030042
   Pooley KA, 2008, CANCER EPIDEM BIOMAR, V17, P3482, DOI 10.1158/1055-9965.EPI-08-0594
   Poplawski T, 2006, MUTAT RES-FUND MOL M, V601, P83, DOI 10.1016/j.mrfmmm.2006.06.002
   Qiu DM, 2005, J EPIDEMIOL, V15, pS157, DOI 10.2188/jea.15.S157
   Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098
   Rollinson S, 2007, LEUKEMIA RES, V31, P169, DOI 10.1016/j.leukres.2006.05.028
   Romanowicz H, 2010, POL J PATHOL, V61, P206
   Romanowicz-Makowska H., 2006, Experimental Oncology, V28, P156
   Romanowicz-Makowska Hanna, 2006, Pol Merkur Lekarski, V21, P55
   Romanowicz-Makowska Hanna, 2005, Polish Journal of Pathology, V56, P161
   Romanowicz-Makowska H, 2012, J OBSTET GYNAECOL RE, V38, P918, DOI 10.1111/j.1447-0756.2011.01811.x
   Romanowicz-Makowska H, 2011, TOHOKU J EXP MED, V224, P201, DOI 10.1620/tjem.224.201
   Scully C, 2000, ORAL ONCOL, V36, P256, DOI 10.1016/S1368-8375(00)00007-5
   Seedhouse C, 2004, CLIN CANCER RES, V10, P2675, DOI 10.1158/1078-0432.CCR-03-0372
   SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239
   Sliwinski T, 2005, BREAST CANCER RES TR, V94, P105, DOI 10.1007/s10549-005-0672-5
   Sliwinski T, 2010, EXP MOL PATHOL, V89, P358, DOI 10.1016/j.yexmp.2010.08.005
   Smilenov LB, 2006, CANCER LETT, V240, P17, DOI 10.1016/j.canlet.2005.08.015
   Smolarz B, 2011, POL J PATHOL, V62, P157
   Sobti RC, 2012, DNA CELL BIOL, V31, P199, DOI 10.1089/dna.2011.1283
   Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004
   Sun HM, 2011, BREAST CANCER RES TR, V125, P157, DOI 10.1007/s10549-010-0922-z
   Synowiec E, 2008, MUTAT RES-FUND MOL M, V648, P65, DOI 10.1016/j.mrfmmm.2008.09.014
   TAKAHASHI E, 1994, GENOMICS, V19, P376, DOI 10.1006/geno.1994.1074
   Tarasov V A, 2006, Dokl Biol Sci, V406, P66, DOI 10.1134/S0012496606010182
   Thacker J, 2005, CANCER LETT, V219, P125, DOI 10.1016/j.canlet.2004.08.018
   Visapaa JP, 2004, GUT, V53, P871, DOI 10.1136/gut.2003.018994
   Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859
   Voso MT, 2007, ANN ONCOL, V18, P1523, DOI 10.1093/annonc/mdm191
   Wang LE, 2004, CANCER RES, V64, P5560, DOI 10.1158/0008-5472.CAN-03-2181
   Wang WW, 2001, CANCER EPIDEM BIOMAR, V10, P955
   Wang ZW, 2010, BREAST CANCER RES TR, V124, P765, DOI 10.1007/s10549-010-0885-0
   Webb PM, 2005, CANCER EPIDEM BIOMAR, V14, P319, DOI 10.1158/1055-9965.EPI-04-0335
   Wei QY, 2000, J NATL CANCER I, V92, P1764
   Werbrouck J, 2008, MUTAT RES-GEN TOX EN, V656, P74, DOI 10.1016/j.mrgentox.2008.07.013
   Wick W, 1996, ONCOGENE, V12, P973
   Wisniewska-Jarosinska Maria, 2009, Pol Merkur Lekarski, V26, P455
   Yu KD, 2011, BREAST CANCER RES TR, V126, P365, DOI 10.1007/s10549-010-0937-5
   Zeljic K, 2014, ORAL DIS, V20, P416, DOI 10.1111/odi.12144
   Zhang Zhan-Qiang, 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V17, P523
   Zhou GW, 2011, BREAST CANCER RES TR, V125, P529, DOI 10.1007/s10549-010-1031-8
NR 92
TC 11
Z9 11
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 9
PY 2013
VL 8
IS 9
AR e75153
DI 10.1371/journal.pone.0075153
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 244QV
UT WOS:000326405300200
PM 24040396
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Goto, A
   Goto, M
   Noda, M
   Tsugane, S
AF Goto, Atsushi
   Goto, Maki
   Noda, Mitsuhiko
   Tsugane, Shoichiro
TI Incidence of Type 2 Diabetes in Japan: A Systematic Review and
   Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID MIDDLE-AGED JAPANESE; IMPAIRED FASTING GLUCOSE; LIFE-STYLE INTERVENTION;
   RISK-FACTORS; PLASMA-GLUCOSE; CIGARETTE-SMOKING; INSULIN-RESPONSE;
   UNITED-STATES; GREEN TEA; MELLITUS
AB Background: The definition of incident type 2 diabetes varies across studies; hence, the actual incidence of type 2 diabetes in Japan is unclear. Here, we reviewed the various definitions of incident type 2 diabetes used in previous epidemiologic studies and estimated the diabetes incidence rate in Japan.
   Methods: We searched for related literature in the MEDLINE, EMBASE, and Ichushi databases through September 2012. Two reviewers selected studies that evaluated incident type 2 diabetes in the Japanese population.
   Results: From 1824 relevant articles, we included 33 studies with 386,803 participants. The follow-up period ranged from 2.3 to 14 years and the studies were initiated between 1980 and 2003. The random-effects model indicated that the pooled incidence rate of diabetes was 8.8 (95% confidence interval, 7.4-10.4) per 1000 person-years. We observed a high degree of heterogeneity in the results (I-2 = 99.2%; p < 0.001), with incidence rates ranging from 2.3 to 52.6 per 1000 person-years. Three studies based their definition of incident type 2 diabetes on self-reports only, 10 on laboratory data only, and 20 on self-reports and laboratory data. Compared with studies defining diabetes using laboratory data (n = 30; pooled incidence rate = 9.6; 95% confidence interval = 8.3-11.1), studies based on self-reports alone tended to show a lower incidence rate (n = 3; pooled incidence rate = 4.0; 95% confidence interval = 3.2-5.0; p for interaction < 0.001). However, stratified analyses could not entirely explain the heterogeneity in the results.
   Conclusions: Our systematic review and meta-analysis indicated the presence of a high degree of heterogeneity, which suggests that there is a considerable amount of uncertainty regarding the incidence of type 2 diabetes in Japan. They also suggested that laboratory data may be important for the accurate estimation of the incidence of type 2 diabetes.
C1 [Goto, Atsushi; Goto, Maki; Noda, Mitsuhiko] Natl Ctr Global Hlth & Med, Dept Diabet Res, Diabet Res Ctr, Tokyo, Japan.
   [Tsugane, Shoichiro] Natl Canc Ctr, Epidemiol & Prevent Div, Res Ctr Canc Prevent & Screening, Tokyo 104, Japan.
RP Noda, M (reprint author), Natl Ctr Global Hlth & Med, Dept Diabet Res, Diabet Res Ctr, Tokyo, Japan.
EM mnoda@hosp.ncgm.go.jp
RI Tsugane, Shoichiro/A-2424-2015
OI Tsugane, Shoichiro/0000-0003-4105-2774; Goto,
   Atsushi/0000-0003-0669-654X; NODA, Mitsuhiko/0000-0003-0413-4631
FU Ministry of Education, Culture, Sports, Science and Technology; Ministry
   of Health, Labour and Welfare of Japan [H22-019, H25-016]
FX This work was based on the Program to Improve Preventive Medicine by
   Analysis of Cohort Data Linked to Medical Records supported by Funds for
   integrated promotion of social system reform and research and
   development, from the Ministry of Education, Culture, Sports, Science
   and Technology. This work was also funded by Health Sciences Research
   Grants (Comprehensive Research on Life-Style Related Diseases including
   Cardiovascular Diseases and Diabetes Mellitus H22-019 and H25-016) from
   the Ministry of Health, Labour and Welfare of Japan. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Akiyama T., 2002, Journal of the Japan Diabetes Society, V45, P791
   Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI [10.2337/dc10-S062, 10.2337/dc11-S062, 10.2337/dc10-s062]
   Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI 10.2337/dc13-S067
   Arase Y, 2009, J GASTROENTEROL, V44, P1064, DOI 10.1007/s00535-009-0091-1
   Beckles Gloria L., 2011, Morbidity and Mortality Weekly Report, V60, P90
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chan JCN, 2009, JAMA-J AM MED ASSOC, V301, P2129, DOI 10.1001/jama.2009.726
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Cugati S, 2007, MED J AUSTRALIA, V186, P131
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Doi Y, 2013, DIABETES CARE, V36, P98, DOI 10.2337/dc12-0166
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Folsom AR, 2000, ARCH INTERN MED, V160, P2117, DOI 10.1001/archinte.160.14.2117
   Fujita M, 2009, EXP BIOL MED, V234, P750, DOI 10.3181/0810-RM-292
   Fukagawa K, 1998, J JAPAN SOC STUDY OB, V4, P38
   Fukui M, 2011, DIABETES RES CLIN PR, V94, pE15, DOI 10.1016/j.diabres.2011.07.006
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   Harbord RM, 2008, STATA J, V8, P493, DOI 10.1177/1536867X0800800403
   Hayashino Y, 2011, DIABETIC MED, V28, P805, DOI 10.1111/j.1464-5491.2011.03239.x
   Heianza Y, 2011, LANCET, V378, P147, DOI 10.1016/S0140-6736(11)60472-8
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hoelzel W, 2004, CLIN CHEM, V50, P166, DOI 10.1373/clinchem.2003.024802
   Inoue K, 2007, DIABETES RES CLIN PR, V77, P451, DOI 10.1016/j.diabres.2007.01.024
   International Expert C, 2009, DIABETES CARE, V32, P1327
   Ishida Sakurako, 2004, Journal of the Japan Diabetes Society, V47, P707
   Iso H, 2006, ANN INTERN MED, V144, P554, DOI 10.7326/0003-4819-144-8-200604180-00005
   Ito C, 1996, DIABETES RES CLIN PR, V34, pS7, DOI 10.1016/S0168-8227(96)90002-9
   KADOWAKI T, 1984, DIABETOLOGIA, V26, P44
   Kameda W, 2005, METABOLISM, V54, P669, DOI 10.1016/j.metabol.2004.12.011
   Kato M, 2009, J ATHEROSCLER THROMB, V16, P857
   Kato M, 2009, ENDOCR J, V56, P459, DOI 10.1507/endocrj.K09E-003
   Kawahara T, 2008, DIABETES CARE, V31, P1949, DOI 10.2337/dc07-2272
   Kawakami N, 1999, DIABETES CARE, V22, P1071, DOI 10.2337/diacare.22.7.1071
   Kawazu S, 1998, J JAPAN DIAB SOC S2, V2, pA53
   Kosaka K, 2005, DIABETES RES CLIN PR, V67, P152, DOI 10.1016/j.diabres.2004.06.010
   Kurotani K, 2013, BRIT J NUTR, V109, P709, DOI 10.1017/S0007114512001705
   Kuzuya T, 1999, J JPN DIAB SOC, V42, P385
   Li YY, 2012, DIABETES-METAB RES, V28, P349, DOI 10.1002/dmrr.2277
   MAEGAWA H, 1992, Journal of the Japan Diabetes Society, V35, P241
   Gonzalez ELM, 2009, J EPIDEMIOL COMMUN H, V63, P332, DOI 10.1136/jech.2008.080382
   Matsumoto Kazunari, 2005, Journal of the Japan Diabetes Society, V48, P849
   Ministry of Health, 1997, NAT DIAB SURV
   Ministry of Health Labour and Welfare, 2002, NAT DIAB SURV
   Ministry of Health Labour and Welfare, 2012, 2 HLTH JAP 21 PROJ
   Ministry of Health Labour and Welfare Japan, 2007, NAT HLTH NUTR SURV
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Muraki I, 2010, DIABETOLOGIA, V53, P481, DOI 10.1007/s00125-009-1616-0
   Nagaya T, 2010, INT J EPIDEMIOL, V39, P215, DOI 10.1093/ije/dyp229
   Nakanishi N, 2004, DIABETES CARE, V27, P1427, DOI 10.2337/diacare.27.6.1427
   Nakanishi N, 2000, J HLTH WELFARE STAT, V47, P28
   Nakano A, 1996, FUKUSHIMA J MED SCI, V46, P39
   Noda M, 2010, ENDOCR J, V57, P629, DOI 10.1507/endocrj.K10E-010
   Nomura K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036309
   Oba S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0017061
   Oba S, 2010, BRIT J NUTR, V103, P453, DOI 10.1017/S0007114509991966
   Ogihara T, 2008, HYPERTENSION, V51, P393, DOI 10.1161/HYPERTENSIONAHA.107.098475
   Ohnishi H, 2006, DIABETES CARE, V29, P1989, DOI 10.2337/dc06-0950
   Okada Kyoko, 2010, Fukuoka Acta Medica, V101, P215
   RIMM EB, 1995, BRIT MED J, V310, P555, DOI 10.1136/bmj.310.6979.555
   Sairenchi T, 2004, AM J EPIDEMIOL, V160, P158, DOI 10.1093/aje/kwh183
   Saito T, 2011, ARCH INTERN MED, V171, P1352, DOI 10.1001/archinternmed.2011.275
   Sakane N, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-40
   Sakurai M, 2012, METABOLISM, V61, P47, DOI 10.1016/j.metabol.2011.05.015
   Sanada H, 2012, INTERNAL MED, V51, P1821, DOI 10.2169/internalmedicine.51.7410
   Sato KK, 2012, J EPIDEMIOL COMMUN H, V66, P507, DOI 10.1136/jech.2010.109777
   Satoh M, 2006, J PREV MED, V419, P48
   Sawada SS, 2010, DIABETES CARE, V33, P1353, DOI 10.2337/dc09-1654
   Seino Y, 2010, J DIABETES INVEST, V1, P1, DOI 10.1111/j.2040-1124.2010.00005.x
   Seki A, 2002, ACTA MED OKAYAMA, V56, P255
   Sohma Mitsuhiro, 2007, Journal of the Japan Diabetes Society, V50, P297
   Takahashi Kaoru, 2006, Kobe Journal of Medical Sciences, V52, P171
   Takahashi Masaki, 2001, Journal of the Japan Diabetes Society, V44, P745
   Takashina S, 1996, NOUSON NO KENKOU HUK, V65, P11
   Tanabe N, 2009, JPN J CARDIOVASC DIS, V44, P152
   Tanabe N, 2009, INTERNAL MED, V48, P401, DOI 10.2169/internalmedicine.48.1325
   Taniguchi Y, 2001, J HYPERTENS, V19, P1209, DOI 10.1097/00004872-200107000-00005
   Thompson SG, 2008, SYSTEMATIC REV HLTH, P157
   Toshihiro M, 2008, DIABETIC MED, V25, P1211, DOI 10.1111/j.1464-5491.2008.02566.x
   Totsuka K, 2011, DIABETES RES CLIN PR, V94, pE72, DOI 10.1016/j.diabres.2011.08.015
   ULM K, 1990, AM J EPIDEMIOL, V131, P373, DOI 10.1093/oxfordjournals.aje.a115507
   Villegas R, 2006, INT J EPIDEMIOL, V35, P1553, DOI 10.1093/ije/dyl209
   Wada K, 2009, J CLIN EPIDEMIOL, V62, P306, DOI 10.1016/j.jclinepi.2008.04.006
   Waki K, 2005, DIABETIC MED, V22, P323, DOI 10.1111/j.1464-5491.2004.01403.x
   Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029
   WHO, 2011, WORLD REPORT ON DISABILITY, P1
   Yatsuya H, 2011, EPMA J, V2, P65, DOI 10.1007/s13167-011-0071-4
   Yoshinaga H, 1999, DIABETES RES CLIN PR, V44, P129, DOI 10.1016/S0168-8227(99)00019-4
NR 88
TC 26
Z9 26
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 6
PY 2013
VL 8
IS 9
AR UNSP e74699
DI 10.1371/journal.pone.0074699
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 224BO
UT WOS:000324856500094
PM 24040326
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Lu, Y
   Tian, N
   Yin, J
   Shi, YH
   Huang, ZP
AF Lu, Yan
   Tian, Nong
   Yin, Jie
   Shi, Yuhua
   Huang, Zhenping
TI Association between Sleep Duration and Cancer Risk: A Meta-Analysis of
   Prospective Cohort Studies
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; POSTMENOPAUSAL WOMEN; COLORECTAL-CANCER; CHINESE WOMEN;
   OHSAKI COHORT; MORTALITY; SINGAPORE; QUALITY; OBESITY; ADULTS
AB Background: Sleep duration has been shown to play an important role in the development of cancer. However, the results have been inconsistent. A meta-analysis with prospective cohort studies was performed to clarify the association between short or long sleep duration and cancer risk.
   Methods: PubMed and Embase databases were searched for eligible publications. Pooled relative risk (RR) with 95% confidence interval (CI) was calculated using random-or fixed-model.
   Results: A total of 10 prospective studies (8392 incident cases and 555678 participants) were included in the meta-analysis. Neither short nor long sleep duration was statistically associated with increased risk of cancer (short sleep duration: RR=1.05, 95% CI=0.90-1.24, p=0.523; long sleep duration: RR=0.92, 95% CI=0.76-1.12, p=0.415). In the subgroup by cancer type, long sleep duration was positively associated with colorectal cancer (RR=1.29, 95% CI=1.09-1.52, p=0.003).
   Conclusion: The present meta-analysis suggested that neither short nor long sleep duration was significantly associated with risk of cancer, although long sleep duration increased risk of with colorectal cancer. Large-scale well-design prospective studies are required to be conducted to further investigate the observed association.
C1 [Lu, Yan; Tian, Nong; Yin, Jie; Shi, Yuhua; Huang, Zhenping] Nanjing Univ, Jinling Hosp, Dept Ophthalmol, Nanjing 210008, Jiangsu, Peoples R China.
RP Huang, ZP (reprint author), Nanjing Univ, Jinling Hosp, Dept Ophthalmol, Nanjing 210008, Jiangsu, Peoples R China.
EM huangzhenping1963@163.com
CR Aeschbach D, 2003, J CLIN ENDOCR METAB, V88, P26, DOI 10.1210/jc.2002-020827
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186
   Cappuccio FP, 2008, SLEEP, V31, P619, DOI 10.1093/sleep/31.5.619
   Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007
   Cappuccio FP, 2010, SLEEP, V33, P585, DOI 10.1093/sleep/33.5.585
   Cappuccio FP, 2010, DIABETES CARE, V33, P414, DOI 10.2337/dc09-1124
   Chen XL, 2008, OBESITY, V16, P265, DOI 10.1038/oby.2007.63
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gallicchio L, 2009, J SLEEP RES, V18, P148, DOI 10.1111/j.1365-2869.2008.00732.x
   Girschik J, 2013, AM J EPIDEMIOL, V177, P316, DOI 10.1093/aje/kws422
   Guo XF, 2013, SLEEP MED, V14, P324, DOI 10.1016/j.sleep.2012.12.001
   Jiao L, 2013, BRIT J CANCER, V108, P213, DOI 10.1038/bjc.2012.561
   Kakizaki M, 2008, BRIT J CANCER, V99, P1502, DOI 10.1038/sj.bjc.6604684
   Kakizaki M, 2008, BRIT J CANCER, V99, P176, DOI 10.1038/sj.bjc.6604425
   Luo JH, 2013, AM J EPIDEMIOL, V177, P42, DOI 10.1093/aje/kws193
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   McElroy JA, 2006, J SLEEP RES, V15, P241, DOI 10.1111/j.1365-2869.2006.00523.x
   Pinheiro SP, 2006, CANCER RES, V66, P5521, DOI 10.1158/0008-5472.CAN-05-4652
   Spiegel K, 2005, J APPL PHYSIOL, V99, P2008, DOI 10.1152/japplphysiol.00660.2005
   Sturgeon SR, 2012, CANCER CAUSE CONTROL, V23, P547, DOI 10.1007/s10552-012-9912-2
   Verkasalo PK, 2005, CANCER RES, V65, P9595, DOI 10.1158/0008-5472.CAN-05-2138
   Wang QJ, 2012, HYPERTENS RES, V35, P1012, DOI 10.1038/hr.2012.91
   Weiderpass E, 2012, INT J ONCOL, V40, P21, DOI 10.3892/ijo.2011.1194
   Wu AH, 2008, CARCINOGENESIS, V29, P1244, DOI 10.1093/carcin/bgn100
   Wu AH, 2013, INT J CANCER, V132, P891, DOI 10.1002/ijc.27653
   Zhang XH, 2013, SLEEP, V36, P681, DOI 10.5665/sleep.2626
NR 28
TC 16
Z9 16
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 4
PY 2013
VL 8
IS 9
AR e74723
DI 10.1371/journal.pone.0074723
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 219OE
UT WOS:000324515600153
PM 24023959
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Toyama, T
   Furuichi, K
   Ninomiya, T
   Shimizu, M
   Hara, A
   Iwata, Y
   Kaneko, S
   Wada, T
AF Toyama, Tadashi
   Furuichi, Kengo
   Ninomiya, Toshiharu
   Shimizu, Miho
   Hara, Akinori
   Iwata, Yasunori
   Kaneko, Shuichi
   Wada, Takashi
TI The Impacts of Albuminuria and Low eGFR on the Risk of Cardiovascular
   Death, All-Cause Mortality, and Renal Events in Diabetic Patients:
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; URINARY ALBUMIN;
   PREDICT MORTALITY; END-POINTS; FOLLOW-UP; MICROALBUMINURIA; MELLITUS;
   NEPHROPATHY; PROGRESSION
AB Background: Precise effects of albuminuria and low estimated glomerular filtration rate (eGFR) on cardiovascular mortality, all-cause mortality, and renal events in diabetic patients are uncertain.
   Materials and Methods: A systematic review was conducted of the literature through MEDLINE, EMBASE, and CINHAL from 1950 to December 2010. Cohort studies of diabetic patients providing adjusted relative risk (RR) of albuminuria and eGFR for risks of cardiovascular mortality, all-cause mortality, and renal events were selected. Two reviewers screened abstracts and full papers of each study using standardized protocol.
   Results: We identified 31 studies fulfilling the criteria from 6546 abstracts. With regard to the risk of cardiovascular mortality, microalbuminuria (RR 1.76, 95% CI 1.38-2.25) and macroalbuminuria (RR 2.96 95% CI 2.44-3.60) were significant risk factors compared to normoalbuminuria. The same trends were seen in microalbuminuria (RR 1.60, 95% CI 1.42-1.81), and macroalbuminuria (RR 2.64, 95% CI 2.13-3.27) for the risk of all-cause mortality, and also in microalbuminuria (RR 3.21, 95% CI 2.05-5.02) and macroalbuminuria (RR 11.63, 95% CI 5.68-23.83) for the risk of renal events. The magnitudes of relative risks associated with low eGFR along with albuminuria were almost equal to multiplying each risk rate of low eGFR and albuminuria. No significant factors were found by investigating potential sources of heterogeneity using subgroup analysis.
   Conclusions: High albuminuria and low eGFR are relevant risk factors in diabetic patients. Albuminuria and low eGFR may be independent of each other. To evaluate the effects of low eGFR, intervention, or race, appropriately designed studies are needed.
C1 [Toyama, Tadashi; Furuichi, Kengo; Shimizu, Miho; Hara, Akinori; Iwata, Yasunori; Wada, Takashi] Kanazawa Univ, Div Nephrol, Kanazawa, Ishikawa, Japan.
   [Ninomiya, Toshiharu] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka, Japan.
   [Kaneko, Shuichi] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Dis Control & Homeostasis, Kanazawa, Ishikawa, Japan.
   [Wada, Takashi] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Lab Med, Kanazawa, Ishikawa, Japan.
RP Wada, T (reprint author), Kanazawa Univ, Div Nephrol, Kanazawa, Ishikawa, Japan.
EM twada@m-kanazawa.jp
FU Ministry of Health, Labor and Welfare of Japan
FX This study was supported in part by a Grant-in-Aid for Diabetic
   Nephropathy Research, from the Ministry of Health, Labor and Welfare of
   Japan. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. No
   additional external funding received for this study.
CR Adler AI, 2003, KIDNEY INT, V63, P225, DOI 10.1046/j.1523-1755.2003.00712.x
   Basevi V, 2011, DIABETES CARE, V34, P1887
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beilin J, 1996, AUST NZ J MED, V26, P519, DOI 10.1111/j.1445-5994.1996.tb00598.x
   Brinkman JW, 2004, KIDNEY INT, V66, pS69, DOI 10.1111/j.1523-1755.2004.09219.x
   Bruno G, 2007, DIABETOLOGIA, V50, P941, DOI 10.1007/s00125-007-0616-1
   Bruno G, 2003, DIABETES CARE, V26, P2353, DOI 10.2337/diacare.26.8.2353
   Casiglia E, 2000, EUR J EPIDEMIOL, V16, P677, DOI 10.1023/A:1007673123716
   Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X
   de Boer IH, 2009, DIABETES CARE, V32, P1833, DOI 10.2337/dc09-0191
   de Grauw WJC, 2001, DIABETIC MED, V18, P139, DOI 10.1046/j.1464-5491.2001.00423.x
   Dinneen SF, 1997, ARCH INTERN MED, V157, P1413, DOI 10.1001/archinte.157.13.1413
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Florkowski CM, 2001, DIABETES RES CLIN PR, V53, P113, DOI 10.1016/S0168-8227(01)00246-7
   Fox CS, 2012, LANCET, V380, P1662, DOI 10.1016/S0140-6736(12)61350-6
   GALL MA, 1995, DIABETES, V44, P1303, DOI 10.2337/diabetes.44.11.1303
   Gansevoort RT, 2011, KIDNEY INT, V80, P93, DOI 10.1038/ki.2010.531
   Gerstein HC, 2001, JAMA-J AM MED ASSOC, V286, P421, DOI 10.1001/jama.286.4.421
   Grauslund J, 2010, J DIABETES COMPLICAT, V24, P223, DOI 10.1016/j.jdiacomp.2009.05.003
   Groop PH, 2009, DIABETES, V58, P1651, DOI 10.2337/db08-1543
   Gross JL, 2005, DIABETES CARE, V28, P164, DOI 10.2337/diacare.28.1.164
   Haller H, 2011, NEW ENGL J MED, V364, P907, DOI 10.1056/NEJMoa1007994
   Hanninen J, 1999, DIABETES RES CLIN PR, V43, P121, DOI 10.1016/S0168-8227(98)00131-4
   Jager A, 1999, ARTERIOSCL THROM VAS, V19, P617, DOI 10.1161/01.ATV.19.3.617
   Jude EB, 2002, QJM-INT J MED, V95, P371, DOI 10.1093/qjmed/95.6.371
   Levey AS, 2011, KIDNEY INT, V80, P17, DOI 10.1038/ki.2010.483
   Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x
   Levin A, 2007, AM J KIDNEY DIS, V49, pS10, DOI 10.1053/j.ajkd.2006.12.004
   LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004
   Luk AOY, 2008, DIABETES CARE, V31, P2357, DOI 10.2337/dc08-0971
   Mattock MB, 1998, DIABETES, V47, P1786, DOI 10.2337/diabetes.47.11.1786
   Miller WG, 2009, CLIN CHEM, V55, P24, DOI 10.1373/clinchem.2008.106567
   Molitch ME, 2010, DIABETES CARE, V33, P1536, DOI 10.2337/dc09-1098
   NEIL A, 1993, DIABETES CARE, V16, P996, DOI 10.2337/diacare.16.7.996
   Ninomiya T, 2009, J AM SOC NEPHROL, V20, P1813, DOI 10.1681/ASN.2008121270
   O'Hare AM, 2010, ARCH INTERN MED, V170, P930, DOI 10.1001/archinternmed.2010.129
   OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K
   Ostgren CJ, 2002, DIABETES CARE, V25, P1297, DOI 10.2337/diacare.25.8.1297
   Pohl MA, 2005, J AM SOC NEPHROL, V16, P3027, DOI 10.1681/ASN.2004110919
   Retnakaran R, 2006, DIABETES, V55, P1832, DOI 10.2337/db05-1620
   Rossing P, 1996, BRIT MED J, V313, P779
   Roy M, 2006, DIABETIC MED, V23, P698, DOI 10.1111/j.1464-5491.2006.01901.x
   Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977
   So WY, 2006, DIABETES CARE, V29, P2046, DOI 10.2337/dc06-0248
   Soriguer F, 2012, DIABETOLOGIA, V55, P88, DOI 10.1007/s00125-011-2336-9
   Stehouwer CDA, 2002, DIABETES, V51, P1157, DOI 10.2337/diabetes.51.4.1157
   Sviridov D, 2006, CLIN CHEM, V52, P389, DOI 10.1373/clinchem.2005.057323
   Tong PCY, 2007, DIABETIC MED, V24, P741, DOI 10.1111/j.1464-5491.2007.02145.x
   Valmadrid CT, 2000, ARCH INTERN MED, V160, P1093, DOI 10.1001/archinte.160.8.1093
   van der Velde M, 2011, KIDNEY INT, V79, P1341, DOI 10.1038/ki.2010.536
   Vlek ALM, 2008, J INTERN MED, V264, P351, DOI 10.1111/j.1365-2796.2008.01970.x
   Wada T, 2012, CLIN EXP NEPHROL, V16, P96, DOI 10.1007/s10157-011-0508-z
   Witte EC, 2009, J AM SOC NEPHROL, V20, P436, DOI 10.1681/ASN.2008030292
   Xu J, 2005, BR J DIABETES VASC D, V5, P334
   Yang SH, 2010, NEW ENGL J MED, V362, P2425
   Yokoyama H, 2008, DIABETIC MED, V25, P1426, DOI 10.1111/j.1464-5491.2008.02592.x
   Yuyun MF, 2003, DIABETIC MED, V20, P277, DOI 10.1046/j.1464-5491.2003.00940.x
NR 59
TC 31
Z9 35
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 30
PY 2013
VL 8
IS 8
AR e71810
DI 10.1371/journal.pone.0071810
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 211BX
UT WOS:000323880200006
PM 24147148
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhou, H
   Zeng, C
   Wei, Y
   Zhou, J
   Yao, WX
AF Zhou, Hang
   Zeng, Chao
   Wei, Yang
   Zhou, Jin
   Yao, Wenxiu
TI Duration of Chemotherapy for Small Cell Lung Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID MAINTENANCE CHEMOTHERAPY; RANDOMIZED-TRIAL; INDUCTION CHEMOTHERAPY;
   PHASE-III; THERAPY; CISPLATIN; RADIOTHERAPY; CARCINOMA; ETOPOSIDE; NO
AB Background: Maintenance chemotherapy is widely provided to patients with small cell lung cancer (SCLC). However, the benefits of maintenance chemotherapy compared with observation are a subject of debate.
   Methodology and Principal Findings: To identify relevant literature, we systematically searched the Medline, Embase, and Cochrane Central Register of Controlled Trials databases. Eligible trials included patients with SCLC who either received maintenance chemotherapy (administered according to a continuous or switch strategy) or underwent observation. The primary outcome was 1-year mortality, and secondary outcomes were 2-year mortality, overall survival (OS), and progression-free survival (PFS). Of the 665 studies found in our search, we identified 14 relevant trials, which together reported data on 1806 patients with SCLC. When compared with observation, maintenance chemotherapy had no effect on 1-year mortality (odds ratio [OR]: 0.88; 95% confidence interval [CI]: 0.66-1.19; P = 0.414), 2-year mortality (OR: 0.82; 95% CI: 0.57-1.19; P = 0.302), OS (hazard ratio [HR]: 0.87; 95% CI: 0.71-1.06; P = 0.172), or PFS (HR: 0.87; 95% CI: 0.62-1.22; P = 0.432). However, subgroup analyses indicated that maintenance chemotherapy was associated with significantly longer PFS than observation in patients with extensive SCLC (HR, 0.72; 95% CI: 0.58-0.89; P = 0.003). Additionally, patients who were managed using the continuous strategy of maintenance chemotherapy appeared to be at a disadvantage in terms of PFS compared with patients who only underwent observation (HR, 1.27; 95% CI: 1.04-1.54; P = 0.018).
   Conclusions/Significance: Maintenance chemotherapy failed to improve survival outcomes in patients with SCLC. However, a significant advantage in terms of PFS was observed for maintenance chemotherapy in patients with extensive disease. Additionally, our results suggest that the continuous strategy is inferior to observation; its clinical value needs to be investigated in additional trials.
C1 [Zhou, Hang; Wei, Yang; Zhou, Jin; Yao, Wenxiu] Sichuan Canc Hosp, Dept Chemotherapy, Chengdu, Peoples R China.
   [Zeng, Chao] Third Peoples Hosp Chengdu, Dept Gastroenterol, Chengdu, Peoples R China.
RP Yao, WX (reprint author), Sichuan Canc Hosp, Dept Chemotherapy, Chengdu, Peoples R China.
EM yaowenxiu_2011@126.com
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beith JM, 1996, EUR J CANCER, V32A, P438, DOI 10.1016/0959-8049(95)00608-7
   BLEEHEN NM, 1989, BRIT J CANCER, V59, P584
   BYRNE MJ, 1989, BRIT J CANCER, V60, P413, DOI 10.1038/bjc.1989.296
   CULLEN M, 1986, CANCER CHEMOTH PHARM, V17, P157, DOI 10.1007/BF00306746
   Deeks JJ, 2008, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   ETTINGER DS, 1990, J CLIN ONCOL, V8, P230, DOI 10.1200/JCO.1990.8.2.230
   GIACCONE G, 1993, J CLIN ONCOL, V11, P1230, DOI 10.1200/JCO.1993.11.7.1230
   Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   Han JY, 2008, J THORAC ONCOL, V3, P1039, DOI 10.1097/JTO.0b013e3181834f8e
   Hanna NH, 2002, ANN ONCOL, V13, P95, DOI 10.1093/annonc/mdf014
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   JOHNSON DH, 1993, J CLIN ONCOL, V11, P1223, DOI 10.1200/JCO.1993.11.7.1223
   LEBEAU B, 1992, EUR RESPIR J, V5, P286
   Minna JD, 1989, CANCER PRINCIPLES PR, P591
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   PATEL AM, 1993, MAYO CLIN PROC, V68, P475, DOI 10.1016/S0025-6196(12)60197-9
   Payne DG, 1989, LUNG CANCER, V5, P135
   PEREZ CA, 1984, J CLIN ONCOL, V2, P1200, DOI 10.1200/JCO.1984.2.11.1200
   Rossi A, 2010, LUNG CANCER, V70, P119, DOI 10.1016/j.lungcan.2010.02.001
   Schiller JH, 2001, J CLIN ONCOL, V19, P2114, DOI 10.1200/JCO.2001.19.8.2114
   Sculier JP, 1996, J CLIN ONCOL, V14, P2337, DOI 10.1200/JCO.1996.14.8.2337
   SEIFTER EJ, 1988, SEMIN ONCOL, V15, P278
NR 28
TC 9
Z9 9
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 30
PY 2013
VL 8
IS 8
AR e73805
DI 10.1371/journal.pone.0073805
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 211BX
UT WOS:000323880200089
PM 24023692
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xu, HR
   Xu, ZF
   Sun, YL
   Han, JJ
   Li, ZJ
AF Xu, Hui-Rong
   Xu, Zhong-Fa
   Sun, Yan-Lai
   Han, Jian-Jun
   Li, Zeng-Jun
TI The-842G/C Polymorphisms of PIN1 Contributes to Cancer Risk: A
   Meta-Analysis of 10 Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID PROLYL ISOMERASE PIN1; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER;
   BETA-CATENIN; CYCLIN D1; SIGNALING PATHWAY; PROSTATE-CANCER;
   CLINICAL-TRIALS; DECREASED RISK; GENE
AB Background: Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) plays an important role in cancer development. The relationship between PIN1 -842G/C (rs2233678) polymorphism and cancer risk was inconclusive according to published literature.
   Methodology/Principal Findings: A literature search, up to February 2013, was carried out using PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) database. A total of 10 case-control studies including 4619 cases and 4661 controls contributed to the quantitative analysis. Odds ratio (OR) and 95% confidence intervals (95% CI) were used to assess the strength of association. Overall, individuals with the variant CG (OR = 0.728, 95% CI: 0.585,0.906; P-heterogeneity < 0.01) and CG/CC (OR = 0.731, 95% CI: 0.602,0.888; P-heterogeneity < 0.01) genotypes were associated with a significantly reduced cancer risk compared with those with wild GG genotype. Sub-group analysis revealed that the variant CG (OR = 0.635, 95% CI: 0.548,0.735; P-heterogeneity = 0.240) and CG/CC (OR = 0.645, 95% CI: 0.559,0.744, Pheterogeneity = 0.258) genotypes still showed an reduced risk of cancer in Asians; while no significant association was observed in Caucasians (CG vs. GG: OR = 0.926, 95% CI: 0.572,1.499, P-heterogeneity < 0.01; CG/CC vs. GG: OR = 0.892, 95% CI: 0.589,1.353; P-heterogeneity < 0.01). Furthermore, sensitivity analysis confirmed the stability of results. Begg's funnel plot and Egger's test did not reveal any publication bias.
   Conclusions: This meta-analysis suggests that the PIN1 -842G/C polymorphism is associated with a significantly reduced risk of cancer, especially in Asian populations.
C1 [Xu, Hui-Rong; Xu, Zhong-Fa; Sun, Yan-Lai; Han, Jian-Jun; Li, Zeng-Jun] Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Gen Surg, Jinan, Shandong, Peoples R China.
RP Li, ZJ (reprint author), Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Gen Surg, Jinan, Shandong, Peoples R China.
EM zj_licn@163.com
FU Natural Science Foundation of Shandong Province, China [2011HW069]
FX This work is supported by Natural Science Foundation of Shandong
   Province, China (2011HW069). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Arboleda MJ, 2003, CANCER RES, V63, P196
   Atkinson GP, 2009, ONCOGENE, V28, P3735, DOI 10.1038/onc.2009.232
   Ayala G, 2003, CANCER RES, V63, P6244
   Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   [曹文平 Cao Wenping], 2012, [江苏医药, Jiangsu Medical Journal], V38, P1067
   Chen SY, 2006, MOL CELL BIOL, V26, P929, DOI 10.1128/MCB.26.3.929-939.2006
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dick DM, 2011, ANNU REV CLIN PSYCHO, V7, P383, DOI 10.1146/annurev-clinpsy-032210-104518
   Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fukuchi M, 2006, INT J ONCOL, V29, P329
   Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862
   Guo J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030585
   Han CH, 2010, BREAST CANCER RES TR, V122, P243, DOI 10.1007/s10549-009-0682-9
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   Lam PB, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-91
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Li HY, 2006, ONCOL REP, V16, P491
   Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099
   Lu JC, 2011, HUM MUTAT, V32, P1299, DOI 10.1002/humu.21574
   Lu JC, 2009, CARCINOGENESIS, V30, P1717, DOI 10.1093/carcin/bgp171
   Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6
   Lu KP, 2004, TRENDS BIOCHEM SCI, V29, P200, DOI 10.1016/j.tibs.2004.02.002
   Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5
   Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261
   Lu Y, 2012, MOL BIOL REP
   Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007
   Miyashita H, 2003, ONCOL REP, V10, P455
   Naidu R, 2011, SCAND J CLIN LAB INV, V71, P500, DOI 10.3109/00365513.2011.590223
   Nakashima M, 2004, J PATHOL, V202, P446, DOI 10.1002/path.1534
   Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002
   Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793
   Segat L, 2007, GASTROENTEROLOGY, V132, P2618, DOI 10.1053/j.gastro.2007.04.037
   Wang F, 2012, MOL BIOL REP, V39, P269, DOI 10.1007/s11033-011-0735-0
   WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105
   Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459
   Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110
   Yeh ES, 2007, NAT REV CANCER, V7, P381, DOI 10.1038/nrc2107
   Yeh ES, 2006, J BIOL CHEM, V281, P241, DOI 10.1074/jbc.M505770200
   You YH, 2013, MOL BIOL REP, V40, P829, DOI 10.1007/s11033-012-2122-x
   Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120
   Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116
NR 44
TC 2
Z9 2
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 27
PY 2013
VL 8
IS 8
AR e71516
DI 10.1371/journal.pone.0071516
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 210FR
UT WOS:000323815200015
PM 24013949
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Huang, GH
   Cai, SX
   Wang, W
   Zhang, Q
   Liu, AH
AF Huang, Guohua
   Cai, Shaoxi
   Wang, Wei
   Zhang, Qing
   Liu, Aihua
TI Association between XRCC1 and XRCC3 Polymorphisms with Lung Cancer Risk:
   A Meta-Analysis from Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID DNA-REPAIR GENES; BASE-EXCISION-REPAIR; SINGLE NUCLEOTIDE POLYMORPHISMS;
   PLATINUM-BASED CHEMOTHERAPY; STRAND BREAK REPAIR; XPD LYS751GLN;
   ENVIRONMENT INTERACTIONS; THR241MET POLYMORPHISM; T-77C POLYMORPHISM;
   CHINESE POPULATION
AB Many studies have reported the association of X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln, Arg194Trp, Arg280His, -77T>C, and X-ray repair cross-complementing group 3 (XRCC3) T241M polymorphisms with lung cancer risk, but the results remained controversial. Hence, we performed a meta-analysis to investigate the association between lung cancer risk and XRCC1 Arg399Gln (14,156 cases and 16,667 controls from 41 studies), Arg194Trp (7,426 cases and 9,603 controls from 23 studies), Arg280His (6,211 cases and 6,763 controls from 16 studies), -77T>C (2,487 cases and 2,576 controls from 5 studies), and XRCC3 T241M (8,560 cases and 11,557 controls from 19 studies) in different inheritance models. We found that -77T>C polymorphism was associated with increased lung cancer risk (dominant model: odds ration [OR] = 1.45, 95% confidence interval [CI] = 1.27-1.66, recessive model: OR = 1.73, 95% CI = 1.14-2.62, additive model: OR = 1.91, 95% CI = 1.24-1.94) when all the eligible studies were pooled into the meta-analysis. In the stratified and sensitive analyses, significantly decreased lung cancer risk was observed in overall analysis (dominant model: OR = 0.83, 95% CI = 0.78-0.89; recessive model: OR = 0.90, 95% CI = 0.81-1.00; additive model: OR = 0.82, 95% CI = 0.74-0.92), Caucasians (dominant model: OR = 0.82, 95% CI = 0.76-0.87; recessive model: OR = 0.89, 95% CI = 0.80-0.99; additive model: OR = 0.81, 95% CI = 0.73-0.91), and hospital-based controls (dominant model: OR = 0.81, 95% CI = 0.76-0.88; recessive model: OR = 0.89, 95% CI = 0.79-1.00; additive model: OR = 0.80, 95% CI = 0.71-0.90) for XRCC3 T241M. In conclusion, this meta-analysis indicates that XRCC1 -77T>C shows an increased lung cancer risk and XRCC3 T241M polymorphism is associated with decreased lung cancer risk, especially in Caucasians.
C1 [Huang, Guohua; Cai, Shaoxi; Liu, Aihua] Southern Med Univ, Nanfang Hosp, Dept Respirat, Guangzhou, Guangdong, Peoples R China.
   [Wang, Wei] Second Peoples Hosp Zhuhai, Dept Gastroenterol, Zhuhai, Peoples R China.
   [Wang, Wei] Beijing Zhendong Guangming Pharmaceut Res Inst Co, Beijing, Peoples R China.
   [Wang, Wei] Shanxi Zhendong Pharmaceut Co Ltd, Changzhi, Peoples R China.
   [Zhang, Qing] Southern Med Univ, Nanfang Hosp, Dept Pharm, Guangzhou, Guangdong, Peoples R China.
RP Huang, GH (reprint author), Southern Med Univ, Nanfang Hosp, Dept Respirat, Guangzhou, Guangdong, Peoples R China.
EM sashimihuang@sina.cn; huxiliuaihua@sina.cn
CR Aquilina G, 2001, J CELL PHYSIOL, V187, P145, DOI 10.1002/jcp.1067
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68
   Chan EC, 2005, CANCER GENET CYTOGEN, V162, P10, DOI 10.1016/j.cancergencyto.2005.03.008
   Chang JS, 2009, CARCINOGENESIS, V30, P78, DOI 10.1093/carcin/bgn261
   Chen SQ, 2002, CARCINOGENESIS, V23, P1321, DOI 10.1093/CARCIN/23.8.1321
   Cote ML, 2009, CARCINOGENESIS, V30, P626, DOI 10.1093/carcin/bgp033
   Dai LP, 2012, MOL BIOL REP, V39, P9535, DOI 10.1007/s11033-012-1818-2
   Davey SG, 1997, LANCET, V350, P1182, DOI DOI 10.1016/S0140-6736(05)63833-0
   David-Beabes GL, 2001, LUNG CANCER-J IASLC, V34, P333, DOI 10.1016/S0169-5002(01)00256-2
   David-Beabes GL, 2001, CANCER EPIDEM BIOMAR, V10, P911
   De Ruyck K, 2005, INT J RADIAT ONCOL, V62, P1140, DOI 10.1016/j.ijrobp.2004.12.027
   De Ruyck K, 2007, MUTAT RES-GEN TOX EN, V631, P101, DOI 10.1016/j.mrgentox.2007.03.010
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Divine KK, 2001, MUTAT RES-DNA REPAIR, V461, P273, DOI 10.1016/S0921-8777(00)00059-8
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513
   Hao B, 2006, ONCOGENE, V25, P3613, DOI 10.1038/sj.onc.1209355
   Harms C, 2004, ENVIRON MOL MUTAGEN, V44, P74, DOI 10.1002/em.20031
   Higgins JP, 2008, COCHRANE HDB SYSTEMA
   Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232
   Hsieh WC, 2009, JPN J CLIN ONCOL, V39, P81, DOI 10.1093/jjco/hyn130
   Hu ZB, 2005, PHARMACOGENET GENOM, V15, P457, DOI 10.1097/01.fpc.0000167329.85163.0d
   Huang Meng, 2011, Wei Sheng Yan Jiu, V40, P187
   Hung RJ, 2005, JNCI-J NATL CANCER I, V97, P567, DOI 10.1093/jnci/dji101
   Improta G, 2008, ANTICANCER RES, V28, P2941
   Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159
   Ito H, 2004, CARCINOGENESIS, V25, P1395, DOI 10.1093/carcin/bgh153
   Jacobsen NR, 2004, CANCER LETT, V213, P67, DOI 10.1016/j.canlet.2004.04.033
   Janik J, 2011, MUTAT RES-FUND MOL M, V709-10, P21, DOI 10.1016/j.mrfmmm.2011.02.009
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kim IS, 2010, J THORAC ONCOL, V5, P1912, DOI 10.1097/JTO.0b013e3181f46708
   Kiyohara C, 2006, LUNG CANCER, V54, P267, DOI 10.1016/j.lungcan.2006.08.009
   Kiyohara C, 2012, J THORAC ONCOL, V7, P954, DOI 10.1097/JTO.0b013e31824de30f
   Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x
   Kuschel B, 2002, HUM MOL GENET, V11, P1399, DOI 10.1093/hmg/11.12.1399
   Landi S, 2006, CANCER RES, V66, P11062, DOI 10.1158/0008-5472.CAN-06-1039
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Li Mingchuan, 2005, Zhongguo Fei Ai Za Zhi, V8, P431, DOI 10.3779/j.issn.1009-3419.2005.05.16
   Li MC, 2008, LUNG CANCER, V62, P145, DOI 10.1016/j.lungcan.2008.03.002
   Li Z, 2011, ARCH MED RES, V42, P226, DOI 10.1016/j.arcmed.2011.04.005
   Liu G, 2004, CANCER-AM CANCER SOC, V101, P2802, DOI 10.1002/cncr.20716
   Liu L, 2013, MOL CARCINOGEN, V52, P923, DOI 10.1002/mc.21942
   Liu L, 2011, LUNG CANCER, V73, P110, DOI 10.1016/j.lungcan.2010.11.004
   Liu L, 2011, BREAST CANCER RES TR, V125, P479, DOI 10.1007/s10549-010-0959-z
   Lopez-Cima MF, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-162
   Lu AL, 2001, CELL BIOCHEM BIOPHYS, V35, P141, DOI 10.1385/CBB:35:2:141
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Matullo G, 2006, CARCINOGENESIS, V27, P997, DOI 10.1093/carcin/bgi280
   Matullo G, 2001, CARCINOGENESIS, V22, P1437, DOI 10.1093/carcin/22.9.1437
   Misra RR, 2003, CANCER LETT, V191, P171, DOI 10.1016/S0304-3835(02)00638-9
   Mohrenweiser HW, 2003, MUTAT RES-FUND MOL M, V526, P93, DOI 10.1016/S0027-5107(03)00049-6
   Osawa K, 2010, ASIAN PAC J CANCER P, V11, P1181
   Pachouri SS, 2007, DNA CELL BIOL, V26, P186, DOI 10.1089/dna.2006.9999
   Park JY, 2002, CANCER EPIDEM BIOMAR, V11, P23
   Popanda O, 2004, CARCINOGENESIS, V25, P2433, DOI 10.1093/carcin/bgh264
   Qian BY, 2011, LUNG CANCER, V73, P138, DOI 10.1016/j.lungcan.2010.11.018
   Ratnasinghe D, 2001, CANCER EPIDEM BIOMAR, V10, P119
   Ratnasinghe DL, 2003, ANTICANCER RES, V23, P627
   Rodriguez V, 2000, AM J IND MED, V38, P644, DOI 10.1002/1097-0274(200012)38:6<644::AID-AJIM5>3.0.CO;2-M
   Ryk C, 2006, LUNG CANCER, V54, P285, DOI 10.1016/j.lungcan.2006.08.004
   Sak SC, 2005, CLIN CANCER RES, V11, P6205, DOI 10.1158/1078-0432.CCR-05-0045
   Schneider J, 2005, INT J MOL MED, V16, P709
   Shen HB, 2003, INT J CANCER, V107, P84, DOI 10.1002/ijc.11346
   Shen M, 2005, ANTICANCER RES, V25, P537
   Shen MR, 1998, CANCER RES, V58, P604
   Shin A, 2008, ASIAN PAC J CANCER P, V9, P501
   Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851
   Spitz MR, 2003, CANCER EPIDEM BIOMAR, V12, P689
   Sreeja L, 2008, J CANCER RES CLIN, V134, P645, DOI 10.1007/s00432-007-0328-4
   Stoehlmacher J, 2001, ANTICANCER RES, V21, P3075
   Sun HM, 2010, CANCER SCI, V101, P1777, DOI 10.1111/j.1349-7006.2010.01608.x
   Tanaka Y, 2010, CANCER-AM CANCER SOC, V116, P896, DOI 10.1002/cncr.24850
   Tardon A, 2005, CANCER CAUSE CONTROL, V16, P389, DOI 10.1007/s10552-004-5026-9
   TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354
   Thacker J, 2004, DNA REPAIR, V3, P1081, DOI 10.1016/j.dnarep.2004.04.012
   Tomescu D, 2001, CARCINOGENESIS, V22, P403, DOI 10.1093/carcin/22.3.403
   Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530
   Vineis P, 2005, JNCI-J NATL CANCER I, V101, P24
   Vispe S, 2000, P NATL ACAD SCI USA, V97, P9886, DOI 10.1073/pnas.170280397
   Vogel U, 2004, BIOCHEM GENET, V42, P453, DOI 10.1023/B:BIGI.0000043957.03420.7e
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691
   Wang N, 2013, WEI SHENG YAN JIU, V41, P251
   Wang YD, 2009, CANCER LETT, V285, P134, DOI 10.1016/j.canlet.2009.05.005
   Wang YF, 2003, CANCER, V98, P1701, DOI 10.1002/cncr.11692
   WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X
   Wei QY, 1996, CANCER RES, V56, P4103
   Wei QY, 2000, J NATL CANCER I, V92, P1764
   Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154
   Xi T, 2004, GENOMICS, V83, P970, DOI 10.1016/j.ygeno.2003.12.016
   Xu YH, 2013, TUMOUR BIOL
   Yin J, 2013, CANCER GENET CYTOGEN, V188, P26
   Yin JY, 2007, LUNG CANCER, V56, P153, DOI 10.1016/j.lungcan.2006.12.012
   Yu Z, 1999, ENVIRON MOL MUTAGEN, V33, P3, DOI 10.1002/(SICI)1098-2280(1999)33:1<3::AID-EM2>3.0.CO;2-L
   Zhan P, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-1
   Zhang XM, 2005, CANCER RES, V65, P722
   Zhang Zeng-li, 2007, Zhonghua Jiehe He Huxi Zazhi, V30, P936
   Zhou W, 2003, CANCER EPIDEM BIOMAR, V12, P359
   Zienolddiny S, 2006, CARCINOGENESIS, V27, P560, DOI 10.1093/carcin/bgi232
NR 99
TC 13
Z9 13
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 26
PY 2013
VL 8
IS 8
AR e68457
DI 10.1371/journal.pone.0068457
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 215RU
UT WOS:000324228800003
PM 23990873
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, LY
   Wang, M
   Ma, ZB
   Yu, LX
   Zhang, Q
   Gao, DZ
   Wang, F
   Yu, ZG
AF Liu, Li-Yuan
   Wang, Meng
   Ma, Zhong-Bing
   Yu, Li-Xiang
   Zhang, Qiang
   Gao, De-Zong
   Wang, Fei
   Yu, Zhi-Gang
TI The Role of Adiponectin in Breast Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID BODY-MASS INDEX; SERUM ADIPONECTIN; INSULIN-RESISTANCE; PLASMA
   ADIPONECTIN; IN-VITRO; RISK; ASSOCIATIONS; OBESITY; LEPTIN; TYPE-2
AB Published results suggests that high adiponectin level may decrease the risk of breast cancer. However, available evidence on breast cancer is conflicting. Therefore a meta-analysis was performed to assess the association between blood adiponectin and breast cancer risk. PubMed database, Web of Science, Elsevier Science, Springer Link and bibliographies of retrieved articles were searched for epidemiological studies published up to March 2013. Meta-analysis was performed on the combined effect values (OR) as well as standardized mean difference (SMD) including 17 studies. Fixed or random effect pooled measure was selected on the basis of homogeneity test among studies. The publication bias was assessed by the Egger's regression asymmetry test and Begg's rank correlation test with Begg's funnel plot. Subgroup analyses and sensitivity analysis were also performed. A total of 13 studies involving 3578 breast cancer cases and 4363 controls contributed to the OR analysis. The high adiponectin level did not significantly affect breast cancer risk (OR=0.902, 95% CI=0.773-1.053). After excluding articles that were the key contributors to between-study heterogeneity, the OR of high adiponectin level was associated with decreased breast cancer risk (OR=0.838, 95% CI=0.744-0.943). There was a significantly association between high adiponectin level and postmenopausal breast cancer women (OR=0.752, 95% CI=0.604-0.936); and it was not associated with premenopausal breast cancer women (OR=0.895, 95% CI=0.638-1.256). The result of pooled measure on SMD was that the high adiponectin level was associated with decreased breast cancer risk (SMD= -0.348, 95% CI= -0.533-0.614) after excluding articles which were the key contributors to between-study heterogeneity. Our findings indicate that high adiponectin level might decrease the risk of postmenopausal breast cancer. More randomized clinical trials and observational studies are needed to confirm this association with underlying biological mechanisms in the future.
C1 [Liu, Li-Yuan; Wang, Meng] Shandong Univ, Inst Epidemiol, Sch Publ Hlth, Jinan 250100, Shandong, Peoples R China.
   [Liu, Li-Yuan; Ma, Zhong-Bing; Yu, Li-Xiang; Zhang, Qiang; Gao, De-Zong; Wang, Fei; Yu, Zhi-Gang] Shandong Univ, Dept Breast Dis, Hosp 2, Jinan 250100, Shandong, Peoples R China.
RP Yu, ZG (reprint author), Shandong Univ, Dept Breast Dis, Hosp 2, Jinan 250100, Shandong, Peoples R China.
EM yzg@medmail.com.cn
OI liu, liyuan/0000-0002-9862-7471
FU Ministry of Health of the People's Republic of China [07090122]
FX This study was primarily granted funding from the minister-affiliated
   hospital key project of the Ministry of Health of the People's Republic
   of China (NO: 07090122). The study sponsors played no role in any aspect
   of the study design; in the collection, analysis, and interpretation of
   data; or in the development of the manuscript.
CR Al Awadhi SA, 2012, INDIAN J MED RES, V135, P500
   Al Khaldi RM, 2011, DIS MARKERS, V30, P197, DOI 10.3233/DMA-2011-0775
   Arita Y, 2002, CIRCULATION, V105, P2893, DOI 10.1161/01.CIR.0000018622.84402.FF
   Barb D, 2007, AM J CLIN NUTR, V86, p858S, DOI 10.1093/ajcn/86.3.858S
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen DC, 2006, CANCER LETT, V237, P109, DOI 10.1016/j.canlet.2005.05.047
   Chen XP, 2011, MED ONCOL, V28, P1288, DOI 10.1007/s12032-010-9617-x
   Cust AE, 2009, BREAST CANCER RES TR, V113, P567, DOI 10.1007/s10549-008-9958-8
   Dalamaga M, 2012, ENDOCR REV, V33, P547, DOI 10.1210/er.2011-1015
   Dalamaga M, 2011, MENOPAUSE, V18, P1198, DOI 10.1097/gme.0b013e31821e21f5
   Delort L, 2012, VITAM HORM, V90, P397, DOI 10.1016/B978-0-12-398313-8.00015-4
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gaudet MM, 2010, CANCER EPIDEMIOL, V34, P580, DOI 10.1016/j.canep.2010.05.014
   Gulcelik MA, 2012, ASIAN PAC J CANCER P, V13, P395, DOI 10.7314/APJCP.2012.13.1.395
   Hancke K, 2010, BREAST CANCER RES TR, V119, P367, DOI 10.1007/s10549-009-0577-9
   Hartemink N, 2006, AM J EPIDEMIOL, V163, P1042, DOI 10.1093/aje/kwj141
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hivert MF, 2008, J CLIN ENDOCR METAB, V93, P3165, DOI 10.1210/jc.2008-0425
   Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595
   Hou WK, 2007, CHINESE MED J-PEKING, V120, P1592, DOI 10.1097/00029330-200709020-00009
   Huang Z, 1997, JAMA-J AM MED ASSOC, V278, P1407, DOI [10.1001/jama.1997.03550170037029, DOI 10.1001/JAMA.1997.03550170037029.PUBMED:9355998]
   Jarde T, 2009, ENDOCR-RELAT CANCER, V16, P1197, DOI 10.1677/ERC-09-0043
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kang JH, 2007, J KOREAN MED SCI, V22, P117, DOI 10.3346/jkms.2007.22.1.117
   Kelesidis I, 2006, BRIT J CANCER, V94, P1221, DOI 10.1038/sj.bjc.6603051
   Kim AY, 2010, MOL ENDOCRINOL, V24, P1441, DOI 10.1210/me.2009-0498
   Korner A, 2007, J CLIN ENDOCRINOL ME, V92, P1041
   Mantzoros C, 2004, J CLIN ENDOCR METAB, V89, P1102, DOI 10.1210/jc.2003-031804
   Miyatani Y, 2008, MENOPAUSE, V15, P536, DOI 10.1097/gme.0b013e31815c85ed
   Miyoshi Y, 2003, CLIN CANCER RES, V9, P5699
   Patsopoulos NA, 2008, INT J EPIDEMIOL, V37, P1148, DOI 10.1093/ije/dyn065
   Paz G, 2011, FRONT BIOSCI-LANDMRK, V16, P1634, DOI 10.2741/3810
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Shahar S, 2010, ASIAN PAC J CANCER P, V11, P61
   Shi JQ, 2004, STAT MED, V23, P3, DOI 10.1002/sim.1595
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tian YF, 2007, ENDOCR-RELAT CANCER, V14, P669, DOI 10.1677/ERC-06-0089
   Tobias A., 1999, STATA TECH B, V47
   Touvier M, 2013, AM J EPIDEMIOL, V177, P3, DOI 10.1093/aje/kws359
   TrenthamDietz A, 1997, AM J EPIDEMIOL, V145, P1011
   Tworoger SS, 2007, J CLIN ENDOCR METAB, V92, P1510, DOI 10.1210/jc.2006-1975
   Vrieling A, 2010, BREAST CANCER RES TR, V123, P641, DOI 10.1007/s10549-010-1116-4
   Waki H, 2005, ENDOCRINOLOGY, V146, P790, DOI 10.1210/en.2004-1096
   Wang Y, 2007, CELL RES, V17, P280, DOI 10.1038/cr.2007.14
   Wang Y, 2006, CANCER RES, V66, P11462, DOI 10.1158/0008-5472.CAN-06-1969
   Wells GA, 2012, NEWCASTLE OTTAWA SCA
   Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930
   Yokota T, 2000, BLOOD, V96, P1723
   Ziemke F, 2010, AM J CLIN NUTR, V91, p258S, DOI 10.3945/ajcn.2009.28449C
NR 52
TC 32
Z9 33
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 22
PY 2013
VL 8
IS 8
AR e73183
DI 10.1371/journal.pone.0073183
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 218ZA
UT WOS:000324470700059
PM 23991180
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, CB
   Mou, SH
   Pan, CQ
AF Liu, Chibo
   Mou, Sihua
   Pan, Chunqin
TI The FTO Gene rs9939609 Polymorphism Predicts Risk of Cardiovascular
   Disease: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID BODY-MASS INDEX; MYOCARDIAL-INFARCTION; COMMON VARIANT; OBESITY;
   ASSOCIATION; CHILDHOOD; EPIDEMIC; WOMEN
AB Objective: Genome-wide association studies have shown that variance in the fat mass-and obesity-associated gene (FTO) is associated with risk of obesity in Europeans and Asians. Since obesity is associated with an increased risk of cardiovascular disease (CVD), several studies have investigated the association between variant in the FTO gene and CVD risk, with inconsistent results. In this study, we performed a meta-analysis to clarify the association of rs9939609 variant (or its proxies [r(2)>0.90]) in the FTO gene with CVD risk.
   Methods: Published literature from PubMed and Embase was retrieved. Pooled odds ratios with 95% confidence intervals were calculated using the fixed- or random-effects model.
   Results: A total of 10 studies (comprising 19,153 CVD cases and 103,720 controls) were included in the meta-analysis. The results indicated that the rs9939609 variant was significantly associated with CVD risk (odds ratio = 1.18, 95% confidence interval = 1.07-1.30, p = 0.001 [Z test], I-2 = 80.6%, p<0.001 [heterogeneity]), and there was an insignificant change after adjustment for body mass index (BMI) and other conventional CVD risk factors (odds ratio = 1.16, 95% confidence interval = 1.05-1.27, p = 0.003 [Z test], I-2 = 75.4%, p<0.001 [heterogeneity]).
   Conclusions: The present meta-analysis confirmed the significant association of the rs9939609 variant in the FTO gene with CVD risk, which was independent of BMI and other conventional CVD risk factors.
C1 [Liu, Chibo; Mou, Sihua; Pan, Chunqin] Taizhou Municipal Hosp, Dept Clin Lab, Taizhou, Zhejiang, Peoples R China.
RP Liu, CB (reprint author), Taizhou Municipal Hosp, Dept Clin Lab, Taizhou, Zhejiang, Peoples R China.
EM chibo_liu@163.com
CR Ahmad T, 2010, AM HEART J, V160, P1163, DOI 10.1016/j.ahj.2010.08.002
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berzuini C, 2012, GENET EPIDEMIOL, V36, P652, DOI 10.1002/gepi.21660
   Borglykke A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050418
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Doney ASF, 2009, CIRC-CARDIOVASC GENE, V2, P255, DOI 10.1161/CIRCGENETICS.108.822320
   Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634
   Freathy RM, 2008, DIABETES, V57, P1419, DOI 10.2337/db07-1466
   He MA, 2010, ARTERIOSCL THROM VAS, V30, P327, DOI 10.1161/ATVBAHA.109.196196
   Hertel JK, 2011, DIABETES, V60, P1637, DOI 10.2337/db10-1340
   Hubacek JA, 2010, CLIN CHIM ACTA, V411, P1069, DOI 10.1016/j.cca.2010.03.037
   James WPT, 2008, INT J OBESITY, V32, pS120, DOI 10.1038/ijo.2008.247
   Kelly T, 2008, INT J OBESITY, V32, P1431, DOI 10.1038/ijo.2008.102
   Kivimaki M, 2008, EUR HEART J, V29, P2552, DOI 10.1093/eurheartj/ehn252
   Lappalainen T, 2011, NUTR METAB CARDIOVAS, V21, P691, DOI 10.1016/j.numecd.2010.01.006
   Li H, 2012, DIABETOLOGIA, V55, P981, DOI 10.1007/s00125-011-2370-7
   Luczynski W, 2012, J PHYSIOL PHARMACOL, V63, P241
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Nordestgaard BG, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001212
   Pausova Z, 2009, CIRC-CARDIOVASC GENE, V2, P260, DOI 10.1161/CIRCGENETICS.109.857359
   Peng SH, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-71
   Ramos AV, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-101
   Ranjith N, 2011, CARDIOVASC J AFR, V22, P25
   Razquin C, 2011, MOL NUTR FOOD RES, V55, P136, DOI 10.1002/mnfr.201000445
   Wang YF, 2012, INT REV PSYCHIATR, V24, P176, DOI 10.3109/09540261.2012.688195
   Willer CJ, 2009, NAT GENET, V41, P25, DOI 10.1038/ng.287
   Winter Y, 2011, OBESITY FACTS, V4, P290, DOI 10.1159/000330881
NR 27
TC 27
Z9 28
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 19
PY 2013
VL 8
IS 8
AR e71901
DI 10.1371/journal.pone.0071901
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 205ER
UT WOS:000323425700112
PM 23977173
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, RS
   Hu, XY
   Gu, WJ
   Hu, Z
   Wei, B
AF Wang, Ren-Sheng
   Hu, Xue-Ying
   Gu, Wan-Jie
   Hu, Zhen
   Wei, Bo
TI Tooth Loss and Risk of Head and Neck Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; ORAL-CANCER; CHRONIC PERIODONTITIS; PHARYNGEAL
   CANCER; INFLAMMATION; INFECTIONS; DENTITION; SMOKING; DISEASE; HYGIENE
AB Background: Observational studies suggest an association between tooth loss and risk of head and neck cancer. However, whether tooth loss is an independent risk factor for head and neck cancer still remains controversial. The aim of this study is to assess the association between tooth loss and head and neck cancer risk.
   Methods: Eligible studies were searched in PubMed and Embase databases from their inception to March 2013. A random-effects model or fixed-effects model was used to calculate the overall combined risk estimates.
   Results: Eight case-control studies and one cross-sectional study involving 5,204 patients and 5,518 controls were included in the meta-analysis. The overall combined odds ratio for tooth loss and head and neck cancer was 2.00 (95% confidence interval, 1.28-3.14). Similar results yielded both in the moderate and severe tooth loss group. Sensitivity analysis based on various exclusion criteria maintained this significance with respect to head and neck cancer individually. Little evidence of publication bias was observed.
   Conclusion: This meta-analysis suggests that tooth loss is associated with increased risk of head and neck cancer. This increase is probably independent of conventional head and neck cancer risk factors.
C1 [Wang, Ren-Sheng] Guangxi Med Univ, Dept Radiotherapy, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Hu, Xue-Ying; Hu, Zhen; Wei, Bo] Guangxi Med Univ, Sch Publ Hlth, Nanning, Guangxi, Peoples R China.
   [Gu, Wan-Jie] Guangxi Med Univ, Dept Anaesthesiol, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
RP Wei, B (reprint author), Guangxi Med Univ, Sch Publ Hlth, Nanning, Guangxi, Peoples R China.
EM doctorwei0771@hotmail.com
OI Gu, Wan-Jie/0000-0003-4923-8282
CR Abnet CC, 2005, INT J EPIDEMIOL, V34, P467, DOI 10.1093/ije/dyh375
   Albandar JM, 1999, J PERIODONTOL, V70, P13, DOI 10.1902/jop.1999.70.1.13
   Alexander J, 2000, METHODS METAANALYSIS
   Balaram P, 2002, INT J CANCER, V98, P440, DOI 10.1002/ijc.10200
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BLOT WJ, 1988, CANCER RES, V48, P3282
   BUNDGAARD T, 1995, CANCER CAUSE CONTROL, V6, P57, DOI 10.1007/BF00051681
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   DAY GL, 1993, JNCI-J NATL CANCER I, V85, P465, DOI 10.1093/jnci/85.6.465
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Divaris K, 2010, CANCER CAUSE CONTROL, V21, P567, DOI 10.1007/s10552-009-9486-9
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Garrote LF, 2001, BRIT J CANCER, V85, P46, DOI 10.1054/bjoc.2000.1825
   Gillison ML, 2004, LANCET, V363, P1488, DOI 10.1016/S0140-6736(04)16194-1
   Guha N, 2007, AM J EPIDEMIOL, V166, P1159, DOI 10.1093/aje/kwm193
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hiraki A, 2008, CANCER EPIDEM BIOMAR, V17, P1222, DOI 10.1158/1055-9965.EPI-07-2761
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016
   Lissowska J, 2003, EUR J CANCER PREV, V12, P25, DOI 10.1097/01.cej.0000043735.13672.78
   Loos BG, 2005, J PERIODONTOL, V76, P2106, DOI 10.1902/jop.2005.76.11-S.2106
   MARSHALL JR, 1992, ORAL ONCOL, V28B, P9, DOI 10.1016/0964-1955(92)90005-L
   Marur S, 2008, MAYO CLIN PROC, V83, P489, DOI 10.4065/83.4.489
   Michaud DS, 2008, LANCET ONCOL, V9, P550, DOI 10.1016/S1470-2045(08)70106-2
   Moutsopoulos NM, 2006, ANN NY ACAD SCI, V1088, P251, DOI 10.1196/annals.1366.032
   Nair J, 1996, CRIT REV TOXICOL, V26, P149, DOI 10.3109/10408449609017928
   Oringer RJ, 2002, J PERIODONTOL, V73, P835, DOI 10.1902/jop.2002.73.8.835
   Papapanou P N, 1996, Ann Periodontol, V1, P1, DOI 10.1902/annals.1996.1.1.1
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Rezende Caio Perrella de, 2008, Braz J Otorhinolaryngol, V74, P596
   Ries L. A. G., 2008, SEER CANC STAT REV 1
   Risch HA, 2003, JNCI-J NATL CANCER I, V95, P948, DOI 10.1093/jnci/95.13.948
   Rosenquist K, 2005, ACTA OTO-LARYNGOL, V125, P1327, DOI 10.1080/00016480510012273
   Schildt EB, 1998, EUR J CANCER PREV, V7, P201, DOI 10.1097/00008469-199806000-00004
   Talamini R, 2000, BRIT J CANCER, V83, P1238, DOI 10.1054/bjoc.2000.1398
   Tezal M, 2005, J PERIODONTOL, V76, P406, DOI 10.1902/jop.2005.76.3.406
   Tezal M, 2007, ARCH OTOLARYNGOL, V133, P450, DOI 10.1001/archotol.133.5.450
   Tezal M, 2009, CANCER EPIDEM BIOMAR, V18, P2406, DOI 10.1158/1055-9965.EPI-09-0334
   Tu YK, 2007, HEART, V93, P1098, DOI 10.1136/hrt.2006.097410
   van Kempen LCL, 2006, EUR J CANCER, V42, P728, DOI 10.1016/j.ejca.2006.01.004
   ZHENG TZ, 1990, CANCER CAUSE CONTROL, V1, P235, DOI 10.1007/BF00117475
NR 42
TC 17
Z9 18
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 19
PY 2013
VL 8
IS 8
AR e71122
DI 10.1371/journal.pone.0071122
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 205ER
UT WOS:000323425700017
PM 23990929
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yu, YM
   Chen, ZG
   Wang, H
   Zhang, Y
AF Yu, Yanmin
   Chen, Zenggan
   Wang, Hong
   Zhang, Yan
TI Quantitative Assessment of Common Genetic Variants on Chromosome 5p12
   and Hormone Receptor Status with Breast Cancer Risk
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; BRCA2 MUTATION CARRIERS; AFRICAN-AMERICAN
   WOMEN; SUSCEPTIBILITY LOCI; CONFER SUSCEPTIBILITY; CHINESE WOMEN;
   ALLELES; METAANALYSIS; DISEASE; EPIDEMIOLOGY
AB Several genome-wide association studies on breast cancer (BC) have reported similar findings of a new susceptibility locus, 5p12. After that, a number of studies reported that the rs10941679, rs4415084, and rs981782 polymorphism in chromosome 5p12 has been implicated in BC risk. However, the studies have yielded contradictory results. To derive a more precise estimation of the relationship, a meta-analysis of 131,983 BC cases and 200,314 controls from 24 published case-control studies was performed. Overall, significantly elevated BC risk was associated with rs10941679, rs4415084, and rs981782 risk allele when all studies were pooled into the meta-analysis. In the subgroup analysis by ethnicity, significantly increased risks were found for the rs10941679 and rs4415084 polymorphism among Caucasians and East Asians, while no significant associations were observed for the two polymorphisms in African and other ethnic populations. For 5p12-rs981782, significant associations were only detected among Caucasians. In addition, we found that rs10941679 and rs4415084 on 5p12 confer risk, exclusively for estrogen receptor (ER)-positive tumors with per-allele OR of 1.16 (95% CI: 1.11-1.21; P<10(-5)) and of 1.14 (95% CI: 1.09-1.19; P<10(-5)) respectively. Ethnicity was identified as a potential source of between-study heterogeneity. In conclusion, this meta-analysis demonstrated that common variations are a risk factor associated with increased BC susceptibility, but these associations vary in different ethnic populations.
C1 [Yu, Yanmin] Huangpu Cent Hosp Shanghai, Dept Breast Surg, Shanghai, Peoples R China.
   [Chen, Zenggan] Fudan Univ, Zhongshan Hosp, Dept Orthoped, Shanghai 200433, Peoples R China.
   [Wang, Hong] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.
   [Zhang, Yan] Huangpu Cent Hosp Shanghai, Dept Radiol, Shanghai, Peoples R China.
RP Wang, H (reprint author), Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.
EM hong_wang01@126.com; dr_yanzhang@163.com
RI Yu, Keith/K-8488-2013
CR Ahmed S, 2009, NAT GENET, V41, P585, DOI 10.1038/ng.354
   Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879
   Antoniou AC, 2002, BRIT J CANCER, V86, P76, DOI 10.1038/sj/bjc/6600008
   Antoniou AC, 2010, CANCER RES, V70, P9742, DOI 10.1158/0008-5472.CAN-10-1907
   Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107
   Barnholtz-Sloan JS, 2010, CARCINOGENESIS, V31, P1417, DOI 10.1093/carcin/bgq128
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beral V, 2002, LANCET, V360, P187
   Bhatti P, 2010, RADIAT RES, V173, P214, DOI 10.1667/RR1985.1
   Campa D, 2011, J NATL CANCER I, V103, P1252, DOI 10.1093/jnci/djr265
   Chan M, 2012, BREAST CANCER RES TR, V136, P209, DOI 10.1007/s10549-012-2234-y
   Chen W, 2012, BREAST CANCER RES TR, V136, P847, DOI 10.1007/s10549-012-2309-9
   Dai JC, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3101
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fletcher O, 2011, JNCI-J NATL CANCER I, V103, P425, DOI 10.1093/jnci/djq563
   Harlid S, 2012, BRIT J CANCER, V106, P389, DOI 10.1038/bjc.2011.461
   Hemminki K, 2006, NAT REV GENET, V7, P958, DOI 10.1038/nrg2009
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Huo DZ, 2012, CARCINOGENESIS, V33, P835, DOI 10.1093/carcin/bgs093
   Kim HC, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3158
   Li JM, 2011, BREAST CANCER RES TR, V126, P717, DOI 10.1007/s10549-010-1172-9
   Liu L, 2011, BREAST CANCER RES TR, V125, P479, DOI 10.1007/s10549-010-0959-z
   Liu XA, 2012, J HUM GENET, V57, P638, DOI 10.1038/jhg.2012.83
   Mcinerney N, 2009, BREAST CANCER RES TR, V117, P151, DOI 10.1007/s10549-008-0235-7
   McPherson K, 2000, BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Milne RL, 2011, CANCER EPIDEM BIOMAR, V20, P2222, DOI 10.1158/1055-9965.EPI-11-0569
   Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853
   Porter P, 2008, NEW ENGL J MED, V358, P213, DOI 10.1056/NEJMp0708307
   Reeves GK, 2010, JAMA-J AM MED ASSOC, V304, P426, DOI 10.1001/jama.2010.1042
   Ruiz-Narvaez EA, 2010, BREAST CANCER RES TR, V123, P525, DOI 10.1007/s10549-010-0775-5
   Stacey SN, 2008, NAT GENET, V40, P703, DOI 10.1038/ng.131
   Stacey SN, 2007, NAT GENET, V39, P865, DOI 10.1038/ng2064
   Sueta A, 2012, BREAST CANCER RES TR, V132, P711, DOI 10.1007/s10549-011-1904-5
   Teraoka SN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3057
   Thomas G, 2009, NAT GENET, V41, P579, DOI 10.1038/ng.353
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Turnbull C, 2010, NAT GENET, V42, P504, DOI 10.1038/ng.586
   Walsh T, 2006, JAMA-J AM MED ASSOC, V295, P1379, DOI 10.1001/jama.295.12.1379
   Wang H, 2013, BREAST CANCER RES TR, V137, P511, DOI 10.1007/s10549-012-2343-7
   Wang XS, 2010, HUM MOL GENET, V19, P2886, DOI 10.1093/hmg/ddq174
   Zheng W, 2013, HUM MOL GENET, V22, P2539, DOI 10.1093/hmg/ddt089
   Zheng W, 2010, J NATL CANCER I, V102, P972, DOI 10.1093/jnci/djq170
   Zheng W, 2009, CANCER EPIDEM BIOMAR, V18, P2761, DOI 10.1158/1055-9965.EPI-09-0624
NR 49
TC 2
Z9 2
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 19
PY 2013
VL 8
IS 8
AR e72154
DI 10.1371/journal.pone.0072154
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 205ER
UT WOS:000323425700141
PM 23977236
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, LS
   Qin, HJ
   Guan, X
   Zhang, K
   Liu, ZR
AF Zhang, LuShun
   Qin, HaoJie
   Guan, Xuan
   Zhang, Kui
   Liu, ZhiRong
TI The TLR9 Gene Polymorphisms and the Risk of Cancer: Evidence from a
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID TOLL-LIKE-RECEPTORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; PROMOTER
   POLYMORPHISM; SIGNALING PATHWAY; GENOTYPING ERRORS; ASSOCIATION;
   LYMPHOMA; INFECTION; DISEASE; INFLAMMATION
AB Background: Growing studies have revealed the association between polymorphisms in the Toll-like receptor 9 (TLR9) and susceptibility to cancer, however, the results remained inconsistent.
   Methodology/Principal Findings: To assess the effect of three selected SNPs (rs352140, rs5743836 and rs187084) in TLR9 on cancer, we performed a meta-analysis based on 11 case-control studies, including a total of 6,585 cancer cases and 7,506 controls. Summary odds ratios (OR) and corresponding 95% confidence intervals (CIs) for polymorphisms in TLR9 and cancer risk were estimated. Our meta-analysis indicated that rs352140 was associated with an increased cancer risk, especially in Caucasian. However, no significantly increased cancer risk was detected to be associated with rs187084 and rs5743836 either the overall or subgroup estimation.
   Conclusions: These meta-analysis results indicate that polymorphisms in TLR9 may play a role in cancer development.
C1 [Zhang, LuShun; Guan, Xuan] Cheng Du Med Coll, Dept Pathol, Chengdu, Peoples R China.
   [Qin, HaoJie] Henan Univ Sci & Technol, Sch Forens Med, Luoyang, Peoples R China.
   [Zhang, Kui] Zun Yi Med Coll, Dept Forens Med, Zunyi, Peoples R China.
   [Liu, ZhiRong] Second Peoples Hosp Chengdu, Dept Breast & Vasc Surg, Chengdu, Peoples R China.
RP Zhang, K (reprint author), Zun Yi Med Coll, Dept Forens Med, Zunyi, Peoples R China.
EM newman-zhk@163.com; liuzr1020@yahoo.com
FU Cheng Du Medical College [CYZ12-017]; Fund Project of Sichuan Provincial
   Department of Education
FX This work was supported by a grant from Cheng Du Medical College
   (CYZ12-017) and Fund Project of Sichuan Provincial Department of
   Education. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Andreakos E, 2004, IMMUNOL REV, V202, P250, DOI 10.1111/j.0105-2896.2004.00202.x
   Ashton KA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-382
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0
   Bhadri VA, 2012, LEUKEMIA LYMPHOMA, V53, P1828, DOI 10.3109/10428194.2012.661858
   Bowden J, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-41
   Carvalho A, 2012, GENES IMMUN, V13, P197, DOI 10.1038/gene.2011.59
   Carvalho A., 2011, PLOS ONE, V6, DOI DOI 10.1371/JOURNAL.PONE.0028256
   Castro FA, 2011, EUR J CANCER, V47, P1203, DOI 10.1016/j.ejca.2010.12.011
   Chang ZL, 2010, INFLAMM RES, V59, P791, DOI 10.1007/s00011-010-0208-2
   Chen KQ, 2007, INT IMMUNOPHARMACOL, V7, P1271, DOI 10.1016/j.intimp.2007.05.016
   Chen XJ, 2012, DNA CELL BIOL, V31, P766, DOI 10.1089/dna.2011.1427
   Chen Z, 2012, J RENIN-ANGIO-ALDO S, V13, P184, DOI 10.1177/1470320311427755
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Du X, 2000, EUR CYTOKINE NETW, V11, P362
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Omar EM, 2008, ONCOGENE, V27, P244, DOI 10.1038/sj.onc.1210912
   Elmaagacli AH, 2011, BONE MARROW TRANSPL, V46, P702, DOI 10.1038/bmt.2010.166
   Etokebe GE, 2009, GENET TEST MOL BIOMA, V13, P729, DOI 10.1089/gtmb.2009.0045
   Guo J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030585
   Hamann L, 2006, CLIN CHIM ACTA, V364, P303, DOI 10.1016/j.cca.2005.07.017
   Hatakeyama M, 2006, HELICOBACTER, V11, P14, DOI 10.1111/j.1478-405X.2006.00424.x
   Hold GL, 2009, EUR J CANCER PREV, V18, P117, DOI 10.1097/CEJ.0b013e3283101292
   Hosking L, 2004, EUR J HUM GENET, V12, P395, DOI 10.1038/sj.ejhg.5201164
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Junjie Xie, 2012, BMC Cancer, V12, P57, DOI 10.1186/1471-2407-12-57
   Kikuchi K, 2005, J AUTOIMMUN, V24, P347, DOI 10.1016/j.jaut.2005.03.002
   Kutikhin AG, 2011, HUM IMMUNOL, V72, P1095, DOI 10.1016/j.humimm.2011.07.307
   Lanciotti M, 2008, PEDIATR BLOOD CANCER, V50, P944, DOI 10.1002/pbc.21367
   Lange NE, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-26
   Li Z, 2011, ASS GENE POLYMORPHIS
   Mandal RK, 2012, MOL BIOL REP, V39, P7263, DOI 10.1007/s11033-012-1556-5
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Miedema KGE, 2012, LEUKEMIA, V26, P1203, DOI 10.1038/leu.2011.341
   Mitchell AA, 2003, AM J HUM GENET, V72, P598, DOI 10.1086/368203
   Mittal RD, 2012, ARCH MED RES
   Mollaki V, 2009, J HUM GENET, V54, P655, DOI 10.1038/jhg.2009.90
   Ng MTH, 2010, INFECT IMMUN, V78, P1345, DOI 10.1128/IAI.01226-09
   Nieters A, 2006, GENES IMMUN, V7, P615, DOI 10.1038/sj.gene.6364337
   Noack J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.60
   Novak N, 2007, ALLERGY, V62, P766, DOI 10.1111/j.1398-9995.2007.01358.x
   Ohara T, 2006, INT J MOL MED, V18, P59
   Pandey S, 2006, IMMUNOL CELL BIOL, V84, P333, DOI 10.1111/j.1440-1711.2006.01444.x
   Pandey S, 2011, MOL BIOL REP, V38, P4715, DOI 10.1007/s11033-010-0607-z
   Qiu MT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050887
   Roszak A, 2012, MOL BIOL REP, V39, P8425, DOI 10.1007/s11033-012-1695-8
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Zeng Hong-Mei, 2011, Zhonghua Yu Fang Yi Xue Za Zhi, V45, P588
   Zhang K, 2012, EUR J CANC
   Zhou L, 2006, ENV OCCUPATIONAL MED, P8
NR 51
TC 18
Z9 18
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 19
PY 2013
VL 8
IS 8
AR e71785
DI 10.1371/journal.pone.0071785
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 205ER
UT WOS:000323425700099
PM 23990988
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, S
   Cai, JG
   Wang, H
   Zhang, HW
   Yang, WG
AF Wu, Sheng
   Cai, Jungang
   Wang, Hong
   Zhang, Hongwei
   Yang, Weige
TI Association between 1p11-rs11249433 Polymorphism and Breast Cancer
   Susceptibility: Evidence from 15 Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMMON VARIANTS; CONFER SUSCEPTIBILITY;
   GENETIC-VARIANTS; 14Q24.1 RAD51L1; RISK ALLELES; LOCI; MUTATIONS; WOMEN;
   METAANALYSIS
AB Genome-wide association studies have identified SNP rs11249433 at chromosome 1p11 as a new breast cancer (BC) susceptibility locus in populations of European descent. Since then, the relationship between 1p11-rs11249433 and breast cancer has been reported in various ethnic groups; however, these studies have yielded inconsistent results. To investigate this inconsistency, we performed a meta-analysis of 15 studies involving a total of 90,154 cases and 137,238 controls for 1p11-rs11249433 polymorphism to evaluate its effect on genetic susceptibility for breast cancer. An overall random effects odds ratio of 1.09 (95% CI: 1.06-1.12, P< 10(-5)) was found for rs11249433-G variant. Significant results were also observed for heterozygous (OR=1.09, 95% CI: 1.05-1.12, P< 10(-5)) and homozygote (OR=1.14, 95% CI: 1.08-1.21, P<10(-5)). There was strong evidence of heterogeneity, which largely disappeared after stratification by ethnicity. After stratified by ethnicity, significant associations were found among Caucasians. However, no significant associations were detected among East Asian and African populations. In addition, we found that rs11249433 polymorphism on 1p11 confer risk, exclusively for ER-positive tumors with perallele OR of 1.13 (95% CI: 1.08-1.18; P <10(-5)) compared to ER-negative tumors of 1.01 (95% CI: 0.98-1.04; P=0.49). Similar results were also observed when stratified by PR status. Our findings demonstrated that rs11249433-G allele is a risk-conferring factor for the development of breast cancer, especially in Caucasians.
C1 [Wu, Sheng; Cai, Jungang] Fudan Univ, Dept Gen Surg, Zhongshan Hosp, Qingpu Branch, Shanghai 200433, Peoples R China.
   [Wang, Hong; Zhang, Hongwei; Yang, Weige] Fudan Univ, Dept Gen Surg, Zhongshan Hosp, Shanghai 200433, Peoples R China.
RP Wang, H (reprint author), Fudan Univ, Dept Gen Surg, Zhongshan Hosp, Shanghai 200433, Peoples R China.
EM hong_wang01@163.com; hongwei_zhang01@163.com
CR Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879
   Antoniou AC, 2011, HUM MOL GENET, V20, P3304, DOI 10.1093/hmg/ddr226
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2
   Bhatti P, 2010, RADIAT RES, V173, P214, DOI 10.1667/RR1985.1
   Campa D, 2011, J NATL CANCER I, V103, P1252, DOI 10.1093/jnci/djr265
   Chen F, 2011, HUM MOL GENET, V20, P4491, DOI 10.1093/hmg/ddr367
   Chlebowski RT, 2005, JNCI-J NATL CANCER I, V97, P439, DOI 10.1093/jnci/dji064
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609
   Figueroa JD, 2011, HUM MOL GENET, V20, P4693, DOI 10.1093/hmg/ddr368
   Fu YP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-113
   Garcia-Closas M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000054
   He CY, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3155
   Huo DZ, 2012, CARCINOGENESIS, V33, P835, DOI 10.1093/carcin/bgs093
   Hutter CM, 2011, CANCER EPIDEM BIOMAR, V20, P1950, DOI 10.1158/1055-9965.EPI-11-0524
   Jiang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021563
   Kim HC, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3158
   Li CI, 2002, CANCER EPIDEM BIOMAR, V11, P601
   Li DW, 2006, HUM MOL GENET, V15, P1995, DOI 10.1093/hmg/ddl122
   Li JM, 2011, BREAST CANCER RES TR, V126, P717, DOI 10.1007/s10549-010-1172-9
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Long JR, 2010, CANCER EPIDEM BIOMAR, V19, P2357, DOI 10.1158/1055-9965.EPI-10-0054
   McPherson K, 2000, BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624
   Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Milne RL, 2011, CANCER EPIDEM BIOMAR, V20, P2222, DOI 10.1158/1055-9965.EPI-11-0569
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959
   Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837
   Seal S, 2006, NAT GENET, V38, P1239, DOI 10.1038/ng1902
   Stacey SN, 2008, NAT GENET, V40, P703, DOI 10.1038/ng.131
   Stacey SN, 2007, NAT GENET, V39, P865, DOI 10.1038/ng2064
   Stevens KN, 2011, CANCER RES, V71, P6240, DOI 10.1158/0008-5472.CAN-11-1266
   Sueta A, 2012, BREAST CANCER RES TR, V132, P711, DOI 10.1007/s10549-011-1904-5
   Thomas G, 2009, NAT GENET, V41, P579, DOI 10.1038/ng.353
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
NR 40
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 15
PY 2013
VL 8
IS 8
AR e72526
DI 10.1371/journal.pone.0072526
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 204OU
UT WOS:000323378000102
PM 23977314
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhu, HC
   Yang, X
   Zhang, C
   Zhu, C
   Tao, GZ
   Zhao, LJ
   Tang, SW
   Shu, Z
   Cai, J
   Dai, SB
   Qin, Q
   Xu, LP
   Cheng, HY
   Sun, XC
AF Zhu, Hongcheng
   Yang, Xi
   Zhang, Chi
   Zhu, Chen
   Tao, Guangzhou
   Zhao, Lianjun
   Tang, Shaowen
   Shu, Zheng
   Cai, Jing
   Dai, Shengbin
   Qin, Qin
   Xu, Liping
   Cheng, Hongyan
   Sun, Xinchen
TI Red and Processed Meat Intake Is Associated with Higher Gastric Cancer
   Risk: A Meta-Analysis of Epidemiological Observational Studies
SO PLOS ONE
LA English
DT Article
ID MULTICENTER CASE-CONTROL; N-NITROSO COMPOUNDS; STOMACH-CANCER; DIETARY
   FACTORS; GASTROINTESTINAL CANCERS; HETEROCYCLIC AMINES;
   HELICOBACTER-PYLORI; ALCOHOL-CONSUMPTION; FAMILY-HISTORY; UNITED-STATES
AB Background: Red and processed meat was concluded as a limited-suggestive risk factor of gastric cancer by the World Cancer Research Fund. However, recent epidemiological studies have yielded inconclusive results.
   Methods: We searched Medline, EMBASE, and the Cochrane Library from their inception to April 2013 for both cohort and case-control studies which assessed the association between red and/or processed meat intake and gastric cancer risk. Study-specific relative risk estimates were polled by random-effect or fixed-effect models.
   Results: Twelve cohort and thirty case-control studies were included in the meta-analysis. Significant associations were found between both red (RR: 1.45, 95% CI: 1.22-1.73) and processed (RR: 1.45, 95% CI: 1.26-1.65) meat intake and gastric cancer risk generally. Positive findings were also existed in the items of beef (RR: 1.28, 95% CI: 1.04-1.57), bacon (RR: 1.37, 95% CI: 1.17-1.61), ham (RR: 1.44, 95% CI: 1.00-2.06), and sausage (RR: 1.33, 95% CI: 1.16-1.52). When conducted by study design, the association was significant in case-control studies (RR: 1.63, 95% CI: 1.33-1.99) but not in cohort studies (RR: 1.02, 95% CI: 0.90-1.17) for red meat. Increased relative risks were seen in high-quality, adenocarcinoma, cardia and European-population studies for red meat. And most subgroup analysis confirmed the significant association between processed meat intake and gastric cancer risk.
   Conclusions: Our findings indicate that consumption of red and/or processed meat contributes to increased gastric cancer risk. However, further investigation is needed to confirm the association, especially for red meat.
C1 [Zhu, Hongcheng; Yang, Xi; Zhang, Chi; Qin, Qin; Xu, Liping; Sun, Xinchen] Nanjing Med Univ, Dept Radiat Oncol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
   [Zhu, Chen; Tang, Shaowen] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China.
   [Zhu, Chen; Tang, Shaowen] Nanjing Med Univ, Sch Publ Hlth, Minist Educ, Key Lab Modern Toxicol, Nanjing, Jiangsu, Peoples R China.
   [Tao, Guangzhou] Nanjing Med Univ, Dept Radiat Oncol, Huaian Peoples Hosp 1, Huaian, Peoples R China.
   [Zhao, Lianjun] Nanjing Med Univ, Nanjing Drum Tower Hosp, Ctr Comprehens Canc, Nanjing, Jiangsu, Peoples R China.
   [Zhao, Lianjun] Nanjing Med Univ, Clin Coll, Nanjing, Jiangsu, Peoples R China.
   [Shu, Zheng] Peking Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Hlth Sci Ctr, Beijing 100871, Peoples R China.
   [Cai, Jing] Nantong Tumor Hosp, Tumor Inst, Nantong, Peoples R China.
   [Dai, Shengbin] Taizhou Peoples Hosp, Dept Oncol, Taizhou, Peoples R China.
   [Cheng, Hongyan] Nanjing Med Univ, Dept Synthet Internal Med, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
RP Cheng, HY (reprint author), Nanjing Med Univ, Dept Synthet Internal Med, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
EM hychennjmu@163.com; sunxinchen2012@163.com
OI Tang, Shaowen/0000-0001-5879-8594
FU Natural Science Foundation of China [81272504]; Innovation Team
   [LJ201123 (EH11)]; Jiangsu Provincial Science and Technology [BK2011854
   (DA11)]; "333" Project of Jiangsu Province [BRA2012210 (RS12)]; Chinese
   Society of Clinical Oncology [T-H2010-033 (KA10)]
FX This work was supported by the Natural Science Foundation of China
   (grant number 81272504), the Innovation Team (number LJ201123 (EH11)),
   and Jiangsu Provincial Science and Technology Projects (BK2011854
   (DA11)), and "333" Project of Jiangsu Province (BRA2012210 (RS12)), and
   research grants from Chinese Society of Clinical Oncology (T-H2010-033
   (KA10)). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Agudo A, 2012, CANCER EPIDEM BIOMAR, V21, P685, DOI 10.1158/1055-9965.EPI-11-1205
   Aune D, 2009, ASIAN PAC J CANCER P, V10, P429
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bergin IL, 2003, DIGEST DIS SCI, V48, P475, DOI 10.1023/A:1022524313355
   BOEING H, 1991, INT J CANCER, V47, P858, DOI 10.1002/ijc.2910470612
   BOEING H, 1991, CANCER CAUSE CONTROL, V2, P227, DOI 10.1007/BF00052138
   BUIATTI E, 1990, INT J CANCER, V45, P896, DOI 10.1002/ijc.2910450520
   BUIATTI E, 1991, INT J CANCER, V48, P369, DOI 10.1002/ijc.2910480310
   BUIATTI E, 1989, INT J CANCER, V44, P611, DOI 10.1002/ijc.2910440409
   Carr JS, 2013, J GASTROINTEST CANC
   Chen HL, 2002, AM J CLIN NUTR, V75, P137
   Cross AJ, 2003, CANCER RES, V63, P2358
   Cross AJ, 2011, AM J GASTROENTEROL, V106, P432, DOI 10.1038/ajg.2010.415
   Daniel CR, 2011, PUBLIC HEALTH NUTR, V14, P575, DOI 10.1017/S1368980010002077
   De Stefani E, 1998, NUTR CANCER, V30, P158, DOI 10.1080/01635589809514656
   De Stefani E, 2012, BRIT J CANCER, V107, P1584, DOI 10.1038/bjc.2012.433
   De Stefani E, 2001, NUTR CANCER, V40, P103, DOI 10.1207/S15327914NC402_5
   De Stefani Eduardo, 2004, Gastric Cancer, V7, P211, DOI 10.1007/s10120-004-0295-2
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Galanis DJ, 1998, INT J EPIDEMIOL, V27, P173, DOI 10.1093/ije/27.2.173
   Gao Y, 2011, CANCER EPIDEMIOL, V35, pE91, DOI 10.1016/j.canep.2011.06.006
   GONZALEZ CA, 1991, INT J CANCER, V49, P513, DOI 10.1002/ijc.2910490407
   Gonzalez CA, 2006, J NATL CANCER I, V98, P345, DOI 10.1093/jnci/djj071
   HANSSON LE, 1993, INT J CANCER, V55, P181, DOI 10.1002/ijc.2910550203
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HOSHIYAMA Y, 1992, CANCER CAUSE CONTROL, V3, P441, DOI 10.1007/BF00051357
   Hu JF, 2008, NUTR CANCER, V60, P313, DOI 10.1080/01635580701759724
   Hu JF, 2011, EUR J CANCER PREV, V20, P132, DOI 10.1097/CEJ.0b013e3283429e32
   Ito LS, 2003, ANN EPIDEMIOL, V13, P24, DOI 10.1016/S1047-2797(02)00269-7
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Ji BT, 1998, INT J CANCER, V76, P659, DOI 10.1002/(SICI)1097-0215(19980529)76:5<659::AID-IJC8>3.0.CO;2-P
   Keszei AP, 2012, ANN ONCOL, V23, P2319, DOI 10.1093/annonc/mdr615
   Kim HJ, 2002, INT J CANCER, V97, P531, DOI 10.1002/ijc.10111
   Knekt P, 1999, INT J CANCER, V80, P852
   KNELLER RW, 1991, CANCER, V68, P672, DOI 10.1002/1097-0142(19910801)68:3<672::AID-CNCR2820680339>3.0.CO;2-T
   Larsson SC, 2006, INT J CANCER, V119, P915, DOI 10.1002/ijc.21925
   Larsson SC, 2006, J NATL CANCER I, V98, P1078, DOI 10.1093/jnci/djj301
   LAVECCHIA C, 1987, INT J CANCER, V40, P484, DOI 10.1002/ijc.2910400409
   LEE HH, 1990, ANTICANCER RES, V10, P875
   Lissowska J, 2004, NUTR CANCER, V48, P149, DOI 10.1207/s15327914nc4802_4
   McCullough ML, 2001, CANCER EPIDEM BIOMAR, V10, P1201
   Munoz SE, 1997, CANCER EPIDEM BIOMAR, V6, P137
   Navarro Silvera SA, 2008, INT J CANCER, V123, P852
   NAZARIO CM, 1993, INT J EPIDEMIOL, V22, P790, DOI 10.1093/ije/22.5.790
   Ngoan LT, 2002, BRIT J CANCER, V87, P37, DOI 10.1038/sj.bjc.6600415
   NOMURA A, 1990, CANCER RES, V50, P627
   Nomura AMY, 2003, CANCER CAUSE CONTROL, V14, P547, DOI 10.1023/A:1024887411846
   Palli D, 2001, CANCER RES, V61, P5415
   Perez-Perez GI, 2000, EUR J GASTROEN HEPAT, V12, P1263, DOI 10.1097/00042737-200012120-00001
   Phukan RK, 2006, J GASTROENTEROL, V41, P418, DOI 10.1007/s00535-006-1761-x
   Pourfarzi F, 2009, INT J CANCER, V125, P1953, DOI 10.1002/ijc.24499
   RISCH HA, 1985, AM J EPIDEMIOL, V122, P947, DOI 10.1093/oxfordjournals.aje.a114199
   SANCHEZDIEZ A, 1992, EUR J EPIDEMIOL, V8, P233
   Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1
   Strumylaite Loreta, 2006, Medicina (Kaunas), V42, P164
   TAKAHASHI M, 1994, CARCINOGENESIS, V15, P1429, DOI 10.1093/carcin/15.7.1429
   Takezaki T, 2001, JPN J CANCER RES, V92, P1157, DOI 10.1111/j.1349-7006.2001.tb02135.x
   Tavani A, 2000, INT J CANCER, V86, P425, DOI 10.1002/(SICI)1097-0215(20000501)86:3<425::AID-IJC19>3.3.CO;2-J
   Tokui N, 2005, J EPIDEMIOL, V15, pS98, DOI 10.2188/jea.15.S98
   Tricker AR, 1997, EUR J CANCER PREV, V6, P226, DOI 10.1097/00008469-199706000-00003
   TUYNS AJ, 1992, INT J CANCER, V51, P1, DOI 10.1002/ijc.2910510102
   van den Brandt PA, 2003, CANCER CAUSE CONTROL, V14, P427, DOI 10.1023/A:1024979314124
   Ward MH, 2012, EUR J CANCER PREV, V21, P134, DOI 10.1097/CEJ.0b013e32834c9b6c
   Ward MH, 1999, AM J EPIDEMIOL, V149, P925
   Ward MH, 1997, INT J CANCER, V71, P14, DOI 10.1002/(SICI)1097-0215(19970328)71:1<14::AID-IJC4>3.0.CO;2-6
   Wells GA, NEWCASTLE OTTAWA SCA
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   World Cancer Research Fund/American Institute forCancer Research, 2007, FOOD NUTR PHYS ACT P
   Wu AH, 2007, CANCER CAUSE CONTROL, V18, P713, DOI 10.1007/s10552-007-9014-8
NR 71
TC 49
Z9 50
U1 0
U2 53
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 14
PY 2013
VL 8
IS 8
AR e70955
DI 10.1371/journal.pone.0070955
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 202MQ
UT WOS:000323221500047
PM 23967140
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wei, BJ
   Chen, YJ
   Yu, L
   Wu, B
AF Wei, Ben-Juan
   Chen, Yi-Jun
   Yu, Li
   Wu, Bin
TI Periodontal Disease and Risk of Preeclampsia: A Meta-Analysis of
   Observational Studies
SO PLOS ONE
LA English
DT Article
ID MATERNAL PERIODONTITIS; ORAL-HEALTH; PREGNANCY; ASSOCIATION; WOMEN
AB Background: Many epidemiological studies have found a positive association between periodontal disease (PD) and the risk of preeclampsia, but the magnitude of this association varies and independent studies have reported conflicting findings. We performed a meta-analysis to ascertain the relationship between PD and preeclampsia.
   Methods: The PubMed database was searched up to January 12, 2013, for relevant observational studies on an association between PD and the risk of preeclampsia. Data were extracted and analyzed independently by two authors. The meta-analysis was performed using comprehensive meta-analysis software.
   Results: Thirteen observational case-control studies and two cohort studies, involving 1089 preeclampsia patients, were identified. Based on a random-effects meta-analysis, a significant association between PD and preeclampsia was identified (odds ratio = 2.79, 95% confidence interval CI, 2.01-3.01, P<0.0001).
   Conclusions: Although the causality remains unclear, the association between PD and preeclampsia may reflect the induction of PD by the preeclamptic state, or it may be part of an overall exaggerated inflammatory response to pregnancy. Larger randomized controlled trials with preeclampsia as the primary outcome and pathophysiological studies are required to explore causality and to dissect the biological mechanisms involved.
C1 [Wei, Ben-Juan; Chen, Yi-Jun; Yu, Li] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Stomatol, Shanghai 200030, Peoples R China.
   [Wu, Bin] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Pharm, Shanghai 200030, Peoples R China.
RP Wu, B (reprint author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Pharm, Shanghai 200030, Peoples R China.
EM wbwithtg@hotmail.com
FU School of Medicine, Shanghai Jiaotong University [12XJ10053]
FX This work was supported by a grant from the School of Medicine, Shanghai
   Jiaotong University (NO. 12XJ10053). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Albandar JM, 1999, J PERIODONTOL, V70, P13, DOI 10.1902/jop.1999.70.1.13
   Azarpazhooh A, 2006, J PERIODONTOL, V77, P1465, DOI 10.1902/jop.2006.060010
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blaizot A, 2009, INT DENT J, V59, P197, DOI 10.1922/IDJ_2114Sixou13
   Boggess KA, 2003, OBSTET GYNECOL, V101, P227, DOI 10.1016/S0029-7844(02)02314-1
   Canakci V, 2004, AUST NZ J OBSTET GYN, V44, P568, DOI 10.1111/j.1479-828X.2004.00323.x
   Canakci V, 2007, J CLIN PERIODONTOL, V34, P639, DOI 10.1111/j.1600-051X.2007.01105.x
   Castaldi JL, 2006, REV PANAM SALUD PUBL, V19, P253, DOI 10.1590/S1020-49892006000400005
   Contreras A, 2006, J PERIODONTOL, V77, P182, DOI 10.1902/jop.2006.050020
   Cullinan MP, 2009, AUST DENT J, V54, pS62, DOI 10.1111/j.1834-7819.2009.01144.x
   da Silva GM, 2012, J PERIODONTOL, V83, P1388, DOI 10.1902/jop.2012.110256
   Detert J, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3106
   Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61
   Ha JE, 2011, J PERIODONTOL, V82, P1685, DOI 10.1902/jop.2011.110035
   Herrera JA, 2007, J HYPERTENS, V25, P1459, DOI 10.1097/HJH.0b013e3281139ea9
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Kunnen A, 2007, J CLIN PERIODONTOL, V34, P202, DOI 10.1111/j.1600-051X.2006.01036.x
   Lohsoonthorn V, 2009, AM J HYPERTENS, V22, P457, DOI 10.1038/ajh.2008.365
   Lopez-Jaramillo P, 2011, J HYPERTENS, V29, P1020, DOI 10.1097/HJH.0b013e328344b6e8
   Megson E, 2010, INT J EVID-BASED HEA, V8, P129, DOI 10.1111/j.1744-1609.2010.00171.x
   Meurman JH, 2006, CLIN ORAL INVEST, V10, P96, DOI 10.1007/s00784-006-0037-4
   Cota LOM, 2006, J PERIODONTOL, V77, P2063, DOI 10.1902/jop.2006.060061
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Nakajima T, 2010, J PERIODONTAL RES, V45, P116, DOI 10.1111/j.1600-0765.2009.01209.x
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Politano GT, 2011, J PERIODONTAL RES, V46, P505, DOI 10.1111/j.1600-0765.2011.01368.x
   Preshaw PM, 2012, DIABETOLOGIA, V55, P21, DOI 10.1007/s00125-011-2342-y
   Sargent IL, 2006, REPROD BIOMED ONLINE, V13, P680, DOI 10.1016/S1472-6483(10)60659-1
   Sayar F, 2011, IRAN J PUBLIC HEALTH, V40, P122
   Shetty M, 2010, ACTA OBSTET GYN SCAN, V89, P718, DOI 10.3109/00016341003623738
   Siqueira FM, 2008, J PERIODONTOL, V79, P207, DOI [10.1902/jop.2008.070174, 10.1902/jop.2008.070174 ]
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Swati P, 2012, ARCH GYNECOL OBSTET, V285, P613, DOI 10.1007/s00404-011-2012-9
   Taghzouti N, 2012, J PERIODONTOL, V83, P871, DOI 10.1902/jop.2011.110342
   Walker JJ, 2000, LANCET, V356, P1260, DOI 10.1016/S0140-6736(00)02800-2
   Xiong X, 2007, OBSTET GYNECOL SURV, V62, P605, DOI 10.1097/01.ogx.0000279292.63435.40
NR 37
TC 14
Z9 15
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 12
PY 2013
VL 8
IS 8
AR e70901
DI 10.1371/journal.pone.0070901
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 200UV
UT WOS:000323097300065
PM 23951033
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, JX
   Yuan, T
   Liu, MG
   Chen, P
AF Chen, Jingxiang
   Yuan, Tao
   Liu, Menggang
   Chen, Ping
TI Association between TCF7L2 Gene Polymorphism and Cancer Risk: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PROSTATE-CANCER; BREAST-CANCER; ATHEROSCLEROSIS RISK; COLORECTAL-CANCER;
   COLON-CANCER; VARIANTS; COMMUNITIES; POPULATION; CONSORTIUM; BIAS
AB Objective: The transcription factor 7-like 2 (TCF7L2) gene has been suggested to play an important role in the pathogenesis of cancer. However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the associations between TCF7L2 polymorphism and cancer risk.
   Methods: Published literature from PubMed and EMBASE were retrieved. Pooled odds ratios (ORs) with 95% confidence interval (CIs) were calculated using fixed-or random-effects model.
   Results: A total of 19 studies (14,814 cases and 33,856 controls) were identified for the analysis of the association between TCF7L2 polymorphism and cancer risk. The results showed that TCF7L2 polymorphism was associated with breast cancer (Homogeneous model: OR = 1.17, 95%CI = 1.02-1.35, I-2 = 21.8%, p for heterogeneity = 0.276; Heterogeneous model: OR = 1.11, 95%CI = 1.03-1.20, I-2 = 0.0%, p for heterogeneity = 0.543), prostate cancer (Homogeneous model: OR = 0.89, 95%CI = 0.84-0.96, I-2 = 0.0%, p for heterogeneity = 0.640; Heterogeneous model: OR = 0.89, 95%CI = 0.84-0.95, I-2 = 0.0%, p for heterogeneity = 0.871), and colon cancer (Heterogeneous model: OR = 1.15, 95%CI = 1.01-1.31, I-2 = 0.0%, p for heterogeneity = 0.658), but not with colorectal cancer, lung cancer, and ovarian cancer.
   Conclusions: The present meta-analysis indicated that there were significantly associations between the TCF7L2 rs7903146 polymorphism and risk of breast, prostate and colon cancers, rather than colorectal cancer, lung cancer, and ovarian cancer.
C1 [Chen, Jingxiang; Yuan, Tao; Liu, Menggang; Chen, Ping] Third Mil Med Univ, Affiliated Hosp 3, Dept Hepatobiliary Surg, Chongqing, Peoples R China.
   [Chen, Jingxiang] Jiangjin Cent Hosp, Dept Hepatobiliary Surg, Chongqing, Peoples R China.
RP Chen, P (reprint author), Third Mil Med Univ, Affiliated Hosp 3, Dept Hepatobiliary Surg, Chongqing, Peoples R China.
EM pingchen1956@163.com
CR Agalliu I, 2008, PROSTATE, V68, P740, DOI 10.1002/pros.20732
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Burwinkel B, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-268
   Connor AE, 2012, BREAST CANCER RES TR, V136, P593, DOI 10.1007/s10549-012-2299-7
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Domenyuk V. P., 2007, Experimental Oncology, V29, P152
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Folsom AR, 2008, DIABETES CARE, V31, P905, DOI 10.2337/dc07-2131
   Goode EL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-312
   Hazra A, 2008, CANCER CAUSE CONTROL, V19, P975, DOI 10.1007/s10552-008-9164-3
   Lyssenko V, 2007, J CLIN INVEST, V117, P2155, DOI 10.1172/JC130706
   Machiela MJ, 2012, AM J EPIDEMIOL, V176, P1121, DOI 10.1093/aje/kws191
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Meyer TE, 2010, CANCER EPIDEM BIOMAR, V19, P558, DOI 10.1158/1055-9965.EPI-09-0902
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Munafo MR, 2004, TRENDS GENET, V20, P439, DOI 10.1016/j.tig.2004.06.014
   Naidu R, 2012, MED ONCOL, V29, P411, DOI 10.1007/s12032-011-9837-8
   Peng SH, 2013, MUTAGENESIS, V28, P25, DOI 10.1093/mutage/ges048
   Sainz J, 2012, J CLIN ENDOCR METAB, V97, pE845, DOI 10.1210/jc.2011-2565
   Salonen JT, 2007, AM J HUM GENET, V81, P338, DOI 10.1086/520599
   Slattery ML, 2008, CANCER EPIDEM BIOMAR, V17, P978, DOI 10.1158/1055-9965.EPI-07-2687
   Tsilidis KK, 2009, CANCER CAUSE CONTROL, V20, P1739, DOI 10.1007/s10552-009-9427-7
   Wang MH, 2009, PROSTATE, V69, P874, DOI 10.1002/pros.20933
NR 23
TC 3
Z9 5
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 9
PY 2013
VL 8
IS 8
AR e71730
DI 10.1371/journal.pone.0071730
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 245OM
UT WOS:000326473200069
PM 23951231
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, Y
   Ji, J
   Liu, YJ
   Deng, X
   He, QQ
AF Wang, Ying
   Ji, Jie
   Liu, Yu-jian
   Deng, Xuan
   He, Qi-qiang
TI Passive Smoking and Risk of Type 2 Diabetes: A Meta-Analysis of
   Prospective Cohort Studies
SO PLOS ONE
LA English
DT Article
ID CIGARETTE-SMOKING; ACTIVE SMOKING; EXPOSURE; ASSOCIATION; POPULATION;
   DISEASE; RATIO; BIAS
AB Backgrounds/Objective: The prevalence of diabetes is increasing rapidly all over the world. However, studies on passive smoking and type 2 diabetes have not been systematically assessed. Therefore, we conducted a meta-analysis to explore whether an association exists between passive smoking and risk of type 2 diabetes.
   Methods: We searched PubMed, EMBASE, Cochrane library and Web of Science up to April 9th, 2013, to identify prospective cohort studies that assessed passive smoking and risk of type 2 diabetes. The fixed-effect model was used to calculate the overall relative risk (RR).
   Result: 4 prospective cohort studies were included for analysis, with a total of 112,351 participants involved. The pooled RR was 1.28 (95% confidence interval (CI) 1.14 to 1.44) comparing those who were exposed to passive smoking with those who were not. Subgroup, sensitivity analysis and publication bias test suggested the overall result of this analysis was robust.
   Conclusions: Passive smoking is associated with a significantly increased risk of type 2 diabetes. Further well-designed studies are warranted to confirm this association.
C1 [Wang, Ying; Ji, Jie; Liu, Yu-jian; Deng, Xuan; He, Qi-qiang] Wuhan Univ, Sch Publ Hlth, Wuhan 430072, Peoples R China.
   [Wang, Ying] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Wuhan 430074, Peoples R China.
   [He, Qi-qiang] Wuhan Univ, Global Hlth Inst, Wuhan 430072, Peoples R China.
RP He, QQ (reprint author), Wuhan Univ, Sch Publ Hlth, Wuhan 430072, Peoples R China.
EM heqiqiang@gmail.com
RI He, Qiqiang/A-7990-2012
CR Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI [10.2337/dc10-S062, 10.2337/dc11-S062, 10.2337/dc10-s062]
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brownson RC, 2002, ONCOGENE, V21, P7341, DOI 10.1038/sj.onc.1205809
   Bruin JE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003371
   Chuang SC, 2011, CANCER CAUSE CONTROL, V22, P487, DOI 10.1007/s10552-010-9723-2
   de Lemos ML, 2002, LANCET, V360, P954, DOI 10.1016/S0140-6736(02)11063-4
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   ERIKSEN MP, 1988, ANNU REV PUBL HEALTH, V9, P47, DOI 10.1146/annurev.pu.09.050188.000403
   Hayashino Y, 2008, DIABETES CARE, V31, P732, DOI 10.2337/dc07-1905
   He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Houston TK, 2006, BRIT MED J, V332, P1064, DOI 10.1136/bmj.38779.584028.55
   Ko KP, 2011, ANN EPIDEMIOL, V21, P42, DOI 10.1016/j.annepidem.2010.10.006
   Kowall B, 2010, EUR J EPIDEMIOL, V25, P393, DOI 10.1007/s10654-010-9452-6
   McCrimmon RJ, 2012, LANCET, V379, P2291, DOI 10.1016/S0140-6736(12)60360-2
   MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220
   Oberg M, 2011, LANCET, V377, P139, DOI 10.1016/S0140-6736(10)61388-8
   Oono IP, 2011, J PUBLIC HEALTH-UK, V33, P496, DOI 10.1093/pubmed/fdr025
   Sasaki S, 2011, SCI TOTAL ENVIRON, V412, P114, DOI 10.1016/j.scitotenv.2011.10.019
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789
   Sikorska-Jaroszynska MHJ, 2012, ANN AGR ENV MED, V19, P547
   Spruance SL, 2004, ANTIMICROB AGENTS CH, V48, P2787, DOI 10.1128/AAC.48.8.2787-2792.2004
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Vrieling A, 2010, INT J CANCER, V126, P2394, DOI 10.1002/ijc.24907
   Willi C, 2007, JAMA-J AM MED ASSOC, V298, P2654, DOI 10.1001/jama.298.22.2654
   Xie XT, 2009, ACTA PHARMACOL SIN, V30, P784, DOI 10.1038/aps.2009.49
   Yanbaeva DG, 2007, CHEST, V131, P1557, DOI 10.1378/chest.06-2179
   Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690
   Zhang LX, 2011, DIABETES CARE, V34, P892, DOI 10.2337/dc10-2087
NR 34
TC 17
Z9 18
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 26
PY 2013
VL 8
IS 7
AR e69915
DI 10.1371/journal.pone.0069915
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 197GU
UT WOS:000322838900113
PM 23922856
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ge, XH
   Han, FF
   Huang, YX
   Zhang, Y
   Yang, TY
   Bai, C
   Guo, XJ
AF Ge, Xiahui
   Han, Fengfeng
   Huang, Yanxi
   Zhang, Yue
   Yang, Tianyun
   Bai, Chong
   Guo, Xuejun
TI Is Obstructive Sleep Apnea Associated with Cardiovascular and All-Cause
   Mortality?
SO PLOS ONE
LA English
DT Article
ID POSITIVE AIRWAY PRESSURE; RISK-FACTOR; HEART HEALTH; FOLLOW-UP;
   POPULATION; METAANALYSIS; HYPOPNEA; EVENTS; STROKE; DEATH
AB Background: Studies have reported inconsistent findings regarding the association between obstructive sleep apnea (OSA) and future risks of cardiovascular and all-cause mortality. We conducted a meta-analysis to investigate whether OSA is an independent predictor for future cardiovascular and all-cause mortality using prospective observational studies.
   Methods: Electronic literature databases (Medline and Embase) were searched for prospective observational studies published prior to December 2012. Only observational studies that assessed baseline OSA and future risk of cardiovascular and all-cause mortality were selected. Pooled hazard risk (HR) and corresponding 95% confidence intervals (CI) were calculated for categorical risk estimates. Subgroup analyses were based on the severity of OSA.
   Results: Six studies with 11932 patients were identified and analyzed, with 239 reporting cardiovascular mortality, and 1397 all-cause mortality. Pooled HR of all-cause mortality was 1.19 (95% CI, 1.00 to 1.41) for moderate OSA and 1.90 (95% CI, 1.29 to 2.81) for severe OSA. Pooled HR of cardiovascular mortality was 1.40 (95% CI, 0.77 to 2.53) for moderate OSA and 2.65 (95% CI, 1.82 to 3.85) for severe OSA. There were no differences in cardiovascular mortality in continuous positive airway pressure (CPAP) treatment compared with healthy subjects (HR 0.82; 95% CI, 0.50 to 1.33).
   Conclusions: Severe OSA is a strong independent predictor for future cardiovascular and all-cause mortality. CPAP treatment was associated with decrease cardiovascular mortality.
C1 [Ge, Xiahui; Han, Fengfeng; Huang, Yanxi; Zhang, Yue; Yang, Tianyun; Guo, Xuejun] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Resp Med, Shanghai 200030, Peoples R China.
   [Bai, Chong] Second Mil Med Univ, Changhai Hosp, Dept Resp Med, Shanghai, Peoples R China.
RP Bai, C (reprint author), Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Resp Med, Shanghai 200030, Peoples R China.
EM guoxj1122@hotmail.com; bai7878@126.com
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bradley TD, 2009, LANCET, V373, P82, DOI 10.1016/S0140-6736(08)61622-0
   Campos-Rodriguez F, 2012, ANN INTERN MED, V156, P115, DOI 10.7326/0003-4819-156-2-201201170-00006
   Caples SM, 2005, ANN INTERN MED, V142, P187, DOI 10.7326/0003-4819-142-3-200502010-00010
   Duran J, 2001, AM J RESP CRIT CARE, V163, P685, DOI 10.1164/ajrccm.163.3.2005065
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Epstein LJ, 2009, J CLIN SLEEP MED, V5, P263
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hudgel DW, 2012, J CLIN SLEEP MED, V8, P9, DOI 10.5664/jcsm.1648
   Johansson P, 2011, SLEEP MED, V12, P748, DOI 10.1016/j.sleep.2011.03.012
   Khayat R, 2009, HEART FAIL REV, V14, P143, DOI 10.1007/s10741-008-9112-z
   Kokkarinen J, 2011, AM J RESP CRIT CARE, V183, P950, DOI 10.1164/ajrccm.183.7.950
   Korostovtseva LS, 2011, MED SCI MONITOR, V17, pCR146, DOI 10.12659/MSM.881448
   Launois SH, 2007, SLEEP MED REV, V11, P87, DOI 10.1016/j.smrv.2006.08.005
   Lavie P, 2005, EUR RESPIR J, V25, P514, DOI 10.1183/09031936.05.00051504
   Loke YK, 2012, CIRC-CARDIOVASC QUAL, V5, P720, DOI 10.1161/CIRCOUTCOMES.111.964783
   Malhotra A, 2002, LANCET, V360, P237, DOI 10.1016/S0140-6736(02)09464-3
   Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7
   Marshall NS, 2008, SLEEP, V31, P1079
   Marti S, 2002, EUR RESPIR J, V20, P1511, DOI 10.1183/09031936.02.00306502
   Martinez-Garcia MA, 2012, AM J RESP CRIT CARE, V186, P909, DOI 10.1164/rccm.201203-0448OC
   McDaid C, 2009, HEALTH TECHNOL ASSES, V13, P143
   Punjabi NM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000132
   Quan SF, 2002, SLEEP, V25, P843
   Rich J, 2012, OTOLARYNG HEAD NECK, V147, P583, DOI 10.1177/0194599812450256
   Sahlin C, 2008, ARCH INTERN MED, V168, P297, DOI 10.1001/archinternmed.2007.70
   Shah NA, 2010, SLEEP BREATH, V14, P131, DOI 10.1007/s11325-009-0298-7
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Valipour A, 2012, Pneumologie, V66, P584, DOI 10.1055/s-0032-1325664
   Wang HQ, 2007, J AM COLL CARDIOL, V49, P1625, DOI 10.1016/j.jacc.2006.12.046
   Won CH, 2012, SLEEP BREATH
   Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104
   Yeboah J, 2011, ATHEROSCLEROSIS, V219, P963, DOI 10.1016/j.atherosclerosis.2011.08.021
   Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080
   YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704
   Young T, 2008, SLEEP, V31, P1071
NR 36
TC 36
Z9 36
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 25
PY 2013
VL 8
IS 7
AR e69432
DI 10.1371/journal.pone.0069432
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 191SQ
UT WOS:000322433300039
PM 23936014
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liyanage, SS
   Rahman, B
   Ridda, I
   Newall, AT
   Tabrizi, SN
   Garland, SM
   Segelov, E
   Seale, H
   Crowe, PJ
   Moa, A
   Maclntyre, CR
AF Liyanage, Surabhi S.
   Rahman, Bayzidur
   Ridda, Iman
   Newall, Anthony T.
   Tabrizi, Sepehr N.
   Garland, Suzanne M.
   Segelov, Eva
   Seale, Holly
   Crowe, Philip J.
   Moa, Aye
   Maclntyre, C. Raina
TI The Aetiological Role of Human Papillomavirus in Oesophageal Squamous
   Cell Carcinoma: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; RISK HUMAN-PAPILLOMAVIRUS; HPV INFECTION; NO
   ASSOCIATION; CANCER; CHINA; PREVALENCE; VACCINE; VIRUS; AREA
AB Background: The aetiological role of human papillomavirus (HPV) in oesophageal squamous cell carcinoma (OSCC) has been widely researched for more than three decades, with conflicting findings. In the absence of a large, adequately powered single case-control study, a meta-analysis of all available case-control studies is the most rigorous way of identifying any potential association between HPV and OSCC. We present the first global meta-analysis of case-control studies investigating the role of HPV in OSCC.
   Methods: Case-control studies investigating OSCC tissue for presence of HPV DNA were identified. 21 case-control studies analyzing a total of 1223 cases and 1415 controls, met our inclusion criteria. HPV detection rates were tabulated for each study and all studies were assessed for quality. The random effects method was used to pool the odds ratios (OR).
   Results: From all OSCC specimens included in this meta-analysis, 35% (426/1223) were positive for HPV DNA. The pooled OR for an HPV-OSCC association was 3.04 (95% CI 2.20 to 4.20). Meta-regression analysis did not find a significant association between OR and any of the quality domains. Influence analysis was non-significant for the effect of individual studies on the pooled estimate. Studies conducted in countries with low to medium OSCC incidence showed a stronger relationship (OR 4.65, 95% CI 2.47 to 8.76) than regions of high OSCC incidence (OR 2.65, 95% CI 1.80 to 3.91).
   Conclusions: Uncertainty around the aetiological role of HPV in OSCC is due largely to the small number and scale of appropriately designed studies. Our meta-analysis of these studies suggests that HPV increases the risk of OSCC three-fold. This study provides the strongest evidence to date of an HPV-OSCC association. The importance of these findings is that prophylactic vaccination could be of public health benefit in prevention of OSCC in countries with high OSCC incidence.
C1 [Liyanage, Surabhi S.; Rahman, Bayzidur; Ridda, Iman; Newall, Anthony T.; Seale, Holly; Moa, Aye; Maclntyre, C. Raina] Univ New S Wales, Sch Publ Hlth & Community Med, UNSW Med, Sydney, NSW, Australia.
   [Tabrizi, Sepehr N.; Garland, Suzanne M.] Royal Womens Hosp, Dept Microbiol & Infect Dis, Melbourne, Australia.
   [Segelov, Eva] Univ New S Wales, Dept Med, St Vincents Hosp Clin Sch, Sydney, NSW, Australia.
   [Crowe, Philip J.] Univ New S Wales, Prince Wales Hosp Clin Sch, Dept Surg, Sydney, NSW, Australia.
RP Liyanage, SS (reprint author), Univ New S Wales, Sch Publ Hlth & Community Med, UNSW Med, Sydney, NSW, Australia.
EM surabhi_liyanage@hotmail.com
RI Segelov, Eva/Q-7611-2019; Rahman, Md Bayzidur/G-5910-2015
OI Segelov, Eva/0000-0002-4410-6144; Crowe, Philip/0000-0002-0927-3721;
   Newall, Anthony/0000-0003-0836-1065
FU NHMRC [630724]; manufacturer of HPV vaccine; National Health and Medical
   Research Council (NHMRC) [1012631]; CSL; GlaxoSmithKline; Merck; GSK;
   Sanofi Pasteur; MSD; CSL Biotherapies; Pfizer
FX ATN holds an NHMRC Training Fellowship (630724 - Australian Based Public
   Health Fellowship) and has previously received research funding for
   other projects from a manufacturer of HPV vaccine. HS currently holds a
   National Health and Medical Research Council (NHMRC) Training Fellowship
   (1012631) - Australian Based Public Health Fellowship). SG has received
   advisory board fees and grants support from CSL and GlaxoSmithKline, and
   lecture fees from Merck, GSK and Sanofi Pasteur; in addition, she has
   also received funding through her institution to conduct HPV vaccine
   studies for MSD and GSK. She is a member of the Merck Global Advisory
   Board as well as the Merck Scientific Advisory Committee for HPV. CRM
   has been on advisory boards for Merck, GSK and Pfizer for vaccines other
   than HPV. She has received funding for investigator-driven research on
   HPV vaccine from Merck. She has received funding for investigator driven
   research for other vaccines from GSK, CSL Biotherapies and Pfizer. The
   other authors have no competing interests to declare. This does not
   alter the authors' adherence to all the PLOS ONE policies on sharing
   data and materials.
CR Agarwal S. K., 1998, Indian Journal of Experimental Biology, V36, P559
   Antonsson A, 2010, CANCER EPIDEM BIOMAR, V19, P2080, DOI 10.1158/1055-9965.EPI-10-0033
   ASHWORTH MT, 1993, J CLIN PATHOL, V46, P573, DOI 10.1136/jcp.46.6.573
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BENAMOUZIG R, 1992, INT J CANCER, V50, P549, DOI 10.1002/ijc.2910500409
   Cao BW, 2005, CARCINOGENESIS, V26, P1280, DOI 10.1093/carcin/bgi071
   COOPER K, 1995, J PATHOL, V175, P273, DOI 10.1002/path.1711750304
   Curado MP, 2007, CANC INCIDENCE 5 CON
   Damin APS, 2006, DIS ESOPHAGUS, V19, P64
   Department of Health and Aging, 2012, HPV VACC PROGR
   DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739
   DOLL R, 1954, BMJ-BRIT MED J, V1, P1451, DOI 10.1136/bmj.1.4877.1451
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Egger M, 2001, SYSTEMATIC REV HLTH
   Farhadi M, 2005, WORLD J GASTROENTERO, V11, P1200, DOI 10.3748/wjg.v11.i8.1200
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   FIDALGO PO, 1995, CANCER, V76, P1522, DOI 10.1002/1097-0142(19951101)76:9<1522::AID-CNCR2820760904>3.0.CO;2-3
   Friis R, 2009, STUDY DESIGNS ECOLOG
   Gao GF, 2006, INT J CANCER, V119, P1354, DOI 10.1002/ijc.21980
   Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760
   Guimaraes DP, 2001, CANCER LETT, V162, P231, DOI 10.1016/S0304-3835(00)00643-1
   Hennekens C, 1987, EPIDEMIOL MED
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA
   HILLE JJ, 1986, S AFR MED J, V69, P417
   HORWITZ RI, 1979, AM J MED, V66, P556, DOI 10.1016/0002-9343(79)91164-1
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007, SMOK TOB SOM TOB SPE
   IBM Corp, 2011, IBM SPSS STAT WIND V
   Joura EA, 2007, LANCET, V369, P1693, DOI 10.1016/S0140-6736(07)60777-6
   Khurshid A, 1998, J Pak Med Assoc, V48, P138
   Koh JS, 2008, DIS ESOPHAGUS, V21, P114, DOI 10.1111/j.1442-2050.2007.00726.x
   Lambot MA, 2000, ACTA GASTRO-ENT BELG, V63, P154
   Lenhart D, 1991, DIS ESOPHAGUS, V4, P123
   Li T, 2001, CARCINOGENESIS, V22, P929, DOI 10.1093/carcin/22.6.929
   Liu WK, 2010, EUR J GASTROEN HEPAT, V22, P67, DOI 10.1097/MEG.0b013e32832c7e76
   Liyanage SS, 2013, ASIA-PAC J CLIN ONCO, V9, P12, DOI 10.1111/j.1743-7563.2012.01555.x
   Lyronis ID, 2005, INT J BIOL MARKER, V20, P5
   MARGETTS BM, 1995, NUTR CANCER, V24, P231, DOI 10.1080/01635589509514412
   MORI M, 1989, AM J GASTROENTEROL, V84, P1126
   Paavonen J, 2007, LANCET, V374, P304
   Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731
   Rahman M, 2010, INT J EPIDEMIOL
   *STATACORP LP, 2007, STAT STAT SOFTW REL
   Syrjanen K, 2013, SCAND J INFECT DIS, V45, P1, DOI 10.3109/00365548.2012.702281
   SYRJANEN K, 1982, DIAGN HISTOPATHOL, V5, P291
   Syrjanen K, 2006, PAPILLOMAVIRUS RESEARCH: FROM NATURAL HISTORY TO VACCINES AND BEYOND, P229
   Syrjanen KJ, 2002, J CLIN PATHOL, V55, P721, DOI 10.1136/jcp.55.10.721
   Villa LL, 2007, J INFECT DIS, V196, P1438, DOI 10.1086/522864
   Weston AC, 2003, DIS ESOPHAGUS, V16, P224, DOI 10.1046/j.1442-2050.2003.00333.x
   WILLIAMSON AL, 1991, ANTICANCER RES, V11, P263
   Zhang DH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-650
   Zhang HX, 2010, DIS ESOPHAGUS, V23, P392, DOI 10.1111/j.1442-2050.2009.01020.x
   Zhao P, 2010, JPN J CLIN ONCOL, V40, P281, DOI 10.1093/jjco/hyp187
NR 53
TC 33
Z9 33
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 24
PY 2013
VL 8
IS 7
AR e69238
DI 10.1371/journal.pone.0069238
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 188BY
UT WOS:000322167900051
PM 23894436
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Gu, C
   Zhou, L
   Yu, JP
AF Gu, Chao
   Zhou, Liang
   Yu, Jianping
TI Quantitative Assessment of 2q35-rs13387042 Polymorphism and Hormone
   Receptor Status with Breast Cancer Risk
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; GENETIC-VARIANTS;
   AFRICAN-AMERICAN; COMMON VARIANTS; CONFER SUSCEPTIBILITY; CHINESE WOMEN;
   METAANALYSIS; FGFR2; 2Q35
AB Background: The association between rs13387042 polymorphism on 2q35 and breast cancer (BC) has been widely evaluated since it was first identified through genome-wide association approach. However, the results have been inconclusive. To investigate this inconsistency, we performed a meta-analysis of all available studies dealing with the relationship between the 2q35-rs13387042 polymorphism and BC.
   Methods: Databases including MEDLINE, PubMed, EMBASE, ISI web of science and CNKI (China National Knowledge Infrastructure) were searched to find relevant studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association. The random-effects model was applied, addressing heterogeneity and publication bias.
   Results: A total of 24 articles involving 99,772 cases and 164,985 controls were included. In a combined analysis, the summary per-allele odds ratio (OR) for BC of 2q35-rs13387042 polymorphism was 1.13 (95% CI: 1.11-1.16; P<10(-5)). Significant associations were also detected under co-dominant, dominant and recessive genetic models. In the subgroup analysis by ethnicity, significantly increased risks were found in Asians, Caucasians and Hispanic whites for the polymorphism in all comparisons; whereas no significant associations were found among Africans. In addition, we find 2q35-rs13387042 polymorphism conferred significantly risks for both ER-positive and ER-negative tumors. Furthermore, significant associations were also detected both in PR-positive and PR-negative cancer.
   Conclusions: Our findings demonstrated that rs13387042-A allele is a risk-conferring factors for the development of BC, especially in Asians, Caucasians and Hispanic whites.
C1 [Gu, Chao; Zhou, Liang; Yu, Jianping] Fudan Univ, Jinshan Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.
RP Yu, JP (reprint author), Fudan Univ, Jinshan Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.
EM jianping_yu001@126.com
CR Antoniou AC, 2009, HUM MOL GENET, V18, P4442, DOI 10.1093/hmg/ddp372
   Barnholtz-Sloan JS, 2010, CARCINOGENESIS, V31, P1417, DOI 10.1093/carcin/bgq128
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benson JR, 2012, FUTURE ONCOL, V8, P697, DOI [10.2217/fon.12.61, 10.2217/FON.12.61]
   Cai Y, 2011, MUTAGENESIS, V26, P309, DOI 10.1093/mutage/geq095
   Campa D, 2011, J NATL CANCER I, V103, P1252, DOI 10.1093/jnci/djr265
   Chen F, 2011, HUM MOL GENET, V20, P4491, DOI 10.1093/hmg/ddr367
   Chen W, 2012, BREAST CANCER RES TR, V136, P847, DOI 10.1007/s10549-012-2309-9
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Coughlin SS, 2009, CANCER EPIDEMIOL, V33, P315, DOI 10.1016/j.canep.2009.10.003
   Dai JC, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3101
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fletcher O, 2011, JNCI-J NATL CANCER I, V103, P425, DOI 10.1093/jnci/djq563
   Garcia-Closas M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000054
   Harlid S, 2012, BRIT J CANCER, V106, P389, DOI 10.1038/bjc.2011.461
   He CY, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3155
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Huo DZ, 2012, CARCINOGENESIS, V33, P835, DOI 10.1093/carcin/bgs093
   Hutter CM, 2011, CANCER EPIDEM BIOMAR, V20, P1950, DOI 10.1158/1055-9965.EPI-11-0524
   Jiang YD, 2011, BREAST CANCER RES TR, V128, P251, DOI 10.1007/s10549-010-1327-8
   Kim HC, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3158
   Li DW, 2006, HUM MOL GENET, V15, P1995, DOI 10.1093/hmg/ddl122
   Li JM, 2011, BREAST CANCER RES TR, V126, P717, DOI 10.1007/s10549-010-1172-9
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Lin CY, 2012, ANTICANCER RES, V32, P475
   Liu L, 2011, BREAST CANCER RES TR, V125, P479, DOI 10.1007/s10549-010-0959-z
   Milne RL, 2009, JNCI-J NATL CANCER I, V101, P1012, DOI 10.1093/jnci/djp167
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Reeves GK, 2010, JAMA-J AM MED ASSOC, V304, P426, DOI 10.1001/jama.2010.1042
   Shan JX, 2012, BREAST CANCER RES TR, V135, P715, DOI 10.1007/s10549-012-2202-6
   Shulman LN, 2010, J ONCOL, DOI 10.1155/2010/595167
   Slattery ML, 2011, BREAST CANCER RES TR, V129, P531, DOI 10.1007/s10549-011-1498-y
   Stacey SN, 2008, NAT GENET, V40, P703, DOI 10.1038/ng.131
   Stacey SN, 2007, NAT GENET, V39, P865, DOI 10.1038/ng2064
   Stevens KN, 2011, CANCER RES, V71, P6240, DOI 10.1158/0008-5472.CAN-11-1266
   Sueta A, 2012, BREAST CANCER RES TR, V132, P711, DOI 10.1007/s10549-011-1904-5
   Teraoka SN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3057
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Walsh T, 2006, JAMA-J AM MED ASSOC, V295, P1379, DOI 10.1001/jama.295.12.1379
   Walsh T, 2010, P NATL ACAD SCI USA, V107, P12629, DOI 10.1073/pnas.1007983107
   Wang H, 2013, BREAST CANCER RES TR, V137, P511, DOI 10.1007/s10549-012-2343-7
   Zheng W, 2010, J NATL CANCER I, V102, P972, DOI 10.1093/jnci/djq170
   Zheng W, 2009, CANCER EPIDEM BIOMAR, V18, P2761, DOI 10.1158/1055-9965.EPI-09-0624
   Zheng W, 2009, NAT GENET, V41, P324, DOI 10.1038/ng.318
NR 46
TC 4
Z9 4
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 22
PY 2013
VL 8
IS 7
AR e66979
DI 10.1371/journal.pone.0066979
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 187PW
UT WOS:000322132100006
PM 23894282
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zou, P
   Xu, HT
   Chen, P
   Yan, Q
   Zhao, L
   Zhao, P
   Gu, AH
AF Zou, Peng
   Xu, Haitao
   Chen, Pin
   Yan, Qing
   Zhao, Lin
   Zhao, Peng
   Gu, Aihua
TI IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of
   Patients with Gliomas: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID ISOCITRATE DEHYDROGENASE 1; CODON 132 MUTATION; PROMOTER
   HYPERMETHYLATION; COLORECTAL TUMORIGENESIS; IDH1 MUTATIONS;
   GLIOBLASTOMA; TUMORS; MGMT; INACTIVATION; TEMOZOLOMIDE
AB Background: Isocitrate dehydrogenase isoforms 1 and 2 (IDH1 and IDH2) mutations have received considerable attention since the discovery of their relation with human gliomas. The predictive value of IDH1 and IDH2 mutations in gliomas remains controversial. Here, we present the results of a meta-analysis of the associations between IDH mutations and both progression-free survival (PFS) and overall survival (OS) in gliomas. The interrelationship between the IDH mutations and MGMT promoter hypermethylation, EGFR amplification, codeletion of chromosomes 1p/19q and TP53 gene mutation were also revealed.
   Methodology and Principal Findings: An electronic literature search of public databases (PubMed, Embase databases) was performed. In total, 10 articles, including 12 studies in English, with 2,190 total cases were included in the meta-analysis. The IDH mutations were frequent in WHO grade II and III glioma (59.5%) and secondary glioblastomas (63.4%) and were less frequent in primary glioblastomas (7.13%). Our study provides evidence that IDH mutations are tightly associated with MGMT promoter hypermethylation (P<0.001), 1p/19q codeletion (P<0.001) and TP53 gene mutation (P<0.001) but are mutually exclusive with EGFR amplification (P<0.001). This meta-analysis showed that the combined hazard ratio (HR) estimate for overall survival and progression-free survival in patients with IDH mutations was 0.33 (95% CI: 0.25-0.42) and 0.38 (95% CI: 0.21-0.68), compared with glioma patients whose tumours harboured the wild-type IDH. Subgroup analyses based on tumour grade also revealed that the presence of IDH mutations was associated with a better outcome.
   Conclusion: Our study suggests that IDH mutations, which are closely linked to the genomic profile of gliomas, are potential prognostic biomarkers for gliomas.
C1 [Zou, Peng; Xu, Haitao; Chen, Pin; Yan, Qing; Zhao, Lin; Zhao, Peng] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.
   [Gu, Aihua] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China.
RP Zhao, P (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.
EM zhaopeng@njmu.edu.cn; aihuagu@njmu.edu.cn
FU National Natural Science Foundation of China [81172694]; 135 Key Medical
   Project of Jiangsu Province [XK201117]; practice innovation training
   program projects for the Jiangsu College students; Priority Academic
   Program Development of Jiangsu Higher Education Institutions
FX This work was supported by the National Natural Science Foundation of
   China (grant No. 81172694); the Grant for the 135 Key Medical Project of
   Jiangsu Province (No. XK201117); the practice innovation training
   program projects for the Jiangsu College students; and the Priority
   Academic Program Development of Jiangsu Higher Education Institutions.
   The funders had no role in study design, data collection and analysis.
CR Balss J, 2008, ACTA NEUROPATHOL, V116, P597, DOI 10.1007/s00401-008-0455-2
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bleeker FE, 2010, ACTA NEUROPATHOL, V119, P487, DOI 10.1007/s00401-010-0645-6
   BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851
   Bralten LBC, 2011, ANN NEUROL, V69, P455, DOI 10.1002/ana.22390
   Cai XM, 2005, INT J CANCER, V117, P905, DOI 10.1002/ijc.21251
   Christensen BC, 2011, JNCI-J NATL CANCER I, V103, DOI 10.1093/jnci/djq497
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Esteller M, 2001, CANCER RES, V61, P4689
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2000, CANCER RES, V60, P2368
   Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319
   Gravendeel LAM, 2009, CANCER RES, V69, P9065, DOI 10.1158/0008-5472.CAN-09-2307
   Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Ichimura K, 2009, NEURO-ONCOLOGY, V11, P341, DOI 10.1215/15228517-2009-025
   Kim SY, 2007, MOL CELL BIOCHEM, V302, P27, DOI 10.1007/s11010-007-9421-x
   KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Li SW, 2012, NEURO-ONCOLOGY, V14, P109, DOI 10.1093/neuonc/nor185
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840
   Mukasa A, 2012, CANCER SCI, V103, P587, DOI 10.1111/j.1349-7006.2011.02175.x
   Nobusawa S, 2009, CLIN CANCER RES, V15, P6002, DOI 10.1158/1078-0432.CCR-09-0715
   Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011
   Ozben T, 2007, J PHARM SCI-US, V96, P2181, DOI 10.1002/jps.20874
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Reitman ZJ, 2010, J NATL CANCER I, V102, P932, DOI 10.1093/jnci/djq187
   Sanson M, 2009, J CLIN ONCOL, V27, P4150, DOI 10.1200/JCO.2009.21.9832
   Shibahara I, 2011, INT J CLIN ONCOL
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020
   Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958
   Weller M, 2009, J CLIN ONCOL, V27, P5743, DOI 10.1200/JCO.2009.23.0805
   Wick W, 2009, J CLIN ONCOL, V27, P5874, DOI 10.1200/JCO.2009.23.6497
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
   Yan W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030339
   Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944
   2008, NATURE, V455, P1061
NR 42
TC 49
Z9 53
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 22
PY 2013
VL 8
IS 7
AR e68782
DI 10.1371/journal.pone.0068782
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 187PW
UT WOS:000322132100026
PM 23894344
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhu, L
   Zhu, QQ
   Zhang, XL
   Wang, HW
AF Zhu, Li
   Zhu, Qingqing
   Zhang, Xinlin
   Wang, Hongwei
TI The Correlation Analysis of Two Common Polymorphisms in STAT6 Gene and
   the Risk of Asthma: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SERUM IGE LEVELS; SIGNAL TRANSDUCER; CHILDHOOD
   ASTHMA; SUSCEPTIBILITY LOCI; TRANSCRIPTION 6; ATOPIC ASTHMA; 1ST EXON;
   POPULATION; HAPLOTYPE
AB Background: Several studies have reported that the GT dinucleotide repeat length polymorphism and the G2964A polymorphism in signal transducer and activator of transcriptional factor 6 gene are associated with asthma susceptibility, but others have conflicting results. Our meta-analysis aimed to elucidate the emerging paradigms.
   Methods: We searched PUBMED, EMBASE, ISI web of knowledge, Chinese National Knowledge Infrastructure, and Wanfang databases. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to evaluate the strength of association. We applied Bonferroni step-down and Benjamini-Hochberg step-up methods to adjust the values for multiple comparisons.
   Results: A total of 12 individual studies in 11 articles were included in the meta-analysis. For GT repeat polymorphism, the S allele had approximately 45% increased risk of asthma (S vs. L: OR = 1.45, 95% CI = 1.22-1.71, P-UNCORRECTED < 0.001, P-Bon < 0.001, P-FDR < 0.001). Further analysis indicated that GT(13) and GT(14) contributed to asthma risk, whereas GT(15) and GT(16) were protective (GT(13) vs. GT(15): OR = 1.38, 95% CI = 1.16-1.65, P-UNCORRECTED = 0.001, P-Bon = 0.005, P-FDR = 0.002). Similar results were obtained in the subgroup analysis of Asian population. G2964A polymorphism analysis showed that the AA genotype moderately increased the risk of asthma by 47% compared with the GG genotype (OR = 1.47, p = 0.068) in Chinese population, whereas the 2964A allele moderately increased the risk of asthma in Chinese population by 18% (2964A vs. 2964G: OR = 1.18, p = 0.08). However, none of the associations reached statistically significant levels particularly after correction for multiple testing.
   Conclusions: This meta-analysis suggests that S allele (GT(13) and GT(14)) of the GT repeat polymorphism confers significant risks to asthma. However, the G2964A polymorphism does not have an association with the susceptibility to asthma.
C1 [Zhu, Li; Zhu, Qingqing; Zhang, Xinlin; Wang, Hongwei] Nanjing Univ, Ctr Translat Med, Nanjing 210008, Jiangsu, Peoples R China.
   [Zhu, Li; Zhu, Qingqing; Zhang, Xinlin; Wang, Hongwei] Nanjing Univ, Jiangsu Key Lab Mol Med, Sch Med, Nanjing 210008, Jiangsu, Peoples R China.
   [Zhu, Li; Zhang, Xinlin] Nanjing Univ, Dept Cardiol, Drum Tower Hosp, Sch Med, Nanjing 210008, Jiangsu, Peoples R China.
RP Zhang, XL (reprint author), Nanjing Univ, Ctr Translat Med, Nanjing 210008, Jiangsu, Peoples R China.
EM xinlzhang0807@gmail.com; hwang@nju.edu.cn
FU Natural Science Foundation of Jiangsu Province China [BK2010245];
   National Natural Science Foundation of China [81030013]; National Basic
   Research Program of China [2009CB918704]
FX This study was supported by the grants from the Natural Science
   Foundation of Jiangsu Province China (No. BK2010245), the National
   Natural Science Foundation of China (81030013), and the grant from
   National Basic Research Program of China (Grant No. 2009CB918704). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Caraballo L., 2004, Journal of Allergy and Clinical Immunology, V113, pS327, DOI 10.1016/j.jaci.2004.01.684
   Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   [丁毅鹏 Ding Yipeng], 2010, [中国全科医学, Chinese General Practice], V13, P1765
   Duetsch G, 2002, HUM MOL GENET, V11, P613, DOI 10.1093/hmg/11.6.613
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748
   Gao PS, 2000, J MED GENET, V37, P380
   Gao PS, 2004, J MED GENET, V41, P535, DOI 10.1136/jmg.2003.015842
   Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887
   Hu JH, 2005, CHINESE J CLIN LAB S, V23, P9
   [胡俊华 Hu Junhua], 2005, [中华微生物学和免疫学杂志, Chinese Journal of Microbiology and Immunology], V25, P243
   Li W, 2007, CHIN J PRIM MED PHAR, V14, P764
   Li YF, 2007, RESP MED, V101, P1977, DOI 10.1016/j.rmed.2007.04.006
   [林荣军 Lin Rongjun], 2012, [实用儿科临床杂志, Journal of Applied Clinical Pediatrics], V27, P1258
   Los H, 2001, Twin Res, V4, P81, DOI 10.1375/1369052012191
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marsh DG, 1997, NAT GENET, V15, P389
   Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087
   Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312
   Patel BKR, 1998, GENOMICS, V52, P192, DOI 10.1006/geno.1998.5436
   Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048
   Shao CC, 2004, J HUM GENET, V49, P115, DOI 10.1007/s10038-003-0118-z
   Spycher BD, 2012, J ALLERGY CLIN IMMUN, V130, P503, DOI 10.1016/j.jaci.2012.06.002
   Suzuki Michiko, 2004, Allergology International, V53, P241, DOI 10.1111/j.1440-1592.2004.00340.x
   Takeda K, 1997, J MOL MED-JMM, V75, P317, DOI 10.1007/s001090050117
   Tamura K, 2003, INT ARCH ALLERGY IMM, V131, P33, DOI 10.1159/000070432
   Tamura K, 2001, CLIN EXP ALLERGY, V31, P1509, DOI 10.1046/j.1365-2222.2001.01191.x
   Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888
   Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257
   Wang Q, 2011, BIOMED ENVIRON SCI, V24, P670, DOI 10.3967/0895-3988.2011.06.012
   Weidinger S, 2004, J MED GENET, V41, P658, DOI 10.1136/jmg.2004.020263
NR 35
TC 7
Z9 7
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 4
PY 2013
VL 8
IS 7
AR e67657
DI 10.1371/journal.pone.0067657
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 204FO
UT WOS:000323350700018
PM 23861779
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, HR
   Liu, L
   Zhao, JZ
   Cui, GL
   Chen, C
   Ding, H
   Wang, DW
AF Wang, Haoran
   Liu, Lei
   Zhao, Jinzhao
   Cui, Guanglin
   Chen, Chen
   Ding, Hu
   Wang, Dao Wen
TI Large Scale Meta-Analyses of Fasting Plasma Glucose Raising Variants in
   GCK, GCKR, MTNR1B and G6PC2 and Their Impacts on Type 2 Diabetes
   Mellitus Risk
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; REGULATORY-PROTEIN GCKR; MELATONIN RECEPTOR 1B;
   BETA-CELL; RS780094 POLYMORPHISM; INSULIN-RESISTANCE; SUSCEPTIBILITY;
   POPULATION; GENE; LOCI
AB Background: The evidence that the variants GCK rs1799884, GCKR rs780094, MTNR1B rs10830963 and G6PC2 rs560887, which are related to fasting plasma glucose levels, increase the risk of type 2 diabetes mellitus (T2DM) is contradictory. We therefore performed a meta-analysis to derive a more precise estimation of the association between these polymorphisms and T2DM.
   Methods: All the publications examining the associations of these variants with risk of T2DM were retrieved from the MEDLINE and EMBASE databases. Using the data from the retrieved articles, we computed summary estimates of the associations of the four variants with T2DM risk. We also examined the studies for heterogeneity, as well as for bias of the publications.
   Results: A total of 113,025 T2DM patients and 199,997 controls from 38 articles were included in the meta-analysis. Overall, the pooled results indicated that GCK (rs1799884), GCKR (rs780094) and MTNR1B (rs10830963) were significantly associated with T2DM susceptibility (OR, 1.04; 95%CI, 1.01-1.08; OR, 1.08; 95%CI, 1.05-1.12 and OR, 1.05; 95%CI, 1.02-1.08, respectively). After stratification by ethnicity, significant associations for the GCK, MTNR1B and G6PC2 variants were detected only in Caucasians (OR, 1.09; 95%CI, 1.02-1.16; OR, 1.10; 95%CI, 1.08-1.13 and OR, 0.97; 95%CI, 0.95-0.99, respectively), but not in Asians (OR, 1.02, 95%CI 0.98-1.05; OR, 1.01; 95%CI, 0.98-1.04 and OR, 1.12; 95%CI, 0.91-1.32, respectively).
   Conclusions: Our meta-analyses demonstrated that GCKR rs780094 variant confers high cross-ethnicity risk for the development of T2DM, while significant associations between GCK, MTNR1B and G6PC2 variants and T2DM risk are limited to Caucasians.
C1 [Wang, Haoran; Liu, Lei; Zhao, Jinzhao; Cui, Guanglin; Ding, Hu; Wang, Dao Wen] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Internal Med, Wuhan 430074, Peoples R China.
   [Chen, Chen; Wang, Dao Wen] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Genet Diag Ctr, Wuhan 430074, Peoples R China.
RP Ding, H (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Internal Med, Wuhan 430074, Peoples R China.
EM dingo8369@163.com; dwwang@tjh.tjmu.edu.cn
RI Chen, Chen/B-2080-2014
OI ding, hu/0000-0002-1814-1552
FU National "973'' project [2012CB518004]; "863'' project [2012AA02A510];
   Ministry of Education of China for Outstanding Young Teachers in
   University [20110142120012]
FX This work was supported by grants from National "973'' project (No.
   2012CB518004), "863'' project (No. 2012AA02A510) and Ministry of
   Education of China for Outstanding Young Teachers in University
   (20110142120012). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Attia J, 2003, J CLIN EPIDEMIOL, V56, P297, DOI 10.1016/S0895-4356(03)00011-8
   Balkau B, 2008, DIABETES CARE, V31, P2056, DOI 10.2337/dc08-0368
   Been LF, 2012, NUTR METAB CARDIOVAS, V22, P944, DOI 10.1016/j.numecd.2011.01.006
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bi M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011690
   Bonetti S, 2011, DIABETES CARE, V34, P1205, DOI 10.2337/dc10-2218
   Bouatia-Naji N, 2008, SCIENCE, V320, P1085, DOI 10.1126/science.1156849
   Brito EC, 2009, DIABETES, V58, P1411, DOI 10.2337/db08-1623
   Cauchi S, 2012, DIABETES METAB, V38, P316, DOI 10.1016/j.diabet.2012.02.003
   Cauchi S, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-45
   Chambers JC, 2009, DIABETES, V58, P2703, DOI 10.2337/db08-1805
   Chen GJ, 2012, HUM MOL GENET, V21, P4530, DOI 10.1093/hmg/dds282
   Cho YS, 2012, NAT GENET, V44, P67, DOI 10.1038/ng.1019
   Dietrich K, 2011, DIABETIC MED, V28, P1373, DOI 10.1111/j.1464-5491.2011.03374.x
   Dupuis J, 2010, NAT GENET, V42, P105, DOI 10.1038/ng.520
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ezzidi I, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-33
   Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202
   Florez JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044424
   Fujita H, 2012, J HUM GENET, V57, P776, DOI 10.1038/jhg.2012.110
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hishida A, 2012, ENDOCR J, V59, P589, DOI 10.1507/endocrj.EJ11-0310
   Holmkvist J, 2008, DIABETES, V57, P1738, DOI 10.2337/db06-1464
   Hu C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011761
   Hunter DJ, 2005, NAT REV GENET, V6, P287, DOI 10.1038/nrg1578
   Iwata M, 2012, DIABETES CARE, V35, P1763, DOI 10.2337/dc11-2006
   Kooner JS, 2011, NAT GENET, V43, P984, DOI 10.1038/ng.921
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Ling Y, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-66
   Ling Y, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-27
   Liu C, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-59
   Lyssenko V, 2009, NAT GENET, V41, P82, DOI 10.1038/ng.288
   Martin CC, 2001, J BIOL CHEM, V276, P25197, DOI 10.1074/jbc.M101549200
   MATSUTANI A, 1992, GENOMICS, V12, P319, DOI 10.1016/0888-7543(92)90380-B
   Mohas M, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-79
   Ng MCY, 2013, DIABETES, V62, P965, DOI [10.2337/db12-0266/-/DC1, 10.2337/db12-0266]
   Ohshige T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026911
   Olsson L, 2011, DIABETOLOGIA, V54, P1375, DOI 10.1007/s00125-011-2106-8
   Onuma H, 2010, J HUM GENET, V55, P600, DOI 10.1038/jhg.2010.75
   Petitti DB, 2001, STAT MED, V20, P3625, DOI 10.1002/sim.1091
   Piche ME, 2004, DIABETES CARE, V27, P2470, DOI 10.2337/diacare.27.10.2470
   Prokopenko I, 2009, NAT GENET, V41, P77, DOI 10.1038/ng.290
   Qi Q, 2009, DIABETOLOGIA, V52, P834, DOI 10.1007/s00125-009-1290-2
   Ramos E, 2011, DIABETOLOGIA, V54, P783, DOI 10.1007/s00125-010-2002-7
   Rees SD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024710
   Reiling E, 2009, DIABETOLOGIA, V52, P1866, DOI 10.1007/s00125-009-1413-9
   Renstrom F, 2011, DIABETES, V60, P345, DOI 10.2337/db10-0933
   Ronn T, 2009, DIABETOLOGIA, V52, P830, DOI 10.1007/s00125-009-1297-8
   Rose CS, 2009, DIABETOLOGIA, V52, P2122, DOI 10.1007/s00125-009-1463-z
   Rose CS, 2005, DIABETES, V54, P3026, DOI 10.2337/diabetes.54.10.3026
   Saxena R, 2010, NAT GENET, V42, P142, DOI 10.1038/ng.521
   Sparso T, 2008, DIABETOLOGIA, V51, P70, DOI 10.1007/s00125-007-0865-z
   Sparso T, 2009, DIABETES, V58, P1450, DOI 10.2337/db08-1660
   Stancakova A, 2011, DIABETES, V60, P1608, DOI 10.2337/db10-1655
   Tabara Y, 2011, METABOLISM, V60, P1634, DOI 10.1016/j.metabol.2011.03.014
   Tabassum R, 2013, DIABETES, V62, P977, DOI [10.2337/db12-0406/-/DC1, 10.2337/db12-0406]
   Takeuchi F, 2010, DIABETOLOGIA, V53, P299, DOI 10.1007/s00125-009-1595-1
   Tam CHT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011428
   Teo YY, 2010, GENET EPIDEMIOL, V34, P653, DOI 10.1002/gepi.20522
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Tirosh A, 2005, NEW ENGL J MED, V353, P1454, DOI 10.1056/NEJMoa050080
   Vaxillaire M, 2008, DIABETES, V57, P2253, DOI 10.2337/db07-1807
   Vaxillaire M, 2008, DIABETES, V57, P244, DOI 10.2337/db07-0615
   Wagner R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023639
   WARNER JP, 1995, MAMM GENOME, V6, P532, DOI 10.1007/BF00356171
   Weber MB, 2012, ANNU REV NUTR, V32, P417, DOI 10.1146/annurev-nutr-071811-150630
   Wen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009153
   Xia Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050107
   Yang QH, 1999, EPIDEMIOLOGY, V10, P167, DOI 10.1097/00001648-199903000-00014
NR 69
TC 15
Z9 16
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 28
PY 2013
VL 8
IS 6
AR e67665
DI 10.1371/journal.pone.0067665
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 174IH
UT WOS:000321148400125
PM 23840762
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, YJ
   Yang, X
   Wang, XX
   Qiu, MT
   You, YZ
   Zhang, ZX
   Zhu, SM
   Xu, L
   Tang, FL
AF Wu, Yu-Jiao
   Yang, Xin
   Wang, Xiao-Xiao
   Qiu, Man-Tang
   You, Yi-Zhong
   Zhang, Zhi-Xin
   Zhu, Shan-Mei
   Xu, Lin
   Tang, Feng-Lei
TI Association of Vitamin D Receptor BsmI Gene Polymorphism with Risk of
   Tuberculosis: A Meta-Analysis of 15 Studies
SO PLOS ONE
LA English
DT Article
ID PULMONARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; FOKI POLYMORPHISMS;
   CLINICAL-TRIALS; REGULATORY ROLE; WEST-AFRICA; VDR GENE; HLA-DR;
   SUSCEPTIBILITY; VARIANTS
AB Background: Genetic variations in vitamin D receptor (VDR) may contribute to tuberculosis (TB) risk. Many studies have investigated the association between VDR BsmI gene polymorphism and TB risk, but yielded inconclusive results.
   Methodology/Principal Findings: We performed a comprehensive meta-analysis of 15 publications with a total of 2309 cases and 3568 controls. We assessed the strength of the association between VDR BsmI gene polymorphism and TB risk and performed sub-group analyses by ethnicity, sample size and Hardy-Weinberg equilibrium (HWE). We found a statistically significant correlation between VDR BsmI gene polymorphism and decreased TB risk in four comparison models: allele model (b vs. B: OR = 0.78, 95% CI = 0.67, 0.89; P-heterogeneity = 0.004), homozygote model (bb vs. BB: OR = 0.61, 95% CI = 0.43, 0.87; P-heterogeneity = 0.001), recessive model (bb vs. Bb+BB: OR = 0.70, 95% CI = 0.56, 0.88; P-heterogeneity = 0.005) and dominant model (bb+Bb vs. BB: OR = 0.77, 95% CI = 0.61, 0.97; P-heterogeneity = 0.010), especially in studies based on Asian population. Sub-group analyses also revealed that there was a statistically decreased TB risk in "small" studies (<500 participants) and studies with P-HWE>0.5. Meta-regression and stratification analysis both showed that the ethnicity and sample size contributed to heterogeneity.
   Conclusions: This meta-analysis suggests that VDR BsmI gene polymorphism is associated with a significant decreased TB risk, especially in Asian population.
C1 [Wu, Yu-Jiao; Zhu, Shan-Mei; Tang, Feng-Lei] Changzhou Third Peoples Hosp, Dept Pharm, Changzhou, Peoples R China.
   [Wu, Yu-Jiao] Soochow Univ, Coll Pharm, Suzhou, Peoples R China.
   [Yang, Xin; Qiu, Man-Tang; Xu, Lin] Nanjing Med Univ, Clin Coll 4, Nanjing, Jiangsu, Peoples R China.
   [Yang, Xin; Qiu, Man-Tang; Xu, Lin] Nanjing Med Univ, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Dept Thorac Surg, Nanjing, Jiangsu, Peoples R China.
   [Wang, Xiao-Xiao] Georgia Hlth Sci Univ, Dept Biostat, Augusta, GA USA.
   [You, Yi-Zhong] Changzhou First Peoples Hosp, Dept Pharm, Changzhou, Peoples R China.
   [Zhang, Zhi-Xin] Changzhou Third Peoples Hosp, Dept Pulm TB, Changzhou, Peoples R China.
RP Xu, L (reprint author), Nanjing Med Univ, Clin Coll 4, Nanjing, Jiangsu, Peoples R China.
EM xulin83cn@gmail.com; tangfengleicn@163.com
RI Qiu, Mantang/L-8937-2019
CR Alagarasu K, 2009, J CLIN IMMUNOL, V29, P196, DOI 10.1007/s10875-008-9234-z
   Ates O, 2011, MOL BIOL REP, V38, P2633, DOI 10.1007/s11033-010-0404-8
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BOISSEL JP, 1988, EUR J CLIN PHARMACOL, V34, P535, DOI 10.1007/BF00615213
   Borgdorff MW, 1998, NEW ENGL J MED, V339, P199
   Bornman L, 2004, J INFECT DIS, V190, P1631, DOI 10.1086/424462
   Bowen EF, 2000, LANCET, V356, P1488, DOI 10.1016/S0140-6736(00)02876-2
   Cao S, 2012, CHINESE MED J-PEKING, V125, P920, DOI 10.3760/cma.j.issn.0366-6999.2012.05.033
   DAVIES PDO, 1995, J ROY COLL PHYS LOND, V29, P113
   Delgado JC, 2002, J INFECT DIS, V186, P1463, DOI 10.1086/344891
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Diagbouga S, 1999, SCAND J IMMUNOL, V49, P203, DOI 10.1046/j.1365-3083.1999.00467.x
   Fitness J, 2004, AM J TROP MED HYG, V71, P341, DOI 10.4269/ajtmh.2004.71.341
   Gao L, 2010, INT J TUBERC LUNG D, V14, P15
   Hillerdal G, 2000, RESPIRATION, V67, P134, DOI 10.1159/000029498
   Kang Tae Jin, 2011, Immune Netw, V11, P253, DOI 10.4110/in.2011.11.5.253
   Lombard Z, 2006, HUM IMMUNOL, V67, P643, DOI 10.1016/j.humimm.2006.04.008
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marashian SM, 2010, TUBERK TORAK, V58, P147
   Merza M, 2009, BRAZ J INFECT DIS, V13, P252, DOI 10.1590/S1413-86702009000400002
   MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0
   Newport M J, 2004, Monaldi Arch Chest Dis, V61, P102
   Olesen R, 2007, GENES IMMUN, V8, P456, DOI 10.1038/sj.gene.6364410
   Price P, 2012, AIDS RES HUM RETROV, V28, P1216, DOI 10.1089/aid.2011.0272
   Qiu MT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050887
   Raghavan S, 2012, TUBERCULOSIS, V92, P18, DOI 10.1016/j.tube.2011.08.004
   ROOK GAW, 1986, IMMUNOLOGY, V57, P159
   Selvaraj P, 2008, J CLIN IMMUNOL, V28, P306, DOI 10.1007/s10875-007-9152-5
   Selvaraj P, 2004, J CLIN IMMUNOL, V24, P523, DOI 10.1023/B:JOCI.0000040923.07879.31
   Selvaraj P, 2004, CLIN GENET, V65, P73, DOI 10.1111/j..2004.00183.x
   Selvaraj P, 2009, J CLIN IMMUNOL, V29, P470, DOI 10.1007/s10875-009-9277-9
   Selvaraj P, 2001, TUBERCULOSIS, V81, P335, DOI 10.1054/tube.2001.0307
   Sharma PR, 2011, INFECT GENET EVOL, V11, P1456, DOI 10.1016/j.meegid.2011.05.019
   Singh A, 2011, INT J TUBERC LUNG D, V15, P1468, DOI 10.5588/ijtld.11.0089
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702
   Tachi Y, 2003, LIFE SCI, V73, P3313, DOI 10.1016/j.lfs.2003.03.001
   TSUKADA Y, 1980, CELL MOL BIOL, V26, P493
   Uitterlinden AG, 2004, GENE, V338, P143, DOI 10.1016/j.gene.2004.05.014
   Verbeek W, 1997, BIOCHEM BIOPH RES CO, V238, P77, DOI 10.1006/bbrc.1997.7239
   Vidyarani M, 2009, EXP MOL PATHOL, V86, P69, DOI 10.1016/j.yexmp.2008.10.002
   Whitfield GK, 2001, MOL CELL ENDOCRINOL, V177, P145
   Wilkinson RJ, 1999, J EXP MED, V189, P1863, DOI 10.1084/jem.189.12.1863
NR 42
TC 18
Z9 20
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 25
PY 2013
VL 8
IS 6
AR e66944
DI 10.1371/journal.pone.0066944
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 175IB
UT WOS:000321223000048
PM 23825591
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Hao, NB
   He, YF
   Zhang, D
   Luo, G
   Chen, BJ
   Zhang, Y
   Yang, SM
AF Hao, Ning-Bo
   He, Ya-Fei
   Zhang, Dan
   Luo, Gang
   Chen, Bai-Jun
   Zhang, Yao
   Yang, Shi-Ming
TI PLCE1 Polymorphism and Upper Gastrointestinal Cancer Risk: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; CHINESE POPULATION; ESOPHAGEAL CANCER;
   PHOSPHOLIPASE-C; GENETIC-VARIATION; TEA DRINKING; SUSCEPTIBILITY;
   ASSOCIATION; ADENOCARCINOMA; TEMPERATURE
AB Background: In recent years, the PLCE1 rs2274223 polymorphism has been extensively investigated as a potential risk factor for upper gastrointestinal cancers, including squamous cell carcinoma (ESCC) and gastric cancer. However, the results of these studies have been inconsistent.
   Methods: A meta-analysis of 13 case-control studies was performed including more than 11,000 subjects with genotyped PLCE1 rs2274223 polymorphisms. Odds ratios (OR) with 95% confidence intervals (CI) were employed to assess the association of the PLCE1 rs2274223 polymorphism with a susceptibility to ESCC or gastric cancer.
   Results: A statistically significant increase in the risk of ESCC was associated with the PLCE1 rs2274223 polymorphism. This included the homozygous genetic model (OR = 1.46), heterozygous genetic model (OR = 1.25) and allelic genetic model (OR = 1.23). Similar results were consistently found for gastric cancer. In a subgroup analysis, the PLCE1 rs2274223 polymorphism was found to be a very sensitive marker for gastric cardia cancer as shown by the homozygous genetic model (OR = 2.23), heterozygous genetic model(OR = 1.59) and allelic genetic model (OR = 1.47). The risk associations of all of the gastric cardia cancer models were statistically significant. In contrast, none of the genetic models for non-cardia gastric cancer were significant.
   Conclusions: In this meta-analysis, the PLCE1 rs2274223 polymorphism was confirmed to have a statistically significant association with an increasing risk of ESCC and gastric cancer. The increase risk was especially observed for gastric cardia cancer.
C1 [Hao, Ning-Bo; He, Ya-Fei; Zhang, Dan; Luo, Gang; Chen, Bai-Jun; Yang, Shi-Ming] Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing, Peoples R China.
   [Zhang, Yao] Third Mil Med Univ, Dept Epidemiol, Chongqing, Peoples R China.
   [Yang, Shi-Ming] Third Mil Med Univ, Evidence Based Med & Clin Epidemiol Ctr, Chongqing, Peoples R China.
   [Zhang, Yao] Third Mil Med Univ, Chongqing Key Lab Dis Prote, Southwest Hosp, Chongqing, Peoples R China.
RP Zhang, Y (reprint author), Third Mil Med Univ, Dept Epidemiol, Chongqing, Peoples R China.
EM sydzy2003@yahoo.com.cn; shimingyang@yahoo.com
FU Chongqing Science Fund for Distinguished Young Scholars (CSTC)
   [2009BA5045]
FX This work was supported by grants from the Chongqing Science Fund for
   Distinguished Young Scholars (CSTC, 2009BA5045). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abnet CC, 2010, NAT GENET, V42, P764, DOI 10.1038/ng.649
   Baertschiger RM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006657
   Bai YF, 2004, CANCER RES, V64, P8808, DOI 10.1158/0008-5472.CAN-04-3143
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bourguignon LYW, 2006, J BIOL CHEM, V281, P14026, DOI 10.1074/jbc.M507734200
   Bunney TD, 2009, ADV ENZYME REGUL, V49, P54, DOI 10.1016/j.advenzreg.2009.01.004
   Bye H, 2012, CARCINOGENESIS, V33, P2155, DOI 10.1093/carcin/bgs262
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dura P, 2012, EUR J CANCER PREV
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gu HY, 2012, MOL BIOL REP, V39, P9105, DOI 10.1007/s11033-012-1782-x
   Hinkes B, 2006, NAT GENET, V38, P1397, DOI 10.1038/ng1918
   Hu HC, 2012, ANN SURG ONCOL, V19, P2403, DOI 10.1245/s10434-011-2160-y
   Islami F, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b929
   Islami F, 2009, INT J CANCER, V125, P491, DOI 10.1002/ijc.24445
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Liu L, 2011, CARCINOGENESIS, V32, P336, DOI 10.1093/carcin/bgq264
   Luo DW, 2011, J GASTROENTEROL, V46, P1260, DOI 10.1007/s00535-011-0445-3
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mbulaiteye SM, 2009, FRONT BIOSCI-LANDMRK, V14, P1490, DOI 10.2741/3320
   Miao XP, 2006, GASTROENTEROLOGY, V131, P420, DOI 10.1053/j.gastro.2006.05.050
   Ou LP, 2010, CANCER GENET CYTOGEN, V200, P110, DOI 10.1016/j.cancergencyto.2010.01.021
   Palmer AJ, 2012, EUR J CANCER PREV, V21, P541, DOI 10.1097/CEJ.0b013e3283529b79
   Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281
   Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200
   Sorli SC, 2005, ONCOGENE, V24, P90, DOI 10.1038/sj.onc.1208168
   Tran GD, 2005, INT J CANCER, V113, P456, DOI 10.1002/ijc.20616
   Wang LD, 2010, NAT GENET, V42, P759, DOI 10.1038/ng.648
   Wang MY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031932
   Wang XL, 2008, HEPATO-GASTROENTEROL, V55, P2039
   Wing Michele R, 2003, Mol Interv, V3, P273, DOI 10.1124/mi.3.5.273
   Wu M, 2009, INT J CANCER, V124, P1907, DOI 10.1002/ijc.24142
   Zhang HZ, 2011, CARCINOGENESIS, V32, P848, DOI 10.1093/carcin/bgr051
   Zhang XM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021894
NR 34
TC 13
Z9 13
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 24
PY 2013
VL 8
IS 6
AR e67229
DI 10.1371/journal.pone.0067229
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 182JP
UT WOS:000321738400123
PM 23826241
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, YQ
   Wang, ZH
   Fu, LN
   Chen, YX
   Fang, JY
AF Wang, Yunqian
   Wang, Zhenhua
   Fu, Linna
   Chen, Yingxuan
   Fang, Jingyuan
TI Legume Consumption and Colorectal Adenoma Risk: A Meta-Analysis of
   Observational Studies
SO PLOS ONE
LA English
DT Article
ID CANCER PREVENTION; VEGETABLE INTAKE; DIETARY FIBER; FRUIT; COLON;
   POLYPS; HEALTH; POPULATION; PREVALENCE; BUTYRATE
AB Background: The anticancer effects of legumes have been explored extensively, but evidence from epidemiologic studies on colorectal adenoma is controversial. We performed a meta-analysis to assess these issues.
   Methods: A systemic search of several databases was conducted for relevant studies evaluating the relationship between legume intake and adenoma risk, with no language restriction, from January 1, 1966, to April 1, 2013.
   Results: Three cohort and eleven case control studies with 8,380 cases and a total of 101,856 participants were included in the analysis; the pooled odds ratio (95% confidence interval) for the highest vs. lowest consumption categories was 0.83 (0.75-0.93), with moderate level of heterogeneity (I-2 = 25.9% and P = 0.146) based on a random effects model. A decreased risk of adenoma was also observed in most of our subgroup meta-analyses.
   Conclusions: Higher intake of legumes significantly reduced the risk of colorectal adenoma in our meta-analysis. Nevertheless, due to possible confounders and bias, further investigations are warranted to confirm this relationship.
C1 [Wang, Yunqian; Wang, Zhenhua; Fu, Linna; Chen, Yingxuan; Fang, Jingyuan] Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Renji Hosp, Shanghai 200030, Peoples R China.
   [Wang, Yunqian; Wang, Zhenhua; Fu, Linna; Chen, Yingxuan; Fang, Jingyuan] Shanghai Inst Digest Dis, Shanghai, Peoples R China.
   [Wang, Yunqian; Wang, Zhenhua; Fu, Linna; Chen, Yingxuan; Fang, Jingyuan] Shanghai Jiao Tong Univ, Minist Hlth, Key Lab Gastroenterol & Hepatol, Shanghai 200030, Peoples R China.
RP Chen, YX (reprint author), Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Renji Hosp, Shanghai 200030, Peoples R China.
EM yingxuanchen2013@yahoo.cn
FU National Natural Science Foundation of China [81172321]; National
   High-tech R&D Program of China [2012AA02A506]
FX Funding provided by the National Natural Science Foundation of China
   (No. 81172321, to C.Y.X), and the National High-tech R&D Program of
   China (No. 2012AA02A506). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Agurs-Collins Tanya, 2006, J Natl Black Nurses Assoc, V17, P6
   Aune D, 2009, CANCER CAUSE CONTROL, V20, P1605, DOI 10.1007/s10552-009-9406-z
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BENITO E, 1993, INT J CANCER, V55, P213, DOI 10.1002/ijc.2910550208
   Bingham SA, 2000, BIOCHEM SOC T, V28, P12, DOI 10.1042/bst0280012
   Blumenstein I, 2013, EUR J GASTROEN HEPAT, V25, P556, DOI 10.1097/MEG.0b013e32835d1ef4
   Bobe G, 2008, CANCER EPIDEM BIOMAR, V17, P1344, DOI 10.1158/1055-9965.EPI-07-0747
   Clarke JM, 2012, CARCINOGENESIS, V33, P197, DOI 10.1093/carcin/bgr254
   Clemente A, 2013, BOWMAN BIRK INHIBITO
   Costa GED, 2006, FOOD CHEM, V94, P327, DOI 10.1016/j.foodchem.2004.11.020
   Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dilis V, 2009, MEDITERR J NUTR META, V1, P149, DOI 10.1007/s12349-008-0023-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
   HAENSZEL W, 1973, J NATL CANCER I, V51, P1765, DOI 10.1093/jnci/51.6.1765
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   HU JF, 1991, INT J EPIDEMIOL, V20, P362, DOI 10.1093/ije/20.2.362
   Iscovich J, 2006, INT J CANCER, V51, P851
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   KATO I, 1990, JPN J CANCER RES, V81, P1101, DOI 10.1111/j.1349-7006.1990.tb02520.x
   Kennedy AR, 1998, AM J CLIN NUTR, V68, p1406S, DOI 10.1093/ajcn/68.6.1406S
   KONO S, 1993, JPN J CANCER RES, V84, P13, DOI 10.1111/j.1349-7006.1993.tb02777.x
   Lee Se Young, 2005, Korean J Gastroenterol, V45, P23
   Lin J, 2005, CANCER CAUSE CONTROL, V16, P225, DOI 10.1007/s10552-004-4025-1
   Manousos O, 2006, INT J CANCER, V32, P1
   Martinez ME, 2009, GASTROENTEROLOGY, V136, P832, DOI 10.1053/j.gastro.2008.12.007
   Mathers JC, 2002, BRIT J NUTR, V88, pS273, DOI [10.1079/BJN.2002717, 10.1079/BJN2002655, 10.1079/BJN2002717]
   Messina MJ, 1999, AM J CLIN NUTR, V70, p439S, DOI 10.1093/ajcn/70.3.439s
   Michels KB, 2006, CANCER RES, V66, P3942, DOI 10.1158/0008-5472.CAN-05-3637
   Millen AE, 2007, AM J CLIN NUTR, V86, P1754
   Nagata C, 2001, DIS COLON RECTUM, V44, P105, DOI 10.1007/BF02234831
   Pan MH, 2011, MOL NUTR FOOD RES, V55, P32, DOI 10.1002/mnfr.201000412
   Platz EA, 1997, CANCER EPIDEM BIOMAR, V6, P661
   Ramadas A, 2009, ASIAN PAC J CANCER P, V10, P925
   Scharlau D, 2009, MUTAT RES-REV MUTAT, V682, P39, DOI 10.1016/j.mrrev.2009.04.001
   Schoenfeld JD, 2013, AM J CLIN NUTR, V97, P127, DOI 10.3945/ajcn.112.047142
   Singh PN, 1998, AM J EPIDEMIOL, V148, P761
   Smith-Warner SA, 2002, AM J EPIDEMIOL, V155, P1104, DOI 10.1093/aje/155.12.1104
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tantamango YM, 2011, NUTR CANCER, V63, P565, DOI 10.1080/01635581.2011.551988
   Toyomura Kengo, 2002, Asian Pac J Cancer Prev, V3, P125
   van Breda SGJ, 2004, CARCINOGENESIS, V25, P2207, DOI 10.1093/carcin/bgh241
   van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   Wilson S., 2002, CANC ENV GENE ENV IN
   Witte JS, 1996, AM J EPIDEMIOL, V144, P1015
   Wu HY, 2009, J NUTR, V139, P340, DOI 10.3945/jn.108.098889
   Yan L, 2010, CANCER EPIDEM BIOMAR, V19, P148, DOI 10.1158/1055-9965.EPI-09-0856
   Zheng X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049581
   Zhong R, 2013, CARCINOGENESIS, V34, P936, DOI 10.1093/carcin/bgs395
NR 51
TC 3
Z9 3
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 24
PY 2013
VL 8
IS 6
AR e67335
DI 10.1371/journal.pone.0067335
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 182JP
UT WOS:000321738400134
PM 23826270
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, JP
   Wang, WB
   Yang, XX
   Yang, L
   Ren, L
   Zhou, FX
   Hu, L
   He, W
   Li, BY
   Zhu, Y
   Jiang, HG
   Zhou, YF
AF Yang, Jun-Ping
   Wang, Wen-Bo
   Yang, Xiao-Xi
   Yang, Lei
   Ren, Li
   Zhou, Fu-Xiang
   Hu, Liu
   He, Wei
   Li, Bai-Yu
   Zhu, Yan
   Jiang, Huan-Gang
   Zhou, Yun-Feng
TI The MPO-463G > A Polymorphism and Lung Cancer Risk: A Meta-Analysis
   Based on 22 Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID MYELOPEROXIDASE GENE; REDUCED RISK; CLINICAL-TRIALS; MPO; SMOKERS; DNA;
   SUSCEPTIBILITY; BIAS; HETEROGENEITY; PUBLICATION
AB Background: Myeloperoxidase (MPO) is an endogenous oxidant enzyme that produces reactive oxygen species (ROS) and may be involved in lung carcinogenesis. The MPO-463G>A polymorphism influences MPO transcription and has been associated with lung cancer susceptibility. However, the association between the MPO-463G>A polymorphism and lung cancer risk remains controversial.
   Method: To investigate the effect of this polymorphism on lung cancer susceptibility, we performed a meta-analysis based on 22 published case-control studies including 7,520 patients with lung cancer and 8,600 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association.
   Results: Overall, there was no evidence for significant association between MPO-463G>A polymorphism and lung cancer susceptibility (for AA versus GG: OR = 0.91, 95% CI = 0.67-1.24; for GA versus GG: OR = 0.87, 95% CI = 0.78-0.98; for AA/GA versus GG: OR = 0.90, 95% CI = 0.80-1.01; for AA versus GA/GG: OR = 0.96, 95% CI = 0.72-1.28). In the stratified analyses by ethnicity, source of controls and smoking status, we also did not find any significant association between them.
   Conclusions: In summary, this meta-analysis suggests MPO-463G>A polymorphism may not be a risk factor for developing lung cancer. However, further prospective well-designed population-based studies with larger sample size are expected to validate the results.
C1 [Yang, Jun-Ping] Wuhan Univ, Affiliated Hosp 3, Dept Radiotherapy Oncol, Wuhan, Hubei, Peoples R China.
   [Wang, Wen-Bo; Yang, Xiao-Xi; Yang, Lei; Ren, Li; Zhou, Fu-Xiang; Hu, Liu; He, Wei; Li, Bai-Yu; Zhu, Yan; Jiang, Huan-Gang; Zhou, Yun-Feng] Wuhan Univ, Zhongnan Hosp, Dept Chemoradiotherapy Oncol, Wuhan, Hubei, Peoples R China.
RP Zhou, YF (reprint author), Wuhan Univ, Zhongnan Hosp, Dept Chemoradiotherapy Oncol, Wuhan, Hubei, Peoples R China.
EM yfzhouwhu@163.com
FU National Natural Science foundation of China [81071825/H1610]
FX This work was supported by the National Natural Science foundation of
   China (81071825/H1610). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 2006, HLTH CONS INV EXP TO
   [Anonymous], 2004, HLTH CONS SMOK REP S
   Arslan S, 2011, MOL MED REP, V4, P87, DOI 10.3892/mmr.2010.378
   AUSTIN GE, 1993, LEUKEMIA, V7, P1445
   Bax L, 2009, AM J EPIDEMIOL, V169, P249, DOI 10.1093/aje/kwn340
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cascorbi I, 2000, CANCER RES, V60, P644
   Chan EC, 2005, CANCER GENET CYTOGEN, V162, P10, DOI 10.1016/j.cancergencyto.2005.03.008
   Chevrier I, 2003, PHARMACOGENETICS, V13, P729, DOI 10.1097/01.fpc.0000054143.14659.ba
   Chu HY, 2010, MUTAGENESIS, V25, P389, DOI 10.1093/mutage/geq018
   Dally H, 2002, INT J CANCER, V102, P530, DOI 10.1002/ijc.10756
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FEIG DI, 1994, CANCER RES, V54, pS1890
   Feyler A, 2002, CANCER EPIDEM BIOMAR, V11, P1550
   GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807
   Harms C, 2004, ENVIRON MOL MUTAGEN, V44, P74, DOI 10.1002/em.20031
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hua Feng, 2010, Zhongguo Fei Ai Za Zhi, V13, P122, DOI 10.3779/j.issn.1009-3419.2010.02.08
   Kantarci OH, 2002, MAYO CLIN PROC, V77, P17, DOI 10.4065/77.1.17
   Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383
   Klinchid J, 2009, CANCER GENET CYTOGEN, V195, P143, DOI 10.1016/j.cancergencyto.2009.08.011
   Larsen JE, 2006, CARCINOGENESIS, V27, P525, DOI 10.1093/carcin/bgi227
   Le Marchand L, 2000, CANCER EPIDEM BIOMAR, V9, P181
   Liu G, 2004, CANCER LETT, V214, P69, DOI 10.1016/j.canlet.2004.06.027
   London SJ, 1997, CANCER RES, V57, P5001
   Lu Wenfu, 2002, Zhonghua Zhongliu Zazhi, V24, P250
   Misra RR, 2001, CANCER LETT, V164, P161, DOI 10.1016/S0304-3835(01)00384-6
   Park JH, 2006, CANCER DETECT PREV, V30, P257, DOI 10.1016/j.cdp.2006.04.002
   Patsopoulos NA, 2008, INT J EPIDEMIOL, V37, P1148, DOI 10.1093/ije/dyn065
   Pharoah PDP, 2004, NAT REV CANCER, V4, P850, DOI 10.1038/nrc1476
   Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412
   Schabath MB, 2002, LUNG CANCER-J IASLC, V37, P35, DOI 10.1016/S0169-5002(02)00034-X
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Skuladottir H, 2005, LUNG CANCER, V48, P187, DOI 10.1016/j.lungcan.2004.10.013
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   van Helden YGJ, 2009, FREE RADICAL BIO MED, V46, P299, DOI 10.1016/j.freeradbiomed.2008.10.038
   Van Schooten FJ, 2004, CANCER EPIDEM BIOMAR, V13, P828
   Xu LL, 2002, CANCER EPIDEM BIOMAR, V11, P1555
   Yang M, 2007, LUNG CANCER, V57, P135, DOI 10.1016/j.lungcan.2007.03.005
   Yoon KA, 2008, LUNG CANCER, V60, P40, DOI 10.1016/j.lungcan.2007.09.009
   Zienolddiny S, 2008, CARCINOGENESIS, V29, P1164, DOI 10.1093/carcin/bgn020
NR 42
TC 7
Z9 7
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 20
PY 2013
VL 8
IS 6
AR e65778
DI 10.1371/journal.pone.0065778
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 190LY
UT WOS:000322342800021
PM 23840365
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Guo, L
   Zhang, LL
   Zheng, B
   Liu, Y
   Cao, XJ
   Pi, Y
   Li, BH
   Li, JC
AF Guo, Lu
   Zhang, Li-Li
   Zheng, Bo
   Liu, Yun
   Cao, Xiao-Jie
   Pi, Yan
   Li, Bing-Hu
   Li, Jing-Cheng
TI The C825T Polymorphism of the G-Protein beta 3 Subunit Gene and Its
   Association with Hypertension and Stroke: An Updated Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID ARTERIAL-BLOOD PRESSURE; ACE I/D POLYMORPHISMS; GNB3 C825T;
   CARDIOVASCULAR-DISEASE; CANDIDATE GENES; 825C/T POLYMORPHISM;
   CLINICAL-TRIALS; ISCHEMIC-STROKE; ALPHA-ADDUCIN; 825T ALLELE
AB Objective: Several epidemiological studies have evaluated the association between the GNB3 C825T polymorphism and hypertension or stroke. The results of these studies were inconsistent; therefore, we performed a meta-analysis to clarify these discrepancies.
   Methods: We systematically searched the PubMed, Embase, Web of Science, CNKI, and CBM databases, and manually searched reference lists of relevant papers, meeting abstracts, and relevant journals. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for dominant, recessive, and allelic models. A fixed or random effects model was separately adopted depending on study heterogeneity. Subgroup and sensitivity analyses were performed to detect study heterogeneity and examine result stability, respectively. Publication bias was tested using funnel plots, the Egger's regression test, and Begg's test.
   Results: We screened 66 studies regarding hypertension and eight concerning stroke. A combined analysis showed that only the allelic model found a marginal association with hypertension (OR = 1.07, 95% CI = 1.01-1.13) and female gender (OR = 1.11, 95% CI = 0.99-1.24). However, no comparison models found an association with stroke (allelic model: OR = 1.11, 95% CI = 0.94-1.32; dominant model: OR = 1.16, 95% CI = 0.92-1.48; and recessive model: OR = 1.05, 95% CI = 0.97-1.14). Sensitivity analysis suggested that all models did not yield a relationship to hypertension or stroke among Asians. Besides, there was a lack of statistical association with hypertension in Caucasians, which maybe due to a small sample size. When we restricted the included studies to normal populations according to the Hardy-Weinberg equilibrium, no association was found.
   Conclusions: There was no evidence indicating that the 825T allele or TT genotype was associated with hypertension or stroke in Asians or hypertension in Caucasians. However, further studies regarding Africans and other ethnicities are needed to identify further correlations.
C1 [Guo, Lu; Zhang, Li-Li; Liu, Yun; Cao, Xiao-Jie; Pi, Yan; Li, Bing-Hu; Li, Jing-Cheng] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Neurol, Chongqing, Peoples R China.
   [Zheng, Bo] Third Mil Med Univ, Southwest Hosp, Dept Neurol, Chongqing, Peoples R China.
RP Li, JC (reprint author), Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Neurol, Chongqing, Peoples R China.
EM lijingcheng11@yahoo.com.cn
FU National Natural Science Foundation of China [81271282, 30970998];
   Chongqing Natural Science Foundation [CSTC2011BB5031]
FX This work was financially supported by the National Natural Science
   Foundation of China (81271282, 30970998) and by the Chongqing Natural
   Science Foundation (CSTC2011BB5031). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alioglu E, 2008, ANADOLU KARDIYOL DER, V8, P331
   Bae Y, 2007, J HUM HYPERTENS, V21, P159, DOI 10.1002/sj.jhh.1002110
   Bagos PG, 2007, J HYPERTENS, V25, P487, DOI 10.1097/HJH.0b013e328011db24
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beige J, 1999, HYPERTENSION, V33, P1049, DOI 10.1161/01.HYP.33.4.1049
   Benjafield AV, 1998, HYPERTENSION, V32, P1094, DOI 10.1161/01.HYP.32.6.1094
   Brand E, 2003, J HYPERTENS, V21, P729, DOI 10.1097/01.hjh.0000052497.18130.5b
   Brand E, 1999, HYPERTENSION, V33, P1175, DOI 10.1161/01.HYP.33.5.1175
   Buchmayer H, 2000, CRIT CARE MED, V28, P3203, DOI 10.1097/00003246-200009000-00015
   Chen XJ, 2007, J CLIN INTERN MED, V24, P333
   Chen YY, 2003, NAT MED J CHINA
   Chistiakov DA, 2009, DIS MARKERS, V26, P111, DOI 10.3233/DMA-2009-0620
   Dai Shu-Ping, 2002, Acta Genetica Sinica, V29, P294
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   Dichgans M, 2007, LANCET NEUROL, V6, P149, DOI 10.1016/S1474-4422(07)70028-5
   Dong H.Y., 2006, S CHINA J CARDIOVASC, V12, P258
   Dong YB, 1999, HYPERTENSION, V34, P1193, DOI 10.1161/01.HYP.34.6.1193
   [窦贵旺 DOU Gui-wang], 2009, [生物学杂志, Journal of Biology], V26, P18
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   [盖小群 GAI Xiaoqun], 2007, [中华流行病学杂志, Chinese Journal of Epidemiology], V28, P413
   GALBRAITH RF, 1988, TECHNOMETRICS, V30, P271, DOI 10.2307/1270081
   Hager A, 2011, INT J CARDIOL, V151, P63, DOI 10.1016/j.ijcard.2010.04.090
   Hayakawa T, 2007, METABOLISM, V56, P44, DOI 10.1016/j.metabol.2006.08.020
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Holmen OL, 2010, AM J HYPERTENS, V23, P1121, DOI 10.1038/ajh.2010.121
   Hu RL, 2006, CHIN J BIRTH HLTH HE, V14, P15
   Huang WT, 2007, PROG BIOCHEM BIOPHYS, V34, P471
   Huang XH, 2003, J MOL MED, V81, P729, DOI 10.1007/s00109-003-0482-3
   Huang XM, 2005, CHIN J BIRTH HLTH HE, V13, P21
   Ioannidis JPA, 2005, J CLIN EPIDEMIOL, V58, P543, DOI 10.1016/j.jclinepi.2004.10.019
   Ishikawa K, 2000, AM J HYPERTENS, V13, P140, DOI 10.1016/S0895-7061(99)00118-1
   Izawa H, 2003, HYPERTENSION, V41, P1035, DOI 10.1161/01.HYP.0000065618.56368.24
   Jing Jian-ying, 2006, Fudan Xuebao (Yixueban), V33, P433
   Kato N, 1998, HYPERTENSION, V32, P935, DOI 10.1161/01.HYP.32.5.935
   Kedzierska K, 2006, ARCH MED RES, V37, P150, DOI 10.1016/j.arcmed.2005.05.012
   Khamidullaeva GA, 2011, TURK KARDIYOL DERN A, V39, P198, DOI 10.5543/tkda.2011.01103
   Klenke S, 2011, PHARMACOGENET GENOM, V21, P594, DOI 10.1097/FPC.0b013e3283491153
   Kuo TY, 2012, AM J HYPERTENS, V25, P804, DOI 10.1038/ajh.2012.44
   Larson N, 2000, HYPERTENSION, V35, P1297, DOI 10.1161/01.HYP.35.6.1297
   Lee JY, 2009, INT J SPORTS MED, V30, P892, DOI 10.1055/s-0029-1233465
   Li B, 2005, ANN HUM GENET, V69, P468, DOI 10.1111/j.1529-8817.2005.00172.x
   Li D.B., 2005, J CAPITAL U MED SCI, V26, P725
   Li DB, 2005, J CAPITAL U MED SCI, V27, P480
   Li QX, 2006, J CHIN MICROCIRC, V10, P205
   Li QX, 2003, THESIS
   Li QX, 2006, CHIN J PUBLIC HLTH, V22, P1334
   Little J, 2002, AM J EPIDEMIOL, V156, P300, DOI 10.1093/aje/kwf054
   Liu L.P., 2003, THESIS
   liu WJ, 2009, CHINESE CIRCULATION, V24
   Lu FH, 2009, CHIN J PUBLIC HLTH, V25, P20
   Lu JP, 2012, MOL BIOL REP, V39, P8937, DOI 10.1007/s11033-012-1762-1
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Montasser ME, 2011, AM J HYPERTENS, V24, P1035, DOI 10.1038/ajh.2011.97
   Morrison AC, 2001, STROKE, V32, P822, DOI 10.1161/01.STR.32.4.822
   Nejatizadeh A, 2011, GENET MOL BIOL, V34, P553, DOI 10.1590/S1415-47572011005000052
   Niu WQ, 2011, PLOS ONE, V6
   Ozkececi E, 2008, TRAK UNIV TIP FAK DE, V25, P100
   Pan ZL, 2005, PLOS MED, V2, P1309, DOI 10.1371/journal.pmed.0020334
   Panoulas VF, 2009, CLIN EXP HYPERTENS, V31, P428, DOI 10.1080/10641960802668748
   Hui P, 2007, HYPERTENS RES, V30, P585, DOI 10.1291/hypres.30.585
   Petiti DB, 1999, METAANALYSIS DECISIO
   Pitsavos C, 2006, J HUM HYPERTENS, V20, P303, DOI 10.1038/sj.jhh.1001985
   Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046
   Sarzynski MA, 2011, J HUM HYPERTENS, V25, P509, DOI 10.1038/jhh.2010.94
   Shioji K, 2004, HYPERTENS RES, V27, P31, DOI 10.1291/hypres.27.31
   Siffert W, 2005, ANNU REV MED, V56, P17, DOI 10.1146/annurev.med.56.082103.104625
   Siffert W, 1999, J AM SOC NEPHROL, V10, P1921
   Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45
   [宋洁 Song Jie], 2011, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V15, P9491
   Sun AJ, 2005, EUR J HUM GENET, V13, P361, DOI 10.1038/sj.ejhg.5201334
   Sun LL, 2003, CHIN J DIABETE, V11, P110
   [孙宁玲 Sun Ninglingf], 2003, [中国糖尿病杂志, Chinese Journal of Diabetes], V11, P110
   Suwazono Y, 2006, ANN HUM GENET, V70, P767, DOI 10.1111/j.1469-1809.2006.00284.x
   Suwazono Y, 2004, J HYPERTENS, V22, P493, DOI 10.1097/01.hjh.0000098269.36684.73
   Tan JC, 2003, CHONGQING MED, V32, P13
   Tan JC, 2003, CHIN J GERIATR CARDI, V5, P177
   [谭建聪 Tan Jiancong], 2003, [第三军医大学学报, Acta Academiae Medicinae Militaris Tertiae], V25, P1381
   Tozawa Y, 2001, BLOOD PRESSURE, V10, P131, DOI 10.1080/080370501753182334
   Tsai CH, 2000, INT J CARDIOL, V73, P191, DOI 10.1016/S0167-5273(00)00209-6
   Turner ST, 2001, HYPERTENSION, V37, P739, DOI 10.1161/01.HYP.37.2.739
   Varda NM, 2006, ACTA PAEDIATR, V95, P353, DOI 10.1080/08035250500434777
   Vasudevan R, 2009, AFR J BIOTECHNOL, V8, P2069
   Wang HL, 2011, INT J CEREBROVASC DI, V19, P580
   Wang Hongyi, 2003, Beijing Da Xue Xue Bao Yi Xue Ban, V35, P423
   Wang HuiLing, 2011, Clinical Focus, V26, P766
   Wang X, 2004, J HUM HYPERTENS, V18, P663, DOI 10.1038/sj.jhh.1001700
   Weinstein LS, 2006, TRENDS PHARMACOL SCI, V27, P260, DOI 10.1016/j.tips.2006.03.005
   Yamagishi K, 2006, ANN HUM GENET, V70, P759, DOI 10.1111/j.1469-1809.2006.00276.x
   Yamamoto M, 2004, BIOCHEM BIOPH RES CO, V316, P744, DOI 10.1016/j.bbrc.2004.02.113
   Yang J. L., 2007, THESIS
   Yin RX, 2009, J HYPERTENS, V27, P251, DOI 10.1097/HJH.0b013e32831bc74d
   You T, 2000, MED J LIAONING, V14, P179
   Young JH, 2005, PLOS GENET, V1, P730, DOI 10.1371/journal.pgen.0010082
   Zeltner R, 2001, HYPERTENSION, V37, P882, DOI 10.1161/01.HYP.37.3.882
   Zhang CY, 2007, NEURAL REGENERATION, V2, P146
   Zhang J, 2005, CHINESE MED INFORM, V18, P358
   Zhang L, 2005, J HUM HYPERTENS, V19, P709, DOI 10.1038/sj.jhh.1001883
   Zhang L., 2006, THESIS
   Zhang MH, 2001, CHIN J HYPERTENS, V9, P288
   [赵红晔 ZHAO Hong-ye], 2009, [基础医学与临床, Basic & Clinical Medicine], V29, P393
   Zhao Y, 2001, STROKE NERVOUS DIS, V8, P14
   Zhao Y, 2004, J APOPLEXY NERVOUS D, P21
   Zhao Y, 2000, THESIS
   Zychma MJ, 2000, AM J NEPHROL, V20, P305, DOI 10.1159/000013605
NR 107
TC 10
Z9 10
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 14
PY 2013
VL 8
IS 6
AR e65863
DI 10.1371/journal.pone.0065863
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163UV
UT WOS:000320363300048
PM 23799054
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Qi, WX
   Huang, YJ
   Yao, Y
   Shen, Z
   Min, DL
AF Qi, Wei-Xiang
   Huang, Yu-Jing
   Yao, Yang
   Shen, Zan
   Min, Da-Liu
TI Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors
   Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID RENAL-CELL CARCINOMA; PHASE-II; SIROLIMUS THERAPY; MAMMALIAN TARGET;
   KINASE INHIBITOR; DOSE LEVELS; RAPAMYCIN; EFFICACY; PNEUMONITIS; CCI-779
AB Background: Two novel mammalian targets of rapamycin (mTOR) inhibitors everolimus and temsirolimus are now approved by regulatory agencies and have been widely investigated among various types of solid tumors, but the risk of fatal adverse events (FAEs) with these drugs is not well defined.
   Methods: We searched PubMed, EMBASE, and Cochrane library databases for relevant trials. Eligible studies included prospective phase II and III trials evaluating everolimus and temsirolimus in patients with all malignancies and data on FAEs were available. Statistical analyses were conducted to calculate the summary incidence, RRs and 95% confidence intervals (CIs) by using either random effects or fixed effect models according to the heterogeneity of the included studies.
   Results: A total of 3322 patients with various advanced solid tumors from 12 trials were included. The overall incidence of mTOR inhibitors associated FAEs was 1.8% (95%CI: 1.3-2.5%), and the incidences of everolimus related FAEs were comparable to that of temsirolimus (1.7% versus 1.8%). Compared with the controls, the use of mTOR inhibitors was associated with an increased risk of FAEs, with a RR of 3.24 (95%CI: 1.21-8.67, p = 0.019). On subgroup analysis, a non-statistically significant increase in the risk of FAEs was found according to different mTOR inhibitors, tumor types or controlled therapy. No evidence of publication bias was observed.
   Conclusion: With the present evidence, the use of mTOR inhibitors seems to increase the risk of FAEs in patients with advanced solid tumors. More high quality trials are still needed to investigate this association.
C1 [Qi, Wei-Xiang; Huang, Yu-Jing; Yao, Yang; Shen, Zan; Min, Da-Liu] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Oncol, Shanghai 200030, Peoples R China.
RP Min, DL (reprint author), Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Oncol, Shanghai 200030, Peoples R China.
EM yaoyang_6@163.com
OI Qi, wei-xiang/0000-0001-5484-3343
CR Albiges L, 2012, ANN ONCOL, V23, P1943, DOI 10.1093/annonc/mds115
   [Anonymous], 2012, BR J CLIN PHARM
   [Anonymous], 2012, CANC TREAT REV
   Assaad U, 2012, CLIN INTERV AGING, V7, P453, DOI 10.2147/CIA.S29675
   Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185
   Barnett CM, 2012, PHARMACOTHERAPY, V32, P383, DOI 10.1002/j.1875-9114.2012.01084.x
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bellmunt J, 2008, ANN ONCOL, V19, P1387, DOI 10.1093/annonc/mdn066
   Bohler T, 2008, CYTOKINE, V42, P306, DOI 10.1016/j.cyto.2008.02.015
   Brugarolas J, 2007, NEW ENGL J MED, V356, P185, DOI 10.1056/NEJMe068263
   Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9
   Champion L, 2006, ANN INTERN MED, V144, P505, DOI 10.7326/0003-4819-144-7-200604040-00009
   Chan S, 2004, BRIT J CANCER, V91, P1420, DOI 10.1038/sj.bjc.6602162
   Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130
   Choueiri TK, 2010, J CLIN ONCOL, V28, P2280, DOI 10.1200/JCO.2009.27.2757
   Chu D, 2009, CLIN GENITOURIN CANC, V7, P11, DOI 10.3816/CGC.2009.n.002
   Drucker AM, 2012, EUR J HAEMATOL
   Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062
   Fasolo A, 2012, CURR PHARM DESIGN, V18, P2766, DOI 10.2174/138161212800626210
   Floc'h N, 2012, ONCOTARGET
   Frost P, 2007, ONCOGENE, V26, P2255, DOI 10.1038/sj.onc.1210019
   Galfrascoli E, 2011, DIGEST LIVER DIS, V43, P286, DOI 10.1016/j.dld.2010.10.010
   Gnant M, 2012, EXPERT REV ANTICANC, V12, P1579, DOI [10.1586/era.12.138, 10.1586/ERA.12.138]
   Hess G, 2009, J CLIN ONCOL, V27, P3822, DOI 10.1200/JCO.2008.20.7977
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Iacovelli R, 2012, ACTA ONCOL, V51, P873, DOI 10.3109/0284186X.2012.705019
   Kahan BD, 2000, LANCET, V356, P194, DOI 10.1016/S0140-6736(00)02480-6
   Kwitkowski VE, 2010, ONCOLOGIST, V15, P428, DOI 10.1634/theoncologist.2009-0178
   Lindenfeld JA, 2005, AM J TRANSPLANT, V5, P1392, DOI 10.1111/j.1600-6143.2005.00849.x
   MacDonald AS, 2003, TRANSPLANT P, V35, p201S, DOI 10.1016/S0041-1345(03)00231-8
   Manito N, 2004, J HEART LUNG TRANSPL, V23, P780, DOI 10.1016/j.healun.2003.07.008
   Matz M, 2012, TRANSPL INT, V25, P1106, DOI 10.1111/j.1432-2277.2012.01537.x
   Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9
   Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   NCI, CTC V 2 0 COMM TERM
   Pandya KJ, 2007, J THORAC ONCOL, V2, P1036, DOI 10.1097/JTO.0b013e318155a439
   Pavel ME, 2011, LANCET, V378, P2005, DOI 10.1016/S0140-6736(11)61742-X
   Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046
   Petrelli F, 2012, EXPERT OPIN DRUG SAF, V11, pS9, DOI 10.1517/14740338.2011.606213
   Qi WX, 2013, CANCER CHEMOTH PHARM, V71, P431, DOI 10.1007/s00280-012-2025-5
   Ranpura V, 2011, JAMA-J AM MED ASSOC, V305, P487, DOI 10.1001/jama.2011.51
   Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095
   Schutz FAB, 2012, J CLIN ONCOL, V30, P871, DOI 10.1200/JCO.2011.37.1195
   Seeliger H, 2007, CANCER METAST REV, V26, P611, DOI 10.1007/s10555-007-9077-8
   Sheppard Karen E., 2012, Critical Reviews in Oncogenesis, V17, P69
   Sun Y, 2012, JPN J CLIN ONCOL, V42, P836, DOI 10.1093/jjco/hys110
   Tarhini A, 2010, CLIN CANCER RES, V16, P5900, DOI 10.1158/1078-0432.CCR-10-0802
   Trotter JF, 2003, TRANSPLANT P, V35, p193S, DOI 10.1016/S0041-1345(03)00234-3
   Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113
   Willcocks LC, 2007, AM J TRANSPLANT, V7, P2006, DOI 10.1111/j.1600-6143.2007.01869.x
   Xu BH, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-3
   Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290
   YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 59
TC 17
Z9 19
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 13
PY 2013
VL 8
IS 6
AR e65166
DI 10.1371/journal.pone.0065166
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 172XB
UT WOS:000321038800111
PM 23785409
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, M
   Zhang, H
   Luo, XJ
   Gao, L
   Qi, XB
   Gourraud, PA
   Su, B
AF Li, Ming
   Zhang, Hui
   Luo, Xiong-jian
   Gao, Lei
   Qi, Xue-bin
   Gourraud, Pierre-Antoine
   Su, Bing
TI Meta-Analysis Indicates That the European GWAS-Identified Risk SNP
   rs1344706 within ZNF804A Is Not Associated with Schizophrenia in Han
   Chinese Population
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMMON VARIANTS; SUSCEPTIBILITY; GENE; BIAS
AB Recent genetic association studies have implicated several candidate susceptibility variants for schizophrenia among general populations. Rs1344706, an intronic SNP within ZNF804A, was identified as one of the most compelling candidate risk SNPs for schizophrenia in Europeans through genome-wide association studies (GWASs) and replications as well as large-scale meta-analyses. However, in Han Chinese, the results for rs1344706 are inconsistent, and whether rs1344706 is an authentic risk SNP for schizophrenia in Han Chinese is inconclusive. Here, we conducted a systematic meta-analysis of rs1344706 with schizophrenia in Chinese population by combining all available case-control samples (N = 12), including a total of 8,982 cases and 12,342 controls. The results of our meta-analysis were not able to confirm an association of rs1344706 A-allele with schizophrenia (p = 0.10, odds ratio = 1.06, 95% confidence interval = 0.99-1.13). Such absence of association was further confirmed by the non-superiority test (p = 0.0003), suggesting that rs1344706 is not a risk SNP for schizophrenia in Han Chinese. Detailed examinations of individual samples revealed potential sampling bias in previous replication studies in Han Chinese. The absence of rs1344706 association in Han Chinese suggest a potential genetic heterogeneity in the susceptibility of schizophrenia on this locus and also demonstrate the difficulties in replicating genome-wide association findings of schizophrenia across different ethnic populations.
C1 [Li, Ming; Zhang, Hui; Qi, Xue-bin; Su, Bing] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming, Yunnan, Peoples R China.
   [Luo, Xiong-jian] Univ Rochester, Flaum Eye Inst, Rochester, NY USA.
   [Gao, Lei] Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China.
   [Gourraud, Pierre-Antoine] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA USA.
   [Li, Ming; Gao, Lei] Univ Chinese Acad Sci, Beijing, Peoples R China.
RP Su, B (reprint author), Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming, Yunnan, Peoples R China.
EM sub@mail.kiz.ac.cn
RI Xuebin, Qi/L-7139-2019; Gourraud, Pierre-Antoine/O-3024-2015
FU National 973 project of China [2011CBA00401]; National Natural Science
   Foundation of China [U1202225, 31130051, 31071101]
FX This work was supported by grants from the National 973 project of China
   (grant numbers, 2011CBA00401) and the National Natural Science
   Foundation of China (U1202225, 31130051 and 31071101). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Allen NC, 2008, NAT GENET, V40, P827, DOI 10.1038/ng.171
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a
   Chen M, 2012, NEUROPSYCHOPHARMACOL, V37, P1572, DOI 10.1038/npp.2012.1
   DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gourraud PA, 2011, GENET EPIDEMIOL, V35, P568, DOI 10.1002/gepi.20592
   Li M, 2012, SCHIZOPHR RES, V142, P200, DOI 10.1016/j.schres.2012.10.008
   Li M, 2013, WORLD J BIOL PSYCHIA, V14, P91, DOI 10.3109/15622975.2011.587891
   Li M, 2012, AM J MED GENET B, V159B, P794, DOI 10.1002/ajmg.b.32084
   Li M, 2011, AM J PSYCHIAT, V168, P1318, DOI 10.1176/appi.ajp.2011.11030381
   Li T, 2010, BIOL PSYCHIAT, V68, P671, DOI 10.1016/j.biopsych.2010.06.014
   Lichtenstein P, 2006, PSYCHOL MED, V36, P1417, DOI 10.1017/S0033291706008385
   Liou YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033598
   O'Donovan MC, 2008, NAT GENET, V40, P1053, DOI 10.1038/ng.201
   Owen MJ, 2010, ARCH GEN PSYCHIAT, V67, P667, DOI 10.1001/archgenpsychiatry.2010.69
   Pagel T, 2013, ACTA PSYCHIAT SCAND, V128, P238, DOI 10.1111/acps.12109
   Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185
   Rietschel M., 2011, MOL PSYCHIATR, V17, P906
   Riley B, 2010, MOL PSYCHIATR, V15, P29, DOI 10.1038/mp.2009.109
   Ripke S, 2011, NAT GENET, V43, P969, DOI 10.1038/ng.940
   Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141
   Shi JX, 2009, NATURE, V460, P753, DOI 10.1038/nature08192
   Shi YY, 2011, NAT GENET, V43, P1224, DOI 10.1038/ng.980
   Shifman S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040028
   Stefansson H, 2009, NATURE, V460, P744, DOI 10.1038/nature08186
   Steinberg S, 2011, MOL PSYCHIATR, V16, P59, DOI 10.1038/mp.2009.149
   Sullivan PF, 2003, ARCH GEN PSYCHIAT, V60, P1187, DOI 10.1001/archpsyc.60.12.1187
   WILLIAMS H, 2011, TLS TIMES LIT S 0114, P16
   Williams HJ, 2009, BRIT MED BULL, V91, P61, DOI 10.1093/bmb/ldp017
   Xiao B, 2011, PSYCHIAT RES, V190, P379, DOI 10.1016/j.psychres.2011.05.031
   Xu SH, 2009, AM J HUM GENET, V85, P762, DOI 10.1016/j.ajhg.2009.10.015
   Yue WH, 2011, NAT GENET, V43, P1228, DOI 10.1038/ng.979
   Zhang FY, 2011, BIOL PSYCHIAT, V69, P914, DOI 10.1016/j.biopsych.2011.01.003
   Zhang R, 2011, MOL PSYCHIATR, V16, P360, DOI 10.1038/mp.2010.55
   Zhong R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028839
NR 36
TC 19
Z9 20
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 12
PY 2013
VL 8
IS 6
AR e65780
DI 10.1371/journal.pone.0065780
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163FW
UT WOS:000320322400055
PM 23776546
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xu, Q
   He, CY
   Liu, JW
   Yuan, Y
AF Xu, Qian
   He, Cai-yun
   Liu, Jing-wei
   Yuan, Yuan
TI Pre-miR-27a rs895819A/G Polymorphisms in Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENETIC VARIANT; RISK; MIR-27A; ASSOCIATION; CONTRIBUTES
AB Background: MicroRNAs (miRNAs) negatively regulate the 3' untranslated region (3'-UTR) of coding genes by suppressing translation or degrading mRNAs, and they act as oncogenes or tumor suppressors. Recently, several studies investigated the association between pre-miR-27a rs895819 polymorphism and the risks of various cancers, but the results were inconsistent.
   Methodology/Principal Findings: We conducted a meta-analysis of 13 studies that included 6501 cancer cases and 7571 controls to address this association. Overall, this meta-analysis showed that the pre-miR-27a rs895819 A/G polymorphism was not statistically associated with cancers risk in all genetic models. In the stratified analysis by cancer types, when compared with the ancestral A allele, individuals with the variant G allele was consistently associated with reduced risks of breast cancer (OR = 0.92, 95% CI = 0.85-0.99), renal cell cancer (OR = 0.81, 95% CI = 0.67-0.97) and nasopharyngeal cancer (OR = 0.84, 95% CI = 0.72-0.97). Inversely, individuals with the heterozygote AG was associated with an increased risk of digestive tract cancers compared with AA genotype (AG vs. AA: OR = 1.16, 95% CI = 1.01-1.32). In the stratified analysis by ethnicity, the pre-miR-27a rs895819 polymorphism showed statistically significant association with decreased risks of cancers in Caucasians (G vs. A allele: OR = 0.90, 95% CI = 0.83-0.97; AG vs. AA: OR = 0.84, 95% CI = 0.75-0.94; AG/GG vs. AA: OR = 0.85, 95% CI = 0.76-0.94) but not in Asians.
   Conclusion/Significance: This meta-analysis suggests that the pre-miR-27a rs895819 polymorphism may contribute to the susceptibilities of some specific-type of cancers, including breast cancer, renal cell cancer, nasopharyngeal cancer and digestive tract cancers, as well as the susceptibilities of cancers in Caucasians to some extent.
C1 [Yuan, Yuan] China Med Univ, Key Lab Canc Etiol & Prevent Liaoning Prov, Affiliated Hosp 1, Inst Canc,Tumor Etiol & Screening Dept, Shenyang, Liaoning Provin, Peoples R China.
   China Med Univ, Key Lab Canc Etiol & Prevent Liaoning Prov, Affiliated Hosp 1, Shenyang, Liaoning Provin, Peoples R China.
RP Yuan, Y (reprint author), China Med Univ, Key Lab Canc Etiol & Prevent Liaoning Prov, Affiliated Hosp 1, Inst Canc,Tumor Etiol & Screening Dept, Shenyang, Liaoning Provin, Peoples R China.
EM yyuan3@mai.cmu.edu.cn
FU National Key Basic Research Program of China (973 Program)
   [2010CB529304]; National Natural Science Foundation of China [31200968];
   Science Technology Project in Liaoning Province [2011225002]
FX This work is supported by grants from the National Key Basic Research
   Program of China (973 Program ref no. 2010CB529304,
   http://www.973.gov.cn/Default_3.aspx), the National Natural Science
   Foundation of China (Ref No. 31200968,
   http://www.nsfc.gov.cn/Portal0/default152.htm), and the Science
   Technology Project in Liaoning Province (Ref No. 2011225002,
   http://kjjh.lninfo.gov.cn/). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Arisawa T, 2007, DIGEST DIS SCI, V52, P1691, DOI 10.1007/s10620-006-9648-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Catucci I, 2012, BREAST CANCER RES TR, V133, P805, DOI 10.1007/s10549-012-2011-y
   Chu H, 2011, PLOS ONE, V6
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duan RH, 2007, HUM MOL GENET, V16, P1124, DOI 10.1093/hmg/ddm062
   Gao LB, 2011, BREAST CANCER RES TR, V125, P571, DOI 10.1007/s10549-010-0993-x
   Hezova R, 2012, WORLD J GASTROENTERO, V18, P2827, DOI 10.3748/wjg.v18.i22.2827
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hirota T, 2012, LUNG CANCER, V77, P16, DOI 10.1016/j.lungcan.2011.12.018
   Jahid S, 2012, CANCER DISCOV, V2, P540, DOI 10.1158/2159-8290.CD-11-0267
   Jian Guo, 2012, International Journal of Mechatronics and Automation, V2, P15, DOI 10.1504/IJMA.2012.046583
   Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8
   Kontorovich T, 2010, INT J CANCER, V127, P589, DOI 10.1002/ijc.25065
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lian H, 2012, PLOS ONE, V7, DOI DOI 10.1371/J0URNAL.P0NE.0031615
   Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003
   Ma YH, 2010, CANCER LETT, V298, P150, DOI 10.1016/j.canlet.2010.06.012
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   P-r Li, 2011, GENETIC ASS MIRNA SN
   Qiu LX, 2011, CYTOKINE, V56, P695, DOI 10.1016/j.cyto.2011.09.001
   Qiu LX, 2011, CYTOKINE, V56, P589, DOI 10.1016/j.cyto.2011.08.019
   Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1
   Shi DN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046566
   Sun QM, 2010, CANCER SCI, V101, P2241, DOI 10.1111/j.1349-7006.2010.01667.x
   Wang B, 2012, ASIAN PAC J CANCER P, V13, P6207, DOI 10.7314/APJCP.2012.13.12.6207
   Wang F, 2012, MOL BIOL REP, V39, P269, DOI 10.1007/s11033-011-0735-0
   Wang J, 2012, MOL BIOL REP, V39, P4571, DOI 10.1007/s11033-011-1247-7
   Wang LN, 2012, GENE, V508, P9, DOI 10.1016/j.gene.2012.08.005
   Wang Q, 2011, ONCOGENE, V30, P3875, DOI 10.1038/onc.2011.103
   Wang W-z, 2011, ASS MIR 146A SINGLE
   WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105
   Xu WM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019120
   Yang Q, 2012, ONCOGENE
   Yang RX, 2012, BREAST CANCER RES TR, V134, P899, DOI 10.1007/s10549-012-2140-3
   Yang RX, 2010, BREAST CANCER RES TR, V121, P693, DOI 10.1007/s10549-009-0633-5
   Yoon KA, 2012, J THORAC CARDIOV SUR, V144, P794, DOI 10.1016/j.jtcvs.2012.06.030
   Zanetti KA, 2012, CANCER RES, V72, P1467, DOI 10.1158/0008-5472.CAN-11-3073
   Zhang M, 2012, EUR J CANCER CARE, V21, P274, DOI 10.1111/j.1365-2354.2011.01308.x
   Zhang M-w, 2012, STUDY ASS LIFESTYLE
   Zhang P, 2011, POLYMORPHISMS MICROR
   Zhang Z, 2009, CANC GENET, V204, P486
   Zhong SL, 2013, MOL BIOL REP, V40, P3181, DOI 10.1007/s11033-012-2392-3
   Zhou Y, 2012, J CANCER RES CLIN, V138, P939, DOI 10.1007/s00432-012-1164-8
NR 45
TC 8
Z9 9
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 7
PY 2013
VL 8
IS 6
AR e65208
DI 10.1371/journal.pone.0065208
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 173QU
UT WOS:000321094800025
PM 23762318
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, CY
   Song, B
   Wang, YY
   Meng, H
   Guo, SB
   Liu, LN
   Lv, HC
   Wu, QJ
AF Li, Chun-Yan
   Song, Bo
   Wang, Ying-Yan
   Meng, Hua
   Guo, Shi-Bin
   Liu, Li-Na
   Lv, Hai-Chen
   Wu, Qi-Jun
TI Age at Menarche and Risk of Colorectal Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID HORMONE REPLACEMENT THERAPY; ORAL-CONTRACEPTIVE USE; GENOME-WIDE
   ASSOCIATION; REPRODUCTIVE FACTORS; COLON-CANCER; MENSTRUAL FACTORS;
   UNITED-STATES; WOMEN; HISTORY; JAPAN
AB Background: Various observational studies have focused on the relationship between menarcheal age and the risk of colorectal cancer (CRC). However, the association is still controversial because of inconsistent results. Therefore, we performed a meta-analysis to assess this issue from epidemiological studies.
   Methods: After a literature search in MEDLINE, EMBASE, and Web of Science for studies of menarcheal age and CRC risk published through the end of January 2013, we pooled the relative risks (RRs) from included studies using a fixed-or random-effects model and performed heterogeneity and publication bias analyses. All statistical tests were two-sided.
   Results: Eleven case-control and 11 cohort studies were eligible for inclusion in our analysis. The random-effects pooled RR for oldest versus youngest menarcheal age was 0.95 [95% confidence intervals (CIs) = 0.85-1.06], with significant heterogeneity (Q = 61.03, P, 0.001, I-2 = 65.6%). When separately analyzed, case-control (RR = 0.95, 95% CI = 0.75-1.21) and cohort studies (RR = 0.97, 95% CI = 0.90-1.04) yielded similar results. Moreover, similar results were also observed among the subgroup analyses by study quality, population, exposure assessment, anatomic cancer site, subsite of colon cancer, and several potential important confounders and risk factors. There was no evidence of publication bias and significant heterogeneity between subgroups detected by meta-regression analyses.
   Conclusions: Findings from this meta-analysis demonstrated that menarcheal age was not associated with the risk of CRC in humans. Further studies are warranted to stratify results by the subsite of colon cancer and menopause status in the future.
C1 [Li, Chun-Yan; Meng, Hua; Guo, Shi-Bin; Liu, Li-Na] Dalian Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Dalian, Peoples R China.
   [Song, Bo] Dalian Med Univ, Dept Pathol, Dalian, Peoples R China.
   [Wang, Ying-Yan] Dalian Med Univ, Lab Ctr Diagnost, Dalian, Peoples R China.
   [Lv, Hai-Chen] Fudan Univ, Shanghai 200433, Peoples R China.
   [Wu, Qi-Jun] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Epidemiol,Shanghai Canc Inst, Shanghai, Peoples R China.
RP Li, CY (reprint author), Dalian Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Dalian, Peoples R China.
EM Lichunyan_dl@163.com
CR Akhter M, 2008, EUR J CANCER PREV, V17, P515, DOI 10.1097/CEJ.0b013e3282f521f8
   ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411
   Aune D, 2011, GASTROENTEROLOGY, V141, P106, DOI 10.1053/j.gastro.2011.04.013
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beral V, 2012, LANCET ONCOL, V13, P1141, DOI 10.1016/S1470-2045(12)70425-4
   Bosetti C, 2009, HUM REPROD UPDATE, V15, P489, DOI 10.1093/humupd/dmp017
   BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725
   CHUTE CG, 1991, EPIDEMIOLOGY, V2, P395, DOI 10.1097/00001648-199109000-00019
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DEVERDIER MG, 1992, CANCER CAUSE CONTROL, V3, P355, DOI 10.1007/BF00146889
   DiDomenico M, 1996, CANCER RES, V56, P4516
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elks CE, 2010, NAT GENET, V42, P1077, DOI 10.1038/ng.714
   English MA, 1999, J CLIN ENDOCR METAB, V84, P2080, DOI 10.1210/jc.84.6.2080
   Fernandez E, 1996, BRIT J CANCER, V73, P1431, DOI 10.1038/bjc.1996.272
   Ferris JS, 2010, PAEDIATR PERINAT EP, V24, P515, DOI 10.1111/j.1365-3016.2010.01154.x
   FRANCESCHI S, 1991, EUR J CANCER, V27, P604, DOI 10.1016/0277-5379(91)90228-6
   Gong TT, 2013, INT J CANCER, V132, P2894, DOI 10.1002/ijc.27952
   HAENSZEL W, 1980, JNCI-J NATL CANCER I, V64, P17
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   He CY, 2009, NAT GENET, V41, P724, DOI 10.1038/ng.385
   Hennessy BA, 2005, MOL CELL ENDOCRINOL, V229, P39, DOI 10.1016/j.mce.2004.10.001
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kabat GC, 2008, INT J CANCER, V122, P643, DOI 10.1002/ijc.23079
   Kampman E, 1994, Eur J Cancer Prev, V3, P329, DOI 10.1097/00008469-199407000-00005
   Kampman E, 1997, CANCER CAUSE CONTROL, V8, P146, DOI 10.1023/A:1018459911147
   Kono S, 2004, EUR J CANCER PREV, V13, P127, DOI 10.1097/00008469-200404000-00006
   KVALE G, 1991, INT J CANCER, V47, P390, DOI 10.1002/ijc.2910470314
   Lin J, 2007, AM J EPIDEMIOL, V165, P794, DOI 10.1093/aje/kwk068
   Liu YZ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000420
   Lo AC, 2010, DIS COLON RECTUM, V53, P830, DOI 10.1007/DCR.0b013e3181d320b1
   Mandel D, 2004, J PEDIATR ENDOCR MET, V17, P1507
   Marcus Pamela M., 1995, Annals of Epidemiology, V5, P303, DOI 10.1016/1047-2797(94)00097-D
   Martinez ME, 1997, CANCER EPIDEM BIOMAR, V6, P1
   MCMICHAEL AJ, 1980, J NATL CANCER I, V65, P1201
   MOISAN J, 1991, Medicine and Science in Sports and Exercise, V23, P1170
   Nanda K, 1999, OBSTET GYNECOL, V93, P880, DOI 10.1016/S0029-7844(98)00424-4
   NEGRI E, 1989, CANCER RES, V49, P7158
   Nichols HB, 2005, CANCER EPIDEM BIOMAR, V14, P1212, DOI 10.1158/1055-9965.EPI-04-0845
   Oduwole OO, 2002, INT J CANCER, V97, P1, DOI 10.1002/ijc.1567
   PAPADIMITRIOU C, 1984, INT J EPIDEMIOL, V13, P155, DOI 10.1093/ije/13.2.155
   PETERS RK, 1990, BRIT J CANCER, V61, P741, DOI 10.1038/bjc.1990.166
   Richards MA, 2011, J ADOLESCENCE, V34, P1065, DOI 10.1016/j.adolescence.2010.11.001
   RONNEMAA T, 1991, ANN MED, V23, P67, DOI 10.3109/07853899109147933
   Sato R, 2009, CANCER RES, V69, P914, DOI 10.1158/0008-5472.CAN-08-0906
   Shin A, 2011, INT J EPIDEMIOL, V40, P1261, DOI 10.1093/ije/dyr121
   Siegert S, 2013, HUM GENET, V132, P219, DOI 10.1007/s00439-012-1239-2
   SLATTERY ML, 1995, CANCER CAUSE CONTROL, V6, P332, DOI 10.1007/BF00051408
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sulem P, 2009, NAT GENET, V41, P734, DOI 10.1038/ng.383
   Talamini R, 1998, EUR J CANCER, V34, P1070, DOI 10.1016/S0959-8049(98)00019-7
   Tamakoshi K, 2004, CANCER SCI, V95, P602, DOI 10.1111/j.1349-7006.2004.tb02494.x
   Troisi R, 1997, EPIDEMIOLOGY, V8, P75, DOI 10.1097/00001648-199701000-00012
   Tsilidis KK, 2010, BRIT J CANCER, V103, P1755, DOI 10.1038/sj.bjc.6605965
   VIHKO R, 1984, J STEROID BIOCHEM, V20, P231, DOI 10.1016/0022-4731(84)90209-7
   Wells GA, NEWCASTLE OTTAWA SCA
   Wernli KJ, 2009, J WOMENS HEALTH, V18, P995, DOI 10.1089/jwh.2008.1068
   WU AH, 1987, BRIT J CANCER, V55, P687, DOI 10.1038/bjc.1987.140
   Wu QJ, 2013, ANN ONCOL, V24, P1079, DOI 10.1093/annonc/mds601
   WUWILLIAMS AH, 1991, CANCER RES, V51, P2307
   Yoo KY, 1999, BRIT J CANCER, V79, P1901, DOI 10.1038/sj.bjc.6690302
   Zervoudakis A, 2011, J NATL CANCER I, V103, P826, DOI 10.1093/jnci/djr101
   Zhong R, 2013, CARCINOGENESIS, V34, P936, DOI 10.1093/carcin/bgs395
NR 65
TC 9
Z9 9
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 6
PY 2013
VL 8
IS 6
AR e65645
DI 10.1371/journal.pone.0065645
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 173SK
UT WOS:000321099000086
PM 23762403
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Areeshi, MY
   Mandal, RK
   Panda, AK
   Bisht, SC
   Haque, S
AF Areeshi, M. Y.
   Mandal, Raju K.
   Panda, Aditya K.
   Bisht, Shekhar C.
   Haque, Shafiul
TI CD14-159 C > T Gene Polymorphism with Increased Risk of Tuberculosis:
   Evidence from a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SERUM-SOLUBLE CD14; PULMONARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS;
   PROMOTER POLYMORPHISM; BINDING-PROTEIN; SUSCEPTIBILITY; ASSOCIATION;
   RECEPTOR; RECOGNITION; ACTIVATION
AB Cluster of differentiation 14 (CD14) gene is an important component of the human innate immune system and its role in tuberculosis (TB) has been sparsely documented. The enhanced plasma CD14 levels in TB patients as compared to healthy controls are associated with CD14 gene promoter (C-159T) polymorphism. In the past few years, the relationship between CD14 - 159 C>T (rs2569190) polymorphism and risk of TB has been reported in various ethnic populations; however, those studies have yielded contradictory results. In this study systemic assessment was done for the published studies based on the association between CD14 - 159 C>T polymorphism and TB risk retrieved from PubMed (Medline) and EMBASE search. A total number of 1389 TB cases and 1421 controls were included in this study and meta-analysis was performed to elucidate the association between CD14 - 159 C>T polymorphism and its susceptibility towards TB. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for allele contrast, homozygous comparison, heterozygous comparison, dominant and recessive genetic model. It was found that T allele carrier was significantly associated with increased TB risk (T vs. C: p-value = 0.023; OR = 1.305, 95% CI = 1.038 to 1.640). Similarly, homozygous mutant TT genotype also revealed 1.6 fold increased risk of TB (TT vs. CC; p-value = 0.040; OR = 1.652, 95% CI = 1.023 to 2.667). Additionally, dominant genetic model demonstrated increased risk of developing TB (TT vs. CC+CT: p-value = 0.006; OR = 1.585, 95% CI = 1.142 to 2.201). The study demonstrates that CD14 gene (-159 C>T) polymorphism contributes increased susceptibility for TB. Moreover, this meta-analysis also suggests for future larger studies with stratified case control population and biological characterization for validation studies.
C1 [Areeshi, M. Y.] Jazan Univ, Coll Nursing & Allied Hlth Sci, Dept Med Microbiol, Jazan, Saudi Arabia.
   [Mandal, Raju K.] Sanjay Gandhi Post Grad Inst Med Sci, Dept Urol, Lucknow, Uttar Pradesh, India.
   [Panda, Aditya K.] Inst Life Sci, Dept Infect Dis Biol, Bhubaneswar, Odisha, India.
   [Bisht, Shekhar C.] Hemwati Nanadan Bahuguna Garhwal Univ, Dept Biotechnol, Srinagar, Uttarakhand, India.
   [Haque, Shafiul] Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India.
RP Haque, S (reprint author), Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India.
EM shafiul.haque@hotmail.com
RI Panda, Aditya K/E-1267-2012; BISHT, SHEKHAR CHANDRA/I-5005-2012
OI Panda, Aditya K/0000-0002-1192-1978; BISHT, SHEKHAR
   CHANDRA/0000-0002-7932-765X; Mandal, Raju/0000-0001-6206-1413
FU Jazan University, KSA; College of Nursing & Allied Health Sciences
FX Annual research grant from Jazan University, KSA. Fund allocated from
   Dean, College of Nursing & Allied Health Sciences. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Alavi-Naini R, 2012, INT J TUBERC LUNG D, V16, P1383, DOI 10.5588/ijtld.11.0827
   Ayaslioglu E, 2005, JPN J INFECT DIS, V58, P11
   Ayaslioglu E, 2012, J MICROBIOL IMMUNOL
   Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bellamy R, 2003, GENES IMMUN, V4, P4, DOI 10.1038/sj.gene.6363915
   Chao YC, 2005, WORLD J GASTROENTERO, V11, P6043, DOI 10.3748/wjg.v11.i38.6043
   Cooke GS, 2001, NAT REV GENET, V2, P967, DOI 10.1038/35103577
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Devitt A, 1998, NATURE, V392, P505
   Druszczynska Magdalena, 2006, Polish Journal of Microbiology, V55, P7
   Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   HAZIOT A, 1988, J IMMUNOL, V141, P547
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HOHEISEL G, 1995, CHEST, V108, P1614, DOI 10.1378/chest.108.6.1614
   Juffermans NP, 1998, J INFECT DIS, V178, P1839, DOI 10.1086/314492
   Kang HJ, 2006, INT J PEDIATR OTORHI, V70, P2081, DOI 10.1016/j.ijporl.2006.07.024
   Kang YA, 2009, FEMS IMMUNOL MED MIC, V57, P229, DOI 10.1111/j.1574-695X.2009.00602.x
   King KY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016317
   LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Pacheco E, 2004, FEMS IMMUNOL MED MIC, V40, P207, DOI 10.1016/S0928-8244(03)00369-9
   PETERSON PK, 1995, INFECT IMMUN, V63, P1598
   PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744
   Rosas-Taraco AG, 2007, J INFECT DIS, V196, P1698, DOI 10.1086/522147
   Shams H, 2003, FEMS IMMUNOL MED MIC, V36, P63, DOI 10.1016/S0928-8244(03)00039-7
   Stein CM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001189
   Thye T, 2010, NAT GENET, V42, P739, DOI 10.1038/ng.639
   Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0
   Vercelli D, 2001, INT ARCH ALLERGY IMM, V124, P20, DOI 10.1159/000053658
   WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311
   Wu RL, 1999, BIOMETRICS, V55, P355
   Zhao MY, 2012, GENET MOL RES, V11, P3425, DOI 10.4238/2012.September.25.11
NR 34
TC 12
Z9 12
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2013
VL 8
IS 5
AR e64747
DI 10.1371/journal.pone.0064747
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 156DC
UT WOS:000319799900096
PM 23741383
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, DW
   Liu, JK
   Zhang, WH
   Ren, JC
   Yan, L
   Liu, HN
   Xu, ZH
AF Li, Dawei
   Liu, Jikai
   Zhang, Wenhua
   Ren, Juchao
   Yan, Lei
   Liu, Hainan
   Xu, Zhonghua
TI Association between HIF1A P582S and A588T Polymorphisms and the Risk of
   Urinary Cancers: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID RENAL-CELL CARCINOMA; INDUCIBLE FACTOR-I; PROSTATE-CANCER; PROLYL
   HYDROXYLATION; ALPHA-GENE; HYPOXIA; HIF-1-ALPHA; FACTOR-1-ALPHA;
   MUTATION; SUSCEPTIBILITY
AB Purpose: The hypoxia-inducible factor-1 alpha (HIF1A) plays a vital role in cancer initiation and progression. Previous studies have reported the existence of HIF1A P582S and A588T missense polymorphisms in renal, urothelial and prostatic carcinomas, however the effects remain conflicting. Therefore, we performed a meta-analysis to assess the association between these sites and the susceptibility of urinary cancers.
   Methods: We searched the PubMed database without limits on language until Nov 25, 2012 for studies exploring the relationship of HIF1A P582S and A588T polymorphisms and urinary cancers. Still, article search was supplemented by screening the references of retrieved studies manually. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to evaluate the strength of the associations between the two by RevMan 5.0 software. Simultaneously, publication bias was estimated by funnel plot and Begg's test with Stata 12.1 software.
   Results: Overall, 11 individual case-control studies with 5195 cases and 5786 controls for P582S polymorphism, and 9 studies with 3482 cases and 4304 controls for A588T polymorphism were respectively included in the final meta-analysis. For HIF1A P582S polymorphism, individuals with TT genotype showed 1.60 fold higher risk than the others carrying CT or CC genotypes in Caucasian population (OR = 1.60, 95% CI = 1.09-2.33, P-heterogeneity = 0.11, P = 0.02). For HIF1A A588T polymorphism, the A allele was significantly correlated with higher urinary cancers risk in Asian population (OR = 1.41, 95% CI = 1.03-1.93, P-heterogeneity = 0.22, P = 0.03). Still, significant associations were found for prostate cancer in the allele and dominant models (OR = 1.46, 95% CI = 1.01-2.12, P-heterogeneity = 0.49, P = 0.04 and OR = 1.45, 95% CI = 1.00-2.12, P-heterogeneity = 0.50, P = 0.05).
   Conclusions: The current findings suggest that HIF1A P582S polymorphism correlates with urinary cancers risk in Caucasian population, while A588T polymorphism may increase the risk of urinary cancers in Asian population and prostate cancer.
C1 [Li, Dawei; Liu, Jikai; Zhang, Wenhua; Ren, Juchao; Yan, Lei; Liu, Hainan; Xu, Zhonghua] Shandong Univ, Qilu Hosp, Dept Urol, Jinan, Shandong, Peoples R China.
   [Li, Dawei] Minist Educ PR China, Key Lab Cardiovasc Remodeling & Funct Res, Jinan, Peoples R China.
   [Li, Dawei] Minist Publ Hlth PR China, Jinan, Peoples R China.
RP Liu, HN (reprint author), Shandong Univ, Qilu Hosp, Dept Urol, Jinan, Shandong, Peoples R China.
EM hainanliu815@yahoo.com.cn; xuzhonghuamd@yahoo.com.cn
FU Natural Science Foundation of Shandong [2010ZRE27284]; China Scholarship
   Council (CSC) [2011622132]
FX The study was partly supported by a research grant to Dr. Xu Z from the
   Natural Science Foundation of Shandong (No. 2010ZRE27284). Dawei Li
   received a scholarship (NO.2011622132) from China Scholarship Council
   (CSC). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Bao B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043726
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Botlagunta M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017563
   Chau CH, 2005, CANCER BIOL THER, V4, P1222, DOI 10.4161/cbt.4.11.2091
   Clifford SC, 2001, ONCOGENE, V20, P5067, DOI 10.1038/sj.onc.1204602
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Foley R, 2009, CANCER BIOL THER, V8, P118, DOI 10.4161/cbt.8.2.7086
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Fu XYS, 2005, PROSTATE, V63, P215, DOI 10.1002/pros.20190
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Jacobs EJ, 2008, CANCER EPIDEM BIOMAR, V17, P972, DOI 10.1158/1055-9965.EPI-07-2787
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jung F, 2000, CIRC RES, V86, P319, DOI 10.1161/01.RES.86.3.319
   Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015
   Li DW, 2012, EXP THER MED, V3, P493, DOI 10.3892/etm.2012.445
   Li DW, 2012, UROL INT, V88, P88, DOI 10.1159/000331931
   Li H, 2007, PROSTATE, V67, P1354, DOI 10.1002/pros.20589
   Li P, 2012, ASIAN J ANDROL, V14, P864, DOI 10.1038/aja.2012.101
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197
   Morris MR, 2009, ANTICANCER RES, V29, P4337
   Nadaoka J, 2008, INT J CANCER, V122, P1297, DOI 10.1002/ijc.23256
   Nakamura H, 2008, ONCOGENE, V27, P4200, DOI 10.1038/onc.2008.58
   Ollerenshaw M, 2004, CANCER GENET CYTOGEN, V153, P122, DOI 10.1016/j.cancergencyto.2004.01.014
   Orr-Urtreger A, 2007, PROSTATE, V67, P8, DOI 10.1002/pros.20433
   Qin C, 2012, ANN ONCOL, V23, P981, DOI 10.1093/annonc/mdr325
   Ratcliffe PJ, 2002, BLOOD PURIFICAT, V20, P445, DOI 10.1159/000065201
   Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214
   Semenza GL, 1996, GENOMICS, V34, P437, DOI 10.1006/geno.1996.0311
   Tanimoto K, 2003, CARCINOGENESIS, V24, P1779, DOI 10.1093/carcin/bgg132
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Yu LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055835
   Zhao TS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043399
   Zhong H, 2004, CANCER DETECT PREV, V28, P88, DOI 10.1016/j.cdp.2003.12.009
NR 36
TC 5
Z9 5
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 27
PY 2013
VL 8
IS 5
AR e63445
DI 10.1371/journal.pone.0063445
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 155HH
UT WOS:000319738100009
PM 23723982
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, XL
   Long, SY
   Deng, JP
   Deng, TX
   Gong, ZH
   Hao, P
AF Yang, Xingliang
   Long, Shuyu
   Deng, Jianping
   Deng, Tianxing
   Gong, Zhihua
   Hao, Ping
TI Glutathione S-Transferase Polymorphisms (GSTM1, GSTT1 and GSTP1) and
   Their Susceptibility to Renal Cell Carcinoma: An Evidence-Based
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CANCER-RISK; GENE POLYMORPHISMS; OCCUPATIONAL-EXPOSURE; LUNG-CANCER;
   ASSOCIATION; M1; T1; TRICHLOROETHYLENE; IDENTIFICATION; HETEROGENEITY
AB Background: The association of the three Glutathione S-transferases (GSTs) polymorphisms (GSTM1, GSTT1 and GSTP1) genotypes with their individual susceptibilities to renal cell carcinoma (RCC) has not been well established. We performed a quantitative meta-analysis to assess the possible associations between the GSTM1, GSTT1 and GSTP1 genotypes and their individual susceptibilities to renal cell carcinoma.
   Methods: We systematically searched the PubMed, CNKI and Embase databases to identify the relevant studies. Finally, 11 eligible studies were selected. The pooled odds ratios (ORs) with their 95% confidence intervals (CIs) were used to assess the association between the GSTs polymorphisms and the risk of RCC. Multiple subgroup analyses and quality assessment of the included studies were performed based on the available information.
   Results: None of the GSTs polymorphisms had a significant association with the RCC risk. Similar results were found in the subgroup analyses, except for the GSTs polymorphisms in the situations described below. The GSTM1 and GSTT1 active genotypes in subjects exposed to pesticides (GSTM1: OR = 3.44; 95% CI, 2.04-5.80; GSTT1: OR = 2.84; 95% CI, 1.75-4.60), most of the GSTs genotypes in Asian populations (GSTT1: OR = 2.39, 95% CI = 1.63-3.51; GSTP1: Dominant model: OR = 1.50, 95% CI = 1.14-1.99; Additive model: OR = 1.39, 95% CI = 1.12-1.73; AG vs. AA: OR = 1.47, 95% CI = 1.10-1.97; GG vs. AA: OR = 1.82, 95% CI = 1.07-3.09) and the dual null genotype of GSTT1-GSTP1 (OR = 2.84, 95% CI = 1.75-4.60) showed positive associations with the RCC risk.
   Conclusion: Our present study provides evidence that the GSTM1, GSTT1 and GSTP1 polymorphisms are not associated with the development of RCC. However, more case-control studies are needed for further confirmation.
C1 [Yang, Xingliang; Deng, Jianping; Deng, Tianxing] Third Mil Med Univ, Xinqiao Hosp, Dept Urol, Chongqing, Peoples R China.
   [Long, Shuyu] Sichuan Univ, West China Hosp 2, Dept Gynecol & Obstet, Chengdu 610064, Sichuan, Peoples R China.
   [Gong, Zhihua; Hao, Ping] Third Mil Med Univ, Xinqiao Hosp, Dept Oncol, Chongqing, Peoples R China.
RP Hao, P (reprint author), Third Mil Med Univ, Xinqiao Hosp, Dept Oncol, Chongqing, Peoples R China.
EM haoping833@hotmail.com
FU National Natural Science Foundation of China [81071911]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81071911). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adams KF, 2008, AM J EPIDEMIOL, V168, P268, DOI 10.1093/aje/kwn122
   Ahmad ST, 2012, DNA CELL BIOL, V31, P636, DOI 10.1089/dna.2011.1392
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bruning T, 1997, ARCH TOXICOL, V71, P596, DOI 10.1007/s002040050432
   Buzio L, 2003, OCCUP ENVIRON MED, V60, P789, DOI 10.1136/oem.60.10.789
   Cheng HY, 2012, RENAL FAILURE, V34, P1052, DOI 10.3109/0886022X.2012.708380
   Chow WH, 1999, JAMA-J AM MED ASSOC, V281, P1628, DOI 10.1001/jama.281.17.1628
   Coric V, 2010, J MED BIOCHEM, V29, P204, DOI 10.2478/v10011-010-0025-8
   CURADO MP, 2008, JAMA-J AM MED ASSOC, V282, P2119
   De Martino M, 2010, J UROLOGY, V183, P878, DOI 10.1016/j.juro.2009.11.032
   DEKANT W, 1986, CHEM-BIOL INTERACT, V60, P31, DOI 10.1016/0009-2797(86)90015-3
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FACCHINI F, 1994, DIABETES CARE, V17, P115, DOI 10.2337/diacare.17.2.115
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gao LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020157
   GROVES CE, 1991, TOXICOL APPL PHARM, V107, P54, DOI 10.1016/0041-008X(91)90330-H
   Harries LW, 1997, CARCINOGENESIS, V18, P641, DOI 10.1093/carcin/18.4.641
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P521
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hu X, 1997, BIOCHEM BIOPH RES CO, V238, P397, DOI 10.1006/bbrc.1997.7311
   Karami S, 2008, CARCINOGENESIS, V29, P1567, DOI 10.1093/carcin/bgn153
   Katner HP, 1999, JAMA-J AM MED ASSOC, V282, P2119, DOI 10.1001/jama.282.22.2119
   KETTERER B, 1988, MUTAT RES, V202, P343, DOI 10.1016/0027-5107(88)90197-2
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   Liu R, 2012, ASIAN PAC J CANCER P, V13, P3109, DOI 10.7314/APJCP.2012.13.7.3109
   Longuemaux S, 1999, CANCER RES, V59, P2903
   McIlwain CC, 2006, ONCOGENE, V25, P1639, DOI 10.1038/sj.onc.1209373
   Palli D, 2005, AM J GASTROENTEROL, V100, P1941, DOI 10.1111/j.1572-0241.2005.50084.x
   PEARSON WR, 1993, AM J HUM GENET, V53, P220
   Pekmezovic T, 2010, J MED BIOCHEM, V29, P131, DOI 10.2478/v10011-010-0021-z
   Salinas-Sanchez AS, 2012, UROL ONCOL-SEMIN ORI, V30, P864, DOI 10.1016/j.urolonc.2010.10.001
   SEIDEGARD J, 1986, CARCINOGENESIS, V7, P751, DOI 10.1093/carcin/7.5.751
   Sergentanis TN, 2010, BREAST CANCER RES TR, V121, P195, DOI 10.1007/s10549-009-0520-0
   Shi XQ, 2008, LUNG CANCER, V59, P155, DOI 10.1016/j.lungcan.2007.08.004
   Simic T, 2009, NAT REV UROL, V6, P281, DOI 10.1038/nrurol.2009.49
   Sui Y, 2011, EUR J OBSTET GYN R B, V159, P443, DOI 10.1016/j.ejogrb.2011.09.012
   Sweeney C, 2000, CANCER EPIDEM BIOMAR, V9, P449
   van Bladeren PJ, 2000, CHEM-BIOL INTERACT, V129, P61, DOI 10.1016/S0009-2797(00)00214-3
   Vineis P, 2004, JNCI-J NATL CANCER I, V96, P99, DOI 10.1093/jnci/djh014
   Webb G, 1996, GENOMICS, V33, P121, DOI 10.1006/geno.1996.0167
   Wiesenhutter B, 2007, INT ARCH OCC ENV HEA, V81, P247, DOI 10.1007/s00420-007-0200-5
   Ye Z, 2005, EUR J CANCER, V41, P980, DOI 10.1016/j.ejca.2005.01.014
   Ye Z, 2006, PLOS MED, V3, P524, DOI 10.1371/journal.pmed.0030091
   Yin J, 2011, CANCER EPIDEMIOL, V36, P177
   ZIMNIAK P, 1994, EUR J BIOCHEM, V224, P893, DOI 10.1111/j.1432-1033.1994.00893.x
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 47
TC 5
Z9 6
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2013
VL 8
IS 5
AR UNSP e63827
DI 10.1371/journal.pone.0063827
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163UP
UT WOS:000320362700069
PM 23717494
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Qin, Q
   Liu, L
   Zhong, R
   Zou, L
   Yin, JY
   Zhu, BB
   Cao, BB
   Chen, W
   Chen, JG
   Li, XR
   Li, TT
   Lu, XZ
   Lou, J
   Ke, JT
   Wei, S
   Miao, XP
   Nie, SF
AF Qin, Qin
   Liu, Li
   Zhong, Rong
   Zou, Li
   Yin, Jieyun
   Zhu, BeiBei
   Cao, BeiBei
   Chen, Wei
   Chen, Jigui
   Li, Xiaorong
   Li, Tingting
   Lu, Xuzai
   Lou, Jiao
   Ke, Juntao
   Wei, Sheng
   Miao, Xiaoping
   Nie, Shaofa
TI The Genetic Variant on Chromosome 10p14 Is Associated with Risk of
   Colorectal Cancer: Results from a Case-Control Study and a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; POLYMORPHISMS; SCAN;
   PREVALENCE
AB Background: A common single nucleotide polymorphism (SNP), rs10795668, located at 10p14, was first identified to be significantly associated with risk of colorectal cancer (CRC) by a genome-wide association study (GWAS) in 2008; however, another GWAS and following replication studies yielded conflicting results.
   Methods: We conducted a case-control study of 470 cases and 475 controls in a Chinese population and then performed a meta-analysis, integrating the current study and 9 publications to evaluate the association between rs10795668 and CRC risk. Heterogeneity among studies and publication bias were assessed by the chi(2)-based Q statistic test and Egger's test, respectively.
   Results: In the case-control study, significant association between the SNP and CRC risk was observed, with per-A-allele OR of 0.71 (95% CI: 0.54-0.94, P = 0.017). The following meta-analysis further confirmed the significant association, with per-A-allele OR of 0.91 (95% CI: 0.89-0.93, P-heterogeneity<0.05) in European population and 0.86 (95% CI: 0.78-0.96, P-heterogeneity>0.05) in Asian population. Besides, sensitivity analyses and publication bias assessment indicated the robust stability and reliability of the results.
   Conclusions: Results from our case-control study and the followed meta-analysis confirmed the significant association of rs10795668 with CRC risk.
C1 [Qin, Qin; Liu, Li; Zhong, Rong; Zou, Li; Yin, Jieyun; Zhu, BeiBei; Cao, BeiBei; Chen, Wei; Li, Xiaorong; Li, Tingting; Lu, Xuzai; Lou, Jiao; Ke, Juntao; Wei, Sheng; Miao, Xiaoping; Nie, Shaofa] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R China.
   [Qin, Qin; Liu, Li; Zhong, Rong; Zou, Li; Yin, Jieyun; Zhu, BeiBei; Cao, BeiBei; Chen, Wei; Li, Xiaorong; Li, Tingting; Lu, Xuzai; Lou, Jiao; Ke, Juntao; Wei, Sheng; Miao, Xiaoping; Nie, Shaofa] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ,Key Lab Environm & Hlth, Wuhan, Hubei, Peoples R China.
   [Chen, Jigui] Eighth Hosp Wuhan, Dept Surg, Wuhan, Hubei, Peoples R China.
RP Miao, XP (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R China.
EM miaoxp@mail.hust.edu.cn; sf_nie@mails.tjmu.edu.cn
RI miao, xiaoping/C-4336-2011
OI miao, xiaoping/0000-0002-6818-9722
FU National Natural Science Foundation of China [NSFC-81172752,
   NSFC-81222038]; Talent introduction plan of Huazhong University of
   Science and Technology
FX This work was supported by the National Natural Science Foundation of
   China (NSFC-81172752, and NSFC-81222038) and the Talent introduction
   plan of Huazhong University of Science and Technology (Li Liu). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Barba C, 2004, LANCET, V363, P157
   Barker D, 2012, INT J CANC
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bray MS, 2001, HUM MUTAT, V17, P296, DOI 10.1002/humu.27
   Broderick P, 2007, NAT GENET, V39, P1315, DOI 10.1038/ng.2007.18
   Cuezva JM, 2002, CANCER RES, V62, P6674
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109
   Duan S, 2008, AM J HUM GENET, V82, P1101, DOI 10.1016/j.ajhg.2008.03.006
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840
   Haiman CA, 2007, NAT GENET, V39, P954, DOI 10.1038/ng2098
   He J, 2011, CANCER EPIDEM BIOMAR, V20, P70, DOI 10.1158/1055-9965.EPI-10-0892
   HERNANDEZ JL, 1989, BIOMETRICS, V45, P53, DOI 10.2307/2532034
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ho JW, 2011, BRIT J CANCER, V104, P369, DOI 10.1038/sj.bjc.6605977
   Houlston RS, 2010, NAT GENET, V42, P973, DOI 10.1038/ng.670
   Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262
   Hutter CM, 2012, CANCER RES, V72, P2036, DOI 10.1158/0008-5472.CAN-11-4067
   Jaeger E, 2008, NAT GENET, V40, P26, DOI 10.1038/ng.2007.41
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kupfer SS, 2010, GASTROENTEROLOGY, V139, P1677, DOI 10.1053/j.gastro.2010.07.038
   Lascorz J, 2010, CARCINOGENESIS, V31, P1612, DOI 10.1093/carcin/bgq146
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494
   Li FX, 2012, CHINESE J CANCER RES, V24, P29, DOI 10.1007/s11670-012-0029-7
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Liljegren A, 2003, GUT, V52, P1140, DOI 10.1136/gut.52.8.1140
   Lindgren G, 2002, GUT, V50, P228, DOI 10.1136/gut.50.2.228
   Liu L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027301
   Loo LWM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030477
   Lubbe SJ, 2012, AM J EPIDEMIOL, V175, P1, DOI 10.1093/aje/kwr285
   Mates IN, 2010, CHIRURGIA-BUCHAREST, V105, P749
   Mates IN, 2012, J GASTROINTEST LIVER, V21, P45
   Middeldorp A, 2009, CANCER EPIDEM BIOMAR, V18, P3062, DOI 10.1158/1055-9965.EPI-09-0601
   Niittymaki I, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-23
   Olson JM, 1996, BIOMETRICS, V52, P971, DOI 10.2307/2533058
   Pardini B, 2012, MUTAGENESIS, V27, P161, DOI 10.1093/mutage/ger057
   Peters U, 2012, HUM GENET, V131, P217, DOI 10.1007/s00439-011-1055-0
   RIES LAG, 2007, SEER CANC STAT REV 1
   Schaid DJ, 1999, AM J EPIDEMIOL, V149, P706
   Sung JJY, 2005, LANCET ONCOL, V6, P871, DOI 10.1016/S1470-2045(05)70422-8
   Talseth-Palmer BA, 2011, J MED GENET, V48, P279, DOI 10.1136/jmg.2010.079962
   Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085
   Tomlinson IPM, 2008, NAT GENET, V40, P623, DOI 10.1038/ng.111
   von Holst S, 2010, BRIT J CANCER, V103, P575, DOI 10.1038/sj.bjc.6605774
   Wan De-Sen, 2009, Ai Zheng, V28, P897
   Wijnen JT, 2009, GASTROENTEROLOGY, V136, P131, DOI 10.1053/j.gastro.2008.09.033
   Willers IM, 2010, BIOCHEM J, V426, P319, DOI 10.1042/BJ20091570
   Xia J, 2008, HEALTH INFO LIBR J, V25, P55, DOI 10.1111/j.1471-1842.2007.00734.x
   Xiong F, 2010, CANCER EPIDEM BIOMAR, V19, P1855, DOI 10.1158/1055-9965.EPI-10-0210
   Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089
NR 55
TC 7
Z9 8
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2013
VL 8
IS 5
AR e64310
DI 10.1371/journal.pone.0064310
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163UP
UT WOS:000320362700136
PM 23717594
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Cheng, SM
   Feng, YF
   Xu, L
   Li, Y
   Huang, JH
AF Cheng, Shi-ming
   Feng, Yi-fan
   Xu, Ling
   Li, Yan
   Huang, Jin-hai
TI Efficacy of Mitomycin C in Endoscopic Dacryocystorhinostomy: A
   Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID EXTERNAL DACRYOCYSTORHINOSTOMY; SURGICAL OUTCOMES; ADJUNCTIVE USE;
   ENDONASAL; QUALITY
AB Background: A number of published comparative studies have been conducted to evaluate the efficacy and safety of intraoperative mitomycin C (MMC) in endoscopic dacryocystorhinostomy (EN-DCR). However, results have not always been consistent. Therefore, we carried out a meta-analysis to compare the clinical results of EN-DCR with and without MMC.
   Methods and Findings: A comprehensive literature search of Cochrane Library, PubMed and EMBASE to identify relevant trials comparing EN-DCR with and without MMC. Eleven studies including 574 eyes were included in this meta-analysis. The success was defined as patency of the nasolacrimal canal and symptomatic improvement. There was significantly higher success rate in the MMC group in comparison with control group [RR = 1.12, 95% CI (1.04, 1.20), P = 0.004]. A sensitivity analysis after the non-randomized controlled trials were excluded from the meta-analysis demonstrated no differences compared with the overall results. Subgroup analyses showed that MMC group had a significantly higher success rate than control group in primary and revision EN-DCR, and EN-DCR without silicone intubation, but no difference in the subgroup of with silicone intubation. The size of the osteotomy site was bigger in the MMC group compared to the control group at 3 months [WMD = 7.65, 95% CI (0.33, 14.98), P = 0.041] and 6 months [WMD = 9.28, 95% CI (2.45, 16.11), P = 0.008] after surgery. However, there was statistically significant difference in the osteotomy surface area between the two groups at 12 months after surgery [WMD = 11.63, 95% CI (-1.04, 24.29), P = 0.072].
   Conclusion: Intraoperative MMC application seems to be a safe adjuvant that could reduce the closure rate of the osteotomy and enhance the success rate after both primary and revision EN-DCR.
   Trial Registration: ClinicalTrials.gov NCT01772277
C1 [Cheng, Shi-ming; Xu, Ling] Hubei Univ Med, Taihe Hosp, Dept Ophthalmol, Shijiazhuang, Hubei, Peoples R China.
   [Feng, Yi-fan] Fudan Univ, Dept Ophthalmol, Zhongshan Hosp, Shanghai 200433, Peoples R China.
   [Li, Yan] Hubei Univ Med, Dongfeng Hosp, Dept Ophthalmol, Shijiazhuang, Hubei, Peoples R China.
   [Huang, Jin-hai] Wenzhou Med Coll, Affiliated Eye Hosp, Wenzhou, Zhejiang, Peoples R China.
RP Feng, YF (reprint author), Fudan Univ, Dept Ophthalmol, Zhongshan Hosp, Shanghai 200433, Peoples R China.
EM wzafengyifan@163.com
CR Allen K M, 1988, Ophthalmic Plast Reconstr Surg, V4, P143, DOI 10.1097/00002341-198804030-00004
   Apuhan T, 2011, J CRANIOFAC SURG, V22, P2057, DOI 10.1097/SCS.0b013e3182319863
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BOUSH GA, 1994, OPHTHALMOLOGY, V101, P955
   Caldwell GW., 1893, AM J OPHTHALMOL, V10, P189
   Dolmetsch AM, 2010, OPHTHALMOLOGY, V117, P1037, DOI 10.1016/j.ophtha.2009.09.028
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farahani F, 2008, SAUDI MED J, V29, P1354
   Feng YF, 2011, EFFICACY MITOMYCIN C
   Feng YF, 2012, OPHTHAL EPIDEMIOL, V19, P364, DOI 10.3109/09286586.2012.733792
   Ghosh S, 2006, INDIAN J OTOLARYNGOL, V58, P368, DOI 10.1007/BF03049597
   Gorgulu O, 2012, B-ENT, V8, P123
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   JOKINEN K, 1974, ARCH OTOLARYNGOL, V100, P41
   KONG YT, 1994, OPHTHALMOLOGY, V101, P1793
   Korkut AY, 2011, EUR ARCH OTO-RHINO-L, V268, P377, DOI 10.1007/s00405-010-1339-3
   Korkut AY, 2010, J CRANIOFAC SURG, V21, P1706, DOI 10.1097/SCS.0b013e3181f3c6c1
   Leong SC, 2010, AM J RHINOL ALLERGY, V24, P81, DOI 10.2500/ajra.2010.24.3393
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Mak ST, 2012, GRAEFES ARC IN PRESS
   Mann BS, 2006, LARYNGOSCOPE, V116, P1172, DOI 10.1097/01.mlg.0000218099.33523.19
   MCDONOGH M, 1989, J LARYNGOL OTOL, V103, P585, DOI 10.1017/S0022215100109405
   MEGEVAND GS, 1995, OPHTHALMOLOGY, V102, P84
   Mudhol R. R., 2012, Al Ameen Journal of Medical Sciences, V5, P320
   Nemet AY, 2007, ORBIT, V26, P97, DOI 10.1080/01676830601174627
   Ozkiris M, 2012, J CRANIOFAC SURG, V23, pE608, DOI 10.1097/SCS.0b013e31826c7cf7
   Ozkiris M, 2012, EUR J OPHTHALMOL, V22, P320, DOI 10.5301/ejo.5000048
   PALMER SS, 1991, OPHTHALMOLOGY, V98, P317
   Penttila E, 2011, AM J RHINOL ALLERGY, V25, P425, DOI 10.2500/ajra.2011.25.3676
   Prasannaraj T, 2012, AM J OTOLARYNG, V33, P47, DOI 10.1016/j.amjoto.2011.01.001
   Qin ZY, 2010, INT J OPBTHALMOL, V10, P1569
   Ragab SM, 2012, OTOLARYNG HEAD NECK, V147, P937, DOI 10.1177/0194599812450280
   RUBINFELD RS, 1992, OPHTHALMOLOGY, V99, P1647
   Selig YK, 2000, AM J RHINOL, V14, P205, DOI 10.2500/105065800782102672
   SINGH G, 1988, OPHTHALMOLOGY, V95, P813
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tirakunwichcha S, 2011, LARYNGOSCOPE, V121, P433, DOI 10.1002/lary.21292
   Tsirbas A, 2005, AM J RHINOL, V19, P322, DOI 10.1177/194589240501900319
   Unlu HH, 2002, ANN OTO RHINOL LARYN, V111, P704, DOI 10.1177/000348940211100809
   WAKAKI S., 1958, ANTIBIOT AND CHEMOTHER, V8, P228
   WOOG JJ, 1993, AM J OPHTHALMOL, V116, P1
   Woog JJ, 2001, OPHTHALMOLOGY, V108, P2369, DOI 10.1016/S0161-6420(01)00945-9
   Yuen K. S. C., 2004, Hong Kong Medical Journal, V10, P394
   ZACHARIA PT, 1993, AM J OPHTHALMOL, V116, P314, DOI 10.1016/S0002-9394(14)71349-2
   Zilelioglu G, 1998, BRIT J OPHTHALMOL, V82, P63
   Zilelioglu Guler, 2002, Documenta Ophthalmologica, V105, P57, DOI 10.1023/A:1015702902769
NR 47
TC 28
Z9 28
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 13
PY 2013
VL 8
IS 5
AR e62737
DI 10.1371/journal.pone.0062737
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145RZ
UT WOS:000319036100010
PM 23675423
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Meng, NN
   Zhang, P
   Huang, HD
   Ma, JL
   Zhang, Y
   Li, H
   Qu, Y
AF Meng, Nana
   Zhang, Ping
   Huang, Huadong
   Ma, Jinlan
   Zhang, Yue
   Li, Hao
   Qu, Yi
TI Color Doppler Imaging Analysis of Retrobulbar Blood Flow Velocities in
   Primary Open-Angle Glaucomatous Eyes: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID OCULAR PERFUSION-PRESSURE; NORMAL-TENSION GLAUCOMA; EXTRAOCULAR VESSELS;
   RESISTIVE INDEX; DUPLEX DOPPLER; HEMODYNAMICS; CIRCULATION; HEALTHY;
   ARTERY; ASSOCIATION
AB Background: To analyze the diagnostic value of color Doppler imaging (CDI) of blood flow in the retrobulbar vessels of eyes with primary open-angle glaucoma (POAG).
   Methods: Pertinent publications were retrieved from the Cochrane Central Register of Controlled Trials, PubMed and the ISI Web of Knowledge up to October 2012. Changes in peak systolic velocity (PSV), end diastolic velocity (EDV) and resistive index (RI) of the ophthalmic artery (OA), central retinal artery (CRA) and short posterior ciliary artery (SPCA) of POAG eyes and normal controls were evaluated by CDI. Subgroup analyses were conducted according to whether patients received IOP-lowering drugs treatment and were defined as treated and untreated.
   Results: PSV and EDV were statistically significantly reduced in the OA of POAG eyes (P=0.0002; P<0.00001; respectively), with significant heterogeneity (P-heterogeneity<0.00001, I-2 = 94%; P-heterogeneity<0.00001, I-2 = 85%; respectively). Similar results were demonstrated for the CRA (P<0.00001; respectively) and SPCA (P = 0.005; P<0.00001; respectively), with significant heterogeneities for both the CRA (P-heterogeneity<0.00001, I-2 = 81%; P-heterogeneity<0.00001, I-2 = 98%; respectively) and the SPCA (P-heterogeneity<0.00001, I-2 = 96%; P-heterogeneity<0.00001, I-2 = 93%; respectively). Significant increases in RI were found in all retrobulbar vessels (P<0.00001; respectively), with significant heterogeneities (P-heterogeneity<0.00001, I-2 = 95%; P-heterogeneity<0.00001, I-2 = 94%; P-heterogeneity<0.00001, I-2 = 97%; respectively).
   Conclusions: This meta-analysis suggests that CDI is a potential diagnostic tool for POAG.
C1 [Meng, Nana; Zhang, Ping; Ma, Jinlan; Zhang, Yue; Li, Hao; Qu, Yi] Shandong Univ, Qilu Hosp, Dept Hlth Care, Jinan 250100, Peoples R China.
   [Huang, Huadong] Qihe Country Hosp, Dept Ophthalmol, Qihe, Peoples R China.
RP Qu, Y (reprint author), Shandong Univ, Qilu Hosp, Dept Hlth Care, Jinan 250100, Peoples R China.
EM drquyi@gmail.com
FU Shandong Science and Technology Developing Project [2012GSF12121];
   Shandong Provincial Natural Science Foundation [Y2008C78]; Independent
   innovation foundation of Shandong University [IIFSDU 2012ZD025]
FX This study was supported partly by Shandong Science and Technology
   Developing Project (2012GSF12121), Shandong Provincial Natural Science
   Foundation (Y2008C78) and Independent innovation foundation of Shandong
   University (IIFSDU 2012ZD025). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abegao Pinto L, 2012, ACTA OPHTHALMOL, V90, P214
   Abegao Pinto L, 2012, ACTA OPHTHALMOL
   Akarsu C, 2004, GRAEF ARCH CLIN EXP, V242, P125, DOI 10.1007/s00417-003-0809-3
   BAXTER GM, 1992, INVEST OPHTH VIS SCI, V33, P604
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Birinci H, 2002, OPHTHALMOLOGICA, V216, P434, DOI 10.1159/000067553
   Brusini P, 2008, EYE, V22, P406, DOI 10.1038/sj.eye.6702654
   Butt Z, 1997, INVEST OPHTH VIS SCI, V38, P690
   BUTT Z, 1995, EYE, V9, P29, DOI 10.1038/eye.1995.4
   Cellini M, 1996, OPHTHALMOLOGICA, V210, P200, DOI 10.1159/000310708
   Chung HS, 1999, BRIT J OPHTHALMOL, V83, P466, DOI 10.1136/bjo.83.4.466
   Costa VP, 2003, PROG RETIN EYE RES, V22, P769, DOI 10.1016/S1350-9462(03)00064-8
   Detorakis ET, 2007, GRAEF ARCH CLIN EXP, V245, P516, DOI 10.1007/s00417-006-0439-7
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   ERICKSON SJ, 1989, RADIOLOGY, V173, P511, DOI 10.1148/radiology.173.2.2678264
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Galambos P, 2006, OPHTHALMOLOGY, V113, P1832, DOI 10.1016/j.ophtha.2006.05.030
   Galassi F, 2008, GRAEF ARCH CLIN EXP, V246, P411, DOI 10.1007/s00417-007-0709-z
   Garhofer G, 2010, INVEST OPHTH VIS SCI, V51, P6652, DOI 10.1167/iovs.10-5490
   Gherghel D, 2000, AM J OPHTHALMOL, V130, P597, DOI 10.1016/S0002-9394(00)00766-2
   Gugleta K, 1999, CURR EYE RES, V19, P496, DOI 10.1076/ceyr.19.6.496.5286
   HANSEN NB, 1983, PEDIATRICS, V72, P526
   HARRIS A, 1994, AM J OPHTHALMOL, V118, P642, DOI 10.1016/S0002-9394(14)76579-1
   HAYREH SS, 1970, BRIT J OPHTHALMOL, V54, P461, DOI 10.1136/bjo.54.7.461
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hosking SL, 2004, BRIT J OPHTHALMOL, V88, P406, DOI 10.1136/bjo.2002.008995
   Januleviciene I, 2008, ACTA OPHTHALMOL, V86, P552, DOI 10.1111/j.1600-0420.2007.01091.x
   Kaiser HJ, 1996, AM J OPHTHALMOL, V122, P364, DOI 10.1016/S0002-9394(14)72063-X
   Kaiser HJ, 1997, AM J OPHTHALMOL, V123, P320, DOI 10.1016/S0002-9394(14)70127-8
   Langham M E, 1994, Surv Ophthalmol, V38 Suppl, pS161, DOI 10.1016/0039-6257(94)90061-2
   Leske MC, 2007, OPHTHALMOLOGY, V114, P1965, DOI 10.1016/j.ophtha.2007.03.016
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   Liu CJ, 1999, ACTA OPHTHALMOL SCAN, V77, P658, DOI 10.1034/j.1600-0420.1999.770610.x
   Liu X, 1998, Yan Ke Xue Bao, V14, P138
   Michelson G, 1996, J GLAUCOMA, V5, P91
   Pemp B, 2012, ACTA OPHTHALMOL, V90, P139, DOI 10.1111/j.1755-3768.2010.01878.x
   PLANIOL T, 1972, REV NEUROL-FRANCE, V126, P127
   PLATT JF, 1990, AM J ROENTGENOL, V154, P1223, DOI 10.2214/ajr.154.6.2110732
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   RANKIN SJA, 1995, AM J OPHTHALMOL, V119, P685, DOI 10.1016/S0002-9394(14)72771-0
   Resch H, 2009, ACTA OPHTHALMOL, V87, P4, DOI 10.1111/j.1755-3768.2007.01167.x
   RIFKIN MD, 1987, AM J ROENTGENOL, V148, P759, DOI 10.2214/ajr.148.4.759
   Sekeroglu MA, 2011, ACTA OPHTHALMOL, V89, P429, DOI 10.1111/j.1755-3768.2009.01713.x
   Sihota R, 2006, INVEST OPHTH VIS SCI, V47, P2006, DOI 10.1167/iovs.05-1102
   Simsek T, 2006, J OCUL PHARMACOL TH, V22, P79, DOI 10.1089/jop.2006.22.79
   Stalmans I, 2009, EUR J OPHTHALMOL, V19, P580
   STEIGERWALT RD, 1993, EYE, V7, P403, DOI 10.1038/eye.1993.79
   TAYLOR GA, 1990, RADIOLOGY, V176, P231, DOI 10.1148/radiology.176.1.2112768
   TREW DR, 1991, BRIT J OPHTHALMOL, V75, P71, DOI 10.1136/bjo.75.2.71
   VANBUSKIRK EM, 1992, AM J OPHTHALMOL, V113, P447, DOI 10.1016/S0002-9394(14)76171-9
   WOLF S, 1993, OPHTHALMOLOGY, V100, P1561
   Yuksel N, 2001, OPHTHALMOLOGICA, V215, P424, DOI 10.1159/000050902
   Zhong YS, 2009, DOC OPHTHALMOL, V119, P171, DOI 10.1007/s10633-009-9192-7
NR 53
TC 76
Z9 78
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 13
PY 2013
VL 8
IS 5
AR e62723
DI 10.1371/journal.pone.0062723
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 145RZ
UT WOS:000319036100008
PM 23675419
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, F
   Sun, GP
   Zou, YF
   Zhong, F
   Ma, T
   Li, XQ
AF Wang, Fang
   Sun, Guoping
   Zou, Yanfeng
   Zhong, Fei
   Ma, Tai
   Li, Xiaoqiu
TI Protective Role of Helicobacter pylori Infection in Prognosis of Gastric
   Cancer: Evidence from 2454 Patients with Gastric Cancer
SO PLOS ONE
LA English
DT Article
ID CLINICOPATHOLOGICAL FEATURES; ADJUVANT CHEMOTHERAPY; SURVIVAL;
   METAANALYSIS; CARCINOMA; MUCOSA
AB Background: A number of studies have investigated the association between Helicobacter pylori (H. pylori) infection and the prognosis of gastric cancer (GC), with inconsistent and inconclusive results. We performed a meta-analysis to derive a more precise estimation of the association.
   Methodology/Principal Findings: A systematic search of PubMed, EMBASE, Cochrane and Chinese wanfang databases was performed with the last search updated on February 19, 2013. The hazard ratio (HR) and its 95% confidence interval (95% CI) were used to assess the strength of association. A total of 12 studies including 2454 patients with GC were involved in this meta-analysis. The pooled HR was 0.71 (95% CI: 0.57-0.87; P = 0.001) for OS and 0.60 (95% CI: 0.30-1.18; P = 0.139) for DFS in GC patients, respectively. The protective role of H. pylori infection in the prognosis of GC was also observed among different subgroups stratified by ethnicity, statistical methodology, H. pylori evaluation method and quality assessment. There was no evidence of publication bias.
   Conclusions/Significance: This meta-analysis suggests a protective role for H. pylori infection in the prognosis of GC. The underlying mechanisms need to be further elucidated, which could provide new therapeutic approaches for GC.
C1 [Wang, Fang; Sun, Guoping; Zhong, Fei; Ma, Tai; Li, Xiaoqiu] Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, Hefei, Anhui, Peoples R China.
   [Zou, Yanfeng] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hefei, Anhui, Peoples R China.
RP Sun, GP (reprint author), Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, Hefei, Anhui, Peoples R China.
EM sunguoping@ahmu.edu.cn
FU National Natural Science Foundation of China [81071986, 81272739,
   81001283]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81071986, 81272739, 81001283). The funders had no
   role in study design, data collection and analysis, decision to pubish,
   or preparation of the manuscript.
CR Ardekani GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047054
   Bamford KB, 1998, GASTROENTEROLOGY, V114, P482, DOI 10.1016/S0016-5085(98)70531-1
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blaser MJ, 1999, J INFECT DIS, V179, P1523, DOI 10.1086/314785
   Chen HY, 2012, CANCER SCI, V103, P73, DOI 10.1111/j.1349-7006.2011.02129.x
   Choi IK, 2012, CANCER CHEMOTH PHARM, V70, P555, DOI 10.1007/s00280-012-1944-5
   Choi J, 2009, EJC SUPPL, V7, P374, DOI 10.1016/S1359-6349(09)71267-4
   Correa Pelayo, 2011, US Gastroenterol Hepatol Rev, V7, P59
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fan J, 2008, LUNG CANCER, V61, P91, DOI 10.1016/j.lungcan.2007.11.011
   FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302
   Gan Lu, 2011, Academic Journal of Second Military Medical University, V32, P1300
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hur H, 2012, J KOREAN SURG SOC, V83, P203, DOI 10.4174/jkss.2012.83.4.203
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kang S, 2009, J CLIN ONCOL, V27
   Kang SY, 2010, ANN ONCOL, V21, P229
   Kang SY, 2012, INT J CANCER, V130, P948, DOI 10.1002/ijc.26081
   Kurtenkov O, 2003, IMMUNOL INVEST, V32, P83, DOI 10.1081/IMM-120019210
   Lee HS, 2002, MODERN PATHOL, V15, P632, DOI 10.1038/modpathol.3880578
   LEE WJ, 1995, J CLIN GASTROENTEROL, V21, P203, DOI 10.1097/00004836-199510000-00007
   LEE WJ, 1995, BRIT J SURG, V82, P802, DOI 10.1002/bjs.1800820627
   Marrelli D, 2009, HELICOBACTER, V14, P379
   Marrelli D, 2009, CANCER, V115, P2071, DOI 10.1002/cncr.24253
   Mattsson A, 1998, J CLIN INVEST, V102, P51, DOI 10.1172/JCI22
   Meimarakis G, 2006, LANCET ONCOL, V7, P211, DOI 10.1016/S1470-2045(06)70586-1
   Meyer HJ, 2011, DTSCH ARZTEBL INT, V108, P698, DOI 10.3238/arztebl.2011.0698
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Popat S, 2004, J CLIN ONCOL, V22, P529, DOI 10.1200/JCO.2004.05.064
   Qiu HB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-374
   Rad R, 2006, LANCET ONCOL, V7, P364, DOI 10.1016/S1470-2045(06)70672-6
   Santos Renata S., 2011, Arq. Gastroenterol., V48, P109, DOI 10.1590/S0004-28032011000200005
   Santos RS, 2010, GASTROENTEROLOGY, V138, pS891
   Syrios J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-264
   Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999
   Van Ness M, 2012, J GASTROINTEST ONCOL, V3, P243, DOI 10.3978/j.issn.2078-6891.2012.017
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Wu MS, 2002, HEPATO-GASTROENTEROL, V49, P285
   Zhang YF, 2012, WORLD J GASTROENTERO, V18, P3602, DOI 10.3748/wjg.v18.i27.3602
NR 41
TC 4
Z9 7
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 7
PY 2013
VL 8
IS 5
AR e62440
DI 10.1371/journal.pone.0062440
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 154EP
UT WOS:000319654700036
PM 23667477
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Sun, H
   Shi, JP
   Li, M
   Chen, X
AF Sun, Hao
   Shi, Jingpu
   Li, Min
   Chen, Xin
TI Impact of Continuous Positive Airway Pressure Treatment on Left
   Ventricular Ejection Fraction in Patients with Obstructive Sleep Apnea:
   A Meta-Analysis of Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID CONGESTIVE-HEART-FAILURE; ACUTE MYOCARDIAL-INFARCTION; DIASTOLIC
   FUNCTION; THERAPY; DYSFUNCTION; PERFUSION; RECOVERY; RISK; CPAP; BIAS
AB Background: It has been known for a long time that obstructive sleep apnea (OSA) is associated with a decreased left ventricular ejection fraction (LVEF). Continuous positive airway pressure (CPAP) is the gold standard treatment for OSA; however, it is unknown whether or not CPAP treatment will improve the LVEF. The aim of the current study was to assess whether or not CPAP treatment improves the LVEF. A meta-analysis was conducted to determine the effect of CPAP treatment on the LVEF among patients with OSA.
   Methods: A literature search of PubMed, the Web of Science, and Cochrane Collaboration's database were utilized to identify eligible reports for this trial. Ten randomized controlled trails were examined and the meta-analysis was performed using STATA 11.
   Results: A significant improvement in the LVEF was observed after CPAP treatment (weighted mean difference(WMD) = 3.59, 95% CI = 1.74-5.44; P<0.001). Subgroup analysis revealed that patients with OSA and heart failure had a significant improvement in the LVEF after CPAP treatment (WMD = 5.18, 95% CI = 3.27-7.08; P<0.001); however, the LVEF of patients with OSA only increased 1.11% and there was no statistical significance (WMD = 1.11, 95% CI = -1.13-3.35; P = 0.331). Furthermore, based on univariate meta-regression analysis, only the baseline AHI had a statistically significant correlation with the LVEF.
   Conclusions: Our meta-analysis supports the notion that CPAP may improve the LVEF among patients with OSA.
C1 [Shi, Jingpu] China Med Univ, Affiliated Hosp 1, Inst Cardiovasc Dis, Dept Clin Epidemiol, Shenyang, Peoples R China.
   China Med Univ, Affiliated Hosp 1, Ctr Evidence Based Med, Shenyang, Peoples R China.
RP Shi, JP (reprint author), China Med Univ, Affiliated Hosp 1, Inst Cardiovasc Dis, Dept Clin Epidemiol, Shenyang, Peoples R China.
EM jingpushi56@yahoo.com
RI Sun, Hao/M-6027-2014
CR Alchanatis M, 2000, RESPIRATION, V67, P367, DOI 10.1159/000029532
   Alchanatis M, 2002, EUR RESPIR J, V20, P1239, DOI 10.1183/09031936.02.00278002
   Arias MA, 2005, CIRCULATION, V112, P375, DOI 10.1161/CIRCULATIONAHA.104.501841
   Bayram NA, 2009, EUR J ECHOCARDIOGR, V10, P376, DOI 10.1093/ejechocard/jen257
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bellone A, 2010, AM J EMERG MED, V28, P230, DOI 10.1016/j.ajem.2008.11.002
   Bradley TD, 2003, CIRCULATION, V107, P1671, DOI 10.1161/01.CIR.0000061757.12581.15
   Edwards N, 1998, THORAX, V53, pS12, DOI 10.1136/thx.53.2008.S12
   Egea CJ, 2008, SLEEP MED, V9, P660, DOI 10.1016/j.sleep.2007.06.018
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferrier K, 2005, CHEST, V128, P2116, DOI 10.1378/chest.128.4.2116
   Ferrier KA, 2008, INTERN MED J, V38, P829, DOI 10.1111/j.1445-5994.2007.01585.x
   Gilman MR, 2008, CLIN SCI, V114, P243, DOI 10.1042/CS20070172
   Haruki N, 2010, EUR J ECHOCARDIOGR, V11, P352, DOI 10.1093/ejechocard/jep215
   He FJ, 2006, LANCET, V367, P320, DOI 10.1016/S0140-6736(06)68069-0
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hoekema A, 2008, INT J CARDIOL, V128, P232, DOI 10.1016/j.ijcard.2007.06.016
   Jackson G, 2012, INT J CLIN PRACT, V66, P421, DOI 10.1111/j.1742-1241.2012.02931.x
   JAVAHERI S, 1995, ANN INTERN MED, V122, P487, DOI 10.7326/0003-4819-122-7-199504010-00002
   Johnson CB, 2008, CAN J CARDIOL, V24, P697, DOI 10.1016/S0828-282X(08)70668-8
   Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479
   Khayat RN, 2008, CHEST, V134, P1162, DOI 10.1378/chest.08-0346
   Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557
   MALONE S, 1991, LANCET, V338, P1480
   Mansfield DR, 2004, AM J RESP CRIT CARE, V169, P361, DOI 10.1164/rccm.200306-752OC
   Martinez D, 2011, SLEEP BREATH
   Nguyen PK, 2010, J CARDIOVASC MAGN R, V12, DOI 10.1186/1532-429X-12-50
   Scharf SM, 1996, SLEEP, V19, pS240
   Shaw LJ, 1996, AM J CARDIOL, V78, P1327, DOI 10.1016/S0002-9149(96)00653-4
   Smith LA, 2007, EUR HEART J, V28, P1221, DOI 10.1093/eurheartj/ehm131
   TAYLOR GJ, 1980, CIRCULATION, V62, P960, DOI 10.1161/01.CIR.62.5.960
   Usui K, 2005, J AM COLL CARDIOL, V45, P2008, DOI 10.1016/j.jacc.2004.12.080
   WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44
   Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080
   YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704
NR 35
TC 24
Z9 25
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2013
VL 8
IS 5
AR e62298
DI 10.1371/journal.pone.0062298
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 147KY
UT WOS:000319167000039
PM 23650511
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, X
   Qiu, MT
   Hu, JW
   Wang, XX
   Jiang, F
   Yin, R
   Xu, L
AF Yang, Xin
   Qiu, Man-Tang
   Hu, Jing-Wen
   Wang, Xiao-xiao
   Jiang, Feng
   Yin, Rong
   Xu, Lin
TI GSTT1 Null Genotype Contributes to Lung Cancer Risk in Asian
   Populations: A Meta-Analysis of 23 Studies
SO PLOS ONE
LA English
DT Article
ID NORTH INDIAN POPULATION; S-TRANSFERASE GENES; ADENOCARCINOMA
   SUSCEPTIBILITY; AFRICAN-AMERICANS; DNA-REPAIR; POLYMORPHISMS; GSTM1;
   CYP1A1; ASSOCIATION; CHINA
AB Background: Genetic variation in glutathione S-transferases (GSTs) may contribute to lung cancer risk. Many studies have investigated the correlation between the Glutathione S-transferase T1 (GSTT1) null genotype and lung cancer risk in Asian population but yielded inconclusive results.
   Methodology/Principal Findings: We performed a meta-analysis of 23 studies including 4065 cases and 5390 controls. We assessed the strength of the association of GSTT1 with lung cancer risk and performed sub-group analyses by source of controls, smoking status, histological types, and sample size. A statistically significant correlation between GSTT1 null genotype and lung cancer in Asian population was observed (OR = 1.28, 95% CI = 1.10, 1.49; P-heterogeneity < 0.001 and I-2 = 62.0%). Sub-group analysis revealed there was a statistically increased lung cancer risk in ever-smokers who carried the GSTT1 null genotype (OR = 1.94, 95% CI = 1.27, 2.96; P heterogeneity = 0.02 and I-2 = 58.1%). It was also indicated that GSTT1 null genotype could increase lung cancer risk among population-based studies (OR = 1.25, 95% CI = 1.04, 1.50; P-heterogeneity = 0.003 and I-2 = 56.8%). The positive association was also found in studies of sample size (<= 500 participants) (OR = 1.34, 95% CI = 1.10, 1.62; P-heterogeneity < 0.001 and I-2 = 65.4%).
   Conclusions: These meta-analysis results suggest that GSTT1 null genotype is associated with a significantly increased risk of lung cancer in Asian population.
C1 [Yang, Xin; Hu, Jing-Wen; Jiang, Feng] Nanjing Med Univ, Clin Coll 1, Nanjing, Jiangsu, Peoples R China.
   [Yang, Xin; Qiu, Man-Tang; Hu, Jing-Wen; Jiang, Feng; Yin, Rong; Xu, Lin] Nanjing Med Univ, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Dept Thorac Surg, Nanjing, Jiangsu, Peoples R China.
   [Wang, Xiao-xiao] Georgia Hlth Sci Univ, Dept Biostat, Augusta, GA USA.
   [Qiu, Man-Tang] Nanjing Med Univ, Clin Coll 4, Nanjing, Jiangsu, Peoples R China.
RP Yin, R (reprint author), Nanjing Med Univ, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Dept Thorac Surg, Nanjing, Jiangsu, Peoples R China.
EM yinhero001@126.com; xulin83cn@gmail.com
RI Qiu, Mantang/L-8937-2019
FU National Natural Science Foundation of China [81201830]; Natural Science
   Foundation of Jiangsu Province, China [BK2010589, BK2011857]
FX This work was supported by the National Natural Science Foundation of
   China (81201830) and Natural Science Foundation of Jiangsu Province
   (BK2010589, BK2011857), China. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abbas A, 2004, WORLD J GASTROENTERO, V10, P3389
   Bailey LR, 1998, CANCER RES, V58, P65
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BOISSEL JP, 1988, EUR J CLIN PHARMACOL, V34, P535, DOI 10.1007/BF00615213
   Chan-Yeung M, 2004, LUNG CANCER, V45, P155, DOI 10.1016/j.lungcan.2004.01.016
   Chen HC, 2006, DIS MARKERS, V22, P141, DOI 10.1155/2006/436497
   David-Beabes GL, 2001, LUNG CANCER-J IASLC, V34, P333, DOI 10.1016/S0169-5002(01)00256-2
   Deakin M, 1996, CARCINOGENESIS, V17, P881, DOI 10.1093/carcin/17.4.881
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fowke JH, 2011, LUNG CANCER, V73, P18, DOI 10.1016/j.lungcan.2010.10.024
   Gao WM, 2003, CARCINOGENESIS, V24, P1671, DOI 10.1093/carcin/bgg115
   Gertig DM, 1998, CANCER EPIDEM BIOMAR, V7, P1001
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Juronen E, 1996, BIOCHEM MOL BIOL INT, V39, P21
   Kiyohara Chikako, 2000, Asian Pac J Cancer Prev, V1, P293
   Kiyohara C, 2012, J THORAC ONCOL, V7, P954, DOI 10.1097/JTO.0b013e31824de30f
   Klinchid J, 2009, CANCER GENET CYTOGEN, V195, P143, DOI 10.1016/j.cancergencyto.2009.08.011
   Kumar M, 2009, MOL CELL BIOCHEM, V322, P73, DOI 10.1007/s11010-008-9941-z
   Lan Q, 2000, CANCER EPIDEM BIOMAR, V9, P605
   Landi S, 2000, MUTAT RES-REV MUTAT, V463, P247, DOI 10.1016/S1383-5742(00)00050-8
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lee KM, 2006, ONCOL REP, V16, P1035
   Liang Ge-Yu, 2004, Yichuan, V26, P584
   Liu G, 2000, BRIT J CANCER, V82, P1646
   London SJ, 2000, LANCET, V356, P724, DOI 10.1016/S0140-6736(00)02631-3
   MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305
   Megiorni Francesca, 2011, Patholog Res Int, V2011, P780652, DOI 10.4061/2011/780652
   Mondal R, 2013, ORAL ONCOL, V49, P345, DOI 10.1016/j.oraloncology.2012.11.003
   Parl FF, 2005, CANCER LETT, V221, P123, DOI 10.1016/j.canlet.2004.06.016
   Qiu MT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050887
   Rotunno M, 2010, BRIT J CANCER, V103, P1870, DOI 10.1038/sj.bjc.6605976
   Shaikh RS, 2010, ENVIRON TOXICOL PHAR, V30, P76, DOI 10.1016/j.etap.2010.04.002
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sobti RC, 2008, BIOMARKERS, V13, P282, DOI 10.1080/13547500701843437 
   Sobti RC, 2004, MOL CELL BIOCHEM, V266, P1, DOI 10.1023/B:MCBI.0000049127.33458.87
   Sreeja L, 2005, J HUM GENET, V50, P618, DOI 10.1007/s10038-005-0303-3
   Sreeja Leelakumari, 2008, J Exp Ther Oncol, V7, P73
   Sugimura H, 1999, CANCER EPIDEM BIOMAR, V8, P669
   Sun HM, 2010, CANCER SCI, V101, P1777, DOI 10.1111/j.1349-7006.2010.01608.x
   Sunaga N, 2002, CANCER EPIDEM BIOMAR, V11, P730
   Tamaki Y, 2011, DRUG METAB PHARMACOK, V26, P516, DOI 10.2133/dmpk.DMPK-11-RG-046
   Wang JW, 2003, CANCER LETT, V201, P185, DOI 10.1016/S0304-3835(03)00480-4
   Wang Na, 2012, Wei Sheng Yan Jiu, V41, P251
   Wu XF, 2003, CARCINOGENESIS, V24, P505, DOI 10.1093/carcin/24.3.505
   Xu XP, 1996, CANCER EPIDEM BIOMAR, V5, P687
   Yadav DS, 2010, GENET TEST MOL BIOMA, V14, P715, DOI 10.1089/gtmb.2010.0087
   Yang M, 2007, LUNG CANCER, V57, P135, DOI 10.1016/j.lungcan.2007.03.005
   Yuan Tianzhu, 2005, Zhongguo Fei Ai Za Zhi, V8, P107, DOI 10.3779/j.issn.1009-3419.2005.02.07
   Zhao B, 2001, CANCER EPIDEM BIOMAR, V10, P1063
NR 50
TC 6
Z9 7
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 24
PY 2013
VL 8
IS 4
AR e62181
DI 10.1371/journal.pone.0062181
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 136DE
UT WOS:000318340400083
PM 23637998
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yu, ZB
   Han, SP
   Zhu, JG
   Sun, XF
   Ji, CB
   Guo, XR
AF Yu, Zhangbin
   Han, Shuping
   Zhu, Jingai
   Sun, Xiaofan
   Ji, Chenbo
   Guo, Xirong
TI Pre-Pregnancy Body Mass Index in Relation to Infant Birth Weight and
   Offspring Overweight/Obesity: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID ADVERSE PREGNANCY OUTCOMES; MATERNAL OBESITY; CHILDHOOD OVERWEIGHT;
   FETAL ORIGINS; RISK-FACTORS; GAIN; CHILDREN; TRENDS; BMI; ASSOCIATIONS
AB Background: Overweight/obesity in women of childbearing age is a serious public-health problem. In China, the incidence of maternal overweight/obesity has been increasing. However, there is not a meta-analysis to determine if pre-pregnancy body mass index (BMI) is related to infant birth weight (BW) and offspring overweight/obesity.
   Methods: Three electronic bibliographic databases (MEDLINE, EMBASE and CINAHL) were searched systematically from January 1970 to November 2012. The dichotomous data on pre-pregnancy overweight/obesity and BW or offspring overweight/obesity were extracted. Summary statistics (odds ratios, ORs) were used by Review Manager, version 5.1.7.
   Results: After screening 665 citations from three electronic databases, we included 45 studies (most of high or medium quality). Compared with normal-weight mothers, pre-pregnancy underweight increased the risk of small for gestational age (SGA) (odds ratios [OR], 1.81; 95% confidence interval [CI], 1.76-1.87); low BW (OR, 1.47; 95% CI, 1.27-1.71). Pre-pregnancy overweight/obesity increased the risk of being large for gestational age (LGA) (OR, 1.53; 95% CI, 1.44-1.63; and OR, 2.08; 95% CI; 1.95-2.23), high BW (OR, 1.53; 95% CI, 1.44-1.63; and OR, 2.00; 95% CI; 1.84-2.18), macrosomia (OR, 1.67; 95% CI, 1.42-1.97; and OR, 3.23; 95% CI, 2.39-4.37), and subsequent offspring overweight/obesity (OR, 1.95; 95% CI, 1.77-2.13; and OR, 3.06; 95% CI, 2.68-3.49), respectively. Sensitivity analyses revealed that sample size, study method, quality grade of study, source of pre-pregnancy BMI or BW had a strong impact on the association between pre-pregnancy obesity and LGA. No significant evidence of publication bias was observed.
   Conclusions: Pre-pregnancy underweight increases the risk of SGA and LBW; pre-pregnancy overweight/obesity increases the risk of LGA, HBW, macrosomia, and subsequent offspring overweight/obesity. A potential effect modification by maternal age, ethnicity, gestational weight gain, as well as the role of gestational diseases should be addressed in future studies.
C1 [Yu, Zhangbin; Han, Shuping; Zhu, Jingai; Sun, Xiaofan; Ji, Chenbo; Guo, Xirong] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Dept Pediat, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.
RP Guo, XR (reprint author), Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Dept Pediat, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.
EM xrguo@njmu.edu.cn
FU National Key Basic Research Program of China [2013CB530604]; National
   Natural Science Foundation of China [81270928]; Priority Academic
   Program Development of Jiangsu Higher Education Institutions
   [201104013]; Natural Science Foundation of Jiangsu Province [BK2011107];
   Medical Innovation Team Project of Jiangsu Province [LJ201108]
FX This work was supported by grants from the National Key Basic Research
   Program of China (2013CB530604), the National Natural Science Foundation
   of China (Grant No. 81270928), the Priority Academic Program Development
   of Jiangsu Higher Education Institutions (Grant No. 201104013), the
   Natural Science Foundation of Jiangsu Province (Grant No. BK2011107),
   and the Medical Innovation Team Project of Jiangsu Province (LJ201108).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adamo KB, 2012, INT J ENV RES PUB HE, V9, P1263, DOI 10.3390/ijerph9041263
   Adams SV, 2011, BIRTH DEFECTS RES A, V91, P241, DOI 10.1002/bdra.20805
   Athukorala C, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-56
   Aydin C, 2010, ARCH GYNECOL OBSTET, V281, P49, DOI 10.1007/s00404-009-1060-x
   Baeten JM, 2001, AM J PUBLIC HEALTH, V91, P436, DOI 10.2105/AJPH.91.3.436
   BARKER DJP, 1995, MOL MED TODAY, V1, P418, DOI 10.1016/S1357-4310(95)90793-9
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Behrman RE, 2003, NELSONS TXB PEDIAT
   Bhattacharya S, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-168
   Chen ZY, 2010, INT J GYNECOL OBSTET, V109, P41, DOI 10.1016/j.ijgo.2009.10.015
   Chu SY, 2007, OBES REV, V8, P385, DOI 10.1111/j.1467-789X.2007.00397.x
   Cresswell JA, 2012, LANCET, V380, P1325, DOI 10.1016/S0140-6736(12)60869-1
   Di Benedetto A, 2012, DIABETES METAB, V38, P63, DOI 10.1016/j.diabet.2011.07.005
   Doherty DA, 2006, INT J GYNECOL OBSTET, V95, P242, DOI 10.1016/j.ijgo.2006.06.021
   Drake AJ, 2010, REPRODUCTION, V140, P387, DOI 10.1530/REP-10-0077
   Dubois L, 2006, INT J OBESITY, V30, P610, DOI 10.1038/sj.ijo.0803141
   England LJ, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.06.031
   Fallucca Sara, 2009, Diabetes Care, V32, pe149, DOI 10.2337/dc09-1489
   Ferraro ZM, 2012, J MATERN-FETAL NEO M, V25, P538, DOI 10.3109/14767058.2011.638953
   Ferreira HS, 2009, BRIT J NUTR, V101, P1239, DOI 10.1017/S0007114508059357
   Frederick IO, 2008, MATERN CHILD HLTH J, V12, P557, DOI 10.1007/s10995-007-0276-2
   Ge K, 1995, DIETARY NUTR STATUS, V1
   Gewa CA, 2010, PUBLIC HEALTH NUTR, V13, P496, DOI 10.1017/S136898000999187X
   Gilboa SM, 2008, ANN EPIDEMIOL, V18, P196, DOI [10.1016/j.annepidem.2007.09.005, 10.1016/j.annepidem.2007.09.0C5]
   Han YS, 2011, INT J OBESITY, V35, P570, DOI 10.1038/ijo.2010.162
   Han Z, 2011, INT J EPIDEMIOL, V40, P65, DOI 10.1093/ije/dyq195
   Hawkins SS, 2009, J EPIDEMIOL COMMUN H, V63, P147, DOI 10.1136/jech.2008.077917
   Hedderson MM, 2006, OBSTET GYNECOL, V108, P1153, DOI 10.1097/01.AOG.0000242568.75785.68
   Hernandez-Valero MA, 2007, OBESITY, V15, P2512, DOI 10.1038/oby.2007.298
   Heslehurst N, 2008, OBES REV, V9, P635, DOI 10.1111/j.1467-789X.2008.00511.x
   Heslehurst N, 2010, INT J OBESITY, V34, P420, DOI 10.1038/ijo.2009.250
   Heude B, 2012, MATERN CHILD HLTH J, V16, P355, DOI 10.1007/s10995-011-0741-9
   Hinkle SN, 2012, MATERN CHILD HLTH J, V16, P1339, DOI 10.1007/s10995-011-0898-2
   Hoff GL, 2009, J WOMENS HEALTH, V18, P1413, DOI 10.1089/jwh.2008.1290
   Hunt KJ, 2012, MATERN CHILD HLTH J
   IOM Institute of Medicine, 1990, NUTR PREGN
   Janjua NZ, 2012, J OBES, DOI 10.1155/2012/457173
   Jensen DM, 2003, AM J OBSTET GYNECOL, V189, P239, DOI 10.1067/mob.2003.441
   Jeric M, 2013, EARLY HUM DEV, V89, P277, DOI 10.1016/j.earlhumdev.2012.10.004
   Joshi S, 2011, INT J GYNECOL OBSTET, V114, P82, DOI 10.1016/j.ijgo.2011.01.020
   Joy S, 2009, AM J PERINAT, V26, P345, DOI 10.1055/s-0028-1110084
   Kalk P, 2009, EUR J MED RES, V14, P216
   Khandaker GM, 2012, OBES REV, V13, P518, DOI 10.1111/j.1467-789X.2011.00971.x
   Khashan AS, 2009, EUR J EPIDEMIOL, V24, P697, DOI 10.1007/s10654-009-9375-2
   Kim SY, 2007, OBESITY, V15, P986, DOI 10.1038/oby.2007.621
   Kopp UMS, 2012, INT J OBESITY, V36, P1325, DOI 10.1038/ijo.2012.140
   Kral JG, 2006, PEDIATRICS, V118, pE1644, DOI 10.1542/peds.2006-1379
   Laitinen J, 2012, BJOG-INT J OBSTET GY, V119, P716, DOI 10.1111/j.1471-0528.2012.03319.x
   Leung TY, 2008, BJOG-INT J OBSTET GY, V115, P1529, DOI 10.1111/j.1471-0528.2008.01931.x
   Li CY, 2005, OBES RES, V13, P362, DOI 10.1038/oby.2005.48
   Li Xiao-yan, 2012, Zhonghua Yu Fang Yi Xue Za Zhi, V46, P683
   Liu XM, 2011, ARCH GYNECOL OBSTET, V283, P65, DOI 10.1007/s00404-009-1288-5
   Maddah M, 2010, PUBLIC HEALTH NUTR, V13, P196, DOI 10.1017/S1368980009990589
   Maggard MA, 2008, JAMA-J AM MED ASSOC, V300, P2286, DOI 10.1001/jama.2008.641
   Mamun AA, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-62
   Mantakas A, 2010, EUR J OBSTET GYN R B, V153, P43, DOI 10.1016/j.ejogrb.2010.06.021
   Galan SM, 2012, J MATERN-FETAL NEO M, V25, P308, DOI 10.3109/14767058.2011.575905
   Meher-Un-Nisa, 2009, Int J Health Sci (Qassim), V3, P187
   Melzer K, 2010, INT J OBESITY, V34, pS44, DOI 10.1038/ijo.2010.239
   MITCHELL MC, 1989, J AM DIET ASSOC, V89, P634
   Moholdt TT, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-154
   Monasta L, 2010, OBES REV, V11, P695, DOI 10.1111/j.1467-789X.2010.00735.x
   Muhlhausler B. S., 2011, Endocrine Metabolic & Immune Disorders-Drug Targets, V11, P189
   Munim S, 2012, JCPSP-J COLL PHYSICI, V22, P694, DOI 11.2012/JCPSP.694698
   Narchi H, 2010, J OBSTET GYNAECOL, V30, P679, DOI 10.3109/01443615.2010.509824
   Oken E, 2009, AM J EPIDEMIOL, V170, P173, DOI 10.1093/aje/kwp101
   Padez C, 2005, ACTA PAEDIATR, V94, P1550, DOI 10.1080/08035250510042924
   Park S, 2011, MATERN CHILD HLTH J, V15, P289, DOI 10.1007/s10995-010-0596-5
   Patel SP, 2012, J EPIDEMIOL COMMUN H, V66, P809, DOI 10.1136/jech.2011.133777
   Payas N, 2010, J CHILD ADOL PS NURS, V23, P223, DOI 10.1111/j.1744-6171.2010.00248.x
   Rayis DA, 2011, INT J GYNECOL OBSTET, V113, P160, DOI 10.1016/j.ijgo.2010.12.008
   Rinaudo PF, 2008, SEMIN REPROD MED, V26, P436, DOI 10.1055/s-0028-1087109
   Rode L, 2005, OBSTET GYNECOL, V105, P537, DOI 10.1097/01.AOG.0000152304.39492.1c
   Ruager-Martin R, 2010, EARLY HUM DEV, V86, P715, DOI 10.1016/j.earlhumdev.2010.08.007
   Saereeporncharenkul Kasem, 2011, J Med Assoc Thai, V94 Suppl 2, pS52
   Salsberry PJ, 2005, PEDIATRICS, V116, P1329, DOI 10.1542/peds.2004-2583
   Samuels-Kalow ME, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.04.043
   Savitz DA, 2011, ANN EPIDEMIOL, V21, P78, DOI 10.1016/j.annepidem.2010.06.009
   Sebire NJ, 2001, INT J OBESITY, V25, P1175, DOI 10.1038/sj.ijo.0801670
   Stothard KJ, 2009, JAMA-J AM MED ASSOC, V301, P636, DOI 10.1001/jama.2009.113
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tabatabaei Mozhgan, 2011, J Prenat Med, V5, P35
   Tooth L, 2005, AM J EPIDEMIOL, V161, P280, DOI 10.1093/aje/kwi042
   Torloni MR, 2009, OBES REV, V10, P194, DOI 10.1111/j.1467-789X.2008.00541.x
   Tzamaloukas AH, 2003, JPEN-PARENTER ENTER, V27, P340, DOI 10.1177/0148607103027005340
   Upadhyay, 2011, Nepal Med Coll J, V13, P42
   Van Lieshout RJ, 2011, OBES REV, V12, pe548, DOI 10.1111/j.1467-789X.2010.00850.x
   Whitaker RC, 2004, PEDIATRICS, V114, pE29, DOI 10.1542/peds.114.1.e29
   World Health Organization, 2000, WHO TECHN REP SER
   Xi B, 2012, OBES REV, V13, P287, DOI 10.1111/j.1467-789X.2011.00944.x
   Yu ZB, 2011, OBES REV, V12, P525, DOI 10.1111/j.1467-789X.2011.00867.x
   Zilko CEM, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.12.007
NR 92
TC 301
Z9 314
U1 6
U2 64
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 16
PY 2013
VL 8
IS 4
AR e61627
DI 10.1371/journal.pone.0061627
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130DR
UT WOS:000317893400083
PM 23613888
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yuan, ZR
   Zeng, X
   Yang, D
   Wang, WL
   Liu, ZH
AF Yuan, Zhengrong
   Zeng, Xu
   Yang, Dan
   Wang, Weilu
   Liu, Zhihua
TI Effects of Common Polymorphism rs11614913 in Hsa-miR-196a2 on Lung
   Cancer Risk
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; GENETIC-VARIANTS; PRE-MICRORNAS;
   HEPATOCELLULAR-CARCINOMA; FUNCTIONAL POLYMORPHISM; SUSCEPTIBILITY;
   METAANALYSIS; EXPRESSION; ASSOCIATION; BIOGENESIS
AB Background: Emerging evidence suggests that single nucleotide polymorphisms (SNPs) in microRNA-coding genes may participate in the pathogenesis of lung cancer by altering the expression of tumor-related microRNAs. Several studies were investigated in recent years to evaluate the association between hsa-miR-196a2 rs11614913 polymorphism and increased/decreased lung cancer risk. In the present study, we performed a meta-analysis to systematically summarize the possible association.
   Methodology/Principal Findings: We performed a meta-analysis of 4 case-control studies that included 2219 lung-cancer cases and 2232 cancer-free controls. We evaluated the strength of the association using odds ratios (ORs) with 95% confidence intervals (CIs). In the overall analysis, it was found that the rs11614913 polymorphism significantly elevated the risk of lung cancer (CC versus (vs.) TT OR = 1.26, 95% CI 1.07-1.49, P = 0.007; CC/CT vs. TT: OR = 1.13, 95% CI 0.98-1.29, P = 0.007; C vs. T: OR = 1.12, 95% CI 1.03-1.22, P = 0.008). In the subgroup analysis by ethnicity, statistically significantly increased cancer risk was found among Asians (CC vs. TT: OR = 1.30, 95% CI 1.10-1.54, P = 0.003; CT vs. TT: OR = 1.16, 95% CI 1.01-1.34, P = 0.039; CC vs. CT/TT: OR = 1.21, 95% CI 1.04-1.41, P = 0.012; C vs. T: OR = 1.14, 95% CI 1.05-1.25, P = 0.002). For Europeans, a significant association with lung cancer risk was found in recessive model (CC vs. CT/TT: OR = 0.63, 95% CI 0.40-0.98, P = 0.040). No publication bias was found in this study.
   Conclusions/Significance: Our meta-analysis suggests that the rs11614913 polymorphism is significant associated with the increased risk of lung cancer, especially in Asians. Besides, the C allele of rs11614913 polymorphism may contribute to increased lung cancer risk.
C1 [Yuan, Zhengrong; Zeng, Xu; Yang, Dan; Wang, Weilu; Liu, Zhihua] Chinese Acad Med Sci, Peking Union Med Coll, Dept Computat Biol & Bioinformat, Inst Med Plant Dev, Beijing 100730, Peoples R China.
   [Liu, Zhihua] Nanjing Forestry Univ, Nanjing, Jiangsu, Peoples R China.
   [Wang, Weilu] Beijing City Univ, Dept Biotechnol, Beijing, Peoples R China.
RP Liu, ZH (reprint author), Chinese Acad Med Sci, Peking Union Med Coll, Dept Computat Biol & Bioinformat, Inst Med Plant Dev, Beijing 100730, Peoples R China.
EM zhliu@implad.ac.cn
FU National Natural Science Foundation of China [81102746, 81100077,
   31201768]; Beijing Natural Science Foundation [5113033]; China
   Postdoctoral Science Foundation [2012M510011]; Scientific Research
   Foundation of the State Human Resource Ministry; Education Ministry for
   Returned Chinese Scholars; New Star Project of Peking Union Medical
   College; Youth Foundation of Peking Union Medical College; Research Fund
   for the Doctoral Program of Higher Education [20111106120028]; "Major
   Drug Discovery" major science and technology research "12nd Five-Year
   Plan" [2012ZX09301-002-001]; China Medical Board of New York [A2009001]
FX This work was supported by National Natural Science Foundation of China
   (81102746, 81100077, 31201768), Beijing Natural Science Foundation
   (5113033), China Postdoctoral Science Foundation funded project
   (2012M510011), Scientific Research Foundation of the State Human
   Resource Ministry and the Education Ministry for Returned Chinese
   Scholars, New Star Project of Peking Union Medical College, Youth
   Foundation of Peking Union Medical College, the Research Fund for the
   Doctoral Program of Higher Education (20111106120028), "Major Drug
   Discovery" major science and technology research "12nd Five-Year Plan"
   (2012ZX09301-002-001), China Medical Board of New York (A2009001)
   granted to Zhihua Liu. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akkiz H, 2011, J VIRAL HEPATITIS, V18, pE399, DOI 10.1111/j.1365-2893.2010.01414.x
   Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776
   Catucci I, 2010, HUM MUTAT, V31, pE1052, DOI 10.1002/humu.21141
   Chen KX, 2008, CARCINOGENESIS, V29, P1306, DOI 10.1093/carcin/bgn116
   Chu HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018108
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dou TH, 2010, J CANCER RES CLIN, V136, P1853, DOI 10.1007/s00432-010-0844-5
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Gao LB, 2011, BREAST CANCER RES TR, V125, P571, DOI 10.1007/s10549-010-0993-x
   George GP, 2011, MOL BIOL REP, V38, P1609, DOI 10.1007/s11033-010-0270-4
   Granville CA, 2005, AM J RESP CELL MOL, V32, P169, DOI 10.1165/rcmb.F290
   Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298
   Hamada J, 2001, INT J CANCER, V93, P516, DOI 10.1002/ijc.1357
   He BS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049032
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   Hoffman AE, 2009, CANCER RES, V69, P5970, DOI 10.1158/0008-5472.CAN-09-0236
   Hong Young-Seoub, 2011, J Prev Med Public Health, V44, P125, DOI 10.3961/jpmph.2011.44.3.125
   Hu RF, 2013, MOL BIOL REP, V40, P1181, DOI 10.1007/s11033-012-2160-4
   Hu ZB, 2008, J CLIN INVEST, V118, P2600, DOI 10.1172/JCI34934
   Hu ZB, 2009, HUM MUTAT, V30, P79, DOI 10.1002/humu.20837
   Jian Guo, 2012, International Journal of Mechatronics and Automation, V2, P15, DOI 10.1504/IJMA.2012.046583
   Kim MJ, 2010, LUNG CANCER, V69, P127, DOI 10.1016/j.lungcan.2010.04.015
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Kwak PB, 2010, CANCER SCI, V101, P2309, DOI 10.1111/j.1349-7006.2010.01683.x
   Landi D, 2008, CARCINOGENESIS, V29, P579, DOI 10.1093/carcin/bgm304
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Li XD, 2010, PATHOLOGY, V42, P669, DOI 10.3109/00313025.2010.522175
   Liu ZS, 2010, CANCER-AM CANCER SOC, V116, P4753, DOI 10.1002/cncr.25323
   Liu ZH, 2013, MOL BIOL REP, V40, P2491, DOI 10.1007/s11033-012-2330-4
   Liu ZH, 2012, CELL PHYSIOL BIOCHEM, V29, P851, DOI 10.1159/000258197
   Liu ZH, 2010, BIOCHEM BIOPH RES CO, V400, P34, DOI 10.1016/j.bbrc.2010.07.132
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Meyerson M, 2005, J CLIN ONCOL, V23, P3219, DOI 10.1200/JCO.2005.15.511
   Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Okubo M, 2010, HELICOBACTER, V15, P524, DOI 10.1111/j.1523-5378.2010.00806.x
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Peng S, 2010, DIGEST DIS SCI, V55, P2288, DOI 10.1007/s10620-009-1007-x
   Qi P, 2010, HUM IMMUNOL, V71, P621, DOI 10.1016/j.humimm.2010.02.017
   Qiu LX, 2011, CYTOKINE, V56, P589, DOI 10.1016/j.cyto.2011.08.019
   Ren GM, 2013, BIOINFORMATICS, V29, P279, DOI 10.1093/bioinformatics/bts666
   Rong BX, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-170
   Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867
   Sassen S, 2008, VIRCHOWS ARCH, V452, P1, DOI 10.1007/s00428-007-0532-2
   Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104
   Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202
   Srivastava K, 2010, J HUM GENET, V55, P495, DOI 10.1038/jhg.2010.54
   Tian T, 2010, INT J MOL EPIDEMIOL, V1, P358
   Tian T, 2009, CANCER EPIDEM BIOMAR, V18, P1183, DOI 10.1158/1055-9965.EPI-08-0814
   Vinci S, 2011, CLIN CHEM LAB MED, V49, P2073, DOI 10.1515/CCLM.2011.708
   Volpe MV, 2003, BIRTH DEFECTS RES A, V67, P550, DOI 10.1002/bdra.10086
   Wang F, 2012, MOL BIOL REP, V39, P269, DOI 10.1007/s11033-011-0735-0
   Wang JB, 2012, MUTAGENESIS, V27, P779, DOI 10.1093/mutage/ges052
   Wang K, 2010, BIOMARKERS, V15, P614, DOI 10.3109/1354750X.2010.505299
   Wang PY, 2012, EXP THER MED, V3, P324, DOI 10.3892/etm.2011.399
   Wang ZX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040039
   Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010
   Xu W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020471
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042076
   Ye YQ, 2008, CANCER PREV RES, V1, P460, DOI 10.1158/1940-6207.CAPR-08-0135
   Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434
   Yoon KA, 2012, J THORAC CARDIOV SUR, V144, P794, DOI 10.1016/j.jtcvs.2012.06.030
   Yuan ZR, 2012, MOL BIOL REP, V39, P6625, DOI 10.1007/s11033-012-1467-5
NR 73
TC 9
Z9 11
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 12
PY 2013
VL 8
IS 4
AR e61047
DI 10.1371/journal.pone.0061047
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 123JP
UT WOS:000317385300044
PM 23593385
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Tang, XY
   Liu, G
   Kang, J
   Hou, Y
   Jiang, FG
   Yuan, W
   Shi, JG
AF Tang, Xianye
   Liu, Gang
   Kang, Jian
   Hou, Yang
   Jiang, Fungui
   Yuan, Wen
   Shi, Jiangang
TI Obesity and Risk of Hip Fracture in Adults: A Meta-Analysis of
   Prospective Cohort Studies
SO PLOS ONE
LA English
DT Article
ID BODY-MASS-INDEX; BONE-MINERAL DENSITY; PHYSICAL-ACTIVITY; NORWEGIAN
   WOMEN; OLDER; ASSOCIATION; OUTCOMES; MEN; BMD
AB Background: Many observational studies assessed the association between obesity and risk of hip fracture in adults, but reported controversial results. Our goal was to evaluate the association between obesity and risk of hip fracture in adults by conducting a meta-analysis of prospective cohort studies.
   Methods: Three databases, PubMed, Embase and Web of Science, were searched through May 2012 to identify eligible cohort studies. Either a fixed-or a random-effects model was used to calculate the pooled relative risk (RR) with its 95% confidence interval (95% CI).
   Results: Fifteen prospective cohort studies involving a total 3,126,313 participants were finally included into this meta-analysis. Overall, adults with obesity compared with the normal weight group had a significantly decreased risk of hip fracture (RR: 0.66, 95% CI 0.57 to 0.77, P<0.001). Meta-analyses by the adjusted status of RRs also suggested adults with obesity compared with the reference group had a significantly decreased risk of hip fracture (adjusted RR: 0.48, 95% CI 0.39 to 0.58, P<0.001; unadjusted RR: 0.66, 95% CI 0.56 to 0.78, P<0.001). Subgroup analyses by gender suggested individuals with obesity had a significantly decreased risk for developing hip fracture compared with the reference group in both men (RR 0.54, 95% CI 0.48 to 0.60, P<0.001) and women (RR 0.70, 95% CI 0.58 to 0.84, P, <0.001). No evidence of publication bias was observed in this meta-analysis.
   Conclusions: This meta-analysis of prospective cohort studies suggests that obesity significantly decreases the risk of hip fracture in adults, and obesity is probably a protective factor of hip fracture in adults.
C1 [Tang, Xianye; Liu, Gang; Kang, Jian; Hou, Yang; Yuan, Wen; Shi, Jiangang] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, Shanghai, Peoples R China.
   [Jiang, Fungui] Peoples Hosp Wujiang City, Dept Orthopaed, Wujiang, Peoples R China.
RP Yuan, W (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, Shanghai, Peoples R China.
EM wenyuancz19@yahoo.com; fuguidoctor@yahoo.com
CR Armstrong MEG, 2011, J BONE MINER RES, V26, P1330, DOI 10.1002/jbmr.315
   Beck TJ, 2009, J BONE MINER RES, V24, P1369, DOI [10.1359/jbmr.090307, 10.1359/JBMR.090307]
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benetou V, 2011, INJURY, V42, P188, DOI 10.1016/j.injury.2010.08.022
   Bischoff-Ferrari HA, 2012, NEW ENGL J MED, V367, P40, DOI 10.1056/NEJMoa1109617
   Chudyk AM, 2012, CLIN RHEUMATOL, V31, P749, DOI 10.1007/s10067-012-1970-z
   Compston JE, 2011, AM J MED, V124, P1043, DOI 10.1016/j.amjmed.2011.06.013
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140-6736(02)08827-X
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dimitri P, 2012, BONE, V50, P457, DOI 10.1016/j.bone.2011.05.011
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fernandez-Ruiz M, 2011, INTERN EMERG MED
   Feskanich D, 2002, JAMA-J AM MED ASSOC, V288, P2300, DOI 10.1001/jama.288.18.2300
   Folsom AR, 2000, ARCH INTERN MED, V160, P2117, DOI 10.1001/archinte.160.14.2117
   Haara M, 2006, ACTA ORTHOP, V77, P9, DOI 10.1080/174536706010045632
   Han JC, 2010, LANCET, V375, P1737, DOI 10.1016/S0140-6736(10)60171-7
   Hartholt KA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022227
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jamal SA, 2007, AM J KIDNEY DIS, V49, P674, DOI 10.1053/j.ajkd.2007.02.264
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   LaFleur J, 2011, J BONE MINER METAB, V29, P193, DOI 10.1007/s00774-010-0207-y
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mayhew PM, 2005, LANCET, V366, P129, DOI 10.1016/S0140-6736(05)66870-5
   MEYER HE, 1995, EPIDEMIOLOGY, V6, P299, DOI 10.1097/00001648-199505000-00019
   MEYER HE, 1993, AM J EPIDEMIOL, V137, P1203, DOI 10.1093/oxfordjournals.aje.a116622
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Nasser KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028042
   Nielson CM, 2011, J BONE MINER RES, V26, P496, DOI 10.1002/jbmr.235
   Orwig DL, 2006, ORTHOP CLIN N AM, V37, P611, DOI 10.1016/j.ocl.2006.08.003
   Ottenbacher KJ, 2002, J GERONTOL A-BIOL, V57, pM648, DOI 10.1093/gerona/57.10.M648
   Plourde G, 2012, CAN MED ASSOC J, V184, P1039, DOI 10.1503/cmaj.111640
   Prieto-Alhambra D, 2012, J BONE MINER RES, V27, P294, DOI 10.1002/jbmr.1466
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Romero-Corral A, 2006, LANCET, V368, P666, DOI 10.1016/S0140-6736(06)69251-9
   Shapses SA, 2012, ANNU REV NUTR, V32, P287, DOI 10.1146/annurev.nutr.012809.104655
   Sienkiewicz E, 2011, METABOLISM, V60, P1211, DOI 10.1016/j.metabol.2011.05.016
   Stolee P, 2009, J GERONTOL A-BIOL, V64, P403, DOI 10.1093/gerona/gln035
   Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140-6736(07)61342-7
   Visschedijk J, 2010, J AM GERIATR SOC, V58, P1739, DOI 10.1111/j.1532-5415.2010.03036.x
   Wells G, 2012, NEWSCASTLE OTTAWA SC
   Yoon KH, 2006, LANCET, V368, P1681, DOI 10.1016/S0140-6736(06)69703-1
NR 42
TC 57
Z9 59
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 12
PY 2013
VL 8
IS 4
AR e55077
DI 10.1371/journal.pone.0055077
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 123JP
UT WOS:000317385300001
PM 23593112
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ma, WY
   Zhuang, L
   Han, B
   Tang, B
AF Ma, Weiyuan
   Zhuang, Le
   Han, Bo
   Tang, Bo
TI Association between Glutathione S-Transferase T1 Null Genotype and
   Gastric Cancer Risk: A Meta-Analysis of 48 Studies
SO PLOS ONE
LA English
DT Article
ID GENETIC POLYMORPHISMS; METABOLIC GENES; STOMACH-CANCER; TOBACCO-SMOKE;
   DNA-REPAIR; M1 GSTM1; GSTT1; SUSCEPTIBILITY; GSTP1; ALCOHOL
AB Background: Glutathione S-transferases (GSTs) have proved to be involved in the detoxifying several carcinogens and may play an important role in carcinogenesis of cancer. Previous studies on the association between Glutathione S-transferase T1 (GSTT1) polymorphism and gastric cancer risk reported inconclusive results. To clarify the possible association, we conducted a meta-analysis of eligible studies.
   Methods: We searched in the Pubmed, Embase, and Wangfang Medicine databases for studies assessing the association between GSTT1 null genotype and gastric cancer risk. The pooled odds ratio (OR) and its 95% confidence interval (95% CI) was calculated to assess the strength of the association. A total of 48 studies with a total of 24,440 individuals were ultimately eligible for meta-analysis.
   Results: Overall, GSTT1 null genotype was significantly associated with increased risk of gastric cancer (Random-effect OR = 1.23, 95% CI 1.13-1.35, P (OR) <0.001, I-2 = 45.5%). Significant association was also found in Caucasians, East Asians, and Indians (P (Caucasians) = 0.010; P (East Asians) = 0.003; P (Indians) = 0.017). After adjusting for other confounding variables, GSTT1 null genotype was also significantly associated with increased risk of gastric cancer (Random-effect OR = 1.43, 95% CI 1.20-1.71, P OR,0.001, I-2 = 48.1%).
   Conclusion: The meta-analysis provides strong evidence for the significant association between GSTT1 null genotype and increased risk of gastric cancer.
C1 [Ma, Weiyuan; Zhuang, Le] Shandong Univ, Dept Dermatol, Qilu Hosp, Jinan 250100, Peoples R China.
   [Han, Bo] Shandong Univ, Inst Pathol, Sch Med, Jinan 250100, Peoples R China.
   [Tang, Bo] Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China.
RP Han, B (reprint author), Shandong Univ, Inst Pathol, Sch Med, Jinan 250100, Peoples R China.
EM doctor19cn@yahoo.cn
CR Agudo A, 2006, CANCER EPIDEM BIOMAR, V15, P2427, DOI 10.1158/1055-9965.EPI-06-0072
   Al-Moundhri MS, 2009, J CLIN GASTROENTEROL, V43, P152, DOI 10.1097/MCG.0b013e31815853fa
   Garcia-Gonzalez MA, 2012, MUTAGENESIS, V27, P771, DOI 10.1093/mutage/ges049
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhardwaj R, 2012, TUMOR BIOL, V33, P1021, DOI 10.1007/s13277-012-0335-1
   Boccia S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-206
   Cai L, 2001, WORLD J GASTROENTERO, V7, P506
   Chen B, 2010, DIGEST DIS SCI, V55, P1831, DOI 10.1007/s10620-009-1000-4
   Chen J, 2012, MOL BIOL REP, V39, P10383, DOI 10.1007/s11033-012-1917-0
   Choi SC, 2003, CANCER LETT, V195, P169, DOI 10.1016/S0304-3835(03)00158-7
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Colombo J, 2004, WORLD J GASTROENTERO, V10, P1240
   Deakin M, 1996, CARCINOGENESIS, V17, P881, DOI 10.1093/carcin/17.4.881
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gao CM, 2002, CANCER LETT, V188, P95, DOI 10.1016/S0304-3835(02)00115-5
   Gonzalez A, 2004, REV BIOL TROP, V52, P591
   Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hong Su Hyung, 2006, J Prev Med Public Health, V39, P135
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jing C, 2012, ASIAN PAC J CANCER P, V13, P3325, DOI 10.7314/APJCP.2012.13.7.3325
   Katoh T, 1996, CARCINOGENESIS, V17, P1855, DOI 10.1093/carcin/17.9.1855
   Lan Q, 2001, PHARMACOGENETICS, V11, P655, DOI 10.1097/00008571-200111000-00003
   Li P, 2011, J ENV OCCUP MED, V28, P1217
   Lourenco GJ, 2011, TUMOR BIOL, V32, P1209, DOI 10.1007/s13277-011-0224-z
   Luo YP, 2011, TUMOR BIOL, V32, P215, DOI 10.1007/s13277-010-0115-8
   Malik Manzoor A, 2009, J Gastrointest Cancer, V40, P26, DOI 10.1007/s12029-009-9072-0
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Martinez C, 2006, PHARMACOGENOMICS, V7, P711, DOI 10.2217/14622416.7.5.711
   Masoudi M, 2009, MOL BIOL REP, V36, P781, DOI 10.1007/s11033-008-9245-0
   Moy KA, 2009, INT J CANCER, V125, P2652, DOI 10.1002/ijc.24583
   Mu LN, 2005, INT J CANCER, V116, P972, DOI 10.1002/ijc.21137
   Nan HM, 2005, WORLD J GASTROENTERO, V11, P3175, DOI 10.3748/wjg.v11.i21.3175
   Nguyen TV, 2009, ONCOL RES, V18, P349, DOI 10.3727/096504010X12626118080064
   Oakley A, 2011, DRUG METAB REV, V43, P138, DOI 10.3109/03602532.2011.558093
   Onul A, 2012, TUMOR BIOL, V33, P739, DOI 10.1007/s13277-011-0271-5
   Palli D, 2005, INT J CANCER, V115, P284, DOI 10.1002/ijc.20864
   Palli D, 2010, MUTAGENESIS, V25, P569, DOI 10.1093/mutage/geq042
   Parvin S, 2012, MOL BIOL REP, V39, P7327, DOI 10.1007/s11033-012-1564-5
   Piao JM, 2009, WORLD J GASTROENTERO, V15, P5716, DOI 10.3748/wjg.15.5716
   Qian Y, 2003, CHINESE J PREVENTION, V11, P107
   Qiu MZ, 2011, TUMOR BIOL, V32, P489, DOI 10.1007/s13277-010-0142-5
   Roth MJ, 2004, CANCER CAUSE CONTROL, V15, P1077, DOI 10.1007/s10552-004-2233-3
   Ruzzo A, 2007, CLIN CHEM LAB MED, V45, P822, DOI 10.1515/CCLM.2007.143
   Saadat I, 2001, CANCER LETT, V169, P21, DOI 10.1016/S0304-3835(01)00550-X
   Setiawan VW, 2000, CANCER EPIDEM BIOMAR, V9, P73
   Setiawan VW, 2001, CANCER CAUSE CONTROL, V12, P673, DOI 10.1023/A:1011261602940
   Shen J, 2002, ZHONG LIU ZA ZHI, V22
   Shen X, 2005, J ENV OCCUP MED, V22, P325
   Shen XB, 2004, HUAN JING YU JIAN KA, V24, P210
   Soerjomataram I, 2012, LANCET
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Tamer L, 2005, CELL BIOCHEM FUNCT, V23, P267, DOI 10.1027/cbf.1148
   Torres María M, 2004, Biomédica, V24, P153
   Tripathi S, 2008, SCAND J GASTROENTERO, V43, P431, DOI 10.1080/00365520701742930
   Tripathi S, 2011, INDIAN J GASTROENTER, V30, P257, DOI 10.1007/s12664-011-0144-2
   Wells GA, 2012, NEWCASTLE OTTAWA SCA
   Wideroff L, 2007, CANCER DETECT PREV, V31, P233, DOI 10.1016/j.cdp.2007.03.004
   Wu MS, 2002, INT J COLORECTAL DIS, V17, P338, DOI 10.1007/s00384-001-0383-2
   Xie S, 2008, CLIN FOCUS, V23, P1393
   Yadav D, 2011, GENE, V487, P166, DOI [10.1016/j.gene.2011.07.010, 10.1016/j.gene.2011.07.017]
   Yadav DS, 2010, GENET TEST MOL BIOMA, V14, P715, DOI 10.1089/gtmb.2010.0087
   Ye M, 2003, WORLD CHIN J DIGESTO, V11, P1314
   Zendehdel K, 2009, CANCER CAUSE CONTROL, V20, P2031, DOI 10.1007/s10552-009-9399-7
   Zhang AP, 2011, ASIAN PAC J CANCER P, V12, P3421
   Zheng T, 2002, SHI YONG ZHONG LIU Z, V17, P155
NR 69
TC 9
Z9 9
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 9
PY 2013
VL 8
IS 4
AR e60833
DI 10.1371/journal.pone.0060833
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130JB
UT WOS:000317909600055
PM 23585855
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhao, Y
   Han, YS
   Zhang, L
   Wang, YC
   Ma, YS
   Zhang, F
   Fu, D
   Wang, XF
AF Zhao, Yuan
   Han, Yusong
   Zhang, Liang
   Wang, Yichao
   Ma, Yushui
   Zhang, Feng
   Fu, Da
   Wang, Xiaofeng
TI Quantitative Assessment of the Effect of Cytochrome P450 2C9 Gene
   Polymorphism and Colorectal Cancer
SO PLOS ONE
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARCINOGEN-METABOLIZING ENZYMES;
   CIGARETTE-SMOKING; CYP2C9 GENOTYPES; RISK; MEAT; METAANALYSIS;
   ASSOCIATION; PREVENTION; RELEVANCE
AB CYP2C9 enzyme activity is involved in the metabolism of substances related to colorectal cancer (CRC), and it is functionally linked to a genetic polymorphism. Two allelic variants of the CYP2C9 gene, namely CYP2C9*2 and CYP2C9*3, differ from wild-type CYP2C9*1 by single amino acid substitutions. These mutated alleles encode enzymes with altered properties that are associated with impaired metabolism. In the past decade, a number of case-control studies have been carried out to investigate the relationship between the CYP2C9 polymorphism and CRC susceptibility, but the results were conflicting. To investigate this inconsistency, we performed a meta-analysis of 13 studies involving a total of 20,879 subjects for CYP2C9*2 and *3 polymorphisms to evaluate the effect of CYP2C9 on genetic susceptibility for CRC. Overall, the summary odds ratio of CRC was 0.94 (95% CI: 0.87-1.03, P = 0.18) and 1.00 (95% CI: 0.86-1.16, P = 0.99) for CYP2C9 *2 and *3 carriers, respectively. No significant results were observed in heterozygous and homozygous when compared with wild genotype for these polymorphisms. In the stratified analyses according to ethnicity, sample size, diagnostic criterion, HWE status and sex, no evidence of any gene-disease association was obtained. Our result suggest that the *2, *3 polymorphisms of CYP2C9 gene are not associated with CRC susceptibility.
C1 [Zhao, Yuan] Fudan Univ, Zhongshan Hosp, Dept Gastroenterol, Shanghai 200433, Peoples R China.
   [Han, Yusong] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.
   [Zhang, Liang; Wang, Yichao; Ma, Yushui; Zhang, Feng; Fu, Da; Wang, Xiaofeng] Fudan Univ, Zhongshan Hosp, Dept Orthopaed Surg, Shanghai 200433, Peoples R China.
RP Fu, D (reprint author), Fudan Univ, Zhongshan Hosp, Dept Orthopaed Surg, Shanghai 200433, Peoples R China.
EM superdafu@hotmail.com; superwangxf@hotmail.com
RI Fu, Da/F-1763-2013
FU China Postdoctoral Science Foundation [20100480542, 201104227]; National
   Natural Science Foundation of China [81201535]; Nature Science
   Foundation of Shanghai [12ZR1436000]; Youth Innovation Promotion
   Association; Knowledge Innovation Program of Shanghai Institutes for
   Biological Sciences, Chinese Academy of Sciences
FX This work was supported by China Postdoctoral Science Foundation Funded
   Project (20100480542, 201104227), National Natural Science Foundation of
   China (81201535), Nature Science Foundation of Shanghai (12ZR1436000),
   Youth Innovation Promotion Association and the Knowledge Innovation
   Program of Shanghai Institutes for Biological Sciences, Chinese Academy
   of Sciences. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511
   Bartsch H, 1999, CARCINOGENESIS, V20, P2209, DOI 10.1093/carcin/20.12.2209
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Buyukdogan M, 2009, UHOD-ULUSLAR HEMATOL, V19, P134
   Calvert PM, 2002, ANN INTERN MED, V137, P603, DOI 10.7326/0003-4819-137-7-200210010-00012
   Chan AT, 2004, CLIN GASTROENTEROL H, V2, P704, DOI 10.1053/S1542-3565(04)00294-0
   Cleary SP, 2010, AM J EPIDEMIOL, V172, P1000, DOI 10.1093/aje/kwq245
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Cotterchio M, 2008, CANCER EPIDEM BIOMAR, V17, P3098, DOI 10.1158/1055-9965.EPI-08-0341
   DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gill HJ, 1999, PHARMACOGENETICS, V9, P43, DOI 10.1097/00008571-199902000-00007
   Gooderham NJ, 2001, DRUG METAB DISPOS, V29, P529
   Haining RL, 1996, ARCH BIOCHEM BIOPHYS, V333, P447, DOI 10.1006/abbi.1996.0414
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   Kury S, 2007, CANCER EPIDEM BIOMAR, V16, P1460, DOI 10.1158/1055-9965.EPI-07-0236
   Landi S, 2005, PHARMACOGENET GENOM, V15, P535, DOI 10.1097/01.fpc.0000165904.48994.3d
   Lee CR, 2004, METHOD FIND EXP CLIN, V26, P463
   Liao LH, 2007, CLIN CHIM ACTA, V380, P191, DOI 10.1016/j.cca.2007.02.033
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Martinez C, 2001, CARCINOGENESIS, V22, P1323, DOI 10.1093/carcin/22.8.1323
   McGreavey LE, 2005, PHARMACOGENET GENOM, V15, P713, DOI 10.1097/01.fpc.0000174786.85238.63
   NAGAO M, 1993, MUTAT RES, V290, P43, DOI 10.1016/0027-5107(93)90031-A
   Northwood EL, 2010, PHARMACOGENET GENOM, V20, P315, DOI 10.1097/FPC.0b013e3283395c6a
   Oda Y, 2001, MUTAT RES-GEN TOX EN, V492, P81, DOI 10.1016/S1383-5718(01)00154-1
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Sainz J, 2011, ENDOCR-RELAT CANCER, V18, P265, DOI 10.1530/ERC-10-0264
   Samowitz WS, 2006, CLIN GASTROENTEROL H, V4, P894, DOI 10.1016/j.cgh.2006.04.021
   Schwarz UI, 2003, EUR J CLIN INVEST, V33, P23, DOI 10.1046/j.1365-2362.33.s2.6.x
   SHOU MG, 1994, MOL CARCINOGEN, V10, P159, DOI 10.1002/mc.2940100307
   Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387
   SullivanKlose TH, 1996, PHARMACOGENETICS, V6, P341, DOI 10.1097/00008571-199608000-00007
   Takahashi H, 1998, PHARMACOGENETICS, V8, P365, DOI 10.1097/00008571-199810000-00001
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Tranah GJ, 2005, MOL CARCINOGEN, V44, P21, DOI 10.1002/mc.20112
NR 36
TC 4
Z9 4
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 5
PY 2013
VL 8
IS 4
AR e60607
DI 10.1371/journal.pone.0060607
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RZ
UT WOS:000319109800072
PM 23577132
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, J
   Yang, YG
   Zhou, M
   Xu, JY
   Zhang, QG
   Zhou, RF
   Chen, B
   Ouyang, J
AF Wang, Jing
   Yang, Yong-Gong
   Zhou, Min
   Xu, Jing-Yan
   Zhang, Qi-Guo
   Zhou, Rong-Fu
   Chen, Bing
   Ouyang, Jian
TI Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin plus
   Cytarabine with Daunorubicin plus Cytarabine as the Induction
   Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
SO PLOS ONE
LA English
DT Article
ID ACUTE MYELOGENOUS LEUKEMIA; 1ST COMPLETE REMISSION; HIGH-DOSE
   DAUNORUBICIN; PHASE-III; PUBLICATION BIAS; ADULT PATIENTS; THERAPY;
   MULTICENTER; COMBINATION; STATISTICS
AB Background: To determine whether the use of idarubicin+cytarabine (IA) is more effective than the use of daunorubicin+cytarabine (DA) as induction chemotherapy for patients with newly diagnosed acute myeloid leukaemia.
   Methods: A computer-based search was performed. Randomised trials comparing IA with DA as induction therapy for newly diagnosed AML were included in this meta-analysis. The primary outcome of interest for our analysis was survival (disease-free survival, event-free survival and overall survival); the secondary endpoint was complete remission.
   Results: Ten trials with 4,060 patients were eligible for this meta-analysis. Our pooled results suggest that IA is associated with a significant advantage in CR (RR = 1.23; 95% CI = 1.07-1.41, p = 0.004), EFS (HR = 0.64; 95% CI = 0.45-0.91, p = 0.013), and OS (HR = 0.88; 95% CI = 0.81-0.95, p = 0.02) but not in DFS (HR = 0.90; 95% CI = 0.80-1.00, p = 0.06). In the subgroup analysis, age had a significant interaction with OS and CR benefits.
   Conclusion: Our analysis indicated that IA could improve the duration of overall survival compared to DA as induction therapy for young patients with newly diagnosed AML. Further study is needed to determine whether IA can produce clinical benefits in selected genetic or molecular subgroups of young AML patients.
C1 [Wang, Jing; Yang, Yong-Gong; Zhou, Min; Xu, Jing-Yan; Zhang, Qi-Guo; Zhou, Rong-Fu; Chen, Bing; Ouyang, Jian] Nanjing Univ, Dept Hematol, Affiliated DrumTower Hosp, Sch Med, Nanjing 210008, Jiangsu, Peoples R China.
RP Ouyang, J (reprint author), Nanjing Univ, Dept Hematol, Affiliated DrumTower Hosp, Sch Med, Nanjing 210008, Jiangsu, Peoples R China.
EM ouyang211@hotmail.com
OI Wang, Jing/0000-0001-9981-5530
CR Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993
   BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202
   BERMAN E, 1991, BLOOD, V77, P1666
   Burnett AK, 2011, J CLIN ONCOL, V29, P369, DOI 10.1200/JCO.2010.31.4310
   Candoni A, 2008, LEUKEMIA RES, V32, P1800, DOI 10.1016/j.leukres.2008.05.011
   Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036
   Chevallier P, 2010, LEUKEMIA, V24, P1380, DOI 10.1038/leu.2010.111
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Creutzig U, 2001, LEUKEMIA, V15, P348, DOI 10.1038/sj.leu.2402046
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fernandez HF, 2009, NEW ENGL J MED, V361, P1249, DOI 10.1056/NEJMoa0904544
   Ferrara F, 2008, CRIT REV ONCOL HEMAT, V66, P181, DOI 10.1016/j.critrevonc.2007.09.008
   Gardin C, 2007, BLOOD, V109, P5129, DOI 10.1182/blood-2006-02-069666
   GREENLAND S, 1994, AM J EPIDEMIOL, V140, P783, DOI 10.1093/oxfordjournals.aje.a117326
   Holowiecki J, 2004, LEUKEMIA, V18, P989, DOI 10.1038/sj.leu.2403336
   Holowiecki J, 2012, J CLIN ONCOL, V30, P2441, DOI 10.1200/JCO.2011.37.1286
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054
   Lee JH, 2011, BLOOD, V118, P3832, DOI 10.1182/blood-2011-06-361410
   Liberati A, 2009, ANN INTERN MED, V151, pW65, DOI 10.7326/0003-4819-151-4-200908180-00136
   Liddle J, 1996, METHOD EVALUATING RE
   Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407
   Lowenberg B, 2009, NEW ENGL J MED, V361, P1235, DOI 10.1056/NEJMoa0901409
   MANDELLI F, 1991, EUR J CANCER, V27, P750, DOI 10.1016/0277-5379(91)90181-C
   Mandelli F, 2009, J CLIN ONCOL, V27, P5397, DOI 10.1200/JCO.2008.20.6490
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Ohtake S, 2011, BLOOD, V117, P2358, DOI 10.1182/blood-2010-03-273243
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Pautas C, 2010, J CLIN ONCOL, V28, P808, DOI 10.1200/JCO.2009.23.2652
   Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010
   Poole C, 1999, AM J EPIDEMIOL, V150, P469
   Reiffers J, 1996, LEUKEMIA, V10, P389
   Roboz GJ, 2011, HEMATOL-AM SOC HEMAT, P43, DOI 10.1182/asheducation-2011.1.43
   Rowe JM, 2004, BLOOD, V103, P479, DOI 10.1182/blood-2003-05-1686
   Rowe JM, 1997, BLOOD, V90, P2121
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   VOGLER WR, 1992, J CLIN ONCOL, V10, P1103, DOI 10.1200/JCO.1992.10.7.1103
   Wheatley D, 1998, BRIT J HAEMATOL, V103, P100
   WIERNIK PH, 1992, BLOOD, V79, P313
NR 43
TC 17
Z9 18
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 5
PY 2013
VL 8
IS 4
AR e60699
DI 10.1371/journal.pone.0060699
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RZ
UT WOS:000319109800092
PM 23593285
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Cao, SY
   Yin, XX
   Wang, YX
   Zhou, HF
   Song, FJ
   Lu, ZX
AF Cao, Shiyi
   Yin, Xiaoxu
   Wang, Yunxia
   Zhou, Hongfeng
   Song, Fujian
   Lu, Zuxun
TI Smoking and Risk of Erectile Dysfunction: Systematic Review of
   Observational Studies with Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PUBLICATION BIAS; IMPOTENCE
AB Background: There are many recent observational studies on smoking and risk of erectile dysfunction (ED) and whether smoking increases the risk of ED is still inconclusive. The objective of this meta-analysis was to synthesize evidence from studies that evaluated the association between smoking and the risk of ED.
   Methods: We searched PubMed, Embase, Web of Science, and Scopus in January 2013 to identify cohort and case-control studies that evaluated the association between smoking and ED. Study quality of included studies was assessed by the Newcastle-Ottawa scale. Random-effects meta-analyses were used to combine the results of included studies.
   Results: Four prospective cohort studies and four case-control studies involving 28, 586 participants were included. Because of significant heterogeneity after including case-control studies in meta-analysis, the consistent results of prospective cohort studies were considered more accurate, Because of significant heterogeneity after including case-control studies in meta-analysis, the consistent results of prospective cohort studies were considered more accurate, Compared with non-smokers, the overall odd ratio of ED in prospective cohort studies was 1.51(95% CI: 1.34 to 1.71) for current smokers, and it was 1.29 (95% CI: 1.07 to 1.47) for former smokers. Evidence of publication bias was not found.
   Conclusion: Evidence from epidemiological studies suggests that smoking, especially current smoking, may significantly increase the risk of ED
C1 [Cao, Shiyi; Yin, Xiaoxu; Wang, Yunxia; Zhou, Hongfeng; Lu, Zuxun] Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, Wuhan 430074, Hubei, Peoples R China.
   [Song, Fujian] Univ E Anglia, Norwich Med Sch, Fac Med & Hlth Sci, Norwich NR4 7TJ, Norfolk, England.
RP Lu, ZX (reprint author), Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, Wuhan 430074, Hubei, Peoples R China.
EM zuxunlu@yahoo.com
RI Song, Fujian/B-3516-2013
CR Bacon CG, 2006, J UROLOGY, V176, P217, DOI 10.1016/S0022-5347(06)00589-1
   Bates MN, 2007, ARCH INTERN MED, V167, P335, DOI 10.1001/archinte.167.4.335
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dong JY, 2011, J AM COLL CARDIOL, V58, P1378, DOI 10.1016/j.jacc.2011.06.024
   DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83
   Elbendary MA, 2009, J ANDROL, V30, P520, DOI 10.2164/jandrol.108.007195
   Feldman HA, 2000, PREV MED, V30, P328, DOI 10.1006/pmed.2000.0643
   Gades NM, 2005, AM J EPIDEMIOL, V161, P346, DOI 10.1093/aje/kwi052
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   KIRBY RS, 1994, BRIT MED J, V308, P957, DOI 10.1136/bmj.308.6934.957
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Polsky JY, 2005, BJU INT, V96, P1355, DOI 10.1111/j.1464-410X.2005.05820.x
   Shiri R, 2005, INT J IMPOT RES, V17, P164, DOI 10.1038/sj.ijir.3901280
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tengs TO, 2001, PREV MED, V32, P447, DOI 10.1006/pmed.2001.0830
   Wells G, 2010, NEWCASTLE OTTAWA SCA
   Zambon JP, 2010, SAO PAULO MED J, V128, P137, DOI 10.1590/S1516-31802010000300006
   Zedan H., 2010, Eastern Mediterranean Health Journal, V16, P281
NR 19
TC 31
Z9 33
U1 1
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 3
PY 2013
VL 8
IS 4
AR e60443
DI 10.1371/journal.pone.0060443
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 143BA
UT WOS:000318840100073
PM 23573257
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, X
   Yao, XP
   Wang, YB
   Hu, FL
   Wang, F
   Jiang, LY
   Liu, YP
   Wang, D
   Sun, GZ
   Zhao, YS
AF Li, Xia
   Yao, Xiaoping
   Wang, Yibaina
   Hu, Fulan
   Wang, Fan
   Jiang, Liying
   Liu, Yupeng
   Wang, Da
   Sun, Guizhi
   Zhao, Yashuang
TI MLH1 Promoter Methylation Frequency in Colorectal Cancer Patients and
   Related Clinicopathological and Molecular Features
SO PLOS ONE
LA English
DT Article
ID REVISED BETHESDA GUIDELINES; MICROSATELLITE INSTABILITY; HMLH1 PROMOTER;
   LYNCH-SYNDROME; COLON-CANCER; INSTITUTE WORKSHOP; GENE METHYLATION; BRAF
   MUTATION; HEREDITARY; HYPERMETHYLATION
AB Purpose: To describe the frequency of MLH1 promoter methylation in colorectal cancer (CRC); to explore the associations between MLH1 promoter methylation and clinicopathological and molecular factors using a systematic review and meta-analysis.
   Methods: A literature search of the PubMed and Embase databases was conducted to identify relevant articles published up to September 7, 2012 that described the frequency of MLH1 promoter methylation or its associations with clinicopathological and molecular factors in CRC. The pooled frequency, odds ratio (OR) and 95% confidence intervals (95% CI) were calculated.
   Results: The pooled frequency of MLH1 promoter methylation in unselected CRC was 20.3% (95% CI: 16.8-24.1%). They were 18.7% (95% CI: 14.7-23.6%) and 16.4% (95% CI: 11.9-22.0%) in sporadic and Lynch syndrome (LS) CRC, respectively. Significant associations were observed between MLH1 promoter methylation and gender (pooled OR = 1.641, 95% CI: 1.215-2.215; P = 0.001), tumor location (pooled OR = 3.804, 95% CI: 2.715-5.329; P<0.001), tumor differentiation (pooled OR = 2.131, 95% CI: 1.464-3.102; P<0.001), MSI (OR: 27.096, 95% CI: 13.717-53.526; P<0.001). Significant associations were also observed between MLH1 promoter methylation and MLH1 protein expression, BRAF mutation (OR = 14.919 (95% CI: 6.427-34.631; P<0.001) and 9.419 (95% CI: 2.613-33.953; P = 0.001), respectively).
   Conclusion: The frequency of MLH1 promoter methylation in unselected CRC was 20.3%. They were 18.7% in sporadic CRC and 16.4% in LS CRC, respectively. MLH1 promoter methylation may be significantly associated with gender, tumor location, tumor differentiation, MSI, MLH1 protein expression, and BRAF mutation.
C1 [Li, Xia; Yao, Xiaoping; Wang, Yibaina; Hu, Fulan; Wang, Fan; Jiang, Liying; Liu, Yupeng; Zhao, Yashuang] Harbin Med Univ, Coll Publ Hlth, Dept Epidemiol, Harbin, Heilongjiang Pr, Peoples R China.
   [Wang, Da] Harbin Med Univ, Dept Sci & Technol Adm, Harbin, Heilongjiang Pr, Peoples R China.
   [Sun, Guizhi] Harbin Med Univ, Canc Hosp, Dept Surg, Harbin, Heilongjiang Pr, Peoples R China.
RP Zhao, YS (reprint author), Harbin Med Univ, Coll Publ Hlth, Dept Epidemiol, Harbin, Heilongjiang Pr, Peoples R China.
EM zhao_yashuang@263.net
RI Zhao, Yashuang/I-6145-2019; Wang, Fan/I-6099-2019
OI Wang, Fan/0000-0002-9869-9504
FU National Natural Science Foundation of China for Priority Areas [NSFC
   30972538]; Education Bureau of Heilongjiang Province [11531100];
   Graduate Foundation; Scientific Research of Heilongjiang Province
   [YJSCX2009-224HLJ]; Harbin Medical University [HCXB2009009]
FX This study was supported by grants from National Natural Science
   Foundation of China for Priority Areas (NSFC 30972538), Education Bureau
   of Heilongjiang Province (11531100), and the Graduate Foundation,
   supported by the Scientific Research of Heilongjiang Province
   (YJSCX2009-224HLJ) and Harbin Medical University (HCXB2009009). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121
   Aguilera O, 2010, J APPL PHYSIOL, V109, P243, DOI 10.1152/japplphysiol.00068.2010
   Ahlquist T, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-94
   Anacleto C, 2005, NEOPLASIA, V7, P331, DOI 10.1593/neo.04502
   Arnold CN, 2004, CANCER BIOL THER, V3, P73, DOI 10.4161/cbt.3.1.590
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belshaw NJ, 2004, CANCER EPIDEM BIOMAR, V13, P1495
   Bettstetter M, 2007, CLIN CANCER RES, V13, P3221, DOI 10.1158/1078-0432.CCR-06-3064
   BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Boland CR, 1998, CANCER RES, V58, P5248
   Brandes JC, 2005, CARCINOGENESIS, V26, P1152, DOI 10.1093/carcin/bgi058
   Cunningham JM, 1998, CANCER RES, V58, P3455
   de Vogel S, 2009, ANN ONCOL, V20, P1216, DOI 10.1093/annonc/mdn782
   Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3
   Deng GR, 1999, CANCER RES, V59, P2029
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DerSimonian R, 1996, STAT MED, V15, P1237, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Dykes SL, 2003, CANCER-AM CANCER SOC, V98, P48, DOI 10.1002/cncr.11445
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fox EJ, 2006, J MOL DIAGN, V8, P68, DOI 10.2353/jmoldx.2006.050084
   Garagnani P, 2012, CURR PHARM DES
   Gay LJ, 2011, NUTR CANCER, V63, P1000, DOI 10.1080/01635581.2011.596987
   Gazzoli I, 2002, CANCER RES, V62, P3925
   GLOBOCAN, 2008, CANC FACT SHEET
   Grady WM, 2001, CANCER RES, V61, P900
   Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang Q, 2012, DIAGN MOL PATHOL, V21, P24, DOI 10.1097/PDM.0b013e318230effd
   Iacopetta B, 2006, INT J CANCER, V119, P2272, DOI 10.1002/ijc.22237
   IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0
   Jass JR, 2002, EUR J CANCER, V38, P858, DOI 10.1016/S0959-8049(02)00041-2
   Julie C, 2008, AM J GASTROENTEROL, V103, P2825, DOI 10.1111/j.1572-0241.2008.02084.x
   Kane MF, 1997, CANCER RES, V57, P808
   Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782
   Kuismanen SA, 1999, P NATL ACAD SCI USA, V96, P12661, DOI 10.1073/pnas.96.22.12661
   Kumar K, 2009, CLIN CANCER RES, V15, P1155, DOI 10.1158/1078-0432.CCR-08-1029
   Lawes DA, 2005, BRIT J CANCER, V93, P472, DOI 10.1038/sj.bjc.6602708
   Lee KH, 2011, LANGENBECK ARCH SURG, V396, P1017, DOI 10.1007/s00423-011-0812-9
   Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0
   Leung WK, 2005, AM J GASTROENTEROL, V100, P2274, DOI 10.1111/j.1572-0241.2005.50412.x
   Lind GE, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-28
   Mathers JC, ADV GENET, V71, P3
   Menigatti M, 2009, ONCOGENE, V28, P899, DOI 10.1038/onc.2008.444
   Menigatti M, 2001, GENE CHROMOSOME CANC, V31, P357, DOI 10.1002/gcc.1154
   Mirchev M, 2007, J IMAB ANN P SCI PAP, P95
   Miyakura Y, 2004, CLIN GASTROENTEROL H, V2, P147, DOI 10.1053/S1542-3565(03)00314-8
   Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154
   Nakagawa H, 2001, CANCER RES, V61, P6991
   Oliveira C, 2004, HUM MOL GENET, V13, P2303, DOI 10.1093/hmg/ddh238
   Park IJ, 2007, J KOREAN MED SCI, V22, pS91, DOI 10.3346/jkms.2007.22.S.S91
   Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509
   Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X
   Potocnik U, 2001, CANCER GENET CYTOGEN, V126, P85, DOI 10.1016/S0165-4608(00)00399-X
   Poynter JN, 2008, CANCER EPIDEM BIOMAR, V17, P3208, DOI 10.1158/1055-9965.EPI-08-0512
   Raedle J, 2001, ANN INTERN MED, V135, P566, DOI 10.7326/0003-4819-135-8_Part_1-200110160-00007
   RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758
   Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020
   Shannon BA, 2001, CANCER LETT, V167, P91, DOI 10.1016/S0304-3835(01)00431-1
   Shi XZ, 2006, BIOMED CHROMATOGR, V20, P815, DOI 10.1002/bmc.606
   Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9
   Strazzullo M, 2003, CANCER, V98, P1540, DOI 10.1002/cncr.11651
   Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585
   THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122
   Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034
   Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X
   VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699
   Velayos FS, 2005, J GASTROINTEST SURG, V9, P329, DOI 10.1016/j.gassur.204.05.007
   Vilkin A, 2009, CANCER-AM CANCER SOC, V115, P760, DOI 10.1002/cncr.24019
   Wallner M, 2006, CLIN CANCER RES, V12, P7347, DOI 10.1158/1078-0432.CCR-06-1264
   Ward R, 2001, GUT, V48, P821, DOI 10.1136/gut.48.6.821
   Ward RL, 2005, J PATHOL, V207, P377, DOI 10.1002/path.1851
   Yamamoto H, 2002, GENE CHROMOSOME CANC, V33, P322, DOI 10.1002/gcc.10010
   Yiu R, 2005, DIS COLON RECTUM, V48, P2061, DOI 10.1007/s10350-005-0171-0
   Zhou HH, 2008, WORLD J GASTROENTERO, V14, P7329, DOI 10.3748/wjg.14.7329
NR 78
TC 23
Z9 24
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 29
PY 2013
VL 8
IS 3
AR e59064
DI 10.1371/journal.pone.0059064
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 121SG
UT WOS:000317263900009
PM 23555617
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Peng, L
   Zhou, Y
   Wang, YN
   Mou, HB
   Zhao, Q
AF Peng, Ling
   Zhou, Yun
   Wang, Yina
   Mou, Haibo
   Zhao, Qiong
TI Prognostic Significance of COX-2 Immunohistochemical Expression in
   Colorectal Cancer: A Meta-Analysis of the Literature
SO PLOS ONE
LA English
DT Article
ID CYCLOOXYGENASE-2 EXPRESSION; RECTAL-CANCER; PREOPERATIVE RADIOTHERAPY;
   MOLECULAR TARGET; P53 ACCUMULATION; GROWTH-FACTOR; BETA-CATENIN;
   CARCINOGENESIS; PREVENTION; CARCINOMA
AB Background: Cyclooxygenase-2 (COX-2) is believed to be an important enzyme in the pathogenesis of colorectal cancer (CRC). Correlations between the expression of COX-2 with tumor growth and distant metastasis have become an issue; thus, attention has been paid to COX-2 as a prognostic factor. Various studies examined the relationship between COX-2 immunohistochemistry (IHC) overexpression with the clinical outcome in patients with colorectal cancer, but yielded conflicting results. The prognostic significance of COX-2 overexpression in colorectal cancer remains controversial.
   Methods: Electronic databases updated to October 2012 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between COX-2 overexpression and survival of patients with colorectal cancer. Survival data were aggregated and quantitatively analyzed.
   Results: We performed a meta-analysis of 23 studies (n = 4567 patients) that evaluated the correlation between COX-2 overexpression detected by IHC and survival in patients with colorectal cancer. Combined hazard ratios suggested that COX-2 overexpression had an unfavorable impact on overall survival (OS) (HR [hazard ratio] = 1.193, 95% CI [confidence interval]: 1.02 similar to 1.37), but not disease free survival (DFS) (HR = 1.25, 95% CI: 0.99 similar to 1.50) in patients with colorectal cancer.
   Conclusions: Cox-2 overexpression in colorectal cancer detected by IHC appears to have slightly worse overall survival. However, the prognostic value of COX-2 on survival in colorectal cancer still needs further large-scale prospective trials to be clarified.
C1 [Peng, Ling; Wang, Yina; Mou, Haibo; Zhao, Qiong] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Thorac Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhou, Yun] Zhejiang Food & Drug Adm, Hangzhou, Zhejiang, Peoples R China.
RP Zhao, Q (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Thorac Oncol, Hangzhou 310003, Zhejiang, Peoples R China.
EM doczq.2008@gmail.com
FU Medical Science Research Foundation of Health Bureau of Zhejiang
   Province [2012KYA072]; Administration of Traditional Chinese Medicine of
   Zhejiang Province [2012ZB084]
FX This study was supported by a grant from Medical Science Research
   Foundation of Health Bureau of Zhejiang Province (Grant number:
   2012KYA072) and a grant from Administration of Traditional Chinese
   Medicine of Zhejiang Province (Grant number: 2012ZB084). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Al-Maghrabi J, 2012, WORLD J GASTROENTERO, V18, P1793, DOI 10.3748/wjg.v18.i15.1793
   Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355
   Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051
   Buecher B, 2003, ALIMENT PHARM THER, V18, P731, DOI 10.1046/j.1365-2036.2003.01758.x
   Chen SQ, 2008, SCAND J GASTROENTERO, V43, P456, DOI 10.1080/00365520701785194
   Cressey R, 2006, CANCER LETT, V233, P232, DOI 10.1016/j.canlet.2005.03.023
   de Heer P, 2007, CLIN CANCER RES, V13, P2955, DOI 10.1158/1078-0432.CCR-06-2042
   Debucquoy A, 2009, INT J COLORECTAL DIS, V24, P129, DOI 10.1007/s00384-008-0608-8
   Dimberg J, 1999, GUT, V45, P730, DOI 10.1136/gut.45.5.730
   DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8
   Fosslien E, 2000, CRIT REV CL LAB SCI, V37, P431, DOI 10.1080/10408360091174286
   Fujita T, 1998, CANCER RES, V58, P4823
   Fux R, 2005, CLIN CANCER RES, V11, P4754, DOI 10.1158/1078-0432.CCR-04-2586
   Giralt J, 2006, ONCOLOGY-BASEL, V71, P312, DOI 10.1159/000107105
   Hao XP, 1999, J PATHOL, V187, P295
   Hida T, 1998, CANCER RES, V58, P3761
   Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455
   Inafuku Y, 2009, CANCER SCI, V100, P852, DOI 10.1111/j.1349-7006.2009.01116.x
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   JONES DA, 1993, J BIOL CHEM, V268, P9049
   Joo YE, 2002, J GASTROINTEST CANC, V31, P147, DOI 10.1385/IJGC:31:1-3:147
   Lagorce C, 2003, HISTOPATHOLOGY, V42, P457, DOI 10.1046/j.1365-2559.2003.01627.x
   Li L, 2009, ALIMENT PHARM THER, V30, P589, DOI 10.1111/j.1365-2036.2009.04069.x
   Lim SC, 2008, J SURG ONCOL, V97, P51, DOI 10.1002/jso.20907
   Mascaux C, 2006, BRIT J CANCER, V95, P139, DOI 10.1038/sj.bjc.6603226
   Masunaga R, 2000, CLIN CANCER RES, V6, P4064
   Miladi-Abdennadher I, 2012, ACTA HISTOCHEM, V114, P577, DOI 10.1016/j.acthis.2011.11.002
   Ogino S, 2009, AM J GASTROENTEROL, V104, P2047, DOI 10.1038/ajg.2009.281
   Pancione M, 2009, HUM PATHOL, V40, P714, DOI 10.1016/j.humpath.2008.08.019
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8
   Sheehan KM, 1999, JAMA-J AM MED ASSOC, V282, P1254, DOI 10.1001/jama.282.13.1254
   Soumaoro LT, 2004, CLIN CANCER RES, V10, P8465, DOI 10.1158/1078-0432.CCR-04-0653
   STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K
   Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3
   Tomozawa S, 2000, BRIT J CANCER, V83, P324, DOI 10.1054/bjoc.2000.1270
   Tucker ON, 1999, CANCER RES, V59, P987
   Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393
   Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286
   Wu AW, 2003, WORLD J GASTROENTERO, V9, P1990, DOI 10.3748/wjg.v9.i9.1990
   Yamac D, 2005, PATHOL RES PRACT, V201, P497, DOI 10.1016/j.prp.2005.04.006
   Yamauchi T, 2002, DIS COLON RECTUM, V45, P98, DOI 10.1007/s10350-004-6120-5
   Yoshinaga M, 2011, DIGEST DIS SCI, V56, P1194, DOI 10.1007/s10620-010-1389-9
   YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7
   Zhan J, 2004, CHINESE MED J-PEKING, V117, P1151
   Zhang H, 2002, AM J GASTROENTEROL, V97, P1037
   Zimmermann KC, 1999, CANCER RES, V59, P198
NR 51
TC 33
Z9 35
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 20
PY 2013
VL 8
IS 3
AR e58891
DI 10.1371/journal.pone.0058891
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 125SW
UT WOS:000317562600043
PM 23527044
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, DD
   Hu, FL
   Wang, F
   Cui, BB
   Dong, XS
   Zhang, WC
   Lin, CQ
   Li, X
   Wang, D
   Zhao, YS
AF Li, Dandan
   Hu, Fulan
   Wang, Fan
   Cui, Binbin
   Dong, Xinshu
   Zhang, Wencui
   Lin, Chunqing
   Li, Xia
   Wang, Da
   Zhao, Yashuang
TI Prevalence of Pathological Germline Mutations of hMLH1 and hMSH2 Genes
   in Colorectal Cancer
SO PLOS ONE
LA English
DT Article
ID MISMATCH-REPAIR GENES; NONPOLYPOSIS COLON-CANCER; TUMOR MICROSATELLITE
   INSTABILITY; REVISED BETHESDA GUIDELINES; LYNCH-SYNDROME; HNPCC
   FAMILIES; AMSTERDAM CRITERIA; PUBLICATION BIAS; MSH2 MUTATIONS; MLH1
   MUTATIONS
AB The prevalence of pathological germline mutations in colorectal cancer has been widely studied, as germline mutations in the DNA mismatch repair genes hMLH1 and hMSH2 confer a high risk of colorectal cancer. However, because the sample size and population of previous studies are very different from each other, the conclusions still remain controversial. In this paper, Databases such as PubMed were applied to search for related papers. The data were imported into Comprehensive Meta-Analysis V2, which was used to estimate the weighted prevalence of hMLH1 and hMSH2 pathological mutations and compare the differences of prevalence among different family histories, ethnicities and related factors. This study collected and utilized data from 102 papers. In the Amsterdam-criteria positive group, the prevalence of pathological germline mutations of the hMLH1 and hMSH2 genes was 28.55% (95% CI 26.04%-31.19%) and 19.41% (95% CI 15.88%-23.51%), respectively, and the prevalence of germline mutations in hMLH1/hMSH2 was 15.44%/10.02%, 20.43%/13.26% and 15.43%/11.70% in Asian, American multiethnic and European/Australian populations, respectively. Substitution mutations accounted for the largest proportion of germline mutations (hMLH1: 52.34%, hMSH2: 43.25%). The total prevalence of mutations of hMLH1 and hMSH2 in Amsterdam-criteria positive, Amsterdam-criteria negative and sporadic colorectal cancers was around 45%, 25% and 15%, respectively, and there were no obvious differences in the prevalence of germline mutations among different ethnicities.
C1 [Li, Dandan; Hu, Fulan; Wang, Fan; Zhang, Wencui; Lin, Chunqing; Li, Xia; Zhao, Yashuang] Harbin Med Univ, Coll Publ Hlth, Dept Epidemiol, Harbin, Heilongjiang Pr, Peoples R China.
   [Cui, Binbin; Dong, Xinshu] Harbin Med Univ, Tumor Hosp, Dept Abdominal Surg, Harbin, Heilongjiang Pr, Peoples R China.
   [Wang, Da] Harbin Med Univ, Dept Sci & Technol Adm, Harbin, Heilongjiang Pr, Peoples R China.
RP Zhao, YS (reprint author), Harbin Med Univ, Coll Publ Hlth, Dept Epidemiol, Harbin, Heilongjiang Pr, Peoples R China.
EM zhao_yashuang@263.net
RI Zhao, Yashuang/I-6145-2019; Wang, Fan/I-6099-2019
OI Wang, Fan/0000-0002-9869-9504
FU National Natural Science Foundation of China [30671801]; Harbin
   Foundation for the Returned Scholars [2005AFLXJ017]; Health Bureau of
   Heilongjiang Province [2005-103]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant number 30671801), the Harbin Foundation for
   the Returned Scholars (Grant number 2005AFLXJ017), and the Health Bureau
   of Heilongjiang Province (Grant number 2005-103). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101
   AALTONEN LA, 1994, ANTICANCER RES, V14, P1657
   Abe Y, 2000, J SURG ONCOL, V74, P249, DOI 10.1002/1096-9098(200008)74:4<249::AID-JSO2>3.0.CO;2-S
   [Anonymous], 1997, IARC SCI PUBL, VVII, p[i, 1]
   Apessos A, 2005, BRIT J CANCER, V92, P396, DOI 10.1038/sj.bjc.6602260
   Bai YQ, 1999, INT J CANCER, V82, P512, DOI 10.1002/(SICI)1097-0215(19990812)82:4<512::AID-IJC7>3.0.CO;2-8
   Balmana J, 2006, JAMA-J AM MED ASSOC, V296, P1469, DOI 10.1001/jama.296.12.1469
   Bapat BV, 1999, HUM GENET, V104, P167, DOI 10.1007/s004390050931
   Barnetson RA, 2006, NEW ENGL J MED, V354, P2751, DOI 10.1056/NEJMoa053493
   Bartosova Z, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9127
   Beck NE, 1997, BRIT J SURG, V84, P233, DOI 10.1002/bjs.1800840228
   Beck NE, 1997, HUM GENET, V99, P219, DOI 10.1007/s004390050343
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boland CR, 1998, CANCER RES, V58, P5248
   BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0
   BUERSTEDDE JM, 1995, J MED GENET, V32, P909, DOI 10.1136/jmg.32.11.909
   Caldes T, 2002, INT J CANCER, V98, P774, DOI 10.1002/ijc.10240
   Calistri D, 2000, INT J CANCER, V89, P87, DOI 10.1002/(SICI)1097-0215(20000120)89:1<87::AID-IJC14>3.0.CO;2-9
   Canard G, 2011, ANN SURG ONCOL
   Casey G, 2005, JAMA-J AM MED ASSOC, V293, P799, DOI 10.1001/jama.293.7.799
   Cederquist K, 2004, INT J CANCER, V109, P370, DOI 10.1002/ijc.11718
   Cederquist K, 2001, INT J CANCER, V91, P486, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1093>3.0.CO;2-P
   Chung DC, 2003, ANN INTERN MED, V138, P560, DOI 10.7326/0003-4819-138-7-200304010-00012
   Coggins RP, 2005, GUT, V54, P636, DOI 10.1136/gut.2003.017517
   Coleman MG, 2001, BRIT J CANCER, V85, P1486, DOI 10.1054/bjoc.2001.2058
   Cotton RGH, 1998, HUM MUTAT, V12, P1, DOI 10.1002/(SICI)1098-1004(1998)12:1<1::AID-HUMU1>3.0.CO;2-M
   Cravo M, 1999, J PATHOL, V188, P252, DOI 10.1002/(SICI)1096-9896(199907)188:3<252::AID-PATH354>3.0.CO;2-3
   Cui L, 2004, WORLD J GASTROENTERO, V10, P209
   Cunningham JM, 2001, AM J HUM GENET, V69, P780, DOI 10.1086/323658
   Curia MC, 1999, CANCER RES, V59, P3570
   de Leon MP, 1999, GUT, V45, P32, DOI 10.1136/gut.45.1.32
   Dietmaier W, 1997, CANCER RES, V57, P4749
   Dieumegard B, 2000, BRIT J CANCER, V82, P871, DOI 10.1054/bjoc.1999.1014
   Dunlop MG, 2000, BRIT J CANCER, V83, P1643, DOI 10.1054/bjoc.2000.1520
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996
   Fidalgo P, 2000, EUR J HUM GENET, V8, P49, DOI 10.1038/sj.ejhg.5200393
   FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3
   Froggatt NJ, 1996, J MED GENET, V33, P726, DOI 10.1136/jmg.33.9.726
   Genuardi M, 1998, INT J CANCER, V75, P835, DOI 10.1002/(SICI)1097-0215(19980316)75:6<835::AID-IJC4>3.0.CO;2-W
   Ghimenti C, 1999, BRIT J CANCER, V80, P11, DOI 10.1038/sj.bjc.6690314
   Giraldo A, 2005, FAM CANCER, V4, P285, DOI 10.1007/s10689-005-4523-7
   Goldberg Y, 2008, FAM CANCER, V7, P309, DOI 10.1007/s10689-008-9191-y
   Green SE, 1998, INT J COLORECTAL DIS, V13, P3, DOI 10.1007/s003840050123
   HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302
   Heinimann K, 1999, CANCER, V85, P2512, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2512::AID-CNCR4>3.0.CO;2-G
   Herfarth KKF, 1997, GENE CHROMOSOME CANC, V18, P42, DOI 10.1002/(SICI)1098-2264(199701)18:1<42::AID-GCC5>3.0.CO;2-1
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hutter P, 1998, INT J CANCER, V78, P680, DOI 10.1002/(SICI)1097-0215(19981209)78:6<680::AID-IJC3>3.0.CO;2-U
   Jeong SY, 2003, DIS COLON RECTUM, V46, P1069, DOI 10.1097/01.DCR.0000074689-32015.C1
   Jin HY, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-44
   Katballe N, 2002, GUT, V50, P43, DOI 10.1136/gut.50.1.43
   KohonenCorish M, 1996, AM J HUM GENET, V59, P818
   Kouraklis G, 2005, DIGEST DIS SCI, V50, P336, DOI 10.1007/s10620-005-1607-z
   Kurzawski G, 2006, CLIN GENET, V69, P40, DOI 10.1111/j.1399-0004.2006.00550.x
   Lamberti C, 1999, GUT, V44, P839, DOI 10.1136/gut.44.6.839
   Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169
   LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348
   Liu SR, 2004, WORLD J GASTROENTERO, V10, P2647, DOI 10.3748/wjg.v10.i18.2647
   Liu T, 1998, CLIN GENET, V53, P131
   Liu T, 2001, CANCER RES, V61, P7798
   Luo DC, 2005, WORLD J GASTROENTERO, V11, P1673
   Lynch HT, 1999, J MED GENET, V36, P801
   Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.0.CO;2-5
   Maliaka YK, 1996, HUM GENET, V97, P251, DOI 10.1007/BF02265276
   Mangold E, 2005, INT J CANCER, V116, P692, DOI 10.1002/ijc.20863
   Mauillon JL, 1996, CANCER RES, V56, P5728
   Millar AL, 1999, HUM MOL GENET, V8, P823, DOI 10.1093/hmg/8.5.823
   MIYAKI M, 1995, J MOL MED-JMM, V73, P515
   MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305
   Montera M, 2000, J Med Genet, V37, pE7, DOI 10.1136/jmg.37.7.e7
   Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245
   Nilbert M, 2009, FAM CANCER, V8, P75, DOI 10.1007/s10689-008-9199-3
   Nomura S, 2000, BIOCHEM BIOPH RES CO, V271, P120, DOI 10.1006/bbrc.2000.2547
   NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763
   Palicio M, 2002, J Med Genet, V39, pE29, DOI 10.1136/jmg.39.6.e29
   PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251
   Papp J, 2007, WORLD J GASTROENTERO, V13, P2727, DOI 10.3748/wjg.v13.i19.2727
   Park JG, 1999, INT J CANCER, V82, P516, DOI 10.1002/(SICI)1097-0215(19990812)82:4<516::AID-IJC8>3.0.CO;2-U
   Peel DJ, 2000, J NATL CANCER I, V92, P1517, DOI 10.1093/jnci/92.18.1517
   Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509
   Pensotti V, 1997, GENE CHROMOSOME CANC, V19, P135
   Percesepe A, 2001, J CLIN ONCOL, V19, P3944, DOI 10.1200/JCO.2001.19.19.3944
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Pinol V, 2005, JAMA-J AM MED ASSOC, V293, P1986, DOI 10.1001/jama.293.16.1986
   Pistorius SR, 2000, INT J COLORECTAL DIS, V15, P255
   Planck M, 1999, INT J CANCER, V83, P197, DOI 10.1002/(SICI)1097-0215(19991008)83:2<197::AID-IJC9>3.0.CO;2-X
   Pucciarelli S, 2003, DIS COLON RECTUM, V46, P305, DOI 10.1097/01.DCR.0000054881.56204.F3
   Raedle J, 2001, ANN INTERN MED, V135, P566, DOI 10.7326/0003-4819-135-8_Part_1-200110160-00007
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Ravnik-Glavac M, 2000, J MED GENET, V37, P533, DOI 10.1136/jmg.37.7.533
   Robinson KL, 2007, J NATL CANCER I, V99, P291, DOI 10.1093/jnci/djk051
   Roh SA, 2003, J KOREAN MED SCI, V18, P387, DOI 10.3346/jkms.2003.18.3.387
   Rossi BM, 2002, ANN SURG ONCOL, V9, P555, DOI 10.1245/aso.2002.9.6.555
   Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193
   Samowitz WS, 2001, GASTROENTEROLOGY, V121, P830, DOI 10.1053/gast.2001.27996
   Sarroca C, 2000, DIS COLON RECTUM, V43, P353, DOI 10.1007/BF02258301
   Scartozzi M, 2002, J CLIN ONCOL, V20, P1203, DOI 10.1200/JCO.20.5.1203
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Scott RJ, 2001, AM J HUM GENET, V68, P118, DOI 10.1086/316942
   Sheng J Q, 2008, Cytogenet Genome Res, V122, P22, DOI 10.1159/000151312
   Sheng Jian Qiu, 2006, Chin J Dig Dis, V7, P197, DOI 10.1111/j.1443-9573.2006.00269.x
   Shin Young-Kyoung, 2004, Hum Mutat, V24, P351, DOI 10.1002/humu.9277
   Southey MC, 2005, J CLIN ONCOL, V23, P6524, DOI 10.1200/JCO.2005.04.671
   Spaepen M, 2006, FAM CANCER, V5, P179, DOI 10.1007/s10689-005-5958-6
   Syngal S, 1999, JAMA-J AM MED ASSOC, V282, P247, DOI 10.1001/jama.282.3.247
   TANNERGARD P, 1995, CANCER RES, V55, P6092
   Taylor CE, 2003, HUM MUTAT, V22, P428, DOI 10.1002/humu.10291
   Terdiman JP, 2001, GASTROENTEROLOGY, V120, P21, DOI 10.1053/gast.2001.20874
   Tomlinson IPM, 1997, J MED GENET, V34, P39, DOI 10.1136/jmg.34.1.39
   Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034
   Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X
   Vasen HFA, 2001, J CLIN ONCOL, V19, P4074, DOI 10.1200/JCO.2001.19.20.4074
   Viel A, 1997, GENE CHROMOSOME CANC, V18, P8, DOI 10.1002/(SICI)1098-2264(199701)18:1<8::AID-GCC2>3.0.CO;2-7
   Wagner A, 2003, AM J HUM GENET, V72, P1088, DOI 10.1086/373963
   Wahlberg SS, 1997, INT J CANCER, V74, P134, DOI 10.1002/(SICI)1097-0215(19970220)74:1<134::AID-IJC22>3.3.CO;2-1
   Wang CF, 2007, WORLD J GASTROENTERO, V13, P6254, DOI 10.3748/wjg.13.6254
   Wang Q, 1999, HUM GENET, V105, P79, DOI 10.1007/s004390051067
   Wang Q, 1997, INT J CANCER, V73, P831, DOI 10.1002/(SICI)1097-0215(19971210)73:6<831::AID-IJC11>3.0.CO;2-7
   Wang XL, 2006, WORLD J GASTROENTERO, V12, P4074, DOI 10.3748/wjg.v12.i25.4074
   Weber TK, 1999, JAMA-J AM MED ASSOC, V281, P2316, DOI 10.1001/jama.281.24.2316
   Weber TK, 1997, CANCER RES, V57, P3798
   Wehner M, 1997, HUM MUTAT, V10, P241
   Wei SC, 2003, CLIN GENET, V64, P243, DOI 10.1034/j.1399-0004.2003.00123.x
   Wei WQ, 2010, J BIOINFORM COMPUT B, V8, P111, DOI 10.1142/S0219720010005154
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X
   Wijnen J, 1998, NAT GENET, V20, P326
   Wijnen J, 1997, AM J HUM GENET, V61, P329, DOI 10.1086/514847
   Wolf B, 2005, WIEN KLIN WOCHENSCHR, V117, P269, DOI 10.1007/s00508-005-0337-8
   Wu Y, 1997, GENE CHROMOSOME CANC, V18, P269, DOI 10.1002/(SICI)1098-2264(199704)18:4<269::AID-GCC4>3.0.CO;2-Z
   Yan HL, 2008, CANCER SCI, V99, P770, DOI 10.1111/j.1349-7006.2008.00737.x
   Yuan Y, 2004, CHINESE MED J-PEKING, V117, P748
   Yuen ST, 2002, ONCOGENE, V21, P7585, DOI 10.1038/sj.onc.1205968
   Zhang CH, 2008, WORLD J GASTROENTERO, V14, P298, DOI 10.3748/wjg.14.298
   Zhao YS, 2009, J TOXICOL ENV HEAL A, V72, P690, DOI 10.1080/15287390902841003
NR 137
TC 5
Z9 5
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 19
PY 2013
VL 8
IS 3
AR e51240
DI 10.1371/journal.pone.0051240
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 125SR
UT WOS:000317562100002
PM 23526924
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xi, B
   Chen, M
   Chandak, GR
   Shen, Y
   Yan, L
   He, J
   Mou, SH
AF Xi, Bo
   Chen, Man
   Chandak, Giriraj R.
   Shen, Yue
   Yan, Li
   He, Juan
   Mou, Si-Hua
TI STK39 Polymorphism Is Associated with Essential Hypertension: A
   Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; BLOOD-PRESSURE; EAST ASIANS; GENETIC-VARIANTS;
   DISEASE; CHINESE; RISK; REPLICATION; SPAK; BIAS
AB Background: A recent genome-wide association study identified STK39as a candidate gene for blood pressure (BP) in Europeans. Subsequently, several studies have attempted to replicate the association across different ethnic populations. However, the results have been inconsistent.
   Objective and Methods: We performed a meta-analysis to elucidate the association between the STK39 rs3754777 polymorphism (or proxy) and hypertension. Published literature from PubMed and Embase databases were retrieved and pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using fixed-or random-effects model.
   Results: Using appropriate inclusion/exclusion criteria, we identified 10 studies that included 21, 863 hypertensive cases and 24, 480 controls from different ethnicities. The meta-analysis showed a significant association of STK39 rs3754777 variant with hypertension (OR = 1.10, 95% CI = 1.06-1.15, p = 7.95x10(-6)). Further subgroup analysis by ethnicity suggested that the association was significant in Europeans (OR = 1.08, 95% CI = 1.03-1.14, p = 0.002) and in East Asians (OR = 1.16, 95% CI = 1.07-1.25, p = 4.34x10(-4)), but not in Africans (OR = 1.01, 95% CI 0.80-1.27, p = 0.932). We further confirmed the positive association by sensitivity analysis. No publication bias was detected (Begg's test, p = 0.721; Egger's test, p = 0.744).
   Conclusions: The present meta-analysis confirms the significant association of STK39 polymorphism with susceptibility to hypertension in Europeans and East Asians. Future studies should include gene-gene and gene-environment interactions to investigate the identified association.
C1 [Xi, Bo] Shandong Univ, Sch Publ Hlth, Inst Maternal & Child Hlth Care, Jinan 250100, Peoples R China.
   [Chen, Man] Chengdu Med Coll, Sch Lab Med, Chengdu, Peoples R China.
   [Chandak, Giriraj R.] CSIR, Ctr Cellular & Mol Biol, Hyderabad, Andhra Pradesh, India.
   [Shen, Yue] Capital Inst Pediat, Dept Epidemiol, Beijing, Peoples R China.
   [Yan, Li] Dalian Med Univ, Dept Social Med & Hlth Serv Management, Dalian, Peoples R China.
   [He, Juan] Kunming Gen Hosp Chengdu Mil Commend, Dept Pharm, Kunming, Peoples R China.
   [Mou, Si-Hua] Taizhou Municipal Hosp, Dept Clin Lab, Taizhou, Peoples R China.
RP Mou, SH (reprint author), Taizhou Municipal Hosp, Dept Clin Lab, Taizhou, Peoples R China.
EM sihuamou@163.com
OI Chandak, Giriraj Ratan/0000-0002-3095-9453
FU Foundation for Outstanding Young Scientist in Shandong Province
   [BS2011YY026]; Independent Innovation Foundation of Shandong University
   [2010GN046]
FX This study was supported by the Foundation for Outstanding Young
   Scientist in Shandong Province (BS2011YY026) and the Independent
   Innovation Foundation of Shandong University (2010GN046). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Adeyemo A, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000564
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen LY, 2012, INT J CARDIOL, V154, P122, DOI 10.1016/j.ijcard.2010.09.007
   Cho YS, 2009, NAT GENET, V41, P527, DOI 10.1038/ng.357
   Cunnington MS, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-135
   Delpire E, 2008, BIOCHEM J, V409, P321, DOI 10.1042/BJ20071324
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ehret GB, 2011, NATURE, V478, P103, DOI 10.1038/nature10405
   Fava C, 2011, J HYPERTENS, V29, P484, DOI 10.1097/HJH.0b013e328342b2c1
   Kato N, 2011, NAT GENET, V43, P530, DOI 10.1038/ng.834
   Kidambi S, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-27
   Lawes CMM, 2008, LANCET, V371, P1513, DOI 10.1016/S0140-6736(08)60655-8
   Levy D, 2009, NAT GENET, V41, P677, DOI 10.1038/ng.384
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Newton-Cheh C, 2009, NAT GENET, V41, P666, DOI 10.1038/ng.361
   Niu WQ, 2011, J HUM HYPERTENS, V25, P278, DOI 10.1038/jhh.2010.114
   Persu A, 2011, J HYPERTENS, V29, P434, DOI 10.1097/HJH.0b013e328344b6b3
   Rafiqi FH, 2010, EMBO MOL MED, V2, P63, DOI 10.1002/emmm.200900058
   Rhee MY, 2011, HYPERTENS RES, V34, P606, DOI 10.1038/hr.2010.278
   Tanira M, 2005, J HUM HYPERTENS, V19, P7, DOI 10.1038/sj.jhh.1001780
   Wang Y, 2009, P NATL ACAD SCI USA, V106, P226, DOI 10.1073/pnas.0808358106
   Xi B, 2012, ATHEROSCLEROSIS, V225, P376, DOI 10.1016/j.atherosclerosis.2012.10.027
   Xi B, 2013, INT J CARDIOL, V165, P577, DOI 10.1016/j.ijcard.2012.09.032
   Xi B, 2013, METABOLISM, V62, P196, DOI 10.1016/j.metabol.2012.07.008
   Xi B, 2012, INT J CARDIOL, V158, P326, DOI 10.1016/j.ijcard.2012.04.140
   Xi B, 2012, BLOOD PRESSURE, V21, P134, DOI 10.3109/08037051.2012.632845
   Xu J, 2013, J HUM HYPERTENS, V27, P294, DOI 10.1038/jhh.2012.46
NR 28
TC 15
Z9 15
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 18
PY 2013
VL 8
IS 3
AR e59584
DI 10.1371/journal.pone.0059584
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 109ZS
UT WOS:000316411600065
PM 23527223
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, RF
   Song, Y
   Zhou, YY
   Sun, LL
AF Zhang, Ruifang
   Song, Yi
   Zhou, Yuanyuan
   Sun, Lulu
TI Comparison of Aortic Annulus Diameter Measurement between Multi-Detector
   Computed Tomography and Echocardiography: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID VALVE IMPLANTATION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; REPLACEMENT;
   STENOSIS; REGURGITATION; PROSTHESIS; DIMENSIONS; BIAS; ROOT
AB Background and Purpose: Accurate measurement of aortic annulus diameter is crucial for choosing suitable prosthetic size for transcatheter aortic valve implantation (TAVI). Several imaging methods are available for the measurement, but significant variability between different modalities has been observed. The purpose of this study was to systematically compare the measurements of aortic annulus diameter between multi-detector computed tomography (MDCT), transthoracic echocardiography (TTE), and transesophegeal echocardiography (TEE).
   Methods: PubMed and EMBASE databases between January 2000 and January 2012 were searched. We extracted data from eligible studies evaluating the aortic annulus diameter by MDCT and echocardiography (TTE, TEE, or both). We performed a random-effects meta-analysis to calculate the weighted mean differences of aortic annulus diameter measurement between MDCT, TTE, and TEE.
   Results: A total of 10 eligible studies involving 581 subjects with aortic valve stenosis were included. Aortic annulus diameter measured on coronal view by MDCT (25.3 +/- 0.52 mm) was respectively larger than that measured on sagittal view by MDCT (22.7 +/- 0.37 mm), TTE (22.6 +/- 0.28 mm), and TEE (23.1 +/- 0.32 mm). The weighted mean difference of aortic annulus diameter between coronal view by MDCT and TTE these two methods was 2.97 mm, followed by the weighted mean difference of 2.53 mm between coronal view and sagittal view by MDCT, and the mean difference of 1.74 mm between coronal view on MDCT and TEE (P<0.0001 for all). The weighted mean difference of aortic annulus diameter measurement between TEE and TTE was significant but somewhat small (0.45 mm, P = 0.007).
   Conclusion: Aortic annulus diameter measured on coronal view by MDCT was robustly and significantly larger than that obtained on sagittal view by MDCT, TTE, or TEE. Such variability of aortic annulus diameter measurement by different imaging modalities cannot be ignored when developing optimal strategies for selection of prosthetic valve size in TAVI.
C1 [Zhang, Ruifang; Song, Yi; Zhou, Yuanyuan; Sun, Lulu] Zhengzhou Univ, Affiliated Hosp 1, Dept Ultrasound, Zhengzhou, Henan Province, Peoples R China.
RP Zhang, RF (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Ultrasound, Zhengzhou, Henan Province, Peoples R China.
EM zhangruifang999@hotmail.com
CR Altiok E, 2011, HEART, V97, P1578, DOI 10.1136/hrt.2011.223974
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cribier A, 2002, CIRCULATION, V106, P3006, DOI 10.1161/01.CIR.0000047200.36165.B8
   Dashkevich A, 2011, ANN THORAC SURG, V91, P709, DOI 10.1016/j.athoracsur.2010.09.038
   Delgado V, 2010, EUR HEART J, V31, P1114, DOI 10.1093/eurheartj/ehq018
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Detaint D, 2009, JACC-CARDIOVASC INTE, V2, P821, DOI 10.1016/j.jcin.2009.07.003
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gurvitch R, 2011, JACC-CARDIOVASC INTE, V4, P1235, DOI 10.1016/j.jcin.2011.07.014
   Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D
   Helton TJ, 2011, INT J CARDIOVAS IMAG, V27, P1143, DOI 10.1007/s10554-011-9825-2
   Hutter A, 2010, CATHETER CARDIO INTE, V76, P1009, DOI 10.1002/ccd.22654
   Jabbour A, 2011, J AM COLL CARDIOL, V58, P2165, DOI 10.1016/j.jacc.2011.09.010
   Koos R, 2011, INT J CARDIOL, V158, P353
   LaBounty TM, 2008, AM J ROENTGENOL, V191, P1652, DOI 10.2214/AJR.07.3703
   Leon MB, 2010, NEW ENGL J MED, V363, P1597, DOI 10.1056/NEJMoa1008232
   Rubio DM, 2011, ECHOCARDIOGR-J CARD, V28, P388, DOI 10.1111/j.1540-8175.2010.01353.x
   Messika-Zeitoun D, 2010, J AM COLL CARDIOL, V55, P186, DOI 10.1016/j.jacc.2009.06.063
   Mizia-Stec K, 2012, INT J CARDIOVAS IMAG, V28, P343, DOI 10.1007/s10554-010-9784-z
   Moss RR, 2008, JACC-CARDIOVASC IMAG, V1, P15, DOI 10.1016/j.jcmg.2007.09.004
   Ng ACT, 2010, CIRC-CARDIOVASC IMAG, V3, P94, DOI 10.1161/CIRCIMAGING.109.885152
   Sherif MA, 2010, J AM COLL CARDIOL, V56, P1623, DOI 10.1016/j.jacc.2010.06.035
   Tops LF, 2008, JACC-CARDIOVASC IMAG, V1, P321, DOI 10.1016/j.jcmg.2007.12.006
   Tzikas A, 2011, CATHETER CARDIO INTE, V77, P868, DOI 10.1002/ccd.22761
   Webb JG, 2007, CIRCULATION, V116, P755, DOI 10.1161/CIRCULATIONAHA.107.698258
   Wood DA, 2009, AM J CARDIOL, V103, P1295, DOI 10.1016/j.amjcard.2009.01.034
   Zajarias A, 2009, J AM COLL CARDIOL, V53, P1829, DOI 10.1016/j.jacc.2008.11.059
NR 27
TC 7
Z9 7
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 14
PY 2013
VL 8
IS 3
AR e58729
DI 10.1371/journal.pone.0058729
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 109YM
UT WOS:000316407400055
PM 23516543
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhu, W
   Wu, Y
   Xu, D
   Li, YH
   Ba, J
   Zhang, XL
   Wang, F
   Yu, J
AF Zhu, Wei
   Wu, Yan
   Xu, Ding
   Li, Yan-Hong
   Ba, Jun
   Zhang, Xiao-Long
   Wang, Fang
   Yu, Jing
TI Aspirin Use and Risk of Age-Related Macular Degeneration: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID LOW-DOSE ASPIRIN; CHOROIDAL NEOVASCULARIZATION; INTRAOCULAR HEMORRHAGE;
   CARDIOVASCULAR-DISEASE; RANDOMIZED-TRIAL; 5-YEAR INCIDENCE; DECREASED
   RATES; MEDICATION USE; MACULOPATHY; EYE
AB Background: Age-related macular degeneration (AMD) is the main cause of blindness and the curative options are limited. The objective of this meta-analysis was to determine the association between aspirin use and risk of AMD.
   Methods: A comprehensive literature search was performed in PubMed, Embase, Web of Science, and reference lists. A meta-analysis was performed by STATA software.
   Results: Ten studies involving 171729 individuals examining the association between aspirin use and risk of AMD were included. Among the included studies, 2 were randomized-controlled trials (RCTs), 4 were case-control studies and 4 were cohort studies. The relative risks (RRs) were pooled using a random-effects model. Relative risks with 95% confidence intervals (CIs) of aspirin use as a risk for AMD. The pooled RR of 10 included studies between the use of aspirin and risk of AMD was 1.09 (95% CI, 0.96-1.24). The same result was detected in early and late stage AMD subgroup analysis. In the subgroup analyses, the pooled RR of RCTs, case-control studies and cohort studies were 0.81 (95% CI, 0.64-1.02), 1.02 (95% CI, 0.92-1.14) and 1.08 (95% CI, 0.91-1.28), respectively.
   Conclusions: The use of aspirin was not associated with the risk of AMD.
C1 [Zhu, Wei; Wu, Yan; Xu, Ding; Li, Yan-Hong; Ba, Jun; Wang, Fang; Yu, Jing] Tongji Univ, Affiliated Peoples Hosp 10, Dept Ophthalmol, Shanghai 200092, Peoples R China.
   [Zhu, Wei; Wu, Yan; Zhang, Xiao-Long] Nanjing Med Univ, Dept Clin Med Coll 1, Nanjing, Jiangsu, Peoples R China.
RP Yu, J (reprint author), Tongji Univ, Affiliated Peoples Hosp 10, Dept Ophthalmol, Shanghai 200092, Peoples R China.
EM dryujing@yahoo.com.cn
FU National Nature Science Foundation [30901643]; Shanghai Science
   Committee Biology Department Pilot Project [10411964900]; New Excellence
   Project of Shanghai Health Bureau [XYQ2011067]
FX This work was supported in whole or in part, by National Nature Science
   Foundation Project (30901643), Shanghai Science Committee Biology
   Department Pilot Project (10411964900) and The New Excellence Project of
   Shanghai Health Bureau (XYQ2011067). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1991, Ophthalmology, V98, P757
   Ayyadevara S, 2012, ANTIOXID REDOX SIGNA
   Baron JA, 2012, JNCI-J NATL CANCER I, V104, P1199, DOI 10.1093/jnci/djs338
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Becker RC, 2008, CHEST, V133, p776S, DOI 10.1378/chest.08-0685
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   de Jong PTVM, 2010, OPHTHALMOLOGY, V117, P1279, DOI 10.1016/j.ophtha.2010.03.011
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Diehl AK, 2012, ANN INTERN MED, V157, pJC1
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Gagne JJ, 2010, NEUROLOGY, V74, P995, DOI 10.1212/WNL.0b013e3181d5a4a3
   Gaynes BI, 2004, AM J OPHTHALMOL, V138, P1089, DOI 10.1016/j.ajo.2004.08.048
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   KINGHAM JD, 1988, NEW ENGL J MED, V318, P1126
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   KLEIN ML, 1991, JAMA-J AM MED ASSOC, V266, P2279
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mascitelli L, 2010, MED HYPOTHESES, V74, P754, DOI 10.1016/j.mehy.2009.11.009
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Moon BG, 2012, J KOREAN MED SCI, V27, P537, DOI 10.3346/jkms.2012.27.5.537
   Nandish S, 2011, AM J CARDIOL, V108, p42B, DOI 10.1016/j.amjcard.2011.03.015
   Olea JL, 2012, EUR J OPHTHALMOL, V22, P404, DOI 10.5301/ejo.5000023
   Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613
   Rudnicka AR, 2010, EYE, V24, P1199, DOI 10.1038/eye.2010.8
   Samoocha David, 2010, J Med Internet Res, V12, pe23, DOI 10.2196/jmir.1286
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Yoshinaga N, 2011, LAB INVEST, V91, P1277, DOI 10.1038/labinvest.2011.101
NR 55
TC 23
Z9 23
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 14
PY 2013
VL 8
IS 3
AR e58821
DI 10.1371/journal.pone.0058821
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 109YM
UT WOS:000316407400066
PM 23516561
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Bianco, A
   Quaresima, B
   Pileggi, C
   Faniello, MC
   De Lorenzo, C
   Costanzo, F
   Pavia, M
AF Bianco, Aida
   Quaresima, Barbara
   Pileggi, Claudia
   Faniello, Maria Concetta
   De Lorenzo, Carlo
   Costanzo, Francesco
   Pavia, Maria
TI Polymorphic Repeat Length in the AIB1 Gene and Breast Cancer Risk in
   BRCA1 and BRCA2 Mutation Carriers: A Meta-Analysis of Observational
   Studies
SO PLOS ONE
LA English
DT Article
ID OVARIAN-CANCER; POLYGLUTAMINE REPEAT; IN-VITRO; GERMLINE MUTATIONS;
   SYSTEMATIC REVIEWS; MISSENSE MUTATIONS; SUSCEPTIBILITY; BIAS; QUALITY;
   EPIDEMIOLOGY
AB Objectives: We carried out a meta-analysis focusing on the relationship between length of AIB1 gene poly-Q repeat domain as a modifier of breast cancer (BC) susceptibility in patients with BRCA1 and BRCA2 mutation carriers.
   Data sources: We searched MEDLINE and EMBASE for all medical literature published until February, 2012.
   Study Eligibility criteria: Studies were included in the meta-analysis if they met all the predetermined criteria, such as: (a) case-control or cohort studies; (b) the primary outcome was clearly defined as BC; (c) the exposure of interest measured was AIB1 polyglutamine repeat length genotype; (d) provided relative risk (RR) or odds ratio (OR) estimates and their 95% confidence intervals (CIs).
   Synthesis methods: Two of the authors independently evaluated the quality of the studies included and extracted the data. Meta-analyses were performed for case-control and cohort studies separately. Heterogeneity was examined and the publication bias was assessed with a funnel plot for asymmetry.
   Result: 7 studies met our predetermined inclusion criteria and were included in the meta-analysis. Overall quality ratings of the studies varied from 0.36 to 0.77, with a median of 0.5. The overall RR estimates of 29/29 poly-Q repeats on risk of BC in BRCA1/2, BRCA1, and BRCA2, were always greater than 1.00; however, this effect was not statistically significant. In the meta-analysis of studies reporting the effect of 28/28 poly-Q repeats on risk of BC in BRCA1/2, BRCA1, and BRCA2, the overall RR decreased below 1.00; however, this effect was not statistically significant. Similar estimates were shown for at least 1 allele of <= 26 repeats.
   Conclusions: Genotypes of AIB1 polyglutamine polymorphism analyzed do not appear to be associated to a modified risk of BC development in BRCA1 and BRCA2 mutation carriers. Future research on length of poly-Q repeat domain and BC susceptibility should be discouraged and more promising potential sources of penetrance variation among BRCA1 and BRCA2 mutation carriers should be investigated.
C1 [Bianco, Aida; Pileggi, Claudia; Pavia, Maria] Univ Catanzaro Magna Graecia, Dept Hlth Sci, Catanzaro, Italy.
   [Quaresima, Barbara; Faniello, Maria Concetta; De Lorenzo, Carlo; Costanzo, Francesco] Univ Catanzaro Magna Graecia, Dept Expt & Clin Med, Catanzaro, Italy.
RP Pavia, M (reprint author), Univ Catanzaro Magna Graecia, Dept Hlth Sci, Catanzaro, Italy.
EM pavia@unicz.it
RI Costanzo, Francesco Saverio/K-3168-2018; Bianco, Aida/R-6612-2016
OI Costanzo, Francesco Saverio/0000-0002-3096-9416; PILEGGI,
   Claudia/0000-0002-6288-5540; De Lorenzo, Carlo/0000-0002-2579-683X;
   FANIELLO, Concetta Maria/0000-0001-6938-2754; PAVIA,
   Maria/0000-0003-3879-1322
CR Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033
   Antoniou AC, 2008, BRIT J CANCER, V98, P1457, DOI 10.1038/sj.bjc.6604305
   Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   Bautista S, 1998, CLIN CANCER RES, V4, P2925
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Begg CB, 2008, JAMA-J AM MED ASSOC, V299, P194, DOI 10.1001/jama.2007.55-a
   Colilla S, 2006, CARCINOGENESIS, V27, P599, DOI 10.1093/carcin/bgi246
   Crugliano T, 2007, INT J BIOCHEM CELL B, V39, P220, DOI 10.1016/j.biocel.2006.08.005
   De Vito C, 2007, VACCINE, V25, P8794, DOI 10.1016/j.vaccine.2007.10.034
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302
   FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399
   GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428
   GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B
   Haiman CA, 2000, BREAST CANCER RES, V2, P378, DOI 10.1186/bcr82
   Hughes DJ, 2005, INT J CANCER, V117, P230, DOI 10.1002/ijc.21176
   Jakubowska A, 2010, BREAST CANCER RES TR, V119, P201, DOI 10.1007/s10549-009-0390-5
   Kadouri L, 2004, INT J CANCER, V108, P399, DOI 10.1002/ijc.11531
   Kleibl Z, 2011, J CANCER RES CLIN, V137, P331, DOI 10.1007/s00432-010-0889-5
   Laird N M, 1990, Int J Technol Assess Health Care, V6, P5
   Manzoli L, 2012, DRUG SAFETY, V35, P191, DOI 10.2165/11598050-000000000-00000
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Milne RL, 2008, CLIN CANCER RES, V14, P2861, DOI 10.1158/1078-0432.CCR-07-4436
   Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3
   Montgomery KG, 2005, BREAST CANCER RES, V7, pR353, DOI 10.1186/bcr1009
   O'Connell D, 2005, NEWCASTLE OTTAWA SCA
   Osorio A, 2011, BRIT J CANCER, V104, P1356, DOI 10.1038/bjc.2011.91
   Pavia M, 2003, B WORLD HEALTH ORGAN, V81, P732
   Pavia M, 2006, AM J CLIN NUTR, V83, P1126
   Quaresima B, 2008, CLIN CANCER RES, V14, P6797, DOI 10.1158/1078-0432.CCR-07-5208
   Quaresima B, 2006, HUM MUTAT, V27, P715, DOI 10.1002/humu.9427
   Quaresima B, 2006, ONCOL REP, V16, P811
   Rebbeck TR, 2001, CANCER RES, V61, P5420
   Sanderson S, 2007, INT J EPIDEMIOL, V36, P666, DOI 10.1093/ije/dym018
   Shirazi SK, 1998, CLIN GENET, V54, P102
   Sinilnikova OM, 2009, BRIT J CANCER, V101, P1456, DOI 10.1038/sj.bjc.6605279
   Spurdle AB, 2005, BREAST CANCER RES, V7, pR176, DOI 10.1186/bcr971
   Spurdle AB, 2006, CANCER EPIDEM BIOMAR, V15, P76, DOI 10.1158/1055-9965.EPI-05-0709
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   StataCorp, 2009, STAT REL 11 STAT SOF
   Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008
   Wong WCW, 2008, EMERG THEMES EPIDEMI, V5, DOI 10.1186/1742-7622-5-23
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
   Yang QF, 2001, CANCER-AM CANCER SOC, V92, P54, DOI 10.1002/1097-0142(20010701)92:1<54::AID-CNCR1291>3.0.CO;2-8
   Zhang Y, 2012, MOL BIOL REP, V39, P6881, DOI 10.1007/s11033-012-1514-2
NR 47
TC 0
Z9 0
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 6
PY 2013
VL 8
IS 3
AR e57781
DI 10.1371/journal.pone.0057781
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 117EP
UT WOS:000316936100044
PM 23483928
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xu, X
   Wu, J
   Mao, YQ
   Zhu, Y
   Hu, ZH
   Xu, XL
   Lin, YW
   Chen, H
   Zheng, XY
   Qin, J
   Xie, LP
AF Xu, Xin
   Wu, Jian
   Mao, Yeqing
   Zhu, Yi
   Hu, Zhenghui
   Xu, Xianglai
   Lin, Yiwei
   Chen, Hong
   Zheng, Xiangyi
   Qin, Jie
   Xie, Liping
TI Diabetes Mellitus and Risk of Bladder Cancer: A Meta-Analysis of Cohort
   Studies
SO PLOS ONE
LA English
DT Article
ID POPULATION-BASED COHORT; GROWTH-FACTOR-I; WOMENS HEALTH; MORTALITY;
   SWEDEN; BIAS; DENMARK; MEN
AB Objective: Diabetes is associated with increased risk of cancer at several sites, but its association with risk of bladder cancer is still controversial. We examined this association by conducting a systematic review and meta-analysis of cohort studies.
   Methods: Studies were identified by searching PubMed, EMBASE, Scopus, Web of Science, Cochrane register, and Chinese National Knowledge Infrastructure (CNKI) databases through April 29, 2012. Summary relative risks (SRRs) with their corresponding 95% confidence intervals (CIs) were calculated using a random-effects model.
   Results: A total of fifteen cohort studies were included in this meta-analysis. Analysis of all studies showed that diabetes was associated with a borderline statistically significant increased risk of bladder cancer (RR 1.11, 95% CI 1.00-1.23; p < 0.001 for heterogeneity; I-2 = 84%). When restricting the analysis to studies that had adjusted for cigarette smoking (n = 6) or more than three confounders (n = 7), the RRs were 1.32 (95% CI 1.18-1.49) and 1.20 (95% CI 1.02-1.42), respectively. There was no significant publication bias (p = 0.62 for Egger's regression asymmetry test).
   Conclusions: Our findings support that diabetes was associated with an increased risk of bladder cancer. More future studies are warranted to get a better understanding of the association and to provide convincing evidence for clinical practice in bladder cancer prevention.
C1 [Xu, Xin; Wu, Jian; Mao, Yeqing; Zhu, Yi; Hu, Zhenghui; Xu, Xianglai; Lin, Yiwei; Chen, Hong; Zheng, Xiangyi; Qin, Jie; Xie, Liping] Zhejiang Univ, Dept Urol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China.
RP Xie, LP (reprint author), Zhejiang Univ, Dept Urol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China.
EM xielp@zjuem.zju.edu.cn
RI zheng, xiang-yi/C-3752-2012
FU National Key Clinical Specialty Construction Project of China; Key
   medical disciplines of Zhejiang province; Combination of traditional
   Chinese and Western medicine key disciplines of Zhejiang Province
   [2012-XK-A23]; Health sector scientific research special project
   [201002010]; National Natural Science Foundation of China [30900552];
   Zhejiang Provincial Natural Science Foundation of China [Z2090356]
FX This study was supported by grants from National Key Clinical Specialty
   Construction Project of China, Key medical disciplines of Zhejiang
   province, Combination of traditional Chinese and Western medicine key
   disciplines of Zhejiang Province (2012-XK-A23), Health sector scientific
   research special project (201002010), National Natural Science
   Foundation of China (Grant No. 30900552) and Zhejiang Provincial Natural
   Science Foundation of China (Z2090356). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ADAMI HO, 1991, CANCER CAUSE CONTROL, V2, P307, DOI 10.1007/BF00051670
   Atchison EA, 2011, INT J CANCER, V128, P635, DOI 10.1002/ijc.25362
   Attner B, 2012, CANCER CAUSE CONTROL, V23, P769, DOI 10.1007/s10552-012-9946-5
   Azoulay L, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3645
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Ben QW, 2011, EUR J CANCER, V47, P1928, DOI 10.1016/j.ejca.2011.03.003
   Burger M, 2012, EUR UROL
   Chaturvedi AK, 2008, ANN EPIDEMIOL, V18, P230, DOI 10.1016/j.annepidem.2007.10.005
   Chen HS, 2012, UROLOGY, V79, P86, DOI 10.1016/j.urology.2011.07.1431
   Clow WH, 1997, J NATL CANCER I, V89, P1453
   Coughlin SS, 2004, AM J EPIDEMIOL, V159, P1160, DOI 10.1093/aje/kwh161
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dunn SE, 1997, CANCER RES, V57, P4667
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Funfstuck R, 2012, CLIN NEPHROL, V77, P40, DOI 10.5414/CN107216
   Hemminki K, 2010, ONCOLOGIST, V15, P548, DOI 10.1634/theoncologist.2009-0300
   Inoue M, 2006, ARCH INTERN MED, V166, P1871, DOI 10.1001/archinte.166.17.1871
   Jankovic S, 2007, TUMORI, V93, P4
   Jee SH, 2005, JAMA-J AM MED ASSOC, V293, P194, DOI 10.1001/jama.293.2.194
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jones ME, 1998, AM J EPIDEMIOL, V148, P1012
   Key TJ, 2010, LANCET ONCOL, V11, P530, DOI 10.1016/S1470-2045(10)70095-4
   Khan Mmh, 2006, Asian Pac J Cancer Prev, V7, P253
   Larsson SC, 2006, DIABETOLOGIA, V49, P2819, DOI 10.1007/s00125-006-0468-0
   Larsson SC, 2011, DIABETOLOGIA, V54, P1013, DOI 10.1007/s00125-011-2051-6
   Larsson SC, 2008, EUR J CANCER, V44, P2655, DOI 10.1016/j.ejca.2008.07.012
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Lo SF, 2012, INT J CANC
   Margolis KL, 2008, CLIN TRIALS, V5, P240, DOI 10.1177/1740774508091749
   Murta-Nascimento C, 2007, WORLD J UROL, V25, P285, DOI 10.1007/s00345-007-0168-5
   Neumann A, 2012, DIABETOLOGIA, V55, P1953, DOI 10.1007/s00125-012-2538-9
   Ogunleye AA, 2009, BRIT J CANCER, V101, P1199, DOI 10.1038/sj.bjc.6605240
   Okura Y, 2004, J CLIN EPIDEMIOL, V57, P1096, DOI 10.1016/j.jclinepi.2004.04.005
   Ploeg M, 2009, WORLD J UROL, V27, P289, DOI 10.1007/s00345-009-0383-3
   RAGOZZINO M, 1982, J CHRON DIS, V35, P13, DOI 10.1016/0021-9681(82)90025-X
   Ren HB, 2011, CANCER CAUSE CONTROL, V22, P837, DOI 10.1007/s10552-011-9754-3
   Rinaldi S, 2010, INT J CANCER, V126, P1702, DOI 10.1002/ijc.24927
   Shu X, 2010, DIABETIC MED, V27, P791, DOI 10.1111/j.1464-5491.2010.03011.x
   Swerdlow AJ, 2005, BRIT J CANCER, V92, P2070, DOI 10.1038/sj.bjc.6602611
   Tripathi A, 2002, CANCER, V95, P2316, DOI 10.1002/cncr.10975
   Tseng CH, 2011, DIABETOLOGIA, V54, P2009, DOI 10.1007/s00125-011-2171-z
   Tseng CH, 2009, ANN MED, V41, P371, DOI 10.1080/07853890902729778
   Wideroff L, 1997, J NATL CANCER I, V89, P1360, DOI 10.1093/jnci/89.18.1360
   Woolcott CG, 2011, CANCER EPIDEMIOL, V35, P551, DOI 10.1016/j.canep.2011.02.014
   Wotton CJ, 2011, DIABETOLOGIA, V54, P527, DOI 10.1007/s00125-010-1987-2
   Yang WS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027326
   Yuhara H, 2011, AM J GASTROENTEROL, V106, P1911, DOI 10.1038/ajg.2011.301
   Zendehdel K, 2003, JNCI-J NATL CANCER I, V95, P1797, DOI 10.1093/jnci/djg105
   Zhao H, 2003, J UROLOGY, V169, P714, DOI 10.1097/01.ju.0000036380.10325.2a
NR 49
TC 18
Z9 19
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 5
PY 2013
VL 8
IS 3
AR e58079
DI 10.1371/journal.pone.0058079
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 099RC
UT WOS:000315637900079
PM 23472134
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Nelson, AW
   Harvey, RC
   Parker, RA
   Kastner, C
   Doble, A
   Gnanapragasam, VJ
AF Nelson, Adam W.
   Harvey, Rebecca C.
   Parker, Richard A.
   Kastner, Christof
   Doble, Andrew
   Gnanapragasam, Vincent J.
TI Repeat Prostate Biopsy Strategies after Initial Negative Biopsy:
   Meta-Regression Comparing Cancer Detection of Transperineal, Transrectal
   Saturation and MRI Guided Biopsy
SO PLOS ONE
LA English
DT Article
ID ANTIGEN LEVELS; ULTRASOUND BIOPSY; CORE DISTRIBUTION; NEEDLE-BIOPSY;
   HIGH-RISK; RESONANCE-SPECTROSCOPY; SEXTANT BIOPSIES; TEMPLATE BIOPSY;
   ENDORECTAL MRI; TUMOR FOCI
AB Introduction: There is no consensus on how to investigate men with negative transrectal ultrasound guided prostate biopsy (TRUS-B) but ongoing suspicion of cancer. Three strategies used are transperineal (TP-B), transrectal saturation (TS-B) and MRI-guided biopsy (MRI-B). We compared cancer yields of these strategies.
   Methods: Papers were identified by search of Pubmed, Embase and Ovid Medline. Included studies investigated biopsy diagnostic yield in men with at least one negative TRUS-B and ongoing suspicion of prostate cancer. Data including age, PSA, number of previous biopsy episodes, number of cores at re-biopsy, cancer yield, and Gleason score of detected cancers were extracted. Meta-regression analyses were used to analyse the data.
   Results: Forty-six studies were included; 12 of TS-B, 14 of TP-B, and 20 of MRI-B, representing 4,657 patients. Mean patient age, PSA and number of previous biopsy episodes were similar between the strategies. The mean number of biopsy cores obtained by TP-B and TS-B were greater than MRI-B. Cancer detection rates were 30.0%, 36.8%, and 37.6% for TS-B, TP-B, and MRI-B respectively. Meta-regression analysis showed that MRI-B had significantly higher cancer detection than TS-B. There were no significant differences however between MRI-B and TP-B, or TP-B and TS-B. In a sensitivity analysis incorporating number of previous biopsy episodes (36 studies) the difference between MRI-B and TP-B was not maintained resulting in no significant difference in cancer detection between the groups. There were no significant differences in median Gleason scores detected comparing the three strategies.
   Conclusions: In the re-biopsy setting, it is unclear which strategy offers the highest cancer detection rate. MRI-B may potentially detect more prostate cancers than other modalities and can achieve this with fewer biopsy cores. However, well-designed prospective studies with standardised outcome measures are needed to accurately compare modalities and define an optimum re-biopsy approach.
C1 [Nelson, Adam W.; Kastner, Christof; Doble, Andrew; Gnanapragasam, Vincent J.] Addenbrookes Hosp, Dept Urol, Cambridge CB2 2QQ, England.
   [Harvey, Rebecca C.; Parker, Richard A.] Univ Cambridge, Ctr Appl Med Stat, Cambridge, England.
   [Gnanapragasam, Vincent J.] Univ Cambridge, Translat Prostate Canc Grp, Hutchison MRC Res Ctr, Cambridge, England.
RP Gnanapragasam, VJ (reprint author), Addenbrookes Hosp, Dept Urol, Cambridge CB2 2QQ, England.
EM vjg29@cam.ac.uk
OI Harvey, Rebecca/0000-0001-8444-6365
CR Abdollah F, 2011, UROLOGY, V77, P921, DOI 10.1016/j.urology.2010.08.048
   Aganovic Damir, 2011, Med Arh, V65, P109
   Amsellem-Ouazana D, 2005, EUR UROL, V47, P582, DOI 10.1016/j.eururo.2005.01.015
   Anastasiadis AG, 2006, EUR UROL, V50, P738, DOI 10.1016/j.eururo.2006.03.007
   Bangma CH, 2012, CRIT REV ONCOL HEMAT
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beyersdorff D, 2002, RADIOLOGY, V224, P701, DOI 10.1148/radiol.2243011553
   Bhatia Cathleeyakorn, 2007, Journal of the Medical Association of Thailand, V90, P1391
   Bittner N, 2009, UROLOGY, V74, P171, DOI 10.1016/j.urology.2008.12.013
   Borboroglu PG, 2000, J UROLOGY, V163, P158, DOI 10.1016/S0022-5347(05)67994-3
   Bott SRJ, 2006, UROLOGY, V68, P1037, DOI 10.1016/j.urology.2006.05.033
   Cheikh AB, 2009, EUR RADIOL, V19, P770, DOI DOI 10.1007/S00330-008-1190-8
   Chiang IN, 2007, J FORMOS MED ASSOC, V106, P929, DOI 10.1016/S0929-6646(08)60063-7
   Cirillo S, 2008, CLIN RADIOL, V63, P871, DOI 10.1016/j.crad.2007.10.020
   D'Amico AV, 2000, J UROLOGY, V164, P385, DOI 10.1016/S0022-5347(05)67366-1
   Demura T, 2005, CANCER-AM CANCER SOC, V103, P1826, DOI 10.1002/cncr.21020
   Dimmen M, 2012, BJU INT, V110, pE69, DOI 10.1111/j.1464-410X.2011.10759.x
   Eichler K, 2006, J UROLOGY, V175, P1605, DOI 10.1016/S0022-5347(05)00957-2
   Engelhard K, 2006, EUR RADIOL, V16, P1237, DOI 10.1007/s00330-005-0100-6
   Fleshner N, 2002, UROLOGY, V60, P93, DOI 10.1016/S0090-4295(02)01625-4
   Franiel T, 2011, RADIOLOGY, V259, P162, DOI 10.1148/radiol.10101251
   Furuno T, 2004, PROSTATE, V58, P76, DOI 10.1002/pros.10298
   Hadaschik BA, 2011, J UROLOGY, V186, P2214, DOI 10.1016/j.juro.2011.07.102
   Hambrock T, 2010, J UROLOGY, V183, P520, DOI 10.1016/j.juro.2009.10.022
   Heidenreich A, 2011, EUR UROL, V59, P61, DOI 10.1016/j.eururo.2010.10.039
   Hoeks CMA, 2012, EUR UROL, V62, P902, DOI 10.1016/j.eururo.2012.01.047
   Igel TC, 2001, J UROLOGY, V165, P1575, DOI 10.1016/S0022-5347(05)66351-3
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   Lattouf JB, 2007, BJU INT, V99, P1041, DOI 10.1111/j.1464-410X.2006.06690.x
   Lawrence EM, 2012, NAT REV UROL, V9, P94, DOI 10.1038/nrurol.2011.222
   Lawrentschuk N, 2009, BJU INT, V103, P730, DOI 10.1111/j.1464-410X.2008.08205.x
   Luciani LG, 2006, UROLOGY, V67, P555, DOI 10.1016/j.urolog.2005.09.036
   Merrick GS, 2007, EUR UROL, V52, P715, DOI 10.1016/j.eururo.2007.02.041
   Miyagawa T, 2010, INT J UROL, V17, P855, DOI 10.1111/j.1442-2042.2010.02612.x
   Moore CM, 2013, EUR UROL, V63, P125, DOI 10.1016/j.eururo.2012.06.004
   Moran BJ, 2006, J UROLOGY, V176, P1376, DOI 10.1016/j.juro.2006.06.030
   Novara G, 2010, BJU INT, V105, P1242, DOI 10.1111/j.1464-410X.2009.08954.x
   Pal RP, 2012, BJU INT, V109, P367, DOI 10.1111/j.1464-410X.2011.10355.x
   Park BK, 2008, INVEST RADIOL, V43, P789, DOI 10.1097/RLI.0b013e318183725e
   Patel AR, 2004, UROLOGY, V63, P87, DOI 10.1016/j.urology.2003.08.040
   Pepe P, 2007, UROLOGY, V70, P1131, DOI 10.1016/j.urology.2007.07.068
   Perrotti M, 1999, J UROLOGY, V162, P1314, DOI 10.1016/S0022-5347(05)68275-4
   Pinkstaff DM, 2005, UROLOGY, V65, P735, DOI 10.1016/j.urology.2004.10.067
   Pinto PA, 2011, J UROLOGY, V186, P1281, DOI 10.1016/j.juro.2011.05.078
   Pondman KM, 2008, EUR UROL, V54, P517, DOI 10.1016/j.eururo.2008.06.001
   Prando A, 2005, RADIOLOGY, V236, P903, DOI 10.1148/radiol.2363040615
   Pryor Michael B, 2002, Clin Prostate Cancer, V1, P172, DOI 10.3816/CGC.2002.n.019
   Rabets JC, 2004, J UROLOGY, V172, P94, DOI 10.1097/01.ju.0000132134.10470.75
   Roehl KA, 2002, J UROLOGY, V167, P2435, DOI 10.1016/S0022-5347(05)64999-3
   Roethke M, 2012, WORLD J UROL, V30, P213, DOI 10.1007/s00345-011-0675-2
   Sajadi KP, 2007, UROLOGY, V70, P691, DOI 10.1016/j.urology.2007.05.017
   Satoh T, 2005, UROLOGY, V66, P114, DOI 10.1016/j.urology.2005.01.051
   Scattoni V, 2007, EUR UROL, V52, P1309, DOI 10.1016/j.eururo.2007.08.006
   Scattoni V, 2011, EUR UROL, V60, P834, DOI 10.1016/j.eururo.2011.07.036
   Scattoni V, 2010, INT J UROL, V17, P432, DOI [10.1111/j.1442-2042.2010.02524.x, 10.1111/j.1442-2042.2010.02479.x]
   Sciarra A, 2010, CLIN CANCER RES, V16, P1875, DOI 10.1158/1078-0432.CCR-09-2195
   Serag H, 2012, BRIT J CANCER, V106, P436, DOI 10.1038/bjc.2011.596
   Simon J, 2008, BJU INT, V102, P459, DOI 10.1111/j.1464-410X.2008.07560.x
   Singh AK, 2008, BJU INT, V101, P841, DOI 10.1111/j.1464-410X.2007.07348.x
   Stav K, 2008, UROLOGY, V71, P399, DOI 10.1016/j.urology.2007.11.007
   Stewart CS, 2001, J UROLOGY, V166, P86, DOI 10.1016/S0022-5347(05)66083-1
   Taira AV, 2010, PROSTATE CANCER P D, V13, P71, DOI 10.1038/pcan.2009.42
   Team R. D. C, 2012, R LANG ENV STAT COMP
   Testa C, 2010, NMR BIOMED, V23, P1017, DOI 10.1002/nbm.1522
   Veichtbauer W, 2010, J STAT SOFTW, V36, P1
   Walz J, 2006, EUR UROL, V50, P498, DOI 10.1016/j.eururo.2006.03.026
   Wetter A, 2005, EUR RADIOL, V15, P645, DOI 10.1007/s00330-004-2562-3
   Yuasa Takeshi, 2008, BMC Urol, V8, P14, DOI 10.1186/1471-2490-8-14
   Yuen JSP, 2004, J UROLOGY, V171, P1482, DOI 10.1097/01.ju.0000118380.90871.ef
   Zaytoun OM, 2011, J UROLOGY, V186, P850, DOI 10.1016/j.juro.2011.04.069
   Zaytoun OM, 2011, INT J UROL, V18, P557, DOI 10.1111/j.1442-2042.2011.02798.x
NR 71
TC 52
Z9 54
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 27
PY 2013
VL 8
IS 2
AR e57480
DI 10.1371/journal.pone.0057480
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 098BN
UT WOS:000315519000119
PM 23460864
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ye, XH
   Fu, JJ
   Yang, Y
   Chen, SD
AF Ye, Xiaohua
   Fu, Jinjian
   Yang, Yi
   Chen, Sidong
TI Dose-Risk and Duration-Risk Relationships between Aspirin and Colorectal
   Cancer: A Meta-Analysis of Published Cohort Studies
SO PLOS ONE
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DAILY SOLUBLE ASPIRIN; ADENOMA
   RECURRENCE; PRIMARY PREVENTION; COLON-CANCER; NSAIDS; BIAS; SEX
AB Background: In previous meta-analyses, aspirin use has been associated with reduced risk of colorectal cancer. However, uncertainty remains on the exact dose-risk and duration-risk relationships.
   Methods: We identified studies by searching several English and Chinese electronic databases and reviewing relevant articles. The dose-response meta-analysis was performed by linear trend regression and restricted cubic spline regression. Subgroup analyses were conducted to explore possible heterogeneity among studies. Potential heterogeneity was calculated as Q statistic and I-2 value. Publication bias was evaluated using funnel plots and quantified by the Begg's and Egger's test.
   Results: Twelve studies were included in this meta-analysis. An inverse association between aspirin use and colorectal cancer was observed in both the overall group (RR = 0.74, 95% CI 0.64-0.83 for aspirin dose; RR = 0.80, 95% CI 0.75-0.85 for frequency of aspirin use; RR = 0.75, 95% CI 0.68-0.81 for years of aspirin use) and subgroups stratified by sex and cancer site. The dose-response meta-analysis showed that there was a 20% statistically significant decreased risk of colorectal cancer for 325 mg aspirin per day increment, 18% decreased risk for 7 times aspirin per week increment and 18% decreased risk for 10 years aspirin increment.
   Conclusion: Long-term (>5 years), low-dose (75-325 mg per day) and regular aspirin use (2-7 times per week) can effectively reduce the risk of colorectal cancer.
C1 [Ye, Xiaohua; Fu, Jinjian] Southern Med Univ, Sch Publ Hlth & Trop Med, Guangzhou, Guangdong, Peoples R China.
   [Ye, Xiaohua; Fu, Jinjian; Yang, Yi; Chen, Sidong] Guangdong Pharmaceut Univ, Sch Publ Hlth, Guangdong Key Lab Mol Epidemiol, Guangzhou, Guangdong, Peoples R China.
   [Fu, Jinjian] Liuzhou Municipal Matern & Child Healthcare Hosp, Liuzhou, Guangxi, Peoples R China.
RP Chen, SD (reprint author), Guangdong Pharmaceut Univ, Sch Publ Hlth, Guangdong Key Lab Mol Epidemiol, Guangzhou, Guangdong, Peoples R China.
EM chensidong1@126.com
FU International cooperation project of the Guangzhou Science and
   Technology Bureau [2011J5200017]
FX This work was supported by fund from International cooperation project
   of the Guangzhou Science and Technology Bureau (No. 2011J5200017). The
   funders had no role in study design, data collection and analysis, and
   interpretation of the data.
CR Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2
   Allison M, 2006, AM J EPIDEMIOL, V164, P567, DOI 10.1093/aje/kwj250
   Baigent C, 2002, BMJ-BRIT MED J, V324, P71
   Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benamouzig R, 2003, GASTROENTEROLOGY, V125, P328, DOI 10.1016/S0016-5085(03)00887-4
   Benamouzig R, 2012, GUT, V61, P255, DOI 10.1136/gutjnl-2011-300113
   Berger JS, 2006, JAMA-J AM MED ASSOC, V295, P306, DOI 10.1001/jama.295.3.306
   BERLIN JA, 1993, EPIDEMIOLOGY, V4, P218, DOI 10.1097/00001648-199305000-00005
   Birkenkamp-Demtroder K, 2005, GUT, V54, P374, DOI 10.1136/gut.2003.036848
   Bosetti C, 2012, ANN ONCOL, V23, P1403, DOI 10.1093/annonc/mds113
   Bosetti C, 2006, CANCER CAUSE CONTROL, V17, P871, DOI 10.1007/s10552-006-0033-7
   Brasky TM, 2012, CANCER CAUSE CONTROL, V23, P431, DOI 10.1007/s10552-011-9891-8
   Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140-6736(11)61049-0
   Chan AT, 2008, GASTROENTEROLOGY, V134, P21, DOI 10.1053/j.gastro.2007.09.035
   Chan AT, 2005, JAMA-J AM MED ASSOC, V294, P914, DOI 10.1001/jama.294.8.914
   Chu Huei-An, 2006, Int J Environ Res Public Health, V3, P316, DOI 10.3390/ijerph2006030039
   Cole BF, 2009, J NATL CANCER I, V101, P256, DOI 10.1093/jnci/djn485
   Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1
   Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47
   Din FVN, 2010, GUT, V59, P1670, DOI 10.1136/gut.2009.203000
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elwood PC, 2009, LANCET, V373, P1301, DOI 10.1016/S0140-6736(09)60243-9
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8
   Friis S, 2009, CANCER CAUSE CONTROL, V20, P731, DOI 10.1007/s10552-008-9286-7
   GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001
   Gonzalez EC, 2001, DIS COLON RECTUM, V44, P251, DOI 10.1007/BF02234301
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Harris RE, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-237
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Irving HM, 2009, J PANCREAS, V10, P387
   Jacobs EJ, 2007, J NATL CANCER I, V99, P608, DOI 10.1093/jnci/djk132
   Jana NR, 2008, CELL MOL LIFE SCI, V65, P1295, DOI 10.1007/s00018-008-7511-x
   Langley RE, 2011, BRIT J CANCER, V105, P1107, DOI 10.1038/bjc.2011.289
   Larsson SC, 2006, BRIT J CANCER, V95, P1277, DOI 10.1038/sj.bjc.6603442
   Leopoldo S, 2008, ANN SURG ONCOL, V15, P1429, DOI 10.1245/s10434-007-9757-1
   Logan RFA, 2008, GASTROENTEROLOGY, V134, P29, DOI 10.1053/j.gastro.2007.10.014
   Mahipal A, 2006, CANCER EPIDEM BIOMAR, V15, P1785, DOI 10.1158/1055-9965.EPI-05-0674
   Meade TW, 1998, LANCET, V351, P233
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103
   Rodriguez LAG, 2001, EPIDEMIOLOGY, V12, P88, DOI 10.1097/00001648-200101000-00015
   Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1
   Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7
   Ruder EH, 2011, AM J GASTROENTEROL, V106, P1340, DOI 10.1038/ajg.2011.38
   Slattery ML, 2004, CANCER EPIDEM BIOMAR, V13, P538
   Sorensen HT, 2000, AM J GASTROENTEROL, V95, P2218
   Vinogradova Y, 2007, GASTROENTEROLOGY, V133, P393, DOI 10.1053/j.gastro.2007.05.023
   Wu XC, 2004, CANCER EPIDEM BIOMAR, V13, P1215
   Zha S, 2004, CANCER LETT, V215, P1, DOI 10.1016/j.canlet.2004.06.014
NR 53
TC 28
Z9 31
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 25
PY 2013
VL 8
IS 2
AR e57578
DI 10.1371/journal.pone.0057578
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 115ZB
UT WOS:000316849500116
PM 23451245
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, K
   Zhang, L
   Lin, XL
   Chen, LL
   Shi, HB
   Magaye, R
   Zou, BB
   Zhao, JS
AF Liu, Kui
   Zhang, Lu
   Lin, Xialu
   Chen, Liangliang
   Shi, Hongbo
   Magaye, Ruth
   Zou, Baobo
   Zhao, Jinshun
TI Association of GST Genetic Polymorphisms with the Susceptibility to
   Hepatocellular Carcinoma (HCC) in Chinese Population Evaluated by an
   Updated Systematic Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID S-TRANSFERASE M1; HEPATITIS-B CARRIERS; NULL GENOTYPES; AFLATOXIN; RISK;
   TAIWAN; CANCER; ADENOCARCINOMA; HETEROGENEITY; PATHOGENESIS
AB Background: Due to the possible involvement of Glutathione S-transferase Mu-1 (GSTM1) and Glutathione S-transferase theta-1 (GSTT1) in the detoxification of environmental carcinogens, environmental toxins, and oxidative stress products, genetic polymorphisms of these two genes may play important roles in the susceptibility of human being to hepatocellular carcinoma. However, the existing research results are not conclusive.
   Methods: A systematic literature search using databases (PubMed, Scopus, Embase, Chinese Biomedical Database, Chinese National Knowledge Infrastructure, Wanfang Data, etc.) for the eligible studies meeting the inclusion criteria including case-control studies or cohort studies is evaluated using an updated systematic meta-analysis.
   Results: Significant increase in the risk of HCC in the Chinese population is found in GSTM1 null genotype (OR = 1.47, 95% CI: 1.21 to 1.79, P<0.001) and GSTT1 null genotype (OR = 1.38, 95% CI: 1.14 to 1.65, P<0.001). Analysis using the random-effects model found an increased risk of HCC in GSTM1-GSTT1 dual null population (OR = 1.79, 95% CI: 1.26 to 2.53, P<0.001). In addition, subgroup analyses showed a significant increase in the association of GST genetic polymorphisms (GSTM1, GSTT1, and GSTM1-GSTT1) with HCC in southeast and central China mainland. However, available data collected by this study fail to show an association between GST genetic polymorphisms and HCC in people from the Taiwan region (for GSTM1: OR = 0.78, 95% CI: 0.60 to 1.01, P = 0.06; for GSTT1: OR = 0.94, 95% CI: 0.78 to 1.14, P = 0.546; for GSTM1-GSTT1: OR = 1.04, 95% CI: 0.81 to 1.32, P = 0.77). Sensitivity analysis and publication bias diagnostics confirmed the reliability and stability of this meta-analysis.
   Conclusions: Our results indicate that both GSTM1 and GSTT1 null genotypes are associated with an increased HCC risk in Chinese population. Peoples with dual null genotypes of GSTM1-GSTT1 are more susceptible to developing HCC. In conclusion, GST genetic polymorphisms play vital roles in the development of HCC in the Chinese population.
C1 [Liu, Kui; Lin, Xialu; Shi, Hongbo; Magaye, Ruth; Zou, Baobo; Zhao, Jinshun] Ningbo Univ, Sch Med, Dept Preventat Med, Ningbo 315211, Zhejiang, Peoples R China.
   [Liu, Kui; Lin, Xialu; Shi, Hongbo; Magaye, Ruth; Zou, Baobo; Zhao, Jinshun] Ningbo Univ, Sch Med, Zhejiang Prov Key Lab Pathol & Physiol Technol, Ningbo 315211, Zhejiang, Peoples R China.
   [Zhang, Lu] Anhui Med Univ, Sch Hlth Management, Hefei, Anhui, Peoples R China.
   [Chen, Liangliang] Ningbo Univ, Yinzhou Peoples Hosp, Ningbo 315211, Zhejiang, Peoples R China.
RP Zhao, JS (reprint author), Ningbo Univ, Sch Med, Dept Preventat Med, Ningbo 315211, Zhejiang, Peoples R China.
EM zhaojinshun@nbu.edu.cn
FU National Nature Science Foundation of China [81273111]; Foundations of
   Innovative Research Team of Educational Commission of Zhejiang Province
   [T200907]; Nature Science Foundation of Ningbo city [2012A610185];
   Ningbo Scientific Projects [2012C5019, SZX11073]; Scientific Innovation
   Team Project of Ningbo [2011B82014]; Innovative Research Team of Ningbo
   [2009B21002]; K. C. Wong Magna Fund in Ningbo University
FX Funding provided by grant number: the National Nature Science Foundation
   of China (Grant No. 81273111), the Foundations of Innovative Research
   Team of Educational Commission of Zhejiang Province (T200907), the
   Nature Science Foundation of Ningbo city (Grant No. 2012A610185), the
   Ningbo Scientific Projects (2012C5019 and SZX11073), the Scientific
   Innovation Team Project of Ningbo (No. 2011B82014), Innovative Research
   Team of Ningbo (2009B21002). This work was partly supported by K. C.
   Wong Magna Fund in Ningbo University. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aghemo A, 2012, HEPATOCELLULAR CARCI, P1
   Atkinson HJ, 2009, BIOCHEMISTRY-US, V48, P11108, DOI 10.1021/bi901180v
   BEASLEY RP, 1981, LANCET, V2, P1129
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bian J, 1999, CHINESE J MED GENET, V16, P171
   Bian JC, 2000, WORLD J GASTROENTERO, V6, P228
   Bian JC, 1996, CHINESE J MED GENET, V13, P353
   Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185
   Cabibbo G, 2012, CAUSES PREVENTION ST, P374
   Chen CC, 2005, INT J EPIDEMIOL, V34, P1310, DOI 10.1093/ije/dyi191
   Chen CJ, 1996, AM J HUM GENET, V59, P128
   Chen JM, 2012, COMM COM INF SC, V346, P1
   Deng CH, 1997, CHINESE J PUBLIC HLT, V16, P141
   Deng ZL, 2005, WORLD J GASTROENTERO, V11, P272, DOI 10.3748/wjg.v11.i2.272
   Dong CH, 1998, WORLD CHINESE J DIGE, V6, P463
   Dong CH, 1997, ZHONG LIU FANG ZHI Y, V24, P327
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934
   French SW, 2012, J GASTROINTEST ONCOL, V3, P174, DOI 10.3978/j.issn.2078-6891.2012.025
   [郭惠媛 Guo Huiyuan], 2005, [肿瘤, Tumor], V25, P58
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   [贺菽嘉 HE Shujia], 2007, [基础医学与临床, Basic & Clinical Medicine], V27, P666
   He SJ, 2008, J GUANGXI MED U, V25
   He SJ, 2004, PRACT J CANC, V19, P460
   He SJ, 2005, J GUANGXI MED U, V22, P875
   Hedges LV, 1998, PSYCHOL METHODS, V3, P486, DOI 10.1037/1082-989X.3.4.486
   Helzlsouer KJ, 1998, J NATL CANCER I, V90, P512, DOI 10.1093/jnci/90.7.512
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hsieh LL, 1996, CANCER LETT, V103, P171, DOI 10.1016/0304-3835(96)04209-7
   Hu Y, 1997, CHINESE J MED GENET, V14, P76
   Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kao CC, 2010, J SURG ONCOL, V102, P301, DOI 10.1002/jso.21643
   Katoh T, 1996, CARCINOGENESIS, V17, P1855, DOI 10.1093/carcin/17.9.1855
   Li CG, 2012, ASIAN PAC J CANCER P, V13, P3247, DOI 10.7314/APJCP.2012.13.7.3247
   Liu C, 2002, CHINA PUBLIC HLTH, V18, P935
   Liu ZG, 2003, J GUANGXI MED U, V2, P002
   Long XD, 2006, HEPATOL RES, V36, P48, DOI 10.1016/j.hepres.2006.06.004
   Long Xi-dai, 2005, Zhonghua Gan Zang Bing Za Zhi, V13, P668
   [龙喜带 Long Xidai], 2005, [中华流行病学杂志, Chinese Journal of Epidemiology], V26, P777
   Ma D, 2005, MED J CHINESE PEOPLE, V27, P656
   MCGLYNN KA, 1995, P NATL ACAD SCI USA, V92, P2384, DOI 10.1073/pnas.92.6.2384
   McGlynn KA, 2003, CANCER RES, V63, P4594
   SP Li, 2004, PRACT J CANC, V19, P229
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Sun CA, 2002, BRIT J CANCER, V87, P966, DOI 10.1038/sj.bjc.6600584
   Sun CA, 2001, CARCINOGENESIS, V22, P1289, DOI 10.1093/carcin/22.8.1289
   Tang YT, 2012, CHIN J LAB DIAGN, P16
   Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339
   Udomsinprasert R, 2005, BIOCHEM J, V388, P763, DOI 10.1042/BJ20042015
   Wang B, 2010, J HEPATOL, V53, P508, DOI 10.1016/j.jhep.2010.03.026
   Wang JW, 2003, CANCER LETT, V201, P185, DOI 10.1016/S0304-3835(03)00480-4
   Wei YiPing, 2010, Cancer Research on Prevention and Treatment, V37, P1162
   Wei YP, 2012, CHIN GERMAN J CLIN O, V11, P138
   Wei YP, 2004, TUMOR, V23, P464
   Wu HL, 2000, PRACT J CANC, V15, P463
   Yang ZG, 2009, CHIN J CANC PREV TRE, V16, P970
   Yu L, 2011, WORLD J GASTROENTERO, V17, P3248, DOI 10.3748/wjg.v17.i27.3248
   Yu MW, 1999, AM J EPIDEMIOL, V149, P621
   YU MW, 1995, GASTROENTEROLOGY, V109, P1266, DOI 10.1016/0016-5085(95)90587-1
   Yu MW, 2003, J NATL CANCER I, V95, P1485, DOI 10.1093/jnci/djg051
   Yu MW, 1997, J HEPATOL, V27, P320, DOI 10.1016/S0168-8278(97)80178-X
   Zhang Y, 2005, WENZHOU YIXUEYUAN XU, V35, P464
   ZHONG S, 1993, CARCINOGENESIS, V14, P1821, DOI 10.1093/carcin/14.9.1821
   [朱曼华 Zhu Manhua], 2005, [浙江大学学报. 医学版, Journal of Zhejiang University], V34, P126
   Zhu W, 2001, CHINA J CANC PREV TR, V8, P572
   马韵, 2001, Chinese Journal of Cancer Research, V13, P176, DOI 10.1007/BF02983879
   邓卓霖, 2001, 中华肿瘤杂志, V23, P477
NR 70
TC 12
Z9 13
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2013
VL 8
IS 2
AR e57043
DI 10.1371/journal.pone.0057043
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093IE
UT WOS:000315184200205
PM 23437305
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ye, YZ
   Li, J
   Yuan, ZX
AF Ye, Yizhou
   Li, Jing
   Yuan, Zhongxiang
TI Effect of Antioxidant Vitamin Supplementation on Cardiovascular
   Outcomes: A Meta-Analysis of Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID BETA-CAROTENE; E CONSUMPTION; DISEASE; RISK; PREVENTION;
   ATHEROSCLEROSIS; WOMEN
AB Background: Antioxidant vitamin (vitamin E, beta-carotene, and vitamin C) are widely used for preventing major cardiovascular outcomes. However, the effect of antioxidant vitamin on cardiovascular events remains unclear.
   Methodology and Principal Findings: We searched PubMed, EmBase, the Cochrane Central Register of Controlled Trials, and the proceedings of major conferences for relevant literature. Eligible studies were randomized controlled trials that reported on the effects of antioxidant vitamin on cardiovascular outcomes as compared to placebo. Outcomes analyzed were major cardiovascular events, myocardial infarction, stroke, cardiac death, total death, and any possible adverse events. We used the I-2 statistic to measure heterogeneity between trials and calculated risk estimates for cardiovascular outcomes with random-effect meta-analysis. Independent extraction was performed by two reviewers and consensus was reached. Of 293 identified studies, we included 15 trials reporting data on 188209 participants. These studies reported 12749 major cardiovascular events, 6699 myocardial infarction, 3749 strokes, 14122 total death, and 5980 cardiac deaths. Overall, antioxidant vitamin supplementation as compared to placebo had no effect on major cardiovascular events (RR, 1.00; 95% CI, 0.96-1.03), myocardial infarction (RR, 0.98; 95% CI, 0.92-1.04), stroke (RR, 0.99; 95% CI, 0.93-1.05), total death (RR, 1.03; 95% CI, 0.98-1.07), cardiac death (RR, 1.02; 95% CI, 0.97-1.07), revascularization (RR, 1.00; 95% CI, 0.95-1.05), total CHD (RR, 0.96; 95% CI, 0.87-1.05), angina (RR, 0.98; 95% CI, 0.90-1.07), and congestive heart failure (RR, 1.07; 95% CI, 0.96 to 1.19).
   Conclusion/Significance: Antioxidant vitamin supplementation has no effect on the incidence of major cardiovascular events, myocardial infarction, stroke, total death, and cardiac death.
C1 [Ye, Yizhou; Yuan, Zhongxiang] Shanghai Jiao Tong Univ, Dept Cardiovasc Surg, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China.
   [Li, Jing] Fudan Univ, Childrens Hosp, Dept Cardiol, Shanghai 200433, Peoples R China.
RP Yuan, ZX (reprint author), Shanghai Jiao Tong Univ, Dept Cardiovasc Surg, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China.
EM yuanzhongxiangno1@126.com
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029
   AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bjelakovic G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007176.pub2
   Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090
   Collins R, 2002, LANCET, V360, P23
   Cook NR, 2007, ARCH INTERN MED, V167, P1610, DOI 10.1001/archinte.167.15.1610
   Deeks JJ, 2008, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DIPLOCK AT, 1991, AM J CLIN NUTR, V53, pS189, DOI 10.1093/ajcn/53.1.189Sb
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FREI B, 1994, AM J MED, V97, pS5, DOI 10.1016/0002-9343(94)90292-5
   Goodman GE, 2004, J NATL CANCER I, V96, P1743, DOI 10.1093/jnci/djh320
   Greenberg ER, 1996, JAMA-J AM MED ASSOC, V275, P699, DOI 10.1001/jama.275.9.699
   Hercberg S, 2004, ARCH INTERN MED, V164, P2335, DOI 10.1001/archinte.164.21.2335
   Hercberg S, 2010, INT J CANCER, V127, P1875, DOI 10.1002/ijc.25201
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kataja-Tuomola MK, 2010, ANN MED, V42, P178, DOI 10.3109/07853890903508887
   KOHLMEIER L, 1995, AM J CLIN NUTR, V62, P1370, DOI 10.1093/ajcn/62.6.1370S
   Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102
   Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56
   Leppala JM, 2000, ARCH NEUROL-CHICAGO, V57, P1503, DOI 10.1001/archneur.57.10.1503
   Liu SM, 2006, DIABETES, V55, P2856, DOI 10.2337/db06-0456
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338
   MOHER D, 2009, PLOS MED, V6
   ODonnell CJ, 1997, CIRCULATION, V95, P1132
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720
   Pilger E, 2007, J INTERN MED, V261, P276, DOI 10.1111/j.1365-2796.2006.01763.x
   Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8
   RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004
   Sesso HD, 2008, JAMA-J AM MED ASSOC, V300, P2123, DOI 10.1001/jama.2008.600
   Sesso HD, 2012, JAMA-J AM MED ASSOC, V308, P1751, DOI 10.1001/jama.2012.14805
   Song YQ, 2009, AM J CLIN NUTR, V90, P429, DOI 10.3945/ajcn.2009.27491
   STAMPFER MJ, 1995, AM J CLIN NUTR, V62, P1365, DOI 10.1093/ajcn/62.6.1365S
   STAMPFER MJ, 1993, CAN J CARDIOL, V9, pB14
   STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003
   STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337
   STEINBERG D, 1991, CIRCULATION, V84, P1420, DOI 10.1161/01.CIR.84.3.1420
   Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1
   The ATBC Cancer Prevention Study Group, 1998, HEART, V79, P454
   The ATBC Cancer Prevention Study Group, 2004, EUR HEART J, V25, P1171
   The ATBC Cancer Prevention Study Group, 2000, ARTERIOSCLER THROMB, V20, P230
   The PHS Study Group, 1996, NEW ENGL J MED, V334, P1145
   Valagussa F, 1999, LANCET, V354, P447
   Virtamo J, 1998, ARCH INTERN MED, V158, P668, DOI 10.1001/archinte.158.6.668
   Vivekananthan DP, 2003, LANCET, V361, P2017, DOI 10.1016/S0140-6736(03)13637-9
   Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432
   Williams GR, 1999, STROKE, V30, P2523, DOI 10.1161/01.STR.30.12.2523
   Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487
NR 52
TC 81
Z9 82
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2013
VL 8
IS 2
AR e56803
DI 10.1371/journal.pone.0056803
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093IE
UT WOS:000315184200167
PM 23437244
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhu, ZW
   Zhang, XH
   Shen, ZJ
   Zhong, S
   Wang, XJ
   Lu, YL
   Xu, C
AF Zhu, Zhaowei
   Zhang, Xiaohua
   Shen, Zhoujun
   Zhong, Shan
   Wang, Xianjin
   Lu, Yingli
   Xu, Chen
TI Diabetes Mellitus and Risk of Bladder Cancer: A Meta-Analysis of Cohort
   Studies
SO PLOS ONE
LA English
DT Article
ID POPULATION-BASED COHORT; GROWTH-FACTOR-I; FOLLOW-UP; PROSTATE-CANCER;
   INCIDENT CANCER; PLASMA-LEVELS; US ADULTS; MORTALITY; ASSOCIATION;
   METFORMIN
AB Background: Increasing evidence suggests that diabetes mellitus (DM) may be associated with an increased risk of bladder cancer. To provide a quantitative assessment of this association, we evaluated the relation between DM and incidence and mortality of bladder cancer in an updated meta-analysis of cohort studies. Methods We identified cohort studies by searching the EMBASE and MEDLINE databases, through 31 March 2012. Summary relative risks (RRs) with 95% confidence intervals (CIs) were calculated with random-effects models.
   Results: A total of 29 cohort studies (27 articles) were included in this meta-analysis. DM was associated with an increased incidence of bladder cancer (RR 1.29, 95% CI: 1.08-1.54), with significant evidence of heterogeneity among these studies (p<0.001, I-2 = 94.9%). In stratified analysis, the RRs of bladder cancer were 1.36 (1.05-1.77) for diabetic men and 1.28 (0.75-2.19) for diabetic women, respectively. DM was also positively associated with bladder cancer mortality (RR 1.33, 95% CI: 1.14-1.55), with evident heterogeneity between studies (p = 0.002, I-2 = 63.3%). The positive association was observed for both men (RR 1.54, 95% CI: 1.30-1.82) and women (RR 1.50, 95% CI: 1.05-2.14).
   Conclusion: These findings suggest that compared to non-diabetic individuals, diabetic individuals have an increased incidence and mortality of bladder cancer.
C1 [Zhu, Zhaowei; Zhang, Xiaohua; Shen, Zhoujun; Zhong, Shan; Wang, Xianjin] Shanghai Jiao Tong Univ, Dept Urol, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China.
   [Lu, Yingli] Shanghai Jiao Tong Univ, Inst & Dept Endocrinol & Metab, Shanghai Peoples Hosp 9, Sch Med, Shanghai 200030, Peoples R China.
   [Xu, Chen] Shanghai Jiao Tong Univ, Dept Histol & Embryol, Sch Med, Shanghai 200030, Peoples R China.
   [Xu, Chen] Shanghai Jiao Tong Univ, Shanghai Key Lab Reprod Med, Sch Med, Shanghai 200030, Peoples R China.
RP Shen, ZJ (reprint author), Shanghai Jiao Tong Univ, Dept Urol, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China.
EM shenzj6@sina.com; luy662003@yahoo.com.cn
FU National Natural Science Foundation of China [81072098]; Science and
   Technology Commission of Shanghai Municipality [10DZ2270600]; Shanghai
   Leading Academic Discipline Project [S30201]; Shanghai Basic Research
   Project [09DJ1400400]
FX This work was supported by The National Natural Science Foundation of
   China (No. 81072098), Science and Technology Commission of Shanghai
   Municipality (No. 10DZ2270600), Shanghai Leading Academic Discipline
   Project (No. S30201) and Shanghai Basic Research Project (No.
   09DJ1400400). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR ADAMI HO, 1991, CANCER CAUSE CONTROL, V2, P307, DOI 10.1007/BF00051670
   Atchison EA, 2011, INT J CANCER, V128, P635, DOI 10.1002/ijc.25362
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Behrens T, 2009, J OCCUP ENVIRON HYG, V6, P555, DOI 10.1080/15459620903077682
   Ben QW, 2011, EUR J CANCER, V47, P1928, DOI 10.1016/j.ejca.2011.03.003
   BULBULYAN MA, 1995, INT J EPIDEMIOL, V24, P266, DOI 10.1093/ije/24.2.266
   Chung H, 2009, UROLOGY, V74, pS36, DOI DOI 10.1016/J.UROLOGY.2009.07.1106
   Colhoun HM, 2009, DIABETOLOGIA, V52, P1755, DOI 10.1007/s00125-009-1453-1
   Colmers IN, 2012, DIABETES METAB, V38, P475, DOI 10.1016/j.diabet.2012.06.003
   Colmers IN, 2012, CAN MED ASSOC J, V184, pE675, DOI 10.1503/cmaj.112102
   Corona G, 2011, INT J ANDROL, V34, P528, DOI 10.1111/j.1365-2605.2010.01117.x
   Coughlin SS, 2004, AM J EPIDEMIOL, V159, P1160, DOI 10.1093/aje/kwh161
   Currie CJ, 2012, DIABETES CARE, V35, P299, DOI 10.2337/dc11-1313
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dunn SE, 1997, CANCER RES, V57, P4667
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fernandez MI, 2012, J UROLOGY, V187, P856, DOI 10.1016/j.juro.2011.10.157
   Ferrucci LM, 2010, CANCER-AM CANCER SOC, V116, P4345, DOI 10.1002/cncr.25463
   Freedman ND, 2011, JAMA-J AM MED ASSOC, V306, P737, DOI 10.1001/jama.2011.1142
   Guha N, 2010, OCCUP ENVIRON MED, V67, P568, DOI 10.1136/oem.2009.051565
   Hemminki K, 2010, ONCOLOGIST, V15, P548, DOI 10.1634/theoncologist.2009-0300
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hwang EC, 2011, INT J UROL, V18, P769, DOI 10.1111/j.1442-2042.2011.02845.x
   Inoue M, 2006, ARCH INTERN MED, V166, P1871, DOI 10.1001/archinte.166.17.1871
   Jee SH, 2005, JAMA-J AM MED ASSOC, V293, P194, DOI 10.1001/jama.293.2.194
   Jiang Y, 2011, EUR J EPIDEMIOL, V26, P863, DOI 10.1007/s10654-011-9617-y
   JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3
   KESSLER II, 1970, J NATL CANCER I, V44, P673
   Kessler TM, 2008, EUR UROL, V53, P1040, DOI 10.1016/j.eururo.2007.09.044
   Khan Mmh, 2006, Asian Pac J Cancer Prev, V7, P253
   Lam EKK, 2011, ANN ONCOL, V22, P730, DOI 10.1093/annonc/mdq405
   Larsson SC, 2006, DIABETOLOGIA, V49, P2819, DOI 10.1007/s00125-006-0468-0
   Larsson SC, 2011, DIABETOLOGIA, V54, P1013, DOI 10.1007/s00125-011-2051-6
   Larsson SC, 2008, EUR J CANCER, V44, P2655, DOI 10.1016/j.ejca.2008.07.012
   Lee MY, 2012, METABOLISM, V61, P242, DOI 10.1016/j.metabol.2011.06.020
   Lewis JD, 2011, DIABETES CARE, V34, P916, DOI 10.2337/dc10-1068
   Li CY, 2011, DIABETES CARE, V34, P1365, DOI 10.2337/dc11-0020
   Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175
   Liu XD, 2012, EUR J CANCER PREV, V21, P300, DOI 10.1097/CEJ.0b013e32834c9cd9
   Liu XD, 2012, CANCER-AM CANCER SOC, V118, P1353, DOI 10.1002/cncr.26420
   Neumann A, 2012, DIABETOLOGIA, V55, P1953, DOI 10.1007/s00125-012-2538-9
   Noto H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033411
   Ogunleye AA, 2009, BRIT J CANCER, V101, P1199, DOI 10.1038/sj.bjc.6605240
   Piccinni C, 2011, DIABETES CARE, V34, P1369, DOI 10.2337/dc10-2412
   Pira E, 2010, JNCI-J NATL CANCER I, V102, P1096, DOI 10.1093/jnci/djq214
   RAGOZZINO M, 1982, J CHRON DIS, V35, P13, DOI 10.1016/0021-9681(82)90025-X
   Seshasai SRK, 2011, NEW ENGL J MED, V364, P829, DOI 10.1056/NEJMoa1008862
   Shariat SF, 2003, UROLOGY, V61, P359, DOI 10.1016/S0090-4295(02)02253-7
   Shu X, 2010, DIABETIC MED, V27, P791, DOI 10.1111/j.1464-5491.2010.03011.x
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Soranna D, 2012, ONCOLOGIST, V17, P813, DOI 10.1634/theoncologist.2011-0462
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Swerdlow AJ, 2005, BRIT J CANCER, V92, P2070, DOI 10.1038/sj.bjc.6602611
   Tripathi A, 2002, CANCER, V95, P2316, DOI 10.1002/cncr.10975
   Tseng CH, 2011, DIABETOLOGIA, V54, P2009, DOI 10.1007/s00125-011-2171-z
   Tseng CH, 2009, ANN MED, V41, P371, DOI 10.1080/07853890902729778
   Verlato G, 2003, DIABETES CARE, V26, P1047, DOI 10.2337/diacare.26.4.1047
   Vigneri P, 2009, ENDOCR-RELAT CANCER, V16, P1103, DOI 10.1677/ERC-09-0087
   Vigneri R, 2009, NAT REV ENDOCRINOL, V5, P651, DOI 10.1038/nrendo.2009.219
   Wang CG, 2012, INT J CANCER, V130, P1639, DOI 10.1002/ijc.26165
   Wideroff L, 1997, J NATL CANCER I, V89, P1360, DOI 10.1093/jnci/89.18.1360
   Woolcott CG, 2011, CANCER EPIDEMIOL, V35, P551, DOI 10.1016/j.canep.2011.02.014
   Wotton CJ, 2011, DIABETOLOGIA, V54, P527, DOI 10.1007/s00125-010-1987-2
   Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292
   Yood MU, 2009, DIABETES METAB SYND, V3, P12, DOI 10.1016/j.dsx.2008.10.003
   Yuhara H, 2011, AM J GASTROENTEROL, V106, P1911, DOI 10.1038/ajg.2011.301
   Zendehdel K, 2003, JNCI-J NATL CANCER I, V95, P1797, DOI 10.1093/jnci/djg105
   Zhang F, 2012, ACTA DIABETOL, V49, pS235, DOI 10.1007/s00592-012-0439-5
   Zhang ZJ, 2011, DIABETES CARE, V34, P2323, DOI 10.2337/dc11-0512
   Zhao H, 2003, J UROLOGY, V169, P714, DOI 10.1097/01.ju.0000036380.10325.2a
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 71
TC 24
Z9 28
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2013
VL 8
IS 2
AR e56662
DI 10.1371/journal.pone.0056662
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093IE
UT WOS:000315184200134
PM 23437204
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Chen, SC
   Song, XM
   Chen, ZH
   Li, XX
   Li, MZ
   Liu, HY
   Li, JC
AF Chen, Shicai
   Song, Xinming
   Chen, Zhihui
   Li, Xinxin
   Li, Mingzhe
   Liu, Haiying
   Li, Jianchang
TI CD133 Expression and the Prognosis of Colorectal Cancer: A Systematic
   Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID CELL MARKERS CD133; STEM-LIKE CELLS; DUKES STAGE B; RECTAL-CANCER;
   COLON-CANCER; PREOPERATIVE CHEMORADIOTHERAPY; CLINICAL-SIGNIFICANCE;
   HEMATOPOIETIC STEM; PANCREATIC-CANCER; TUMOR-REGRESSION
AB Objective: CD133 has recently been reported as a marker of cancer stem-like cells in colorectal cancer (CRC). However, its predictive value in CRC still remains controversial. In this study, we aimed to evaluate the association between the expression of CD133 and clinicopathological features and the outcome of CRC patients by performing a meta-analysis.
   Methods: A comprehensive literature search for relevant studies published up to December 2012 was performed using PubMed, MEDLINE and ISI Web of Science. Only articles in which CD133 antigen was detected in situ localisation by immunohistochemical staining were included. This meta-analysis was done using RevMan 4.2 software.
   Results: We found that a total of 15 studies involving 810 CD133-high and 1487 CD133-low patients met the inclusion criteria for the analysis of 5-year overall survival (OS) rate. In a random-effects model, the results showed that CD133-high expression in colorectal cancer was an independent prognostic marker correlating with both OS rate (RR = 0.67, 95% CI 0.54-0.82, P<0.01) and disease free survival (DFS) rate (RR = 0.71, 95% CI 0.52-0.96, P = 0.03). CD133-high expression was also associated with more T3,4 tumor invasion, N positive and vascular invasion cases, corresponding to a risk difference of 1.12 (95% CI 1.01-1.23, P = 0.03), 1.31 (95% CI 1.06-1.63, P = 0.01) and 1.24 (95% CI 1.08-1.41, P<0.01), respectively. However, when types of histology, lymphatic invasion and distant metastasis were considered, CD133 overexpression was not significantly related with these clinicopathological parameters.
   Conclusion: Our meta-analysis results suggest that CD133 is an efficient prognostic factor in CRC. Higher CD133 expression is significantly associated with poorer clinical outcome and some clinicopathological factors such as T category, N category and vascular invasion in CRC patients.
C1 [Chen, Shicai; Liu, Haiying; Li, Jianchang] Guangzhou Med Univ, Affiliated Tumor Hosp, Dept Gastrointestinal Tumor Surg, Guangzhou, Guangdong, Peoples R China.
   [Song, Xinming; Chen, Zhihui; Li, Xinxin; Li, Mingzhe] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal & Pancreat Surg, Guangzhou 510275, Guangdong, Peoples R China.
RP Song, XM (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal & Pancreat Surg, Guangzhou 510275, Guangdong, Peoples R China.
EM songxm2010@163.com
FU Doctoral Research Foundation of Guangzhou Medical College [2011C 57];
   Nature Science Foundation of Guangdong Province [8151008901000207];
   National Nature Science Foundation, China [81172339]
FX This study was supported by the Doctoral Research Foundation of
   Guangzhou Medical College (2011C 57), the Nature Science Foundation of
   Guangdong Province (8151008901000207) and the National Nature Science
   Foundation (81172339), China. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Artells R, 2010, EUR J CANCER, V46, P642, DOI 10.1016/j.ejca.2009.11.003
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bidlingmaier S, 2008, J MOL MED, V86, P1025, DOI 10.1007/s00109-008-0357-8
   Bonetti LR, 2012, SCAND J GASTROENTERO, V47, P1211, DOI 10.3109/00365521.2012.694904
   Chapman MAS, 1998, BRIT J CANCER, V78, P1346, DOI 10.1038/bjc.1998.682
   Choi D, 2009, WORLD J GASTROENTERO, V15, P2258, DOI 10.3748/wjg.15.2258
   Coco C, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-71
   Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018
   Corbeil D, 2001, TRAFFIC, V2, P82, DOI 10.1034/j.1600-0854.2001.020202.x
   EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2
   Ferrandina G, 2008, INT J GYNECOL CANCER, V18, P506, DOI 10.1111/j.1525-1438.2007.01056.x
   GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248
   Hayama T, 2011, J SURG ONCOL, V104, P110, DOI 10.1002/jso.21895
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Herszenyi L, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-194
   Hongo K, 2012, MED ONCOL, V29, P2849, DOI 10.1007/s12032-012-0161-8
   Horst D, 2008, BRIT J CANCER, V99, P1285, DOI 10.1038/sj.bjc.6604664
   Horst D, 2009, J PATHOL, V219, P427, DOI 10.1002/path.2597
   Horst D, 2009, CANCER INVEST, V27, P844, DOI 10.1080/07357900902744502
   Horst D, 2009, EUR J CANCER, V45, P2034, DOI 10.1016/j.ejca.2009.04.004
   Huang XD, 2012, SURG ONCOL, V21, P103, DOI 10.1016/j.suronc.2011.06.001
   Huh JW, 2010, J SURG ONCOL, V102, P765, DOI 10.1002/jso.21734
   Iinuma H, 2011, J CLIN ONCOL, V29, P1547, DOI 10.1200/JCO.2010.30.5151
   Jao SW, 2012, ANN SURG ONCOL, V19, P3432, DOI 10.1245/s10434-012-2394-3
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054
   Kemper K, 2012, CLIN CANCER RES, V18, P3132, DOI 10.1158/1078-0432.CCR-11-3066
   Kojima M, 2008, CANCER SCI, V99, P1578, DOI 10.1111/j.1349-7006.2008.00849.x
   Kojima M, 2010, CANCER SCI, V101, P906, DOI 10.1111/j.1349-7006.2009.01478.x
   Li CY, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-56
   Li H, 2012, INT J COLORECTAL DIS, V27, P1015, DOI 10.1007/s00384-012-1421-y
   Lin EH, 2007, CANCER-AM CANCER SOC, V110, P534, DOI 10.1002/cncr.22774
   Lugli A, 2010, BRIT J CANCER, V103, P382, DOI 10.1038/sj.bjc.6605762
   Maeda S, 2008, BRIT J CANCER, V98, P1389, DOI 10.1038/sj.bjc.6604307
   Miraglia S, 1997, BLOOD, V90, P5013
   Morales-Gutierrez C, 1999, CANCER, V86, P1675
   Garcia VM, 2011, COLORECTAL DIS, V13, P989, DOI 10.1111/j.1463-1318.2010.02386.x
   Nagata T, 2011, ANTICANCER RES, V31, P495
   Nakamura K, 2010, ONCOLOGY-BASEL, V78, P309, DOI 10.1159/000318862
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Ong CW, 2010, MODERN PATHOL, V23, P450, DOI 10.1038/modpathol.2009.181
   PETITTI DB, 1994, METAANALYSIS DECISIO, P90
   Pohl A, 2012, PHARMACOGENOMICS J
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Saigusa S, 2011, CLIN ONCOL-UK, V23, P323, DOI 10.1016/j.clon.2010.09.012
   Saigusa S, 2010, ONCOL REP, V24, P345, DOI 10.3892/or_00000865
   Saigusa S, 2009, ANN SURG ONCOL, V16, P3488, DOI 10.1245/s10434-009-0617-z
   Shimada R, 2012, ONCOL REP, V27, P947, DOI 10.3892/or.2012.1649
   Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Suetsugi A, 2006, BIOCHEM BIOPH RES CO, V351, P820, DOI 10.1016/j.bbrc.2006.10.128
   Takahashi S, 2010, ONCOL REP, V24, P1201, DOI 10.3892/or_00000973
   Ueno H, 2002, HISTOPATHOLOGY, V40, P127, DOI 10.1046/j.1365-2559.2002.01324.x
   Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105
   Wang Q, 2009, HISTOPATHOLOGY, V55, P284, DOI 10.1111/j.1365-2559.2009.03378.x
   Weichert W, 2005, CLIN CANCER RES, V11, P6574, DOI 10.1158/1078-0432.CCR-05-0606
   Xi HQ, 2011, J CLIN PATHOL, V64, P498, DOI 10.1136/jcp.2010.087213
   Yang K, 2011, INT J BIOL MARKER, V26, P173, DOI 10.5301/JBM.2011.8551
   Yasuda H, 2009, ONCOL REP, V22, P709, DOI 10.3892/or_00000491
   Yin AH, 1997, BLOOD, V90, P5002
   Zhang NH, 2012, EXP THER MED, V3, P973, DOI 10.3892/etm.2012.527
NR 62
TC 60
Z9 64
U1 2
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 11
PY 2013
VL 8
IS 2
AR e56380
DI 10.1371/journal.pone.0056380
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 092DU
UT WOS:000315100000052
PM 23409180
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Qi, WX
   Wang, Q
   Jiang, YL
   Sun, YJ
   Tang, LN
   He, AN
   Min, DL
   Lin, F
   Shen, Z
   Yao, Y
AF Qi, Wei-Xiang
   Wang, Qiong
   Jiang, Yan-Ling
   Sun, Yuan-Jue
   Tang, Li-na
   He, Ai-na
   Min, Da-liu
   Lin, Feng
   Shen, Zan
   Yao, Yang
TI Overall Survival Benefits for Combining Targeted Therapy as Second-Line
   Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of
   Published Data
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED PHASE-II; TYROSINE KINASE INHIBITORS; GROWTH-FACTOR RECEPTOR;
   PLUS ERLOTINIB; DOUBLE-BLIND; PLACEBO; CHEMOTHERAPY; COMBINATION;
   MULTICENTER; GEFITINIB
AB Background: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. We thus performed a meta-analysis of randomized controlled trials to compare the efficacy and safety of combining targeted therapy versus erlotinib alone as second-line treatment for advanced NSCLC.
   Methods: Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and grade 3 or 4 adverse event (AEs). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.
   Results: Eight eligible trials involved 2417 patients were ultimately identified. The intention to treatment (ITT) analysis demonstrated that combining targeted therapy significantly improved OS (HR 0.90, 95% CI: 0.82-0.99, p = 0.024), PFS (HR 0.83, 95% CI: 0.72-0.97, p = 0.018), and ORR (OR 1.35, 95% CI 1.01-1.80, P = 0.04). Sub-group analysis based on phases of trials, EGFR-status and KRAS status also showed that there was a tendency to improve PFS and OS in combining targeted therapy, except that PFS for patients with EGFR-mutation or wild type KRAS favored erlotinib monotherapy. Additionally, more incidence of grade 3 or 4 rash, fatigue and hypertension were observed in combining targeted therapy.
   Conclusions: With the available evidence, combining targeted therapy seems superior over erlotinib monotherapy as second-line treatment for advanced NSCLC. More studies are still needed to identify patients who will most likely benefit from the appropriate combining targeted therapy.
C1 [Qi, Wei-Xiang; Wang, Qiong; Sun, Yuan-Jue; Tang, Li-na; He, Ai-na; Min, Da-liu; Lin, Feng; Shen, Zan; Yao, Yang] Shanghai Jiao Tong Univ, Dept Oncol, Peoples Hosp 6, Shanghai 200030, Peoples R China.
   [Jiang, Yan-Ling] Kunming Med Univ, Dept Oncol, Kunming, Yunnan, Peoples R China.
RP Yao, Y (reprint author), Shanghai Jiao Tong Univ, Dept Oncol, Peoples Hosp 6, Shanghai 200030, Peoples R China.
EM shenzanok@yahoo.com; qwxzlk@163.com
OI Qi, wei-xiang/0000-0001-5484-3343
FU National Natural Science Foundation of China [81001191]; Science and
   Technology Commission of Shanghai [10PJ1408300]
FX The study was supported by grants from the National Natural Science
   Foundation of China (81001191) and Science and Technology Commission of
   Shanghai (10PJ1408300). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belani CP, 2012, CANCER TREAT REV, V38, P173, DOI 10.1016/j.ctrv.2011.05.009
   Bennouna J, 2010, ANN ONCOLOGY S21
   Ciuleanu T, 2012, LANCET ONCOL, V13, P300, DOI 10.1016/S1470-2045(11)70385-0
   Custodio A, 2012, CANCER TREAT REV, V38, P36, DOI 10.1016/j.ctrv.2011.04.001
   Dupont WD, 1998, CONTROL CLIN TRIALS, V19, P589, DOI 10.1016/S0197-2456(98)00037-3
   Gatzemeier U, 2007, J CLIN ONCOL, V25, P1545, DOI 10.1200/JCO.2005.05.1474
   Herbst RS, 2011, LANCET, V377, P1846, DOI 10.1016/S0140-6736(11)60545-X
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jiang H, 2009, JPN J CLIN ONCOL, V39, P137, DOI 10.1093/jjco/hyn139
   KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011
   Lin H, 2010, LUNG CANCER, V70, P57, DOI 10.1016/j.lungcan.2010.01.009
   Lynch TJ, 2009, J THORAC ONCOL, V4, P1002, DOI 10.1097/JTO.0b013e3181aba89f
   Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
   Mortenson MM, 2004, CANCER CHEMOTH PHARM, V54, P343, DOI 10.1007/s00280-004-0811-4
   Natale RB, 2011, J CLIN ONCOL, V29, P1059, DOI 10.1200/JCO.2010.28.5981
   NCI Cancer Therapy Evaluation Program, 2006, CTC V 2 0 COMM TERM
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Passaro A, 2011, EXPERT REV ANTICANC, V11, P1587, DOI [10.1586/era.11.120, 10.1586/ERA.11.120]
   Pennell NA, 2009, ONCOLOGIST, V14, P399, DOI 10.1634/theoncologist.2008-0276
   Qi WX, 2012, CURR MED RES OPIN, V28, P643, DOI 10.1185/03007995.2012.675880
   Qi WX, 2011, LUNG, V189, P437, DOI 10.1007/s00408-011-9332-1
   Ramalingam SS, 2011, J CLIN ONCOL, V29, P4574, DOI 10.1200/JCO.2011.36.6799
   Rubin BP, 2006, LAB INVEST, V86, P981, DOI 10.1038/labinvest.3700466
   Scagliotti GV, 2012, J CLIN ONCOL, V30, P2070, DOI 10.1200/JCO.2011.39.2993
   Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954
   Sequist LV, 2011, J CLIN ONCOL, V29, P3307, DOI 10.1200/JCO.2010.34.0570
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   Spigel DR, 2011, J CLIN ONCOL, V29, P2582, DOI 10.1200/JCO.2010.30.7678
   Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Tiwari D, 2012, THER ADV RESPIR DIS, V6, P41, DOI 10.1177/1753465811404590
   Tortora G, 2003, CLIN CANCER RES, V9, P1566
   Uhm JE, 2009, J THORAC ONCOL, V4, P1136, DOI 10.1097/JTO.0b013e3181b270a7
   van der Kuip H, 2005, AM J PHARMACOGENOMIC, V5, P101, DOI 10.2165/00129785-200505020-00003
   Witta SE, 2012, J CLIN ONCOL, V30, P2248, DOI 10.1200/JCO.2011.38.9411
   Yang CH, 2008, LUNG CANCER, V60, pS23, DOI 10.1016/S0169-5002(08)70102-8
   YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 41
TC 27
Z9 27
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 8
PY 2013
VL 8
IS 2
AR e55637
DI 10.1371/journal.pone.0055637
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 086CJ
UT WOS:000314660300026
PM 23409011
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ma, F
   Yang, Y
   Li, XW
   Zhou, F
   Gao, C
   Li, MF
   Gao, L
AF Ma, Fang
   Yang, Yu
   Li, Xiangwei
   Zhou, Feng
   Gao, Cong
   Li, Mufei
   Gao, Lei
TI The Association of Sport Performance with ACE and ACTN3 Genetic
   Polymorphisms: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME; ELITE ATHLETIC PERFORMANCE; I/D
   POLYMORPHISM; DELETION POLYMORPHISM; R577X POLYMORPHISM;
   INSERTION/DELETION POLYMORPHISM; MYOCARDIAL-INFARCTION; PHYSICAL
   PERFORMANCE; GREEK TRACK; GENOTYPE
AB Background: Genetic polymorphism is suggested to be associated with human physical performance. The angiotensin I-converting enzyme insertion/deletion (ACE I/D) polymorphism and the alpha-actinin-3 gene (ACTN3) R577X polymorphism have been most widely studied for such association analysis. However, the findings are frequently heterogeneous. We aim to summarize the associations of ACE I/D and ACTN3 R577X with sport performance by means of meta-analysis.
   Methods: We systematically reviewed and quantitatively summarized published studies, until October 31, 2012, on relationship between ACE/ACTN3 genetic polymorphisms and sports performance, respectively.
   Results: A total of 366 articles on ACE and 88 articles on ACTN3 were achieved by literature search. A significant association was found for ACE II genotype compared to D allele carriage (DD+ID) with increased possibility of physical performance (OR, 1.23; 95% CI, 1.05-1.45). With respect to sport discipline, the II genotype was found to be associated with performance in endurance athletes (OR, 1.35; 95% CI, 1.17-1.55). On the other hand, no significant association was observed for ACTN3 RR genotype as compared to X allele carriage (XX+RX) (OR, 1.03; 95% CI, 0.92-1.15). However, when restricted the analyses to power events, a significant association was observed (OR, 1.21; 95% CI, 1.03-1.42).
   Conclusion: Our results provide more solid evidence for the associations between ACE II genotype and endurance events and between ACTN3 R allele and power events. The findings suggest that the genetic profiles might influence human physical performance.
C1 [Ma, Fang] Xinjiang Normal Univ, Phys Educ Inst, Kinesiol Lab, Urumqi, Peoples R China.
   [Yang, Yu; Li, Xiangwei; Zhou, Feng; Gao, Cong; Li, Mufei; Gao, Lei] Chinese Acad Med Sci, MOH Key Lab Syst Biol Pathogens, Inst Pathogen Biol, Beijing 100730, Peoples R China.
   [Yang, Yu; Li, Xiangwei; Zhou, Feng; Gao, Cong; Li, Mufei; Gao, Lei] Peking Union Med Coll, Beijing 100021, Peoples R China.
RP Gao, L (reprint author), Chinese Acad Med Sci, MOH Key Lab Syst Biol Pathogens, Inst Pathogen Biol, Beijing 100730, Peoples R China.
EM gaolei@ipbcams.ac.cn
FU Chinese Ministry of Education [NCET-01-0288]
FX This study was supported by the New Century Excellent Talents Support
   Program of the Chinese Ministry of Education (NCET-01-0288). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alfred T., 2011, HUM MUTAT
   Amir O, 2007, EXP PHYSIOL, V92, P881, DOI 10.1113/expphysiol.2007.038711
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0
   Chiu LL, 2011, INT J SPORTS MED, V32, P476, DOI 10.1055/s-0030-1263115
   Cieszczyk P, 2009, INT J SPORTS MED, V30, P624, DOI 10.1055/s-0029-1202825
   Costa AM, 2009, EUR J APPL PHYSIOL, V106, P785, DOI 10.1007/s00421-009-1080-z
   DANSER AHJ, 1995, CIRCULATION, V92, P1387, DOI 10.1161/01.CIR.92.6.1387
   De Moor MHM, 2007, TWIN RES HUM GENET, V10, P812, DOI 10.1375/twin.10.6.812
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eynon N, 2009, INT J SPORTS MED, V30, P695, DOI 10.1055/s-0029-1220731
   Gayagay G, 1998, HUM GENET, V103, P48, DOI 10.1007/s004390050781
   Jones A, 2002, EXERC SPORT SCI REV, V30, P184, DOI 10.1097/00003677-200210000-00008
   Li XW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015831
   MacArthur D, 2005, HUM GENET, V116, P331, DOI 10.1007/s00439-005-1261-8
   MacArthur DG, 2007, EXERC SPORT SCI REV, V35, P30, DOI 10.1097/JES.0b013e31802d8874
   Mills MA, 2001, HUM MOL GENET, V10, P1335, DOI 10.1093/hmg/10.13.1335
   Min SK, 2009, APPL PHYSIOL NUTR ME, V34, P926, DOI 10.1139/H09-097
   Montgomery HE, 1998, NATURE, V393, P221, DOI 10.1038/30374
   Myerson S, 1999, J APPL PHYSIOL, V87, P1313
   Nazarov IB, 2001, EUR J HUM GENET, V9, P797, DOI 10.1038/sj.ejhg.5200711
   North KN, 1999, NAT GENET, V21, P353, DOI 10.1038/7675
   Oh SD, 2007, J SPORT MED PHYS FIT, V47, P250
   Papadimitriou ID, 2008, INT J SPORTS MED, V29, P352, DOI 10.1055/s-2007-965339
   Papadimitriou ID, 2009, J SPORT MED PHYS FIT, V49, P459
   Paparini A, 2007, MED SCI SPORT EXER, V39, P810, DOI 10.1097/mss.0b013e3180317491
   Puthucheary Z, 2011, SPORTS MED, V41, P433, DOI 10.2165/11588720-000000000-00000
   RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844
   Shang X, 2010, INT J SPORTS MED, V31, P913, DOI 10.1055/s-0030-1265176
   Shenoy Shweta, 2010, Asian J Sports Med, V1, P143
   Thompson WR, 2006, PHYS THER, V86, P585
   TIRET L, 1993, LANCET, V341, P991, DOI 10.1016/0140-6736(93)91075-W
   Tobina T, 2010, J PHYSIOL SCI, V60, P325, DOI 10.1007/s12576-010-0100-4
   Tsianos G, 2004, EUR J APPL PHYSIOL, V92, P360, DOI 10.1007/s00421-004-1120-7
   Williams AG, 2000, NATURE, V403, P614, DOI 10.1038/35001141
   Yang N, 2003, AM J HUM GENET, V73, P627, DOI 10.1086/377590
   Yang N, 2007, MED SCI SPORT EXER, V39, P1985, DOI 10.1249/mss.0013e1814844c9
   Yang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020343
   Zilberman-Schapira G, 2012, RECENT PAT DNA GENE
NR 39
TC 64
Z9 72
U1 2
U2 57
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 24
PY 2013
VL 8
IS 1
AR e54685
DI 10.1371/journal.pone.0054685
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 077JK
UT WOS:000314023600092
PM 23358679
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Pineda, B
   Garcia-Perez, MA
   Cano, A
   Lluch, A
   Eroles, P
AF Pineda, Begona
   Angel Garcia-Perez, Miguel
   Cano, Antonio
   Lluch, Ana
   Eroles, Pilar
TI Associations between Aromatase CYP19 rs10046 Polymorphism and Breast
   Cancer Risk: From a Case-Control to a Meta-Analysis of 20,098 Subjects
SO PLOS ONE
LA English
DT Article
ID SINGLE-NUCLEOTIDE POLYMORPHISM; GENETIC POLYMORPHISMS; SITE
   POLYMORPHISM; ESTROGEN-LEVELS; PATHWAY; VARIANTS; JAPANESE; BRCA1
AB Lifetime exposure to estrogen is a factor that plays an important role in the pathogenesis and progression of breast cancer. Genetic variants in genes of the biosynthesis and metabolism of estrogen have been associated with breast cancer risk. Among them, the CYP19 gene encodes for aromatase, the enzyme that catalyzes the conversion of androgens to estrogens. The rs10046 polymorphism on the CYP19 gene has been related to levels of circulating estradiol and to the estradiol/testosterone ratio. To date, epidemiological studies of rs10046 have been performed in different populations with contradictory results. In the present study, we have conducted a case-control analysis (522 cases and 1221 controls) in a Spanish population. Furthermore, we have performed a meta-analysis including 20,098 subjects (7,998 cases and 12,100 controls) to summarize the data available for rs10046 and breast cancer risk. An odds ratio (OR) with a 95% confidence interval (CI) was applied to assess the association. The results of our case-control study show an association between the carriers of at least one C allele (dominant model) and breast cancer risk (OR = 1.29, 95% CI 1.01-1.66, p-value = 0.038). The meta-analysis shows no significant association with breast cancer risk in any of the genetic models tested. The analysis by ethnic subgroups also failed to produce associations. The evaluation of heterogeneity, influence analysis, and publication bias confirms the reliability of the analysis. We can conclude that the rs10046 polymorphism on CYP19 by itself does not constitute breast cancer risk. We cannot, however, reject the possibility that it could contribute (interact), together with other genetic variants, to modify the circulating levels of estradiol.
C1 [Pineda, Begona; Angel Garcia-Perez, Miguel; Cano, Antonio; Lluch, Ana; Eroles, Pilar] Inst Hlth Res INCLIVA, Valencia, Spain.
   [Angel Garcia-Perez, Miguel] Univ Valencia, Dept Genet, Valencia, Spain.
   [Cano, Antonio] Univ Valencia, Dept Pediat Obstet & Gynecol, Valencia, Spain.
   [Lluch, Ana] Univ Hosp Valencia, Dept Haematol & Med Oncol, Valencia, Spain.
RP Eroles, P (reprint author), Inst Hlth Res INCLIVA, Valencia, Spain.
EM pilar.eroles@uv.es
RI Perez, Miguel Angel Garcia/S-8090-2018; Lluch, Ana/R-5493-2019
OI Lluch, Ana/0000-0003-2766-407X
FU Ministerio de Ciencia y Tecnologia- Fondo de Investigacion Sanitaria del
   Instituto de Salud Carlos III [PS09/01700]; RTICC [RD06/0020/0080];
   Conselleria de Sanidad Valenciana [GE-004/09]; Miguel Servet program
   (Instituto Salud Carlos III) [FIS03/0090]; Ministerio de Ciencia e
   Innovacion [JCI-2011-11435];  [PS09/0184];  [PS09/01687]
FX This work has been supported by grants PS09/01700 (Ministerio de Ciencia
   y Tecnologia- Fondo de Investigacion Sanitaria del Instituto de Salud
   Carlos III) and RD06/0020/0080 (RTICC) to ALL, by grant GE-004/09
   (Conselleria de Sanidad Valenciana) to PE, by grant PS09/0184 to MAG and
   by grant PS09/01687 to AC. PE is supported by the Miguel Servet program
   (Instituto Salud Carlos III, FIS03/0090), and BP has been hired under
   the Juan de la Cierva program (ref. JCI-2011-11435, Ministerio de
   Ciencia e Innovacion). The funders had no role in study design, data
   collection and analysis, decsion to publish, or preparation of the
   manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022
   Bulun SE, 2003, J STEROID BIOCHEM, V86, P219, DOI 10.1016/S0960-0760(03)00359-5
   Chen C, 2008, OBES REV, V9, P1, DOI 10.1111/j.1467-789X.2007.00429.x
   Chen XW, 2006, HUM MUTAT, V27, P427, DOI 10.1002/humu.20319
   Colomer R, 2008, CLIN CANCER RES, V14, P811, DOI 10.1158/1078-0432.CCR-07-1923
   Darabi H, 2011, BREAST CANCER RES TR, V127, P503, DOI 10.1007/s10549-010-1218-z
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055
   Dumas I, 2011, ANTICANCER RES, V31, P4369
   Dunning AM, 2004, JNCI-J NATL CANCER I, V96, P936, DOI 10.1093/jnci/djh167
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eroles P, 2012, CANCER TREAT REV, V38, P698, DOI 10.1016/j.ctrv.2011.11.005
   Fasching PA, 2008, BREAST CANCER RES TR, V112, P89, DOI 10.1007/s10549-007-9822-2
   Garcia-Casado Z, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-36
   Gennari L, 2004, J CLIN ENDOCR METAB, V89, P2803, DOI 10.1210/jc.2003-031342
   Germain D, 2011, ENDOCRIN METAB CLIN, V40, P473, DOI 10.1016/j.ecl.2011.05.009
   Gleser LJ, 1996, STAT MED, V15, P2493, DOI 10.1002/(SICI)1097-0258(19961215)15:23<2493::AID-SIM381>3.0.CO;2-C
   Haiman CA, 2000, INT J CANCER, V87, P204, DOI 10.1002/1097-0215(20000715)87:2<204::AID-IJC8>3.3.CO;2-V
   Haiman CA, 2002, CANCER EPIDEM BIOMAR, V11, P215
   Haiman CA, 2007, CANCER RES, V67, P1893, DOI 10.1158/0008-5472.CAN-06-4123
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hortobagyi Gabriel N, 2005, Clin Breast Cancer, V6, P391, DOI 10.3816/CBC.2005.n.043
   Iwasaki M, 2010, NUTR CANCER, V62, P466, DOI 10.1080/01635580903441279
   JENG GT, 1995, JAMA-J AM MED ASSOC, V274, P830, DOI 10.1001/jama.274.10.830
   Jin Y, 1996, J CLIN INVEST, V98, P1745, DOI 10.1172/JCI118973
   Kristensen VN, 2000, ONCOGENE, V19, P1329, DOI 10.1038/sj.onc.1203425
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lian K, 2005, ARTHRITIS RHEUM-US, V52, P1431, DOI 10.1002/art.21011
   Long JR, 2006, CANCER EPIDEM BIOMAR, V15, P2115, DOI 10.1158/1055-9965.EPI-06-0464
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Martin AM, 2000, JNCI-J NATL CANCER I, V92, P1126, DOI 10.1093/jnci/92.14.1126
   Olson JE, 2007, BREAST CANCER RES TR, V102, P237, DOI 10.1007/s10549-006-9324-7
   Park IH, 2011, CANCER CHEMOTH PHARM, V68, P1263, DOI 10.1007/s00280-011-1615-y
   Pedraza AM, 2012, BREAST CANC RES TREA
   Ralph DA, 2007, CANCER, V109, P1940, DOI 10.1002/cncr.22634
   Raskin L, 2009, CANCER EPIDEM BIOMAR, V18, P1617, DOI 10.1158/1055-9965.EPI-09-0060
   Rodrigues P, 2012, BREAST CANC RES TREA
   Skorupski P, 2006, AM J OBSTET GYNECOL, V194, P346, DOI 10.1016/j.ajog.2005.07.034
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Song M, 2011, MOL CARCINOGEN, V50, P280, DOI 10.1002/mc.20639
   Tworoger SS, 2004, CANCER EPIDEM BIOMAR, V13, P94, DOI 10.1158/1055-9965.EPI-03-0026
   Yoshimoto N, 2011, CANCER SCI, V102, P2065, DOI 10.1111/j.1349-7006.2011.02047.x
   Zhang LN, 2009, BREAST CANCER RES TR, V114, P327, DOI 10.1007/s10549-008-9998-0
NR 44
TC 18
Z9 18
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 16
PY 2013
VL 8
IS 1
AR e53902
DI 10.1371/journal.pone.0053902
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 072OV
UT WOS:000313682700061
PM 23342035
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yu, YB
   Weng, Y
   Guo, J
   Chen, GD
   Yao, K
AF Yu, Yibo
   Weng, Yu
   Guo, Jing
   Chen, Guangdi
   Yao, Ke
TI Association of Glutathione S transferases Polymorphisms with Glaucoma: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; RISK-FACTOR; GENE POLYMORPHISM; PUBLICATION BIAS;
   GSTM1; GSTT1; GLUTATHIONE-S-TRANSFERASE-M1; POPULATION; DAMAGE; M1
AB Background: Glutathione S transferase (GST) polymorphisms have been considered risk factors for the development of glaucoma, including primary open angle glaucoma (POAG) and other types of glaucoma. However, the results remain controversial. In this study, we have conducted a meta-analysis to assess the association between polymorphisms of GSTM1, GSTT1 and GSTP1 and glaucoma risk.
   Methods: Published literature from PubMed and other databases were retrieved. All studies evaluating the association between GSTM1, GSTT1 and GSTP1 polymorphisms and glaucoma risk were included. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using random- or fixed-effects model.
   Results: Twelve studies on GSTM1 (1109 cases and 844 controls), ten studies on GSTT1 (709 cases and 664 controls) and four studies on GSTP1 (543 cases and 511 controls) were included. By pooling all the studies, either GSTM1 or GSTT1 null polymorphism was not associated with a POAG risk, and this negative association maintained in Caucasian. The GSTP1 Ile 105 Val polymorphism was significantly correlated with increased POAG risk among Caucasian in a recessive model (Val/Val vs. Ile/Ile+Ile/Val: OR, 1.62, 95% CI: 1.00-2.61). Interestingly, increased glaucoma risk was associated with the combined GSTM1 and GSTT1 null genotypes (OR, 2.20; 95% CI, 1.47-3.31), and with the combined GSTM1 null and GSTP1 Val genotypes (OR, 1.86; 95% CI, 1.15-3.01).
   Conclusions: This meta-analysis suggests that combinations of GST polymorphisms are associated with glaucoma risk. Given the limited sample size, the associations between single GST polymorphism and glaucoma risk await further investigation.
C1 [Yu, Yibo; Yao, Ke] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou 310003, Zhejiang, Peoples R China.
   [Weng, Yu] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Clin Lab, Hangzhou 310003, Zhejiang, Peoples R China.
   [Guo, Jing; Chen, Guangdi] Zhejiang Univ, Sch Med, Dept Publ Hlth, Hangzhou 310003, Zhejiang, Peoples R China.
RP Chen, GD (reprint author), Zhejiang Univ, Sch Med, Dept Publ Hlth, Hangzhou 310003, Zhejiang, Peoples R China.
EM chenguangdi@gmail.com; xlren@zju.edu.cn
FU Zhejiang Key Innovation Team Project of China [2009R50039]; Zhejiang Key
   Laboratory Fund of China [2011E10006]; National Natural Science
   Foundation of China [30900273]; Qianjiang Talents Program of Zhejiang
   Province [2012R10023]; Fundamental Research Funds for the Central
   Universities [2011QNA7018, 2012QNA7019]; Technology Foundation for
   Excellent Overseas Chinese Scholar, Zhejiang Province Human Resources
   and Social Security Bureau
FX This work was supported by the Zhejiang Key Innovation Team Project of
   China (No. 2009R50039), the Zhejiang Key Laboratory Fund of China (No.
   2011E10006), the National Natural Science Foundation of China (No.
   30900273), the Qianjiang Talents Program of Zhejiang Province
   (2012R10023) and the Fundamental Research Funds for the Central
   Universities (No. 2011QNA7018, 2012QNA7019). Dr. Guangdi Chen was
   supported by Technology Foundation for Excellent Overseas Chinese
   Scholar, Zhejiang Province Human Resources and Social Security Bureau.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abu-Amero KK, 2008, MOL VIS, V14, P425
   Allingham RR, 2009, EXP EYE RES, V88, P837, DOI 10.1016/j.exer.2008.11.003
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Eaton DL, 1999, TOXICOL SCI, V49, P156, DOI 10.1093/toxsci/49.2.156
   Fan BJ, 2010, INVEST OPHTH VIS SCI, V51, P4110, DOI 10.1167/iovs.09-4974
   Fan BJ, 2006, CLIN BIOCHEM, V39, P249, DOI 10.1016/j.clinbiochem.2005.11.001
   Ginsberg G, 2009, J TOXICOL ENV HEAL B, V12, P389, DOI 10.1080/10937400903158375
   Hayashino Y, 2005, J EPIDEMIOL, V15, P235, DOI 10.2188/jea.15.235
   Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396
   Izzotti A, 2004, EXP EYE RES, V79, P141, DOI 10.1016/j.exer.2004.03.007
   Izzotti A, 2003, AM J MED, V114, P638, DOI 10.1016/S0002-9343(03)00114-1
   Izzotti A, 2010, ARCH OPHTHALMOL-CHIC, V128, P724, DOI 10.1001/archophthalmol.2010.87
   Izzotti A, 2009, INVEST OPHTH VIS SCI, V50, P5251, DOI 10.1167/iovs.09-3871
   Jansson M, 2003, EXP EYE RES, V77, P239, DOI 10.1016/S0014-4835(03)00109-X
   Johansson AS, 1998, J MOL BIOL, V278, P687, DOI 10.1006/jmbi.1998.1708
   Josephy P David, 2010, Hum Genomics Proteomics, V2010, P876940, DOI 10.4061/2010/876940
   Juronen E, 2000, EXP EYE RES, V71, P447, DOI 10.1006/exer.2000.0899
   Juronen E, 2000, INVEST OPHTH VIS SCI, V41, P2262
   Khan MI, 2010, MOL VIS, V16, P2146
   Minelli C, 2010, INT J EPIDEMIOL, V39, P539, DOI 10.1093/ije/dyp337
   Othman H, 2012, MOL BIOL REP, V39, P3299, DOI 10.1007/s11033-011-1098-2
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Ramprasath T, 2011, BIOCHEM BIOPH RES CO, V407, P49, DOI 10.1016/j.bbrc.2011.02.097
   Rasool HAA, 2010, J AM SCI, V6, P375
   Rocha AV, 2011, MOL VIS, V17, P1679
   Sun L, 2010, INVEST OPHTH VIS SCI, V51, P6381, DOI 10.1167/iovs.10-5815
   Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003
   Unal M, 2007, BRIT J OPHTHALMOL, V91, P527, DOI 10.1136/bjo.2006.102418
   van Koolwijk LME, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002611
   Vithana EN, 2012, NAT GENET, V44, P1142, DOI 10.1038/ng.2390
   Wiggs JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P30, DOI 10.1001/archopht.125.1.30
   Wiggs JL, 2012, PLOS GENET, V8, P413, DOI 10.1371/journal.pgen.1002654
   Worley A, 2011, AUST J PRIM HEALTH, V17, P233, DOI 10.1071/PY10042
   Ye Z, 2005, EUR J CANCER, V41, P980, DOI 10.1016/j.ejca.2005.01.014
   Yildirim O, 2005, GRAEF ARCH CLIN EXP, V243, P327, DOI 10.1007/s00417-004-1013-9
   Yilmaz A, 2005, CURR EYE RES, V30, P575, DOI 10.1080/02713680590968123
NR 36
TC 11
Z9 11
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 14
PY 2013
VL 8
IS 1
AR e54037
DI 10.1371/journal.pone.0054037
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 087KE
UT WOS:000314759400112
PM 23342067
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Sun, XS
   Lai, R
   Li, JX
   Luo, M
   Wang, YF
   Sheng, WL
AF Sun, Xunsha
   Lai, Rong
   Li, Jiaoxing
   Luo, Man
   Wang, Yufang
   Sheng, Wenli
TI The-7351C/T Polymorphism in the TPA Gene and Ischemic Stroke Risk: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; TISSUE-PLASMINOGEN-ACTIVATOR; T-PA;
   ENHANCER POLYMORPHISM; MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY;
   LACUNAR STROKE; ASSOCIATION; SUBTYPES; RELEASE
AB Background: A number of studies assessed the association of tissue plasminogen activator(TPA) gene polymorphisms with ischemic stroke, but the results were contradictory. We aimed to explore the role of TPA -7351C/T SNP in the susceptibility to ischemic stroke through a meta-analysis.
   Methods: The PubMed, MEDLINE, EMBASE, China Biological Medicine Database and WANFANG DATA databases were searched until August 2012. The strict selection criteria and exclusion criteria were determined, and odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations. Stroke subtype was determined using Trial of Org 10172 in Acute Treatment criteria (TOAST). Statistical analyses were performed using the STATA12.0 software.
   Results: A total of 2,299 ischemic stroke cases and 1,948 controls in seven case-control studies were included in the meta-analysis. Significant association between -7351C/T polymorphism in the TPA gene and ischemic stroke was observed in all comparison models (TT+CT versus CC, TT versus CT+CC and T versus C). In the subgroup analysis by ethnicity, TT homozygote carriers had a 142% increased risk of ischemic stroke compared with the C allele carriers among East-Asians (TT versus CT+CC: OR = 2.42, 95% CI = 1.07-5.48), but not in South-Asians and Caucasians, and significantly increased risks were found for T versus C among both East-Asians (OR = 1.33, 95% CI = 1.05-1.68) and Caucasians(OR = 1.16, 95% CI = 1.02-1.31). Further stratification for stroke subtype in three Caucasian studies showed the association between -7351C/T polymorphism and Large-artery atherosclerosis (LAA), but not Small-vessel occlusion (SVO) and Cardioembolism (CE).
   Conclusions: This meta-analysis suggested that the -7351C/T polymorphism in TPA gene would be a risk factor for ischemic stroke, especially among East-Asians compared with Caucasians, but not in South-Asians, and it may play a role in the pathogenesis of LAA in Caucasians, but not in SVO and CE.
C1 [Sun, Xunsha; Lai, Rong; Li, Jiaoxing; Luo, Man; Wang, Yufang; Sheng, Wenli] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China.
RP Sheng, WL (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China.
EM shengwl@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81070912]; Shandong
   Province Excellent Young Scientist Research Award Fund [2012BSA07022];
   Self-financing Science Foundation of Guangxi Health Bureau [Z2012096]
FX This study was supported by grants #81070912 from the National Natural
   Science Foundation of China and grant #2012BSA07022 from the Shandong
   Province Excellent Young Scientist Research Award Fund and grant
   #Z2012096 from Self-financing Science Foundation of Guangxi Health
   Bureau. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Armstrong CA, 2006, STROKE, V37, P329, DOI 10.1161/01.STR.0000199663.64894.4f
   Attia John, 2007, J Stroke Cerebrovasc Dis, V16, P173, DOI 10.1016/j.jstrokecerebrovasdis.2007.03.002
   Babu MS, 2012, GENE, V495, P76, DOI 10.1016/j.gene.2011.12.046
   BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bellenguez C, 2012, NAT GENET, V44, P328, DOI 10.1038/ng.1081
   Del BA, 2012, INT J STROKE, V7, P321
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Furie B, 2008, NEW ENGL J MED, V359, P938, DOI 10.1056/NEJMra0801082
   Geng Z., 2008, CHIN J CLIN NEUROSCI, V16, P134
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   Holliday EG, 2012, NAT GENET, V44, P1147, DOI 10.1038/ng.2397
   Horsley T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000026.pub2
   Ihle-Hansen H, 2012, FUNCT NEUROL, V27, P35
   Jannes J, 2004, STROKE, V35, P1090, DOI 10.1161/01.STR.0000124123.76658.6c
   Jern C, 1999, ARTERIOSCL THROM VAS, V19, P454, DOI 10.1161/01.ATV.19.2.454
   Jood K, 2005, STROKE, V36, P2077, DOI 10.1161/01.STR.0000183617.54752.69
   KOOISTRA T, 1994, INT J HEMATOL, V59, P233
   Kristensen B, 1998, STROKE, V29, P2261, DOI 10.1161/01.STR.29.11.2261
   Ladenvall P, 2002, THROMB HAEMOSTASIS, V87, P105
   Ladenvall P, 2000, THROMB HAEMOSTASIS, V84, P150
   Lee Brian, 2012, J Med Assoc Thai, V95 Suppl 2, pS227
   Macko RF, 1999, STROKE, V30, P7, DOI 10.1161/01.STR.30.1.7
   Maguire J, 2011, J STROKE CEREBROVASC, V20, P134, DOI 10.1016/j.jstrokecerebrovasdis.2009.10.011
   Olson DM, 2011, J NEUROSCI NURS, V43, P329, DOI 10.1097/JNN.0b013e318234e7fb
   RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7
   Roquer J, 2012, CEREBROVASC DIS, V33, P310, DOI 10.1159/000335306
   Sharma VK, 2012, EXPERT REV NEUROTHER, V12, P209, DOI [10.1586/ERN.11.148, 10.1586/ern.11.148]
   Tuttolomondo A, 2012, CYTOKINE, V58, P398, DOI 10.1016/j.cyto.2012.02.012
   Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075
   Wang YY, 2006, RELATIONSHIP SINGLE
   Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5
   WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804
NR 34
TC 6
Z9 7
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 9
PY 2013
VL 8
IS 1
AR e53558
DI 10.1371/journal.pone.0053558
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 070YR
UT WOS:000313551500083
PM 23326456
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Long, SY
   Yang, XL
   Liu, XJ
   Yang, P
AF Long, Shuyu
   Yang, Xingliang
   Liu, Xiaojiao
   Yang, Pei
TI Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms and
   Susceptibility for Cervical Lesions: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID HUMAN-PAPILLOMAVIRUS; COLORECTAL-CANCER; NATURAL-HISTORY; COMMON
   MUTATION; FOLATE; RISK; ASSOCIATION; C677T; GENE; CARCINOGENESIS
AB Background: The association between the methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and the susceptibility to cervical lesions was unclear. This study was designed to investigate their precise association using a large-scale meta-analysis.
   Methods: The previous 16 studies were identified by searching PubMed, Embase and CBM databases. The crude odds ratios and their corresponding 95% confidence intervals (CIs) were used to estimate the association between the MTHFR C677T/A1298C polymorphisms and the susceptibility to the cervical lesions. The subgroup analyses were made on the following: pathological history, geographic region, ethnicity, source of controls and source of DNA for genotyping.
   Results: Neither of the polymorphisms had a significant association with the susceptibility to the cervical lesions in all genetic models. Similar results were found in the subgroup analyses. No association was found between the MTHFR C677T polymorphism and the cervical lesions in the Asia or the America populations though a significant inverse association was found in the Europe population (additive model: P = 0.006, OR = 0.83, 95% CI = 0.72-0.95; CT vs. CC: P = 0.05, OR = 0.83, 95% CI = 0.69-1.00; TT vs. CC: P = 0.05, OR = 0.73, 95% CI = 0.53-1.00). Interestingly, women with the MTHFR A1298C polymorphisms had a marginally increased susceptibility to invasive cancer (ICC) when compared with no carriers but no statistically significant difference in the dominant model (P = 0.06, OR = 1.21, 95% CI = 0.99-1.49) and AC vs. AA (P = 0.09, OR = 1.21, 95% CI = 0.97-1.51).
   Conclusions: The MTHFR C677T and A1298C polymorphisms may not increase the susceptibility to cervical lesions. However, the meta-analysis reveals a negative association between the MTHFR C677T polymorphisms and the cervical lesions, especially in the European populations. The marginal association between the MTHFR A1298C polymorphisms and the susceptibility to cervical cancer requires a further study.
C1 [Long, Shuyu; Liu, Xiaojiao; Yang, Pei] Sichuan Univ, W China Hosp 2, Dept Gynecol & Obstet, Chengdu 610064, Sichuan, Peoples R China.
   [Yang, Xingliang] Third Mil Med Univ, Affiliated Hosp 2, Dept Urol, Chongqing, Peoples R China.
RP Yang, P (reprint author), Sichuan Univ, W China Hosp 2, Dept Gynecol & Obstet, Chengdu 610064, Sichuan, Peoples R China.
EM YangP790@126.com
CR Agodi A, 2010, INT J GYNECOL CANCER, V20, P141, DOI 10.1111/IGC.0b013e3181c20842
   Ashfield-Watt PAL, 2002, AM J CLIN NUTR, V76, P180
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   BUTTERWORTH CE, 1992, JAMA-J AM MED ASSOC, V267, P528, DOI 10.1001/jama.267.4.528
   Castellsague X, 2002, VIRUS RES, V89, P191, DOI 10.1016/S0168-1702(02)00188-0
   Castellsague Xavier, 2003, J Natl Cancer Inst Monogr, P20
   Collin SM, 2009, CANCER EPIDEM BIOMAR, V18, P2528, DOI 10.1158/1055-9965.EPI-09-0223
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elfgren K, 2000, AM J OBSTET GYNECOL, V183, P561, DOI 10.1067/mob.2000.106749
   Garcia-Closas R, 2005, INT J CANCER, V117, P629, DOI 10.1002/ijc.21193
   Goodman MT, 2001, CANCER EPIDEM BIOMAR, V10, P1275
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Huang Y, 2007, J HUM GENET, V52, P73, DOI 10.1007/s10038-006-0082-5
   Hubner RA, 2007, INT J CANCER, V120, P1027, DOI 10.1002/ijc.22440
   Insinga RP, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-119
   Jacques PF, 1996, CIRCULATION, V93, P7, DOI 10.1161/01.CIR.93.1.7
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kang S, 2005, GYNECOL ONCOL, V96, P173, DOI 10.1016/j.ygyno.2004.09.031
   Kohaar I, 2010, BIOMARKERS, V15, P61, DOI 10.3109/13547500903295881
   Lambropoulos AF, 2003, CANCER LETT, V191, P187, DOI 10.1016/S0304-3835(02)00675-4
   Langevin SM, 2009, TOXICOL LETT, V184, P73, DOI 10.1016/j.toxlet.2008.09.003
   Larsson SC, 2006, GASTROENTEROLOGY, V131, P1271, DOI 10.1053/j.gastro.2006.08.010
   Ma X, 2006, CHINA PUBLIC HLTH, V22, P1247
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Mostowska A, 2011, CLIN BIOCHEM, V44, P596, DOI 10.1016/j.clinbiochem.2011.02.007
   Nandan Naveen Kumar, 2008, Drug Metab Lett, V2, P18
   Pillai MR, 2003, J CLIN PATHOL, V56, P569, DOI 10.1136/jcp.56.8.569
   Piyathilake CJ, 2007, NUTRITION, V23, P229, DOI 10.1016/j.nut.2006.12.006
   Piyathilake CJ, 2004, CANCER RES, V64, P8788, DOI 10.1158/0008-5472.CAN-04-2402
   Piyathilake CJ, 2000, ANTICANCER RES, V20, P1751
   POTISCHMAN N, 1991, CANCER RES, V51, P4785
   Prasad VVTS, 2011, ONKOLOGIE, V34, P422, DOI 10.1159/000331131
   Sedjo RL, 2002, CANCER EPIDEM BIOMAR, V11, P353
   Shekari M, 2008, ARCH GYNECOL OBSTET, V278, P517, DOI 10.1007/s00404-008-0623-6
   Sull JW, 2004, GYNECOL ONCOL, V95, P557, DOI 10.1016/j.ygyno.2004.08.008
   Tong SY, 2011, CANCER CAUSE CONTROL, V22, P63, DOI 10.1007/s10552-010-9675-6
   van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825
   VANEENWYK J, 1992, CANCER EPIDEM BIOMAR, V1, P119
   VANNIEKERK WA, 1966, ACTA CYTOL, V10, P67
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
   WHITEHEAD N, 1973, JAMA-J AM MED ASSOC, V226, P1421, DOI 10.1001/jama.226.12.1421
   Yamada K, 2001, P NATL ACAD SCI USA, V98, P14853, DOI 10.1073/pnas.261469998
   Yang F, 2010, J CHINA MATERNAL CHI, V23, P4122
   Zacho J, 2011, INT J CANCER, V128, P644, DOI 10.1002/ijc.25375
   Zintzaras E, 2006, J HUM GENET, V51, P618, DOI 10.1007/s10038-006-0405-6
   Zoodsma M, 2005, HUM GENET, V116, P247, DOI 10.1007/s00439-004-1233-4
NR 49
TC 11
Z9 11
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 21
PY 2012
VL 7
IS 12
AR e52381
DI 10.1371/journal.pone.0052381
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 065OW
UT WOS:000313158800059
PM 23285018
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Elley, CR
   Gupta, AK
   Webster, R
   Selak, V
   Jun, M
   Patel, A
   Rodgers, A
   Thom, S
AF Elley, C. Raina
   Gupta, Ajay K.
   Webster, Ruth
   Selak, Vanessa
   Jun, Min
   Patel, Anushka
   Rodgers, Anthony
   Thom, Simon
TI The Efficacy and Tolerability of 'Polypills': Meta-Analysis of
   Randomised Controlled Trials
SO PLOS ONE
LA English
DT Article
ID CARDIOVASCULAR RISK-FACTORS; PRESSURE-LOWERING DRUGS; BLOOD-PRESSURE;
   PRIMARY PREVENTION; COST-EFFECTIVENESS; INCOME COUNTRIES; CHRONIC
   DISEASES; MIDDLE-INCOME; PRIMARY-CARE; DOUBLE-BLIND
AB Background: To assess the blood pressure and lipid-lowering efficacy and tolerability of 'polypills' used in cardiovascular disease prevention trials.
   Methodology/Principal Findings: Systematic review and meta-analysis. Search strategy: The Cochrane Central Register of Controlled Trials, Medline, and PubMed databases were searched for eligible trials. Study inclusion criteria: Randomised controlled trials of at least six weeks duration, which compared a 'polypill' (that included at least one anti-hypertensive and one lipid-lowering medication) with a placebo (or one active component). Outcome measures: Change from baseline in systolic and diastolic blood pressures, and total and LDL-cholesterol; discontinuation of study medication and reported adverse effects. Of 44 potentially eligible studies, six trials (including 2,218 patients without previous cardiovascular disease) fulfilled the inclusion criteria. Compared with placebo, 'polypills' reduced systolic blood pressure by -9.2 mmHg (95% confidence interval (CI): -13.4, -5.0) diastolic blood pressure by -5.0 mmHg (95% CI: -7.4, -2.6), total cholesterol by -1.22 mmol/L (95% CI: -1.60, -0.84) and LDL-cholesterol by -1.02 mmol/L (95% CI: -1.37, -0.67). However, those taking a 'polypill' (vs. placebo or component) were more likely to discontinue medication (20% vs 14%) (Odds ratio: 1.5 (95% CI: 1.2, 1.9)). There was no significant difference in reported adverse effects amongst those on a 'polypill' (36% vs. 28%) (OR: 1.3 (95% CI: 0.7, 2.5)). There was high statistical heterogeneity in comparisons for blood pressure and lipid-lowering but use of random-effects and quality-effects models produced very similar results.
   Conclusions/Significance: Compared with placebo, the 'polypills' reduced blood pressure and lipids. Tolerability was lower amongst those on 'polypills' than those on placebo or one component, but differences were moderate. Effectiveness trials are needed to help clarify the status of 'polypills' in primary care and prevention strategies.
C1 [Elley, C. Raina; Selak, Vanessa] Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand.
   [Gupta, Ajay K.; Thom, Simon] Univ London Imperial Coll Sci Technol & Med, Int Ctr Circulatory Hlth, London, England.
   [Webster, Ruth; Jun, Min; Patel, Anushka; Rodgers, Anthony] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia.
RP Elley, CR (reprint author), Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand.
EM c.elley@auckland.ac.nz
OI Selak, Vanessa/0000-0002-9824-8674; Jun, Min/0000-0003-1460-7535;
   Rodgers, Anthony/0000-0003-1282-1896; Webster, Ruth/0000-0002-7444-3037
FU Dr Reddy's Ltd (DRL)
FX The authors have read the journal's policy and have the following
   conflicts: AR and RW have received a grant from Dr Reddy's Ltd (DRL) for
   the SPACE collaboration centre but this is unrelated to the current
   meta-analysis. DRL also provided a fixed dose combination formulation
   free of charge for four randomized controlled trials to assess the
   effectiveness of a "polypill-based strategy." CRE, VS, AP, ST and AR are
   investigators or are on the steering committee of at least one of these
   trials. The George Institute for Global Health is now negotiating a
   global license for these products, following a decision by DRL not to
   proceed with taking the products to market because of existing
   regulatory requirements. DRL has provided travel assistance to meetings
   on "polypills" for CRE, RW, VS, AP, ST and AR in the past. AKG has
   received travel assistance to attend a conference from Pfizer. This does
   not alter the authors' adherence to all the PLOS ONE policies on sharing
   data and materials.
CR [Anonymous], 2002, WHO WELLC TRUST M 1
   Banerjee A, 2010, LANCET, V375, P166, DOI 10.1016/S0140-6736(09)61296-4
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Calonge N, 2009, ANN INTERN MED, V150, P396
   Chapman RH, 2005, ARCH INTERN MED, V165, P1147, DOI 10.1001/archinte.165.10.1147
   Cholesterol Treatment Trialists' (CTT) Collaborators, 2012, LANCET, V6736, P60367
   Cobiac LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041842
   Doi SAR, 2011, CONTEMP CLIN TRIALS, V32, P288, DOI 10.1016/j.cct.2010.12.006
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elley CR, 2008, DIABETES RES CLIN PR, V79, P468, DOI 10.1016/j.diabres.2007.09.018
   Furukawa TA, 2006, J CLIN EPIDEMIOL, V59, P7, DOI 10.1016/j.jclinepi.2005.06.006
   Gaziano TA, 2006, LANCET, V368, P679, DOI 10.1016/S0140-6736(06)69252-0
   Grimm R, 2010, VASC HEALTH RISK MAN, V6, P261
   Gupta AK, 2010, HYPERTENSION, V55, P399, DOI 10.1161/HYPERTENSIONAHA.109.139816
   Higgins J. P. T., 2011, COCHRANE HDB SYSTEMA
   Jadad AR, 1996, CONTROL CLIN TRIALS, V1, P1, DOI DOI 10.1016/0197-2456(95)00134-4]
   Kulkarni SP, 2006, AM HEART J, V151, P185, DOI 10.1016/j.ahj.2005.02.038
   Lafeber M, 2011, EUR J PREV CARDIOL, P1
   Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665
   Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427
   Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423
   Liew D, 2009, CLIN THER, V31, P2189, DOI 10.1016/j.clinthera.2009.10.015
   Lim SS, 2007, LANCET, V370, P2054, DOI 10.1016/S0140-6736(07)61699-7
   Liu HM, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-458
   Lonn E, 2010, CIRCULATION, V122, P2078, DOI 10.1161/CIRCULATIONAHA.109.873232
   Malekzadeh F, 2010, INT J CLIN PRACT, V64, P1220, DOI 10.1111/j.1742-1241.2010.02412.x
   Murray CJL, 2003, LANCET, V361, P717, DOI 10.1016/S0140-6736(03)12655-4
   National Institute for Health and Clinical Excellence, 2011, SEC PREV PRIM SEC CA
   Neutel JM, 2009, J CLIN HYPERTENS, V11, P22, DOI 10.1111/j.1751-7176.2008.00058.x
   New Zealand Guidelines Group, 2012, NZ PRIM CAR HDB 2012
   Niens LM, 2010, PLOS MED, V7
   Rodgers A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019857
   Sanz G, 2011, AM HEART J, V162, DOI 10.1016/j.ahj.2011.08.012
   Selak V, 2011, CONTEMP CLIN TRIALS, V32, P909, DOI 10.1016/j.cct.2011.07.006
   Selak V, 2009, NEW ZEAL MED J, V122, P41
   Soliman EZ, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-3
   Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101
   Strong K, 2005, LANCET, V366, P1578, DOI 10.1016/S0140-6736(05)67341-2
   Thom S, 2012, EUR J PREVENTIVE CAR
   van Gils PF, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000363
   Wald DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041297
   Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419
   World Health Organization, 2003, ADHERENCE LONG TERM
   World Health Organization, 2008, GLOB BURD DIS 2004 U
   Yusuf S, 2009, LANCET, V373, P1341, DOI 10.1016/S0140-6736(09)60611-5
   Yusuf S, 2002, LANCET, V360, P2, DOI 10.1016/S0140-6736(02)09358-3
   Yusuf S, 2012, CIRC-CARDIOVASC QUAL, V5, P463, DOI 10.1161/CIRCOUTCOMES.111.963637
   Yusuf S, 2011, LANCET, V378, P1231, DOI 10.1016/S0140-6736(11)61215-4
   Zamorano J, 2010, POSTGRAD MED, V122, P7, DOI 10.3810/pgm.2010.03.2117
   2002, BMJ, V324, P71
NR 50
TC 52
Z9 53
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 19
PY 2012
VL 7
IS 12
AR e52145
DI 10.1371/journal.pone.0052145
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 059HF
UT WOS:000312694300075
PM 23284906
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Guo, H
   Ming, J
   Liu, CP
   Li, Z
   Zhang, N
   Cheng, HT
   Wang, W
   Shi, W
   Shen, N
   Zhao, QZ
   Li, DP
   Yi, PF
   Wang, LQ
   Wang, R
   Xin, Y
   Zhao, XW
   Nie, X
   Huang, T
AF Guo, Hui
   Ming, Jie
   Liu, Chunping
   Li, Zhi
   Zhang, Ning
   Cheng, Hongtao
   Wang, Wei
   Shi, Wei
   Shen, Na
   Zhao, Qunzi
   Li, Dapeng
   Yi, Pengfei
   Wang, Longqiang
   Wang, Rui
   Xin, Yue
   Zhao, Xiangwang
   Nie, Xiu
   Huang, Tao
TI A Common Polymorphism near the ESR1 Gene Is Associated with Risk of
   Breast Cancer: Evidence from a Case-Control Study and a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; BRCA2 MUTATION CARRIERS; SUSCEPTIBILITY LOCUS;
   CHINESE WOMEN; ESTROGEN-RECEPTOR; ALLELES; CONSORTIUM; VARIANTS; 6Q25.1;
   JAPANESE
AB Background: Genome-wide association studies have reported that a polymorphism near the estrogen receptor gene (ESR1) (rs2046210) is associated with a risk of breast cancer, with the A allele conferring an increased risk. However, considering the controversial results from more recent replicated studies, we conducted a case-control study in an independent Chinese Han population and a meta-analysis to clarify the association of this polymorphism with breast cancer risk.
   Method and Findings: A hospital-based case-control study including 461 cases and 537 controls from a Chinese Han population was conducted initially, and this study showed that the rs2046210 A allele was significantly associated with breast cancer risk, with an OR of 1.32 (95% CI = 1.10-1.59). Subsequently, a meta-analysis integrating the current study and previous publications with a total of 53,379 cases and 55,493 controls was performed to further confirm our findings. Similarly, a significant association between this polymorphism and breast cancer risk was also observed in the overall population especially among Asians, with ORs for per A allele of 1.14 (95% CI = 1.10-1.18) in the overall population and 1.27 (95% CI = 1.23-1.31) in the Asian population.
   Conclusion: Our results provide strong evidence to support that the common polymorphism near the ESR1 gene, rs2046210, is associated with an increased risk of breast cancer in Asian and European populations but not in Africans, although the biological mechanisms need to be further investigated.
C1 [Nie, Xiu] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pathol, Wuhan 430074, Peoples R China.
   [Cheng, Hongtao; Wang, Wei] Hubei Canc Hosp, Dept Breast Surg, Wuhan, Peoples R China.
   [Guo, Hui; Ming, Jie; Liu, Chunping; Li, Zhi; Zhang, Ning; Shi, Wei; Shen, Na; Zhao, Qunzi; Li, Dapeng; Yi, Pengfei; Wang, Longqiang; Wang, Rui; Xin, Yue; Zhao, Xiangwang; Huang, Tao] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Breast & Thyroid Surg, Wuhan 430074, Peoples R China.
RP Nie, X (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pathol, Wuhan 430074, Peoples R China.
EM niexiuyishi@126.com; huangtaowh@gmail.com
FU National Natural Science Foundation of China [30972935, 81001171,
   81202094]; Key Technologies R & D Program of Hubei Province
   [2007AA302B07]
FX This work was supported by the National Natural Science Foundation of
   China (grants 30972935, 81001171 and 81202094) and Key Technologies R &
   D Program of Hubei Province (grant 2007AA302B07). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Antoniou AC, 2011, HUM MOL GENET, V20, P3304, DOI 10.1093/hmg/ddr226
   Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cai QY, 2011, HUM MOL GENET, V20, P4991, DOI 10.1093/hmg/ddr405
   Cai QY, 2011, CANCER RES, V71, P1344, DOI 10.1158/0008-5472.CAN-10-2733
   Cai QY, 2003, CANCER EPIDEM BIOMAR, V12, P853
   Campa D, 2011, J NATL CANCER I, V103, P1252, DOI 10.1093/jnci/djr265
   Carlson RW, 2012, NCCN CLIN PRACTICE G
   Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407
   Dai JC, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3101
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Easton D F, 1999, Breast Cancer Res, V1, P14, DOI 10.1186/bcr6
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fletcher O, 2011, JNCI-J NATL CANCER I, V103, P425, DOI 10.1093/jnci/djq563
   Gold B, 2008, P NATL ACAD SCI USA, V105, P4340, DOI 10.1073/pnas.0800441105
   Han J, 2011, BREAST CANCER RES TR, V129, P901, DOI 10.1007/s10549-011-1527-x
   Han W, 2011, CANCER EPIDEM BIOMAR, V20, P793, DOI 10.1158/1055-9965.EPI-10-1282
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jiang YD, 2011, BREAST CANCER RES TR, V128, P251, DOI 10.1007/s10549-010-1327-8
   Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091
   Kibriya MG, 2009, BREAST CANCER RES TR, V114, P463, DOI 10.1007/s10549-008-0039-9
   Kim HC, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3158
   Kiyotani K, 2012, HUM MOL GENET, V21, P1665, DOI 10.1093/hmg/ddr597
   Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Li Guoliang, 2011, Chin J Cancer, V30, P138
   Li N, 2010, BREAST CANCER RES TR, V121, P177, DOI 10.1007/s10549-009-0532-9
   Long JR, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002532
   Long JR, 2010, CANCER EPIDEM BIOMAR, V19, P2357, DOI 10.1158/1055-9965.EPI-10-0054
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mullen B, 2001, PERS SOC PSYCHOL B, V27, P1450, DOI 10.1177/01461672012711006
   Mulligan AM, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3052
   Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876
   Pabalan NA, 2010, ASIAN PAC J CANCER P, V11, P33
   Shu XO, 2012, CANCER RES, V72, P1182, DOI 10.1158/0008-5472.CAN-11-2561
   Stacey SN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001029
   Stevens KN, 2011, CANCER RES, V71, P6240, DOI 10.1158/0008-5472.CAN-11-1266
   Sueta A, 2012, BREAST CANCER RES TR, V132, P711, DOI 10.1007/s10549-011-1904-5
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thomas G, 2009, NAT GENET, V41, P579, DOI 10.1038/ng.353
   Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187
   Turnbull C, 2010, NAT GENET, V42, P504, DOI 10.1038/ng.586
   WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231
   Zheng W, 2010, J NATL CANCER I, V102, P972, DOI 10.1093/jnci/djq170
   Zheng W, 2009, NAT GENET, V41, P324, DOI 10.1038/ng.318
   Zhong H, 2010, GENET EPIDEMIOL, V34, P78, DOI 10.1002/gepi.20437
NR 48
TC 17
Z9 17
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 18
PY 2012
VL 7
IS 12
AR e52445
DI 10.1371/journal.pone.0052445
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 056JC
UT WOS:000312483300087
PM 23272245
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yu, ZB
   Han, SP
   Chu, JH
   Xu, ZY
   Zhu, C
   Guo, XR
AF Yu, Zhangbin
   Han, Shuping
   Chu, Jiahui
   Xu, Zhongya
   Zhu, Chun
   Guo, Xirong
TI Trends in Overweight and Obesity among Children and Adolescents in China
   from 1981 to 2010: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID BODY-MASS INDEX; CORONARY-HEART-DISEASE; UNITED-STATES; CHILDHOOD
   OBESITY; RISK-FACTORS; SOCIOECONOMIC-STATUS; ADULT HYPERTENSION;
   PRESCHOOL-CHILDREN; FEEDING BEHAVIORS; MAINLAND CHINA
AB Background: Overweight/obesity is a serious public health problem that affects a large part of the world population across all age and racial/ethnic groups. However, there has not been a meta-analysis of the prevalence of childhood and adolescent overweight/obesity in China during the past 30 years.
   Methods: The China National Knowledge Infrastructure and Wanfang DATA, MEDLINE, EMBASE and Cumulative Index to Nursing and Allied Health Literature were searched for relevant studies published between January 1970 and June 2012. The prevalence of overweight/obesity over time was pooled using Stata/SE, version 9. Summary statistics (odds ratios, ORs) were used to compare sex-specific and urban-rural preponderance of overweight/obesity using Review Manager.
   Results: After screening 1326 papers, we included 35 papers (41 studies), most of medium quality. The prevalence of overweight/obesity increased from 1.8% (95% confidence interval [CI], 0.4%-3.1%) and 0.4% (95% CI, -0.1% to -0.8%) respectively in 1981-1985 to 13.1% (95% CI, 11.2%-15.0%) and 7.5% (95% CI, 6.6%-8.4%) respectively in 2006-2010. The average annual increase was 8.3% and 12.4% respectively. Boys were more likely to be overweight/obese than girls (OR, 1.36; 95% CI, 1.24-1.49 and OR, 1.68; 95% CI, 1.52-1.86 respectively). The prevalence of overweight/obesity was higher in urban areas than in rural areas (OR, 1.66; 95% CI, 1.54-1.79 and OR, 1.97; 95% CI, 1.68-2.30 respectively). For age-specific subgroup analyses, both overweight and obesity increased more rapidly in the toddler stage than in other developmental stages. Sensitivity analyses showed that sample-size differences, study quality, overweight/obesity criteria and geographical distribution affected overweight/obesity prevalence.
   Conclusions: Toddlers and urban boys were at particularly high risk; the prevalence in these groups increased more rapidly than in their counterparts. Public health prevention strategies are urgently needed to modify health behaviors of children and adolescents and control overweight/obesity in China.
C1 [Yu, Zhangbin; Han, Shuping; Chu, Jiahui; Xu, Zhongya; Zhu, Chun; Guo, Xirong] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Dept Pediat, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.
   [Chu, Jiahui; Xu, Zhongya] Nanjing Med Univ, Sch Clin Med 1, Nanjing, Jiangsu, Peoples R China.
RP Guo, XR (reprint author), Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Dept Pediat, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.
EM xrguo@njmu.edu.cn
FU National Key Basic Research Program of China [2013CB530604]; National
   Natural Science Foundation of China [81270928]; Priority Academic
   Program Development of Jiangsu Higher Education Institutions
   [201104013]; Natural Science Foundation of Jiangsu Province [BK2011107]
FX This work was supported by grants from the National Key Basic Research
   Program of China (2013CB530604), the National Natural Science Foundation
   of China (grant no. 81270928), the Priority Academic Program Development
   of Jiangsu Higher Education Institutions (grant no. 201104013), and the
   Natural Science Foundation of Jiangsu Province (grant no. BK2011107).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ahmed ML, 2009, TRENDS ENDOCRIN MET, V20, P237, DOI 10.1016/j.tem.2009.02.004
   Andegiorgish AK, 2012, EUR J PEDIATR, V171, P697, DOI 10.1007/s00431-011-1636-x
   Baker JL, 2007, NEW ENGL J MED, V357, P2329, DOI 10.1056/NEJMoa072515
   Baskin ML, 2005, OBES REV, V6, P5, DOI 10.1111/j.1467-789X.2005.00165.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benton D, 2004, INT J OBESITY, V28, P858, DOI 10.1038/sj.ijo.0802532
   Boehmer Tegan K, 2007, Prev Chronic Dis, V4, pA56
   Bovet P, 2008, OBES REV, V9, P511, DOI 10.1111/j.1467-789X.2008.00513.x
   Burdette HL, 2005, PEDIATRICS, V116, P657, DOI 10.1542/peds.2004-2443
   Cao ZQ, 2012, AM J HYPERTENS, V25, P576, DOI 10.1038/ajh.2012.5
   Carruth BR, 2004, J AM DIET ASSOC, V104, pS51, DOI 10.1016/j.jada.2003.10.019
   Chan L, 2011, MATERN CHILD HLTH J, V15, P1363, DOI 10.1007/s10995-010-0686-4
   Chen CM, 2008, OBES REV, V9, P14, DOI 10.1111/j.1467-789X.2007.00433.x
   Chen C M, 1986, Food Nutr (Roma), V12, P58
   Chen CM, 2009, GUIDELINE PREVENTION
   Chen M, 2002, CHINA PUBLIC HLTH, V18, P161
   Chen TJ, 2011, ACTA PAEDIATR, V100, P1583, DOI 10.1111/j.1651-2227.2011.02397.x
   Cheng TO, 2005, INT J CARDIOL, V98, P173, DOI 10.1016/j.ijcard.2004.08.019
   Chinese National Survey on Students Constitution and Health (CNSSCH), 1993, 1991 CHIN NAT SURV S
   Chinese National Survey on Students Constitution and Health (CNSSCH), 1997, 1995 CHIN NAT SURV S
   Chinese National Survey on Students Constitution and Health (CNSSCH), 2007, 2005 CHIN NAT SURV S
   Chinese National Survey on Students Constitution and Health (CNSSCH), 1987, 1985 CHIN NAT SURV S
   Chinese National Survey on Students Constitution and Health (CNSSCH), 2002, 2000 CHIN NAT SURV S
   Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Cui ZH, 2010, INT J PEDIATR OBES, V5, P365, DOI 10.3109/17477166.2010.490262
   Davis AM, 2011, J PEDIATR PSYCHOL, V36, P669, DOI 10.1093/jpepsy/jsq117
   Ding Z, 1998, Zhonghua Yi Xue Za Zhi, V78, P121
   DING Z, 1989, Acta Nutrimenta Sinica, V11, P266
   Ding ZY, 1988, J CLIN  PEDIAT, V6, P293
   Ge K, 1995, DIETARY NUTR STATUS, V1
   Group of China Obesity Task Force, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P97
   Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hui L, 2003, HEALTH PLACE, V9, P371, DOI 10.1016/S1353-8292(03)00049-2
   James WPT, 2008, OBES REV, V9, P2, DOI 10.1111/j.1467-789X.2007.00430.x
   Ji CY, 2008, OBES REV, V9, P78, DOI 10.1111/j.1467-789X.2007.00443.x
   Ko GTC, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-10
   Kollias A, 2011, J PEDIATR ENDOCR MET, V24, P929, DOI 10.1515/JPEM.2011.309
   Lawlor DA, 2005, CIRCULATION, V111, P1891, DOI 10.1161/01.CIR.0000161798.45728.4D
   LEBOEUFYDE C, 1995, SPINE, V20, P2112, DOI 10.1097/00007632-199510000-00009
   Levine JA, 2008, CHINESE MED J-PEKING, V121, P1043, DOI 10.1097/00029330-200806010-00015
   Li Li-ming, 2005, Zhonghua Liu Xing Bing Xue Za Zhi, V26, P478
   Li LL, 2007, HENAN J PREVENT MED, V18, P18
   Liang YJ, 2012, PEDIATR OBES, V7, P355, DOI 10.1111/j.2047-6310.2012.00066.x
   Liu JM, 2007, ARCH MED RES, V38, P882, DOI 10.1016/j.arcmed.2007.05.006
   Liu XJ, 2012, CHIN J SCL HLTH, V33, P209
   [吕建中 LV Jian-zhong], 2009, [中华流行病学杂志, Chinese Journal of Epidemiology], V30, P868
   Ma YN, 2011, ARCH MED RES, V42, P633, DOI 10.1016/j.arcmed.2011.10.011
   Maclaren NK, 2007, CELL BIOCHEM BIOPHYS, V48, P73, DOI 10.1007/s12013-07-0017-6
   Ming C, 2012, J CHILD HEALTH CARE, V20, P224
   National Task Force on Childhood Obesity National Center for Women's and Children's Health, 2008, Zhonghua Er Ke Za Zhi, V46, P179
   Ogden CL, 2002, PEDIATRICS, V109, P45, DOI 10.1542/peds.109.1.45
   Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549
   Ogden CL, 2012, JAMA-J AM MED ASSOC, V307, P483, DOI 10.1001/jama.2012.40
   Park MH, 2012, OBES REV, V13, P985, DOI 10.1111/j.1467-789X.2012.01015.x
   Popkin BM, 2010, INT J EPIDEMIOL, V39, P1435, DOI 10.1093/ije/dyp322
   Sabo RT, 2012, OBESITY, V20, P1741, DOI 10.1038/oby.2012.58
   Sandhu N, 2008, J PEDIATR ENDOCR MET, V21, P631
   Scaglioni S, 2008, BRIT J NUTR, V99, pS22, DOI 10.1017/S0007114508892471
   Shan XY, 2010, INT J PEDIATR OBES, V5, P383, DOI 10.3109/17477160903572001
   Shang XW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043183
   Sjoberg A, 2011, OBES REV, V12, P305, DOI 10.1111/j.1467-789X.2010.00838.x
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tzamaloukas AH, 2003, JPEN-PARENTER ENTER, V27, P340, DOI 10.1177/0148607103027005340
   Vander Wal JS, 2011, PEDIATR CLIN N AM, V58, P1393, DOI 10.1016/j.pcl.2011.09.008
   Virdis A, 2009, CURR PHARM DESIGN, V15, P1063, DOI 10.2174/138161209787846900
   Wang DM, 2012, CHIN J SCL HLTH, V33, P248
   Wang HY, 2011, CHIN J PRIMARY MED P, V18, P353
   Wang JL, 2008, J CHILD HEALTH CARE, V16, P55
   Wang SF, 2005, MATERN CHILD HLTH J, V20, P169
   Wang YF, 2001, INT J EPIDEMIOL, V30, P1129, DOI 10.1093/ije/30.5.1129
   Wei M, 2007, J PREV MED, V19, P349
   Wisniewski AB, 2009, GENDER MED, V6, P76, DOI 10.1016/j.genm.2008.12.001
   Wolman Julia, 2008, Community Pract, V81, P28
   Wu Jing, 2008, Zhongguo Dang Dai Er Ke Za Zhi, V10, P231
   Xi B, 2012, OBES REV, V13, P287, DOI 10.1111/j.1467-789X.2011.00944.x
   Xiong F, 2005, CHONGQING MED J, V34, P1838, DOI [DOI 10.3969/J.ISSN.1671-8348.2005.12.033, 10.3969/j.issn.1671-8348.2005.12.033]
   Yang JH, 2007, SOC SCI MED, V64, P2043, DOI 10.1016/j.socscimed.2007.02.024
   Yu ZB, 2010, OBES REV, V11, P656, DOI 10.1111/j.1467-789X.2009.00656.x
   Zhang JM, 2003, ANTHOLOGY MED, V22, P41
   Zhang MY, 2012, PEDIATR DIABETES, V13, P572, DOI 10.1111/j.1399-5448.2012.00877.x
   Zhang X, 2011, PUBLIC HEALTH NUTR, P1
   Zhang YX, 2012, J PUBLIC HEALTH-UK, V34, P131, DOI 10.1093/pubmed/fdr053
   Zhao W, 2008, OBES REV, V9, P62, DOI 10.1111/j.1467-789X.2007.00440.x
   Zuo H, 2000, SHAANXI MED J, V29, P693
NR 85
TC 74
Z9 80
U1 3
U2 65
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 17
PY 2012
VL 7
IS 12
AR e51949
DI 10.1371/journal.pone.0051949
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 055RZ
UT WOS:000312435900066
PM 23284829
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Jiang, YS
   Zhang, RJ
   Zheng, JJ
   Liu, PP
   Tang, GP
   Lv, HC
   Zhang, LY
   Shang, ZW
   Zhan, YB
   Lv, WH
   Shi, M
   Zhang, RM
AF Jiang, Yongshuai
   Zhang, Ruijie
   Zheng, Jiajia
   Liu, Panpan
   Tang, Guoping
   Lv, Hongchao
   Zhang, Lanying
   Shang, Zhenwei
   Zhan, Yuanbo
   Lv, Wenhua
   Shi, Miao
   Zhang, Ruimin
TI Meta-Analysis of 125 Rheumatoid Arthritis-Related Single Nucleotide
   Polymorphisms Studied in the Past Two Decades
SO PLOS ONE
LA English
DT Article
ID SUSCEPTIBILITY; ASSOCIATION; GENETICS; HETEROGENEITY; PHOSPHATASE;
   DISEASE; PADI4; BIAS
AB Objective: Candidate gene association studies and genome-wide association studies (GWAs) have identified a large number of single nucleotide polymorphisms (SNPs) loci affecting susceptibility to rheumatoid arthritis (RA). However, for the same locus, some studies have yielded inconsistent results. To assess all the available evidence for association, we performed a meta-analysis on previously published case-control studies investigating the association between SNPs and RA.
   Methods: Two hundred and sixteen studies, involving 125 SNPs, were reviewed. For each SNP, three genetic models were considered: the allele, dominant and recessive effects models. For each model, the effect summary odds ratio (OR) and 95% CIs were calculated. Cochran's Q-statistics were used to assess heterogeneity. If the heterogeneity was high, a random effects model was used for meta-analysis, otherwise a fixed effects model was used.
   Results: The meta-analysis results showed that: (1) 30, 28 and 26 SNPs were significantly associated with RA (P<0.01) for the allele, dominant, and recessive models, respectively. (2) rs2476601 (PTPN22) showed the strongest association for all the three models: OR = 1.605, 95% CI: 1.540-1.672, P<1.00E215 for the T-allele; OR = 1.638, 95% CI: 1.565-1.714, P<1.00E-15 for the T/T+T/C genotype and OR = 2.544, 95% CI: 2.173-2.978, P<1.00E215 for the T/T genotype. (3) Only 23 (18.4%), 13 (10.4%) and 15 (12.0%) SNPs had high heterogeneity (P<0.01) for the three models, respectively. (4) For some of the SNPs, there was no publication bias according to Funnel plots and Egger's regression tests (P<0.01). For the other SNPs, the associations were tested in only a few studies, and may have been subject to publication bias. More studies on these loci are required.
   Conclusion: Our meta-analysis provides a comprehensive evaluation of the RA association studies from the past two decades. The detailed meta-analysis results are available at: http://210.46.85.180/DRAP/index.php/Metaanalysis/index.
C1 [Jiang, Yongshuai; Zhang, Ruijie; Zheng, Jiajia; Liu, Panpan; Tang, Guoping; Lv, Hongchao; Zhang, Lanying; Shang, Zhenwei; Lv, Wenhua; Shi, Miao] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.
   [Zhan, Yuanbo; Zhang, Ruimin] Harbin Med Univ, Affiliated Hosp 2, Harbin, Peoples R China.
RP Zhang, RJ (reprint author), Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.
EM zhangruijie2009@yahoo.com.cn; zhangrmokok@126.com
OI Jiang, Yongshuai/0000-0002-7163-6554
FU National Natural Science Foundation of China [81172842, 31200934];
   Natural Science Foundation of Heilongjiang Province [C201206]
FX This work was supported in part by the National Natural Science
   Foundation of China (Grant Nos. 81172842, 31200934) and Natural Science
   Foundation of Heilongjiang Province (Grant No. C201206). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bowes J, 2008, RHEUMATOLOGY, V47, P399, DOI 10.1093/rheumatology/ken005
   Egger M, 1997, BMJ-BRIT MED J, V315, P1371, DOI 10.1136/bmj.315.7119.1371
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fiorillo E, 2010, J BIOL CHEM, V285, P26506, DOI 10.1074/jbc.M110.111104
   GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102
   HASSTEDT SJ, 1994, AM J HUM GENET, V55, P738
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Iwamoto T, 2006, RHEUMATOLOGY, V45, P804, DOI 10.1093/rheumatology/ke1023
   Ji JD, 2010, MOL BIOL REP, V37, P141, DOI 10.1007/s11033-009-9553-z
   Ke-Wei R, 2012, ARCH MED RES
   Klareskog L, 2006, NAT CLIN PRACT RHEUM, V2, P425, DOI 10.1038/ncprheum0249
   Klareskog L, 2009, LANCET, V373, P659, DOI 10.1016/S0140-6736(09)60008-8
   Kvien TK, 1997, SCAND J RHEUMATOL, V26, P412, DOI 10.3109/03009749709065712
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lee YH, 2007, RHEUMATOL INT, V27, P827, DOI 10.1007/s00296-007-0320-y
   Lee YH, 2011, MOL BIOL REP, V38, P3643, DOI 10.1007/s11033-010-0477-4
   Lee YH, 2010, RHEUMATOL INT, V30, P661, DOI 10.1007/s00296-009-1051-z
   Li YH, 2009, SEMIN IMMUNOL, V21, P318, DOI 10.1016/j.smim.2009.04.002
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   MacGregor AJ, 2000, ARTHRITIS RHEUM, V43, P30, DOI 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B
   Milicic A, 2001, TISSUE ANTIGENS, V58, P50, DOI 10.1034/j.1399-0039.2001.580110.x
   Munoz-Valle JF, 2010, CLIN CHIM ACTA, V411, P725, DOI 10.1016/j.cca.2010.02.001
   Raychaudhuri S, 2010, CURR OPIN RHEUMATOL, V22, P109, DOI 10.1097/BOR.0b013e328336474d
   Totaro MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024292
   van der Woude D, 2009, ARTHRITIS RHEUM-US, V60, P916, DOI 10.1002/art.24385
   Vang T, 2005, NAT GENET, V37, P1317, DOI 10.1038/ng1673
   Zintzaras E, 2006, CLIN GENET, V69, P327, DOI 10.1111/j.1399-0004.2006.00605.x
NR 30
TC 2
Z9 2
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 10
PY 2012
VL 7
IS 12
AR e51571
DI 10.1371/journal.pone.0051571
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 052ML
UT WOS:000312201900105
PM 23251581
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Qin, H
   Luo, J
   Zhu, YP
   Xie, HL
   Yang, WQ
   Lei, WB
AF Qin, Hao
   Luo, Jie
   Zhu, Yuan-Ping
   Xie, Hai-Li
   Yang, Wei-Qiang
   Lei, Wen-Bin
TI Combination of Taxanes, Cisplatin and Fluorouracil as Induction
   Chemotherapy for Locally Advanced Head and Neck Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; PHASE-III; RANDOMIZED-TRIAL; DOCETAXEL;
   CHEMORADIOTHERAPY; RADIOTHERAPY; PACLITAXEL; STANDARD; SURVIVAL; THERAPY
AB Background: Some investigations have suggested that induction chemotherapy with a combination of taxanes, cisplatin and fluorouracil (TPF) is effective in locally advanced head and neck cancer. However, other trials have indicated that TPF does not improve outcomes. The objective of this study was to compare the efficacy and safety of TPF with a cisplatin and fluorouracil (PF) regimen through a meta-analysis.
   Methods: Four randomized clinical trials were identified, which included 1,552 patients with locally advanced head and neck cancer who underwent induction chemotherapy with either a TPF or PF protocol. The outcomes included the 3-year survival rate, overall response rate and different types of adverse events. Risk ratios (RRs) and their 95% confidence intervals (CIs) were pooled using RevMan 5.1 software.
   Results: The 3-year survival rate (51.0% vs. 42.4%; p = 0.002), 3-year progression-free survival rate (35.9% vs. 27.2%; p = 0.007) and overall response to chemotherapy (72.9% vs. 62.1%; p < 0.00001) of the patients in the TPF group was statistically superior to those in the PF group. In terms of toxicities, the incidence of febrile neutropenia (7.0% vs. 3.2%; p = 0.001) and alopecia (10.8% vs. 1.1%; p < 0.00001) was higher in the TPF group.
   Conclusion: The TPF induction chemotherapy regimen leads to a significant survival advantage with acceptable toxicity rates for patients with locally advanced head and neck cancer compared with the PF regimen.
C1 [Qin, Hao; Luo, Jie; Zhu, Yuan-Ping; Yang, Wei-Qiang; Lei, Wen-Bin] Sun Yat Sen Univ, Otorhinolaryngol Inst, Affiliated Hosp 1, Dept Otorhinolaryngol, Guangzhou 510275, Guangdong, Peoples R China.
   [Xie, Hai-Li] Sun Yat Sen Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, Guangzhou 510275, Guangdong, Peoples R China.
RP Lei, WB (reprint author), Sun Yat Sen Univ, Otorhinolaryngol Inst, Affiliated Hosp 1, Dept Otorhinolaryngol, Guangzhou 510275, Guangdong, Peoples R China.
EM leiwb2003@yahoo.com.cn
FU National Natural Science Foundation of China [81072224]; Young Faculty
   Cultivation Project of Sun Yat-sen University [10ykpy10]; Science and
   Technology Planning Project of Guangdong Province [2009B030801109]
FX This study was supported by National Natural Science Foundation of China
   (81072224), Young Faculty Cultivation Project of Sun Yat-sen University
   (10ykpy10) and Science and Technology Planning Project of Guangdong
   Province (2009B030801109). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brockstein B, 2004, ANN ONCOL, V15, P1179, DOI 10.1093/annonc/mdh308
   Chandana SR, 2009, CURR OPIN ONCOL, V21, P218, DOI 10.1097/CCO.0b013e328329abe5
   Denis F, 2004, J CLIN ONCOL, V22, P69, DOI 10.1200/JCO.2004.08.021
   Forastiere AA, 2006, LONG TERM RESULTS IN
   FRANCIS PA, 1995, LUNG CANCER-J IASLC, V12, pS163, DOI 10.1016/0169-5002(95)00432-Z
   Harari PM, 1997, J CLIN ONCOL, V15, P2050, DOI 10.1200/JCO.1997.15.5.2050
   Hitt R, 2005, J CLIN ONCOL, V23, P8636, DOI 10.1200/JCO.2004.00.1990
   Hitt R, 2009, ASCO M, V27, P6009
   HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kutter J, 2005, EUR ARCH OTO-RHINO-L, V262, P1, DOI 10.1007/s00405-003-0725-5
   Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890
   Lorch JH, 2011, LANCET ONCOL, V12, P153, DOI 10.1016/S1420-2045(10)20279-5
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   PACCAGNELLA A, 1994, J NATL CANCER I, V86, P265, DOI 10.1093/jnci/86.4.265
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Parthan A, 2009, HEAD NECK-J SCI SPEC, V31, P1255, DOI 10.1002/hed.21096
   Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4
   Pignon JP, 2004, ANTI-CANCER DRUG, V15, P331, DOI 10.1097/00001813-200404000-00004
   Pointreau Y, 2009, JNCI-J NATL CANCER I, V101, P498, DOI 10.1093/jnci/djp007
   Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956
   ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247
   Schrijvers D, 2000, Oncologist, V5, P199, DOI 10.1634/theoncologist.5-3-199
   Seiwert TY, 2005, BRIT J CANCER, V92, P1341, DOI 10.1038/sj.bjc.6602510
   Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028
   Yano R, 2011, INT J CLIN ONCOL
NR 28
TC 13
Z9 14
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 7
PY 2012
VL 7
IS 12
AR e51526
DI 10.1371/journal.pone.0051526
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 050OT
UT WOS:000312064100127
PM 23236511
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Cheraghi, Z
   Poorolajal, J
   Hashem, T
   Esmailnasab, N
   Irani, AD
AF Cheraghi, Zahra
   Poorolajal, Jalal
   Hashem, Tahereh
   Esmailnasab, Nader
   Irani, Amin Doosti
TI Effect of Body Mass Index on Breast Cancer during Premenopausal and
   Postmenopausal Periods: A Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID PROGESTERONE-RECEPTOR STATUS; PHYSICAL-ACTIVITY; RISK-FACTORS; FAT
   DISTRIBUTION; HORMONE-THERAPY; ANTHROPOMETRIC MEASUREMENTS; MENOPAUSAL
   STATUS; WEIGHT CHANGE; BLACK-WOMEN; SIZE
AB Objective: There is no universal consensus on the relationship between body mass index (BMI) and breast cancer. This meta-analysis was conducted to estimate the overall effect of overweight and obesity on breast cancer risk during pre- and post-menopausal period.
   Data Sources: All major electronic databases were searched until April 2012 including Web of Knowledge, Medline, Scopus, and ScienceDirect. Furthermore, the reference lists and related scientific conference databases were searched.
   Review Methods: All prospective cohort and case-control studies investigating the association between BMI and breast cancer were retrieved irrespective of publication date and language. Women were assessed irrespective of age, race and marital status. The exposure of interest was BMI. The primary outcome of interest was all kinds of breast cancers confirmed pathologically. Study quality was assessed using the checklist of STROBE. Study selection and data extraction were performed by two authors separately. The effect measure of choice was risk ratio (RRi) and rate ratio (RRa) for cohort studies and odds ratio (OR) in case-control studies.
   Results: Of 9163 retrieved studies, 50 studies were included in meta-analysis including 15 cohort studies involving 2,104,203 subjects and 3,414,806 person-years and 35 case-control studies involving 71,216 subjects. There was an inverse but non-significant correlation between BMI and breast cancer risk during premenopausal period: OR = 0.93 (95% CI 0.86, 1.02); RRi = 0.97 (95% CI 0.82, 1.16); and RRa = 0.99 (95% CI 0.94, 1.05), but a direct and significant correlation during postmenopausal period: OR = 1.15 (95% CI 1.07, 1.24); RRi = 1.16 (95% CI 1.08, 1.25); and RRa = 0.98 (95% CI 0.88, 1.09).
   Conclusion: The results of this meta-analysis showed that body mass index has no significant effect on the incidence of breast cancer during premenopausal period. On the other hand, overweight and obesity may have a minimal effect on breast cancer, although significant, but really small and not clinically so important.
C1 [Poorolajal, Jalal] Hamadan Univ Med Sci, Sch Publ Hlth, Res Ctr Hlth Sci, Hamadan, Iran.
   [Cheraghi, Zahra; Poorolajal, Jalal; Irani, Amin Doosti] Hamadan Univ Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Hamadan, Iran.
   [Hashem, Tahereh] Hamadan Univ Med Sci, Fatemieh Hosp, Hamadan, Iran.
   [Esmailnasab, Nader] Kurdistan Univ Med Sci, Sch Med, Dept Community Med, Kurdistan, Iran.
RP Poorolajal, J (reprint author), Hamadan Univ Med Sci, Sch Publ Hlth, Res Ctr Hlth Sci, Hamadan, Iran.
EM poorolajal@umsha.ac.ir
RI Poorolajal, Jalal/D-3506-2013; Cheraghi, Zahra/H-6376-2013;
   Doosti-Irani, Amin/Q-1260-2016
OI Cheraghi, Zahra/0000-0001-6076-4916; Doosti-Irani,
   Amin/0000-0003-0623-7503; Cheraghi, Zahra/0000-0001-9041-559X
FU Research and Technology of Hamadan University of Medical Sciences
FX This study was funded by the Vice-Chancellor of Research and Technology
   of Hamadan University of Medical Sciences. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adebamowo CA, 2003, BREAST CANCER RES, V5, pR18, DOI 10.1186/bcr567
   Barlow WE, 2006, J NATL CANCER I, P98
   Barnes BBE, 2011, CANCER EPIDEMIOL, V35, P345, DOI 10.1016/j.canep.2010.11.003
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berstad P, 2010, CANCER EPIDEM BIOMAR, V19, P1532, DOI 10.1158/1055-9965.EPI-10-0025
   Brinton LA, 2008, CANCER EPIDEM BIOMAR, V17, P3150, DOI 10.1158/1055-9965.EPI-08-0435
   Chow LWC, 2005, ASIAN J SURG, V28, P1791
   Coates RJ, 1999, BRIT J CANCER, V81, P167, DOI 10.1038/sj.bjc.6690667
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Enger SM, 2000, CANCER EPIDEM BIOMAR, V9, P681
   Friedenreich CM, 2002, INT J CANCER, V99, P445, DOI 10.1002/ijc.10389
   Gordis L., 2008, EPIDEMIOLOGY
   Hall IJ, 2000, AM J EPIDEMIOL, V151, P754
   Higgins JP, 2008, COCHRANE HDB SYSTEMA
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hirose K, 2003, INT J CANCER, V107, P276, DOI 10.1002/ijc.11373
   Hu YH, 1997, BREAST CANCER RES TR, V43, P65, DOI 10.1023/A:1005745824388
   Huang ZP, 1997, JAMA-J AM MED ASSOC, V278, P1407, DOI 10.1001/jama.278.17.1407
   John EM, 2010, AM J EPIDEMIOL, V173, P201, DOI DOI 10.1093/AJE/KWQ345
   Jordan S, 2009, BREAST, V18, P299, DOI 10.1016/j.breast.2009.09.004
   Kaaks R, 1998, INT J CANCER, V76, P647, DOI 10.1002/(SICI)1097-0215(19980529)76:5<647::AID-IJC6>3.0.CO;2-Q
   Kerlikowske K, 2008, J NATL CANCER I, V100, P1724, DOI 10.1093/jnci/djn388
   Kim Y, 2009, CANCER EPIDEM BIOMAR, V18, P508, DOI 10.1158/1055-9965.EPI-08-0133
   Kruk J, 2003, CANCER DETECT PREV, V27, P187, DOI 10.1016/S0361-090X(03)00032-1
   Kruk J, 2007, ASIAN PAC J CANCER P, V8, P513
   Lacey JV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-84
   LaVecchia C, 1997, BRIT J CANCER, V75, P441, DOI 10.1038/bjc.1997.73
   Lee S, 2006, INT J CANCER, V118, P1285, DOI 10.1002/ijc.21481
   Li CI, 2000, INT J EPIDEMIOL, V29, P208, DOI 10.1093/ije/29.2.208
   Li CI, 2006, CANCER CAUSE CONTROL, V17, P695, DOI 10.1007/s10552-005-0001-7
   Loi S, 2005, CANCER EPIDEM BIOMAR, V14, P1686, DOI 10.1158/1055-9965.EPI-05-0042
   Magnusson C, 1998, INT J CANCER, V76, P29, DOI 10.1002/(SICI)1097-0215(19980330)76:1<29::AID-IJC6>3.3.CO;2-1
   Magnusson CMK, 2005, BRIT J CANCER, V93, P817, DOI 10.1038/sj.bjc.6602758
   Mathew A, 2008, BRIT J CANCER, V99, P207, DOI 10.1038/sj.bjc.6604423
   McCredie MRE, 1998, CANCER CAUSE CONTROL, V9, P189, DOI 10.1023/A:1008886328352
   Mezzetti M, 1998, J NATL CANCER I, V90, P389, DOI 10.1093/jnci/90.5.389
   Michels KB, 2006, ARCH INTERN MED, V166, P2395, DOI 10.1001/archinte.166.21.2395
   Montazeri A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-278
   Palmer JR, 2007, CANCER EPIDEM BIOMAR, V16, P1795, DOI 10.1158/1055-9965.EPI-07-0336
   Rev Man, 2008, REV MAN REVMAN COMP
   Rosato V, 2011, ANN ONCOL
   Ryu SY, 2001, J KOREAN MED SCI, V16, P610, DOI 10.3346/jkms.2001.16.5.610
   Sangaramoorthy M, 2011, CANCER EPIDEM BIOMAR, V20, P2572, DOI 10.1158/1055-9965.EPI-11-0848
   Sellers TA, 2002, AM J EPIDEMIOL, V155, P225, DOI 10.1093/aje/155.3.225
   Setiawan VW, 2009, AM J EPIDEMIOL, V169, P1251, DOI 10.1093/aje/kwp036
   Shin A, 2009, BREAST CANCER RES TR, V113, P153, DOI 10.1007/s10549-008-9903-x
   Shoff SM, 2000, CANCER EPIDEM BIOMAR, V9, P591
   Shu XO, 2001, INT J CANCER, V94, P449, DOI 10.1002/ijc.1487
   Sonnenschein E, 1999, INT J EPIDEMIOL, V28, P1026, DOI 10.1093/ije/28.6.1026
   Suzuki R, 2009, INT J CANCER, V124, P698, DOI 10.1002/ijc.23943
   Suzuki R, 2006, INT J CANCER, V119, P1683, DOI 10.1002/ijc.22034
   Tehard B, 2006, INT J OBESITY, V30, P156, DOI 10.1038/sj.ijo.0803133
   Tian YF, 2007, ENDOCR-RELAT CANCER, V14, P669, DOI 10.1677/ERC-06-0089
   Titus-Ernstoff L, 1998, CANCER EPIDEM BIOMAR, V7, P783
   TrenthamDietz A, 1997, AM J EPIDEMIOL, V145, P1011
   Tung HT, 1999, JPN J CLIN ONCOL, V29, P137, DOI 10.1093/jjco/29.3.137
   van de Water W, 2012, JAMA-J AM MED ASSOC, V307, P590, DOI 10.1001/jama.2012.84
   vandenBrandt PA, 1997, CANCER CAUSE CONTROL, V8, P39, DOI 10.1023/A:1018479020716
   Vandenbroucke JP, 2007, PLOS MED, V4, P1628, DOI 10.1371/journal.pmed.0040297
   Verla-Tebit E, 2005, EUR J CANCER PREV, V14, P419, DOI 10.1097/00008469-200508000-00016
   Weiderpass E, 2004, CANCER EPIDEM BIOMAR, V13, P1121
   World Health Organization, 2006, EMRO TECHN PUBL SER
   World Health Organization, 2012, 10 FACTS OB
   World Health Organization, 2012, BREAST CANC PREV CON
   Wrensch M, 2003, BREAST CANCER RES, V5, pR88, DOI 10.1186/bcr605
NR 66
TC 129
Z9 131
U1 0
U2 45
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 7
PY 2012
VL 7
IS 12
AR e51446
DI 10.1371/journal.pone.0051446
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 050OT
UT WOS:000312064100120
PM 23236502
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Xia, Q
   Chen, ZX
   Wang, YC
   Ma, YS
   Zhang, F
   Che, W
   Fu, D
   Wang, XF
AF Xia, Qing
   Chen, Zi-Xian
   Wang, Yi-Chao
   Ma, Yu-Shui
   Zhang, Feng
   Che, Wu
   Fu, Da
   Wang, Xiao-Feng
TI Association between the Melatonin Receptor 1B Gene Polymorphism on the
   Risk of Type 2 Diabetes, Impaired Glucose Regulation: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID FASTING PLASMA-GLUCOSE; HAN CHINESE INDIVIDUALS; BETA-CELL FUNCTION;
   INSULIN-SECRETION; COMMON VARIANT; MTNR1B; RS10830963; HOMEOSTASIS;
   MELLITUS; SLEEP
AB Background: Melatonin receptor 1B (MTNR1B) belongs to the seven-transmembrane G protein-coupled receptor superfamily involved in insulin secretion, which has attracted considerable attention as a candidate gene for type 2 diabetes (T2D) since it was first identified as a loci associated with fasting plasma glucose level through genome wide association approach. The relationship between MTNR1B and T2D has been reported in various ethnic groups. The aim of this study was to consolidate and summarize published data on the potential of MTNR1B polymorphisms in T2D risk prediction.
   Methods: PubMed, EMBASE, ISI web of science and the CNKI databases were systematically searched to identify relevant studies. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. Heterogeneity and publication bias were also tested.
   Results: A total of 23 studies involving 172,963 subjects for two common polymorphisms (rs10830963, rs1387153) on MTNR1B were included. An overall random effects per-allele OR of 1.05 (95% CI: 1.02-1.08; P<10(-4)) and 1.04 (95% CI: 0.98-1.10; P = 0.20) were found for the two variants respectively. Similar results were also observed using dominant or recessive genetic model. There was strong evidence of heterogeneity, which largely disappeared after stratification by ethnicity. Significant results were found in Caucasians when stratified by ethnicity; while no significant associations were observed in East Asians and South Asians. Besides, we found that the rs10830963 polymorphism is a risk factor associated with increased impaired glucose regulation susceptibility.
   Conclusions: This meta-analysis demonstrated that the rs10830963 polymorphism is a risk factor for developing impaired glucose regulation and T2D.
C1 [Xia, Qing; Chen, Zi-Xian; Wang, Yi-Chao; Ma, Yu-Shui; Zhang, Feng; Che, Wu; Fu, Da; Wang, Xiao-Feng] Fudan Univ, Zhongshan Hosp, Dept Orthoped Surg, Shanghai 200433, Peoples R China.
RP Fu, D (reprint author), Fudan Univ, Zhongshan Hosp, Dept Orthoped Surg, Shanghai 200433, Peoples R China.
EM superdafu@hotmail.com; superwangxf@hotmail.com
RI Fu, Da/F-1763-2013
FU China Postdoctoral Science Foundation [20100480542, 201104227]; Nature
   Science Foundation of Shanghai [12ZR1436000]; Youth Innovation Promotion
   Association, Chinese Academy of Sciences
FX This work was supported by China Postdoctoral Science Foundation Funded
   Project (20100480542, 201104227), Nature Science Foundation of Shanghai
   (12ZR1436000) and Youth Innovation Promotion Association, Chinese
   Academy of Sciences. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Been LF, 2012, NUTR METAB CARDIOVAS, V22, P944, DOI 10.1016/j.numecd.2011.01.006
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bonnefond A, 2012, NAT GENET, V44, P297, DOI 10.1038/ng.1053
   Bouatia-Naji N, 2008, SCIENCE, V320, P1085, DOI 10.1126/science.1156849
   Bouatia-Naji N, 2009, NAT GENET, V41, P89, DOI 10.1038/ng.277
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dietrich K, 2011, DIABETIC MED, V28, P1373, DOI 10.1111/j.1464-5491.2011.03374.x
   Dupuis J, 2010, NAT GENET, V42, P105, DOI 10.1038/ng.520
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gerstein HC, 2007, DIABETES RES CLIN PR, V78, P305, DOI 10.1016/j.diabres.2007.05.004
   Hu C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011761
   Jaworek J, 2007, J PHYSIOL PHARMACOL, V58, P65
   Kan MY, 2010, DIABETIC MED, V27, P598, DOI 10.1111/j.1464-5491.2010.02975.x
   Knutson KL, 2007, SLEEP MED REV, V11, P163, DOI 10.1016/j.smrv.2007.01.002
   Konturek SJ, 2007, J PHYSIOL PHARMACOL, V58, P23
   Laposky AD, 2008, FEBS LETT, V582, P142, DOI 10.1016/j.febslet.2007.06.079
   Ling Y, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-27
   Liu C, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-59
   LIU Y, 2012, ZHONGGUO LAO NIAN XU, V6, P111
   Lyssenko V, 2009, NAT GENET, V41, P82, DOI 10.1038/ng.288
   Mulder H, 2009, DIABETOLOGIA, V52, P1240, DOI 10.1007/s00125-009-1359-y
   Ohshige T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026911
   Olsson L, 2011, DIABETOLOGIA, V54, P1375, DOI 10.1007/s00125-011-2106-8
   Peschke E, 2006, J PINEAL RES, V40, P184, DOI 10.1111/j.1600-079X.2005.00297.x
   Peschke E, 2008, J PINEAL RES, V44, P26, DOI 10.1111/j.1600-079X.2007.00519.x
   Peschke E, 2007, J PINEAL RES, V42, P350, DOI 10.1111/j.1600-079X.2007.00426.x
   Prokopenko I, 2009, NAT GENET, V41, P77, DOI 10.1038/ng.290
   Ramraeheya RD, 2008, J PINEAL RES, V44, P273, DOI 10.1111/j.1600-079X.2007.00523.x
   Rees SD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024710
   Reiling E, 2009, DIABETOLOGIA, V52, P1866, DOI 10.1007/s00125-009-1413-9
   Renstrom F, 2011, DIABETES, V60, P345, DOI 10.2337/db10-0933
   Ronn T, 2009, DIABETOLOGIA, V52, P830, DOI 10.1007/s00125-009-1297-8
   SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302
   Saxena R, 2010, NAT GENET, V42, P142, DOI 10.1038/ng.521
   Simonis-Bik AM, 2010, DIABETES, V59, P293, DOI 10.2337/db09-1048
   Song JY, 2011, OBESITY FACTS, V4, P197, DOI 10.1159/000329306
   Sparso T, 2009, DIABETES, V58, P1450, DOI 10.2337/db08-1660
   Staiger H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003962
   Tabara Y, 2011, METABOLISM, V60, P1634, DOI 10.1016/j.metabol.2011.03.014
   Tam CHT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011428
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Walford GA, 2012, DIABETOLOGIA, V55, P331, DOI 10.1007/s00125-011-2353-8
   Wang J, 2007, DIABETOLOGIA, V50, P1192, DOI 10.1007/s00125-007-0656-6
   Wang Y, 2007, DIABETOLOGIA, V50, P774, DOI 10.1007/s00125-006-0564-1
   Watanabe RM, 1999, HUM HERED, V49, P159, DOI 10.1159/000022865
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Wuehlbauer E, 2009, EUR J PHARMACOL, V606, P61, DOI 10.1016/j.ejphar.2009.01.029
   Xu M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014022
NR 49
TC 20
Z9 20
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 30
PY 2012
VL 7
IS 11
AR e50107
DI 10.1371/journal.pone.0050107
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 054WM
UT WOS:000312376100050
PM 23226241
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhou, HJ
   Chen, GD
   Chen, CJ
   Yu, YX
   Xu, ZP
AF Zhou, Hongjie
   Chen, Guangdi
   Chen, Chunjing
   Yu, Yunxian
   Xu, Zhengping
TI Association between Extremely Low-Frequency Electromagnetic Fields
   Occupations and Amyotrophic Lateral Sclerosis: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; MOTOR-NEURON DISEASE; MAGNETIC-FIELDS;
   NEURODEGENERATIVE DISEASE; UTILITY WORKERS; DNA-DAMAGE; RAT-BRAIN;
   EXPOSURE; MORTALITY; ALS
AB Objectives: To estimate the relationship between exposure to extremely low-frequency electromagnetic fields (ELF-EMF) and the risk of amyotrophic lateral sclerosis (ALS) by a meta-analysis.
   Methods: Through searching PubMed databases (or manual searching) up to April 2012 using the following keywords: "occupational exposure'', "electromagnetic fields'' and "amyotrophic lateral sclerosis'' or "motor neuron disease'', seventeen studies were identified as eligible for this meta-analysis. The associations between ELF-EMF exposure and the ALS risk were estimated based on study design (case-control or cohort study), and ELF-EMF exposure level assessment (job title or job-exposure matrix). The heterogeneity across the studies was tested, as was publication bias.
   Results: Occupational exposure to ELF-EMF was significantly associated with increased risk of ALS in pooled studies (RR = 1.29, 95%CI = 1.02-1.62), and case-control studies (OR = 1.39, 95%CI = 1.05-1.84), but not cohort studies (RR = 1.16, 95% CI = 0.80-1.69). In sub-analyses, similar significant associations were found when the exposure level was defined by the job title, but not the job-exposure matrix. In addition, significant associations between occupational exposure to ELF-EMF and increased risk of ALS were found in studies of subjects who were clinically diagnosed but not those based on the death certificate. Moderate heterogeneity was observed in all analyses.
   Conclusions: Our data suggest a slight but significant ALS risk increase among those with job titles related to relatively high levels of ELF-EMF exposure. Since the magnitude of estimated RR was relatively small, we cannot deny the possibility of potential biases at work. Electrical shocks or other unidentified variables associated with electrical occupations, rather than magnetic-field exposure, may be responsible for the observed associations with ALS.
C1 [Yu, Yunxian] Zhejiang Univ, Sch Med, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhou, Hongjie; Chen, Guangdi; Chen, Chunjing; Xu, Zhengping] Zhejiang Univ, Sch Med, Sch Publ Hlth, Bioelectromagnet Lab, Hangzhou 310003, Zhejiang, Peoples R China.
RP Yu, YX (reprint author), Zhejiang Univ, Sch Med, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Hangzhou 310003, Zhejiang, Peoples R China.
EM yunxianyu@gmail.com; zpxu@zju.edu.cn
FU Ministry of Science and Technology [2011CB503702, 2011CB503706];
   Fundamental Research Funds for the Central Universities [2012QNA7019,
   2012FZA7019]; Zhejiang Provincial Program for the Cultivation of
   High-level Innovative Health Talents
FX This work is supported by grants from the Ministry of Science and
   Technology (2011CB503702 and 2011CB503706), and the Fundamental Research
   Funds for the Central Universities (2012QNA7019 and 2012FZA7019). ZX was
   sponsored by the Zhejiang Provincial Program for the Cultivation of
   High-level Innovative Health Talents. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abhinav K, 2007, J NEUROL NEUROSUR PS, V78, P450, DOI 10.1136/jnnp.2006.104414
   Ahlbom A, 2001, ENVIRON HEALTH PERSP, V109, P911, DOI 10.2307/3454653
   Barber SC, 2010, FREE RADICAL BIO MED, V48, P629, DOI 10.1016/j.freeradbiomed.2009.11.018
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Busljeta Ivana, 2000, Arhiv za Higijenu Rada i Toksikologiju, V51, P35
   CHANCELLOR AM, 1993, J NEUROL, V240, P339, DOI 10.1007/BF00839964
   Davanipour Z, 1997, BIOELECTROMAGNETICS, V18, P28, DOI 10.1002/(SICI)1521-186X(1997)18:1<28::AID-BEM6>3.0.CO;2-7
   DAVANIPOUR Z, 1991, NEUROEPIDEMIOLOGY, V10, P308, DOI 10.1159/000110288
   de Gannes FP, 2009, AMYOTROPH LATERAL SC, V10, P370, DOI 10.3109/17482960802320396
   DEAPEN DM, 1986, AM J EPIDEMIOL, V123, P790, DOI 10.1093/oxfordjournals.aje.a114308
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Falone S, 2008, INT J BIOCHEM CELL B, V40, P2762, DOI 10.1016/j.biocel.2008.05.022
   Fang F, 2009, ENVIRON HEALTH PERSP, V117, P1387, DOI 10.1289/ehp.0900580
   Feychting M, 2003, EPIDEMIOLOGY, V14, P413, DOI 10.1097/01.EDE.0000071409.23291.7b
   Feychting M, 2005, ANNU REV PUBL HEALTH, V26, P165, DOI 10.1146/annurev.publhealth.26.021304.144445
   GUNNARSSON LG, 1992, BRIT J IND MED, V49, P791
   GUNNARSSON LG, 1991, ACTA NEUROL SCAND, V83, P394, DOI 10.1111/j.1600-0404.1991.tb03970.x
   Hakansson N, 2003, EPIDEMIOLOGY, V14, P420, DOI 10.1097/01.EDE.0000078446.76859.c9
   Hug K, 2006, SOZ PRAVENTIV MED, V51, P210, DOI 10.1007/s00038-006-5096-4
   Johansen C, 2001, Ugeskr Laeger, V164, P50
   Johansen C, 2004, SCAND J WORK ENV HEA, V30, P1
   Johansen C, 1998, AM J EPIDEMIOL, V148, P362
   Johansen C, 2000, EPIDEMIOLOGY, V11, P539, DOI 10.1097/00001648-200009000-00009
   Johnson FO, 2009, NEUROTOXICOLOGY, V30, P761, DOI 10.1016/j.neuro.2009.07.010
   Kheifets L, 2009, OCCUP ENVIRON MED, V66, P72, DOI 10.1136/oem.2007.037994
   Li CY, 2003, AM J IND MED, V43, P212, DOI 10.1002/ajim.10148
   Martinez-Samano J, 2012, ARCH MED RES, V43, P183, DOI 10.1016/j.arcmed.2012.04.003
   McGuire V, 1997, AM J EPIDEMIOL, V145, P1076
   Mitchell JD, 2000, AMYOTROPH LATERAL SC, V1, P235, DOI 10.1080/14660820050515061
   Morahan JM, 2007, AM J MED GENET B, V144B, P885, DOI 10.1002/ajmg.b.30543
   Noonan CW, 2002, SCAND J WORK ENV HEA, V28, P42, DOI 10.5271/sjweh.645
   Park RM, 2005, AM J IND MED, V48, P63, DOI 10.1002/ajim.20178
   Parlett LE, 2011, J OCCUP ENVIRON MED, V53, P1447, DOI 10.1097/JOM.0b013e318237a1d0
   Phillips J L, 2009, Pathophysiology, V16, P79, DOI 10.1016/j.pathophys.2008.11.005
   Roosli M, 2007, NEUROEPIDEMIOLOGY, V28, P197, DOI 10.1159/000108111
   Savitz DA, 1998, ARCH ENVIRON HEALTH, V53, P71, DOI 10.1080/00039899809605691
   Savitz DA, 1998, EPIDEMIOLOGY, V9, P398, DOI 10.1097/00001648-199807000-00009
   Simko M, 2007, CURR MED CHEM, V14, P1141, DOI 10.2174/092986707780362835
   Simpson CL, 2006, BBA-MOL BASIS DIS, V1762, P973, DOI 10.1016/j.bbadis.2006.08.001
   Sorahan T, 2007, OCCUP ENVIRON MED, V64, P820, DOI 10.1136/oem.2006.031559
   Strickland D, 1996, ARCH NEUROL-CHICAGO, V53, P730, DOI 10.1001/archneur.1996.00550080044011
   Sutedja NA, 2007, NEUROLOGY, V69, P1508, DOI 10.1212/01.wnl.0000277463.87361.8c
   Weisskopf MG, 2005, AM J EPIDEMIOL, V162, P1146, DOI 10.1093/aje/kwi343
   Wijesekera LC, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-3
   Wolf FI, 2005, BBA-MOL CELL RES, V1743, P120, DOI 10.1016/j.bbamer.2004.09.005
   Worms PA, 2001, J NEUROL SCI, V191, P3, DOI 10.1016/S0022-510X(01)00630-X
   Yokus B, 2008, INT J RADIAT BIOL, V84, P789, DOI 10.1080/09553000802348203
NR 47
TC 37
Z9 40
U1 1
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 26
PY 2012
VL 7
IS 11
AR e48354
DI 10.1371/journal.pone.0048354
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 048RI
UT WOS:000311929800009
PM 23189129
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Lang, JT
   Song, XC
   Cheng, JW
   Zhao, SW
   Fan, JP
AF Lang, Juntian
   Song, Xicheng
   Cheng, Jinwei
   Zhao, Shuwei
   Fan, Jingping
TI Association of GSTP1 Ile105Val Polymorphism and Risk of Head and Neck
   Cancers: A Meta-Analysis of 28 Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID S-TRANSFERASE P1; SQUAMOUS-CELL CARCINOMA; POLYCYCLIC
   AROMATIC-HYDROCARBONS; GENETIC POLYMORPHISMS; ORAL-CANCER;
   METABOLIZING-ENZYMES; LARYNGEAL CARCINOMA; DIOL EPOXIDES; GLUTATHIONE;
   GSTM1
AB Background and Aims: The Glutathione S-transferase P1 (GSTP1) polymorphism have been considered a risk modifier for developing head and neck cancer (HNC) in many studies; however, the results of such studies are inconsistent. The aim of this study was to evaluate the possible association between the GSTP1 Ile105Val polymorphism and risk of HNC.
   Method: We performed a search in the relevant electronic database and a meta-analysis based on 28 published case-control studies that included 6,404 cases and 6,523 controls. To take into account the possibility of heterogeneity across the studies, a Chi-square based I-2-statistic test was performed. Crude pooled odds ratios (ORs) with 95% confidence intervals (CIs) were assessed using both fixed-effects and random-effects models.
   Results: The results of this meta-analysis showed that the GSTP1 Ile105Val polymorphism was not significantly associated with risk of HNC in the overall study population (pooled OR 1.00, 95% CI 0.92-1.09) or in subgroup analyses stratified by ethnicity, sample size, tumor site or publication year. Moreover, substantial evidence of heterogeneity among the studies was observed. Publication year was identified as the main cause of heterogeneity.
   Conclusion: This meta-analysis does not support a significant association between the GSTP1 Ile105Val polymorphism and risk of HNC.
C1 [Lang, Juntian; Zhao, Shuwei; Fan, Jingping] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Otorhinolaryngol Head & Neck Surg, Shanghai, Peoples R China.
   [Song, Xicheng] Qingdao Univ, Yuhuangding Hosp, Dept Otolaryngol Head & Neck Surg, Yantai, Peoples R China.
   [Cheng, Jinwei] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
RP Fan, JP (reprint author), Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Otorhinolaryngol Head & Neck Surg, Shanghai, Peoples R China.
EM fanjingp@163.com
CR AliOsman F, 1997, J BIOL CHEM, V272, P10004
   Amador AG, 2002, ORAL SURG ORAL MED O, V93, P440, DOI 10.1067/moe.2002.122586
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen MK, 2010, HEAD NECK-J SCI SPEC, V32, P1079, DOI 10.1002/hed.21297
   Cheng YJ, 2003, CANCER EPIDEM BIOMAR, V12, P179
   Cho CG, 2006, J KOREAN MED SCI, V21, P1075, DOI 10.3346/jkms.2006.21.6.1075
   Datta S, 2007, CANCER-AM CANCER SOC, V110, P1991, DOI 10.1002/cncr.23016
   DAY GL, 1993, JNCI-J NATL CANCER I, V85, P465, DOI 10.1093/jnci/85.6.465
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Evans AJ, 2004, HEAD NECK-J SCI SPEC, V26, P63, DOI 10.1002/.10342
   Geisler SA, 2001, AM J EPIDEMIOL, V154, P95, DOI 10.1093/aje/154.2.95
   Harth V, 2008, J TOXICOL ENV HEAL A, V71, P887, DOI 10.1080/15287390801988160
   Hashibe M, 2003, CANCER EPIDEM BIOMAR, V12, P1509
   Hatagima A, 2008, ORAL ONCOL, V44, P200, DOI 10.1016/j.oraloncology.2007.02.001
   Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190
   Hu X, 1997, BIOCHEM BIOPH RES CO, V238, P397, DOI 10.1006/bbrc.1997.7311
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Johansson AS, 1998, J MOL BIOL, V278, P687, DOI 10.1006/jmbi.1998.1708
   Jourenkova-Mironova N, 1999, CANCER EPIDEM BIOMAR, V8, P185
   Jourenkova-Mironova N, 1999, INT J CANCER, V81, P44, DOI 10.1002/(SICI)1097-0215(19990331)81:1<44::AID-IJC9>3.0.CO;2-A
   Karen-Ng LP, 2011, ASIAN PAC J CANCER P, V12, P1161
   Katoh T, 1999, PHARMACOGENETICS, V9, P165
   Kelders WPA, 2002, LARYNGOSCOPE, V112, P462, DOI 10.1097/00005537-200203000-00011
   Lee SA, 2008, AM J CLIN NUTR, V87, P753
   Leichsenring A, 2006, BRAZ J MED BIOL RES, V39, P1569, DOI 10.1590/S0100-879X2006005000035
   MAIER H, 1992, CLIN INVESTIGATOR, V70, P320
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Matthias C, 1998, PHARMACOGENETICS, V8, P1, DOI 10.1097/00008571-199802000-00001
   McWilliams JE, 2000, HEAD NECK-J SCI SPEC, V22, P609, DOI 10.1002/1097-0347(200009)22:6<609::AID-HED10>3.0.CO;2-L
   Miller DP, 2003, INT J CANCER, V104, P758, DOI 10.1002/ijc.10989
   Morita S, 1999, INT J CANCER, V80, P685, DOI 10.1002/(SICI)1097-0215(19990301)80:5<685::AID-IJC9>3.0.CO;2-W
   Olshan AF, 2000, CANCER EPIDEM BIOMAR, V9, P185
   Ophuis MBO, 2003, HEAD NECK-J SCI SPEC, V25, P37, DOI 10.1002/hed.10182
   Park JY, 1999, PHARMACOGENETICS, V9, P497
   Peters ES, 2006, CANCER EPIDEM BIOMAR, V15, P2196, DOI 10.1158/1055-9965.EPI-06-0503
   Reszka E, 2008, CLIN CHEM LAB MED, V46, P1090, DOI 10.1515/CCLM.2008.227
   Ruwali M, 2011, XENOBIOTICA, V41, P1122, DOI 10.3109/00498254.2011.614020
   Ruwali M, 2009, MUTAT RES-FUND MOL M, V669, P36, DOI 10.1016/j.mrfmmm.2009.04.007
   Ryberg D, 1997, CARCINOGENESIS, V18, P1285, DOI 10.1093/carcin/18.7.1285
   Rybicki BA, 2006, CANCER DETECT PREV, V30, P412, DOI 10.1016/j.cdp.2006.09.004
   Singh M, 2008, MUTAT RES-FUND MOL M, V638, P184, DOI 10.1016/j.mrfmmm.2007.10.003
   Soucek P, 2010, NEOPLASMA, V57, P415, DOI 10.4149/neo_2010_05_415
   Soya SS, 2007, EUR J CANCER, V43, P2698, DOI 10.1016/j.ejca.2007.07.006
   Sundberg K, 1998, CARCINOGENESIS, V19, P433, DOI 10.1093/carcin/19.3.433
   To-Figueras J, 2002, CANCER LETT, V187, P95, DOI 10.1016/S0304-3835(02)00406-8
   Wittke-Thompson JK, 2005, AM J HUM GENET, V76, P967, DOI 10.1086/430507
   Zhang ZJ, 2011, AM J EPIDEMIOL, V173, P847, DOI 10.1093/aje/kwq480
   Zhuo WL, 2009, J CANCER RES CLIN, V135, P1081, DOI 10.1007/s00432-009-0548-x
   Zhuo XL, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-46
   ZIMNIAK P, 1994, EUR J BIOCHEM, V224, P893, DOI 10.1111/j.1432-1033.1994.00893.x
NR 52
TC 11
Z9 12
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 7
PY 2012
VL 7
IS 11
AR e48132
DI 10.1371/journal.pone.0048132
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 048TK
UT WOS:000311935800038
PM 23144854
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liang, S
   Hu, JS
   Cao, WJ
   Cai, SJ
AF Liang, Shuo
   Hu, Jingsong
   Cao, Weijun
   Cai, Sanjun
TI Meta-Analysis of Cytochrome P-450 2C9 Polymorphism and Colorectal Cancer
   Risk
SO PLOS ONE
LA English
DT Article
ID XENOBIOTIC-METABOLIZING ENZYMES; GENE POLYMORPHISMS; CIGARETTE-SMOKING;
   CYP2C9 GENOTYPES; IN-VITRO; ASSOCIATION; CARCINOMA; CELECOXIB; P4502C9;
   OXIDOREDUCTASE
AB Background: CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes which play a central role in activating and detoxifying many carcinogens and endogenous compounds thought to be involved in the development of colorectal cancer (CRC). In the past decade, the relationship between CYP2C9 common polymorphisms (R144C and 1359L) and CRC has been reported in various ethnic groups; however, these studies have yielded contradictory results. To investigate this inconsistency, we performed this meta-analysis.
   Methods: Databases including Pubmed, EMBASE, Web of Science and China National Knowledge Infrastructure (CNKI) were searched to find relevant studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association.
   Results: A total of 13 articles involving 9,463 cases and 11,416 controls were included. Overall, the summary odds ratio of CRC was 0.98 (95% CI: 0.89-1.06) and 0.99 (95% CI: 0.87-1.14) for CYP2C9 144C and 359L alleles, respectively. No significant results were observed using dominant or recessive genetic model for these polymorphisms. In the stratified analyses according to ethnicity and sex, no evidence of any gene-disease association was obtained.
   Conclusions: This meta-analysis suggests that the CYP2C9 may not be associated with colorectal cancer development.
C1 [Liang, Shuo; Cao, Weijun] Tongji Univ, Sch Med, Dept Resp, Pulm Hosp Shanghai, Shanghai 200092, Peoples R China.
   [Hu, Jingsong; Cai, Sanjun] Fudan Univ, Sch Med, Dept Colorectal Canc, Shanghai Canc Ctr, Shanghai 200433, Peoples R China.
RP Cao, WJ (reprint author), Tongji Univ, Sch Med, Dept Resp, Pulm Hosp Shanghai, Shanghai 200092, Peoples R China.
EM Weijun_Cao@163.com; Sanjun_Cai@163.com
FU Natural Science Foundation of Shanghai [10ZR1425000]; Doctoral Fund of
   Ministry of Education of China [20100072120060]; key projects of
   Shanghai Municipal Health Bureau [2010006]; Science and Technology
   Commission of Shanghai Municipality [0852nm05600, 09411951500]; National
   Science Foundation of China [30971323]; Shanghai Subject Chief Scientist
   [08XD14034]
FX This work was supported by the Natural Science Foundation of Shanghai
   (10ZR1425000), Doctoral Fund of Ministry of Education of China
   (20100072120060), key projects of Shanghai Municipal Health Bureau
   (2010006), the Science and Technology Commission of Shanghai
   Municipality (0852nm05600, 09411951500), National Science Foundation of
   China (30971323) and Shanghai Subject Chief Scientist (08XD14034). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Buyukdogan M, 2009, UHOD-ULUSLAR HEMATOL, V19, P134
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Chan AT, 2004, CLIN GASTROENTEROL H, V2, P704, DOI 10.1053/S1542-3565(04)00294-0
   Cleary SP, 2010, AM J EPIDEMIOL, V172, P1000, DOI 10.1093/aje/kwq245
   Cotterchio M, 2008, CANCER EPIDEM BIOMAR, V17, P3098, DOI 10.1158/1055-9965.EPI-08-0341
   Crespi CL, 1997, PHARMACOGENETICS, V7, P203, DOI 10.1097/00008571-199706000-00005
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gertig DM, 1998, SEMIN CANCER BIOL, V8, P285, DOI 10.1006/scbi.1998.0078
   GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001
   ILETT KF, 1994, BIOCHEM PHARMACOL, V47, P914, DOI 10.1016/0006-2952(94)90493-6
   Inoue K, 1997, PHARMACOGENETICS, V7, P103, DOI 10.1097/00008571-199704000-00003
   Kury S, 2007, CANCER EPIDEM BIOMAR, V16, P1460, DOI 10.1158/1055-9965.EPI-07-0236
   Lafuente MJ, 2000, CARCINOGENESIS, V21, P1813, DOI 10.1093/carcin/21.10.1813
   Landi S, 2005, PHARMACOGENET GENOM, V15, P535, DOI 10.1097/01.fpc.0000165904.48994.3d
   Liao LH, 2007, CLIN CHIM ACTA, V380, P191, DOI 10.1016/j.cca.2007.02.033
   Marchand Loic Le, 1999, Journal of the National Cancer Institute Monographs, P101
   Martinez C, 2001, CARCINOGENESIS, V22, P1323, DOI 10.1093/carcin/22.8.1323
   McGreavey LE, 2005, PHARMACOGENET GENOM, V15, P713, DOI 10.1097/01.fpc.0000174786.85238.63
   Northwood EL, 2010, PHARMACOGENET GENOM, V20, P315, DOI 10.1097/FPC.0b013e3283395c6a
   Sainz J, 2011, ENDOCR-RELAT CANCER, V18, P265, DOI 10.1530/ERC-10-0264
   Samowitz WS, 2006, CLIN GASTROENTEROL H, V4, P894, DOI 10.1016/j.cgh.2006.04.021
   Sandberg M, 2002, BRIT J CLIN PHARMACO, V54, P423, DOI 10.1046/j.1365-2125.2002.01660.x
   Takahashi H, 1998, PHARMACOGENETICS, V8, P365, DOI 10.1097/00008571-199810000-00001
   Takanashi K, 2000, PHARMACOGENETICS, V10, P95, DOI 10.1097/00008571-200003000-00001
   Tang CY, 2000, J PHARMACOL EXP THER, V293, P453
   Tang CY, 2000, DRUG METAB DISPOS, V28, P567
   Tang CY, 2001, PHARMACOGENETICS, V11, P223, DOI 10.1097/00008571-200104000-00006
   Tranah GJ, 2005, MOL CARCINOGEN, V44, P21, DOI 10.1002/mc.20112
   Windmill KF, 1997, MUTAT RES-FUND MOL M, V376, P153, DOI 10.1016/S0027-5107(97)00038-9
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Xiong YY, 2011, GENOMICS, V97, P277, DOI 10.1016/j.ygeno.2010.11.004
   Zhou SF, 2009, CURR MED CHEM, V16, P3480, DOI 10.2174/092986709789057635
NR 34
TC 26
Z9 26
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 7
PY 2012
VL 7
IS 11
AR e49134
DI 10.1371/journal.pone.0049134
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 048TK
UT WOS:000311935800217
PM 23145098
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wu, Y
   Zhu, W
   Xu, D
   Li, YH
   Ba, J
   Zhang, XL
   Wang, F
   Yu, J
AF Wu, Yan
   Zhu, Wei
   Xu, Ding
   Li, Yan-Hong
   Ba, Jun
   Zhang, Xiao-Long
   Wang, Fang
   Yu, Jing
TI Indocyanine Green-Assisted Internal Limiting Membrane Peeling in Macular
   Hole Surgery: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; VISUAL-FIELD DEFECTS; NERVE-FIBER LAYER;
   BRILLIANT BLUE G; TRYPAN BLUE; VITRECTOMY; OUTCOMES; REMOVAL; HISTOLOGY;
   TOXICITY
AB Background: The opinion of application of indocyanine green (ICG) in the macular hole surgery was contradictory. Here we conducted a meta-analysis to evaluate the effect of in internal limiting membrane (ILM) peeling for macular hole surgery.
   Methods and Findings: We searched electronic databases for comparative studies published before July 2012 of ILM peeling with and without ICG. Twenty-two studies including 1585 eyes were included. Visual acuity (VA) improvement, including the postoperative rate of >= 20/40 VA gained (OR, 0.65; 95% CI, 0.43 to 0.97; P = 0.033) and increased LogMAR (WMD, -0.09; 95% CI, -0.16 to -0.02; P = 0.011), was less in the ICG group. The risk of visual field defects was greater in the ICG group than in the non-ICG group. There was no significant difference in the rate of anatomical outcomes between ILM peeling procedures performed with and without ICG. RPE changes and other postoperative complications were not significantly different between the ICG and non-ICG groups. An additional analysis showed that the VA improvement of the ICG group was less than the non-ICG group only within the first year of follow up. A subgroup analysis showed that the rate of VA improvement was lower in the ICG group than in other adjuncts group. A higher rate of secondary closure and less VA improvement were observed in a high proportion (> 0.1%) of the ICG group. A sensitivity analysis after the randomized-controlled trials were excluded from the meta-analysis demonstrated no differences compared with the overall results.
   Conclusions: This meta-analysis demonstrated that there is no evidence of clinical superiority in outcomes for ICG-assisted ILM peeling procedure over the non-ICG one. The toxicity of ICG should be considered when choosing the various staining methods.
C1 [Wu, Yan; Zhu, Wei; Xu, Ding; Li, Yan-Hong; Ba, Jun; Wang, Fang; Yu, Jing] Tongji Univ, Affiliated Peoples Hosp 10, Dept Ophthalmol, Shanghai 200092, Peoples R China.
   [Wu, Yan; Zhu, Wei; Zhang, Xiao-Long] Nanjing Med Univ, Dept Clin Med Coll 1, Nanjing, Jiangsu, Peoples R China.
RP Yu, J (reprint author), Tongji Univ, Affiliated Peoples Hosp 10, Dept Ophthalmol, Shanghai 200092, Peoples R China.
EM dryujing@yahoo.com.cn
FU National Nature Science Foundation [30901643]; Phosphor Project
   [09QA1405100]; Shanghai Science Committee Biology Department Pilot
   Project [10411964900]; New Excellence Project of Shanghai Health Bureau
   [XYQ2011067]
FX This work was supported in whole or in part by National Nature Science
   Foundation Project (30901643), Phosphor Project (09QA1405100), Shanghai
   Science Committee Biology Department Pilot Project (10411964900), and
   the New Excellence Project of Shanghai Health Bureau (XYQ2011067). No
   additional external funding was received. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ando F, 2004, AM J OPHTHALMOL, V137, P609, DOI 10.1016/j.ajo.2003.08.038
   Anijeet DR, 2012, INVEST OPHTH VIS SCI, V53, P650, DOI 10.1167/iovs.11-8014
   Aziz O, 2006, ANN SURG, V243, P17, DOI 10.1097/01.sla.0000193602.74417.14
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Beutel J, 2007, ARCH OPHTHALMOL-CHIC, V125, P326, DOI 10.1001/archopht.125.3.326
   Brockmann T, 2011, OPHTHALMOLOGICA, V226, P228, DOI 10.1159/000331218
   Burk SE, 2000, OPHTHALMOLOGY, V107, P2010, DOI 10.1016/S0161-6420(00)00375-4
   Christensen UC, 2009, BRIT J OPHTHALMOL, V93, P1005, DOI 10.1136/bjo.2008.151266
   Chung CF, 2005, J CATARACT REFR SURG, V31, P938, DOI 10.1016/j.jcrs.2004.12.046
   Cullen R, 1998, J Ophthalmic Nurs Technol, V17, P179
   Da Mata AP, 2001, OPHTHALMOLOGY, V108, P1187, DOI 10.1016/S0161-6420(01)00593-0
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Engelbrecht NE, 2002, AM J OPHTHALMOL, V133, P89, DOI 10.1016/S0002-9394(01)01293-4
   Ferencz M, 2006, AM J OPHTHALMOL, V142, P765, DOI 10.1016/j.ajo.2006.05.054
   Freeman WR, 1997, ARCH OPHTHALMOL-CHIC, V115, P11, DOI 10.1001/archopht.1997.01100150013002
   Fukuda K, 2011, RETINA-J RET VIT DIS, V31, P1720, DOI 10.1097/IAE.0b013e31822a33d0
   Gale JS, 2004, AM J OPHTHALMOL, V138, P64, DOI 10.1016/j.ajo.2004.02.061
   Gandorfer A, 2003, INVEST OPHTH VIS SCI, V44, P316, DOI 10.1167/iovs.02-0545
   Gandorfer A, 2001, AM J OPHTHALMOL, V131, P387, DOI 10.1016/S0002-9394(00)00924-7
   Haritoglou C, 2004, AM J OPHTHALMOL, V137, P345, DOI 10.1016/S0002-9394(03)00845-6
   Haritoglou C, 2003, AM J OPHTHALMOL, V136, P389, DOI 10.1016/S0002-9394(03)00200-9
   Haritoglou C, 2003, INVEST OPHTH VIS SCI, V44, P2722, DOI 10.1167/iovs.02-1283
   Haritoglou C, 2002, AM J OPHTHALMOL, V134, P836, DOI 10.1016/S0002-9394(02)01816-0
   Haritoglou C, 2002, AM J OPHTHALMOL, V133, P587, DOI 10.1016/S0002-9394(01)01396-4
   Haritoglou C, 2001, BRIT J OPHTHALMOL, V85, P231, DOI 10.1136/bjo.85.2.231
   Horio N, 2004, ARCH OPHTHALMOL-CHIC, V122, P992, DOI 10.1001/archopht.122.7.992
   Husson-Danan A, 2006, GRAEF ARCH CLIN EXP, V244, P291, DOI 10.1007/s00417-005-0046-z
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P2778, DOI 10.1167/iovs.04-0320
   Kanda S, 2004, ARCH OPHTHALMOL-CHIC, V122, P1447, DOI 10.1001/archopht.122.10.1447
   Karacorlu M, 2005, GRAEF ARCH CLIN EXP, V243, P754, DOI 10.1007/s00417-005-1133-x
   Kumagai K, 2006, RETINA-J RET VIT DIS, V26, P613, DOI 10.1097/00006982-200607000-00004
   Kwok AKH, 2003, BRIT J OPHTHALMOL, V87, P71, DOI 10.1136/bjo.87.1.71
   Kwok AKH, 2003, AM J OPHTHALMOL, V136, P223, DOI 10.1016/S0002-9394(02)02144-X
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P178, DOI 10.1016/S0002-9394(01)00976-X
   Lee KL, 2005, BRIT J OPHTHALMOL, V89, P420, DOI 10.1136/bjo.2004.049684
   Lochhead J, 2004, EYE, V18, P804, DOI 10.1038/sj.eye.6701328
   Mavrofrides E, 2006, RETINA-J RET VIT DIS, V26, P637, DOI 10.1097/00006982-200607000-00008
   Meyer CH, 2004, AM J OPHTHALMOL, V137, P386, DOI 10.1016/j.ajo.2003.10.017
   Miura M, 2003, RETINA-J RET VIT DIS, V23, P561, DOI 10.1097/00006982-200308000-00024
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Nagai N, 2007, ACTA OPHTHALMOL SCAN, V85, P883, DOI 10.1111/j.1600-0420.2007.00973.x
   Nakamura Y, 2009, OPHTHALMIC RES, V41, P136, DOI 10.1159/000209666
   Nomoto H, 2008, RETINA-J RET VIT DIS, V28, P427, DOI 10.1097/IAE.0b013e31815ec2f1
   Penha FM, 2007, OPHTHALMOLOGY, V114, P899, DOI 10.1016/j.ophtha.2006.09.028
   Rodrigues EB, 2008, OPHTHALMOLOGICA, V222, P123, DOI 10.1159/000112630
   Rodrigues EB, 2007, RETINA-J RET VIT DIS, V27, P958, DOI 10.1097/01.iae.0000253051.01194.ab
   Samoocha David, 2010, J Med Internet Res, V12, pe23, DOI 10.2196/jmir.1286
   Schaal S, 2009, RETINA-J RET VIT DIS, V29, P1091, DOI 10.1097/IAE.0b013e31819f4b8c
   Sheidow TG, 2003, OPHTHALMOLOGY, V110, P1697, DOI 10.1016/S0161-6420(03)00562-1
   Shukla D, 2011, RETINA-J RET VIT DIS, V31, P2021, DOI 10.1097/IAE.0b013e318213618c
   Sippy BD, 2001, AM J OPHTHALMOL, V132, P433, DOI 10.1016/S0002-9394(01)01061-3
   Slaughter K, 2004, EYE, V18, P376, DOI 10.1038/sj.eye.6700666
   Stalmans P, 2002, AM J OPHTHALMOL, V134, P282, DOI 10.1016/S0002-9394(02)01468-X
   Stanescu-Segall D, 2009, EYE, V23, P504, DOI 10.1038/eye.2008.249
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Thompson John T, 2007, Trans Am Ophthalmol Soc, V105, P198
   Thompson JT, 2007, T AM OPHTHAL SOC, V105, P205
   Tognetto D, 2006, OPHTHALMOLOGY, V113, P1401, DOI 10.1016/j.ophtha.2006.02.061
   Tsuiki E, 2007, AM J OPHTHALMOL, V143, P704, DOI 10.1016/j.ajo.2006.10.051
   Vanner EA, 2011, AM J OPHTHALMOL, V152, P345, DOI 10.1016/j.ajo.2011.02.010
   Volk RJ, 2011, JAMA-J AM MED ASSOC, V306, P2715, DOI 10.1001/jama.2011.1893
   Welch JC, 1997, AM J OPHTHALMOL, V124, P698, DOI 10.1016/S0002-9394(14)70915-8
   Yamashita T, 2006, OPHTHALMOLOGY, V113, P280, DOI 10.1016/j.ophtha.2005.10.046
NR 66
TC 11
Z9 13
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 7
PY 2012
VL 7
IS 11
AR e48405
DI 10.1371/journal.pone.0048405
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 048TK
UT WOS:000311935800055
PM 23144875
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Cai, Y
   Yi, JY
   Zhou, CH
   Shen, XZ
AF Cai, Yu
   Yi, JiaYong
   Zhou, ChaoHui
   Shen, XiZhong
TI Pharmacogenetic Study of Drug-Metabolising Enzyme Polymorphisms on the
   Risk of Anti-Tuberculosis Drug-Induced Liver Injury: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GLUTATHIONE-S-TRANSFERASE; CYTOCHROME-P450 2E1 GENOTYPE; INDUCED
   HEPATOTOXICITY; GENETIC POLYMORPHISMS; INDUCED HEPATITIS; TUBERCULOSIS
   PATIENTS; N-ACETYLTRANSFERASE-2 GENE; ISONIAZID HEPATOTOXICITY; NULL
   MUTATIONS; SUSCEPTIBILITY
AB Background: Three first-line antituberculosis drugs, isoniazid, rifampicin and pyrazinamide, may induce liver injury, especially isoniazid. This antituberculosis drug-induced liver injury (ATLI) ranges from a mild to severe form, and the associated mortality cases are not rare. In the past decade, many investigations have focused the association between drug-metabolising enzyme (DME) gene polymorphisms and risk for ATLI; however, these studies have yielded contradictory results.
   Methods: PubMed, EMBASE, ISI web of science and the Chinese National Knowledge Infrastructure databases were systematically searched to identify relevant studies. A meta-analysis was performed to examine the association between polymorphisms from 4 DME genes (NAT2, CYP2E1, GSTM1 and GSTT1) and susceptibility to ATLI. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Heterogeneity among articles and their publication bias were also tested.
   Results: 38 studies involving 2,225 patients and 4,906 controls were included. Overall, significantly increased ATLI risk was associated with slow NAT2 genotype and GSTM1 null genotype when all studies were pooled into the meta-analysis. Significantly increased risk was also found for CYP2E1*1A in East Asians when stratified by ethnicity. However, no significant results were observed for GSTT1.
   Conclusions: Our results demonstrated that slow NAT2 genotype, CYP2E1*1A and GSTM1 null have a modest effect on genetic susceptibility to ATLI.
C1 [Cai, Yu; Zhou, ChaoHui; Shen, XiZhong] Fudan Unvers, Zhongshan Hosp, Dept Gastroenterol, Shanghai, Peoples R China.
   [Yi, JiaYong] Fudan Unvers, Zhongshan Hosp, Dept Orthoped, Shanghai, Peoples R China.
RP Zhou, CH (reprint author), Fudan Unvers, Zhongshan Hosp, Dept Gastroenterol, Shanghai, Peoples R China.
EM chaohuizhou001@163.com
FU Shanghai Natural Science Foundation [12ZR1405300]; Shanghai Science and
   Technology Commission [10410709400, 10411950100]
FX This work was supported by Shanghai Natural Science Foundation
   (12ZR1405300) and Shanghai Science and Technology Commission
   (10410709400; 10411950100). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR An HR, 2012, CLIN EXP PHARMACOL P, V39, P535, DOI 10.1111/j.1440-1681.2012.05713.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Ben Mahmoud L, 2012, PATHOL BIOL, V60, P324, DOI 10.1016/j.patbio.2011.07.001
   Bose PD, 2011, J GASTROEN HEPATOL, V26, P312, DOI 10.1111/j.1440-1746.2010.06355.x
   Bozok Cetintas V, 2008, TUBERK TORAK, V56, P81
   Chatterjee S, 2010, J CLIN PHARM THER, V35, P465, DOI 10.1111/j.1365-2710.2009.01101.x
   [陈怡 Chen Yi], 2010, [中华传染病杂志, Chinese Journal of Infections Diseases], V28, P748
   Cho HJ, 2007, TUBERCULOSIS, V87, P551, DOI 10.1016/j.tube.2007.05.012
   Teixeira RLD, 2011, MEM I OSWALDO CRUZ, V106, P716, DOI 10.1590/S0074-02762011000600011
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   [郭梅 GUO Mei], 2010, [中华传染病杂志, Chinese Journal of Infections Diseases], V28, P99
   Guo MR, 2009, WOODHEAD PUBL FOOD S, P1
   Higuchi N, 2007, WORLD J GASTROENTERO, V13, P6003, DOI 10.3748/wjg.13.6003
   Huang DS, 2011, ZHONGHUA SHENG WU YI, V17, P444
   Huang YS, 2007, J HEPATOL, V47, P128, DOI 10.1016/j.jhep.2007.02.009
   Huang YS, 2003, HEPATOLOGY, V37, P924, DOI 10.1053/jhep.2003.50144
   Huang YS, 2002, HEPATOLOGY, V35, P883, DOI 10.1053/jhep.2002.32102
   Kim SH, 2010, TUBERCULOSIS, V90, P39, DOI 10.1016/j.tube.2009.12.001
   Kim SH, 2009, PHARMACOGENOMICS, V10, P1767, DOI 10.2217/PGS.09.100
   LAUTERBURG BH, 1985, J PHARMACOL EXP THER, V235, P566
   Lee SW, 2010, INT J TUBERC LUNG D, V14, P622
   LEE WM, 1995, NEW ENGL J MED, V333, P1118, DOI 10.1056/NEJM199510263331706
   Leiro V, 2008, LIVER INT, V28, P835, DOI 10.1111/j.1478-3231.2008.01700.x
   Leiro-Fernandez V, 2011, INT J TUBERC LUNG D, V15, P1403, DOI 10.5588/ijtld.10.0648
   MITCHELL JR, 1976, ANN INTERN MED, V84, P181, DOI 10.7326/0003-4819-84-2-181
   Naisbitt D J, 2001, Curr Opin Allergy Clin Immunol, V1, P317
   Ohno M, 2000, INT J TUBERC LUNG D, V4, P256
   Possuelo LG, 2008, EUR J CLIN PHARMACOL, V64, P673, DOI 10.1007/s00228-008-0484-8
   Rana SV, 2012, HEPATOL INT, V6, P397, DOI 10.1007/s12072-011-9309-4
   Roy B, 2006, J GASTROEN HEPATOL, V21, P784, DOI 10.1111/j.1440-1746.2006.04197.x
   Roy B, 2001, J GASTROEN HEPATOL, V16, P1033, DOI 10.1046/j.1440-1746.2001.02585.x
   RungeMorris M, 1996, DRUG METAB DISPOS, V24, P734
   Saukkonen JJ, 2006, AM J RESP CRIT CARE, V174, P935, DOI 10.1164/rccm.200510-1666ST
   Shimizu Y, 2006, TUBERCULOSIS, V86, P374, DOI 10.1016/j.tube.2005.09.002
   Sistanizad M, 2011, IRAN J PHARM RES, V10, P633
   Sotsuka T, 2011, IN VIVO, V25, P803
   Strange RC, 2000, TOXICOL LETT, V112, P357, DOI 10.1016/S0378-4274(99)00230-1
   Tang KF, 2010, GENOMICS, V95, P224, DOI 10.1016/j.ygeno.2010.01.005
   Tang SW, 2012, J CLIN PHARM THER, V37, P588, DOI 10.1111/j.1365-2710.2012.01334.x
   Tostmann A, 2008, J GASTROEN HEPATOL, V23, P192, DOI 10.1111/j.1440-1746.2007.05207.x
   Vuilleumier Nicolas, 2006, Eur J Clin Pharmacol, V62, P423
   Wang JH, 2004, ACAD J PLA POSTGRAD, V25, P239
   Wang P, 2009, CHIN J PUBLIC HLTH, V25, P300
   Wang T, 2010, J INT MED RES, V38, P977, DOI 10.1177/147323001003800324
   Wang Tao, 2009, Zhonghua Jie He He Hu Xi Za Zhi, V32, P585
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Wu Yu-Mei, 2010, Zhonghua Gan Zang Bing Za Zhi, V18, P467, DOI 10.3760/cma.j.issn.1007-3418.2010.06.017
   Yamada S, 2009, PHARMACOGENOMICS, V10, P1433, DOI [10.2217/pgs.09.66, 10.2217/PGS.09.66]
   Yimer G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027810
   Zhu Dong-lin, 2011, Zhongguo Kangshengsu Zazhi, V36, P864
NR 51
TC 51
Z9 57
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 17
PY 2012
VL 7
IS 10
AR e47769
DI 10.1371/journal.pone.0047769
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038AF
UT WOS:000311146900110
PM 23082213
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Gillet, E
   Meys, JFA
   Verstraelen, H
   Verhelst, R
   De Sutter, P
   Temmerman, M
   Vanden Broeck, D
AF Gillet, Evy
   Meys, Joris F. A.
   Verstraelen, Hans
   Verhelst, Rita
   De Sutter, Philippe
   Temmerman, Marleen
   Vanden Broeck, Davy
TI Association between Bacterial Vaginosis and Cervical Intraepithelial
   Neoplasia: Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID HUMAN-PAPILLOMAVIRUS INFECTION; RISK-FACTORS; WOMEN; DIAGNOSIS; CANCER;
   DYSBACTERIOSIS; NITROSAMINES; EPIDEMIOLOGY; PATHOGENESIS; INFLAMMATION
AB Objective: Bacterial vaginosis (BV), the most common vaginal disorder among women of reproductive age, has been suggested as co-factor in the development of cervical cancer. Previous studies examining the relationship between BV and cervical intra-epithelial neoplasia (CIN) provided inconsistent and conflicting results. The aim of this study is to clarify the association between these two conditions.
   Methods: A systematic review and meta-analysis were conducted to summarize published literature on the association between BV and cervical pre-cancerous lesions. An extensive search of electronic databases Medline (Pubmed) and Web of Science was performed. The key words 'bacterial vaginosis' and 'bacterial infections and vaginitis' were used in combination with 'cervical intraepithelial neoplasia', 'squamous intraepithelial lesions', 'cervical lesions', 'cervical dysplasia', and 'cervical screening'. Eligible studies required a clear description of diagnostic methods used for detecting both BV and cervical precancerous lesions. Publications were included if they either reported odds ratios (OR) and corresponding 95% confidence intervals (CI) representing the magnitude of association between these two conditions, or presented data that allowed calculation of the OR.
   Results: Out of 329 articles, 17 cross-sectional and 2 incidence studies were selected. In addition, two studies conducted in The Netherlands, using the national KOPAC system, were retained. After testing for heterogeneity and publication bias, meta-analysis and meta-regression were performed, using a random effects model. Although heterogeneity among studies was high (chi(2) = 164.7, p < 0.01, I-2 = 88.5), a positive association between BV and cervical pre-cancerous lesions was found, with an overall estimated odds ratio of 1.51 (95% CI, 1.24-1.83). Meta-regression analysis could not detect a significant difference between studies based on BV diagnosis, CIN diagnosis or study population.
   Conclusions: Although most studies were cross-sectional and heterogeneity was high, this meta-analysis confirms a connection between BV and CIN.
C1 [Gillet, Evy; Verhelst, Rita; Temmerman, Marleen; Vanden Broeck, Davy] Univ Ghent, Int Ctr Reprod Hlth ICRH, B-9000 Ghent, Belgium.
   [Gillet, Evy; De Sutter, Philippe] Vrije Univ Brussel, Dept Gynaecol, Brussels, Belgium.
   [Meys, Joris F. A.] Univ Ghent, Dept Appl Math Biometr & Proc Control, Fac Biosci Engn, B-9000 Ghent, Belgium.
   [Verstraelen, Hans] Ghent Univ Hosp, Dept Obstet & Gynaecol, Ghent, Belgium.
RP Vanden Broeck, D (reprint author), Univ Ghent, Int Ctr Reprod Hlth ICRH, B-9000 Ghent, Belgium.
EM davy.vandenbroeck@ugent.be
RI Verstraelen, Hans/A-5602-2008
OI Verstraelen, Hans/0000-0002-4070-1587
FU Research Foundation - Flanders (FWO); FWO
FX DVB has a post-doctoral fellowship of the Research Foundation - Flanders
   (FWO). Part of this work was supported by the FWO. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Barrington J. W., 1997, Journal of Obstetrics and Gynaecology (Abingdon), V17, P383
   Bauer G, 2001, MED HYPOTHESES, V57, P252, DOI 10.1054/mehy.2001.1285
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Behbakht Kian, 2002, Infect Dis Obstet Gynecol, V10, P181, DOI 10.1155/S1064744902000200
   Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3
   Bosch FX, 2007, DIS MARKERS, V23, P213, DOI 10.1155/2007/914823
   Boyle DCM, 2003, INT J GYNECOL CANCER, V13, P159, DOI 10.1046/j.1525-1438.2003.13007.x
   Boyle DCM, 1999, INT J GYNECOL CANCER, V9, P177
   Castellsague X, 2002, VIRUS RES, V89, P191, DOI 10.1016/S0168-1702(02)00188-0
   Castle PE, 2001, CANCER EPIDEM BIOMAR, V10, P1021
   Cauci Sabina, 2004, Curr Infect Dis Rep, V6, P450, DOI 10.1007/s11908-004-0064-8
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   da Silva CS, 2004, GYNECOL OBSTET INVES, V58, P189, DOI 10.1159/000079822
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Discacciati MG, 2006, DIAGN CYTOPATHOL, V34, P323, DOI 10.1002/dc.20431
   Discacciati MG, 2006, DIAGN CYTOPATHOL, V34, P272, DOI 10.1002/dc.20418
   Eichholzer M, 1998, NUTR REV, V56, P95
   ELTABBAKH GH, 1995, OBSTET GYNECOL, V85, P499, DOI 10.1016/0029-7844(94)00450-R
   Engberts MK, 2007, CANCER CYTOPATHOL, V111, P269, DOI 10.1002/cncr22947
   Fethers KA, 2008, CLIN INFECT DIS, V47, P1426, DOI 10.1086/592974
   FIGO IFoGaO, 2009, GLOB GUID CERV CANC
   Frega A, 1997, EUR J GYNAECOL ONCOL, V18, P76
   GUIJON F, 1992, INT J GYNECOL OBSTET, V37, P185, DOI 10.1016/0020-7292(92)90379-W
   GUIJON FB, 1985, AM J OBSTET GYNECOL, V151, P185, DOI 10.1016/0002-9378(85)90009-2
   Gutman RE, 2005, OBSTET GYNECOL, V105, P551, DOI 10.1097/01.AOG.0000145752.97999.67
   HARINGTON JS, 1975, S AFR MED J, V49, P443
   Hawes SE, 2002, J NATL CANCER I, V94, P1592
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hudson MMT, 1997, GENITOURIN MED, V73, P306
   Huh WK, 2009, OBSTET GYNECOL, V114, P139, DOI 10.1097/AOG.0b013e3181ab6878
   Juneja A, 2003, Indian J Cancer, V40, P15
   KHARSANY ABM, 1993, GENITOURIN MED, V69, P357
   Knapp G, 2003, STAT MED, V22, P2693, DOI 10.1002/sim.1482
   Koshiol J, 2008, AM J EPIDEMIOL, V168, P123, DOI 10.1093/aje/kwn036
   Lehtovirta P, 2008, INT J STD AIDS, V19, P37, DOI 10.1258/ijsa.2007.005672
   MOHER D, 2009, PLOS MED, V6
   Nam KH, 2009, J GYNECOL ONCOL, V20, P39, DOI 10.3802/jgo.2009.20.1.39
   PAVIC N, 1984, MED HYPOTHESES, V15, P433, DOI 10.1016/0306-9877(84)90159-2
   PETERS N, 1995, SEX TRANSM DIS, V22, P296, DOI 10.1097/00007435-199509000-00005
   PLATZCHRISTENSEN JJ, 1994, ACTA OBSTET GYN SCAN, V73, P586, DOI 10.3109/00016349409006278
   Roeters AME, 2010, DIAGN CYTOPATHOL, V38, P85, DOI 10.1002/dc.21169
   Schiff M, 2000, AM J EPIDEMIOL, V152, P716, DOI 10.1093/aje/152.8.716
   Simoes JA, 2006, INT J GYNECOL OBSTET, V94, P28, DOI 10.1016/j.ijgo.2006.04.013
   Spinillo A, 2006, OBSTET GYNECOL, V107, P314, DOI 10.1097/01.AOG.0000196723.76228.ea
   Stanley MA, 2009, INDIAN J MED RES, V130, P266
   Sterne JAC, 2009, METAANALYSIS STATA U
   Sweet R L, 2000, Infect Dis Obstet Gynecol, V8, P184
   Tavares-Murta BM, 2008, EUR J OBSTET GYN R B, V138, P93, DOI 10.1016/j.ejogrb.2007.06.015
   Team R. D. C., 2009, R LANG ENV STAT COMP
   Uthayakumar S., 1998, Journal of Obstetrics and Gynaecology (Abingdon), V18, P572
   Verbrucigen BSM, 2006, DIAGN CYTOPATHOL, V34, P377, DOI 10.1002/dc.20374
   Verstraelen H, 2008, INT J STD AIDS, V19, P575, DOI 10.1258/ijsa.2008.008189
   Verstraelen H, 2009, EXPERT REV ANTI-INFE, V7, P1109, DOI [10.1586/eri.09.87, 10.1586/ERI.09.87]
   Vetrano G, 2007, EUR J GYNAECOL ONCOL, V28, P310
   Viechtbauer W, J STAT SOFT IN PRESS
   Wolrath H, 2001, J CLIN MICROBIOL, V39, P4026, DOI 10.1128/JCM.39.11.4026-4031.2001
NR 56
TC 50
Z9 64
U1 0
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 2
PY 2012
VL 7
IS 10
AR e45201
DI 10.1371/journal.pone.0045201
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 015NG
UT WOS:000309452600008
PM 23056195
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Bansal, D
   Undela, K
   D'Cruz, S
   Schifano, F
AF Bansal, Dipika
   Undela, Krishna
   D'Cruz, Sanjay
   Schifano, Fabrizio
TI Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational
   Studies
SO PLOS ONE
LA English
DT Article
ID CHOLESTEROL-LOWERING DRUGS; POPULATION-BASED COHORT; VETERANS
   POPULATION; FOLLOW-UP; PREVENTION; EPIDEMIOLOGY; ASSOCIATION; DATABASE;
   CELLS; BIAS
AB Background: Emerging evidence suggests that statins may decrease the risk of cancers. However, available evidence on prostate cancer (PCa) is conflicting. We therefore examined the association between statin use and risk of PCa by conducting a detailed meta-analysis of all observational studies published regarding this subject.
   Methods: Literature search in PubMed database was undertaken through February 2012 looking for observational studies evaluating the association between statin use and risk of PCa. Before meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using random-effects model (DerSimonian and Laird method). Subgroup analyses, sensitivity analysis and cumulative meta-analysis were also performed.
   Results: A total of 27 (15 cohort and 12 case-control) studies contributed to the analysis. There was heterogeneity among the studies but no publication bias. Statin use significantly reduced the risk of both total PCa by 7% (RR 0.93, 95% CI 0.87-0.99, p = 0.03) and clinically important advanced PCa by 20% (RR 0.80, 95% CI 0.70-0.90, p<0.001). Long-term statin use did not significantly affect the risk of total PCa (RR 0.94, 95% CI 0.84-1.05, p = 0.31). Stratification by study design did not substantially influence the RR. Furthermore, sensitivity analysis confirmed the stability of results. Cumulative meta-analysis showed a change in trend of reporting risk from positive to negative in statin users between 1993 and 2011.
   Conclusions: Our meta-analysis provides evidence supporting the hypothesis that statins reduce the risk of both total PCa and clinically important advanced PCa. Further research is needed to confirm these findings and to identify the underlying biological mechanisms.
C1 [Bansal, Dipika; Undela, Krishna] Natl Inst Pharmaceut Educ & Res, Dept Pharm Practice, Sas Nagar Mohali, Punjab, India.
   [D'Cruz, Sanjay] Govt Med Coll & Hosp, Dept Gen Med, Chandigarh, India.
   [Schifano, Fabrizio] Univ Hertfordshire, Sch Pharm, Hatfield AL10 9AB, Herts, England.
RP Bansal, D (reprint author), Natl Inst Pharmaceut Educ & Res, Dept Pharm Practice, Sas Nagar Mohali, Punjab, India.
EM drdeep97@gmail.com
RI Undela, Krishna/K-1294-2016
OI Undela, Krishna/0000-0002-7480-8761
CR Agalliu I, 2008, AM J EPIDEMIOL, V168, P250, DOI 10.1093/aje/kwn141
   Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   [Anonymous], 2011, SEER STAT FACT SHEET
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blais L, 2000, ARCH INTERN MED, V160, P2363, DOI 10.1001/archinte.160.15.2363
   Bonovas S, 2008, INT J CANCER, V123, P899, DOI 10.1002/ijc.23550
   Boudreau DM, 2008, CANCER CAUSE CONTROL, V19, P767, DOI 10.1007/s10552-008-9139-4
   Boudreau DM, 2010, EXPERT OPIN DRUG SAF, V9, P603, DOI 10.1517/14740331003662620
   Breau RH, 2010, J UROLOGY, V184, P494, DOI 10.1016/j.juro.2010.03.149
   Browning DRL, 2007, INT J CANCER, V120, P833, DOI 10.1002/ijc.22366
   Buschemeyer WC, 2007, EUR UROL, V52, P331, DOI 10.1016/j.eururo.2007.04.069
   Chang CC, 2011, PROSTATE, V71, P1818, DOI 10.1002/pros.21401
   Coogan PF, 2007, EPIDEMIOLOGY, V18, P213, DOI 10.1097/01.ede.0000254694.03027.a1
   Coogan PF, 2010, PHARMACOEPIDEM DR S, V19, P752, DOI 10.1002/pds.1970
   Coogan PF, 2002, EPIDEMIOLOGY, V13, P262, DOI 10.1097/00001648-200205000-00005
   Dale KM, 2006, JAMA-J AM MED ASSOC, V295, P74, DOI 10.1001/jama.295.1.74
   DAVIGNON J, 1993, ARCH INTERN MED, V153, P1079
   Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farwell WR, 2008, J NATL CANCER I, V100, P134, DOI 10.1093/jnci/djm286
   Farwell WR, 2011, J NATL CANCER I, V103, P885, DOI 10.1093/jnci/djr108
   Flick ED, 2007, CANCER EPIDEM BIOMAR, V16, P2218, DOI 10.1158/1055-9965.EPI-07-0197
   Ford I, 2007, NEW ENGL J MED, V357, P1477, DOI 10.1056/NEJMoa065994
   Fowke JH, 2011, CANCER CAUSE CONTROL, V22, P417, DOI 10.1007/s10552-010-9713-4
   Friedman GD, 2008, PHARMACOEPIDEM DR S, V17, P27, DOI 10.1002/pds.1507
   Friis S, 2005, INT J CANCER, V114, P643, DOI 10.1002/ijc.20758
   Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027
   Hamilton Robert J, 2008, J Natl Cancer Inst, V100, P1511, DOI 10.1093/jnci/djn362
   Haukka J, 2010, INT J CANCER, V126, P279, DOI 10.1002/ijc.24536
   Heart Protection Study Collaborative Group, 2005, BMC MED, V3, P6
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hippisley-Cox J, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2197
   Jacobs EJ, 2007, CANCER EPIDEM BIOMAR, V16, P2213, DOI 10.1138/1055-9965.EPI-07-0448
   Jacobs EJ, 2011, CANCER RES, V71, P1763, DOI 10.1158/0008-5472.CAN-10-2953
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kaye JA, 2004, BRIT J CANCER, V90, P635, DOI 10.1038/sj.bjc.6601566
   Kuoppala J, 2008, EUR J CANCER, V44, P2122, DOI 10.1016/j.ejca.2008.06.025
   Loeb S, 2010, BJU INT, V105, P1222, DOI 10.1111/j.1464-410X.2009.09007.x
   Marcella SW, 2011, CANCER IN PRESS
   Mondul AM, 2011, J UROLOGY, V185, P1268, DOI 10.1016/j.juro.2010.11.089
   Mondul AM, 2010, CANCER CAUSE CONTROL, V21, P61, DOI 10.1007/s10552-009-9434-8
   Murtola TJ, 2007, CANCER EPIDEM BIOMAR, V16, P2226, DOI 10.1158/1055-9965.EPI-07-0599
   Murtola TJ, 2010, INT J CANCER, V127, P1650, DOI 10.1002/ijc.25165
   Murtola TJ, 2009, PROSTATE, V69, P1017, DOI 10.1002/pros.20951
   Oh HY, 2010, BIOCHEM BIOPH RES CO, V393, P319, DOI 10.1016/j.bbrc.2010.01.133
   Ottawa Hospital Research Institute, 2011, NEWCASTLE OTTAWA SCA
   Platz EA, 2006, J NATL CANCER I, V98, P1819, DOI 10.1093/jnci/djj499
   Sato S, 2006, J EPIDEMIOL, V16, P201, DOI 10.2188/jea.16.201
   Shannon J, 2005, AM J EPIDEMIOL, V162, P318, DOI 10.1093/aje/kwi203
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365-2125.2008.03308.x
   Solomon KR, 2011, UROL CLIN N AM, V38, P243, DOI 10.1016/j.ucl.2011.04.001
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tan N, 2011, J UROLOGY, V186, P86, DOI 10.1016/j.juro.2011.03.004
   World Health Organization, 2011, CANCERSTATS CANC WOR
   Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690
   Zheng X, 2010, CANCER PREV RES, V3, P114, DOI 10.1158/1940-6207.CAPR-09-0059
NR 56
TC 115
Z9 120
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 1
PY 2012
VL 7
IS 10
AR e46691
DI 10.1371/journal.pone.0046691
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 014PQ
UT WOS:000309388500040
PM 23049713
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Luo, YL
   Ye, P
   Zhang, QH
   Hu, TT
   Luo, MH
   Li, MQ
   Chen, Q
AF Luo, Ya Li
   Ye, Ping
   Zhang, Qiong Hua
   Hu, Ting Ting
   Luo, Min Hong
   Li, Mei Qing
   Chen, Qing
TI Methylenetetrahydrofolate Reductase C677T Polymorphism and
   Susceptibility to Cervical Cancer and Cervical Intraepithelial
   Neoplasia: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID MTHFR POLYMORPHISMS; UTERINE CERVIX; A1298C POLYMORPHISMS; INDIAN
   POPULATION; COMMON MUTATION; PLASMA FOLATE; RISK-FACTOR; ASSOCIATION;
   DYSPLASIA; GENE
AB Background: A number of studies have explored the association between methyl enetetrahydrofolate reductase (MTHFR) C677T polymorphism and susceptibility to cervical cancer and cervical intraepithelial neoplasia (CIN). However, results remained controversial. To address this gap, we decided to conduct a meta-analysis of all available published studies.
   Methods: Electronic literature searches of the PubMed, EmBase and Medline databases were performed up to April 30, 2012. Fixed-effects or random-effects model was used to calculate the pooled ORs for different genetic models.
   Results: A total of 12 case-control studies were ultimately identified. No statistical correlation was found between C677T variants and cervical cancer for the overall population. However, subgroup analyses on the White women pointed to a significant protective effect for individuals heterozygous or homozygous for the T-allele (for CT vs. CC: OR = 0.72, 95% CI 0.59-0.88; for TT vs. CC: OR = 0.69, 95% CI = 0.49-0.97; for CT+TT vs. CC: OR = 0.71, 95% CI 0.59-0.86). C677T variants were associated with neither combined nor stratified CIN among the overall population.
   Conclusions: This meta-analysis suggests that White women with mutant C677T genotypes might have a lower risk of cervical cancer, yet lacking enough statistical robustness. Further investigations are needed to get more insight into the role of this polymorphism in cervical carcinogenesis.
C1 [Luo, Ya Li; Ye, Ping; Zhang, Qiong Hua; Hu, Ting Ting; Luo, Min Hong; Li, Mei Qing; Chen, Qing] So Med Univ, Dept Epidemiol, Sch Publ Hlth & Trop Med, Guangzhou, Guangdong, Peoples R China.
RP Chen, Q (reprint author), So Med Univ, Dept Epidemiol, Sch Publ Hlth & Trop Med, Guangzhou, Guangdong, Peoples R China.
EM Qingchen_smu@163.com
CR American Cancer Society, 2011, CANC FACTS FIG 2011, P22
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boccia S, 2009, CANCER LETT, V273, P55, DOI 10.1016/j.canlet.2008.07.026
   BRINTON LA, 1992, EPIDEMIOLOGY CERVICA, P3
   Cerqueira EMM, 1998, ACTA CYTOL, V42, P639, DOI 10.1159/000331820
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8
   Collin SM, 2009, CANCER EPIDEM BIOMAR, V18, P2528, DOI 10.1158/1055-9965.EPI-09-0223
   Delgado-Enciso I, 2006, REV INVEST CLIN, V58, P462
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duthie SJ, 2002, J NUTR, V132, p2444S, DOI 10.1093/jn/132.8.2444S
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Flatley JE, 2009, CANCER EPIDEM BIOMAR, V18, P2782, DOI 10.1158/1055-9965.EPI-09-0493
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   Goodman MT, 2001, CANCER EPIDEM BIOMAR, V10, P1275
   Goodman MT, 2000, CANCER, V89, P376, DOI 10.1002/1097-0142(20000715)89:2<376::AID-CNCR24>3.0.CO;2-O
   HERRERO R, 1990, CANCER-AM CANCER SOC, V65, P380, DOI 10.1002/1097-0142(19900115)65:2<380::AID-CNCR2820650234>3.0.CO;2-9
   Kang S, 2005, GYNECOL ONCOL, V96, P173, DOI 10.1016/j.ygyno.2004.09.031
   Kohaar I, 2010, BIOMARKERS, V15, P61, DOI 10.3109/13547500903295881
   Lambropoulos AF, 2003, CANCER LETT, V191, P187, DOI 10.1016/S0304-3835(02)00675-4
   LUTHRA UK, 1987, ACTA CYTOL, V31, P226
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Molloy AM, 1997, LANCET, V349, P1591, DOI 10.1016/S0140-6736(96)12049-3
   Mostowska A, 2011, CLIN BIOCHEM, V44, P596, DOI 10.1016/j.clinbiochem.2011.02.007
   Office of Management and Budget, 2003, REV STAND CLASS FED
   Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Piyathilake CJ, 2007, NUTRITION, V23, P203, DOI 10.1016/j.nut.2006.12.002
   Piyathilake CJ, 2009, CANCER PREV RES, V2, P658, DOI 10.1158/1940-6207.CAPR-08-0175
   Piyathilake CJ, 2000, ANTICANCER RES, V20, P1751
   Prasad VVTS, 2011, ONKOLOGIE, V34, P422, DOI 10.1159/000331131
   Qi XW, 2010, BREAST CANCER RES TR, V123, P499, DOI 10.1007/s10549-010-0773-7
   ROMNEY SL, 1987, ANN NY ACAD SCI, V498, P132, DOI 10.1111/j.1749-6632.1987.tb23757.x
   SADEGHI SB, 1988, CANCER-AM CANCER SOC, V61, P2359, DOI 10.1002/1097-0142(19880601)61:11<2359::AID-CNCR2820611135>3.0.CO;2-7
   Salanti G, 2005, EUR J HUM GENET, V13, P840, DOI 10.1038/sj.ejhg.5201410
   SCHIFFMAN MH, 1993, J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958
   SCHIFFMAN MH, 1995, CANCER, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H
   Shaw GM, 2002, AM J MED GENET, V108, P1, DOI 10.1002/ajmg.10195
   Shekari M, 2008, ARCH GYNECOL OBSTET, V278, P517, DOI 10.1007/s00404-008-0623-6
   Sheng X, 2012, MOL BIOL REP
   Shin HR, 2008, INT J CANCER, V122, P393, DOI 10.1002/ijc.23015
   Sull JW, 2004, GYNECOL ONCOL, V95, P557, DOI 10.1016/j.ygyno.2004.08.008
   Tong SY, 2011, CANCER CAUSE CONTROL, V22, P63, DOI 10.1007/s10552-010-9675-6
   van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825
   VANEENWYK J, 1992, CANCER EPIDEM BIOMAR, V1, P119
   Yan JR, 2012, PEDIATR BLOOD CANCER, V58, P513, DOI 10.1002/pbc.23137
   Zacho J, 2011, INT J CANCER, V128, P644, DOI 10.1002/ijc.25375
   Zhang Y, 2012, MOL BIOL REP, V39, P6203, DOI 10.1007/s11033-011-1439-1
   Zoodsma M, 2005, HUM GENET, V116, P247, DOI 10.1007/s00439-004-1233-4
NR 49
TC 6
Z9 6
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 28
PY 2012
VL 7
IS 9
AR e46272
DI 10.1371/journal.pone.0046272
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 022PZ
UT WOS:000309973900122
PM 23029458
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Marx, FM
   Dunbar, R
   Enarson, DA
   Beyers, N
AF Marx, Florian M.
   Dunbar, Rory
   Enarson, Donald A.
   Beyers, Nulda
TI The Rate of Sputum Smear-Positive Tuberculosis after Treatment Default
   in a High-Burden Setting: A Retrospective Cohort Study
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; BODY-MASS INDEX; SINGLE NUCLEOTIDE
   POLYMORPHISMS; COMMON VARIANTS; CHILDHOOD OBESITY; ADULT OBESITY;
   GENETIC-VARIANTS; CHINESE CHILDREN; FTO GENE; MC4R
AB Rationale: High rates of recurrent tuberculosis after successful treatment have been reported from different high burden settings in Sub-Saharan Africa. However, little is known about the rate of smear-positive tuberculosis after treatment default. In particular, it is not known whether or not treatment defaulters continue to be or become again smear-positive and thus pose a potential for transmission of infection to others.
   Objective: To investigate, in a high tuberculosis burden setting, the rate of re-treatment for smear-positive tuberculosis among cases defaulting from standardized treatment compared to successfully treated cases.
   Methods: Retrospective cohort study among smear-positive tuberculosis cases treated between 1996 and 2008 in two urban communities in Cape Town, South Africa. Episodes of re-treatment for smear-positive tuberculosis were ascertained via probabilistic record linkage. Survival analysis and Poisson regression were used to compare the rate of smear-positive tuberculosis after treatment default to that after successful treatment.
   Results: A total of 2,136 smear-positive tuberculosis cases were included in the study. After treatment default, the rate of re-treatment for smear-positive tuberculosis was 6.86 (95% confidence interval [CI]: 5.59-8.41) per 100 person-years compared to 2.09 (95% CI: 1.81-2.41) after cure (adjusted Hazard Ratio [aHR]: 3.97; 95% CI: 3.00-5.26). Among defaulters, the rate was inversely associated with treatment duration and sputum conversion prior to defaulting. Smear grade at start of the index treatment episode (Smear3+: aHR 1.61; 95% CI 1.11-2.33) was independently associated with smear-positive tuberculosis re-treatment, regardless of treatment outcome.
   Conclusions: In this high-burden setting, there is a high rate of subsequent smear-positive tuberculosis after treatment default. Treatment defaulters are therefore likely to contribute to the pool of infectious source cases in the community. Our findings underscore the importance of preventing treatment default, as a means of successful tuberculosis control in high-burden settings.
C1 [Marx, Florian M.] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany.
   [Marx, Florian M.; Dunbar, Rory; Enarson, Donald A.; Beyers, Nulda] Univ Stellenbosch, Desmond Tutu TB Ctr, ZA-7505 Tygerberg, South Africa.
   [Enarson, Donald A.] Int Union TB & Lung Dis, Paris, France.
RP Marx, FM (reprint author), Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany.
EM florian.marx@charite.de
OI Marx, Florian/0000-0003-4630-4598
FU TREAT TB
FX This study was supported by a grant from TREAT TB, managed by the
   International Union Against Tuberculosis and Lung Disease and provided
   by USAID. The contents of this document are the sole responsibility of
   the authors and can under no circumstances be regarded as reflecting the
   positions of the International Union Against Tuberculosis and Lung
   Disease (The Union) or those of the donor. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Beckers S, 2011, MOL GENET METAB, V103, P71, DOI 10.1016/j.ymgme.2011.01.007
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cauchi S, 2009, J MOL MED, V87, P537, DOI 10.1007/s00109-009-0451-6
   Chambers JC, 2008, NAT GENET, V40, P716, DOI 10.1038/ng.156
   Cheung CYY, 2010, J CLIN ENDOCR METAB, V95, P1395, DOI 10.1210/jc.2009-1465
   Clark MF, 2006, INTENS CARE MED, V32, P1706, DOI 10.1007/s00134-006-0327-y
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dixon JB, 2010, MOL CELL ENDOCRINOL, V316, P104, DOI 10.1016/j.mce.2009.07.008
   Doak CM, 2012, OBES REV, V13, P174, DOI 10.1111/j.1467-789X.2011.00943.x
   Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634
   Grant SFA, 2009, OBESITY, V17, P1461, DOI 10.1038/oby.2009.53
   Holzapfel C, 2010, INT J OBESITY, V34, P1538, DOI 10.1038/ijo.2010.79
   Hong J, 2013, INT J OBESITY, V37, P673, DOI 10.1038/ijo.2012.87
   Hotta K, 2009, J HUM GENET, V54, P727, DOI 10.1038/jhg.2009.106
   Huang H, 2012, MOL BIOL REP, V39, P1739, DOI 10.1007/s11033-011-0914-z
   Huang W, 2011, ENDOCRINE, V39, P69, DOI 10.1007/s12020-010-9413-6
   Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159
   Li H, 2012, DIABETOLOGIA, V55, P981, DOI 10.1007/s00125-011-2370-7
   Li SX, 2010, AM J CLIN NUTR, V91, P184, DOI 10.3945/ajcn.2009.28403
   Liem ET, 2010, AM J CLIN NUTR, V91, P321, DOI 10.3945/ajcn.2009.28186
   Loos RJF, 2008, NAT GENET, V40, P768, DOI 10.1038/ng.140
   Loos RJF, 2011, EUR J PHARMACOL, V660, P156, DOI 10.1016/j.ejphar.2011.01.033
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Meyre D, 2009, NAT GENET, V41, P157, DOI 10.1038/ng.301
   Munafo MR, 2004, TRENDS GENET, V20, P439, DOI 10.1016/j.tig.2004.06.014
   Ng MCY, 2010, J CLIN ENDOCR METAB, V95, P2418, DOI 10.1210/jc.2009-2077
   Okada Y, 2012, NAT GENET, V44, P302, DOI 10.1038/ng.1086
   Pan ZL, 2005, PLOS MED, V2, P1309, DOI 10.1371/journal.pmed.0020334
   Paternoster L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024303
   Peng SH, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-71
   Razquin C, 2011, MOL NUTR FOOD RES, V55, P136, DOI 10.1002/mnfr.201000445
   Renstrom F, 2009, HUM MOL GENET, V18, P1489, DOI 10.1093/hmg/ddp041
   Rouskas K, 2012, OBESITY, V20, P389, DOI 10.1038/oby.2011.177
   Scherag A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013967
   Scherag A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000916
   Shi JJ, 2010, AM J EPIDEMIOL, V172, P244, DOI 10.1093/aje/kwq129
   Speliotes EK, 2010, NAT GENET, V42, P937, DOI 10.1038/ng.686
   Stutzmann F, 2007, HUM MOL GENET, V16, P1837, DOI 10.1093/hmg/ddm132
   Tabara Y, 2009, INT J OBESITY, V33, P1243, DOI 10.1038/ijo.2009.161
   Tao LM, 2012, MOL BIOL REP, V39, P6487, DOI 10.1007/s11033-012-1476-4
   Thomsen M, 2012, J CLIN ENDOCR METAB, V97, pE1074, DOI 10.1210/jc.2011-3282
   Thorleifsson G, 2009, NAT GENET, V41, P18, DOI 10.1038/ng.274
   Valladares M, 2010, NUTR NEUROSCI, V13, P71, DOI 10.1179/147683010X12611460763643
   Vogel CIG, 2011, OBESITY FACTS, V4, P67, DOI 10.1159/000324557
   Wang D, 2010, OBESITY, V18, P573, DOI 10.1038/oby.2009.268
   Wang J, 2012, INT J OBESITY, V36, P542, DOI 10.1038/ijo.2011.218
   Wen WQ, 2012, NAT GENET, V44, P307, DOI 10.1038/ng.1087
   Willer CJ, 2009, NAT GENET, V41, P25, DOI 10.1038/ng.287
   Wu LJ, 2010, DIABETES, V59, P3085, DOI 10.2337/db10-0273
   Xi B, 2011, AM J EPIDEMIOL, V173, P1256, DOI 10.1093/aje/kwr008
   Zhao JH, 2011, OBESITY, V19, P2436, DOI 10.1038/oby.2011.237
   Zobel DP, 2009, DIABETES, V58, P757, DOI 10.2337/db08-0620
NR 52
TC 11
Z9 11
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 25
PY 2012
VL 7
IS 9
AR e45724
DI 10.1371/journal.pone.0045724
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 016YP
UT WOS:000309556100074
PM 23049846
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Weng, MZ
   Zhang, Y
   Zhou, D
   Yang, Y
   Tang, ZH
   Zhao, MN
   Quan, ZW
   Gong, W
AF Weng, Mingzhe
   Zhang, Yong
   Zhou, Di
   Yang, Yong
   Tang, Zhaohui
   Zhao, Mingning
   Quan, Zhiwei
   Gong, Wei
TI Radiofrequency Ablation versus Resection for Colorectal Cancer Liver
   Metastases: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID LONG-TERM SURVIVAL; SMALL HEPATOCELLULAR-CARCINOMA; HEPATIC RESECTION;
   RANDOMIZED-TRIAL; MICROWAVE COAGULATION; INJECTION THERAPY;
   NATURAL-HISTORY; RECURRENCE; HEPATECTOMY; OUTCOMES
AB Background: No randomized controlled trial (RCT) has yet been performed to provide the evidence to clarify the therapeutic debate on liver resection (LR) and radiofrequency ablation (RFA) in treating colorectal liver metastases (CLM). The meta-analysis was performed to summarize the evidence mostly from retrospective clinical trials and to investigate the effect of LR and RFA.
   Methodology/Principal Findings: Systematic literature search of clinical studies was carried out to compare RFA and LR for CLM in Pubmed, Embase and the Cochrane Library Central databases. The meta-analysis was performed using risk ratio (RR) and random effect model, in which 95% confidence intervals (95% CI) for RR were calculated. Primary outcomes were the overall survival (OS) and disease-free survival (DFS) at 3 and 5 years plus mortality and morbidity. 1 prospective study and 12 retrospective studies were finally eligible for meta-analysis. LR was significantly superior to RFA in 3-year OS (RR 1.377, 95% CI: 1.246-1.522); 5-year OS (RR: 1.474, 95% CI: 1.284-1.692); 3-year DFS (RR 1.735, 95% CI: 1.483-2.029) and 5-year DFS (RR 2.227, 95% CI: 1.823-2.720). The postoperative morbidity was higher in LR (RR: 2.495, 95% CI: 1.881-3.308), but no significant difference was found in mortality between LR and RFA. The data from the 3 subgroups (tumor<3 cm; solitary tumor; open surgery or laparoscopic approach) showed significantly better OS and DFS in patients who received surgical resection.
   Conclusions/Significances: Although multiple confounders exist in the clinical trials especially the bias in patient selection, LR was significantly superior to RFA in the treatment of CLM, even when conditions limited to tumor<3 cm, solitary tumor and open surgery or laparoscopic (lap) approach. Therefore, caution should be taken when treating CLM with RFA before more supportive evidences for RFA from RCTs are obtained.
C1 [Weng, Mingzhe; Zhang, Yong; Zhou, Di; Yang, Yong; Tang, Zhaohui; Zhao, Mingning; Quan, Zhiwei; Gong, Wei] Shanghai Jiao Tong Univ, Dept Gen Surg, Xinhua Hosp, Sch Med, Shanghai 200030, Peoples R China.
RP Quan, ZW (reprint author), Shanghai Jiao Tong Univ, Dept Gen Surg, Xinhua Hosp, Sch Med, Shanghai 200030, Peoples R China.
EM zhiwquan@yahoo.com.cn; gongweius@hotmail.com
FU China Natural Science Project [30972919]; Shanghai Scientific Bureau
   International Cooperation Project [10410700100]; Shanghai Municipal
   Health Bureau funding [2009064]
FX Funding agencies: China Natural Science Project to ZWQ (30972919);
   Shanghai Scientific Bureau International Cooperation Project to WG
   (10410700100); and Shanghai Municipal Health Bureau funding to WG
   (2009064). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abdalla EK, 2006, ANN SURG ONCOL, V13, P1271, DOI 10.1245/s10434-006-9045-5
   Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71
   American Cancer Society, 2002, CANC FACTS FIG
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BENGTSSON G, 1981, AM J SURG, V141, P586, DOI 10.1016/0002-9610(81)90057-X
   Berber E, 2004, SURG ENDOSC, V18, P390, DOI 10.1007/s00464-003-8911-5
   Berber E, 2008, J GASTROINTEST SURG, V12, P1967, DOI 10.1007/s11605-008-0622-8
   Chen MS, 2006, ANN SURG, V243, P321, DOI 10.1097/01.sla.0000201480.65519.b8
   Choti MA, 2002, ANN SURG, V235, P759, DOI 10.1097/00000658-200206000-00002
   Danila M, 2009, J GASTROINTEST LIVER, V18, P317
   Elias D, 2004, HEPATO-GASTROENTEROL, V51, P1788
   Elias D, 2002, BRIT J SURG, V89, P752, DOI 10.1046/j.1365-2168.2002.02081.x
   Evrard S, 2004, EJSO, V30, P399, DOI 10.1016/j.ejso.2004.01.019
   Gillams AR, 2005, ABDOM IMAGING, V30, P419, DOI 10.1007/s00261-004-0256-6
   Gleisner AL, 2008, ARCH SURG-CHICAGO, V143, P1204, DOI 10.1001/archsurg.143.12.1204
   Goldberg SN, 2003, RADIOLOGY, V228, P335, DOI 10.1148/radiol.2282021787
   Hildebrand P, 2006, EJSO, V32, P430, DOI 10.1016/j.ejso.2006.01.006
   Huo TI, 2006, J CLIN GASTROENTEROL, V40, P639, DOI 10.1097/00004836-200608000-00017
   Hur H, 2009, AM J SURG, V197, P728, DOI [DOI 10.1016/J.AMJSURG.2008.04.013, 10.1016/j.amjsurg.2008.04.013]
   Hur H, 2009, AM J SURG, V197, P728, DOI 10.1016/j.amjsurg.2008.04.013
   Kannerup Anne-Sofie, 2008, Ugeskr Laeger, V170, P1338
   Kawamoto C, 2005, CANCER-AM CANCER SOC, V103, P985, DOI 10.1002/cncr.20880
   Kim KH, 2011, J KOREAN SURG SOC, V81, P25, DOI 10.4174/jkss.2011.81.1.25
   Lau WY, 2009, ANN SURG, V249, P20, DOI 10.1097/SLA.0b013e31818eec29
   Leblanc F, 2008, EJSO-EUR J SURG ONC, V34, P185, DOI 10.1016/j.ejso.2007.09.028
   Lee KH, 2011, KOREAN J GASTROENTER, V59, P218
   Lee WS, 2008, J CLIN GASTROENTEROL, V42, P945, DOI 10.1097/MCG.0b013e318064e752
   Lencioni Riccardo, 2004, Liver Transpl, V10, pS91, DOI 10.1002/lt.20043
   Livraghi T, 2003, CANCER, V97, P3027, DOI 10.1002/cncr.11426
   Lu Ming-de, 2006, Zhonghua Yi Xue Za Zhi, V86, P801
   Majeed AW, 2003, BRIT J SURG, V90, P1240
   McKay A, 2009, HPB SURG, P1
   Mulier S, 2005, ANN SURG, V242, P158, DOI 10.1097/01.sla.0000171032.99149.fe
   Mulier S, 2009, DIGEST SURG, V25, P445
   Mulier S, 2008, ANN SURG ONCOL, V15, P144, DOI 10.1245/s10434-007-9478-5
   Oshowo A, 2003, BRIT J SURG, V90, P1240, DOI 10.1002/bjs.4264
   Otto G, 2010, ANN SURG, V251, P796, DOI 10.1097/SLA.0b013e3181bc9fae
   PELLETIER G, 1990, J HEPATOL, V11, P181, DOI 10.1016/0168-8278(90)90110-D
   Reuter NP, 2009, J GASTROINTEST SURG, V13, P486, DOI 10.1007/s11605-008-0727-0
   SCHEELE J, 1995, WORLD J SURG, V19, P59, DOI 10.1007/BF00316981
   Shibata T, 2002, RADIOLOGY, V223, P331, DOI 10.1148/radiol.2232010775
   SILEN W, 1989, ARCH SURG-CHICAGO, V124, P1021
   Solbiati L, 2001, RADIOLOGY, V221, P625
   Sorensen SM, 2007, ACTA RADIOL, V48, P253, DOI 10.1080/02841850601161539
   Vauthey JN, 2004, ANN SURG, V239, P722, DOI 10.1097/01.sia.0000124385.83887.d5
   WAGNER JS, 1984, ANN SURG, V199, P502, DOI 10.1097/00000658-198405000-00002
   White RR, 2007, J GASTROINTEST SURG, V11, P256, DOI 10.1007/s11605-007-0100-8
   Wood TF, 2000, ANN SURG ONCOL, V7, P593, DOI 10.1007/BF02725339
   Wu YZ, 2011, WORLD J GASTROENTERO, V17, P4143, DOI 10.3748/wjg.v17.i36.4143
   Zhou XD, 1998, SEMIN SURG ONCOL, V14, P171, DOI 10.1002/(SICI)1098-2388(199803)14:2<171::AID-SSU9>3.0.CO;2-2
NR 50
TC 43
Z9 49
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 21
PY 2012
VL 7
IS 9
AR e45493
DI 10.1371/journal.pone.0045493
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 014RG
UT WOS:000309392800054
PM 23029051
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Bonovas, S
   Nikolopoulos, GK
   Bagos, PG
AF Bonovas, Stefanos
   Nikolopoulos, Georgios K.
   Bagos, Pantelis G.
TI Use of Fibrates and Cancer Risk: A Systematic Review and Meta-Analysis
   of 17 Long-Term Randomized Placebo-Controlled Trials
SO PLOS ONE
LA English
DT Review
ID CORONARY-ARTERY-DISEASE; CHOLESTEROL-LOWERING DRUGS; TYPE-2
   DIABETES-MELLITUS; CLINICAL-TRIALS; HEART-DISEASE; CARDIOVASCULAR
   OUTCOMES; SECONDARY PREVENTION; COLORECTAL-CANCER; PROSTATE-CANCER; HDL
   CHOLESTEROL
AB Background: Fibrates comprise a class of well-established antilipidemic agents that significantly reduce cardiovascular events. Given the concerns of cancer with fibrate therapy, we undertook a systematic review and meta-analysis to investigate the effects of fibrates on cancer outcomes.
   Methods: We systematically searched Medline, Scopus, SCI Expanded, and the Cochrane Library for studies published up to 2012. We included randomized controlled trials (RCTs) that evaluated a fibrate therapy compared with placebo, had a minimum duration of two years, and reported data on the incidence of and/or deaths from cancer during the trial. Reviews of each study were performed and the relative data were abstracted. Pooled relative risk estimates (RR) and 95% confidence intervals (CIs) were calculated using the inverse variance weighted approach. Subgroup, sensitivity and meta-regression analyses were also conducted.
   Results: Seventeen RCTs, involving 44,929 participants with an average follow-up of 5.2 years, contributed to the analysis. The degree of variability between trials was consistent with what would be expected to occur by chance alone. The quantitative synthesis of data retrieved from the RCTs was not indicative of a fibrate effect on cancer incidence (780 [fibrate] vs 814 [control]; RR = 1.02, 95% CI 0.92-1.12) or cancer death (385 [fibrate] vs 377 [control]; RR = 1.06, 95% CI: 0.92-1.22). When the analysis was restricted to major RCTs, the results did not substantially change. Similarly, we found no evidence of differential effects by length of follow-up or type of fibrate. Insignificant results were also obtained for the role of fibrates in cancers of the respiratory tract, breast, colon, gastrointestinal tract, prostate, genitourinary tract, or in melanoma.
   Conclusion: Our findings demonstrate that fibrates have a neutral effect on cancer outcomes. However, it is important to continue monitoring their long-term safety profiles.
C1 [Bonovas, Stefanos] Univ Athens, Sch Med, Dept Pharmacol, GR-11527 Athens, Greece.
   [Bonovas, Stefanos; Nikolopoulos, Georgios K.] Hellen Ctr Dis Control & Prevent, Athens, Greece.
   [Bonovas, Stefanos; Bagos, Pantelis G.] Univ Cent Greece, Dept Comp Sci & Biomed Informat, Lamia, Greece.
RP Bonovas, S (reprint author), Univ Athens, Sch Med, Dept Pharmacol, GR-11527 Athens, Greece.
EM sbonovas@med.uoa.gr
RI Nikolopoulos, Georgios/H-5698-2011; Bonovas, Stefanos/H-5653-2011;
   Bagos, Pantelis/H-5658-2011
OI Nikolopoulos, Georgios/0000-0002-3307-0246; Bagos,
   Pantelis/0000-0003-4935-2325
CR Abourbih S, 2009, AM J MED, V122, DOI 10.1016/j.amjmed.2009.03.030
   ACHESON J, 1972, ATHEROSCLEROSIS, V15, P177, DOI 10.1016/0021-9150(72)90067-6
   [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
   [Anonymous], 1978, JAMA-J AM MED ASSOC, V239, P2758
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Begg T B, 1971, Minerva Med, V62, P3469
   BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406
   Blais L, 2000, ARCH INTERN MED, V160, P2363, DOI 10.1001/archinte.160.15.2363
   Bonovas S, 2005, J CLIN ONCOL, V23, P8606, DOI 10.1200/JCO.2005.02.7045
   Bonovas S, 2008, AM J GASTROENTEROL, V103, P2646, DOI 10.1111/j.1572-0241.2008.02051.x
   Bonovas S, 2008, INT J CANCER, V123, P899, DOI 10.1002/ijc.23550
   Bonovas S, 2007, J CLIN ONCOL, V25, P3462, DOI 10.1200/JCO.2007.10.8936
   Bonovas S, 2007, BRIT J CLIN PHARMACO, V64, P255, DOI 10.1111/j.1365-2125.2007.02959.x
   Bonovas S, 2006, J CLIN ONCOL, V24, P4808, DOI 10.1200/JCO.2006.06.3560
   Bonovas S, 2010, EUR J EPIDEMIOL, V25, P29, DOI 10.1007/s10654-009-9396-x
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Cullen JF, 1972, T OPHTHAL SOC UK, V94, P554
   Dalen JE, 1996, JAMA-J AM MED ASSOC, V275, P67, DOI 10.1001/jama.275.1.67
   David NJ, 1973, STROKE, V4, P684
   Despres JP, 2004, DRUGS, V64, P2177, DOI 10.2165/00003495-200464190-00003
   DEWAR HA, 1972, BRIT MED J, V2, P228, DOI 10.1136/bmj.2.5807.228
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elkeles RS, 1998, DIABETES CARE, V21, P641, DOI 10.2337/diacare.21.4.641
   Emberson JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029849
   Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4
   Fortuny J, 2006, CANCER EPIDEM BIOMAR, V15, P921, DOI 10.1158/1055-9965.EPI-05-0866
   Freeman SR, 2006, JNCI-J NATL CANCER I, V98, P1538, DOI 10.1093/jnci/djj412
   FRICK MH, 1993, ANN MED, V25, P41, DOI 10.3109/07853899309147855
   Frick MH, 1997, CIRCULATION, V96, P2137
   Gardette V, 2009, AM J CARDIOL, V103, P381, DOI 10.1016/j.amjcard.2008.09.092
   Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282
   GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248
   *GROUP PHYS NEWC U, 1971, BMJ-BRIT MED J, V4, P767
   HANEFELD M, 1991, DIABETES CARE, V14, P308, DOI 10.2337/diacare.14.4.308
   HEADY JA, 1992, LANCET, V340, P1405, DOI 10.1016/0140-6736(92)92588-7
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   HIGGINS JPT, 2008, COCHRANE COLLABORATI
   HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026
   HUTTUNEN JK, 1994, J INTERN MED, V235, P31, DOI 10.1111/j.1365-2796.1994.tb01029.x
   Jackevicius CA, 2011, JAMA-J AM MED ASSOC, V305, P1217, DOI 10.1001/jama.2011.353
   Jun M, 2010, LANCET, V375, P1875, DOI 10.1016/S0140-6736(10)60656-3
   Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054
   Keech A, 2005, LANCET, V366, P1849, DOI 10.1016/S0140-6736(05)67667-2
   Meade T, 2002, BRIT MED J, V325, P1139, DOI 10.1136/bmj.325.7373.1139
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   MULDOON MF, 1990, BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309
   Murtola TJ, 2007, CANCER EPIDEM BIOMAR, V16, P2226, DOI 10.1158/1055-9965.EPI-07-0599
   Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55
   OLIVER MF, 1991, LANCET, V337, P1529, DOI 10.1016/0140-6736(91)93208-Q
   Olsen JH, 1999, J CLIN EPIDEMIOL, V52, P167, DOI 10.1016/S0895-4356(98)00147-4
   Pedersen TR, 2009, CURR ATHEROSCLER REP, V11, P350, DOI 10.1007/s11883-009-0053-3
   Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792
   Report From the Committee of Principal Investigators, 1978, BRIT HEART J, V40, P1069
   Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604
   Saha SA, 2010, INT J CARDIOL, V141, P157, DOI 10.1016/j.ijcard.2008.11.211
   Schlesinger Z, 2000, CIRCULATION, V102, P21, DOI 10.1161/01.CIR.102.1.21
   SHARP S, 1998, STATA TECH B, V42, P16, DOI DOI 10.1002/SIM.1187/FULL)
   Smith GD, 2002, BRIT MED J, V325, P1437
   SMITH GD, 1992, BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431
   Staels B, 2005, DIABETES, V54, P2460, DOI 10.2337/diabetes.54.8.2460
   Steiner G, 2001, LANCET, V357, P905
   Tenenbaum A, 2008, CARDIOVASC DIABETOL, V7, DOI 10.1186/1475-2840-7-18
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   WHO Cooperative Trial Committee of Principal Investigators, 1985, LANCET, V2, P379
   1971, BR MED J, V4, P775
NR 66
TC 16
Z9 16
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 19
PY 2012
VL 7
IS 9
AR e45259
DI 10.1371/journal.pone.0045259
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 014PP
UT WOS:000309388400069
PM 23028888
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhou, L
   Cai, JG
   Liu, G
   Wei, Y
   Tang, H
AF Zhou, Liang
   Cai, Jianguang
   Liu, Gang
   Wei, Yuan
   Tang, Hui
TI Associations between Interleukin-1 Gene Polymorphisms and Coronary Heart
   Disease Risk: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID RECEPTOR ANTAGONIST GENE; MESSENGER-RNA LEVELS; MYOCARDIAL-INFARCTION;
   ARTERY-DISEASE; ISCHEMIC-STROKE; CLUSTER POLYMORPHISMS; TURKISH
   POPULATION; IN-VITRO; ATHEROSCLEROSIS; PERIODONTITIS
AB Objective: A great number of studies regarding the associations between IL-1B-511, IL-1B+3954 and IL-1RN VNTR polymorphisms within the IL-1gene cluster and coronary heart disease (CHD) have been published. However, results have been inconsistent. In this study, a meta-analysis was performed to investigate the associations.
   Methods: Published literature from PubMed and Embase databases were searched for eligible publications. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-or fixed-effect model.
   Results: Thirteen studies (3,219 cases/2,445 controls) for IL-1B-511 polymorphism, nine studies (1,828 cases/1,818 controls) for IL-1B+3954 polymorphism and twelve studies (2,987 cases/2,208 controls) for IL-1RN VNTR polymorphism were included in this meta analysis. The results indicated that both IL-1B-511 and IL-1B+3954 polymorphisms were not associated with CHD risk (IL-1B-511 T vs. C: OR = 0.98, 95% CI 0.87-1.09; IL-1B+3954 T vs. C: OR = 1.06, 95% CI 0.95-1.19). Similarly, there was no association between IL-1RN VNTR polymorphism and CHD risk (*2 vs. L: OR = 1.00, 95% CI 0.85-1.17).
   Conclusions: This meta-analysis suggested that there were no associations between IL-1 gene cluster polymorphisms and CHD.
C1 [Zhou, Liang; Cai, Jianguang; Liu, Gang; Tang, Hui] Hunan Univ Sci & Technol, Dept Sports Physiol, Xiangtan, Hunan, Peoples R China.
   [Wei, Yuan] Guangzhou Sports Univ, Dept Sports Physiol, Guangzhou, Guangdong, Peoples R China.
RP Zhou, L (reprint author), Hunan Univ Sci & Technol, Dept Sports Physiol, Xiangtan, Hunan, Peoples R China.
EM liangzhou0731@163.com
FU Key Project of Chinese Ministry of Education [2010148]; Natural Science
   Foundation of China [30971413]
FX This work was supported by Key Project of Chinese Ministry of Education
   (2010148) and Natural Science Foundation of China (30971413). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andreotti F, 2002, HEART, V87, P107, DOI 10.1136/heart.87.2.107
   [Anonymous], CAUS DEATH 2008 DAT
   Arman A, 2008, ARQ BRAS CARDIOL, V91, P268
   Auer J, 2002, CLIN INFECT DIS, V34, P1536, DOI 10.1086/340531
   Banerjee I, 2009, J THROMB THROMBOLYS, V27, P88, DOI 10.1007/s11239-007-0184-8
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brown BD, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-5
   Buffon A, 2002, NEW ENGL J MED, V347, P5, DOI 10.1056/NEJMoa012295
   Chen Fan, 2010, Nan Fang Yi Ke Da Xue Xue Bao, V30, P1635
   Coker A, 2011, INT J IMMUNOGENET, V38, P201, DOI 10.1111/j.1744-313X.2010.00988.x
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dinarello CA, 1996, BLOOD, V87, P2095
   DINARELLO CA, 1991, BLOOD, V77, P1627
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Omar EM, 2001, GUT, V48, P743, DOI 10.1136/gut.48.6.743
   Francis SE, 1999, CIRCULATION, V99, P861, DOI 10.1161/01.CIR.99.7.861
   Geismar K, 2008, J PERIODONTOL, V79, P2322, DOI [10.1902/jop.2008.070454, 10.1902/jop.2008.070454 ]
   Goracy J, 2011, ARCH MED RES, V42, P426, DOI 10.1016/j.arcmed.2011.08.002
   Hackett TL, 2011, INT J CHRONIC OBSTR, V6, P277, DOI 10.2147/COPD.S18279
   Hurme M, 1998, EUR J IMMUNOL, V28, P2598, DOI 10.1002/(SICI)1521-4141(199808)28:08<2598::AID-IMMU2598>3.0.CO;2-K
   Iacoviello L, 2005, ARTERIOSCL THROM VAS, V25, P222, DOI 10.1161/01.ATV.0000150039.60906.02
   Iacoviello L, 2000, CIRCULATION, V101, pE193
   Kariz S, 2007, COLLEGIUM ANTROPOL, V31, P503
   Keavney B, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-6
   Kim HJ, 2010, CELL MOL LIFE SCI, V67, P2119, DOI 10.1007/s00018-010-0328-4
   Kornman KS, 1999, J PERIODONTAL RES, V34, P353, DOI 10.1111/j.1600-0765.1999.tb02265.x
   Libby P, 2002, NATURE, V420, P868, DOI 10.1038/nature01323
   Licastro F, 2004, MECH AGEING DEV, V125, P575, DOI 10.1016/j.mad.2004.06.008
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Fragoso JM, 2010, IMMUNOL LETT, V133, P106, DOI 10.1016/j.imlet.2010.08.003
   Marculescu R, 2002, DIABETES, V51, P3582, DOI 10.2337/diabetes.51.12.3582
   Memon RA, 1998, AM J PHYSIOL-ENDOC M, V274, pE210
   Momiyama Y, 2005, ARTERIOSCL THROM VAS, V25, pE36, DOI 10.1161/01.ATV.0000159700.18731.d2
   Momiyama Y, 2001, J AM COLL CARDIOL, V38, P712, DOI 10.1016/S0735-1097(01)01438-3
   Nicklin MJH, 2002, GENOMICS, V79, P718, DOI 10.1006/geno.2002.6751
   Olofsson PS, 2009, CIRC J, V73, P1531, DOI 10.1253/circj.CJ-08-1150
   Rios DLS, 2010, CYTOKINE, V50, P292, DOI 10.1016/j.cyto.2010.02.012
   Santtila S, 1998, SCAND J IMMUNOL, V47, P195
   Sims JE, 2001, TRENDS IMMUNOL, V22, P536, DOI 10.1016/S1471-4906(01)02040-3
   Smith DE, 2000, J BIOL CHEM, V275, P1169, DOI 10.1074/jbc.275.2.1169
   Soylu O, 2008, EUR CYTOKINE NETW, V19, P42, DOI 10.1684/ecn.2008.0119
   Stein JM, 2009, J PERIODONTOL, V80, P1095, DOI 10.1902/jop.2009.080639
   Taube A, 2012, AM J PHYSIOL-HEART C, V302, pH2148, DOI 10.1152/ajpheart.00907.2011
   Vamvakopoulos JE, 2002, EUR J IMMUNOGENET, V29, P337, DOI 10.1046/j.1365-2370.2002.00319.x
   van Minkelen R, 2009, ATHEROSCLEROSIS, V203, P201, DOI 10.1016/j.atherosclerosis.2008.06.029
   Vohnout B, 2003, HAEMATOLOGICA, V88, P54
   Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538
   WHO, GLOB ATL CARD DIS PR
   Yang L, 2012, INFLAMMATION, DOI [10.1016/j.gene.2012.02.026, DOI 10.1016/J.GENE.2012.02.026]
   Ye F, 2012, GENE, V499, P61, DOI 10.1016/j.gene.2012.02.026
   Zee RYL, 2008, ATHEROSCLEROSIS, V201, P124, DOI 10.1016/j.atherosclerosis.2008.01.004
   Zee RYL, 2001, THROMB HAEMOSTASIS, V86, P1141
   Zeybek U, 2011, MOL BIOL REP, V38, P5453, DOI 10.1007/s11033-011-0701-x
   Zhang Yuan-ming, 2006, Zhonghua Yixue Yichuanxue Zazhi, V23, P86
   Zhu Yin-Hua, 2009, Sichuan Da Xue Xue Bao Yi Xue Ban, V40, P73
NR 55
TC 16
Z9 18
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 19
PY 2012
VL 7
IS 9
AR e45641
DI 10.1371/journal.pone.0045641
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 014PP
UT WOS:000309388400116
PM 23029154
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, Y
   Liu, F
   Tan, SQ
   Wang, Y
   Li, SW
AF Li, Ya
   Liu, Fei
   Tan, Shi-Qiao
   Wang, Yan
   Li, Shang-Wei
TI X-Ray Repair Cross-Complementing Group 1 (XRCC1) Genetic Polymorphisms
   and Cervical Cancer Risk: A HuGE Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID BASE EXCISION-REPAIR; HUMAN-PAPILLOMAVIRUS INFECTION; ACID SUBSTITUTION
   VARIANTS; DNA-REPAIR; CARCINOMA; ARG399GLN; SUSCEPTIBILITY; PROTEIN;
   WOMEN; BIAS
AB Background: Previous studies investigating the association between X-ray repair cross-complementation group 1(XRCC1) polymorphisms and cervical cancer (CC) risk has provided inconsistent results. The aim of our study was to assess the association between the XRCC1 gene Arg399Gln, Arg194Trp, Arg280His polymorphisms and risk of CC.
   Methods: Two investigators independently searched the Medline, Embase, CNKI, and Chinese Biomedicine Databases for studies published before March 2011. Summary odds ratios (ORs) and 95% confidence intervals (CIs) for XRCC1 polymorphisms and CC were calculated in a fixed-effects model or a random-effects model when appropriate.
   Results: Ultimately, 9, 5 and 2 studies were found to be eligible for meta-analyses of Arg399Gln, Arg194Trp and Arg280His, respectively. Our analysis suggested that the variant genotypes of Arg194Trp were associated with a significantly increased CC risk (Trp/Trp vs Arg/Arg, OR = 2.21, 95% CI = 1.60-3.06; Arg/Trp vs Arg/Arg, OR = 1.23, 95% CI = 1.02-1.49; dominant model, OR = 1.36, 95% CI = 1.14-1.63; recessive model, OR = 2.06, 95% CI = 1.51-2.82). For Arg280His polymorphism, no obvious associations were found for all genetic models. For Arg399Gln polymorphism, also no obvious associations were found for all genetic models. In the subgroup analyses by ethnicity/country, a significantly increased risk was observed among Asian, especially among Chinese. To get more precise evidences, adjusted ORs (95% CI) by potential confounders (such as age, ethnicity or smoking, etc) were also calculated for XRCC1 Arg399Gln and Arg194Trp, however, the estimated pooled adjusted OR still did not change at all.
   Conclusion: This meta-analysis suggests that Arg194Trp polymorphism may be associated with CC risk, Arg399Gln polymorphism might be a low-penetrent risk factor for CC only in Asians, and there may be no association between Arg280His polymorphism and CC risk.
C1 [Li, Ya; Wang, Yan; Li, Shang-Wei] Sichuan Univ, Div Reprod Med Ctr, W China Univ Hosp 2, Chengdu 610064, Sichuan Provinc, Peoples R China.
   [Liu, Fei] Sichuan Univ, Div Liver Transplantat, Dept Liver & Vasc Surg, W China Hosp, Chengdu 610064, Sichuan Provinc, Peoples R China.
   [Tan, Shi-Qiao] Sichuan Univ, Div Reprod Endocrinol & Infertil, W China Univ Hosp 2, Chengdu 610064, Sichuan Provinc, Peoples R China.
RP Li, Y (reprint author), Sichuan Univ, Div Reprod Med Ctr, W China Univ Hosp 2, Chengdu 610064, Sichuan Provinc, Peoples R China.
EM lishangwei688@foxmail.com
CR Almeida KH, 2007, DNA REPAIR, V6, P695, DOI 10.1016/j.dnarep.2007.01.009
   Barbisan G, 2011, EUR J GYNAECOL ONCOL, V32, P274
   Basso D, 2007, CLIN CHIM ACTA, V381, P50, DOI 10.1016/j.cca.2007.02.020
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berumen-Campos Jaime, 2006, Gac Med Mex, V142 Suppl 2, P51
   Campalans A, 2005, DNA REPAIR, V4, P826, DOI 10.1016/j.dnarep.2005.04.014
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farkasova T, 2008, NEOPLASMA, V55, P330
   Geng J, 2008, WORLD J GASTROENTERO, V14, P6733, DOI 10.3748/wjg.14.6733
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hong Q, 2008, ASS ADPRT XRCC1 GENE
   Hong-yu X, 2010, HAINAN MED J, V8, P35
   Huang J, 2007, INT J GYNECOL CANCER, V17, P668, DOI 10.1111/j.1525-1438.2007.00840.x
   International Agency for Research on Cancer, 2006, IARC MON EV CARC RIS
   [蒋雯 JIANG Wen], 2009, [南京医科大学学报. 自然科学版, Acta Universitatis Medicinalis Nanjing], V29, P1
   LAMERDIN JE, 1995, GENOMICS, V25, P547, DOI 10.1016/0888-7543(95)80056-R
   Lao T, 2008, MUTAGENESIS, V23, P523, DOI 10.1093/mutage/gen046
   Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563
   Matullo G, 2006, CARCINOGENESIS, V27, P997, DOI 10.1093/carcin/bgi280
   Monaco R, 2007, PROTEIN J, V26, P541, DOI 10.1007/s10930-007-9095-y
   Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3
   Niwa Y, 2005, GYNECOL ONCOL, V99, P43, DOI 10.1016/j.ygyno.2005.05.018
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Ratnasinghe LD, 2004, CANCER LETT, V216, P157, DOI 10.1016/j.canlet.2004.03.012
   Roszak A, 2011, INT J BIOL MARKER, V26, P216, DOI 10.5301/JBM.2011.8581
   SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6
   Settheetham-Ishida W, 2011, ASIAN PAC J CANCER P, V12, P963
   Shen MR, 1998, CANCER RES, V58, P604
   SICILIANO MJ, 1986, MUTAT RES, V174, P303, DOI 10.1016/0165-7992(86)90051-5
   Smith TR, 2003, CANCER LETT, V190, P183, DOI 10.1016/S0304-3835(02)00595-5
   Tudek B, 2007, MOL ASPECTS MED, V28, P258, DOI 10.1016/j.mam.2007.05.003
   Vizcaino AP, 2000, INT J CANCER, V86, P429, DOI 10.1002/(SICI)1097-0215(20000501)86:3<429::AID-IJC20>3.0.CO;2-D
   Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
   Wang X, 2010, MODERN MED HLTH, V26, P2137
NR 39
TC 20
Z9 22
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 12
PY 2012
VL 7
IS 9
AR e44441
DI 10.1371/journal.pone.0044441
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 005GJ
UT WOS:000308738500058
PM 22984511
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, H
   Yu, XM
   Wang, JX
   Hong, ZH
   Tang, NLS
AF Li, Hui
   Yu, Xiao-Min
   Wang, Jia-Xin
   Hong, Ze-Hui
   Tang, Nelson Leung-Sang
TI The VNTR Polymorphism of the DC-SIGNR Gene and Susceptibility to HIV-1
   Infection: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID TANDEM-REPEAT POLYMORPHISM; TYPE-1 INFECTION; REGION POLYMORPHISMS;
   VARIANTS; DISEASE; PATHOGENESIS; INDIVIDUALS; PROGRESSION; POPULATION;
   RECEPTOR
AB Background: Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin related (DC-SIGNR) can bind to the human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein and is thus important for the host-pathogen interaction in HIV-1 infection. Studies of the association between the variable number tandem repeat (VNTR) polymorphism of the DC-SIGNR gene and HIV-1 susceptibility have produced controversial results.
   Methods and Findings: We conducted a meta-analysis of the data contained in the literature to clarify these findings. In total, 10 studies consisting of 2683 HIV-1 patients and 3263 controls (2130 healthy controls and 1133 HIV-1 exposed but seronegative (HESN) controls) were included. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were assessed in the main analyses. Further stratified analyses by ethnicity and sample size were performed. By dividing the controls into two groups, healthy controls and HIV-1 exposed but seronegative (HESN) controls, we explored different genetic models to detect any association between the VNTR polymorphism and predisposition to HIV-1 infection. The results showed that the 5-repeat allele carriers (OR = 0.84, 95% CI = 0.73-0.96) and the 5/5 homozygous (OR = 0.68, 95% CI = 0.50-0.93) had significantly reduced risk when using the HIV-1 exposed but seronegative (HESN) as controls. The stratified analyses by ethnicity and sample size confirmed these findings. However, a low to moderate degree of heterogeneity was also found across studies.
   Conclusions: Our findings demonstrate that the VNTR polymorphism of the DC-SIGNR gene is associated with a moderate effect on host susceptibility to HIV-1 infection. Similar to the 32-bp deletion in the chemokine receptor-5 gene (CCR5 Delta 32), the DC-SIGNR VNTR 5-repeat allele might have a role in resistance to HIV infection, particularly in Asian populations.
C1 [Li, Hui; Hong, Ze-Hui] Southeast Univ, Sch Med, Dept Genet & Dev Biol, Nanjing, Jiangsu, Peoples R China.
   [Yu, Xiao-Min] Southeast Univ, Sch Med, Dept Biochem, Nanjing, Jiangsu, Peoples R China.
   [Li, Hui; Yu, Xiao-Min; Hong, Ze-Hui] Southeast Univ, Minist Educ, Key Lab Dev Genes & Human Dis, Nanjing, Jiangsu, Peoples R China.
   [Wang, Jia-Xin] Yunnan Univ, Lab Conservat & Utilizat Bioresource, Kunming, Peoples R China.
   [Wang, Jia-Xin] Yunnan Univ, Minist Educ, Key Lab Microbial Resources, Kunming, Peoples R China.
   [Tang, Nelson Leung-Sang] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
   [Tang, Nelson Leung-Sang] Chinese Univ Hong Kong, Fac Med, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China.
   [Tang, Nelson Leung-Sang] CUHK, Shenzhen Res Inst, Shenzhen, Peoples R China.
RP Li, H (reprint author), Southeast Univ, Sch Med, Dept Genet & Dev Biol, Nanjing, Jiangsu, Peoples R China.
EM hongzehui@seu.edu.cn
RI Tang, Nelson/P-5018-2017
OI Tang, Nelson/0000-0002-3607-5819
FU National Natural Science Foundation of China [31000955, 30900812,
   90919007]; Science & Technology of Southeast University [KJ2010439,
   KJ2010437]
FX This work was supported by grants from the National Natural Science
   Foundation of China (31000955, 30900812 and 90919007) and the fund from
   Science & Technology of Southeast University (KJ2010439 and KJ2010437).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Barreiro LB, 2006, J INFECT DIS, V194, P1184, DOI 10.1086/507845
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boily-Larouche G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007211
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   Chan VSF, 2006, NAT GENET, V38, P38, DOI 10.1038/ng1698
   Chaudhary O, 2008, J CLIN VIROL, V43, P196, DOI 10.1016/j.jcv.2008.06.005
   Cochran W.G., 1954, BIOMETRICS, V10, P29, DOI DOI 10.2307/3001666
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Gramberg T, 2006, VIROLOGY, V347, P354, DOI 10.1016/j.virol.2005.11.033
   Guo Y, 2006, J BIOL CHEM, V281, P16794, DOI 10.1074/jbc.M602430200
   Hill AVS, 2001, ANNU REV GENOM HUM G, V2, P373, DOI 10.1146/annurev.genom.2.1.373
   Kaslow RA, 2005, J INFECT DIS, V191, pS68, DOI 10.1086/425269
   Kasten S, 2000, Eur J Med Res, V5, P323
   Kavvoura FK, 2008, HUM GENET, V123, P1, DOI 10.1007/s00439-007-0445-9
   Lichterfeld M, 2003, CLIN IMMUNOL, V107, P55, DOI 10.1016/S1521-6616(02)00050-5
   Liu HL, 2006, J INFECT DIS, V193, P698, DOI 10.1086/499820
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Pantaleo G, 1997, RES IMMUNOL, V148, P417, DOI 10.1016/S0923-2494(97)82875-1
   Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398
   Rathore A, 2008, J CLIN IMMUNOL, V28, P50, DOI 10.1007/s10875-007-9131-x
   Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959
   Snyder GA, 2005, J VIROL, V79, P4589, DOI 10.1128/JVI.79.8.4589-4598.2005
   Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937
   Tang NLS, 2007, NAT GENET, V39, P690, DOI 10.1038/ng0607-692
   Wang Hui, 2008, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V25, P542
   Wang XiaoHui, 2010, China Tropical Medicine, V10, P273
   Wichukchinda N, 2007, AIDS RES HUM RETROV, V23, P686, DOI 10.1089/aid.2006.0212
   Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389
   Xu LJ, 2010, J CLIN IMMUNOL, V30, P402, DOI 10.1007/s10875-010-9376-7
   Young JM, 2011, AIDS RES HUM RETROV, V27, P737, DOI [10.1089/aid.2010.0313, 10.1089/AID.2010.0313]
   Zhao G.L., 2008, CHIN J AIDS STU, V14, P21
   Zhao Jin, 2008, Zhonghua Yufang Yixue Zazhi, V42, P901
   Zhi LT, 2007, NAT GENET, V39, P691, DOI 10.1038/ng0607-692
NR 36
TC 5
Z9 5
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 5
PY 2012
VL 7
IS 9
AR e42972
DI 10.1371/journal.pone.0042972
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 001MC
UT WOS:000308463800018
PM 22957026
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, F
   Yuan, D
   Wei, YG
   Wang, WT
   Yan, LN
   Wen, TF
   Xu, MQ
   Yang, JY
   Li, B
AF Liu, Fei
   Yuan, Ding
   Wei, Yonggang
   Wang, Wentao
   Yan, Lvnan
   Wen, Tianfu
   Xu, Mingqing
   Yang, Jiayin
   Li, Bo
TI Systematic Review and Meta-Analysis of the Relationship between EPHX1
   Polymorphisms and Colorectal Cancer Risk
SO PLOS ONE
LA English
DT Article
ID MICROSOMAL EPOXIDE HYDROLASE; CARCINOGEN-METABOLIZING ENZYMES; GENE
   POLYMORPHISMS; CIGARETTE-SMOKING; CLINICAL-TRIALS; COLON-CANCER;
   LUNG-CANCER; ASSOCIATION; SUSCEPTIBILITY; GENOTYPES
AB Background: Microsomal epoxide hydrolase (EPHX1) plays an important role in both the activation and detoxification of PAHs, which are carcinogens found in cooked meat and tobacco smoking. Polymorphisms at exons 3 and 4 of the EPHX1 gene have been reported to be associated with variations in EPHX1 activity. The aim of this study is to quantitatively summarize the relationship between EPHX1 polymorphisms and colorectal cancer (CRC) risk.
   Methods: Two investigators independently searched the Medline, Embase, CNKI, and Chinese Biomedicine Databases for studies published before June 2012. Summary odds ratios (ORs) and 95% confidence intervals (CIs) for EPHX1 Tyr113His (rs1051740) and His139Arg (rs2234922) polymorphisms and CRC were calculated in a fixed-effects model and a random-effects model when appropriate.
   Results: This meta-analysis yielded 14 case-control studies, which included 13 studies for Tyr113His (6395 cases and 7893 controls) and 13 studies for His139Arg polymorphisms (5375 cases and 6962 controls). Overall, the pooled results indicated that EPHX1 Tyr113His polymorphism was not associated with CRC risk; while the His139Arg polymorphism was significantly associated with decreased CRC risk (Arg/His vs. His/His, OR = 0.90, 95% CI = 0.83-0.98; dominant model, OR = 0.92, 95% CI = 0.85-0.99). The statistically significant association between EPHX1 His139Arg polymorphism and CRC was observed among Caucasians and population-based case-control studies. This association showed little heterogeneity and remained consistently strong when analyses were limited to studies in which genotype frequencies were in Hardy-Weinberg equilibrium, or limited to studies with matched controls. When cumulative meta-analyses of the two associations were conducted by studies' publication time, the results were persistent and robust.
   Conclusion: This meta-analysis suggests that EPHX1 Tyr113His polymorphism may be not associated with CRC development; while the EPHX1 His139Arg polymorphism may have a potential protective effect on CRC.
C1 [Liu, Fei; Yuan, Ding; Wei, Yonggang; Wang, Wentao; Yan, Lvnan; Wen, Tianfu; Xu, Mingqing; Yang, Jiayin; Li, Bo] Sichuan Univ, W China Hosp, Dept Liver & Vasc Surg, Div Liver Transplantat, Chengdu 610064, Sichuan Provinc, Peoples R China.
RP Liu, F (reprint author), Sichuan Univ, W China Hosp, Dept Liver & Vasc Surg, Div Liver Transplantat, Chengdu 610064, Sichuan Provinc, Peoples R China.
EM yourwyg@163.com; cdlibo688@163.com
FU National Natural Science Foundation of China [30901720]; Ph.D. Programs
   Foundation of Ministry of Education of China [20090181120111]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 30901720) and Ph.D. Programs Foundation of
   Ministry of Education of China (No. 20090181120111). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR American Cancer Society, 2010, CANC FACTS FIG
   Arand M, 2005, METHOD ENZYMOL, V400, P569, DOI 10.1016/S0076-6879(05)00032-7
   Attia J, 2003, J CLIN EPIDEMIOL, V56, P297, DOI 10.1016/S0895-4356(03)00011-8
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benhamou S, 2002, CARCINOGENESIS, V23, P1343, DOI 10.1093/carcin/23.8.1343
   Benhamou S, 1998, CANCER RES, V58, P5291
   Cleary SP, 2010, AM J EPIDEMIOL, V172, P1000, DOI 10.1093/aje/kwq245
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Cotterchio M, 2008, CANCER EPIDEM BIOMAR, V17, P3098, DOI 10.1158/1055-9965.EPI-08-0341
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807
   Harrison DJ, 1999, BRIT J CANCER, V79, P168, DOI 10.1038/sj.bjc.6690028
   Hassett C, 1997, ARCH BIOCHEM BIOPHYS, V337, P275, DOI 10.1006/abbi.1996.9794
   HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hlavata I, 2010, ONCOL REP, V24, P1347, DOI 10.3892/or_0000992
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kiss I, 2007, ANTICANCER RES, V27, P2931
   Landi S, 2005, PHARMACOGENET GENOM, V15, P535, DOI 10.1097/01.fpc.0000165904.48994.3d
   Li XA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014749
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Liu L, 2011, J CANCER RES CLIN, V137, P1027, DOI 10.1007/s00432-010-0966-9
   Ma HX, 2006, INT J CANCER, V119, P2173, DOI 10.1002/ijc.22094
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Nisa H, 2013, MOL CARCINOGEN, V52, P619, DOI 10.1002/mc.21897
   Norat T, 2005, J NATL CANCER I, V97, P906, DOI 10.1093/jnci/dji164
   OESCH F, 1973, XENOBIOTICA, V3, P305, DOI 10.3109/00498257309151525
   Omiecinski CJ, 2000, TOXICOL LETT, V112, P365, DOI 10.1016/S0378-4274(99)00235-0
   Robien K, 2005, CANCER EPIDEM BIOMAR, V14, P1350, DOI 10.1158/1055-9965.EPI-04-0877
   Sachse C, 2002, CARCINOGENESIS, V23, P1839, DOI 10.1093/carcin/23.11.1839
   Sahin O, 2012, GENET TEST MOL BIOMA, V16, P423, DOI 10.1089/gtmb.2011.0223
   Skjelbred CF, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-228
   Smith CAD, 1997, LANCET, V350, P630, DOI 10.1016/S0140-6736(96)08061-0
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sung JJY, 2005, LANCET ONCOL, V6, P871, DOI 10.1016/S1470-2045(05)70422-8
   Tranah GJ, 2005, MOL CARCINOGEN, V44, P21, DOI 10.1002/mc.20112
   van der Logt EMJ, 2006, MUTAT RES-FUND MOL M, V593, P39, DOI 10.1016/j.mrfmmm.2005.06.018
   WP Yu, 2004, EPIDEMIOLOGICAL STUD
   Zhang JH, 2003, WORLD J GASTROENTERO, V9, P2654
   Zhao P, 2010, JPN J CLIN ONCOL, V40, P281, DOI 10.1093/jjco/hyp187
   Zhao ZQ, 2012, TUMOR BIOL, V33, P523, DOI 10.1007/s13277-011-0287-x
NR 43
TC 19
Z9 21
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 23
PY 2012
VL 7
IS 8
AR e43821
DI 10.1371/journal.pone.0043821
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 998GE
UT WOS:000308224700029
PM 22928041
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zhang, XJ
   Li, YS
   Li, H
   Qin, YY
   Bai, C
   Xu, F
   Zhu, TY
   Xu, JF
   Wu, MJ
   Wang, CX
   Wei, LX
   He, J
AF Zhang, Xinji
   Li, Yesheng
   Li, Hui
   Qin, Yingyi
   Bai, Chong
   Xu, Feng
   Zhu, Tianyi
   Xu, Jinfang
   Wu, Mengjie
   Wang, Chaoxiang
   Wei, Lixin
   He, Jia
TI Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition
   Therapy for NSCLC: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; FACTOR RECEPTOR;
   DOUBLE-BLIND; TARGETED THERAPIES; PHASE-II; GEFITINIB; ERLOTINIB;
   RESISTANCE; TRIAL
AB Background: Lung cancer is a heterogeneous disease with multiple signaling pathways influencing tumor cell survival and proliferation, and it is likely that blocking only one of these pathways allows others to act as salvage or escape mechanisms for cancer cells. Whether combined inhibition therapy has greater anti-tumor activity than single inhibition therapy is a matter of debate. Hence, a meta-analysis comparing therapy inhibiting both VEGFR and EGFR signaling pathways with that inhibiting EGFR signaling pathway alone was performed.
   Methodology and Principal Findings: We searched PubMed, EMBASE database and the proceedings of major conferences for relevant clinical trials. Outcomes analyzed were objective tumor response rate (ORR), progression-free survival (PFS), overall survival (OS) and toxicity. Besides, subgroup analyses were performed to investigate whether the combined inhibition therapy is best performed using combination of selective agents or a single agent with multiple targets. Six trials recruiting 3,302 patients were included in the analysis. Combined inhibition therapy was associated with a 3% improvement in OS as compared with single-targeted therapy, but this difference was not statistically significant (HR, 0.97; 95% CI, 0.89-1.05; P = 0.472). Patients receiving combined inhibition therapy had significant longer PFS than the group with single-targeted therapy (HR, 0.80; 95% CI, 0.67-0.95; P = 0.011). There was no difference in the ORR between the groups (OR, 1.44; 95% CI, 0.95-2.18; P = 0.085). Subgroup analysis revealed that combined inhibition therapy using combination regimens was associated with statistically significant improvement in both ORR and PFS. Toxicity was greater in combined inhibition therapy.
   Conclusions: There is no evidence to support the use of combined inhibition therapy in unselected patients with advanced NSCLC. However, given the significant advantage in ORR and PFS, combined inhibition therapy using combination regimens may be considered for further evaluation in subsets of patients who may benefit from this treatment.
C1 [Zhang, Xinji; Li, Hui; Qin, Yingyi; Xu, Jinfang; Wu, Mengjie; Wang, Chaoxiang; He, Jia] Second Mil Med Univ, Dept Hlth Stat, Shanghai, Peoples R China.
   [Li, Yesheng; Xu, Feng] Second Mil Med Univ, Eastern Hepatobiliary Hosp, Dept Special Treatment, Shanghai, Peoples R China.
   [Bai, Chong; Zhu, Tianyi] Second Mil Med Univ, Changhai Hosp, Resp Dept, Shanghai, Peoples R China.
   [Wei, Lixin] Second Mil Med Univ, Eastern Hepatobiliary Hosp, Tumor Immunol & Gene Therapy Ctr, Shanghai, Peoples R China.
RP Zhang, XJ (reprint author), Second Mil Med Univ, Dept Hlth Stat, Shanghai, Peoples R China.
EM hejia63@yahoo.com
FU National Nature Science Foundation of China [30872186, 81072388];
   leading talents of science in Shanghai [022]; Program of Shanghai
   Subject Chief Scientist [09XD1405500]; Second Military Medical
   University
FX The work was supported by the National Nature Science Foundation of
   China (30872186, 81072388), a grant from the leading talents of science
   in Shanghai 2010 (022), a grant sponsored by Program of Shanghai Subject
   Chief Scientist (09XD1405500) and a grant from the innovative program
   for PhD in Second Military Medical University. The funders had no role
   in study design, data collection, analysis, decision to publish or
   preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Belani CP, 2011, CANC TREAT REV, DOI [10.1016/j.ctrv.2011.1005.1009, DOI 10.1016/J.CTRV.2011.1005.1009]
   Cappuzzo F, 2009, J CLIN ONCOL, V27, P1667, DOI 10.1200/JCO.2008.19.1635
   Cascone T, 2007, CURR OPIN ONCOL, V19, P98, DOI 10.1097/CCO.0b013e328011beec
   Ciardiello F, 2006, ANN ONCOL, V17, pVII109, DOI 10.1093/annonc/mdl962
   Ciardiello F, 2004, CLIN CANCER RES, V10, P784, DOI 10.1158/1078-0432.CCR-1100-03
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Deeks J, 2011, COCHRANE HDB SYSTEMA
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Fontanini G, 1997, CLIN CANCER RES, V3, P861
   Govindan R, 2011, SUNITINIB COMBINATIO
   Groen HJM, 2010, ANN ONCOL, V21, P139
   Herbst RS, 2011, LANCET, V377, P1846, DOI 10.1016/S0140-6736(11)60545-X
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Johnson BE, 2010, J CONTRACEPT FERTIL, P28
   Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4
   Kim ES, 2009, J THORAC ONCOL, V4, P444, DOI 10.1097/JTO.0b013e31819d6f91
   Kim ES, 2011, CANCER DISCOV, P1, DOI [10.1158/2159-8274.CD-1110-0010, DOI 10.1158/2159-8274.CD-1110-0010]
   Leighl NB, 2010, J CONTRACEPT FERTIL, P28
   Lynch TJ, 2009, J THORAC ONCOL, V4, P1002, DOI 10.1097/JTO.0b013e3181aba89f
   Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
   Maione P, 2006, ONCOLOGIST, V11, P274, DOI 10.1634/theoncologist.11-3-274
   Martinelli E, CLIN CANC RES, V16, P4990
   Miller VA, 2009, J CONTRACEPT FERTIL, P27
   Natale RB, 2011, J CLIN ONCOL, V29, P1059, DOI 10.1200/JCO.2010.28.5981
   Natale RB, 2009, J CLIN ONCOL, V27, P2523, DOI 10.1200/JCO.2008.18.6015
   Naumov GN, 2009, CLIN CANCER RES, V15, P3484, DOI 10.1158/1078-0432.CCR-08-2904
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Pennell NA, 2009, ONCOLOGIST, V14, P399, DOI 10.1634/theoncologist.2008-0276
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Scagliotti GV, 2007, ANN ONCOL, V18, P32, DOI 10.1093/annonc/mdm412
   Schiller JH, 2010, J CONTRACEPT FERTIL, P28
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   Sibilia M, 2007, DIFFERENTIATION, V75, P770, DOI 10.1111/j.1432-0436.2007.00238.x
   Spigel DR, 2011, J CLIN ONCOL, V29, P2582, DOI 10.1200/JCO.2010.30.7678
   Spigel DR, 2011, J CONTRACEPT FERTIL, P29
   STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K
   Wu WJ, 2007, MOL CANCER THER, V6, P471, DOI 10.1158/1535-7163.MCT-06-0416
NR 43
TC 5
Z9 6
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 16
PY 2012
VL 7
IS 8
AR e40178
DI 10.1371/journal.pone.0040178
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 993AN
UT WOS:000307824300002
PM 22916093
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ying, XJ
   Dong, P
   Shen, B
   Xu, CZ
   Xu, HM
   Zhao, SW
AF Ying, Xin-Jiang
   Dong, Pin
   Shen, Bin
   Xu, Cheng-Zhi
   Xu, Hong-Ming
   Zhao, Shu-Wei
TI Glutathione S-Transferase M1 Gene Polymorphism and Laryngeal Cancer
   Risk: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; GSTM1 POLYMORPHISMS; NAT2 POLYMORPHISMS; T1
   GENOTYPES; LUNG-CANCER; GSTT1; TOBACCO; CYP1A1; HEAD; ALCOHOL
AB Background and Objectives: Studies investigating the association between glutathione S-transferase M1 (GSTM1) gene polymorphism and laryngeal cancer risk have reported conflicting results. The aim of the present study was to conduct a meta-analysis assessing the possible associations of GSTM1 gene polymorphism with laryngeal cancer risk.
   Methods: The relevant studies were identified through a search of PubMed, Embase, ISI Web of Knowledge and Chinese National Knowledge Infrastructure until May 2011 and selected on the basis of the established inclusion criteria for publications, then a meta-analysis was performed to quantitatively summarize association of GSTM1 polymorphism with laryngeal cancer susceptibility.
   Results: Seventeen studies were included in the present meta-analysis (2,180 cases and 2,868 controls). The combined results based on all studies showed that GSTM1 null genotype was associated with increased laryngeal cancer risk (OR = 1.17, 95% CI = 1.04 similar to 1.31). When stratifying for race, GSTM1 null genotype exhibited increased laryngeal cancer risk in Caucasians (OR = 1.15, 95% CI = 1.01 similar to 1.31), while no significant association was detected in Asians (OR = 1.25, 95% CI = 0.80 similar to 1.96). In the subgroup analysis based on source of controls, significant associations were observed in the population-based studies (OR = 1.15, 95% CI = 1.01 similar to 1.31) yet not in the hospital-based studies (OR = 1.25, 95% CI = 0.93 similar to 1.67). Furthermore, in the subgroup analysis based on sample size, significant associations were also found in studies with at least 50 cases and 50 controls (OR = 1.15, 95% CI = 1.02 similar to 1.30) but not in studies with fewer than 50 cases or 50 controls (OR = 1.46, 95% CI = 0.87 similar to 2.46).
   Conclusions: This meta-analysis supported that the GSTM1 gene polymorphism was associated with laryngeal cancer, particularly in Caucasians, and these associations varied in different subgroup, which indicated that population-based study with larger sample size was more appropriate in design of future study.
C1 [Ying, Xin-Jiang; Dong, Pin; Shen, Bin; Xu, Cheng-Zhi; Xu, Hong-Ming] Shanghai Jiao Tong Univ, Dept Otolaryngol Head & Neck Surg, Shanghai Peoples Hosp 1, Sch Med, Shanghai 200030, Peoples R China.
   [Zhao, Shu-Wei] Second Mil Med Univ, Dept Otolaryngol, Changzheng Hosp, Shanghai, Peoples R China.
RP Ying, XJ (reprint author), Shanghai Jiao Tong Univ, Dept Otolaryngol Head & Neck Surg, Shanghai Peoples Hosp 1, Sch Med, Shanghai 200030, Peoples R China.
EM yingxinjiang@126.com; dongpin64@yahoo.com.cn; zhaoshw1@yahoo.com.cn
CR Acar H, 2006, CANCER GENET CYTOGEN, V169, P89, DOI 10.1016/j.cancergencyto.2005.12.007
   Bardakci F, 2003, J CELL MOL MED, V7, P307, DOI 10.1111/j.1582-4934.2003.tb00231.x
   Becher H, 2005, INT J CANCER, V116, P451, DOI 10.1002/ijc.21049
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bennett DA, 2004, J CLIN EPIDEMIOL, V57, P349, DOI 10.1016/j.jclinepi.2003.09.015
   Boccia S, 2008, J CANCER RES CLIN, V134, P93, DOI 10.1007/s00432-007-0254-5
   Bolt HM, 2006, CURR DRUG METAB, V7, P613, DOI 10.2174/138920006778017786
   Cabelguenne A, 2001, INT J CANCER, V93, P725, DOI 10.1002/ijc.1392
   Carlsten C, 2008, AM J EPIDEMIOL, V167, P759, DOI 10.1093/aje/kwm383
   Chatzimichalis M, 2010, J LARYNGOL OTOL, V124, P318, DOI 10.1017/S002221510999154X
   Cotton SC, 2000, AM J EPIDEMIOL, V151, P7
   Coutelle C, 1997, HUM GENET, V99, P319, DOI 10.1007/s004390050365
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Frank SA, 2004, NAT REV GENET, V5, P764, DOI 10.1038/nrg1450
   Gajecka M, 2005, MUTAT RES-FUND MOL M, V574, P112, DOI 10.1016/j.mrfmmm.2005.01.027
   Gronau S, 2003, OTOLARYNG HEAD NECK, V128, P674, DOI 10.1016/S0194-5998(03)00176-1
   Hanna E, 2001, AM J OTOLARYNG, V22, P121, DOI 10.1053/ajot.2001.22571
   Hashibe M, 2003, CANCER EPIDEM BIOMAR, V12, P1509
   Hashibe M, 2007, AM J EPIDEMIOL, V165, P814, DOI 10.1093/aje/kwk066
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hong YJ, 2000, CLIN CHEM LAB MED, V38, P917, DOI 10.1515/CCLM.2000.134
   Jahnke V, 1996, AM J SURG, V172, P671, DOI 10.1016/S0002-9610(96)00298-X
   Jahnke V, 1997, EUR ARCH OTO-RHINO-L, V254, pS147, DOI 10.1007/BF02439747
   JAHNKE V, 1995, LARYNGO RHINO OTOL, V74, P691, DOI 10.1055/s-2007-997826
   Jourenkova N, 1998, CANCER EPIDEM BIOMAR, V7, P19
   Kihara M, 1997, CANCER LETT, V112, P257, DOI 10.1016/S0304-3835(96)04584-3
   Koskinen WJ, 2007, J CANCER RES CLIN, V133, P673, DOI 10.1007/s00432-007-0219-8
   La Torre G, 2005, CANCER LETT, V217, P53, DOI 10.1016/j.canlet.2004.08.020
   Li Li, 2004, Zhonghua Er Bi Yan Hou Ke Za Zhi, V39, P2
   Matthias C, 1998, PHARMACOGENETICS, V8, P91
   MOHER D, 2009, PLOS MED, V6
   Morita S, 1999, INT J CANCER, V80, P685, DOI 10.1002/(SICI)1097-0215(19990301)80:5<685::AID-IJC9>3.0.CO;2-W
   Ntais C, 2005, CANCER EPIDEM BIOMAR, V14, P176
   Olshan AF, 2000, CANCER EPIDEM BIOMAR, V9, P185
   Peters ES, 2006, CANCER EPIDEM BIOMAR, V15, P2196, DOI 10.1158/1055-9965.EPI-06-0503
   Risch A, 2003, PHARMACOGENETICS, V13, P225, DOI 10.1097/01.fpc.0000054081.64000.b8
   Shi XQ, 2008, LUNG CANCER, V59, P155, DOI 10.1016/j.lungcan.2007.08.004
   Sull JW, 2004, YONSEI MED J, V45, P683, DOI 10.3349/ymj.2004.45.4.683
   To-Figueras J, 2002, CANCER LETT, V187, P95, DOI 10.1016/S0304-3835(02)00406-8
   Unal M, 2004, AM J OTOLARYNG, V25, P318, DOI 10.1016/j.amjoto.2004.04.003
   White DL, 2008, AM J EPIDEMIOL, V167, P377, DOI 10.1093/aje/kwm315
   Yang CX, 2005, WORLD J GASTROENTERO, V11, P2531, DOI 10.3748/wjg.v11.i17.2531
   Zhuo WL, 2009, J CANCER RES CLIN, V135, P1081, DOI 10.1007/s00432-009-0548-x
NR 43
TC 4
Z9 5
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 10
PY 2012
VL 7
IS 8
AR e42826
DI 10.1371/journal.pone.0042826
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 986XO
UT WOS:000307380900073
PM 22900055
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, YQ
   Qi, XW
   Wang, F
   Jiang, J
   Guo, QN
AF Wang, Yong-qiang
   Qi, Xiao-wei
   Wang, Fan
   Jiang, Jun
   Guo, Qiao-nan
TI Association between TGFBR1 Polymorphisms and Cancer Risk: A
   Meta-Analysis of 35 Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-BETA; RECEPTOR-TYPE-I; TUMOR SUSCEPTIBILITY ALLELE;
   COLORECTAL-CANCER; BREAST-CANCER; INT7G24A VARIANT; SPANISH POPULATION;
   PROSTATE-CANCER; CLINICAL-TRIALS; BLADDER-CANCER
AB Background: Numerous epidemiological studies have evaluated the association between TGFBR1 polymorphisms and the risk of cancer, however, the results remain inconclusive. To derive a more precise estimation of the relation, we conducted a comprehensive meta-analysis of all available case-control studies relating the TGFBR1*6A and IVS7+24G>A polymorphisms of the TGFBR1 gene to the risk of cancer.
   Methods: Eligible studies were identified by search of electronic databases. Overall and subgroup analyses were performed. Odds ratio (OR) and 95% confidence interval (CI) were applied to assess the associations between TGFBR1*6A and IVS7+24G>A polymorphisms and cancer risk.
   Results: A total of 35 studies were identified, 32 with 19,767 cases and 18,516 controls for TGFBR1*6A polymorphism and 12 with 4,195 cases and 4,383 controls for IVS7+24G>A polymorphism. For TGFBR1*6A, significantly elevated cancer risk was found in all genetic models (dominant OR = 1.11, 95% CI = 1.04 similar to 1.18; recessive: OR = 1.36, 95% CI = 1.11 similar to 1.66; additive: OR = 1.13, 95% CI = 1.05 similar to 1.20). In subgroup analysis based on cancer type, increased cancer risk was found in ovarian and breast cancer. For IVS7+24G>A, significant correlation with overall cancer risk (dominant: OR = 1.39, 95% CI = 1.15 similar to 1.67; recessive: OR = 2.23, 95% CI = 1.26 similar to 3.92; additive: OR = 1.43, 95% CI = 1.14 similar to 1.80) was found, especially in Asian population. In the subgroup analysis stratified by cancer type, significant association was found in breast and colorectal cancer.
   Conclusions: Our investigations demonstrate that TGFBR1*6A and IVS7+24G>A polymorphisms of TGFBR1 are associated with the susceptibility of cancer, and further functional research should be performed to explain the inconsistent results in different ethnicities and cancer types.
C1 [Wang, Yong-qiang; Guo, Qiao-nan] Third Mil Med Univ, Inst Pathol, Southwest Hosp, Chongqing, Peoples R China.
   [Qi, Xiao-wei; Jiang, Jun] Third Mil Med Univ, Breast Dis Ctr, Southwest Hosp, Chongqing, Peoples R China.
   [Wang, Fan] Jiangjin Cent Hosp, Dept Oncol, Chongqing, Peoples R China.
RP Wang, YQ (reprint author), Third Mil Med Univ, Inst Pathol, Southwest Hosp, Chongqing, Peoples R China.
EM jcbd@medmail.com.cn; qiaonan85@263.net
RI Qi, Xiaowei/O-1338-2018
OI Qi, Xiaowei/0000-0002-5876-4957
FU National Natural Science Foundation of China [30971139, 81172554]
FX This work was supported by grants No.30971139 and No.81172554 from
   National Natural Science Foundation of China. No additional external
   funding received for this study. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abuli A, 2011, BRIT J CANCER, V105, P870, DOI 10.1038/bjc.2011.296
   Baxter SW, 2002, CANCER EPIDEM BIOMAR, V11, P211
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benson JR, 2004, LANCET ONCOL, V5, P229, DOI 10.1016/S1470-2045(04)01426-3
   Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926
   Bredberg A, 2011, CANCER-AM CANCER SOC, V117, P440, DOI 10.1002/cncr.25440
   Carvajal-Carmona LG, 2010, P NATL ACAD SCI USA, V107, P7858, DOI 10.1073/pnas.1002816107
   Castillejo A, 2009, INT J CANCER, V124, P608, DOI 10.1002/ijc.24013
   Castillejo A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-406
   Castillejo A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-193
   Chen TP, 1999, INT J CANCER, V82, P43
   Chen TP, 2006, CLIN CANCER RES, V12, P392, DOI 10.1158/1078-0432.CCR-05-1518
   Chen TP, 2004, INT J CANCER, V112, P420, DOI 10.1002/ijc.20419
   Colleran G, 2010, BREAST CANCER RES TR, V119, P437, DOI 10.1007/s10549-009-0395-0
   Cox DG, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-175
   Dai LP, 2009, PEDIATR BLOOD CANCER, V52, P819, DOI 10.1002/pbc.21971
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   [董稚明 Dong Zhiming], 2011, [癌变·畸变·突变, Carcinogenesis, Teratogenesis and Mutagenesis], V23, P16
   Duan YH, 2011, MOL BIOL REP, V38, P301, DOI 10.1007/s11033-010-0108-0
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047
   Feigelson HS, 2006, CANCER EPIDEM BIOMAR, V15, P1236, DOI 10.1158/1055-9965.EPI-06-0163
   Forsti A, 2010, GENE CHROMOSOME CANC, V49, P270, DOI 10.1002/gcc.20738
   Galliher Amy J, 2006, Future Oncol, V2, P743, DOI 10.2217/14796694.2.6.743
   Gordon KJ, 2008, BBA-MOL BASIS DIS, V1782, P197, DOI 10.1016/j.bbadis.2008.01.006
   Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232
   Hu YS, 2011, MED ONCOL, V28, P622, DOI 10.1007/s12032-010-9483-6
   Hu YS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-169
   Jakubowska A, 2010, BREAST CANCER RES TR, V119, P201, DOI 10.1007/s10549-009-0390-5
   Jin QR, 2004, INT J CANCER, V112, P94, DOI 10.1002/ijc.20370
   Joshi NN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021866
   Kaklamani V, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-28
   Kaklamani VG, 2005, CANCER RES, V65, P3454, DOI 10.1158/0008-5472.CAN-04-2961
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Liao RY, 2010, MOL BIOL REP, V37, P3227, DOI 10.1007/s11033-009-9906-7
   Little J, 2002, AM J EPIDEMIOL, V156, P300, DOI 10.1093/aje/kwf054
   Lundin JS, 2009, BRIT J CANCER, V100, P1674, DOI 10.1038/sj.bjc.6605054
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Martinez-Canto A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030812
   MOSES HL, 1981, CANCER RES, V41, P2842
   Pasche B, 1999, CANCER RES, V59, P5678
   Pasche B, 2005, JAMA-J AM MED ASSOC, V294, P1634, DOI 10.1001/jama.294.13.1634
   Pasche B, 1998, CANCER RES, V58, P2727
   Pasche B, 2004, J CLIN ONCOL, V22, P756, DOI 10.1200/JCO.2004.99.271
   Pharoah PDP, 2004, NAT REV CANCER, V4, P850, DOI 10.1038/nrc1476
   Qi XW, 2010, BREAST CANCER RES TR, V123, P499, DOI 10.1007/s10549-010-0773-7
   Qi XW, 2010, BREAST CANCER RES TR, V122, P273, DOI 10.1007/s10549-010-0847-6
   ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339
   Samowitz WS, 2001, GENE CHROMOSOME CANC, V32, P381, DOI 10.1002/gcc.1203
   Skoglund J, 2007, CLIN CANCER RES, V13, P3748, DOI 10.1158/1078-0432.CCR-06-2865
   Song B, 2007, BRIT J CANCER, V97, P1175, DOI 10.1038/sj.bjc.6603961
   Spillman MA, 2005, GYNECOL ONCOL, V97, P543, DOI 10.1016/j.ygyno.2005.01.025
   Stefanovska AM, 2001, CANCER RES, V61, P8351
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Suarez BK, 2005, PROSTATE CANCER P D, V8, P50, DOI 10.1038/sj.pcan.4500765
   van Tilborg AAG, 2001, J PATHOL, V194, P76, DOI 10.1002/path.860
   You W, 2007, J THORAC ONCOL, V2, P657, DOI 10.1097/JTO.0b013e318070ccd7
   Zhang HT, 2005, LUNG CANCER-J IASLC, V49, P419, DOI 10.1016/j.lungcan.2005.03.038
   Zhang XL, 2012, MOL BIOL REP, V39, P2567, DOI 10.1007/s11033-011-1009-6
   Zhang Y, 2011, BREAST CANCER RES TR, V130, P1073, DOI 10.1007/s10549-011-1806-6
   Zhang YJ, 2009, CANCER LETT, V275, P102, DOI 10.1016/j.canlet.2008.10.017
NR 62
TC 6
Z9 7
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 8
PY 2012
VL 7
IS 8
AR e42899
DI 10.1371/journal.pone.0042899
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 986GX
UT WOS:000307331100073
PM 22905183
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Nie, W
   Chen, JQ
   Xiu, QY
AF Nie, Wei
   Chen, Jiquan
   Xiu, Qingyu
TI Cytotoxic T-Lymphocyte Associated Antigen 4 Polymorphisms and Asthma
   Risk: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID INHIBITS AIRWAY EOSINOPHILIA; GENOME-WIDE ASSOCIATION; SERUM IGE LEVELS;
   GENE POLYMORPHISMS; ALLERGIC-ASTHMA; SOLUBLE CTLA-4; ATOPIC ASTHMA;
   MURINE MODEL; BRONCHIAL-ASTHMA; PUBLICATION BIAS
AB Background: A number of studies assessed the association of cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) gene polymorphisms with asthma in different populations. However, the results were contradictory. We performed a meta-analysis to examine the association between CTLA-4 polymorphisms and asthma susceptibility.
   Methods: Pubmed, EMBASE, HuGE Navigator, and Wanfang Database were searched. Data were extracted independently by two reviewers. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations.
   Results: Seventeen studies involving 6378 cases and 8674 controls were included. Significant association between +49 A/G polymorphism and asthma was observed for AA vs. AG+GG (OR = 1.18, 95% CI 1.01-1.37, P = 0.04). There were no significant associations between -318 C/T, -1147 C/T, CT60 A/G, -1722 C/T, or rs926169 polymorphisms and asthma risk.
   Conclusions: This meta-analysis suggested that the +49 A/G polymorphism in CTLA-4 was a risk factor for asthma.
C1 [Nie, Wei; Chen, Jiquan; Xiu, Qingyu] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Resp Dis, Shanghai, Peoples R China.
RP Xiu, QY (reprint author), Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Resp Dis, Shanghai, Peoples R China.
EM xiu_qingyu@126.com
FU National Natural Science Foundation of China [81170025]; National
   Ministry of Science and Technology [2011ZX09302-003-001]
FX This study was supported by grants NO. 81170025 from National Natural
   Science Foundation of China and projects of "Major New Drugs Innovation
   and Development" from the National Ministry of Science and Technology
   (NO. 2011ZX09302-003-001). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alegre ML, 1998, J IMMUNOL, V161, P3347
   Anantharaman R, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-170
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berce V, 2010, BIOMARKERS, V15, P158, DOI 10.3109/13547500903384318
   BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0
   Chan IHS, 2008, ALLERGY, V63, P1031, DOI 10.1111/j.1398-9995.2008.01639.x
   Choi JM, 2006, NAT MED, V12, P574, DOI 10.1038/nm1385
   Daley D, 2009, HUM GENET, V125, P445, DOI 10.1007/s00439-009-0643-8
   Deurloo DT, 2001, AM J RESP CELL MOL, V25, P751, DOI 10.1165/ajrcmb.25.6.4607
   DeWan AT, 2010, J ALLERGY CLIN IMMUN, V126, P871, DOI 10.1016/j.jaci.2010.06.051
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Heinzmann A, 2000, EUR J IMMUNOGENET, V27, P57, DOI 10.1046/j.1365-2370.2000.00198.x
   Hizawa N, 2001, J ALLERGY CLIN IMMUN, V108, P74, DOI 10.1067/mai.2001.116119
   Howard TD, 2002, J ALLERGY CLIN IMMUN, V110, P743, DOI 10.1067/mai.2002.128723
   Ip WK, 2006, PEDIATR PULM, V41, P674, DOI 10.1002/ppul.20432
   Jasek M, 2006, INT ARCH ALLERGY IMM, V141, P223, DOI 10.1159/000095292
   Jones G, 2006, BRIT J DERMATOL, V154, P467, DOI 10.1111/j.1365-2133.2005.07080.x
   Kavvoura FK, 2007, J CLIN ENDOCR METAB, V92, P3162, DOI 10.1210/jc.2007-0147
   KeaneMyers A, 1997, J IMMUNOL, V158, P2042
   Lee SY, 2002, CHEST, V122, P171, DOI 10.1378/chest.122.1.171
   Li YF, 2008, RESP MED, V102, P984, DOI 10.1016/j.rmed.2008.02.008
   Ligers A, 2001, GENES IMMUN, V2, P145, DOI 10.1038/sj.gene.6363752
   Lin KW, 2010, J IMMUNOL, V184, P6343, DOI 10.4049/jimmunol.0901947
   Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x
   Miyake Y, 2011, HEPATOL RES, V41, P151, DOI 10.1111/j.1872-034X.2010.00757.x
   Munoz-Valle JF, 2010, CLIN CHIM ACTA, V411, P725, DOI 10.1016/j.cca.2010.02.001
   Munthe-Kaas MC, 2004, J ALLERGY CLIN IMMUN, V114, P280, DOI 10.1016/j.jaci.2004.03.050
   Nakao F, 2000, EXP CLIN IMMUNOGENET, V17, P179, DOI 10.1159/000019137
   Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075
   Noguchi E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002170
   Oh KY, 2010, ALLERGY ASTHMA IMMUN, V2, P127, DOI 10.4168/aair.2010.2.2.127
   Oosterwegel MA, 1999, J IMMUNOL, V163, P2634
   Padrid PA, 1998, AM J RESP CELL MOL, V18, P453, DOI 10.1165/ajrcmb.18.4.3055
   Park KS, 2009, TISSUE ANTIGENS, V74, P222, DOI 10.1111/j.1399-0039.2009.01303.x
   Qian L, 2006, J CLIN PEDIAT, V25, P660
   Qin XJ, 2005, ALLERGY, V60, P774, DOI 10.1111/j.1398-9995.2005.00784.x
   Schubert K, 2006, DIS MARKERS, V22, P127, DOI 10.1155/2006/373620
   Shi HZ, 2005, J ASTHMA, V42, P133, DOI 10.1081/JAS-200051331
   Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867
   Sohn MH, 2007, PEDIATR PULM, V42, P542, DOI 10.1002/pput.20622
   Sun T, 2008, CANCER RES, V68, P7025, DOI 10.1158/0008-5472.CAN-08-0806
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4
   Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621
   Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715
   Undarmaa S, 2010, J HUM GENET, V55, P342, DOI 10.1038/jhg.2010.32
   VanOosterhout AJM, 1997, AM J RESP CELL MOL, V17, P386, DOI 10.1165/ajrcmb.17.3.2679
   von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046
   Wilson DH, 2006, MED J AUSTRALIA, V184, P226
   Wong CK, 2005, CLIN EXP IMMUNOL, V141, P122, DOI 10.1111/j.1365-2249.2005.02815.x
   Yang KD, 2004, CLIN EXP ALLERGY, V34, P32, DOI 10.1111/j.1365-2222.2004.01776.x
NR 52
TC 20
Z9 21
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 26
PY 2012
VL 7
IS 7
AR e42062
DI 10.1371/journal.pone.0042062
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 012MO
UT WOS:000309240600067
PM 22844542
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yin, JY
   Huang, Q
   Zhao, YC
   Zhou, HH
   Liu, ZQ
AF Yin, Ji-Ye
   Huang, Qiong
   Zhao, Ying-Chun
   Zhou, Hong-Hao
   Liu, Zhao-Qian
TI Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non
   Small Cell Lung Cancer (NSCLC) Patients
SO PLOS ONE
LA English
DT Article
ID SINGLE NUCLEOTIDE POLYMORPHISMS; CISPLATIN-INDUCED CYTOTOXICITY;
   GENOME-WIDE ASSOCIATION; DNA-REPAIR; GENETIC POLYMORPHISMS;
   MULTIDRUG-RESISTANCE; SUSCEPTIBILITY LOCUS; CHINESE POPULATION;
   CLINICAL-TRIALS; ERCC1
AB Aim: To determine the pharmacogenetics of platinum-based chemotherapy in Non Small Cell Lung Cancer (NSCLC) patients.
   Methods: Publications were selected from PubMed, Cochrane Library and ISI Web of Knowledge. A meta-analysis was conducted to determine the association between genetic polymorphisms and platinum-based chemotherapy by checking odds ratio (OR) and 95% confidence interval (CI).
   Results: Data were extracted from 24 publications, which included 11 polymorphisms in 8 genes for meta-analysis. MDR1 C3435T (OR = 1.97, 95% CI: 1.11-3.50, P = 0.02), G2677A/T (OR = 2.61, 95% CI: 1.44-4.74, P = 0.002) and GSTP1 A313G (OR = 0.32, 95% CI: 0.17-0.58, P = 0.0002) were significantly correlated with platinum-based chemotherapy in Asian NSCLC patients.
   Conclusion: Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for personalized chemotherapy treatment for NSCLC patients in Asian population in the future.
C1 [Yin, Ji-Ye; Zhou, Hong-Hao; Liu, Zhao-Qian] Cent S Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha, Hunan, Peoples R China.
   [Huang, Qiong] Anhui Med Univ, Inst Clin Pharmacol, Key Lab Antiinflammatory & Immunopharmacol Educ M, Hefei, Anhui, Peoples R China.
   [Zhao, Ying-Chun] Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68178 USA.
RP Yin, JY (reprint author), Cent S Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha, Hunan, Peoples R China.
EM liuzhaoqian63@126.com
RI Zhao, Yingchun/F-3683-2012
OI Zhao, Yingchun/0000-0001-7216-9727; Liu, Zhaoqian/0000-0003-0428-3928;
   Yin, Ji-Ye/0000-0002-1244-5045
FU National Natural Science Foundation of China [81173129]; National
   High-Tech R&D Program of China (863Program) [2009AA022703]; Specialized
   Research Fund for the Doctoral Program of Higher Education
   [20113420120006]; BSKY from Anhui Medical University [XJ201021];
   Ministry of Education of China
FX This work was supported by National Natural Science Foundation of China
   (81173129) (Z.Q.L.), National High-Tech R&D Program of China
   (863Program) (2009AA022703) (Z.Q.L. and J.Y.Y.), Specialized Research
   Fund for the Doctoral Program of Higher Education (20113420120006) (Q.
   H.) and Grants for Scientific Research of BSKY (XJ201021) from Anhui
   Medical University (Q.H.). J.Y.Y. was supported in part by Scholarship
   Award for Excellent Doctoral Student granted by the Ministry of
   Education of China. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Booten R, 2006, J THORAC ONCOL, V1, P679, DOI 10.1097/01243894-200609000-00013
   Booton R, 2006, CANCER, V106, P2421, DOI 10.1002/cncr.21885
   Camps Carlos, 2003, Clin Lung Cancer, V4, P237, DOI 10.3816/CLC.2003.n.004
   Chen SJ, 2010, INT J HYG ENVIR HEAL, V213, P140, DOI 10.1016/j.ijheh.2010.01.004
   Chen XX, 2012, CLIN TRANSL ONCOL, V14, P207, DOI 10.1007/s12094-012-0785-3
   Cheng HY, 2010, ACTA BIOCH BIOPH SIN, V42, P311, DOI 10.1093/abbs/gmq023
   Cheng J, 2012, J CANCER RES CLIN, V138, P231, DOI 10.1007/s00432-011-1090-1
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   Dolan ME, 2004, CANCER RES, V64, P4353, DOI 10.1158/0008-5472.CAN-04-0340
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feng JF, 2009, LUNG CANCER, V66, P344, DOI 10.1016/j.lungcan.2009.02.015
   Feng JF, 2009, ACTA BIOCH BIOPH SIN, V41, P429, DOI 10.1093/abbs/gmp027
   Garcia-Campelo R, 2005, EXPERT OPIN PHARMACO, V6, P2015, DOI 10.1517/14656566.6.12.2015
   Gautschi O, 2006, LUNG CANCER, V51, P303, DOI 10.1016/j.lungcan.2005.10.025
   Giachino DF, 2007, CLIN CANCER RES, V13, P2876, DOI 10.1158/1078-0432.CCR-06-2543
   Hall MD, 2008, ANNU REV PHARMACOL, V48, P495, DOI 10.1146/annurev.pharmtox.48.080907.180426
   Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hildebrandt MAT, 2009, EXPERT OPIN DRUG MET, V5, P745, DOI 10.1517/17425250902973711
   Huang QO, 2010, EUR J CLIN PHARMACOL, V66, P1207, DOI 10.1007/s00228-010-0882-6
   Huang RS, 2008, MOL CANCER THER, V7, P3038, DOI 10.1158/1535-7163.MCT-08-0248
   Huang RS, 2007, AM J HUM GENET, V81, P427, DOI 10.1086/519850
   Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885
   Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399
   Isla D, 2004, ANN ONCOL, V15, P1194, DOI 10.1093/annonc/mdh319
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   Kalikaki A, 2009, CLIN LUNG CANCER, V10, P118, DOI 10.3816/CLC.2009.n.015
   Katano K, 2002, CANCER RES, V62, P6559
   Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308
   Kweekel DM, 2005, CANCER TREAT REV, V31, P90, DOI 10.1016/j.ctrv.2004.12.006
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Li F, 2010, AM J CLIN ONCOL-CANC, V33, P489, DOI 10.1097/COC.0b013e3181b9cedc
   Li WY, 2012, LUNG, V190, P91, DOI 10.1007/s00408-011-9338-8
   Li YF, 2011, CLIN CANCER RES, V17, P3830, DOI 10.1158/1078-0432.CCR-10-2877
   Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Pan JH, 2008, RESPIRATION, V75, P380, DOI 10.1159/000108407
   Pan JH, 2009, RESPIRATION, V78, P49, DOI 10.1159/000158454
   Park DJ, 2001, CANCER RES, V61, P8654
   Ryu JS, 2004, LUNG CANCER, V44, P311, DOI 10.1016/j.lungcan.2003.11.019
   Safaei R, 2004, J INORG BIOCHEM, V98, P1607, DOI 10.1016/j.jinorgbio.2004.05.006
   Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723
   Shiraishi K, 2010, J CLIN ONCOL, V28, P4945, DOI 10.1200/JCO.2010.30.5334
   Shukla SJ, 2008, PHARMACOGENET GENOM, V18, P253, DOI 10.1097/FPC.0b013e3282f5e605
   Stewart DJ, 2007, CRIT REV ONCOL HEMAT, V63, P12, DOI 10.1016/j.critrevonc.2007.02.001
   Su D, 2007, LUNG CANCER, V56, P281, DOI 10.1016/j.lungcan.2006.12.002
   Sun N, 2010, CANCER CHEMOTH PHARM, V65, P437, DOI 10.1007/s00280-009-1046-1
   Sun XC, 2009, LUNG CANCER, V65, P230, DOI 10.1016/j.lungcan.2008.11.014
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Tan XL, 2011, CLIN CANCER RES, V17, P5801, DOI 10.1158/1078-0432.CCR-11-1133
   Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846
   Tibaldi C, 2008, CLIN CANCER RES, V14, P1797, DOI 10.1158/1078-0432.CCR-07-1364
   Vinolas N, 2011, LUNG CANCER, V71, P191, DOI 10.1016/j.lungcan.2010.05.005
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691
   Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275
   Wei HB, 2011, ARCH MED RES, V42, P412, DOI 10.1016/j.arcmed.2011.07.008
   Wei SZ, 2010, MED ONCOL
   Woodahl EL, 2004, CURR DRUG METAB, V5, P11, DOI 10.2174/1389200043489108
   Wu XF, 2011, J NATL CANCER I, V103, P817, DOI 10.1093/jnci/djr075
   Yao CY, 2009, ASIAN PAC J CANCER P, V10, P859
   Yin JY, 2011, CLIN EXP PHARMACOL P, V38, P632, DOI 10.1111/j.1440-1681.2011.05571.x
   Yin JY, 2009, PHARMACOGENET GENOM, V19, P206, DOI 10.1097/FPC.0b013e328323f680
   Yin Jiye, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P927, DOI 10.3969/j.issn.1672-7347.2011.10.002
   Yu D, 2012, TUMOUR BIOL
   Yu DK, 2008, CLIN CANCER RES, V14, P2878, DOI 10.1158/1078-0432.CCR-07-1612
   Yu JJ, 2000, INT J ONCOL, V16, P555
   Yu M, 2010, CLIN PHARMACOL THER, V87, P330, DOI 10.1038/clpt.2009.242
   Zhou CC, 2010, JPN J CLIN ONCOL, V40, P954, DOI 10.1093/jjco/hyq071
   Zhou F, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13275
NR 72
TC 32
Z9 37
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 26
PY 2012
VL 7
IS 6
AR e38150
DI 10.1371/journal.pone.0038150
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 966AK
UT WOS:000305808700002
PM 22761669
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Gu, ML
   Dong, XQ
   Zhang, XZ
   Wang, XM
   Qi, Y
   Yu, J
   Niu, WQ
AF Gu, Mingliang
   Dong, Xiaoqun
   Zhang, Xuezhi
   Wang, Xumin
   Qi, Yue
   Yu, Jun
   Niu, Wenquan
TI Strong Association between Two Polymorphisms on 15q25.1 and Lung Cancer
   Risk: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCUS; GENETIC-VARIANTS;
   CHROMOSOME 15Q25; HUMAN-DISEASE; HETEROGENEITY; STATEMENT; SNPS
AB Background: The association between polymorphisms on 15q25.1 and lung cancer has been widely evaluated; however, the studies have yielded contradictory results. We sought to investigate this inconsistency by performing a comprehensive meta-analysis on two polymorphisms (CHRNA3 gene: rs1051730 and AGPHD1 gene: rs8034191) on 15q25.1.
   Methods: Data were extracted from 15 and 14 studies on polymorphisms rs1051730 and rs8034191 involving 12301/14000 and 14075/12873 lung cancer cases/controls, respectively. The random-effects model was applied, addressing heterogeneity and publication bias.
   Results: The two polymorphisms followed Hardy-Weinberg equilibrium for all studies (P>0.05). For rs1051730-G/A, carriers of A allele had a 36% increased risk for lung cancer (95% confidence interval [CI]: 1.27-1.46; P<0.0005), without heterogeneity (P = 0.258) or publication bias (P-Egger = 0.462). For rs8034191-T/C, the allelic contrast indicated that C allele conferred a 23% increased risk for lung cancer (95% CI: 1.08-1.4; P = 0.002), with significant heterogeneity (P < 0.0005), without publication bias (P-Egger = 0.682). Subgroup analyses suggested that the between-study heterogeneity was derived from ethnicity, study design, matched information, and lung cancer subtypes. For example, the association of polymorphisms rs1051730 and rs8034191 with lung cancer was heterogeneous between Caucasians (OR = 1.32 and 1.22; 95% CI: 1.25-1.44 and 1.05-1.42; P < 0.0005 and 0.008, respectively) and East Asians (OR = 1.51 and 1.03; 95% CI: 0.76-3 and 0.47-2.27; P = 0.237 and 0.934, respectively) under the allelic model, and this association was relatively strengthened under the dominant model. There was no observable publication bias for both polymorphisms.
   Conclusions: Our findings demonstrated that CHRNA3 gene rs1051730-A allele and AGPHD1 gene rs8034191-T allele might be risk-conferring factors for the development of lung cancer in Caucasians, but not in East-Asians.
C1 [Gu, Mingliang; Wang, Xumin; Yu, Jun] Chinese Acad Sci, Beijing Inst Genom, Beijing, Peoples R China.
   [Dong, Xiaoqun] Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
   [Gu, Mingliang; Wang, Xumin; Yu, Jun] Chinese Acad Sci, Key Lab Genome Sci & Informat, Beijing, Peoples R China.
   [Zhang, Xuezhi] China Petrochem Corp, Cent Hosp Shengli Oil Field, Clin Lab Biochem, Dongying, Shandong, Peoples R China.
   [Qi, Yue] Capital Med Univ, Dept Epidemiol, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing Anzhen Hosp, Beijing, Peoples R China.
   [Niu, Wenquan] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, State Key Lab Med Genom, Shanghai 200030, Peoples R China.
RP Gu, ML (reprint author), Chinese Acad Sci, Beijing Inst Genom, Beijing, Peoples R China.
EM niuwenquan@yahoo.cn
FU Shanghai Rising Star Program [11QA1405500]; National Science Foundation
   for Young Scientists of China [30900808]
FX This work was supported by the Shanghai Rising Star Program
   (11QA1405500) and National Science Foundation for Young Scientists of
   China (30900808). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109
   Amos CI, 2010, J NATL CANCER I, V102, P1199, DOI 10.1093/jnci/djq232
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Biesalski HK, 1998, CA-CANCER J CLIN, V48, P167, DOI 10.3322/canjclin.48.3.167
   Broderick P, 2009, CANCER RES, V69, P6633, DOI 10.1158/0008-5472.CAN-09-0680
   Cohn LD, 2003, PSYCHOL METHODS, V8, P243, DOI 10.1037/1082-989X.8.3.243
   Girard N, 2010, CLIN CANCER RES, V16, P755, DOI 10.1158/1078-0432.CCR-09-2437
   Heller G, 2010, CANCER METAST REV, V29, P95, DOI 10.1007/s10555-010-9203-x
   Hemminki K, 2006, NAT REV GENET, V7, P958, DOI 10.1038/nrg2009
   Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885
   Kohno T, 2011, J THORAC ONCOL, V6, P813, DOI 10.1097/JTO.0b013e3181ee80ef
   Lau J, 2006, BMJ-BRIT MED J, V333, P597, DOI 10.1136/bmj.333.7568.597
   Liu PY, 2008, JNCI-J NATL CANCER I, V100, P1326, DOI 10.1093/jnci/djn268
   McClellan J, 2010, CELL, V141, P210, DOI 10.1016/j.cell.2010.03.032
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Ruano-Ravina A, 2008, GAC SANIT, V22, P609, DOI 10.1016/S0213-9111(08)75363-9
   Sakoda LC, 2011, CANCER CAUSE CONTROL, V22, P449, DOI 10.1007/s10552-010-9716-1
   Salanti G, 2005, GENET MED, V7, P13, DOI 10.1097/01.GIM.0000151839.12032.1A
   Schwartz AG, 2009, J THORAC ONCOL, V4, P1195, DOI 10.1097/JTO.0b013e3181b244ef
   Shibuya K, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-37
   Shiraishi K, 2009, CARCINOGENESIS, V30, P65, DOI 10.1093/carcin/bgn257
   Spitz Margaret R, 2008, J Natl Cancer Inst, V100, P1552, DOI 10.1093/jnci/djn363
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846
   Tseng RC, 2009, CANCER-AM CANCER SOC, V115, P2939, DOI 10.1002/cncr.24327
   Wu C, 2009, CANCER RES, V69, P5065, DOI 10.1158/0008-5472.CAN-09-0081
   Xu HY, 2005, HUM GENET, V116, P121, DOI 10.1007/s00439-004-1212-9
   Yu K, 2010, EUR J HUM GENET, V18, P370, DOI 10.1038/ejhg.2009.131
   Zienolddiny S, 2009, CARCINOGENESIS, V30, P1368, DOI 10.1093/carcin/bgp131
NR 32
TC 29
Z9 29
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 6
PY 2012
VL 7
IS 6
AR e37970
DI 10.1371/journal.pone.0037970
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959WK
UT WOS:000305348400027
PM 22701590
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liang, Y
   Zhang, LL
   Gao, J
   Hu, D
   Ai, Y
AF Liang, Yi
   Zhang, Lingli
   Gao, Ju
   Hu, Die
   Ai, Yuan
TI Rituximab for Children with Immune Thrombocytopenia: A Systematic Review
SO PLOS ONE
LA English
DT Review
ID MONOCLONAL-ANTIBODY RITUXIMAB; B-CELL DEPLETION; AUTOIMMUNE CYTOPENIAS;
   ANTI-CD20 RITUXIMAB; SERUM SICKNESS; PURPURA ITP; CHILDHOOD; THERAPY;
   ADULTS; METAANALYSIS
AB Background: Rituximab has been widely used off-label as a second line treatment for children with immune thrombocytopenia (ITP). However, its role in the management of pediatric ITP requires clarification. To understand and interpret the available evidence, we conducted a systematic review to assess the efficacy and safety of rituximab for children with ITP.
   Methodology/Principal Findings: We searched MEDLINE, EMBASE, Cochrane Library, CBM, CNKI, abstract databases of American Society of Hematology, American Society of Clinical Oncology and Pediatric Academic Society. Clinical studies published in full text or abstract only in any language that met predefined inclusion criteria were eligible. Efficacy analysis was restricted to studies enrolling 5 or more patients. Safety was evaluated from all studies that reported data of toxicity. 14 studies (323 patients) were included for efficacy assessment in children with primary ITP. The pooled complete response (platelet count >= 100 x 10(9)/L) and response (platelet count >= 30 x 10(9)/L) rate after rituximab treatment were 39% (95% CI, 30% to 49%) and 68% (95% CI, 58% to 77%), respectively, with median response duration of 12.8 month. 4 studies (29 patients) were included for efficacy assessment in children with secondary ITP. 11 (64.7%) of 17 patients associated with Evans syndrome achieved response. All 6 patients with systemic lupus erythematosus associated ITP and all 6 patients with autoimmune lymphoproliferative syndrome associated ITP achieved response. 91 patients experienced 108 adverse events associated with rituximab, among that, 91 (84.3%) were mild to moderate, and no death was reported.
   Conclusions/Significance: Randomized controlled studies on effect of rituximab for children with ITP are urgently needed, although a series of uncontrolled studies found that rituximab resulted in a good platelet count response both in children with primary and children secondary ITP. Most adverse events associated with rituximab were mild to moderate, and no death was reported.
C1 [Liang, Yi; Zhang, Lingli; Hu, Die] Sichuan Univ, W China Univ Hosp 2, Dept Pharm, Chengdu 610064, Peoples R China.
   [Liang, Yi; Hu, Die] Sichuan Univ, W China Sch Pharm, Chengdu 610064, Peoples R China.
   [Gao, Ju; Ai, Yuan] Sichuan Univ, W China Univ Hosp 2, Dept Pediat Hematol & Oncol, Chengdu 610064, Peoples R China.
RP Liang, Y (reprint author), Sichuan Univ, W China Univ Hosp 2, Dept Pharm, Chengdu 610064, Peoples R China.
EM zhlingli@sina.com
CR Adeli MMG, 2009, PEDIATR HEMAT ONCOL, V26, P566, DOI 10.3109/08880010903271697
   Arnold DM, 2007, ANN INTERN MED, V146, P25, DOI 10.7326/0003-4819-146-1-200701020-00006
   Bader-Meunier B, 2007, HAEMATOL-HEMATOL J, V92, P1691, DOI 10.3324/haematol.11540
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bengtson KL, 2003, J PEDIATR-US, V143, P670, DOI 10.1067/S0022-3476(03)00446-3
   Bennett CM, 2006, BLOOD, V107, P2639, DOI 10.1182/blood-2005-08-3518
   Bisogno G, 2007, EUR J PEDIATR, V166, P85, DOI 10.1007/s00431-006-0222-0
   Carson KR, 2009, BLOOD, V113, P4834, DOI 10.1182/blood-2008-10-186999
   Citak EC, 2011, J TROP PEDIATRICS, V57, P71, DOI 10.1093/tropej/fmq033
   Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795
   Cooper Nichola, 2010, Curr Rheumatol Rep, V12, P94, DOI 10.1007/s11926-010-0090-5
   Cooper N, 2009, BRIT J HAEMATOL, V146, P120, DOI 10.1111/j.1365-2141.2009.07715.x
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Di Gaetano N, 2003, J IMMUNOL, V171, P1581, DOI 10.4049/jimmunol.171.3.1581
   Dogan M, 2009, INDIAN J PEDIATR, V76, P1141, DOI 10.1007/s12098-009-0230-y
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eupropean Medicine Agency website, SUMM EUR PUBL ASS RE
   Gentner Jennifer, 2008, Pediatric Asthma Allergy & Immunology, V21, P99, DOI 10.1089/pai.2008.0003
   Golay J, 2000, BLOOD, V95, P3900
   Goto S, 2009, INT J HEMATOL, V89, P305, DOI 10.1007/s12185-009-0269-6
   Grace RF, 2011, PEDIAT BLOOD CA 0614
   Kim JJ, 2007, BRIT J HAEMATOL, V138, P94, DOI 10.1111/j.1365-2141.2007.06616.x
   Kim JY, 2009, BLOOD, V114, P4461
   Kuhne T, 2003, J PEDIATR-US, V143, P605, DOI 10.1067/S0022-3476(03)00535-3
   Kumar S, 2009, PEDIATRICS, V123, pE159, DOI 10.1542/peds.2008-2361
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lorenzana AN, 2002, THERAPEUTIC EFFECT R, P1043
   National Cancer Institute, 2009, NAT CANC I COMM TERM
   National Institute for Health and Clinical Excellence (NICE) website, QUAL ASS CAS SER
   Parodi E, 2008, BRIT J HAEMATOL, V144, P552
   Pescovitz MD, 2006, AM J TRANSPLANT, V6, P859, DOI 10.1111/j.1600-6143.2006.01288.x
   Pospisilova D, 2010, ANN HEMATOL S1, V89, pS105
   Provan D, 2010, BLOOD, V115, P168, DOI 10.1182/blood-2009-06-225565
   Pusiol A, 2004, EUR J PEDIATR, V163, P305, DOI 10.1007/s00431-004-1417-x
   Quartier P, 2003, CLIN INFECT DIS, V36, pE47, DOI 10.1086/345746
   Rafailidis PI, 2007, CANCER, V109, P2182, DOI 10.1002/cncr.22666
   Rao A, 2008, PEDIATR BLOOD CANCER, V50, P822, DOI 10.1002/pbc.21264
   Rao VK, 2009, PEDIATR BLOOD CANCER, V52, P847, DOI 10.1002/pbc.21965
   Rodeghiero F, 2009, BLOOD, V113, P2386, DOI 10.1182/blood-2008-07-162503
   Romanos-Sirakis E, 2011, J ALLERGY CLIN IMMUN, V127, pAB198, DOI 10.1016/j.jaci.2010.12.789
   Sampaio I, 2010, HAEMATOL-HEMATOL J, V95, P750
   Sharma A, 2005, BLOOD, V106, p82B
   Taube T, 2005, HAEMATOLOGICA, V90, P281
   Terrell DR, 2010, AM J HEMATOL, V85, P174, DOI 10.1002/ajh.21616
   Wang H-M, 2011, J PEDIAT, V146, P330
   Wang J, 2005, J PEDIATR-US, V146, P217, DOI 10.1016/j.jpeds.2004.09.004
   Xu S, 2011, J CHINA PEDIAT BLOOD, V16, P129
   Yadav SP, 2006, BLOOD, V108, p50B
   Yang J, 2011, CHINESE J OBSTET GYN, V7, P474
NR 49
TC 40
Z9 40
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 30
PY 2012
VL 7
IS 5
AR e36698
DI 10.1371/journal.pone.0036698
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959YF
UT WOS:000305353400011
PM 22666325
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, YZ
   Wang, F
   Shi, CZ
   Zou, Y
   Qin, HL
   Ma, YL
AF Yang, Yongzhi
   Wang, Feng
   Shi, Chenzhang
   Zou, Yang
   Qin, Huanlong
   Ma, Yanlei
TI Cyclin D1 G870A Polymorphism Contributes to Colorectal Cancer
   Susceptibility: Evidence from a Systematic Review of 22 Case-Control
   Studies
SO PLOS ONE
LA English
DT Article
ID AGE-OF-ONSET; MAMMALIAN-CELL CYCLE; E-CADHERIN CDH1; A870G POLYMORPHISM;
   SPLICE VARIANTS; CLINICAL-TRIALS; INCREASED RISK; METAANALYSIS;
   ASSOCIATION; CCND1
AB Background: Cyclin D1 (CCND1) plays a vital role in cancer cell cycle progression. Numerous epidemiological studies have evaluated the association between the CCND1 G870A polymorphism and the risk of colorectal cancer. However, these studies have yielded conflicting results. To derive a more precise estimation of this association, we conducted a meta-analysis and systematic review.
   Methodology/Principal Findings: A comprehensive search was conducted to identify eligible studies of the CCND1 G870A polymorphism and colorectal cancer risk. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were derived from a fixed effect or random effect model. We applied a grading system (Venice criteria) that assessed the epidemiological strength of the association. A total of 22 publications that included 6157 cases and 8198 controls were identified. We found that the CCND1 G870A polymorphism was significantly associated with overall colorectal cancer risk (homozygote genetic model: OR = 1.130, 95% CI = 1.023-1.248, P = 0.016; heterozygote genetic model: OR = 1.124, 95% CI = 1.030-1.226, P = 0.009; dominant genetic model: OR = 1.127, 95% CI = 1.037-1.224, P = 0.005). After further stratified analyses, the increased risk was observed only in the subgroups of hospital-based studies, PCR-RFLP genotyping methods, sporadic colorectal cancer, and Caucasian ethnicity.
   Conclusions: The available evidence demonstrates that the CCND1 870A allele might be a low-penetrant risk factor for colorectal cancer.
C1 [Yang, Yongzhi; Wang, Feng; Qin, Huanlong; Ma, Yanlei] Tongji Univ, Dept Surg, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China.
   [Yang, Yongzhi; Shi, Chenzhang; Zou, Yang] Shanghai Jiao Tong Univ, Dept Surg, Peoples Hosp 6, Shanghai 200030, Peoples R China.
RP Yang, YZ (reprint author), Tongji Univ, Dept Surg, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China.
EM hl-qin@hotmail.com; yanleima@live.cn
RI huanlong, Qin/B-3844-2015
FU Shanghai Rising-Star Program [11QA1404800]; National Natural Science
   Foundation of China [81001069]; National 863 High Technology Foundation
   [2009AA02Z118]
FX This work was financially sponsored by Shanghai Rising-Star Program (No.
   11QA1404800), grants from the National Natural Science Foundation of
   China (No. 81001069) and the National 863 High Technology Foundation
   (No. 2009AA02Z118). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bala S, 2001, CANCER RES, V61, P6042
   Barrett JH, 2011, NAT GENET, V43, P1108, DOI 10.1038/ng.959
   Bax L, 2009, AM J EPIDEMIOL, V169, P249, DOI 10.1093/aje/kwn340
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berthet C, 2006, DEV CELL, V10, P563, DOI 10.1016/j.devcel.2006.03.004
   BETTICHER DC, 1995, ONCOGENE, V11, P1005
   Chen B, 2011, CANC EPIDEMIOL
   Comstock CES, 2009, CLIN CANCER RES, V15, P5338, DOI 10.1158/1078-0432.CCR-08-2865
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Forones Nora Manoukian, 2008, J Gastrointest Cancer, V39, P118, DOI 10.1007/s12029-009-9057-z
   GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807
   Gerard C, 2009, P NATL ACAD SCI USA, V106, P21643, DOI 10.1073/pnas.0903827106
   Grieu F, 2003, ANTICANCER RES, V23, P4257
   Grunhage F, 2008, INT J COLORECTAL DIS, V23, P147, DOI 10.1007/s00384-007-0388-6
   HABER M, 1981, HUM HERED, V31, P161, DOI 10.1159/000153199
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holley SL, 2001, AM J PATHOL, V159, P1917, DOI 10.1016/S0002-9440(10)63038-6
   Hong Y, 2005, EUR J CANCER, V41, P1037, DOI 10.1016/j.ejca.2005.01.009
   Huang WS, 2006, DIS COLON RECTUM, V49, P602, DOI 10.1007/s10350-005-0311-6
   Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159
   Jelonek K, 2010, J APPL GENET, V51, P343, DOI 10.1007/BF03208865
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   Jiang J, 2006, J CANCER RES CLIN, V132, P193, DOI 10.1007/s00432-005-0039-7
   Kanaan Z, 2010, INT J BIOL MARKER, V25, P27
   Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371
   Kong SM, 2001, JNCI-J NATL CANCER I, V93, P1106, DOI 10.1093/jnci/93.14.1106
   Kong SM, 2000, CANCER RES, V60, P249
   Kruger S, 2006, CANCER LETT, V236, P191, DOI 10.1016/j.canlet.2005.05.013
   LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224
   Le Marchand L, 2003, JAMA-J AM MED ASSOC, V290, P2843
   Lewis RC, 2003, CANCER RES, V63, P8549
   Liu B, 2010, MOL CARCINOGEN, V49, P75, DOI 10.1002/mc.20579
   Lu FM, 2003, CANCER RES, V63, P7056
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   McKay JA, 2000, INT J CANCER, V88, P77, DOI 10.1002/1097-0215(20001001)88:1<77::AID-IJC12>3.0.CO;2-O
   Pabalan N, 2008, CANCER EPIDEM BIOMAR, V17, P2773, DOI 10.1158/1055-9965.EPI-08-0169
   Porter TR, 2002, ONCOGENE, V21, P1928, DOI 10.1038/sj/onc/1205245
   Probst-Hensch NM, 2006, CARCINOGENESIS, V27, P2475, DOI 10.1093/carcin/bgl116
   Schernhammer ES, 2006, BRIT J CANCER, V94, P928, DOI 10.1038/sj.bjc.6603007
   Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200
   Song FJ, 1999, J CLIN EPIDEMIOL, V52, P725, DOI 10.1016/S0895-4356(99)00066-9
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Talseth BA, 2008, INT J CANCER, V122, P1273, DOI 10.1002/ijc.23177
   Tan XL, 2008, INT J CANCER, V122, P2573, DOI 10.1002/ijc.23363
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Yaylim-Eraltan I, 2010, ANTICANCER RES, V30, P2875
NR 53
TC 13
Z9 13
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 11
PY 2012
VL 7
IS 5
AR e36813
DI 10.1371/journal.pone.0036813
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959TW
UT WOS:000305338200045
PM 22606291
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Sapari, NS
   Loh, M
   Vaithilingam, A
   Soong, R
AF Sapari, Nur Sabrina
   Loh, Marie
   Vaithilingam, Aparna
   Soong, Richie
TI Clinical Potential of DNA Methylation in Gastric Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID TUMOR-RELATED GENES; CPG ISLAND HYPERMETHYLATION; HELICOBACTER-PYLORI;
   EPIGENETIC ALTERATIONS; PROMOTER METHYLATION; ABERRANT METHYLATION;
   BIOMARKERS; ASSOCIATION; PROGRESSION; SUPPRESSOR
AB Background: Accumulating evidence indicates aberrant DNA methylation is involved in gastric tumourigenesis, suggesting it may be a useful clinical biomarker for the disease. The aim of this study was to consolidate and summarize published data on the potential of methylation in gastric cancer (GC) risk prediction, prognostication and prediction of treatment response.
   Methods: Relevant studies were identified from PubMed using a systematic search approach. Results were summarized by meta-analysis. Mantel-Haenszel odds ratios were computed for each methylation event assuming the random-effects model.
   Results: A review of 589 retrieved publications identified 415 relevant articles, including 143 case-control studies on gene methylation of 142 individual genes in GC clinical samples. A total of 77 genes were significantly differentially methylated between tumour and normal gastric tissue from GC subjects, of which data on 62 was derived from single studies. Methylation of 15, 4 and 7 genes in normal gastric tissue, plasma and serum respectively was significantly different in frequency between GC and non-cancer subjects. A prognostic significance was reported for 18 genes and predictive significance was reported for p16 methylation, although many inconsistent findings were also observed. No bias due to assay, use of fixed tissue or CpG sites analysed was detected, however a slight bias towards publication of positive findings was observed.
   Conclusions: DNA methylation is a promising biomarker for GC risk prediction and prognostication. Further focused validation of candidate methylation markers in independent cohorts is required to develop its clinical potential.
C1 [Sapari, Nur Sabrina; Loh, Marie; Vaithilingam, Aparna; Soong, Richie] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore.
   [Loh, Marie] Univ Western Australia, Sch Surg, Crawley, Australia.
   [Soong, Richie] Natl Univ Singapore, Dept Pathol, Singapore 117548, Singapore.
RP Sapari, NS (reprint author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore.
EM csirs@nus.edu.sg
OI Soong, Richie/0000-0002-0152-1225
FU National Medical Research Council [NMRC/TCR/001/2007]
FX This work was supported by a grant from the National Medical Research
   Council (NMRC/TCR/001/2007). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Castellvi-Bel Sergi, 2006, Gastroenterology, V131, P1647, DOI 10.1053/j.gastro.2006.09.038
   Chan AOO, 2003, AM J PATHOL, V163, P370, DOI 10.1016/S0002-9440(10)63663-2
   Choi IS, 2005, CELL RES, V15, P247, DOI 10.1038/sj.cr.7290293
   Corvalan AH, 2010, RECENT PAT DNA GENE
   Enomoto S, 2010, WORLD J GASTRO ENDOS, V2, P381, DOI 10.4253/wjge.v2.i12.381
   Estecio MRH, 2011, FEBS LETT, V585, P2078, DOI 10.1016/j.febslet.2010.12.001
   Fan XY, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-92
   Fang JY, 1996, CHINESE MED J-PEKING, V109, P787
   Garcia M, 2007, GLOBAL CANC FACTS FI
   Hou P, 2005, BIOCHEM GENET, V43, P1, DOI 10.1007/s10528-005-1062-8
   Kang GH, 2008, LAB INVEST, V88, P161, DOI 10.1038/labinvest.3700707
   Kato K, 2008, INT J CANCER, V122, P603, DOI 10.1002/ijc.23143
   Kim TY, 2004, ALIMENT PHARM THER, V20, P131, DOI 10.1111/j.1365-2036.2004.01984.x
   Kiyohara Chikako, 2007, Int J Med Sci, V4, P59
   Koga Y, 2006, J GASTROENTEROL, V41, P133, DOI 10.1007/s00535-005-1732-7
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Levenson VV, 2004, PHARMACOGENOMICS, V5, P699, DOI 10.1517/14622416.5.6.699
   Mitsuno M, 2007, J GASTROENTEROL, V42, P866, DOI 10.1007/s00535-007-2113-1
   Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616
   Miyamoto K, 2005, JPN J CLIN ONCOL, V35, P293, DOI 10.1093/jjco/hyi088
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Munafo MR, 2004, PSYCHIAT RES, V129, P39, DOI 10.1016/j.psychres.2004.06.011
   Nakajima Takeshi, 2008, Environmental Health and Preventive Medicine, V13, P8, DOI 10.1007/s12199-007-0005-x
   Napieralski R, 2007, CLIN CANCER RES, V13, P5095, DOI 10.1158/1078-0432.CCR-07-0241
   Nardone G, 2004, ALIMENT PHARM THERAP, V20, P261, DOI 10.1111/j.1365-2036.2004.02075.x
   Nardone G, 2007, DIGEST DIS, V25, P225, DOI 10.1159/000103890
   Nardone Gerardo, 2008, Expert Rev Gastroenterol Hepatol, V2, P243, DOI 10.1586/17474124.2.2.243
   Nobili S, 2011, WORLD J GASTROENTERO, V17, P290, DOI 10.3748/wjg.v17.i3.290
   Ottini L, 2006, ANN ONCOL, V17, pVII97, DOI 10.1093/annonc/mdl960
   Oue N, 2003, CANCER SCI, V94, P901, DOI 10.1111/j.1349-7006.2003.tb01373.x
   Oue N, 2006, CANCER-AM CANCER SOC, V106, P1250, DOI 10.1002/cncr.21754
   Paluszczak J, 2006, J APPL GENET, V47, P365, DOI 10.1007/BF03194647
   Park SY, 2010, VIRCHOWS ARCH, V457, P415, DOI 10.1007/s00428-010-0962-0
   Rashid A, 2004, GASTROENTEROLOGY, V127, P1578, DOI 10.1053/j.gastro.2004.09.007
   Sato F, 2006, CANCER-AM CANCER SOC, V106, P483, DOI 10.1002/cncr.21657
   Shivapurkar N, 2010, CURR MOL MED, V10, P123, DOI 10.2174/156652410790963303
   Suzuki T, 2007, ONCOL REP, V18, P329
   Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085
   Tamura G, 2004, HISTOL HISTOPATHOL, V19, P221, DOI 10.14670/HH-19.221
   Tamura G, 2002, HISTOL HISTOPATHOL, V17, P323, DOI 10.14670/HH-17.323
   Tamura G, 2006, WORLD J GASTROENTERO, V12, P192, DOI 10.3748/wjg.v12.i2.192
   Toyota M, 1999, CANCER RES, V59, P5438
   Ushijima T, 2006, J GASTROENTEROL, V41, P401, DOI 10.1007/s00535-006-1846-6
   Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142
   Ushijima T, 2012, CLIN CANCER RES, V18, P923, DOI 10.1158/1078-0432.CCR-11-2011
   Ushijima T, 2010, CANCER SCI, V101, P300, DOI 10.1111/j.1349-7006.2009.01434.x
   van Vlodrop IJH, 2011, CLIN CANCER RES, V17, P4225, DOI 10.1158/1078-0432.CCR-10-3394
   Vogiatzi P, 2007, J CELL PHYSIOL, V211, P287, DOI 10.1002/jcp.20982
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Widschwendter M, 2002, CLIN CANCER RES, V8, P17
   Yamamoto E, 2011, DIGESTION, V83, P241, DOI 10.1159/000320453
   Yamashita K, 2011, SURG TODAY, V41, P24, DOI 10.1007/s00595-010-4370-5
   Yasui W, 2006, SCAND J SURG, V95, P225, DOI 10.1177/145749690609500403
   Yasui Wataru, 2005, Gastric Cancer, V8, P86, DOI 10.1007/s10120-005-0320-0
   Ye T, 2010, MINI-REV MED CHEM, V10, P1034, DOI 10.2174/1389557511009011034
   Yoshida K, 2006, ANTICANCER RES, V26, P49
NR 57
TC 56
Z9 58
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 27
PY 2012
VL 7
IS 4
AR e36275
DI 10.1371/journal.pone.0036275
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959TJ
UT WOS:000305336000178
PM 22558417
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Ritchie, ML
   Romanuk, TN
AF Ritchie, Marina L.
   Romanuk, Tamara N.
TI A Meta-Analysis of Probiotic Efficacy for Gastrointestinal Diseases
SO PLOS ONE
LA English
DT Article
ID IRRITABLE-BOWEL-SYNDROME; ANTIBIOTIC-ASSOCIATED DIARRHEA;
   CLOSTRIDIUM-DIFFICILE DISEASE; LACTOBACILLUS-PLANTARUM 299V;
   PLACEBO-CONTROLLED TRIALS; DOUBLE-BLIND; HELICOBACTER-PYLORI;
   SACCHAROMYCES-BOULARDII; BIFIDOBACTERIUM-LONGUM; ORAL BACTERIOTHERAPY
AB Background: Meta-analyses on the effects of probiotics on specific gastrointestinal diseases have generally shown positive effects on disease prevention and treatment; however, the relative efficacy of probiotic use for treatment and prevention across different gastrointestinal diseases, with differing etiology and mechanisms of action, has not been addressed.
   Methods/Principal Findings: We included randomized controlled trials in humans that used a specified probiotic in the treatment or prevention of Pouchitis, Infectious diarrhea, Irritable Bowel Syndrome, Helicobacter pylori, Clostridium difficile Disease, Antibiotic Associated Diarrhea, Traveler's Diarrhea, or Necrotizing Enterocolitis. Random effects models were used to evaluate efficacy as pooled relative risks across the eight diseases as well as across probiotic species, single vs. multiple species, patient ages, dosages, and length of treatment. Probiotics had a positive significant effect across all eight gastrointestinal diseases with a relative risk of 0.58 (95% (CI) 0.51-0.65). Six of the eight diseases: Pouchitis, Infectious diarrhea, Irritable Bowel Syndrome, Helicobacter pylori, Clostridium difficile Disease, and Antibiotic Associated Diarrhea, showed positive significant effects. Traveler's Diarrhea and Necrotizing Enterocolitis did not show significant effects of probiotcs. Of the 11 species and species mixtures, all showed positive significant effects except for Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium infantis. Across all diseases and probiotic species, positive significant effects of probiotics were observed for all age groups, single vs. multiple species, and treatment lengths.
   Conclusions/Significance: Probiotics are generally beneficial in treatment and prevention of gastrointestinal diseases. Efficacy was not observed for Traveler's Diarrhea or Necrotizing Enterocolitis or for the probiotic species L. acidophilus, L. plantarum, and B. infantis. When choosing to use probiotics in the treatment or prevention of gastrointestinal disease, the type of disease and probiotic species (strain) are the most important factors to take into consideration.
C1 [Ritchie, Marina L.; Romanuk, Tamara N.] Dalhousie Univ, Dept Biol, Halifax, NS, Canada.
RP Ritchie, ML (reprint author), Dalhousie Univ, Dept Biol, Halifax, NS, Canada.
EM marina.ritchie@gmail.com
RI Romanuk, t N/C-6493-2008
FU National Sciences and Engineering Research Council of Canada (NSERC)
   Discovery Grant
FX This research was supported by a National Sciences and Engineering
   Research Council of Canada (NSERC) Discovery Grant to Tamara Romanuk.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR [Anonymous], BAX L MIX 2 0 PROF S
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bengmark S, 1998, GUT, V42, P2, DOI 10.1136/gut.42.1.2
   BENNO Y, 1992, MICROBIOL IMMUNOL, V36, P683, DOI 10.1111/j.1348-0421.1992.tb02071.x
   Bezkorovainy A, 2001, AM J CLIN NUTR, V73, p399S, DOI 10.1093/ajcn/73.2.399s
   Blumberg D, 2002, GASTROENTEROL CLIN N, V31, P219, DOI 10.1016/S0889-8553(01)00013-9
   Bodilis JY, 1983, MED ACTUELLE, V10, P232
   BOULLOCHE J, 1994, ANN PEDIATR-PARIS, V41, P457
   Canducci F, 2000, ALIMENT PHARM THER, V14, P1625, DOI 10.1046/j.1365-2036.2000.00885.x
   Carol M, 1998, GUT, V42, P643, DOI 10.1136/gut.42.5.643
   Cats A, 2003, ALIMENT PHARM THER, V17, P429, DOI 10.1046/j.0269-2813.2003.01452.x
   Cindoruk M, 2007, HELICOBACTER, V12, P309, DOI 10.1111/j.1523-5378.2007.00516.x
   Cremonini F, 2002, ALIMENT PHARM THERAP, V16, P1461, DOI 10.1046/j.1365-2036.2002.01318.x
   D'Souza AL, 2002, BRIT MED J, V324, P1361, DOI 10.1136/bmj.324.7350.1361
   Dendukuri N, 2005, CAN MED ASSOC J, V173, P167, DOI 10.1503/cmaj.050350
   Deshpande G, 2007, LANCET, V369, P1614, DOI 10.1016/S0140-6736(07)60748-X
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   EGGER M, 1995, BRIT MED J, V311, P753, DOI 10.1136/bmj.311.7007.753c
   Elahi B, 2008, DIGEST DIS SCI, V53, P1278, DOI 10.1007/s10620-007-0006-z
   Elmer GW, 2001, AM J HEALTH-SYST PH, V58, P1101, DOI 10.1093/ajhp/58.12.1101
   Fric P, 2002, Z GASTROENTEROL, V40, P197, DOI 10.1055/s-2002-22328
   Gade J, 1989, Scand J Prim Health Care, V7, P23, DOI 10.3109/02813438909103666
   Gionchetti P, 2000, GASTROENTEROLOGY, V119, P305, DOI 10.1053/gast.2000.9370
   Gionchetti P, 2003, BEST PRACT RES CL GA, V17, P821, DOI 10.1016/S1521-6918(03)00071-4
   Goodgame Richard, 2003, Curr Infect Dis Rep, V5, P66, DOI 10.1007/s11908-003-0067-x
   Gorbach SL, 1996, NUTRITION, V31, P2
   Halpern GM, 1996, AM J GASTROENTEROL, V91, P1579
   Hart AL, 2003, J CLIN GASTROENTEROL, V36, P111, DOI 10.1097/00004836-200302000-00005
   Hawrelak JA, 2005, DIGESTION, V72, P51, DOI 10.1159/000087637
   Hilton, 1997, J Travel Med, V4, P41, DOI 10.1111/j.1708-8305.1997.tb00772.x
   Hoveyda N, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-15
   ISOLAURI E, 1994, DIGEST DIS SCI, V39, P2595, DOI 10.1007/BF02087695
   Isolauri E, 2001, AM J CLIN NUTR, V73, p1142S
   ISOLAURI E, 1993, PEDIATR RES, V33, P548, DOI 10.1203/00006450-199306000-00002
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Johnston BC, 2006, CAN MED ASSOC J, V175, P377, DOI 10.1503/cmaj.051603
   Katelaris PH, 1995, NEW ENGL J MED, V333, P1046
   Keighley MRB, 1996, ALIMENT PHARM THER, V10, P449, DOI 10.1046/j.1365-2036.1996.32174000.x
   KMIOT WA, 1993, BRIT J SURG, V80, P1445, DOI 10.1002/bjs.1800801132
   Lin HC, 2004, JAMA-J AM MED ASSOC, V292, P852, DOI 10.1001/jama.292.7.852
   LING WH, 1994, J NUTR, V124, P18
   Marteau PR, 2001, AM J CLIN NUTR, V73, p430S, DOI 10.1093/ajcn/73.2.430s
   McFarland LV, 1998, DIGEST DIS, V16, P292, DOI 10.1159/000016879
   McFarland LV, 2006, AM J GASTROENTEROL, V101, P812, DOI 10.1111/j.1572-0241.2006.00465.x
   MCFARLAND LV, 1994, JAMA-J AM MED ASSOC, V271, P1913, DOI 10.1001/jama.271.24.1913
   McFarland LV, 2008, WORLD J GASTROENTERO, V14, P2650, DOI 10.3748/wjg.14.2650
   McFarland Lynne V., 2000, Microbial Ecology in Health and Disease, V12, P193, DOI 10.1080/08910600050216183
   Mimura T, 2004, GUT, V53, P108, DOI 10.1136/gut.53.1.108
   Nicholls RJ, 1998, WORLD J SURG, V22, P347, DOI 10.1007/s002689900395
   Niedzielin K, 2001, EUR J GASTROEN HEPAT, V13, P1143, DOI 10.1097/00042737-200110000-00004
   Nobaek S, 2000, AM J GASTROENTEROL, V95, P1231
   Olson JW, 2002, SCIENCE, V298, P1788, DOI 10.1126/science.1077123
   ORRHAGE K, 1994, MICROB ECOL HEALTH D, V7, P17, DOI 10.3109/08910609409141570
   Perin NM, 1997, J PEDIATR GASTR NUTR, V24, P419, DOI 10.1097/00005176-199704000-00011
   Pessi T, 1999, APPL ENVIRON MICROB, V65, P4725
   POZOOLANO JDD, 1978, GASTROENTEROLOGY, V74, P829
   Qamar A, 2001, INFECT IMMUN, V69, P2762, DOI 10.1128/IAI.69.4.2762-2765.2001
   Rath HC, 2003, EUR J GASTROEN HEPAT, V15, P615, DOI 10.1097/01.meg.0000059148.68845.5e
   Ruszczynski M, 2008, ALIMENT PHARM THER, V28, P154, DOI 10.1111/j.1365-2036.2008.03714.x
   Saarela M, 2002, INT J FOOD MICROBIOL, V78, P99, DOI 10.1016/S0168-1605(02)00235-0
   SAAVEDRA JM, 1994, LANCET, V344, P1046, DOI 10.1016/S0140-6736(94)91708-6
   Sakaguchi T, 2002, CELL MICROBIOL, V4, P367, DOI 10.1046/j.1462-5822.2002.00197.x
   Salminen S, 1998, BRIT J NUTR, V80, pS147, DOI 10.1079/BJN19980108
   SANDBORN WJ, 1994, GASTROENTEROLOGY, V107, P1856, DOI 10.1016/0016-5085(94)90832-X
   SANDERSON IR, 1993, GASTROENTEROLOGY, V104, P622, DOI 10.1016/0016-5085(93)90436-G
   Santosa S, 2006, NUTR REV, V64, P265, DOI 10.1301/nr.2006.jun.265-274
   SARTOR RB, 1995, GASTROENTEROL CLIN N, V24, P475
   Sazawal S, 2006, LANCET INFECT DIS, V6, P374, DOI 10.1016/S1473-3099(06)70495-9
   Sen S, 2002, DIGEST DIS SCI, V47, P2615, DOI 10.1023/A:1020597001460
   SIMON GL, 1986, DIGEST DIS SCI, V31, pS147
   Simren M, 2006, GASTROENTEROLOGY, V130, pA600
   Sistrom CL, 2004, RADIOLOGY, V230, P12, DOI 10.1148/radiol.2301031028
   Soutar A, 1997, THORAX, V52, P166, DOI 10.1136/thx.52.2.166
   Sutas Y, 1996, J ALLERGY CLIN IMMUN, V98, P216, DOI 10.1016/S0091-6749(96)70245-2
   Tannock GW, 1997, TRENDS BIOTECHNOL, V15, P270, DOI 10.1016/S0167-7799(97)01056-1
   Tong JL, 2007, ALIMENT PHARM THER, V25, P155, DOI 10.1111/j.1365-2036.2006.03179.x
   Van Niel CW, 2005, PEDIATRICS, V115, P174, DOI 10.1542/peds.2004-2356
   Vanderhoof JA, 2000, J PEDIATR GASTR NUTR, V30, pS34, DOI 10.1097/00005176-200000002-00006
   VANEMBDEN JGHR, 1994, GUT, V35, P658, DOI 10.1136/gut.35.5.658
   Weizman Z, 2005, PEDIATRICS, V115, P5, DOI 10.1542/peds.2004-1815
   Wenus C, 2008, EUR J CLIN NUTR, V62, P299, DOI 10.1038/sj.ejcn.1602718
   Whorwell PJ, 2006, AM J GASTROENTEROL, V101, P1581, DOI 10.1111/j.1572-0241.2006.00734.x
   Wilson M., 2008, BACTERIOLOGY HUMANS
   WITSELL DL, 1995, J OTOLARYNGOL, V24, P230
   Wullt M, 2003, SCAND J INFECT DIS, V35, P365, DOI 10.1080/00365540310010985
NR 85
TC 196
Z9 200
U1 1
U2 70
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 18
PY 2012
VL 7
IS 4
AR e34938
DI 10.1371/journal.pone.0034938
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959XD
UT WOS:000305350600044
PM 22529959
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, YC
   Liu, YW
   Fu, LL
   Mei, CL
   Dai, B
AF Li, Yongchuan
   Liu, Yawei
   Fu, Lili
   Mei, Changlin
   Dai, Bing
TI Efficacy of Short-Term High-Dose Statin in Preventing Contrast-Induced
   Nephropathy: A Meta-Analysis of Seven Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; ACUTE CORONARY SYNDROMES; ACUTE-RENAL-FAILURE;
   REDUCTASE INHIBITORS; CLINICAL-TRIALS; RISK-FACTORS; ATORVASTATIN;
   ANGIOGRAPHY; THERAPY; PRETREATMENT
AB Background: A few studies focused on statin therapy as specific prophylactic measures of contrast-induced nephropathy have been published with conflicting results. In this meta-analysis of randomized controlled trials, we aimed to assess the effectiveness of shor-term high-dose statin treatment for the prevention of CIN and clinical outcomes and re-evaluate of the potential benefits of statin therapy.
   Methods: We searched PubMed, OVID, EMBASE, Web of science and the Cochrane Central Register of Controlled Trials databases for randomized controlled trials comparing short-term high-dose statin treatment versus low-dose statin treatment or placebo for preventing CIN. Our outcome measures were the risk of CIN within 2-5 days after contrast administration and need for dialysis.
   Results: Seven randomized controlled trials with a total of 1,399 patients were identified and analyzed. The overall results based on fixed-effect model showed that the use of short-term high-dose statin treatment was associated with a significant reduction in risk of CIN (RR = 0.51, 95% CI 0.34-0.76, p = 0.001; I-2 = 0%). The incidence of acute renal failure requiring dialysis was not significant different after the use of statin (RR = 0.33, 95% CI 0.05-2.10, p = 0.24; I-2 = 0%). The use of statin was not associated with a significant decrease in the plasma C-reactive protein level (SMD 20.64, 95% CI: 21.57 to 0.29, P = 0.18, I-2 = 97%).
   Conclusions: Although this meta-analysis supports the use of statin to reduce the incidence of CIN, it must be considered in the context of variable patient demographics. Only a limited recommendation can be made in favour of the use of statin based on current data. Considering the limitations of included studies, a large, well designed trial that incorporates the evaluation of clinically relevant outcomes in participants with different underlying risks of CIN is required to more adequately assess the role for statin in CIN prevention.
C1 [Li, Yongchuan; Liu, Yawei; Fu, Lili; Mei, Changlin; Dai, Bing] Second Mil Med Univ, Div Nephrol, Nephrol Inst PLA, Shanghai Changzheng Hosp, Shanghai, Peoples R China.
RP Li, YC (reprint author), Second Mil Med Univ, Div Nephrol, Nephrol Inst PLA, Shanghai Changzheng Hosp, Shanghai, Peoples R China.
EM chlmei1954@yahoo.com.cn; daibin105@yahoo.com.cn
FU National Natural Science Foundation of China [30900692, 81000283,
   30971368]; Shanghai Leading Academic Discipline Project [B902]
FX This work was supported by grants from the National Natural Science
   Foundation of China (30900692, 81000283, 30971368) and Shanghai Leading
   Academic Discipline Project (B902). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Acikel S, 2010, BLOOD COAGUL FIBRIN, V21, P750, DOI 10.1097/MBC.0b013e32834014a4
   Attallah N, 2004, CLIN NEPHROL, V62, P273
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bonetti PO, 2003, EUR HEART J, V24, P225, DOI 10.1016/S0195-668X(02)00419-0
   Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583
   Davignon J, 2004, CIRCULATION, V109, P39, DOI 10.1161/01.CIR.0000131517.20177.5a
   Goldenberg I, 2005, CAN MED ASSOC J, V172, P1461, DOI 10.1503/cmaj.1040847
   Gruberg L, 2001, CATHETER CARDIO INTE, V52, P409, DOI 10.1002/ccd.1093
   Hernandez-Perera O, 1998, J CLIN INVEST, V101, P2711, DOI 10.1172/JCI1500
   Ichiki T, 2001, ARTERIOSCL THROM VAS, V21, P1896, DOI 10.1161/hq1201.099430
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jia XW, 2009, AM J CARDIOL, V104, P519, DOI 10.1016/j.amjcard.2009.04.014
   Jo SH, 2008, AM HEART J, V155, DOI 10.1016/j.ahj.2007.11.042
   Jo SH, 2005, AM J CARDIOL, V96, p115H
   John S, 2005, AM HEART J, V149, DOI 10.1016/j.ahj.2004.06.027
   Kaesemeyer WH, 1999, J AM COLL CARDIOL, V33, P234, DOI 10.1016/S0735-1097(98)00514-2
   Katholi RE, 1998, AM J KIDNEY DIS, V32, P64, DOI 10.1053/ajkd.1998.v32.pm9669426
   Khanal S, 2005, AM J MED, V118, P843, DOI 10.1016/j.amjmed.2005.03.031
   LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461
   Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266
   McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2
   McCullough PA, 2008, AM J KIDNEY DIS, V51, P169, DOI 10.1053/j.ajkd.2007.12.004
   Morikawa Shigeru, 2002, J Atheroscler Thromb, V9, P178
   Nash K, 2002, AM J KIDNEY DIS, V39, P930, DOI 10.1053/ajkd.2002.32766
   Ozhan H, 2010, ANGIOLOGY, V61, P711, DOI 10.1177/0003319710364216
   Pappy R, 2011, INT J CARDIOL, V151, P348, DOI 10.1016/j.ijcard.2011.05.045
   Patti G, 2011, AM J CARDIOL, V108, P1, DOI 10.1016/j.amjcard.2011.03.001
   Piorkowski M, 2007, J AM COLL CARDIOL, V49, P1035, DOI 10.1016/j.jacc.2006.10.064
   Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601
   Tepel M, 2006, CIRCULATION, V113, P1799, DOI 10.1161/CIRCULATIONAHA.105.595090
   Tepel M, 2002, CURR OPIN NEPHROL HY, V11, P503, DOI 10.1097/00041552-200209000-00005
   Toso A, 2010, AM J CARDIOL, V105, P288, DOI 10.1016/j.amjcard.2009.09.026
   Tumlin J, 2006, AM J CARDIOL, V98, p14K, DOI 10.1016/j.amjcard.2006.01.020
   Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0
   Wagner AH, 2000, ARTERIOSCL THROM VAS, V20, P61, DOI 10.1161/01.ATV.20.1.61
   Zhang BC, 2011, CAN J CARDIOL, V27, P851, DOI 10.1016/j.cjca.2011.05.005
   Zhang L, 2011, INT J CLIN PRACT, V65, P624, DOI 10.1111/j.1742-1241.2010.02588.x
   Zhang T, 2011, AM J NEPHROL, V33, P344, DOI 10.1159/000326269
   Zhou Xia, 2009, Zhonghua Xinxueguanbing Zazhi, V37, P394, DOI 10.3760/cma.j.issn.0253-3758.2009.05.003
   Zhou Y, 2011, CLIN NEPHROL, V76, P475, DOI 10.5414/CN106950
NR 40
TC 61
Z9 63
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 12
PY 2012
VL 7
IS 4
AR e34450
DI 10.1371/journal.pone.0034450
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959TZ
UT WOS:000305338600028
PM 22511942
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zheng, XW
   Wang, L
   Zhu, YW
   Guan, Q
   Li, HJ
   Xiong, ZG
   Deng, LY
   Lu, J
   Miao, XP
   Cheng, LM
AF Zheng, Xiawen
   Wang, Li
   Zhu, Yaowu
   Guan, Qing
   Li, Huijun
   Xiong, Zhigang
   Deng, Lingyan
   Lu, Jie
   Miao, Xiaoping
   Cheng, Liming
TI The SNP rs961253 in 20p12.3 Is Associated with Colorectal Cancer Risk: A
   Case-Control Study and a Meta-Analysis of the Published Literature
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; GENETIC-VARIANTS;
   PUBLICATION BIAS; SCAN; POLYMORPHISMS; SUPPRESSION; COLON; 8Q24
AB Background: Colorectal cancer (CRC) is the third common cancer and the fourth leading cause of cancer death worldwide. A single nucleotide polymorphism (SNP), rs961253 located in 20p12, was firstly described to be associated with the increased risk of CRC in a genome-wide association study; however, more recent replication studies yielded controversial results.
   Methodology/Principal Findings: A hospital-based case-control study in a Chinese population was firstly performed, and then a meta-analysis combining the current and previously published studies were conducted to explore the real effect of rs961253 in CRC susceptibility. In the Chinese population including 641 cases and 1037 controls, per-A-allele conferred an OR of 1.60 (95% CI = 1.26-2.02) under additive model. In the meta-analysis including 29859 cases and 29696 controls, per-A-allele have an OR of 1.13 (95% CI = 1.09-1.18) under a random-effects model due to heterogeneity (P = 0.019). Nevertheless, the heterogeneity can be totally explained by ethnicity, with the tau(2)reduced to 0 after including ethnicity in meta-regression model. In stratified analysis by ethnicity, per-A-allele had ORs of 1.34 (95% CI = 1.20-1.50) and 1.11 (95% CI = 1.08-1.14) for Asian and European, respectively, without heterogeneity. Modest influence of each study was observed on overall estimate in sensitive analysis, and evident tendency to significant association was seen in cumulative analysis over time, together indicating the robust stability of the current results.
   Conclusions/Significance: The results from our study and the meta-analysis provided firm evidence that rs961253 significantly contributed to CRC risk in both Asian and European population.
C1 [Zheng, Xiawen; Zhu, Yaowu; Guan, Qing; Li, Huijun; Xiong, Zhigang; Deng, Lingyan; Lu, Jie; Cheng, Liming] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Lab Med, Wuhan 430074, Peoples R China.
   [Zheng, Xiawen; Miao, Xiaoping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth,Dept Epidemiol & Biostat, MOE Key Lab Environm & Hlth, Wuhan 430074, Peoples R China.
   [Wang, Li] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Epidemiol & Biostat, Beijing, Peoples R China.
   [Wang, Li] Peking Union Med Coll, Sch Basic Med, Beijing, Peoples R China.
RP Cheng, LM (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Lab Med, Wuhan 430074, Peoples R China.
EM chengliming@tjh.tjmu.edu.cn
RI miao, xiaoping/C-4336-2011
OI miao, xiaoping/0000-0002-6818-9722
FU Natural Science Foundation of China [NSFC-81001275, 81171878]; Fok Ying
   Tung Foundation for Young Teachers in the Higher Education Institutions
   of China [131038]
FX This work was supported by the National Natural Science Foundation of
   China [NSFC-81001275 and 81171878 to X.M.] and the Fok Ying Tung
   Foundation for Young Teachers in the Higher Education Institutions of
   China (131038) to X.M. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Beck SE, 2006, AM J PHYSIOL-GASTR L, V291, pG135, DOI 10.1152/ajpgi.00482.2005
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Broderick P, 2007, NAT GENET, V39, P1315, DOI 10.1038/ng.2007.18
   de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Haiman CA, 2007, NAT GENET, V39, P954, DOI 10.1038/ng2098
   Hardwick JCH, 2004, GASTROENTEROLOGY, V126, P111, DOI 10.1053/j.gastro.2003.10.067
   He J, 2011, CANCER EPIDEM BIOMAR, V20, P70, DOI 10.1158/1055-9965.EPI-10-0892
   He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ho JW, 2011, BRIT J CANCER, V104, P369, DOI 10.1038/sj.bjc.6605977
   Houlston RS, 2010, NAT GENET, V42, P973, DOI 10.1038/ng.670
   Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262
   Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919
   Jaeger E, 2008, NAT GENET, V40, P26, DOI 10.1038/ng.2007.41
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kupfer SS, 2010, GASTROENTEROLOGY, V139, P1677, DOI 10.1053/j.gastro.2010.07.038
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mullen B, 2001, PERS SOC PSYCHOL B, V27, P1450, DOI 10.1177/01461672012711006
   Niittymaki I, 2010, CANCER EPIDEM BIOMAR, V19, P1478, DOI 10.1158/1055-9965.EPI-09-1320
   Pabalan NA, 2010, ASIAN PAC J CANCER P, V11, P33
   Park JH, 2011, P NATL ACAD SCI USA, V108, P18026, DOI 10.1073/pnas.1114759108
   Qiu L, 2008, EUR J CANCER, V44, P2241, DOI 10.1016/j.ejca.2008.06.024
   Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133
   Tenesa A, 2009, NAT REV GENET, V10, P353, DOI 10.1038/nrg2574
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187
   Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085
   Tomlinson IPM, 2008, NAT GENET, V40, P623, DOI 10.1038/ng.111
   Tomlinson IPM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002105
   von Holst S, 2010, BRIT J CANCER, V103, P575, DOI 10.1038/sj.bjc.6605774
   Xiong F, 2010, CANCER EPIDEM BIOMAR, V19, P1855, DOI 10.1158/1055-9965.EPI-10-0210
   Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089
   Zhong H, 2010, GENET EPIDEMIOL, V34, P78, DOI 10.1002/gepi.20437
NR 38
TC 7
Z9 8
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 11
PY 2012
VL 7
IS 4
AR e34625
DI 10.1371/journal.pone.0034625
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959TP
UT WOS:000305336600042
PM 22509336
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, SJ
   Kong, CJ
   Wu, J
   Ying, H
   Zhu, HZ
AF Liu, SiJie
   Kong, ChuiJin
   Wu, Jie
   Ying, Hao
   Zhu, HuanZhang
TI Effect of CCR5-Delta 32 Heterozygosity on HIV-1 Susceptibility: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTION; CCR5; TRANSMISSION;
   INDIVIDUALS; PROGRESSION; AIDS; RESISTANCE; DETERMINANTS; GENOTYPES
AB Background: So far, many studies have investigated the distribution of CCR5 genotype between HIV-1 infected patients and uninfected people. However, no definite results have been put forward about whether heterozygosity for a 32-basepair deletion in CCR5 gene (CCR5-Delta 32) can affect HIV-1 susceptibility.
   Methods: We performed a meta-analysis of 18 studies including more than 12000 subjects for whom the CCR5-Delta 32 polymorphism was genotyped. Odds ratio (OR) with 95% confidence interval (CI) were employed to assess the association of CCR5-Delta 32 polymorphism with HIV-1 susceptibility.
   Results: Compared with the wild-type CCR5 homozygotes, the pooled OR for CCR5-Delta 32 heterozygotes was 1.02 (95% CI, 0.88-1.19) for healthy controls (HC) and 0.95 (95% CI, 0.71-1.26) for exposed uninfected (EU) controls. Similar results were found in stratified analysis by ethnicity, sample size and method of CCR5-Delta 32 genotyping.
   Conclusions: The meta-analysis indicated that HIV-1 susceptibility is not significantly affected by heterozygosity for CCR5-Delta 32.
C1 [Liu, SiJie; Kong, ChuiJin; Wu, Jie; Ying, Hao; Zhu, HuanZhang] Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
RP Liu, SJ (reprint author), Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
EM hzzhu@fudan.edu.cn
FU National Grand Program on Key Infectious Disease [2012ZX10001-003];
   National Natural Science Funding of China [31171247]
FX This work is supported by National Grand Program on Key Infectious
   Disease (2012ZX10001-003), National Natural Science Funding of China
   (No.31171247). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Allers K, 2011, BLOOD, V117, P2791, DOI 10.1182/blood-2010-09-309591
   Battiloro E, 2000, AIDS RES HUM RETROV, V16, P181, DOI 10.1089/088922200309520
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cochran WG, 1954, BIOMETRICS, V10, P9
   Contopoulos-Ioannidis DG, 2003, JAIDS-J ACQ IMM DEF, V32, P70, DOI 10.1097/00126334-200301010-00010
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Deng XL, 2004, CHIN J EPIDEMIOL, V25, P050
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Diaz FJ, 2000, MEM I OSWALDO CRUZ, V95, P237, DOI 10.1590/S0074-02762000000200018
   Downer MV, 2002, GENES IMMUN, V3, P295, DOI 10.1038/sj.gene.6363884
   Egger M, 1997, BMJ-BRIT MED J, V315, P29
   Ghaffari G, 2005, J VIROL, V79, P13250, DOI 10.1128/JVI.79.21.13250-13261.2005
   Grimaldi R, 2002, HUM GENET, V111, P102, DOI 10.1007/s00439-002-0747-x
   Hladik F, 2005, J VIROL, V79, P11677, DOI 10.1128/JVI.79.18.11677-11684.2005
   Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905
   Husman AD, 1999, J IMMUNOL, V163, P4597
   Ioannidis JPA, 2001, ANN INTERN MED, V135, P782, DOI 10.7326/0003-4819-135-9-200111060-00008
   Isaacman-Beck J, 2009, J VIROL, V83, P8208, DOI 10.1128/JVI.00296-09
   Kaur G, 2009, TISSUE ANTIGENS, V73, P289, DOI 10.1111/j.1399-0039.2009.01220.x
   Li GH, 2003, CHIN J MICROBIOL IMM, V23, P65
   Liu H, 2004, J INFECT DIS, V190, P055
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Lockett SF, 1999, J INFECT DIS, V180, P614, DOI 10.1086/314918
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marmor M, 2001, J ACQ IMMUN DEF SYND, V27, P472
   O'Brien SJ, 2004, NAT GENET, V36, P565, DOI 10.1038/ng1369
   O'Brien SJ, 2000, IMMUNOL REV, V177, P99, DOI 10.1034/j.1600-065X.2000.17710.x
   Oh DY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002747
   Papa A, 2000, FEMS IMMUNOL MED MIC, V28, P87, DOI 10.1016/S0928-8244(00)00137-1
   Pasi KJ, 2000, BRIT J HAEMATOL, V111, P136, DOI 10.1046/j.1365-2141.2000.02325.x
   Paz-y-Mino C, 2005, HUM BIOL, V77, P521, DOI 10.1353/hub.2005.0068
   Philpott S, 2003, J INFECT DIS, V187, P569, DOI 10.1086/367995
   SCHUITEMAKER H, 1991, J VIROL, V65, P356
   Schuitemaker H, 2009, J TRANSL MED S1, pS5
   Takacova M, 2008, ACTA VIROL, V52, P261
   Tan XH, 2010, INFECT GENET EVOL, V10, P268, DOI 10.1016/j.meegid.2009.11.015
   Tang H, 2010, J SHIHEZI U NATURAL, V28, P98
   Trecarichi Enrico M, 2006, AIDS Res Ther, V3, P22, DOI 10.1186/1742-6405-3-22
   Veloso S, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-63
   Wang FS, 2003, J ACQ IMMUN DEF SYND, V32, P24
   Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681
NR 41
TC 12
Z9 12
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2012
VL 7
IS 4
AR e35020
DI 10.1371/journal.pone.0035020
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 953GO
UT WOS:000304855200094
PM 22496885
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Nie, W
   Li, B
   Xiu, QY
AF Nie, Wei
   Li, Bing
   Xiu, Qing-yu
TI The-675 4G/5G Polymorphism in Plasminogen Activator Inhibitor-1 Gene Is
   Associated with Risk of Asthma: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID PAI-1; EXPRESSION; MODEL; BIAS
AB Background: A number of studies assessed the association of -675 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor (PAI)-1 gene with asthma in different populations. However, most studies reported inconclusive results. A meta-analysis was conducted to investigate the association between polymorphism in the PAI-1 gene and asthma susceptibility.
   Methods: Databases including Pubmed, EMBASE, HuGE Literature Finder, Wanfang Database, China National Knowledge Infrastructure (CNKI) and Weipu Database were searched to find relevant studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association in the dominant model, recessive model, codominant model, and additive model.
   Results: Eight studies involving 1817 cases and 2327 controls were included. Overall, significant association between 4G/5G polymorphism and asthma susceptibility was observed for 4G4G + 4G5G vs. 5G5G (OR = 1.56, 95% CI 1.12-2.18, P = 0.008), 4G/4G vs. 4G/5G + 5G/5G (OR = 1.38, 95% CI 1.06-1.80, P = 0.02), 4G/4G vs. 5G/5G (OR = 1.80, 95% CI 1.17-2.76, P = 0.007), 4G/5G vs. 5G/5G (OR = 1.40, 95% CI 1.07-1.84, P = 0.02), and 4G vs. 5G (OR = 1.35, 95% CI 1.08-1.68, P = 0.008).
   Conclusions: This meta-analysis suggested that the -675 4G/5G polymorphism of PAI-1 gene was a risk factor of asthma.
C1 [Nie, Wei; Li, Bing; Xiu, Qing-yu] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Resp Dis, Shanghai, Peoples R China.
RP Nie, W (reprint author), Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Resp Dis, Shanghai, Peoples R China.
EM xiu_qingyu@126.com
FU National Natural Science Foundation of China [81170025]
FX This study was supported by grants NO. 81170025 from National Natural
   Science Foundation of China. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Buckova D, 2002, ALLERGY, V57, P446
   Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P212, DOI 10.1067/mai.2001.117260
   Cosan D, 2009, GENET TEST MOL BIOMA, V13, P543, DOI 10.1089/gtmb.2009.0036
   Dijkstra A, 2011, EUR RESPIR J, V38, P1036, DOI 10.1183/09031936.00182410
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851
   Festa A, 2003, CIRCULATION, V107, P2422, DOI 10.1161/01.CIR.0000066908.82782.3A
   Hizawa N, 2006, CLIN EXP ALLERGY, V36, P872, DOI 10.1111/j.1365-2222.2006.02413.x
   Kelly MM, 2005, AM J RESP CELL MOL, V32, P99, DOI 10.1165/rcmb.2004-0190OC
   Koppelman GH, 2006, CURR ALLERGY ASTHM R, V6, P103, DOI 10.1007/s11882-006-0047-y
   Kowal K, 2008, J INVEST ALLERG CLIN, V18, P284
   Kowal K, 2007, INT ARCH ALLERGY IMM, V144, P240, DOI 10.1159/000103998
   Ma Z, 2009, CLIN EXP ALLERGY, V39, P1136, DOI 10.1111/j.1365-2222.2009.03272.x
   Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x
   Mukherjee AB, 2011, J BIOL CHEM, V286, P32883, DOI 10.1074/jbc.R110.197046
   Murphy DM, 2010, CHEST, V137, P1417, DOI 10.1378/chest.09-1895
   Oh CK, 2002, BIOCHEM BIOPH RES CO, V294, P1155, DOI 10.1016/S0006-291X(02)00577-6
   Ozbek OY, 2009, ALLERGY ASTHMA PROC, V30, P41, DOI 10.2500/aap.2009.30.3183
   Pampuch A, 2006, ALLERGY, V61, P234, DOI 10.1111/j.1398-9995.2005.00948.x
   Salanti G, 2005, GENET MED, V7, P13, DOI 10.1097/01.GIM.0000151839.12032.1A
   Savov JD, 2003, AM J PHYSIOL-LUNG C, V285, pL940, DOI 10.1152/ajplung.00102.2003
   Sejima T, 2005, J IMMUNOL, V174, P8135, DOI 10.4049/jimmunol.174.12.8135
   Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190
   Zhang XP, 2009, INFLAMMATION, V32, P1, DOI 10.1007/s10753-008-9096-9
NR 25
TC 13
Z9 13
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 27
PY 2012
VL 7
IS 3
AR e34385
DI 10.1371/journal.pone.0034385
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 940MY
UT WOS:000303894900088
PM 22479620
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Song, QB
   Zhu, BB
   Hu, WG
   Cheng, LM
   Gong, HY
   Xu, B
   Zheng, XW
   Zou, L
   Zhong, R
   Duan, SY
   Chen, W
   Rui, R
   Wu, J
   Miao, XP
AF Song, Qibin
   Zhu, Beibei
   Hu, Weiguo
   Cheng, Liming
   Gong, Hongyun
   Xu, Bin
   Zheng, Xiawen
   Zou, Li
   Zhong, Rong
   Duan, Shengyu
   Chen, Wei
   Rui, Rui
   Wu, Jing
   Miao, Xiaoping
TI A Common SMAD7 Variant Is Associated with Risk of Colorectal Cancer:
   Evidence from a Case-Control Study and a Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GENETIC-VARIANTS; SUSCEPTIBILITY LOCI;
   COLON-CANCER; 18Q21; SCAN; 8Q24; ALLELES; BIAS
AB Background: A common genetic variant, rs4939827, located in SMAD7, was identified by two recent genome-wide association (GWA) studies to be strongly associated with the risk of colorectal cancer (CRC). However, the following replication studies yielded conflicting results.
   Method and Findings: We conducted a case-control study of 641 cases and 1037 controls in a Chinese population and then performed a meta-analysis, integrating our and published data of 34313 cases and 33251 controls, to clarify the relationship between rs4939827 and CRC risk. In our case-control study, the dominant model was significant associated with increased CRC risk [Odds Ratio (OR) = 1.46; 95% confidence interval (95% CI), 1.19-1.80]. The following meta-analysis further confirmed this significant association for all genetic models but with significant between-study heterogeneity (all P for heterogeneity <0.1). By stratified analysis, we revealed that ethnicity, sample size, and tumor sites might constitute the source of heterogeneity. The cumulative analysis suggested that evident tendency to significant association was seen with adding study samples over time; whilst, sensitive analysis showed results before and after removal of each study were similar, indicating the highly stability of the current results.
   Conclusion: Results from our case-control study and the meta-analysis collectively confirmed the significant association of the variant rs4939827 with increased risk of colorectal cancer. Nevertheless, fine-mapping of the susceptibility loci defined by rs4939287 should be imposed to reveal causal variant.
C1 [Song, Qibin; Zhu, Beibei; Hu, Weiguo; Gong, Hongyun; Xu, Bin] Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan 430072, Peoples R China.
   [Zhu, Beibei; Zheng, Xiawen; Zou, Li; Zhong, Rong; Duan, Shengyu; Chen, Wei; Rui, Rui; Wu, Jing; Miao, Xiaoping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430074, Peoples R China.
   [Zhu, Beibei; Zheng, Xiawen; Zou, Li; Zhong, Rong; Duan, Shengyu; Chen, Wei; Rui, Rui; Wu, Jing; Miao, Xiaoping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, MOE Key Lab Environm & Hlth, Wuhan 430074, Peoples R China.
   [Cheng, Liming] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Lab Med, Wuhan 430074, Peoples R China.
RP Song, QB (reprint author), Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan 430072, Peoples R China.
EM miaoxp@mail.hust.edu.cn
RI miao, xiaoping/C-4336-2011; Zhong, Rong/Q-1813-2019
OI miao, xiaoping/0000-0002-6818-9722; 
FU National Natural Science Foundation of China [NSFC-81001275, 81171878];
   Fok Ying Tung Foundation for Young Teachers in the Higher Education
   Institutions of China [131038]; HUST [2011QN200]
FX This work was supported by the National Natural Science Foundation of
   China NSFC-81001275 and 81171878 and the Fok Ying Tung Foundation for
   Young Teachers in the Higher Education Institutions of China (131038) to
   X.M. and the fundamental research funds for the central universities
   (HUST: NO. 2011QN200) to J.W. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Broderick P, 2007, NAT GENET, V39, P1315, DOI 10.1038/ng.2007.18
   Cui R, 2011, GUT
   Curtin K, 2009, CANCER EPIDEM BIOMAR, V18, P616, DOI 10.1158/1055-9965.EPI-08-0690
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Haiman CA, 2007, NAT GENET, V39, P954, DOI 10.1038/ng2098
   Halder SK, 2008, BRIT J CANCER, V99, P957, DOI 10.1038/sj.bjc.6604562
   He J, 2010, CANCER EPIDEM BIOMAR, V20, P70
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Ho JW, 2011, BRIT J CANCER, V104, P369, DOI 10.1038/sj.bjc.6605977
   Houlston RS, 2010, NAT GENET, V42, P973, DOI 10.1038/ng.670
   Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262
   Jaeger E, 2008, NAT GENET, V40, P26, DOI 10.1038/ng.2007.41
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Li X, 2011, MOL BIOL REPORTS
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Loh YH, 2010, CANC EPIDEMIOLOGY
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mates IN, 2010, CHIRURGIA-BUCHAREST, V105, P749
   Mochizuki T, 2004, J BIOL CHEM, V279, P31568, DOI 10.1074/jbc.M313977200
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Mullen B, 2001, PERS SOC PSYCHOL B, V27, P1450, DOI 10.1177/01461672012711006
   Niittymaki I, 2010, CANCER EPIDEM BIOMAR, V19, P1478, DOI 10.1158/1055-9965.EPI-09-1320
   Pabalan NA, 2010, ASIAN PAC J CANCER P, V11, P33
   Pittman AM, 2009, GENOME RES, V19, P987, DOI 10.1101/gr.092668.109
   Slattery ML, 2010, CANCER RES, V70, P1479, DOI 10.1158/0008-5472.CAN-08-1792
   Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thompson CL, 2009, CARCINOGENESIS, V30, P982, DOI 10.1093/carcin/bgp086
   Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085
   Tomlinson IPM, 2008, NAT GENET, V40, P623, DOI 10.1038/ng.111
   von Holst S, 2010, BRIT J CANCER, V103, P575, DOI 10.1038/sj.bjc.6605774
   Xiong F, 2010, CANCER EPIDEM BIOMAR, V19, P1855, DOI 10.1158/1055-9965.EPI-10-0210
   Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089
NR 37
TC 17
Z9 17
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 21
PY 2012
VL 7
IS 3
AR e33318
DI 10.1371/journal.pone.0033318
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 939YN
UT WOS:000303857100028
PM 22457752
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Wang, J
   Zou, ZH
   Xia, HL
   He, JX
   Zhong, NS
   Tao, AL
AF Wang, Juan
   Zou, Ze-Hong
   Xia, Hong-Lin
   He, Jian-Xing
   Zhong, Nan-Shan
   Tao, Ai-Lin
TI Strengths and Weaknesses of Immunotherapy for Advanced Non-Small-Cell
   Lung Cancer: A Meta-Analysis of 12 Randomized Controlled Trials
SO PLOS ONE
LA English
DT Article
ID ACTIVE SPECIFIC IMMUNOTHERAPY; INDUCED KILLER-CELLS; PHASE-II TRIAL;
   CHEMOTHERAPY; VACCINE; CETUXIMAB; THERAPY; QUALITY; INTERLEUKIN-2;
   CISPLATIN
AB Background: Lung cancer is one of the leading causes of cancer death worldwide. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Immunotherapy has yielded no consistent benefit to date for those patients. Assessing the objective efficacy and safety of immunotherapy for advanced NSCLC patients will help to instruct the future development of immunotherapeutic drugs.
   Methodology and Principal Findings: We performed a meta-analysis of 12 randomized controlled trials including 3134 patients (1570 patients in the immunotherapy group and 1564 patients in the control group) with histologically confirmed stage IIIA, IIIB, or IV NSCLC. The analysis was executed with efficacy end points regarding overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), and total effective rate. Overall unstratified OS, PFS, PR, and total effective rate were significantly improved in advanced NSCLC patients in the immunotherapy group (P = 0.0007, 0.0004, 0.002, 0.003, respectively), whereas CR was not improved (P = 0.97). Subgroup analysis showed that monoclonal antibody (mAb) immunotherapy significantly improved the PFS, PR, and total effective rate and showed a trend of improving OS of advanced NSCLC patients compared with the control group, with one kind of adverse event being significantly dominant. Compared with the control group, the vaccine subgroup showed no significant difference with regard to serious adverse events, whereas cytokine immunotherapy significantly induced three kinds of serious adverse events.
   Conclusions: Immunotherapy works efficiently on advanced NSCLC patients. Of several immunotherapies, mAb therapy may be a potential immunotherapy for advanced NSCLC patients, and become a standard complementary therapeutic approach in the future if the issues concerning toxicity and allergenicity of mAbs have been overcome.
C1 [Wang, Juan; Zou, Ze-Hong; Xia, Hong-Lin; He, Jian-Xing; Zhong, Nan-Shan; Tao, Ai-Lin] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou Municipal Key Lab Allergy & Clin Immuno, Allergy Res Branch,State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China.
RP Wang, J (reprint author), Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou Municipal Key Lab Allergy & Clin Immuno, Allergy Res Branch,State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China.
EM taoailin@gzhmc.edu.cn
RI Tao, Ailin/V-2751-2017
OI Tao, Ailin/0000-0002-0584-921X
FU Guangdong Provincial Natural Science Foundation [8251018201000002];
   National Natural Science Foundation of China [30640033, 30771240]
FX This work was supported by Key Program from Guangdong Provincial Natural
   Science Foundation (8251018201000002) and Programs from National Natural
   Science Foundation of China (No.30640033, No.30771240). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bettauer RH, 2011, ALTEX-ALTERN ANIM EX, V28, P103, DOI 10.14573/altex.2011.2.103
   Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528
   Butts C, 2005, J CLIN ONCOL, V23, P6674, DOI 10.1200/JCO.2005.13.011
   Chrischilles EA, 2010, J CLIN ONCOL, V28, P620, DOI 10.1200/JCO.2009.23.8485
   Clark HD, 1999, CONTROL CLIN TRIALS, V20, P448, DOI 10.1016/S0197-2456(99)00026-4
   COX DR, 1972, J R STAT SOC B, V34, P187
   Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032
   Gadgeel SM, 2011, CURR ONCOL REP, V13, P272, DOI 10.1007/s11912-011-0170-3
   Garcia B, 2008, CLIN CANCER RES, V14, P840, DOI 10.1158/1078-0432.CCR-07-1050
   Gatzemeier U, 2004, ANN ONCOL, V15, P19, DOI 10.1093/annonc/mdh031
   Gridelli C, 2009, ONCOLOGIST, V14, P909, DOI 10.1634/theoncologist.2009-0017
   Hamada C, 2005, J CLIN ONCOL, V23, P4999, DOI 10.1200/JCO.2005.09.017
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holt Gregory E, 2011, Therapy, V8, P43, DOI 10.2217/thy.10.84
   Huncharek M, 2000, J CLIN EPIDEMIOL, V53, P676, DOI 10.1016/S0895-4356(99)00203-6
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kakimi K, 2009, LUNG CANCER, V65, P1, DOI 10.1016/j.lungcan.2008.10.018
   Lasalvia-Prisco E, 2008, BIOL-TARGETS THER, V2, P555
   Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022
   LISSONI P, 1994, TUMORI, V80, P464, DOI 10.1177/030089169408000611
   Lynch TJ, 2010, J CLIN ONCOL, V28, P911, DOI 10.1200/JCO.2009.21.9618
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Morgensztern D, 2010, J THORAC ONCOL, V5, pS463, DOI 10.1097/01.JTO.0000391367.63882.79
   Nemunaitis J, 2006, CANCER GENE THER, V13, P555, DOI 10.1038/sj.cgt.7700922
   Nemunaitis J, 2009, CANCER GENE THER, V16, P620, DOI 10.1038/cgt.2009.15
   Vinageras EN, 2008, J CLIN ONCOL, V26, P1452, DOI 10.1200/JCO.2007.11.5980
   O'Brien MER, 2004, ANN ONCOL, V15, P906, DOI 10.1093/annonc/mdh220
   Palmer M, 2001, Clin Lung Cancer, V3, P49, DOI 10.3816/CLC.2001.n.018
   Perroud MW, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-65
   Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9
   Raez LE, 2004, J CLIN ONCOL, V22, P2800, DOI 10.1200/JCO.2004.10.197
   Rao BQ, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-17
   Ridolfi L, 2011, INT J ONCOL, V39, P1011, DOI 10.3892/ijo.2011.1099
   Rosell R, 2008, ANN ONCOL, V19, P362, DOI 10.1093/annonc/mdm474
   STRAND LM, 1990, DICP ANN PHARMAC, V24, P1093, DOI 10.1177/106002809002401114
   Sun X, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c117
   Thatcher N, 2010, ONCOLOGIST, V15, P1034, DOI 10.1634/theoncologist.2009-0292
   Wu CP, 2008, ANTICANCER RES, V28, P3997
   Wu SW, 2011, CANCER INVEST, V29, P460, DOI 10.3109/07357907.2011.597815
   Yasumoto K, 2009, GEN THORAC CARDIOVAS, V57, P449, DOI 10.1007/s11748-008-0433-6
   Zhong RB, 2011, CANCER IMMUNOL IMMUN, V60, P1497, DOI 10.1007/s00262-011-1060-0
NR 43
TC 10
Z9 15
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 5
PY 2012
VL 7
IS 3
AR e32695
DI 10.1371/journal.pone.0032695
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 928WA
UT WOS:000303017700096
PM 22403699
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Drogan, D
   Sheldrick, AJ
   Schutze, M
   Knuppel, S
   Andersohn, F
   Di Giuseppe, R
   Herrmann, B
   Willich, SN
   Garbe, E
   Bergmann, MM
   Boeing, H
   Weikert, C
AF Drogan, Dagmar
   Sheldrick, Abigail J.
   Schuetze, Madlen
   Knueppel, Sven
   Andersohn, Frank
   Di Giuseppe, Romina
   Herrmann, Bianca
   Willich, Stefan N.
   Garbe, Edeltraut
   Bergmann, Manuela M.
   Boeing, Heiner
   Weikert, Cornelia
TI Alcohol Consumption, Genetic Variants in Alcohol Deydrogenases, and Risk
   of Cardiovascular Diseases: A Prospective Study and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; DEHYDROGENASE GENOTYPES;
   RELATIVE VALIDITY; DRINKING HABITS; EPIC PROJECT; GERMAN PART;
   CASE-COHORT; STROKE; REPRODUCIBILITY
AB Objective: First, to investigate and compare associations between alcohol consumption and variants in alcohol dehydrogenase (ADH) genes with incidence of cardiovascular diseases (CVD) in a large German cohort. Second, to quantitatively summarize available evidence of prospective studies on polymorphisms in ADH1B and ADH1C and CVD-risk.
   Methods: We conducted a case-cohort study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort including a randomly drawn subcohort (n = 2175) and incident cases of myocardial infarction (MI; n = 230) or stroke (n = 208). Mean follow-up time was 8.2 +/- 2.2 years. The association between alcohol consumption, ADH1B or ADH1C genotypes, and CVD-risk was assessed using Cox proportional hazards regression. Additionally, we report results on associations of variants in ADH1B and ADH1C with ischemic heart disease and stroke in the context of a meta-analysis of previously published prospective studies published up to November 2011.
   Results: Compared to individuals who drank >0 to 6 g alcohol/d, we observed a reduced risk of MI among females consuming >12 g alcohol/d (HR = 0.31; 95% CI: 0.10-0.97) and among males consuming >24 to 60 g/d (HR = 0.57; 95% CI: 0.33-0.98) or >60 g alcohol/d (HR = 0.30; 95% CI: 0.12-0.78). Stroke risk was not significantly related to alcohol consumption >6 g/d, but we observed an increased risk of stroke in men reporting no alcohol consumption. Individuals with the slow-coding ADH1B*1/1 genotype reported higher median alcohol consumption. Yet, polymorphisms in ADH1B or ADH1C were not significantly associated with risk of CVD in our data and after pooling results of eligible prospective studies [ADH1B*1/1: RR = 1.35 (95% CI: 0.98-1.88; p for heterogeneity: 0.364); ADH1C*2/2: RR = 1.07 (95% CI: 0.90-1.27; p for heterogeneity: 0.098)].
   Conclusion: The well described association between alcohol consumption and CVD-risk is not reflected by ADH polymorphisms, which modify the rate of ethanol oxidation.
C1 [Drogan, Dagmar; Schuetze, Madlen; Knueppel, Sven; Di Giuseppe, Romina; Herrmann, Bianca; Bergmann, Manuela M.; Boeing, Heiner; Weikert, Cornelia] German Inst Human Nutr Potsdam Rehbrucke, Dept Epidemiol, Nuthetal, Germany.
   [Sheldrick, Abigail J.] Charite Univ Med Ctr, Inst Clin Pharmacol & Toxicol, Berlin, Germany.
   [Andersohn, Frank; Willich, Stefan N.; Weikert, Cornelia] Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany.
   [Garbe, Edeltraut] Bremen Inst Prevent Res & Social Med, Dept Clin Epidemiol, Bremen, Germany.
   [Sheldrick, Abigail J.] Rhein Westfal TH Aachen, Sch Med, Dept Psychiat Psychotherapy & Psychosomat, Aachen, Germany.
   [Herrmann, Bianca] Fed Inst Mat Res & Testing, Dept Biol Mat Protect & Environm Issues 4 1, Berlin, Germany.
RP Drogan, D (reprint author), German Inst Human Nutr Potsdam Rehbrucke, Dept Epidemiol, Nuthetal, Germany.
EM drogan@dife.de
FU Federal Ministry of Science, Germany [01 EA 9401]; European Union [SOC
   95201408 05F02]; German Cancer Aid [70-2488-Ha I]; European Community
   [SOC 98200769 05F02]
FX The recruitment phase of the EPIC-Potsdam Study was supported by the
   Federal Ministry of Science, Germany (01 EA 9401), and the European
   Union (SOC 95201408 05F02). The follow-up was supported by the German
   Cancer Aid (70-2488-Ha I) and the European Community (SOC 98200769
   05F02). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bergmann MM, 1999, ANN NUTR METAB, V43, P225, DOI 10.1159/000012789
   Boeing H, 1999, ANN NUTR METAB, V43, P205, DOI 10.1159/000012787
   BohlscheidThomas S, 1997, INT J EPIDEMIOL, V26, pS71, DOI 10.1093/ije/26.suppl_1.S71
   BohlscheidThomas S, 1997, INT J EPIDEMIOL, V26, pS59, DOI 10.1093/ije/26.suppl_1.S59
   Brien SE, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d636
   Chen L, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050052
   Corrao G, 2004, PREV MED, V38, P613, DOI 10.1016/j.ypmed.2003.11.027
   Corrao G, 2000, ADDICTION, V95, P1505, DOI 10.1046/j.1360-0443.2000.951015056.x
   Davey Smith G, 2008, ANN MED, V40, P524, DOI 10.1080/07853890802010709
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Djousse L, 2005, AM J CARDIOL, V96, P227, DOI 10.1016/j.amjcard.2005.03.050
   Djousse L, 2009, CIRCULATION, V120, P237, DOI 10.1161/CIRCULATIONAHA.108.832360
   Ebrahim S, 2008, ATHEROSCLEROSIS, V196, P871, DOI 10.1016/j.atherosclerosis.2007.02.002
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   EHRIG T, 1990, ALCOHOL ALCOHOLISM, V25, P105, DOI 10.1093/oxfordjournals.alcalc.a044985
   Greenland S, 2008, MODERN EPIDEMIOLOGY, V3, P238
   Hashibe M, 2006, CANCER EPIDEM BIOMAR, V15, P696, DOI 10.1158/1055-9965.EPl-05-0/10
   Heidrich J, 2007, EUR J CARDIOV PREV R, V14, P769, DOI 10.1097/HJR.0b013e328270b924
   Hines LM, 2001, NEW ENGL J MED, V344, P549, DOI 10.1056/NEJM200102223440802
   HOOG JO, 1986, EUR J BIOCHEM, V159, P215, DOI 10.1111/j.1432-1033.1986.tb09855.x
   Jia CQ, 2007, THROMB RES, V120, P679, DOI 10.1016/j.thromres.2006.12.023
   Kim MY, 2006, BIOMETRICS, V62, P929, DOI 10.1111/j.1541-0420.2006.00639.x
   Kroke A, 1999, ANN NUTR METAB, V43, P216, DOI 10.1159/000012788
   Lee SL, 2004, PHARMACOGENETICS, V14, P725, DOI 10.1097/00008571-200411000-00003
   Lewis SJ, 2005, CANCER EPIDEM BIOMAR, V14, P1967, DOI 10.1158/1055-9965.EPI-05-0196
   Macgregor S, 2009, HUM MOL GENET, V18, P580, DOI 10.1093/hmg/ddn372
   Patra J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-258
   PRENTICE RL, 1986, BIOMETRIKA, V73, P1
   Roerecke M, 2011, AM J EPIDEMIOL, V173, P245, DOI 10.1093/aje/kwq364
   Ronksley PE, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d671
   Schutze M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1584
   Schwarzer G, 2011, METAANALYSIS R
   Suzuki Y, 2004, NEUROLOGY, V63, P1711, DOI 10.1212/01.WNL.0000142971.08275.DB
   Tolstrup JS, 2010, SCAND J PUBLIC HEALT, V38, P489, DOI 10.1177/1403494810371248
   Tolstrup JS, 2009, CIRC-CARDIOVASC GENE, V2, P507, DOI 10.1161/CIRCGENETICS.109.873604
   Tolstrup JS, 2008, PHARMACOGENOMICS J, V8, P220, DOI 10.1038/sj.tpj.6500471
   Weikert C, 2007, J NEUROL, V254, P315, DOI 10.1007/s00415-006-0358-x
   Weikert C, 2008, CIRCULATION, V118, P2555, DOI 10.1161/CIRCULATIONAHA.108.814418
   Younis J, 2005, ATHEROSCLEROSIS, V180, P225, DOI 10.1016/j.athersclerosis.2004.12.010
   Zee RYL, 2004, STROKE, V35, pE39, DOI 10.1161/01.STR.0000114202.86942.61
   Zhang GH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013679
NR 42
TC 17
Z9 17
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 21
PY 2012
VL 7
IS 2
AR e32176
DI 10.1371/journal.pone.0032176
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 926ZM
UT WOS:000302873700151
PM 22363810
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Zang, JJ
   Wu, SQ
   Tang, L
   Xu, XD
   Bai, J
   Ding, CC
   Chang, Y
   Yue, L
   Kang, EM
   He, J
AF Zang, Jiajie
   Wu, Shunquan
   Tang, Lei
   Xu, Xudong
   Bai, Jie
   Ding, Caicui
   Chang, Yue
   Yue, Long
   Kang, Enming
   He, Jia
TI Incidence and Risk of QTc Interval Prolongation among Cancer Patients
   Treated with Vandetanib: A Systematic Review and Meta-analysis
SO PLOS ONE
LA English
DT Review
ID CELL LUNG-CANCER; RANDOMIZED PHASE-II; CLINICAL-TRIALS; DOUBLE-BLIND;
   THYROID-HORMONE; ZD6474; HYPOTHYROIDISM; INHIBITOR; ONCOLOGY; THERAPY
AB Background: Vandetanib is a multikinase inhibitor that is under assessment for the treatment of various cancers. QTc interval prolongation is one of the major adverse effects of this drug, but the reported incidence varies substantially among clinical trials. We performed a systematic review and meta-analysis to obtain a better understanding in the risk of QTc interval prolongation among cancer patients administered vandetanib.
   Methodology and Principal Findings: Eligible studies were phase II and III prospective clinical trials that involved cancer patients who were prescribed vandetanib 300 mg/d and that included data on QTc interval prolongation. The overall incidence and risk of QTc interval prolongation were calculated using random-effects or fixed-effects models, depending on the heterogeneity of the included studies. Nine trials with 2,188 patients were included for the meta-analysis. The overall incidence of all-grade and high-grade QTc interval prolongation was 16.4% (95% CI, 8.1-30.4%) and 3.7% (8.1-30.4%), respectively, among non-thyroid cancer patients, and 18.0% (10.7-28.6%) and 12.0% (4.5-28.0%), respectively, among thyroid cancer patients. Patients with thyroid cancer who had longer treatment duration also had a higher incidence of high-grade events, with a relative risk of 3.24 (1.57-6.71), than patients who had non-thyroid cancer. Vandetanib was associated with a significantly increased risk of all-grade QTc interval prolongation with overall Peto odds ratios of 7.26 (4.36-12.09) and 5.70 (3.09-10.53) among patients with non-thyroid cancer and thyroid cancer, respectively, compared to the controls.
   Conclusions/Significance: Treatment with vandetanib is associated with a significant increase in the overall incidence and risk of QTc interval prolongation. Different cancer types and treatment durations may affect the risk of developing high-grade QTc interval prolongation.
C1 [Zang, Jiajie; Wu, Shunquan; Tang, Lei; He, Jia] Second Mil Med Univ, Dept Hlth Stat, Shanghai, Peoples R China.
   [Zang, Jiajie; Wu, Shunquan; Tang, Lei; He, Jia] Second Mil Med Univ, Ctr Evidence Based Med, Shanghai, Peoples R China.
   [Xu, Xudong] Second Mil Med Univ, Changhai Hosp, Dept Cardiol, Shanghai, Peoples R China.
   [Bai, Jie] Second Mil Med Univ, Changhai Hosp, Dept Geriatr, Shanghai, Peoples R China.
   [Ding, Caicui] Peking Univ, Lib Hosp 1, Beijing 100871, Peoples R China.
   [Chang, Yue; Yue, Long; Kang, Enming] Second Mil Med Univ, Changhai Hosp, Dept Endocrinol, Shanghai, Peoples R China.
RP Zang, JJ (reprint author), Second Mil Med Univ, Dept Hlth Stat, Shanghai, Peoples R China.
EM hejia63@yahoo.com
OI Zang, Jiajie/0000-0003-2476-2176
FU National Nature Science Foundation of China [30872186, 81072388];
   Leading Talents of Science in Shanghai [022]; Program of Shanghai
   Subject Chief Scientist [09XD1405500]; Chinese Academy of Sciences, Stem
   Cell and Regenerative Medicine Research [XDA01040104]
FX This study was supported by two grants from the National Nature Science
   Foundation of China (30872186, 81072388), a grant from the Leading
   Talents of Science in Shanghai 2010 (022), a grant sponsored by the
   Program of Shanghai Subject Chief Scientist (09XD1405500), and a
   "Strategic Priority Research Program" of the Chinese Academy of
   Sciences, Stem Cell and Regenerative Medicine Research (XDA01040104).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR [Anonymous], 2011, FDA APPROVES NEW TRE
   Arnold AM, 2007, J CLIN ONCOL, V25, P4278, DOI 10.1200/JCO.2007.12.3083
   Bakiner O, 2008, MED PRIN PRACT, V17, P390, DOI 10.1159/000141503
   Barbey JT, 2003, J CLIN ONCOL, V21, P3609, DOI 10.1200/JCO.2003.10.009
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Brell JM, 2010, PROG CARDIOVASC DIS, V53, P164, DOI 10.1016/j.pcad.2010.05.005
   Carlomagno F, 2002, CANCER RES, V62, P7284
   Colzani RM, 2001, CLIN ENDOCRINOL, V55, P27, DOI 10.1046/j.1365-2265.2001.01295.x
   CROWLEY WF, 1977, NEW ENGL J MED, V296, P1, DOI 10.1056/NEJM197701062960101
   Danzi S, 2004, Minerva Endocrinol, V29, P139
   de Boer RH, 2011, J CLIN ONCOL, V29, P1067, DOI 10.1200/JCO.2010.29.5717
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fazio S, 2004, RECENT PROG HORM RES, V59, P31, DOI 10.1210/rp.59.1.31
   Floyd JD, 2005, J CLIN ONCOL, V23, P7685, DOI 10.1200/JCO.2005.08.789
   Gillen MS, 2001, BRIT J CLIN PHARMACO, V52, P201, DOI 10.1046/j.0306-5251.2001.01345.x
   Herbst RS, 2010, LANCET ONCOL, V11, P619, DOI 10.1016/S1470-2045(10)70132-7
   Heymach JV, 2008, J CLIN ONCOL, V26, P5407, DOI 10.1200/JCO.2008.17.3138
   Higgins J., 2011, ANAL DATA UNDERTAKIN
   Horti J, 2009, CANCER BIOTHER RADIO, V24, P175, DOI 10.1089/cbr.2008.0588
   Hsu C, ESMO MULT C 2009
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kiura K, 2008, J THORAC ONCOL, V3, P386, DOI 10.1097/JTO.0b013e318168d228
   Leboulleux S, ESMO C OCT 2010
   Miller KD, 2005, CLIN CANCER RES, V11, P3369, DOI 10.1158/1078-0432.CCR-04-1923
   Natale RB, 2011, J CLIN ONCOL, V29, P1059, DOI 10.1200/JCO.2010.28.5981
   Natale RB, 2009, J CLIN ONCOL, V27, P2523, DOI 10.1200/JCO.2008.18.6015
   National Cancer Institute, CTC V 2 0 COMM TERM
   Ojamaa K, 1999, ENDOCRINOLOGY, V140, P3170, DOI 10.1210/en.140.7.3170
   Priori SG, 2003, NEW ENGL J MED, V348, P1866, DOI 10.1056/NEJMoa022147
   Strevel EL, 2007, J CLIN ONCOL, V25, P3362, DOI 10.1200/JCO.2006.09.6925
   van Noord C, 2008, J ENDOCRINOL, V198, P253, DOI 10.1677/JOE-08-0140
   Varterasian M, 2003, J CLIN ONCOL, V21, P3378, DOI 10.1200/JCO.2003.99.104
   Viskin S, 2003, PROG CARDIOVASC DIS, V45, P415, DOI 10.1053/pcad.2003.00101
   Wedge SR, 2002, CANCER RES, V62, P4645
   Wells SA, ESMO C OCT 2010
   Wells SA, 2010, J CLIN ONCOL, V28, P767, DOI 10.1200/JCO.2009.23.6604
   Woodward M, EPIDEMIOLOGY DESIGN
   Yang TS, 2009, J CLIN ONCOL S, V27, p15s
NR 38
TC 43
Z9 43
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 17
PY 2012
VL 7
IS 2
AR e30353
DI 10.1371/journal.pone.0030353
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 926TC
UT WOS:000302853600021
PM 22363427
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Brown, JC
   Huedo-Medina, TB
   Pescatello, LS
   Ryan, SM
   Pescatello, SM
   Moker, E
   LaCroix, JM
   Ferrer, RA
   Johnson, BT
AF Brown, Justin C.
   Huedo-Medina, Tania B.
   Pescatello, Linda S.
   Ryan, Stacey M.
   Pescatello, Shannon M.
   Moker, Emily
   LaCroix, Jessica M.
   Ferrer, Rebecca A.
   Johnson, Blair T.
TI The Efficacy of Exercise in Reducing Depressive Symptoms among Cancer
   Survivors: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; POPULATION-BASED COHORT;
   BREAST-CANCER; PHYSICAL-ACTIVITY; REHABILITATION PROGRAM; ADJUVANT
   CHEMOTHERAPY; AEROBIC EXERCISE; PUBLICATION BIAS; META-REGRESSION
AB Introduction: The purpose of this meta-analysis was to examine the efficacy of exercise to reduce depressive symptoms among cancer survivors. In addition, we examined the extent to which exercise dose and clinical characteristics of cancer survivors influence the relationship between exercise and reductions in depressive symptoms.
   Methods: We conducted a systematic search identifying randomized controlled trials of exercise interventions among adult cancer survivors, examining depressive symptoms as an outcome. We calculated effect sizes for each study and performed weighted multiple regression moderator analysis.
   Results: We identified 40 exercise interventions including 2,929 cancer survivors. Diverse groups of cancer survivors were examined in seven exercise interventions; breast cancer survivors were examined in 26; prostate cancer, leukemia, and lymphoma were examined in two; and colorectal cancer in one. Cancer survivors who completed an exercise intervention reduced depression more than controls, d(+) = 20.13 (95% CI: -0.26, -0.01). Increases in weekly volume of aerobic exercise reduced depressive symptoms in dose-response fashion (beta = -0.24, p = 0.03), a pattern evident only in higher quality trials. Exercise reduced depressive symptoms most when exercise sessions were supervised (beta = -0.26, p = 0.01) and when cancer survivors were between 47-62 yr (beta = 0.27, p = 0.01).
   Conclusion: Exercise training provides a small overall reduction in depressive symptoms among cancer survivors but one that increased in dose-response fashion with weekly volume of aerobic exercise in high quality trials. Depressive symptoms were reduced to the greatest degree among breast cancer survivors, among cancer survivors aged between 47-62 yr, or when exercise sessions were supervised.
C1 [Brown, Justin C.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
   [Brown, Justin C.] Univ Penn, Perelman Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA.
   [Huedo-Medina, Tania B.; Pescatello, Linda S.; Moker, Emily; LaCroix, Jessica M.; Johnson, Blair T.] Univ Connecticut, Ctr Hlth Intervent & Prevent, Storrs, CT USA.
   [Ryan, Stacey M.] Univ Texas MD Anderson Canc Ctr, Dept Phys Therapy, Houston, TX 77030 USA.
   [Pescatello, Shannon M.] Western New England Coll, Dept Psychol, Springfield, MA USA.
   [Ferrer, Rebecca A.] NCI, Rockville, MD USA.
RP Brown, JC (reprint author), Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
EM brownjus@mail.med.upenn.edu
RI Brown, Jennifer Valeska Elli/C-6947-2019
OI Brown, Jennifer Valeska Elli/0000-0003-0943-5177
FU University of Connecticut Research Advisory Council Foundation [433527]
FX Funding was provided by the University of Connecticut Research Advisory
   Council Foundation grant no. 433527 (PIs: Blair T. Johnson and Linda S.
   Pescatello). The funder had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009
   Becker B.J., 2000, HDB APPL MULTIVARIAT, P499, DOI DOI 10.1016/B978-012691360-6/50018-5
   BECKER BJ, 1988, BRIT J MATH STAT PSY, V41, P257, DOI 10.1111/j.2044-8317.1988.tb00901.x
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERGLUND G, 1994, EUR J CANCER, V30A, P1744, DOI 10.1016/0959-8049(94)00330-8
   Brosse AL, 2002, SPORTS MED, V32, P741, DOI 10.2165/00007256-200232120-00001
   Brown JC, 2011, CANCER EPIDEM BIOMAR, V20, P123, DOI 10.1158/1055-9965.EPI-10-0988
   Burnham TR, 2002, MED SCI SPORT EXER, V34, P1863, DOI 10.1249/01.MSS.0000040995.26076.CC
   Cadmus LA, 2009, PSYCHO-ONCOLOGY, V18, P343, DOI 10.1002/pon.1525
   Chandwani Kavita D, 2010, J Soc Integr Oncol, V8, P43
   Chang PH, 2008, J PAIN SYMPTOM MANAG, V35, P524, DOI 10.1016/j.jpainsymman.2007.06.013
   Clark AM, 2010, EUR J CARDIOV PREV R, V17, P261, DOI 10.1097/HJR.0b013e32833090ef
   Cohen J, 1998, STAT POWER ANAL BEHA
   Cohen L, 2004, CANCER-AM CANCER SOC, V100, P2253, DOI 10.1002/cncr.20236
   Conn VS, 2010, ANN BEHAV MED, V39, P128, DOI 10.1007/s12160-010-9172-x
   Courneya KS, 2007, J CLIN ONCOL, V25, P4396, DOI 10.1200/JCO.2006.08.2024
   Courneya KS, 2009, J CLIN ONCOL, V27, P4605, DOI 10.1200/JCO.2008.20.0634
   Courneya KS, 2003, EUR J CANCER CARE, V12, P347, DOI 10.1046/j.1365-2354.2003.00437.x
   Courneya KS, 2003, PSYCHO-ONCOLOGY, V12, P357, DOI 10.1002/pon.658
   Coventry PA, 2007, J PSYCHOSOM RES, V63, P551, DOI 10.1016/j.jpsychores.2007.08.002
   Craft L, 2011, CANC EPIDEMIOL BIOMA
   Culos-Reed SN, 2006, PSYCHO-ONCOLOGY, V15, P891, DOI 10.1002/pon.1021
   Culos-Reed SN, 2010, SUPPORT CARE CANCER, V18, P591, DOI 10.1007/s00520-009-0694-3
   Daley AJ, 2007, J CLIN ONCOL, V25, P1713, DOI 10.1200/JCO.2006.09.5083
   Danhauer SC, 2009, PSYCHO-ONCOL, V18, P360, DOI 10.1002/pon.1503
   Demark-Wahnefried W, 2008, CLIN BREAST CANCER, V8, P70, DOI 10.3816/CBC.2008.n.005
   Dimeo FC, 1999, CANCER, V85, P2273, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2273::AID-CNCR24>3.0.CO;2-B
   Dodd MJ, 2010, CANCER NURS, V33, P245, DOI 10.1097/NCC.0b013e3181ddc58c
   Drown JS, 2005, REHABIL ONCOL, V23, P11, DOI 10.1097/01893697-200523010-00004
   Duijts SFA, 2011, PSYCHO-ONCOLOGY, V20, P115, DOI 10.1002/pon.1728
   Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003
   Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eyigor S, 2010, EUR J PHYS REHAB MED, V46, P481
   Ferrer RA, 2011, ANN BEHAV MED, V41, P32, DOI 10.1007/s12160-010-9225-1
   GILBAR O, 1989, J PSYCHOSOM RES, V33, P1, DOI 10.1016/0022-3999(89)90100-1
   Greenwood BN, 2011, EXERC SPORT SCI REV, V39, P140, DOI 10.1097/JES.0b013e31821f7e45
   Harbord RM, 2008, STATA J, V8, P493, DOI 10.1177/1536867X0800800403
   Hedges LV, 1985, STAT METHODS METAANA, P369
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holland JC, 2010, J NATL COMPR CANC NE, V8, P448, DOI 10.6004/jnccn.2010.0034
   Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193
   Jarden M, 2009, J PAIN SYMPTOM MANAG, V38, P174, DOI 10.1016/j.jpainsymman.2008.09.005
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Johnson BT, 2011, RES SYN METHOD
   Jones LW, 2010, LANCET ONCOL, V11, P914, DOI 10.1016/S1470-2045(10)70184-4
   Kelly CM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c693
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617
   Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202
   Latka RN, 2009, J CANCER SURVIV, V3, P148, DOI 10.1007/s11764-009-0088-z
   LEBOVITS AH, 1990, CANCER, V65, P17, DOI 10.1002/1097-0142(19900101)65:1<17::AID-CNCR2820650106>3.0.CO;2-I
   Lee SA, 2010, CLIN REHABIL, V24, P600, DOI 10.1177/0269215510362324
   LIPSEY MW, 2001, PRACTICAL METAANALYS, P247
   Maher CG, 2003, PHYS THER, V83, P713
   Mao JJ, 2007, J AM BOARD FAM MED, V20, P434, DOI 10.3122/jabfm.2007.05.060225
   McClure MK, 2010, AM J OCCUP THER, V64, P59, DOI 10.5014/ajot.64.1.59
   Mock V, 1994, Oncol Nurs Forum, V21, P899
   Mock V, 1997, Oncol Nurs Forum, V24, P991
   Mock V, 1994, ONCOL NURS FORUM, V21, P908
   Monga U, 2007, ARCH PHYS MED REHAB, V88, P1416, DOI 10.1016/j.apmr.2007.08.110
   MOR V, 1994, CANCER-AM CANCER SOC, V74, P2118, DOI 10.1002/1097-0142(19941001)74:7+<2118::AID-CNCR2820741720>3.0.CO;2-N
   Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105
   Mutrie N, 2007, BRIT MED J, V334, P517, DOI 10.1136/bmj.39094.648553.AE
   Newport DJ, 1998, J PSYCHOSOM RES, V45, P215, DOI 10.1016/S0022-3999(98)00011-7
   North T C, 1990, Exerc Sport Sci Rev, V18, P379
   O'Brien K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001796.pub3
   Ohira T, 2006, CANCER-AM CANCER SOC, V106, P2076, DOI 10.1002/cncr.21829
   Papakostas GI, 2008, J CLIN PSYCHIAT, V69, P1287, DOI 10.4088/JCP.v69n0812
   Pasquini Massimo, 2007, Clin Pract Epidemiol Ment Health, V3, P2, DOI 10.1186/1745-0179-3-2
   Patel S. V., 2004, THESIS
   Payne JK, 2008, ONCOL NURS FORUM, V35, P635, DOI 10.1188/08.ONF.635-642
   Perna FM, 2010, INT J SPORT EXERC PS, V8, P36, DOI 10.1080/1612197X.2010.9671932
   Pinto BM, 2003, PSYCHO-ONCOL, V12, P118, DOI 10.1002/pon.618
   Raghavendra RM, 2009, INTEGR CANCER THER, V8, P37, DOI 10.1177/1534735409331456
   Rausch SM, 2007, THESIS
   REDDON JR, 1985, J PSYCHOPATHOL BEHAV, V7, P243, DOI 10.1007/BF00960756
   Reich M, 2008, BREAST CANCER RES TR, V110, P9, DOI 10.1007/s10549-007-9706-5
   Salkind M R, 1969, J R Coll Gen Pract, V18, P267
   Schmitz KH, 2010, MED SCI SPORT EXER, V42, P1409, DOI 10.1249/MSS.0b013e3181e0c112
   Speck RM, 2010, J CANCER SURVIV, V4, P87, DOI 10.1007/s11764-009-0110-5
   Spence RR, 2011, EUR J CANCER CARE, V20, P257, DOI 10.1111/j.1365-2354.2010.01214.x
   SUTHERLAND HJ, 1988, CANCER NURS, V11, P303
   Targ EF, 2002, GEN HOSP PSYCHIAT, V24, P238, DOI 10.1016/S0163-8343(02)00191-3
   Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187
   THOMPSON WR, ACSMS GUIDELINES EXE
   Thorsen L, 2005, J CLIN ONCOL, V23, P2378, DOI 10.1200/JCO.2005.04.106
   Velthuis MJ, 2010, CLIN ONCOL-UK, V22, P208, DOI 10.1016/j.clon.2009.12.005
   Vito NL, 2007, THESIS
   Watson M, 1999, LANCET, V354, P1331, DOI 10.1016/S0140-6736(98)11392-2
   Whitehead S, 2009, QUAL HEALTH RES, V19, P894, DOI 10.1177/1049732309337523
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 91
TC 148
Z9 151
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 27
PY 2012
VL 7
IS 1
AR e30955
DI 10.1371/journal.pone.0030955
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 911GB
UT WOS:000301704200049
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Guo, J
   Jin, MJ
   Zhang, MW
   Chen, K
AF Guo, Jing
   Jin, Mingjuan
   Zhang, Mingwu
   Chen, Kun
TI A Genetic Variant in miR-196a2 Increased Digestive System Cancer Risks:
   A Meta-Analysis of 15 Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; NORTH INDIAN POPULATION; PUBLICATION BIAS;
   HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; MICRORNA GENES;
   GASTRIC-CANCER; BREAST-CANCER; PRE-MICRORNAS; SUSCEPTIBILITY
AB Background: MicroRNAs (miRNAs) negatively regulate the gene expression and act as tumor suppressors or oncogenes in oncogenesis. The association between single nucleotide polymorphism (SNP) in miR-196a2 rs11614913 and the susceptibility of digestive system cancers was inconsistent in previous studies.
   Methodology/Principal Findings: An updated meta-analysis based on 15 independent case-control studies consisting of 4999 cancer patients and 7606 controls was performed to address this association. It was found that miR-196a2 polymorphism significantly elevated the risks of digestive system cancers (CT vs. TT, OR=1.25, 95% CI=1.07-1.45; CC vs. TT, OR=1.38, 95% CI=1.13-1.67; CC/CT vs. TT, OR=1.29, 95% CI=1.10-1.50; CC vs. CT/TT, OR=1.14, 95% CI=1.01-1.30; C vs. T, OR=1.15, 95% CI=1.05-1.26). We also found that variant in miR-196a2 increased the susceptibility of colorectal cancer (CRC) (CT vs. TT, OR=1.23, 95% CI=1.04-1.44; CC vs. TT, OR=1.32, 95% CI=1.08-1.61; CC/CT vs. TT, OR=1.25, 95% CI=1.07-1.46; C vs. T, OR=1.15, 95% CI=1.05-1.28), while the association in recessive model (CC vs. CT/TT, OR=1.16, 95% CI=0.98-1.38) showed a marginal significance. Additionally, significant association between miR-196a2 polymorphism and increased risk of hepatocellular cancer (HCC) was detected. By stratifying tumors on the basis of site of origin, source of controls, ethnicity and allele frequency in controls, elevated cancer risks were observed.
   Conclusion/Significance: Our findings suggest the significant association between miR-196a2 polymorphism and increased susceptibility of digestive system cancers, especially of CRC, HCC and Asians. Besides, C allele may contribute to increased digestive cancer risks.
C1 [Guo, Jing; Jin, Mingjuan; Zhang, Mingwu; Chen, Kun] Zhejiang Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Hangzhou 310003, Zhejiang, Peoples R China.
RP Guo, J (reprint author), Zhejiang Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Hangzhou 310003, Zhejiang, Peoples R China.
EM ck@zju.edu.cn
FU National Natural Science Foundation of China [81072356]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81072356). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akkiz H, 2011, J VIRAL HEPATITIS, V18, pE399, DOI 10.1111/j.1365-2893.2010.01414.x
   Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Camargo MC, 2006, CANCER EPIDEM BIOMAR, V15, P1674, DOI 10.1158/1055-9965.EPI-06-0189
   Carthew RW, 2006, CURR OPIN GENET DEV, V16, P203, DOI 10.1016/j.gde.2006.02.012
   Chen H, 2011, INTERN MED J
   Chen KX, 2008, CARCINOGENESIS, V29, P1306, DOI 10.1093/carcin/bgn116
   Christensen BC, 2010, CLIN CANCER RES, V16, P3713, DOI 10.1158/1078-0432.CCR-10-0657
   Chu HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018108
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dick DM, 2011, ANNU REV CLIN PSYCHO, V7, P383, DOI 10.1146/annurev-clinpsy-032210-104518
   Dou TH, 2010, J CANCER RES CLIN, V136, P1853, DOI 10.1007/s00432-010-0844-5
   Gao LB, 2011, BREAST CANCER RES TR, V125, P827, DOI 10.1007/s10549-010-0995-8
   Gao LB, 2011, BREAST CANCER RES TR, V125, P571, DOI 10.1007/s10549-010-0993-x
   Gao LB, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-117
   George GP, 2011, MOL BIOL REP, V38, P1609, DOI 10.1007/s11033-010-0270-4
   Hayashino Y, 2005, J EPIDEMIOL, V15, P235, DOI 10.2188/jea.15.235
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hong Young-Seoub, 2011, J Prev Med Public Health, V44, P125, DOI 10.3961/jpmph.2011.44.3.125
   Hu ZB, 2008, J CLIN INVEST, V118, P2600, DOI 10.1172/JCI34934
   Hu ZB, 2009, HUM MUTAT, V30, P79, DOI 10.1002/humu.20837
   Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913
   Landi D, 2008, CARCINOGENESIS, V29, P579, DOI 10.1093/carcin/bgm304
   Li XD, 2010, PATHOLOGY, V42, P669, DOI 10.3109/00313025.2010.522175
   Liu ZS, 2010, CANCER-AM CANCER SOC, V116, P4753, DOI 10.1002/cncr.25323
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Okubo M, 2010, HELICOBACTER, V15, P524, DOI 10.1111/j.1523-5378.2010.00806.x
   Peng S, 2010, DIGEST DIS SCI, V55, P2288, DOI 10.1007/s10620-009-1007-x
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107
   Qi P, 2010, HUM IMMUNOL, V71, P621, DOI 10.1016/j.humimm.2010.02.017
   Srivastava K, 2010, J HUM GENET, V55, P495, DOI 10.1038/jhg.2010.54
   Tapia T, 2008, BREAST CANCER RES TR, V107, P281, DOI 10.1007/s10549-007-9544-5
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Tian T, 2010, INT J MOL EPIDEMIOL, V1, P358
   Wallace TA, 2011, CARCINOGENESIS, V32, P1107, DOI 10.1093/carcin/bgr066
   Wang F, 2011, MOL BIOL REP
   Wang K, 2010, BIOMARKERS, V15, P614, DOI 10.3109/1354750X.2010.505299
   Xu W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020471
   Yu ZB, 2007, NUCLEIC ACIDS RES, V35, P4535, DOI 10.1093/nar/gkm480
   Zhan JF, 2011, ARCH MED RES, V42, P144, DOI 10.1016/j.arcmed.2011.04.001
   Zhu L, 2011, DNA CELL BIOL
NR 44
TC 75
Z9 77
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 24
PY 2012
VL 7
IS 1
AR e30585
DI 10.1371/journal.pone.0030585
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 910LV
UT WOS:000301639600034
PM 22291993
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yu, HP
   Liu, HL
   Wang, LE
   Wei, QY
AF Yu, Hongping
   Liu, Hongliang
   Wang, Li-E
   Wei, Qingyi
TI A Functional NQO1 609C > T Polymorphism and Risk of Gastrointestinal
   Cancers: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; OXIDOREDUCTASE 1 NQO1; DT-DIAPHORASE ACTIVITY;
   ENDOSCOPY-BASED POPULATION; SQUAMOUS-CELL CARCINOMA; COLORECTAL-CANCER;
   NAD(P)H-QUINONE OXIDOREDUCTASE; C609T POLYMORPHISM; GASTRIC-CANCER;
   HEPATOCELLULAR-CARCINOMA
AB Background: The functional polymorphism (rs1800566) in the NQO1 gene, a 609C>T substitution, leading to proline-toserine amino-acid and enzyme activity changes, has been implicated in cancer risk, but individually published studies showed inconclusive results.
   Methodology/Principal Findings: We performed a meta-analysis of 20 publications with a total of 5,491 cases and 5,917 controls, mainly on gastrointestinal (GI) cancers. We summarized the data on the association between the NQO1 609C>T polymorphism and risk of GI cancers and performed subgroup analyses by ethnicity, cancer site, and study quality. We found that the variant CT heterozygous and CT/TT genotypes of the NQO1 609 C>T polymorphism were associated with a modestly increased risk of GI cancers (CT vs. CC; OR = 1.10, 95% CI = 1.01 - 1.19, P-heterogeneity = 0.27, I-2 = 0.15; CT/TT vs. CC: OR = 1.11, 95% CI = 1.02-1.20, P-heterogeneity = 0.14; I-2 = 0.27). Following further stratified analyses, the increased risk was only observed in subgroups of Caucasians, colorectal cancer in Caucasians, and high quality studies.
   Conclusions: This meta-analysis suggests that the NQO1 609T allele is a low-penetrance risk factor for GI cancers. Although the effect on GI cancers may be modified by ethnicity and cancer sites, small sample seizes of the subgroup analyses suggest that further larger studies are needed, especially for non-colorectal GI cancers in Caucasians and GI cancers in Asians.
C1 [Yu, Hongping; Liu, Hongliang; Wang, Li-E; Wei, Qingyi] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
RP Yu, HP (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
EM hyu1@mdanderson.org; qwei@mdanderson.org
RI Liu, Hongliang/P-3444-2014
OI Liu, Hongliang/0000-0001-7639-0904
FU National Institutes of Health [R01ES011740, R01CA131274]
FX This work was supported in part by National Institutes of Health grants
   R01ES011740 and R01CA131274 (Qingyi Wei). Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the National Institutes of Health. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript. No additional external funding
   received for this study.
CR Akkiz H, 2010, ASIAN PAC J CANCER P, V11, P1051
   Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052726799
   Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905
   Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499
   Awadallah NS, 2008, APPL IMMUNOHISTO M M, V16, P24
   Baglietto L, 2006, J CLIN EPIDEMIOL, V59, P114, DOI 10.1016/j.jclinepi.2005.07.018
   Bartsch H, 1998, EUR J CANCER PREV, V7, P215, DOI 10.1097/00008469-199806000-00006
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Begleiter A, 2006, CANCER EPIDEM BIOMAR, V15, P2422, DOI 10.1158/1055-9965.EPI-06-0661
   BELINSKY M, 1993, CANCER METAST REV, V12, P103, DOI 10.1007/BF00689804
   Bouchard MJ, 2011, CANCER LETT, V305, P123, DOI 10.1016/j.canlet.2010.11.014
   Chao C, 2006, CANCER EPIDEM BIOMAR, V15, P979, DOI 10.1158/1055-9965.EPI-05-0899
   Chiu MM, 2009, HISTOL HISTOPATHOL, V24, P1223, DOI 10.14670/HH-24.1223
   Compare D, 2010, EUR REV MED PHARMACO, V14, P302
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Di Luzio R, 2010, EUR REV MED PHARMACO, V14, P277
   di Martino E, 2007, GENET MED, V9, P341, DOI 10.1097/GIM.0b013e3180654ccd
   Dinkova-Kostova AT, 2010, ARCH BIOCHEM BIOPHYS, V501, P116, DOI 10.1016/j.abb.2010.03.019
   Dragani TA, 2010, J HEPATOL, V52, P252, DOI 10.1016/j.jhep.2009.11.015
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Goto Yasuyuki, 2005, Gastric Cancer, V8, P12, DOI 10.1007/s10120-004-0308-1
   Grady WM, 2003, GASTROENTEROLOGY, V124, P1574, DOI 10.1016/S0016-5085(03)00376-7
   Haerian MS, 2011, J GASTROEN HEPATOL, V26, P1475, DOI 10.1111/j.1440-1746.2011.06831.x
   Hamajima Nobuyuki, 2002, Int J Clin Oncol, V7, P103
   Hamajima N, 2006, CANCER SCI, V97, P1129, DOI 10.1111/j.1349-7006.2006.00290.x
   Harth V, 2000, ARCH TOXICOL, V73, P528, DOI 10.1007/s002040050004
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hlavata I, 2010, ONCOL REP, V24, P1347, DOI 10.3892/or_0000992
   Hou LF, 2005, CARCINOGENESIS, V26, P1122, DOI 10.1093/carcin/bgi054
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Johns LE, 2001, AM J GASTROENTEROL, V96, P2992, DOI 10.1016/S0002-9270(01)03239-7
   Kelsey KT, 1997, BRIT J CANCER, V76, P852, DOI 10.1038/bjc.1997.474
   Key TJ, 2011, BRIT J CANCER, V104, P6, DOI 10.1038/sj.bjc.6606032
   KUEHL BL, 1995, BRIT J CANCER, V72, P555, DOI 10.1038/bjc.1995.373
   Lafuente MJ, 2000, CARCINOGENESIS, V21, P1813, DOI 10.1093/carcin/21.10.1813
   Landi S, 2005, PHARMACOGENET GENOM, V15, P535, DOI 10.1097/01.fpc.0000165904.48994.3d
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Le Marchand L, 2009, SURG ONCOL CLIN N AM, V18, P663, DOI 10.1016/j.soc.2009.07.004
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Long DJ, 2000, CANCER RES, V60, P5913
   Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166
   Lyn-Cook BD, 2006, CELL BIOL TOXICOL, V22, P73, DOI 10.1007/s10565-006-0156-3
   Malik MA, 2011, DNA CELL BIOL, V30, P297, DOI 10.1089/dna.2010.1115
   MALKINSON AM, 1992, CANCER RES, V52, P4752
   Marin A, 1997, BRIT J CANCER, V76, P923, DOI 10.1038/bjc.1997.485
   Marjani HA, 2010, GENET MOL RES, V9, P239, DOI 10.4238/vol9-1gmr693
   Menon R, 2011, GASTROENTEROL CLIN N, V40, P427, DOI 10.1016/j.gtc.2011.03.002
   Milosavljevic T, 2010, EUR REV MED PHARMACO, V14, P259
   Misra V, 1998, BRIT J CANCER, V77, P1236, DOI 10.1038/bjc.1998.208
   Mitrou P, 2002, IARC Sci Publ, V156, P495
   Mitrou PN, 2007, CARCINOGENESIS, V28, P875, DOI 10.1093/carcin/bgl194
   Mohelnikova-Duchonova B, 2011, PANCREAS, V40, P72, DOI 10.1097/MPA.0b013e3181f74ad7
   Moran JL, 1999, P NATL ACAD SCI USA, V96, P8150, DOI 10.1073/pnas.96.14.8150
   Nioi P, 2004, MUTAT RES-FUND MOL M, V555, P149, DOI 10.1016/j.mrfmmm.2004.05.023
   Nisa H, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-274
   Piazuelo MB, 2010, INFECT DIS CLIN N AM, V24, P853, DOI 10.1016/j.idc.2010.07.010
   Randi G, 2010, NUTR REV, V68, P389, DOI 10.1111/j.1753-4887.2010.00299.x
   Rauth AM, 1997, ONCOL RES, V9, P339
   Ross D, 2004, DRUG METAB REV, V36, P639, DOI 10.1081/DMR-200033465
   Ross D, 2004, METHOD ENZYMOL, V382, P115
   Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X
   ROSVOLD EA, 1995, PHARMACOGENETICS, V5, P199, DOI 10.1097/00008571-199508000-00003
   Sachse C, 2002, CARCINOGENESIS, V23, P1839, DOI 10.1093/carcin/23.11.1839
   Sameer AS, 2010, ASIAN PAC J CANCER P, V11, P209
   Sarbia M, 2003, INT J CANCER, V107, P381, DOI 10.1002/ijc.11430
   SCHLAGER JJ, 1990, INT J CANCER, V45, P403, DOI 10.1002/ijc.2910450304
   Siegel D, 1999, PHARMACOGENETICS, V9, P113, DOI 10.1097/00008571-199902000-00015
   Siegel D, 2001, MOL PHARMACOL, V59, P263
   Siegel D, 2004, MOL PHARMACOL, V65, P1238, DOI 10.1124/mol.65.5.1238
   Sieger D, 2000, FREE RADICAL BIO MED, V29, P246, DOI 10.1016/S0891-5849(00)00310-5
   Takagi S, 2002, ANTICANCER RES, V22, P2749
   Thakkinstian A, 2004, J BONE MINER RES, V19, P419, DOI 10.1359/JBMR.0301265
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Tijhuis MJ, 2008, NUTR CANCER, V60, P204, DOI 10.1080/01635580701684849
   Tijhuis MJ, 2008, INT J CANCER, V122, P1842, DOI 10.1002/ijc.23246
   Tomlinson IPM, 2008, NAT GENET, V40, P623, DOI 10.1038/ng.111
   Traver RD, 1997, BRIT J CANCER, V75, P69, DOI 10.1038/bjc.1997.11
   TRAVER RD, 1992, CANCER RES, V52, P797
   Tsvetkov P, 2010, CELL DEATH DIFFER, V17, P103, DOI 10.1038/cdd.2009.67
   Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057
   van der Logt EMJ, 2006, MUTAT RES-FUND MOL M, V593, P39, DOI 10.1016/j.mrfmmm.2005.06.018
   von Rahden BHA, 2005, INT J CANCER, V113, P506, DOI 10.1002/ijc.20576
   Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075
   Wang LD, 2010, NAT GENET, V42, P759, DOI 10.1038/ng.648
   Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10
   Yaghoobi M, 2010, BRIT J CANCER, V102, P237, DOI 10.1038/sj.bjc.6605380
   Zhang HX, 2010, NAT GENET, V42, P755, DOI 10.1038/ng.638
   Zhang JH, 2003, WORLD J GASTROENTERO, V9, P1390, DOI 10.3748/wjg.v9.i7.1390
   Zhang JH, 2003, CARCINOGENESIS, V24, P905, DOI 10.1093/carcin/bgg019
NR 89
TC 16
Z9 16
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 17
PY 2012
VL 7
IS 1
AR e30566
DI 10.1371/journal.pone.0030566
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 907XU
UT WOS:000301454400139
PM 22272361
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Gupta, A
   Nadkarni, G
   Yang, WT
   Chandrasekhar, A
   Gupte, N
   Bisson, GP
   Hosseinipour, M
   Gummadi, N
AF Gupta, Amita
   Nadkarni, Girish
   Yang, Wei-Teng
   Chandrasekhar, Aditya
   Gupte, Nikhil
   Bisson, Gregory P.
   Hosseinipour, Mina
   Gummadi, Naveen
TI Early Mortality in Adults Initiating Antiretroviral Therapy (ART) in
   Low- and Middle-Income Countries (LMIC): A Systematic Review and
   Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID HIV-INFECTED PATIENTS; RAPID SCALE-UP; RESOURCE-LIMITED SETTINGS;
   SUB-SAHARAN AFRICA; SOUTH-AFRICA; HIV-1-INFECTED PATIENTS; 1ST YEAR;
   OBSERVATIONAL COHORT; TREATMENT PROGRAM; CLINICAL-TRIALS
AB Background: We systematically reviewed observational studies of early mortality post-antiretroviral therapy (ART) initiation in low- and middle-income countries (LMIC) in Asia, Africa, and Central and South America, as defined by the World Bank, to summarize what is known.
   Methods and Findings: Studies published in English between January 1996 and December 2010 were searched in Medline and EMBASE. Three independent reviewers examined studies of mortality within one year post-ART. An article was included if the study was conducted in a LMIC, participants were initiating ART in a non-clinical trial setting and were >= 15 years. Fifty studies were included; 38 (76%) from sub-Saharan Africa (SSA), 5 (10%) from Asia, 2 (4%) from the Americas, and 5 (10%) were multi-regional. Median follow-up time and pre-ART CD4 cell count ranged from 3-55 months and 11-192 cells/mm(3), respectively. Loss-to-follow-up, reported in 40 (80%) studies, ranged from 0.3%-27%. Overall, SSA had the highest pooled 12-month mortality probability of 0.17 (95% CI 0.11-0.24) versus 0.11 (95% CI 0.10-0.13) for Asia, and 0.07 (95% CI 0.007-0.20) for the Americas. Of 14 (28%) studies reporting cause-specific mortality, tuberculosis (TB) (5%-44%), wasting (5%-53%), advanced HIV (20%-37%), and chronic diarrhea (10%-25%) were most common. Independent factors associated with early mortality in 30 (60%) studies included: low baseline CD4 cell count, male sex, advanced World Health Organization clinical stage, low body mass index, anemia, age greater than 40 years, and pre-ART quantitative HIV RNA.
   Conclusions: Significant heterogeneity in outcomes and in methods of reporting outcomes exist among published studies evaluating mortality in the first year after ART initiation in LMIC. Early mortality rates are highest in SSA, and opportunistic illnesses such as TB and wasting syndrome are the most common reported causes of death. Strategies addressing modifiable risk factors associated with early death are urgently needed.
C1 [Gupta, Amita; Yang, Wei-Teng; Chandrasekhar, Aditya; Gupte, Nikhil; Gummadi, Naveen] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
   [Gupta, Amita; Nadkarni, Girish] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Gupte, Nikhil] Byramjee Jeejeebhoy Med Coll, Johns Hopkins Clin Trial Unit, Pune, Maharashtra, India.
   [Bisson, Gregory P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
   [Hosseinipour, Mina] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
RP Gupta, A (reprint author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
EM agupta25@jhmi.edu
FU National Institutes of Health [R01 AI080417]
FX Funding for this project was provided by National Institutes of Health
   Grant R01 AI080417 awarded to Dr. Gupta. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abaasa AM, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-241
   Alemu AW, 2010, GLOBAL HEALTH ACTION, V3, DOI 10.3402/gha.v3i0.5398
   Alibhai A, 2010, IN J WOMENS HEALTH, V2, P45
   Banda AC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001445
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bekker LG, 2006, SAMJ S AFR MED J, V96, P315
   Bisson GP, 2008, JAIDS-J ACQ IMM DEF, V49, P227, DOI 10.1097/QAI.0b013e318183181e
   Blanco JR, 2010, AIDS REV, V12, P218
   Boulle A, 2008, B WORLD HEALTH ORGAN, V86, P678, DOI 10.2471/BLT.07.045294
   Bourgeois A, 2005, ANTIVIR THER, V10, P335
   Braitstein P, 2006, LANCET, V367, P817
   Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248
   Bussmann H, 2008, AIDS, V22, P2303, DOI 10.1097/QAD.0b013e3283129db0
   Calmy A, 2006, AIDS, V20, P1163, DOI 10.1097/01.aids.0000226957.79847.d6
   Chasombat S, 2009, JAIDS-J ACQ IMM DEF, V50, P506, DOI 10.1097/QAI.0b013e3181967602
   Coetzee D, 2004, AIDS, V18, P887, DOI [10.1097/01.aids.0000125925.87797.38, 10.1097/00002030-200406003-00006]
   Corey DM, 2007, JAIDS-J ACQ IMM DEF, V44, P451, DOI 10.1097/QAI.0b013e31802f8512
   De Beaudrap P, 2008, EUR J EPIDEMIOL, V23, P227, DOI 10.1007/s10654-007-9221-3
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Djomand G, 2003, AIDS, V17, pS5, DOI 10.1097/00002030-200317003-00002
   Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01
   Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2
   Ferradini L, 2007, AIDS, V21, P2293, DOI 10.1097/QAD.0b013e32828cc8b7
   Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hoffmann CJ, 2008, AIDS, V22, P67, DOI 10.1097/QAD.0b013e3282f2306e
   Jerene D, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-136
   Johannessen A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-52
   Karcher H, 2007, TROP MED INT HEALTH, V12, P687, DOI 10.1111/j.1365-3156.2007.01830.x
   Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252
   Kumarasamy N, 2008, J WOMENS HEALTH, V17, P1471, DOI 10.1089/jwh.2007.0670
   Laurent C, 2008, AIDS RES HUM RETROV, V24, P393, DOI 10.1089/aid.2007.0219
   Lawn SD, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-59
   Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd
   Lawn SD, 2010, CURR OPIN HIV AIDS, V5, P18, DOI 10.1097/COH.0b013e328333850f
   Libamba E, 2006, B WORLD HEALTH ORGAN, V84, P320, DOI 10.2471/BLT.05.023952
   Lowrance D, 2007, JAIDS-J ACQ IMM DEF, V46, P56
   MacPherson P, 2009, T ROY SOC TROP MED H, V103, P588, DOI 10.1016/j.trstmh.2008.10.001
   Madec Y, 2007, AIDS, V21, P351, DOI 10.1097/QAD.0b013e328012c54f
   Makombe SD, 2007, INT J TUBERC LUNG D, V11, P412
   Makombe SD, 2007, B WORLD HEALTH ORGAN, V85, P851
   Marazzi MC, 2008, AIDS RES HUM RETROV, V24, P555, DOI 10.1089/aid.2007.0217
   Morineau G, 2009, AIDS PATIENT CARE ST, V23, P669, DOI 10.1089/apc.2008.0241
   Mulenga LB, 2008, AIDS, V22, P1821, DOI 10.1097/QAD.0b013e328307a051
   Mzileni Mogiyana Olga, 2008, Pol Arch Med Wewn, V118, P548
   Nakanjako Damalie, 2008, AIDS Res Ther, V5, P23, DOI 10.1186/1742-6405-5-23
   Nicastri E, 2007, J ANTIMICROB CHEMOTH, V60, P724, DOI 10.1093/jac/dkm302
   O'Brien Daniel P, 2010, Confl Health, V4, P12, DOI 10.1186/1752-1505-4-12
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Palombi L, 2009, CLIN INFECT DIS, V48, P115, DOI 10.1086/593312
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Rougemont Mathieu, 2009, AIDS Res Ther, V6, P21, DOI 10.1186/1742-6405-6-21
   Ruan YH, 2010, TROP MED INT HEALTH, V15, P1357, DOI 10.1111/j.1365-3156.2010.02621.x
   Sanne IM, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-38
   Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908
   Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002
   Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7
   Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782
   Toure S, 2008, AIDS, V22, P873, DOI 10.1097/QAD.0b013e3282f768f8
   Tuboi SH, 2009, JAIDS-J ACQ IMM DEF, V51, P615, DOI 10.1097/QAI.0b013e3181a44f0a
   UNAIDS, 2007, FIN RES REQ ACH UN A
   Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3
   Wester CW, 2005, JAIDS-J ACQ IMM DEF, V40, P336, DOI 10.1097/01.qai.0000159668.80207.5b
   WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105
   Wong EB, 2010, 8 INT AIDS C VIENN A
   Yu JKL, 2008, INT J TUBERC LUNG D, V12, P692
   Zachariah R, 2006, AIDS, V20, P2355, DOI 10.1097/QAD.0b013e32801086b0
NR 68
TC 18
Z9 21
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 29
PY 2011
VL 6
IS 12
AR e28691
DI 10.1371/journal.pone.0028691
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 897SP
UT WOS:000300677000005
PM 22220193
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Yang, WS
   Va, P
   Bray, F
   Gao, S
   Gao, J
   Li, HL
   Xiang, YB
AF Yang, Wan-Shui
   Va, Puthiery
   Bray, Freddie
   Gao, Shan
   Gao, Jing
   Li, Hong-Lan
   Xiang, Yong-Bing
TI The Role of Pre-Existing Diabetes Mellitus on Hepatocellular Carcinoma
   Occurrence and Prognosis: A Meta-Analysis of Prospective Cohort Studies
SO PLOS ONE
LA English
DT Article
ID CHRONIC HEPATITIS-C; POPULATION-BASED COHORT; CANCER-MORTALITY;
   UNITED-STATES; VIRAL-HEPATITIS; VIRUS-INFECTION; BREAST-CANCER;
   METABOLIC SYNDROME; PUBLICATION BIAS; LIVER-DISEASE
AB Background: The impact of pre-existing diabetes mellitus (DM) on hepatocellular carcinoma (HCC) occurrence and prognosis is complex and unclear. The aim of this meta-analysis is to evaluate the association between pre-existing diabetes mellitus and hepatocellular carcinoma occurrence and prognosis.
   Methods: We searched PubMed, Embase and the Cochrane Library from their inception to January, 2011 for prospective epidemiological studies assessing the effect of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence, mortality outcomes, cancer recurrence, and treatment-related complications. Study-specific risk estimates were combined by using fixed effect or random effect models.
   Results: The database search generated a total of 28 prospective studies that met the inclusion criteria. Among these studies, 14 reported the risk of HCC incidence and 6 studies reported risk of HCC specific mortality. Six studies provided a total of 8 results for all-cause mortality in HCC patients. Four studies documented HCC recurrence risks and 2 studies reported risks for hepatic decomposition occurrence in HCC patients. Meta-analysis indicated that pre-existing diabetes mellitus (DM) was significantly associated with increased risk of HCC incidence [meta-relative risk (RR) = 1.87, 95% confidence interval (CI): 1.15-2.27] and HCC-specific mortality (meta-RR = 1.88, 95% CI: 1.39-2.55) compared with their non-DM counterparts. HCC patients with pre-existing DM had a 38% increased (95% CI: 1.13-1.48) risk of death from all-causes and 91% increased (95% CI: 1.41-2.57) risk of hepatic decomposition occurrence compared to those without DM. In DM patients, the meta-RR for HCC recurrence-free survival was 1.93(95% CI: 1.12-3.33) compared with non-diabetic patients.
   Conclusion: The findings from the current meta-analysis suggest that DM may be both associated with elevated risks of both HCC incidence and mortality. Furthermore, HCC patients with pre-existing diabetes have a poorer prognosis relative to their non-diabetic counterparts.
C1 [Yang, Wan-Shui] Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200433, Peoples R China.
   [Yang, Wan-Shui; Gao, Shan; Gao, Jing; Li, Hong-Lan; Xiang, Yong-Bing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogene & Related Genes,Renji Hosp, Shanghai 200030, Peoples R China.
   [Yang, Wan-Shui; Gao, Shan; Gao, Jing; Li, Hong-Lan; Xiang, Yong-Bing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, Dept Epidemiol,Renji Hosp, Shanghai 200030, Peoples R China.
   [Va, Puthiery] Univ New England, Coll Osteopath Med, Biddeford, ME USA.
   [Bray, Freddie] Int Agcy Res Canc, Sect Canc Informat, F-69372 Lyon, France.
RP Yang, WS (reprint author), Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200433, Peoples R China.
EM ybxiang@shsci.org
FU State Key Project Specialized for Infectious Diseases of China
   [2008ZX10002-015]; Fogarty International Clinical Research Scholars;
   Fogarty International Center, National Institutes of Health
   [R24TW007988]
FX This study is supported by the fund of the State Key Project Specialized
   for Infectious Diseases of China (No. 2008ZX10002-015). W-SY and PV are
   also supported by the Fogarty International Clinical Research Scholars
   and Fellows Support Center at the Vanderbilt Institute for Global
   Health, funded by the Fogarty International Center, National Institutes
   of Health, through an R24 Training Grant (Grant number: R24TW007988).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753
   Barone BB, 2008, JAMA-J AM MED ASSOC, V300, P2754, DOI 10.1001/jama.2008.824
   Batty GD, 2004, CANCER CAUSE CONTROL, V15, P873, DOI 10.1007/s10552-004-1050-z
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen Jian-guo, 2005, Zhonghua Yi Xue Za Zhi, V85, P3052
   Cheruvattath R, 2007, J CLIN GASTROENTEROL, V41, P403, DOI 10.1097/01.mcg.0000248018.08515.f9
   Chodick G, 2010, CANCER CAUSE CONTROL, V21, P879, DOI 10.1007/s10552-010-9515-8
   Clemmons DR, 2007, GROWTH HORM IGF RES, V17, P265, DOI 10.1016/j.ghir.2007.01.004
   Coughlin SS, 2004, AM J EPIDEMIOL, V159, P1160, DOI 10.1093/aje/kwh161
   Cowie CC, 2009, DIABETES CARE, V32, P287, DOI 10.2337/dc08-1296
   Cucchetti A, 2011, ANN SURG ONCOL, V18, P1630, DOI 10.1245/s10434-010-1463-8
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6
   Davila JA, 2005, GUT, V54, P533, DOI 10.1136/gut.2004.052167
   Davila JA, 2004, GASTROENTEROLOGY, V127, P1372, DOI 10.1053/j.gastro.2004.07.020
   Denley A, 2007, MOL CELL BIOL, V27, P3569, DOI 10.1128/MCB.01447-06
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Di Costanzo GG, 2008, EUR J GASTROEN HEPAT, V20, P674, DOI 10.1097/MEG.0b013e3282f762e1
   Donadon Valter, 2009, Expert Rev Gastroenterol Hepatol, V3, P465, DOI 10.1586/egh.09.41
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Serag HB, 2004, GASTROENTEROLOGY, V126, P460, DOI 10.1053/j.gastro.2003.10.065
   El-Serag HB, 2001, AM J GASTROENTEROL, V96, P2462, DOI 10.1111/j.1572-0241.2001.04054.x
   Feng YH, 2011, MED ONCOL, V28, P1080, DOI 10.1007/s12032-010-9650-9
   Ferlay J., 2010, IARC CANC BASE
   Fujino Y, 2001, DIABETES METAB RES, V17, P374, DOI 10.1002/dmrr.214
   FULLER JH, 1983, DIABETOLOGIA, V24, P336
   Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Hassan MM, 2002, J CLIN GASTROENTEROL, V35, P266, DOI 10.1097/01.MCG.0000024617.97388.72
   Hassan MM, 2002, HEPATOLOGY, V36, P1206, DOI 10.1053/jhep.2002.36780
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hoerger TJ, 2008, DIABETES CARE, V31, P81, DOI 10.2337/dc07-1.572
   Hung CH, 2011, INT J CANCER, V128, P2344, DOI 10.1002/ijc.25585
   Huo TI, 2010, LIVER INT, V30, P198, DOI 10.1111/j.1478-3231.2009.02143.x
   Huo TI, 2004, AM J GASTROENTEROL, V99, P1479, DOI 10.1111/j.1572-0241.2004.30024.x
   Huo TI, 2003, EUR J GASTROEN HEPAT, V15, P1203, DOI 10.1097/01.meg.0000085498.01212.6a
   Huo TI, 2003, AM J GASTROENTEROL, V98, P2293, DOI 10.1016/S0002-9270(03)00694-4
   Ikeda Y, 1998, HEPATOLOGY, V27, P1567, DOI 10.1002/hep.510270615
   Inoue M, 2006, ARCH INTERN MED, V166, P1871, DOI 10.1001/archinte.166.17.1871
   Ioannou GN, 2007, CLIN GASTROENTEROL H, V5, P938, DOI 10.1016/j.cgh.2007.02.039
   Jee SH, 2005, JAMA-J AM MED ASSOC, V293, P194, DOI 10.1001/jama.293.2.194
   Jin F, 1999, INT J CANCER, V83, P435, DOI 10.1002/(SICI)1097-0215(19991112)83:4<435::AID-IJC1>3.3.CO;2-A
   Jonsson JR, 2005, J HEPATOL, V43, P929, DOI 10.1016/j.jhep.2005.05.030
   Kawamura Y, 2008, J GASTROEN HEPATOL, V23, P1739, DOI 10.1111/j.1440-1746.2008.05436.x
   Khan Mmh, 2006, Asian Pac J Cancer Prev, V7, P253
   Komura T, 2007, AM J GASTROENTEROL, V102, P1939, DOI 10.1111/j.1572-0241.2007.01354.x
   Lai MS, 2006, HEPATOLOGY, V43, P1295, DOI 10.1002/hep.21208
   Lam EKK, 2011, ANN ONCOL, V22, P730, DOI 10.1093/annonc/mdq405
   Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380
   Lau WY, 2008, HEPATOB PANCREAT DIS, V7, P237
   LaVecchia C, 1997, INT J CANCER, V73, P204, DOI 10.1002/(SICI)1097-0215(19971009)73:2<204::AID-IJC7>3.0.CO;2-#
   Lee CL, 2003, CANCER EPIDEM BIOMAR, V12, P57
   Lipscombe LL, 2006, BREAST CANCER RES TR, V98, P349, DOI 10.1007/s10549-006-9172-5
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mardilovich K, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-14
   Martin LM, 2000, AM J PREV MED, V18, P215, DOI 10.1016/S0749-3797(99)00158-0
   Meyerkardt JA, 2003, J CLIN ONCOL, V21, P433, DOI 10.1200/JCO.2003.07.125
   Monami M, 2008, EXP CLIN ENDOCR DIAB, V116, P184, DOI 10.1055/s-2007-992157
   Morss AS, 2007, J BIOL CHEM, V282, P14635, DOI 10.1074/jbc.M608565200
   Oba S, 2008, J EPIDEMIOL, V18, P197, DOI 10.2188/jea.JE2008004
   Ogunleye AA, 2009, BRIT J CANCER, V101, P1199, DOI 10.1038/sj.bjc.6605240
   Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052
   Park SM, 2006, J CLIN ONCOL, V24, P5017, DOI 10.1200/JCO.2006.07.0243
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   PAYNE JE, 1995, AUST NZ J SURG, V65, P398, DOI 10.1111/j.1445-2197.1995.tb01767.x
   Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536
   Poon RTP, 2002, AM J GASTROENTEROL, V97, P1480, DOI 10.1016/S0002-9270(02)04148-5
   Radhakrishnan Y, 2008, J BIOL CHEM, V283, P16320, DOI 10.1074/jbc.M801687200
   Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006
   Richardson LC, 2005, NAT CLIN PRACT ONCOL, V2, P48, DOI 10.1038/ncponc0062
   Roden M, 2006, NAT CLIN PRACT ENDOC, V2, P335, DOI 10.1038/ncpendmet0190
   Rose DP, 2007, ENDOCR REV, V28, P763, DOI 10.1210/er.2006-0019
   Rousseau MC, 2006, INT J CANCER, V118, P2105, DOI 10.1002/ijc.21600
   Sanyal AJ, 2010, ONCOLOGIST, V15, P14, DOI 10.1634/theoncologist.2010-S4-14
   Sanz C, 2010, DIABETES METAB, V36, P346, DOI 10.1016/j.diabet.2010.06.001
   Shi M, 2004, WORLD J SURG, V28, P376, DOI 10.1007/s00268-003-7308-x
   Snyder CF, 2010, PROSTATE CANCER P D, V13, P58, DOI 10.1038/pcan.2009.39
   Takiya L, 2002, AM J MANAG CARE, V8, P1009
   Tazawa J, 2002, DIGEST DIS SCI, V47, P710, DOI 10.1023/A:1014715327729
   Torisu Y, 2007, HEPATOL RES, V37, P517, DOI 10.1111/j.1872-034X.2007.00077.x
   van de Poll-Franse LV, 2007, INT J CANCER, V120, P1986, DOI 10.1002/ijc.22532
   Veldt BJ, 2008, HEPATOLOGY, V47, P1856, DOI 10.1002/hep.22251
   Wang CS, 2009, CANCER EPIDEM BIOMAR, V18, P2054, DOI 10.1158/1055-9965.EPI-08-1131
   Weiser MA, 2004, CANCER, V100, P1179, DOI 10.1002/cncr.20071
   Whitehead JP, 2006, DIABETES OBES METAB, V8, P264, DOI 10.1111/j.1463-1326.2005.00510.x
   Wong IHN, 2001, CANCER LETT, V167, P183, DOI 10.1016/S0304-3835(01)00455-4
   Wu SC, 2000, PUBLIC HEALTH, V114, P137, DOI 10.1016/S0033-3506(00)00323-1
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820
   Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229
   Zhang H, 2007, CANCER RES, V67, P391, DOI 10.1158/0008-5472.CAN-06-1712
   Zhu AX, 2010, ONCOLOGIST, V15, P1, DOI 10.1634/theoncologist.2010-S4-01
NR 93
TC 54
Z9 57
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 21
PY 2011
VL 6
IS 12
AR e27326
DI 10.1371/journal.pone.0027326
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 876NF
UT WOS:000299113600002
PM 22205924
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Qin, YY
   Li, H
   Guo, XJ
   Ye, XF
   Wei, X
   Zhou, YH
   Zhang, XJ
   Wang, C
   Qian, W
   Lu, J
   He, J
AF Qin, Ying-Yi
   Li, Hui
   Guo, Xiao-Jing
   Ye, Xiao-Fei
   Wei, Xin
   Zhou, Yu-Hao
   Zhang, Xin-Ji
   Wang, Chao
   Qian, Wei
   Lu, Jian
   He, Jia
TI Adjuvant Chemotherapy, with or without Taxanes, in Early or Operable
   Breast Cancer: A Meta-Analysis of 19 Randomized Trials with 30698
   Patients
SO PLOS ONE
LA English
DT Article
ID DOXORUBICIN PLUS CYCLOPHOSPHAMIDE; PHASE-III TRIAL; HIGH-RISK; COMPARING
   DOXORUBICIN; DOCETAXEL; PACLITAXEL; EPIRUBICIN; FLUOROURACIL;
   METHOTREXATE; VINORELBINE
AB Background: Taxanes have been extensively used as adjuvant chemotherapy for the treatment of early or operable breast cancer, particularly in high risk, node-negative breast cancer. Previous studies, however, have reported inconsistent findings regarding their clinical efficacy and safety. We investigated disease-free survival (DFS), overall survival (OS), and drug-related toxicities of taxanes by a systematic review and meta-analysis.
   Methodology and Principal Findings: We systematically searched PubMed, EMBASE, the Cochrane Center Register of Controlled Trials, proceedings of major meetings, and reference lists of articles for studies conducted between January 1980 and April 2011. Randomized controlled trials (RCTs) comparing chemotherapy with and without taxanes in the treatment of patients with early-stage or operable breast cancer were eligible for inclusion in our analysis. The primary endpoint was DFS. Nineteen RCTs including 30698 patients were identified, including 8426 recurrence events and 3803 deaths. Taxanes administration yielded a 17% reduction of hazard ratio (HR) for DFS (HR = 0.83, 95% CI 0.79-0.88, p<0.001) and a 17% reduction of HR for OS (HR = 0.83, 95% CI 0.77-0.90, p<0.001). For high risk, node-negative breast cancer, the pooled HR also favoured the taxane-based treatment arm over the taxane-free treatment arm (HR = 0.82, 95% CI 0.77-0.87, p = 0.022). A significantly increased rate of neutropenia, febrile neutropenia, fatigue, diarrhea, stomatitis, and oedema was observed in the taxane-based treatment arm.
   Conclusions/Significance: Adjuvant chemotherapy with taxanes could reduce the risk of cancer recurrence and death in patients with early or operable breast cancer, although the drug-related toxicities should be balanced. Furthermore, we also demonstrated that patients with high risk, node-negative breast cancer also benefited from taxanes therapy, a result that was not observed in previous studies.
C1 [Qin, Ying-Yi; Li, Hui; Guo, Xiao-Jing; Ye, Xiao-Fei; Zhou, Yu-Hao; Zhang, Xin-Ji; Wang, Chao; Qian, Wei; Lu, Jian; He, Jia] Second Mil Med Univ, Dept Hlth Stat, Shanghai, Peoples R China.
   [Wei, Xin] Shanghai Jiao Tong Univ, Coll Basic Med, Sch Med, Shanghai 200030, Peoples R China.
RP Qin, YY (reprint author), Second Mil Med Univ, Dept Hlth Stat, Shanghai, Peoples R China.
EM hejia63@yahoo.com
OI Wei, Qian/0000-0001-5753-7579
FU National Nature Science Foundation of China [30872186, 81072388];
   leading talents of science in Shanghai [022]; Shanghai Subject Chief
   Scientist [09XD1405500]
FX National Nature Science Foundation of China (30872186, 81072388), a
   grant from the leading talents of science in Shanghai 2010 (022) and a
   grant sponsored by Program of Shanghai Subject Chief Scientist
   (09XD1405500). The funders had no role in the study design, data
   collection, analysis, decision to publish or preparation of the
   manuscript. The corresponding author had full access to all the data in
   the study and had the final responsibility for the decision to submit
   for publication.
CR Abe O, 2005, LANCET, V365, P1687
   Abe O, 1998, LANCET, V352, P930
   Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   Andre F, 2008, J CLIN ONCOL, V26, P2636, DOI 10.1200/JCO.2007.14.9146
   Bear HD, 2006, J CLIN ONCOL, V24, P2019, DOI 10.1200/JCO.2005.04.1665
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bianco AR, 2008, BREAST CANC S S
   Boccardo F, 2010, ONCOLOGY-BASEL, V78, P274, DOI 10.1159/000315735
   Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5
   Buzdar AU, 2002, CLIN CANCER RES, V8, P1073
   Cognetti F, 2008, ANN ONCOL, V19, P77
   Crown JP, 2006, J CLIN ONCOL ASC S18
   De Laurentiis M, 2008, J CLIN ONCOL, V26, P44, DOI 10.1200/JCO.2007.11.3787
   Deeks JJ, 2008, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ellis P, 2009, LANCET, V373, P1681, DOI 10.1016/S0140-6736(09)60740-6
   Ferguson T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004421.pub2
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fisher B, 2004, JNCI-J NATL CANCER I, V96, P1823, DOI 10.1093/jnci/djh338
   Fountzilas G, 2005, ANN ONCOL, V16, P1762, DOI 10.1093/annonc/mdi366
   Gianni L, 2005, CLIN CANCER RES, V11, P8715, DOI 10.1158/1078-0432.CCR-05-0539
   Gianni L, 2005, J CLIN ONCOL ASC S16
   Goldstein L, 2005, J CLIN ONCOL ASC S16
   Goldstein LJ, 2008, J CLIN ONCOL, V26, P4092, DOI 10.1200/JCO.2008.16.7841
   Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028
   Jones S, 2009, J CLIN ONCOL, V27, P1177, DOI 10.1200/JCO.2008.18.4028
   Jones SE, 2006, J CLIN ONCOL, V24, P5381, DOI 10.1200/JCO.2006.06.5391
   Lee KS, 2008, BREAST CANCER RES TR, V109, P481, DOI 10.1007/s10549-007-9672-y
   Mamounas EP, 2005, J CLIN ONCOL, V23, P3686, DOI 10.1200/JCO.2005.10.517
   Mansi JL, 2010, BREAST CANCER RES TR, V122, P787, DOI 10.1007/s10549-010-0989-6
   Martin M, 2005, NEW ENGL J MED, V352, P2302, DOI 10.1056/NEJMoa043681
   Martin M, 2007, BREAST, V16, pS127, DOI 10.1016/j.breast.2007.09.001
   Martin M, 2008, JNCI-J NATL CANCER I, V100, P805, DOI 10.1093/jnci/djn151
   Martin M, 2010, NEW ENGL J MED, V363, P2200, DOI 10.1056/NEJMoa0910320
   MOHER D, 2009, PLOS MED, V6
   Moore HCF, 2007, J CLIN ONCOL, V25, P1677, DOI 10.1200/JCO.2006.08.9383
   Polyzos A, 2010, BREAST CANCER RES TR, V119, P95, DOI 10.1007/s10549-009-0468-0
   Roche H, 2006, J CLIN ONCOL, V24, P5664, DOI 10.1200/JCO.2006.07.3916
   Sparano JA, 2008, NEW ENGL J MED, V358, P1663, DOI 10.1056/NEJMoa0707056
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Verma Su, 2010, Curr Oncol, V17, P20
NR 46
TC 37
Z9 37
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 1
PY 2011
VL 6
IS 11
AR e26946
DI 10.1371/journal.pone.0026946
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 849UN
UT WOS:000297150900039
PM 22069477
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Boillot, A
   El Halabi, B
   Batty, GD
   Range, H
   Czernichow, S
   Bouchard, P
AF Boillot, Adrien
   El Halabi, Bechara
   Batty, George David
   Range, Helene
   Czernichow, Sebastien
   Bouchard, Philippe
TI Education as a Predictor of Chronic Periodontitis: A Systematic Review
   with Meta-Analysis Population-Based Studies
SO PLOS ONE
LA English
DT Review
ID ORAL-HEALTH; ATTACHMENT LOSS; RISK INDICATORS; OSLO CITIZENS; TOOTH
   LOSS; DISEASE; ADULTS; ASSOCIATION; INEQUALITIES; PERSPECTIVE
AB Background: The impact of socioeconomic inequalities on health is well-documented. Despite the links of periodontal disease with cardiovascular diseases, adverse pregnancy outcomes and diabetes, no meta-analysis of socioeconomic variations in periodontal disease exists. This meta-analytic review was conducted to determine the extent to which education attainment influences risk of periodontitis in adults aged 35+ years in the general population.
   Methods: The authors searched studies published until November 2010 using EMBASE and MEDLINE databases. References listed were then scrutinised, our own files were checked, and, finally, we contacted experts in the field. The authors included only general population-based studies conducted in adults aged 35 years and more. All articles were blind reviewed by two investigators. In the case of disagreement, a third investigator arbitrated. Using PRISMA statement, two reviewers independently extracted papers of interest.
   Results: Relative to the higher education group, people with low education attainment experience a greater risk of periodontitis (OR: 1.86 [1.66-2.10]; p<0.00001). The association was partially attenuated after adjustment for covariates (OR: 1.55 [1.30-1.86]; p<0.00001). Sensitivity analyses showed that methods used to assess periodontitis, definition of cases, study country and categorization of education are largely responsible for the heterogeneity between studies. No significant bias of publication was shown using both the Egger (p = 0.16) and rank correlation tests (p = 0.35).
   Conclusions: In the studies reviewed, low educational attainment was associated with an increased risk of periodontitis. Although this evidence should be cautiously interpreted due to methodological problems in selected studies, efforts to eliminate educational inequalities in periodontitis should focus on early life interventions.
C1 [Boillot, Adrien; El Halabi, Bechara; Range, Helene; Bouchard, Philippe] Univ Paris 07, Rothschild Hosp, AP HP, Dept Periodontol,Serv Odontol,UFR Odontol, Paris, France.
   [Czernichow, Sebastien] Univ Versailles St Quentin, Ambroise Pare Hosp, Dept Nutr, Boulogne, France.
   [Czernichow, Sebastien] Ctr Res Epidemiol & Populat Hlth, INSERM, U1018, Villejuif, France.
   [Batty, George David] UCL, Dept Epidemiol & Publ Hlth, London, England.
RP Boillot, A (reprint author), Univ Paris 07, Rothschild Hosp, AP HP, Dept Periodontol,Serv Odontol,UFR Odontol, Paris, France.
EM phbouch@noos.fr
RI Batty, GD/Y-4401-2018
OI Batty, GD/0000-0003-1822-5753; Range, Helene/0000-0002-4761-0805
CR Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   Alwaeli H A, 2005, Int J Dent Hyg, V3, P74, DOI 10.1111/j.1601-5037.2005.00121.x
   BECK JD, 1990, J PERIODONTOL, V61, P521, DOI 10.1902/jop.1990.61.8.521
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bergstrom Jan, 2006, J Evid Based Dent Pract, V6, P33, DOI 10.1016/j.jebdp.2005.12.018
   Borges-Yanez SA, 2004, J CLIN PERIODONTOL, V31, P112
   Borrell LN, 2006, AM J PUBLIC HEALTH, V96, P332, DOI 10.2105/AJPH.2004.055277
   Borrell LN, 2006, J PERIODONTOL, V77, P444, DOI 10.1902/jop.2006.050158
   Brennan DS, 2007, AUST DENT J, V52, P55, DOI 10.1111/j.1834-7819.2007.tb00466.x
   BROWN LF, 1994, J PERIODONTOL, V65, P316, DOI 10.1902/jop.1994.65.4.316
   Cascaes AM, 2009, J CLIN PERIODONTOL, V36, P25, DOI 10.1111/j.1600-051X.2008.01337.x
   Chaffee BW, 2010, J PERIODONTOL, V81, P1708, DOI 10.1902/jop.2010.100321
   Chang-Quan H, 2010, INT J PSYCHIAT MED, V40, P109, DOI 10.2190/PM.40.1.i
   Christensen U, 2006, SCAND J PUBLIC HEALT, V34, P363, DOI 10.1080/14034940500489339
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Conway DI, 2008, INT J CANCER, V122, P2811, DOI 10.1002/ijc.23430
   D'Aiuto F, 2008, J CLIN ENDOCR METAB, V93, P3989, DOI 10.1210/jc.2007-2522
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   Dietrich T, 2006, J DENT RES, V85, P1134, DOI 10.1177/154405910608501213
   Dolan TA, 1997, J CLIN PERIODONTOL, V24, P223, DOI 10.1111/j.1600-051X.1997.tb01835.x
   Dye BA, 2009, J PERIODONTOL, V80, P634, DOI 10.1902/jop.2009.080474
   Eaton KA, 2001, J PERIODONTOL, V72, P140, DOI 10.1902/jop.2001.72.2.140
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Famili P, 2005, J PERIODONTOL, V76, P11, DOI 10.1902/jop.2005.76.1.11
   Garcia R I, 2001, Ann Periodontol, V6, P71, DOI 10.1902/annals.2001.6.1.71
   Gilbert GH, 2005, J PERIODONTOL, V76, P1161, DOI 10.1902/jop.2005.76.7.1161
   Graham H, 2002, SOC SCI MED, V55, P2005, DOI 10.1016/S0277-9536(01)00343-4
   HANSEN BF, 1993, J CLIN PERIODONTOL, V20, P584, DOI 10.1111/j.1600-051X.1993.tb00775.x
   HANSEN BF, 1995, J PERIODONTAL RES, V30, P410, DOI 10.1111/j.1600-0765.1995.tb01295.x
   HANSEN BF, 1990, J CLIN PERIODONTOL, V17, P249, DOI 10.1111/j.1600-051X.1990.tb00021.x
   Hessari H, 2007, MED PRIN PRACT, V16, P280, DOI 10.1159/000102150
   Hessari H, 2009, ORAL HLTH PREV DENT, V7, P61
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HUISMAN M, 2011, EUR J PUBLI IN PRESS
   Kavanagh A, 2010, SOC SCI MED, V71, P1150, DOI 10.1016/j.socscimed.2010.05.038
   Kerr GD, 2011, CEREBROVASC DIS, V31, P57, DOI 10.1159/000320855
   Klinge B, 2005, J CLIN PERIODONTOL, V32, P314, DOI 10.1111/j.1600-051X.2005.00801.x
   Kolenbrander PE, 2010, NAT REV MICROBIOL, V8, P471, DOI 10.1038/nrmicro2381
   Krustrup U, 2006, ACTA ODONTOL SCAND, V64, P65, DOI 10.1080/00016350500377859
   Lai H, 2007, J CLIN PERIODONTOL, V34, P851, DOI 10.1111/j.1600-051X.2007.01121.x
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lang IA, 2008, J PUBLIC HEALTH-UK, V30, P472, DOI 10.1093/pubmed/fdn047
   Lang NP, 1999, ANN PERIODONTOL, V4, P53, DOI DOI 10.1902/ANNALS.1999.4.1.53
   Li Q, 2010, DIABETOLOGIA, V53, P2320, DOI 10.1007/s00125-010-1862-1
   LOCKER D, 1993, J DENT RES, V72, P9, DOI 10.1177/00220345930720011501
   MOHER D, 2009, PLOS MED, V6
   Molarius A, 2000, AM J PUBLIC HEALTH, V90, P1260, DOI 10.2105/AJPH.90.8.1260
   Mucci LA, 2004, AM J EPIDEMIOL, V159, P499, DOI 10.1093/aje/kwh063
   Nicolau B, 2007, J CLIN PERIODONTOL, V34, P844, DOI 10.1111/j.1600-051X.2007.01123.x
   Paulander J, 2004, ACTA ODONTOL SCAND, V62, P199, DOI 10.1080/00016350410001621
   Peres MA, 2007, J CLIN PERIODONTOL, V34, P196, DOI 10.1111/j.1600-051X.2006.01043.x
   Petersen PE, 2000, ACTA ODONTOL SCAND, V58, P243, DOI 10.1080/00016350050217073
   Phipps KR, 2009, GERODONTOLOGY, V26, P122, DOI 10.1111/j.1741-2358.2008.00231.x
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Ribet C, 2007, REV EPIDEMIOL SANTE, V55, P285, DOI 10.1016/j.respe.2007.04.001
   Shankar A, 2010, AM J PREV MED, V38, P39, DOI 10.1016/j.amepre.2009.08.026
   TAYLOR GW, 2010, ANN PERIODONTOL, V6, P99
   Tonetti MS, 2007, NEW ENGL J MED, V356, P911, DOI 10.1056/NEJMoa063186
   Torrungruang K, 2005, J PERIODONTOL, V76, P558, DOI 10.1902/jop.2005.76.4.558
   Torrungruang K, 2009, J PERIODONTOL, V80, P122, DOI [10.1902/jop.2009.080248, 10.1902/jop.2009.080248 ]
   Tsai C, 2002, COMMUNITY DENT ORAL, V30, P182, DOI 10.1034/j.1600-0528.2002.300304.x
   Watt RG, 2002, COMMUNITY DENT ORAL, V30, P241, DOI 10.1034/j.1600-0528.2002.300401.x
   Wimmer G, 2008, J CLIN PERIODONTOL, V35, P380, DOI 10.1111/j.1600-051X.2008.01284.x
   Zini A, 2011, J CLIN PERIODONTOL, V38, P229, DOI 10.1111/j.1600-051X.2010.01689.x
NR 64
TC 35
Z9 35
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 21
PY 2011
VL 6
IS 7
AR e21508
DI 10.1371/journal.pone.0021508
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 795FA
UT WOS:000292956800004
PM 21814546
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, YP
   Li, XL
   Shi, L
   Yang, M
   Yang, Y
   Tao, WY
   Shi, L
   Xiong, YX
   Zhang, Y
   Yao, YF
AF Li, Yiping
   Li, Xianli
   Shi, Li
   Yang, Man
   Yang, Ying
   Tao, Wenyu
   Shi, Lei
   Xiong, Yuxin
   Zhang, Ying
   Yao, Yufeng
TI Association of Adiponectin SNP+45 and SNP+276 with Type 2 Diabetes in
   Han Chinese Populations: A Meta-Analysis of 26 Case-Control Studies
SO PLOS ONE
LA English
DT Article
ID SINGLE NUCLEOTIDE POLYMORPHISMS; IMPAIRED GLUCOSE-TOLERANCE;
   GENE-ENCODING ADIPONECTIN; ADIPOSE-SPECIFIC PROTEIN; INSULIN-RESISTANCE;
   APM1 GENE; SUSCEPTIBILITY GENES; METABOLIC SYNDROME; FRENCH CAUCASIANS;
   PROXIMAL PROMOTER
AB Recently, many studies have reported that the SNP+45(T>G) and SNP+276(G>T) polymorphisms in the adiponectin gene are associated with type 2 diabetes (T2DM) in the Chinese Han population. However, the previous studies yielded many conflicting results. Thus, a meta-analysis of the association of the adiponectin gene with T2DM in the Chinese Han population is required. In the current study, we first determined the distribution of the adiponectin SNP+276 polymorphism in T2DM and nondiabetes (NDM) control groups. Our results suggested that the genotype and allele frequencies for SNP+276 did not differ significantly between the T2DM and NDM groups. Then, a meta-analysis of 23 case-control studies of SNP+45, with a total of 4161 T2DM patients and 3709 controls, and 11 case-control studies of SNP+276, with 2533 T2DM patients and 2212 controls, was performed. All subjects were Han Chinese. The fixed-effects model and random-effects model were applied for dichotomous outcomes to combine the results of the included studies. The results revealed a trend towards an increased risk of T2DM for the SNP+45G allele as compared with the SNP+45T allele (OR = 1.34; 95% CI, 1.11-1.62; P<0.01) in the Chinese Han population. However, there was no association between SNP+276 and T2DM (OR = 0.90; 95% CI, 0.73-1.10; P = 0.31). The results of our association study showed there was no association between the adiponectin SNP+276 polymorphism and T2DM in the Yunnan Han population. The meta-analysis results suggested that the SNP+45G allele might be a susceptibility allele for T2DM in the Chinese Han population. However, we did not observe an association between SNP+276 and T2DM.
C1 [Li, Yiping; Li, Xianli; Yang, Man; Yang, Ying; Tao, Wenyu; Xiong, Yuxin; Zhang, Ying] Second Peoples Hosp Yunnan Prov, Dept Endocrinol & Metab, Kunming, Yunnan, Peoples R China.
   [Shi, Li; Shi, Lei; Yao, Yufeng] Chinese Acad Med Sci, Inst Med Biol, Kunming, Yunnan, Peoples R China.
   [Shi, Li; Shi, Lei; Yao, Yufeng] Peking Union Med Coll, Kunming, Yunnan, Peoples R China.
RP Li, YP (reprint author), Second Peoples Hosp Yunnan Prov, Dept Endocrinol & Metab, Kunming, Yunnan, Peoples R China.
EM zy5311780@126.com; leoyyf@gmail.com
FU Education Department Fund of Yunnan Province [09C0296]
FX This work was supported by grants 09C0296 from Education Department Fund
   of Yunnan Province. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abbasi F, 2004, DIABETES, V53, P585, DOI 10.2337/diabetes.53.3.585
   Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Behre CJ, 2007, METABOLISM, V56, P1022, DOI 10.1016/j.metabol.2007.03.010
   Chen W., 2007, J ZHENGZHOU U MED SC, V42, P1145
   [初明峰 CHU Mingfeng], 2006, [中华内分泌代谢杂志, Chinese Journal of Endocrinology and Metabolism], V22, P24
   [董艳 Dong Yan], 2004, [上海第二医科大学学报, Acta Universitatis Medicinalis Secondae Shanghai], V24, P1001
   DU PF, 2004, CHINESE J DIABETES, V12, P393
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fumeron F, 2004, DIABETES, V53, P1150, DOI 10.2337/diabetes.53.4.1150
   Gibson F, 2004, DIABETES, V53, P2977, DOI 10.2337/diabetes.53.11.2977
   Gu HF, 2004, DIABETES, V53, pS31, DOI 10.2337/diabetes.53.2007.S31
   Gu M.F., 2007, J JIANGSU U MED ED, V17, P498
   Hao J.M., 2009, HAINAN MED J, V20, P1
   Hara K, 2002, DIABETES, V51, P536, DOI 10.2337/diabetes.51.2.536
   [何岚 HE Lan], 2006, [第四军医大学学报, Journal of the Fourth Military Medical University], V27, P1493
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595
   JIN LZ, 2003, J TIANJIN MED U, V9, P211
   [康庄 KANG Zhuang], 2008, [中国糖尿病杂志, = Chinese Journal of Diabetes], V16, P718
   Kern PA, 2003, DIABETES, V52, P1779, DOI 10.2337/diabetes.52.7.1779
   Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Li SB, 2008, CLIN ENDOCRINOL, V68, P885, DOI 10.1111/j.1365-2265.2007.03114.x
   [李奕平 Li Yiping], 2011, [中国糖尿病杂志, Chinese Journal of Diabetes], V19, P101
   Mori Y, 2002, DIABETES, V51, P1247, DOI 10.2337/diabetes.51.4.1247
   Nakaoka H, 2009, J HUM GENET, V54, P615, DOI 10.1038/jhg.2009.95
   Populaire C, 2003, DIABETOLOGIA, V46, P443, DOI 10.1007/s00125-003-1050-7
   Ru Ying, 2005, Zhonghua Yixue Yichuanxue Zazhi, V22, P698
   [史晓红 Shi XH], 2007, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V11, P6815
   [史晓红 Shi Xiaohong], 2007, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V11, P4941
   Stumvoll M, 2002, DIABETES, V51, P37, DOI 10.2337/diabetes.51.1.37
   Sun H, 2008, BRIT J CLIN PHARMACO, V65, P917, DOI 10.1111/j.1365-2125.2008.03145.x
   Sun Y. Z., 2007, SHANXI MED J, V36, P661
   Takahashi M, 2000, INT J OBESITY, V24, P861, DOI 10.1038/sj.ijo.0801244
   Tschritter O, 2003, DIABETES, V52, P239, DOI 10.2337/diabetes.52.2.239
   Tso AWK, 2006, DIABETOLOGIA, V49, P1806, DOI 10.1007/s00125-006-0324-2
   Vasseur F, 2005, DIABETOLOGIA, V48, P892, DOI 10.1007/s00125-005-1729-z
   Vasseur F, 2002, HUM MOL GENET, V11, P2607, DOI 10.1093/hmg/11.21.2607
   Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887
   [王长江 Wang Changjiang], 2005, [中华糖尿病杂志, Chinese Journal of Diabetes], V13, P324
   [王吉影 WANG Jiying], 2007, [第二军医大学学报, Academic Journal of Second Military Medical University], V28, P143
   Wang K, 2009, J TIANJIN MED U
   [王淑芳 WANG Shufang], 2007, [中华内分泌代谢杂志, Chinese Journal of Endocrinology and Metabolism], V23, P51
   Wang Y.X., 2010, SHANDONG MED J, V50, P1
   Wang YB, 2009, J GENET GENOMICS, V36, P417, DOI 10.1016/S1673-8527(08)60131-9
   Wang Yan, 2008, Progress in Modern Biomedicine, V8, P84
   [魏颖丽 WEI Yingli], 2007, [中国糖尿病杂志, Chinese Journal of Diabetes], V15, P583
   Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930
   Xia Z, 2004, CHIN J ENDOCRINOL ME, V20, P236
   Xin YP, 2009, CHINESE J PRACTICAL, V12, P29
   [叶红 YE Hong], 2009, [药学服务与研究, Pharmaceutical Care and Research], V9, P158
   Zacharova J, 2005, DIABETES, V54, P893, DOI 10.2337/diabetes.54.3.893
   Zhai B., 2006, CHIN J CLIN REHABIL, V10, P28
   Zhang HX, 2007, SHANDONG MED J, V47, P1
NR 55
TC 26
Z9 29
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 11
PY 2011
VL 6
IS 5
AR e19686
DI 10.1371/journal.pone.0019686
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 762MQ
UT WOS:000290483600021
PM 21589658
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Brenner, DR
   McLaughlin, JR
   Hung, RJ
AF Brenner, Darren R.
   McLaughlin, John R.
   Hung, Rayjean J.
TI Previous Lung Diseases and Lung Cancer Risk: A Systematic Review and
   Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID OBSTRUCTIVE PULMONARY-DISEASE; FORCED EXPIRATORY VOLUME;
   CHLAMYDIA-PNEUMONIAE INFECTION; ENVIRONMENTAL TOBACCO-SMOKE; NONSMOKING
   WOMEN; NORTHEAST CHINA; UNITED-STATES; RESPIRATORY SYMPTOMS; CHRONIC
   BRONCHITIS; FAMILY-HISTORY
AB Background: In order to review the epidemiologic evidence concerning previous lung diseases as risk factors for lung cancer, a meta-analysis and systematic review was conducted.
   Methods: Relevant studies were identified through MEDLINE searches. Using random effects models, summary effects of specific previous conditions were evaluated separately and combined. Stratified analyses were conducted based on smoking status, gender, control sources and continent.
   Results: A previous history of COPD, chronic bronchitis or emphysema conferred relative risks (RR) of 2.22 (95% confidence interval (CI): 1.66, 2.97) (from 16 studies), 1.52 (95% CI: 1.25, 1.84) (from 23 studies) and 2.04 (95% CI: 1.72, 2.41) (from 20 studies), respectively, and for all these diseases combined 1.80 (95% CI: 1.60, 2.11) (from 39 studies). The RR of lung cancer for subjects with a previous history of pneumonia was 1.43 (95% CI: 1.22-1.68) (from 22 studies) and for subjects with a previous history of tuberculosis was 1.76 (95% CI = 1.49, 2.08), (from 30 studies). Effects were attenuated when restricting analysis to never smokers only for COPD/emphysema/chronic bronchitis (RR = 1.22, 0.97-1.53), however remained significant for pneumonia 1.36 (95% CI: 1.10, 1.69) (from 8 studies) and tuberculosis 1.90 (95% CI: 1.45, 2.50) (from 11 studies).
   Conclusions: Previous lung diseases are associated with an increased risk of lung cancer with the evidence among never smokers supporting a direct relationship between previous lung diseases and lung cancer.
C1 [Brenner, Darren R.; McLaughlin, John R.; Hung, Rayjean J.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
   [Brenner, Darren R.; McLaughlin, John R.; Hung, Rayjean J.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [McLaughlin, John R.] Canc Care Ontario, Toronto, ON, Canada.
RP Brenner, DR (reprint author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.
EM Rayjean.Hung@lunenfeld.ca
RI McLaughlin, John/E-4577-2013; Hung, Rayjean/A-7439-2013
FU Canadian Cancer Society Research Institute [020214]; Canadian Institutes
   of Health Research Canada
FX RJH holds a Cancer Care Ontario Chair in Population Studies. The study
   was supported by a Canadian Cancer Society Research Institute grant (no.
   020214). DB holds a Canadian Institutes of Health Research Canada
   Graduate Scholarship. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ALAVANJA MCR, 1992, AM J EPIDEMIOL, V136, P623, DOI 10.1093/oxfordjournals.aje.a116542
   *AM LUNG ASS, 2007, PNUEM FACT SHEET
   Anttila T, 2003, INT J CANCER, V107, P681, DOI 10.1002/ijc.11353
   Apfalter P, 2003, J CLIN MICROBIOL, V41, P592, DOI 10.1128/JCM.41.2.592-600.2003
   Azad N, 2008, J TOXICOL ENV HEAL B, V11, P1, DOI 10.1080/10937400701436460
   Ballaz Santiago, 2003, Clin Lung Cancer, V5, P46, DOI 10.3816/CLC.2003.n.021
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406
   Boffetta P, 2002, EUR RESPIR J, V19, P127, DOI 10.1183/09031936.02.00245802
   BOUCOT KR, 1977, ENVIRON RES, V13, P451, DOI 10.1016/0013-9351(77)90025-1
   Brenner AV, 2001, INT J EPIDEMIOL, V30, P118, DOI 10.1093/ije/30.1.118
   Brenner DR, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-285
   Brownson RC, 2000, CANCER CAUSE CONTROL, V11, P853, DOI 10.1023/A:1008999202040
   CAMPBELL AH, 1963, BRIT J DIS CHEST, V57, P113, DOI 10.1016/S0366-0850(63)80055-1
   CAMPBELL AH, 1961, BRIT J CANCER, V15, P10, DOI 10.1038/bjc.1961.2
   Cassidy A, 2008, BRIT J CANCER, V98, P270, DOI 10.1038/sj.bjc.6604158
   CHANYEUNG M, 2003, INT J CANCER, V40, P131, DOI DOI 10.1002/IJC.24042
   Chapman KR, 2001, CHEST, V119, P1691, DOI 10.1378/chest.119.6.1691
   Cocco P, 2000, J OCCUP ENVIRON MED, V42, P639, DOI 10.1097/00043764-200006000-00014
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   DAVIS AL, 1976, JAMA-J AM MED ASSOC, V256, P621
   de Torres JP, 2007, CHEST, V132, P1932, DOI 10.1378/chest.07-1490
   DEAN G, 1966, J THORAC ONCOL, V1, P1506
   DEFRANCES C, 2007, ADV DATA VITAL HLTH, V385
   Di Dio R, 1994, Rev Assoc Med Bras (1992), V40, P225
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Engels EA, 2008, EXPERT REV ANTICANC, V8, P605, DOI 10.1586/14737140.8.4.605
   Engels EA, 2009, INT J CANCER, V124, P1183, DOI 10.1002/ijc.24042
   Fitzpatrick FA, 2001, INT IMMUNOPHARMACOL, V1, P1651, DOI 10.1016/S1567-5769(01)00102-3
   Galeone C, 2008, EUR J CANCER PREV, V17, P473, DOI 10.1097/CEJ.0b013e328305a0b9
   GAO YT, 1987, INT J CANCER, V40, P604, DOI 10.1002/ijc.2910400505
   GER LP, 1993, ANTICANCER RES, V13, P1491
   Gorlova OY, 2006, INT J CANCER, V118, P1798, DOI 10.1002/ijc.21561
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HINDS MW, 1982, AM REV RESPIR DIS, V125, P776
   Jackson LA, 2000, CANCER EPIDEM BIOMAR, V9, P1263
   Kishi K, 2002, EUR RESPIR J, V19, P1093, DOI 10.1183/09031936.02.00264202
   Ko YC, 1997, INT J EPIDEMIOL, V26, P24, DOI 10.1093/ije/26.1.24
   Kocazeybek B, 2003, J MED MICROBIOL, V52, P721, DOI 10.1099/jmm.0.04845-0
   Koshiol J, 2010, CANCER EPIDEM BIOMAR, V19, P716, DOI 10.1158/1055-9965.EPI-09-0873
   Koshiol J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007380
   Koyi H, 2001, APMIS, V109, P572, DOI 10.1034/j.1600-0463.2001.d01-177.x
   Kreuzer M, 2002, INT J CANCER, V100, P706, DOI 10.1002/ijc.10549
   Kreuzer M, 2001, BRIT J CANCER, V84, P134, DOI 10.1054/bjoc.2000.1518
   KULLER LH, 1990, AM J EPIDEMIOL, V132, P265, DOI 10.1093/oxfordjournals.aje.a115656
   Laurila AL, 1997, INT J CANCER, V74, P31, DOI 10.1002/(SICI)1097-0215(19970220)74:1<31::AID-IJC6>3.0.CO;2-1
   Lee CH, 2001, CANCER CAUSE CONTROL, V12, P289, DOI 10.1023/A:1011270521900
   Liang HY, 2009, J WOMENS HEALTH, V18, P1989, DOI 10.1089/jwh.2008.1355
   Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537
   Lindberg A, 2005, RESPIRATION, V72, P471, DOI 10.1159/000087670
   Littman AJ, 2004, CANCER EPIDEM BIOMAR, V13, P1624
   Littman AJ, 2004, CANCER CAUSE CONTROL, V15, P819, DOI 10.1023/B:CACO.0000043432.71626.45
   LIU ZY, 1991, INT J EPIDEMIOL, V20, P26, DOI 10.1093/ije/20.1.26
   Mannino DM, 2002, CHEST, V121, p121S, DOI 10.1378/chest.121.5_suppl.121S
   Mannino DM, 2003, THORAX, V58, P388, DOI 10.1136/thorax.58.5.388
   Marsh S, 2006, EUR RESPIR J, V28, P883, DOI 10.1183/09031936.06.00074806
   Mayne ST, 1999, AM J EPIDEMIOL, V149, P13
   Moldoveanu B, 2009, J INFLAMM RES, V2, P1
   Mortensen EM, 2010, AM J MED, V123, P66, DOI 10.1016/j.amjmed.2009.08.009
   Moulin JJ, 1997, SCAND J WORK ENV HEA, V23, P104, DOI 10.5271/sjweh.187
   Neuberger JS, 2006, CANCER DETECT PREV, V30, P158, DOI 10.1016/j.cdp.2006.03.001
   NOMURA A, 1991, AM REV RESPIR DIS, V144, P307, DOI 10.1164/ajrccm/144.2.307
   OSANN KE, 2000, EUR RESPIR J, V28, P1
   Parmet Sharon, 2003, JAMA, V290, P2362, DOI 10.1001/jama.290.17.2362
   Peek RM, 2005, CANCER RES, V65, P8583, DOI 10.1158/0008-5472.CAN-05-1777
   Purdue MP, 2007, THORAX, V62, P51, DOI 10.1136/thx.2006.064196
   Rakoff-Nahoum S, 2009, NAT REV CANCER, V9, P57, DOI 10.1038/nrc2541
   RAMANAKUMAR AV, 2006, AM J EPIDEMIOL, V53, P5
   Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   Reardon JZ, 2007, CLIN CHEST MED, V28, P559, DOI 10.1016/j.ccm.2007.06.006
   Rennard SI, 1998, CHEST, V113, p235S, DOI 10.1378/chest.113.4_Supplement.235S
   RIMINGTON J, 1971, BMJ-BRIT MED J, V2, P373, DOI 10.1136/bmj.2.5758.373
   Rutgers SR, 2000, CHEST, V117, p262S, DOI 10.1378/chest.117.5_suppl_1.262S
   SAMET JM, 1986, AM REV RESPIR DIS, V134, P466
   Sasco AJ, 2002, CANCER CAUSE CONTROL, V13, P609, DOI 10.1023/A:1019504210176
   Schabath MB, 2005, AM J EPIDEMIOL, V161, P412, DOI 10.1093/aje/kwi063
   Schwartz AG, 1996, AM J EPIDEMIOL, V144, P554
   Schwartz AG, 2009, J THORAC ONCOL, V4, P291, DOI 10.1097/JTO.0b013e3181951cd1
   Shen XB, 1996, LUNG CANCER-J IASLC, V14, pS107, DOI 10.1016/S0169-5002(96)90216-0
   SKILLRUD D M, 1986, Comprehensive Therapy, V12, P13
   SKILLRUD DM, 1986, ANN INTERN MED, V105, P503, DOI 10.7326/0003-4819-105-4-503
   Stang P, 2000, CHEST, V117, p354S, DOI 10.1378/chest.117.5_suppl_2.354S
   Stayner L, 2007, AM J PUBLIC HEALTH, V97, P545, DOI 10.2105/AJPH.2004.061275
   STEINITZ R, 1965, AM REV RESPIR DIS, V92, P758
   Stewart BW, 2003, WORLD CANC REPORT
   TENKANEN L, 1987, INT J EPIDEMIOL, V16, P509, DOI 10.1093/ije/16.4.509
   TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512
   *US SURG GEN, 1984, DLIHS PUBL
   VANDENEEDEN SK, 1992, EPIDEMIOLOGY, V3, P253, DOI 10.1097/00001648-199205000-00011
   VESTBO J, 1991, INT J EPIDEMIOL, V20, P375, DOI 10.1093/ije/20.2.375
   Wang SY, 1996, LUNG CANCER-J IASLC, V14, pS99, DOI 10.1016/S0169-5002(96)90215-9
   Wang TJ, 1996, LUNG CANCER-J IASLC, V14, pS93, DOI 10.1016/S0169-5002(96)90214-7
   Wang XR, 2009, CANCER CAUSE CONTROL, V20, P757, DOI 10.1007/s10552-008-9289-4
   Wasswa-Kintu S, 2005, THORAX, V60, P570, DOI 10.1136/thx.2004.037135
   WEITZMAN SA, 1990, BLOOD, V76, P655
   Wilson DO, 2008, AM J RESP CRIT CARE, V178, P738, DOI 10.1164/rccm.200803-435OC
   WU AH, 1995, AM J EPIDEMIOL, V141, P1023, DOI 10.1093/oxfordjournals.aje.a117366
   WU AH, 1988, CANCER RES, V48, P7279
   WUWILLIAMS AH, 1990, BRIT J CANCER, V62, P982, DOI 10.1038/bjc.1990.421
   Yang P, 2008, ARCH INTERN MED, V168, P1097, DOI 10.1001/archinte.168.10.1097
   ZATLOUKAL P, 2003, INT J CANCER, V41, P283, DOI DOI 10.1002/IJC.21561
   ZHENG W, 1987, BRIT J CANCER, V56, P501, DOI 10.1038/bjc.1987.233
   2004, LANCET, V364, P417, DOI DOI 10.1136/THX.2004.037135
NR 105
TC 105
Z9 112
U1 2
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 31
PY 2011
VL 6
IS 3
AR e17479
DI 10.1371/journal.pone.0017479
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 743YU
UT WOS:000289057200007
PM 21483846
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, MA
   Zhou, YH
   Chen, PZ
   Yang, HA
   Yuan, XY
   Tajima, KZ
   Cao, J
   Wang, H
AF Li, Mian
   Zhou, Yanhong
   Chen, Peizhan
   Yang, Huan
   Yuan, Xiaoyan
   Tajima, Kazuo
   Cao, Jia
   Wang, Hui
TI Genetic Variants on Chromosome 8q24 and Colorectal Neoplasia Risk: A
   Case-Control Study in China and a Meta-Analysis of the Published
   Literature
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; CANCER SUSCEPTIBILITY LOCUS; COLON-CANCER;
   PROSTATE-CANCER; SAMPLE-SIZE; POPULATION; RS6983267; SCAN; ALLELES;
   RANGE
AB Previous studies have found that common genetic variants on chromosome 8q24 are associated with the risk of developing colorectal neoplasia. We conducted a hospital-based case-control study, including 435 cases and 788 unrelated controls to investigate the associations between common variants on 8q24 and the risk of colorectal cancer in a Chinese population. We also evaluated the association of rs6983267 with colorectal neoplasia in the published literature via a meta-analysis study. We found that rs6983267 was significantly associated with the risk of colorectal cancer in the Chinese population, with an adjusted odds-ratio (OR) for the GT heterozygotes and GG homozygotes of 1.30 (95% CI = 0.98-1.71, P = 0.069) and 1.66 (95% CI = 1.18-2.34, P = 0.004), respectively, compared to the TT homozygotes, with a P-trend value of 0.003. No association was found for the other three loci (rs16901979, rs1447295 and rs7837688). In the meta-analysis of the published genetic association studies, the rs6983267 variant was found to be associated with an increased risk of colorectal neoplasia. The heterozygous GT carriers showed a 20% increased risk of colorectal neoplasia (OR = 1.20, 95% CI = 1.16-1.25; random effects model) with a summary OR for homozygous GG carriers of 1.39 (95% CI = 1.32-1.48; random effects model) compared to the TT genotype carriers. We found no significant differences between the association of rs6983267 and colorectal cancer and colorectal adenomas. In summary, our study confirms that the variant rs6983267 is a risk factor for colorectal neoplasia in various populations, including the Chinese population.
C1 [Li, Mian; Chen, Peizhan; Wang, Hui] Chinese Acad Sci, Grad Sch, Shanghai Inst Biol Sci, Inst Nutr Sci,Key Lab Nutr & Metab, Shanghai, Peoples R China.
   [Zhou, Yanhong; Yang, Huan; Yuan, Xiaoyan; Cao, Jia] Third Mil Med Univ, Dept Hyg Toxicol, Coll Prevent Med,Minist Educ China, Key Lab Med Protect Electmagnet Radiat, Chongqing, Peoples R China.
   [Tajima, Kazuo] Aichi Canc Ctr Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi, Japan.
RP Li, MA (reprint author), Chinese Acad Sci, Grad Sch, Shanghai Inst Biol Sci, Inst Nutr Sci,Key Lab Nutr & Metab, Shanghai, Peoples R China.
EM caojia@mail.tmmu.com.cn; huiwang@sibs.ac.cn
FU Chinese Academy of Sciences; National Nature Science Foundation
   [30870513, 30800933, 31070680, 91029715]; Ministry of Science and
   Technology of China [2007CB947100]; Science and Technology Commission of
   Shanghai Municipality [08391910800, 10391902100]; National Science and
   Technology Major Project [2009ZX09102-114, 2009ZX09301-011]; Ministry of
   Education, Culture, Sports, Science and Technology of Japan [12670383];
   Major International (Regional) Joint Research Projects [30320140461];
   Science and Technology Commission of Xuhui District of Shanghai
   Municipality [RCT201001, CRC2010002]; Director Foundation of INS
   [20090101]; Food Safety Research Center; INS; SIBS; CAS
FX This study was supported by grants from One Hundred Talents Program of
   the Chinese Academy of Sciences, the National Nature Science Foundation
   (30870513, 30800933, 31070680 and 91029715), the Ministry of Science and
   Technology of China (2007CB947100), the Science and Technology
   Commission of Shanghai Municipality (08391910800, 10391902100), National
   Science and Technology Major Project "Key New Drug Creation and
   Manufacturing Program'' (2009ZX09102-114, 2009ZX09301-011), the Grant-in
   Aid for Scientific Research on Special Priority Areas of Cancer from the
   Ministry of Education, Culture, Sports, Science and Technology of Japan
   (12670383), and grants from the Major International (Regional) Joint
   Research Projects (30320140461), the Science and Technology Commission
   of Xuhui District of Shanghai Municipality (RCT201001, CRC2010002),
   Director Foundation of INS (20090101), the Food Safety Research Center
   and Key Laboratory of Nutrition and Metabolism of INS, SIBS, CAS. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berndt SI, 2008, HUM MOL GENET, V17, P2665, DOI 10.1093/hmg/ddn166
   Broderick P, 2007, NAT GENET, V39, P1315, DOI 10.1038/ng.2007.18
   Cicek MS, 2009, CANCER EPIDEM BIOMAR, V18, P2492, DOI 10.1158/1055-9965.EPI-09-0362
   Cui R, 2011, GUT
   Curtin K, 2009, CANCER EPIDEM BIOMAR, V18, P616, DOI 10.1158/1055-9965.EPI-08-0690
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Garcia-Closas M, 1999, AM J EPIDEMIOL, V149, P689
   Ghoussaini M, 2008, J NATL CANCER I, V100, P962, DOI 10.1093/jnci/djn190
   Gruber SB, 2007, CANCER BIOL THER, V6, P1143, DOI 10.4161/cbt.6.7.4704
   Haiman CA, 2007, NAT GENET, V39, P954, DOI 10.1038/ng2098
   Haiman CA, 2007, NAT GENET, V39, P638, DOI 10.1038/ng2015
   He J, 2011, CANCER EPIDEM BIOMAR, V20, P70, DOI 10.1158/1055-9965.EPI-10-0892
   Hutter CM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-670
   Jaeger E, 2008, NAT GENET, V40, P26, DOI 10.1038/ng.2007.41
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
   KRUPFER SS, 2010, GASTROENTEROLOGY, V139, P1677
   Kupfer SS, 2009, CARCINOGENESIS, V30, P1353, DOI 10.1093/carcin/bgp123
   KUPFER SS, 2010, GASTROENTEROLOGY, V139, pE1671
   Li L, 2008, CANCER EPIDEM BIOMAR, V17, P339, DOI 10.1158/1055-9965.EPI-07-0713
   LUBIN JH, 1990, AM J EPIDEMIOL, V131, P552, DOI 10.1093/oxfordjournals.aje.a115530
   Matsuo K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-379
   Middeldorp A, 2009, CANCER EPIDEM BIOMAR, V18, P3062, DOI 10.1158/1055-9965.EPI-09-0601
   Niittymaki I, 2010, CANCER EPIDEM BIOMAR, V19, P1478, DOI 10.1158/1055-9965.EPI-09-1320
   Pittman AM, 2008, BRIT J CANCER, V98, P1434, DOI 10.1038/sj.bjc.6604314
   Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403
   Poynter JN, 2007, CANCER RES, V67, P11128, DOI 10.1158/0008-5472.CAN-07-3239
   Schafmayer C, 2009, INT J CANCER, V124, P75, DOI 10.1002/ijc.23872
   Sung JJY, 2005, LANCET ONCOL, V6, P871, DOI 10.1016/S1470-2045(05)70422-8
   Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133
   Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085
   Tomlinson IPM, 2008, NAT GENET, V40, P623, DOI 10.1038/ng.111
   Tuupanen S, 2008, CANCER RES, V68, P14, DOI 10.1158/0008-5472.CAN-07-5766
   Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406
   von Holst S, 2010, BRIT J CANCER, V103, P575, DOI 10.1038/sj.bjc.6605774
   White KL, 2010, TWIN RES HUM GENET, V13, P43, DOI 10.1375/twin.13.1.43
   Wokolorczyk D, 2008, CANCER RES, V68, P9982, DOI 10.1158/0008-5472.CAN-08-1838
   Xiong F, 2010, CANCER EPIDEM BIOMAR, V19, P1855, DOI 10.1158/1055-9965.EPI-10-0210
   Xu YF, 2007, HUM MOL GENET, V16, pR14, DOI 10.1093/hmg/ddl486
   Yang H, 2009, CANCER EPIDEM BIOMAR, V18, P2522, DOI 10.1158/1055-9965.EPI-09-0398
   Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089
   Zheng SL, 2008, NEW ENGL J MED, V358, P910, DOI 10.1056/NEJMoa075819
NR 42
TC 27
Z9 28
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 24
PY 2011
VL 6
IS 3
AR e18251
DI 10.1371/journal.pone.0018251
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 740RG
UT WOS:000288811500033
PM 21455501
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Li, XA
   Hu, Z
   Qu, XS
   Zhu, JD
   Li, L
   Ring, BZ
   Su, L
AF Li, Xiang
   Hu, Zheng
   Qu, Xinshun
   Zhu, Jiadong
   Li, Lin
   Ring, Brian Z.
   Su, Li
TI Putative EPHX1 Enzyme Activity Is Related with Risk of Lung and Upper
   Aerodigestive Tract Cancers: A Comprehensive Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID MICROSOMAL EPOXIDE HYDROLASE; GLUTATHIONE-S-TRANSFERASE;
   SQUAMOUS-CELL-CARCINOMA; XENOBIOTIC-METABOLIZING ENZYMES;
   GENE-ENVIRONMENT INTERACTION; COLORECTAL-CANCER; CIGARETTE-SMOKING;
   BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; BLADDER-CANCER
AB Background: EPHX1 is a key enzyme in metabolizing some exogenous carcinogens such as products of cigarette-smoking. Two functional polymorphisms in the EPHX1 gene, Tyr113His and His139Arg can alter the enzyme activity, suggesting their possible association with carcinogenesis risk, particularly of some tobacco-related cancers.
   Methodology/Principal Findings: A comprehensive systematic review and meta-analysis was performed of available studies on these two polymorphisms and cancer risk published up to November 2010, consisting of 84 studies (31144 cases and 42439 controls) for Tyr113His and 77 studies (28496 cases and 38506 controls) for His139Arg primarily focused on lung cancer, upper aerodigestive tract (UADT) cancers (including oral, pharynx, larynx and esophagus cancers), colorectal cancer or adenoma, bladder cancer and breast cancer. Results showed that Y113H low activity allele (H) was significantly associated with decreased risk of lung cancer (OR = 0.88, 95%Cl = 0.80-0.96) and UADT cancers (OR = 0.86, 95%Cl = 0.77-0.97) and H139R high activity allele (R) with increased risk of lung cancer (OR = 1.18, 95%Cl = 1.04-1.33) but not of UADT cancers (OR = 1.05, 95%Cl = 0.93-1.17). Pooled analysis of lung and UADT cancers revealed that low EPHX1 enzyme activity, predicted by the combination of Y113H and H139R showed decreased risk of these cancers (OR = 0.83, 95%Cl = 0.75-0.93) whereas high EPHX1 activity increased risk of the cancers (OR = 1.20, 95% Cl = 0.98-1.46). Furthermore, modest difference for the risk of lung and UADT cancers was found between cigarette smokers and nonsmokers both in single SNP analyses (low activity allele H: OR = 0.77/0.85 for smokers/nonsmokers; high activity allele R: OR = 1.20/1.09 for smokers/nonsmokers) and in combined double SNP analyses (putative low activity: OR = 0.73/0.88 for smokers/nonsmokers; putative high activity: OR = 1.02/0.93 for smokers/nonsmokers).
   Conclusions/Significance: Putative low EPHX1 enzyme activity may have a potential protective effect on tobacco-related carcinogenesis of lung and UADT cancers, whereas putative high EPHX1 activity may have a harmful effect. Moreover, cigarette-smoking status may influence the association of EPHX1 enzyme activity and the related cancer risk.
C1 [Li, Xiang; Zhu, Jiadong; Li, Lin; Su, Li] Huazhong Univ Sci & Technol, Key Lab Mol Biophys, Minist Educ,Sino France Joint Ctr Drug Res & Scre, Sch Life Sci & Technol, Wuhan 430074, Peoples R China.
   [Hu, Zheng] Chinese Acad Sci, Beijing Inst Genom, Beijing, Peoples R China.
   [Qu, Xinshun] Penn State Univ, Dept Plant Pathol, University Pk, PA 16802 USA.
   [Ring, Brian Z.] Yigene Inc, Beijing, Peoples R China.
RP Li, XA (reprint author), Huazhong Univ Sci & Technol, Key Lab Mol Biophys, Minist Educ,Sino France Joint Ctr Drug Res & Scre, Sch Life Sci & Technol, Wuhan 430074, Peoples R China.
EM lisu@mail.hust.edu.cn
FU Ministry of Science and Technology, China [2009DFA31940,
   2009ZX10001-017-06]
FX This study was funded in part by a grant 2009DFA31940 and
   2009ZX10001-017-06 from The Ministry of Science and Technology, China.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. Dr. Ring is
   employed by Yigene Inc. and helped to prepare the manuscript. Yigene
   Inc. did have a role in the preparation of the manuscript.
CR Agudo A, 2006, CANCER EPIDEM BIOMAR, V15, P2427, DOI 10.1158/1055-9965.EPI-06-0072
   Amador AG, 2002, ORAL SURG ORAL MED O, V93, P440, DOI 10.1067/moe.2002.122586
   Baxter SW, 2002, CANCER LETT, V177, P75, DOI 10.1016/S0304-3835(01)00782-0
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benhamou S, 1998, CANCER RES, V58, P5291
   Boccia S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-206
   Boccia S, 2008, J CANCER RES CLIN, V134, P93, DOI 10.1007/s00432-007-0254-5
   Broberg K, 2005, CARCINOGENESIS, V26, P1263, DOI 10.1093/carcin/bgi063
   Brockmoller J, 1996, PHARMACOGENETICS, V6, P535, DOI 10.1097/00008571-199612000-00007
   Cajas-Salazar N, 2003, CANCER GENET CYTOGEN, V145, P97, DOI 10.1016/S0165-4908(03)00058-X
   Casson AG, 2003, CANCER DETECT PREV, V27, P139, DOI 10.1016/S0361-090X(03)00033-3
   Casson AG, 2006, CANCER DETECT PREV, V30, P423, DOI 10.1016/j.cdp.2006.09.005
   CHAUHAN PS, 2010, DNA CELL BIOL   0823
   Clavel J, 2005, EUR J CANCER PREV, V14, P531, DOI 10.1097/00008469-200512000-00007
   Cleary SP, 2010, AM J EPIDEMIOL, V172, P1000, DOI 10.1093/aje/kwq245
   Cortessis V, 2001, CANCER RES, V61, P2381
   Cotterchio M, 2008, CANCER EPIDEM BIOMAR, V17, P3098, DOI 10.1158/1055-9965.EPI-08-0341
   de Assis S, 2002, CANCER EPIDEM BIOMAR, V11, P1697
   De Roos AJ, 2006, NEURO-ONCOLOGY, V8, P145, DOI 10.1215/15228517-2005-003
   De Roos AJ, 2006, CANCER EPIDEM BIOMAR, V15, P1647, DOI 10.1158/1055-9965.EPI-06-0193
   Decker M, 2009, ARCH TOXICOL, V83, P297, DOI 10.1007/s00204-009-0416-0
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Figueroa JD, 2008, CARCINOGENESIS, V29, P1955, DOI 10.1093/carcin/bgn163
   Fretland AJ, 2000, CHEM-BIOL INTERACT, V129, P41, DOI 10.1016/S0009-2797(00)00197-6
   Gemignani F, 2007, CARCINOGENESIS, V28, P1287, DOI 10.1093/carcin/bgm021
   Gold LS, 2009, CANCER EPIDEMIOL, V33, P276, DOI 10.1016/j.canep.2009.08.005
   Graziano C, 2009, LUNG CANCER, V63, P187, DOI 10.1016/j.lungcan.2008.05.004
   Gsur A, 2003, BRIT J CANCER, V89, P702, DOI 10.1038/sj.bjc.6601142
   Harrison DJ, 1999, BRIT J CANCER, V79, P168, DOI 10.1038/sj.bjc.6690028
   Hassett C, 1997, ARCH BIOCHEM BIOPHYS, V337, P275, DOI 10.1006/abbi.1996.9794
   HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421
   Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2008, INT J EPIDEMIOL, V37, P1158, DOI 10.1093/ije/dyn204
   Hlavata I, 2010, ONCOL REP, V24, P1347, DOI 10.3892/or_0000992
   Hsu LI, 2008, TOXICOL APPL PHARM, V228, P144, DOI 10.1016/j.taap.2007.12.003
   Huang WY, 2005, CANCER EPIDEM BIOMAR, V14, P152
   *IARC, 2004, TOB SMOK INV SM
   Ihsan R, 2010, J GASTROEN HEPATOL, V25, P1456, DOI 10.1111/j.1440-1746.2010.06354.x
   Jourenkova-Mironova N, 2000, CANCER RES, V60, P534
   Justenhoven C, 2008, BREAST CANCER RES TR, V108, P137, DOI 10.1007/s10549-007-9586-8
   Khedhaier A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-109
   Kiran M, 2008, DNA CELL BIOL, V27, P687, DOI 10.1089/dna.2008.0805
   Kiran M, 2009, DNA CELL BIOL, V28, P573, DOI 10.1089/dna.2009.0921
   Kirk GD, 2005, CANCER EPIDEM BIOMAR, V14, P373, DOI 10.1158/1055-9965.EPI-04-0161
   Kiss I, 2007, ANTICANCER RES, V27, P2931
   Kiyohara C, 2006, EPIDEMIOLOGY, V17, P89, DOI 10.1097/01.ece.0000187627.70026.23
   Lacko M, 2008, HEAD NECK-J SCI SPEC, V30, P836, DOI 10.1002/hed.20781
   Landi S, 2005, PHARMACOGENET GENOM, V15, P535, DOI 10.1097/01.fpc.0000165904.48994.3d
   Lebailly P, 2002, BRIT J HAEMATOL, V116, P587, DOI 10.1046/j.0007-1048.2001.03320.x
   Lin YC, 2006, CANCER LETT, V237, P281, DOI 10.1016/j.canlet.2005.06.010
   Lincz LF, 2007, LEUKEMIA RES, V31, P759, DOI 10.1016/j.leukres.2006.07.012
   London SJ, 2000, LUNG CANCER-J IASLC, V28, P147, DOI 10.1016/S0169-5002(99)00130-0
   *MARIE GENICA CONS, 2010, BREAST CANC RES TREA, V120, P737, DOI DOI 10.1007/S10549-009-0490-2
   Mckay JD, 2008, CANCER EPIDEM BIOMAR, V17, P141, DOI 10.1158/1055-9965.EPI-07-0553
   Minelli C, 2005, STAT MED, V24, P3845, DOI 10.1002/sim.2393
   Minelli C, 2005, INT J EPIDEMIOL, V34, P1319, DOI 10.1093/ije/dyi169
   Mitrou PN, 2007, CARCINOGENESIS, V28, P875, DOI 10.1093/carcin/bgl194
   Mittal RD, 2007, DNA CELL BIOL, V26, P791, DOI 10.1089/dna.2007.0630
   Morisseau C, 2005, ANNU REV PHARMACOL, V45, P311, DOI 10.1146/annurev.pharmtox.45.120403.095920
   Nishino K, 2008, J OBSTET GYNAECOL RE, V34, P994, DOI 10.1111/j.1447-0756.2008.00798.x
   Northwood EL, 2010, PHARMACOGENET GENOM, V20, P315, DOI 10.1097/FPC.0b013e3283395c6a
   Ockenga J, 2009, PANCREAS, V38, pE97, DOI 10.1097/MPA.0b013e31819feeed
   OESCH F, 1973, XENOBIOTICA, V3, P305, DOI 10.3109/00498257309151525
   Park JH, 2003, TRANSPORT RES E-LOG, V39, P1, DOI 10.1016/S1366-5545(02)00023-6
   Park JY, 2005, EUR J CANCER PREV, V14, P223, DOI 10.1097/00008469-200506000-00005
   Patsopoulos NA, 2008, INT J EPIDEMIOL, V37, P1148, DOI 10.1093/ije/dyn065
   Persson I, 1999, INT J CANCER, V81, P325, DOI 10.1002/(SICI)1097-0215(19990505)81:3<325::AID-IJC2>3.3.CO;2-J
   Petiti DB, 1994, METAANALYSIS DECISIO, V24
   Robien K, 2005, CANCER EPIDEM BIOMAR, V14, P1350, DOI 10.1158/1055-9965.EPI-04-0877
   Rosenberger A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-60
   Rotunno M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005652
   Sachse C, 2002, CARCINOGENESIS, V23, P1839, DOI 10.1093/carcin/23.11.1839
   Sangrajrang S, 2009, INT J CANCER, V125, P837, DOI 10.1002/ijc.24434
   Sarmanova J, 2004, EUR J HUM GENET, V12, P848, DOI 10.1038/sj.ejhg.5201249
   Sarmanova J, 2001, HUM MOL GENET, V10, P1265, DOI 10.1093/hmg/10.12.1265
   SEIDEGARD J, 1983, BIOCHIM BIOPHYS ACTA, V695, P251, DOI 10.1016/0304-419X(83)90014-8
   Sierra-Torres CH, 2003, ENVIRON MOL MUTAGEN, V41, P69, DOI 10.1002/em.10132
   Silveira VD, 2010, ENVIRON MOL MUTAGEN, V51, P48, DOI 10.1002/em.20510
   SIMS P, 1974, NATURE, V252, P326, DOI 10.1038/252326a0
   Skjelbred CF, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-228
   Smith CAD, 1997, LANCET, V350, P630, DOI 10.1016/S0140-6736(96)08061-0
   Soucek P, 2010, NEOPLASMA, V57, P415, DOI 10.4149/neo_2010_05_415
   Spurdle AB, 2001, MOL CARCINOGEN, V30, P71, DOI 10.1002/1098-2744(200101)30:1<71::AID-MC1015>3.0.CO;2-9
   Spurdle AB, 2007, CANCER EPIDEM BIOMAR, V16, P769, DOI 10.1158/1055-9965.EPI-06-0776
   Srivastava DS, 2008, ARCH TOXICOL, V82, P633, DOI 10.1007/s00204-007-0276-4
   Taioli E, 2008, CARCINOGENESIS, V29, P1467, DOI 10.1093/carcin/bgn062
   Tiemersma EW, 2004, INT J CANCER, V108, P97, DOI 10.1002/ijc.11533
   Tiemersma EW, 2001, CANCER EPIDEM BIOMAR, V10, P785
   Timofeeva M, 2010, INT J CANCER, V127, P1547, DOI 10.1002/ijc.25175
   To-Figueras J, 2002, CANCER LETT, V187, P95, DOI 10.1016/S0304-3835(02)00406-8
   To-Figueras J, 2001, CANCER LETT, V173, P155, DOI 10.1016/S0304-3835(01)00626-7
   Tranah GJ, 2004, CARCINOGENESIS, V25, P1211, DOI 10.1093/carcin/bgh126
   Tranah GJ, 2005, MOL CARCINOGEN, V44, P21, DOI 10.1002/mc.20112
   Tsai YY, 2003, LUNG CANCER-J IASLC, V41, P269, DOI 10.1016/S0169-5002(03)00238-1
   Ulrich CM, 2001, CANCER EPIDEM BIOMAR, V10, P875
   van der Logt EMJ, 2006, MUTAT RES-FUND MOL M, V593, P39, DOI 10.1016/j.mrfmmm.2005.06.018
   Varela-Lema L, 2008, J ONCOL, DOI 10.1155/2008/741310
   Voho A, 2006, CANCER LETT, V237, P102, DOI 10.1016/j.canlet.2005.05.029
   Wenghoefer M, 2003, ARCH TOXICOL, V77, P37, DOI 10.1007/s00204-002-0414-y
   Wong NACS, 2000, TOXICOL LETT, V115, P17, DOI 10.1016/S0378-4274(00)00166-1
   Wu XF, 2001, CARCINOGENESIS, V22, P923, DOI 10.1093/carcin/22.6.923
   Yin L, 2001, LUNG CANCER-J IASLC, V33, P133, DOI 10.1016/S0169-5002(01)00182-9
   Yoshikawa M, 2000, INT J MOL MED, V5, P49
   Zhang JH, 2003, WORLD J GASTROENTERO, V9, P2654
   Zhao H, 2002, MOL CARCINOGEN, V33, P99, DOI 10.1002/mc.10023
   Zhou W, 2001, CANCER EPIDEM BIOMAR, V10, P461
   Zienolddiny S, 2008, CARCINOGENESIS, V29, P1164, DOI 10.1093/carcin/bgn020
NR 110
TC 25
Z9 26
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 18
PY 2011
VL 6
IS 3
AR e14749
DI 10.1371/journal.pone.0014749
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 737CD
UT WOS:000288545100001
PM 21445251
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Liu, SJ
   Yao, L
   Ding, DL
   Zhu, HZ
AF Liu, Sijie
   Yao, Lei
   Ding, DongLin
   Zhu, HuanZhang
TI CCL3L1 Copy Number Variation and Susceptibility to HIV-1 Infection: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENETIC-VARIATION; DISEASE PROGRESSION; AIDS SUSCEPTIBILITY;
   EPIDEMIOLOGY; TRANSMISSION; CCR5; PATHOGENESIS; ASSOCIATION; COMPLEX;
   FALSE
AB Background: Although several studies have investigated whether CCL3L1 copy number variation (CNV) influences the risk of HIV-1 infection, there are still no clear conclusions. Therefore, we performed a meta-analysis using two models to generate a more robust estimate of the association between CCL3L1 CNV and susceptibility to HIV-1 infection.
   Methods: We divided the cases and controls into two parts as individuals with CCL3L1 gene copy number (GCN) above the population specific median copy number (PMN) and individuals with CCL3L1 GCN below PMN, respectively. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were given for the main analysis. We also conducted stratified analyses by ethnicity, age group and sample size. Relevant literatures were searched through PubMed and ISI Web of Knowledge up to March 2010.
   Results: In total, 9 studies with 2434 cases and 4029 controls were included. ORs for the main analysis were 1.35 (95% CI, 1.02-1.78, model: GCN <= PMN Vs. GCN > PMN) and 1.70 (95% CI, 1.30-2.23, model: GCN < PMN Vs. GCN >= PMN), respectively. Either in stratified analysis, statistically significant results can be detected in some subgroups.
   Conclusions: Our analyses indicate that CCL3L1 CNV is associated with susceptibility to HIV-1 infection. A lower copy number is associated with an increased risk of HIV-1 infection, while a higher copy number is associated with reduced risk for acquiring HIV-1.
C1 [Liu, Sijie; Yao, Lei; Ding, DongLin; Zhu, HuanZhang] Fudan Univ, State Key Lab Genet Engn, Inst Genet, Sch Life Sci, Shanghai 200433, Peoples R China.
RP Liu, SJ (reprint author), Fudan Univ, State Key Lab Genet Engn, Inst Genet, Sch Life Sci, Shanghai 200433, Peoples R China.
EM hzzhu@fudan.edu.cn
FU National Grand Program on Key Infectious Disease [2008ZX10001-006];
   National Natural Science Funding of China [30972609]; Basic Science Key
   Program of Shanghai [08JC1401300]; National Talent Training Fund in
   Basic Research of China [J1030627]
FX This work was supported by National Grand Program on Key Infectious
   Disease (2008ZX10001-006), National Natural Science Funding of China
   (No. 30972609), Basic Science Key Program of Shanghai (No. 08JC1401300)
   and National Talent Training Fund in Basic Research of China (No.
   J1030627). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Arenzana-Seisdedos F, 2006, SEMIN IMMUNOL, V18, P387, DOI 10.1016/j.smim.2006.07.007
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhattacharya T, 2009, NAT MED, V15, P1112, DOI 10.1038/nm1009-1112
   Bugeja MJ, 2004, AIDS, V18, P1069, DOI 10.1097/01.aids.0000125927.95420.c0
   Cochran W.G., 1954, BIOMETRICS, V10, P29, DOI DOI 10.2307/3001666
   Colobran R, 2010, CLIN EXP IMMUNOL, V162, P41, DOI 10.1111/j.1365-2249.2010.04224.x
   Degenhardt JD, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000346
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dolan MJ, 2007, NAT IMMUNOL, V8, P1324, DOI 10.1038/ni1521
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   *EP AIDS, DEATH TOLL AIDS HAS
   Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160
   Gonzalez E, 2001, P NATL ACAD SCI USA, V98, P5199, DOI 10.1073/pnas.091056898
   He WJ, 2009, NAT MED, V15, P1117, DOI 10.1038/nm1009-1117
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   Huik K, 2010, J INFECT DIS, V201, P730, DOI 10.1086/650491
   Ioannidis JPA, 2002, AM J EPIDEMIOL, V156, P204, DOI 10.1093/aje/kwf031
   Ioannidis JPA, 2003, TRENDS MOL MED, V9, P135, DOI 10.1016/S1471-4914(03)00030-3
   Julg B, 2005, INFECTION, V33, P160, DOI 10.1007/s15010-005-6305-4
   Kaslow RA, 2005, J INFECT DIS, V191, pS68, DOI 10.1086/425269
   Kaur G, 2009, TISSUE ANTIGENS, V73, P289, DOI 10.1111/j.1399-0039.2009.01220.x
   Kuhn L, 2007, AIDS, V21, P1753, DOI 10.1097/QAD.0b013e3282ba553a
   Kulkarni H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003165
   Mackay CR, 2005, TRENDS MOL MED, V11, P203, DOI 10.1016/j.molmed.2005.03.003
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Meddows-Taylor S, 2006, J GEN VIROL, V87, P2055, DOI 10.1099/vir.0.81709-0
   Modi WS, 2006, AM J HUM GENET, V79, P120, DOI 10.1086/505331
   Moore JP, 2007, CELL HOST MICROBE, V2, P281, DOI 10.1016/j.chom.2007.10.005
   Nakajima T, 2008, CYTOGENET GENOME RES, V123, P156, DOI 10.1159/000184703
   Nakajima T, 2007, IMMUNOGENETICS, V59, P793, DOI 10.1007/s00251-007-0252-4
   *NCBI ENTR GEN, CCL3L1 CHEM C C MOT
   Rathore A, 2009, AIDS RES HUM RETROV, V25, P1149, DOI 10.1089/aid.2008.0019
   Shalekoff S, 2008, JAIDS-J ACQ IMM DEF, V48, P245, DOI 10.1097/QAI.0b013e31816fdc77
   Shao W, 2007, GENES IMMUN, V8, P224, DOI 10.1038/sj.gene.6364378
   Shostakovich-Koretskaya L, 2009, AIDS, V23, P679, DOI 10.1097/QAD.0b013e3283270b3f
   Shrestha S, 2009, NAT MED, V15, P1127, DOI 10.1038/nm1009-1127
   Telenti A, 2006, NAT REV MICROBIOL, V4, P9
   Tobias A., 1999, STATA TECH B, V8
   URBAN TJ, 2009, NAT MED, V15, P1009
   Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075
NR 40
TC 18
Z9 21
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 30
PY 2010
VL 5
IS 12
AR e15778
DI 10.1371/journal.pone.0015778
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 701DD
UT WOS:000285793600038
PM 21209899
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Gkrania-Klotsas, E
   Ye, Z
   Cooper, AJ
   Sharp, SJ
   Luben, R
   Biggs, ML
   Chen, LK
   Gokulakrishnan, K
   Hanefeld, M
   Ingelsson, E
   Lai, WA
   Lin, SY
   Lind, L
   Lohsoonthorn, V
   Mohan, V
   Muscari, A
   Nilsson, G
   Ohrvik, J
   Qiang, JC
   Jenny, NS
   Tamakoshi, K
   Temelkova-Kurktschiev, T
   Wang, YY
   Yajnik, CS
   Zoli, M
   Khaw, KT
   Forouhi, NG
   Wareham, NJ
   Langenberg, C
AF Gkrania-Klotsas, Effrossyni
   Ye, Zheng
   Cooper, Andrew J.
   Sharp, Stephen J.
   Luben, Robert
   Biggs, Mary L.
   Chen, Liang-Kung
   Gokulakrishnan, Kuppan
   Hanefeld, Markolf
   Ingelsson, Erik
   Lai, Wen-An
   Lin, Shih-Yi
   Lind, Lars
   Lohsoonthorn, Vitool
   Mohan, Viswanathan
   Muscari, Antonio
   Nilsson, Goran
   Ohrvik, John
   Qiang, Jiang Chao
   Jenny, Nancy Swords
   Tamakoshi, Koji
   Temelkova-Kurktschiev, Theodora
   Wang, Ya-Yu
   Yajnik, Chittaranjan Sakerlal
   Zoli, Marco
   Khaw, Kay-Tee
   Forouhi, Nita G.
   Wareham, Nicholas J.
   Langenberg, Claudia
TI Differential White Blood Cell Count and Type 2 Diabetes: Systematic
   Review and Meta-Analysis of Cross-Sectional and Prospective Studies
SO PLOS ONE
LA English
DT Article
ID C-REACTIVE PROTEIN; ERYTHROCYTE SEDIMENTATION-RATE; METABOLIC SYNDROME;
   INSULIN-RESISTANCE; LEUKOCYTE COUNT; CARDIOVASCULAR-DISEASE;
   EPIC-NORFOLK; ENDOTHELIAL DYSFUNCTION; ATHEROSCLEROSIS RISK;
   INFLAMMATORY MARKERS
AB Objective: Biological evidence suggests that inflammation might induce type 2 diabetes (T2D), and epidemiological studies have shown an association between higher white blood cell count (WBC) and T2D. However, the association has not been systematically investigated.
   Research Design and Methods: Studies were identified through computer-based and manual searches. Previously unreported studies were sought through correspondence. 20 studies were identified (8,647 T2D cases and 85,040 non-cases). Estimates of the association of WBC with T2D were combined using random effects meta-analysis; sources of heterogeneity as well as presence of publication bias were explored.
   Results: The combined relative risk (RR) comparing the top to bottom tertile of the WBC count was 1.61 (95% CI: 1.45; 1.79, p = 1.5*10(-18)). Substantial heterogeneity was present (I(2) = 83%). For granulocytes the RR was 1.38 (95% CI: 1.17; 1.64, p = 1.5*10(-4)), for lymphocytes 1.26 (95% CI: 1.02; 1.56, p = 0.029), and for monocytes 0.93 (95% CI: 0.68; 1.28, p = 0.67) comparing top to bottom tertile. In cross-sectional studies, RR was 1.74 (95% CI: 1.49; 2.02, p = 7.7*10(-13)), while in cohort studies it was 1.48 (95% CI: 1.22; 1.79, p = 7.7*10(-5)). We assessed the impact of confounding in EPIC-Norfolk study and found that the age and sex adjusted HR of 2.19 (95% CI: 1.74; 2.75) was attenuated to 1.82 (95% CI: 1.45; 2.29) after further accounting for smoking, T2D family history, physical activity, education, BMI and waist circumference.
   Conclusions: A raised WBC is associated with higher risk of T2D. The presence of publication bias and failure to control for all potential confounders in all studies means the observed association is likely an overestimate.
C1 [Gkrania-Klotsas, Effrossyni; Ye, Zheng; Cooper, Andrew J.; Sharp, Stephen J.; Forouhi, Nita G.; Wareham, Nicholas J.; Langenberg, Claudia] Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England.
   [Luben, Robert; Khaw, Kay-Tee] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
   [Biggs, Mary L.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
   [Chen, Liang-Kung] Natl Yang Ming Univ, Sch Med, Taipei Vet Gen Hosp, Dept Family Med, Taipei 112, Taiwan.
   [Gokulakrishnan, Kuppan; Mohan, Viswanathan] Madras Diabet Res Fdn, Madras, Tamil Nadu, India.
   [Gokulakrishnan, Kuppan; Mohan, Viswanathan] Dr Mohans Diabet Special Ctr, Madras, Tamil Nadu, India.
   [Hanefeld, Markolf; Temelkova-Kurktschiev, Theodora] Tech Univ Dresden GmBH, Ctr Clin Study Gesell Wissens & Technol Transfer, Dresden, Germany.
   [Ingelsson, Erik] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [Lai, Wen-An; Wang, Ya-Yu] Kuang Tien Gen Hosp, Dept Family Med, Taichung, Taiwan.
   [Lin, Shih-Yi] Taichung Vet Gen Hosp, Div Endrocrinol & Metab, Taichung, Taiwan.
   [Lind, Lars] Univ Uppsala Hosp, Dept Med Sci, Uppsala, Sweden.
   [Lohsoonthorn, Vitool] Chulalongkorn Univ, Fac Med, Dept Prevent & Social Med, Bangkok 10330, Thailand.
   [Muscari, Antonio; Zoli, Marco] Univ Bologna, Dept Internal Med Aging & Nephrol Dis, Bologna, Italy.
   [Nilsson, Goran] Uppsala Univ, Clin Res Ctr, Vasteras, Sweden.
   [Ohrvik, John] Karolinska Inst, Dept Med, Stockholm, Sweden.
   [Qiang, Jiang Chao] Guangzhou 12 Hosp, Guangzhou, Guangdong, Peoples R China.
   [Jenny, Nancy Swords] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA.
   [Tamakoshi, Koji] Nagoya Univ, Sch Hlth Sci, Dept Nursing, Nagoya, Aichi 4648601, Japan.
   [Temelkova-Kurktschiev, Theodora] Natl Sports Acad, Int Sci Inst, Medicobiol Unit, Sofia, Bulgaria.
   [Temelkova-Kurktschiev, Theodora] Robert Koch German Med Ctr, Sofia, Bulgaria.
   [Yajnik, Chittaranjan Sakerlal] King Edward Mem Hosp, Pune, Maharashtra, India.
RP Gkrania-Klotsas, E (reprint author), Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England.
EM eg318@cam.ac.uk
RI Luben, Robert N/H-5519-2015
OI Luben, Robert N/0000-0002-5088-6343; Cooper, Andrew/0000-0003-1025-0268;
   Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330; Forouhi,
   Nita/0000-0002-5041-248X; Langenberg, Claudia/0000-0002-5017-7344
FU Medical Research Council; Cambridge BRC-NIHR; Cancer Research United
   Kingdom; Faculty of Medicine, Chulalongkorn University, Thailand;
   National Institutes of Health [T37-TW00049, T37-MD-100449]; Swedish
   Research Council; Swedish Foundation for Strategic Research; Royal
   Swedish Academy of Science; Uppsala University Hospital; AstraZeneca RD,
   Moelndal; National Heart, Lung, and Blood Institute [N01-HC-85079,
   N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150,
   N01-HC-45133, U01 HL080295, R01 HL-075366, R01 HL-094555]; National
   Institute on Aging [R01 AG-023629, R01 AG-15928, R01 AG-20098,
   AG-027058]; University of Pittsburgh Claude; Medical Research Council
   [MC_U106179471, MC_UP_A100_1003, G0701652, G0401527]
FX EGK is supported by the Medical Research Council through a Clinical
   Research Training Fellowship and the Cambridge BRC-NIHR. EPIC-Norfolk is
   supported by grant funding from the Medical Research Council and Cancer
   Research United Kingdom with additional support from the Stroke
   Association, British Heart Foundation, Research Into Ageing, and the
   Academy of Medical Science. The sponsors had no role in the design and
   conduct of the study, collection, management, analysis and
   interpretation of the data, and preparation, review, or approval of the
   manuscript. VL is supported by the Rachadapiseksompoj Faculty of
   Medicine Research Fund Chulalongkorn University, Thailand, and by the
   National Institutes of Health ( grants T37-TW00049 and T37-MD-100449).
   PIVUS work was supported by the Swedish Research Council, the Swedish
   Foundation for Strategic Research, the Royal Swedish Academy of Science,
   Uppsala University Hospital and AstraZeneca R&D, Moelndal. The sponsors
   had no role in the PIVUS study design, analyses, writing or decision to
   publish the manuscript. The Cardiovascular Health Study research was
   supported by contract numbers N01-HC-85079 through N01-HC-85086,
   N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133,
   and grant numbers U01 HL080295, R01 HL-075366 and R01 HL-094555 from the
   National Heart, Lung, and Blood Institute; R01 AG-023629, R01 AG-15928,
   R01 AG-20098, and AG-027058 from the National Institute on Aging; the
   University of Pittsburgh Claude. D. Pepper Older Americans Independence
   Center P30-AG-024827, with additional contribution from the National
   Institute of Neurological Disorders and Stroke. A full list of principal
   CHS investigators and institutions can be found at
   http://www.chs-nhlbi.org/pi.htm. JO and GN's work was supported by
   grants from Vastmanland's research foundation against cardiovascular
   disease and SparbanksstiftelsenNya. GN had full access to all of the
   data in the study and takes responsibility for the integrity of the data
   and the accuracy of the data analysis.
CR Barzilay JI, 2001, DIABETES, V50, P2384, DOI 10.2337/diabetes.50.10.2384
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen Liang-Kung, 2006, J Chin Med Assoc, V69, P248
   Chien K, 2009, DIABETOLOGIA, V52, P443, DOI 10.1007/s00125-008-1232-4
   Chuo SK, 2005, ENDOCR RES, V31, P39, DOI 10.1080/07435800500229151
   Dandona P, 2001, J CLIN ENDOCR METAB, V86, P3257, DOI 10.1210/jc.86.7.3257
   Dandona P, 2004, REV ENDOCR METAB DIS, V5, P189, DOI 10.1023/B:REMD.0000032407.88070.0a
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477
   Day N, 1999, BRIT J CANCER, V80, P95
   Donath MY, 2005, DIABETES, V54, pS108, DOI 10.2337/diabetes.54.suppl_2.S108
   Duncan BB, 2003, DIABETES, V52, P1799, DOI 10.2337/diabetes.52.7.1799
   Duncan BB, 2000, OBES RES, V8, P279, DOI 10.1038/oby.2000.33
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ford ES, 2002, AM J EPIDEMIOL, V155, P57, DOI 10.1093/aje/155.1.57
   Gokulakrishnan K, 2009, METAB SYNDR RELAT D, V7, P205, DOI 10.1089/met.2008.0024
   Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23
   Hak AE, 1999, ARTERIOSCL THROM VAS, V19, P1986, DOI 10.1161/01.ATV.19.8.1986
   Hanefeld M, 2009, HORM METAB RES, V41, P132, DOI 10.1055/s-0028-1119407
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Ingelsson E, 2008, EUR J CLIN INVEST, V38, P502, DOI 10.1111/j.1365-2362.2008.01962.x
   Ishizaka N, 2007, INTERNAL MED, V46, P1167, DOI 10.2169/internalmedicine.46.0136
   Khaw KT, 2008, PLOS MED, V5, P39, DOI 10.1371/journal.pmed.0050012
   Kim DJ, 2008, J KOREAN MED SCI, V23, P193, DOI 10.3346/jkms.2008.23.2.193
   Kim JA, 2006, ENDOCR J, V53, P133, DOI 10.1507/endocrj.53.133
   Kim JA, 2008, METABOLISM, V57, P1375, DOI 10.1016/j.metabol.2008.05.005
   Lao XQ, 2008, ATHEROSCLEROSIS, V201, P418, DOI 10.1016/j.atherosclerosis.2007.12.053
   Lohsoonthorn V, 2006, AM J HYPERTENS, V19, P339, DOI 10.1016/j.amjhyper.2005.10.008
   Lundgren CH, 1996, CIRCULATION, V93, P106, DOI 10.1161/01.CIR.93.1.106
   Marques-Vidal P, 2002, DIABETES CARE, V25, P1371, DOI 10.2337/diacare.25.8.1371
   MCCARTHY DA, 1988, SPORTS MED, V6, P333, DOI 10.2165/00007256-198806060-00002
   Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196
   Muntner P, 2004, ANN EPIDEMIOL, V14, P686, DOI 10.1016/j.annepidem.2004.01.002
   Muscari A, 2007, DIABETES CARE, V30, P2362, DOI 10.2337/dc07-0637
   Nagasawa N, 2004, CIRC J, V68, P892, DOI 10.1253/circj.68.892
   Nakanishi N, 2002, IND HEALTH, V40, P273, DOI 10.2486/indhealth.40.273
   Natale Valéria Maria, 2003, Sao Paulo Med. J., V121, P09, DOI 10.1590/S1516-31802003000100003
   Nilsson G., 2007, Metabolic Syndrome and Related Disorders, V5, P359, DOI 10.1089/met.2007.0012
   Pannacciulli N, 2003, OBES RES, V11, P1232, DOI 10.1038/oby.2003.169
   Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822
   Pollitt RA, 2007, EUR J EPIDEMIOL, V22, P55, DOI 10.1007/s10654-006-9082-1
   Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327
   Schmidt MI, 1999, LANCET, V353, P1649, DOI 10.1016/S0140-6736(99)01046-6
   Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391
   SHIZAKA N, 2006, DIABETES CARE, V29, P741
   Smith MR, 2003, ATHEROSCLEROSIS, V169, P331, DOI 10.1016/S0021-9150(03)00200-4
   Stranges S, 2008, OBESITY, V16, P1370, DOI 10.1038/oby.2008.59
   Temelkova-Kurktschiev T, 2002, METABOLISM, V51, P743, DOI 10.1053/meta.2002.32804
   Tian JY, 2008, DIABETES RES CLIN PR, V82, P132, DOI 10.1016/j.diabres.2008.05.014
   Van Wijk JPH, 2006, ATHEROSCLEROSIS, V186, P152, DOI 10.1016/j.atherosclerosis.2005.07.001
   VANFURTH R, 1973, J EXP MED, V138, P1314, DOI 10.1084/jem.138.6.1314
   Vozarova B, 2002, DIABETES, V51, P455, DOI 10.2337/diabetes.51.2.455
   Wang YY, 2004, J DIABETES COMPLICAT, V18, P322, DOI 10.1016/S1056-8727(04)00003-0
   Wannamethee SG, 2005, ATHEROSCLEROSIS, V181, P101, DOI 10.1016/j.atherosclerosis.2004.12.031
   WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105
   World Health Organization, 2006, DEF DIAGN DIAB MELL, P1
   Yajnik CS, 2008, DIABETOLOGIA, V51, P39, DOI 10.1007/s00125-007-0847-1
   Yeh HC, 2010, ANN INTERN MED, V152, P10, DOI 10.7326/0003-4819-152-1-201001050-00005
   Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972
NR 60
TC 53
Z9 54
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 18
PY 2010
VL 5
IS 10
AR e13405
DI 10.1371/journal.pone.0013405
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 665ON
UT WOS:000283045300009
PM 20976133
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Peng, XN
   Zeng, XM
   Peng, SH
   Deng, DF
   Zhang, J
AF Peng, Xiaoning
   Zeng, Xiaomin
   Peng, Sihua
   Deng, Defeng
   Zhang, Jian
TI The Association Risk of Male Subfertility and Testicular Cancer: A
   Systematic Review
SO PLOS ONE
LA English
DT Review
AB Background: An association between male subfertility and an increased risk of testicular cancer has been proposed, but conflicting results of research on this topic have rendered this theory equivocal. To more precisely assess the association between subfertility and the risk of testicular cancer, we performed a systematic review of international epidemiologic evidence.
   Principal Findings: We searched the Medline database for records from January 1966 to March 2008 complemented with manual searches of the literature and then identified studies that met our inclusion criteria. Study design, sample size, exposure to subfertility and risk estimates of testicular cancer incidence were abstracted. Summary relative risks (RRs) with 95% confidence intervals (CIs) were calculated using the DerSimonian and Laird model. All statistical tests were two-sided. We identified seven case-control studies and two cohort studies published between 1987 and 2005. Analysis of the seven case-control studies that included 4,954 participants revealed an overall statistically significant association between subfertility and increased risk of testicular cancer (summary RR = 1.68, 95% CI: 1.22 to 2.31), without heterogeneity between studies (Q = 8.46, P heterogeneity = 0.21, I(2) statistics = 0.29). The association between subfertility and testicular cancer was somewhat stronger in the United States (summary RR = 1.75, 95% CI: 1.01 to 3.02) than it was in Europe (summary RR = 1.53, 95% CI: 1.22 to 1.92). The source of the control subjects had a statistically significant effect on the magnitude of the association (population-based summary-RR = 2.15, 95% CI: 1.11 to 4.17; hospital-based summary-RR = 1.56, 95% CI: 0.93 to 2.61). After excluding possible cryptorchidism, an important confounding factor, we also found a positive association between subfertility and increased risk of testicular cancer (summary RR = 1.59, 95% CI: 1.28 to 1.98). These results were consistent between studies conducted in the United States and in Europe (Q = 0.20, P heterogeneity = 0.66). Of the two cohort studies that reported standardized incidence ratios, both reported a statistically significant positive association between subfertility and increased risk of testicular cancer.
   Conclusions: Our findings support a relationship between subfertility and increased risk of testicular cancer and apply to the management of men with subfertility, and prevention and diagnosis of testicular cancer.
RP Peng, XN (reprint author), Hunan Normal Univ, Dept Internal Med, Coll Med, Changsha, Hunan, Peoples R China.
EM pxiaoning@hunnu.edu.cn; zhangjian@hunnu.edu.cn
CR Baker JA, 2005, CANCER CAUSE CONTROL, V16, P295, DOI 10.1007/s10552-004-4024-2
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BROWN LM, 1987, J EPIDEMIOL COMMUN H, V41, P349, DOI 10.1136/jech.41.4.349
   Chow V, 2006, J REPROD MED, V51, P149
   de Kretser DM, 2000, BRIT MED J, V321, P781, DOI 10.1136/bmj.321.7264.781
   DEPUE RH, 1983, J NATL CANCER I, V71, P1151
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dieckmann KP, 2004, WORLD J UROL, V22, P2, DOI 10.1007/s00345-004-0398-8
   Doria-Rose VP, 2005, CANCER CAUSE CONTROL, V16, P651, DOI 10.1007/s10552-005-0169-x
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Evers JLH, 2002, LANCET, V360, P151, DOI 10.1016/S0140-6736(02)09417-5
   FORMAN D, 1994, BRIT MED J, V308, P1393, DOI 10.1136/bmj.308.6941.1393
   Fossa SD, 2000, BRIT J CANCER, V82, P737, DOI 10.1054/bjoc.1999.0989
   Garner MJ, 2005, INT J CANCER, V116, P331, DOI 10.1002/ijc.21032
   Giwercman A, 2007, REPROD BIOMED ONLINE, V15, P633, DOI 10.1016/S1472-6483(10)60530-5
   GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
   HAUGHEY BP, 1989, AM J EPIDEMIOL, V130, P25, DOI 10.1093/oxfordjournals.aje.a115319
   Heimdal K, 1996, BRIT J CANCER, V73, P970, DOI 10.1038/bjc.1996.174
   HENDERSON BE, 1979, INT J CANCER, V23, P598, DOI 10.1002/ijc.2910230503
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hoei-Hansen CE, 2005, ANN ONCOL, V16, P863, DOI 10.1093/annonc/mdi175
   HORWITZ RI, 1979, AM J MED, V66, P556, DOI 10.1016/0002-9343(79)91164-1
   Huyghe E, 2003, J UROLOGY, V170, P5, DOI 10.1097/01.ju.0000053866.68623.da
   Jacobsen R, 2000, BMJ-BRIT MED J, V321, P789, DOI 10.1136/bmj.321.7264.789
   Jacobsen R, 2000, HUM REPROD, V15, P1958, DOI 10.1093/humrep/15.9.1958
   KAHN HA, 1989, EPIDEMIOLOGY BIOSTAT, V12, pE3
   Mancini M, 2007, HUM REPROD, V22, P1042, DOI 10.1093/humrep/del500
   Moller H, 1999, BMJ-BRIT MED J, V318, P559, DOI 10.1136/bmj.318.7183.559
   Nathanson KL, 2005, AM J HUM GENET, V77, P1034, DOI 10.1086/498455
   Olesen IA, 2007, INT J ANDROL, V30, P406, DOI 10.1111/j.1365-2605.2007.00798.x
   Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568
   Raman JD, 2005, J UROLOGY, V174, P1819, DOI 10.1097/01.ju.0000177491.98461.aa
   Richiardi L, 2004, J NATL CANCER I, V96, P145, DOI 10.1093/jnci/djh012
   Skakkebaek NE, 2006, INT J ANDROL, V29, P2, DOI 10.1111/j.1365-2605.2005.00573.x
   Snick HKA, 1997, HUM REPROD, V12, P1582, DOI 10.1093/humrep/12.7.1582
   SWERDLOW AJ, 1989, INT J CANCER, V43, P549, DOI 10.1002/ijc.2910430403
   Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.1289/ehp.96104s4741
   Walschaerts M, 2008, CANCER CAUSE CONTROL, V19, P155, DOI 10.1007/s10552-007-9081-x
   Weir HK, 2000, INT J CANCER, V87, P438, DOI 10.1002/1097-0215(20000801)87:3<438::AID-IJC20>3.0.CO;2-1
   Youngren KK, 2005, NATURE, V435, P360, DOI 10.1038/nature03595
NR 41
TC 34
Z9 35
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 18
PY 2009
VL 4
IS 5
AR e5591
DI 10.1371/journal.pone.0005591
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 446FZ
UT WOS:000266107500019
PM 19440348
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Kalil, AC
   Freifeld, AG
   Lyden, ER
   Stoner, JA
AF Kalil, Andre C.
   Freifeld, Alison G.
   Lyden, Elizabeth R.
   Stoner, Julie A.
TI Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant
   Patients: An Evidence-Based Reassessment of Safety and Efficacy
SO PLOS ONE
LA English
DT Article
AB Background: Several anti-viral drugs have demonstrated efficacy in preventing Cytomegalovirus (CMV) infections in solid organ transplant (SOT) patients. The recently approved valganciclovir is the most commonly used and most expensive drug for CMV prevention. The safety and efficacy data have been drawn from a single trial. We hypothesized that valganciclovir may not be as safe as nor more effective than other therapies for CMV prevention.
   Methods: All experimental and analytical studies that compared valganciclovir with other therapies for prevention of CMV infection after SOT were selected. Based on meta-analytic and multivariate regression methodologies we critically analyzed all available evidence.
   Findings: Nine studies were included (N = 1,831). In trials comparing valganciclovir with ganciclovir, the risk for CMV disease is 0.98 (95% Confidence Interval (95% CI) 0.67 to 1.43; P = 0.92; I-2 = 0%). Valganciclovir was significantly associated with the risk of absolute neutropenia (< 1,500/mm(3)) compared with all therapies (Odds Ratio (OR) 3.63 95% CI 1.75 to 7.53; P = 0.001; I-2 = 0%); with ganciclovir only (OR 2.88, 95%CI 1.27 to 6.53; P = 0.01; I-2 = 0%); or with non-ganciclovir therapies (OR 8.30, 95% CI 1.51 to 45.58; P = 0.01; I-2 = 10%). For a neutropenia cut-off of < 1,000/mm(3), the risk remained elevated (OR 1.97, 95% CI 1.03 to 3.67; P = 0.04; I-2 = 0%). For every 24 patients who receive valganciclovir prophylaxis, one more will develop neutropenia compared to other therapies. The risk of late-onset CMV disease with valganciclovir was similar to ganciclovir and higher than those with non-ganciclovir therapies [OR 8.95, 95% CI 1.07 to 74.83; P = 0.04; I-2 = 0%]. One more patient will develop late-onset CMV disease for every 25 who receive valganciclovir compared to treatment with non-ganciclovir therapies. The risk of CMV tissue-invasive disease in liver recipients receiving valganciclovir was 4.5 times the risk seen with ganciclovir [95% CI 1.00 to 20.14] (p = 0.04). All results remained consistent across different study designs, valganciclovir doses, and CMV serostatus.
   Conclusions: Valganciclovir shows no superior efficacy and significantly higher risk of absolute neutropenia, CMV late-onset disease, and CMV tissue-invasive disease compared to other standard therapies. Due to the availability of efficacious, safer, and lower cost drugs (high-dose acyclovir, valacyclovir, ganciclovir), our results do not favor the use of valganciclovir as a first-line agent for CMV preemptive or universal prophylaxis in SOT patients.
RP Kalil, AC (reprint author), Univ Nebraska Med Ctr, Dept Internal Med, Div Infect Dis, Omaha, NE USA.
EM akalil@unmc.edu
CR Aigner C, 2005, WIEN KLIN WOCHENSCHR, V117, P480, DOI 10.1007/s00508-005-0413-0
   Akalin E, 2003, AM J TRANSPLANT, V3, P731, DOI 10.1034/j.1600-6143.2003.00140.x
   Baliga RS, 2004, AM J TRANSPLANT, V4, P495
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506
   Boivin G, 2004, J INFECT DIS, V189, P1615, DOI 10.1086/382753
   Brennan DC, 1997, TRANSPLANTATION, V64, P1843, DOI 10.1097/00007890-199712270-00036
   Bucher HC, 1999, JAMA-J AM MED ASSOC, V282, P771, DOI 10.1001/jama.282.8.771
   Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507
   COUCHOUD C, 2000, COCHRANE DB SYST REV
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Devyatko E, 2004, J HEART LUNG TRANSPL, V23, P1277, DOI 10.1016/j.healun.2003.08.034
   Diaz-Pedroche C, 2006, TRANSPLANTATION, V82, P30, DOI 10.1097/01.tp.0000225830.76907.d0
   Einsele H, 2006, BLOOD, V107, P3002, DOI 10.1182/bllod-2005-09-3786
   Fiddian P, 2002, J INFECT DIS, V186, pS110, DOI 10.1086/342965
   Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011
   Freeman RB, 2004, TRANSPLANTATION, V78, P1765, DOI 10.1097/01.TP.0000142619.01510.A5
   Gane E, 1997, LANCET, V350, P1729, DOI 10.1016/S0140-6736(97)05535-9
   Gomberg-Maitland M, 2003, AM HEART J, V146, P398, DOI 10.1016/S0002-8703(03)00324-7
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Humar A, 2005, AM J TRANSPLANT, V5, P1462, DOI 10.1111/j.1600=6143.2005.00866.x
   Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009
   Jain A, 2006, LIVER TRANSPLANT, V12, P1020, DOI 10.1002/lt.20749
   Jain A, 2005, TRANSPLANT P, V37, P3182, DOI 10.1016/j.transproceed.2005.07.032
   Kalil AC, 2005, ANN INTERN MED, V143, P870, DOI 10.7326/0003-4819-143-12-200512200-00005
   Keven K, 2004, TRANSPL P, V36, P3107, DOI 10.1016/j.transproceed.2004.11.092
   Khoury JA, 2006, AM J TRANSPLANT, V6, P2134, DOI 10.1111/j.1600-6143.2006.01413.x
   Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185
   LANGE WR, 2007, 2003 SAFETY ALERT VA
   Levitsky J, 2007, AM J TRANSPLANT, V7, P197
   Limaye AP, 2006, TRANSPLANTATION, V81, P1645, DOI 10.1097/01.tp.0000226071.12562.1a
   Limaye AP, 2004, TRANSPLANTATION, V78, P1390, DOI 10.1097/01.TP.0000145989.22373.03
   Ljungman P, 2002, CLIN INFECT DIS, V34, P1094, DOI 10.1086/339329
   Lopau K, 2007, CLIN TRANSPLANT, V21, P80, DOI 10.1111/j.1399-0012.2006.00586.x
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mattes FM, 2005, J INFECT DIS, V191, P89, DOI 10.1086/425905
   MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803
   MULROW CD, 1998, SYSTEMATIC REV SYNTH, P117
   MUNOZ V, EPIDEMIOLOGY CITOMEG
   *NAT CANC I, 2006, GUID TOOLS PROT DEV
   Park JM, 2006, LIVER TRANSPLANT, V12, P112, DOI 10.1002/lt.20562
   Paya C, 2004, AM J TRANSPLANT, V4, P611, DOI 10.1111/j.1600-6143.2004.00382.x
   Pescovitz M D, 1999, Transpl Infect Dis, V1 Suppl 1, P31
   Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152
   Pocock SJ, 2003, FUND CLIN PHARMACOL, V17, P483, DOI 10.1046/j.1472-8206.2003.00162.x
   SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4
   Said T, 2007, TRANSPL P, V39, P997, DOI 10.1016/j.transproceed.2007.03.046
   Sia IG, 2000, CLIN MICROBIOL REV, V13, P83, DOI 10.1128/CMR.13.1.83-121.2000
   Singh N, 2000, TRANSPLANTATION, V70, P717, DOI 10.1097/00007890-200009150-00002
   Singh N, 2005, TRANSPLANTATION, V79, P85, DOI 10.1097/01.TP.0000146844.65273.62
   Singh N, 2005, CLIN INFECT DIS, V40, P704, DOI 10.1086/427506
   Small LN, 2006, CLIN INFECT DIS, V43, P869, DOI 10.1086/507337
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   Strippoli GFM, 2006, TRANSPLANTATION, V81, P139, DOI 10.1097/01.tp.0000183970.71366.da
   Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014
   Walker JK, 2007, TRANSPLANTATION, V83, P874, DOI 10.1097/01.tp.0000257923.69422.4d
   Weng FL, 2007, TRANSPLANTATION, V83, P290, DOI 10.1097/01.tp.0000251371.34968.ca
   Zamora MR, 2004, AM J TRANSPLANT, V4, P1635, DOI 10.1111/j.1600-6143.2004.00571.x
NR 58
TC 52
Z9 53
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 13
PY 2009
VL 4
IS 5
AR e5512
DI 10.1371/journal.pone.0005512
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 444WA
UT WOS:000266009900005
PM 19436751
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

PT J
AU Preisser, EL
   Bolnick, DI
AF Preisser, Evan L.
   Bolnick, Daniel I.
TI The Many Faces of Fear: Comparing the Pathways and Impacts of
   Nonconsumptive Predator Effects on Prey Populations
SO PLOS ONE
LA English
DT Article
AB Background: Most ecological models assume that predator and prey populations interact solely through consumption: predators reduce prey densities by killing and consuming individual prey. However, predators can also reduce prey densities by forcing prey to adopt costly defensive strategies.
   Methodology/Principal Findings: We build on a simple Lotka-Volterra predator-prey model to provide a heuristic tool for distinguishing between the demographic effects of consumption (consumptive effects) and of anti-predator defenses (nonconsumptive effects), and for distinguishing among the multiple mechanisms by which anti-predator defenses might reduce prey population growth rates. We illustrate these alternative pathways for nonconsumptive effects with selected empirical examples, and use a meta-analysis of published literature to estimate the mean effect size of each pathway. Overall, predation risk tends to have a much larger impact on prey foraging behavior than measures of growth, survivorship, or fecundity.
   Conclusions/Significance: While our model provides a concise framework for understanding the many potential NCE pathways and their relationships to each other, our results confirm empirical research showing that prey are able to partially compensate for changes in energy income, mitigating the fitness effects of defensive changes in time budgets. Distinguishing the many facets of nonconsumptive effects raises some novel questions, and will help guide both empirical and theoretical studies of how predation risk affects prey dynamics.
C1 [Preisser, Evan L.] Univ Rhode Isl, Dept Biol Sci, Kingston, RI 02881 USA.
   [Bolnick, Daniel I.] Univ Texas Austin, Sect Integrative Biol, Austin, TX USA.
RP Preisser, EL (reprint author), Univ Rhode Isl, Dept Biol Sci, Kingston, RI 02881 USA.
EM preisser@uri.edu
RI Bolnick, Daniel I./G-4440-2015; Preisser, Evan/C-3469-2013
OI Bolnick, Daniel I./0000-0003-3148-6296; Preisser,
   Evan/0000-0002-8737-5619
FU NSF [DEB-0089716, DEB-0072909]; University of Texas at Austin; Center
   for Population Biology at the University of California at Davis;
   University of California, Santa Barbara Campus
FX The authors were supported by NSF grant# DEB-0089716 to M. Turelli and
   J. Gillespie and the University of Texas at Austin (DIB) and by the
   Center for Population Biology at the University of California at Davis
   (ELP). This work was conducted as part of the "Does Fear Matter?"
   Working Group (headed by ELP and DIB) at the National Center for
   Ecological Analysis and Synthesis, a Center funded by NSF (grant#
   DEB-0072909), the University of California, and the Santa Barbara
   Campus. None of these sponsors or funders played any role in the design
   and conduct of the study, in the collection, analysis, and
   interpretation of the data, and in the preparation, review, or approval
   of the manuscript.
CR Abrams PA, 1996, ECOLOGY, V77, P610, DOI 10.2307/2265634
   ABRAMS PA, 1991, OIKOS, V62, P167, DOI 10.2307/3545262
   ABRAMS PA, 1990, ECOLOGY, V71, P877, DOI 10.2307/1937359
   ABRAMS PA, 1995, AM NAT, V146, P112, DOI 10.1086/285789
   ABRAMS PA, 1984, AM NAT, V124, P80, DOI 10.1086/284253
   ABRAMS PA, 1982, AM NAT, V120, P382, DOI 10.1086/283996
   ABRAMS PA, 1991, ECOLOGY, V72, P1242, DOI 10.2307/1941098
   Abrams PA, 2007, ECOLOGY, V88, P2555, DOI 10.1890/06-1381.1
   Abrams PA, 2007, AM NAT, V169, P581, DOI 10.1086/512688
   BARRY MJ, 1994, OECOLOGIA, V97, P278, DOI 10.1007/BF00323161
   Beckerman AP, 1997, P NATL ACAD SCI USA, V94, P10735, DOI 10.1073/pnas.94.20.10735
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blaustein L, 1997, OECOLOGIA, V110, P212, DOI 10.1007/s004420050152
   Bolker B, 2003, ECOLOGY, V84, P1101, DOI 10.1890/0012-9658(2003)084[1101:CTAESO]2.0.CO;2
   Bolnick DI, 2005, ECOLOGY, V86, P2771, DOI 10.1890/04-1249
   Brown JS, 2004, ECOL LETT, V7, P999, DOI 10.1111/j.1461-0248.2004.00661.x
   COOPER SD, 1990, ECOLOGY, V71, P1503, DOI 10.2307/1938287
   Crowder LB, 1997, ECOLOGY, V78, P1796
   Dahl J, 1998, OECOLOGIA, V116, P426, DOI 10.1007/s004420050606
   DAYTON PK, 1973, AM NAT, V107, P662, DOI 10.1086/282865
   Downes S, 2001, ECOLOGY, V82, P2870, DOI 10.1890/0012-9658(2001)082[2870:THAFFS]2.0.CO;2
   Englund G, 2004, ECOLOGY, V85, P320, DOI 10.1890/03-3039
   Englund G, 2001, OIKOS, V92, P501, DOI 10.1034/j.1600-0706.2001.920311.x
   Fiske P, 1998, BEHAV ECOL, V9, P328, DOI 10.1093/beheco/9.4.328
   FRASER DF, 1992, ECOLOGY, V73, P959, DOI 10.2307/1940172
   GILLIAM JF, 1987, ECOLOGY, V68, P1856, DOI 10.2307/1939877
   Hansson LA, 2000, ECOLOGY, V81, P842, DOI 10.1890/0012-9658(2000)081[0842:SEOFCD]2.0.CO;2
   Hedges LV, 1999, ECOLOGY, V80, P1150, DOI 10.1890/0012-9658(1999)080[1150:TMAORR]2.0.CO;2
   HEIKKILA J, 1993, ANN ZOOL FENN, V30, P153
   Kelly DW, 2002, FRESHWATER BIOL, V47, P1257, DOI 10.1046/j.1365-2427.2002.00864.x
   Kuhara N, 1999, OIKOS, V87, P27, DOI 10.2307/3546993
   Kunert G, 2003, OECOLOGIA, V135, P304, DOI [10.1007/s00442-003-1185-8, 10.1007/s00442-003-1338-9]
   Langerhans RB, 2002, EVOL ECOL RES, V4, P857
   Lima SL, 1999, AM NAT, V153, P649, DOI 10.1086/303202
   LIMA SL, 1986, ANIM BEHAV, V34, P536, DOI 10.1016/S0003-3472(86)80122-1
   Lima SL, 1998, ADV STUD BEHAV, V27, P215
   LIMA SL, 1990, CAN J ZOOL, V68, P619, DOI 10.1139/z90-092
   Lopez DA, 1995, REV CHIL HIST NAT, V68, P469
   Losey JE, 1998, ECOLOGY, V79, P2143, DOI 10.1890/0012-9658(1998)079[2143:PPPIEP]2.0.CO;2
   Lotka A. J., 1925, ELEMENTS PHYS BIOL
   Luttbeg B, 2003, ECOLOGY, V84, P1140, DOI 10.1890/0012-9658(2003)084[1140:PSAEDA]2.0.CO;2
   McCollum EW, 1998, ECOLOGY, V79, P1980
   McIntosh AR, 1999, OIKOS, V85, P554, DOI 10.2307/3546705
   MCNEELY DL, 1990, OECOLOGIA, V85, P69, DOI 10.1007/BF00317344
   McPeek M. A., 2004, AM NAT, V163, P88
   MORAN MD, 1994, OECOLOGIA, V98, P269, DOI 10.1007/BF00324214
   Morrison LW, 1999, OECOLOGIA, V121, P113, DOI 10.1007/s004420050912
   Murdoch W., 2003, CONSUMER RESOURCE DY
   Nelson EH, 2004, ECOLOGY, V85, P1853, DOI 10.1890/03-3109
   Palmer AR, 1999, AM NAT, V154, P220, DOI 10.1086/303223
   Preisser EL, 2005, ECOLOGY, V86, P501, DOI 10.1890/04-0719
   Preisser EL, 2007, ECOLOGY, V88, P2744, DOI 10.1890/07-0260.1
   Pusenius J, 2000, OIKOS, V91, P123, DOI 10.1034/j.1600-0706.2000.910111.x
   Resetarits WJ, 2001, OECOLOGIA, V129, P155, DOI 10.1007/s004420100704
   Rosenberg MS, 2000, METAWIN STAT SOFTWAR, P128
   Schmitz OJ, 2004, ECOL LETT, V7, P153, DOI 10.1111/j.1461-0248.2003.00560.x
   Schmitz OJ, 1998, AM NAT, V151, P327, DOI 10.1086/286122
   Schmitz OJ, 2008, SCIENCE, V319, P952, DOI 10.1126/science.1152355
   SCRIMGEOUR GJ, 1994, OIKOS, V69, P71, DOI 10.2307/3545285
   Sih A, 1996, OECOLOGIA, V105, P179, DOI 10.1007/BF00328544
   Sih A, 2001, ANIM BEHAV, V61, P379, DOI 10.1006/anbe.2000.1592
   Stankowich T, 2005, P ROY SOC B-BIOL SCI, V272, P2627, DOI 10.1098/rspb.2005.3251
   Steiner UK, 2007, ANIM BEHAV, V74, P1473, DOI 10.1016/j.anbehav.2007.02.016
   Stoks R, 2001, OECOLOGIA, V127, P222, DOI 10.1007/s004420000595
   STRONG DR, 1973, ECOLOGY, V54, P1383
   Trussell GC, 2003, ECOLOGY, V84, P629, DOI 10.1890/0012-9658(2003)084[0629:TMEIRI]2.0.CO;2
   Trussell GC, 2006, ECOLOGY, V87, P2979, DOI 10.1890/0012-9658(2006)87[2979:TFOBER]2.0.CO;2
   Volterra V, 1926, NATURE, V118, P558, DOI 10.1038/118558a0
   Walker SE, 2003, J ARACHNOL, V31, P425, DOI 10.1636/S02-63
   WALLS M, 1991, OECOLOGIA, V87, P43, DOI 10.1007/BF00323778
   WERNER EE, 1983, ECOLOGY, V64, P1540, DOI 10.2307/1937508
   Werner EE, 2003, ECOLOGY, V84, P1083, DOI 10.1890/0012-9658(2003)084[1083:AROTII]2.0.CO;2
   WOOTTON JT, 1993, AM NAT, V141, P71, DOI 10.1086/285461
NR 73
TC 84
Z9 88
U1 1
U2 79
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 18
PY 2008
VL 3
IS 6
AR e2465
DI 10.1371/journal.pone.0002465
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 406FP
UT WOS:000263280700046
PM 18560575
OA DOAJ Gold, Green Published
DA 2019-07-16
ER

EF